Am	O
J	O
Surg	O
Pathol	O
2001	O
May	O
;	O
25	O
(	O
5	O
)	O
:	O
595-601	O
Small	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
pathology	O
study	O
of	O
12	O
cases	O
.	O
Maitra	O
A	O
,	O
Tascilar	O
M	O
,	O
Hruban	O
RH	O
,	O
Offerhaus	O
GJ	O
,	O
Albores-Saavedra	O
J	O
.	O
Departments	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
,	O
Texas	O
,	O
USA	O
.	O
Small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
are	O
unusual	O
neoplasms	O
that	O
have	O
been	O
characterized	O
only	O
recently	O
.	O
The	O
authors	O
describe	O
the	O
clinical	O
,	O
histopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
features	O
of	O
12	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	O
gallbladder	O
.	O
The	O
mean	O
age	O
at	O
diagnosis	O
was	O
69	O
years	O
,	O
and	O
the	O
male	O
-	O
to	O
-	O
female	O
ratio	O
was	O
5	O
:	O
7	O
.	O
The	O
neoplasms	O
had	O
an	O
average	O
size	O
of	O
3	O
cm	O
,	O
and	O
90	O
%	O
showed	O
invasion	O
of	O
the	O
muscularis	O
propria	O
and	O
perimuscular	O
connective	O
tissue	O
.	O
Seventy-five	O
percent	O
of	O
the	O
carcinomas	B-malignancy-type
had	O
metastasized	O
or	O
extended	O
locally	O
beyond	O
the	O
gallbladder	O
at	O
surgery	O
.	O
Survival	O
was	O
uniformly	O
poor	O
,	O
with	O
a	O
mean	O
survival	O
of	O
10.7	O
months	O
(	O
range	O
,	O
3	O
-	O
25	O
months	O
)	O
.	O
Half	O
the	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
combined	O
with	O
other	O
neoplasms	O
.	O
Four	O
had	O
foci	O
of	O
adenocarcinoma	B-malignancy-type
,	O
one	O
contained	O
areas	O
of	O
squamous	O
differentiation	O
,	O
and	O
another	O
had	O
a	O
component	O
of	O
carcinosarcoma	B-malignancy-type
.	O
Immunohistochemical	O
analysis	O
showed	O
focal	O
reactivity	O
for	O
chromogranin	O
(	O
six	O
of	O
six	O
cases	O
)	O
,	O
neuron	O
-	O
specific	O
enolase	O
(	O
six	O
of	O
six	O
cases	O
)	O
,	O
and	O
Leu-7	O
(	O
three	O
of	O
three	O
cases	O
)	O
.	O
The	O
molecular	O
changes	O
in	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
similar	O
to	O
those	O
of	O
adenocarcinomas	B-malignancy-type
occurring	O
at	O
this	O
site	O
,	O
with	O
a	O
high	O
frequency	O
of	O
p53	O
(	O
75	O
%	O
)	O
and	O
p16INK4a	O
(	O
33	O
%	O
)	O
abnormalities	O
,	O
and	O
a	O
low	O
frequency	O
of	O
deleted	O
in	O
pancreatic	O
carcinoma-4	O
inactivation	O
(	O
0	O
%	O
)	O
and	O
K-ras	O
codon	O
12	O
mutations	O
(	O
17	O
%	O
)	O
.	O
In	O
contrast	O
to	O
pulmonary	B-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
p16INK4a	O
function	O
appears	O
to	O
be	O
abrogated	O
more	O
frequently	O
in	O
these	O
carcinomas	B-malignancy-type
.	O
PMID	O
:	O
11342770	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Jpn	O
J	O
Clin	O
Oncol	O
2002	O
Jun	O
;	O
32	O
(	O
6	O
)	O
:	O
219-21	O
Concurrent	O
mutations	O
of	O
K-ras	O
oncogene	O
at	O
codons	O
12	O
and	O
22	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Miyakura	O
Y	O
,	O
Sugano	O
K	O
,	O
Fukayama	O
N	O
,	O
Konishi	O
F	O
,	O
Nagai	O
H	O
.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Minami	O
Kawachi	O
,	O
Tochigi	O
,	O
Japan	O
.	O
K-ras	O
mutation	O
is	O
the	O
most	O
common	O
oncogenic	O
alteration	O
in	O
various	O
human	O
cancers	O
including	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Point	O
mutations	O
have	O
the	O
potential	O
to	O
activate	O
the	O
K-ras	O
gene	O
if	O
they	O
occur	O
in	O
the	O
critical	O
coding	O
sequences	O
.	O
Almost	O
all	O
of	O
these	O
mutations	O
have	O
been	O
localized	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
We	O
report	O
a	O
case	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
presenting	O
point	O
mutations	O
at	O
both	O
codons	O
12	O
and	O
22	O
of	O
the	O
K-ras	O
gene	O
.	O
PCR	O
-	O
SSCP	O
and	O
subsequent	O
sequencing	O
revealed	O
that	O
GGT	O
(	O
glycine	O
,	O
wild	O
-	O
type	O
)	O
to	O
AGT	O
(	O
serine	O
)	O
substitution	O
at	O
codon	O
12	O
and	O
CAG	O
(	O
glutamine	O
,	O
wild	O
-	O
type	O
)	O
to	O
CGG	O
(	O
arginine	O
)	O
substitution	O
at	O
codon	O
22	O
occurred	O
in	O
the	O
same	O
allele	O
.	O
PMID	O
:	O
12110640	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2002	O
Jul	O
11	O
;	O
21	O
(	O
30	O
)	O
:	O
4646-62	O
Novel	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
leading	O
to	O
better	O
understanding	O
of	O
the	O
diversity	O
of	O
respective	O
primary	O
cancers	O
.	O
Vecsey-Semjen	O
B	O
,	O
Becker	O
KF	O
,	O
Sinski	O
A	O
,	O
Blennow	O
E	O
,	O
Vietor	O
I	O
,	O
Zatloukal	O
K	O
,	O
Beug	O
H	O
,	O
Wagner	O
E	O
,	O
Huber	O
LA	O
.	O
IMP	O
,	O
Research	O
Institute	O
of	O
Molecular	O
Pathology	O
,	O
Vienna	O
,	O
Austria	O
.	O
A	O
major	O
obstacle	O
to	O
obtaining	O
more	O
detailed	O
insights	O
into	O
the	O
diversity	O
of	O
phenotypic	O
and	O
molecular	O
changes	O
occurring	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
is	O
the	O
lack	O
of	O
low	O
-	O
passage	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
which	O
would	O
still	O
closely	O
reflect	O
the	O
phenotype	O
of	O
the	O
colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
in	O
vivo	O
.	O
Here	O
,	O
we	O
characterize	O
eight	O
novel	O
,	O
low	O
passage	O
number	O
human	O
colon	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
originating	O
from	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
extensively	O
characterized	O
in	O
the	O
clinics	O
.	O
All	O
cell	O
lines	O
closely	O
resemble	O
the	O
original	O
tumors	O
with	O
respect	O
to	O
phenotype	O
,	O
markers	O
and	O
detectable	O
genetic	O
changes	O
.	O
Cell	O
morphology	O
and	O
marker	O
expression	O
is	O
highly	O
variable	O
,	O
ranging	O
from	O
fully	O
polarized	O
cells	O
correctly	O
expressing	O
all	O
basolateral	O
epithelial	O
markers	O
,	O
to	O
cells	O
with	O
mesenchymal	O
characteristics	O
and	O
a	O
complete	O
loss	O
of	O
polarity	O
due	O
to	O
delocalization	O
or	O
loss	O
of	O
junction	O
complex	O
proteins	O
.	O
The	O
alterations	O
in	O
phenotype	O
and	O
epithelial	O
marker	O
expression	O
correspond	O
to	O
changes	O
already	O
detectable	O
in	O
the	O
primary	O
tumor	O
in	O
vivo	O
.	O
Seven	O
of	O
the	O
cell	O
lines	O
show	O
chromosomal	O
instability	O
,	O
while	O
one	O
cell	O
line	O
is	O
characterized	O
by	O
microsatellite	O
instability	O
.	O
p53	O
associated	O
with	O
K-ras	O
mutations	O
were	O
detected	O
in	O
three	O
cell	O
lines	O
.	O
Hitherto	O
non	O
-	O
described	O
E-cadherin	O
mutations	O
were	O
found	O
at	O
both	O
alleles	O
in	O
one	O
cell	O
line	O
whereas	O
in	O
another	O
cell	O
line	O
the	O
E-cadherin	O
protein	O
was	O
down	O
-	O
regulated	O
.	O
A	O
stabilizing	O
beta-catenin	O
mutation	O
(	O
S	O
45	O
F	O
)	O
appears	O
in	O
the	O
same	O
cell	O
line	O
that	O
carried	O
the	O
mutated	O
E-cadherin	O
gene	O
.	O
Six	O
cell	O
lines	O
carried	O
APC	O
mutations	O
,	O
which	O
in	O
five	O
of	O
the	O
lines	O
led	O
to	O
an	O
activated	O
beta-catenin	O
/	O
Tcf	O
/	O
LEF	O
signaling	O
pathway	O
.	O
In	O
accordance	O
with	O
beta-catenin	O
/	O
Tcf	O
/	O
LEF	O
activation	O
,	O
the	O
cell	O
lines	O
show	O
increased	O
migration	O
and	O
invasiveness	O
.	O
Our	O
results	O
show	O
that	O
the	O
characterized	O
,	O
low	O
-	O
passage	O
cell	O
lines	O
mirror	O
the	O
diversity	O
of	O
the	O
individual	O
tumors	O
from	O
which	O
they	O
were	O
derived	O
.	O
Through	O
molecular	O
analyses	O
of	O
these	O
cell	O
lines	O
we	O
demonstrate	O
that	O
tumorgenicity	O
events	O
are	O
much	O
more	O
diverse	O
in	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
than	O
expected	O
,	O
despite	O
the	O
common	O
origin	O
of	O
the	O
tumors	O
from	O
a	O
small	O
patient	O
group	O
with	O
similar	O
tumor	O
grading	O
and	O
clinical	O
prognosis	O
.	O
PMID	O
:	O
12096341	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2002	O
Jun	O
20	O
;	O
21	O
(	O
27	O
)	O
:	O
4301-6	O
Common	O
occurrence	O
of	O
multiple	O
K-RAS	O
mutations	O
in	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
with	O
associated	O
precursor	O
lesions	O
and	O
in	O
biliary	B-malignancy-type
cancers	I-malignancy-type
.	O
Laghi	O
L	O
,	O
Orbetegli	O
O	O
,	O
Bianchi	O
P	O
,	O
Zerbi	O
A	O
,	O
Di	O
Carlo	O
V	O
,	O
Boland	O
CR	O
,	O
Malesci	O
A	O
.	O
Division	O
of	O
Gastroenterology	O
,	O
Istituto	O
Clinico	O
Humanitas	O
,	O
Rozzano	O
,	O
Milan	O
,	O
20089	O
Italy	O
.	O
Recent	O
studies	O
on	O
small	O
series	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
(	O
PC	B-malignancy-type
)	O
with	O
foci	O
of	O
pancreatic	O
intraepithelial	O
neoplasia	O
(	O
PanIN	O
)	O
,	O
a	O
putative	O
precursor	O
lesion	O
,	O
have	O
shown	O
that	O
multiple	O
K-RAS	O
mutations	O
may	O
coexist	O
in	O
the	O
same	O
neoplastic	O
pancreas	O
.	O
To	O
see	O
whether	O
mutant	O
-	O
K-RAS	O
polyclonality	O
is	O
a	O
common	O
and	O
specific	O
feature	O
of	O
pancreatic	O
carcinogenesis	O
,	O
we	O
investigated	O
a	O
unselected	O
series	O
of	O
periampullary	B-malignancy-type
cancers	I-malignancy-type
(	O
41	O
pancreatic	B-malignancy-type
,	O
13	O
biliary	B-malignancy-type
and	O
two	O
ampullary	B-malignancy-type
adenocarcinomas	I-malignancy-type
)	O
.	O
After	O
hemi	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
mutations	O
identified	O
with	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
were	O
confirmed	O
by	O
allele	O
-	O
specific	O
PCR	O
and	O
sequencing	O
.	O
K-RAS	O
codon	O
12	O
was	O
mutated	O
in	O
34	O
(	O
83	O
%	O
)	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
and	O
in	O
11	O
(	O
85	O
%	O
)	O
biliary	B-malignancy-type
cancers	I-malignancy-type
.	O
Multiple	O
distinct	O
K-RAS	O
mutations	O
were	O
found	O
in	O
16	O
PC	B-malignancy-type
(	O
39	O
%	O
of	O
all	O
cases	O
,	O
47	O
%	O
of	O
those	O
with	O
mutated	O
K-RAS	O
)	O
and	O
in	O
eight	O
biliary	O
cancers	O
(	O
62	O
and	O
72	O
%	O
,	O
respectively	O
)	O
.	O
In	O
PC	O
,	O
multiple	O
K-RAS	O
mutations	O
were	O
more	O
frequent	O
(	O
P	O
<	O
0.001	O
)	O
in	O
cancers	O
with	O
(	O
nine	O
of	O
12	O
,	O
75	O
%	O
)	O
than	O
in	O
those	O
without	O
detectable	O
PanIN	O
(	O
seven	O
of	O
29	O
,	O
24	O
%	O
)	O
.	O
Individual	O
precursor	O
lesions	O
of	O
the	O
same	O
neoplastic	O
pancreas	O
were	O
found	O
to	O
harbor	O
distinct	O
mutations	O
.	O
Results	O
show	O
that	O
multiple	O
K-RAS	O
mutations	O
are	O
frequent	O
both	O
in	O
PC	B-malignancy-type
with	O
associated	O
PanIN	O
and	O
in	O
biliary	B-malignancy-type
cancers	I-malignancy-type
,	O
and	O
indicate	O
that	O
clonally	O
distinct	O
precursor	O
lesions	O
of	O
PC	B-malignancy-type
might	O
variably	O
contribute	O
to	O
tumor	O
development	O
.	O
PMID	O
:	O
12082617	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Oncol	O
2002	O
Jun	O
1	O
;	O
20	O
(	O
11	O
)	O
:	O
2726-35	O
Phase	O
I	O
clinical	O
and	O
pharmacologic	O
study	O
of	O
chronic	O
oral	O
administration	O
of	O
the	O
farnesyl	O
protein	O
transferase	O
inhibitor	O
R115777	O
in	O
advanced	O
cancer	O
.	O
Crul	O
M	O
,	O
de	O
Klerk	O
GJ	O
,	O
Swart	O
M	O
,	O
van't	O
Veer	O
LJ	O
,	O
de	O
Jong	O
D	O
,	O
Boerrigter	O
L	O
,	O
Palmer	O
PA	O
,	O
Bol	O
CJ	O
,	O
Tan	O
H	O
,	O
de	O
Gast	O
GC	O
,	O
Beijnen	O
JH	O
,	O
Schellens	O
JH	O
.	O
Netherlands	O
Cancer	O
Institute	O
and	O
Academic	O
Medical	O
Centre	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
apmcr@slz.nl	O
PURPOSE	O
:	O
To	O
determine	O
the	O
maximum	O
-	O
tolerated	O
dose	O
,	O
toxicities	O
,	O
and	O
pharmacokinetics	O
of	O
R115777	O
,	O
a	O
farnesyl	O
transferase	O
inhibitor	O
,	O
when	O
administered	O
continuously	O
via	O
the	O
oral	O
route	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
advanced	O
solid	O
malignancies	O
were	O
treated	O
with	O
R115777	O
using	O
an	O
interpatient	O
dose	O
escalation	O
scheme	O
starting	O
at	O
50	O
mg	O
bid	O
.	O
Pharmacokinetics	O
were	O
assessed	O
on	O
days	O
1	O
,	O
28	O
,	O
and	O
56	O
.	O
RESULTS	O
:	O
Twenty-eight	O
patients	O
were	O
entered	O
onto	O
the	O
study	O
and	O
the	O
median	O
duration	O
of	O
treatment	O
was	O
55	O
days	O
.	O
The	O
dose	O
-	O
limiting	O
toxicities	O
were	O
myelosuppression	O
and	O
neurotoxicity	O
.	O
At	O
a	O
dose	O
of	O
400	O
mg	O
bid	O
,	O
grade	O
4	O
leukocytopenia	B-malignancy-type
and	O
neutropenia	B-malignancy-type
were	O
seen	O
in	O
two	O
of	O
four	O
patients	O
.	O
Neurotoxicity	O
grade	O
3	O
developed	O
in	O
one	O
of	O
five	O
patients	O
at	O
500	O
mg	O
bid	O
and	O
in	O
one	O
of	O
13	O
at	O
300	O
mg	O
bid	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O
Common	O
nonhematologic	O
toxicities	O
were	O
nausea	O
,	O
vomiting	O
,	O
and	O
fatigue	O
.	O
The	O
recommended	O
dose	O
for	O
phase	O
II	O
/	O
III	O
testing	O
in	O
this	O
scheme	O
is	O
300	O
mg	O
bid	O
.	O
The	O
pharmacokinetic	O
studies	O
indicated	O
dose	O
proportionality	O
.	O
Little	O
accumulation	O
occurred	O
and	O
steady	O
-	O
state	O
levels	O
were	O
reached	O
within	O
2	O
to	O
3	O
days	O
.	O
Analyses	O
of	O
historic	O
tumor	O
material	O
showed	O
that	O
five	O
of	O
15	O
of	O
patients	O
had	O
a	O
K-ras	O
mutation	O
in	O
codon	O
12	O
.	O
Three	O
patients	O
with	O
pancreatic	B-malignancy-type
,	O
colon	B-malignancy-type
,	O
and	O
cervix	B-malignancy-type
carcinomas	I-malignancy-type
had	O
stable	O
disease	O
and	O
one	O
patient	O
with	O
a	O
colon	O
carcinoma	O
had	O
a	O
minor	O
response	O
accompanied	O
by	O
a	O
more	O
than	O
50	O
%	O
decrease	O
in	O
carcinoembryonic	O
antigen	O
tumor	O
marker	O
.	O
A	O
fifth	O
patient	O
,	O
with	O
platinum	B-malignancy-type
-	I-malignancy-type
refractory	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
,	O
showed	O
a	O
partial	O
response	O
that	O
lasted	O
for	O
5	O
months	O
.	O
CONCLUSION	O
:	O
Continuous	O
dosing	O
of	O
R115777	O
is	O
feasible	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
at	O
a	O
dose	O
of	O
300	O
mg	O
bid	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Clinical	O
Trial	O
,	O
Phase	O
I	O
PMID	O
:	O
12039935	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
2002	O
May	O
;	O
34	O
(	O
1	O
)	O
:9-16	O
APC	O
/	O
CTNNB1	O
(	O
beta-catenin	O
)	O
pathway	O
alterations	O
in	O
human	O
prostate	B-malignancy-type
cancers	I-malignancy-type
.	O
Gerstein	O
AV	O
,	O
Almeida	O
TA	O
,	O
Zhao	O
G	O
,	O
Chess	O
E	O
,	O
Shih	O
IeM	O
,	O
Buhler	O
K	O
,	O
Pienta	O
K	O
,	O
Rubin	O
MA	O
,	O
Vessella	O
R	O
,	O
Papadopoulos	O
N	O
.	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Cancer	O
Genetics	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
New	O
York	O
,	O
USA	O
.	O
Genetic	O
alterations	O
serve	O
as	O
beacons	O
for	O
the	O
involvement	O
of	O
specific	O
pathways	O
in	O
tumorigenesis	O
.	O
It	O
was	O
previously	O
shown	O
that	O
5	O
%	O
of	O
prostate	B-malignancy-type
tumors	I-malignancy-type
harbor	O
CTNNB1	O
mutations	O
,	O
suggesting	O
that	O
this	B-malignancy-type
tumor	I-malignancy-type
type	I-malignancy-type
may	O
involve	O
a	O
deregulated	O
APC	O
/	O
CTNNB1	O
pathway	O
.	O
To	O
explore	O
this	O
possibility	O
further	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
genes	O
implicated	O
in	O
this	O
pathway	O
in	O
22	O
samples	O
that	O
included	O
cell	O
lines	O
,	O
xenografts	O
,	O
and	O
primary	O
tumors	O
.	O
We	O
identified	O
seven	O
alterations	O
:	O
two	O
in	O
CTNNB1	O
,	O
three	O
in	O
APC	O
,	O
and	O
two	O
in	O
hTRCP1	O
(	O
also	O
known	O
as	O
BTRC	O
)	O
which	O
controls	O
the	O
degradation	O
of	O
CTNNB1	O
.	O
Alterations	O
in	O
the	O
CTNNB1	O
regulatory	O
domain	O
,	O
APC	O
,	O
and	O
hTRCP1	O
were	O
mutually	O
exclusive	O
,	O
consistent	O
with	O
their	O
equivalent	O
effects	O
on	O
CTNNB1	O
stability	O
.	O
These	O
results	O
suggest	O
that	O
CTNNB1	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
a	O
significant	O
fraction	O
of	O
prostate	B-malignancy-type
cancers	I-malignancy-type
.	O
Moreover	O
,	O
they	O
provide	O
the	O
first	O
evidence	O
that	O
hTRCP1	O
plays	O
a	O
role	O
in	O
human	O
neoplasia	B-malignancy-type
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O
PMID	O
:	O
11921277	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Histopathology	O
2001	O
Dec	O
;	O
39	O
(	O
6	O
)	O
:	O
629-37	O
Secondary	O
malignant	B-malignancy-type
giant	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
bone	I-malignancy-type
:	O
molecular	O
abnormalities	O
of	O
p53	O
and	O
H-ras	O
gene	O
correlated	O
with	O
malignant	O
transformation	O
.	O
Oda	O
Y	O
,	O
Sakamoto	O
A	O
,	O
Saito	O
T	O
,	O
Matsuda	O
S	O
,	O
Tanaka	O
K	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M	O
.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
3-1-1	O
Maidashi	O
,	O
Higashi-ku	O
,	O
Fukuoka	O
812-8582	O
,	O
Japan	O
.	O
AIMS	O
:	O
We	O
report	O
two	O
cases	O
of	O
secondary	O
malignant	B-malignancy-type
giant	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
occurring	O
without	O
irradiation	O
therapy	O
.	O
To	O
elucidate	O
the	O
mechanism	O
of	O
malignant	O
transformation	O
in	O
this	B-malignancy-type
tumour	I-malignancy-type
,	O
we	O
searched	O
for	O
the	O
molecular	O
abnormalities	O
of	O
p53	O
,	O
MDM2	O
and	O
the	O
H-ras	O
genes	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
These	O
cases	O
were	O
retrieved	O
after	O
a	O
review	O
of	O
103	O
cases	O
of	O
primary	O
giant	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
bone	I-malignancy-type
,	O
registered	O
in	O
our	O
institute	O
.	O
One	O
case	O
occurred	O
in	O
the	O
distal	O
femur	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
female	O
after	O
surgical	O
curettage	O
,	O
while	O
the	O
other	O
arose	O
in	O
the	O
acetabulum	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
male	O
after	O
en	O
bloc	O
resection	O
.	O
Microscopically	O
,	O
the	O
malignant	B-malignancy-type
tumour	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
distal	I-malignancy-type
femur	I-malignancy-type
was	O
composed	O
of	O
a	O
proliferation	O
of	O
ovoid	O
or	O
fusiform	O
cells	O
arranged	O
in	O
fascicles	O
with	O
high	O
mitotic	O
activities	O
.	O
The	O
malignant	B-malignancy-type
transformed	I-malignancy-type
tumour	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
acetabulum	I-malignancy-type
was	O
made	O
up	O
of	O
pleomorphic	B-malignancy-type
tumour	I-malignancy-type
cells	I-malignancy-type
with	O
atypical	O
mitoses	O
.	O
In	O
the	O
tumour	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
distal	I-malignancy-type
femur	I-malignancy-type
,	O
both	O
p53	O
and	O
H-ras	O
mutations	O
were	O
detected	O
.	O
Abnormal	O
nuclear	O
accumulation	O
of	O
p53	O
protein	O
and	O
c-myc	O
expression	O
were	O
also	O
revealed	O
by	O
immunohistochemistry	O
.	O
In	O
both	O
cases	O
,	O
the	O
recurrent	O
malignant	B-malignancy-type
tumour	I-malignancy-type
over	O
-	O
expressed	O
MMP-9	O
and	O
revealed	O
a	O
higher	O
MIB-1	O
-	O
labelling	O
index	O
compared	O
with	O
the	O
primary	O
conventional	O
giant	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
multiple	O
oncogene	O
or	O
tumour	O
suppressor	O
gene	O
mutations	O
may	O
play	O
an	O
important	O
role	O
during	O
malignant	O
transformation	O
in	O
conventional	O
giant	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumours	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
of	O
Reported	O
Cases	O
PMID	O
:	O
11903582	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Sep	O
15	O
;	O
92	O
(	O
6	O
)	O
:	O
1525-30	O
Cigarette	O
smoking	O
is	O
strongly	O
associated	O
with	O
mutation	O
of	O
the	O
K-ras	O
gene	O
in	O
patients	O
with	O
primary	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
Ahrendt	O
SA	O
,	O
Decker	O
PA	O
,	O
Alawi	O
EA	O
,	O
Zhu	O
Yr	O
YR	O
,	O
Sanchez-Cespedes	O
M	O
,	O
Yang	O
SC	O
,	O
Haasler	O
GB	O
,	O
Kajdacsy-Balla	O
A	O
,	O
Demeure	O
MJ	O
,	O
Sidransky	O
D	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Rochester	O
,	O
Rochester	O
,	O
New	O
York	O
14642	O
,	O
USA	O
.	O
Steven_Ahrendt@urmc.rochester.edu	O
BACKGROUND	O
:	O
The	O
majority	O
of	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
cases	O
occur	O
in	O
current	O
or	O
former	O
smokers	O
.	O
K-ras	O
gene	O
mutations	O
are	O
common	O
in	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
have	O
been	O
associated	O
with	O
cigarette	O
smoking	O
,	O
asbestos	O
exposure	O
,	O
and	O
female	O
gender	O
.	O
METHODS	O
:	O
In	O
the	O
current	O
study	O
,	O
the	O
authors	O
examined	O
the	O
contribution	O
of	O
cigarette	O
smoking	O
to	O
K-ras	O
gene	O
mutations	O
in	O
patients	O
with	O
primary	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Smoking	O
histories	O
were	O
obtained	O
from	O
106	O
prospectively	O
enrolled	O
patients	O
with	O
primary	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
the	O
primary	O
tumor	B-malignancy-type
using	O
an	O
allele	O
-	O
specific	O
ligation	O
assay	O
.	O
Ninety-two	O
of	O
the	O
106	O
patients	O
(	O
87	O
%	O
)	O
with	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
smokers	O
.	O
Nonsmokers	O
with	O
this	B-malignancy-type
tumor	I-malignancy-type
were	O
more	O
likely	O
to	O
be	O
women	O
(	O
11	O
of	O
14	O
;	O
79	O
%	O
)	O
,	O
whereas	O
the	O
majority	O
of	O
smokers	O
(	O
57	O
%	O
)	O
were	O
men	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
40	O
of	O
106	O
tumors	B-malignancy-type
(	O
38	O
%	O
)	O
and	O
were	O
significantly	O
more	O
common	O
in	O
smokers	O
compared	O
with	O
nonsmokers	O
(	O
43	O
%	O
vs.	O
0	O
%	O
;	O
P	O
=	O
0.001	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
the	O
current	O
study	O
confirm	O
and	O
extend	O
previous	O
observations	O
that	O
smokers	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
are	O
more	O
likely	O
to	O
have	O
K-ras	O
mutant	O
tumors	B-malignancy-type
compared	O
with	O
nonsmokers	O
.	O
The	O
strong	O
link	O
between	O
cigarette	O
smoking	O
and	O
K-ras	O
mutations	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
supports	O
the	O
role	O
of	O
specific	O
tobacco	O
carcinogens	O
in	O
the	O
etiology	O
of	O
this	B-malignancy-type
malignancy	I-malignancy-type
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11745231	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Dermatol	O
2001	O
Oct	O
;	O
145	O
(	O
4	O
)	O
:	O
576-81	O
beta-catenin	O
expression	O
in	O
pilomatrixomas	B-malignancy-type
.	O
Relationship	O
with	O
beta-catenin	O
gene	O
mutations	O
and	O
comparison	O
with	O
beta-catenin	O
expression	O
in	O
normal	O
hair	O
follicles	O
.	O
Moreno-Bueno	O
G	O
,	O
Gamallo	O
C	O
,	O
Perez-Gallego	O
L	O
,	O
Contreras	O
F	O
,	O
Palacios	O
J	O
.	O
Programa	O
de	O
Patologia	O
Molecular	O
,	O
Centro	O
Nacional	O
de	O
Investigaciones	O
Oncologicas	O
Carlos	O
III	O
,	O
Instituto	O
de	O
Salud	O
Carlos	O
III	O
,	O
Ctra	O
Majadahonda-Pozuelo	O
Km	O
2	O
,	O
280220	O
Majadahonda	O
Madrid	O
,	O
Spain	O
.	O
BACKGROUND	O
:	O
beta-catenin	O
functions	O
in	O
signal	O
transduction	O
in	O
the	O
Wnt	O
signalling	O
pathway	O
,	O
which	O
has	O
recently	O
been	O
implicated	O
in	O
hair	O
follicle	O
(	O
HF	O
)	O
morphogenesis	O
.	O
beta-catenin	O
gene	O
mutations	O
affecting	O
exon	O
3	O
have	O
been	O
reported	O
in	O
a	O
high	O
percentage	O
of	O
human	O
pilomatrixomas	B-malignancy-type
.	O
However	O
,	O
the	O
expression	O
pattern	O
of	O
beta-catenin	O
in	O
human	O
HFs	O
and	O
pilomatrixomas	B-malignancy-type
has	O
not	O
been	O
reported	O
.	O
OBJECTIVES	O
:	O
To	O
analyse	O
immunohistochemically	O
the	O
expression	O
pattern	O
of	O
beta-catenin	O
in	O
normal	O
anagen	O
HFs	O
and	O
in	O
40	O
human	O
pilomatrixomas	B-malignancy-type
.	O
METHODS	O
:	O
In	O
11	O
of	O
these	O
tumours	O
we	O
also	O
studied	O
exon	O
3	O
beta-catenin	O
gene	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
As	O
these	O
mutations	O
have	O
been	O
related	O
to	O
a	O
replication	O
error	O
(	O
RER	O
)	O
phenotype	O
in	O
other	O
tumour	O
types	O
,	O
we	O
explored	O
whether	O
or	O
not	O
this	O
association	O
also	O
occurs	O
in	O
pilomatrixomas	B-malignancy-type
.	O
RESULTS	O
:	O
beta-catenin	O
was	O
expressed	O
in	O
the	O
cell	O
membranes	O
of	O
the	O
outer	O
and	O
inner	O
root	O
sheaths	O
and	O
in	O
matrix	O
cells	O
located	O
at	O
the	O
base	O
and	O
periphery	O
of	O
the	O
HF	O
bulb	O
.	O
However	O
,	O
central	O
matrix	O
cells	O
that	O
differentiate	O
into	O
cortical	O
cells	O
,	O
cortical	O
and	O
cuticular	O
cells	O
expressed	O
beta-catenin	O
in	O
the	O
nucleus	O
,	O
suggesting	O
a	O
role	O
in	O
signal	O
transduction	O
.	O
In	O
addition	O
,	O
some	O
fibroblasts	O
of	O
the	O
dermal	O
papilla	O
also	O
showed	O
nuclear	O
expression	O
of	O
beta-catenin	O
.	O
All	O
40	O
analysed	O
pilomatrixomas	B-malignancy-type
showed	O
intense	O
nuclear	O
and	O
cytoplasmic	O
beta-catenin	O
expression	O
in	O
proliferating	O
matrix	O
(	O
basaloid	O
)	O
cells	O
.	O
In	O
areas	O
of	O
maturation	O
,	O
transitional	O
cells	O
mainly	O
showed	O
cytoplasmic	O
and	O
membranous	O
expression	O
of	O
beta-catenin	O
,	O
while	O
only	O
a	O
few	O
cells	O
retained	O
nuclear	O
expression	O
.	O
Shadow	O
or	O
ghost	O
cells	O
did	O
not	O
show	O
beta-catenin	O
expression	O
.	O
Three	O
of	O
11	O
tumours	O
(	O
26	O
%	O
)	O
had	O
beta-catenin	O
mutations	O
.	O
All	O
three	O
had	O
the	O
same	O
heterozygote	O
mis	O
-	O
sense	O
mutation	O
:	O
a	O
G	O
to	O
T	O
change	O
affecting	O
the	O
first	O
nucleotide	O
at	O
codon	O
32	O
(	O
D	O
32	O
Y	O
)	O
.	O
None	O
of	O
the	O
11	O
tumours	O
studied	O
had	O
a	O
positive	O
RER	O
phenotype	O
.	O
CONCLUSIONS	O
:	O
Present	O
and	O
previous	O
studies	O
suggest	O
that	O
the	O
Wnt	O
/	O
beta-catenin	O
/	O
Tcf-Lef	O
pathway	O
is	O
activated	O
in	O
normal	O
matrix	O
cells	O
of	O
the	O
HF	O
to	O
induce	O
differentiation	O
to	O
the	O
hair	O
shaft	O
.	O
Additionally	O
,	O
the	O
beta-catenin	O
mutation	O
in	O
matrix	O
cells	O
of	O
the	O
HF	O
stabilizes	O
beta-catenin	O
protein	O
,	O
which	O
translocates	O
into	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
of	O
gene	O
transcription	O
together	O
with	O
lymphoid	O
enhancer	O
factor-1	O
producing	O
pilomatrixoma	B-malignancy-type
.	O
These	O
mutations	O
occur	O
without	O
an	O
underlying	O
defect	O
in	O
DNA	O
mismatch	O
repair	O
.	O
PMID	O
:	O
11703283	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncol	O
Rep	O
2001	O
Nov	O
-	O
Dec	O
;	O
8	O
(	O
6	O
)	O
:	O
1301-4	O
Fibroblast	O
growth	O
factor	O
receptor	O
3	O
S	O
249	O
C	O
mutation	O
in	O
virus	O
associated	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Shotelersuk	O
V	O
,	O
Ittiwut	O
C	O
,	O
Shotelersuk	O
K	O
,	O
Triratanachat	O
S	O
,	O
Poovorawan	O
Y	O
,	O
Mutirangura	O
A	O
.	O
Genetics	O
Unit	O
,	O
Department	O
of	O
Pediatrics	O
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
,	O
Bangkok	O
10330	O
,	O
Thailand	O
.	O
vorasuk.s@chula.ac.th	O
An	O
S	O
249	O
C	O
mutation	O
in	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
gene	O
was	O
recently	O
identified	O
in	O
patients	O
with	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
(	O
CC	B-malignancy-type
)	O
.	O
However	O
,	O
its	O
importance	O
in	O
cervical	O
tumorigenesis	O
is	O
still	O
inconclusive	O
.	O
Apart	O
from	O
CC	B-malignancy-type
,	O
nasopharyngeal	B-malignancy-type
carcinoma	I-malignancy-type
(	O
NPC	B-malignancy-type
)	O
is	O
the	O
other	O
major	O
virus	O
associated	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
sought	O
to	O
clarify	O
the	O
frequency	O
of	O
the	O
FGFR3	O
S	O
249	O
C	O
mutation	O
in	O
75	O
primary	O
CC	B-malignancy-type
in	O
the	O
Thai	O
population	O
and	O
to	O
determine	O
its	O
prevalence	O
in	O
69	O
primary	O
NPC	B-malignancy-type
by	O
PCR	O
and	O
restriction	O
enzyme	O
digestion	O
.	O
None	O
of	O
the	O
patients	O
but	O
one	O
NPC	B-malignancy-type
showed	O
the	O
enzyme	O
digestion	O
pattern	O
consistent	O
with	O
the	O
mutation	O
.	O
This	O
is	O
the	O
first	O
report	O
demonstrating	O
the	O
role	O
of	O
FGFR3	O
in	O
the	O
development	O
of	O
human	O
NPC	B-malignancy-type
.	O
This	O
study	O
confirms	O
the	O
low	O
frequency	O
of	O
the	O
FGFR3	O
S	O
249	O
C	O
mutation	O
in	O
CC	B-malignancy-type
.	O
Nevertheless	O
,	O
the	O
discovery	O
of	O
the	O
mutation	O
,	O
not	O
only	O
in	O
CC	B-malignancy-type
as	O
reported	O
by	O
previous	O
studies	O
,	O
but	O
in	O
NPC	B-malignancy-type
based	O
on	O
this	O
report	O
,	O
suggests	O
that	O
FGFR3	O
may	O
play	O
a	O
significant	O
role	O
in	O
human	O
CC	B-malignancy-type
and	O
NPC	B-malignancy-type
development	O
.	O
PMID	O
:	O
11605053	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Hepatol	O
2001	O
Aug	O
;	O
35	O
(	O
2	O
)	O
:	O
235-44	O
Microsatellite	O
instability	O
and	O
alternative	O
genetic	O
pathway	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
.	O
Momoi	O
H	O
,	O
Itoh	O
T	O
,	O
Nozaki	O
Y	O
,	O
Arima	O
Y	O
,	O
Okabe	O
H	O
,	O
Satoh	O
S	O
,	O
Toda	O
Y	O
,	O
Sakai	O
E	O
,	O
Nakagawara	O
K	O
,	O
Flemming	O
P	O
,	O
Yamamoto	O
M	O
,	O
Shimahara	O
Y	O
,	O
Yamaoka	O
Y	O
,	O
Fukumoto	O
M	O
.	O
Department	O
of	O
Gastroenterological	O
Surgery	O
,	O
Kyoto	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
Intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
(	O
ICC	B-malignancy-type
)	O
arises	O
from	O
intrahepatic	O
bile	O
duct	O
epithelium	O
and	O
is	O
the	O
second	O
most	O
prevalent	O
among	O
primary	O
liver	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
mechanism	O
of	O
cholangiocarcinogenesis	O
.	O
METHODS	O
:	O
We	O
studied	O
the	O
incidence	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
involving	O
eight	O
highly	O
polymorphic	O
microsatellite	O
markers	O
and	O
alternations	O
of	O
the	O
K-ras	O
,	O
p53	O
and	O
mdm-2	O
genes	O
in	O
human	O
ICC	B-malignancy-type
tissues	O
.	O
Overexpression	O
of	O
mdm-2	O
oncoprotein	O
was	O
also	O
immunohistochemically	O
studied	O
.	O
RESULTS	O
:	O
Of	O
all	O
65	O
cases	O
examined	O
,	O
K-ras	O
gene	O
mutation	O
was	O
found	O
in	O
three	O
cases	O
(	O
4.6	O
%	O
)	O
at	O
codon	O
12	O
.	O
Analysis	O
of	O
p53	O
alterations	O
was	O
performed	O
in	O
28	O
cases	O
including	O
22	O
frozen	O
samples	O
and	O
mutations	O
were	O
found	O
in	O
three	O
cases	O
(	O
10.7	O
%	O
)	O
.	O
Overexpression	O
of	O
mdm-2	O
protein	O
was	O
observed	O
in	O
25	O
(	O
41.7	O
%	O
)	O
out	O
of	O
60	O
cases	O
analyzed	O
.	O
In	O
22	O
frozen	O
samples	O
,	O
seven	O
(	O
31.8	O
%	O
)	O
cases	O
showed	O
mdm-2	O
amplification	O
and	O
four	O
(	O
18.2	O
%	O
)	O
cases	O
revealed	O
MSI	O
-	O
positive	O
phenotype	O
.	O
Among	O
the	O
cases	O
analyzed	O
,	O
all	O
the	O
tumors	O
with	O
mdm-2	O
amplification	O
/	O
overexpression	O
harbored	O
the	O
wild	O
-	O
type	O
p53	O
gene	O
and	O
all	O
the	O
microsatellite	O
instability	O
-	O
positive	O
cases	O
were	O
from	O
mass	O
-	O
forming	O
(	O
MF	O
)	O
+	O
periductal	O
-	O
infiltrating	O
(	O
PI	O
)	O
subtype	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
mdm-2	O
plays	O
a	O
role	O
,	O
which	O
might	O
be	O
partially	O
through	O
inhibiting	O
p53	O
activity	O
,	O
in	O
cholangiocarcinogenesis	O
and	O
that	O
M	O
PMID	O
:	O
11580146	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Mol	O
Med	O
2001	O
Oct;8	O
(	O
4	O
)	O
:453-	O
9	O
Molecular	O
analysis	O
of	O
p53	O
and	O
K-ras	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
of	O
coal	O
miners	O
.	O
Sarkar	O
FH	O
,	O
Li	O
Y	O
,	O
Vallyathan	O
V	O
.	O
Department	O
of	O
Pathology	O
,	O
Wayne	O
State	O
University	O
School	O
of	O
Medicine	O
,	O
540	O
E.	O
Canfield	O
Avenue	O
,	O
Detroit	O
,	O
MI	O
48201	O
,	O
USA	O
.	O
fsarkar@med.wayne.edu	O
Thirty-three	O
cases	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
from	O
the	O
archives	O
of	O
National	O
Coal	O
Workers	O
'	O
Autopsy	O
Study	O
were	O
studied	O
for	O
mutational	O
alterations	O
in	O
p53	O
and	O
K-ras	O
using	O
PCR	O
-	O
SSCP	O
,	O
DNA	O
sequencing	O
and	O
PCR	O
-	O
oligonucleotide	O
probe	O
hybridization	O
techniques	O
.	O
Mutations	O
of	O
the	O
p53	O
were	O
observed	O
in	O
4	O
smokers	O
(	O
19	O
%	O
)	O
and	O
one	O
in	O
a	O
never	O
smoker	O
(	O
8	O
%	O
)	O
.	O
Two	O
polymorphisms	O
in	O
smokers	O
were	O
detected	O
at	O
codon	O
213	O
,	O
a	O
common	O
site	O
for	O
sequence	O
variation	O
.	O
Among	O
the	O
smokers	O
the	O
p53	O
mutations	O
were	O
in	O
the	O
heavy	O
smokers	O
.	O
In	O
never	O
smokers	O
there	O
was	O
only	O
a	O
single	O
p53	O
mutation	O
and	O
two	O
K-ras	O
mutations	O
.	O
In	O
never	O
smokers	O
the	O
frequency	O
of	O
K-ras	O
mutations	O
was	O
similar	O
(	O
17	O
%	O
)	O
in	O
smokers	O
,	O
but	O
one	O
never	O
smoker	O
had	O
two	O
K-ras	O
mutations	O
.	O
Mutations	O
of	O
p53	O
were	O
more	O
frequent	O
in	O
adenocarcinomas	B-malignancy-type
(	O
27	O
%	O
)	O
and	O
they	O
were	O
AT	O
-->	O
GC	O
transitions	O
.	O
Four	O
of	O
11	O
(	O
36	O
%	O
)	O
adenocarcinomas	B-malignancy-type
were	O
found	O
to	O
have	O
K-ras	O
codon	O
12	O
mutations	O
,	O
and	O
one	O
adenocarcinoma	B-malignancy-type
had	O
two	O
K-ras	O
mutations	O
.	O
There	O
were	O
two	O
large	B-malignancy-type
cell	I-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
with	O
p53	O
mutation	O
and	O
one	O
with	O
a	O
K-ras	O
mutation	O
.	O
Two	O
of	O
the	O
16	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
positive	O
for	O
p53	O
mutation	O
,	O
while	O
no	O
K-ras	O
mutations	O
were	O
found	O
in	O
this	O
group	O
.	O
The	O
results	O
of	O
these	O
preliminary	O
studies	O
indicate	O
a	O
moderately	O
different	O
mutational	O
spectrum	O
of	O
p53	O
and	O
K-ras	O
in	O
coal	O
miners	O
independent	O
of	O
cigarette	O
smoking	O
.	O
The	O
mutational	O
spectrum	O
observed	O
in	O
this	O
study	O
of	O
coal	O
miners	O
with	O
heavy	O
cigarette	O
smoking	O
history	O
suggest	O
a	O
protective	O
effect	O
of	O
coal	O
mine	O
dust	O
in	O
preventing	O
abnormal	O
mutations	O
induced	O
by	O
chemical	O
carcinogens	O
in	O
cigarette	O
smoke	O
or	O
reactive	O
oxygen	O
species	O
.	O
These	O
limited	O
preliminary	O
studies	O
provide	O
insight	O
into	O
the	O
possibility	O
of	O
accurately	O
measuring	O
changes	O
in	O
etiologic	O
markers	O
to	O
unravel	O
the	O
uncertainties	O
of	O
cancer	O
in	O
coal	O
miners	O
.	O
PMID	O
:	O
11562787	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
2001	O
Sep	O
15	O
;	O
61	O
(	O
18	O
)	O
:	O
6679-81	O
Lung	B-malignancy-type
tumor	I-malignancy-type
KRAS	O
and	O
TP53	O
mutations	O
in	O
nonsmokers	O
reflect	O
exposure	O
to	O
PAH	O
-	O
rich	O
coal	O
combustion	O
emissions	O
.	O
DeMarini	O
DM	O
,	O
Landi	O
S	O
,	O
Tian	O
D	O
,	O
Hanley	O
NM	O
,	O
Li	O
X	O
,	O
Hu	O
F	O
,	O
Roop	O
BC	O
,	O
Mass	O
MJ	O
,	O
Keohavong	O
P	O
,	O
Gao	O
W	O
,	O
Olivier	O
M	O
,	O
Hainaut	O
P	O
,	O
Mumford	O
JL	O
.	O
Environmental	O
Carcinogenesis	O
Division	O
(	O
MD-68	O
)	O
,	O
United	O
States	O
Environmental	O
Protection	O
Agency	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27711	O
,	O
USA	O
.	O
demarini.david@epa.gov	O
We	O
determined	O
the	O
TP53	O
and	O
codon	O
12	O
KRAS	O
mutations	O
in	O
lung	B-malignancy-type
tumors	I-malignancy-type
from	O
24	O
nonsmokers	O
whose	O
tumors	O
were	O
associated	O
with	O
exposure	O
to	O
smoky	O
coal	O
.	O
Among	O
any	O
tumors	O
studied	O
previously	O
,	O
these	O
showed	O
the	O
highest	O
percentage	O
of	O
mutations	O
that	O
(a)	O
were	O
G	O
-->	O
T	O
transversions	O
at	O
either	O
KRAS	O
(	O
86	O
%	O
)	O
or	O
TP53	O
(	O
76	O
%	O
)	O
,	O
(b)	O
clustered	O
at	O
the	O
G	O
-	O
rich	O
codons	O
153	O
-	O
158	O
of	O
TP53	O
(	O
33	O
%	O
)	O
,	O
and	O
(c)	O
had	O
100	O
%	O
of	O
the	O
guanines	O
of	O
the	O
G	O
-->	O
T	O
transversions	O
on	O
the	O
nontranscribed	O
strand	O
.	O
This	O
mutation	O
spectrum	O
is	O
consistent	O
with	O
an	O
exposure	O
to	O
polycyclic	O
aromatic	O
hydrocarbons	O
,	O
which	O
are	O
the	O
primary	O
component	O
of	O
the	O
smoky	O
coal	O
emissions	O
.	O
These	O
results	O
show	O
that	O
mutations	O
in	O
the	O
TP53	O
and	O
KRAS	O
genes	O
can	O
reflect	O
a	O
specific	O
environmental	O
exposure	O
.	O
PMID	O
:	O
11559534	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2001	O
Jul	O
19	O
;	O
20	O
(	O
32	O
)	O
:	O
4416-8	O
Frequency	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
mutations	O
in	O
sporadic	O
tumours	O
.	O
Sibley	O
K	O
,	O
Stern	O
P	O
,	O
Knowles	O
MA	O
.	O
ICRF	O
Clinical	O
Centre	O
,	O
St.	O
James's	O
University	O
Hospital	O
,	O
Leeds	O
,	O
LS9	O
7TF	O
,	O
UK	O
.	O
Mutations	O
in	O
FGFR3	O
have	O
been	O
identified	O
in	O
several	O
tumour	O
types	O
including	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
,	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
In	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
recently	O
identified	O
FGFR3	O
mutations	O
in	O
41	O
%	O
of	O
tumours	O
,	O
making	O
this	O
the	O
most	O
frequently	O
mutated	O
putative	O
oncogene	O
identified	O
in	O
bladder	B-malignancy-type
cancer	I-malignancy-type
to	O
date	O
.	O
We	O
have	O
now	O
investigated	O
the	O
frequency	O
of	O
FGFR3	O
mutation	O
in	O
a	O
panel	O
of	O
125	O
tumours	O
and	O
13	O
cell	O
lines	O
from	O
various	O
other	O
organs	O
.	O
We	O
analysed	O
the	O
mutation	O
hotspots	O
in	O
exons	O
7	O
,	O
10	O
and	O
15	O
by	O
direct	O
DNA	O
sequencing	O
,	O
and	O
found	O
one	O
mutation	O
in	O
exon	O
7	O
(	O
S	O
249	O
C	O
)	O
in	O
1	O
/	O
28	O
(	O
3.5	O
%	O
)	O
cervical	B-malignancy-type
tumours	I-malignancy-type
.	O
Mutations	O
were	O
not	O
detected	O
in	O
stomach	B-malignancy-type
,	O
rectum	B-malignancy-type
,	O
colon	B-malignancy-type
,	O
prostate	B-malignancy-type
,	O
ovarian	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
brain	B-malignancy-type
,	O
or	O
renal	B-malignancy-type
tumours	I-malignancy-type
,	O
nor	O
were	O
they	O
found	O
in	O
any	O
of	O
the	O
cell	O
lines	O
included	O
in	O
this	O
study	O
.	O
We	O
conclude	O
that	O
FGFR3	O
is	O
commonly	O
mutated	O
in	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
and	O
only	O
rarely	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Several	O
tumour	O
types	O
appear	O
not	O
to	O
possess	O
any	O
mutations	O
in	O
FGFR3	O
,	O
suggesting	O
that	O
these	O
mutations	O
are	O
important	O
only	O
in	O
the	O
development	O
of	O
certain	O
types	O
of	O
tumour	O
.	O
PMID	O
:	O
11466624	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2001	O
Aug	O
10	O
;	O
169	O
(	O
1	O
)	O
:	O
59-68	O
Genetic	O
alterations	O
in	O
gallbladder	B-malignancy-type
adenoma	I-malignancy-type
,	O
dysplasia	B-malignancy-type
and	O
carcinoma	B-malignancy-type
.	O
Kim	O
YT	O
,	O
Kim	O
J	O
,	O
Jang	O
YH	O
,	O
Lee	O
WJ	O
,	O
Ryu	O
JK	O
,	O
Park	O
YK	O
,	O
Kim	O
SW	O
,	O
Kim	O
WH	O
,	O
Yoon	O
YB	O
,	O
Kim	O
CY	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
South	O
Korea	O
.	O
yongtkim@plaza.snu.ac.kr	O
Adenoma	B-malignancy-type
and	O
dysplasia	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
(	O
GB	O
)	O
have	O
been	O
reported	O
as	O
precancerous	O
lesions	O
,	O
but	O
the	O
genetic	O
evidence	O
of	O
this	O
is	O
not	O
clearly	O
defined	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
frequencies	O
of	O
K-ras	O
,	O
p53	O
,	O
and	O
p16	O
gene	O
mutations	O
,	O
of	O
microsatellite	O
instability	O
(	O
MI	O
)	O
and	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
GB	B-malignancy-type
cancer	I-malignancy-type
,	O
dysplasia	B-malignancy-type
,	O
and	O
adenoma	B-malignancy-type
.	O
Tissues	O
from	O
15	O
GB	B-malignancy-type
cancers	I-malignancy-type
,	O
five	O
dysplasias	B-malignancy-type
around	O
cancerous	O
tumors	O
,	O
and	O
three	O
adenomas	B-malignancy-type
were	O
collected	O
prospectively	O
.	O
The	O
mutation	O
rates	O
of	O
K-ras	O
,	O
p53	O
,	O
and	O
p16	O
were	O
20.0	O
,	O
35.7	O
,	O
and	O
30.7	O
%	O
,	O
respectively	O
,	O
in	O
GB	B-malignancy-type
cancers	I-malignancy-type
.	O
However	O
,	O
no	O
mutations	O
were	O
found	O
in	O
dysplasia	B-malignancy-type
or	O
adenoma	B-malignancy-type
.	O
Reduced	O
staining	O
for	O
p16	O
was	O
seen	O
in	O
23	O
%	O
of	O
carcinomas	B-malignancy-type
.	O
All	O
of	O
the	O
GB	B-malignancy-type
carcinomas	I-malignancy-type
and	O
four	O
out	O
of	O
five	O
(	O
80	O
%	O
)	O
of	O
the	O
dysplasias	B-malignancy-type
showed	O
LOH	O
in	O
a	O
minimum	O
of	O
one	O
locus	O
,	O
but	O
one	O
out	O
of	O
three	O
(	O
33	O
%	O
)	O
cases	O
of	O
adenoma	B-malignancy-type
displayed	O
LOH	O
in	O
only	O
one	O
locus	O
.	O
All	O
of	O
the	O
loci	O
of	O
LOH	O
in	O
the	O
dysplasias	B-malignancy-type
,	O
except	O
one	O
,	O
showed	O
the	O
same	O
patterns	O
of	O
allelic	O
loss	O
as	O
the	O
adjacent	O
carcinomas	B-malignancy-type
.	O
Only	O
one	O
dysplasia	B-malignancy-type
showed	O
multiple	O
MI	O
.	O
In	O
conclusion	O
,	O
multiple	O
LOH	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
dysplasia	B-malignancy-type
and	O
the	O
malignant	O
transformation	O
of	O
GB	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Gene	O
alterations	O
of	O
K-ras	O
,	O
p53	O
,	O
and	O
p16	O
are	O
important	O
steps	O
in	O
the	O
malignant	O
changes	O
of	O
dysplasia	B-malignancy-type
.	O
However	O
,	O
MI	O
seems	O
to	O
have	O
only	O
a	O
limited	O
role	O
in	O
GB	B-malignancy-type
cancer	I-malignancy-type
development	O
.	O
PMID	O
:	O
11410326	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Diagn	O
Mol	O
Pathol	O
2001	O
Jun;10(	O
2	O
)	O
:	O
116-22	O
beta-Catenin	O
expression	O
pattern	O
,	O
beta-catenin	O
gene	O
mutations	O
,	O
and	O
microsatellite	O
instability	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
and	O
synchronous	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Moreno-Bueno	O
G	O
,	O
Gamallo	O
C	O
,	O
Perez-Gallego	O
L,	O
de	O
Mora	O
JC	O
,	O
Suarez	O
A	O
,	O
Palacios	O
J.	O
Programa	O
de	O
Patologia	O
Molecular	O
,	O
Centro	O
Nacional	O
de	O
Investigaciones	O
Oncologicas	O
(	O
CNIO	O
)	O
,	O
Madrid	O
,	O
Spain	O
.	O
beta-Catenin	O
gene	O
mutations	O
and	O
microsatellite	O
instability	O
(	O
MI	O
)	O
have	O
been	O
reported	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
In	O
colon	B-malignancy-type
but	O
not	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
,	O
beta-catenin	O
gene	O
mutations	O
are	O
associated	O
with	O
a	O
replication	O
error	O
phenotype	O
and	O
MI	O
.	O
In	O
this	O
study	O
the	O
authors	O
investigate	O
whether	O
beta-catenin	O
mutations	O
and	O
MI	O
are	O
two	O
independent	O
oncogenic	O
pathways	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
They	O
also	O
evaluate	O
the	O
usefulness	O
of	O
these	O
molecular	O
markers	O
in	O
determining	O
the	O
primary	O
origin	O
of	O
simultaneous	O
tumors	O
in	O
the	O
ovary	O
and	O
endometrium	O
.	O
This	O
study	O
was	O
performed	O
on	O
26	O
patients	O
diagnosed	O
with	O
primary	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
,	O
five	O
of	O
whom	O
also	O
had	O
pathologically	O
diagnosed	O
primary	O
synchronous	O
endometrioid	B-malignancy-type
endometrial	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Immunohistochemical	O
and	O
molecular	O
analyses	O
indicated	O
that	O
there	O
were	O
25	O
primary	O
ovarian	B-malignancy-type
tumors	I-malignancy-type
with	O
four	O
primary	O
synchronous	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
and	O
one	O
ovarian	B-malignancy-type
metastasis	I-malignancy-type
of	O
a	O
primary	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
All	O
studies	O
were	O
performed	O
on	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
samples	O
.	O
The	O
beta-catenin	O
expression	O
pattern	O
(	O
nuclear	O
vs.	O
membranous	O
)	O
was	O
analyzed	O
immunohistochemically	O
.	O
Mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
were	O
studied	O
by	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
,	O
and	O
direct	O
sequencing	O
.	O
MI	O
status	O
was	O
established	O
by	O
studying	O
BAT-26	O
and	O
BAT-25	O
mononucleotide	O
repeats	O
.	O
In	O
the	O
group	O
with	O
21	O
single	O
ovarian	B-malignancy-type
tumors	I-malignancy-type
,	O
18	O
(	O
85	O
%	O
)	O
had	O
beta-catenin	O
nuclear	O
expression	O
,	O
eight	O
(	O
38	O
%	O
)	O
had	O
beta-catenin	O
gene	O
mutations	O
(	O
always	O
associated	O
with	O
beta-catenin	O
nuclear	O
expression	O
)	O
,	O
and	O
four	O
(	O
19	O
%	O
)	O
had	O
MI	O
.	O
Only	O
one	O
case	O
(	O
5	O
%	O
)	O
had	O
both	O
beta-catenin	O
gene	O
mutations	O
and	O
MI	O
.	O
The	O
mutations	O
affected	O
one	O
of	O
the	O
serine	O
/	O
threonine	O
residues	O
targeted	O
for	O
phosphorylation	O
by	O
glycogen	O
synthase	O
kinase-3beta	O
or	O
adjacent	O
residues	O
.	O
At	O
codon	O
32	O
,	O
a	O
GAC	O
-	O
to	O
-	O
TAC	O
(	O
D	O
32	O
Y	O
)	O
change	O
was	O
found	O
;	O
at	O
codon	O
33	O
,	O
two	O
TCT	O
-	O
to	O
-	O
TGT	O
(	O
S	O
33	O
C	O
)	O
changes	O
were	O
found	O
;	O
at	O
codon	O
37	O
,	O
three	O
TCT	O
-	O
to	O
-	O
TTT	O
(	O
S	O
37	O
F	O
)	O
changes	O
and	O
one	O
TCT	O
-	O
to	O
-	O
TGT	O
(	O
S	O
37	O
C	O
)	O
change	O
were	O
found	O
;	O
and	O
,	O
lastly	O
,	O
one	O
ACC	O
-	O
to	O
-	O
GCC	O
change	O
at	O
codon	O
41	O
(	O
T	O
41	O
A	O
)	O
was	O
detected	O
.	O
Four	O
of	O
the	O
25	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
(	O
16	O
%	O
)	O
had	O
an	O
associated	O
synchronous	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
There	O
was	O
a	O
higher	O
percentage	O
of	O
beta-catenin	O
mutations	O
(	O
n	O
=	O
3	O
,	O
75	O
%	O
)	O
in	O
synchronous	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
than	O
in	O
single	O
ones	O
,	O
although	O
with	O
a	O
similar	O
percentage	O
of	O
MI	O
(	O
n	O
=	O
1	O
,	O
25	O
%	O
)	O
.	O
beta-catenin	O
mutations	O
were	O
S	O
37	O
C	O
in	O
two	O
cases	O
and	O
D	O
32	O
G	O
in	O
one	O
.	O
One	O
of	O
the	O
four	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
an	O
S	O
33	O
C	O
beta-catenin	O
mutation	O
,	O
and	O
two	O
carcinomas	B-malignancy-type
had	O
MI	O
.	O
None	O
of	O
the	O
four	O
tumors	O
had	O
both	O
beta-catenin	O
gene	O
mutation	O
and	O
MI	O
.	O
beta-catenin	O
gene	O
mutations	O
were	O
always	O
associated	O
with	O
a	O
nuclear	O
beta-catenin	O
expression	O
pattern	O
,	O
whereas	O
MI	O
was	O
associated	O
with	O
a	O
membranous	O
pattern	O
.	O
In	O
one	O
patient	O
both	O
the	O
ovarian	B-malignancy-type
and	O
the	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
had	O
beta-catenin	O
gene	O
mutations	O
,	O
in	O
another	O
patient	O
both	O
tumors	O
showed	O
MI	O
,	O
whereas	O
in	O
the	O
remaining	O
two	O
patients	O
the	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
beta-catenin	O
gene	O
mutations	O
and	O
the	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
MI	O
.	O
To	O
summarize	O
,	O
the	O
results	O
of	O
this	O
study	O
suggest	O
that	O
beta-catenin	O
mutations	O
and	O
MI	O
could	O
represent	O
two	O
independent	O
pathways	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
because	O
they	O
occur	O
simultaneously	O
very	O
infrequently	O
(	O
in	O
5	O
%	O
of	O
these	O
cases	O
)	O
.	O
beta-catenin	O
mutations	O
are	O
always	O
associated	O
with	O
a	O
nuclear	O
beta-catenin	O
expression	O
pattern	O
,	O
whereas	O
cases	O
with	O
a	O
replication	O
error	O
-	O
plus	O
phenotype	O
showed	O
no	O
abnormal	O
beta-catenin	O
subcellular	O
localization	O
.	O
The	O
study	O
of	O
the	O
beta-catenin	O
expression	O
pattern	O
,	O
beta-catenin	O
mutations	O
,	O
and	O
MI	O
,	O
together	O
with	O
conventional	O
clinicopathologic	O
findings	O
,	O
could	O
aid	O
in	O
distinguishing	O
between	O
the	O
metastatic	O
or	O
independent	O
origin	O
of	O
simultaneous	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
and	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Tumors	O
with	O
identical	O
immunohistochemical	O
and	O
molecular	O
features	O
should	O
therefore	O
be	O
considered	O
to	O
have	O
a	O
common	O
origin	O
.	O
PMID	O
:	O
11385321	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
2002	O
Jun	O
28;180(	O
2	O
)	O
:153	O
-	O
8	O
Unique	O
K-ras	O
mutational	O
pattern	O
in	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
from	O
Taiwanese	O
patients	O
.	O
Wang	O
JY	O
,	O
Lian	O
ST	O
,	O
Chen	O
YF	O
,	O
Yang	O
YC	O
,	O
Chen	O
LT	O
,	O
Lee	O
KT	O
,	O
Huang	O
TJ	O
,	O
Lin	O
SR.	O
Department	O
of	O
Surgery	O
,	O
Kaohsiung	O
Medical	O
University	O
,	O
No	O
.	O
100	O
,	O
Shih	O
-Chuan	O
1st	O
Road	O
,	O
Kaohsiung	O
807	O
,	O
Taiwan	O
.	O
To	O
assess	O
the	O
prevalence	O
and	O
spectrum	O
of	O
K-ras	O
mutations	O
in	O
Taiwanese	O
patients	O
with	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
we	O
analyzed	O
20	O
patients	O
of	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
head	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
undergoing	O
pancreaticoduodenectomy	O
.	O
The	O
study	O
included	O
K-ras	O
mutations	O
that	O
were	O
detected	O
using	O
DNA	O
direct	O
sequencing	O
analysis	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products	O
and	O
confirmed	O
by	O
reverse	O
sequencing	O
primers	O
.	O
The	O
results	O
showed	O
that	O
K-ras	O
codon	O
12	O
mutation	O
was	O
detected	O
in	O
90	O
%	O
of	O
the	O
cancer	O
tissues	O
(	O
18	O
/	O
20	O
)	O
.	O
Moreover	O
,	O
the	O
results	O
from	O
direct	O
sequencing	O
indicated	O
that	O
missense	O
mutations	O
were	O
found	O
to	O
be	O
a	O
GGT	O
to	O
GTT	O
in	O
94.5	O
%	O
of	O
the	O
cases	O
(	O
17	O
/	O
18	O
)	O
and	O
a	O
GGT	O
to	O
TTT	O
in	O
5.5	O
%	O
of	O
the	O
cases	O
(	O
1	O
/	O
18	O
)	O
.	O
All	O
cases	O
with	O
K-ras	O
codon	O
12	O
mutations	O
were	O
found	O
to	O
be	O
G	O
to	O
T	O
transversion	O
.	O
However	O
,	O
no	O
alterations	O
were	O
found	O
at	O
codons	O
13	O
and	O
61	O
.	O
From	O
these	O
findings	O
,	O
the	O
high	O
prevalence	O
of	O
K-ras	O
codon	O
12	O
mutation	O
in	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
the	O
predominant	O
G	O
to	O
T	O
transversion	O
with	O
the	O
preferential	O
substitution	O
of	O
glycine	O
with	O
valine	O
might	O
indicate	O
an	O
unusual	O
sensitivity	O
and	O
specificity	O
of	O
this	O
codon	O
in	O
genetic	O
alterations	O
for	O
pancreatic	O
carcinogenesis	O
.	O
The	O
strikingly	O
high	O
mutational	O
rate	O
and	O
the	O
unique	O
mutational	O
spectrum	O
of	O
K-ras	O
codon	O
12	O
in	O
Taiwanese	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
can	O
provide	O
us	O
with	O
more	O
information	O
about	O
the	O
alternative	O
diagnostic	O
and	O
therapeutic	O
strategies	O
in	O
Taiwan	O
.	O
PMID	O
:	O
12175546	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
2001	O
Apr;44(	O
4	O
)	O
:	O
54	O
9-	O
57	O
Prognostic	O
value	O
of	O
K-ras	O
mutations	O
and	O
allelic	O
imbalance	O
on	O
chromosome	O
18q	O
in	O
patients	O
with	O
resected	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Font	O
A	O
,	O
Abad	O
A	O
,	O
Monzo	O
M,	O
Sanchez	O
JJ	O
,	O
Guillot	O
M,	O
Manzano	O
JL	O
,	O
Pinol	O
M,	O
Ojanguren	O
I	O
,	O
Rosell	O
R.	O
Laboratory	O
of	O
Molecular	O
Biology	O
of	O
Cancer	O
,	O
Hospital	O
Germans	O
Trias	O
i	O
Pujol	O
,	O
Badalona	O
,	O
Spain	O
.	O
PURPOSE	O
:	O
We	O
designed	O
this	O
study	O
to	O
assess	O
the	O
frequency	O
of	O
K-ras	O
mutations	O
in	O
patients	O
with	O
resected	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
and	O
their	O
association	O
with	O
survival	O
.	O
A	O
second	O
objective	O
was	O
to	O
analyze	O
the	O
prognostic	O
value	O
of	O
different	O
K-ras	O
genotypes	O
.	O
In	O
a	O
subgroup	O
of	O
patients	O
we	O
also	O
investigated	O
the	O
presence	O
of	O
allelic	O
imbalance	O
on	O
chromosome	O
18q	O
and	O
its	O
relationship	O
to	O
clinical	O
outcome	O
.	O
METHODS	O
:	O
One	O
hundred	O
fourteen	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
resected	O
between	O
1983	O
and	O
1986	O
were	O
analyzed	O
to	O
detect	O
K-ras	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
by	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
allele	O
specific	O
oligonucleotide	O
hybridization	O
.	O
A	O
subgroup	O
of	O
77	O
tumors	B-malignancy-type
was	O
further	O
screened	O
to	O
detect	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
18q	O
using	O
three	O
polymorphic	O
microsatellite	O
markers	O
(	O
D18S67	O
,	O
D18S474	O
and	O
D18S58	O
)	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
29	O
percent	O
(	O
33	O
/	O
114	O
)	O
of	O
patients	O
.	O
K-ras	O
mutations	O
correlated	O
with	O
age	O
and	O
preoperative	O
carcinoembryonic	O
antigen	O
levels	O
,	O
and	O
there	O
was	O
some	O
indication	O
that	O
they	O
may	O
be	O
linked	O
to	O
poor	O
survival	O
,	O
especially	O
in	O
Stage	O
II	O
tumors	O
,	O
where	O
a	O
subgroup	O
of	O
patients	O
with	O
aspartic	O
and	O
serine	O
mutations	O
showed	O
significantly	O
reduced	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
compared	O
with	O
K-ras	O
-	O
negative	O
patients	O
.	O
18q	O
loss	O
of	O
heterozygosity	O
was	O
present	O
in	O
39	O
percent	O
(	O
25	O
/	O
63	O
)	O
of	O
tumors	B-malignancy-type
.	O
A	O
multivariate	O
analysis	O
of	O
Stage	O
II	O
tumors	O
showed	O
that	O
18q	O
loss	O
of	O
heterozygosity	O
was	O
significantly	O
associated	O
with	O
a	O
worse	O
prognosis	O
(	O
P	O
=	O
0.006	O
)	O
.	O
A	O
significant	O
decrease	O
in	O
survival	O
was	O
identified	O
in	O
ten	O
patients	O
harboring	O
both	O
genetic	O
alterations	O
(	O
K-i	O
mutations	O
and	O
18q	O
loss	O
of	O
heterozygosity	O
;	O
P	O
=	O
0.02	O
)	O
.	O
CONCLUSIONS	O
:	O
In	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
,	O
K-ras	O
mutations	O
and	O
18q	O
loss	O
of	O
heterozygosity	O
are	O
two	O
genetic	O
markers	O
which	O
may	O
identify	O
patients	O
with	O
more	O
aggressive	O
behavior	O
,	O
mainly	O
in	O
Stage	O
II	O
tumors	O
.	O
These	O
findings	O
warrant	O
further	O
research	O
,	O
because	O
they	O
can	O
be	O
useful	O
in	O
customizing	O
adjuvant	O
chemotherapy	O
.	O
PMID	O
:	O
11330582	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2001	O
Apr;158	O
(	O
4	O
)	O
:1517-24	O
Inverse	O
relationship	O
between	O
microsatellite	O
instability	O
and	O
K-ras	O
and	O
p53	O
gene	O
alterations	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Samowitz	O
WS	O
,	O
Holden	O
JA	O
,	O
Curtin	O
K,	O
Edwards	O
SL	O
,	O
Walker	O
AR	O
,	O
Lin	O
HA	O
,	O
Robertson	O
MA	O
,	O
Nichols	O
MF	O
,	O
Gruenthal	O
KM	O
,	O
Lynch	O
BJ	O
,	O
Leppert	O
MF	O
,	O
Slattery	O
ML	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Utah	O
Health	O
Sciences	O
Center	O
,	O
50	O
North	O
Medical	O
Dr.	O
,	O
Salt	O
Lake	O
City	O
,	O
UT	O
84132	O
,	O
USA	O
.	O
wsamowitz@msscc.med	O
.utah	O
.edu	O
Some	O
studies	O
have	O
shown	O
an	O
inverse	O
relationship	O
between	O
microsatellite	O
instability	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
and	O
mutations	O
in	O
p53	O
and	O
K-ras	O
,	O
whereas	O
others	O
have	O
not	O
.	O
We	O
therefore	O
evaluated	O
these	O
features	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
496	O
individuals	O
with	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Microsatellite	O
instability	O
was	O
determined	O
by	O
a	O
panel	O
of	O
10	O
tetranucleotide	O
repeats	O
,	O
the	O
Bethesda	O
consensus	O
panel	O
of	O
mono	O
-	O
and	O
di	O
nucleotide	O
repeats	O
,	O
and	O
coding	O
mononucleotide	O
repeats	O
in	O
transforming	O
growth	O
factor	O
-	O
beta	O
receptor	O
type	O
II	O
,	O
hMSH3	O
,	O
BAX	O
,	O
hMSH6	O
,	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
receptor	O
type	O
II	O
.	O
Mutations	O
in	O
codons	O
12	O
and	O
13	O
in	O
K-ras	O
were	O
evaluated	O
by	O
sequencing	O
.	O
p53	O
overexpression	O
(	O
as	O
detected	O
by	O
immunohistochemistry	O
)	O
was	O
used	O
as	O
an	O
indicator	O
of	O
p53	O
mutation	O
;	O
this	O
was	O
evaluated	O
in	O
275	O
of	O
the	B-malignancy-type
tumors	I-malignancy-type
.	O
K-ras	O
mutations	O
were	O
present	O
in	O
33.2	O
%	O
of	O
tumors	B-malignancy-type
,	O
p53	O
overexpression	O
in	O
51.5	O
%	O
,	O
and	O
microsatellite	O
instability	O
(	O
as	O
determined	O
by	O
the	O
Bethesda	O
consensus	O
panel	O
)	O
in	O
12.5	O
%	O
.	O
K-ras	O
mutations	O
were	O
significantly	O
less	O
common	O
in	O
unstable	O
tumors	B-malignancy-type
than	O
stable	O
tumors	B-malignancy-type
(	O
11.8	O
%	O
versus	O
36.9	O
%	O
,	O
P	O
:	O
<	O
0.001	O
)	O
.	O
p53	O
overexpression	O
was	O
significantly	O
less	O
common	O
in	O
unstable	O
tumors	B-malignancy-type
than	O
stable	O
tumors	B-malignancy-type
(	O
20.0	O
%	O
versus	O
55.7	O
%	O
,	O
P	O
:	O
<	O
0.001	O
)	O
.	O
These	O
inverse	O
relationships	O
between	O
microsatellite	O
instability	O
and	O
ras	O
gene	O
mutations	O
and	O
p53	O
overexpression	O
were	O
shown	O
to	O
be	O
independent	O
of	O
tumor	B-malignancy-type
site	O
in	O
logistic	O
regression	O
analyses	O
.	O
All	O
other	O
measures	O
of	O
instability	O
also	O
showed	O
statistically	O
significant	O
inverse	O
relationships	O
independent	O
of	O
tumor	B-malignancy-type
site	O
with	O
alterations	O
in	O
ras	O
and	O
p53	O
,	O
and	O
instability	O
results	O
determined	O
by	O
the	O
panel	O
of	O
10	O
tetranucleotide	O
repeats	O
were	O
highly	O
significantly	O
related	O
to	O
those	O
determined	O
by	O
the	O
Bethesda	O
consensus	O
panel	O
.	O
Coding	O
mononucleotide	O
repeat	O
mutations	O
were	O
significantly	O
more	O
common	O
in	O
unstable	O
tumors	B-malignancy-type
than	O
stable	O
tumors	B-malignancy-type
(	O
85.7	O
%	O
versus	O
1.0	O
%	O
,	O
P	O
:	O
<	O
0.001	O
)	O
.	O
We	O
conclude	O
that	O
there	O
is	O
an	O
inverse	O
relationship	O
between	O
microsatellite	O
instability	O
and	O
mutations	O
in	O
p53	O
and	O
K-ras	O
,	O
and	O
that	O
the	O
molecular	O
profile	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
with	O
microsatellite	O
instability	O
is	O
characterized	O
by	O
relatively	O
infrequent	O
mutations	O
in	O
K-ras	O
and	O
p53	O
and	O
relatively	O
frequent	O
mutations	O
in	O
coding	O
mononucleotide	O
repeats	O
.	O
PMID	O
:	O
11290569	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Jan;25(	O
1	O
)	O
:	O
26-42	O
Colloid	B-malignancy-type
(	I-malignancy-type
mucinous	I-malignancy-type
noncystic	I-malignancy-type
)	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Adsay	O
NV	O
,	O
Pierson	O
C	O
,	O
Sarkar	O
F	O
,	O
Abrams	O
J,	O
Weaver	O
D	O
,	O
Conlon	O
KC	O
,	O
Brennan	O
MF	O
,	O
Klimstra	O
DS	O
.	O
Department	O
of	O
Pathology	O
,	O
Karmanos	O
Cancer	O
Institute	O
,	O
Harper	O
Hospital	O
,	O
Wayne	O
State	O
University	O
School	O
of	O
Medicine	O
,	O
Detroit	O
,	O
Michigan	O
48201	O
,	O
USA	O
.	O
adsayv@med	O
.wayne	O
.edu	O
In	O
the	O
past	O
,	O
colloid	B-malignancy-type
(	I-malignancy-type
mucinous	I-malignancy-type
noncystic	I-malignancy-type
)	I-malignancy-type
carcinoma	I-malignancy-type
(	O
CC	B-malignancy-type
)	O
of	B-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
had	O
been	O
included	O
under	O
the	O
category	O
of	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
a	O
tumor	O
with	O
a	O
dismal	O
prognosis	O
,	O
or	O
was	O
frequently	O
misdiagnosed	O
as	O
mucinous	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
.	O
The	O
clinicopathologic	O
features	O
of	O
CC	B-malignancy-type
have	O
not	O
yet	O
been	O
well	O
characterized	O
,	O
because	O
most	O
cases	O
on	O
record	O
have	O
been	O
parts	O
of	O
studies	O
on	O
either	O
mucinous	B-malignancy-type
cystic	I-malignancy-type
neoplasms	I-malignancy-type
(	O
MCN	B-malignancy-type
)	O
or	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
neoplasms	I-malignancy-type
(	O
IPMN	B-malignancy-type
)	O
,	O
with	O
which	O
colloid	B-malignancy-type
carcinomas	I-malignancy-type
are	O
frequently	O
associated	O
.	O
To	O
determine	O
the	O
clinicopathologic	O
characteristics	O
of	O
CC	B-malignancy-type
,	O
17	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
composed	O
predominantly	O
(	O
>	O
80	O
%	O
)	O
of	O
CC	B-malignancy-type
(	O
defined	O
as	O
nodular	O
extracellular	O
mucin	O
lakes	O
with	O
scanty	O
malignant	B-malignancy-type
epithelial	I-malignancy-type
cells	I-malignancy-type
)	O
and	O
in	O
which	O
the	O
invasive	O
carcinoma	B-malignancy-type
measured	O
larger	O
than	O
1	O
cm	O
were	O
studied	O
.	O
Ten	O
of	O
these	O
were	O
originally	O
classified	O
as	O
mucinous	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
four	O
as	O
mucinous	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
.	O
The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
61	O
years	O
;	O
9	O
were	O
men	O
and	O
8	O
were	O
women	O
.	O
The	O
mean	O
size	O
of	O
the	O
CC	B-malignancy-type
was	O
5.3	O
cm	O
(	O
range	O
,	O
1.2	O
-	O
16	O
cm	O
)	O
.	O
In	O
more	O
than	O
half	O
of	O
the	O
patients	O
,	O
CC	B-malignancy-type
represented	O
the	O
invasive	O
component	O
of	O
an	O
IPMN	B-malignancy-type
(	O
in	O
nine	O
cases	O
)	O
or	O
MCN	B-malignancy-type
(	O
in	O
one	O
case	O
)	O
.	O
The	O
tumors	O
were	O
composed	O
of	O
well	O
-	O
defined	O
pools	O
of	O
mucin	O
with	O
sparse	O
malignant	O
cells	O
in	O
various	O
patterns	O
of	O
distribution	O
.	O
Signet	B-malignancy-type
-	I-malignancy-type
ring	I-malignancy-type
cells	I-malignancy-type
floating	O
in	O
the	O
mucin	O
(	O
but	O
not	O
as	O
individual	O
cells	O
infiltrating	O
stroma	O
,	O
a	O
characteristic	O
finding	O
of	O
signet	B-malignancy-type
-	I-malignancy-type
ring	I-malignancy-type
cell	I-malignancy-type
adenocarcinomas	I-malignancy-type
)	O
were	O
commonly	O
identified	O
and	O
were	O
prominent	O
in	O
five	O
cases	O
.	O
Perineurial	O
invasion	O
was	O
noted	O
in	O
six	O
cases	O
and	O
regional	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
in	O
eight	O
.	O
Mutation	O
in	O
codon	O
12	O
of	O
the	O
k-ras	O
gene	O
was	O
detected	O
in	O
only	O
4	O
of	O
12	O
cases	O
studied	O
and	O
p53	O
mutation	O
in	O
2	O
of	O
9	O
.	O
Immunohistochemical	O
and	O
histochemical	O
mucin	O
stains	O
suggested	O
luminalization	O
of	O
the	O
basal	O
aspects	O
of	O
the	O
cells	O
.	O
Five	O
-	O
year	O
survival	O
was	O
57	O
%	O
.	O
At	O
an	O
overall	O
mean	O
follow	O
up	O
of	O
57	O
months	O
,	O
10	O
patients	O
were	O
alive	O
with	O
no	O
evidence	O
of	O
disease	O
(	O
median	O
,	O
79	O
mos	O
)	O
,	O
including	O
four	O
with	O
lymph	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
,	O
three	O
others	O
with	O
perineurial	O
invasion	O
,	O
and	O
another	O
with	O
vascular	O
invasion	O
.	O
Four	O
patients	O
died	O
of	O
disease	O
(	O
18	O
,	O
18	O
,	O
25	O
,	O
and	O
26	O
mos	O
)	O
,	O
and	O
three	O
died	O
of	O
thromboembolism	O
(	O
with	O
persistent	O
disease	O
)	O
at	O
2	O
,	O
5	O
,	O
10	O
months	O
.	O
All	O
seven	O
patients	O
who	O
died	O
with	O
or	O
of	O
tumor	B-malignancy-type
had	O
undergone	O
incisional	O
biopsy	O
of	O
the	B-malignancy-type
tumor	I-malignancy-type
either	O
before	O
the	O
operation	O
or	O
intraoperatively	O
,	O
whereas	O
none	O
of	O
the	O
patients	O
who	O
were	O
alive	O
had	O
incisional	O
biopsy	O
.	O
When	O
compared	O
with	O
82	O
cases	O
of	O
resectable	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
on	O
whom	O
follow-up	O
and	O
staging	O
information	O
was	O
complete	O
,	O
it	O
was	O
found	O
that	O
the	O
patients	O
with	O
CC	B-malignancy-type
present	O
with	O
larger	O
tumors	B-malignancy-type
(	O
p	O
=	O
0.03	O
)	O
but	O
lower	O
stage	O
(	O
p	O
=	O
0.01	O
)	O
.	O
The	O
prognosis	O
of	O
CC	B-malignancy-type
is	O
significantly	O
better	O
:	O
2	O
-	O
year	O
and	O
5	O
-	O
year	O
survival	O
are	O
70	O
%	O
versus	O
28	O
%	O
and	O
57	O
%	O
versus	O
12	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.001	O
)	O
.	O
In	O
conclusion	O
,	O
pancreatic	B-malignancy-type
CC	I-malignancy-type
may	O
occur	O
with	O
or	O
without	O
an	O
identifiable	O
IPMN	B-malignancy-type
and	O
MCN	B-malignancy-type
component	O
,	O
and	O
should	O
be	O
distinguished	O
from	O
mucinous	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
,	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
and	O
signet	B-malignancy-type
-	I-malignancy-type
ring	I-malignancy-type
cell	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
CC	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
is	O
associated	O
with	O
a	O
significantly	O
better	O
prognosis	O
than	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
In	O
addition	O
to	O
its	O
distinctive	O
morphologic	O
and	O
clinical	O
characteristics	O
,	O
CC	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
also	O
appears	O
to	O
have	O
a	O
low	O
incidence	O
of	O
mutation	O
in	O
codon	O
12	O
of	O
the	O
k-ras	O
gene	O
.	O
In	O
cases	O
with	O
a	O
clinical	O
suspicion	O
of	O
colloid	B-malignancy-type
carcinoma	I-malignancy-type
,	O
the	O
possibility	O
that	O
an	O
incisional	O
biopsy	O
may	O
contribute	O
to	O
thromboembolic	O
complications	O
or	O
even	O
dissemination	O
of	O
the	B-malignancy-type
tumor	I-malignancy-type
may	O
need	O
to	O
be	O
considered	O
.	O
The	O
luminalization	O
of	O
the	O
basal	O
aspects	O
of	O
the	B-malignancy-type
tumor	I-malignancy-type
cells	O
may	O
be	O
the	O
cause	O
of	O
stromal	O
mucin	O
accumulation	O
that	O
characterizes	O
colloid	B-malignancy-type
carcinoma	I-malignancy-type
and	O
may	O
act	O
as	O
a	O
containing	O
factor	O
.	O
PMID	O
:	O
11145249	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2001	O
Jan	O
-	O
Feb	O
;	O
8	O
(	O
1	O
)	O
:	O
89	O
-	O
92	O
Characterization	O
of	O
the	O
mutations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
p16	O
,	O
and	O
SMAD4	O
genes	O
in	O
15	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Sun	O
C	O
,	O
Yamato	O
T	O
,	O
Furukawa	O
T	O
,	O
Ohnishi	O
Y	O
,	O
Kijima	O
H	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Aoba-ku	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
Human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
one	O
of	O
the	O
most	O
malignant	O
diseases	O
in	O
the	O
world	O
.	O
In	O
order	O
to	O
save	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
it	O
is	O
necessary	O
to	O
develop	O
novel	O
methods	O
for	O
treatment	O
.	O
For	O
such	O
a	O
purpose	O
,	O
a	O
series	O
of	O
well	O
-	O
characterized	O
cancer	O
cell	O
lines	O
are	O
of	O
great	O
help	O
for	O
in	O
vitro	O
studies	O
that	O
are	O
generally	O
the	O
first	O
step	O
in	O
approaching	O
the	O
invention	O
of	O
novel	O
methods	O
for	O
treatment	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
15	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
for	O
genetic	O
alterations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
p16	O
,	O
and	O
SMAD4	O
genes	O
,	O
which	O
are	O
very	O
frequent	O
targets	O
for	O
mutation	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
;	O
these	O
cell	O
lines	O
are	O
useful	O
resources	O
in	O
cancer	O
research	O
.	O
PMID	O
:	O
11115575	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Hematol	O
2000	O
Dec	O
;	O
65	O
(	O
4	O
)	O
:	O
307-9	O
Mast	B-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
associated	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
:	O
detection	O
of	O
a	O
new	O
c-kit	O
mutation	O
Asp	O
816	O
His	O
.	O
Pullarkat	O
VA	O
,	O
Pullarkat	O
ST	O
,	O
Calverley	O
DC	O
,	O
Brynes	O
RK	O
.	O
Division	O
of	O
Hematology	O
,	O
University	O
of	O
Southern	O
California	O
School	O
of	O
Medicine	O
,	O
Los	O
Angeles	O
,	O
California	O
90033-	O
0804	O
,	O
USA	O
.	O
vinodpullarkat@pol.net	O
Mast	B-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
(	O
MCD	B-malignancy-type
)	O
,	O
a	O
proliferation	O
of	O
mast	O
cells	O
(	O
MC	O
)	O
,	O
is	O
occasionally	O
associated	O
with	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
Neoplastic	O
MC	B-malignancy-type
have	O
activating	O
c-kit	O
mutations	O
.	O
c-kit	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
required	O
for	O
the	O
development	O
,	O
proliferation	O
,	O
and	O
survival	O
of	O
MC	O
.	O
Interaction	O
of	O
c-kit	O
with	O
its	O
ligand	O
stem	O
cell	O
factor	O
induces	O
dimerization	O
,	O
receptor	O
phosphorylation	O
,	O
and	O
signal	O
transduction	O
.	O
The	O
most	O
common	O
c-kit	O
mutation	O
detected	O
in	O
neoplastic	O
MCD	B-malignancy-type
is	O
Asp	O
816	O
Val	O
,	O
which	O
results	O
in	O
ligand	O
-	O
independent	O
autophosphorylation	O
of	O
the	O
receptor	O
leading	O
to	O
MC	O
proliferation	O
.	O
We	O
describe	O
the	O
rare	O
occurrence	O
of	O
MCD	B-malignancy-type
associated	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
report	O
a	O
novel	O
c-kit	O
mutation	O
Asp	O
816	O
His	O
,	O
and	O
discuss	O
the	O
pathogenesis	O
of	O
MCD	B-malignancy-type
associated	O
with	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11074560	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Oct	O
;	O
9	O
(	O
10	O
)	O
:	O
1027-35	O
Molecular	O
changes	O
in	O
second	B-malignancy-type
primary	I-malignancy-type
lung	I-malignancy-type
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
after	O
therapy	O
for	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
.	O
Behrens	O
C	O
,	O
Travis	O
LB	O
,	O
Wistuba	O
II	O
,	O
Davis	O
S	O
,	O
Maitra	O
A	O
,	O
Clarke	O
EA	O
,	O
Lynch	O
CF	O
,	O
Glimelius	O
B	O
,	O
Wiklund	O
T	O
,	O
Tarone	O
R	O
,	O
Gazdar	O
AF	O
.	O
Hamon	O
Center	O
for	O
Therapeutic	O
Oncology	O
Research	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75390-8593	O
,	O
USA	O
.	O
The	O
risk	O
of	O
lung	B-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
is	O
significantly	O
increased	O
after	O
therapy	O
for	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
(	O
HD	B-malignancy-type
)	O
,	O
but	O
there	O
are	O
few	O
data	O
that	O
describe	O
the	O
molecular	O
profiles	O
of	O
these	O
tumors	O
.	O
We	O
investigated	O
the	O
genetic	O
abnormalities	O
in	O
second	O
primary	O
lung	B-malignancy-type
(	O
n	O
=	O
19	O
)	O
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
(	O
n	O
=	O
19	O
)	O
that	O
follow	O
therapy	O
for	O
HD	B-malignancy-type
(	O
"	O
post	B-malignancy-type
-	I-malignancy-type
HD	I-malignancy-type
cancers	I-malignancy-type
"	O
)	O
and	O
compared	O
these	O
with	O
changes	O
observed	O
in	O
corresponding	O
tumor	O
types	O
(	O
57	O
lung	B-malignancy-type
and	O
20	O
breast	B-malignancy-type
cancers	I-malignancy-type
)	O
arising	O
in	O
the	O
general	O
population	O
(	O
"	O
sporadic	O
cancers	O
"	O
)	O
.	O
DNA	O
obtained	O
from	O
archival	O
tissues	O
was	O
examined	O
using	O
PCR	O
-	O
based	O
analyses	O
for	O
loss	O
of	O
heterozygosity	O
and	O
microsatellite	O
alterations	O
(	O
MAs	O
)	O
at	O
several	O
chromosomal	O
regions	O
,	O
TP53	O
and	O
K-ras	O
gene	O
mutations	O
,	O
and	O
frameshift	O
mutations	O
at	O
minisatellite	O
sequences	O
at	O
the	O
coding	O
regions	O
of	O
several	O
genes	O
(	O
TGF-betaRII	O
,	O
IGFIIR	O
,	O
BAX	O
,	O
hMSH6	O
,	O
and	O
hMSH3	O
)	O
.	O
The	O
occurrence	O
of	O
loss	O
of	O
heterozygosity	O
at	O
all	O
chromosomal	O
regions	O
taken	O
together	O
and	O
frequencies	O
at	O
most	O
individual	O
areas	O
were	O
similar	O
for	O
the	O
post	O
-	O
HD	O
and	O
sporadic	O
cancers	O
for	O
both	O
lung	B-malignancy-type
and	O
breast	B-malignancy-type
sites	O
.	O
The	O
overall	O
frequency	O
of	O
MAs	O
in	O
the	O
post	B-malignancy-type
-	I-malignancy-type
HD	I-malignancy-type
tumors	I-malignancy-type
was	O
substantially	O
greater	O
(	O
lung	O
,	O
2.4	O
-	O
fold	O
,	O
P	O
=	O
0.004	O
;	O
breast	O
,	O
4.2	O
-	O
fold	O
,	O
P	O
=	O
0.16	O
)	O
than	O
that	O
in	O
the	O
respective	O
sporadic	O
cancers	O
.	O
No	O
differences	O
in	O
the	O
pattern	O
of	O
TP53	O
and	O
K-ras	O
mutations	O
were	O
detected	O
between	O
post	O
-	O
HD	O
and	O
sporadic	O
cancers	O
.	O
No	O
mutations	O
were	O
detected	O
at	O
the	O
minisatellite	O
sequences	O
examined	O
.	O
MAs	O
,	O
which	O
reflect	O
widespread	O
genomic	O
instability	O
,	O
occur	O
at	O
greatly	O
increased	O
frequency	O
in	O
post	O
-	O
HD	O
lung	B-malignancy-type
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
.	O
Although	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
increased	O
MAs	O
are	O
unknown	O
,	O
they	O
have	O
been	O
associated	O
with	O
immunosuppression	O
and	O
radiation	O
exposure	O
.	O
Future	O
research	O
should	O
address	O
the	O
role	O
that	O
MAs	O
,	O
as	O
well	O
as	O
other	O
influences	O
,	O
may	O
play	O
in	O
the	O
development	O
of	O
neoplasias	O
that	O
occur	O
after	O
therapy	O
for	O
HD	B-malignancy-type
.	O
PMID	O
:	O
11045784	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Pathol	O
2000	O
Aug	O
;	O
53	O
(	O
4	O
)	O
:	O
188	O
-	O
93	O
Detection	O
of	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
in	O
microdissected	O
bone	O
marrow	O
infiltrates	O
in	O
a	O
case	O
of	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
associated	O
with	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukaemia	I-malignancy-type
.	O
Sotlar	O
K	O
,	O
Marafioti	O
T	O
,	O
Griesser	O
H	O
,	O
Theil	O
J	O
,	O
Aepinus	O
C	O
,	O
Jaussi	O
R	O
,	O
Stein	O
H	O
,	O
Valent	O
P	O
,	O
Horny	O
HP	O
.	O
Institute	O
of	O
Pathology	O
,	O
University	O
Hospital	O
Tubingen	O
,	O
Germany	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
The	O
occurrence	O
of	O
myeloid	B-malignancy-type
leukaemia	I-malignancy-type
in	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
is	O
a	O
well	O
recognised	O
phenomenon	O
.	O
However	O
,	O
the	O
pathophysiological	O
basis	O
of	O
such	O
a	O
coevolution	O
has	O
not	O
been	O
clarified	O
.	O
Recent	O
data	O
have	O
shown	O
that	O
the	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
is	O
detectable	O
in	O
neoplastic	O
mast	O
cells	O
in	O
most	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
including	O
those	O
who	O
have	O
associated	O
haematological	O
disorders	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
study	O
clonal	O
disease	O
evolution	O
by	O
analysing	O
bone	O
marrow	O
cells	O
from	O
a	O
patient	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
associated	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukaemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
for	O
the	O
presence	O
of	O
this	O
mutation	O
.	O
METHODS	O
:	O
The	O
DNA	O
of	O
microdissected	O
bone	O
marrow	O
cells	O
from	O
a	O
patient	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
associated	O
CMML	B-malignancy-type
was	O
analysed	O
for	O
the	O
presence	O
of	O
the	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
by	O
means	O
of	O
HinfI	O
digestion	O
and	O
direct	O
sequencing	O
of	O
semi	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O
RESULTS	O
:	O
The	O
two	O
neoplasms	O
could	O
easily	O
be	O
identified	O
and	O
discriminated	O
in	O
paraffin	O
wax	O
embedded	O
bone	O
marrow	O
sections	O
by	O
tryptase	O
and	O
chloroacetate	O
esterase	O
staining	O
.	O
A	O
total	O
number	O
of	O
10	O
tryptase	O
positive	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
infiltrates	O
and	O
10	O
tryptase	O
negative	O
CMML	B-malignancy-type
infiltrates	O
were	O
removed	O
by	O
microdissection	O
.	O
As	O
assessed	O
by	O
HinfI	O
digestion	O
and	O
direct	O
sequencing	O
of	O
semi	O
-	O
nested	O
PCR	O
products	O
,	O
the	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
was	O
detected	O
in	O
five	O
of	O
seven	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
infiltrates	O
and	O
four	O
of	O
six	O
CMML	B-malignancy-type
infiltrates	O
.	O
By	O
contrast	O
,	O
no	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
was	O
found	O
in	O
bone	O
marrow	O
infiltrates	O
in	O
patients	O
with	O
CMML	B-malignancy-type
without	O
associated	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
n	O
=	O
20	O
)	O
.	O
CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
monoclonal	O
evolution	O
of	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
concurrent	O
CMML	B-malignancy-type
in	O
the	O
patient	O
studied	O
.	O
PMID	O
:	O
11040941	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2000	O
Oct	O
16	O
;	O
159	O
(	O
1	O
)	O
:	O
73	O
-	O
8	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
as	O
an	O
early	O
event	O
in	O
colorectal	O
tumorigenesis	O
.	O
Murata	O
M	O
,	O
Iwao	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nagasawa	O
Y	O
,	O
Yabu	O
M	O
,	O
Himeno	O
S	O
,	O
Imanishi	O
K	O
,	O
Ohsawa	O
M	O
,	O
Wada	O
H	O
,	O
Tominaga	O
S	O
,	O
Shimano	O
T	O
,	O
Kobayashi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Surgery	O
,	O
Ikeda	O
Municipal	O
Hospital	O
,	O
3-1-18	O
Jyonan	O
,	O
Ikeda-shi	O
,	O
563-8510	O
,	O
Osaka	O
,	O
Japan	O
.	O
muratamasaru@mth.biglobe.ne.jp	O
beta-Catenin	O
has	O
been	O
identified	O
as	O
an	O
oncogene	O
in	O
several	O
tumors	O
including	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
beta-Catenin	O
gene	O
is	O
activated	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
of	O
Japanese	O
population	O
,	O
in	O
contrast	O
to	O
amino	O
acid	O
substitutions	O
detected	O
among	O
Caucasian	O
population	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
type	O
and	O
frequency	O
of	O
beta-catenin	O
gene	O
mutation	O
during	O
early	O
stages	O
of	O
colorectal	O
tumorigenesis	O
.	O
We	O
screened	O
100	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
for	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
,	O
as	O
well	O
as	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O
In	O
cases	O
with	O
mutations	O
,	O
sequencing	O
analyses	O
and	O
immunohistochemical	O
staining	O
were	O
also	O
performed	O
.	O
Somatic	O
interstitial	O
deletions	O
of	O
272	O
-	O
413	O
bp	O
,	O
each	O
of	O
which	O
included	O
all	O
parts	O
of	O
exon	O
3	O
,	O
were	O
detected	O
in	O
three	O
tumors	O
.	O
However	O
,	O
no	O
adenoma	B-malignancy-type
carried	O
missense	O
mutations	O
.	O
We	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
adenoma	B-malignancy-type
cells	O
by	O
immunohistochemical	O
analysis	O
.	O
Our	O
results	O
suggested	O
that	O
activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
might	O
be	O
less	O
frequent	O
compared	O
with	O
frequent	O
alterations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
but	O
could	O
be	O
an	O
early	O
event	O
in	O
colorectal	O
tumorigenesis	O
equivalent	O
to	O
APC	O
gene	O
alterations	O
in	O
the	O
Japanese	O
population	O
.	O
PMID	O
:	O
10974408	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gynecol	O
Oncol	O
2000	O
Apr	O
;	O
77	O
(	O
1	O
)	O
:	O
105-11	O
ras	O
gene	O
activation	O
and	O
infrequent	O
mutation	O
in	O
papillary	B-malignancy-type
serous	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
peritoneum	I-malignancy-type
.	O
.	O
.	O
OBJECTIVE	O
:	O
The	O
ras	O
genes	O
are	O
a	O
well	O
-	O
studied	O
family	O
of	O
proto	O
-	O
oncogenes	O
whose	O
involvement	O
in	O
many	O
cancers	O
has	O
been	O
delineated	O
.	O
However	O
,	O
K-ras	O
mutations	O
have	O
not	O
previously	O
been	O
examined	O
in	O
papillary	B-malignancy-type
serous	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
peritoneum	I-malignancy-type
(	O
PSCP	B-malignancy-type
)	O
,	O
a	O
tumor	B-malignancy-type
which	O
resembles	O
serous	B-malignancy-type
epithelial	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
(	O
SEOC	B-malignancy-type
)	O
both	O
in	O
histology	O
and	O
epidemiology	O
.	O
In	O
this	O
study	O
we	O
examine	O
the	O
role	O
of	O
the	O
K-ras	O
oncogene	O
in	O
PSCP	B-malignancy-type
compared	O
to	O
SEOC	B-malignancy-type
.	O
METHODS	O
:	O
Using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
cycle	O
sequencing	O
protocols	O
,	O
we	O
evaluated	O
our	O
collection	O
of	O
51	O
cases	O
of	O
PSCP	B-malignancy-type
for	O
K-ras	O
mutations	O
and	O
compared	O
these	O
findings	O
with	O
the	O
experience	O
in	O
SEOC	B-malignancy-type
.	O
We	O
then	O
examined	O
5	O
cases	O
of	O
PSCP	B-malignancy-type
for	O
activation	O
of	O
ras	O
proteins	O
and	O
MAP	O
kinase	O
to	O
evaluate	O
the	O
potential	O
involvement	O
of	O
the	O
ras	O
pathway	O
in	O
PSCP	B-malignancy-type
tumorigenesis	O
.	O
RESULTS	O
:	O
We	O
found	O
only	O
one	O
K-ras	O
mutation	O
in	O
our	O
51	O
cases	O
(	O
2	O
%	O
)	O
of	O
PSCP	B-malignancy-type
compared	O
to	O
three	O
mutations	O
in	O
46	O
cases	O
(	O
6.5	O
%	O
)	O
of	O
high	O
-	O
grade	O
,	O
late	O
-	O
stage	O
SEOC	B-malignancy-type
.	O
This	O
was	O
not	O
significantly	O
different	O
(	O
P	O
>	O
0.10	O
)	O
.	O
In	O
the	O
single	O
PSCP	B-malignancy-type
case	O
with	O
a	O
K-ras	O
mutation	O
,	O
the	O
mutation	O
was	O
found	O
in	O
only	O
one	O
of	O
five	O
tumor	B-malignancy-type
sites	O
tested	O
.	O
All	O
four	O
mutations	O
involved	O
a	O
single	O
nucleotide	O
alteration	O
in	O
codon	O
12	O
(	O
GGT	O
to	O
GTT	O
,	O
Gly	O
to	O
Val	O
)	O
.	O
To	O
evaluate	O
the	O
ras	O
pathway	O
in	O
PSCP	B-malignancy-type
,	O
we	O
used	O
the	O
known	O
activated	O
ras	O
binding	O
domain	O
on	O
Raf-1	O
to	O
perform	O
an	O
assay	O
to	O
test	O
for	O
activated	O
ras	O
.	O
We	O
identified	O
ras	O
activation	O
in	O
4	O
of	O
5	O
PSCP	B-malignancy-type
cases	O
tested	O
and	O
,	O
to	O
confirm	O
that	O
the	O
activation	O
was	O
functional	O
,	O
we	O
tested	O
and	O
found	O
similar	O
activation	O
of	O
MAP	O
kinase	O
,	O
a	O
downstream	O
mediator	O
for	O
K-ras	O
expression	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
mutations	O
occur	O
at	O
low	O
rates	O
in	O
both	O
PSCP	B-malignancy-type
and	O
high	O
-	O
grade	O
,	O
late	O
-	O
stage	O
SEOC	B-malignancy-type
,	O
and	O
therefore	O
K-ras	O
mutations	O
are	O
not	O
involved	O
in	O
the	O
development	O
of	O
these	O
two	O
diseases	O
.	O
Finding	O
the	O
mutation	O
in	O
only	O
one	O
of	O
multiple	O
tumor	B-malignancy-type
sites	O
in	O
the	O
PSCP	B-malignancy-type
case	O
supports	O
growing	O
evidence	O
for	O
a	O
multifocal	O
origin	O
of	O
PSCP	B-malignancy-type
.	O
Our	O
findings	O
of	O
ras	O
activation	O
in	O
four	O
of	O
five	O
cases	O
of	O
PSCP	B-malignancy-type
suggest	O
that	O
ras	O
activation	O
by	O
mechanisms	O
other	O
than	O
genetic	O
mutation	O
is	O
important	O
for	O
PSCP	B-malignancy-type
tumorigenesis	O
.	O
Copyright	O
2000	O
Academic	O
Press	O
.	O

Cancer	O
Res	O
2000	O
Feb	O
1	O
;	O
60	O
(	O
3	O
)	O
:	O
522-4	O
High	O
frequency	O
of	O
K-ras	O
mutations	O
in	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
of	O
cases	O
with	O
a	O
long	O
common	O
channel	O
in	O
the	O
papilla	O
of	O
Vater	O
.	O
Hidaka	O
E	O
,	O
Yanagisawa	O
A	O
,	O
Seki	O
M	O
,	O
Takano	O
K	O
,	O
Setoguchi	O
T	O
,	O
Kato	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Cancer	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
frequency	O
of	O
K-ras	O
mutation	O
in	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
in	O
different	O
locations	O
and	O
the	O
relationship	O
to	O
the	O
form	O
of	O
the	O
junction	O
of	O
the	O
pancreaticobiliary	O
duct	O
(	O
JPBD	O
)	O
are	O
not	O
understood	O
clearly	O
.	O
These	O
points	O
were	O
investigated	O
in	O
the	O
present	O
study	O
.	O
Thirty-seven	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
in	O
patients	O
without	O
anomalous	O
JPBD	O
were	O
investigated	O
for	O
K-ras	O
mutations	O
.	O
Regarding	O
location	O
,	O
12	O
were	O
hilar	O
,	O
4	O
in	O
the	O
upper	O
,	O
11	O
in	O
the	O
middle	O
,	O
and	O
10	O
in	O
the	O
lower	O
portion	O
of	O
the	O
duct	O
.	O
Furthermore	O
,	O
with	O
14	O
cases	O
for	O
which	O
the	O
form	O
of	O
the	O
JPBD	O
could	O
be	O
confirmed	O
by	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
or	O
postoperative	O
cholangiopancreatography	O
,	O
division	O
was	O
made	O
into	O
two	O
types	O
:	O
those	O
with	O
a	O
long	O
common	O
channel	O
(	O
>	O
5	O
mm	O
)	O
in	O
the	O
papilla	O
of	O
Vater	O
(	O
type	O
1	O
,	O
n	O
=	O
4	O
)	O
,	O
and	O
the	O
other	O
with	O
a	O
shorter	O
or	O
nonapparent	O
common	O
channel	O
(	O
type	O
2	O
,	O
n	O
=	O
10	O
)	O
.	O
The	O
overall	O
frequency	O
of	O
K-ras	O
mutation	O
was	O
30	O
%	O
,	O
the	O
incidence	O
gradually	O
increasing	O
from	O
upper	O
to	O
lower	O
regions	O
.	O
K-ras	O
mutations	O
were	O
significantly	O
more	O
frequent	O
in	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
long	O
common	O
channels	O
(	O
P	O
<	O
0.05	O
)	O
.	O
These	O
results	O
suggest	O
that	O
a	O
long	O
common	O
channel	O
may	O
bear	O
a	O
relation	O
to	O
K-ras	O
mutations	O
in	O
biliary	O
duct	O
carcinogenesis	O
,	O
presumably	O
through	O
its	O
influence	O
on	O
pancreatic	O
juice	O
regurgitation	O
.	O
PMID	O
:	O
10676628	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
2000	O
Feb	O
;	O
14	O
2	O
)	O
:	O
312-5	O
Rapid	O
and	O
reliable	O
detection	O
of	O
N-ras	O
mutations	O
in	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
by	O
melting	O
curve	O
analysis	O
using	O
LightCycler	O
technology	O
.	O
Nakao	O
M	O
,	O
Janssen	O
JW	O
,	O
Seriu	O
T	O
,	O
Bartram	O
CR	O
.	O
Institute	O
of	O
Human	O
Genetics	O
,	O
University	O
of	O
Heidelberg	O
,	O
Germany	O
.	O
We	O
applied	O
a	O
new	O
strategy	O
for	O
the	O
detection	O
of	O
N-ras	O
gene	O
mutations	O
based	O
on	O
LightCycler	O
technology	O
.	O
We	O
designed	O
two	O
sets	O
of	O
amplimers	O
and	O
internal	O
hybridization	O
probes	O
representing	O
N-ras	O
codons	O
12	O
/	O
13	O
and	O
codon	O
61	O
,	O
respectively	O
.	O
Genomic	O
DNAs	O
from	O
134	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
patients	O
(	O
83	O
common	O
ALL	B-malignancy-type
,	O
nine	O
pre	B-malignancy-type
-	I-malignancy-type
pre	I-malignancy-type
-	I-malignancy-type
B	I-malignancy-type
ALL	I-malignancy-type
,	O
19	O
pre	B-malignancy-type
-	I-malignancy-type
B	I-malignancy-type
ALL	I-malignancy-type
,	O
23	O
T	B-malignancy-type
-	I-malignancy-type
ALL	I-malignancy-type
)	O
were	O
amplified	O
,	O
followed	O
by	O
the	O
analysis	O
of	O
the	O
melting	O
temperatures	O
of	O
the	O
PCR	O
products	O
on	O
the	O
LightCycler	O
.	O
PCR	O
products	O
exhibiting	O
an	O
abnormal	O
melting	O
characteristic	O
were	O
directly	O
sequenced	O
.	O
Sequence	O
analyses	O
unravelled	O
nucleotide	O
substitutions	O
at	O
codon	O
12	O
in	O
10	O
patients	O
,	O
at	O
codon	O
13	O
in	O
three	O
,	O
and	O
at	O
codon	O
61	O
in	O
one	O
case	O
.	O
The	O
incidence	O
of	O
N-ras	O
mutations	O
(	O
10	O
%	O
)	O
is	O
compatible	O
with	O
previous	O
reports	O
.	O
The	O
LightCycler	O
technology	O
facilitates	O
the	O
rapid	O
analysis	O
of	O
other	O
genes	O
exhibiting	O
hot	O
spot	O
mutations	O
in	O
human	O
malignancies	O
.	O
PMID	O
:	O
10673750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Endocrinol	O
Invest	O
1999	O
Nov	O
;	O
22	O
(	O
10	O
)	O
:	O
781-9	O
Ras	O
mutations	O
are	O
uncommon	O
in	O
sporadic	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
in	O
children	O
and	O
young	O
adults	O
.	O
Fenton	O
C	O
,	O
Anderson	O
J	O
,	O
Lukes	O
Y	O
,	O
Dinauer	O
CA	O
,	O
Tuttle	O
RM	O
,	O
Francis	O
GL	O
.	O
Department	O
of	O
Pediatrics	O
,	O
F	O
.	O
Edward	O
Hebert	O
School	O
of	O
Medicine	O
,	O
Uniformed	O
Services	O
University	O
of	O
the	O
Health	O
Sciences	O
,	O
Bethesda	O
,	O
MD	O
20814	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
ras	O
genes	O
(	O
H-ras	O
,	O
K-ras	O
,	O
and	O
N-ras	O
)	O
occur	O
in	O
10	O
-	O
15	O
%	O
of	O
all	O
human	O
cancers	O
,	O
and	O
commonly	O
arise	O
from	O
single	O
base	O
substitutions	O
at	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
Although	O
ras	O
mutations	O
have	O
been	O
found	O
in	O
adult	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
,	O
they	O
were	O
absent	O
from	O
the	O
two	O
studies	O
which	O
examined	O
childhood	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
.	O
Both	O
studies	O
included	O
only	O
children	O
with	O
radiation	O
induced	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
it	O
remains	O
unclear	O
if	O
ras	O
mutations	O
occur	O
in	O
children	O
without	O
radiation	O
exposure	O
.	O
To	O
answer	O
this	O
question	O
,	O
we	O
examined	O
archival	O
tissue	O
blocks	O
from	O
31	O
children	O
with	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
(	O
PTC	B-malignancy-type
)	O
4	O
with	O
follicular	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
(	O
FTC	B-malignancy-type
)	O
,	O
2	O
with	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
(	O
MTC	B-malignancy-type
)	O
,	O
and	O
1	O
with	O
lymphoma	B-malignancy-type
(	O
LYM	B-malignancy-type
)	O
.	O
Only	O
1	O
patient	O
with	O
PTC	B-malignancy-type
had	O
previous	O
radiation	O
exposure	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
and	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
ras	O
genes	O
.	O
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
oligospecific	O
hybridization	O
for	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
Two	O
of	O
the	O
PTCs	B-malignancy-type
(	O
6.5	O
%	O
)	O
contained	O
ras	O
mutations	O
.	O
Both	O
patients	O
had	O
class	O
II	O
disease	O
and	O
no	O
history	O
of	O
previous	O
radiation	O
exposure	O
.	O
One	O
patient	O
subsequently	O
developed	O
bone	O
and	O
lung	O
metastases	O
.	O
The	O
patient	O
with	O
lymphoma	B-malignancy-type
also	O
had	O
a	O
ras	O
mutation	O
(	O
N	O
-	O
61	O
)	O
,	O
but	O
ras	O
mutations	O
were	O
absent	O
from	O
all	O
FTC	B-malignancy-type
and	O
MTC	B-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
spontaneous	O
childhood	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
occur	O
with	O
a	O
frequency	O
similar	O
to	O
that	O
found	O
in	O
previous	O
reports	O
of	O
adult	O
differentiated	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
number	O
of	O
subjects	O
was	O
too	O
small	O
to	O
determine	O
if	O
ras	O
mutations	O
are	O
more	O
common	O
in	O
patients	O
with	O
aggressive	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10614528	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1999	O
Sep	O
1	O
;	O
59	O
(	O
17	O
)	O
:	O
4297-300	O
Effect	O
of	O
c-kit	O
mutation	O
on	O
prognosis	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Taniguchi	O
M	O
,	O
Nishida	O
T	O
,	O
Hirota	O
S	O
,	O
Isozaki	O
K	O
,	O
Ito	O
T	O
,	O
Nomura	O
T	O
,	O
Matsuda	O
H	O
,	O
Kitamura	O
Y	O
.	O
Department	O
of	O
Surgery	O
I	O
,	O
Osaka	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Suita	O
,	O
Japan	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
is	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
.	O
Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
juxtamembrane	O
domain	O
of	O
the	O
c-kit	O
gene	O
have	O
been	O
found	O
in	O
several	O
GISTs	B-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
correlation	O
between	O
the	O
presence	O
of	O
c-kit	O
mutation	O
and	O
prognosis	O
in	O
124	O
cases	O
of	O
GIST	B-malignancy-type
.	O
DNA	O
samples	O
were	O
extracted	O
from	O
paraffin	O
sections	O
.	O
Exon	O
11	O
of	O
the	O
c-kit	O
gene	O
encoding	O
the	O
juxtamembrane	O
domain	O
and	O
exon	O
17	O
encoding	O
the	O
kinase	O
domain	O
were	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
.	O
Most	O
GISTs	B-malignancy-type
(	O
89	O
%	O
)	O
express	O
the	O
KIT	O
protein	O
,	O
and	O
missense	O
mutations	O
of	O
exon	O
11	O
were	O
found	O
in	O
71	O
of	O
124	O
GISTs	B-malignancy-type
(	O
57	O
%	O
)	O
.	O
No	O
mutations	O
were	O
detectable	O
in	O
exon	O
17	O
.	O
These	O
71	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
were	O
larger	O
in	O
size	O
and	O
had	O
more	O
frequently	O
invaded	O
adjacent	O
tissues	O
than	O
did	O
the	O
53	O
mutation	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
GISTs	I-malignancy-type
.	O
Histologically	O
,	O
the	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
showed	O
higher	O
mitotic	O
figures	O
and	O
more	O
necrosis	O
and	O
hemorrhage	O
.	O
The	O
patients	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
showed	O
more	O
frequent	O
recurrences	O
(	O
P	O
=	O
0.0005	O
)	O
and	O
higher	O
mortality	O
(	O
P	O
=	O
0.0001	O
)	O
than	O
did	O
those	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
GISTs	I-malignancy-type
.	O
The	O
c-kit	O
mutation	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
overall	O
and	O
cause	O
-	O
specific	O
survival	O
of	O
the	O
patients	O
with	O
GISTs	B-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
GISTs	B-malignancy-type
may	O
be	O
divided	O
into	O
mutation	O
-	O
positive	O
and	O
-	O
negative	O
subtypes	O
.	O
The	O
prognosis	O
was	O
worse	O
in	O
patients	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
than	O
in	O
those	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
GISTs	I-malignancy-type
.	O
Thus	O
,	O
mutation	O
of	O
the	O
c-kit	O
gene	O
may	O
be	O
a	O
good	O
prognostic	O
marker	O
of	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
10485475	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
1999	O
Jun;154	O
(	O
6	O
)	O
:1643-7	O
Activating	O
c-kit	O
gene	O
mutations	O
in	O
human	O
germ	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Tian	O
Q	O
,	O
Frierson	O
HF	O
Jr	O
,	O
Krystal	O
GW	O
,	O
Moskaluk	O
CA.	O
Departments	O
of	O
Pathology	O
,	O
University	O
of	O
Virginia	O
Health	O
Sciences	O
Center	O
,	O
Charlottesville	O
,	O
USA	O
.	O
The	O
c-kit	O
gene	O
encodes	O
a	O
tyrosine	O
kinase	O
receptor	O
(	O
KIT	O
)	O
that	O
is	O
required	O
in	O
normal	O
spermatogenesis	O
and	O
is	O
expressed	O
in	O
seminomas	B-malignancy-type
and	O
dysgerminomas	B-malignancy-type
,	O
a	O
subset	O
of	O
human	O
germ	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
(	O
GCTs	B-malignancy-type
)	O
.	O
To	O
determine	O
whether	O
activating	O
mutations	O
of	O
the	O
c-kit	O
gene	O
occur	O
in	O
GCTs	B-malignancy-type
,	O
primary	O
tissue	O
samples	O
of	O
33	O
testicular	B-malignancy-type
and	O
ovarian	B-malignancy-type
tumors	I-malignancy-type
were	O
examined	O
for	O
mutations	O
in	O
the	O
juxtamembrane	O
and	O
phosphotransferase	O
domains	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
DNA	O
sequencing	O
.	O
A	O
novel	O
missense	O
mutation	O
(	O
D	O
816	O
H	O
)	O
was	O
found	O
in	O
the	O
phosphotransferase	O
domain	O
in	O
tumors	B-malignancy-type
of	I-malignancy-type
seminoma	I-malignancy-type
/	O
dysgerminoma	B-malignancy-type
differentiation	O
.	O
The	O
c-kit	O
alleles	O
in	O
nonneoplastic	O
tissues	O
from	O
these	O
patients	O
were	O
wild	O
type	O
,	O
suggesting	O
that	O
the	O
mutant	O
alleles	O
were	O
acquired	O
and	O
selected	O
for	O
during	O
malignant	O
transformation	O
.	O
In	O
cell	O
transfection	O
experiments	O
,	O
the	O
D	O
816	O
H	O
mutant	O
protein	O
was	O
a	O
constitutively	O
activated	O
kinase	O
and	O
was	O
constitutively	O
phosphorylated	O
on	O
tyrosine	O
residues	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
an	O
activating	O
c-kit	O
mutation	O
in	O
GCTs	B-malignancy-type
and	O
is	O
evidence	O
that	O
the	O
KIT	O
signal	O
transduction	O
pathway	O
is	O
important	O
in	O
the	O
pathogenesis	O
of	O
neoplasms	O
with	O
seminoma	O
differentiation	O
.	O
PMID	O
:	O
10362788	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
May	O
;12(	O
5	O
)	O
:	O
518	O
-28	O
A	O
clinicopathologic	O
and	O
immunohistochemical	O
study	O
of	O
22	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
neoplasms	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
,	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O
Paal	O
E	O
,	O
Thompson	O
LD	O
,	O
Przygodzki	O
RM	O
,	O
Bratthauer	O
GL	O
,	O
Heffess	O
CS	O
.	O
American	O
Registry	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
,	O
USA	O
.	O
Intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
neoplasms	I-malignancy-type
(	I-malignancy-type
IPMNs	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
are	O
rare	O
lesions	O
.	O
We	O
undertook	O
this	O
study	O
to	O
analyze	O
these	O
tumors	O
by	O
focusing	O
on	O
the	O
diagnostic	O
criteria	O
and	O
correlating	O
the	O
histologic	O
features	O
with	O
clinical	O
prognosis	O
.	O
Twenty-two	O
cases	O
of	O
IPMN	B-malignancy-type
were	O
retrieved	O
from	O
the	O
Endocrine	B-malignancy-type
Tumor	I-malignancy-type
Registry	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Blocks	O
or	O
unstained	O
slides	O
were	O
available	O
for	O
histochemical	O
and	O
immunohistochemical	O
studies	O
(	O
including	O
proliferative	O
markers	O
and	O
cell	O
cycle	O
regulators	O
)	O
and	O
K-ras	O
oncogene	O
mutations	O
in	O
15	O
cases	O
.	O
Patient	O
follow	O
-	O
up	O
was	O
obtained	O
in	O
all	O
of	O
the	O
cases	O
.	O
IPMN	B-malignancy-type
occurs	O
in	O
both	O
genders	O
with	O
a	O
slight	O
male	O
predominance	O
,	O
with	O
a	O
mean	O
age	O
at	O
presentation	O
of	O
64.4	O
years	O
(	O
range	O
,	O
48	O
-	O
85	O
yr	O
)	O
.	O
The	O
patients	O
presented	O
with	O
abdominal	O
pain	O
.	O
The	O
neoplasms	B-malignancy-type
were	O
radiologically	O
and	O
grossly	O
cystic	O
,	O
usually	O
(	O
18	O
cases	O
of	O
22	O
)	O
located	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
.	O
Histologically	O
,	O
the	O
tumors	B-malignancy-type
consisted	O
of	O
intraductal	O
papillary	O
proliferations	O
protruding	O
into	O
and	O
expanding	O
the	O
pancreatic	O
ducts	O
.	O
Invasion	O
into	O
the	O
surrounding	O
pancreatic	O
parenchyma	O
was	O
detected	O
in	O
15	O
cases	O
.	O
Chronic	O
pancreatitis	O
was	O
present	O
in	O
all	O
of	O
the	O
cases	O
.	O
p27	O
immunoreactivity	O
always	O
exceeded	O
the	O
immunoreactivity	O
of	O
cyclin	O
E	O
.	O
K-ras	O
oncogene	O
mutations	O
were	O
detected	O
in	O
two	O
cases	O
.	O
Patients	O
were	O
treated	O
with	O
a	O
complete	O
surgical	O
resection	O
(	O
n	O
=	O
7	O
)	O
or	O
a	O
Whipple	O
procedure	O
(	O
n	O
=	O
13	O
)	O
.	O
Only	O
2	O
of	O
22	O
patients	O
died	O
of	O
disease	O
(	O
3	O
died	O
immediately	O
postoperatively	O
and	O
3	O
died	O
of	O
unrelated	O
causes	O
)	O
,	O
whereas	O
the	O
remaining	O
14	O
patients	O
were	O
alive	O
at	O
last	O
follow	O
-	O
up	O
,	O
without	O
evidence	O
of	O
disease	O
,	O
an	O
average	O
of	O
58.2	O
months	O
after	O
initial	O
presentation	O
.	O
IPMNs	B-malignancy-type
are	O
rare	O
,	O
distinctive	O
neoplasms	O
,	O
with	O
complex	O
intraductal	O
papillae	O
,	O
that	O
can	O
be	O
easily	O
separated	O
from	O
in	O
situ	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
mucinous	B-malignancy-type
cystic	I-malignancy-type
neoplasms	I-malignancy-type
.	O
The	O
high	O
ratio	O
of	O
p27	O
protein	O
to	O
cyclin	O
E	O
supports	O
the	O
excellent	O
prognosis	O
of	O
these	O
neoplasms	B-malignancy-type
,	O
despite	O
the	O
presence	O
of	O
invasion	O
and	O
K-ras	O
oncogene	O
mutation	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
Literature	O
PMID	O
:	O
10349991	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1999	O
Feb;17(	O
2	O
)	O
:	O
668	O
-	O
75	O
Prognostic	O
significance	O
of	O
K-ras	O
codon	O
12	O
mutations	O
in	O
patients	O
with	O
resected	O
stage	O
I	O
and	O
II	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
Graziano	O
SL	O
,	O
Gamble	O
GP	O
,	O
Newman	O
NB	O
,	O
Abbott	O
LZ	O
,	O
Rooney	O
M,	O
Mookherjee	O
S	O
,	O
Lamb	O
ML	O
,	O
Kohman	O
LJ	O
,	O
Poiesz	O
BJ.	O
Department	O
of	O
Medicine	O
,	O
State	O
University	O
of	O
New	O
York	O
Health	O
Science	O
Center	O
and	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
Syracuse	O
13210	O
,	O
USA	O
.	O
PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prognostic	O
importance	O
of	O
codon	O
12	O
K-ras	O
mutations	O
in	O
patients	O
with	O
early	O
-	O
stage	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
identified	O
260	O
patients	O
with	O
surgically	O
resected	O
stage	O
I	O
(	O
n	O
=	O
193	O
)	O
and	O
stage	O
II	O
(	O
n	O
=	O
67	O
)	O
NSCLC	B-malignancy-type
with	O
at	O
least	O
a	O
5	O
-	O
year	O
follow	O
-	O
up	O
.	O
We	O
performed	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
DNA	O
obtained	O
from	O
paraffin	O
-	O
embedded	O
NSCLC	B-malignancy-type
tissue	O
,	O
using	O
mutation	O
-	O
specific	O
probes	O
for	O
codon	O
12	O
K-ras	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
35	O
of	O
213	O
assessable	O
specimens	O
(	O
16.4	O
%	O
)	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
27	O
of	O
93	O
adenocarcinomas	B-malignancy-type
(	O
29.0	O
%	O
)	O
,	O
one	O
of	O
61	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
1.6	O
%	O
)	O
,	O
five	O
of	O
39	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
12.8	O
%	O
)	O
,	O
and	O
two	O
of	O
20	O
adenosquamous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
10	O
%	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O
G	O
to	O
T	O
transversions	O
accounted	O
for	O
71	O
%	O
of	O
the	O
mutations	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
overall	O
survival	O
for	O
all	O
patients	O
with	O
K-ras	O
mutations	O
(	O
median	O
survival	O
,	O
39	O
months	O
)	O
compared	O
with	O
patients	O
without	O
K-ras	O
mutations	O
(	O
median	O
survival	O
,	O
53	O
months	O
;	O
P	O
=	O
.33	O
)	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
overall	O
or	O
disease	O
-	O
free	O
survival	O
for	O
subgroups	O
with	O
stage	O
I	O
disease	O
,	O
adenocarcinoma	B-malignancy-type
,	O
or	O
non	B-malignancy-type
-	I-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
or	O
for	O
specific	O
amino	O
acid	O
substitutions	O
.	O
The	O
median	O
survival	O
time	O
for	O
stage	O
II	O
patients	O
with	O
K-ras	O
mutations	O
was	O
13	O
months	O
,	O
compared	O
with	O
38	O
months	O
for	O
patients	O
without	O
K-ras	O
mutations	O
(	O
P	O
=	O
.03	O
)	O
.	O
CONCLUSION	O
:	O
Codon	O
12	O
K-ras	O
mutations	O
were	O
more	O
common	O
in	O
adenocarcinomas	B-malignancy-type
than	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
For	O
the	O
subgroup	O
with	O
stage	O
II	O
NSCLC	B-malignancy-type
,	O
there	O
was	O
a	O
statistically	O
significant	O
adverse	O
effect	O
on	O
survival	O
for	O
the	O
presence	O
of	O
K-ras	O
mutations	O
.	O
However	O
,	O
when	O
the	O
entire	O
group	O
was	O
considered	O
,	O
the	O
presence	O
of	O
K-ras	O
mutations	O
was	O
not	O
of	O
prognostic	O
significance	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
resected	O
early	O
-	O
stage	O
NSCLC	B-malignancy-type
.	O
PMID	O
:	O
10080613	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Feb;154	O
(	O
2	O
)	O
:	O
32	O
5-9	O
Frequent	O
nuclear	O
/	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
without	O
exon	O
3	O
mutations	O
in	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
.	I-malignancy-type
Rimm	O
DL	O
,	O
Caca	O
K,	O
Hu	O
G	O
,	O
Harrison	O
FB	O
,	O
Fearon	O
ER	O
.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06510	O
,	O
USA	O
.	O
david	O
.rimm@yale	O
.edu	O
Beta-Catenin	O
has	O
a	O
critical	O
role	O
in	O
E-cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
,	O
and	O
it	O
also	O
functions	O
as	O
a	O
downstream	O
signaling	O
molecule	O
in	O
the	O
wnt	O
pathway	O
.	O
Mutations	O
in	O
the	O
putative	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
near	O
the	O
beta-catenin	O
amino	O
terminus	O
have	O
been	O
found	O
in	O
some	O
cancers	O
and	O
cancer	O
cell	O
lines	O
.	O
The	O
mutations	O
render	O
beta-catenin	O
resistant	O
to	O
regulation	O
by	O
a	O
complex	O
containing	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
,	O
adenomatous	O
polyposis	O
coli	O
,	O
and	O
axin	O
proteins	O
.	O
As	O
a	O
result	O
,	O
beta-catenin	O
accumulates	O
in	O
the	O
cytosol	O
and	O
nucleus	O
and	O
activates	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancing	O
factor	O
transcription	O
factors	O
.	O
Previously	O
,	O
6	O
of	O
27	O
melanoma	B-malignancy-type
cell	O
lines	O
were	O
found	O
to	O
have	O
beta-catenin	O
exon	O
3	O
mutations	O
affecting	O
the	O
N	O
-	O
terminal	O
phosphorylation	O
sites	O
(	O
Rubinfeld	O
B	O
,	O
Robbins	O
P	O
,	O
Elgamil	O
M	O
,	O
Albert	O
I	O
,	O
Porfiri	O
E	O
,	O
Polakis	O
P	O
:	O
Stabilization	O
of	O
beta-catenin	O
by	O
genetic	O
defects	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Science	O
1997	O
,	O
275	O
:	O
1790	O
-	O
1792	O
)	O
.	O
To	O
assess	O
the	O
role	O
of	O
beta-catenin	O
defects	O
in	O
primary	B-malignancy-type
melanomas	I-malignancy-type
,	O
we	O
undertook	O
immunohistochemical	O
and	O
DNA	O
sequencing	O
studies	O
in	O
65	O
melanoma	B-malignancy-type
specimens	O
.	O
Nuclear	O
and/or	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
,	O
a	O
potential	O
indicator	O
of	O
wnt	O
pathway	O
activation	O
,	O
was	O
seen	O
focally	O
within	O
roughly	O
one	O
third	O
of	O
the	O
tumors	O
,	O
though	O
a	O
clonal	O
somatic	O
mutation	O
in	O
beta-catenin	O
was	O
found	O
in	O
only	O
one	O
case	O
(	O
codon	O
45	O
Ser	O
-->	O
Pro	O
)	O
.	O
Our	O
findings	O
demonstrate	O
that	O
beta-catenin	O
mutations	O
are	O
rare	O
in	O
primary	O
melanoma	B-malignancy-type
,	O
in	O
contrast	O
to	O
the	O
situation	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Nonetheless	O
,	O
activation	O
of	O
beta-catenin	O
,	O
as	O
indicated	O
by	O
its	O
nuclear	O
and/or	O
cytoplasmic	O
localization	O
,	O
appears	O
to	O
be	O
frequent	O
in	O
melanoma	B-malignancy-type
,	O
and	O
in	O
some	O
cases	O
,	O
it	O
may	O
reflect	O
focal	O
and	O
transient	O
activation	O
of	O
the	O
wnt	O
pathway	O
within	O
the	O
tumor	O
.	O
PMID	O
:	O
10027390	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Jun	O
15	O
;58	O
(	O
12	O
)	O
:2520-3	O
Beta-catenin	O
mutations	O
in	O
human	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Voeller	O
HJ	O
,	O
Truica	O
CI	O
,	O
Gelmann	O
EP	O
.	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Lombardi	O
Cancer	O
Center	O
,	O
Georgetown	O
University	O
School	O
of	O
Medicine	O
,	O
Washington	O
,	O
DC	O
20007	O
-	O
2197	O
,	O
USA	O
.	O
Beta-catenin	O
plays	O
essential	O
roles	O
in	O
both	O
intercellular	O
adhesion	O
and	O
signal	O
transduction	O
.	O
As	O
a	O
signaling	O
molecule	O
,	O
beta-catenin	O
supplies	O
an	O
activating	O
domain	O
to	O
the	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancer	O
-	O
binding	O
factor	O
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
activates	O
gene	O
transcription	O
.	O
Posttranslational	O
stabilization	O
of	O
beta-catenin	O
,	O
leading	O
to	O
elevated	O
protein	O
levels	O
and	O
constitutive	O
gene	O
activation	O
,	O
has	O
been	O
proposed	O
as	O
an	O
important	O
step	O
in	O
oncogenesis	O
.	O
Stabilization	O
of	O
beta-catenin	O
can	O
occur	O
through	O
mutation	O
to	O
highly	O
conserved	O
amino	O
acids	O
encoded	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
.	O
To	O
determine	O
whether	O
this	O
pathway	O
of	O
malignant	O
transformation	O
is	O
important	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
analyzed	O
104	O
prostate	B-malignancy-type
cancer	I-malignancy-type
tissue	O
specimens	O
,	O
4	O
prostate	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
and	O
3	O
prostate	O
tumor	O
xenografts	O
for	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
CTNNB1	O
.	O
Mutations	O
were	O
detected	O
in	O
5	O
of	O
the	O
104	O
prostate	B-malignancy-type
cancer	I-malignancy-type
tissue	O
samples	O
.	O
Four	O
of	O
the	O
five	O
mutations	O
involved	O
serine	O
or	O
threonine	O
residues	O
implicated	O
in	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
A	O
fifth	O
tumor	B-malignancy-type
had	O
a	O
mutation	O
at	O
codon	O
32	O
,	O
changing	O
a	O
highly	O
conserved	O
aspartic	O
acid	O
to	O
a	O
tyrosine	O
.	O
Mutational	O
analysis	O
of	O
multiple	O
regions	O
from	O
several	O
tumor	O
samples	O
showed	O
that	O
the	O
beta-catenin	O
mutations	O
were	O
present	O
focally	O
and	O
therefore	O
may	O
occur	O
during	O
tumor	O
progression	O
.	O
PMID	O
:	O
9635571	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Apr	O
10	O
;126	O
(	O
1	O
)	O
:	O
59	O
-	O
65	O
K-ras	O
mutations	O
in	O
sinonasal	B-malignancy-type
adenocarcinomas	I-malignancy-type
in	O
patients	O
occupationally	O
exposed	O
to	O
wood	O
or	O
leather	O
dust	O
.	O
Saber	O
AT	O
,	O
Nielsen	O
LR	O
,	O
Dictor	O
M,	O
Hagmar	O
L,	O
Mikoczy	O
Z	O
,	O
Wallin	O
H.	O
National	O
Institute	O
of	O
Occupational	O
Health	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
Of	O
39	O
males	O
diagnosed	O
with	O
sinonasal	B-malignancy-type
adenocarcinomas	I-malignancy-type
over	O
30	O
years	O
in	O
the	O
Lund	O
University	O
Hospital	O
catchment	O
area	O
(	O
1.5	O
million	O
inhabitants	O
)	O
,	O
archival	O
tumor	O
tissue	O
was	O
available	O
from	O
29	O
.	O
Of	O
these	O
,	O
16	O
had	O
been	O
exposed	O
to	O
wood	O
dust	O
and	O
three	O
had	O
been	O
exposed	O
to	O
leather	O
dust	O
.	O
The	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
and	O
papillary	B-malignancy-type
adenocarcinomas	I-malignancy-type
were	O
more	O
common	O
in	O
the	O
exposed	O
patients	O
(	O
P	O
=	O
0.0002	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
The	O
tumors	O
from	O
all	O
but	O
one	O
of	O
the	O
29	O
sinonasal	B-malignancy-type
adenocarcinomas	I-malignancy-type
could	O
be	O
analyzed	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
K-ras	O
gene	O
.	O
Four	O
mutations	O
were	O
detected	O
in	O
the	O
28	O
tumors	B-malignancy-type
.	O
The	O
three	O
mutations	O
in	O
the	O
patients	O
exposed	O
to	O
wood	O
and	O
leather	O
dust	O
were	O
all	O
G	O
:	O
C	O
-->	O
A	O
:	O
T	O
transitions	O
,	O
with	O
two	O
at	O
position	O
2	O
of	O
codon	O
12	O
and	O
one	O
at	O
position	O
2	O
of	O
codon	O
13	O
.	O
The	O
high	O
proportion	O
of	O
G	O
:	O
C	O
-->	O
A	O
:	O
T	O
mutations	O
in	O
this	O
rare	O
tumor	O
may	O
reflect	O
a	O
genotoxic	O
agent	O
in	O
wood	O
and	O
leather	O
dust	O
.	O
PMID	O
:	O
9563649	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
15	O
;58	O
(	O
6	O
)	O
:	O
1130	O
-4	O
Mutational	O
analysis	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Sparks	O
AB	O
,	O
Morin	O
PJ	O
,	O
Vogelstein	O
B	O
,	O
Kinzler	O
KW	O
.	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
Maryland	O
21231	O
,	O
USA	O
.	O
Mutation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
initiates	O
the	O
majority	O
of	O
colorectal	B-malignancy-type
(	I-malignancy-type
CR	I-malignancy-type
)	I-malignancy-type
cancers	I-malignancy-type
.	O
One	O
consequence	O
of	O
this	O
inactivation	O
is	O
constitutive	O
activation	O
of	O
beta-catenin	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
.	O
To	O
further	O
explore	O
the	O
role	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
CR	B-malignancy-type
tumorigenesis	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
genes	O
implicated	O
in	O
this	O
pathway	O
in	O
CR	B-malignancy-type
tumors	I-malignancy-type
lacking	O
APC	O
mutations	O
.	O
No	O
mutations	O
of	O
the	O
gamma-catenin	O
(	O
CTNNG1	O
)	O
,	O
GSK-3alpha	O
(	O
GSK3A	O
)	O
,	O
or	O
GSK-3beta	O
(	O
GSK3B	O
)	O
genes	O
were	O
detected	O
.	O
In	O
contrast	O
,	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
domain	O
of	O
beta-catenin	O
(	O
CTNNB1	O
)	O
were	O
found	O
in	O
13	O
of	O
27	O
(	O
48	O
%	O
)	O
CR	O
tumors	O
lacking	O
APC	O
mutations	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
regulatory	O
domain	O
and	O
APC	O
were	O
observed	O
to	O
be	O
mutually	O
exclusive	O
,	O
consistent	O
with	O
their	O
equivalent	O
effects	O
on	O
beta-catenin	O
stability	O
and	O
Tcf	O
transactivation	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
CTNNB1	O
mutations	O
can	O
occur	O
in	O
the	O
early	O
,	O
adenomatous	O
stage	O
of	O
CR	B-malignancy-type
neoplasia	O
,	O
as	O
has	O
been	O
observed	O
previously	O
with	O
APC	O
mutations	O
.	O
These	O
results	O
suggest	O
that	O
CTNNB1	O
mutations	O
can	O
uniquely	O
substitute	O
for	O
APC	O
mutations	O
in	O
CR	B-malignancy-type
tumors	O
and	O
that	O
beta-catenin	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
CR	B-malignancy-type
tumorigenesis	O
.	O
PMID	O
:	O
9515795	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1998	O
Mar;77	O
(	O
5	O
)	O
:720-3	O
K-ras	O
point	O
mutation	O
occurs	O
in	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Sagawa	O
M,	O
Saito	O
Y	O
,	O
Fujimura	O
S	O
,	O
Linnoila	O
RI.	O
Biomarkers	O
and	O
Prevention	O
Research	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Rockville	O
,	O
Maryland	O
20850	O
,	O
USA	O
.	O
In	O
order	O
to	O
determine	O
the	O
topographical	O
distribution	O
of	O
the	O
K-ras	O
codon	O
12	O
mutations	O
in	O
carcinoma	B-malignancy-type
and	O
preneoplastic	B-malignancy-type
lesions	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
,	O
selective	O
ultraviolet	O
radiation	O
fractionation	O
,	O
as	O
well	O
as	O
microdissection	O
followed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RELP	O
)	O
,	O
was	O
performed	O
.	O
Fourteen	O
of	O
61	O
samples	O
amplified	O
(	O
23.0	O
%	O
)	O
had	O
a	O
mutation	O
in	O
the	O
K-ras	O
codon	O
12	O
.	O
Of	O
41	O
adenocarcinoma	B-malignancy-type
,	O
12	O
samples	O
(	O
29.3	O
%	O
)	O
had	O
a	O
mutation	O
,	O
whereas	O
none	O
of	O
the	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
had	O
a	O
mutation	O
.	O
One	O
of	O
six	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
of	O
three	O
carcinoid	O
tumours	O
and	O
none	O
of	O
three	O
other	O
carcinomas	B-malignancy-type
had	O
a	O
mutation	O
.	O
Direct	O
sequencing	O
revealed	O
that	O
K-ras	O
codon	O
12	O
of	O
six	O
samples	O
were	O
TGT	O
(	O
Cys	O
)	O
,	O
five	O
samples	O
were	O
GTT	O
(	O
Val	O
)	O
,	O
two	O
samples	O
were	O
GCT	O
(	O
Ala	O
)	O
and	O
one	O
sample	O
was	O
TTT	O
(	O
Phe	O
)	O
.	O
A	O
total	O
of	O
113	O
lesions	B-malignancy-type
of	O
13	O
cases	O
covered	O
by	O
dot	O
were	O
amplified	O
after	O
UV	O
radiation	O
.	O
All	O
of	O
74	O
carcinoma	B-malignancy-type
lesions	O
had	O
the	O
mutation	O
,	O
and	O
intratumour	O
heterogeneity	O
was	O
not	O
observed	O
.	O
Of	O
39	O
non	B-malignancy-type
-	I-malignancy-type
malignant	I-malignancy-type
lesions	I-malignancy-type
,	O
one	O
type	O
II	O
cell	O
hyperplasia	O
had	O
the	O
mutation	O
,	O
which	O
suggests	O
that	O
the	O
K-ras	O
mutation	O
occurs	O
in	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
.	O
The	O
lack	O
of	O
intratumour	O
heterogeneity	O
supports	O
the	O
hypothesis	O
.	O
PMID	O
:	O
9514049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1997	O
Nov	O
14;73	O
(	O
4	O
)	O
:	O
492	O
-	O
6	O
Molecular	O
analysis	O
of	O
occupational	O
cancer	O
:	O
infrequent	O
p53	O
and	O
ras	O
mutations	O
in	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
in	O
workers	O
exposed	O
to	O
gasoline	O
.	O
Roth	O
S	O
,	O
Partanen	O
T	O
,	O
Suitiala	O
T	O
,	O
Anttila	O
S	O
,	O
Ojajarvi	O
A	O
,	O
Hemminki	O
K,	O
Vainio	O
H,	O
Husgafvel	O
-	O
Pursiainen	O
K.	O
Department	O
of	O
Epidemiology	O
and	O
Biostatistics	O
,	O
Finnish	O
Institute	O
of	O
Occupational	O
Health	O
,	O
Helsinki	O
.	O
Occupational	O
exposure	O
to	O
gasoline	O
has	O
been	O
identified	O
in	O
several	O
studies	O
as	O
a	O
risk	O
factor	O
for	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
.	O
Cases	O
of	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
with	O
and	O
without	O
work	O
-	O
related	O
exposure	O
to	O
gasoline	O
or	O
gasoline	O
and	O
diesel	O
fuel	O
were	O
studied	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
tumour	O
-	O
suppressor	O
gene	O
p53	O
(	O
n	O
=	O
23	O
exposed	O
and	O
30	O
non	O
-	O
exposed	O
cases	O
studied	O
)	O
and	O
ras	O
oncogene	O
(	O
n	O
=	O
30	O
exposed	O
and	O
36	O
non	O
-	O
exposed	O
cases	O
studied	O
)	O
.	O
An	O
average	O
cumulative	O
exposure	O
was	O
estimated	O
at	O
10	O
ppm	O
-	O
years	O
benzene	O
among	O
the	O
exposed	O
.	O
Three	O
p53	O
mutations	O
were	O
detected	O
by	O
denaturing	O
-	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
among	O
the	O
23	O
exposed	O
cases	O
(	O
3	O
/	O
23	O
,	O
13	O
%	O
)	O
.	O
Of	O
the	O
non	O
-	O
exposed	O
referent	O
cases	O
,	O
4	O
had	O
a	O
mutation	O
(	O
4	O
/	O
30	O
,	O
13	O
%	O
)	O
.	O
All	O
but	O
one	O
of	O
the	O
cases	O
with	O
a	O
p53	O
mutation	O
had	O
smoked	O
.	O
A	O
ras	O
gene	O
(	O
K-ras	O
or	O
N-ras	O
)	O
mutation	O
was	O
found	O
in	O
3	O
(	O
3	O
/	O
66	O
,	O
4.5	O
%	O
)	O
cases	O
,	O
all	O
of	O
whom	O
were	O
smoker	O
referents	O
.	O
We	O
conclude	O
that	O
p53	O
and	O
ras	O
mutations	O
are	O
infrequent	O
in	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
associated	O
with	O
occupational	O
exposure	O
to	O
gasoline	O
.	O
However	O
,	O
the	O
majority	O
of	O
the	O
mutations	O
(	O
6	O
/	O
7	O
for	O
p53	O
,	O
and	O
3	O
/	O
3	O
for	O
ras	O
genes	O
)	O
were	O
seen	O
in	O
smokers	O
.	O
PMID	O
:	O
9389561	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1997	O
Aug;21(	O
8	O
)	O
:69	O
7	O
-	O
701	O
Mutations	O
of	O
the	O
RAS	O
genes	O
in	O
childhood	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
juvenile	O
chronic	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Sheng	O
XM	O
,	O
Kawamura	O
M,	O
Ohnishi	O
H,	O
Ida	O
K,	O
Hanada	O
R	O
,	O
Kojima	O
S	O
,	O
Kobayashi	O
M,	O
Bessho	O
F	O
,	O
Yanagisawa	O
M,	O
Hayashi	O
Y	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
Using	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
method	O
and	O
direct	O
sequencing	O
,	O
12	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
cell	O
lines	O
and	O
108	O
fresh	O
childhood	O
myeloid	B-malignancy-type
tumor	I-malignancy-type
specimens	O
,	O
including	O
67	O
AML	O
,	O
29	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
,	O
and	O
12	O
juvenile	O
chronic	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
JCML	O
)	O
were	O
examined	O
for	O
mutation	O
in	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
RAS	O
genes	O
.	O
The	O
mutation	O
was	O
found	O
in	O
eight	O
of	O
the	O
120	O
samples	O
(	O
6.7	O
%	O
)	O
,	O
which	O
consisted	O
of	O
four	O
cell	O
lines	O
(	O
33.3	O
%	O
)	O
and	O
four	O
fresh	O
myeloid	O
tumors	O
(	O
3.7	O
%	O
)	O
.	O
The	O
frequency	O
of	O
the	O
mutation	O
in	O
the	O
cell	O
lines	O
was	O
apparently	O
higher	O
than	O
that	O
in	O
fresh	O
myeloid	B-malignancy-type
tumors	I-malignancy-type
.	O
K-RAS	O
gene	O
mutations	O
were	O
found	O
in	O
two	O
of	O
the	O
67	O
fresh	O
AML	B-malignancy-type
specimens	O
(	O
3	O
%	O
)	O
.	O
Interestingly	O
,	O
these	O
two	O
patients	O
had	O
11q23	O
translocations	O
.	O
The	O
N-RAS	O
gene	O
mutation	O
was	O
found	O
in	O
one	O
of	O
the	O
29	O
specimens	O
(	O
3.4	O
%	O
)	O
of	O
MDS	B-malignancy-type
and	O
in	O
one	O
of	O
the	O
12	O
specimens	O
(	O
8.3	O
%	O
)	O
of	O
JCML	O
.	O
All	O
mutations	O
were	O
found	O
in	O
codon	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
N-RAS	O
and	O
K-RAS	O
genes	O
.	O
Frequency	O
of	O
mutation	O
of	O
RAS	O
genes	O
in	O
fresh	O
myeloid	B-malignancy-type
malignancies	I-malignancy-type
was	O
very	O
low	O
.	O
These	O
findings	O
suggest	O
that	O
mutation	O
of	O
RAS	O
genes	O
does	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
childhood	O
myeloid	B-malignancy-type
malignancies	I-malignancy-type
.	O
PMID	O
:	O
9379676	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1997	O
Sep	O
;	O
88	O
(	O
9	O
)	O
:	O
846	O
-	O
54	O
Frequent	O
somatic	O
mutations	O
of	O
the	O
APC	O
and	O
p53	O
genes	O
in	O
sporadic	B-malignancy-type
ampullary	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Imai	O
Y	O
,	O
Oda	O
H	O
,	O
Tsurutani	O
N	O
,	O
Nakatsuru	O
Y	O
,	O
Inoue	O
T	O
,	O
Ishikawa	O
T	O
.	O
Department	O
of	O
Pathology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
.	O
Although	O
a	O
close	O
relation	O
of	O
somatic	O
mutations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
with	O
ampullary	B-malignancy-type
carcinomas	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
has	O
been	O
reported	O
,	O
the	O
possible	O
association	O
with	O
sporadic	B-malignancy-type
ampullary	I-malignancy-type
neoplasms	I-malignancy-type
has	O
not	O
been	O
fully	O
examined	O
.	O
We	O
have	O
therefore	O
investigated	O
loss	O
of	O
heterozygosity	O
at	O
the	O
adenomatous	O
polyposis	O
coli	O
locus	O
and	O
the	O
mutational	O
status	O
of	O
a	O
portion	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
,	O
including	O
the	O
mutation	O
cluster	O
region	O
,	O
in	O
17	O
ampullary	B-malignancy-type
carcinomas	I-malignancy-type
of	O
non	B-malignancy-type
-	I-malignancy-type
familial	I-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
.	O
Alteration	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
was	O
found	O
in	O
8	O
of	O
17	O
(	O
47.1	O
%	O
)	O
cases	O
,	O
as	O
missense	O
or	O
insertion	O
mutations	O
,	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
.	O
Additional	O
investigation	O
of	O
p53	O
(	O
exons	O
5	O
-	O
8	O
)	O
and	O
K-ras	O
(	O
codons	O
12	O
and	O
13	O
)	O
gene	O
mutations	O
revealed	O
a	O
striking	O
mutational	O
pattern	O
of	O
the	O
p53	O
gene	O
.	O
Nine	O
of	O
the	O
17	O
cases	O
demonstrated	O
a	O
total	O
of	O
12	O
mutations	O
,	O
6	O
clustered	O
at	O
codon	O
189	O
and	O
3	O
at	O
codon	O
166	O
.	O
Furthermore	O
,	O
5	O
of	O
the	O
12	O
mutations	O
were	O
nonsense	O
mutations	O
.	O
Regarding	O
the	O
K-ras	O
gene	O
,	O
4	O
of	O
the	O
17	O
(	O
23.5	O
%	O
)	O
cases	O
had	O
mutations	O
in	O
codon	O
12	O
,	O
3	O
of	O
the	O
4	O
cases	O
being	O
derived	O
from	O
the	O
intraduodenal	O
bile	O
duct	O
.	O
The	O
findings	O
indicate	O
that	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
and	O
the	O
p53	O
genes	O
are	O
relatively	O
frequent	O
in	O
sporadic	B-malignancy-type
ampullary	I-malignancy-type
carcinomas	I-malignancy-type
.	O
In	O
particular	O
,	O
the	O
clustering	O
at	O
specific	O
p53	O
codons	O
might	O
offer	O
an	O
etiological	O
clue	O
to	O
clarify	O
ampullary	O
carcinogenesis	O
.	O
Mutations	O
of	O
the	O
K-ras	O
gene	O
,	O
on	O
the	O
other	O
hand	O
,	O
might	O
be	O
characteristic	O
of	O
intraduodenal	O
bile	O
duct	O
origin	O
.	O
PMID	O
:	O
9369932	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Nat	O
Genet	O
1997	O
Jul	O
;	O
16	O
(	O
3	O
)	O
:	O
260	O
-	O
4	O
Frequent	O
translocation	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32.3	O
)	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
is	O
associated	O
with	O
increased	O
expression	O
and	O
activating	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
.	O
Chesi	O
M	O
,	O
Nardini	O
E	O
,	O
Brents	O
LA	O
,	O
Schrock	O
E	O
,	O
Ried	O
T	O
,	O
Kuehl	O
WM	O
,	O
Bergsagel	O
PL	O
.	O
Genetics	O
Department	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20889	O
-	O
5105	O
,	O
USA	O
.	O
Dysregulation	O
of	O
oncogenes	O
by	O
translocation	O
to	O
the	O
IgH	O
locus	O
(	O
14q32	O
)	O
is	O
a	O
seminal	O
event	O
in	O
the	O
pathogenesis	O
of	O
B-cell	B-malignancy-type
tumours	I-malignancy-type
.	O
In	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	B-malignancy-type
MM	I-malignancy-type
)	O
,	O
translocations	O
to	O
the	O
IgH	O
locus	O
have	O
been	O
reported	O
at	O
an	O
incidence	O
of	O
20	O
-	O
60	O
%	O
.	O
For	O
most	O
translocations	O
,	O
the	O
partner	O
chromosome	O
is	O
unknown	O
(	O
14q	O
+	O
)	O
;	O
for	O
the	O
others	O
,	O
a	O
diverse	O
array	O
of	O
chromosomal	O
partners	O
have	O
been	O
identified	O
,	O
with	O
11q13	O
(	O
cyclin	O
D1	O
)	O
the	O
only	O
chromosome	O
that	O
is	O
frequently	O
involved	O
.	O
Recently	O
,	O
we	O
developed	O
a	O
Southern	O
-	O
blot	O
assay	O
that	O
detects	O
translocation	O
breakpoint	O
fragments	O
in	O
most	O
MM	B-malignancy-type
tumours	I-malignancy-type
,	O
including	O
those	O
with	O
no	O
translocation	O
detected	O
by	O
conventional	O
karyotyping	O
.	O
In	O
a	O
continuing	O
analysis	O
of	O
translocation	O
in	O
21	O
myeloma	B-malignancy-type
cell	O
lines	O
and	O
primary	O
tumours	O
,	O
we	O
show	O
that	O
the	O
novel	O
,	O
karyotypically	O
silent	O
translocation	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32.3	O
)	O
is	O
present	O
in	O
five	O
lines	O
and	O
at	O
least	O
three	O
of	O
ten	O
primary	O
tumours	O
.	O
The	O
chromosome	O
-	O
4	O
breakpoints	O
are	O
clustered	O
in	O
a	O
70	O
-	O
kb	O
region	O
centromeric	O
to	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
gene	O
(	O
FGFR3	O
)	O
,	O
the	O
apparent	O
dysregulated	O
oncogene	O
.	O
Two	O
lines	O
and	O
one	O
primary	O
tumour	O
with	O
this	O
translocation	O
selectively	O
express	O
an	O
FGFR3	O
allele	O
containing	O
activating	O
mutations	O
identified	O
previously	O
in	O
thanatophoric	O
dwarfism	O
.	O
We	O
propose	O
that	O
after	O
the	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
,	O
somatic	O
mutation	O
during	O
tumour	O
progression	O
frequently	O
generates	O
in	O
FGFR3	O
protein	O
that	O
is	O
active	O
in	O
the	O
absence	O
of	O
ligand	O
.	O
PMID	O
:	O
9207791	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1997	O
Jun	O
;	O
11	O
(	O
6	O
)	O
:	O
863	O
-	O
5	O
No	O
concomitant	O
occurrence	O
of	O
the	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
.	O
Mitani	O
K	O
,	O
Hangaishi	O
A	O
,	O
Imamura	O
N	O
,	O
Miyagawa	O
K	O
,	O
Ogawa	O
S	O
,	O
Kanda	O
Y	O
,	O
Yazaki	O
Y	O
,	O
Hirai	O
H	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Bunkyo-ku	O
,	O
Japan	O
.	O
Mutations	O
of	O
the	O
N-ras	O
oncogene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
were	O
simultaneously	O
investigated	O
in	O
bone	O
marrow	O
cells	O
from	O
44	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
or	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
.	O
The	O
mutations	O
of	O
the	O
N-ras	O
gene	O
were	O
detected	O
only	O
in	O
two	O
cases	O
with	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
.	O
Three	O
patients	O
with	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
and	O
one	O
with	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
exhibited	O
five	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O
No	O
concomitant	O
mutations	O
of	O
both	O
genes	O
were	O
observed	O
in	O
our	O
study	O
,	O
suggesting	O
that	O
alterations	O
of	O
both	O
genes	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
progression	O
of	O
MDS	B-malignancy-type
in	O
a	O
non	O
-	O
cooperative	O
manner	O
.	O
PMID	O
:	O
9177441	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1997	O
Apr	O
;	O
25	O
(3-4)	O
:	O
281	O
-	O
7	O
c-kit	O
Point	O
mutation	O
in	O
patients	O
with	O
myeloproliferative	B-malignancy-type
disorders	I-malignancy-type
.	O
Kimura	O
A	O
,	O
Nakata	O
Y	O
,	O
Katoh	O
O	O
,	O
Hyodo	O
H	O
.	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Myeloproliferative	B-malignancy-type
disorders	I-malignancy-type
(	O
MPD	B-malignancy-type
)	O
constitute	O
a	O
group	O
of	O
hematopoietic	B-malignancy-type
neoplasms	I-malignancy-type
at	O
the	O
myeloid	O
stem	O
cell	O
level	O
.	O
Myeloid	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
from	O
MPD	B-malignancy-type
have	O
been	O
considered	O
sensitive	O
to	O
hematopoietic	O
growth	O
factors	O
,	O
including	O
erythropoietin	O
,	O
thrombopoietin	O
and	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O
SCF	O
is	O
a	O
ligand	O
for	O
c-kit	O
receptor	O
with	O
tyrosine	O
kinase	O
.	O
We	O
analysed	O
the	O
gene	O
alteration	O
of	O
the	O
c-kit	O
extracellular	O
domain	O
in	O
MPD	O
patients	O
by	O
PCR	O
-	O
SSCP	O
and	O
subsequent	O
nucleotide	O
sequencing	O
.	O
The	O
point	O
mutation	O
in	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
domain	O
,	O
codon	O
52	O
(	O
Asp	O
-->	O
Asn	O
)	O
,	O
was	O
found	O
in	O
two	O
patients	O
with	O
primary	O
myelofibrosis	O
and	O
one	O
with	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
We	O
review	O
the	O
literature	O
regarding	O
the	O
role	O
of	O
SCF	O
/	O
c-kit	O
system	O
in	O
the	O
oncogenesis	O
of	O
leukemia	B-malignancy-type
and	O
MPD	B-malignancy-type
,	O
and	O
then	O
discuss	O
the	O
significance	O
of	O
our	O
finding	O
in	O
the	O
context	O
of	O
growth	O
advantage	O
of	O
the	O
mutated	O
clones	O
over	O
the	O
normal	O
clones	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9168438	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1997	O
Jan	O
;	O
24	O
(	O
3-4	O
)	O
:	O
309	O
-	O
17	O
N-ras	O
gene	O
point	O
mutations	O
in	O
Brazilian	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
patients	O
correlate	O
with	O
a	O
poor	O
prognosis	O
.	O
De	O
Melo	O
MB	O
,	O
Lorand-Metze	O
I	O
,	O
Lima	O
CS	O
,	O
Saad	O
ST	O
,	O
Costa	O
FF	O
.	O
Department	O
of	O
Clinical	O
Medicine-Hemocentro	O
,	O
School	O
of	O
Medical	O
Sciences	O
,	O
State	O
University	O
of	O
Campinas	O
(	O
UNICAMP	O
)	O
,	O
SP-Brazil	O
.	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
varies	O
from	O
11	O
to	O
27	O
%	O
in	O
AML	B-malignancy-type
populations	O
from	O
the	O
United	O
States	O
and	O
Europe	O
but	O
it	O
seems	O
that	O
there	O
is	O
no	O
study	O
regarding	O
the	O
frequency	O
of	O
mutated	O
N-ras	O
gene	O
in	O
patients	O
with	O
AML	B-malignancy-type
in	O
South	O
America	O
.	O
In	O
order	O
to	O
study	O
the	O
frequency	O
of	O
N-ras	O
gene	O
mutations	O
(	O
exons	O
1	O
and	O
2	O
)	O
in	O
Brazilian	O
patients	O
with	O
AML	B-malignancy-type
and	O
to	O
evaluate	O
the	O
possible	O
correlation	O
between	O
the	O
presence	O
of	O
the	O
mutation	O
and	O
clinical	O
features	O
,	O
40	O
patients	O
were	O
analyzed	O
.	O
N-ras	O
mutations	O
were	O
identified	O
in	O
DNA	O
samples	O
from	O
eight	O
of	O
40	O
AML	B-malignancy-type
patients	O
(	O
20	O
%	O
)	O
.	O
No	O
significant	O
correlation	O
was	O
found	O
between	O
N-ras	O
mutation	O
and	O
age	O
,	O
sex	O
,	O
race	O
,	O
response	O
to	O
therapy	O
,	O
FAB	O
subtype	O
or	O
occupational	O
exposure	O
.	O
However	O
,	O
the	O
overall	O
survival	O
and	O
AML	B-malignancy-type
-	O
free	O
survival	O
were	O
significantly	O
shorter	O
in	O
patients	O
with	O
N-ras	O
mutations	O
than	O
in	O
those	O
without	O
these	O
abnormalities	O
.	O
PMID	O
:	O
9156660	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Nat	O
Genet	O
1997	O
May	O
;16	O
(	O
1	O
)	O
:68	O
-	O
73	O
Germline	O
and	O
somatic	O
mutations	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Schmidt	O
L,	O
Duh	O
FM	O
,	O
Chen	O
F	O
,	O
Kishida	O
T	O
,	O
Glenn	O
G	O
,	O
Choyke	O
P,	O
Scherer	O
SW	O
,	O
Zhuang	O
Z	O
,	O
Lubensky	O
I	O
,	O
Dean	O
M,	O
Allikmets	O
R	O
,	O
Chidambaram	O
A	O
,	O
Bergerheim	O
UR	O
,	O
Feltis	O
JT	O
,	O
Casadevall	O
C	O
,	O
Zamarron	O
A	O
,	O
Bernues	O
M,	O
Richard	O
S	O
,	O
Lips	O
CJ	O
,	O
Walther	O
MM	O
,	O
Tsui	O
LC	O
,	O
Geil	O
L,	O
Orcutt	O
ML	O
,	O
Stackhouse	O
T	O
,	O
Zbar	O
B	O
,	O
et	O
al	O
.	O
Intramural	O
Research	O
Support	O
Program	O
,	O
SAIC	O
Frederick	O
,	O
MD	O
,	O
USA	O
.	O
Hereditary	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
(	O
HPRC	O
)	O
is	O
a	O
recently	O
recognized	O
form	O
of	O
inherited	O
kidney	B-malignancy-type
cancer	I-malignancy-type
characterized	O
by	O
a	O
predisposition	O
to	O
develop	O
multiple	O
,	O
bilateral	O
papillary	B-malignancy-type
renal	I-malignancy-type
tumours	I-malignancy-type
.	O
The	O
pattern	O
of	O
inheritance	O
of	O
HPRC	O
is	O
consistent	O
with	O
autosomal	O
dominant	O
transmission	O
with	O
reduced	O
penetrance	O
.	O
HPRC	O
is	O
histologically	O
and	O
genetically	O
distinct	O
from	O
two	O
other	O
causes	O
of	O
inherited	O
renal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
von	B-malignancy-type
Hippel	I-malignancy-type
-	I-malignancy-type
Lindau	I-malignancy-type
disease	I-malignancy-type
(	O
VHL	B-malignancy-type
)	O
and	O
the	O
chromosome	O
translocation	O
(	O
3	O
;	O
8	O
)	O
.	O
Malignant	O
papillary	O
renal	O
carcinomas	O
are	O
characterized	O
by	O
trisomy	O
of	O
chromosomes	O
7	O
,	O
16	O
and	O
17	O
,	O
and	O
in	O
men	O
,	O
by	O
loss	O
of	O
the	O
Y	O
chromosome	O
.	O
Inherited	O
and	O
sporadic	B-malignancy-type
clear	I-malignancy-type
cell	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
are	O
characterized	O
by	O
inactivation	O
of	O
both	O
copies	O
of	O
the	O
VHL	O
gene	O
by	O
mutation	O
,	O
and/or	O
by	O
hypermethylation	O
.	O
We	O
found	O
that	O
the	O
HPRC	O
gene	O
was	O
located	O
at	O
chromosome	O
7q	O
31	O
.	O
1	O
-	O
34	O
in	O
a	O
27	O
-	O
centimorgan	O
(	O
cM	O
)	O
interval	O
between	O
D7S496	O
and	O
D7S1837	O
.	O
We	O
identified	O
missense	O
mutations	O
located	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
in	O
the	O
germline	O
of	O
affected	O
members	O
of	O
HPRC	O
families	O
and	O
in	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Three	O
mutations	O
in	O
the	O
MET	O
gene	O
are	O
located	O
in	O
codons	O
that	O
are	O
homologous	O
to	O
those	O
in	O
c-kit	O
and	O
RET	O
,	O
proto	O
-	O
oncogenes	O
that	O
are	O
targets	O
of	O
naturally	O
-	O
occurring	O
mutations	O
.	O
The	O
results	O
suggest	O
that	O
missense	O
mutations	O
located	O
in	O
the	O
MET	O
proto	O
-	O
oncogene	O
lead	O
to	O
constitutive	O
activation	O
of	O
the	O
MET	O
protein	O
and	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9140397	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1997	O
Mar	O
21;275	O
(	O
5307	O
)	O
:1790	O
-2	O
Comment	O
in	O
:	O
Science	O
.	O
1997	O
Mar	O
21;275	O
(	O
5307	O
)	O
:1752-3.	O
Stabilization	O
of	O
beta-catenin	O
by	O
genetic	O
defects	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Rubinfeld	O
B	O
,	O
Robbins	O
P,	O
El	O
-Gamil	O
M,	O
Albert	O
I	O
,	O
Porfiri	O
E	O
,	O
Polakis	O
P.	O
Onyx	O
Pharmaceuticals	O
,	O
3031	O
Research	O
Drive	O
,	O
Richmond	O
,	O
CA	O
94806	O
,	O
USA	O
.	O
Signal	O
transduction	O
by	O
beta-catenin	O
involves	O
its	O
posttranslational	O
stabilization	O
and	O
downstream	O
coupling	O
to	O
the	O
Lef	O
and	O
Tcf	O
transcription	O
factors	O
.	O
Abnormally	O
high	O
amounts	O
of	O
beta-catenin	O
were	O
detected	O
in	O
7	O
of	O
26	O
human	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Unusual	O
messenger	O
RNA	O
splicing	O
and	O
missense	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
that	O
result	O
in	O
stabilization	O
of	O
the	O
protein	O
were	O
identified	O
in	O
six	O
of	O
the	O
lines	O
,	O
and	O
the	O
adenomatous	O
polyposis	O
coli	O
tumor	O
suppressor	O
protein	O
(	O
APC	O
)	O
was	O
altered	O
or	O
missing	O
in	O
two	O
others	O
.	O
In	O
the	O
APC	O
-	O
deficient	O
cells	O
,	O
ectopic	O
expression	O
of	O
wild	O
-	O
type	O
APC	O
eliminated	O
the	O
excess	O
beta-catenin	O
.	O
Cells	O
with	O
stabilized	O
beta-catenin	O
contained	O
a	O
constitutive	O
beta-catenin	O
-	O
Lef-1	O
complex	O
.	O
Thus	O
,	O
genetic	O
defects	O
that	O
result	O
in	O
up	O
-	O
regulation	O
of	O
beta-catenin	O
may	O
play	O
a	O
role	O
in	O
melanoma	B-malignancy-type
progression	O
.	O
PMID	O
:	O
9065403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Thyroid	O
1996	O
Oct;	O
6	O
(	O
5	O
)	O
:	O
409	O
-	O
16	O
Prevalence	O
of	O
activating	O
ras	O
mutations	O
in	O
morphologically	O
characterized	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
Ezzat	O
S	O
,	O
Zheng	O
L,	O
Kolenda	O
J,	O
Safarian	O
A	O
,	O
Freeman	O
JL	O
,	O
Asa	O
SL	O
.	O
Department	O
of	O
Medicine	O
,	O
Wellesley	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Ras	O
proteins	O
are	O
signal	O
-	O
transducing	O
proteins	O
that	O
share	O
common	O
properties	O
with	O
membrane	O
-	O
anchored	O
G	O
proteins	O
.	O
Mutations	O
at	O
codon	O
12	O
/	O
13	O
or	O
codon	O
61	O
alter	O
GTP	O
-	O
binding	O
or	O
GTPase	O
activity	O
,	O
respectively	O
.	O
Such	O
activating	O
mutations	O
are	O
present	O
in	O
nearly	O
30	O
-	O
50	O
%	O
of	O
various	O
malignancies	O
including	O
colon	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
and	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
.	O
There	O
are	O
conflicting	O
data	O
regarding	O
the	O
prevalence	O
of	O
ras	O
mutations	O
in	O
the	O
thyroid	O
and	O
their	O
possible	O
pathogenetic	O
role	O
in	O
the	O
different	O
tumor	O
types	O
.	O
To	O
address	O
this	O
question	O
,	O
we	O
examined	O
45	O
morphologically	O
characterized	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
,	O
adenomas	B-malignancy-type
,	O
and	O
hyperplastic	B-malignancy-type
nodules	I-malignancy-type
using	O
a	O
highly	O
sensitive	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
approach	O
combined	O
with	O
DNA	O
-	O
sequencing	O
.	O
DNA	O
from	O
cell	O
lines	O
with	O
known	O
mutations	O
served	O
as	O
controls	O
.	O
A	O
G	O
to	O
A	O
H	O
13	O
codon	O
substitution	O
replacing	O
an	O
Asp	O
for	O
a	O
Gly	O
residue	O
was	O
detected	O
in	O
1	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Although	O
no	O
H	O
12	O
or	O
H	O
61	O
codon	O
substitutions	O
were	O
identified	O
,	O
2	O
discrete	O
alterations	O
were	O
identified	O
in	O
codons	O
H	O
17	O
and	O
22	O
.	O
No	O
N	O
12	O
/	O
13	O
codon	O
substitutions	O
were	O
identified	O
.	O
N	O
61	O
codon	O
substitutions	O
of	O
A	O
to	O
G	O
resulting	O
in	O
a	O
Gly	O
to	O
Arg	O
substitution	O
were	O
detected	O
in	O
2	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
;	O
the	O
same	O
mutation	O
was	O
also	O
found	O
in	O
one	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
.	O
Interestingly	O
,	O
K	O
12	O
/	O
13	O
and	O
K	O
61	O
ras	O
mutations	O
were	O
not	O
present	O
in	O
any	O
of	O
the	O
tumors	O
examined	O
.	O
These	O
data	O
establish	O
a	O
low	O
prevalence	O
of	O
mutations	O
in	O
all	O
ras	O
gene	O
family	O
members	O
in	O
human	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
This	O
difference	O
from	O
neoplasms	O
of	O
other	O
organs	O
may	O
explain	O
the	O
relatively	O
indolent	O
biologic	O
behavior	O
of	O
many	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
and	O
supports	O
an	O
alternate	O
early	O
genetic	O
mutation	O
that	O
is	O
more	O
characteristic	O
of	O
these	O
neoplasms	O
.	O
PMID	O
:	O
8936664	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1996	O
Sep;149(	O
3	O
)	O
:	O
883	O
-	O
93	O
Comment	O
in	O
:	O
Am	O
J	O
Pathol	O
.	O
1996	O
Sep;149(	O
3	O
)	O
:739	O
-	O
44	O
.	O
Relevance	O
of	O
ultraviolet	O
-	O
induced	O
N-ras	O
oncogene	O
point	O
mutations	O
in	O
development	O
of	O
primary	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
van	O
Elsas	O
A	O
,	O
Zerp	O
SF	O
,	O
van	O
der	O
Flier	O
S	O
,	O
Kruse	O
KM	O
,	O
Aarnoudse	O
C	O
,	O
Hayward	O
NK	O
,	O
Ruiter	O
DJ	O
,	O
Schrier	O
PI.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
University	O
Hospital	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Intermittent	O
or	O
recreational	O
exposure	O
to	O
sunlight	O
is	O
thought	O
to	O
contribute	O
to	O
development	O
of	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
We	O
investigated	O
the	O
incidence	O
of	O
ras	O
oncogene	O
mutation	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
in	O
connection	O
to	O
sun	O
-	O
exposed	O
body	O
sites	O
in	O
the	O
patient	O
,	O
using	O
a	O
large	O
series	O
of	O
DNA	O
samples	O
derived	O
from	O
paraffin	O
-	O
embedded	O
material	O
as	O
well	O
as	O
from	O
fresh	O
tumor	O
samples	O
and	O
cell	O
lines	O
.	O
We	O
first	O
show	O
that	O
,	O
of	O
the	O
ras	O
family	O
,	O
predominantly	O
N-ras	O
is	O
activated	O
(	O
15	O
%	O
)	O
,	O
whereas	O
rarely	O
H-ras	O
or	O
K-ras	O
are	O
mutated	O
.	O
The	O
occurrence	O
of	O
N-ras	O
mutations	O
correlates	O
with	O
continuous	O
exposure	O
to	O
sunlight	O
of	O
the	O
primary	O
tumor	O
site	O
.	O
Of	O
all	O
tumors	O
initiated	O
on	O
chronically	O
sun	O
-	O
exposed	O
body	O
sites	O
,	O
26	O
%	O
contained	O
mutated	O
N-ras	O
,	O
in	O
contrast	O
to	O
0	O
%	O
of	O
sun	O
-	O
protected	O
melanomas	B-malignancy-type
.	O
Melanoma	B-malignancy-type
lesions	I-malignancy-type
obtained	O
from	O
patients	O
from	O
North	O
or	O
Central	O
Europe	O
contained	O
fewer	O
N-ras	O
mutations	O
(	O
12	O
%	O
)	O
as	O
compared	O
with	O
patients	O
from	O
Australia	O
(	O
24	O
%	O
)	O
.	O
Mutations	O
were	O
specifically	O
associated	O
with	O
nodular	B-malignancy-type
melanoma	I-malignancy-type
and	O
to	O
a	O
lesser	O
extent	O
with	O
lentigo	B-malignancy-type
malignant	I-malignancy-type
melanoma	I-malignancy-type
.	O
N-ras	O
mutations	O
did	O
not	O
correlate	O
with	O
metastasis	O
or	O
survival	O
parameters	O
.	O
This	O
study	O
identifies	O
a	O
subset	O
of	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
that	O
contain	O
in	O
the	O
primary	O
lesion	O
ultraviolet	O
-	O
induced	O
N-ras	O
mutations	O
,	O
which	O
are	O
maintained	O
through	O
further	O
progression	O
.	O
PMID	O
:	O
8780392	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
1995	O
Aug;	O
62(	O
2	O
)	O
:91-7	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
are	O
very	O
rare	O
events	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
Yasuga	O
Y	O
,	O
Hirosawa	O
S	O
,	O
Yamamoto	O
K,	O
Tomiyama	O
J,	O
Nagata	O
K,	O
Aokia	O
N	O
.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
,	O
Japan	O
.	O
The	O
frequencies	O
of	O
p53	O
and	O
N-ras	O
gene	O
mutations	O
were	O
examined	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
DNA	O
samples	O
of	O
45	O
cases	O
of	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
were	O
obtained	O
from	O
stored	O
bone	O
marrow	O
smears	O
.	O
All	O
samples	O
were	O
analyzed	O
for	O
the	O
N-ras	O
gene	O
at	O
codon	O
12	O
by	O
the	O
allele	O
specific	O
restriction	O
analysis	O
method	O
and	O
at	O
codon	O
61	O
by	O
direct	O
sequencing	O
.	O
DNA	O
was	O
screened	O
for	O
mutations	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
for	O
the	O
p53	O
gene	O
in	O
exons	O
5	O
to	O
8	O
.	O
DNA	O
fragments	O
showing	O
an	O
altered	O
electrophoretic	O
pattern	O
were	O
further	O
studied	O
by	O
direct	O
sequencing	O
to	O
confirm	O
the	O
mutations	O
.	O
Ras	O
mutations	O
were	O
found	O
in	O
two	O
cases	O
at	O
codon	O
61	O
(	O
4.4	O
%	O
)	O
.	O
A	O
point	O
mutation	O
of	O
the	O
p53	O
gene	O
was	O
detected	O
in	O
one	O
of	O
45	O
cases	O
(	O
2.2	O
%	O
)	O
.	O
These	O
3	O
cases	O
with	O
mutations	O
were	O
in	O
an	O
advanced	O
stage	O
.	O
In	O
conclusion	O
,	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
may	O
occur	O
at	O
a	O
late	O
stage	O
of	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
,	O
but	O
the	O
frequencies	O
of	O
the	O
mutations	O
are	O
very	O
low	O
.	O
PMID	O
:	O
8590778	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
1995	O
Nov;30	O
Suppl	O
8	O
:	O
30-2	O
Detection	O
of	O
c-ras	O
gene	O
mutation	O
and	O
expression	O
of	O
p21	O
protein	O
in	O
dysplasias	B-malignancy-type
and	O
carcinomas	B-malignancy-type
complicating	O
ulcerative	O
colitis	O
.	O
Tsuda	O
T	O
,	O
Mochizuki	O
M,	O
Wakasa	O
H.	O
Department	O
of	O
Pathology	O
,	O
Fukushima	O
Medical	O
College	O
,	O
Japan	O
.	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
and	O
the	O
expression	O
of	O
p21	O
protein	O
were	O
analyzed	O
in	O
13	O
patients	O
with	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
complicating	O
ulcerative	O
colitis	O
;	O
in	O
12	O
of	O
the	O
13	O
,	O
there	O
were	O
dysplastic	B-malignancy-type
lesions	I-malignancy-type
close	O
to	O
the	O
carcinomas	B-malignancy-type
.	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
were	O
studied	O
by	O
polymerase	O
chain	O
reaction	O
and	O
dot	O
blot	O
hybridization	O
with	O
32p	O
-	O
labeled	O
oligonucleotide	O
probes	O
.	O
Findings	O
indicated	O
mutations	O
of	O
c-Ki-ras	O
at	O
condons	O
12	O
,	O
13	O
,	O
and	O
61	O
and	O
c-Ha-ras	O
and	O
c-N-ras	O
at	O
condons	O
12	O
and	O
61	O
.	O
The	O
expression	O
of	O
p21	O
protein	O
was	O
analyzed	O
by	O
immunohistochemical	O
staining	O
using	O
a	O
monoclonal	O
antibody	O
.	O
Only	O
1	O
of	O
the	O
13	O
patients	O
with	O
carcinoma	B-malignancy-type
showed	O
a	O
point	O
mutation	O
,	O
this	O
being	O
from	O
G	O
to	O
A	O
transition	O
at	O
the	O
second	O
position	O
of	O
codon	O
12	O
of	O
c-Ki-ras	O
.	O
No	O
point	O
mutations	O
of	O
c-Ki-ras	O
,	O
c-Ha-ras	O
,	O
or	O
c-N-ras	O
were	O
found	O
in	O
other	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
and	O
dysplasias	B-malignancy-type
.	O
In	O
the	O
dysplastic	B-malignancy-type
or	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
of	O
11	O
patients	O
,	O
the	O
increased	O
expression	O
of	O
p21	O
protein	O
was	O
observed	O
.	O
These	O
results	O
suggest	O
that	O
point	O
mutations	O
of	O
c-ras	O
genes	O
are	O
rare	O
in	O
dysplasias	B-malignancy-type
and	O
carcinomas	B-malignancy-type
complicating	O
ulcerative	O
colitis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
p21	O
protein	O
is	O
not	O
always	O
correlated	O
with	O
point	O
mutations	O
of	O
c-ras	O
genes	O
.	O
PMID	O
:	O
8563883	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1993	O
Apr;8	O
4	O
(	O
4	O
)	O
:	O
379	O
-	O
87	O
Clonal	O
analysis	O
of	O
multiple	O
point	O
mutations	O
in	O
the	O
N-ras	O
gene	O
in	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Kubo	O
K,	O
Naoe	O
T	O
,	O
Kiyoi	O
H,	O
Fukutani	O
H,	O
Kato	O
Y	O
,	O
Oguri	O
T	O
,	O
Yamamori	O
S	O
,	O
Akatsuka	O
Y	O
,	O
Kodera	O
Y	O
,	O
Ohno	O
R.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nagoya	O
University	O
Branch	O
Hospital	O
.	O
We	O
have	O
screened	O
mutations	O
of	O
the	O
N-ras	O
gene	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
in	O
leukemia	B-malignancy-type
cells	O
obtained	O
from	O
100	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
and	O
found	O
mutated	O
N-ras	O
alleles	O
in	O
9	O
patients	O
.	O
We	O
further	O
analyzed	O
the	O
polyclonality	O
of	O
multiple	O
N-ras	O
gene	O
mutations	O
in	O
4	O
AML	B-malignancy-type
patients	O
.	O
One	O
patient	O
,	O
who	O
had	O
the	O
monoclonal	O
karyotype	O
,	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
had	O
two	O
types	O
of	O
double	O
missense	O
mutations	O
at	O
codons	O
13	O
and	O
61	O
in	O
the	O
same	O
allele	O
.	O
Each	O
of	O
the	O
remaining	O
three	O
patients	O
,	O
one	O
of	O
whom	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
a	O
monoclonal	O
rearrangement	O
of	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
and	O
PML	O
genes	O
,	O
carried	O
two	O
missense	O
mutations	O
in	O
a	O
relatively	O
small	O
population	O
of	O
leukemia	B-malignancy-type
cells	O
.	O
We	O
have	O
demonstrated	O
that	O
multiple	O
clonality	O
of	O
the	O
N-ras	O
gene	O
is	O
occasionally	O
observed	O
in	O
leukemia	B-malignancy-type
with	O
a	O
monoclonal	O
karyotype	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
N-ras	O
mutations	O
may	O
not	O
always	O
be	O
characterized	O
simply	O
by	O
an	O
accumulative	O
process	O
and	O
that	O
the	O
activated	O
N-ras	O
gene	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
leukemia	B-malignancy-type
.	O
PMID	O
:	O
8514604	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1993	O
Apr	O
1;53(	O
7)	O
:1625	O
-	O
9	O
High	O
mutation	O
frequency	O
in	O
ras	O
genes	O
of	O
skin	B-malignancy-type
tumors	I-malignancy-type
isolated	O
from	O
DNA	O
repair	O
deficient	O
xeroderma	B-malignancy-type
pigmentosum	I-malignancy-type
patients	O
.	O
Daya	O
-	O
Grosjean	O
L,	O
Robert	O
C	O
,	O
Drougard	O
C	O
,	O
Suarez	O
H	O
,	O
Sarasin	O
A.	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O
Institut	O
de	O
Recherches	O
Scientifiques	O
sur	O
le	O
Cancer	O
,	O
Villejuif	O
,	O
France	O
.	O
Xeroderma	B-malignancy-type
pigmentosum	I-malignancy-type
(	O
XP	B-malignancy-type
)	O
patients	O
are	O
clinically	O
characterized	O
by	O
a	O
very	O
high	O
incidence	O
of	O
skin	O
cancers	O
on	O
exposed	O
skin	O
,	O
at	O
an	O
early	O
age	O
.	O
XP	O
cells	O
in	O
vitro	O
are	O
strongly	O
deficient	O
in	O
excision	O
-	O
repair	O
and	O
highly	O
mutagenized	O
by	O
UV	O
light	O
.	O
We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
measuring	O
mutation	O
frequency	O
and	O
in	O
determining	O
mutation	O
spectra	O
in	O
patients	O
'	O
tumors	O
exposed	O
to	O
UV	O
lesions	O
.	O
We	O
chose	O
to	O
look	O
at	O
oncogene	O
activation	O
in	O
skin	B-malignancy-type
tumors	I-malignancy-type
with	O
the	O
idea	O
that	O
more	O
mutations	O
,	O
particularly	O
of	O
the	O
ras	O
gene	O
family	O
,	O
would	O
be	O
found	O
in	O
XP	B-malignancy-type
tumors	I-malignancy-type
where	O
lesions	O
remain	O
unrepaired	O
compared	O
to	O
normal	O
individuals	O
.	O
Our	O
results	O
clearly	O
show	O
that	O
more	O
than	O
a	O
2	O
-	O
fold	O
significantly	O
higher	O
mutation	O
frequency	O
(	O
50	O
%	O
)	O
of	O
the	O
ras	O
genes	O
was	O
found	O
in	O
XP	B-malignancy-type
in	O
contrast	O
to	O
control	O
tumors	O
(	O
22	O
%	O
)	O
.	O
The	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
at	O
codon	O
12	O
of	O
all	O
three	O
ras	O
genes	O
with	O
a	O
preponderance	O
for	O
N-ras	O
in	O
XP	B-malignancy-type
samples	O
.	O
The	O
mutation	O
spectra	O
indicate	O
that	O
all	O
mutations	O
found	O
were	O
located	O
opposite	O
pyrimidine	O
-	O
pyrimidine	O
sequences	O
which	O
represent	O
a	O
hot	O
spot	O
for	O
UV	O
-	O
induced	O
DNA	O
lesions	O
.	O
Most	O
of	O
the	O
mutations	O
were	O
of	O
the	O
type	O
expected	O
from	O
studies	O
performed	O
in	O
vitro	O
with	O
model	O
systems	O
.	O
This	O
high	O
mutation	O
frequency	O
in	O
XP	B-malignancy-type
was	O
accompanied	O
by	O
a	O
very	O
high	O
level	O
of	O
Ha-ras	O
and	O
c-myc	O
gene	O
amplification	O
and	O
rearrangement	O
.	O
All	O
these	O
data	O
are	O
consistent	O
with	O
a	O
fundamental	O
role	O
of	O
unrepaired	O
UV	O
-	O
induced	O
DNA	O
lesions	O
as	O
an	O
initiating	O
event	O
in	O
human	O
skin	B-malignancy-type
tumors	I-malignancy-type
on	O
exposed	O
parts	O
of	O
the	O
body	O
.	O
PMID	O
:	O
8453633	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Aug;8(	O
8	O
)	O
:1331	O
-	O
6	O
N-ras	O
mutation	O
and	O
karyotypic	O
evolution	O
are	O
closely	O
associated	O
with	O
leukemic	O
transformation	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Horiike	O
S,	O
Misawa	O
S,	O
Nakai	O
H	O
,	O
Kaneko	O
H	O
,	O
Yokota	O
S,	O
Taniwaki	O
M,	O
Yamane	O
Y	O
,	O
Inazawa	O
J,	O
Abe	O
T	O
,	O
Kashima	O
K.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
III	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
performed	O
a	O
longitudinal	O
analysis	O
of	O
the	O
karyotypes	O
and	O
N-ras	O
gene	O
configuration	O
of	O
bone	O
marrow	O
cells	O
in	O
35	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Karyotypic	O
evolution	O
was	O
found	O
in	O
eight	O
patients	O
,	O
and	O
was	O
associated	O
with	O
disease	O
progression	O
,	O
including	O
leukemic	O
transformation	O
,	O
in	O
all	O
the	O
patients	O
.	O
We	O
identified	O
N-ras	O
mutations	O
in	O
six	O
patients	O
,	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
,	O
in	O
which	O
oligonucleotide	O
primers	O
were	O
constructed	O
with	O
induced	O
mismatches	O
,	O
followed	O
by	O
endonuclease	O
digestion	O
.	O
Direct	O
sequencing	O
confirmed	O
single	O
base	O
substitutions	O
at	O
codon	O
12	O
in	O
two	O
patients	O
and	O
at	O
codon	O
13	O
in	O
four	O
.	O
The	O
incidence	O
of	O
N-ras	O
gene	O
mutations	O
was	O
significantly	O
higher	O
in	O
the	O
karyotypically	O
evolved	O
group	O
(	O
five	O
of	O
eight	O
patients	O
)	O
than	O
in	O
the	O
stable	O
group	O
(	O
one	O
of	O
27	O
patients	O
)	O
.	O
All	O
of	O
five	O
patients	O
harboring	O
both	O
karyotypic	O
evolution	O
and	O
an	O
N-ras	O
mutation	O
showed	O
concomitant	O
disease	O
progression	O
to	O
overt	B-malignancy-type
leukemia	I-malignancy-type
or	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
in	O
transformation	O
(	O
RAEB-T	O
)	O
.	O
Two	O
of	O
four	O
patients	O
with	O
either	O
karyotypic	O
evolution	O
or	O
N-ras	O
mutation	O
and	O
six	O
of	O
26	O
patients	O
without	O
any	O
of	O
these	O
alterations	O
also	O
progressed	O
to	O
overt	B-malignancy-type
leukemia	I-malignancy-type
.	O
Our	O
results	O
indicate	O
that	O
the	O
accumulation	O
of	O
these	O
genetic	O
alterations	O
is	O
closely	O
associated	O
with	O
leukemic	O
transformation	O
of	O
MDS	B-malignancy-type
,	O
although	O
other	O
genetic	O
alterations	O
may	O
also	O
play	O
a	O
key	O
role	O
in	O
the	O
remaining	O
patients	O
.	O
PMID	O
:	O
8057669	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Dermatol	O
1994	O
Jul;131(	O
1	O
)	O
:72	O
-	O
7	O
Point	O
mutations	O
in	O
the	O
N-ras	O
oncogene	O
in	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
and	O
congenital	B-malignancy-type
naevi	I-malignancy-type
.	O
Carr	O
J,	O
Mackie	O
RM	O
.	O
Department	O
of	O
Dermatology	O
,	O
University	O
of	O
Glasgow	O
,	O
U.K.	O
DNA	O
from	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
processed	O
samples	O
from	O
100	O
melanocytic	B-malignancy-type
lesions	I-malignancy-type
(	O
39	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
,	O
18	O
cases	O
of	O
dysplastic	B-malignancy-type
naevi	I-malignancy-type
,	O
and	O
43	O
congenital	B-malignancy-type
naevi	I-malignancy-type
)	O
was	O
extracted	O
,	O
and	O
the	O
sequences	O
around	O
codons	O
12	O
/	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
oncogene	O
were	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
The	O
amplified	O
product	O
was	O
then	O
analysed	O
both	O
by	O
dot	O
-	O
blotting	O
and	O
by	O
direct	O
sequencing	O
for	O
point	O
mutations	O
.	O
By	O
the	O
dot	O
-	O
blotting	O
technique	O
,	O
mutations	O
were	O
seen	O
in	O
18	O
of	O
100	O
lesions	O
.	O
These	O
were	O
in	O
one	O
of	O
five	O
distant	O
metastases	O
(	O
20	O
%	O
)	O
,	O
in	O
one	O
of	O
three	O
nodal	O
metastases	O
(	O
33	O
%	O
)	O
,	O
in	O
four	O
of	O
31	O
(	O
13	O
%	O
)	O
primary	O
melanomas	B-malignancy-type
,	O
in	O
none	O
of	O
18	O
dysplastic	O
naevi	O
,	O
and	O
in	O
12	O
of	O
43	O
(	O
28	O
%	O
)	O
congenital	B-malignancy-type
naevi	I-malignancy-type
,	O
all	O
at	O
codon	O
61	O
.	O
On	O
direct	O
sequencing	O
,	O
nine	O
of	O
18	O
mutations	O
were	O
confirmed	O
,	O
in	O
two	O
of	O
31	O
(	O
6	O
%	O
)	O
primary	O
tumours	O
,	O
one	O
distant	O
metastasis	O
,	O
and	O
six	O
of	O
43	O
(	O
14	O
%	O
)	O
congenital	B-malignancy-type
naevi	I-malignancy-type
.	O
Of	O
the	O
23	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanomas	I-malignancy-type
examined	O
,	O
eight	O
were	O
on	O
sun	O
-	O
exposed	O
skin	O
.	O
A	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanoma	I-malignancy-type
,	O
in	O
which	O
the	O
N-ras	O
mutation	O
at	O
codon	O
61	O
was	O
confirmed	O
,	O
was	O
on	O
non	O
-	O
exposed	O
skin	O
,	O
and	O
an	O
unconfirmed	O
mutation	O
was	O
from	O
an	O
exposed	O
site	O
.	O
One	O
of	O
three	O
nodular	B-malignancy-type
melanomas	I-malignancy-type
with	O
a	O
confirmed	O
mutation	O
was	O
on	O
a	O
light	O
-	O
exposed	O
site	O
,	O
and	O
the	O
other	O
two	O
nodular	B-malignancy-type
melanomas	I-malignancy-type
were	O
from	O
non	O
-	O
exposed	O
areas	O
.	O
All	O
four	O
lentigo	B-malignancy-type
maligna	I-malignancy-type
melanomas	I-malignancy-type
were	O
from	O
exposed	O
sites	O
,	O
and	O
one	O
of	O
these	O
had	O
an	O
unconfirmed	O
mutation	O
.	O
The	O
only	O
acral	B-malignancy-type
lentiginous	I-malignancy-type
melanoma	I-malignancy-type
,	O
which	O
had	O
no	O
mutation	O
,	O
was	O
from	O
a	O
sun	O
-	O
exposed	O
area	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
8043423	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Oct;8(	O
10	O
)	O
:1682	O
-	O
7	O
The	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutations	O
in	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Coghlan	O
DW	O
,	O
Morley	O
AA	O
,	O
Matthews	O
JP	O
,	O
Bishop	O
JF.	O
Department	O
of	O
Haematology	O
,	O
Flinders	O
Medical	O
Centre	O
,	O
Bedford	O
Park	O
,	O
South	O
Australia	O
.	O
To	O
determine	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutation	O
in	O
the	O
N-ras	O
gene	O
in	O
de	O
novo	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
we	O
performed	O
an	O
analysis	O
of	O
bone	O
marrow	O
smears	O
from	O
219	O
patients	O
with	O
de	O
novo	O
AML	B-malignancy-type
treated	O
between	O
1984	O
and	O
1986	O
and	O
followed	O
for	O
at	O
least	O
six	O
years	O
.	O
DNA	O
extracted	O
from	O
bone	O
marrow	O
smears	O
taken	O
at	O
diagnosis	O
was	O
screened	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
exon	O
1	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
to	O
insert	O
an	O
Hph1	O
restriction	O
enzyme	O
site	O
into	O
DNA	O
.	O
Presumptive	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
Mutations	O
were	O
detected	O
in	O
a	O
total	O
of	O
26	O
patients	O
(	O
12	O
%	O
)	O
;	O
in	O
nine	O
patients	O
(	O
4	O
%	O
)	O
in	O
codon	O
12	O
only	O
,	O
in	O
ten	O
patients	O
(	O
5	O
%	O
)	O
in	O
codon	O
13	O
only	O
,	O
and	O
in	O
seven	O
patients	O
(	O
3	O
%	O
)	O
in	O
both	O
codons	O
.	O
Mutations	O
in	O
codon	O
12	O
or	O
codon	O
13	O
were	O
not	O
associated	O
with	O
any	O
clinical	O
features	O
.	O
Mutations	O
in	O
codon	O
12	O
had	O
no	O
prognostic	O
significance	O
but	O
mutations	O
in	O
codon	O
13	O
were	O
associated	O
with	O
an	O
increased	O
remission	O
rate	O
,	O
a	O
more	O
durable	O
remission	O
,	O
and	O
a	O
significantly	O
prolonged	O
survival	O
which	O
appeared	O
to	O
be	O
independent	O
of	O
other	O
prognostic	O
factors	O
.	O
PMID	O
:	O
7934163	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Oncol	O
1995	O
;34(	O
6)	O
:759	O
-	O
65	O
Glutathione	O
transferase	O
P1-1	O
expression	O
in	O
human	O
melanoma	B-malignancy-type
metastases	O
:	O
correlation	O
to	O
N-RAS	O
mutations	O
and	O
expression	O
.	O
Platz	O
A	O
,	O
Jungnelius	O
U	O
,	O
Grafstrom	O
E	O
,	O
Lagerlof	O
B	O
,	O
Mannervik	O
B	O
,	O
Ringborg	O
U.	O
Department	O
of	O
Oncology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Expression	O
of	O
the	O
detoxication	O
enzyme	O
glutathione	O
transferase	O
P1-1	O
(	O
GST	O
P1-1	O
)	O
at	O
elevated	O
levels	O
has	O
been	O
noted	O
in	O
many	O
types	O
of	O
human	O
tumors	O
,	O
including	O
melanomas	B-malignancy-type
.	O
The	O
products	O
of	O
the	O
human	O
H-RAS	O
,	O
K-RAS	O
and	O
N-RAS	O
genes	O
play	O
a	O
key	O
role	O
in	O
intracellular	O
signal	O
transduction	O
leading	O
to	O
transcriptional	O
activation	O
of	O
AP-1	O
(	O
Fos	O
/	O
Jun	O
)	O
responsive	O
genes	O
.	O
The	O
oncogenic	O
mutated	O
forms	O
of	O
the	O
ras	O
proteins	O
are	O
constitutively	O
active	O
and	O
interfere	O
with	O
normal	O
signal	O
transduction	O
.	O
Mutated	O
RAS	O
genes	O
as	O
well	O
as	O
increased	O
expression	O
of	O
wild	O
-	O
type	O
ras	O
proteins	O
are	O
common	O
features	O
in	O
human	O
tumors	O
including	O
melanoma	B-malignancy-type
.	O
We	O
have	O
characterized	O
30	O
melanoma	B-malignancy-type
metastases	O
from	O
23	O
melanoma	B-malignancy-type
patients	O
with	O
reference	O
to	O
N-RAS	O
expression	O
and	O
mutation	O
as	O
well	O
as	O
to	O
GST	O
P1	O
expression	O
(	O
immunohistochemistry	O
and	O
genetic	O
analysis	O
)	O
.	O
Twenty-three	O
of	O
30	O
samples	O
(	O
70	O
%	O
)	O
had	O
high	O
N-Ras	O
p21	O
and/or	O
N-RAS	O
codon	O
61	O
mutations	O
and	O
18	O
of	O
these	O
23	O
samples	O
also	O
had	O
high	O
GST	O
P1-1	O
immunoreactivity	O
.	O
Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
samples	O
had	O
low	O
N-Ras	O
p21	O
immunoreactivity	O
and	O
no	O
detectable	O
N-RAS	O
codon	O
61	O
mutations	O
.	O
Six	O
of	O
these	O
7	O
samples	O
(	O
86	O
%	O
)	O
also	O
had	O
low	O
GST	O
P1-1	O
immunoreactivity	O
.	O
The	O
results	O
indicate	O
a	O
statistically	O
significant	O
correlation	O
(	O
Spearman	O
correlation	O
coefficient	O
,	O
r	O
=	O
0.56	O
,	O
p	O
=	O
0.001	O
,	O
2	O
-	O
tailed	O
test	O
)	O
and	O
provide	O
,	O
for	O
the	O
first	O
time	O
,	O
indirect	O
evidence	O
for	O
a	O
possible	O
coregulation	O
of	O
N-RAS	O
and	O
GST	O
P1	O
in	O
human	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
which	O
should	O
be	O
further	O
evaluated	O
.	O
PMID	O
:	O
7576742	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nippon	O
Shokakibyo	O
Gakkai	O
Zasshi	O
1989	O
Nov;86(	O
11	O
)	O
:2566	O
-	O
71	O
[	O
Detection	O
of	O
ras	O
gene	O
mutations	O
of	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
method	O
]	O
[Article	O
in	O
Japanese	O
]	O
Tada	O
M,	O
Yokosuka	O
O	O
,	O
Omata	O
M,	O
Ohto	O
M,	O
Isono	O
K.	O
Ras	O
genes	O
(	O
H	O
-	O
,	O
K	O
-	O
,	O
N	O
-	O
ras	O
)	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
occurring	O
in	O
either	O
codon	O
12	O
,	O
13	O
or	O
61	O
.	O
We	O
analyzed	O
19	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
(	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
)	O
of	O
these	O
codons	O
by	O
a	O
method	O
to	O
directly	O
sequence	O
nucleotides	O
around	O
codons	O
12	O
/	O
13	O
and	O
61	O
of	O
the	O
three	O
ras	O
genes	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
method	O
.	O
Of	O
19	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
,	O
all	O
17	O
duct	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
involving	O
2	O
mucous	O
producing	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
had	O
point	O
mutations	O
of	O
the	O
K-ras	O
codon	O
12	O
,	O
but	O
2	O
islet	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
had	O
ano	O
point	O
mutation	O
around	O
codons	O
12	O
,	O
13	O
,	O
61	O
of	O
the	O
three	O
ras	O
genes	O
.	O
Extremely	O
high	O
incidence	O
of	O
ras	O
gene	O
mutation	O
may	O
be	O
relevant	O
to	O
certain	O
pathogenesis	O
of	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
2689731	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1989	O
Jul;3(	O
7)	O
:511	O
-	O
5	O
c-myc	O
amplification	O
coexistent	O
with	O
activating	O
N-ras	O
point	O
mutation	O
in	O
the	O
biphenotypic	O
leukemic	O
cell	O
line	O
RED-3	O
.	O
Mallet	O
MK	O
,	O
Mane	O
SM	O
,	O
Meltzer	O
SJ	O
,	O
Needleman	O
SW.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Maryland	O
Hospital	O
,	O
Baltimore	O
21201	O
.	O
While	O
activation	O
of	O
the	O
protooncogene	O
c-N-ras	O
is	O
observed	O
regularly	O
in	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
,	O
amplification	O
of	O
c-myc	O
in	O
AML	B-malignancy-type
cells	O
or	O
derived	O
lines	O
is	O
uncommon	O
.	O
In	O
particular	O
,	O
concurrent	O
ras	O
/	O
myc	O
activation	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
critical	O
in	O
several	O
elegant	O
models	O
of	O
malignancy	O
,	O
has	O
been	O
demonstrated	O
in	O
a	O
very	O
small	O
number	O
of	O
human	O
tumors	O
or	O
derivative	O
cell	O
lines	O
.	O
A	O
cell	O
line	O
,	O
RED-3	O
,	O
is	O
described	O
which	O
was	O
derived	O
from	O
cells	O
of	O
a	O
patient	O
with	O
aggressive	B-malignancy-type
acute	I-malignancy-type
leukemia	I-malignancy-type
which	O
exhibits	O
many	O
markers	O
of	O
lineage	O
infidelity	O
.	O
DNA	O
from	O
this	O
cell	O
line	O
contains	O
an	O
activating	O
point	O
mutation	O
of	O
c-N-ras	O
as	O
well	O
as	O
20	O
-	O
30	O
-	O
fold	O
amplification	O
of	O
c-myc	O
.	O
After	O
HL-60	O
,	O
this	O
is	O
the	O
second	O
example	O
of	O
ras	O
/	O
myc	O
activation	O
in	O
AML	B-malignancy-type
derived	O
cells	O
and	O
demonstrates	O
that	O
this	O
lesion	O
is	O
not	O
unique	O
to	O
HL-60	O
.	O
Rather	O
,	O
it	O
may	O
be	O
important	O
in	O
leukemogenesis	O
in	O
a	O
small	O
proportion	O
of	O
AML	B-malignancy-type
patients	O
.	O
PMID	O
:	O
2659902	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Feb;4(	O
2	O
)	O
:159	O
-	O
64	O
High	O
frequency	O
of	O
ras	O
oncogene	O
activation	O
in	O
all	O
stages	O
of	O
human	O
thyroid	O
tumorigenesis	O
.	O
Lemoine	O
NR	O
,	O
Mayall	O
ES	O
,	O
Wyllie	O
FS	O
,	O
Williams	O
ED	O
,	O
Goyns	O
M,	O
Stringer	O
B	O
,	O
Wynford	O
-	O
Thomas	O
D.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Health	O
Park	O
,	O
Cardiff	O
,	O
UK.	O
Using	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
oligonucleotide	O
probing	O
,	O
the	O
activation	O
of	O
ras	O
oncogenes	O
in	O
24	O
benign	B-malignancy-type
and	O
20	O
malignant	B-malignancy-type
human	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
was	O
examined	O
.	O
The	O
frequency	O
of	O
ras	O
oncogene	O
activation	O
was	O
similar	O
at	O
all	O
stages	O
of	O
tumorigenesis	O
in	O
this	O
system	O
,	O
being	O
found	O
in	O
33	O
%	O
of	O
adenomas	B-malignancy-type
overall	O
(	O
50	O
%	O
of	O
microfollicular	O
tumours	O
)	O
,	O
53	O
%	O
of	O
differentiated	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
and	O
60	O
%	O
of	O
undifferentiated	O
carcinomas	O
.	O
This	O
supports	O
the	O
contention	O
that	O
mutation	O
of	O
these	O
oncogenes	O
occurs	O
at	O
an	O
early	O
step	O
in	O
tumorigenesis	O
.	O
The	O
predominant	O
amino	O
acid	O
substitution	O
in	O
the	O
differentiated	O
tumours	B-malignancy-type
was	O
glutamine	O
to	O
arginine	O
at	O
position	O
61	O
of	O
Ha-ras	O
or	O
N-ras	O
,	O
but	O
this	O
mutation	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
undifferentiated	B-malignancy-type
tumours	I-malignancy-type
.	O
It	O
was	O
noted	O
that	O
while	O
transition	O
mutations	O
predominated	O
in	O
differentiated	B-malignancy-type
tumours	I-malignancy-type
(	O
both	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
)	O
,	O
transversions	O
were	O
more	O
common	O
in	O
the	O
undifferentiated	B-malignancy-type
tumours	I-malignancy-type
.	O
PMID	O
:	O
2648253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Jan	O
15	O
;49(	O
2	O
)	O
:357	O
-	O
60	O
Incidence	O
of	O
activating	O
ras	O
oncogene	O
mutations	O
associated	O
with	O
primary	B-malignancy-type
and	O
metastatic	O
human	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
Rochlitz	O
CF	O
,	O
Scott	O
GK	O
,	O
Dodson	O
JM	O
,	O
Liu	O
E	O
,	O
Dollbaum	O
C	O
,	O
Smith	O
HS	O
,	O
Benz	O
CC.	O
Cancer	O
Research	O
Institute	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
ras	O
activation	O
is	O
involved	O
in	O
the	O
final	O
stages	O
of	O
breast	B-malignancy-type
cancer	I-malignancy-type
progression	O
,	O
we	O
analyzed	O
tumor	O
DNA	O
derived	O
from	O
60	O
different	O
patients	O
and	O
extracted	O
from	O
40	O
invasive	O
primary	O
breast	B-malignancy-type
tumors	I-malignancy-type
,	O
seven	O
lymph	B-malignancy-type
node	I-malignancy-type
and	O
skin	B-malignancy-type
metastases	I-malignancy-type
,	O
nine	O
metastatic	O
effusions	O
,	O
and	O
five	O
established	O
breast	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
The	O
polymerase	O
chain	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
Kirsten	O
-	O
(	O
Ki	O
-	O
)	O
,	O
Harvey	O
-	O
(	O
Ha	O
-	O
)	O
,	O
and	O
N	O
-	O
ras	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
which	O
were	O
then	O
probed	O
on	O
slot	O
-	O
blots	O
with	O
labeled	O
synthetic	O
oligomers	O
to	O
detect	O
nonconservative	O
single	O
base	O
mutations	O
.	O
Activating	O
mutations	O
were	O
found	O
in	O
one	O
of	O
40	O
primary	O
tumors	O
(	O
Ki-ras	O
codon	O
13	O
)	O
,	O
zero	O
of	O
seven	O
lymph	B-malignancy-type
node	I-malignancy-type
and	O
skin	B-malignancy-type
metastases	I-malignancy-type
,	O
one	O
of	O
nine	O
metastatic	O
effusions	O
(	O
Ki-ras	O
codon	O
12	O
)	O
,	O
and	O
two	O
of	O
five	O
cell	O
lines	O
(	O
Ki-ras	O
codons	O
12	O
and	O
13	O
)	O
.	O
These	O
results	O
indicate	O
that	O
activating	O
ras	O
mutations	O
are	O
rarely	O
involved	O
in	O
either	O
the	O
initiation	O
or	O
metastatic	O
progression	O
of	O
human	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
2642738	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1990	O
Mar;61(	O
3	O
)	O
:365	O
-	O
8	O
Low	O
incidence	O
of	O
ras	O
oncogene	O
activation	O
in	O
human	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Rumsby	O
G	O
,	O
Carter	O
RL	O
,	O
Gusterson	O
BA.	O
Department	O
of	O
Chemical	O
Pathology	O
,	O
Royal	O
Marsden	O
Hospital	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Activation	O
of	O
the	O
ras	O
gene	O
family	O
by	O
point	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
has	O
been	O
demonstrated	O
in	O
up	O
to	O
20	O
%	O
of	O
unselected	O
series	O
of	O
human	O
tumours	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
assess	O
the	O
incidence	O
of	O
ras	O
activation	O
in	O
37	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
head	I-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
,	O
seven	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
skin	I-malignancy-type
and	O
eight	O
squamous	O
carcinoma	O
cell	O
lines	O
.	O
Oligonucleotide	O
probes	O
and	O
the	O
polymerase	O
chain	O
reaction	O
were	O
used	O
on	O
DNA	O
extracted	O
from	O
achival	O
paraffin	O
embedded	O
material	O
.	O
Mutations	O
in	O
codon	O
12	O
of	O
the	O
Harvey	O
ras	O
gene	O
was	O
found	O
in	O
a	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
larynx	I-malignancy-type
and	O
a	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lip	I-malignancy-type
,	O
both	O
of	O
which	O
had	O
received	O
prior	O
irradiation	O
.	O
A	O
cell	O
line	O
(	O
LICR-LON-HN8	O
)	O
established	O
from	O
the	O
same	O
laryngeal	B-malignancy-type
cancer	I-malignancy-type
showed	O
the	O
same	O
mutation	O
.	O
This	O
study	O
indicates	O
that	O
there	O
is	O
a	O
low	O
incidence	O
of	O
ras	O
mutation	O
in	O
human	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
that	O
activation	O
of	O
this	O
family	O
of	O
genes	O
is	O
probably	O
not	O
a	O
common	O
factor	O
in	O
the	O
development	O
of	O
this	O
group	O
of	O
tumours	B-malignancy-type
.	O
PMID	O
:	O
2183872	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1990	O
Mar;5(	O
3	O
)	O
:411	O
-	O
6	O
RAS	O
mutations	O
in	O
patients	O
following	O
cytotoxic	O
therapy	O
for	O
lymphoma	B-malignancy-type
.	O
Carter	O
G	O
,	O
Hughes	O
DC	O
,	O
Clark	O
RE	O
,	O
McCormick	O
F	O
,	O
Jacobs	O
A	O
,	O
Whittaker	O
JA	O
,	O
Padua	O
RA.	O
Department	O
of	O
Haematology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Cardiff	O
,	O
UK.	O
The	O
occurrence	O
of	O
Myelodysplastic	B-malignancy-type
Syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
Acute	B-malignancy-type
Myeloblastic	I-malignancy-type
Leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
following	O
cytotoxic	O
therapy	O
for	O
neoplastic	O
disease	O
is	O
well	O
recognised	O
.	O
RAS	O
mutations	O
are	O
common	O
in	O
patients	O
with	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
To	O
determine	O
whether	O
these	O
lesions	O
are	O
found	O
as	O
early	O
markers	O
of	O
secondary	O
disease	O
,	O
we	O
have	O
studied	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
the	O
peripheral	O
blood	O
of	O
70	O
patients	O
in	O
complete	O
remission	O
from	O
lymphoma	B-malignancy-type
.	O
Patients	O
were	O
treated	O
by	O
standard	O
chemotherapy	O
regimes	O
and/or	O
localised	O
radiotherapy	O
.	O
Treatment	O
had	O
been	O
given	O
6	O
months	O
to	O
14	O
1	O
/	O
2	O
years	O
previously	O
and	O
no	O
patient	O
showed	O
any	O
sign	O
of	O
residual	O
disease	O
.	O
Genomic	O
DNA	O
from	O
peripheral	O
blood	O
leukocytes	O
was	O
amplified	O
in	O
vitro	O
at	O
target	O
codons	O
of	O
N	O
,	O
K	O
and	O
H	O
RAS	O
genes	O
,	O
and	O
mutations	O
detected	O
by	O
hybridisation	O
with	O
oligonucleotide	O
probes	O
.	O
RAS	O
mutations	O
were	O
detected	O
in	O
9	O
subjects	O
.	O
One	O
patient	O
with	O
an	O
N	O
12	O
valine	O
(	O
Val	O
)	O
substitution	O
had	O
been	O
in	O
complete	O
remission	O
from	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
(	O
HD	B-malignancy-type
)	O
for	O
9	O
years	O
.	O
DNA	O
from	O
this	O
patient	O
registered	O
in	O
a	O
nude	O
mouse	O
tumorigenicity	O
assay	O
(	O
NMT	O
)	O
.	O
The	O
N	O
12	O
Val	O
mutation	O
was	O
not	O
detected	O
in	O
the	O
original	O
tumour	O
tissue	O
from	O
the	O
same	O
patient	O
.	O
A	O
second	O
patient	O
in	O
remission	O
from	O
HD	B-malignancy-type
showed	O
evidence	O
of	O
co	O
-	O
existent	O
N	O
12	O
cysteine	O
(	O
Cys	O
)	O
and	O
N	O
13	O
valine	O
(	O
Val	O
)	O
substitutions	O
which	O
were	O
not	O
detected	O
in	O
presentation	O
material	O
or	O
unaffected	O
tissues	O
.	O
All	O
patients	O
are	O
currently	O
haematologically	O
normal	O
,	O
indicating	O
that	O
clones	O
of	O
mutant	O
RAS	O
bearing	O
cells	O
may	O
be	O
detected	O
prior	O
to	O
any	O
overt	O
sign	O
of	O
disease	O
.	O
PMID	O
:	O
2179819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1990	O
Apr;94(	O
4)	O
:423	O
-	O
5	O
Ras	O
oncogene	O
mutations	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
human	I-malignancy-type
skin	I-malignancy-type
.	O
van	O
der	O
Schroeff	O
JG	O
,	O
Evers	O
LM	O
,	O
Boot	O
AJ	O
,	O
Bos	O
JL.	O
Department	O
of	O
Dermatology	O
,	O
University	O
Hospital	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Activated	O
ras	O
oncogenes	O
have	O
been	O
detected	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
.	O
Activation	O
of	O
ras	O
oncogenes	O
usually	O
occurs	O
by	O
point	O
mutations	O
within	O
specific	O
codons	O
of	O
the	O
H-ras	O
,	O
N-ras	O
,	O
and	O
K-ras	O
genes	O
.	O
For	O
the	O
present	O
study	O
,	O
DNA	O
was	O
isolated	O
from	O
30	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
BCC	B-malignancy-type
)	O
and	O
12	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCC	B-malignancy-type
)	O
.	O
After	O
amplification	O
of	O
genomic	O
DNA	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
the	O
occurrence	O
of	O
point	O
mutations	O
was	O
investigated	O
with	O
32P	O
-	O
labeled	O
synthetic	O
oligonucleotides	O
.	O
These	O
probes	O
are	O
complementary	O
to	O
the	O
known	O
point	O
-	O
mutated	O
nucleotide	O
sequences	O
of	O
the	O
ras	O
genes	O
.	O
In	O
four	O
out	O
of	O
the	O
30	O
BCC	B-malignancy-type
studied	O
,	O
point	O
mutations	O
were	O
detected	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
and	O
at	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
.	O
The	O
K-ras	O
mutations	O
involve	O
glycine	O
to	O
cysteine	O
and	O
glycine	O
to	O
asparagine	O
amino	O
acid	O
changes	O
.	O
The	O
mutation	O
at	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
is	O
consistent	O
with	O
a	O
replacement	O
of	O
glutamine	O
by	O
histidine	O
.	O
In	O
one	O
SCC	B-malignancy-type
,	O
a	O
point	O
mutation	O
was	O
detected	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
,	O
involving	O
a	O
glycine	O
to	O
cysteine	O
substitution	O
in	O
the	O
gene	O
product	O
.	O
These	O
findings	O
demonstrate	O
that	O
mutational	O
activation	O
of	O
ras	O
genes	O
takes	O
place	O
in	O
skin	B-malignancy-type
carcinomas	I-malignancy-type
,	O
but	O
the	O
rate	O
at	O
which	O
these	O
mutations	O
occur	O
seems	O
to	O
be	O
relatively	O
low	O
.	O
PMID	O
:	O
2179417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1991	O
Apr;63(	O
4)	O
:573	O
-	O
8	O
High	O
frequency	O
mutation	O
in	O
codons	O
12	O
and	O
61	O
of	O
H-ras	O
oncogene	O
in	O
chewing	O
tobacco	O
-	O
related	O
human	O
oral	B-malignancy-type
carcinoma	I-malignancy-type
in	O
India	O
.	O
Saranath	O
D	O
,	O
Chang	O
SE	O
,	O
Bhoite	O
LT	O
,	O
Panchal	O
RG	O
,	O
Kerr	O
IB	O
,	O
Mehta	O
AR	O
,	O
Johnson	O
NW	O
,	O
Deo	O
MG.	O
Cell	O
and	O
Developmental	O
Pathology	O
Division	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Bombay	O
,	O
India	O
.	O
57	O
primary	O
tumour	O
samples	O
from	O
Indian	O
oral	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
a	O
5	O
-	O
15	O
year	O
tobacco	O
chewing	O
habit	O
,	O
were	O
examined	O
for	O
mutational	O
activation	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
oncogenes	O
.	O
The	O
highly	O
sensitive	O
assay	O
based	O
on	O
specific	O
oligonucleotide	O
hybridisation	O
following	O
in	O
vitro	O
amplification	O
of	O
unique	O
sequences	O
by	O
polymerase	O
chain	O
reaction	O
was	O
employed	O
.	O
Mutations	O
were	O
detected	O
in	O
twenty	O
(	O
35	O
%	O
)	O
of	O
the	O
samples	O
and	O
were	O
restricted	O
to	O
H-ras	O
,	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
Two	O
cases	O
had	O
concurrent	O
mutations	O
in	O
codons	O
12	O
and	O
61	O
.	O
The	O
majority	O
of	O
the	O
mutations	O
were	O
at	O
H-ras	O
61.2	O
(	O
Glutamine	O
to	O
Arginine	O
)	O
and	O
H-ras	O
12.2	O
(	O
Glycine	O
to	O
Valine	O
)	O
.	O
Three	O
of	O
the	O
less	O
frequent	O
mutations	O
are	O
apparently	O
novel	O
.	O
Interestingly	O
,	O
eight	O
of	O
the	O
samples	O
with	O
H-ras	O
mutations	O
also	O
showed	O
loss	O
of	O
wild	O
-	O
type	O
H-ras	O
,	O
as	O
judged	O
by	O
absence	O
of	O
signals	O
for	O
wild	O
-	O
type	O
codons	O
12	O
or	O
61	O
on	O
dot	O
blots	O
.	O
The	O
specific	O
H-ras	O
mutations	O
in	O
these	O
oral	B-malignancy-type
malignancies	I-malignancy-type
associated	O
with	O
tobacco	O
chewing	O
,	O
may	O
represent	O
an	O
important	O
example	O
of	O
an	O
environmental	O
carcinogen	O
-	O
induced	O
step	O
,	O
in	O
a	O
pathway	O
leading	O
to	O
malignant	O
transformation	O
.	O
PMID	O
:	O
2021541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Jan	O
15;75(	O
2	O
)	O
:453	O
-	O
7	O
Alteration	O
of	O
N-ras	O
gene	O
mutation	O
after	O
relapse	O
in	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Terada	O
N	O
,	O
Miyoshi	O
J,	O
Kawa	O
-	O
Ha	O
K	O
,	O
Sasai	O
H	O
,	O
Orita	O
S,	O
Yumura	O
-	O
Yagi	O
K	O
,	O
Hara	O
J,	O
Fujinami	O
A	O
,	O
Kakunaga	O
T.	O
Department	O
of	O
Oncogene	O
Research	O
,	O
Osaka	O
University	O
,	O
Japan	O
.	O
We	O
investigated	O
N-ras	O
activation	O
in	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
dALL	O
)	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
the	O
oligonucleotide	O
hybridization	O
method	O
.	O
The	O
frequency	O
of	O
point	O
-	O
mutation	O
of	O
the	O
N-ras	O
gene	O
was	O
not	O
high	O
(	O
2	O
of	O
15	O
)	O
,	O
and	O
one	O
positive	O
case	O
who	O
relapsed	O
was	O
analyzed	O
in	O
detail	O
.	O
Although	O
N-ras	O
gene	O
activation	O
was	O
detected	O
at	O
both	O
onset	O
and	O
relapse	O
,	O
the	O
mutation	O
sites	O
were	O
different	O
.	O
At	O
onset	O
,	O
Gly	O
(	O
GGT	O
)	O
was	O
changed	O
to	O
Ser	O
(	O
AGT	O
)	O
at	O
codon	O
12	O
,	O
and	O
at	O
relapse	O
,	O
Gly	O
(	O
GGT	O
)	O
to	O
Asp	O
(	O
GAT	O
)	O
was	O
observed	O
at	O
the	O
same	O
codon	O
.	O
In	O
addition	O
,	O
the	O
DNA	O
at	O
relapse	O
showed	O
a	O
remarkably	O
higher	O
transforming	O
activity	O
than	O
the	O
DNA	O
at	O
onset	O
on	O
two	O
independent	O
recipient	O
cell	O
lines	O
.	O
The	O
identical	O
cell	O
surface	O
phenotype	O
and	O
the	O
same	O
rearrangement	O
patterns	O
of	O
both	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
heavy	O
chain	O
and	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
gamma	O
chain	O
genes	O
indicated	O
that	O
the	O
leukemic	O
cells	O
at	O
onset	O
and	O
those	O
at	O
relapse	O
were	O
derived	O
from	O
the	O
same	O
precursor	O
cell	O
.	O
Therefore	O
,	O
this	O
case	O
supports	O
the	O
concept	O
that	O
ras	O
activation	O
is	O
not	O
the	O
event	O
initiating	O
leukemogenesis	O
,	O
but	O
may	O
be	O
involved	O
in	O
leukemic	O
progression	O
.	O
PMID	O
:	O
1967219	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1991	O
Sep;59(	O
3	O
)	O
:231	O
-	O
5	O
Low	O
incidence	O
of	O
Ha-ras	O
oncogene	O
mutations	O
in	O
human	O
epidermal	B-malignancy-type
tumors	I-malignancy-type
.	O
Lieu	O
FM	O
,	O
Yamanishi	O
K	O
,	O
Konishi	O
K	O
,	O
Kishimoto	O
S,	O
Yasuno	O
H.	O
Department	O
of	O
Dermatology	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
Activation	O
of	O
the	O
Ha-ras	O
oncogene	O
by	O
point	O
mutations	O
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
animal	O
skin	O
carcinogenesis	O
models	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
the	O
Ha-ras	O
mutations	O
in	O
human	O
epidermal	B-malignancy-type
tumors	I-malignancy-type
.	O
DNAs	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
of	O
benign	O
and	O
malignant	O
human	O
epidermal	B-malignancy-type
tumors	I-malignancy-type
(	O
27	O
samples	O
from	O
25	O
patients	O
)	O
were	O
prepared	O
and	O
examined	O
for	O
point	O
mutations	O
of	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
Ha-ras	O
gene	O
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
.	O
Only	O
one	O
sample	O
of	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
and	O
one	O
sample	O
of	O
keratoacanthoma	B-malignancy-type
were	O
found	O
to	O
carry	O
an	O
A	O
to	O
T	O
transversion	O
at	O
the	O
second	O
position	O
of	O
codon	O
61	O
.	O
This	O
low	O
incidence	O
of	O
Ha-ras	O
mutations	O
suggests	O
that	O
the	O
mutational	O
activation	O
of	O
the	O
gene	O
may	O
not	O
be	O
primarily	O
involved	O
in	O
human	O
epidermal	O
tumorigenesis	O
.	O
PMID	O
:	O
1913619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Feb	O
1;50(	O
3	O
)	O
:382	O
-	O
5	O
Infrequent	O
mutation	O
of	O
the	O
ras	O
genes	O
in	O
skin	B-malignancy-type
tumors	I-malignancy-type
of	O
xeroderma	O
pigmentosum	O
patients	O
in	O
Japan	O
.	O
Ishizaki	O
K	O
,	O
Tsujimura	O
T	O
,	O
Nakai	O
M,	O
Nishigori	O
C	O
,	O
Sato	O
K	O
,	O
Katayama	O
S,	O
Kurimura	O
O	O
,	O
Yoshikawa	O
K	O
,	O
Imamura	O
S,	O
Ikenaga	O
M.	O
Radiation	O
Biology	O
Center	O
,	O
Kyoto	O
University	O
,	O
Japan	O
.	O
By	O
using	O
PCR	O
amplification	O
and	O
oligonucleotide	O
mismatch	O
hybridization	O
,	O
base	O
-	O
substitution	O
mutations	O
of	O
the	O
ras	O
genes	O
in	O
26	O
skin	B-malignancy-type
tumors	I-malignancy-type
of	O
Japanese	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
patients	O
were	O
studied	O
.	O
Thin	O
sections	O
of	O
tumor	O
tissues	O
which	O
were	O
fixed	O
and	O
embedded	O
in	O
paraffin	O
blocks	O
were	O
used	O
in	O
this	O
study	O
.	O
After	O
analyzing	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
by	O
using	O
66	O
oligomer	O
probes	O
,	O
we	O
detected	O
only	O
one	O
mutation	O
of	O
the	O
K-ras	O
gene	O
at	O
codon	O
61	O
in	O
one	O
tumor	O
sample	O
.	O
All	O
the	O
other	O
tumors	O
were	O
therefore	O
considered	O
not	O
to	O
have	O
a	O
mutation	O
in	O
the	O
ras	O
genes	O
.	O
These	O
results	O
suggest	O
that	O
mutations	O
of	O
the	O
ras	O
genes	O
are	O
not	O
particularly	O
associated	O
with	O
skin	B-malignancy-type
tumors	I-malignancy-type
of	O
Japanese	O
XP	O
patients	O
.	O
PMID	O
:	O
1735606	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Keio	O
J	O
Med	O
1992	O
Jun;41(	O
2	O
)	O
:80	O
-	O
6	O
Detection	O
of	O
H-ras	O
gene	O
point	O
mutations	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
human	O
urinary	B-malignancy-type
bladder	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
.	O
Saito	O
S.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Keio	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
It	O
has	O
been	O
reported	O
that	O
the	O
H-ras	O
gene	O
is	O
activated	O
as	O
oncogene	O
in	O
human	O
bladder	B-malignancy-type
cancer	I-malignancy-type
cases	O
,	O
and	O
that	O
codon	O
12	O
and	O
codon	O
61	O
are	O
the	O
major	O
"	O
hot	O
spots	O
"	O
of	O
its	O
activation	O
.	O
A	O
simple	O
method	O
to	O
detect	O
point	O
mutations	O
in	O
these	O
codons	O
of	O
H-ras	O
gene	O
was	O
established	O
for	O
the	O
use	O
of	O
clinical	O
diagnosis	O
.	O
In	O
this	O
method	O
,	O
the	O
DNA	O
segments	O
including	O
codon	O
12	O
or	O
codon	O
61	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
the	O
reaction	O
products	O
were	O
examined	O
for	O
their	O
susceptibility	O
to	O
the	O
restriction	O
enzyme	O
NaeI	O
or	O
BstNI	O
,	O
and	O
by	O
dot	O
blot	O
hybridization	O
assay	O
with	O
oligonucleotide	O
probes	O
.	O
Point	O
mutations	O
were	O
detectable	O
in	O
small	O
amounts	O
of	O
DNAs	O
isolated	O
from	O
fresh	O
or	O
frozen	O
tumor	O
tissues	O
,	O
urine	O
cells	O
and	O
paraffin	O
sections	O
.	O
The	O
method	O
was	O
applied	O
for	O
a	O
clinical	O
sample	O
and	O
a	O
case	O
that	O
had	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
H-ras	O
gene	O
was	O
detected	O
.	O
The	O
point	O
mutation	O
was	O
existed	O
in	O
DNAs	O
of	O
primary	O
tumor	O
tissue	O
,	O
all	O
recurrent	O
tumor	O
tissues	O
and	O
cells	O
isolated	O
from	O
urine	O
of	O
this	O
case	O
.	O
PMID	O
:	O
1619852	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
May	O
15;52(	O
10	O
)	O
:2777	O
-	O
81	O
Clinical	O
implications	O
of	O
K-ras	O
mutations	O
in	O
malignant	O
epithelial	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
endometrium	I-malignancy-type
.	O
Mizuuchi	O
H	O
,	O
Nasim	O
S,	O
Kudo	O
R,	O
Silverberg	O
SG	O
,	O
Greenhouse	O
S,	O
Garrett	O
CT.	O
Department	O
of	O
Pathology	O
,	O
George	O
Washington	O
University	O
,	O
Washington	O
,	O
DC	O
20037	O
.	O
Tumorigenesis	O
in	O
humans	O
and	O
experimental	O
animals	O
appears	O
to	O
involve	O
the	O
activation	O
of	O
ras	O
protooncogenes	O
for	O
a	O
number	O
of	O
organ	O
systems	O
and	O
seems	O
to	O
be	O
important	O
to	O
the	O
development	O
of	O
the	O
metastatic	O
phenotype	O
in	O
several	O
model	O
systems	O
.	O
Clinically	O
,	O
the	O
presence	O
of	O
activated	O
ras	O
protooncogenes	O
has	O
been	O
reported	O
to	O
be	O
a	O
negative	O
prognostic	O
factor	O
in	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
In	O
the	O
present	O
study	O
we	O
examined	O
49	O
cases	O
of	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
for	O
mutations	O
in	O
the	O
first	O
exon	O
of	O
K-ras	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Mutations	O
in	O
codon	O
12	O
or	O
13	O
of	O
K-ras	O
were	O
detected	O
in	O
6	O
of	O
49	O
cases	O
(	O
12.2	O
%	O
)	O
.	O
These	O
six	O
cases	O
consisted	O
of	O
five	O
endometrioid	B-malignancy-type
endometrial	I-malignancy-type
carcinomas	I-malignancy-type
,	O
each	O
of	O
which	O
had	O
a	O
mutation	O
in	O
codon	O
12	O
,	O
and	O
one	O
case	O
of	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
which	O
had	O
a	O
mutation	O
in	O
codon	O
13	O
.	O
In	O
our	O
study	O
the	O
presence	O
of	O
mutations	O
in	O
K-ras	O
appeared	O
to	O
be	O
an	O
unfavorable	O
prognostic	O
factor	O
.	O
Three	O
of	O
six	O
patients	O
with	O
the	O
mutation	O
died	O
during	O
follow	O
-	O
up	O
,	O
while	O
only	O
7	O
%	O
of	O
the	O
43	O
patients	O
without	O
K-ras	O
mutations	O
expired	O
during	O
this	O
same	O
period	O
.	O
In	O
multivariate	O
analysis	O
using	O
the	O
Cox	O
proportional	O
hazard	O
model	O
,	O
K-ras	O
activation	O
appeared	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
when	O
compared	O
with	O
clinical	O
stage	O
,	O
depth	O
of	O
myometrial	O
invasion	O
,	O
and	O
patient	O
age	O
.	O
Thus	O
,	O
our	O
findings	O
support	O
the	O
hypothesis	O
that	O
K-ras	O
protooncogene	O
activation	O
plays	O
an	O
important	O
role	O
in	O
determining	O
the	O
aggressiveness	O
of	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
1581890	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
1992	O
Nov;23(	O
11	O
)	O
:1199	O
-	O
204	O
Concurrent	O
mutations	O
of	O
coding	O
and	O
regulatory	O
sequences	O
of	O
the	O
Ha-ras	O
gene	O
in	O
urinary	B-malignancy-type
bladder	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Czerniak	O
B	O
,	O
Cohen	O
GL	O
,	O
Etkind	O
P	O
,	O
Deitch	O
D	O
,	O
Simmons	O
H	O
,	O
Herz	O
F	O
,	O
Koss	O
LG.	O
Department	O
of	O
Pathology	O
,	O
Montefiore	O
Medical	O
Center	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Bronx	O
,	O
NY	O
10467	O
.	O
This	O
report	O
concerns	O
the	O
study	O
of	O
Ha-ras	O
gene	O
mutations	O
and	O
ras	O
p21	O
expression	O
in	O
primary	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
urinary	I-malignancy-type
bladder	I-malignancy-type
.	O
Polymerase	O
chain	O
reaction	O
-	O
based	O
techniques	O
and	O
computerized	O
image	O
analysis	O
were	O
used	O
.	O
The	O
data	O
obtained	O
were	O
related	O
to	O
tumor	O
grade	O
,	O
DNA	O
ploidy	O
,	O
and	O
tumor	O
invasion	O
.	O
A	O
point	O
mutation	O
(	O
G	O
-->	O
T	O
)	O
at	O
Ha-ras	O
codon	O
12	O
was	O
found	O
in	O
30	O
of	O
67	O
tumors	O
.	O
The	O
mutation	O
frequency	O
was	O
greater	O
in	O
grade	O
III	O
(	O
65	O
%	O
)	O
than	O
in	O
grade	O
II	O
(	O
44	O
%	O
)	O
tumors	O
;	O
no	O
mutations	O
were	O
observed	O
in	O
grade	O
I	O
tumors	O
.	O
The	O
mutation	O
was	O
observed	O
more	O
often	O
in	O
aneuploid	O
(	O
58	O
%	O
)	O
than	O
in	O
diploid	O
(	O
28	O
%	O
)	O
tumors	O
.	O
No	O
other	O
substitution	O
at	O
codon	O
12	O
was	O
seen	O
and	O
no	O
codon	O
61	O
mutation	O
was	O
detected	O
.	O
The	O
tumors	O
were	O
also	O
tested	O
for	O
the	O
A	O
-->	O
G	O
mutation	O
at	O
position	O
2719	O
of	O
Ha-ras	O
intron	O
D	O
.	O
Concurrent	O
codon	O
12	O
and	O
intron	O
D	O
mutations	O
were	O
identified	O
in	O
seven	O
high	O
-	O
grade	O
aneuploid	O
tumors	O
;	O
six	O
were	O
invasive	O
.	O
The	O
levels	O
of	O
the	O
ras	O
gene	O
product	O
p21	O
were	O
approximately	O
10	O
times	O
higher	O
in	O
tumors	O
with	O
intron	O
D	O
mutation	O
than	O
in	O
those	O
without	O
.	O
These	O
findings	O
confirm	O
on	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
the	O
observations	O
of	O
the	O
effect	O
of	O
synchronous	O
exon	O
-	O
intron	O
mutations	O
reported	O
on	O
the	O
bladder	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
T24	O
.	O
Our	O
results	O
are	O
the	O
first	O
demonstration	O
of	O
Ha-ras	O
intron	O
D	O
alterations	O
in	O
human	O
tumor	O
tissues	O
and	O
suggest	O
that	O
concurrent	O
mutations	O
at	O
codon	O
12	O
and	O
intron	O
D	O
of	O
this	O
gene	O
within	O
the	O
same	O
tumor	O
may	O
contribute	O
to	O
the	O
aggressive	O
behavior	O
of	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
1427748	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1992	O
Sep;5(	O
2	O
)	O
:109	O
-	O
18	O
Detection	O
of	O
RAS	O
mutations	O
in	O
archival	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
.	O
Moul	O
JW	O
,	O
Theune	O
SM	O
,	O
Chang	O
EH.	O
Department	O
of	O
Surgery	O
,	O
Uniformed	O
Services	O
University	O
of	O
the	O
Health	O
Sciences	O
,	O
Bethesda	O
,	O
Maryland	O
20814	O
-	O
4799	O
.	O
Preliminary	O
studies	O
of	O
RAS	O
mutational	O
activation	O
in	O
human	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
neoplasms	I-malignancy-type
have	O
yielded	O
conflicting	O
results	O
.	O
Whereas	O
two	O
studies	O
of	O
clinical	O
material	O
revealed	O
a	O
significant	O
incidence	O
of	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
,	O
two	O
studies	O
of	O
a	O
variety	O
of	O
germ	O
cell	O
lines	O
failed	O
to	O
document	O
RAS	O
mutations	O
.	O
To	O
clarify	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
these	O
tumors	B-malignancy-type
,	O
we	O
studied	O
archival	O
paraffin	O
-	O
embedded	O
,	O
formalin	O
-	O
fixed	O
orchiectomy	O
specimens	O
from	O
25	O
nonseminomas	B-malignancy-type
(	O
NSGCT	B-malignancy-type
)	O
,	O
18	O
seminomas	B-malignancy-type
(	O
SEM	B-malignancy-type
)	O
,	O
and	O
one	O
Leydig	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
.	O
For	O
14	O
of	O
the	O
44	O
neoplasms	O
,	O
DNA	O
was	O
also	O
available	O
from	O
nonmalignant	O
testis	O
adjacent	O
to	O
the	O
tumor	O
.	O
Six	O
age	O
-	O
matched	O
patients	O
had	O
testes	O
removed	O
because	O
of	O
nonmalignant	O
disease	O
and	O
were	O
studied	O
as	O
controls	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
the	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
RAS	O
12	O
,	O
13	O
,	O
and	O
61	O
codons	O
of	O
these	O
specimens	O
,	O
and	O
mutations	O
were	O
detected	O
with	O
mutation	O
-	O
specific	O
oligonucleotide	O
probe	O
hybridization	O
of	O
Southern	O
and	O
slot	O
blots	O
.	O
Four	O
mutations	O
were	O
found	O
in	O
KRAS	O
12	O
(	O
4	O
/	O
44	O
;	O
[	O
9.1	O
%	O
]	O
)	O
.	O
One	O
seminoma	B-malignancy-type
[	O
1	O
/	O
18	O
(	O
5.6	O
%	O
)	O
]	O
contained	O
the	O
mutation	O
GGT	O
(	O
GLY	O
)	O
----	O
CGT	O
(	O
ARG	O
)	O
,	O
and	O
three	O
NSGCT	B-malignancy-type
[	O
3	O
/	O
25	O
(	O
12	O
%	O
)	O
]	O
were	O
found	O
to	O
have	O
GGT	O
(	O
GLY	O
)	O
----	O
GAT	O
(	O
ASP	O
)	O
mutations	O
.	O
One	O
of	O
the	O
NSGCT	B-malignancy-type
mutations	O
was	O
detected	O
in	O
adjacent	O
nonmalignant	O
tissue	O
,	O
but	O
the	O
corresponding	O
tumor	O
did	O
not	O
contain	O
any	O
detectable	O
mutation	O
.	O
No	O
mutations	O
were	O
detected	O
at	O
KRAS	O
13	O
or	O
61	O
,	O
in	O
NRAS	O
or	O
HRAS	O
12	O
,	O
13	O
,	O
or	O
61	O
,	O
or	O
in	O
the	O
control	O
normal	O
testes	O
.	O
PCR	O
,	O
slot	O
blots	O
,	O
and	O
hybridizations	O
were	O
performed	O
twice	O
by	O
two	O
separate	O
investigators	O
for	O
confirmation	O
of	O
results	O
.	O
PCR	O
-	O
generated	O
mutation	O
-	O
specific	O
positive	O
controls	O
were	O
created	O
for	O
all	O
possible	O
RAS	O
mutations	O
,	O
and	O
these	O
along	O
with	O
wild	O
-	O
type	O
DNA	O
controls	O
were	O
integral	O
to	O
interpretation	O
of	O
the	O
oligonucleotide	O
mismatch	O
hybridization	O
assay	O
.	O
By	O
using	O
positive	O
and	O
negative	O
controls	O
,	O
we	O
have	O
detected	O
a	O
relatively	O
low	O
incidence	O
of	O
RAS	O
mutations	O
in	O
archival	O
human	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
1381946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreatology	O
2002	O
;2	O
(	O
1	O
)	O
:17-25	O
Frequent	O
deletions	O
of	O
tumor	O
suppressor	O
genes	O
in	O
pure	O
pancreatic	O
juice	O
from	O
patients	O
with	O
tumoral	O
or	O
nontumoral	O
pancreatic	O
diseases	O
.	O
Costentin	O
L,	O
Pages	O
P,	O
Bouisson	O
M,	O
Berthelemy	O
P,	O
Buscail	O
L,	O
Escourrou	O
J,	O
Pradayrol	O
L,	O
Vaysse	O
N	O
.	O
INSERM	O
,	O
U531	O
Biologie	O
,	O
Pathologie	O
Digestive	O
et	O
Departement	O
de	O
Gastroenterologie	O
,	O
CHU	O
Rangueil	O
,	O
1	O
,	O
avenue	O
J.-Poulhes	O
F-31403	O
Toulouse	O
,	O
France	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
K-ras	O
codon	O
12	O
mutation	O
is	O
the	O
most	O
frequent	O
genetic	O
alteration	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Sensitivity	O
and	O
specificity	O
of	O
K-ras	O
are	O
not	O
high	O
enough	O
to	O
detect	O
all	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
especially	O
at	O
early	O
stage	O
.	O
This	O
study	O
investigated	O
whether	O
detection	O
of	O
p16	O
and/or	O
DPC4	O
deletions	O
along	O
with	O
K-ras	O
mutation	O
in	O
DNA	O
samples	O
could	O
improve	O
the	O
definition	O
of	O
patients	O
at	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
K-ras	O
mutations	O
were	O
investigated	O
by	O
sequencing	O
.	O
p16	O
and	O
DPC4	O
homozygous	O
deletions	O
were	O
studied	O
using	O
comparative	O
multiplex	O
polymerase	O
chain	O
reaction	O
of	O
DNA	O
in	O
pancreatic	O
juice	O
sampled	O
during	O
endoscopic	O
retrograde	O
pancreatography	O
in	O
57	O
patients	O
with	O
either	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
(	O
group	O
I	O
,	O
18	O
patients	O
)	O
,	O
chronic	O
pancreatitis	O
(	O
group	O
II	O
,	O
20	O
patients	O
)	O
,	O
or	O
nontumoral	O
pancreatobiliary	O
disease	O
(	O
group	O
III	O
,	O
19	O
patients	O
)	O
.	O
RESULTS	O
:	O
The	O
frequencies	O
of	O
Ki-ras	O
mutations	O
were	O
61	O
%	O
in	O
group	O
I	O
,	O
10	O
%	O
in	O
group	O
II	O
,	O
and	O
10.5	O
%	O
in	O
group	O
III	O
.	O
The	O
frequencies	O
of	O
p16	O
exon	O
2	O
and	O
DPC4	O
deletions	O
were	O
,	O
respectively	O
,	O
28	O
and	O
36	O
%	O
in	O
group	O
I	O
,	O
50	O
and	O
58	O
%	O
in	O
group	O
II	O
,	O
and	O
24	O
and	O
36	O
%	O
in	O
group	O
III	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
p16	O
and	O
DPC4	O
deletions	O
with	O
K-ras	O
mutation	O
does	O
not	O
improve	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
based	O
on	O
K-ras	O
mutation	O
alone	O
.	O
These	O
data	O
suggest	O
that	O
tumor	O
suppressor	O
gene	O
inactivation	O
can	O
occur	O
with	O
a	O
high	O
frequency	O
during	O
nonmalignant	O
pancreatic	O
diseases	O
.	O
PMID	O
:	O
12120000	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Radiat	O
Oncol	O
Biol	O
Phys	O
1996	O
Jan	O
1;34(	O
1	O
)	O
:161	O
-	O
6	O
C-Ki-ras	O
mutations	O
in	O
peripheral	O
blood	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
patients	O
:	O
a	O
marker	O
for	O
early	O
tumor	O
metastasis	O
.	O
Mohiuddin	O
M,	O
Ahmed	O
MM	O
,	O
Venkatasubbarao	O
K.	O
Department	O
of	O
Radiation	O
Medicine	O
,	O
University	O
of	O
Kentucky	O
,	O
Lexington	O
40536	O
-0084	O
,	O
USA	O
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
circulating	O
minimal	O
malignant	O
clone	O
(	O
CMMC	O
)	O
(	O
harboring	O
c-Ki-ras-2	O
mutation	O
)	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
samples	O
of	O
untreated	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analysis	O
of	O
c-Ki-ras-2	O
oncogene	O
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
Experiments	O
were	O
carried	O
out	O
in	O
fresh	O
tumor	O
,	O
peritoneal	O
washings	O
(	O
PW	O
)	O
,	O
and	O
PB	O
samples	O
of	O
untreated	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
patients	O
(	O
both	O
resectable	O
and	O
unresectable	O
)	O
.	O
Samples	O
were	O
taken	O
from	O
16	O
patients	O
diagnosed	O
with	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
for	O
the	O
PCR	O
analysis	O
of	O
mutated	O
c-Ki-ras	O
oncogene	O
.	O
Five	O
tumor	O
samples	O
,	O
15	O
PB	O
samples	O
,	O
and	O
3	O
PW	O
samples	O
were	O
analyzed	O
for	O
point	O
mutation	O
of	O
the	O
c-Ki-ras	O
gene	O
at	O
codon	O
12	O
.	O
RESULTS	O
:	O
Out	O
of	O
five	O
tumor	O
samples	O
analyzed	O
for	O
c-Ki-ras	O
mutation	O
,	O
four	O
were	O
positive	O
at	O
the	O
12th	O
codon	O
.	O
Out	O
of	O
total	O
15	O
PB	O
samples	O
,	O
nine	O
were	O
positive	O
for	O
the	O
c-Ki-ras	O
point	O
mutation	O
at	O
the	O
12th	O
codon	O
.	O
All	O
the	O
positive	O
PB	O
samples	O
showed	O
a	O
base	O
substitution	O
from	O
GGT	O
to	O
GAT	O
in	O
the	O
second	O
position	O
of	O
the	O
12th	O
codon	O
.	O
Out	O
of	O
three	O
PW	O
samples	O
,	O
two	O
showed	O
mutation	O
at	O
the	O
second	O
position	O
from	O
GGT	O
to	O
GAT	O
similar	O
to	O
their	O
PB	O
and	O
tumor	O
samples	O
.	O
CONCLUSION	O
:	O
Our	O
study	O
indicated	O
the	O
presence	O
of	O
the	O
tumor	O
cells	O
(	O
CMMC	O
)	O
in	O
PB	O
of	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
that	O
can	O
be	O
identified	O
by	O
PCR	O
analysis	O
of	O
c-Ki-ras	O
oncogene	O
.	O
Patients	O
with	O
presence	O
of	O
CMMC	O
in	O
PB	O
and	O
mutation	O
in	O
PW	O
had	O
aggressive	O
tumors	O
that	O
responded	O
poorly	O
to	O
treatment	O
.	O
PMID	O
:	O
12118546	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2002	O
Mar;9	O
3	O
(	O
3	O
)	O
:	O
267	O
-	O
74	O
Mutations	O
of	O
p53	O
,	O
c-kit	O
,	O
K-ras	O
,	O
and	O
beta-catenin	O
gene	O
in	O
non	B-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
adrenal	I-malignancy-type
gland	I-malignancy-type
.	O
Nakatsuka	O
S	O
,	O
Hongyo	O
T	O
,	O
Syaifudin	O
M,	O
Nomura	O
T	O
,	O
Shingu	O
N	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Suita	O
,	O
Osaka	O
56	O
5	O
-0871	O
,	O
Japan	O
.	O
Malignant	O
lymphoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
adrenal	I-malignancy-type
gland	I-malignancy-type
is	O
a	O
rare	O
disease	O
,	O
usually	O
with	O
diffuse	O
large	O
cell	O
morphology	O
and	O
B-cell	O
immunophenotype	O
,	O
and	O
often	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
.	O
In	O
this	O
study	O
,	O
mutations	O
of	O
p53	O
,	O
c-kit	O
,	O
K-ras	O
,	O
and	O
beta-catenin	O
gene	O
were	O
analyzed	O
in	O
17	O
cases	O
(	O
13	O
males	O
and	O
four	O
females	O
with	O
ages	O
ranging	O
from	O
25	O
to	O
84	O
years	O
)	O
of	O
such	O
lymphomas	B-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
direct	O
sequencing	O
.	O
Selected	O
exons	O
in	O
each	O
gene	O
,	O
representing	O
hot	O
spots	O
,	O
were	O
analyzed	O
.	O
All	O
44	O
mutations	O
detected	O
were	O
single	O
-	O
nucleotide	O
substitutions	O
and	O
33	O
were	O
missense	O
mutations	O
.	O
Nineteen	O
mutations	O
were	O
detected	O
in	O
exon	O
5	O
and	O
/	O
or	O
7	O
of	O
the	O
p53	O
gene	O
in	O
nine	O
of	O
17	O
cases	O
(	O
52.9	O
%	O
)	O
and	O
21	O
in	O
exon	O
11	O
and	O
/	O
or	O
17	O
of	O
the	O
c-kit	O
gene	O
in	O
10	O
of	O
14	O
cases	O
(	O
71.4	O
%	O
)	O
.	O
Bilateral	O
adrenal	B-malignancy-type
lesions	I-malignancy-type
in	O
one	O
case	O
who	O
had	O
not	O
received	O
any	O
adjuvant	O
therapy	O
showed	O
different	O
mutational	O
patterns	O
of	O
the	O
p53	O
and	O
c-kit	O
genes	O
,	O
suggesting	O
different	O
clonal	O
evolution	O
of	O
lymphoma	B-malignancy-type
between	O
the	O
left	O
and	O
right	O
sides	O
.	O
Mutation	O
at	O
codon	O
13	O
of	O
the	O
K-ras	O
gene	O
was	O
detected	O
in	O
one	O
of	O
14	O
cases	O
(	O
7.1	O
%	O
)	O
,	O
and	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
three	O
of	O
12	O
cases	O
(	O
25	O
%	O
)	O
.	O
All	O
but	O
one	O
mutation	O
were	O
transition	O
mutations	O
,	O
indicating	O
that	O
some	O
endogenous	O
mutagens	O
act	O
in	O
lymphomagenesis	O
in	O
the	O
adrenal	O
gland	O
.	O
Our	O
results	O
suggest	O
that	O
p53	O
and	O
c-kit	O
gene	O
mutations	O
might	O
play	O
a	O
role	O
in	O
adrenal	O
lymphomagenesis	O
.	O
PMID	O
:	O
11927008	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
2002	O
Mar;82	O
(	O
3	O
)	O
:257	O
-64	O
Gene	O
mutations	O
in	O
lymphoproliferative	B-malignancy-type
disorders	I-malignancy-type
of	I-malignancy-type
T	I-malignancy-type
and	I-malignancy-type
NK	I-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
cell	I-malignancy-type
phenotypes	I-malignancy-type
developing	O
in	O
renal	O
transplant	O
patients	O
.	O
Hoshida	O
Y	O
,	O
Hongyo	O
T	O
,	O
Nakatsuka	O
S	O
,	O
Nishiu	O
M,	O
Takakuwa	O
T	O
,	O
Tomita	O
Y	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Osaka	O
,	O
Japan	O
.	O
Post	B-malignancy-type
-	I-malignancy-type
transplantation	I-malignancy-type
lymphoproliferative	I-malignancy-type
disorder	I-malignancy-type
(	O
PT-LPD	B-malignancy-type
)	O
is	O
characterized	O
by	O
lymphoid	O
proliferation	O
after	O
organ	O
or	O
bone	O
marrow	O
transplantation	O
.	O
In	O
Western	O
countries	O
,	O
most	O
cases	O
of	O
PT-LPD	O
are	O
B-cell	O
-	O
derived	O
and	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
,	O
in	O
which	O
alterations	O
of	O
c-myc	O
,	O
p53	O
,	O
and	O
N-ras	O
genes	O
might	O
play	O
a	O
role	O
in	O
disease	O
progression	O
.	O
In	O
Japan	O
,	O
PT-LPD	B-malignancy-type
of	I-malignancy-type
T	I-malignancy-type
-	I-malignancy-type
and	I-malignancy-type
NK	I-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
types	I-malignancy-type
are	O
not	O
uncommon	O
in	O
renal	O
transplant	O
patients	O
.	O
Mutations	O
of	O
p53	O
(	O
exons	O
4	O
through	O
8	O
)	O
,	O
K-ras	O
(	O
exons	O
1	O
and	O
2	O
)	O
,	O
c-kit	O
(	O
exons	O
11	O
and	O
17	O
)	O
,	O
and	O
beta-catenin	O
genes	O
(	O
exon	O
3	O
)	O
in	O
12	O
cases	O
of	O
these	O
diseases	O
were	O
analyzed	O
by	O
PCR	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
then	O
by	O
direct	O
sequencing	O
.	O
p53	O
gene	O
mutations	O
were	O
detected	O
in	O
5	O
of	O
5	O
cases	O
of	O
peripheral	B-malignancy-type
T-cell	I-malignancy-type
lymphoma	I-malignancy-type
,	O
3	O
(	O
60	O
%	O
)	O
of	O
5	O
cases	O
of	O
adult	B-malignancy-type
T-cell	I-malignancy-type
leukemia	I-malignancy-type
/	I-malignancy-type
lymphoma	I-malignancy-type
,	O
and	O
1	O
of	O
2	O
cases	O
of	O
NK	B-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Twenty-five	O
percent	O
of	O
T	B-malignancy-type
and	I-malignancy-type
NK	I-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
cell	I-malignancy-type
lymphomas	I-malignancy-type
showed	O
K-ras	O
mutations	O
.	O
Mutations	O
of	O
c-kit	O
and	O
beta-catenin	O
genes	O
were	O
found	O
in	O
33	O
%	O
of	O
cases	O
.	O
Among	O
a	O
total	O
of	O
42	O
substitution	O
mutations	O
,	O
40	O
were	O
transitions	O
with	O
involvement	O
of	O
CpG	O
sites	O
in	O
20	O
to	O
30	O
%	O
of	O
cases	O
.	O
Most	O
cases	O
had	O
at	O
least	O
one	O
mutation	O
that	O
changed	O
an	O
amino	O
acid	O
,	O
which	O
might	O
have	O
provided	O
the	O
selection	O
pressure	O
for	O
expansion	O
.	O
These	O
findings	O
suggested	O
that	O
p53	O
gene	O
mutations	O
might	O
play	O
a	O
central	O
role	O
in	O
development	O
of	O
peripheral	B-malignancy-type
T-cell	I-malignancy-type
lymphoma	I-malignancy-type
including	O
adult	B-malignancy-type
T-cell	I-malignancy-type
leukemia	I-malignancy-type
/	I-malignancy-type
lymphoma	I-malignancy-type
in	O
renal	O
transplant	O
patients	O
.	O
PMID	O
:	O
11896204	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2002	O
Jan	O
1;94	O
(	O
1	O
)	O
:	O
219	O
-	O
27	O
Detection	O
of	O
genetic	O
alterations	O
in	O
the	O
p53	O
suppressor	O
gene	O
and	O
the	O
K-ras	O
oncogene	O
among	O
different	O
grades	O
of	O
dysplasia	O
in	O
patients	O
with	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
Hosaka	O
S	O
,	O
Aoki	O
Y	O
,	O
Akamatsu	O
T	O
,	O
Nakamura	O
N	O
,	O
Hosaka	O
N	O
,	O
Kiyosawa	O
K.	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Nagano	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Although	O
it	O
is	O
believed	O
that	O
p53	O
suppressor	O
gene	O
mutations	O
,	O
compared	O
with	O
mutations	O
in	O
the	O
K-ras	O
oncogene	O
,	O
occur	O
at	O
a	O
later	O
stage	O
of	O
colorectal	O
tumorigenesis	O
,	O
the	O
distribution	O
of	O
these	O
genetic	O
alterations	O
at	O
an	O
early	O
stage	O
remains	O
poorly	O
characterized	O
.	O
METHODS	O
:	O
The	O
authors	O
analyzed	O
the	O
immunoreactivity	O
for	O
p53	O
protein	O
(	O
p53	O
protein	O
expression	O
)	O
,	O
which	O
reflects	O
the	O
functionally	O
altered	O
p53	O
gene	O
,	O
and	O
K-ras	O
mutations	O
at	O
codons	O
12	O
in	O
68	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
with	O
both	O
low	O
-	O
grade	O
and	O
high	O
-	O
grade	O
dysplasia	O
obtained	O
from	O
62	O
patients	O
.	O
RESULTS	O
:	O
The	O
prevalence	O
of	O
p53	O
positive	O
immunostaining	O
was	O
significantly	O
greater	O
compared	O
with	O
the	O
prevalence	O
of	O
K-ras	O
mutations	O
both	O
in	O
low	O
-	O
grade	O
dysplasia	O
and	O
in	O
high	O
-	O
grade	O
dysplasia	O
.	O
Twenty-two	O
adenomas	B-malignancy-type
(	O
32.3	O
%	O
)	O
showed	O
positive	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
also	O
were	O
positive	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
20	O
adenomas	B-malignancy-type
(	O
29.4	O
%	O
)	O
showed	O
positive	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
were	O
negative	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
8	O
adenomas	B-malignancy-type
(	O
11.7	O
%	O
)	O
showed	O
negative	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
were	O
positive	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
and	O
18	O
adenomas	B-malignancy-type
(	O
26.4	O
%	O
)	O
showed	O
negative	O
immunostaining	O
for	O
p53	O
protein	O
in	O
both	O
high	O
-	O
grade	O
dysplasia	O
and	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
.	O
On	O
the	O
whole	O
,	O
a	O
significant	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
was	O
seen	O
in	O
the	O
frequency	O
of	O
p53	O
positive	O
immunostaining	O
between	O
low	O
-	O
grade	O
dysplasia	O
and	O
high	O
-	O
grade	O
dysplasia	O
(	O
44.1	O
%	O
and	O
61.8	O
%	O
,	O
respectively	O
)	O
but	O
not	O
in	O
that	O
of	O
K-ras	O
mutations	O
(	O
20.3	O
%	O
and	O
23.4	O
%	O
,	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
mutation	O
of	O
the	O
p53	O
suppressor	O
gene	O
occurs	O
earlier	O
in	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
than	O
K-ras	O
mutation	O
,	O
providing	O
a	O
clue	O
for	O
further	O
understanding	O
of	O
the	O
role	O
of	O
the	O
p53	O
gene	O
in	O
the	O
early	O
stage	O
of	O
colorectal	O
tumorigenesis	O
.	O
Copyright	O
2002	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11815980	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virchows	O
Arch	O
2001	O
Dec;439	O
(	O
6	O
)	O
:	O
798-802	O
Genetic	O
profile	O
of	O
22	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
.	O
Analysis	O
of	O
K-ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
/	O
Smad4	O
.	O
Moore	O
PS	O
,	O
Sipos	O
B	O
,	O
Orlandini	O
S	O
,	O
Sorio	O
C	O
,	O
Real	O
FX	O
,	O
Lemoine	O
NR	O
,	O
Gress	O
T	O
,	O
Bassi	O
C	O
,	O
Kloppel	O
G	O
,	O
Kalthoff	O
H,	O
Ungefroren	O
H,	O
Lohr	O
M,	O
Scarpa	O
A	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Verona	O
,	O
Italy	O
.	O
The	O
K-ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
genes	O
are	O
among	O
those	O
most	O
frequently	O
altered	O
in	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
analyzed	O
22	O
cell	O
lines	O
for	O
alterations	O
in	O
these	O
genes	O
by	O
direct	O
sequence	O
analysis	O
and	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O
These	O
cell	O
lines	O
showed	O
mutations	O
in	O
K-ras	O
and	O
p53	O
at	O
frequencies	O
of	O
91	O
%	O
and	O
95	O
%	O
,	O
respectively	O
.	O
Alterations	O
in	O
p16INK4a	O
were	O
found	O
in	O
all	O
cases	O
and	O
included	O
nine	O
homozygous	O
deletions	O
,	O
seven	O
mutations	O
and	O
promoter	O
methylation	O
in	O
six	O
cases	O
.	O
Eight	O
cell	O
lines	O
(	O
36	O
%	O
)	O
had	O
an	O
alteration	O
of	O
DPC4	O
,	O
including	O
one	O
mutation	O
and	O
seven	O
homozygous	O
deletions	O
.	O
The	O
most	O
typical	O
mutational	O
profile	O
involved	O
K-ras	O
,	O
p53	O
,	O
and	O
p16INK4a	O
,	O
concurrently	O
aberrated	O
in	O
20	O
cases	O
(	O
91	O
%	O
)	O
.	O
Eight	O
cell	O
lines	O
had	O
alterations	O
in	O
all	O
four	O
genes	O
.	O
Inactivation	O
of	O
DPC4	O
was	O
always	O
accompanied	O
by	O
alteration	O
of	O
all	O
of	O
the	O
other	O
three	O
genes	O
.	O
This	O
comprehensive	O
data	O
regarding	O
the	O
cumulative	O
genetic	O
alterations	O
in	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
will	O
be	O
of	O
great	O
value	O
for	O
studies	O
involving	O
drug	O
sensitivity	O
or	O
resistance	O
that	O
may	O
be	O
associated	O
with	O
inactivation	O
of	O
a	O
particular	O
gene	O
or	O
molecular	O
pathway	O
.	O
PMID	O
:	O
11787853	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Lymphoma	O
2001	O
Jul;42(	O
3	O
)	O
:473	O
-	O
9	O
Lack	O
of	O
association	O
between	O
N-ras	O
gene	O
mutations	O
and	O
clinical	O
prognosis	O
in	O
Brazilian	O
children	O
with	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Clementino	O
NC	O
,	O
Yamamoto	O
M,	O
Viana	O
MB	O
,	O
Figueiredo	O
MS	O
,	O
Kerbauy	O
J,	O
Saad	O
ST	O
,	O
Costa	O
FF.	O
Federal	O
University	O
of	O
Sao	O
Paulo	O
,	O
UNIFESP-EPM	O
,	O
Federal	O
University	O
of	O
Minas	O
Gerais	O
,	O
UFMG	O
,	O
S.	O
Paulo	O
,	O
Brazil	O
.	O
Point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
have	O
been	O
detected	O
in	O
several	O
human	O
malignancies	O
.	O
We	O
studied	O
170	O
patients	O
with	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
,	O
treated	O
from	O
1988	O
to	O
1994	O
according	O
to	O
a	O
protocol	O
derived	O
from	O
BFM-83	O
studies	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
childhood	O
ALL	O
.	O
DNA	O
was	O
extracted	O
from	O
bone	O
marrow	O
smears	O
at	O
diagnosis	O
and	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
After	O
screening	O
with	O
SSCP	O
,	O
PCR	O
products	O
were	O
hybridized	O
with	O
allele	O
specific	O
probes	O
and	O
,	O
in	O
some	O
cases	O
,	O
cloned	O
in	O
a	O
pMOS	O
Blue	O
T	O
vector	O
and	O
sequenced	O
.	O
Exon	O
2	O
was	O
also	O
studied	O
in	O
101	O
children	O
.	O
Our	O
results	O
showed	O
4	O
%	O
of	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
and	O
2	O
%	O
in	O
exon	O
2	O
.	O
Similar	O
to	O
a	O
previous	O
report	O
,	O
we	O
identified	O
7	O
%	O
of	O
mutations	O
among	O
children	O
who	O
were	O
studied	O
for	O
both	O
exons	O
.	O
A	O
new	O
mutation	O
in	O
codon	O
64	O
of	O
the	O
N-ras	O
gene	O
was	O
detected	O
in	O
one	O
patient	O
.	O
No	O
significant	O
clinical	O
differences	O
between	O
patients	O
with	O
and	O
without	O
mutations	O
were	O
detected	O
(	O
sex	O
,	O
age	O
,	O
leukocyte	O
counts	O
at	O
diagnosis	O
,	O
nutritional	O
status	O
,	O
and	O
risk	O
factor	O
according	O
to	O
the	O
BFM	O
protocol	O
)	O
.	O
Children	O
with	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
showed	O
significantly	O
higher	O
reactivity	O
to	O
PAS	O
staining	O
on	O
blast	O
cells	O
than	O
children	O
with	O
a	O
wild	O
type	O
N-ras	O
gene	O
configuration	O
.	O
Comparison	O
of	O
overall	O
-	O
and	O
recurrence	O
-	O
free	O
survival	O
did	O
not	O
show	O
significant	O
difference	O
between	O
groups	O
with	O
and	O
without	O
mutations	O
.	O
Our	O
results	O
suggest	O
that	O
mutations	O
in	O
the	O
ras	O
gene	O
are	O
infrequent	O
in	O
children	O
with	O
ALL	B-malignancy-type
at	O
diagnosis	O
and	O
seem	O
to	O
be	O
of	O
low	O
prognostic	O
value	O
.	O
PMID	O
:	O
11699412	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Jul	O
1;9	O
2	O
(	O
1	O
)	O
:	O
136-45	O
beta-Catenin	O
mutation	O
and	O
overexpression	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
:	O
clinicopathologic	O
and	O
prognostic	O
significance	O
.	O
Wong	O
CM	O
,	O
Fan	O
ST	O
,	O
Ng	O
IO	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Hong	O
Kong	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
Pokfulam	O
,	O
Hong	O
Kong	O
.	O
BACKGROUND	O
:	O
beta-Catenin	O
has	O
been	O
recognized	O
as	O
a	O
critical	O
member	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
inappropriate	O
activation	O
of	O
this	O
pathway	O
has	O
been	O
implicated	O
in	O
carcinogenesis	O
.	O
METHODS	O
:	O
To	O
determine	O
the	O
clinical	O
significance	O
of	O
beta-catenin	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
,	O
we	O
performed	O
mutational	O
analysis	O
at	O
exon	O
3	O
of	O
the	O
gene	O
,	O
investigated	O
the	O
subcellular	O
protein	O
expression	O
,	O
and	O
analyzed	O
their	O
clinicopathologic	O
and	O
prognostic	O
significance	O
in	O
60	O
patients	O
with	O
resected	O
primary	O
HCC	B-malignancy-type
.	O
RESULTS	O
:	O
By	O
direct	O
DNA	O
sequencing	O
,	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
were	O
detected	O
in	O
7	O
(	O
12	O
%	O
)	O
HCCs	O
.	O
All	O
the	O
mutations	O
were	O
found	O
at	O
the	O
region	O
(	O
exon	O
3	O
)	O
responsible	O
for	O
phosphorylation	O
and	O
ubiquitination	O
,	O
therefore	O
likely	O
to	O
result	O
in	O
stabilization	O
of	O
free	O
cytoplasmic	O
beta-catenin	O
.	O
Nuclear	O
accumulation	O
of	O
the	O
beta-catenin	O
protein	O
,	O
similar	O
to	O
the	O
response	O
to	O
the	O
Wnt	O
signal	O
,	O
was	O
found	O
in	O
10	O
(	O
17	O
%	O
)	O
HCCs	B-malignancy-type
and	O
was	O
closely	O
associated	O
with	O
gene	O
mutation	O
(	O
P	O
<	O
0.001	O
)	O
.	O
In	O
the	O
remaining	O
cases	O
,	O
nonnuclear	O
type	O
overexpression	O
,	O
that	O
is	O
,	O
overexpression	O
in	O
the	O
cytoplasm	O
and/or	O
cytoplasmic	O
membrane	O
,	O
was	O
observed	O
in	O
31	O
(	O
62	O
%	O
)	O
HCCs	B-malignancy-type
,	O
thus	O
suggesting	O
that	O
the	O
mechanisms	O
leading	O
to	O
beta-catenin	O
overexpression	O
may	O
be	O
heterogeneous	O
.	O
HCCs	B-malignancy-type
with	O
a	O
nonnuclear	O
type	O
of	O
beta-catenin	O
overexpression	O
were	O
more	O
frequently	O
larger	O
than	O
5	O
cm	O
in	O
diameter	O
(	O
P	O
=	O
0.022	O
)	O
and	O
had	O
poorer	O
cellular	O
differentiation	O
(	O
P	O
=	O
0.037	O
)	O
,	O
and	O
the	O
patients	O
had	O
significantly	O
shorter	O
disease	O
-	O
free	O
survival	O
lengths	O
(	O
P	O
=	O
0.041	O
)	O
.	O
Review	O
of	O
the	O
data	O
from	O
previous	O
studies	O
in	O
HCC	B-malignancy-type
showed	O
that	O
beta-catenin	O
mutations	O
were	O
more	O
frequent	O
in	O
HCV	O
-	O
associated	O
HCC	B-malignancy-type
than	O
in	O
HBV	O
-	O
associated	O
ones	O
.	O
CONCLUSIONS	O
:	O
beta-catenin	O
mutation	O
and	O
deregulation	O
may	O
play	O
an	O
important	O
role	O
in	O
hepatocarcinogenesis	O
.	O
Nonnuclear	O
type	O
beta-catenin	O
overexpression	O
appeared	O
to	O
have	O
pathologic	O
and	O
prognostic	O
significance	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11443619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Mol	O
Pathol	O
2001	O
Jun;70	O
(	O
3	O
)	O
:195-200	O
Rapid	O
,	O
efficient	O
genotyping	O
of	O
clinical	O
tumor	O
samples	O
by	O
laser	O
-	O
capture	O
microdissection	O
/	O
PCR	O
/	O
SSCP	O
.	O
Dillon	O
D	O
,	O
Zheng	O
K,	O
Costa	O
J.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06520	O
,	O
USA	O
.	O
Background	O
:	O
Mutation	O
analysis	O
is	O
becoming	O
increasingly	O
important	O
in	O
clinical	O
practice	O
,	O
since	O
sporadic	O
mutations	O
in	O
tumors	O
often	O
correlate	O
with	O
prognosis	O
and/or	O
therapeutic	O
response	O
.	O
However	O
,	O
the	O
labor	O
-	O
intensive	O
nature	O
of	O
the	O
molecular	O
analyses	O
has	O
limited	O
the	O
routine	O
clinical	O
use	O
of	O
tumor	O
genotyping	O
.	O
Laser	O
-	O
capture	O
microdissection	O
(	O
LCM	O
)	O
allows	O
procurement	O
of	O
relatively	O
pure	O
tumor	O
cell	O
populations	O
.	O
We	O
have	O
investigated	O
the	O
possibility	O
that	O
the	O
use	O
of	O
laser	O
-	O
capture	O
microdissection	O
would	O
allow	O
elimination	O
of	O
time	O
-	O
consuming	O
intermediate	O
steps	O
in	O
tumor	O
genotyping	O
.	O
Design	O
.	O
Archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
seven	O
cases	O
of	O
colorectal	B-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
laser	O
-	O
and	O
hand	O
-	O
microdissected	O
and	O
subsequently	O
evaluated	O
by	O
PCR	O
/	O
SSCP	O
/	O
sequencing	O
for	O
Ki-ras	O
exon	O
1	O
and	O
p53	O
exons	O
5	O
,	O
7	O
,	O
and	O
8	O
.	O
Results	O
.	O
Mutations	O
in	O
Ki-ras	O
exon	O
1	O
and/or	O
p53	O
exons	O
5	O
and	O
7	O
were	O
detected	O
in	O
five	O
of	O
the	O
seven	O
samples	O
.	O
In	O
the	O
hand	O
-	O
microdissected	O
samples	O
,	O
confident	O
identification	O
of	O
mutations	O
was	O
possible	O
in	O
several	O
cases	O
only	O
after	O
band	O
excision	O
,	O
DNA	O
elution	O
,	O
reamplification	O
,	O
and	O
verification	O
of	O
mutant	O
enrichment	O
by	O
a	O
second	O
SSCP	O
analysis	O
prior	O
to	O
sequencing	O
.	O
In	O
the	O
laser	O
-	O
microdissected	O
samples	O
,	O
confident	O
mutation	O
identification	O
was	O
possible	O
in	O
all	O
cases	O
with	O
direct	O
sequencing	O
of	O
the	O
original	O
PCR	O
product	O
,	O
reducing	O
the	O
time	O
required	O
for	O
molecular	O
analysis	O
to	O
3	O
days	O
.	O
Conclusion	O
.	O
Using	O
laser	O
-	O
capture	O
microdissection	O
,	O
mutant	O
signals	O
are	O
strong	O
enough	O
to	O
sequence	O
directly	O
from	O
original	O
PCR	O
products	O
.	O
With	O
rapid	O
,	O
efficient	O
genotyping	O
by	O
LCM	O
/	O
PCR	O
/	O
SSCP	O
,	O
results	O
can	O
be	O
incorporated	O
directly	O
into	O
the	O
surgical	O
pathology	O
report	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11417998	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dig	O
Dis	O
Sci	O
2000	O
Nov;45(	O
11	O
)	O
:2187	O
-	O
94	O
No	O
major	O
difference	O
in	O
K-ras	O
and	O
p53	O
abnormalities	O
in	O
sporadic	B-malignancy-type
and	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
.	O
Voskuil	O
DW	O
,	O
Kampman	O
E	O
,	O
van	O
Geloof	O
W	O
,	O
Grubben	O
M,	O
Kok	O
F	O
,	O
van	O
Muijen	O
G	O
,	O
Nagengast	O
F	O
,	O
Vasen	O
H	O
,	O
van't	O
Veer	O
P.	O
Division	O
of	O
Human	O
Nutrition	O
and	O
Epidemiology	O
,	O
Wageningen	O
University	O
,	O
The	O
Netherlands	O
.	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
are	O
known	O
to	O
occur	O
in	O
high	O
frequencies	O
in	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
cancers	I-malignancy-type
,	O
but	O
findings	O
are	O
inconsistent	O
in	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
HNPCC	B-malignancy-type
)	O
.	O
We	O
compared	O
K-ras	O
codon	O
12	O
and	O
13	O
gene	O
mutations	O
and	O
p53	O
protein	O
overexpression	O
in	O
48	O
HNPCC	B-malignancy-type
(	O
positive	O
for	O
Amsterdam	O
criteria	O
)	O
and	O
59	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
,	O
to	O
examine	O
whether	O
they	O
may	O
represent	O
similar	O
or	O
different	O
molecular	O
pathways	O
to	O
cancer	O
.	O
In	O
sporadic	B-malignancy-type
adenomas	I-malignancy-type
K-ras	O
mutations	O
were	O
detected	O
in	O
32	O
%	O
and	O
p53	O
overexpression	O
in	O
31	O
%	O
of	O
the	O
cases	O
.	O
Similarly	O
,	O
K-ras	O
mutations	O
and	O
p53	O
overexpression	O
were	O
both	O
found	O
in	O
25	O
%	O
of	O
HNPCC	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
frequencies	O
of	O
these	O
abnormalities	O
were	O
not	O
significantly	O
different	O
between	O
HNPCC	B-malignancy-type
and	O
sporadic	B-malignancy-type
adenomas	I-malignancy-type
.	O
When	O
taking	O
differences	O
in	O
adenoma	B-malignancy-type
size	O
into	O
account	O
,	O
the	O
frequencies	O
were	O
even	O
more	O
similar	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
suggest	O
a	O
similar	O
molecular	O
pathway	O
to	O
adenomas	B-malignancy-type
in	O
HNPCC	B-malignancy-type
and	O
sporadic	O
carcinogenesis	O
,	O
with	O
respect	O
to	O
involvement	O
of	O
K-ras	O
and	O
p53	O
.	O
PMID	O
:	O
11215737	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dig	O
Dis	O
Sci	O
2000	O
Oct;45(	O
10	O
)	O
:2022	O
-	O
8	O
Combination	O
analysis	O
of	O
genetic	O
alterations	O
and	O
cell	O
proliferation	O
in	O
small	B-malignancy-type
intestinal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Muneyuki	O
T	O
,	O
Watanabe	O
M,	O
Yamanaka	O
M,	O
Isaji	O
S,	O
Kawarada	O
Y	O
,	O
Yatani	O
R.	O
First	O
Department	O
of	O
Surgery	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Tsu	O
-	O
shi	O
,	O
Japan	O
.	O
We	O
analyzed	O
K-ras	O
and	O
p53	O
mutations	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
methods	O
,	O
as	O
well	O
as	O
p53	O
expression	O
and	O
the	O
Ki-67	O
labeling	O
index	O
(	O
LI	O
)	O
using	O
immunohistochemistry	O
in	O
10	O
duodenal	B-malignancy-type
and	O
10	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
two	O
duodenal	B-malignancy-type
(	O
20	O
%	O
)	O
and	O
three	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
30	O
%	O
)	O
carcinomas	B-malignancy-type
and	O
p53	O
mutations	O
in	O
one	O
(	O
10	O
%	O
)	O
and	O
three	O
(	O
30	O
%	O
)	O
,	O
respectively	O
.	O
LOH	O
of	O
17p	O
was	O
detected	O
in	O
two	O
duodenal	B-malignancy-type
(	O
20	O
%	O
)	O
and	O
two	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
20	O
%	O
)	O
carcinomas	B-malignancy-type
and	O
p53	O
expression	O
in	O
four	O
duodenal	B-malignancy-type
(	O
40	O
%	O
)	O
and	O
four	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
40	O
%	O
)	O
.	O
One	O
duodenal	B-malignancy-type
(	O
10	O
%	O
)	O
and	O
two	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
20	O
%	O
)	O
carcinomas	B-malignancy-type
demonstrated	O
MSI	O
.	O
LOH	O
of	O
APC	O
was	O
detected	O
in	O
three	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
30	O
%	O
)	O
,	O
but	O
none	O
of	O
the	O
duodenal	B-malignancy-type
carcinomas	B-malignancy-type
.	O
The	O
Ki-67	O
LI	O
was	O
44	O
%	O
in	O
duodenal	B-malignancy-type
and	O
52.6	O
%	O
in	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
carcinomas	B-malignancy-type
.	O
A	O
subset	O
of	O
small	B-malignancy-type
intestinal	I-malignancy-type
carcinomas	I-malignancy-type
showed	O
involvement	O
of	O
K-ras	O
and	O
p53	O
mutations	O
,	O
LOH	O
of	O
APC	O
,	O
and	O
MSI	O
.	O
A	O
difference	O
was	O
also	O
apparent	O
for	O
LOH	O
of	O
APC	O
between	O
duodenal	B-malignancy-type
and	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
11117578	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Gastroenterol	O
Hepatol	O
2000	O
Oct;15(	O
10	O
)	O
:1151	O
-	O
7	O
Analysis	O
of	O
K-ras	O
codon	O
12	O
mutations	O
and	O
p53	O
overexpression	O
in	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
.	O
Kusaka	O
T	O
,	O
Fukui	O
H	O
,	O
Sano	O
Y	O
,	O
Ueda	O
Y	O
,	O
Chiba	O
T	O
,	O
Fujimori	O
T.	O
Department	O
of	O
Pathology	O
,	O
Dokkyo	O
University	O
School	O
of	O
Medicine	O
,	O
Shimotsuga	O
,	O
Tochigi	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
AIMS	O
:	O
Morphologically	O
,	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
are	O
quite	O
different	O
from	O
polypoid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
that	O
develop	O
via	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
.	O
Although	O
polypoid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
are	O
well	O
known	O
to	O
have	O
a	O
high	O
incidence	O
of	O
K-ras	O
gene	O
mutation	O
and	O
p53	O
overexpression	O
,	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
have	O
not	O
been	O
examined	O
in	O
terms	O
of	O
genetic	O
changes	O
and	O
clinicopathological	O
features	O
.	O
In	O
the	O
present	O
study	O
,	O
therefore	O
,	O
we	O
analysed	O
the	O
clinicopathological	O
features	O
,	O
genetic	O
changes	O
in	O
K-ras	O
codon	O
12	O
,	O
and	O
p53	O
overexpression	O
in	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
.	O
METHODS	O
:	O
A	O
total	O
of	O
18	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
were	O
surgically	O
resected	O
and	O
then	O
analysed	O
clinicopathologically	O
.	O
Immunohistochemistry	O
and	O
polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
were	O
performed	O
to	O
analyse	O
p53	O
abnormalities	O
in	O
the	O
tumors	O
.	O
K-ras	O
codon	O
12	O
mutations	O
were	O
screened	O
out	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
and	O
analysed	O
by	O
fluorescence	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
p53	O
overexpression	O
was	O
observed	O
in	O
six	O
lesions	O
(	O
33	O
%	O
)	O
.	O
p53	O
-	O
overexpressing	O
cells	O
were	O
observed	O
in	O
parts	O
of	O
carcinoma	B-malignancy-type
or	O
adenoma	B-malignancy-type
showing	O
high	O
-	O
grade	O
atypia	O
.	O
Four	O
of	O
the	O
10	O
(	O
40	O
%	O
)	O
samples	O
had	O
a	O
p53	O
gene	O
mutation	O
.	O
Nine	O
of	O
the	O
18	O
(	O
50	O
%	O
)	O
samples	O
had	O
a	O
K-ras	O
codon	O
12	O
point	O
mutation	O
.	O
In	O
eight	O
cases	O
(	O
89	O
%	O
)	O
,	O
the	O
mutations	O
of	O
the	O
K-ras	O
codon	O
12	O
were	O
of	O
the	O
same	O
type	O
:	O
GGT	O
(	O
glycine	O
)	O
to	O
GTT	O
(	O
valine	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumor	I-malignancy-type
has	O
distinctive	O
characteristics	O
showing	O
a	O
morphological	O
phenotype	O
of	O
the	O
superficial	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
and	O
genotype	O
of	O
the	O
polypoid	B-malignancy-type
tumors	I-malignancy-type
in	O
terms	O
of	O
K-ras	O
gene	O
mutation	O
and	O
p53	O
overexpression	O
.	O
PMID	O
:	O
11106095	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Gastroenterol	O
2000	O
Oct;95(	O
10	O
)	O
:2953	O
-	O
7	O
Impact	O
of	O
KRAS	O
and	O
TP53	O
mutations	O
on	O
survival	O
in	O
patients	O
with	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
Dukes	I-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
.	O
Bleeker	O
WA	O
,	O
Hayes	O
VM	O
,	O
Karrenbeld	O
A	O
,	O
Hofstra	O
RM	O
,	O
Hermans	O
J,	O
Buys	O
CC	O
,	O
Plukker	O
JT.	O
Department	O
of	O
Surgery	O
,	O
Medical	O
Genetics	O
and	O
Pathology	O
,	O
University	O
Hospital	O
Groningen	O
,	O
The	O
Netherlands	O
.	O
OBJECTIVE	O
:	O
It	O
has	O
been	O
suggested	O
that	O
KRAS	O
and	O
TP53	O
mutated	O
tumors	O
might	O
influence	O
the	O
phenotypic	O
behavior	O
of	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
.	O
We	O
investigated	O
the	O
incidence	O
of	O
these	O
mutations	O
in	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
and	O
their	O
possible	O
influence	O
on	O
survival	O
in	O
a	O
homogeneous	O
group	O
of	O
patients	O
with	O
Dukes	B-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancers	I-malignancy-type
.	O
METHODS	O
:	O
The	O
primary	O
tumors	O
of	O
55	O
patients	O
with	O
a	O
sporadic	B-malignancy-type
Dukes	I-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
,	O
all	O
treated	O
with	O
adjuvant	O
chemotherapy	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
KRAS	O
and	O
TP53	O
mutations	O
.	O
Mutation	O
detection	O
of	O
the	O
KRAS	O
and	O
TP53	O
genes	O
was	O
performed	O
on	O
paraffin	O
-	O
embedded	O
tumor	O
material	O
,	O
using	O
denaturating	O
gradient	O
gel	O
electrophoresis	O
.	O
The	O
5	O
-	O
yr	O
survival	O
rates	O
of	O
KRAS	O
and	O
TP53	O
mutated	O
tumors	O
were	O
analyzed	O
regarding	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
(	O
defined	O
as	O
tumors	B-malignancy-type
up	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
splenic	I-malignancy-type
flexure	I-malignancy-type
)	O
and	O
left	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
(	O
defined	O
as	O
tumors	B-malignancy-type
from	I-malignancy-type
the	I-malignancy-type
splenic	I-malignancy-type
flexure	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
rectosigmoid	I-malignancy-type
peritoneal	I-malignancy-type
reflection	I-malignancy-type
)	O
.	O
RESULTS	O
:	O
KRAS	O
mutations	O
occurred	O
more	O
frequently	O
in	O
the	O
right	O
colon	O
compared	O
to	O
the	O
left	O
colon	O
(	O
R	O
=	O
38	O
%	O
(	O
10	O
/	O
26	O
)	O
;	O
L	O
=	O
10	O
%	O
(	O
3	O
/	O
29	O
)	O
;	O
chi2	O
test	O
:	O
p	O
=	O
0.014	O
)	O
.	O
KRAS	O
mutations	O
did	O
not	O
influence	O
survival	O
in	O
patients	O
with	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
.	O
Patients	O
with	O
KRAS	O
mutation	O
-	O
negative	O
tumors	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
right	I-malignancy-type
colon	I-malignancy-type
,	O
however	O
,	O
had	O
a	O
significantly	O
worse	O
survival	O
than	O
patients	O
with	O
left	O
-	O
sided	O
KRAS	O
mutation	O
-	O
negative	O
tumors	O
(	O
5	O
-	O
yr	O
survival	O
;	O
R	O
:	O
34	O
%	O
vs	O
L	O
:	O
65	O
%	O
,	O
log	O
-	O
rank	O
test	O
:	O
p	O
=	O
0.007	O
)	O
.	O
TP53	O
mutations	O
of	O
a	O
possible	O
causative	O
nature	O
were	O
found	O
in	O
24	O
tumors	O
(	O
44	O
%	O
)	O
.	O
Neither	O
the	O
incidence	O
(	O
R	O
=	O
42	O
%	O
(	O
11	O
/	O
26	O
)	O
;	O
L	O
=	O
45	O
%	O
(	O
13	O
/	O
29	O
)	O
)	O
nor	O
the	O
survival	O
of	O
TP53	O
mutated	O
tumors	O
differed	O
significantly	O
between	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
.	O
Furthermore	O
,	O
survival	O
of	O
patients	O
with	O
TP53	O
mutation	O
-	O
negative	O
tumors	O
did	O
not	O
differ	O
significantly	O
between	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
There	O
seems	O
to	O
be	O
no	O
difference	O
in	O
survival	O
rate	O
between	O
patients	O
with	O
KRAS	O
mutated	O
and	O
KRAS	O
negative	O
Dukes	B-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
;	O
however	O
,	O
KRAS	O
mutations	O
are	O
more	O
frequently	O
found	O
in	O
the	O
right	O
colon	O
compared	O
to	O
the	O
left	O
colon	O
.	O
TP53	O
mutations	O
do	O
not	O
have	O
predominance	O
for	O
either	O
side	O
of	O
the	O
colon	O
,	O
and	O
there	O
are	O
no	O
differences	O
in	O
survival	O
in	O
patients	O
with	O
left	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
versus	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
.	O
Patients	O
with	O
KRAS	O
-	O
nonmutated	O
tumors	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
right	I-malignancy-type
colon	I-malignancy-type
did	O
have	O
a	O
worse	O
survival	O
compared	O
to	O
those	O
with	O
such	O
tumors	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
left	I-malignancy-type
colon	I-malignancy-type
.	O
This	O
suggests	O
that	O
other	O
genetic	O
factors	O
may	O
play	O
a	O
role	O
in	O
tumor	O
genesis	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O
PMID	O
:	O
11051374	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mod	O
Pathol	O
2000	O
Oct;13(	O
10	O
)	O
:1066	O
-	O
71	O
Mutational	O
analysis	O
of	O
the	O
CTNNB1	O
and	O
APC	O
genes	O
in	O
uterine	B-malignancy-type
endometrioid	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Schlosshauer	O
PW	O
,	O
Pirog	O
EC	O
,	O
Levine	O
RL	O
,	O
Ellenson	O
LH.	O
Department	O
of	O
Pathology	O
,	O
Joan	O
and	O
Sanford	O
I	O
.	O
Weill	O
Medical	O
College	O
of	O
Cornell	O
University	O
,	O
New	O
York	O
,	O
USA	O
.	O
Despite	O
recent	O
studies	O
,	O
the	O
molecular	O
genetic	O
events	O
responsible	O
for	O
the	O
development	O
of	O
uterine	B-malignancy-type
endometrioid	I-malignancy-type
carcinoma	I-malignancy-type
(	O
UEC	B-malignancy-type
)	O
remain	O
incompletely	O
characterized	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
(	O
CTNNB1	O
)	O
gene	O
have	O
been	O
recently	O
reported	O
in	O
a	O
small	O
percentage	O
of	O
UECs	B-malignancy-type
and	O
in	O
the	O
endometrioid	B-malignancy-type
variant	I-malignancy-type
of	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
involved	O
in	O
the	O
development	O
of	O
female	B-malignancy-type
genital	I-malignancy-type
tract	I-malignancy-type
tumors	I-malignancy-type
with	O
endometrioid	O
morphology	O
.	O
The	O
Wnt	O
pathway	O
is	O
a	O
critical	O
pathway	O
in	O
the	O
development	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
(	O
CRC	B-malignancy-type
)	O
with	O
mutations	O
occurring	O
in	O
the	O
beta-catenin	O
(	O
CTNNB1	O
)	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
genes	O
in	O
10	O
to	O
15	O
%	O
and	O
85	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
Because	O
UEC	B-malignancy-type
and	O
CRC	B-malignancy-type
share	O
other	O
molecular	O
genetic	O
alterations	O
and	O
histologic	O
features	O
and	O
previous	O
studies	O
of	O
UEC	B-malignancy-type
have	O
not	O
reported	O
an	O
analysis	O
of	O
the	O
APC	O
gene	O
,	O
we	O
chose	O
to	O
further	O
elucidate	O
the	O
role	O
of	O
the	O
Wnt	O
pathway	O
in	O
UEC	B-malignancy-type
.	O
To	O
this	O
end	O
,	O
we	O
analyzed	O
32	O
cases	O
of	O
UEC	B-malignancy-type
for	O
mutations	O
of	O
the	O
CTNNB1	O
and	O
APC	O
genes	O
.	O
Mutations	O
of	O
CTNNB1	O
were	O
present	O
in	O
six	O
of	O
32	O
(	O
18	O
%	O
)	O
cases	O
:	O
four	O
grade	B-malignancy-type
1	I-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
grade	B-malignancy-type
2	I-malignancy-type
,	O
and	O
one	O
grade	B-malignancy-type
3	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Five	O
missense	O
mutations	O
were	O
identified	O
,	O
three	O
involving	O
Ser	O
/	O
Thr	O
phosphorylation	O
sites	O
and	O
two	O
adjacent	O
to	O
a	O
Ser	O
phosphorylation	O
site	O
.	O
One	O
case	O
contained	O
a	O
deletion	O
encompassing	O
codons	O
34	O
to	O
37	O
,	O
which	O
includes	O
a	O
Ser	O
phosphorylation	O
site	O
.	O
No	O
mutations	O
resulting	O
in	O
truncation	O
of	O
the	O
APC	O
protein	O
were	O
found	O
.	O
Our	O
results	O
support	O
a	O
role	O
for	O
the	O
Wnt	O
signaling	O
pathway	O
via	O
mutation	O
of	O
CTNNB1	O
,	O
but	O
not	O
APC	O
,	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
UECs	B-malignancy-type
.	O
PMID	O
:	O
11048799	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pathol	O
Res	O
Pract	O
2000	O
;196(9	O
)	O
:601	O
-	O
5	O
Ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
analysis	O
in	O
cardiac	B-malignancy-type
myxomas	I-malignancy-type
.	O
Karga	O
H	O
,	O
Papaioannou	O
P	O
,	O
Karayianni	O
M,	O
Papadimitriou	O
K	O
,	O
Priftis	O
D	O
,	O
Voujuklakis	O
T	O
,	O
Migdou	O
B	O
,	O
Nanas	O
J,	O
Papapetrou	O
P.	O
Endocrine	O
Unit	O
,	O
Alexandra	O
Hospital	O
,	O
Athens	O
,	O
Greece	O
.	O
Although	O
ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
mutations	O
are	O
implicated	O
in	O
the	O
development	O
of	O
several	O
human	O
tumors	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
the	O
pathogenesis	O
of	O
primary	O
cardiac	B-malignancy-type
tumors	I-malignancy-type
.	O
Paraffin	O
-	O
embedded	O
tissue	O
from	O
19	O
cardiac	B-malignancy-type
myxomas	I-malignancy-type
were	O
investigated	O
for	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
abnormalities	O
.	O
Immunohistochemical	O
analysis	O
was	O
used	O
to	O
identify	O
the	O
accumulation	O
of	O
p21	O
-	O
ras	O
and	O
p53	O
proteins	O
.	O
A	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
exons	O
1	O
and	O
2	O
of	O
the	O
ras	O
genes	O
and	O
exons	O
5	O
to	O
8	O
of	O
the	O
p53	O
gene	O
.	O
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
by	O
direct	O
DNA	O
sequencing	O
.	O
Three	O
of	O
19	O
myxomas	B-malignancy-type
showed	O
strong	O
positive	O
staining	O
for	O
the	O
ras	O
p21	O
protein	O
.	O
In	O
contrast	O
,	O
nuclear	O
p53	O
was	O
not	O
detectable	O
in	O
any	O
of	O
the	O
myxomas	B-malignancy-type
.	O
Among	O
the	O
ras	O
p21	O
immunopositive	O
myxomas	B-malignancy-type
,	O
2	O
were	O
heterozygous	O
for	O
a	O
missense	O
point	O
mutation	O
of	O
the	O
K-ras	O
,	O
Gly	O
12	O
Asp	O
.	O
Further	O
screening	O
of	O
the	O
remaining	O
myxomas	B-malignancy-type
showed	O
no	O
mutation	O
or	O
even	O
silent	O
polymorphism	O
in	O
any	O
exon	O
of	O
the	O
ras	O
and	O
p53	O
.	O
The	O
results	O
suggest	O
that	O
although	O
genetic	O
alterations	O
of	O
ras	O
oncogenes	O
and	O
p53	O
are	O
uncommon	O
events	O
in	O
cardiac	B-malignancy-type
myxomas	I-malignancy-type
,	O
ras	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
a	O
subgroup	O
of	O
this	O
type	O
of	O
tumor	B-malignancy-type
.	O
PMID	O
:	O
10997733	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Arch	O
Pathol	O
Lab	O
Med	O
2000	O
Jun;124(	O
6)	O
:836	O
-	O
9	O
ras	O
gene	O
mutations	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
Republic	O
of	O
Korea	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
the	O
prevalence	O
of	O
activating	O
mutations	O
in	O
K-ras	O
and	O
H-ras	O
genes	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
with	I-malignancy-type
ductal	I-malignancy-type
or	O
acinar	B-malignancy-type
differentiation	I-malignancy-type
and	O
to	O
evaluate	O
their	O
potential	O
correlation	O
with	O
clinical	O
parameters	O
.	O
DESIGN	O
:	O
Paraffin	O
-	O
embedded	O
tissue	O
samples	O
of	O
salivary	B-malignancy-type
gland	I-malignancy-type
carcinomas	I-malignancy-type
were	O
investigated	O
by	O
the	O
application	O
of	O
a	O
direct	O
sequence	O
analysis	O
procedure	O
with	O
automated	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
ras	O
sequences	O
.	O
SETTING	O
:	O
Tertiary	O
care	O
teaching	O
hospital	O
.	O
PATIENTS	O
:	O
Twenty-four	O
patients	O
with	O
salivary	B-malignancy-type
gland	I-malignancy-type
carcinoma	I-malignancy-type
were	O
surgically	O
treated	O
.	O
Nine	O
had	O
adenocarcinoma	B-malignancy-type
,	O
1	O
had	O
adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
,	O
11	O
had	O
mucoepidermoid	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
3	O
had	O
acinic	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
RESULTS	O
:	O
Point	O
mutations	O
were	O
detected	O
in	O
7	O
(	O
29	O
%	O
)	O
of	O
the	O
24	O
carcinomas	B-malignancy-type
examined	O
.	O
The	O
K-ras	O
gene	O
was	O
mutated	O
in	O
only	O
2	O
samples	O
(	O
8	O
%	O
)	O
:	O
a	O
GGC	O
-	O
to	O
-	O
ATC	O
mutation	O
at	O
codon	O
13	O
in	O
an	O
adenocarcinoma	B-malignancy-type
and	O
a	O
GGC	O
-	O
to	O
-	O
GTC	O
transversion	O
mutation	O
at	O
codon	O
13	O
in	O
a	O
mucoepidermoid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Five	O
(	O
21	O
%	O
)	O
harbored	O
H-ras	O
mutations	O
:	O
4	O
contained	O
a	O
GGC	O
-	O
to	O
-	O
GTC	O
transversion	O
mutation	O
at	O
codon	O
12	O
and	O
1	O
had	O
2	O
distinct	O
mutations	O
,	O
the	O
same	O
G	O
-	O
to	O
-	O
T	O
at	O
codon	O
12	O
as	O
was	O
shown	O
in	O
the	O
other	O
cases	O
and	O
a	O
GGT	O
-	O
to	O
-	O
GGA	O
heterozygous	O
mutation	O
at	O
codon	O
13	O
.	O
All	O
the	O
H-ras	O
mutations	O
were	O
in	O
the	O
group	O
of	O
mucoepidermoid	B-malignancy-type
carcinoma	I-malignancy-type
lesions	I-malignancy-type
(	O
45	O
%	O
;	O
5	O
/	O
11	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
K-ras	O
gene	O
alteration	O
is	O
probably	O
not	O
an	O
important	O
factor	O
in	O
the	O
oncogenesis	O
of	O
human	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
.	O
However	O
,	O
mutational	O
activation	O
of	O
the	O
H-ras	O
gene	O
appears	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
salivary	B-malignancy-type
gland	I-malignancy-type
mucoepidermoid	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
10835516	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Apr	O
1;60(	O
7)	O
:1800	O
-	O
4	O
Relative	O
reciprocity	O
of	O
NRAS	O
and	O
PTEN	O
/	O
MMAC1	O
alterations	O
in	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
cell	O
lines	O
.	O
Tsao	O
H	O
,	O
Zhang	O
X	O
,	O
Fowlkes	O
K	O
,	O
Haluska	O
FG.	O
Department	O
of	O
Dermatology	O
,	O
Massachusetts	O
General	O
Hospital	O
and	O
Dana	O
-	O
Farber	O
/	O
Partners	O
CancerCare	O
,	O
Boston	O
02114	O
,	O
USA	O
.	O
Both	O
inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
and	O
oncogenic	O
activation	O
of	O
RAS	O
have	O
been	O
described	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
In	O
mice	O
,	O
activation	O
of	O
a	O
RAS	O
-	O
containing	O
pathway	O
is	O
a	O
necessary	O
step	O
in	O
the	O
pathogenesis	O
of	O
murine	O
melanomas	B-malignancy-type
.	O
Because	O
PTEN	O
negatively	O
regulates	O
on	O
the	O
downstream	O
effects	O
of	O
phosphatidylinositol-3-kinase	O
(	O
PI3-K	O
)	O
,	O
we	O
hypothesized	O
that	O
the	O
loss	O
of	O
PTEN	O
/	O
MMAC1	O
and	O
the	O
activation	O
of	O
RAS	O
may	O
be	O
largely	O
equivalent	O
because	O
RAS	O
is	O
a	O
known	O
positive	O
upstream	O
regulator	O
of	O
PI3-K	O
.	O
We	O
expanded	O
our	O
previous	O
survey	O
of	O
PTEN	O
/	O
MMAC1	O
mutations	O
and	O
analyzed	O
the	O
RAS	O
status	O
of	O
53	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
cell	O
lines	O
,	O
18	O
glioma	B-malignancy-type
cell	O
lines	O
,	O
and	O
17	O
uncultured	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
metastasis	O
.	O
Overall	O
,	O
51	O
%	O
of	O
the	O
cell	O
lines	O
had	O
alterations	O
in	O
either	O
PTEN	O
/	O
MMAC1	O
or	O
RAS	O
.	O
We	O
found	O
16	O
cell	O
lines	O
(	O
30	O
%	O
)	O
with	O
alterations	O
in	O
PTEN	O
/	O
MMAC1	O
and	O
11	O
cell	O
lines	O
(	O
21	O
%	O
)	O
with	O
activating	O
NRAS	O
mutations	O
;	O
only	O
1	O
cell	O
line	O
had	O
concurrent	O
alterations	O
in	O
both	O
genes	O
.	O
Moreover	O
,	O
glioma	B-malignancy-type
cell	O
lines	O
with	O
a	O
high	O
frequency	O
of	O
PTEN	O
/	O
MMAC1	O
inactivation	O
had	O
no	O
identifiable	O
RAS	O
alterations	O
.	O
Ectopic	O
expression	O
of	O
PTEN	O
in	O
several	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
cell	O
lines	O
suppressed	O
colony	O
formation	O
irrespective	O
of	O
PTEN	O
/	O
MMAC1	O
status	O
;	O
furthermore	O
,	O
PTEN	O
expression	O
in	O
cell	O
lines	O
carrying	O
activated	O
RAS	O
also	O
suppressed	O
colony	O
formation	O
.	O
The	O
relative	O
reciprocity	O
of	O
PTEN	O
/	O
MMAC1	O
abrogation	O
and	O
NRAS	O
activation	O
suggests	O
that	O
the	O
two	O
genetic	O
changes	O
,	O
in	O
a	O
subset	O
of	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
,	O
are	O
functionally	O
overlapping	O
.	O
PMID	O
:	O
10766161	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
Lab	O
Med	O
1999	O
Jul;37(	O
7)	O
:723	O
-	O
7	O
A	O
relationship	O
between	O
K-ras	O
gene	O
mutations	O
and	O
some	O
clinical	O
and	O
histologic	O
variables	O
in	O
patients	O
with	O
primary	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Beranek	O
M,	O
Bures	O
J,	O
Palicka	O
V	O
,	O
Jandik	O
P	O
,	O
Langr	O
F	O
,	O
Nejedla	O
E.	O
Institute	O
of	O
Clinical	O
Biochemistry	O
and	O
Diagnostics	O
,	O
University	O
Hospital	O
,	O
Hradec	O
Kralove	O
,	O
Czech	O
Republic	O
.	O
Mutations	O
in	O
the	O
Kirsten	O
ras	O
2	O
(	O
K-ras	O
)	O
gene	O
were	O
described	O
as	O
early	O
events	O
in	O
the	O
process	O
of	O
colorectal	O
carcinogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
a	O
possible	O
relationship	O
between	O
the	O
presence	O
of	O
K-ras	O
mutation	O
in	O
samples	O
of	O
primary	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
and	O
the	O
clinico	O
-	O
pathological	O
data	O
of	O
the	O
investigated	O
patients	O
.	O
Mutation	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
was	O
determined	O
in	O
18	O
of	O
53	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
(	O
34	O
%	O
)	O
in	O
our	O
group	O
of	O
patients	O
.	O
The	O
presence	O
of	O
K-ras	O
gene	O
mutations	O
was	O
not	O
related	O
to	O
gender	O
,	O
age	O
of	O
subject	O
at	O
diagnosis	O
,	O
staging	O
or	O
cancer	O
location	O
(	O
p	O
>	O
0.05	O
)	O
.	O
Sixteen	O
of	O
the	O
42	O
(	O
38	O
%	O
)	O
moderately	O
differentiated	O
carcinomas	B-malignancy-type
,	O
and	O
two	O
of	O
the	O
eight	O
(	O
25	O
%	O
)	O
well	O
differentiated	O
carcinomas	B-malignancy-type
contained	O
K-ras	O
mutation	O
in	O
codon	O
12	O
,	O
but	O
none	O
of	O
the	O
three	O
poorly	O
differentiated	O
carcinomas	B-malignancy-type
contained	O
the	O
mutation	O
.	O
Moderately	O
differentiated	O
tumours	O
contained	O
an	O
aspartate	O
code	O
GAT	O
(	O
in	O
eight	O
cases	O
)	O
,	O
a	O
valine	O
code	O
GTT	O
(	O
in	O
six	O
cases	O
)	O
,	O
an	O
alanine	O
code	O
GCT	O
(	O
in	O
one	O
case	O
)	O
and	O
a	O
serine	O
code	O
AGT	O
(	O
in	O
one	O
case	O
)	O
in	O
codon	O
12	O
.	O
Well	O
differentiated	O
tumours	O
contained	O
only	O
the	O
valine	O
code	O
GTT	O
(	O
two	O
cases	O
)	O
.	O
Our	O
results	O
show	O
that	O
the	O
frequency	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
in	O
carcinomas	B-malignancy-type
in	O
Central	O
Europe	O
is	O
not	O
different	O
from	O
the	O
frequencies	O
found	O
in	O
other	O
parts	O
of	O
the	O
world	O
.	O
The	O
homogeneous	O
incidence	O
of	O
K-ras	O
mutation	O
does	O
not	O
seem	O
to	O
be	O
related	O
to	O
ethnic	O
factors	O
,	O
dietary	O
habits	O
,	O
or	O
the	O
composition	O
of	O
the	O
diet	O
.	O
PMID	O
:	O
10510729	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Sep	O
1;59(	O
17	O
)	O
:4257	O
-	O
60	O
Frequent	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
Park	O
WS	O
,	O
Oh	O
RR	O
,	O
Park	O
JY	O
,	O
Lee	O
SH	O
,	O
Shin	O
MS	O
,	O
Kim	O
YS	O
,	O
Kim	O
SY	O
,	O
Lee	O
HK	O
,	O
Kim	O
PJ	O
,	O
Oh	O
ST	O
,	O
Yoo	O
NJ	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Catholic	O
University	O
Medical	O
College	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
increased	O
level	O
of	O
cytoplasmic	O
beta-catenin	O
through	O
the	O
mutations	O
to	O
either	O
beta-catenin	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
has	O
been	O
proposed	O
as	O
an	O
important	O
oncogenic	O
step	O
in	O
various	O
tumors	O
.	O
Gastric	B-malignancy-type
cancer	I-malignancy-type
showed	O
frequent	O
genetic	O
alterations	O
of	O
the	O
APC	O
gene	O
,	O
and	O
the	O
risk	O
for	O
gastric	B-malignancy-type
cancer	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatosus	I-malignancy-type
polyposis	I-malignancy-type
patients	O
is	O
10	O
times	O
higher	O
than	O
that	O
in	O
the	O
general	O
population	O
.	O
These	O
findings	O
raise	O
the	O
possibility	O
that	O
mutations	O
of	O
beta-catenin	O
may	O
also	O
be	O
associated	O
with	O
the	O
development	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
.	O
We	O
detected	O
seven	O
somatic	O
mutations	O
in	O
a	O
portion	O
of	O
exon	O
3	O
encoding	O
for	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
consensus	O
region	O
of	O
the	O
beta-catenin	O
gene	O
in	O
43	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
All	O
of	O
these	O
mutations	O
were	O
missense	O
mutations	O
,	O
of	O
which	O
five	O
are	O
in	O
the	O
highly	O
conserved	O
aspartic	O
acid	O
32	O
and	O
two	O
are	O
in	O
serine	O
29	O
;	O
all	O
of	O
these	O
seven	O
mutations	O
were	O
detected	O
exclusively	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
(	O
7	O
of	O
26	O
;	O
26.9	O
%	O
)	O
,	O
but	O
not	O
in	O
the	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
(	O
0	O
of	O
17	O
)	O
.	O
We	O
concluded	O
that	O
disruption	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
T	O
cell	O
factor	O
-	O
lymphoid	O
enhancer	O
binding	O
factor	O
pathway	O
might	O
play	O
an	O
important	O
role	O
especially	O
in	O
the	O
development	O
of	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10485468	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
1999	O
Aug;15(	O
2	O
)	O
:391	O
-	O
8	O
Sampling	O
technique	O
influences	O
the	O
detection	O
of	O
K-ras	O
mutations	O
in	O
normal	O
appearing	O
mucosa	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Schimanski	O
CC	O
,	O
Sutter	O
C	O
,	O
Linnemann	O
U	O
,	O
Berger	O
MR	O
.	O
Unit	O
of	O
Toxicology	O
and	O
Chemotherapy	O
,	O
German	O
Cancer	O
Research	O
Centre	O
,	O
69120	O
Heidelberg	O
,	O
Germany	O
.	O
Based	O
on	O
three	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
with	O
specified	O
K-ras	O
status	O
,	O
a	O
sensitive	O
PCR	O
-	O
RFLP	O
assay	O
was	O
established	O
detecting	O
one	O
K-ras	O
mutant	O
among	O
106	O
wild	O
-	O
type	O
cells	O
.	O
Using	O
this	O
assay	O
for	O
tissues	O
of	O
124	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
59	O
tumor	O
(	O
46	O
%	O
)	O
and	O
11	O
mucosa	O
samples	O
(	O
9	O
%	O
)	O
were	O
found	O
to	O
harbor	O
a	O
K-ras	O
mutation	O
.	O
When	O
using	O
the	O
same	O
scalpel	O
for	O
collecting	O
tumor	O
and	O
mucosa	O
tissues	O
(	O
group	O
A	O
)	O
,	O
18	O
%	O
of	O
the	O
patients	O
had	O
a	O
matching	O
K-ras	O
mutation	O
in	O
both	O
tissues	O
,	O
but	O
this	O
coincidence	O
was	O
seen	O
in	O
3	O
%	O
of	O
patients	O
only	O
,	O
when	O
separate	O
scalpels	O
were	O
used	O
(	O
group	O
B	O
)	O
.	O
Thus	O
we	O
conclude	O
that	O
the	O
sampling	O
technique	O
used	O
for	O
collecting	O
specimens	O
is	O
a	O
major	O
contributor	O
to	O
the	O
detection	O
of	O
K-ras	O
mutations	O
in	O
normal	O
appearing	O
mucosa	O
when	O
a	O
highly	O
sensitive	O
detection	O
technique	O
is	O
used	O
.	O
PMID	O
:	O
10402253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Apr	O
1;59(	O
7)	O
:1442	O
-	O
4	O
Beta-catenin	O
mutations	O
are	O
more	O
frequent	O
in	O
small	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
than	O
in	O
larger	B-malignancy-type
adenomas	I-malignancy-type
and	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Samowitz	O
WS	O
,	O
Powers	O
MD	O
,	O
Spirio	O
LN	O
,	O
Nollet	O
F	O
,	O
van	O
Roy	O
F	O
,	O
Slattery	O
ML.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Utah	O
Health	O
Sciences	O
Center	O
,	O
Salt	O
Lake	O
City	O
84132	O
,	O
USA	O
.	O
Loss	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
from	O
exon	O
3	O
of	O
beta-catenin	O
has	O
been	O
identified	O
in	O
approximately	O
half	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
which	O
lack	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
,	O
but	O
the	O
overall	O
contribution	O
of	O
beta-catenin	O
mutations	O
to	O
sporadic	O
colorectal	O
tumorigenesis	O
is	O
unclear	O
.	O
We	O
therefore	O
used	O
PCR	O
to	O
amplify	O
and	O
sequence	O
exon	O
3	O
of	O
beta-catenin	O
from	O
202	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Exon	O
3	O
beta-catenin	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
48	O
small	B-malignancy-type
(	O
<	O
1	O
cm	O
)	O
adenomas	B-malignancy-type
,	O
2	O
of	O
82	O
large	B-malignancy-type
(	O
>	O
or	O
=	O
1	O
cm	O
)	O
adenomas	B-malignancy-type
,	O
and	O
1	O
of	O
72	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Eight	O
of	O
the	O
nine	O
mutations	O
,	O
including	O
all	O
of	O
those	O
in	O
the	O
small	B-malignancy-type
adenomas	I-malignancy-type
and	O
the	O
invasive	O
cancer	O
,	O
involved	O
loss	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
.	O
The	O
percentage	O
of	O
beta-catenin	O
mutations	O
in	O
small	B-malignancy-type
adenomas	I-malignancy-type
(	O
12.5	O
%	O
)	O
was	O
significantly	O
greater	O
than	O
that	O
in	O
large	B-malignancy-type
adenomas	I-malignancy-type
(	O
2.4	O
%	O
)	O
and	O
invasive	O
cancers	O
(	O
1.4	O
%	O
;	O
P	O
=	O
0.05	O
and	O
P	O
=	O
0.02	O
,	O
respectively	O
)	O
.	O
We	O
conclude	O
that	O
mutation	O
of	O
beta-catenin	O
can	O
be	O
an	O
early	O
,	O
perhaps	O
initiating	O
,	O
event	O
in	O
colorectal	O
tumorigenesis	O
.	O
Small	B-malignancy-type
adenomas	I-malignancy-type
with	O
beta-catenin	O
mutations	O
do	O
not	O
appear	O
to	O
be	O
as	O
likely	O
to	O
progress	O
to	O
larger	B-malignancy-type
adenomas	I-malignancy-type
and	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
as	O
other	O
adenomas	B-malignancy-type
,	O
however	O
,	O
with	O
the	O
result	O
that	O
beta-catenin	O
mutations	O
are	O
only	O
rarely	O
seen	O
in	O
invasive	O
cancers	O
.	O
This	O
suggests	O
that	O
APC	O
and	O
beta-catenin	O
mutations	O
are	O
not	O
functionally	O
equivalent	O
,	O
and	O
that	O
the	O
APC	O
gene	O
may	O
have	O
other	O
tumor	O
suppressor	O
functions	O
besides	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
PMID	O
:	O
10197610	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1999	O
Apr;21(	O
4)	O
:410	O
-	O
3	O
A	O
common	O
human	O
skin	B-malignancy-type
tumour	I-malignancy-type
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta-catenin	O
.	O
Chan	O
EF	O
,	O
Gat	O
U	O
,	O
McNiff	O
JM	O
,	O
Fuchs	O
E.	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
Department	O
of	O
Molecular	O
Genetics	O
and	O
Cell	O
Biology	O
,	O
The	O
University	O
of	O
Chicago	O
,	O
Illinois	O
60637	O
,	O
USA	O
.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O
In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta-catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta-catenin	O
/	O
TCF	O
encodes	O
c-MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B-malignancy-type
,	O
particularly	O
in	B-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
Most	O
colon	B-malignancy-type
cancers	I-malignancy-type
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta-catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	B-malignancy-type
and	O
some	O
other	O
cancers	B-malignancy-type
harbour	O
beta-catenin	O
-	O
stabilizing	O
mutations	O
.	O
Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-malignancy-type
tumours	I-malignancy-type
resembling	O
pilomatricomas	B-malignancy-type
.	O
Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B-malignancy-type
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta-catenin	O
-	O
stabilizing	O
mutations	O
.	O
Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-malignancy-type
tumour	I-malignancy-type
.	O
We	O
found	O
nuclear	O
LEF-1	O
in	O
the	O
dividing	O
tumour	O
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	B-malignancy-type
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O
At	O
least	O
75	O
%	O
of	O
these	O
tumours	O
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	O
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta-catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
PMID	O
:	O
10192393	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
1998	O
Jun;33(	O
3	O
)	O
:390	O
-	O
6	O
Detection	O
of	O
Ki-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
tissue	O
and	O
pancreatic	O
juice	O
from	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Kondoh	O
S,	O
Kaino	O
M,	O
Okita	O
S,	O
Ryozawa	O
S,	O
Akiyama	O
T	O
,	O
Okita	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yamaguchi	O
University	O
School	O
of	O
Medicine	O
,	O
Ube	O
,	O
Japan	O
.	O
Pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
have	O
a	O
high	O
incidence	O
of	O
Ki-ras	O
mutations	O
,	O
and	O
the	O
genetic	O
change	O
is	O
thought	O
to	O
occur	O
at	O
an	O
early	O
stage	O
in	O
the	O
carcinogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
usefulness	O
of	O
detecting	O
genetic	O
mutations	O
in	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
tissue	O
specimens	O
of	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
and	O
from	O
cells	O
in	O
PPJ	O
,	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
Two	O
types	O
of	O
mobility	O
shifts	O
that	O
indicate	O
Ki-ras	O
mutations	O
were	O
observed	O
in	O
13	O
of	O
the	O
20	O
(	O
65	O
%	O
)	O
tissue	O
specimens	O
obtained	O
by	O
operation	O
or	O
autopsy	O
.	O
Ten	O
of	O
15	O
specimens	O
(	O
67	O
%	O
)	O
of	O
PPJ	O
collected	O
from	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
two	O
types	O
of	O
mobility	O
shifts	O
.	O
Conventional	O
imaging	O
techniques	O
did	O
not	O
show	O
two	O
in	O
10	O
of	O
these	O
patients	O
.	O
PPJ	O
from	O
patients	O
with	O
non	O
-	O
cancerous	O
pancreatic	O
diseases	O
showed	O
no	O
Ki-ras	O
mutations	O
.	O
The	O
p53	O
tumor	O
suppressor	O
gene	O
,	O
examined	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
,	O
was	O
mutated	O
in	O
8	O
of	O
the	O
20	O
tissue	O
specimens	O
obtained	O
by	O
operation	O
or	O
autopsy	O
(	O
40	O
%	O
)	O
.	O
The	O
detection	O
of	O
Ki-ras	O
and	O
p53	O
mutations	O
in	O
PPJ	O
could	O
be	O
useful	O
for	O
the	O
early	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
,	O
especially	O
for	O
neoplastic	B-malignancy-type
lesions	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
intraductal	I-malignancy-type
type	I-malignancy-type
.	O
PMID	O
:	O
9658319	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1998	O
Jul	O
1;83(	O
1	O
)	O
:122	O
-	O
9	O
A	O
c-rasHa	O
mutation	O
in	O
the	O
metastasis	O
of	O
a	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-	O
18	O
positive	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
suggests	O
a	O
cooperative	O
effect	O
between	O
HPV-18	O
and	O
c-rasHa	O
activation	O
in	O
malignant	O
progression	O
.	O
Leis	O
PF	O
,	O
Stevens	O
KR	O
,	O
Baer	O
SC	O
,	O
Kadmon	O
D	O
,	O
Goldberg	O
LH	O
,	O
Wang	O
XJ	O
.	O
Department	O
of	O
Dermatology	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Human	O
papillomaviruses	O
(	O
HPV	O
)	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
anogenital	B-malignancy-type
squamous	I-malignancy-type
epithelial	I-malignancy-type
tumors	I-malignancy-type
.	O
Of	O
the	O
65	O
HPV	O
strains	O
,	O
subtypes	O
HPV-16	O
and	O
HPV-18	O
frequently	O
are	O
associated	O
with	O
malignant	O
conditions	O
and	O
are	O
capable	O
of	O
transforming	O
keratinocytes	O
in	O
vitro	O
.	O
However	O
,	O
additional	O
cellular	O
changes	O
are	O
necessary	O
to	O
confer	O
tumorigenicity	O
to	O
HPV	O
-	O
infected	O
cells	O
.	O
Secondary	O
events	O
implicated	O
in	O
the	O
progression	O
to	O
malignancy	O
include	O
loss	O
of	O
tumor	O
suppressor	O
genes	O
such	O
as	O
p53	O
and/or	O
activation	O
of	O
cellular	O
oncogenes	O
such	O
as	O
c-rasHa	O
.	O
METHODS	O
:	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
identify	O
HPV-16	O
or	O
HPV-18	O
genetic	O
sequence	O
in	O
primary	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
and	O
two	O
inguinal	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
.	O
p53	O
and	O
c-rasHa	O
loci	O
were	O
analyzed	O
by	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O
RESULTS	O
:	O
HPV-18	O
but	O
not	O
HPV-16	O
infection	O
was	O
found	O
in	O
the	O
primary	O
carcinoma	B-malignancy-type
and	O
in	O
inguinal	O
metastases	O
occurring	O
5	O
and	O
7	O
years	O
after	O
the	O
initial	O
lesion	O
.	O
Sequence	O
analysis	O
did	O
not	O
identify	O
any	O
p53	O
mutations	O
in	O
the	O
primary	O
carcinoma	B-malignancy-type
or	O
its	O
metastases	O
.	O
However	O
,	O
although	O
the	O
primary	O
lesion	O
and	O
the	O
5	O
-	O
year	O
metastasis	O
encoded	O
wild	O
-	O
type	O
c-rasHa	O
,	O
the	O
7	O
-	O
year	O
metastasis	O
had	O
a	O
missense	O
mutation	O
within	O
c-rasHa	O
codon	O
61	O
.	O
CONCLUSIONS	O
:	O
To	O
the	O
authors	O
'	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
activating	O
c-rasHa	O
mutation	O
associated	O
with	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
penis	I-malignancy-type
.	O
The	O
presence	O
of	O
activated	O
c-rasHa	O
in	O
the	O
second	O
metastasis	O
but	O
not	O
in	O
the	O
first	O
metastasis	O
or	O
the	O
primary	O
lesion	O
suggests	O
that	O
activation	O
of	O
c-rasHa	O
may	O
be	O
a	O
late	O
event	O
in	O
the	O
malignant	O
progression	O
of	O
HPV-18	O
-	O
associated	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Analysis	O
of	O
additional	O
samples	O
from	O
primary	O
lesions	O
and	O
their	O
resultant	O
metastases	O
is	O
necessary	O
to	O
elucidate	O
the	O
incidence	O
and	O
significance	O
of	O
c-rasHa	O
activation	O
in	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9655301	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Apr	O
24;126(	O
2	O
)	O
:179	O
-	O
85	O
Role	O
of	O
K-ras	O
mutations	O
in	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Chiang	O
JM	O
.	O
Division	O
of	O
Colon	O
and	O
Rectal	O
Surgery	O
,	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
In	O
order	O
to	O
investigate	O
whether	O
two	O
common	O
types	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
with	O
different	O
gross	O
appearances	O
share	O
the	O
same	O
incidence	O
of	O
K-ras	O
mutation	O
,	O
the	O
occurrence	O
of	O
a	O
point	O
mutation	O
in	O
codon	O
12	O
or	O
codon	O
13	O
of	O
the	O
K-ras	O
oncogene	O
was	O
determined	O
in	O
50	O
cases	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
PCR	O
technique	O
was	O
employed	O
,	O
followed	O
by	O
RFLP	O
analysis	O
and	O
sequencing	O
to	O
identify	O
specific	O
point	O
mutations	O
.	O
No	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
a	O
K-ras	O
gene	O
mutation	O
and	O
histological	O
parameters	O
.	O
A	O
strong	O
association	O
was	O
found	O
between	O
K-ras	O
mutations	O
and	O
the	O
gross	O
polypoid	O
appearance	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
(	O
polypoid	O
73	O
%	O
versus	O
ulcerative	O
8	O
%	O
)	O
.	O
The	O
results	O
indicate	O
a	O
preferential	O
association	O
with	O
the	O
K-ras	O
oncogene	O
involved	O
in	O
polypoid	B-malignancy-type
type	I-malignancy-type
colorectal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9585064	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
1;58(	O
5	O
)	O
:1021	O
-	O
6	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
in	O
primary	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
without	O
adenomatous	O
polyposis	O
coli	O
mutations	O
.	O
Iwao	O
K	O
,	O
Nakamori	O
S,	O
Kameyama	O
M,	O
Imaoka	O
S,	O
Kinoshita	O
M,	O
Fukui	O
T	O
,	O
Ishiguro	O
S,	O
Nakamura	O
Y	O
,	O
Miyoshi	O
Y.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
City	O
,	O
Japan	O
.	O
Among	O
222	O
primary	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
we	O
examined	O
,	O
58	O
showed	O
no	O
detectable	O
APC	O
mutations	O
by	O
the	O
protein	O
truncation	O
test	O
.	O
We	O
screened	O
those	O
58	O
tumors	O
for	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Although	O
amino	O
acid	O
substitutions	O
in	O
serine	O
or	O
threonine	O
residues	O
in	O
exon	O
3	O
had	O
been	O
reported	O
,	O
we	O
found	O
no	O
such	O
mutations	O
;	O
however	O
,	O
in	O
seven	O
tumors	O
,	O
we	O
detected	O
somatic	O
interstitial	O
deletions	O
of	O
234	O
-	O
760	O
bp	O
,	O
each	O
of	O
which	O
included	O
all	O
or	O
part	O
of	O
exon	O
3	O
.	O
Short	O
nucleotide	O
sequences	O
at	O
both	O
ends	O
of	O
each	O
deletion	O
were	O
either	O
identical	O
or	O
complementary	O
,	O
indicating	O
that	O
repeated	O
or	O
inversely	O
repeated	O
sequences	O
were	O
involved	O
in	O
the	O
somatic	O
rearrangements	O
.	O
Reverse	O
transcription	O
-	O
PCR	O
experiments	O
using	O
RNAs	O
isolated	O
from	O
three	O
of	O
these	O
seven	O
tumors	O
detected	O
transcripts	O
that	O
lacked	O
exon	O
3	O
,	O
in	O
addition	O
to	O
the	O
normal	O
transcript	O
.	O
In	O
one	O
of	O
these	O
cases	O
,	O
we	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
cancer	O
cells	O
by	O
Western	O
and	O
immunohistochemical	O
analyses	O
.	O
This	O
result	O
suggested	O
that	O
,	O
in	O
the	O
absence	O
of	O
a	O
peptide	O
encoded	O
by	O
exon	O
3	O
,	O
beta-catenin	O
is	O
stabilized	O
and	O
has	O
a	O
dominant	O
oncogenic	O
effect	O
on	O
colorectal	O
tumorigenesis	O
.	O
PMID	O
:	O
9500465	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1997	O
Sep;11(	O
9	O
)	O
:1442	O
-	O
6	O
Tandem	O
duplications	O
of	O
the	O
FLT3	O
receptor	O
gene	O
are	O
associated	O
with	O
leukemic	O
transformation	O
of	O
myelodysplasia	B-malignancy-type
.	O
Horiike	O
S,	O
Yokota	O
S,	O
Nakao	O
M,	O
Iwai	O
T	O
,	O
Sasai	O
Y	O
,	O
Kaneko	O
H	O
,	O
Taniwaki	O
M,	O
Kashima	O
K	O
,	O
Fujii	O
H	O
,	O
Abe	O
T	O
,	O
Misawa	O
S.	O
Department	O
of	O
Internal	O
Medicine	O
III	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
recently	O
reported	O
an	O
internal	O
tandem	O
duplication	O
of	O
the	O
human	O
flt3	O
receptor	O
gene	O
(	O
FLT3	O
)	O
as	O
a	O
somatic	O
mutation	O
in	O
17	O
%	O
of	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
The	O
present	O
study	O
revealed	O
the	O
duplication	O
at	O
the	O
juxtamembrane	O
and	O
the	O
first	O
tyrosine	O
kinase	O
domains	O
of	O
FLT3	O
in	O
seven	O
of	O
92	O
(	O
8	O
%	O
)	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
AML	B-malignancy-type
with	O
trilineage	B-malignancy-type
myelodysplasia	I-malignancy-type
(	O
AML	B-malignancy-type
/	O
TMDS	B-malignancy-type
)	O
,	O
the	O
diseases	O
which	O
may	O
represent	O
neoplastic	O
changes	O
of	O
pluripotent	O
stem	O
cells	O
.	O
A	O
tandem	O
duplication	O
of	O
exon	O
11	O
of	O
FLT3	O
was	O
harbored	O
by	O
two	O
of	O
58	O
(	O
3	O
%	O
)	O
patients	O
with	O
MDS	B-malignancy-type
and	O
five	O
of	O
34	O
(	O
15	O
%	O
)	O
with	O
overt	B-malignancy-type
leukemia	I-malignancy-type
,	O
including	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
,	O
AML	B-malignancy-type
/	O
TMDS	B-malignancy-type
and	O
therapy	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
leukemia	I-malignancy-type
.	O
Although	O
the	O
duplicated	O
regions	O
varied	O
within	O
exon	O
11	O
in	O
each	O
case	O
,	O
they	O
occurred	O
in	O
-	O
frame	O
,	O
and	O
altered	O
mRNA	O
expressions	O
were	O
demonstrated	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
Two	O
cases	O
of	O
MDS	B-malignancy-type
with	O
a	O
FLT3	O
duplication	O
transformed	O
to	O
overt	B-malignancy-type
leukemia	I-malignancy-type
within	O
a	O
few	O
months	O
.	O
Longitudinal	O
analyses	O
in	O
two	O
other	O
patients	O
with	O
leukemia	B-malignancy-type
revealed	O
that	O
the	O
duplication	O
was	O
a	O
late	O
genetic	O
event	O
during	O
the	O
disease	O
course	O
;	O
one	O
of	O
whom	O
showed	O
two	O
independent	O
duplications	O
of	O
FLT3	O
at	O
the	O
terminal	O
therapy	O
-	O
resistant	O
phase	O
.	O
Of	O
seven	O
patients	O
with	O
the	O
FLT3	O
duplication	O
,	O
six	O
had	O
abnormal	O
karyotypes	O
,	O
and	O
four	O
harbored	O
a	O
point	O
mutation	O
of	O
the	O
N-RAS	O
and/or	O
TP53	O
genes	O
.	O
Patients	O
with	O
FLT3	O
mutations	O
have	O
poor	O
prognoses	O
.	O
This	O
study	O
uncovered	O
the	O
fact	O
that	O
the	O
accumulation	O
of	O
genetic	O
events	O
,	O
including	O
FLT3	O
duplication	O
,	O
correlates	O
with	O
leukemic	O
transformation	O
from	O
antecedent	O
myelodysplasia	B-malignancy-type
and	O
with	O
subsequent	O
disease	O
progression	O
.	O
PMID	O
:	O
9305595	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
Arch	O
Allergy	O
Immunol	O
1997	O
May	O
-	O
Jul;113(	O
1	O
-	O
3	O
)	O
:184	O
-	O
6	O
c-kit	O
mutation	O
in	O
a	O
population	O
of	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Nagata	O
H	O
,	O
Okada	O
T	O
,	O
Worobec	O
AS	O
,	O
Semere	O
T	O
,	O
Metcalfe	O
DD.	O
Department	O
of	O
Otolaryngology	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
c-kit	O
Asp	O
816	O
Val	O
activating	O
mutation	O
is	O
found	O
in	O
all	O
patients	O
with	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
,	O
and	O
at	O
least	O
in	O
a	O
subset	O
of	O
patients	O
with	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
The	O
case	O
of	O
an	O
11	O
-	O
month	O
-	O
old	O
child	O
is	O
presented	O
who	O
was	O
categorized	O
as	O
having	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
and	O
where	O
the	O
Asp	O
816	O
Val	O
mutation	O
was	O
identified	O
in	O
lesional	O
skin	O
,	O
but	O
not	O
in	O
bone	O
marrow	O
or	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
populations	O
.	O
The	O
significance	O
of	O
these	O
findings	O
is	O
discussed	O
.	O
PMID	O
:	O
9130517	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
1997	O
Feb;40(	O
2	O
)	O
:161	O
-	O
7	O
Ki-ras	O
point	O
mutation	O
in	O
different	O
types	O
of	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
in	O
early	O
stages	O
.	O
Kojima	O
M,	O
Konishi	O
F	O
,	O
Tsukamoto	O
T	O
,	O
Yamashita	O
K	O
,	O
Kanazawa	O
K.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Tochigi	O
,	O
Japan	O
.	O
PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
pathways	O
of	O
carcinogenesis	O
in	O
the	O
colon	O
and	O
rectum	O
by	O
investigating	O
Ki-ras	O
point	O
mutation	O
in	O
different	O
types	O
of	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
in	O
the	O
early	O
stage	O
.	O
METHODS	O
:	O
We	O
analyzed	O
rates	O
of	O
Ki-ras	O
codon	O
12	O
mutations	O
in	O
34	O
small	B-malignancy-type
,	I-malignancy-type
polypoid	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
carcinomas	I-malignancy-type
(	O
Tis	B-malignancy-type
or	O
T1	B-malignancy-type
)	O
,	O
21	O
superficial	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
carcinomas	I-malignancy-type
(	O
Tis	B-malignancy-type
or	O
T1	B-malignancy-type
)	O
,	O
and	O
42	O
advanced	B-malignancy-type
carcinomas	I-malignancy-type
(	O
T2	B-malignancy-type
,	O
T3	B-malignancy-type
,	O
and	O
T4	O
)	O
.	O
RESULTS	O
:	O
Frequency	O
of	O
Ki-ras	O
mutations	O
in	O
superficial	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
carcinomas	I-malignancy-type
was	O
14.3	O
percent	O
(	O
3	O
/	O
21	O
)	O
,	O
which	O
was	O
significantly	O
lower	O
than	O
50	O
percent	O
(	O
17	O
/	O
34	O
)	O
in	O
small	B-malignancy-type
polypoid	I-malignancy-type
carcinomas	I-malignancy-type
and	O
40.5	O
percent	O
(	O
17	O
/	O
42	O
)	O
in	O
advanced	O
carcinomas	B-malignancy-type
.	O
These	O
data	O
suggest	O
that	O
another	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
that	O
does	O
not	O
involve	O
Ki-ras	O
point	O
mutation	O
might	O
exist	O
.	O
Among	O
the	O
17	O
small	B-malignancy-type
polypoid	I-malignancy-type
carcinomas	I-malignancy-type
with	O
Ki-ras	O
point	O
mutation	O
in	O
which	O
both	O
adenomatous	B-malignancy-type
and	O
carcinomatous	B-malignancy-type
tissue	I-malignancy-type
were	O
examined	O
,	O
12	O
showed	O
a	O
mutation	O
of	O
the	O
same	O
type	O
in	O
both	O
carcinomatous	B-malignancy-type
and	O
adenomatous	B-malignancy-type
tissues	I-malignancy-type
.	O
In	O
two	O
cases	O
,	O
mutation	O
was	O
present	O
only	O
in	O
carcinomatous	B-malignancy-type
tissue	I-malignancy-type
and	O
not	O
in	O
adenomatous	B-malignancy-type
tissue	I-malignancy-type
;	O
in	O
the	O
other	O
three	O
cases	O
,	O
Ki-ras	O
point	O
mutation	O
was	O
present	O
only	O
in	O
adenomatous	B-malignancy-type
tissue	I-malignancy-type
but	O
not	O
in	O
carcinomatous	B-malignancy-type
tissue	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
carcinoma	B-malignancy-type
in	O
a	O
small	O
polypoid	O
lesion	O
does	O
not	O
always	O
develop	O
from	O
pre	O
-	O
existing	O
adenoma	B-malignancy-type
with	O
Ki-ras	O
point	O
mutation	O
;	O
in	O
a	O
small	O
number	O
of	O
the	O
polypoid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
early	I-malignancy-type
carcinomas	I-malignancy-type
,	O
polyclonal	O
composition	O
concerning	O
the	O
Ki-ras	O
gene	O
may	O
exist	O
.	O
PMID	O
:	O
9075750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Yonsei	O
Med	O
J	O
1996	O
Dec;37(	O
6)	O
:371	O
-	O
9	O
A	O
PCR	O
-	O
RFLP	O
method	O
for	O
the	O
detection	O
of	O
activated	O
H-ras	O
oncogene	O
with	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
and	O
61	O
.	O
Hong	O
SJ	O
,	O
Lee	O
T	O
,	O
Park	O
YS	O
,	O
Lee	O
KO	O
,	O
Chung	O
BH	O
,	O
Lee	O
SH.	O
Department	O
of	O
Urology	O
,	O
Yonsei	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
To	O
investigate	O
the	O
incidence	O
of	O
the	O
H-ras	O
gene	O
activation	O
in	O
bladder	B-malignancy-type
tumor	I-malignancy-type
and	O
the	O
feasibility	O
of	O
using	O
urinary	O
washout	O
samples	O
for	O
screening	O
,	O
a	O
series	O
of	O
33	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
and	O
their	O
preoperatively	O
collected	O
urinary	O
washout	O
samples	O
were	O
screened	O
using	O
a	O
mutant	O
specific	O
PCR	O
-	O
RFLP	O
(	O
polymerase	O
chain	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
)	O
to	O
detect	O
a	O
point	O
mutation	O
of	O
the	O
H-ras	O
gene	O
.	O
Five	O
tumors	B-malignancy-type
were	O
found	O
to	O
harbor	O
H-ras	O
mutations	O
where	O
two	O
tumors	B-malignancy-type
had	O
a	O
glycine	O
to	O
valine	O
(	O
G	O
-->	O
T	O
)	O
change	O
in	O
codon	O
12	O
and	O
three	O
tumors	B-malignancy-type
had	O
a	O
glutamine	O
to	O
lysine	O
(	O
C	O
-->	O
A	O
)	O
change	O
in	O
codon	O
61	O
,	O
respectively	O
.	O
Moreover	O
,	O
we	O
could	O
also	O
detect	O
the	O
same	O
point	O
mutations	O
of	O
the	O
H-ras	O
gene	O
in	O
corresponding	O
urine	O
washout	O
samples	O
.	O
The	O
incidence	O
of	O
H-ras	O
mutation	O
in	O
Korean	O
bladder	B-malignancy-type
cancer	I-malignancy-type
was	O
estimated	O
at	O
approximately	O
15.2	O
%	O
.	O
In	O
conclusion	O
,	O
a	O
mutant	O
specific	O
PCR	O
-	O
RFLP	O
method	O
for	O
the	O
detection	O
of	O
H-ras	O
gene	O
mutation	O
is	O
useful	O
for	O
screening	O
or	O
postoperative	O
follow	O
-	O
up	O
of	O
bladder	B-malignancy-type
tumor	I-malignancy-type
due	O
to	O
its	O
simplicity	O
and	O
high	O
specificity	O
even	O
in	O
urinary	O
samples	O
.	O
PMID	O
:	O
9048488	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
1997	O
Jan;76(	O
1	O
)	O
:153	O
-	O
9	O
Sporadic	O
and	O
Thorotrast	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
angiosarcomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
manifest	O
frequent	O
and	O
multiple	O
point	O
mutations	O
in	O
K-ras-2	O
.	O
Przygodzki	O
RM	O
,	O
Finkelstein	O
SD	O
,	O
Keohavong	O
P	O
,	O
Zhu	O
D	O
,	O
Bakker	O
A	O
,	O
Swalsky	O
PA	O
,	O
Soini	O
Y	O
,	O
Ishak	O
KG	O
,	O
Bennett	O
WP	O
.	O
Laboratory	O
of	O
Human	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
,	O
USA	O
.	O
Hepatic	B-malignancy-type
angiosarcoma	I-malignancy-type
(	O
HA	B-malignancy-type
)	O
is	O
an	O
uncommon	O
neoplasm	O
associated	O
with	O
known	O
etiologic	O
factors	O
in	O
25	O
%	O
to	O
42	O
%	O
of	O
cases	O
.	O
It	O
is	O
,	O
however	O
,	O
one	O
of	O
the	O
most	O
common	O
sarcomas	B-malignancy-type
found	O
in	O
the	O
liver	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
was	O
to	O
find	O
mutations	O
in	O
the	O
K-ras-2	O
oncogene	O
in	O
sporadic	B-malignancy-type
and	O
Thorotrast	B-malignancy-type
(	I-malignancy-type
TT	I-malignancy-type
)	I-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
.	O
Point	O
mutations	O
in	O
K-ras-2	O
were	O
sought	O
in	O
archival	O
,	O
formalin	O
-	O
fixed	O
tissue	O
blocks	O
from	O
24	O
patients	O
with	O
angiosarcoma	B-malignancy-type
.	O
Of	O
these	O
,	O
19	O
cases	O
were	O
sporadic	B-malignancy-type
and	O
5	O
were	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
.	O
Mutational	O
analysis	O
was	O
performed	O
by	O
topographic	O
microdissection	O
with	O
PCR	O
amplification	O
followed	O
by	O
genotyping	O
.	O
Specific	O
mutations	O
were	O
determined	O
by	O
two	O
independent	O
methods	O
:	O
(a)	O
direct	O
sequencing	O
of	O
the	O
PCR	O
product	O
confirmed	O
by	O
rePCR	O
and	O
by	O
using	O
a	O
different	O
sequencing	O
primer	O
,	O
and	O
(b)	O
PCR	O
-	O
based	O
selective	O
enrichment	O
of	O
mutant	O
DNA	O
by	O
endonuclease	O
digestion	O
followed	O
by	O
heteroduplex	O
DNA	O
analysis	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Eleven	O
K-ras-2	O
point	O
mutations	O
were	O
detected	O
in	O
7	O
of	O
24	O
(	O
29	O
%	O
)	O
tumors	O
,	O
including	O
5	O
of	O
19	O
(	O
26	O
%	O
)	O
sporadic	B-malignancy-type
HA	I-malignancy-type
and	O
2	O
of	O
5	O
(	O
40	O
%	O
)	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
.	O
There	O
were	O
seven	O
G:C	O
>	O
A:T	O
and	O
four	O
G:C	O
>	O
T:A	O
mutations	O
.	O
All	O
seven	O
mutated	O
tumors	O
contained	O
a	O
codon	O
12	O
-	O
aspartate	O
amino	O
acid	O
substitution	O
.	O
In	O
addition	O
,	O
a	O
second	O
codon	O
12	O
-	O
cysteine	O
mutant	O
cell	O
population	O
was	O
present	O
in	O
one	O
of	O
two	O
codon	O
12	O
-	O
aspartate	O
mutated	O
TT	O
-	O
induced	O
HA	O
and	O
in	O
three	O
of	O
five	O
codon	O
12	O
-	O
aspartate	O
sporadic	O
tumors	O
.	O
Of	O
these	O
four	O
tumors	O
,	O
three	O
contained	O
both	O
aspartate	O
and	O
cysteine	O
mutations	O
and	O
were	O
composed	O
of	O
multiple	O
nodules	O
;	O
the	O
fourth	O
was	O
a	O
single	O
mass	O
.	O
Seventeen	O
tumors	O
had	O
multiple	O
nodules	O
;	O
whereas	O
5	O
had	O
a	O
K-ras-2	O
mutation	O
,	O
12	O
were	O
wild	O
-	O
type	O
.	O
The	O
molecular	O
pathology	O
of	O
both	O
sporadic	B-malignancy-type
and	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
is	O
characterized	O
by	O
a	O
high	O
rate	O
of	O
K-ras-2	O
mutations	O
characteristic	O
of	O
oxidative	O
damage	O
(	O
ie	O
,	O
G:C	O
>	O
A:T	O
and	O
G:C	O
>	O
T:A	O
mutations	O
)	O
resulting	O
in	O
two	O
mutated	O
population	O
sets	O
:	O
codon	O
12	O
GGT	O
>	O
GAT	O
and	O
GGT	O
>	O
TGT	O
(	O
glycine	O
to	O
aspartic	O
acid	O
and	O
cysteine	O
)	O
.	O
This	O
is	O
,	O
to	O
date	O
,	O
the	O
first	O
study	O
to	O
characterize	O
the	O
K-ras-2	O
gene	O
mutations	O
within	O
human	O
sporadic	B-malignancy-type
and	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
by	O
direct	O
sequence	O
analysis	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
These	O
data	O
further	O
support	O
the	O
hypothesis	O
linking	O
adduct	O
-	O
forming	O
vinyl	O
chloride	O
exposure	O
to	O
HA	B-malignancy-type
containing	O
a	O
much	O
higher	O
frequency	O
of	O
K-ras-2	O
mutations	O
and	O
a	O
mutational	O
spectrum	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
a	O
carcinogenic	O
metabolite	O
of	O
vinyl	O
chloride	O
.	O
PMID	O
:	O
9010458	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1996	O
Nov-	O
Dec;20(	O
11	O
-	O
12	O
)	O
:901	O
-	O
3	O
RAS	O
gene	O
mutations	O
in	O
Chinese	O
leukaemia	B-malignancy-type
patients	O
and	O
members	O
of	O
a	O
family	O
with	O
high	O
incidence	O
of	O
leukaemia	B-malignancy-type
.	O
He	O
LZ	O
,	O
Stephenson	O
J,	O
He	O
GY	O
,	O
Mufti	O
GJ.	O
Department	O
of	O
Haematological	O
Medicine	O
,	O
King	O
's	O
College	O
School	O
of	O
Medicine	O
and	O
Dentistry	O
,	O
London	O
,	O
UK.	O
We	O
investigated	O
mutations	O
of	O
N-RAS	O
and	O
K-RAS	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
oligonucleotide	O
hybridization	O
techniques	O
in	O
40	O
cases	O
of	O
Chinese	O
leukaemia	B-malignancy-type
patients	O
and	O
17	O
presently	O
healthy	O
members	O
of	O
a	O
family	O
with	O
high	O
incidence	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
.	O
The	O
results	O
showed	O
only	O
two	O
patients	O
carried	O
the	O
mutation	O
in	O
codon	O
12	O
of	O
N-RAS	O
.	O
Strikingly	O
,	O
however	O
,	O
in	O
both	O
cases	O
the	O
malignancies	O
involved	O
lymphoid	O
lineage	O
.	O
There	O
was	O
no	O
hereditary	O
RAS	O
mutation	O
in	O
the	O
members	O
of	O
the	O
remarkable	O
family	O
.	O
PMID	O
:	O
9009246	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1996	O
Mar;12(	O
3	O
)	O
:312	O
-	O
4	O
Somatic	O
c-KIT	O
activating	O
mutation	O
in	O
urticaria	O
pigmentosa	O
and	O
aggressive	B-malignancy-type
mastocytosis	I-malignancy-type
:	O
establishment	O
of	O
clonality	O
in	O
a	O
human	O
mast	B-malignancy-type
cell	I-malignancy-type
neoplasm	I-malignancy-type
.	O
Longley	O
BJ	O
,	O
Tyrrell	O
L,	O
Lu	O
SZ	O
,	O
Ma	O
YS	O
,	O
Langley	O
K	O
,	O
Ding	O
TG	O
,	O
Duffy	O
T	O
,	O
Jacobs	O
P	O
,	O
Tang	O
LH	O
,	O
Modlin	O
I.	O
Department	O
of	O
Dermatology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
Connecticut	O
06510	O
,	O
USA	O
.	O
Mastocytosis	B-malignancy-type
is	O
characterized	O
by	O
accumulations	O
of	O
mast	O
cells	O
in	O
various	O
organs	O
(	O
1	O
)	O
.	O
Most	O
cases	O
are	O
indolent	O
and	O
confined	O
to	O
the	O
skin	O
,	O
where	O
discrete	O
mast	O
cell	O
infiltrates	O
are	O
associated	O
increased	O
epidermal	O
melanin	O
,	O
a	O
clinical	O
picture	O
known	O
as	O
urticaria	O
pigmentosa	O
(	O
UP	O
)	O
.	O
Other	O
forms	O
of	O
mastocytosis	B-malignancy-type
combine	O
UP	O
with	O
aggressive	O
involvement	O
of	O
other	O
organs	O
or	O
with	O
haemotologic	O
abnormalities	O
(	O
1	O
-	O
4	O
)	O
.	O
It	O
is	O
not	O
known	O
whether	O
all	O
forms	O
of	O
mastocytosis	B-malignancy-type
are	O
true	O
neoplasms	B-malignancy-type
or	O
whether	O
some	O
might	O
represent	O
reactive	B-malignancy-type
hyperplasias	I-malignancy-type
(	O
5	O
-	O
7	O
)	O
.	O
The	O
c-KIT	O
proto	O
-	O
oncogene	O
encodes	O
a	O
type	O
III	O
receptor	O
tyrosine	O
kinase	O
(	O
KIT	O
)	O
that	O
is	O
critical	O
to	O
the	O
development	O
and	O
survival	O
of	O
mast	O
cells	O
and	O
melanocytes	O
(	O
8	O
-	O
11	O
)	O
.	O
The	O
ligand	O
for	O
KIT	O
(	O
KL	O
)	O
can	O
stimulate	O
mast	O
cell	O
development	O
,	O
proliferation	O
,	O
and	O
mediator	O
release	O
(	O
9	O
,	O
12	O
-	O
17	O
)	O
,	O
as	O
well	O
as	O
melanocyte	O
proliferation	O
and	O
pigment	O
production	O
(	O
18	O
-	O
20	O
)	O
.	O
To	O
determine	O
the	O
role	O
of	O
c-KIT	O
in	O
the	O
pathogenesis	O
of	O
mastocytosis	B-malignancy-type
,	O
we	O
examined	O
tissue	O
and	O
cells	O
isolated	O
from	O
a	O
patient	O
with	O
UP	O
and	O
aggressive	B-malignancy-type
systemic	I-malignancy-type
mastocytosis	I-malignancy-type
with	O
massive	O
splenic	O
involvement	O
.	O
We	O
found	O
a	O
mutation	O
that	O
results	O
in	O
constitutive	O
activation	O
and	O
expression	O
of	O
c-KIT	O
in	O
mast	O
cells	O
of	O
both	O
skin	O
and	O
spleen	O
.	O
This	O
is	O
the	O
first	O
in	O
situ	O
demonstration	O
of	O
an	O
activation	O
c-KIT	O
mutation	O
in	O
neoplastic	O
cells	O
.	O
It	O
also	O
demonstrates	O
the	O
clonal	O
and	O
neoplastic	O
nature	O
of	O
this	O
form	O
of	O
mastocytes	O
.	O
PMID	O
:	O
8589724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1993	O
Mar;6(	O
2	O
)	O
:129	O
-	O
32	O
H-ras-1	O
point	O
mutations	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
Wilke	O
W	O
,	O
Maillet	O
M,	O
Robinson	O
R.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
.	O
The	O
H-ras-1	O
protooncogene	O
is	O
activated	O
by	O
single	O
base	O
substitutions	O
occurring	O
in	O
either	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
These	O
mutations	O
have	O
been	O
described	O
with	O
varying	O
frequencies	O
in	O
several	O
human	O
tumor	O
types	O
.	O
Since	O
ras	O
oncogenes	O
were	O
first	O
discovered	O
as	O
the	O
transforming	O
sequences	O
of	O
Harvey	O
and	O
Kirsten	O
murine	O
sarcoma	O
viruses	O
(	O
which	O
also	O
contain	O
activating	O
point	O
mutations	O
compared	O
to	O
the	O
homologous	O
cellular	O
sequences	O
)	O
,	O
we	O
wished	O
to	O
investigate	O
the	O
possibility	O
that	O
ras	O
mutations	O
might	O
also	O
occur	O
in	O
human	O
sarcomas	B-malignancy-type
.	O
We	O
extracted	O
DNA	O
from	O
six	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFH	B-malignancy-type
)	O
,	O
three	O
embryonal	B-malignancy-type
rhabdomyosarcomas	I-malignancy-type
(	O
ER	B-malignancy-type
)	O
,	O
one	O
alveolar	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
,	O
one	O
pleomorphic	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
,	O
and	O
one	O
leiomyosarcoma	B-malignancy-type
.	O
The	O
DNA	O
from	O
regions	O
flanking	O
codons	O
12	O
/	O
13	O
and	O
codon	O
61	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
sequenced	O
with	O
an	O
automated	O
DNA	O
sequencer	O
.	O
As	O
controls	O
,	O
we	O
amplified	O
and	O
sequenced	O
normal	O
DNA	O
(	O
placenta	O
)	O
and	O
DNA	O
with	O
known	O
point	O
mutations	O
(	O
T24	B-malignancy-type
bladder	I-malignancy-type
carcinoma	I-malignancy-type
cells	I-malignancy-type
)	O
.	O
We	O
found	O
three	O
cases	O
with	O
mutations	O
,	O
all	O
occurring	O
in	O
codon	O
12	O
.	O
One	O
ER	B-malignancy-type
showed	O
a	O
G	O
-	O
to	O
-	O
T	O
mutation	O
in	O
the	O
second	O
position	O
of	O
codon	O
12	O
(	O
coding	O
for	O
valine	O
instead	O
of	O
glycine	O
)	O
.	O
Two	O
MFHs	B-malignancy-type
showed	O
G	O
-	O
to	O
-	O
A	O
mutations	O
in	O
the	O
second	O
position	O
of	O
codon	O
12	O
(	O
coding	O
for	O
aspartic	O
acid	O
instead	O
of	O
glycine	O
)	O
.	O
Although	O
a	O
limited	O
number	O
of	O
cases	O
were	O
sampled	O
,	O
we	O
conclude	O
that	O
study	O
of	O
H-ras-1	O
mutations	O
may	O
be	O
relevant	O
to	O
MFH	B-malignancy-type
and	O
ER	B-malignancy-type
.	O
Additional	O
studies	O
of	O
N	O
and	O
K	O
-	O
ras	O
mutations	O
as	O
well	O
as	O
more	O
cases	O
investigating	O
H-ras	O
will	O
be	O
required	O
before	O
we	O
can	O
ascertain	O
the	O
significance	O
of	O
ras	O
mutations	O
in	O
the	O
oncogenesis	O
of	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
PMID	O
:	O
8483882	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1993	O
Mar;7(	O
3	O
)	O
:469	O
-	O
71	O
Amplification	O
of	O
c-MYC	O
oncogene	O
and	O
point	O
mutation	O
of	O
N-RAS	O
oncogene	O
point	O
mutation	O
in	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemias	I-malignancy-type
with	O
double	O
minute	O
chromosomes	O
.	O
Tanaka	O
K	O
,	O
Takechi	O
M,	O
Nishimura	O
S,	O
Oguma	O
N	O
,	O
Kamada	O
N.	O
Department	O
of	O
Hematology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Two	O
patients	O
with	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
showing	O
double	O
minute	O
(	O
dmin	O
)	O
chromosomes	O
were	O
analysed	O
to	O
identify	O
oncogene	O
activation	O
.	O
Cytogenetic	O
analysis	O
showed	O
1	O
-	O
53	O
dmin	O
chromosomes	O
with	O
the	O
normal	O
karyotype	O
in	O
the	O
first	O
patient	O
and	O
1	O
-	O
84	O
dmin	O
chromosomes	O
with	O
complex	O
chromosome	O
aberrations	O
.	O
Analysis	O
of	O
DNA	O
from	O
two	O
patients	O
revealed	O
five	O
-	O
to	O
ten	O
fold	O
amplification	O
of	O
c-MYC	O
oncogene	O
in	O
the	O
leukemic	O
cells	O
.	O
The	O
other	O
sixteen	O
oncogenes	O
studied	O
showed	O
no	O
increase	O
in	O
the	O
gene	O
content	O
.	O
Furthermore	O
,	O
a	O
transforming	O
gene	O
,	O
N-RAS	O
was	O
detected	O
in	O
the	O
first	O
patient	O
by	O
nude	O
mouse	O
tumorigenicity	O
assay	O
(	O
in	O
vivo	O
selection	O
assay	O
)	O
.	O
These	O
results	O
suggest	O
that	O
the	O
amplification	O
of	O
c-MYC	O
gene	O
is	O
common	O
in	O
dmin	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
AML	I-malignancy-type
patients	O
and	O
co	O
-	O
ordination	O
of	O
c-MYC	O
and	O
N-RAS	O
oncogene	O
might	O
also	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
AML	B-malignancy-type
patients	O
.	O
PMID	O
:	O
8445953	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1994	O
May;74(	O
1	O
)	O
:40	O
-	O
9	O
Cytogenetic	O
studies	O
,	O
ras	O
mutation	O
,	O
and	O
clinical	O
characteristics	O
in	O
primary	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
A	O
study	O
on	O
68	O
Chinese	O
patients	O
in	O
Taiwan	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH	O
,	O
Chuang	O
SM	O
,	O
Chow	O
JM	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
DT	O
,	O
Lin	O
KH.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
R.O.C.	O
Cytogenetics	O
and	O
clinical	O
features	O
were	O
studied	O
for	O
68	O
Chinese	O
patients	O
with	O
primary	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Ras	O
mutation	O
was	O
analyzed	O
in	O
25	O
of	O
them	O
.	O
Thirty-four	O
patients	O
(	O
50	O
%	O
)	O
had	O
clonal	O
chromosomal	O
abnormalities	O
at	O
initial	O
analysis	O
.	O
The	O
most	O
common	O
cytogenetic	O
aberrations	O
were	O
-	O
7	O
,	O
+	O
8	O
,	O
5q	O
-	O
,	O
and	O
20q	O
-	O
,	O
which	O
occurred	O
in	O
11	O
(	O
16.2	O
%	O
)	O
,	O
seven	O
(	O
10.3	O
%	O
)	O
,	O
five	O
(	O
7.4	O
%	O
)	O
and	O
three	O
patients	O
,	O
respectively	O
.	O
The	O
incidence	O
of	O
-	O
7	O
was	O
higher	O
and	O
that	O
of	O
5q	O
-	O
lower	O
in	O
our	O
patients	O
than	O
in	O
patients	O
from	O
most	O
other	O
geographic	O
areas	O
.	O
The	O
17	O
patients	O
with	O
multiple	O
chromosomal	O
abnormalities	O
had	O
a	O
significantly	O
shorter	O
median	O
survival	O
(	O
9	O
months	O
)	O
than	O
the	O
34	O
patients	O
with	O
normal	O
karyotype	O
(	O
33	O
months	O
)	O
and	O
the	O
17	O
patients	O
with	O
patients	O
with	O
single	O
anomalies	O
(	O
26	O
months	O
)	O
.	O
Evolution	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
occurred	O
in	O
20	O
patients	O
(	O
29	O
%	O
)	O
after	O
a	O
median	O
interval	O
of	O
8	O
months	O
following	O
the	O
diagnosis	O
.	O
Patients	O
with	O
multiple	O
cytogenetic	O
changes	O
at	O
initial	O
analysis	O
or	O
in	O
subsequent	O
studies	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
acute	O
transformation	O
than	O
others	O
(	O
55	O
%	O
vs.	O
18.6	O
%	O
,	O
p	O
=	O
0.007	O
)	O
;	O
the	O
same	O
was	O
not	O
true	O
if	O
only	O
the	O
data	O
of	O
initial	O
study	O
were	O
considered	O
.	O
Serial	O
cytogenetic	O
studies	O
are	O
important	O
in	O
patient	O
follow	O
-	O
up	O
.	O
N-ras	O
mutation	O
was	O
detected	O
in	O
5	O
(	O
20	O
%	O
)	O
of	O
25	O
patients	O
within	O
the	O
study	O
.	O
There	O
was	O
no	O
correlation	O
between	O
the	O
gene	O
mutation	O
and	O
acute	O
transformation	O
.	O
But	O
combing	O
the	O
data	O
of	O
N-ras	O
mutation	O
and	O
cytogenetics	O
,	O
patients	O
with	O
either	O
the	O
N-ras	O
mutation	O
or	O
clonal	O
chromosomal	O
abnormalities	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
developing	O
acute	B-malignancy-type
leukemia	I-malignancy-type
than	O
those	O
with	O
neither	O
of	O
the	O
changes	O
(	O
77	O
%	O
vs.	O
25	O
%	O
)	O
.	O
PMID	O
:	O
8194046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1994	O
Apr	O
15	O
;83(	O
8	O
)	O
:2248	O
-	O
54	O
Mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
juvenile	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Miyauchi	O
J,	O
Asada	O
M,	O
Sasaki	O
M,	O
Tsunematsu	O
Y	O
,	O
Kojima	O
S,	O
Mizutani	O
S.	O
Department	O
of	O
Virology	O
,	O
National	O
Children	O
's	O
Medical	O
Research	O
Center	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Juvenile	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
JCML	B-malignancy-type
)	O
,	O
a	O
myeloproliferative	O
disorder	O
of	O
childhood	O
,	O
is	O
distinct	O
from	O
adult	O
-	O
type	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
and	O
bears	O
resemblance	O
to	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CMMoL	B-malignancy-type
)	O
.	O
Since	O
mutations	O
in	O
the	O
N-ras	O
gene	O
have	O
been	O
found	O
at	O
high	O
frequencies	O
in	O
CMMoL	B-malignancy-type
,	O
but	O
only	O
rarely	O
in	O
CML	B-malignancy-type
,	O
we	O
analyzed	O
mutations	O
activating	O
the	O
N-ras	O
gene	O
in	O
20	O
patients	O
with	O
JCML	B-malignancy-type
.	O
We	O
used	O
the	O
strategy	O
for	O
analysis	O
of	O
gene	O
mutations	O
based	O
on	O
in	O
vitro	O
DNA	O
amplification	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and/or	O
direct	O
sequence	O
analysis	O
.	O
Nucleotide	O
sequence	O
analysis	O
showed	O
single	O
nucleotide	O
substitutions	O
involving	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
in	O
six	O
of	O
20	O
patients	O
(	O
30	O
%	O
)	O
.	O
Four	O
of	O
six	O
patients	O
with	O
mutations	O
were	O
in	O
chronic	O
phase	O
and	O
the	O
other	O
two	O
in	O
blast	O
crisis	O
,	O
indicating	O
no	O
apparent	O
correlation	O
with	O
disease	O
stage	O
.	O
Most	O
of	O
the	O
patients	O
with	O
mutations	O
were	O
in	O
the	O
older	O
age	O
group	O
with	O
poor	O
prognosis	O
,	O
although	O
one	O
patient	O
in	O
the	O
younger	O
age	O
group	O
also	O
harbored	O
the	O
mutation	O
.	O
These	O
data	O
suggest	O
that	O
N-ras	O
gene	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
and/or	O
prognosis	O
of	O
JCML	B-malignancy-type
and	O
provide	O
further	O
evidence	O
that	O
JCML	B-malignancy-type
is	O
an	O
entity	O
distinct	O
from	O
CML	B-malignancy-type
.	O
PMID	O
:	O
8161790	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Jun;87(	O
2	O
)	O
:235	O
-	O
42	O
Establishment	O
and	O
characterization	O
of	O
a	O
novel	O
myeloid	O
cell	O
line	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Tohyama	O
K	O
,	O
Tsutani	O
H	O
,	O
Ueda	O
T	O
,	O
Nakamura	O
T	O
,	O
Yoshida	O
Y.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Fukui	O
Medical	O
School	O
,	O
Japan	O
.	O
A	O
novel	O
long	O
-	O
term	O
cultured	O
myeloid	O
cell	O
line	O
was	O
established	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
This	O
cell	O
line	O
,	O
designated	O
MDS92	O
,	O
proliferated	O
in	O
the	O
presence	O
of	O
interleukin-3	O
or	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
transiently	O
in	O
the	O
presence	O
of	O
Steel	O
factor	O
,	O
with	O
a	O
tendency	O
for	O
gradual	O
maturation	O
,	O
and	O
formed	O
myeloid	O
colonies	O
in	O
the	O
semi	O
-	O
solid	O
culture	O
condition	O
.	O
In	O
addition	O
,	O
the	O
MDS92	O
cell	O
line	O
represented	O
rather	O
complicated	O
karyotypic	O
abnormalities	O
including	O
the	O
deletion	O
of	O
fifth	O
and	O
seventh	O
chromosomes	O
and	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
N-ras	O
oncogene	O
.	O
These	O
characteristics	O
of	O
the	O
MDS92	O
cell	O
line	O
are	O
exclusively	O
compatible	O
with	O
the	O
property	O
of	O
preleukaemia	B-malignancy-type
.	O
PMID	O
:	O
7947263	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1994	O
Aug;85(	O
8	O
)	O
:847	O
-	O
52	O
State	O
of	O
adenomatous	B-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
gene	O
and	O
ras	O
oncogenes	O
in	O
Japanese	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Suzuki	O
H	O
,	O
Aida	O
S,	O
Akimoto	O
S,	O
Igarashi	O
T	O
,	O
Yatani	O
R,	O
Shimazaki	O
J.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
.	O
Genetic	O
alterations	O
of	O
ras	O
oncogenes	O
(	O
K	O
-	O
,	O
H	O
-	O
and	O
N	O
-	O
ras	O
)	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
in	O
tissues	O
of	O
prostate	B-malignancy-type
cancer	I-malignancy-type
from	O
Japanese	O
patients	O
were	O
examined	O
using	O
PCR	O
-	O
SSCP	O
(	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Tissues	O
from	O
8	O
cases	O
of	O
untreated	O
stage	O
B	O
prostate	B-malignancy-type
cancer	I-malignancy-type
surgically	O
removed	O
and	O
from	O
10	O
cases	O
of	O
endocrine	O
therapy	O
-	O
resistant	O
metastatic	O
disease	O
obtained	O
at	O
autopsy	O
were	O
used	O
in	O
the	O
present	O
study	O
.	O
In	O
four	O
out	O
of	O
18	O
cases	O
(	O
22	O
%	O
)	O
,	O
ras	O
point	O
mutations	O
were	O
found	O
,	O
two	O
in	O
either	O
codon	O
12	O
or	O
61	O
of	O
K-ras	O
and	O
two	O
in	O
either	O
13	O
or	O
61	O
of	O
H-ras	O
.	O
These	O
point	O
mutations	O
were	O
detected	O
in	O
one	O
of	O
the	O
stage	O
B	O
cases	O
(	O
13	O
%	O
)	O
and	O
in	O
three	O
of	O
the	O
autopsy	O
cases	O
(	O
30	O
%	O
)	O
.	O
All	O
these	O
cases	O
were	O
poorly	O
differentiated	O
adenocarcinoma	B-malignancy-type
.	O
In	O
autopsy	O
cases	O
showing	O
ras	O
mutation	O
in	O
cancerous	B-malignancy-type
prostate	I-malignancy-type
,	O
the	O
same	O
alteration	O
was	O
observed	O
in	O
metastatic	O
tissues	O
.	O
No	O
APC	O
gene	O
mutation	O
was	O
detected	O
in	O
any	O
sample	O
,	O
although	O
polymorphism	O
was	O
found	O
in	O
some	O
cases	O
.	O
These	O
results	O
indicate	O
that	O
ras	O
oncogene	O
mutations	O
are	O
related	O
to	O
the	O
progression	O
of	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
whereas	O
APC	O
gene	O
alteration	O
is	O
not	O
involved	O
in	O
tumorigenesis	O
and	O
development	O
of	O
this	O
cancer	B-malignancy-type
.	O
PMID	O
:	O
7928631	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
1995	O
;121(	O
1	O
)	O
:23	O
-	O
30	O
Analysis	O
of	O
ras	O
mutations	O
in	O
human	O
melanocytic	O
lesions	O
:	O
activation	O
of	O
the	O
ras	O
gene	O
seems	O
to	O
be	O
associated	O
with	O
the	O
nodular	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
human	I-malignancy-type
malignant	I-malignancy-type
melanoma	I-malignancy-type
.	O
Jafari	O
M,	O
Papp	O
T	O
,	O
Kirchner	O
S,	O
Diener	O
U	O
,	O
Henschler	O
D	O
,	O
Burg	O
G	O
,	O
Schiffmann	O
D.	O
Institute	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Wurzburg	O
,	O
Germany	O
.	O
We	O
have	O
analyzed	O
the	O
Ha-ras	O
,	O
Ki-ras	O
and	O
N-ras	O
gene	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
via	O
restriction	O
fragment	O
length	O
polymorphism	O
/	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
subsequent	O
direct	O
sequencing	O
in	O
non	O
-	O
cultured	O
fresh	O
-	O
frozen	O
tissues	O
of	O
16	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanomas	I-malignancy-type
(	O
SSM	B-malignancy-type
)	O
,	O
13	O
nodular	B-malignancy-type
malignant	I-malignancy-type
melanomas	I-malignancy-type
(	O
NMM	B-malignancy-type
)	O
,	O
2	O
lentigo	B-malignancy-type
malignant	I-malignancy-type
melanomas	I-malignancy-type
(	O
LMM	B-malignancy-type
)	O
,	O
1	O
dysplastic	B-malignancy-type
nevus	I-malignancy-type
,	O
1	O
congenital	B-malignancy-type
nevus	I-malignancy-type
and	O
5	O
normal	B-malignancy-type
nevi	I-malignancy-type
from	O
38	O
patients	O
.	O
Mutations	O
were	O
found	O
in	O
4	O
melanoma	B-malignancy-type
samples	O
,	O
all	O
belonging	O
to	O
the	O
nodular	B-malignancy-type
malignant	I-malignancy-type
type	I-malignancy-type
.	O
Three	O
of	O
them	O
were	O
mutated	O
in	O
N-ras	O
and	O
one	O
in	O
the	O
Ha-ras	O
gene	O
.	O
Mutation	O
in	O
N-ras	O
was	O
also	O
detected	O
in	O
the	O
congenital	B-malignancy-type
nevus	I-malignancy-type
.	O
All	O
mutations	O
were	O
exclusively	O
located	O
at	O
the	O
first	O
two	O
base	O
pairs	O
of	O
codon	O
61	O
.	O
No	O
Ki-ras	O
mutation	O
was	O
detected	O
in	O
any	O
lesion	O
.	O
No	O
mutation	O
could	O
be	O
found	O
in	O
SSM	B-malignancy-type
and	O
LMM	B-malignancy-type
in	O
addition	O
to	O
dysplastic	B-malignancy-type
and	O
normal	B-malignancy-type
nevi	B-malignancy-type
.	O
The	O
frequency	O
of	O
ras	O
mutation	O
in	O
NMM	B-malignancy-type
was	O
31	O
%	O
,	O
whereas	O
in	O
SSM	B-malignancy-type
it	O
was	O
0	O
%	O
.	O
Our	O
study	O
suggests	O
(a)	O
an	O
association	O
between	O
ras	O
mutations	O
(	O
mainly	O
N-ras	O
)	O
and	O
the	O
NMM	B-malignancy-type
as	O
a	O
subgroup	O
of	O
human	O
melanoma	B-malignancy-type
;	O
(b)	O
that	O
activation	O
of	O
Ki-ras	O
is	O
not	O
involved	O
in	O
the	O
pathogenesis	O
of	O
melanoma	B-malignancy-type
.	O
The	O
role	O
of	O
UV	O
radiation	O
in	O
point	O
mutations	O
of	O
ras	O
genes	O
in	O
human	O
melanoma	B-malignancy-type
is	O
discussed	O
.	O
PMID	O
:	O
7860615	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1995	O
May	O
;104(	O
5	O
)	O
:868	O
-	O
71	O
Ras	O
gene	O
mutations	O
:	O
a	O
rare	O
event	O
in	O
nonmetastatic	O
primary	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
.	O
Wagner	O
SN	O
,	O
Ockenfels	O
HM	O
,	O
Wagner	O
C	O
,	O
Hofler	O
H	O
,	O
Goos	O
M.	O
Department	O
of	O
Dermatology	O
,	O
University	O
Essen	O
,	O
Germany	O
.	O
Ras	O
gene	O
mutations	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
Mutated	O
ras	O
genes	O
have	O
been	O
isolated	O
from	O
human	O
melanoma	B-malignancy-type
cell	O
lines	O
,	O
but	O
subsequent	O
studies	O
indicated	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
a	O
rare	O
event	O
in	O
melanocytic	O
lesions	O
.	O
Recently	O
,	O
a	O
study	O
reported	O
a	O
high	O
frequency	O
of	O
ras	O
mutations	O
correlated	O
with	O
increasing	O
invasion	O
level	O
.	O
To	O
address	O
this	O
inconsistency	O
in	O
the	O
published	O
data	O
,	O
we	O
analyzed	O
50	O
primary	O
melanomas	B-malignancy-type
to	O
correlate	O
invasion	O
level	O
,	O
tumor	O
thickness	O
,	O
histologic	O
typing	O
,	O
and	O
body	O
localization	O
with	O
point	O
mutations	O
around	O
codons	O
12	O
/	O
13	O
/	O
61	O
of	O
the	O
three	O
ras	O
genes	O
.	O
After	O
micro	O
-	O
dissection	O
of	O
paraffin	O
-	O
embedded	O
tumor	O
tissue	O
,	O
ras	O
gene	O
mutations	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
of	O
tumor	O
DNA	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Only	O
two	O
melanomas	B-malignancy-type
exhibited	O
ras	O
gene	O
mutations	O
,	O
one	O
sample	O
containing	O
a	O
transition	O
from	O
A	O
to	O
G	O
at	O
position	O
2	O
of	O
N-ras	O
codon	O
61	O
and	O
the	O
other	O
exhibiting	O
a	O
transversion	O
from	O
C	O
to	O
A	O
at	O
position	O
1	O
and	O
a	O
transition	O
from	O
A	O
to	O
G	O
at	O
position	O
2	O
of	O
N-ras	O
codon	O
61	O
.	O
Both	O
tumors	O
were	O
classified	O
as	O
Clark	O
level	O
IV	O
,	O
with	O
a	O
tumor	O
thickness	O
of	O
2.5	O
and	O
1.2	O
mm	O
,	O
respectively	O
.	O
Both	O
were	O
typed	O
as	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanoma	I-malignancy-type
and	O
localized	O
to	O
intermittently	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
The	O
low	O
frequency	O
of	O
ras	O
mutations	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
the	O
lack	O
of	O
ras	O
mutations	O
in	O
melanoma	B-malignancy-type
samples	O
from	O
constantly	O
sun	O
-	O
exposed	O
body	O
sites	O
argue	O
against	O
the	O
hypothesis	O
of	O
ras	O
mutations	O
as	O
a	O
marker	O
of	O
progression	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
the	O
suggestion	O
that	O
ras	O
mutations	O
occur	O
predominantly	O
in	O
melanomas	B-malignancy-type
from	O
constantly	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
PMID	O
:	O
7738369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1984	O
Jun;81(	O
12	O
)	O
:3670	O
-	O
4	O
Mechanism	O
of	O
activation	O
of	O
an	O
N-ras	O
oncogene	O
of	O
SW-1271	O
human	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
cells	O
.	O
Yuasa	O
Y	O
,	O
Gol	O
RA	O
,	O
Chang	O
A	O
,	O
Chiu	O
IM	O
,	O
Reddy	O
EP	O
,	O
Tronick	O
SR	O
,	O
Aaronson	O
SA	O
.	O
An	O
N-ras	O
-	O
related	O
transforming	O
gene	O
was	O
detected	O
in	O
the	O
human	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
line	O
SW-1271	O
and	O
molecularly	O
cloned	O
.	O
The	O
lesion	O
responsible	O
for	O
its	O
acquisition	O
of	O
transforming	O
activity	O
was	O
localized	O
to	O
a	O
single	O
nucleotide	O
transition	O
from	O
A	O
to	O
G	O
in	O
codon	O
61	O
of	O
the	O
predicted	O
protein	O
.	O
This	O
lesion	O
in	O
the	O
second	O
exon	O
results	O
in	O
the	O
substitution	O
of	O
arginine	O
for	O
glutamine	O
at	O
this	O
position	O
.	O
These	O
findings	O
,	O
together	O
with	O
previous	O
studies	O
,	O
indicate	O
that	O
the	O
activation	O
of	O
ras	O
oncogenes	O
in	O
human	O
tumors	O
is	O
most	O
commonly	O
due	O
to	O
point	O
mutations	O
at	O
one	O
of	O
two	O
major	O
"	O
hot	O
spots	O
"	O
in	O
the	O
ras	O
coding	O
sequence	O
.	O
PMID	O
:	O
6587382	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
1987	O
Jul	O
15	O
;146(	O
1	O
)	O
:247	O
-	O
52	O
A	O
point	O
mutation	O
at	O
codon	O
13	O
of	O
the	O
N-ras	O
oncogene	O
in	O
a	O
human	O
stomach	B-malignancy-type
cancer	I-malignancy-type
.	O
Nishida	O
J,	O
Kobayashi	O
Y	O
,	O
Hirai	O
H	O
,	O
Takaku	O
F.	O
A	O
surgically	O
removed	O
human	O
stomach	B-malignancy-type
cancer	I-malignancy-type
with	O
the	O
histological	O
diagnosis	O
of	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenocarcinoma	I-malignancy-type
contained	O
an	O
activated	O
N-ras	O
oncogene	O
detected	O
by	O
an	O
in	O
vivo	O
selection	O
assay	O
in	O
nude	O
mice	O
using	O
transfected	O
NIH3T3	O
cells	O
.	O
Analysis	O
using	O
synthetic	O
20	O
-	O
mer	O
oligonucleotide	O
probes	O
revealed	O
a	O
point	O
mutation	O
from	O
G	O
to	O
C	O
at	O
the	O
first	O
letter	O
of	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
for	O
glycine	O
.	O
This	O
is	O
the	O
first	O
observation	O
of	O
an	O
activated	O
N-ras	O
oncogene	O
in	O
human	O
stomach	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
3038106	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Dec;74(	O
8	O
)	O
:2629	O
-	O
33	O
Mutations	O
of	O
the	O
ras	O
protooncogenes	O
in	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
:	O
a	O
high	O
frequency	O
of	O
ras	O
mutations	O
in	O
bcr	O
/	O
abl	O
rearrangement	O
-	O
negative	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Cogswell	O
PC	O
,	O
Morgan	O
R,	O
Dunn	O
M,	O
Neubauer	O
A	O
,	O
Nelson	O
P	O
,	O
Poland	O
-	O
Johnston	O
NK	O
,	O
Sandberg	O
AA	O
,	O
Liu	O
E.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
27599	O
.	O
Seventy	O
cases	O
of	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
oligonucleotide	O
hybridization	O
,	O
and	O
direct	O
PCR	O
sequencing	O
.	O
All	O
cases	O
had	O
preceding	O
cytogenetic	O
and	O
bcr	O
rearrangement	O
studies	O
.	O
Aberrant	O
ras	O
genes	O
were	O
detected	O
in	O
none	O
of	O
39	O
patients	O
with	O
Philadelphia	O
(	O
Ph	O
)	O
chromosome	O
or	O
bcr	O
/	O
abl	O
rearrangement	O
positive	O
chronic	O
-	O
phase	O
CML	B-malignancy-type
and	O
in	O
only	O
1	O
of	O
18	O
patients	O
in	O
blast	O
crisis	O
,	O
suggesting	O
that	O
ras	O
mutations	O
have	O
little	O
or	O
no	O
role	O
in	O
initiation	O
or	O
progression	O
of	O
common	O
CML	B-malignancy-type
.	O
Seven	O
of	O
13	O
,	O
or	O
54	O
%	O
of	O
patients	O
with	O
bcr	O
/	O
abl	O
rearrangement	O
negative	O
chronic	O
phase	O
CML	B-malignancy-type
(	O
atypical	O
CML	B-malignancy-type
)	O
harbored	O
mutations	O
in	O
ras	O
,	O
however	O
.	O
This	O
high	O
incidence	O
of	O
ras	O
mutations	O
,	O
together	O
with	O
the	O
absence	O
of	O
bcr	O
/	O
abl	O
rearrangement	O
,	O
provides	O
evidence	O
that	O
atypical	O
CML	B-malignancy-type
is	O
an	O
entity	O
that	O
is	O
molecularly	O
distinct	O
from	O
common	B-malignancy-type
CML	I-malignancy-type
.	O
Moreover	O
,	O
the	O
clinical	O
characteristics	O
and	O
the	O
high	O
frequency	O
of	O
ras	O
mutations	O
suggest	O
that	O
atypical	O
CML	B-malignancy-type
may	O
constitute	O
a	O
subset	O
of	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
may	O
be	O
best	O
classified	O
as	O
a	O
variant	O
of	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
.	O
PMID	O
:	O
2684296	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1989	O
Aug;86(	O
16	O
)	O
:6372	O
-	O
6	O
Oncogene	O
activation	O
in	O
human	O
benign	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
skin	I-malignancy-type
(	O
keratoacanthomas	B-malignancy-type
)	O
:	O
is	O
HRAS	O
involved	O
in	O
differentiation	O
as	O
well	O
as	O
proliferation	O
?	O
Corominas	O
M,	O
Kamino	O
H	O
,	O
Leon	O
J,	O
Pellicer	O
A.	O
Department	O
of	O
Pathology	O
,	O
New	O
York	O
University	O
Medical	O
Center	O
,	O
NY	O
10016	O
.	O
In	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
mismatch	O
hybridization	O
was	O
used	O
to	O
study	O
the	O
frequency	O
of	O
HRAS	O
mutations	O
in	O
the	O
benign	O
self	O
-	O
regressing	O
skin	B-malignancy-type
tumors	I-malignancy-type
keratoacanthomas	B-malignancy-type
and	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
We	O
used	O
freshly	O
obtained	O
keratoacanthomas	B-malignancy-type
as	O
well	O
as	O
Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
both	O
types	O
of	O
tumors	O
.	O
DNA	O
from	O
50	O
samples	O
of	O
each	O
tumor	O
type	O
was	O
analyzed	O
for	O
activating	O
mutations	O
involving	O
codons	O
12	O
and	O
61	O
.	O
A	O
relatively	O
high	O
percentage	O
(	O
30	O
%	O
)	O
of	O
HRAS	O
mutations	O
was	O
found	O
in	O
the	O
keratoacanthomas	B-malignancy-type
compared	O
with	O
13	O
%	O
in	O
the	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
most	O
frequent	O
mutation	O
identified	O
is	O
the	O
A-T	O
-	O
to	O
-	O
T.A	O
transversion	O
in	O
the	O
second	O
position	O
of	O
codon	O
61	O
.	O
The	O
present	O
findings	O
demonstrate	O
the	O
involvement	O
of	O
the	O
HRAS	O
oncogene	O
in	O
human	O
benign	B-malignancy-type
tumors	I-malignancy-type
.	O
Moreover	O
,	O
they	O
indicate	O
that	O
an	O
activated	O
HRAS	O
oncogene	O
is	O
not	O
sufficient	O
to	O
maintain	O
a	O
neoplastic	O
phenotype	O
and	O
argue	O
against	O
a	O
role	O
of	O
HRAS	O
in	O
the	O
progression	O
of	O
skin	O
tumorigenesis	O
.	O
PMID	O
:	O
2668964	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
May	O
;4(	O
5	O
)	O
:609	O
-	O
14	O
Mechanisms	O
of	O
ras	O
mutation	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Yunis	O
JJ	O
,	O
Boot	O
AJ	O
,	O
Mayer	O
MG	O
,	O
Bos	O
JL.	O
Department	O
of	O
Laboratory	O
Medicine	O
and	O
Pathology	O
,	O
University	O
of	O
Minnesota	O
Medical	O
School	O
,	O
Minneapolis	O
.	O
Using	O
synthetic	O
oligonucleotide	O
hybridization	O
,	O
we	O
have	O
found	O
a	O
ras	O
mutation	O
in	O
11	O
of	O
27	O
patients	O
(	O
41	O
%	O
)	O
with	O
primary	O
or	O
non	O
-	O
therapy	O
related	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
This	O
high	O
incidence	O
of	O
mutation	O
,	O
mainly	O
of	O
the	O
N-ras	O
oncogene	O
,	O
was	O
generally	O
found	O
in	O
patients	O
with	O
disease	O
progression	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
(	O
8	O
of	O
11	O
patients	O
=	O
73	O
%	O
)	O
.	O
Two	O
general	O
mechanisms	O
of	O
ras	O
mutation	O
were	O
found	O
.	O
In	O
five	O
patients	O
the	O
ras	O
mutation	O
was	O
present	O
in	O
only	O
a	O
fraction	O
of	O
the	O
cells	O
;	O
sometimes	O
appearing	O
in	O
late	O
stages	O
of	O
the	O
disease	O
,	O
suggesting	O
that	O
it	O
can	O
occur	O
in	O
a	O
differentiated	O
cell	O
clone	O
.	O
In	O
six	O
other	O
patients	O
,	O
the	O
ras	O
mutation	O
was	O
present	O
in	O
the	O
great	O
majority	O
of	O
bone	O
marrow	O
or	O
blood	O
cells	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
mature	O
normal	O
lymphocytes	O
and	O
persisted	O
following	O
a	O
complete	O
clinical	O
remission	O
in	O
two	O
of	O
these	O
patients	O
,	O
implying	O
that	O
the	O
ras	O
mutation	O
can	O
occur	O
in	O
an	O
early	O
stage	O
of	O
cell	O
differentiation	O
or	O
stem	O
cell	O
.	O
Patients	O
with	O
a	O
ras	O
mutation	O
had	O
a	O
median	O
survival	O
of	O
nine	O
months	O
(	O
all	O
patients	O
dead	O
)	O
compared	O
to	O
16	O
patients	O
without	O
a	O
ras	O
mutation	O
that	O
had	O
a	O
median	O
follow	O
-	O
up	O
of	O
16	O
months	O
(	O
10	O
patients	O
alive	O
;	O
P	O
less	O
than	O
0.005	O
)	O
.	O
Since	O
9	O
of	O
the	O
11	O
patients	O
(	O
82	O
%	O
)	O
with	O
a	O
ras	O
mutation	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
monocytic	O
component	O
at	O
diagnosis	O
or	O
during	O
disease	O
evolution	O
,	O
it	O
is	O
possible	O
that	O
in	O
myeloid	O
disorders	O
a	O
ras	O
mutation	O
is	O
preferentially	O
associated	O
with	O
myelomonocytic	O
cell	O
differentiation	O
.	O
PMID	O
:	O
2657575	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Apr	O
15;75(	O
8	O
)	O
:1684	O
-	O
90	O
The	O
pattern	O
of	O
mutational	O
involvement	O
of	O
RAS	O
genes	O
in	O
human	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
determined	O
by	O
DNA	O
amplification	O
and	O
direct	O
sequencing	O
.	O
Ahuja	O
HG	O
,	O
Foti	O
A	O
,	O
Bar	O
-	O
Eli	O
M,	O
Cline	O
MJ.	O
Department	O
of	O
Medicine	O
,	O
Jonsson	O
Cancer	O
Center	O
,	O
UCLA	O
School	O
of	O
Medicine	O
90024	O
-	O
1678	O
.	O
DNA	O
from	O
161	O
patients	O
with	O
various	O
forms	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
were	O
investigated	O
for	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
N-RAS	O
,	O
K-RAS	O
and	O
Ha-RAS	O
gene	O
by	O
direct	O
sequencing	O
of	O
DNA	O
amplified	O
in	O
vitro	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
involving	O
either	O
codons	O
11	O
,	O
12	O
,	O
or	O
13	O
of	O
the	O
N-RAS	O
gene	O
were	O
identified	O
in	O
18	O
of	O
the	O
161	O
patients	O
.	O
The	O
relative	O
frequencies	O
of	O
N-RAS	O
gene	O
mutations	O
in	O
these	O
hematologic	O
disorders	O
was	O
as	O
follows	O
:	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	O
)	O
,	O
15	O
%	O
;	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	O
)	O
,	O
14	O
%	O
;	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
,	O
24	O
%	O
;	O
and	O
myeloid	O
and	O
lymphoid	O
blast	O
crisis	O
of	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
,	O
3	O
%	O
.	O
No	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
of	O
mutations	O
and	O
cytologic	O
features	O
or	O
immunophenotype	O
of	O
these	O
malignancies	O
.	O
Mutations	O
involving	O
codons	O
12	O
or	O
13	O
were	O
equally	O
prevalent	O
,	O
with	O
a	O
glycine	O
to	O
aspartic	O
acid	O
substitution	O
being	O
the	O
most	O
frequently	O
encountered	O
change	O
.	O
A	O
single	O
T-ALL	B-malignancy-type
case	O
had	O
a	O
codon	O
11	O
mutation	O
resulting	O
in	O
substitution	O
of	O
alanine	O
with	O
threonine	O
.	O
We	O
failed	O
to	O
find	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
K-RAS	O
or	O
Ha-RAS	O
genes	O
in	O
any	O
case	O
except	O
a	O
single	O
AML	B-malignancy-type
with	O
a	O
mutation	O
in	O
codon	O
61	O
of	O
the	O
K-RAS	O
gene	O
.	O
Also	O
,	O
no	O
mutations	O
were	O
identified	O
in	O
chronic	O
phase	O
of	O
CML	B-malignancy-type
,	O
chronic	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Ph1	O
positive	O
ALL	B-malignancy-type
,	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
,	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
,	O
or	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
RAS	O
mutations	O
,	O
especially	O
those	O
involving	O
exon	O
1	O
of	O
the	O
N-RAS	O
gene	O
,	O
are	O
frequent	O
only	O
in	O
a	O
subset	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
PMID	O
:	O
2183888	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
May	O
15;51(	O
10	O
)	O
:2690	O
-	O
3	O
High	O
rates	O
of	O
ras	O
codon	O
61	O
mutation	O
in	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
in	O
an	O
iodide	O
-	O
deficient	O
area	O
.	O
Shi	O
YF	O
,	O
Zou	O
MJ	O
,	O
Schmidt	O
H	O
,	O
Juhasz	O
F	O
,	O
Stensky	O
V	O
,	O
Robb	O
D	O
,	O
Farid	O
NR	O
.	O
Thyroid	O
Research	O
Laboratory	O
,	O
Health	O
Sciences	O
Centre	O
,	O
St.	O
John	O
's	O
,	O
Newfoundland	O
,	O
Canada	O
.	O
Using	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
,	O
the	O
frequency	O
of	O
three	O
ras	O
oncogene	O
mutations	O
(	O
N-ras	O
,	O
Ha-ras	O
,	O
and	O
K-ras	O
)	O
in	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
(	O
25	O
adenomas	B-malignancy-type
,	O
16	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
22	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
)	O
was	O
investigated	O
in	O
both	O
iodide	O
-	O
deficient	O
and	O
iodide	O
-	O
sufficient	O
areas	O
.	O
The	O
ras	O
oncogene	O
mutation	O
rate	O
was	O
significantly	O
higher	O
in	O
the	O
iodide	O
-	O
deficient	O
area	O
,	O
being	O
85	O
versus	O
17	O
%	O
in	O
the	O
adenomas	B-malignancy-type
,	O
and	O
50	O
versus	O
10	O
%	O
in	O
the	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
No	O
mutations	O
were	O
found	O
in	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
most	O
common	O
mutation	O
site	O
was	O
Ha-ras	O
codon	O
61	O
with	O
Gln	O
----	O
Arg	O
substitution	O
.	O
Two	O
ras	O
mutations	O
at	O
codon	O
61	O
(	O
Gln	O
----	O
Lys	O
in	O
N-ras	O
and	O
Gln	O
----	O
Arg	O
in	O
Ha-ras	O
)	O
were	O
found	O
in	O
a	O
microfollicular	B-malignancy-type
adenoma	I-malignancy-type
specimen	O
from	O
Eastern	O
Hungary	O
.	O
We	O
conclude	O
that	O
dietary	O
iodine	O
may	O
modulate	O
ras	O
oncogene	O
mutations	O
,	O
and	O
that	O
in	O
the	O
iodide	O
-	O
deficient	O
area	O
,	O
ras	O
oncogene	O
activation	O
may	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
initiation	O
and/or	O
maintenance	O
of	O
follicular	B-malignancy-type
tumors	I-malignancy-type
.	O
Additional	O
factors	O
are	O
,	O
however	O
,	O
necessary	O
to	O
initiate	O
carcinogenesis	O
.	O
PMID	O
:	O
2021946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1992	O
Apr;74(	O
4)	O
:914	O
-	O
9	O
Ras	O
mutations	O
in	O
human	O
pituitary	B-malignancy-type
tumors	I-malignancy-type
.	O
Karga	O
HJ	O
,	O
Alexander	O
JM	O
,	O
Hedley	O
-	O
Whyte	O
ET	O
,	O
Klibanski	O
A	O
,	O
Jameson	O
JL.	O
Department	O
of	O
Medicine	O
,	O
Massachusetts	O
General	O
General	O
Hospital	O
,	O
Boston	O
02114	O
.	O
The	O
cellular	O
basis	O
for	O
pituitary	B-malignancy-type
neoplasia	I-malignancy-type
is	O
poorly	O
understood	O
.	O
Mutations	O
that	O
activate	O
the	O
ras	O
protooncogenes	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
different	O
types	O
of	O
human	O
cancers	O
and	O
potentially	O
represent	O
one	O
of	O
the	O
genetic	O
alterations	O
that	O
occur	O
in	O
pituitary	B-malignancy-type
tumors	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
examined	O
19	O
pituitary	B-malignancy-type
tumors	I-malignancy-type
for	O
the	O
occurrence	O
of	O
ras	O
mutations	O
.	O
The	O
tumor	O
types	O
included	O
11	O
nonfunctioning	B-malignancy-type
adenomas	I-malignancy-type
,	O
6	O
somatotroph	B-malignancy-type
adenomas	I-malignancy-type
,	O
and	O
2	O
prolactinomas	B-malignancy-type
.	O
Each	O
of	O
the	O
three	O
ras	O
genes	O
(	O
K-ras	O
,	O
N-ras	O
,	O
and	O
H-ras	O
)	O
was	O
amplified	O
from	O
pituitary	B-malignancy-type
tumor	I-malignancy-type
DNA	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Oligonucleotide	O
-	O
specific	O
hybridization	O
was	O
used	O
to	O
screen	O
for	O
mutations	O
that	O
inhibit	O
GTPase	O
activity	O
and	O
cause	O
activation	O
of	O
the	O
ras	O
oncogene	O
.	O
No	O
ras	O
mutations	O
were	O
observed	O
in	O
18	O
of	O
the	O
pituitary	B-malignancy-type
adenomas	I-malignancy-type
.	O
However	O
,	O
a	O
mutation	O
was	O
identified	O
in	O
codon	O
12	O
of	O
the	O
H-ras	O
gene	O
(	O
Gly	O
to	O
Val	O
)	O
in	O
a	O
recurrent	O
prolactinoma	B-malignancy-type
that	O
was	O
highly	O
invasive	O
and	O
ultimately	O
proved	O
to	O
be	O
fatal	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
pituitary	B-malignancy-type
adenomas	I-malignancy-type
,	O
but	O
may	O
provide	O
a	O
marker	O
for	O
highly	O
invasive	O
tumors	O
.	O
PMID	O
:	O
1312542	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2001	O
Nov;32	O
(	O
11	O
)	O
:	O
1203	O
-	O
8	O
Heterogeneous	O
genetic	O
alterations	O
in	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
:	O
application	O
and	O
usefulness	O
of	O
laser	O
capture	O
microdissection	O
.	O
Takeshima	O
Y	O
,	O
Amatya	O
VJ	O
,	O
Daimaru	O
Y	O
,	O
Nakayori	O
F	O
,	O
Nakano	O
T	O
,	O
Inai	O
K.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
Histologic	O
observation	O
of	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
suggests	O
that	O
there	O
is	O
a	O
multistep	O
transition	O
through	O
the	O
accumulation	O
of	O
genetic	O
alterations	O
.	O
We	O
analyzed	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
and	O
replication	O
error	O
(	O
RER	O
)	O
on	O
TP53	O
and	O
D17S855	O
as	O
well	O
as	O
K-ras	O
point	O
mutations	O
of	O
the	O
heterogeneous	O
histologic	O
areas	O
of	O
the	O
same	O
tumor	O
in	O
26	O
cases	O
of	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumor	I-malignancy-type
.	O
The	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
technique	O
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
K-ras	O
point	O
mutation	O
in	O
10	O
cases	O
.	O
As	O
for	O
genetic	O
alterations	O
for	O
LOH	O
or	O
RER	O
on	O
TP53	O
and	O
D17S855	O
,	O
2	O
(	O
1	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
1	O
carcinoma	B-malignancy-type
)	O
of	O
14	O
cases	O
and	O
4	O
(	O
1	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
3	O
carcinomas	B-malignancy-type
)	O
of	O
12	O
cases	O
,	O
respectively	O
,	O
showed	O
genetic	O
heterogeneities	O
in	O
different	O
histologic	O
areas	O
.	O
Six	O
(	O
2	O
borderline	B-malignancy-type
tumors	I-malignancy-type
and	O
4	O
carcinomas	O
)	O
of	O
18	O
cases	O
showed	O
heterogeneity	O
of	O
K-ras	O
point	O
mutation	O
in	O
the	O
different	O
histologic	O
areas	O
of	O
the	O
same	O
tumor	O
,	O
and	O
5	O
(	O
1	O
cystadenoma	B-malignancy-type
with	I-malignancy-type
Brenner	I-malignancy-type
tumor	I-malignancy-type
component	I-malignancy-type
,	O
2	O
borderline	B-malignancy-type
tumors	I-malignancy-type
,	O
and	O
2	O
carcinomas	B-malignancy-type
)	O
of	O
10	O
cases	O
showed	O
heterogeneous	O
K-ras	O
mutation	O
pattern	O
in	O
the	O
same	O
tumor	O
when	O
the	O
LCM	O
technique	O
was	O
used	O
.	O
Atypical	O
areas	O
tended	O
to	O
show	O
K-ras	O
point	O
mutations	O
frequently	O
.	O
Out	O
of	O
3	O
cases	O
of	O
mixed	B-malignancy-type
mucinous	I-malignancy-type
cystadenoma	I-malignancy-type
and	I-malignancy-type
Brenner	I-malignancy-type
tumor	I-malignancy-type
,	O
1	O
case	O
showed	O
K-ras	O
point	O
mutation	O
in	O
the	O
Brenner	B-malignancy-type
tumor	I-malignancy-type
area	O
but	O
not	O
in	O
the	O
area	O
of	O
mucinous	B-malignancy-type
cystadenoma	I-malignancy-type
.	O
These	O
preliminary	O
results	O
suggest	O
that	O
a	O
subset	O
of	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
occur	O
through	O
multistep	O
carcinogenesis	O
and	O
show	O
that	O
LCM	O
is	O
useful	O
for	O
molecular	O
pathologic	O
studies	O
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
Publication	O
Types	O
:	O
Evaluation	O
Studies	O
PMID	O
:	O
11727259	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Electron	O
Microsc	O
2002	O
Mar;35	O
(	O
1	O
)	O
:	O
9-15	O
Mutation	O
of	O
beta-catenin	O
gene	O
in	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
but	O
not	O
in	O
associated	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
Ashihara	O
K,	O
Saito	O
T	O
,	O
Mizumoto	O
H,	O
Nishimura	O
M,	O
Tanaka	O
R	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Sapporo	O
Medical	O
University	O
,	O
S-1	O
,	O
W-16	O
,	O
Chuo-ku	O
,	O
Sapporo	O
060	O
-0061	O
,	O
Japan	O
.	O
Endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
is	O
a	O
recognized	O
effect	O
of	O
excessive	O
or	O
unopposed	O
estrogen	O
stimulation	O
and	O
is	O
considered	O
to	O
be	O
a	O
precancerous	O
condition	O
of	O
endometrial	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
in	O
the	O
human	O
endometrium	O
is	O
changed	O
according	O
to	O
cell	O
proliferation	O
,	O
suggesting	O
a	O
role	O
of	O
intercellular	O
transduction	O
in	O
cell	O
-	O
growth	O
control	O
in	O
human	O
endometrium	O
,	O
not	O
only	O
in	O
the	O
physiological	O
condition	O
but	O
also	O
in	O
the	O
carcinogenic	O
endometrium	O
.	O
In	O
the	O
present	O
study	O
,	O
to	O
clarify	O
at	O
which	O
stage	O
of	O
endometrial	O
carcinogenesis	O
molecular	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
occurs	O
,	O
we	O
analyzed	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
by	O
immunohistochemistry	O
,	O
and	O
we	O
analyzed	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
in	O
25	O
patients	O
-	O
with	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
and	O
20	O
patients	O
with	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
associated	O
with	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
,	O
digesting	O
DNA	O
from	O
the	O
cancer	O
and	O
hyperplasia	O
parts	O
,	O
separately	O
.	O
Fourteen	O
of	O
the	O
25	O
(	O
56.0	O
%	O
)	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
samples	O
,	O
12	O
(	O
60.0	O
%	O
)	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
,	O
and	O
11	O
(	O
55.0	O
%	O
)	O
associated	B-malignancy-type
hyperplasias	I-malignancy-type
of	O
the	O
20	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
associated	O
with	O
hyperplasia	B-malignancy-type
showed	O
nuclear	O
localization	O
of	O
beta-catenin	O
.	O
Mutation	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
found	O
in	O
2	O
of	O
the	O
20	O
endometrial	O
cancer	O
samples	O
;	O
however	O
,	O
it	O
was	O
not	O
found	O
in	O
the	O
25	O
endometrial	B-malignancy-type
hyperplasias	I-malignancy-type
or	O
the	O
20	O
associated	O
hyperplasias	B-malignancy-type
.	O
The	O
results	O
suggest	O
that	O
molecular	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
occurs	O
in	O
atypical	B-malignancy-type
hyperplasia	I-malignancy-type
or	O
cancer	O
,	O
rather	O
than	O
in	O
simple	B-malignancy-type
or	O
complex	B-malignancy-type
hyperplasia	I-malignancy-type
without	I-malignancy-type
atypia	I-malignancy-type
,	O
during	O
endometrial	O
carcinogenesis	O
.	O
PMID	O
:	O
12111402	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
2002	O
Jun;20	O
(	O
6	O
)	O
:	O
1263	O
-	O
8	O
Frequent	O
detection	O
of	O
K-ras	O
mutation	O
in	O
stool	O
samples	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
patients	O
after	O
improved	O
DNA	O
extraction	O
:	O
comparison	O
with	O
tissue	O
samples	O
.	O
Ito	O
Y	O
,	O
Kobayashi	O
S	O
,	O
Taniguchi	O
T	O
,	O
Kainuma	O
O	O
,	O
Hara	O
T	O
,	O
Ochiai	O
T.	O
Department	O
of	O
Surgery	O
,	O
Shimizu	O
Kosei	O
General	O
Hospital	O
,	O
Chiba	O
,	O
Japan	O
.	O
Fecal	O
occult	O
blood	O
testing	O
is	O
widely	O
used	O
in	O
the	O
clinical	O
screening	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
.	O
However	O
,	O
this	O
method	O
has	O
so	O
frequent	O
false	O
-	O
positive	O
results	O
that	O
more	O
accurate	O
screening	O
-	O
strategy	O
should	O
be	O
established	O
.	O
Although	O
the	O
molecular	O
screening	O
using	O
K-ras	O
gene	O
mutation	O
in	O
stools	O
has	O
been	O
attempted	O
to	O
improve	O
the	O
results	O
,	O
the	O
low	O
rate	O
of	O
DNA	O
extraction	O
from	O
stools	O
leaves	O
this	O
measurement	O
under	O
utility	O
value	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
or	O
not	O
our	O
applied	O
DNA	O
extraction	O
method	O
from	O
stools	O
could	O
produce	O
enough	O
DNA	O
for	O
the	O
molecular	O
screening	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
by	O
K-ras	O
gene	O
mutations	O
in	O
stools	O
.	O
We	O
applied	O
cetyltrimethylammonium	O
bromide	O
(	O
CTAB	O
)	O
solution	O
to	O
improve	O
human	O
DNA	O
extraction	O
from	O
stools	O
and	O
a	O
mutant	O
-	O
allele	O
-	O
sensitive	O
amplification	O
(	O
MASA	O
)	O
method	O
to	O
detect	O
K-ras	O
mutation	O
within	O
codon	O
12	O
.	O
We	O
were	O
able	O
to	O
confirm	O
the	O
stool	O
DNA	O
by	O
identifying	O
K-ras	O
fragments	O
in	O
all	O
the	O
20	O
patients	O
.	O
Tissue	O
K-ras	O
mutation	O
was	O
identified	O
in	O
4	O
(	O
2	O
cancers	B-malignancy-type
and	O
2	O
adenomas	B-malignancy-type
)	O
of	O
20	O
patients	O
.	O
Stool	O
K-ras	O
mutations	O
were	O
found	O
in	O
6	O
patients	O
,	O
3	O
tissue	O
K-ras	O
mutation	O
positive	O
patients	O
(	O
2	O
cancers	B-malignancy-type
and	O
an	O
adenoma	B-malignancy-type
)	O
and	O
3	O
tissue	O
K-ras	O
mutation	O
negative	O
patients	O
.	O
These	O
results	O
indicate	O
that	O
it	O
is	O
possible	O
to	O
extract	O
enough	O
DNA	O
from	O
human	O
stool	O
samples	O
of	O
all	O
patients	O
with	O
colorectal	O
tumors	O
for	O
K-ras	O
mutation	O
studies	O
.	O
K-ras	O
mutations	O
are	O
more	O
frequently	O
detected	O
in	O
stools	O
than	O
in	O
resected	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
.	O
This	O
study	O
indicates	O
that	O
K-ras	O
mutation	O
screening	O
in	O
stools	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
may	O
include	O
not	O
only	O
a	O
primary	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
but	O
also	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
in	O
all	O
parts	O
of	O
a	O
gastrointestinal	O
tract	O
.	O
PMID	O
:	O
12012008	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
May	O
;160	O
(	O
5	O
)	O
:1567	O
-72	O
KIT	O
mutations	O
are	O
common	O
in	O
incidental	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
one	O
centimeter	O
or	O
less	O
in	O
size	O
.	O
Corless	O
CL	O
,	O
McGreevey	O
L,	O
Haley	O
A	O
,	O
Town	O
A	O
,	O
Heinrich	O
MC	O
.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Oregon	O
Health	O
and	O
Science	O
University	O
,	O
Portland	O
,	O
97201	O
,	O
USA	O
.	O
corrlessc@ohsu.edu	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
mesenchymal	B-malignancy-type
neoplasms	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gut	I-malignancy-type
wall	I-malignancy-type
that	O
express	O
the	O
receptor	O
tyrosine	O
kinase	O
KIT	O
.	O
Somatic	O
mutations	O
that	O
result	O
in	O
constitutive	O
activation	O
of	O
KIT	O
kinase	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
studies	O
of	O
GISTs	O
,	O
although	O
the	O
reported	O
frequency	O
of	O
these	O
mutations	O
has	O
varied	O
over	O
a	O
wide	O
range	O
(	O
20	O
to	O
92	O
%	O
)	O
.	O
Several	O
reports	O
have	O
suggested	O
that	O
KIT	O
gene	O
mutations	O
are	O
more	O
common	O
in	O
malignant	O
GISTs	B-malignancy-type
than	O
in	O
benign	O
lesions	O
,	O
and	O
it	O
has	O
been	O
proposed	O
that	O
mutations	O
in	O
exon	O
11	O
of	O
KIT	O
are	O
a	O
negative	O
prognostic	O
factor	O
.	O
To	O
maximize	O
sensitivity	O
for	O
KIT	O
mutations	O
we	O
have	O
adapted	O
denaturing	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
as	O
a	O
method	O
for	O
screening	O
polymerase	O
chain	O
reaction	O
amplimers	O
of	O
exons	O
9	O
,	O
11	O
,	O
13	O
,	O
and	O
17	O
from	O
GIST	B-malignancy-type
genomic	O
DNA	O
.	O
This	O
approach	O
was	O
used	O
to	O
assess	O
the	O
frequency	O
of	O
KIT	O
mutations	O
in	O
13	O
morphologically	O
benign	O
,	O
incidentally	O
discovered	O
,	O
GISTs	B-malignancy-type
identified	O
at	O
autopsy	O
,	O
endoscopy	O
,	O
or	O
laparotomy	O
for	O
unrelated	O
disease	O
.	O
Representing	O
the	O
smallest	O
pathologically	O
recognizable	O
GISTs	B-malignancy-type
,	O
these	O
lesions	O
ranged	O
in	O
size	O
from	O
4	O
to	O
10	O
mm	O
in	O
diameter	O
and	O
were	O
all	O
immunohistochemically	O
positive	O
for	O
KIT	O
.	O
Eleven	O
of	O
the	O
13	O
tumors	O
had	O
sequence	O
-	O
confirmed	O
mutations	O
in	O
KIT	O
,	O
including	O
10	O
mutations	O
in	O
exon	O
11	O
(	O
77	O
%	O
)	O
and	O
one	O
mutation	O
in	O
exon	O
9	O
(	O
7.7	O
%	O
)	O
.	O
The	O
remaining	O
two	O
tumors	O
were	O
wild	O
type	O
for	O
exons	O
9	O
,	O
11	O
,	O
and	O
17	O
;	O
one	O
of	O
these	O
was	O
also	O
analyzed	O
for	O
exon	O
13	O
and	O
was	O
wild	O
type	O
in	O
this	O
exon	O
as	O
well	O
.	O
The	O
mutations	O
found	O
in	O
the	O
incidental	O
GISTs	B-malignancy-type
were	O
identical	O
to	O
those	O
that	O
have	O
been	O
documented	O
in	O
larger	O
GISTs	B-malignancy-type
.	O
In	O
addition	O
,	O
the	O
overall	O
frequency	O
of	O
mutations	O
in	O
the	O
incidental	O
tumors	O
(	O
85	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
we	O
previously	O
reported	O
in	O
a	O
series	O
of	O
72	O
advanced	O
/	O
metastatic	O
GISTs	B-malignancy-type
(	O
86	O
%	O
)	O
,	O
strongly	O
supporting	O
the	O
view	O
that	O
activating	O
mutations	O
in	O
KIT	O
are	O
acquired	O
very	O
early	O
in	O
the	O
development	O
of	O
most	O
GISTs	B-malignancy-type
.	O
The	O
findings	O
suggest	O
that	O
KIT	O
mutations	O
per	O
se	O
are	O
of	O
little	O
prognostic	O
importance	O
in	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
12000708	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Gastroenterol	O
Hepatol	O
2002	O
Apr;14(	O
4	O
)	O
:	O
445-	O
8	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
oesophagus	I-malignancy-type
:	O
significance	O
of	O
immunohistochemical	O
and	O
genetic	O
analyses	O
of	O
the	O
c-kit	O
gene	O
.	O
Iijima	O
S	O
,	O
Maesawa	O
C	O
,	O
Sato	O
N	O
,	O
Ikeda	O
K,	O
Inaba	O
T	O
,	O
Akiyama	O
Y	O
,	O
Ishida	O
K,	O
Saito	O
K,	O
Masuda	O
T.	O
Departments	O
of	O
Pathology	O
,	O
Iwate	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Uchimaru	O
19-1	O
,	O
020	O
-	O
8505	O
Morioka	O
,	O
Japan	O
.	O
Oesophageal	B-malignancy-type
gastrointestinal	I-malignancy-type
stromal	I-malignancy-type
tumours	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
rare	O
in	O
comparison	O
to	O
those	O
of	O
the	O
stomach	B-malignancy-type
and	O
intestines	B-malignancy-type
.	O
Recently	O
,	O
it	O
has	O
been	O
clarified	O
that	O
mutations	O
of	O
the	O
c-kit	O
gene	O
resulting	O
in	O
gain	O
of	O
function	O
might	O
be	O
associated	O
with	O
histogenesis	O
of	O
this	O
type	O
of	O
tumour	B-malignancy-type
arising	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
stomach	I-malignancy-type
and	I-malignancy-type
intestines	I-malignancy-type
.	O
We	O
describe	O
an	O
oesophageal	B-malignancy-type
GIST	I-malignancy-type
on	O
immunohistochemical	O
and	O
genetic	O
analyses	O
of	O
the	O
gene	O
.	O
A	O
71	O
-	O
year	O
-	O
old	O
man	O
had	O
an	O
intramural	B-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
middle	I-malignancy-type
third	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
oesophagus	I-malignancy-type
.	O
Tumour	O
cells	O
were	O
composed	O
predominantly	O
of	O
spindle	O
-	O
shaped	O
and	O
partially	O
epithelioid	O
cells	O
.	O
They	O
were	O
diffusely	O
positive	O
for	O
CD117	O
.	O
Six	O
base	O
deletion	O
resulting	O
in	O
in	O
-	O
frame	O
mutation	O
of	O
the	O
c-kit	O
gene	O
was	O
confirmed	O
at	O
codon	O
556	O
-	O
558	O
(	O
cag	O
tgg	O
aag	O
to	O
cag	O
)	O
of	O
exon	O
11	O
.	O
Patients	O
with	O
mutations	O
of	O
the	O
c-kit	O
gene	O
revealed	O
worse	O
prognoses	O
in	O
GISTs	B-malignancy-type
arising	I-malignancy-type
from	I-malignancy-type
other	I-malignancy-type
locations	I-malignancy-type
.	O
A	O
long	O
-	O
term	O
follow	O
-	O
up	O
observation	O
is	O
needed	O
for	O
the	O
case	O
.	O
PMID	O
:	O
11943962	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
Mar;160	O
(	O
3	O
)	O
:953	O
-	O
62	O
Genetic	O
and	O
immunohistochemical	O
analysis	O
of	O
pancreatic	B-malignancy-type
acinar	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
:	O
frequent	O
allelic	O
loss	O
on	O
chromosome	O
11p	O
and	O
alterations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
.	O
Abraham	O
SC	O
,	O
Wu	O
TT	O
,	O
Hruban	O
RH	O
,	O
Lee	O
JH	O
,	O
Yeo	O
CJ	O
,	O
Conlon	O
K,	O
Brennan	O
M,	O
Cameron	O
JL	O
,	O
Klimstra	O
DS	O
.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
GI	O
/	O
LiverPathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
-2196	O
,	O
USA	O
.	O
sabraham@jhmi.edu	O
Acinar	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
ACCs	B-malignancy-type
)	O
are	O
rare	O
malignant	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
exocrine	I-malignancy-type
pancreas	I-malignancy-type
.	O
The	O
specific	O
molecular	O
alterations	O
that	O
characterize	O
ACCs	B-malignancy-type
have	O
not	O
yet	O
been	O
elucidated	O
.	O
ACCs	B-malignancy-type
are	O
morphologically	O
and	O
genetically	O
distinct	O
from	O
the	O
more	O
common	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Instead	O
,	O
the	O
morphological	O
,	O
immunohistochemical	O
,	O
and	O
clinical	O
features	O
of	O
ACCs	B-malignancy-type
overlap	O
with	O
those	O
of	O
another	O
rare	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
,	O
pancreatoblastoma	B-malignancy-type
.	O
We	O
have	O
recently	O
demonstrated	O
a	O
high	O
frequency	O
of	O
allelic	O
loss	O
on	O
chromosome	O
arm	O
11p	O
and	O
mutations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
in	O
pancreatoblastomas	B-malignancy-type
,	O
suggesting	O
that	O
similar	O
alterations	O
might	O
also	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
ACCs	B-malignancy-type
.	O
We	O
analyzed	O
a	O
series	O
of	O
21	O
ACCs	O
for	O
somatic	O
alterations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
and	O
for	O
allelic	O
loss	O
on	O
chromosome	O
11p	O
.	O
In	O
addition	O
,	O
we	O
evaluated	O
the	O
ACCs	B-malignancy-type
for	O
alterations	O
in	O
p53	O
and	O
Dpc4	O
expression	O
using	O
immunohistochemistry	O
,	O
and	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
using	O
polymerase	O
chain	O
amplification	O
of	O
a	O
panel	O
of	O
microsatellite	O
markers	O
.	O
Allelic	O
loss	O
on	O
chromosome	O
11p	O
was	O
the	O
most	O
common	O
genetic	O
alteration	O
in	O
ACCs	B-malignancy-type
,	O
present	O
in	O
50	O
%	O
(	O
6	O
of	O
12	O
informative	O
cases	O
)	O
.	O
Molecular	O
alterations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
were	O
detected	O
in	O
23.5	O
%	O
(	O
4	O
of	O
17	O
)	O
of	O
the	O
carcinomas	B-malignancy-type
,	O
including	O
one	O
ACC	B-malignancy-type
with	O
an	O
activating	O
mutation	O
of	O
the	O
beta-catenin	O
oncogene	O
and	O
three	O
ACCs	B-malignancy-type
with	O
truncating	O
APC	O
mutations	O
.	O
One	O
ACC	B-malignancy-type
(	O
1	O
of	O
13	O
,	O
7.6	O
%	O
)	O
showed	O
allelic	O
shifts	O
in	O
four	O
of	O
the	O
five	O
markers	O
tested	O
(	O
MSI	O
-	O
high	O
)	O
,	O
two	O
(	O
15.4	O
%	O
)	O
showed	O
an	O
allelic	O
shift	O
in	O
only	O
one	O
of	O
the	O
five	O
markers	O
tested	O
(	O
MSI	O
-	O
low	O
)	O
,	O
and	O
no	O
shifts	O
were	O
detected	O
in	O
the	O
remaining	O
10	O
cases	O
.	O
The	O
MSI	O
-	O
high	O
ACC	B-malignancy-type
showed	O
medullary	O
histological	O
features	O
.	O
In	O
contrast	O
,	O
no	O
loss	O
of	O
Dpc4	O
protein	O
expression	O
or	O
p53	O
accumulation	O
was	O
detected	O
.	O
These	O
results	O
indicate	O
that	O
ACCs	O
are	O
genetically	O
distinct	O
from	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
but	O
some	O
cases	O
contain	O
genetic	O
alterations	O
common	O
to	O
histologically	O
similar	O
pancreatoblastomas	B-malignancy-type
.	O
PMID	O
:	O
11891193	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Carcinogenesis	O
2002	O
Jan;23(	O
1	O
)	O
:	O
87	O
-	O
91	O
Increased	O
beta-catenin	O
mRNA	O
levels	O
and	O
mutational	O
alterations	O
of	O
the	O
APC	O
and	O
beta-catenin	O
gene	O
are	O
present	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
Ebert	O
MP	O
,	O
Fei	O
G	O
,	O
Kahmann	O
S	O
,	O
Muller	O
O	O
,	O
Yu	O
J,	O
Sung	O
JJ	O
,	O
Malfertheiner	O
P.	O
Department	O
of	O
Gastroenterology	O
,	O
Hepatology	O
and	O
Infectious	O
Diseases	O
,	O
Otto-von	O
-	O
Guericke	O
University	O
,	O
D-	O
39120	O
Magdeburg	O
,	O
Germany	O
.	O
Beta-catenin	O
is	O
critical	O
for	O
intercellular	O
adhesion	O
and	O
also	O
plays	O
a	O
role	O
as	O
a	O
transcription	O
activating	O
protein	O
in	O
the	O
Wnt	O
signalling	O
pathway	O
.	O
Increased	O
protein	O
levels	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
have	O
been	O
demonstrated	O
in	O
various	O
cancers	O
;	O
however	O
,	O
the	O
role	O
of	O
beta-catenin	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
remains	O
largely	O
unknown	O
.	O
Using	O
gastric	B-malignancy-type
cancer	I-malignancy-type
tissues	O
and	O
normal	O
adjacent	O
gastric	O
mucosa	O
obtained	O
from	O
20	O
patients	O
with	O
gastric	B-malignancy-type
cancer	I-malignancy-type
(	O
eight	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
,	O
12	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
)	O
undergoing	O
gastric	O
resection	O
or	O
endoscopy	O
,	O
we	O
assessed	O
the	O
expression	O
of	O
beta-catenin	O
by	O
immunohistochemistry	O
and	O
quantitative	O
PCR	O
analysis	O
.	O
Furthermore	O
,	O
the	O
tumour	O
suppressor	O
gene	O
APC	O
,	O
which	O
down	O
-	O
regulates	O
the	O
beta-catenin	O
levels	O
was	O
analysed	O
for	O
mutations	O
.	O
Overall	O
mRNA	O
levels	O
of	O
beta-catenin	O
were	O
significantly	O
increased	O
in	O
the	O
tumour	O
samples	O
compared	O
with	O
the	O
matched	O
normal	O
gastric	O
mucosa	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Increased	O
beta-catenin	O
mRNA	O
levels	O
were	O
significantly	O
more	O
frequent	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
as	O
compared	O
to	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
(	O
P	O
<	O
0.01	O
)	O
.	O
Six	O
out	O
of	O
20	O
tumours	O
exhibited	O
>	O
6	O
-	O
fold	O
increased	O
beta-catenin	O
mRNA	O
levels	O
as	O
compared	O
with	O
normal	O
mucosa	O
.	O
APC	O
gene	O
mutations	O
were	O
found	O
in	O
four	O
cases	O
.	O
A	O
beta-catenin	O
gene	O
mutation	O
was	O
identified	O
only	O
in	O
one	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
exhibiting	O
a	O
massive	O
overexpression	O
of	O
beta-catenin	O
mRNA	O
in	O
the	O
tumour	O
.	O
In	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
beta-catenin	O
mRNA	O
levels	O
are	O
greatly	O
enhanced	O
.	O
APC	O
and	O
beta-catenin	O
gene	O
mutations	O
are	O
also	O
present	O
primarily	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
.	O
These	O
findings	O
support	O
the	O
hypothesis	O
that	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
the	O
accumulation	O
of	O
beta-catenin	O
protein	O
may	O
result	O
from	O
impaired	O
degradation	O
of	O
the	O
beta-catenin	O
protein	O
due	O
to	O
alterations	O
of	O
the	O
beta-catenin	O
and	O
APC	O
genes	O
,	O
as	O
well	O
as	O
from	O
enhanced	O
beta-catenin	O
transcription	O
which	O
is	O
present	O
in	O
the	O
great	O
majority	O
of	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
11756228	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Dec	O
1;61	O
(	O
23	O
)	O
:	O
8401-4	O
Frequent	O
beta-catenin	O
mutation	O
and	O
cytoplasmic	O
/	O
nuclear	O
accumulation	O
in	O
pancreatic	B-malignancy-type
solid	I-malignancy-type
-	I-malignancy-type
pseudopapillary	I-malignancy-type
neoplasm	I-malignancy-type
.	O
Tanaka	O
Y	O
,	O
Kato	O
K,	O
Notohara	O
K,	O
Hojo	O
H,	O
Ijiri	O
R	O
,	O
Miyake	O
T	O
,	O
Nagahara	O
N	O
,	O
Sasaki	O
F	O
,	O
Kitagawa	O
N	O
,	O
Nakatani	O
Y	O
,	O
Kobayashi	O
Y	O
.	O
Division	O
of	O
Pathology	O
,	O
Kanagawa	O
Children	O
's	O
Medical	O
Center	O
,	O
Yokohama	O
,	O
Japan	O
.	O
Significance	O
of	O
Wnt	O
signaling	O
with	O
beta-catenin	O
mutations	O
on	O
solid	B-malignancy-type
-	I-malignancy-type
pseudopapillary	I-malignancy-type
neoplasm	I-malignancy-type
(	I-malignancy-type
SPN	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
was	O
studied	O
by	O
immunohistochemistry	O
and	O
molecular	O
analysis	O
.	O
On	O
immunohistochemistry	O
,	O
all	O
18	O
SPNs	B-malignancy-type
tested	O
showed	O
diffuse	O
cytoplasmic	O
/	O
nuclear	O
positivity	O
for	O
beta-catenin	O
.	O
Upon	O
direct	O
DNA	O
sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
15	O
(	O
83	O
%	O
)	O
of	O
the	O
18	O
SPNs	B-malignancy-type
showed	O
1	O
-	O
bp	O
missense	O
mutation	O
in	O
codons	O
32	O
(	O
5	O
cases	O
)	O
,	O
33	O
(	O
3	O
cases	O
)	O
,	O
34	O
(	O
3	O
cases	O
)	O
,	O
37	O
(	O
3	O
cases	O
)	O
,	O
and	O
41	O
(	O
1	O
case	O
)	O
.	O
Immunoreactivity	O
for	O
cyclin	O
D1	O
,	O
one	O
of	O
the	O
intranuclear	O
targets	O
of	O
beta-catenin	O
complexes	O
,	O
was	O
found	O
in	O
tumor	O
cells	O
of	O
more	O
than	O
half	O
the	O
tumor	O
cells	O
of	O
all	O
of	O
the	O
18	O
SPNs	B-malignancy-type
.	O
The	O
present	O
study	O
strongly	O
suggested	O
a	O
significant	O
role	O
of	O
Wnt	O
signaling	O
,	O
mostly	O
associated	O
with	O
beta-catenin	O
mutations	O
in	O
the	O
tumorigenesis	O
of	O
SPN	B-malignancy-type
.	O
PMID	O
:	O
11731417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2002	O
Aug	O
27;87	O
(	O
5	O
)	O
:	O
551	O
-4	O
Differential	O
diagnosis	O
between	O
chronic	O
pancreatitis	O
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
value	O
of	O
the	O
detection	O
of	O
KRAS2	O
mutations	O
in	O
circulating	O
DNA	O
.	O
Maire	O
F	O
,	O
Micard	O
S	O
,	O
Hammel	O
P,	O
Voitot	O
H,	O
Levy	O
P,	O
Cugnenc	O
PH	O
,	O
Ruszniewski	O
P,	O
Puig	O
PL.	O
Federation	O
Medico-Chirurgicale	O
d'Hepato-Gastroenterologie	O
,	O
Hopital	O
Beaujon	O
,	O
AP-HP	O
,	O
92110	O
Clichy	O
,	O
France	O
.	O
frederique	O
.maire@bjn	O
.ap-hop	O
-	O
paris	O
.fr	O
KRAS2	O
mutations	O
in	O
codon	O
12	O
have	O
been	O
detected	O
in	O
about	O
80	O
%	O
of	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
value	O
of	O
KRAS2	O
mutations	O
detection	O
in	O
circulating	O
deoxyribo	O
nucleic	O
acid	O
to	O
differentiate	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
from	O
chronic	O
pancreatitis	O
.	O
Circulating	O
deoxyribonucleic	O
acid	O
was	O
isolated	O
from	O
serum	O
in	O
47	O
patients	O
with	O
histologically	O
proven	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
(	O
26	O
males	O
,	O
median	O
age	O
65	O
years	O
)	O
and	O
31	O
controls	O
with	O
chronic	O
pancreatitis	O
(	O
26	O
males	O
,	O
median	O
age	O
48	O
years	O
)	O
.	O
Mutations	O
at	O
codon	O
12	O
of	O
KRAS2	O
gene	O
were	O
searched	O
for	O
using	O
polymerase	O
chain	O
reaction	O
and	O
allele	O
specific	O
amplification	O
.	O
Serum	O
carbohydrate	O
antigen	O
19.9	O
levels	O
were	O
also	O
determined	O
.	O
KRAS2	O
mutations	O
were	O
found	O
in	O
22	O
patients	O
(	O
47	O
%	O
)	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
and	O
in	O
four	O
controls	O
with	O
chronic	O
pancreatitis	O
(	O
13	O
%	O
)	O
(	O
P	O
<	O
0.002	O
)	O
.	O
None	O
of	O
the	O
latter	O
developed	O
a	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
within	O
the	O
36	O
months	O
of	O
median	O
follow	O
-	O
up	O
.	O
The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
serum	O
serum	O
KRAS2	O
mutations	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
were	O
47	O
,	O
87	O
,	O
85	O
and	O
52	O
%	O
,	O
respectively	O
.	O
KRAS2	O
mutations	O
were	O
not	O
related	O
to	O
age	O
,	O
gender	O
,	O
smoking	O
habit	O
,	O
tumour	O
stage	O
,	O
or	O
survival	O
.	O
Among	O
the	O
26	O
patients	O
with	O
normal	O
or	O
non	O
-	O
contributive	O
(	O
due	O
to	O
cholestasis	O
)	O
serum	O
carbohydrate	O
antigen	O
19.9	O
levels	O
,	O
14	O
(	O
54	O
%	O
)	O
had	O
KRAS2	O
mutations	O
.	O
The	O
combination	O
of	O
KRAS2	O
and	O
carbohydrate	O
antigen	O
19.9	O
gave	O
a	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
predictive	O
values	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
of	O
98	O
,	O
77	O
,	O
87	O
and	O
96	O
%	O
,	O
respectively	O
.	O
Detection	O
of	O
KRAS2	O
mutations	O
in	O
circulating	O
deoxyribo	O
nucleic	O
acid	O
has	O
a	O
low	O
sensitivity	O
but	O
a	O
specificity	O
about	O
90	O
%	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
It	O
seems	O
particularly	O
useful	O
when	O
serum	O
carbohydrate	O
antigen	O
19.9	O
levels	O
are	O
normal	O
or	O
inconclusive	O
.	O
A	O
combined	O
normal	O
serum	O
carbohydrate	O
antigen	O
19.9	O
and	O
absence	O
of	O
circulating	O
KRAS2	O
mutations	O
makes	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
extremely	O
unlikely	O
.	O
PMID	O
:	O
12189555	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
2001	O
Nov;23(	O
4	O
)	O
:	O
356-63	O
Usefulness	O
of	O
supernatant	O
of	O
pancreatic	O
juice	O
for	O
genetic	O
analysis	O
of	O
K-ras	O
in	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Ha	O
A	O
,	O
Watanabe	O
H,	O
Yamaguchi	O
Y	O
,	O
Ohtsubo	O
K,	O
Wang	O
Y	O
,	O
Motoo	O
Y	O
,	O
Okai	O
T	O
,	O
Wakabayahi	O
T	O
,	O
Sawabu	O
N	O
.	O
Department	O
of	O
Internal	O
Medicine	O
and	O
Medical	O
Oncology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
4-86	O
,	O
Yoneizumi	O
,	O
Kanazawa	O
921	O
-8044	O
,	O
Japan	O
.	O
AIMS	O
:	O
To	O
ascertain	O
whether	O
analysis	O
of	O
K-ras	O
mutations	O
at	O
codon	O
12	O
(	O
KRM	O
)	O
in	O
the	O
supernatant	O
of	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
is	O
more	O
useful	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
(	O
PCa	B-malignancy-type
)	O
than	O
that	O
in	O
sediment	O
,	O
the	O
authors	O
analyzed	O
KRM	O
in	O
DNA	O
extract	O
from	O
not	O
only	O
the	O
sediment	O
but	O
also	O
the	O
supernatant	O
of	O
PPJ	O
and	O
compared	O
the	O
results	O
.	O
METHODOLOGY	O
:	O
PPJ	O
was	O
collected	O
endoscopically	O
from	O
19	O
patients	O
with	O
PCa	B-malignancy-type
and	O
25	O
patients	O
with	O
chronic	O
pancreatitis	O
(	O
CP	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
the	O
supernatant	O
and	O
the	O
sediment	O
of	O
PPJ	O
.	O
Mutant	O
allele	O
-	O
specific	O
amplification	O
(	O
MASA	O
)	O
was	O
performed	O
for	O
KRM	O
analysis	O
with	O
the	O
DNA	O
extracts	O
from	O
these	O
samples	O
.	O
RESULTS	O
:	O
The	O
incidence	O
of	O
KRM	O
in	O
the	O
supernatant	O
of	O
PPJ	O
was	O
89	O
%	O
(	O
17	O
of	O
19	O
)	O
in	O
patients	O
with	O
PCa	B-malignancy-type
and	O
28	O
%	O
(	O
7	O
of	O
25	O
)	O
in	O
patients	O
with	O
CP	O
,	O
whereas	O
that	O
in	O
the	O
sediment	O
was	O
79	O
%	O
(	O
15	O
of	O
19	O
)	O
in	O
patients	O
with	O
PCa	B-malignancy-type
and	O
20	O
%	O
(	O
5	O
of	O
25	O
)	O
in	O
patients	O
with	O
CP	O
.	O
Although	O
there	O
was	O
no	O
significant	O
difference	O
in	O
KRM	O
incidence	O
between	O
supernatant	O
and	O
sediment	O
,	O
the	O
positive	O
rate	O
of	O
KRM	O
was	O
higher	O
in	O
the	O
former	O
.	O
Additionally	O
,	O
with	O
regard	O
to	O
the	O
PCa	B-malignancy-type
cases	O
,	O
KRM	O
were	O
found	O
in	O
the	O
supernatant	O
alone	O
in	O
four	O
cases	O
and	O
in	O
the	O
sediment	O
alone	O
in	O
two	O
cases	O
.	O
Consequently	O
,	O
by	O
a	O
combination	O
assay	O
,	O
all	O
of	O
the	O
patients	O
with	O
PCa	B-malignancy-type
showed	O
KRM	O
in	O
either	O
the	O
supernatant	O
or	O
sediment	O
of	O
PPJ	O
.	O
Although	O
there	O
was	O
no	O
relation	O
between	O
the	O
incidence	O
of	O
KRM	O
in	O
PPJ	O
and	O
the	O
location	O
and	O
size	O
of	O
tumor	O
,	O
and	O
clinical	O
stage	O
of	O
carcinoma	B-malignancy-type
in	O
the	O
patients	O
with	O
PCa	B-malignancy-type
,	O
two	O
patients	O
with	O
clinical	O
stage	O
I	O
disease	O
showed	O
KRM	O
in	O
the	O
supernatant	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
positive	O
rate	O
of	O
KRM	O
in	O
the	O
supernatant	O
is	O
not	O
lower	O
than	O
that	O
in	O
the	O
sediment	O
,	O
and	O
simultaneous	O
analysis	O
of	O
KRM	O
in	O
the	O
supernatant	O
and	O
sediment	O
of	O
PPJ	O
enhances	O
the	O
genetic	O
diagnosis	O
of	O
PCa	B-malignancy-type
.	O
PMID	O
:	O
11668203	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
2001	O
Sep;127	O
(	O
9	O
)	O
:	O
577	O
-	O
81	O
Mutation	O
and	O
overexpression	O
of	O
the	O
beta-catenin	O
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
primary	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
among	O
Chinese	O
people	O
.	O
Cui	O
J,	O
Zhou	O
X	O
,	O
Liu	O
Y	O
,	O
Tang	O
Z	O
.	O
Department	O
of	O
Food	O
Science	O
and	O
Human	O
Nutrition	O
,	O
Michigan	O
State	O
University	O
,	O
East	O
Lansing	O
48824	O
,	O
USA	O
.	O
cuij@msu.edu	O
AIM	O
:	O
To	O
study	O
the	O
role	O
of	O
beta-catenin	O
gene	O
mutation	O
and	O
expression	O
in	O
hepatocellular	O
carcinogenesis	O
.	O
METHOD	O
:	O
Thirty-four	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
specimens	O
and	O
adjacent	O
para	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
tissues	I-malignancy-type
,	O
and	O
four	O
normal	O
liver	O
tissues	O
were	O
analyzed	O
.	O
Subcellular	O
distribution	O
of	O
beta-catenin	O
was	O
examined	O
by	O
immunohistochemistry	O
staining	O
.	O
Mutation	O
and	O
semiquantitative	O
expression	O
of	O
beta-catenin	O
gene	O
exon	O
3	O
mRNA	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
-	O
SSCP	O
and	O
in	O
situ	O
hybridization	O
.	O
RESULT	O
:	O
Immunohistochemistry	O
showed	O
that	O
all	O
normal	O
liver	O
tissues	O
and	O
para	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
tissues	I-malignancy-type
examined	O
showed	O
membranous	O
-	O
type	O
staining	O
for	O
beta-catenin	O
protein	O
,	O
frequently	O
with	O
weak	O
expression	O
in	O
the	O
cytoplasm	O
,	O
but	O
no	O
beta-catenin	O
accumulation	O
in	O
nuclei	O
was	O
found	O
;	O
while	O
in	O
liver	B-malignancy-type
cancer	I-malignancy-type
,	O
21	O
cases	O
(	O
61.8	O
%	O
)	O
of	O
HCC	B-malignancy-type
examined	O
showed	O
accumulated	O
type	O
in	O
cytoplasms	O
or	O
nuclei	O
.	O
On	O
SSCP	O
,	O
15	O
cases	O
(	O
44.1	O
%	O
)	O
of	O
HCC	B-malignancy-type
altogether	O
displayed	O
three	O
kinds	O
of	O
characteristic	O
mutational	O
mobility	O
shifts	O
.	O
No	O
abnormal	O
shifting	O
bands	O
were	O
found	O
in	O
tissues	O
from	O
normal	O
liver	O
or	O
para	O
-	O
cancerous	O
area	O
.	O
The	O
beta-catenin	O
gene	O
exon	O
3	O
mRNA	O
expression	O
index	O
of	O
34	O
HCCs	B-malignancy-type
was	O
higher	O
than	O
that	O
of	O
para	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
tissue	I-malignancy-type
and	O
normal	O
liver	O
tissue	O
.	O
Using	O
in	O
situ	O
hybridization	O
,	O
the	O
signal	O
corresponding	O
to	O
beta-catenin	O
gene	O
exon	O
3	O
mRNA	O
was	O
particularly	O
strong	O
in	O
cytoplasm	O
of	O
HCC	B-malignancy-type
when	O
compared	O
with	O
those	O
of	O
paracancerous	B-malignancy-type
tissues	I-malignancy-type
and	O
normal	O
liver	O
tissues	O
.	O
CONCLUSION	O
:	O
beta-catenin	O
gene	O
mutation	O
and	O
overexpression	O
may	O
have	O
a	O
critical	O
role	O
in	O
malignant	O
progression	O
of	O
hepatic	O
carcinogenesis	O
among	O
Chinese	O
people	O
.	O
PMID	O
:	O
11570580	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
2001	O
Aug;114(	O
2	O
)	O
:	O
362-4	O
Analysis	O
of	O
FGFR3	O
gene	O
mutations	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
patients	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
Intini	O
D	O
,	O
Baldini	O
L,	O
Fabris	O
S	O
,	O
Lombardi	O
L,	O
Ciceri	O
G	O
,	O
Maiolo	O
AT	O
,	O
Neri	O
A	O
.	O
Servizio	O
Ematologia	O
,	O
Dipartimento	O
di	O
Scienze	O
Mediche	O
,	O
Universita	O
di	O
Milano	O
,	O
Ospedale	O
Maggiore	O
di	O
Milano	O
,	O
IRCCS	O
,	O
Milano	O
,	O
Italy	O
.	O
The	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
leads	O
to	O
an	O
apparent	O
deregulation	O
of	O
the	O
FGFR3	O
and	O
WHSC1	O
/	O
MMSET	O
genes	O
.	O
FGFR3	O
mutations	O
,	O
known	O
to	O
be	O
associated	O
with	O
genetic	O
skeletal	O
disorders	O
,	O
have	O
also	O
been	O
identified	O
in	O
a	O
few	O
cases	O
of	O
MM	B-malignancy-type
(	O
mainly	O
cell	O
lines	O
)	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
We	O
investigated	O
FGFR3	O
mutations	O
in	O
a	O
series	O
of	O
53	O
MM	B-malignancy-type
cases	O
;	O
11	O
cases	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
and	O
FGFR3	O
overexpression	O
were	O
analysed	O
using	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
while	O
the	O
remaining	O
cases	O
were	O
studied	O
at	O
DNA	O
level	O
.	O
The	O
Arg	O
248	O
Cys	O
mutation	O
,	O
which	O
is	O
associated	O
with	O
some	O
lethal	O
forms	O
of	O
skeletal	O
disorders	O
,	O
was	O
found	O
in	O
one	O
case	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
FGFR3	O
mutations	O
occur	O
in	O
only	O
a	O
small	O
fraction	O
of	O
MM	B-malignancy-type
cases	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
PMID	O
:	O
11529856	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
2001	O
Sep	O
1;98(	O
5	O
)	O
:1555	O
-60	O
Detection	O
of	O
N-Ras	O
codon	O
61	O
mutations	O
in	O
subpopulations	O
of	O
tumor	O
cells	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
at	O
presentation	O
.	O
Kalakonda	O
N	O
,	O
Rothwell	O
DG	O
,	O
Scarffe	O
JH	O
,	O
Norton	O
JD.	O
CRC	O
Gene	O
Regulation	O
Group	O
,	O
Paterson	O
Institute	O
for	O
Cancer	O
Research	O
,	O
and	O
CRC	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Christie	O
Hospital	O
NHS	O
Trust	O
,	O
Manchester	O
,	O
United	O
Kingdom	O
.	O
Activating	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
of	O
the	O
K-ras	O
and	O
N-ras	O
genes	O
have	O
been	O
reported	O
to	O
occur	O
in	O
up	O
to	O
40	O
%	O
of	O
patients	O
with	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
at	O
presentation	O
.	O
In	O
a	O
study	O
of	O
34	O
presentation	O
myeloma	B-malignancy-type
cases	O
using	O
a	O
sensitive	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
strategy	O
on	O
enriched	O
tumor	O
cell	O
populations	O
,	O
the	O
present	O
study	O
detected	O
N-ras	O
codon	O
61	O
mutation	O
-	O
positive	O
cells	O
in	O
all	O
patients	O
.	O
Quantitative	O
plaque	O
hybridization	O
using	O
allele	O
-	O
specific	O
oligonucleotide	O
probes	O
showed	O
that	O
in	O
the	O
majority	O
of	O
patients	O
,	O
ras	O
mutation	O
-	O
positive	O
cells	O
comprise	O
only	O
a	O
subpopulation	O
of	O
the	O
total	O
malignant	O
plasma	O
cell	O
compartment	O
(	O
range	O
,	O
12	O
%	O
-	O
100	O
%	O
)	O
.	O
Using	O
clonospecific	O
point	O
mutations	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
BCL6	O
gene	O
to	O
quantitate	O
clonal	O
B	O
cells	O
in	O
FACS	O
-	O
sorted	O
bone	O
marrow	O
populations	O
from	O
2	O
patients	O
,	O
the	O
representation	O
of	O
ras	O
mutation	O
-	O
positive	O
cells	O
was	O
independent	O
of	O
immunophenotype	O
.	O
These	O
observations	O
imply	O
that	O
mutational	O
activation	O
of	O
N-ras	O
codon	O
61	O
is	O
a	O
mandatory	O
event	O
in	O
the	O
pathogenesis	O
of	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
;	O
such	O
mutations	O
provide	O
a	O
marker	O
of	O
intraclonal	O
heterogeneity	O
that	O
may	O
originate	O
at	O
an	O
earlier	O
ontologic	O
stage	O
than	O
immunophenotypic	O
diversification	O
of	O
the	O
malignant	O
B	O
cell	O
clone	O
.	O
PMID	O
:	O
11520807	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
2001	O
Sep;82	O
(	O
3	O
)	O
:	O
563-7	O
Carcinosarcoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
:	O
immunohistochemical	O
and	O
genetic	O
analysis	O
of	O
clonality	O
of	O
one	O
case	O
.	O
Watanabe	O
M,	O
Shimizu	O
K,	O
Kato	O
H,	O
Imai	O
H,	O
Nakano	O
H,	O
Sugawa	O
M,	O
Shiraishi	O
T.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
2-174	O
Edobashi	O
,	O
Tsu	O
,	O
Mie	O
514	O
-8507	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Carcinosarcomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
are	O
characterized	O
by	O
admixtures	O
of	O
malignant	O
epithelial	O
and	O
stromal	O
cells	O
,	O
and	O
their	O
histogenesis	O
remains	O
controversial	O
.	O
CASE	O
:	O
An	O
operated	O
case	O
of	O
carcinosarcoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
in	O
a	O
49	O
-	O
year	O
-	O
old	O
woman	O
is	O
reported	O
with	O
clonal	O
analysis	O
.	O
The	O
tumor	O
was	O
composed	O
of	O
carcinomatous	O
,	O
sarcomatous	O
,	O
and	O
transitional	O
elements	O
in	O
the	O
frontal	O
wall	O
of	O
the	O
uterine	O
body	O
and	O
therefore	O
was	O
diagnosed	O
as	O
a	O
carcinosarcoma	B-malignancy-type
.	O
On	O
immunohistochemical	O
analysis	O
,	O
the	O
sarcomatous	O
component	O
proved	O
negative	O
for	O
epithelial	O
membrane	O
antigen	O
and	O
keratin	O
while	O
both	O
components	O
were	O
positive	O
for	O
vimentin	O
.	O
Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
showed	O
the	O
same	O
pattern	O
throughout	O
and	O
additionally	O
,	O
the	O
same	O
K-ras	O
and	O
p53	O
mutations	O
were	O
homogeneously	O
detected	O
.	O
Microsatellite	O
instability	O
analysis	O
showed	O
loss	O
of	O
heterozygosity	O
at	O
D5S346	O
in	O
the	O
sarcomatous	O
but	O
not	O
the	O
carcinomatous	O
component	O
.	O
CONCLUSIONS	O
:	O
This	O
tumor	O
appears	O
monoclonal	O
in	O
line	O
with	O
the	O
combination	O
tumor	O
theory	O
,	O
with	O
late	O
divergence	O
in	O
genetic	O
alteration	O
in	O
the	O
sarcomatous	O
elements	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11520156	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Aug	O
25;9	O
3	O
(	O
4	O
)	O
:	O
269	O
-	O
75	O
Fine	O
-	O
needle	O
aspiration	O
biopsy	O
diagnosis	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
using	O
morphology	O
,	O
immunocytochemistry	O
,	O
and	O
mutational	O
analysis	O
of	O
c-kit	O
.	O
Rader	O
AE	O
,	O
Avery	O
A	O
,	O
Wait	O
CL	O
,	O
McGreevey	O
LS	O
,	O
Faigel	O
D	O
,	O
Heinrich	O
MC	O
.	O
Department	O
of	O
Pathology	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
Oregon	O
97201-3098	O
,	O
USA	O
.	O
radera@ohsu.edu	O
BACKGROUND	O
:	O
Differentiating	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
from	O
other	O
intramural	B-malignancy-type
mesenchymal	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
GI	I-malignancy-type
tract	I-malignancy-type
on	O
fine	O
-	O
needle	O
aspiration	O
biopsies	O
(	O
FNABs	O
)	O
is	O
difficult	O
.	O
Recent	O
studies	O
have	O
shown	O
that	O
GISTs	B-malignancy-type
are	O
immunophenotypically	O
and	O
genetically	O
distinct	O
.	O
GISTs	B-malignancy-type
exhibit	O
consistent	O
immunohistochemical	O
expression	O
of	O
CD-117	O
(	O
KIT	O
)	O
and	O
often	O
express	O
activating	O
mutations	O
of	O
this	O
protooncogene	O
.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
employ	O
immunocytochemistry	O
and	O
mutational	O
analysis	O
of	O
the	O
c-kit	O
gene	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
GISTs	B-malignancy-type
on	O
FNAB	O
.	O
METHODS	O
:	O
Five	O
endoscopic	O
ultrasound	O
-	O
guided	O
FNABs	O
of	O
gastrointestinal	B-malignancy-type
spindle	I-malignancy-type
cell	I-malignancy-type
neoplasms	I-malignancy-type
performed	O
at	O
the	O
Veterans	O
Affairs	O
Medical	O
Center	O
(	O
VAMC	O
)	O
in	O
Portland	O
,	O
Oregon	O
,	O
from	O
1998	O
-	O
1999	O
were	O
reviewed	O
.	O
A	O
panel	O
of	O
immunocytochemical	O
stains	O
was	O
performed	O
on	O
each	O
cellblock	O
including	O
CD-117	O
(	O
KIT	O
)	O
,	O
smooth	O
muscle	O
actin	O
(	O
SMA	O
)	O
,	O
desmin	O
,	O
S-100	O
,	O
and	O
CD34	O
.	O
Genomic	O
DNA	O
(	O
gDNA	O
)	O
was	O
extracted	O
,	O
and	O
amplification	O
of	O
exons	O
9	O
,	O
11	O
,	O
13	O
and	O
17	O
of	O
c-kit	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
on	O
CD-117	O
(	O
KIT	O
)	O
and	O
CD34	O
positive	O
cases	O
.	O
Direct	O
sequencing	O
of	O
amplicons	O
identified	O
the	O
mutations	O
.	O
RESULTS	O
:	O
Five	O
patients	O
were	O
diagnosed	O
with	O
GISTs	B-malignancy-type
based	O
on	O
morphology	O
and	O
immunocytochemical	O
positivity	O
for	O
CD-117	O
and	O
CD34	O
.	O
PCR	O
analysis	O
of	O
c-kit	O
exon	O
11	O
revealed	O
three	O
cases	O
with	O
novel	O
-	O
sized	O
PCR	O
bands	O
in	O
addition	O
to	O
the	O
expected	O
wild	O
-	O
type	O
-	O
sized	O
PCR	O
product	O
.	O
Amplicons	O
from	O
these	O
cases	O
contained	O
an	O
in	O
-	O
frame	O
deletion	O
mutation	O
.	O
One	O
of	O
the	O
two	O
cases	O
with	O
wild	O
-	O
type	O
-	O
;	O
sized	O
exon	O
11	O
amplicons	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
point	O
mutation	O
producing	O
an	O
amino	O
acid	O
substitution	O
(	O
W	O
557	O
R	O
)	O
.	O
No	O
mutations	O
in	O
exon	O
9	O
,	O
11	O
,	O
13	O
,	O
or	O
17	O
of	O
c-kit	O
were	O
found	O
in	O
the	O
remaining	O
case	O
.	O
CONCLUSIONS	O
:	O
Ancillary	O
techniques	O
such	O
as	O
immunocytochemistry	O
and	O
c-kit	O
gene	O
mutational	O
analysis	O
may	O
aid	O
in	O
the	O
diagnosis	O
of	O
GISTs	B-malignancy-type
on	O
FNABs	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11507701	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Carcinogenesis	O
2001	O
Aug;22(	O
8	O
)	O
:	O
1327	O
-	O
30	O
Glutathione	O
S-transferase	O
mu1	O
null	O
genotype	O
is	O
associated	O
with	O
K-ras	O
gene	O
mutation	O
in	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
among	O
smokers	O
.	O
Matsuzoe	O
D	O
,	O
Hideshima	O
T	O
,	O
Iwasaki	O
A	O
,	O
Yoneda	O
S	O
,	O
Kawahara	O
K,	O
Shirakusa	O
T	O
,	O
Kimura	O
A	O
.	O
Second	O
Department	O
of	O
Surgery	O
,	O
School	O
of	O
Medicine	O
,	O
Fukuoka	O
University	O
,	O
7-45-1	O
Nanakuma	O
,	O
Jonanku	O
,	O
Fukuoka	O
814	O
-0180	O
,	O
Japan	O
.	O
Glutathione	O
S-transferase	O
mu1	O
(	O
GSTM1	O
)	O
plays	O
a	O
role	O
in	O
the	O
detoxification	O
of	O
benzo[a]pyrene	O
(	O
BP	O
)	O
diol	O
epoxide	O
in	O
tobacco	O
smoke	O
.	O
Individuals	O
who	O
genetically	O
lack	O
the	O
GSTM1	O
gene	O
are	O
likely	O
to	O
have	O
an	O
increased	O
risk	O
of	O
smoking	O
-	O
related	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
however	O
,	O
the	O
target	O
oncogenes	O
for	O
mutation	O
are	O
unknown	O
.	O
To	O
investigate	O
the	O
relation	O
between	O
GSTM1	O
genotype	O
and	O
K-ras	O
gene	O
mutation	O
we	O
examined	O
193	O
adenocarcinomas	B-malignancy-type
and	O
119	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
lung	I-malignancy-type
.	O
The	O
GSTM1	O
genotype	O
was	O
determined	O
by	O
PCR	O
and	O
K-ras	O
gene	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
were	O
detected	O
by	O
dot	O
-	O
blot	O
hybridization	O
analysis	O
using	O
sequence	O
-	O
specific	O
oligonucleotide	O
probes	O
.	O
K-ras	O
gene	O
mutations	O
were	O
found	O
in	O
29	O
of	O
312	O
(	O
9.3	O
%	O
)	O
tumors	O
.	O
All	O
of	O
them	O
arose	O
in	O
patients	O
who	O
were	O
habitual	O
smokers	O
.	O
Mutations	O
of	O
the	O
K-ras	O
gene	O
were	O
detected	O
in	O
6	O
of	O
100	O
(	O
6	O
%	O
)	O
and	O
15	O
of	O
93	O
(	O
16.1	O
%	O
)	O
adenocarcinoma	B-malignancy-type
cases	O
with	O
the	O
GSTM1	O
(	O
+	O
)	O
and	O
GSTM1	O
(	O
-	O
)	O
genotypes	O
,	O
respectively	O
,	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
cause	O
of	O
K-ras	O
gene	O
mutation	O
in	O
smokers	O
with	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
may	O
be	O
in	O
part	O
an	O
accumulation	O
of	O
BP	O
diol	O
epoxide	O
which	O
is	O
not	O
well	O
detoxified	O
in	O
individuals	O
with	O
the	O
GSTM1	O
null	O
genotype	O
.	O
PMID	O
:	O
11470766	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2001	O
Jul	O
6;8	O
5	O
(	O
1	O
)	O
:64	O
-	O
8	O
Mutations	O
of	O
the	O
beta	O
-	O
and	O
gamma	O
-	O
catenin	O
genes	O
are	O
uncommon	O
in	O
human	O
lung	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
kidney	B-malignancy-type
,	O
cervical	B-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Ueda	O
M,	O
Gemmill	O
RM	O
,	O
West	O
J,	O
Winn	O
R	O
,	O
Sugita	O
M,	O
Tanaka	O
N	O
,	O
Ueki	O
M,	O
Drabkin	O
HA	O
.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Osaka	O
Medical	O
College	O
,	O
2-7	O
Daigakumachi	O
,	O
Takatsuki	O
,	O
Osaka	O
569	O
-	O
8686	O
,	O
Japan	O
.	O
Beta-catenin	O
forms	O
complexes	O
with	O
Tcf	O
and	O
Lef-1	O
and	O
functions	O
as	O
a	O
transcriptional	O
activator	O
in	O
the	O
Wnt	O
signalling	O
pathway	O
.	O
Although	O
recent	O
investigations	O
have	O
been	O
focused	O
on	O
the	O
role	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
human	O
tumorigenesis	O
,	O
there	O
have	O
been	O
very	O
few	O
reports	O
on	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
a	O
variety	O
of	O
tumour	O
types	O
.	O
Using	O
PCR	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
,	O
we	O
examined	O
93	O
lung	B-malignancy-type
,	O
9	O
breast	B-malignancy-type
,	O
6	O
kidney	B-malignancy-type
,	O
19	O
cervical	B-malignancy-type
and	O
7	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
for	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
In	O
addition	O
,	O
we	O
tested	O
these	O
same	O
samples	O
for	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
region	O
of	O
the	O
gamma-catenin	O
gene	O
.	O
Mutational	O
analysis	O
for	O
the	O
entire	O
coding	O
region	O
of	O
beta-catenin	O
cDNA	O
was	O
also	O
undertaken	O
in	O
20	O
lung	B-malignancy-type
,	O
9	O
breast	B-malignancy-type
,	O
5	O
kidney	B-malignancy-type
and	O
6	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
.	O
Deletion	O
of	O
most	O
beta-catenin	O
coding	O
exons	O
was	O
confirmed	O
in	O
line	O
NCI-H28	O
(	O
lung	B-malignancy-type
mesothelioma	I-malignancy-type
)	O
and	O
a	O
silent	O
mutation	O
at	O
codon	O
214	O
in	O
exon	O
5	O
was	O
found	O
in	O
HeLa	O
(	O
cervical	B-malignancy-type
adenocarcinoma	I-malignancy-type
)	O
.	O
A	O
missense	O
mutation	O
at	O
codon	O
19	O
and	O
a	O
silent	O
mutation	O
at	O
codon	O
28	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
region	O
of	O
the	O
gamma-catenin	O
gene	O
were	O
found	O
in	O
H1726	O
(	O
squamous	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
)	O
and	O
H1048	O
(	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
)	O
,	O
respectively	O
.	O
Neither	O
deletions	O
nor	O
mutations	O
of	O
these	O
genes	O
were	O
detected	O
in	O
the	O
other	O
cell	O
lines	O
examined	O
.	O
These	O
results	O
suggest	O
that	O
beta	O
-	O
and	O
gamma	O
-	O
catenins	O
are	O
infrequent	O
mutational	O
targets	O
during	O
development	O
of	O
human	O
lung	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
kidney	B-malignancy-type
,	O
cervical	B-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11437403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2001	O
Jun	O
14;20(	O
27	O
)	O
:	O
3553	O
-	O
62	O
Deregulated	O
FGFR3	O
mutants	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
cell	O
lines	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
:	O
comparative	O
analysis	O
of	O
Y	O
373	O
C	O
,	O
K	O
650	O
E	O
and	O
the	O
novel	O
G	O
384	O
D	O
mutations	O
.	O
Ronchetti	O
D	O
,	O
Greco	O
A	O
,	O
Compasso	O
S	O
,	O
Colombo	O
G	O
,	O
Dell'Era	O
P,	O
Otsuki	O
T	O
,	O
Lombardi	O
L,	O
Neri	O
A	O
.	O
Hematology	O
Service	O
,	O
Department	O
of	O
Medical	O
Sciences	O
,	O
Universita	O
degli	O
Studi	O
,	O
Ospedale	O
Maggiore	O
IRCCS	O
,	O
Milan	O
,	O
Italy	O
.	O
The	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
chromosomal	O
translocation	O
occurs	O
in	O
approximately	O
20	O
%	O
of	O
multiple	B-malignancy-type
myelomas	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
and	O
leads	O
to	O
the	O
apparent	O
deregulation	O
of	O
two	O
genes	O
located	O
on	O
4p16.3	O
:	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
and	O
the	O
putative	O
transcription	O
factor	O
WHSC1	O
/	O
MMSET	O
.	O
Interestingly	O
,	O
FGFR3	O
mutations	O
known	O
to	O
be	O
associated	O
with	O
autosomal	O
dominant	O
human	O
skeletal	O
disorders	O
have	O
also	O
been	O
found	O
in	O
some	O
MM	B-malignancy-type
cell	O
lines	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
but	O
their	O
pathogenetic	O
role	O
in	O
MM	B-malignancy-type
is	O
still	O
controversial	O
.	O
Since	O
cell	O
lines	O
may	O
represent	O
useful	O
models	O
for	O
investigating	O
the	O
effects	O
of	O
deregulated	O
FGFR3	O
mutants	O
in	O
MM	B-malignancy-type
,	O
we	O
analysed	O
the	O
expression	O
,	O
activation	O
,	O
signaling	O
pathways	O
and	O
oncogenic	O
potential	O
of	O
three	O
mutants	O
identified	O
so	O
far	O
:	O
the	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
in	O
the	O
KMS-11	O
and	O
OPM-2	O
cell	O
lines	O
respectively	O
,	O
and	O
the	O
novel	O
G	O
384	O
D	O
mutation	O
here	O
identified	O
in	O
the	O
KMS-18	O
cell	O
line	O
.	O
All	O
of	O
the	O
cell	O
lines	O
present	O
a	O
heterozygous	O
FGFR3	O
gene	O
mutation	O
and	O
transcribe	O
the	O
mutated	O
allele	O
;	O
unlike	O
KMS-11	O
and	O
OPM-2	O
(	O
which	O
express	O
the	O
IIIc	O
isoform	O
)	O
,	O
the	O
KMS-18	O
cell	O
line	O
expresses	O
prevalently	O
the	O
isoform	O
IIIb	O
.	O
We	O
demonstrated	O
that	O
,	O
under	O
serum	O
-	O
starved	O
conditions	O
,	O
KMS-11	O
and	O
OPM-2	O
cells	O
express	O
appreciable	O
levels	O
of	O
phosphorylated	O
FGFR3	O
mutants	O
indicating	O
a	O
constitutive	O
activation	O
of	O
the	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
receptors	O
;	O
the	O
addition	O
of	O
the	O
aFGF	O
ligand	O
further	O
increased	O
the	O
level	O
of	O
receptor	O
phosphorylation	O
.	O
Conversely	O
,	O
the	O
FGFR3	O
mutant	O
in	O
KMS-18	O
does	O
not	O
seem	O
to	O
be	O
constitutively	O
activated	O
since	O
it	O
was	O
phosphorylated	O
only	O
in	O
the	O
presence	O
of	O
the	O
ligand	O
.	O
In	O
all	O
three	O
MM	B-malignancy-type
cell	O
lines	O
,	O
ligand	O
-	O
stimulated	O
FGFR3	O
mutants	O
activated	O
the	O
MAP	O
kinase	O
signaling	O
pathway	O
but	O
did	O
not	O
apparently	O
involve	O
either	O
the	O
STAT1	O
or	O
STAT3	O
cascades	O
.	O
However	O
,	O
when	O
transfected	O
in	O
293T	O
cells	O
,	O
G	O
384	O
D	O
,	O
like	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
,	O
was	O
capable	O
of	O
activating	O
MAPK	O
,	O
STAT1	O
and	O
STAT3	O
under	O
serum	O
-	O
starved	O
condition	O
.	O
Finally	O
,	O
a	O
focus	O
formation	O
assay	O
of	O
NIH3T3	O
cells	O
transfected	O
with	O
FGFR3	O
-	O
expressing	O
plasmid	O
vectors	O
showed	O
that	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
(	O
albeit	O
at	O
different	O
levels	O
)	O
but	O
not	O
G	O
384	O
D	O
or	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
can	O
induce	O
transformed	O
foci	O
.	O
Overall	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
FGFR3	O
mutations	O
are	O
graded	O
in	O
terms	O
of	O
their	O
activation	O
capability	O
,	O
thus	O
suggesting	O
that	O
they	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
tumor	O
progression	O
of	O
MM	B-malignancy-type
patients	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
PMID	O
:	O
11429702	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
2001	O
May	O
;113(	O
2	O
)	O
:	O
357	O
-64	O
Mutation	O
analysis	O
of	O
C-KIT	O
in	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
without	I-malignancy-type
mastocytosis	I-malignancy-type
and	O
cases	O
of	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
Fritsche-	O
Polanz	O
R	O
,	O
Jordan	O
JH	O
,	O
Feix	O
A	O
,	O
Sperr	O
WR	O
,	O
Sunder	O
-	O
Plassmann	O
G	O
,	O
Valent	O
P,	O
Fodinger	O
M.	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Division	O
of	O
Endocrinology	O
and	O
Metabolism	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
The	O
proto	O
-	O
oncogene	O
C-KIT	O
encodes	O
a	O
tyrosine	O
kinase	O
receptor	O
that	O
is	O
expressed	O
on	O
mast	O
cells	O
and	O
haematopoietic	O
stem	O
cells	O
and	O
can	O
show	O
somatic	O
mutations	O
in	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Only	O
scattered	O
information	O
is	O
available	O
about	O
mutations	O
in	O
C-KIT	O
in	O
patients	O
with	O
other	O
myeloid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
Moreover	O
,	O
the	O
prevalence	O
of	O
mutations	O
in	O
C-KIT	O
in	O
bone	O
marrow	O
specimens	O
of	O
individuals	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
is	O
largely	O
unknown	O
.	O
Using	O
sequence	O
analysis	O
,	O
we	O
have	O
screened	O
cDNAs	O
of	O
the	O
C-KIT	O
domain	O
encompassing	O
codon	O
510	O
-	O
626	O
and	O
codon	O
763	O
-	O
858	O
in	O
bone	O
marrow	O
(	O
BM	O
)	O
mononuclear	O
cells	O
(	O
MNCs	O
)	O
of	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
n	O
=	O
28	O
)	O
and	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
n	O
=	O
12	O
)	O
for	O
the	O
presence	O
of	O
mutations	O
.	O
Furthermore	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
was	O
applied	O
for	O
identification	O
of	O
the	O
C-KIT	O
2468	O
A	O
-->	O
T	O
and	O
the	O
C-KIT	O
1700	O
T	O
-->	O
G	O
mutation	O
,	O
as	O
well	O
as	O
the	O
C-KIT	O
1642	O
A	O
-->	O
C	O
polymorphism	O
.	O
All	O
11	O
patients	O
with	O
systemic	B-malignancy-type
indolent	I-malignancy-type
mastocytosis	I-malignancy-type
tested	O
positive	O
for	O
C-KIT	O
2468	O
A	O
-->	O
T	O
.	O
In	O
contrast	O
,	O
no	O
mutation	O
was	O
identified	O
in	O
the	O
case	O
of	O
aggressive	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
Among	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
,	O
no	O
patient	O
showed	O
a	O
somatic	O
mutation	O
in	O
C-KIT	O
.	O
The	O
allele	O
frequency	O
for	O
C-KIT	O
1642	O
A	O
-->	O
C	O
among	O
the	O
entire	O
patient	O
population	O
was	O
0.038	O
and	O
was	O
0.125	O
among	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
.	O
Our	O
data	O
demonstrate	O
that	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
without	O
histological	O
or	O
cytological	O
evidence	O
of	O
mastocytosis	B-malignancy-type
do	O
not	O
exhibit	O
somatic	O
mutations	O
in	O
exons	O
10	O
,	O
11	O
,	O
12	O
,	O
16	O
,	O
17	O
and	O
18	O
of	O
C-KIT	O
.	O
In	O
contrast	O
,	O
BM	O
MNCs	O
of	O
patients	O
with	O
systemic	B-malignancy-type
indolent	I-malignancy-type
mastocytosis	I-malignancy-type
were	O
all	O
positive	O
for	O
C-KIT	O
2468	O
A	O
-->	O
T	O
and	O
negative	O
for	O
additional	O
mutations	O
in	O
these	O
exons	O
.	O
The	O
C-KIT	O
1642	O
A	O
-->	O
C	O
polymorphism	O
is	O
not	O
associated	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
or	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
PMID	O
:	O
11380399	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2001	O
Jun	O
15;9	O
2	O
(	O
6	O
)	O
:839	O
-	O
42	O
Cytoplasmic	O
and	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
is	O
rarely	O
caused	O
by	O
CTNNB1	O
exon	O
3	O
mutations	O
in	O
cutaneous	B-malignancy-type
malignant	I-malignancy-type
melanoma	I-malignancy-type
.	O
Omholt	O
K,	O
Platz	O
A	O
,	O
Ringborg	O
U	O
,	O
Hansson	O
J.	O
Cancer	O
Centre	O
Karolinska	O
,	O
Department	O
of	O
Oncology-Pathology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Beta-catenin	O
plays	O
an	O
important	O
role	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
by	O
activating	O
T-cell	O
factor	O
(	O
Tcf	O
)	O
/	O
lymphoid	O
enhancer	O
factor	O
(	O
Lef	O
)	O
-	O
regulated	O
gene	O
transcription	O
.	O
The	O
level	O
of	O
beta-catenin	O
is	O
regulated	O
through	O
GSK-3beta	O
phosphorylation	O
of	O
specific	O
serine	O
and	O
threonine	O
residues	O
,	O
all	O
of	O
which	O
are	O
encoded	O
for	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
.	O
Mutations	O
altering	O
the	O
GSK-3beta	O
phosphorylation	O
sites	O
lead	O
to	O
cellular	O
accumulation	O
of	O
beta-catenin	O
and	O
constitutive	O
transcription	O
of	O
Tcf	O
/	O
Lef	O
target	O
genes	O
.	O
Such	O
mutations	O
have	O
previously	O
been	O
found	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
In	O
our	O
study	O
,	O
primary	O
melanomas	B-malignancy-type
and	O
their	O
corresponding	O
metastases	O
were	O
screened	O
for	O
CTNNB1	O
exon	O
3	O
mutations	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
analysis	O
.	O
One	O
of	O
31	O
primary	O
tumors	O
and	O
1	O
of	O
37	O
metastases	O
,	O
both	O
originating	O
from	O
the	O
same	O
patient	O
,	O
had	O
a	O
TCT	O
to	O
TTT	O
mutation	O
at	O
codon	O
45	O
,	O
changing	O
serine	O
to	O
phenylalanine	O
.	O
Immunohistochemical	O
analysis	O
revealed	O
membranous	O
localization	O
of	O
beta-catenin	O
in	O
a	O
majority	O
of	O
the	O
samples	O
.	O
The	O
mutated	O
primary	O
tumor	O
and	O
metastasis	O
,	O
however	O
,	O
displayed	O
widespread	O
cytoplasmic	O
and	O
nuclear	O
expression	O
of	O
beta-catenin	O
.	O
An	O
additional	O
30	O
%	O
of	O
the	O
primary	O
tumors	O
showed	O
focal	O
cytoplasmic	O
and	O
nuclear	O
staining	O
.	O
Thus	O
,	O
beta-catenin	O
exon	O
3	O
mutations	O
are	O
rare	O
in	O
primary	O
as	O
well	O
as	O
metastatic	O
melanomas	B-malignancy-type
and	O
do	O
not	O
explain	O
the	O
abnormal	O
cytoplasmic	O
and	O
nuclear	O
localization	O
of	O
beta-catenin	O
found	O
in	O
a	O
relatively	O
large	O
fraction	O
of	O
primary	O
melanomas	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11351304	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
2001	O
Apr;	O
7(	O
4	O
)	O
:	O
901	O
-	O
8	O
Frequent	O
deletions	O
and	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
associated	O
with	O
overexpression	O
of	O
cyclin	O
D1	O
and	O
fibronectin	O
and	O
poorly	O
differentiated	O
histology	O
in	O
childhood	O
hepatoblastoma	B-malignancy-type
.	O
Takayasu	O
H,	O
Horie	O
H,	O
Hiyama	O
E	O
,	O
Matsunaga	O
T	O
,	O
Hayashi	O
Y	O
,	O
Watanabe	O
Y	O
,	O
Suita	O
S	O
,	O
Kaneko	O
M,	O
Sasaki	O
F	O
,	O
Hashizume	O
K,	O
Ozaki	O
T	O
,	O
Furuuchi	O
K,	O
Tada	O
M,	O
Ohnuma	O
N	O
,	O
Nakagawara	O
A	O
.	O
Division	O
of	O
Biochemistry	O
,	O
Chiba	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Chiba	O
260	O
-	O
8717	O
,	O
Japan	O
.	O
Hepatoblastoma	B-malignancy-type
(	O
HBL	B-malignancy-type
)	O
is	O
the	O
most	O
common	O
malignant	O
liver	B-malignancy-type
tumor	I-malignancy-type
in	O
young	O
children	O
.	O
Recent	O
reports	O
have	O
shown	O
that	O
the	O
beta-catenin	O
gene	O
was	O
frequently	O
mutated	O
or	O
deleted	O
in	O
HBLS	B-malignancy-type
:	O
To	O
elucidate	O
the	O
role	O
of	O
beta-catenin	O
abnormalities	O
in	O
HBLs	B-malignancy-type
,	O
we	O
searched	O
for	O
mutations	O
of	O
beta-catenin	O
and	O
APC	O
as	O
well	O
as	O
expression	O
of	O
the	O
target	O
genes	O
,	O
cyclin	O
D1	O
,	O
c-myc	O
,	O
and	O
fibronectin	O
,	O
in	O
68	O
primary	O
HBLS	B-malignancy-type
:	O
The	O
mutation	O
analysis	O
revealed	O
that	O
44	O
(	O
65	O
%	O
)	O
tumors	O
carried	O
missense	O
mutations	O
or	O
deletions	O
of	O
beta-catenin	O
,	O
all	O
of	O
which	O
were	O
somatic	O
and	O
targeted	O
to	O
the	O
exon	O
3	O
encoding	O
the	O
amino	O
acid	O
residues	O
involved	O
in	O
its	O
degradation	O
.	O
However	O
,	O
no	O
loss	O
of	O
function	O
mutation	O
of	O
the	O
APC	O
gene	O
was	O
detected	O
by	O
the	O
yeast	O
functional	O
assay	O
.	O
Of	O
interest	O
,	O
beta-catenin	O
mutation	O
was	O
significantly	O
correlated	O
with	O
overexpression	O
of	O
the	O
target	O
genes	O
,	O
cyclin	O
D1	O
and	O
fibronectin	O
,	O
but	O
not	O
with	O
that	O
of	O
c-myc	O
in	O
HBLs	B-malignancy-type
as	O
measured	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
.	O
The	O
immunohistochemical	O
studies	O
in	O
15	O
HBLs	B-malignancy-type
demonstrated	O
that	O
the	O
nuclear	O
/	O
cytoplasmic	O
accumulation	O
of	O
beta-catenin	O
was	O
positive	O
in	O
13	O
tumors	O
,	O
9	O
of	O
which	O
had	O
the	O
deletion	O
or	O
mutation	O
of	O
the	O
gene	O
.	O
The	O
significant	O
correlation	O
between	O
the	O
beta-catenin	O
gene	O
abnormality	O
and	O
the	O
positive	O
staining	O
of	O
cyclin	O
D1	O
was	O
also	O
confirmed	O
.	O
Furthermore	O
,	O
the	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
strongly	O
associated	O
with	O
the	O
poorly	O
differentiated	O
tumor	O
cell	O
components	O
as	O
well	O
as	O
with	O
the	O
positive	O
staining	O
of	O
cyclin	O
D1	O
within	O
the	O
tumor	O
.	O
Thus	O
,	O
our	O
present	O
results	O
suggested	O
that	O
the	O
gain	O
of	O
function	O
mutation	O
of	O
beta-catenin	O
played	O
a	O
crucial	O
role	O
in	O
the	O
malignant	O
progression	O
of	O
HBL	B-malignancy-type
in	O
vivo	O
.	O
PMID	O
:	O
11309340	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2001	O
May	O
20;95	O
(	O
3	O
)	O
:162-7	O
Determination	O
of	O
microsatellite	O
instability	O
,	O
p53	O
and	O
K-RAS	O
mutations	O
in	O
hepatic	O
metastases	O
from	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
:	O
relationship	O
with	O
response	O
to	O
5-fluorouracil	O
and	O
survival	O
.	O
Rosty	O
C	O
,	O
Chazal	O
M,	O
Etienne	O
MC	O
,	O
Letoublon	O
C	O
,	O
Bourgeon	O
A	O
,	O
Delpero	O
JR	O
,	O
Pezet	O
D	O
,	O
Beaune	O
P,	O
Laurent	O
-	O
Puig	O
P,	O
Milano	O
G.	O
Laboratoire	O
de	O
Toxicologie	O
Moleculaire	O
,	O
INSERM	O
U490	O
,	O
Faculte	O
de	O
Medecine	O
des	O
Saints	O
-	O
Peres	O
,	O
45	O
Rue	O
des	O
Saints	O
-	O
Peres	O
,	O
75270	O
Paris	O
Cedex	O
06	O
,	O
France	O
.	O
In	O
vitro	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
high	O
-	O
frequency	O
microsatellite	O
instability	O
(	O
MSI-H	O
)	O
phenotype	O
,	O
p53	O
and	O
K-ras	O
mutations	O
might	O
influence	O
the	O
response	O
to	O
chemotherapy	O
in	O
a	O
variety	O
of	O
tumors	O
,	O
including	O
primary	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
(	O
CRC	B-malignancy-type
)	O
.	O
Unresectable	O
hepatic	O
metastases	O
from	O
CRC	B-malignancy-type
are	O
commonly	O
treated	O
with	O
5-fluorouracil	O
(	O
5FU	O
)	O
and	O
folinic	O
acid	O
.	O
Since	O
several	O
new	O
active	O
drugs	O
are	O
now	O
used	O
for	O
treating	O
CRC	B-malignancy-type
,	O
molecular	O
determinants	O
predictive	O
to	O
response	O
to	O
5FU	O
would	O
thus	O
be	O
crucial	O
for	O
optimizing	O
indications	O
of	O
chemotherapy	O
to	O
those	O
patients	O
.	O
MSI-H	O
phenotype	O
,	O
p53	O
and	O
K-ras	O
status	O
were	O
characterized	O
in	O
a	O
prospective	O
study	O
of	O
56	O
patients	O
with	O
CRC	B-malignancy-type
metastatic	O
to	O
the	O
liver	O
and	O
treated	O
with	O
5FU	O
-	O
based	O
chemotherapy	O
.	O
The	O
objective	O
response	O
rate	O
after	O
a	O
3	O
-	O
month	O
treatment	O
was	O
32.1	O
%	O
.	O
The	O
prevalence	O
of	O
p53	O
mutations	O
,	O
K-ras	O
mutations	O
and	O
MSI-H	O
phenotype	O
was	O
62.5	O
%	O
,	O
30.3	O
%	O
and	O
1.8	O
%	O
,	O
respectively	O
.	O
No	O
significant	O
association	O
was	O
found	O
between	O
response	O
to	O
chemotherapy	O
and	O
p53	O
mutations	O
(	O
78	O
%	O
mutated	O
tumors	O
in	O
responders	O
vs.	O
55	O
%	O
in	O
nonresponders	O
;	O
p	O
=	O
0.10	O
)	O
and	O
K-ras	O
mutations	O
(	O
39	O
%	O
mutated	O
tumors	O
in	O
responders	O
vs.	O
26	O
%	O
in	O
nonresponders	O
;	O
p	O
=	O
0.34	O
)	O
.	O
Survival	O
was	O
longer	O
for	O
patients	O
with	O
p53	O
-	O
mutated	O
metastases	O
than	O
for	O
patients	O
with	O
unresected	O
wild	O
-	O
type	O
p53	O
metastases	O
(	O
median	O
survival	O
15	O
months	O
vs.	O
17	O
months	O
;	O
p	O
=	O
0.06	O
)	O
.	O
The	O
determination	O
of	O
the	O
MSI-H	O
phenotype	O
,	O
p53	O
and	O
K-ras	O
status	O
in	O
hepatic	O
metastases	O
from	O
CRC	B-malignancy-type
does	O
not	O
discriminate	O
a	O
group	O
of	O
patients	O
that	O
should	O
preferentially	O
benefit	O
from	O
5FU	O
-	O
based	O
chemotherapy	O
.	O
The	O
prognosis	O
of	O
patients	O
with	O
treated	O
liver	O
metastases	O
is	O
better	O
when	O
p53	O
is	O
mutated	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11307149	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Mar	O
15	O
;61	O
(	O
6	O
)	O
:	O
267	O
6-83	O
Genetic	O
pathways	O
in	O
the	O
evolution	O
of	O
morphologically	O
distinct	O
colorectal	O
neoplasms	O
.	O
Yashiro	O
M,	O
Carethers	O
JM	O
,	O
Laghi	O
L,	O
Saito	O
K,	O
Slezak	O
P,	O
Jaramillo	O
E	O
,	O
Rubio	O
C	O
,	O
Koizumi	O
K,	O
Hirakawa	O
K,	O
Boland	O
CR	O
.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
California	O
,	O
San	O
Diego	O
,	O
La	O
Jolla	O
92093	O
-0688	O
,	O
USA	O
.	O
Colorectal	B-malignancy-type
adenomas	I-malignancy-type
can	O
be	O
morphologically	O
classified	O
as	O
exophytic	O
or	O
flat	O
.	O
Polypoid	B-malignancy-type
cancers	I-malignancy-type
and	O
cancers	O
arising	O
de	O
novo	O
(	O
ie.	O
,	O
without	O
any	O
adenomatous	O
component	O
)	O
might	O
be	O
the	O
results	O
of	O
genetic	O
progression	O
from	O
exophytic	O
and	O
flat	O
adenomas	B-malignancy-type
,	O
respectively	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
94	O
morphologically	O
distinct	O
neoplastic	O
specimens	O
for	O
mutations	O
in	O
K-RAS	O
and	O
analyzed	O
10	O
microsatellite	O
loci	O
tightly	O
linked	O
to	O
the	O
tumor	O
suppressor	O
genes	O
APC	O
,	O
p53	O
,	O
DCC	O
/	O
SMAD4	O
,	O
hMSH2	O
,	O
and	O
hMLH1	O
.	O
K-RAS	O
mutations	O
were	O
significantly	O
associated	O
with	O
exophytic	B-malignancy-type
adenomas	I-malignancy-type
[	O
11	O
of	O
21	O
(	O
52	O
%	O
)	O
]	O
compared	O
to	O
flat	B-malignancy-type
adenomas	I-malignancy-type
[	O
2	O
of	O
13	O
(	O
15	O
%	O
)	O
,	O
P	O
<	O
0.03	O
]	O
and	O
polypoid	B-malignancy-type
cancers	I-malignancy-type
[	O
17	O
of	O
25	O
(	O
68	O
%	O
)	O
]	O
compared	O
to	O
cancers	O
arising	O
de	O
novo	O
[	O
7	O
of	O
25	O
(	O
28	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O
Two	O
polypoid	B-malignancy-type
cancer	I-malignancy-type
cases	O
demonstrated	O
three	O
and	O
four	O
different	O
K-RAS	O
mutations	O
,	O
respectively	O
,	O
suggesting	O
multiple	O
areas	O
of	O
clonal	O
expansion	O
.	O
Cancers	O
arising	O
de	O
novo	O
were	O
significantly	O
associated	O
with	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
chromosome	O
3p	O
compared	O
to	O
pol	B-malignancy-type
ypoid	I-malignancy-type
cancers	I-malignancy-type
[	O
6	O
of	O
18	O
(	O
33	O
%	O
)	O
versus	O
1	O
of	O
20	O
(	O
5	O
%	O
)	O
,	O
P	O
<	O
0.03	O
]	O
,	O
whereas	O
the	O
prevalence	O
of	O
LOH	O
at	O
chromosomes	O
2p	O
,	O
5q	O
,	O
17p	O
,	O
and	O
18q	O
and	O
microsatellite	O
instability	O
were	O
not	O
different	O
between	O
the	O
groups	O
.	O
For	O
all	O
cancers	O
,	O
LOH	O
at	O
chromosomes	O
17p	O
and	O
18q	O
occurred	O
in	O
47	O
and	O
51	O
%	O
,	O
respectively	O
.	O
However	O
,	O
LOH	O
at	O
17p	O
and	O
18q	O
occurred	O
in	O
0	O
and	O
16	O
%	O
of	O
benign	O
lesions	O
,	O
respectively	O
,	O
suggesting	O
their	O
role	O
in	O
malignant	O
transformation	O
.	O
There	O
was	O
no	O
difference	O
in	O
LOH	O
at	O
chromosomes	O
17p	O
and	O
18q	O
between	O
exophytic	O
and	O
flat	O
lesions	O
.	O
These	O
findings	O
suggest	O
that	O
(a)	O
mutant	O
K-RAS	O
is	O
associated	O
with	O
the	O
exophytic	O
growth	O
of	O
colonic	B-malignancy-type
neoplasms	I-malignancy-type
,	O
and	O
that	O
(b)	O
some	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
arising	O
de	O
novo	O
lose	O
chromosome	O
3p	O
during	O
their	O
evolution	O
,	O
which	O
is	O
not	O
seen	O
in	O
polypoid	B-malignancy-type
cancers	I-malignancy-type
.	O
Half	O
of	O
all	O
cancers	O
lose	O
chromosomes	O
17p	O
and	O
18q	O
at	O
or	O
near	O
the	O
malignant	O
transition	O
of	O
benign	O
lesions	O
as	O
reported	O
previously	O
,	O
irrespective	O
of	O
morphology	O
.	O
There	O
may	O
be	O
more	O
than	O
one	O
genetic	O
avenue	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
formation	O
,	O
and	O
this	O
correlates	O
with	O
the	O
morphological	O
characteristics	O
.	O
PMID	O
:	O
11289147	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hepatol	O
Res	O
2001	O
May	O
1;20(	O
1	O
)	O
:	O
39	O
-	O
51	O
Frequent	O
beta-catenin	O
aberration	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Fujie	O
H,	O
Moriya	O
K,	O
Shintani	O
Y	O
,	O
Tsutsumi	O
T	O
,	O
Takayama	O
T	O
,	O
Makuuchi	O
M,	O
Kimura	O
S	O
,	O
Koike	O
K.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Graduate	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
7-	O
3-1	O
Hongo	O
,	O
Bunkyo-ku	O
,	O
113-8655	O
,	O
Tokyo	O
,	O
Japan	O
Recently	O
,	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
have	O
been	O
reported	O
:	O
approximately	O
20	O
%	O
of	O
HCCs	B-malignancy-type
had	O
activating	O
mutations	O
at	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
within	O
the	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
However	O
,	O
changes	O
in	O
the	O
level	O
of	O
the	O
beta-catenin	O
protein	O
in	O
HCC	B-malignancy-type
have	O
not	O
been	O
well	O
studied	O
.	O
We	O
examined	O
,	O
by	O
Western	O
blotting	O
,	O
the	O
expression	O
level	O
of	O
the	O
beta-catenin	O
protein	O
in	O
cancerous	O
tissues	O
in	O
comparison	O
with	O
that	O
in	O
adjacent	O
non	O
-	O
cancerous	O
tissues	O
obtained	O
from	O
32	O
cases	O
of	O
HCC	B-malignancy-type
with	O
hepatitis	O
C	O
.	O
An	O
increase	O
in	O
the	O
beta-catenin	O
protein	O
level	O
in	O
cancerous	O
tissue	O
compared	O
to	O
that	O
in	O
adjacent	O
non	O
-	O
cancerous	O
tissue	O
was	O
found	O
in	O
15	O
(	O
46.9	O
%	O
)	O
of	O
32	O
cases	O
of	O
HCC	B-malignancy-type
.	O
Mutation	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
found	O
in	O
six	O
(	O
18.8	O
%	O
)	O
of	O
the	O
32	O
cases	O
,	O
in	O
five	O
of	O
which	O
the	O
beta-catenin	O
protein	O
level	O
was	O
increased	O
.	O
In	O
total	O
,	O
beta-catenin	O
aberration	O
was	O
found	O
in	O
16	O
(	O
50.0	O
%	O
)	O
of	O
32	O
cases	O
of	O
HCC	B-malignancy-type
.	O
It	O
should	O
be	O
noted	O
that	O
beta-catenin	O
aberration	O
was	O
also	O
found	O
in	O
early	O
HCC	B-malignancy-type
although	O
it	O
was	O
observed	O
chiefly	O
in	O
advanced	O
HCCs	B-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
beta-catenin	O
aberration	O
is	O
a	O
frequent	O
event	O
in	O
the	O
development	O
of	O
HCC	B-malignancy-type
and	O
may	O
facilitate	O
the	O
development	O
of	O
HCC	B-malignancy-type
in	O
the	O
course	O
of	O
chronic	O
hepatitis	O
.	O
PMID	O
:	O
11282485	O
[	O
PubMed	O
-	O
as	O
supplied	O
by	O
publisher	O
]	O

J	O
Pathol	O
2001	O
Apr;19	O
3	O
(	O
4	O
)	O
:	O
483	O
-	O
90	O
Nuclear	O
localization	O
of	O
beta-catenin	O
is	O
an	O
important	O
prognostic	O
factor	O
in	O
hepatoblastoma	B-malignancy-type
.	O
Park	O
WS	O
,	O
Oh	O
RR	O
,	O
Park	O
JY	O
,	O
Kim	O
PJ	O
,	O
Shin	O
MS	O
,	O
Lee	O
JH	O
,	O
Kim	O
HS	O
,	O
Lee	O
SH	O
,	O
Kim	O
SY	O
,	O
Park	O
YG	O
,	O
An	O
WG	O
,	O
Kim	O
HS	O
,	O
Jang	O
JJ	O
,	O
Yoo	O
NJ	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
College	O
of	O
Medicine	O
,	O
The	O
Catholic	O
University	O
of	O
Korea	O
,	O
505	O
Banpo	O
-dong	O
,	O
Sacho-	O
gu	O
,	O
Seoul	O
137	O
-	O
701	O
,	O
Korea	O
.	O
In	O
this	O
study	O
,	O
mutational	O
and	O
immunohistochemical	O
analyses	O
of	O
beta-catenin	O
were	O
performed	O
in	O
30	O
hepatoblastomas	B-malignancy-type
,	O
to	O
assess	O
the	O
prevalence	O
of	O
alterations	O
of	O
the	O
Wnt	O
pathway	O
with	O
respect	O
to	O
clinicopathological	O
parameters	O
and	O
survival	O
.	O
Four	O
missense	O
mutations	O
of	O
beta-catenin	O
(	O
13.3	O
%	O
)	O
were	O
detected	O
and	O
there	O
was	O
strong	O
immunoreactivity	O
for	O
beta-catenin	O
in	O
the	O
cytoplasm	O
and/or	O
the	O
nucleus	O
in	O
97	O
%	O
of	O
hepatoblastomas	O
.	O
Nuclear	O
and	O
cytoplasmic	O
staining	O
was	O
demonstrated	O
in	O
19	O
of	O
30	O
tumours	O
(	O
63	O
%	O
)	O
,	O
while	O
ten	O
revealed	O
only	O
cytoplasmic	O
staining	O
.	O
Statistically	O
,	O
this	O
nuclear	O
beta-catenin	O
staining	O
was	O
significantly	O
higher	O
in	O
the	O
embryonal	O
(	O
Fisher	O
exact	O
test	O
;	O
p	O
=	O
0.00393	O
)	O
or	O
undifferentiated	O
type	O
(	O
p	O
=	O
0.00156	O
)	O
of	O
hepatoblastoma	B-malignancy-type
than	O
in	O
the	O
fetal	O
type	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
clinical	O
stages	O
I	O
and	O
II	O
and	O
clinical	O
stages	O
III	O
and	O
IV	O
(	O
p	O
=	O
0.175	O
)	O
.	O
Cumulative	O
survival	O
curves	O
showed	O
that	O
nuclear	O
beta-catenin	O
staining	O
(	O
generalized	O
Wilcoxon	O
test	O
;	O
p	O
=	O
0.0088	O
)	O
,	O
undifferentiated	O
histological	O
type	O
(	O
p	O
=	O
0.0305	O
)	O
,	O
and	O
clinical	O
stages	O
III	O
and	O
IV	O
(	O
p	O
=	O
0.0107	O
)	O
were	O
significantly	O
correlated	O
with	O
shorter	O
survival	O
time	O
in	O
these	O
patients	O
.	O
Moreover	O
,	O
Cox	O
multivariate	O
analysis	O
provides	O
evidence	O
that	O
nuclear	O
beta-catenin	O
staining	O
is	O
the	O
most	O
important	O
prognostic	O
factor	O
for	O
survival	O
(	O
p	O
=	O
0.0090	O
)	O
.	O
It	O
is	O
therefore	O
concluded	O
that	O
immunohistochemical	O
analysis	O
of	O
beta-catenin	O
might	O
be	O
a	O
useful	O
clinical	O
tool	O
for	O
estimating	O
the	O
prognosis	O
for	O
patients	O
with	O
hepatoblastoma	B-malignancy-type
.	O
Copyright	O
2000	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
PMID	O
:	O
11276007	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Pathol	O
Lab	O
Med	O
2001	O
Mar;125(	O
3	O
)	O
:	O
347	O
-52	O
Novel	O
method	O
for	O
simultaneous	O
analysis	O
of	O
p53	O
and	O
K-ras	O
mutations	O
and	O
p53	O
protein	O
expression	O
in	O
single	O
histologic	O
sections	O
.	O
Yamashita	O
K,	O
Yoshida	O
T	O
,	O
Shinoda	O
H,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
East	O
Hospital	O
,	O
Sagamihara	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Abnormal	O
protein	O
expression	O
and	O
gene	O
mutation	O
should	O
be	O
examined	O
on	O
exactly	O
identified	O
lesions	O
.	O
To	O
perform	O
simultaneous	O
analyses	O
of	O
oncogene	O
or	O
tumor	O
suppressor	O
gene	O
mutations	O
and	O
related	O
protein	O
expression	O
in	O
single	O
histologic	O
sections	O
,	O
we	O
have	O
developed	O
a	O
novel	O
method	O
using	O
an	O
antigen	O
-	O
retrieval	O
solution	O
for	O
a	O
polymerase	O
chain	O
reaction	O
template	O
before	O
immunohistochemical	O
staining	O
.	O
METHODS	O
:	O
Using	O
20	O
cases	O
of	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
carcinoma	I-malignancy-type
,	O
several	O
kinds	O
of	O
antigen	O
-	O
retrieval	O
solutions	O
were	O
tested	O
after	O
heating	O
rehydrated	O
,	O
4	O
-	O
microm	O
-	O
thick	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
histologic	O
sections	O
at	O
96	O
degrees	O
C	O
for	O
20	O
minutes	O
.	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
was	O
conducted	O
for	O
p53	O
(	O
exons	O
5	O
through	O
9	O
)	O
and	O
K-ras	O
(	O
exons	O
1	O
and	O
2	O
)	O
,	O
and	O
the	O
histologic	O
sections	O
were	O
then	O
immunostained	O
with	O
monoclonal	O
antibody	O
against	O
p53	O
.	O
RESULTS	O
:	O
DNA	O
analysis	O
of	O
antigen	O
-	O
retrieval	O
solutions	O
was	O
possible	O
in	O
all	O
20	O
cases	O
and	O
revealed	O
completely	O
consistent	O
results	O
(	O
100	O
%	O
)	O
with	O
fresh	O
cancer	O
tissue	O
and	O
microdissected	O
cancer	O
tissue	O
of	O
paraffin	O
-	O
embedded	O
histologic	O
sections	O
.	O
With	O
this	O
method	O
,	O
K-ras	O
mutations	O
were	O
positive	O
in	O
10	O
of	O
20	O
cases	O
(	O
exon	O
1	O
in	O
9	O
cases	O
and	O
exon	O
2	O
in	O
1	O
case	O
)	O
and	O
p53	O
mutations	O
were	O
positive	O
in	O
9	O
of	O
20	O
cases	O
(	O
exon	O
5	O
in	O
4	O
cases	O
,	O
exon	O
6	O
in	O
1	O
,	O
exon	O
7	O
in	O
3	O
,	O
and	O
exon	O
8	O
in	O
1	O
case	O
)	O
,	O
with	O
8	O
of	O
the	O
9	O
p53	O
mutation	O
cases	O
showing	O
diffuse	O
p53	O
protein	O
expression	O
on	O
immunostaining	O
.	O
Base	O
alterations	O
of	O
all	O
abnormal	O
conformers	O
were	O
confirmed	O
with	O
direct	O
sequencing	O
.	O
For	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
sodium	O
citrate	O
buffer	O
(	O
pH	O
6.0	O
)	O
was	O
found	O
to	O
be	O
the	O
optimal	O
antigen	O
-	O
retrieval	O
solution	O
.	O
CONCLUSIONS	O
:	O
This	O
newly	O
developed	O
method	O
can	O
be	O
used	O
for	O
routine	O
immunostaining	O
and	O
genetic	O
analysis	O
with	O
single	O
histologic	O
sections	O
.	O
PMID	O
:	O
11231481	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Jan	O
1;61	O
(	O
1	O
)	O
:19	O
-22	O
More	O
frequent	O
beta-catenin	O
exon	O
3	O
mutations	O
in	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
than	O
in	O
carcinomas	B-malignancy-type
indicate	O
different	O
lineages	O
.	O
Yanagisawa	O
N	O
,	O
Mikami	O
T	O
,	O
Saegusa	O
M,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
Sagamihara	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
To	O
clarify	O
the	O
contribution	O
of	O
beta-catenin	O
,	O
which	O
is	O
related	O
to	O
cell	O
adhesion	O
and	O
intranuclear	O
transcription	O
,	O
to	O
gallbladder	O
carcinogenesis	O
,	O
we	O
investigated	O
its	O
expression	O
using	O
immunohistochemistry	O
,	O
and	O
beta-catenin	O
exon	O
3	O
mutations	O
by	O
DNA	O
direct	O
sequencing	O
,	O
in	O
18	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
and	O
82	O
adenocarcinomas	B-malignancy-type
.	O
Membranous	O
expression	O
was	O
significantly	O
lower	O
in	O
moderately	O
and	O
poorly	O
differentiated	O
than	O
in	O
well	O
-	O
differentiated	O
adenocarcinoma	B-malignancy-type
cases	O
(	O
P	O
<	O
0.001	O
)	O
.	O
The	O
gallbladder	O
adenomas	O
showed	O
significantly	O
stronger	O
expression	O
in	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
than	O
carcinomas	B-malignancy-type
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
,	O
and	O
exon	O
3	O
mutations	O
were	O
observed	O
in	O
62.5	O
%	O
(	O
10	O
of	O
16	O
)	O
of	O
adenomas	B-malignancy-type
,	O
but	O
only	O
4.8	O
%	O
(	O
1	O
of	O
21	O
)	O
of	O
carcinomas	B-malignancy-type
.	O
With	O
beta-catenin	O
as	O
a	O
molecular	O
marker	O
,	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
can	O
be	O
considered	O
to	O
be	O
a	O
minor	O
pathway	O
in	O
gallbladder	O
carcinogenesis	O
.	O
PMID	O
:	O
11196159	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatobiliary	O
Pancreat	O
Surg	O
2000	O
;	O
7	O
(	O
4	O
)	O
:	O
426-31	O
p53	O
overexpression	O
and	O
K-ras	O
gene	O
mutations	O
in	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
-	O
associated	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
.	O
Ahrendt	O
SA	O
,	O
Rashid	O
A	O
,	O
Chow	O
JT	O
,	O
Eisenberger	O
CF	O
,	O
Pitt	O
HA	O
,	O
Sidransky	O
D	O
.	O
Department	O
of	O
Surgery	O
,	O
Medical	O
College	O
of	O
Wisconsin	O
,	O
9200	O
West	O
Wisconsin	O
Avenue	O
,	O
Milwaukee	O
,	O
WI	O
53226	O
,	O
USA	O
.	O
Cholangiocarcinoma	B-malignancy-type
occurs	O
frequently	O
in	O
patients	O
with	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
(	O
PSC	B-malignancy-type
)	O
.	O
We	O
evaluated	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
p53	O
protein	O
overexpression	O
and	O
K-ras	O
gene	O
mutations	O
in	O
patients	O
with	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
and	O
PSC	B-malignancy-type
.	O
p53	O
protein	O
expression	O
was	O
determined	O
in	O
specimens	O
from	O
12	O
patients	O
with	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
,	O
using	O
the	O
antibody	O
,	O
D07	O
.	O
K-ras	O
mutations	O
were	O
detected	O
using	O
DNA	O
sequencing	O
and	O
a	O
mutation	O
ligation	O
assay	O
.	O
Accumulation	O
of	O
p53	O
protein	O
was	O
detected	O
in	O
6	O
of	O
12	O
tumors	O
(	O
50	O
%	O
)	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
4	O
of	O
12	O
tumors	O
(	O
33	O
%	O
)	O
.	O
Overall	O
survival	O
in	O
patients	O
with	O
p53	O
-	O
negative	O
tumors	O
was	O
significantly	O
longer	O
(	O
P	O
<	O
0.05	O
)	O
than	O
that	O
in	O
patients	O
with	O
p53	O
-	O
positive	O
(	O
mutant	O
)	O
tumors	O
.	O
Similarly	O
,	O
overall	O
survival	O
was	O
significantly	O
longer	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
absence	O
of	O
a	O
K-ras	O
mutation	O
than	O
in	O
patients	O
with	O
a	O
tumor	O
containing	O
a	O
K-ras	O
mutation	O
.	O
Mean	O
interval	O
from	O
the	O
time	O
of	O
diagnosis	O
of	O
PSC	O
until	O
the	O
diagnosis	O
of	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
was	O
significantly	O
shorter	O
(	O
P	O
<	O
0.05	O
)	O
in	O
patients	O
with	O
p53	O
overexpression	O
than	O
in	O
those	O
patients	O
without	O
p53	O
overexpression	O
(	O
2	O
versus	O
47	O
months	O
)	O
.	O
p53	O
overexpression	O
and	O
K-ras	O
mutations	O
occur	O
commonly	O
in	O
patients	O
with	O
PSC	B-malignancy-type
and	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
and	O
are	O
associated	O
with	O
a	O
shortened	O
survival	O
.	O
Patients	O
with	O
longstanding	O
PSC	B-malignancy-type
are	O
less	O
likely	O
to	O
have	O
these	O
genetic	O
alterations	O
and	O
may	O
have	O
a	O
better	O
prognosis	O
.	O
PMID	O
:	O
11180865	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
2001	O
Mar	O
;	O
30	O
(	O
3	O
)	O
:	O
316-21	O
Constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
by	O
CTNNB1	O
(	O
beta-catenin	O
)	O
mutations	O
in	O
a	O
subset	O
of	O
human	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Sunaga	O
N	O
,	O
Kohno	O
T	O
,	O
Kolligs	O
FT	O
,	O
Fearon	O
ER	O
,	O
Saito	O
R	O
,	O
Yokota	O
J	O
.	O
Biology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
as	O
a	O
result	O
of	O
genetic	O
alterations	O
of	O
APC	O
,	O
AXIN1	O
,	O
and	O
CTNNB1	O
has	O
been	O
found	O
in	O
various	O
human	O
cancers	O
,	O
including	O
those	O
of	O
the	O
colon	B-malignancy-type
,	O
liver	B-malignancy-type
,	O
endometrium	B-malignancy-type
,	O
ovary	B-malignancy-type
,	O
prostate	B-malignancy-type
,	O
and	O
stomach	B-malignancy-type
.	O
To	O
investigate	O
the	O
pathogenetic	O
significance	O
of	O
constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
in	O
human	O
lung	O
carcinogenesis	O
,	O
CTNNB1	O
alterations	O
in	O
exon	O
3	O
,	O
a	O
region	O
known	O
to	O
represent	O
a	O
mutation	O
hot	O
spot	O
,	O
were	O
screened	O
in	O
46	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
and	O
47	O
primary	O
lung	B-malignancy-type
cancers	I-malignancy-type
.	O
Missense	O
mutations	O
causing	O
substitutions	O
of	O
Ser	O
/	O
Thr	O
residues	O
critical	O
for	O
regulation	O
by	O
GSK	O
-	O
3beta	O
were	O
detected	O
in	O
one	O
(	O
2	O
%	O
)	O
of	O
the	O
cell	O
lines	O
,	O
A427	O
,	O
and	O
two	O
(	O
4	O
%	O
)	O
of	O
the	O
surgical	O
specimens	O
.	O
The	O
three	O
lung	B-malignancy-type
cancers	I-malignancy-type
with	O
CTNNB1	O
mutations	O
were	O
adenocarcinomas	B-malignancy-type
.	O
To	O
explore	O
the	O
prevalence	O
of	O
constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
assessed	O
15	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
representing	O
major	O
histological	O
subtypes	O
of	O
lung	B-malignancy-type
cancers	I-malignancy-type
for	O
constitutive	O
Tcf	O
transcriptional	O
activity	O
(	O
CTTA	O
)	O
.	O
CTTA	O
was	O
observed	O
only	O
in	O
the	O
A427	O
adenocarcinoma	B-malignancy-type
cell	O
line	O
,	O
but	O
not	O
in	O
the	O
remaining	O
14	O
cell	O
lines	O
.	O
The	O
data	O
indicate	O
that	O
constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
caused	O
by	O
CTNNB1	O
mutation	O
is	O
involved	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
a	O
subset	O
of	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
,	O
preferentially	O
in	O
adenocarcinoma	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O
PMID	O
:	O
11170292	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gynecol	O
Oncol	O
2001	O
Feb	O
;	O
80	O
(	O
2	O
)	O
:	O
201	O
-	O
6	O
K-ras	O
mutations	O
in	O
Mullerian	B-malignancy-type
inclusion	I-malignancy-type
cysts	I-malignancy-type
associated	O
with	O
serous	B-malignancy-type
borderline	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ovary	I-malignancy-type
.	O
Alvarez	O
AA	O
,	O
Moore	O
WF	O
,	O
Robboy	O
SJ	O
,	O
Bentley	O
RC	O
,	O
Gumbs	O
C	O
,	O
Futreal	O
PA	O
,	O
Berchuck	O
A	O
.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
/	O
Division	O
of	O
Gynecologic	O
Oncology	O
,	O
Duke	O
University	O
Medical	O
Center	O
,	O
Durham	O
,	O
North	O
Carolina	O
27710	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
Mullerian	B-malignancy-type
inclusion	I-malignancy-type
cysts	I-malignancy-type
(	O
MIC	B-malignancy-type
)	O
are	O
small	O
benign	O
appearing	O
glands	O
that	O
are	O
occasionally	O
noted	O
in	O
lymph	O
nodes	O
and	O
peritoneal	O
biopsies	O
.	O
They	O
occur	O
most	O
frequently	O
in	O
women	O
with	O
serous	B-malignancy-type
ovarian	I-malignancy-type
tumors	I-malignancy-type
,	O
with	O
borderline	O
tumors	O
(	O
SBOT	B-malignancy-type
)	O
having	O
a	O
higher	O
incidence	O
than	O
invasive	O
cancers	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
MIC	B-malignancy-type
and	O
SBOT	B-malignancy-type
have	O
identical	O
K-ras	O
mutations	O
,	O
which	O
would	O
suggest	O
that	O
they	O
are	O
related	O
.	O
Methods	O
.	O
Six	O
patients	O
in	O
whom	O
adequate	O
tissue	O
was	O
available	O
from	O
SBOT	B-malignancy-type
,	O
MIC	B-malignancy-type
,	O
and	O
normal	O
tissue	O
were	O
identified	O
from	O
a	O
consecutive	O
series	O
of	O
patients	O
with	O
SBOT	B-malignancy-type
who	O
underwent	O
lymph	O
node	O
sampling	O
from	O
1992	O
to	O
1997	O
at	O
Duke	O
University	O
Medical	O
Center	O
.	O
DNA	O
extraction	O
was	O
performed	O
using	O
laser	O
capture	O
microdissection	O
.	O
Exon	O
1	O
of	O
the	O
K-ras	O
gene	O
was	O
amplified	O
using	O
PCR	O
and	O
subjected	O
to	O
single	O
-	O
strand	O
conformation	O
analysis	O
to	O
screen	O
for	O
mutations	O
.	O
Shifted	O
bands	O
were	O
sequenced	O
to	O
confirm	O
the	O
presence	O
of	O
mutations	O
.	O
RESULTS	O
:	O
Mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
were	O
found	O
in	O
three	O
of	O
six	O
(	O
50	O
%	O
)	O
SBOT	B-malignancy-type
.	O
In	O
two	O
of	O
these	O
three	O
cases	O
,	O
the	O
identical	O
mutation	O
was	O
found	O
in	O
the	O
SBOT	B-malignancy-type
and	O
the	O
MIC	B-malignancy-type
(	O
gly	O
to	O
val	O
in	O
both	O
cases	O
)	O
,	O
but	O
not	O
in	O
the	O
corresponding	O
normal	O
DNA	O
.	O
In	O
one	O
case	O
,	O
a	O
mutation	O
was	O
seen	O
in	O
the	O
ovarian	B-malignancy-type
tumor	I-malignancy-type
(	O
gly	O
to	O
asp	O
)	O
,	O
but	O
not	O
in	O
the	O
corresponding	O
MIC	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
Mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
are	O
a	O
hallmark	O
of	O
serous	B-malignancy-type
borderline	I-malignancy-type
tumors	I-malignancy-type
.	O
The	O
presence	O
of	O
identical	O
K-ras	O
mutations	O
in	O
some	O
SBOT	B-malignancy-type
and	O
their	O
associated	O
MIC	B-malignancy-type
suggests	O
that	O
they	O
are	O
related	O
processes	O
.	O
Both	O
may	O
arise	O
due	O
to	O
a	O
field	O
effect	O
,	O
or	O
alternatively	O
some	O
MIC	B-malignancy-type
may	O
represent	O
metastases	O
from	O
the	O
primary	O
ovarian	B-malignancy-type
tumor	I-malignancy-type
.	O
PMID	O
:	O
11161860	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Arch	O
Surg	O
2000	O
Dec	O
;	O
135	O
(	O
12	O
)	O
:	O
1450	O
-	O
5	O
K-ras	O
point	O
mutation	O
in	O
the	O
nerve	O
plexuses	O
around	O
the	O
superior	O
mesenteric	O
artery	O
in	O
resectable	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
head	I-malignancy-type
:	O
distribution	O
pattern	O
and	O
related	O
factors	O
.	O
Ohigashi	O
H	O
,	O
Ishikawa	O
O	O
,	O
Sasaki	O
Y	O
,	O
Yamada	O
T	O
,	O
Furukawa	O
H	O
,	O
Imaoka	O
S	O
,	O
Kasugai	O
T	O
,	O
Ishiguro	O
S	O
,	O
Ueda	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nakamura	O
Y	O
.	O
MD	O
,	O
Department	O
of	O
Surgery	O
,	O
Osaka	O
Medical	O
Center	O
for	O
Cancer	O
and	O
Cardiovascular	O
Diseases	O
,	O
3-Nakamichi	O
,	O
1-chome	O
,	O
Higashinari-ku	O
,	O
Osaka	O
,	O
537	O
-	O
8511	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
is	O
likely	O
to	O
spread	O
into	O
the	O
nerve	O
plexuses	O
around	O
the	O
superior	O
mesenteric	O
artery	O
(	O
SMA	O
)	O
at	O
a	O
microscopic	O
level	O
.	O
Since	O
there	O
has	O
been	O
no	O
detailed	O
report	O
on	O
how	O
minute	O
cancer	O
invasion	O
is	O
distributed	O
among	O
the	O
peri	O
-	O
SMA	O
plexuses	O
or	O
which	O
cases	O
are	O
more	O
vulnerable	O
to	O
such	O
an	O
event	O
,	O
it	O
has	O
long	O
been	O
controversial	O
how	O
to	O
treat	O
this	O
area	O
when	O
resecting	O
the	O
pancreatic	B-malignancy-type
head	I-malignancy-type
cancer	I-malignancy-type
.	O
HYPOTHESIS	O
:	O
The	O
K-ras	O
mutation	O
assay	O
is	O
more	O
sensitive	O
than	O
the	O
conventional	O
histologic	O
diagnosis	O
in	O
detecting	O
minute	O
cancer	O
invasion	O
around	O
the	O
SMA	O
.	O
DESIGN	O
:	O
Prospective	O
consecutive	O
series	O
.	O
SETTING	O
:	O
Cancer	O
center	O
hospital	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
entire	O
circle	O
of	O
the	O
peri	O
-	O
SMA	O
tissues	O
was	O
obtained	O
from	O
24	O
patients	O
who	O
had	O
received	O
an	O
extended	O
pancreatectomy	O
for	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
head	I-malignancy-type
.	O
They	O
were	O
divided	O
into	O
right	O
and	O
left	O
hemicircular	O
samples	O
(	O
48	O
samples	O
)	O
,	O
and	O
each	O
sample	O
was	O
used	O
for	O
both	O
histologic	O
and	O
genetic	O
diagnoses	O
.	O
Since	O
all	O
patients	O
'	O
primary	O
tumors	O
were	O
positive	O
for	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
,	O
the	O
presence	O
or	O
absence	O
of	O
the	O
mutation	O
was	O
determined	O
for	O
the	O
peri	O
-	O
SMA	O
plexuses	O
using	O
the	O
mutant	O
allele	O
specific	O
amplification	O
method	O
.	O
RESULTS	O
:	O
Compared	O
with	O
results	O
of	O
the	O
histologic	O
examination	O
,	O
the	O
K-ras	O
mutation	O
assay	O
was	O
more	O
sensitive	O
in	O
detecting	O
positive	O
findings	O
in	O
the	O
peri	O
-	O
SMA	O
plexuses	O
(	O
12	O
samples	O
from	O
9	O
patients	O
)	O
.	O
According	O
to	O
the	O
distribution	O
of	O
the	O
K-ras	O
mutation	O
into	O
the	O
right	O
-	O
and	O
left	O
-	O
half	O
samples	O
,	O
24	O
patients	O
were	O
classified	O
into	O
the	O
following	O
4	O
patterns	O
(	O
right	O
/	O
left	O
)	O
:	O
negative	O
/	O
negative	O
in	O
15	O
patients	O
;	O
positive	O
/	O
negative	O
in	O
6	O
patients	O
;	O
positive	O
/	O
positive	O
in	O
3	O
patients	O
;	O
and	O
negative	O
/	O
positive	O
in	O
0	O
patients	O
.	O
In	O
3	O
patients	O
who	O
showed	O
a	O
positive	O
/	O
positive	O
pattern	O
in	O
the	O
genetic	O
diagnosis	O
,	O
their	O
right	O
-	O
half	O
samples	O
included	O
more	O
cancer	O
cells	O
that	O
were	O
detectable	O
by	O
routine	O
microscopy	O
.	O
There	O
was	O
no	O
relation	O
between	O
K-ras	O
mutation	O
and	O
lymphatic	O
invasion	O
,	O
while	O
K-ras	O
mutation	O
was	O
particularly	O
related	O
with	O
the	O
invasion	O
of	O
portal	O
vein	O
(	O
P	O
=	O
.04	O
)	O
and	O
posterior	O
peripancreatic	O
tissues	O
(	O
P	O
=	O
.002	O
)	O
.	O
All	O
3	O
patients	O
with	O
K-ras	O
mutation	O
in	O
bilateral	O
plexuses	O
were	O
classified	O
by	O
the	O
TNM	O
staging	O
system	O
as	O
T4	O
using	O
Union	O
Internationale	O
Contre	O
le	O
Cancer	O
classification	O
.	O
CONCLUSIONS	O
:	O
The	O
K-ras	O
mutation	O
(	O
at	O
codon	O
12	O
)	O
assay	O
indicated	O
a	O
simple	O
and	O
regular	O
pattern	O
of	O
cancer	O
extension	O
into	O
the	O
nerve	O
plexuses	O
around	O
the	O
SMA	O
from	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
head	I-malignancy-type
:	O
(1)	O
The	O
left	O
half	O
of	O
the	O
plexus	O
was	O
unlikely	O
to	O
be	O
involved	O
by	O
cancer	O
in	O
cases	O
in	O
which	O
the	O
right	O
half	O
was	O
intact	O
.	O
(2)	O
Cancer	O
extension	O
into	O
the	O
peri	O
-	O
SMA	O
plexuses	O
occurred	O
after	O
the	O
posterior	O
confine	O
of	O
the	O
pancreas	O
had	O
been	O
involved	O
by	O
direct	O
invasion	O
from	O
the	O
primary	O
pancreatic	B-malignancy-type
tumor	I-malignancy-type
.	O
(3)	O
The	O
left	O
half	O
was	O
not	O
involved	O
in	O
cancerous	B-malignancy-type
tumors	I-malignancy-type
classified	I-malignancy-type
as	I-malignancy-type
T1	I-malignancy-type
to	I-malignancy-type
T3	I-malignancy-type
but	O
was	O
occasionally	O
involved	O
in	O
those	O
classified	O
as	O
T4	B-malignancy-type
tumors	I-malignancy-type
.	O
These	O
data	O
seem	O
to	O
provide	O
a	O
useful	O
indicator	O
of	O
some	O
additional	O
treatments	O
(	O
resection	O
,	O
irradiation	O
,	O
etc	O
)	O
for	O
the	O
peri	O
-	O
SMA	O
region	O
when	O
a	O
locally	O
advanced	O
pancreatic	B-malignancy-type
head	I-malignancy-type
cancer	I-malignancy-type
is	O
treated	O
with	O
a	O
curative	O
intent	O
.	O
PMID	O
:	O
11115351	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2000	O
Nov	O
16	O
;	O
19	O
(	O
48	O
)	O
:	O
5543	O
-	O
6	O
Somatic	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
are	O
uncommon	O
in	O
carcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
cervix	I-malignancy-type
.	O
Wu	O
R	O
,	O
Connolly	O
D	O
,	O
Ngelangel	O
C	O
,	O
Bosch	O
FX	O
,	O
Munoz	O
N	O
,	O
Cho	O
KR	O
.	O
Department	O
of	O
Pathology	O
,	O
The	O
University	O
of	O
Michigan	O
Medical	O
School	O
,	O
Ann	O
Arbor	O
48109	O
,	O
USA	O
.	O
Germline	O
mutations	O
of	O
the	O
gene	O
encoding	O
human	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
have	O
been	O
shown	O
to	O
be	O
responsible	O
for	O
several	O
related	O
autosomal	O
dominant	O
forms	O
of	O
syndromic	O
craniosynostosis	O
and	O
short	O
limb	O
dwarfism	O
.	O
Somatic	O
activating	O
mutations	O
of	O
FGFR3	O
were	O
recently	O
reported	O
to	O
occur	O
in	O
three	O
of	O
12	O
(	O
25	O
%	O
)	O
uterine	B-malignancy-type
cervical	I-malignancy-type
carcinomas	I-malignancy-type
and	O
nine	O
of	O
26	O
(	O
35	O
%	O
)	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
that	O
constitutive	O
activation	O
of	O
FGFR3	O
may	O
be	O
an	O
important	O
mechanism	O
underlying	O
the	O
development	O
and/or	O
progression	O
of	O
these	O
common	O
epithelial	B-malignancy-type
malignancies	I-malignancy-type
.	O
In	O
order	O
to	O
investigate	O
further	O
a	O
possible	O
role	O
for	O
FGFR3	O
mutations	O
in	O
cervical	O
carcinogenesis	O
,	O
we	O
performed	O
sequence	O
-	O
based	O
mutational	O
analysis	O
of	O
FGFR3	O
in	O
51	O
primary	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
and	O
seven	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
-	O
derived	O
cell	O
lines	O
.	O
The	O
regions	O
analysed	O
(	O
exons	O
7	O
,	O
10	O
,	O
13	O
,	O
15	O
,	O
and	O
19	O
)	O
encompassed	O
all	O
previously	O
described	O
FGFR3	O
mutations	O
.	O
A	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
249	O
,	O
predicting	O
a	O
serine	O
to	O
cysteine	O
amino	O
acid	O
substitution	O
(	O
S	O
249	O
C	O
)	O
in	O
the	O
FGFR3	O
extracellular	O
domain	O
,	O
was	O
identified	O
in	O
one	O
primary	O
tumor	O
.	O
Only	O
wild	O
type	O
FGFR3	O
alleles	O
were	O
identified	O
in	O
the	O
remaining	O
tumors	O
and	O
cell	O
lines	O
.	O
The	O
S	O
249	O
C	O
mutation	O
is	O
the	O
only	O
FGFR3	O
mutation	O
described	O
to	O
date	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
.	O
These	O
findings	O
suggest	O
that	O
while	O
activating	O
mutations	O
of	O
FGFR3	O
occur	O
in	O
cervical	B-malignancy-type
cancer	I-malignancy-type
,	O
they	O
may	O
not	O
be	O
as	O
common	O
as	O
initially	O
reported	O
.	O
PMID	O
:	O
11114733	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
2001	O
Jan;30	O
(	O
1	O
)	O
:	O
32-7	O
Frequent	O
activation	O
of	O
the	O
beta-catenin	O
-	O
Tcf	O
signaling	O
pathway	O
in	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
with	O
microsatellite	O
instability	O
.	O
Shitoh	O
K,	O
Furukawa	O
T	O
,	O
Kojima	O
M,	O
Konishi	O
F	O
,	O
Miyaki	O
M,	O
Tsukamoto	O
T	O
,	O
Nagai	O
H.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Tochigi	O
,	O
Japan	O
.	O
kshitoh@jichi.ac.jp	O
It	O
has	O
been	O
reported	O
that	O
wild	O
-	O
type	O
APC	O
protein	O
forms	O
a	O
complex	O
with	O
beta-Catenin	O
and	O
GSK3beta	O
,	O
inducing	O
degradation	O
of	O
beta-Catenin	O
in	O
normal	O
cells	O
.	O
Both	O
beta-Catenin	O
and	O
APC	O
gene	O
mutations	O
have	O
recently	O
been	O
shown	O
to	O
activate	O
the	O
same	O
signaling	O
pathway	O
.	O
Frequent	O
mutations	O
of	O
beta-Catenin	O
in	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
have	O
also	O
been	O
reported	O
.	O
It	O
was	O
,	O
however	O
,	O
controversial	O
whether	O
the	O
mutation	O
of	O
the	O
beta-Catenin	O
gene	O
was	O
frequent	O
in	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
with	O
high	O
-	O
frequency	O
microsatellite	O
instability	O
(	O
MSI-H	O
)	O
.	O
We	O
analyzed	O
the	O
mutations	O
of	O
the	O
APC	O
and	O
beta-Catenin	O
genes	O
in	O
56	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
stratified	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
APC	O
mutations	O
were	O
identified	O
in	O
11	O
of	O
22	O
(	O
50	O
%	O
)	O
cases	O
of	O
MSI-H	O
and	O
14	O
of	O
34	O
(	O
41	O
%	O
)	O
cases	O
of	O
microsatellite	O
-	O
stable	O
(	O
MSS	O
)	O
/	O
low	O
-	O
frequency	O
microsatellite	O
instability	O
(	O
MSI-L	O
)	O
.	O
In	O
contrast	O
,	O
the	O
frequency	O
of	O
beta-Catenin	O
mutations	O
was	O
significantly	O
higher	O
in	O
MSI-H	O
(	O
6	O
/	O
22	O
;	O
27	O
%	O
)	O
than	O
in	O
MSS	O
/	O
MSI-L	O
(	O
1	O
/	O
34	O
;	O
3	O
%	O
)	O
(	O
P	O
=	O
0.01	O
)	O
.	O
beta-Catenin	O
mutations	O
were	O
not	O
detected	O
in	O
carcinomas	B-malignancy-type
with	O
APC	O
mutation	O
.	O
APC	O
mutation	O
occurred	O
irrespective	O
of	O
MSI	O
status	O
.	O
beta-Catenin	O
mutation	O
,	O
however	O
,	O
occurred	O
frequently	O
in	O
MSI-H	O
carcinomas	B-malignancy-type
.	O
Our	O
data	O
suggest	O
that	O
activation	O
of	O
the	O
beta-Catenin	O
-	O
Tcf	O
signaling	O
pathway	O
,	O
through	O
either	O
beta-Catenin	O
or	O
APC	O
mutation	O
,	O
frequently	O
contributes	O
to	O
MSI-H	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
(	O
17	O
/	O
22	O
;	O
77	O
%	O
)	O
.	O
PMID	O
:	O
11107173	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Nov	O
15	O
;60	O
(22	O
)	O
:	O
6311-3	O
Somatic	O
mutations	O
of	O
LKB1	O
and	O
beta-catenin	O
genes	O
in	O
gastrointestinal	B-malignancy-type
polyps	I-malignancy-type
from	O
patients	O
with	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
syndrome	I-malignancy-type
.	O
Miyaki	O
M,	O
Iijima	O
T	O
,	O
Hosono	O
K,	O
Ishii	O
R	O
,	O
Yasuno	O
M,	O
Mori	O
T	O
,	O
Toi	O
M,	O
Hishima	O
T	O
,	O
Shitara	O
N	O
,	O
Tamura	O
K,	O
Utsunomiya	O
J,	O
Kobayashi	O
N	O
,	O
Kuroki	O
T	O
,	O
Iwama	O
T.	O
Hereditary	O
Tumor	O
Research	O
Project	O
,	O
Tokyo	O
Metropolitan	O
Komagome	O
Hospital	O
,	O
Japan	O
.	O
mmiyaki@opal	O
.famille	O
.ne	O
.jp	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
syndrome	I-malignancy-type
(	O
PJS	B-malignancy-type
)	O
is	O
characterized	O
by	O
multiple	B-malignancy-type
gastrointestinal	I-malignancy-type
hamartomatous	I-malignancy-type
polyps	I-malignancy-type
,	O
mucocutaneous	O
melanin	O
deposition	O
,	O
and	O
increased	O
risk	O
of	O
cancer	B-malignancy-type
,	O
mainly	O
in	B-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
.	O
We	O
examined	O
mutations	O
of	O
the	O
LKB1	O
,	O
beta-catenin	O
,	O
APC	O
,	O
K-ras	O
,	O
and	O
p53	O
genes	O
in	O
27	O
gastrointestinal	B-malignancy-type
hamartomatous	I-malignancy-type
polyps	I-malignancy-type
from	O
10	O
patients	O
in	O
nine	O
PJS	B-malignancy-type
families	O
.	O
Of	O
these	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
,	O
one	O
intestinal	B-malignancy-type
polyp	I-malignancy-type
had	O
an	O
adenomatous	B-malignancy-type
lesion	I-malignancy-type
,	O
and	O
one	O
gastric	B-malignancy-type
polyp	I-malignancy-type
contained	O
adenomatous	B-malignancy-type
and	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
.	O
Germ	O
-	O
line	O
mutations	O
of	O
the	O
LKB1	O
gene	O
were	O
detected	O
in	O
six	O
PJS	B-malignancy-type
families	O
.	O
Somatic	O
mutations	O
of	O
the	O
LKB1	O
gene	O
were	O
found	O
in	O
5	O
polyps	B-malignancy-type
,	O
whereas	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
LKB1	O
locus	O
at	O
19p	O
was	O
seen	O
in	O
14	O
other	O
polyps	B-malignancy-type
.	O
In	O
adenomatous	B-malignancy-type
lesions	I-malignancy-type
microdissected	O
from	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
,	O
both	O
beta-catenin	O
mutation	O
and	O
19p	O
LOH	O
were	O
detected	O
.	O
Furthermore	O
,	O
a	O
carcinomatous	B-malignancy-type
lesion	I-malignancy-type
in	O
a	O
gastric	B-malignancy-type
hamartomatous	I-malignancy-type
polyp	I-malignancy-type
was	O
found	O
to	O
contain	O
a	O
mutation	O
of	O
the	O
p53	O
gene	O
and	O
LOH	O
at	O
the	O
p53	O
locus	O
in	O
addition	O
to	O
LOH	O
at	O
the	O
LKB1	O
locus	O
and	O
a	O
beta-catenin	O
mutation	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
a	O
few	O
polyps	B-malignancy-type
,	O
whereas	O
no	O
APC	O
mutation	O
or	O
5q	O
LOH	O
was	O
detected	O
in	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
gastrointestinal	B-malignancy-type
hamartomatous	I-malignancy-type
polyps	I-malignancy-type
in	O
PJS	B-malignancy-type
patients	O
develop	O
through	O
inactivation	O
of	O
the	O
LKB1	O
gene	O
by	O
germ	O
-	O
line	O
mutation	O
plus	O
somatic	O
mutation	O
or	O
LOH	O
of	O
the	O
unaffected	O
LKB1	O
allele	O
,	O
and	O
that	O
additional	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
and	O
p53	O
gene	O
convert	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
into	O
adenomatous	B-malignancy-type
and	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
.	O
PMID	O
:	O
11103790	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Nov	O
15	O
;60	O
(22	O
)	O
:	O
6288	O
-	O
92	O
Frequent	O
association	O
of	O
beta-catenin	O
and	O
WT1	O
mutations	O
in	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
Maiti	O
S	O
,	O
Alam	O
R	O
,	O
Amos	O
CI	O
,	O
Huff	O
V	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
The	O
etiology	O
of	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
,	O
an	O
embryonic	O
kidney	B-malignancy-type
tumor	I-malignancy-type
,	O
is	O
genetically	O
heterogeneous	O
.	O
One	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
gene	O
,	O
WT1	O
,	O
which	O
encodes	O
a	O
zinc	O
finger	O
transcription	O
factor	O
,	O
is	O
mutated	O
in	O
10	O
-	O
20	O
%	O
of	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
,	O
but	O
it	O
is	O
still	O
not	O
clear	O
what	O
critical	O
cellular	O
pathway(s)	O
is	O
affected	O
by	O
these	O
mutations	O
.	O
Recently	O
beta-catenin	O
mutations	O
have	O
been	O
reported	O
in	O
6	O
of	O
40	O
(	O
15	O
%	O
)	O
of	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
Beta-catenin	O
is	O
the	O
central	O
effector	O
in	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
,	O
and	O
deregulation	O
of	O
beta-catenin	O
signaling	O
is	O
critical	O
in	O
the	O
development	O
of	O
a	O
number	O
of	O
malignancies	O
.	O
The	O
observation	O
of	O
beta-catenin	O
mutations	O
in	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
suggests	O
that	O
abrogation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
also	O
plays	O
a	O
role	O
in	O
some	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
To	O
assess	O
the	O
relationship	O
of	O
WT1	O
mutations	O
vis-a-vis	O
beta-catenin	O
mutations	O
in	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
,	O
we	O
analyzed	O
153	O
primary	O
tumors	O
,	O
and	O
21	O
of	O
153	O
(	O
14	O
%	O
)	O
carried	O
beta-catenin	O
mutations	O
.	O
Surprisingly	O
,	O
we	O
observed	O
a	O
highly	O
significant	O
(	O
P	O
=	O
3.6	O
x	O
10(-13)	O
)	O
association	O
between	O
WT1	O
and	O
beta-catenin	O
mutations	O
;	O
19	O
of	O
20	O
beta-catenin	O
-	O
mutant	O
tumors	O
had	O
also	O
sustained	O
WT1	O
mutations	O
.	O
By	O
analogy	O
to	O
the	O
patterns	O
of	O
concordant	O
and	O
discordant	O
gene	O
mutations	O
observed	O
in	O
other	O
tumors	O
,	O
our	O
data	O
suggest	O
that	O
mutation	O
of	O
WT1	O
and	O
beta-catenin	O
affects	O
two	O
different	O
cellular	O
pathways	O
,	O
both	O
of	O
which	O
are	O
critically	O
altered	O
in	O
at	O
least	O
a	O
subset	O
of	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
11103785	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2000	O
Nov	O
20;89	O
(	O
6	O
)	O
:469	O
-	O
74	O
K-ras	O
oncogene	O
subtype	O
mutations	O
are	O
associated	O
with	O
survival	O
but	O
not	O
expression	O
of	O
p53	O
,	O
p16	O
(	O
INK4A	O
)	O
,	O
p21	O
(	O
WAF-1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
in	O
resected	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Kawesha	O
A	O
,	O
Ghaneh	O
P,	O
Andren-Sandberg	O
A	O
,	O
Ograed	O
D	O
,	O
Skar	O
R	O
,	O
Dawiskiba	O
S	O
,	O
Evans	O
JD	O
,	O
Campbell	O
F	O
,	O
Lemoine	O
N	O
,	O
Neoptolemos	O
JP	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Liverpool	O
,	O
Liverpool	O
,	O
UK.	O
Previous	O
studies	O
of	O
molecular	O
prognostic	O
markers	O
following	O
resection	O
for	O
exocrine	B-malignancy-type
pancreatic	I-malignancy-type
cancer	I-malignancy-type
have	O
produced	O
conflicting	O
results	O
.	O
Our	O
aim	O
was	O
to	O
undertake	O
a	O
comprehensive	O
analysis	O
of	O
potentially	O
useful	O
molecular	O
markers	O
in	O
a	O
large	O
,	O
multicentre	O
patient	O
population	O
and	O
to	O
compare	O
these	O
markers	O
with	O
standard	O
pathological	O
prognostic	O
variables	O
.	O
Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
specimens	O
of	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
analysed	O
from	O
157	O
patients	O
[	O
100	O
men	O
and	O
57	O
women	O
with	O
a	O
median	O
(	O
range	O
)	O
age	O
of	O
60	O
(	O
33	O
-	O
77	O
)	O
years	O
]	O
who	O
had	O
undergone	O
pancreatectomy	O
.	O
Immunohistochemistry	O
was	O
used	O
to	O
detect	O
expression	O
of	O
p16	O
(	O
INK4	O
)	O
,	O
p53	O
,	O
p21	O
(	O
WAF1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
.	O
Mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
oncogene	O
were	O
detected	O
by	O
SSCP	O
and	O
sequencing	O
following	O
DNA	O
extraction	O
and	O
amplification	O
by	O
PCR	O
.	O
The	O
median	O
(	O
range	O
)	O
survival	O
post	O
-	O
resection	O
was	O
12.5	O
(	O
3	O
-	O
83	O
)	O
months	O
.	O
Abnormalities	O
of	O
p16	O
(	O
INK4	O
)	O
,	O
p53	O
,	O
p21	O
(	O
WAF1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
expression	O
were	O
found	O
in	O
87	O
%	O
,	O
41	O
%	O
,	O
75	O
%	O
,	O
72	O
%	O
,	O
33	O
%	O
and	O
57	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
There	O
was	O
no	O
significant	O
correlation	O
between	O
expression	O
of	O
any	O
of	O
these	O
markers	O
and	O
patient	O
survival	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
73	O
(	O
75	O
%	O
)	O
of	O
97	O
cases	O
with	O
amplifiable	O
DNA	O
.	O
The	O
presence	O
of	O
K-ras	O
mutation	O
alone	O
did	O
not	O
correlate	O
with	O
survival	O
,	O
but	O
there	O
were	O
significant	O
differences	O
in	O
survival	O
according	O
to	O
the	O
type	O
of	O
K-ras	O
mutation	O
(	O
p	O
=	O
0.0007	O
)	O
.	O
Reduced	O
survival	O
was	O
found	O
in	O
patients	O
with	O
GaT	O
,	O
cGT	O
and	O
GcT	O
K-ras	O
mutations	O
compared	O
to	O
GtT	O
,	O
aGT	O
and	O
GaC	O
mutations	O
.	O
In	O
conclusion	O
,	O
survival	O
was	O
associated	O
with	O
type	O
of	O
K-ras	O
mutation	O
but	O
not	O
expression	O
of	O
p16	O
(	O
INK4	O
)	O
,	O
p53	O
,	O
p21	O
(	O
WAF1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
11102889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
2000	O
;35	O
(	O
10	O
)	O
:779	O
-83	O
Specific	O
mutation	O
in	O
exon	O
11	O
of	O
c-kit	O
proto	O
-	O
oncogene	O
in	O
a	O
malignant	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
.	O
Yamaguchi	O
M,	O
Miyaki	O
M,	O
Iijima	O
T	O
,	O
Matsumoto	O
T	O
,	O
Kuzume	O
M,	O
Matsumiya	O
A	O
,	O
Endo	O
Y	O
,	O
Sanada	O
Y	O
,	O
Kumada	O
K.	O
Department	O
of	O
Surgery	O
,	O
Showa	O
University	O
Fujigaoka	O
Hospital	O
,	O
Yokohama	O
,	O
Japan	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
in	B-malignancy-type
the	I-malignancy-type
distal	I-malignancy-type
third	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
was	O
detected	O
in	O
a	O
57	O
-	O
year	O
-	O
old	O
man	O
who	O
underwent	O
an	O
abdominoperineal	O
resection	O
of	O
the	O
rectum	O
.	O
Because	O
the	O
tumor	O
expressed	O
CD34	O
and	O
c-kit	O
gene	O
product	O
,	O
but	O
did	O
not	O
express	O
smooth	O
muscle	O
actin	O
or	O
S-100	O
protein	O
,	O
it	O
was	O
diagnosed	O
as	O
an	O
uncommitted	O
type	O
of	O
GIST	B-malignancy-type
.	O
Moreover	O
,	O
a	O
specific	O
mutation	O
in	O
the	O
sequence	O
coding	O
the	O
juxtamembrane	O
domain	O
in	O
exon	O
11	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
was	O
revealed	O
by	O
a	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
.	O
One	O
year	O
after	O
resection	O
,	O
the	O
patient	O
developed	O
multiple	O
liver	O
metastases	O
.	O
It	O
is	O
suggested	O
that	O
a	O
specific	O
mutation	O
in	O
exon	O
11	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
may	O
have	O
played	O
an	O
essential	O
role	O
in	O
the	O
development	O
of	O
the	O
liver	O
metastases	O
.	O
PMID	O
:	O
11063223	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2000	O
Oct;13(	O
10	O
)	O
:	O
1055-9	O
Mutations	O
in	O
beta-catenin	O
and	O
APC	O
genes	O
are	O
uncommon	O
in	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Choi	O
YW	O
,	O
Heath	O
EI	O
,	O
Heitmiller	O
R	O
,	O
Forastiere	O
AA	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
-2196	O
,	O
USA	O
.	O
Beta-catenin	O
plays	O
important	O
roles	O
in	O
both	O
intercellular	O
adhesion	O
and	O
signal	O
transduction	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
can	O
alter	O
the	O
degradation	O
of	O
beta-catenin	O
and	O
cause	O
aberrant	O
accumulation	O
of	O
beta-catenin	O
result	O
in	O
increased	O
transcription	O
of	O
target	O
genes	O
.	O
The	O
dysregulated	O
APC	O
/	O
beta-catenin	O
pathway	O
has	O
been	O
recently	O
discovered	O
as	O
an	O
important	O
mechanism	O
of	O
tumorigenesis	O
in	O
various	O
cancers	O
,	O
but	O
its	O
role	O
in	O
esophageal	B-malignancy-type
adenocarcinomas	I-malignancy-type
is	O
not	O
clear	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
beta-catenin	O
gene	O
mutation	O
,	O
allelic	O
loss	O
of	O
chromosome	O
5q	O
,	O
and	O
APC	O
gene	O
mutation	O
in	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Two	O
(	O
2	O
%	O
)	O
somatic	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
encompassing	O
the	O
region	O
for	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
phosphorylation	O
,	O
were	O
detected	O
from	O
109	O
adenocarcinomas	B-malignancy-type
.	O
Chromosomal	O
allelic	O
loss	O
on	O
5q	O
was	O
frequent	O
in	O
45.3	O
%	O
(	O
44	O
/	O
97	O
)	O
of	O
tumors	O
.	O
Only	O
one	O
missense	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
was	O
detected	O
from	O
38	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinomas	I-malignancy-type
with	O
the	O
5q	O
allelic	O
loss	O
.	O
Our	O
results	O
based	O
on	O
partial	O
screening	O
mutational	O
analyses	O
indicate	O
that	O
mutations	O
of	O
APC	O
/	O
beta-catenin	O
pathway	O
,	O
unlike	O
in	O
colorectal	O
carcinoma	O
,	O
involve	O
only	O
a	O
small	O
subset	O
of	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
11048797	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
2000	O
Nov;47	O
(	O
5	O
)	O
:721-7	O
Frequency	O
of	O
p16	O
(	O
INK4A	O
)	O
alterations	O
and	O
K-ras	O
mutations	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
.	O
Tannapfel	O
A	O
,	O
Benicke	O
M,	O
Katalinic	O
A	O
,	O
Uhlmann	O
D	O
,	O
Kockerling	O
F	O
,	O
Hauss	O
J,	O
Wittekind	O
C.	O
Institute	O
of	O
Pathology	O
,	O
University	O
of	O
Leipzig	O
,	O
Liebigstr	O
26	O
,	O
04103	O
Leipzig	O
,	O
Germany	O
.	O
tana@medizin	O
.uni-	O
leipzig.de	O
BACKGROUND	O
:	O
Inactivation	O
of	O
the	O
tumour	O
suppressor	O
gene	O
p16	O
(	O
CDKN2	O
/	O
MTS-1	O
/	O
INK4A	O
)	O
and	O
K-ras	O
mutations	O
are	O
among	O
the	O
most	O
frequent	O
genetic	O
alterations	O
in	O
human	O
malignancies	O
.	O
AIMS	O
:	O
To	O
investigate	O
the	O
tumour	O
suppressor	O
gene	O
p16	O
and	O
its	O
possible	O
association	O
with	O
K-ras	O
mutations	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
.	O
METHODS	O
:	O
The	O
status	O
of	O
p16	O
was	O
evaluated	O
in	O
41	O
cholangiocarcinomas	B-malignancy-type
by	O
methylation	O
specific	O
polymerase	O
chain	O
reaction	O
,	O
microsatellite	O
analysis	O
,	O
DNA	O
sequencing	O
,	O
and	O
immunohistochemical	O
staining	O
.	O
K-ras	O
mutations	O
were	O
determined	O
by	O
direct	O
DNA	O
sequencing	O
analyses	O
after	O
microdissection	O
.	O
The	O
results	O
obtained	O
were	O
correlated	O
with	O
histopathological	O
variables	O
and	O
patient	O
survival	O
.	O
RESULTS	O
:	O
Hypermethylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p16	O
gene	O
was	O
found	O
in	O
34	O
of	O
41	O
(	O
83	O
%	O
)	O
carcinomas	B-malignancy-type
.	O
Homozygous	O
deletion	O
at	O
the	O
p16	O
region	O
was	O
present	O
in	O
two	O
(	O
5	O
%	O
)	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
eight	O
cases	O
(	O
20	O
%	O
)	O
.	O
We	O
failed	O
to	O
detect	O
p16	O
gene	O
missense	O
mutations	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
22	O
of	O
41	O
(	O
54	O
%	O
)	O
cholangiocarcinomas	B-malignancy-type
and	O
in	O
two	O
cases	O
of	O
tumour	O
surrounding	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
.	O
All	O
22	O
cancers	O
with	O
K-ras	O
mutations	O
also	O
exhibited	O
methylated	O
p16	O
.	O
We	O
failed	O
to	O
observe	O
a	O
correlation	O
between	O
K-ras	O
or	O
p16	O
status	O
and	O
histopathological	O
factors	O
or	O
prognosis	O
of	O
patients	O
.	O
CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
inactivation	O
of	O
the	O
p16	O
gene	O
is	O
a	O
frequent	O
event	O
in	O
cholangiocarcinoma	B-malignancy-type
.	O
The	O
most	O
common	O
somatic	O
alteration	O
is	O
promotor	O
methylation	O
of	O
the	O
p16	O
gene	O
which	O
is	O
closely	O
associated	O
with	O
K-ras	O
mutations	O
.	O
We	O
failed	O
to	O
establish	O
p16	O
or	O
K-ras	O
status	O
as	O
independent	O
prognostic	O
factors	O
in	O
these	O
tumours	O
.	O
PMID	O
:	O
11034592	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2000	O
Oct;2	O
4(	O
10	O
)	O
:	O
1339	O
-52	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
genetic	O
study	O
of	O
44	O
cases	O
.	O
Miettinen	O
M,	O
Sarlomo-Rikala	O
M,	O
Sobin	O
LH	O
,	O
Lasota	O
J.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-6000	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
,	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
largely	O
specific	O
for	O
the	O
gastrointestinal	O
tract	O
,	O
have	O
been	O
well	O
defined	O
in	O
the	O
stomach	O
and	O
small	O
intestine	O
,	O
but	O
have	O
not	O
been	O
extensively	O
documented	O
or	O
contrasted	O
with	O
true	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
clinicopathologic	O
features	O
of	O
GISTs	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
,	O
excluding	O
the	O
rectum	O
,	O
and	O
to	O
compare	O
them	O
with	O
leiomyosarcomas	B-malignancy-type
(	O
LMSs	B-malignancy-type
)	O
of	O
the	O
same	O
location	O
.	O
A	O
total	O
of	O
37	O
colonic	B-malignancy-type
GISTs	I-malignancy-type
and	O
seven	O
LMSs	B-malignancy-type
from	O
the	O
files	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
and	O
the	O
Haartman	O
Institute	O
of	O
the	O
University	O
of	O
Helsinki	O
were	O
analyzed	O
.	O
The	O
GISTs	B-malignancy-type
occurred	O
predominantly	O
in	O
adults	O
older	O
than	O
50	O
years	O
of	O
age	O
(	O
median	O
,	O
67	O
yrs	O
)	O
,	O
and	O
most	O
were	O
histologically	O
malignant	O
;	O
four	O
small	O
benign	O
tumors	O
(	O
<	O
or	O
=	O
1	O
cm	O
)	O
were	O
incidentally	O
detected	O
,	O
and	O
10	O
others	O
had	O
minimal	O
mitotic	O
activity	O
(	O
five	O
or	O
fewer	O
mitoses	O
per	O
50	O
high	O
-	O
power	O
fields	O
)	O
.	O
The	O
colonic	B-malignancy-type
GISTs	I-malignancy-type
were	O
typically	O
transmural	B-malignancy-type
tumors	I-malignancy-type
with	O
frequent	O
intraluminal	O
and	O
outward	O
bulging	O
components	O
.	O
Histologically	O
,	O
they	O
usually	O
showed	O
a	O
spindle	O
cell	O
pattern	O
(	O
92	O
%	O
)	O
,	O
whereas	O
8	O
%	O
were	O
epithelioid	O
.	O
Most	O
tumors	O
(	O
19	O
of	O
25	O
)	O
were	O
positive	O
for	O
CD117	O
(	O
KIT	O
)	O
and	O
for	O
CD34	O
(	O
16	O
of	O
27	O
)	O
;	O
six	O
tumors	O
coexpressed	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
and	O
CD117	O
;	O
none	O
showed	O
desmin	O
or	O
S-100	O
protein	O
.	O
C-kit	O
mutations	O
in	O
exon	O
11	O
were	O
seen	O
in	O
5	O
(	O
36	O
%	O
)	O
of	O
14	O
colonic	B-malignancy-type
GISTs	I-malignancy-type
.	O
None	O
of	O
the	O
patients	O
with	O
incidental	O
small	O
tumors	O
had	O
a	O
recurrence	O
,	O
whereas	O
2	O
of	O
10	O
patients	O
with	O
tumors	O
larger	O
than	O
1	O
cm	O
but	O
minimal	O
mitotic	O
activity	O
died	O
of	O
the	O
disease	O
with	O
liver	O
metastasis	O
.	O
Nearly	O
all	O
patients	O
whose	O
tumor	O
was	O
larger	O
than	O
1	O
cm	O
and	O
showed	O
more	O
than	O
five	O
mitoses	O
per	O
50	O
high	O
-	O
power	O
fields	O
died	O
of	O
disease	O
;	O
half	O
had	O
evidence	O
of	O
metastasis	O
.	O
LMSs	B-malignancy-type
were	O
typically	O
intraluminally	O
bulging	O
,	O
polypoid	O
masses	O
that	O
showed	O
a	O
histologic	O
likeness	O
to	O
differentiated	O
smooth	O
muscle	O
cells	O
.	O
They	O
occurred	O
in	O
five	O
men	O
and	O
two	O
women	O
with	O
a	O
median	O
age	O
of	O
61	O
years	O
.	O
Most	O
LMSs	B-malignancy-type
were	O
high	O
-	O
grade	O
histologically	O
and	O
showed	O
smooth	O
muscle	O
actin	O
,	O
desmin	O
,	O
or	O
both	O
.	O
All	O
were	O
negative	O
for	O
CD34	O
and	O
CD117	O
and	O
lacked	O
c-kit	O
mutations	O
.	O
Five	O
of	O
the	O
seven	O
patients	O
died	O
of	O
disease	O
,	O
and	O
two	O
had	O
a	O
long	O
-	O
term	O
survival	O
,	O
despite	O
high	O
mitotic	O
activity	O
.	O
These	O
results	O
show	O
that	O
KIT	O
-	O
positive	O
GISTs	B-malignancy-type
are	O
more	O
common	O
than	O
LMSs	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
,	O
and	O
these	O
tumor	O
groups	O
have	O
clinicopathologic	O
differences	O
that	O
warrant	O
their	O
separation	O
.	O
PMID	O
:	O
11023095	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2000	O
Jul	O
20;89	O
(	O
4	O
)	O
:	O
33	O
7-44	O
Detection	O
of	O
tumor	O
cells	O
in	O
blood	O
using	O
CD45	O
magnetic	O
cell	O
separation	O
followed	O
by	O
nested	O
mutant	O
allele	O
-	O
specific	O
amplification	O
of	O
p53	O
and	O
K-ras	O
genes	O
in	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Iinuma	O
H,	O
Okinaga	O
K,	O
Adachi	O
M,	O
Suda	O
K,	O
Sekine	O
T	O
,	O
Sakagawa	O
K,	O
Baba	O
Y	O
,	O
Tamura	O
J,	O
Kumagai	O
H,	O
Ida	O
A	O
.	O
Second	O
Department	O
of	O
Surgery	O
,	O
Teikyo	O
University	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
iinuma@med	O
.teikyo	O
-u.ac.jp	O
A	O
new	O
method	O
for	O
detecting	O
circulating	O
tumor	O
cells	O
that	O
is	O
based	O
on	O
magnetic	O
-	O
activated	O
cell	O
separation	O
(	O
MACS	O
)	O
and	O
nested	O
mutant	O
allele	O
-	O
specific	O
amplification	O
(	O
nested	O
MASA	O
)	O
was	O
evaluated	O
in	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
using	O
the	O
p53	O
and	O
K-ras	O
genes	O
as	O
genetic	O
markers	O
.	O
By	O
negative	O
selection	O
with	O
anti	O
-	O
CD45	O
monoclonal	O
antibody	O
-	O
conjugated	O
supermagnetic	O
microbeads	O
,	O
the	O
proportion	O
of	O
tumor	O
cells	O
was	O
enriched	O
9	O
-	O
fold	O
.	O
By	O
the	O
combination	O
of	O
MACS	O
and	O
nested	O
MASA	O
,	O
10	O
tumor	O
cells	O
in	O
10(7)	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
could	O
be	O
detected	O
without	O
false	O
-	O
positives	O
.	O
Using	O
this	O
method	O
,	O
we	O
examined	O
blood	O
taken	O
from	O
the	O
tumor	O
drainage	O
veins	O
of	O
23	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Eighty-seven	O
percent	O
(	O
20	O
/	O
23	O
)	O
of	O
primary	O
tumor	O
tissues	O
showed	O
p53	O
and/or	O
K-ras	O
gene	O
mutations	O
.	O
Forty-five	O
percent	O
(	O
9	O
/	O
20	O
)	O
of	O
patients	O
with	O
p53	O
and/or	O
K-ras	O
mutations	O
in	O
the	O
primary	O
tumor	O
showed	O
the	O
same	O
mutated	O
genes	O
in	O
the	O
blood	O
samples	O
.	O
There	O
was	O
a	O
significant	O
association	O
between	O
the	O
presence	O
of	O
p53	O
and	O
K-ras	O
gene	O
mutation	O
in	O
the	O
blood	O
and	O
tumor	O
size	O
,	O
depth	O
of	O
invasion	O
,	O
and	O
venous	O
invasion	O
.	O
Blood	O
gene	O
mutation	O
was	O
detected	O
in	O
80	O
%	O
(	O
4	O
/	O
5	O
)	O
of	O
samples	O
from	O
patients	O
with	O
synchronous	O
liver	O
metastases	O
.	O
Sixty	O
percent	O
(	O
3	O
/	O
5	O
)	O
of	O
patients	O
with	O
mutant	O
genes	O
in	O
the	O
blood	O
developed	O
asynchronous	O
liver	O
metastases	O
after	O
surgery	O
.	O
The	O
overall	O
survival	O
of	O
patients	O
with	O
p53	O
and/or	O
K-ras	O
gene	O
mutation	O
-	O
positive	O
findings	O
in	O
blood	O
was	O
significantly	O
shorter	O
than	O
that	O
of	O
patients	O
testing	O
negative	O
on	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
method	O
may	O
be	O
useful	O
for	O
reliable	O
detection	O
of	O
tumor	O
cells	O
circulating	O
in	O
the	O
blood	O
and	O
may	O
help	O
to	O
identify	O
patients	O
at	O
high	O
risk	O
for	O
relapse	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
10956407	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2000	O
Jul;31(	O
7	O
)	O
:	O
795-803	O
K-ras	O
gene	O
mutations	O
and	O
loss	O
of	O
heterozygosity	O
at	O
the	O
p53	O
gene	O
locus	O
relative	O
to	O
histological	O
characteristics	O
of	O
mucin	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Sakai	O
Y	O
,	O
Yanagisawa	O
A	O
,	O
Shimada	O
M,	O
Hidaka	O
E	O
,	O
Seki	O
M,	O
Tada	O
Y	O
,	O
Harada	O
T	O
,	O
Saisho	O
H,	O
Kato	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Cancer	O
Institute	O
Hospital	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Mucin	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
tumors	I-malignancy-type
(	I-malignancy-type
MPTs	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
accompanied	O
by	O
carcinomas	B-malignancy-type
usually	O
include	O
various	O
grades	O
of	O
dysplasia	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
ductal	I-malignancy-type
epithelium	I-malignancy-type
,	O
and	O
invasive	O
areas	O
are	O
histologically	O
similar	O
to	O
those	O
of	O
common	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
that	O
MPTs	O
provide	O
a	O
good	O
tool	O
to	O
investigate	O
early	O
stages	O
of	O
pancreatic	O
carcinogenesis	O
.	O
Thus	O
,	O
to	O
clarify	O
genetic	O
alterations	O
in	O
the	O
early	O
stage	O
of	O
pancreatic	O
carcinogenesis	O
,	O
we	O
analyzed	O
K-ras	O
gene	O
mutations	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
p53	O
gene	O
locus	O
using	O
37	O
cases	O
of	O
MPTs	B-malignancy-type
harboring	O
dysplastic	B-malignancy-type
epithelium	I-malignancy-type
.	O
Further	O
,	O
we	O
conducted	O
an	O
extended	O
,	O
multifocal	O
microdissection	O
analysis	O
focusing	O
on	O
the	O
histological	O
features	O
of	O
ductal	O
epithelium	O
and	O
the	O
distribution	O
of	O
genetic	O
alterations	O
for	O
3	O
cases	O
of	O
MPT	B-malignancy-type
positive	O
for	O
LOH	O
of	O
the	O
p53	O
gene	O
to	O
determine	O
the	O
relation	O
to	O
tumor	O
progression	O
.	O
K-ras	O
gene	O
mutations	O
were	O
detected	O
with	O
high	O
frequency	O
in	O
50	O
%	O
or	O
more	O
cases	O
of	O
the	O
adenomas	B-malignancy-type
(	O
14	O
of	O
19	O
)	O
,	O
borderline	B-malignancy-type
tumors	I-malignancy-type
(	O
4	O
of	O
7	O
)	O
,	O
and	O
carcinomas	B-malignancy-type
(	O
8	O
of	O
11	O
)	O
,	O
whereas	O
LOH	O
of	O
the	O
p53	O
gene	O
was	O
limited	O
to	O
carcinomas	B-malignancy-type
(	O
3	O
of	O
5	O
informative	O
cases	O
,	O
60	O
%	O
)	O
and	O
always	O
accompanied	O
by	O
K-ras	O
gene	O
mutation	O
.	O
Investigation	O
of	O
a	O
total	O
of	O
126	O
microdissection	O
sites	O
from	O
3	O
cases	O
showed	O
the	O
presence	O
of	O
K-ras	O
gene	O
mutations	O
in	O
mild	B-malignancy-type
dysplasia	I-malignancy-type
and	O
all	O
(	O
100	O
%	O
)	O
regions	O
of	O
moderate	O
or	O
more	O
marked	O
dysplasia	B-malignancy-type
,	O
whereas	O
LOH	O
of	O
the	O
p53	O
gene	O
showed	O
more	O
gradual	O
tendency	O
to	O
increase	O
with	O
grade	O
from	O
moderate	B-malignancy-type
dysplasia	I-malignancy-type
.	O
In	O
addition	O
,	O
the	O
multifocal	O
genetic	O
analysis	O
showed	O
K-ras	O
gene	O
mutations	O
to	O
be	O
widely	O
distributed	O
throughout	O
tumors	O
,	O
whereas	O
LOH	O
of	O
the	O
p53	O
gene	O
was	O
localized	O
to	O
1	O
or	O
a	O
few	O
areas	O
.	O
Further	O
,	O
topographically	O
delimited	O
areas	O
with	O
the	O
same	O
histology	O
in	O
the	O
same	O
tumor	O
did	O
not	O
always	O
show	O
the	O
same	O
genetic	O
alteration	O
.	O
In	O
conclusion	O
,	O
we	O
could	O
confirm	O
that	O
both	O
the	O
K-ras	O
and	O
p53	O
gene	O
alterations	O
occur	O
in	O
the	O
intraductal	O
stage	O
of	O
MPT	B-malignancy-type
,	O
and	O
the	O
latter	O
is	O
superimposed	O
on	O
the	O
former	O
during	O
the	O
course	O
of	O
tumor	O
progression	O
.	O
However	O
,	O
the	O
pattern	O
of	O
association	O
of	O
histological	O
features	O
with	O
genetic	O
alteration	O
differs	O
from	O
tumor	O
to	O
tumor	O
.	O
PMID	O
:	O
10923915	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
May	O
1;60	O
(	O
9	O
)	O
:	O
2345-7	O
Specific	O
c-kit	O
mutations	O
in	O
sinonasal	B-malignancy-type
natural	I-malignancy-type
killer	I-malignancy-type
/	O
T-cell	B-malignancy-type
lymphoma	I-malignancy-type
in	O
China	O
and	O
Japan	O
.	O
Hongyo	O
T	O
,	O
Li	O
T	O
,	O
Syaifudin	O
M	O
,	O
Baskar	O
R	O
,	O
Ikeda	O
H	O
,	O
Kanakura	O
Y	O
,	O
Aozasa	O
K	O
,	O
Nomura	O
T	O
.	O
Department	O
of	O
Radiation	O
Biology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Osaka	O
University	O
,	O
Japan	O
.	O
Sinonasal	B-malignancy-type
lymphoma	I-malignancy-type
is	O
one	O
of	O
the	O
constituents	O
of	O
lethal	B-malignancy-type
midline	I-malignancy-type
granuloma	I-malignancy-type
,	O
which	O
is	O
a	O
clinical	O
term	O
for	O
progressive	O
,	O
destructive	O
lesions	B-malignancy-type
affecting	I-malignancy-type
the	I-malignancy-type
midline	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
face	I-malignancy-type
.	O
The	O
majority	O
of	O
sinonasal	B-malignancy-type
lymphomas	I-malignancy-type
,	O
especially	O
those	O
showing	O
polymorphous	O
patterns	O
of	O
proliferation	O
and	O
thus	O
termed	O
polymorphic	B-malignancy-type
reticulosis	I-malignancy-type
,	O
recently	O
were	O
categorized	O
as	O
sinonasal	B-malignancy-type
natural	I-malignancy-type
killer	I-malignancy-type
/	O
T-cell	B-malignancy-type
lymphomas	I-malignancy-type
.	O
They	O
are	O
more	O
prevalent	O
in	O
Asia	O
than	O
Europe	O
or	O
North	O
America	O
and	O
are	O
associated	O
with	O
EBV	O
infection	O
.	O
Twenty-three	O
cases	O
with	O
sinonasal	B-malignancy-type
natural	I-malignancy-type
killer	I-malignancy-type
/	O
T-cell	B-malignancy-type
lymphomas	I-malignancy-type
were	O
collected	O
from	O
two	O
high	O
-	O
incidence	O
regions	O
:	O
Beijing	O
,	O
China	O
(	O
14	O
cases	O
)	O
and	O
Osaka	O
,	O
Japan	O
(	O
9	O
cases	O
)	O
.	O
c-kit	O
mutations	O
were	O
analyzed	O
on	O
paraffin	O
-	O
embedded	O
specimens	O
by	O
PCR	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
direct	O
sequencing	O
;	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
encodes	O
a	O
receptor	O
of	O
tyrosine	O
kinase	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
and	O
neoplastic	O
hematopoiesis	O
by	O
the	O
interaction	O
with	O
its	O
specific	O
ligand	O
,	O
termed	O
stem	O
cell	O
factor	O
.	O
Twelve	O
single	O
nucleotide	O
substitution	O
mutations	O
were	O
seen	O
in	O
23	O
cases	O
.	O
Ten	O
of	O
14	O
Chinese	O
cases	O
(	O
71.4	O
%	O
)	O
had	O
mutations	O
at	O
exon	O
11	O
or	O
exon	O
17	O
,	O
whereas	O
only	O
two	O
of	O
nine	O
Japanese	O
cases	O
(	O
22.2	O
%	O
)	O
had	O
mutations	O
,	O
showing	O
a	O
significant	O
difference	O
in	O
frequency	O
between	O
Chinese	O
and	O
Japanese	O
cases	O
.	O
Furthermore	O
,	O
seven	O
of	O
eight	O
mutations	O
(	O
92	O
%	O
)	O
in	O
exon	O
17	O
occurred	O
at	O
codon	O
825	O
and	O
three	O
of	O
four	O
mutations	O
(	O
75	O
%	O
)	O
in	O
exon	O
11	O
occurred	O
at	O
codon	O
561	O
.	O
Such	O
a	O
specificity	O
has	O
not	O
been	O
reported	O
before	O
,	O
and	O
these	O
results	O
,	O
taken	O
together	O
,	O
suggest	O
that	O
location	O
-	O
specific	O
differences	O
in	O
etiological	O
factors	O
cause	O
specific	O
mutations	O
in	O
c-kit	O
gene	O
.	O
PMID	O
:	O
10811105	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncol	O
Rep	O
2000	O
May	O
-	O
Jun	O
;	O
7	O
(	O
3	O
)	O
:	O
567	O
-	O
70	O
Anticorresponding	O
mutations	O
of	O
the	O
KRAS	O
and	O
PTEN	O
genes	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
Ikeda	O
T	O
,	O
Yoshinaga	O
K	O
,	O
Suzuki	O
A	O
,	O
Sakurada	O
A	O
,	O
Ohmori	O
H	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
PTEN	O
is	O
a	O
newly	O
isolated	O
candidate	O
tumor	O
suppressor	O
gene	O
and	O
its	O
mutation	O
is	O
the	O
most	O
frequently	O
found	O
in	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
(	O
EC	B-malignancy-type
)	O
,	O
a	O
very	O
common	O
female	O
pelvic	B-malignancy-type
malignant	I-malignancy-type
disease	I-malignancy-type
.	O
Mutations	O
of	O
the	O
KRAS	O
gene	O
are	O
also	O
reported	O
in	O
this	O
disease	O
.	O
Recent	O
analysis	O
of	O
the	O
PTEN	O
protein	O
suggested	O
the	O
possibility	O
that	O
this	O
protein	O
acts	O
in	O
the	O
same	O
pathway	O
as	O
does	O
the	O
RAS	O
protein	O
.	O
To	O
elucidate	O
this	O
possibility	O
further	O
,	O
we	O
performed	O
a	O
mutation	O
analysis	O
of	O
these	O
two	O
genes	O
in	O
44	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
specimens	O
(	O
38	O
primary	O
tumors	O
and	O
6	O
cell	O
lines	O
)	O
.	O
Altogether	O
23	O
(	O
52	O
%	O
)	O
of	O
44	O
tumors	O
had	O
mutations	O
in	O
either	O
PTEN	O
or	O
KRAS	O
,	O
but	O
none	O
of	O
them	O
had	O
mutations	O
in	O
both	O
of	O
these	O
genes	O
.	O
These	O
results	O
support	O
the	O
idea	O
that	O
the	O
protein	O
products	O
of	O
these	O
two	O
genes	O
act	O
in	O
the	O
same	O
growth	O
regulatory	O
pathway	O
in	O
the	O
endometrium	O
.	O
PMID	O
:	O
10767369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Mar	O
;	O
9	O
(	O
3	O
)	O
:	O
279	O
-	O
84	O
Ki-ras	O
point	O
mutation	O
and	O
p53	O
expression	O
in	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
a	O
comparative	O
study	O
among	O
Chinese	O
,	O
Japanese	O
,	O
and	O
Western	O
patients	O
.	O
Dong	O
M	O
,	O
Nio	O
Y	O
,	O
Tamura	O
K	O
,	O
Song	O
MM	O
,	O
Guo	O
KJ	O
,	O
Guo	O
RX	O
,	O
Dong	O
YT	O
.	O
First	O
Department	O
of	O
Surgery	O
,	O
Shimane	O
Medical	O
University	O
,	O
Izumo	O
,	O
Japan	O
.	O
mingdong@shimane-med.ac.jp	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
features	O
of	O
Ki-ras	O
point	O
mutation	O
(	O
PM	O
)	O
and	O
p53	O
expression	O
in	O
Chinese	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
and	O
to	O
compare	O
those	O
with	O
that	O
in	O
other	O
countries	O
.	O
Dot	O
blot	O
hybridization	O
and	O
immunohistochemical	O
methods	O
were	O
performed	O
in	O
59	O
Chinese	O
patients	O
.	O
The	O
results	O
showed	O
that	O
Ki-ras	O
PMs	O
at	O
codon	O
12	O
and	O
p53	O
expression	O
were	O
frequent	O
in	O
this	O
group	O
.	O
No	O
relationships	O
were	O
found	O
between	O
Ki-ras	O
PM	O
alone	O
and	O
p53	O
expression	O
alone	O
,	O
and	O
clinicopathological	O
parameters	O
,	O
including	O
age	O
,	O
gender	O
,	O
clinical	O
stage	O
,	O
and	O
histological	O
grade	O
and	O
classification	O
in	O
Chinese	O
patients	O
.	O
However	O
,	O
their	O
cooperation	O
was	O
significantly	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
this	O
group	O
.	O
Comparison	O
showed	O
that	O
there	O
were	O
significant	O
differences	O
in	O
the	O
overall	O
frequency	O
and	O
substitution	O
of	O
Ki-ras	O
PM	O
and	O
in	O
the	O
ratio	O
of	O
transition	O
:	O
transversion	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
among	O
various	O
countries	O
.	O
In	O
addition	O
,	O
the	O
effect	O
of	O
Ki-ras	O
PM	O
and	O
p53	O
expression	O
on	O
a	O
poor	O
prognosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
different	O
among	O
various	O
countries	O
.	O
These	O
findings	O
suggested	O
that	O
not	O
only	O
Ki-ras	O
PM	O
and	O
p53	O
expression	O
are	O
frequent	O
in	O
Chinese	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
also	O
a	O
gene	O
component	O
to	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
different	O
between	O
Asian	O
and	O
Western	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
addition	O
,	O
it	O
seems	O
that	O
cooperation	O
of	O
Ki-ras	O
PM	O
and	O
p53	O
expression	O
may	O
predict	O
a	O
poor	O
prognosis	O
in	O
Chinese	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10750666	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
2000	O
Mar	O
;	O
82	O
(	O
6	O
)	O
:	O
1183	O
-	O
5	O
Mutational	O
status	O
of	O
K-ras	O
and	O
TP53	O
genes	O
in	O
primary	B-malignancy-type
sarcomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
heart	I-malignancy-type
.	O
Garcia	O
JM	O
,	O
Gonzalez	O
R	O
,	O
Silva	O
JM	O
,	O
Dominguez	O
G	O
,	O
Vegazo	O
IS	O
,	O
Gamallo	O
C	O
,	O
Provencio	O
M	O
,	O
Espana	O
P	O
,	O
Bonilla	O
F	O
.	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Clinica	O
Puerta	O
de	O
Hierro	O
,	O
Madrid	O
,	O
Spain	O
.	O
We	O
investigated	O
three	O
patients	O
with	O
cardiac	B-malignancy-type
angiosarcomas	I-malignancy-type
and	O
two	O
with	O
cardiac	B-malignancy-type
rhabdomyosarcomas	I-malignancy-type
,	O
all	O
for	O
mutations	O
at	O
exons	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
of	O
the	O
p53	O
gene	O
and	O
at	O
exon	O
1	O
of	O
K-ras	O
.	O
No	O
point	O
mutations	O
were	O
observed	O
in	O
the	O
p53	O
gene	O
in	O
any	O
of	O
the	O
five	O
cases	O
;	O
however	O
,	O
at	O
exon	O
1	O
of	O
K-ras	O
,	O
three	O
patients	O
(	O
60	O
%	O
)	O
presented	O
the	O
same	O
mutation	O
at	O
the	O
first	O
base	O
of	O
codon	O
13	O
(	O
G	O
to	O
A	O
transition	O
)	O
.	O
Interestingly	O
,	O
this	O
mutation	O
was	O
detected	O
in	O
both	O
rhabdomyosarcoma	B-malignancy-type
and	O
angiosarcoma	B-malignancy-type
histologic	O
sarcoma	B-malignancy-type
types	O
.	O
PMID	O
:	O
10735503	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Exp	O
Hematol	O
2000	O
Feb	O
;	O
28	O
(	O
2	O
)	O
:	O
140	O
-	O
7	O
Analysis	O
of	O
the	O
surface	O
expression	O
of	O
c-kit	O
and	O
occurrence	O
of	O
the	O
c-kit	O
Asp	O
816	O
Val	O
activating	O
mutation	O
in	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
myelomonocytic	O
cells	O
in	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Akin	O
C	O
,	O
Kirshenbaum	O
AS	O
,	O
Semere	O
T	O
,	O
Worobec	O
AS	O
,	O
Scott	O
LM	O
,	O
Metcalfe	O
DD	O
.	O
Laboratory	O
of	O
Allergic	O
Diseases	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
-	O
1881	O
,	O
USA	O
.	O
cakin@atlas.niaid.nih.gov	O
OBJECTIVE	O
:	O
The	O
Asp	O
816	O
Val	O
c-kit	O
activating	O
mutation	O
is	O
detectable	O
in	O
the	O
peripheral	O
blood	O
cells	O
of	O
some	O
patients	O
with	O
mastocytosis	B-malignancy-type
and	O
in	O
lesional	B-malignancy-type
skin	I-malignancy-type
biopsies	O
obtained	O
from	O
adult	O
patients	O
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
.	O
These	O
observations	O
led	O
to	O
the	O
conclusion	O
that	O
this	O
mutation	O
is	O
present	O
in	O
mast	O
cells	O
and	O
mast	O
cell	O
precursors	O
that	O
express	O
c-kit	O
.	O
However	O
,	O
the	O
distribution	O
of	O
the	O
Asp	O
816	O
Val	O
mutation	O
among	O
hematopoietic	O
lineages	O
is	O
unknown	O
.	O
To	O
determine	O
the	O
distribution	O
of	O
the	O
Asp	O
816	O
Val	O
mutation	O
among	O
hematopoietic	O
lineages	O
and	O
to	O
explore	O
its	O
relationship	O
to	O
clinical	O
disease	O
,	O
we	O
examined	O
cells	O
bearing	O
differentiation	O
markers	O
for	O
myelomonocytic	O
cells	O
as	O
well	O
as	O
T	O
and	O
B	O
lymphocytes	O
,	O
in	O
both	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
obtained	O
from	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
presence	O
of	O
Asp	O
816	O
Val	O
c-kit	O
mutation	O
in	O
cells	O
magnetically	O
sorted	O
from	O
peripheral	O
blood	O
or	O
bone	O
marrow	O
according	O
to	O
surface	O
differentiation	O
markers	O
was	O
studied	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
The	O
surface	O
expression	O
of	O
c-kit	O
was	O
determined	O
by	O
flow	O
cytometry	O
.	O
RESULTS	O
:	O
The	O
mutation	O
was	O
detectable	O
by	O
RT	O
-	O
PCR	O
in	O
at	O
least	O
one	O
cell	O
lineage	O
in	O
the	O
bone	O
marrow	O
in	O
7	O
of	O
7	O
patients	O
examined	O
and	O
in	O
the	O
peripheral	O
blood	O
of	O
11	O
of	O
11	O
adult	O
patients	O
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
and	O
indolent	O
disease	O
.	O
The	O
mutation	O
was	O
identified	O
most	O
frequently	O
in	O
B	O
cells	O
and	O
myeloid	O
cells	O
.	O
Flow	O
cytometric	O
analysis	O
demonstrated	O
that	O
the	O
differentiated	O
cells	O
expressing	O
mutated	O
c-kit	O
were	O
negative	O
for	O
surface	O
KIT	O
.	O
CONCLUSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
the	O
conclusion	O
that	O
the	O
c-kit	O
Asp	O
816	O
Val	O
mutation	O
occurs	O
in	O
an	O
early	O
progenitor	O
cell	O
and	O
is	O
carried	O
by	O
myelomonocytic	O
cells	O
,	O
T	O
cells	O
,	O
and	O
B	O
cells	O
in	O
addition	O
to	O
mast	O
cells	O
.	O
However	O
,	O
unlike	O
mast	O
cells	O
,	O
these	O
myelomonocytic	O
cells	O
,	O
T	O
cells	O
,	O
and	O
B	O
cells	O
do	O
not	O
concomitantly	O
express	O
surface	O
c-kit	O
and	O
thus	O
may	O
be	O
less	O
susceptible	O
to	O
the	O
effects	O
of	O
this	O
mutation	O
.	O
PMID	O
:	O
10706069	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Oncol	O
2000	O
Mar;16	O
(	O
3	O
)	O
:	O
501-11	O
The	O
K-ras	O
gene	O
regulates	O
vascular	O
endothelial	O
growth	O
factor	O
gene	O
expression	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Konishi	O
T	O
,	O
Huang	O
CL	O
,	O
Adachi	O
M,	O
Taki	O
T	O
,	O
Inufusa	O
H,	O
Kodama	O
K,	O
Kohno	O
N	O
,	O
Miyake	O
M.	O
Department	O
of	O
Thoracic	O
Surgery	O
,	O
Kitano	O
Hospital	O
,	O
Tazuke	O
Kofukai	O
Medical	O
Research	O
Institute	O
,	O
Kamiyama-cho	O
,	O
Osaka	O
530	O
-	O
8480	O
,	O
Japan	O
.	O
Tumor	O
angiogenesis	O
is	O
an	O
essential	O
step	O
for	O
tumor	O
cell	O
growth	O
,	O
progression	O
and	O
metastasis	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
mitogen	O
specific	O
for	O
endothelial	O
cells	O
,	O
and	O
therefore	O
is	O
believed	O
to	O
play	O
a	O
key	O
role	O
in	O
tumor	O
angiogenesis	O
.	O
However	O
,	O
the	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
VEGF	O
expression	O
remain	O
virtually	O
unknown	O
and	O
the	O
only	O
major	O
regulator	O
of	O
VEGF	O
expression	O
has	O
been	O
reported	O
to	O
be	O
hypoxia	O
.	O
Recently	O
,	O
it	O
was	O
reported	O
that	O
a	O
mutant	O
p53	O
in#duced	O
the	O
expression	O
of	O
VEGF	O
mRNA	O
,	O
and	O
that	O
wild	O
-	O
type	O
p53	O
down	O
-	O
regulated	O
endogenous	O
VEGF	O
mRNA	O
levels	O
.	O
In	O
contrast	O
,	O
it	O
has	O
also	O
been	O
reported	O
that	O
mutant	O
ras	O
oncogenes	O
were	O
associated	O
with	O
the	O
marked	O
up	O
-	O
regulation	O
of	O
VEGF	O
in	O
transformed	O
epithelial	O
cells	O
.	O
Based	O
on	O
these	O
results	O
,	O
we	O
performed	O
a	O
retrospective	O
study	O
of	O
the	O
p53	O
and	O
K-ras	O
genes	O
status	O
and	O
VEGF	O
gene	O
expression	O
in	O
the	O
tumor	O
tissues	O
from	O
181	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
using	O
SSCP	O
,	O
sequencing	O
,	O
RT	O
-	O
PCR	O
and	O
immunohistochemical	O
techniques	O
.	O
Forty-six	O
carcinomas	B-malignancy-type
(	O
25.4	O
%	O
)	O
were	O
evaluated	O
as	O
having	O
high	O
VEGF	O
expression	O
,	O
and	O
135	O
tumors	O
(	O
74.6	O
%	O
)	O
had	O
low	O
VEGF	O
expression	O
.	O
Of	O
the	O
181	O
primary	O
NSCLC	B-malignancy-type
studied	O
,	O
63	O
carcinomas	B-malignancy-type
(	O
34.8	O
%	O
)	O
contained	O
mutations	O
of	O
p53	O
,	O
whereas	O
only	O
14	O
carcinomas	B-malignancy-type
(	O
7.7	O
%	O
)	O
had	O
mutations	O
of	O
K-ras	O
.	O
There	O
were	O
no	O
significant	O
relationships	O
between	O
VEGF	O
expression	O
and	O
p53	O
status	O
or	O
each	O
mutant	O
exon	O
of	O
p53	O
.	O
In	O
contrast	O
,	O
a	O
significant	O
difference	O
was	O
found	O
between	O
VEGF	O
expression	O
and	O
K-ras	O
status	O
.	O
Of	O
the	O
14	O
tumors	O
with	O
mutant	O
K-ras	O
genes	O
,	O
7	O
cases	O
(	O
50.0	O
%	O
)	O
had	O
high	O
VEGF	O
expression	O
whereas	O
only	O
39	O
of	O
the	O
167	O
tumors	O
with	O
wild	O
-	O
type	O
K-ras	O
(	O
23.4	O
%	O
)	O
had	O
high	O
VEGF	O
expression	O
(	O
p	O
=	O
0.0278	O
)	O
.	O
The	O
mean	O
VEGF	O
conservation	O
rate	O
for	O
the	O
14	O
tumors	O
with	O
mutant	O
K-ras	O
genes	O
was	O
0.77	O
+/-	O
0.58	O
and	O
the	O
rate	O
of	O
the	O
167	O
tumors	O
with	O
wild	O
-	O
type	O
K-ras	O
genes	O
was	O
0.49	O
+/-	O
0.46	O
(	O
p	O
=	O
0.	O
0350	O
)	O
.	O
Moreover	O
,	O
the	O
overall	O
survival	O
rate	O
of	O
patients	O
with	O
high	O
VEGF	O
expression	O
was	O
lower	O
than	O
patients	O
with	O
low	O
VEGF	O
expression	O
(	O
45.7	O
%	O
vs	O
60.7	O
%	O
,	O
p	O
=	O
0.0419	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
overall	O
survival	O
rate	O
between	O
patients	O
with	O
a	O
mutant	O
p53	O
and	O
those	O
with	O
a	O
wild	O
-	O
type	O
p53	O
;	O
there	O
was	O
also	O
no	O
difference	O
in	O
the	O
overall	O
survival	O
between	O
patients	O
with	O
a	O
mutant	O
K-ras	O
and	O
those	O
with	O
a	O
wild	O
-	O
type	O
K-ras	O
.	O
The	O
Cox	O
regression	O
model	O
analysis	O
indicated	O
that	O
three	O
variables	O
,	O
VEGF	O
status	O
,	O
K-ras	O
status	O
and	O
nodal	O
status	O
,	O
were	O
found	O
to	O
be	O
significant	O
indicators	O
for	O
prognosis	O
(	O
p	O
=	O
0.0236	O
,	O
p	O
=	O
0.0172	O
and	O
p	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O
Our	O
data	O
suggest	O
that	O
a	O
high	O
expression	O
of	O
VEGF	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
This	O
may	O
be	O
a	O
clue	O
to	O
improving	O
lung	B-malignancy-type
cancer	I-malignancy-type
diagnoses	O
and	O
therapies	O
aimed	O
at	O
inhibiting	O
tumor	O
angiogenesis	O
due	O
to	O
VEGF	O
.	O
PMID	O
:	O
10675482	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2000	O
Feb;156	O
(	O
2	O
)	O
:433	O
-7	O
APC	O
mutations	O
in	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
.	O
Huang	O
H,	O
Mahler	O
-	O
Araujo	O
BM	O
,	O
Sankila	O
A	O
,	O
Chimelli	O
L,	O
Yonekawa	O
Y	O
,	O
Kleihues	O
P,	O
Ohgaki	O
H.	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
,	O
Lyon	O
,	O
France	O
.	O
The	O
cerebellar	B-malignancy-type
medulloblastoma	I-malignancy-type
(	O
WHO	O
Grade	O
IV	O
)	O
is	O
a	O
highly	O
malignant	O
,	O
invasive	O
embryonal	O
tumor	O
with	O
preferential	O
manifestation	O
in	O
children	O
.	O
Several	O
molecular	O
alterations	O
appear	O
to	O
be	O
involved	O
,	O
including	O
isochromosome	O
17q	O
and	O
the	O
p53	O
,	O
PTCH	O
,	O
and	O
beta-catenin	O
gene	O
mutations	O
.	O
In	O
this	O
study	O
,	O
46	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
were	O
screened	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
genes	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
(	O
APC	O
and	O
beta-catenin	O
)	O
.	O
Single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
revealed	O
3	O
miscoding	O
APC	O
mutations	O
in	O
2	O
(	O
4.3	O
%	O
)	O
medulloblastomas	B-malignancy-type
.	O
One	O
case	O
contained	O
a	O
GCA	O
-->	O
GTA	O
mutation	O
at	O
codon	O
1296	O
(	O
Ala	O
-->	O
Val	O
)	O
,	O
and	O
another	O
case	O
had	O
double	O
point	O
mutations	O
at	O
codons	O
1472	O
(	O
GTA	O
-->	O
ATA	O
,	O
Val	O
-->	O
Ile	O
)	O
and	O
1495	O
(	O
AGT	O
-->	O
GGT	O
,	O
Ser	O
-->	O
Gly	O
)	O
.	O
Miscoding	O
beta-catenin	O
mutations	O
were	O
detected	O
in	O
4	O
tumors	O
(	O
8.7	O
%	O
)	O
.	O
Three	O
of	O
these	O
were	O
located	O
at	O
codon	O
33	O
(	O
TCT	O
-->	O
TTT	O
,	O
Ser	O
-->	O
Phe	O
)	O
and	O
another	O
at	O
codon	O
37	O
(	O
TCT	O
-->	O
GCT	O
,	O
Ser	O
-->	O
Ala	O
)	O
.	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
and	O
beta-catenin	O
mutations	O
were	O
mutually	O
exclusive	O
and	O
occurred	O
in	O
a	O
total	O
of	O
6	O
of	O
46	O
cases	O
(	O
13	O
%	O
)	O
.	O
Although	O
germline	O
APC	O
mutations	O
are	O
a	O
well	O
established	O
cause	O
of	O
familial	B-malignancy-type
colon	I-malignancy-type
and	O
brain	B-malignancy-type
tumors	I-malignancy-type
(	O
Turcot	B-malignancy-type
syndrome	I-malignancy-type
)	O
,	O
this	O
study	O
provides	O
the	O
first	O
evidence	O
that	O
APC	O
mutations	O
are	O
also	O
operative	O
in	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
.	O
PMID	O
:	O
10666372	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
1999	O
Dec	O
1;91(	O
23	O
)	O
:	O
2032	O
-	O
8	O
Implications	O
and	O
prognostic	O
value	O
of	O
K-ras	O
mutation	O
for	O
early	O
-	O
stage	O
lung	B-malignancy-type
cancer	I-malignancy-type
in	O
women	O
.	O
Nelson	O
HH	O
,	O
Christiani	O
DC	O
,	O
Mark	O
EJ	O
,	O
Wiencke	O
JK	O
,	O
Wain	O
JC	O
,	O
Kelsey	O
KT.	O
Department	O
of	O
Cancer	O
Cell	O
Biology	O
,	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
MA	O
02115-6021	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Because	O
there	O
is	O
no	O
clear	O
consensus	O
as	O
to	O
the	O
predictive	O
value	O
of	O
K-ras	O
gene	O
mutation	O
for	O
survival	O
in	O
patients	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
examined	O
the	O
occurrence	O
of	O
K-ras	O
mutations	O
in	O
a	O
large	O
,	O
prospective	O
case	O
series	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
.	O
Our	O
goals	O
were	O
to	O
define	O
the	O
patient	O
characteristics	O
associated	O
with	O
K-ras	O
mutation	O
and	O
to	O
determine	O
whether	O
mutation	O
of	O
this	O
gene	O
might	O
be	O
a	O
biomarker	O
of	O
patient	O
prognosis	O
.	O
METHODS	O
:	O
Consecutive	O
,	O
newly	O
diagnosed	O
patients	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
treated	O
with	O
potentially	O
curative	O
resection	O
over	O
a	O
4	O
-	O
year	O
period	O
were	O
recruited	O
for	O
study	O
.	O
The	O
mutation	O
status	O
of	O
K-ras	O
codon	O
12	O
in	O
each	O
patient	O
's	O
tumor	O
DNA	O
was	O
determined	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
archived	O
pathology	O
specimens	O
.	O
Analyses	O
were	O
restricted	O
to	O
adenocarcinoma	B-malignancy-type
.	O
RESULTS	O
:	O
There	O
was	O
a	O
statistically	O
significant	O
association	O
between	O
female	O
sex	O
and	O
K-ras	O
mutation	O
after	O
adjustment	O
for	O
carcinogen	O
exposures	O
(	O
odds	O
ratio	O
=	O
3.3	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.3	O
-	O
7.9	O
)	O
;	O
mutations	O
were	O
found	O
only	O
in	O
smokers	O
.	O
Comparison	O
of	O
Kaplan	O
-	O
Meier	O
curves	O
indicated	O
a	O
strong	O
association	O
between	O
K-ras	O
mutation	O
and	O
decreased	O
patient	O
survival	O
(	O
two	O
-	O
sided	O
P	O
=	O
.009	O
)	O
;	O
analysis	O
stratified	O
by	O
pathologic	O
staging	O
groups	O
revealed	O
that	O
this	O
association	O
was	O
statistically	O
significant	O
only	O
for	O
stage	O
I	O
tumors	O
(	O
two	O
-	O
sided	O
P	O
=	O
.002	O
)	O
.	O
Cox	O
proportional	O
hazards	O
modeling	O
indicated	O
that	O
K-ras	O
codon	O
12	O
mutation	O
was	O
a	O
statistically	O
significant	O
predictor	O
of	O
patient	O
survival	O
,	O
after	O
adjustment	O
for	O
the	O
effects	O
of	O
age	O
,	O
sex	O
,	O
and	O
stage	O
(	O
risk	O
ratio	O
=	O
1.8	O
;	O
95	O
%	O
CI	O
=	O
1.1	O
-	O
3.1	O
)	O
.	O
CONCLUSIONS	O
:	O
After	O
adjustment	O
for	O
environmental	O
exposures	O
,	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
tumors	I-malignancy-type
in	O
women	O
appear	O
to	O
be	O
more	O
likely	O
than	O
those	O
in	O
men	O
to	O
harbor	O
K-ras	O
mutations	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
estrogen	O
exposure	O
in	O
either	O
the	O
initiation	O
or	O
the	O
selection	O
of	O
K-ras	O
mutant	O
clones	O
in	O
adenocarcinoma	B-malignancy-type
.	O
In	O
addition	O
,	O
our	O
data	O
suggest	O
that	O
K-ras	O
codon	O
12	O
mutation	O
is	O
a	O
marker	O
of	O
aggressive	B-malignancy-type
NSCLC	I-malignancy-type
,	O
as	O
evidenced	O
by	O
its	O
association	O
with	O
decreased	O
patient	O
survival	O
,	O
particularly	O
for	O
early	O
-	O
stage	O
disease	O
.	O
PMID	O
:	O
10580029	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Radiat	O
Res	O
1999	O
Dec;152(	O
6	O
Suppl	O
)	O
:S118	O
-24	O
Analysis	O
of	O
genetic	O
changes	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
induced	O
by	O
thorotrast	O
.	O
Kamikawa	O
T	O
,	O
Amenomori	O
M,	O
Itoh	O
T	O
,	O
Momoi	O
H,	O
Hiai	O
H,	O
Machinami	O
R	O
,	O
Ishikawa	O
Y	O
,	O
Mori	O
T	O
,	O
Shimahara	O
Y	O
,	O
Yamaoka	O
Y	O
,	O
Fukumoto	O
M.	O
Department	O
of	O
Pathology	O
,	O
Kyoto	O
University	O
,	O
Kyoto	O
,	O
Japan	O
.	O
Thorotrast	O
,	O
a	O
colloidal	O
suspension	O
of	O
radioactive	O
(232)ThO(2)	O
that	O
emits	O
alpha	O
particles	O
,	O
was	O
used	O
as	O
a	O
radiographic	O
contrast	O
agent	O
in	O
the	O
1930s	O
-	O
1950s	O
.	O
Several	O
decades	O
after	O
injection	O
,	O
Thorotrast	O
causes	O
liver	B-malignancy-type
cancers	I-malignancy-type
,	O
among	O
which	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
(	O
ICC	B-malignancy-type
)	O
is	O
prominent	O
.	O
We	O
investigated	O
mutations	O
of	O
the	O
RAS	O
and	O
the	O
TP53	O
genes	O
in	O
archival	O
sections	O
of	O
ICC	B-malignancy-type
induced	O
by	O
Thorotrast	O
.	O
Compared	O
to	O
ICC	O
that	O
was	O
not	O
associated	O
with	O
Thorotrast	O
,	O
the	O
frequency	O
of	O
mutation	O
of	O
the	O
KRAS	O
gene	O
was	O
lower	O
,	O
while	O
that	O
of	O
the	O
TP53	O
gene	O
was	O
more	O
than	O
two	O
times	O
higher	O
.	O
The	O
most	O
common	O
mutation	O
of	O
the	O
TP53	O
gene	O
was	O
A	O
-	O
G	O
transitions	O
.	O
Interestingly	O
,	O
TP53	O
mutations	O
were	O
also	O
found	O
in	O
noncancerous	O
areas	O
of	O
livers	O
in	O
which	O
Thorotrast	O
had	O
been	O
deposited	O
.	O
Furthermore	O
,	O
mutations	O
tended	O
to	O
accumulate	O
in	O
tissues	O
from	O
more	O
advanced	O
tumors	O
.	O
These	O
results	O
suggest	O
that	O
deposited	O
Thorotrast	O
continuously	O
damages	O
DNA	O
in	O
liver	O
cells	O
in	O
some	O
way	O
,	O
resulting	O
in	O
A	O
-	O
G	O
transitions	O
of	O
the	O
TP53	O
gene	O
.	O
However	O
,	O
we	O
have	O
not	O
been	O
able	O
to	O
rule	O
out	O
the	O
possibility	O
that	O
genetic	O
insults	O
occur	O
indirectly	O
in	O
the	O
proliferating	O
cells	O
adjacent	O
to	O
the	O
necrosis	O
rather	O
than	O
being	O
a	O
direct	O
effect	O
of	O
alpha	O
particles	O
.	O
PMID	O
:	O
10564951	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Med	O
Genet	O
1999	O
Aug;36	O
(	O
8	O
)	O
:	O
610-4	O
Mutational	O
analysis	O
of	O
the	O
N-ras	O
,	O
p53	O
,	O
p16INK4a	O
,	O
CDK4	O
,	O
and	O
MC1R	O
genes	O
in	O
human	O
congenital	B-malignancy-type
melanocytic	I-malignancy-type
naevi	I-malignancy-type
.	O
Papp	O
T	O
,	O
Pemsel	O
H,	O
Zimmermann	O
R	O
,	O
Bastrop	O
R	O
,	O
Weiss	O
DG	O
,	O
Schiffmann	O
D.	O
University	O
of	O
Rostock	O
,	O
Department	O
of	O
Biology	O
,	O
Germany	O
.	O
Eighteen	O
human	O
congenital	B-malignancy-type
melanocytic	I-malignancy-type
naevi	I-malignancy-type
(	O
CMN	B-malignancy-type
)	O
from	O
17	O
patients	O
were	O
screened	O
for	O
activating	O
point	O
mutations	O
in	O
the	O
oncogenes	O
N-ras	O
and	O
CDK4	O
and	O
for	O
sequence	O
variants	O
in	O
the	O
MC1R	O
gene	O
by	O
combined	O
RFLP	O
-	O
PCR	O
/	O
SSCP	O
analysis	O
.	O
In	O
addition	O
,	O
all	O
lesions	O
were	O
screened	O
for	O
deletions	O
and	O
point	O
mutations	O
in	O
the	O
tumour	O
suppressor	O
genes	O
p53	O
and	O
p16INK4a	O
(	O
CDKN2A	O
)	O
by	O
combined	O
multiplex	O
PCR	O
/	O
SSCP	O
analysis	O
.	O
Positive	O
screening	O
data	O
were	O
specified	O
by	O
sequencing	O
of	O
the	O
corresponding	O
PCR	O
product	O
.	O
Activating	O
point	O
mutations	O
in	O
the	O
N-ras	O
gene	O
(	O
nine	O
CAA	O
(	O
Gln	O
)	O
to	O
AAA	O
(	O
Lys	O
)	O
transversions	O
and	O
one	O
CAA	O
(	O
Gln	O
)	O
to	O
CGA	O
(	O
Arg	O
)	O
transition	O
at	O
codon	O
61	O
)	O
were	O
detected	O
at	O
high	O
frequency	O
(	O
56	O
%	O
)	O
.	O
Furthermore	O
,	O
three	O
missense	O
mutations	O
(	O
V	O
92	O
M	O
)	O
and	O
two	O
silent	O
mutations	O
(	O
CGA	O
(	O
Arg	O
)	O
to	O
CGG	O
(	O
Arg	O
)	O
,	O
codon	O
213	O
,	O
exon	O
6	O
)	O
were	O
found	O
in	O
the	O
MC1R	O
and	O
p53	O
genes	O
,	O
respectively	O
.	O
No	O
mutations	O
were	O
found	O
in	O
p16	O
or	O
CDK4	O
.	O
The	O
activated	O
N-ras	O
oncogene	O
,	O
which	O
is	O
also	O
found	O
in	O
human	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
,	O
may	O
constitute	O
a	O
potential	O
risk	O
factor	O
for	O
melanoma	B-malignancy-type
formation	O
within	O
CMN	B-malignancy-type
.	O
PMID	O
:	O
10465111	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
Aug;12(	O
8	O
)	O
:775	O
-80	O
H-ras	O
and	O
K-ras	O
gene	O
mutations	O
in	O
primary	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcoma	I-malignancy-type
:	O
concomitant	O
mutations	O
of	O
the	O
ras	O
genes	O
.	O
Yoo	O
J,	O
Robinson	O
RA	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St.	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
South	O
Korea	O
.	O
ras	O
gene	O
mutations	O
have	O
been	O
described	O
with	O
varying	O
frequency	O
in	O
several	O
types	O
of	O
human	O
malignancies	O
.	O
To	O
determine	O
the	O
incidence	O
and	O
type	O
of	O
ras	O
mutations	O
in	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
tumors	I-malignancy-type
,	O
we	O
studied	O
45	O
sarcomas	B-malignancy-type
,	O
including	O
27	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFHs	B-malignancy-type
)	O
,	O
10	O
liposarcomas	B-malignancy-type
,	O
2	O
rhabdomyosarcomas	B-malignancy-type
,	O
and	O
6	O
leiomyosarcomas	B-malignancy-type
.	O
Al	O
of	O
the	O
tumors	O
were	O
investigated	O
by	O
direct	O
sequence	O
analysis	O
with	O
the	O
automated	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
ras	O
sequences	O
.	O
Twenty	O
(	O
44	O
%	O
)	O
of	O
the	O
sarcomas	B-malignancy-type
examined	O
harbored	O
K-ras	O
mutations	O
,	O
18	O
(	O
90	O
%	O
)	O
of	O
which	O
were	O
MFHs	B-malignancy-type
.	O
All	O
of	O
the	O
K-ras	O
mutations	O
were	O
G	O
-	O
to	O
-	O
A	O
transition	O
mutations	O
in	O
the	O
second	O
position	O
of	O
codon	O
13	O
(	O
glycine	O
-->	O
aspartic	O
acid	O
)	O
.	O
Of	O
the	O
samples	O
with	O
K-ras	O
activation	O
,	O
7	O
(	O
16	O
%	O
of	O
the	O
total	O
of	O
45	O
tumors	O
)	O
,	O
including	O
6	O
MFHs	B-malignancy-type
and	O
1	O
leiomyosarcoma	B-malignancy-type
,	O
also	O
contained	O
H-ras	O
mutation	O
.	O
All	O
of	O
the	O
tumors	O
that	O
showed	O
H-ras	O
alteration	O
had	O
G	O
-	O
to	O
-	O
T	O
transversion	O
mutations	O
in	O
the	O
second	O
base	O
of	O
codon	O
12	O
(	O
glycine	O
-->	O
valine	O
)	O
.	O
These	O
data	O
possibly	O
implicate	O
that	O
ras	O
gene	O
activation	O
may	O
be	O
a	O
relatively	O
uncommon	O
event	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
tumors	I-malignancy-type
,	O
with	O
the	O
exception	O
of	O
MFH	B-malignancy-type
.	O
It	O
is	O
suggested	O
that	O
the	O
oncogenic	O
process	O
underlying	O
the	O
development	O
of	O
tumors	O
between	O
these	O
groups	O
may	O
be	O
different	O
and	O
that	O
ras	O
gene	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
etiology	O
and/or	O
progression	O
of	O
MFH	B-malignancy-type
.	O
It	O
is	O
noteworthy	O
that	O
when	O
ras	O
gene	O
activation	O
occurs	O
in	O
sarcoma	B-malignancy-type
,	O
it	O
predominantly	O
affects	O
the	O
K-ras	O
gene	O
,	O
particularly	O
codon	O
13	O
.	O
Moreover	O
,	O
H-ras	O
mutations	O
in	O
our	O
samples	O
were	O
detected	O
only	O
in	O
association	O
with	O
tumors	O
that	O
also	O
displayed	O
K-ras	O
-	O
mutated	O
genes	O
.	O
This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
concomitant	O
mutations	O
in	O
two	O
different	O
members	O
of	O
the	O
ras	O
gene	O
family	O
in	O
sarcoma	B-malignancy-type
PMID	O
:	O
10463479	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
May;90	O
(	O
5	O
)	O
:	O
510	O
-	O
5	O
Mutational	O
analysis	O
of	O
beta-catenin	O
gene	O
in	O
Japanese	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
:	O
frequent	O
mutations	O
in	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Sagae	O
S	O
,	O
Kobayashi	O
K,	O
Nishioka	O
Y	O
,	O
Sugimura	O
M,	O
Ishioka	O
S	O
,	O
Nagata	O
M,	O
Terasawa	O
K,	O
Tokino	O
T	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Hokkaido	O
.	O
sagaes@sapmed	O
.ac.jp	O
To	O
investigate	O
the	O
contribution	O
of	O
the	O
beta-catenin	O
gene	O
to	O
the	O
development	O
of	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
mutational	O
analysis	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
conducted	O
.	O
We	O
analyzed	O
61	O
primary	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
consisting	O
of	O
49	O
non	B-malignancy-type
-	I-malignancy-type
endometrioid	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
and	O
12	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
,	O
for	O
genetic	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Five	O
carcinomas	B-malignancy-type
showed	O
beta-catenin	O
mutations	O
(	O
S	O
37	O
C	O
,	O
T	O
41	O
I	O
,	O
T	O
41	O
A	O
)	O
,	O
including	O
4	O
(	O
33	O
%	O
)	O
of	O
12	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
and	O
1	O
(	O
14	O
%	O
)	O
of	O
7	O
mucinous	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
.	O
All	O
of	O
these	O
mutations	O
altered	O
at	O
the	O
serine	O
/	O
threonine	O
residues	O
that	O
are	O
potential	O
sites	O
of	O
GSK	O
3-beta	O
phosphorylation	O
.	O
We	O
detected	O
no	O
carcinomas	B-malignancy-type
with	O
interstitial	O
deletion	O
involving	O
exon	O
3	O
of	O
beta-catenin	O
.	O
Furthermore	O
,	O
we	O
immunohistochemically	O
studied	O
27	O
of	O
the	O
61	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Both	O
nuclear	O
and	O
cytoplasmic	O
beta-catenin	O
expressions	O
were	O
demonstrated	O
in	O
4	O
of	O
the	O
27	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
for	O
which	O
tissue	O
samples	O
were	O
available	O
for	O
examination	O
.	O
All	O
4	O
cases	O
exhibited	O
mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
,	O
including	O
a	O
mucinous	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Our	O
results	O
suggested	O
that	O
beta-catenin	O
gene	O
mutation	O
at	O
potential	O
GSK	O
3-beta	O
phosphorylation	O
sites	O
results	O
in	O
accumulation	O
of	O
beta-catenin	O
protein	O
within	O
the	O
cells	O
and	O
its	O
translocation	O
to	O
nuclei	O
.	O
Accumulated	O
beta-catenin	O
protein	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
some	O
mucinous	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10391090	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Chin	O
Med	O
J	O
(	O
Engl	O
)	O
1998	O
Apr;111(	O
4	O
)	O
:	O
343	O
-	O
5	O
N-ras	O
mutations	O
in	O
43	O
Chinese	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Guo	O
W	O
,	O
Tang	O
B	O
,	O
Xu	O
S	O
,	O
Yao	O
Y	O
,	O
Ye	O
D.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Post	O
and	O
Telecommunications	O
General	O
Hospital	O
,	O
Beijing	O
,	O
China	O
.	O
OBJECTIVE	O
:	O
To	O
detect	O
3	O
kinds	O
of	O
N-ras	O
mutations	O
in	O
Chinese	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
METHODS	O
:	O
In	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
dot	O
analysis	O
were	O
used	O
to	O
study	O
N-ras	O
gene	O
mutations	O
in	O
43	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
25	O
healthy	O
people	O
were	O
used	O
as	O
controls	O
.	O
Patients	O
were	O
selected	O
in	O
the	O
Beijing	O
district	O
and	O
consisted	O
of	O
19	O
males	O
and	O
24	O
females	O
.	O
The	O
average	O
age	O
was	O
37	O
.	O
The	O
controls	O
were	O
healthy	O
individuals	O
with	O
the	O
average	O
age	O
of	O
36.5	O
from	O
the	O
same	O
region	O
.	O
3	O
oligonucleotide	O
probes	O
were	O
artificially	O
synthesized	O
to	O
detect	O
mutations	O
in	O
codon	O
12	O
and	O
13	O
of	O
N-ras	O
.	O
RESULTS	O
:	O
Five	O
out	O
of	O
43	O
AML	B-malignancy-type
samples	O
have	O
been	O
found	O
contain	O
G	O
-->	O
A	O
mutation	O
in	O
codon	O
12.2	O
have	O
G	O
-->	O
T	O
mutation	O
in	O
codon	O
12	O
.	O
One	O
has	O
G	O
-->	O
A	O
mutation	O
in	O
codon	O
13	O
.	O
The	O
mutation	O
rate	O
was	O
18.6	O
%	O
.	O
None	O
of	O
the	O
controls	O
presented	O
these	O
mutations	O
.	O
The	O
frequency	O
of	O
mutation	O
of	O
N-ras	O
in	O
the	O
AML	B-malignancy-type
samples	O
showed	O
statistical	O
differences	O
with	O
that	O
of	O
the	O
controls	O
.	O
CONCLUSION	O
:	O
Analysis	O
of	O
the	O
results	O
suggests	O
the	O
N-ras	O
mutations	O
may	O
have	O
some	O
relationship	O
with	O
the	O
etiology	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
PMID	O
:	O
10374400	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1999	O
Jun;94	O
(	O
6	O
)	O
:1638-42	O
Gene	O
mutations	O
of	O
K-ras	O
in	O
gallbladder	O
mucosae	O
and	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
with	O
an	O
anomalous	O
junction	O
of	O
the	O
pancreaticobiliary	O
duct	O
.	O
Hanada	O
K,	O
Tsuchida	O
A	O
,	O
Iwao	O
T	O
,	O
Eguchi	O
N	O
,	O
Sasaki	O
T	O
,	O
Morinaka	O
K,	O
Matsubara	O
K,	O
Kawasaki	O
Y	O
,	O
Yamamoto	O
S	O
,	O
Kajiyama	O
G.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Onomichi	O
General	O
Hospital	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
OBJECTIVE	O
:	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
mutational	O
spectrum	O
of	O
K-ras	O
in	O
cases	O
of	O
gallbladder	O
and	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
with	O
an	O
anomalous	O
junction	O
of	O
the	O
pancreaticobiliary	O
duct	O
(	O
AJPBD	O
)	O
.	O
METHODS	O
:	O
We	O
examined	O
35	O
gallbladders	O
with	O
AJPBD	O
(	O
20	O
with	O
hyperplasia	B-malignancy-type
,	O
15	O
with	O
carcinoma	B-malignancy-type
)	O
and	O
38	O
gallbladders	O
without	O
AJPBD	O
(	O
four	O
normal	O
gallbladders	O
,	O
four	O
with	O
hyperplasia	B-malignancy-type
,	O
six	O
with	O
adenoma	B-malignancy-type
,	O
24	O
with	O
carcinoma	B-malignancy-type
)	O
.	O
Polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
were	O
performed	O
to	O
detect	O
mutations	O
in	O
codon	O
12	O
or	O
13	O
of	O
K-ras	O
.	O
RESULTS	O
:	O
In	O
the	O
cases	O
with	O
AJPBD	O
,	O
the	O
prevalences	O
of	O
K-ras	O
mutation	O
were	O
15	O
%	O
(	O
3	O
/	O
20	O
)	O
in	O
hyperplasia	B-malignancy-type
,	O
60	O
%	O
(	O
6	O
/	O
10	O
)	O
in	O
stage	O
I	O
carcinoma	B-malignancy-type
,	O
and	O
100	O
%	O
(	O
5	O
/	O
5	O
)	O
in	O
stage	O
II	O
-	O
IV	O
carcinoma	B-malignancy-type
.	O
In	O
the	O
cases	O
without	O
AJPBD	O
,	O
the	O
prevalences	O
of	O
K-ras	O
mutation	O
were	O
0	O
%	O
(	O
0	O
/	O
4	O
)	O
in	O
normal	O
gallbladder	O
,	O
0	O
%	O
(	O
0	O
/	O
4	O
)	O
in	O
hyperplasia	B-malignancy-type
,	O
17	O
%	O
(	O
1	O
/	O
6	O
)	O
in	O
adenoma	B-malignancy-type
,	O
7	O
%	O
(	O
1	O
/	O
16	O
)	O
in	O
stage	O
I	O
carcinoma	B-malignancy-type
,	O
and	O
38	O
%	O
(	O
3	O
/	O
8	O
)	O
in	O
stage	O
II	O
-	O
IV	O
carcinoma	B-malignancy-type
.	O
Prevalences	O
of	O
K-ras	O
mutation	O
in	O
hyperplasia	B-malignancy-type
and	O
carcinoma	B-malignancy-type
with	O
AJPBD	O
were	O
greater	O
than	O
those	O
without	O
AJPBD	O
(	O
p	O
<	O
0.05	O
)	O
.	O
The	O
point	O
mutation	O
of	O
GGT	O
to	O
GAT	O
in	O
codon	O
12	O
was	O
frequently	O
observed	O
in	O
the	O
cases	O
with	O
AJPBD	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
specific	O
K-ras	O
mutation	O
in	O
codon	O
12	O
(	O
GGT	O
to	O
GAT	O
)	O
may	O
contribute	O
to	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
in	O
the	O
gallbladder	O
with	O
AJPBD	O
.	O
PMID	O
:	O
10364037	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
1999	O
May	O
;	O
5	O
(	O
5	O
)	O
:	O
1147	O
-	O
53	O
Detection	O
of	O
mutations	O
of	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
pancreatic	O
juice	O
and	O
its	O
application	O
to	O
diagnosis	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
comparison	O
with	O
K-ras	O
mutation	O
.	O
Yamaguchi	O
Y	O
,	O
Watanabe	O
H,	O
Yrdiran	O
S	O
,	O
Ohtsubo	O
K,	O
Motoo	O
Y	O
,	O
Okai	O
T	O
,	O
Sawabu	O
N	O
.	O
Department	O
of	O
Internal	O
Medicine	O
and	O
Medical	O
Oncology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
Because	O
of	O
the	O
difficulty	O
in	O
obtaining	O
biopsy	O
specimens	O
from	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
K-ras	O
mutation	O
analysis	O
in	O
pancreatic	O
juice	O
has	O
been	O
used	O
for	O
specific	O
diagnosis	O
.	O
But	O
recently	O
,	O
false	O
positives	O
have	O
been	O
obtained	O
with	O
this	O
method	O
.	O
To	O
improve	O
the	O
genetic	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
detection	O
of	O
p53	O
gene	O
mutation	O
in	O
pancreatic	O
juice	O
was	O
studied	O
.	O
Pancreatic	O
juice	O
was	O
sampled	O
endoscopically	O
.	O
Single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
was	O
used	O
for	O
p53	O
mutation	O
analysis	O
.	O
Furthermore	O
,	O
K-ras	O
mutations	O
at	O
codon	O
12	O
were	O
also	O
studied	O
in	O
the	O
same	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Of	O
26	O
cases	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
p53	O
mutations	O
were	O
detected	O
in	O
11	O
(	O
42.3	O
%	O
)	O
.	O
No	O
mutations	O
were	O
seen	O
in	O
the	O
cases	O
with	O
mucin	O
-	O
producing	O
adenoma	B-malignancy-type
nor	O
with	O
chronic	O
pancreatitis	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
84.0	O
%	O
of	O
cases	O
by	O
RFLP	O
analysis	O
,	O
which	O
has	O
high	O
sensitivity	O
,	O
and	O
in	O
65.3	O
%	O
by	O
hybridization	O
protection	O
assay	O
,	O
which	O
has	O
high	O
specificity	O
.	O
Using	O
a	O
combination	O
assay	O
with	O
both	O
genes	O
,	O
genetic	O
abnormalities	O
were	O
detected	O
in	O
92.0	O
%	O
by	O
RFLP	O
and	O
73	O
.1	O
%	O
by	O
hybridization	O
protection	O
assay	O
including	O
two	O
cases	O
in	O
which	O
p53	O
alone	O
was	O
positive	O
by	O
both	O
methods	O
.	O
The	O
specificity	O
of	O
p53	O
mutation	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
very	O
high	O
.	O
Therefore	O
,	O
simultaneous	O
analysis	O
of	O
p53	O
and	O
K-ras	O
mutation	O
is	O
suggested	O
to	O
enhance	O
the	O
genetic	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10353750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1999	O
May	O
;116	O
(	O
5	O
)	O
:	O
1063	O
-	O
71	O
Association	O
of	O
K-ras	O
mutations	O
with	O
p16	O
methylation	O
in	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Guan	O
RJ	O
,	O
Fu	O
Y	O
,	O
Holt	O
PR	O
,	O
Pardee	O
AB	O
.	O
Division	O
of	O
Gastroenterology	O
,	O
Brigham	O
&	O
Women	O
's	O
Hospital	O
,	O
Boston	O
,	O
USA	O
.	O
rguan@mbcrr	O
.harvard	O
.edu	O
BACKGROUND	O
&	O
AIMS	O
:	O
K-ras	O
mutations	O
are	O
early	O
genetic	O
changes	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
p16	O
,	O
a	O
tumor	O
-	O
suppressor	O
gene	O
,	O
is	O
inactivated	O
in	O
neoplasms	O
by	O
mutation	O
,	O
deletion	O
,	O
or	O
methylation	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
p16	O
methylation	O
status	O
and	O
its	O
possible	O
association	O
with	O
K-ras	O
mutations	O
in	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
DNA	O
isolated	O
from	O
8	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
and	O
41	O
microdissected	O
human	O
colon	O
tissue	O
samples	O
was	O
analyzed	O
.	O
p16	O
methylation	O
status	O
was	O
determined	O
using	O
two	O
analytical	O
methods	O
.	O
The	O
level	O
of	O
p16	O
expression	O
was	O
determined	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
Northern	O
blot	O
.	O
K-ras	O
mutations	O
were	O
determined	O
by	O
DNA	O
sequence	O
analysis	O
.	O
The	O
DNA	O
methyltransferase	O
activity	O
was	O
determined	O
by	O
microassay	O
.	O
Parental	O
and	O
K-ras	O
-	O
transformed	O
IEC-18	O
cells	O
were	O
used	O
to	O
determine	O
the	O
potential	O
association	O
between	O
K-ras	O
mutations	O
and	O
p16	O
methylation	O
.	O
RESULTS	O
:	O
Methylated	O
p16	O
was	O
found	O
in	O
100	O
%	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
55	O
%	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
,	O
54	O
%	O
of	O
adenomas	B-malignancy-type
,	O
and	O
25	O
%	O
of	O
transitional	O
mucosa	O
but	O
not	O
in	O
normal	O
colonic	O
epithelium	O
.	O
Forty	O
-five	O
percent	O
of	O
cancers	O
and	O
38	O
%	O
of	O
adenomas	B-malignancy-type
showed	O
both	O
K-ras	O
mutations	O
and	O
p16	O
methylation	O
.	O
Of	O
11	O
cancers	O
and	O
adenomas	B-malignancy-type
with	O
K-ras	O
mutation	O
,	O
10	O
specimens	O
showed	O
methylated	O
p16	O
.	O
In	O
contrast	O
,	O
of	O
13	O
adenomas	B-malignancy-type
and	O
cancers	O
with	O
wild-type	O
K-ras	O
,	O
only	O
3	O
specimens	O
showed	O
methylated	O
p16	O
(	O
P	O
=	O
0.001	O
)	O
.	O
Stable	O
transformation	O
of	O
IEC-18	O
cells	O
with	O
K-ras	O
increased	O
the	O
DNA	O
methyltransferase	O
activity	O
,	O
methylated	O
the	O
p16	O
gene	O
,	O
and	O
suppressed	O
the	O
expression	O
of	O
p16	O
.	O
Treatment	O
with	O
a	O
DNA	O
methylation	O
inhibitor	O
(	O
azadeoxycytidine	O
)	O
resulted	O
in	O
reexpression	O
of	O
p16	O
in	O
K-ras	O
-	O
transformed	O
IEC-18	O
cells	O
,	O
suggesting	O
that	O
the	O
expression	O
of	O
p16	O
was	O
suppressed	O
by	O
DNA	O
methylation	O
.	O
CONCLUSIONS	O
:	O
p16	O
methylation	O
occurs	O
frequently	O
in	O
human	O
colonic	B-malignancy-type
adenomas	I-malignancy-type
and	O
cancers	B-malignancy-type
and	O
is	O
closely	O
associated	O
with	O
K-ras	O
mutations	O
.	O
PMID	O
:	O
10220498	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Apr	O
15	O
;5	O
9	O
(	O
8	O
)	O
:	O
1811	O
-5	O
Frequent	O
mutation	O
and	O
nuclear	O
localization	O
of	O
beta-catenin	O
in	O
anaplastic	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Garcia-Rostan	O
G	O
,	O
Tallini	O
G	O
,	O
Herrero	O
A	O
,	O
D'Aquila	O
TG	O
,	O
Carcangiu	O
ML	O
,	O
Rimm	O
DL.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06520	O
,	O
USA	O
.	O
ginesa.rostan@yale	O
.edu	O
Beta-catenin	O
is	O
an	O
ubiquitously	O
expressed	O
cytoplasmic	O
protein	O
that	O
has	O
a	O
crucial	O
role	O
in	O
both	O
E-cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
and	O
as	O
a	O
downstream	O
signaling	O
molecule	O
in	O
the	O
wingless	O
pathway	O
.	O
Stabilization	O
of	O
beta-catenin	O
followed	O
by	O
nuclear	O
translocation	O
and	O
subsequent	O
T-cell	O
factor	O
/	O
lymphoid	O
-	O
enhancing	O
factor	O
-	O
mediated	O
transcriptional	O
activation	O
has	O
been	O
proposed	O
as	O
an	O
important	O
step	O
in	O
oncogenesis	O
.	O
Stabilization	O
may	O
occur	O
through	O
activating	O
mutations	O
in	O
exon-3	O
at	O
the	O
phosphorylation	O
sites	O
for	O
ubiquitination	O
and	O
degradation	O
of	O
beta-catenin	O
.	O
Immunohistochemical	O
subcellular	O
localization	O
of	O
beta-catenin	O
and	O
mutational	O
analysis	O
of	O
exon-3	O
of	O
the	O
beta-catenin	O
gene	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
followed	O
by	O
DNA	O
sequencing	O
was	O
performed	O
on	O
37	O
samples	O
from	O
31	O
patients	O
with	O
anaplastic	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Immunofluorescent	O
staining	O
showed	O
nuclear	O
localization	O
in	O
15	O
(	O
42	O
%	O
)	O
of	O
the	O
36	O
samples	O
examined	O
.	O
Nucleotide	O
sequencing	O
of	O
mobility	O
shifts	O
detected	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
revealed	O
somatic	O
alterations	O
in	O
19	O
(	O
61	O
%	O
)	O
of	O
the	O
31	O
patients	O
analyzed	O
.	O
We	O
conclude	O
that	O
mutations	O
in	O
beta-catenin	O
are	O
common	O
in	O
anaplastic	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
and	O
that	O
they	O
may	O
activate	O
transcription	O
,	O
as	O
illustrated	O
by	O
frequent	O
nuclear	O
localization	O
of	O
the	O
protein	O
.	O
These	O
findings	O
support	O
the	O
idea	O
that	O
beta-catenin	O
acts	O
as	O
an	O
oncogene	O
and	O
contributes	O
to	O
the	O
highly	O
aggressive	O
behavior	O
of	O
this	O
tumor	O
.	O
PMID	O
:	O
10213482	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
1999	O
Apr;18	O
(	O
3	O
)	O
:	O
308-15	O
Immunohistochemical	O
and	O
molecular	O
analysis	O
of	O
giant	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
:	O
a	O
report	O
of	O
three	O
cases	O
.	O
Imai	O
Y	O
,	O
Morishita	O
S	O
,	O
Ikeda	O
Y	O
,	O
Toyoda	O
M,	O
Ashizawa	O
T	O
,	O
Yamamoto	O
K,	O
Inoue	O
T	O
,	O
Ishikawa	O
T.	O
Department	O
of	O
Pathology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
We	O
performed	O
molecular	O
biological	O
studies	O
as	O
well	O
as	O
immunohistochemical	O
analysis	O
of	O
three	O
cases	O
of	O
giant	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Histologically	O
,	O
one	O
case	O
was	O
a	O
pleomorphic	O
giant	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
consisting	O
of	O
pleomorphic	O
giant	O
/	O
small	O
cells	O
and	O
spindle	O
cells	O
,	O
one	O
an	O
osteoclast	O
-	O
like	O
giant	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
composed	O
of	O
osteoclastoid	O
giant	O
cells	O
and	O
pleomorphic	O
small	O
cells	O
,	O
and	O
one	O
a	O
pleomorphic	O
giant	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
with	O
osteoclastoid	O
giant	O
cells	O
.	O
Immunohistochemically	O
,	O
pleomorphic	O
giant	O
cells	O
and	O
small	O
pleomorphic	O
cells	O
were	O
positive	O
for	O
epithelial	O
and	O
mesenchymal	O
markers	O
throughout	O
the	O
cases	O
.	O
Osteoclastoid	O
cells	O
were	O
strongly	O
positive	O
for	O
PG-M1	O
(	O
CD68	O
)	O
,	O
but	O
negative	O
for	O
lysozyme	O
and	O
epithelial	O
markers	O
.	O
Pleomorphic	O
spindle	O
cells	O
showed	O
the	O
same	O
immunoreactivity	O
as	O
pleomorphic	O
giant	O
/small	O
cells	O
.	O
Genetically	O
,	O
all	O
cases	O
contained	O
a	O
mutation	O
in	O
the	O
K-ras	O
(	O
codons	O
12	O
,	O
13	O
)	O
oncogene	O
,	O
but	O
neither	O
p53	O
(	O
exons	O
5-	O
8	O
)	O
nor	O
p16INK4	O
(	O
exons	O
1	O
,	O
2	O
)	O
gene	O
mutations	O
were	O
found	O
in	O
any	O
case	O
.	O
Furthermore	O
,	O
Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
the	O
p53	O
,	O
p161NK4	O
.	O
APC	O
,	O
and	O
DPC4	O
gene	O
loci	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
cases	O
.	O
Immunohistochemical	O
study	O
demonstrated	O
this	O
tumor	O
to	O
be	O
of	O
epithelial	O
origin	O
with	O
mesenchymal	O
differentiation	O
.	O
Genetically	O
,	O
initiation	O
of	O
the	O
tumor	O
is	O
similar	O
to	O
that	O
of	O
usual	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
but	O
progression	O
might	O
be	O
rather	O
different	O
.	O
The	O
peculiar	O
histologic	O
and	O
biologic	O
features	O
of	O
this	O
tumor	O
would	O
be	O
the	O
result	O
of	O
changes	O
in	O
other	O
functional	O
genes	O
.	O
PMID	O
:	O
10206490	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Surg	O
1998	O
Jul;228	O
(	O
1	O
)	O
:	O
79	O
-	O
86	O
K-ras	O
oncogene	O
mutations	O
indicate	O
malignancy	O
in	O
cystic	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Bartsch	O
D	O
,	O
Bastian	O
D	O
,	O
Barth	O
P,	O
Schudy	O
A	O
,	O
Nies	O
C	O
,	O
Kisker	O
O	O
,	O
Wagner	O
HJ	O
,	O
Rothmund	O
M.	O
Department	O
of	O
Surgery	O
,	O
Philips	O
-University	O
Marburg	O
,	O
Germany	O
.	O
OBJECTIVE	O
:	O
To	O
evaluate	O
clinical	O
parameters	O
,	O
presurgical	O
diagnostic	O
tests	O
,	O
histologic	O
findings	O
,	O
and	O
the	O
presence	O
of	O
K-ras	O
oncogene	O
mutations	O
in	O
cystic	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
to	O
determine	O
which	O
best	O
predict	O
malignancy	O
.	O
SUMMARY	O
BACKGROUND	O
DATA	O
:	O
Because	O
presurgical	O
,	O
intraoperative	O
,	O
and	O
final	O
pathologic	O
differentiation	O
is	O
difficult	O
in	O
cystic	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
,	O
it	O
would	O
be	O
a	O
major	O
benefit	O
to	O
identify	O
markers	O
that	O
accurately	O
predict	O
malignancy	O
in	O
these	O
rare	O
tumors	O
.	O
The	O
role	O
of	O
K-ras	O
oncogene	O
mutations	O
as	O
an	O
indicator	O
of	O
malignancy	O
has	O
not	O
been	O
determined	O
in	O
these	O
tumors	O
.	O
METHODS	O
:	O
Nineteen	O
patients	O
with	O
cystic	O
tumors	O
of	O
the	O
pancreas	O
were	O
evaluated	O
,	O
including	O
K-ras	O
mutation	O
analysis	O
based	O
on	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
digestion	O
assays	O
and	O
direct	O
DNA	O
sequencing	O
,	O
to	O
screen	O
for	O
parameters	O
that	O
accurately	O
predict	O
malignancy	O
.	O
RESULTS	O
:	O
All	O
malignant	O
cystic	B-malignancy-type
pancreatic	I-malignancy-type
tumors	I-malignancy-type
(	O
five	O
cystadenocarcinomas	B-malignancy-type
and	O
three	O
mucin	O
-	O
producing	O
adenocarcinomas	B-malignancy-type
)	O
harbored	O
K-ras	O
mutations	O
at	O
codon	O
12	O
or	O
13	O
.	O
K-ras	O
mutations	O
were	O
also	O
detected	O
in	O
the	O
percutaneous	O
fine	O
-	O
needle	O
aspirates	O
of	O
two	O
of	O
these	O
patients	O
.	O
In	O
contrast	O
,	O
none	O
of	O
nine	O
benign	O
cystadenomas	B-malignancy-type
or	O
the	O
solid	B-malignancy-type
-	I-malignancy-type
papillary	I-malignancy-type
neoplasm	I-malignancy-type
had	O
K-ras	O
mutations	O
.	O
None	O
of	O
the	O
patients	O
with	O
a	O
benign	O
tumor	O
carrying	O
K-ras	O
wild-type	O
sequences	O
developed	O
recurrent	O
disease	O
after	O
a	O
mean	O
follow-up	O
of	O
50	O
months	O
.	O
Seven	O
of	O
the	O
8	O
malignant	O
cystic	B-malignancy-type
pancreatic	I-malignancy-type
tumors	I-malignancy-type
,	O
but	O
none	O
of	O
the	O
11	O
benign	B-malignancy-type
tumors	I-malignancy-type
,	O
showed	O
dilatation	O
of	O
the	O
main	O
pancreatic	O
duct	O
on	O
computed	O
tomography	O
or	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
mutation	O
analysis	O
seems	O
to	O
be	O
a	O
powerful	O
tool	O
to	O
determine	O
the	O
malignant	O
potential	O
of	O
cystic	B-malignancy-type
pancreatic	I-malignancy-type
tumors	I-malignancy-type
before	O
and	O
after	O
surgery	O
.	O
Dilatation	O
of	O
the	O
main	O
pancreatic	O
duct	O
on	O
computed	O
tomography	O
or	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
is	O
highly	O
suggestive	O
for	O
malignancy	O
in	O
these	O
rare	O
tumors	O
.	O
PMID	O
:	O
9671070	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Clin	O
Oncol	O
1998	O
Apr;21(	O
2	O
)	O
:155	O
-60	O
Prognostic	O
value	O
of	O
K-ras	O
mutations	O
,	O
ras	O
oncoprotein	O
,	O
and	O
c-erb	O
B-2	O
oncoprotein	O
expression	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
Nemunaitis	O
J,	O
Klemow	O
S	O
,	O
Tong	O
A	O
,	O
Courtney	O
A	O
,	O
Johnston	O
W	O
,	O
Mack	O
M,	O
Taylor	O
W	O
,	O
Solano	O
M,	O
Stone	O
M,	O
Mallams	O
J,	O
Mues	O
G.	O
Texas	O
Oncology	O
,	O
P.A.	O
,	O
Dallas	O
75246	O
,	O
USA	O
.	O
This	O
trial	O
was	O
undertaken	O
to	O
determine	O
the	O
prognostic	O
role	O
of	O
K-ras	O
(	O
p21	O
)	O
,	O
c-erb	O
B-2	O
(	O
p185	O
)	O
protein	O
expression	O
,	O
and	O
the	O
presence	O
or	O
nonpresence	O
of	O
a	O
K-ras	O
gene	O
mutation	O
in	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
This	O
was	O
a	O
retrospective	O
study	O
of	O
103	O
patients	O
with	O
adeno	B-malignancy-type
-	I-malignancy-type
or	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
who	O
had	O
available	O
paraffin	O
-	O
stored	O
tumor	O
material	O
.	O
The	O
relation	O
of	O
several	O
clinical	O
variables	O
to	O
survival	O
was	O
analyzed	O
.	O
Immunohistochemical	O
techniques	O
were	O
used	O
to	O
determine	O
expression	O
of	O
p21	O
and	O
p185	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
sequencing	O
were	O
used	O
to	O
determine	O
K-ras	O
mutation	O
status	O
.	O
Tumor	O
stage	O
was	O
the	O
only	O
nonmolecular	O
clinical	O
variable	O
predictive	O
of	O
survival	O
(	O
p	O
=	O
0.0001	O
)	O
.	O
A	O
combination	O
of	O
K-ras	O
mutation	O
and	O
p	O
185	O
expression	O
(	O
p	O
=	O
0.0144	O
)	O
,	O
ras	O
mutation	O
and	O
strong	O
p21	O
expression	O
(	O
p	O
=	O
0.0137	O
)	O
,	O
and	O
K-ras	O
mutation	O
and	O
the	O
combined	O
expression	O
of	O
p21	O
and	O
p185	O
were	O
predictive	O
of	O
poor	O
survival	O
(	O
p	O
=	O
0.0415	O
)	O
in	O
univariate	O
analysis	O
of	O
all	O
patients	O
.	O
The	O
sole	O
presence	O
of	O
K-ras	O
mutation	O
was	O
predictive	O
of	O
survival	O
.	O
Additionally	O
,	O
when	O
combined	O
with	O
elevated	O
p21	O
or	O
p185	O
expression	O
in	O
a	O
subset	O
of	O
patients	O
with	O
4	O
or	O
more	O
years	O
of	O
follow-up	O
,	O
negative	O
correlation	O
with	O
survival	O
was	O
observed	O
.	O
PMID	O
:	O
9537203	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1997	O
Oct;151	O
(	O
4	O
)	O
:943-	O
9	O
Can	O
K-ras	O
codon	O
12	O
mutations	O
be	O
used	O
to	O
distinguish	O
benign	O
bile	O
duct	O
proliferations	O
from	O
metastases	O
in	O
the	O
liver	O
?	O
A	O
molecular	O
analysis	O
of	O
101	O
liver	B-malignancy-type
lesions	I-malignancy-type
from	O
93	O
patients	O
.	O
Hruban	O
RH	O
,	O
Sturm	O
PD	O
,	O
Slebos	O
RJ	O
,	O
Wilentz	O
RE	O
,	O
Musler	O
AR	O
,	O
Yeo	O
CJ	O
,	O
Sohn	O
TA	O
,	O
van	O
Velthuysen	O
ML	O
,	O
Offerhaus	O
GJ.	O
Department	O
of	O
Pathology	O
,	O
Johns	O
Hopkins	O
Medical	O
Institutions	O
,	O
Baltimore	O
,	O
Maryland	O
,	O
USA	O
.	O
It	O
can	O
be	O
difficult	O
to	O
distinguish	O
benign	O
bile	O
duct	O
proliferations	O
(	O
BDPs	O
)	O
from	O
well	O
-differentiated	O
metastatic	O
peripancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
on	O
histological	O
grounds	O
alone	O
.	O
Most	O
peripancreatic	B-malignancy-type
carcinomas	I-malignancy-type
harbor	O
activating	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
,	O
suggesting	O
that	O
K-ras	O
mutational	O
status	O
may	O
provide	O
a	O
molecular	O
basis	O
for	O
distinguishing	O
BDPs	O
from	O
liver	B-malignancy-type
metastases	O
.	O
The	O
ability	O
of	O
tests	O
for	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
to	O
make	O
this	O
distinction	O
was	O
examined	O
in	O
a	O
two	O
-	O
part	O
study	O
.	O
In	O
the	O
first	O
part	O
we	O
determined	O
the	O
K-ras	O
mutational	O
status	O
of	O
56	O
liver	B-malignancy-type
lesions	I-malignancy-type
and	O
48	O
primary	O
peripancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
obtained	O
from	O
48	O
patients	O
.	O
In	O
the	O
second	O
part	O
of	O
this	O
study	O
an	O
additional	O
45	O
liver	B-malignancy-type
lesions	I-malignancy-type
were	O
studied	O
.	O
In	O
the	O
first	O
48	O
patients	O
,	O
activating	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
were	O
detected	O
in	O
28	O
(	O
61	O
%	O
)	O
of	O
the	O
46	O
primary	O
carcinomas	B-malignancy-type
,	O
in	O
8	O
(	O
100	O
%	O
)	O
of	O
8	O
liver	B-malignancy-type
metastases	O
,	O
in	O
2	O
(	O
6.5	O
%	O
)	O
of	O
31	O
BDPs	O
,	O
and	O
in	O
none	O
(	O
0	O
%	O
)	O
of	O
14	O
liver	B-malignancy-type
granulomas	I-malignancy-type
.	O
Three	O
BDPs	O
and	O
two	O
primary	O
carcinomas	B-malignancy-type
did	O
not	O
amplify	O
.	O
To	O
further	O
estimate	O
the	O
prevalence	O
of	O
K-ras	O
mutations	O
in	O
BDPs	O
we	O
analyzed	O
an	O
additional	O
series	O
of	O
45	O
mostly	O
incidental	O
BDPs	O
for	O
K-ras	O
mutations	O
.	O
Three	O
(	O
6.7	O
%	O
)	O
of	O
these	O
45	O
harbored	O
K-ras	O
mutations	O
.	O
These	O
results	O
suggest	O
that	O
K-ras	O
mutations	O
may	O
be	O
useful	O
in	O
distinguishing	O
BDPs	O
from	O
metastases	O
in	O
the	O
liver	O
;	O
however	O
,	O
there	O
is	O
some	O
overlap	O
in	O
the	O
mutational	O
spectra	O
of	O
BDPs	O
and	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9327727	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
1997	O
Apr;	O
6	O
(	O
4	O
)	O
:	O
239	O
-43	O
Ras	O
oncogene	O
mutations	O
in	O
childhood	O
brain	B-malignancy-type
tumors	I-malignancy-type
.	O
Maltzman	O
TH	O
,	O
Mueller	O
BA	O
,	O
Schroeder	O
J,	O
Rutledge	O
JC	O
,	O
Patterson	O
K,	O
Preston	O
-Martin	O
S	O
,	O
Faustman	O
EM	O
.	O
Division	O
of	O
Gastroenterology	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
,	O
Denver	O
80262	O
,	O
USA	O
.	O
Although	O
N-nitroso	O
compounds	O
(	O
NNC	O
)	O
are	O
ubiquitous	O
in	O
the	O
human	O
environment	O
and	O
are	O
known	O
neurocarcinogens	O
in	O
animal	O
models	O
,	O
results	O
of	O
epidemiological	O
studies	O
have	O
not	O
yet	O
convincingly	O
associated	O
NNCs	O
with	O
brain	B-malignancy-type
tumor	I-malignancy-type
occurrence	O
in	O
humans	O
.	O
Animal	O
studies	O
have	O
suggested	O
that	O
specific	O
codons	O
(	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
in	O
the	O
ras	O
family	O
are	O
mutable	O
by	O
exposure	O
to	O
NNCs	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
measure	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
ras	O
family	O
of	O
oncogenes	O
in	O
tissue	O
from	O
childhood	O
brain	B-malignancy-type
(	I-malignancy-type
CB	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
as	O
a	O
preliminary	O
step	O
toward	O
investigating	O
their	O
potential	O
use	O
as	O
biomarkers	O
of	O
chemical	O
exposure	O
.	O
DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
formalin	O
-	O
fixed	O
CB	B-malignancy-type
tumors	I-malignancy-type
from	O
tissues	O
resected	O
during	O
neurosurgical	O
operations	O
.	O
Using	O
the	O
PCR	O
,	O
designed	O
RFLP	O
-screening	O
methods	O
,	O
and	O
sequencing	O
,	O
we	O
attempted	O
to	O
screen	O
brain	B-malignancy-type
tumors	I-malignancy-type
from	O
46	O
children	O
for	O
the	O
presence	O
of	O
H	O
,	O
K	O
,	O
and	O
N-	O
ras	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
Screening	O
for	O
oncogene	O
mutations	O
using	O
PCR	O
,	O
RFLP	O
methods	O
,	O
and	O
DNA	O
sequencing	O
was	O
successfully	O
completed	O
for	O
a	O
high	O
proportion	O
of	O
the	O
available	O
specimens	O
.	O
Astrocytoma	B-malignancy-type
specimens	O
from	O
three	O
children	O
for	O
whom	O
screening	O
with	O
PCR	O
was	O
successfully	O
completed	O
were	O
found	O
to	O
contain	O
CAA	O
-->	O
GAA	O
point	O
mutations	O
in	O
K-ras	O
at	O
codon	O
61	O
.	O
None	O
of	O
the	O
specimens	O
contained	O
mutations	O
at	O
any	O
of	O
the	O
other	O
locations	O
.	O
These	O
results	O
,	O
although	O
preliminary	O
,	O
provide	O
a	O
potential	O
clue	O
for	O
future	O
mechanistic	O
studies	O
of	O
CB	B-malignancy-type
tumors	I-malignancy-type
.	O
The	O
possible	O
roles	O
of	O
NNCs	O
in	O
inducing	O
this	O
mutation	O
,	O
or	O
of	O
this	O
mutation	O
as	O
an	O
early	O
or	O
late	O
event	O
in	O
tumor	O
progression	O
,	O
however	O
,	O
remain	O
unclear	O
.	O
PMID	O
:	O
9107428	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Invest	O
Ophthalmol	O
Vis	O
Sci	O
1996	O
Oct;37	O
(	O
11	O
)	O
:	O
2313-7	O
Identification	O
of	O
mutations	O
in	O
the	O
Ki-ras	O
gene	O
in	O
human	O
retinoblastoma	B-malignancy-type
.	O
Bautista	O
D	O
,	O
Emanuel	O
JR	O
,	O
Granville	O
C	O
,	O
Howard	O
R	O
,	O
Costa	O
J.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06520	O
-	O
8023	O
,	O
USA	O
.	O
PURPOSE	O
:	O
To	O
investigate	O
the	O
mutational	O
status	O
of	O
the	O
Ki-ras	O
gene	O
in	O
retinoblastoma	B-malignancy-type
and	O
to	O
evaluate	O
a	O
correlation	O
of	O
the	O
genotype	O
with	O
clinical	O
and	O
histopathologic	O
variables	O
.	O
METHODS	O
:	O
Tumor	O
samples	O
were	O
microdissected	O
from	O
sectioned	O
archival	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Ki-ras	O
genomic	O
sequences	O
(	O
exons	O
1	O
and	O
2	O
)	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
then	O
analyzed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
.	O
Tissue	O
sections	O
,	O
flanking	O
the	O
analyzed	O
samples	O
,	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
for	O
examination	O
by	O
light	O
microscopy	O
.	O
RESULTS	O
:	O
Four	O
of	O
12	O
tumors	O
had	O
mutation	O
in	O
exon	O
1	O
,	O
codon	O
12	O
of	O
the	O
Ki-ras	O
gene	O
;	O
none	O
had	O
mutation	O
in	O
exon	O
2	O
.	O
Signal	O
intensity	O
of	O
the	O
mutated	O
alleles	O
indicates	O
clonal	O
mutation	O
in	O
the	O
tumor	O
cell	O
populations	O
.	O
One	O
of	O
four	O
bilateral	B-malignancy-type
tumors	I-malignancy-type
was	O
mutated	O
,	O
and	O
all	O
three	O
samples	O
with	O
undifferentiated	O
histologic	O
appearance	O
harbored	O
a	O
clonal	O
Ki-ras	O
mutation	O
.	O
However	O
,	O
only	O
one	O
of	O
nine	O
moderately	O
to	O
poorly	O
differentiated	O
tumors	O
harbored	O
a	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Ki-ras	O
,	O
an	O
oncogene	O
seldom	O
altered	O
in	O
neuroectodermal	B-malignancy-type
neoplasms	I-malignancy-type
,	O
is	O
mutated	O
in	O
one	O
third	O
of	O
the	O
retinoblastomas	B-malignancy-type
studied	O
.	O
The	O
Ki-ras	O
mutations	O
are	O
clonal	O
,	O
suggesting	O
that	O
affected	O
cells	O
have	O
a	O
selective	O
growth	O
advantage	O
.	O
The	O
mutations	O
are	O
present	O
and	O
are	O
likely	O
to	O
play	O
a	O
pathogenetic	O
role	O
in	O
heritable	O
and	O
sporadic	O
retinoblastomas	B-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
mutations	O
in	O
Ki-ras	O
are	O
preferentially	O
associated	O
with	O
undifferentiated	O
tumors	O
.	O
PMID	O
:	O
8843915	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1995	O
Nov;91(	O
3	O
)	O
:	O
661-3	O
c-kit	O
point	O
mutation	O
of	O
extracellular	O
domain	O
in	O
patients	O
with	O
myeloproliferative	B-malignancy-type
disorders	I-malignancy-type
.	O
Nakata	O
Y	O
,	O
Kimura	O
A	O
,	O
Katoh	O
O	O
,	O
Kawaishi	O
K,	O
Hyodo	O
H,	O
Abe	O
K,	O
Kuramoto	O
A	O
,	O
Satow	O
Y	O
.	O
Department	O
of	O
Environment	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
c-kit	O
is	O
a	O
tyrosine	O
kinase	O
receptor	O
whose	O
ligand	O
is	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O
Gene	O
alteration	O
of	O
the	O
c-kit	O
extracellular	O
domain	O
was	O
analysed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
in	O
25	O
patients	O
with	O
myeloproliferative	B-malignancy-type
disorders	I-malignancy-type
(	O
MPD	B-malignancy-type
)	O
.	O
In	O
the	O
N-terminal	O
part	O
of	O
the	O
domain	O
,	O
mobility	O
shifts	O
indicating	O
sequence	O
alteration	O
were	O
detected	O
in	O
three	O
of	O
the	O
patients	O
,	O
two	O
primary	O
myelofibrosis	B-malignancy-type
(	O
PMF	B-malignancy-type
)	O
and	O
one	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukaemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
.	O
The	O
subsequent	O
sequencing	O
revealed	O
the	O
same	O
point	O
mutations	O
at	O
codon	O
52	O
causing	O
amino	O
acid	O
substitution	O
(	O
Asp	O
-->	O
Asn	O
)	O
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
with	O
a	O
c-kit	O
point	O
mutation	O
found	O
in	O
human	O
fresh	O
tumour	O
cells	O
.	O
PMID	O
:	O
8555071	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Lymphoma	O
1993	O
;11	O
Suppl	O
1	O
:25-	O
8	O
Molecular	O
defects	O
associated	O
with	O
the	O
acute	O
phase	O
CML	B-malignancy-type
.	O
Serra	O
A	O
,	O
Guerrasio	O
A	O
,	O
Gaidano	O
G	O
,	O
Rosso	O
C	O
,	O
Rege	O
-	O
Cambrin	O
G	O
,	O
Petroni	O
D	O
,	O
Mazza	O
U	O
,	O
Saglio	O
G.	O
Dipartimento	O
di	O
Scienze	O
Biomediche	O
e	O
Oncologia	O
Umana	O
,	O
Universita	O
di	O
Torino	O
,	O
Italy	O
.	O
Parts	O
of	O
the	O
Bcr	O
/	O
Abl	O
hybrid	O
transcript	O
supposed	O
to	O
be	O
important	O
for	O
its	O
transforming	O
ability	O
were	O
sequenced	O
in	O
a	O
series	O
of	O
CML	B-malignancy-type
blast	O
crises	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
possible	O
presence	O
of	O
alterations	O
responsible	O
for	O
the	O
disease	O
transition	O
from	O
the	O
chronic	O
to	O
the	O
acute	O
phase	O
.	O
In	O
addition	O
,	O
the	O
N	O
-	O
and	O
Ki	O
-	O
ras	O
as	O
well	O
as	O
the	O
p53	O
involvement	O
was	O
investigated	O
by	O
exploring	O
their	O
structure	O
and	O
expression	O
in	O
the	O
same	O
patients	O
.	O
We	O
used	O
traditional	O
types	O
of	O
molecular	O
analysis	O
including	O
Southern	O
and	O
Northern	O
blot	O
,	O
together	O
with	O
methods	O
that	O
allow	O
a	O
rapid	O
detection	O
of	O
point	O
mutations	O
and	O
microdeletions	O
,	O
such	O
as	O
SSCP	O
,	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
.	O
The	O
results	O
obtained	O
may	O
be	O
summarized	O
as	O
follows	O
:	O
no	O
alterations	O
were	O
found	O
in	O
the	O
parts	O
of	O
the	O
Bcr	O
/	O
Abl	O
transcripts	O
investigated	O
in	O
the	O
present	O
study	O
(	O
SH2	O
,	O
SH3	O
and	O
the	O
region	O
surrounding	O
codon	O
832	O
)	O
;	O
p53	O
alterations	O
were	O
observed	O
in	O
5	O
%	O
and	O
N	O
-	O
and	O
Ki	O
-	O
RAS	O
mutations	O
in	O
5	O
%	O
of	O
the	O
cases	O
examined	O
.	O
These	O
molecular	O
defects	O
are	O
therefore	O
responsible	O
for	O
the	O
clinical	O
progression	O
of	O
the	O
Ph1	O
-	O
positive	O
CML	B-malignancy-type
only	O
in	O
a	O
minority	O
of	O
cases	O
.	O
PMID	O
:	O
8251905	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1993	O
Jul;8	O
4	O
(	O
3	O
)	O
:	O
443	O
-50	O
Occurrence	O
of	O
point	O
mutations	O
in	O
p53	O
gene	O
is	O
not	O
increased	O
in	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
carrying	O
an	O
activating	O
N-ras	O
mutation	O
.	O
Buhler	O
-	O
Leclerc	O
M,	O
Gratwohl	O
A	O
,	O
Senn	O
HP	O
.	O
Institut	O
fur	O
Medizinische	O
Mikrobiologie	O
,	O
Universitat	O
Basel	O
,	O
Switzerland	O
.	O
The	O
frequency	O
of	O
simultaneously	O
detecting	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
was	O
studied	O
in	O
leukaemia	B-malignancy-type
cells	O
of	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
or	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Using	O
in	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
hybridization	O
analysis	O
,	O
45	O
AML	B-malignancy-type
and	O
six	O
MDS	B-malignancy-type
patients	O
were	O
screened	O
for	O
activating	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N-ras	O
.	O
Ten	O
of	O
them	O
(	O
eight	O
AML	B-malignancy-type
and	O
two	O
MDS	B-malignancy-type
)	O
were	O
found	O
positive	O
.	O
These	O
10	O
patients	O
and	O
10	O
others	O
without	O
activating	O
N-ras	O
mutation	O
were	O
further	O
analysed	O
by	O
direct	O
sequencing	O
of	O
the	O
amplified	O
exons	O
for	O
p53	O
mutations	O
and	O
for	O
atypical	O
N-ras	O
mutations	O
.	O
Beside	O
the	O
activating	O
mutations	O
in	O
the	O
N-ras	O
gene	O
,	O
no	O
additional	O
transforming	O
or	O
nontransforming	O
mutations	O
could	O
be	O
detected	O
in	O
the	O
N-ras	O
.	O
However	O
,	O
exon	O
7	O
of	O
p53	O
was	O
mutated	O
in	O
two	O
AML	B-malignancy-type
patients	O
without	O
activating	O
N-ras	O
mutation	O
.	O
These	O
data	O
show	O
that	O
p53	O
mutations	O
occurred	O
with	O
half	O
the	O
frequency	O
of	O
N-ras	O
mutations	O
in	O
AML	B-malignancy-type
and	O
that	O
no	O
positive	O
correlation	O
could	O
be	O
found	O
between	O
the	O
onset	O
of	O
mutations	O
in	O
N-ras	O
and	O
p53	O
genes	O
.	O
PMID	O
:	O
8217795	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surgery	O
1993	O
Oct;114(	O
4	O
)	O
:758-63	O
;	O
discussion	O
763-4	O
Comparison	O
of	O
mutations	O
of	O
ras	O
oncogene	O
in	O
human	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
and	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
.	O
Yashiro	O
T	O
,	O
Fulton	O
N	O
,	O
Hara	O
H,	O
Yasuda	O
K,	O
Montag	O
A	O
,	O
Yashiro	O
N	O
,	O
Straus	O
F	O
2nd	O
,	O
Ito	O
K,	O
Aiyoshi	O
Y	O
,	O
Kaplan	O
EL	O
.	O
Department	O
of	O
Surgery	O
,	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
University	O
of	O
Chicago	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
IL	O
60637	O
.	O
BACKGROUND	O
.	O
Ras	O
oncogene	O
mutations	O
have	O
been	O
found	O
in	O
many	O
human	O
cancers	O
;	O
however	O
,	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
have	O
rarely	O
been	O
studied	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
ras	O
mutations	O
in	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
and	O
to	O
compare	O
these	O
results	O
with	O
the	O
incidence	O
of	O
ras	O
mutations	O
in	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
cancers	I-malignancy-type
studied	O
in	O
our	O
laboratory	O
.	O
METHODS	O
.	O
Ras	O
oncogene	O
mutations	O
were	O
studied	O
in	O
33	O
foregut	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
(	O
pancreatic	B-malignancy-type
31	O
,	O
duodenal	B-malignancy-type
submucosa	I-malignancy-type
2	O
)	O
.	O
Eleven	O
were	O
insulinomas	B-malignancy-type
,	O
12	O
gastrinomas	B-malignancy-type
,	O
2	O
glucagonomas	B-malignancy-type
,	O
and	O
11	O
others	O
were	O
nonfunctioning	B-malignancy-type
islet	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Thirteen	O
were	O
benign	O
and	O
20	O
were	O
malignant	O
.	O
These	O
were	O
compared	O
with	O
65	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
cancers	I-malignancy-type
.	O
Tumors	O
were	O
microdissected	O
from	O
paraffin	O
-	O
embedded	O
sections	O
.	O
DNA	O
was	O
extracted	O
and	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
were	O
detected	O
by	O
a	O
oligonucleotide	O
hybridization	O
method	O
with	O
sequence	O
-	O
specific	O
phosphorus	O
32	O
-	O
radiolabeled	O
probes	O
.	O
RESULTS	O
.	O
No	O
ras	O
mutations	O
were	O
identified	O
among	O
the	O
33	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
.	O
In	O
contrast	O
,	O
51	O
of	O
65	O
(	O
78.5	O
%	O
)	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
cancers	I-malignancy-type
exhibited	O
a	O
ras	O
mutation	O
.	O
Fifty	O
were	O
K-ras	O
mutations	O
and	O
one	O
unusual	O
tumor	O
exhibited	O
a	O
N-	O
61	O
ras	O
mutation	O
.	O
CONCLUSIONS	O
.	O
Ras	O
oncogene	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
the	O
tumorigenesis	O
of	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8211691	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
May	O
1;	O
57	O
(	O
3	O
)	O
:	O
362-4	O
Association	O
of	O
H-ras	O
mutations	O
with	O
adenocarcinomas	B-malignancy-type
of	O
the	O
parotid	O
gland	O
.	O
van	O
Halteren	O
HK	O
,	O
Top	O
B	O
,	O
Mooi	O
WJ	O
,	O
Balm	O
AJ	O
,	O
Rodenhuis	O
S.	O
Department	O
of	O
Surgery	O
,	O
The	O
Netherlands	O
Cancer	O
Institute	O
,	O
Amsterdam	O
.	O
We	O
have	O
examined	O
17	O
adenocarcinomas	B-malignancy-type
and	O
2	O
mixed	O
tumors	O
of	O
the	O
salivary	O
glands	O
for	O
mutational	O
activation	O
of	O
the	O
oncogenes	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
.	O
The	O
presence	O
of	O
mutations	O
was	O
determined	O
by	O
in	O
vitro	O
amplification	O
of	O
gene	O
fragments	O
spanning	O
codons	O
12	O
,	O
13	O
and	O
61	O
and	O
the	O
use	O
of	O
mutation	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
ras	O
mutations	O
were	O
present	O
in	O
3	O
of	O
13	O
adenocarcinomas	B-malignancy-type
(	O
23	O
%	O
)	O
of	O
the	O
parotid	O
gland	O
.	O
The	O
mutations	O
were	O
confirmed	O
and	O
characterized	O
by	O
means	O
of	O
cycle	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
fragments	O
.	O
In	O
all	O
3	O
cases	O
,	O
the	O
mutation	O
was	O
an	O
A	O
:	O
T	O
to	O
G	O
:	O
C	O
transition	O
at	O
the	O
second	O
position	O
of	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
.	O
This	O
rather	O
unusual	O
ras	O
mutation	O
could	O
provide	O
a	O
clue	O
to	O
identify	O
one	O
or	O
more	O
carcinogens	O
involved	O
in	O
the	O
pathogenesis	O
of	O
parotid	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
8168996	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
Jul	O
15	O
;58(	O
2	O
)	O
:174	O
-	O
8	O
International	O
comparison	O
on	O
ras	O
gene	O
mutations	O
in	O
latent	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Watanabe	O
M,	O
Shiraishi	O
T	O
,	O
Yatani	O
R	O
,	O
Nomura	O
AM	O
,	O
Stemmermann	O
GN	O
.	O
Department	O
of	O
Pathology	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Tsu	O
,	O
Japan	O
.	O
Latent	O
carcinomas	B-malignancy-type
of	O
the	O
prostate	O
,	O
discovered	O
at	O
autopsy	O
in	O
men	O
with	O
no	O
prior	O
treatment	O
for	O
prostatic	B-malignancy-type
disease	I-malignancy-type
,	O
were	O
studied	O
for	O
ras	O
proto	O
-	O
oncogene	O
mutations	O
.	O
Subjects	O
included	O
21	O
Japanese	O
,	O
15	O
U.S.	O
whites	O
,	O
15	O
U.S.	O
blacks	O
,	O
20	O
Hawaiian	O
Japanese	O
and	O
10	O
Colombians	O
.	O
PCR	O
and	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
identified	O
mutations	O
in	O
5	O
Japanese	O
,	O
in	O
1	O
Hawaiian	O
Japanese	O
,	O
in	O
1	O
U.S.	O
black	O
,	O
in	O
1	O
U.S.	O
white	O
and	O
in	O
3	O
Colombians	O
.	O
The	O
5	O
Japanese	O
tumor	O
samples	O
contained	O
3	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
and	O
2	O
mutations	O
in	O
codon	O
12	O
of	O
N-ras	O
respectively	O
.	O
One	O
tumor	O
in	O
a	O
Hawaiian	O
Japanese	O
man	O
also	O
showed	O
a	O
K-ras	O
point	O
mutation	O
at	O
codon	O
12	O
.	O
Two	O
Colombians	O
and	O
one	O
U.S.	O
black	O
man	O
had	O
tumors	O
with	O
mutations	O
at	O
codon	O
61	O
of	O
H-ras	O
,	O
while	O
1	O
Colombian	O
showed	O
an	O
N-ras	O
mutation	O
at	O
this	O
codon	O
.	O
The	O
overall	O
frequency	O
of	O
ras	O
gene	O
mutations	O
was	O
low	O
,	O
but	O
point	O
mutations	O
in	O
codon	O
12	O
were	O
most	O
common	O
in	O
latent	O
tumors	O
of	O
Japanese	O
,	O
who	O
experienced	O
the	O
lowest	O
incidence	O
and	O
mortality	O
from	O
this	O
tumor	O
.	O
Latent	O
tumors	O
in	O
men	O
from	O
ethnic	O
groups	O
with	O
high	O
mortality	O
and	O
incidence	O
rates	O
showed	O
fewer	O
ras	O
mutations	O
than	O
the	O
Japanese	O
,	O
and	O
these	O
were	O
more	O
likely	O
to	O
involve	O
codon	O
61	O
.	O
This	O
finding	O
is	O
consistent	O
with	O
prior	O
studies	O
of	O
more	O
aggressive	O
clinical	O
cancers	O
in	O
Japanese	O
men	O
that	O
indicated	O
a	O
higher	O
frequency	O
of	O
mutations	O
at	O
codon	O
61	O
.	O
PMID	O
:	O
8026877	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Oral	O
Pathol	O
Med	O
1994	O
Aug;23(	O
7	O
)	O
:	O
298-301	O
High	O
incidence	O
of	O
H-ras	O
oncogene	O
mutations	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
lip	O
vermilion	O
.	O
Milasin	O
J,	O
Pujic	O
N	O
,	O
Dedovic	O
N	O
,	O
Nikolic	O
Z	O
,	O
Petrovic	O
V	O
,	O
Dimitrijevic	O
B.	O
Nine	O
specimens	O
of	O
well	O
-	O
differentiated	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
lip	O
vermilion	O
have	O
been	O
analyzed	O
for	O
the	O
presence	O
of	O
H-ras	O
oncogene	O
mutations	O
,	O
using	O
the	O
technique	O
of	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
on	O
in	O
vitro	O
amplified	O
tumour	O
DNA	O
.	O
Five	O
specimens	O
harbored	O
mutations	O
:	O
four	O
in	O
codon	O
12	O
and	O
one	O
in	O
codon	O
13	O
.	O
This	O
high	O
incidence	O
(	O
55	O
%	O
)	O
of	O
mutated	O
H-ras	O
genes	O
suggests	O
that	O
their	O
activation	O
may	O
play	O
an	O
important	O
role	O
in	O
lip	B-malignancy-type
tumour	I-malignancy-type
development	O
and	O
may	O
be	O
connected	O
to	O
the	O
exposure	O
to	O
chemical	O
and/or	O
physical	O
carcinogens	O
.	O
PMID	O
:	O
7965884	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1994;30A(	O
7	O
)	O
:987	O
-	O
93	O
Selective	O
activation	O
of	O
ras	O
oncogenes	O
in	O
follicular	B-malignancy-type
and	O
undifferentiated	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Manenti	O
G	O
,	O
Pilotti	O
S	O
,	O
Re	O
FC	O
,	O
Della	O
Porta	O
G	O
,	O
Pierotti	O
MA.	O
Divisione	O
di	O
Oncologia	O
Sperimentale	O
A	O
,	O
Istituto	O
Nazionale	O
Tumori	O
,	O
Milan	O
,	O
Italy	O
.	O
A	O
total	O
of	O
96	O
tumour	O
samples	O
(	O
88	O
primary	O
tumours	O
and	O
8	O
nodal	O
metastases	O
)	O
from	O
88	O
patients	O
with	O
thyroid	B-malignancy-type
adenomas	B-malignancy-type
and	O
carcinomas	B-malignancy-type
were	O
investigated	O
for	O
ras	O
gene	O
mutations	O
using	O
polymerase	O
chain	O
reaction	O
,	O
oligonucleotide	O
probing	O
and	O
sequencing	O
.	O
Neither	O
the	O
19	O
adenomas	B-malignancy-type
nor	O
the	O
31	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
analysed	O
harboured	O
point	O
mutations	O
.	O
In	O
our	O
cases	O
,	O
mutations	O
in	O
all	O
three	O
ras	O
oncogenes	O
were	O
found	O
in	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
five	O
out	O
of	O
21	O
)	O
and	O
in	O
the	O
less	O
differentiated	O
thyroid	B-malignancy-type
tumour	I-malignancy-type
:	O
poorly	O
differentiated	O
carcinomas	B-malignancy-type
(	O
three	O
out	O
of	O
11	O
)	O
and	O
undifferentiated	O
carcinomas	B-malignancy-type
(	O
one	O
out	O
of	O
five	O
)	O
.	O
Finally	O
,	O
mutated	O
ras	O
oncogenes	O
had	O
a	O
significant	O
association	O
with	O
the	O
appearance	O
of	O
haematogenous	O
(	O
particularly	O
bone	O
)	O
metastases	O
,	O
suggesting	O
a	O
role	O
of	O
ras	O
genes	O
activation	O
in	O
the	O
metastatic	O
capability	O
of	O
these	O
tumours	O
.	O
PMID	O
:	O
7946598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1995	O
Jun	O
15	O
;55	O
(	O
12	O
)	O
:2511	O
-5	O
Allele	O
-	O
specific	O
mutations	O
involved	O
in	O
the	O
pathogenesis	O
of	O
endemic	B-malignancy-type
gallbladder	I-malignancy-type
carcinoma	I-malignancy-type
in	O
Chile	O
.	O
Wistuba	O
II	O
,	O
Sugio	O
K,	O
Hung	O
J,	O
Kishimoto	O
Y	O
,	O
Virmani	O
AK	O
,	O
Roa	O
I	O
,	O
Albores-Saavedra	O
J,	O
Gazdar	O
AF.	O
Simmons	O
Cancer	O
Center	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
,	O
USA	O
.	O
Although	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
is	O
one	O
of	O
the	O
most	O
frequent	O
neoplasms	B-malignancy-type
in	O
Chile	O
,	O
there	O
is	O
limited	O
information	O
about	O
the	O
molecular	O
changes	O
involved	O
in	O
its	O
pathogenesis	O
.	O
We	O
investigated	O
the	O
incidence	O
of	O
ras	O
gene	O
mutations	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
following	O
genes	O
/	O
loci	O
:	O
p53	O
,	O
DCC	O
,	O
rb	O
,	O
5q	O
3p	O
,	O
8p	O
,	O
and	O
9p	O
.	O
We	O
precisely	O
microdissected	O
194	O
relevant	O
areas	O
from	O
paraffin	O
-	O
embedded	O
microslides	O
from	O
25	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
and	O
their	O
accompanying	O
nonneoplastic	O
lesions	O
(	O
which	O
were	O
present	O
in	O
15	O
cases	O
)	O
from	O
patients	O
in	O
Chile	O
.	O
The	O
specimens	O
were	O
analyzed	O
by	O
PCR	O
-	O
based	O
assays	O
for	O
LOH	O
,	O
and	O
we	O
designed	O
a	O
RFLP	O
method	O
for	O
ras	O
mutations	O
and	O
immunohistochemistry	O
for	O
p53	O
protein	O
overexpression	O
.	O
We	O
determined	O
that	O
LOH	O
at	O
p53	O
(	O
91	O
%	O
)	O
,	O
9p	O
(	O
50	O
%	O
)	O
,	O
8p	O
(	O
44	O
%	O
)	O
and	O
DCC	O
(	O
31	O
%	O
)	O
are	O
frequent	O
events	O
and	O
that	O
LOH	O
at	O
p53	O
,	O
9p	O
,	O
and	O
DCC	O
are	O
early	O
events	O
,	O
while	O
ras	O
mutations	O
and	O
LOH	O
at	O
3p	O
,	O
rb	O
,	O
and	O
5q	O
occurred	O
occasionally	O
.	O
LOH	O
at	O
p53	O
occurred	O
more	O
frequently	O
and	O
earlier	O
than	O
protein	O
overexpression	O
.	O
The	O
mean	O
number	O
of	O
mutations	O
present	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
was	O
2.1	O
,	O
and	O
in	O
six	O
cases	O
,	O
LOH	O
at	O
the	O
p53	O
gene	O
was	O
the	O
sole	O
mutation	O
detected	O
.	O
The	O
same	O
allele	O
was	O
lost	O
in	O
61	O
(	O
93	O
%	O
)	O
of	O
71	O
nonneoplastic	O
foci	O
as	O
in	O
the	O
corresponding	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
for	O
all	O
four	O
mutations	O
studied	O
.	O
The	O
odds	O
of	O
this	O
occurring	O
by	O
chance	O
are	O
approximately	O
4	O
x	O
10(-15)	O
.	O
Although	O
clonality	O
cannot	O
be	O
excluded	O
,	O
allelic	O
loss	O
appears	O
to	O
be	O
highly	O
directed	O
,	O
but	O
the	O
mechanism	O
for	O
allele	O
-	O
specific	O
mutations	O
remains	O
to	O
be	O
determined	O
.	O
PMID	O
:	O
7780959	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1995	O
May	O
1;8	O
5	O
(	O
9	O
)	O
:2546-52	O
Mutations	O
of	O
the	O
p53	O
and	O
ras	O
genes	O
in	O
childhood	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Kawamura	O
M,	O
Kikuchi	O
A	O
,	O
Kobayashi	O
S	O
,	O
Hanada	O
R	O
,	O
Yamamoto	O
K,	O
Horibe	O
K,	O
Shikano	O
T	O
,	O
Ueda	O
K,	O
Hayashi	O
K,	O
Sekiya	O
T	O
,	O
et	O
al	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
We	O
have	O
investigated	O
the	O
alterations	O
of	O
p53	O
and	O
ras	O
genes	O
including	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
in	O
22	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
cases	O
and	O
five	O
cell	O
lines	O
carrying	O
t	O
(	O
1	O
;	O
19	O
)	O
by	O
use	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
The	O
mutations	O
of	O
the	O
p53	O
gene	O
were	O
found	O
in	O
2	O
of	O
20	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
cases	O
at	O
diagnosis	O
(	O
10	O
%	O
)	O
,	O
all	O
of	O
4	O
cases	O
at	O
relapse	O
(	O
100	O
%	O
)	O
,	O
and	O
4	O
of	O
the	O
5	O
cell	O
lines	O
(	O
80	O
%	O
)	O
.	O
Four	O
of	O
the	O
five	O
patients	O
who	O
died	O
had	O
missense	O
mutations	O
at	O
codons	O
49	O
,	O
177	O
,	O
179	O
,	O
and	O
248	O
.	O
In	O
cases	O
examined	O
sequentially	O
,	O
one	O
had	O
the	O
same	O
point	O
mutation	O
at	O
codon	O
179	O
at	O
both	O
diagnosis	O
and	O
relapse	O
,	O
and	O
another	O
had	O
the	O
same	O
p53	O
gene	O
mutation	O
at	O
codon	O
240	O
both	O
in	O
leukemic	O
cells	O
at	O
relapse	O
and	O
in	O
a	O
cell	O
line	O
derived	O
at	O
that	O
time	O
.	O
The	O
other	O
case	O
had	O
no	O
mutation	O
at	O
diagnosis	O
but	O
had	O
the	O
mutation	O
at	O
codon	O
177	O
at	O
relapse	O
and	O
cell	O
lines	O
derived	O
from	O
blast	O
cells	O
at	O
diagnosis	O
,	O
suggesting	O
that	O
a	O
small	O
number	O
of	O
leukemic	O
cells	O
with	O
the	O
p53	O
gene	O
mutation	O
at	O
diagnosis	O
might	O
have	O
escaped	O
PCR	O
-	O
SSCP	O
analysis	O
.	O
In	O
cell	O
lines	O
,	O
SCMC	O
-	O
L9	O
had	O
three	O
point	O
mutations	O
in	O
the	O
p53	O
gene	O
at	O
codons	O
175	O
,	O
248	O
,	O
and	O
358	O
,	O
whereas	O
SCMC	O
-	O
L10	O
had	O
frame	O
shift	O
at	O
codons	O
209	O
-	O
211	O
.	O
One	O
case	O
had	O
a	O
rare	O
polymorphism	O
at	O
codon	O
11	O
.	O
We	O
found	O
only	O
one	O
mutation	O
of	O
the	O
N-ras	O
gene	O
that	O
was	O
a	O
2	O
-	O
bp	O
substitution	O
of	O
GGT	O
(	O
Gly	O
)	O
to	O
GTC	O
(	O
Val	O
)	O
at	O
codon	O
13	O
among	O
22	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
cases	O
and	O
five	O
cell	O
lines	O
.	O
This	O
case	O
showed	O
no	O
mutation	O
of	O
the	O
p53	O
gene	O
and	O
has	O
had	O
a	O
good	O
course	O
.	O
These	O
results	O
suggest	O
that	O
in	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
,	O
mutations	O
of	O
the	O
p53	O
and	O
ras	O
genes	O
are	O
infrequent	O
at	O
diagnosis	O
and	O
that	O
p53	O
gene	O
alterations	O
may	O
be	O
associated	O
with	O
relapse	O
phase	O
or	O
progression	O
of	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
.	O
PMID	O
:	O
7727782	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Invest	O
1993	O
;11(	O
1	O
)	O
:25-32	O
Comment	O
in	O
:	O
Cancer	O
Invest	O
.	O
1993	O
;11(	O
1	O
)	O
:92	O
-3.	O
Mutational	O
status	O
of	O
codons	O
12	O
and	O
13	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
genes	O
in	O
tissue	O
and	O
cell	O
lines	O
derived	O
from	O
primary	O
and	O
metastatic	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Pergolizzi	O
RG	O
,	O
Kreis	O
W	O
,	O
Rottach	O
C	O
,	O
Susin	O
M,	O
Broome	O
JD.	O
Department	O
of	O
Research	O
,	O
North	O
Shore	O
University	O
Hospital	O
-Cornell	O
University	O
Medical	O
College	O
,	O
Manhasset	O
,	O
New	O
York	O
11030	O
.	O
N	O
-	O
and	O
K	O
-	O
ras	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
were	O
investigated	O
using	O
oligonucleotide	O
hybridization	O
analysis	O
after	O
PCR	O
amplification	O
and	O
subsequent	O
sequence	O
analysis	O
of	O
the	O
amplified	O
DNA	O
from	O
the	O
region	O
of	O
interest	O
in	O
the	O
following	O
prostatic	B-malignancy-type
primary	O
and	O
metastatic	O
(	O
met	O
)	O
carcinoma	B-malignancy-type
-	O
derived	O
cell	O
lines	O
:	O
1013L	O
(	O
primary	O
)	O
,	O
PC3	O
(	O
bone	O
met	O
)	O
,	O
DU145	O
(	O
brain	O
met	O
)	O
,	O
and	O
LNCaP	O
(	O
lymph	O
node	O
met	O
)	O
.	O
We	O
also	O
examined	O
fresh	O
and	O
archival	O
primary	O
and	O
metastatic	O
prostate	B-malignancy-type
tumor	I-malignancy-type
tissue	O
and	O
benign	O
prostatic	O
hypertrophy	O
specimens	O
.	O
All	O
prostatic	O
cells	O
and	O
tissues	O
examined	O
contain	O
at	O
least	O
one	O
wild	O
-	O
type	O
N	O
-	O
and	O
K	O
-	O
ras	O
allele	O
with	O
respect	O
to	O
codons	O
12	O
and	O
13	O
.	O
No	O
mutations	O
were	O
found	O
at	O
N-ras	O
codon	O
13	O
.	O
The	O
only	O
mutation	O
seen	O
in	O
the	O
prostatic	O
cell	O
lines	O
and	O
tissues	O
was	O
a	O
K-ras	O
codon	O
12	O
position	O
II	O
G	O
-	O
to	O
-	O
T	O
transversion	O
.	O
Since	O
these	O
are	O
established	O
nonclonal	O
cell	O
lines	O
that	O
have	O
adapted	O
to	O
tissue	O
culture	O
,	O
it	O
is	O
possible	O
that	O
this	O
mutation	O
does	O
not	O
represent	O
the	O
mutational	O
state	O
of	O
prostatic	B-malignancy-type
carcinoma	I-malignancy-type
in	O
vivo	O
.	O
However	O
,	O
the	O
lack	O
of	O
consistent	O
mutation	O
in	O
the	O
ras	O
genes	O
amplified	O
directly	O
from	O
tumors	O
suggests	O
that	O
when	O
ras	O
mutations	O
occur	O
during	O
the	O
progression	O
of	O
prostatic	B-malignancy-type
carcinoma	I-malignancy-type
,	O
they	O
are	O
late	O
-	O
stage	O
events	O
not	O
directly	O
involved	O
in	O
the	O
initial	O
development	O
of	O
disease	O
.	O
Immunoprecipitation	O
studies	O
using	O
pan	O
-	O
ras	O
antibodies	O
revealed	O
no	O
evidence	O
of	O
altered	O
expression	O
of	O
Ras	O
proteins	O
.	O
PMID	O
:	O
7678540	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1995	O
Aug	O
3;11(	O
3	O
)	O
:601-3	O
Pattern	O
of	O
ras	O
and	O
gsp	O
oncogene	O
mutations	O
in	O
radiation	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
human	I-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
.	O
Challeton	O
C	O
,	O
Bounacer	O
A	O
,	O
Du	O
Villard	O
JA	O
,	O
Caillou	O
B	O
,	O
De	O
Vathaire	O
F	O
,	O
Monier	O
R	O
,	O
Schlumberger	O
M,	O
Suarez	O
HG.	O
IFC	O
HO1	O
,	O
Laboratoire	O
de	O
Genetique	O
Moleculaire	O
,	O
Villejuif	O
,	O
France	O
.	O
The	O
preferential	O
activation	O
of	O
the	O
Ki-ras	O
oncogene	O
in	O
follicular	B-malignancy-type
radiation	I-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
human	I-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
,	O
has	O
been	O
suggested	O
by	O
Wright	O
et	O
al.	O
(	O
1991	O
)	O
.	O
However	O
,	O
only	O
12	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
were	O
analysed	O
in	O
this	O
study	O
.	O
In	O
order	O
to	O
confirm	O
if	O
radiation	O
favours	O
,	O
in	O
human	O
thyroid	O
tumorigenesis	O
,	O
the	O
appearance	O
of	O
a	O
particular	O
molecular	O
lesion	O
,	O
we	O
studied	O
33	O
benign	O
and	O
malignant	O
human	O
radiation	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
.	O
We	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
allele	O
-	O
specific	O
hybridization	O
with	O
mutant	O
-	O
specific	O
probes	O
for	O
the	O
three	O
ras	O
genes	O
and	O
the	O
gsp	O
oncogene	O
.	O
Compared	O
to	O
85	O
'	B-malignancy-type
spontaneous	I-malignancy-type
'	I-malignancy-type
human	I-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
,	O
the	O
radiation	O
-	O
associated	O
cases	O
:	O
(1)	O
show	O
a	O
similar	O
overall	O
frequency	O
of	O
ras	O
and	O
gsp	O
mutations	O
(	O
about	O
30	O
%	O
and	O
6	O
%	O
respectively	O
)	O
;	O
(2)	O
present	O
a	O
similar	O
frequency	O
of	O
mutation	O
of	O
the	O
three	O
ras	O
genes	O
without	O
any	O
predominance	O
in	O
adenomas	B-malignancy-type
and	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
and	O
(3)	O
all	O
Ki-ras	O
mutations	O
were	O
found	O
in	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
(	O
4	O
/	O
15	O
)	O
.	O
ras	O
and	O
gsp	O
genes	O
were	O
never	O
found	O
mutated	O
simultaneously	O
,	O
suggesting	O
an	O
alternative	O
role	O
for	O
both	O
oncogenes	O
in	O
the	O
thyroid	O
tumorigenic	O
radiation	O
-	O
associated	O
process	O
.	O
PMID	O
:	O
7630645	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1995	O
Oct;147	O
(	O
4	O
)	O
:	O
1112-22	O
Intratumor	O
cellular	O
heterogeneity	O
and	O
alterations	O
in	O
ras	O
oncogene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
human	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Konishi	O
N	O
,	O
Hiasa	O
Y	O
,	O
Matsuda	O
H,	O
Tao	O
M,	O
Tsuzuki	O
T	O
,	O
Hayashi	O
I	O
,	O
Kitahori	O
Y	O
,	O
Shiraishi	O
T	O
,	O
Yatani	O
R	O
,	O
Shimazaki	O
J,	O
et	O
al	O
.	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Japan	O
.	O
To	O
assess	O
the	O
potential	O
role	O
of	O
ras	O
oncogene	O
activation	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
mutations	O
in	O
the	O
development	O
of	O
human	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
,	O
nine	O
cases	O
of	O
histologically	O
heterogeneous	O
prostate	B-malignancy-type
tumors	I-malignancy-type
obtained	O
from	O
total	O
prostatectomies	O
were	O
probed	O
for	O
these	O
specific	O
events	O
.	O
Each	O
tumor	O
was	O
divided	O
into	O
5	O
to	O
10	O
areas	O
according	O
to	O
different	O
growth	O
or	O
histological	O
patterns	O
.	O
Targeted	O
DNA	O
sequences	O
coding	O
for	O
ras	O
and	O
p53	O
were	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
analyzed	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphisms	O
,	O
and	O
confirmed	O
by	O
direct	O
DNA	O
sequencing	O
.	O
Point	O
mutations	O
of	O
the	O
ras	O
gene	O
were	O
found	O
in	O
three	O
of	O
the	O
nine	O
tumors	O
.	O
Two	O
contained	O
K-ras	O
codon	O
13	O
and	O
H-ras	O
codon	O
61	O
mutations	O
,	O
found	O
in	O
only	O
one	O
and	O
three	O
areas	O
of	O
each	O
lesion	O
,	O
respectively	O
.	O
The	O
third	O
tumor	O
contained	O
two	O
different	O
point	O
mutations	O
in	O
K-ras	O
codons	O
13	O
and	O
61	O
in	O
different	O
foci	O
of	O
the	O
sample	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
polymorphic	O
codon	O
72	O
in	O
the	O
p53	O
gene	O
was	O
detected	O
in	O
two	O
of	O
four	O
informative	O
cases	O
(	O
50	O
%	O
)	O
showing	O
fragment	O
cleavage	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O
Mutations	O
in	O
p53	O
,	O
missense	O
transversions	O
,	O
single	O
base	O
insertions	O
,	O
and	O
two	O
base	O
deletions	O
were	O
also	O
detected	O
in	O
three	O
tumors	O
.	O
The	O
present	O
results	O
reveal	O
mutated	O
ras	O
and	O
p53	O
occasionally	O
occurring	O
in	O
small	O
foci	O
of	O
the	O
tumor	O
and	O
that	O
genetic	O
mutations	O
in	O
p53	O
,	O
as	O
opposed	O
to	O
those	O
in	O
ras	O
,	O
are	O
more	O
closely	O
associated	O
with	O
invasive	O
growth	O
of	O
heterogeneous	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
7573356	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1995	O
Feb;12(	O
2	O
)	O
:	O
110	O
-	O
6	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
in	O
primary	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
:	O
incidence	O
and	O
possible	O
biological	O
implications	O
.	O
Olie	O
RA	O
,	O
Looijenga	O
LH	O
,	O
Boerrigter	O
L,	O
Top	O
B	O
,	O
Rodenhuis	O
S	O
,	O
Langeveld	O
A	O
,	O
Mulder	O
MP	O
,	O
Oosterhuis	O
JW	O
.	O
Laboratory	O
of	O
Experimental	O
Patho-Oncology	O
,	O
Dr	O
.	O
Daniel	O
den	O
Hoed	O
Cancer	O
Center	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
.	O
Recently	O
,	O
conflicting	O
results	O
have	O
been	O
reported	O
on	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
primary	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
adults	O
(	O
TGCTs	B-malignancy-type
)	O
.	O
In	O
four	O
studies	O
a	O
low	O
incidence	O
of	O
mutations	O
(	O
less	O
than	O
15	O
%	O
)	O
in	O
a	O
variety	O
of	O
TGCTs	B-malignancy-type
or	O
derived	O
cell	O
lines	O
was	O
found	O
,	O
whereas	O
in	O
two	O
other	O
studies	O
a	O
high	O
incidence	O
of	O
N	O
-	O
or	O
K	O
RAS	O
mutations	O
(	O
over	O
40	O
%	O
)	O
was	O
shown	O
.	O
A	O
total	O
of	O
62	O
testicular	B-malignancy-type
seminomas	I-malignancy-type
(	O
SE	B-malignancy-type
)	O
and	O
34	O
nonseminomatous	B-malignancy-type
TGCTs	I-malignancy-type
(	O
NS	B-malignancy-type
)	O
were	O
studied	O
thus	O
far	O
.	O
The	O
largest	O
series	O
consisted	O
of	O
42	O
TGCTs	B-malignancy-type
,	O
studied	O
on	O
paraffin	O
embedded	O
tissue	O
.	O
We	O
present	O
the	O
results	O
of	O
analysis	O
for	O
the	O
presence	O
of	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
,	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
,	O
in	O
snap	O
frozen	O
samples	O
of	O
100	O
primary	O
TGCTs	B-malignancy-type
,	O
comprising	O
40	O
SE	B-malignancy-type
and	O
60	O
NS	B-malignancy-type
.	O
Using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
allele	O
specific	O
oligonucleotide	O
hybridization	O
(	O
ASO	O
)	O
,	O
mutations	O
were	O
found	O
in	O
five	O
SE	O
(	O
three	O
in	O
NRAS	O
and	O
two	O
in	O
KRAS	O
,	O
all	O
codon	O
12	O
)	O
,	O
and	O
in	O
one	O
NS	B-malignancy-type
(	O
KRAS	O
,	O
codon	O
12	O
)	O
.	O
To	O
exclude	O
underestimation	O
of	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
TGCTs	B-malignancy-type
due	O
to	O
the	O
presence	O
of	O
an	O
excess	O
of	O
wild	O
type	O
alleles	O
in	O
the	O
analyzed	O
sample	O
,	O
a	O
PCR	O
technique	O
preferentially	O
amplifying	O
KRAS	O
alleles	O
with	O
a	O
mutation	O
in	O
codon	O
12	O
was	O
applied	O
to	O
all	O
SE	B-malignancy-type
.	O
This	O
approach	O
,	O
allowing	O
a	O
250	O
times	O
more	O
sensitive	O
assay	O
,	O
resulted	O
in	O
the	O
detection	O
of	O
only	O
one	O
additional	O
SE	B-malignancy-type
with	O
a	O
mutation	O
.	O
Based	O
on	O
a	O
critical	O
analysis	O
of	O
published	O
data	O
and	O
on	O
our	O
results	O
from	O
the	O
largest	O
series	O
of	O
frozen	O
samples	O
investigated	O
thus	O
far	O
,	O
we	O
conclude	O
that	O
N	O
-	O
or	O
K	O
RAS	O
mutations	O
are	O
rare	O
and	O
apparently	O
not	O
essential	O
for	O
initiation	O
or	O
progression	O
of	O
TGCTs	B-malignancy-type
.	O
PMID	O
:	O
7535083	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1995	O
Oct	O
1;8	O
4	O
(	O
1	O
)	O
:60	O
-	O
8	O
Correlation	O
of	O
cytogenetic	O
results	O
with	O
immunophenotype	O
,	O
genotype	O
,	O
clinical	O
features	O
,	O
and	O
ras	O
mutation	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
A	O
study	O
of	O
235	O
Chinese	O
patients	O
in	O
Taiwan	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH	O
,	O
Lin	O
MT	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chuang	O
SM	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
KH	O
,	O
Lin	O
DT.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Republic	O
of	O
China	O
.	O
Of	O
235	O
consecutive	O
patients	O
with	O
de	O
novo	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
clonal	O
chromosomal	O
abnormalities	O
were	O
detected	O
in	O
151	O
(	O
64	O
%	O
)	O
of	O
them	O
.	O
Twenty-four	O
of	O
the	O
71	O
patients	O
with	O
M2	O
AML	B-malignancy-type
had	O
t	O
(	O
8	O
;	O
21	O
)	O
,	O
35	O
of	O
the	O
36	O
M3	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
11	O
of	O
the	O
45	O
M4	O
leukemia	B-malignancy-type
disclosed	O
inv	O
(	O
16	O
)	O
.	O
Six	O
of	O
the	O
eight	O
patients	O
with	O
11	O
q	O
23	O
abnormality	O
had	O
M4	O
or	O
M5	O
subtype	O
of	O
leukemia	B-malignancy-type
.	O
The	O
incidence	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
t	O
(	O
8	O
;	O
21	O
)	O
was	O
higher	O
in	O
our	O
patients	O
than	O
in	O
patients	O
from	O
most	O
Western	O
countries	O
.	O
Immunophenotyping	O
was	O
performed	O
on	O
197	O
patients	O
.	O
Patients	O
with	O
t	O
(	O
15	O
;	O
17	O
)	O
were	O
associated	O
with	O
negativity	O
to	O
HLA	O
-	O
DR	O
,	O
CD11b	O
,	O
and	O
CD34	O
.	O
Patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
expressed	O
CD13	O
and	O
CD33	O
less	O
frequently	O
than	O
other	O
patients	O
,	O
but	O
all	O
showed	O
CD15	O
positivity	O
.	O
Coexpression	O
of	O
lymphoid	O
-	O
associated	O
antigens	O
on	O
the	O
leukemic	O
blasts	O
was	O
detected	O
in	O
52	O
patients	O
(	O
26	O
%	O
)	O
,	O
including	O
all	O
7	O
patients	O
with	O
t	O
(	O
9	O
;	O
22	O
)	O
,	O
3	O
of	O
the	O
8	O
patients	O
with	O
t	O
/	O
del	O
(	O
11	O
)	O
(	O
q23	O
)	O
,	O
2	O
of	O
the	O
25	O
patients	O
with	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
2	O
of	O
the	O
22	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
.	O
Seven	O
(	O
35	O
%	O
)	O
of	O
the	O
20	O
patients	O
coexpressing	O
lymphoid	O
markers	O
showed	O
immunoglobulin	O
heavy	O
chain	O
or	O
T-cell	O
receptor	O
beta	O
-	O
chain	O
gene	O
rearrangements	O
,	O
while	O
only	O
2	O
(	O
4	O
%	O
)	O
of	O
the	O
53	O
patients	O
without	O
lymphoid	O
antigen	O
expression	O
did	O
so	O
.	O
Patients	O
with	O
inv	O
(	O
16	O
)	O
,	O
t	O
(	O
8	O
;	O
21	O
)	O
,	O
and	O
t	O
(	O
15	O
;	O
17	O
)	O
had	O
a	O
better	O
prognosis	O
than	O
other	O
patients	O
.	O
Of	O
all	O
surface	O
antigens	O
tested	O
,	O
only	O
CD15	O
,	O
CD11b	O
,	O
and	O
HLA	O
-	O
DR	O
were	O
of	O
prognostic	O
value	O
:	O
CD15	O
with	O
a	O
higher	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
and	O
CD11b	O
or	O
HLA	O
-	O
DR	O
with	O
a	O
shorter	O
CR	O
duration	O
.	O
N-ras	O
mutations	O
were	O
detected	O
in	O
7	O
(	O
18	O
%	O
)	O
of	O
the	O
40	O
patients	O
in	O
the	O
study	O
,	O
including	O
two	O
of	O
the	O
three	O
patients	O
with	O
inv	O
(	O
16	O
)	O
.	O
This	O
study	O
demonstrated	O
differences	O
in	O
clinical	O
features	O
,	O
immunophenotypes	O
,	O
and	O
genotypes	O
among	O
different	O
cytogenetic	O
subgroups	O
.	O
PMID	O
:	O
7497445	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Nov;4(	O
11	O
)	O
:	O
1363	O
-	O
74	O
Analysis	O
of	O
ras	O
oncogenes	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
precursor	B-malignancy-type
lesions	I-malignancy-type
:	O
correlation	O
of	O
point	O
mutations	O
with	O
differentiation	O
phenotype	O
.	O
Albino	O
AP	O
,	O
Nanus	O
DM	O
,	O
Mentle	O
IR	O
,	O
Cordon	O
-	O
Cardo	O
C	O
,	O
McNutt	O
NS	O
,	O
Bressler	O
J,	O
Andreeff	O
M.	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
New	O
York	O
10021	O
.	O
This	O
study	O
examined	O
noncultured	O
and	O
cultured	O
melanomas	B-malignancy-type
and	O
related	O
precursor	O
specimens	O
for	O
(i)	O
mutated	O
ras	O
genes	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
methodology	O
,	O
(ii)	O
correlation	O
of	O
mutated	O
ras	O
genes	O
with	O
differentiation	O
related	O
phenotypic	O
characteristics	O
,	O
(iii)	O
expression	O
of	O
ras	O
-	O
encoded	O
p21	O
proteins	O
in	O
tissues	O
by	O
immunoperoxidase	O
analysis	O
,	O
(iv)	O
quantitative	O
expression	O
of	O
mutated	O
and	O
wild	O
-	O
type	O
ras	O
encoded	O
p21	O
proteins	O
by	O
flow	O
cytometry	O
,	O
and	O
(v)	O
correlation	O
between	O
p21	O
expression	O
,	O
the	O
occurrence	O
of	O
ras	O
mutations	O
,	O
and	O
cell	O
cycle	O
kinetics	O
.	O
The	O
results	O
of	O
these	O
studies	O
are	O
(1)	O
24	O
%	O
of	O
cultured	O
malignant	O
melanomas	B-malignancy-type
have	O
activated	O
ras	O
genes	O
,	O
with	O
N-ras	O
being	O
activated	O
ten	O
times	O
as	O
frequently	O
as	O
Harvey	O
(	O
Ha	O
)	O
-	O
ras	O
.	O
Each	O
example	O
of	O
an	O
activated	O
ras	O
gene	O
showed	O
a	O
mutation	O
at	O
the	O
61st	O
codon	O
of	O
the	O
protein	O
,	O
with	O
the	O
exception	O
of	O
one	O
melanoma	B-malignancy-type
which	O
showed	O
a	O
mutation	O
at	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
;	O
(2)	O
all	O
the	O
melanomas	B-malignancy-type
displaying	O
an	O
activated	O
ras	O
gene	O
had	O
a	O
similar	O
cell	O
surface	O
phenotype	O
and	O
appear	O
to	O
come	O
from	O
a	O
similar	O
phase	O
of	O
differentiation	O
;	O
(3)	O
5	O
-	O
6	O
%	O
of	O
noncultured	O
primary	O
and	O
metastatic	O
melanomas	B-malignancy-type
have	O
mutated	O
ras	O
genes	O
;	O
(4)	O
no	O
ras	O
gene	O
mutations	O
were	O
found	O
in	O
any	O
precursor	B-malignancy-type
lesion	I-malignancy-type
,	O
specifically	O
normal	B-malignancy-type
nevi	I-malignancy-type
and	O
dysplastic	B-malignancy-type
nevi	I-malignancy-type
;	O
(5)	O
immunoperoxidase	O
analysis	O
of	O
paraffin	O
-	O
embedded	O
specimens	O
indicated	O
no	O
quantitative	O
or	O
qualitative	O
alterations	O
in	O
p21	O
expression	O
that	O
correlate	O
with	O
tumor	O
progression	O
;	O
(6)	O
there	O
were	O
no	O
observable	O
differences	O
in	O
p21	O
expression	O
between	O
melanoma	B-malignancy-type
cells	O
growing	O
exponentially	O
or	O
in	O
plateau	O
phase	O
,	O
or	O
between	O
melanoma	B-malignancy-type
cells	O
with	O
or	O
without	O
ras	O
mutations	O
;	O
nor	O
were	O
any	O
cell	O
kinetic	O
differences	O
found	O
between	O
cells	O
with	O
and	O
without	O
mutated	O
ras	O
genes	O
.	O
These	O
studies	O
suggest	O
that	O
the	O
role	O
of	O
ras	O
mutations	O
may	O
be	O
limited	O
to	O
an	O
indirect	O
involvement	O
in	O
the	O
transformation	O
of	O
a	O
subset	O
of	O
melanomas	B-malignancy-type
.	O
PMID	O
:	O
2682463	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Nov;4(	O
11	O
)	O
:	O
1345-51	O
Activated	O
ras	O
genes	O
in	O
human	O
seminoma	B-malignancy-type
:	O
evidence	O
for	O
tumor	O
heterogeneity	O
.	O
Mulder	O
MP	O
,	O
Keijzer	O
W	O
,	O
Verkerk	O
A	O
,	O
Boot	O
AJ	O
,	O
Prins	O
ME	O
,	O
Splinter	O
TA	O
,	O
Bos	O
JL.	O
Department	O
of	O
Cell	O
Biology	O
and	O
Genetics	O
,	O
Erasmus	O
University	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
.	O
The	O
incidence	O
of	O
mutations	O
in	O
cellular	O
ras	O
genes	O
was	O
determined	O
in	O
human	O
seminoma	B-malignancy-type
,	O
a	O
germ	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
testis	I-malignancy-type
,	O
with	O
the	O
aid	O
of	O
specific	O
oligonucleotide	O
probe	O
hybridization	O
.	O
To	O
eliminate	O
the	O
large	O
number	O
of	O
nonneoplastic	O
cells	O
present	O
in	O
seminomas	B-malignancy-type
,	O
aneuploid	O
tumor	O
cell	O
nuclei	O
were	O
isolated	O
from	O
the	O
tumor	O
tissue	O
by	O
flow	O
sorting	O
.	O
Mutations	O
were	O
detected	O
in	O
40	O
%	O
of	O
the	O
seminomas	B-malignancy-type
at	O
codons	O
12	O
or	O
61	O
of	O
either	O
the	O
Ki-ras	O
or	O
the	O
N-ras	O
gene	O
.	O
No	O
correlation	O
was	O
found	O
with	O
histopathological	O
or	O
clinical	O
features	O
.	O
In	O
some	O
seminomas	B-malignancy-type
the	O
mutant	O
gene	O
was	O
present	O
in	O
only	O
a	O
fraction	O
of	O
the	O
tumor	O
cell	O
population	O
,	O
suggesting	O
tumor	O
heterogeneity	O
for	O
ras	O
gene	O
mutations	O
.	O
Yet	O
,	O
flow	O
cytometric	O
measurement	O
of	O
nuclear	O
DNA	O
contents	O
and	O
histological	O
examination	O
of	O
tumor	O
tissue	O
did	O
not	O
reveal	O
two	O
different	O
tumor	O
cell	O
populations	O
.	O
We	O
conclude	O
from	O
these	O
observations	O
that	O
ras	O
mutation	O
is	O
probably	O
not	O
the	O
initial	O
genetic	O
event	O
in	O
the	O
development	O
of	O
seminoma	B-malignancy-type
.	O
PMID	O
:	O
2682461	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Aug;	O
4(	O
8	O
)	O
:	O
1029-	O
36	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
and	O
methylation	O
state	O
in	O
human	O
leukemias	B-malignancy-type
.	O
Browett	O
PJ	O
,	O
Norton	O
JD.	O
Department	O
of	O
Hematology	O
,	O
Royal	O
Free	O
Hospital	O
School	O
of	O
Medicine	O
,	O
Hampstead	O
,	O
London	O
,	O
UK.	O
We	O
have	O
screened	O
a	O
large	O
series	O
of	O
primary	O
human	O
leukemias	B-malignancy-type
for	O
activating	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
and	O
K-ras	O
proto	O
-	O
oncogenes	O
and	O
at	O
codons	O
12	O
and	O
61	O
of	O
the	O
H-ras	O
proto	O
-	O
oncogene	O
by	O
using	O
panels	O
of	O
oligonucleotide	O
probes	O
in	O
conjunction	O
with	O
polymerase	O
chain	O
reaction	O
gene	O
amplification	O
.	O
13	O
of	O
64	O
(	O
20	O
%	O
)	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
cases	O
had	O
ras	O
gene	O
mutations	O
mostly	O
involving	O
N-ras	O
codon	O
12	O
/	O
13	O
,	O
G	O
-	O
A	O
(	O
gly	O
-	O
asp	O
)	O
transitions	O
.	O
Consistent	O
with	O
previous	O
studies	O
,	O
a	O
comparable	O
pattern	O
and	O
frequency	O
of	O
ras	O
mutation	O
was	O
found	O
amongst	O
45	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
and	O
myelodysplasia	B-malignancy-type
.	O
By	O
contrast	O
,	O
of	O
30	O
cases	O
of	O
mature	B-malignancy-type
B	I-malignancy-type
cell	I-malignancy-type
chronic	I-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
,	O
only	O
one	O
in	O
terminal	O
prolymphocytoid	O
transformation	O
harboured	O
an	O
activated	O
ras	O
gene	O
.	O
These	O
patterns	O
of	O
mutation	O
did	O
not	O
correlate	O
with	O
ras	O
gene	O
methylation	O
state	O
,	O
a	O
finding	O
not	O
obviously	O
compatible	O
with	O
differential	O
gene	O
accessibility	O
being	O
an	O
important	O
determinant	O
of	O
ras	O
gene	O
mutation	O
patterns	O
in	O
leukemogenesis	O
.	O
Our	O
data	O
suggest	O
that	O
activated	O
ras	O
is	O
more	O
important	O
in	O
tumourigenesis	O
of	O
immature	O
than	O
mature	O
lymphocyte	O
progenitors	O
whilst	O
similar	O
mechanisms	O
associated	O
with	O
aetiology	O
and/or	O
target	O
cell	O
susceptibility	O
probably	O
underlie	O
the	O
similar	O
patterns	O
of	O
ras	O
gene	O
mutations	O
seen	O
in	O
acute	B-malignancy-type
leukemias	I-malignancy-type
of	I-malignancy-type
both	I-malignancy-type
myeloid	I-malignancy-type
and	I-malignancy-type
lymphoid	I-malignancy-type
cell	I-malignancy-type
lineages	I-malignancy-type
.	O
PMID	O
:	O
2668844	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Mar;73	O
(	O
4	O
)	O
:	O
889	O
-	O
91	O
Ras	O
oncogene	O
mutations	O
are	O
rare	O
late	O
stage	O
events	O
in	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
LeMaistre	O
A	O
,	O
Lee	O
MS	O
,	O
Talpaz	O
M,	O
Kantarjian	O
HM	O
,	O
Freireich	O
EJ	O
,	O
Deisseroth	O
AB	O
,	O
Trujillo	O
JM	O
,	O
Stass	O
SA	O
.	O
Division	O
of	O
Laboratory	O
Medicine	O
,	O
University	O
of	O
Texas	O
,	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
77030	O
.	O
DNA	O
from	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
samples	O
of	O
44	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
patients	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
mutations	O
of	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
N-ras	O
,	O
H-ras	O
,	O
or	O
K-ras	O
genes	O
.	O
In	O
seven	O
patients	O
,	O
samples	O
were	O
available	O
from	O
both	O
their	O
chronic	O
phase	O
and	O
blast	O
crisis	O
.	O
A	O
total	O
of	O
29	O
samples	O
examined	O
were	O
at	O
chronic	O
phase	O
and	O
22	O
were	O
at	O
blast	O
crisis	O
(	O
eight	O
lymphoid	O
,	O
eight	O
myeloid	O
,	O
and	O
six	O
undifferentiated	O
)	O
.	O
No	O
mutations	O
were	O
identified	O
in	O
N-ras	O
or	O
H-ras	O
.	O
Two	O
patients	O
in	O
myeloid	O
blast	O
crisis	O
had	O
K-ras	O
mutations	O
,	O
one	O
patient	O
at	O
codon	O
12	O
,	O
the	O
other	O
at	O
codon	O
13	O
.	O
In	O
the	O
former	O
patient	O
the	O
mutation	O
was	O
not	O
present	O
and	O
the	O
latter	O
patient	O
was	O
not	O
tested	O
in	O
chronic	O
phase	O
.	O
Our	O
findings	O
indicate	O
ras	O
mutations	O
are	O
an	O
infrequent	O
late	O
stage	O
event	O
in	O
CML	B-malignancy-type
that	O
occur	O
in	O
myeloid	O
blast	O
crisis	O
.	O
PMID	O
:	O
2645949	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Henry	O
Ford	O
Hosp	O
Med	O
J	O
1989	O
;37	O
(	O
3-	O
4)	O
:	O
112-5	O
Allele	O
loss	O
on	O
chromosome	O
10	O
and	O
point	O
mutation	O
of	O
ras	O
oncogenes	O
are	O
infrequent	O
in	O
tumors	O
of	O
MEN	O
2A	O
.	O
Okazaki	O
M,	O
Miya	O
A	O
,	O
Tanaka	O
N	O
,	O
Miki	O
T	O
,	O
Yamamoto	O
M,	O
Motomura	O
K,	O
Miyauchi	O
A	O
,	O
Mori	O
T	O
,	O
Takai	O
S.	O
The	O
multiple	O
endocrine	O
neoplasia	O
type	O
2A	O
(	O
MEN	O
2A	O
)	O
gene	O
has	O
been	O
mapped	O
to	O
the	O
centromeric	O
region	O
of	O
chromosome	O
10	O
by	O
linkage	O
analysis	O
.	O
We	O
examined	O
36	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
(	O
MTCs	B-malignancy-type
)	O
(	O
16	O
hereditary	B-malignancy-type
and	O
20	O
sporadic	B-malignancy-type
)	O
and	O
ten	O
pheochromocytomas	B-malignancy-type
(	O
eight	O
hereditary	B-malignancy-type
and	O
two	O
sporadic	B-malignancy-type
)	O
to	O
detect	O
loss	O
of	O
alleles	O
on	O
chromosome	O
10	O
using	O
seven	O
polymorphic	O
DNA	O
markers	O
mapped	O
to	O
this	O
chromosome	O
.	O
Of	O
20	O
informative	O
cases	O
,	O
only	O
one	O
(	O
5	O
%	O
)	O
sporadic	B-malignancy-type
MTC	I-malignancy-type
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
locus	O
RBP3	O
.	O
Allele	O
loss	O
at	O
the	O
RBP3	O
locus	O
was	O
not	O
found	O
in	O
pheochromocytomas	B-malignancy-type
from	O
six	O
heterozygotes	O
.	O
All	O
tumors	O
retained	O
constitutional	O
heterozygosity	O
at	O
six	O
other	O
loci	O
on	O
chromosome	O
10	O
(	O
D10S17	O
,	O
D10S34	O
,	O
D10S24	O
on	O
the	O
short	O
arm	O
,	O
D10S15	O
in	O
the	O
pericentromeric	O
region	O
,	O
D10S20	O
,	O
and	O
D10S4	O
on	O
the	O
long	O
arm	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
second	O
hit	O
for	O
tumorigenesis	O
in	O
MEN	O
2A	O
may	O
not	O
be	O
loss	O
of	O
function	O
of	O
the	O
normal	O
allele	O
at	O
the	O
homologous	O
locus	O
on	O
the	O
other	O
copy	O
of	O
chromosome	O
10	O
.	O
Mutated	O
ras	O
oncogene	O
was	O
found	O
only	O
in	O
one	O
of	O
18	O
MTCs	B-malignancy-type
at	O
the	O
codon	O
61	O
of	O
H-ras	O
.	O
PMID	O
:	O
2576939	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1989	O
Mar;80	O
(	O
3	O
)	O
:196-9	O
Low	O
incidence	O
of	O
point	O
mutation	O
of	O
c-Ki-ras	O
and	O
N-ras	O
oncogenes	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Tsuda	O
H,	O
Hirohashi	O
S	O
,	O
Shimosato	O
Y	O
,	O
Ino	O
Y	O
,	O
Yoshida	O
T	O
,	O
Terada	O
M.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
.	O
We	O
examined	O
the	O
incidence	O
of	O
point	O
mutation	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
c-Ki-ras	O
and	O
N-ras	O
genes	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
techniques	O
.	O
Among	O
34	O
tissues	O
specimens	O
surgically	O
resected	O
from	O
30	O
patients	O
and	O
5	O
cell	O
lines	O
of	O
human	O
HCC	B-malignancy-type
,	O
only	O
two	O
had	O
ras	O
point	O
mutations	O
;	O
in	O
one	O
case	O
,	O
codon	O
12	O
of	O
c-Ki-ras	O
was	O
altered	O
from	O
GGT	O
,	O
coding	O
glycine	O
,	O
to	O
GTT	O
,	O
coding	O
valine	O
;	O
in	O
the	O
other	O
case	O
,	O
codon	O
61	O
of	O
N-ras	O
was	O
altered	O
from	O
CAA	O
,	O
coding	O
glutamine	O
,	O
to	O
AAA	O
,	O
coding	O
lysine	O
.	O
Thus	O
,	O
point	O
-	O
mutational	O
activation	O
of	O
ras	O
oncogenes	O
is	O
an	O
uncommon	O
event	O
in	O
human	O
HCC	B-malignancy-type
.	O
PMID	O
:	O
2542205	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hematol	O
Pathol	O
1990	O
;4(	O
3	O
)	O
:	O
149-	O
55	O
Hypereosinophilic	O
syndrome	O
with	O
evolution	O
to	O
myeloproliferative	B-malignancy-type
disorder	I-malignancy-type
:	O
temporal	O
relationship	O
to	O
loss	O
of	O
Y	O
chromosome	O
and	O
c-N-ras	O
activation	O
.	O
Needleman	O
SW	O
,	O
Mane	O
SM	O
,	O
Gutheil	O
JC	O
,	O
Kapil	O
V	O
,	O
Heyman	O
MR	O
,	O
Testa	O
JR.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Maryland	O
Hospital	O
,	O
Baltimore	O
21201	O
.	O
A	O
case	O
of	O
hypereosinophilic	O
syndrome	O
is	O
presented	O
in	O
which	O
the	O
patient	O
was	O
serially	O
observed	O
for	O
4	O
years	O
.	O
Transformation	O
to	O
a	O
disorder	O
resembling	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemic	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
occurred	O
36	O
months	O
after	O
diagnosis	O
;	O
at	O
42	O
months	O
,	O
blastic	O
transformation	O
and	O
marrow	O
failure	O
ensued	O
,	O
leading	O
to	O
death	O
.	O
Marrow	O
examination	O
for	O
histopathologic	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
biologic	O
analyses	O
were	O
performed	O
during	O
the	O
eosinophilic	O
,	O
myeloproliferative	O
,	O
and	O
blastic	O
stages	O
.	O
These	O
demonstrated	O
ras	O
activation	O
by	O
virtue	O
of	O
a	O
codon	O
12	O
G	O
to	O
C	O
transversion	O
mutation	O
,	O
predicting	O
for	O
substitution	O
of	O
glycine	O
by	O
alanine	O
;	O
in	O
addition	O
,	O
we	O
observed	O
Y	O
chromosome	O
loss	O
late	O
in	O
the	O
natural	O
history	O
of	O
this	O
illness	O
,	O
suggesting	O
that	O
these	O
genetic	O
lesions	O
can	O
play	O
a	O
role	O
in	O
the	O
profound	O
loss	O
of	O
myeloid	O
differentiation	O
characteristic	O
of	O
the	O
accelerated	O
phase	O
commonly	O
observed	O
in	O
myeloproliferative	B-malignancy-type
syndromes	I-malignancy-type
.	O
PMID	O
:	O
2258361	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Aug	O
15	O
;76	O
(	O
4	O
)	O
:	O
801-7	O
N-ras	O
mutations	O
in	O
adult	O
de	O
novo	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
:	O
prevalence	O
and	O
clinical	O
significance	O
.	O
Radich	O
JP	O
,	O
Kopecky	O
KJ	O
,	O
Willman	O
CL	O
,	O
Weick	O
J,	O
Head	O
D	O
,	O
Appelbaum	O
F	O
,	O
Collins	O
SJ.	O
Molecular	O
Medicine	O
Program	O
,	O
Fred	O
Hutchinson	O
Cancer	O
Research	O
Center	O
,	O
Seattle	O
,	O
WA	O
98104	O
.	O
Point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogenes	O
have	O
been	O
previously	O
detected	O
in	O
20	O
%	O
to	O
60	O
%	O
of	O
samples	O
of	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
but	O
the	O
clinical	O
significance	O
of	O
these	O
mutations	O
is	O
presently	O
unclear	O
.	O
We	O
directly	O
sequenced	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
N-ras	O
fragments	O
to	O
determine	O
the	O
frequency	O
of	O
N-ras	O
point	O
mutations	O
in	O
55	O
adult	O
patients	O
with	O
de	O
novo	O
AML	B-malignancy-type
.	O
Mutations	O
were	O
present	O
in	O
8	O
of	O
55	O
(	O
15	O
%	O
)	O
patients	O
.	O
These	O
mutations	O
were	O
usually	O
in	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
,	O
but	O
one	O
patient	O
had	O
mutations	O
in	O
both	O
codons	O
13	O
and	O
61	O
,	O
and	O
another	O
had	O
an	O
unusual	O
point	O
mutation	O
in	O
N-ras	O
codon	O
60	O
.	O
A	O
comparison	O
of	O
patients	O
with	O
and	O
without	O
N-ras	O
mutations	O
showed	O
no	O
statistically	O
significant	O
differences	O
in	O
pretreatment	O
clinical	O
variables	O
,	O
response	O
to	O
induction	O
therapy	O
,	O
or	O
survival	O
,	O
except	O
for	O
a	O
possibly	O
higher	O
percentage	O
of	O
FAB	O
M4	O
subtypes	O
in	O
patients	O
with	O
the	O
N-ras	O
mutation	O
.	O
These	O
data	O
together	O
with	O
previous	O
reports	O
suggest	O
that	O
the	O
presence	O
of	O
N-ras	O
point	O
mutations	O
do	O
not	O
clearly	O
define	O
a	O
unique	O
clinical	O
or	O
biologic	O
subset	O
of	O
AML	B-malignancy-type
patients	O
.	O
PMID	O
:	O
2200539	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1990	O
Apr;98(	O
4	O
)	O
:955	O
-60	O
Infrequent	O
point	O
mutations	O
of	O
ras	O
oncogenes	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
Nanus	O
DM	O
,	O
Kelsen	O
DP	O
,	O
Mentle	O
IR	O
,	O
Altorki	O
N	O
,	O
Albino	O
AP	O
.	O
Laboratory	O
of	O
Mammalian	O
Cell	O
Transformation	O
,	O
Sloan	O
Kettering	O
Institute	O
,	O
New	O
York	O
,	O
New	O
York	O
.	O
Adenocarcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
proximal	I-malignancy-type
and	I-malignancy-type
distal	I-malignancy-type
stomach	I-malignancy-type
have	O
significant	O
clinical	O
and	O
biological	O
differences	O
.	O
A	O
study	O
was	O
undertaken	O
to	O
determine	O
if	O
a	O
difference	O
in	O
the	O
incidence	O
of	O
mutated	O
ras	O
oncogenes	O
exists	O
between	O
proximal	B-malignancy-type
(	O
gastroesophageal	B-malignancy-type
junction	I-malignancy-type
or	O
cardia	B-malignancy-type
)	O
and	O
distal	B-malignancy-type
(	O
body	B-malignancy-type
or	O
antrum	B-malignancy-type
)	O
gastric	B-malignancy-type
tumors	I-malignancy-type
,	O
and	O
to	O
assess	O
the	O
overall	O
incidence	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
from	O
non	O
-	O
Asian	O
patients	O
.	O
Deoxyribonucleic	O
acid	O
from	O
28	O
primary	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
were	O
analyzed	O
for	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
protooncogenes	O
using	O
polymerase	O
-	O
catalyzed	O
chain	O
reaction	O
methodology	O
.	O
Twelve	O
tumors	O
were	O
located	O
at	O
the	O
gastroesophageal	O
junction	O
or	O
cardia	O
,	O
and	O
16	O
in	O
the	O
body	O
or	O
antrum	O
.	O
Mutated	O
ras	O
genes	O
were	O
detected	O
in	O
2	O
of	O
28	O
tumors	O
for	O
an	O
overall	O
incidence	O
of	O
7	O
%	O
.	O
The	O
mutations	O
occurred	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
gene	O
in	O
a	O
proximal	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
and	O
in	O
codon	O
12	O
of	O
the	O
Ki-ras	O
gene	O
in	O
a	O
distal	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
These	O
data	O
indicate	O
that	O
mutations	O
in	O
ras	O
genes	O
are	O
an	O
uncommon	O
event	O
in	O
primary	O
gastric	O
cancers	O
and	O
that	O
there	O
is	O
no	O
meaningful	O
difference	O
in	O
the	O
incidence	O
of	O
ras	O
mutations	O
in	O
proximal	B-malignancy-type
and	O
distal	B-malignancy-type
stomach	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
2179035	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1990	O
Mar	O
1;50(	O
5	O
)	O
:1521-7	O
Characterization	O
of	O
a	O
transforming	O
N-ras	O
gene	O
in	O
the	O
human	O
hepatoma	B-malignancy-type
cell	O
line	O
Hep	O
G2	O
:	O
additional	O
evidence	O
for	O
the	O
importance	O
of	O
c-myc	O
and	O
ras	O
cooperation	O
in	O
hepatocarcinogenesis	O
.	O
Richards	O
CA	O
,	O
Short	O
SA	O
,	O
Thorgeirsson	O
SS	O
,	O
Huber	O
BE.	O
Wellcome	O
Research	O
Laboratories	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
.	O
The	O
expression	O
of	O
the	O
c-myc	O
gene	O
has	O
previously	O
been	O
shown	O
to	O
be	O
elevated	O
and	O
deregulated	O
in	O
the	O
human	O
hepatoma	B-malignancy-type
cell	O
line	O
Hep	O
G2	O
(	O
B.	O
E.	O
Huber	O
and	O
S.	O
S.	O
Thorgeirsson	O
,	O
Cancer	O
Res.	O
,	O
47	O
:	O
3414	O
-	O
3420	O
,	O
1987	O
)	O
.	O
We	O
now	O
report	O
that	O
the	O
Hep	O
G2	O
N-ras	O
gene	O
is	O
activated	O
to	O
a	O
dominant	O
-	O
acting	O
,	O
transforming	O
gene	O
by	O
a	O
missense	O
mutation	O
in	O
codon	O
61	O
.	O
Hep	O
G2	O
DNA	O
produced	O
transformed	O
foci	O
when	O
transfected	O
into	O
NIH	O
3T3	O
cells	O
.	O
Subsequent	O
to	O
a	O
secondary	O
round	O
of	O
transfection	O
,	O
Southern	O
blot	O
analysis	O
of	O
tumorigenic	O
NIH	O
3T3	O
foci	O
demonstrated	O
the	O
presence	O
of	O
human	O
N-ras	O
sequences	O
.	O
Nucleotide	O
sequence	O
analysis	O
of	O
one	O
Hep	O
G2	O
N-ras	O
allele	O
demonstrated	O
that	O
codons	O
12	O
,	O
13	O
,	O
and	O
59	O
were	O
normal	O
and	O
that	O
codon	O
61	O
had	O
a	O
missense	O
mutation	O
(	O
CAA	O
to	O
CTA	O
)	O
.	O
This	O
mutation	O
results	O
in	O
the	O
incorporation	O
of	O
leucine	O
instead	O
of	O
glutamine	O
at	O
residue	O
61	O
of	O
the	O
N-ras	O
gene	O
product	O
,	O
p21	O
.	O
N-ras	O
sequences	O
were	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
from	O
both	O
Hep	O
G2	O
genomic	O
DNA	O
and	O
Hep	O
G2	O
complementary	O
DNA	O
.	O
Analysis	O
of	O
the	O
amplified	O
sequences	O
demonstrated	O
that	O
only	O
one	O
Hep	O
G2	O
N-ras	O
allele	O
exhibited	O
the	O
codon	O
61	O
mutation	O
and	O
that	O
both	O
the	O
mutant	O
and	O
normal	O
alleles	O
were	O
transcribed	O
.	O
Northern	O
blot	O
analysis	O
demonstrated	O
equivalent	O
steady	O
-	O
state	O
levels	O
of	O
N-ras	O
transcripts	O
in	O
Hep	O
G2	O
cells	O
and	O
normal	O
human	O
liver	O
.	O
The	O
steady	O
-	O
state	O
levels	O
of	O
N-ras	O
and	O
ornithine	O
decarboxylase	O
transcripts	O
were	O
positively	O
correlated	O
suggesting	O
a	O
positive	O
relationship	O
between	O
N-ras	O
expression	O
and	O
the	O
replication	O
rate	O
of	O
Hep	O
G2	O
cells	O
.	O
c-Ki-ras	O
and	O
c-Ha-ras	O
transcripts	O
were	O
not	O
detected	O
in	O
either	O
Hep	O
G2	O
cells	O
or	O
normal	O
human	O
liver	O
.	O
Immunoprecipitation	O
experiments	O
using	O
the	O
monoclonal	O
antibody	O
Y13-259	O
demonstrated	O
the	O
presence	O
of	O
p21	O
in	O
Hep	O
G2	O
cells	O
.	O
Expression	O
of	O
a	O
dominant	O
-	O
acting	O
,	O
transforming	O
N-ras	O
gene	O
,	O
in	O
conjunction	O
with	O
the	O
altered	O
regulation	O
of	O
the	O
c-myc	O
gene	O
,	O
documents	O
two	O
important	O
genetic	O
lesions	O
that	O
could	O
be	O
responsible	O
for	O
the	O
transformed	O
phenotype	O
of	O
Hep	O
G2	O
cells	O
.	O
PMID	O
:	O
2154325	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1991	O
Mar;77	O
(	O
3	O
)	O
:	O
323-7	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
childhood	O
myeloid	B-malignancy-type
leukaemia	I-malignancy-type
.	O
Farr	O
C	O
,	O
Gill	O
R	O
,	O
Katz	O
F	O
,	O
Gibbons	O
B	O
,	O
Marshall	O
CJ.	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
London	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
approximately	O
30	O
%	O
of	O
adult	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemias	I-malignancy-type
and	O
20	O
%	O
of	O
adult	O
acute	B-malignancy-type
lymphoid	I-malignancy-type
leukaemias	I-malignancy-type
contain	O
point	O
mutated	O
ras	O
oncogenes	O
.	O
In	O
order	O
to	O
assess	O
whether	O
ras	O
oncogenes	O
are	O
also	O
involved	O
in	O
childhood	O
leukaemias	B-malignancy-type
,	O
we	O
have	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
synthetic	O
oligonucleotide	O
probes	O
to	O
study	O
the	O
nature	O
and	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
childhood	O
leukaemias	B-malignancy-type
,	O
concentrating	O
largely	O
on	O
the	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemias	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Thirty-four	O
childhood	O
presentation	O
AML	B-malignancy-type
DNAs	O
were	O
screened	O
for	O
mutations	O
in	O
and	O
around	O
codons	O
12	O
,	O
61	O
and	O
117	O
of	O
N	O
-	O
,	O
K	O
-	O
and	O
H	O
-	O
ras	O
.	O
Eight	O
of	O
these	O
samples	O
(	O
24	O
%	O
)	O
contained	O
ras	O
mutations	O
.	O
As	O
in	O
the	O
adult	O
disease	O
,	O
the	O
gene	O
predominantly	O
involved	O
was	O
N-ras	O
(	O
6	O
/	O
8	O
)	O
,	O
with	O
occasional	O
activation	O
of	O
K-ras	O
(	O
2	O
/	O
6	O
)	O
.	O
The	O
most	O
common	O
base	O
change	O
was	O
a	O
G	O
----	O
A	O
transition	O
at	O
codon	O
12	O
or	O
13	O
(	O
4	O
/	O
8	O
)	O
.	O
Of	O
the	O
patients	O
with	O
mutant	O
ras	O
,	O
4	O
/	O
8	O
were	O
diagnosed	O
as	O
AML	B-malignancy-type
FAB	I-malignancy-type
subtype	I-malignancy-type
M5	I-malignancy-type
.	O
Five	O
of	O
the	O
34	O
childhood	O
AMLs	B-malignancy-type
analysed	O
displayed	O
abnormalities	O
of	O
chromosome	O
7	O
.	O
However	O
,	O
none	O
of	O
these	O
cases	O
contained	O
a	O
mutant	O
ras	O
gene	O
.	O
One	O
AML	B-malignancy-type
patient	O
was	O
studied	O
at	O
relapse	O
,	O
14	O
months	O
after	O
initial	O
presentation	O
.	O
The	O
presentation	O
mutation	O
(	O
N	O
61	O
p3	O
)	O
was	O
not	O
detectable	O
,	O
although	O
a	O
new	O
mutation	O
(	O
N	O
13	O
Cys	O
)	O
was	O
readily	O
identified	O
.	O
This	O
observation	O
extends	O
our	O
original	O
finding	O
with	O
presentation	O
and	O
relapse	O
samples	O
of	O
adult	O
AML	B-malignancy-type
,	O
in	O
which	O
it	O
was	O
uncommon	O
for	O
the	O
relapse	O
sample	O
to	O
contain	O
the	O
same	O
ras	O
mutation	O
as	O
the	O
presentation	O
DNA	O
.	O
In	O
addition	O
,	O
two	O
out	O
of	O
five	O
patients	O
diagnosed	O
as	O
juvenile	O
CML	B-malignancy-type
,	O
were	O
found	O
to	O
harbour	O
mutant	O
ras	O
.	O
PMID	O
:	O
2012756	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1991	O
Mar;	O
6	O
(	O
3	O
)	O
:471-3	O
Radiation	O
-	O
associated	O
and	O
'	O
spontaneous	O
'	O
human	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
show	O
a	O
different	O
pattern	O
of	O
ras	O
oncogene	O
mutation	O
.	O
Wright	O
PA	O
,	O
Williams	O
ED	O
,	O
Lemoine	O
NR	O
,	O
Wynford	O
-	O
Thomas	O
D.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Heath	O
Park	O
,	O
Cardiff	O
,	O
UK.	O
Activated	O
ras	O
oncogenes	O
in	O
experimentally	O
induced	O
rodent	O
tumours	O
have	O
been	O
demonstrated	O
to	O
show	O
specific	O
patterns	O
of	O
oncogene	O
activation	O
which	O
depend	O
on	O
the	O
inducing	O
agent	O
,	O
with	O
H-ras	O
activation	O
in	O
nitrosomethylurea	O
(	O
NMU	O
)	O
induced	O
tumours	O
,	O
and	O
K-ras	O
activation	O
in	O
tumours	O
induced	O
by	O
ionising	O
radiation	O
.	O
We	O
report	O
a	O
study	O
of	O
12	O
radiation	O
-	O
associated	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
paraffin	O
-	O
embedded	O
material	O
and	O
allele	O
-	O
specific	O
hybridisation	O
with	O
mutant	O
-	O
specific	O
probes	O
for	O
the	O
3	O
ras	O
oncogenes	O
.	O
Compared	O
to	O
68	O
'	O
spontaneous	O
'	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
the	O
radiation	O
-	O
associated	O
cases	O
show	O
the	O
same	O
overall	O
prevalence	O
of	O
ras	O
mutation	O
.	O
However	O
there	O
is	O
a	O
significantly	O
higher	O
rate	O
of	O
K-ras	O
mutation	O
in	O
radiation	O
-	O
associated	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
than	O
in	O
'	O
spontaneous	O
'	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
60	O
%	O
compared	O
to	O
6	O
%	O
,	O
P	O
less	O
than	O
0.05	O
)	O
,	O
suggesting	O
that	O
radiation	O
may	O
preferentially	O
activate	O
K-ras	O
in	O
human	O
as	O
well	O
as	O
rodent	O
tumours	O
.	O
PMID	O
:	O
2011403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
Mar	O
15;51(	O
6)	O
:1596	O
-	O
9	O
Low	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
cancers	I-malignancy-type
.	O
Moley	O
JF	O
,	O
Brother	O
MB	O
,	O
Wells	O
SA	O
,	O
Spengler	O
BA	O
,	O
Biedler	O
JL	O
,	O
Brodeur	O
GM	O
.	O
Department	O
of	O
Surgery	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
Missouri	O
63110	O
.	O
Little	O
is	O
known	O
about	O
the	O
prevalence	O
and	O
significance	O
of	O
ras	O
gene	O
activation	O
in	O
neural	B-malignancy-type
crest	I-malignancy-type
tumors	I-malignancy-type
such	O
as	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
cancers	I-malignancy-type
(	O
MTCs	O
)	O
.	O
Therefore	O
,	O
we	O
analyzed	O
DNA	O
from	O
10	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
10	O
primary	O
human	O
pheochromocytomas	B-malignancy-type
for	O
activating	O
mutations	O
in	O
N-ras	O
,	O
H-ras	O
,	O
and	O
K-ras	O
.	O
We	O
also	O
studied	O
DNA	O
from	O
24	O
primary	O
neuroblastomas	B-malignancy-type
and	O
10	O
MTCs	B-malignancy-type
for	O
N-ras	O
mutations	O
.	O
ras	O
genes	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
of	O
specific	O
DNA	O
fragments	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
With	O
the	O
exception	O
of	O
the	O
SK-N-SH	O
cell	O
line	O
,	O
the	O
examined	O
ras	O
gene	O
sequences	O
were	O
normal	O
in	O
all	O
the	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
MTCs	B-malignancy-type
tested	O
.	O
A	O
single	O
point	O
mutation	O
was	O
identified	O
at	O
codon	O
59	O
(	O
GCT	O
(	O
ala	O
)	O
----	O
ACT	O
(	O
thr	O
)	O
)	O
in	O
one	O
N-ras	O
allele	O
in	O
an	O
SK-N-SH	O
subline	O
.	O
Interestingly	O
,	O
this	O
mutation	O
is	O
different	O
from	O
the	O
activating	O
codon	O
61	O
mutation	O
which	O
resulted	O
in	O
the	O
initial	O
identification	O
of	O
N-ras	O
from	O
SK-N-SH	O
DNA	O
.	O
Therefore	O
,	O
we	O
analyzed	O
the	O
sequences	O
of	O
earlier	O
passages	O
and	O
sublines	O
of	O
the	O
SK-N-SH	O
cell	O
line	O
,	O
but	O
mutations	O
at	O
codon	O
59	O
or	O
61	O
were	O
not	O
detected	O
,	O
suggesting	O
that	O
neither	O
mutation	O
was	O
present	O
in	O
the	O
primary	O
tumor	O
.	O
Our	O
results	O
indicate	O
that	O
N-ras	O
mutations	O
may	O
occur	O
spontaneously	O
during	O
in	O
vitro	O
passage	O
of	O
cell	O
lines	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
occur	O
in	O
primary	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
MTCs	B-malignancy-type
.	O
In	O
addition	O
,	O
we	O
have	O
not	O
found	O
H-ras	O
or	O
K-ras	O
mutations	O
in	O
any	O
neuroblastoma	B-malignancy-type
cell	O
line	O
or	O
primary	O
pheochromocytoma	B-malignancy-type
.	O
PMID	O
:	O
1998949	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1991	O
Sep;6(9	O
)	O
:1651	O
-	O
6	O
Detection	O
of	O
transforming	O
genes	O
by	O
transfection	O
of	O
DNA	O
from	O
primary	O
soft	B-malignancy-type
-	I-malignancy-type
tissue	I-malignancy-type
tumours	I-malignancy-type
.	O
Gill	O
S,	O
Stratton	O
MR	O
,	O
Patterson	O
H	O
,	O
Spurr	O
NK	O
,	O
Fisher	O
C	O
,	O
Gusterson	O
BA	O
,	O
Cooper	O
CS	O
.	O
Section	O
of	O
Molecular	O
Carcinogenesis	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK.	O
A	O
series	O
of	O
adult	O
soft	B-malignancy-type
-	I-malignancy-type
tissue	I-malignancy-type
tumours	I-malignancy-type
were	O
screened	O
for	O
the	O
presence	O
of	O
activated	O
oncogenes	O
by	O
transfecting	O
tumour	O
DNA	O
into	O
NIH3T3	O
mouse	O
fibroblasts	O
.	O
In	O
these	O
studies	O
an	O
activated	O
K-ras	O
gene	O
that	O
contained	O
a	O
mutation	O
at	O
the	O
second	O
position	O
of	O
codon	O
12	O
(	O
GGT	O
----	O
GAT	O
)	O
was	O
found	O
in	O
a	O
leiomyosarcoma	B-malignancy-type
.	O
In	O
addition	O
,	O
following	O
transfection	O
of	O
DNA	O
from	O
a	O
liposarcoma	B-malignancy-type
,	O
we	O
identified	O
an	O
activated	O
gene	O
that	O
failed	O
to	O
hybridize	O
to	O
probes	O
prepared	O
from	O
10	O
known	O
human	O
oncogenes	O
(	O
K-ras	O
,	O
H-ras	O
,	O
N-ras	O
,	O
ret	O
,	O
met	O
,	O
trk	O
,	O
mas	O
,	O
dbl	O
,	O
raf	O
and	O
hst	O
)	O
that	O
have	O
previously	O
been	O
detected	O
in	O
DNA	O
transfection	O
experiments	O
.	O
BamHI	O
-	O
BamHI	O
fragments	O
of	O
this	O
activated	O
gene	O
of	O
3.5	O
and	O
8.5	O
kb	O
were	O
cloned	O
from	O
NIH3T3	O
secondary	O
transfectants	O
using	O
a	O
probe	O
that	O
detects	O
the	O
human	O
alu	O
family	O
of	O
highly	O
repetitive	O
DNA	O
sequences	O
.	O
Repeat	O
-	O
free	O
subclones	O
of	O
these	O
BamHI	O
fragments	O
were	O
used	O
to	O
map	O
this	O
gene	O
to	O
human	O
chromosome	O
19	O
(	O
p13.2	O
-	O
q13.3	O
)	O
.	O
Our	O
studies	O
also	O
demonstrate	O
that	O
a	O
subclone	O
from	O
one	O
of	O
the	O
BamHI	O
fragments	O
detects	O
a	O
3.0	O
kb	O
transcript	O
in	O
primary	O
and	O
secondary	O
transfectants	O
.	O
PMID	O
:	O
1923531	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1991	O
;15(	O
10	O
)	O
:935	O
-	O
41	O
N-ras	O
gene	O
mutations	O
in	O
childhood	O
acute	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Terada	O
N	O
,	O
Smith	O
TJ	O
,	O
Stork	O
LC	O
,	O
Odom	O
LF	O
,	O
Gelfand	O
EW.	O
Division	O
of	O
Basic	O
Sciences	O
,	O
National	O
Jewish	O
Center	O
for	O
Immunology	O
and	O
Respiratory	O
Medicine	O
,	O
Denver	O
,	O
CO	O
80206	O
.	O
In	O
view	O
of	O
the	O
potential	O
role	O
for	O
ras	O
activation	O
in	O
leukemogenesis	O
,	O
we	O
have	O
screened	O
a	O
number	O
of	O
children	O
with	O
acute	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ANLL	B-malignancy-type
)	O
for	O
activating	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
using	O
panels	O
of	O
oligonucleotide	O
probes	O
in	O
conjunction	O
with	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
gene	O
amplification	O
.	O
In	O
contrast	O
to	O
the	O
frequent	O
occurrence	O
(	O
approximately	O
30	O
%	O
)	O
of	O
N-ras	O
mutation	O
reported	O
in	O
adult	O
ANLL	B-malignancy-type
,	O
6	O
of	O
46	O
cases	O
(	O
13	O
%	O
)	O
at	O
the	O
time	O
of	O
diagnosis	O
had	O
N-ras	O
mutations	O
involving	O
codons	O
12	O
and	O
13	O
.	O
In	O
these	O
patients	O
we	O
also	O
determine	O
whether	O
presenting	O
clinical	O
symptoms	O
,	O
cellular	O
pathology	O
,	O
karyotype	O
,	O
or	O
eventual	O
outcome	O
distinguished	O
them	O
from	O
the	O
ras	O
-	O
negative	O
group	O
.	O
N-ras	O
activation	O
tended	O
to	O
be	O
associated	O
with	O
a	O
higher	O
white	O
blood	O
cell	O
count	O
at	O
diagnosis	O
(	O
mean	O
of	O
225,000	O
/	O
microliters	O
vs	O
91,000	O
/	O
microliters	O
)	O
and	O
fewer	O
remissions	O
obtained	O
after	O
28	O
days	O
of	O
therapy	O
(	O
3	O
/	O
6	O
,	O
50	O
%	O
vs	O
24	O
/	O
32	O
,	O
75	O
%	O
)	O
.	O
It	O
is	O
possible	O
that	O
activation	O
of	O
N-ras	O
oncogene	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
some	O
cases	O
of	O
childhood	O
ANLL	B-malignancy-type
.	O
PMID	O
:	O
1921453	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncology	O
1992	O
;49(	O
2	O
)	O
:114	O
-	O
22	O
Multiple	O
point	O
mutation	O
of	O
N-ras	O
and	O
K-ras	O
oncogenes	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Nakagawa	O
T	O
,	O
Saitoh	O
S,	O
Imoto	O
S,	O
Itoh	O
M,	O
Tsutsumi	O
M,	O
Hikiji	O
K	O
,	O
Nakamura	O
H	O
,	O
Matozaki	O
S,	O
Ogawa	O
R,	O
Nakao	O
Y	O
,	O
et	O
al	O
.	O
Department	O
of	O
Medicine	O
,	O
Hyogo	O
Medical	O
Center	O
for	O
Adults	O
,	O
Akashi	O
,	O
Japan	O
.	O
We	O
analyzed	O
activating	O
mutations	O
of	O
N-ras	O
and	O
K-ras	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
in	O
hematological	O
disorders	O
.	O
Activating	O
mutations	O
of	O
these	O
codons	O
were	O
detected	O
in	O
4	O
of	O
20	O
cases	O
of	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
15	O
of	O
77	O
cases	O
of	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Our	O
of	O
19	O
cases	O
of	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
who	O
carried	O
active	O
mutations	O
,	O
7	O
cases	O
were	O
found	O
to	O
have	O
two	O
or	O
more	O
distinct	O
mutations	O
in	O
activating	O
codons	O
of	O
N-ras	O
and	O
K-ras	O
.	O
Ras	O
mutation	O
was	O
found	O
preferentially	O
in	O
progressive	O
disease	O
such	O
as	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
(	O
RAEB	O
)	O
of	O
RAEB	O
in	O
transformation	O
(	O
RAEB-t	O
)	O
.	O
A	O
relatively	O
high	O
incidence	O
of	O
ras	O
mutation	O
was	O
found	O
in	O
M5	O
AML	B-malignancy-type
(	O
40	O
%	O
)	O
.	O
No	O
ras	O
mutations	O
were	O
found	O
in	O
other	O
hematological	O
disorders	O
,	O
such	O
as	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
and	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
-	I-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
most	O
frequent	O
amino	O
acid	O
substitution	O
was	O
that	O
of	O
an	O
aspartate	O
for	O
glycine	O
at	O
codon	O
12	O
of	O
N-ras	O
resulting	O
from	O
G	O
to	O
A	O
mutation	O
(	O
11	O
/	O
35	O
)	O
.	O
The	O
survival	O
of	O
AML	B-malignancy-type
patients	O
who	O
carried	O
ras	O
mutations	O
showed	O
no	O
significant	O
differences	O
from	O
those	O
without	O
ras	O
mutations	O
calculated	O
by	O
Kaplan	O
-	O
Meier	O
.	O
Seven	O
cases	O
of	O
MDS	B-malignancy-type
and	O
7	O
cases	O
of	O
AML	B-malignancy-type
patients	O
could	O
be	O
investigated	O
at	O
various	O
points	O
during	O
their	O
clinical	O
course	O
.	O
Among	O
these	O
14	O
cases	O
,	O
we	O
found	O
2	O
interesting	O
cases	O
of	O
MDS	B-malignancy-type
.	O
The	O
first	O
case	O
lost	O
multiple	O
clones	O
carrying	O
ras	O
mutations	O
during	O
disease	O
progression	O
,	O
the	O
second	O
case	O
acquired	O
mutation	O
of	O
the	O
ras	O
gene	O
during	O
disease	O
progression	O
.	O
These	O
results	O
suggested	O
that	O
multiple	O
point	O
mutations	O
of	O
ras	O
genes	O
may	O
not	O
be	O
initiating	O
events	O
but	O
may	O
contribute	O
to	O
a	O
clonal	O
evolution	O
of	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
PMID	O
:	O
1574246	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Korean	O
Med	O
Sci	O
1992	O
Jun;7(	O
2	O
)	O
:110	O
-	O
5	O
Point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
c-Ha-ras	O
gene	O
in	O
human	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
Koh	O
EH	O
,	O
Chung	O
HC	O
,	O
Lee	O
KB	O
,	O
Han	O
EK	O
,	O
Oh	O
SH	O
,	O
Min	O
JS	O
,	O
Choi	O
EM	O
,	O
Youn	O
JK	O
,	O
Kim	O
BS	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yonsei	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
molecular	O
mechanisms	O
of	O
the	O
carcinogenic	O
process	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
have	O
not	O
been	O
fully	O
understood	O
yet	O
.	O
In	O
order	O
to	O
know	O
whether	O
c-Ha-ras	O
gene	O
is	O
being	O
involved	O
in	O
the	O
process	O
of	O
gastric	O
carcinogenesis	O
,	O
8	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
8	O
cases	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
and	O
same	O
number	O
of	O
adjacent	O
dysplasia	B-malignancy-type
were	O
analyzed	O
for	O
the	O
presence	O
of	O
mutation	O
at	O
codon	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
c-Ha-ras	O
gene	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
mutant	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Point	O
mutations	O
at	O
codon	O
12	O
of	O
the	O
c-Ha-ras	O
gene	O
were	O
found	O
in	O
2	O
out	O
of	O
8	O
gastric	B-malignancy-type
cancer	I-malignancy-type
and	O
dysplasia	B-malignancy-type
samples	O
in	O
one	O
case	O
,	O
but	O
we	O
found	O
no	O
mutation	O
at	O
codon	O
13	O
or	O
61	O
of	O
the	O
c-Ha-ras	O
gene	O
.	O
These	O
results	O
suggest	O
that	O
the	O
frequency	O
of	O
mutation	O
of	O
the	O
c-Ha-ras	O
gene	O
detected	O
by	O
sensitive	O
PCR	O
technique	O
is	O
low	O
indeed	O
,	O
however	O
it	O
would	O
be	O
notable	O
that	O
such	O
a	O
genetic	O
change	O
has	O
been	O
detected	O
in	O
the	O
dysplastic	B-malignancy-type
lesion	I-malignancy-type
of	O
the	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patient	O
.	O
PMID	O
:	O
1524724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Dec	O
2;52(	O
6)	O
:867	O
-	O
72	O
The	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
and	O
ras	O
oncogene	O
mutations	O
in	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Sakai	O
E	O
,	O
Rikimaru	O
K	O
,	O
Ueda	O
M,	O
Matsumoto	O
Y	O
,	O
Ishii	O
N	O
,	O
Enomoto	O
S,	O
Yamamoto	O
H	O
,	O
Tsuchida	O
N.	O
Department	O
of	O
Molecular	O
Cellular	O
Oncology	O
and	O
Microbiology	O
,	O
Faculty	O
of	O
Dentistry	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
,	O
Japan	O
.	O
The	O
frequencies	O
of	O
mutations	O
in	O
the	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
and	O
ras	O
proto	O
-	O
oncogenes	O
were	O
investigated	O
systematically	O
in	O
surgically	O
resected	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCCs	B-malignancy-type
)	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and/or	O
dot	O
-	O
blot	O
hybridization	O
analysis	O
of	O
DNA	O
fragments	O
which	O
had	O
been	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
p53	O
gene	O
mutations	O
,	O
within	O
the	O
region	O
of	O
exons	O
5	O
to	O
8	O
,	O
were	O
detected	O
in	O
17	O
out	O
of	O
27	O
(	O
63	O
%	O
)	O
tumor	O
specimens	O
.	O
The	O
role	O
of	O
p53	O
mutations	O
in	O
cell	O
-	O
line	O
establishment	O
was	O
investigated	O
.	O
p53	O
gene	O
mutations	O
were	O
detected	O
in	O
5	O
out	O
of	O
6	O
tissue	O
samples	O
from	O
which	O
cell	O
lines	O
were	O
established	O
and	O
in	O
4	O
out	O
of	O
5	O
specimens	O
from	O
which	O
cell	O
lines	O
could	O
not	O
be	O
established	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
p53	O
gene	O
mutations	O
is	O
not	O
by	O
itself	O
sufficient	O
for	O
cell	O
-	O
line	O
establishment	O
.	O
Tumor	O
samples	O
were	O
also	O
analyzed	O
for	O
point	O
mutational	O
activation	O
of	O
the	O
ras	O
proto	O
-	O
oncogenes	O
.	O
One	O
out	O
of	O
30	O
(	O
3	O
%	O
)	O
tumors	O
showed	O
an	O
activating	O
point	O
mutation	O
in	O
codon	O
12	O
of	O
H-ras	O
,	O
this	O
being	O
consistent	O
with	O
reports	O
from	O
Europe	O
and	O
USA	O
but	O
not	O
with	O
any	O
from	O
India	O
.	O
Compared	O
to	O
frequencies	O
of	O
the	O
other	O
genetic	O
changes	O
so	O
far	O
reported	O
for	O
oral	B-malignancy-type
SCC	I-malignancy-type
,	O
the	O
p53	O
mutations	O
have	O
been	O
observed	O
most	O
often	O
to	O
undergo	O
genetic	O
change	O
.	O
p53	O
gene	O
mutation	O
is	O
thus	O
intimately	O
involved	O
in	O
the	O
genesis	O
of	O
oral	B-malignancy-type
SCC	I-malignancy-type
and	O
consequently	O
should	O
be	O
useful	O
as	O
a	O
marker	O
for	O
the	O
diagnosis	O
of	O
this	O
neoplasm	B-malignancy-type
.	O
PMID	O
:	O
1459726	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Thorac	O
Cardiovasc	O
Surg	O
1992	O
Nov;104(	O
5	O
)	O
:1465	O
-	O
9	O
Ras	O
oncogene	O
point	O
mutation	O
:	O
an	O
infrequent	O
event	O
in	O
bronchioloalveolar	B-malignancy-type
cancer	I-malignancy-type
.	O
Rusch	O
VW	O
,	O
Reuter	O
VE	O
,	O
Kris	O
MG	O
,	O
Kurie	O
J,	O
Miller	O
WH	O
Jr	O
,	O
Nanus	O
DM	O
,	O
Albino	O
AP	O
,	O
Dmitrovsky	O
E.	O
Laboratory	O
of	O
Molecular	O
Medicine	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
N.Y	O
.	O
Ras	O
oncogene	O
point	O
mutation	O
,	O
primarily	O
activating	O
the	O
K-ras	O
gene	O
,	O
has	O
been	O
reported	O
in	O
approximately	O
one	O
third	O
of	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
This	O
identifies	O
a	O
subset	O
of	O
early	O
stage	O
tumors	O
clinically	O
associated	O
with	O
smoking	O
and	O
an	O
aggressive	O
clinical	O
course	O
.	O
Because	O
of	O
these	O
findings	O
,	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
occurrence	O
of	O
ras	O
point	O
mutations	O
in	O
bronchioloalveolar	B-malignancy-type
carcinoma	I-malignancy-type
.	O
This	O
uncommon	O
form	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
is	O
usually	O
indolent	O
but	O
can	O
sometimes	O
present	O
as	O
a	O
rapidly	O
growing	O
,	O
multifocal	B-malignancy-type
tumor	I-malignancy-type
.	O
Twenty	O
tumor	O
samples	O
obtained	O
at	O
thoracotomy	O
were	O
examined	O
for	O
H-ras	O
,	O
K-ras	O
,	O
and	O
N-ras	O
oncogene	O
mutational	O
activation	O
involving	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
This	O
was	O
performed	O
by	O
an	O
oligonucleotide	O
hybridization	O
technique	O
following	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
these	O
specific	O
sequences	O
.	O
K-ras	O
point	O
mutation	O
involving	O
codon	O
12	O
was	O
observed	O
in	O
two	O
tumors	O
,	O
but	O
not	O
in	O
the	O
adjacent	O
histologically	O
benign	O
lung	O
tissue	O
.	O
These	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
of	O
these	O
polymerase	O
chain	O
reaction	O
products	O
.	O
Both	O
patients	O
were	O
smokers	O
,	O
had	O
stage	O
I	O
tumors	O
,	O
and	O
remain	O
disease	O
-	O
free	O
at	O
27	O
and	O
40	O
months	O
postoperatively	O
.	O
No	O
H-ras	O
or	O
N-ras	O
point	O
mutations	O
were	O
found	O
.	O
These	O
findings	O
suggest	O
that	O
ras	O
activation	O
is	O
an	O
infrequent	O
event	O
in	O
bronchioloalveolar	B-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
speculate	O
that	O
ras	O
activation	O
is	O
not	O
a	O
common	O
transformational	O
event	O
in	O
this	O
form	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
1331621	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1992	O
Aug	O
15;70(	O
4)	O
:760	O
-	O
3	O
Incidence	O
of	O
ras	O
oncogene	O
activation	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
in	O
Hong	O
Kong	O
.	O
Lung	O
ML	O
,	O
Wong	O
M,	O
Lam	O
WK	O
,	O
Lau	O
KS	O
,	O
Kwan	O
S,	O
Fu	O
KH	O
,	O
Cheung	O
H	O
,	O
Yew	O
WW.	O
Department	O
of	O
Microbiology	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
University	O
of	O
Hong	O
Kong	O
.	O
BACKGROUND	O
.	O
In	O
Hong	O
Kong	O
,	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
contribute	O
to	O
the	O
majority	O
of	O
cancer	O
deaths	O
among	O
Chinese	O
.	O
Point	O
mutational	O
activation	O
of	O
ras	O
oncogenes	O
has	O
been	O
observed	O
in	O
several	O
populations	O
.	O
The	O
incidence	O
of	O
these	O
mutations	O
in	O
Hong	O
Kong	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
was	O
investigated	O
.	O
METHODS	O
.	O
Lung	O
resections	O
obtained	O
from	O
52	O
Chinese	O
patients	O
whose	O
conditions	O
were	O
newly	O
diagnosed	O
as	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
,	O
paraffin	O
sections	O
from	O
29	O
Chinese	O
patients	O
with	O
previously	O
diagnosed	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
,	O
and	O
paraffin	O
sections	O
from	O
49	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
examined	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
in	O
Ki-ras	O
codon	O
12	O
,	O
N-ras	O
codon	O
61	O
,	O
and	O
Ha-ras	O
codon	O
12	O
oncogenes	O
by	O
allele	O
-	O
specific	O
hybridization	O
after	O
specific	O
amplification	O
of	O
appropriate	O
regions	O
of	O
the	O
DNA	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
RESULTS	O
.	O
Among	O
the	O
130	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
investigated	O
,	O
Ki-ras	O
point	O
mutations	O
were	O
detected	O
in	O
seven	O
cases	O
,	O
of	O
which	O
six	O
were	O
adenocarcinomas	B-malignancy-type
and	O
one	O
a	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
No	O
mutations	O
were	O
detected	O
in	O
the	O
N-ras	O
and	O
Ha-ras	O
codons	O
.	O
CONCLUSIONS	O
.	O
The	O
incidence	O
of	O
Ki-ras	O
codon	O
12	O
point	O
mutational	O
activation	O
in	O
Chinese	O
patients	O
with	O
adenocarcinomas	B-malignancy-type
was	O
6	O
of	O
63	O
(	O
9.5	O
%	O
)	O
.	O
The	O
incidence	O
of	O
Ki-ras	O
12	O
point	O
mutational	O
activation	O
among	O
men	O
with	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
in	O
Hong	O
Kong	O
(	O
6	O
of	O
32	O
patients	O
,	O
18.8	O
%	O
)	O
is	O
significantly	O
different	O
from	O
that	O
in	O
women	O
in	O
Hong	O
Kong	O
(	O
0	O
of	O
31	O
patients	O
,	O
0	O
%	O
)	O
.	O
Although	O
ras	O
oncogenes	O
are	O
implicated	O
as	O
having	O
a	O
role	O
in	O
the	O
development	O
of	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
especially	O
among	O
smokers	O
,	O
it	O
is	O
clear	O
from	O
these	O
data	O
that	O
they	O
are	O
not	O
associated	O
with	O
the	O
unusually	O
high	O
incidence	O
of	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
among	O
women	O
in	O
Hong	O
Kong	O
.	O
PMID	O
:	O
1322782	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2002	O
Jul	O
18;21(	O
31	O
)	O
:4863	O
-	O
71	O
Mutational	O
spectrum	O
of	O
beta-catenin	O
,	O
AXIN1	O
,	O
and	O
AXIN2	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
and	O
hepatoblastomas	B-malignancy-type
.	O
Taniguchi	O
K	O
,	O
Roberts	O
LR	O
,	O
Aderca	O
IN	O
,	O
Dong	O
X	O
,	O
Qian	O
C	O
,	O
Murphy	O
LM	O
,	O
Nagorney	O
DM	O
,	O
Burgart	O
LJ	O
,	O
Roche	O
PC	O
,	O
Smith	O
DI	O
,	O
Ross	O
JA	O
,	O
Liu	O
W.	O
Division	O
of	O
Experimental	O
Pathology	O
,	O
Mayo	O
Clinic	O
,	O
Rochester	O
,	O
Minnesota	O
,	O
MN	O
55905	O
,	O
USA	O
.	O
Activation	O
of	O
Wnt	O
signaling	O
through	O
beta-catenin	O
mutations	O
contributes	O
to	O
the	O
development	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
and	O
hepatoblastoma	B-malignancy-type
(	O
HB	B-malignancy-type
)	O
.	O
To	O
explore	O
the	O
contribution	O
of	O
additional	O
Wnt	O
pathway	O
molecules	O
to	O
hepatocarcinogenesis	O
,	O
we	O
examined	O
beta-catenin	O
,	O
AXIN1	O
and	O
AXIN2	O
mutations	O
in	O
73	O
HCCs	B-malignancy-type
and	O
27	O
HBs	B-malignancy-type
.	O
beta-catenin	O
mutations	O
were	O
detected	O
in	O
19.2	O
%	O
(	O
14	O
out	O
of	O
73	O
)	O
HCCs	B-malignancy-type
and	O
70.4	O
%	O
(	O
19	O
out	O
of	O
27	O
)	O
HBs	B-malignancy-type
.	O
beta-catenin	O
mutations	O
in	O
HCCs	B-malignancy-type
were	O
primarily	O
point	O
mutations	O
,	O
whereas	O
more	O
than	O
half	O
of	O
the	O
HBs	B-malignancy-type
had	O
deletions	O
.	O
AXIN1	O
mutations	O
occurred	O
in	O
seven	O
(	O
9.6	O
%	O
)	O
HCCs	B-malignancy-type
and	O
two	O
(	O
7.4	O
%	O
)	O
HBs	B-malignancy-type
.	O
The	O
AXIN1	O
mutations	O
included	O
seven	O
missense	O
mutations	O
,	O
a	O
1	O
bp	O
deletion	O
,	O
and	O
a	O
12	O
bp	O
insertion	O
.	O
The	O
predominance	O
of	O
missense	O
mutations	O
found	O
in	O
the	O
AXIN1	O
gene	O
is	O
different	O
from	O
the	O
small	O
deletions	O
or	O
nonsense	O
mutations	O
described	O
previously	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
AXIN1	O
locus	O
was	O
present	O
in	O
four	O
of	O
five	O
informative	O
HCCs	B-malignancy-type
with	O
AXIN1	O
mutations	O
,	O
suggesting	O
a	O
tumor	O
suppressor	O
function	O
of	O
this	O
gene	O
.	O
AXIN2	O
mutations	O
were	O
found	O
in	O
two	O
(	O
2.7	O
%	O
)	O
HCCs	B-malignancy-type
but	O
not	O
in	O
HBs	B-malignancy-type
.	O
Two	O
HCCs	B-malignancy-type
had	O
both	O
AXIN1	O
and	O
beta-catenin	O
mutations	O
,	O
and	O
one	O
HCC	B-malignancy-type
had	O
both	O
AXIN2	O
and	O
beta-catenin	O
mutations	O
.	O
About	O
half	O
the	O
HCCs	B-malignancy-type
with	O
AXIN1	O
or	O
AXIN2	O
mutations	O
showed	O
beta-catenin	O
accumulation	O
in	O
the	O
nucleus	O
,	O
cytoplasm	O
or	O
membrane	O
.	O
Overall	O
,	O
these	O
data	O
indicate	O
that	O
besides	O
the	O
approximately	O
20	O
%	O
of	O
HCCs	B-malignancy-type
and	O
80	O
%	O
of	O
HBs	B-malignancy-type
with	O
beta-catenin	O
mutations	O
contributing	O
to	O
hepatocarcinogenesis	O
,	O
AXIN1	O
and	O
AXIN2	O
mutations	O
appear	O
to	O
be	O
important	O
in	O
an	O
additional	O
10	O
%	O
of	O
HCCs	B-malignancy-type
and	O
HBs	B-malignancy-type
.	O
PMID	O
:	O
12101426	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
2001	O
Dec;7(	O
12	O
)	O
:4000	O
-	O
7	O
Molecular	O
analysis	O
of	O
sulindac	B-malignancy-type
-	I-malignancy-type
resistant	I-malignancy-type
adenomas	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
.	O
Keller	O
JJ	O
,	O
Offerhaus	O
GJ	O
,	O
Drillenburg	O
P	O
,	O
Caspers	O
E	O
,	O
Musler	O
A	O
,	O
Ristimaki	O
A	O
,	O
Giardiello	O
FM	O
.	O
Department	O
of	O
Pathology	O
,	O
Academic	O
Medical	O
Center	O
,	O
1100	O
DD	O
Amsterdam	O
,	O
the	O
Netherlands	O
.	O
j.j.keller@amc.uva.nl	O
PURPOSE	O
:	O
Sulindac	O
causes	O
the	O
reduction	O
of	O
adenomas	B-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
patients	O
,	O
but	O
complete	O
regression	O
is	O
unusual	O
,	O
and	O
breakthrough	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
during	O
sulindac	O
treatment	O
has	O
been	O
described	O
.	O
The	O
molecular	O
features	O
related	O
to	O
sulindac	O
resistance	O
are	O
unknown	O
.	O
Therefore	O
,	O
we	O
investigated	O
molecular	O
alterations	O
in	O
adenomas	B-malignancy-type
from	O
FAP	B-malignancy-type
patients	O
with	O
complete	O
adenoma	B-malignancy-type
regression	O
on	O
sulindac	O
(	O
responsive	O
patients	O
)	O
and	O
from	O
FAP	B-malignancy-type
patients	O
with	O
sulindac	B-malignancy-type
-	I-malignancy-type
resistant	I-malignancy-type
adenomas	I-malignancy-type
(	O
resistant	O
patients	O
)	O
.	O
DESIGN	O
:	O
Fourteen	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
(	O
removed	O
before	O
sulindac	O
treatment	O
)	O
from	O
six	O
responsive	O
patients	O
were	O
studied	O
.	O
Also	O
,	O
9	O
baseline	O
adenomas	O
and	O
34	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
(	O
removed	O
during	O
sulindac	O
treatment	O
)	O
from	O
three	O
resistant	O
patients	O
were	O
analyzed	O
.	O
Using	O
immunohistochemistry	O
,	O
we	O
evaluated	O
the	O
expression	O
of	O
beta-catenin	O
,	O
cyclooxygenase-2	O
(	O
Cox-2	O
)	O
,	O
p53	O
,	O
Bcl-2	O
,	O
and	O
Bax	O
.	O
K-ras	O
codon	O
12	O
mutations	O
,	O
loss	O
of	O
heterozygosity	O
at	O
5q	O
(	O
APC	O
locus	O
)	O
,	O
and	O
microsatellite	O
instability	O
were	O
studied	O
with	O
PCR	O
-	O
based	O
techniques	O
.	O
RESULTS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
between	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
sulindac	O
-	O
responsive	O
and	O
-	O
resistant	O
patients	O
(	O
P	O
>	O
0.05	O
)	O
.	O
There	O
was	O
less	O
loss	O
of	O
membranous	O
beta-catenin	O
staining	O
and	O
less	O
nuclear	O
beta-catenin	O
accumulation	O
in	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
compared	O
with	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
the	O
same	O
(	O
sulindac	O
-	O
resistant	O
)	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
or	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
responsive	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Epithelial	O
Cox-2	O
expression	O
was	O
less	O
,	O
though	O
not	O
significant	O
,	O
in	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
compared	O
with	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
resistant	O
patients	O
,	O
but	O
was	O
significantly	O
less	O
in	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
responsive	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
8	O
of	O
34	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
(	O
24	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
(	O
P	O
<	O
0.05	O
)	O
.	O
Stromal	O
Cox-2	O
expression	O
,	O
staining	O
of	O
p53	O
and	O
Bcl-2	O
,	O
and	O
loss	O
of	O
heterozygosity	O
at	O
5q	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
Loss	O
of	O
Bax	O
staining	O
and	O
microsatellite	O
instability	O
were	O
not	O
found	O
in	O
any	O
adenoma	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
Sulindac	B-malignancy-type
-	I-malignancy-type
resistant	I-malignancy-type
adenomas	I-malignancy-type
display	O
less	O
alteration	O
in	O
beta-catenin	O
staining	O
and	O
less	O
epithelial	O
Cox-2	O
expression	O
when	O
compared	O
with	O
adenomas	B-malignancy-type
removed	O
before	O
sulindac	O
treatment	O
.	O
K-ras	O
mutations	O
may	O
contribute	O
to	O
sulindac	O
-	O
resistance	O
.	O
Continued	O
research	O
is	O
needed	O
to	O
investigate	O
molecular	O
alterations	O
related	O
to	O
sulindac	O
resistance	O
.	O
PMID	O
:	O
11751493	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2001	O
Nov;32(	O
11	O
)	O
:1225	O
-	O
31	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
gene	O
mutation	O
in	O
atypical	B-malignancy-type
fibroxanthoma	I-malignancy-type
and	O
malignant	O
fibrous	B-malignancy-type
histiocytoma	I-malignancy-type
.	O
Sakamoto	O
A	O
,	O
Oda	O
Y	O
,	O
Itakura	O
E	O
,	O
Oshiro	O
Y	O
,	O
Tamiya	O
S,	O
Honda	O
Y	O
,	O
Ishihara	O
A	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Atypical	B-malignancy-type
fibroxanthoma	I-malignancy-type
(	O
AFX	B-malignancy-type
)	O
which	O
is	O
histologically	O
similar	O
to	O
malignant	O
fibrous	B-malignancy-type
histiocytoma	I-malignancy-type
(	O
MFH	B-malignancy-type
)	O
,	O
occurs	O
in	O
the	O
sun	O
-	O
exposed	O
skin	O
.	O
The	O
presence	O
of	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
H	O
-	O
and	O
K	O
-	O
ras	O
genes	O
and	O
in	O
exons	O
1	O
and	O
2	O
,	O
which	O
include	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
,	O
of	O
the	O
N-ras	O
gene	O
was	O
studied	O
in	O
8	O
cases	O
of	O
AFX	O
and	O
8	O
cases	O
of	O
storiform	B-malignancy-type
-	I-malignancy-type
pleomorphic	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
MFH	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
PCR	O
-	O
single	O
-	O
conformation	O
polymorphism	O
.	O
Two	O
of	O
the	O
8	O
cases	O
of	O
MFH	B-malignancy-type
showed	O
ras	O
mutations	O
in	O
the	O
H-ras	O
gene	O
at	O
codon	O
12	O
(	O
GGC	O
-	O
AGC	O
)	O
and	O
in	O
the	O
K-ras	O
gene	O
at	O
codon	O
13	O
(	O
GGC	O
-	O
GAC	O
)	O
.	O
H	O
-	O
and	O
K	O
-	O
ras	O
gene	O
mutations	O
were	O
not	O
seen	O
in	O
any	O
of	O
the	O
cases	O
of	O
AFX	B-malignancy-type
(	O
0	O
of	O
8	O
)	O
.	O
N-ras	O
gene	O
mutation	O
was	O
not	O
detected	O
in	O
either	O
the	O
AFX	B-malignancy-type
(	O
0	O
of	O
8	O
)	O
or	O
MFH	B-malignancy-type
(	O
0	O
of	O
8	O
)	O
cases	O
.	O
In	O
conclusion	O
,	O
although	O
the	O
number	O
of	O
cases	O
in	O
this	O
study	O
was	O
small	O
,	O
H	O
-	O
and	O
K	O
-	O
ras	O
genes	O
were	O
present	O
in	O
some	O
of	O
the	O
MFH	B-malignancy-type
cases	O
and	O
accordingly	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
MFH	B-malignancy-type
.	O
In	O
addition	O
,	O
the	O
finding	O
that	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
gene	O
mutations	O
are	O
not	O
present	O
in	O
AFX	B-malignancy-type
may	O
indicate	O
why	O
AFX	B-malignancy-type
has	O
a	O
more	O
favorable	O
behavior	O
than	O
MFH	B-malignancy-type
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
PMID	O
:	O
11727262	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Pediatr	O
Surg	O
Int	O
2001	O
Sep;17(	O
7)	O
:508	O
-	O
12	O
High	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
hepatoblastoma	B-malignancy-type
.	O
Udatsu	O
Y	O
,	O
Kusafuka	O
T	O
,	O
Kuroda	O
S,	O
Miao	O
J,	O
Okada	O
A.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Japan	O
.	O
Hepatoblastoma	B-malignancy-type
(	O
HB	B-malignancy-type
)	O
is	O
an	O
embryonic	B-malignancy-type
neoplasm	I-malignancy-type
representing	O
the	O
most	O
frequent	O
malignant	O
liver	B-malignancy-type
tumour	I-malignancy-type
in	O
childhood	O
.	O
Its	O
tumourigenesis	O
at	O
the	O
molecular	O
level	O
is	O
still	O
poorly	O
understood	O
,	O
and	O
candidate	O
genes	O
are	O
yet	O
to	O
be	O
identified	O
.	O
According	O
to	O
recent	O
reports	O
describing	O
beta-catenin	O
mutations	O
(	O
BCM	O
)	O
at	O
hot	O
-	O
spot	O
regions	O
involving	O
exon	O
3	O
in	O
several	O
types	O
of	O
malignancies	O
including	O
HB	B-malignancy-type
,	O
we	O
investigated	O
BCM	O
in	O
16	O
HBs	B-malignancy-type
classified	O
into	O
different	O
histological	O
types	O
.	O
One	O
tumour	O
had	O
been	O
previously	O
confirmed	O
to	O
harbour	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
that	O
exhibit	O
a	O
similar	O
oncogenic	O
effect	O
to	O
that	O
of	O
BCM	O
.	O
Mutations	O
in	O
both	O
exon	O
3	O
and	O
its	O
flanking	O
region	O
of	O
the	O
beta-catenin	O
gene	O
were	O
investigated	O
and	O
determined	O
.	O
Twelve	O
tumours	O
(	O
75	O
%	O
)	O
revealed	O
pathogenic	O
BCM	O
,	O
including	O
5	O
with	O
missense	O
mutations	O
at	O
codons	O
32	O
,	O
34	O
,	O
or	O
37	O
and	O
7	O
with	O
interstitial	O
deletions	O
that	O
partially	O
or	O
totally	O
affected	O
exon	O
3	O
.	O
All	O
7	O
deletions	O
were	O
in	O
-	O
frame	O
deletions	O
without	O
frameshift	O
.	O
A	O
single	O
nucleotide	O
change	O
at	O
codon	O
31	O
regarded	O
as	O
non	O
-	O
pathogenic	O
polymorphism	O
was	O
detected	O
in	O
the	O
tumour	O
possessing	O
APC	O
mutations	O
.	O
Therefore	O
,	O
a	O
total	O
of	O
13	O
tumours	O
(	O
81	O
%	O
)	O
were	O
compromised	O
by	O
an	O
enhanced	O
beta-catenin	O
-	O
mediated	O
transcription	O
pathway	O
.	O
Mutations	O
were	O
observed	O
in	O
every	O
histological	O
type	O
of	O
HB	B-malignancy-type
.	O
The	O
very	O
high	O
frequency	O
without	O
correlation	O
to	O
histological	O
type	O
indicates	O
that	O
BCM	O
are	O
crucial	O
events	O
in	O
the	O
tumourigenesis	O
of	O
HB	B-malignancy-type
.	O
PMID	O
:	O
11666046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Tumour	O
Biol	O
2001	O
Sep	O
-	O
Oct;22(	O
5	O
)	O
:299	O
-	O
309	O
Oncogenic	O
potential	O
of	O
c-erbB-2	O
and	O
its	O
association	O
with	O
c-K-ras	O
in	O
premalignant	O
and	O
malignant	O
lesions	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
uterine	I-malignancy-type
endometrium	I-malignancy-type
.	O
Manavi	O
M,	O
Bauer	O
M,	O
Baghestanian	O
M,	O
Berger	O
A	O
,	O
Kucera	O
E	O
,	O
Pischinger	O
K	O
,	O
Battistutti	O
W	O
,	O
Czerwenka	O
K.	O
Department	O
of	O
Gynecology	O
and	O
Obstetrics	O
,	O
Division	O
of	O
Special	O
Gynecology	O
,	O
University	O
Hospital	O
of	O
Vienna	O
,	O
Austria	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
detect	O
activated	O
c-K-ras	O
by	O
gene	O
point	O
mutation	O
and	O
to	O
find	O
c-erbB-2	O
gene	O
amplification	O
with	O
p185	O
expression	O
in	O
association	O
with	O
the	O
c-K-ras	O
gene	O
product	O
p21	O
in	O
the	O
human	O
endometrium	O
.	O
Specimens	O
obtained	O
from	O
25	O
normal	O
,	O
31	O
hyperplastic	B-malignancy-type
and	O
72	O
malignant	B-malignancy-type
samples	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
endometrium	I-malignancy-type
were	O
examined	O
for	O
point	O
mutation	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
c-K-ras	O
by	O
direct	O
sequencing	O
and	O
c-erbB-2	O
gene	O
amplification	O
with	O
p185	O
and	O
p21	O
expression	O
by	O
differential	O
polymerase	O
chain	O
reaction	O
(	O
DPCR	O
)	O
and	O
immunohistochemistry	O
.	O
Neither	O
the	O
normal	O
endometrium	O
nor	O
endometrial	B-malignancy-type
hyperplasias	I-malignancy-type
were	O
found	O
to	O
have	O
mutations	O
in	O
the	O
c-K-ras	O
gene	O
,	O
although	O
a	O
double	O
mutation	O
of	O
codons	O
12	O
and	O
13	O
as	O
a	O
single	O
-	O
point	O
mutation	O
was	O
observed	O
in	O
one	O
case	O
of	O
endometrioid	B-malignancy-type
carcinoma	I-malignancy-type
(	O
2.8	O
%	O
)	O
.	O
In	O
each	O
of	O
two	O
other	O
cases	O
of	O
endometrioid	B-malignancy-type
carcinoma	I-malignancy-type
(	O
2	O
/	O
72	O
)	O
,	O
two	O
single	O
-	O
point	O
mutations	O
of	O
codon	O
13	O
(	O
5.6	O
%	O
)	O
were	O
shown	O
.	O
Using	O
DPCR	O
,	O
we	O
found	O
c-erbB-2	O
to	O
be	O
amplified	O
in	O
15	O
premalignant	O
(	O
48	O
%	O
)	O
and	O
45	O
malignant	O
(	O
63	O
%	O
)	O
samples	O
.	O
We	O
noticed	O
that	O
nonamplification	O
of	O
the	O
c-erbB-2	O
gene	O
was	O
associated	O
with	O
the	O
absence	O
of	O
immunoreactivity	O
.	O
Our	O
data	O
indicate	O
that	O
,	O
while	O
c-erbB-2	O
plays	O
a	O
role	O
in	O
the	O
early	O
development	O
of	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
,	O
c-K-ras	O
gene	O
activation	O
by	O
point	O
mutation	O
does	O
not	O
.	O
Copyright	O
2001	O
S	O
.	O
Karger	O
AG	O
,	O
Basel	O
PMID	O
:	O
11553860	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gastroenterology	O
2001	O
Aug;121(	O
2	O
)	O
:302	O
-	O
9	O
Ki-ras	O
proto	O
-	O
oncogene	O
mutations	O
in	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
:	O
relationship	O
to	O
histologic	O
and	O
clinical	O
characteristics	O
.	O
Maltzman	O
T	O
,	O
Knoll	O
K	O
,	O
Martinez	O
ME	O
,	O
Byers	O
T	O
,	O
Stevens	O
BR	O
,	O
Marshall	O
JR	O
,	O
Reid	O
ME	O
,	O
Einspahr	O
J,	O
Hart	O
N	O
,	O
Bhattacharyya	O
AK	O
,	O
Kramer	O
CB	O
,	O
Sampliner	O
R,	O
Alberts	O
DS	O
,	O
Ahnen	O
DJ.	O
Department	O
of	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
111E	O
,	O
1055	O
Clermont	O
Street	O
,	O
Denver	O
,	O
Colorado	O
80220	O
,	O
USA	O
.	O
BACXKGROUND	O
&	O
AIMS	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
Ki-ras	O
mutations	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
characteristics	O
of	O
both	O
the	O
subject	O
(	O
age	O
,	O
gender	O
,	O
and	O
family	O
/	O
personal	O
history	O
of	O
colonic	B-malignancy-type
neoplasia	I-malignancy-type
)	O
and	O
the	O
adenoma	B-malignancy-type
(	O
multiplicity	O
,	O
size	O
,	O
location	O
,	O
and	O
histologic	O
features	O
)	O
.	O
METHODS	O
:	O
Ki-ras	O
mutations	O
were	O
detected	O
by	O
direct	O
sequencing	O
in	O
738	O
adenomatous	B-malignancy-type
polyps	I-malignancy-type
removed	O
at	O
baseline	O
from	O
639	O
participants	O
in	O
a	O
nutritional	O
trial	O
of	O
adenoma	B-malignancy-type
recurrence	O
.	O
RESULTS	O
:	O
Ki-ras	O
mutations	O
were	O
detected	O
in	O
17.2	O
%	O
of	O
the	O
adenomas	B-malignancy-type
.	O
Ki-ras	O
mutations	O
were	O
unrelated	O
to	O
gender	O
,	O
family	O
,	O
or	O
personal	O
history	O
of	O
colonic	B-malignancy-type
neoplasia	I-malignancy-type
,	O
location	O
within	O
the	O
colorectum	O
,	O
or	O
adenoma	B-malignancy-type
multiplicity	O
,	O
but	O
were	O
more	O
common	O
in	O
older	O
subjects	O
(	O
P	O
=	O
0.01	O
for	O
trend	O
)	O
,	O
in	O
larger	B-malignancy-type
adenomas	I-malignancy-type
(	O
P	O
<	O
0.0001	O
for	O
trend	O
)	O
,	O
in	O
adenomas	B-malignancy-type
with	I-malignancy-type
villous	I-malignancy-type
histology	I-malignancy-type
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
3.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
2.1	O
-	O
4.9	O
vs.	O
tubular	B-malignancy-type
)	O
,	O
and	O
in	O
adenomas	B-malignancy-type
with	I-malignancy-type
high	I-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
(	O
32.0	O
%	O
vs.	O
13.6	O
%	O
;	O
OR	O
,	O
3.0	O
;	O
95	O
%	O
CI	O
,	O
1.9	O
-	O
4.6	O
vs.	O
low	B-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
)	O
.	O
Multivariate	O
analysis	O
showed	O
Ki-ras	O
mutations	O
to	O
be	O
independently	O
associated	O
with	O
subject	O
age	O
(	O
P	O
=	O
0.01	O
for	O
trend	O
)	O
,	O
tubulovillous	O
/	O
villous	O
histology	O
(	O
OR	O
,	O
2.3	O
;	O
95	O
%	O
CI	O
,	O
1.5	O
-	O
3.7	O
)	O
,	O
and	O
high	B-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
(	O
OR	O
,	O
1.9	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
3.1	O
)	O
.	O
Adenoma	B-malignancy-type
size	O
was	O
not	O
independently	O
related	O
to	O
Ki-ras	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Ki-ras	O
mutations	O
are	O
associated	O
with	O
the	O
histologic	O
features	O
of	O
adenoma	B-malignancy-type
progression	O
(	O
villous	O
histology	O
and	O
high	B-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
)	O
rather	O
than	O
with	O
adenoma	B-malignancy-type
growth	O
.	O
PMID	O
:	O
11487539	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O
	O

Am	O
J	O
Pathol	O
2001	O
Jun;158(	O
6)	O
:1955	O
-	O
9	O
Frequent	O
FGFR3	O
mutations	O
in	O
papillary	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
invasive	I-malignancy-type
bladder	I-malignancy-type
(	I-malignancy-type
pTa	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
.	O
Billerey	O
C	O
,	O
Chopin	O
D	O
,	O
Aubriot	O
-	O
Lorton	O
MH	O
,	O
Ricol	O
D	O
,	O
Gil	O
Diez	O
de	O
Medina	O
S,	O
Van	O
Rhijn	O
B	O
,	O
Bralet	O
MP	O
,	O
Lefrere	O
-	O
Belda	O
MA	O
,	O
Lahaye	O
JB	O
,	O
Abbou	O
CC	O
,	O
Bonaventure	O
J,	O
Zafrani	O
ES	O
,	O
van	O
der	O
Kwast	O
T	O
,	O
Thiery	O
JP	O
,	O
Radvanyi	O
F.	O
Service	O
d'Anatomie	O
et	O
de	O
Cytologie	O
Pathologiques	O
,	O
Centre	O
Hospitalo	O
-	O
Universitaire	O
de	O
Rouen	O
,	O
Hopital	O
Charles	O
Nicolle	O
,	O
Rouen	O
,	O
France	O
.	O
We	O
recently	O
identified	O
activating	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
in	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
assessed	O
the	O
incidence	O
of	O
FGFR3	O
mutations	O
in	O
a	O
series	O
of	O
132	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
:	O
20	O
carcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
(	O
CIS	B-malignancy-type
)	O
,	O
50	O
pTa	O
,	O
19	O
pT1	O
,	O
and	O
43	O
pT2-4	O
.	O
All	O
48	O
mutations	O
identified	O
were	O
identical	O
to	O
the	O
germinal	O
activating	O
mutations	O
that	O
cause	O
thanatophoric	B-malignancy-type
dysplasia	I-malignancy-type
,	O
a	O
lethal	O
form	O
of	O
dwarfism	O
.	O
The	O
S	O
249	O
C	O
mutation	O
,	O
found	O
in	O
33	O
of	O
the	O
48	O
mutated	O
tumors	O
,	O
was	O
the	O
most	O
common	O
.	O
The	O
frequency	O
of	O
mutations	O
was	O
higher	O
in	O
pTa	B-malignancy-type
tumors	I-malignancy-type
(	O
37	O
of	O
50	O
,	O
74	O
%	O
)	O
than	O
in	O
CIS	B-malignancy-type
(	O
0	O
of	O
20	O
,	O
0	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
pT1	B-malignancy-type
(	O
4	O
of	O
19	O
,	O
21	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
pT2-4	B-malignancy-type
tumors	I-malignancy-type
(	O
7	O
of	O
43	O
,	O
16	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O
FGFR3	O
mutations	O
were	O
detected	O
in	O
27	O
of	O
32	O
(	O
84	O
%	O
)	O
G1	B-malignancy-type
,	O
16	O
of	O
29	O
(	O
55	O
%	O
)	O
G2	B-malignancy-type
,	O
and	O
5	O
of	O
71	O
(	O
7	O
%	O
)	O
G3	B-malignancy-type
tumors	I-malignancy-type
.	O
This	O
association	O
between	O
FGFR3	O
mutations	O
and	O
low	O
grade	O
was	O
highly	O
significant	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
FGFR3	O
is	O
the	O
first	O
gene	O
found	O
to	O
be	O
mutated	O
at	O
a	O
high	O
frequency	O
in	O
pTa	B-malignancy-type
tumors	I-malignancy-type
.	O
The	O
absence	O
of	O
FGFR3	O
mutations	O
in	O
CIS	B-malignancy-type
and	O
the	O
low	O
frequency	O
of	O
FGFR3	O
mutations	O
in	O
pT1	B-malignancy-type
and	O
pT2-4	B-malignancy-type
tumors	I-malignancy-type
are	O
consistent	O
with	O
the	O
model	O
of	O
bladder	B-malignancy-type
tumor	I-malignancy-type
progression	O
in	O
which	O
the	O
most	O
common	O
precursor	O
of	O
pT1	B-malignancy-type
and	O
pT2-4	B-malignancy-type
tumors	I-malignancy-type
is	O
CIS	B-malignancy-type
.	O
PMID	O
:	O
11395371	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Cancer	O
Res	O
2001	O
Feb	O
15;61(	O
4)	O
:1265	O
-	O
8	O
The	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
mutation	O
is	O
a	O
strong	O
indicator	O
of	O
superficial	B-malignancy-type
bladder	I-malignancy-type
cancer	I-malignancy-type
with	O
low	O
recurrence	O
rate	O
.	O
van	O
Rhijn	O
BW	O
,	O
Lurkin	O
I	O
,	O
Radvanyi	O
F	O
,	O
Kirkels	O
WJ	O
,	O
van	O
der	O
Kwast	O
TH	O
,	O
Zwarthoff	O
EC	O
.	O
Department	O
of	O
Pathology	O
,	O
Josephine	O
Nefkens	O
Institute	O
,	O
Erasmus	O
University	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
.	O
We	O
analyzed	O
the	O
possible	O
prognostic	O
value	O
of	O
the	O
recently	O
discovered	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
mutations	O
in	O
bladder	B-malignancy-type
cancer	O
.	O
A	O
FGFR3	O
mutation	O
was	O
found	O
in	O
34	O
of	O
53	O
pTaG	B-malignancy-type
1	I-malignancy-type
-	I-malignancy-type
2	I-malignancy-type
bladder	I-malignancy-type
cancers	I-malignancy-type
,	O
whereas	O
none	O
of	O
the	O
19	O
higher	O
-	O
staged	O
tumors	O
had	O
a	O
mutation	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
In	O
57	O
patients	O
with	O
superficial	O
disease	O
followed	O
prospectively	O
by	O
cystoscopy	O
for	O
12	O
months	O
,	O
14	O
of	O
23	O
patients	O
in	O
the	O
wild	O
-	O
type	O
FGFR3	O
group	O
developed	O
recurrent	B-malignancy-type
bladder	I-malignancy-type
cancer	I-malignancy-type
compared	O
with	O
only	O
7	O
of	O
34	O
patients	O
in	O
the	O
mutant	O
group	O
(	O
P	O
=	O
0.004	O
)	O
.	O
The	O
recurrence	O
rate	O
per	O
year	O
was	O
0.24	O
for	O
the	O
FGFR3	O
mutant	O
tumors	O
and	O
1.12	O
for	O
tumors	O
with	O
a	O
wild	O
-	O
type	O
FGFR3	O
gene	O
.	O
In	O
addition	O
,	O
FGFR3	O
mutation	O
status	O
was	O
the	O
strongest	O
predictor	O
of	O
recurrence	O
when	O
compared	O
with	O
stage	O
and	O
grade	O
(	O
P	O
=	O
0.008	O
)	O
.	O
This	O
is	O
the	O
first	O
mutation	O
in	O
bladder	B-malignancy-type
cancer	I-malignancy-type
that	O
selectively	O
identifies	O
patients	O
with	O
favorable	O
disease	O
characteristics	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
frequency	O
of	O
cystoscopic	O
examinations	O
can	O
be	O
reduced	O
considerably	O
in	O
patients	O
with	O
FGFR3	O
-	O
positive	O
tumors	O
.	O
PMID	O
:	O
11245416	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Cytol	O
2000	O
Nov-	O
Dec;44(	O
6)	O
:981	O
-	O
6	O
Analysis	O
of	O
KIT	O
mutation	O
and	O
protein	O
expression	O
in	O
fine	O
needle	O
aspirates	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
/	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
.	O
Li	O
SQ	O
,	O
O'Leary	O
TJ	O
,	O
Sobin	O
LH	O
,	O
Erozan	O
YS	O
,	O
Rosenthal	O
DL	O
,	O
Przygodzki	O
RM	O
.	O
Department	O
of	O
Pathology	O
,	O
Columbia	O
University	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
VC	O
14	O
-	O
215	O
,	O
630	O
West	O
168th	O
Street	O
,	O
New	O
York	O
,	O
New	O
York	O
100	O
32	O
,	O
USA	O
.	O
sl828@columbia	O
.edu	O
OBJECTIVE	O
:	O
To	O
determine	O
if	O
sequencing	O
the	O
KIT	O
gene	O
could	O
facilitate	O
more	O
definitive	O
FNA	O
diagnosis	O
.	O
STUDY	O
DESIGN	O
:	O
Sixteen	O
cases	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
/	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
in	O
which	O
fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
was	O
performed	O
(	O
mean	O
age	O
,	O
67	O
;	O
M	O
/	O
F	O
=	O
12	O
/	O
4	O
)	O
were	O
studied	O
.	O
DNA	O
was	O
extracted	O
from	O
cytologic	O
preparations	O
from	O
all	O
patients	O
(	O
15	O
cell	O
blocks	O
,	O
1	O
alcohol	O
-	O
fixed	O
smear	O
)	O
and	O
seven	O
subsequent	O
resection	O
specimens	O
.	O
DNA	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
,	O
using	O
primers	O
designed	O
to	O
amplify	O
a	O
segment	O
of	O
the	O
KIT	O
gene	O
exon	O
11	O
and	O
sequenced	O
on	O
an	O
ABI	O
Prism	O
377	O
DNA	O
sequence	O
analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Indianapolis	O
,	O
Indiana	O
,	O
U.S.A.	O
)	O
.	O
Immunocytochemical	O
staining	O
for	O
CD	O
117	O
(	O
the	O
KIT	O
gene	O
product	O
)	O
was	O
performed	O
on	O
sections	O
from	O
12	O
cell	O
blocks	O
and	O
7	O
surgical	O
resections	O
.	O
RESULTS	O
:	O
In	O
-	O
frame	O
deletion	O
of	O
exon	O
11	O
was	O
detected	O
in	O
eight	O
cases	O
(	O
7	O
monoalleic	O
,	O
1	O
bialleic	O
)	O
;	O
a	O
point	O
mutation	O
was	O
found	O
in	O
one	O
case	O
.	O
Mutation	O
was	O
found	O
only	O
in	O
histologically	O
malignant	O
(	O
6	O
of	O
10	O
cases	O
)	O
and	O
borderline	B-malignancy-type
GISTs	I-malignancy-type
(	O
3	O
of	O
4	O
cases	O
)	O
.	O
No	O
mutation	O
was	O
identified	O
in	O
benign	O
tumors	O
.	O
In	O
three	O
cases	O
,	O
scant	O
cellularity	O
or	O
blood	O
precluded	O
sequencing	O
.	O
CD	O
117	O
was	O
expressed	O
in	O
12	O
of	O
15	O
cases	O
.	O
CONCLUSION	O
:	O
Immunocytochemical	O
staining	O
for	O
CD	O
117	O
is	O
useful	O
in	O
confirming	O
a	O
cytologic	O
diagnosis	O
of	O
GIST	B-malignancy-type
but	O
does	O
not	O
facilitate	O
diagnosis	O
of	O
malignancy	O
.	O
FNA	O
biopsy	O
specimens	O
are	O
suitable	O
for	O
KIT	O
gene	O
sequencing	O
;	O
detection	O
of	O
a	O
KIT	O
mutation	O
favors	O
a	O
malignant	O
diagnosis	O
,	O
though	O
absence	O
of	O
mutation	O
does	O
not	O
preclude	O
malignancy	O
.	O
PMID	O
:	O
11127756	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Hematol	O
2000	O
Nov;65(	O
3	O
)	O
:234	O
-	O
8	O
Epstein	O
-	O
Barr	O
virus	O
associated	O
B-cell	O
lymphoma	O
of	O
brain	O
developing	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
with	O
c-kit	O
mutation	O
(	O
Try	O
-	O
557	O
-->	O
stop	O
)	O
.	O
Kuwahara	O
Y	O
,	O
Hirata	O
A	O
,	O
Miwa	O
H	O
,	O
Munakata	O
S,	O
Ueda	O
S,	O
Kanakura	O
Y	O
,	O
Maruno	O
M,	O
Hongyo	O
T	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Japan	O
.	O
The	O
first	O
case	O
of	O
B-cell	B-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
brain	I-malignancy-type
in	O
a	O
patient	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
was	O
reported	O
.	O
A	O
68	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
because	O
of	O
anemia	O
,	O
fever	O
,	O
and	O
thrombocytopenia	O
and	O
was	O
diagnosed	O
as	O
having	O
MDS	O
(	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
)	O
on	O
the	O
basis	O
of	O
the	O
findings	O
of	O
bone	O
marrow	O
aspiration	O
and	O
chromosomal	O
analysis	O
.	O
The	O
patient	O
was	O
followed	O
up	O
without	O
chemotherapy	O
,	O
but	O
a	O
brain	B-malignancy-type
tumor	I-malignancy-type
appeared	O
after	O
3	O
years	O
.	O
Histologic	O
and	O
immunohistologic	O
examinations	O
revealed	O
diffuse	B-malignancy-type
large	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Mutations	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
(	O
stem	O
cell	O
factor	O
receptor	O
)	O
and	O
the	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
were	O
examined	O
in	O
the	O
MDS	B-malignancy-type
lesion	I-malignancy-type
and	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
(	O
ML	B-malignancy-type
)	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
method	O
followed	O
by	O
direct	O
sequencing	O
.	O
The	O
p53	O
mutation	O
was	O
not	O
found	O
in	O
either	O
MDS	B-malignancy-type
or	O
ML	B-malignancy-type
,	O
but	O
a	O
nonsense	O
mutation	O
(	O
Try	O
-	O
557	O
-->	O
stop	O
)	O
in	O
exon	O
11	O
of	O
the	O
c-kit	O
,	O
which	O
might	O
lead	O
to	O
dysfunction	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
was	O
detected	O
in	O
MDS	B-malignancy-type
.	O
This	O
is	O
the	O
first	O
report	O
of	O
c-kit	O
mutation	O
in	O
MDS	B-malignancy-type
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
was	O
demonstrated	O
in	O
the	O
nucleus	O
of	O
brain	B-malignancy-type
ML	I-malignancy-type
cells	O
by	O
in	O
situ	O
hybridization	O
with	O
EBV	O
-	O
encoded	O
RNA-1	O
probe	O
.	O
Immunohistochemistry	O
showed	O
that	O
the	O
tumor	O
cells	O
expressed	O
latent	O
infection	O
gene	O
products	O
,	O
including	O
EBV	O
nuclear	O
antigen-2	O
and	O
latent	O
membrane	O
protein-1	O
.	O
This	O
pattern	O
of	O
latent	O
gene	O
expression	O
was	O
Lat	O
III	O
,	O
which	O
is	O
usually	O
found	O
in	O
malignant	B-malignancy-type
lymphomas	I-malignancy-type
developing	O
in	O
immunocompromised	O
hosts	O
.	O
These	O
findings	O
suggest	O
that	O
a	O
profound	O
pancytopenia	O
in	O
MDS	B-malignancy-type
resulted	O
in	O
an	O
immunodeficient	O
condition	O
,	O
after	O
which	O
EBV	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
brain	I-malignancy-type
developed	O
.	O
PMID	O
:	O
11074541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
2000	O
Sep;157(	O
3	O
)	O
:763	O
-	O
70	O
Beta-catenin	O
mutations	O
are	O
associated	O
with	O
a	O
subset	O
of	O
low	O
-	O
stage	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
negative	O
for	O
hepatitis	O
B	O
virus	O
and	O
with	O
favorable	O
prognosis	O
.	O
Hsu	O
HC	O
,	O
Jeng	O
YM	O
,	O
Mao	O
TL	O
,	O
Chu	O
JS	O
,	O
Lai	O
PL	O
,	O
Peng	O
SY	O
.	O
Department	O
of	O
Pathology	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
heychi@ha.mc.ntu.edu.tw	O
To	O
better	O
understand	O
the	O
role	O
of	O
beta-catenin	O
mutation	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
,	O
we	O
correlated	O
the	O
gene	O
mutation	O
with	O
hepatitis	O
virus	O
B	O
(	O
HBV	O
)	O
and	O
hepatitis	O
virus	O
C	O
(	O
HCV	O
)	O
status	O
and	O
the	O
clinicopathological	O
features	O
in	O
366	O
patients	O
with	O
resected	O
primary	O
unifocal	B-malignancy-type
HCC	I-malignancy-type
.	O
beta-Catenin	O
mutations	O
were	O
also	O
analyzed	O
in	O
55	O
patients	O
with	O
multifocal	B-malignancy-type
HCC	I-malignancy-type
(	O
68	O
tumors	O
)	O
.	O
Of	O
the	O
whole	O
series	O
,	O
57	O
(	O
13.1	O
%	O
)	O
of	O
434	O
tumors	O
examined	O
had	O
beta-catenin	O
mutations	O
,	O
34	O
occurred	O
at	O
the	O
serine	O
/	O
threonine	O
residues	O
of	O
the	O
GSK-3beta	O
region	O
of	O
beta-catenin	O
.	O
Outside	O
the	O
GSK-3beta	O
phosphorylation	O
site	O
,	O
codons	O
32	O
and	O
34	O
were	O
two	O
mutational	O
hot	O
spots	O
(	O
17	O
tumors	O
)	O
.	O
The	O
non	B-malignancy-type
-	I-malignancy-type
HBV	I-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCC	I-malignancy-type
that	O
was	O
predominantly	O
HCV	O
related	O
had	O
a	O
higher	O
frequency	O
of	O
mutation	O
(	O
P	O
:	O
<	O
0.00001	O
)	O
and	O
more	O
frequent	O
mutations	O
at	O
codon	O
45	O
than	O
HBV	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCC	I-malignancy-type
.	O
HBV	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCC	I-malignancy-type
had	O
a	O
younger	O
mean	O
age	O
(	O
P	O
:	O
<	O
0.00001	O
)	O
,	O
and	O
higher	O
male	O
-	O
to	O
-	O
female	O
ratio	O
(	O
P	O
:	O
<	O
0.003	O
)	O
and	O
positive	O
familial	O
history	O
of	O
HCC	O
(	O
P	O
:	O
<	O
0.014	O
)	O
.	O
Among	O
366	O
unifocal	B-malignancy-type
HCCs	I-malignancy-type
selected	O
for	O
clinicopathological	O
analysis	O
,	O
beta-catenin	O
mutations	O
were	O
associated	O
with	O
grade	O
I	O
(	O
P	O
:	O
=	O
0.005	O
)	O
and	O
stage	O
I	O
and	O
II	O
HCC	B-malignancy-type
(	O
P	O
:	O
<	O
0.0001	O
)	O
,	O
and	O
a	O
better	O
5	O
-	O
year	O
survival	O
rate	O
(	O
P	O
:	O
=	O
0.	O
00003	O
)	O
.	O
These	O
findings	O
suggest	O
mechanisms	O
for	O
beta-catenin	O
mutations	O
differ	O
between	O
HBV	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
and	O
non	B-malignancy-type
-	I-malignancy-type
HBV	I-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCCs	I-malignancy-type
,	O
and	O
that	O
beta-catenin	O
mutation	O
is	O
a	O
favorable	O
prognostic	O
factor	O
related	O
to	O
low	O
stage	O
.	O
beta-Catenin	O
mutation	O
was	O
associated	O
with	O
nuclear	O
expression	O
of	O
the	O
protein	O
(	O
P	O
:	O
<	O
0.00001	O
)	O
,	O
but	O
we	O
failed	O
to	O
detect	O
point	O
or	O
large	O
fragment	O
deletion	O
mutation	O
in	O
39	O
HCCs	B-malignancy-type
with	O
nuclear	O
beta-catenin	O
expression	O
,	O
presumably	O
wild	O
-	O
type	O
protein	O
.	O
HCCs	B-malignancy-type
expressing	O
mutant	O
nuclear	O
beta-catenin	O
had	O
a	O
better	O
5	O
-	O
year	O
survival	O
rate	O
(	O
P	O
:	O
<	O
0.007	O
)	O
,	O
suggesting	O
that	O
mutant	O
and	O
wild	O
-	O
type	O
nuclear	O
beta-catenin	O
proteins	O
are	O
not	O
functionally	O
equivalent	O
and	O
deserve	O
more	O
studies	O
for	O
further	O
clarification	O
.	O
PMID	O
:	O
10980116	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
2000	O
Aug	O
25;90(	O
4)	O
:258	O
-	O
63	O
Application	O
of	O
the	O
p53	O
and	O
K-ras	O
gene	O
mutation	O
patterns	O
for	O
cytologic	O
diagnosis	O
of	O
recurrent	B-malignancy-type
lung	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Dai	O
Y	O
,	O
Morishita	O
Y	O
,	O
Mase	O
K	O
,	O
Sato	O
N	O
,	O
Akaogi	O
E	O
,	O
Mitsui	O
T	O
,	O
Noguchi	O
M.	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Basic	O
Medical	O
Sciences	O
,	O
University	O
of	O
Tsukuba	O
,	O
Tennodai	O
,	O
Tsukuba	O
-	O
shi	O
,	O
Ibaraki	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Cytologic	O
specimens	O
are	O
one	O
of	O
the	O
most	O
important	O
materials	O
for	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
diagnosis	O
,	O
because	O
they	O
can	O
be	O
used	O
in	O
mass	O
screening	O
for	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
and	O
early	O
detection	O
of	O
cancer	O
recurrence	O
by	O
examination	O
of	O
sputum	O
and	O
pleural	O
fluid	O
.	O
METHODS	O
:	O
To	O
prove	O
the	O
potentiality	O
of	O
the	O
cytologic	O
specimens	O
to	O
be	O
subjected	O
to	O
molecular	O
detection	O
of	O
recurrent	B-malignancy-type
lung	I-malignancy-type
carcinomas	I-malignancy-type
,	O
the	O
authors	O
enrolled	O
16	O
patients	O
who	O
had	O
undergone	O
surgical	O
treatment	O
for	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
with	I-malignancy-type
recurrence	I-malignancy-type
detected	O
by	O
malignant	O
pleural	O
fluid	O
.	O
First	O
,	O
they	O
examined	O
K-ras	O
gene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
abnormalities	O
in	O
resected	O
tumors	O
by	O
polymerase	O
chain	O
reaction	O
-	O
based	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
.	O
Next	O
,	O
using	O
a	O
microdissection	O
method	O
,	O
they	O
investigated	O
the	O
use	O
of	O
cytologic	O
specimens	O
such	O
as	O
pleural	O
fluid	O
for	O
the	O
detection	O
of	O
recurrence	O
by	O
finding	O
the	O
same	O
mutations	O
observed	O
in	O
the	O
initially	O
resected	O
tumor	O
.	O
RESULTS	O
:	O
Seven	O
abnormally	O
shifted	O
bands	O
were	O
detected	O
among	O
six	O
patients	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
of	O
surgical	O
materials	O
.	O
Five	O
of	O
7	O
abnormally	O
shifted	O
bands	O
(	O
71.4	O
%	O
)	O
also	O
were	O
detected	O
from	O
microdissected	O
malignant	O
cells	O
in	O
cytologic	O
smears	O
.	O
In	O
two	O
cases	O
,	O
they	O
detected	O
mutations	O
by	O
using	O
single	O
malignant	O
cells	O
in	O
pleural	O
fluid	O
.	O
CONCLUSIONS	O
:	O
The	O
authors	O
successfully	O
detected	O
the	O
same	O
mutations	O
in	O
recurrent	O
cytologic	O
specimens	O
as	O
those	O
in	O
the	O
initially	O
resected	O
tumors	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
p53	O
and	O
K-ras	O
gene	O
mutation	O
patterns	O
are	O
effective	O
markers	O
for	O
the	O
detection	O
of	O
recurrent	B-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
in	O
cytologic	O
specimens	O
.	O
Cancer	O
(	O
Cancer	O
Cytopathol	O
)	O
Copyright	O
2000	O
American	O
Cancer	O
Society	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10966568	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2000	O
Sep	O
1;157(	O
2	O
)	O
:185	O
-	O
91	O
Beta-catenin	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
in	O
adenomas	B-malignancy-type
from	O
hereditary	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
polyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Akiyama	O
Y	O
,	O
Nagasaki	O
H	O
,	O
Yagi	O
KO	O
,	O
Nomizu	O
T	O
,	O
Yuasa	O
Y.	O
Department	O
of	O
Hygiene	O
and	O
Oncology	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
School	O
of	O
Medicine	O
,	O
1	O
-	O
5	O
-	O
45	O
Yushima	O
,	O
Bunkyo	O
-	O
ku	O
,	O
113	O
-	O
8519	O
,	O
Tokyo	O
,	O
Japan	O
.	O
To	O
clarify	O
the	O
roles	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta-catenin	O
genes	O
in	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
HNPCC	B-malignancy-type
)	O
tumorigenesis	O
,	O
we	O
searched	O
for	O
their	O
mutations	O
in	O
14	O
HNPCC	B-malignancy-type
adenomas	I-malignancy-type
with	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
Seven	O
(	O
50	O
%	O
)	O
adenomas	B-malignancy-type
exhibited	O
somatic	O
APC	O
mutations	O
,	O
five	O
of	O
which	O
were	O
frameshift	O
mutations	O
and	O
the	O
other	O
two	O
nonsense	O
ones	O
.	O
However	O
,	O
the	O
APC	O
mutational	O
spectrum	O
of	O
these	O
adenomas	B-malignancy-type
was	O
similar	O
to	O
that	O
of	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Two	O
adenomas	B-malignancy-type
(	O
14.3	O
%	O
)	O
with	O
undetectable	O
APC	O
alterations	O
showed	O
missense	O
mutations	O
at	O
codon	O
45	O
(	O
TCT	O
to	O
TTT	O
or	O
to	O
CCT	O
)	O
in	O
beta-catenin	O
.	O
The	O
MSI	O
frequency	O
in	O
adenomas	B-malignancy-type
with	O
beta-catenin	O
mutations	O
was	O
significantly	O
higher	O
than	O
that	O
with	O
APC	O
ones	O
(	O
P	O
<	O
0.001	O
)	O
,	O
indicating	O
that	O
mutations	O
of	O
beta-catenin	O
rather	O
than	O
APC	O
are	O
strongly	O
associated	O
with	O
MSI	O
.	O
These	O
data	O
suggest	O
that	O
adenomas	B-malignancy-type
with	O
beta-catenin	O
activating	O
mutations	O
and	O
some	O
with	O
APC	O
inactivating	O
mutations	O
may	O
be	O
precursors	O
of	O
HNPCC	B-malignancy-type
colorectal	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
10936679	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
2000	O
Apr	O
28;152(	O
1	O
)	O
:45	O
-	O
51	O
Somatic	O
mutations	O
of	O
beta-catenin	O
play	O
a	O
crucial	O
role	O
in	O
the	O
tumorigenesis	O
of	O
sporadic	B-malignancy-type
hepatoblastoma	I-malignancy-type
.	O
Jeng	O
YM	O
,	O
Wu	O
MZ	O
,	O
Mao	O
TL	O
,	O
Chang	O
MH	O
,	O
Hsu	O
HC.	O
Department	O
of	O
Pathology	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
7	O
Chung	O
-	O
Shan	O
South	O
Road	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
Hepatoblastoma	B-malignancy-type
(	O
HB	B-malignancy-type
)	O
is	O
the	O
most	O
common	O
malignant	B-malignancy-type
hepatic	I-malignancy-type
tumor	I-malignancy-type
during	O
early	O
childhood	O
.	O
Its	O
molecular	O
pathogenesis	O
is	O
still	O
poorly	O
understood	O
.	O
Mutations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
have	O
been	O
identified	O
in	O
sporadic	O
cases	O
and	O
in	O
individuals	O
associated	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
syndrome	I-malignancy-type
.	O
beta-catenin	O
is	O
a	O
key	O
element	O
in	O
the	O
cadherin	O
-	O
mediated	O
cell	O
adhesion	O
system	O
and	O
Wnt	O
/	O
wingless	O
pathway	O
,	O
and	O
is	O
controlled	O
by	O
APC	O
.	O
APC	O
affects	O
the	O
degradation	O
of	O
beta-catenin	O
by	O
its	O
NH(2)	O
-	O
terminal	O
phosphorylation	O
on	O
the	O
serine	O
/	O
threonine	O
residues	O
of	O
exon	O
3	O
.	O
Mutations	O
of	O
these	O
phosphorylation	O
sites	O
are	O
primary	O
targets	O
for	O
activating	O
mutations	O
in	O
several	O
types	O
of	O
human	O
cancer	O
and	O
lead	O
to	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
protein	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
nine	O
patients	O
with	O
HB	O
using	O
immunohistochemistry	O
and	O
direct	O
DNA	O
sequencing	O
.	O
All	O
nine	O
cases	O
showed	O
predominant	O
nuclear	O
expression	O
of	O
beta-catenin	O
.	O
Eight	O
cases	O
(	O
89	O
%	O
)	O
showed	O
mutations	O
involving	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
including	O
five	O
with	O
deletions	O
and	O
three	O
with	O
missense	O
mutations	O
.	O
All	O
five	O
deletions	O
were	O
in	O
-	O
frame	O
deletions	O
without	O
frameshift	O
.	O
The	O
very	O
high	O
frequency	O
of	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
suggests	O
that	O
beta-catenin	O
mutations	O
are	O
crucial	O
in	O
the	O
tumorigenesis	O
of	O
HB	B-malignancy-type
.	O
PMID	O
:	O
10754205	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
2000	O
Mar;24(	O
3	O
)	O
:245	O
-	O
50	O
AXIN1	O
mutations	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
growth	O
suppression	O
in	O
cancer	O
cells	O
by	O
virus	O
-	O
mediated	O
transfer	O
of	O
AXIN1	O
.	O
Satoh	O
S,	O
Daigo	O
Y	O
,	O
Furukawa	O
Y	O
,	O
Kato	O
T	O
,	O
Miwa	O
N	O
,	O
Nishiwaki	O
T	O
,	O
Kawasoe	O
T	O
,	O
Ishiguro	O
H	O
,	O
Fujita	O
M,	O
Tokino	O
T	O
,	O
Sasaki	O
Y	O
,	O
Imaoka	O
S,	O
Murata	O
M,	O
Shimano	O
T	O
,	O
Yamaoka	O
Y	O
,	O
Nakamura	O
Y.	O
Laboratory	O
of	O
Molecular	O
Medicine	O
,	O
Human	O
Genome	O
Center	O
,	O
Institute	O
of	O
Medical	O
Science	O
,	O
The	O
University	O
of	O
Tokyo	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
Wnt	O
signaling	O
pathway	O
is	O
essential	O
for	O
development	O
and	O
organogenesis	O
.	O
Wnt	O
signaling	O
stabilizes	O
beta-catenin	O
,	O
which	O
accumulates	O
in	O
the	O
cytoplasm	O
,	O
binds	O
to	O
1-cell	O
factor	O
(	O
TCF	O
;	O
also	O
known	O
as	O
lymphocyte	O
enhancer	O
-	O
binding	O
factor	O
,	O
LEF	O
)	O
and	O
then	O
upregulates	O
downstream	O
genes	O
.	O
Mutations	O
in	O
CTNNB1	O
(	O
encoding	O
beta-catenin	O
)	O
or	O
APC	O
(	O
adenomatous	O
polyposis	O
coli	O
)	O
have	O
been	O
reported	O
in	O
human	O
neoplasms	B-malignancy-type
including	O
colon	B-malignancy-type
cancers	I-malignancy-type
and	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
.	O
Because	O
HCC5	B-malignancy-type
tend	O
to	O
show	O
accumulation	O
of	O
beta-catenin	O
more	O
often	O
than	O
mutations	O
in	O
CTNNB1	O
,	O
we	O
looked	O
for	O
mutations	O
in	O
AXIN1	O
,	O
encoding	O
a	O
key	O
factor	O
for	O
Wnt	O
signaling	O
,	O
in	O
6	O
HCC	B-malignancy-type
cell	O
lines	O
and	O
100	O
primary	O
HCC5	B-malignancy-type
.	O
Among	O
the	O
4	O
cell	O
lines	O
and	O
87	O
HCC5	B-malignancy-type
in	O
which	O
we	O
did	O
not	O
detect	O
CTNNB1	O
mutations	O
,	O
we	O
identified	O
AXIN1	O
mutations	O
in	O
3	O
cell	O
lines	O
and	O
6	O
mutations	O
in	O
5	O
of	O
the	O
primary	O
HCCs	B-malignancy-type
.	O
In	O
cell	O
lines	O
containing	O
mutations	O
in	O
either	O
gene	O
,	O
we	O
observed	O
increased	O
DNA	O
binding	O
of	O
TCF	O
associated	O
with	O
beta-catenin	O
in	O
nuclei	O
.	O
Adenovirus	O
mediated	O
gene	O
transfer	O
of	O
wild	O
-	O
type	O
AXINI	O
induced	O
apoptosis	O
in	O
hepatocellular	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancer	B-malignancy-type
cells	O
that	O
had	O
accumulated	O
beta-catenin	O
as	O
a	O
consequence	O
of	O
either	O
APC	O
,	O
CTNNB1	O
or	O
AXIN1	O
mutation	O
,	O
suggesting	O
that	O
axin	O
may	O
be	O
an	O
effective	O
therapeutic	O
molecule	O
for	O
suppressing	O
growth	O
of	O
hepatocellular	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
10700176	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Dec;90(	O
12	O
)	O
:1301	O
-	O
9	O
Erratum	O
in	O
:	O
Jpn	O
J	O
Cancer	O
Res	O
2000	O
Feb;91(	O
2	O
)	O
:270	O
Comment	O
in	O
:	O
Jpn	O
J	O
Cancer	O
Res	O
.	O
1999	O
Dec;90(	O
12	O
)	O
:inside	O
front	O
cover	O
.	O
Beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Kondo	O
Y	O
,	O
Kanai	O
Y	O
,	O
Sakamoto	O
M,	O
Genda	O
T	O
,	O
Mizokami	O
M,	O
Ueda	O
R,	O
Hirohashi	O
S.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
.	O
A	O
study	O
was	O
conducted	O
to	O
clarify	O
the	O
contribution	O
of	O
beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
to	O
hepatocarcinogenesis	O
.	O
Beta-catenin	O
accumulation	O
was	O
examined	O
immunohistochemically	O
in	O
38	O
paired	O
samples	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
and	O
corresponding	O
non	O
-	O
cancerous	O
liver	O
tissue	O
.	O
Gene	O
mutation	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
using	O
intronic	O
primers	O
encompassing	O
exon	O
3	O
.	O
Neither	O
accumulation	O
nor	O
mutation	O
was	O
detected	O
in	O
non	O
-	O
cancerous	O
liver	O
tissues	O
that	O
showed	O
no	O
remarkable	O
histological	O
features	O
,	O
chronic	O
hepatitis	O
or	O
liver	O
cirrhosis	O
.	O
Accumulation	O
of	O
beta-catenin	O
was	O
seen	O
in	O
the	O
nucleus	O
,	O
cytoplasm	O
or	O
cell	O
membrane	O
in	O
15	O
of	O
38	O
(	O
39	O
%	O
)	O
HCC	B-malignancy-type
samples	O
,	O
and	O
gene	O
mutation	O
was	O
seen	O
in	O
9	O
of	O
38	O
(	O
24	O
%	O
)	O
HCC	B-malignancy-type
samples	O
.	O
Although	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
accumulation	O
and	O
mutation	O
(	O
P	O
<	O
0.01	O
)	O
,	O
six	O
HCCs	B-malignancy-type
without	O
mutation	O
also	O
showed	O
accumulation	O
.	O
Samples	O
of	O
early	O
HCC	B-malignancy-type
showed	O
neither	O
accumulation	O
nor	O
mutation	O
,	O
and	O
accumulation	O
and	O
mutation	O
were	O
each	O
correlated	O
significantly	O
with	O
portal	B-malignancy-type
vein	I-malignancy-type
tumor	I-malignancy-type
involvement	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
present	O
results	O
indicate	O
that	O
(1)	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
can	O
lead	O
to	O
beta-catenin	O
accumulation	O
,	O
although	O
other	O
mechanisms	O
of	O
accumulation	O
may	O
also	O
operate	O
in	O
HCC	B-malignancy-type
,	O
and	O
(2)	O
beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
are	O
not	O
early	O
events	O
in	O
hepatocarcinogenesis	O
,	O
and	O
may	O
be	O
associated	O
with	O
the	O
malignant	O
progression	O
of	O
HCC	B-malignancy-type
.	O
PMID	O
:	O
10665646	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anal	O
Cell	O
Pathol	O
1999;19(	O
1	O
)	O
:39	O
-	O
46	O
K-ras2	O
activation	O
and	O
genome	O
instability	O
increase	O
proliferation	O
and	O
size	O
of	O
FAP	B-malignancy-type
adenomas	I-malignancy-type
.	O
Rapallo	O
A	O
,	O
Sciutto	O
A	O
,	O
Geido	O
E	O
,	O
Orecchia	O
R,	O
Infusini	O
E	O
,	O
Pujic	O
N	O
,	O
d'Amore	O
ES	O
,	O
Monaco	O
R,	O
Risio	O
M,	O
Rossini	O
FP	O
,	O
Giaretti	O
W.	O
Laboratory	O
of	O
Biophysics	O
and	O
Cytometry	O
,	O
National	O
Cancer	O
Institute	O
,	O
Genoa	O
,	O
Italy	O
.	O
The	O
possible	O
role	O
of	O
K-ras2	O
mutations	O
and	O
aneuploidy	O
toward	O
increase	O
of	O
proliferation	O
and	O
adenoma	B-malignancy-type
size	O
in	O
Familial	B-malignancy-type
Adenomatous	I-malignancy-type
Polyposis	I-malignancy-type
(	I-malignancy-type
FAP	I-malignancy-type
)	I-malignancy-type
adenomas	I-malignancy-type
is	O
not	O
known	O
.	O
The	O
present	O
study	O
addresses	O
these	O
issues	O
by	O
investigating	O
147	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
obtained	O
from	O
four	O
FAP	B-malignancy-type
patients	O
.	O
The	O
majority	O
of	O
adenomas	B-malignancy-type
had	O
size	O
lower	O
than	O
or	O
equal	O
to	O
10	O
mm	O
(	O
86	O
%	O
)	O
,	O
low	B-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
(	O
63	O
%	O
)	O
,	O
and	O
were	O
preferentially	O
located	O
in	O
the	O
right	O
colon	O
(	O
60	O
%	O
)	O
.	O
Normal	O
mucosa	O
samples	O
were	O
obtained	O
from	O
19	O
healthy	O
donors	O
.	O
Three	O
synchronous	O
adenocarcinomas	B-malignancy-type
were	O
also	O
investigated	O
.	O
K-ras2	O
mutation	O
spectrum	O
was	O
analysed	O
by	O
PCR	O
and	O
Sequence	O
Specific	O
Oligonucleotide	O
(	O
SSO	O
)	O
hybridization	O
,	O
while	O
flow	O
cytometry	O
(	O
FCM	O
)	O
was	O
used	O
for	O
evaluating	O
degree	O
of	O
DNA	O
ploidy	O
and	O
S-phase	O
fraction	O
.	O
Overall	O
,	O
incidences	O
of	O
K-ras2	O
mutations	O
,	O
DNA	O
aneuploidy	O
and	O
high	O
S-phase	O
values	O
(	O
>	O
7.2	O
%	O
)	O
were	O
6.6	O
%	O
,	O
5.4	O
%	O
and	O
10.5	O
%	O
,	O
respectively	O
.	O
In	O
particular	O
,	O
among	O
the	O
adenomas	B-malignancy-type
with	O
size	O
lower	O
than	O
5	O
mm	O
,	O
K-ras2	O
mutation	O
and	O
DNA	O
aneuploidy	O
frequencies	O
were	O
only	O
slightly	O
above	O
1	O
%	O
.	O
Statistically	O
significant	O
correlations	O
were	O
found	O
between	O
K-ras2	O
and	O
size	O
,	O
DNA	O
ploidy	O
and	O
size	O
and	O
K-ras2	O
and	O
S-phase	O
(	O
p	O
<	O
0.001	O
)	O
.	O
In	O
particular	O
,	O
among	O
the	O
wild	O
type	O
K-ras2	O
adenomas	B-malignancy-type
,	O
high	O
S-phase	O
values	O
were	O
detected	O
in	O
8	O
%	O
of	O
the	O
cases	O
versus	O
57	O
%	O
among	O
the	O
K-ras2	O
mutated	O
adenomas	B-malignancy-type
(	O
p	O
=	O
0.0005	O
)	O
.	O
The	O
present	O
series	O
of	O
FAP	B-malignancy-type
adenomas	I-malignancy-type
indicates	O
that	O
K-ras2	O
activation	O
and	O
gross	O
genomic	O
changes	O
play	O
a	O
role	O
toward	O
a	O
proliferative	O
gain	O
and	O
tumour	O
growth	O
in	O
size	O
.	O
PMID	O
:	O
10661623	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1999	O
Feb;17(	O
2	O
)	O
:578	O
-	O
84	O
K-ras	O
mutations	O
in	O
DNA	O
extracted	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
:	O
diagnostic	O
utility	O
and	O
prognostic	O
significance	O
.	O
Castells	O
A	O
,	O
Puig	O
P	O
,	O
Mora	O
J,	O
Boadas	O
J,	O
Boix	O
L,	O
Urgell	O
E	O
,	O
Sole	O
M,	O
Capella	O
G	O
,	O
Lluis	O
F	O
,	O
Fernandez	O
-	O
Cruz	O
L,	O
Navarro	O
S,	O
Farre	O
A.	O
Institut	O
Clinic	O
de	O
Malalties	O
Digestives	O
and	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
Clinic	O
i	O
Provincial	O
,	O
University	O
of	O
Barcelona	O
,	O
Catalonia	O
,	O
Spain	O
.	O
castells	O
@helix	O
.mgh	O
.harvard	O
.edu	O
PURPOSE	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
the	O
presence	O
of	O
K-ras	O
mutations	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
However	O
,	O
the	O
diagnostic	O
utility	O
and	O
the	O
prognostic	O
significance	O
of	O
this	O
finding	O
have	O
never	O
been	O
addressed	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Forty-four	O
consecutive	O
patients	O
with	O
histologically	O
confirmed	O
primary	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
included	O
.	O
A	O
control	O
group	O
of	O
37	O
patients	O
with	O
chronic	O
pancreatitis	O
,	O
10	O
patients	O
with	O
other	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
area	I-malignancy-type
,	O
nine	O
patients	O
with	O
acute	O
pancreatitis	O
,	O
and	O
four	O
healthy	O
volunteers	O
was	O
also	O
included	O
.	O
Plasma	O
DNA	O
was	O
isolated	O
and	O
K-ras	O
codon	O
-	O
12	O
mutations	O
were	O
analyzed	O
by	O
means	O
of	O
restriction	O
fragment	O
length	O
polymorphism	O
-	O
polymerase	O
chain	O
reaction	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
techniques	O
.	O
Patients	O
were	O
followed	O
up	O
to	O
establish	O
their	O
clinical	O
outcome	O
.	O
RESULTS	O
:	O
The	O
mutant	O
-	O
type	O
K-ras	O
gene	O
was	O
found	O
in	O
plasma	O
DNA	O
samples	O
of	O
12	O
(	O
27	O
%	O
)	O
of	O
44	O
patients	O
with	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
;	O
this	O
finding	O
was	O
related	O
to	O
the	O
tumor	O
stage	O
(	O
P	O
=	O
.05	O
)	O
,	O
mainly	O
in	O
the	O
presence	O
of	O
distant	O
metastases	O
(	O
P	O
=	O
.02	O
)	O
.	O
In	O
addition	O
,	O
K-ras	O
mutations	O
were	O
detected	O
in	O
the	O
plasma	O
DNA	O
of	O
two	O
(	O
5	O
%	O
)	O
of	O
37	O
patients	O
with	O
chronic	O
pancreatitis	O
.	O
In	O
the	O
subset	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
masses	I-malignancy-type
,	O
the	O
sensitivity	O
and	O
specificity	O
of	O
plasma	O
K-ras	O
analysis	O
for	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
27	O
%	O
and	O
100	O
%	O
,	O
respectively	O
.	O
Finally	O
,	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
patients	O
with	O
the	O
mutant	O
-	O
type	O
K-ras	O
gene	O
in	O
plasma	O
DNA	O
exhibited	O
a	O
shorter	O
survival	O
time	O
than	O
patients	O
with	O
the	O
wild	O
-	O
type	O
gene	O
(	O
P	O
<	O
.005	O
)	O
,	O
and	O
plasma	O
K-ras	O
mutations	O
were	O
identified	O
as	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
odds	O
ratio	O
,	O
1.51	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.02	O
to	O
2.23	O
)	O
.	O
CONCLUSION	O
:	O
Plasma	O
K-ras	O
analysis	O
is	O
a	O
highly	O
specific	O
,	O
low	O
-	O
sensitivity	O
approach	O
that	O
has	O
diagnostic	O
and	O
prognostic	O
clinical	O
implications	O
in	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
10080602	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1999	O
Feb;23(	O
2	O
)	O
:115	O
-	O
26	O
Alterations	O
of	O
the	O
p53	O
,	O
p21	O
,	O
p16	O
,	O
p15	O
and	O
RAS	O
genes	O
in	O
childhood	O
T-cell	B-malignancy-type
acute	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Kawamura	O
M,	O
Ohnishi	O
H	O
,	O
Guo	O
SX	O
,	O
Sheng	O
XM	O
,	O
Minegishi	O
M,	O
Hanada	O
R,	O
Horibe	O
K	O
,	O
Hongo	O
T	O
,	O
Kaneko	O
Y	O
,	O
Bessho	O
F	O
,	O
Yanagisawa	O
M,	O
Sekiya	O
T	O
,	O
Hayashi	O
Y.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
We	O
investigated	O
the	O
alterations	O
of	O
the	O
p53	O
,	O
p21	O
,	O
p16	O
,	O
p15	O
and	O
RAS	O
genes	O
in	O
childhood	O
T-cell	B-malignancy-type
acute	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
T-ALL	B-malignancy-type
)	O
and	O
T-ALL	B-malignancy-type
cell	O
lines	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Mutations	O
of	O
the	O
p53	O
gene	O
were	O
found	O
in	O
three	O
of	O
57	O
(	O
5	O
%	O
)	O
patients	O
at	O
diagnosis	O
,	O
one	O
of	O
14	O
(	O
7	O
%	O
)	O
patients	O
at	O
relapse	O
and	O
in	O
12	O
of	O
18	O
(	O
67	O
%	O
)	O
cell	O
lines	O
.	O
In	O
these	O
12	O
cell	O
lines	O
,	O
four	O
had	O
more	O
than	O
two	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O
The	O
p53	O
mutations	O
were	O
found	O
in	O
four	O
of	O
five	O
cell	O
lines	O
whose	O
original	O
fresh	O
leukemic	O
cells	O
were	O
simultaneously	O
examined	O
original	O
fresh	O
leukemic	O
cells	O
.	O
However	O
,	O
only	O
one	O
of	O
the	O
four	O
fresh	O
leukemic	O
cells	O
had	O
the	O
same	O
mutation	O
.	O
All	O
patients	O
with	O
p53	O
mutations	O
in	O
the	O
course	O
of	O
disease	O
died	O
.	O
Mutations	O
of	O
the	O
p21	O
gene	O
were	O
not	O
identified	O
in	O
71	O
fresh	O
samples	O
and	O
in	O
18	O
cell	O
lines	O
.	O
N-RAS	O
mutations	O
were	O
found	O
in	O
two	O
of	O
57	O
(	O
4	O
%	O
)	O
fresh	O
T-ALL	B-malignancy-type
patients	O
at	O
diagnosis	O
,	O
and	O
four	O
of	O
18	O
cell	O
lines	O
(	O
22	O
%	O
)	O
,	O
whereas	O
no	O
mutations	O
were	O
detected	O
in	O
any	O
samples	O
at	O
relapse	O
.	O
Alterations	O
of	O
the	O
p16	O
gene	O
were	O
found	O
in	O
18	O
of	O
47	O
(	O
38	O
%	O
)	O
patients	O
at	O
diagnosis	O
and	O
in	O
seven	O
of	O
14	O
(	O
50	O
%	O
)	O
at	O
relapse	O
.	O
These	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
There	O
were	O
no	O
differences	O
in	O
the	O
frequency	O
of	O
alteration	O
of	O
the	O
p16	O
and	O
p15	O
genes	O
between	O
event	O
-	O
free	O
patients	O
and	O
the	O
remaining	O
patients	O
.	O
Furthermore	O
,	O
we	O
found	O
the	O
methylation	O
of	O
p16	O
gene	O
in	O
three	O
of	O
seven	O
patients	O
lacking	O
homozygous	O
deletions	O
,	O
suggesting	O
higher	O
frequency	O
of	O
p16	O
inactivation	O
than	O
previous	O
reports	O
in	O
T-ALL	B-malignancy-type
.	O
Interestingly	O
,	O
we	O
found	O
that	O
one	O
allele	O
is	O
inactivated	O
by	O
methylation	O
and	O
another	O
allele	O
had	O
nonsense	O
mutation	O
in	O
one	O
cell	O
line	O
(	O
KOPT-KI	O
)	O
,	O
resulting	O
in	O
loss	O
of	O
protein	O
expression	O
of	O
p16	O
.	O
This	O
type	O
of	O
p16	O
inactivation	O
has	O
not	O
been	O
so	O
far	O
reported	O
in	O
leukemia	B-malignancy-type
.	O
We	O
conclude	O
that	O
,	O
(1)	O
p53	O
mutations	O
are	O
infrequent	O
at	O
diagnosis	O
but	O
tend	O
to	O
be	O
associated	O
with	O
poor	O
clinical	O
outcome	O
;	O
(2)	O
RAS	O
and	O
p21	O
mutations	O
may	O
not	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
T-ALL	B-malignancy-type
;	O
(3)	O
not	O
only	O
frequent	O
alterations	O
of	O
p16	O
and	O
p15	O
genes	O
but	O
also	O
methylation	O
of	O
p16	O
gene	O
are	O
involved	O
in	O
initiating	O
the	O
leukemogenesis	O
of	O
T-ALLs	B-malignancy-type
,	O
and	O
(4)	O
these	O
5	O
genes	O
are	O
independently	O
involved	O
in	O
T-ALL	B-malignancy-type
.	O
PMID	O
:	O
10071127	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Dec	O
25	O
;134(	O
2	O
)	O
:169	O
-	O
76	O
Ki-ras	O
codon	O
12	O
point	O
mutational	O
activation	O
in	O
Hong	O
Kong	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
patients	O
.	O
Ko	O
JM	O
,	O
Cheung	O
MH	O
,	O
Wong	O
CM	O
,	O
Lau	O
KW	O
,	O
Tang	O
CM	O
,	O
Kwan	O
MW	O
,	O
Lung	O
ML.	O
Department	O
of	O
Biology	O
,	O
Hong	O
Kong	O
University	O
of	O
Science	O
and	O
Technology	O
,	O
Clear	O
Water	O
Bay	O
,	O
Kowloon	O
.	O
This	O
study	O
investigated	O
the	O
frequency	O
and	O
importance	O
of	O
Ki-ras	O
codon	O
12	O
mutations	O
in	O
99	O
Hong	O
Kong	O
Chinese	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
specimens	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
The	O
frequency	O
of	O
mutations	O
detected	O
was	O
30	O
%	O
and	O
the	O
most	O
common	O
mutation	O
observed	O
resulted	O
in	O
aspartic	O
acid	O
substitutions	O
.	O
Previous	O
studies	O
showed	O
that	O
specific	O
Ki-ras	O
mutations	O
have	O
been	O
significantly	O
associated	O
with	O
prognosis	O
.	O
Ki-ras	O
codon	O
12	O
point	O
mutational	O
activation	O
in	O
CRC	B-malignancy-type
was	O
significantly	O
associated	O
with	O
the	O
differentiation	O
status	O
of	O
tumors	O
in	O
this	O
study	O
.	O
Ethnic	O
differences	O
in	O
the	O
patterns	O
of	O
Ki-ras	O
codon	O
12	O
point	O
mutations	O
were	O
observed	O
.	O
PMID	O
:	O
10025877	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1999	O
Feb	O
16;96(	O
4)	O
:1609	O
-	O
14	O
Activating	O
and	O
dominant	O
inactivating	O
c-KIT	O
catalytic	O
domain	O
mutations	O
in	O
distinct	O
clinical	O
forms	O
of	O
human	O
mastocytosis	B-malignancy-type
.	O
Longley	O
BJ	O
Jr	O
,	O
Metcalfe	O
DD	O
,	O
Tharp	O
M,	O
Wang	O
X	O
,	O
Tyrrell	O
L,	O
Lu	O
SZ	O
,	O
Heitjan	O
D	O
,	O
Ma	O
Y.	O
Departments	O
of	O
Dermatology	O
and	O
Pathology	O
,	O
Section	O
of	O
Dermatopathology	O
,	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
of	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
100	O
32	O
,	O
USA	O
.	O
jack	O
.longley	O
@columbia	O
.edu	O
Human	O
mastocytosis	B-malignancy-type
is	O
characterized	O
by	O
increased	O
mast	O
cells	O
.	O
It	O
usually	O
occurs	O
as	O
a	O
sporadic	O
disease	O
that	O
is	O
often	O
transient	O
and	O
limited	O
in	O
children	O
and	O
persistent	O
or	O
progressive	O
in	O
adults	O
.	O
The	O
c-KIT	O
protooncogene	O
encodes	O
KIT	O
,	O
a	O
tyrosine	O
kinase	O
that	O
is	O
the	O
receptor	O
for	O
mast	O
cell	O
growth	O
factor	O
.	O
Because	O
mutated	O
KIT	O
can	O
transform	O
cells	O
,	O
we	O
examined	O
c-KIT	O
in	O
skin	B-malignancy-type
lesions	I-malignancy-type
of	O
22	O
patients	O
with	O
sporadic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
3	O
patients	O
with	O
familial	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
All	O
patients	O
with	O
adult	O
sporadic	B-malignancy-type
mastocytosis	I-malignancy-type
had	O
somatic	O
c-KIT	O
mutations	O
in	O
codon	O
816	O
causing	O
substitution	O
of	O
valine	O
for	O
aspartate	O
and	O
spontaneous	O
activation	O
of	O
mast	O
cell	O
growth	O
factor	O
receptor	O
(	O
P	O
=	O
0.0001	O
)	O
.	O
A	O
subset	O
of	O
four	O
pediatric	O
onset	O
cases	O
with	O
clinically	O
unusual	O
disease	O
also	O
had	O
codon	O
816	O
activating	O
mutations	O
substituting	O
valine	O
,	O
tyrosine	O
,	O
or	O
phenylalanine	O
for	O
aspartate	O
.	O
Typical	O
pediatric	O
patients	O
lacked	O
816	O
mutations	O
,	O
but	O
limited	O
sequencing	O
showed	O
three	O
of	O
six	O
had	O
a	O
novel	O
dominant	O
inactivating	O
mutation	O
substituting	O
lysine	O
for	O
glutamic	O
acid	O
in	O
position	O
839	O
,	O
the	O
site	O
of	O
a	O
potential	O
salt	O
bridge	O
that	O
is	O
highly	O
conserved	O
in	O
receptor	O
tyrosine	O
kinases	O
.	O
No	O
c-KIT	O
mutations	O
were	O
found	O
in	O
the	O
entire	O
coding	O
region	O
of	O
three	O
patients	O
with	O
familial	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
We	O
conclude	O
that	O
c-KIT	O
somatic	O
mutations	O
substituting	O
valine	O
in	O
position	O
816	O
of	O
KIT	O
are	O
characteristic	O
of	O
sporadic	B-malignancy-type
adult	I-malignancy-type
mastocytosis	I-malignancy-type
and	O
may	O
cause	O
this	O
disease	O
.	O
Similar	O
mutations	O
causing	O
activation	O
of	O
the	O
mast	O
cell	O
growth	O
factor	O
receptor	O
are	O
found	O
in	O
children	O
apparently	O
at	O
risk	O
for	O
extensive	O
or	O
persistent	O
disease	O
.	O
In	O
contrast	O
,	O
typical	O
pediatric	B-malignancy-type
mastocytosis	I-malignancy-type
patients	O
lack	O
these	O
mutations	O
and	O
may	O
express	O
inactivating	O
c-KIT	O
mutations	O
.	O
Familial	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
however	O
,	O
may	O
occur	O
in	O
the	O
absence	O
of	O
c-KIT	O
coding	O
mutations	O
.	O
PMID	O
:	O
9990072	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1999	O
Feb;21(	O
2	O
)	O
:187	O
-	O
90	O
Activating	O
SRC	O
mutation	O
in	O
a	O
subset	O
of	O
advanced	O
human	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
Irby	O
RB	O
,	O
Mao	O
W	O
,	O
Coppola	O
D	O
,	O
Kang	O
J,	O
Loubeau	O
JM	O
,	O
Trudeau	O
W	O
,	O
Karl	O
R,	O
Fujita	O
DJ	O
,	O
Jove	O
R,	O
Yeatman	O
TJ.	O
Department	O
of	O
Surgery	O
,	O
H.	O
Lee	O
Moffitt	O
Cancer	O
Center	O
&	O
Research	O
Institute	O
,	O
University	O
of	O
South	O
Florida	O
College	O
of	O
Medicine	O
,	O
Tampa	O
33612	O
,	O
USA	O
.	O
The	O
discovery	O
of	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
led	O
to	O
the	O
identification	O
of	O
cellular	O
Src	O
(	O
c-Src	O
)	O
,	O
a	O
non	O
-	O
receptor	O
tyrosine	O
kinase	O
,	O
which	O
has	O
since	O
been	O
implicated	O
in	O
the	O
development	O
of	O
numerous	O
human	O
cancers	O
.	O
c-Src	O
has	O
been	O
found	O
to	O
be	O
highly	O
activated	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
,	O
particularly	O
in	O
those	O
metastatic	O
to	O
the	O
liver	O
.	O
Studies	O
of	O
the	O
mechanism	O
of	O
c-Src	O
regulation	O
have	O
suggested	O
that	O
c-Src	O
kinase	O
activity	O
is	O
downregulated	O
by	O
phosphorylation	O
of	O
a	O
critical	O
carboxy	O
-	O
terminal	O
tyrosine	O
(	O
Tyr	O
530	O
in	O
human	O
c-Src	O
,	O
equivalent	O
to	O
Tyr	O
527	O
in	O
chicken	O
Src	O
)	O
and	O
have	O
implied	O
the	O
existence	O
of	O
activating	O
mutations	O
in	O
this	O
C-terminal	O
regulatory	O
region	O
.	O
We	O
report	O
here	O
the	O
identification	O
of	O
a	O
truncating	O
mutation	O
in	O
SRC	O
at	O
codon	O
531	O
in	O
12	O
%	O
of	O
cases	O
of	O
advanced	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
tested	O
and	O
demonstrate	O
that	O
the	O
mutation	O
is	O
activating	O
,	O
transforming	O
,	O
tumorigenic	O
and	O
promotes	O
metastasis	O
.	O
These	O
results	O
provide	O
,	O
for	O
the	O
first	O
time	O
,	O
genetic	O
evidence	O
that	O
activating	O
SRC	O
mutations	O
may	O
have	O
a	O
role	O
in	O
the	O
malignant	O
progression	O
of	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9988270	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Jan	O
15;59(	O
2	O
)	O
:307	O
-	O
10	O
Somatic	O
mutations	O
in	O
the	O
kinase	O
domain	O
of	O
the	O
Met	O
/	O
hepatocyte	O
growth	O
factor	O
receptor	O
gene	O
in	O
childhood	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Park	O
WS	O
,	O
Dong	O
SM	O
,	O
Kim	O
SY	O
,	O
Na	O
EY	O
,	O
Shin	O
MS	O
,	O
Pi	O
JH	O
,	O
Kim	O
BJ	O
,	O
Bae	O
JH	O
,	O
Hong	O
YK	O
,	O
Lee	O
KS	O
,	O
Lee	O
SH	O
,	O
Yoo	O
NJ	O
,	O
Jang	O
JJ	O
,	O
Pack	O
S,	O
Zhuang	O
Z	O
,	O
Schmidt	O
L,	O
Zbar	O
B	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Catholic	O
University	O
Medical	O
College	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
MET	O
protooncogene	O
encodes	O
a	O
transmembrane	O
tyrosine	O
kinase	O
identified	O
as	O
the	O
receptor	O
of	O
a	O
polypeptide	O
known	O
as	O
hepatocyte	O
growth	O
factor	O
/	O
scatter	O
factor	O
.	O
We	O
performed	O
PCR	O
-	O
based	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
and	O
sequencing	O
analysis	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
(	O
exon	O
15	O
-	O
19	O
)	O
in	O
75	O
primary	O
liver	B-malignancy-type
cancers	I-malignancy-type
.	O
Three	O
missense	O
mutations	O
were	O
detected	O
exclusively	O
in	O
10	O
childhood	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
,	O
while	O
no	O
mutations	O
were	O
detected	O
in	O
16	O
adult	O
HCCs	B-malignancy-type
,	O
21	O
cholangiocarcinomas	B-malignancy-type
,	O
or	O
28	O
hepatoblastomas	B-malignancy-type
.	O
The	O
extremely	O
short	O
incubation	O
period	O
from	O
hepatitis	O
B	O
virus	O
infection	O
to	O
the	O
genesis	O
of	O
childhood	O
HCC	B-malignancy-type
as	O
compared	O
with	O
the	O
adult	O
HCC	B-malignancy-type
suggests	O
that	O
there	O
may	O
be	O
an	O
additional	O
mechanism	O
that	O
accelerates	O
the	O
carcinogenesis	O
of	O
childhood	O
HCC	B-malignancy-type
.	O
Our	O
results	O
indicate	O
that	O
mutations	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
may	O
be	O
involved	O
in	O
the	O
acceleration	O
of	O
the	O
carcinogenesis	O
in	O
childhood	O
HCC	B-malignancy-type
.	O
PMID	O
:	O
9927037	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1999	O
Jan	O
15;59(	O
2	O
)	O
:269	O
-	O
73	O
Childhood	O
hepatoblastomas	O
frequently	O
carry	O
a	O
mutated	O
degradation	O
targeting	O
box	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Koch	O
A	O
,	O
Denkhaus	O
D	O
,	O
Albrecht	O
S,	O
Leuschner	O
I	O
,	O
von	O
Schweinitz	O
D	O
,	O
Pietsch	O
T.	O
Department	O
of	O
Neuropathology	O
,	O
University	O
of	O
Bonn	O
Medical	O
Center	O
,	O
Germany	O
.	O
Hepatoblastomas	B-malignancy-type
(	O
HBs	B-malignancy-type
)	O
are	O
embryonal	B-malignancy-type
tumors	I-malignancy-type
affecting	O
young	O
children	O
and	O
representing	O
the	O
most	O
frequent	O
malignant	O
liver	B-malignancy-type
tumors	I-malignancy-type
in	O
childhood	O
.	O
The	O
molecular	O
pathogenesis	O
of	O
HB	B-malignancy-type
is	O
poorly	O
understood	O
.	O
Although	O
most	O
cases	O
are	O
sporadic	O
,	O
the	O
incidence	O
is	O
highly	O
elevated	O
in	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
.	O
These	O
patients	O
carry	O
germline	O
mutations	O
of	O
the	O
APC	O
tumor	O
suppressor	O
gene	O
.	O
APC	O
controls	O
the	O
degradation	O
of	O
the	O
oncogene	O
product	O
beta-catenin	O
after	O
its	O
NH2	O
-	O
terminal	O
phosphorylation	O
on	O
serine	O
/	O
threonine	O
residues	O
.	O
APC	O
,	O
as	O
well	O
as	O
beta-catenin	O
,	O
has	O
been	O
found	O
to	O
be	O
a	O
central	O
effector	O
of	O
the	O
growth	O
promoting	O
wingless	O
signaling	O
pathway	O
in	O
development	O
.	O
To	O
find	O
out	O
if	O
this	O
pathway	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
HBs	I-malignancy-type
,	O
we	O
examined	O
52	O
biopsies	O
and	O
three	O
cell	O
lines	O
from	O
sporadic	B-malignancy-type
HBs	I-malignancy-type
for	O
mutations	O
in	O
the	O
APC	O
and	O
beta-catenin	O
genes	O
.	O
Using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
,	O
deletion	O
screening	O
by	O
PCR	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
sporadic	B-malignancy-type
HBs	I-malignancy-type
(	O
48	O
%	O
)	O
.	O
The	O
mutations	O
affected	O
exon	O
3	O
encoding	O
the	O
degradation	O
targeting	O
box	O
of	O
beta-catenin	O
leading	O
to	O
accumulation	O
of	O
intracytoplasmic	O
and	O
nuclear	O
beta-catenin	O
protein	O
.	O
The	O
high	O
frequency	O
of	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
indicates	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HB	B-malignancy-type
.	O
PMID	O
:	O
9927029	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Hum	O
Pathol	O
1999	O
Jan;30(	O
1	O
)	O
:21	O
-	O
5	O
Gallbladder	B-malignancy-type
adenomas	I-malignancy-type
have	O
molecular	O
abnormalities	O
different	O
from	O
those	O
present	O
in	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Wistuba	O
II	O
,	O
Miquel	O
JF	O
,	O
Gazdar	O
AF	O
,	O
Albores	O
-	O
Saavedra	O
J.	O
Hamon	O
Center	O
for	O
Therapeutic	O
and	O
Oncology	O
Research	O
,	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
-	O
9072	O
,	O
USA	O
.	O
Although	O
most	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
evolve	O
from	O
dysplasia	B-malignancy-type
and	O
carcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
,	O
the	O
role	O
of	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
in	O
the	O
pathogenesis	O
of	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
is	O
still	O
controversial	O
.	O
A	O
series	O
of	O
molecular	O
changes	O
including	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
17p	O
(	O
TP53	O
gene	O
)	O
,	O
13q	O
(	O
RB	O
gene	O
)	O
,	O
18q	O
(	O
DCC	O
gene	O
)	O
,	O
and	O
9p21	O
(	O
CDKN2a	O
gene	O
)	O
chromosomal	O
regions	O
have	O
been	O
identified	O
in	O
dysplasias	B-malignancy-type
,	O
carcinomas	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
,	O
and	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
,	O
whereas	O
mutations	O
in	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
are	O
rare	O
.	O
To	O
determine	O
whether	O
the	O
molecular	O
abnormalities	O
of	O
adenomas	B-malignancy-type
are	O
similar	O
to	O
those	O
found	O
in	O
carcinomas	B-malignancy-type
,	O
we	O
obtained	O
extracted	O
DNA	O
from	O
precisely	O
microdissected	O
tissue	O
from	O
16	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
(	O
14	O
pyloric	B-malignancy-type
and	O
2	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
)	O
.	O
We	O
determined	O
the	O
presence	O
of	O
mutations	O
in	O
TP53	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
,	O
and	O
LOH	O
at	O
five	O
chromosomal	O
regions	O
(	O
5q22	O
APC	O
-	O
MCC	O
region	O
,	O
RB	O
,	O
TP53	O
,	O
DCC	O
and	O
9p21	O
-	O
CDKN2a	O
)	O
.	O
For	O
the	O
TP53	O
mutation	O
study	O
,	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
in	O
exons	O
4	O
to	O
8	O
were	O
performed	O
.	O
K	O
-	O
and	O
N	O
-	O
ras	O
mutations	O
detection	O
was	O
performed	O
by	O
designed	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
method	O
and	O
sequencing	O
.	O
Only	O
a	O
single	O
LOH	O
(	O
at	O
5q22	O
)	O
was	O
detected	O
in	O
a	O
gallbladder	B-malignancy-type
adenoma	I-malignancy-type
of	I-malignancy-type
intestinal	I-malignancy-type
type	I-malignancy-type
.	O
No	O
mutations	O
at	O
the	O
TP53	O
were	O
detected	O
.	O
Four	O
adenomas	B-malignancy-type
(	O
25	O
%	O
)	O
showed	O
K-ras	O
mutations	O
(	O
two	O
in	O
codon	O
12	O
and	O
two	O
in	O
codon	O
61	O
)	O
.	O
We	O
conclude	O
that	O
gallbladder	B-malignancy-type
adenoma	I-malignancy-type
lacks	O
the	O
molecular	O
changes	O
frequently	O
detected	O
in	O
dysplasia	B-malignancy-type
,	O
carcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
,	O
and	O
invasive	B-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
.	O
Likewise	O
the	O
occurrence	O
of	O
K-ras	O
mutations	O
at	O
codon	O
12	O
and	O
61	O
in	O
25	O
%	O
of	O
adenomas	B-malignancy-type
strongly	O
suggests	O
that	O
these	O
lesions	B-malignancy-type
are	O
not	O
precursors	O
of	O
invasive	B-malignancy-type
gallbladder	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9923922	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Am	O
J	O
Pathol	O
1999	O
Jan;154(	O
1	O
)	O
:53	O
-	O
60	O
Mutations	O
in	O
exon	O
11	O
of	O
c-Kit	O
occur	O
preferentially	O
in	O
malignant	O
versus	O
benign	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
and	O
do	O
not	O
occur	O
in	O
leiomyomas	B-malignancy-type
or	O
leiomyosarcomas	B-malignancy-type
.	O
Lasota	O
J,	O
Jasinski	O
M,	O
Sarlomo	O
-	O
Rikala	O
M,	O
Miettinen	O
M.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
comprise	O
the	O
largest	O
subset	O
of	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
.	O
These	O
neoplasms	B-malignancy-type
differ	O
histologically	O
and	O
immunohistochemically	O
from	O
typical	O
leiomyomas	B-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
.	O
Most	O
GISTs	B-malignancy-type
express	O
CD34	O
and	O
CD117	O
(	O
c-kit	O
protein	O
)	O
but	O
not	O
desmin	O
.	O
Recently	O
,	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
c-kit	O
proto	O
-	O
oncogene	O
have	O
been	O
shown	O
in	O
five	O
solitary	B-malignancy-type
GISTs	I-malignancy-type
and	O
in	O
tumors	O
and	O
leukocytes	O
from	O
a	O
family	O
with	O
multiple	B-malignancy-type
GISTs	I-malignancy-type
.	O
An	O
in-frame	O
deletion	O
or	O
a	O
point	O
mutation	O
in	O
exon	O
11	O
of	O
c-kit	O
was	O
detected	O
in	O
these	O
cases	O
.	O
Stable	O
transfection	O
of	O
the	O
mutant	O
c-kit	O
complementary	O
DNA	O
was	O
also	O
shown	O
to	O
induce	O
malignant	O
transformation	O
of	O
murine	O
lymphoid	O
cells	O
,	O
suggesting	O
that	O
the	O
c-kit	O
mutations	O
contribute	O
to	O
tumor	O
development	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
43	O
GISTs	B-malignancy-type
and	O
14	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
for	O
mutations	O
in	O
the	O
exon	O
11	O
of	O
c-kit	O
by	O
a	O
PCR	O
-	O
assay	O
.	O
Half	O
of	O
the	O
malignant	O
GISTs	B-malignancy-type
(	O
12	O
/	O
24	O
)	O
and	O
only	O
one	O
benign	O
GIST	B-malignancy-type
(	O
1	O
/	O
19	O
)	O
revealed	O
mutant	O
bands	O
.	O
No	O
mutant	O
bands	O
were	O
found	O
in	O
3	O
leiomyomas	B-malignancy-type
and	O
11	O
leiomyosarcomas	B-malignancy-type
.	O
Sequence	O
analysis	O
confirmed	O
the	O
presence	O
of	O
an	O
in-frame	O
deletion	O
of	O
3	O
-	O
21	O
bp	O
in	O
all	O
13	O
GISTs	B-malignancy-type
with	O
mutant	O
bands	O
.	O
Wild	O
-	O
type	O
bands	O
from	O
8	O
malignant	O
and	O
11	O
benign	O
GISTs	B-malignancy-type
and	O
7	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
without	O
mutant	O
bands	O
were	O
cloned	O
and	O
sequenced	O
.	O
Additional	O
mutations	O
were	O
found	O
in	O
3	O
malignant	O
and	O
2	O
benign	O
GISTs	B-malignancy-type
.	O
There	O
were	O
no	O
mutations	O
in	O
3	O
leiomyomas	B-malignancy-type
and	O
4	O
leiomyosarcomas	B-malignancy-type
.	O
The	O
mutation	O
status	O
of	O
exon	O
11	O
did	O
not	O
correlate	O
with	O
immunohistochemically	O
detectable	O
expression	O
of	O
the	O
CD117	O
,	O
as	O
virtually	O
all	O
GISTs	B-malignancy-type
with	O
or	O
without	O
such	O
mutations	O
showed	O
CD117	O
immunoreactivity	O
.	O
The	O
c-kit	O
mutations	O
occur	O
preferentially	O
in	O
malignant	O
GISTs	B-malignancy-type
and	O
might	O
be	O
a	O
clinically	O
useful	O
adjunct	O
marker	O
in	O
the	O
evaluation	O
of	O
GISTs	B-malignancy-type
.	O
The	O
conservation	O
of	O
the	O
c-kit	O
mutation	O
pattern	O
,	O
observed	O
in	O
consecutive	O
lesions	B-malignancy-type
from	O
the	O
same	O
patients	O
,	O
suggests	O
that	O
these	O
mutations	O
might	O
be	O
useful	O
tumor	O
markers	O
in	O
monitoring	O
recurrence	O
or	O
minimal	O
residual	O
disease	O
.	O
PMID	O
:	O
9916918	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Eur	O
J	O
Gastroenterol	O
Hepatol	O
1998	O
Dec;10(	O
12	O
)	O
:1025	O
-	O
9	O
Analysis	O
of	O
K-ras	O
gene	O
mutations	O
in	O
rare	O
pancreatic	B-malignancy-type
and	O
ampullary	B-malignancy-type
tumours	I-malignancy-type
.	O
Ebert	O
MP	O
,	O
Hoffmann	O
J,	O
Schneider	O
-	O
Stock	O
R,	O
Kasper	O
HU	O
,	O
Schulz	O
HU	O
,	O
Lippert	O
H	O
,	O
Roessner	O
A	O
,	O
Malfertheiner	O
P.	O
Department	O
of	O
Gastroenterology	O
,	O
Otto	O
-	O
von	O
-	O
Guericke	O
Universitat	O
Magdeburg	O
,	O
Germany	O
.	O
OBJECTIVE	O
:	O
Mutation	O
of	O
the	O
K-ras	O
oncogene	O
is	O
a	O
frequent	O
event	O
in	O
pancreatic	O
ductal	O
carcinogenesis	O
and	O
it	O
is	O
believed	O
to	O
occur	O
at	O
an	O
early	O
stage	O
in	O
the	O
development	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
However	O
,	O
little	O
is	O
known	O
of	O
the	O
role	O
of	O
K-ras	O
mutations	O
in	O
rare	O
pancreatic	B-malignancy-type
epithelial	I-malignancy-type
neoplasms	I-malignancy-type
,	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
or	O
other	O
non	B-malignancy-type
-	I-malignancy-type
epithelial	I-malignancy-type
tumours	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Furthermore	O
,	O
limited	O
data	O
are	O
available	O
regarding	O
the	O
role	O
of	O
K-ras	O
mutations	O
in	O
the	O
pathogenesis	O
of	O
ampullary	O
tumours	O
.	O
DESIGN	O
AND	O
METHODS	O
:	O
Using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
amplified	O
fragments	O
,	O
we	O
analysed	O
codons	O
12	O
and	O
13	O
for	O
the	O
presence	O
of	O
oncogenic	O
mutations	O
of	O
the	O
K-ras	O
oncogene	O
.	O
Tissues	O
were	O
obtained	O
from	O
patients	O
undergoing	O
tumour	O
resection	O
for	O
various	O
rare	O
pancreatic	B-malignancy-type
or	O
ampullary	B-malignancy-type
neoplasms	I-malignancy-type
(	O
number	O
of	O
cases	O
in	O
brackets	O
)	O
:	O
ampullary	B-malignancy-type
adenoma	I-malignancy-type
(	O
1	O
)	O
,	O
neuro	B-malignancy-type
-	I-malignancy-type
endocrine	I-malignancy-type
tumour	I-malignancy-type
(	O
3	O
)	O
,	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
(	O
1	O
)	O
,	O
pancreatic	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
(	O
1	O
)	O
,	O
serous	B-malignancy-type
cystadenoma	I-malignancy-type
(	O
1	O
)	O
,	O
and	O
primary	B-malignancy-type
and	O
metastatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ampulla	I-malignancy-type
(	I-malignancy-type
5	I-malignancy-type
)	I-malignancy-type
and	I-malignancy-type
pancreas	I-malignancy-type
(	O
3	O
)	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutations	O
at	O
codon	O
12	O
were	O
detected	O
in	O
both	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
in	O
the	O
metastatic	B-malignancy-type
lesion	I-malignancy-type
,	O
whereas	O
two	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
harboured	O
a	O
point	O
mutation	O
at	O
codon	O
13	O
:	O
GGC	O
-->	O
GGG	O
and	O
GGC	O
-->	O
GGT	O
.	O
None	O
of	O
the	O
other	O
tumours	O
exhibited	O
a	O
K-ras	O
gene	O
mutation	O
at	O
codons	O
12	O
or	O
13	O
.	O
CONCLUSION	O
:	O
Pancreatic	B-malignancy-type
tumours	I-malignancy-type
other	O
than	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
do	O
not	O
harbour	O
mutations	O
of	O
the	O
K-ras	O
oncogene	O
.	O
In	O
addition	O
,	O
ampullary	B-malignancy-type
adenocarcinomas	I-malignancy-type
may	O
present	O
with	O
codon	O
13	O
mutations	O
;	O
however	O
,	O
these	O
mutations	O
were	O
not	O
associated	O
with	O
amino	O
acid	O
substitution	O
.	O
Therefore	O
,	O
K-ras	O
gene	O
mutations	O
seem	O
to	O
be	O
a	O
specific	O
genetic	O
alteration	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
9895049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Neurosci	O
Lett	O
.	O
2003	O
May	O
1;341(	O
2	O
)	O
:	O
139	O
-	O
42	O
.	O
Parkin	O
is	O
not	O
regulated	O
by	O
the	O
unfolded	O
protein	O
response	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
West	O
AB	O
,	O
Gonzalez-de	O
-	O
Chavez	O
F	O
,	O
Wilkes	O
K,	O
O'Farrell	O
C	O
,	O
Farrer	O
MJ.	O
Program	O
for	O
Molecular	O
Neuroscience	O
,	O
Department	O
of	O
Neuroscience	O
,	O
Mayo	O
Clinic	O
Jacksonville	O
,	O
32224	O
,	O
Jacksonville	O
,	O
FL	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
parkin	O
gene	O
cause	O
the	O
majority	O
of	O
cases	O
of	O
familial	O
-	O
linked	O
Parkinson	O
's	O
disease	O
,	O
and	O
mounting	O
evidence	O
suggests	O
that	O
parkin	O
may	O
play	O
a	O
role	O
in	O
idiopathic	O
disease	O
.	O
Previous	O
reports	O
suggest	O
that	O
parkin	O
may	O
respond	O
to	O
and	O
relieve	O
,	O
via	O
E3	O
-	O
ligase	O
activity	O
,	O
cellular	O
stress	O
at	O
the	O
endoplasmic	O
reticulum	O
caused	O
by	O
the	O
accumulation	O
of	O
unfolded	O
proteins	O
.	O
However	O
,	O
parkin	O
's	O
relationship	O
to	O
the	O
mammalian	O
unfolded	O
protein	O
response	O
is	O
unclear	O
.	O
Here	O
,	O
we	O
comprehensively	O
evaluate	O
endogenous	O
parkin	O
in	O
SH-SY5Y	O
neuroblastomas	B-malignancy-type
at	O
the	O
promoter	O
,	O
RNA	O
,	O
and	O
protein	O
levels	O
in	O
response	O
to	O
unfolded	O
protein	O
stress	O
induced	O
by	O
tunicamycin	O
.	O
While	O
we	O
find	O
strong	O
up	O
-	O
regulation	O
of	O
genes	O
linked	O
to	O
the	O
unfolded	O
protein	O
stress	O
pathway	O
,	O
we	O
detect	O
no	O
significant	O
changes	O
in	O
parkin	O
.	O
These	O
data	O
suggest	O
a	O
lack	O
of	O
association	O
between	O
parkin	O
and	O
the	O
unfolded	O
protein	O
response	O
in	O
SH-SY5Y	O
cells	O
.	O
PMID	O
:	O
12686385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
2003	O
Jul	O
18	O
;	O
197	O
(	O
1-2	O
)	O
:	O
165-72	O
.	O
The	O
N-myc	O
paradox	O
:	O
N-myc	O
overexpression	O
in	O
neuroblastomas	B-malignancy-type
is	O
associated	O
with	O
sensitivity	O
as	O
well	O
as	O
resistance	O
to	O
apoptosis	O
.	O
van	O
Noesel	O
MM	O
,	O
Pieters	O
R	O
,	O
Voute	O
PA	O
,	O
Versteeg	O
R	O
.	O
Department	O
of	O
Human	O
Genetics	O
,	O
Academic	O
Medical	O
Center	O
,	O
Meibergdreef	O
9	O
,	O
1105	O
AZ	O
Amsterdam	O
,	O
the	O
Netherlands	O
.	O
Neuroblastomas	B-malignancy-type
are	O
characterized	O
by	O
defects	O
in	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
induced	O
apoptosis	O
,	O
especially	O
down	O
-	O
regulation	O
and	O
methylation	O
of	O
Caspase-8	O
(	O
CASP8	O
)	O
.	O
This	O
defect	O
is	O
associated	O
with	O
amplification	O
of	O
N-myc	O
.	O
However	O
,	O
N-myc	O
has	O
also	O
been	O
implicated	O
in	O
induction	O
of	O
apoptosis	O
,	O
especially	O
activation	O
of	O
CASP9	O
mediated	O
apoptosis	O
.	O
Here	O
we	O
found	O
that	O
ectopic	O
N-myc	O
expression	O
induces	O
TRAIL	O
susceptibility	O
,	O
both	O
by	O
CASP8	O
and	O
CASP9	O
mediated	O
apoptosis	O
.	O
N-myc	O
did	O
not	O
modify	O
CASP8	O
expression	O
and	O
methylation	O
.	O
CASP8	O
defects	O
therefore	O
represent	O
an	O
independent	O
event	O
in	O
neuroblastoma	B-malignancy-type
,	O
counteracting	O
the	O
N-myc	O
induced	O
susceptibility	O
to	O
apoptosis	O
.	O
Analysis	O
of	O
the	O
CASP9	O
mediated	O
route	O
in	O
a	O
series	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
we	O
found	O
normal	O
expression	O
and	O
no	O
aberrant	O
methylation	O
of	O
four	O
apoptotic	O
intermediates	O
,	O
including	O
CASP9	O
itself	O
.	O
PMID	O
:	O
12880977	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Immunol	O
Res	O
.	O
2000	O
;	O
21	O
(	O
2-3	O
)	O
:	O
279-88	O
.	O
Targeted	O
cytokines	O
for	O
cancer	O
immunotherapy	O
.	O
Lode	O
HN	O
,	O
Reisfeld	O
RA	O
.	O
Department	O
of	O
Immunology	O
,	O
The	O
Scripps	O
Research	O
Institute	O
,	O
La	O
Jolla	O
,	O
CA	O
92037	O
,	O
USA	O
.	O
Targeting	O
of	O
cytokines	O
into	O
the	O
tumor	O
microenvironment	O
using	O
antibody-cytokine	O
fusion	O
proteins	O
,	O
called	O
immunocytokines	O
,	O
represents	O
a	O
novel	O
approach	O
in	O
cancer	O
immunotherapy	O
.	O
This	O
article	O
summarizes	O
therapeutic	O
efficacy	O
and	O
immune	O
mechanisms	O
involved	O
in	O
targeting	O
interleukin-2	O
(	O
IL-2	O
)	O
to	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
using	O
ganglioside	O
GD2-specific	O
antibody-IL-2	O
fusion	O
protein	O
(	O
ch14.18-IL-2	O
)	O
.	O
Treatment	O
of	O
established	O
melanoma	B-malignancy-type
metastases	O
with	O
ch14.18-IL-2	O
resulted	O
in	O
eradication	O
of	O
disease	O
followed	O
by	O
a	O
vaccination	O
effect	O
protecting	O
mice	O
from	O
lethal	O
challenges	O
with	O
wild-type	O
tumor	O
calls	O
.	O
In	O
a	O
syngeneic	O
neuroblastoma	B-malignancy-type
model	O
,	O
targeted	O
IL-2	O
was	O
effective	O
in	O
the	O
amplification	O
of	O
a	O
weak	O
memory	O
immune	O
response	O
previously	O
induced	O
by	O
IL-12	O
gene	O
therapy	O
using	O
an	O
engineered	O
linear	O
version	O
of	O
this	O
heterodimeric	O
cytokine	O
.	O
These	O
findings	O
show	O
that	O
targeted	O
IL-2	O
may	O
provide	O
an	O
effective	O
tool	O
in	O
cancer	O
immunotherapy	O
and	O
establish	O
the	O
missing	O
link	O
between	O
T	O
cell	O
-	O
mediated	O
vaccination	O
and	O
objective	O
clinical	O
responses	O
.	O
PMID	O
:	O
10852128	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

FEBS	O
Lett	O
.	O
1992	O
Mar	O
30	O
;	O
300	O
(	O
2	O
)	O
:	O
114-8	O
.	O
Staurosporine	O
induces	O
a	O
neuronal	O
phenotype	O
in	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
that	O
resembles	O
that	O
induced	O
by	O
the	O
phorbol	O
ester	O
12-O-tetradecanoyl	O
phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O
Jalava	O
A	O
,	O
Heikkila	O
J	O
,	O
Lintunen	O
M	O
,	O
Akerman	O
K	O
,	O
Pahlman	O
S	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Pharmacy	O
,	O
Abo	O
Akademi	O
University	O
,	O
Turku	O
,	O
Finland	O
.	O
Treatment	O
of	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
with	O
the	O
protein	O
kinase	O
inhibitor	O
staurosporine	O
,	O
induced	O
both	O
morphological	O
and	O
functional	O
differentiation	O
in	O
these	O
cells	O
.	O
The	O
effects	O
of	O
staurosporine	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
the	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activator	O
,	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
(	O
TPA	O
)	O
,	O
with	O
respect	O
to	O
induction	O
of	O
neuronal	O
differentiation	O
,	O
i.e	O
.	O
neurite	O
outgrowth	O
,	O
inhibition	O
of	O
DNA	O
synthesis	O
,	O
induction	O
and	O
down	O
-	O
regulation	O
of	O
c-myc	O
protein	O
expression	O
,	O
induction	O
of	O
mRNA	O
for	O
both	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
and	O
growth	O
associated	O
protein	O
43	O
(	O
GAP-43	O
)	O
and	O
stimulation	O
of	O
tyrosine	O
hydroxylase	O
expression	O
.	O
Staurosporine	O
failed	O
to	O
translocate	O
PKC	O
to	O
the	O
membrane	O
fraction	O
or	O
to	O
stimulate	O
phosphorylation	O
of	O
the	O
endogenous	O
PKC	O
substrate	O
M(r)	O
80	O
,000	O
(	O
p80	O
)	O
.	O
Instead	O
,	O
staurosporine	O
inhibited	O
TPA	O
-	O
induced	O
phosphorylation	O
of	O
p80	O
.	O
PMID	O
:	O
1348695	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1990	O
Aug	O
16	O
;	O
170	O
(	O
3	O
)	O
:	O
1242-8	O
.	O
Reduction	O
of	O
N-myc	O
expression	O
by	O
antisense	O
RNA	O
is	O
amplified	O
by	O
interferon	O
:	O
possible	O
involvement	O
of	O
the	O
2-5A	O
system	O
.	O
Schilbach	O
K	O
Pollwein	O
P	O
,	O
Schwab	O
M	O
,	O
Handgretinger	O
R	O
,	O
Treuner	O
J	O
,	O
Niethammer	O
D	O
,	O
Bruchelt	O
G.	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
Children	O
's	O
Hospital	O
,	O
University	O
of	O
Tuebingen	O
,	O
FRG.	O
Expression	O
of	O
myc-box	O
genes	O
can	O
be	O
reduced	O
by	O
Interferon	O
(	O
c-myc	O
in	O
Daudi	O
cells	O
)	O
or	O
Retinoic	O
acid	O
(	O
N-myc	O
in	O
neuroblastoma	B-malignancy-type
cells	O
)	O
.	O
Interferon	O
did	O
not	O
reduce	O
N-myc	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
However	O
,	O
after	O
transfection	O
of	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
LS	O
with	O
a	O
vector	O
,	O
providing	O
the	O
Cadmium	O
inducible	O
expression	O
of	O
an	O
antisense	O
N-myc	O
transcript	O
,	O
drastic	O
reduction	O
of	O
N-myc	O
RNA	O
was	O
achieved	O
in	O
these	O
cells	O
by	O
incubation	O
with	O
Cadmium	O
and	O
Interferon	O
.	O
Treatment	O
with	O
Cadmium	O
alone	O
resulted	O
in	O
a	O
comparably	O
small	O
reduction	O
of	O
N-myc	O
transcripts	O
in	O
these	O
cells	O
.	O
Interferon	O
alone	O
did	O
not	O
appreciably	O
affect	O
N-myc	O
expression	O
.	O
Reduction	O
of	O
N-myc	O
was	O
accompanied	O
with	O
reduced	O
cell	O
proliferation	O
and	O
morphological	O
differentiation	O
.	O
It	O
is	O
assumed	O
that	O
most	O
of	O
the	O
inhibitory	O
effects	O
observed	O
are	O
mediated	O
by	O
the	O
Interferon	O
inducible	O
2-5A	O
system	O
.	O
PMID	O
:	O
1697169	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Virol	O
.	O
1992	O
Mar	O
;	O
66	O
(	O
3	O
)	O
:	O
1769-73	O
.	O
Irreversible	O
modification	O
of	O
measles	O
virus	O
RNA	O
in	O
vitro	O
by	O
nuclear	O
RNA-unwinding	O
activity	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Rataul	O
SM	O
,	O
Hirano	O
A	O
,	O
Wong	O
TC	O
.	O
Department	O
of	O
Microbiology	O
,	O
University	O
of	O
Washington	O
School	O
of	O
Medicine	O
,	O
Seattle	O
98195	O
.	O
The	O
matrix	O
(	O
M	O
)	O
gene	O
of	O
a	O
measles	O
virus	O
(	O
MV	O
)	O
variant	O
passaged	O
in	O
IMR-32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
displays	O
numerous	O
uridine	O
-to-	O
cytosine	O
transitions	O
called	O
biased	O
hypermutation	O
.	O
Using	O
an	O
in	O
vitro	O
assay	O
,	O
we	O
show	O
that	O
IMR-32	O
cells	O
contain	O
high	O
levels	O
of	O
an	O
activity	O
which	O
unwinds	O
and	O
irreversibly	O
alters	O
the	O
base	O
pairing	O
of	O
double	O
-	O
stranded	O
RNA	O
synthesized	O
from	O
the	O
M	O
gene	O
of	O
MV	O
.	O
This	O
activity	O
is	O
found	O
exclusively	O
in	O
the	O
cellular	O
nucleus	O
and	O
is	O
present	O
at	O
a	O
lower	O
level	O
in	O
African	O
green	O
monkey	O
kidney	O
Vero	O
cells	O
.	O
Experiments	O
with	O
mixed	O
cell	O
extracts	O
suggest	O
that	O
the	O
low	O
activity	O
in	O
Vero	O
cells	O
is	O
not	O
due	O
to	O
inhibitory	O
factors	O
.	O
These	O
findings	O
support	O
the	O
hypothesis	O
that	O
this	O
RNA-modifying	O
and	O
-unwinding	O
activity	O
is	O
responsible	O
for	O
biased	O
hypermutation	O
of	O
MV	O
strains	O
that	O
infect	O
the	O
central	O
nervous	O
system	O
.	O
Possible	O
functions	O
of	O
this	O
neural	O
cell	O
activity	O
and	O
implications	O
for	O
central	O
nervous	O
system	O
disorders	O
are	O
discussed	O
.	O
PMID	O
:	O
1738207	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Genet	O
Cytogenet	O
.	O
1991	O
Jul	O
1	O
;	O
54	O
(	O
1	O
)	O
:	O
109-13	O
.	O
Loss	O
of	O
allelic	O
heterozygosity	O
on	O
distal	O
chromosome	O
1p	O
in	O
Merkel	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
marker	O
of	O
neural	O
crest	O
origins	O
?	O
Harnett	O
PR	O
,	O
Kearsley	O
JH	O
,	O
Hayward	O
NK	O
,	O
Dracopoli	O
NC	O
,	O
Kefford	O
RF	O
.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Sydney	O
Westmead	O
Centre	O
,	O
NSW	O
,	O
Australia	O
.	O
The	O
location	O
of	O
genes	O
involved	O
in	O
tumor	O
evolution	O
has	O
been	O
inferred	O
from	O
experiments	O
in	O
which	O
loss	O
of	O
constitutional	O
heterozygosity	O
has	O
been	O
detected	O
in	O
tumor	O
DNA	O
at	O
high	O
frequency	O
in	O
specific	O
chromosome	O
regions	O
.	O
For	O
example	O
,	O
cytogenetic	O
and	O
molecular	O
abnormalities	O
on	O
chromosome	O
1p	O
have	O
been	O
reported	O
in	O
tumors	O
such	O
as	O
malignant	O
melanoma	B-malignancy-type
and	O
neuroblastoma	B-malignancy-type
which	O
arise	O
in	O
cells	O
derived	O
from	O
embryonic	O
neural	O
crest	O
tissue	O
.	O
To	O
extend	O
these	O
observations	O
,	O
we	O
have	O
examined	O
tumor	O
DNA	O
from	O
three	O
cases	O
of	O
Merkel	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
for	O
evidence	O
of	O
loss	O
of	O
constitutional	O
heterozygosity	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
.	O
In	O
all	O
three	O
cases	O
,	O
heterozygous	O
allelic	O
deletions	O
of	O
varying	O
extent	O
on	O
distal	O
chromosome	O
1p	O
were	O
detected	O
in	O
tumor	O
DNA	O
.	O
Comparisons	O
with	O
neural	B-malignancy-type
crest	I-malignancy-type
tumors	I-malignancy-type
suggest	O
that	O
loss	O
of	O
heterozygosity	O
on	O
distal	O
chromosome	O
1p	O
in	O
Merkel	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
may	O
be	O
a	O
marker	O
of	O
neural	O
crest	O
origin	O
.	O
PMID	O
:	O
1676609	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Natl	O
Cancer	O
Inst	O
.	O
1988	O
Dec	O
21	O
;	O
80	O
(	O
20	O
)	O
:	O
1633-7	O
.	O
N-myc	O
oncogene	O
RNA	O
expression	O
in	O
neuroblastoma	B-malignancy-type
.	O
Nisen	O
PD	O
,	O
Waber	O
PG	O
,	O
Rich	O
MA	O
,	O
Pierce	O
S	O
,	O
Garvin	O
JR	O
Jr	O
,	O
Gilbert	O
F	O
,	O
Lanzkowsky	O
P	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Schneider	O
Children's	O
Hospital	O
,	O
Long	O
Island	O
Jewish	O
Medical	O
Center	O
,	O
New	O
Hyde	O
Park	O
,	O
NY	O
.	O
Tumor	O
specimens	O
from	O
33	O
patients	O
with	O
neuroblastoma	B-malignancy-type
were	O
assayed	O
for	O
amplification	O
of	O
the	O
N-myc	O
oncogene	O
and	O
RNA	O
expression	O
to	O
determine	O
whether	O
N-myc	O
RNA	O
expression	O
levels	O
correlated	O
with	O
N-myc	O
gene	O
amplification	O
and	O
clinical	O
outcome	O
.	O
N-myc	O
gene	O
amplification	O
was	O
detected	O
in	O
one	O
stage	O
II	O
tumor	O
,	O
one	O
stage	O
IV-S	O
tumor	O
,	O
and	O
seven	O
stage	O
III	O
or	O
IV	O
tumors	O
.	O
In	O
each	O
case	O
,	O
N-myc	O
RNA	O
expression	O
roughly	O
paralleled	O
N-myc	O
gene	O
amplification	O
.	O
However	O
,	O
enhanced	O
N-myc	O
RNA	O
expression	O
was	O
not	O
confined	O
to	O
tumors	O
with	O
N-myc	O
gene	O
amplification	O
:	O
all	O
of	O
the	O
early	O
(	O
stage	O
I	O
and	O
II	O
)	O
tumors	O
,	O
five	O
stage	O
IV-S	O
tumors	O
,	O
and	O
12	O
advanced	O
(	O
stage	O
III	O
and	O
IV	O
)	O
tumors	O
had	O
levels	O
of	O
N-myc	O
RNA	O
that	O
were	O
elevated	O
up	O
to	O
50-fold	O
.	O
While	O
N-myc	O
gene	O
amplification	O
correlated	O
with	O
prognosis	O
,	O
there	O
was	O
no	O
such	O
correlation	O
with	O
levels	O
of	O
N-myc	O
RNA	O
expression	O
.	O
The	O
precise	O
role	O
of	O
the	O
N-myc	O
gene	O
in	O
the	O
pathogenesis	O
of	O
neuroblastoma	B-malignancy-type
remains	O
unclear	O
.	O
PMID	O
:	O
2461451	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Med	O
Pediatr	O
Oncol	O
.	O
2000	O
Dec	O
;	O
35	O
(	O
6	O
)	O
:	O
669-72	O
.	O
Differential	O
expression	O
in	O
an	O
antisense	O
MYCN	O
neuroblastoma	B-malignancy-type
model	O
.	O
Schmidt	O
ML	O
,	O
Lal	O
A	O
,	O
Dittmann	O
D	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Illinois	O
at	O
Chicago	O
,	O
Chicago	O
,	O
Illinois	O
,	O
USA	O
.	O
mls3@uic.edu	O
BACKGROUND	O
:	O
A	O
previously	O
published	O
antisense	O
MYCN	O
-	O
expressing	O
model	O
system	O
was	O
utilized	O
to	O
identify	O
genes	O
whose	O
expression	O
is	O
altered	O
by	O
the	O
down	O
-	O
regulation	O
of	O
MYCN	O
by	O
AS	O
MYCN	O
.	O
RESULTS	O
:	O
Differential	O
display	O
comparing	O
nontransfected	O
human	O
NB	B-malignancy-type
NBL-S	O
cells	O
to	O
three	O
AS	O
MYCN	O
-	O
expressing	O
cell	O
lines	O
(	O
NBAS-4	O
,	O
-5	O
,	O
and	O
-6	O
)	O
yielded	O
nine	O
differentially	O
expressed	O
cDNAs	O
designated	O
NDDE	O
:1-	O
9	O
,	O
for	O
MYCN	O
-	O
dependent	O
differential	O
expression	O
genes	O
A	O
GenBank	O
search	O
revealed	O
matches	O
for	O
seven	O
of	O
the	O
nine	O
cDNAs	O
.	O
Differential	O
expression	O
was	O
confirmed	O
for	O
five	O
of	O
the	O
cDNAs	O
by	O
Northern	O
blot	O
analysis	O
.	O
RESULTS	O
:	O
NDDE:8	O
is	O
up-regulated	O
in	O
the	O
AS	O
MYCN	O
-	O
expressing	O
clones	O
and	O
shares	O
homology	O
with	O
the	O
EB1	O
clone	O
p53-induced	O
gene	O
(	O
PRG3	O
)	O
.	O
NDDE:2	O
is	O
up-regulated	O
in	O
the	O
high-expressing	O
N-myc	O
protein	O
NBL-S	O
cells	O
and	O
shares	O
homology	O
with	O
a	O
27	O
kD	O
heat	O
shock	O
protein	O
PAN1	O
clone	O
.	O
Further	O
analysis	O
of	O
all	O
five	O
cDNAs	O
might	O
further	O
elucidate	O
the	O
targets	O
of	O
MYCN	O
in	O
NB	B-malignancy-type
.	O
Copyright	O
2000	O
Wiley-Liss	O
,	O
Inc.	O
PMID	O
:	O
11107143	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Eur	O
J	O
Cancer	O
.	O
1997	O
Oct	O
;	O
33	O
(	O
12	O
)	O
:	O
1986-90	O
.	O
A	O
product	O
of	O
DAN	O
,	O
a	O
novel	O
candidate	O
tumour	O
suppressor	O
gene	O
,	O
is	O
secreted	O
into	O
culture	O
medium	O
and	O
suppresses	O
DNA	O
synthesis	O
.	O
Nakamura	O
Y	O
,	O
Ozaki	O
T	O
,	O
Nakagawara	O
A	O
,	O
Sakiyama	O
S	O
.	O
Division	O
of	O
Biochemistry	O
,	O
Chiba	O
Cancer	O
Centre	O
Research	O
Institute	O
,	O
Japan	O
.	O
Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
DAN	O
gene	O
product	O
possesses	O
an	O
ability	O
to	O
revert	O
phenotypes	O
of	O
transformed	O
rat	O
fibroblasts	O
and	O
represents	O
a	O
candidate	O
tumour	O
suppressor	O
gene	O
for	O
neuroblastoma	B-malignancy-type
.	O
In	O
the	O
present	O
study	O
,	O
characterisation	O
of	O
DAN	O
was	O
carried	O
out	O
using	O
rat	O
fibroblast	O
3Y1	O
cells	O
and	O
their	O
DAN	O
-	O
overexpressor	O
counterparts	O
(	O
S-9	O
)	O
.	O
The	O
N-terminal	O
region	O
of	O
DAN	O
(	O
amino	O
acids	O
1-24	O
)	O
was	O
highly	O
hydrophobic	O
and	O
DAN	O
protein	O
was	O
found	O
to	O
be	O
secreted	O
into	O
the	O
culture	O
medium	O
.	O
When	O
DAN	O
was	O
treated	O
with	O
PNGase	O
F	O
,	O
a	O
enzyme	O
that	O
cleaves	O
most	O
N-linked	O
carbohydrate	O
residues	O
,	O
the	O
mobility	O
of	O
both	O
cytoplasmic	O
and	O
secreted	O
DAN	O
was	O
increased	O
in	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
,	O
suggesting	O
DAN	O
is	O
N-glycosylated	O
,	O
irrespective	O
of	O
its	O
localisation	O
.	O
When	O
partially	O
purified	O
,	O
DAN	O
was	O
able	O
,	O
when	O
added	O
to	O
the	O
culture	O
,	O
to	O
suppress	O
DNA	O
synthesis	O
of	O
Rous	B-malignancy-type
sarcoma	I-malignancy-type
virus	O
-	O
transformed	O
3Y1	O
cells	O
,	O
which	O
lack	O
the	O
expression	O
of	O
DAN	O
.	O
PMID	O
:	O
9516839	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neurosci	O
Lett	O
.	O
1997	O
Nov	O
28	O
;	O
238	O
(	O
1-2	O
)	O
:	O
21-4	O
.	O
Effect	O
of	O
lipopolysaccharide	O
on	O
the	O
gene	O
expression	O
of	O
the	O
enzymes	O
involved	O
in	O
tetrahydrobiopterin	O
de	O
novo	O
biosynthesis	O
in	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
line	O
N1E-115	O
.	O
Mori	O
K	O
,	O
Nakashima	O
A	O
,	O
Nagatsu	O
T	O
,	O
Ota	O
A	O
.	O
Department	O
of	O
Physiology	O
,	O
School	O
of	O
Medicine	O
,	O
Fujita	O
Health	O
University	O
,	O
Toyoake	O
,	O
Aichi	O
,	O
Japan	O
.	O
The	O
amounts	O
of	O
messenger	O
RNA	O
for	O
three	O
enzymes	O
,	O
namely	O
guanosine	O
triphosphate	O
(	O
GTP	O
)	O
cyclohydrolase	O
1,6-pyruvoyltetrahydropterin	O
synthase	O
,	O
and	O
sepiapterin	O
reductase	O
,	O
all	O
of	O
which	O
are	O
involved	O
in	O
the	O
de	O
novo	O
biosynthesis	O
of	O
(6R)-L-erythrodihydroxypropyl-2-amino-4-hydroxy-5,6,7,8-tetrahydro	O
pteridine	O
(	O
BH4	O
)	O
from	O
GTP	O
,	O
were	O
measured	O
quantitatively	O
in	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
line	O
N1E-115	O
by	O
the	O
competitive	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
after	O
reverse	O
transcription	O
using	O
a	O
heterologous	O
DNA	O
fragment	O
as	O
an	O
internal	O
standard	O
.	O
Twenty-four	O
hour	O
activation	O
of	O
this	O
cell	O
line	O
with	O
1	O
microg/ml	O
lipopolysaccharide	O
resulted	O
in	O
statistically	O
significant	O
increases	O
in	O
the	O
amounts	O
of	O
the	O
messages	O
of	O
all	O
three	O
enzymes	O
.	O
Our	O
data	O
suggest	O
that	O
lipopolysaccharide	O
can	O
activate	O
the	O
intrinsic	O
pathway	O
resulting	O
in	O
the	O
enhanced	O
gene	O
expression	O
of	O
these	O
three	O
enzymes	O
in	O
neuron-derived	O
cells	O
such	O
as	O
N1E-115	O
.	O
PMID	O
:	O
9464645	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
.	O
1995	O
Dec	O
;	O
147	O
(	O
6	O
)	O
:	O
1790-8	O
.	O
Insulin-like	O
growth	O
factor	O
II	O
in	O
the	O
pathogenesis	O
of	O
human	O
neuroblastoma	B-malignancy-type
.	O
Sullivan	O
KA	O
,	O
Castle	O
VP	O
,	O
Hanash	O
SM	O
,	O
Feldman	O
EL	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
University	O
of	O
Michigan	O
Medical	O
Center	O
,	O
Ann	O
Arbor	O
,	O
USA	O
.	O
Insulin-like	O
growth	O
factor	O
II	O
(	O
IGF-II	O
)	O
acts	O
as	O
an	O
autocrine	O
growth	O
factor	O
for	O
many	O
in	O
vitro	O
tumor	O
cell	O
lines	O
including	O
neuroblastoma	B-malignancy-type
.	O
To	O
examine	O
the	O
role	O
of	O
IGF-II	O
in	O
tumor	O
biology	O
we	O
have	O
analyzed	O
a	O
total	O
of	O
56	O
primary	O
neuroblastoma	B-malignancy-type
tumor	I-malignancy-type
samples	O
for	O
the	O
presence	O
of	O
IGF-II	O
using	O
a	O
combination	O
of	O
mRNA	O
and	O
protein	O
analysis	O
.	O
A	O
group	O
of	O
21	O
samples	O
was	O
examined	O
for	O
the	O
presence	O
of	O
IGF-II	O
mRNA	O
by	O
slot	O
blot	O
and	O
a	O
separate	O
group	O
of	O
37	O
samples	O
was	O
examined	O
for	O
IGF-II	O
immunoreactivity	O
.	O
IGF-II	O
was	O
detected	O
in	O
48%	O
of	O
the	O
total	O
tumor	O
specimens	O
analyzed	O
.	O
IGF-II	O
immunoreactivity	O
was	O
observed	O
in	O
cells	O
resembling	O
developing	O
neuroblasts	O
and	O
was	O
confined	O
to	O
the	O
cytoplasm	O
and	O
proximal	O
neurites	O
.	O
The	O
appearance	O
of	O
IGF-II	O
mRNA	O
and	O
protein	O
did	O
not	O
correlate	O
with	O
tumor	O
prognostic	O
features	O
including	O
stage	O
,	O
histology	O
,	O
or	O
N-myc	O
amplification	O
.	O
These	O
data	O
suggest	O
that	O
the	O
expression	O
of	O
IGF-II	O
is	O
not	O
confined	O
to	O
a	O
specific	O
stage	O
of	O
the	O
disease	O
but	O
may	O
have	O
a	O
broader	O
role	O
in	O
the	O
pathogenesis	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
7495303	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
.	O
1987	O
Apr	O
;	O
55	O
(	O
4	O
)	O
:	O
407-11	O
.	O
Biological	O
properties	O
of	O
a	O
tumour	O
cell	O
line	O
(	O
NB1	O
-G	O
)	O
derived	O
from	O
human	O
neuroblastoma	B-malignancy-type
.	O
Carachi	O
R	O
,	O
Raza	O
T	O
,	O
Robertson	O
D	O
,	O
Wheldon	O
TW	O
,	O
Wilson	O
L	O
,	O
Livingstone	O
A	O
,	O
van	O
Heyningen	O
V	O
,	O
Spowart	O
G	O
,	O
Middleton	O
P	O
,	O
Gosden	O
JR	O
,	O
et	O
al	O
.	O
The	O
properties	O
of	O
a	O
new	O
tumour	O
cell	O
line	O
(	O
NB1-G	O
)	O
derived	O
from	O
human	O
neuroblastoma	B-malignancy-type
by	O
xenografting	O
in	O
nude	O
rats	O
followed	O
by	O
adaptation	O
to	O
tissue	O
culture	O
are	O
described	O
.	O
Studies	O
using	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
demonstrate	O
the	O
neuro-ectodermal	O
nature	O
of	O
the	O
cells	O
and	O
support	O
the	O
diagnosis	O
of	O
the	O
primary	O
tumour	B-malignancy-type
as	O
neuroblastoma	B-malignancy-type
.	O
Cytogenetic	O
studies	O
have	O
revealed	O
a	O
human	O
karyotype	O
with	O
several	O
chromosomal	O
abnormalities	O
.	O
Genetic	O
analysis	O
by	O
in	O
situ	O
DNA	O
hybridization	O
has	O
demonstrated	O
the	O
presence	O
of	O
multiple	O
copies	O
of	O
the	O
N-myc	O
gene	O
.	O
Approximately	O
20-30	O
fold	O
amplification	O
of	O
the	O
gene	O
is	O
observed	O
on	O
Southern	O
blot	O
analysis	O
.	O
The	O
cell	O
line	O
has	O
been	O
adapted	O
to	O
growth	O
as	O
multicellular	O
tumour	O
spheroids	O
as	O
well	O
as	O
monolayer	O
culture	O
.	O
Radiobiological	O
studies	O
on	O
spheroids	O
show	O
the	O
cells	O
to	O
be	O
radiosensitive	O
with	O
low	O
capacity	O
for	O
sub-lethal	O
damage	O
accumulation	O
and	O
repair	O
.	O
The	O
cell	O
line	O
should	O
be	O
useful	O
for	O
fundamental	O
studies	O
of	O
human	O
neuroblastoma	B-malignancy-type
as	O
well	O
as	O
experimental	O
therapy	O
in	O
vitro	O
.	O
PMID	O
:	O
2437946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Anticancer	O
Res	O
.	O
1995	O
Nov-Dec	O
;	O
15	O
(	O
6B	O
)	O
:	O
2899-905	O
.	O
N-myc	O
protein	O
expression	O
in	O
human	O
breast	B-malignancy-type
carcinoma	I-malignancy-type
:	O
prognostic	O
implications	O
.	O
Mizukami	O
Y	O
,	O
Nonomura	O
A	O
,	O
Takizawa	O
T	O
,	O
Noguchi	O
M	O
,	O
Michigishi	O
T	O
,	O
Nakamura	O
S	O
,	O
Ishizaki	O
T	O
.	O
Pathology	O
Section	O
,	O
Kanazawa	O
University	O
Hospital	O
,	O
Japan	O
.	O
The	O
overexpression	O
of	O
N-myc	O
gene	O
and	O
its	O
protein	O
products	O
has	O
been	O
thought	O
to	O
be	O
limited	O
to	O
cases	O
of	O
neuroblastoma	B-malignancy-type
,	O
retinoblastoma	B-malignancy-type
and	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
,	O
but	O
there	O
is	O
increasing	O
evidence	O
of	O
its	O
wider	O
distribution	O
in	O
human	O
tumors	O
.	O
This	O
study	O
showed	O
that	O
the	O
protein	O
of	O
N-myc	O
gene	O
is	O
associated	O
in	O
normal	O
,	O
benign	O
and	O
malignant	O
human	O
breast	O
tissues	O
.	O
We	O
found	O
that	O
N-myc	O
oncoprotein	O
is	O
overexpressed	O
in	O
most	O
breast	B-malignancy-type
carcinomas	I-malignancy-type
and	O
that	O
N-myc	O
overexpression	O
is	O
significantly	O
correlated	O
with	O
clinical	O
stage	O
,	O
and	O
histological	O
grading	O
of	O
the	O
tumors	O
,	O
and	O
,	O
more	O
importantly	O
with	O
the	O
clinical	O
outcome	O
of	O
the	O
patients	O
.	O
Analysis	O
of	O
DNA	O
,	O
mRNA	O
and	O
protein	O
levels	O
suggested	O
that	O
the	O
high	O
N-myc	O
expression	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
occurs	O
without	O
concomitant	O
gene	O
amplification	O
.	O
The	O
finding	O
of	O
a	O
direct	O
inverse	O
correlation	O
between	O
N-myc	O
overexpression	O
and	O
the	O
prognosis	O
of	O
patients	O
with	O
breast	B-malignancy-type
carcinoma	I-malignancy-type
suggests	O
that	O
N-myc	O
expression	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
factor	O
in	O
human	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
8669886	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gene	O
.	O
2001	O
Jun	O
13;271	O
(	O
1	O
)	O
:	O
87	O
-	O
92	O
.	O
Structure	O
of	O
the	O
human	O
M(2	O
)	O
muscarinic	O
acetylcholine	O
receptor	O
gene	O
and	O
its	O
promoter	O
.	O
Zhou	O
C	O
,	O
Fryer	O
AD	O
,	O
Jacoby	O
DB.	O
Division	O
of	O
Pulmonary	O
and	O
Critical	O
Care	O
Medicine	O
,	O
School	O
of	O
Medicine	O
,	O
Johns	O
Hopkins	O
University	O
,	O
615	O
North	O
Wolfe	O
Street	O
,	O
Baltimore	O
,	O
MD	O
21205	O
,	O
USA	O
.	O
The	O
M(2	O
)	O
muscarinic	O
receptor	O
inhibits	O
the	O
release	O
of	O
acetylcholine	O
from	O
cholinergic	O
fibers	O
in	O
the	O
lungs	O
and	O
elsewhere	O
.	O
In	O
airway	O
parasympathetic	O
neurons	O
,	O
M(2	O
)	O
receptor	O
expression	O
is	O
decreased	O
by	O
viral	O
infections	O
and	O
by	O
interferon	O
-	O
gamma	O
,	O
increasing	O
actylcholine	O
release	O
.	O
Dexamethasone	O
increases	O
M(2	O
)	O
receptor	O
expression	O
,	O
decreasing	O
acetylcholine	O
release	O
.	O
We	O
carried	O
out	O
5	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
beginning	O
with	O
mRNA	O
from	O
human	O
heart	O
and	O
IMR32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
This	O
demonstrated	O
a	O
5	O
'	O
UTR	O
of	O
100	O
BP	O
,	O
corresponding	O
to	O
two	O
sequences	O
on	O
chromosome	O
7	O
,	O
separated	O
by	O
a	O
22.6	O
kB	O
intron	O
.	O
The	O
splice	O
acceptor	O
site	O
is	O
at	O
-45	O
relative	O
to	O
the	O
initiating	O
atg	O
.	O
The	O
3000	O
BP	O
upstream	O
of	O
5	O
'	O
RACE	O
product	O
were	O
subcloned	O
into	O
a	O
pGL3	O
luciferase	O
reporter	O
vector	O
.	O
Deletional	O
constructs	O
were	O
expressed	O
in	O
IMR32	O
cells	O
.	O
These	O
demonstrated	O
that	O
412	O
BP	O
provided	O
full	O
expression	O
of	O
the	O
reporter	O
gene	O
,	O
and	O
suggested	O
a	O
repressor	O
element	O
between	O
-	O
1848	O
and	O
-	O
1510	O
.	O
PMID	O
:	O
11410369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1997	O
Oct;33	O
(	O
12	O
)	O
:193	O
7-	O
41	O
.	O
Expression	O
of	O
a	O
260	O
kDa	O
neuroblastoma	B-malignancy-type
surface	O
antigen	O
,	O
the	O
target	O
of	O
cytotoxic	O
natural	O
human	O
IgM	O
:	O
correlation	O
to	O
MYCN	O
amplification	O
and	O
effects	O
of	O
retinoic	O
acid	O
.	O
David	O
K,	O
Ehrhardt	O
A	O
,	O
Ollert	O
MW	O
,	O
Erttmann	O
R	O
,	O
Bredehorst	O
R	O
,	O
Vogel	O
CW	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
University	O
of	O
Hamburg	O
,	O
Germany	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cells	O
contain	O
a	O
260	O
kDa	O
surface	O
-	O
associated	O
antigen	O
(	O
NB	O
-	O
p260	O
)	O
that	O
is	O
recognised	O
by	O
natural	O
cytotoxic	O
IgM	O
antibodies	O
.	O
In	O
this	O
study	O
we	O
demonstrate	O
that	O
NB	O
-	O
p260	O
is	O
expressed	O
in	O
vivo	O
in	O
a	O
neuroblastoma	B-malignancy-type
tumour	I-malignancy-type
specimen	O
but	O
not	O
in	O
normal	O
human	O
tissues	O
of	O
neuronal	O
origin	O
.	O
Since	O
MYCN	O
amplification	O
is	O
a	O
clinical	O
marker	O
of	O
neuroblastoma	B-malignancy-type
disease	O
progression	O
,	O
we	O
analysed	O
the	O
expression	O
of	O
NB	O
-	O
p260	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
different	O
MYCN	O
amplification	O
status	O
.	O
However	O
,	O
both	O
amplified	O
and	O
non	O
-	O
amplified	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
exhibited	O
comparable	O
NB	O
-	O
p260	O
expression	O
.	O
Treatment	O
of	O
neuroblastoma	B-malignancy-type
cells	O
with	O
the	O
differentiation	O
-	O
inducing	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
also	O
had	O
no	O
effect	O
on	O
the	O
expression	O
of	O
NB	O
-	O
p260	O
.	O
Collectively	O
,	O
the	O
data	O
suggest	O
that	O
expression	O
of	O
NB	O
-	O
p260	O
on	O
human	O
neuroblastoma	B-malignancy-type
cells	O
is	O
independent	O
of	O
malignancy	O
and	O
differentiation	O
status	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
9516828	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prog	O
Clin	O
Biol	O
Res	O
.	O
1994;385	O
:	O
103	O
-	O
10	O
.	O
Retinoic	O
acid	O
and	O
forskolin	O
activate	O
the	O
human	O
MDR1	O
gene	O
promoter	O
in	O
differentiated	O
neuroblasts	O
.	O
Ferrandis	O
E	O
,	O
Benard	O
J.	O
Laboratory	O
of	O
Clinical	O
and	O
Molecular	O
Pharmacology	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
Villejuif	O
,	O
France	O
.	O
To	O
determine	O
whether	O
over	O
-	O
expression	O
of	O
the	O
MDR1	O
gene	O
may	O
result	O
from	O
activation	O
of	O
its	O
promoter	O
by	O
differentiating	O
agents	O
,	O
the	O
activity	O
of	O
the	O
human	O
MDR1	O
proximal	O
promoter	O
(	O
MDR1	O
pp	O
)	O
transfected	O
to	O
2	O
neuroblastoma	B-malignancy-type
lines	O
treated	O
with	O
retinoic	O
acid	O
and	O
forskolin	O
was	O
first	O
measured	O
using	O
transient	O
expression	O
assays	O
while	O
the	O
MDR1	O
mRNA	O
levels	O
were	O
measured	O
by	O
Northern	O
blots	O
.	O
The	O
results	O
indicate	O
that	O
retinoic	O
acid	O
and	O
forskolin	O
were	O
able	O
to	O
activate	O
the	O
human	O
MDR1	O
pp	O
in	O
a	O
dose	O
dependent	O
manner	O
after	O
transfection	O
of	O
the	O
MDR1	O
pp	O
-	O
CAT	O
constructs	O
in	O
the	O
2	O
cell	O
models	O
tested	O
,	O
i.e.	O
,	O
SK-N-SH	O
and	O
IGR-N-91	O
,	O
a	O
new	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
A	O
significant	O
increase	O
in	O
MDR1	O
gene	O
transcript	O
levels	O
was	O
observed	O
upon	O
treatment	O
with	O
differentiation	O
inducers	O
in	O
SK-N-SH	O
but	O
not	O
in	O
IGR-N-91	O
neuroblasts	O
.	O
These	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
the	O
MDR1	O
gene	O
promoter	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
lead	O
to	O
an	O
increase	O
in	O
MDR1	O
gene	O
transcript	O
levels	O
,	O
according	O
to	O
the	O
neuroblast	O
cell	O
line	O
considered	O
.	O
PMID	O
:	O
7972200	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

HNO	O
.	O
1992	O
Aug;40(	O
8	O
)	O
:	O
283	O
-	O
91	O
.	O
[Oncogenes	O
and	O
their	O
significance	O
for	O
head	B-malignancy-type
and	O
neck	B-malignancy-type
cancers	B-malignancy-type
]	O
[	O
Article	O
in	O
German	O
]	O
Issing	O
WJ	O
,	O
Wustrow	O
TP	O
,	O
Heppt	O
W	O
.	O
Klinik	O
und	O
Poliklinik	O
fur	O
Hals	O
-	O
Nasen	O
-	O
und	O
Ohrenkranke	O
,	O
Ludwig-	O
Maximilians	O
-Universitat	O
Munchen	O
,	O
Klinikum	O
Grosshadern	O
.	O
During	O
the	O
past	O
few	O
decades	O
medical	O
science	O
has	O
accepted	O
the	O
concept	O
that	O
cancer	O
is	O
a	O
fundamental	O
disorder	O
of	O
cellular	O
growth	O
control	O
.	O
A	O
disorder	O
can	O
originate	O
in	O
some	O
cells	O
through	O
changes	O
in	O
genes	O
(	O
DNA	O
level	O
:	O
gene	O
amplification	O
,	O
mutation	O
and	O
rearrangement	O
)	O
or	O
their	O
expression	O
(	O
RNA	O
and	O
protein	O
levels	O
)	O
,	O
and	O
stimulates	O
growth	O
in	O
contrast	O
to	O
surrounding	O
cells	O
.	O
Over	O
the	O
last	O
decade	O
genes	O
affected	O
in	O
the	O
cancer	O
cell	O
have	O
been	O
identified	O
as	O
well	O
as	O
the	O
nature	O
of	O
changes	O
undergone	O
.	O
Only	O
a	O
few	O
of	O
the	O
known	O
oncogenes	O
play	O
a	O
role	O
in	O
head	B-malignancy-type
and	O
neck	B-malignancy-type
cancer	I-malignancy-type
.	O
These	O
are	O
epidermal	O
growth	O
factor	O
receptor	O
,	O
c-myc	O
,	O
the	O
ras	O
gene	O
family	O
,	O
int-2	O
,	O
hst-1	O
and	O
bcl-1	O
.	O
In	O
some	O
clinical	O
disorders	O
,	O
such	O
as	O
childhood	O
neuroblastoma	B-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
,	O
oncogenes	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
tumor	O
staging	O
or	O
as	O
a	O
prognostic	O
parameter	O
.	O
The	O
aim	O
for	O
future	O
therapy	O
is	O
the	O
effective	O
application	O
of	O
oncogenes	O
(	O
or	O
"	O
gene	O
therapy	O
"	O
)	O
in	O
clinical	O
practice	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
1517116	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Life	O
Sci	O
.	O
1990	O
;46	O
(	O
18	O
)	O
:	O
1279	O
-	O
86	O
.	O
Sigma	O
and	O
opioid	O
receptors	O
in	O
human	O
brain	B-malignancy-type
tumors	I-malignancy-type
.	O
Thomas	O
GE	O
,	O
Szucs	O
M,	O
Mamone	O
JY	O
,	O
Bem	O
WT	O
,	O
Rush	O
MD	O
,	O
Johnson	O
FE	O
,	O
Coscia	O
CJ.	O
Department	O
of	O
Biochemistry	O
,	O
St.	O
Louis	O
University	O
School	O
of	O
Medicine	O
,	O
Missouri	O
63104	O
.	O
Human	O
brain	B-malignancy-type
tumors	I-malignancy-type
(	O
obtained	O
as	O
surgical	O
specimens	O
)	O
and	O
nude	O
mouse	O
-borne	O
human	O
neuroblastomas	B-malignancy-type
and	O
gliomas	B-malignancy-type
were	O
analyzed	O
for	O
sigma	O
and	O
opioid	O
receptor	O
content	O
.	O
Sigma	O
binding	O
was	O
assessed	O
using	O
[3H]1,3-di	O
-	O
o-tolylguanidine	O
(	O
DTG	O
)	O
,	O
whereas	O
opoid	O
receptor	O
subtypes	O
were	O
measured	O
with	O
tritiated	O
forms	O
of	O
the	O
following	O
:	O
mu	O
,	O
[D-	O
ala2	O
,mePhe4,gly-ol5]enkephalin	O
(	O
DAMGE	O
)	O
;	O
kappa	O
,	O
ethylketocyclazocine	O
(	O
EKC	O
)	O
or	O
U69	O
,593	O
;	O
delta	O
,	O
[D-	O
pen2	O
,D-	O
pen5]enkephalin	O
(	O
DPDPE	O
)	O
or	O
[D-	O
ala2	O
,D-	O
leu5]enkephalin	O
(	O
DADLE	O
)	O
with	O
mu	O
suppressor	O
present	O
.	O
Binding	O
parameters	O
were	O
estimated	O
by	O
homologous	O
displacement	O
assays	O
followed	O
by	O
analysis	O
using	O
the	O
LIGAND	O
program	O
.	O
Sigma	O
binding	O
was	O
detected	O
in	O
15	O
of	O
16	O
tumors	O
examined	O
with	O
very	O
high	O
levels	O
(	O
pmol	O
/	O
mg	O
protein	O
)	O
found	O
in	O
a	O
brain	B-malignancy-type
metastasis	I-malignancy-type
from	O
an	O
adenocarcinoma	B-malignancy-type
of	O
lung	O
and	O
a	O
human	O
neuroblastoma	B-malignancy-type
(	O
SK-N-MC	O
)	O
passaged	O
in	O
nude	O
mice	O
.	O
kappa	O
opioid	O
receptor	O
binding	O
was	O
detected	O
in	O
4	O
of	O
4	O
glioblastoma	B-malignancy-type
multiforme	I-malignancy-type
specimens	O
and	O
2	O
of	O
2	O
human	O
astrocytoma	B-malignancy-type
cell	O
lines	O
tested	O
but	O
not	O
in	O
the	O
other	O
brain	B-malignancy-type
tumors	I-malignancy-type
analyzed	O
.	O
PMID	O
:	O
1971702	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mech	O
Dev	O
.	O
2002	O
Mar;112(	O
1-2	O
)	O
:191-3.	O
Etr	O
-	O
r3	O
/	O
mNapor	O
,	O
encoding	O
an	O
ELAV-type	O
RNA	O
binding	O
protein	O
,	O
is	O
expressed	O
in	O
differentiating	O
cells	O
in	O
the	O
developing	O
rodent	O
forebrain	O
.	O
Levers	O
TE	O
,	O
Tait	O
S	O
,	O
Birling	O
MC	O
,	O
Brophy	O
PJ	O
,	O
Price	O
DJ.	O
Biomedical	O
Sciences	O
,	O
University	O
of	O
Edinburgh	O
,	O
Hugh	O
Robson	O
Building	O
,	O
George	O
Square	O
,	O
Edinburgh	O
EH8	O
9XD	O
,	O
UK.	O
The	O
gene	O
encoding	O
human	O
neuroblastoma	B-malignancy-type
apoptosis	O
-	O
related	O
RNA	O
binding	O
protein	O
(	O
NAPOR	O
)	O
has	O
rat	O
and	O
mouse	O
homologues	O
,	O
Etr	O
-	O
r3	O
and	O
mNapor	O
,	O
cloned	O
recently	O
by	O
ourselves	O
and	O
others	O
.	O
Etr	O
-	O
r3	O
/	O
mNapor	O
is	O
transcribed	O
in	O
embryonic	O
brain	O
but	O
its	O
detailed	O
expression	O
patterns	O
are	O
unknown	O
.	O
It	O
has	O
been	O
hypothesised	O
that	O
its	O
expression	O
coincides	O
with	O
the	O
occurrence	O
of	O
programmed	O
cell	O
death	O
,	O
but	O
existing	O
expression	O
data	O
are	O
insufficient	O
to	O
evaluate	O
this	O
possibility	O
.	O
We	O
used	O
northern	O
blots	O
and	O
in	O
situ	O
hybridisation	O
to	O
show	O
that	O
Etr	O
-	O
r3	O
/	O
mNapor	O
is	O
expressed	O
by	O
most	O
postmitotic	O
differentiating	O
cells	O
throughout	O
the	O
forebrain	O
during	O
embryogenesis	O
and	O
the	O
first	O
weeks	O
of	O
postnatal	O
life	O
.	O
Expression	O
is	O
particularly	O
high	O
in	O
the	O
developing	O
cerebral	O
cortex	O
,	O
in	O
nuclei	O
of	O
the	O
ventral	O
telencephalon	O
,	O
in	O
dorsal	O
thalamus	O
and	O
in	O
hypothalamus	O
.	O
In	O
contrast	O
,	O
Etr	O
-	O
r3	O
/	O
mNapor	O
is	O
expressed	O
by	O
very	O
few	O
cells	O
in	O
proliferative	O
regions	O
,	O
where	O
cell	O
death	O
rates	O
are	O
highest	O
.	O
PMID	O
:	O
11850193	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cell	O
Biol	O
.	O
2002	O
Mar	O
18;156	O
(	O
6	O
)	O
:	O
1051	O
-63	O
.	O
Tau	O
blocks	O
traffic	O
of	O
organelles	O
,	O
neurofilaments	O
,	O
and	O
APP	O
vesicles	O
in	O
neurons	O
and	O
enhances	O
oxidative	O
stress	O
.	O
Stamer	O
K,	O
Vogel	O
R	O
,	O
Thies	O
E	O
,	O
Mandelkow	O
E	O
,	O
Mandelkow	O
EM	O
.	O
Max-Planck	O
-Unit	O
for	O
Structural	O
Molecular	O
Biology	O
,	O
22607	O
Hamburg	O
,	O
Germany	O
.	O
We	O
studied	O
the	O
effect	O
of	O
microtubule	O
-	O
associated	O
tau	O
protein	O
on	O
trafficking	O
of	O
vesicles	O
and	O
organelles	O
in	O
primary	O
cortical	O
neurons	O
,	O
retinal	O
ganglion	O
cells	O
,	O
and	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Tau	O
inhibits	O
kinesin	O
-	O
dependent	O
transport	O
of	O
peroxisomes	O
,	O
neurofilaments	O
,	O
and	O
Golgi	O
-	O
derived	O
vesicles	O
into	O
neurites	O
.	O
Loss	O
of	O
peroxisomes	O
makes	O
cells	O
vulnerable	O
to	O
oxidative	O
stress	O
and	O
leads	O
to	O
degeneration	O
.	O
In	O
particular	O
,	O
tau	O
inhibits	O
transport	O
of	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
into	O
axons	O
and	O
dendrites	O
,	O
causing	O
its	O
accumulation	O
in	O
the	O
cell	O
body	O
.	O
APP	O
tagged	O
with	O
yellow	O
fluorescent	O
protein	O
and	O
transfected	O
by	O
adenovirus	O
associates	O
with	O
vesicles	O
moving	O
rapidly	O
forward	O
in	O
the	O
axon	O
(	O
approximately	O
80	O
%	O
)	O
and	O
slowly	O
back	O
(	O
approximately	O
20	O
%	O
)	O
.	O
Both	O
movements	O
are	O
strongly	O
inhibited	O
by	O
cotransfection	O
with	O
fluorescently	O
tagged	O
tau	O
(	O
cyan	O
fluorescent	O
protein	O
-	O
tau	O
)	O
as	O
seen	O
by	O
two	O
-	O
color	O
confocal	O
microscopy	O
.	O
The	O
data	O
suggests	O
a	O
linkage	O
between	O
tau	O
and	O
APP	O
trafficking	O
,	O
which	O
may	O
be	O
significant	O
in	O
Alzheimer	O
's	O
disease	O
.	O
PMID	O
:	O
11901170	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gen	O
Virol	O
.	O
1999	O
Aug;80	O
(	O
Pt	O
8	O
)	O
:2275	O
-83	O
.	O
PrP	O
(	O
prion	O
)	O
gene	O
expression	O
in	O
sheep	O
may	O
be	O
modulated	O
by	O
alternative	O
polyadenylation	O
of	O
its	O
messenger	O
RNA	O
.	O
Goldmann	O
W	O
,	O
O'Neill	O
G	O
,	O
Cheung	O
F	O
,	O
Charleson	O
F	O
,	O
Ford	O
P,	O
Hunter	O
N	O
.	O
Neuropathogenesis	O
Unit	O
,	O
BBSRC	O
Institute	O
for	O
Animal	O
Health	O
,	O
Edinburgh	O
,	O
UK.	O
Wilfred	O
.Goldmann@bbsrc.ac.uk	O
Scrapie	O
-	O
associated	O
fibrils	O
and	O
their	O
major	O
protein	O
component	O
,	O
PrP	O
or	O
prion	O
protein	O
,	O
accumulate	O
in	O
the	O
brains	O
and	O
some	O
other	O
tissues	O
of	O
all	O
species	O
affected	O
by	O
transmissible	O
spongiform	O
encephalopathies	O
or	O
prion	O
diseases	O
.	O
To	O
investigate	O
the	O
role	O
of	O
PrP	O
gene	O
expression	O
in	O
the	O
hosts	O
of	O
these	O
diseases	O
,	O
we	O
have	O
analysed	O
some	O
characteristics	O
of	O
PrP	O
gene	O
RNA	O
transcripts	O
in	O
sheep	O
and	O
cattle	O
tissues	O
and	O
made	O
comparisons	O
with	O
PrP	O
RNA	O
transcripts	O
in	O
human	O
and	O
mouse	O
tissues	O
.	O
Two	O
PrP	O
messenger	O
RNAs	O
of	O
4.6	O
kb	O
and	O
2.1	O
kb	O
,	O
the	O
result	O
of	O
alternative	O
polyadenylation	O
,	O
were	O
found	O
first	O
in	O
sheep	O
peripheral	O
tissues	O
and	O
also	O
occurred	O
at	O
low	O
levels	O
in	O
sheep	O
brain	O
and	O
bovine	O
tissues	O
,	O
but	O
not	O
in	O
human	O
and	O
mouse	O
tissues	O
.	O
Our	O
results	O
from	O
transfection	O
assays	O
of	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
with	O
constructs	O
expressing	O
different	O
regions	O
of	O
ovine	O
PrP	O
messenger	O
RNA	O
revealed	O
the	O
presence	O
of	O
sequences	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
gene	O
that	O
modulate	O
protein	O
synthesis	O
.	O
PMID	O
:	O
10466827	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocrinology	O
.	O
1991	O
Sep;129(	O
3	O
)	O
:1682	O
-4.	O
Human	O
galanin	O
:	O
molecular	O
cloning	O
reveals	O
a	O
unique	O
structure	O
.	O
Evans	O
HF	O
,	O
Shine	O
J.	O
Garvan	O
Institute	O
of	O
Medical	O
Research	O
,	O
St	O
Vincent	O
's	O
Hospital	O
,	O
Darlinghurst	O
,	O
NSW	O
,	O
Australia	O
.	O
Galanin	O
,	O
a	O
novel	O
neuropeptide	O
/	O
hypothalamic	O
hormone	O
originally	O
identified	O
and	O
isolated	O
by	O
virtue	O
of	O
its	O
carboxy-terminal	O
amide	O
group	O
,	O
has	O
recently	O
been	O
shown	O
to	O
have	O
a	O
diverse	O
range	O
of	O
biological	O
activities	O
,	O
including	O
potent	O
effects	O
on	O
the	O
secretion	O
of	O
insulin	O
and	O
growth	O
hormone	O
.	O
The	O
physiological	O
role	O
of	O
galanin	O
remains	O
unclear	O
,	O
with	O
different	O
effects	O
being	O
observed	O
when	O
porcine	O
and	O
rat	O
galanin	O
have	O
been	O
used	O
in	O
various	O
animal	O
model	O
systems	O
and	O
in	O
human	O
studies	O
.	O
Molecular	O
cloning	O
of	O
cDNA	O
encoding	O
human	O
galanin	O
and	O
galanin	O
mRNA	O
associated	O
peptide	O
(	O
GMAP	O
)	O
from	O
both	O
pituitary	O
and	O
neuroblastoma	B-malignancy-type
sources	O
has	O
revealed	O
a	O
unique	O
and	O
unexpected	O
structure	O
.	O
In	O
contrast	O
to	O
porcine	O
,	O
bovine	O
and	O
rodent	O
galanin	O
,	O
human	O
galanin	O
lacks	O
a	O
carboxy-terminal	O
amide	O
.	O
By	O
analogy	O
to	O
other	O
neurohormones	O
,	O
the	O
absence	O
of	O
carboxy-terminal	O
amidation	O
would	O
be	O
expected	O
to	O
have	O
significant	O
effects	O
on	O
functional	O
properties	O
such	O
as	O
affinity	O
for	O
different	O
receptor	O
subtypes	O
and	O
physiological	O
half	O
life	O
,	O
and	O
may	O
be	O
responsible	O
for	O
the	O
species	O
specificity	O
observed	O
in	O
the	O
action	O
of	O
galanin	O
.	O
PMID	O
:	O
1714839	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1994	O
May	O
30	O
;201	O
(	O
1	O
)	O
:	O
180	O
-5	O
.	O
Anti	O
-	O
beta	O
2	O
subunit	O
antisense	O
oligonucleotides	O
modulate	O
the	O
surface	O
expression	O
of	O
the	O
alpha	O
1	O
subunit	O
of	O
N-type	O
omega-CTX	O
sensitive	O
Ca2	O
+	O
channels	O
in	O
IMR	O
32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Tarroni	O
P,	O
Passafaro	O
M,	O
Pollo	O
A	O
,	O
Popoli	O
M,	O
Clementi	O
F	O
,	O
Sher	O
E.	O
Department	O
of	O
Medical	O
Pharmacology	O
,	O
University	O
of	O
Milan	O
,	O
Italy	O
.	O
High	O
voltage	O
activated	O
Ca2	O
+	O
channels	O
are	O
heteropolymeric	O
complexes	O
in	O
which	O
the	O
alpha	O
1	O
subunit	O
forms	O
the	O
channel	O
,	O
while	O
the	O
alpha	O
2-delta	O
and	O
beta	O
subunits	O
are	O
important	O
for	O
the	O
assembly	O
and	O
regulation	O
of	O
the	O
biophysical	O
properties	O
of	O
the	O
channel	O
.	O
We	O
have	O
tested	O
the	O
role	O
of	O
the	O
beta	O
2	O
subunit	O
on	O
the	O
expression	O
and	O
electrophysiological	O
properties	O
of	O
the	O
omega-conotoxin	O
GVIA	O
-	O
sensitive	O
Ca2	O
+	O
channel	O
expressed	O
in	O
the	O
IMR	O
32	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Anti	O
-	O
beta	O
2	O
subunit	O
antisense	O
oligonucleotides	O
supplied	O
to	O
the	O
cells	O
in	O
culture	O
induced	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
the	O
number	O
of	O
[125I]	O
-omega-conotoxin	O
binding	O
sites	O
on	O
the	O
cell	O
surface	O
,	O
which	O
was	O
not	O
paralleled	O
by	O
an	O
increase	O
in	O
current	O
amplitude	O
.	O
We	O
suggest	O
that	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
beta	O
2	O
stimulates	O
the	O
transport	O
to	O
the	O
plasma	O
membrane	O
of	O
non	O
-	O
functioning	O
Ca2	O
+	O
channels	O
and	O
,	O
in	O
particular	O
,	O
of	O
the	O
alpha	O
1	O
omega-conotoxin	O
binding	O
subunit	O
.	O
PMID	O
:	O
8198573	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Mol	O
Genet	O
.	O
1996	O
Mar;	O
5	O
(	O
3	O
)	O
:	O
309	O
-17	O
.	O
A	O
human	O
modifier	O
of	O
methylation	O
for	O
class	O
I	O
HLA	O
genes	O
(	O
MEMO-1	O
)	O
maps	O
to	O
chromosomal	O
bands	O
1p35-36.1	O
.	O
Cheng	O
NC	O
,	O
Chan	O
AJ	O
,	O
Beitsma	O
MM	O
,	O
Speleman	O
F	O
,	O
Westerveld	O
A	O
,	O
Versteeg	O
R.	O
Department	O
of	O
Human	O
Genetics	O
,	O
University	O
of	O
Amsterdam	O
.	O
Class	O
I	O
HLA	O
genes	O
are	O
expressed	O
in	O
almost	O
all	O
tissues	O
,	O
but	O
expression	O
is	O
low	O
or	O
undetectable	O
in	O
many	O
neuroblastomas	B-malignancy-type
.	O
We	O
analysed	O
class	O
I	O
HLA	O
methylation	O
in	O
normal	O
tissues	O
and	O
in	O
28	O
neuroectodermal	B-malignancy-type
tumour	I-malignancy-type
cell	O
lines	O
.	O
HLA-	O
C	O
is	O
hypermethylated	O
in	O
normal	O
adult	O
tissues	O
and	O
13	O
cell	O
lines	O
,	O
while	O
15	O
cell	O
lines	O
show	O
the	O
hypomethylated	O
phenotype	O
.	O
Hypomethylation	O
of	O
HLA-	O
C	O
strongly	O
correlates	O
with	O
hemizygous	O
deletion	O
of	O
a	O
9	O
cM	O
interval	O
on	O
1p35-36.1	O
,	O
suggesting	O
that	O
this	O
region	O
encodes	O
a	O
modifier	O
of	O
methylation	O
for	O
HLA-C	O
.	O
To	O
test	O
whether	O
hypomethylation	O
of	O
class	O
I	O
HLA	O
genes	O
results	O
from	O
loss	O
of	O
a	O
modifier	O
gene	O
,	O
we	O
fused	O
a	O
hypomethylating	O
neuroblastoma	B-malignancy-type
cell	O
line	O
with	O
a	O
hypermethylating	O
cell	O
line	O
.	O
Methylation	O
of	O
class	O
I	O
HLA	O
genes	O
was	O
induced	O
in	O
the	O
hybrids	O
.	O
Furthermore	O
,	O
methylation	O
of	O
HLA	O
-	O
C	O
,	O
-	O
E	O
and	O
-	O
A	O
genes	O
,	O
which	O
are	O
encoded	O
in	O
a	O
1.4	O
Mb	O
region	O
on	O
6p21	O
,	O
is	O
correlated	O
in	O
most	O
cell	O
lines	O
.	O
Our	O
results	O
suggest	O
that	O
1p35-36.1	O
encodes	O
a	O
modifier	O
of	O
methylation	O
for	O
class	O
I	O
HLA	O
genes	O
,	O
that	O
is	O
deleted	O
in	O
many	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
8852654	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Oct	O
4;277	O
(	O
40	O
)	O
:	O
3778	O
8	O
-	O
97	O
.	O
Epub	O
2002	O
Jul	O
30	O
.	O
The	O
adaptor	O
protein	O
Nck-1	O
couples	O
the	O
netrin-1	O
receptor	O
DCC	O
(	O
deleted	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
)	O
to	O
the	O
activation	O
of	O
the	O
small	O
GTPase	O
Rac1	O
through	O
an	O
atypical	O
mechanism	O
.	O
Li	O
X	O
,	O
Meriane	O
M,	O
Triki	O
I	O
,	O
Shekarabi	O
M,	O
Kennedy	O
TE	O
,	O
Larose	O
L,	O
Lamarche-	O
Vane	O
N	O
.	O
Department	O
of	O
Anatomy	O
and	O
Cell	O
Biology	O
,	O
McGill	O
University	O
,	O
Montreal	O
,	O
Quebec	O
H3A	O
2B2	O
,	O
Canada	O
.	O
Netrins	O
are	O
a	O
family	O
of	O
secreted	O
proteins	O
that	O
guide	O
the	O
migration	O
of	O
cells	O
and	O
axonal	O
growth	O
cones	O
during	O
development	O
.	O
DCC	O
(	O
deleted	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
)	O
is	O
a	O
receptor	O
for	O
netrin-1	O
implicated	O
in	O
mediating	O
these	O
responses	O
.	O
Here	O
,	O
we	O
show	O
that	O
DCC	O
interacts	O
constitutively	O
with	O
the	O
SH3	O
/	O
SH2	O
adaptor	O
Nck	O
in	O
commissural	O
neurons	O
.	O
This	O
interaction	O
is	O
direct	O
and	O
requires	O
the	O
SH3	O
but	O
not	O
SH2	O
domains	O
of	O
Nck-1	O
.	O
Moreover	O
,	O
both	O
DCC	O
and	O
Nck-1	O
associate	O
with	O
the	O
actin	O
cytoskeleton	O
,	O
and	O
this	O
association	O
is	O
mediated	O
by	O
DCC	O
.	O
A	O
dominant	O
negative	O
Nck-1	O
inhibits	O
the	O
ability	O
of	O
DCC	O
to	O
induce	O
neurite	O
outgrowth	O
in	O
N1E-115	O
cells	O
and	O
to	O
activate	O
Rac1	O
in	O
fibroblasts	O
in	O
response	O
to	O
netrin-1	O
.	O
These	O
studies	O
provide	O
evidence	O
for	O
an	O
important	O
role	O
of	O
mammalian	O
Nck-1	O
in	O
a	O
novel	O
signaling	O
pathway	O
from	O
an	O
extracellular	O
guidance	O
cue	O
to	O
changes	O
in	O
the	O
actin	O
-	O
based	O
cytoskeleton	O
responsible	O
for	O
axonal	O
guidance	O
.	O
PMID	O
:	O
12149262	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1975	O
Aug;72(	O
8	O
)	O
:3119	O
-	O
23	O
.	O
Gene	O
expression	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
:	O
properties	O
of	O
the	O
genome	O
.	O
Zornetzer	O
MS	O
,	O
Stein	O
GS	O
.	O
Chromatin	O
was	O
prepared	O
from	O
isolated	O
nuclei	O
of	O
proliferating	O
and	O
differentiated	O
cultures	O
of	O
C1300	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Differentiation	O
was	O
induced	O
by	O
serum	O
withdrawal	O
or	O
treatment	O
with	O
dibutyryl	O
cyclic	O
AMP	O
.	O
The	O
ability	O
to	O
support	O
DNA	O
-	O
dependent	O
RNA	O
synthesis	O
when	O
assayed	O
in	O
a	O
cell	O
-	O
free	O
system	O
is	O
three	O
times	O
greater	O
for	O
chromatin	O
from	O
proliferating	O
cells	O
.	O
Histones	O
isolated	O
from	O
proliferating	O
and	O
differentiated	O
cells	O
were	O
fractionated	O
electrophoretically	O
.	O
The	O
relative	O
amounts	O
of	O
proteins	O
present	O
in	O
the	O
five	O
major	O
histone	O
fractions	O
were	O
similar	O
.	O
In	O
contrast	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
nonhistone	O
chromosomal	O
proteins	O
synthesized	O
and	O
associated	O
with	O
the	O
genome	O
of	O
proliferating	O
and	O
differentiating	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Such	O
differences	O
are	O
reflected	O
by	O
modifications	O
in	O
the	O
electrophoretic	O
banding	O
patterns	O
and	O
in	O
incorporation	O
of	O
[3H]tryptophan	O
into	O
various	O
molecular	O
weight	O
classes	O
of	O
nonhistone	O
chromosomal	O
polypeptides	O
.	O
A	O
functional	O
relationship	O
between	O
changes	O
in	O
the	O
nonhistone	O
chromosomal	O
proteins	O
and	O
variations	O
in	O
the	O
transcriptional	O
activity	O
accompanying	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
may	O
exist	O
.	O
PMID	O
:	O
1059097	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Semin	O
Pediatr	O
Surg	O
.	O
1996	O
Aug;	O
5	O
(	O
3	O
)	O
:	O
149-	O
54	O
.	O
cDNA	O
subtraction	O
hybridization	O
:	O
a	O
review	O
and	O
an	O
application	O
to	O
neuroblastoma	B-malignancy-type
.	O
Swendeman	O
SL	O
,	O
La	O
Quaglia	O
MP	O
.	O
Department	O
of	O
Surgery	O
(	O
Pediatric	O
Surgical	O
Service	O
)	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
NY	O
10021	O
,	O
USA	O
.	O
Recent	O
advances	O
in	O
molecular	O
biological	O
techniques	O
have	O
increased	O
our	O
capability	O
to	O
distinguish	O
the	O
small	O
differences	O
in	O
gene	O
expression	O
between	O
subpopulations	O
of	O
cells	O
found	O
within	O
specific	O
tissues	O
or	O
tumor	O
isolates	O
.	O
We	O
use	O
subtractive	O
hybridization	O
or	O
subtractive	O
cloning	O
to	O
generate	O
information	O
regarding	O
genes	O
that	O
direct	O
various	O
aspects	O
of	O
mammalian	O
embryonic	O
development	O
.	O
The	O
technique	O
also	O
is	O
used	O
to	O
identify	O
genes	O
with	O
specificity	O
for	O
particular	O
tissues	O
or	O
cell	O
types	O
or	O
those	O
that	O
regulate	O
various	O
processes	O
in	O
the	O
cell	O
.	O
Also	O
,	O
subject	O
to	O
analysis	O
is	O
the	O
aberrant	O
expression	O
of	O
genes	O
involved	O
in	O
tumorigenesis	O
.	O
Another	O
use	O
is	O
analysis	O
of	O
subpopulations	O
of	O
cell	O
types	O
previously	O
identified	O
within	O
individual	O
solid	O
tumors	O
.	O
We	O
used	O
subtractive	O
cloning	O
in	O
the	O
analysis	O
of	O
cell	O
line	O
subpopulations	O
derived	O
from	O
the	O
human	O
pediatric	O
tumor	O
neuroblastoma	B-malignancy-type
.	O
This	O
has	O
resulted	O
in	O
the	O
identification	O
of	O
novel	O
genes	O
that	O
may	O
be	O
useful	O
in	O
the	O
study	O
of	O
this	O
disease	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
8858760	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1998	O
Jun;70	O
(	O
6	O
)	O
:	O
2327	O
-35	O
.	O
Effects	O
of	O
a	O
peptide	O
analogue	O
of	O
the	O
amphiphilic	O
domain	O
of	O
the	O
common	O
neurotrophin	O
receptor	O
on	O
nerve	O
growth	O
factor	O
-	O
mediated	O
motility	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Wang	O
W	O
,	O
Dostaler	O
SM	O
,	O
Lawrence	O
G	O
,	O
Ross	O
GM	O
,	O
Riopelle	O
RJ	O
,	O
Dow	O
KE.	O
Department	O
of	O
Pediatrics	O
,	O
Queen	O
's	O
University	O
,	O
Kingston	O
,	O
Ontario	O
,	O
Canada	O
.	O
Exposure	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
IMR-32	O
)	O
to	O
a	O
peptide	O
mimic	O
of	O
the	O
cytoplasmic	O
amphiphilic	O
domain	O
of	O
the	O
common	O
neurotrophin	O
receptor	O
(	O
p75NTR	O
367	O
-379	O
)	O
resulted	O
in	O
enhanced	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
mediated	O
inhibition	O
of	O
cell	O
invasion	O
in	O
vitro	O
.	O
The	O
peptide	O
also	O
enhanced	O
NGF	O
-	O
mediated	O
neurite	O
extension	O
and	O
GAP-43	O
gene	O
expression	O
but	O
had	O
no	O
effect	O
on	O
NGF	O
-	O
mediated	O
cell	O
survival	O
.	O
These	O
latter	O
functional	O
effects	O
mimicked	O
influences	O
on	O
NGF	O
-	O
mediated	O
neurite	O
growth	O
in	O
other	O
trkA	O
-	O
positive	O
cells	O
as	O
reported	O
previously	O
.	O
NGF	O
-	O
dependent	O
trkA	O
phosphorylation	O
was	O
significantly	O
enhanced	O
by	O
the	O
presence	O
of	O
the	O
peptide	O
,	O
whereas	O
high	O
-	O
affinity	O
binding	O
of	O
125I	O
-	O
NGF	O
,	O
both	O
NGF	O
receptors	O
mRNA	O
and	O
protein	O
expression	O
,	O
and	O
trkA	O
dimer	O
/	O
monomer	O
ratios	O
were	O
not	O
influenced	O
.	O
The	O
studies	O
suggest	O
that	O
ligand	O
-	O
mediated	O
trkA	O
activation	O
has	O
differential	O
effects	O
on	O
cell	O
motility	O
phenomena	O
and	O
that	O
the	O
amphiphilic	O
domain	O
of	O
p75NTR	O
has	O
a	O
role	O
in	O
this	O
differential	O
signaling	O
.	O
PMID	O
:	O
9603197	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neoplasia	O
.	O
2001	O
Jul-	O
Aug;	O
3(	O
4	O
)	O
:	O
304-13	O
.	O
Bcl-2	O
and	O
M-Myc	O
coexpression	O
increases	O
IGF-IR	O
and	O
features	O
of	O
malignant	O
growth	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Jasty	O
R	O
,	O
van	O
Golen	O
C	O
,	O
Lin	O
HJ	O
,	O
Solomon	O
G	O
,	O
Heidelberger	O
K,	O
Polverini	O
P,	O
Opipari	O
A	O
,	O
Feldman	O
E	O
,	O
Castle	O
VP	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Medical	O
College	O
of	O
Ohio	O
,	O
Toledo	O
,	O
OH	O
43614	O
,	O
USA	O
.	O
The	O
bcl-2	O
and	O
c-myc	O
oncogenes	O
cooperate	O
to	O
transform	O
multiple	O
cell	O
types	O
.	O
In	O
the	O
pediatric	O
malignancy	O
NB(	B-malignancy-type
2	I-malignancy-type
)	I-malignancy-type
,	O
Bcl-2	O
is	O
highly	O
expressed	O
.	O
In	O
tumors	O
with	O
a	O
poor	O
prognosis	O
,	O
N-Myc	O
,	O
a	O
protein	O
homologous	O
to	O
c-Myc	O
,	O
is	O
overexpressed	O
as	O
a	O
result	O
of	O
gene	O
amplification	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
Bcl-2	O
cooperates	O
with	O
N-Myc	O
to	O
bestow	O
a	O
tumorigenic	O
phenotype	O
to	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cells	O
.	O
NB	B-malignancy-type
cell	O
lines	O
that	O
at	O
baseline	O
express	O
neither	O
Bcl-2	O
nor	O
N-Myc	O
were	O
stably	O
transfected	O
to	O
express	O
these	O
gene	O
products	O
.	O
In	O
this	O
model	O
,	O
we	O
found	O
Bcl-2	O
rescues	O
N-Myc	O
-	O
expressing	O
cells	O
from	O
apoptosis	O
induced	O
by	O
serum	O
withdrawal	O
.	O
Coexpression	O
of	O
Bcl-2	O
and	O
N-Myc	O
supports	O
growth	O
in	O
low	O
serum	O
conditions	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
.	O
Similarly	O
,	O
in	O
vivo	O
tumorigenic	O
and	O
angiogenic	O
activity	O
was	O
dependent	O
on	O
coexpression	O
.	O
Our	O
data	O
further	O
suggests	O
that	O
the	O
mechanism	O
underlying	O
these	O
changes	O
involves	O
the	O
receptor	O
for	O
insulin	O
growth	O
factor	O
type	O
I	O
(	O
IGF-IR	O
)	O
.	O
PMID	O
:	O
11571630	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Pediatr	O
Surg	O
.	O
2000	O
Apr;10(	O
2	O
)	O
:	O
79	O
-	O
82	O
.	O
Neuroblastoma	B-malignancy-type
:	O
induction	O
of	O
differentiation	O
(	O
Part	O
I	O
)	O
.	O
Basical	O
science	O
in	O
pediatric	O
surgery	O
.	O
Girgert	O
R	O
,	O
Schweizer	O
P,	O
Schwable	O
J.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Tubingen	O
,	O
Germany	O
.	O
Neuroblastoma	B-malignancy-type
is	O
the	O
second	O
-most	O
common	O
solid	B-malignancy-type
tumor	I-malignancy-type
in	O
childhood	O
.	O
The	O
majority	O
of	O
patients	O
have	O
a	O
very	O
poor	O
outcome	O
due	O
to	O
aggressive	O
growth	O
and	O
metastatic	O
spread	O
.	O
In	O
contrast	O
,	O
in	O
rare	O
cases	O
,	O
spontaneous	O
regression	O
or	O
differentiation	O
towards	O
a	O
benign	O
ganglioneuroma	B-malignancy-type
are	O
observed	O
.	O
The	O
mechanism	O
leading	O
to	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
is	O
of	O
particular	O
therapeutic	O
interest	O
.	O
In	O
this	O
paper	O
we	O
report	O
the	O
results	O
of	O
our	O
attempts	O
to	O
induce	O
the	O
expression	O
of	O
genes	O
necessary	O
for	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
TrkA	O
codes	O
for	O
the	O
high	O
affinity	O
receptor	O
of	O
NGF	O
,	O
a	O
neurotrophin	O
known	O
to	O
promote	O
differentiation	O
.	O
Treatment	O
with	O
retinoic	O
acid	O
caused	O
a	O
3	O
-	O
fold	O
increase	O
of	O
the	O
trkA	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Neurofibromin	O
,	O
the	O
gene	O
product	O
of	O
the	O
NF-1	O
gene	O
,	O
is	O
involved	O
in	O
downregulation	O
of	O
the	O
activity	O
of	O
ras	O
-	O
proteins	O
.	O
In	O
contrast	O
to	O
immature	O
neuronal	O
tissues	O
in	O
mature	O
brain	O
,	O
the	O
type	O
II	O
isoform	O
of	O
neurofibromin	O
is	O
predominantly	O
expressed	O
.	O
Retinoic	O
acid	O
was	O
able	O
to	O
raise	O
the	O
proportion	O
of	O
type	O
II	O
NF-1	O
expressed	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
10877072	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gene	O
.	O
1991	O
Jun	O
30	O
;102(	O
2	O
)	O
:	O
283	O
-	O
8.	O
Isolation	O
and	O
analysis	O
of	O
a	O
human	O
cDNA	O
highly	O
homologous	O
to	O
the	O
yeast	O
gene	O
encoding	O
L17A	O
ribosomal	O
protein	O
.	O
Berchtold	O
MW	O
,	O
Berger	O
MC	O
.	O
Institut	O
fur	O
Pharmakologie	O
und	O
Biochemie	O
,	O
Zurich	O
,	O
Switzerland	O
.	O
A	O
cDNA	O
from	O
human	O
brain	O
poly(A)	O
+RNA	O
with	O
significant	O
similarity	O
to	O
the	O
gene	O
encoding	O
yeast	O
L17A	O
large	O
subunit	O
ribosomal	O
(	O
r	O
)	O
protein	O
(	O
L17A	O
)	O
was	O
isolated	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
The	O
deduced	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
of	O
140	O
aa	O
(	O
calculated	O
pI	O
of	O
10.79	O
)	O
exhibits	O
a	O
78	O
%	O
similarity	O
to	O
that	O
of	O
the	O
yeast	O
L17A	O
r	O
protein	O
(	O
88	O
%	O
when	O
conservative	O
aa	O
replacements	O
are	O
considered	O
as	O
well	O
)	O
.	O
This	O
indicates	O
that	O
L17A	O
is	O
one	O
of	O
the	O
best	O
conserved	O
r	O
-	O
proteins	O
and	O
therefore	O
may	O
play	O
a	O
critical	O
role	O
in	O
ribosome	O
function	O
.	O
In	O
contrast	O
to	O
its	O
eubacterial	O
and	O
chloroplast	O
counterparts	O
,	O
human	O
L17A	O
contains	O
an	O
N-terminal	O
extension	O
of	O
19	O
aa	O
which	O
may	O
be	O
involved	O
in	O
nuclear	O
targeting	O
of	O
the	O
r	O
-	O
protein	O
.	O
Approximately	O
five	O
to	O
seven	O
genes	O
in	O
mammalian	O
genomes	O
give	O
strong	O
hybridization	O
signals	O
when	O
probed	O
with	O
the	O
human	O
L17A	O
homologue	O
cDNA	O
.	O
Whereas	O
the	O
L17A	O
homologue	O
was	O
found	O
to	O
be	O
expressed	O
at	O
similar	O
levels	O
in	O
several	O
human	O
tissues	O
as	O
a	O
transcript	O
of	O
600	O
nucleotides	O
,	O
a	O
several	O
-	O
fold	O
higher	O
transcript	O
level	O
was	O
detected	O
in	O
the	O
rapidly	O
growing	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SK-N-BE.	O
PMID	O
:	O
1874450	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
1987	O
Jan	O
15;39	O
(	O
1	O
)	O
:73	O
-	O
6.	O
Shedding	O
of	O
GD2	O
ganglioside	O
by	O
human	O
neuroblastoma	B-malignancy-type
.	O
Ladisch	O
S	O
,	O
Wu	O
ZL	O
,	O
Feig	O
S	O
,	O
Ulsh	O
L,	O
Schwartz	O
E	O
,	O
Floutsis	O
G	O
,	O
Wiley	O
F	O
,	O
Lenarsky	O
C	O
,	O
Seeger	O
R.	O
Substantial	O
concentrations	O
of	O
the	O
cell	O
-	O
surface	O
glycosphingolipid	O
,	O
the	O
disialoganglioside	O
GD2	O
,	O
are	O
uniformly	O
present	O
in	O
human	O
neuroblastoma	B-malignancy-type
tumors	O
.	O
This	O
ganglioside	O
can	O
also	O
be	O
detected	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
neuroblastoma	B-malignancy-type
by	O
direct	O
thin	O
-	O
layer	O
chromatographic	O
analysis	O
.	O
Among	O
32	O
neuroblastoma	B-malignancy-type
patients	O
in	O
all	O
clinical	O
stages	O
studied	O
prior	O
to	O
the	O
initiation	O
of	O
treatment	O
,	O
27	O
(	O
84	O
%	O
)	O
showed	O
measurably	O
elevated	O
plasma	O
concentrations	O
of	O
GD2	O
(	O
greater	O
than	O
or	O
equal	O
to	O
50	O
pmol	O
/	O
ml	O
)	O
.	O
The	O
mean	O
level	O
(	O
545	O
+/-	O
108	O
pmol	O
/	O
ml	O
)	O
was	O
more	O
than	O
50	O
times	O
the	O
normal	O
plasma	O
GD2	O
concentration	O
of	O
less	O
than	O
or	O
equal	O
to	O
10	O
pmol	O
/	O
ml	O
.	O
Circulating	O
GD2	O
was	O
not	O
detected	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
the	O
related	O
,	O
more	O
differentiated	O
tumors	O
,	O
ganglioneuroblastoma	B-malignancy-type
and	O
ganglioneuroma	B-malignancy-type
,	O
indicating	O
an	O
association	O
of	O
the	O
shedding	O
of	O
this	O
ganglioside	O
with	O
the	O
undifferentiated	O
phenotype	O
.	O
Circulating	O
GD2	O
diminished	O
in	O
patients	O
in	O
response	O
to	O
therapy	O
,	O
and	O
reappeared	O
in	O
patients	O
whose	O
disease	O
recurred	O
.	O
The	O
results	O
suggest	O
that	O
the	O
sequential	O
determination	O
of	O
circulating	O
GD2	O
will	O
be	O
of	O
value	O
in	O
monitoring	O
individual	O
patients	O
with	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
3539825	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1991	O
May	O
1;88	O
(	O
9	O
)	O
:	O
3554	O
-	O
8.	O
Neurotrophic	O
protein	O
S100	O
beta	O
stimulates	O
glial	O
cell	O
proliferation	O
.	O
Selinfreund	O
RH	O
,	O
Barger	O
SW	O
,	O
Pledger	O
WJ	O
,	O
Van	O
Eldik	O
LJ.	O
Department	O
of	O
Pharmacology	O
,	O
Vanderbilt	O
University	O
,	O
Nashville	O
,	O
TN	O
37232	O
.	O
Nervous	O
system	O
development	O
involves	O
a	O
coordinated	O
series	O
of	O
events	O
,	O
including	O
regulation	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
by	O
specific	O
extracellular	O
factors	O
.	O
S100	O
beta	O
is	O
a	O
neurotrophic	O
protein	O
that	O
has	O
been	O
implicated	O
in	O
regulation	O
of	O
cellular	O
proliferation	O
,	O
but	O
direct	O
evidence	O
was	O
lacking	O
.	O
In	O
this	O
report	O
,	O
nanomolar	O
concentrations	O
of	O
S100	O
beta	O
are	O
shown	O
to	O
stimulate	O
proliferation	O
of	O
rat	O
C6	O
glioma	B-malignancy-type
cells	I-malignancy-type
and	O
primary	O
astrocytes	O
.	O
An	O
S100	O
mutant	O
with	O
a	O
single	O
amino	O
acid	O
change	O
was	O
inactive	O
.	O
S100	O
beta	O
also	O
stimulated	O
increases	O
in	O
the	O
steady	O
-state	O
levels	O
of	O
c-myc	O
and	O
c-	O
fos	O
protooncogene	O
mRNAs	O
and	O
complemented	O
the	O
effects	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
.	O
Two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
did	O
not	O
proliferate	O
in	O
response	O
to	O
S100	O
beta	O
,	O
suggesting	O
that	O
the	O
mitogenic	O
activity	O
of	O
S100	O
beta	O
is	O
selective	O
for	O
astroglial	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
S100	O
beta	O
may	O
be	O
involved	O
in	O
the	O
coordinate	O
development	O
and	O
maintenance	O
of	O
the	O
central	O
nervous	O
system	O
by	O
synchronously	O
stimulating	O
the	O
differentiation	O
of	O
neurons	O
and	O
the	O
proliferation	O
of	O
astroglia	O
.	O
PMID	O
:	O
1902567	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neural	O
Transm	O
.	O
1984	O
;5	O
9	O
(	O
4	O
)	O
:	O
309	O
-17	O
.	O
Herpes	O
simplex	O
virus	O
persistence	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
(	O
C	O
1300	O
)	O
cell	O
cultures	O
:	O
role	O
of	O
interferon	O
.	O
Dawson	O
GJ	O
,	O
Mowshowitz	O
SL	O
,	O
Cohen	O
R	O
,	O
Elizan	O
TS	O
.	O
The	O
Mp	O
strain	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV1	O
)	O
induced	O
a	O
persistent	O
infection	O
in	O
the	O
mouse	O
C	O
1300	O
neuronal	O
cell	O
line	O
(	O
clone	O
N	O
115	O
)	O
.	O
C	O
1300	O
cultures	O
infected	O
at	O
an	O
MOI	O
of	O
0.01	O
or	O
0.001	O
survived	O
the	O
initial	O
infection	O
and	O
continued	O
to	O
produce	O
infectious	O
virus	O
and	O
viral	O
antigens	O
for	O
185	O
days	O
and	O
31	O
days	O
,	O
respectively	O
.	O
Viral	O
antigens	O
were	O
not	O
detected	O
in	O
cultures	O
no	O
longer	O
producing	O
infectious	O
virus	B-malignancy-type
;	O
these	O
"	O
cured	O
"	O
cultures	O
had	O
comparable	O
susceptibility	O
to	O
reinfection	O
with	O
HSV	B-malignancy-type
as	O
previously	O
uninfected	O
C	O
1300	O
cells	O
.	O
While	O
significant	O
amounts	O
of	O
interferon	O
were	O
produced	O
by	O
C	O
1300	O
cells	O
when	O
challenged	O
with	O
Newcastle	O
Disease	O
Virus	O
(	O
NDV	O
)	O
or	O
when	O
treated	O
with	O
poly	O
I	O
:	O
C	O
,	O
HSV	O
-	O
induced	O
interferon	O
could	O
not	O
be	O
detected	O
in	O
either	O
the	O
acutely	O
or	O
persistently	O
infected	O
cell	O
lines	O
.	O
The	O
persistent	O
state	O
was	O
not	O
significantly	O
altered	O
by	O
the	O
addition	O
of	O
1,000	O
units	O
/	O
ml	O
of	O
murine	O
interferon	O
alpha	O
plus	O
beta	O
(	O
MuIFN	O
alpha	O
+	O
beta	O
)	O
,	O
nor	O
was	O
it	O
affected	O
by	O
the	O
addition	O
of	O
antibody	O
to	O
MuIFN	O
.	O
It	O
appears	O
that	O
IFN	O
does	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and/or	O
maintenance	O
of	O
viral	O
persistence	O
in	O
this	O
neuronal	O
system	O
.	O
PMID	O
:	O
6205121	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroscience	O
.	O
1999;91(	O
2	O
)	O
:771	O
-6.	O
Cyclic	O
AMP	O
responsive	O
element	O
binding	O
protein	O
phosphorylation	O
and	O
DNA	O
binding	O
is	O
decreased	O
by	O
chronic	O
lithium	O
but	O
not	O
valproate	O
treatment	O
of	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
.	O
Wang	O
JF	O
,	O
Asghari	O
V	O
,	O
Rockel	O
C	O
,	O
Young	O
LT.	O
Department	O
of	O
Psychiatry	O
,	O
McMaster	O
University	O
,	O
Hamilton	O
,	O
Ontario	O
,	O
Canada	O
.	O
ood	O
stabilizing	O
drugs	O
decrease	O
central	O
nervous	O
system	O
cyclic	O
AMP	O
signaling	O
.	O
We	O
report	O
here	O
that	O
chronic	O
,	O
but	O
not	O
acute	O
treatment	O
with	O
lithium	O
chloride	O
in	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
cells	O
,	O
inhibits	O
phosphorylation	O
of	O
cyclic	O
AMP	O
responsive	O
element	O
binding	O
protein	O
and	O
cyclic	O
AMP	O
responsive	O
element	O
DNA	O
binding	O
induced	O
by	O
the	O
adenylyl	O
cyclase	O
activator	O
forskolin	O
,	O
but	O
has	O
no	O
effect	O
on	O
constitutive	O
expression	O
of	O
cyclic	O
AMP	O
responsive	O
element	O
binding	O
protein	O
.	O
These	O
results	O
are	O
consistent	O
with	O
an	O
effect	O
of	O
lithium	O
to	O
blunt	O
the	O
cyclic	O
AMP	O
signal	O
transduction	O
pathway	O
.	O
Such	O
an	O
effect	O
is	O
not	O
shared	O
by	O
the	O
other	O
commonly	O
prescribed	O
mood	O
stabilizer	O
,	O
sodium	O
valproate	O
.	O
Our	O
results	O
suggest	O
that	O
cyclic	O
AMP	O
responsive	O
element	O
binding	O
protein	O
regulated	O
gene	O
expression	O
may	O
be	O
relevant	O
to	O
the	O
long-term	O
prophylactic	O
effect	O
of	O
lithium	O
.	O
Furthermore	O
,	O
sodium	O
valproate	O
,	O
which	O
is	O
also	O
effective	O
in	O
bipolar	O
disorder	O
,	O
would	O
appear	O
to	O
act	O
on	O
other	O
pathways	O
to	O
bring	O
about	O
its	O
therapeutic	O
effects	O
.	O
PMID	O
:	O
10366032	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Semin	O
Diagn	O
Pathol	O
.	O
2000	O
Aug;17(	O
3	O
)	O
:194	O
-203	O
.	O
Immunohistology	O
of	O
neuroendocrine	B-malignancy-type
and	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
.	O
Wick	O
MR.	O
Fechner	O
Laboratory	O
of	O
Surgical	O
Pathology	O
,	O
University	O
of	O
Virginia	O
Medical	O
Center	O
,	O
Charlottesville	O
2290	O
8	O
-0214	O
,	O
USA	O
.	O
Neuroendocrine	B-malignancy-type
and	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
are	O
interrelated	O
,	O
and	O
comprise	O
a	O
neoplastic	B-malignancy-type
family	O
including	O
lesions	B-malignancy-type
formerly	O
termed	O
"	O
carcinoid	B-malignancy-type
,	O
"	O
"	O
atypical	B-malignancy-type
carcinoid	I-malignancy-type
,	O
"	O
"	O
small	B-malignancy-type
cell	I-malignancy-type
undifferentiated	I-malignancy-type
carcinoma	I-malignancy-type
,	O
"	O
"	O
primitive	O
neuroepithelioma	B-malignancy-type
,	O
"	O
"	O
chemodectoma	B-malignancy-type
,	O
"	O
and	O
"	O
neuroblastoma	B-malignancy-type
,	O
"	O
to	O
name	O
but	O
a	O
few	O
entities	O
.	O
The	O
nosology	O
of	O
these	O
neoplasms	B-malignancy-type
has	O
been	O
simplified	O
recently	O
,	O
in	O
part	O
as	O
a	O
result	O
of	O
a	O
better	O
understanding	O
of	O
their	O
immunophenotypes	O
and	O
molecular	O
biological	O
attributes	O
.	O
This	O
review	O
considers	O
those	O
immunohistochemical	O
markers	O
that	O
are	O
now	O
generally	O
available	O
for	O
diagnostic	O
evaluation	O
of	O
neuroendocrine	O
and	O
neuroectodermal	O
differentiation	O
,	O
and	O
provides	O
information	O
on	O
the	O
relative	O
sensitivity	O
and	O
specificity	O
of	O
each	O
of	O
them	O
.	O
Intermediate	O
filament	O
proteins	O
,	O
chromogranins	O
,	O
synaptophysin	O
,	O
CD56	O
,	O
CD57	O
,	O
CD99	O
,	O
neuron	O
-	O
specific	O
(	O
gamma	O
-dimer	O
)	O
enolase	O
,	O
protein	O
gene	O
product	O
9.5	O
,	O
and	O
specific	O
neuropeptide	O
products	O
are	O
discussed	O
.	O
The	O
application	O
of	O
such	O
determinants	O
in	O
regional	O
differential	O
diagnosis	O
is	O
also	O
summarized	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Academic	O
PMID	O
:	O
10968705	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Minn	O
Med	O
.	O
1991	O
Aug;74(	O
8	O
)	O
:	O
23	O
-	O
6.	O
Incidentally	O
discovered	O
adrenal	O
masses	O
.	O
Caplan	O
RH	O
,	O
Kisken	O
WA	O
,	O
Huiras	O
CM	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Gundersen	O
Clinic	O
,	O
Ltd.	O
,	O
La	O
Crosse	O
,	O
Wisconsin	O
.	O
This	O
report	O
describes	O
a	O
retrospective	O
study	O
of	O
23	O
patients	O
with	O
incidentally	O
discovered	O
adrenal	O
masses	O
.	O
Two	O
patients	O
with	O
subclinical	O
cortisol	O
secretion	O
developed	O
adrenal	O
insufficiency	O
after	O
removal	O
of	O
benign	O
adenomas	B-malignancy-type
.	O
Another	O
patient	O
,	O
who	O
probably	O
harbors	O
an	O
asymptomatic	O
pheochromocytoma	B-malignancy-type
,	O
developed	O
a	O
hypertensive	O
crisis	O
when	O
a	O
mass	O
was	O
palpated	O
during	O
aortic	O
vascular	O
surgery	O
.	O
Twelve	O
patients	O
underwent	O
surgery	O
.	O
Seven	O
benign	O
adenomas	B-malignancy-type
,	O
an	O
angiomyolipoma	B-malignancy-type
,	O
and	O
a	O
cyst	O
were	O
removed	O
.	O
Three	O
patients	O
had	O
malignant	O
masses	O
that	O
include	O
an	O
angiosarcoma	B-malignancy-type
,	O
an	O
adrenal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
and	O
a	O
congenital	O
neuroblastoma	B-malignancy-type
.	O
We	O
conclude	O
that	O
hormones	O
,	O
especially	O
cortisol	O
,	O
may	O
be	O
secreted	O
in	O
subclinical	O
amounts	O
by	O
incidentally	O
discovered	O
masses	O
.	O
We	O
recommend	O
a	O
concise	O
laboratory	O
evaluation	O
that	O
includes	O
an	O
overnight	O
dexamethasone	O
suppression	O
test	O
.	O
Based	O
on	O
our	O
interpretation	O
of	O
the	O
literature	O
,	O
we	O
believe	O
masses	O
greater	O
than	O
3	O
cm	O
in	O
size	O
should	O
be	O
removed	O
.	O
Patients	O
who	O
do	O
not	O
undergo	O
surgery	O
should	O
have	O
computed	O
tomographic	O
scans	O
repeated	O
for	O
one	O
year	O
and	O
should	O
be	O
reassessed	O
periodically	O
for	O
the	O
development	O
of	O
hormone	O
secretion	O
.	O
PMID	O
:	O
1921930	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
.	O
1987	O
Dec;	O
7(	O
12	O
)	O
:	O
4266-72	O
.	O
Alternative	O
processing	O
of	O
RNA	O
transcribed	O
from	O
NMYC	O
.	O
Stanton	O
LW	O
,	O
Bishop	O
JM	O
.	O
Department	O
of	O
Microbiology	O
and	O
Immunology	O
,	O
University	O
of	O
California	O
Medical	O
Center	O
,	O
San	O
Francisco	O
94143	O
.	O
NMYC	O
is	O
a	O
gene	O
whose	O
amplification	O
and	O
overexpression	O
have	O
been	O
implicated	O
in	O
the	O
generation	O
of	O
certain	O
human	O
malignancies	O
.	O
Little	O
is	O
known	O
of	O
how	O
the	O
expression	O
of	O
NMYC	O
is	O
normally	O
controlled	O
.	O
We	O
have	O
therefore	O
characterized	O
transcription	O
from	O
the	O
gene	O
and	O
the	O
structure	O
and	O
stability	O
of	O
the	O
resulting	O
mRNAs	O
.	O
Transcription	O
from	O
NMYC	O
is	O
exceptionally	O
complex	O
:	O
it	O
initiates	O
at	O
numerous	O
sites	O
that	O
may	O
be	O
grouped	O
under	O
the	O
control	O
of	O
two	O
promoters	O
,	O
and	O
the	O
multiplicity	O
of	O
initiation	O
sites	O
combines	O
with	O
alternative	O
splicing	O
to	O
engender	O
two	O
forms	O
of	O
mRNA	O
.	O
The	O
mRNAs	O
have	O
different	O
5	O
'	O
leader	O
sequences	O
(	O
alternative	O
first	O
exons	O
of	O
the	O
gene	O
)	O
but	O
identical	O
bodies	O
(	O
the	O
second	O
and	O
third	O
exons	O
of	O
the	O
gene	O
)	O
.	O
Both	O
forms	O
of	O
mRNA	O
are	O
unstable	O
,	O
with	O
half-	O
lives	O
of	O
ca	O
.	O
15	O
min	O
.	O
Both	O
encode	O
the	O
previously	O
identified	O
65	O
,000	O
and	O
67	O
,000	O
-	O
dalton	O
products	O
of	O
NMYC	O
.	O
However	O
,	O
the	O
alternative	O
first	O
exons	O
contain	O
distinctive	O
open	O
reading	O
frames	O
that	O
may	O
diversify	O
the	O
coding	O
potential	O
of	O
NMYC	O
.	O
The	O
complexities	O
in	O
transcription	O
of	O
NMYC	O
expand	O
the	O
means	O
by	O
which	O
expression	O
of	O
the	O
gene	O
might	O
be	O
controlled	O
.	O
PMID	O
:	O
3437890	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1992	O
;28A(	O
8-	O
9	O
)	O
:	O
1319	O
-	O
23	O
.	O
Comment	O
in	O
:	O
Eur	O
J	O
Cancer	O
.	O
1992	O
;28A(	O
8-	O
9	O
)	O
:	O
1301-2.	O
Toxicity	O
of	O
single-	O
day	O
high	O
-dose	O
vincristine	O
,	O
melphalan	O
,	O
etoposide	O
and	O
carboplatin	O
consolidation	O
with	O
autologous	O
bone	O
marrow	O
rescue	O
in	O
advanced	O
neuroblastoma	B-malignancy-type
.	O
Gordon	O
SJ	O
,	O
Pearson	O
AD	O
,	O
Reid	O
MM	O
,	O
Craft	O
AW	O
.	O
Department	O
of	O
Child	O
Health	O
,	O
Medical	O
School	O
,	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
U.K.	O
16	O
unselected	O
patients	O
with	O
advanced	O
neuroblastoma	B-malignancy-type
were	O
given	O
high	O
-dose	O
consolidation	O
chemotherapy	O
with	O
vincristine	O
,	O
melphalan	O
,	O
etoposide	O
and	O
carboplatin	O
over	O
5	O
h	O
followed	O
by	O
autologous	O
bone	O
marrow	O
rescue	O
.	O
3	O
patients	O
died	O
from	O
treatment	O
-	O
related	O
toxicity	O
,	O
2	O
from	O
disease	O
,	O
1	O
is	O
alive	O
with	O
disease	O
and	O
10	O
are	O
alive	O
and	O
disease	O
-	O
free	O
a	O
median	O
of	O
12.5	O
months	O
(	O
range	O
2-38	O
months	O
)	O
after	O
bone	O
marrow	O
rescue	O
.	O
All	O
had	O
bone	O
marrow	O
toxicity	O
,	O
most	O
mucositis	O
and	O
6	O
had	O
seizures	O
.	O
Renal	O
failure	O
was	O
unexpectedly	O
severe	O
.	O
In	O
the	O
last	O
3	O
patients	O
,	O
administration	O
of	O
carboplatin	O
was	O
delayed	O
by	O
18	O
h	O
in	O
an	O
attempt	O
to	O
reduce	O
renal	O
damage	O
.	O
The	O
results	O
show	O
that	O
this	O
regimen	O
produces	O
significant	O
morbidity	O
and	O
has	O
a	O
high	O
mortality	O
.	O
Although	O
the	O
overall	O
outcome	O
is	O
encouraging	O
,	O
too	O
few	O
patients	O
have	O
been	O
studied	O
to	O
gauge	O
its	O
efficacy	O
.	O
Whether	O
such	O
aggressive	O
consolidation	O
is	O
necessary	O
in	O
heavily	O
pretreated	O
children	O
with	O
neuroblastoma	B-malignancy-type
remains	O
unknown	O
.	O
PMID	O
:	O
1515242	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
1997	O
Jul;29(	O
1	O
)	O
:	O
11-5	O
.	O
Chemotherapy	O
-	O
induced	O
expression	O
of	O
alpha	O
B-	O
crystallin	O
in	O
neuroblastoma	B-malignancy-type
.	O
Ishiguro	O
Y	O
,	O
Kato	O
K,	O
Akatsuka	O
H,	O
Iwata	O
H,	O
Nagaya	O
M.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Nagoya	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Since	O
alpha	O
B-	O
crystallin	O
is	O
known	O
to	O
be	O
expressed	O
in	O
glial	O
tissues	O
of	O
human	O
brain	O
and	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
,	O
the	O
alpha	O
B-	O
crystallin	O
content	O
of	O
neuroblastomas	B-malignancy-type
,	O
may	O
be	O
related	O
to	O
the	O
degree	O
of	O
glial	O
or	O
neuronal	O
differentiation	O
.	O
The	O
alpha	O
B-	O
crystallin	O
content	O
of	O
73	O
neuroblastomas	B-malignancy-type
,	O
was	O
determined	O
by	O
enzyme	O
immunoassay	O
.	O
The	O
concentration	O
of	O
alpha	O
B-	O
crystallin	O
was	O
examined	O
in	O
light	O
of	O
neuroblastoma	B-malignancy-type
prognostic	O
factors	O
.	O
Neuroblastomas	B-malignancy-type
from	O
patients	O
who	O
received	O
chemotherapy	O
(	O
n	O
=	O
23	O
)	O
contained	O
higher	O
concentrations	O
of	O
alpha	O
B-	O
crystallin	O
than	O
those	O
from	O
patients	O
who	O
did	O
not	O
receive	O
chemotherapy	O
(	O
n	O
=	O
50	O
)	O
(	O
P	O
>	O
0.05	O
)	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
alpha	O
B-	O
crystallin	O
concentrations	O
in	O
advanced	O
stage	O
patients	O
who	O
received	O
preoperative	O
chemotherapy	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Immunohistochemistry	O
demonstrated	O
alpha	O
B-	O
crystallin	O
expression	O
in	O
the	O
nerve	O
-	O
like	O
fibers	O
and	O
a	O
few	O
ganglion	O
-	O
like	O
cells	O
.	O
Staining	O
was	O
not	O
apparent	O
in	O
the	O
less	O
differentiated	O
cells	O
in	O
the	O
tumor	O
cell	O
nest	O
.	O
alpha	O
B-	O
crystallin	O
may	O
play	O
a	O
role	O
in	O
the	O
response	O
to	O
cellular	O
stress	O
in	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
9142199	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1998	O
Oct;34(	O
11	O
)	O
:1736-40	O
.	O
Modulation	O
of	O
the	O
proteolytic	O
balance	O
plasminogen	O
activator	O
/	O
plasminogen	O
activator	O
inhibitor	O
by	O
enhanced	O
N-myc	O
oncogene	O
expression	O
or	O
application	O
of	O
genistein	O
.	O
Garcia	O
de	O
Veas	O
R	O
,	O
Schweigerer	O
L,	O
Medina	O
MA.	O
Laboratorio	O
de	O
Bioquimica	O
y	O
Biologia	O
Molecular	O
,	O
Facultad	O
de	O
Ciencias	O
,	O
Universidad	O
de	O
Malaga	O
,	O
Spain	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
enhanced	O
expression	O
of	O
N-myc	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
affects	O
the	O
balance	O
of	O
plasminogen	O
activator	O
/	O
plasminogen	O
activator	O
inhibitor	O
(	O
PA	O
/	O
PAI	O
)	O
,	O
a	O
shift	O
towards	O
proteolysis	O
having	O
been	O
observed	O
in	O
other	O
malignant	O
tissues	O
.	O
Two	O
transfected	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
(	O
WAC2	O
cells	O
)	O
or	O
without	O
(	O
SH-EP007	O
cells	O
)	O
enhanced	O
expression	O
of	O
the	O
N-myc	O
oncogene	O
were	O
examined	O
by	O
zymography	O
and	O
RNA	O
extraction	O
to	O
determine	O
UPA	O
and	O
PAI	O
enzyme	O
activity	O
and	O
uPA	O
RNA	O
and	O
PAI	O
RNA	O
expression	O
,	O
respectively	O
.	O
The	O
effect	O
of	O
genistein	O
,	O
an	O
inhibitor	O
of	O
tyrosine	O
protein	O
kinase	O
,	O
on	O
uPA	O
/	O
PAI	O
was	O
also	O
investigated	O
.	O
Both	O
the	O
uPA	O
/	O
PAI-1	O
ratio	O
at	O
mRNA	O
level	O
and	O
the	O
PA	O
/	O
PAI	O
ratio	O
at	O
protein	O
activity	O
level	O
were	O
higher	O
in	O
the	O
more	O
malignant	O
,	O
WAC2	O
cell	O
line	O
.	O
Genistein	O
attenuated	O
uPA	O
activity	O
and	O
stimulated	O
PAI	O
activity	O
in	O
both	O
cell	O
lines	O
,	O
leading	O
to	O
a	O
decrease	O
in	O
the	O
PA	O
/	O
PAI	O
ratio	O
.	O
This	O
effect	O
was	O
more	O
pronounced	O
in	O
the	O
more	O
malignant	O
,	O
WAC2	O
cell	O
line	O
.	O
PMID	O
:	O
9893662	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1993	O
Aug	O
31	O
;195	O
(	O
1	O
)	O
:	O
442-8.	O
Neuron	O
-	O
specific	O
splicing	O
of	O
the	O
Alzheimer	O
amyloid	O
precursor	O
protein	O
gene	O
in	O
a	O
mini-	O
gene	O
system	O
.	O
Yamada	O
T	O
,	O
Goto	O
I	O
,	O
Sakaki	O
Y	O
.	O
Department	O
of	O
Neurology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Several	O
forms	O
of	O
Alzheimer	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
mRNA	O
are	O
generated	O
by	O
alternative	O
splicing	O
.	O
Among	O
them	O
,	O
the	O
APP695	O
mRNA	O
skipping	O
the	O
exon	O
7	O
and	O
8	O
is	O
expressed	O
specifically	O
in	O
neurons	O
,	O
suggesting	O
that	O
this	O
alternative	O
splicing	O
is	O
regulated	O
in	O
a	O
neuron	O
-	O
specific	O
manner	O
.	O
As	O
the	O
first	O
step	O
for	O
investigating	O
the	O
mechanism	O
of	O
the	O
neuron	O
-	O
specific	O
splicing	O
,	O
a	O
mini-	O
gene	O
system	O
was	O
developed	O
,	O
in	O
which	O
mini-	O
APP	O
genes	O
consisting	O
of	O
the	O
exon	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
and	O
their	O
flanking	O
regions	O
were	O
introduced	O
into	O
neuronal	O
and	O
nonneuronal	O
cultured	O
cell	O
lines	O
to	O
see	O
their	O
expression	O
profiles	O
.	O
In	O
the	O
system	O
the	O
exon	O
7	O
and	O
8	O
of	O
the	O
mini-	O
gene	O
were	O
significantly	O
skipped	O
in	O
the	O
neuronal	O
cell	O
,	O
and	O
the	O
deletion	O
study	O
indicated	O
that	O
cis	O
-	O
acting	O
elements	O
for	O
skipping	O
the	O
exons	O
existed	O
in	O
the	O
corresponding	O
skipped	O
-	O
exon	O
and	O
its	O
flanking	O
regions	O
.	O
A	O
small	O
deletion	O
upstream	O
of	O
the	O
exon	O
8	O
suppressed	O
the	O
skipping	O
of	O
the	O
exon	O
8	O
in	O
the	O
neuronal	O
cell	O
,	O
suggesting	O
that	O
one	O
of	O
the	O
regulatory	O
sequence(s)	O
for	O
the	O
exon	O
skipping	O
exists	O
in	O
a	O
small	O
region	O
upstream	O
of	O
the	O
skipped	O
exon	O
.	O
PMID	O
:	O
8363619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
2001	O
Nov	O
13;314(	O
1-2	O
)	O
:	O
61	O
-4.	O
Hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
-	O
deficiency	O
produces	O
aberrant	O
neurite	O
outgrowth	O
of	O
rodent	O
neuroblastoma	B-malignancy-type
used	O
to	O
model	O
the	O
neurological	O
disorder	O
Lesch	B-malignancy-type
Nyhan	I-malignancy-type
syndrome	I-malignancy-type
.	O
Connolly	O
GP	O
.	O
Purine	O
NeuroScience	O
Laboratory	O
,	O
Chemical	O
Pathology	O
,	O
Guy	O
's	O
King	O
's	O
and	O
St.	O
Thomas	O
'	O
Medical	O
School	O
,	O
Kings	O
College	O
London	O
,	O
Guy	O
's	O
Hospital	O
,	O
London	O
SE1	O
9RT	O
,	O
UK.	O
g.connolly@ucl	O
.ac.uk	O
Lesch	B-malignancy-type
Nyhan	I-malignancy-type
syndrome	I-malignancy-type
(	O
LNS	B-malignancy-type
)	O
manifests	O
in	O
bizarre	O
and	O
horrific	O
neurological	O
symptoms	O
,	O
the	O
primary	O
cause	O
being	O
a	O
deficiency	O
of	O
the	O
purine	O
salvage	O
enzyme	O
,	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HGPRT	O
)	O
.	O
How	O
and	O
why	O
this	O
enzyme	O
deficiency	O
leads	O
to	O
abnormal	O
brain	O
development	O
is	O
unknown	O
.	O
To	O
investigate	O
this	O
phenomenon	O
the	O
present	O
study	O
was	O
designed	O
to	O
examine	O
if	O
the	O
growth	O
of	O
two	O
HGPRT	O
-	O
deficient	O
neuroblastomas	B-malignancy-type
,	O
mouse	O
N2aTG	O
and	O
rat	O
B103-4C	O
was	O
different	O
with	O
respect	O
to	O
their	O
corresponding	O
control	O
cell	O
lines	O
,	O
N2a	O
and	O
B103	O
.	O
Data	O
is	O
provided	O
showing	O
that	O
compared	O
to	O
control	O
cell	O
lines	O
,	O
HGPRT	O
-	O
deficient	O
cells	O
proliferated	O
less	O
and	O
exhibited	O
greater	O
morphological	O
complexity	O
.	O
If	O
these	O
abnormalities	O
occur	O
during	O
neurogenesis	O
of	O
human	O
HGPRT	O
-	O
deficient	O
brain	O
neurones	O
,	O
they	O
could	O
profoundly	O
influence	O
central	O
nervous	O
system	O
development	O
and	O
thus	O
,	O
may	O
form	O
the	O
aetiological	O
basis	O
for	O
the	O
symptoms	O
of	O
LNS	B-malignancy-type
.	O
PMID	O
:	O
11698147	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
Res	O
.	O
1989	O
Jul;23(	O
3	O
)	O
:274	O
-	O
81	O
.	O
Induction	O
of	O
morphological	O
differentiation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
is	O
accompanied	O
by	O
induction	O
of	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
.	O
Neuman	O
T	O
,	O
Stephens	O
RW	O
,	O
Salonen	O
EM	O
,	O
Timmusk	O
T	O
,	O
Vaheri	O
A	O
.	O
Department	O
of	O
Virology	O
,	O
University	O
of	O
Helsinki	O
,	O
Finland	O
.	O
Human	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
treated	O
with	O
retinoic	O
acid	O
,	O
12-O-tetradecanoyl-phorbol-13	O
-acetate	O
(	O
TPA	O
)	O
or	O
nerve	O
growth	O
factor	O
differentiated	O
morphologically	O
to	O
neuronlike	O
cells	O
with	O
increased	O
amounts	O
of	O
neurofilament	O
protein	O
and	O
mRNA	O
.	O
All	O
three	O
effectors	O
induced	O
an	O
increase	O
in	O
the	O
amount	O
of	O
relative	O
molecular	O
weight	O
(	O
Mr	O
)	O
70	O
,000	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
t-	O
PA	O
)	O
and	O
its	O
mRNA	O
,	O
as	O
determined	O
by	O
immunocapture	O
,	O
enzyme	O
activity	O
,	O
and	O
Northern	O
blotting	O
analyses	O
.	O
About	O
90	O
%	O
of	O
the	O
t	O
-	O
PA	O
activity	O
was	O
secreted	O
to	O
the	O
culture	O
medium	O
.	O
In	O
contrast	O
,	O
of	O
the	O
three	O
effectors	O
studied	O
,	O
only	O
TPA	O
induced	O
transcription	O
of	O
the	O
proto	O
-	O
oncogene	O
c-	O
fos	O
,	O
studied	O
as	O
a	O
control	O
gene	O
responsive	O
to	O
various	O
stimuli	O
,	O
and	O
induced	O
a	O
rapid	O
increase	O
in	O
urokinase	O
-	O
type	O
PA	O
(	O
u-PA	O
)	O
.	O
Most	O
of	O
the	O
u-PA	O
activity	O
induced	O
by	O
TPA	O
remained	O
cell	O
-associated	O
.	O
Because	O
induction	O
of	O
differentiation	O
correlated	O
closely	O
with	O
induction	O
of	O
t	O
-	O
PA	O
,	O
and	O
not	O
u-PA	O
,	O
the	O
authors	O
propose	O
that	O
t	O
-	O
PA	O
may	O
have	O
a	O
functional	O
role	O
in	O
the	O
morphological	O
differentiation	O
of	O
neuronal	O
cells	O
.	O
PMID	O
:	O
2504935	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
J.	O
1989	O
Jan	O
15	O
;257	O
(	O
2	O
)	O
:	O
375	O
-	O
82	O
.	O
Purification	O
of	O
a	O
growth	O
factor	O
related	O
to	O
platelet	O
-	O
derived	O
growth	O
factor	O
and	O
a	O
type	O
beta	O
transforming	O
growth	O
factor	O
secreted	O
by	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
A	O
general	O
strategy	O
for	O
the	O
purification	O
of	O
basic	O
polypeptide	O
growth	O
factors	O
.	O
Van	O
den	O
Eijnden	O
-	O
Van	O
Raaij	O
AJ	O
,	O
Koornneef	O
I	O
,	O
Van	O
Oostwaard	O
TM	O
,	O
Feyen	O
A	O
,	O
Kruijer	O
W	O
,	O
De	O
Laat	O
SW	O
,	O
Van	O
Zoelen	O
EJ.	O
Hubrecht	O
Laboratory	O
,	O
Netherlands	O
Institute	O
for	O
Developmental	O
Biology	O
,	O
Utrecht	O
,	O
The	O
Netherlands	O
.	O
A	O
general	O
strategy	O
was	O
developed	O
for	O
the	O
purification	O
of	O
basic	O
polypeptide	O
growth	O
factors	O
.	O
This	O
method	O
is	O
a	O
combination	O
of	O
gel	O
filtration	O
,	O
weak-cation	O
-	O
exchange	O
h.p.l	O
.c.	O
and	O
reverse	O
-phase	O
h.p.l	O
.c.	O
,	O
separating	O
the	O
proteins	O
according	O
to	O
size	O
,	O
charge	O
and	O
hydrophobicity	O
respectively	O
.	O
All	O
steps	O
are	O
carried	O
out	O
at	O
low	O
pH	O
with	O
exclusively	O
volatile	O
acidic	O
buffer	O
solutions	O
.	O
The	O
sterile	O
conditions	O
and	O
easy	O
removal	O
of	O
salt	O
by	O
freeze-	O
drying	O
facilitate	O
the	O
detection	O
of	O
the	O
growth	O
factors	O
by	O
biological	O
assays	O
.	O
By	O
using	O
this	O
method	O
,	O
homogeneous	O
preparations	O
of	O
two	O
basic	O
growth	O
factors	O
were	O
purified	O
in	O
high	O
yield	O
from	O
mouse	O
-	O
neuroblastoma	B-malignancy-type
-	O
Neuro	O
-	O
2A	O
-	O
cell	O
-conditioned	O
medium	O
.	O
It	O
is	O
shown	O
that	O
these	O
purified	O
factors	O
are	O
biochemically	O
and	O
immunologically	O
related	O
to	O
platelet	O
-	O
derived	O
growth	O
factor	O
and	O
type	O
beta	O
transforming	O
growth	O
factor	O
from	O
human	O
platelets	O
.	O
PMID	O
:	O
2930456	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncodev	O
Biol	O
Med	O
.	O
1981	O
;2	O
(	O
1-2	O
)	O
:77	O
-	O
87	O
.	O
Progressive	O
growth	O
of	O
transplanted	O
tumors	O
is	O
accompanied	O
by	O
increasing	O
serum	O
concentrations	O
of	O
murine	O
gamma	O
fetal	O
antigen	O
.	O
Higgins	O
PJ	O
,	O
Marucs	O
S	O
,	O
Hawrylko	O
E.	O
BALB/	O
c	O
mice	O
bearing	O
growing	O
Meth	B-malignancy-type
A	I-malignancy-type
sarcomas	I-malignancy-type
developed	O
gradually	O
increasing	O
serum	O
concentrations	O
of	O
the	O
tumor	O
-	O
associated	O
murine	O
gamma	O
fetal	O
antigen	O
(	O
gamma-FA	O
)	O
,	O
a	O
trend	O
which	O
could	O
be	O
reversed	O
by	O
surgical	O
excision	O
of	O
the	O
tumor	O
tissue	O
.	O
This	O
antigen	O
was	O
not	O
detected	O
in	O
the	O
sera	O
of	O
normal	O
adult	O
mice	O
or	O
in	O
the	O
sera	O
of	O
animals	O
with	O
non	O
-	O
neoplastic	O
proliferative	O
condition	O
.	O
Although	O
gamma-FA	O
occurs	O
in	O
splenic	O
tissue	O
,	O
its	O
concentration	O
in	O
tumor	O
-	O
bearer	O
serum	O
was	O
unaffected	O
by	O
splenectomy	O
suggesting	O
that	O
gamma-FA	O
is	O
not	O
released	O
by	O
the	O
spleen	O
in	O
response	O
to	O
tumor	O
growth	O
.	O
Agar	O
gel	O
precipitin	O
and	O
radioimmunoprecipitation	O
assays	O
,	O
using	O
antisera	O
prepared	O
to	O
the	O
major	O
internal	O
protein	O
(	O
P	O
30	O
)	O
and	O
external	O
glycoprotein	O
(	O
gp	O
70	O
)	O
of	O
Rauscher	O
murine	O
leukemia	B-malignancy-type
virus	O
and	O
to	O
the	O
secondary	O
glycoprotein	O
(	O
gp	O
34	O
)	O
of	O
mouse	O
mammary	B-malignancy-type
tumor	I-malignancy-type
virus	O
,	O
indicated	O
that	O
gamma-FA	O
is	O
not	O
a	O
major	O
structural	O
component	O
of	O
the	O
more	O
wide	O
-	O
spread	O
murine	O
retroviruses	O
.	O
The	O
appearance	O
of	O
gamma-FA	O
in	O
the	O
sera	O
of	O
tumor	O
-	O
bearing	O
mice	O
may	O
reflect	O
the	O
ectopic	O
activation	O
of	O
a	O
specific	O
cellular	O
gene	O
,	O
the	O
expression	O
of	O
which	O
bears	O
some	O
relationship	O
to	O
neoplastic	B-malignancy-type
transformation	O
.	O
PMID	O
:	O
6795603	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1993	O
May	O
15	O
;	O
71	O
(	O
10	O
Suppl	O
)	O
:	O
3310-3	O
.	O
Disordered	O
differentiation	O
as	O
a	O
target	O
for	O
novel	O
approaches	O
to	O
the	O
treatment	O
of	O
neuroblastoma	B-malignancy-type
.	O
Israel	O
MA	O
.	O
Pediatrics	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
.	O
Some	O
childhood	O
malignant	O
neoplasms	B-malignancy-type
are	O
thought	O
to	O
arise	O
in	O
embryonic	O
tissues	O
.	O
These	O
tumors	O
present	O
unique	O
opportunities	O
for	O
studying	O
the	O
maturation	O
of	O
specific	O
cellular	O
lineages	O
and	O
examining	O
the	O
possible	O
role	O
of	O
alterations	O
in	O
the	O
regulation	O
of	O
differentiation	O
in	O
tumor	O
development	O
.	O
Several	O
features	O
of	O
neuroblastoma	B-malignancy-type
,	O
a	O
tumor	O
thought	O
to	O
arise	O
in	O
cells	O
originating	O
in	O
the	O
embryonic	O
neural	O
crest	O
,	O
suggest	O
that	O
it	O
may	O
be	O
particularly	O
useful	O
in	O
this	O
regard	O
.	O
The	O
identification	O
of	O
a	O
series	O
of	O
markers	O
that	O
characterize	O
the	O
various	O
cell	O
types	O
of	O
the	O
peripheral	O
nervous	O
system	O
that	O
are	O
detectable	O
in	O
neuroblastoma	B-malignancy-type
tumor	O
tissues	O
has	O
made	O
it	O
possible	O
to	O
recognize	O
that	O
the	O
cells	O
of	O
neuroblastoma	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
and	O
tissues	O
correspond	O
to	O
specific	O
stages	O
of	O
adrenal	O
gland	O
development	O
.	O
Experiments	O
directed	O
at	O
understanding	O
the	O
cellular	O
signals	O
by	O
which	O
neural	O
crest	O
cell	O
maturation	O
is	O
mediated	O
may	O
provide	O
insights	O
of	O
therapeutic	O
import	O
because	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
corresponding	O
to	O
some	O
stages	O
of	O
differentiation	O
respond	O
very	O
differently	O
to	O
nonspecific	O
cytotoxic	O
therapies	O
than	O
tumors	O
corresponding	O
to	O
other	O
stages	O
.	O
PMID	O
:	O
8490873	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Acta	O
Cytol	O
.	O
2000	O
Jul-Aug	O
;	O
44	O
(	O
4	O
)	O
:	O
543-6	O
.	O
Bull's	O
eye	O
(	O
target	O
)	O
inclusions	O
in	O
neoplastic	B-malignancy-type
cells	I-malignancy-type
in	O
malignant	O
serous	O
effusions	O
.	O
A	O
study	O
of	O
289	O
cases	O
.	O
Kumar	O
PV	O
,	O
Eqbali	O
S	O
,	O
Monabati	O
A	O
,	O
Talei	O
AR	O
.	O
Department	O
of	O
Pathology	O
,	O
Shiraz	O
Medical	O
School	O
,	O
Shiraz	O
University	O
of	O
Medical	O
Sciences	O
,	O
Iran	O
.	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
prevalence	O
and	O
significance	O
of	O
bull's	O
eye	O
(	O
target	O
)	O
inclusions	O
in	O
neoplastic	B-malignancy-type
cells	I-malignancy-type
in	O
malignant	O
serous	O
effusions	O
.	O
STUDY	O
DESIGN	O
:	O
We	O
reviewed	O
malignant	O
pleural	O
,	O
peritoneal	O
and	O
pericardial	O
effusions	O
from	O
289	O
patients	O
who	O
had	O
proven	O
cancer	O
at	O
known	O
primary	O
sites	O
.	O
The	O
ages	O
of	O
the	O
patients	O
ranged	O
from	O
5	O
to	O
72	O
years	O
;	O
166	O
were	O
male	O
and	O
123	O
female	O
.	O
RESULTS	O
:	O
Bull's	O
eye	O
inclusions	O
are	O
an	O
uncommon	O
finding	O
and	O
appeared	O
in	O
only	O
13	O
cases	O
of	O
metastatic	O
adenocarcinoma	B-malignancy-type
of	O
the	O
breast	B-malignancy-type
,	O
stomach	B-malignancy-type
,	O
colon	B-malignancy-type
,	O
lung	B-malignancy-type
,	O
ovary	B-malignancy-type
,	O
pancreas	B-malignancy-type
and	O
urinary	B-malignancy-type
bladder	I-malignancy-type
.	O
They	O
were	O
positively	O
stained	O
with	O
periodic	O
acid-Schiff	O
stain	O
with	O
diastase	O
.	O
The	O
inclusions	O
were	O
not	O
seen	O
in	O
cells	O
of	O
nonadenocarcinomatous	B-malignancy-type
neoplasms	I-malignancy-type
,	O
such	O
as	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
oat	B-malignancy-type
cell	I-malignancy-type
(	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
carcinoma	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
lymphoma	B-malignancy-type
and	O
germ	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
CONCLUSION	O
:	O
Bull's	O
eye	O
inclusions	O
are	O
found	O
in	O
about	O
5%	O
of	O
malignant	O
serous	O
effusions	O
containing	O
cells	O
of	O
metastatic	O
adenocarcinoma	B-malignancy-type
.	O
The	O
primary	O
site	O
of	O
an	O
adenocarcinoma	B-malignancy-type
cannot	O
be	O
deduced	O
on	O
the	O
basis	O
of	O
the	O
presence	O
of	O
inclusions	O
.	O
PMID	O
:	O
10934946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Genet	O
Cytogenet	O
.	O
1982	O
Mar	O
;	O
5	O
(	O
3	O
)	O
:	O
203-13	O
.	O
Bilateral	B-malignancy-type
retinoblastoma	I-malignancy-type
with	O
ectopic	B-malignancy-type
intracranial	I-malignancy-type
retinoblastoma	I-malignancy-type
:	O
trilateral	B-malignancy-type
retinoblastoma	I-malignancy-type
.	O
Bader	O
JL	O
,	O
Meadows	O
AT	O
,	O
Zimmerman	O
LE	O
,	O
Rorke	O
LB	O
,	O
Voute	O
PA	O
,	O
Champion	O
LA	O
,	O
Miller	O
RW	O
.	O
In	O
11	O
patients	O
,	O
bilateral	B-malignancy-type
retinoblastoma	I-malignancy-type
presented	O
at	O
a	O
mean	O
age	O
of	O
6	O
months	O
and	O
pineoblastoma	B-malignancy-type
at	O
4	O
years	O
.	O
We	O
suggest	O
that	O
the	O
hereditary	O
multicentric	O
retinoblastoma	B-malignancy-type
arose	O
in	O
vestigeal	O
photoreceptors	O
in	O
the	O
pineal	O
as	O
well	O
as	O
in	O
the	O
hypothetical	O
retinoblasts	O
of	O
the	O
retina	O
.	O
In	O
certain	O
lower	O
animals	O
,	O
the	O
pineal	O
functions	O
as	O
a	O
photoreceptor	O
organ	O
,	O
resembles	O
the	O
retina	O
histologically	O
,	O
and	O
is	O
described	O
as	O
a	O
"	O
third	O
eye	O
.	O
"	O
Hence	O
,	O
the	O
patients	O
we	O
describe	O
may	O
be	O
considered	O
as	O
having	O
"	O
trilateral	B-malignancy-type
retinoblastoma	I-malignancy-type
.	O
"	O
Two	O
possible	O
variants	O
of	O
this	O
entity	O
were	O
also	O
noted	O
:	O
(	O
1	O
)	O
three	O
children	O
without	O
retinoblastoma	B-malignancy-type
with	O
rosettes	O
and	O
photoreceptor	O
differentiation	O
characteristic	O
of	O
retinoblastoma	B-malignancy-type
,	O
and	O
(	O
2	O
)	O
three	O
additional	O
cases	O
involving	O
children	O
who	O
presented	O
with	O
retinoblastoma	B-malignancy-type
-	I-malignancy-type
like	I-malignancy-type
tumors	I-malignancy-type
in	O
the	O
suprasellar	O
or	O
parasellar	O
region	O
2	O
to	O
6	O
months	O
before	O
the	O
discovery	O
of	O
intraocular	B-malignancy-type
retinoblastoma	I-malignancy-type
.	O
These	O
observations	O
suggest	O
that	O
the	O
retinoblastoma	O
gene	O
confers	O
a	O
previously	O
unappreciated	O
susceptibility	O
to	O
a	O
narrow	O
spectrum	O
of	O
neuroblastic	B-malignancy-type
tumors	I-malignancy-type
,	O
which	O
usually	O
present	O
in	O
the	O
retina	O
but	O
which	O
can	O
also	O
occur	O
ectopically	O
.	O
PMID	O
:	O
7066879	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Life	O
Sci	O
.	O
1995	O
;	O
56	O
(	O
10	O
)	O
:	O
PL219-24	O
.	O
Inhibition	O
of	O
plasma	O
membrane	O
Ca(2+)-ATPase	O
pump	O
activity	O
in	O
cultured	O
C6	B-malignancy-type
glioma	I-malignancy-type
cells	I-malignancy-type
by	O
halothane	O
and	O
xenon	O
.	O
Singh	O
G	O
,	O
Janicki	O
PK	O
,	O
Horn	O
JL	O
,	O
Janson	O
VE	O
,	O
Franks	O
JJ.	O
Department	O
of	O
Anesthesiology	O
,	O
Vanderbilt	O
University	O
Medical	O
Center	O
,	O
Nashville	O
,	O
TN	O
37232	O
.	O
We	O
have	O
compared	O
the	O
effect	O
of	O
two	O
inhalational	O
anesthetics	O
,	O
halothane	O
and	O
xenon	O
,	O
on	O
Ca(2+)-ATPase	O
(	O
PMCA	O
)	O
pumping	O
activity	O
in	O
plasma	O
membrane	O
vesicles	O
prepared	O
from	O
cultured	O
rat	O
C6	B-malignancy-type
glioma	I-malignancy-type
cells	I-malignancy-type
.	O
Halothane	O
,	O
at	O
concentrations	O
ranging	O
from	O
0.5	O
to	O
1.75	O
vol%	O
(	O
equivalent	O
to	O
0.5	O
to	O
1.6	O
MAC	O
)	O
,	O
significantly	O
inhibited	O
Ca2+	O
uptake	O
(	O
transport	O
)	O
by	O
plasma	O
membrane	O
vesicles	O
in	O
a	O
dose	O
-	O
related	O
fashion	O
.	O
Xenon	O
,	O
at	O
partial	O
pressures	O
ranging	O
from	O
0.5	O
to	O
1.5	O
atm	O
(	O
equivalent	O
to	O
0.5	O
to	O
1.6	O
MAC	O
)	O
,	O
similarly	O
inhibited	O
PMCA	O
pumping	O
activity	O
.	O
Additive	O
effects	O
on	O
suppression	O
of	O
PMCA	O
pump	O
activity	O
were	O
observed	O
when	O
C6	B-malignancy-type
cell	I-malignancy-type
plasma	O
membrane	O
vesicles	O
were	O
exposed	O
to	O
increasing	O
partial	O
pressures	O
of	O
xenon	O
in	O
the	O
presence	O
of	O
halothane	O
(	O
1	O
vol%	O
)	O
.	O
Halothane	O
also	O
inhibited	O
PMCA	O
pumping	O
in	O
cells	O
from	O
two	O
other	O
lines	O
of	O
neural	O
origin	O
,	O
B104	O
(	O
rat	O
neuroblastoma	B-malignancy-type
)	O
and	O
PC12	O
(	O
rat	O
pheochromocytoma	B-malignancy-type
)	O
.	O
Studies	O
described	O
in	O
this	O
report	O
support	O
the	O
thesis	O
that	O
PMCA	O
in	O
cells	O
of	O
neural	O
origin	O
is	O
inhibited	O
by	O
quite	O
different	O
inhalational	O
anesthetics	O
at	O
clinically	O
relevant	O
concentrations	O
.	O
PMID	O
:	O
7885185	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neurosci	O
Lett	O
.	O
1999	O
Oct	O
8	O
;	O
273	O
(	O
3	O
)	O
:	O
167-70	O
.	O
Characterization	O
of	O
a	O
putative	O
calcitonin	O
receptor	O
in	O
IMR	O
32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Spampinato	O
S	O
,	O
Falcucci	O
B	O
,	O
Cacciaguerra	O
S	O
,	O
Campana	O
G	O
,	O
Murari	O
G	O
.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Bologna	O
,	O
Italy	O
.	O
spampi@biocfarm.unibo.it	O
In	O
this	O
study	O
we	O
characterized	O
calcitonin	O
(	O
CT	O
)	O
receptors	O
in	O
human	O
neuroblastoma	B-malignancy-type
IMR	O
32	O
cells	O
.	O
Saturation	O
binding	O
assays	O
indicated	O
that	O
[125I]-human	O
CT	O
bound	O
with	O
high	O
affinity	O
to	O
IMR	O
32	O
cell	O
membranes	O
(	O
K(d)	O
=	O
253.6	O
pM	O
;	O
Bmax	O
=	O
3.84	O
fmol	O
/	O
mg	O
protein	O
)	O
.	O
In	O
competition	O
binding	O
studies	O
,	O
human	O
adrenomedullin	O
displayed	O
high	O
affinity	O
for	O
these	O
sites	O
(	O
IC50	O
=	O
30	O
nM	O
)	O
whereas	O
human	O
alpha	O
calcitonin	O
-	O
gene	O
related	O
peptide	O
(	O
alphaCGRP	O
;	O
IC50	O
=	O
145	O
nM	O
)	O
and	O
human	O
amylin	O
(	O
IC50	O
=	O
415	O
nM	O
)	O
showed	O
lower	O
affinity	O
.	O
These	O
peptides	O
increased	O
cAMP	O
levels	O
in	O
viable	O
cells	O
;	O
the	O
relative	O
potencies	O
were	O
:	O
human	O
CT	O
>	O
human	O
adrenomedullin	O
>	O
human	O
cCGRP	O
>	O
or	O
=	O
human	O
amylin	O
.	O
The	O
expression	O
of	O
mRNA	O
coding	O
for	O
the	O
published	O
sequences	O
of	O
the	O
human	O
calcitonin	O
receptor	O
and	O
of	O
the	O
human	O
calcitonin	O
receptor	O
-	O
like	O
receptorwas	O
evaluated	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O
Electrophoretic	O
analysis	O
did	O
not	O
confirm	O
the	O
occurrence	O
of	O
mRNA	O
coding	O
for	O
the	O
above	O
mentioned	O
receptors	O
in	O
these	O
cells	O
.	O
This	O
study	O
suggests	O
the	O
presence	O
of	O
a	O
novel	O
,	O
putative	O
CT	O
receptor	O
in	O
IMR	O
32	O
cells	O
.	O
PMID	O
:	O
10515185	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Med	O
Pediatr	O
Oncol	O
.	O
2000	O
Dec;35	O
(	O
6	O
)	O
:	O
512-5	O
.	O
Identification	O
of	O
a	O
1-megabase	O
consensus	O
region	O
of	O
deletion	O
at	O
1p36.3	O
in	O
primary	O
neuroblastomas	B-malignancy-type
.	O
Hogarty	O
MD	O
,	O
Liu	O
X	O
,	O
Guo	O
C	O
,	O
Thompson	O
PM	O
,	O
Weiss	O
MJ	O
,	O
White	O
PS	O
,	O
Sulman	O
EP	O
,	O
Brodeur	O
GM	O
,	O
Maris	O
JM	O
.	O
Division	O
of	O
Oncology	O
,	O
The	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
Philadelphia	O
,	O
Pennsylvania	O
19104-4318	O
,	O
USA	O
.	O
hogartym@email	O
.chop.edu	O
BACKGROUND	O
:	O
Deletion	O
of	O
the	O
distal	O
short	O
arm	O
of	O
chromosome	O
1	O
occurs	O
frequently	O
in	O
neuroblastoma	B-malignancy-type
.	O
In	O
addition	O
,	O
neuroblastoma	B-malignancy-type
has	O
been	O
described	O
in	O
children	O
with	O
constitutional	O
deletions	O
within	O
1p36	O
,	O
supporting	O
the	O
existence	O
of	O
one	O
or	O
more	O
neuroblastoma	O
suppressor	O
genes	O
within	O
this	O
region	O
.	O
PROCEDURE	O
:	O
We	O
have	O
pursued	O
a	O
1p36	O
tumor	O
suppressor	O
gene	O
identification	O
strategy	O
that	O
has	O
included	O
deletion	O
mapping	O
of	O
566	O
primary	O
neuroblastomas	B-malignancy-type
and	O
46	O
neuroblastoma	B-malignancy-type
-	O
derived	O
cell	O
lines	O
,	O
and	O
have	O
determined	O
the	O
parental	O
origin	O
of	O
the	O
deleted	O
1p	O
homologue	O
in	O
44	O
cases	O
to	O
determine	O
whether	O
there	O
is	O
evidence	O
for	O
genomic	O
imprinting	O
within	O
this	O
region	O
.	O
RESULTS	O
AND	O
CONCLUSIONS	O
:	O
We	O
have	O
identified	O
a	O
1-Mb	O
consensus	O
region	O
of	O
deletion	O
within	O
1p36.3	O
defined	O
by	O
primary	O
tumor	B-malignancy-type
deletions	O
,	O
constructed	O
a	O
physical	O
map	O
of	O
the	O
region	O
that	O
is	O
being	O
sequenced	O
to	O
completion	O
,	O
and	O
have	O
identified	O
and	O
prioritized	O
candidate	O
genes	O
within	O
this	O
region	O
for	O
further	O
analyses	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11107105	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Dev	O
Neurosci	O
.	O
2000	O
Apr	O
-	O
Jun;18	O
(	O
2-3	O
)	O
:317-	O
20	O
.	O
Expression	O
of	O
the	O
estrogen	O
-	O
regulated	O
gene	O
Nip2	O
during	O
rat	O
brain	O
maturation	O
.	O
Brusadelli	O
A	O
,	O
Sialino	O
H,	O
Piepoli	O
T	O
,	O
Pollio	O
G	O
,	O
Maggi	O
A	O
.	O
Center	O
Milano	O
Molecular	O
Pharmacology	O
Laboratory	O
,	O
Institute	O
of	O
Pharmacological	O
Sciences	O
,	O
University	O
of	O
Milan	O
,	O
Via	O
Balzaretti	O
9	O
20133	O
,	O
Milan	O
,	O
Italy	O
.	O
The	O
present	O
study	O
stems	O
from	O
previous	O
observations	O
demonstrating	O
that	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-ER3	O
the	O
mRNA	O
content	O
of	O
the	O
pro	O
-apoptotic	O
gene	O
Nip2	O
is	O
decreased	O
following	O
treatment	O
with	O
estradiol	O
.	O
We	O
investigate	O
the	O
content	O
of	O
Nip2	O
mRNA	O
during	O
the	O
maturation	O
of	O
rat	O
embryo	O
brain	O
and	O
we	O
show	O
that	O
Nip2	O
mRNA	O
is	O
very	O
low	O
at	O
embryo	O
day	O
15	O
and	O
steadily	O
increases	O
up	O
to	O
day	O
20	O
.	O
At	O
day	O
21	O
Nip2	O
mRNA	O
is	O
decreased	O
almost	O
to	O
the	O
low	O
levels	O
observed	O
in	O
the	O
mature	O
brain	O
.	O
Studies	O
in	O
neurons	O
from	O
rat	O
embryo	O
at	O
day	O
18	O
show	O
that	O
Nip2	O
mRNA	O
content	O
is	O
significantly	O
decreased	O
by	O
exposure	O
to	O
estradiol	O
at	O
1	O
nM	O
concentration	O
demonstrating	O
that	O
the	O
observations	O
previously	O
done	O
in	O
the	O
SK-ER3	O
neuroblastoma	B-malignancy-type
cell	O
line	O
can	O
be	O
reproduced	O
in	O
neurons	O
in	O
culture	O
.	O
The	O
finding	O
that	O
estrogens	O
may	O
modulate	O
the	O
activity	O
of	O
Nip2	O
gene	O
activity	O
may	O
be	O
of	O
relevance	O
not	O
only	O
with	O
regard	O
to	O
the	O
effects	O
of	O
estradiol	O
on	O
brain	O
maturation	O
,	O
but	O
also	O
for	O
the	O
understanding	O
of	O
the	O
neuroprotective	O
effects	O
recently	O
described	O
for	O
this	O
hormone	O
.	O
PMID	O
:	O
10715586	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2003	O
Jul;8	O
6(	O
2	O
)	O
:	O
394	O
-404	O
.	O
Alzheimer	O
's	O
associated	O
variant	O
ubiquitin	O
causes	O
inhibition	O
of	O
the	O
26S	O
proteasome	O
and	O
chaperone	O
expression	O
.	O
Hope	O
AD	O
,	O
de	O
Silva	O
R	O
,	O
Fischer	O
DF	O
,	O
Hol	O
EM	O
,	O
van	O
Leeuwen	O
FW	O
,	O
Lees	O
AJ.	O
Reta	O
Lila	O
Weston	O
Institute	O
of	O
Neurological	O
Studies	O
,	O
University	O
College	O
,	O
London	O
,	O
UK.	O
a	O
.hope@ucl	O
.ac.uk	O
Intracellular	O
protein	O
inclusions	O
in	O
Alzheimer	O
's	O
disease	O
and	O
progressive	O
supranuclear	O
palsy	O
contain	O
UBB+1	O
,	O
a	O
variant	O
ubiquitin	O
.	O
UBB+1	O
is	O
able	O
block	O
the	O
26S	O
proteasome	O
in	O
cell	O
lines	O
.	O
Proteasome	O
inhibition	O
by	O
drug	O
action	O
has	O
previously	O
been	O
shown	O
to	O
induce	O
a	O
heat	O
-	O
shock	O
response	O
and	O
render	O
protection	O
against	O
stress	O
.	O
We	O
investigated	O
UBB+1	O
by	O
developing	O
a	O
stable	O
,	O
conditional	O
expression	O
model	O
in	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Induction	O
of	O
UBB+1	O
expression	O
caused	O
proteasome	O
inhibition	O
as	O
was	O
confirmed	O
by	O
reduced	O
ability	O
to	O
process	O
misfolded	O
canavanyl	O
proteins	O
,	O
accumulation	O
of	O
GF	O
Pu	O
,	O
a	O
proteasome	O
substrate	O
,	O
and	O
reduced	O
cleavage	O
of	O
a	O
fluorogenic	O
substrate	O
.	O
We	O
show	O
that	O
expression	O
of	O
UBB+1	O
induces	O
expression	O
of	O
heat	O
-	O
shock	O
proteins	O
.	O
This	O
priming	O
of	O
the	O
chaperone	O
system	O
in	O
these	O
cells	O
promotes	O
a	O
subsequent	O
resistance	O
to	O
tert	O
-butyl	O
hydroperoxide	O
-	O
mediated	O
oxidative	O
stress	O
.	O
We	O
conclude	O
that	O
although	O
UBB+1-	O
expressing	O
cells	O
have	O
a	O
compromised	O
ubiquitin	O
-	O
proteasome	O
system	O
,	O
they	O
are	O
protected	O
against	O
oxidative	O
stress	O
conditions	O
.	O
PMID	O
:	O
12871580	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1988	O
Jan	O
25;949(	O
1	O
)	O
:	O
58-64	O
.	O
Expression	O
of	O
transfected	O
human	O
CuZn	O
superoxide	O
dismutase	O
gene	O
in	O
mouse	O
L	O
cells	O
and	O
NS20Y	O
neuroblastoma	B-malignancy-type
cells	O
induces	O
enhancement	O
of	O
glutathione	O
peroxidase	O
activity	O
.	O
Ceballos	O
I	O
,	O
Delabar	O
JM	O
,	O
Nicole	O
A	O
,	O
Lynch	O
RE	O
,	O
Hallewell	O
RA	O
,	O
Kamoun	O
P,	O
Sinet	O
PM	O
.	O
Laboratoire	O
de	O
Biochimie	O
Genetique	O
,	O
Hopital	O
Necker	O
,	O
Paris	O
,	O
France	O
.	O
The	O
human	O
CuZn	O
superoxide	O
dismutase	O
(	O
superoxide	O
dismutase	O
1	O
)	O
a	O
key	O
enzyme	O
in	O
the	O
metabolism	O
of	O
oxygen	O
free	O
-	O
radicals	O
,	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
21	O
in	O
the	O
region	O
21	O
q	O
22.1	O
known	O
to	O
be	O
involved	O
in	O
Down	O
's	O
syndrome	O
.	O
A	O
gene	O
dosage	O
effect	O
for	O
this	O
enzyme	O
has	O
been	O
reported	O
in	O
trisomy	O
21	O
.	O
To	O
assess	O
the	O
biological	O
consequences	O
of	O
superoxide	O
dismutase	O
1	O
overproduction	O
within	O
cells	O
,	O
the	O
human	O
superoxide	O
dismutase	O
1	O
gene	O
and	O
a	O
human	O
superoxide	O
dismutase	O
1	O
cDNA	O
were	O
introduced	O
into	O
mouse	O
L	O
cells	O
and	O
NS20Y	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Both	O
cell	O
types	O
expressed	O
elevated	O
levels	O
(	O
up	O
to	O
3	O
-	O
fold	O
)	O
of	O
enzymatically	O
active	O
human	O
superoxide	O
dismutase	O
1	O
.	O
These	O
human	O
superoxide	O
dismutase	O
1	O
overproducers	O
,	O
especially	O
neuronal	O
cell	O
lines	O
,	O
showed	O
an	O
increased	O
activity	O
in	O
the	O
selenodependent	O
glutathione	O
peroxidase	O
.	O
These	O
data	O
are	O
consistent	O
with	O
the	O
possibility	O
that	O
gene	O
dosage	O
of	O
superoxide	O
dismutase	O
1	O
contributes	O
to	O
oxygen	O
metabolism	O
modifications	O
previously	O
described	O
in	O
Down	O
's	O
syndrome	O
.	O
PMID	O
:	O
3334851	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1984	O
Aug;	O
81	O
(	O
15	O
)	O
:	O
4940	O
-4.	O
Enhanced	O
expression	O
of	O
the	O
human	O
gene	O
N-myc	O
consequent	O
to	O
amplification	O
of	O
DNA	O
may	O
contribute	O
to	O
malignant	O
progression	O
of	O
neuroblastoma	B-malignancy-type
.	O
Schwab	O
M,	O
Ellison	O
J,	O
Busch	O
M,	O
Rosenau	O
W	O
,	O
Varmus	O
HE	O
,	O
Bishop	O
JM	O
.	O
Previous	O
studies	O
had	O
revealed	O
that	O
DNA	O
with	O
partial	O
similarity	O
to	O
the	O
myc	O
oncogene	O
(	O
N-myc	O
)	O
is	O
frequently	O
amplified	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
.	O
We	O
show	O
here	O
for	O
one	O
patient	O
that	O
N-myc	O
amplification	O
is	O
confined	O
to	O
the	O
neuroblastoma	B-malignancy-type
tumor	I-malignancy-type
and	O
is	O
not	O
present	O
in	O
normal	O
tissue	O
.	O
N-myc	O
mRNA	O
approximately	O
equal	O
to	O
4.0	O
kilobases	O
in	O
size	O
is	O
detectable	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
tumors	O
and	O
in	O
a	O
retinoblastoma	B-malignancy-type
cell	O
line	O
.	O
By	O
contrast	O
,	O
appreciable	O
amounts	O
of	O
this	O
RNA	O
were	O
not	O
present	O
in	O
a	O
number	O
of	O
cell	O
lines	O
derived	O
from	O
other	O
human	O
tumors	O
and	O
in	O
fibroblasts	O
from	O
a	O
normal	O
individual	O
and	O
from	O
a	O
neuroblastoma	B-malignancy-type
patient	O
.	O
Low	O
levels	O
of	O
N-myc	O
RNA	O
were	O
found	O
in	O
human	O
and	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
lacking	O
amplification	O
of	O
this	O
gene	O
,	O
up	O
to	O
80	O
-	O
fold	O
greater	O
levels	O
in	O
all	O
cell	O
lines	O
carrying	O
amplified	O
N-myc	O
.	O
In	O
situ	O
hybridization	O
to	O
sections	O
of	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
revealed	O
high	O
expression	O
of	O
N-myc	O
predominantly	O
in	O
undifferentiated	O
neuroblasts	O
.	O
We	O
hypothesize	O
that	O
amplification	O
and	O
consequent	O
elevated	O
expression	O
of	O
N-myc	O
may	O
be	O
related	O
to	O
malignant	O
progression	O
.	O
PMID	O
:	O
6589638	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
1992	O
Jun;41	O
(	O
6	O
)	O
:	O
1016-22	O
.	O
Increased	O
glucocorticoid	O
receptor	O
gene	O
promoter	O
activity	O
after	O
antidepressant	O
treatment	O
.	O
Pepin	O
MC	O
,	O
Govindan	O
MV	O
,	O
Barden	O
N	O
.	O
Molecular	O
Psychogenetics	O
Laboratory	O
,	O
Research	O
Center	O
,	O
Ste	O
Foy	O
,	O
Quebec	O
,	O
Canada	O
.	O
We	O
have	O
tested	O
the	O
hypothesis	O
that	O
antidepressants	O
affect	O
the	O
expression	O
of	O
the	O
glucocorticoid	O
receptor	O
gene	O
,	O
by	O
looking	O
at	O
glucocorticoid	O
receptor	O
gene	O
promoter	O
activity	O
,	O
glucocorticoid	O
receptor	O
mRNA	O
levels	O
,	O
and	O
glucocorticoid	O
-	O
binding	O
activity	O
after	O
treatment	O
of	O
different	O
cell	O
lines	O
with	O
desipramine	O
.	O
Treatment	O
of	O
LTK	O
-	O
cells	O
or	O
Neuro	O
2A	O
cells	O
with	O
desipramine	O
produced	O
a	O
50	O
-	O
200	O
%	O
increase	O
in	O
chloramphenicol	O
acetyltransferase	O
activity	O
transcribed	O
from	O
a	O
2.7-kilobase	O
glucocorticoid	O
receptor	O
gene	O
promoter	O
region	O
.	O
In	O
cell	O
lines	O
derived	O
from	O
both	O
neuronal	O
and	O
non	O
-	O
neuronal	O
sources	O
,	O
glucocorticoid	O
receptor	O
mRNA	O
concentration	O
doubled	O
after	O
desipramine	O
treatment	O
,	O
and	O
this	O
was	O
associated	O
with	O
a	O
2	O
-	O
fold	O
higher	O
functional	O
glucocorticoid	O
binding	O
capacity	O
and	O
increased	O
glucocorticoid	O
sensitivity	O
,	O
as	O
measured	O
with	O
the	O
reporter	O
plasmid	O
pMMTVCAT	O
.	O
Antidepressant	O
-	O
induced	O
increases	O
in	O
glucocorticoid	O
receptor	O
gene	O
promoter	O
activity	O
,	O
glucocorticoid	O
receptor	O
mRNA	O
levels	O
,	O
and	O
functional	O
glucocorticoid	O
binding	O
activity	O
suggest	O
a	O
novel	O
mechanism	O
of	O
action	O
for	O
these	O
drugs	O
on	O
the	O
hypothalamic	O
-	O
pituitary-adrenal	O
axis	O
.	O
PMID	O
:	O
1614406	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1989	O
Apr;4(	O
4	O
)	O
:	O
421	O
-	O
7.	O
Coordinate	O
alteration	O
of	O
pp60	O
c	O
-	O
src	O
abundance	O
and	O
c-	O
src	O
RNA	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
variants	O
.	O
Veillette	O
A	O
,	O
O'Shaughnessy	O
J,	O
Horak	O
ID	O
,	O
Israel	O
MA	O
,	O
Yee	O
D	O
,	O
Rosen	O
N	O
,	O
Fujita	O
DJ	O
,	O
Kung	O
HJ	O
,	O
Biedler	O
JL	O
,	O
Bolen	O
JB.	O
Laboratory	O
of	O
Tumor	O
Virus	O
Biology	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
We	O
examined	O
the	O
expression	O
,	O
abundance	O
,	O
and	O
protein	O
kinase	O
activity	O
of	O
pp60	O
c	O
-	O
src	O
in	O
two	O
different	O
pairs	O
of	O
genetically	O
indistinguishable	O
cloned	O
human	O
neuroblastoma	B-malignancy-type
cell	O
variants	O
which	O
display	O
altered	O
phenotypes	O
as	O
the	O
result	O
of	O
conversion	O
from	O
a	O
neuronal	O
to	O
a	O
non	O
-	O
neuronal	O
phenotype	O
.	O
The	O
results	O
demonstrate	O
that	O
cells	O
which	O
exhibit	O
the	O
neuroblastic	O
(	O
N-type	O
)	O
phenotype	O
possess	O
high	O
levels	O
of	O
pp60	O
c	O
-	O
src	O
protein	O
and	O
that	O
one	O
of	O
the	O
two	O
N-type	O
cell	O
lines	O
is	O
capable	O
of	O
expressing	O
the	O
neuronal	O
-	O
specific	O
isoenzyme	O
of	O
pp60	O
c	O
-	O
src	O
.	O
In	O
contrast	O
,	O
cells	O
which	O
display	O
the	O
substrate	O
-	O
adherent	O
(	O
S-type	O
)	O
phenotype	O
have	O
low	O
levels	O
of	O
pp60	O
c	O
-	O
src	O
protein	O
and	O
express	O
exclusively	O
the	O
non	O
-	O
neuronal	O
isoenzyme	O
of	O
pp60	O
c	O
-	O
src	O
.	O
In	O
all	O
cells	O
examined	O
the	O
abundance	O
of	O
pp60	O
c	O
-	O
src	O
was	O
found	O
to	O
be	O
proportional	O
to	O
the	O
steady	O
-state	O
level	O
of	O
c-	O
src	O
RNA	O
.	O
In	O
each	O
case	O
the	O
protein	O
kinase	O
activity	O
of	O
pp60	O
c	O
-	O
src	O
was	O
found	O
to	O
be	O
proportional	O
to	O
the	O
abundance	O
of	O
the	O
protein	O
and	O
independent	O
of	O
the	O
ratio	O
of	O
neuronal	O
to	O
non	O
-	O
neuronal	O
species	O
of	O
pp60	O
c	O
-	O
src	O
.	O
PMID	O
:	O
2470006	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1997	O
Oct	O
15	O
;57	O
(	O
20	O
)	O
:4578	O
-84	O
.	O
High	O
levels	O
of	O
expression	O
and	O
nuclear	O
localization	O
of	O
interleukin-1	O
beta	O
converting	O
enzyme	O
(	O
ICE	O
)	O
and	O
CPP32	O
in	O
favorable	O
human	O
neuroblastomas	B-malignancy-type
.	O
Nakagawara	O
A	O
,	O
Nakamura	O
Y	O
,	O
Ikeda	O
H,	O
Hiwasa	O
T	O
,	O
Kuida	O
K,	O
Su	O
MS	O
,	O
Zhao	O
H,	O
Cnaan	O
A	O
,	O
Sakiyama	O
S.	O
Division	O
of	O
Biochemistry	O
,	O
Chiba	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Japan	O
.	O
akiranak@biolab.kazusa.or	O
.jp	O
Neuroblastomas	B-malignancy-type
frequently	O
show	O
spontaneous	O
regression	O
and	O
differentiation	O
,	O
which	O
may	O
at	O
least	O
partly	O
be	O
regulated	O
by	O
signaling	O
through	O
nerve	O
growth	O
factor	O
and	O
its	O
receptors	O
,	O
TRK-A	O
and	O
p75LNTR	O
.	O
We	O
studied	O
52	O
neuroblastic	B-malignancy-type
tumors	I-malignancy-type
to	O
test	O
whether	O
the	O
cell	O
death	O
-	O
related	O
proteases	O
,	O
interleukin-1	O
beta	O
converting	O
enzyme	O
(	O
ICE	O
)	O
,	O
CPP32	O
,	O
and	O
Ich-1	O
,	O
were	O
involved	O
in	O
the	O
regression	O
of	O
the	O
tumors	O
.	O
High	O
levels	O
of	O
expression	O
of	O
ICE	O
and	O
CPP32	O
were	O
significantly	O
correlated	O
with	O
a	O
high	O
level	O
of	O
TRK-A	O
expression	O
,	O
single	O
copy	O
of	O
N-myc	O
,	O
younger	O
age	O
,	O
lower	O
stages	O
,	O
and	O
better	O
prognosis	O
.	O
The	O
immunohistochemical	O
studies	O
and	O
Western	O
analyses	O
as	O
well	O
as	O
the	O
terminal	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
method	O
revealed	O
that	O
both	O
ICE	O
and	O
CPP32	O
were	O
translocated	O
from	O
the	O
cytoplasm	O
into	O
the	O
nuclei	O
in	O
regressing	O
,	O
apoptotic	O
tumor	O
cells	O
.	O
Our	O
results	O
suggest	O
that	O
ICE	O
and	O
CPP32	O
cysteine	O
proteases	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
apoptotic	O
process	O
of	O
the	O
favorable	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
9377572	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
.	O
1997	O
Jul	O
15;96	O
(	O
2	O
)	O
:	O
134	O
-	O
9.	O
Loss	O
of	O
heterozygosity	O
at	O
chromosome	O
9p21	O
in	O
primary	O
neuroblastomas	B-malignancy-type
:	O
evidence	O
for	O
two	O
deleted	O
regions	O
.	O
Marshall	O
B	O
,	O
Isidro	O
G	O
,	O
Martins	O
AG	O
,	O
Boavida	O
MG.	O
Departamento	O
de	O
Genetica	O
Humana	O
,	O
Instituto	O
Nacional	O
de	O
Saude	O
Dr	O
Ricardo	O
Jorge	O
,	O
Lisboa	O
,	O
Portugal	O
.	O
The	O
genes	O
responsible	O
for	O
the	O
development	O
of	O
neuroblastoma	B-malignancy-type
following	O
in	O
vivo	O
deletion	O
or	O
mutation	O
are	O
largely	O
unknown	O
.	O
We	O
have	O
performed	O
loss	O
of	O
heterozygosity	O
studies	O
on	O
a	O
series	O
of	O
24	O
Portuguese	O
primary	O
neuroblastomas	B-malignancy-type
using	O
6	O
polymorphic	O
markers	O
located	O
at	O
chromosome	O
9p21	O
spanning	O
the	O
p16	O
/	O
MTS1	O
/	O
CDKN2	O
,	O
p15	O
/	O
MTS2	O
/	O
CDKN2B	O
,	O
and	O
the	O
interferon	O
alpha	O
and	O
beta	O
genes	O
.	O
Loss	O
of	O
heterozygosity	O
was	O
observed	O
in	O
4	O
of	O
the	O
24	O
tumors	O
(	O
17	O
%	O
)	O
,	O
a	O
somewhat	O
lower	O
percentage	O
than	O
a	O
previous	O
study	O
that	O
identified	O
patients	O
by	O
a	O
mass	O
screening	O
program	O
.	O
A	O
correlation	O
was	O
also	O
observed	O
between	O
9p21	O
LOH	O
and	O
1p36	O
LOH	O
in	O
our	O
group	O
of	O
tumors	O
.	O
Two	O
distinct	O
regions	O
of	O
9p21	O
deletion	O
were	O
observed	O
:	O
one	O
located	O
in	O
the	O
region	O
adjacent	O
to	O
the	O
markers	O
D9S162	O
and	O
D9S1747	O
and	O
a	O
second	O
located	O
centromerically	O
of	O
the	O
p16	O
gene	O
near	O
the	O
D9S171	O
marker	O
.	O
The	O
latter	O
region	O
is	O
exclusive	O
of	O
the	O
p16	O
gene	O
.	O
This	O
result	O
suggests	O
the	O
presence	O
of	O
at	O
least	O
one	O
other	O
tumor	O
suppressor	O
gene	O
at	O
9p21	O
,	O
apart	O
from	O
the	O
p16	O
and	O
p15	O
genes	O
,	O
which	O
may	O
be	O
of	O
importance	O
to	O
the	O
development	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
9216721	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Exp	O
Pharmacol	O
Physiol	O
.	O
1995	O
May	O
;22	O
(	O
5	O
)	O
:	O
364	O
-5	O
.	O
Subunit	O
-	O
dependent	O
action	O
of	O
lead	O
on	O
neuronal	O
nicotinic	O
acetylcholine	O
receptors	O
expressed	O
in	O
Xenopus	O
oocytes	O
.	O
Oortgiesen	O
M,	O
Zwart	O
R	O
,	O
van	O
Kleef	O
RG	O
,	O
Vijverberg	O
HP	O
.	O
Research	O
Institute	O
of	O
Toxicology	O
,	O
Utrecht	O
University	O
,	O
The	O
Netherlands	O
.	O
1	O
.	O
Pb2	O
+	O
affects	O
neuronal	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChR	O
)	O
in	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
in	O
a	O
dual	O
manner	O
.	O
At	O
nanomolar	O
concentrations	O
a	O
blockade	O
is	O
observed	O
,	O
while	O
at	O
submillimolar	O
concentrations	O
this	O
blocking	O
effect	O
is	O
reversed	O
.	O
2.	O
The	O
Xenopus	O
oocyte	O
expression	O
system	O
was	O
used	O
to	O
examine	O
whether	O
the	O
dual	O
effect	O
of	O
Pb2	O
+	O
is	O
related	O
to	O
a	O
differential	O
action	O
on	O
nAChR	O
subtypes	O
.	O
Effects	O
of	O
Pb2	O
+	O
were	O
investigated	O
in	O
oocytes	O
expressing	O
nAChR	O
after	O
co	O
-	O
injection	O
of	O
alpha	O
3	O
and	O
beta	O
2	O
or	O
alpha	O
3	O
and	O
beta	O
4	O
cDNA	O
.	O
3	O
.	O
At	O
1-250	O
mumol	O
/	O
L	O
,	O
Pb2	O
+	O
causes	O
a	O
10-	O
1000	O
%	O
increase	O
of	O
the	O
response	O
mediated	O
by	O
the	O
alpha	O
3	O
beta	O
2	O
nAChR	O
	O
4	O
.	O
Pb2	O
+	O
blocks	O
ACh	O
-	O
induced	O
inward	O
currents	O
mediated	O
by	O
alpha	O
3	O
beta	O
4	O
nAChR.	O
The	O
inhibitory	O
potency	O
of	O
Pb2	O
+	O
greatly	O
varies	O
between	O
cells	O
.	O
In	O
50	O
%	O
of	O
the	O
cells	O
concentrations	O
<	O
or	O
=	O
1	O
mumol	O
/	O
L	O
Pb2	O
+	O
blocked	O
the	O
nicotinic	O
response	O
by	O
31	O
-	O
93	O
%	O
.	O
In	O
the	O
other	O
cells	O
even	O
at	O
higher	O
concentrations	O
Pb2	O
+	O
caused	O
only	O
0-	O
65	O
%	O
inhibition	O
.	O
5	O
.	O
These	O
results	O
show	O
that	O
Pb2	O
+	O
may	O
both	O
potentiate	O
and	O
block	O
nAChR	O
,	O
depending	O
on	O
the	O
type	O
of	O
nAChR	O
subunit	O
expressed	O
.	O
PMID	O
:	O
7554431	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncology	O
.	O
1988	O
;45(	O
2	O
)	O
:93	O
-	O
7.	O
Decline	O
of	O
childhood	O
cancer	O
mortality	O
in	O
Italy	O
,	O
1955-1980	O
.	O
La	O
Vecchia	O
C	O
,	O
Decarli	O
A	O
.	O
Istituto	O
di	O
Ricerche	O
Farmacologiche	O
Mario	O
Negri	O
,	O
Universita	O
di	O
Milano	O
,	O
Italia	O
.	O
The	O
decline	O
in	O
childhood	O
cancer	O
mortality	O
in	O
Italy	O
from	O
1955	O
to	O
1980	O
has	O
been	O
evaluated	O
through	O
(1)	O
comparison	O
of	O
age	O
-	O
specific	O
and	O
age	O
-	O
standardized	O
(	O
0-	O
14	O
years	O
)	O
rates	O
for	O
the	O
periods	O
1955-1960	O
and	O
1979	O
-	O
1980	O
and	O
(	O
2)	O
computation	O
of	O
expected	O
numbers	O
of	O
deaths	O
by	O
application	O
of	O
the	O
age	O
-	O
specific	O
rates	O
for	O
the	O
period	O
1955-1960	O
to	O
the	O
population	O
structure	O
of	O
subsequent	O
periods	O
.	O
Certified	O
mortality	O
fell	O
by	O
35	O
%	O
for	O
leukaemias	B-malignancy-type
,	O
90	O
%	O
for	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
,	O
30	O
%	O
for	O
non	B-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphomas	I-malignancy-type
,	O
40	O
%	O
for	O
bone	B-malignancy-type
sarcomas	I-malignancy-type
,	O
30	O
%	O
for	O
kidney	B-malignancy-type
(	I-malignancy-type
Wilms	I-malignancy-type
'	I-malignancy-type
)	I-malignancy-type
tumours	I-malignancy-type
,	O
65	O
%	O
for	O
retinoblastoma	B-malignancy-type
.	O
No	O
clear	O
trend	O
was	O
reported	O
for	O
other	O
neoplasms	O
,	O
including	O
neuroblastoma	B-malignancy-type
.	O
About	O
300	O
cancer	O
deaths	O
per	O
year	O
were	O
avoided	O
in	O
the	O
period	O
1979	O
-	O
1980	O
compared	O
with	O
the	O
expected	O
number	O
based	O
on	O
the	O
1955-1960	O
rates	O
(	O
170	O
for	O
leukaemias	B-malignancy-type
alone	O
)	O
.	O
Although	O
clearly	O
encouraging	O
,	O
these	O
trends	O
are	O
substantially	O
less	O
favourable	O
than	O
those	O
from	O
several	O
other	O
developed	O
countries	O
.	O
It	O
is	O
therefore	O
likely	O
that	O
several	O
dozen	O
other	O
deaths	O
from	O
childhood	O
cancer	O
could	O
be	O
avoided	O
each	O
year	O
through	O
earlier	O
(	O
or	O
more	O
accurate	O
)	O
application	O
of	O
effective	O
therapies	O
,	O
particularly	O
for	O
neoplasms	O
requiring	O
radiotherapy	O
or	O
surgical	O
treatment	O
.	O
PMID	O
:	O
3353078	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biol	O
Pharm	O
Bull	O
.	O
1999	O
Jul;22	O
(	O
7	O
)	O
:	O
67	O
9	O
-	O
82	O
.	O
Trigonelline	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
human	O
neuroblastoma	B-malignancy-type
SK-N-SH	O
cells	O
.	O
Tohda	O
C	O
,	O
Nakamura	O
N	O
,	O
Komatsu	O
K,	O
Hattori	O
M.	O
Research	O
Center	O
for	O
Ethnomedicines	O
,	O
Institute	O
of	O
Natural	O
Medicine	O
,	O
Toyama	O
Medical	O
and	O
Pharmaceutical	O
University	O
,	O
Japan	O
.	O
Extension	O
of	O
dendrites	O
and	O
axons	O
in	O
neurons	O
may	O
compensate	O
and	O
rescue	O
damaged	O
neuronal	O
networks	O
in	O
the	O
dementia	O
brain	O
.	O
Our	O
aim	O
is	O
to	O
isolate	O
and	O
identify	O
constituents	O
of	O
coffee	O
beans	O
exhibiting	O
neurite	O
outgrowth	O
activity	O
.	O
Among	O
the	O
extracts	O
of	O
raw	O
and	O
roasted	O
coffee	O
beans	O
,	O
a	O
methanol	O
fraction	O
of	O
the	O
ethanol	O
extract	O
(	O
1	O
microg	O
/	O
ml	O
)	O
of	O
raw	O
beans	O
increased	O
significantly	O
the	O
percentage	O
of	O
cells	O
with	O
neurites	O
in	O
human	O
neuroblastoma	B-malignancy-type
SK-N-SH	O
cells	O
.	O
Among	O
subfractions	O
of	O
this	O
methanol	O
fraction	O
was	O
a	O
basic	O
fraction	O
(	O
5	O
microg	O
/	O
ml	O
)	O
which	O
exhibited	O
significant	O
neurite	O
outgrowth	O
activity	O
.	O
Finally	O
,	O
trigonelline	O
in	O
the	O
basic	O
fraction	O
was	O
identified	O
to	O
be	O
active	O
as	O
far	O
neurite	O
extension	O
was	O
concerned	O
.	O
Treatment	O
with	O
trigonelline	O
(	O
30	O
microM	O
)	O
increased	O
the	O
percentage	O
of	O
cells	O
with	O
neurites	O
at	O
3	O
and	O
6	O
d	O
after	O
treatment	O
.	O
In	O
addition	O
,	O
the	O
number	O
of	O
neurites	O
reacting	O
positively	O
to	O
phosphorylated	O
neurofilament-H	O
was	O
increased	O
by	O
treatment	O
with	O
30	O
microM	O
trigonelline	O
for	O
6	O
d	O
,	O
suggesting	O
enhancement	O
of	O
axonal	O
extension	O
.	O
These	O
results	O
show	O
that	O
trigonelline	O
promotes	O
functional	O
neurite	O
outgrowth	O
.	O
PMID	O
:	O
10443461	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Virol	O
.	O
1992	O
Sep;66(	O
9	O
)	O
:	O
5534-41	O
.	O
Antibody	O
-	O
dependent	O
transcriptional	O
regulation	O
of	O
measles	O
virus	O
in	O
persistently	O
infected	O
neural	O
cells	O
.	O
Schneider-Schaulies	O
S	O
,	O
Liebert	O
UG	O
,	O
Segev	O
Y	O
,	O
Rager-Zisman	O
B	O
,	O
Wolfson	O
M,	O
ter	O
Meulen	O
V	O
.	O
Institut	O
fur	O
Virologie	O
und	O
Immunbiologie	O
,	O
Universitat	O
Wurzburg	O
,	O
Germany	O
.	O
Application	O
of	O
neutralizing	O
anti	O
-	O
hemagglutinin	O
antibodies	O
to	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
(	O
NS20Y	O
/	O
MS	O
)	O
persistently	O
infected	O
with	O
measles	O
virus	O
(	O
MV	O
)	O
leads	O
to	O
a	O
significant	O
reduction	O
of	O
viral	O
structural	O
proteins	O
within	O
6	O
days	O
.	O
While	O
the	O
transcriptional	O
gradient	O
for	O
MV	O
-	O
specific	O
mRNAs	O
remained	O
unaffected	O
upon	O
antibody	O
treatment	O
,	O
the	O
total	O
amount	O
of	O
MV	O
-	O
specific	O
transcripts	O
dropped	O
by	O
80	O
%	O
after	O
24	O
h	O
.	O
The	O
expression	O
of	O
genomic	O
RNA	O
was	O
affected	O
similarly	O
,	O
with	O
slightly	O
slower	O
time	O
kinetics	O
.	O
Both	O
transcription	O
and	O
expression	O
of	O
the	O
viral	O
structural	O
proteins	O
could	O
be	O
completely	O
reactivated	O
when	O
viral	O
antibodies	O
were	O
removed	O
from	O
the	O
tissue	O
culture	O
.	O
The	O
same	O
findings	O
could	O
be	O
obtained	O
in	O
rat	O
glioma	B-malignancy-type
cells	O
persistently	O
infected	O
with	O
subacute	O
sclerosing	O
panencephalitis	O
virus	O
(	O
C6	O
/	O
SSPE	O
)	O
but	O
not	O
in	O
cells	O
of	O
nonneural	O
origin	O
.	O
The	O
data	O
indicate	O
that	O
antibody	O
-	O
induced	O
antigenic	O
modulation	O
affects	O
the	O
early	O
stages	O
of	O
viral	O
transcription	O
within	O
a	O
few	O
hours	O
after	O
the	O
addition	O
of	O
antibodies	O
and	O
leads	O
to	O
an	O
almost	O
complete	O
repression	O
of	O
viral	O
gene	O
expression	O
in	O
cells	O
of	O
neural	O
origin	O
.	O
PMID	O
:	O
1501288	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Neurol	O
.	O
2001	O
Jun;169	O
(	O
2	O
)	O
:479	O
-	O
85	O
.	O
Biochemical	O
analysis	O
of	O
cybrids	O
expressing	O
mitochondrial	O
DNA	O
from	O
Contursi	O
kindred	O
Parkinson	O
's	O
subjects	O
.	O
Swerdlow	O
RH	O
,	O
Parks	O
JK	O
,	O
Cassarino	O
DS	O
,	O
Binder	O
DR	O
,	O
Bennett	O
JP	O
Jr	O
,	O
Di	O
Iorio	O
G	O
,	O
Golbe	O
LI	O
,	O
Parker	O
WD	O
Jr	O
.	O
Center	O
for	O
the	O
Study	O
of	O
Neurodegenerative	O
Diseases	O
,	O
University	O
of	O
Virginia	O
Health	O
System	O
,	O
Charlottesville	O
,	O
Virginia	O
,	O
USA	O
.	O
Complex	O
I	O
activity	O
is	O
reduced	O
in	O
cytoplasmic	O
hybrid	O
(	O
cybrid	O
)	O
cell	O
lines	O
that	O
contain	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
from	O
sporadic	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
patients	O
.	O
This	O
implies	O
that	O
mtDNA	O
aberration	O
occurs	O
in	O
sporadic	O
PD.	O
To	O
assess	O
the	O
integrity	O
of	O
mtDNA	O
in	O
autosomal	O
dominant	O
PD	O
arising	O
from	O
mutation	O
of	O
the	O
alpha	O
-	O
synuclein	O
gene	O
,	O
we	O
transferred	O
mitochondrial	O
genes	O
from	O
PD	O
-	O
affected	O
members	O
of	O
the	O
Italian	O
-	O
American	O
Contursi	O
kindred	O
to	O
cells	O
previously	O
depleted	O
of	O
their	O
endogenous	O
mtDNA	O
.	O
Unlike	O
cybrid	O
cell	O
lines	O
expressing	O
mtDNA	O
from	O
persons	O
with	O
sporadic	O
or	O
maternally	O
inherited	O
PD	O
,	O
the	O
resultant	O
Contursi	O
cybrid	O
lines	O
did	O
not	O
manifest	O
complex	O
I	O
deficiency	O
,	O
indicating	O
that	O
in	O
Contursi	O
PD	O
mtDNA	O
integrity	O
is	O
relatively	O
preserved	O
.	O
Compared	O
to	O
control	O
cybrids	O
,	O
however	O
,	O
Contursi	O
cybrid	O
lines	O
did	O
show	O
some	O
evidence	O
of	O
oxidative	O
stress	O
.	O
For	O
reasons	O
that	O
are	O
unclear	O
,	O
at	O
least	O
a	O
limited	O
amount	O
of	O
mtDNA	O
damage	O
may	O
nevertheless	O
develop	O
in	O
PD	O
patients	O
with	O
alpha	O
-	O
synuclein	O
mutation	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11358461	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Neurosci	O
.	O
1992	O
Feb;62(	O
3-	O
4)	O
:	O
287	O
-	O
97	O
.	O
Fc	O
gamma	O
receptors	O
are	O
expressed	O
on	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
:	O
lack	O
of	O
correlation	O
with	O
N-myc	O
oncogene	O
activity	O
.	O
Gorini	O
G	O
,	O
Ciotti	O
MT	O
,	O
Starace	O
G	O
,	O
Vigneti	O
E	O
,	O
Raschella	O
G.	O
Division	O
of	O
Biophysics	O
,	O
CRE	O
ENEA	O
Casaccia	O
,	O
Rome	O
,	O
Italy	O
.	O
FcRs	O
(	O
Fc	O
Receptors	O
)	O
have	O
been	O
detected	O
on	O
the	O
cell	O
surface	O
of	O
two	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
;	O
IMR	O
32	O
and	O
SK-N-SH	O
,	O
by	O
immunocytochemistry	O
and	O
flow	O
cytometric	O
analysis	O
,	O
using	O
a	O
previously	O
characterized	O
polyclonal	O
antiserum	O
raised	O
against	O
the	O
Fc	O
gamma	O
R	O
isolated	O
from	O
a	O
human	O
CLL	O
line	O
(	O
Gorini	O
,	O
Medgyesi	O
,	O
Garavini	O
,	O
Dorrington	O
and	O
Down	O
,	O
1987	O
;	O
Rozsnay	O
,	O
Sarmay	O
,	O
Szabo	O
,	O
Medgyesi	O
,	O
Gorini	O
and	O
Gergely	O
,	O
1990	O
)	O
.	O
FcR	O
is	O
expressed	O
on	O
all	O
the	O
cells	O
of	O
both	O
lines	O
at	O
least	O
at	O
the	O
same	O
level	O
as	O
on	O
the	O
HL60	O
promyelocyte	O
cell	O
line	O
used	O
as	O
positive	O
control	O
.	O
Two	O
electrophoretic	O
components	O
displaying	O
apparent	O
molecular	O
masses	O
of	O
70	O
and	O
43	O
kDa	O
respectively	O
have	O
been	O
identified	O
by	O
SDS	O
-PAGE	O
followed	O
by	O
Western	O
blotting	O
analysis	O
of	O
crude	O
cell	O
membranes	O
.	O
In	O
addition	O
,	O
"	O
in	O
situ"	O
hybridization	O
experiments	O
seem	O
to	O
exclude	O
a	O
correlation	O
between	O
FcR	O
expression	O
and	O
N-myc	O
oncogene	O
activity	O
.	O
The	O
presence	O
of	O
FcR	O
in	O
neuroblastoma	B-malignancy-type
could	O
be	O
related	O
to	O
a	O
possible	O
functional	O
role	O
even	O
on	O
these	O
cells	O
which	O
do	O
not	O
belong	O
to	O
the	O
immune	O
system	O
;	O
moreover	O
,	O
they	O
could	O
also	O
be	O
exploited	O
for	O
a	O
diagnostic	O
characterization	O
of	O
this	O
tumor	O
.	O
PMID	O
:	O
1305613	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Drug	O
Target	O
.	O
1998;	O
5	O
(	O
3	O
)	O
:163	O
-	O
9.	O
Nuclear	O
localization	O
signal	O
peptides	O
enhance	O
cationic	O
liposome	O
-	O
mediated	O
gene	O
therapy	O
.	O
Aronsohn	O
AI	O
,	O
Hughes	O
JA	O
.	O
Department	O
of	O
Pharmaceutics	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
32610	O
,	O
USA	O
.	O
The	O
use	O
of	O
genes	O
as	O
therapeutic	O
drugs	O
will	O
likely	O
involve	O
non	O
-viral	O
delivery	O
systems	O
.	O
While	O
traditionally	O
less	O
effective	O
for	O
gene	O
expression	O
,	O
the	O
advantages	O
of	O
a	O
non	O
-viral	O
delivery	O
system	O
include	O
ease	O
of	O
production	O
,	O
lower	O
toxicity	O
,	O
and	O
no	O
risk	O
of	O
infection	O
.	O
However	O
,	O
most	O
non	O
-viral	O
systems	O
do	O
not	O
incorporate	O
a	O
mechanism	O
for	O
gene	O
transport	O
into	O
the	O
nucleus	O
.	O
Nuclear	O
localization	O
signal	O
peptides	O
can	O
combine	O
the	O
increased	O
expression	O
of	O
viral	O
delivery	O
systems	O
with	O
the	O
safety	O
and	O
ease	O
of	O
preparation	O
of	O
non	O
-viral	O
delivery	O
systems	O
.	O
A	O
novel	O
non	O
-viral	O
delivery	O
vehicle	O
consisting	O
of	O
a	O
conglomerate	O
of	O
a	O
synthetic	O
nuclear	O
localization	O
signal	O
peptide	O
derived	O
from	O
the	O
SV40	O
virus	O
,	O
a	O
luciferase	O
encoding	O
PGL3	O
plasmid	O
,	O
and	O
a	O
cationic	O
lipid	O
DOTAP	O
:DOPE	O
(	O
1	O
:1	O
w	O
/	O
w	O
)	O
liposome	O
was	O
transfected	O
into	O
SKnSH	O
mammalian	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
.	O
A	O
three	O
-	O
fold	O
increase	O
in	O
luciferase	O
expression	O
was	O
seen	O
with	O
the	O
delivery	O
system	O
containing	O
a	O
NLS	O
peptide	O
over	O
cationic	O
liposome	O
controls	O
.	O
Examination	O
of	O
the	O
factors	O
that	O
limit	O
the	O
rate	O
of	O
transgene	O
expression	O
can	O
potentially	O
lead	O
to	O
the	O
discovery	O
of	O
new	O
ways	O
to	O
improve	O
the	O
efficiency	O
and	O
efficacy	O
of	O
nonviral	O
methods	O
of	O
gene	O
therapy	O
.	O
PMID	O
:	O
9606006	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Gene	O
Ther	O
.	O
1994	O
Dec;1	O
(	O
4	O
)	O
:253	O
-	O
8.	O
Immunomodulatory	O
effects	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
transduced	O
with	O
a	O
retroviral	O
vector	O
encoding	O
interleukin	O
-	O
2	O
.	O
Leimig	O
T	O
,	O
Foreman	O
N	O
,	O
Rill	O
D	O
,	O
Coze	O
C	O
,	O
Holladay	O
M,	O
Brenner	O
M.	O
Department	O
of	O
Hematology	O
/Oncology	O
,	O
St	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
Memphis	O
,	O
TN	O
38105	O
,	O
USA	O
.	O
We	O
have	O
investigated	O
whether	O
retroviral	O
mediated	O
transfer	O
of	O
the	O
IL-2	O
gene	O
renders	O
human	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
immunogenic	O
,	O
justifying	O
their	O
use	O
in	O
a	O
clinical	O
tumor	O
immunization	O
study	O
.	O
Fourteen	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
were	O
established	O
from	O
patients	O
with	O
disseminated	O
neuroblastoma	B-malignancy-type
and	O
transduced	O
with	O
the	O
vector	O
G1Ncvl2	O
,	O
which	O
contains	O
the	O
neomycin	O
phosphotransferase	O
gene	O
and	O
the	O
cDNA	O
of	O
the	O
human	O
interleukin-2	O
gene	O
.	O
Clones	O
secreting	O
>	O
150	O
pg	O
/	O
10(6)	O
cells	O
/	O
24	O
h	O
of	O
IL-2	O
were	O
selected	O
for	O
further	O
study	O
.	O
Secretion	O
of	O
IL-2	O
was	O
maintained	O
for	O
at	O
least	O
3	O
weeks	O
in	O
nonselective	O
media	O
,	O
implying	O
that	O
production	O
of	O
the	O
cytokine	O
would	O
continue	O
under	O
in	O
vivo	O
conditions	O
.	O
Co-culture	O
of	O
IL-2	O
transduced	O
cell	O
lines	O
with	O
patient	O
lymphocytes	O
induced	O
potent	O
cytotoxic	O
activity	O
against	O
both	O
transduced	O
and	O
parental	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
This	O
activity	O
was	O
HLA	O
unrestricted	O
,	O
and	O
predominantly	O
mediated	O
by	O
CD16	O
+	O
or	O
CD56	O
+	O
and	O
CD8	O
-	O
lymphocytes	O
.	O
These	O
data	O
form	O
the	O
preclinical	O
justification	O
for	O
our	O
current	O
immunization	O
protocol	O
for	O
patients	O
with	O
relapsed	O
or	O
resistant	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
7627815	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1991	O
Nov	O
15	O
;88	O
(	O
22	O
)	O
:9994	O
-	O
8.	O
Insulin	O
-	O
like	O
growth	O
factor	O
I	O
shifts	O
from	O
promoting	O
cell	O
division	O
to	O
potentiating	O
maturation	O
during	O
neuronal	O
differentiation	O
.	O
Pahlman	O
S	O
,	O
Meyerson	O
G	O
,	O
Lindgren	O
E	O
,	O
Schalling	O
M,	O
Johansson	O
I.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Uppsala	O
,	O
University	O
Hospital	O
,	O
Sweden	O
.	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
undergo	O
neuronal	O
differentiation	O
and	O
their	O
proliferation	O
is	O
inhibited	O
when	O
they	O
are	O
treated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
Insulin	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
are	O
mitogens	O
for	O
the	O
nontreated	O
SH-SY5Y	O
cells	O
,	O
whereas	O
the	O
proliferative	O
response	O
to	O
such	O
factor	O
stimulation	O
is	O
lost	O
upon	O
differentiation	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
receptors	O
for	O
insulin	O
and	O
IGF-	O
I	O
remain	O
expressed	O
and	O
functional	O
in	O
the	O
differentiated	O
cells	O
.	O
Here	O
we	O
show	O
that	O
the	O
PMA	O
-	O
induced	O
differentiation	O
of	O
SH-SY5Y	O
cells	O
grown	O
in	O
a	O
serum	O
-	O
free	O
medium	O
is	O
strongly	O
potentiated	O
by	O
nanomolar	O
concentrations	O
of	O
IGF-I	O
,	O
as	O
judged	O
by	O
morphology	O
and	O
markers	O
for	O
neuronal	O
differentiation	O
--e.g.	O
,	O
neuropeptide	O
tyrosine	O
and	O
growth	O
-	O
associated	O
protein	O
43	O
.	O
Also	O
,	O
insulin	O
and	O
IGF-II	O
potentiated	O
the	O
phorbol	O
ester	O
-	O
induced	O
differentiation	O
,	O
although	O
less	O
efficiently	O
than	O
IGF-I	O
.	O
Using	O
blocking	O
anti	O
-	O
receptor	O
antibodies	O
,	O
it	O
could	O
be	O
shown	O
that	O
the	O
differentiation	O
induced	O
by	O
these	O
factors	O
,	O
in	O
combination	O
with	O
PMA	O
,	O
was	O
primarily	O
mediated	O
through	O
the	O
IGF-	O
I	O
receptor	O
.	O
PMID	O
:	O
1946468	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1992	O
Sep	O
15	O
;89	O
(	O
18	O
)	O
:	O
8492	O
-6.	O
HEN1	O
and	O
HEN2	O
:	O
a	O
subgroup	O
of	O
basic	O
helix-loop-helix	O
genes	O
that	O
are	O
coexpressed	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
.	O
Brown	O
L,	O
Espinosa	O
R	O
3rd	O
,	O
Le	O
Beau	O
MM	O
,	O
Siciliano	O
MJ	O
,	O
Baer	O
R.	O
Department	O
of	O
Microbiology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
.	O
An	O
important	O
family	O
of	O
regulatory	O
molecules	O
is	O
made	O
up	O
of	O
proteins	O
that	O
possess	O
the	O
DNA	O
-	O
binding	O
and	O
dimerization	O
motif	O
known	O
as	O
the	O
basic	O
helix-loop-helix	O
(	O
bHLH	O
)	O
domain	O
.	O
The	O
bHLH	O
family	O
includes	O
subgroups	O
of	O
closely	O
related	O
proteins	O
that	O
share	O
common	O
functional	O
properties	O
and	O
overlapping	O
patterns	O
of	O
expression	O
(	O
e.g.	O
,	O
the	O
MyoD1	O
and	O
achaete	O
-	O
scute	O
subgroups	O
)	O
.	O
In	O
this	O
report	O
we	O
describe	O
HEN1	O
and	O
HEN2	O
,	O
mammalian	O
genes	O
that	O
encode	O
a	O
distinct	O
subgroup	O
of	O
bHLH	O
proteins	O
.	O
The	O
HEN1	O
gene	O
was	O
identified	O
on	O
the	O
basis	O
of	O
cross	O
-hybridization	O
with	O
TAL1	O
,	O
a	O
known	O
bHLH	O
gene	O
implicated	O
in	O
T-cell	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
In	O
situ	O
fluorescence	O
hybridization	O
was	O
used	O
to	O
localize	O
the	O
human	O
HEN1	O
gene	O
to	O
chromosome	O
band	O
1q22	O
.	O
HEN1	O
and	O
HEN2	O
are	O
coexpressed	O
in	O
the	O
IMR-32	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
and	O
they	O
encode	O
highly	O
related	O
proteins	O
of	O
133	O
and	O
135	O
residues	O
,	O
respectively	O
,	O
that	O
share	O
98	O
%	O
amino	O
acid	O
identity	O
in	O
their	O
hHLH	O
domains	O
.	O
These	O
data	O
imply	O
that	O
the	O
bHLH	O
protein	O
subgroup	O
encoded	O
by	O
HEN1	O
and	O
HEN2	O
may	O
serve	O
important	O
regulatory	O
functions	O
in	O
the	O
developing	O
nervous	O
system	O
.	O
PMID	O
:	O
1528853	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurochem	O
Res	O
.	O
2002	O
Aug;27	O
(	O
7-	O
8	O
)	O
:	O
841-6.	O
Modulation	O
of	O
neuritogenesis	O
by	O
ganglioside	O
-	O
specific	O
sialidase	O
(	O
Neu	O
3	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
NB-1	B-malignancy-type
cells	I-malignancy-type
.	O
Proshin	O
S	O
,	O
Yamaguchi	O
K,	O
Wada	O
T	O
,	O
Miyagi	O
T.	O
Division	O
of	O
Biochemistry	O
,	O
Research	O
Institute	O
of	O
Miyagi	O
Prefectural	O
Cancer	O
Center	O
,	O
Natori	O
,	O
Japan	O
.	O
Plasma	O
membrane	O
-	O
associated	O
sialidase	O
(	O
Neu	O
3	O
)	O
,	O
which	O
specifically	O
hydrolyzes	O
gangliosides	O
,	O
is	O
relatively	O
abundantly	O
present	O
in	O
the	O
nervous	O
system	O
.	O
To	O
understand	O
the	O
role	O
of	O
Neu	O
3	O
in	O
neuronal	O
differentiation	O
,	O
we	O
studied	O
the	O
relationship	O
between	O
neurite	O
outgrowth	O
and	O
Neu	O
3	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
NB-1	B-malignancy-type
cells	I-malignancy-type
.	O
The	O
expression	O
of	O
Neu	O
3	O
in	O
NB-1	B-malignancy-type
cells	I-malignancy-type
increased	O
when	O
neurite	O
outgrowth	O
in	O
these	O
cells	O
was	O
induced	O
by	O
dibutyryl	O
cAMP	O
.	O
While	O
treatment	O
with	O
dibutyryl	O
cAMP	O
alone	O
enhanced	O
the	O
outgrowth	O
of	O
dendrite	O
-	O
like	O
processes	O
,	O
transfection	O
of	O
the	O
Neu	O
3	O
gave	O
rise	O
to	O
a	O
more	O
prominent	O
outgrowth	O
of	O
neurites	O
with	O
axon	O
-	O
like	O
characteristics	O
,	O
even	O
in	O
the	O
absence	O
of	O
dibutyryl	O
cAMP	O
.	O
Neu	O
3	O
induction	O
by	O
dibutyryl	O
cAMP	O
is	O
probably	O
attributable	O
,	O
in	O
part	O
,	O
to	O
transactivation	O
of	O
the	O
Neu	O
3	O
gene	O
through	O
cAMP	O
responsive	O
elements	O
in	O
the	O
5'-upstream	O
region	O
,	O
as	O
revealed	O
by	O
the	O
promotor	O
activity	O
assay	O
using	O
Neu	O
3	O
promotor	O
expression	O
plasmid	O
.	O
These	O
results	O
indicate	O
that	O
Neu	O
3	O
regulates	O
neurite	O
formation	O
in	O
NB-1	B-malignancy-type
cells	I-malignancy-type
,	O
and	O
suggest	O
that	O
this	O
effect	O
may	O
be	O
enhanced	O
by	O
dibutyryl	O
cAMP	O
via	O
a	O
cAMP	O
-	O
dependent	O
pathway	O
.	O
PMID	O
:	O
12374221	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1995	O
Aug	O
15	O
;55	O
(	O
16	O
)	O
:	O
3471-4.	O
Duplication	O
of	O
N-MYC	O
at	O
its	O
resident	O
site	O
2p24	O
may	O
be	O
a	O
mechanism	O
of	O
activation	O
alternative	O
to	O
amplification	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
.	O
Corvi	O
R	O
,	O
Savelyeva	O
L,	O
Schwab	O
M.	O
Division	O
of	O
Cytogenetics	O
-0130	O
,	O
Deutsches	O
Krebsforschungszentrum	O
,	O
German	O
Cancer	O
Research	O
Center	O
,	O
Heidelberg	O
.	O
Amplification	O
of	O
the	O
human	O
N-MYC	O
proto	O
-	O
oncogene	O
is	O
frequently	O
seen	O
either	O
in	O
extrachromosomal	O
double	O
minutes	O
or	O
in	O
homogeneously	O
staining	O
regions	O
of	O
aggressively	O
growing	O
neuroblastomas	B-malignancy-type
.	O
N-MYC	O
maps	O
to	O
chromosome	O
2	O
band	O
p23-24	O
,	O
but	O
homogeneously	O
staining	O
regions	O
have	O
never	O
been	O
observed	O
at	O
this	O
band	O
,	O
suggesting	O
transposition	O
of	O
N-MYC	O
during	O
amplification	O
.	O
Previous	O
studies	O
had	O
suggested	O
that	O
in	O
cells	O
with	O
amplified	O
N-MYC	O
the	O
chromosomes	O
2	O
appear	O
to	O
be	O
unaltered	O
and	O
to	O
carry	O
one	O
apparently	O
normal	O
copy	O
of	O
N-MYC	O
each	O
.	O
In	O
contrast	O
,	O
the	O
contribution	O
of	O
N-MYC	O
to	O
tumors	O
which	O
lack	O
amplification	O
has	O
been	O
unclear	O
.	O
We	O
here	O
show	O
,	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
that	O
N-MYC	O
is	O
occasionally	O
duplicated	O
at	O
its	O
resident	O
site	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
previously	O
thought	O
to	O
have	O
a	O
single	O
copy	O
gene	O
.	O
Additionally	O
,	O
we	O
detected	O
duplication	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
carrying	O
amplification	O
.	O
Our	O
results	O
raise	O
the	O
possibility	O
that	O
duplication	O
may	O
,	O
in	O
some	O
neuroblastomas	B-malignancy-type
,	O
either	O
be	O
a	O
prelude	O
to	O
amplification	O
or	O
an	O
alternative	O
pathway	O
by	O
which	O
N-MYC	O
becomes	O
activated	O
.	O
PMID	O
:	O
7627947	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Med	O
Genet	O
.	O
2003	O
May	O
1;118A(	O
4	O
)	O
:	O
309	O
-	O
13	O
.	O
Homozygous	O
inactivation	O
of	O
NF1	O
gene	O
in	O
a	O
patient	O
with	O
familial	B-malignancy-type
NF1	I-malignancy-type
and	O
disseminated	O
neuroblastoma	B-malignancy-type
.	O
Origone	O
P,	O
Defferrari	O
R	O
,	O
Mazzocco	O
K,	O
Lo	O
Cunsolo	O
C	O
,	O
De	O
Bernardi	O
B	O
,	O
Tonini	O
GP	O
.	O
Department	O
of	O
Oncology	O
,	O
Biology	O
and	O
Genetics	O
,	O
University	O
of	O
Genoa	O
,	O
Italy	O
.	O
Neurofibromatosis	B-malignancy-type
type	I-malignancy-type
1	I-malignancy-type
(	O
NF1	B-malignancy-type
)	O
patients	O
are	O
susceptible	O
to	O
tumor	O
development	O
.	O
In	O
the	O
present	O
study	O
we	O
describe	O
a	O
child	O
with	O
NF1	B-malignancy-type
and	O
disseminated	O
neuroblastoma	B-malignancy-type
whose	O
death	O
resulted	O
from	O
disease	O
progression	O
.	O
The	O
mother	O
had	O
cafe	O
-	O
au-	O
lait	O
spots	O
suggesting	O
a	O
familial	B-malignancy-type
NF1	I-malignancy-type
.	O
Neuroblastoma	B-malignancy-type
cells	I-malignancy-type
showed	O
MYCN	O
amplification	O
and	O
chromosome	O
1p36	O
deletion	O
,	O
common	O
features	O
associated	O
with	O
tumor	O
progression	O
in	O
this	O
malignancy	O
.	O
The	O
NF1	O
gene	O
displayed	O
a	O
germline	O
T	O
-->	O
C	O
transition	O
of	O
intron	O
14	O
in	O
both	O
the	O
proband	O
and	O
mother	O
DNA	O
.	O
This	O
mutation	O
,	O
not	O
yet	O
previously	O
described	O
,	O
occurs	O
in	O
a	O
splicing	O
donor	O
site	O
and	O
produces	O
a	O
new	O
mRNA	O
variant	O
observed	O
together	O
with	O
normal	O
NF1	O
mRNA	O
.	O
Furthermore	O
,	O
the	O
SSCP	O
analysis	O
of	O
the	O
NF1	O
gene	O
in	O
tumor	O
cells	O
showed	O
a	O
somatic	O
deletion	O
encompassing	O
the	O
intron	O
26	O
and	O
27b	O
of	O
the	O
paternal	O
NF1	O
allele	O
.	O
Hence	O
,	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
displayed	O
both	O
somatic	O
and	O
germline	O
mutation	O
of	O
the	O
NF1	O
gene	O
.	O
Our	O
data	O
suggest	O
that	O
,	O
although	O
rare	O
,	O
neuroblastoma	B-malignancy-type
in	O
patients	O
with	O
NF1	B-malignancy-type
may	O
display	O
homozygous	O
gene	O
inactivation	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
12687660	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1986	O
Jun;46	O
(	O
6	O
)	O
:3196	O
-	O
9.	O
Detection	O
of	O
N-myc	O
oncogene	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
by	O
in	O
situ	O
hybridization	O
and	O
blot	O
analysis	O
:	O
relationship	O
to	O
clinical	O
outcome	O
.	O
Grady-Leopardi	O
EF	O
,	O
Schwab	O
M,	O
Ablin	O
AR	O
,	O
Rosenau	O
W	O
.	O
We	O
studied	O
N-myc	O
oncogene	O
expression	O
in	O
13	O
human	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
and	O
one	O
teratoma	B-malignancy-type
by	O
in	O
situ	O
hybridization	O
.	O
In	O
four	O
of	O
six	O
neuroblastomas	B-malignancy-type
,	O
there	O
was	O
increased	O
N-myc	O
expression	O
(	O
15	O
to	O
49	O
%	O
of	O
the	O
cells	O
)	O
.	O
Many	O
of	O
the	O
primitive	O
neuroblastic	B-malignancy-type
cells	I-malignancy-type
had	O
an	O
increase	O
of	O
N-myc	O
RNA	O
not	O
observed	O
in	O
the	O
larger	O
,	O
more	O
differentiated	O
cells	B-malignancy-type
.	O
Two	O
neuroblastomas	B-malignancy-type
matured	O
to	O
ganglioneuromas	B-malignancy-type
;	O
no	O
biopsies	O
performed	O
during	O
this	O
progression	O
expressed	O
increased	O
N-myc	O
RNA	O
.	O
Three	O
ganglioneuroblastomas	B-malignancy-type
,	O
two	O
tumors	B-malignancy-type
presenting	O
as	O
ganglioneuromas	B-malignancy-type
,	O
a	O
cerebral	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
,	O
a	O
neurofibrosarcoma	B-malignancy-type
,	O
and	O
the	O
teratoma	B-malignancy-type
did	O
not	O
have	O
increased	O
N-myc	O
expression	O
.	O
The	O
data	O
obtained	O
by	O
in	O
situ	O
hybridization	O
correlated	O
well	O
with	O
data	O
obtained	O
by	O
blot	O
analysis	O
.	O
Neuroblastomas	B-malignancy-type
/	O
ganglioneuroblastomas	B-malignancy-type
with	O
a	O
favorable	O
course	O
did	O
not	O
have	O
appreciable	O
elevation	O
of	O
N-myc	O
expression	O
over	O
10	O
to	O
77	O
mo	O
of	O
follow-up	O
;	O
thus	O
N-myc	O
may	O
not	O
be	O
involved	O
in	O
the	O
maintenance	O
of	O
the	O
neoplastic	O
state	O
.	O
However	O
,	O
such	O
tumors	B-malignancy-type
with	O
a	O
fatal	O
outcome	O
2	O
to	O
14	O
mo	O
after	O
diagnosis	O
usually	O
had	O
elevated	O
N-myc	O
expression	O
.	O
These	O
findings	O
suggest	O
a	O
relationship	O
between	O
elevated	O
levels	O
of	O
N-myc	O
RNA	O
and	O
poor	O
prognosis	O
.	O
PMID	O
:	O
2421891	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2002	O
Mar	O
22	O
;292	O
(	O
1	O
)	O
:	O
71	O
-	O
8.	O
Sp1	O
and	O
Sp3	O
activate	O
the	O
rat	O
connexin40	O
proximal	O
promoter	O
.	O
Teunissen	O
BE	O
,	O
van	O
Amersfoorth	O
SC	O
,	O
Opthof	O
T	O
,	O
Jongsma	O
HJ	O
,	O
Bierhuizen	O
MF.	O
Department	O
of	O
Medical	O
Physiology	O
,	O
University	O
Medical	O
Center	O
Utrecht	O
,	O
3508	O
AB	O
Utrecht	O
,	O
The	O
Netherlands	O
.	O
B.E.J.Teunissen@med	O
.uu.nl	O
The	O
rat	O
gap	O
junction	O
protein	O
connexin40	O
(	O
rCx40	O
)	O
has	O
a	O
characteristic	O
developmental	O
and	O
regional	O
expression	O
pattern	O
,	O
for	O
which	O
the	O
exact	O
regulatory	O
mechanisms	O
are	O
not	O
known	O
.	O
To	O
identify	O
the	O
molecular	O
factors	O
controlling	O
Cx40	O
expression	O
,	O
its	O
proximal	O
promoter	O
was	O
characterized	O
.	O
The	O
proximal	O
rCx40	O
promoter	O
is	O
the	O
most	O
conserved	O
noncoding	O
region	O
within	O
the	O
Cx40	O
-	O
gene	O
known	O
thus	O
far	O
and	O
contains	O
five	O
potential	O
binding	O
sites	O
for	O
Sp	O
-family	O
transcription	O
factors	O
.	O
The	O
binding	O
of	O
both	O
Sp1	O
and	O
Sp3	O
to	O
each	O
of	O
these	O
DNA	O
elements	O
was	O
demonstrated	O
by	O
EMSA	O
.	O
Luciferase	O
assays	O
of	O
the	O
natural	O
rCx40	O
proximal	O
promoter	O
or	O
mutated	O
derivatives	O
in	O
Cx40	O
-	O
expressing	O
(	O
NCM	O
,	O
primary	O
rat	O
neonatal	O
cardiomyocytes	O
and	O
A7r5	O
,	O
rat	O
smooth	O
muscle	O
embryonic	O
thoracic	O
aorta	O
cells	O
)	O
and	O
-	O
nonexpressing	O
cells	O
(	O
N2A	O
,	O
mouse	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
)	O
revealed	O
that	O
all	O
sites	O
are	O
contributing	O
to	O
basal	O
promoter	O
activity	O
.	O
Trans	O
-	O
activation	O
assays	O
in	O
Drosophila	O
Schneider	O
line	O
2	O
cells	O
demonstrated	O
that	O
Sp1	O
and	O
Sp3	O
activate	O
the	O
rCx40	O
proximal	O
promoter	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
additive	O
manner	O
.	O
(	O
C)2002	O
Elsevier	O
Science	O
(	O
USA	O
)	O
.	O
PMID	O
:	O
11890673	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Cell	O
Res	O
.	O
1987	O
Aug;171(	O
2	O
)	O
:	O
367	O
-	O
75	O
.	O
Heat	O
shock	O
gene	O
expression	O
and	O
cytoskeletal	O
alterations	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
van	O
Bergen	O
en	O
Henegouwen	O
PM	O
,	O
Linnemans	O
AM	O
.	O
The	O
cytoskeleton	O
of	O
neuroblastoma	B-malignancy-type
cells	O
,	O
clone	O
Neuro	O
2A	O
,	O
is	O
altered	O
by	O
two	O
stress	O
conditions	O
:	O
heat	O
shock	O
and	O
arsenite	O
treatment	O
.	O
Microtubules	O
are	O
reorganized	O
,	O
intermediate	O
filaments	O
are	O
aggregated	O
around	O
the	O
nucleus	O
,	O
and	O
the	O
number	O
of	O
stress	O
fibers	O
is	O
reduced	O
.	O
Since	O
both	O
stress	O
modalities	O
induce	O
similar	O
cytoskeletal	O
alterations	O
,	O
no	O
thermic	O
denaturation	O
of	O
one	O
or	O
more	O
cytoskeletal	O
components	O
can	O
be	O
involved	O
in	O
this	O
process	O
.	O
Heat	O
shock	O
proteins	O
are	O
induced	O
both	O
by	O
heat	O
and	O
by	O
arsenite	O
.	O
However	O
,	O
cells	O
treated	O
with	O
arsenite	O
synthesize	O
hsp28	O
which	O
is	O
not	O
detected	O
in	O
heat	O
-	O
treated	O
cells	O
.	O
Synthesis	O
of	O
all	O
hsps	O
is	O
prevented	O
by	O
addition	O
of	O
actinomycin	O
D	O
or	O
cycloheximide	O
.	O
Under	O
these	O
conditions	O
no	O
alterations	O
are	O
observed	O
in	O
the	O
organization	O
of	O
microtubules	O
and	O
intermediate	O
filaments	O
during	O
heat	O
or	O
arsenite	O
treatment	O
.	O
However	O
,	O
these	O
drugs	O
are	O
not	O
able	O
to	O
prevent	O
the	O
rapid	O
loss	O
of	O
stress	O
fibers	O
.	O
A	O
re	O
-	O
formation	O
of	O
the	O
cytoskeleton	O
during	O
the	O
recovery	O
period	O
proceeds	O
within	O
3	O
h	O
and	O
is	O
also	O
found	O
to	O
occur	O
in	O
the	O
presence	O
of	O
a	O
protein	O
synthesis	O
inhibitor	O
.	O
These	O
data	O
suggest	O
that	O
reorganization	O
of	O
microtubules	O
and	O
intermediate	O
filaments	O
during	O
a	O
stress	O
treatment	O
requires	O
the	O
synthesis	O
of	O
a	O
new	O
protein(s)	O
,	O
probably	O
hsp(s)	O
.	O
PMID	O
:	O
3305049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pharmacol	O
Exp	O
Ther	O
.	O
1989	O
Jan;248	O
(	O
1	O
)	O
:	O
111-	O
8.	O
Spontaneous	O
regeneration	O
of	O
free	O
muscarinic	O
receptor	O
after	O
alkylation	O
by	O
BM	O
123	O
.	O
I	O
.	O
Recovery	O
in	O
vivo	O
and	O
in	O
cell	O
culture	O
.	O
Waite	O
JJ	O
,	O
Jenden	O
DJ.	O
Department	O
of	O
Pharmacology	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
.	O
The	O
recovery	O
of	O
rat	O
muscarinic	O
receptor	O
number	O
from	O
the	O
effects	O
of	O
a	O
specific	O
alkylating	O
ligand	O
,	O
N	O
-	O
[	O
4	O
-	O
(	O
2	O
-	O
chloroethylmethylamino	O
)	O
-	O
2	O
-	O
butynyl	O
]	O
-	O
2	O
-	O
pyrrolidone	O
(	O
BM	O
123	O
)	O
,	O
in	O
three	O
tissues	O
is	O
presented	O
as	O
an	O
exponential	O
function	O
of	O
time	O
.	O
No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
recovery	O
rate	O
constants	O
derived	O
from	O
analysis	O
of	O
recovery	O
time	O
courses	O
in	O
corpus	O
striatum	O
,	O
cerebral	O
cortex	O
and	O
ileal	O
longitudinal	O
muscle	O
.	O
The	O
single	O
rate	O
constant	O
(	O
0.021	O
/	O
hr	O
)	O
was	O
also	O
independent	O
of	O
amount	O
and	O
duration	O
of	O
BM	O
123	O
dose	O
.	O
Additional	O
analysis	O
of	O
agonist	O
-	O
defined	O
high	O
and	O
low	O
affinity	O
subsites	O
in	O
cortex	O
revealed	O
that	O
recovery	O
of	O
these	O
populations	O
also	O
followed	O
similar	O
time	O
courses	O
although	O
the	O
alkylation	O
proceeds	O
more	O
slowly	O
for	O
the	O
high	O
affinity	O
sites	O
.	O
The	O
rate	O
constant	O
for	O
recovery	O
of	O
both	O
subsites	O
was	O
0.029	O
/	O
hr	O
.	O
Recovery	O
from	O
BM	O
123	O
alkylation	O
occurred	O
in	O
NG108	O
-	O
15	O
neuroblastoma	B-malignancy-type
X	O
glioma	B-malignancy-type
cells	O
.	O
The	O
presence	O
of	O
cycloheximide	O
in	O
the	O
recovery	O
medium	O
did	O
not	O
significantly	O
inhibit	O
this	O
recovery	O
process	O
in	O
the	O
clonal	O
cell	O
line	O
,	O
suggesting	O
that	O
de	O
novo	O
receptor	O
synthesis	O
is	O
unnecessary	O
for	O
regeneration	O
of	O
unalkylated	O
receptors	O
.	O
PMID	O
:	O
2913265	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuron	O
.	O
1996	O
Nov;17(	O
5	O
)	O
:	O
1005	O
-13	O
.	O
Familial	O
Alzheimer	O
'	O
s	O
disease	O
-	O
linked	O
presenilin	O
1	O
variants	O
elevate	O
Abeta	O
1	O
-	O
42	O
/	O
1	O
-	O
40	O
ratio	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Borchelt	O
DR	O
,	O
Thinakaran	O
G	O
,	O
Eckman	O
CB	O
,	O
Lee	O
MK	O
,	O
Davenport	O
F	O
,	O
Ratovitsky	O
T	O
,	O
Prada	O
CM	O
,	O
Kim	O
G	O
,	O
Seekins	O
S	O
,	O
Yager	O
D	O
,	O
Slunt	O
HH	O
,	O
Wang	O
R	O
,	O
Seeger	O
M,	O
Levey	O
AI	O
,	O
Gandy	O
SE	O
,	O
Copeland	O
NG	O
,	O
Jenkins	O
NA	O
,	O
Price	O
DL	O
,	O
Younkin	O
SG	O
,	O
Sisodia	O
SS	O
.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
presenilin	O
1	O
(	O
PS1	O
)	O
and	O
presenilin	O
2	O
genes	O
cosegregate	O
with	O
the	O
majority	O
of	O
early	O
-	O
onset	O
familial	O
Alzheimer	O
'	O
s	O
disease	O
(	O
FAD	O
)	O
pedigrees	O
.	O
We	O
now	O
document	O
that	O
the	O
Abeta	O
1	O
-	O
42	O
(	O
43	O
)	O
/	O
Abeta	O
1	O
-	O
40	O
ratio	O
in	O
the	O
conditioned	O
media	O
of	O
independent	O
N2a	O
cell	O
lines	O
expressing	O
three	O
FAD	O
-	O
linked	O
PS1	O
variants	O
is	O
uniformly	O
elevated	O
relative	O
to	O
cells	O
expressing	O
similar	O
levels	O
of	O
wild	O
-	O
type	O
PS1	O
.	O
Similarly	O
,	O
the	O
Abeta	O
1	O
-	O
42	O
(	O
43	O
)	O
/	O
Abeta	O
1	O
-	O
40	O
ratio	O
is	O
elevated	O
in	O
the	O
brains	O
of	O
young	O
transgenic	O
animals	O
coexpressing	O
a	O
chimeric	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
and	O
an	O
FAD	O
-	O
linked	O
PS1	O
variant	O
compared	O
with	O
brains	O
of	O
transgenic	O
mice	O
expressing	O
APP	O
alone	O
or	O
transgenic	O
mice	O
coexpressing	O
wild	O
-	O
type	O
human	O
PS1	O
and	O
APP	O
.	O
These	O
studies	O
provide	O
compelling	O
support	O
for	O
the	O
view	O
that	O
one	O
mechanism	O
by	O
which	O
these	O
mutant	O
PS1	O
cause	O
AD	O
is	O
by	O
increasing	O
the	O
extracellular	O
concentration	O
of	O
Abeta	O
peptides	O
terminating	O
at	O
42	O
(	O
43	O
)	O
,	O
species	O
that	O
foster	O
Abeta	O
deposition	O
.	O
PMID	O
:	O
8938131	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genomics	O
.	O
1998	O
May	O
1;49(	O
3	O
)	O
:	O
385	O
-	O
93	O
.	O
Duplication	O
of	O
the	O
DR	O
3	O
gene	O
on	O
human	O
chromosome	O
1	O
p	O
36	O
and	O
its	O
deletion	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Grenet	O
J,	O
Valentine	O
V	O
,	O
Kitson	O
J,	O
Li	O
H,	O
Farrow	O
SN	O
,	O
Kidd	O
VJ.	O
Department	O
of	O
Tumor	O
Cell	O
Biology	O
,	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
Memphis	O
,	O
Tennessee	O
38101	O
,	O
USA	O
.	O
The	O
human	O
DR	O
3	O
gene	O
,	O
whose	O
product	O
is	O
also	O
known	O
as	O
Wsl	O
-	O
1	O
/	O
APO	O
-	O
3	O
/	O
TRAMP	O
/	O
LARD	O
,	O
encodes	O
a	O
tumor	O
necrosis	O
factor	O
-	O
related	O
receptor	O
that	O
is	O
expressed	O
primarily	O
on	O
the	O
surface	O
of	O
thymocytes	O
and	O
lymphocytes	O
.	O
DR	O
3	O
is	O
capable	O
of	O
inducing	O
both	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
apoptosis	O
when	O
overexpressed	O
in	O
mammalian	O
cells	O
,	O
although	O
its	O
ligand	O
has	O
not	O
yet	O
been	O
identified	O
.	O
We	O
report	O
here	O
that	O
the	O
DR	O
3	O
gene	O
locus	O
is	O
tandemly	O
duplicated	O
on	O
human	O
chromosome	O
band	O
1	O
p	O
36.2	O
-	O
p	O
36.3	O
and	O
that	O
these	O
genes	O
are	O
hemizygously	O
deleted	O
and	O
/	O
or	O
translocated	O
to	O
another	O
chromosome	O
in	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cell	O
lines	O
with	O
amplified	O
MYCN	O
.	O
Duplication	O
of	O
at	O
least	O
a	O
portion	O
of	O
the	O
DR	O
3	O
gene	O
,	O
including	O
the	O
extracellular	O
and	O
transmembrane	O
regions	O
but	O
not	O
the	O
cytoplasmic	O
domain	O
,	O
was	O
demonstrated	O
by	O
both	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
genomic	O
Southern	O
blotting	O
.	O
In	O
most	O
NB	B-malignancy-type
cell	O
lines	O
,	O
both	O
the	O
DR	O
3	O
and	O
the	O
DR	O
3	O
L	O
sequences	O
are	O
simultaneously	O
deleted	O
and	O
/	O
or	O
translocated	O
to	O
another	O
chromosome	O
.	O
Finally	O
,	O
DR3	O
/	O
Wsl	O
-	O
1	O
protein	O
expression	O
is	O
quite	O
variable	O
among	O
these	O
NB	B-malignancy-type
cell	O
lines	O
,	O
with	O
very	O
low	O
or	O
undetectable	O
levels	O
in	O
7	O
of	O
17	O
NB	B-malignancy-type
cell	O
lines	O
.	O
PMID	O
:	O
9615223	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Biol	O
Rep.	O
2000	O
Jun;27	O
(	O
2	O
)	O
:	O
113-	O
21	O
.	O
Efficient	O
DNA	O
transfection	O
in	O
neuronal	O
and	O
astrocytic	O
cell	O
lines	O
.	O
Ghosh	O
C	O
,	O
Song	O
W	O
,	O
Lahiri	O
DK.	O
Institute	O
of	O
Psychiatric	O
Research	O
,	O
Department	O
of	O
Psychiatry	O
,	O
Indiana	O
University	O
School	O
of	O
Medicine	O
,	O
Indianapolis	O
46202	O
,	O
USA	O
.	O
We	O
have	O
studied	O
different	O
parameters	O
for	O
efficient	O
DNA	O
transfection	O
in	O
various	O
cell	O
types	O
and	O
with	O
different	O
size	O
of	O
the	O
promoter	O
.	O
Here	O
we	O
report	O
that	O
the	O
optimum	O
condition	O
for	O
DNA	O
transfection	O
by	O
electroporation	O
is	O
350	O
V	O
/	O
960	O
microF	O
for	O
PC	O
12	O
,	O
450	O
V	O
/	O
960	O
microF	O
C6	O
cells	O
,	O
and	O
250	O
V	O
/	O
500	O
microF	O
for	O
COS-1	O
cells	O
.	O
For	O
the	O
human	O
neuroblastoma	B-malignancy-type
(	O
SK	O
-	O
N	O
-	O
SH	O
)	O
cells	O
the	O
optimum	O
condition	O
for	O
DNA	O
transfection	O
is	O
by	O
the	O
calcium	O
phosphate	O
method	O
.	O
In	O
promoter	O
mapping	O
studies	O
,	O
a	O
serial	O
deletion	O
approach	O
is	O
commonly	O
used	O
.	O
To	O
optimize	O
transfection	O
we	O
have	O
selected	O
three	O
DNA	O
constructs	O
that	O
varied	O
in	O
size	O
from	O
4.5	O
to	O
12.4	O
kilobases	O
(	O
kb	O
)	O
.	O
We	O
measured	O
the	O
promoter	O
activity	O
of	O
these	O
constructs	O
under	O
conditions	O
of	O
'	O
equal	O
amount	O
'	O
,	O
'	O
equimolar	O
'	O
,	O
and	O
'	O
equimolar	O
plus	O
carrier	O
DNA	O
to	O
make	O
it	O
equal	O
amount	O
'	O
.	O
We	O
recommend	O
that	O
for	O
comparative	O
purpose	O
,	O
transfection	O
should	O
be	O
carried	O
out	O
under	O
'	O
equimolar	O
condition	O
'	O
without	O
a	O
need	O
to	O
adjust	O
the	O
total	O
amount	O
of	O
DNA	O
by	O
carrier	O
DNA	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
efficient	O
methods	O
for	O
DNA	O
transfection	O
are	O
important	O
to	O
study	O
gene	O
regulation	O
by	O
devising	O
better	O
ways	O
to	O
deliver	O
DNA	O
into	O
the	O
mammalian	O
cells	O
.	O
PMID	O
:	O
11092558	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Radiol	O
Diagn	O
(	O
Stockh	O
)	O
.	O
1986	O
Jan-	O
Feb;27	O
(	O
1	O
)	O
:	O
3-	O
10	O
.	O
Suprarenal	B-malignancy-type
haematoma	I-malignancy-type
versus	O
neuroblastoma	B-malignancy-type
complicated	O
by	O
haemorrhage	O
.	O
A	O
diagnostic	O
dilemma	O
in	O
the	O
newborn	O
.	O
Eklof	O
O	O
,	O
Mortensson	O
W	O
,	O
Sandstedt	O
B.	O
Concomitant	O
neonatal	O
suprarenal	O
haemorrhage	O
and	O
neuroblastoma	B-malignancy-type
is	O
rare	O
.	O
The	O
clinical	O
and	O
radiologic	O
manifestations	O
recorded	O
in	O
11	O
patients	O
with	O
this	O
entity	O
are	O
compared	O
with	O
the	O
findings	O
in	O
32	O
cases	O
with	O
simple	O
adrenal	O
haemorrhage	O
.	O
Because	O
of	O
the	O
many	O
similarities	O
in	O
presentation	O
the	O
combined	O
lesion	O
must	O
always	O
be	O
considered	O
when	O
a	O
neonate	O
is	O
found	O
to	O
have	O
a	O
retroperitoneal	O
,	O
extra	O
-	O
renal	O
mass	O
.	O
Our	O
present	O
approach	O
to	O
the	O
investigation	O
includes	O
conventional	O
chest	O
and	O
abdominal	O
radiography	O
aimed	O
to	O
demonstrate	O
possible	O
paravertebral	O
widening	O
.	O
Serial	O
ultrasonographies	O
are	O
easy	O
to	O
carry	O
out	O
and	O
indispensable	O
.	O
The	O
low	O
specificity	O
of	O
urography	O
makes	O
us	O
refrain	O
from	O
this	O
modality	O
as	O
a	O
routine	O
.	O
Scintigraphy	O
,	O
in	O
infants	O
and	O
children	O
considered	O
useful	O
in	O
demonstrating	O
extent	O
and	O
spread	O
of	O
neuroblastoma	B-malignancy-type
,	O
has	O
hardly	O
been	O
employed	O
in	O
neonates	O
.	O
The	O
true	O
value	O
of	O
the	O
modality	O
in	O
this	O
particular	O
age	O
group	O
remains	O
to	O
be	O
settled	O
.	O
CT	O
scanning	O
does	O
not	O
seem	O
to	O
provide	O
essential	O
information	O
additional	O
to	O
that	O
of	O
sonography	O
and	O
may	O
therefore	O
be	O
excluded	O
from	O
the	O
protocol	O
.	O
Determination	O
of	O
urinary	O
excretion	O
of	O
catecholamine	O
metabolites	O
is	O
of	O
crucial	O
significance	O
and	O
a	O
compulsory	O
part	O
of	O
the	O
investigation	O
.	O
PMID	O
:	O
3515856	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Parasitol	O
.	O
1982	O
Dec;68	O
(	O
6	O
)	O
:	O
1110-	O
6.	O
Cytopathogenicity	O
of	O
Naegleria	O
fowleri	O
and	O
Naegleria	O
gruberi	O
for	O
established	O
mammalian	O
cell	O
cultures	O
.	O
Marciano-	O
Cabral	O
FM	O
,	O
Patterson	O
M,	O
John	O
DT	O
,	O
Bradley	O
SG.	O
Amebae	O
of	O
Naegleria	O
fowleri	O
and	O
Naegleria	O
gruberi	O
were	O
cytopathic	O
for	O
nine	O
established	O
mammalian	O
cell	O
cultures	O
,	O
including	O
mouse	O
and	O
human	O
fibroblasts	O
,	O
rabbit	O
and	O
monkey	O
kidney	O
cells	O
,	O
rat	O
and	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
,	O
baby	O
hamster	O
kidney	O
cells	O
,	O
and	O
human	O
epithelioma	B-malignancy-type
and	O
carcinoma	B-malignancy-type
cells	O
.	O
Nine	O
strains	O
of	O
N	O
.	O
fowleri	O
were	O
equally	O
cytopathic	O
for	O
rodent	O
neuroblastoma	B-malignancy-type
cells	O
.	O
As	O
few	O
as	O
one	O
ameba	O
per	O
million	O
neuroblastoma	B-malignancy-type
cells	O
destroyed	O
the	O
mammalian	O
target	O
cells	O
after	O
9	O
days	O
.	O
The	O
N	O
.	O
fowleri	O
grew	O
and	O
destroyed	O
rat	O
neuroblastoma	B-malignancy-type
cells	O
at	O
30	O
to	O
37	O
C	O
whereas	O
N	O
.	O
gruberi	O
grew	O
and	O
destroyed	O
the	O
target	O
cells	O
at	O
25	O
to	O
30	O
C	O
.	O
Both	O
N	O
.	O
fowleri	O
and	O
N	O
.	O
gruberi	O
attached	O
efficiently	O
to	O
the	O
target	O
cells	O
at	O
30	O
to	O
37	O
C	O
;	O
N	O
.	O
gruberi	O
but	O
not	O
N	O
.	O
fowleri	O
attached	O
efficiently	O
at	O
25	O
C	O
.	O
Electron	O
microscopic	O
observations	O
of	O
mixed	O
cultures	O
of	O
N	O
.	O
fowleri	O
and	O
neuroblastoma	B-malignancy-type
cells	O
established	O
that	O
the	O
amebae	O
,	O
after	O
12	O
hr	O
,	O
had	O
ingested	O
portions	O
of	O
the	O
neuroblastoma	B-malignancy-type
target	O
cells	O
without	O
causing	O
cell	O
lysis	O
.	O
Conversely	O
,	O
N	O
.	O
gruberi	O
amebae	O
,	O
after	O
attaching	O
to	O
target	O
cells	O
,	O
disrupted	O
the	O
plasma	O
membrane	O
and	O
cytoplasm	O
of	O
the	O
target	O
cells	O
although	O
the	O
target	O
cell	O
nucleus	O
remained	O
intact	O
.	O
The	O
amebae	O
then	O
ingested	O
the	O
target	O
cell	O
debris	O
.	O
PMID	O
:	O
6816913	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
.	O
1992	O
Apr;5	O
9	O
(	O
2	O
)	O
:	O
128-34	O
.	O
Detection	O
of	O
MYCN	O
amplification	O
in	O
three	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
by	O
non	O
-	O
radioactive	O
chromosomal	O
in	O
situ	O
hybridization	O
.	O
McRobert	O
TL	O
,	O
Rudduck	O
C	O
,	O
Kees	O
UR	O
,	O
Garson	O
OM	O
.	O
Department	O
of	O
Cytogenetics	O
,	O
St.	O
Vincent	O
's	O
Hospital	O
,	O
Fitzroy	O
,	O
Victoria	O
,	O
Australia	O
.	O
A	O
non	O
-	O
radioactive	O
chromosomal	O
in	O
situ	O
hybridization	O
technique	O
utilizing	O
a	O
biotin	O
-	O
streptavidin	O
-	O
polyalkaline	O
-	O
phosphatase	O
complex	O
was	O
successfully	O
applied	O
to	O
three	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
for	O
detection	O
of	O
MYCN	O
amplification	O
.	O
These	O
cell	O
lines	O
,	O
designated	O
PER	O
-	O
106	O
,	O
PER	O
-	O
107	O
,	O
and	O
PER	O
-	O
108	O
,	O
were	O
derived	O
from	O
consecutive	O
bone	O
marrow	O
samples	O
taken	O
from	O
a	O
patient	O
with	O
stage	O
IV	O
neuroblastoma	B-malignancy-type
.	O
The	O
cell	O
line	O
derived	O
at	O
diagnosis	O
(	O
PER	O
-	O
106	O
)	O
exhibited	O
MYCN	O
amplification	O
in	O
the	O
form	O
of	O
variable	O
numbers	O
of	O
double	O
-	O
minute	O
chromosomes	O
,	O
small	O
fragments	O
,	O
and	O
rings	O
of	O
varying	O
sizes	O
.	O
This	O
observed	O
variability	O
of	O
MYCN	O
amplification	O
may	O
explain	O
the	O
reported	O
heterogeneity	O
of	O
both	O
MYCN	O
mRNA	O
and	O
protein	O
expression	O
among	O
individual	O
cells	O
of	O
some	O
neuroblastomas	B-malignancy-type
.	O
The	O
cell	O
lines	O
derived	O
from	O
subsequent	O
samples	O
(	O
PER	O
-	O
107	O
and	O
PER	O
-	O
108	O
)	O
contained	O
amplified	O
MYCN	O
as	O
two	O
consistent	O
homogeneously	O
staining	O
regions	O
in	O
every	O
cell	O
.	O
These	O
were	O
located	O
on	O
the	O
short	O
arms	O
of	O
chromosomes	O
6	O
and	O
14	O
.	O
Thus	O
,	O
amplified	O
MYCN	O
was	O
identified	O
in	O
each	O
cell	O
line	O
and	O
demonstrated	O
the	O
concurrent	O
evolution	O
of	O
amplification	O
with	O
cytogenetic	O
abnormalities	O
.	O
PMID	O
:	O
1581879	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gene	O
.	O
1995	O
Jan	O
11	O
;152(	O
1	O
)	O
:	O
35	O
-	O
9.	O
Functional	O
phage	O
display	O
of	O
ciliary	O
neurotrophic	O
factor	O
.	O
Saggio	O
I	O
,	O
Gloaguen	O
I	O
,	O
Laufer	O
R.	O
Istituto	O
di	O
Ricerche	O
di	O
Biologia	O
Molecolare	O
P.	O
Angeletti	O
(	O
IRBM	O
)	O
,	O
Pomezia	O
(	O
Roma	O
)	O
,	O
Italy	O
.	O
We	O
report	O
the	O
display	O
of	O
human	O
ciliary	O
neurotrophic	O
factor	O
(	O
hCNTF	O
)	O
,	O
a	O
survival	O
factor	O
for	O
neuronal	O
cells	O
belonging	O
to	O
the	O
alpha	O
-	O
helical	O
cytokine	O
superfamily	O
,	O
on	O
the	O
surface	O
of	O
the	O
filamentous	O
bacteriophage	O
fd	O
.	O
The	O
hCNTF	O
cDNA	O
was	O
fused	O
to	O
a	O
DNA	O
sequence	O
encoding	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
pIII	O
,	O
a	O
minor	O
coat	O
protein	O
exposed	O
at	O
one	O
end	O
of	O
fd	O
.	O
Gene	O
fusions	O
were	O
cloned	O
into	O
a	O
plasmid	O
containing	O
the	O
ColE1	O
plasmid	O
and	O
fd	O
origins	O
of	O
replication	O
,	O
and	O
were	O
packaged	O
into	O
phagemid	O
particles	O
upon	O
superinfection	O
with	O
M13KO7	O
helper	O
phage	O
.	O
The	O
resulting	O
fusion	O
phage	O
bound	O
specifically	O
to	O
anti	O
-	O
CNTF	O
antibodies	O
and	O
to	O
the	O
recombinant	O
soluble	O
CNTF	O
alpha	O
-	O
receptor	O
.	O
Moreover	O
,	O
phage	O
-	O
displayed	O
hCNTF	O
was	O
found	O
to	O
possess	O
biological	O
activity	O
at	O
concentrations	O
comparable	O
to	O
those	O
of	O
the	O
soluble	O
cytokine	O
.	O
These	O
results	O
demonstrate	O
that	O
CNTF	O
can	O
be	O
displayed	O
on	O
phage	O
in	O
a	O
correctly	O
folded	O
and	O
functionally	O
active	O
form	O
.	O
Binding	O
of	O
fusion	O
phage	O
to	O
immobilized	O
CNTF	O
alpha	O
-	O
receptor	O
and	O
subsequent	O
elution	O
at	O
low	O
pH	O
resulted	O
in	O
affinity	O
purification	O
of	O
CNTF	O
-	O
displaying	O
virions	O
.	O
Utilization	O
of	O
this	O
technology	O
should	O
enable	O
the	O
selection	O
of	O
high	O
-	O
affinity	O
variants	O
from	O
libraries	O
of	O
CNTF	O
mutants	O
displayed	O
on	O
phage	O
.	O
PMID	O
:	O
7828925	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuropeptides	O
.	O
2002	O
Feb;36	O
(	O
1	O
)	O
:	O
13-	O
21	O
.	O
Differences	O
in	O
the	O
expression	O
of	O
neurokinin	O
receptor	O
in	O
neural	O
and	O
bone	O
marrow	O
mesenchymal	O
cells	O
:	O
implications	O
for	O
neuronal	O
expansion	O
from	O
bone	O
marrow	O
cells	O
.	O
Bandari	O
PS	O
,	O
Qian	O
J,	O
Yehia	O
G	O
,	O
Seegopaul	O
HP	O
,	O
Harrison	O
JS	O
,	O
Gascon	O
P,	O
Fernandes	O
H,	O
Rameshwar	O
P.	O
UMDNJ-New	O
Jersey	O
Medical	O
School	O
,	O
Newark	O
,	O
NJ	O
07103	O
,	O
USA	O
.	O
The	O
neurokinin	O
-	O
1	O
(	O
NK	O
-	O
1	O
)	O
receptor	O
interacts	O
with	O
peptides	O
that	O
belong	O
to	O
the	O
tachykinin	O
family	O
.	O
NK	O
-	O
1	O
is	O
inducible	O
in	O
bone	O
marrow	O
(	O
BM	O
)	O
stroma	O
.	O
In	O
neural	O
cells	O
,	O
its	O
expression	O
is	O
high	O
to	O
constitutive	O
.	O
Screening	O
of	O
three	O
cDNA	O
libraries	O
indicated	O
that	O
this	O
different	O
in	O
NK	O
-	O
1	O
expression	O
in	O
neural	O
and	O
BM	O
cells	O
could	O
not	O
be	O
explained	O
by	O
differences	O
in	O
the	O
cDNA	O
sequence	O
.	O
Analyses	O
the	O
5	O
'	O
flanking	O
sequence	O
in	O
BM	O
stroma	O
and	O
three	O
neural	O
cell	O
lines	O
indicated	O
that	O
sequence	O
+1	O
/	O
+358	O
relative	O
to	O
the	O
transcription	O
start	O
(	O
TS	O
)	O
site	O
could	O
account	O
for	O
the	O
differences	O
in	O
NK	O
-	O
1	O
expression	O
.	O
Particular	O
cytokines	O
could	O
reverse	O
the	O
repressive	O
effects	O
of	O
region	O
+1	O
/	O
+358	O
in	O
BM	O
stroma	O
.	O
The	O
effects	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
cAMP	O
activators	O
were	O
studied	O
in	O
stromal	O
cells	O
using	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
I	O
kappa	O
B	O
)	O
or	O
a	O
repressor	O
of	O
CRE	O
activators	O
(	O
ICERII	O
gamma	O
)	O
.	O
The	O
results	O
showed	O
that	O
their	O
effects	O
of	O
these	O
transcription	O
factors	O
depended	O
on	O
the	O
stimulating	O
cytokine	O
.	O
This	O
study	O
provides	O
insight	O
into	O
the	O
tissue	O
-	O
specific	O
differences	O
in	O
the	O
expression	O
of	O
the	O
NK	O
-	O
1	O
gene	O
.	O
PMID	O
:	O
12147210	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
1994	O
Apr	O
18	O
;	O
643	O
(	O
1-2	O
:	O
108-14	O
.	O
Cytotoxicity	O
of	O
the	O
cocaine	O
metabolite	O
benzoylecgonine	O
.	O
Lin	O
Y	O
,	O
Leskawa	O
KC	O
.	O
Department	O
of	O
Anatomical	O
Sciences	O
and	O
Neurobiology	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Louisville	O
,	O
KY	O
40292	O
.	O
The	O
NG108-15	O
and	O
C6	O
cell	O
lines	O
were	O
used	O
in	O
the	O
present	O
study	O
as	O
neuronal	O
and	O
glial	O
models	O
,	O
respectively	O
,	O
to	O
examine	O
the	O
cytotoxicity	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	O
,	O
benzoylecgonine	O
(	O
BE	O
)	O
.	O
Exposure	O
of	O
both	O
cell	O
types	O
to	O
varying	O
concentrations	O
of	O
BE	O
resulted	O
in	O
a	O
loss	O
of	O
cells	O
from	O
the	O
growth	O
surface	O
.	O
Analysis	O
of	O
the	O
unattached	O
cells	O
after	O
such	O
exposure	O
,	O
using	O
a	O
variety	O
of	O
techniques	O
,	O
revealed	O
that	O
these	O
cells	O
were	O
not	O
viable	O
.	O
Therefore	O
,	O
this	O
effect	O
could	O
not	O
be	O
ascribed	O
to	O
BE	O
interfering	O
with	O
cell	O
-	O
substratum	O
interactions	O
.	O
The	O
early	O
events	O
in	O
BE	O
cytotoxicity	O
were	O
examined	O
by	O
observing	O
cells	O
cultivated	O
on	O
the	O
stage	O
of	O
an	O
inverted	O
microscope	O
,	O
using	O
differential	O
interference	O
contrast	O
(	O
Nomarski	O
)	O
optics	O
.	O
Upon	O
exposure	O
of	O
either	O
cell	O
type	O
to	O
10	O
microM	O
BE	O
a	O
retraction	O
of	O
cellular	O
processes	O
could	O
be	O
observed	O
within	O
30	O
min	O
.	O
Within	O
6	O
h	O
cell	O
death	O
was	O
apparent	O
.	O
Similar	O
analyses	O
using	O
50	O
microM	O
BE	O
in	O
the	O
growth	O
medium	O
resulted	O
in	O
similar	O
results	O
,	O
except	O
that	O
process	O
retraction	O
could	O
be	O
observed	O
as	O
early	O
as	O
15	O
min	O
after	O
exposure	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
major	O
metabolite	O
of	O
cocaine	O
,	O
benzoylecgonine	O
,	O
is	O
cytotoxic	O
to	O
in	O
vitro	O
models	O
of	O
neuronal	O
and	O
glial	O
cells	O
.	O
PMID	O
:	O
8032908	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neurosci	O
Lett	O
.	O
2001	O
Nov	O
13	O
;	O
314	O
(	O
)	O
21-4	O
Characterization	O
of	O
the	O
5'-sequence	O
of	O
the	O
mouse	O
fatty	O
acid	O
amide	O
hydrolase	O
.	O
Puffenbarger	O
RA	O
,	O
Kapulina	O
O	O
,	O
Howell	O
JM	O
,	O
Deutsch	O
DG.	O
Department	O
of	O
Biology	O
,	O
Bridgewater	O
College	O
,	O
402	O
East	O
College	O
Street	O
,	O
Bridgewater	O
,	O
VA	O
22812-1599	O
,	O
USA	O
.	O
Fatty	O
acid	O
amide	O
hydrolase	O
(	O
FAAH	O
)	O
is	O
critical	O
for	O
degradation	O
of	O
several	O
important	O
fatty	O
acid	O
amides	O
including	O
anandamide	O
,	O
an	O
endocannabinoid	O
,	O
as	O
well	O
as	O
oleamide	O
,	O
a	O
sleep	O
-	O
inducing	O
factor	O
.	O
These	O
compounds	O
play	O
roles	O
in	O
diverse	O
physiological	O
processes	O
ranging	O
from	O
memory	O
and	O
learning	O
to	O
the	O
regulation	O
of	O
blood	O
pressure	O
.	O
The	O
mechanisms	O
that	O
regulate	O
FAAH	O
expression	O
have	O
not	O
been	O
characterized	O
.	O
A	O
5'-region	O
of	O
the	O
mouse	O
FAAH	O
with	O
promoter	O
activity	O
was	O
isolated	O
from	O
1.8	O
kbp	O
of	O
genomic	O
sequence	O
.	O
Characterization	O
of	O
+1	O
of	O
transcription	O
of	O
FAAH	O
by	O
RNA	O
ligase	O
mediated	O
-rapid	O
amplification	O
of	O
cDNA	O
ends	O
showed	O
that	O
FAAH	O
mRNA	O
is	O
transcribed	O
from	O
multiple	O
transcription	O
start	O
sites	O
lacking	O
a	O
TATA	O
-box	O
element	O
.	O
Functional	O
analysis	O
of	O
the	O
FAAH	O
upstream	O
sequence	O
fused	O
to	O
a	O
luciferase	O
reporter	O
gene	O
revealed	O
a	O
FAAH	O
-	O
promoter	O
construct	O
with	O
tissue	O
specific	O
activity	O
.	O
A	O
674-bp	O
FAAH	O
-	O
promoter	O
construct	O
was	O
active	O
in	O
N18TG2	O
(	O
N18	O
)	O
neuroblastoma	B-malignancy-type
cells	O
and	O
C6	O
glioma	B-malignancy-type
cells	O
,	O
lines	O
that	O
have	O
endogenous	O
FAAH	O
activity	O
.	O
The	O
same	O
674	O
-bp	O
FAAH	O
-	O
promoter	O
construct	O
was	O
not	O
active	O
in	O
C2C12	O
or	O
L6	O
myogenic	O
cells	O
,	O
two	O
lines	O
that	O
do	O
not	O
have	O
FAAH	O
activity	O
.	O
PMID	O
:	O
11698137	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

EMBO	O
J	O
.	O
1987	O
May	O
;	O
6	O
(	O
5	O
)	O
:	O
1339-44	O
.	O
Characterization	O
of	O
a	O
cell	O
type	O
-	O
specific	O
enhancer	O
found	O
in	O
the	O
human	O
papilloma	O
virus	O
type	O
18	O
genome	O
.	O
Swift	O
FV	O
,	O
Bhat	O
K,	O
Younghusband	O
HB	O
,	O
Hamada	O
H	O
.	O
We	O
have	O
previously	O
isolated	O
long-range	O
acting	O
enhancer	O
elements	O
from	O
the	O
HeLa	O
genome	O
by	O
functional	O
selection	O
.	O
In	O
this	O
report	O
,	O
the	O
structural	O
and	O
functional	O
characteristics	O
of	O
one	O
(	O
GA1	O
)	O
of	O
the	O
enhancers	O
are	O
reported	O
.	O
By	O
cloning	O
various	O
restriction	O
fragments	O
and	O
by	O
deletion	O
mutagenesis	O
,	O
the	O
activity	O
of	O
GA1	O
was	O
located	O
in	O
a	O
230-bp	O
region	O
.	O
The	O
nucleotide	O
sequence	O
of	O
GA1	O
and	O
genomic	O
Southern	O
blot	O
analysis	O
indicated	O
that	O
GA1	O
is	O
derived	O
from	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
18	O
DNA	O
that	O
had	O
been	O
integrated	O
into	O
the	O
HeLa	O
genome	O
.	O
The	O
enhancer	O
is	O
located	O
in	O
the	O
non	O
-	O
coding	O
region	O
of	O
the	O
HPV	O
18	O
genome	O
.	O
The	O
HPV	O
18	O
enhancer	O
consists	O
of	O
two	O
functional	O
domains	O
,	O
both	O
of	O
which	O
have	O
full	O
enhancer	O
activity	O
in	O
HeLa	O
cells	O
.	O
The	O
enhancer	O
does	O
not	O
contain	O
enhancer	O
core	O
sequences	O
but	O
contains	O
several	O
blocks	O
of	O
potential	O
Z-DNA	O
sequence	O
.	O
Like	O
SV40	O
and	O
polyoma	O
virus	O
enhancers	O
,	O
the	O
activity	O
of	O
the	O
HPV	O
18	O
enhancer	O
was	O
repressed	O
by	O
adenovirus	O
E1a	O
products	O
.	O
The	O
HPV	O
18	O
enhancer	O
shows	O
a	O
narrow	O
cell	O
type	O
specificity	O
:	O
it	O
is	O
active	O
in	O
some	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
but	O
inactive	O
in	O
all	O
non	O
-	O
cervical	O
cells	O
except	O
for	O
one	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
These	O
results	O
suggest	O
that	O
the	O
HPV	O
18	O
enhancer	O
plays	O
an	O
important	O
role	O
in	O
regulation	O
of	O
the	O
viral	O
genes	O
.	O
PMID	O
:	O
3038518	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan	O
;	O
36	O
(	O
1	O
)	O
:	O
111-4	O
.	O
Expression	O
of	O
Fas	O
(	O
APO-1	O
/	O
CD95	O
)	O
and	O
Fas	O
ligand	O
(	O
FasL	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Gross	O
N	O
,	O
Balmas	O
K	O
,	O
Beretta	O
Brognara	O
C	O
,	O
Tschopp	O
J	O
.	O
Onco-hematology	O
Unit	O
,	O
University	O
Hospital	O
,	O
Lausanne	O
,	O
Switzerland	O
.	O
Nicole.Gross@chuv.hospvd.ch	O
BACKGROUND	O
AND	O
PROCEDURE	O
:	O
To	O
determine	O
the	O
possible	O
role	O
of	O
Fas	O
/	O
FasL	O
system	O
in	O
the	O
particularly	O
heterogeneous	O
behaviour	O
of	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
,	O
we	O
have	O
measured	O
the	O
functional	O
expression	O
of	O
Fas	O
and	O
its	O
ligand	O
,	O
FasL	O
,	O
in	O
primary	O
neuroblastoma	B-malignancy-type
samples	O
and	O
cell	O
lines	O
by	O
immunohistochemistry	O
and	O
flow	O
cytometry	O
.	O
RESULTS	O
:	O
Our	O
results	O
reveal	O
that	O
while	O
Fas	O
expression	O
is	O
associated	O
with	O
low	O
stage	O
and	O
more	O
mature	O
tumors	O
,	O
heterogeneous	O
FasL	O
expression	O
was	O
mostly	O
detected	O
in	O
high	O
stage	O
tumors	O
,	O
with	O
our	O
apparent	O
correlation	O
to	O
MYCN	O
amplification	O
.	O
Flow	O
cytometric	O
analysis	O
of	O
cell	O
lines	O
demonstrated	O
a	O
high	O
expression	O
of	O
Fas	O
in	O
epithelial	O
-type	O
,	O
HLA	O
class	O
I	O
positive	O
cell	O
lines	O
,	O
which	O
was	O
lost	O
upon	O
activation	O
with	O
phorbol	O
esters	O
.	O
In	O
contrast	O
,	O
Fas	O
ligand	O
was	O
detected	O
in	O
only	O
a	O
small	O
subset	O
of	O
cell	O
lines	O
.	O
CONCLUSIONS	O
:	O
In	O
some	O
cell	O
lines	O
,	O
cytotoxic	O
assays	O
revealed	O
the	O
ability	O
of	O
NB	B-malignancy-type
-	O
associated	O
Fas	O
receptor	O
to	O
transduce	O
an	O
apoptotic	O
signal	O
upon	O
triggering	O
.	O
The	O
pattern	O
of	O
functional	O
Fas	O
/	O
FasL	O
expression	O
in	O
tumours	O
and	O
cell	O
lines	O
suggests	O
that	O
this	O
system	O
may	O
be	O
involved	O
in	O
the	O
evasion	O
of	O
highly	O
malignant	O
neuroblastoma	B-malignancy-type
cells	O
to	O
host	O
immune	O
response	O
.	O
PMID	O
:	O
11464860	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
.	O
1991	O
Jan	O
1	O
;	O
51	O
(	O
1	O
)	O
:	O
336-40	O
.	O
Biochemical	O
and	O
genetic	O
characterization	O
of	O
the	O
HBA71	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
cell	O
surface	O
antigen	O
.	O
Fellinger	O
EJ	O
,	O
Garin-Chesa	O
P,	O
Su	O
SL	O
,	O
DeAngelis	O
P,	O
Lane	O
JM	O
,	O
Rettig	O
WJ.	O
Department	O
of	O
Immunology	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
New	O
York	O
10021	O
.	O
Monoclonal	O
antibody	O
HBA71	O
detects	O
a	O
cell	O
surface	O
antigen	O
of	O
human	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcomas	I-malignancy-type
and	O
peripheral	B-malignancy-type
neuroepitheliomas	I-malignancy-type
that	O
distinguishes	O
these	O
tumors	O
from	O
other	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
and	O
adolescence	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
monoclonal	O
antibody	O
HBA71	O
reacts	O
with	O
polypeptides	O
of	O
Mr	O
32	O
,000	O
and	O
30	O
,000	O
and	O
that	O
the	O
HBA71	O
-	O
coding	O
gene	O
segregates	O
with	O
human	O
chromosomes	O
X	O
and	O
Y	O
in	O
rodent-human	O
hybrids	O
.	O
Therefore	O
,	O
we	O
compared	O
HBA71	O
to	O
the	O
T-cell	O
leukemia	B-malignancy-type
antigen	O
12E7	O
,	O
which	O
is	O
encoded	O
by	O
the	O
pseudoautosomal	O
region	O
of	O
chromosomes	O
X	O
and	O
Y	O
.	O
We	O
show	O
that	O
monoclonal	O
antibodies	O
HBA71	O
and	O
12E7	O
(	O
a	O
)	O
detect	O
polypeptides	O
of	O
identical	O
size	O
,	O
(	O
b	O
)	O
react	O
with	O
mouse	O
cells	O
transfected	O
with	O
complementary	O
DNA	O
corresponding	O
to	O
the	O
12E7	O
-	O
coding	O
gene	O
,	O
MIC2	O
,	O
and	O
(	O
c)	O
give	O
similar	O
patterns	O
of	O
reactivity	O
with	O
human	O
tumor	O
cell	O
lines	O
and	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
tissues	O
.	O
Thus	O
,	O
HBA71	O
and	O
12E7	O
are	O
identical	O
or	O
closely	O
related	O
antigens	O
and	O
the	O
available	O
MIC2	O
probes	O
will	O
facilitate	O
analysis	O
of	O
the	O
molecular	O
mechanisms	O
that	O
determine	O
differential	O
HBA71	O
expression	O
in	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
and	O
adolescence	O
.	O
PMID	O
:	O
1988096	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
.	O
1990	O
Mar	O
1;50(	O
5	O
)	O
:	O
1459	O
-	O
63	O
.	O
myc	O
gene	O
amplification	O
and	O
expression	O
in	O
primary	O
human	O
neuroblastoma	B-malignancy-type
.	O
Slavc	O
I	O
,	O
Ellenbogen	O
R	O
,	O
Jung	O
WH	O
,	O
Vawter	O
GF	O
,	O
Kretschmar	O
C	O
,	O
Grier	O
H,	O
Korf	O
BR.	O
Division	O
of	O
Genetics	O
,	O
Children	O
's	O
Hospital	O
,	O
Boston	O
,	O
Massachusetts	O
.	O
Although	O
N-myc	O
amplification	O
in	O
neuroblastomas	B-malignancy-type
correlates	O
with	O
poor	O
prognosis	O
,	O
not	O
all	O
neuroblastomas	B-malignancy-type
which	O
fail	O
to	O
respond	O
to	O
therapy	O
have	O
N-myc	O
amplification	O
.	O
To	O
determine	O
whether	O
other	O
modes	O
of	O
myc	O
gene	O
activation	O
underlie	O
progression	O
of	O
some	O
neuroblastomas	B-malignancy-type
,	O
45	O
were	O
analyzed	O
for	O
amplification	O
of	O
N-myc	O
,	O
c-myc	O
and	O
L-myc	O
and	O
26	O
were	O
studied	O
for	O
transcription	O
of	O
these	O
oncogenes	O
.	O
N-myc	O
amplification	O
was	O
found	O
in	O
6	O
of	O
45	O
tumors	O
;	O
no	O
tumor	O
had	O
amplification	O
of	O
c-myc	O
or	O
L-myc	O
.	O
Transcription	O
of	O
both	O
N-myc	O
and	O
c-myc	O
occurred	O
in	O
21	O
of	O
26	O
neuroblastomas	B-malignancy-type
.	O
No	O
tumor	O
without	O
N-myc	O
amplification	O
had	O
a	O
level	O
of	O
N-myc	O
expression	O
near	O
that	O
of	O
a	O
tumor	O
or	O
cell	O
line	O
with	O
amplification	O
.	O
One	O
tumor	O
with	O
N-myc	O
amplification	O
was	O
the	O
only	O
specimen	O
with	O
N-myc	O
but	O
not	O
c-myc	O
expression	O
.	O
Five	O
samples	O
had	O
c-myc	O
but	O
not	O
N-myc	O
expression	O
;	O
all	O
had	O
histological	O
features	O
of	O
ganglioneuroma	B-malignancy-type
.	O
DNA	O
index	O
did	O
not	O
correlate	O
with	O
myc	O
gene	O
amplification	O
or	O
expression	O
.	O
It	O
is	O
concluded	O
that	O
N-myc	O
and	O
c-myc	O
are	O
commonly	O
expressed	O
in	O
primary	O
untreated	O
neuroblastomas	B-malignancy-type
,	O
but	O
in	O
the	O
absence	O
of	O
N-myc	O
amplification	O
,	O
expression	O
of	O
these	O
genes	O
does	O
not	O
appear	O
to	O
correlate	O
with	O
disease	O
progression	O
.	O
PMID	O
:	O
2302711	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Cell	O
Res	O
.	O
1999	O
Jan	O
10	O
;246	O
(	O
1	O
)	O
:	O
183	O
-	O
92	O
.	O
Depletion	O
of	O
glutathione	O
by	O
buthionine	O
sulfoxine	O
is	O
cytotoxic	O
for	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
via	O
apoptosis	O
.	O
Anderson	O
CP	O
,	O
Tsai	O
JM	O
,	O
Meek	O
WE	O
,	O
Liu	O
RM	O
,	O
Tang	O
Y	O
,	O
Forman	O
HJ	O
,	O
Reynolds	O
CP	O
.	O
Division	O
of	O
Hematology-Oncology	O
,	O
Childrens	O
Hospital	O
Los	O
Angeles	O
,	O
4650	O
Sunset	O
Boulevard	O
,	O
Los	O
Angeles	O
,	O
California	O
,	O
90027	O
,	O
USA	O
.	O
cpreynol@hsc.usc.edu	O
Buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
selectively	O
inhibits	O
glutathione	O
(	O
GSH	O
)	O
synthesis	O
and	O
has	O
been	O
used	O
to	O
sensitize	O
tumor	O
cells	O
to	O
alkylating	O
agents	O
,	O
but	O
has	O
minimal	O
single-agent	O
cytotoxicity	O
for	O
most	O
cell	O
types	O
.	O
We	O
determined	O
the	O
cytotoxicity	O
of	O
BSO	O
for	O
18	O
(	O
12	O
MYCN	O
amplified	O
;	O
6	O
MYCN	O
nonamplified	O
)	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
using	O
DIMSCAN	O
,	O
a	O
digital	O
image	O
microscopy	O
cytotoxicity	O
assay	O
.	O
D-	O
L(R	O
:S	O
)	O
BSO	O
was	O
highly	O
cytotoxic	O
(	O
>3	O
logs	O
of	O
cell	O
kill	O
)	O
for	O
most	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
with	O
17	O
/	O
18	O
cell	O
lines	O
having	O
IC90	O
values	O
(	O
range	O
2.	O
1->	O
1000	O
microM	O
)	O
below	O
equivalent	O
steady	O
state	O
plasma	O
levels	O
of	O
L(R	O
:S	O
)	O
BSO	O
reported	O
in	O
adult	O
human	O
trials	O
.	O
Cell	O
lines	O
with	O
genomic	O
amplification	O
of	O
MYCN	O
were	O
more	O
sensitive	O
to	O
BSO	O
than	O
MYCN	O
nonamplified	O
cell	O
lines	O
(	O
P	O
=	O
0.04	O
)	O
.	O
D-	O
L(R	O
:S	O
)	O
BSO	O
(	O
500	O
microM	O
for	O
72	O
h	O
)	O
induced	O
apoptosis	O
as	O
detected	O
by	O
DNA	O
laddering	O
,	O
nuclear	O
morphology	O
,	O
and	O
TUNEL	O
staining	O
of	O
DNA	O
fragments	O
using	O
flow	O
cytometry	O
.	O
Maximal	O
cell	O
killing	O
occurred	O
within	O
48	O
h	O
and	O
was	O
antagonized	O
byic	O
value	O
in	O
neuroblastoma	B-malignancy-type
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
PMID	O
:	O
9882527	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1998	O
Jun	O
25	O
;16(	O
25	O
)	O
:	O
333	O
7-43	O
.	O
p27Kip1	O
:	O
a	O
key	O
mediator	O
of	O
retinoic	O
acid	O
induced	O
growth	O
arrest	O
in	O
the	O
SMS-KCNR	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Matsuo	O
T	O
,	O
Thiele	O
CJ.	O
Cell	O
&	O
Molecular	O
Biology	O
Section	O
,	O
Pediatric	O
Oncology	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
-1928	O
,	O
USA	O
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
treatment	O
of	O
SMS-KCNR	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cells	O
leads	O
to	O
G1	O
growth	O
arrest	O
and	O
neuronal	O
differentiation	O
.	O
To	O
investigate	O
the	O
molecular	O
mechanisms	O
by	O
which	O
RA	O
alters	O
cell	O
growth	O
,	O
we	O
analysed	O
the	O
expression	O
and	O
activity	O
of	O
components	O
of	O
the	O
cell	O
cycle	O
machinery	O
after	O
culture	O
in	O
RA.	O
Within	O
2	O
days	O
of	O
RA	O
treatment	O
and	O
prior	O
to	O
the	O
arrest	O
of	O
NB	B-malignancy-type
cells	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
there	O
is	O
a	O
complete	O
downregulation	O
of	O
G1	O
cyclin	O
/	O
Cdk	O
activities	O
.	O
Protein	O
levels	O
for	O
the	O
G1	O
cyclin	O
/	O
Cdks	O
were	O
essentially	O
unchanged	O
during	O
this	O
time	O
although	O
there	O
was	O
a	O
decrease	O
in	O
the	O
steady	O
-state	O
levels	O
of	O
p67N-Myc	O
and	O
hyperphosphorylated	O
Rb	O
proteins	O
.	O
The	O
Cdk	O
inhibitors	O
,	O
p21Cip1	O
and	O
p27Kip1	O
were	O
constitutively	O
expressed	O
in	O
KCNR	O
while	O
p15INK4B	O
and	O
p16INK4A	O
were	O
not	O
detected	O
.	O
RA	O
induced	O
an	O
increase	O
in	O
the	O
expression	O
of	O
p27Kip1	O
but	O
not	O
p21Cip1	O
.	O
Furthermore	O
,	O
coincident	O
with	O
the	O
decrease	O
in	O
kinase	O
activity	O
there	O
was	O
an	O
increase	O
in	O
G1	O
cyclin	O
/	O
Cdk	O
bound	O
p27Kip1	O
.	O
These	O
results	O
indicate	O
that	O
changes	O
in	O
the	O
level	O
of	O
p27Kip1	O
and	O
its	O
binding	O
to	O
G1	O
cyclin	O
/	O
Cdks	O
may	O
play	O
a	O
key	O
role	O
in	O
RA	O
induced	O
growth	O
arrest	O
of	O
NB	B-malignancy-type
cells	O
.	O
PMID	O
:	O
9681834	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2002	O
Jan	O
1;	O
62(	O
1	O
)	O
:	O
301	O
-6.	O
Id2	O
is	O
critical	O
for	O
cellular	O
proliferation	O
and	O
is	O
the	O
oncogenic	O
effector	O
of	O
N-myc	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Lasorella	O
A	O
,	O
Boldrini	O
R	O
,	O
Dominici	O
C	O
,	O
Donfrancesco	O
A	O
,	O
Yokota	O
Y	O
,	O
Inserra	O
A	O
,	O
Iavarone	O
A	O
.	O
Department	O
of	O
Neurology	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Bronx	O
,	O
New	O
York	O
10461	O
,	O
USA	O
.	O
iavarone@aecom.yu.edu	O
Perturbation	O
of	O
the	O
function	O
of	O
the	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
is	O
found	O
in	O
most	O
human	O
tumors	O
.	O
Id2	O
is	O
a	O
natural	O
target	O
of	O
the	O
Rb	O
protein	O
that	O
is	O
recruited	O
by	O
Myc	O
oncoproteins	O
to	O
bypass	O
the	O
tumor	O
suppressor	O
function	O
of	O
Rb	O
.	O
Here	O
we	O
report	O
that	O
an	O
"	O
N-Myc	O
-	O
Id2	O
pathway	O
"	O
persists	O
during	O
late	O
development	O
of	O
the	O
nervous	O
system	O
and	O
parallels	O
the	O
rising	O
levels	O
of	O
active	O
Rb	O
in	O
neuronal	O
precursors	O
withdrawing	O
from	O
the	O
cell	O
cycle	O
.	O
An	O
immunohistochemical	O
analysis	O
of	O
primary	O
neuroblastoma	B-malignancy-type
from	O
47	O
patients	O
shows	O
that	O
expression	O
of	O
Id2	O
is	O
strongly	O
predictive	O
of	O
poor	O
outcome	O
,	O
irrespective	O
of	O
other	O
clinical	O
and	O
biological	O
variables	O
.	O
Overexpression	O
of	O
Id2	O
mediates	O
cellular	O
transformation	O
and	O
is	O
required	O
to	O
maintain	O
the	O
malignant	O
behavior	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Correspondingly	O
,	O
embryonic	O
fibroblasts	O
from	O
Id2-	O
null	O
mice	O
display	O
impaired	O
ability	O
to	O
proliferate	O
.	O
We	O
suggest	O
that	O
Id2	O
overexpression	O
may	O
be	O
a	O
better	O
prognostic	O
indicator	O
than	O
N-myc	O
gene	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
.	O
Thus	O
,	O
disrupting	O
Id2	O
function	O
may	O
lead	O
to	O
new	O
and	O
useful	O
therapeutic	O
strategies	O
for	O
cancer	O
patients	O
.	O
PMID	O
:	O
11782392	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1981	O
Dec;37	O
(	O
6	O
)	O
:1613-	O
7.	O
Dermorphins	O
,	O
opioid	O
peptides	O
from	O
amphibian	O
skin	O
,	O
act	O
on	O
opioid	O
receptors	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
x	O
rat	O
glioma	B-malignancy-type
hybrid	O
cells	O
.	O
Glaser	O
T	O
,	O
Hubner	O
K,	O
de	O
Castiglione	O
R	O
,	O
Hamprecht	O
B.	O
Dermorphin	O
and	O
its	O
Hyp6	O
analogue	O
are	O
opiate	O
-	O
like	O
heptapeptides	O
originally	O
discovered	O
in	O
frog	O
skin	O
and	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
D	O
-	O
Ala2	O
residue	O
in	O
their	O
sequence	O
.	O
They	O
were	O
assayed	O
for	O
their	O
capacity	O
to	O
compete	O
with	O
[3H]Leu-	O
enkephalin	O
for	O
binding	O
to	O
opioid	O
receptors	O
in	O
membranes	O
of	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
cells	O
.	O
In	O
the	O
presence	O
of	O
7	O
nM-[3H]Leu-	O
enkephalin	O
,	O
the	O
concentrations	O
at	O
which	O
they	O
caused	O
50	O
%	O
inhibition	O
of	O
[3H]	O
enkephalin	O
binding	O
(	O
IC50	O
values	O
)	O
are	O
0.1	O
micro	O
M	O
and	O
0.3	O
micro	O
M,	O
respectively	O
.	O
In	O
contrast	O
,	O
the	O
synthetic	O
L-Ala2	O
-	O
dermorphin	O
shows	O
very	O
low	O
affinity	O
for	O
the	O
opioid	O
receptors	O
.	O
In	O
addition	O
,	O
like	O
other	O
opioid	O
peptides	O
,	O
dermorphin	O
and	O
hyp6-dermorphin	O
inhibit	O
the	O
elevation	O
by	O
prostaglandin	O
E1	O
(	O
PGE1	O
)	O
of	O
the	O
level	O
of	O
adenosine	O
3':5'-cyclic	O
monophosphate	O
(	O
cyclic	O
AMP	O
)	O
(	O
IC50	O
values	O
0.2	O
micro	O
M	O
and	O
0.4	O
micro	O
M,	O
respectively	O
)	O
.	O
The	O
inhibition	O
is	O
prevented	O
by	O
the	O
opiate	O
antagonist	O
naloxone	O
,	O
L-Ala2	O
-	O
dermorphin	O
is	O
at	O
least	O
three	O
orders	O
of	O
magnitude	O
less	O
potent	O
in	O
inhibiting	O
the	O
PGE1	O
-evoked	O
increase	O
in	O
the	O
level	O
of	O
cyclic	O
AMP	O
.	O
The	O
results	O
show	O
that	O
peptides	O
with	O
an	O
amino	O
acid	O
sequence	O
quite	O
different	O
from	O
that	O
of	O
the	O
enkephalins	O
can	O
bind	O
to	O
opioid	O
receptors	O
of	O
the	O
hybrid	O
cells	O
.	O
PMID	O
:	O
6278080	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Mol	O
Neurobiol	O
.	O
1993	O
Apr;13(	O
2	O
)	O
:	O
137-45	O
.	O
Differential	O
expression	O
of	O
neuron	O
-	O
specific	O
enolase	O
mRNA	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
in	O
response	O
to	O
differentiation	O
inducing	O
agents	O
.	O
Matranga	O
V	O
,	O
Oliva	O
D	O
,	O
Sciarrino	O
S	O
,	O
D'Amelio	O
L,	O
Giallongo	O
A	O
.	O
Istituto	O
di	O
Biologia	O
dello	O
Sviluppo	O
,	O
Consiglio	O
Nazionale	O
delle	O
Ricerche	O
,	O
Palermo	O
,	O
Italy	O
.	O
1	O
.	O
The	O
mouse	O
neuroblastoma	B-malignancy-type
cell	O
line	O
N-115	O
was	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
neuronal	O
differentiation	O
induced	O
by	O
treatment	O
of	O
cells	O
with	O
different	O
agents	O
.	O
2.	O
The	O
extent	O
of	O
morphological	O
differentiation	O
obtained	O
with	O
dibutyryl	O
cyclic	O
AMP	O
(	O
db	O
c	O
-	O
AMP	O
)	O
,	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
and	O
serum	O
-	O
free	O
medium	O
was	O
correlated	O
to	O
the	O
expression	O
of	O
the	O
mRNA	O
for	O
the	O
gamma	O
isoform	O
of	O
the	O
glycolytic	O
enzyme	O
enolase	O
,	O
a	O
recognized	O
neuron	O
-	O
specific	O
marker	O
.	O
3	O
.	O
A	O
4-	O
day	O
treatment	O
of	O
the	O
cells	O
with	O
any	O
of	O
the	O
differentiation	O
inducing	O
agents	O
used	O
in	O
this	O
study	O
resulted	O
in	O
the	O
extension	O
of	O
long	O
neurites	O
,	O
though	O
differences	O
in	O
cell	O
body	O
shape	O
were	O
observed	O
depending	O
on	O
the	O
agent	O
used	O
.	O
4	O
.	O
Northern	O
blot	O
analysis	O
revealed	O
that	O
changes	O
in	O
the	O
level	O
of	O
gamma	O
enolase	O
-	O
specific	O
mRNA	O
correlate	O
with	O
the	O
extent	O
of	O
morphological	O
differentiation	O
,	O
with	O
a	O
5	O
-	O
to	O
20	O
-	O
fold	O
increase	O
depending	O
on	O
the	O
differentiation	O
inducing	O
agent	O
used	O
.	O
5	O
.	O
Finally	O
,	O
we	O
found	O
that	O
a	O
high	O
cell	O
density	O
causes	O
a	O
significative	O
increase	O
in	O
the	O
level	O
of	O
the	O
gamma	O
enolase	O
-	O
specific	O
message	O
in	O
cells	O
maintained	O
in	O
growing	O
conditions	O
.	O
PMID	O
:	O
8394214	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1999	O
Mar;72	O
(	O
3	O
)	O
:	O
1224-31	O
.	O
Scrapie	O
-	O
infected	O
mice	O
and	O
PrP	O
knockout	O
mice	O
share	O
abnormal	O
localization	O
and	O
activity	O
of	O
neuronal	O
nitric	O
oxide	O
synthase	O
.	O
Keshet	O
GI	O
,	O
Ovadia	O
H,	O
Taraboulos	O
A	O
,	O
Gabizon	O
R.	O
Department	O
of	O
Neurology	O
,	O
Hadassah	O
Hebrew	O
University	O
Hospital	O
,	O
Jerusalem	O
,	O
Israel	O
.	O
PrP(Sc	O
)	O
,	O
the	O
only	O
identified	O
component	O
of	O
the	O
scrapie	O
prion	O
,	O
is	O
a	O
conformational	O
isoform	O
of	O
PrPc	O
.	O
The	O
physiological	O
role	O
of	O
PrPc	O
,	O
a	O
glycolipid	O
-anchored	O
glycoprotein	O
,	O
is	O
still	O
unknown	O
.	O
We	O
have	O
shown	O
previously	O
that	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
)	O
activity	O
is	O
impaired	O
in	O
the	O
brains	O
of	O
mice	O
sick	O
with	O
experimental	O
scrapie	O
as	O
well	O
as	O
in	O
scrapie	O
-	O
infected	O
neuroblastoma	B-malignancy-type
cells	O
.	O
In	O
this	O
work	O
we	O
investigated	O
the	O
cell	O
localization	O
of	O
nNOS	O
in	O
brains	O
of	O
wild-type	O
and	O
scrapie	O
-	O
infected	O
mice	O
as	O
well	O
as	O
in	O
mice	O
in	O
which	O
the	O
PrP	O
gene	O
was	O
ablated	O
.	O
We	O
now	O
report	O
that	O
whereas	O
in	O
wild-type	O
mice	O
,	O
nNOS	O
,	O
like	O
PrPc	O
,	O
is	O
associated	O
with	O
detergent	O
-	O
insoluble	O
cholesterol	O
-rich	O
membranous	O
microdomains	O
(	O
rafts	O
)	O
,	O
this	O
is	O
not	O
the	O
case	O
in	O
brains	O
of	O
scrapie	O
-	O
infected	O
or	O
in	O
those	O
of	O
adult	O
PrP	O
(	O
0	O
/0	O
)	O
mice	O
.	O
Also	O
,	O
adult	O
PrP	O
(	O
0	O
/	O
0	O
)	O
,	O
like	O
scrapie	O
-	O
infected	O
mice	O
,	O
show	O
reduced	O
nNOS	O
activity	O
.	O
We	O
suggest	O
that	O
PrPc	O
may	O
play	O
a	O
role	O
in	O
the	O
targeting	O
of	O
nNOS	O
to	O
its	O
proper	O
subcellular	O
localization	O
.	O
The	O
similarities	O
of	O
nNOS	O
properties	O
in	O
PrP	O
(	O
0	O
/0	O
)	O
as	O
compared	O
with	O
scrapie	O
-	O
infected	O
mice	O
suggest	O
that	O
at	O
least	O
this	O
role	O
of	O
PrPc	O
may	O
be	O
impaired	O
in	O
scrapie	O
-	O
infected	O
brains	O
.	O
PMID	O
:	O
10037495	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
2000	O
Jun;82	O
(	O
11	O
)	O
:	O
1801	O
-	O
7.	O
Detailed	O
deletion	O
mapping	O
of	O
chromosome	O
band	O
14q32	O
in	O
human	O
neuroblastoma	B-malignancy-type
defines	O
a	O
1.1-Mb	O
region	O
of	O
common	O
allelic	O
loss	O
.	O
Hoshi	O
M,	O
Otagiri	O
N	O
,	O
Shiwaku	O
HO	O
,	O
Asakawa	O
S	O
,	O
Shimizu	O
N	O
,	O
Kaneko	O
Y	O
,	O
Ohi	O
R	O
,	O
Hayashi	O
Y	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Sendai	O
,	O
Japan	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
is	O
a	O
well	O
-known	O
malignant	O
disease	O
in	O
infants	O
,	O
but	O
its	O
molecular	O
mechanisms	O
have	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O
To	O
investigate	O
the	O
genetic	O
contribution	O
of	O
abnormalities	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
14	O
(	O
14q	O
)	O
in	O
NB	B-malignancy-type
,	O
we	O
analysed	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
54	O
primary	O
NB	B-malignancy-type
samples	O
using	O
12	O
microsatellite	O
markers	O
on	O
14q32	O
.	O
Seventeen	O
(	O
31	O
%	O
)	O
of	O
54	O
tumours	O
showed	O
LOH	O
at	O
one	O
or	O
more	O
of	O
the	O
markers	O
analysed	O
,	O
and	O
the	O
smallest	O
common	O
region	O
of	O
allelic	O
loss	O
was	O
identified	O
between	O
D14S62	O
and	O
D14S987	O
.	O
This	O
region	O
was	O
estimated	O
to	O
be	O
1-cM	O
long	O
from	O
the	O
linkage	O
map	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
also	O
confirmed	O
the	O
loss	O
.	O
There	O
was	O
no	O
statistical	O
correlation	O
between	O
LOH	O
and	O
any	O
clinicopathologic	O
features	O
,	O
including	O
age	O
,	O
stage	O
,	O
amplification	O
of	O
MYCN	O
and	O
ploidy	O
.	O
We	O
further	O
constructed	O
a	O
contig	O
spanning	O
the	O
lost	O
region	O
using	O
bacterial	O
artificial	O
chromosome	O
and	O
estimated	O
this	O
region	O
to	O
be	O
approximately	O
1.1-Mb	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
.	O
Our	O
results	O
will	O
contribute	O
to	O
cloning	O
and	O
characterizing	O
the	O
putative	O
tumour	O
-	O
associated	O
gene(s)	O
in	O
14q32	O
in	O
NB	B-malignancy-type
.	O
PMID	O
:	O
10839294	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1999	O
May	O
19;258	O
(	O
3	O
)	O
:745-51	O
.	O
BCL-2	O
is	O
upregulated	O
in	O
human	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
differentiated	O
by	O
overexpression	O
of	O
fibroblast	O
growth	O
factor	O
1	O
.	O
Raguenez	O
G	O
,	O
Desire	O
L,	O
Lantrua	O
V	O
,	O
Courtois	O
Y	O
.	O
Developpement	O
,	O
Vieillissement	O
et	O
Pathologie	O
de	O
la	O
Retine	O
,	O
INSERM	O
U	O
.	O
450	O
,	O
Affiliee	O
CNRS	O
,	O
Association	O
Claude	O
Bernard	O
-	O
29	O
rue	O
Wilhem	O
,	O
Paris	O
,	O
75016	O
,	O
France	O
.	O
raguenez@kinfobiogen	O
.fr	O
Fibroblast	O
growth	O
factor	O
1	O
(	O
FGF1	O
)	O
is	O
a	O
multipotent	O
factor	O
in	O
the	O
development	O
and	O
differentiation	O
of	O
the	O
central	O
nervous	O
system	O
.	O
Recent	O
studies	O
in	O
PC12	O
cells	O
attribute	O
these	O
effects	O
to	O
high	O
endogenous	O
FGF1	O
expression	O
.	O
To	O
examine	O
the	O
differentiation	O
mechanisms	O
induced	O
by	O
FGF1	O
,	O
we	O
performed	O
studies	O
in	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
We	O
monitored	O
the	O
impact	O
of	O
FGF1	O
overexpression	O
in	O
SH-SY5Y	O
either	O
after	O
addition	O
of	O
exogenous	O
FGF1	O
and	O
heparin	O
or	O
after	O
stable	O
transfection	O
with	O
the	O
FGF1	O
eukaryotic	O
expression	O
vector	O
.	O
Under	O
both	O
conditions	O
,	O
the	O
FGF1	O
endogenous	O
rise	O
caused	O
SH-SY5Y	O
cell	O
differentiation	O
with	O
morphological	O
changes	O
(	O
appearance	O
of	O
neuritic	O
extensions	O
)	O
,	O
increased	O
GAP-43	O
gene	O
expression	O
,	O
decreased	O
of	O
N-myc	O
gene	O
expression	O
,	O
and	O
prolonged	O
long-term	O
survival	O
in	O
serum	O
-	O
free	O
media	O
.	O
These	O
modifications	O
were	O
correlated	O
with	O
Bcl-2	O
upregulation	O
.	O
These	O
results	O
suggest	O
that	O
there	O
is	O
a	O
link	O
between	O
the	O
endogenous	O
FGF1	O
signaling	O
pathway	O
and	O
Bcl-2	O
in	O
neuronal	O
survival	O
modulation	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
PMID	O
:	O
10329457	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
2003	O
Apr	O
10	O
;112(	O
1-2	O
)	O
:95-	O
102	O
.	O
Modulation	O
of	O
the	O
N-type	O
calcium	O
channel	O
gene	O
expression	O
by	O
the	O
alpha	O
subunit	O
of	O
Go	O
.	O
Kim	O
BJ	O
,	O
Ghil	O
SH	O
,	O
Kim	O
MJ	O
,	O
Yun	O
Park	O
S	O
,	O
Kim	O
DS	O
,	O
Hwan	O
Kim	O
S	O
,	O
Chin	O
H,	O
Birnbaumer	O
L,	O
Jiang	O
M,	O
Hong	O
SY	O
,	O
Suh-Kim	O
H,	O
Lee	O
YD.	O
Department	O
of	O
Anatomy	O
,	O
School	O
of	O
Medicine	O
,	O
Ajou	O
University	O
,	O
San	O
5	O
,	O
Wonchon	O
-	O
dong	O
,	O
Paldal	O
-	O
gu	O
,	O
Suwon	O
,	O
442	O
-749	O
,	O
South	O
Korea	O
.	O
Go	O
,	O
a	O
heterotrimeric	O
G-protein	O
,	O
is	O
enriched	O
in	O
brain	O
and	O
neuronal	O
growth	O
cones	O
.	O
Although	O
several	O
reports	O
suggest	O
that	O
Go	O
may	O
be	O
involved	O
in	O
modulation	O
of	O
neuronal	O
differentiation	O
,	O
the	O
precise	O
role	O
of	O
Go	O
is	O
not	O
clear	O
.	O
To	O
investigate	O
the	O
function	O
of	O
Go	O
in	O
neuronal	O
differentiation	O
,	O
we	O
determined	O
the	O
effect	O
of	O
Goalpha	O
,	O
the	O
alpha	O
subunit	O
of	O
Go	O
,	O
on	O
the	O
expression	O
of	O
Ca(	O
v)2.2	O
,	O
the	O
pore	O
-	O
forming	O
unit	O
of	O
N-type	O
calcium	O
channels	O
,	O
at	O
the	O
transcription	O
level	O
.	O
Treatment	O
with	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
,	O
which	O
triggers	O
neurite	O
outgrowth	O
in	O
neuroblastoma	B-malignancy-type
F11	O
cells	O
,	O
increased	O
the	O
mRNA	O
level	O
and	O
the	O
promoter	O
activity	O
of	O
the	O
Ca(	O
v)2.2	O
gene	O
.	O
Overexpression	O
of	O
Goalpha	O
inhibited	O
neurite	O
extension	O
in	O
F11	O
cells	O
and	O
simultaneously	O
repressed	O
the	O
stimulatory	O
effect	O
of	O
cAMP	O
on	O
the	O
Ca(	O
v)2.2	O
gene	O
expression	O
to	O
the	O
basal	O
level	O
.	O
Targeted	O
mutation	O
of	O
the	O
Goalpha	O
gene	O
also	O
increased	O
the	O
level	O
of	O
Ca(	O
v)2.2	O
in	O
the	O
brain	O
.	O
These	O
results	O
suggest	O
that	O
Go	O
may	O
regulate	O
neuronal	O
differentiation	O
through	O
modulation	O
of	O
gene	O
expression	O
of	O
target	O
genes	O
such	O
as	O
N-type	O
calcium	O
channels	O
.	O
PMID	O
:	O
12670707	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Differ	O
.	O
1984	O
Jun;14(	O
2	O
)	O
:	O
135-44	O
.	O
Retinoic	O
acid	O
-	O
induced	O
differentiation	O
of	O
cultured	O
human	O
neuroblastoma	B-malignancy-type
cells	O
:	O
a	O
comparison	O
with	O
phorbolester	O
-	O
induced	O
differentiation	O
.	O
Pahlman	O
S	O
,	O
Ruusala	O
AI	O
,	O
Abrahamsson	O
L,	O
Mattsson	O
ME	O
,	O
Esscher	O
T.	O
Cultured	O
human	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
differentiated	O
in	O
the	O
presence	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
or	O
12	O
-	O
0-tetradecanoyl-phorbol-13	O
-acetate	O
(	O
TPA	O
)	O
.	O
In	O
both	O
cases	O
,	O
the	O
cells	O
acquired	O
long	O
cell	O
processes	O
and	O
the	O
cell	O
growth	O
was	O
partially	O
inhibited	O
.	O
Treatment	O
with	O
RA	O
or	O
TPA	O
resulted	O
in	O
an	O
increased	O
neuron	O
-	O
specific	O
enolase	O
activity	O
,	O
relative	O
to	O
the	O
total	O
cellular	O
enolase	O
activity	O
.	O
At	O
the	O
optimal	O
concentration	O
,	O
TPA	O
induced	O
a	O
200	O
-	O
fold	O
increase	O
in	O
the	O
concentration	O
of	O
noradrenalin	O
,	O
whereas	O
in	O
RA	O
-	O
treated	O
cells	O
the	O
corresponding	O
increase	O
was	O
only	O
fourfold	O
.	O
Cells	O
treated	O
with	O
a	O
combination	O
of	O
RA	O
and	O
TPA	O
were	O
morphologically	O
differentiated	O
and	O
growth	O
inhibited	O
and	O
had	O
a	O
high	O
relative	O
activity	O
of	O
neuron	O
-	O
specific	O
enolase	O
.	O
The	O
increase	O
in	O
the	O
concentration	O
of	O
noradrenalin	O
induced	O
by	O
TPA	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
.	O
However	O
,	O
despite	O
this	O
result	O
there	O
seemed	O
to	O
be	O
no	O
general	O
antagonistic	O
effect	O
of	O
RA	O
on	O
the	O
TPA	O
-	O
induced	O
differentiation	O
.	O
The	O
phenotypes	O
of	O
the	O
cells	O
treated	O
by	O
RA	O
,	O
TPA	O
,	O
or	O
the	O
combination	O
of	O
RA	O
and	O
TPA	O
,	O
did	O
,	O
on	O
the	O
other	O
hand	O
,	O
differ	O
from	O
each	O
other	O
.	O
Our	O
results	O
suggest	O
that	O
RA	O
and	O
TPA	O
induce	O
the	O
SH-SY5Y	O
cells	O
to	O
differentiate	O
along	O
different	O
pathways	O
.	O
PMID	O
:	O
6467378	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Nucl	O
Med	O
.	O
1990	O
Dec;31(	O
12	O
)	O
:1945-	O
9.	O
SPECT	O
quantitation	O
of	O
iodine	O
-	O
131	O
concentration	O
in	O
phantoms	O
and	O
human	O
tumors	O
.	O
Israel	O
O	O
,	O
Iosilevsky	O
G	O
,	O
Front	O
D	O
,	O
Bettman	O
L,	O
Frenkel	O
A	O
,	O
Ish-Shalom	O
S	O
,	O
Steiner	O
M,	O
Ben-Harush	O
M,	O
Kolodny	O
GM	O
.	O
Department	O
of	O
Nuclear	O
Medicine	O
,	O
Rambam	O
Medical	O
Center	O
,	O
Haifa	O
,	O
Israel	O
.	O
The	O
validity	O
of	O
SPECT	O
measurement	O
of	O
iodine	O
-	O
131	O
(	O
131I	O
)	O
concentration	O
was	O
tested	O
in	O
vitro	O
in	O
phantoms	O
and	O
in	O
vivo	O
by	O
measuring	O
bladder	O
urine	O
concentrations	O
.	O
Phantom	O
studies	O
comparing	O
known	O
and	O
SPECT	O
measured	O
concentrations	O
showed	O
a	O
good	O
correlation	O
for	O
131I	O
(	O
r	O
=	O
0.98	O
,	O
s	O
.e	O
.e	O
.	O
=	O
20.94	O
counts	O
/	O
voxel	O
)	O
for	O
phantoms	O
of	O
25	O
to	O
127	O
cc	O
and	O
concentrations	O
of	O
0.13	O
to	O
9.5	O
microCi/cc	O
.	O
The	O
in	O
vivo	O
,	O
in	O
vitro	O
correlation	O
of	O
131I	O
concentrations	O
in	O
the	O
urine	O
was	O
also	O
good	O
(	O
r	O
=	O
0.98	O
,	O
s	O
.e	O
.e	O
.	O
=	O
0.677	O
microCi/cc	O
)	O
.	O
Quantitative	O
SPECT	O
was	O
used	O
to	O
calculate	O
the	O
effective	O
half-	O
life	O
and	O
dosimetry	O
of	O
radioiodine	O
in	O
12	O
sites	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
in	O
seven	O
patients	O
.	O
SPECT	O
was	O
also	O
used	O
to	O
determine	O
the	O
dosimetry	O
of	O
[131I]MIBG	O
(	O
metaiodobenzylguanidine	O
)	O
in	O
two	O
patients	O
with	O
carcinoid	B-malignancy-type
,	O
two	O
with	O
neuroblastoma	B-malignancy-type
,	O
and	O
one	O
with	O
pheochromocytoma	B-malignancy-type
.	O
The	O
radiation	O
dose	O
for	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
metastases	O
varied	O
between	O
6.3	O
and	O
276.9	O
rad/	O
mCi	O
.	O
The	O
dose	O
from	O
MIBG	O
varied	O
between	O
13.4	O
and	O
57.8	O
rad/	O
mCi	O
.	O
These	O
results	O
indicate	O
the	O
validity	O
of	O
quantitative	O
SPECT	O
for	O
in	O
vivo	O
measurement	O
of	O
131I	O
and	O
the	O
need	O
to	O
measure	O
the	O
concentration	O
of	O
131I	O
in	O
individual	O
human	O
tumor	O
sites	O
.	O
PMID	O
:	O
2266390	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Pediatr	O
Surg	O
.	O
2001	O
Dec;11	O
(	O
6	O
)	O
:	O
363	O
-	O
7.	O
Neuroblastoma	B-malignancy-type
:	O
inhibition	O
of	O
progression	O
(	O
Part	O
II	O
)	O
.	O
Basic	O
science	O
in	O
pediatric	O
surgery	O
.	O
Girgert	O
R	O
,	O
Wittrock	O
J,	O
Schweizer	O
P.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Tubingen	O
,	O
Germany	O
.	O
rainer	O
.girgert@medizin	O
.uni-ulm	O
.de	O
In	O
neuroblastoma	B-malignancy-type
,	O
amplification	O
of	O
the	O
protooncogene	O
N-myc	O
is	O
the	O
most	O
important	O
molecular	O
characteristic	O
predicting	O
a	O
bad	O
outcome	O
for	O
the	O
patients	O
.	O
Despite	O
the	O
importance	O
of	O
the	O
N-myc	O
gene	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
its	O
expression	O
.	O
We	O
found	O
evidence	O
that	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
stimulates	O
the	O
growth	O
of	O
neuroblastoma	B-malignancy-type
in	O
a	O
paracrine	O
fashion	O
.	O
Two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
predominantly	O
expressed	O
IGF-II	O
whereas	O
two	O
other	O
cell	O
lines	O
expressed	O
the	O
IGF-receptor	O
.	O
In	O
a	O
receptor	O
-	O
positive	O
cell	O
line	O
,	O
N-myc	O
expression	O
was	O
enhanced	O
by	O
stimulation	O
with	O
IGF-II	O
.	O
As	O
the	O
growth	O
-	O
stimulating	O
signals	O
of	O
the	O
IGF	O
receptor	O
are	O
transmitted	O
via	O
Ras	O
proteins	O
,	O
inactivation	O
of	O
Ras	O
is	O
one	O
promising	O
tool	O
to	O
prevent	O
the	O
induction	O
of	O
N-myc	O
expression	O
by	O
IGF-II	O
.	O
Treatment	O
of	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
with	O
an	O
inhibitor	O
of	O
the	O
farnesyl-	O
protein	O
-	O
transferase	O
(	O
FPTase	O
)	O
inactivated	O
H-ras	O
protein	O
completely	O
and	O
N-ras	O
protein	O
by	O
more	O
than	O
50	O
%	O
.	O
Cell	O
growth	O
of	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
in	O
serum	O
containing	O
medium	O
was	O
clearly	O
diminished	O
by	O
inhibition	O
of	O
FPTase	O
.	O
The	O
growth	O
-	O
promoting	O
effect	O
of	O
IGF-II	O
was	O
reduced	O
to	O
exactly	O
half	O
the	O
amount	O
observed	O
in	O
non	O
-	O
inhibited	O
cells	O
.	O
PMID	O
:	O
11807663	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1994	O
Aug	O
1;74	O
(	O
3	O
)	O
:	O
972	O
-7.	O
Comment	O
in	O
:	O
Cancer	O
.	O
1995	O
Oct	O
1;76	O
(	O
7	O
)	O
:	O
1295	O
-7.	O
Autologous	O
bone	O
marrow	O
transplantation	O
in	O
children	O
with	O
advanced	O
neuroblastoma	B-malignancy-type
.	O
Mugishima	O
H,	O
Iwata	O
M,	O
Okabe	O
I	O
,	O
Sanuki	O
E	O
,	O
Onuma	O
N	O
,	O
Fujimoto	O
T	O
,	O
Ohira	O
M,	O
Kaneko	O
M,	O
Tsuchida	O
Y	O
,	O
Okuni	O
M.	O
Department	O
of	O
Pediatrics	O
,	O
Nihon	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
BACKGROUND.	O
Encouraging	O
results	O
have	O
been	O
reported	O
with	O
high	O
dose	O
chemotherapy	O
and	O
total	O
body	O
radiation	O
followed	O
by	O
bone	O
marrow	O
autotransplantation	O
in	O
children	O
with	O
advanced	O
neuroblastoma	B-malignancy-type
;	O
however	O
,	O
relapse	O
remains	O
a	O
significant	O
problem	O
.	O
METHODS	O
.	O
The	O
authors	O
treated	O
22	O
children	O
with	O
advanced	O
neuroblastoma	B-malignancy-type
with	O
high	O
dose	O
chemotherapy	O
,	O
surgery	O
,	O
intraoperative	O
radiation	O
,	O
and	O
a	O
bone	O
marrow	O
autotransplant	O
(	O
treated	O
in	O
vitro	O
to	O
remove	O
tumor	O
cells	O
)	O
followed	O
by	O
13-cis	O
-	O
retinoic	O
acid	O
.	O
RESULTS	O
.	O
The	O
3-year	O
relapse	O
rate	O
was	O
25	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI]	O
,	O
6-44	O
%	O
)	O
.	O
The	O
3-year	O
disease	O
free	O
survival	O
rate	O
was	O
72	O
%	O
(	O
95	O
%	O
CI	O
,	O
52-	O
92	O
%	O
)	O
.	O
Toxicities	O
included	O
hemolytic	O
uremic	O
syndrome	O
,	O
herpes	O
infection	O
,	O
and	O
hepatic	O
venoocclusive	O
disease	O
.	O
CONCLUSION	O
.	O
These	O
data	O
suggest	O
that	O
this	O
treatment	O
strategy	O
offers	O
an	O
increased	O
rate	O
of	O
3-year	O
disease	O
free	O
survival	O
.	O
The	O
nonrandomized	O
nature	O
of	O
this	O
study	O
and	O
its	O
use	O
of	O
multiple	O
modalities	O
precludes	O
the	O
analysis	O
of	O
the	O
specific	O
contribution	O
of	O
each	O
treatment	O
component	O
and	O
comparison	O
with	O
conventional	O
therapy	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Multicenter	O
Study	O
PMID	O
:	O
8039127	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
.	O
2003	O
Oct;23(	O
4	O
)	O
:	O
1151	O
-	O
7.	O
Aberrations	O
of	O
p16INK4A	O
,	O
p14ARF	O
and	O
p15INK4B	O
genes	O
in	O
pediatric	O
solid	B-malignancy-type
tumors	I-malignancy-type
.	O
Obana	O
K,	O
Yang	O
HW	O
,	O
Piao	O
HY	O
,	O
Taki	O
T	O
,	O
Hashizume	O
K,	O
Hanada	O
R	O
,	O
Yamamoto	O
K,	O
Tanaka	O
Y	O
,	O
Toyoda	O
Y	O
,	O
Takita	O
J,	O
Tsuchida	O
Y	O
,	O
Hayashi	O
Y	O
.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Graduate	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Tokyo	O
113-8655	O
,	O
Japan	O
.	O
Expression	O
of	O
the	O
p16INK4A	O
(	O
p16	O
)	O
,	O
p15INK4B	O
(	O
p15	O
)	O
,	O
and	O
p14ARF	O
genes	O
,	O
located	O
at	O
9p21	O
,	O
was	O
examined	O
in	O
pediatric	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
,	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
(	O
ES	B-malignancy-type
)	O
,	O
and	O
rhabdomyosarcoma	B-malignancy-type
(	O
RMS	B-malignancy-type
)	O
.	O
p16	O
expression	O
was	O
absent	O
in	O
4	O
of	O
5	O
ESs	B-malignancy-type
,	O
and	O
2	O
of	O
these	O
4	O
cases	O
died	O
.	O
p16	O
expression	O
was	O
reduced	O
or	O
absent	O
in	O
10	O
of	O
12	O
RMSs	B-malignancy-type
,	O
and	O
4	O
of	O
these	O
10	O
cases	O
died	O
.	O
These	O
results	O
suggested	O
the	O
possibility	O
that	O
p16	O
expression	O
was	O
associated	O
with	O
the	O
progression	O
of	O
ES	B-malignancy-type
and	O
RMS	B-malignancy-type
.	O
There	O
has	O
been	O
no	O
previous	O
report	O
on	O
p14ARF	O
in	O
NB	B-malignancy-type
.	O
Our	O
investigation	O
might	O
indicate	O
that	O
abnormal	O
expression	O
of	O
the	O
p16	O
and	O
p14ARF	O
was	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
NB	B-malignancy-type
,	O
although	O
in	O
some	O
cases	O
of	O
NB	B-malignancy-type
normal	O
p16	O
and	O
abnormal	O
p14ARF	O
expression	O
was	O
seen	O
.	O
These	O
findings	O
suggest	O
an	O
important	O
role	O
of	O
p14ARF	O
gene	O
in	O
the	O
tumorigenesis	O
of	O
NB	B-malignancy-type
.	O
The	O
different	O
incidence	O
of	O
expression	O
of	O
the	O
p16	O
,	O
p15	O
,	O
and	O
p14ARF	O
genes	O
in	O
these	O
3	O
tumor	O
types	O
may	O
reflect	O
differences	O
of	O
the	O
molecular	O
process	O
through	O
which	O
the	O
3	O
tumors	O
develop	O
.	O
Our	O
results	O
suggest	O
that	O
abnormal	O
expression	O
of	O
the	O
p16	O
and/or	O
p14ARF	O
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
these	O
3	O
tumors	O
.	O
PMID	O
:	O
12963998	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Cancer	O
Res	O
.	O
2000	O
May	O
1;60	O
(	O
9	O
)	O
:2483	O
-	O
7.	O
Genome	O
-	O
wide	O
screen	O
for	O
allelic	O
imbalance	O
in	O
a	O
mouse	O
model	O
for	O
neuroblastoma	B-malignancy-type
.	O
Weiss	O
WA	O
,	O
Godfrey	O
T	O
,	O
Francisco	O
C	O
,	O
Bishop	O
JM	O
.	O
Department	O
of	O
Neurology	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
-0114	O
,	O
USA	O
.	O
weiss@cgl	O
.ucsf.edu	O
We	O
have	O
used	O
the	O
rat	O
tyrosine	O
hydroxylase	O
promotor	O
to	O
overexpress	O
MYCN	O
in	O
the	O
neural	O
crest	O
of	O
transgenic	O
mice	O
,	O
resulting	O
in	O
a	O
mouse	O
model	O
for	O
neuroblastoma	B-malignancy-type
.	O
Using	O
PCR	O
analysis	O
of	O
microsatellite	O
markers	O
,	O
we	O
conducted	O
a	O
genome	O
-	O
wide	O
analysis	O
in	O
tumors	O
from	O
these	O
animals	O
.	O
Regions	O
of	O
chromosomes	O
1	O
,	O
3	O
,	O
10	O
,	O
11	O
,	O
14	O
,	O
and	O
18	O
were	O
affected	O
in	O
20-50	O
%	O
of	O
tumors	O
.	O
Analysis	O
of	O
a	O
subset	O
of	O
these	O
tumors	O
by	O
comparative	O
genomic	O
hybridization	O
was	O
consistent	O
with	O
the	O
microsatellite	O
data	O
.	O
The	O
changes	O
on	O
mouse	O
chromosomes	O
1	O
,	O
11	O
,	O
14	O
,	O
and	O
18	O
were	O
syntenic	O
with	O
corresponding	O
regions	O
of	O
loss	O
of	O
heterozygosity	O
in	O
human	O
neuroblastoma	B-malignancy-type
,	O
suggesting	O
that	O
genes	O
implicated	O
in	O
the	O
mouse	O
tumors	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
the	O
human	O
disease	O
.	O
One	O
-third	O
of	O
the	O
mouse	O
tumors	O
shared	O
abnormalities	O
on	O
chromosomes	O
1	O
,	O
3	O
,	O
and	O
10	O
,	O
whereas	O
the	O
remainder	O
of	O
tumors	O
did	O
not	O
show	O
this	O
combination	O
.	O
These	O
data	O
suggest	O
that	O
genetic	O
mutations	O
on	O
chromosomes	O
1	O
,	O
3	O
,	O
and	O
10	O
cooperate	O
in	O
the	O
pathogenesis	O
of	O
neuroblastoma	B-malignancy-type
and	O
that	O
neuroblastoma	B-malignancy-type
in	O
the	O
mouse	O
arises	O
from	O
at	O
least	O
two	O
distinct	O
genetic	O
pathways	O
,	O
one	O
of	O
which	O
is	O
dependent	O
on	O
lesions	O
in	O
chromosomes	O
1	O
,	O
3	O
,	O
and	O
10	O
,	O
the	O
other	O
of	O
which	O
is	O
not	O
.	O
PMID	O
:	O
10811128	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuropeptides	O
.	O
1992	O
Oct;23(	O
2	O
)	O
:	O
107	O
-	O
13	O
.	O
Modulation	O
of	O
cholecystokinin	O
(	O
CCK	O
)	O
gene	O
-	O
expression	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
:	O
effects	O
of	O
serum	O
on	O
enhanced	O
CCK	O
and	O
c-	O
fos	O
mRNA	O
expression	O
.	O
Monstein	O
HJ	O
,	O
Pedersen	O
K,	O
Haahr	O
PM	O
.	O
Department	O
of	O
Clinical	O
Biochemistry	O
(	O
KK	O
3013	O
)	O
,	O
State	O
University	O
Hospital	O
(	O
Rigshospitalet	O
)	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
The	O
effect	O
of	O
fetal-calf	O
serum	O
(	O
FCS	O
)	O
and	O
Forskolin	O
(	O
FKN	O
)	O
on	O
cholecystokinin	O
(	O
CCK	O
)	O
and	O
proto	O
-	O
oncogene	O
c-	O
fos	O
mRNA	O
expression	O
in	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-MC	O
,	O
cultured	O
in	O
serum	O
free	O
medium	O
was	O
studied	O
by	O
Northern	O
blot	O
analysis	O
and	O
nuclear	O
run	O
-	O
off	O
transcription	O
analysis	O
.	O
Addition	O
of	O
FCS	O
or	O
FKN	O
gradually	O
increased	O
the	O
basal	O
CCK	O
mRNA	O
level	O
approximately	O
four	O
to	O
six	O
-	O
fold	O
after	O
2-4	O
h	O
.	O
In	O
contrast	O
,	O
a	O
strong	O
and	O
transient	O
increase	O
of	O
the	O
c-	O
fos	O
mRNA	O
-	O
level	O
was	O
observed	O
,	O
approximately	O
forty	O
to	O
fifty	O
-	O
fold	O
after	O
50	O
-	O
60	O
min	O
over	O
unstimulated	O
cells	O
.	O
Nuclear	O
run	O
-	O
off	O
transcription	O
analysis	O
indicates	O
that	O
c-	O
fos	O
mRNA	O
is	O
constitutively	O
expressed	O
and	O
transcription	O
may	O
be	O
further	O
stimulated	O
by	O
FCS	O
and	O
FKN	O
.	O
Moreover	O
,	O
in	O
SK-N-MC	O
nuclei	O
,	O
transcription	O
of	O
the	O
c-	O
fos	O
gene	O
clearly	O
precedes	O
stimulated	O
CCK	O
-mRNA	O
expression	O
.	O
This	O
suggests	O
that	O
FOS	O
,	O
which	O
is	O
known	O
to	O
form	O
a	O
AP-1	O
heterodimer	O
transcription	O
complex	O
with	O
the	O
proto	O
-	O
oncogen	O
product	O
,	O
Jun	O
,	O
may	O
bind	O
to	O
the	O
tentative	O
AP-1	O
binding	O
site	O
,	O
found	O
within	O
the	O
human	O
CCK	O
promoter	O
and	O
thereby	O
modulates	O
basal	O
and	O
enhanced	O
CCK	O
-mRNA	O
expression	O
in	O
SK-N-MC	O
cells	O
.	O
PMID	O
:	O
1360635	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

EMBO	O
J.	O
1982	O
;1	O
(	O
10	O
)	O
:	O
1239	O
-	O
44	O
.	O
Tissue	O
-	O
and	O
developmental	O
stage	O
-	O
specific	O
forms	O
of	O
a	O
neural	O
cell	O
surface	O
antigen	O
linked	O
to	O
differences	O
in	O
glycosylation	O
of	O
a	O
common	O
polypeptide	O
.	O
Rougon	O
G	O
,	O
Deagostini-	O
Bazin	O
H,	O
Hirn	O
M,	O
Goridis	O
C.	O
We	O
have	O
previously	O
identified	O
a	O
cell	O
surface	O
glycoprotein	O
of	O
the	O
mouse	O
nervous	O
system	O
named	O
brain	O
cell	O
surface	O
protein-2	O
(	O
BSP-2	O
)	O
.	O
Here	O
we	O
report	O
that	O
this	O
antigen	O
is	O
not	O
a	O
single	O
,	O
discrete	O
entity	O
,	O
but	O
a	O
family	O
of	O
antigenically	O
and	O
structurally	O
related	O
molecules	O
.	O
Three	O
components	O
of	O
180	O
,	O
140	O
,	O
and	O
120	O
K	O
were	O
characteristic	O
for	O
more	O
mature	O
nervous	O
tissues	O
.	O
Adult	O
cerebral	O
cortex	O
contained	O
the	O
140	O
-	O
K	O
and	O
120	O
-	O
K	O
antigens	O
,	O
adult	O
spinal	O
cord	O
only	O
the	O
120	O
-K	O
,	O
and	O
dorsal	O
root	O
ganglia	O
from	O
young	O
mice	O
mainly	O
the	O
180	O
-	O
K	O
component	O
.	O
Very	O
different	O
forms	O
of	O
the	O
antigen	O
that	O
migrated	O
as	O
a	O
diffuse	O
zone	O
from	O
180	O
-	O
250	O
-	O
K	O
in	O
SDS	O
-	O
polyacrylamide	O
gels	O
were	O
found	O
in	O
immature	O
nervous	O
tissues	O
.	O
A	O
molecule	O
different	O
from	O
the	O
previous	O
ones	O
was	O
found	O
in	O
a	O
neuroblastoma	B-malignancy-type
line	O
.	O
Evidence	O
is	O
presented	O
that	O
the	O
structural	O
diversity	O
of	O
BSP-2	O
is	O
due	O
to	O
differences	O
in	O
glycosylation	O
.	O
This	O
result	O
indicates	O
that	O
cell	O
type	O
-	O
and	O
developmental	O
stage	O
-	O
specific	O
glycoprotein	O
patterns	O
previously	O
found	O
in	O
the	O
nervous	O
system	O
may	O
in	O
part	O
be	O
due	O
to	O
different	O
glycosylation	O
of	O
identical	O
polypeptides	O
.	O
The	O
finding	O
that	O
a	O
neural	O
cell	O
surface	O
protein	O
may	O
be	O
glycosylated	O
in	O
different	O
ways	O
has	O
important	O
implications	O
for	O
the	O
generation	O
of	O
cell	O
surface	O
specificity	O
.	O
PMID	O
:	O
7188249	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochemistry	O
.	O
1980	O
Feb	O
5;19(	O
3	O
)	O
:457	O
-	O
62	O
.	O
Binding	O
of	O
scorpion	O
neurotoxins	O
to	O
chick	O
embryonic	O
heart	O
cells	O
in	O
culture	O
and	O
relationship	O
to	O
calcium	O
uptake	O
and	O
membrane	O
potential	O
.	O
Couraud	O
F	O
,	O
Rochat	O
H,	O
Lissitzky	O
S.	O
Stimulation	O
of	O
45Ca	O
uptake	O
by	O
scorpion	O
neurotoxins	O
in	O
cultured	O
chick	O
embryonic	O
heart	O
cells	O
has	O
been	O
shown	O
to	O
be	O
directly	O
linked	O
to	O
their	O
effect	O
on	O
sodium	O
channels	O
.	O
This	O
property	O
was	O
used	O
to	O
compare	O
the	O
activity	O
of	O
15	O
neurotoxins	O
from	O
five	O
different	O
species	O
to	O
their	O
lethal	O
effect	O
in	O
the	O
mouse	O
and	O
immunological	O
properties	O
.	O
As	O
scorpion	O
neurotoxins	O
,	O
the	O
alkaloid	O
neurotoxin	O
veratridine	O
enhanced	O
45Ca	O
uptake	O
,	O
and	O
an	O
apparent	O
positive	O
cooperativity	O
between	O
the	O
two	O
drugs	O
was	O
observed	O
.	O
125I-Labeled	O
toxin	O
II	O
from	O
the	O
scorpion	O
Androctonus	O
australis	O
Hector	O
was	O
shown	O
to	O
bind	O
to	O
chick	O
heart	O
cells	O
specifically	O
,	O
saturably	O
,	O
and	O
reversibly	O
with	O
high	O
affinity	O
(	O
KD	O
=	O
1--3	O
nM	O
in	O
sodium	O
-	O
free	O
medium	O
)	O
and	O
low	O
capacity	O
(	O
10	O
--20	O
fmol	O
/	O
mg	O
cell	O
protein	O
)	O
.	O
As	O
shown	O
by	O
45Ca	O
uptake	O
and	O
radioactive	O
toxin	O
binding	O
experiments	O
,	O
the	O
affinity	O
of	O
scorpion	O
neurotoxin	O
to	O
heart	O
cell	O
receptors	O
was	O
dependent	O
on	O
external	O
K	O
+	O
concentration	O
.	O
Toxin	O
binding	O
was	O
lowered	O
by	O
increasing	O
Na	O
+	O
concentration	O
in	O
the	O
medium	O
and	O
was	O
abolished	O
by	O
veratridine	O
in	O
a	O
sodium	O
(	O
140	O
mM	O
)	O
containing	O
medium	O
.	O
As	O
previously	O
reported	O
for	O
neuroblastoma	B-malignancy-type
cells	O
,	O
all	O
these	O
results	O
are	O
in	O
agreement	O
with	O
the	O
membrane	O
potential	O
dependence	O
of	O
scorpion	O
neurotoxin	O
affinity	O
for	O
its	O
membrane	O
receptor	O
.	O
PMID	O
:	O
7356938	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2003	O
Mar	O
13;22	O
(	O
10	O
)	O
:	O
148	O
6-	O
90	O
.	O
Alterations	O
of	O
anaphase	O
-	O
promoting	O
complex	O
genes	O
in	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
.	O
Wang	O
Q	O
,	O
Moyret-	O
Lalle	O
C	O
,	O
Couzon	O
F	O
,	O
Surbiguet-Clippe	O
C	O
,	O
Saurin	O
JC	O
,	O
Lorca	O
T	O
,	O
Navarro	O
C	O
,	O
Puisieux	O
A	O
.	O
Centre	O
d'Oncologie	O
Genetique	O
,	O
INSERM	O
U	O
453	O
,	O
Centre	O
Leon	O
Berard	O
,	O
Lyon	O
,	O
France	O
.	O
Ubiquitin	O
-	O
mediated	O
proteolysis	O
of	O
cell	O
cycle	O
regulators	O
is	O
a	O
major	O
element	O
of	O
the	O
cell	O
cycle	O
control	O
.	O
The	O
anaphase	O
-	O
promoting	O
complex	O
(	O
APC	O
/C	O
)	O
is	O
a	O
large	O
multisubunit	O
ubiquitin	O
-	O
protein	O
ligase	O
required	O
for	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
G1	O
and	O
mitotic	O
checkpoint	O
regulators	O
.	O
APC	O
/	O
C	O
-	O
dependent	O
proteolysis	O
regulates	O
cyclin	O
levels	O
in	O
G1	O
,	O
and	O
triggers	O
the	O
separation	O
of	O
sister	O
chromatids	O
at	O
the	O
metaphase	O
-anaphase	O
transition	O
and	O
the	O
destruction	O
of	O
mitotic	O
cyclins	O
at	O
the	O
end	O
of	O
mitosis	O
.	O
Furthermore	O
,	O
it	O
was	O
recently	O
shown	O
that	O
APC	O
/	O
C	O
regulates	O
the	O
degradation	O
of	O
crucial	O
regulators	O
of	O
signal	O
transduction	O
pathways	O
.	O
We	O
report	O
here	O
gene	O
alterations	O
in	O
several	O
components	O
of	O
this	O
complex	O
in	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
,	O
including	O
APC6	O
/	O
CDC16	O
and	O
APC8	O
/	O
CDC23	O
which	O
are	O
known	O
to	O
be	O
key	O
function	O
elements	O
.	O
The	O
experimental	O
expression	O
of	O
a	O
truncation	O
mutant	O
of	O
APC8	O
/	O
CDC23	O
subunit	O
(	O
CDC23DeltaTPR	O
)	O
leads	O
to	O
abnormal	O
levels	O
of	O
APC	O
/	O
C	O
targets	O
such	O
as	O
cyclin	O
B1	O
and	O
disturbs	O
the	O
cell	O
cycle	O
progression	O
of	O
colon	O
epithelial	O
cells	O
through	O
mitosis	O
.	O
Overall	O
,	O
these	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
deleterious	O
role	O
of	O
these	O
mutations	O
during	O
colorectal	O
carcinogenesis	O
.	O
PMID	O
:	O
12629511	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1995	O
Apr	O
1;75	O
(	O
7	O
)	O
:1694	O
-	O
9.	O
Morphologic	O
and	O
molecular	O
cytogenetics	O
in	O
neuroblastoma	B-malignancy-type
.	O
Avet-	O
Loiseau	O
H,	O
Venuat	O
AM	O
,	O
Benard	O
J,	O
Leibovitch	O
MP	O
,	O
Hartmann	O
O	O
,	O
Bernheim	O
A	O
.	O
Laboratoire	O
de	O
Cytogenetique	O
et	O
Genetique	O
Oncologiques	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
France	O
.	O
BACKGROUND	O
:	O
Some	O
genetic	O
alterations	O
have	O
been	O
shown	O
to	O
have	O
prognostic	O
implication	O
for	O
patients	O
with	O
neuroblastoma	B-malignancy-type
:	O
MYCN	O
oncogene	O
amplification	O
,	O
deletion	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
and	O
di	O
-	O
or	O
tetraploidy	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
analyze	O
these	O
factors	O
in	O
children	O
with	O
neuroblastoma	B-malignancy-type
.	O
METHODS	O
:	O
Twenty	O
neuroblastoma	B-malignancy-type
samples	O
were	O
analyzed	O
with	O
morphologic	O
cytogenetics	O
,	O
and	O
each	O
of	O
them	O
was	O
compared	O
with	O
MYCN	O
amplification	O
status	O
by	O
Southern	O
blot	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
a	O
genomic	O
probe	O
.	O
RESULTS	O
:	O
A	O
complete	O
karyotype	O
was	O
obtained	O
for	O
14	O
children	O
.	O
A	O
diploid	O
or	O
tetraploid	O
mode	O
and	O
a	O
1p	O
deletion	O
were	O
found	O
in	O
most	O
children	O
with	O
advanced	O
stages	O
.	O
MYCN	O
amplification	O
status	O
was	O
totally	O
concordant	O
with	O
both	O
methods	O
in	O
all	O
patients	O
,	O
even	O
in	O
a	O
case	O
with	O
low	O
level	O
amplification	O
.	O
A	O
wide	O
intercellular	O
variation	O
in	O
the	O
amplification	O
level	O
in	O
each	O
MYCN	O
amplified	O
sample	O
was	O
shown	O
.	O
CONCLUSION	O
:	O
The	O
use	O
of	O
FISH	O
to	O
assess	O
MYCN	O
amplification	O
rapidly	O
in	O
neuroblastoma	B-malignancy-type
is	O
recommended	O
.	O
This	O
method	O
could	O
be	O
very	O
useful	O
in	O
future	O
therapeutic	O
protocols	O
in	O
which	O
treatment	O
is	O
based	O
on	O
MYCN	O
status	O
(	O
and	O
especially	O
for	O
infants	O
and	O
children	O
with	O
localized	O
tumor	O
)	O
.	O
PMID	O
:	O
8826929	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Cytol	O
.	O
2002	O
Jan-	O
Feb;46	O
(	O
1	O
)	O
:	O
40	O
-5	O
.	O
Fine	O
needle	O
aspiration	O
cytology	O
of	O
metastatic	O
olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
:	O
a	O
case	O
report	O
.	O
Chung	O
J,	O
Park	O
ST	O
,	O
Jang	O
J.	O
Department	O
of	O
Diagnostic	O
Pathology	O
,	O
Asan	O
Kangnung	O
Hospital	O
,	O
KangNungSi	O
,	O
South	O
Korea	O
.	O
gzz@ghil	O
.com	O
BACKGROUND	O
:	O
Olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
(	O
ONB	B-malignancy-type
)	O
is	O
an	O
uncommon	O
tumor	O
,	O
presenting	O
as	O
a	O
polypoid	O
mass	O
arising	O
from	O
the	O
upper	O
nasal	O
cavity	O
.	O
This	O
tumor	O
has	O
been	O
seldom	O
diagnosed	O
by	O
direct	O
fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
.	O
CASE	O
:	O
Metastatic	O
ONB	B-malignancy-type
was	O
diagnosed	O
by	O
FNA	O
.	O
The	O
patient	O
was	O
a	O
40	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
polypoid	O
mass	O
in	O
the	O
nasal	O
cavity	O
and	O
ipsilateral	O
cervical	O
lymphadenopathy	O
.	O
The	O
punch	O
biopsy	O
of	O
the	O
nasal	O
tumor	O
revealed	O
a	O
smudged	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
neoplasm	I-malignancy-type
with	O
neuroendocrine	O
differentiation	O
,	O
consistent	O
with	O
ONB	B-malignancy-type
.	O
In	O
FNA	O
smears	O
from	O
the	O
cervical	O
lymph	O
node	O
,	O
there	O
were	O
well	O
-	O
preserved	O
,	O
small	O
,	O
monotonous	O
cells	O
with	O
hyperchromatic	O
nuclei	O
,	O
fibrillary	O
cytoplasm	O
and	O
indistinct	O
cell	O
borders	O
.	O
Also	O
noteworthy	O
were	O
occasional	O
pseudorosettes	O
as	O
well	O
as	O
rare	O
true	O
rosettes	O
.	O
By	O
immunocytochemistry	O
,	O
tumor	O
cells	O
were	O
positive	O
for	O
cytokeratin	O
,	O
chromogranin	O
and	O
synaptophysin	O
.	O
CONCLUSION	O
:	O
ONB	B-malignancy-type
,	O
like	O
adrenal	B-malignancy-type
neuroblastoma	I-malignancy-type
,	O
shows	O
distinctive	O
cytologic	O
features	O
,	O
including	O
a	O
rosette	O
or	O
pseudorosette	O
and	O
fibrillary	O
network	O
.	O
FNA	O
can	O
accurately	O
demonstrate	O
these	O
characteristic	O
findings	O
,	O
and	O
in	O
some	O
cases	O
it	O
may	O
be	O
a	O
better	O
diagnostic	O
modality	O
than	O
incisional	O
biopsy	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
11843557	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nature	O
.	O
1993	O
Feb	O
25;361	O
(	O
6414	O
)	O
:739	O
-	O
42	O
.	O
Conversion	O
of	O
lytic	O
to	O
persistent	O
alphavirus	O
infection	O
by	O
the	O
bcl-2	O
cellular	O
oncogene	O
.	O
Levine	O
B	O
,	O
Huang	O
Q	O
,	O
Isaacs	O
JT	O
,	O
Reed	O
JC	O
,	O
Griffin	O
DE	O
,	O
Hardwick	O
JM	O
.	O
Department	O
of	O
Medicine	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21287	O
-	O
7681	O
.	O
Little	O
is	O
known	O
about	O
virus	O
-host	O
cell	O
interactions	O
that	O
regulate	O
the	O
lytic	O
potential	O
of	O
viruses	O
during	O
productive	O
replication	O
.	O
Sindbis	O
virus	O
(	O
SV	O
)	O
,	O
a	O
single	O
-	O
stranded	O
positive	O
-	O
sense	O
RNA	O
virus	O
in	O
the	O
alphavirus	O
genus	O
(	O
family	O
Togaviridae	O
)	O
,	O
results	O
in	O
lytic	O
infection	O
in	O
most	O
vertebrate	O
cell	O
lines	O
,	O
but	O
persistent	O
productive	O
infection	O
in	O
post	O
-	O
mitotic	O
neurons	O
.	O
The	O
cellular	O
oncogene	O
bcl-2	O
,	O
which	O
encodes	O
an	O
inner	O
mitochondrial	O
membrane	O
protein	O
of	O
M(r)	O
26	O
,000	O
(	O
ref	O
.	O
2	O
)	O
,	O
blocks	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
in	O
neurons	O
.	O
We	O
therefore	O
investigated	O
whether	O
SV	O
infection	O
induces	O
programmed	O
cell	O
death	O
in	O
non	O
-	O
neuronal	O
cells	O
,	O
and	O
if	O
so	O
,	O
whether	O
virus	O
-	O
induced	O
programmed	O
cell	O
death	O
can	O
be	O
blocked	O
by	O
transfection	O
with	O
bcl-2.	O
We	O
demonstrate	O
that	O
SV	O
infection	O
of	O
baby	O
hamster	O
kidney	O
(	O
BHK-2	O
)	O
,	O
mouse	O
neuroblastoma	B-malignancy-type
(	O
N18	O
)	O
,	O
and	O
rat	O
prostatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
(	O
AT-3)	O
cells	O
results	O
in	O
programmed	O
cell	O
death	O
,	O
whereas	O
SV	O
infection	O
of	O
bcl-2	O
-transfected	O
AT-3	O
cells	O
results	O
in	O
long-term	O
persistent	O
productive	O
infection	O
.	O
Thus	O
cellular	O
bcl-2	O
oncogene	O
expression	O
plays	O
a	O
role	O
in	O
the	O
establishment	O
of	O
persistent	O
viral	O
infection	O
by	O
blocking	O
virus	O
-	O
induced	O
programmed	O
cell	O
death	O
.	O
PMID	O
:	O
8441470	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
Surg	O
.	O
1997	O
Mar;32	O
(	O
3	O
)	O
:	O
420	O
-2.	O
Expression	O
of	O
multidrug	O
resistance	O
-	O
related	O
P-glycoprotein	O
shows	O
good	O
prognosis	O
in	O
neuroblastoma	B-malignancy-type
.	O
Obana	O
K,	O
Hashizume	O
K.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
Expression	O
of	O
P-glycoprotein	O
was	O
studied	O
in	O
formalin	O
-	O
fixed	O
tissue	O
sections	O
from	O
75	O
materials	O
with	O
an	O
immunoperoxidase	O
(	O
ABC	O
)	O
method	O
using	O
the	O
monoclonal	O
antibody	O
MRK-16	O
.	O
Specimens	O
examined	O
were	O
from	O
three	O
monkey	O
fetuses	O
,	O
eight	O
autopsy	O
cases	O
,	O
and	O
64	O
neuroblastoma	B-malignancy-type
patients	O
,	O
25	O
of	O
whom	O
were	O
underwent	O
mass	O
screening	O
for	O
diagnosis	O
.	O
P-glycoprotein	O
test	O
results	O
were	O
positive	O
in	O
fetal	O
lung	O
alveolar	O
tissue	O
and	O
in	O
the	O
adrenal	O
medulla	O
of	O
three	O
of	O
seven	O
adult	O
autopsy	O
cases	O
.	O
Expression	O
of	O
P-glycoprotein	O
was	O
demonstrated	O
in	O
22	O
of	O
35	O
cases	O
(	O
63	O
%	O
)	O
in	O
a	O
group	O
of	O
neuroblastoma	B-malignancy-type
patients	O
younger	O
than	O
12	O
months	O
of	O
age	O
,	O
as	O
compared	O
with	O
9	O
of	O
20	O
(	O
31	O
%	O
)	O
who	O
were	O
older	O
than	O
12	O
months	O
of	O
age	O
at	O
diagnosis	O
.	O
P-glycoprotein	O
positivity	O
was	O
higher	O
in	O
patients	O
who	O
were	O
alive	O
(	O
25	O
of	O
40	O
,	O
63	O
%	O
)	O
than	O
in	O
those	O
who	O
had	O
died	O
(	O
6	O
of	O
24	O
,	O
25	O
%	O
)	O
.	O
Previous	O
studies	O
on	O
P-glycoprotein	O
expression	O
in	O
neuroblastoma	B-malignancy-type
were	O
carried	O
out	O
using	O
specimens	O
mainly	O
from	O
older	O
children	O
,	O
and	O
the	O
results	O
were	O
not	O
analyzed	O
with	O
reference	O
to	O
the	O
findings	O
in	O
normal	O
tissues	O
.	O
The	O
present	O
study	O
has	O
clearly	O
shown	O
that	O
positive	O
P-glycoprotein	O
expression	O
in	O
neuroblastoma	B-malignancy-type
patients	O
should	O
be	O
evaluated	O
carefully	O
in	O
infant	O
cases	O
because	O
it	O
stains	O
frequently	O
in	O
normal	O
adrenal	O
glands	O
.	O
PMID	O
:	O
9094007	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1999	O
Aug;35	O
(	O
8	O
)	O
:	O
1227	O
-34	O
.	O
Comment	O
in	O
:	O
Eur	O
J	O
Cancer	O
.	O
1999	O
Aug;35	O
(	O
8	O
)	O
:	O
1171-3.	O
Influence	O
of	O
cisplatin	O
and	O
doxorubicin	O
on	O
125I-meta	O
-	O
iodobenzylguanidine	O
uptake	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Meco	O
D	O
,	O
Lasorella	O
A	O
,	O
Riccardi	O
A	O
,	O
Servidei	O
T	O
,	O
Mastrangelo	O
R	O
,	O
Riccardi	O
R.	O
Division	O
of	O
Paediatric	O
Oncology	O
,	O
Catholic	O
University	O
,	O
Rome	O
,	O
Italy	O
.	O
The	O
combination	O
of	O
131I-meta	O
-	O
iodobenzylguanidine	O
(	O
MIBG	O
)	O
with	O
chemotherapy	O
has	O
recently	O
been	O
employed	O
in	O
the	O
treatment	O
of	O
advanced	O
stage	O
neuroblastoma	B-malignancy-type
with	O
encouraging	O
results	O
.	O
However	O
,	O
the	O
mechanisms	O
underlying	O
the	O
interaction	O
between	O
these	O
two	O
different	O
modalities	O
of	O
treatment	O
have	O
not	O
yet	O
been	O
explored	O
.	O
In	O
this	O
study	O
,	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
pretreatment	O
with	O
cisplatin	O
and	O
doxorubicin	O
increased	O
cellular	O
125I-MIBG	O
accumulation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Cell	O
cycle	O
analysis	O
showed	O
that	O
increased	O
125I-MIBG	O
accumulation	O
correlated	O
with	O
the	O
drug	O
-	O
induced	O
G2/	O
M	O
phase	O
block	O
.	O
Northern	O
blot	O
analysis	O
demonstrated	O
an	O
increase	O
in	O
gene	O
expression	O
of	O
the	O
noradrenaline	O
transporter	O
induced	O
by	O
doxorubicin	O
,	O
but	O
not	O
by	O
cisplatin	O
treatment	O
.	O
Increased	O
125I-MIBG	O
accumulation	O
was	O
also	O
observed	O
in	O
murine	O
xenografts	O
of	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-DZ	O
or	O
BE(2)M17	O
treated	O
intraperitoneally	O
(	O
i.p.	O
)	O
with	O
cisplatin	O
or	O
doxorubicin	O
,	O
respectively	O
.	O
These	O
results	O
suggest	O
that	O
the	O
combination	O
of	O
131I-MIBG	O
and	O
these	O
drugs	O
could	O
selectively	O
increase	O
radiation	O
doses	O
delivered	O
to	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
10615234	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
J.	O
1997	O
Apr	O
1;323	O
(	O
Pt	O
1	O
)	O
:245-50	O
.	O
The	O
transcription	O
of	O
the	O
human	O
fructose	O
-	O
bisphosphate	O
aldolase	O
C	O
gene	O
is	O
activated	O
by	O
nerve	O
-growth	O
-	O
factor	O
-	O
induced	O
B	O
factor	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Buono	O
P,	O
Conciliis	O
LD	O
,	O
Izzo	O
P,	O
Salvatore	O
F.	O
Dipartimento	O
di	O
Biochimica	O
e	O
Biotecnologie	O
Mediche	O
,	O
Universita	O
'	O
di	O
Napoli	O
'Federico	O
II'	O
,	O
Via	O
S.	O
Pansini	O
5	O
,	O
Napoli	O
,	O
I-80131	O
,	O
Italy	O
.	O
A	O
DNA	O
region	O
located	O
at	O
around	O
-	O
200	O
bp	O
in	O
the	O
5	O
'	O
flanking	O
region	O
(	O
region	O
D	O
)	O
of	O
the	O
human	O
brain	O
-	O
type	O
fructose	O
-	O
bisphosphate	O
aldolase	O
(	O
aldolase	O
C	O
)	O
gene	O
has	O
been	O
analysed	O
.	O
We	O
show	O
by	O
transient	O
transfection	O
assay	O
and	O
electrophoretic	O
-mobility	O
-	O
shift	O
assay	O
(	O
EMSA	O
)	O
that	O
the	O
binding	O
of	O
transcriptional	O
activators	O
to	O
region	O
D	O
is	O
much	O
more	O
efficient	O
(	O
80	O
%	O
versus	O
30	O
%	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
SKNBE	O
)	O
than	O
in	O
the	O
non	O
-	O
neuronal	O
cell	O
line	O
A1251	O
,	O
which	O
contains	O
low	O
levels	O
of	O
aldolase	O
C	O
mRNA	O
.	O
The	O
sequence	O
of	O
region	O
D	O
,	O
CAAGGTCA	O
,	O
is	O
very	O
similar	O
to	O
the	O
AAAGGTCA	O
motif	O
present	O
in	O
the	O
mouse	O
steroid	O
21-hydroxylase	O
gene	O
;	O
the	O
latter	O
motif	O
binds	O
nerve	O
-growth	O
-	O
factor	O
-	O
induced	O
B	O
factor	O
(	O
NGFI-B	O
)	O
,	O
which	O
is	O
a	O
member	O
of	O
the	O
thyroid	O
steroid	O
retinoid	O
nuclear	O
receptor	O
gene	O
family	O
.	O
Competition	O
experiments	O
in	O
EMSA	O
and	O
antibody-directed	O
supershift	O
experiments	O
showed	O
that	O
NGFI-B	O
is	O
involved	O
in	O
the	O
binding	O
to	O
region	O
D	O
of	O
the	O
human	O
aldolase	O
C	O
gene	O
.	O
Furthermore	O
,	O
the	O
regulation	O
of	O
the	O
aldolase	O
C	O
gene	O
(	O
which	O
is	O
the	O
second	O
known	O
target	O
of	O
NGFI-B	O
)	O
expression	O
during	O
development	O
parallels	O
that	O
of	O
NGFI-B	O
	O
PMID	O
:	O
9173889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1984	O
Oct;81	O
(	O
20	O
)	O
:6476-80	O
.	O
Weak	O
HLA	O
and	O
beta	O
2-microglobulin	O
expression	O
of	O
neuronal	O
cell	O
lines	O
can	O
be	O
modulated	O
by	O
interferon	O
.	O
Lampson	O
LA	O
,	O
Fisher	O
CA.	O
Previous	O
work	O
showed	O
that	O
each	O
of	O
four	O
human	O
neuronal	O
cell	O
lines	O
expresses	O
less	O
than	O
or	O
equal	O
to	O
0.5	O
%	O
of	O
the	O
HLA-	O
A	O
B	O
C	O
and	O
beta	O
2-microglobulin	O
seen	O
in	O
glial	O
,	O
lymphoid	O
,	O
and	O
other	O
cell	O
types	O
,	O
and	O
there	O
is	O
a	O
corresponding	O
weak	O
expression	O
in	O
neuroblastoma	B-malignancy-type
tumor	O
and	O
adult	O
brain	O
.	O
Here	O
,	O
we	O
probe	O
the	O
genetic	O
basis	O
of	O
this	O
weak	O
expression	O
.	O
For	O
each	O
of	O
three	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
we	O
show	O
that	O
HLA-	O
A	O
B	O
C	O
and	O
beta	O
2-microglobulin	O
can	O
be	O
induced	O
by	O
interferon	O
and	O
that	O
the	O
induction	O
occurs	O
within	O
every	O
cell	O
of	O
the	O
population	O
.	O
Class	O
II	O
(	O
Ia	O
)	O
molecules	O
are	O
not	O
detected	O
.	O
Microscopic	O
assay	O
and	O
radioimmunoassay	O
of	O
intact	O
cells	O
suggest	O
that	O
the	O
induced	O
antigen	O
appears	O
at	O
the	O
cell	O
surface	O
as	O
well	O
as	O
within	O
each	O
cell	O
.	O
Immunoblot	O
analysis	O
confirms	O
that	O
the	O
induced	O
proteins	O
have	O
the	O
structure	O
of	O
class	O
I	O
molecules	O
.	O
Thus	O
,	O
the	O
normal	O
weak	O
HLA	O
and	O
beta	O
2-microglobulin	O
expression	O
of	O
these	O
cell	O
lines	O
appears	O
to	O
reflect	O
a	O
regulatory	O
control	O
rather	O
than	O
a	O
primary	O
genetic	O
lesion	O
.	O
According	O
to	O
current	O
theory	O
,	O
lack	O
of	O
HLA-	O
A	O
B	O
C	O
should	O
protect	O
transformed	O
,	O
infected	O
,	O
or	O
damaged	O
neurons	O
-	O
-but	O
also	O
neurons	O
in	O
neural	O
transplants	O
-	O
-	O
from	O
T-cell	O
-	O
mediated	O
immunosurveillance	O
.	O
The	O
possibility	O
that	O
neuronal	O
HLA-	O
A	O
B	O
C	O
expression	O
may	O
be	O
under	O
regulatory	O
control	O
is	O
of	O
importance	O
in	O
this	O
context	O
.	O
PMID	O
:	O
6436814	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Dec	O
27;277	O
(	O
52	O
)	O
:	O
50966-72	O
.	O
Epub	O
2002	O
Oct	O
21	O
.	O
Mitochondrial	O
localization	O
of	O
mutant	O
superoxide	O
dismutase	O
1	O
triggers	O
caspase	O
-	O
dependent	O
cell	O
death	O
in	O
a	O
cellular	O
model	O
of	O
familial	O
amyotrophic	O
lateral	O
sclerosis	O
.	O
Takeuchi	O
H,	O
Kobayashi	O
Y	O
,	O
Ishigaki	O
S	O
,	O
Doyu	O
M,	O
Sobue	O
G.	O
Department	O
of	O
Neurology	O
,	O
Nagoya	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
65	O
Tsurumai	O
-	O
cho	O
,	O
Showa-ku	O
,	O
Nagoya	O
466-8550	O
,	O
Japan	O
.	O
The	O
mutations	O
in	O
superoxide	O
dismutase	O
1	O
(	O
SOD1	O
)	O
cause	O
approximately	O
20	O
%	O
of	O
familial	O
amyotrophic	O
lateral	O
sclerosis	O
cases	O
.	O
A	O
toxic	O
gain	O
of	O
function	O
has	O
been	O
considered	O
to	O
be	O
the	O
cause	O
of	O
the	O
disease	O
,	O
but	O
its	O
molecular	O
mechanism	O
remains	O
uncertain	O
.	O
To	O
determine	O
whether	O
the	O
subcellular	O
localization	O
of	O
mutant	O
SOD1	O
is	O
crucial	O
to	O
mutant	O
SOD1	O
-	O
mediated	O
cell	O
death	O
,	O
we	O
produced	O
neuronal	O
cell	O
models	O
with	O
accumulation	O
of	O
SOD1	O
in	O
each	O
subcellular	O
fraction	O
/organelle	O
,	O
such	O
as	O
the	O
cytosol	O
,	O
nucleus	O
,	O
endoplasmic	O
reticulum	O
,	O
and	O
mitochondria	O
.	O
We	O
showed	O
that	O
the	O
localization	O
of	O
mutant	O
SOD1	O
in	O
the	O
mitochondria	O
triggered	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	O
c	O
followed	O
by	O
the	O
activation	O
of	O
caspase	O
cascade	O
and	O
induced	O
neuronal	O
cell	O
death	O
without	O
cytoplasmic	O
mutant	O
SOD1	O
aggregate	O
formation	O
.	O
Nuclear	O
and	O
endoplasmic	O
reticulum	O
localization	O
of	O
mutant	O
SOD1	O
did	O
not	O
induce	O
cell	O
death	O
.	O
These	O
results	O
suggest	O
that	O
the	O
localization	O
of	O
mutant	O
SOD1	O
in	O
the	O
mitochondria	O
is	O
critical	O
in	O
the	O
pathogenesis	O
of	O
mutant	O
SOD1	O
-	O
associated	O
familial	O
amyotrophic	O
lateral	O
sclerosis	O
.	O
PMID	O
:	O
12393885	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Infect	O
Dis	O
.	O
2003	O
Oct	O
1	O
188	O
(	O
7	O
)	O
:	O
954-9	O
.	O
Epub	O
2003	O
Sep	O
26	O
.	O
Comment	O
in	O
:	O
J	O
Infect	O
Dis	O
.	O
2003	O
Oct	O
1	O
;	O
188	O
(	O
7	O
:	O
945-7	O
.	O
Development	O
of	O
resistance	O
to	O
acyclovir	O
during	O
chronic	O
infection	O
with	O
the	O
Oka	O
vaccine	O
strain	O
of	O
varicella-zoster	O
virus	O
,	O
in	O
an	O
immunosuppressed	O
child	O
.	O
Levin	O
MJ	O
,	O
Dahl	O
KM	O
,	O
Weinberg	O
A	O
,	O
Giller	O
R	O
,	O
Patel	O
A	O
,	O
Krause	O
PR	O
.	O
Section	O
of	O
Pediatric	O
Infectious	O
Diseases	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
,	O
Denver	O
,	O
Colorado	O
80262	O
,	O
USA	O
.	O
myron.levin@uchsc.edu	O
A	O
1-year-old	O
boy	O
was	O
vaccinated	O
with	O
the	O
Oka	O
strain	O
of	O
varicella	O
just	O
prior	O
to	O
the	O
discovery	O
of	O
a	O
tumor	O
that	O
required	O
intensive	O
antitumor	O
therapy	O
.	O
Three	O
months	O
later	O
he	O
developed	O
herpes	O
zoster	O
,	O
which	O
developed	O
into	O
chronic	O
verrucous	B-malignancy-type
lesions	I-malignancy-type
that	O
were	O
refractory	O
to	O
treatment	O
with	O
acyclovir	O
and	O
which	O
subsequently	O
disseminated	O
.	O
DNA	O
from	O
a	O
biopsy	O
specimen	O
of	O
a	O
chronic	B-malignancy-type
herpes-zoster	I-malignancy-type
lesion	I-malignancy-type
indicated	O
that	O
the	O
Oka	O
vaccine	O
strain	O
of	O
the	O
the	O
virus	O
caused	O
this	O
severe	O
complication	O
.	O
Analysis	O
of	O
this	O
viral	O
DNA	O
demonstrated	O
a	O
mutation	O
in	O
the	O
viral	O
thymidine	O
kinase	O
gene	O
.	O
Plasmids	O
containing	O
this	O
altered	O
gene	O
were	O
unable	O
to	O
produce	O
functional	O
thymidine	O
kinase	O
in	O
an	O
in	O
vitro	O
translation	O
system	O
.	O
The	O
presence	O
of	O
this	O
mutation	O
would	O
explain	O
the	O
clinical	O
resistance	O
to	O
acyclovir	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
Oka-strain	O
varicella	O
virus	O
causing	O
severe	O
disease	O
after	O
reactivation	O
and	O
of	O
resistance	O
to	O
acyclovir	O
during	O
an	O
infection	O
caused	O
by	O
this	O
virus	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
14513413	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Semin	O
Diagn	O
Pathol	O
.	O
1996	O
Aug	O
;	O
13	O
(	O
3	O
)	O
:	O
171-83	O
.	O
Cytogenetics	O
and	O
tissue	O
culture	O
of	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
bone	O
and	O
soft	O
tissue	O
.	O
Noguera	O
R	O
.	O
Department	O
of	O
Pathology	O
,	O
Medical	O
School	O
,	O
University	O
of	O
Valencia	O
,	O
Spain	O
.	O
The	O
variety	O
of	O
tumor	O
-	O
specific	O
cytogenetic	O
and	O
genetic	O
alterations	O
among	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
(	O
Ewing	B-malignancy-type
family	I-malignancy-type
of	I-malignancy-type
tumors	I-malignancy-type
,	O
rhabdomyosarcoma	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
and	O
lymphoma	B-malignancy-type
)	O
increases	O
the	O
possibility	O
of	O
genotypic	O
diagnosis	O
of	O
them	O
.	O
In	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
and	O
related	O
peripheral	B-malignancy-type
primitive	I-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
,	O
a	O
(	O
11	O
;	O
22	O
)	O
(	O
q24	O
;	O
q12	O
)	O
translocation	B-malignancy-type
is	O
associated	O
with	O
hybrid	O
transcripts	O
of	O
the	O
EWS	O
gene	O
with	O
the	O
FLIl	O
gene	O
.	O
In	O
alveolar	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
,	O
a	O
(	O
2	O
;	O
13	O
(	O
q35	O
;	O
qt4	O
)	O
translocation	O
is	O
associated	O
with	O
a	O
chimeric	O
gene	O
between	O
PAX3	O
and	O
FKHR	O
.	O
Specific	O
genetic	O
alterations	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
and	O
amplification	O
of	O
the	O
MYCN	O
gene	O
are	O
diagnostically	O
useful	O
in	O
neuroblastomas	B-malignancy-type
as	O
the	O
immunoglobulin	O
or	O
T-cell	O
receptor	O
gene	O
rearrangements	O
and	O
chromosome	O
translocations	O
in	O
lymphomas	B-malignancy-type
.	O
Thus	O
,	O
cytogenetics	O
and	O
genetics	O
provide	O
an	O
essential	O
adjunct	O
to	O
diagnostic	O
surgical	O
pathology	O
in	O
the	O
case	O
of	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
,	O
which	O
often	O
present	O
substantial	O
diagnostic	O
challenges	O
.	O
Likewise	O
,	O
in	O
vitro	O
culture	O
studies	O
represent	O
another	O
approach	O
in	O
determining	O
histogenetic	O
origin	O
,	O
novel	O
genes	O
,	O
novel	O
mechanisms	O
of	O
gene	O
dysregulation	O
,	O
and	O
the	O
biological	O
characteristics	O
of	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
8875708	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1998	O
Mar	O
27	O
;	O
244	O
(	O
3	O
)	O
:	O
706-11	O
.	O
Long-term	O
exposure	O
to	O
retinoic	O
acid	O
induces	O
the	O
expression	O
of	O
IRK1	O
channels	O
in	O
HERG	O
channel	O
-	O
endowed	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Arcangeli	O
A	O
,	O
Rosati	O
B	O
,	O
Cherubini	O
A	O
,	O
Crociani	O
O	O
,	O
Fontana	O
L	O
,	O
Passani	O
B	O
,	O
Wanke	O
E	O
,	O
Olivotto	O
M	O
.	O
Institute	O
of	O
General	O
Pathology	O
,	O
University	O
of	O
Florence	O
,	O
Italy	O
.	O
The	O
modulation	O
of	O
inward	O
K+	O
conductances	O
was	O
studied	O
during	O
neuronal	O
differentiation	O
of	O
human	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Under	O
standard	O
culture	O
conditions	O
,	O
these	O
cells	O
express	O
the	O
herg	O
gene	O
,	O
and	O
the	O
HERG	O
current	O
is	O
the	O
main	O
inward	O
K	O
+	O
current	O
regulating	O
their	O
Vrest	O
.	O
After	O
10-20	O
days	O
exposure	O
to	O
Retinoic	O
Acid	O
(	O
RA	O
)	O
,	O
SH-SY5Y	O
cells	O
showed	O
,	O
in	O
addition	O
to	O
HERG	O
currents	O
,	O
a	O
novel	O
current	O
characterized	O
by	O
inward	O
rectification	O
,	O
dependence	O
on	O
the	O
extracellular	O
K+	O
concentration	O
,	O
and	O
blockade	O
by	O
Cs+	O
and	O
Ba2+	O
,	O
the	O
main	O
features	O
of	O
the	O
IRK1	O
current	O
.	O
The	O
appearance	O
of	O
this	O
current	O
is	O
accompanied	O
by	O
a	O
strong	O
hyperpolarisation	O
of	O
Vrest	O
.	O
RT-PCR	O
experiments	O
confirmed	O
that	O
a	O
transcript	O
of	O
the	O
IRK1	O
(	O
Kir	O
2.1	O
)	O
gene	O
actually	O
appears	O
in	O
SH-SY5Y	O
cells	O
treated	O
for	O
10-20	O
days	O
with	O
RA.	O
On	O
the	O
whole	O
,	O
data	O
here	O
presented	O
demonstrate	O
that	O
RA	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
is	O
accompanied	O
by	O
the	O
switch	O
from	O
a	O
HERG	O
-	O
driven	O
to	O
a	O
IRK1	O
-	O
driven	O
control	O
of	O
Vrest	O
,	O
similarly	O
to	O
what	O
happens	O
in	O
normal	O
differentiating	O
neurons	O
;	O
however	O
,	O
in	O
tumor	O
cells	O
,	O
this	O
switch	O
does	O
not	O
imply	O
the	O
abolition	O
of	O
HERG	O
channel	O
expression	O
.	O
PMID	O
:	O
9535729	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O

Life	O
Sci	O
.	O
1995	O
;	O
56	O
(	O
1	O
)	O
:	O
PL19-25	O
.	O
Adrenomedullin	O
mediates	O
vasodilation	O
via	O
CGRP1	O
receptors	O
.	O
Entzeroth	O
M	O
Doods	O
HN	O
,	O
Wieland	O
HA	O
,	O
Wienen	O
W	O
.	O
Dr	O
.	O
Karl	O
Thomae	O
GmbH	O
,	O
Biberach	O
,	O
Germany	O
.	O
Adrenomedullin	O
is	O
a	O
recently	O
discovered	O
52	O
amino	O
acid	O
polypeptide	O
with	O
potent	O
hypotensive	O
activity	O
.	O
The	O
peptide	O
possesses	O
21%	O
homology	O
with	O
the	O
amino	O
acid	O
sequence	O
of	O
human	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
-	O
alpha	O
(	O
hCGRP-alpha	O
)	O
.	O
In	O
125I-hCGRP-alpha	O
receptor	O
binding	O
experiments	O
using	O
membranes	O
from	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
SK-N-MC	O
)	O
adrenomedullin	O
is	O
a	O
potent	O
competitor	O
with	O
a	O
Ki	O
of	O
0.37	O
nM	O
.	O
In	O
SK-N-MC	O
cells	O
hCGRP-alpha	O
and	O
adrenomedullin	O
concentration-dependently	O
increase	O
cAMP	O
levels	O
with	O
-logEC50	O
values	O
of	O
9.65	O
and	O
7.75	O
,	O
respectively	O
.	O
Both	O
responses	O
were	O
attenuated	O
in	O
the	O
presence	O
of	O
30	O
nM	O
CGRP[8-37]	O
,	O
a	O
CGRP1	O
receptor	O
antagonist	O
.	O
In	O
isolated	O
rat	O
hearts	O
,	O
perfused	O
at	O
constant	O
flow	O
,	O
bolus	O
infusion	O
of	O
adrenomedullin	O
(	O
1	O
to	O
100	O
nM	O
)	O
resulted	O
in	O
a	O
concentration	O
-	O
dependent	O
,	O
pronounced	O
and	O
long-	O
lasting	O
vasodilation	O
with	O
an	O
approximate	O
EC50	O
of	O
about	O
3	O
nM	O
.	O
This	O
effect	O
was	O
markedly	O
attenuated	O
in	O
the	O
presence	O
of	O
100	O
nM	O
CGRP[8-37]	O
.	O
In	O
this	O
model	O
,	O
bolus	O
infusion	O
of	O
hCGRP-alpha	O
(	O
0.01	O
to	O
100	O
nM	O
)	O
evoked	O
a	O
comparable	O
vasodilation	O
with	O
an	O
approximate	O
EC50	O
of	O
0.5	O
nM	O
.	O
This	O
effect	O
was	O
also	O
potently	O
inhibited	O
in	O
the	O
presence	O
of	O
CGRP[8-37]	O
.	O
These	O
results	O
suggest	O
that	O
adrenomedullin	O
-	O
mediated	O
vasodilation	O
is	O
linked	O
to	O
the	O
activation	O
of	O
CGRP1	O
receptors	O
in	O
the	O
coronary	O
vascular	O
system	O
.	O
PMID	O
:	O
7830489	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
.	O
2003	O
Jul	O
18	O
;	O
197	O
(	O
1-2	O
)	O
:	O
87-92	O
.	O
The	O
role	O
of	O
the	O
MEIS	O
homeobox	O
genes	O
in	O
neuroblastoma	B-malignancy-type
.	O
Geerts	O
D	O
,	O
Schilderink	O
N	O
,	O
Jorritsma	O
G	O
,	O
Versteeg	O
R	O
Department	O
of	O
Human	O
Genetics	O
M1-159	O
,	O
Academic	O
Medical	O
Centre	O
,	O
University	O
of	O
Amsterdam	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
d.geerts@amc.uva.nl	O
We	O
recently	O
found	O
amplification	O
of	O
the	O
TALE	O
homeobox	O
gene	O
MEIS1	O
in	O
the	O
IMR32	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
We	O
now	O
demonstrate	O
high	O
-	O
level	O
expression	O
of	O
the	O
MEIS1	O
and	O
MEIS2	O
genes	O
,	O
as	O
well	O
as	O
efficient	O
expression	O
of	O
most	O
other	O
TALE	O
family	O
member	O
genes	O
in	O
a	O
panel	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Stable	O
transfection	O
of	O
MEIS1	O
-	O
expressing	O
cell	O
lines	O
with	O
cDNA	O
encoding	O
a	O
naturally	O
occurring	O
dominant-	O
negative	O
splice	O
variant	O
of	O
MEIS1	O
(	O
MEIS1E	O
)	O
yielded	O
clones	O
with	O
impaired	O
cell	O
proliferation	O
,	O
gain	O
of	O
differentiated	O
phenotype	O
,	O
and	O
increased	O
contact	O
inhibition	O
and	O
cell	O
death	O
.	O
This	O
indicated	O
a	O
relevance	O
of	O
MEIS	O
expression	O
for	O
neuroblastoma	B-malignancy-type
cell	O
growth	O
and	O
proliferation	O
.	O
We	O
therefore	O
determined	O
the	O
gene	O
expression	O
profiles	O
of	O
several	O
MEIS1E	O
transfectants	O
using	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
.	O
A	O
large	O
number	O
of	O
genes	O
showed	O
differential	O
expression	O
as	O
a	O
result	O
of	O
MEIS1E	O
expression	O
.	O
These	O
include	O
genes	O
involved	O
in	O
developmental	O
signalling	O
pathways	O
,	O
chromatin	O
binding	O
,	O
cell	O
cycle	O
control	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
.	O
The	O
results	O
presented	O
provide	O
important	O
clues	O
for	O
the	O
oncogenic	O
function	O
of	O
MEIS1	O
in	O
neuroblastoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
12880965	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Chin	O
Med	O
Sci	O
J.	O
1994	O
Sep;9(	O
3	O
)	O
:152-6.	O
Down	O
-	O
regulation	O
of	O
c-myc	O
oncogene	O
during	O
NGF	O
-	O
induced	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Chen	O
J,	O
Liu	O
T	O
,	O
Ross	O
AH	O
.	O
Department	O
of	O
Pathology	O
,	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
,	O
CAMS	O
&	O
PUMC	O
,	O
Beijing	O
.	O
There	O
may	O
be	O
a	O
close	O
relationship	O
between	O
myc	O
oncogenes	O
and	O
carcinogenesis	O
of	O
human	O
neuroblastoma	B-malignancy-type
.	O
In	O
previous	O
studies	O
,	O
we	O
were	O
able	O
to	O
induce	O
differentiation	O
of	O
certain	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
NGF	O
.	O
In	O
order	O
to	O
study	O
gene	O
regulation	O
during	O
differentiation	O
,	O
N-myc	O
and	O
c-myc	O
cDNA	O
probes	O
were	O
hybridized	O
with	O
RNA	O
extracted	O
from	O
different	O
cell	O
lines	O
before	O
and	O
after	O
NGF	O
treatment	O
.	O
It	O
was	O
found	O
that	O
cell	O
lines	O
which	O
expressed	O
N-myc	O
did	O
not	O
express	O
c-myc	O
while	O
those	O
with	O
c-myc	O
did	O
not	O
express	O
N-myc	O
except	O
for	O
SHEP	O
cell	O
line	O
which	O
had	O
neither	O
c-myc	O
nor	O
N-myc	O
expression	O
.	O
In	O
NGF	O
-	O
induced	O
differentiated	O
neuroblastoma	B-malignancy-type
cells	O
,	O
c-myc	O
oncogene	O
was	O
down	O
-	O
regulated	O
in	O
comparison	O
with	O
the	O
control	O
samples	O
.	O
The	O
time	O
course	O
of	O
c-myc	O
down	O
-	O
regulation	O
was	O
concomitant	O
with	O
the	O
appearance	O
of	O
morphological	O
differentiation	O
.	O
In	O
situ	O
hybridization	O
also	O
showed	O
remarkable	O
reduction	O
of	O
c-myc	O
oncogene	O
expression	O
in	O
NGF	O
-	O
induced	O
differentiated	O
cells	O
as	O
compared	O
with	O
the	O
untreated	O
control	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
down	O
-	O
regulation	O
of	O
c-myc	O
oncogene	O
may	O
be	O
a	O
key	O
event	O
during	O
NGF	O
-	O
induced	O
differentiation	O
and	O
over	O
-	O
expression	O
of	O
c-myc	O
oncogene	O
may	O
,	O
at	O
least	O
partially	O
,	O
be	O
responsible	O
for	O
the	O
genesis	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
7865834	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
1993	O
Jul	O
30	O
;54	O
(	O
6	O
)	O
:987	O
-	O
91	O
.	O
Activation	O
of	O
the	O
human	O
MDR1	O
gene	O
promoter	O
in	O
differentiated	O
neuroblasts	O
.	O
Ferrandis	O
E	O
,	O
Benard	O
J.	O
Laboratory	O
of	O
Clinical	O
and	O
Molecular	O
Pharmacology	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
Villejuif	O
,	O
France	O
.	O
When	O
treated	O
in	O
vitro	O
with	O
retinoic	O
acid	O
,	O
many	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
undergo	O
neuronal	O
differentiation	O
and	O
show	O
a	O
significant	O
increase	O
in	O
human	O
multi	O
-	O
drug	O
resistance	O
gene	O
(	O
MDRI	O
)	O
transcript	O
levels	O
.	O
To	O
determine	O
whether	O
over	O
-	O
expression	O
of	O
the	O
gene	O
may	O
result	O
from	O
activation	O
of	O
its	O
promoter	O
by	O
differentiating	O
agents	O
,	O
the	O
activity	O
of	O
the	O
human	O
MDRI	O
proximal	O
promoter	O
(	O
MDRI	O
pp	O
)	O
transfected	O
to	O
2	O
neuroblastoma	B-malignancy-type
lines	O
treated	O
with	O
retinoic	O
acid	O
and	O
forskolin	O
was	O
first	O
measured	O
using	O
transient	O
expression	O
assays	O
.	O
The	O
MDRI	O
gene	O
transcript	O
levels	O
of	O
these	O
2	O
lines	O
were	O
then	O
measured	O
by	O
Northern	O
blots	O
.	O
The	O
results	O
indicate	O
that	O
retinoic	O
acid	O
and	O
forskolin	O
were	O
able	O
to	O
activate	O
the	O
human	O
MDRI	O
pp	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
after	O
transfection	O
of	O
the	O
MDRI	O
pp	O
-	O
CAT	O
constructs	O
in	O
the	O
2	O
cell	O
models	O
tested	O
,	O
i.e.	O
,	O
SK-N-SH	O
and	O
IGR-N-91	O
,	O
a	O
new	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
A	O
significant	O
increase	O
in	O
MDRI	O
gene	O
transcript	O
levels	O
was	O
observed	O
upon	O
treatment	O
with	O
differentiation	O
inducers	O
in	O
SK-N-SH	O
but	O
not	O
in	O
IGR-N-91	O
neuroblasts	O
.	O
These	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
the	O
MDRI	O
gene	O
promoter	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
lead	O
to	O
an	O
increase	O
in	O
MDRI	O
gene	O
transcript	O
levels	O
,	O
according	O
to	O
the	O
neuroblast	O
cell	O
line	O
considered	O
.	O
PMID	O
:	O
8101511	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Signal	O
.	O
1991;3(	O
4	O
)	O
:	O
333	O
-	O
9.	O
A	O
quantitative	O
analysis	O
of	O
the	O
role	O
of	O
K	O
+	O
channels	O
in	O
mitogenesis	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Rouzaire	O
-	O
Dubois	O
B	O
,	O
Dubois	O
JM	O
.	O
Laboratoire	O
de	O
Physiologie	O
Comparee	O
,	O
URA	O
CNRS	O
1121	O
,	O
Universite	O
Paris-Sud	O
,	O
Orsay	O
,	O
France	O
.	O
The	O
role	O
of	O
K	O
+	O
channels	O
in	O
mitogenesis	O
was	O
studied	O
on	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
by	O
analysing	O
the	O
effects	O
of	O
various	O
chemical	O
agents	O
on	O
the	O
whole	O
-	O
cell	O
K	O
+	O
current	O
and	O
the	O
cell	O
proliferation	O
.	O
The	O
outward	O
current	O
recorded	O
during	O
depolarizations	O
on	O
undifferentiated	O
cells	O
was	O
made	O
up	O
of	O
a	O
small	O
and	O
slow	O
inactivating	O
K	O
+	O
current	O
.	O
Foetal	O
calf	O
serum	O
,	O
which	O
is	O
mitogen	O
for	O
neuroblastoma	B-malignancy-type
cells	O
,	O
shifted	O
in	O
opposite	O
directions	O
by	O
7-	O
10	O
mV	O
peak	O
activation	O
and	O
steady	O
-state	O
inactivation	O
-voltage	O
curves	O
of	O
the	O
K	O
+	O
current	O
.	O
The	O
resulting	O
effect	O
was	O
an	O
increase	O
in	O
K	O
+	O
conductance	O
.	O
The	O
effect	O
on	O
the	O
resting	O
K	O
+	O
flux	O
of	O
the	O
classical	O
K	O
+	O
channel	O
blockers	O
tetraethylammonium	O
,	O
4-aminopyridine	O
and	O
capsaicin	O
,	O
the	O
anticancer	O
agent	O
tamoxifen	O
,	O
the	O
heat	O
inactivated	O
serum	O
and	O
the	O
increase	O
in	O
external	O
K	O
+	O
concentration	O
were	O
estimated	O
from	O
their	O
effects	O
on	O
the	O
K	O
+	O
current	O
.	O
The	O
cell	O
proliferation	O
was	O
determined	O
under	O
the	O
same	O
conditions	O
.	O
The	O
results	O
indicate	O
that	O
cell	O
proliferation	O
is	O
correlated	O
to	O
the	O
resulting	O
K	O
+	O
flux	O
.	O
It	O
is	O
supposed	O
that	O
mitogenesis	O
is	O
controlled	O
by	O
the	O
intracellular	O
Na	O
+	O
concentration	O
which	O
,	O
via	O
a	O
cell	O
volume	O
regulation	O
,	O
is	O
a	O
function	O
of	O
the	O
K	O
+	O
flux	O
.	O
A	O
quantitative	O
model	O
is	O
developed	O
on	O
the	O
basis	O
of	O
these	O
hypotheses	O
.	O
PMID	O
:	O
1931483	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Physiol	O
(	O
Paris	O
)	O
.	O
1984	O
;79	O
(	O
4	O
)	O
:275	O
-	O
9.	O
A	O
new	O
scorpion	O
toxin	O
with	O
a	O
very	O
high	O
affinity	O
for	O
sodium	O
channels	O
.	O
An	O
electrophysiological	O
study	O
.	O
Vijverberg	O
HP	O
,	O
Lazdunski	O
M.	O
The	O
neurotoxic	O
action	O
of	O
toxin	O
gamma	O
from	O
the	O
venom	O
of	O
the	O
Brazilian	O
scorpion	O
Tityus	O
serrulatus	O
(	O
TiTx	O
gamma	O
)	O
has	O
been	O
investigated	O
in	O
cultured	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
(	O
N1E115	O
)	O
using	O
the	O
suction	O
pipette	O
technique	O
.	O
Addition	O
of	O
14	O
to	O
53	O
nM	O
TiTx	O
gamma	O
to	O
the	O
external	O
solution	O
causes	O
nerve	O
cell	O
membrane	O
depolarization	O
,	O
membrane	O
potential	O
oscillations	O
and	O
spontaneous	O
action	O
potentials	O
within	O
10	O
min	O
.	O
None	O
of	O
these	O
effects	O
were	O
observed	O
within	O
15	O
min	O
after	O
application	O
of	O
1	O
microM	O
toxin	O
IV	O
from	O
Centruroides	O
sculpturatus	O
venom	O
.	O
Under	O
voltage	O
clamp	O
the	O
amplitude	O
of	O
the	O
sodium	O
current	O
evoked	O
by	O
test	O
pulses	O
to	O
potentials	O
more	O
positive	O
than	O
-	O
30	O
mV	O
is	O
reversibly	O
reduced	O
by	O
50	O
%	O
after	O
17	O
to	O
105	O
nM	O
TiTx	O
gamma	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
sodium	O
current	O
component	O
appears	O
after	O
TiTx	O
gamma	O
at	O
test	O
pulse	O
potentials	O
between	O
-	O
70	O
and	O
-	O
40	O
mV	O
,	O
for	O
which	O
no	O
sodium	O
current	O
is	O
observed	O
in	O
the	O
control	O
experiment	O
.	O
The	O
outward	O
potassium	O
current	O
is	O
not	O
significantly	O
affected	O
by	O
the	O
highest	O
TiTx	O
gamma	O
concentrations	O
used	O
.	O
The	O
potential	O
-dependence	O
of	O
inactivation	O
of	O
the	O
sodium	O
current	O
component	O
that	O
is	O
induced	O
by	O
TiTx	O
gamma	O
is	O
shifted	O
by	O
-	O
30	O
mV	O
with	O
respect	O
to	O
control	O
values	O
.	O
The	O
local	O
anaesthetic	O
procain	O
at	O
1	O
mM	O
discriminates	O
between	O
the	O
two	O
populations	O
of	O
sodium	O
channels	O
observed	O
in	O
the	O
presence	O
of	O
TiTx	O
gamma	O
.	O
PMID	O
:	O
6099413	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2002	O
Apr;81	O
(	O
2	O
)	O
:	O
307	O
-	O
13	O
.	O
Cdk5	O
phosphorylates	O
p53	O
and	O
regulates	O
its	O
activity	O
.	O
Zhang	O
J,	O
Krishnamurthy	O
PK	O
,	O
Johnson	O
GV	O
.	O
Department	O
of	O
Psychiatry	O
and	O
Neurobiology	O
,	O
University	O
of	O
Alabama	O
at	O
Birmingham	O
,	O
35294	O
-0017	O
,	O
USA	O
.	O
Cyclin	O
dependent	O
kinase	O
5	O
(	O
Cdk5	O
)	O
is	O
a	O
proline	O
-direct	O
protein	O
kinase	O
that	O
is	O
most	O
active	O
in	O
the	O
CNS	O
,	O
and	O
has	O
been	O
implicated	O
as	O
a	O
contributing	O
factor	O
in	O
certain	O
neurodegenerative	O
diseases	O
.	O
Further	O
,	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
Cdk5	O
may	O
facilitate	O
the	O
progression	O
of	O
apoptosis	O
.	O
However	O
,	O
the	O
mechanisms	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O
The	O
tumor	O
suppressor	O
protein	O
p53	O
,	O
a	O
transcription	O
factor	O
that	O
is	O
regulated	O
by	O
phosphorylation	O
,	O
increases	O
the	O
expression	O
of	O
genes	O
that	O
control	O
growth	O
arrest	O
or	O
cell	O
death	O
.	O
To	O
understand	O
how	O
Cdk5	O
could	O
facilitate	O
apoptosis	O
,	O
the	O
effects	O
of	O
Cdk5	O
on	O
p53	O
activity	O
were	O
examined	O
.	O
In	O
the	O
present	O
study	O
it	O
is	O
shown	O
that	O
in	O
apoptotic	O
PC12	O
cells	O
the	O
levels	O
of	O
p53	O
and	O
Cdk5	O
increase	O
concomitantly	O
.	O
Further	O
,	O
Cdk5	O
/	O
p25	O
effectively	O
phosphorylates	O
recombinant	O
p53	O
in	O
vitro	O
.	O
Transient	O
transfection	O
of	O
Cdk5	O
/	O
p25	O
into	O
cells	O
results	O
in	O
an	O
increase	O
in	O
p53	O
levels	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
p53	O
-	O
responsive	O
genes	O
p21	O
and	O
Bax	O
.	O
Furthermore	O
,	O
evidence	O
is	O
provided	O
that	O
increased	O
Cdk5	O
activity	O
increases	O
p53	O
transcriptional	O
activity	O
significantly	O
,	O
suggesting	O
that	O
p53	O
is	O
modulated	O
in	O
situ	O
by	O
Cdk5	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
that	O
p53	O
is	O
a	O
substrate	O
of	O
Cdk5	O
,	O
and	O
that	O
Cdk5	O
can	O
modulate	O
p53	O
levels	O
and	O
activity	O
.	O
PMID	O
:	O
12064478	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prog	O
Clin	O
Biol	O
Res	O
.	O
1990	O
;	O
333	O
:	O
285-92	O
.	O
Immunomagnetic	O
microsphere	O
mediated	O
purging	O
of	O
cALLa	O
positive	O
leukemic	B-malignancy-type
cells	O
from	O
bone	O
marrow	O
for	O
autologous	O
reinfusion	O
.	O
Janssen	O
WE	O
,	O
Lee	O
C	O
,	O
Johnson	O
KS	O
,	O
Spencer	O
C	O
,	O
Rios	O
AM	O
,	O
Graham-Pole	O
JR	O
,	O
Gross	O
S	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
32610	O
.	O
Bone	O
marrow	O
from	O
sixteen	O
patients	O
with	O
cALLa	O
positive	O
ALL	B-malignancy-type
have	O
been	O
treated	O
with	O
a	O
monoclonal	O
antibody	O
(	O
MoAb	O
)	O
cocktail	O
which	O
includes	O
DuALL-1	O
(	O
CD9	O
)	O
,	O
WCMH15.14	O
(	O
CD10	O
)	O
and	O
HD-37	O
(	O
CD19	O
)	O
.	O
Following	O
antibody	O
treatment	O
,	O
marrows	O
were	O
incubated	O
(	O
30	O
minutes	O
)	O
with	O
anti-murine-IgG1	O
(	O
Fc	O
)	O
coated	O
magnetic	O
microbeads	O
and	O
passed	O
through	O
a	O
graded	O
magnetic	O
field	O
chamber	O
.	O
Two	O
problems	O
have	O
had	O
to	O
be	O
addressed	O
:	O
(	O
1	O
)	O
More	O
marrow	O
cells	O
must	O
be	O
processed	O
than	O
in	O
marrows	O
from	O
patients	O
with	O
neuroblastoma	B-malignancy-type
,	O
for	O
which	O
the	O
separation	O
chamber	O
was	O
originally	O
developed	O
,	O
requiring	O
the	O
use	O
of	O
more	O
beads	O
,	O
causing	O
occlusion	O
of	O
the	O
chamber	O
's	O
collection	O
surface	O
.	O
This	O
has	O
been	O
corrected	O
by	O
using	O
a	O
large	O
surface	O
area	O
pre	O
-	O
magnet	O
for	O
the	O
elimination	O
of	O
excess	O
microbeads	O
prior	O
to	O
processing	O
in	O
the	O
main	O
chamber	O
;	O
(	O
2	O
)	O
Up-modulation	O
(	O
up	O
to	O
40%	O
positive	O
cells	O
)	O
of	O
the	O
CD9	O
associated	O
antigen	O
has	O
been	O
detected	O
.	O
To	O
avoid	O
difficulty	O
,	O
marrows	O
are	O
being	O
routinely	O
screened	O
prior	O
to	O
harvest	O
for	O
purging	O
,	O
and	O
purging	O
is	O
delayed	O
for	O
patients	O
with	O
elevated	O
CD9	O
levels	O
.	O
Eight	O
patients	O
have	O
been	O
reinfused	O
,	O
with	O
no	O
morbidity	O
or	O
mortality	O
associated	O
with	O
the	O
purging	O
or	O
other	O
ex	O
vivo	O
handling	O
of	O
the	O
marrow	O
.	O
PMID	O
:	O
2137931	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gan	O
To	O
Kagaku	O
Ryoho	O
.	O
1997	O
Sep	O
;	O
24	O
(	O
11	O
)	O
:	O
1465-70	O
.	O
[	O
DAN	O
gene	O
]	O
[	O
Article	O
in	O
Japanese	O
]	O
Sakiyama	O
S	O
,	O
Ozaki	O
T	O
.	O
Chiba	O
Cancer	O
Center	O
Research	O
Institute	O
.	O
DAN	O
gene	O
has	O
been	O
isolated	O
by	O
means	O
of	O
differential	O
screening	O
method	O
between	O
rat	O
fibroblast	O
3Y1	O
and	O
Rous	O
sarcoma	O
virus	O
-transformed	O
3Y1	O
(	O
SR-Y1	O
)	O
cells	O
.	O
DAN	O
expression	O
was	O
suppressed	O
in	O
some	O
of	O
the	O
transformed	O
cells	O
and	O
its	O
re	O
-	O
expression	O
reverted	O
the	O
various	O
transformed	O
phenotypes	O
such	O
as	O
colony	O
formation	O
in	O
soft	O
agar	O
and	O
tumor	O
formation	O
in	O
mice	O
.	O
When	O
DAN	O
was	O
overexpressed	O
in	O
3Y1	O
cells	O
,	O
these	O
cell	O
showed	O
the	O
retardation	O
of	O
the	O
entry	O
into	O
the	O
S	O
phase	O
.	O
DAN	O
cDNA	O
encodes	O
a	O
27-kD	O
protein	O
which	O
consists	O
of	O
178	O
amino	O
acids	O
.	O
The	O
deduced	O
amino	O
acid	O
sequence	O
has	O
no	O
homology	O
with	O
known	O
proteins	O
.	O
The	O
amino	O
terminal	O
of	O
DAN	O
is	O
highly	O
hydrophobic	O
and	O
DAN	O
is	O
indeed	O
secreted	O
into	O
the	O
culture	O
medium	O
.	O
This	O
secreted	O
DAN	O
,	O
when	O
added	O
to	O
the	O
culture	O
of	O
SR-3Y1	O
cells	O
,	O
suppressed	O
DNA	O
synthesis	O
.	O
Human	O
DAN	O
is	O
mapped	O
to	O
1p36.11-p36.13	O
,	O
a	O
region	O
known	O
to	O
have	O
highly	O
significant	O
linkage	O
with	O
the	O
genesis	O
and/or	O
progression	O
of	O
human	O
neuroblastoma	B-malignancy-type
.	O
Aberrant	O
bands	O
on	O
Southern	O
blot	O
were	O
detected	O
in	O
some	O
of	O
the	O
neuroblastoma	B-malignancy-type
cases	O
.	O
Rat	O
and	O
human	O
genomic	O
DANs	O
were	O
isolated	O
.	O
CAT	O
and	O
the	O
electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
the	O
presence	O
of	O
possible	O
positive	O
and	O
negative	O
regulatory	O
elements	O
at	O
-57	O
approximately	O
+118	O
and	O
-1,232	O
approximately	O
-987	O
of	O
rat	O
genome	O
,	O
respectively	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9309143	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

EMBO	O
Rep	O
.	O
2003	O
Mar	O
;	O
4	O
(	O
3	O
:	O
290-5	O
.	O
Erratum	O
in	O
:	O
EMBO	O
Rep	O
.	O
2003	O
Apr	O
;	O
(	O
4	O
)	O
:	O
439	O
.	O
The	O
37	O
kDa/67	O
kDa	O
laminin	O
receptor	O
is	O
required	O
for	O
PrP(Sc)	O
propagation	O
in	O
scrapie-infected	O
neuronal	O
cells	O
.	O
Leucht	O
C	O
,	O
Simoneau	O
S	O
,	O
Rey	O
C	O
,	O
Vana	O
K	O
,	O
Rieger	O
R	O
,	O
Lasmezas	O
CI	O
,	O
Weiss	O
S.	O
Laboratorium	O
fur	O
Molekulare	O
Biologie-Genzentrum-Institut	O
fur	O
Biochemie	O
der	O
LMU	O
Munchen	O
,	O
Feodor-Lynen	O
Str	O
.	O
25	O
,	O
D-	O
81377	O
Munich	O
,	O
Germany	O
.	O
The	O
accumulation	O
of	O
PrP(Sc)	O
in	O
scrapie	O
-	O
infected	O
neuronal	O
cells	O
has	O
been	O
prevented	O
by	O
three	O
approaches	O
:	O
(	O
i	O
)	O
transfection	O
of	O
ScMNB	O
cells	O
with	O
an	O
antisense	O
laminin	O
receptor	O
precursor	O
(	O
LRP	O
)	O
RNA	O
-	O
expression	O
plasmid	O
,	O
(ii)	O
transfection	O
of	O
ScN2a	O
cells	O
and	O
ScGT1	O
cells	O
with	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
specific	O
for	O
the	O
LRP	O
mRNA	O
,	O
and	O
(	O
iii	O
)	O
incubation	O
of	O
ScN2a	O
cells	O
with	O
an	O
anti-LRP/LR	O
antibody	O
.	O
LRP	O
antisense	O
RNA	O
and	O
LRP	O
siRNAs	O
reduced	O
LRP	O
/	O
LR	O
expression	O
and	O
inhibited	O
the	O
accumulation	O
of	O
PrP(Sc)	O
in	O
these	O
cells	O
.	O
The	O
treatments	O
also	O
reduced	O
PrP(c)	O
levels	O
.	O
The	O
anti-LRP/LR	O
antibody	O
,	O
W3	O
,	O
abolished	O
PrP(Sc)	O
accumulation	O
and	O
reduced	O
PrP(c)	O
levels	O
after	O
seven	O
days	O
of	O
incubation	O
.	O
Cells	O
remained	O
free	O
of	O
PrP(Sc)	O
after	O
being	O
cultured	O
for	O
14	O
additional	O
days	O
without	O
the	O
antibody	O
,	O
whereas	O
the	O
PrP(c)	O
level	O
was	O
restored	O
.	O
Our	O
results	O
demonstrate	O
the	O
necessity	O
of	O
the	O
laminin	O
receptor	O
(	O
LRP/LR	O
)	O
for	O
PrP(Sc)	O
propagation	O
in	O
cultured	O
cells	O
and	O
suggest	O
that	O
LRP/LR-specific	O
antibodies	O
could	O
be	O
used	O
as	O
powerful	O
therapeutic	O
tools	O
in	O
the	O
treatment	O
of	O
transmissible	O
spongiform	O
encephalopathies	O
.	O
PMID	O
:	O
12634848	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
.	O
1992	O
Oct	O
1	O
;	O
70	O
(	O
7	O
)	O
:	O
2005-12	O
.	O
Neuroblastoma	B-malignancy-type
.	O
Correlation	O
of	O
neuropeptide	O
expression	O
in	O
tumor	O
tissue	O
with	O
other	O
prognostic	O
factors	O
.	O
Qualman	O
SJ	O
,	O
O'Dorisio	O
MS	O
,	O
Fleshman	O
DJ	O
,	O
Shimada	O
H	O
,	O
O'Dorisio	O
TM	O
.	O
Department	O
of	O
Pathology	O
,	O
Ohio	O
State	O
University	O
,	O
Columbus	O
.	O
BACKGROUND.	O
The	O
neuropeptide	O
contents	O
in	O
neuroblastomas	B-malignancy-type
were	O
quantified	O
by	O
radioimmunoassay	O
(	O
RIA	O
)	O
to	O
assess	O
their	O
possible	O
biologic	O
significance	O
.	O
METHODS	O
.	O
Neuroblastoma	B-malignancy-type
tumor	I-malignancy-type
tissue	O
was	O
obtained	O
from	O
the	O
primary	O
tumor	O
site	O
before	O
therapy	O
in	O
16	O
patients	O
with	O
newly	O
diagnosed	O
neuroblastoma	B-malignancy-type
and	O
in	O
7	O
patients	O
with	O
central	O
nervous	O
system	O
medulloblastomas	B-malignancy-type
or	O
gliomas	B-malignancy-type
.	O
RESULTS	O
.	O
The	O
tumor	O
tissue	O
was	O
assayed	O
for	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
,	O
somatostatin	O
(	O
SRIF	O
)	O
,	O
substance	O
P	O
,	O
and	O
neurotensin	O
by	O
both	O
immunostaining	O
and	O
RIA	O
techniques	O
.	O
Increased	O
VIP	O
levels	O
of	O
1.2	O
pg/micrograms	O
DNA	O
or	O
more	O
correlated	O
significantly	O
with	O
cellular	O
differentiation	O
(	O
P	O
=	O
0.003	O
)	O
and	O
favorable	O
disease	O
stage	O
(	O
P	O
=	O
0.002	O
)	O
in	O
neuroblastomas	B-malignancy-type
.	O
Increased	O
SRIF	O
contents	O
(	O
greater	O
than	O
1.3	O
pg/micrograms	O
DNA	O
)	O
correlated	O
with	O
differentiation	O
of	O
the	O
tumor	O
(	O
P	O
=	O
0.002	O
)	O
.	O
Increased	O
VIP	O
and	O
SRIF	O
content	O
did	O
not	O
correlate	O
with	O
N-myc	O
oncogene	O
expression	O
or	O
ras	O
oncogene	O
protein	O
immunostaining	O
.	O
No	O
VIP	O
was	O
detectable	O
in	O
brain	B-malignancy-type
tumors	I-malignancy-type
,	O
and	O
other	O
neuropeptides	O
were	O
variable	O
in	O
content	O
.	O
CONCLUSIONS	O
.	O
RIA	O
of	O
VIP	O
and	O
SRIF	O
levels	O
in	O
primary	O
tumor	O
tissue	O
may	O
offer	O
an	O
independent	O
objective	O
assay	O
of	O
biologic	O
behavior	O
in	O
neuroblastoma	B-malignancy-type
biopsy	O
specimens	O
.	O
PMID	O
:	O
1381992	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Neurochem	O
.	O
1982	O
Mar	O
;	O
38	O
(	O
3	O
)	O
:	O
675-9	O
.	O
Acid	O
:	O
coenzyme	O
A	O
ligase	O
in	O
brain	O
:	O
fatty	O
acid	O
specificity	O
in	O
cellular	O
and	O
subcellular	O
fractions	O
.	O
Murphy	O
MG	O
,	O
Spence	O
MW	O
.	O
We	O
measured	O
long-	O
chain	O
fatty	O
acid	O
:	O
coenzyme	O
A	O
(	O
CoA	O
)	O
ligase	O
(	O
EC	O
6.2.1.3	O
)	O
activity	O
with	O
four	O
fatty	O
acids	O
in	O
brain	O
homogenates	O
,	O
and	O
cellular	O
and	O
subcellular	O
fractions	O
to	O
determine	O
whether	O
there	O
are	O
differences	O
in	O
activity	O
that	O
could	O
be	O
correlated	O
with	O
differences	O
in	O
fatty	O
acid	O
composition	O
and	O
metabolism	O
.	O
In	O
rat	O
brain	O
homogenates	O
,	O
ligase	O
activity	O
varied	O
appreciably	O
with	O
the	O
four	O
acids	O
,	O
with	O
18:2	O
greater	O
than	O
18:1	O
greater	O
than	O
16:0	O
greater	O
than	O
22:1	O
(	O
nmol	O
acyl-CoA	O
formed	O
/	O
min	O
/	O
mg	O
protein	O
:	O
1.46	O
,	O
1.20	O
,	O
0.96	O
,	O
and	O
0.57	O
,	O
respectively	O
)	O
.	O
This	O
order	O
was	O
similar	O
under	O
all	O
incubation	O
conditions	O
tested	O
,	O
including	O
variable	O
pH	O
and	O
fatty	O
acid	O
concentrations	O
.	O
The	O
relative	O
specific	O
activities	O
(	O
RSA	O
,	O
16:0	O
=	O
1.0)	O
with	O
the	O
four	O
substrates	O
were	O
similar	O
in	O
rat	O
brain	O
homogenate	O
,	O
mitochondria	O
,	O
and	O
microsomes	O
,	O
with	O
the	O
highest	O
specific	O
activities	O
in	O
the	O
latter	O
fraction	O
.	O
The	O
RSA	O
were	O
also	O
similar	O
in	O
ox	O
brain	O
homogenates	O
,	O
in	O
rabbit	O
brain	O
microsomes	O
prepared	O
from	O
gray	O
and	O
white	O
matter	O
,	O
in	O
neurons	O
isolated	O
from	O
rat	O
brain	O
,	O
and	O
in	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Rat	O
liver	O
homogenates	O
had	O
a	O
significantly	O
different	O
pattern	O
of	O
RSA	O
.	O
These	O
results	O
indicate	O
that	O
the	O
ligase(s)	O
has	O
a	O
preference	O
for	O
certain	O
fatty	O
acids	O
,	O
but	O
suggest	O
that	O
the	O
major	O
control	O
of	O
fatty	O
acid	O
composition	O
and	O
metabolism	O
is	O
a	O
function	O
of	O
subsequent	O
metabolic	O
steps	O
.	O
PMID	O
:	O
7057186	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cell	O
Biophys	O
.	O
1994	O
;24	O
-25	O
:15-25	O
.	O
Potent	O
antitumor	O
effects	O
of	O
an	O
antitumor	O
endothelial	O
cell	O
immunotoxin	O
in	O
a	O
murine	O
vascular	O
targeting	O
model	O
.	O
Burrows	O
FJ	O
,	O
Overholser	O
JP	O
,	O
Thorpe	O
PE.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
-8576	O
.	O
Immunotoxins	O
and	O
other	O
antibody	O
-	O
based	O
therapeutic	O
reagents	O
have	O
proved	O
effective	O
agonist	O
lymphomas	B-malignancy-type
and	O
leukemias	B-malignancy-type
,	O
but	O
results	O
with	O
carcinomas	B-malignancy-type
and	O
other	O
solid	B-malignancy-type
tumors	I-malignancy-type
have	O
thus	O
far	O
been	O
less	O
impressive	O
.	O
A	O
major	O
reason	O
for	O
this	O
difference	O
is	O
that	O
macromolecules	O
penetrate	O
poorly	O
and	O
unevenly	O
into	O
solid	B-malignancy-type
tumors	I-malignancy-type
.	O
A	O
solution	O
to	O
this	O
problem	O
would	O
be	O
to	O
attack	O
the	O
endothelial	O
cells	O
of	O
the	O
tumor	O
vascular	O
bed	O
rather	O
than	O
the	O
tumor	O
cells	O
themselves	O
.	O
We	O
have	O
developed	O
a	O
murine	O
model	O
of	O
this	O
vascular	O
targeting	O
approach	O
where	O
transfection	O
of	O
the	O
tumor	O
cells	O
with	O
a	O
cytokine	O
gene	O
causes	O
them	O
to	O
induce	O
the	O
expression	O
of	O
an	O
experimental	O
marker	O
(	O
MHC	O
Class	O
II	O
)	O
on	O
tumor	O
endothelium	O
.	O
In	O
this	O
report	O
we	O
show	O
that	O
an	O
anti	O
-	O
Class	O
II	O
-	O
deglycosylated	O
Ricin	O
A	O
-	O
chain	O
immunotoxin	O
kills	O
IFN	O
-	O
gamma	O
-	O
activated	O
endothelial	O
cells	O
in	O
culture	O
and	O
,	O
when	O
injected	O
into	O
tumor	O
-	O
bearing	O
Balb	O
/	O
c	O
nude	O
mice	O
,	O
causes	O
complete	O
thrombosis	O
of	O
the	O
tumor	O
vasculature	O
,	O
widespread	O
infarction	O
,	O
and	O
dramatic	O
regressions	O
of	O
large	O
solid	B-malignancy-type
tumors	I-malignancy-type
.	O
These	O
findings	O
suggest	O
that	O
immunoconjugates	O
prepared	O
with	O
recently	O
described	O
antibodies	O
against	O
human	O
tumor	O
endothelium	O
could	O
provide	O
a	O
broad	O
-	O
based	O
therapy	O
for	O
variety	O
of	O
solid	B-malignancy-type
cancers	I-malignancy-type
in	O
humans	O
.	O
PMID	O
:	O
7736519	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gene	O
Expr	O
Patterns	O
.	O
2003	O
Mar;	O
3(	O
1	O
)	O
:	O
29-	O
33	O
.	O
HMGB1	O
,	O
an	O
architectural	O
chromatin	O
protein	O
and	O
extracellular	O
signalling	O
factor	O
,	O
has	O
a	O
spatially	O
and	O
temporally	O
restricted	O
expression	O
pattern	O
in	O
mouse	O
brain	O
.	O
Guazzi	O
S	O
,	O
Strangio	O
A	O
,	O
Franzi	O
AT	O
,	O
Bianchi	O
ME.	O
DIBIT	O
,	O
San	O
Raffaele	O
Scientific	O
Institute	O
,	O
Via	O
Olgettina	O
,	O
58	O
,	O
20132	O
Milan	O
,	O
Italy	O
.	O
guazzi.stefani@hsr	O
.it	O
HMGB1	O
is	O
an	O
abundant	O
chromatin	O
component	O
,	O
so	O
far	O
considered	O
ubiquitous	O
.	O
HMGB1	O
also	O
has	O
an	O
extracellular	O
signalling	O
role	O
:	O
when	O
passively	O
released	O
by	O
necrotic	O
cells	O
,	O
it	O
triggers	O
inflammation	O
;	O
moreover	O
,	O
it	O
can	O
be	O
actively	O
secreted	O
by	O
myeloid	B-malignancy-type
cells	O
,	O
neurons	O
and	O
neuronal	B-malignancy-type
cancer	I-malignancy-type
cells	O
.	O
We	O
show	O
here	O
that	O
HMGB1	O
protein	O
is	O
undetectable	O
in	O
most	O
cells	O
in	O
adult	O
mouse	O
brain	O
,	O
and	O
is	O
present	O
in	O
a	O
subset	O
of	O
brain	O
cells	O
during	O
development	O
,	O
with	O
a	O
very	O
complex	O
temporal	O
,	O
spatial	O
and	O
subcellular	O
expression	O
pattern	O
.	O
HMGB1	O
is	O
expressed	O
in	O
the	O
cortical	O
plate	O
of	O
E	O
14.5	O
embryos	O
,	O
predominantly	O
in	O
the	O
nucleus	O
,	O
although	O
roughly	O
1	O
%	O
of	O
cells	O
show	O
a	O
cytoplasmic	O
localization	O
as	O
well	O
.	O
In	O
E	O
16	O
embryos	O
,	O
HMGB1	O
is	O
nuclearly	O
expressed	O
in	O
scattered	O
cells	O
apparently	O
moving	O
from	O
the	O
ventricular	O
zone	O
to	O
the	O
cortical	O
plate	O
.	O
HMGB1	O
expression	O
is	O
strongly	O
down	O
-	O
regulated	O
at	O
later	O
developmental	O
stages	O
;	O
in	O
adult	O
mice	O
significant	O
expression	O
is	O
maintained	O
only	O
in	O
areas	O
of	O
continuing	O
neurogenesis	O
.	O
Finally	O
,	O
HMGB1	O
subcellular	O
localization	O
changes	O
during	O
retinoic	O
acid	O
induced	O
differentiation	O
of	O
P19	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Copyright	O
2003	O
Elsevier	O
Science	O
B.V	O
.	O
PMID	O
:	O
12609598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Surg	O
Oncol	O
.	O
1995	O
May	O
;5	O
9	O
(	O
1	O
)	O
:	O
21	O
-	O
7.	O
Prognostic	O
indicators	O
for	O
neuroblastoma	B-malignancy-type
:	O
stage	O
,	O
grade	O
,	O
DNA	O
ploidy	O
,	O
MIB	O
-	O
1	O
-	O
proliferation	O
index	O
,	O
p53	O
,	O
HER	O
-	O
2	O
/	O
neu	O
and	O
EGFr	O
-	O
-	O
a	O
survival	O
study	O
.	O
Layfield	O
LJ	O
,	O
Thompson	O
JK	O
,	O
Dodge	O
RK	O
,	O
Kerns	O
BJ.	O
Department	O
of	O
Pathology	O
,	O
Duke	O
University	O
Medical	O
Center	O
,	O
Durham	O
,	O
North	O
Carolina	O
27710	O
,	O
USA	O
.	O
Neuroblastoma	B-malignancy-type
,	O
a	O
tumor	O
of	O
the	O
sympathetic	O
nervous	O
system	O
,	O
is	O
one	O
of	O
the	O
most	O
common	O
solid	B-malignancy-type
malignancies	I-malignancy-type
in	O
infants	O
and	O
represents	O
7	O
%	O
of	O
all	O
cases	O
of	O
childhood	O
cancer	O
outside	O
of	O
the	O
central	O
nervous	O
system	O
.	O
Thirty	O
-	O
five	O
samples	O
of	O
neuroblastoma	B-malignancy-type
from	O
31	O
patients	O
were	O
obtained	O
from	O
Duke	O
University	O
Medical	O
Center	O
between	O
1979	O
and	O
1991	O
and	O
studied	O
to	O
determine	O
the	O
relative	O
prognostic	O
value	O
of	O
a	O
number	O
of	O
clinical	O
,	O
histologic	O
,	O
nuclear	O
,	O
and	O
oncogenic	O
features	O
.	O
The	O
features	O
studied	O
were	O
:	O
stage	O
,	O
Shimada	O
classification	O
,	O
DNA	O
ploidy	O
,	O
MIB	O
-	O
1	O
-	O
proliferation	O
index	O
and	O
status	O
for	O
HER	O
-	O
2	O
/	O
neu	O
,	O
p53	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFr	O
)	O
.	O
Only	O
age	O
(	O
P	O
=	O
.03	O
)	O
,	O
HER	O
-	O
2	O
/	O
neu	O
(	O
P	O
=	O
.01	O
)	O
,	O
and	O
p53	O
(	O
P	O
=	O
.02	O
)	O
reached	O
statistical	O
significance	O
as	O
prognostic	O
indicators	O
.	O
The	O
median	O
survival	O
for	O
patients	O
with	O
HER	O
-	O
2	O
/	O
neu	O
expression	O
was	O
12	O
months	O
;	O
median	O
survival	O
for	O
patients	O
with	O
no	O
HER	O
-	O
2	O
/	O
neu	O
expression	O
was	O
138	O
months	O
.	O
Similarly	O
,	O
the	O
median	O
survival	O
for	O
patients	O
with	O
p53	O
expression	O
was	O
12	O
months	O
;	O
patients	O
with	O
no	O
p53	O
expression	O
had	O
a	O
median	O
survival	O
was	O
144	O
months	O
.	O
The	O
combination	O
of	O
either	O
HER	O
-	O
2	O
/	O
neu	O
or	O
p53	O
positivity	O
was	O
especially	O
strong	O
as	O
a	O
prognostic	O
indicator	O
(	O
P	O
=	O
.002	O
)	O
.	O
PMID	O
:	O
7745972	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1994	O
Apr	O
15	O
;73	O
(	O
8	O
)	O
:2231	O
-	O
7.	O
MYCN	O
gene	O
amplification	O
in	O
rhabdomyosarcoma	B-malignancy-type
.	O
Driman	O
D	O
,	O
Thorner	O
PS	O
,	O
Greenberg	O
ML	O
,	O
Chilton	O
-MacNeill	O
S	O
,	O
Squire	O
J.	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
BACKGROUND	O
.	O
Amplification	O
of	O
the	O
MYCN	O
oncogene	O
,	O
formerly	O
known	O
as	O
N	O
-	O
myc	O
,	O
has	O
been	O
seen	O
in	O
several	O
malignant	O
tumors	O
,	O
particularly	O
neuroblastoma	B-malignancy-type
,	O
where	O
its	O
association	O
with	O
a	O
poor	O
clinical	O
outcome	O
is	O
the	O
clearest	O
example	O
of	O
a	O
clinically	O
relevant	O
oncogene	O
mutation	O
in	O
any	O
human	O
cancer	O
.	O
METHODS	O
.	O
The	O
incidence	O
and	O
clinical	O
significance	O
of	O
MYCN	O
amplification	O
in	O
rhabdomyosarcoma	B-malignancy-type
(	O
RMS	B-malignancy-type
)	O
was	O
assessed	O
by	O
Southern	O
blot	O
analysis	O
in	O
this	O
retrospective	O
study	O
of	O
seven	O
alveolar	B-malignancy-type
RMS	I-malignancy-type
and	O
six	O
embryonal	O
RMS	B-malignancy-type
.	O
RESULTS	O
.	O
MYCN	O
amplification	O
(	O
4	O
-	O
to	O
13	O
-	O
fold	O
)	O
was	O
present	O
in	O
three	O
of	O
seven	O
alveolar	B-malignancy-type
RMS	I-malignancy-type
(	O
42.9	O
%	O
)	O
but	O
in	O
none	O
of	O
the	O
embryonal	O
RMS	B-malignancy-type
.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
clinical	O
behavior	O
of	O
the	O
MYCN	O
-	O
amplified	O
and	O
unamplified	O
tumors	O
,	O
and	O
no	O
correlation	O
was	O
found	O
with	O
the	O
light	O
microscopic	O
appearances	O
of	O
the	O
tumors	O
or	O
with	O
desmin	O
immunoreactivity	O
.	O
CONCLUSIONS	O
.	O
The	O
findings	O
are	O
compatible	O
with	O
previous	O
studies	O
that	O
demonstrated	O
cytogenetic	O
evidence	O
of	O
gene	O
amplification	O
in	O
RMS	B-malignancy-type
,	O
and	O
help	O
to	O
clarify	O
conflicting	O
reports	O
in	O
the	O
literature	O
about	O
MYCN	O
amplification	O
in	O
alveolar	B-malignancy-type
and	O
embryonal	O
RMS	B-malignancy-type
.	O
The	O
results	O
raise	O
the	O
possibility	O
of	O
important	O
biologic	O
differences	O
between	O
these	O
subtypes	O
of	O
RMS	B-malignancy-type
,	O
differences	O
that	O
warrant	O
further	O
investigation	O
.	O
PMID	O
:	O
8156531	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1997	O
Feb;68(	O
2	O
)	O
:	O
570	O
-	O
7.	O
Expression	O
of	O
endothelin	O
-	O
converting	O
enzyme	O
in	O
both	O
neuroblastoma	B-malignancy-type
and	O
glial	O
cell	O
lines	O
and	O
its	O
localization	O
in	O
rat	O
hippocampus	O
.	O
Barnes	O
K,	O
Walkden	O
BJ	O
,	O
Wilkinson	O
TC	O
,	O
Turner	O
AJ.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
University	O
of	O
Leeds	O
,	O
England	O
.	O
Endothelin	O
-	O
converting	O
enzyme	O
is	O
a	O
phosphoramidon	O
-	O
sensitive	O
metalloprotease	O
that	O
cleaves	O
big	O
endothelin	O
to	O
the	O
potent	O
vasoconstrictor	O
peptide	O
,	O
endothelin	O
.	O
The	O
converting	O
enzyme	O
is	O
expressed	O
in	O
endothelial	O
cells	O
in	O
a	O
variety	O
of	O
tissues	O
and	O
in	O
some	O
secretory	O
cells	O
.	O
In	O
the	O
present	O
study	O
,	O
phosphoramidon	O
-	O
sensitive	O
endothelin	O
-	O
converting	O
enzyme	O
activity	O
has	O
been	O
demonstrated	O
by	O
radioimmunoassay	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SH	O
-	O
SY5Y	O
,	O
and	O
in	O
Bu17	O
and	O
C6	O
glioma	B-malignancy-type
lines	O
.	O
The	O
identity	O
of	O
the	O
activity	O
was	O
confirmed	O
by	O
immunoblotting	O
,	O
revealing	O
a	O
polypeptide	O
of	O
approximately	O
120	O
kDa	O
in	O
each	O
of	O
these	O
lines	O
,	O
in	O
D	O
384	O
glioma	B-malignancy-type
cells	O
,	O
and	O
in	O
primary	O
astrocytes	O
.	O
Immunofluorescence	O
revealed	O
the	O
cell	O
-	O
surface	O
location	O
of	O
endothelin	O
-	O
converting	O
enzyme	O
in	O
the	O
neuronal	O
and	O
glial	O
cell	O
lines	O
and	O
in	O
primary	O
astrocytes	O
.	O
Pretreatment	O
of	O
SH	O
-	O
SY5Y	O
and	O
Bu17	O
cells	O
with	O
phosphoramidon	O
resulted	O
in	O
an	O
apparent	O
concentration	O
of	O
the	O
enzyme	O
protein	O
in	O
an	O
intracellular	O
compartment	O
.	O
Immunoperoxidase	O
-	O
staining	O
of	O
rat	O
brain	O
sections	O
located	O
this	O
metalloprotease	O
to	O
the	O
pyramidal	O
cells	O
of	O
the	O
hippocampus	O
.	O
Endothelin	O
-	O
converting	O
enzyme	O
-	O
1	O
was	O
revealed	O
by	O
in	O
situ	O
hybridisation	O
in	O
the	O
neuronal	O
and	O
glial	O
cell	O
lines	O
.	O
PMID	O
:	O
9003042	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurooncol	O
.	O
1995	O
Oct;26	O
(	O
1	O
)	O
:	O
35-43	O
.	O
Expression	O
of	O
the	O
human	O
Achaete	O
-	O
scute	O
1	O
gene	O
in	O
olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
(	O
esthesioneuroblastoma	B-malignancy-type
)	O
.	O
Carney	O
ME	O
,	O
O'Reilly	O
RC	O
,	O
Sholevar	O
B	O
,	O
Buiakova	O
OI	O
,	O
Lowry	O
LD	O
,	O
Keane	O
WM	O
,	O
Margolis	O
FL	O
,	O
Rothstein	O
JL.	O
Department	O
of	O
Otolaryngology-Head	O
and	O
Neck	O
Surgery	O
,	O
Jefferson	O
Medical	O
College	O
,	O
Jefferson	O
Cancer	O
Institute	O
,	O
Philadelphia	O
,	O
PA	O
19107	O
,	O
USA	O
.	O
Olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
(	O
ONB	B-malignancy-type
)	O
is	O
a	O
rare	O
neuronal	O
malignancy	O
of	O
the	O
olfactory	O
mucosal	O
.	O
Markers	O
used	O
in	O
the	O
diagnosis	O
of	O
ONB	B-malignancy-type
do	O
not	O
distinguish	O
ONB	B-malignancy-type
from	O
other	O
neuronal	B-malignancy-type
tumors	I-malignancy-type
or	O
tumors	O
with	O
neuroendocrine	O
features	O
thus	O
making	O
the	O
diagnosis	O
of	O
ONB	B-malignancy-type
difficult	O
.	O
Using	O
a	O
modified	O
RT	O
-	O
PCR	O
technique	O
,	O
we	O
show	O
that	O
the	O
human	O
homologue	O
of	O
the	O
Drosophila	O
achaete	O
-	O
scute	O
gene	O
HASH1	O
is	O
expressed	O
in	O
6	O
primary	O
and	O
one	O
metastatic	O
ONB	B-malignancy-type
specimens	O
,	O
whereas	O
Olfactory	O
Marker	O
Protein	O
(	O
OMP	O
)	O
is	O
not	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
HASH1	O
is	O
expressed	O
in	O
immature	O
olfactory	O
neurons	O
and	O
is	O
required	O
for	O
their	O
development	O
.	O
OMP	O
,	O
whose	O
function	O
is	O
unknown	O
,	O
is	O
expressed	O
exclusively	O
in	O
mature	O
olfactory	O
neurons	O
.	O
Together	O
,	O
these	O
data	O
suggest	O
that	O
ONB	B-malignancy-type
is	O
derived	O
from	O
immature	O
olfactory	O
neurons	O
of	O
neuroectodermal	O
origin	O
.	O
Analysis	O
of	O
RNA	O
expression	O
in	O
primary	O
tumor	O
specimens	O
and	O
in	O
an	O
established	O
cell	O
line	O
make	O
this	O
an	O
ideal	O
system	O
to	O
study	O
olfactory	O
growth	O
and	O
differentiation	O
.	O
Furthermore	O
,	O
these	O
studies	O
represent	O
the	O
first	O
molecular	O
genetic	O
analysis	O
of	O
this	O
rare	O
and	O
unusual	O
neuronal	B-malignancy-type
tumor	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
8583243	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
2002	O
Aug	O
2;945(	O
2	O
)	O
:160	O
-	O
73	O
.	O
Survival	O
motor	O
neuron	O
protein	O
in	O
the	O
nucleolus	O
of	O
mammalian	O
neurons	O
.	O
Wehner	O
KA	O
,	O
Ayala	O
L,	O
Kim	O
Y	O
,	O
Young	O
PJ	O
,	O
Hosler	O
BA	O
,	O
Lorson	O
CL	O
,	O
Baserga	O
SJ	O
,	O
Francis	O
JW	O
.	O
Department	O
of	O
Therapeutic	O
Radiology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
CT	O
06520	O
,	O
USA	O
.	O
Spinal	O
muscular	O
atrophy	O
(	O
SMA	O
)	O
is	O
an	O
inherited	O
motor	O
neuron	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
survival	O
motor	O
neuron	O
gene	O
(	O
SMN1	O
)	O
.	O
While	O
it	O
has	O
been	O
shown	O
that	O
the	O
SMN	O
protein	O
is	O
involved	O
in	O
spliceosome	O
biogenesis	O
and	O
pre	O
-	O
mRNA	O
splicing	O
,	O
there	O
is	O
increasing	O
evidence	O
indicating	O
that	O
SMN	O
may	O
also	O
perform	O
important	O
functions	O
in	O
the	O
nucleolus	O
.	O
We	O
demonstrate	O
here	O
through	O
the	O
use	O
of	O
a	O
previously	O
characterized	O
polyclonal	O
anti	O
-	O
SMN	O
antibody	O
,	O
abSMN	O
,	O
that	O
the	O
SMN	O
protein	O
shows	O
a	O
striking	O
colocalization	O
with	O
the	O
nucleolar	O
protein	O
,	O
fibrillarin	O
,	O
in	O
both	O
nucleoli	O
and	O
Cajal	O
bodies	O
/	O
gems	O
of	O
primary	O
neurons	O
.	O
Immunoblot	O
analysis	O
with	O
antifibrillarin	O
and	O
two	O
different	O
anti	O
-	O
SMN	O
antibodies	O
reveals	O
that	O
SMN	O
and	O
fibrillarin	O
also	O
cofractionate	O
in	O
the	O
insoluble	O
protein	O
fraction	O
of	O
cultured	O
cell	O
lysates	O
.	O
Immunoprecipitation	O
experiments	O
using	O
whole	O
cell	O
extracts	O
of	O
HeLa	O
cells	O
and	O
cultured	O
neurons	O
revealed	O
that	O
abSMN	O
coprecipitated	O
small	O
amounts	O
of	O
the	O
U3	O
small	O
nucleolar	O
RNA	O
(	O
snoRNA	O
)	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
fibrillarin	O
in	O
vivo	O
.	O
These	O
studies	O
raise	O
the	O
possibility	O
that	O
SMN	O
may	O
serve	O
a	O
function	O
in	O
rRNA	O
maturation	O
/	O
ribosome	O
synthesis	O
similar	O
to	O
its	O
role	O
in	O
spliceosome	O
biogenesis	O
.	O
PMID	O
:	O
12126878	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Neurosurg	O
.	O
1992	O
;18	O
(	O
5-	O
6	O
)	O
:310-4.	O
Ganglioglioma	B-malignancy-type
in	O
children	O
.	O
A	O
review	O
of	O
32	O
cases	O
at	O
the	O
University	O
of	O
Florida	O
.	O
Mickle	O
JP	O
.	O
Department	O
of	O
Neurological	O
Surgery	O
,	O
JHM	O
Health	O
Center	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
32610	O
.	O
The	O
entity	O
ganglioglioma	B-malignancy-type
in	O
children	O
seems	O
to	O
be	O
an	O
increasingly	O
more	O
common	O
tumor	O
.	O
Most	O
of	O
these	O
lesions	O
are	O
pathologically	O
and	O
clinically	O
benign	O
but	O
have	O
a	O
pathological	O
and	O
clinical	O
continuum	O
in	O
their	O
behavior	O
.	O
Gross	O
total	O
resection	O
,	O
especially	O
involving	O
the	O
lesions	O
in	O
the	O
supratentorial	O
compartment	O
,	O
is	O
often	O
curative	O
.	O
The	O
most	O
common	O
symptom	O
,	O
seizures	O
,	O
in	O
this	O
group	O
of	O
lesions	O
,	O
can	O
often	O
be	O
alleviated	O
with	O
removal	O
of	O
the	O
tumor	O
.	O
This	O
may	O
be	O
enhanced	O
with	O
the	O
use	O
of	O
corticography	O
at	O
the	O
initial	O
surgery	O
.	O
The	O
group	O
of	O
lesions	O
located	O
in	O
the	O
brainstem	O
are	O
more	O
difficult	O
to	O
control	O
and	O
may	O
require	O
multiple	O
operations	O
and	O
other	O
therapies	O
including	O
radiation	O
and	O
chemotherapy	O
for	O
optimum	O
outcome	O
.	O
Malignant	O
lesions	O
in	O
the	O
ganglioglioma	B-malignancy-type
series	O
are	O
rare	O
and	O
optimum	O
therapy	O
for	O
these	O
tumors	O
is	O
not	O
well	O
defined	O
at	O
this	O
time	O
.	O
Pathologically	O
,	O
this	O
group	O
of	O
tumors	O
needs	O
better	O
definition	O
for	O
designing	O
the	O
best	O
therapy	O
.	O
We	O
are	O
planning	O
a	O
survey	O
both	O
retrospectively	O
and	O
prospectively	O
with	O
flow	O
cytometry	O
and	O
the	O
use	O
of	O
various	O
makers	O
such	O
as	O
the	O
K	O
167	O
proliferation	O
antigen	O
to	O
better	O
define	O
potential	O
biological	O
behavior	O
.	O
Clearly	O
,	O
a	O
broader	O
discussion	O
with	O
the	O
patient	O
and	O
family	O
is	O
indicated	O
when	O
one	O
of	O
these	O
tumors	O
is	O
discovered	O
and	O
operated	O
.	O
PMID	O
:	O
1476942	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1990	O
May	O
15	O
;50(	O
10	O
)	O
:	O
3043	O
-	O
7.	O
Inverse	O
correlation	O
between	O
expression	O
of	O
multidrug	O
resistance	O
gene	O
and	O
N	O
-	O
myc	O
oncogene	O
in	O
human	O
neuroblastomas	B-malignancy-type
.	O
Nakagawara	O
A	O
,	O
Kadomatsu	O
K,	O
Sato	O
S	O
,	O
Kohno	O
K,	O
Takano	O
H,	O
Akazawa	O
K,	O
Nose	O
Y	O
,	O
Kuwano	O
M.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
60	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Genomic	O
amplification	O
of	O
N	O
-	O
myc	O
is	O
an	O
important	O
prognostic	O
indicator	O
in	O
neuroblastoma	B-malignancy-type
.	O
The	O
tumors	O
with	O
amplified	O
N	O
-	O
myc	O
are	O
initially	O
sensitive	O
to	O
chemotherapy	O
but	O
often	O
acquire	O
resistance	O
to	O
therapy	O
,	O
recur	O
,	O
and	O
ultimately	O
kill	O
the	O
patients	O
.	O
We	O
measured	O
amplification	O
and	O
expression	O
of	O
N	O
-	O
myc	O
and	O
expression	O
of	O
mdr	O
-	O
1	O
in	O
35	O
surgically	O
resected	O
neuroblastomas	B-malignancy-type
,	O
before	O
acquisition	O
of	O
drug	O
resistance	O
and	O
in	O
4	O
recurrent	O
tumors	O
resistant	O
to	O
chemotherapy	O
.	O
The	O
mdr	O
-	O
1	O
mRNA	O
expression	O
was	O
found	O
to	O
be	O
inversely	O
correlated	O
with	O
the	O
N	O
-	O
myc	O
expression	O
.	O
The	O
mdr	O
-	O
1	O
gene	O
expression	O
was	O
at	O
a	O
low	O
level	O
in	O
advanced	O
stage	O
and	O
histologically	O
undifferentiated	O
neuroblastomas	B-malignancy-type
,	O
the	O
same	O
group	O
of	O
tumors	O
in	O
which	O
N	O
-	O
myc	O
expression	O
is	O
elevated	O
.	O
A	O
significantly	O
better	O
prognosis	O
was	O
noted	O
in	O
those	O
patients	O
whose	O
tumors	O
had	O
a	O
high	O
level	O
of	O
mdr	O
-	O
1	O
expression	O
and	O
a	O
low	O
level	O
of	O
N	O
-	O
myc	O
expression	O
.	O
The	O
role	O
,	O
if	O
any	O
,	O
of	O
increased	O
expression	O
of	O
mdr	O
-	O
1	O
in	O
the	O
acquisition	O
of	O
multidrug	O
resistance	O
in	O
neuroblastoma	B-malignancy-type
remains	O
unclear	O
.	O
However	O
,	O
the	O
aggressive	O
clinical	O
behavior	O
associated	O
with	O
N	O
-	O
myc	O
amplification	O
and	O
/	O
or	O
expression	O
appears	O
to	O
be	O
linked	O
to	O
down	O
-	O
regulation	O
of	O
mdr	O
-	O
1	O
expression	O
.	O
PMID	O
:	O
2185879	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2003	O
Mar	O
14;278	O
(	O
11	O
)	O
:9655	O
-	O
62	O
.	O
Enhancement	O
of	O
B	O
-	O
MYB	O
transcriptional	O
activity	O
by	O
ZPR9	O
,	O
a	O
novel	O
zinc	O
finger	O
protein	O
.	O
Seong	O
HA	O
,	O
Kim	O
KT	O
,	O
Ha	O
H.	O
Department	O
of	O
Biochemistry	O
,	O
School	O
of	O
Life	O
Sciences	O
,	O
Research	O
Center	O
for	O
Bioresource	O
and	O
Health	O
,	O
Chungbuk	O
National	O
University	O
,	O
Cheongju	O
361	O
-763	O
,	O
Republic	O
of	O
Korea	O
.	O
By	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
the	O
zinc	O
finger	O
protein	O
ZPR9	O
was	O
identified	O
as	O
one	O
of	O
the	O
B	O
-	O
MYB	O
interacting	O
proteins	O
that	O
associates	O
with	O
the	O
carboxyl	O
-	O
terminal	O
conserved	O
region	O
of	O
B	O
-	O
MYB	O
.	O
ZPR9	O
was	O
found	O
to	O
form	O
in	O
vivo	O
complexes	O
with	O
B	O
-	O
MYB	O
,	O
as	O
demonstrated	O
by	O
in	O
vivo	O
binding	O
assay	O
and	O
coimmunoprecipitation	O
experiments	O
of	O
the	O
endogenously	O
and	O
exogenously	O
expressed	O
proteins	O
.	O
Deletion	O
analysis	O
revealed	O
that	O
this	O
binding	O
was	O
mediated	O
by	O
all	O
three	O
functional	O
domains	O
,	O
an	O
amino	O
-	O
terminal	O
DNA	O
-	O
binding	O
domain	O
,	O
a	O
transactivation	O
domain	O
,	O
and	O
a	O
carboxyl	O
-	O
terminal	O
conserved	O
region	O
of	O
B	O
-	O
MYB	O
.	O
We	O
show	O
that	O
the	O
interaction	O
of	O
ZPR9	O
with	O
B	O
-	O
MYB	O
is	O
functional	O
because	O
cotransfection	O
of	O
ZPR9	O
significantly	O
up	O
-	O
regulates	O
B	O
-	O
MYB	O
transcriptional	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
In	O
addition	O
,	O
coexpression	O
of	O
ZPR9	O
with	O
B	O
-	O
MYB	O
caused	O
the	O
accumulation	O
of	O
B	O
-	O
MYB	O
,	O
as	O
well	O
as	O
ZPR9	O
,	O
in	O
the	O
nucleus	O
.	O
Furthermore	O
,	O
constitutive	O
expression	O
of	O
ZPR9	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
induces	O
apoptosis	O
in	O
the	O
presence	O
of	O
retinoic	O
acid	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
ZPR9	O
plays	O
an	O
important	O
role	O
in	O
modulation	O
of	O
the	O
transactivation	O
by	O
B	O
-	O
MYB	O
and	O
cellular	O
growth	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
12645566	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2004	O
Jan;88	O
(	O
2	O
)	O
:462-8.	O
Signalling	O
pathways	O
for	O
insulin	O
-	O
like	O
growth	O
factor	O
type	O
1	O
-	O
mediated	O
expression	O
of	O
uncoupling	O
protein	O
3	O
.	O
Gustafsson	O
H,	O
Tamm	O
C	O
,	O
Forsby	O
A	O
.	O
Department	O
of	O
Neurochemistry	O
and	O
Neurotoxicology	O
,	O
Stockholm	O
University	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
helena@neurochem	O
.su.se	O
Uncoupling	O
protein	O
3	O
(	O
UCP3	O
)	O
is	O
a	O
mitochondrial	O
protein	O
with	O
antioxidant	O
properties	O
and	O
its	O
regulation	O
by	O
factors	O
promoting	O
cell	O
-	O
survival	O
may	O
be	O
important	O
for	O
protection	O
of	O
,	O
for	O
instance	O
,	O
neurons	O
in	O
states	O
of	O
oxidative	O
stress	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
regulatory	O
pathways	O
for	O
UCP3	O
expression	O
mediated	O
by	O
the	O
neuroprotective	O
hormone	O
insulin	O
-	O
like	O
growth	O
factor	O
type	O
1	O
(	O
IGF	O
-	O
1	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
SH	O
-	O
SY5Y	O
cells	O
.	O
Northern	O
blot	O
analysis	O
and	O
RT	O
-	O
PCR	O
showed	O
that	O
treatment	O
with	O
10	O
nm	O
IGF	O
-	O
1	O
increased	O
the	O
UCP3	O
mRNA	O
levels	O
2.5	O
-	O
fold	O
after	O
5	O
h	O
.	O
Co	O
-	O
incubation	O
with	O
the	O
phosphatidylinositol	O
3	O
(	O
PI3	O
)	O
-	O
kinase	O
inhibitor	O
LY294002	O
prohibited	O
IGF	O
-	O
1	O
-	O
mediated	O
induction	O
of	O
both	O
UCP3	O
mRNA	O
and	O
protein	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
complete	O
blockage	O
at	O
1	O
microm	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
and	O
western	O
blot	O
analyses	O
.	O
The	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
kinase	O
1	O
(	O
MKK1	O
or	O
MEK	O
)	O
inhibitor	O
PD98059	O
also	O
decreased	O
the	O
UCP3	O
mRNA	O
expression	O
at	O
10	O
microm	O
,	O
however	O
,	O
this	O
concentration	O
only	O
partly	O
inhibited	O
the	O
protein	O
expression	O
.	O
We	O
conclude	O
that	O
IGF	O
-	O
1	O
enhanced	O
UCP3	O
expression	O
at	O
transcriptional	O
level	O
,	O
primarily	O
through	O
the	O
PI3	O
-	O
kinase	O
-	O
dependent	O
pathway	O
and	O
partly	O
through	O
the	O
MAP	O
kinase	O
pathway	O
.	O
PMID	O
:	O
14690534	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2000	O
Dec;35	O
(	O
6	O
)	O
:659	O
-	O
62	O
.	O
Synergism	O
of	O
buthionine	O
sulfoximine	O
and	O
melphalan	O
against	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
derived	O
after	O
disease	O
progression	O
.	O
Anderson	O
CP	O
,	O
Keshelava	O
N	O
,	O
Satake	O
N	O
,	O
Meek	O
WH	O
,	O
Reynolds	O
CP	O
.	O
Division	O
of	O
Hematology-Oncology	O
,	O
Childrens	O
Hospital	O
Los	O
Angeles	O
,	O
Los	O
Angeles	O
,	O
California	O
90027	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Despite	O
intensive	O
-	O
alkylator	O
based	O
regimens	O
,	O
>	O
50	O
%	O
of	O
patients	O
with	O
high	O
-	O
risk	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
die	O
from	O
recurrent	O
disease	O
that	O
is	O
probably	O
due	O
,	O
in	O
part	O
,	O
to	O
acquired	O
alkylator	O
resistance	O
.	O
PROCEDURE	O
:	O
Using	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
-	O
mediated	O
,	O
glutathione	O
(	O
GSH	O
)	O
depletion	O
to	O
modulate	O
melphalan	O
(	O
L	O
-	O
PAM	O
)	O
resistance	O
,	O
we	O
examined	O
six	O
NB	B-malignancy-type
cell	O
lines	O
established	O
after	O
progressive	O
disease	O
following	O
either	O
standard	O
chemotherapy	O
,	O
BSO	O
/	O
L	O
-	O
PAM	O
therapy	O
,	O
or	O
myeloablative	O
therapy	O
and	O
autologous	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
AHSCT	O
)	O
.	O
RESULTS	O
:	O
Four	O
of	O
the	O
six	O
cell	O
lines	O
(	O
three	O
p53	O
-	O
nonfunctional	O
and	O
one	O
p53	O
-	O
functional	O
)	O
showed	O
high	O
-	O
level	O
L	O
-	O
PAM	O
resistance	O
.	O
CONCLUSIONS	O
:	O
Fixed	O
ratio	O
analysis	O
demonstrated	O
BSO	O
/	O
L	O
-	O
PAM	O
synergy	O
(	O
combination	O
index	O
>	O
1	O
)	O
for	O
all	O
cell	O
lines	O
tested	O
.	O
In	O
L	O
-	O
PAM	O
-	O
resistant	O
cell	O
lines	O
,	O
the	O
minimal	O
cytotoxicity	O
observed	O
for	O
BSO	O
combined	O
with	O
nonmyeloablative	O
concentrations	O
of	O
L	O
-	O
PAM	O
was	O
markedly	O
enhanced	O
(	O
>	O
4	O
logs	O
total	O
cell	O
kill	O
)	O
when	O
BSO	O
was	O
combined	O
with	O
myeloablative	O
concentrations	O
of	O
L	O
-	O
PAM	O
.	O
In	O
alkylator	O
-	O
resistant	O
NB	B-malignancy-type
,	O
the	O
optimal	O
use	O
of	O
BSO	O
may	O
require	O
dose	O
escalation	O
of	O
L	O
-	O
PAM	O
to	O
levels	O
requiring	O
AHSCT	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11107141	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1995	O
;31A(	O
2	O
)	O
:252-6.	O
Comment	O
in	O
:	O
Eur	O
J	O
Cancer	O
.	O
1995	O
;31A(	O
2	O
)	O
:	O
134	O
-6.	O
Multi	O
-	O
modality	O
megatherapy	O
with	O
[	O
131I	O
]	O
meta	O
-	O
iodobenzylguanidine	O
,	O
high	O
dose	O
melphalan	O
and	O
total	O
body	O
irradiation	O
with	O
bone	O
marrow	O
rescue	O
:	O
feasibility	O
study	O
of	O
a	O
new	O
strategy	O
for	O
advanced	O
neuroblastoma	B-malignancy-type
.	O
Gaze	O
MN	O
,	O
Wheldon	O
TE	O
,	O
O'Donoghue	O
JA	O
,	O
Hilditch	O
TE	O
,	O
McNee	O
SG	O
,	O
Simpson	O
E	O
,	O
Barrett	O
A	O
.	O
Meyerstein	O
Institute	O
of	O
Oncology	O
,	O
Middlesex	O
Hospital	O
,	O
London	O
,	O
U.K.	O
New	O
therapeutic	O
approaches	O
are	O
needed	O
for	O
advanced	O
neuroblastoma	B-malignancy-type
as	O
few	O
patients	O
are	O
currently	O
curable	O
.	O
We	O
describe	O
an	O
innovative	O
strategy	O
combining	O
[	O
131I	O
]	O
meta	O
-	O
iodobenzylguanidine	O
(	O
[	O
131I	O
]	O
mIBG	O
)	O
therapy	O
with	O
high	O
dose	O
chemotherapy	O
and	O
total	O
body	O
irradiation	O
.	O
The	O
aim	O
of	O
combining	O
these	O
treatments	O
is	O
to	O
overcome	O
the	O
specific	O
limitations	O
of	O
each	O
when	O
used	O
alone	O
to	O
maximise	O
killing	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Five	O
children	O
received	O
combined	O
therapy	O
with	O
[	O
131I	O
]	O
mIBG	O
followed	O
by	O
high	O
dose	O
melphalan	O
and	O
fractionated	O
total	O
body	O
irradiation	O
.	O
Autologous	O
bone	O
marrow	O
transplantation	O
was	O
undertaken	O
in	O
3	O
patients	O
and	O
allogeneic	O
in	O
2	O
patients	O
.	O
One	O
patient	O
received	O
additional	O
localised	O
radiotherapy	O
to	O
residual	O
bulk	O
disease	O
.	O
One	O
patient	O
is	O
alive	O
without	O
relapse	O
32	O
months	O
after	O
treatment	O
.	O
4	O
patients	O
relapsed	O
after	O
remissions	O
of	O
9	O
,	O
10	O
,	O
14	O
and	O
21	O
months	O
.	O
These	O
results	O
indicate	O
that	O
this	O
combined	O
modality	O
approach	O
is	O
feasible	O
and	O
safe	O
,	O
but	O
further	O
evaluation	O
is	O
necessary	O
to	O
establish	O
whether	O
it	O
has	O
advantages	O
over	O
conventional	O
megatherapy	O
using	O
melphalan	O
alone	O
.	O
PMID	O
:	O
7718333	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
1997	O
Aug	O
22	O
;766(	O
1-2	O
)	O
:	O
66-	O
71	O
.	O
Mu	O
and	O
delta	O
opioids	O
but	O
not	O
kappa	O
opioid	O
inhibit	O
voltage	O
-	O
activated	O
Ba2	O
+	O
currents	O
in	O
neuronal	O
F	O
-	O
11	O
cell	O
.	O
Nah	O
SY	O
,	O
Unteutsch	O
A	O
,	O
Bunzow	O
JR	O
,	O
Cook	O
SP	O
,	O
Beacham	O
DW	O
,	O
Grandy	O
DK.	O
Department	O
of	O
Physiology	O
,	O
School	O
of	O
Veterinary	O
Medicine	O
,	O
Chonnam	O
National	O
University	O
,	O
Kwangju	O
,	O
South	O
Korea	O
.	O
synah@chonnam	O
.chonnam	O
.ac.kr	O
Whole	O
-	O
cell	O
patch	O
-	O
clamp	O
recordings	O
were	O
used	O
to	O
study	O
Ba2	O
+	O
currents	O
through	O
voltage	O
-	O
dependent	O
Ca2	O
+	O
channels	O
in	O
dorsal	O
root	O
ganglion	O
x	O
mouse	O
neuroblastoma	B-malignancy-type
hybrid	O
(	O
F	O
-	O
11	O
)	O
cells	O
.	O
Opioid	O
agonists	O
selective	O
for	O
either	O
mu	O
(	O
Tyr	O
-	O
D	O
-	O
Ala	O
-	O
Gly	O
-	O
Mephe	O
-	O
Gly	O
-	O
ol	O
;	O
DAMGO	O
)	O
or	O
delta	O
(	O
Tyr	O
-	O
D	O
-	O
Pen	O
-	O
Gly	O
-	O
Phe	O
-	O
D	O
-	O
Pen	O
-	O
OH	O
;	O
DPDPE	O
)	O
receptors	O
inhibited	O
high	O
-	O
threshold	O
Ba2	O
+	O
currents	O
.	O
The	O
inhibition	O
was	O
reversible	O
,	O
naloxone	O
-	O
sensitive	O
,	O
and	O
dose	O
-	O
dependent	O
.	O
The	O
inhibitory	O
effects	O
of	O
both	O
DAMGO	O
and	O
DPDPE	O
were	O
blocked	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
pertussis	O
toxin	O
(	O
PTX	O
)	O
as	O
well	O
as	O
by	O
brief	O
exposure	O
to	O
the	O
sulfhydryl	O
alkylating	O
agent	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
NEM	O
)	O
.	O
The	O
N	O
-	O
type	O
Ca2	O
+	O
channel	O
antagonist	O
omega	O
-	O
conotoxin	O
GVIA	O
(	O
omega	O
-	O
CTX	O
GVIA	O
)	O
irreversibly	O
inhibited	O
high	O
threshold	O
Ba2	O
+	O
currents	O
by	O
66	O
%	O
and	O
blocked	O
the	O
inhibitory	O
effect	O
of	O
DAMGO	O
or	O
DPDPE	O
.	O
In	O
contrast	O
,	O
the	O
L	O
-	O
type	O
Ca2	O
+	O
channel	O
blocker	O
nifedipine	O
inhibited	O
high	O
threshold	O
Ba2	O
+	O
currents	O
by	O
15	O
%	O
and	O
failed	O
to	O
block	O
the	O
inhibitory	O
effect	O
of	O
DAMGO	O
or	O
DPDPE	O
.	O
These	O
results	O
demonstrate	O
that	O
mu	O
and	O
delta	O
opioid	O
receptors	O
are	O
negatively	O
coupled	O
to	O
N	O
-	O
type	O
Ca2	O
+	O
channels	O
via	O
PTX	O
-	O
and	O
NEM	O
-	O
sensitive	O
GTP	O
-	O
binding	O
proteins	O
in	O
F	O
-	O
11	O
cells	O
.	O
PMID	O
:	O
9359588	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Neurosci	O
.	O
2003	O
Aug;18	O
(	O
3	O
)	O
:	O
571	O
-	O
9.	O
A	O
novel	O
method	O
of	O
generating	O
neuronal	O
cell	O
lines	O
from	O
gene	O
-	O
knockout	O
mice	O
to	O
study	O
prion	O
protein	O
membrane	O
orientation	O
.	O
Holme	O
A	O
,	O
Daniels	O
M,	O
Sassoon	O
J,	O
Brown	O
DR.	O
Department	O
of	O
Biology	O
and	O
Biochemistry	O
,	O
University	O
of	O
Bath	O
,	O
Claverton	O
Down	O
,	O
Bath	O
BA2	O
7AY	O
,	O
UK.	O
The	O
technology	O
of	O
gene	O
knockout	O
and	O
transgenic	O
mice	O
has	O
allowed	O
the	O
study	O
of	O
the	O
role	O
of	O
genes	O
and	O
their	O
proteins	O
in	O
animal	O
physiology	O
and	O
metabolism	O
.	O
However	O
,	O
these	O
techniques	O
have	O
often	O
been	O
found	O
to	O
be	O
limited	O
in	O
that	O
some	O
genetic	O
manipulations	O
of	O
mice	O
led	O
either	O
to	O
a	O
fatal	O
phenotype	O
or	O
to	O
compensations	O
that	O
mask	O
the	O
loss	O
of	O
function	O
of	O
the	O
target	O
protein	O
.	O
The	O
experimentation	O
on	O
neurons	O
from	O
transgenic	O
mice	O
is	O
particularly	O
critical	O
in	O
the	O
study	O
of	O
key	O
proteins	O
that	O
may	O
be	O
involved	O
in	O
neurodegeneration	O
.	O
The	O
cell	O
fusion	O
technique	O
has	O
been	O
implemented	O
as	O
a	O
novel	O
way	O
to	O
generate	O
cell	O
lines	O
from	O
prion	O
protein	O
knockout	O
mice	O
.	O
Fusion	O
between	O
neonatal	O
mouse	O
neurons	O
and	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
have	O
led	O
to	O
a	O
Prnp	O
degrees	O
/	O
degrees	O
cell	O
line	O
that	O
facilitates	O
the	O
study	O
of	O
the	O
knockout	O
phenotype	O
.	O
These	O
cells	O
are	O
readily	O
transfectable	O
and	O
allowed	O
us	O
to	O
study	O
the	O
expression	O
of	O
prion	O
protein	O
mutants	O
on	O
a	O
PrP	O
-	O
knockout	O
background	O
.	O
Using	O
this	O
cell	O
line	O
we	O
have	O
examined	O
the	O
effect	O
of	O
PrP	O
mutations	O
reported	O
to	O
alter	O
PrPc	O
to	O
a	O
transmembrane	O
form	O
.	O
Our	O
results	O
suggest	O
that	O
these	O
mutations	O
do	O
not	O
create	O
transmembrane	O
forms	O
of	O
the	O
protein	O
,	O
but	O
block	O
normal	O
transport	O
of	O
PrP	O
to	O
the	O
cell	O
membrane	O
.	O
PMID	O
:	O
12911753	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1989	O
Oct	O
1;64	O
(	O
7	O
)	O
:	O
1383	O
-	O
7.	O
The	O
effects	O
of	O
gamma	O
interferon	O
on	O
the	O
natural	O
killer	O
and	O
tumor	O
cells	O
of	O
children	O
with	O
neuroblastoma	B-malignancy-type
.	O
A	O
preliminary	O
report	O
.	O
Evans	O
A	O
,	O
Main	O
E	O
,	O
Zier	O
K,	O
Ikegaki	O
N	O
,	O
Tartaglione	O
M,	O
Kennett	O
R	O
,	O
Lampson	O
L.	O
Children	O
's	O
Cancer	O
Research	O
Center	O
,	O
Children	O
's	O
Hospital	O
of	O
PhiladelphiaPA	O
19104	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cells	O
lack	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
C	O
molecules	O
which	O
can	O
be	O
induced	O
in	O
vitro	O
by	O
gamma	O
interferon	O
(	O
gamma	O
IFN	O
)	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
the	O
same	O
induction	O
would	O
occur	O
in	O
vivo	O
leading	O
to	O
tumor	O
regression	O
,	O
a	O
Phase	O
I	O
study	O
was	O
initiated	O
.	O
Seven	O
patients	O
with	O
neuroblastoma	B-malignancy-type
were	O
entered	O
on	O
a	O
Phase	O
I	O
study	O
of	O
recombinant	O
gamma	O
IFN	O
in	O
children	O
.	O
Three	O
received	O
0.05	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
three	O
times	O
a	O
week	O
,	O
three	O
received	O
0.1	O
mg	O
/	O
m2	O
for	O
4	O
weeks	O
,	O
and	O
one	O
patient	O
withdrew	O
from	O
study	O
before	O
receiving	O
adequate	O
treatment	O
for	O
evaluation	O
.	O
No	O
significant	O
clinical	O
response	O
was	O
seen	O
.	O
The	O
side	O
effects	O
were	O
fever	O
and	O
chills	O
,	O
and	O
no	O
serious	O
toxicity	O
occurred	O
.	O
Natural	O
killer	O
(	O
NK	O
)	O
and	O
lymphocyte	O
activated	O
killer	O
(	O
LAK	O
)	O
precursor	O
activity	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
determined	O
before	O
and	O
during	O
treatment	O
,	O
and	O
expression	O
of	O
HLA	O
-	O
A	O
,	O
B	O
,	O
C	O
molecules	O
was	O
looked	O
for	O
on	O
the	O
tumor	O
cells	O
in	O
the	O
bone	O
marrow	O
of	O
five	O
patients	O
.	O
The	O
NK	O
activity	O
initially	O
low	O
,	O
reached	O
control	O
levels	O
in	O
six	O
patients	O
,	O
but	O
the	O
increase	O
was	O
transient	O
.	O
The	O
LAK	O
precursor	O
activity	O
remained	O
normal	O
.	O
Expression	O
of	O
HLA	O
-	O
A	O
,	O
B	O
,	O
C	O
,	O
initially	O
absent	O
,	O
was	O
induced	O
on	O
the	O
neuroblastoma	B-malignancy-type
cells	O
in	O
four	O
of	O
six	O
patients	O
.	O
PMID	O
:	O
2505918	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1990	O
Apr;87	O
(	O
8	O
)	O
:	O
3077	O
-	O
81	O
.	O
Cerebellar	O
degeneration	O
-	O
related	O
antigen	O
:	O
a	O
highly	O
conserved	O
neuroectodermal	O
marker	O
mapped	O
to	O
chromosomes	O
X	O
in	O
human	O
and	O
mouse	O
.	O
Chen	O
YT	O
,	O
Rettig	O
WJ	O
,	O
Yenamandra	O
AK	O
,	O
Kozak	O
CA	O
,	O
Chaganti	O
RS	O
,	O
Posner	O
JB	O
,	O
Old	O
LJ.	O
Samuel	O
Freeman	O
Laboratory	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
NY	O
10021	O
.	O
Cerebellar	O
degeneration	O
-	O
related	O
antigen	O
(	O
designated	O
CDR34	O
)	O
was	O
previously	O
cloned	O
by	O
antibody	O
screening	O
of	O
a	O
cDNA	O
library	O
and	O
was	O
shown	O
to	O
be	O
one	O
of	O
the	O
target	O
molecules	O
recognized	O
by	O
autoantibodies	O
in	O
patients	O
with	O
paraneoplastic	B-malignancy-type
cerebellar	O
degeneration	O
.	O
This	O
molecule	O
is	O
distinctive	O
in	O
that	O
it	O
contains	O
a	O
tandem	O
hexapeptide	O
repetitive	O
structure	O
,	O
presumably	O
the	O
basis	O
for	O
its	O
high	O
immunogenicity	O
.	O
In	O
this	O
study	O
,	O
we	O
cloned	O
the	O
human	O
CDR34	O
gene	O
and	O
proved	O
that	O
the	O
entire	O
repetitive	O
sequence	O
is	O
encoded	O
by	O
a	O
single	O
exon	O
without	O
introns	O
.	O
We	O
also	O
showed	O
that	O
the	O
nucleotide	O
repeats	O
are	O
preserved	O
only	O
in	O
the	O
protein	O
-	O
coding	O
sequences	O
,	O
suggesting	O
evolutionary	O
constraint	O
in	O
this	O
region	O
of	O
the	O
gene	O
.	O
Corresponding	O
mouse	O
cDNA	O
clones	O
were	O
also	O
isolated	O
,	O
which	O
encoded	O
a	O
larger	O
molecule	O
with	O
very	O
similar	O
hexapeptide	O
repeating	O
units	O
.	O
Comparison	O
of	O
the	O
human	O
and	O
mouse	O
repeats	O
revealed	O
a	O
highly	O
conserved	O
Glu	O
-	O
Asp	O
core	O
in	O
each	O
unit	O
,	O
implicating	O
the	O
functional	O
significance	O
of	O
this	O
motif	O
.	O
Chromosomal	O
mapping	O
by	O
somatic	O
cell	O
hybrid	O
analysis	O
mapped	O
CDR34	O
to	O
both	O
human	O
and	O
mouse	O
chromosomes	O
X	O
,	O
and	O
in	O
situ	O
hybridization	O
further	O
assigned	O
CDR34	O
to	O
human	O
Xq24	O
-	O
q27	O
.	O
PMID	O
:	O
2326268	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1983	O
Apr;80	O
(	O
7	O
)	O
:1929-	O
32	O
.	O
Inhibitors	O
of	O
endocytosis	O
perturb	O
phospholipid	O
metabolism	O
in	O
rabbit	O
neutrophils	O
and	O
other	O
cells	O
.	O
Mato	O
JM	O
,	O
Pencev	O
D	O
,	O
Vasanthakumar	O
G	O
,	O
Schiffmann	O
E	O
,	O
Pastan	O
I.	O
Dansylcadaverine	O
,	O
amantadine	O
,	O
and	O
rimantadine	O
,	O
which	O
have	O
been	O
shown	O
to	O
inhibit	O
the	O
endocytosis	O
of	O
alpha	O
2	O
-	O
macroglobulin	O
,	O
epidermal	O
growth	O
factor	O
,	O
and	O
vesicular	O
stomatitis	O
virus	O
[Schlegel	O
,	O
R.	O
,	O
Dickson	O
,	O
R.	O
B.	O
,	O
Willingham	O
,	O
M.	O
C.	O
&	O
Pastan	O
,	O
I.	O
(	O
1982	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
79	O
,	O
2291-2295]	O
,	O
were	O
found	O
to	O
decrease	O
phosphatidylcholine	O
synthesis	O
,	O
chemotaxis	O
,	O
and	O
internalization	O
of	O
a	O
formylated	O
peptide	O
but	O
to	O
stimulate	O
the	O
incorporation	O
of	O
inositol	O
into	O
phosphatidylinositol	O
in	O
rabbit	O
neutrophils	O
.	O
Dansylcadaverine	O
decreased	O
phosphatidylcholine	O
synthesis	O
by	O
both	O
the	O
CDP	O
-	O
choline	O
and	O
transmethylation	O
pathways	O
and	O
also	O
inhibited	O
the	O
synthesis	O
of	O
phosphatidylethanolamine	O
by	O
the	O
CDP	O
-	O
ethanolamine	O
pathway	O
.	O
Dansylcadaverine	O
had	O
no	O
effect	O
on	O
the	O
phosphocholine	O
,	O
CDP	O
-	O
choline	O
,	O
or	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
homocysteine	O
pools	O
but	O
increased	O
2	O
-	O
fold	O
the	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
pool	O
.	O
These	O
results	O
suggest	O
that	O
dansylcadaverine	O
in	O
some	O
manner	O
inhibited	O
the	O
condensation	O
of	O
CDP	O
-	O
choline	O
with	O
diacylglycerol	O
to	O
form	O
phosphatidylcholine	O
.	O
Dansylcadaverine	O
also	O
inhibited	O
phosphatidylcholine	O
synthesis	O
in	O
human	O
neutrophils	O
,	O
human	O
fibroblasts	O
,	O
chicken	O
embryo	O
fibroblasts	O
,	O
rat	O
hepatocytes	O
,	O
osteosarcoma	B-malignancy-type
cells	O
,	O
and	O
neuroblastoma	B-malignancy-type
cells	O
.	O
It	O
did	O
not	O
stimulate	O
phosphatidylinositol	O
synthesis	O
in	O
chicken	O
embryo	O
fibroblasts	O
.	O
PMID	O
:	O
6572951	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Sep	O
20;277	O
(	O
38	O
)	O
:	O
3481	O
5-25	O
.	O
Epub	O
2002	O
Jul	O
02	O
.	O
The	O
expression	O
of	O
the	O
developmentally	O
regulated	O
proto	O
-	O
oncogene	O
Pax	O
-	O
3	O
is	O
modulated	O
by	O
N	O
-	O
Myc	O
.	O
Harris	O
RG	O
,	O
White	O
E	O
,	O
Phillips	O
ES	O
,	O
Lillycrop	O
KA	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
School	O
of	O
Biological	O
Sciences	O
,	O
University	O
of	O
Southampton	O
,	O
Bassett	O
Crescent	O
East	O
,	O
Southampton	O
SO16	O
7PX	O
,	O
United	O
Kingdom	O
.	O
N	O
-	O
Myc	O
is	O
a	O
member	O
of	O
the	O
Myc	O
family	O
of	O
transcription	O
factors	O
that	O
have	O
been	O
shown	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
investigated	O
the	O
relationship	O
between	O
N	O
-	O
Myc	O
and	O
the	O
developmental	O
control	O
gene	O
Pax	O
-	O
3	O
.	O
Using	O
transient	O
transfection	O
assays	O
,	O
we	O
show	O
that	O
the	O
Pax	O
-	O
3	O
promoter	O
is	O
activated	O
by	O
both	O
N	O
-	O
Myc	O
-	O
Max	O
and	O
c	O
-	O
Myc	O
-	O
Max	O
.	O
Moreover	O
,	O
we	O
show	O
that	O
Myc	O
regulation	O
of	O
Pax	O
-	O
3	O
promoter	O
activity	O
is	O
dependent	O
upon	O
a	O
noncanonical	O
E	O
box	O
site	O
in	O
the	O
5	O
'	O
promoter	O
region	O
of	O
Pax	O
-	O
3	O
.	O
In	O
addition	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
both	O
N	O
-	O
Myc	O
and	O
c	O
-	O
Myc	O
leads	O
to	O
increased	O
expression	O
of	O
Pax	O
-	O
3	O
mRNA	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
Pax	O
-	O
3	O
mRNA	O
expression	O
is	O
cell	O
cycle	O
-	O
regulated	O
and	O
that	O
the	O
5	O
'	O
promoter	O
region	O
of	O
Pax	O
-	O
3	O
(	O
bp	O
-	O
1578	O
to	O
+	O
56	O
)	O
can	O
direct	O
cell	O
cycle	O
-	O
dependent	O
gene	O
expression	O
with	O
kinetics	O
similar	O
to	O
that	O
of	O
the	O
endogenous	O
transcript	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
E	O
box	O
site	O
within	O
the	O
Pax	O
-	O
3	O
promoter	O
significantly	O
altered	O
the	O
pattern	O
of	O
expression	O
through	O
the	O
cell	O
cycle	O
.	O
These	O
results	O
suggest	O
that	O
the	O
Myc	O
family	O
of	O
transcription	O
factors	O
may	O
modulate	O
Pax	O
-	O
3	O
expression	O
in	O
vivo	O
.	O
PMID	O
:	O
12095979	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Clin	O
Lab	O
Sci	O
.	O
1995	O
Jan-	O
Feb;25(	O
1	O
)	O
:	O
66-78	O
.	O
Immunohistology	O
,	O
cytogenetics	O
,	O
and	O
molecular	O
studies	O
of	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
.	O
A	O
review	O
.	O
Winters	O
JL	O
,	O
Geil	O
JD	O
,	O
O'Connor	O
WN	O
.	O
Department	O
of	O
Pathology	O
and	O
Laboratory	O
Medicine	O
,	O
College	O
of	O
Medicine	O
,	O
University	O
of	O
Kentucky	O
,	O
Lexington	O
40536	O
,	O
USA	O
.	O
Malignancies	O
of	O
childhood	O
include	O
a	O
well	O
-	O
defined	O
spectrum	O
of	O
hematolymphoid	B-malignancy-type
,	O
organ	O
specific	O
(	O
adrenal	B-malignancy-type
,	O
kidney	B-malignancy-type
,	O
liver	B-malignancy-type
)	O
,	O
soft	B-malignancy-type
tissue	I-malignancy-type
,	O
bone	B-malignancy-type
,	O
and	O
nervous	B-malignancy-type
system	I-malignancy-type
(	O
central	B-malignancy-type
and	O
peripheral	B-malignancy-type
)	O
neoplasms	B-malignancy-type
with	O
variable	O
biology	O
.	O
Small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
neoplasms	I-malignancy-type
,	O
a	O
subset	O
of	O
childhood	O
malignancies	O
,	O
are	O
histologically	O
similar	O
but	O
differ	O
markedly	O
in	O
their	O
histogenesis	O
,	O
therapy	O
,	O
and	O
prognosis	O
.	O
Traditionally	O
,	O
clinical	O
information	O
and	O
light	O
microscopy	O
,	O
with	O
the	O
aid	O
of	O
histochemistry	O
and	O
ultrastructural	O
evaluation	O
,	O
establish	O
a	O
diagnosis	O
or	O
at	O
least	O
narrow	O
the	O
differential	O
diagnosis	O
.	O
Additionally	O
,	O
immunohistology	O
,	O
cytogenetics	O
,	O
and	O
molecular	O
studies	O
have	O
become	O
important	O
in	O
diagnosis	O
and	O
in	O
defining	O
phenotype	O
/	O
genotype	O
,	O
patient	O
treatment	O
modalities	O
,	O
and	O
prognosis	O
in	O
specific	O
cases	O
.	O
The	O
11	O
;	O
22	O
chromosomal	O
translocation	O
typifies	O
Ewing	B-malignancy-type
'	I-malignancy-type
s	I-malignancy-type
sarcoma	I-malignancy-type
,	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
,	O
and	O
Askin	B-malignancy-type
'	I-malignancy-type
s	I-malignancy-type
tumor	I-malignancy-type
,	O
as	O
does	O
the	O
resultant	O
chimeric	O
transcript	O
,	O
while	O
expression	O
and	O
amplification	O
of	O
N	O
-	O
myc	O
oncogene	O
are	O
predictive	O
of	O
the	O
prognosis	O
in	O
neuroblastoma	B-malignancy-type
.	O
Furthermore	O
,	O
studies	O
of	O
genes	O
and	O
gene	O
products	O
are	O
elucidating	O
mechanisms	O
of	O
oncogenesis	O
and	O
tumor	O
progression	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
7762971	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuron	O
.	O
1995	O
May	O
;	O
14	O
(	O
5	O
)	O
:	O
1075-81	O
.	O
Huntingtin	O
is	O
a	O
cytoplasmic	O
protein	O
associated	O
with	O
vesicles	O
in	O
human	O
and	O
rat	O
brain	O
neurons	O
.	O
DiFiglia	O
M	O
,	O
Sapp	O
E	O
,	O
Chase	O
K	O
,	O
Schwarz	O
C	O
,	O
Meloni	O
A	O
,	O
Young	O
C	O
,	O
Martin	O
E	O
,	O
Vonsattel	O
JP	O
,	O
Carraway	O
R	O
,	O
Reeves	O
SA	O
,	O
et	O
al	O
.	O
Department	O
of	O
Neurology	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
02114	O
,	O
USA	O
.	O
The	O
gene	O
defective	O
in	O
Huntington's	O
disease	O
encodes	O
a	O
protein	O
,	O
huntingtin	O
,	O
with	O
unknown	O
function	O
.	O
Antisera	O
generated	O
against	O
three	O
separate	O
regions	O
of	O
huntingtin	O
identified	O
a	O
single	O
high	O
molecular	O
weight	O
protein	O
of	O
approximately	O
320	O
kDa	O
on	O
immunoblots	O
of	O
human	O
neuroblastoma	B-malignancy-type
extracts	O
.	O
The	O
same	O
protein	O
species	O
was	O
detected	O
in	O
human	O
and	O
rat	O
cortex	O
synaptosomes	O
and	O
in	O
sucrose	O
density	O
gradients	O
of	O
vesicle-enriched	O
fractions	O
,	O
where	O
huntingtin	O
immunoreactivity	O
overlapped	O
with	O
the	O
distribution	O
of	O
vesicle	O
membrane	O
proteins	O
(	O
SV2	O
,	O
transferrin	O
receptor	O
,	O
and	O
synaptophysin	O
)	O
.	O
Immunohistochemistry	O
in	O
human	O
and	O
rat	O
brain	O
revealed	O
widespread	O
cytoplasmic	O
labeling	O
of	O
huntingtin	O
within	O
neurons	O
,	O
particularly	O
cell	O
bodies	O
and	O
dendrites	O
,	O
rather	O
than	O
the	O
more	O
selective	O
pattern	O
of	O
axon	O
terminal	O
labeling	O
characteristic	O
of	O
many	O
vesicle-associated	O
proteins	O
.	O
At	O
the	O
ultrastructural	O
level	O
,	O
immunoreactivity	O
in	O
cortical	O
neurons	O
was	O
detected	O
in	O
the	O
matrix	O
of	O
the	O
cytoplasm	O
and	O
around	O
the	O
membranes	O
of	O
the	O
vesicles	O
.	O
The	O
ubiquitous	O
cytoplasmic	O
distribution	O
of	O
huntingtin	O
in	O
neurons	O
and	O
its	O
association	O
with	O
vesicles	O
suggest	O
that	O
huntingtin	O
may	O
have	O
a	O
role	O
in	O
vesicle	O
trafficking	O
.	O
PMID	O
:	O
7748555	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan	O
;	O
36	O
(	O
1	O
)	O
:	O
135-8	O
.	O
Differential	O
gene	O
regulation	O
by	O
9-cis	O
and	O
all-trans	O
retinoic	O
acid	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Lovat	O
PE	O
,	O
Dobson	O
M	O
,	O
Malcolm	O
AJ	O
,	O
Pearson	O
AD	O
,	O
Redfern	O
CP	O
.	O
Department	O
of	O
Medicine	O
,	O
Medical	O
School	O
,	O
University	O
of	O
Newcastle	O
Upon	O
Tyne	O
,	O
United	O
Kingdom	O
.	O
BACKGROUND	O
:	O
9-cis	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
more	O
effective	O
than	O
all-trans	O
RA	O
at	O
inducing	O
neuroblastoma	B-malignancy-type
differentiation	O
in	O
vitro	O
,	O
and	O
has	O
distinct	O
biological	O
properties	O
with	O
respect	O
to	O
its	O
ability	O
to	O
promote	O
apoptosis	O
in	O
N-type	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
cellular	O
effects	O
of	O
9-cis	O
RA	O
may	O
,	O
in	O
part	O
,	O
result	O
from	O
activation	O
of	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
homodimers	O
.	O
If	O
this	O
hypothesis	O
is	O
correct	O
,	O
9-cis	O
RA	O
may	O
control	O
the	O
expression	O
of	O
a	O
different	O
subset	O
of	O
retinoid	O
-	O
regulated	O
genes	O
compared	O
to	O
all-trans	O
RA.	O
PROCEDURE	O
:	O
We	O
have	O
therefore	O
used	O
differential	O
mRNA	O
display	O
to	O
identify	O
genes	O
differentially	O
expressed	O
in	O
neuroblastoma	B-malignancy-type
cells	O
in	O
response	O
to	O
all-trans	O
and	O
9-cis	O
RA.	O
RESULTS	O
:	O
The	O
majority	O
of	O
cDNAs	O
differentially	O
expressed	O
in	O
response	O
to	O
all-trans	O
or	O
9-cis	O
RA	O
matched	O
to	O
nonredundant	O
Genbank	O
sequences	O
or	O
EST	O
database	O
sequences	O
.	O
Differential	O
-display	O
profiles	O
were	O
similar	O
in	O
SH	O
SY	O
5Y	O
and	O
SH	O
S	O
EP	O
cells	O
,	O
clonal	O
derivatives	O
of	O
the	O
mixed	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK	O
N	O
SH	O
,	O
although	O
there	O
were	O
apparent	O
differences	O
between	O
these	O
cell	O
lines	O
with	O
respect	O
to	O
the	O
retinoid	O
-	O
regulation	O
of	O
specific	O
RT-PCR	O
cDNA	O
fragments	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
view	O
that	O
9-cis	O
and	O
all-trans	O
RA	O
act	O
via	O
different	O
receptor	O
mechanisms	O
.	O
PMID	O
:	O
11464866	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Biol	O
Chem	O
.	O
2003	O
May	O
23	O
;	O
278	O
(	O
21	O
)	O
:	O
18997-9007	O
.	O
Epub	O
2003	O
Mar	O
20	O
.	O
Mutations	O
in	O
tau	O
gene	O
exon	O
10	O
associated	O
with	O
FTDP-17	O
alter	O
the	O
activity	O
of	O
an	O
exonic	O
splicing	O
enhancer	O
to	O
interact	O
with	O
Tra2	O
beta	O
.	O
Jiang	O
Z	O
,	O
Tang	O
H	O
,	O
Havlioglu	O
N	O
,	O
Zhang	O
X	O
,	O
Stamm	O
S	O
,	O
Yan	O
R	O
,	O
Wu	O
JY	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
Missouri	O
63110	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
human	O
tau	O
gene	O
leading	O
to	O
aberrant	O
splicing	O
have	O
been	O
identified	O
in	O
FTDP-17	O
,	O
an	O
autosomal	O
dominant	O
hereditary	O
neurodegenerative	O
disorder	O
.	O
Molecular	O
mechanisms	O
by	O
which	O
such	O
mutations	O
cause	O
tau	O
aberrant	O
splicing	O
were	O
not	O
understood	O
.	O
We	O
characterized	O
two	O
mutations	O
in	O
exon	O
10	O
of	O
the	O
tau	O
gene	O
,	O
N	O
279	O
K	O
and	O
Del	O
280	O
K	O
.	O
Our	O
results	O
revealed	O
an	O
exonic	O
splicing	O
enhancer	O
element	O
located	O
in	O
exon	O
10	O
.	O
The	O
activity	O
of	O
this	O
AG-rich	O
splicing	O
enhancer	O
was	O
altered	O
by	O
N	O
279	O
K	O
and	O
Del	O
280	O
K	O
mutations	O
.	O
This	O
exonic	O
enhancer	O
element	O
interacts	O
with	O
human	O
Tra2	O
beta	O
protein	O
.	O
The	O
interaction	O
between	O
Tra2	O
beta	O
and	O
the	O
exonic	O
splicing	O
enhancer	O
correlates	O
with	O
the	O
activity	O
of	O
this	O
enhancer	O
element	O
in	O
stimulating	O
splicing	O
.	O
Biochemical	O
studies	O
including	O
in	O
vitro	O
splicing	O
and	O
RNA	O
interference	O
experiments	O
in	O
transfected	O
cells	O
support	O
a	O
role	O
for	O
Tra2	O
beta	O
protein	O
in	O
regulating	O
alternative	O
splicing	O
of	O
human	O
tau	O
gene	O
.	O
Our	O
results	O
implicate	O
the	O
human	O
tau	O
gene	O
as	O
a	O
target	O
gene	O
for	O
the	O
alternative	O
splicing	O
regulator	O
Tra2	O
beta	O
,	O
suggesting	O
that	O
Tra2	O
beta	O
may	O
play	O
a	O
role	O
in	O
aberrant	O
tau	O
exon	O
10	O
alternative	O
splicing	O
and	O
in	O
the	O
pathogenesis	O
of	O
tauopathies	O
.	O
PMID	O
:	O
12649279	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Pharmacol	O
.	O
1993	O
Aug	O
;	O
44	O
(	O
2	O
)	O
:	O
346-55	O
.	O
Erratum	O
in	O
:	O
Mol	O
Pharmacol	O
1994	O
Mar	O
;	O
45	O
(	O
3	O
)	O
:	O
561	O
.	O
Cloned	O
murine	O
bradykinin	O
receptor	O
exhibits	O
a	O
mixed	O
B1	O
and	O
B2	O
pharmacological	O
selectivity	O
.	O
McIntyre	O
P	O
,	O
Phillips	O
E	O
,	O
Skidmore	O
E	O
,	O
Brown	O
M	O
,	O
Webb	O
M	O
.	O
Sandoz	O
Institute	O
for	O
Medical	O
Research	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
We	O
have	O
isolated	O
DNA	O
clones	O
encoding	O
functional	O
bradykinin	O
receptors	O
from	O
human	O
,	O
rat	O
,	O
and	O
mouse	O
sources	O
.	O
Genomic	O
bradykinin	O
receptor	O
clones	O
have	O
been	O
isolated	O
from	O
mouse	O
and	O
human	O
cosmid	O
libraries	O
and	O
cDNA	O
clones	O
have	O
been	O
isolated	O
from	O
the	O
human	O
lung	O
fibroblast	O
cell	O
line	O
W138	O
,	O
from	O
the	O
neuroblastoma	B-malignancy-type
/	O
glioma	B-malignancy-type
hybrid	O
NG108-15	O
,	O
and	O
from	O
rat	O
dorsal	O
root	O
ganglion	O
cells	O
.	O
The	O
receptor	O
protein	O
is	O
encoded	O
by	O
an	O
intronless	O
region	O
of	O
the	O
gene	O
in	O
both	O
mouse	O
and	O
human	O
.	O
There	O
is	O
evidence	O
of	O
a	O
splice	O
acceptor	O
site	O
8	O
bases	O
upstream	O
from	O
the	O
initiation	O
codon	O
in	O
all	O
three	O
species	O
.	O
The	O
function	O
of	O
the	O
expressed	O
receptor	O
proteins	O
from	O
mouse	O
,	O
rat	O
,	O
and	O
human	O
was	O
tested	O
by	O
electrophysiological	O
assays	O
after	O
injection	O
of	O
cRNA	O
into	O
Xenopus	O
laevis	O
oocytes	O
and	O
also	O
by	O
binding	O
assays	O
with	O
membranes	O
from	O
COS-7	O
cells	O
transfected	O
with	O
cloned	O
receptor	O
-	O
encoding	O
DNA	O
.	O
The	O
receptors	O
from	O
human	O
and	O
rat	O
showed	O
the	O
pharmacological	O
properties	O
of	O
B2	O
receptors	O
in	O
both	O
expression	O
systems	O
when	O
tested	O
with	O
a	O
variety	O
of	O
bradykinin	O
analogues	O
,	O
but	O
receptors	O
from	O
mouse	O
divided	O
into	O
two	O
populations	O
,	O
one	O
population	O
with	O
pharmacological	O
properties	O
of	O
B1-like	O
receptors	O
and	O
another	O
,	O
larger	O
,	O
population	O
with	O
properties	O
of	O
B2	O
receptors	O
.	O
PMID	O
:	O
8394991	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

N	O
Engl	O
J	O
Med	O
.	O
1985	O
Oct	O
31	O
;	O
313	O
(	O
18	O
)	O
:	O
1111-6	O
.	O
Association	O
of	O
multiple	O
copies	O
of	O
the	O
N-myc	O
oncogene	O
with	O
rapid	O
progression	O
of	O
neuroblastomas	B-malignancy-type
.	O
Seeger	O
RC	O
,	O
Brodeur	O
GM	O
,	O
Sather	O
H	O
,	O
Dalton	O
A	O
,	O
Siegel	O
SE	O
,	O
Wong	O
KY	O
,	O
Hammond	O
D	O
.	O
Eighty-nine	O
patients	O
with	O
untreated	O
primary	O
neuroblastomas	B-malignancy-type
were	O
studied	O
to	O
determine	O
the	O
relation	O
between	O
the	O
number	O
of	O
copies	O
of	O
the	O
N-myc	O
oncogene	O
and	O
survival	O
without	O
disease	O
progression	O
.	O
Genomic	O
amplification	O
(	O
3	O
to	O
300	O
copies	O
)	O
of	O
N-myc	O
was	O
detected	O
in	O
2	O
of	O
16	O
tumors	O
in	O
Stage	O
II	O
,	O
13	O
of	O
20	O
in	O
Stage	O
III	O
,	O
and	O
19	O
of	O
40	O
in	O
Stage	O
IV	O
;	O
in	O
contrast	O
,	O
8	O
Stage	O
I	O
and	O
5	O
Stage	O
IV-S	O
tumors	O
all	O
had	O
1	O
copy	O
of	O
the	O
gene	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
Analysis	O
of	O
progression-free	O
survival	O
in	O
all	O
patients	O
revealed	O
that	O
amplification	O
of	O
N-myc	O
was	O
associated	O
with	O
the	O
worst	O
prognosis	O
(	O
P	O
less	O
than	O
0.0001)	O
;	O
the	O
estimated	O
progression-free	O
survival	O
at	O
18	O
months	O
was	O
70	O
per	O
cent	O
,	O
30	O
per	O
cent	O
,	O
and	O
5	O
per	O
cent	O
for	O
patients	O
whose	O
tumors	O
had	O
1	O
,	O
3	O
to	O
10	O
,	O
or	O
more	O
than	O
10	O
N-myc	O
copies	O
,	O
respectively	O
.	O
Of	O
16	O
Stage	O
II	O
tumors	O
,	O
2	O
with	O
amplification	O
metastasized	O
,	O
whereas	O
only	O
1	O
of	O
14	O
without	O
amplification	O
did	O
so	O
(	O
P	O
=	O
0.03	O
)	O
.	O
Stage	O
IV	O
tumors	O
with	O
amplification	O
progressed	O
most	O
rapidly	O
:	O
nine	O
months	O
after	O
diagnosis	O
the	O
estimated	O
progression-free	O
survival	O
was	O
61	O
per	O
cent	O
,	O
47	O
per	O
cent	O
,	O
and	O
0	O
per	O
cent	O
in	O
patients	O
whose	O
tumors	O
had	O
1	O
,	O
3	O
to	O
10	O
,	O
or	O
more	O
than	O
10	O
copies	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
.	O
These	O
results	O
suggest	O
that	O
genomic	O
amplification	O
of	O
N-myc	O
may	O
have	O
a	O
key	O
role	O
in	O
determining	O
the	O
aggressiveness	O
of	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
4047115	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2000	O
Jan	O
19;267	O
(	O
2	O
)	O
:	O
521	O
-6.	O
Induction	O
of	O
peptidylglycine	O
alpha	O
-	O
amidating	O
monooxygenase	O
in	O
N	O
(	O
18	O
)	O
TG	O
(	O
2	O
)	O
cells	O
:	O
a	O
model	O
for	O
studying	O
oleamide	O
biosynthesis	O
.	O
Ritenour-Rodgers	O
KJ	O
,	O
Driscoll	O
WJ	O
,	O
Merkler	O
KA	O
,	O
Merkler	O
DJ	O
,	O
Mueller	O
GP	O
.	O
Department	O
of	O
Chemistry	O
and	O
Biochemistry	O
,	O
Duquesne	O
University	O
,	O
Pittsburgh	O
,	O
Pennsylvania	O
15282	O
,	O
USA	O
.	O
The	O
fatty-acid	O
primary	O
amide	O
,	O
oleamide	O
,	O
is	O
a	O
novel	O
signaling	O
molecule	O
whose	O
mechanism	O
of	O
biosynthesis	O
is	O
unknown	O
.	O
Recently	O
,	O
the	O
N	O
(	O
18	O
)	O
TG	O
(	O
2	O
)	O
cell	O
line	O
was	O
shown	O
to	O
synthesize	O
oleamide	O
from	O
oleic	O
acid	O
,	O
thereby	O
demonstrating	O
that	O
these	O
cells	O
contain	O
the	O
necessary	O
catalytic	O
activities	O
for	O
generating	O
the	O
fatty-acid	O
primary	O
amide	O
.	O
The	O
ability	O
of	O
peptide	O
alpha	O
-	O
amidating	O
enzyme	O
,	O
peptidylglycine	O
-	O
alpha	O
-	O
amidating	O
monooxygenase	O
(	O
PAM	O
;	O
EC	O
1.14.17.3	O
)	O
,	O
to	O
catalyze	O
the	O
formation	O
of	O
oleamide	O
from	O
oleoylglycine	O
in	O
vitro	O
suggests	O
this	O
as	O
a	O
function	O
for	O
the	O
enzyme	O
in	O
vivo	O
.	O
This	O
investigation	O
shows	O
that	O
N	O
(	O
18	O
)	O
TG	O
(	O
2	O
)	O
cells	O
,	O
in	O
fact	O
,	O
express	O
PAM	O
and	O
that	O
cellular	O
differentiation	O
dramatically	O
increases	O
this	O
expression	O
.	O
PAM	O
expression	O
was	O
confirmed	O
by	O
the	O
detection	O
of	O
PAM	O
mRNA	O
,	O
PAM	O
protein	O
,	O
and	O
enzymatic	O
activity	O
that	O
exhibits	O
the	O
functional	O
characteristics	O
of	O
PAM	O
isolated	O
from	O
mammalian	O
neuroendocrine	O
tissues	O
.	O
The	O
regulated	O
expression	O
of	O
PAM	O
in	O
N	O
(	O
18	O
)	O
TG	O
(	O
2	O
)	O
cells	O
is	O
consistent	O
with	O
the	O
proposed	O
role	O
of	O
PAM	O
in	O
the	O
biosynthesis	O
of	O
fatty-acid	O
primary	O
amides	O
and	O
further	O
establishes	O
this	O
cell	O
line	O
as	O
a	O
model	O
for	O
studying	O
the	O
pathway	O
.	O
Copyright	O
2000	O
Academic	O
Press	O
.	O
PMID	O
:	O
10631094	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
.	O
1991	O
Aug;	O
9(	O
8	O
)	O
:	O
1371	O
-5	O
.	O
N-myc	O
genomic	O
content	O
and	O
DNA	O
ploidy	O
in	O
stage	O
IVS	O
neuroblastoma	B-malignancy-type
.	O
Bourhis	O
J,	O
Dominici	O
C	O
,	O
McDowell	O
H,	O
Raschella	O
G	O
,	O
Wilson	O
G	O
,	O
Castello	O
MA	O
,	O
Plouvier	O
E	O
,	O
Lemerle	O
J,	O
Riou	O
G	O
,	O
Benard	O
J,	O
et	O
al	O
.	O
Laboratory	O
of	O
Clinical	O
and	O
Molecular	O
Pharmacology	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
Villejuif	O
,	O
France	O
.	O
DNA	O
ploidy	O
and	O
N-myc	O
genomic	O
content	O
were	O
analyzed	O
in	O
a	O
series	O
of	O
stage	O
IVS	O
neuroblastomas	B-malignancy-type
by	O
flow	O
cytometry	O
and	O
Southern	O
blot	O
hybridization	O
,	O
respectively	O
.	O
Of	O
the	O
12	O
stage	O
IVS	O
neuroblastomas	B-malignancy-type
studied	O
,	O
nine	O
were	O
aneuploid	O
(	O
DNA	O
index	O
[	O
DI	O
]	O
greater	O
than	O
1	O
)	O
,	O
two	O
were	O
diploid	O
(	O
DI	O
=	O
1	O
)	O
,	O
and	O
one	O
was	O
not	O
assessable	O
for	O
DNA	O
content	O
due	O
to	O
insufficient	O
tumor	O
material	O
.	O
N-myc	O
gene	O
amplification	O
was	O
present	O
in	O
two	O
of	O
12	O
tumors	O
.	O
None	O
of	O
the	O
aneuploid	O
tumors	O
exhibited	O
N-myc	O
amplification	O
.	O
Among	O
the	O
aneuploid	O
neuroblastomas	B-malignancy-type
,	O
the	O
DIs	O
were	O
between	O
1.27	O
and	O
1.60	O
,	O
ie	O
,	O
in	O
the	O
near	O
-	O
triploid	O
range	O
.	O
The	O
follow-up	O
from	O
diagnosis	O
ranged	O
from	O
1	O
to	O
41	O
months	O
(	O
mean	O
,	O
20	O
months	O
)	O
.	O
The	O
nine	O
neuroblastomas	B-malignancy-type
with	O
near	O
-	O
triploid	O
DNA	O
content	O
were	O
free	O
of	O
disease	O
at	O
the	O
end	O
of	O
the	O
follow-up	O
period	O
.	O
In	O
contrast	O
,	O
a	O
rapid	O
and	O
fatal	O
tumor	O
progression	O
was	O
observed	O
for	O
the	O
three	O
neuroblastomas	B-malignancy-type
with	O
N-myc	O
amplification	O
and/or	O
diploidy	O
.	O
Although	O
involving	O
only	O
a	O
limited	O
series	O
,	O
these	O
results	O
strongly	O
suggest	O
that	O
the	O
combined	O
analysis	O
of	O
DNA	O
ploidy	O
and	O
N-myc	O
genomic	O
content	O
could	O
predict	O
clinical	O
outcome	O
in	O
stage	O
IVS	O
neuroblastoma	B-malignancy-type
and	O
should	O
help	O
to	O
identify	O
patients	O
for	O
whom	O
a	O
more	O
aggressive	O
therapy	O
is	O
required	O
.	O
PMID	O
:	O
2072140	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
.	O
1991	O
Sep;11(	O
9	O
)	O
:4627	O
-34	O
.	O
The	O
human	O
fibroblast	O
growth	O
factor	O
receptor	O
genes	O
:	O
a	O
common	O
structural	O
arrangement	O
underlies	O
the	O
mechanisms	O
for	O
generating	O
receptor	O
forms	O
that	O
differ	O
in	O
their	O
third	O
immunoglobulin	O
domain	O
.	O
Johnson	O
DE	O
,	O
Lu	O
J,	O
Chen	O
H,	O
Werner	O
S	O
,	O
Williams	O
LT.	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
Program	O
of	O
Excellence	O
in	O
Molecular	O
Biology	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
-07	O
24	O
.	O
To	O
determine	O
the	O
mechanisms	O
by	O
which	O
multiple	O
forms	O
of	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
receptors	O
are	O
generated	O
,	O
we	O
have	O
mapped	O
the	O
arrangement	O
of	O
exons	O
and	O
introns	O
in	O
the	O
human	O
FGF	O
receptor	O
1	O
(	O
FGFR	O
1	O
)	O
gene	O
(	O
flg	O
)	O
.	O
We	O
found	O
three	O
alternative	O
exons	O
encoding	O
a	O
portion	O
of	O
the	O
third	O
immunoglobulin	O
(	O
Ig	O
)	O
-	O
like	O
domain	O
of	O
the	O
receptor	O
.	O
One	O
of	O
these	O
alternatives	O
encodes	O
a	O
sequence	O
that	O
is	O
part	O
of	O
a	O
secreted	O
form	O
of	O
FGFR	O
1	O
.	O
The	O
other	O
two	O
encode	O
sequences	O
that	O
are	O
likely	O
part	O
of	O
transmembrane	O
forms	O
of	O
FGFR	O
1	O
.	O
One	O
of	O
these	O
forms	O
has	O
not	O
been	O
previously	O
reported	O
in	O
published	O
cDNAs	O
.	O
Also	O
,	O
we	O
have	O
determined	O
the	O
structural	O
organization	O
of	O
a	O
portion	O
of	O
the	O
human	O
FGFR	O
2	O
gene	O
(	O
bek	O
)	O
and	O
found	O
a	O
similar	O
arrangement	O
of	O
alternative	O
exons	O
for	O
the	O
third	O
Ig	O
-	O
like	O
domain	O
.	O
The	O
arrangement	O
of	O
these	O
genes	O
suggests	O
that	O
there	O
are	O
conserved	O
mechanisms	O
governing	O
the	O
expression	O
of	O
secreted	O
FGF	O
receptors	O
as	O
well	O
as	O
the	O
expression	O
of	O
at	O
least	O
two	O
distinct	O
membrane	O
-	O
spanning	O
forms	O
of	O
the	O
FGF	O
receptors	O
.	O
The	O
diverse	O
forms	O
appear	O
to	O
be	O
generated	O
by	O
alternative	O
splicing	O
of	O
mRNA	O
and	O
selective	O
use	O
of	O
polyadenylation	O
signals	O
.	O
PMID	O
:	O
1652059	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
.	O
1986	O
Aug;55	O
(	O
2	O
)	O
:	O
18	O
6-93	O
.	O
Paucity	O
of	O
beta	O
2-microglobulin	O
expression	O
on	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
,	O
bronchial	B-malignancy-type
carcinoids	I-malignancy-type
and	O
certain	O
other	O
neuroendocrine	B-malignancy-type
tumors	I-malignancy-type
.	O
Funa	O
K,	O
Gazdar	O
AF	O
,	O
Minna	O
JD	O
,	O
Linnoila	O
RI.	O
Cell	O
lines	O
established	O
from	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
SCLC	B-malignancy-type
)	O
,	O
a	O
neuroendocrine	B-malignancy-type
tumor	I-malignancy-type
,	O
have	O
low	O
or	O
absent	O
expression	O
of	O
class	O
I	O
major	O
histocompatibility	O
complex	O
antigens	O
.	O
To	O
determine	O
whether	O
this	O
phenomenon	O
occurs	O
also	O
in	O
vivo	O
,	O
244	O
routine	O
paraffin	O
-	O
embedded	O
tumors	O
including	O
32	O
SCLC	B-malignancy-type
and	O
79	O
non	B-malignancy-type
-	I-malignancy-type
SCLC	I-malignancy-type
(	I-malignancy-type
NSCLC	I-malignancy-type
)	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
were	O
studied	O
for	O
expression	O
of	O
beta	O
2-microglobulin	O
(	O
beta	O
2m	O
)	O
by	O
an	O
avidin	O
-	O
biotin	O
coupled	O
immunoperoxidase	O
technique	O
.	O
The	O
majority	O
of	O
SCLC	B-malignancy-type
tumors	O
lacked	O
beta	O
2m	O
expression	O
,	O
while	O
some	O
had	O
weak	O
,	O
focal	O
expression	O
.	O
In	O
contrast	O
,	O
most	O
NSCLC	B-malignancy-type
expressed	O
beta	O
2m	O
,	O
often	O
strongly	O
.	O
The	O
difference	O
between	O
SCLC	B-malignancy-type
and	O
NSCLC	B-malignancy-type
was	O
highly	O
significant	O
statistically	O
,	O
suggesting	O
that	O
beta	O
2m	O
can	O
be	O
used	O
as	O
a	O
clinical	O
immunodiagnostic	O
marker	O
for	O
distinguishing	O
NSCLC	B-malignancy-type
from	O
SCLC	B-malignancy-type
.	O
In	O
addition	O
,	O
certain	O
other	O
neuroendocrine	B-malignancy-type
tumors	I-malignancy-type
(	O
neuroblastoma	B-malignancy-type
,	O
bronchial	B-malignancy-type
and	O
midgut	B-malignancy-type
carcinoid	I-malignancy-type
tumors	I-malignancy-type
)	O
lacked	O
beta	O
2m	O
expression	O
,	O
whereas	O
some	O
(	O
pheochromocytoma	B-malignancy-type
,	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
peripheral	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
)	O
usually	O
stained	O
positively	O
.	O
Such	O
non	B-malignancy-type
-	I-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
as	O
colon	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
and	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
moderate	O
to	O
high	O
expression	O
of	O
beta	O
2m	O
.	O
Selective	O
absence	O
of	O
beta	O
2m	O
expression	O
by	O
certain	O
neuroendocrine	B-malignancy-type
tumors	I-malignancy-type
appears	O
to	O
be	O
a	O
phenomenon	O
of	O
biological	O
and	O
diagnostic	O
importance	O
.	O
PMID	O
:	O
3525983	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Diagn	O
Mol	O
Pathol	O
.	O
1992	O
Mar;1	O
(	O
1	O
)	O
:16	O
-	O
24	O
.	O
Expression	O
of	O
members	O
of	O
the	O
chromogranin	O
family	O
in	O
primary	O
neuroblastomas	B-malignancy-type
.	O
Pagani	O
A	O
,	O
Forni	O
M,	O
Tonini	O
GP	O
,	O
Papotti	O
M,	O
Bussolati	O
G.	O
Department	O
of	O
Biomedical	O
Sciences	O
and	O
Human	O
Oncology	O
,	O
University	O
of	O
Turin	O
,	O
Italy	O
.	O
Expression	O
of	O
the	O
members	O
of	O
the	O
chromogranin	O
family	O
[i.e.	O
,	O
chromogranin	O
A	O
(	O
CgA	O
)	O
,	O
chromogranin	O
B	O
,	O
and	O
secretogranin	O
II	O
(	O
SgII	O
)	O
]	O
,	O
the	O
acidic	O
proteins	O
of	O
the	O
matrix	O
of	O
the	O
chromaffin	O
granules	O
presently	O
regarded	O
as	O
specific	O
neuroendocrine	O
markers	O
,	O
was	O
investigated	O
at	O
gene	O
and	O
protein	O
levels	O
in	O
a	O
series	O
of	O
14	O
cases	O
of	O
primary	O
untreated	O
neuroblastomas	B-malignancy-type
.	O
Oligonucleotides	O
and	O
cRNA	O
probes	O
were	O
employed	O
for	O
hybridization	O
analysis	O
of	O
specific	O
mRNAs	O
(	O
both	O
by	O
Northern	O
blots	O
and	O
nonradioactive	O
in	O
situ	O
hybridization	O
)	O
;	O
proteins	O
were	O
localized	O
by	O
immunocytochemistry	O
.	O
Expression	O
of	O
different	O
amounts	O
of	O
each	O
type	O
of	O
chromogranin	O
was	O
determined	O
in	O
all	O
tumors	O
.	O
Cases	O
found	O
immunocytochemically	O
negative	O
were	O
all	O
positive	O
by	O
Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
.	O
A	O
better	O
prognosis	O
was	O
associated	O
with	O
a	O
higher	O
relative	O
expression	O
of	O
SgII	O
;	O
on	O
the	O
contrary	O
,	O
a	O
worse	O
outcome	O
was	O
observed	O
in	O
cases	O
with	O
a	O
higher	O
expression	O
of	O
CgA	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
SgII	O
is	O
preferentially	O
expressed	O
in	O
neuroblastomas	B-malignancy-type
undergoing	O
neuronal	O
differentiation	O
.	O
In	O
cases	O
of	O
neuroblastomas	B-malignancy-type
,	O
determination	O
of	O
expression	O
levels	O
of	O
the	O
different	O
chromogranins	O
in	O
the	O
tissues	O
(	O
and	O
in	O
the	O
serum	O
)	O
can	O
provide	O
parameters	O
of	O
high	O
diagnostic	O
and	O
prognostic	O
value	O
.	O
PMID	O
:	O
1342949	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nature	O
.	O
1989	O
Nov	O
30	O
;	O
342	O
(	O
6249	O
)	O
:	O
548	O
-	O
50	O
.	O
Induction	O
of	O
glia	O
-	O
derived	O
nexin	O
after	O
lesion	O
of	O
a	O
peripheral	O
nerve	O
.	O
Meier	O
R	O
,	O
Spreyer	O
P	O
,	O
Ortmann	O
R	O
,	O
Harel	O
A	O
,	O
Monard	O
D	O
.	O
Friedrich	O
Miescher	O
-	O
Institute	O
,	O
Basel	O
,	O
Switzerland	O
.	O
Glia	O
-	O
derived	O
nexin	O
(	O
GDN	O
)	O
,	O
also	O
known	O
as	O
protease	O
nexin	O
I	O
,	O
is	O
a	O
serine	O
protease	O
inhibitor	O
of	O
deduced	O
relative	O
molecular	O
mass	O
41	O
,	O
700	O
,	O
identified	O
in	O
conditioned	O
media	O
of	O
glioma	B-malignancy-type
cells	O
by	O
its	O
neurite	O
-	O
promoting	O
activity	O
.	O
GDN	O
can	O
promote	O
neurite	O
outgrowth	O
in	O
vitro	O
from	O
neuroblastoma	B-malignancy-type
cells	O
,	O
sympathetic	O
neurons	O
and	O
hippocampal	O
neurons	O
(	O
L	O
.	O
Farmer	O
et	O
al	O
.	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O
In	O
vivo	O
,	O
GDN	O
is	O
constitutively	O
expressed	O
in	O
all	O
parts	O
of	O
the	O
olfactory	O
system	O
,	O
where	O
axonal	O
regeneration	O
and	O
neurogenesis	O
occur	O
continuously	O
throughout	O
life	O
.	O
This	O
observation	O
indicates	O
that	O
GDN	O
could	O
be	O
important	O
for	O
axonal	O
regeneration	O
in	O
vivo	O
.	O
To	O
investigate	O
this	O
possibility	O
,	O
we	O
have	O
taken	O
advantage	O
of	O
the	O
fact	O
that	O
damage	O
to	O
nerves	O
in	O
the	O
peripheral	O
nervous	O
system	O
leads	O
to	O
their	O
regeneration	O
,	O
whereas	O
in	O
the	O
central	O
nervous	O
system	O
no	O
such	O
regeneration	O
can	O
occur	O
.	O
Here	O
we	O
report	O
that	O
after	O
lesion	O
of	O
the	O
rat	O
sciatic	O
nerve	O
there	O
is	O
a	O
large	O
transient	O
increase	O
in	O
the	O
amount	O
of	O
GDN	O
messenger	O
RNA	O
and	O
of	O
released	O
GDN	O
.	O
The	O
cells	O
showing	O
GDN	O
immunoreactivity	O
are	O
mainly	O
localized	O
distal	O
to	O
the	O
lesion	O
site	O
.	O
These	O
results	O
further	O
support	O
the	O
suggestion	O
that	O
GDN	O
is	O
important	O
for	O
axonal	O
regeneration	O
in	O
vivo	O
,	O
and	O
indicate	O
that	O
protease	O
inhibitors	O
could	O
have	O
a	O
role	O
in	O
Wallerian	O
degeneration	O
and	O
peripheral	O
nerve	O
regeneration	O
.	O
PMID	O
:	O
2685611	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
.	O
1997	O
Mar	O
27;14(	O
12	O
)	O
:	O
1463	O
-	O
70	O
.	O
Induction	O
of	O
apoptosis	O
by	O
p	O
75	O
neurotrophin	O
receptor	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Bunone	O
G	O
,	O
Mariotti	O
A	O
,	O
Compagni	O
A	O
,	O
Morandi	O
E	O
,	O
Della	O
Valle	O
G.	O
Department	O
of	O
Genetics	O
and	O
Microbiology	O
,	O
University	O
of	O
Pavia	O
,	O
Italy	O
.	O
The	O
low	O
-	O
affinity	O
nerve	O
growth	O
factor	O
receptor	O
p75NTR	O
belongs	O
to	O
a	O
membrane	O
receptor	O
superfamily	O
whose	O
members	O
,	O
in	O
certain	O
cell	O
types	O
,	O
are	O
able	O
to	O
transduce	O
an	O
apoptotic	O
signal	O
.	O
To	O
investigate	O
the	O
effect	O
of	O
p75NTR	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
we	O
transfected	O
the	O
p75NTR	O
cDNA	O
into	O
SK	O
-	O
N	O
-	O
BE	O
cells	O
,	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
that	O
lacks	O
expression	O
of	O
both	O
p75NTR	O
and	O
TrkA	O
.	O
Cell	O
clones	O
expressing	O
elevated	O
levels	O
of	O
p75NTR	O
showed	O
a	O
high	O
degree	O
of	O
cell	O
death	O
by	O
apoptosis	O
,	O
even	O
in	O
serum	O
-	O
supplemented	O
medium	O
.	O
Moreover	O
,	O
the	O
level	O
of	O
apoptosis	O
correlated	O
directly	O
with	O
the	O
expression	O
level	O
of	O
the	O
receptor	O
,	O
indicating	O
that	O
p75NTR	O
could	O
activate	O
the	O
cell	O
death	O
program	O
by	O
itself	O
.	O
Clones	O
expressing	O
p75NTR	O
showed	O
a	O
dramatic	O
increase	O
of	O
cell	O
death	O
when	O
switched	O
into	O
serum	O
-	O
free	O
medium	O
;	O
these	O
cultures	O
rapidly	O
extinguished	O
.	O
This	O
apoptotic	O
effect	O
was	O
greatly	O
inhibited	O
by	O
NGF	O
treatment	O
.	O
Our	O
results	O
support	O
the	O
hypothesis	O
that	O
p75NTR	O
,	O
when	O
it	O
is	O
not	O
bound	O
by	O
NGF	O
,	O
may	O
play	O
a	O
role	O
in	O
neuronal	O
selection	O
during	O
embryonic	O
development	O
and	O
suggest	O
that	O
neuroblastomas	B-malignancy-type
may	O
arise	O
from	O
immature	O
neuroblasts	O
that	O
escape	O
programmed	O
cell	O
death	O
.	O
Therefore	O
,	O
the	O
loss	O
of	O
p75NTR	O
expression	O
in	O
developing	O
neural	O
crest	O
cells	O
might	O
be	O
a	O
primary	O
event	O
in	O
the	O
genesis	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
9136990	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Dev	O
Brain	O
Res	O
.	O
1999	O
May	O
14;114(	O
2	O
)	O
:193	O
-200	O
.	O
Suppression	O
of	O
an	O
actin	O
-	O
binding	O
protein	O
,	O
drebrin	O
,	O
by	O
antisense	O
transfection	O
attenuates	O
neurite	O
outgrowth	O
in	O
neuroblastoma	B-malignancy-type
B104	O
cells	O
.	O
Toda	O
M,	O
Shirao	O
T	O
,	O
Uyemura	O
K.	O
Department	O
of	O
Physiology	O
,	O
Keio	O
University	O
School	O
of	O
Medicine	O
,	O
35	O
Shinanomachi	O
,	O
Shinjuku-ku	O
,	O
Tokyo	O
,	O
160	O
-	O
8582	O
,	O
Japan	O
.	O
Drebrins	O
,	O
actin	O
-	O
binding	O
proteins	O
,	O
are	O
dominantly	O
expressed	O
during	O
embryogenesis	O
and	O
accumulated	O
in	O
neurite	O
processes	O
of	O
postmigratory	O
neurons	O
.	O
While	O
the	O
cytoskeletal	O
proteins	O
are	O
the	O
important	O
factors	O
for	O
regulating	O
neurite	O
outgrowth	O
,	O
the	O
cellular	O
mechanism	O
in	O
neurons	O
is	O
still	O
unclear	O
.	O
To	O
address	O
the	O
role	O
of	O
drebrins	O
in	O
the	O
neurite	O
outgrowth	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
suppression	O
of	O
drebrin	O
on	O
a	O
rat	O
neuroblastoma	B-malignancy-type
B104	O
cell	O
line	O
,	O
which	O
constitutively	O
expresses	O
drebrin	O
.	O
Deprivation	O
of	O
serum	O
or	O
addition	O
of	O
gangliosides	O
in	O
the	O
culture	O
medium	O
induced	O
remarkable	O
neurite	O
outgrowth	O
of	O
B104	O
cells	O
.	O
We	O
transfected	O
B104	O
cells	O
with	O
an	O
antisense	O
construct	O
of	O
human	O
drebrin	O
E	O
cDNA	O
and	O
found	O
that	O
the	O
drebrin	O
expression	O
was	O
significantly	O
reduced	O
in	O
the	O
stable	O
antisense	O
cell	O
lines	O
.	O
In	O
response	O
to	O
serum	O
deprivation	O
and	O
gangliosides	O
treatment	O
,	O
their	O
ability	O
to	O
extend	O
neurite	O
processes	O
was	O
significantly	O
attenuated	O
.	O
In	O
contrast	O
,	O
the	O
cell	O
proliferation	O
of	O
the	O
antisense	O
transfectants	O
was	O
arrested	O
by	O
serum	O
deprivation	O
similar	O
to	O
control	O
B104	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
the	O
drebrins	O
are	O
required	O
for	O
neurite	O
outgrowth	O
in	O
neuronal	O
cells	O
.	O
Copyright	O
1999	O
Elsevier	O
Science	O
B.V	O
.	O
PMID	O
:	O
10320758	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep.	O
2003	O
Jan-	O
Feb;10(	O
1	O
)	O
:243	O
-	O
7.	O
Prognostic	O
significance	O
of	O
cell	O
proliferation	O
in	O
human	O
neuroblastoma	B-malignancy-type
:	O
comparison	O
with	O
other	O
prognostic	O
factors	O
.	O
Mejia	O
C	O
,	O
Navarro	O
S	O
,	O
Pellin	O
A	O
,	O
Ruiz	O
A	O
,	O
Castel	O
V	O
,	O
Llombart-Bosch	O
A	O
.	O
Department	O
of	O
Neurosciences	O
,	O
Institute	O
of	O
Cell	O
Physiology	O
,	O
Universidad	O
Nacional	O
Autonoma	O
de	O
Mexico	O
,	O
Mexico	O
City	O
04510	O
,	O
D.F.	O
Mexico	O
.	O
mmejia@ifisiol	O
.unam	O
.mx	O
Peripheral	B-malignancy-type
neuroblastic	I-malignancy-type
tumors	I-malignancy-type
(	O
PNT	B-malignancy-type
)	O
,	O
are	O
heterogeneous	O
neoplasms	O
that	O
include	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
,	O
ganglioneuroblastoma	B-malignancy-type
(	O
GNB	B-malignancy-type
)	O
and	O
ganglioneuroma	B-malignancy-type
(	O
GN	B-malignancy-type
)	O
and	O
present	O
great	O
biological	O
heterogeneity	O
.	O
There	O
are	O
few	O
reports	O
analyzing	O
PCNA	O
and	O
Ki	O
-	O
67	O
expression	O
in	O
PNT	B-malignancy-type
;	O
however	O
,	O
controversy	O
exists	O
concerning	O
the	O
specificity	O
of	O
PCNA	O
as	O
a	O
real	O
proliferative	O
marker	O
.	O
The	O
objective	O
of	O
our	O
study	O
was	O
to	O
determine	O
which	O
of	O
these	O
cellular	O
proliferation	O
markers	O
is	O
more	O
specific	O
on	O
cellular	O
cycle	O
and	O
could	O
contribute	O
with	O
more	O
information	O
on	O
the	O
cell	O
cycle	O
.	O
We	O
found	O
that	O
PCNA	O
was	O
expressed	O
in	O
NB	B-malignancy-type
unfavourable	O
cases	O
,	O
with	O
MYCN	O
amplification	O
and	O
high	O
mitosis	O
-	O
karyorrhexis	O
-	O
index	O
(	O
MKI	O
)	O
.	O
Whereas	O
,	O
Ki	O
-	O
67	O
showed	O
statistical	O
significance	O
regarding	O
cases	O
unfavourable	O
with	O
intermediate	O
and	O
high	O
MKI	O
,	O
aneuploid	O
and	O
stages	O
3	O
and	O
4	O
.	O
Survival	O
showed	O
that	O
patients	O
with	O
tumor	O
not	O
expressing	O
Ki	O
-	O
67	O
(	O
MIB1	O
)	O
lived	O
longer	O
than	O
those	O
without	O
PCNA	O
(	O
88.93	O
vs	O
74.05	O
%	O
)	O
.	O
We	O
conclude	O
that	O
Ki	O
-	O
67	O
expression	O
permits	O
reliable	O
detection	O
of	O
the	O
cellular	O
proliferation	O
neuroblastoma	B-malignancy-type
fraction	O
and	O
provides	O
useful	O
prognostic	O
information	O
when	O
associated	O
with	O
other	O
biological	O
factors	O
.	O
PMID	O
:	O
12469176	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1986	O
Dec	O
15	O
;261	O
(	O
35	O
)	O
:16414	O
-20	O
.	O
Calcium	O
modulation	O
of	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
-	O
induced	O
calcium	O
release	O
from	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
(	O
NG108	O
-	O
15	O
)	O
microsomes	O
.	O
Jean	O
T	O
,	O
Klee	O
CB	O
.	O
Subcellular	O
fractions	O
of	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
(	O
NG108	O
-	O
15	O
)	O
hybrid	O
cells	O
were	O
used	O
to	O
study	O
the	O
mechanism	O
of	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
-	O
induced	O
calcium	O
release	O
.	O
A	O
microsomal	O
fraction	O
,	O
enriched	O
in	O
endoplasmic	O
reticulum	O
and	O
plasma	O
membranes	O
and	O
almost	O
devoid	O
of	O
mitochondria	O
,	O
was	O
the	O
most	O
active	O
in	O
inositol	O
trisphosphate	O
-	O
or	O
GTP	O
-	O
dependent	O
release	O
of	O
calcium	O
.	O
Neither	O
GTP	O
nor	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
affected	O
the	O
calcium	O
efflux	O
mediated	O
by	O
the	O
other	O
reagent	O
,	O
suggesting	O
that	O
inositol	O
trisphosphate	O
and	O
GTP	O
act	O
on	O
different	O
calcium	O
-	O
sequestrating	O
vesicles	O
.	O
The	O
stimulation	O
of	O
calcium	O
release	O
by	O
GTP	O
was	O
relatively	O
slow	O
(	O
t	O
1	O
/	O
2	O
=	O
90	O
s	O
)	O
,	O
dependent	O
on	O
polyethyleneglycol	O
,	O
and	O
greater	O
at	O
2	O
X	O
10(-5)	O
M	O
calcium	O
(	O
5	O
nmol	O
X	O
min	O
-	O
1	O
X	O
mg	O
-	O
1	O
)	O
than	O
at	O
10(-6)	O
M	O
calcium	O
(	O
0.8	O
nmol	O
X	O
min	O
-	O
1	O
X	O
mg	O
-	O
1	O
)	O
.	O
The	O
inositol	O
trisphosphate	O
-	O
induced	O
calcium	O
efflux	O
was	O
not	O
mimicked	O
by	O
inositol	O
monophosphate	O
;	O
it	O
was	O
fast	O
(	O
t	O
1	O
/	O
2	O
less	O
than	O
10	O
s	O
)	O
and	O
unaffected	O
by	O
3	O
%	O
polyethyleneglycol	O
.	O
The	O
amount	O
of	O
calcium	O
released	O
by	O
inositol	O
trisphosphate	O
was	O
greatest	O
at	O
10(-6)	O
M	O
external	O
calcium	O
(	O
1	O
nmol	O
X	O
min	O
-	O
1	O
X	O
mg	O
-	O
1	O
)	O
and	O
it	O
was	O
undetectable	O
at	O
2	O
X	O
10(-5)	O
M	O
calcium	O
.	O
A	O
feedback	O
inhibition	O
of	O
the	O
inositol	O
trisphosphate	O
-	O
induced	O
calcium	O
release	O
by	O
cytoplasmic	O
calcium	O
provides	O
a	O
safety	O
mechanism	O
preventing	O
deleterious	O
effects	O
of	O
abnormally	O
high	O
calcium	O
levels	O
.	O
PMID	O
:	O
3491073	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
1988	O
Apr;427	O
(	O
2	O
)	O
:95-	O
106	O
.	O
Regulation	O
of	O
viral	O
and	O
cellular	O
genes	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
latently	O
infected	O
with	O
herpes	O
simplex	O
virus	O
type	O
2	O
.	O
Biswal	O
N	O
,	O
Patel	O
AG	O
,	O
Max	O
SR.	O
Division	O
of	O
Molecular	O
Biology	O
,	O
University	O
of	O
Maryland	O
Cancer	O
Center	O
,	O
Baltimore	O
21201	O
.	O
A	O
latent	O
state	O
of	O
the	O
herpes	O
simplex	O
virus	O
type	O
2	O
genome	O
was	O
established	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
(	O
SMS	O
-	O
KCNR	O
)	O
to	O
initiate	O
studies	O
on	O
the	O
mechanism	O
by	O
which	O
host	O
cells	O
interact	O
and	O
regulate	O
latent	O
viral	O
genes	O
.	O
To	O
establish	O
viral	O
latency	O
,	O
it	O
was	O
necessary	O
to	O
prevent	O
virus	O
replication	O
by	O
briefly	O
exposing	O
the	O
infected	O
cells	O
to	O
antiherpetic	O
acycloguanosine	O
(	O
20	O
microM	O
)	O
and	O
human	O
interferon	O
(	O
120	O
U	O
/	O
ml	O
)	O
.	O
Subsequently	O
however	O
,	O
these	O
cells	O
could	O
be	O
propagated	O
without	O
any	O
antiherpetic	O
agents	O
and	O
almost	O
60	O
%	O
of	O
the	O
cell	O
population	O
contained	O
viral	O
genome	O
.	O
While	O
these	O
cells	O
did	O
not	O
produce	O
any	O
infectious	O
virus	O
,	O
immunoblot	O
analysis	O
revealed	O
two	O
intracellular	O
polypeptides	O
with	O
molecular	O
weights	O
of	O
87.5	O
kDa	O
and	O
67	O
kDa	O
,	O
respectively	O
,	O
that	O
interacted	O
with	O
hyperimmune	O
anti	O
-	O
HSV2	O
rabbit	O
serum	O
.	O
Two	O
cellular	O
enzymes	O
,	O
acetylcholinesterase	O
and	O
choline	O
acetyltransferase	O
,	O
involved	O
in	O
metabolism	O
of	O
neurotransmitters	O
were	O
expressed	O
at	O
a	O
higher	O
level	O
in	O
the	O
latently	O
infected	O
cells	O
than	O
in	O
the	O
mock	O
-	O
infected	O
control	O
cells	O
.	O
Infectious	O
HSV	O
-	O
2	O
could	O
be	O
reactivated	O
from	O
these	O
cells	O
only	O
after	O
the	O
cells	O
had	O
undergone	O
massive	O
morphological	O
differentiation	O
and	O
maturation	O
to	O
flat	O
cell	O
types	O
by	O
extensive	O
treatment	O
with	O
20	O
micron	O
bromodeoxyuridine	O
.	O
PMID	O
:	O
2838126	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan;36	O
(	O
1	O
)	O
:93	O
-	O
6.	O
DR	O
-	O
nm23	O
expression	O
affects	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
,	O
integrin	O
expression	O
,	O
and	O
adhesion	O
characteristics	O
.	O
Amendola	O
R	O
,	O
Martinez	O
R	O
,	O
Negroni	O
A	O
,	O
Venturelli	O
D	O
,	O
Tanno	O
B	O
,	O
Calabretta	O
B	O
,	O
Raschella	O
G.	O
Enea	O
,	O
CR	O
-	O
Casaccia	O
,	O
Section	O
of	O
Toxicology	O
and	O
Biomedical	O
Sciences	O
,	O
Rome	O
,	O
Italy	O
PA	O
.	O
amendola@casaccia	O
.enea	O
.it	O
BACKGROUND	O
AND	O
PROCEDURE	O
:	O
Nm23	O
gene	O
family	O
has	O
been	O
associated	O
with	O
metastasis	O
suppression	O
and	O
differentiation	O
.	O
We	O
studied	O
DR	O
-	O
nm23	O
during	O
neuroblastoma	B-malignancy-type
cells	O
differentiation	O
.	O
DR	O
-	O
nm23	O
expression	O
increased	O
after	O
retinoic	O
acid	O
induction	O
of	O
differentiation	O
in	O
human	O
cell	O
lines	O
SK	O
-	O
N	O
-	O
SH	O
and	O
LAN	O
-	O
5	O
.	O
RESULTS	O
:	O
In	O
several	O
cell	O
lines	O
,	O
overexpression	O
of	O
DR	O
-	O
nm23	O
was	O
associated	O
with	O
more	O
differentiated	O
phenotypes	O
.	O
SK	O
-	O
N	O
-	O
SH	O
cells	O
increased	O
vimentin	O
expression	O
,	O
increased	O
deposition	O
of	O
collagen	O
type	O
IV	O
,	O
modulated	O
integrin	O
expression	O
,	O
and	O
underwent	O
growth	O
arrest	O
;	O
the	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
line	O
N1E	O
-	O
115	O
showed	O
neurite	O
outgrowth	O
and	O
a	O
striking	O
enhancement	O
of	O
beta1	O
integrin	O
expression	O
.	O
Up	O
-	O
regulation	O
of	O
beta1	O
integrin	O
was	O
specifically	O
responsible	O
for	O
the	O
increase	O
in	O
the	O
adhesion	O
to	O
collagen	O
type	O
I	O
-	O
coated	O
plates	O
.	O
Finally	O
,	O
cells	O
overexpressing	O
DR	O
-	O
nm23	O
were	O
unable	O
to	O
growth	O
in	O
soft	O
agar	O
.	O
CONCLUSIONS	O
:	O
In	O
conclusion	O
,	O
DR	O
-	O
nm23	O
expression	O
is	O
directly	O
involved	O
in	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
,	O
and	O
its	O
ability	O
to	O
affects	O
the	O
adhesion	O
to	O
extracellular	O
substrates	O
and	O
to	O
inhibit	O
growth	O
in	O
soft	O
agar	O
suggests	O
an	O
involvement	O
in	O
the	O
metastatic	O
potential	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
11464913	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Death	O
Differ	O
.	O
2003	O
Jun;10(	O
6	O
)	O
:698-	O
708	O
.	O
Induced	O
HMGA1a	O
expression	O
causes	O
aberrant	O
splicing	O
of	O
Presenilin	O
-	O
2	O
pre	O
-	O
mRNA	O
in	O
sporadic	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Manabe	O
T	O
,	O
Katayama	O
T	O
,	O
Sato	O
N	O
,	O
Gomi	O
F	O
,	O
Hitomi	O
J,	O
Yanagita	O
T	O
,	O
Kudo	O
T	O
,	O
Honda	O
A	O
,	O
Mori	O
Y	O
,	O
Matsuzaki	O
S	O
,	O
Imaizumi	O
K,	O
Mayeda	O
A	O
,	O
Tohyama	O
M.	O
Department	O
of	O
Anatomy	O
and	O
Neuroscience	O
,	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Osaka	O
University	O
,	O
Suita	O
,	O
Japan	O
.	O
The	O
aberrant	O
splicing	O
isoform	O
(	O
PS2V	O
)	O
,	O
generated	O
by	O
exon	O
5	O
skipping	O
of	O
the	O
Presenilin	O
-	O
2	O
(	O
PS2	O
)	O
gene	O
transcript	O
,	O
is	O
a	O
diagnostic	O
feature	O
of	O
sporadic	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O
We	O
found	O
PS2V	O
is	O
hypoxia	O
-	O
inducible	O
in	O
human	O
neuroblastoma	B-malignancy-type
SK	O
-	O
N	O
-	O
SH	O
cells	O
.	O
We	O
purified	O
a	O
responsible	O
trans	O
-	O
acting	O
factor	O
based	O
on	O
its	O
binding	O
to	O
an	O
exon	O
5	O
fragment	O
.	O
The	O
factor	O
was	O
identified	O
as	O
the	O
high	O
mobility	O
group	O
A1a	O
protein	O
(	O
HMGA1a	O
;	O
formerly	O
HMG	O
-	O
I	O
)	O
.	O
HMGA1a	O
bound	O
to	O
a	O
specific	O
sequence	O
on	O
exon	O
5	O
,	O
located	O
upstream	O
of	O
the	O
5	O
'	O
splice	O
site	O
.	O
HMGA1a	O
expression	O
was	O
induced	O
by	O
hypoxia	O
and	O
the	O
protein	O
was	O
accumulated	O
in	O
the	O
nuclear	O
speckles	O
with	O
the	O
endogenous	O
splicing	O
factor	O
SC35	O
.	O
Overexpression	O
of	O
HMGA1a	O
generated	O
PS2V	O
,	O
but	O
PS2V	O
was	O
repressed	O
by	O
cotransfection	O
with	O
the	O
U1	O
snRNP	O
70	O
K	O
protein	O
that	O
has	O
a	O
strong	O
affinity	O
to	O
HMGA1a	O
.	O
HMGA1a	O
could	O
interfere	O
with	O
U1	O
snRNP	O
binding	O
to	O
the	O
5	O
'	O
splice	O
site	O
and	O
caused	O
exon	O
5	O
skipping	O
.	O
HMGA1a	O
levels	O
were	O
significantly	O
increased	O
in	O
the	O
brain	O
tissue	O
from	O
sporadic	O
AD	O
patients	O
.	O
We	O
propose	O
a	O
novel	O
mechanism	O
of	O
sporadic	O
AD	O
that	O
involves	O
HMGA1a	O
-	O
induced	O
aberrant	O
splicing	O
of	O
PS2	O
pre	O
-	O
mRNA	O
in	O
the	O
absence	O
of	O
any	O
mutations	O
.	O
PMID	O
:	O
12761578	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Pharmacol	O
.	O
1998	O
Mar	O
1;55	O
(	O
5	O
)	O
:	O
567	O
-	O
71	O
.	O
Regulation	O
of	O
methionine	O
adenosyltransferase	O
catalytic	O
activity	O
and	O
messenger	O
RNA	O
in	O
SH	O
-	O
SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Gomes	O
Trolin	O
C	O
,	O
Ekblom	O
J,	O
Oreland	O
L.	O
Department	O
of	O
Medical	O
Pharmacology	O
,	O
Uppsala	O
University	O
,	O
BMC	O
,	O
Sweden	O
.	O
The	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SH	O
-	O
SY5Y	O
was	O
used	O
to	O
study	O
the	O
regulation	O
of	O
methionine	O
adenosyltransferase	O
(	O
MAT	O
II	O
;	O
E.C.2.5	O
.1.6	O
.	O
)	O
catalytic	O
activity	O
and	O
transcript	O
levels	O
in	O
cells	O
of	O
neuronal	O
origin	O
.	O
The	O
cells	O
were	O
exposed	O
for	O
24	O
hr	O
to	O
a	O
medium	O
containing	O
different	O
concentrations	O
of	O
methionine	O
(	O
MAT	O
substrate	O
)	O
as	O
well	O
as	O
medium	O
deficient	O
of	O
methionine	O
.	O
Furthermore	O
,	O
cells	O
were	O
treated	O
with	O
hydroxycobalamin	O
,	O
SAM	O
,	O
and	O
the	O
competitive	O
MAT	O
inhibitor	O
cycloleucine	O
.	O
The	O
MAT	O
catalytic	O
activity	O
was	O
inversely	O
correlated	O
to	O
methionine	O
concentrations	O
,	O
e	O
.	O
g	O
.	O
MAT	O
Vmax	O
increased	O
2	O
-	O
fold	O
in	O
cells	O
grown	O
in	O
methionine	O
-	O
deficient	O
medium	O
as	O
compared	O
with	O
cells	O
cultured	O
under	O
standard	O
conditions	O
.	O
Interestingly	O
,	O
MAT	O
Km	O
also	O
increased	O
from	O
9.04	O
+/-	O
0.44	O
to	O
12.08	O
+/-	O
0.83	O
in	O
the	O
methionine	O
-	O
deficient	O
medium	O
.	O
Hydroxycobalamin	O
caused	O
an	O
increase	O
in	O
activity	O
at	O
40	O
microM	O
while	O
a	O
decrease	O
was	O
observed	O
at	O
higher	O
concentrations	O
(	O
100	O
,	O
200	O
,	O
and	O
400	O
microM	O
)	O
.	O
Cycloleucine	O
caused	O
a	O
significant	O
inhibition	O
of	O
MAT	O
catalytic	O
activity	O
,	O
i	O
.	O
e	O
.	O
the	O
inhibition	O
was	O
approximately	O
50	O
%	O
in	O
the	O
presence	O
of	O
4	O
mM	O
cycloleucine	O
.	O
The	O
relevance	O
of	O
these	O
results	O
for	O
the	O
understanding	O
of	O
observations	O
on	O
MAT	O
catalytic	O
activity	O
in	O
brains	O
of	O
patients	O
with	O
Alzheimer	O
'	O
s	O
disease	O
is	O
discussed	O
.	O
PMID	O
:	O
9515567	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Tissue	O
Antigens	O
.	O
2001	O
Feb;57	O
(	O
2	O
)	O
:	O
110	O
-	O
7.	O
Lack	O
of	O
HLA	O
-	O
class	O
I	O
antigens	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
:	O
analysis	O
of	O
its	O
relationship	O
to	O
TAP	O
and	O
tapasin	O
expression	O
.	O
Corrias	O
MV	O
,	O
Occhino	O
M,	O
Croce	O
M,	O
De	O
Ambrosis	O
A	O
,	O
Pistillo	O
MP	O
,	O
Bocca	O
P,	O
Pistoia	O
V	O
,	O
Ferrini	O
S.	O
Laboratorio	O
di	O
Oncologia	O
,	O
Istituto	O
Scientifico	O
G.	O
Gaslini	O
,	O
Genoa	O
,	O
Italy	O
.	O
We	O
studied	O
the	O
constitutive	O
and	O
the	O
interferon	O
(	O
IFN	O
)	O
-	O
gamma	O
-	O
induced	O
expression	O
of	O
HLA	O
class	O
I	O
antigen	O
heavy	O
chain	O
,	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
,	O
TAP	O
-	O
1	O
,	O
TAP	O
-	O
2	O
and	O
tapasin	O
in	O
a	O
panel	O
of	O
eleven	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Surface	O
expression	O
of	O
HLA	O
class	O
I	O
antigens	O
was	O
low	O
in	O
eight	O
out	O
of	O
eight	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
bearing	O
MYC	O
-	O
N	O
amplification	O
and	O
/	O
or	O
1p	O
deletion	O
,	O
while	O
two	O
out	O
of	O
three	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
lacking	O
these	O
genetic	O
alterations	O
showed	O
normal	O
expression	O
.	O
IFN	O
-	O
gamma	O
treatment	O
restored	O
HLA	O
class	O
I	O
antigen	O
surface	O
expression	O
in	O
all	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Eight	O
out	O
of	O
11	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
did	O
not	O
express	O
TAP	O
-	O
1	O
mRNA	O
and	O
three	O
of	O
them	O
also	O
lacked	O
TAP	O
-	O
2	O
mRNA	O
.	O
beta2	O
m	O
mRNA	O
was	O
barely	O
detectable	O
or	O
absent	O
in	O
five	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
while	O
tapasin	O
mRNA	O
was	O
always	O
expressed	O
.	O
IFN	O
-	O
gamma	O
upregulated	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
heavy	O
chain	O
,	O
beta2	O
m	O
,	O
TAP	O
-	O
1	O
,	O
TAP	O
-	O
2	O
and	O
tapasin	O
,	O
as	O
detected	O
at	O
mRNA	O
or	O
protein	O
level	O
.	O
Post	O
-	O
transcriptional	O
events	O
were	O
involved	O
in	O
altered	O
TAP	O
-	O
1	O
and	O
beta2	O
m	O
expression	O
in	O
one	O
peculiar	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
These	O
data	O
indicate	O
that	O
multiple	O
mechanisms	O
play	O
a	O
role	O
in	O
the	O
HLA	O
class	O
I	O
antigen	O
-	O
deficient	O
phenotype	O
of	O
human	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
11260505	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Clin	O
Pathol	O
.	O
1998	O
May	O
;	O
109	O
(	O
5	O
)	O
:	O
565	O
-	O
70	O
.	O
Genetic	O
changes	O
associated	O
with	O
primary	O
Merkel	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Vortmeyer	O
AO	O
,	O
Merino	O
MJ	O
,	O
Boni	O
R	O
,	O
Liotta	O
LA	O
,	O
Cavazzana	O
A	O
,	O
Zhuang	O
Z	O
.	O
Laboratory	O
of	O
Pathology	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
Merkel	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
(	O
MCC	B-malignancy-type
)	O
is	O
a	O
malignant	O
tumor	O
of	O
the	O
skin	O
with	O
a	O
well	O
-	O
established	O
neuroendocrine	O
phenotype	O
but	O
an	O
unknown	O
histogenetic	O
origin	O
.	O
Cytogenetic	O
and	O
molecular	O
studies	O
have	O
shown	O
evidence	O
for	O
genetic	O
changes	O
on	O
the	O
distal	O
portion	O
of	O
chromosome	O
1	O
p	O
in	O
different	O
tumors	O
with	O
well	O
-	O
established	O
neuroendocrine	O
origins	O
,	O
specifically	O
neuroblastomas	B-malignancy-type
,	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
,	O
and	O
pheochromocytomas	B-malignancy-type
.	O
Involvement	O
of	O
chromosome	O
1	O
in	O
MCC	B-malignancy-type
recently	O
has	O
been	O
demonstrated	O
by	O
cytogenetic	O
analysis	O
and	O
analysis	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
metastatic	O
tumor	O
tissue	O
.	O
We	O
performed	O
analysis	O
of	O
LOH	O
of	O
the	O
distal	O
portion	O
of	O
chromosome	O
1	O
p	O
in	O
paraffin	O
material	O
of	O
10	O
primary	O
MCCs	B-malignancy-type
after	O
tissue	O
microdissection	O
,	O
using	O
the	O
polymorphic	O
markers	O
D	O
1	O
S	O
160	O
,	O
D	O
1	O
S	O
243	O
,	O
D	O
1	O
S	O
468	O
,	O
D	O
1	O
S	O
1646	O
,	O
and	O
D	O
1	O
S	O
1598	O
.	O
Seven	O
of	O
10	O
analyzed	O
MCCs	B-malignancy-type
shared	O
a	O
distal	O
deletion	O
involving	O
1	O
p	O
35	O
-	O
36	O
.	O
None	O
of	O
the	O
cases	O
showed	O
1	O
p	O
involvement	O
proximal	O
to	O
1	O
p	O
35	O
.	O
The	O
findings	O
are	O
similar	O
to	O
those	O
described	O
for	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
,	O
pheochromocytoma	B-malignancy-type
,	O
and	O
neuroblastoma	B-malignancy-type
,	O
tumors	O
known	O
to	O
originate	O
from	O
neural	O
crest	O
cells	O
.	O
In	O
conjunction	O
with	O
previous	O
cytogenetic	O
data	O
,	O
we	O
conclude	O
that	O
Merkel	O
cell	O
carcinogenesis	O
shares	O
pathogenetic	O
mechanisms	O
with	O
other	O
neoplasms	O
of	O
neural	O
crest	O
derivation	O
.	O
PMID	O
:	O
9576574	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Biol	O
Chem	O
.	O
1996	O
Nov	O
29	O
;271(	O
48	O
)	O
:	O
30992	O
-	O
9.	O
Active	O
repression	O
of	O
major	O
histocompatibility	O
complex	O
class	O
I	O
genes	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Murphy	O
C	O
,	O
Nikodem	O
D	O
,	O
Howcroft	O
K,	O
Weissman	O
JD	O
,	O
Singer	O
DS	O
.	O
Experimental	O
Immunology	O
Branch	O
,	O
DBS	O
,	O
NCI	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
-1360	O
,	O
USA	O
.	O
Human	O
neuronal	O
cells	O
express	O
neither	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
RNA	O
nor	O
cell	O
surface	O
molecules	O
but	O
can	O
be	O
induced	O
to	O
do	O
so	O
by	O
various	O
cytokines	O
.	O
In	O
the	O
present	O
studies	O
,	O
we	O
report	O
that	O
expression	O
of	O
MHC	O
class	O
I	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
CHP	O
-	O
126	O
,	O
is	O
actively	O
repressed	O
.	O
This	O
repression	O
is	O
mediated	O
by	O
the	O
combined	O
effects	O
of	O
a	O
series	O
of	O
upstream	O
silencer	O
elements	O
.	O
Removal	O
of	O
the	O
silencers	O
reveals	O
not	O
only	O
an	O
active	O
promoter	O
element	O
but	O
also	O
the	O
presence	O
of	O
an	O
active	O
enhancer	O
.	O
Four	O
silencers	O
have	O
been	O
identified	O
and	O
shown	O
to	O
have	O
distinct	O
sequences	O
,	O
binding	O
factors	O
,	O
and	O
patterns	O
of	O
function	O
.	O
One	O
element	O
is	O
located	O
between	O
-	O
724	O
and	O
-	O
697	O
base	O
pairs	O
(	O
bp	O
)	O
and	O
corresponds	O
to	O
a	O
silencer	O
involved	O
in	O
tissue	O
-	O
specific	O
regulation	O
of	O
class	O
I	O
gene	O
expression	O
.	O
Three	O
additional	O
elements	O
occur	O
between	O
-	O
503	O
and	O
-	O
402	O
bp	O
.	O
One	O
of	O
these	O
corresponds	O
to	O
a	O
c	O
-	O
jun	O
responsive	O
element	O
.	O
Neither	O
of	O
the	O
remaining	O
elements	O
corresponds	O
to	O
DNA	O
sequences	O
known	O
to	O
regulate	O
expression	O
of	O
other	O
genes	O
.	O
These	O
data	O
demonstrate	O
that	O
MHC	O
class	O
I	O
expression	O
normally	O
is	O
actively	O
repressed	O
in	O
neuronal	O
cells	O
and	O
suggest	O
a	O
model	O
of	O
rapid	O
and	O
specific	O
triggering	O
of	O
class	O
I	O
in	O
neuronal	O
cells	O
in	O
response	O
to	O
infection	O
.	O
PMID	O
:	O
8940088	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1998	O
Dec	O
18;253(	O
2	O
)	O
:	O
305	O
-	O
10	O
.	O
Identification	O
of	O
a	O
human	O
cDNA	O
encoding	O
a	O
kinase	O
-	O
defective	O
cdk5	O
isoform	O
.	O
Moorthamer	O
M,	O
Zumstein	O
-Mecker	O
S	O
,	O
Stephan	O
C	O
,	O
Mittl	O
P,	O
Chaudhuri	O
B.	O
Oncology	O
Research	O
,	O
Novartis	O
Pharma	O
AG	O
,	O
Basel	O
,	O
Switzerland	O
.	O
The	O
cyclin	O
-	O
dependent	O
kinase	O
5	O
(	O
Cdk5	O
)	O
catalytic	O
subunit	O
is	O
expressed	O
in	O
both	O
cycling	O
and	O
noncycling	O
cells	O
and	O
is	O
present	O
in	O
many	O
tissues	O
.	O
Neuronal	O
and	O
muscle	O
cells	O
contain	O
the	O
highest	O
amount	O
of	O
this	O
protein	O
.	O
The	O
p35	O
protein	O
,	O
which	O
is	O
expressed	O
solely	O
in	O
the	O
brain	O
,	O
activates	O
Cdk5	O
.	O
Cdk5	O
activity	O
is	O
involved	O
in	O
terminal	O
differentiation	O
of	O
neurons	O
and	O
muscle	O
cells	O
.	O
We	O
attempted	O
to	O
clone	O
cdk5	O
by	O
PCR	O
from	O
a	O
human	O
fetal	O
brain	O
cDNA	O
library	O
.	O
Surprisingly	O
,	O
we	O
amplified	O
two	O
forms	O
of	O
the	O
cdk5	O
gene	O
,	O
the	O
wild	O
type	O
and	O
a	O
cdk5	O
variant	O
that	O
lacks	O
the	O
complete	O
kinase	O
domain	O
VI	O
.	O
The	O
variant	O
is	O
also	O
found	O
in	O
SH	O
-	O
SY	O
-	O
5Y	O
neuroblastoma	B-malignancy-type
cells	O
but	O
not	O
in	O
T	O
-	O
cells	O
,	O
HeLa	O
cells	O
,	O
the	O
thymus	O
,	O
and	O
placental	O
tissue	O
.	O
The	O
protein	O
encoded	O
by	O
the	O
cdk5	O
variant	O
,	O
the	O
Cdk5	O
isoform	O
(	O
Cdk5i	O
)	O
,	O
purifies	O
with	O
p35	O
when	O
coexpressed	O
in	O
insect	O
cells	O
.	O
The	O
activity	O
associated	O
with	O
the	O
heterodimer	O
Cdk5i	O
/	O
p35	O
is	O
found	O
to	O
be	O
appreciably	O
weaker	O
than	O
the	O
wild	O
-	O
type	O
Cdk5	O
/	O
p35	O
kinase	O
.	O
Moreover	O
,	O
Cdk5i	O
/	O
p35	O
cannot	O
autophosphorylate	O
its	O
two	O
subunits	O
as	O
with	O
Cdk5	O
/	O
p35	O
.	O
Interestingly	O
,	O
kinase	O
-	O
defective	O
Cdk5i	O
can	O
abolish	O
the	O
activity	O
of	O
wild	O
-	O
type	O
Cdk5	O
when	O
both	O
are	O
coexpressed	O
with	O
p35	O
in	O
insect	O
cells	O
,	O
suggesting	O
that	O
Cdk5i	O
may	O
have	O
a	O
function	O
in	O
regulating	O
Cdk5	O
activity	O
in	O
human	O
cells	O
too	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
PMID	O
:	O
9878533	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Biochem	O
.	O
1994	O
Apr	O
1;221	O
(	O
1	O
)	O
:227	O
-37	O
.	O
Differential	O
effect	O
of	O
p53	O
on	O
the	O
promoters	O
of	O
mouse	O
DNA	O
polymerase	O
beta	O
gene	O
and	O
proliferating	O
-	O
cell	O
-	O
nuclear	O
-	O
antigen	O
gene	O
.	O
Yamaguchi	O
M,	O
Hayashi	O
Y	O
,	O
Matsuoka	O
S	O
,	O
Takahashi	O
T	O
,	O
Matsukage	O
A	O
.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
Aichi	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Nagoya	O
,	O
Japan	O
.	O
A	O
plasmid	O
carrying	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
mouse	O
proliferating	O
-	O
cell	O
-	O
nuclear	O
-	O
antigen	O
(	O
PCNA	O
)	O
gene	O
or	O
DNA	O
polymerase	O
beta	O
gene	O
was	O
fused	O
with	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
,	O
then	O
cotransfected	O
into	O
mouse	O
N18TG2	O
cells	O
with	O
the	O
expression	O
plasmid	O
for	O
the	O
p53	O
gene	O
.	O
Expression	O
of	O
the	O
wild	O
-	O
type	O
p53	O
repressed	O
the	O
CAT	O
expression	O
directed	O
by	O
the	O
PCNA	O
gene	O
promoter	O
,	O
while	O
it	O
had	O
little	O
effect	O
on	O
the	O
DNA	O
polymerase	O
beta	O
gene	O
promoter	O
.	O
RNase	O
protection	O
analysis	O
revealed	O
that	O
the	O
repression	O
of	O
the	O
PCNA	O
gene	O
promoter	O
by	O
p53	O
was	O
at	O
the	O
transcription	O
step	O
.	O
Analysis	O
with	O
various	O
deletion	O
mutants	O
in	O
the	O
PCNA	O
gene	O
promoter	O
revealed	O
that	O
a	O
specific	O
sequence	O
is	O
not	O
required	O
for	O
the	O
repression	O
,	O
suggesting	O
that	O
p53	O
represses	O
the	O
PCNA	O
gene	O
promoter	O
by	O
interacting	O
with	O
some	O
components	O
of	O
the	O
basic	O
transcription	O
machinery	O
.	O
By	O
analysis	O
with	O
various	O
deletion	O
mutants	O
in	O
the	O
DNA	O
polymerase	O
beta	O
gene	O
promoter	O
,	O
we	O
identified	O
the	O
unique	O
10	O
-	O
bp	O
palindromic	O
sequence	O
(	O
-	O
24	O
to	O
-	O
15	O
)	O
,	O
in	O
the	O
presence	O
of	O
which	O
p53	O
was	O
not	O
able	O
to	O
repress	O
the	O
promoter	O
activity	O
.	O
This	O
sequence	O
conferred	O
resistance	O
to	O
p53	O
repression	O
onto	O
the	O
PCNA	O
gene	O
promoter	O
,	O
when	O
it	O
was	O
placed	O
21	O
-	O
bp	O
upstream	O
from	O
the	O
transcription	O
-	O
initiation	O
site	O
.	O
PMID	O
:	O
7909518	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1987	O
Dec	O
15	O
;47(	O
24	O
Pt	O
1	O
)	O
:6505	O
-	O
10	O
.	O
Differential	O
collagen	O
biosynthesis	O
by	O
human	O
neuroblastoma	B-malignancy-type
cell	O
variants	O
.	O
DeClerck	O
YA	O
,	O
Bomann	O
ET	O
,	O
Spengler	O
BA	O
,	O
Biedler	O
JL.	O
Department	O
of	O
Pediatrics	O
,	O
Childrens	O
'	O
Hospital	O
of	O
Los	O
Angeles	O
,	O
California	O
90027	O
.	O
Two	O
morphologically	O
distinct	O
types	O
of	O
cells	O
have	O
been	O
observed	O
in	O
cultures	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
One	O
,	O
designated	O
N	O
-	O
type	O
,	O
is	O
composed	O
of	O
small	O
neuroblast	O
-	O
like	O
cells	O
;	O
the	O
other	O
,	O
designated	O
S	O
-	O
type	O
,	O
is	O
composed	O
of	O
large	O
,	O
substrate	O
-	O
adherent	O
cells	O
.	O
To	O
obtain	O
additional	O
information	O
on	O
the	O
nature	O
of	O
these	O
two	O
phenotypes	O
,	O
we	O
have	O
investigated	O
the	O
collagen	O
biosynthesis	O
in	O
several	O
clones	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
with	O
N	O
-	O
type	O
,	O
S	O
-	O
type	O
,	O
or	O
mixed	O
morphology	O
,	O
using	O
acrylamide	O
gel	O
electrophoresis	O
,	O
ion	O
exchange	O
chromatography	O
,	O
and	O
Northern	O
and	O
Southern	O
blots	O
.	O
A	O
direct	O
correlation	O
between	O
the	O
proportion	O
of	O
cells	O
with	O
S	O
-	O
type	O
morphology	O
and	O
the	O
amount	O
of	O
collagen	O
secreted	O
was	O
observed	O
,	O
with	O
the	O
largest	O
amount	O
of	O
collagen	O
being	O
produced	O
by	O
clones	O
composed	O
exclusively	O
of	O
S	O
-	O
type	O
cells	O
.	O
Type	O
I	O
trimer	O
and	O
type	O
III	O
collagens	O
were	O
the	O
two	O
major	O
isotypes	O
secreted	O
by	O
these	O
cells	O
.	O
The	O
absence	O
of	O
secretion	O
of	O
the	O
alpha	O
2	O
(	O
I	O
)	O
collagen	O
chain	O
was	O
associated	O
with	O
absence	O
of	O
RNA	O
coding	O
for	O
this	O
protein	O
chain	O
.	O
The	O
pro	O
-	O
alpha	O
2	O
gene	O
of	O
type	O
I	O
collagen	O
was	O
found	O
highly	O
methylated	O
in	O
these	O
cells	O
.	O
Our	O
data	O
indicate	O
that	O
the	O
presence	O
of	O
S	O
-	O
type	O
cells	O
in	O
neuroblastoma	B-malignancy-type
cultures	O
represents	O
a	O
differentiation	O
of	O
these	O
neural	O
crest	O
-	O
derived	O
neuroblastic	O
cells	O
into	O
glial	O
cells	O
such	O
as	O
Schwann	O
cells	O
.	O
PMID	O
:	O
2445473	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Klin	O
Padiatr	O
.	O
2001	O
Jul-	O
Aug;213(	O
4	O
)	O
:	O
18	O
6-	O
90	O
.	O
Traditional	O
and	O
emerging	O
molecular	O
markers	O
in	O
neuroblastoma	B-malignancy-type
prognosis	O
:	O
the	O
good	O
,	O
the	O
bad	O
and	O
the	O
ugly	O
.	O
Poremba	O
C	O
,	O
Hero	O
B	O
,	O
Goertz	O
HG	O
,	O
Scheel	O
C	O
,	O
Wai	O
D	O
,	O
Schaefer	O
KL	O
,	O
Christiansen	O
H,	O
Berthold	O
F	O
,	O
Juergens	O
H,	O
Boecker	O
W	O
,	O
Dockhorn	O
-	O
Dworniczak	O
B.	O
Gerhard	O
-	O
Domagk-	O
Institute	O
of	O
Pathology	O
,	O
Westfalische	O
Wilhelms	O
-University	O
,	O
Domagkstrasse	O
17	O
,	O
48149	O
Munster	O
,	O
Germany	O
.	O
poremba@uni-	O
muenster	O
.de	O
BACKGROUND	O
:	O
Neuroblastomas	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
childhood	O
tumours	O
with	O
a	O
wide	O
range	O
of	O
likelihood	O
for	O
tumour	O
progression	O
.	O
As	O
traditional	O
parameters	O
do	O
not	O
ensure	O
completely	O
accurate	O
prognostic	O
grouping	O
,	O
new	O
molecular	O
markers	O
are	O
needed	O
for	O
assessing	O
the	O
individual	O
patient	O
'	O
s	O
prognosis	O
more	O
precisely	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
133	O
NB	B-malignancy-type
of	O
all	O
stages	O
were	O
analysed	O
in	O
blind	O
-	O
trial	O
fashion	O
for	O
telomerase	O
activity	O
(	O
TA	O
)	O
,	O
expression	O
of	O
surviving	O
,	O
and	O
MYCN	O
status	O
.	O
These	O
data	O
were	O
correlated	O
with	O
other	O
traditional	O
prognostic	O
indicators	O
and	O
disease	O
outcome	O
.	O
RESULTS	O
AND	O
CONCLUSIONS	O
:	O
TA	O
is	O
a	O
powerful	O
independent	O
prognostic	O
marker	O
for	O
all	O
stages	O
and	O
is	O
capable	O
of	O
differentiating	O
between	O
good	O
and	O
poor	O
outcome	O
in	O
putative	O
"	O
favourable	O
"	O
clinical	O
or	O
biological	O
subgroups	O
of	O
NB	B-malignancy-type
patients	O
.	O
High	O
surviving	O
expression	O
is	O
associated	O
with	O
an	O
adverse	O
outcome	O
,	O
but	O
is	O
more	O
difficult	O
to	O
interprete	O
than	O
TA	O
because	O
survivin	O
expression	O
needs	O
to	O
be	O
accurately	O
quantified	O
to	O
be	O
of	O
predictive	O
value	O
.	O
We	O
propose	O
an	O
extended	O
progression	O
model	O
for	O
NB	B-malignancy-type
including	O
emerging	O
prognostic	O
markers	O
,	O
with	O
emphasis	O
on	O
telomerase	O
activity	O
.	O
PMID	O
:	O
11528552	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1991	O
Nov	O
18;293	O
(	O
1-2	O
)	O
:	O
145-	O
8.	O
Phorbol	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
stimulates	O
a	O
differential	O
expression	O
of	O
cholecystokinin	O
(	O
CCK	O
)	O
and	O
c	O
-	O
fos	O
mRNA	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Monstein	O
HJ	O
,	O
Folkesson	O
R.	O
Department	O
of	O
Clinical	O
Biochemistry	O
,	O
State	O
University	O
Hospital	O
Rigshospitalet	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
Regulation	O
of	O
cholecystokinin	O
(	O
CCK	O
)	O
and	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
mRNA	O
expression	O
was	O
studied	O
in	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK	O
-	O
N	O
-	O
MC	O
.	O
Cells	O
were	O
treated	O
either	O
with	O
the	O
tumor	O
promoting	O
phorbol	O
-	O
ester	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
phosphodiesterase	O
inhibitor	O
isobutyl	O
-	O
methylxanthine	O
(	O
IBMX	O
)	O
,	O
which	O
results	O
in	O
an	O
elevated	O
intracellular	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
level	O
,	O
or	O
with	O
a	O
combination	O
of	O
PMA	O
and	O
IBMX	O
.	O
The	O
level	O
of	O
CCK	O
and	O
c	O
-	O
fos	O
mRNA	O
was	O
determined	O
by	O
Northern	O
-	O
blot	O
analysis	O
with	O
CCK	O
and	O
c	O
-	O
fos	O
specific	O
antisense	O
RNA	O
probes	O
after	O
4	O
-	O
24	O
h	O
of	O
drug	O
treatment	O
.	O
Treatment	O
with	O
PMA	O
and	O
IBMX	O
for	O
4	O
-	O
24	O
hours	O
transiently	O
raised	O
the	O
CCK	O
mRNA	O
level	O
approximately	O
1.5	O
-	O
3.5	O
times	O
compared	O
to	O
the	O
controls	O
,	O
and	O
the	O
combination	O
PMA	O
and	O
IBMX	O
had	O
an	O
additive	O
effect	O
and	O
elevated	O
CCK	O
mRNA	O
abundance	O
1.5	O
-	O
6.5	O
times	O
.	O
Under	O
the	O
same	O
experimental	O
conditions	O
,	O
both	O
PMA	O
and	O
IBMX	O
elevated	O
the	O
c	O
-	O
fos	O
mRNA	O
level	O
approximately	O
3	O
-	O
5.5	O
times	O
.	O
The	O
drug	O
combination	O
showed	O
a	O
pronounced	O
synergistic	O
effect	O
and	O
raised	O
the	O
c	O
-	O
fos	O
mRNA	O
level	O
approximately	O
3	O
-	O
20	O
times	O
as	O
compared	O
to	O
controls	O
.	O
Apparently	O
,	O
CCK	O
and	O
c	O
-	O
fos	O
mRNA	O
expression	O
appears	O
to	O
be	O
regulated	O
by	O
similar	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
cAMP	O
-	O
dependent	O
mechanisms	O
in	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
.	O
PMID	O
:	O
1720402	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
N	O
Y	O
Acad	O
Sci	O
.	O
1985	O
;450	O
:43	O
-	O
54	O
.	O
Expression	O
of	O
genes	O
on	O
human	O
chromosome	O
21	O
.	O
Davidson	O
JN	O
,	O
Rumsby	O
G	O
,	O
Niswander	O
LA.	O
Gene	O
sequences	O
were	O
isolated	O
from	O
a	O
lambda	O
library	O
containing	O
inserts	O
originating	O
from	O
human	O
chromosome	O
21	O
.	O
One	O
phage	O
,	O
CP21G1	O
,	O
had	O
been	O
selected	O
on	O
the	O
basis	O
of	O
its	O
lack	O
of	O
middle	O
-	O
repetitive	O
sequences	O
and	O
its	O
ability	O
to	O
hybridize	O
with	O
32P	O
-	O
labeled	O
cDNA	O
synthesized	O
from	O
the	O
cytoplasmic	O
poly	O
A	O
+	O
RNA	O
of	O
cultured	O
fibroblasts	O
.	O
Further	O
experiments	O
revealed	O
that	O
the	O
human	O
insert	O
in	O
this	O
phage	O
is	O
unique	O
-	O
sequence	O
DNA	O
,	O
maps	O
to	O
the	O
long	O
arm	O
of	O
chromosome	O
21	O
,	O
and	O
is	O
expressed	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O
A	O
panel	O
of	O
127	O
"	O
unique	O
-	O
sequence	O
"	O
phage	O
were	O
also	O
selected	O
from	O
the	O
lambda	O
library	O
and	O
were	O
tested	O
for	O
hybridization	O
to	O
32P	O
-	O
labeled	O
cDNA	O
synthesized	O
from	O
the	O
cytoplasmic	O
poly	O
A	O
+	O
RNA	O
of	O
CCRF	O
-	O
HSB	O
-	O
2	O
,	O
a	O
T	O
-	O
blast	O
leukemic	O
line	O
.	O
Seventeen	O
recombinants	O
hybridized	O
to	O
the	O
probe	O
.	O
One	O
of	O
these	O
phages	O
,	O
CP8	O
,	O
contains	O
a	O
human	O
unique	O
-	O
sequence	O
DNA	O
expressed	O
in	O
T	O
cells	O
and	O
neuroblastoma	B-malignancy-type
cells	O
.	O
One	O
phage	O
(	O
CP5	O
)	O
in	O
the	O
"	O
unique	O
-	O
sequence	O
"	O
panel	O
that	O
had	O
not	O
hybridized	O
to	O
cDNA	O
from	O
T	O
-	O
cell	O
RNA	O
was	O
found	O
to	O
carry	O
a	O
low	O
-	O
repeat	O
sequence	O
and	O
to	O
hybridize	O
specifically	O
to	O
RNA	O
from	O
a	O
neuroblastoma	B-malignancy-type
line	O
.	O
This	O
phage	O
appears	O
to	O
carry	O
a	O
brain	O
-	O
specific	O
gene	O
.	O
Many	O
of	O
the	O
genomic	O
sequences	O
related	O
to	O
the	O
low	O
-	O
repeat	O
sequence	O
contained	O
in	O
CP5	O
map	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
21	O
.	O
The	O
cloned	O
genes	O
described	O
here	O
represent	O
new	O
markers	O
for	O
the	O
detailed	O
mapping	O
of	O
human	O
chromosome	O
21	O
and	O
may	O
prove	O
valuable	O
in	O
studying	O
tissue	O
-	O
specific	O
gene	O
regulation	O
.	O
PMID	O
:	O
2409886	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cell	O
Sci	O
.	O
2003	O
Jul	O
1;116	O
(	O
Pt	O
13	O
)	O
:2775	O
-	O
9.	O
Epub	O
2003	O
May	O
20	O
.	O
Specific	O
inhibition	O
of	O
pathological	O
prion	O
protein	O
accumulation	O
by	O
small	O
interfering	O
RNAs	O
.	O
Daude	O
N	O
,	O
Marella	O
M,	O
Chabry	O
J.	O
Institut	O
de	O
Pharmacologie	O
Moleculaire	O
et	O
Cellulaire	O
,	O
Unite	O
Mixte	O
de	O
Recherche	O
6097	O
,	O
Centre	O
National	O
de	O
la	O
Recherche	O
Scientifique	O
.	O
660	O
,	O
route	O
des	O
lucioles	O
,	O
06560	O
Valbonne	O
,	O
France	O
.	O
Development	O
of	O
transmissible	O
spongiform	O
encephalopathies	O
(	O
TSEs	O
)	O
pathogenesis	O
requires	O
the	O
presence	O
of	O
both	O
the	O
normal	O
host	O
prion	O
protein	O
(	O
PrP	O
-	O
sen	O
)	O
and	O
the	O
abnormal	O
pathological	O
proteinase	O
-	O
K	O
resistant	O
isoform	O
(	O
PrP	O
-	O
res	O
)	O
.	O
PrP	O
-	O
res	O
forms	O
highly	O
insoluble	O
aggregates	O
,	O
with	O
self	O
-	O
perpetuating	O
properties	O
,	O
by	O
binding	O
and	O
converting	O
PrP	O
-	O
sen	O
molecules	O
into	O
a	O
likeness	O
of	O
themselves	O
.	O
In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
duplexes	O
trigger	O
specific	O
Prnp	O
gene	O
silencing	O
in	O
scrapie	O
-	O
infected	O
neuroblastoma	B-malignancy-type
cells	O
.	O
A	O
non	O
-	O
passaged	O
,	O
scrapie	O
-	O
infected	O
culture	O
transfected	O
with	O
siRNA	O
duplexes	O
is	O
depleted	O
of	O
PrP	O
-	O
sen	O
and	O
rapidly	O
loses	O
its	O
PrP	O
-	O
res	O
content	O
.	O
The	O
use	O
of	O
different	O
murine	O
-	O
adapted	O
scrapie	O
strains	O
and	O
host	O
cells	O
did	O
not	O
influence	O
the	O
siRNA	O
-	O
induced	O
gene	O
silencing	O
efficiency	O
.	O
More	O
than	O
80	O
%	O
of	O
transfected	O
cells	O
were	O
positive	O
for	O
the	O
presence	O
of	O
fluorescein	O
-	O
labeled	O
siRNA	O
duplexes	O
.	O
No	O
cytotoxicity	O
associated	O
with	O
the	O
use	O
of	O
siRNA	O
was	O
observed	O
during	O
the	O
time	O
course	O
of	O
these	O
experiments	O
.	O
Despite	O
a	O
transient	O
abrogation	O
of	O
PrP	O
-	O
res	O
accumulation	O
,	O
our	O
results	O
suggest	O
that	O
the	O
use	O
of	O
siRNA	O
may	O
provide	O
a	O
new	O
and	O
promising	O
therapeutic	O
approach	O
against	O
prion	O
diseases	O
.	O
PMID	O
:	O
12759373	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Curr	O
Opin	O
Oncol	O
.	O
1997	O
Jan;	O
9	O
(	O
1	O
)	O
:45-54	O
.	O
Familial	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
as	O
a	O
model	O
of	O
hereditary	O
cancer	O
.	O
Anderson	O
RJ	O
,	O
Lynch	O
HT.	O
Department	O
of	O
Preventive	O
Medicine	O
,	O
Creighton	O
University	O
School	O
of	O
Medicine	O
,	O
Omaha	O
,	O
NE	O
68131	O
,	O
USA	O
.	O
Familial	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
are	O
reviewed	O
.	O
The	O
most	O
dramatic	O
advances	O
have	O
been	O
in	O
the	O
application	O
of	O
molecular	O
genetic	O
techniques	O
to	O
define	O
the	O
affected	O
genes	O
and	O
to	O
develop	O
predictive	O
testing	O
for	O
patients	O
with	O
multiple	B-malignancy-type
endocrine	I-malignancy-type
neoplasia	I-malignancy-type
syndromes	O
.	O
Germline	O
mutations	O
at	O
specific	O
loci	O
of	O
the	O
RET	O
proto	O
-	O
oncogene	O
have	O
been	O
demonstrated	O
in	O
patients	O
with	O
multiple	B-malignancy-type
endocrine	I-malignancy-type
neoplasia	I-malignancy-type
types	I-malignancy-type
IIA	I-malignancy-type
,	O
IIB	B-malignancy-type
,	O
and	O
familial	B-malignancy-type
medullary	I-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
not	O
associated	O
with	O
multiple	B-malignancy-type
endocrine	I-malignancy-type
neoplasia	I-malignancy-type
.	O
This	O
has	O
led	O
to	O
direct	O
DNA	O
testing	O
for	O
these	O
mutations	O
in	O
patients	O
at	O
risk	O
for	O
these	O
syndromes	O
.	O
The	O
approach	O
to	O
predictive	O
testing	O
,	O
diagnosis	O
,	O
and	O
early	O
treatment	O
of	O
these	O
patients	O
is	O
discussed	O
as	O
a	O
model	O
for	O
the	O
approach	O
to	O
hereditary	O
cancers	O
.	O
Linkage	O
testing	O
with	O
DNA	O
markers	O
is	O
still	O
required	O
for	O
patients	O
with	O
multiple	B-malignancy-type
endocrine	I-malignancy-type
neoplasia	I-malignancy-type
type	I-malignancy-type
I	I-malignancy-type
because	O
the	O
responsible	O
gene	O
has	O
not	O
yet	O
been	O
isolated	O
.	O
Efforts	O
to	O
clarify	O
the	O
etiologies	O
of	O
other	O
familial	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
not	O
associated	O
with	O
multiple	B-malignancy-type
endocrine	I-malignancy-type
neoplasia	I-malignancy-type
continue	O
.	O
Familial	B-malignancy-type
pheochromocytoma	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
and	O
carcinoid	B-malignancy-type
also	O
are	O
reviewed	O
.	O
The	O
use	O
of	O
molecular	O
genetic	O
techniques	O
as	O
a	O
powerful	O
tool	O
for	O
the	O
early	O
identification	O
and	O
treatment	O
of	O
susceptible	O
individuals	O
is	O
emphasized	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9090493	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1997	O
Mar	O
13;14(	O
10	O
)	O
:	O
1129-	O
36	O
.	O
Identification	O
and	O
characterization	O
of	O
neogenin	O
,	O
a	O
DCC	O
-	O
related	O
gene	O
.	O
Meyerhardt	O
JA	O
,	O
Look	O
AT	O
,	O
Bigner	O
SH	O
,	O
Fearon	O
ER	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
University	O
of	O
Michigan	O
Medical	O
Center	O
,	O
Ann	O
Arbor	O
,	O
USA	O
.	O
DCC	O
(	O
deleted	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
)	O
,	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
located	O
in	O
chromosome	O
band	O
18q21.2	O
,	O
encodes	O
a	O
transmembrane	O
protein	O
of	O
1447	O
amino	O
acids	O
.	O
Neogenin	O
,	O
a	O
protein	O
with	O
nearly	O
50	O
%	O
amino	O
acid	O
identity	O
to	O
DCC	O
,	O
was	O
recently	O
identified	O
because	O
of	O
its	O
dynamic	O
expression	O
in	O
the	O
developing	O
nervous	O
system	O
and	O
gastrointestinal	O
tract	O
of	O
the	O
chicken	O
.	O
To	O
explore	O
a	O
role	O
for	O
the	O
human	O
neogenin	O
(	O
NGN	O
)	O
gene	O
in	O
cancer	O
,	O
we	O
have	O
isolated	O
cDNAs	O
for	O
two	O
alternatively	O
spliced	O
forms	O
of	O
NGN	O
,	O
encoding	O
proteins	O
of	O
1461	O
and	O
1408	O
amino	O
acids	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
studies	O
(	O
FISH	O
)	O
localized	O
NGN	O
in	O
chromosome	O
band	O
15q22	O
,	O
a	O
region	O
infrequently	O
affected	O
by	O
alterations	O
in	O
cancer	O
.	O
NGN	O
transcripts	O
of	O
about	O
7.5	O
and	O
5.5	O
kb	O
were	O
detected	O
in	O
all	O
adult	O
tissues	O
studied	O
.	O
In	O
contrast	O
to	O
the	O
frequent	O
loss	O
of	O
DCC	O
expression	O
,	O
no	O
alterations	O
in	O
NGN	O
expression	O
were	O
observed	O
in	O
more	O
than	O
50	O
cancers	O
studied	O
,	O
including	O
glioblastoma	B-malignancy-type
,	O
medulloblastoma	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
colorectal	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
cervical	B-malignancy-type
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
and	O
xenografts	O
.	O
Based	O
on	O
their	O
sequence	O
conservation	O
and	O
similar	O
expression	O
during	O
development	O
,	O
DCC	O
and	O
NGN	O
may	O
have	O
related	O
functions	O
.	O
However	O
,	O
the	O
chromosomal	O
location	O
and	O
ubiquitous	O
expression	O
of	O
NGN	O
in	O
various	O
human	O
tumors	O
suggest	O
it	O
is	O
infrequently	O
altered	O
in	O
cancer	O
.	O
PMID	O
:	O
9121761	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurobiol	O
Dis	O
.	O
1997;4(	O
5	O
)	O
:	O
356-64	O
.	O
ApoE	O
synthesis	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Dupont	O
-	O
Wallois	O
L,	O
Soulie	O
C	O
,	O
Sergeant	O
N	O
,	O
Wavrant	O
-	O
de	O
Wrieze	O
N	O
,	O
Chartier-Harlin	O
MC	O
,	O
Delacourte	O
A	O
,	O
Caillet-Boudin	O
ML	O
.	O
INSERM	O
U422	O
,	O
Lille	O
,	O
France	O
.	O
Apolipoprotein	O
E	O
(	O
apoE	O
)	O
is	O
associated	O
with	O
the	O
two	O
hallmarks	O
of	O
Alzheimer	O
'	O
s	O
disease	O
:	O
A	O
beta	O
deposits	O
and	O
neurofibrillary	O
tangles	O
.	O
ApoE	O
synthesis	O
was	O
detected	O
in	O
astrocytes	O
by	O
in	O
situ	O
hybridization	O
but	O
was	O
not	O
detected	O
in	O
neurons	O
.	O
Nevertheless	O
,	O
different	O
studies	O
on	O
apoE	O
immunoreactivity	O
reported	O
the	O
presence	O
of	O
apoE	O
in	O
neurons	O
of	O
Alzheimer	O
,	O
control	O
,	O
and	O
necrosis	O
pontisubicular	O
brains	O
.	O
In	O
this	O
study	O
,	O
we	O
addressed	O
the	O
question	O
of	O
potential	O
synthesis	O
of	O
apoE	O
in	O
neurons	O
and	O
its	O
possible	O
involvement	O
in	O
or	O
in	O
response	O
to	O
pathological	O
conditions	O
.	O
To	O
this	O
purpose	O
,	O
we	O
have	O
studied	O
human	O
neuronal	O
cell	O
lines	O
(	O
SY	O
5Y	O
and	O
Kelly	O
cells	O
)	O
originating	O
from	O
neuroblastoma	B-malignancy-type
.	O
Using	O
monoclonal	O
and	O
polyclonal	O
antibodies	O
,	O
a	O
32	O
-	O
kDa	O
band	O
was	O
detected	O
in	O
SY	O
5Y	O
and	O
Kelly	O
cells	O
,	O
before	O
and	O
after	O
NGF	O
differentiation	O
.	O
Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
analysis	O
showed	O
a	O
typical	O
profile	O
of	O
apoE	O
spots	O
resolved	O
to	O
the	O
exact	O
isoelectric	O
points	O
.	O
By	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
experiments	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
apoE	O
mRNA	O
in	O
these	O
cell	O
lines	O
.	O
SY	O
5Y	O
cells	O
synthesized	O
the	O
apoE3	O
variant	O
,	O
whereas	O
Kelly	O
cells	O
expressed	O
both	O
apoE3	O
and	O
apoE4	O
isoforms	O
,	O
corroborating	O
the	O
two	O
-	O
dimensional	O
gel	O
results	O
.	O
These	O
results	O
suggested	O
that	O
apoE	O
synthesis	O
could	O
occur	O
in	O
human	O
neuronal	O
cell	O
lines	O
under	O
certain	O
conditions	O
.	O
PMID	O
:	O
9440124	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Clin	O
Lab	O
Sci	O
.	O
2003	O
Winter;33	O
(	O
1	O
)	O
:68	O
-78	O
.	O
Internalization	O
of	O
beta	O
-	O
amyloid	O
causes	O
downregulation	O
of	O
apolipoprotein	O
E	O
mRNA	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Yamauchi	O
K,	O
Tozuka	O
M,	O
Hidaka	O
E	O
,	O
Ueno	O
I	O
,	O
Matsuda	O
K,	O
Katsuyama	O
T.	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Shinshu	O
University	O
Hospital	O
and	O
Medical	O
School	O
,	O
Asahi	O
,	O
Matsumoto	O
,	O
Japan	O
.	O
yamauchi@hsp.md	O
.shinshu-u.ac.jp	O
Apolipoprotein	O
(	O
apo	O
)	O
E	O
,	O
like	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
,	O
is	O
a	O
key	O
component	O
of	O
the	O
senile	O
plaques	O
that	O
characterize	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O
Understanding	O
how	O
apoE	O
participates	O
in	O
the	O
formation	O
of	O
senile	O
plaques	O
is	O
necessary	O
to	O
clarify	O
the	O
pathogenesis	O
of	O
AD	O
;	O
however	O
,	O
the	O
mechanism	O
remains	O
unknown	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
of	O
cellular	O
apoE	O
and	O
its	O
mRNA	O
level	O
induced	O
by	O
addition	O
of	O
extracellular	O
Abeta	O
to	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
presence	O
of	O
>	O
or	O
=	O
1.0	O
micromol	O
/	O
L	O
of	O
Abeta	O
induced	O
a	O
decrease	O
of	O
apoE	O
mRNA	O
expression	O
and	O
an	O
increase	O
in	O
the	O
immunofluorescence	O
reactivity	O
for	O
intracellular	O
apoE	O
.	O
Both	O
Abeta	O
and	O
apoE	O
were	O
observed	O
by	O
electron	O
-	O
microscopy	O
to	O
be	O
localized	O
within	O
lysosomes	O
.	O
The	O
levels	O
of	O
intracellular	O
apoE	O
and	O
its	O
mRNA	O
returned	O
to	O
the	O
steady	O
state	O
time	O
-	O
dependently	O
.	O
These	O
changes	O
were	O
attenuated	O
by	O
treatments	O
with	O
heparinase	O
I	O
or	O
receptor	O
-	O
associated	O
protein	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
internalized	O
Abeta	O
,	O
along	O
with	O
cellular	O
apoE	O
,	O
induces	O
downregulation	O
of	O
apoE	O
mRNA	O
via	O
a	O
pathway	O
possibly	O
mediated	O
by	O
apoE	O
receptors	O
and	O
heparin	O
sulfate	O
proteoglycans	O
.	O
A	O
disorder	O
of	O
this	O
physiological	O
response	O
could	O
be	O
linked	O
to	O
the	O
development	O
of	O
AD	O
.	O
PMID	O
:	O
12661900	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

New	O
Biol	O
.	O
1990	O
Jun;	O
2	O
(	O
6	O
)	O
:	O
533	O
-43	O
.	O
Sympathetic	O
hyperplasia	O
and	O
neuroblastomas	B-malignancy-type
in	O
transgenic	O
mice	O
expressing	O
polyoma	O
middle	O
T	O
antigen	O
.	O
Aguzzi	O
A	O
,	O
Wagner	O
EF	O
,	O
Williams	O
RL	O
,	O
Courtneidge	O
SA	O
.	O
Laboratory	O
of	O
Neuropathology	O
,	O
University	O
Hospital	O
,	O
Zurich	O
,	O
Switzerland	O
.	O
Transgenic	O
mice	O
carrying	O
a	O
cDNA	O
to	O
the	O
polyoma	O
virus	O
middle	O
T	O
(	O
mT	O
)	O
antigen	O
linked	O
to	O
the	O
thymidine	O
kinase	O
promoter	O
were	O
generated	O
to	O
study	O
the	O
consequences	O
of	O
deregulated	O
expression	O
of	O
mT	O
-	O
associated	O
tyrosine	O
kinase	O
activity	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
.	O
Four	O
independent	O
transgenic	O
founder	O
animals	O
were	O
obtained	O
,	O
from	O
one	O
of	O
which	O
was	O
established	O
a	O
transgenic	O
line	O
.	O
This	O
mouse	O
and	O
all	O
its	O
offspring	O
developed	O
multiple	O
neuroblastomas	B-malignancy-type
between	O
2	O
and	O
3	O
months	O
of	O
age	O
.	O
Expression	O
of	O
the	O
transgene	O
(	O
assayed	O
by	O
tyrosine	O
kinase	O
assay	O
and	O
in	O
situ	O
hybridization	O
)	O
was	O
restricted	O
to	O
the	O
neurons	O
of	O
the	O
central	O
and	O
peripheral	O
nervous	O
tissue	O
,	O
probably	O
because	O
of	O
a	O
positional	O
effect	O
of	O
the	O
transgene	O
integration	O
.	O
Characteristic	O
preneoplastic	O
lesions	O
in	O
the	O
sympathetic	O
ganglia	O
and	O
in	O
the	O
adrenal	O
medulla	O
were	O
identified	O
from	O
which	O
the	O
neuroblastomas	B-malignancy-type
originated	O
.	O
The	O
tumors	O
arising	O
in	O
these	O
mice	O
show	O
striking	O
analogies	O
to	O
human	O
neuroblastomas	B-malignancy-type
,	O
including	O
the	O
sites	O
of	O
development	O
of	O
the	O
tumors	O
,	O
their	O
histological	O
and	O
ultrastructural	O
appearance	O
,	O
and	O
the	O
expression	O
of	O
diagnostic	O
markers	O
,	O
such	O
as	O
synaptophysin	O
,	O
and	O
high	O
expression	O
of	O
the	O
N	O
-	O
myc	O
oncogene	O
.	O
This	O
animal	O
model	O
thus	O
provides	O
a	O
unique	O
tool	O
for	O
studying	O
growth	O
control	O
in	O
sympathetic	O
neuroblasts	O
and	O
the	O
pathogenesis	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
2088503	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurol	O
Med	O
Chir	O
(	O
Tokyo	O
)	O
.	O
2001	O
Dec;41(	O
12	O
)	O
:	O
582	O
-	O
8;	O
discussion	O
589	O
.	O
Brain	O
specific	O
human	O
genes	O
,	O
NELL1	O
and	O
NELL2	O
,	O
are	O
predominantly	O
expressed	O
in	O
neuroblastoma	B-malignancy-type
and	O
other	O
embryonal	B-malignancy-type
neuroepithelial	I-malignancy-type
tumors	I-malignancy-type
.	O
Maeda	O
K,	O
Matsuhashi	O
S	O
,	O
Tabuchi	O
K,	O
Watanabe	O
T	O
,	O
Katagiri	O
T	O
,	O
Oyasu	O
M,	O
Saito	O
N	O
,	O
Kuroda	O
S.	O
Departments	O
of	O
Biochemistry	O
and	O
Neurosurgery	O
,	O
Saga	O
Medical	O
School	O
,	O
Saga	O
,	O
Japan	O
.	O
NELL1	O
and	O
NELL2	O
encode	O
cysteine	O
-	O
rich	O
amino	O
acid	O
sequences	O
including	O
six	O
epidermal	O
growth	O
factor	O
-	O
like	O
motifs	O
,	O
which	O
contain	O
signal	O
peptides	O
at	O
the	O
N	O
-	O
terminals	O
.	O
The	O
deduced	O
amino	O
acid	O
sequences	O
of	O
both	O
genes	O
are	O
55	O
%	O
identical	O
and	O
their	O
cysteine	O
stretch	O
structures	O
are	O
conserved	O
.	O
NELL1	O
is	O
expressed	O
in	O
the	O
brain	O
and	O
kidney	O
,	O
whereas	O
NELL2	O
is	O
expressed	O
specifically	O
in	O
the	O
brain	O
.	O
The	O
cell	O
lineage	O
expressing	O
NELLs	O
in	O
the	O
nervous	O
system	O
was	O
investigated	O
in	O
established	O
cell	O
lines	O
and	O
central	O
nervous	O
system	O
tumor	O
tissues	O
obtained	O
from	O
patients	O
by	O
Northern	O
blot	O
and	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
analyses	O
.	O
NELL1	O
and	O
NELL2	O
were	O
predominantly	O
expressed	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
little	O
expressed	O
in	O
glioblastoma	B-malignancy-type
cell	O
lines	O
.	O
NELL1	O
and	O
NELL2	O
were	O
also	O
expressed	O
in	O
central	O
neurocytoma	B-malignancy-type
,	O
medulloblastoma	B-malignancy-type
,	O
and	O
some	O
astrocytic	B-malignancy-type
tumors	I-malignancy-type
.	O
Immunohistochemical	O
analysis	O
revealed	O
that	O
NELL2	O
protein	O
was	O
localized	O
in	O
the	O
cytoplasm	O
of	O
neurons	O
.	O
These	O
results	O
suggest	O
that	O
NELL2	O
is	O
predominantly	O
expressed	O
in	O
the	O
neuronal	O
cell	O
lineage	O
in	O
the	O
human	O
nervous	O
system	O
.	O
NELL1	O
is	O
expressed	O
mainly	O
in	O
tumors	O
in	O
the	O
neuronal	O
cell	O
lineage	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
11803583	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1998	O
Mar;70	O
(	O
3	O
)	O
:	O
971	O
-	O
82	O
.	O
Transcriptional	O
activation	O
of	O
the	O
mouse	O
peripherin	O
gene	O
by	O
leukemia	B-malignancy-type
inhibitory	O
factor	O
:	O
involvement	O
of	O
STAT	O
proteins	O
.	O
Lecomte	O
MJ	O
,	O
Basseville	O
M,	O
Landon	O
F	O
,	O
Karpov	O
V	O
,	O
Fauquet	O
M.	O
CNRS	O
,	O
URA	O
2115	O
CHU	O
Pitie-Salpetriere	O
,	O
Paris	O
,	O
France	O
.	O
Peripherin	O
is	O
a	O
neuron	O
-	O
specific	O
intermediate	O
filament	O
protein	O
whose	O
expression	O
is	O
activated	O
in	O
vitro	O
by	O
the	O
neuropoietic	O
cytokines	O
leukemia	B-malignancy-type
inhibitory	O
factor	O
(	O
LIF	O
)	O
and	O
interleukin	O
-	O
6	O
.	O
We	O
have	O
studied	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
the	O
peripherin	O
gene	O
by	O
LIF	O
.	O
In	O
particular	O
,	O
we	O
have	O
identified	O
a	O
70	O
-	O
bp	O
element	O
[	O
peripherin	O
cytokine	O
-	O
responsive	O
element	O
(	O
Pe	O
-	O
CyRE	O
)	O
]	O
within	O
the	O
5'	O
-	O
flanking	O
sequences	O
of	O
the	O
mouse	O
peripherin	O
gene	O
(	O
between	O
-	O
930	O
and	O
-	O
860	O
)	O
that	O
enhances	O
transcription	O
in	O
two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
NBFL	O
and	O
LA	O
-	O
N	O
-	O
2	O
,	O
in	O
response	O
to	O
LIF	O
treatment	O
.	O
We	O
have	O
also	O
shown	O
by	O
DNA	O
mobility	O
shift	O
assays	O
that	O
treatment	O
of	O
cells	O
by	O
LIF	O
induces	O
the	O
binding	O
of	O
protein	O
complexes	O
composed	O
of	O
at	O
least	O
two	O
members	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factor	O
family	O
to	O
a	O
cis	O
element	O
(	O
Pe	O
-	O
APRE2	O
)	O
within	O
Pe	O
-	O
CyRE	O
.	O
Furthermore	O
,	O
the	O
entire	O
Pe	O
-	O
CyRE	O
,	O
as	O
well	O
as	O
Pe	O
-	O
APRE2	O
,	O
conferred	O
responsiveness	O
onto	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
.	O
However	O
,	O
the	O
response	O
amplitude	O
of	O
the	O
heterologous	O
promoter	O
to	O
LIF	O
was	O
lower	O
than	O
that	O
observed	O
with	O
the	O
5'	O
-	O
flanking	O
sequences	O
of	O
the	O
peripherin	O
promoter	O
,	O
suggesting	O
that	O
cooperative	O
interactions	O
with	O
surrounding	O
sequences	O
of	O
the	O
peripherin	O
gene	O
are	O
required	O
for	O
a	O
full	O
transcriptional	O
activation	O
.	O
PMID	O
:	O
9489716	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1988	O
May	O
1;61	O
(	O
9	O
)	O
:	O
1821	O
-6.	O
N	O
-	O
myc	O
oncogene	O
expression	O
in	O
histopathologically	O
unrelated	O
bilateral	B-malignancy-type
pediatric	I-malignancy-type
renal	I-malignancy-type
tumors	I-malignancy-type
.	O
Nisen	O
PD	O
,	O
Rich	O
MA	O
,	O
Gloster	O
E	O
,	O
Valderrama	O
E	O
,	O
Saric	O
O	O
,	O
Shende	O
A	O
,	O
Lanzkowsky	O
P,	O
Alt	O
FW	O
.	O
Department	O
of	O
Hematology-Oncology	O
,	O
Schneider	O
Children	O
's	O
Hospital	O
of	O
Long	O
Island	O
Jewish	O
Medical	O
Center	O
,	O
New	O
Hyde	O
Park	O
,	O
NY	O
11042	O
.	O
Renal	B-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
occasionally	O
exhibit	O
histopathologic	O
and	O
clinical	O
features	O
that	O
preclude	O
accurate	O
diagnosis	O
.	O
Molecular	O
and	O
cell	O
culture	O
techniques	O
may	O
be	O
helpful	O
in	O
better	O
characterizing	O
these	O
cases	O
.	O
This	O
approach	O
was	O
used	O
to	O
examine	O
unusual	O
bilateral	B-malignancy-type
renal	I-malignancy-type
tumors	I-malignancy-type
from	O
a	O
young	O
boy	O
.	O
The	O
left	B-malignancy-type
kidney	I-malignancy-type
tumor	I-malignancy-type
was	O
an	O
undifferentiated	O
neoplasm	O
with	O
light	O
microscopic	O
features	O
suggestive	O
of	O
both	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
and	O
neuroblastoma	B-malignancy-type
,	O
and	O
the	O
right	B-malignancy-type
kidney	I-malignancy-type
tumor	I-malignancy-type
was	O
identified	O
as	O
multilocular	B-malignancy-type
cystic	I-malignancy-type
nephroma	I-malignancy-type
(	O
MLCN	B-malignancy-type
)	O
.	O
In	O
vitro	O
tissue	O
culture	O
of	O
tumor	O
cells	O
and	O
hybridization	O
experiments	O
with	O
an	O
N	O
-	O
myc	O
oncogene	O
DNA	O
probe	O
contributed	O
to	O
a	O
revised	O
diagnosis	O
of	O
intrarenal	B-malignancy-type
neuroblastoma	I-malignancy-type
of	O
the	O
left	O
kidney	O
.	O
A	O
cell	O
line	O
established	O
from	O
the	O
left	B-malignancy-type
tumor	I-malignancy-type
exhibited	O
neurite	O
outgrowth	O
and	O
was	O
positive	O
for	O
neuron	O
-	O
specific	O
enolase	O
and	O
synaptophysin	O
.	O
N	O
-	O
myc	O
was	O
greater	O
than	O
ten	O
-	O
fold	O
amplified	O
in	O
chromosomal	O
DNA	O
from	O
the	O
left	B-malignancy-type
kidney	I-malignancy-type
tumor	I-malignancy-type
.	O
Measurement	O
of	O
N	O
-	O
myc	O
RNA	O
expression	O
enabled	O
distinction	O
between	O
benign	O
and	O
malignant	O
tumor	O
tissue	O
.	O
The	O
detection	O
of	O
N	O
-	O
myc	O
gene	O
amplification	O
predicted	O
a	O
poor	O
prognosis	O
which	O
was	O
confirmed	O
by	O
the	O
patient	O
'	O
s	O
subsequent	O
clinical	O
course	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
2833341	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
1989	O
Feb	O
15	O
;43(	O
2	O
)	O
:	O
305	O
-	O
9.	O
Differential	O
expression	O
of	O
N	O
-	O
myc	O
and	O
c	O
-	O
src	O
proto	O
-	O
oncogenes	O
during	O
neuronal	O
and	O
schwannian	O
differentiation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Horii	O
Y	O
,	O
Sugimoto	O
T	O
,	O
Sawada	O
T	O
,	O
Imanishi	O
J,	O
Tsuboi	O
K,	O
Hatanaka	O
M.	O
Department	O
of	O
Pediatrics	O
,	O
Children	O
's	O
Research	O
Hospital	O
,	O
Kyoto	O
,	O
Japan	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cells	O
can	O
be	O
induced	O
to	O
differentiate	O
bidirectionally	O
into	O
either	O
neuronal	O
or	O
schwannian	O
cells	O
by	O
different	O
inducers	O
.	O
However	O
,	O
the	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O
We	O
examined	O
the	O
expression	O
of	O
N	O
-	O
myc	O
and	O
c	O
-	O
src	O
genes	O
in	O
3	O
human	O
NB	B-malignancy-type
-	O
cell	O
lines	O
during	O
either	O
neuronal	O
or	O
schwannian	O
differentiation	O
in	O
vitro	O
,	O
since	O
proto	O
-	O
oncogenes	O
are	O
considered	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
regulating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
Decreased	O
N	O
-	O
myc	O
expression	O
and	O
increased	O
c	O
-	O
src	O
expression	O
were	O
observed	O
during	O
neuronal	O
differentiation	O
by	O
retinoic	O
acid	O
,	O
polyprenoic	O
acid	O
(	O
E5166	O
)	O
and	O
dibutyryl	O
cyclic	O
AMP	O
,	O
whereas	O
the	O
expression	O
of	O
N	O
-	O
myc	O
and	O
c	O
-	O
src	O
genes	O
was	O
considerably	O
reduced	O
during	O
schwannian	O
differentiation	O
by	O
bromodeoxyuridine	O
,	O
demonstrating	O
that	O
the	O
expression	O
of	O
N	O
-	O
myc	O
and	O
c	O
-	O
src	O
genes	O
was	O
regulated	O
independently	O
in	O
the	O
bipolar	O
differentiation	O
processes	O
of	O
NB	B-malignancy-type
cells	O
.	O
Our	O
results	O
suggest	O
that	O
enhanced	O
N	O
-	O
myc	O
expression	O
might	O
be	O
closely	O
linked	O
to	O
the	O
undifferentiated	O
phenotypes	O
of	O
NB	B-malignancy-type
cells	O
,	O
that	O
c	O
-	O
src	O
expression	O
might	O
be	O
related	O
to	O
the	O
neuronal	O
differentiation	O
of	O
NB	B-malignancy-type
cells	O
,	O
and	O
that	O
N	O
-	O
myc	O
and	O
c	O
-	O
src	O
genes	O
might	O
be	O
regulated	O
independently	O
in	O
the	O
determination	O
of	O
the	O
bipolar	O
differentiation	O
of	O
NB	B-malignancy-type
cells	O
.	O
PMID	O
:	O
2917804	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
1997;75	O
(	O
8	O
)	O
:	O
1151	O
-5	O
.	O
Clinical	O
relevance	O
of	O
TRKA	O
expression	O
on	O
neuroblastoma	B-malignancy-type
:	O
comparison	O
with	O
N	O
-	O
MYC	O
amplification	O
and	O
CD44	O
expression	O
.	O
Combaret	O
V	O
,	O
Gross	O
N	O
,	O
Lasset	O
C	O
,	O
Balmas	O
K,	O
Bouvier	O
R	O
,	O
Frappaz	O
D	O
,	O
Beretta-Brognara	O
C	O
,	O
Philip	O
T	O
,	O
Favrot	O
MC	O
,	O
Coll	O
JL.	O
Departement	O
de	O
Biologie	O
des	O
Tumeurs	O
,	O
Centre	O
Leon	O
Berard	O
,	O
Lyon	O
,	O
France	O
.	O
TRKA	O
expression	O
was	O
evaluated	O
on	O
122	O
untreated	O
neuroblastomas	B-malignancy-type
by	O
immunohistochemistry	O
using	O
an	O
antibody	O
with	O
predetermined	O
specificity	O
.	O
This	O
procedure	O
is	O
simple	O
and	O
reliable	O
for	O
protein	O
detection	O
at	O
cellular	O
level	O
in	O
a	O
routine	O
clinical	O
setting	O
.	O
Fourteen	O
tumours	O
were	O
classified	O
as	O
benign	O
ganglioneuroma	B-malignancy-type
with	O
a	O
restricted	O
expression	O
of	O
TRKA	O
on	O
ganglion	O
cells	O
;	O
these	O
patients	O
were	O
excluded	O
from	O
the	O
following	O
analysis	O
.	O
A	O
total	O
of	O
108	O
tumours	O
were	O
classified	O
as	O
neuroblastoma	B-malignancy-type
or	O
ganglioneuroblastoma	B-malignancy-type
;	O
74	O
expressed	O
TRKA	O
protein	O
,	O
which	O
strongly	O
correlated	O
with	O
low	O
stage	O
,	O
absence	O
of	O
N	O
-	O
MYC	O
amplification	O
,	O
age	O
(	O
<	O
1	O
year	O
)	O
,	O
CD44	O
expression	O
and	O
favourable	O
clinical	O
outcome	O
.	O
In	O
a	O
univariate	O
analysis	O
including	O
tumour	O
stage	O
,	O
age	O
,	O
histology	O
,	O
N	O
-	O
MYC	O
amplification	O
,	O
CD44	O
and	O
TRKA	O
expression	O
,	O
all	O
parameters	O
had	O
significant	O
prognostic	O
value	O
.	O
The	O
absence	O
of	O
TRKA	O
expression	O
on	O
CD44	O
-	O
positive	O
or	O
N	O
-	O
MYC	O
non	O
-	O
amplified	O
tumours	O
permits	O
the	O
characterization	O
of	O
a	O
subgroup	O
of	O
patients	O
with	O
intermediate	O
prognosis	O
.	O
However	O
,	O
in	O
a	O
multivariate	O
analysis	O
taking	O
into	O
consideration	O
the	O
prognostic	O
factors	O
mentioned	O
above	O
,	O
CD44	O
and	O
tumour	O
stage	O
were	O
the	O
only	O
independent	O
prognostic	O
factors	O
for	O
the	O
prediction	O
of	O
patients	O
'	O
event	O
-	O
free	O
survival	O
.	O
PMID	O
:	O
9099963	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Mol	O
Med	O
.	O
1999	O
Jun;	O
3	O
(	O
6	O
)	O
:	O
58	O
5	O
-	O
9.	O
Variable	O
expression	O
and	O
absence	O
of	O
mutations	O
in	O
p73	O
in	O
primary	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
argues	O
against	O
a	O
role	O
in	O
neuroblastoma	B-malignancy-type
development	O
.	O
Ejeskar	O
K,	O
Sjoberg	O
RM	O
,	O
Kogner	O
P,	O
Martinsson	O
T.	O
Department	O
of	O
Clinical	O
Genetics	O
,	O
University	O
of	O
Gothenburg	O
,	O
Sahlgrenska	O
University	O
Hospital	O
/	O
East	O
,	O
S-	O
416	O
85	O
Gothenburg	O
,	O
Sweden	O
.	O
In	O
neuroblastoma	B-malignancy-type
,	O
a	O
childhood	O
tumor	O
of	O
neural	O
crest	O
,	O
a	O
tumor	O
suppressor	O
gene	O
located	O
at	O
1p36	O
has	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
tumor	O
aggressiveness	O
and	O
clinical	O
prognosis	O
.	O
We	O
have	O
examined	O
30	O
different	O
staged	O
primary	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
using	O
RT	O
-	O
PCR	O
,	O
for	O
expression	O
of	O
the	O
p73	O
gene	O
located	O
at	O
1p36.3	O
,	O
and	O
its	O
correlation	O
to	O
other	O
clinical	O
and	O
biological	O
features	O
of	O
these	O
tumors	O
.	O
No	O
correlation	O
between	O
expression	O
of	O
p73	O
and	O
MYCN	O
-	O
amplification	O
or	O
1p	O
-	O
deletion	O
could	O
be	O
found	O
,	O
five	O
of	O
ten	O
1p	O
-	O
deleted	O
tumors	O
showed	O
detectable	O
levels	O
of	O
p73	O
,	O
and	O
no	O
mutations	O
could	O
be	O
detected	O
,	O
neither	O
in	O
the	O
retained	O
alleles	O
nor	O
in	O
any	O
other	O
parts	O
of	O
the	O
material	O
.	O
In	O
five	O
1p	O
-	O
deleted	O
cases	O
the	O
origin	O
of	O
deletion	O
were	O
determined	O
,	O
two	O
were	O
of	O
maternal	O
and	O
three	O
of	O
paternal	O
origin	O
.	O
Both	O
tumors	O
with	O
maternal	O
1p	O
-	O
loss	O
showed	O
detectable	O
levels	O
of	O
p73	O
,	O
whereas	O
the	O
three	O
with	O
paternal	O
loss	O
did	O
not	O
.	O
This	O
suggests	O
that	O
p73	O
is	O
expressed	O
from	O
the	O
paternal	O
allele	O
only	O
in	O
advanced	O
staged	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
.	O
Furthermore	O
,	O
it	O
suggests	O
absence	O
of	O
correlation	O
between	O
p73	O
-	O
expression	O
and	O
stage	O
in	O
these	O
tumors	O
.	O
In	O
conclusion	O
,	O
we	O
could	O
find	O
no	O
evidence	O
for	O
p73	O
being	O
the	O
neuroblastoma	B-malignancy-type
tumor	O
suppressor	O
gene	O
in	O
1p36	O
.	O
PMID	O
:	O
10341287	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Res	O
.	O
1990	O
Jan;27	O
(	O
1	O
)	O
:	O
1-6.	O
A	O
new	O
human	O
highly	O
tumorigenic	O
neuroblastoma	B-malignancy-type
cell	O
line	O
with	O
undetectable	O
expression	O
of	O
N-myc	O
.	O
Cornaglia-Ferraris	O
P,	O
Ponzoni	O
M,	O
Montaldo	O
P,	O
Mariottini	O
GL	O
,	O
Donti	O
E	O
,	O
Di	O
Martino	O
D	O
,	O
Tonini	O
GP	O
.	O
Pediatric	O
Oncology	O
Research	O
Laboratory	O
,	O
G.	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genoa	O
,	O
Italy	O
.	O
A	O
peculiar	O
human	O
cell	O
line	O
(	O
GI-ME-N	O
)	O
derived	O
from	O
the	O
metastatic	O
bone	O
marrow	O
of	O
a	O
2-yr	O
-	O
old	O
patient	O
with	O
stage	O
IV	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
was	O
extensively	O
characterized	O
.	O
Cell	O
-type	O
-	O
specific	O
markers	O
,	O
tumorigenicity	O
in	O
nude	O
mice	O
,	O
morphology	O
,	O
cytogenetics	O
,	O
and	O
amplification	O
/	O
expression	O
of	O
the	O
N-myc	O
gene	O
were	O
evaluated	O
.	O
All	O
metaphases	O
presented	O
the	O
typical	O
1p	O
deletion	O
.	O
Surface	O
markers	O
specific	O
for	O
NB	B-malignancy-type
cells	O
,	O
vimentin	O
,	O
and	O
neurofilament	O
proteins	O
were	O
all	O
clearly	O
detectable	O
with	O
immunofluorescence	O
and/or	O
western	O
blot	O
procedures	O
.	O
Moreover	O
,	O
it	O
was	O
found	O
that	O
GI-ME-N	O
cells	O
did	O
not	O
express	O
N-myc	O
oncogene	O
or	O
HLA	O
class	O
1	O
antigens	O
,	O
and	O
were	O
not	O
classified	O
as	O
peripheral	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
cells	O
.	O
However	O
,	O
extremely	O
short	O
latency	O
and	O
survival	O
times	O
,	O
comparable	O
to	O
peripheral	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
cells	O
,	O
were	O
observed	O
in	O
nude	O
mice	O
grafted	O
with	O
GI-ME-N	O
.	O
In	O
addition	O
,	O
no	O
correlations	O
were	O
observed	O
in	O
tumorigenicity	O
of	O
N-myc	O
amplified	O
(	O
IMR32	O
)	O
versus	O
unamplified	O
(	O
SK-N-SH	O
GI-ME-N	O
)	O
human	O
NB	B-malignancy-type
cell	O
lines	O
in	O
nude	O
mice	O
.	O
We	O
conclude	O
that	O
N-myc	O
amplification	O
/	O
expression	O
do	O
not	O
correlate	O
with	O
the	O
aggressiveness	O
of	O
human	O
NB	B-malignancy-type
in	O
athymic	O
animals	O
,	O
which	O
is	O
not	O
always	O
explained	O
by	O
the	O
peripheral	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
cell	O
nature	O
of	O
the	O
malignant	O
cells	O
,	O
either	O
.	O
PMID	O
:	O
2296463	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
1993	O
Aug;68(	O
2	O
)	O
:	O
385-	O
8.	O
High	O
levels	O
of	O
Nm23	O
gene	O
expression	O
in	O
advanced	O
stage	O
of	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Zou	O
M,	O
Shi	O
Y	O
,	O
al-Sedairy	O
S	O
,	O
Farid	O
NR.	O
Department	O
of	O
Medicine	O
,	O
King	O
Faisal	O
Specialist	O
Hospital	O
and	O
Research	O
Centre	O
,	O
Riyadh	O
,	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O
The	O
product	O
of	O
Nm23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
candidate	O
tumour	O
metastasis	O
suppressor	O
protein	O
.	O
A	O
strong	O
association	O
has	O
been	O
observed	O
between	O
reduced	O
expression	O
of	O
Nm23	O
gene	O
and	O
acquisition	O
of	O
metastatic	O
behaviour	O
in	O
some	O
tumour	O
cells	O
including	O
breast	B-malignancy-type
cancer	I-malignancy-type
and	O
melanoma	B-malignancy-type
,	O
but	O
not	O
in	O
others	O
such	O
as	O
colon	B-malignancy-type
cancer	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
and	O
cervical	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
abundance	O
of	O
Nm23	O
mRNA	O
in	O
39	O
thyroid	O
tissue	O
specimens	O
including	O
five	O
multinodular	O
goitres	O
,	O
one	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
26	O
papillary	B-malignancy-type
and	O
three	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
four	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Nm23	O
was	O
found	O
to	O
be	O
expressed	O
in	O
all	O
the	O
tissue	O
specimens	O
.	O
The	O
expression	O
was	O
,	O
however	O
,	O
variable	O
in	O
different	O
stages	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
stages	O
I	O
through	O
III	O
of	O
differentiated	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
,	O
the	O
average	O
level	O
of	O
Nm23	O
gene	O
expression	O
was	O
comparable	O
to	O
that	O
in	O
multinodular	O
goitres	O
.	O
In	O
advanced	O
stage	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
(	O
stage	O
IV	O
and	O
anaplastic	B-malignancy-type
)	O
,	O
2	O
-	O
fold	O
increase	O
of	O
Nm23	O
expression	O
was	O
noted	O
.	O
No	O
mutations	O
were	O
found	O
in	O
the	O
coding	O
region	O
of	O
the	O
gene	O
.	O
Nm23	O
mRNA	O
level	O
cannot	O
,	O
therefore	O
,	O
be	O
used	O
as	O
a	O
marker	O
of	O
low	O
metastatic	O
potential	O
in	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
association	O
of	O
high	O
level	O
Nm23	O
expression	O
with	O
anaplastic	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
suggests	O
its	O
correlation	O
with	O
rapid	O
cell	O
proliferation	O
.	O
PMID	O
:	O
8394105	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1997	O
Feb;68(	O
2	O
)	O
:	O
554	O
-63	O
.	O
Synthesis	O
and	O
cytotoxic	O
profile	O
of	O
a	O
diphtheria	O
toxin	O
-	O
neurotrophin	O
-	O
4	O
chimera	O
.	O
Negro	O
A	O
,	O
Skaper	O
SD.	O
Department	O
of	O
Biological	O
Chemistry	O
,	O
CRIBI	O
,	O
University	O
of	O
Padova	O
,	O
Italy	O
.	O
A	O
diphtheria	O
toxin	O
-	O
neurotrophin	O
-	O
4/	O
5	O
(	O
NT-4/	O
5	O
)	O
chimera	O
(	O
DAB389	O
-	O
NT4	O
)	O
,	O
in	O
which	O
the	O
native	O
receptor	O
binding	O
domain	O
of	O
diphtheria	O
toxin	O
was	O
replaced	O
with	O
a	O
synthetic	O
gene	O
encoding	O
rat	O
NT-4/	O
5	O
,	O
was	O
expressed	O
,	O
refolded	O
,	O
and	O
purified	O
.	O
This	O
fusion	O
toxin	O
has	O
a	O
deduced	O
molecular	O
mass	O
of	O
60,163	O
and	O
is	O
formed	O
by	O
joining	O
the	O
first	O
389	O
amino	O
acids	O
of	O
diptheria	O
toxin	O
to	O
amino	O
acids	O
1-130	O
of	O
mature	O
rat	O
NT-4/	O
5	O
,	O
using	O
an	O
NH2-terminal	O
bridge	O
of	O
33	O
additional	O
amino	O
acids	O
including	O
six	O
consecutive	O
histidines	O
.	O
Neural	O
cell	O
types	O
expressing	O
only	O
p75LNGFR	O
or	O
p75LNGFR	O
and	O
full	O
-	O
length	O
or	O
truncated	O
TrkB	O
were	O
used	O
to	O
evaluate	O
the	O
cytotoxic	O
efficacy	O
of	O
DAB389	O
-	O
NT4	O
.	O
The	O
fusion	O
toxin	O
produced	O
a	O
concentration	O
-	O
dependent	O
killing	O
of	O
all	O
cell	O
populations	O
,	O
with	O
LC50	O
values	O
that	O
largely	O
reflected	O
the	O
known	O
NT-4/	O
5	O
binding	O
affinities	O
for	O
these	O
receptor	O
proteins	O
.	O
Mean	O
LC50	O
values	O
ranged	O
from	O
2,960	O
pM	O
in	O
p75LNGFR	O
-	O
expressing	O
neuro-2a	O
neuroblastoma	B-malignancy-type
cells	O
to	O
1,075	O
and	O
70	O
pM	O
,	O
respectively	O
,	O
in	O
hippocampal	O
astrocytes	O
(	O
p75LNGFR	O
+	O
/truncated	O
TrkB	O
+	O
)	O
and	O
cerebellar	O
granule	O
cells	O
(	O
p75LNGFR	O
+	O
/	O
TrkB	O
+	O
)	O
.	O
The	O
LC50	O
for	O
DAB389	O
-	O
NT4	O
in	O
receptor	O
-	O
negative	O
3T3	O
fibroblasts	O
was	O
20	O
nM	O
.	O
NT-4/	O
5	O
and	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
but	O
not	O
ciliary	O
neurotrophic	O
factor	O
added	O
in	O
excess	O
neutralized	O
DAB389	O
-	O
NT4	O
cytotoxicity	O
.	O
NT-4/	O
5	O
,	O
however	O
,	O
did	O
not	O
reduce	O
the	O
cytotoxicity	O
of	O
intact	O
diphtheria	O
toxin	O
.	O
PMID	O
:	O
9003040	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biochem	O
(	O
Tokyo	O
)	O
.	O
1991	O
Jul;110(	O
1	O
)	O
:	O
146-50	O
.	O
Down	O
modulation	O
of	O
N-myc	O
,	O
heat	O
-	O
shock	O
protein	O
70	O
,	O
and	O
nucleolin	O
during	O
the	O
differentiation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Murakami	O
T	O
,	O
Ohmori	O
H,	O
Gotoh	O
S	O
,	O
Tsuda	O
T	O
,	O
Ohya	O
R	O
,	O
Akiya	O
S	O
,	O
Higashi	O
K.	O
Department	O
of	O
Biochemistry	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Occupational	O
and	O
Environmental	O
Health	O
,	O
Fukuoka	O
.	O
Cultured	O
human	O
neuroblastoma	B-malignancy-type
(	O
GOTO	O
)	O
cells	O
were	O
induced	O
to	O
differentiate	O
by	O
dibutyryl	O
cyclic	O
AMP	O
(	O
Bt2cAMP	O
)	O
and/or	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O
A	O
combination	O
of	O
Bt2cAMP	O
(	O
1	O
mM	O
)	O
and	O
RA	O
(	O
1	O
microM	O
)	O
yielded	O
the	O
most	O
significant	O
networks	O
of	O
neurites	O
after	O
3	O
to	O
4	O
days	O
,	O
this	O
being	O
associated	O
with	O
the	O
reduction	O
of	O
N-myc	O
mRNA	O
levels	O
.	O
Next	O
,	O
we	O
examined	O
several	O
cellular	O
genes	O
that	O
were	O
possibly	O
linked	O
with	O
changes	O
in	O
N-myc	O
gene	O
expression	O
under	O
these	O
conditions	O
.	O
Among	O
the	O
genes	O
examined	O
,	O
both	O
nucleolin	O
and	O
a	O
major	O
heat	O
-	O
shock	O
protein	O
(	O
hsp70	O
)	O
mRNAs	O
showed	O
changes	O
concomitant	O
with	O
those	O
in	O
N-myc	O
mRNA	O
levels	O
when	O
induced	O
by	O
Bt2cAMP	O
and	O
RA.	O
Dibutyryl	O
cAMP	O
alone	O
induced	O
several	O
short	O
cellular	O
processes	O
and	O
caused	O
a	O
marked	O
decrease	O
in	O
N-myc	O
mRNA	O
within	O
2	O
days	O
.	O
RA	O
alone	O
induced	O
a	O
few	O
long	O
and	O
straight	O
neurites	O
along	O
the	O
longitudinal	O
axis	O
of	O
individual	O
cells	O
and	O
a	O
significant	O
decrease	O
in	O
growth	O
rate	O
but	O
showed	O
neither	O
network	O
formation	O
nor	O
a	O
decrease	O
in	O
N-myc	O
gene	O
expression	O
.	O
These	O
results	O
indicate	O
differential	O
effects	O
of	O
Bt2cAMP	O
and	O
RA	O
on	O
the	O
regulatory	O
mechanisms	O
of	O
both	O
cell	O
proliferation	O
and	O
differentiation	O
and	O
also	O
indicate	O
a	O
possible	O
association	O
of	O
expression	O
of	O
N-myc	O
gene	O
with	O
those	O
of	O
hsp70	O
and	O
nucleolin	O
genes	O
.	O
PMID	O
:	O
1657899	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
1982	O
;10(	O
4	O
)	O
:	O
321-30	O
.	O
Immune	O
evaluation	O
of	O
50	O
children	O
with	O
neuroblastoma	B-malignancy-type
at	O
onset	O
.	O
Rosanda	O
C	O
,	O
De	O
Bernardi	O
B	O
,	O
Pasino	O
M,	O
Bisogni	O
MC	O
,	O
Maggio	O
A	O
,	O
Haupt	O
R	O
,	O
Tonini	O
GP	O
,	O
Ponzoni	O
M.	O
Several	O
studies	O
document	O
the	O
importance	O
of	O
immunity	O
in	O
the	O
host	O
-	O
tumor	O
relationship	O
in	O
neuroblastoma	B-malignancy-type
patients	O
,	O
evidentiating	O
a	O
correlation	O
between	O
clinical	O
compromission	O
and	O
immune	O
impairment	O
.	O
In	O
this	O
study	O
we	O
evaluated	O
some	O
aspects	O
of	O
cellular	O
and	O
humoral	O
immune	O
capacity	O
in	O
50	O
neuroblastoma	B-malignancy-type
patients	O
at	O
onset	O
.	O
The	O
aim	O
of	O
this	O
investigation	O
was	O
to	O
define	O
,	O
if	O
any	O
,	O
the	O
common	O
immune	O
pattern	O
of	O
these	O
patients	O
,	O
and	O
to	O
evidentiate	O
a	O
possible	O
correlation	O
with	O
prognosis	O
.	O
Immune	O
tests	O
performed	O
were	O
serum	O
immunoglobulin	O
quantitation	O
,	O
absolute	O
value	O
of	O
total	O
T	O
and	O
B	O
lymphocytes	O
,	O
and	O
lymphocyte	O
reactivity	O
to	O
phytohemagglutinin	O
(	O
PHA	O
)	O
,	O
Concanavalin	O
A	O
(	O
ConA	O
)	O
,	O
and	O
Pokeweed	O
mitogen	O
(	O
PWM	O
)	O
.	O
In	O
patients	O
with	O
localized	O
or	O
regional	O
disease	O
,	O
diminished	O
values	O
of	O
lymphocytes	O
were	O
observed	O
in	O
4	O
/	O
16	O
cases	O
,	O
a	O
datum	O
highly	O
correlated	O
to	O
a	O
poor	O
final	O
outcome	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
Mitogen	O
response	O
and	O
serum	O
immunoglobulin	O
levels	O
were	O
frequently	O
altered	O
,	O
but	O
no	O
prognostic	O
value	O
was	O
evidentiated	O
.	O
Thirty-one	O
children	O
with	O
disseminated	O
disease	O
presented	O
more	O
frequent	O
and	O
extended	O
abnormalities	O
:	O
No	O
parameter	O
was	O
found	O
to	O
correlate	O
with	O
prognosis	O
,	O
except	O
for	O
an	O
impaired	O
PHA	O
response	O
that	O
paradoxically	O
assumed	O
a	O
favourable	O
prognostic	O
meaning	O
.	O
Our	O
results	O
suggest	O
that	O
only	O
the	O
total	O
lymphocyte	O
number	O
can	O
contribute	O
to	O
predict	O
the	O
survival	O
ratio	O
in	O
patients	O
with	O
regional	O
disease	O
.	O
PMID	O
:	O
6981051	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Toxicol	O
In	O
Vitro	O
.	O
2003	O
Jun;17(	O
3	O
)	O
:	O
367	O
-	O
73	O
.	O
Ara-	O
C	O
induces	O
apoptosis	O
in	O
monkey	O
fibroblast	O
cells	O
.	O
Manakova	O
S	O
,	O
Puttonen	O
KA	O
,	O
Raasmaja	O
A	O
,	O
Mannisto	O
PT.	O
Department	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Kuopio	O
,	O
PO	O
Box	O
1627	O
,	O
FIN-70211	O
,	O
Kuopio	O
,	O
Finland	O
.	O
manakova@uku.fi	O
The	O
effect	O
of	O
cytosine	O
arabinoside	O
(	O
Ara-C	O
)	O
on	O
cell	O
viability	O
has	O
been	O
studied	O
in	O
African	O
green	O
monkey	O
kidney	O
fibroblasts	O
(	O
CV1	O
-P	O
)	O
.	O
It	O
has	O
been	O
shown	O
previously	O
that	O
Ara-C	O
-	O
induced	O
cell	O
death	O
in	O
neurons	O
is	O
mediated	O
by	O
apoptosis	O
.	O
We	O
investigated	O
whether	O
Ara-	O
C	O
can	O
induce	O
apoptosis	O
also	O
in	O
CV1	O
-	O
P	O
cells	O
,	O
and	O
if	O
the	O
apoptosis	O
is	O
p53	O
-associated	O
.	O
For	O
comparison	O
,	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
SH-SY5Y	O
)	O
were	O
studied	O
as	O
a	O
model	O
of	O
human	O
neuronal	O
cells	O
.	O
SYTO13	O
/	O
propidium	O
iodide	O
staining	O
revealed	O
condensed	O
and	O
fragmented	O
nuclei	O
in	O
both	O
cell	O
lines	O
.	O
Ara-	O
C	O
treatment	O
for	O
48	O
h	O
induced	O
approximately	O
24	O
%	O
apoptosis	O
in	O
CV1	O
-	O
P	O
cells	O
whereas	O
approximately	O
55	O
%	O
of	O
SH-SY5Y	O
cells	O
were	O
apoptotic	O
.	O
Ara-	O
C	O
increased	O
the	O
level	O
of	O
p53	O
in	O
both	O
CV1	O
-	O
P	O
and	O
SH-SY5Y	O
cells	O
compared	O
to	O
control	O
.	O
The	O
maximum	O
level	O
of	O
p53	O
in	O
SH-SY5Y	O
cells	O
was	O
reached	O
at	O
12	O
h	O
and	O
this	O
then	O
rapidly	O
faded	O
whereas	O
CV1	O
-	O
P	O
cells	O
p53	O
levels	O
remained	O
elevated	O
after	O
reaching	O
their	O
maximum	O
.	O
Caspase-3	O
activity	O
was	O
5	O
-	O
fold	O
higher	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
than	O
in	O
monkey	O
fibroblasts	O
,	O
this	O
reflected	O
the	O
decreased	O
cell	O
viability	O
.	O
Our	O
results	O
prove	O
that	O
Ara-C	O
-	O
induced	O
apoptosis	O
in	O
CV1	O
-	O
P	O
cells	O
is	O
associated	O
with	O
an	O
increase	O
of	O
p53	O
and	O
activation	O
of	O
caspase-3	O
.	O
Ara-C	O
-	O
induced	O
toxicity	O
in	O
CV1	O
-	O
P	O
cells	O
is	O
modest	O
compared	O
to	O
that	O
seen	O
in	O
neuronal	O
cells	O
.	O
PMID	O
:	O
12781215	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1998	O
Nov	O
27;440	O
(	O
1-2	O
)	O
:25-	O
8.	O
Down	O
-	O
regulation	O
of	O
protein	O
kinase	O
C	O
alpha	O
and	O
gamma	O
and	O
enhanced	O
TPA	O
-	O
induced	O
neurite	O
formation	O
in	O
DAN	O
-	O
transfected	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Hiwasa	O
T	O
,	O
Nakamura	O
Y	O
,	O
Ozaki	O
T	O
,	O
Kondo	O
K,	O
Saido	O
T	O
,	O
Nakagawara	O
A	O
,	O
Sakiyama	O
S.	O
Department	O
of	O
Biochemistry	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
,	O
Japan	O
.	O
hiwasa@med	O
.m	O
.chiba-u.ac.jp	O
DAN	O
gene	O
was	O
first	O
isolated	O
by	O
differential	O
screening	O
between	O
rat	O
3Y1	O
and	O
v	O
-	O
sr	O
c	O
-	O
transformed	O
3Y1	O
cells	O
and	O
showed	O
a	O
tumor	O
-	O
suppressive	O
activity	O
toward	O
v	O
-	O
sr	O
c	O
-	O
transformed	O
3Y1	O
cells	O
.	O
When	O
DAN	O
-transfected	O
neuroblastoma	B-malignancy-type
cells	O
were	O
treated	O
with	O
a	O
tumor	O
promoter	O
phorbol	O
ester	O
,	O
TPA	O
,	O
neurite	O
-	O
like	O
processes	O
appeared	O
within	O
2	O
h	O
whereas	O
no	O
apparent	O
change	O
was	O
observed	O
in	O
the	O
parent	O
and	O
vector	O
-	O
transfected	O
cells	O
up	O
to	O
8	O
h	O
.	O
This	O
suggests	O
some	O
difference	O
in	O
TPA	O
-	O
receptor	O
,	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
between	O
DAN	O
-transfectants	O
and	O
the	O
control	O
cells	O
.	O
DAN	O
-transfected	O
SH-SY5Y	O
cells	O
showed	O
complete	O
loss	O
in	O
PKC	O
alpha	O
and	O
a	O
large	O
decrease	O
in	O
PKC	O
gamma	O
.	O
Similar	O
down	O
-	O
regulation	O
in	O
PKC	O
alpha	O
and	O
PKC	O
gamma	O
was	O
also	O
observed	O
in	O
DAN	O
-	O
transfected	O
Ha-ras	O
-	O
transformed	O
NIH	O
3T3	O
cells	O
.	O
The	O
decreased	O
level	O
of	O
PKC	O
alpha	O
was	O
partially	O
recovered	O
after	O
treatment	O
with	O
a	O
calpain	O
inhibitor	O
,	O
ZLLH.	O
A	O
150-	O
kDa	O
proteolytic	O
product	O
of	O
a	O
calpain	O
-	O
specific	O
substrate	O
,	O
non	O
-	O
erythroid	O
alpha	O
-	O
spectrin	O
,	O
was	O
detectable	O
in	O
DAN	O
-	O
transfected	O
SH-SY5Y	O
cells	O
but	O
not	O
in	O
the	O
parent	O
or	O
vector	O
-	O
transfected	O
control	O
cells	O
.	O
This	O
suggests	O
that	O
DAN	O
-	O
transfected	O
cells	O
contain	O
activated	O
calpain	O
which	O
may	O
cause	O
down	O
-	O
regulation	O
of	O
PKC	O
and	O
hence	O
induce	O
the	O
altered	O
TPA	O
response	O
.	O
PMID	O
:	O
9862417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocrinology	O
.	O
1992	O
Jun;130	O
(	O
6	O
)	O
:	O
3669	O
-	O
76	O
.	O
Retinoic	O
acid	O
regulates	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
expression	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Matsumoto	O
K,	O
Gaetano	O
C	O
,	O
Daughaday	O
WH	O
,	O
Thiele	O
CJ.	O
Molecular	O
Genetics	O
Section	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
Insulin	O
-	O
like	O
growth	O
factors	O
(	O
IGF-	O
I	O
and	O
IGF-II	O
)	O
are	O
mitogenic	O
polypeptides	O
that	O
play	O
an	O
important	O
role	O
in	O
normal	O
growth	O
and	O
development	O
.	O
IGF-II	O
has	O
been	O
shown	O
to	O
stimulate	O
the	O
growth	O
of	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
in	O
an	O
autocrine	O
and	O
paracrine	O
fashion	O
.	O
Critical	O
in	O
determining	O
the	O
role	O
of	O
IGF-II	O
in	O
tumorigenesis	O
is	O
the	O
necessity	O
to	O
delineate	O
factors	O
affecting	O
the	O
transcription	O
of	O
IGF-II	O
in	O
normal	O
and	O
tumor	O
tissues	O
.	O
To	O
date	O
such	O
factors	O
are	O
poorly	O
characterized	O
.	O
In	O
this	O
study	O
we	O
find	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
naturally	O
occurring	O
morphogen	O
,	O
that	O
has	O
been	O
shown	O
to	O
be	O
indispensable	O
in	O
the	O
development	O
of	O
the	O
chick	O
limb	O
bud	O
,	O
stimulates	O
an	O
increase	O
in	O
IGF-II	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
in	O
the	O
Lan-	O
1-15N	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
This	O
increase	O
in	O
IGF-II	O
is	O
coincident	O
with	O
RA	O
mediated	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O
An	O
increase	O
in	O
the	O
steady	O
state	O
levels	O
of	O
IGF-II	O
mRNA	O
is	O
detectable	O
within	O
2	O
h	O
of	O
RA	O
treatment	O
and	O
maximal	O
by	O
24	O
h	O
.	O
In	O
RA	O
-	O
treated	O
Lan-	O
1-15N	O
cells	O
,	O
IGF-II	O
mRNA	O
levels	O
are	O
regulated	O
at	O
the	O
level	O
of	O
new	O
gene	O
transcription	O
and	O
result	O
in	O
an	O
increase	O
in	O
IGF-II	O
protein	O
in	O
the	O
culture	O
supernatant	O
.	O
These	O
studies	O
suggest	O
one	O
mechanism	O
affecting	O
the	O
production	O
of	O
IGF-II	O
in	O
vivo	O
may	O
be	O
mediated	O
by	O
RA	O
and	O
detail	O
a	O
model	O
system	O
by	O
which	O
transcriptional	O
regulation	O
of	O
IGF-II	O
mRNA	O
can	O
be	O
analyzed	O
.	O
PMID	O
:	O
1375906	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
.	O
1993	O
May	O
;142(	O
5	O
)	O
:	O
1339	O
-46	O
.	O
Detection	O
of	O
N-myc	O
gene	O
amplification	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
Diagnostic	O
utility	O
for	O
neuroblastoma	B-malignancy-type
.	O
Shapiro	O
DN	O
,	O
Valentine	O
MB	O
,	O
Rowe	O
ST	O
,	O
Sinclair	O
AE	O
,	O
Sublett	O
JE	O
,	O
Roberts	O
WM	O
,	O
Look	O
AT	O
.	O
Department	O
of	O
Experimental	O
Oncology	O
,	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
Memphis	O
,	O
TN	O
38105	O
.	O
We	O
assessed	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
as	O
an	O
alternative	O
to	O
Southern	O
blot	O
analysis	O
for	O
determination	O
of	O
N-myc	O
gene	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
.	O
In	O
the	O
44	O
pediatric	B-malignancy-type
solid	I-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
examined	O
(	O
20	O
neuroblastomas	B-malignancy-type
)	O
,	O
the	O
mean	O
number	O
of	O
N-myc	O
copies	O
determined	O
by	O
FISH	O
correlated	O
closely	O
with	O
Southern	O
blot	O
results	O
.	O
There	O
was	O
wide	O
intercellular	O
variability	O
in	O
gene	O
copy	O
number	O
in	O
tumors	O
that	O
had	O
evidence	O
of	O
amplification	O
;	O
however	O
,	O
tumors	O
judged	O
to	O
be	O
non	O
-	O
amplified	O
completely	O
lacked	O
any	O
cells	O
with	O
high	O
N-myc	O
copy	O
number	O
.	O
FISH	O
provided	O
reliable	O
estimates	O
of	O
N-myc	O
amplification	O
in	O
12	O
clinical	O
samples	O
even	O
when	O
the	O
percentage	O
of	O
tumor	O
was	O
low	O
.	O
The	O
other	O
advantages	O
of	O
FISH	O
over	O
Southern	O
blot	O
analysis	O
were	O
speed	O
and	O
technical	O
simplicity	O
,	O
ability	O
to	O
discern	O
heterogeneous	O
gene	O
amplification	O
among	O
tumor	O
cells	O
in	O
the	O
same	O
specimen	O
,	O
and	O
capacity	O
to	O
determine	O
the	O
source	O
of	O
the	O
amplified	O
N-myc	O
signal	O
,	O
whether	O
extrachromosomal	O
double	O
-	O
minute	O
chromosomes	O
,	O
expanded	O
intrachromosomal	O
regions	O
,	O
or	O
chromosome	O
2	O
aneuploidy	O
.	O
We	O
conclude	O
that	O
FISH	O
would	O
refine	O
the	O
analysis	O
of	O
N-myc	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
and	O
thus	O
improve	O
the	O
assignment	O
of	O
patients	O
to	O
prognostic	O
groups	O
based	O
on	O
this	O
unfavorable	O
risk	O
factor	O
.	O
PMID	O
:	O
7684192	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Death	O
Differ	O
.	O
1998	O
May	O
;	O
5	O
(	O
5	O
)	O
:	O
401	O
-	O
7.	O
The	O
RB	O
-	O
related	O
gene	O
Rb2	O
/	O
p130	O
in	O
neuroblastoma	B-malignancy-type
differentiation	O
and	O
in	O
B	O
-	O
myb	O
promoter	O
down	O
-	O
regulation	O
.	O
Raschella	O
G	O
,	O
Tanno	O
B	O
,	O
Bonetto	O
F	O
,	O
Negroni	O
A	O
,	O
Claudio	O
PP	O
,	O
Baldi	O
A	O
,	O
Amendola	O
R	O
,	O
Calabretta	O
B	O
,	O
Giordano	O
A	O
,	O
Paggi	O
MG.	O
Section	O
of	O
Toxicology	O
and	O
Biomedical	O
Sciences	O
,	O
Ente	O
Nuove	O
Tecnologie	O
Energia	O
e	O
Ambiente	O
(	O
ENEA	O
)	O
Via	O
Anguillarese	O
301	O
,	O
00060	O
Rome	O
,	O
Italy	O
.	O
The	O
retinoblastoma	B-malignancy-type
family	O
of	O
nuclear	O
factors	O
is	O
composed	O
of	O
RB	O
,	O
the	O
prototype	O
of	O
the	O
tumour	O
suppressor	O
genes	O
and	O
of	O
the	O
strictly	O
related	O
genes	O
p107	O
and	O
Rb2	O
/	O
p130	O
.	O
The	O
three	O
genes	O
code	O
for	O
proteins	O
,	O
namely	O
pRb	O
,	O
p107	O
and	O
pRb2	O
/	O
p130	O
,	O
that	O
share	O
similar	O
structures	O
and	O
functions	O
.	O
These	O
proteins	O
are	O
expressed	O
,	O
often	O
simultaneously	O
,	O
in	O
many	O
cell	O
types	O
and	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
proliferation	O
and	O
differentiation	O
.	O
We	O
determined	O
the	O
expression	O
and	O
the	O
phosphorylation	O
of	O
the	O
RB	O
family	O
gene	O
products	O
during	O
the	O
DMSO	O
-	O
induced	O
differentiation	O
of	O
the	O
N1E-115	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
.	O
In	O
this	O
system	O
,	O
pRb2	O
/	O
p130	O
was	O
strongly	O
up	O
-	O
regulated	O
during	O
mid	O
-	O
late	O
differentiation	O
stages	O
,	O
while	O
,	O
on	O
the	O
contrary	O
,	O
pRb	O
and	O
p107	O
resulted	O
markedly	O
decreased	O
at	O
late	O
stages	O
.	O
Differentiating	O
N1E-115	O
cells	O
also	O
showed	O
a	O
progressive	O
decrease	O
in	O
B	O
-	O
myb	O
levels	O
,	O
a	O
proliferation	O
-	O
related	O
protein	O
whose	O
constitutive	O
expression	O
inhibits	O
neuronal	O
differentiation	O
.	O
Transfection	O
of	O
each	O
of	O
the	O
RB	O
family	O
genes	O
in	O
these	O
cells	O
was	O
able	O
,	O
at	O
different	O
degrees	O
,	O
to	O
induce	O
neuronal	O
differentiation	O
,	O
to	O
inhibit	O
[3H]thymidine	O
incorporation	O
and	O
to	O
down	O
-	O
regulate	O
the	O
activity	O
of	O
the	O
B	O
-	O
myb	O
promoter	O
.	O
PMID	O
:	O
10200489	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2001	O
Feb	O
23	O
;	O
281	O
(	O
2	O
)	O
:	O
483-90	O
.	O
Cyclooxygenase-2	O
stimulates	O
production	O
of	O
amyloid	O
beta-peptide	O
in	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
NG108-15	O
cells	O
.	O
Kadoyama	O
K	O
,	O
Takahashi	O
Y	O
,	O
Higashida	O
H	O
,	O
Tanabe	O
T	O
,	O
Yoshimoto	O
T	O
.	O
Department	O
of	O
Pharmacology	O
,	O
Kanazawa	O
University	O
School	O
of	O
Medicine	O
,	O
Kanazawa	O
,	O
Ishikawa	O
920-8640	O
,	O
Japan	O
.	O
Cyclooxygenase	O
(	O
COX	O
)	O
synthesizes	O
bioactive	O
prostaglandins	O
from	O
arachidonic	O
acid	O
,	O
and	O
there	O
are	O
COX-1	O
and	O
COX-2	O
isoforms	O
with	O
distinct	O
pathophysiological	O
functions	O
.	O
Recent	O
studies	O
demonstrated	O
that	O
COX-2	O
expression	O
was	O
up-regulated	O
in	O
the	O
brain	O
of	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
.	O
We	O
established	O
mouse	O
neuroblastoma	B-malignancy-type
x	O
rat	O
glioma	B-malignancy-type
hybrid	O
NG108-15	O
cells	O
stably	O
expressing	O
human	O
COX-2	O
	O
The	O
COX-2	O
-	O
expressing	O
cells	O
showed	O
3-	O
to	O
4-fold	O
increases	O
in	O
both	O
COX	O
activity	O
and	O
prostaglandin	O
E(2)	O
production	O
.	O
The	O
mRNA	O
level	O
of	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
was	O
elevated	O
by	O
approximately	O
2-fold	O
in	O
the	O
COX-2	O
-	O
expressing	O
cells	O
compared	O
with	O
mock-transfected	O
cells	O
.	O
Amyloid	O
beta-peptide	O
and	O
a	O
secreted	O
form	O
of	O
APP	O
,	O
both	O
derived	O
from	O
APP	O
by	O
proteolysis	O
was	O
also	O
increased	O
.	O
Interestingly	O
,	O
neurite	O
outgrowth	O
was	O
stimulated	O
in	O
the	O
COX-2	O
-	O
expressing	O
cells	O
with	O
concomitant	O
reduction	O
of	O
the	O
cell	O
proliferation	O
rate	O
.	O
A	O
selective	O
COX-2	O
inhibitor	O
(	O
JTE-522	O
)	O
and	O
a	O
nonselective	O
COX	O
inhibitor	O
(	O
indomethacin	O
)	O
suppressed	O
production	O
of	O
amyloid	O
beta-peptide	O
and	O
a	O
secreted	O
form	O
of	O
APP	O
by	O
inhibition	O
of	O
APP	O
mRNA	O
level	O
,	O
suggesting	O
that	O
COX-2	O
plays	O
important	O
roles	O
in	O
the	O
neurodegenerative	O
processes	O
of	O
Alzheimer	O
's	O
disease	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11181073	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Biol	O
Chem	O
.	O
1997	O
May	O
2	O
;	O
272	O
(	O
18	O
)	O
:	O
12195-201	O
.	O
Identification	O
and	O
characterization	O
of	O
a	O
retinoic	O
acid	O
-	O
regulated	O
human	O
homologue	O
of	O
the	O
unc-33-like	O
phosphoprotein	O
gene	O
(	O
hUlip	O
)	O
from	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Gaetano	O
C	O
,	O
Matsuo	O
T	O
,	O
Thiele	O
CJ	O
.	O
Cell	O
and	O
Molecular	O
Biology	O
Section	O
,	O
Pediatric	O
Oncology	O
Branch	O
,	O
NCI	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
A	O
cDNA	O
,	O
7G1	O
,	O
was	O
isolated	O
from	O
retinoic	O
acid	O
(	O
RA	O
)	O
differentiated	O
neuroblastoma	B-malignancy-type
cells	O
whose	O
expression	O
was	O
high	O
in	O
human	O
fetal	O
brain	O
and	O
spinal	O
cord	O
mRNA	O
but	O
undetectable	O
in	O
adult	O
brain	O
or	O
non	O
-	O
neuronal	O
tissues	O
.	O
Sequence	O
analysis	O
indicates	O
that	O
7G1	O
is	O
homologous	O
to	O
the	O
Caenorhabditis	O
elegans	O
gene	O
unc-33	O
.	O
A	O
5.5-kilobase	O
pair	O
full-length	O
cDNA	O
from	O
a	O
human	O
fetal	O
brain	O
cDNA	O
library	O
contains	O
an	O
1710-base	O
pair	O
open	O
reading	O
frame	O
.	O
Because	O
the	O
predicted	O
570	O
amino	O
acid	O
sequence	O
of	O
7G1	O
shares	O
98%	O
identity	O
with	O
the	O
murine	O
Ulip	O
gene	O
product	O
,	O
an	O
un	O
c-33	O
-	O
like	O
-phosphoprotein	O
,	O
we	O
refer	O
to	O
7G1	O
as	O
the	O
human	O
Ulip	O
(	O
hUlip	O
)	O
.	O
hUlip	O
is	O
also	O
similar	O
to	O
the	O
bacterial	O
enzyme	O
D-hydantoinase	O
and	O
the	O
recently	O
described	O
vertebrate	O
gene	O
products	O
CRMP62	O
,	O
TOAD-64	O
,	O
CRMP1	O
,	O
CRMP2	O
,	O
and	O
mUNC	O
.	O
RA	O
stimulates	O
an	O
increase	O
in	O
hUlip	O
mRNA	O
that	O
is	O
transcriptionally	O
regulated	O
.	O
RA	O
stimulates	O
an	O
increase	O
in	O
polypeptides	O
of	O
58	O
,	O
60	O
,	O
65	O
,	O
and	O
70	O
kDa	O
with	O
the	O
58-	O
and	O
65-kDa	O
species	O
being	O
dephosphorylated	O
forms	O
of	O
the	O
60-	O
and	O
70-kDa	O
species	O
.	O
This	O
study	O
presents	O
a	O
model	O
in	O
which	O
to	O
study	O
the	O
regulation	O
and	O
expression	O
of	O
the	O
hUlip	O
gene	O
,	O
a	O
member	O
of	O
an	O
emerging	O
family	O
of	O
molecules	O
that	O
potentially	O
mediates	O
signals	O
involved	O
in	O
axonal	O
outgrowth	O
.	O
PMID	O
:	O
9115293	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Acta	O
Pathol	O
Jpn	O
.	O
1991	O
Jul	O
;	O
41	O
(	O
7	O
)	O
:	O
507-15	O
.	O
Morphological	O
and	O
cytogenetic	O
characterization	O
and	O
N-myc	O
oncogene	O
analysis	O
of	O
a	O
newly	O
established	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Nojima	O
T	O
,	O
Abe	O
S	O
,	O
Furuta	O
Y	O
,	O
Nagashima	O
K	O
,	O
Alam	O
AF	O
,	O
Takada	O
N	O
,	O
Sasaki	O
F	O
,	O
Hata	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Hokkaido	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
A	O
permanent	O
cell	O
line	O
established	O
from	O
a	O
xenograft	O
of	O
neuroblastoma	B-malignancy-type
which	O
occurred	O
in	O
a	O
5-year-old	O
girl	O
was	O
investigated	O
for	O
its	O
morphological	O
and	O
biological	O
characteristics	O
.	O
The	O
cultured	O
cells	O
were	O
tumorigenic	O
in	O
nude	O
mice	O
.	O
Microscopically	O
,	O
each	O
tumor	O
consisted	O
of	O
small	O
round	O
to	O
polygonal	O
cells	O
with	O
irregular	O
nuclei	O
and	O
prominent	O
nucleoli	O
,	O
corresponding	O
to	O
the	O
features	O
of	O
the	O
primary	O
and	O
xenografted	O
tumor	O
cells	O
.	O
Electron	O
microscopic	O
examination	O
revealed	O
that	O
both	O
the	O
transplanted	O
tumor	O
cells	O
and	O
the	O
cultured	O
cells	O
contained	O
scanty	O
microtubules	O
and	O
dense	O
-	O
core	O
neurosecretory	O
granules	O
.	O
Chromosome	O
analysis	O
of	O
this	O
cell	O
line	O
showed	O
monosomy	O
for	O
chromosomes	O
1	O
,	O
10	O
,	O
19	O
and	O
X	O
,	O
and	O
structural	O
rearrangements	O
involving	O
chromosomes	O
8	O
,	O
17	O
and	O
20	O
,	O
in	O
addition	O
to	O
numerous	O
double	O
minutes	O
.	O
The	O
N-myc	O
oncogene	O
was	O
found	O
to	O
be	O
amplified	O
40-	O
to	O
80-fold	O
in	O
the	O
transplanted	O
and	O
cultured	O
tumor	O
cells	O
,	O
as	O
well	O
as	O
in	O
the	O
primary	O
tumor	O
cells	O
.	O
In	O
situ	O
hybridization	O
with	O
a	O
digoxigenin-labeled	O
uridine-triphosphate	O
N-myc	O
RNA	O
probe	O
detected	O
abundant	O
mRNA	O
in	O
the	O
tumor	O
cells	O
.	O
This	O
neuroblastoma	B-malignancy-type
line	O
may	O
become	O
a	O
valuable	O
in	O
vitro	O
experimental	O
model	O
system	O
for	O
studies	O
aimed	O
at	O
better	O
characterization	O
of	O
neuroblastoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
1755317	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Cell	O
Sci	O
.	O
2003	O
May	O
15	O
;	O
116	O
(	O
Pt	O
10	O
)	O
:	O
1925-35	O
.	O
Epub	O
2003	O
Mar	O
26	O
.	O
Rit	O
promotes	O
MEK	O
-	O
independent	O
neurite	O
branching	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Hynds	O
DL	O
,	O
Spencer	O
ML	O
,	O
Andres	O
DA	O
,	O
Snow	O
DM	O
.	O
Department	O
of	O
Anatomy	O
and	O
Neurobiology	O
,	O
University	O
of	O
Kentucky	O
Medical	O
Center	O
,	O
Lexington	O
,	O
KY	O
40536-0298	O
,	O
USA	O
.	O
dlhynd0@uky.edu	O
Rit	O
,	O
by	O
sequence	O
homology	O
,	O
is	O
a	O
member	O
of	O
the	O
Ras	O
subfamily	O
of	O
small	O
guanine	O
triphosphatases	O
(	O
GTPases	O
)	O
.	O
In	O
PC6	O
cells	O
,	O
Rit	O
signals	O
through	O
pathways	O
both	O
common	O
to	O
and	O
different	O
from	O
those	O
activated	O
by	O
Ras	O
to	O
promote	O
cell	O
survival	O
and	O
neurite	O
outgrowth	O
.	O
However	O
,	O
the	O
specific	O
morphological	O
changes	O
induced	O
by	O
Rit	O
in	O
human	O
cells	O
are	O
not	O
known	O
.	O
Here	O
,	O
we	O
show	O
in	O
a	O
human	O
neuronal	O
model	O
that	O
Rit	O
increases	O
neurite	O
outgrowth	O
and	O
branching	O
through	O
MEK	O
-	O
dependent	O
and	O
MEK	O
-	O
independent	O
signaling	O
mechanisms	O
,	O
respectively	O
.	O
Adenoviral	O
expression	O
of	O
wild-type	O
or	O
constitutively	O
active	O
Rit	O
increased	O
neurite	O
initiation	O
,	O
elongation	O
and	O
branching	O
on	O
endogenous	O
matrix	O
or	O
a	O
purified	O
laminin-1	O
substratum	O
of	O
SH-SY5Y	O
cells	O
as	O
assessed	O
using	O
image	O
analysis	O
.	O
This	O
outgrowth	O
was	O
morphologically	O
distinct	O
from	O
that	O
promoted	O
by	O
constitutively	O
active	O
Ras	O
or	O
Raf	O
(	O
evidenced	O
by	O
increased	O
branching	O
and	O
elongation	O
)	O
.	O
Constitutively	O
active	O
Rit	O
increased	O
phosphorylation	O
of	O
ERK	O
1	O
/	O
2	O
,	O
but	O
not	O
Akt	O
,	O
and	O
the	O
MEK	O
inhibitor	O
PD	O
098059	O
blocked	O
constitutively	O
active	O
Rit	O
-	O
induced	O
neurite	O
initiation	O
but	O
not	O
elongation	O
or	O
branching	O
.	O
These	O
results	O
suggest	O
that	O
Rit	O
plays	O
a	O
key	O
role	O
in	O
human	O
neuronal	O
development	O
and	O
regeneration	O
through	O
activating	O
both	O
known	O
and	O
as	O
yet	O
undefined	O
signaling	O
pathways	O
.	O
PMID	O
:	O
12668729	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Invest	O
.	O
1990	O
Dec	O
;	O
86	O
(	O
6	O
)	O
:	O
1806-14	O
.	O
Insulin-like	O
growth	O
factor	O
I	O
expression	O
by	O
tumors	B-malignancy-type
of	I-malignancy-type
neuroectodermal	I-malignancy-type
origin	I-malignancy-type
with	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
chromosomal	O
translocation	O
.	O
A	O
potential	O
autocrine	O
growth	O
factor	O
.	O
Yee	O
D	O
,	O
Favoni	O
RE	O
,	O
Lebovic	O
GS	O
,	O
Lombana	O
F	O
,	O
Powell	O
DR	O
,	O
Reynolds	O
CP	O
,	O
Rosen	O
N	O
.	O
Lombardi	O
Cancer	O
Research	O
Center	O
,	O
Georgetown	O
University	O
Medical	O
Center	O
,	O
Washington	O
,	O
D.C.	O
20007	O
.	O
Expression	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
mRNA	O
by	O
some	O
tumor	O
cell	O
lines	O
of	O
neuroectodermal	O
origin	O
has	O
been	O
described	O
.	O
To	O
further	O
explore	O
the	O
significance	O
of	O
IGF-I	O
mRNA	O
expression	O
in	O
these	O
tumors	O
,	O
a	O
more	O
extensive	O
analysis	O
was	O
performed	O
.	O
Most	O
(	O
9	O
of	O
10	O
)	O
neuroectodermal	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
with	O
a	O
t	O
(	O
11	O
;	O
22	O
)	O
translocation	O
(	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
[	O
PNET	B-malignancy-type
]	O
,	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
,	O
esthesioneuroblastoma	B-malignancy-type
)	O
expressed	O
IGF-I	O
mRNA	O
,	O
whereas	O
0	O
of	O
15	O
cell	O
lines	O
without	O
the	O
translocation	O
(	O
PNET	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
)	O
expressed	O
IGF-I	O
.	O
Furthermore	O
,	O
inasmuch	O
as	O
all	O
neuroblastoma	B-malignancy-type
(	O
12	O
of	O
12	O
)	O
cell	O
lines	O
examined	O
expressed	O
IGF-II	O
RNA	O
,	O
the	O
pattern	O
of	O
IGF	O
expression	O
could	O
distinguish	O
between	O
these	O
closely	O
related	O
tumors	O
.	O
CHP-100	O
,	O
a	O
PNET	B-malignancy-type
cell	O
line	O
with	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
translocation	O
,	O
was	O
shown	O
to	O
secrete	O
both	O
IGF-I	O
protein	O
and	O
an	O
IGF	O
binding	O
protein	O
,	O
IGFBP-2	O
.	O
This	O
cell	O
line	O
also	O
expressed	O
the	O
type	O
I	O
IGF	O
receptor	O
mRNA	O
,	O
and	O
blockade	O
of	O
this	O
receptor	O
by	O
a	O
monoclonal	O
antibody	O
(	O
alpha	O
IR3	O
)	O
inhibited	O
serum	O
-	O
free	O
growth	O
.	O
These	O
data	O
demonstrate	O
that	O
IGF-I	O
expression	O
is	O
a	O
property	O
of	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
with	O
a	O
t	O
(	O
11	O
;	O
22	O
)	O
translocation	O
and	O
that	O
interruption	O
of	O
an	O
IGF-I	O
autocrine	O
loop	O
inhibits	O
the	O
growth	O
of	O
these	O
tumor	O
cells	O
.	O
PMID	O
:	O
2174908	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Curr	O
Pharm	O
Des	O
.	O
2000	O
Sep	O
;	O
6	O
(	O
14	O
)	O
:	O
1419-32	O
.	O
Applications	O
of	O
gene	O
transfer	O
to	O
targeted	O
radiotherapy	O
.	O
Mairs	O
RJ	O
,	O
Cunningham	O
SH	O
,	O
Boyd	O
M	O
,	O
Carlin	O
S	O
.	O
Departments	O
of	O
Radiation	O
Oncology	O
and	O
Child	O
Health	O
,	O
University	O
of	O
Glasgow	O
,	O
CRC	O
Beatson	O
Laboratories	O
,	O
Garscube	O
Estate	O
,	O
Glasgow	O
,	O
G61	O
1BD	O
,	O
Scotland	O
,	O
UK.	O
r.mairs@beatson.gla.ac.uk	O
For	O
targeted	O
radionuclide	O
therapy	O
to	O
succeed	O
as	O
a	O
single	O
modality	O
treatment	O
,	O
schemes	O
must	O
be	O
devised	O
which	O
will	O
enable	O
the	O
deposition	O
in	O
malignant	O
cells	O
of	O
sterilising	O
doses	O
of	O
radiation	O
.	O
Until	O
such	O
methods	O
have	O
been	O
perfected	O
,	O
it	O
is	O
necessary	O
to	O
combine	O
targeted	O
radiotherapy	O
in	O
a	O
rational	O
manner	O
with	O
conventional	O
anti-cancer	O
treatments	O
.	O
Several	O
means	O
of	O
delivery	O
of	O
therapeutic	O
radionuclides	O
are	O
being	O
evaluated	O
but	O
none	O
of	O
these	O
yet	O
appears	O
to	O
be	O
as	O
powerful	O
as	O
the	O
simplest	O
and	O
most	O
effective	O
example	O
,	O
viz	O
:	O
sodium	O
[131I]iodide	O
treatment	O
of	O
disseminated	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
radiopharmaceutical	O
[131I]meta-iodobenzylguanidine	O
(	O
[131I]MIBG	O
)	O
is	O
an	O
effective	O
single	O
agent	O
for	O
the	O
treatment	O
of	O
neuroblastoma	B-malignancy-type
.	O
However	O
,	O
uptake	O
of	O
the	O
drug	O
in	O
malignant	O
sites	O
is	O
heterogeneous	O
,	O
suggesting	O
that	O
this	O
therapy	O
alone	O
is	O
unlikely	O
to	O
cure	O
disease	O
.	O
A	O
growing	O
body	O
of	O
experimental	O
evidence	O
indicates	O
exciting	O
possibilities	O
for	O
the	O
integration	O
of	O
gene	O
transfer	O
with	O
radionuclide	O
targeting	O
.	O
This	O
review	O
covers	O
aspects	O
of	O
the	O
combination	O
of	O
gene	O
manipulation	O
and	O
targeted	O
radiotherapy	O
,	O
emphasising	O
the	O
potential	O
of	O
gene	O
transfer	O
to	O
facilitate	O
tumour	O
targeting	O
with	O
low	O
molecular	O
weight	O
radiopharmaceuticals	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
10903401	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Neurosci	O
Res	O
.	O
1990	O
Dec	O
;	O
27	O
(	O
4	O
)	O
:	O
620-32	O
.	O
Reverse	O
-phase	O
high-performance	O
liquid	O
chromatography	O
of	O
nerve	O
growth	O
factor	O
receptor-like	O
proteins	O
identified	O
with	O
monoclonal	O
antibodies	O
.	O
Shan	O
DE	O
,	O
Beck	O
CE	O
,	O
Werrbach-Perez	O
K	O
,	O
Perez-Polo	O
JR	O
.	O
Department	O
of	O
Human	O
Biological	O
Chemistry	O
and	O
Genetics	O
,	O
University	O
of	O
Texas	O
Medical	O
Branch	O
,	O
Galveston	O
.	O
Human	O
neuroblastoma	B-malignancy-type
SK-N-SH-SY5Y	O
(	O
SY5Y	O
)	O
and	O
rat	O
pheochromocytoma	B-malignancy-type
PC12	O
cells	O
are	O
model	O
cell	O
lines	O
used	O
in	O
the	O
study	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
effect	O
.	O
The	O
effects	O
of	O
NGF	O
are	O
initiated	O
by	O
binding	O
to	O
cell	O
surface	O
receptors	O
(	O
NGFR	O
)	O
.	O
The	O
amino	O
acid	O
sequence	O
for	O
NGFR	O
has	O
been	O
deduced	O
based	O
on	O
the	O
identification	O
of	O
a	O
single	O
gene	O
for	O
NGFR	O
.	O
However	O
,	O
there	O
are	O
two	O
kinds	O
of	O
NGF	O
binding	O
activities	O
and	O
several	O
reported	O
molecular	O
weights	O
of	O
NGFR	O
.	O
We	O
report	O
here	O
on	O
the	O
demonstration	O
of	O
NGFR-like	O
proteins	O
from	O
PC12	O
and	O
SY5Y	O
cells	O
by	O
sequential	O
lectin	O
chromatography	O
,	O
reverse-phase	O
HPLC	O
,	O
and	O
SDS-PAGE	O
analysis	O
of	O
immunoprecipitates	O
obtained	O
with	O
NGFR-specific	O
monoclonal	O
antibodies	O
.	O
For	O
both	O
human	O
and	O
rodent	O
NGFR	O
,	O
there	O
was	O
a	O
tendency	O
for	O
the	O
higher	O
molecular	O
-	O
weight	O
species	O
of	O
NGFR-like	O
proteins	O
to	O
be	O
eluted	O
in	O
more	O
hydrophobic	O
fractions	O
.	O
Also	O
,	O
the	O
expression	O
of	O
different	O
species	O
of	O
NGFR	O
could	O
be	O
modified	O
by	O
treatment	O
with	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
different	O
molecular	O
species	O
of	O
NGFR	O
may	O
result	O
from	O
the	O
generation	O
of	O
a	O
truncated	O
form	O
of	O
NGFR	O
,	O
the	O
presence	O
of	O
sugar	O
residues	O
on	O
the	O
NGFR	O
protein	O
,	O
dimer	O
formation	O
between	O
NGFR	O
,	O
or	O
the	O
association	O
of	O
NGFR	O
with	O
a	O
receptor-associated	O
protein	O
.	O
PMID	O
:	O
1964179	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Dev	O
.	O
2001	O
Jan	O
1	O
;	O
15	O
(	O
1	O
)	O
:	O
66-78	O
.	O
The	O
transcription	O
factor	O
Sox10	O
is	O
a	O
key	O
regulator	O
of	O
peripheral	O
glial	O
development	O
.	O
Britsch	O
S	O
,	O
Goerich	O
DE	O
,	O
Riethmacher	O
D	O
,	O
Peirano	O
RI	O
,	O
Rossner	O
M	O
,	O
Nave	O
KA	O
,	O
Birchmeier	O
C	O
,	O
Wegner	O
M	O
.	O
Max-Delbruck-Center	O
for	O
Molecular	O
Medicine	O
,	O
D-13122	O
Berlin	O
,	O
Germany	O
.	O
The	O
molecular	O
mechanisms	O
that	O
determine	O
glial	O
cell	O
fate	O
in	O
the	O
vertebrate	O
nervous	O
system	O
have	O
not	O
been	O
elucidated	O
.	O
Peripheral	O
glial	O
cells	O
differentiate	O
from	O
pluripotent	O
neural	O
crest	O
cells	O
.	O
We	O
show	O
here	O
that	O
the	O
transcription	O
factor	O
Sox10	O
is	O
a	O
key	O
regulator	O
in	O
differentiation	O
of	O
peripheral	O
glial	O
cells	O
.	O
In	O
mice	O
that	O
carry	O
a	O
spontaneous	O
or	O
a	O
targeted	O
mutation	O
of	O
Sox10	O
,	O
neuronal	O
cells	O
form	O
in	O
dorsal	O
root	O
ganglia	O
,	O
but	O
Schwann	O
cells	O
or	O
satellite	O
cells	O
are	O
not	O
generated	O
.	O
At	O
later	O
developmental	O
stages	O
,	O
this	O
lack	O
of	O
peripheral	O
glial	O
cells	O
results	O
in	O
a	O
severe	O
degeneration	O
of	O
sensory	O
and	O
motor	O
neurons	O
.	O
Moreover	O
,	O
we	O
show	O
that	O
Sox10	O
controls	O
expression	O
of	O
ErbB3	O
in	O
neural	O
crest	O
cells	O
.	O
ErbB3	O
encodes	O
a	O
Neuregulin	O
receptor	O
,	O
and	O
down	O
-	O
regulation	O
of	O
ErbB3	O
accounts	O
for	O
many	O
changes	O
in	O
development	O
of	O
neural	O
crest	O
cells	O
observed	O
in	O
Sox10	O
mutant	O
mice	O
.	O
Sox10	O
also	O
has	O
functions	O
not	O
mediated	O
by	O
ErbB3	O
,	O
for	O
instance	O
in	O
the	O
melanocyte	O
lineage	O
.	O
Phenotypes	O
observed	O
in	O
heterozygous	O
mice	O
that	O
carry	O
a	O
targeted	O
Sox10	O
null	O
allele	O
reproduce	O
those	O
observed	O
in	O
heterozygous	O
Sox10	O
(	O
Dom	O
)	O
mice	O
.	O
Haploinsufficiency	O
of	O
Sox10	O
can	O
thus	O
cause	O
pigmentation	O
and	O
megacolon	O
defects	O
,	O
which	O
are	O
also	O
observed	O
in	O
Sox10	O
(	O
Dom	O
)/+	O
mice	O
and	O
in	O
patients	O
with	O
Waardenburg-Hirschsprung	O
disease	O
caused	O
by	O
heterozygous	O
SOX10	O
mutations	O
.	O
PMID	O
:	O
11156606	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
.	O
1983	O
Jun	O
;	O
43	O
(	O
6	O
)	O
:	O
2812-8	O
.	O
Effects	O
of	O
inhibitors	O
of	O
ornithine	O
decarboxylase	O
on	O
the	O
differentiation	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Chen	O
KY	O
,	O
Nau	O
D	O
,	O
Liu	O
AY	O
.	O
(R,_S)-alpha-Fluoromethylornithine	O
(	O
alpha-FMO	O
)	O
,	O
a	O
catalytic	O
irreversible	O
inhibitor	O
of	O
ornithine	O
decarboxylase	O
(	O
L-ornithine	O
carboxy-lyase	O
,	O
EC	O
4.1.1.17	O
)	O
,	O
induced	O
the	O
differentiation	O
of	O
N2a	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
effect	O
of	O
alpha-FMO	O
was	O
concentration	O
dependent	O
;	O
approximately	O
50%	O
of	O
the	O
cell	O
population	O
exhibited	O
neurite	O
outgrowth	O
in	O
the	O
presence	O
of	O
1	O
mM	O
alpha-FMO	O
,	O
while	O
higher	O
concentrations	O
caused	O
severe	O
growth	O
inhibition	O
and	O
cell	O
death	O
.	O
The	O
effect	O
of	O
1	O
mM	O
alpha-FMO	O
on	O
neuroblastoma	B-malignancy-type
differentiation	O
was	O
potentiated	O
greatly	O
by	O
0.1	O
to	O
0.2	O
mM	O
N6,O2'-dibutyryl	O
adenosine	O
cyclic	O
3':5'-monophosphate	O
(	O
Bt2cAMP	O
)	O
causing	O
more	O
than	O
90%	O
of	O
the	O
cell	O
population	O
to	O
differentiate	O
morphologically	O
with	O
thick	O
and	O
long	O
processes	O
;	O
0.1	O
to	O
0.2	O
mM	O
Bt2cAMP	O
,	O
by	O
itself	O
,	O
had	O
no	O
effect	O
on	O
cell	O
growth	O
and	O
did	O
not	O
induce	O
neurite	O
outgrowth	O
.	O
The	O
effect	O
of	O
alpha-FMO	O
,	O
either	O
by	O
itself	O
or	O
in	O
combination	O
with	O
0.1	O
to	O
0.2	O
mM	O
Bt2cAMP	O
,	O
on	O
the	O
morphological	O
differentiation	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
was	O
reversed	O
by	O
the	O
addition	O
of	O
exogenous	O
putrescine	O
or	O
spermidine	O
.	O
The	O
morphological	O
differentiation	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
induced	O
by	O
1	O
mM	O
alpha-FMO	O
plus	O
0.2	O
mM	O
Bt2cAMP	O
was	O
accompanied	O
by	O
increases	O
of	O
the	O
regulatory	O
subunit	O
of	O
the	O
type	O
I	O
cAMP	O
-binding	O
protein	O
and	O
acetylcholinesterase	O
activity	O
.	O
These	O
results	O
indicate	O
that	O
the	O
modulation	O
of	O
cellular	O
polyamine	O
contents	O
may	O
be	O
important	O
in	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
.	O
PMID	O
:	O
6303569	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1997	O
Aug	O
;	O
48	O
(	O
1	O
)	O
:	O
30-6	O
.	O
CNTF	O
up	O
-	O
regulation	O
of	O
TIMP-2	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Negro	O
A	O
,	O
Onisto	O
M	O
,	O
Pellati	O
D	O
,	O
Garbisa	O
S	O
.	O
Department	O
of	O
Biochemistry	O
,	O
CRIBI	O
,	O
University	O
of	O
Padova	O
,	O
Italy	O
.	O
The	O
ciliary	O
neurotrophic	O
factor	O
(	O
CNTF	O
)	O
can	O
regulate	O
survival	O
and	O
differentiation	O
of	O
many	O
types	O
of	O
developing	O
and	O
adult	O
neurons	O
;	O
in	O
metastatic	O
SK-N-BE	O
neuroblastoma	B-malignancy-type
cells	O
,	O
it	O
promotes	O
differentiation	O
and	O
neurite	O
outgrowth	O
.	O
The	O
expression	O
of	O
Gelatinase	O
A	O
(	O
MMP-2	O
)	O
and	O
its	O
specific	O
tissue	O
inhibitor	O
(	O
TIMP-2	O
)	O
,	O
a	O
degradative	O
system	O
whose	O
balance	O
is	O
involved	O
in	O
matrix	O
invasion	O
and	O
metastasis	O
,	O
was	O
investigated	O
in	O
SK-N-BE	O
cells	O
cultured	O
with	O
and	O
without	O
CNTF	O
or	O
NGF	O
.	O
	O
Zymographic	O
analysis	O
of	O
conditioned	O
media	O
revealed	O
that	O
the	O
cells	O
constitutively	O
secrete	O
two	O
gelatinases	O
,	O
mainly	O
pro-MMP-2	O
but	O
also	O
traces	O
of	O
pro-MMP-9	O
	O
In	O
a	O
time	O
-	O
course	O
experiment	O
in	O
the	O
presence	O
of	O
25	O
ng/ml	O
of	O
CNTF	O
,	O
the	O
MMP-2	O
mRNA	O
expression	O
showed	O
no	O
significant	O
modulation	O
,	O
while	O
TIMP-2	O
mRNA	O
up-regulated	O
to	O
>	O
2-fold	O
after	O
48	O
h	O
and	O
then	O
fell	O
dramatically	O
At	O
the	O
same	O
concentrations	O
,	O
NGF	O
showed	O
no	O
effect	O
.	O
TIMP-2	O
mRNA	O
expression	O
showed	O
a	O
dose	O
-	O
dependent	O
increase	O
of	O
up	O
to	O
8-fold	O
from	O
1	O
to	O
250	O
ng/ml	O
of	O
CNTF	O
and	O
increased	O
secretion	O
of	O
TIMP-2	O
was	O
confirmed	O
by	O
Western	O
blotting	O
.	O
MMP-2	O
was	O
only	O
slightly	O
over-expressed	O
under	O
the	O
same	O
conditions	O
,	O
at	O
either	O
mRNA	O
or	O
protein	O
level	O
,	O
with	O
no	O
correlation	O
with	O
neurocytokine	O
concentration	O
.	O
These	O
results	O
suggest	O
that	O
boosting	O
the	O
expression	O
of	O
TIMP-2	O
by	O
CNTF	O
could	O
restrain	O
both	O
matrix	O
degradation	O
following	O
nervous	O
system	O
injury	O
and	O
neuroblastoma	B-malignancy-type
aggressiveness	O
.	O
PMID	O
:	O
9379846	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Neurochem	O
.	O
1995	O
Jun;64	O
(	O
6	O
)	O
:2404-12	O
.	O
Regulation	O
of	O
tyrosine	O
hydroxylase	O
gene	O
expression	O
in	O
IMR-32	O
neuroblastoma	B-malignancy-type
cells	O
by	O
basic	O
fibroblast	O
growth	O
factor	O
and	O
ciliary	O
neurotrophic	O
factor	O
.	O
Rabinovsky	O
ED	O
,	O
Ramchatesingh	O
J,	O
McManaman	O
JL.	O
Department	O
of	O
Neurology	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
,	O
USA	O
.	O
The	O
actions	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
ciliary	O
neurotrophic	O
factor	O
(	O
CNTF	O
)	O
on	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
gene	O
expression	O
were	O
studied	O
using	O
IMR-32	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Treatment	O
of	O
these	O
cells	O
with	O
bFGF	O
for	O
3	O
days	O
induced	O
the	O
expression	O
of	O
detectable	O
levels	O
of	O
immunoreactive	O
TH	O
protein	O
and	O
TH	O
mRNA	O
.	O
In	O
contrast	O
,	O
CNTF	O
did	O
not	O
affect	O
TH	O
expression	O
unless	O
bFGF	O
was	O
present	O
.	O
In	O
the	O
presence	O
of	O
saturating	O
amounts	O
of	O
bFGF	O
,	O
CNTF	O
increased	O
TH	O
protein	O
and	O
mRNA	O
levels	O
of	O
TH	O
two	O
-	O
to	O
threefold	O
over	O
those	O
found	O
in	O
bFGF	O
-	O
treated	O
cultures	O
.	O
The	O
effects	O
of	O
CNTF	O
on	O
TH	O
expression	O
diminished	O
with	O
increasing	O
culture	O
time	O
,	O
and	O
after	O
6	O
days	O
of	O
incubation	O
CNTF	O
no	O
longer	O
enhanced	O
TH	O
levels	O
.	O
The	O
requirement	O
for	O
bFGF	O
as	O
cofactor	O
in	O
the	O
effects	O
of	O
CNTF	O
on	O
TH	O
was	O
specific	O
,	O
as	O
CNTF	O
did	O
not	O
affect	O
TH	O
when	O
it	O
was	O
coadministered	O
with	O
8-(4-chlorophenylthio)-cyclic	O
AMP	O
,	O
another	O
agent	O
that	O
stimulates	O
TH	O
development	O
in	O
this	O
cell	O
line	O
,	O
and	O
bFGF	O
was	O
not	O
required	O
for	O
CNTF	O
to	O
stimulate	O
the	O
development	O
of	O
choline	O
acetyltransferase	O
.	O
Moreover	O
,	O
cotreatment	O
with	O
bFGF	O
reduced	O
the	O
ability	O
of	O
CNTF	O
to	O
enhance	O
choline	O
acetyltransferase	O
.	O
These	O
results	O
demonstrate	O
that	O
bFGF	O
and	O
CNTF	O
can	O
enhance	O
expression	O
of	O
TH	O
and	O
that	O
bFGF	O
can	O
modify	O
the	O
effects	O
of	O
CNTF	O
on	O
neurotransmitter	O
phenotype	O
.	O
PMID	O
:	O
7760021	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1993	O
Nov	O
16;1216(	O
2	O
)	O
:273	O
-85	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
N-myc	O
gene	O
:	O
identification	O
of	O
positive	O
regulatory	O
element	O
and	O
its	O
double	O
-	O
and	O
single	O
-	O
stranded	O
DNA	O
binding	O
proteins	O
.	O
Imamura	O
Y	O
,	O
Nakagawa	O
T	O
,	O
Iguchi-	O
Ariga	O
SM	O
,	O
Ariga	O
H.	O
Faculty	O
of	O
Pharmaceutical	O
Sciences	O
,	O
Hokkaido	O
University	O
,	O
Sapporo	O
,	O
Japan	O
.	O
The	O
N-myc	O
gene	O
is	O
amplified	O
and	O
overexpressed	O
in	O
neuroblastoma	B-malignancy-type
,	O
retinoblastoma	B-malignancy-type
and	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
is	O
considered	O
to	O
be	O
related	O
to	O
cell	O
proliferation	O
and/or	O
differentiation	O
.	O
The	O
transcriptional	O
regulatory	O
sequences	O
of	O
the	O
c-myc	O
gene	O
have	O
been	O
already	O
identified	O
,	O
while	O
those	O
of	O
N-myc	O
have	O
remained	O
obscure	O
for	O
a	O
long	O
time	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
identified	O
several	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
in	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
N-myc	O
gene	O
.	O
Among	O
them	O
,	O
an	O
activating	O
sequence	O
spanning	O
-	O
860	O
to	O
-	O
797	O
bp	O
(	O
63	O
bp	O
)	O
could	O
be	O
reduced	O
to	O
a	O
functional	O
core	O
of	O
21	O
bp	O
from	O
-	O
846	O
to	O
-	O
826	O
.	O
This	O
sequence	O
,	O
termed	O
N21	O
box	O
,	O
worked	O
as	O
a	O
positive	O
transcriptional	O
element	O
when	O
linked	O
directly	O
upstream	O
(	O
but	O
not	O
downstream	O
)	O
of	O
the	O
putative	O
N-myc	O
promoter	O
in	O
HeLa	O
,	O
not	O
in	O
IMR32	O
cells	O
.	O
At	O
least	O
two	O
proteins	O
,	O
of	O
42	O
kDa	O
and	O
100	O
kDa	O
,	O
bound	O
to	O
the	O
double	O
-	O
stranded	O
N21	O
box	O
,	O
and	O
were	O
expressed	O
in	O
HeLa	O
as	O
well	O
as	O
in	O
IMR32	O
cells	O
.	O
Moreover	O
,	O
the	O
plus	O
strand	O
of	O
N21	O
box	O
could	O
be	O
specifically	O
bound	O
by	O
a	O
species	O
of	O
42	O
kDa	O
from	O
either	O
cell	O
type	O
and	O
by	O
a	O
37	O
kDa	O
protein	O
found	O
only	O
in	O
HeLa	O
cells	O
.	O
These	O
proteins	O
may	O
be	O
factors	O
binding	O
to	O
positive	O
transcriptional	O
regulatory	O
elements	O
and	O
may	O
have	O
a	O
role	O
in	O
the	O
regulation	O
of	O
N-myc	O
expression	O
.	O
PMID	O
:	O
8241268	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Neurobiol	O
.	O
2003	O
Apr;27	O
(	O
2	O
)	O
:	O
107	O
-	O
20	O
.	O
Regulation	O
of	O
neuronal	O
proliferation	O
and	O
differentiation	O
by	O
nitric	O
oxide	O
.	O
Gibbs	O
SM	O
.	O
Department	O
of	O
Biology	O
,	O
Haverford	O
College	O
,	O
Haverford	O
,	O
PA	O
19041	O
,	O
USA	O
.	O
sgibbs@haverford	O
.edu	O
Many	O
studies	O
have	O
revealed	O
the	O
free	O
radical	O
nitric	O
oxide	O
(	O
NO	O
)	O
to	O
be	O
an	O
important	O
modulator	O
of	O
vascular	O
and	O
neuronal	O
physiology	O
.	O
It	O
also	O
plays	O
a	O
developmental	O
role	O
in	O
regulating	O
synapse	O
formation	O
and	O
patterning	O
.	O
Recent	O
studies	O
suggest	O
that	O
NO	O
may	O
also	O
mediate	O
the	O
switch	O
from	O
proliferation	O
to	O
differentiation	O
during	O
neurogenesis	O
.	O
Many	O
mechanisms	O
of	O
this	O
response	O
are	O
conserved	O
between	O
neuronal	O
precursor	O
cells	O
and	O
the	O
cells	O
of	O
the	O
vascular	O
system	O
,	O
where	O
NO	O
can	O
inhibit	O
the	O
proliferative	O
response	O
of	O
endothelial	O
and	O
smooth-	O
muscle	O
cells	O
to	O
injury	O
.	O
In	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
,	O
NO	O
synthase	O
(	O
NOS	O
)	O
expression	O
is	O
increased	O
in	O
the	O
presence	O
of	O
various	O
growth	O
factors	O
and	O
mitogens	O
.	O
Subsequent	O
production	O
of	O
NO	O
leads	O
to	O
cessation	O
of	O
cell	O
division	O
and	O
the	O
acquisition	O
of	O
a	O
differentiated	O
phenotype	O
.	O
The	O
inhibitory	O
action	O
of	O
NO	O
on	O
neuroblast	O
proliferation	O
has	O
also	O
been	O
demonstrated	O
in	O
vivo	O
for	O
vertebrate	O
and	O
invertebrate	O
nervous	O
systems	O
,	O
as	O
well	O
as	O
in	O
the	O
adult	O
brain	O
.	O
Potential	O
downstream	O
effectors	O
of	O
NO	O
include	O
the	O
second	O
messenger	O
cyclic	O
GMP	O
,	O
activation	O
of	O
the	O
tumor	O
-	O
suppressor	O
genes	O
p53	O
and	O
Rb	O
,	O
and	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
.	O
These	O
studies	O
highlight	O
a	O
new	O
role	O
for	O
NO	O
in	O
the	O
nervous	O
system	O
,	O
as	O
a	O
coordinator	O
of	O
proliferation	O
and	O
patterning	O
during	O
neural	O
development	O
and	O
adult	O
neurogenesis	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Academic	O
PMID	O
:	O
12777682	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroendocrinology	O
.	O
2002	O
Feb;75	O
(	O
2	O
)	O
:	O
130	O
-	O
8.	O
Elevated	O
expression	O
of	O
galanin	O
receptors	O
in	O
childhood	O
neuroblastic	B-malignancy-type
tumors	I-malignancy-type
.	O
Berger	O
A	O
,	O
Tuechler	O
C	O
,	O
Almer	O
D	O
,	O
Kogner	O
P,	O
Ratschek	O
M,	O
Kerbl	O
R	O
,	O
Iismaa	O
TP	O
,	O
Jones	O
N	O
,	O
Sperl	O
W	O
,	O
Kofler	O
B.	O
Department	O
of	O
Pediatrics	O
,	O
General	O
Hospital	O
Salzburg	O
,	O
Salzburg	O
,	O
Austria	O
.	O
The	O
neuropeptide	O
galanin	O
(	O
GAL	O
)	O
has	O
been	O
shown	O
to	O
be	O
present	O
in	O
certain	O
brain	B-malignancy-type
tumors	I-malignancy-type
.	O
In	O
order	O
to	O
learn	O
more	O
about	O
GAL	O
and	O
its	O
receptors	O
in	O
human	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
peripheral	I-malignancy-type
nervous	I-malignancy-type
system	I-malignancy-type
,	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
GAL	O
peptide	O
and	O
the	O
GAL	O
receptors	O
in	O
tumor	O
tissue	O
from	O
childhood	O
neuroblastic	B-malignancy-type
tumors	I-malignancy-type
.	O
GAL	O
peptide	O
concentrations	O
up	O
to	O
674	O
+/-	O
166	O
fmol	O
/	O
mg	O
of	O
tissue	O
were	O
detected	O
by	O
radioimmunoassay	O
,	O
but	O
no	O
significant	O
correlation	O
with	O
standard	O
tumor	O
markers	O
or	O
the	O
prognosis	O
of	O
the	O
14	O
patients	O
investigated	O
was	O
observed	O
.	O
Ligand	O
binding	O
experiments	O
showed	O
different	O
levels	O
of	O
GAL	O
binding	O
in	O
all	O
28	O
primary	O
neuroblastomas	B-malignancy-type
and	O
7	O
ganglioneuromas	B-malignancy-type
investigated	O
.	O
All	O
three	O
human	O
GAL	O
receptor	O
subtypes	O
cloned	O
to	O
date	O
could	O
be	O
detected	O
,	O
with	O
the	O
GALR1	O
receptor	O
subtype	O
being	O
expressed	O
most	O
prominently	O
.	O
GAL	O
binding	O
did	O
not	O
significantly	O
correlate	O
with	O
genetic	O
markers	O
such	O
as	O
unfavorable	O
DNA	O
ploidy	O
,	O
amplification	O
of	O
the	O
oncogene	O
MYCN	O
and	O
allelic	O
loss	O
of	O
chromosome	O
1p	O
.	O
However	O
,	O
low	O
galanin	O
binding	O
was	O
significantly	O
correlated	O
with	O
survival	O
(	O
p	O
=	O
0.021	O
)	O
in	O
this	O
limited	O
analysis	O
of	O
neuroblastic	B-malignancy-type
tumor	I-malignancy-type
samples	O
.	O
These	O
results	O
raise	O
the	O
possibility	O
that	O
the	O
expression	O
of	O
GAL	O
binding	O
sites	O
may	O
play	O
a	O
role	O
in	O
neuroblastic	B-malignancy-type
tumor	I-malignancy-type
biology	O
and	O
behavior	O
.	O
Copyright	O
2002	O
S.	O
Karger	O
AG	O
,	O
Basel	O
PMID	O
:	O
11867941	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
.	O
2003	O
Mar;36	O
(	O
3	O
)	O
:242	O
-	O
9.	O
Rearrangements	O
and	O
increased	O
expression	O
of	O
cyclin	O
D1	O
(	O
CCND1	O
)	O
in	O
neuroblastoma	B-malignancy-type
.	O
Molenaar	O
JJ	O
,	O
van	O
Sluis	O
P,	O
Boon	O
K,	O
Versteeg	O
R	O
,	O
Caron	O
HN	O
.	O
Department	O
of	O
Human	O
Genetics	O
,	O
Academic	O
Medical	O
Centre	O
,	O
University	O
of	O
Amsterdam	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
Cyclin	O
D1	O
regulates	O
G1	O
cell	O
cycle	O
progression	O
by	O
controlling	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	O
protein	O
.	O
This	O
pathway	O
is	O
frequently	O
deregulated	O
in	O
many	O
malignancies	O
.	O
In	O
neuroblastoma	B-malignancy-type
,	O
however	O
,	O
no	O
consistent	O
G1	O
cell	O
cycle	O
checkpoint	O
aberrations	O
have	O
been	O
found	O
.	O
We	O
examined	O
the	O
possible	O
deregulation	O
of	O
cyclin	O
D1	O
(	O
CCND1	O
)	O
in	O
this	O
tumor	O
.	O
mRNA	O
expression	O
profiles	O
of	O
neuroblastoma	B-malignancy-type
generated	O
by	O
SAGE	O
(	O
Serial	O
Analysis	O
of	O
Gene	O
Expression	O
)	O
revealed	O
a	O
high	O
expression	O
of	O
CCND1	O
in	O
a	O
subset	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
tumors	O
.	O
The	O
CCND1	O
expression	O
level	O
can	O
be	O
0.3	O
%	O
of	O
the	O
total	O
cellular	O
mRNA	O
.	O
Northern	O
blot	O
analysis	O
of	O
CCND1	O
expression	O
showed	O
a	O
relative	O
overexpression	O
in	O
16	O
of	O
23	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
10	O
of	O
15	O
tumor	O
samples	O
.	O
In	O
the	O
majority	O
of	O
cases	O
,	O
the	O
high	O
CCND1	O
mRNA	O
levels	O
also	O
led	O
to	O
high	O
CCND1	O
protein	O
levels	O
.	O
In	O
the	O
search	O
for	O
mechanisms	O
causing	O
this	O
relative	O
overexpression	O
,	O
we	O
screened	O
for	O
amplifications	O
and	O
rearrangements	O
of	O
CCND1	O
.	O
Five	O
amplifications	O
were	O
found	O
in	O
202	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
and	O
cell	O
lines	O
.	O
Analysis	O
of	O
the	O
3'-UTR	O
of	O
CCND1	O
showed	O
a	O
rearrangement	O
in	O
1	O
of	O
96	O
tumors	O
.	O
These	O
clonal	O
aberrations	O
of	O
CCND1	O
together	O
with	O
the	O
high	O
expression	O
suggest	O
a	O
role	O
for	O
deregulated	O
CCND1	O
activity	O
in	O
neuroblastoma	B-malignancy-type
tumorigenesis	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12557224	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1988	O
Sep;3(	O
3	O
)	O
:	O
281	O
-	O
8.	O
The	O
expression	O
of	O
multiple	O
proto	O
-	O
oncogenes	O
is	O
differentially	O
regulated	O
during	O
retinoic	O
acid	O
induced	O
maturation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Thiele	O
CJ	O
,	O
Deutsch	O
LA	O
,	O
Israel	O
MA.	O
Molecular	O
Genetics	O
Section	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
Human	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
is	O
a	O
highly	O
malignant	O
tumor	O
arising	O
in	O
cells	O
that	O
originate	O
in	O
the	O
embryonal	O
neural	O
crest	O
.	O
Several	O
lines	O
of	O
investigation	O
suggest	O
that	O
both	O
NB	B-malignancy-type
and	O
other	O
tumors	O
of	O
developing	O
tissues	O
are	O
blocked	O
in	O
their	O
ability	O
to	O
differentiate	O
and	O
achieve	O
growth	O
arrest	O
.	O
Since	O
in	O
vivo	O
differentiation	O
of	O
NB	B-malignancy-type
has	O
been	O
frequently	O
observed	O
and	O
may	O
be	O
of	O
clinical	O
importance	O
(	O
Fox	O
et	O
al.	O
,	O
1959	O
;	O
Evans	O
et	O
al.	O
,	O
1976	O
)	O
,	O
we	O
have	O
utilized	O
the	O
in	O
vitro	O
induction	O
of	O
NB	B-malignancy-type
differentiation	O
by	O
retinoic	O
acid	O
(	O
RA	O
)	O
to	O
study	O
the	O
molecular	O
events	O
associated	O
with	O
NB	B-malignancy-type
differentiation	O
.	O
We	O
have	O
focused	O
our	O
studies	O
on	O
changes	O
that	O
occur	O
in	O
the	O
expression	O
of	O
various	O
proto	O
-	O
oncogenes	O
during	O
NB	B-malignancy-type
tumors	I-malignancy-type
cell	O
differentiation	O
because	O
proto	O
-	O
oncogenes	O
are	O
likely	O
to	O
be	O
of	O
central	O
importance	O
in	O
mediating	O
processes	O
critical	O
for	O
cellular	O
growth	O
and	O
maturation	O
.	O
In	O
these	O
studies	O
,	O
we	O
have	O
found	O
that	O
the	O
expression	O
of	O
no	O
fewer	O
than	O
five	O
proto	O
-	O
oncogenes	O
including	O
c-Ha-ras	O
,	O
c-ets	O
-1	O
,	O
and	O
c-	O
fos	O
change	O
during	O
the	O
differentiation	O
of	O
NB	B-malignancy-type
cells	O
,	O
while	O
the	O
expression	O
of	O
c-erb-B	O
changes	O
in	O
association	O
with	O
the	O
arrest	O
of	O
growth	O
that	O
occurs	O
during	O
NB	B-malignancy-type
differentiation	O
.	O
In	O
some	O
cases	O
the	O
altered	O
expression	O
of	O
a	O
proto	O
-	O
oncogene	O
was	O
transcriptionally	O
regulated	O
,	O
while	O
in	O
others	O
post	O
-	O
transcriptional	O
mechanisms	O
were	O
important	O
.	O
PMID	O
:	O
3060792	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1996	O
Sep	O
20;271	O
(	O
38	O
)	O
:	O
23126-33	O
.	O
Genesis	O
,	O
a	O
winged	O
helix	O
transcriptional	O
repressor	O
with	O
expression	O
restricted	O
to	O
embryonic	O
stem	O
cells	O
.	O
Sutton	O
J,	O
Costa	O
R	O
,	O
Klug	O
M,	O
Field	O
L,	O
Xu	O
D	O
,	O
Largaespada	O
DA	O
,	O
Fletcher	O
CF	O
,	O
Jenkins	O
NA	O
,	O
Copeland	O
NG	O
,	O
Klemsz	O
M,	O
Hromas	O
R.	O
Division	O
of	O
Hematology	O
/Oncology	O
and	O
the	O
Walther	O
Oncology	O
Center	O
,	O
IB	O
442	O
,	O
Indiana	O
University	O
Medical	O
Center	O
,	O
Indianapolis	O
,	O
Indiana	O
46202	O
-5121	O
,	O
USA	O
.	O
A	O
novel	O
member	O
of	O
the	O
winged	O
helix	O
(	O
formerly	O
HNF-3	O
/	O
Forkhead	O
)	O
transcriptional	O
regulatory	O
family	O
,	O
termed	O
Genesis	O
,	O
was	O
isolated	O
and	O
characterized	O
.	O
Putative	O
translation	O
of	O
the	O
complete	O
cDNA	O
revealed	O
the	O
winged	O
helix	O
DNA	O
binding	O
domain	O
to	O
be	O
centrally	O
located	O
within	O
the	O
protein	O
,	O
with	O
regions	O
on	O
either	O
side	O
that	O
contain	O
known	O
transcriptional	O
regulatory	O
motifs	O
.	O
Extensive	O
Northern	O
analysis	O
of	O
Genesis	O
found	O
that	O
the	O
message	O
was	O
exclusively	O
expressed	O
in	O
embryonic	O
stem	O
cells	O
or	O
their	O
malignant	O
equivalent	O
,	O
embryonal	O
carcinoma	B-malignancy-type
cells	O
.	O
The	O
Genesis	O
transcript	O
was	O
down	O
-	O
regulated	O
when	O
these	O
cells	O
were	O
stimulated	O
to	O
differentiate	O
.	O
DNA	O
sequences	O
that	O
Genesis	O
protein	O
would	O
interact	O
with	O
were	O
characterized	O
and	O
were	O
found	O
to	O
contain	O
a	O
consensus	O
similar	O
to	O
that	O
found	O
in	O
an	O
embryonic	O
stem	O
cell	O
enhancer	O
sequence	O
.	O
Co	O
-transfection	O
experiments	O
revealed	O
that	O
Genesis	O
is	O
a	O
transcriptional	O
repressor	O
.	O
Genesis	O
mapped	O
to	O
mouse	O
chromosome	O
4	O
in	O
a	O
region	O
syntenic	O
with	O
human	O
chromosome	O
1p31	O
,	O
a	O
site	O
of	O
nonrandom	O
abnormalities	O
in	O
germ	O
cell	O
neoplasia	O
,	O
neuroblastoma	B-malignancy-type
,	O
and	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Genesis	O
is	O
a	O
candidate	O
for	O
regulating	O
the	O
phenotype	O
of	O
normal	O
or	O
malignant	O
embryonic	O
stem	O
cells	O
.	O
PMID	O
:	O
8798505	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
2001	O
Oct	O
19;94	O
(	O
1-2	O
)	O
:	O
35-47	O
.	O
Genomic	O
organization	O
and	O
neuronal	O
cell	O
type	O
specific	O
promoter	O
activity	O
of	O
beta	O
isoform	O
of	O
Ca(2+)	O
/	O
calmodulin	O
dependent	O
protein	O
kinase	O
II	O
of	O
rat	O
brain	O
.	O
Donai	O
H,	O
Morinaga	O
H,	O
Yamauchi	O
T.	O
Department	O
of	O
Biochemistry	O
,	O
Faculty	O
of	O
Pharmaceutical	O
Sciences	O
,	O
Tokushima	O
University	O
,	O
Shomachi	O
1	O
,	O
770	O
-	O
8505	O
,	O
Tokushima	O
,	O
Japan	O
.	O
The	O
gene	O
encoding	O
the	O
beta	O
isoform	O
of	O
rat	O
Ca(2+)	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
was	O
cloned	O
,	O
and	O
its	O
exon	O
-	O
intron	O
organization	O
was	O
analyzed	O
.	O
The	O
gene	O
consisted	O
of	O
21	O
exons	O
spanning	O
more	O
than	O
80	O
kilobase	O
pairs	O
and	O
the	O
coding	O
sequence	O
was	O
made	O
up	O
of	O
20	O
exons	O
.	O
Each	O
discrete	O
functional	O
unit	O
,	O
such	O
as	O
the	O
ATP	O
-binding	O
site	O
,	O
the	O
autophosphorylation	O
site	O
responsible	O
for	O
Ca(2+)	O
-	O
independent	O
activity	O
,	O
the	O
calmodulin	O
binding	O
site	O
,	O
and	O
the	O
link	O
structure	O
,	O
was	O
encoded	O
by	O
a	O
single	O
exon	O
.	O
All	O
splice	O
junction	O
sequences	O
flanking	O
the	O
introns	O
conformed	O
to	O
the	O
consensus	O
splice	O
junction	O
sequence	O
and	O
the	O
GT	O
-AG	O
splice	O
rule	O
.	O
The	O
site	O
of	O
transcription	O
initiation	O
was	O
-	O
78	O
bases	O
from	O
the	O
initiation	O
codon	O
as	O
determined	O
by	O
5	O
'	O
RACE	O
analysis	O
.	O
The	O
promoter	O
activity	O
of	O
the	O
gene	O
was	O
analyzed	O
using	O
neuroblastomas	B-malignancy-type
,	O
as	O
well	O
as	O
non	O
-	O
neuronal	O
cell	O
lines	O
.	O
Neuronal	O
cell	O
type	O
-	O
specific	O
promoter	O
activity	O
was	O
found	O
in	O
the	O
5'-upstream	O
region	O
-	O
66	O
to	O
-	O
35	O
bp	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O
Silence	O
elements	O
were	O
found	O
further	O
upstream	O
at	O
-	O
222	O
to	O
-	O
123	O
bp	O
and	O
-	O
576	O
to	O
-	O
323	O
bp	O
.	O
A	O
protein	O
bound	O
to	O
the	O
-	O
66	O
to	O
-	O
35	O
region	O
was	O
found	O
in	O
the	O
nuclear	O
extract	O
of	O
rat	O
brain	O
,	O
including	O
the	O
cerebellum	O
,	O
forebrain	O
,	O
and	O
brainstem	O
,	O
by	O
gel	O
mobility	O
shift	O
assay	O
.	O
PMID	O
:	O
11597763	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Thorac	O
Cardiovasc	O
Surg	O
.	O
1994	O
Aug;42(	O
4	O
)	O
:	O
233	O
-	O
6.	O
Treatment	O
of	O
postoperative	O
chylothorax	O
by	O
pleurodesis	O
with	O
the	O
streptococcal	O
preparation	O
OK-432	O
.	O
Shimizu	O
J,	O
Hayashi	O
Y	O
,	O
Oda	O
M,	O
Morita	O
K,	O
Arano	O
Y	O
,	O
Nagao	O
S	O
,	O
Murakami	O
S	O
,	O
Urayama	O
H,	O
Watanabe	O
Y	O
.	O
Department	O
of	O
Surgery	O
,	O
Kanazawa	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Of	O
the	O
2877	O
patients	O
who	O
underwent	O
chest	O
surgery	O
at	O
our	O
department	O
during	O
the	O
20	O
-	O
year	O
period	O
between	O
1973	O
and	O
1992	O
,	O
9	O
(	O
0.3	O
%	O
)	O
developed	O
postoperative	O
chylothorax	O
.	O
The	O
underlying	O
disease	O
included	O
primary	O
lung	B-malignancy-type
cancer	I-malignancy-type
in	O
5	O
patients	O
,	O
pulmonary	B-malignancy-type
metastasis	I-malignancy-type
in	O
1	O
,	O
invasive	O
thymoma	B-malignancy-type
in	O
2	O
,	O
and	O
neuroblastoma	B-malignancy-type
of	O
the	O
posterior	O
mediastinum	O
in	O
1	O
.	O
For	O
the	O
treatment	O
of	O
chylothorax	O
,	O
the	O
thoracic	O
duct	O
was	O
ligated	O
in	O
2	O
patients	O
with	O
a	O
high	O
volume	O
of	O
chylous	O
leakage	O
.	O
In	O
6	O
patients	O
treated	O
conservatively	O
,	O
early	O
pleurodesis	O
was	O
attained	O
by	O
injecting	O
1	O
to	O
5	O
doses	O
(	O
mean	O
:	O
2.2	O
doses	O
)	O
of	O
the	O
streptoccal	O
preparation	O
OK-432	O
intrathoracically	O
;	O
favorable	O
results	O
were	O
achieved	O
.	O
In	O
1	O
patient	O
,	O
the	O
diagnosis	O
of	O
chylothorax	O
was	O
delayed	O
because	O
of	O
postoperative	O
pyothorax	O
.	O
This	O
patient	O
developed	O
nutritional	O
deficiency	O
,	O
compromised	O
immunity	O
,	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
)	O
,	O
which	O
led	O
to	O
death	O
before	O
the	O
chylothorax	O
could	O
be	O
treated	O
.	O
In	O
principle	O
,	O
postoperative	O
chylothorax	O
should	O
be	O
treated	O
conservatively	O
.	O
Favorable	O
results	O
can	O
be	O
expected	O
with	O
the	O
intrathoracic	O
injection	O
of	O
OK-432	O
beginning	O
at	O
the	O
early	O
postoperative	O
period	O
to	O
achieve	O
pleurodesis	O
,	O
combined	O
with	O
the	O
prevention	O
of	O
nutritional	O
deficiency	O
,	O
electrolyte	O
imbalance	O
,	O
and	O
infection	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
7825162	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biophys	O
J.	O
2003	O
Jan;8	O
4	O
(	O
1	O
)	O
:	O
205	O
-19	O
.	O
Voltage	O
-	O
dependent	O
blockade	O
of	O
connexin40	O
gap	O
junctions	O
by	O
spermine	O
.	O
Musa	O
H,	O
Veenstra	O
RD.	O
Department	O
of	O
Pharmacology	O
,	O
SUNY	O
Upstate	O
Medical	O
University	O
,	O
Syracuse	O
,	O
New	O
York	O
13210	O
,	O
USA	O
.	O
The	O
effects	O
of	O
spermine	O
and	O
spermidine	O
,	O
endogenous	O
polyamines	O
that	O
block	O
many	O
forms	O
of	O
ion	O
channels	O
,	O
were	O
investigated	O
in	O
homotypic	O
connexin	O
(	O
Cx	O
)-40	O
gap	O
junctions	O
expressed	O
in	O
N2A	O
cells	O
.	O
Spermine	O
blocked	O
up	O
to	O
95	O
%	O
of	O
I(j)	O
through	O
homotypic	O
Cx40	O
gap	O
junctions	O
in	O
a	O
concentration	O
-	O
and	O
transjunctional	O
voltage	O
(	O
V(	O
j)	O
)	O
-	O
dependent	O
manner	O
.	O
V(	O
j)	O
was	O
varied	O
from	O
5	O
to	O
50	O
mV	O
in	O
5-mV	O
steps	O
and	O
the	O
dissociation	O
constants	O
(	O
K(m)	O
)	O
were	O
determined	O
from	O
spermine	O
concentrations	O
ranging	O
from	O
10	O
micro	O
M	O
to	O
2	O
mM	O
.	O
The	O
K(m)	O
values	O
ranged	O
from	O
4.9	O
mM	O
to	O
107	O
micro	O
M	O
for	O
8.6	O
<	O
or	O
=	O
V(	O
j)	O
<	O
or	O
=	O
37.7	O
mV	O
,	O
within	O
the	O
physiological	O
range	O
of	O
intracellular	O
spermine	O
for	O
V(	O
j)	O
>	O
or	O
=	O
20	O
mV	O
.	O
The	O
K(m)	O
values	O
for	O
spermidine	O
were	O
>	O
or	O
=	O
5	O
mM	O
.	O
Estimates	O
of	O
the	O
electrical	O
distance	O
(	O
delta	O
)	O
for	O
spermine	O
(	O
z	O
=	O
+4)	O
and	O
spermidine	O
(	O
z	O
=	O
+3	O
)	O
were	O
0.96	O
and	O
0.76	O
respectively	O
.	O
Cx40	O
single	O
channel	O
conductance	O
was	O
129	O
pS	O
in	O
the	O
presence	O
of	O
2-mM	O
spermine	O
and	O
channel	O
open	O
probability	O
was	O
significantly	O
reduced	O
in	O
a	O
V(	O
j)	O
-	O
dependent	O
manner	O
.	O
Similar	O
concentrations	O
of	O
spermine	O
did	O
not	O
block	O
I(j)	O
through	O
homotypic	O
Cx43	O
gap	O
junctions	O
,	O
indicating	O
that	O
spermine	O
selectively	O
blocks	O
Cx40	O
gap	O
junctions	O
.	O
This	O
is	O
contrary	O
to	O
our	O
previous	O
findings	O
that	O
large	O
tetraalkylammonium	O
ions	O
,	O
also	O
known	O
to	O
block	O
several	O
forms	O
of	O
ion	O
channels	O
,	O
block	O
junctional	O
currents	O
(	O
I(j)	O
)	O
through	O
homotypic	O
connexin	O
Cx40	O
and	O
Cx43	O
gap	O
junctions	O
.	O
PMID	O
:	O
12524276	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
May	O
10	O
;277	O
(	O
19	O
)	O
:16798-804	O
.	O
Epub	O
2002	O
Mar	O
04	O
.	O
Tyrosine	O
phosphorylation	O
of	O
the	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
cytoplasmic	O
tail	O
promotes	O
interaction	O
with	O
Shc	O
.	O
Tarr	O
PE	O
,	O
Roncarati	O
R	O
,	O
Pelicci	O
G	O
,	O
Pelicci	O
PG	O
,	O
D'Adamio	O
L.	O
Department	O
of	O
Microbiology	O
and	O
Immunology	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Bronx	O
,	O
New	O
York	O
10461	O
,	O
USA	O
.	O
beta	O
-	O
Amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
is	O
a	O
widely	O
expressed	O
transmembrane	O
protein	O
of	O
unknown	O
function	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O
The	O
cytoplasmic	O
tail	O
of	O
APP	O
interacts	O
with	O
phosphotyrosine	O
binding	O
(	O
PTB	O
)	O
domain	O
containing	O
proteins	O
(	O
Fe65	O
,	O
X11	O
,	O
mDab	O
-	O
1	O
,	O
and	O
JIP	O
-	O
1	O
)	O
and	O
may	O
modulate	O
gene	O
expression	O
and	O
apoptosis	O
.	O
We	O
now	O
identify	O
Shc	O
A	O
and	O
Shc	O
C	O
,	O
PTB	O
-	O
containing	O
adapter	O
proteins	O
that	O
signal	O
to	O
cellular	O
differentiation	O
and	O
survival	O
pathways	O
,	O
as	O
novel	O
APP	O
-	O
interacting	O
proteins	O
.	O
The	O
APP	O
cytoplasmic	O
tail	O
contains	O
a	O
PTB	O
-	O
binding	O
motif	O
(	O
Y	O
(	O
682	O
)	O
ENPTY	O
(	O
687	O
)	O
)	O
that	O
,	O
when	O
phosphorylated	O
on	O
Tyr	O
(	O
682	O
)	O
,	O
precipitated	O
the	O
PTB	O
domain	O
of	O
Shc	O
A	O
and	O
Shc	O
C	O
,	O
as	O
well	O
as	O
endogenous	O
full	O
-	O
length	O
Shc	O
A	O
.	O
APP	O
and	O
Shc	O
C	O
were	O
physically	O
associated	O
in	O
adult	O
mouse	O
brain	O
homogenates	O
.	O
Increase	O
in	O
phosphorylation	O
of	O
APP	O
by	O
overexpression	O
of	O
the	O
nerve	O
growth	O
factor	O
receptor	O
Trk	O
A	O
in	O
293T	O
cells	O
promoted	O
the	O
interaction	O
of	O
transfected	O
APP	O
and	O
endogenous	O
Shc	O
A	O
.	O
Pervanadate	O
treatment	O
of	O
N2a	O
neuroblastoma	B-malignancy-type
cells	O
resulted	O
in	O
tyrosine	O
phosphorylation	O
and	O
association	O
of	O
endogenous	O
APP	O
and	O
Shc	O
A	O
.	O
Thus	O
,	O
APP	O
and	O
Shc	O
proteins	O
interact	O
in	O
vitro	O
,	O
in	O
cells	O
,	O
and	O
in	O
the	O
mouse	O
brain	O
.	O
Tyrosine	O
phosphorylation	O
of	O
APP	O
may	O
promote	O
the	O
interaction	O
with	O
Shc	O
proteins	O
.	O
PMID	O
:	O
11877420	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
2004	O
Feb	O
5;121	O
(	O
1-2	O
)	O
:	O
131	O
-6.	O
Muscarinic	O
acetylcholine	O
receptor	O
stimulation	O
induces	O
expression	O
of	O
the	O
activity	O
-	O
regulated	O
cytoskeleton	O
-	O
associated	O
gene	O
(	O
ARC	O
)	O
.	O
Teber	O
I	O
,	O
Kohling	O
R	O
,	O
Speckmann	O
EJ	O
,	O
Barnekow	O
A	O
,	O
Kremerskothen	O
J.	O
Department	O
for	O
Experimental	O
Tumorbiology	O
,	O
Institute	O
for	O
Neurobiology	O
,	O
University	O
Muenster	O
,	O
Badestrasse	O
9	O
,	O
D-	O
48149	O
Muenster	O
,	O
Germany	O
.	O
Muscarinic	O
acetylcholine	O
receptors	O
(	O
mAChR	O
)	O
are	O
involved	O
in	O
learning	O
and	O
memory	O
but	O
their	O
molecular	O
function	O
in	O
these	O
processes	O
is	O
not	O
fully	O
understood	O
.	O
In	O
this	O
study	O
,	O
the	O
signal	O
transduction	O
pathway	O
coupling	O
mAChR	O
activation	O
to	O
induction	O
of	O
the	O
activity	O
-	O
regulated	O
cytoskeleton	O
-	O
associated	O
gene	O
(	O
ARC	O
)	O
was	O
examined	O
.	O
ARC	O
was	O
first	O
identified	O
as	O
an	O
effector	O
immediate	O
early	O
gene	O
induced	O
by	O
neuronal	O
activity	O
and	O
ARC	O
protein	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
synaptic	O
plasticity	O
.	O
In	O
rats	O
,	O
intraperitoneal	O
injection	O
of	O
pilocarpine	O
,	O
a	O
potent	O
agonist	O
of	O
mAChR	O
,	O
led	O
to	O
increased	O
ARC	O
expression	O
in	O
the	O
brain	O
.	O
In	O
human	O
SH	O
-	O
SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
mAChR	O
stimulation	O
with	O
carbachol	O
caused	O
a	O
rapid	O
and	O
robust	O
induction	O
of	O
ARC	O
expression	O
.	O
This	O
effect	O
was	O
inhibited	O
by	O
atropine	O
,	O
a	O
nonselective	O
muscarinic	O
receptor	O
antagonist	O
as	O
well	O
as	O
by	O
M1	O
/	O
M3	O
subtype	O
-	O
specific	O
antagonists	O
.	O
Analysis	O
of	O
mAChR	O
downstream	O
effectors	O
revealed	O
that	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
tyrosine	O
kinases	O
of	O
the	O
src	O
family	O
are	O
key	O
molecules	O
in	O
the	O
signal	O
cascade	O
leading	O
to	O
ARC	O
expression	O
.	O
Our	O
data	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
a	O
correlation	O
exists	O
among	O
mAChR	O
-	O
controlled	O
signal	O
cascades	O
,	O
the	O
induction	O
of	O
the	O
effector	O
immediate	O
early	O
gene	O
ARC	O
and	O
synaptic	O
plasticity	O
.	O
PMID	O
:	O
14969744	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Anticancer	O
Res	O
.	O
1994	O
Jan-	O
Feb;14(	O
1A	O
)	O
:221	O
-	O
7.	O
Uptake	O
and	O
cytotoxicity	O
of	O
ascorbic	O
acid	O
and	O
dehydroascorbic	O
acid	O
in	O
neuroblastoma	B-malignancy-type
(	O
SK	O
-	O
N	O
-	O
SH	O
)	O
and	O
neuroectodermal	O
(	O
SK	O
-	O
N	O
-	O
LO	O
)	O
cells	O
.	O
Baader	O
SL	O
,	O
Bruchelt	O
G	O
,	O
Trautner	O
MC	O
,	O
Boschert	O
H,	O
Niethammer	O
D.	O
Children	O
's	O
Hospital	O
,	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
University	O
of	O
Tuebingen	O
,	O
Germany	O
.	O
Ascorbic	O
acid	O
(	O
AA	O
)	O
was	O
found	O
to	O
be	O
cytotoxic	O
to	O
neuroblastoma	B-malignancy-type
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
the	O
present	O
,	O
study	O
we	O
investigated	O
whether	O
the	O
reduced	O
--	O
(	O
AA	O
)	O
or	O
oxidized	O
form	O
(	O
dehydroascorbic	O
acid	O
,	O
DhAA	O
)	O
and	O
its	O
rapidly	O
formed	O
metabolites	O
were	O
the	O
main	O
cytotoxic	O
agents	O
.	O
In	O
neuroblastoma	B-malignancy-type
SK	O
-	O
N	O
-	O
SH	O
cells	O
,	O
AA	O
was	O
found	O
to	O
be	O
more	O
cytotoxic	O
than	O
DhAA	O
,	O
although	O
considerably	O
higher	O
amounts	O
of	O
[14C]DhAA	O
than	O
of	O
[14C]AA	O
were	O
incorporated	O
.	O
In	O
contrast	O
,	O
SK	O
-	O
N	O
-	O
LO	O
cells	O
derived	O
from	O
neuroectodermal	O
tissue	O
in	O
fact	O
showed	O
a	O
similar	O
uptake	O
but	O
were	O
much	O
less	O
injured	O
by	O
both	O
substances	O
.	O
We	O
observed	O
that	O
uptake	O
of	O
[14C]AA	O
and	O
[14C]DhAA	O
was	O
impaired	O
in	O
the	O
presence	O
of	O
dithiothreitol	O
and	O
glutathione	O
.	O
Once	O
inside	O
the	O
cell	O
,	O
[14C]DhAA	O
was	O
partially	O
reduced	O
to	O
[14C]AA	O
.	O
From	O
these	O
data	O
we	O
conclude	O
first	O
that	O
at	O
least	O
part	O
of	O
AA	O
is	O
oxidized	O
prior	O
to	O
its	O
uptake	O
,	O
and	O
second	O
that	O
the	O
reduced	O
form	O
of	O
AA	O
and	O
perhaps	O
ascorbyl	O
radicals	O
but	O
not	O
DhAA	O
or	O
its	O
metabolites	O
are	O
the	O
most	O
important	O
forms	O
in	O
mediating	O
cytotoxic	O
reactions	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Furthermore	O
,	O
the	O
results	O
strengthen	O
the	O
previous	O
assumption	O
that	O
AA	O
acts	O
as	O
a	O
pro	O
-	O
oxidant	O
in	O
neuroblastoma	B-malignancy-type
cells	O
and	O
supports	O
its	O
use	O
in	O
the	O
treatment	O
of	O
neuroblastoma	B-malignancy-type
,	O
especially	O
in	O
combination	O
with	O
existing	O
chemotherapeutics	O
.	O
PMID	O
:	O
8166453	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
2000	O
Mar;36	O
(	O
4	O
)	O
:	O
508-13	O
.	O
Allelic	O
imbalance	O
on	O
chromosome	O
18	O
in	O
neuroblastoma	B-malignancy-type
.	O
Takita	O
J,	O
Hayashi	O
Y	O
,	O
Takei	O
K,	O
Yamaguchi	O
N	O
,	O
Hanada	O
R	O
,	O
Yamamoto	O
K,	O
Yokota	O
J.	O
Biology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
5-1-1	O
,	O
Tsukiji	O
,	O
Chuo-ku	O
,	O
Tokyo	O
,	O
Japan	O
.	O
We	O
previously	O
demonstrated	O
that	O
chromosome	O
18	O
is	O
frequently	O
deleted	O
in	O
neuroblastoma	B-malignancy-type
.	O
To	O
further	O
elucidate	O
the	O
role	O
of	O
chromosome	O
18	O
deletions	O
in	O
the	O
development	O
of	O
neuroblastomas	B-malignancy-type
we	O
examined	O
82	O
cases	O
of	O
neuroblastomas	B-malignancy-type
for	O
allelic	O
imbalance	O
(	O
AI	O
)	O
at	O
17	O
loci	O
on	O
chromosome	O
18	O
to	O
define	O
the	O
common	O
region	O
of	O
AI	O
in	O
neuroblastoma	B-malignancy-type
.	O
AI	O
at	O
one	O
or	O
more	O
loci	O
on	O
chromosome	O
18	O
was	O
detected	O
in	O
18	O
/	O
82	O
(	O
22	O
%	O
)	O
cases	O
.	O
AI	O
on	O
18q	O
was	O
detected	O
in	O
17	O
/	O
82	O
(	O
21	O
%	O
)	O
cases	O
,	O
whereas	O
AI	O
on	O
18p	O
was	O
detected	O
in	O
4	O
/	O
82	O
(	O
5	O
%	O
)	O
cases	O
.	O
There	O
was	O
a	O
distinct	O
common	O
region	O
of	O
AI	O
at	O
18q21.1	O
between	O
the	O
D18S363	O
and	O
D18S858	O
loci	O
.	O
In	O
addition	O
,	O
cases	O
16	O
and	O
53	O
,	O
which	O
did	O
not	O
show	O
AI	O
at	O
18q21.1	O
,	O
showed	O
AI	O
at	O
18pter	O
-	O
q12.3	O
between	O
the	O
D18S52	O
and	O
D18S36	O
loci	O
,	O
indicating	O
that	O
another	O
common	O
region	O
of	O
AI	O
may	O
exist	O
on	O
chromosome	O
18	O
.	O
AI	O
on	O
chromosome	O
18	O
did	O
not	O
significantly	O
correlate	O
with	O
any	O
clinicopathological	O
findings	O
of	O
patients	O
with	O
neuroblastoma	B-malignancy-type
.	O
The	O
common	O
region	O
of	O
AI	O
at	O
18q21.1	O
includes	O
the	O
DCC	O
gene	O
but	O
not	O
the	O
Smad2	O
and	O
Smad4	O
genes	O
.	O
However	O
,	O
our	O
previous	O
studies	O
together	O
with	O
the	O
present	O
study	O
indicated	O
that	O
the	O
incidence	O
of	O
DCC	O
mutation	O
is	O
much	O
less	O
than	O
that	O
of	O
AI	O
at	O
18q21.1	O
in	O
neuroblastoma	B-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
novel	O
tumour	O
suppressor	O
genes	O
involved	O
in	O
the	O
development	O
of	O
neuroblastoma	B-malignancy-type
are	O
present	O
at	O
18q21.1	O
,	O
and	O
possibly	O
at	O
18pter	O
-	O
q12.3	O
.	O
PMID	O
:	O
10717528	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurochem	O
Res	O
.	O
1995	O
Jun;20	O
(	O
6	O
)	O
:	O
675	O
-80	O
.	O
Ciliary	O
neurotrophic	O
factor	O
-	O
induced	O
gene	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Rossino	O
P,	O
Volpe	O
G	O
,	O
Negro	O
A	O
,	O
Callegaro	O
L,	O
Altruda	O
F	O
,	O
Tarone	O
G	O
,	O
Silengo	O
L.	O
Department	O
of	O
Genetics	O
,	O
Biology	O
and	O
Medical	O
Chemistry	O
,	O
University	O
of	O
Torino	O
,	O
Italy	O
.	O
We	O
have	O
analyzed	O
the	O
response	O
of	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
SK	O
-	O
N	O
-	O
SH	O
(	O
clone	O
SY5Y	O
)	O
and	O
SK	O
-	O
N	O
-	O
BE	O
to	O
the	O
ciliary	O
neurotrophic	O
factor	O
CNTF	O
.	O
In	O
both	O
cell	O
lines	O
CNTF	O
induced	O
the	O
expression	O
of	O
the	O
mRNA	O
for	O
two	O
transcription	O
factors	O
,	O
c	O
-	O
fos	O
and	O
NGF1A	O
.	O
The	O
induction	O
was	O
rapid	O
and	O
transient	O
reaching	O
a	O
maximum	O
between	O
30	O
and	O
60	O
min	O
after	O
exposure	O
to	O
CNTF	O
and	O
subsequently	O
declining	O
.	O
The	O
level	O
of	O
induction	O
of	O
both	O
c	O
-	O
fos	O
and	O
NGF1A	O
mRNAs	O
was	O
much	O
higher	O
in	O
SK	O
-	O
N	O
-	O
BE	O
neuroblastoma	B-malignancy-type
cells	O
compared	O
to	O
the	O
SY5Y	O
.	O
Both	O
cells	O
express	O
comparable	O
levels	O
of	O
the	O
transcript	O
for	O
the	O
CNTF	O
receptor	O
-	O
alpha	O
.	O
This	O
mRNA	O
was	O
down	O
regulated	O
after	O
5	O
days	O
of	O
CNTF	O
stimulation	O
in	O
both	O
cell	O
lines	O
.	O
CNTF	O
also	O
induced	O
increased	O
levels	O
of	O
the	O
transcript	O
for	O
the	O
growth	O
cone	O
associated	O
protein	O
GAP43	O
in	O
SK	O
-	O
N	O
-	O
BE	O
,	O
but	O
not	O
in	O
SY5Y	O
cells	O
.	O
Induction	O
followed	O
a	O
slower	O
kinetic	O
compared	O
to	O
that	O
observed	O
for	O
c	O
-	O
fos	O
and	O
NGF1A	O
.	O
In	O
fact	O
,	O
the	O
GAP43	O
mRNA	O
levels	O
increased	O
during	O
2	O
days	O
of	O
exposure	O
to	O
CNTF	O
.	O
Morphological	O
analysis	O
of	O
CNTF	O
treated	O
cells	O
showed	O
that	O
SK	O
-	O
N	O
-	O
BE	O
undergo	O
significant	O
differentiation	O
in	O
response	O
to	O
CNTF	O
(	O
increased	O
number	O
of	O
cells	O
with	O
neurites	O
and	O
increased	O
neurite	O
length	O
)	O
while	O
SY5Y	O
did	O
not	O
show	O
appreciable	O
morphological	O
differentiation	O
.	O
These	O
data	O
shows	O
that	O
CNTF	O
may	O
elicit	O
different	O
response	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
PMID	O
:	O
7566363	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Life	O
Sci	O
.	O
1983;33	O
Suppl	O
1	O
:401-4.	O
Megadoses	O
of	O
vitamin	O
C	O
prevent	O
the	O
development	O
of	O
tolerance	O
and	O
physical	O
dependence	O
on	O
morphine	O
in	O
mice	O
.	O
Khanna	O
NC	O
,	O
Sharma	O
SK.	O
In	O
mice	O
ascorbate	O
,	O
when	O
co	O
-	O
administered	O
with	O
morphine	O
,	O
suppresses	O
the	O
development	O
of	O
tolerance	O
and	O
physical	O
dependence	O
on	O
the	O
drug	O
,	O
without	O
significantly	O
affecting	O
its	O
analgesic	O
properties	O
as	O
inferred	O
from	O
unaltered	O
ED50	O
values	O
.	O
The	O
duration	O
of	O
morphine	O
-	O
induced	O
analgesia	O
,	O
however	O
,	O
is	O
progressively	O
reduced	O
with	O
an	O
increase	O
in	O
the	O
amounts	O
of	O
ascorbate	O
.	O
Ascorbate	O
at	O
1	O
g	O
/	O
kg	O
body	O
weight	O
does	O
not	O
alter	O
the	O
pH	O
of	O
blood	O
,	O
and	O
has	O
no	O
effect	O
on	O
the	O
levels	O
of	O
lipid	O
-	O
peroxides	O
in	O
blood	O
and	O
brain	O
.	O
Studies	O
presented	O
in	O
this	O
paper	O
suggest	O
the	O
potential	O
use	O
of	O
ascorbate	O
in	O
the	O
prevention	O
of	O
development	O
of	O
tolerance	O
in	O
therapeutic	O
applications	O
of	O
narcotics	O
as	O
analgesics	O
.	O
Cultured	O
Neuroblastoma	B-malignancy-type
X	O
Glioma	B-malignancy-type
hybrid	I-malignancy-type
cells	O
(	O
NG	O
108	O
-	O
15	O
)	O
respond	O
to	O
opiates	O
in	O
two	O
different	O
ways	O
.	O
The	O
rapid	O
receptor	O
mediated	O
inhibition	O
of	O
adenylate	O
cyclase	O
is	O
followed	O
by	O
a	O
long	O
-	O
lived	O
compensatory	O
increase	O
in	O
its	O
activity	O
(	O
1	O
-	O
4	O
)	O
.	O
In	O
a	O
recent	O
report	O
(	O
5	O
)	O
we	O
have	O
shown	O
that	O
ascorbate	O
suppresses	O
the	O
delayed	O
etorphine	O
-	O
induced	O
compensatory	O
increase	O
in	O
cAMP	O
levels	O
in	O
NG	O
108	O
-	O
15	O
cells	O
without	O
affecting	O
the	O
short	O
-	O
term	O
inhibitory	O
response	O
of	O
cells	O
to	O
the	O
drug	O
.	O
It	O
has	O
been	O
suggested	O
that	O
while	O
the	O
former	O
may	O
be	O
the	O
basis	O
of	O
narcotic	O
dependence	O
and	O
tolerance	O
,	O
the	O
latter	O
is	O
responsible	O
for	O
the	O
analgesic	O
effect	O
.	O
These	O
observations	O
,	O
based	O
on	O
a	O
model	O
system	O
,	O
prompted	O
us	O
to	O
examine	O
the	O
effect	O
of	O
ascorbate	O
on	O
the	O
pharmacological	O
properties	O
of	O
morphine	O
at	O
the	O
organismal	O
level	O
.	O
PMID	O
:	O
6686637	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neoplasma	O
.	O
1996	O
;43(	O
1	O
)	O
:	O
23	O
-	O
6.	O
DNA	O
ploidy	O
in	O
neuroblastoma	B-malignancy-type
.	O
Eckschlager	O
T	O
,	O
Pilat	O
D	O
,	O
Kodet	O
R	O
,	O
Dahbiova	O
R	O
,	O
Stankova	O
J,	O
Jasinska	O
J,	O
Hrusak	O
O	O
.	O
Department	O
of	O
Pediatric	O
Oncology	O
,	O
University	O
Hospital	O
Motol	O
,	O
Prague	O
,	O
Czech	O
Republic	O
.	O
Neuroblastoma	B-malignancy-type
is	O
perhaps	O
the	O
most	O
heterogeneous	O
childhood	O
cancer	O
in	O
terms	O
of	O
clinical	O
behavior	O
.	O
Stage	O
of	O
disease	O
,	O
age	O
at	O
diagnosis	O
,	O
levels	O
of	O
urinary	O
catecholamine	O
excretion	O
,	O
N	O
-	O
myc	O
amplification	O
,	O
and	O
DNA	O
ploidy	O
have	O
been	O
found	O
to	O
be	O
significant	O
prognostic	O
factors	O
.	O
The	O
aims	O
of	O
this	O
combined	O
retrospective	O
-	O
prospective	O
study	O
are	O
to	O
verify	O
the	O
prognostic	O
significance	O
of	O
DNA	O
ploidy	O
and	O
to	O
show	O
its	O
correlation	O
with	O
other	O
prognostic	O
signs	O
.	O
Thirty	O
six	O
fresh	O
and	O
thirty	O
three	O
paraffin	O
embedded	O
samples	O
from	O
patients	O
with	O
histologically	O
confirmed	O
neuroblastoma	B-malignancy-type
(	O
41	O
prior	O
to	O
receiving	O
any	O
chemotherapy	O
)	O
were	O
available	O
for	O
flow	O
cytometry	O
DNA	O
analysis	O
.	O
Our	O
results	O
showed	O
that	O
the	O
maturation	O
induced	O
during	O
chemotherapy	O
could	O
give	O
rise	O
to	O
aneuploidy	O
therefore	O
we	O
analyzed	O
the	O
associations	O
between	O
the	O
DNA	O
ploidy	O
and	O
other	O
prognostic	O
markers	O
only	O
in	O
patients	O
examined	O
before	O
chemotherapy	O
.	O
There	O
were	O
no	O
significant	O
correlations	O
between	O
DNA	O
ploidy	O
and	O
urinary	O
catecholamine	O
metabolites	O
levels	O
or	O
tumor	O
localization	O
.	O
DNA	O
aneuploidy	O
was	O
significantly	O
more	O
frequent	O
in	O
patients	O
with	O
lower	O
clinical	O
stage	O
,	O
lower	O
age	O
at	O
diagnosis	O
,	O
and	O
without	O
N	O
-	O
myc	O
gene	O
amplification	O
.	O
Patients	O
with	O
DNA	O
aneuploid	O
neuroblastomas	B-malignancy-type
died	O
less	O
frequently	O
than	O
patients	O
with	O
DNA	O
diploid	O
tumors	O
.	O
There	O
were	O
no	O
significant	O
associations	O
among	O
the	O
S	O
-	O
phase	O
or	O
proliferation	O
fraction	O
and	O
other	O
prognostic	O
factors	O
.	O
PMID	O
:	O
8843955	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Toxicol	O
Lett	O
.	O
2003	O
Apr	O
4;139	O
(	O
2-3	O
)	O
:	O
213	O
-	O
9.	O
Caspase	O
-	O
1	O
inhibitors	O
abolish	O
deleterious	O
enhancement	O
of	O
COX	O
-	O
2	O
expression	O
induced	O
by	O
HIV	O
-	O
1	O
gp	O
120	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Corasaniti	O
MT	O
,	O
Bellizzi	O
C	O
,	O
Russo	O
R	O
,	O
Colica	O
C	O
,	O
Amantea	O
D	O
,	O
Di	O
Renzo	O
G.	O
Department	O
of	O
Pharmacobiological	O
Sciences	O
,	O
University	O
'Magna	O
Graecia	O
'	O
of	O
Catanzaro	O
,	O
Faculty	O
of	O
Pharmacy	O
,	O
C/	O
o	O
Complesso	O
'Nini;	O
Barbieri'	O
,	O
88021	O
Roccelletta	O
di	O
Borgia	O
(	O
CZ	O
)	O
,	O
Catanzaro	O
,	O
Italy	O
.	O
mtcorasa@unicz.it	O
The	O
human	O
CHP100	O
neuroblastoma	B-malignancy-type
cell	O
line	O
has	O
been	O
shown	O
to	O
provide	O
an	O
useful	O
in	O
vitro	O
model	O
to	O
elucidate	O
the	O
mechanisms	O
underlying	O
HIV	O
-	O
1	O
gp	O
120	O
neurotoxicity	O
.	O
Here	O
we	O
report	O
western	O
blotting	O
evidence	O
demonstrating	O
that	O
exposure	O
to	O
a	O
cytotoxic	O
concentration	O
of	O
the	O
viral	O
coat	O
protein	O
up	O
-	O
regulates	O
expression	O
of	O
the	O
inducible	O
isoform	O
of	O
cyclooxygenase	O
(	O
COX	O
-	O
2	O
)	O
in	O
neuroblastoma	B-malignancy-type
cells	O
and	O
this	O
seems	O
to	O
be	O
due	O
to	O
the	O
previously	O
observed	O
increase	O
in	O
secreted	O
IL	O
-	O
1beta	O
.	O
In	O
fact	O
,	O
here	O
we	O
show	O
that	O
acetyl	O
-	O
Tyr	O
-	O
Val	O
-	O
Ala	O
-	O
Asp	O
-	O
chloromethylketone	O
(	O
Ac	O
-	O
YVAD	O
-	O
CMK	O
)	O
and	O
t	O
-	O
butoxycarbonyl	O
-	O
L	O
-	O
aspartic	O
acid	O
benzyl	O
ester	O
-	O
chloromethylketone	O
(	O
Boc	O
-	O
Asp	O
-	O
(	O
OBzl	O
)	O
-	O
CMK	O
)	O
,	O
two	O
inhibitors	O
of	O
Interleukin	O
-	O
1	O
Converting	O
Enzyme	O
(	O
ICE	O
;	O
also	O
referred	O
to	O
as	O
caspase	O
-	O
1	O
)	O
,	O
abolish	O
COX	O
-	O
2	O
expression	O
enhanced	O
by	O
gp	O
120	O
and	O
consequent	O
cell	O
death	O
.	O
In	O
addition	O
,	O
NS	O
-	O
398	O
,	O
a	O
selective	O
inhibitor	O
of	O
COX	O
-	O
2	O
activity	O
,	O
affords	O
neuroprotection	O
strengthening	O
the	O
role	O
of	O
COX	O
-	O
2	O
in	O
the	O
mechanisms	O
of	O
death	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
data	O
support	O
the	O
notion	O
that	O
IL	O
-	O
1beta	O
is	O
the	O
signal	O
through	O
which	O
gp	O
120	O
elevates	O
COX	O
-	O
2	O
expression	O
and	O
the	O
latter	O
is	O
strongly	O
implicated	O
in	O
the	O
mechanisms	O
underlying	O
cytotoxicity	O
.	O
PMID	O
:	O
12628757	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neuroendocrinol	O
.	O
1994	O
Aug;	O
6	O
(	O
4	O
)	O
:	O
409	O
-	O
13	O
.	O
Expression	O
and	O
down	O
-	O
regulation	O
by	O
retinoic	O
acid	O
of	O
IGF	O
binding	O
protein	O
-	O
2	O
and	O
-	O
4	O
in	O
medium	O
from	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Bernardini	O
S	O
,	O
Cianfarani	O
S	O
,	O
Spagnoli	O
A	O
,	O
Annicchiarico-Petruzzelli	O
M,	O
Melino	O
G	O
,	O
Massoud	O
R	O
,	O
Boscherini	O
B	O
,	O
Finazzi-	O
Agro	O
A	O
,	O
Rosenfeld	O
RG	O
,	O
Federici	O
G.	O
Department	O
of	O
Biology	O
,	O
University	O
of	O
Rome	O
Tor	O
Vergata	O
,	O
Italy	O
.	O
Insulin	O
-	O
like	O
growth	O
factors	O
(	O
IGFs	O
)	O
regulate	O
the	O
autocrine	O
/	O
paracrine	O
growth	O
of	O
neuroblastomas	B-malignancy-type
.	O
The	O
IGFs	O
bind	O
to	O
specific	O
binding	O
proteins	O
(	O
IGFBPs	O
)	O
which	O
modulate	O
their	O
biological	O
activity	O
.	O
We	O
investigated	O
,	O
by	O
Western	O
ligand	O
blotting	O
(	O
WLB	O
)	O
,	O
the	O
presence	O
of	O
IGFBPs	O
and	O
their	O
possible	O
modulation	O
by	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
IGF	O
-	O
I	O
,	O
IGF	O
-	O
II	O
and	O
truncated	O
Des	O
(	O
1	O
-	O
3	O
)	O
IGF	O
-	O
I	O
in	O
conditioned	O
medium	O
(	O
CM	O
)	O
of	O
the	O
human	O
neuroblastoma	B-malignancy-type
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
.	O
We	O
demonstrated	O
the	O
presence	O
of	O
two	O
IGFBPs	O
,	O
with	O
MW	O
37	O
kDa	O
and	O
25	O
kDa	O
.	O
Following	O
immunoprecipitation	O
,	O
they	O
turned	O
out	O
to	O
be	O
IGFBP	O
-	O
2	O
and	O
-	O
4	O
,	O
respectively	O
.	O
The	O
RA	O
-	O
induced	O
differentiation	O
in	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cells	O
was	O
accompanied	O
by	O
a	O
marked	O
reduction	O
of	O
the	O
intensity	O
of	O
both	O
IGFBP	O
bands	O
after	O
48	O
h	O
(	O
32	O
%	O
and	O
24	O
%	O
of	O
control	O
,	O
respectively	O
)	O
and	O
72	O
h	O
(	O
2	O
%	O
and	O
0	O
%	O
of	O
control	O
,	O
respectively	O
)	O
incubation	O
.	O
The	O
addition	O
of	O
exogenous	O
IGFs	O
,	O
which	O
did	O
not	O
induce	O
cell	O
differentiation	O
,	O
did	O
not	O
change	O
the	O
IGFBP	O
pattern	O
significantly	O
,	O
except	O
for	O
the	O
truncated	O
form	O
of	O
IGF	O
-	O
I	O
,	O
which	O
induced	O
a	O
marked	O
decrease	O
in	O
both	O
the	O
37	O
kDa	O
and	O
25	O
kDa	O
bands	O
after	O
72	O
h	O
incubation	O
(	O
45	O
%	O
and	O
18	O
%	O
of	O
control	O
,	O
respectively	O
)	O
.	O
These	O
findings	O
suggest	O
that	O
IGFBPs	O
have	O
a	O
role	O
in	O
RA	O
-	O
induced	O
differentiation	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
7527270	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1998	O
Jan;34(	O
1	O
)	O
:	O
111	O
-	O
7.	O
Retinoid	O
-	O
induced	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
:	O
comparison	O
between	O
LG69	O
,	O
an	O
RXR	O
-	O
selective	O
analogue	O
and	O
9	O
-	O
cis	O
retinoic	O
acid	O
.	O
Irving	O
H,	O
Lovat	O
PE	O
,	O
Hewson	O
QC	O
,	O
Malcolm	O
AJ	O
,	O
Pearson	O
AD	O
,	O
Redfern	O
CP	O
.	O
Department	O
of	O
Child	O
Health	O
,	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
U.K.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
in	O
vitro	O
the	O
effects	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9	O
-	O
cis	O
RA	O
and	O
the	O
RXR	O
-	O
selective	O
analogue	O
,	O
LG69	O
,	O
on	O
the	O
morphological	O
differentiation	O
,	O
proliferation	O
and	O
gene	O
expression	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Three	O
different	O
cell	O
lines	O
were	O
cultured	O
with	O
the	O
retinoid	O
for	O
either	O
9	O
continuous	O
days	O
or	O
for	O
5	O
days	O
followed	O
by	O
4	O
days	O
without	O
the	O
retinoid	O
and	O
morphological	O
differentiation	O
was	O
assessed	O
both	O
qualitatively	O
and	O
quantitatively	O
.	O
SH	O
SY	O
5Y	O
cell	O
proliferation	O
was	O
examined	O
by	O
measuring	O
cell	O
numbers	O
after	O
exposure	O
to	O
the	O
retinoids	O
and	O
RAR	O
-	O
beta	O
gene	O
expression	O
was	O
examined	O
by	O
Northern	O
blot	O
analysis	O
.	O
Morphological	O
differentiation	O
was	O
more	O
effectively	O
induced	O
by	O
all	O
-	O
trans	O
and	O
9	O
-	O
cis	O
RA	O
than	O
by	O
LG69	O
.	O
SH	O
SY	O
5Y	O
cells	O
,	O
when	O
treated	O
with	O
9	O
-	O
cis	O
RA	O
for	O
only	O
5	O
of	O
the	O
9	O
days	O
of	O
culture	O
,	O
underwent	O
apoptosis	O
,	O
but	O
this	O
was	O
not	O
seen	O
with	O
9	O
days	O
continuous	O
exposure	O
nor	O
with	O
LG69	O
.	O
Inhibition	O
of	O
SH	O
SY	O
5Y	O
cell	O
proliferation	O
by	O
all	O
-	O
trans	O
or	O
9	O
-	O
cis	O
RA	O
was	O
dose	O
-	O
dependent	O
,	O
but	O
LG69	O
had	O
little	O
effect	O
.	O
Conversely	O
,	O
LG69	O
induced	O
higher	O
expression	O
of	O
RAR	O
-	O
beta	O
than	O
all	O
-	O
trans	O
RA	O
,	O
but	O
less	O
than	O
that	O
produced	O
by	O
9	O
-	O
cis	O
RA	O
.	O
These	O
data	O
suggest	O
that	O
9	O
-	O
cis	O
RA	O
as	O
a	O
single	O
agent	O
is	O
the	O
most	O
effective	O
modulator	O
of	O
neuroblastoma	B-malignancy-type
behaviour	O
and	O
may	O
be	O
the	O
most	O
appropriate	O
therapeutic	O
agent	O
.	O
PMID	O
:	O
9624247	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cancer	O
Ther	O
.	O
2003	O
Sep;2	O
(	O
9	O
)	O
:911	O
-	O
7.	O
Transduction	O
of	O
green	O
fluorescent	O
protein	O
increased	O
oxidative	O
stress	O
and	O
enhanced	O
sensitivity	O
to	O
cytotoxic	O
drugs	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Goto	O
H,	O
Yang	O
B	O
,	O
Petersen	O
D	O
,	O
Pepper	O
KA	O
,	O
Alfaro	O
PA	O
,	O
Kohn	O
DB	O
,	O
Reynolds	O
CP	O
.	O
Divisions	O
of	O
Hematology-Oncology	O
and	O
Research	O
Immunology	O
/Bone	O
Marrow	O
Transplantation	O
,	O
Childrens	O
Hospital	O
Los	O
Angeles	O
,	O
CA	O
90027	O
,	O
USA	O
.	O
Green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
is	O
employed	O
as	O
a	O
selection	O
marker	O
for	O
gene	O
transduction	O
and	O
to	O
track	O
tumor	O
cells	O
.	O
Transduction	O
of	O
enhanced	O
GFP	O
(	O
eGFP	O
)	O
into	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
via	O
a	O
lentiviral	O
vector	O
significantly	O
sensitized	O
CHLA	O
-	O
20	O
(	O
wild	O
-	O
type	O
and	O
functional	O
TP53	O
)	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
CHLA	O
-	O
90	O
cells	O
(	O
multidrug	O
-	O
resistant	O
,	O
mutant	O
,	O
and	O
nonfunctional	O
TP53	O
)	O
to	O
carboplatin	O
,	O
doxorubicin	O
,	O
etoposide	O
,	O
or	O
melphalan	O
,	O
relative	O
to	O
cells	O
transduced	O
using	O
the	O
cell	O
surface	O
antigen	O
CD80	O
as	O
a	O
selection	O
marker	O
.	O
Total	O
glutathione	O
(	O
GSH	O
)	O
was	O
significantly	O
up	O
-	O
regulated	O
(	O
1.8	O
-	O
to	O
2.8	O
-	O
fold	O
)	O
after	O
eGFP	O
(	O
but	O
not	O
CD80	O
)	O
transduction	O
in	O
cell	O
lines	O
with	O
,	O
but	O
not	O
in	O
those	O
lacking	O
,	O
functional	O
p53	O
.	O
Cytotoxicity	O
of	O
GSH	O
depletion	O
by	O
buthionine	O
sulfoximine	O
in	O
CHLA	O
-	O
20	O
(	O
but	O
not	O
in	O
CHLA	O
-	O
20	O
-	O
eGFP	O
)	O
was	O
diminished	O
by	O
hypoxia	O
(	O
2	O
%	O
O(2)	O
)	O
.	O
Thus	O
,	O
oxidative	O
stress	O
produced	O
by	O
GFP	O
selects	O
for	O
cells	O
with	O
up	O
-	O
regulated	O
GSH	O
in	O
a	O
p53	O
-	O
dependent	O
manner	O
,	O
and	O
also	O
enhanced	O
the	O
cytotoxicity	O
of	O
anticancer	O
drugs	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Our	O
data	O
suggest	O
caution	O
when	O
employing	O
GFP	O
-	O
transduced	O
cells	O
to	O
assess	O
drug	O
sensitivity	O
and	O
that	O
using	O
a	O
cell	O
surface	O
antigen	O
as	O
a	O
selection	O
marker	O
for	O
gene	O
transduction	O
may	O
perturb	O
cells	O
less	O
than	O
GFP	O
.	O
PMID	O
:	O
14555710	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2002	O
Nov	O
15	O
;62(	O
22	O
)	O
:6481	O
-4.	O
No	O
evidence	O
for	O
the	O
presence	O
of	O
an	O
imprinted	O
neuroblastoma	B-malignancy-type
suppressor	O
gene	O
within	O
chromosome	O
sub	O
-	O
band	O
1p36.3	O
.	O
Hogarty	O
MD	O
,	O
Winter	O
CL	O
,	O
Liu	O
X	O
,	O
Guo	O
C	O
,	O
White	O
PS	O
,	O
Look	O
AT	O
,	O
Brodeur	O
GM	O
,	O
Maris	O
JM	O
.	O
Division	O
of	O
Oncology	O
,	O
The	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
Philadelphia	O
,	O
Pennsylvania	O
19104-4318	O
,	O
USA	O
.	O
hogartym@email	O
.chop.edu	O
Deletion	O
of	O
the	O
distal	O
short	O
arm	O
of	O
chromosome	O
1	O
occurs	O
in	O
35	O
%	O
of	O
primary	O
neuroblastomas	B-malignancy-type
(	O
NBs	B-malignancy-type
)	O
.	O
These	O
deletions	O
tend	O
to	O
be	O
large	O
and	O
extend	O
to	O
the	O
telomere	O
,	O
but	O
a	O
common	O
region	O
within	O
sub	O
-	O
band	O
1p36.3	O
is	O
consistently	O
lost	O
.	O
Despite	O
intensive	O
investigation	O
,	O
no	O
candidate	O
tumor	O
suppressor	O
gene	O
within	O
this	O
region	O
has	O
been	O
shown	O
to	O
undergo	O
tumor	O
-	O
specific	O
mutation	O
consistent	O
with	O
biallelic	O
inactivation	O
.	O
In	O
addition	O
,	O
initial	O
studies	O
demonstrated	O
preferential	O
loss	O
of	O
the	O
maternally	O
inherited	O
1p	O
homologue	O
in	O
NBs	B-malignancy-type
with	O
1p	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
without	O
MYCN	O
amplification	O
.	O
This	O
has	O
led	O
to	O
the	O
widely	O
accepted	O
hypothesis	O
that	O
a	O
genomically	O
imprinted	O
NB	B-malignancy-type
suppressor	O
gene	O
is	O
the	O
target	O
of	O
1p	O
deletion	O
in	O
this	O
subset	O
.	O
To	O
test	O
this	O
hypothesis	O
we	O
have	O
studied	O
293	O
primary	O
NBs	B-malignancy-type
for	O
LOH	O
within	O
1p36.3	O
and	O
determined	O
the	O
parental	O
origin	O
of	O
the	O
deleted	O
1p	O
homologue	O
.	O
LOH	O
within	O
1p36.3	O
was	O
demonstrated	O
in	O
55	O
NBs	B-malignancy-type
(	O
19	O
%	O
)	O
.	O
Of	O
these	O
,	O
29	O
occurred	O
in	O
tumors	O
without	O
MYCN	O
amplification	O
:	O
13	O
had	O
deletion	O
of	O
the	O
maternally	O
inherited	O
1p	O
,	O
whereas	O
16	O
had	O
deletion	O
of	O
the	O
paternally	O
inherited	O
1p	O
(	O
P	O
=	O
0.58	O
)	O
.	O
These	O
data	O
strongly	O
refute	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
for	O
1p	O
deletions	O
in	O
NB	B-malignancy-type
and	O
exclude	O
the	O
existence	O
of	O
an	O
imprinted	O
NB	B-malignancy-type
suppressor	O
locus	O
in	O
this	O
region	O
.	O
PMID	O
:	O
12438240	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
2000	O
Jul	O
7;288	O
(	O
1	O
)	O
:	O
81	O
-5	O
.	O
The	O
promoter	O
of	O
human	O
acetylcholinesterase	O
is	O
activated	O
by	O
a	O
cyclic	O
adenosine	O
3'	O
,	O
5'	O
-	O
monophosphate	O
-	O
dependent	O
pathway	O
in	O
cultured	O
NG108	O
-	O
15	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Wan	O
DC	O
,	O
Choi	O
RC	O
,	O
Siow	O
NL	O
,	O
Tsim	O
KW	O
.	O
Department	O
of	O
Biochemistry	O
,	O
The	O
Chinese	O
University	O
of	O
Hong	O
Kong	O
,	O
Shatin	O
,	O
China	O
.	O
Different	O
transcription	O
elements	O
have	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
muscle	O
and	O
neuron	O
,	O
and	O
cyclic	O
adenosine	O
3'	O
,	O
5'	O
-	O
monophosphate	O
(	O
cAMP	O
)	O
-	O
dependent	O
pathway	O
is	O
one	O
of	O
them	O
.	O
In	O
order	O
to	O
test	O
the	O
possible	O
role	O
of	O
cAMP	O
in	O
regulating	O
the	O
expression	O
of	O
human	O
AChE	O
,	O
an	O
approximately	O
2.2	O
kb	O
DNA	O
fragment	O
of	O
human	O
AChE	O
promoter	O
was	O
linked	O
up	O
stream	O
to	O
a	O
luciferase	O
reporter	O
.	O
The	O
chimeric	O
DNA	O
was	O
transfected	O
into	O
cultured	O
NG108	O
-	O
15	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Application	O
of	O
Bt(2)	O
-	O
cAMP	O
and	O
forskolin	O
increased	O
the	O
promoter	O
driven	O
luciferase	O
activity	O
over	O
2	O
-	O
fold	O
in	O
the	O
transfected	O
NG108	O
-	O
15	O
cells	O
;	O
the	O
increase	O
was	O
parallel	O
to	O
the	O
activation	O
of	O
endogenous	O
AChE	O
protein	O
and	O
enzymatic	O
activity	O
.	O
The	O
intracellular	O
cAMP	O
level	O
was	O
increased	O
in	O
the	O
Galpha	O
(	O
sQL	O
)	O
(	O
constitutively	O
active	O
mutant	O
of	O
Galpha(s)	O
)	O
cDNA	O
transfected	O
NG108	O
-	O
15	O
cells	O
.	O
The	O
Galpha	O
(	O
sQL	O
)	O
cDNA	O
transfected	O
cells	O
showed	O
an	O
increase	O
of	O
over	O
10	O
-	O
fold	O
in	O
the	O
luciferase	O
activity	O
.	O
In	O
addition	O
,	O
a	O
constitutively	O
active	O
mutant	O
of	O
activating	O
transcription	O
factor	O
-	O
1	O
(	O
ATF	O
-	O
1	O
)	O
was	O
able	O
to	O
turn	O
on	O
human	O
AChE	O
promoter	O
by	O
approximately	O
4	O
-	O
fold	O
when	O
they	O
were	O
co	O
-	O
expressed	O
in	O
the	O
neuroblastoma	B-malignancy-type
cells	O
.	O
These	O
results	O
support	O
the	O
involvement	O
of	O
a	O
cAMP	O
-	O
dependent	O
pathway	O
in	O
regulating	O
the	O
expression	O
of	O
human	O
AChE	O
.	O
PMID	O
:	O
10869820	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1998	O
Oct	O
1;58	O
(	O
19	O
)	O
:	O
4238-44	O
.	O
RIZ1	O
,	O
but	O
not	O
the	O
alternative	O
RIZ2	O
product	O
of	O
the	O
same	O
gene	O
,	O
is	O
underexpressed	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
forced	O
RIZ1	O
expression	O
causes	O
G2	O
-	O
M	O
cell	O
cycle	O
arrest	O
and/or	O
apoptosis	O
.	O
He	O
L,	O
Yu	O
JX	O
,	O
Liu	O
L,	O
Buyse	O
IM	O
,	O
Wang	O
MS	O
,	O
Yang	O
QC	O
,	O
Nakagawara	O
A	O
,	O
Brodeur	O
GM	O
,	O
Shi	O
YE	O
,	O
Huang	O
S.	O
Program	O
in	O
Oncogenes	O
and	O
Tumor	O
Suppressor	O
Genes	O
,	O
The	O
Burnham	O
Institute	O
,	O
La	O
Jolla	O
,	O
California	O
92037	O
,	O
USA	O
.	O
The	O
retinoblastoma	O
protein	O
-	O
interacting	O
zinc	O
finger	O
gene	O
RIZ	O
maps	O
to	O
the	O
distal	O
short	O
arm	O
of	O
human	O
chromosome	O
1	O
(	O
1p36	O
)	O
,	O
a	O
region	O
thought	O
to	O
harbor	O
tumor	O
suppressor	O
genes	O
for	O
a	O
variety	O
of	O
human	O
cancers	O
including	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
RIZ	O
gene	O
normally	O
produces	O
two	O
protein	O
products	O
of	O
different	O
length	O
,	O
RIZ1	O
and	O
RIZ2	O
.	O
RIZ2	O
is	O
generated	O
by	O
an	O
internal	O
promoter	O
and	O
lacks	O
an	O
NH2	O
-	O
terminal	O
motif	O
of	O
RIZ1	O
,	O
the	O
PR	O
domain	O
conserved	O
in	O
a	O
subfamily	O
of	O
zinc	O
finger	O
genes	O
that	O
function	O
as	O
negative	O
regulators	O
of	O
tumorigenesis	O
.	O
We	O
have	O
here	O
studied	O
whether	O
the	O
RIZ	O
gene	O
may	O
play	O
a	O
role	O
in	O
human	O
neoplasia	O
.	O
We	O
found	O
that	O
expression	O
of	O
RIZ1	O
is	O
commonly	O
decreased	O
or	O
at	O
undetectable	O
levels	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
tissues	O
and	O
cell	O
lines	O
.	O
Decreased	O
RIZ1	O
expression	O
was	O
also	O
found	O
in	O
other	O
tumor	O
types	O
including	O
neuroblastoma	B-malignancy-type
and	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Remarkably	O
,	O
RIZ2	O
is	O
normally	O
expressed	O
in	O
all	O
cases	O
examined	O
,	O
suggesting	O
that	O
the	O
abnormality	O
observed	O
for	O
RIZ1	O
is	O
specific	O
.	O
Forced	O
RIZ1	O
expression	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
cells	O
caused	O
cell	O
cycle	O
arrest	O
in	O
G2	O
-	O
M	O
and	O
/	O
or	O
programmed	O
cell	O
death	O
.	O
These	O
observations	O
suggest	O
an	O
exclusive	O
negative	O
selection	O
for	O
RIZ1	O
but	O
not	O
RIZ2	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
and	O
a	O
role	O
for	O
RIZ1	O
in	O
tumor	O
suppression	O
.	O
PMID	O
:	O
9766644	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2000	O
Jul	O
14;275	O
(	O
28	O
)	O
:	O
21055	O
-60	O
.	O
Direct	O
transactivation	O
of	O
the	O
anti	O
-	O
apoptotic	O
gene	O
apolipoprotein	O
J	O
(	O
clusterin	O
)	O
by	O
B	O
-	O
MYB	O
.	O
Cervellera	O
M,	O
Raschella	O
G	O
,	O
Santilli	O
G	O
,	O
Tanno	O
B	O
,	O
Ventura	O
A	O
,	O
Mancini	O
C	O
,	O
Sevignani	O
C	O
,	O
Calabretta	O
B	O
,	O
Sala	O
A	O
.	O
Laboratory	O
of	O
Molecular	O
Pharmacology	O
and	O
Pathology	O
,	O
Consorzio	O
Mario	O
Negri	O
Sud	O
,	O
66030	O
S.	O
Maria	O
Imbaro	O
,	O
Italy	O
.	O
B	O
-	O
MYB	O
is	O
a	O
ubiquitously	O
expressed	O
transcription	O
factor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
survival	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O
In	O
an	O
attempt	O
to	O
isolate	O
B	O
-	O
MYB	O
-	O
regulated	O
genes	O
that	O
may	O
explain	O
the	O
role	O
of	O
B	O
-	O
MYB	O
in	O
cellular	O
processes	O
,	O
representational	O
difference	O
analysis	O
was	O
performed	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
different	O
levels	O
of	O
B	O
-	O
MYB	O
expression	O
.	O
One	O
of	O
the	O
genes	O
,	O
the	O
mRNA	O
levels	O
of	O
which	O
were	O
enhanced	O
in	O
B	O
-	O
MYB	O
expressing	O
cells	O
,	O
was	O
ApoJ	O
/	O
Clusterin	O
(	O
SGP	O
-	O
2	O
/	O
TRMP	O
-	O
2	O
)	O
(	O
ApoJ	O
/	O
Clusterin	O
)	O
,	O
previously	O
implicated	O
in	O
regulation	O
of	O
apoptosis	O
and	O
tumor	O
progression	O
.	O
Here	O
we	O
show	O
that	O
the	O
human	O
ApoJ	O
/	O
Clusterin	O
gene	O
contains	O
a	O
Myb	O
binding	O
site	O
in	O
its	O
5	O
'	O
flanking	O
region	O
,	O
which	O
interacts	O
with	O
bacterially	O
synthesized	O
B	O
-	O
MYB	O
protein	O
and	O
mediates	O
B	O
-	O
MYB	O
-	O
dependent	O
transactivation	O
of	O
the	O
ApoJ	O
/	O
Clusterin	O
promoter	O
in	O
transient	O
transfection	O
assays	O
.	O
Endogenous	O
ApoJ	O
/	O
Clusterin	O
expression	O
is	O
induced	O
in	O
mammalian	O
cell	O
lines	O
following	O
transient	O
transfection	O
of	O
a	O
B	O
-	O
MYB	O
cDNA	O
.	O
Blockage	O
of	O
secreted	O
clusterin	O
by	O
a	O
monoclonal	O
antibody	O
results	O
in	O
increased	O
apoptosis	O
of	O
neuroblastoma	B-malignancy-type
cells	O
exposed	O
to	O
the	O
chemotherapeutic	O
drug	O
doxorubicin	O
.	O
Thus	O
,	O
activation	O
of	O
ApoJ	O
/	O
Clusterin	O
by	O
B	O
-	O
MYB	O
may	O
be	O
an	O
important	O
step	O
in	O
the	O
regulation	O
of	O
apoptosis	O
in	O
normal	O
and	O
diseased	O
cells	O
.	O
PMID	O
:	O
10770937	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Growth	O
Differ	O
.	O
1994	O
Feb	O
;	O
5	O
(	O
2	O
)	O
:	O
171-8	O
.	O
The	O
biological	O
effects	O
of	O
antisense	O
N-myc	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Schmidt	O
ML	O
,	O
Salwen	O
HR	O
,	O
Manohar	O
CF	O
,	O
Ikegaki	O
N	O
,	O
Cohn	O
SL	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Illinois	O
,	O
Chicago	O
60612	O
.	O
Although	O
N-myc	O
amplification	O
and	O
overexpression	O
are	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
determining	O
the	O
clinical	O
behavior	O
of	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
,	O
the	O
exact	O
function	O
of	O
N-myc	O
in	O
NB	B-malignancy-type
cell	O
growth	O
and	O
differentiation	O
remains	O
unknown	O
.	O
To	O
better	O
understand	O
the	O
function	O
of	O
N-myc	O
,	O
an	O
established	O
human	O
NB	B-malignancy-type
cell	O
line	O
was	O
transfected	O
with	O
N-myc	O
antisense	O
(	O
AS	O
)	O
complementary	O
DNA	O
in	O
an	O
effort	O
to	O
down-regulate	O
N-myc	O
gene	O
expression	O
.	O
Five	O
clones	O
expressing	O
AS	O
N-myc	O
RNA	O
have	O
been	O
maintained	O
in	O
culture	O
for	O
over	O
2	O
years	O
.	O
Compared	O
to	O
control	O
cells	O
,	O
a	O
30-69%	O
decrease	O
in	O
the	O
quantity	O
of	O
N-myc	O
protein	O
was	O
demonstrated	O
by	O
Western	O
blot	O
analysis	O
in	O
4	O
of	O
the	O
5	O
AS	O
clones	O
.	O
All	O
5	O
of	O
the	O
AS	O
clones	O
exhibited	O
a	O
50-75%	O
decrease	O
in	O
colony	O
formation	O
in	O
soft	O
agar	O
assays	O
compared	O
to	O
control	O
cells	O
.	O
In	O
addition	O
,	O
all	O
5	O
AS	O
clones	O
expressed	O
a	O
3.2-kilobase	O
protein	O
kinase	O
C-alpha	O
transcript	O
,	O
whereas	O
this	O
message	O
was	O
not	O
detected	O
by	O
Northern	O
blot	O
analysis	O
in	O
any	O
of	O
the	O
control	O
clones	O
.	O
These	O
results	O
suggest	O
that	O
N-myc	O
may	O
play	O
an	O
important	O
role	O
in	O
NB	B-malignancy-type
cell	O
growth	O
and	O
that	O
antisense	O
N-myc	O
expression	O
is	O
associated	O
with	O
an	O
induction	O
of	O
protein	O
kinase	O
C-alpha	O
RNA	O
expression	O
.	O
Further	O
characterization	O
of	O
the	O
AS	O
clones	O
may	O
provide	O
insight	O
into	O
the	O
function	O
of	O
N-myc	O
and	O
may	O
thus	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
role	O
that	O
N-myc	O
plays	O
in	O
determining	O
the	O
clinical	O
behavior	O
of	O
this	O
childhood	O
neoplasm	O
.	O
PMID	O
:	O
8180130	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pharmacol	O
Biochem	O
Behav	O
.	O
1991	O
Nov	O
;	O
40	O
(	O
3	O
)	O
:	O
565-9	O
.	O
The	O
cannabinoid	O
receptor	O
:	O
biochemical	O
and	O
cellular	O
properties	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Howlett	O
AC	O
,	O
Champion-Dorow	O
TM	O
,	O
McMahon	O
LL	O
,	O
Westlake	O
TM	O
.	O
Department	O
of	O
Pharmacological	O
and	O
Physiological	O
Science	O
,	O
St.	O
Louis	O
University	O
Medical	O
School	O
,	O
MO	O
63104	O
.	O
The	O
cannabinoid	O
receptor	O
that	O
has	O
been	O
pharmacologically	O
characterized	O
for	O
hypothermia	O
,	O
spontaneous	O
activity	O
,	O
analgesia	O
and	O
catalepsy	O
in	O
rodents	O
is	O
the	O
same	O
pharmacological	O
receptor	O
that	O
inhibits	O
adenylate	O
cyclase	O
in	O
vitro	O
.	O
The	O
inhibition	O
of	O
adenylate	O
cyclase	O
by	O
the	O
cannabinoid	O
receptor	O
results	O
from	O
an	O
interaction	O
with	O
Gi	O
,	O
based	O
on	O
the	O
biochemical	O
kinetic	O
properties	O
of	O
the	O
response	O
,	O
the	O
sensitivity	O
to	O
pertussis	O
toxin	O
ADP-ribosylation	O
,	O
and	O
the	O
thermodynamic	O
characteristics	O
of	O
the	O
response	O
.	O
From	O
precedents	O
based	O
on	O
studies	O
of	O
the	O
well-characterized	O
G	O
protein	O
coupled	O
receptors	O
,	O
rhodopsin	O
and	O
the	O
beta-adrenergic	O
receptor	O
,	O
we	O
can	O
predict	O
the	O
tertiary	O
structure	O
of	O
the	O
cannabinoid	O
receptor	O
.	O
Three	O
sites	O
of	O
potential	O
glycosylation	O
are	O
present	O
on	O
the	O
receptor	O
.	O
However	O
,	O
treatment	O
of	O
N18TG2	O
neuroblastoma	B-malignancy-type
cells	O
with	O
tunicamycin	O
to	O
prevent	O
glycosylation	O
of	O
newly	O
synthesized	O
receptors	O
failed	O
to	O
alter	O
cannabinoid	O
-	O
induced	O
inhibition	O
of	O
cyclic	O
AMP	O
accumulation	O
.	O
The	O
cannabinoid	O
response	O
was	O
rapidly	O
desensitized	O
(	O
within	O
1/2	O
h	O
)	O
.	O
Treatment	O
of	O
cells	O
with	O
tunicamycin	O
failed	O
to	O
alter	O
agonist	O
-	O
induced	O
desensitization	O
processes	O
.	O
These	O
findings	O
can	O
be	O
more	O
veraciously	O
interpreted	O
as	O
we	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
cellular	O
dynamics	O
of	O
the	O
cannabinoid	O
receptor	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
1806946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
J	O
.	O
1995	O
Jan	O
15	O
;	O
305	O
(	O
Pt	O
2	O
)	O
:	O
577-81	O
.	O
Erratum	O
in	O
:	O
Biochem	O
J	O
1995	O
May	O
1	O
;	O
307	O
(	O
Pt	O
3	O
)	O
:	O
879	O
.	O
Mu-opioids	O
activate	O
phospholipase	O
C	O
in	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
via	O
calcium-channel	O
opening	O
.	O
Smart	O
D	O
,	O
Smith	O
G	O
,	O
Lambert	O
DG	O
.	O
University	O
Department	O
of	O
Anaesthesia	O
,	O
Leicester	O
Royal	O
Infirmary	O
,	O
U.K.	O
We	O
have	O
recently	O
reported	O
that	O
,	O
in	O
SH-SY5Y	O
cells	O
,	O
mu-opioid	O
receptor	O
occupancy	O
activates	O
phospholipase	O
C	O
via	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
G-protein	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
further	O
characterized	O
the	O
mechanisms	O
involved	O
in	O
this	O
process	O
.	O
Fentanyl	O
(	O
0.1	O
microM	O
)	O
caused	O
a	O
monophasic	O
increase	O
in	O
inositol	O
1,4,5-trisphosphate	O
mass	O
formation	O
,	O
with	O
a	O
peak	O
(	O
20.5	O
+/-	O
3.6	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
at	O
15	O
s	O
.	O
Incubation	O
in	O
Ca(2+)-free	O
buffer	O
abolished	O
this	O
response	O
,	O
while	O
Ca2+	O
replacement	O
1	O
min	O
later	O
restored	O
the	O
stimulation	O
of	O
inositol	O
1,4,5-trisphosphate	O
formation	O
(	O
20.1	O
+/-	O
0.6	O
pmol/mg	O
of	O
protein	O
)	O
.	O
In	O
addition	O
,	O
nifedipine	O
(	O
1	O
nM-0.1	O
mM	O
)	O
,	O
an	O
L-type	O
Ca(2+)-channel	O
antagonist	O
,	O
caused	O
a	O
dose-dependent	O
inhibition	O
of	O
inositol	O
1,4,5-trisphosphate	O
formation	O
,	O
with	O
an	O
IC50	O
of	O
60.3	O
+/-	O
1.1	O
nM	O
.	O
Elevation	O
of	O
endogenous	O
beta/gamma	O
subunits	O
by	O
selective	O
activation	O
of	O
delta-opioid	O
and	O
alpha	O
2	O
adrenoceptors	O
failed	O
to	O
stimulate	O
phospholipase	O
C	O
.	O
Fentanyl	O
also	O
caused	O
a	O
dose-dependent	O
(	O
EC50	O
of	O
16.2	O
+/-	O
1.0	O
nM	O
)	O
,	O
additive	O
enhancement	O
of	O
carbachol	O
-	O
induced	O
inositol	O
1,4,5-trisphosphate	O
formation	O
.	O
In	O
summary	O
,	O
we	O
have	O
demonstrated	O
that	O
in	O
SH-SY5Y	O
cells	O
activation	O
of	O
the	O
mu-opioid	O
receptor	O
allows	O
Ca2+	O
influx	O
to	O
activate	O
phospholipase	O
C	O
.	O
However	O
,	O
the	O
possible	O
role	O
of	O
this	O
mechanism	O
in	O
the	O
process	O
of	O
analgesia	O
remains	O
to	O
be	O
elucidated	O
.	O
PMID	O
:	O
7832776	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Invest	O
.	O
1993	O
Sep	O
2	O
(	O
3	O
)	O
:	O
1153	O
-60	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cells	O
express	O
alpha	O
and	O
beta	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptors	O
coupling	O
with	O
neurotrophic	O
and	O
chemotactic	O
signaling	O
.	O
Matsui	O
T	O
,	O
Sano	O
K,	O
Tsukamoto	O
T	O
,	O
Ito	O
M,	O
Takaishi	O
T	O
,	O
Nakata	O
H,	O
Nakamura	O
H,	O
Chihara	O
K.	O
Department	O
of	O
Medicine	O
,	O
Kobe	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Both	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
A	O
-	O
and	O
B	O
-chains	O
are	O
expressed	O
in	O
mammalian	O
neurons	O
,	O
but	O
their	O
precise	O
roles	O
still	O
remain	O
to	O
be	O
clarified	O
.	O
In	O
the	O
present	O
studies	O
,	O
we	O
examined	O
the	O
expression	O
of	O
two	O
PDGF	O
receptor	O
genes	O
in	O
human	O
tumor	O
cell	O
lines	O
derived	O
from	O
neural	O
crest	O
.	O
The	O
expression	O
of	O
alpha	O
and/or	O
beta	O
PDGF	O
receptors	O
was	O
detected	O
in	O
a	O
wide	O
variety	O
of	O
neural	O
crest	O
-	O
derived	O
human	O
tumor	O
cell	O
lines	O
such	O
as	O
neuroblastoma	B-malignancy-type
,	O
primitive	O
neuroectodermal	B-malignancy-type
tumor	I-malignancy-type
,	O
and	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
by	O
RNA	O
blot	O
analysis	O
,	O
and	O
confirmed	O
by	O
immunoblot	O
analysis	O
.	O
We	O
have	O
also	O
demonstrated	O
that	O
PDGF	O
receptors	O
on	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
were	O
biologically	O
functional	O
.	O
Accordingly	O
,	O
chemotactic	O
and	O
mitogenic	O
activities	O
were	O
induced	O
by	O
either	O
PDGF-AA	O
or	O
PDGF-BB	O
in	O
serum-free	O
medium	O
.	O
PDGF	O
isoforms	O
as	O
well	O
as	O
nerve	O
growth	O
factor	O
induced	O
morphological	O
changes	O
showing	O
neuronal	O
cell	O
maturation	O
.	O
Moreover	O
,	O
PDGF	O
coordinately	O
increased	O
the	O
levels	O
of	O
the	O
transcript	O
of	O
the	O
midsize	O
neurofilament	O
gene	O
.	O
The	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
also	O
expressed	O
the	O
transcripts	O
of	O
PDGF	O
A	O
-	O
and	O
B	O
-chains	O
.	O
These	O
findings	O
suggest	O
that	O
PDGF	O
isoforms	O
are	O
involved	O
not	O
only	O
in	O
the	O
promotion	O
of	O
the	O
neuroblastoma	B-malignancy-type
cell	O
growth	O
,	O
but	O
also	O
in	O
neuronal	O
cell	O
migration	O
,	O
growth	O
,	O
and	O
differentiation	O
in	O
human	O
brain	O
development	O
.	O
PMID	O
:	O
8376577	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Biol	O
Chem	O
.	O
2004	O
Feb	O
13	O
;	O
279	O
(	O
7	O
)	O
:	O
5110-7	O
.	O
Epub	O
2003	O
Nov	O
26	O
.	O
E2F	O
and	O
Sp1	O
/	O
Sp3	O
Synergize	O
but	O
are	O
not	O
sufficient	O
to	O
activate	O
the	O
MYCN	O
gene	O
in	O
neuroblastomas	B-malignancy-type
.	O
Kramps	O
C	O
,	O
Strieder	O
V	O
,	O
Sapetschnig	O
A	O
,	O
Suske	O
G	O
,	O
Lutz	O
W	O
.	O
Institute	O
of	O
Molecular	O
Biology	O
and	O
Tumor	O
Research	O
,	O
35033	O
Marburg	O
,	O
Germany	O
.	O
Amplification	O
of	O
the	O
MYCN	O
gene	O
,	O
resulting	O
in	O
overexpression	O
of	O
MYCN	O
,	O
distinguishes	O
a	O
subset	O
of	O
neuroblastomas	B-malignancy-type
with	O
poor	O
prognosis	O
.	O
We	O
recently	O
identified	O
MYCN	O
as	O
a	O
target	O
gene	O
of	O
the	O
E2F	O
transcription	O
factors	O
.	O
Here	O
we	O
show	O
that	O
Sp1	O
and	O
Sp3	O
cooperate	O
with	O
E2F-1	O
to	O
activate	O
the	O
MYCN	O
promoter	O
.	O
However	O
,	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
that	O
does	O
not	O
express	O
MYCN	O
,	O
overexpression	O
of	O
E2F-1	O
was	O
not	O
sufficient	O
to	O
activate	O
the	O
MYCN	O
promoter	O
even	O
in	O
the	O
presence	O
of	O
trichostatin	O
A	O
and	O
5-aza-cytidine	O
.	O
This	O
was	O
because	O
of	O
a	O
failure	O
of	O
E2F-1	O
to	O
bind	O
to	O
the	O
MYCN	O
promoter	O
in	O
these	O
cells	O
,	O
although	O
access	O
of	O
E2F-1	O
to	O
the	O
inactive	O
MYCN	O
promoter	O
was	O
not	O
blocked	O
by	O
a	O
nucleosome	O
.	O
Differences	O
in	O
nucleosomal	O
organization	O
of	O
the	O
MYCN	O
promoter	O
in	O
different	O
cell	O
lines	O
did	O
not	O
correlate	O
with	O
gene	O
activation	O
per	O
se	O
but	O
with	O
the	O
switch	O
from	O
basal	O
to	O
activated	O
transcription	O
.	O
Binding	O
of	O
E2F	O
and	O
Sp1	O
/	O
Sp3	O
to	O
the	O
MYCN	O
promoter	O
in	O
vivo	O
correlated	O
with	O
acetylation	O
of	O
histones	O
H3	O
and	O
H4	O
and	O
recruitment	O
of	O
RNA	O
polymerase	O
II	O
and	O
the	O
protein	O
acetyltransferase	O
Tip60	O
but	O
not	O
with	O
nucleosome	O
remodeling	O
.	O
Our	O
results	O
define	O
distinct	O
chromatin	O
states	O
of	O
the	O
MYCN	O
promoter	O
,	O
indicate	O
that	O
factors	O
in	O
addition	O
to	O
E2F	O
and	O
Sp1	O
/	O
Sp3	O
are	O
required	O
to	O
activate	O
MYCN	O
in	O
neuroblastomas	B-malignancy-type
,	O
and	O
provide	O
evidence	O
for	O
a	O
novel	O
mechanism	O
of	O
controlling	O
access	O
of	O
E2F	O
to	O
selected	O
target	O
genes	O
.	O
PMID	O
:	O
14645238	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Cancer	O
Res	O
.	O
1991	O
Mar	O
15	O
;5	O
1	O
(	O
6	O
)	O
:1733	O
-	O
7.	O
Inducible	O
expression	O
of	O
calcyclin	O
,	O
a	O
gene	O
with	O
strong	O
homology	O
to	O
S	O
-	O
100	O
protein	O
,	O
during	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
and	O
its	O
prevalent	O
expression	O
in	O
Schwann	O
-	O
like	O
cell	O
lines	O
.	O
Tonini	O
GP	O
,	O
Casalaro	O
A	O
,	O
Cara	O
A	O
,	O
Di	O
Martino	O
D.	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
G.	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genoa	O
,	O
Italy	O
.	O
Calcyclin	O
gene	O
expression	O
was	O
evaluated	O
in	O
different	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
during	O
neuronal	O
differentiation	O
induced	O
by	O
retinoic	O
acid	O
.	O
Calcyclin	O
gene	O
expression	O
was	O
more	O
frequently	O
detected	O
in	O
epithelial	O
-	O
type	O
or	O
Schwann	O
-	O
like	O
cells	O
rather	O
than	O
in	O
neuroblastic	O
cells	O
.	O
This	O
result	O
indicates	O
an	O
increase	O
of	O
G1	O
cell	O
fraction	O
,	O
which	O
may	O
explain	O
the	O
limited	O
growth	O
potential	O
usually	O
observed	O
for	O
these	O
cells	O
.	O
LAN	O
-	O
5	O
cell	O
(	O
neuronal	O
type	O
)	O
differentiation	O
experiments	O
showed	O
that	O
calcyclin	O
gene	O
is	O
detectable	O
after	O
4	O
days	O
of	O
retinoic	O
acid	O
treatment	O
,	O
which	O
induces	O
G1	O
phase	O
accumulation	O
(	O
as	O
detected	O
by	O
cytofluorometric	O
analysis	O
)	O
,	O
and	O
cell	O
growth	O
arrest	O
.	O
Otherwise	O
,	O
neither	O
block	O
of	O
cell	O
proliferation	O
by	O
0.5	O
%	O
fetal	O
calf	O
serum	O
medium	O
nor	O
addition	O
of	O
15	O
%	O
fresh	O
fetal	O
calf	O
serum	O
after	O
cell	O
arrest	O
induce	O
calcyclin	O
expression	O
.	O
The	O
increase	O
of	O
calcyclin	O
mRNA	O
levels	O
during	O
cell	O
differentiation	O
shows	O
that	O
calcyclin	O
gene	O
expression	O
is	O
associated	O
with	O
neuronal	O
differentiation	O
.	O
This	O
bivalent	O
role	O
of	O
the	O
calcyclin	O
gene	O
,	O
which	O
is	O
normally	O
expressed	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
but	O
also	O
expressed	O
during	O
retinoic	O
acid	O
-	O
induced	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
,	O
suggests	O
that	O
(	O
at	O
least	O
in	O
neuroblastoma	B-malignancy-type
cells	O
)	O
the	O
gene	O
is	O
subject	O
to	O
a	O
complex	O
transcriptional	O
regulation	O
.	O
PMID	O
:	O
1998963	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1999	O
Oct	O
22	O
;460	O
(	O
1	O
)	O
:	O
11-6.	O
Subcellular	O
trafficking	O
abnormalities	O
of	O
a	O
prion	O
protein	O
with	O
a	O
disrupted	O
disulfide	O
loop	O
.	O
Yanai	O
A	O
,	O
Meiner	O
Z	O
,	O
Gahali	O
I	O
,	O
Gabizon	O
R	O
,	O
Taraboulos	O
A	O
.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
The	O
Hebrew	O
University-Hadassah	O
Medical	O
School	O
,	O
Jerusalem	O
,	O
Israel	O
.	O
The	O
single	O
disulfide	O
loop	O
(	O
Cys178	O
-	O
Cys213	O
)	O
of	O
the	O
prion	O
protein	O
(	O
PrP	O
)	O
may	O
stabilize	O
the	O
conformation	O
of	O
this	O
protein	O
by	O
bridging	O
the	O
C	O
-	O
terminal	O
alpha	O
-	O
helices	O
.	O
The	O
substitution	O
mutant	O
Cys	O
178	O
Ala	O
fails	O
to	O
form	O
the	O
prion	O
isoform	O
PrPSc	O
when	O
expressed	O
in	O
scrapie	O
-	O
infected	O
neuroblastoma	B-malignancy-type
ScN2a	O
cells	O
(	O
Muramoto	O
et	O
al.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
93	O
,	O
15457	O
-	O
15462	O
)	O
.	O
To	O
investigate	O
the	O
reasons	O
for	O
this	O
failure	O
,	O
we	O
introduced	O
the	O
C	O
178	O
A	O
substitution	O
in	O
the	O
full	O
length	O
mouse	O
PrP	O
gene	O
as	O
well	O
as	O
in	O
its	O
N	O
-	O
terminally	O
truncated	O
delta23	O
-	O
88	O
version	O
.	O
The	O
resulting	O
mutants	O
(	O
C	O
178	O
A	O
and	O
delta	O
C	O
178	O
A	O
,	O
respectively	O
)	O
were	O
transiently	O
expressed	O
in	O
N2a	O
and	O
CHO	O
cells	O
.	O
Wild	O
-	O
type	O
PrP	O
,	O
wild	O
-	O
type	O
delta	O
23	O
-	O
88	O
and	O
the	O
point	O
mutant	O
E	O
199	O
K	O
served	O
as	O
controls	O
in	O
these	O
experiments	O
.	O
Compared	O
to	O
the	O
wild	O
-	O
type	O
controls	O
,	O
the	O
C	O
178	O
A	O
mutants	O
were	O
markedly	O
resistant	O
to	O
proteolysis	O
and	O
they	O
were	O
also	O
vastly	O
insoluble	O
in	O
sarcosyl	O
.	O
Studying	O
the	O
metabolic	O
fate	O
of	O
the	O
C	O
178	O
A	O
mutants	O
,	O
we	O
found	O
that	O
in	O
contrast	O
to	O
control	O
PrP	O
molecules	O
,	O
these	O
mutants	O
(	O
i	O
)	O
remained	O
sensitive	O
to	O
the	O
diagnostic	O
endoglycosidase	O
EndoH	O
,	O
(	O
ii	O
)	O
failed	O
to	O
reach	O
the	O
cell	O
surface	O
and	O
(	O
iii	O
)	O
congregated	O
in	O
large	O
juxtanuclear	O
spots	O
.	O
We	O
surmise	O
that	O
these	O
severe	O
trafficking	O
abnormalities	O
may	O
contribute	O
both	O
to	O
the	O
spontaneous	O
aggregation	O
of	O
the	O
C	O
178	O
A	O
mutants	O
and	O
to	O
their	O
reported	O
inability	O
to	O
form	O
PrP	O
(	O
Sc	O
)	O
.	O
PMID	O
:	O
10571052	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2000	O
Dec;35	O
(	O
6	O
)	O
:603	O
-	O
7.	O
Resistance	O
to	O
TRAIL	O
-	O
induced	O
apoptosis	O
in	O
neuroblastoma	B-malignancy-type
cells	O
correlates	O
with	O
a	O
loss	O
of	O
caspase	O
-	O
8	O
expression	O
.	O
Eggert	O
A	O
,	O
Grotzer	O
MA	O
,	O
Zuzak	O
TJ	O
,	O
Wiewrodt	O
BR	O
,	O
Ikegaki	O
N	O
,	O
Brodeur	O
GM	O
.	O
Division	O
of	O
Oncology	O
,	O
The	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
Philadelphia	O
,	O
Pennsylvania	O
19104	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Disruption	O
of	O
apoptotic	O
pathways	O
may	O
be	O
involved	O
in	O
tumor	O
formation	O
,	O
regression	O
,	O
and	O
treatment	O
resistance	O
of	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
.	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
is	O
a	O
potent	O
inducer	O
of	O
apoptosis	O
in	O
cancer	O
cell	O
lines	O
.	O
PROCEDURE	O
:	O
In	O
this	O
study	O
we	O
analyzed	O
the	O
expression	O
and	O
function	O
of	O
TRAIL	O
,	O
its	O
agonistic	O
and	O
antagonistic	O
receptors	O
,	O
and	O
important	O
intracellular	O
signaling	O
elements	O
in	O
18	O
NB	B-malignancy-type
cell	O
lines	O
.	O
RESULTS	O
:	O
Semiquantitative	O
RT	O
-	O
PCR	O
revealed	O
that	O
TRAIL	O
-	O
R2	O
and	O
TRAIL	O
-	O
R3	O
are	O
the	O
main	O
TRAIL	O
-	O
receptors	O
used	O
by	O
NB	B-malignancy-type
cells	O
.	O
Sensitivity	O
to	O
TRAIL	O
-	O
induced	O
apoptosis	O
did	O
not	O
correlate	O
with	O
mRNA	O
expression	O
of	O
TRAIL	O
receptors	O
or	O
cFLIP	O
.	O
Surprisingly	O
,	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
10	O
mRNA	O
was	O
detected	O
in	O
only	O
5	O
of	O
18	O
NB	B-malignancy-type
cell	O
lines	O
.	O
Interestingly	O
,	O
only	O
these	O
five	O
NB	B-malignancy-type
cell	O
lines	O
were	O
susceptible	O
to	O
TRAIL	O
-	O
induced	O
apoptosis	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
CONCLUSIONS	O
:	O
Treatment	O
with	O
5	O
-	O
aza	O
-	O
2'	O
-	O
deoxycytidine	O
restored	O
mRNA	O
expression	O
of	O
caspase	O
-	O
8	O
and	O
-	O
10	O
and	O
TRAIL	O
sensitivity	O
of	O
resistant	O
cell	O
lines	O
,	O
suggesting	O
that	O
gene	O
methylation	O
is	O
involved	O
in	O
caspase	O
inactivation	O
.	O
Since	O
many	O
cytotoxic	O
drugs	O
induce	O
caspase	O
-	O
dependent	O
apoptosis	O
,	O
failure	O
to	O
express	O
caspase	O
-	O
8	O
and	O
/	O
or	O
caspase	O
-	O
10	O
might	O
be	O
an	O
important	O
mechanism	O
of	O
resistance	O
to	O
chemotherapy	O
in	O
NB	B-malignancy-type
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11107127	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1996	O
Jan;35	O
(	O
1-2	O
)	O
:47	O
-	O
57	O
.	O
Developmental	O
expression	O
in	O
the	O
mouse	O
nervous	O
system	O
of	O
the	O
p493F12	O
SAP	O
kinase	O
.	O
Martin	O
JH	O
,	O
Mohit	O
AA	O
,	O
Miller	O
CA.	O
Department	O
of	O
Pathology	O
and	O
Neurology	O
,	O
University	O
of	O
Southern	O
California	O
School	O
of	O
Medicine	O
,	O
Los	O
Angeles	O
90033	O
,	O
USA	O
.	O
Mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
are	O
proline	O
-	O
directed	O
,	O
serine	O
/	O
threonine	O
kinases	O
that	O
respond	O
to	O
a	O
variety	O
of	O
extracellular	O
signals	O
.	O
A	O
subgroup	O
of	O
these	O
kinases	O
,	O
stress	O
-	O
activated	O
protein	O
(	O
SAP	O
)	O
kinases	O
,	O
phosphorylate	O
c	O
-	O
jun	O
in	O
response	O
to	O
cellular	O
stress	O
.	O
Using	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
3F12	O
,	O
we	O
have	O
cloned	O
and	O
partially	O
characterized	O
p493F12	O
kinase	O
,	O
a	O
mouse	O
homologue	O
of	O
the	O
rat	O
SAP	O
beta	O
kinase	O
and	O
described	O
its	O
expression	O
in	O
the	O
adult	O
and	O
developing	O
mouse	O
.	O
Unlike	O
previously	O
reported	O
MAP	O
and	O
SAP	O
kinases	O
,	O
it	O
is	O
primarily	O
expressed	O
as	O
a	O
2.7	O
kb	O
transcript	O
in	O
neurons	O
in	O
the	O
nervous	O
system	O
of	O
the	O
adult	O
mouse	O
.	O
A	O
2.4	O
kb	O
transcript	O
is	O
also	O
expressed	O
in	O
the	O
testis	O
.	O
Immunocytochemically	O
,	O
MAb	O
3F12	O
decorates	O
a	O
loop	O
-	O
like	O
structure	O
encircling	O
the	O
nucleus	O
in	O
the	O
cytoplasm	O
of	O
neurons	O
in	O
the	O
adult	O
brain	O
,	O
and	O
distinct	O
perinuclear	O
dots	O
in	O
the	O
embryos	O
.	O
In	O
situ	O
hybridization	O
first	O
reveals	O
expression	O
in	O
post	O
-	O
mitotic	O
neurons	O
,	O
on	O
embryonic	O
day	O
11	O
.	O
The	O
mRNA	O
is	O
also	O
expressed	O
in	O
the	O
Neuro	O
-	O
2A	O
neuroblastoma	B-malignancy-type
cell	O
line	O
and	O
is	O
not	O
upregulated	O
in	O
response	O
to	O
differentiating	O
agents	O
.	O
The	O
neuronal	O
specificity	O
of	O
this	O
kinase	O
suggests	O
the	O
presence	O
of	O
a	O
signal	O
transduction	O
cascade	O
unique	O
to	O
neurons	O
.	O
As	O
the	O
amino	O
acid	O
sequence	O
is	O
highly	O
conserved	O
in	O
the	O
human	O
and	O
mouse	O
,	O
the	O
latter	O
may	O
serve	O
as	O
a	O
model	O
for	O
regulation	O
and	O
expression	O
of	O
this	O
kinase	O
.	O
PMID	O
:	O
8717339	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan;36	O
(	O
1	O
)	O
:	O
139	O
-	O
41	O
.	O
Role	O
of	O
CD44H	O
carbohydrate	O
structure	O
in	O
neuroblastoma	B-malignancy-type
adhesive	O
properties	O
.	O
Gross	O
N	O
,	O
Balmas	O
K,	O
Beretta	O
Brognara	O
C.	O
Department	O
of	O
Paediatrics	O
,	O
University	O
Hospital	O
,	O
CHUV	O
,	O
Lausanne	O
,	O
Switzerland	O
.	O
BACKGROUND	O
:	O
CD44	O
represents	O
a	O
heterogeneous	O
group	O
of	O
surface	O
glycoproteins	O
involved	O
in	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
matrix	O
interactions	O
.	O
CD44H	O
is	O
the	O
major	O
receptor	O
for	O
hyaluronate	O
,	O
and	O
most	O
if	O
not	O
all	O
CD44H	O
known	O
functions	O
are	O
attributed	O
to	O
its	O
ability	O
to	O
recognize	O
hyaluronate	O
.	O
We	O
have	O
previously	O
demonstrated	O
a	O
lack	O
of	O
CD44	O
expression	O
in	O
high	O
stages	O
and	O
NMYC	O
-	O
amplified	O
tumors	O
and	O
further	O
have	O
shown	O
that	O
NMYC	O
-	O
amplified	O
cell	O
lines	O
either	O
did	O
not	O
express	O
CD44	O
at	O
all	O
or	O
expressed	O
a	O
nonfunctional	O
receptor	O
.	O
On	O
the	O
other	O
hand	O
,	O
nonamplified	O
cells	O
constitutively	O
expressed	O
an	O
active	O
receptor	O
,	O
suggesting	O
that	O
absence	O
of	O
CD44	O
-	O
mediated	O
hy	O
aluronate	O
binding	O
could	O
be	O
related	O
to	O
increased	O
malignancy	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
PROCEDURE	O
:	O
In	O
the	O
present	O
study	O
we	O
have	O
compared	O
the	O
glycosylated	O
structure	O
of	O
CD44	O
expressed	O
by	O
NMYC	O
amplified	O
vs	O
.	O
nonamplified	O
cell	O
lines	O
in	O
relation	O
to	O
their	O
adhesive	O
properties	O
for	O
hyaluronate	O
.	O
These	O
adhesive	O
properties	O
were	O
measured	O
after	O
modifications	O
of	O
the	O
carbohydrate	O
structure	O
with	O
enzymes	O
and	O
inhibitors	O
of	O
N	O
-	O
or	O
O	O
-	O
linked	O
glycosylation	O
.	O
RESULTS	O
AND	O
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
increased	O
sialylation	O
,	O
defective	O
N	O
-	O
linked	O
glycosylation	O
,	O
and	O
substitution	O
of	O
the	O
CD44	O
glycoprotein	O
with	O
keratan	O
sulfate	O
glycosaminoglycan	O
might	O
include	O
modifications	O
observed	O
on	O
neuroblastoma	B-malignancy-type
cells	O
that	O
could	O
account	O
for	O
the	O
inability	O
of	O
the	O
receptor	O
to	O
bind	O
hyaluronate	O
.	O
PMID	O
:	O
11464867	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pharmacol	O
Exp	O
Ther	O
.	O
1986	O
Feb;236	O
(	O
2	O
)	O
:458-63	O
.	O
Acute	O
effects	O
of	O
ethanol	O
and	O
other	O
short	O
-	O
chain	O
alcohols	O
on	O
the	O
guanylate	O
cyclase	O
system	O
of	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
(	O
clone	O
N1E	O
-	O
115	O
)	O
.	O
Stenstrom	O
S	O
,	O
Enloe	O
L,	O
Pfenning	O
M,	O
Richelson	O
E.	O
The	O
acute	O
effects	O
of	O
ethanol	O
were	O
studied	O
on	O
the	O
guanylate	O
cyclase	O
system	O
of	O
cultured	O
murine	O
neuroblastoma	B-malignancy-type
clone	O
N1E	O
-	O
115	O
.	O
Using	O
intact	O
cells	O
,	O
we	O
found	O
that	O
although	O
ethanol	O
had	O
no	O
effect	O
on	O
basal	O
levels	O
of	O
cyclic	O
GMP	O
synthesis	O
,	O
it	O
rapidly	O
inhibited	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
cyclic	O
GMP	O
synthesis	O
mediated	O
by	O
the	O
agonists	O
histamine	O
(	O
histamine	O
H1	O
receptor	O
)	O
and	O
carbachol	O
(	O
low	O
-	O
affinity	O
muscarinic	O
receptor	O
)	O
and	O
by	O
ionophore	O
X537A	O
and	O
melittin	O
,	O
agents	O
which	O
bypass	O
these	O
receptors	O
.	O
At	O
200	O
mM	O
ethanol	O
,	O
inhibition	O
was	O
about	O
40	O
to	O
50	O
%	O
with	O
the	O
agonists	O
,	O
X537A	O
and	O
melittin	O
.	O
Ethanol	O
had	O
no	O
effect	O
on	O
the	O
high	O
-	O
affinity	O
muscarinic	O
receptor	O
,	O
that	O
mediates	O
inhibition	O
of	O
cyclic	O
AMP	O
synthesis	O
.	O
With	O
carbachol	O
ethanol	O
'	O
s	O
inhibition	O
was	O
reversible	O
and	O
was	O
a	O
mixed	O
competitive	O
/	O
noncompetitive	O
type	O
.	O
For	O
a	O
series	O
of	O
alcohols	O
,	O
inhibitory	O
potency	O
with	O
carbachol	O
correlated	O
with	O
chain	O
length	O
directly	O
.	O
In	O
addition	O
,	O
sucrose	O
and	O
sodium	O
chloride	O
,	O
which	O
like	O
ethanol	O
increases	O
the	O
osmolality	O
of	O
the	O
incubation	O
medium	O
,	O
mimicked	O
the	O
effects	O
of	O
ethanol	O
.	O
In	O
a	O
crude	O
cellular	O
homogenate	O
,	O
ethanol	O
and	O
other	O
alcohols	O
inhibited	O
both	O
basal	O
and	O
sodium	O
nitroprusside	O
-	O
stimulated	O
guanylate	O
cyclase	O
activity	O
.	O
The	O
effect	O
of	O
ethanol	O
on	O
basal	O
enzyme	O
activity	O
was	O
noncompetitive	O
.	O
Thus	O
,	O
the	O
inhibition	O
by	O
ethanol	O
and	O
other	O
alcohols	O
of	O
receptor	O
-	O
mediated	O
cyclic	O
GMP	O
synthesis	O
appears	O
to	O
be	O
at	O
the	O
level	O
of	O
guanylate	O
cyclase	O
.	O
PMID	O
:	O
2868120	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathology	O
.	O
1998	O
Nov;30	O
(	O
4	O
)	O
:	O
33	O
5-47	O
.	O
Gene	O
transfer	O
:	O
a	O
review	O
of	O
methods	O
and	O
applications	O
.	O
Prince	O
HM	O
.	O
Department	O
of	O
Hematology	O
,	O
Peter	O
MacCallum	O
Cancer	O
Institute	O
,	O
Melbourne	O
,	O
Victoria	O
,	O
Australia	O
.	O
Gene	O
transfer	O
is	O
a	O
potentially	O
powerful	O
tool	O
for	O
the	O
treatment	O
of	O
a	O
wide	O
variety	O
of	O
diseases	O
.	O
The	O
transfer	O
of	O
these	O
genes	O
is	O
achieved	O
by	O
utilizing	O
a	O
variety	O
of	O
vectors	O
,	O
including	O
retroviral	O
,	O
adenoviral	O
,	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
and	O
a	O
number	O
of	O
non	O
-	O
viral	O
mechanisms	O
.	O
Numerous	O
studies	O
have	O
successfully	O
demonstrated	O
transduction	O
of	O
genes	O
into	O
target	O
cells	O
with	O
a	O
variety	O
of	O
vectors	O
,	O
and	O
have	O
provided	O
'	O
proof	O
-	O
in	O
-	O
principle	O
'	O
that	O
gene	O
transfer	O
can	O
result	O
in	O
prolonged	O
in	O
vivo	O
expression	O
of	O
transduced	O
genes	O
,	O
albeit	O
at	O
low	O
quantities	O
.	O
Furthermore	O
,	O
gene	O
marking	O
studies	O
in	O
acute	B-malignancy-type
myeloblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
and	O
neuroblastoma	B-malignancy-type
have	O
elegantly	O
demonstrated	O
that	O
gene	O
-	O
marked	O
tumor	O
cells	O
contribute	O
to	O
relapse	O
following	O
autologous	O
transplantation	O
.	O
However	O
none	O
of	O
the	O
studies	O
examining	O
the	O
therapeutic	O
benefit	O
of	O
gene	O
therapy	O
has	O
definitively	O
demonstrated	O
a	O
clinically	O
meaningful	O
benefit	O
.	O
Nonetheless	O
,	O
the	O
results	O
of	O
studies	O
involving	O
gene	O
transfer	O
for	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
,	O
chronic	O
granulomatous	O
disease	O
(	O
CGD	O
)	O
,	O
melanoma	B-malignancy-type
and	O
lung	B-malignancy-type
cancer	I-malignancy-type
highlight	O
the	O
potential	O
benefit	O
of	O
this	O
strategy	O
.	O
This	O
review	O
will	O
discuss	O
mechanisms	O
of	O
achieving	O
gene	O
transfer	O
into	O
target	O
cells	O
.	O
It	O
will	O
examine	O
some	O
of	O
the	O
pre	O
-	O
clinical	O
and	O
clinical	O
results	O
to	O
date	O
and	O
will	O
discuss	O
some	O
of	O
the	O
potential	O
uses	O
of	O
gene	O
transfer	O
for	O
therapeutic	O
purposes	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9839307	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gan	O
To	O
Kagaku	O
Ryoho	O
.	O
1993	O
Mar;20(	O
4	O
)	O
:	O
51	O
5-20	O
.	O
[	O
Peripheral	O
blood	O
stem	O
cell	O
transplantation	O
in	O
adult	O
patients	O
]	O
[	O
Article	O
in	O
Japanese	O
]	O
Fujii	O
H,	O
Nakagawa	O
H,	O
Sonoda	O
Y	O
,	O
Maekawa	O
T	O
,	O
Kuzuyama	O
Y	O
.	O
Third	O
Dept	O
.	O
of	O
Internal	O
Medicine	O
,	O
Kyoto	O
First	O
Red	O
Cross	O
Hospital	O
.	O
We	O
reported	O
the	O
experience	O
of	O
peripheral	O
blood	O
stem	O
cell	O
transplantation	O
(	O
PBSCT	O
)	O
performed	O
in	O
adult	O
patients	O
with	O
hematological	O
malignancies	O
and	O
solid	B-malignancy-type
tumors	I-malignancy-type
.	O
After	O
myelosuppressive	O
chemotherapy	O
,	O
peripheral	O
blood	O
stem	O
cells	O
were	O
collected	O
using	O
a	O
Blood	O
Cell	O
Separator	O
(	O
CS	O
-	O
3000	O
)	O
during	O
bone	O
marrow	O
recovery	O
and	O
subsequently	O
cryopreserved	O
in	O
17	O
patients	O
(	O
9	O
:	O
malignant	O
lymphoma	B-malignancy-type
;	O
2	O
:	O
ALL	B-malignancy-type
;	O
2	O
:	O
AML	B-malignancy-type
;	O
2	O
:	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
;	O
2	O
:	O
solid	B-malignancy-type
tumors	I-malignancy-type
)	O
.	O
In	O
28	O
apheresis	O
cases	O
,	O
the	O
collected	O
number	O
of	O
granulocyte	O
/	O
macrophage	O
progenitors	O
(	O
CFU	O
-	O
GM	O
)	O
was	O
more	O
than	O
5	O
x	O
10	O
(	O
5	O
)	O
/	O
kg	O
BW	O
in	O
17	O
apheresis	O
cases	O
and	O
ranged	O
between	O
2	O
and	O
5	O
x	O
10	O
(	O
5	O
)	O
/	O
kg	O
BW	O
in	O
4	O
of	O
such	O
cases	O
.	O
Eleven	O
patients	O
(	O
7	O
:	O
malignant	O
lymphoma	B-malignancy-type
;	O
1	O
:	O
ALL	B-malignancy-type
;	O
1	O
:	O
AML	B-malignancy-type
;	O
1	O
:	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
;	O
1	O
:	O
neuroblastoma	B-malignancy-type
)	O
underwent	O
PBSCT	O
following	O
myeloablative	O
chemotherapy	O
.	O
The	O
infused	O
number	O
of	O
CFU	O
-	O
GM	O
ranged	O
between	O
0.6	O
and	O
18.1	O
x	O
10	O
(	O
5	O
)	O
/	O
kg	O
BW	O
.	O
In	O
7	O
patients	O
,	O
more	O
than	O
5	O
x	O
10	O
(	O
5	O
)	O
CFU	O
-	O
GM	O
/	O
kg	O
BW	O
were	O
infused	O
.	O
The	O
median	O
time	O
to	O
reach	O
500	O
neutrophils	O
/	O
microliter	O
or	O
50,000	O
platelets	O
/	O
microliter	O
was	O
10	O
(	O
range	O
:	O
8	O
-	O
17	O
)	O
and	O
20	O
(	O
range	O
:	O
8	O
-	O
63	O
)	O
days	O
,	O
respectively	O
.	O
One	O
patient	O
died	O
from	O
sepsis	O
before	O
hematologic	O
recovery	O
occurred	O
.	O
Eight	O
patients	O
are	O
alive	O
with	O
no	O
evidence	O
of	O
active	O
disease	O
for	O
7	O
-	O
19	O
months	O
after	O
PBSCT	O
.	O
When	O
the	O
infused	O
number	O
of	O
CFU	O
-	O
GM	O
is	O
more	O
than	O
2	O
x	O
10	O
(	O
5	O
)	O
/	O
kg	O
BW	O
,	O
PBSCT	O
following	O
myeloablative	O
chemotherapy	O
seems	O
to	O
be	O
safe	O
and	O
useful	O
treatment	O
.	O
PMID	O
:	O
7680848	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
2002	O
Jan	O
1;94	O
(	O
1	O
)	O
:258-63	O
.	O
Selective	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
neuropilin	O
-	O
1	O
and	O
-	O
2	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Fakhari	O
M,	O
Pullirsch	O
D	O
,	O
Abraham	O
D	O
,	O
Paya	O
K,	O
Hofbauer	O
R	O
,	O
Holzfeind	O
P,	O
Hofmann	O
M,	O
Aharinejad	O
S.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
BACKGROUND	O
:	O
Recent	O
studies	O
show	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
receptors	O
Flt	O
-	O
1	O
and	O
KDR	O
,	O
and	O
a	O
series	O
of	O
other	O
angiogenic	O
molecules	O
,	O
are	O
upregulated	O
in	O
advanced	O
but	O
not	O
low	O
stage	O
human	O
neuroblastoma	B-malignancy-type
.	O
Neuropilin	O
-	O
1	O
and	O
2	O
(	O
NRP	O
)	O
are	O
novel	O
specific	O
receptors	O
of	O
VEGF	O
(	O
165	O
)	O
,	O
whose	O
role	O
is	O
unknown	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
METHODS	O
:	O
Tissue	O
biopsies	O
of	O
37	O
children	O
with	O
Stage	O
I	O
-	O
IV	O
neuroblastoma	B-malignancy-type
were	O
obtained	O
,	O
as	O
well	O
as	O
biopsies	O
of	O
7	O
normal	O
adrenals	O
as	O
controls	O
.	O
The	O
mRNA	O
expression	O
of	O
VEGF	O
(	O
165	O
)	O
and	O
its	O
receptors	O
Flt	O
-	O
1	O
,	O
KDR	O
,	O
NRP1	O
,	O
and	O
NRP2	O
was	O
evaluated	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
NRP	O
protein	O
expression	O
was	O
detected	O
by	O
immunocytochemistry	O
and	O
Western	O
blotting	O
.	O
RESULTS	O
:	O
VEGF	O
(	O
165	O
)	O
mRNA	O
was	O
upregulated	O
in	O
Stage	O
III	O
and	O
IV	O
and	O
Flt	O
-	O
1	O
and	O
KDR	O
gene	O
expression	O
was	O
increased	O
in	O
Stage	O
III	O
,	O
while	O
NRP	O
1	O
and	O
2	O
mRNA	O
and	O
protein	O
levels	O
were	O
higher	O
in	O
Stages	O
I	O
-	O
IV	O
vs	O
.	O
controls	O
(	O
P	O
<	O
0.05	O
)	O
.	O
NRP	O
was	O
expressed	O
in	O
vascular	O
endothelial	O
but	O
not	O
tumor	O
cells	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
human	O
neuroblastoma	B-malignancy-type
expresses	O
NRP	O
,	O
and	O
that	O
NRP	O
co	O
-	O
regulates	O
VEGF	O
angiogenic	O
effect	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
NRP	O
might	O
be	O
a	O
sensitive	O
angiogenic	O
measure	O
of	O
VEGF	O
systems	O
in	O
neuroblastoma	B-malignancy-type
,	O
particularly	O
in	O
its	O
early	O
stages	O
.	O
Copyright	O
2002	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11815985	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2003	O
Jan	O
31	O
;278	O
(	O
5	O
)	O
:	O
2947	O
-	O
55	O
.	O
Epub	O
2002	O
Nov	O
12	O
.	O
Cell	O
cycle	O
-	O
dependent	O
expression	O
of	O
HERG1	O
and	O
HERG1B	O
isoforms	O
in	O
tumor	O
cells	O
.	O
Crociani	O
O	O
,	O
Guasti	O
L,	O
Balzi	O
M,	O
Becchetti	O
A	O
,	O
Wanke	O
E	O
,	O
Olivotto	O
M,	O
Wymore	O
RS	O
,	O
Arcangeli	O
A	O
.	O
Department	O
of	O
Experimental	O
Pathology	O
and	O
Oncology	O
,	O
University	O
of	O
Firenze	O
,	O
Viale	O
G.	O
B.	O
Morgagni	O
50	O
,	O
50134	O
Firenze	O
,	O
Italy	O
.	O
The	O
role	O
of	O
K(+)	O
channel	O
activity	O
during	O
cell	O
cycle	O
progression	O
has	O
become	O
a	O
research	O
topic	O
of	O
considerable	O
interest	O
.	O
Blocking	O
of	O
K(+)	O
channels	O
inhibits	O
the	O
proliferation	O
of	O
many	O
cell	O
types	O
,	O
although	O
the	O
mechanism	O
of	O
this	O
inhibition	O
is	O
unclear	O
.	O
There	O
is	O
speculation	O
that	O
K(+)	O
channels	O
differentially	O
regulate	O
the	O
electrical	O
potential	O
of	O
the	O
plasma	O
membrane	O
(	O
V	O
(	O
m	O
)	O
)	O
during	O
proliferation	O
.	O
We	O
have	O
demonstrated	O
that	O
in	O
tumor	O
cells	O
the	O
value	O
of	O
V	O
(	O
m	O
)	O
is	O
clamped	O
to	O
rather	O
depolarized	O
values	O
by	O
K(+)	O
channels	O
belonging	O
to	O
the	O
HERG	O
family	O
.	O
We	O
report	O
here	O
that	O
tumor	O
cell	O
lines	O
preferentially	O
express	O
the	O
herg1	O
gene	O
and	O
a	O
truncated	O
,	O
N	O
-	O
deleted	O
form	O
that	O
corresponds	O
to	O
herg1b	O
.	O
This	O
alternative	O
transcript	O
is	O
also	O
expressed	O
in	O
human	O
primary	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemias	I-malignancy-type
.	O
Both	O
HERG1	O
and	O
HERG1B	O
proteins	O
are	O
expressed	O
on	O
the	O
plasma	O
membrane	O
of	O
tumor	O
cells	O
and	O
can	O
form	O
heterotetramers	O
.	O
The	O
expression	O
of	O
HERG	O
protein	O
isoforms	O
is	O
strongly	O
cell	O
cycle	O
-	O
dependent	O
,	O
accounting	O
for	O
variations	O
in	O
HERG	O
currents	O
along	O
the	O
mitotic	O
cycle	O
.	O
Moreover	O
,	O
the	O
blocking	O
of	O
HERG	O
channels	O
dramatically	O
impairs	O
cell	O
growth	O
of	O
HERG	O
-	O
bearing	O
tumor	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
modulated	O
expression	O
of	O
different	O
K(+)	O
channels	O
is	O
the	O
molecular	O
basis	O
of	O
a	O
novel	O
mechanism	O
regulating	O
neoplastic	O
cell	O
proliferation	O
.	O
PMID	O
:	O
12431979	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Korean	O
Med	O
Sci	O
.	O
2003	O
Apr	O
;	O
18	O
(	O
2	O
)	O
:	O
184	O
-	O
90	O
.	O
Myeloablative	O
treatment	O
supported	O
by	O
autologous	O
stem	O
cell	O
infusion	O
with	O
neuroblastoma	B-malignancy-type
.	O
Ryu	O
KH	O
,	O
Seoh	O
JY	O
,	O
Jang	O
PS	O
,	O
Kim	O
CW	O
,	O
Koh	O
SH	O
,	O
Shin	O
HY	O
,	O
Ahn	O
HS	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Ewha	O
Womans	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
Bcr	O
-	O
abl	O
antisense	O
oligodeoxynucleotides	O
(	O
AS	O
-	O
ODNs	O
)	O
have	O
provided	O
evidence	O
of	O
an	O
antileukemia	O
effect	O
when	O
tested	O
in	O
vitro	O
against	O
Philadelphia	O
-	O
positive	O
cells	O
.	O
In	O
order	O
to	O
investigate	O
the	O
efficacy	O
of	O
AS	O
-	O
ODNs	O
as	O
purging	O
agents	O
in	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
patients	O
,	O
K	O
562	O
cells	O
,	O
a	O
human	O
CML	B-malignancy-type
cell	O
line	O
,	O
were	O
treated	O
in	O
vitro	O
with	O
various	O
types	O
of	O
AS	O
-	O
ODNs	O
and	O
interferon	O
-	O
alpha	O
.	O
Cells	O
were	O
treated	O
in	O
vitro	O
for	O
0	O
and	O
36	O
hr	O
with	O
40	O
microgram	O
/	O
mL	O
of	O
AS	O
-	O
ODNs	O
,	O
respectively	O
,	O
and	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
36	O
hr	O
.	O
Cytotoxic	O
effects	O
were	O
measured	O
by	O
counting	O
the	O
number	O
of	O
viable	O
cells	O
as	O
well	O
as	O
by	O
MTT	O
test	O
.	O
Clonogenic	O
activities	O
were	O
evaluated	O
by	O
methylcellulose	O
culture	O
for	O
2	O
weeks	O
.	O
The	O
effects	O
of	O
purging	O
agents	O
on	O
the	O
rearrangement	O
of	O
bcrabl	O
gene	O
were	O
evaluated	O
by	O
RT	O
-	O
PCR	O
.	O
AS	O
-	O
ODNs	O
inhibited	O
the	O
proliferation	O
of	O
K	O
562	O
cells	O
with	O
time	O
in	O
cell	O
count	O
assay	O
and	O
MTT	O
test	O
.	O
AS	O
-	O
ODNs	O
were	O
superior	O
to	O
INF	O
-	O
alpha	O
in	O
inhibiting	O
clonogenic	O
activity	O
(	O
recovery	O
rate	O
;	O
26	O
.	O
3	O
%	O
vs	O
64	O
.	O
0	O
%	O
)	O
.	O
After	O
incubation	O
with	O
bcr	O
-	O
abl	O
AS	O
-	O
ODNs	O
primers	O
and	O
mRNA	O
isolated	O
from	O
K	O
562	O
cells	O
,	O
positive	O
bands	O
were	O
abolished	O
,	O
especially	O
of	O
b	O
3	O
a	O
2	O
type	O
and	O
phosphorothioate	O
type	O
.	O
Our	O
results	O
suggest	O
that	O
AS	O
-	O
ODNs	O
mediated	O
purging	O
may	O
be	O
one	O
of	O
the	O
efficient	O
methods	O
and	O
that	O
autograft	O
may	O
be	O
an	O
alternative	O
treatment	O
for	O
allograft	O
in	O
high	O
-	O
risk	O
group	O
patients	O
of	O
CML	B-malignancy-type
if	O
they	O
do	O
not	O
have	O
a	O
stem	O
cell	O
donor	O
.	O
PMID	O
:	O
12692414	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Clin	O
Cancer	O
Res	O
.	O
1996	O
Jul;2	O
(	O
7	O
)	O
:	O
109	O
7-	O
102	O
.	O
Loss	O
of	O
DCC	O
expression	O
in	O
neuroblastoma	B-malignancy-type
is	O
associated	O
with	O
disease	O
dissemination	O
.	O
Reale	O
MA	O
,	O
Reyes	O
-Mugica	O
M,	O
Pierceall	O
WE	O
,	O
Rubinstein	O
MC	O
,	O
Hedrick	O
L,	O
Cohn	O
SL	O
,	O
Nakagawara	O
A	O
,	O
Brodeur	O
GM	O
,	O
Fearon	O
ER	O
.	O
Sections	O
of	O
Medical	O
Oncology	O
and	O
Gastroenterology	O
,	O
Departments	O
of	O
Medicine	O
and	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06520	O
,	O
USA	O
.	O
DCC	O
,	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
from	O
chromosome	O
18q21	O
,	O
is	O
most	O
highly	O
expressed	O
in	O
the	O
developing	O
nervous	O
system	O
.	O
In	O
vitro	O
studies	O
suggest	O
a	O
role	O
for	O
DCC	O
in	O
neuronal	O
differentiation	O
,	O
and	O
18q	O
allelic	O
loss	O
occurs	O
in	O
a	O
subset	O
of	O
neuroblastomas	B-malignancy-type
.	O
To	O
address	O
the	O
hypothesis	O
that	O
loss	O
of	O
DCC	O
function	O
may	O
contribute	O
to	O
tumorigenesis	O
in	O
cells	O
of	O
neural	O
origin	O
,	O
we	O
utilized	O
a	O
combination	O
of	O
RNase	O
protection	O
,	O
immunoblotting	O
,	O
and	O
immunohistochemical	O
approaches	O
to	O
characterize	O
DCC	O
expression	O
in	O
62	O
primary	O
neuroblastomas	B-malignancy-type
and	O
16	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
The	O
DCC	O
protein	O
was	O
undetectable	O
in	O
38	O
%	O
of	O
the	O
primary	O
tumors	O
and	O
56	O
%	O
of	O
the	O
cell	O
lines	O
.	O
Of	O
note	O
,	O
primary	O
tumors	O
lacking	O
DCC	O
expression	O
were	O
more	O
likely	O
to	O
have	O
been	O
obtained	O
from	O
patients	O
with	O
disseminated	O
or	O
stage	O
D	O
disease	O
(	O
P	O
=	O
0.01	O
)	O
.	O
In	O
addition	O
,	O
loss	O
of	O
DCC	O
expression	O
was	O
observed	O
in	O
three	O
of	O
six	O
primary	O
tumors	O
from	O
stage	O
DS	O
patients	O
.	O
No	O
consistent	O
relationship	O
between	O
the	O
loss	O
of	O
DCC	O
expression	O
and	O
N-myc	O
amplification	O
was	O
observed	O
in	O
our	O
studies	O
.	O
Our	O
findings	O
suggest	O
that	O
loss	O
of	O
DCC	O
expression	O
may	O
contribute	O
to	O
the	O
dissemination	O
of	O
neuroblastoma	B-malignancy-type
cells	O
,	O
perhaps	O
through	O
alterations	O
in	O
growth	O
and	O
differentiation	O
pathways	O
distinct	O
from	O
those	O
regulated	O
by	O
N-myc	O
.	O
PMID	O
:	O
9816273	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2000	O
Jul	O
5;273	O
(	O
2	O
)	O
:784	O
-	O
8.	O
Epolactaene	O
,	O
a	O
novel	O
neuritogenic	O
compound	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
,	O
selectively	O
inhibits	O
the	O
activities	O
of	O
mammalian	O
DNA	O
polymerases	O
and	O
human	O
DNA	O
topoisomerase	O
II	O
.	O
Mizushina	O
Y	O
,	O
Kobayashi	O
S	O
,	O
Kuramochi	O
K,	O
Nagata	O
S	O
,	O
Sugawara	O
F	O
,	O
Sakaguchi	O
K.	O
Department	O
of	O
Applied	O
Biological	O
Science	O
,	O
Faculty	O
of	O
Science	O
and	O
Technology	O
,	O
Science	O
University	O
of	O
Tokyo	O
,	O
2641	O
Yamazaki	O
,	O
Noda	O
,	O
Chiba	O
,	O
278	O
-8510	O
,	O
Japan	O
.	O
We	O
chemically	O
synthesized	O
epolactaene	O
,	O
a	O
neuritogenic	O
compound	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
,	O
and	O
investigated	O
its	O
biochemical	O
action	O
in	O
vitro	O
.	O
Epolactaene	O
and	O
its	O
derivatives	O
selectively	O
inhibited	O
the	O
activities	O
of	O
mammalian	O
DNA	O
polymerase	O
alpha	O
and	O
beta	O
and	O
human	O
DNA	O
topoisomerase	O
II	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
25	O
,	O
94	O
,	O
and	O
10	O
microM	O
,	O
respectively	O
.	O
By	O
comparison	O
with	O
its	O
structural	O
derivatives	O
,	O
the	O
long	O
alkyl	O
side	O
chain	O
in	O
epolactaene	O
seemed	O
to	O
have	O
an	O
important	O
role	O
in	O
this	O
inhibitory	O
effect	O
.	O
The	O
compound	O
did	O
not	O
influence	O
the	O
activities	O
of	O
plant	O
or	O
prokaryotic	O
DNA	O
polymerases	O
or	O
of	O
other	O
DNA	O
metabolic	O
enzymes	O
such	O
as	O
telomerase	O
,	O
RNA	O
polymerase	O
,	O
and	O
deoxyribonuclease	O
I	O
.	O
Epolactaene	O
did	O
not	O
intercalate	O
into	O
DNA	O
.	O
These	O
results	O
suggested	O
that	O
the	O
neuritogenic	O
compound	O
epolactaene	O
influences	O
both	O
DNA	O
polymerases	O
and	O
topoisomerase	O
II	O
despite	O
the	O
dissimilarity	O
in	O
both	O
structure	O
and	O
properties	O
of	O
these	O
two	O
enzymes	O
and	O
that	O
inhibition	O
of	O
these	O
enzymes	O
could	O
be	O
related	O
to	O
the	O
neuritogenic	O
effect	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
relationship	O
between	O
the	O
neuritogenic	O
mechanism	O
and	O
cell	O
cycle	O
regulation	O
by	O
epolactaene	O
was	O
also	O
discussed	O
.	O
Copyright	O
2000	O
Academic	O
Press	O
.	O
PMID	O
:	O
10873681	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Synapse	O
.	O
1999	O
Dec;34(	O
3	O
)	O
:222	O
-7.	O
Regulation	O
of	O
striatal	O
dopamine	O
receptors	O
by	O
estrogen	O
.	O
Lammers	O
CH	O
,	O
D'Souza	O
U	O
,	O
Qin	O
ZH	O
,	O
Lee	O
SH	O
,	O
Yajima	O
S	O
,	O
Mouradian	O
MM	O
.	O
Genetic	O
Pharmacology	O
Unit	O
,	O
Experimental	O
Therapeutics	O
Branch	O
,	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
The	O
ability	O
of	O
estrogen	O
to	O
modulate	O
the	O
expression	O
of	O
ventral	O
and	O
dorsal	O
striatal	O
dopamine	O
receptors	O
D	O
(	O
1	O
)	O
,	O
D	O
(	O
2	O
,	O
)	O
and	O
D	O
(	O
3	O
)	O
was	O
examined	O
in	O
vivo	O
using	O
semi-quantitative	O
in	O
situ	O
hybridization	O
and	O
ligand	O
binding	O
autoradiography	O
.	O
Two	O
-	O
week	O
treatment	O
with	O
subcutaneous	O
pellets	O
of	O
17beta-estradiol	O
(	O
25	O
mg	O
)	O
downregulated	O
D	O
(	O
2	O
)	O
dopamine	O
receptor	O
mRNA	O
in	O
both	O
dorsal	O
and	O
ventral	O
striatum	O
(	O
shell	O
and	O
core	O
regions	O
of	O
nucleus	O
accumbens	O
)	O
.	O
No	O
significant	O
changes	O
in	O
D	O
(	O
1	O
)	O
or	O
D	O
(	O
3	O
)	O
mRNA	O
expression	O
were	O
detected	O
.	O
Ligand	O
binding	O
autoradiography	O
did	O
not	O
reveal	O
changes	O
in	O
D	O
(	O
1	O
)	O
,	O
D	O
(	O
2	O
,	O
)	O
or	O
D	O
(	O
3	O
)	O
receptor	O
protein	O
expression	O
.	O
We	O
also	O
assessed	O
the	O
ability	O
of	O
17beta-estradiol	O
to	O
regulate	O
D	O
(	O
2	O
)	O
gene	O
promoter	O
activity	O
in	O
NB41A3	O
neuroblastoma	B-malignancy-type
cells	O
that	O
express	O
this	O
gene	O
endogenously	O
using	O
co	O
-	O
transfections	O
with	O
an	O
estrogen	O
receptor	O
expression	O
vector	O
.	O
While	O
a	O
small	O
fragment	O
of	O
the	O
D	O
(	O
2	O
)	O
promoter	O
could	O
be	O
activated	O
2.5	O
-	O
fold	O
by	O
estrogen	O
,	O
a	O
larger	O
portion	O
of	O
the	O
D	O
(	O
2	O
)	O
gene	O
was	O
not	O
regulated	O
by	O
this	O
treatment	O
.	O
Estrogens	O
do	O
not	O
appear	O
to	O
have	O
a	O
net	O
effect	O
on	O
striatal	O
dopamine	O
receptor	O
expression	O
.	O
The	O
observed	O
downregulation	O
of	O
D	O
(	O
2	O
)	O
receptor	O
mRNA	O
in	O
the	O
dorsal	O
and	O
ventral	O
striatum	O
in	O
vivo	O
could	O
be	O
secondary	O
to	O
the	O
increased	O
striatal	O
dopamine	O
release	O
induced	O
by	O
estrogen	O
.	O
Synapse	O
34	O
:	O
222-227	O
,	O
1999	O
.	O
Published	O
1999	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
10523759	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1994	O
Nov;27	O
(	O
1	O
)	O
:95-	O
102	O
.	O
Ethanol	O
and	O
naloxone	O
differentially	O
upregulate	O
delta	O
opioid	O
receptor	O
gene	O
expression	O
in	O
neuroblastoma	B-malignancy-type
hybrid	O
(	O
NG108-15	O
)	O
cells	O
.	O
Jenab	O
S	O
,	O
Inturrisi	O
CE.	O
Department	O
of	O
Pharmacology	O
,	O
Cornell	O
University	O
Medical	O
College	O
,	O
New	O
York	O
,	O
NY	O
10021	O
.	O
We	O
have	O
used	O
a	O
sensitive	O
solution	O
hybridization	O
assay	O
with	O
a	O
riboprobe	O
transcribed	O
from	O
the	O
coding	O
sequence	O
of	O
the	O
delta	O
opioid	O
receptor	O
(	O
DOR	O
)	O
to	O
quantitate	O
the	O
changes	O
in	O
DOR	O
mRNA	O
transcript	O
levels	O
following	O
exposure	O
of	O
NG108-15	O
cells	O
to	O
ethanol	O
and/or	O
the	O
opioid	O
antagonist	O
,	O
naloxone	O
.	O
Incubation	O
of	O
NG108-15	O
cells	O
with	O
200	O
mM	O
ethanol	O
or	O
1	O
microM	O
naloxone	O
,	O
treatments	O
that	O
have	O
previously	O
been	O
shown	O
to	O
upregulate	O
DOR	O
binding	O
,	O
increased	O
DOR	O
mRNA	O
transcript	O
levels	O
2	O
to	O
3	O
fold	O
.	O
DOR	O
mRNA	O
levels	O
peaked	O
at	O
24	O
to	O
48	O
h	O
after	O
exposure	O
to	O
either	O
ethanol	O
or	O
naloxone	O
.	O
At	O
168	O
h	O
,	O
DOR	O
mRNA	O
levels	O
in	O
NG108-15	O
cells	O
exposed	O
to	O
naloxone	O
had	O
returned	O
to	O
control	O
(	O
untreated	O
)	O
levels	O
while	O
the	O
levels	O
in	O
ethanol	O
treated	O
cells	O
remained	O
nearly	O
equal	O
to	O
peak	O
values	O
.	O
Exposure	O
to	O
a	O
combination	O
of	O
ethanol	O
plus	O
naloxone	O
for	O
24	O
h	O
produced	O
an	O
additive	O
effect	O
,	O
so	O
that	O
DOR	O
mRNA	O
transcripts	O
were	O
increased	O
3	O
fold	O
.	O
Northern	O
blot	O
analysis	O
identified	O
six	O
DOR	O
transcript	O
bands	O
ranging	O
in	O
size	O
from	O
8.7	O
to	O
2.1	O
kb	O
.	O
The	O
above	O
treatments	O
increased	O
each	O
of	O
the	O
six	O
bands	O
proportionately	O
,	O
so	O
that	O
no	O
difference	O
was	O
observed	O
in	O
the	O
fraction	O
of	O
the	O
total	O
hybridization	O
signal	O
produced	O
by	O
each	O
band	O
of	O
the	O
Northern	O
blot	O
.	O
These	O
results	O
demonstrate	O
that	O
each	O
of	O
the	O
DOR	O
transcripts	O
in	O
NG108-15	O
cells	O
are	O
subject	O
to	O
homologous	O
(	O
naloxone	O
)	O
as	O
well	O
as	O
heterologous	O
(	O
ethanol	O
)	O
upregulation	O
.	O
PMID	O
:	O
7877460	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
Surg	O
.	O
2002	O
Sep;37	O
(	O
9	O
)	O
:	O
1293	O
-	O
7.	O
Expression	O
of	O
the	O
periostin	O
mRNA	O
level	O
in	O
neuroblastoma	B-malignancy-type
.	O
Sasaki	O
H,	O
Sato	O
Y	O
,	O
Kondo	O
S	O
,	O
Fukai	O
I	O
,	O
Kiriyama	O
M,	O
Yamakawa	O
Y	O
,	O
Fuji	O
Y	O
.	O
Department	O
of	O
Surgery	O
II	O
,	O
Nagoya	O
City	O
University	O
Medical	O
School	O
,	O
Nagoya	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Neuroblastoma	B-malignancy-type
is	O
the	O
most	O
common	O
malignant	O
solid	B-malignancy-type
tumor	I-malignancy-type
in	O
early	O
childhood	O
.	O
Whether	O
neuroblastoma	B-malignancy-type
is	O
diagnosed	O
by	O
mass	O
screening	O
or	O
by	O
clinical	O
symptom	O
,	O
it	O
has	O
been	O
reported	O
to	O
be	O
correlated	O
with	O
prognosis	O
of	O
the	O
disease	O
.	O
The	O
periostin	O
protein	O
shares	O
structural	O
and	O
sequence	O
homology	O
with	O
fasciclin	O
I	O
,	O
which	O
is	O
an	O
insect	O
adhesion	O
molecule	O
.	O
METHODS	O
:	O
Expression	O
of	O
periostin	O
messenger	O
RNAs	O
were	O
evaluated	O
by	O
real	O
-time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
in	O
24	O
tumor	O
samples	O
from	O
neuroblastoma	B-malignancy-type
using	O
LightCycler	O
.	O
The	O
data	O
were	O
analyzed	O
in	O
reference	O
to	O
clinicopathologic	O
factors	O
.	O
RESULTS	O
:	O
There	O
was	O
a	O
tendency	O
for	O
higher	O
periostin	O
transcripts	O
levels	O
in	O
the	O
tumor	O
samples	O
from	O
stage	O
IV	O
when	O
compared	O
with	O
the	O
stage	O
I	O
(	O
P	O
=	O
.0845	O
)	O
.	O
The	O
periostin	O
mRNA	O
level	O
was	O
higher	O
in	O
the	O
group	O
with	O
disease	O
diagnosed	O
by	O
symptom	O
than	O
in	O
the	O
group	O
with	O
disease	O
diagnosed	O
by	O
mass	O
screening	O
(	O
P	O
=	O
.0266	O
)	O
.	O
The	O
periostin	O
mRNA	O
level	O
also	O
was	O
higher	O
in	O
the	O
group	O
with	O
disease	O
diagnosed	O
after	O
1	O
year	O
of	O
age	O
than	O
in	O
the	O
group	O
with	O
disease	O
diagnosed	O
before	O
1	O
year	O
of	O
age	O
(	O
P	O
=	O
.0059	O
)	O
.	O
CONCLUSION	O
:	O
Because	O
the	O
groups	O
with	O
disease	O
diagnosed	O
by	O
symptom	O
or	O
after	O
1	O
year	O
of	O
age	O
were	O
reported	O
to	O
be	O
the	O
worse	O
prognosis	O
,	O
the	O
periostin	O
mRNA	O
expression	O
levels	O
were	O
correlated	O
with	O
tumor	O
progression	O
or	O
prognosis	O
of	O
neuroblastoma	B-malignancy-type
.	O
Copyright	O
2002	O
,	O
Elsevier	O
Science	O
(	O
USA	O
)	O
.	O
All	O
rights	O
reserved	O
.	O
PMID	O
:	O
12194119	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2003	O
Nov	O
1;6	O
3(	O
21	O
)	O
:7310-	O
3.	O
Bak	O
:	O
a	O
downstream	O
mediator	O
of	O
fenretinide	O
-	O
induced	O
apoptosis	O
of	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Lovat	O
PE	O
,	O
Oliverio	O
S	O
,	O
Corazzari	O
M,	O
Rodolfo	O
C	O
,	O
Ranalli	O
M,	O
Goranov	O
B	O
,	O
Melino	O
G	O
,	O
Redfern	O
CP	O
,	O
Piacentini	O
M.	O
Northern	O
Institute	O
for	O
Cancer	O
Research	O
,	O
4th	O
Floor	O
Cookson	O
Building	O
,	O
Medical	O
School	O
,	O
University	O
of	O
Newcastle	O
,	O
Newcastle	O
Upon	O
Tyne	O
NE2	O
4HH	O
,	O
United	O
Kingdom	O
.	O
Unlike	O
13-cis	O
-	O
retinoic	O
acid	O
,	O
the	O
synthetic	O
retinoid	O
fenretinide	O
[	O
N-(4-hydroxyphenyl)retinamide	O
]	O
induces	O
apoptosis	O
of	O
neuroblastoma	B-malignancy-type
cells	O
by	O
mechanisms	O
involving	O
retinoic	O
acid	O
receptors	O
and	O
oxidative	O
stress	O
.	O
After	O
screening	O
a	O
cDNA	O
array	O
for	O
apoptosis	O
-	O
related	O
genes	O
,	O
the	O
Bcl2	O
-	O
related	O
protein	O
Bak	O
was	O
identified	O
as	O
a	O
fenretinide	O
-	O
inducible	O
gene	O
in	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
,	O
and	O
this	O
was	O
confirmed	O
by	O
Western	O
blotting	O
and	O
flow	O
cytometry	O
.	O
Although	O
fenretinide	O
acts	O
synergistically	O
in	O
vitro	O
with	O
chemotherapeutic	O
drugs	O
,	O
these	O
drugs	O
did	O
not	O
induce	O
Bak	O
expression	O
.	O
Retinoic	O
acid	O
receptor	O
antagonists	O
did	O
not	O
block	O
the	O
induction	O
of	O
Bak	O
by	O
fenretinide	O
.	O
Conversely	O
,	O
Bak	O
induction	O
was	O
blocked	O
by	O
the	O
antioxidant	O
vitamin	O
C	O
.	O
Overexpression	O
of	O
Bak	O
increased	O
apoptosis	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
fenretinide	O
,	O
whereas	O
expression	O
of	O
antisense	O
Bak	O
inhibited	O
fenretinide	O
-	O
induced	O
apoptosis	O
.	O
Bak	O
expression	O
was	O
also	O
induced	O
in	O
cells	O
overexpressing	O
the	O
stress	O
-	O
induced	O
transcription	O
factor	O
GADD153	O
,	O
but	O
Bak	O
expression	O
was	O
inhibited	O
in	O
cells	O
expressing	O
an	O
antisense	O
GADD153	O
construct	O
.	O
These	O
results	O
suggest	O
that	O
Bak	O
is	O
a	O
downstream	O
mediator	O
of	O
an	O
oxidative	O
stress	O
pathway	O
leading	O
to	O
apoptosis	O
of	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
in	O
response	O
to	O
fenretinide	O
.	O
PMID	O
:	O
14612528	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
.	O
2002	O
Apr;196	O
(	O
4	O
)	O
:450	O
-	O
8.	O
MYCN	O
expression	O
in	O
human	O
rhabdomyosarcoma	B-malignancy-type
cell	O
lines	O
and	O
tumour	O
samples	O
.	O
Toffolatti	O
L,	O
Frascella	O
E	O
,	O
Ninfo	O
V	O
,	O
Gambini	O
C	O
,	O
Forni	O
M,	O
Carli	O
M,	O
Rosolen	O
A	O
.	O
Clinica	O
di	O
Oncoematologia	O
Pediatrica	O
,	O
Azienda	O
Ospedaliera-Universita	O
di	O
Padova	O
,	O
Padova	O
,	O
Italy	O
.	O
The	O
MYCN	O
oncogene	O
encodes	O
a	O
phosphoprotein	O
that	O
acts	O
as	O
a	O
transcription	O
factor	O
and	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
in	O
normal	O
as	O
well	O
as	O
in	O
cancer	O
cells	O
.	O
MYCN	O
amplification	O
and	O
expression	O
have	O
been	O
reported	O
in	O
various	O
tumours	O
,	O
including	O
neuroblastoma	B-malignancy-type
and	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
little	O
is	O
known	O
about	O
its	O
expression	O
in	O
human	O
rhabdomyosarcoma	B-malignancy-type
.	O
MYCN	O
expression	O
and	O
amplification	O
were	O
studied	O
in	O
five	O
alveolar	B-malignancy-type
and	O
five	O
embryonal	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
cell	O
lines	O
and	O
in	O
19	O
tumour	O
biopsies	O
.	O
All	O
the	O
cell	O
lines	O
studied	O
expressed	O
MYCN	O
RNA	O
,	O
as	O
demonstrated	O
by	O
northern	O
blot	O
analysis	O
and	O
RT-PCR	O
,	O
but	O
the	O
oncogene	O
was	O
amplified	O
in	O
only	O
one	O
.	O
Similarly	O
,	O
MYCN	O
protein	O
was	O
detected	O
in	O
all	O
cell	O
lines	O
by	O
western	O
blot	O
analysis	O
,	O
with	O
higher	O
levels	O
of	O
expression	O
in	O
alveolar	B-malignancy-type
than	O
in	O
embryonal	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
cells	O
.	O
RT-PCR	O
analysis	O
of	O
tumour	O
samples	O
demonstrated	O
18	O
/	O
19	O
cases	O
positive	O
for	O
MYCN	O
RNA	O
.	O
Although	O
MYCN	O
expression	O
was	O
higher	O
in	O
alveolar	B-malignancy-type
than	O
in	O
embryonal	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
cell	O
lines	O
,	O
no	O
clear	O
relationship	O
between	O
histology	O
and	O
level	O
of	O
MYCN	O
expression	O
could	O
be	O
established	O
in	O
this	O
tumour	O
series	O
.	O
These	O
data	O
suggest	O
that	O
MYCN	O
expression	O
is	O
a	O
common	O
feature	O
of	O
rhabdomyosarcoma	B-malignancy-type
,	O
independent	O
of	O
gene	O
amplification	O
and	O
without	O
a	O
clear	O
relationship	O
with	O
specific	O
histological	O
and	O
clinical	O
features	O
.	O
Copyright	O
2002	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
PMID	O
:	O
11920742	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Mol	O
Biol	O
(	O
Noisy-le	O
-grand	O
)	O
.	O
2001	O
;47	O
Online	O
Pub:OL29-	O
38	O
.	O
Functional	O
characterization	O
of	O
the	O
promoter	O
region	O
of	O
the	O
human	O
mu	O
opioid	O
receptor	O
(	O
hMOR	O
)	O
gene	O
:	O
identification	O
of	O
activating	O
and	O
inhibitory	O
regions	O
.	O
Xu	O
Y	O
,	O
Carr	O
LG.	O
Department	O
of	O
Medicine	O
,	O
Indiana	O
University	O
School	O
of	O
Medicine	O
,	O
Indianapolis	O
46202	O
-5121	O
,	O
USA	O
.	O
The	O
mu	O
opioid	O
receptor	O
(	O
MOR	O
)	O
is	O
thought	O
to	O
mediate	O
a	O
variety	O
of	O
morphine	O
's	O
effects	O
,	O
including	O
analgesia	O
and	O
addiction	O
.	O
The	O
expression	O
of	O
opioid	O
receptors	O
can	O
be	O
up	O
and	O
down	O
regulated	O
,	O
but	O
little	O
is	O
known	O
about	O
molecular	O
processes	O
that	O
regulate	O
expression	O
of	O
the	O
MOR	O
gene	O
.	O
To	O
study	O
the	O
regulatory	O
elements	O
that	O
control	O
expression	O
of	O
the	O
human	O
MOR	O
(	O
hMOR	O
)	O
gene	O
,	O
2325	O
bp	O
of	O
the	O
5'-	O
regulatory	O
sequence	O
of	O
the	O
hMOR	O
gene	O
were	O
cloned	O
and	O
sequenced	O
.	O
A	O
transcription	O
initiation	O
site	O
(	O
TIS	O
)	O
was	O
mapped	O
252	O
(	O
-252	O
)	O
nucleotides	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
(	O
+1	O
)	O
by	O
primer	O
extension	O
experiments	O
using	O
human	O
thalamus	O
poly(A)	O
+	O
mRNA	O
.	O
In	O
addition	O
,	O
several	O
putative	O
distal	O
TISs	O
were	O
also	O
identified	O
;	O
the	O
most	O
distal	O
site	O
was	O
mapped	O
663	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
site	O
.	O
A	O
series	O
of	O
5'-deleted	O
hMOR	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
made	O
and	O
transiently	O
transfected	O
into	O
a	O
MOR	O
expressing	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SK-N-SH	O
,	O
and	O
a	O
non	O
-	O
expressing	O
cell	O
line	O
,	O
HeLa	O
.	O
These	O
transient	O
transfection	O
studies	O
indicated	O
that	O
the	O
region	O
from	O
-	O
563	O
to	O
-	O
292	O
contained	O
a	O
strong	O
enhancer	O
element(s)	O
,	O
while	O
the	O
region	O
from	O
-	O
776	O
to	O
-	O
564	O
possessed	O
a	O
repressor	O
element(s)	O
.	O
A	O
similar	O
transfection	O
pattern	O
was	O
observed	O
with	O
SK-N-SH	O
and	O
HeLa	O
cells	O
,	O
suggesting	O
that	O
there	O
is	O
not	O
a	O
tissue	O
-	O
specific	O
element	O
in	O
the	O
region	O
from	O
-	O
2325	O
to	O
-	O
252	O
.	O
PMID	O
:	O
11936871	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nucleic	O
Acids	O
Res	O
.	O
2000	O
Aug	O
15	O
;28	O
(	O
16	O
)	O
:	O
3047	O
-	O
55	O
.	O
The	O
glial	O
transcription	O
factor	O
Sox10	O
binds	O
to	O
DNA	O
both	O
as	O
monomer	O
and	O
dimer	O
with	O
different	O
functional	O
consequences	O
.	O
Peirano	O
RI	O
,	O
Wegner	O
M.	O
Institut	O
fur	O
Biochemie	O
,	O
Fahrstrasse	O
17	O
,	O
D	O
-	O
91054	O
Erlangen	O
,	O
Germany	O
and	O
Zentrum	O
fur	O
Molekulare	O
Neurobiologie	O
,	O
Martinistrasse	O
52	O
,	O
20246	O
Hamburg	O
,	O
Germany	O
.	O
Sox10	O
is	O
an	O
important	O
transcriptional	O
regulator	O
in	O
the	O
neural	O
crest	O
and	O
various	O
neural-crest	O
derived	O
lineages	O
,	O
such	O
as	O
the	O
Schwann	O
cells	O
of	O
the	O
peripheral	O
nervous	O
system	O
.	O
Recently	O
,	O
we	O
identified	O
the	O
gene	O
for	O
myelin	O
Protein	O
zero	O
(	O
P(0)	O
)	O
as	O
a	O
transcriptional	O
target	O
of	O
Sox10	O
in	O
Schwann	O
cells	O
,	O
allowing	O
for	O
the	O
first	O
time	O
a	O
detailed	O
analysis	O
of	O
Sox10	O
responsive	O
elements	O
and	O
their	O
functional	O
interaction	O
with	O
Sox10	O
.	O
Here	O
we	O
show	O
that	O
Sox10	O
functions	O
through	O
two	O
different	O
types	O
of	O
DNA	O
response	O
elements	O
,	O
one	O
that	O
allows	O
binding	O
of	O
monomers	O
,	O
and	O
a	O
second	O
that	O
favors	O
cooperative	O
binding	O
of	O
two	O
molecules	O
.	O
This	O
dimeric	O
binding	O
required	O
the	O
presence	O
of	O
two	O
heptameric	O
Sox	O
binding	O
sites	O
in	O
a	O
specific	O
orientation	O
and	O
spacing	O
,	O
and	O
was	O
mediated	O
by	O
an	O
N-terminal	O
region	O
of	O
Sox10	O
with	O
high	O
conservation	O
in	O
the	O
related	O
Sox9	O
,	O
which	O
also	O
exhibited	O
dimeric	O
binding	O
.	O
This	O
argues	O
that	O
the	O
conserved	O
region	O
has	O
the	O
capacity	O
to	O
function	O
as	O
a	O
DNA	O
-	O
dependent	O
dimerization	O
domain	O
.	O
The	O
interaction	O
between	O
Sox10	O
dimers	O
and	O
DNA	O
differed	O
dramatically	O
from	O
that	O
of	O
Sox10	O
monomers	O
,	O
as	O
it	O
drastically	O
reduced	O
the	O
protein	O
's	O
off-rate	O
and	O
increased	O
the	O
protein	O
-	O
induced	O
angle	O
of	O
DNA	O
bending	O
.	O
These	O
results	O
indicate	O
that	O
functionally	O
relevant	O
interactions	O
between	O
Sox10	O
and	O
DNA	O
occur	O
through	O
completely	O
different	O
modes	O
of	O
binding	O
.	O
PMID	O
:	O
10931919	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Alcohol	O
Alcohol	O
Suppl	O
.	O
1994	O
;2	O
:	O
103	O
-	O
8.	O
Muscarinic	O
receptor	O
-	O
stimulated	O
expression	O
of	O
c-	O
fos	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Alling	O
C	O
,	O
Larsson	O
C	O
,	O
Ding	O
W	O
.	O
Department	O
of	O
Psychiatry	O
and	O
Neurochemistry	O
,	O
Lund	O
University	O
,	O
Sweden	O
.	O
The	O
intracellular	O
signal	O
cascade	O
transducing	O
muscarinic	O
-	O
receptor	O
-	O
stimulation	O
to	O
gene	O
expression	O
was	O
investigated	O
in	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
cells	O
.	O
Naive	O
and	O
ethanol	O
-	O
exposed	O
SH-SU5Y	O
cells	O
were	O
stimulated	O
with	O
carbachol	O
(	O
CCh	O
)	O
and	O
inositol	O
1,4-	O
5-trisphosphate	O
(	O
IP3	O
)	O
,	O
1,2-diacylglycerol	O
(	O
DAG	O
)	O
,	O
and	O
c-	O
fos	O
mRNA	O
levels	O
were	O
analyzed	O
using	O
a	O
radioreceptor	O
assay	O
(	O
IP3	O
)	O
thin	O
-	O
layer	O
chromatography	O
(	O
DAG	O
)	O
and	O
Northern	O
blot	O
(	O
c	O
-	O
fos	O
mRNA	O
)	O
.	O
Application	O
of	O
the	O
muscarinic	O
agonist	O
CCh	O
induced	O
a	O
rapid	O
increase	O
in	O
(	O
IP3	O
)	O
,	O
peaking	O
within	O
seconds	O
after	O
the	O
CCh	O
-	O
addition	O
.	O
There	O
was	O
also	O
an	O
accumulation	O
of	O
DAG	O
reaching	O
maximum	O
after	O
5	O
min	O
of	O
receptor	O
-	O
stimulation	O
.	O
Stimulation	O
with	O
CCh	O
also	O
induced	O
expression	O
of	O
the	O
immediate	O
-	O
early	O
gene	O
c-	O
fos	O
in	O
these	O
cells	O
.	O
These	O
events	O
were	O
mediated	O
via	O
muscarinic	O
M1	O
receptors	O
and	O
the	O
inhibitory	O
effects	O
of	O
H7	O
,	O
staurosporin	O
,	O
and	O
RO31	O
-	O
7549	O
on	O
the	O
c-	O
fos	O
expression	O
indicated	O
that	O
it	O
was	O
mediated	O
via	O
protein	O
kinase	O
C	O
.	O
Acute	O
exposure	O
to	O
100	O
mM	O
ethanol	O
inhibited	O
the	O
formation	O
of	O
IP3	O
and	O
the	O
expression	O
of	O
c-	O
fos	O
.	O
These	O
effects	O
were	O
due	O
to	O
an	O
increase	O
in	O
the	O
EC50	O
of	O
CCh	O
for	O
the	O
events	O
.	O
Exposure	O
to	O
100	O
mM	O
ethanol	O
for	O
4	O
days	O
caused	O
a	O
potentiation	O
of	O
these	O
two	O
events	O
.	O
The	O
EC50	O
was	O
unaffected	O
but	O
the	O
maximal	O
response	O
was	O
increased	O
.	O
These	O
data	O
indicate	O
that	O
this	O
signal	O
transduction	O
system	O
is	O
inhibited	O
by	O
acute	O
exposure	O
to	O
100	O
mM	O
ethanol	O
,	O
an	O
effect	O
that	O
is	O
compensated	O
for	O
after	O
exposure	O
to	O
ethanol	O
for	O
4	O
days	O
.	O
PMID	O
:	O
8974323	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1999	O
Feb	O
26;274	O
(	O
9	O
)	O
:	O
5279	O
-84	O
.	O
Cadmium	O
-	O
mediated	O
activation	O
of	O
the	O
metal	O
response	O
element	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
lacking	O
functional	O
metal	O
response	O
element	O
-	O
binding	O
transcription	O
factor	O
-	O
1	O
.	O
Chu	O
WA	O
,	O
Moehlenkamp	O
JD	O
,	O
Bittel	O
D	O
,	O
Andrews	O
GK	O
,	O
Johnson	O
JA	O
.	O
Departments	O
of	O
Pharmacology	O
,	O
Toxicology	O
,	O
and	O
Therapeutics	O
,	O
University	O
of	O
Kansas	O
Medical	O
Center	O
,	O
Kansas	O
City	O
,	O
Kansas	O
66160	O
-	O
7417	O
,	O
USA	O
.	O
Metal	O
response	O
element	O
-	O
binding	O
transcription	O
factor-1	O
(	O
MTF-1	O
)	O
binds	O
specifically	O
to	O
metal	O
response	O
elements	O
(	O
MREs	O
)	O
and	O
transactivates	O
metallothionein	O
(	O
MT	O
)	O
gene	O
expression	O
in	O
response	O
to	O
zinc	O
and	O
cadmium	O
.	O
This	O
investigation	O
contrasts	O
the	O
mechanism	O
of	O
mouse	O
MT	O
gene	O
(	O
mMT-I	O
)	O
promoter	O
activation	O
by	O
cadmium	O
and	O
zinc	O
in	O
IMR-32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
to	O
determine	O
whether	O
MTF-1	O
binding	O
to	O
the	O
MRE	O
is	O
necessary	O
for	O
activation	O
by	O
these	O
metals	O
.	O
Cadmium	O
activated	O
a	O
mMT-1	O
promoter	O
(	O
-150	O
base	O
pairs	O
)	O
luciferase	O
reporter	O
20-25	O
-	O
fold	O
through	O
a	O
MRE-	O
dependent	O
mechanism	O
.	O
In	O
contrast	O
,	O
zinc	O
had	O
little	O
effect	O
on	O
the	O
mMT-1	O
luciferase	O
reporter	O
.	O
IMR-32	O
cells	O
lacked	O
MRE	O
binding	O
activity	O
,	O
and	O
treatment	O
with	O
zinc	O
in	O
vitro	O
or	O
in	O
vivo	O
did	O
not	O
generate	O
a	O
MTF-1	O
.	O
MRE	O
complex	O
,	O
suggesting	O
that	O
IMR-32	O
cells	O
lack	O
functional	O
MTF-1	O
.	O
Overexpression	O
of	O
mMTF-1	O
regenerated	O
a	O
zin	O
c-	O
mediated	O
induction	O
of	O
the	O
MRE	O
without	O
affecting	O
cadmium	O
activation	O
.	O
Because	O
no	O
other	O
transition	O
metals	O
tested	O
activated	O
the	O
MRE	O
,	O
this	O
effect	O
appeared	O
to	O
be	O
cadmium	O
-	O
specific	O
.	O
These	O
data	O
demonstrate	O
that	O
in	O
IMR-32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
,	O
zinc	O
and	O
cadmium	O
can	O
use	O
independent	O
mechanisms	O
for	O
activation	O
of	O
the	O
mMT-	O
I	O
promoter	O
and	O
cadmium	O
-	O
mediated	O
MRE	O
activation	O
is	O
independent	O
of	O
MTF-1	O
and	O
zinc	O
.	O
PMID	O
:	O
10026134	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
2003	O
Apr	O
15	O
;100(	O
8	O
)	O
:4690	O
-5	O
.	O
Epub	O
2003	O
Mar	O
28	O
.	O
alpha-Synuclein	O
maps	O
to	O
a	O
quantitative	O
trait	O
locus	O
for	O
alcohol	O
preference	O
and	O
is	O
differentially	O
expressed	O
in	O
alcohol	O
-	O
preferring	O
and	O
-	O
nonpreferring	O
rats	O
.	O
Liang	O
T	O
,	O
Spence	O
J,	O
Liu	O
L,	O
Strother	O
WN	O
,	O
Chang	O
HW	O
,	O
Ellison	O
JA	O
,	O
Lumeng	O
L,	O
Li	O
TK	O
,	O
Foroud	O
T	O
,	O
Carr	O
LG.	O
Department	O
of	O
Medicine	O
,	O
Indiana	O
University	O
School	O
of	O
Medicine	O
,	O
Indianapolis	O
,	O
IN	O
46202	O
,	O
USA	O
.	O
Total	O
gene	O
expression	O
analysis	O
(	O
TOGA	O
)	O
was	O
used	O
to	O
identify	O
genes	O
that	O
are	O
differentially	O
expressed	O
in	O
brain	O
regions	O
between	O
the	O
alcohol-naive	O
,	O
inbred	O
alcohol	O
-	O
preferring	O
(	O
iP	O
)	O
,	O
and	O
-	O
nonpreferring	O
(	O
iNP	O
)	O
rats	O
.	O
alpha-Synuclein	O
,	O
expressed	O
at	O
>	O
2	O
-	O
fold	O
higher	O
levels	O
in	O
the	O
hippocampus	O
of	O
the	O
iP	O
than	O
the	O
iNP	O
rat	O
,	O
was	O
prioritized	O
for	O
further	O
study	O
.	O
In	O
situ	O
hybridization	O
was	O
used	O
to	O
determine	O
specific	O
brain	O
regions	O
and	O
cells	O
expressing	O
alpha	O
-	O
synuclein	O
in	O
the	O
iP	O
and	O
iNP	O
rats	O
.	O
Similar	O
to	O
alpha	O
-	O
synuclein	O
mRNA	O
levels	O
,	O
protein	O
levels	O
in	O
the	O
hippocampus	O
were	O
higher	O
in	O
iP	O
rats	O
than	O
iNP	O
rats	O
.	O
Higher	O
protein	O
levels	O
were	O
also	O
observed	O
in	O
the	O
caudate	O
putamen	O
of	O
iP	O
rats	O
compared	O
with	O
iNP	O
rats	O
.	O
Sequence	O
analysis	O
identified	O
two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
cDNA	O
.	O
The	O
polymorphism	O
was	O
used	O
to	O
map	O
the	O
gene	O
,	O
by	O
using	O
recombination	O
-	O
based	O
methods	O
,	O
to	O
chromosome	O
4	O
,	O
within	O
a	O
quantitative	O
trait	O
locus	O
for	O
alcohol	O
consumption	O
that	O
was	O
identified	O
in	O
the	O
iP	O
and	O
iNP	O
rats	O
.	O
A	O
nucleotide	O
exchange	O
in	O
the	O
iNP	O
3	O
'	O
UTR	O
reduced	O
expression	O
of	O
the	O
luciferase	O
reporter	O
gene	O
in	O
SK-N-SH	O
neuroblastoma	B-malignancy-type
cells	O
.	O
These	O
results	O
suggest	O
that	O
differential	O
expression	O
of	O
the	O
alpha	O
-	O
synuclein	O
gene	O
may	O
contribute	O
to	O
alcohol	O
preference	O
in	O
the	O
iP	O
rats	O
.	O
PMID	O
:	O
12665621	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2003	O
Feb;8	O
4	O
(	O
3	O
)	O
:	O
480	O
-	O
90	O
.	O
Tethering	O
the	O
N-terminus	O
of	O
the	O
prion	O
protein	O
compromises	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
.	O
Zeng	O
F	O
,	O
Watt	O
NT	O
,	O
Walmsley	O
AR	O
,	O
Hooper	O
NM	O
.	O
School	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
University	O
of	O
Leeds	O
,	O
Leeds	O
,	O
UK.	O
The	O
role	O
of	O
the	O
N-terminal	O
half	O
of	O
the	O
prion	O
protein	O
(	O
PrPC	O
)	O
in	O
normal	O
cellular	O
function	O
and	O
pathology	O
remains	O
enigmatic	O
.	O
To	O
investigate	O
the	O
biological	O
role	O
of	O
the	O
N-terminus	O
of	O
PrP	O
,	O
we	O
examined	O
the	O
cellular	O
properties	O
of	O
a	O
construct	O
of	O
murine	O
PrP	O
,	O
PrP-DA	O
,	O
in	O
which	O
the	O
N-terminus	O
is	O
tethered	O
to	O
the	O
membrane	O
by	O
an	O
uncleaved	O
signal	O
peptide	O
and	O
which	O
retains	O
the	O
glycosyl-phosphatidylinositol	O
anchor	O
.	O
Human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
cells	O
expressing	O
PrP-DA	O
were	O
more	O
susceptible	O
to	O
hydrogen	O
peroxide	O
and	O
copper	O
induced	O
toxicity	O
than	O
wtPrP	O
expressing	O
cells	O
.	O
The	O
PrP-DA	O
expressing	O
cells	O
had	O
an	O
increased	O
level	O
of	O
intracellular	O
free	O
radicals	O
and	O
reduced	O
levels	O
of	O
superoxide	O
dismutase	O
and	O
glutathione	O
peroxidase	O
as	O
compared	O
to	O
the	O
wtPrP	O
expressing	O
cells	O
.	O
The	O
membrane	O
topology	O
,	O
cell	O
surface	O
location	O
,	O
lipid	O
raft	O
localisation	O
,	O
intracellular	O
trafficking	O
and	O
copper	O
-	O
mediated	O
endocytosis	O
of	O
PrP-DA	O
were	O
not	O
significantly	O
different	O
from	O
wtPrP	O
.	O
However	O
,	O
cells	O
expressing	O
PrP-DA	O
accumulated	O
an	O
N-terminal	O
fragment	O
that	O
was	O
resistant	O
to	O
proteinase	O
K	O
.	O
The	O
data	O
presented	O
here	O
are	O
consistent	O
with	O
the	O
N-terminal	O
region	O
of	O
PrPC	O
having	O
a	O
role	O
in	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
,	O
and	O
that	O
tethering	O
this	O
region	O
of	O
the	O
protein	O
to	O
the	O
membrane	O
compromises	O
this	O
function	O
through	O
the	O
accumulation	O
of	O
a	O
protease	O
-	O
resistant	O
N-terminal	O
fragment	O
,	O
similar	O
to	O
that	O
seen	O
in	O
some	O
forms	O
of	O
human	O
prion	O
disease	O
.	O
PMID	O
:	O
12558968	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Peptides	O
.	O
1997;18	O
(	O
6	O
)	O
:835-41	O
.	O
Retinoic	O
acid	O
regulation	O
of	O
the	O
VIP	O
and	O
PACAP	O
autocrine	O
ligand	O
and	O
receptor	O
system	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Waschek	O
JA	O
,	O
Lelievre	O
V	O
,	O
Bravo	O
DT	O
,	O
Nguyen	O
T	O
,	O
Muller	O
JM	O
.	O
Department	O
of	O
Psychiatry	O
,	O
University	O
of	O
California	O
at	O
Los	O
Angeles	O
90024	O
,	O
USA	O
.	O
jwaschek@npimain	O
.medsch	O
.ucla	O
.edu	O
Neuroendocrine	B-malignancy-type
tumors	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
in	O
particular	O
,	O
commonly	O
express	O
the	O
neuropeptides	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
and	O
pituitary	O
adenylate	O
cyclase	O
activating	O
peptide	O
(	O
PACAP	O
)	O
and	O
their	O
receptors	O
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
shown	O
to	O
induce	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
possibly	O
by	O
augmenting	O
or	O
interfering	O
with	O
neuropeptide	O
autocrine	O
loops	O
.	O
We	O
sought	O
to	O
determine	O
which	O
receptor	O
gene	O
subtypes	O
are	O
expressed	O
in	O
selected	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
(	O
SH-SY5Y	O
,	O
IMR-32	O
,	O
and	O
LA-N-5	O
)	O
,	O
and	O
the	O
effect	O
of	O
RA	O
on	O
the	O
VIP	O
/	O
PACAP	O
ligand	O
/	O
receptor	O
system	O
.	O
Expression	O
of	O
both	O
PACAP1	O
and	O
VIP1	O
/	O
PACAP2	O
receptor	O
genes	O
was	O
detected	O
by	O
Northern	O
analysis	O
,	O
which	O
characteristically	O
encode	O
Type	O
I	O
(	O
PACAP	O
-preferring	O
)	O
,	O
and	O
Type	O
II	O
(	O
bivalent	O
VIP	O
/	O
PACAP	O
)	O
receptors	O
,	O
respectively	O
.	O
Binding	O
experiments	O
carried	O
out	O
on	O
IMR-32	O
cells	O
,	O
using	O
125I	O
VIP	O
and	O
125I	O
PACAP-27	O
as	O
tracers	O
,	O
corroborated	O
that	O
both	O
receptor	O
subtypes	O
were	O
expressed	O
.	O
In	O
contrast	O
to	O
RA	O
upregulation	O
of	O
VIP	O
binding	O
(	O
confirmed	O
here	O
in	O
IMR-32	O
cells	O
)	O
,	O
levels	O
of	O
both	O
receptor	O
mRNAs	O
were	O
reduced	O
after	O
RA	O
treatment	O
.	O
VIP	O
mRNA	O
in	O
each	O
cell	O
line	O
was	O
increased	O
by	O
RA	O
,	O
whereas	O
PACAP	O
mRNA	O
,	O
detected	O
in	O
IMR-32	O
cells	O
only	O
,	O
was	O
reduced	O
.	O
The	O
studies	O
indicate	O
that	O
several	O
components	O
of	O
the	O
VIP	O
/	O
PACAP	O
autocrine	O
system	O
are	O
regulated	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
during	O
RA	O
differentiation	O
.	O
PMID	O
:	O
9285932	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
.	O
2001	O
Oct	O
15	O
;130(	O
2	O
)	O
:	O
133	O
-40	O
.	O
Molecular	O
cytogenetic	O
characterization	O
of	O
two	O
non	O
-	O
MYCN	O
amplified	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
complex	O
t	O
(	O
11	O
;	O
17	O
)	O
.	O
McConville	O
CM	O
,	O
Dyer	O
S	O
,	O
Rees	O
SA	O
,	O
Luttikhuis	O
ME	O
,	O
McMullan	O
DJ	O
,	O
Vickers	O
SJ	O
,	O
Ramani	O
P,	O
Redfern	O
D	O
,	O
Morland	O
BJ.	O
Division	O
of	O
Medical	O
and	O
Molecular	O
Genetics	O
,	O
University	O
of	O
Birmingham	O
,	O
Birmingham	O
B15	O
2TT	O
,	O
UK.	O
c.mcconville@bham	O
.ac.uk	O
The	O
pediatric	O
tumor	O
neuroblastoma	B-malignancy-type
is	O
characterized	O
by	O
a	O
very	O
variable	O
,	O
and	O
at	O
times	O
unpredictable	O
,	O
pattern	O
of	O
clinical	O
behavior	O
,	O
ranging	O
from	O
a	O
benign	O
localized	O
tumor	O
to	O
an	O
aggressive	O
malignancy	O
with	O
poor	O
prognosis	O
.	O
Standard	O
clinical	O
and	O
pathological	O
assessments	O
do	O
not	O
always	O
differentiate	O
reliably	O
between	O
tumor	O
subtypes	O
and	O
,	O
therefore	O
,	O
genetic	O
markers	O
are	O
now	O
playing	O
an	O
increasingly	O
important	O
role	O
in	O
treatment	O
decisions	O
.	O
MYCN	O
oncogene	O
amplification	O
,	O
for	O
example	O
,	O
provides	O
a	O
useful	O
marker	O
of	O
poor	O
prognosis	O
.	O
However	O
,	O
less	O
than	O
one	O
-half	O
of	O
all	O
patients	O
who	O
present	O
with	O
,	O
or	O
who	O
later	O
develop	O
,	O
metastatic	O
disease	O
show	O
MYCN	O
amplification	O
.	O
Consequently	O
,	O
the	O
identification	O
of	O
characteristic	O
patterns	O
of	O
genetic	O
alteration	O
in	O
the	O
remaining	O
tumors	O
is	O
of	O
importance	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
two	O
new	O
cell	O
lines	O
that	O
we	O
have	O
established	O
from	O
metastatic	O
,	O
non	O
-	O
MYCN	O
amplified	O
,	O
advanced	O
stage	O
neuroblastomas	B-malignancy-type
.	O
These	O
cell	O
lines	O
show	O
a	O
number	O
of	O
features	O
in	O
common	O
,	O
including	O
unbalanced	O
translocation	O
between	O
11	O
q	O
and	O
17	O
q	O
,	O
loss	O
of	O
3	O
p	O
,	O
4	O
p	O
and	O
11	O
q	O
and	O
gain	O
of	O
17	O
q	O
.	O
Therefore	O
,	O
they	O
provide	O
a	O
valuable	O
resource	O
for	O
the	O
characterization	O
of	O
genetic	O
pathways	O
leading	O
to	O
aggressive	O
tumor	O
growth	O
in	O
non	O
-	O
MYCN	O
amplified	O
neuroblastomas	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
11675134	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Infect	O
Immun	O
.	O
1989	O
Jan;57	O
(	O
1	O
)	O
:272	O
-7.	O
Erratum	O
in	O
:	O
Infect	O
Immun	O
1989	O
Jul;57	O
(	O
7	O
)	O
:2265	O
.	O
Binding	O
of	O
Clostridium	O
botulinum	O
type	O
C	O
neurotoxin	O
to	O
different	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Yokosawa	O
N	O
,	O
Kurokawa	O
Y	O
,	O
Tsuzuki	O
K,	O
Syuto	O
B	O
,	O
Fujii	O
N	O
,	O
Kimura	O
K,	O
Oguma	O
K.	O
Department	O
of	O
Microbiology	O
,	O
Sapporo	O
Medical	O
College	O
,	O
Japan	O
.	O
Binding	O
of	O
type	O
C	O
neurotoxin	O
(	O
C1	O
toxin	O
)	O
from	O
Clostridium	O
botulinum	O
(	O
strain	O
Stockholm	O
)	O
to	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
was	O
studied	O
by	O
using	O
biotinylated	O
anti	O
-	O
toxin	O
antibody	O
and	O
avidin	O
-	O
biotinylated	O
peroxidase	O
complex	O
.	O
The	O
neurotoxin	O
bound	O
with	O
high	O
efficiency	O
to	O
mouse	O
neuroblastoma	B-malignancy-type
(	O
NS-20Y	O
and	O
NIE-115	O
)	O
cells	O
and	O
to	O
hybridomas	B-malignancy-type
of	O
rat	O
glioblastoma	B-malignancy-type
and	O
mouse	O
neuroblastoma	B-malignancy-type
(	O
NG108	O
-C15	O
)	O
cells	O
.	O
The	O
toxin	O
bound	O
little	O
to	O
human	O
neuroblastoma	B-malignancy-type
,	O
rat	O
astrocytoma	B-malignancy-type
,	O
and	O
nonneural	O
cell	O
lines	O
.	O
Binding	O
of	O
the	O
neurotoxin	O
to	O
NG108	O
-C15	O
cells	O
was	O
inhibited	O
by	O
gangliosides	O
(	O
GT1b	O
and	O
GM1	O
)	O
and	O
by	O
monoclonal	O
antibodies	O
(	O
CA	O
-	O
12	O
and	O
C-	O
9	O
)	O
,	O
although	O
inhibition	O
was	O
not	O
complete	O
.	O
Sequential	O
preincubation	O
of	O
C1	O
toxin	O
with	O
GT1b	O
and	O
CA-	O
12	O
caused	O
complete	O
inhibition	O
.	O
A	O
Scatchard	O
plot	O
of	O
binding	O
of	O
125I	O
-	O
labeled	O
C1	O
toxin	O
to	O
NG108	O
-C15	O
cells	O
showed	O
a	O
hyperbolic	O
curve	O
.	O
Monoclonal	O
antibody	O
CA-	O
12	O
but	O
not	O
C-9	O
neutralized	O
the	O
lethal	O
activity	O
of	O
the	O
toxin	O
toward	O
mice	O
.	O
Only	O
C-9	O
clearly	O
inhibited	O
toxin	O
binding	O
to	O
GT1b	O
.	O
These	O
results	O
suggest	O
that	O
NG108	O
-C15	O
cells	O
have	O
at	O
least	O
two	O
kinds	O
of	O
receptors	O
for	O
C1	O
toxin	O
.	O
From	O
the	O
results	O
of	O
binding	O
tests	O
with	O
neuraminidase	O
-	O
,	O
pronase	O
-	O
,	O
and	O
trypsin	O
-	O
treated	O
NG108	O
-C15	O
cells	O
,	O
the	O
chemical	O
nature	O
of	O
the	O
high	O
-	O
affinity	O
site	O
was	O
presumed	O
to	O
be	O
a	O
glycoprotein	O
containing	O
sialic	O
acid	O
.	O
GT1b	O
may	O
have	O
an	O
important	O
role	O
in	O
low-	O
affinity	O
sites	O
.	O
PMID	O
:	O
2535834	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Metastasis	O
Rev	O
.	O
1997	O
Jun;16	O
(	O
1-2	O
)	O
:	O
207	O
-27	O
.	O
The	O
clinical	O
role	O
of	O
molecular	O
genetics	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
tumor	I-malignancy-type
pathology	O
.	O
Busam	O
KJ	O
,	O
Fletcher	O
CD.	O
Department	O
of	O
Pathology	O
,	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
.	O
Cytogenetic	O
and	O
molecular	O
analysis	O
of	O
soft	B-malignancy-type
tissue	I-malignancy-type
tumors	I-malignancy-type
has	O
yielded	O
a	O
wealth	O
of	O
information	O
over	O
the	O
past	O
decade	O
.	O
Some	O
of	O
the	O
genetic	O
aberrations	O
that	O
have	O
been	O
identified	O
appear	O
to	O
be	O
fairly	O
specific	O
for	O
individual	O
tumor	O
types	O
.	O
It	O
is	O
because	O
of	O
this	O
specificity	O
that	O
these	O
findings	O
harbor	O
the	O
promise	O
to	O
become	O
useful	O
as	O
diagnostic	O
and/or	O
prognostic	O
markers	O
.	O
Technical	O
advances	O
that	O
allow	O
the	O
application	O
of	O
cytogenetic	O
and	O
molecular	O
techniques	O
to	O
archival	O
material	O
have	O
been	O
crucial	O
in	O
this	O
respect	O
.	O
Molecular	O
genetics	O
has	O
already	O
become	O
an	O
integral	O
part	O
of	O
the	O
work-up	O
of	O
some	O
tumors	O
,	O
e	O
.g.	O
,	O
small	B-malignancy-type
cell	I-malignancy-type
sarcomas	I-malignancy-type
of	O
childhood	O
,	O
which	O
demonstrate	O
fairly	O
characteristic	O
translocations	O
,	O
often	O
involving	O
the	O
Ewing	O
's	O
sarcoma	O
gene	O
.	O
Some	O
genetic	O
abnormalities	O
have	O
become	O
established	O
as	O
prognostic	O
markers	O
,	O
such	O
as	O
the	O
deletion	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
for	O
neuroblastomas	B-malignancy-type
.	O
Soft	B-malignancy-type
tissue	I-malignancy-type
tumor	I-malignancy-type
pathology	O
has	O
also	O
benefitted	O
from	O
major	O
advances	O
in	O
identifying	O
genes	O
that	O
are	O
critical	O
in	O
mesenchymal	O
differentiation	O
or	O
cell	O
cycle	O
control	O
.	O
MyoD	O
is	O
a	O
good	O
example	O
of	O
a	O
such	O
a	O
gene	O
,	O
that	O
has	O
become	O
useful	O
as	O
a	O
diagnostic	O
tool	O
in	O
rhabdomyosarcomas	B-malignancy-type
.	O
Beyond	O
potential	O
practical	O
applications	O
of	O
cytogenetic	O
and	O
molecular	O
analyses	O
in	O
the	O
diagnosis	O
of	O
these	O
tumors	O
,	O
we	O
also	O
review	O
their	O
impact	O
on	O
several	O
philosophical	O
concepts	O
concerning	O
soft	B-malignancy-type
tissue	I-malignancy-type
neoplasia	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Academic	O
PMID	O
:	O
9156287	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
2002	O
May	O
14;99	O
(	O
10	O
)	O
:	O
7021	O
-6.	O
Hypoxia	O
alters	O
gene	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
toward	O
an	O
immature	O
and	O
neural	O
crest	O
-	O
like	O
phenotype	O
.	O
Jogi	O
A	O
,	O
Ora	O
I	O
,	O
Nilsson	O
H,	O
Lindeheim	O
A	O
,	O
Makino	O
Y	O
,	O
Poellinger	O
L,	O
Axelson	O
H,	O
Pahlman	O
S.	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Division	O
of	O
Molecular	O
Medicine	O
,	O
Lund	O
University	O
,	O
University	O
Hospital	O
MAS	O
,	O
S-205	O
02	O
Malmo	O
,	O
Sweden	O
.	O
Insufficient	O
oxygen	O
and	O
nutrient	O
supply	O
often	O
restrain	O
solid	B-malignancy-type
tumor	I-malignancy-type
growth	O
,	O
and	O
the	O
hypoxia	O
-	O
inducible	O
factors	O
(	O
HIF	O
)	O
1	O
alpha	O
and	O
HIF-2	O
alpha	O
are	O
key	O
transcription	O
regulators	O
of	O
phenotypic	O
adaptation	O
to	O
low	O
oxygen	O
levels	O
.	O
Moreover	O
,	O
mouse	O
gene	O
disruption	O
studies	O
have	O
implicated	O
HIF-2	O
alpha	O
in	O
embryonic	O
regulation	O
of	O
tyrosine	O
hydroxylase	O
,	O
a	O
hallmark	O
gene	O
of	O
the	O
sympathetic	O
nervous	O
system	O
.	O
Neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
originate	O
from	O
immature	O
sympathetic	O
cells	O
,	O
and	O
therefore	O
we	O
investigated	O
the	O
effect	O
of	O
hypoxia	O
on	O
the	O
differentiation	O
status	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Hypoxia	O
stabilized	O
HIF-1	O
alpha	O
and	O
HIF-2	O
alpha	O
proteins	O
and	O
activated	O
the	O
expression	O
of	O
known	O
hypoxia	O
-	O
induced	O
genes	O
,	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
tyrosine	O
hydroxylase	O
.	O
These	O
changes	O
in	O
gene	O
expression	O
also	O
occurred	O
in	O
hypoxic	O
regions	O
of	O
experimental	O
neuroblastoma	B-malignancy-type
xenografts	O
grown	O
in	O
mice	O
.	O
In	O
contrast	O
,	O
hypoxia	O
decreased	O
the	O
expression	O
of	O
several	O
neuronal	O
/	O
neuroendocrine	O
marker	O
genes	O
but	O
induced	O
genes	O
expressed	O
in	O
neural	O
crest	O
sympathetic	O
progenitors	O
,	O
for	O
instance	O
c-kit	O
and	O
Notch-1	O
.	O
Thus	O
,	O
hypoxia	O
apparently	O
causes	O
dedifferentiation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
These	O
findings	O
suggest	O
a	O
novel	O
mechanism	O
for	O
selection	O
of	O
highly	O
malignant	O
tumor	O
cells	O
with	O
stem	O
-	O
cell	O
characteristics	O
.	O
PMID	O
:	O
12011461	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2004	O
Jan	O
8;23(	O
1	O
)	O
:	O
213-25	O
.	O
The	O
RET	O
and	O
TRKA	O
pathways	O
collaborate	O
to	O
regulate	O
neuroblastoma	B-malignancy-type
differentiation	O
.	O
Peterson	O
S	O
,	O
Bogenmann	O
E.	O
Childrens	O
Hospital	O
Los	O
Angeles	O
,	O
Division	O
of	O
Hematology	O
Oncology	O
,	O
4650	O
Sunset	O
Boulevard	O
,	O
Los	O
Angeles	O
,	O
CA	O
90027	O
,	O
USA	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
is	O
a	O
childhood	O
cancer	O
that	O
arises	O
in	O
the	O
adrenal	O
gland	O
and	O
often	O
shows	O
differentiated	O
neuronal	O
and	O
glial	O
elements	O
.	O
The	O
RET	O
receptor	O
signal	O
pathway	O
is	O
functional	O
in	O
most	O
NB	B-malignancy-type
,	O
while	O
loss	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
receptor	O
(	O
trkA	O
)	O
gene	O
expression	O
correlates	O
with	O
an	O
aggressive	O
phenotype	O
.	O
Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
RET	O
and	O
TRKA	O
signal	O
pathways	O
collaborate	O
to	O
instruct	O
NB	B-malignancy-type
differentiation	O
,	O
reminiscent	O
of	O
normal	O
neuronal	O
maturation	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
activation	O
of	O
the	O
RET	O
receptor	O
by	O
glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
increases	O
expression	O
of	O
the	O
RET	O
receptor	O
complex	O
in	O
a	O
panel	O
of	O
malignant	O
human	O
NB	B-malignancy-type
cell	O
lines	O
,	O
indicative	O
of	O
a	O
positive	O
feedback	O
mechanism	O
.	O
GDNF	O
also	O
induces	O
growth	O
cessation	O
concomitant	O
with	O
an	O
arrest	O
of	O
cells	O
in	O
the	O
G(0)	O
/	O
G(1)	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
Furthermore	O
,	O
GDNF	O
synergizes	O
with	O
ciliary	O
neurotrophic	O
factor	O
(	O
CNTF	O
)	O
to	O
enhance	O
TRKA	O
receptor	O
expression	O
,	O
thereby	O
strengthening	O
the	O
NGF	O
-	O
mediated	O
differentiation	O
signal	O
.	O
Differentiated	O
NB	B-malignancy-type
cells	O
downregulate	O
expression	O
of	O
the	O
amplified	O
N-myc	O
gene	O
,	O
concurrent	O
with	O
the	O
arrest	O
of	O
cell	O
proliferation	O
,	O
while	O
expressing	O
neuron	O
-	O
specific	O
markers	O
(	O
i.e.	O
,	O
SCG10	O
)	O
.	O
Interestingly	O
,	O
maintenance	O
of	O
differentiated	O
NB	B-malignancy-type
cells	O
in	O
culture	O
is	O
independent	O
of	O
the	O
trophic	O
activity	O
of	O
GDNF	O
,	O
but	O
depends	O
on	O
TRKA	O
signaling	O
,	O
thereby	O
re	O
-	O
enacting	O
the	O
differentiation	O
of	O
normal	O
sympathoadrenal	O
(	O
SA	O
)	O
progenitor	O
cells	O
.	O
PMID	O
:	O
14712226	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosurgery	O
.	O
1987	O
Mar;20(	O
3	O
)	O
:	O
428-33	O
.	O
Ganglioglioma	B-malignancy-type
:	O
a	O
correlative	O
clinicopathological	O
and	O
radiological	O
study	O
of	O
ten	O
surgically	O
treated	O
cases	O
with	O
follow-up	O
.	O
Kalyan-Raman	O
UP	O
,	O
Olivero	O
WC	O
.	O
Gangliogliomas	B-malignancy-type
are	O
rare	O
benign	O
tumors	O
of	O
the	O
central	O
nervous	O
system	O
containing	O
neoplastic	O
ganglion	O
and	O
low	O
grade	O
glial	O
cells	O
.	O
In	O
studying	O
10	O
surgically	O
treated	O
cases	O
,	O
we	O
evaluated	O
the	O
clinical	O
,	O
pathological	O
,	O
radiological	O
,	O
and	O
immunocytochemical	O
features	O
,	O
with	O
follow-up	O
.	O
Ranging	O
from	O
18	O
to	O
58	O
years	O
in	O
age	O
,	O
7	O
patients	O
were	O
women	O
,	O
and	O
3	O
were	O
men	O
.	O
The	O
most	O
common	O
presenting	O
symptom	O
was	O
seizure	O
.	O
Computed	O
tomographic	O
scan	O
showed	O
a	O
low	O
density	O
enhancing	O
mass	O
in	O
8	O
and	O
calcification	O
in	O
5	O
.	O
Six	O
had	O
minimally	O
abnormal	O
vascularity	O
on	O
angiography	O
.	O
Seven	O
patients	O
had	O
total	O
and	O
3	O
had	O
subtotal	O
resections	O
of	O
the	O
tumor	O
.	O
The	O
temporal	O
lobe	O
was	O
the	O
location	O
of	O
the	O
tumor	O
in	O
6	O
cases	O
.	O
All	O
of	O
the	O
cases	O
met	O
the	O
histological	O
criteria	O
of	O
Russell	O
and	O
Rubinstein	O
for	O
ganglioglioma	B-malignancy-type
.	O
Four	O
patients	O
received	O
postoperative	O
radiotherapy	O
because	O
of	O
subtotal	O
resection	O
or	O
aggressive	O
histological	O
makeup	O
.	O
On	O
follow-up	O
,	O
from	O
2.5	O
to	O
7	O
years	O
,	O
8	O
patients	O
are	O
alive	O
and	O
tumor	O
-	O
free	O
,	O
and	O
7	O
are	O
also	O
seizure	O
-	O
free	O
.	O
Two	O
died	O
after	O
operation	O
:	O
one	O
immediately	O
and	O
the	O
other	O
of	O
a	O
glioblastoma	B-malignancy-type
that	O
developed	O
5	O
years	O
later	O
.	O
Our	O
study	O
confirms	O
that	O
ganglioglioma	B-malignancy-type
is	O
a	O
distinct	O
histological	O
entity	O
,	O
anatomically	O
localized	O
,	O
with	O
characteristic	O
clinical	O
and	O
radiological	O
findings	O
and	O
long	O
term	O
survival	O
.	O
Aggressive	O
histological	O
makeup	O
is	O
not	O
a	O
definite	O
indication	O
of	O
malignant	O
potential	O
.	O
The	O
definitive	O
role	O
of	O
follow-up	O
radiotherapy	O
for	O
this	O
tumor	O
needs	O
further	O
study	O
.	O
Malignant	O
evolution	O
is	O
rare	O
,	O
but	O
warrants	O
follow-up	O
.	O
PMID	O
:	O
3574619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Supramol	O
Struct	O
.	O
1979	O
;10(	O
2	O
)	O
:	O
125-35	O
.	O
Activation	O
of	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
stimulation	O
of	O
protein	O
phosphorylation	O
in	O
response	O
to	O
adenosine	O
in	O
C-1300	O
murine	O
neuroblastoma	B-malignancy-type
.	O
Green	O
RD	O
,	O
Noland	O
TA	O
Jr	O
.	O
DEAE-cellulose	O
chromatography	O
of	O
the	O
20	O
,000g	O
supernatant	O
fraction	O
of	O
homogenates	O
of	O
C-1300	O
murine	O
neuroblastoma	B-malignancy-type
(	O
clone	O
N2a	O
)	O
yields	O
one	O
major	O
and	O
two	O
minor	O
peaks	O
of	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinase	O
activity	O
.	O
Assessment	O
of	O
the	O
endogenous	O
activation	O
state	O
of	O
the	O
enzyme(s)	O
reveals	O
that	O
the	O
enzyme	O
is	O
fully	O
activated	O
by	O
the	O
treatment	O
of	O
whole	O
cells	O
with	O
adenosine	O
(	O
10	O
microM	O
)	O
in	O
the	O
presence	O
of	O
the	O
phosphodiesterase	O
inhibitor	O
Ro	O
20	O
1724	O
(	O
0.7	O
mM	O
)	O
.	O
This	O
treatment	O
produces	O
a	O
large	O
elevation	O
in	O
the	O
cyclic	O
AMP	O
content	O
of	O
the	O
cells	O
.	O
The	O
treatment	O
of	O
whole	O
cells	O
with	O
adenosine	O
alone	O
(	O
1-	O
100	O
microM	O
)	O
or	O
Ro	O
20	O
1724	O
alone	O
(	O
0.1	O
-	O
0.7	O
mM	O
)	O
produces	O
minimal	O
elevations	O
in	O
cyclic	O
AMP	O
but	O
nevertheless	O
causes	O
significant	O
activations	O
of	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinase	O
.	O
The	O
autophosphorylation	O
of	O
whole	O
homogenates	O
of	O
treated	O
and	O
untreated	O
cells	O
was	O
studied	O
using	O
[gamma-32P	O
]	O
ATP	O
,	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O
Treatments	O
which	O
activate	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinase	O
selectively	O
stimulate	O
the	O
incorporation	O
of	O
32P	O
into	O
several	O
proteins	O
.	O
This	O
stimulation	O
is	O
most	O
prominent	O
in	O
the	O
15,000	O
-	O
dalton	O
protein	O
band	O
.	O
The	O
addition	O
of	O
cyclic	O
AMP	O
to	O
phosphorylation	O
reactions	O
containing	O
homogenate	O
of	O
untreated	O
cells	O
stimulates	O
the	O
phosphorylation	O
of	O
the	O
same	O
protein	O
bands	O
.	O
These	O
results	O
indicate	O
that	O
adenosine	O
may	O
have	O
regulatory	O
functions	O
through	O
its	O
effect	O
on	O
the	O
cyclic	O
AMP	O
:	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinase	O
system	O
.	O
PMID	O
:	O
222964	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Endocrinol	O
.	O
1994	O
Jan;	O
8	O
(	O
1	O
)	O
:	O
59	O
-	O
68	O
.	O
Activating	O
transcription	O
factor-3	O
stimulates	O
3',5'-cyclic	O
adenosine	O
monophosphate	O
-	O
dependent	O
gene	O
expression	O
.	O
Chu	O
HM	O
,	O
Tan	O
Y	O
,	O
Kobierski	O
LA	O
,	O
Balsam	O
LB	O
,	O
Comb	O
MJ.	O
Laboratory	O
of	O
Molecular	O
Neurobiology	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Charlestown	O
02129	O
.	O
Activating	O
transcription	O
factor-3	O
(	O
ATF-3	O
)	O
is	O
one	O
member	O
of	O
a	O
large	O
family	O
of	O
leucine	O
zipper	O
transcription	O
factors	O
which	O
bind	O
to	O
promoters	O
responsive	O
to	O
cAMP	O
and	O
phorbol	O
ester	O
at	O
the	O
related	O
cAMP	O
(	O
CRE	O
)	O
and	O
phorbol	O
ester	O
response	O
elements	O
.	O
We	O
report	O
here	O
that	O
ATF-3	O
is	O
coexpressed	O
with	O
the	O
neuropeptide	O
precursor	O
proenkephalin	O
in	O
human	O
neuroblastoma	B-malignancy-type
SK-N-MC	O
cells	O
.	O
Cotransfection	O
experiments	O
indicate	O
that	O
activation	O
of	O
proenkephalin	O
gene	O
expression	O
by	O
ATF-3	O
is	O
dependent	O
upon	O
both	O
the	O
catalytic	O
subunit	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
the	O
CRE-2	O
element	O
.	O
The	O
CRE-2	O
element	O
is	O
essential	O
for	O
second	O
messenger	O
-	O
inducible	O
expression	O
and	O
is	O
known	O
to	O
bind	O
AP-1	O
-	O
like	O
transcription	O
factors	O
.	O
ATF-3	O
expressed	O
in	O
bacteria	O
or	O
from	O
rabbit	O
reticulocyte	O
lysates	O
binds	O
to	O
the	O
proenkephalin	O
CRE-2	O
element	O
as	O
a	O
homodimer	O
and	O
as	O
a	O
heterodimer	O
with	O
Jun-	O
D	O
,	O
another	O
activator	O
of	O
proenkephalin	O
transcription	O
.	O
ATF-3	O
stimulates	O
binding	O
of	O
Jun-	O
D	O
to	O
the	O
proenkephalin	O
CRE-2	O
element	O
and	O
acts	O
synergistically	O
with	O
Jun-	O
D	O
to	O
induce	O
proenkephalin	O
gene	O
expression	O
.	O
Sequential	O
immunoprecipitations	O
of	O
ATF-3	O
from	O
SK-N-MC	O
cells	O
expressing	O
proenkephalin	O
indicate	O
that	O
ATF-3	O
is	O
complexed	O
with	O
Jun-	O
D	O
in	O
vivo	O
and	O
that	O
both	O
proteins	O
are	O
highly	O
phosphorylated	O
.	O
Together	O
,	O
our	O
results	O
suggest	O
that	O
ATF-3	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	O
-	O
dependent	O
intracellular	O
signaling	O
pathways	O
.	O
PMID	O
:	O
8152431	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1999	O
Jul	O
9;274(	O
28	O
)	O
:19919	O
-	O
24	O
.	O
Receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
-	O
mediated	O
neurite	O
outgrowth	O
and	O
activation	O
of	O
NF-kappaB	O
require	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
receptor	O
but	O
different	O
downstream	O
signaling	O
pathways	O
.	O
Huttunen	O
HJ	O
,	O
Fages	O
C	O
,	O
Rauvala	O
H.	O
Laboratory	O
of	O
Molecular	O
Neurobiology	O
,	O
Institute	O
of	O
Biotechnology	O
,	O
and	O
Department	O
of	O
Biosciences	O
,	O
Division	O
of	O
Biochemistry	O
,	O
University	O
of	O
Helsinki	O
,	O
Finland	O
.	O
Henri.Huttunen@helsinki.fi	O
Receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
mediates	O
neurite	O
outgrowth	O
in	O
vitro	O
on	O
amphoterin	O
-	O
coated	O
substrates	O
.	O
Ligation	O
of	O
RAGE	O
by	O
two	O
other	O
ligands	O
,	O
advanced	O
glycation	O
end	O
products	O
or	O
amyloid	O
beta-peptide	O
,	O
is	O
suggested	O
to	O
play	O
a	O
role	O
in	O
cell	O
injury	O
mechanisms	O
involving	O
cellular	O
oxidant	O
stress	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
.	O
However	O
,	O
the	O
RAGE	O
signaling	O
pathways	O
in	O
neurite	O
outgrowth	O
and	O
cell	O
injury	O
are	O
largely	O
unknown	O
.	O
Here	O
we	O
show	O
that	O
transfection	O
of	O
RAGE	O
to	O
neuroblastoma	B-malignancy-type
cells	O
induces	O
extension	O
of	O
filopodia	O
and	O
neurites	O
on	O
amphoterin	O
-	O
coated	O
substrates	O
.	O
Furthermore	O
,	O
ligation	O
of	O
RAGE	O
in	O
transfected	O
cells	O
enhances	O
NF-kappaB	O
-	O
dependent	O
transcription	O
.	O
Both	O
the	O
RAGE	O
-mediated	O
neurite	O
outgrowth	O
and	O
activation	O
of	O
NF-kappaB	O
are	O
blocked	O
by	O
deletion	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
RAGE	O
.	O
Moreover	O
,	O
dominant	O
negative	O
Rac	O
and	O
Cdc42	O
but	O
not	O
dominant	O
negative	O
Ras	O
inhibit	O
the	O
extension	O
of	O
neurites	O
induced	O
by	O
RAGE	O
-	O
amphoterin	O
interaction	O
.	O
In	O
contrast	O
,	O
the	O
activation	O
of	O
NF-kappaB	O
is	O
inhibited	O
by	O
dominant	O
negative	O
Ras	O
but	O
not	O
Rac	O
or	O
Cdc42	O
.	O
These	O
data	O
suggest	O
that	O
distinct	O
signaling	O
pathways	O
are	O
used	O
by	O
RAGE	O
to	O
induce	O
neurite	O
outgrowth	O
and	O
regulate	O
gene	O
expression	O
through	O
NF-kappaB	O
.	O
PMID	O
:	O
10391939	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
.	O
1999	O
Nov;155	O
(	O
5	O
)	O
:1661	O
-	O
70	O
.	O
Up	O
-	O
regulation	O
of	O
insulin	O
-	O
like	O
growth	O
factor-II	O
expression	O
is	O
a	O
feature	O
of	O
TrkA	O
but	O
not	O
TrkB	O
activation	O
in	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Kim	O
CJ	O
,	O
Matsuo	O
T	O
,	O
Lee	O
KH	O
,	O
Thiele	O
CJ.	O
Cell	O
and	O
Molecular	O
Biology	O
Section	O
,	O
Pediatric	O
Oncology	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
,	O
USA	O
.	O
cjkim@plaza	O
.snu.ac.kr	O
The	O
types	O
of	O
neurotrophin	O
receptors	O
that	O
are	O
expressed	O
in	O
neuroblastomas	B-malignancy-type
have	O
different	O
prognostic	O
implications	O
;	O
trkA	O
is	O
a	O
marker	O
of	O
good	O
prognosis	O
,	O
whereas	O
trkB	O
expression	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O
This	O
suggests	O
that	O
either	O
the	O
signaling	O
that	O
is	O
mediated	O
via	O
these	O
receptors	O
modulates	O
the	O
biological	O
features	O
of	O
neuroblastoma	B-malignancy-type
cells	O
differently	O
,	O
or	O
that	O
distinct	O
lineages	O
of	O
sympathoadrenal	O
precursors	O
have	O
been	O
transformed	O
.	O
In	O
this	O
report	O
,	O
we	O
evaluate	O
the	O
biological	O
effects	O
after	O
activation	O
of	O
trkA	O
or	O
trkB	O
by	O
their	O
major	O
ligands	O
in	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Both	O
trkA	O
and	O
trkB	O
induce	O
differentiation	O
,	O
inhibit	O
growth	O
,	O
and	O
promote	O
the	O
survival	O
of	O
cells	O
under	O
conditions	O
of	O
nutrient	O
deprivation	O
.	O
However	O
,	O
the	O
up	O
-	O
regulation	O
of	O
insulin	O
-	O
like	O
growth	O
factor-II	O
(	O
IGF-II	O
)	O
expression	O
is	O
a	O
predominant	O
feature	O
of	O
trkA	O
activation	O
by	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
.	O
The	O
growth	O
inhibition	O
induced	O
by	O
blocking	O
the	O
insulin	O
-	O
like	O
growth	O
factor-	O
I	O
receptor	O
suggests	O
that	O
IGF-II	O
is	O
a	O
component	O
of	O
the	O
effector	O
mechanism	O
of	O
trkA	O
activation	O
by	O
NGF	O
in	O
trkA	O
-	O
transfected	O
cells	O
.	O
Although	O
trkA	O
and	O
trkB	O
expression	O
is	O
associated	O
with	O
different	O
prognoses	O
in	O
neuroblastoma	B-malignancy-type
,	O
our	O
study	O
indicates	O
that	O
the	O
effects	O
mediated	O
by	O
these	O
receptors	O
in	O
vivo	O
may	O
be	O
quite	O
similar	O
for	O
certain	O
subsets	O
of	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
10550322	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2002	O
Aug	O
29	O
;21	O
(	O
38	O
)	O
:	O
5823-34	O
.	O
Activation	O
of	O
anaplastic	O
lymphoma	O
kinase	O
is	O
responsible	O
for	O
hyperphosphorylation	O
of	O
ShcC	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Miyake	O
I	O
,	O
Hakomori	O
Y	O
,	O
Shinohara	O
A	O
,	O
Gamou	O
T	O
,	O
Saito	O
M,	O
Iwamatsu	O
A	O
,	O
Sakai	O
R.	O
Cancer	O
Signal	O
Transduction	O
Project	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
5-1-1	O
Tsukuji	O
,	O
Chuo-ku	O
,	O
Tokyo	O
104	O
-0045	O
,	O
Japan	O
.	O
Shc	O
family	O
of	O
docking	O
proteins	O
,	O
ShcA	O
,	O
ShcB	O
and	O
ShcC	O
,	O
play	O
roles	O
in	O
cellular	O
signal	O
transduction	O
by	O
binding	O
to	O
phosphotyrosine	O
residues	O
of	O
various	O
activated	O
receptor	O
tyrosine	O
kinases	O
.	O
Both	O
ShcB	O
and	O
ShcC	O
proteins	O
are	O
selectively	O
expressed	O
in	O
the	O
neural	O
system	O
of	O
adult	O
mouse	O
tissues	O
.	O
n	O
most	O
of	O
neuroblastoma	B-malignancy-type
cells	O
,	O
obvious	O
tyrosine	O
phosphorylation	O
of	O
ShcC	O
was	O
observed	O
,	O
whereas	O
expression	O
of	O
ShcB	O
was	O
considerably	O
low	O
.	O
Phosphoproteins	O
associated	O
with	O
hyperphosphorylated	O
ShcC	O
were	O
purified	O
from	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
and	O
identified	O
by	O
mass	O
-	O
spectrometry	O
.	O
Anaplastic	O
lymphoma	O
kinase	O
(	O
ALK	O
)	O
,	O
which	O
turned	O
out	O
to	O
be	O
one	O
of	O
these	O
phosphoproteins	O
,	O
was	O
constitutively	O
activated	O
and	O
associated	O
with	O
the	O
PTB	O
domain	O
of	O
ShcC	O
in	O
three	O
neuroblastoma	B-malignancy-type
cells	O
.	O
In	O
vitro	O
kinase	O
assay	O
revealed	O
that	O
ShcC	O
is	O
a	O
potent	O
substrate	O
of	O
the	O
activated	O
ALK	O
kinase	O
.	O
The	O
ALK	O
gene	O
locus	O
was	O
significantly	O
amplified	O
in	O
both	O
of	O
these	O
cell	O
lines	O
,	O
suggesting	O
that	O
gene	O
amplification	O
leads	O
to	O
constitutive	O
activation	O
of	O
the	O
ALK	O
kinase	O
,	O
which	O
results	O
in	O
hyperphosphorylation	O
of	O
ShcC	O
.	O
Constitutive	O
activation	O
of	O
ALK	O
appeared	O
to	O
interfere	O
with	O
signals	O
from	O
other	O
receptor	O
tyrosine	O
kinases	O
.	O
ALK	O
-	O
ShcC	O
signal	O
activation	O
,	O
possibly	O
caused	O
by	O
co	O
-	O
amplification	O
with	O
the	O
N-myc	O
gene	O
,	O
might	O
give	O
additional	O
effects	O
on	O
malignant	O
tumor	O
progression	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
12185581	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neoplasia	O
.	O
2003	O
Sep-Oct;	O
5	O
(	O
5	O
)	O
:457	O
-	O
66	O
.	O
TRAIL	O
activates	O
a	O
caspase	O
9	O
/	O
7	O
-	O
dependent	O
pathway	O
in	O
caspase	O
8	O
/	O
10	O
-	O
defective	O
SK-N-SH	O
neuroblastoma	B-malignancy-type
cells	O
with	O
two	O
functional	O
end	O
points	O
:	O
induction	O
of	O
apoptosis	O
and	O
PGE2	O
release	O
.	O
Zauli	O
G	O
,	O
Milani	O
D	O
,	O
Rimondi	O
E	O
,	O
Baldini	O
G	O
,	O
Nicolin	O
V	O
,	O
Grill	O
V	O
,	O
Secchiero	O
P.	O
Department	O
of	O
Human	O
Normal	O
Morphology	O
,	O
University	O
of	O
Trieste	O
,	O
Trieste	O
34138	O
,	O
Italy	O
.	O
zauli@units	O
.it	O
Most	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
do	O
not	O
express	O
apical	O
caspases	O
8	O
and	O
10	O
,	O
which	O
play	O
a	O
key	O
role	O
in	O
mediating	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
cytotoxicity	O
in	O
a	O
variety	O
of	O
malignant	O
cell	O
types	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
TRAIL	O
induced	O
a	O
moderate	O
but	O
significant	O
increase	O
of	O
apoptosis	O
in	O
the	O
caspase	O
8	O
/	O
10	O
-	O
deficient	O
SK-N-SH	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
through	O
activation	O
of	O
a	O
novel	O
caspase	O
9	O
/	O
7	O
pathway	O
.	O
Concomitant	O
to	O
the	O
induction	O
of	O
apoptosis	O
,	O
TRAIL	O
also	O
promoted	O
a	O
significant	O
increase	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
release	O
by	O
SK-N-SH	O
cells	O
.	O
Moreover	O
,	O
coadministration	O
of	O
TRAIL	O
plus	O
indomethacin	O
,	O
a	O
pharmacological	O
inhibitor	O
of	O
cyclooxygenase	O
(	O
COX	O
)	O
,	O
showed	O
an	O
additive	O
effect	O
on	O
SK-N-SH	O
cell	O
death	O
.	O
In	O
spite	O
of	O
the	O
ability	O
of	O
TRAIL	O
to	O
promote	O
the	O
phosphorylation	O
of	O
both	O
ERK	O
1	O
/	O
2	O
and	O
p38	O
/	O
MAPK	O
,	O
which	O
have	O
been	O
involved	O
in	O
the	O
control	O
of	O
COX	O
expression	O
/	O
activity	O
,	O
neither	O
PD98059	O
nor	O
SB203580	O
,	O
pharmacological	O
inhibitors	O
of	O
the	O
ERK	O
1	O
/	O
2	O
and	O
p38	O
/	O
MAPK	O
pathways	O
,	O
respectively	O
,	O
affected	O
either	O
PGE2	O
production	O
or	O
apoptosis	O
induced	O
by	O
TRAIL	O
.	O
Finally	O
,	O
both	O
induction	O
of	O
apoptosis	O
and	O
PGE2	O
release	O
were	O
completely	O
abrogated	O
by	O
the	O
broad	O
caspase	O
inhibitor	O
z-VAD	O
-	O
fmk	O
,	O
suggesting	O
that	O
both	O
biologic	O
end	O
points	O
were	O
regulated	O
in	O
SK-N-SH	O
cells	O
through	O
a	O
caspase	O
9	O
/	O
7	O
-	O
dependent	O
pathway	O
.	O
PMID	O
:	O
14670183	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Int	O
J	O
Cancer	O
.	O
1998	O
Nov	O
9;78	O
(	O
4	O
)	O
:437-40	O
.	O
p73	O
,	O
a	O
gene	O
related	O
to	O
p53	O
,	O
is	O
not	O
mutated	O
in	O
esophageal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Nimura	O
Y	O
,	O
Mihara	O
M,	O
Ichimiya	O
S	O
,	O
Sakiyama	O
S	O
,	O
Seki	O
N	O
,	O
Ohira	O
M,	O
Nomura	O
N	O
,	O
Fujimori	O
M,	O
Adachi	O
W	O
,	O
Amano	O
J,	O
He	O
M,	O
Ping	O
YM	O
,	O
Nakagawara	O
A	O
.	O
Division	O
of	O
Biochemistry	O
,	O
Chiba	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Japan	O
.	O
A	O
novel	O
gene	O
,	O
termed	O
p73	O
,	O
encodes	O
a	O
protein	O
with	O
a	O
significant	O
homology	O
to	O
p53	O
and	O
has	O
been	O
mapped	O
at	O
chromosome	O
1p36.3	O
,	O
which	O
is	O
a	O
locus	O
of	O
multiple	O
suppressor	O
genes	O
for	O
tumors	O
including	O
neuroblastoma	B-malignancy-type
and	O
other	O
cancers	O
.	O
Since	O
the	O
1p36	O
locus	O
is	O
reported	O
to	O
be	O
deleted	O
and	O
p53	O
is	O
frequently	O
mutated	O
in	O
esophageal	B-malignancy-type
carcinomas	I-malignancy-type
,	O
we	O
examined	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
mutation	O
of	O
the	O
p73	O
gene	O
in	O
48	O
untreated	O
esophageal	B-malignancy-type
tumors	I-malignancy-type
,	O
as	O
well	O
as	O
mRNA	O
expression	O
in	O
8	O
tumors	O
.	O
We	O
screened	O
the	O
P1	O
genomic	O
library	O
to	O
obtain	O
a	O
P1	O
clone	O
containing	O
the	O
p73	O
gene	O
and	O
found	O
a	O
polymorphic	O
short	O
tandem	O
CT	O
repeat	O
site	O
at	O
intron	O
9	O
.	O
Intragenic	O
sequences	O
for	O
14	O
PCR	O
primer	O
sets	O
and	O
a	O
primer	O
pair	O
flanking	O
the	O
repeat	O
were	O
also	O
determined	O
for	O
the	O
analysis	O
of	O
PCR	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
LOH	O
studies	O
,	O
respectively	O
.	O
Expression	O
of	O
p73	O
mRNA	O
was	O
detectable	O
but	O
at	O
low	O
levels	O
in	O
all	O
8	O
tumor	O
tissues	O
by	O
reverse	O
transcriptase	O
PCR	O
.	O
We	O
did	O
not	O
find	O
any	O
type	O
of	O
mutation	O
other	O
than	O
polymorphisms	O
in	O
the	O
48	O
esophageal	B-malignancy-type
carcinomas	I-malignancy-type
,	O
though	O
aberration	O
of	O
the	O
p53	O
gene	O
on	O
the	O
PCR-SSCP	O
gels	O
was	O
observed	O
in	O
15	O
of	O
38	O
(	O
39	O
%	O
)	O
tumors	O
of	O
the	O
same	O
set	O
.	O
In	O
addition	O
,	O
LOH	O
for	O
p73	O
was	O
found	O
in	O
only	O
2	O
of	O
25	O
(	O
8	O
%	O
)	O
tumors	O
.	O
These	O
results	O
suggest	O
that	O
,	O
at	O
least	O
in	O
esophageal	B-malignancy-type
carcinomas	I-malignancy-type
,	O
allelic	O
loss	O
or	O
mutation	O
of	O
p73	O
may	O
not	O
be	O
a	O
main	O
genetic	O
event	O
for	O
the	O
tumorigenesis	O
as	O
it	O
is	O
with	O
p53	O
.	O
PMID	O
:	O
9797131	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Mol	O
Genet	O
.	O
2000	O
Jan	O
1;	O
9	O
(	O
1	O
)	O
:	O
133	O
-44	O
.	O
Motoneuronal	O
cell	O
death	O
is	O
not	O
correlated	O
with	O
aggregate	O
formation	O
of	O
androgen	O
receptors	O
containing	O
an	O
elongated	O
polyglutamine	O
tract	O
.	O
Simeoni	O
S	O
,	O
Mancini	O
MA	O
,	O
Stenoien	O
DL	O
,	O
Marcelli	O
M,	O
Weigel	O
NL	O
,	O
Zanisi	O
M,	O
Martini	O
L,	O
Poletti	O
A	O
.	O
Istituto	O
di	O
Endocrinologia	O
,	O
Universita	O
di	O
Milano	O
,	O
via	O
Balzaretti	O
9	O
,	O
20133	O
Milano	O
,	O
Italy	O
.	O
Spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
is	O
associated	O
with	O
an	O
abnormal	O
expansion	O
of	O
the	O
(	O
CAG	O
)	O
(n)repeat	O
in	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
.	O
Similar	O
mutations	O
have	O
been	O
reported	O
in	O
other	O
proteins	O
that	O
cause	O
neurodegenerative	O
disorders	O
.	O
The	O
CAG	O
-coded	O
elongated	O
polyglutamine	O
(	O
polyGln	O
)	O
tracts	O
induce	O
the	O
formation	O
of	O
neuronal	O
intracellular	O
aggregates	O
.	O
We	O
have	O
produced	O
a	O
model	O
to	O
study	O
the	O
effects	O
of	O
potentially	O
'neurotoxic	O
'	O
aggregates	O
in	O
SBMA	O
using	O
immortalized	O
motoneuronal	O
cells	O
(	O
NSC34	O
)	O
transfected	O
with	O
AR	O
containing	O
polyGln	O
repeats	O
of	O
different	O
sizes	O
[(	O
AR	O
.	O
Q	O
(n	O
=	O
0	O
,	O
23	O
or	O
46)	O
]	O
.	O
Using	O
chimeras	O
of	O
AR	O
.	O
Q	O
(n)	O
and	O
the	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
,	O
we	O
have	O
shown	O
that	O
aggregate	O
formation	O
occurs	O
when	O
the	O
polyGln	O
tract	O
is	O
elongated	O
and	O
AR	O
is	O
activated	O
by	O
androgens	O
.	O
In	O
NSC34	O
cells	O
co	O
-	O
expressing	O
the	O
AR	O
with	O
the	O
polyGln	O
of	O
pathological	O
length	O
(	O
AR	O
.Q46	O
)	O
and	O
the	O
GFP	O
we	O
have	O
noted	O
the	O
presence	O
of	O
several	O
dystrophic	O
neurites	O
.	O
Cell	O
viability	O
analyses	O
have	O
shown	O
a	O
reduced	O
growth	O
/survival	O
rate	O
in	O
NSC34	O
expressing	O
the	O
AR	O
.Q46	O
,	O
whereas	O
testosterone	O
treatment	O
partially	O
counteracted	O
both	O
cell	O
death	O
and	O
the	O
formation	O
of	O
dystrophic	O
neurites	O
.	O
These	O
observations	O
indicate	O
the	O
lack	O
of	O
correlation	O
between	O
aggregate	O
formation	O
and	O
cell	O
survival	O
,	O
and	O
suggest	O
that	O
neuronal	O
degeneration	O
in	O
SBMA	O
might	O
be	O
secondary	O
to	O
axonal	O
/	O
dendritic	O
insults	O
.	O
PMID	O
:	O
10587588	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Growth	O
Differ	O
.	O
1996	O
Apr;	O
7(	O
4	O
)	O
:	O
429-	O
37	O
.	O
EWS	O
/	O
FLI-1	O
antagonists	O
induce	O
growth	O
inhibition	O
of	O
Ewing	B-malignancy-type
tumor	I-malignancy-type
cells	O
in	O
vitro	O
.	O
Kovar	O
H,	O
Aryee	O
DN	O
,	O
Jug	O
G	O
,	O
Henockl	O
C	O
,	O
Schemper	O
M,	O
Delattre	O
O	O
,	O
Thomas	O
G	O
,	O
Gadner	O
H.	O
Childrens	O
Cancer	O
Research	O
Institute	O
,	O
St.	O
Anna	O
Kinderspital	O
,	O
Vienna	O
,	O
Austria	O
.	O
Among	O
primitive	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
,	O
Ewing	B-malignancy-type
tumors	I-malignancy-type
are	O
characterized	O
by	O
a	O
gene	O
rearrangement	O
recombining	O
the	O
5'-	O
EWS	O
gene	O
portion	O
with	O
one	O
of	O
two	O
ETS	O
-	O
related	O
proto	O
-	O
oncogenes	O
,	O
FLI-1	O
or	O
ERG	O
,	O
in	O
roughly	O
90	O
and	O
10	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
We	O
attempted	O
to	O
antagonize	O
EWS	O
/	O
FLI-1	O
function	O
in	O
Ewing	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
.	O
As	O
a	O
control	O
,	O
a	O
cell	O
line	O
derived	O
from	O
another	O
small	O
round	O
cell	O
tumor	O
of	O
neuroectodermal	O
origin	O
,	O
neuroblastoma	B-malignancy-type
,	O
was	O
used	O
.	O
This	O
cell	O
line	O
was	O
found	O
to	O
express	O
almost	O
identical	O
patterns	O
of	O
ETS	O
proteins	O
except	O
for	O
EWS	O
/	O
FLI-1	O
and	O
a	O
novel	O
,	O
ELF	O
-	O
related	O
gene	O
product	O
.	O
Stable	O
expression	O
of	O
antisense	O
EWS	O
/	O
FLI-1	O
cDNA	O
resulted	O
in	O
decreased	O
endogenous	O
EWS	O
/	O
FLI-1	O
RNA	O
levels	O
and	O
growth	O
reduction	O
of	O
ET	B-malignancy-type
cells	O
but	O
not	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
DNA	O
-	O
binding	O
FLI-1	O
derivatives	O
localizing	O
to	O
the	O
nucleus	O
in	O
which	O
the	O
5'-	O
EWS	O
regulatory	O
domain	O
was	O
replaced	O
by	O
bacterial	O
beta-galactosidase	O
dominantly	O
modulated	O
transcriptional	O
transactivation	O
from	O
a	O
degenerate	O
ETS	O
-binding	O
motif	O
.	O
Transient	O
transfection	O
of	O
these	O
dominant-	O
negative	O
recombinants	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
relative	O
number	O
of	O
mitoses	O
in	O
four	O
Ewing	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
tested	O
but	O
not	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
The	O
presented	O
evidence	O
for	O
modulation	O
of	O
tumor	O
cell	O
proliferation	O
by	O
EWS	O
/	O
FLI-1	O
antagonists	O
suggests	O
a	O
causal	O
role	O
for	O
EWS	O
/	O
FLI-1	O
-	O
mediated	O
gene	O
activation	O
in	O
the	O
malignant	O
transformation	O
of	O
the	O
enigmatic	O
Ewing	B-malignancy-type
tumor	I-malignancy-type
-	O
precursor	O
cell	O
.	O
PMID	O
:	O
9052984	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2003	O
May;8	O
5	O
(	O
3	O
)	O
:729-	O
39	O
.	O
Differential	O
regulation	O
of	O
NF-kappaB	O
,	O
SRE	O
and	O
CRE	O
by	O
dopamine	O
D1	O
and	O
D2	O
receptors	O
in	O
transfected	O
NG108-15	O
cells	O
.	O
Takeuchi	O
Y	O
,	O
Fukunaga	O
K.	O
Department	O
of	O
Pharmacology	O
,	O
Kumamoto	O
University	O
School	O
of	O
Medicine	O
,	O
Kumamoto	O
,	O
Japan	O
.	O
yusuket@gpo.kumamoto-u.ac.jp	O
To	O
investigate	O
transcriptional	O
regulation	O
by	O
dopamine	O
receptors	O
,	O
we	O
established	O
NG108-15	O
cells	O
stably	O
expressing	O
D1R	O
,	O
D2LR	O
and	O
D2SR	O
(	O
NGD1R	O
,	O
NGD2LR	O
and	O
NGD2SR	O
)	O
and	O
evaluated	O
the	O
effects	O
of	O
these	O
receptors	O
on	O
NF-kappaB	O
,	O
SRE	O
and	O
CRE	O
activity	O
using	O
luciferase	O
reporter	O
constructs	O
.	O
Stimulation	O
with	O
quinpirole	O
,	O
a	O
selective	O
D2R	O
agonist	O
,	O
increased	O
NF-kappaB	O
and	O
SRE	O
activity	O
but	O
decreased	O
CRE	O
activity	O
in	O
both	O
NGD2R	O
cell	O
lines	O
.	O
By	O
contrast	O
,	O
stimulation	O
with	O
SKF	O
38393	O
,	O
a	O
selective	O
D1R	O
agonist	O
,	O
decreased	O
NF-kappaB	O
and	O
SRE	O
activity	O
but	O
increased	O
CRE	O
activity	O
in	O
NGD1R	O
cells	O
.	O
Stimulation	O
with	O
forskolin	O
and	O
overexpression	O
of	O
constitutively	O
active	O
PKA	O
suppressed	O
NF-kappaB	O
activity	O
,	O
likely	O
due	O
to	O
D1R	O
stimulation	O
.	O
D2R	O
stimulation	O
activated	O
ERK	O
,	O
and	O
treatment	O
with	O
U1026	O
,	O
a	O
selective	O
MEK	O
inhibitor	O
,	O
eliminated	O
D2R	O
-	O
induced	O
NF-kappaB	O
activation	O
.	O
D2R	O
stimulation	O
also	O
activated	O
the	O
neural	O
cell	O
adhesion	O
molecule	O
(	O
NCAM	O
)	O
promoter	O
,	O
which	O
includes	O
a	O
potential	O
NF-kappaB	O
site	O
.	O
Furthermore	O
,	O
by	O
transfecting	O
constitutively	O
active	O
CaM	O
KII	O
and	O
MEKK	O
,	O
and	O
dominant	O
negative	O
p38	O
MAPK	O
,	O
we	O
show	O
that	O
the	O
NCAM	O
promoter	O
is	O
positively	O
regulated	O
by	O
CaM	O
KII	O
but	O
negatively	O
regulated	O
by	O
p38	O
MAPK	O
.	O
These	O
results	O
indicate	O
that	O
D2R	O
-	O
induced	O
NF-kappaB	O
activation	O
through	O
ERK	O
may	O
be	O
involved	O
in	O
activation	O
of	O
the	O
NCAM	O
promoter	O
,	O
and	O
additionally	O
that	O
other	O
protein	O
kinases	O
such	O
as	O
CaM	O
KII	O
and	O
p38	O
MAPK	O
also	O
regulate	O
NCAM	O
expression	O
.	O
PMID	O
:	O
12694399	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2002	O
Jul	O
4;21(	O
29	O
)	O
:454	O
9-	O
57	O
.	O
N-Myc	O
and	O
Bcl-2	O
coexpression	O
induces	O
MMP-2	O
secretion	O
and	O
activation	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Noujaim	O
D	O
,	O
van	O
Golen	O
CM	O
,	O
van	O
Golen	O
KL	O
,	O
Grauman	O
A	O
,	O
Feldman	O
EL	O
.	O
Department	O
of	O
Neurology	O
,	O
University	O
of	O
Michigan	O
,	O
Ann	O
Arbor	O
48109	O
,	O
USA	O
.	O
Neuroblastoma	B-malignancy-type
is	O
a	O
peripheral	O
nervous	O
system	O
tumor	O
that	O
accounts	O
for	O
8-	O
10	O
%	O
of	O
all	O
solid	B-malignancy-type
childhood	I-malignancy-type
tumors	I-malignancy-type
.	O
N-Myc	O
is	O
the	O
most	O
reliable	O
prognostic	O
indicator	O
for	O
neuroblastoma	B-malignancy-type
.	O
Bcl-2	O
is	O
detected	O
in	O
40	O
-	O
60	O
%	O
of	O
primary	O
neuroblastoma	B-malignancy-type
tumors	O
and	O
demonstrates	O
anti	O
-	O
apoptotic	O
action	O
by	O
conferring	O
resistance	O
to	O
chemotherapy	O
and	O
radiation	O
treatment	O
.	O
In	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
the	O
coexpression	O
of	O
N-Myc	O
and	O
Bcl-2	O
leads	O
to	O
increased	O
tumorigenic	O
properties	O
.	O
Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
endopeptidases	O
that	O
degrade	O
a	O
wide	O
range	O
of	O
basement	O
membrane	O
components	O
,	O
a	O
process	O
important	O
for	O
tumor	O
invasion	O
.	O
This	O
study	O
investigates	O
the	O
effect	O
of	O
N-Myc	O
and	O
Bcl-2	O
on	O
MMP	O
expression	O
and	O
activation	O
.	O
MMP-2	O
expression	O
and	O
secretion	O
are	O
increased	O
in	O
SHEP	O
neuroblastoma	B-malignancy-type
cells	O
expressing	O
Bcl-2	O
alone	O
(	O
SHEP	O
/Bcl-2	O
cells	O
)	O
or	O
both	O
N-Myc	O
and	O
Bcl-2	O
(	O
SHEP	O
/	O
N-Myc	O
/	O
Bcl-2	O
cells	O
)	O
.	O
MMP-2	O
activity	O
is	O
increased	O
in	O
the	O
SHEP	O
/	O
N-Myc	O
/	O
Bcl-2	O
cells	O
yet	O
remains	O
unchanged	O
in	O
SHEP	O
/Bcl-2	O
cells	O
.	O
TIMP-2	O
expression	O
is	O
high	O
in	O
SHEP	O
/Bcl-2	O
cells	O
,	O
which	O
likely	O
inhibits	O
MMP-2	O
activity	O
,	O
and	O
absent	O
in	O
SHEP	O
/	O
N-Myc	O
/	O
Bcl-2	O
cells	O
,	O
allowing	O
MMP-2	O
activity	O
.	O
Invasion	O
is	O
increased	O
in	O
SHEP	O
/	O
N-Myc	O
/	O
Bcl-2	O
cells	O
and	O
prevented	O
by	O
the	O
use	O
of	O
a	O
pharmacologic	O
MMP-2	O
inhibitor	O
.	O
These	O
data	O
imply	O
that	O
N-Myc	O
and	O
Bcl-2	O
cooperate	O
to	O
increase	O
the	O
expression	O
,	O
secretion	O
,	O
and	O
activation	O
of	O
MMP	O
-2	O
,	O
which	O
likely	O
leads	O
to	O
a	O
more	O
tumorigenic	O
phenotype	O
due	O
to	O
increased	O
MMP-2	O
mediated	O
invasion	O
.	O
PMID	O
:	O
12085233	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
.	O
1997	O
Nov;17(	O
11	O
)	O
:6537-45	O
.	O
A	O
complex	O
intronic	O
splicing	O
enhancer	O
from	O
the	O
c-	O
src	O
pre	O
-	O
mRNA	O
activates	O
inclusion	O
of	O
a	O
heterologous	O
exon	O
.	O
Modafferi	O
EF	O
,	O
Black	O
DL.	O
Department	O
of	O
Microbiology	O
and	O
Molecular	O
Genetics	O
,	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
9009	O
5-1662	O
,	O
USA	O
.	O
The	O
mouse	O
c-	O
src	O
gene	O
contains	O
a	O
short	O
neuron	O
-	O
specific	O
exon	O
,	O
N1	O
.	O
To	O
characterize	O
the	O
sequences	O
that	O
regulate	O
N1	O
splicing	O
,	O
we	O
used	O
a	O
heterologous	O
gene	O
,	O
derived	O
from	O
the	O
human	O
beta-globin	O
gene	O
,	O
containing	O
a	O
short	O
internal	O
exon	O
that	O
is	O
usually	O
skipped	O
by	O
the	O
splicing	O
machinery	O
.	O
Various	O
fragments	O
from	O
the	O
src	O
gene	O
were	O
inserted	O
into	O
the	O
globin	O
substrate	O
to	O
measure	O
their	O
effects	O
on	O
the	O
splicing	O
of	O
the	O
test	O
exon	O
.	O
These	O
clones	O
were	O
transiently	O
expressed	O
in	O
neuronal	O
and	O
nonneuronal	O
cell	O
lines	O
,	O
and	O
the	O
level	O
of	O
exon	O
inclusion	O
was	O
measured	O
by	O
primer	O
extension	O
.	O
Several	O
sequences	O
from	O
the	O
N1	O
exon	O
region	O
induced	O
the	O
splicing	O
of	O
the	O
heterologous	O
exon	O
.	O
The	O
most	O
powerful	O
effect	O
was	O
seen	O
with	O
a	O
sequence	O
from	O
the	O
intron	O
downstream	O
of	O
the	O
N1	O
exon	O
.	O
This	O
sequence	O
acted	O
as	O
a	O
strong	O
splicing	O
enhancer	O
,	O
activating	O
splicing	O
of	O
the	O
test	O
exon	O
when	O
placed	O
in	O
the	O
intron	O
downstream	O
.	O
The	O
enhancer	O
was	O
strongest	O
in	O
neuronal	O
LA-N-5	O
cells	O
but	O
also	O
activated	O
splicing	O
in	O
nonneuronal	O
HEK293	O
cells	O
.	O
Deletion	O
and	O
linker	O
scanning	O
mutagenesis	O
indicate	O
that	O
the	O
enhancer	O
is	O
made	O
up	O
of	O
multiple	O
smaller	O
elements	O
that	O
must	O
act	O
in	O
combination	O
.	O
One	O
of	O
these	O
elements	O
was	O
identified	O
as	O
the	O
sequence	O
UGCAUG	O
.	O
Three	O
copies	O
of	O
this	O
element	O
can	O
strongly	O
activate	O
splicing	O
of	O
the	O
test	O
exon	O
in	O
LA-N-5	O
neuroblastoma	B-malignancy-type
cells	O
.	O
These	O
component	O
elements	O
of	O
the	O
src	O
splicing	O
enhancer	O
are	O
also	O
apparently	O
involved	O
in	O
the	O
splicing	O
of	O
other	O
short	O
cassette	O
exons	O
.	O
PMID	O
:	O
9343417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genomics	O
.	O
2001	O
Jan	O
15	O
;	O
71(	O
2	O
)	O
:	O
214	O
-21	O
.	O
The	O
MEIS1	O
oncogene	O
is	O
highly	O
expressed	O
in	O
neuroblastoma	B-malignancy-type
and	O
amplified	O
in	O
cell	O
line	O
IMR32	O
.	O
Spieker	O
N	O
,	O
van	O
Sluis	O
P,	O
Beitsma	O
M,	O
Boon	O
K,	O
van	O
Schaik	O
BD	O
,	O
van	O
Kampen	O
AH	O
,	O
Caron	O
H,	O
Versteeg	O
R.	O
Department	O
of	O
Human	O
Genetics	O
,	O
University	O
of	O
Amsterdam	O
,	O
Amsterdam	O
,	O
1100DE	O
,	O
The	O
Netherlands	O
.	O
Neuroblastoma	B-malignancy-type
is	O
an	O
embryonal	O
tumor	O
originating	O
from	O
neural	O
crest	O
-	O
derived	O
cells	O
.	O
Here	O
we	O
present	O
the	O
serendipitous	O
cloning	O
of	O
amplified	O
sequences	O
of	O
chromosome	O
2p15	O
in	O
neuroblastoma	B-malignancy-type
cell	O
line	O
IMR32	O
.	O
The	O
amplified	O
region	O
was	O
analyzed	O
for	O
oncogene	O
activation	O
using	O
a	O
SAGE	O
(	O
serial	O
analysis	O
of	O
gene	O
expression	O
)	O
library	O
of	O
IMR32	O
.	O
SAGE	O
permits	O
a	O
quantitative	O
analysis	O
of	O
all	O
transcripts	O
of	O
a	O
tissue	O
or	O
cell	O
line	O
.	O
The	O
expression	O
of	O
genes	O
and	O
ESTs	O
mapping	O
within	O
a	O
30	O
-	O
cR	O
region	O
covering	O
the	O
amplicon	O
was	O
compared	O
to	O
4	O
additional	O
SAGE	O
libraries	O
of	O
neuroblastomas	B-malignancy-type
and	O
12	O
SAGE	O
libraries	O
of	O
other	O
tissues	O
in	O
the	O
CGAP	O
databases	O
.	O
The	O
IMR32	O
SAGE	O
database	O
revealed	O
increased	O
expression	O
of	O
the	O
MEIS1	O
oncogene	O
,	O
whereas	O
other	O
SAGE	O
libraries	O
showed	O
little	O
or	O
no	O
MEIS1	O
expression	O
.	O
MEIS1	O
turned	O
out	O
to	O
be	O
highly	O
amplified	O
and	O
overexpressed	O
in	O
IMR32	O
.	O
Analysis	O
of	O
24	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
22	O
tumors	O
showed	O
high	O
-	O
level	O
expression	O
in	O
about	O
25	O
%	O
of	O
the	O
cases	O
.	O
The	O
MEIS1	O
homeobox	O
protein	O
forms	O
a	O
complex	O
with	O
the	O
HOXA9	O
and	O
PBX	O
proteins	O
that	O
are	O
implicated	O
in	O
human	O
leukemia	B-malignancy-type
.	O
MEIS1	O
is	O
a	O
target	O
of	O
retroviral	O
insertion	O
in	O
murine	O
leukemia	B-malignancy-type
.	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
MEIS1	O
amplification	O
and	O
high	O
expression	O
levels	O
in	O
human	O
cancer	O
and	O
the	O
first	O
time	O
that	O
identification	O
of	O
a	O
candidate	O
target	O
of	O
amplification	O
is	O
facilitated	O
by	O
high	O
-throughput	O
mRNA	O
expression	O
profiling	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11161815	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dev	O
Growth	O
Differ	O
.	O
1998	O
Jun;40	O
(	O
3	O
)	O
:	O
343	O
-	O
53	O
.	O
Sequence	O
and	O
expression	O
of	O
a	O
novel	O
mouse	O
gene	O
PRDC	O
(	O
protein	O
related	O
to	O
DAN	O
and	O
cerberus	O
)	O
identified	O
by	O
a	O
gene	O
trap	O
approach	O
.	O
Minabe-Saegusa	O
C	O
,	O
Saegusa	O
H,	O
Tsukahara	O
M,	O
Noguchi	O
S.	O
Bio	O
Signal	O
Pathway	O
Project	O
,	O
Kanagawa	O
Academy	O
of	O
Science	O
and	O
Technology	O
,	O
Meiji	O
Institute	O
of	O
Health	O
Science	O
,	O
Japan	O
.	O
Gene	O
trapping	O
in	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
was	O
used	O
to	O
identify	O
a	O
novel	O
gene	O
involved	O
in	O
mouse	O
development	O
.	O
In	O
order	O
to	O
screen	O
trapped	O
ES	O
cell	O
lines	O
for	O
the	O
presence	O
of	O
developmentally	O
regulated	O
genes	O
,	O
an	O
in	O
vitro	O
differentiation	O
test	O
was	O
used	O
.	O
One	O
of	O
the	O
G418	O
resistant	O
cell	O
lines	O
,	O
in	O
conjunction	O
with	O
the	O
lacZ	O
reporter	O
gene	O
,	O
showed	O
differential	O
expression	O
patterns	O
under	O
differentiated	O
and	O
undifferentiated	O
conditions	O
.	O
The	O
gene	O
trap	O
insertion	O
in	O
this	O
cell	O
line	O
was	O
germ	O
-	O
line	O
transmitted	O
and	O
X-gal	O
staining	O
was	O
used	O
to	O
assess	O
the	O
expression	O
pattern	O
of	O
lacZ	O
in	O
embryos	O
heterozygous	O
for	O
the	O
trapped	O
allele	O
.	O
The	O
reporter	O
gene	O
's	O
expression	O
was	O
detected	O
in	O
commissural	O
neurons	O
in	O
the	O
developing	O
spinal	O
cord	O
,	O
suggesting	O
functions	O
for	O
the	O
trapped	O
gene	O
in	O
mouse	O
neural	O
development	O
.	O
Structural	O
analysis	O
of	O
the	O
cDNA	O
revealed	O
that	O
this	O
trapped	O
gene	O
,	O
named	O
PRDC	O
(	O
protein	O
related	O
to	O
DAN	O
and	O
cerberus	O
)	O
,	O
is	O
a	O
novel	O
gene	O
that	O
encodes	O
a	O
putative	O
secretory	O
protein	O
consisting	O
of	O
168	O
amino	O
acid	O
residues	O
.	O
PRDC	O
gene	O
product	O
shows	O
limited	O
similarities	O
to	O
the	O
products	O
of	O
DAN	O
(	O
differential	O
screening	O
-	O
selected	O
gene	O
aberrative	O
in	O
neuroblastoma	O
)	O
and	O
cerberus	O
.	O
(	O
DAN	O
is	O
a	O
possible	O
tumor	O
-	O
suppressor	O
for	O
neuroblastoma	B-malignancy-type
in	O
human	O
.	O
Cerberus	O
can	O
induce	O
an	O
ectopic	O
head	O
in	O
Xenopus	O
embryos	O
when	O
ectopically	O
expressed	O
.	O
)	O
These	O
three	O
gene	O
products	O
may	O
form	O
a	O
novel	O
family	O
of	O
signaling	O
molecules	O
.	O
PMID	O
:	O
9639362	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2000	O
Aug	O
15	O
;60	O
(	O
16	O
)	O
:4305	O
-	O
10	O
.	O
Midkine	O
promoter	O
-	O
based	O
adenoviral	O
vector	O
gene	O
delivery	O
for	O
pediatric	B-malignancy-type
solid	I-malignancy-type
tumors	I-malignancy-type
.	O
Adachi	O
Y	O
,	O
Reynolds	O
PN	O
,	O
Yamamoto	O
M,	O
Grizzle	O
WE	O
,	O
Overturf	O
K,	O
Matsubara	O
S	O
,	O
Muramatsu	O
T	O
,	O
Curiel	O
DT.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Alabama	O
at	O
Birmingham	O
,	O
35294	O
,	O
USA	O
.	O
It	O
is	O
important	O
to	O
develop	O
a	O
system	O
to	O
express	O
therapeutic	O
genes	O
in	O
tumor	O
cells	O
with	O
sufficient	O
selectivity	O
for	O
cancer	O
gene	O
therapy	O
.	O
Midkine	O
(	O
MK	O
)	O
is	O
a	O
newly	O
identified	O
heparin	O
-	O
binding	O
growth	O
factor	O
that	O
is	O
transiently	O
expressed	O
in	O
the	O
early	O
stages	O
of	O
retinoic	O
acid	O
-	O
induced	O
differentiation	O
of	O
embryonal	B-malignancy-type
carcinoma	I-malignancy-type
cells	O
.	O
It	O
has	O
been	O
reported	O
that	O
many	O
human	O
malignant	O
tumors	O
express	O
high	O
levels	O
of	O
MK	O
mRNA	O
or	O
protein	O
.	O
However	O
,	O
no	O
MK	O
expression	O
is	O
detected	O
in	O
human	O
or	O
mouse	O
liver	O
.	O
These	O
interesting	O
features	O
of	O
MK	O
led	O
us	O
to	O
examine	O
the	O
MK	O
promoter	O
as	O
a	O
candidate	O
for	O
tumor	O
-	O
specific	O
gene	O
expression	O
.	O
We	O
thus	O
developed	O
new	O
recombinant	O
adenoviral	O
(	O
Ad	O
)	O
vectors	O
containing	O
either	O
luciferase	O
reporter	O
gene	O
(	O
AdMKLuc	O
)	O
or	O
herpes	O
simplex	O
thymidine	O
kinase	O
gene	O
(	O
AdMKTK	O
)	O
under	O
the	O
control	O
of	O
the	O
human	O
MK	O
promoter	O
.	O
AdMKLuc	O
achieved	O
relatively	O
high	O
activity	O
in	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
(	O
G-401	O
)	O
and	O
neuroblastoma	B-malignancy-type
(	O
SK-N-SH	O
)	O
cell	O
lines	O
.	O
In	O
addition	O
,	O
AdMKTK	O
induced	O
marked	O
cell	O
death	O
in	O
response	O
to	O
ganciclovir	O
(	O
GCV	O
)	O
in	O
these	O
same	O
lines	O
.	O
Conversely	O
,	O
very	O
low	O
activity	O
of	O
the	O
MK	O
promoter	O
was	O
observed	O
in	O
mouse	O
liver	O
in	O
vivo	O
compared	O
with	O
the	O
cytomegalovirus	O
promoter	O
.	O
Importantly	O
,	O
AdMKTK	O
+	O
GCV	O
did	O
not	O
induce	O
liver	O
toxicity	O
,	O
whereas	O
substantial	O
toxicity	O
was	O
seen	O
with	O
AdCMVTK	O
+	O
GCV	O
treatment	O
.	O
On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
we	O
conclude	O
that	O
the	O
MK	O
promoter	O
is	O
a	O
candidate	O
tumor	O
-	O
specific	O
promoter	O
for	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
or	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
10969765	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
2001	O
Aug	O
17;8	O
5	O
(	O
4	O
)	O
:	O
531	O
-	O
7.	O
Neuroblastomas	B-malignancy-type
with	O
chromosome	O
11q	O
loss	O
and	O
single	O
copy	O
MYCN	O
comprise	O
a	O
biologically	O
distinct	O
group	O
of	O
tumours	O
with	O
adverse	O
prognosis	O
.	O
Luttikhuis	O
ME	O
,	O
Powell	O
JE	O
,	O
Rees	O
SA	O
,	O
Genus	O
T	O
,	O
Chughtai	O
S	O
,	O
Ramani	O
P,	O
Mann	O
JR	O
,	O
McConville	O
CM	O
.	O
Division	O
of	O
Medical	O
and	O
Molecular	O
Genetics	O
,	O
University	O
of	O
Birmingham	O
B15	O
2TT	O
,	O
UK.	O
Neuroblastoma	B-malignancy-type
is	O
a	O
heterogeneous	O
tumour	O
and	O
its	O
effective	O
clinical	O
management	O
is	O
dependent	O
on	O
accurate	O
prognostic	O
evaluation	O
.	O
In	O
approximately	O
25	O
%	O
of	O
patients	O
amplification	O
of	O
the	O
MYCN	O
oncogene	O
is	O
known	O
to	O
be	O
associated	O
with	O
a	O
poor	O
outcome	O
.	O
In	O
order	O
to	O
identify	O
additional	O
molecular	O
markers	O
with	O
prognostic	O
potential	O
in	O
non	O
-	O
MYCN	O
-	O
amplified	O
neuroblastomas	B-malignancy-type
,	O
we	O
looked	O
for	O
a	O
correlation	O
between	O
clinical	O
outcome	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
four	O
chromosomes	O
that	O
frequently	O
show	O
alteration	O
in	O
neuroblastoma	B-malignancy-type
(	O
chromosomes	O
3	O
,	O
4	O
,	O
11	O
and	O
14	O
)	O
.	O
Chromosome	O
11q	O
loss	O
(	O
with	O
frequent	O
parallel	O
loss	O
of	O
chromosomes	O
3p	O
,	O
4p	O
and/or	O
14q	O
)	O
was	O
found	O
exclusively	O
in	O
tumours	O
without	O
MYCN	O
amplification	O
and	O
was	O
significantly	O
associated	O
with	O
poor	O
event	O
-	O
free	O
survival	O
.	O
The	O
2-	O
year	O
event	O
-	O
free	O
survival	O
rate	O
for	O
11q	O
LOH	O
cases	O
was	O
30	O
%	O
,	O
compared	O
to	O
34	O
%	O
for	O
MYCN	O
-	O
amplified	O
cases	O
and	O
100	O
%	O
for	O
cases	O
without	O
these	O
abnormalities	O
.	O
While	O
11q	O
LOH	O
was	O
associated	O
predominantly	O
with	O
advanced	O
-	O
stage	O
disease	O
,	O
2	O
cases	O
with	O
low	O
-	O
stage	O
disease	O
and	O
11q	O
LOH	O
both	O
suffered	O
relapses	O
.	O
We	O
conclude	O
that	O
chromosome	O
11q	O
loss	O
defines	O
a	O
biologically	O
distinct	O
group	O
of	O
tumours	O
without	O
MYCN	O
amplification	O
that	O
appear	O
to	O
have	O
potential	O
for	O
aggressive	O
metastatic	O
growth	O
.	O
Thus	O
this	O
genetic	O
alteration	O
may	O
be	O
an	O
important	O
new	O
prognostic	O
marker	O
in	O
neuroblastoma	B-malignancy-type
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11506492	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
1990	O
Apr	O
15	O
;	O
45	O
(	O
4	O
)	O
:	O
705-11	O
.	O
Characterization	O
of	O
an	O
embryonal	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
cell	O
line	O
showing	O
amplification	O
and	O
over-expression	O
of	O
the	O
N-myc	O
oncogene	O
.	O
Hayashi	O
Y	O
,	O
Sugimoto	O
T	O
,	O
Horii	O
Y	O
,	O
Hosoi	O
H	O
,	O
Inazawa	O
J	O
,	O
Kemshead	O
JT	O
,	O
Inaba	O
T	O
,	O
Hanada	O
R	O
,	O
Yamamoto	O
K	O
,	O
Gown	O
AM	O
,	O
et	O
al	O
.	O
Saitama	O
Children	O
's	O
Medical	O
Center	O
,	O
Japan	O
.	O
A	O
parent	O
rhabdomyosarcoma	B-malignancy-type
cell	O
line	O
designated	O
SCMC-RM2	O
was	O
established	O
from	O
bone-marrow	B-malignancy-type
tumor	I-malignancy-type
cells	O
taken	O
from	O
an	O
11-year-old	O
girl	O
with	O
an	O
embryonal	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
.	O
Subsequently	O
a	O
cloned	O
SCMC-RM2-1	O
cell	O
line	O
was	O
isolated	O
from	O
a	O
parent	O
line	O
.	O
These	O
cell	O
lines	O
grew	O
as	O
adherent	O
monolayers	O
in	O
liquid	O
culture	O
with	O
a	O
doubling	O
time	O
of	O
50	O
and	O
52	O
hr	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
colonies	O
were	O
established	O
in	O
soft	O
agar	O
,	O
which	O
grew	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
with	O
a	O
cloning	O
efficiency	O
of	O
0.7	O
and	O
0.8%	O
,	O
respectively	O
.	O
Chromosomal	O
analysis	O
showed	O
these	O
cell	O
lines	O
had	O
neither	O
double	O
minutes	O
nor	O
homogeneously	O
staining	O
regions	O
.	O
Chromosome	O
number	O
ranged	O
from	O
61	O
to	O
93	O
,	O
translocation	O
;	O
t	O
(	O
9	O
;	O
13	O
)	O
(	O
p22	O
;	O
q14	O
)	O
was	O
identified	O
,	O
and	O
no	O
alteration	O
of	O
chromosome	O
2	O
was	O
observed	O
.	O
Surface	O
membrane	O
antigen	O
profile	O
of	O
parent	O
and	O
cloned	O
lines	O
by	O
using	O
a	O
panel	O
of	O
24	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
excluded	O
the	O
possibility	O
of	O
these	O
being	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
In	O
addition	O
,	O
MAbs	O
to	O
the	O
cytoplasmic	O
protein	O
desmin	O
,	O
myoglobin	O
,	O
muscle	O
actin	O
(	O
alpha	O
and	O
gamma	O
)	O
and	O
alpha-sarcomeric	O
actin	O
reacted	O
with	O
these	O
cell	O
lines	O
,	O
SCMC-RM2	O
and	O
SCMC-RM2-1	O
being	O
thus	O
identified	O
as	O
rhabdomyosarcoma	B-malignancy-type
.	O
Southern	O
blot	O
analyses	O
revealed	O
8-	O
and	O
7-fold	O
amplification	O
of	O
the	O
N-myc	O
gene	O
in	O
SCMC-RM2	O
and	O
SCMC-RM2-1	O
as	O
compared	O
with	O
the	O
promyelocytic	O
cell	O
line	O
HL60	O
.	O
Over-expression	O
of	O
the	O
N-myc	O
mRNA	O
was	O
noted	O
over	O
control	O
cell	O
lines	O
.	O
PMID	O
:	O
2323848	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Pharmacol	O
.	O
1987	O
Mar	O
15	O
;	O
36	O
(	O
6	O
869	O
-	O
74	O
.	O
Comparison	O
of	O
the	O
stimulation	O
of	O
inositol	O
phospholipid	O
hydrolysis	O
and	O
of	O
cyclic	O
GMP	O
formation	O
by	O
neurotensin	O
,	O
some	O
of	O
its	O
analogs	O
,	O
and	O
neuromedin	O
N	O
in	O
neuroblastoma	B-malignancy-type
clone	O
N1E-115	O
.	O
Kanba	O
KS	O
,	O
Richelson	O
E	O
.	O
Neurotensin	O
,	O
some	O
of	O
its	O
analogs	O
,	O
and	O
neuromedin	O
N	O
were	O
examined	O
for	O
comparison	O
of	O
their	O
potencies	O
at	O
stimulating	O
inositol	O
phospholipid	O
hydrolysis	O
and	O
cyclic	O
GMP	O
synthesis	O
in	O
intact	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
(	O
clone	O
N1E-115	O
)	O
.	O
Neurotensin	O
(8-13)	O
and	O
acetylneurotensin	O
(8-13)	O
had	O
the	O
highest	O
potencies	O
for	O
the	O
stimulation	O
of	O
the	O
hydrolysis	O
of	O
inositol	O
phospholipid	O
,	O
which	O
were	O
about	O
three	O
times	O
as	O
potent	O
as	O
neurotensin	O
(	O
EC50	O
=	O
0.9	O
nM	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
fragments	O
of	O
the	O
amino-terminal	O
portion	O
of	O
neurotensin	O
,	O
such	O
as	O
neurotensin	O
(1-6)	O
,	O
neurotensin	O
(1-8)	O
and	O
neurotensin	O
(1-11)	O
,	O
showed	O
no	O
ability	O
to	O
stimulate	O
this	O
hydrolysis	O
.	O
Neuromedin	O
N	O
,	O
which	O
is	O
similar	O
in	O
structure	O
to	O
neurotensin	O
(8-13)	O
and	O
which	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
cyclic	O
GMP	O
formation	O
[	O
J.A	O
.	O
Gilbert	O
and	O
E.	O
Richelson	O
,	O
Eur	O
.	O
J.	O
Pharmac.	O
129	O
,	O
379	O
(	O
1986	O
)	O
]	O
,	O
had	O
EC50	O
values	O
of	O
2.5	O
and	O
4.5	O
nM	O
for	O
release	O
of	O
[3H]inositol	O
phosphates	O
and	O
stimulation	O
of	O
cyclic	O
[3H]GMP	O
respectively	O
.	O
A	O
strong	O
correlation	O
was	O
obtained	O
between	O
the	O
EC50	O
values	O
for	O
neurotensin	O
and	O
several	O
analogs	O
in	O
the	O
stimulation	O
of	O
the	O
release	O
of	O
inositol	O
phosphates	O
and	O
the	O
EC50	O
values	O
for	O
these	O
peptides	O
in	O
the	O
stimulation	O
of	O
cyclic	O
GMP	O
formation	O
in	O
neuroblastoma	B-malignancy-type
clone	O
N1E-115	O
cells	O
under	O
similar	O
experimental	O
conditions	O
.	O
Thus	O
,	O
these	O
two	O
different	O
biochemical	O
effects	O
of	O
neurotensin	O
and	O
its	O
analogs	O
appear	O
to	O
be	O
mediated	O
by	O
the	O
same	O
receptor	O
site	O
,	O
which	O
may	O
also	O
have	O
been	O
the	O
site	O
of	O
action	O
of	O
neuromedin	O
N	O
in	O
these	O
cells	O
.	O
PMID	O
:	O
3032199	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O

Oncogene	O
.	O
1992	O
Jan	O
;	O
7	O
(	O
1	O
)	O
:	O
127-33	O
.	O
Expression	O
of	O
p53	O
in	O
human	O
neuroblastoma	B-malignancy-type
-	O
and	O
neuroepithelioma	B-malignancy-type
-	O
derived	O
cell	O
lines	O
.	O
Davidoff	O
AM	O
,	O
Pence	O
JC	O
,	O
Shorter	O
NA	O
,	O
Iglehart	O
JD	O
,	O
Marks	O
JR	O
.	O
Department	O
of	O
Surgery	O
,	O
Duke	O
University	O
Medical	O
Center	O
,	O
Durham	O
,	O
North	O
Carolina	O
27710	O
.	O
Overexpression	O
of	O
the	O
nuclear	O
phosphoprotein	O
p53	O
has	O
been	O
detected	O
in	O
many	O
different	O
transformed	O
human	O
cell	O
lines	O
and	O
primary	O
adult	O
tumors	O
.	O
Elevated	O
steady	O
-state	O
levels	O
of	O
p53	O
appear	O
to	O
be	O
the	O
result	O
of	O
an	O
increase	O
in	O
the	O
stability	O
of	O
the	O
protein	O
and	O
,	O
in	O
adult	O
cancers	O
,	O
high	O
levels	O
of	O
the	O
protein	O
are	O
associated	O
with	O
mutation	O
of	O
the	O
p53	O
gene	O
.	O
In	O
this	O
study	O
,	O
overexpression	O
of	O
p53	O
was	O
detected	O
in	O
4	O
out	O
of	O
5	O
human	O
neuroblastoma	B-malignancy-type
-	O
derived	O
cell	O
lines	O
.	O
The	O
protein	O
expressed	O
by	O
each	O
of	O
these	O
four	O
lines	O
had	O
a	O
significantly	O
prolonged	O
half-life	O
relative	O
to	O
the	O
p53	O
protein	O
in	O
immortalized	O
rodent	O
fibroblasts	O
and	O
normal	O
bovine	O
adrenal	O
medullary	O
cells	O
.	O
However	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
highly	O
conserved	O
regions	O
of	O
the	O
p53	O
gene	O
in	O
these	O
four	O
neuroblastoma	B-malignancy-type
lines	O
and	O
the	O
protein	O
being	O
expressed	O
was	O
not	O
recognized	O
by	O
the	O
mutant-specific	O
anti-p53	O
monoclonal	O
antibody	O
,	O
PAb	O
240	O
.	O
Upon	O
retinoic	O
acid-induced	O
differentiation	O
of	O
the	O
LA-N-5	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
the	O
level	O
of	O
p53	O
protein	O
declined	O
,	O
as	O
did	O
the	O
level	O
of	O
p53	O
mRNA	O
,	O
but	O
the	O
half-life	O
of	O
the	O
protein	O
remained	O
unchanged	O
.	O
The	O
high	O
level	O
of	O
protein	O
observed	O
in	O
the	O
undifferentiated	O
cell	O
lines	O
appears	O
to	O
result	O
from	O
expression	O
of	O
a	O
stable	O
wild-type	O
p53	O
protein	O
and	O
increased	O
transcription	O
.	O
In	O
contrast	O
,	O
p53	O
protein	O
was	O
undetectable	O
in	O
two	O
neuroepithelioma	B-malignancy-type
-	O
derived	O
cell	O
lines	O
;	O
the	O
p53	O
gene	O
in	O
one	O
of	O
these	O
lines	O
contained	O
a	O
nonsense	O
mutation	O
,	O
while	O
the	O
other	O
transcribed	O
truncated	O
p53	O
mRNA	O
.	O
PMID	O
:	O
1741160	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Cell	O
Sci	O
.	O
2000	O
Feb	O
;	O
113	O
(	O
Pt	O
4	O
)	O
:	O
611-20	O
.	O
Regulation	O
of	O
cell	O
migration	O
by	O
amphoterin	O
.	O
Fages	O
C	O
,	O
Nolo	O
R	O
,	O
Huttunen	O
HJ	O
,	O
Eskelinen	O
E	O
,	O
Rauvala	O
H	O
.	O
Laboratory	O
of	O
Molecular	O
Neurobiology	O
,	O
Institute	O
of	O
Biotechnology	O
,	O
Division	O
of	O
Biochemistry	O
,	O
Department	O
of	O
Biosciences	O
,	O
Viikinkaari	O
5	O
,	O
FIN	O
-00014	O
University	O
of	O
Helsinki	O
,	O
Finland	O
.	O
Amphoterin	O
,	O
a	O
major	O
form	O
of	O
HMG	O
(	O
high	O
mobility	O
group	O
)	O
1	O
proteins	O
,	O
is	O
highly	O
expressed	O
in	O
immature	O
and	O
malignant	O
cells	O
.	O
A	O
role	O
in	O
cell	O
motility	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
amphoterin	O
to	O
promote	O
neurite	O
extension	O
through	O
RAGE	O
(	O
receptor	O
of	O
advanced	O
glycation	O
end	O
products	O
)	O
,	O
an	O
immunoglobulin	O
superfamily	O
member	O
that	O
communicates	O
with	O
the	O
GTPases	O
Cdc42	O
and	O
Rac	O
.	O
We	O
show	O
here	O
that	O
cell	O
contact	O
with	O
the	O
laminin	O
matrix	O
induces	O
accumulation	O
of	O
both	O
amphoterin	O
mRNA	O
and	O
protein	O
close	O
to	O
the	O
plasma	O
membrane	O
,	O
which	O
is	O
accompanied	O
by	O
extracellular	O
export	O
of	O
amphoterin	O
.	O
A	O
role	O
for	O
amphoterin	O
in	O
extracellular	O
matrix-	O
dependent	O
cell	O
regulation	O
is	O
further	O
suggested	O
by	O
the	O
finding	O
that	O
specific	O
decrease	O
of	O
amphoterin	O
mRNA	O
and	O
protein	O
,	O
using	O
antisense	O
oligonucleotides	O
transfected	O
into	O
cells	O
,	O
inhibits	O
cell	O
migration	O
to	O
laminin	O
in	O
a	O
transfilter	O
assay	O
whereas	O
the	O
oligonucleotides	O
in	O
the	O
culture	O
medium	O
have	O
no	O
effect	O
.	O
Moreover	O
,	O
affinity-purified	O
anti-amphoterin	O
antibodies	O
inhibit	O
cell	O
migration	O
to	O
laminin	O
,	O
supporting	O
an	O
extracellular	O
role	O
for	O
the	O
endogenous	O
amphoterin	O
in	O
cell	O
motility	O
.	O
The	O
finding	O
that	O
amphoterin	O
expression	O
is	O
more	O
pronounced	O
in	O
cells	O
with	O
a	O
motile	O
phenotype	O
as	O
compared	O
to	O
cells	O
of	O
dense	O
cultures	O
,	O
is	O
consistent	O
with	O
the	O
results	O
of	O
the	O
cell	O
migration	O
assays	O
.	O
Our	O
results	O
strongly	O
suggest	O
that	O
amphoterin	O
is	O
a	O
key	O
player	O
in	O
the	O
migration	O
of	O
immature	O
and	O
transformed	O
cells	O
.	O
PMID	O
:	O
10652254	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
J	O
.	O
1990	O
Apr	O
1	O
;	O
267	O
(	O
1	O
)	O
:	O
23-9	O
.	O
Protein	O
kinase	O
C	O
is	O
involved	O
in	O
desensitization	O
of	O
muscarinic	O
receptors	O
induced	O
by	O
phorbol	O
esters	O
but	O
not	O
by	O
receptor	O
agonists	O
.	O
Lai	O
WS	O
,	O
Rogers	O
TB	O
,	O
el-Fakahany	O
EE	O
.	O
Department	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Maryland	O
School	O
of	O
Pharmacy	O
,	O
Baltimore	O
21201	O
.	O
Preincubation	O
with	O
receptor	O
agonists	O
or	O
phorbol	O
esters	O
desensitized	O
muscarinic-receptor	O
-mediated	O
[3H]cyclic	O
GMP	O
responses	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
N1E-115	O
cells	O
.	O
However	O
,	O
desensitization	O
mediated	O
by	O
phorbol	O
esters	O
was	O
heterologous	O
,	O
whereas	O
that	O
effected	O
by	O
receptor	O
agonist	O
was	O
specific	O
towards	O
the	O
muscarinic	O
receptors	O
.	O
In	O
addition	O
,	O
there	O
was	O
no	O
loss	O
of	O
cell	O
surface	O
muscarinic	O
receptors	O
,	O
as	O
measured	O
by	O
the	O
binding	O
of	O
the	O
hydrophilic	O
ligand	O
[3H]N-methylscopolamine	O
,	O
when	O
cells	O
were	O
treated	O
with	O
phorbol	O
esters	O
,	O
but	O
receptor-agonist-induced	O
desensitization	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
surface	O
receptor	O
density	O
.	O
We	O
examined	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
the	O
desensitization	O
of	O
muscarinic	O
receptors	O
by	O
employing	O
a	O
kinase	O
inhibitor	O
and	O
by	O
down-regulation	O
of	O
PKC	O
by	O
long-term	O
incubation	O
of	O
cells	O
with	O
phorbol	O
esters	O
.	O
Whereas	O
these	O
manoeuvres	O
had	O
marked	O
effects	O
on	O
phorbol-ester-induced	O
desensitization	O
of	O
muscarinic	O
responses	O
,	O
they	O
did	O
not	O
block	O
agonist-induced	O
down-regulation	O
and	O
desensitization	O
of	O
muscarinic	O
receptors	O
.	O
In	O
addition	O
,	O
when	O
phosphoinositide	O
hydrolysis	O
was	O
suppressed	O
,	O
the	O
muscarinic	O
agonist	O
was	O
still	O
capable	O
of	O
mediating	O
receptor	O
sequestration	O
and	O
desensitization	O
.	O
These	O
results	O
suggest	O
that	O
the	O
mechanisms	O
for	O
regulating	O
muscarinic	O
receptor	O
sensitivity	O
could	O
be	O
both	O
PKC	O
-dependent	O
and	O
PKC	O
-independent	O
,	O
being	O
mediated	O
by	O
phorbol	O
esters	O
and	O
receptor	O
agonists	O
respectively	O
.	O
PMID	O
:	O
2158308	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Pharmacol	O
.	O
1982	O
Jan	O
15;31(	O
2	O
)	O
:	O
181	O
-	O
8.	O
Participation	O
of	O
active	O
oxygen	O
species	O
in	O
6-hydroxydopamine	O
toxicity	O
to	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Tiffany-Castiglioni	O
E	O
,	O
Saneto	O
RP	O
,	O
Proctor	O
PH	O
,	O
Perez-Polo	O
JR.	O
Catalase	O
,	O
superoxide	O
dismutase	O
,	O
and	O
dimethylsulfoxide	O
were	O
tested	O
for	O
their	O
ability	O
to	O
prevent	O
the	O
cytotoxic	O
effect	O
of	O
6-hydroxydopamine	O
(	O
6-OHDA	O
)	O
on	O
the	O
human	O
neuroblastoma	B-malignancy-type
line	O
SY5Y	O
.	O
Viability	O
was	O
measured	O
at	O
two	O
time	O
points	O
after	O
6-OHDA	O
treatment	O
:	O
at	O
3	O
hr	O
by	O
means	O
of	O
amino	O
acid	O
incorporation	O
and	O
at	O
24	O
hr	O
by	O
trypan	O
blue	O
dye	O
exclusion	O
.	O
Survival	O
of	O
cells	O
treated	O
concomitantly	O
with	O
catalase	O
(	O
50	O
microgram	O
/	O
ml	O
)	O
and	O
6-OHDA	O
was	O
at	O
least	O
90	O
per	O
cent	O
that	O
of	O
untreated	O
controls	O
.	O
Cells	O
receiving	O
6-OHDA	O
alone	O
showed	O
less	O
than	O
30	O
per	O
cent	O
survival	O
relative	O
to	O
untreated	O
controls	O
.	O
Superoxide	O
dismutase	O
(	O
50	O
microgram	O
/	O
ml	O
)	O
temporarily	O
protected	O
cells	O
from	O
a	O
high	O
concentration	O
of	O
60	O
-OHDA	O
.	O
Dimethylsulfoxide	O
treatment	O
increased	O
survival	O
from	O
the	O
control	O
level	O
24	O
hr	O
after	O
treatment	O
with	O
6-OHDA	O
.	O
Two	O
other	O
cell	O
lines	O
(	O
A1B1	O
human	O
glial	O
cells	O
and	O
CHO	O
fibroblasts	O
)	O
had	O
intermediate	O
and	O
high	O
resistance	O
to	O
the	O
drug	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
low	O
resistance	O
of	O
SY5Y	O
cells	O
.	O
CHO	O
and	O
SY5Y	O
cells	O
had	O
similar	O
responses	O
to	O
6-OHDA	O
and	O
to	O
H2O2	O
when	O
tested	O
at	O
twice	O
the	O
molarity	O
of	O
6-OHDA	O
.	O
Specific	O
activities	O
of	O
three	O
enzymes	O
known	O
to	O
detoxify	O
H2O2	O
or	O
H2O2-	O
generated	O
organic	O
hydroperoxides	O
(	O
catalase	O
,	O
glutathione	O
S-	O
transferase	O
,	O
and	O
glutathione	O
peroxidase	O
)	O
were	O
compared	O
in	O
the	O
three	O
cell	O
lines	O
.	O
Catalase	O
activity	O
was	O
2.5	O
times	O
as	O
high	O
as	O
in	O
A1B1	O
and	O
CHO	O
cells	O
as	O
in	O
SY5Y	O
cells	O
when	O
expressed	O
as	O
units	O
/	O
mg	O
protein	O
and	O
7	O
times	O
as	O
high	O
in	O
units	O
/	O
culture	O
dish	O
.	O
Other	O
enzyme	O
activities	O
showed	O
no	O
correlation	O
to	O
6-OHDA	O
resistance	O
.	O
PMID	O
:	O
7059360	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biol	O
Chem	O
.	O
2000	O
May-Jun;381	O
(	O
5-	O
6	O
)	O
:463	O
-	O
9.	O
Cationic	O
lipopolyamines	O
induce	O
degradation	O
of	O
PrPSc	O
in	O
scrapie	O
-	O
infected	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Winklhofer	O
KF	O
,	O
Tatzelt	O
J.	O
Abteilung	O
Zellulare	O
Biochemie	O
,	O
Max-Planck	O
-	O
Institut	O
fur	O
Biochemie	O
,	O
Martinsried	O
,	O
Germany	O
.	O
In	O
prion	O
diseases	O
the	O
endogenous	O
prion	O
protein	O
(	O
PrPC	O
)	O
is	O
converted	O
into	O
an	O
abnormally	O
folded	O
isoform	O
,	O
denoted	O
PrPSc	O
,	O
which	O
represents	O
the	O
major	O
component	O
of	O
infectious	O
scrapie	O
prions	O
.	O
The	O
mechanism	O
of	O
the	O
conversion	O
is	O
largely	O
unknown	O
,	O
but	O
the	O
conversion	O
is	O
thought	O
to	O
occur	O
after	O
PrPC	O
has	O
reached	O
the	O
plasma	O
membrane	O
.	O
Here	O
we	O
show	O
that	O
exogenous	O
administration	O
of	O
the	O
cationic	O
lipopolyamine	O
DOSPA	O
interfered	O
with	O
the	O
accumulation	O
of	O
PrPSc	O
in	O
scrapie	O
-	O
infected	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Structural	O
analysis	O
of	O
the	O
compounds	O
tested	O
revealed	O
that	O
inhibition	O
of	O
PrPSc	O
was	O
specific	O
for	O
lipids	O
with	O
a	O
headgroup	O
composed	O
of	O
the	O
polyamine	O
spermine	O
and	O
a	O
quarternary	O
ammonium	O
ion	O
between	O
the	O
headgroup	O
and	O
the	O
lipophilic	O
tail	O
.	O
The	O
cationic	O
lipopolyamine	O
DOSPA	O
induced	O
the	O
cellular	O
degradation	O
of	O
preexisting	O
PrPSc	O
aggregates	O
within	O
12	O
hours	O
and	O
interfered	O
with	O
the	O
de	O
novo	O
synthesis	O
of	O
PrPSc	O
.	O
Biosynthesis	O
of	O
PrPC	O
,	O
or	O
the	O
assembly	O
of	O
sphingolipid	O
-	O
cholesterol	O
microdomains	O
(	O
rafts	O
)	O
on	O
the	O
plasma	O
membrane	O
,	O
were	O
not	O
affected	O
by	O
this	O
inhibitor	O
.	O
After	O
removal	O
of	O
DOSPA	O
and	O
replating	O
into	O
normal	O
medium	O
propagation	O
of	O
PrPSc	O
commenced	O
,	O
although	O
initially	O
at	O
a	O
reduced	O
rate	O
.	O
Incubation	O
of	O
ScN2a	O
cells	O
in	O
free	O
spermidine	O
had	O
no	O
inhibitory	O
effect	O
on	O
the	O
accumulation	O
of	O
PrPSc	O
.	O
Our	O
results	O
indicate	O
that	O
membrane	O
targeting	O
of	O
a	O
small	O
polyamine	O
molecule	O
creates	O
a	O
potent	O
inhibitor	O
of	O
PrPSc	O
propagation	O
and	O
offers	O
the	O
possibility	O
to	O
degrade	O
preexisting	O
PrPSc	O
aggregates	O
in	O
living	O
cells	O
.	O
PMID	O
:	O
10937879	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Nov	O
1;277	O
(	O
44	O
)	O
:	O
42144	O
-50	O
.	O
Epub	O
2002	O
Aug	O
26	O
.	O
Constitutively	O
active	O
NFkappa	O
B	O
is	O
required	O
for	O
the	O
survival	O
of	O
S	O
-	O
type	O
neuroblastoma	B-malignancy-type
.	O
Bian	O
X	O
,	O
Opipari	O
AW	O
Jr	O
,	O
Ratanaproeksa	O
AB	O
,	O
Boitano	O
AE	O
,	O
Lucas	O
PC	O
,	O
Castle	O
VP	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Michigan	O
,	O
Ann	O
Arbor	O
48109	O
,	O
USA	O
.	O
The	O
NFkappaB	O
transcription	O
factors	O
can	O
both	O
promote	O
cell	O
survival	O
and	O
induce	O
apoptosis	O
depending	O
on	O
cell	O
type	O
and	O
context	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cells	O
display	O
two	O
predominant	O
culture	O
phenotypes	O
identified	O
as	O
N	O
-	O
and	O
S	O
-	O
types	O
.	O
Malignant	O
S	O
-	O
type	O
cells	O
express	O
neither	O
high	O
levels	O
of	O
MYCN	O
nor	O
Bcl	O
-	O
2	O
,	O
suggesting	O
that	O
other	O
survival	O
mechanisms	O
are	O
important	O
.	O
We	O
characterized	O
NFkappaB	O
activity	O
in	O
S	O
-	O
type	O
cells	O
and	O
determined	O
its	O
role	O
in	O
their	O
survival	O
.	O
S	O
-	O
type	O
lines	O
(	O
SH	O
-	O
EP1	O
and	O
SK	O
-	O
N	O
-	O
AS	O
)	O
were	O
treated	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
a	O
NFkappaB	O
inhibitor	O
,	O
or	O
l	O
-	O
1	O
-	O
tosylamido	O
-	O
2	O
-	O
phenylethyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
,	O
a	O
serine	O
protease	O
inhibitor	O
that	O
blocks	O
IkappaBalpha	O
degradation	O
.	O
Both	O
agents	O
induced	O
cell	O
death	O
,	O
suggesting	O
that	O
constitutive	O
NFkappaB	O
activity	O
is	O
required	O
for	O
survival	O
.	O
The	O
transient	O
expression	O
of	O
a	O
super	O
-	O
repressor	O
IkappaBalpha	O
mutant	O
killed	O
S	O
-	O
type	O
cells	O
.	O
The	O
inhibition	O
of	O
NFkappaB	O
produced	O
an	O
apoptotic	O
response	O
characterized	O
by	O
the	O
collapse	O
of	O
the	O
mitochondrial	O
transmembrane	O
electrochemical	O
gradient	O
,	O
caspase	O
-	O
9	O
activation	O
,	O
and	O
apoptotic	O
DNA	O
changes	O
.	O
Constitutive	O
NFkappaB	O
DNA	O
binding	O
activity	O
specifically	O
involving	O
p65	O
and	O
p50	O
was	O
demonstrated	O
in	O
S	O
-	O
but	O
not	O
N	O
-	O
type	O
cells	O
by	O
electromobility	O
supershift	O
and	O
gene	O
reporter	O
assays	O
.	O
This	O
study	O
demonstrates	O
a	O
role	O
for	O
NFkappaB	O
in	O
the	O
survival	O
of	O
S	O
-	O
type	O
NB	B-malignancy-type
tumor	I-malignancy-type
cells	O
and	O
suggests	O
that	O
NFkappaB	O
activity	O
and	O
function	O
differ	O
according	O
to	O
NB	B-malignancy-type
tumor	I-malignancy-type
cell	O
phenotype	O
.	O
PMID	O
:	O
12198114	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2004	O
Jan	O
22	O
;23(	O
3	O
)	O
:753	O
-	O
62	O
.	O
MYCN	O
-	O
mediated	O
regulation	O
of	O
the	O
MRP1	O
promoter	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Manohar	O
CF	O
,	O
Bray	O
JA	O
,	O
Salwen	O
HR	O
,	O
Madafiglio	O
J,	O
Cheng	O
A	O
,	O
Flemming	O
C	O
,	O
Marshall	O
GM	O
,	O
Norris	O
MD	O
,	O
Haber	O
M,	O
Cohn	O
SL	O
.	O
The	O
Robert	O
H	O
Lurie	O
Comprehensive	O
Cancer	O
Center	O
,	O
Northwestern	O
University	O
's	O
Feinberg	O
School	O
of	O
Medicine	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
.	O
In	O
the	O
childhood	O
cancer	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
,	O
the	O
level	O
of	O
expression	O
of	O
the	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
(	O
MRP1	O
)	O
gene	O
is	O
strongly	O
correlated	O
with	O
expression	O
of	O
the	O
MYCN	O
oncogene	O
in	O
primary	O
NB	B-malignancy-type
tumors	I-malignancy-type
,	O
suggesting	O
that	O
MRP1	O
may	O
be	O
a	O
target	O
for	O
MYCN	O
-	O
mediated	O
gene	O
regulation	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
MYCN	O
induction	O
in	O
human	O
NB	B-malignancy-type
cells	O
results	O
in	O
increased	O
MRP1	O
mRNA	O
and	O
protein	O
levels	O
,	O
which	O
in	O
turn	O
is	O
accompanied	O
by	O
increased	O
drug	O
resistance	O
and	O
enhanced	O
MRP1	O
-	O
mediated	O
drug	O
efflux	O
.	O
Furthermore	O
,	O
luciferase	O
activity	O
from	O
MRP1	O
promoter	O
/	O
luciferase	O
gene	O
reporter	O
constructs	O
was	O
significantly	O
increased	O
in	O
NB	B-malignancy-type
cells	O
with	O
exogenous	O
overexpression	O
of	O
MYCN	O
,	O
whereas	O
activity	O
was	O
decreased	O
in	O
NB	B-malignancy-type
cells	O
stably	O
transfected	O
with	O
MYCN	O
-	O
antisense	O
vectors	O
.	O
Decreased	O
luciferase	O
activity	O
was	O
observed	O
with	O
promoter	O
constructs	O
that	O
lacked	O
one	O
or	O
two	O
E	O
-	O
box	O
sequences	O
or	O
had	O
E	O
-	O
box	O
double	O
point	O
mutations	O
,	O
while	O
a	O
truncated	O
MRP1	O
promoter	O
lacking	O
all	O
three	O
E	O
-	O
boxes	O
exhibited	O
only	O
basal	O
levels	O
of	O
activity	O
.	O
Specific	O
electrophoretic	O
mobility	O
shifts	O
of	O
MRP1	O
E	O
-	O
box	O
sequences	O
were	O
detected	O
with	O
nuclear	O
extracts	O
from	O
NB	B-malignancy-type
cells	O
with	O
MYCN	O
overexpression	O
,	O
and	O
complex	O
formation	O
was	O
inhibited	O
with	O
the	O
addition	O
of	O
antibodies	O
directed	O
against	O
MYCN	O
or	O
MYC	O
.	O
These	O
findings	O
indicate	O
that	O
by	O
interacting	O
with	O
E	O
-	O
box	O
elements	O
within	O
the	O
promoter	O
,	O
MYCN	O
can	O
upregulate	O
MRP1	O
expression	O
and	O
modulate	O
drug	O
resistance	O
in	O
NB	B-malignancy-type
.	O
PMID	O
:	O
14737110	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Hum	O
Genet	O
.	O
2003	O
Oct;113(	O
5	O
)	O
:	O
426-31	O
.	O
Epub	O
2003	O
Aug	O
16	O
.	O
Functional	O
analysis	O
of	O
intra	O
-	O
allelic	O
variation	O
at	O
NACP	O
-	O
Rep1	O
in	O
the	O
alpha	O
-	O
synuclein	O
gene	O
.	O
Chiba-Falek	O
O	O
,	O
Touchman	O
JW	O
,	O
Nussbaum	O
RL	O
.	O
Genetic	O
Disease	O
Research	O
Branch	O
,	O
National	O
Human	O
Genome	O
Research	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
49	O
Convent	O
Drive	O
MSC	O
4472	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
-4472	O
,	O
USA	O
.	O
NACP	O
-	O
Rep1	O
,	O
a	O
polymorphic	O
microsatellite	O
upstream	O
of	O
the	O
alpha	O
-	O
synuclein	O
gene	O
(	O
SNCA	O
)	O
,	O
consisting	O
of	O
the	O
nucleotides	O
(	O
TC	O
)	O
(	O
x	O
)	O
(	O
T	O
)	O
(	O
2	O
)	O
(	O
TC	O
)	O
(	O
y	O
)	O
(	O
TA	O
)	O
(	O
z	O
)	O
(	O
CA	O
)	O
(	O
w	O
)	O
,	O
has	O
five	O
alleles	O
originally	O
defined	O
by	O
2	O
-	O
bp	O
differences	O
in	O
(	O
CA	O
)	O
(	O
w	O
)	O
.	O
Different	O
NACP	O
-	O
Rep1	O
alleles	O
have	O
been	O
associated	O
with	O
sporadic	O
Parkinson	O
'	O
s	O
disease	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
and	O
can	O
effect	O
expression	O
driven	O
by	O
the	O
SNCA	O
promoter	O
over	O
a	O
three	O
-	O
fold	O
range	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SH	O
-	O
SY5Y	O
.	O
By	O
analyzing	O
children	O
in	O
CEPH	O
families	O
in	O
which	O
parents	O
appeared	O
to	O
be	O
homozygous	O
for	O
a	O
NACP	O
-	O
Rep1	O
allele	O
,	O
we	O
found	O
that	O
there	O
are	O
sequence	O
differences	O
within	O
same	O
-	O
sized	O
NACP	O
-	O
Rep1	O
alleles	O
,	O
contributed	O
mainly	O
by	O
variation	O
of	O
the	O
(	O
TC	O
)	O
(	O
y	O
)	O
(	O
TA	O
)	O
(	O
z	O
)	O
portion	O
of	O
the	O
microsatellite	O
repeat	O
.	O
To	O
test	O
whether	O
these	O
sequence	O
differences	O
might	O
impact	O
on	O
promoter	O
function	O
we	O
determined	O
the	O
effect	O
of	O
two	O
sequence	O
variant	O
alleles	O
,	O
both	O
of	O
size	O
"	O
1	O
"	O
,	O
using	O
the	O
luciferase	O
reporter	O
system	O
.	O
There	O
was	O
only	O
a	O
very	O
small	O
expression	O
difference	O
between	O
these	O
two	O
variant	O
alleles	O
.	O
This	O
finding	O
implies	O
that	O
the	O
overall	O
length	O
of	O
the	O
NACP	O
-	O
Rep1	O
allele	O
plays	O
the	O
main	O
role	O
in	O
the	O
transcription	O
regulation	O
by	O
the	O
NACP	O
-	O
Rep1	O
element	O
and	O
suggests	O
that	O
functional	O
differences	O
due	O
to	O
sequence	O
heterogeneity	O
within	O
NACP	O
-	O
Rep1	O
alleles	O
of	O
the	O
same	O
length	O
are	O
probably	O
not	O
confounding	O
factors	O
in	O
association	O
studies	O
based	O
on	O
alleles	O
defined	O
by	O
length	O
.	O
PMID	O
:	O
12923682	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
.	O
2000	O
Aug;	O
6	O
(	O
8	O
)	O
:3199	O
-	O
204	O
.	O
Enhanced	O
expression	O
of	O
N	O
-	O
myc	O
messenger	O
RNA	O
in	O
neuroblastomas	B-malignancy-type
found	O
by	O
mass	O
screening	O
.	O
Matsunaga	O
T	O
,	O
Shirasawa	O
H,	O
Hishiki	O
T	O
,	O
Yoshida	O
H,	O
Kouchi	O
K,	O
Ohtsuka	O
Y	O
,	O
Kawamura	O
K,	O
Etoh	O
T	O
,	O
Ohnuma	O
N	O
.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Chiba	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
mtng@ho.chiba-u.ac.jp	O
A	O
substantial	O
fraction	O
of	O
neuroblastomas	B-malignancy-type
found	O
by	O
mass	O
screening	O
have	O
been	O
suggested	O
to	O
regress	O
spontaneously	O
because	O
of	O
the	O
high	O
incidence	O
of	O
infantile	O
neuroblastomas	B-malignancy-type
in	O
the	O
screening	O
population	O
.	O
In	O
this	O
study	O
,	O
70	O
neuroblastomas	B-malignancy-type
were	O
analyzed	O
for	O
expression	O
of	O
proto	O
-	O
oncogenes	O
related	O
to	O
neuronal	O
differentiation	O
to	O
clarify	O
the	O
biological	O
significance	O
of	O
proto	O
-	O
oncogene	O
expression	O
in	O
the	O
screening	O
-	O
positive	O
and	O
-	O
negative	O
tumors	O
.	O
The	O
tumors	O
consisted	O
of	O
39	O
neuroblastomas	B-malignancy-type
found	O
by	O
screening	O
(	O
group	O
1	O
)	O
,	O
16	O
non	O
-	O
N	O
-	O
myc	O
-	O
amplified	O
neuroblastomas	B-malignancy-type
found	O
by	O
clinical	O
symptom(s)	O
(	O
group	O
2	O
)	O
,	O
and	O
15	O
N	O
-	O
myc	O
-	O
amplified	O
neuroblastomas	B-malignancy-type
found	O
by	O
clinical	O
symptom(s)	O
(	O
group	O
3	O
)	O
.	O
The	O
expression	O
of	O
c	O
-	O
src	O
,	O
trk	O
A	O
,	O
and	O
N	O
-	O
myc	O
in	O
tumor	O
tissues	O
was	O
analyzed	O
by	O
quantitative	O
RNA	O
PCR	O
.	O
Neuronal	O
c	O
-	O
srcN2	O
expression	O
varied	O
significantly	O
in	O
the	O
following	O
order	O
:	O
group	O
1	O
>	O
group	O
2	O
>	O
group	O
3	O
.	O
The	O
level	O
of	O
expression	O
of	O
trk	O
A	O
was	O
markedly	O
reduced	O
in	O
group	O
3	O
but	O
did	O
not	O
differ	O
in	O
groups	O
1	O
and	O
2	O
.	O
Most	O
tumors	O
in	O
group	O
3	O
overexpressed	O
N	O
-	O
myc	O
.	O
However	O
,	O
N	O
-	O
myc	O
expression	O
in	O
group	O
1	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
group	O
2	O
.	O
Thus	O
,	O
the	O
characteristics	O
of	O
proto	O
-	O
oncogene	O
expression	O
in	O
screening	O
-	O
positive	O
tumors	O
included	O
enhanced	O
expression	O
of	O
c	O
-	O
srcN2	O
and	O
N	O
-	O
myc	O
mRNA	O
,	O
regardless	O
of	O
nonamplification	O
of	O
N	O
-	O
myc	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
role	O
of	O
N	O
-	O
myc	O
differs	O
in	O
neuroblastomas	B-malignancy-type
detected	O
by	O
screening	O
and	O
in	O
N	O
-	O
myc	O
-	O
amplified	O
tumors	O
.	O
PMID	O
:	O
10955804	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Electrophoresis	O
.	O
2003	O
Jan;2	O
4(	O
1-2	O
)	O
:	O
260	O
-	O
75	O
.	O
The	O
mitochondrial	O
proteins	O
of	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
IMR	O
-	O
32	O
.	O
Fountoulakis	O
M,	O
Schlaeger	O
EJ.	O
Center	O
for	O
Medical	O
Genomics	O
,	O
F.	O
Hoffmann	O
-	O
La	O
Roche	O
Ltd.	O
,	O
Pharmaceutical	O
Research	O
,	O
Basel	O
,	O
Switzerland	O
.	O
michael	O
.fountoulakis@roche.com	O
Mitochondrial	O
proteins	O
exert	O
important	O
functions	O
in	O
biological	O
pathways	O
,	O
particularly	O
they	O
are	O
involved	O
in	O
apoptotic	O
processes	O
.	O
We	O
applied	O
proteomics	O
technologies	O
to	O
analyze	O
the	O
mitochondrial	O
proteins	O
of	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
IMR	O
-	O
32	O
,	O
which	O
is	O
often	O
used	O
in	O
apoptosis	O
studies	O
.	O
The	O
proteins	O
were	O
analyzed	O
by	O
two	O
-	O
dimensional	O
(	O
2	O
-	O
D	O
)	O
electrophoresis	O
followed	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
-	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
MS	O
)	O
.	O
185	O
different	O
gene	O
products	O
were	O
identified	O
,	O
of	O
which	O
approximately	O
55	O
%	O
were	O
enzymes	O
with	O
a	O
broad	O
spectrum	O
of	O
catalytic	O
activities	O
.	O
Sixteen	O
proteins	O
were	O
detected	O
only	O
in	O
this	O
preparation	O
,	O
the	O
others	O
have	O
been	O
detected	O
in	O
two	O
or	O
more	O
protein	O
samples	O
analyzed	O
by	O
MS	O
in	O
our	O
laboratory	O
.	O
The	O
16	O
unique	O
gene	O
products	O
were	O
represented	O
by	O
one	O
spot	O
each	O
,	O
whereas	O
most	O
of	O
the	O
frequently	O
detected	O
proteins	O
were	O
represented	O
by	O
multiple	O
spots	O
.	O
In	O
average	O
,	O
approximately	O
5	O
-	O
10	O
spots	O
corresponded	O
to	O
one	O
gene	O
product	O
.	O
For	O
two	O
thirds	O
of	O
the	O
proteins	O
identified	O
,	O
an	O
annotation	O
exists	O
in	O
the	O
SWISS	O
-	O
PROT	O
database	O
about	O
their	O
subcellular	O
location	O
.	O
They	O
are	O
mainly	O
described	O
as	O
mitochondrial	O
,	O
8	O
as	O
endoplasmic	O
reticulum	O
,	O
3	O
as	O
peroxisomal	O
and	O
only	O
12	O
low	O
-	O
abundance	O
proteins	O
are	O
described	O
as	O
cytosolic	O
proteins	O
.	O
The	O
list	O
includes	O
about	O
30	O
unknown	O
,	O
hypothetical	O
or	O
poorly	O
described	O
gene	O
products	O
.	O
Some	O
of	O
them	O
are	O
represented	O
by	O
strong	O
spots	O
and	O
the	O
present	O
study	O
shows	O
that	O
they	O
are	O
indeed	O
expressed	O
and	O
are	O
localized	O
in	O
the	O
mitochondria	O
.	O
PMID	O
:	O
12652598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Neurosci	O
.	O
2003	O
Aug;18	O
(	O
4	O
)	O
:	O
829-40	O
.	O
GRP94	O
(	O
94	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
)	O
suppresses	O
ischemic	O
neuronal	O
cell	O
death	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O
Bando	O
Y	O
,	O
Katayama	O
T	O
,	O
Kasai	O
K,	O
Taniguchi	O
M,	O
Tamatani	O
M,	O
Tohyama	O
M.	O
Department	O
of	O
Anatomy	O
and	O
Neuroscience	O
,	O
Osaka	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Osaka	O
,	O
Japan	O
.	O
ybando@asahikawa-med	O
.ac.jp	O
The	O
94	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP94	O
)	O
,	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
resident	O
molecular	O
chaperone	O
,	O
has	O
a	O
role	O
in	O
cell	O
death	O
due	O
to	O
endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
stress	O
)	O
.	O
Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
GRP94	O
was	O
increased	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
SH	O
-	O
SY5Y	O
(	O
SY5Y	O
)	O
cells	O
)	O
exposed	O
to	O
hypoxia	O
/	O
reoxygenation	O
(	O
H	O
/	O
R	O
)	O
.	O
H	O
/	O
R	O
mediated	O
death	O
of	O
SY5Y	O
cells	O
was	O
associated	O
with	O
the	O
activation	O
of	O
major	O
cysteine	O
proteases	O
,	O
caspase	O
-	O
3	O
and	O
calpain	O
,	O
along	O
with	O
an	O
elevated	O
intracellular	O
calcium	O
concentration	O
.	O
Pretreatment	O
with	O
adenovirus	O
-	O
mediated	O
antisense	O
GRP94	O
(	O
AdGRP94AS	O
)	O
led	O
to	O
reduced	O
viability	O
of	O
SY5Y	O
cells	O
after	O
being	O
subjected	O
to	O
H	O
/	O
R	O
compared	O
with	O
wild	O
-	O
type	O
cells	O
or	O
cells	O
with	O
adenovirus	O
-	O
mediated	O
overexpression	O
of	O
GRP94	O
(	O
AdGRP94S	O
)	O
.	O
These	O
results	O
indicate	O
that	O
suppression	O
of	O
GRP94	O
is	O
associated	O
with	O
accelerated	O
apoptosis	O
and	O
that	O
expression	O
of	O
GRP94	O
(	O
as	O
a	O
stress	O
protein	O
)	O
suppresses	O
oxidative	O
stress	O
-	O
mediated	O
neuronal	O
death	O
and	O
stabilizes	O
calcium	O
homeostasis	O
in	O
the	O
ER	O
.	O
We	O
also	O
used	O
gerbils	O
with	O
transient	O
forebrain	O
ischemia	O
to	O
study	O
the	O
role	O
of	O
GRP94	O
in	O
vivo	O
.	O
Neurons	O
with	O
adenovirus	O
-	O
mediated	O
overexpression	O
of	O
GRP94	O
were	O
resistant	O
to	O
ischemic	O
damage	O
.	O
These	O
results	O
confirmed	O
that	O
GRP94	O
could	O
suppress	O
ischemic	O
injury	O
to	O
neurons	O
,	O
suggesting	O
that	O
gene	O
transfer	O
of	O
GRP94	O
into	O
the	O
brain	O
may	O
have	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
cerebrovascular	O
disease	O
.	O
PMID	O
:	O
12925009	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Growth	O
Differ	O
.	O
1990	O
Feb;1(	O
2	O
)	O
:	O
79	O
-	O
85	O
.	O
Nerve	O
growth	O
factor	O
-	O
induced	O
differentiation	O
of	O
human	O
neuroblastoma	B-malignancy-type
and	O
neuroepithelioma	B-malignancy-type
cell	O
lines	O
.	O
Chen	O
J,	O
Chattopadhyay	O
B	O
,	O
Venkatakrishnan	O
G	O
,	O
Ross	O
AH	O
.	O
Worcester	O
Foundation	O
for	O
Experimental	O
Biology	O
,	O
Shrewsbury	O
,	O
Massachusetts	O
01545	O
.	O
A	O
series	O
of	O
neuroepithelioma	B-malignancy-type
and	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
were	O
screened	O
for	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
induced	O
differentiation	O
.	O
All	O
three	O
neuroepithelioma	B-malignancy-type
cell	O
lines	O
and	O
all	O
nine	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
amplified	O
N	O
-	O
myc	O
oncogene	O
did	O
not	O
show	O
any	O
apparent	O
NGF	O
-	O
induced	O
differentiation	O
.	O
However	O
,	O
neurite	O
extension	O
was	O
observed	O
for	O
three	O
of	O
six	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
single	O
-	O
copy	O
N	O
-	O
myc	O
oncogene	O
.	O
The	O
three	O
responsive	O
lines	O
had	O
a	O
neuronal	O
phenotype	O
(	O
short	O
processes	O
)	O
which	O
was	O
enhanced	O
by	O
the	O
addition	O
of	O
NGF	O
.	O
The	O
three	O
nonresponsive	O
cell	O
lines	O
were	O
flat	O
without	O
any	O
processes	O
.	O
The	O
addition	O
of	O
NGF	O
to	O
the	O
responsive	O
cell	O
lines	O
resulted	O
in	O
an	O
up	O
-	O
regulation	O
of	O
neurofilament	O
mRNA	O
expression	O
.	O
Peripherin	O
and	O
synapsin	O
,	O
two	O
markers	O
of	O
terminal	O
neuronal	O
differentiation	O
,	O
were	O
not	O
induced	O
.	O
There	O
was	O
little	O
effect	O
of	O
NGF	O
on	O
the	O
rate	O
of	O
cell	O
growth	O
or	O
colony	O
formation	O
on	O
soft	O
agar	O
.	O
Binding	O
of	O
NGF	O
to	O
eight	O
of	O
the	O
cell	O
lines	O
was	O
analyzed	O
by	O
the	O
method	O
of	O
Scatchard	O
.	O
Two	O
responsive	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
one	O
nonresponsive	O
neuroepithelioma	B-malignancy-type
cell	O
line	O
expressed	O
both	O
low	O
-	O
and	O
high	O
-	O
affinity	O
binding	O
sites	O
.	O
Two	O
nonresponsive	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
expressed	O
only	O
a	O
small	O
number	O
of	O
high	O
-	O
affinity	O
binding	O
sites	O
,	O
and	O
two	O
other	O
nonresponsive	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
did	O
not	O
detectably	O
bind	O
NGF	O
.	O
Hence	O
,	O
NGF	O
-	O
induced	O
differentiation	O
is	O
confined	O
to	O
a	O
particular	O
class	O
of	O
neural	O
-	O
related	O
tumors	O
,	O
and	O
,	O
even	O
for	O
these	O
cell	O
lines	O
,	O
differentiation	O
is	O
incomplete	O
.	O
PMID	O
:	O
1964795	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Pharmacol	O
.	O
1994	O
Jul	O
15	O
;268(	O
2	O
)	O
:169	O
-	O
76	O
.	O
Distinct	O
induction	O
of	O
c	O
-	O
fos	O
mRNA	O
in	O
NG108	O
-	O
15	O
cells	O
transfected	O
with	O
muscarinic	O
m1	O
and	O
m3	O
receptors	O
.	O
Tohda	O
M,	O
Tohda	O
C	O
,	O
Sakuma	O
S	O
,	O
Higashida	O
H,	O
Nomura	O
Y	O
.	O
Department	O
of	O
Pharmacology	O
,	O
Faculty	O
of	O
Pharmaceutical	O
Sciences	O
,	O
Hokkaido	O
University	O
,	O
Sapporo	O
,	O
Japan	O
.	O
The	O
differences	O
of	O
intracellular	O
signalling	O
mechanisms	O
between	O
muscarinic	O
acetylcholine	O
m1	O
and	O
m3	O
receptors	O
,	O
which	O
are	O
coupled	O
with	O
polyphosphoinositide	O
turnover	O
,	O
were	O
examined	O
by	O
using	O
m1	O
-	O
and	O
m3	O
-	O
transfected	O
NG108	O
-	O
15	O
cells	O
.	O
The	O
c	O
-	O
fos	O
mRNA	O
was	O
induced	O
by	O
1	O
mM	O
acetylcholine	O
peak	O
at	O
60	O
min	O
in	O
both	O
m1	O
and	O
m3	O
cells	O
.	O
The	O
c	O
-	O
fos	O
induction	O
in	O
m1	O
cells	O
was	O
inhibited	O
by	O
1	O
,	O
2	O
-	O
bis	O
(	O
2	O
-	O
aminophenoxy	O
)	O
ethane	O
-	O
N	O
,	O
N	O
,	O
N'	O
,	O
N'	O
-	O
tetraacetic	O
acid	O
tetraacetoxymethyl	O
ester	O
(	O
BAPTA	O
-	O
AM	O
)	O
and	O
N	O
-	O
(	O
6	O
-	O
aminohexyl	O
)	O
-	O
5	O
-	O
chloro	O
-	O
1	O
-	O
naphthalenesulfonamide	O
hydrochloride	O
(	O
W	O
-	O
7	O
)	O
,	O
but	O
was	O
not	O
inhibited	O
by	O
prolonged	O
treatment	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
suggesting	O
that	O
intracellular	O
Ca2	O
+	O
and	O
calmodulin	O
are	O
involved	O
in	O
the	O
induction	O
.	O
The	O
c	O
-	O
fos	O
induction	O
in	O
m3	O
cells	O
was	O
inhibited	O
by	O
BAPTA	O
-	O
AM	O
and	O
prolonged	O
treatment	O
with	O
TPA	O
,	O
but	O
was	O
not	O
influenced	O
by	O
W	O
-	O
7	O
,	O
suggesting	O
that	O
protein	O
kinase	O
C	O
is	O
mainly	O
involved	O
in	O
m3	O
-	O
induced	O
c	O
-	O
fos	O
expression	O
.	O
Acetylcholine	O
induced	O
an	O
increase	O
in	O
inositol	O
phosphates	O
and	O
a	O
transient	O
increase	O
in	O
the	O
intracellular	O
concentration	O
of	O
Ca2	O
+	O
in	O
both	O
m1	O
and	O
m3	O
cells	O
.	O
Sustained	O
stimulation	O
of	O
acetylcholine	O
strongly	O
increased	O
the	O
inositol	O
monophosphate	O
content	O
in	O
m3	O
cells	O
,	O
but	O
that	O
of	O
inositol	O
trisphosphate	O
and	O
inositol	O
diphosphate	O
in	O
m1	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
difference	O
between	O
m1	O
-	O
and	O
m3	O
-	O
induced	O
c	O
-	O
fos	O
mRNA	O
induction	O
mechanisms	O
is	O
due	O
to	O
the	O
difference	O
in	O
respective	O
properties	O
in	O
polyphosphoinositide	O
turnover	O
.	O
PMID	O
:	O
7957639	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2001	O
Mar	O
15	O
;20(	O
11	O
)	O
:	O
1307	O
-17	O
.	O
Evidence	O
that	O
wild	O
-	O
type	O
p53	O
in	O
neuroblastoma	B-malignancy-type
cells	O
is	O
in	O
a	O
conformation	O
refractory	O
to	O
integration	O
into	O
the	O
transcriptional	O
complex	O
.	O
Wolff	O
A	O
,	O
Technau	O
A	O
,	O
Ihling	O
C	O
,	O
Technau-Ihling	O
K,	O
Erber	O
R	O
,	O
Bosch	O
FX	O
,	O
Brandner	O
G.	O
Department	O
of	O
Virology	O
,	O
Institute	O
for	O
Medical	O
Microbiology	O
and	O
Hygiene	O
,	O
University	O
of	O
Freiburg	O
,	O
Hermann-Herder-Str	O
.	O
11	O
,	O
D	O
-	O
79104	O
Freiburg	O
i	O
.	O
Br	O
,	O
Germany	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cells	O
reportedly	O
accumulate	O
wild	O
-	O
type	O
p53	O
exclusively	O
in	O
the	O
cytoplasm	O
.	O
However	O
,	O
immunofluorescence	O
assays	O
with	O
five	O
different	O
antibodies	O
showed	O
that	O
p53	O
accumulates	O
in	O
the	O
nucleus	O
of	O
up	O
to	O
10	O
%	O
of	O
NB	B-malignancy-type
cells	O
.	O
PAb1801	O
detected	O
cytoplasmic	O
'	O
punctate	O
structures	O
'	O
which	O
were	O
also	O
found	O
in	O
p53	O
-	O
null	O
cells	O
,	O
rendering	O
this	O
antibody	O
unsuitable	O
for	O
p53	O
detection	O
.	O
A	O
comparison	O
of	O
DO	O
-	O
1	O
and	O
PAb1801	O
staining	O
in	O
NB	B-malignancy-type
tissue	O
sections	O
confirmed	O
the	O
results	O
obtained	O
with	O
NB	B-malignancy-type
cells	O
.	O
Nuclear	O
accumulation	O
of	O
p53	O
was	O
induced	O
in	O
NB	B-malignancy-type
cells	O
using	O
substances	O
which	O
disturb	O
p53	O
'	O
s	O
tertiary	O
structure	O
at	O
its	O
zinc	O
finger	O
motif	O
,	O
or	O
by	O
treatment	O
with	O
mitomycin	O
C	O
.	O
Constitutive	O
nuclear	O
accumulation	O
was	O
observed	O
in	O
an	O
SK	O
-	O
N	O
-	O
SH	O
variant	O
,	O
AW	O
-	O
1	O
,	O
which	O
has	O
a	O
point	O
mutation	O
in	O
p53	O
at	O
Cys	O
176	O
>	O
Ser	O
,	O
disturbing	O
the	O
same	O
motif	O
.	O
Even	O
though	O
p53	O
showed	O
DNA	O
-	O
binding	O
capability	O
after	O
mitomycin	O
C	O
treatment	O
of	O
NB	B-malignancy-type
cells	O
,	O
the	O
target	O
gene	O
products	O
MDM2	O
and	O
p21	O
(	O
WAF1	O
,	O
CIP1	O
,	O
SDI1	O
)	O
were	O
not	O
synthesized	O
and	O
no	O
p53	O
transactivating	O
activity	O
measured	O
in	O
a	O
reporter	O
gene	O
assay	O
.	O
Therefore	O
we	O
suggest	O
that	O
p53	O
in	O
NB	B-malignancy-type
cells	O
might	O
be	O
predominantly	O
in	O
a	O
conformation	O
refractory	O
to	O
integration	O
into	O
the	O
transcriptional	O
complex	O
,	O
resulting	O
in	O
at	O
least	O
partial	O
transcriptional	O
inactivity	O
,	O
hyperactive	O
nuclear	O
export	O
and	O
resistance	O
to	O
degradation	O
by	O
exogenously	O
expressed	O
MDM2	O
.	O
PMID	O
:	O
11313875	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
Surg	O
.	O
2001	O
Jul;36	O
(	O
7	O
)	O
:	O
1040	O
-4.	O
Expression	O
of	O
matrix	O
metalloproteinases	O
and	O
the	O
metastasis	O
-	O
associated	O
gene	O
S100A4	O
in	O
human	O
neuroblastoma	B-malignancy-type
and	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
cells	O
.	O
Bjornland	O
K,	O
Bratland	O
A	O
,	O
Rugnes	O
E	O
,	O
Pettersen	O
S	O
,	O
Johansen	O
HT	O
,	O
Aasen	O
AO	O
,	O
Fodstad	O
O	O
,	O
Ree	O
AH	O
,	O
Maelandsmo	O
GM	O
.	O
Institute	O
for	O
Surgical	O
Research	O
and	O
the	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
The	O
National	O
Hospital	O
,	O
Oslo	O
,	O
Norway	O
.	O
BACKGROUND	O
:	O
Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
tissue	O
inhibitors	O
of	O
MMPs	O
;	O
TIMPs	O
)	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
in	O
vitro	O
invasiveness	O
and	O
clinical	O
outcome	O
in	O
several	O
adult	O
malignancies	O
.	O
The	O
importance	O
of	O
MMP	O
and	O
TIMP	O
expression	O
in	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
and	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
(	O
PNET	B-malignancy-type
)	O
is	O
incompletely	O
understood	O
.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
relate	O
in	O
vitro	O
invasion	O
of	O
NB	B-malignancy-type
and	O
PNET	B-malignancy-type
cell	O
lines	O
with	O
MMP	O
and	O
TIMP	O
expression	O
and	O
evaluate	O
the	O
effect	O
of	O
a	O
synthetic	O
MMP	O
inhibitor	O
.	O
Furthermore	O
,	O
S100A4	O
levels	O
were	O
determined	O
because	O
recent	O
reports	O
have	O
suggested	O
a	O
possible	O
association	O
between	O
MMPs	O
,	O
TIMPs	O
,	O
and	O
the	O
metastasis	O
-	O
associated	O
gene	O
S100A4	O
.	O
METHODS	O
:	O
Expression	O
of	O
MMPs	O
,	O
TIMPs	O
,	O
and	O
S100A4	O
was	O
evaluated	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
in	O
2	O
human	O
NB	B-malignancy-type
and	O
2	O
PNET	B-malignancy-type
cell	O
lines	O
.	O
In	O
vitro	O
invasion	O
and	O
effects	O
of	O
the	O
synthetic	O
MMP	O
inhibitor	O
Marimastat	O
were	O
assessed	O
in	O
the	O
Transwell	O
chamber	O
assay	O
.	O
RESULTS	O
:	O
The	O
most	O
invasive	O
cells	O
expressed	O
the	O
highest	O
levels	O
of	O
MMPs	O
and	O
S100A4	O
.	O
Marimastat	O
reduced	O
invasion	O
by	O
30	O
%	O
.	O
CONCLUSIONS	O
:	O
In	O
vitro	O
invasion	O
correlated	O
with	O
MMP	O
and	O
S100A4	O
expression	O
.	O
The	O
fact	O
that	O
Marimastat	O
reduced	O
in	O
vitro	O
invasion	O
is	O
encouraging	O
for	O
further	O
studies	O
on	O
a	O
possible	O
therapeutic	O
application	O
for	O
proteinase	O
inhibitors	O
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
.	O
PMID	O
:	O
11431772	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Nov	O
22	O
;277	O
(	O
47	O
)	O
:45299	O
-305	O
.	O
Epub	O
2002	O
Sep	O
15	O
.	O
Neuronal	O
differentiation	O
-	O
dependent	O
expression	O
of	O
the	O
disialic	O
acid	O
epitope	O
on	O
CD166	O
and	O
its	O
involvement	O
in	O
neurite	O
formation	O
in	O
Neuro2A	O
cells	O
.	O
Sato	O
C	O
,	O
Matsuda	O
T	O
,	O
Kitajima	O
K.	O
Department	O
of	O
Applied	O
Molecular	O
Biosciences	O
,	O
Graduate	O
School	O
of	O
Bioagricultural	O
Sciences	O
,	O
Nagoya	O
University	O
,	O
Japan	O
.	O
We	O
previously	O
demonstrated	O
that	O
alpha2	O
,8-	O
linked	O
disialic	O
acid	O
(	O
diSia	O
)	O
residues	O
occur	O
in	O
several	O
glycoproteins	O
of	O
mammalian	O
brains	O
(	O
Sato	O
,	O
C.	O
,	O
Fukuoka	O
,	O
H.	O
,	O
Ohta	O
,	O
K.	O
,	O
Matsuda	O
,	O
T.	O
,	O
Koshino	O
,	O
R.	O
,	O
Kobayashi	O
,	O
K.	O
,	O
Troy	O
,	O
F.	O
A.	O
,	O
II	O
,	O
and	O
Kitajima	O
,	O
K.	O
(	O
2000	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
275	O
,	O
15422	O
-15431	O
)	O
.	O
The	O
role	O
of	O
the	O
diSia	O
epitope	O
on	O
these	O
glycoproteins	O
is	O
not	O
known	O
,	O
whereas	O
the	O
importance	O
of	O
the	O
diSia	O
epitope	O
on	O
glycolipids	O
is	O
well	O
documented	O
in	O
neurite	O
formation	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
diSia	O
epitope	O
(	O
Neu5Acalpha2	O
-->	O
8Neu5Acalpha2	O
-->	O
3Gal	O
)	O
on	O
glycoproteins	O
,	O
but	O
not	O
on	O
glycolipids	O
,	O
is	O
involved	O
in	O
neurite	O
formation	O
in	O
a	O
mouse	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
Neuro2A	O
,	O
based	O
on	O
the	O
following	O
lines	O
of	O
evidence	O
.	O
First	O
,	O
the	O
amount	O
of	O
diSia	O
epitope	O
on	O
glycoproteins	O
increased	O
during	O
retinoic	O
acid	O
-	O
induced	O
neurite	O
formation	O
.	O
Second	O
,	O
retinoic	O
acid	O
treatment	O
primarily	O
increased	O
the	O
diSia	O
epitope	O
on	O
a	O
100	O
-	O
kDa	O
glycoprotein	O
.	O
We	O
identified	O
this	O
protein	O
as	O
CD166	O
(	O
SC1	O
)	O
,	O
an	O
immunoglobulin	O
superfamily	O
cell	O
adhesion	O
molecule	O
involved	O
in	O
neurite	O
extension	O
.	O
Third	O
,	O
a	O
monoclonal	O
antibody	O
against	O
the	O
diSia	O
epitope	O
specifically	O
inhibited	O
neurite	O
formation	O
.	O
We	O
also	O
demonstrated	O
that	O
alpha2	O
,8-	O
sialyltransferase	O
III	O
mRNA	O
expression	O
increased	O
1.7	O
-	O
fold	O
after	O
the	O
induction	O
of	O
neurite	O
formation	O
,	O
suggesting	O
that	O
alpha2	O
,8-	O
sialyltransferase	O
III	O
is	O
responsible	O
for	O
formation	O
of	O
the	O
diSia	O
epitope	O
on	O
CD166	O
.	O
PMID	O
:	O
12235144	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Metastasis	O
Rev	O
.	O
1991	O
Dec;10(	O
4	O
)	O
:	O
321-33	O
.	O
Biology	O
of	O
tumors	O
of	O
the	O
peripheral	O
nervous	O
system	O
.	O
Brodeur	O
GM	O
,	O
Moley	O
JF.	O
Department	O
of	O
Pediatrics	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
MO	O
63110	O
.	O
Tumors	O
of	O
the	O
peripheral	O
nervous	O
system	O
include	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
neuroepitheliomas	B-malignancy-type
.	O
Neuroblastomas	B-malignancy-type
and	O
pheochromocytomas	B-malignancy-type
are	O
adrenergic	O
in	O
origin	O
and	O
share	O
certain	O
genetic	O
features	O
,	O
whereas	O
neuroepitheliomas	B-malignancy-type
are	O
thought	O
to	O
be	O
cholinergic	O
and	O
are	O
characterized	O
by	O
distinct	O
genetic	O
features	O
.	O
Neuroblastomas	B-malignancy-type
are	O
characterized	O
by	O
deletion	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
1p	O
)	O
,	O
amplification	O
of	O
the	O
MYCN	O
proto	O
-	O
oncogene	O
,	O
and	O
hyperdiploidy	O
in	O
subsets	O
of	O
tumors	O
.	O
All	O
three	O
of	O
these	O
genetic	O
features	O
have	O
prognostic	O
value	O
in	O
subsets	O
of	O
patients	O
.	O
Allelic	O
loss	O
of	O
14q	O
also	O
occurs	O
with	O
increased	O
frequency	O
,	O
but	O
the	O
prognostic	O
importance	O
of	O
this	O
abnormality	O
is	O
not	O
known	O
yet	O
.	O
Pheochromocytomas	B-malignancy-type
have	O
not	O
been	O
studied	O
as	O
extensively	O
,	O
but	O
allelic	O
loss	O
for	O
1p	O
appears	O
to	O
be	O
a	O
frequent	O
change	O
,	O
and	O
no	O
clear	O
examples	O
of	O
oncogene	O
activation	O
have	O
been	O
identified	O
to	O
date	O
.	O
Neuroepitheliomas	B-malignancy-type
are	O
characterized	O
by	O
translocation	O
between	O
chromosomes	O
11	O
and	O
22	O
.	O
Although	O
they	O
have	O
a	O
characteristic	O
pattern	O
of	O
proto	O
-	O
oncogene	O
expression	O
,	O
it	O
is	O
not	O
clear	O
that	O
any	O
of	O
these	O
oncogenes	O
are	O
activated	O
specifically	O
,	O
and	O
no	O
sites	O
of	O
allelic	O
loss	O
have	O
been	O
identified	O
to	O
date	O
.	O
Thus	O
,	O
cytogenetic	O
and	O
molecular	O
analysis	O
of	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
neuroepitheliomas	B-malignancy-type
are	O
useful	O
in	O
distinguishing	O
them	O
from	O
each	O
other	O
and	O
from	O
other	O
tumors	O
in	O
selected	O
cases	O
.	O
Furthermore	O
,	O
certain	O
genetic	O
markers	O
are	O
useful	O
in	O
predicting	O
clinical	O
behavior	O
,	O
especially	O
for	O
neuroblastoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Academic	O
PMID	O
:	O
1786633	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Cell	O
.	O
1999	O
Mar;12(	O
1	O
)	O
:47	O
-	O
56	O
.	O
[Smooth	O
muscle	O
myosin	O
of	O
SM1	O
and	O
SM2	O
isoforms	O
expressing	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
of	O
MP-N-MS	O
]	O
[	O
Article	O
in	O
Japanese	O
]	O
Sugimoto	O
T	O
,	O
Komada	O
Y	O
,	O
Sakurai	O
M,	O
Horii	O
Y	O
,	O
Morishita	O
R	O
,	O
Nagai	O
R	O
,	O
Takahashi	O
K,	O
Asada	O
Y	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Miyazaki	O
Medical	O
College	O
,	O
Japan	O
.	O
Human	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cell	O
lines	O
have	O
at	O
least	O
three	O
morphological	O
appearance	O
of	O
neuroblastic	O
(	O
N-type	O
)	O
,	O
substrate	O
-	O
adhessive	O
(	O
S-type	O
)	O
and	O
intermediate(	O
I)	O
cells	O
.	O
Our	O
previous	O
study	O
revealed	O
S-type	O
cells	O
expressed	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
,	O
desmin	O
and/or	O
basic	O
-calponin	O
,	O
indicating	O
the	O
plausible	O
smooth	O
muscle	O
cell	O
characteristics	O
of	O
S-type	O
cells	O
.	O
In	O
this	O
study	O
,	O
a	O
new	O
human	O
NB	B-malignancy-type
cell	O
line	O
,	O
MP-N-MS	O
,	O
was	O
established	O
from	O
bone	B-malignancy-type
marrow	I-malignancy-type
metastasis	I-malignancy-type
of	O
a	O
one	O
year	O
and	O
six-month	O
old	O
girl	O
with	O
advanced	O
NB	B-malignancy-type
,	O
originating	O
from	O
right	O
adrenal	O
gland	O
.	O
Morphology	O
of	O
this	O
cell	O
line	O
is	O
composed	O
of	O
S-type	O
cells	O
.	O
MP-N-MS	O
was	O
identified	O
as	O
a	O
NB	B-malignancy-type
cell	O
line	O
by	O
surface	O
membrane	O
antigen	O
analysis	O
and	O
MYCN	O
gene	O
amplification	O
.	O
EWS-FLI1	O
and	O
EWS-ERG	O
chimeric	O
products	O
,	O
observed	O
in	O
Ewing	B-malignancy-type
family	I-malignancy-type
tumors	I-malignancy-type
,	O
were	O
not	O
detected	O
by	O
RT-PCR	O
(	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
)	O
.	O
In	O
cytoskeletal	O
protein	O
analysis	O
,	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
and	O
basic	O
calponin	O
of	O
smooth	O
muscle	O
cell	O
markers	O
were	O
detected	O
.	O
Furthermore	O
,	O
smooth	O
myosin	O
of	O
SM1	O
isoform	O
was	O
identified	O
in	O
MP-N-MS	O
cell	O
line	O
by	O
immunofluorescence	O
,	O
Western	O
blot	O
and	O
RT-PCR	O
,	O
whereas	O
smooth	O
myosin	O
of	O
SM2	O
was	O
detected	O
by	O
RT-PCR	O
.	O
MP-N-MS	O
is	O
the	O
first	O
cell	O
line	O
,	O
showing	O
SM1	O
and	O
SM2	O
isoforms	O
.	O
The	O
presence	O
of	O
smooth	O
muscle	O
myosin	O
of	O
SM1	O
and	O
SM2	O
isoforms	O
in	O
MP-N-MS	O
demonstrated	O
the	O
mature	O
smooth	O
muscle	O
phenotype	O
of	O
this	O
NB	B-malignancy-type
cell	O
line	O
,	O
and	O
the	O
ability	O
of	O
NB	B-malignancy-type
cells	O
to	O
differentiate	O
into	O
smooth	O
muscle	O
cell	O
.	O
PMID	O
:	O
10457905	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan;36	O
(	O
1	O
)	O
:	O
210-2.	O
Detection	O
of	O
microscopic	O
disease	O
:	O
comparing	O
histology	O
,	O
immunocytology	O
,	O
and	O
RT-PCR	O
of	O
tyrosine	O
hydroxylase	O
,	O
GAGE	O
,	O
and	O
MAGE	O
.	O
Cheung	O
IY	O
,	O
Cheung	O
NK.	O
Department	O
of	O
Pediatrics	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
New	O
York	O
10021	O
,	O
USA	O
.	O
cheungn@mskcc.org	O
BACKGROUND	O
:	O
We	O
first	O
explored	O
the	O
use	O
of	O
multiple	O
molecular	O
markers	O
to	O
overcome	O
tumor	O
heterogeneity	O
.	O
Sixty	O
-seven	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
tumors	O
were	O
tested	O
for	O
the	O
expression	O
of	O
GAGE	O
,	O
MAGE-2	O
,	O
MAGE-2	O
,	O
MAGE-3	O
,	O
and	O
MAGE-4	O
by	O
RT-PCR	O
and	O
then	O
chemiluminescence	O
;	O
82	O
%	O
of	O
tumors	O
had	O
detectable	O
GAGE	O
,	O
and	O
88	O
%	O
expressed	O
at	O
least	O
one	O
of	O
the	O
four	O
MAGE	O
genes	O
.	O
PROCEDURE	O
AND	O
RESULTS	O
:	O
By	O
combining	O
GAGE	O
and	O
MAGE	O
,	O
64	O
of	O
67	O
(	O
95	O
%	O
)	O
of	O
tumors	O
became	O
detectable	O
;	O
17	O
of	O
67	O
coexpressed	O
all	O
five	O
molecular	O
markers	O
.	O
Neither	O
GAGE	O
nor	O
MAGE	O
expression	O
correlated	O
with	O
stage	O
.	O
GAGE	O
was	O
found	O
to	O
have	O
the	O
broadest	O
(	O
18	O
of	O
18	O
)	O
expression	O
among	O
stage	O
4	O
tumors	O
.	O
Two	O
hundred	O
fifty-nine	O
bone	O
marrows	O
from	O
99	O
patients	O
were	O
then	O
studied	O
for	O
NB	B-malignancy-type
positivity	O
by	O
four	O
detection	O
methods	O
:	O
histology	O
,	O
immunocytology	O
,	O
and	O
molecular	O
detection	O
by	O
GAGE	O
and	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
mRNA	O
.	O
Two	O
hundred	O
seven	O
samples	O
were	O
NB	B-malignancy-type
-	O
positive	O
by	O
one	O
detection	O
method	O
.	O
All	O
four	O
techniques	O
were	O
comparable	O
in	O
detecting	O
tumor	O
cells	O
at	O
diagnosis	O
and	O
at	O
relapse	O
.	O
GAGE	O
and	O
immunocytology	O
were	O
far	O
more	O
sensitive	O
than	O
histology	O
and	O
TH	O
mRNA	O
when	O
marrows	O
were	O
sampled	O
during	O
chemotherapy	O
and	O
at	O
the	O
time	O
of	O
clinical	O
remission	O
.	O
CONCLUSIONS	O
:	O
By	O
combining	O
multiple	O
molecular	O
markers	O
and	O
independent	O
screening	O
techniques	O
,	O
we	O
may	O
be	O
able	O
to	O
overcome	O
tumor	O
heterogeneity	O
and	O
expedite	O
the	O
detection	O
of	O
microscopic	O
disease	O
in	O
the	O
clinical	O
management	O
of	O
neuroblastoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Evaluation	O
Studies	O
PMID	O
:	O
11464887	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1999	O
Dec	O
2;18	O
(	O
51	O
)	O
:7244	O
-52	O
.	O
Evidence	O
for	O
interaction	O
between	O
human	O
PRUNE	O
and	O
nm23-H1	O
NDPKinase	O
.	O
Reymond	O
A	O
,	O
Volorio	O
S	O
,	O
Merla	O
G	O
,	O
Al-Maghtheh	O
M,	O
Zuffardi	O
O	O
,	O
Bulfone	O
A	O
,	O
Ballabio	O
A	O
,	O
Zollo	O
M.	O
Telethon	O
Institute	O
of	O
Genetics	O
and	O
Medicine	O
(	O
TIGEM	O
)	O
,	O
San	O
Raffaele	O
Biomedical	O
Science	O
Park	O
,	O
20132	O
,	O
Milan	O
,	O
Italy	O
.	O
We	O
have	O
isolated	O
a	O
human	O
and	O
murine	O
homologue	O
of	O
the	O
Drosophila	O
prune	O
gene	O
through	O
dbEST	O
searches	O
.	O
The	O
gene	O
is	O
ubiquitously	O
expressed	O
in	O
human	O
adult	O
tissues	O
,	O
while	O
in	O
mouse	O
developing	O
embryos	O
a	O
high	O
level	O
of	O
expression	O
is	O
confined	O
to	O
the	O
nervous	O
system	O
particularly	O
in	O
the	O
dorsal	O
root	O
ganglia	O
,	O
cranial	O
nerves	O
,	O
and	O
neural	O
retina	O
.	O
The	O
gene	O
is	O
composed	O
of	O
eight	O
exons	O
and	O
is	O
located	O
in	O
the	O
1q21.3	O
chromosomal	O
region	O
.	O
A	O
pseudogene	O
has	O
been	O
sequenced	O
and	O
mapped	O
to	O
chromosomal	O
region	O
13q12	O
.	O
PRUNE	O
protein	O
retains	O
the	O
four	O
characteristic	O
domains	O
of	O
DHH	O
phosphoesterases	O
.	O
The	O
synergism	O
between	O
prune	O
and	O
awdK-pn	O
in	O
Drosophila	O
has	O
led	O
various	O
authors	O
to	O
propose	O
an	O
interaction	O
between	O
these	O
genes	O
.	O
However	O
,	O
such	O
an	O
interaction	O
has	O
never	O
been	O
supported	O
by	O
biochemical	O
data	O
.	O
By	O
using	O
interaction	O
-	O
mating	O
and	O
in	O
vitro	O
co	O
-	O
immunoprecipitation	O
experiments	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
the	O
ability	O
of	O
human	O
PRUNE	O
to	O
interact	O
with	O
the	O
human	O
homologue	O
of	O
awd	O
protein	O
(	O
nm23-H1	O
)	O
.	O
In	O
contrast	O
,	O
PRUNE	O
is	O
impaired	O
in	O
its	O
interaction	O
with	O
nm-	O
23-H1-S120G	O
mutant	O
,	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
associated	O
with	O
advanced	O
neuroblastoma	B-malignancy-type
stages	O
.	O
Consistently	O
,	O
PRUNE	O
and	O
nm23-H1	O
proteins	O
partially	O
colocalize	O
in	O
the	O
cytoplasm	O
.	O
The	O
data	O
presented	O
are	O
consistent	O
with	O
the	O
view	O
that	O
PRUNE	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
nm23-H1	O
protein	O
.	O
We	O
discuss	O
how	O
PRUNE	O
regulates	O
nm23-H1	O
protein	O
and	O
postulate	O
possible	O
implications	O
of	O
PRUNE	O
in	O
neuroblastoma	B-malignancy-type
progression	O
.	O
PMID	O
:	O
10602478	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1997	O
Oct;69	O
(	O
4	O
)	O
:	O
1374	O
-	O
81	O
.	O
Cellular	O
acetylcholine	O
content	O
and	O
neuronal	O
differentiation	O
.	O
Bignami	O
F	O
,	O
Bevilacqua	O
P,	O
Biagioni	O
S	O
,	O
De	O
Jaco	O
A	O
,	O
Casamenti	O
F	O
,	O
Felsani	O
A	O
,	O
Augusti	O
-	O
Tocco	O
G.	O
Dipartimento	O
di	O
Biologia	O
Cellulare	O
e	O
dello	O
Sviluppo	O
,	O
Universita	O
La	O
Sapienza	O
,	O
Roma	O
,	O
Italy	O
.	O
N18TG2	O
neuroblastoma	B-malignancy-type
clone	O
is	O
defective	O
for	O
biosynthetic	O
neurotransmitter	O
enzymes	O
;	O
its	O
inability	O
to	O
establish	O
functional	O
synapses	O
is	O
overcome	O
in	O
the	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
108CC15	O
,	O
where	O
acetylcholine	O
synthesis	O
is	O
also	O
activated	O
.	O
These	O
observations	O
suggest	O
a	O
possible	O
relation	O
between	O
the	O
ability	O
to	O
produce	O
acetylcholine	O
and	O
the	O
capability	O
to	O
advance	O
in	O
the	O
differentiation	O
program	O
and	O
achieve	O
a	O
fully	O
differentiated	O
state	O
.	O
Here	O
,	O
we	O
report	O
the	O
characterization	O
of	O
several	O
clones	O
after	O
transfection	O
of	O
N18TG2	O
cells	O
with	O
a	O
construct	O
containing	O
a	O
cDNA	O
for	O
rat	O
choline	O
acetyltransferase	O
(	O
ChAT	O
)	O
.	O
The	O
ability	O
of	O
these	O
clones	O
to	O
synthesize	O
acetylcholine	O
is	O
demonstrated	O
by	O
HPLC	O
determination	O
on	O
cellular	O
extracts	O
.	O
In	O
the	O
transfected	O
clones	O
,	O
northern	O
blot	O
analysis	O
shows	O
increased	O
expression	O
of	O
mRNAs	O
for	O
a	O
specific	O
neuronal	O
protein	O
associated	O
with	O
synaptic	O
vesicles	O
,	O
synapsin_I	O
.	O
Fiber	O
outgrowth	O
of	O
transfected	O
clones	O
is	O
also	O
evaluated	O
to	O
establish	O
whether	O
there	O
is	O
any	O
relation	O
between	O
ChAT	O
levels	O
and	O
morphological	O
differentiation	O
.	O
This	O
analysis	O
shows	O
that	O
the	O
transfected	O
clone	O
1	O
/	O
2	O
,	O
not	O
expressing	O
ChAT	O
activity	O
,	O
displays	O
a	O
very	O
immature	O
morphology	O
,	O
and	O
its	O
ability	O
to	O
extend	O
fibers	O
also	O
remains	O
rather	O
poor	O
in	O
the	O
presence	O
of	O
"differentiation	O
"	O
agents	O
such	O
as	O
retinoic	O
acid	O
.	O
In	O
contrast	O
,	O
clones	O
2/4	O
,	O
3	O
/1	O
,	O
and	O
3/2	O
,	O
exhibiting	O
high	O
ChAT	O
levels	O
,	O
display	O
higher	O
fiber	O
outgrowth	O
compared	O
with	O
clone	O
1	O
/	O
2	O
in	O
both	O
the	O
absence	O
and	O
the	O
presence	O
of	O
differentiating	O
agents	O
.	O
PMID	O
:	O
9326265	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Growth	O
Differ	O
.	O
1994	O
Apr;	O
5	O
(	O
4	O
)	O
:	O
373	O
-84	O
.	O
NUB	O
-	O
7	O
:	O
a	O
stable	O
I-type	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
inducible	O
along	O
N	O
-	O
and	O
S-	O
type	O
cell	O
lineages	O
.	O
Dimitroulakos	O
J,	O
Squire	O
J,	O
Pawlin	O
G	O
,	O
Yeger	O
H.	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Toronto	O
,	O
Canada	O
.	O
Human	O
NB	B-malignancy-type
cell	O
lines	O
express	O
features	O
of	O
one	O
or	O
more	O
of	O
three	O
recognizable	O
phenotypes	O
that	O
include	O
N-type	O
(	O
neuroblastic	O
)	O
,	O
S-type	O
(	O
Schwannian	O
)	O
,	O
and	O
I-type	O
(	O
intermediate	O
phenotype	O
)	O
cells	O
.	O
The	O
I-type	O
cell	O
,	O
which	O
shares	O
properties	O
of	O
both	O
N	O
-	O
and	O
S-	O
type	O
cells	O
,	O
is	O
thought	O
to	O
represent	O
the	O
progenitor	O
cell	O
from	O
which	O
the	O
other	O
two	O
cell	O
types	O
are	O
derived	O
.	O
The	O
MYCN	O
amplified	O
NB	B-malignancy-type
cell	O
line	O
NUB	O
-	O
7	O
,	O
established	O
in	O
our	O
laboratory	O
,	O
is	O
now	O
shown	O
to	O
be	O
composed	O
principally	O
of	O
I-type	O
cells	O
.	O
The	O
observed	O
phenotype	O
was	O
stable	O
in	O
culture	O
and	O
was	O
representative	O
of	O
the	O
original	O
surgically	O
resected	O
tumor	O
.	O
The	O
I-type	O
cell	O
designation	O
was	O
established	O
based	O
on	O
morphological	O
characteristics	O
,	O
the	O
coexpression	O
of	O
various	O
N-type	O
(	O
neurofilaments	O
,	O
peripherin	O
,	O
GAP-43	O
,	O
NCAM	O
,	O
MYCN	O
)	O
and	O
S-type	O
cell	O
(	O
vimentin	O
,	O
laminin	O
,	O
fibronectin	O
)	O
markers	O
,	O
and	O
the	O
relatively	O
high	O
level	O
of	O
expression	O
of	O
these	O
markers	O
in	O
comparison	O
to	O
five	O
predominantly	O
N-type	O
,	O
one	O
S-type	O
,	O
and	O
one	O
N	O
/	O
S	O
mixed	O
NB	B-malignancy-type
cell	O
lines	O
.	O
Dibutyryl	O
cyclic	O
AMP	O
and	O
retinoic	O
acid	O
induced	O
enhanced	O
expression	O
of	O
N	O
-	O
and	O
S-	O
type	O
phenotypes	O
,	O
respectively	O
,	O
in	O
NUB-	O
7	O
as	O
supported	O
by	O
specific	O
morphological	O
changes	O
,	O
reduced	O
growth	O
,	O
and	O
changes	O
in	O
the	O
levels	O
of	O
expression	O
of	O
both	O
N	O
-	O
and	O
S-	O
type	O
markers	O
.	O
Our	O
studies	O
with	O
the	O
NUB-	O
7	O
cell	O
line	O
have	O
now	O
provided	O
convincing	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
bipotential	O
progenitor	O
of	O
N	O
-	O
and	O
S-	O
type	O
cells	O
in	O
NB	B-malignancy-type
.	O
As	O
well	O
,	O
the	O
NUB-	O
7	O
cell	O
line	O
may	O
also	O
represent	O
the	O
tumor	O
counterpart	O
of	O
a	O
sympathetic	O
ganglion	O
progenitor	O
cell	O
.	O
PMID	O
:	O
8043511	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1990	O
Jun	O
15	O
;50(	O
12	O
)	O
:	O
3694	O
-	O
700	O
.	O
Beta	O
2-microglobulin	O
expression	O
in	O
human	O
embryonal	O
neuroblastoma	B-malignancy-type
reflects	O
its	O
developmental	O
regulation	O
.	O
Cooper	O
MJ	O
,	O
Hutchins	O
GM	O
,	O
Mennie	O
RJ	O
,	O
Israel	O
MA.	O
Molecular	O
Genetics	O
Section	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
Class	O
I	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
antigen	O
expression	O
in	O
neuroblastoma	B-malignancy-type
may	O
play	O
a	O
role	O
in	O
the	O
oncogenicity	O
of	O
this	O
embryonal	O
tumor	O
of	O
childhood	O
.	O
Since	O
N-myc	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
is	O
associated	O
with	O
rapid	O
tumor	O
progression	O
(	O
33	O
)	O
and	O
N-myc	O
decreases	O
Class	O
I	O
MHC	O
antigen	O
expression	O
in	O
rat	O
neuroblastoma	B-malignancy-type
cells	O
(	O
21	O
)	O
,	O
we	O
quantitated	O
levels	O
of	O
N-myc	O
mRNA	O
and	O
Class	O
I	O
MHC	O
cell	O
surface	O
antigens	O
in	O
a	O
panel	O
of	O
24	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
We	O
found	O
that	O
N-myc	O
expression	O
is	O
not	O
invariably	O
associated	O
with	O
low	O
levels	O
of	O
beta	O
2-microglobulin	O
(	O
B2M	O
)	O
and	O
Class	O
I	O
MHC	O
antigen	O
expression	O
.	O
As	O
we	O
considered	O
that	O
Class	O
I	O
MHC	O
antigens	O
may	O
be	O
regulated	O
in	O
association	O
with	O
the	O
differentiation	O
stage	O
of	O
the	O
neuroblastoma	B-malignancy-type
tumor	I-malignancy-type
,	O
we	O
examined	O
the	O
expression	O
of	O
B2M	O
during	O
development	O
of	O
the	O
human	O
adrenal	O
medulla	O
,	O
the	O
tissue	O
of	O
origin	O
of	O
most	O
neuroblastomas	B-malignancy-type
.	O
We	O
found	O
that	O
B2M	O
is	O
a	O
marker	O
of	O
differentiated	O
adrenal	O
medullary	O
cells	O
,	O
expressed	O
late	O
during	O
the	O
third	O
trimester	O
of	O
development	O
.	O
Moreover	O
,	O
using	O
morphological	O
and	O
immunological	O
criteria	O
,	O
we	O
found	O
that	O
B2M	O
is	O
expressed	O
in	O
differentiated	O
tumor	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
the	O
expression	O
of	O
B2M	O
in	O
neuroblastoma	B-malignancy-type
is	O
associated	O
with	O
the	O
stage	O
of	O
differentiation	O
of	O
the	O
tumor	O
cell	O
and	O
not	O
N-myc	O
expression	O
.	O
Furthermore	O
,	O
these	O
findings	O
suggest	O
that	O
neuroblastomas	B-malignancy-type
may	O
correspond	O
to	O
the	O
arrested	O
differentiation	O
of	O
adrenal	O
neuroblasts	O
at	O
different	O
stages	O
of	O
development	O
.	O
PMID	O
:	O
2187600	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2001	O
Aug	O
9;20(	O
35	O
)	O
:	O
4853	O
-	O
63	O
.	O
Expression	O
,	O
cellular	O
distribution	O
and	O
protein	O
binding	O
of	O
the	O
glioma	O
amplified	O
sequence	O
(	O
GAS41	O
)	O
,	O
a	O
highly	O
conserved	O
putative	O
transcription	O
factor	O
.	O
Munnia	O
A	O
,	O
Schutz	O
N	O
,	O
Romeike	O
BF	O
,	O
Maldener	O
E	O
,	O
Glass	O
B	O
,	O
Maas	O
R	O
,	O
Nastainczyk	O
W	O
,	O
Feiden	O
W	O
,	O
Fischer	O
U	O
,	O
Meese	O
E.	O
Institut	O
fur	O
Humangenetik	O
,	O
Universitatskliniken	O
des	O
Saarlandes	O
,	O
66421	O
Homburg	O
/	O
Saar	O
,	O
Germany	O
.	O
The	O
glioma	O
amplified	O
sequence	O
41	O
(	O
GAS41	O
)	O
was	O
previously	O
isolated	O
by	O
microdissection	O
mediated	O
cDNA	O
capture	O
from	O
the	O
glioblastoma	B-malignancy-type
multiforme	I-malignancy-type
cell	O
line	O
TX3868	O
and	O
shown	O
to	O
be	O
frequently	O
amplified	O
in	O
human	O
gliomas	B-malignancy-type
.	O
We	O
determined	O
the	O
complete	O
cDNA	O
sequence	O
of	O
the	O
GAS41	O
gene	O
,	O
demonstrated	O
that	O
the	O
GAS41	O
protein	O
is	O
evolutionarily	O
conserved	O
,	O
specifically	O
at	O
the	O
N-terminus	O
,	O
and	O
identified	O
the	O
yeast	O
transcription	O
factor	O
tf2f	O
domain	O
within	O
the	O
GAS41	O
sequence	O
.	O
A	O
human	O
multiple	O
-	O
tissue	O
Northern	O
blot	O
revealed	O
ubiquitous	O
expression	O
of	O
GAS41	O
with	O
the	O
highest	O
expression	O
in	O
human	O
brain	O
.	O
After	O
generating	O
polyclonal	O
antibodies	O
we	O
found	O
GAS41	O
protein	O
expression	O
in	O
the	O
nucleus	O
of	O
the	O
TX3868	O
cell	O
line	O
by	O
Western	O
blot	O
analysis	O
and	O
immunofluorescence	O
microscopy	O
.	O
The	O
nuclear	O
localization	O
was	O
confirmed	O
for	O
several	O
human	O
tumors	O
including	O
gliomas	B-malignancy-type
of	O
different	O
grades	O
of	O
malignancy	O
.	O
In	O
neuroblastoma	B-malignancy-type
however	O
,	O
GAS41	O
was	O
found	O
in	O
the	O
nucleoli	O
but	O
not	O
in	O
the	O
nucleoplasm	O
.	O
Yeast	O
two	O
-	O
hybrid	O
screening	O
of	O
the	O
TX3868	O
cell	O
line	O
identified	O
the	O
nuclear	O
mitotic	O
apparatus	O
protein	O
(	O
NuMA	O
)	O
,	O
the	O
KIAA1009	O
protein	O
,	O
and	O
prefoldin	O
subunit	O
1	O
(	O
PFDN1	O
)	O
as	O
potential	O
interacting	O
partners	O
of	O
GAS41	O
.	O
We	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
the	O
KIAA1009	O
protein	O
and	O
we	O
demonstrated	O
that	O
the	O
KIAA1009	O
protein	O
is	O
a	O
nuclear	O
protein	O
,	O
which	O
appears	O
to	O
be	O
co	O
-	O
localized	O
with	O
the	O
GAS41	O
protein	O
and	O
NuMA	O
.	O
PMID	O
:	O
11521196	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
2001	O
Nov	O
1;94	O
(	O
3	O
)	O
:	O
377	O
-	O
82	O
.	O
Overexpression	O
of	O
the	O
human	O
major	O
vault	O
protein	O
in	O
astrocytic	B-malignancy-type
brain	I-malignancy-type
tumor	I-malignancy-type
cells	O
.	O
Berger	O
W	O
,	O
Spiegl	O
-Kreinecker	O
S	O
,	O
Buchroithner	O
J,	O
Elbling	O
L,	O
Pirker	O
C	O
,	O
Fischer	O
J,	O
Micksche	O
M.	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Division	O
of	O
Applied	O
and	O
Experimental	O
Oncology	O
,	O
Borschke	O
gasse	O
8a	O
Vienna	O
University	O
,	O
Vienna	O
,	O
Austria	O
.	O
walter	O
.berger@univie	O
.ac.at	O
Evidence	O
has	O
shown	O
that	O
the	O
major	O
human	O
vault	O
protein	O
(	O
MVP	O
)	O
,	O
which	O
is	O
identical	O
to	O
lung	O
resistance	O
-	O
related	O
protein	O
(	O
LRP	O
)	O
,	O
may	O
be	O
causally	O
involved	O
in	O
a	O
special	O
type	O
of	O
multidrug	O
resistance	O
(	O
MDR	O
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
cellular	O
localization	O
of	O
MVP	O
in	O
cells	O
derived	O
from	O
brain	B-malignancy-type
tumors	I-malignancy-type
and	O
other	O
tumors	O
of	O
neuroectodermal	O
origin	O
.	O
Using	O
both	O
established	O
cell	O
lines	O
(	O
n	O
=	O
22	O
)	O
and	O
primary	O
explants	O
(	O
n	O
=	O
30	O
)	O
,	O
we	O
show	O
that	O
a	O
distinct	O
overexpression	O
of	O
the	O
MVP	O
gene	O
at	O
the	O
mRNA	O
(	O
RT-PCR	O
)	O
and	O
protein	O
(	O
Western	O
blot	O
)	O
levels	O
is	O
a	O
characteristic	O
feature	O
of	O
cells	O
derived	O
from	O
astrocytic	B-malignancy-type
brain	I-malignancy-type
tumors	I-malignancy-type
.	O
Primary	O
cultures	O
obtained	O
from	O
meningioma	B-malignancy-type
specimens	O
also	O
expressed	O
high	O
MVP	O
levels	O
,	O
in	O
contrast	O
to	O
neuroblastoma	B-malignancy-type
and	O
medulloblastoma	B-malignancy-type
cells	O
,	O
which	O
rarely	O
contained	O
detectable	O
amounts	O
of	O
MVP	O
.	O
Normal	O
human	O
astrocytes	O
cultured	O
in	O
vitro	O
expressed	O
MVP	O
,	O
although	O
at	O
low	O
amounts	O
compared	O
with	O
most	O
malignant	O
cell	O
types	O
.	O
Basal	O
MVP	O
expression	O
correlated	O
with	O
resistance	O
against	O
diverse	O
antineoplastic	O
drugs	O
including	O
anthracyclins	O
,	O
cisplatin	O
and	O
etoposide	O
.	O
By	O
Western	O
blot	O
,	O
MVP	O
was	O
also	O
detected	O
in	O
all	O
tumor	O
samples	O
taken	O
from	O
7	O
glioma	B-malignancy-type
and	O
3	O
meningioma	B-malignancy-type
patients	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
overexpression	O
of	O
MVP	O
as	O
one	O
explanation	O
for	O
the	O
low	O
efficacy	O
of	O
chemotherapeutic	O
treatment	O
of	O
astrocytic	B-malignancy-type
brain	I-malignancy-type
tumors	I-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11745417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
1989	O
Feb;5	O
9	O
(	O
2	O
)	O
:160	O
-4.	O
High	O
intrinsic	O
radiosensitivity	O
of	O
a	O
newly	O
established	O
and	O
characterised	O
human	O
embryonal	O
rhabdomyosarcoma	O
cell	O
line	O
.	O
Kelland	O
LR	O
,	O
Bingle	O
L,	O
Edwards	O
S	O
,	O
Steel	O
GG.	O
Radiotherapy	O
Research	O
Unit	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK.	O
A	O
new	O
human	O
rhabdomyosarcoma	B-malignancy-type
cell	O
line	O
(	O
HX170c	O
)	O
has	O
been	O
established	O
from	O
a	O
paratesticular	B-malignancy-type
embryonal	I-malignancy-type
tumour	I-malignancy-type
in	O
a	O
5	O
-	O
year	O
-	O
old	O
male	O
.	O
The	O
cells	O
grew	O
as	O
an	O
adherent	O
monolayer	O
with	O
a	O
doubling	O
time	O
of	O
32	O
h	O
and	O
showed	O
pleomorphic	O
features	O
.	O
Intermediate	O
filament	O
analysis	O
revealed	O
the	O
line	O
to	O
be	O
mesenchymal	O
in	O
origin	O
(	O
reactivity	O
to	O
vimentin	O
and	O
desmin	O
antibodies	O
)	O
.	O
The	O
line	O
was	O
tumorigenic	O
in	O
nude	O
mice	O
,	O
possessed	O
elevated	O
levels	O
of	O
creatine	O
phosphokinase	O
(	O
mainly	O
of	O
the	O
MM	O
isoenzyme	O
form	O
)	O
and	O
had	O
a	O
near	O
diploid	O
mean	O
chromosome	O
number	O
of	O
50	O
.	O
In	O
vitro	O
cell	O
cloning	O
determinations	O
gave	O
colony	O
forming	O
efficiencies	O
of	O
0.01	O
%	O
in	O
soft	O
agar	O
and	O
24	O
%	O
in	O
a	O
monolayer	O
anchorage	O
-	O
dependent	O
assay	O
.	O
Radiosensitivity	O
determinations	O
using	O
a	O
monolayer	O
clonogenic	O
assay	O
with	O
feeder	O
layer	O
support	O
showed	O
the	O
cells	O
to	O
be	O
among	O
the	O
more	O
radiosensitive	O
human	O
tumour	O
cell	O
types	O
(	O
surviving	O
fraction	O
at	O
2	O
Gy	O
of	O
0.26	O
)	O
that	O
have	O
been	O
investigated	O
.	O
Furthermore	O
,	O
experiments	O
utilising	O
continuous	O
low	O
dose	O
rate	O
radiation	O
at	O
3.2	O
cGy	O
min	O
-1	O
,	O
showed	O
that	O
,	O
under	O
these	O
experimental	O
conditions	O
,	O
the	O
cells	O
possessed	O
only	O
a	O
very	O
low	O
capacity	O
to	O
recover	O
from	O
radiation	O
-	O
induced	O
damage	O
(	O
dose	O
reduction	O
factor	O
at	O
1	O
%	O
cell	O
survival	O
of	O
1.07	O
for	O
150	O
versus	O
3.2	O
cGy	O
min	O
-1	O
)	O
.	O
As	O
other	O
human	O
tumour	O
cells	O
of	O
an	O
embryonal	O
cell	O
origin	O
(	O
e.g	O
.	O
neuroblastoma	B-malignancy-type
and	O
germ	B-malignancy-type
cell	I-malignancy-type
tumours	I-malignancy-type
of	O
the	O
testis	O
)	O
have	O
also	O
been	O
shown	O
to	O
be	O
radiosensitive	O
it	O
appears	O
that	O
sensitivity	O
to	O
radiation	O
may	O
be	O
a	O
common	O
property	O
of	O
this	O
group	O
of	O
tumours	O
.	O
PMID	O
:	O
2930681	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Probes	O
.	O
1993	O
Jun;	O
7(	O
3	O
)	O
:227	O
-34	O
.	O
Determination	O
of	O
N-myc	O
gene	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
by	O
differential	O
polymerase	O
chain	O
reaction	O
.	O
Gilbert	O
J,	O
Norris	O
MD	O
,	O
Haber	O
M,	O
Kavallaris	O
M,	O
Marshall	O
GM	O
,	O
Stewart	O
BW	O
.	O
Children	O
's	O
Leukaemia	O
and	O
Cancer	O
Research	O
Centre	O
,	O
Prince	O
of	O
Wales	O
Children	O
's	O
Hospital	O
,	O
Randwick	O
,	O
Sydney	O
,	O
N.S.W.	O
,	O
Australia	O
.	O
Determination	O
of	O
N-myc	O
gene	O
amplification	O
,	O
a	O
powerful	O
prognostic	O
indicator	O
in	O
the	O
childhood	O
tumour	O
,	O
neuroblastoma	B-malignancy-type
,	O
has	O
routinely	O
been	O
performed	O
by	O
Southern	O
analysis	O
.	O
We	O
have	O
developed	O
a	O
differential	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
,	O
in	O
which	O
the	O
N-myc	O
target	O
gene	O
is	O
co	O
-amplified	O
with	O
a	O
control	O
gene	O
,	O
glyceraldehyde	O
-	O
3-phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
.	O
Following	O
electrophoresis	O
,	O
a	O
ratio	O
between	O
the	O
two	O
PCR	O
products	O
within	O
a	O
given	O
DNA	O
sample	O
is	O
then	O
determined	O
by	O
densitometry	O
.	O
This	O
assay	O
was	O
applied	O
to	O
DNA	O
isolated	O
from	O
32	O
primary	B-malignancy-type
neuroblastoma	I-malignancy-type
tumours	O
for	O
which	O
the	O
N-myc	O
status	O
had	O
previously	O
been	O
determined	O
by	O
Southern	O
analysis	O
.	O
Following	O
PCR	O
,	O
samples	O
containing	O
a	O
single	O
copy	O
of	O
the	O
N-myc	O
oncogene	O
were	O
clearly	O
distinguishable	O
from	O
samples	O
with	O
N-myc	O
gene	O
amplification	O
,	O
based	O
on	O
an	O
N-myc	O
/	O
GAPDH	O
ratio	O
of	O
below	O
or	O
above	O
1.0	O
,	O
respectively	O
.	O
Linear	O
regression	O
indicated	O
a	O
highly	O
significant	O
relationship	O
(	O
R	O
=	O
0.94	O
;	O
P	O
<	O
0.0001	O
)	O
between	O
N-myc	O
copy	O
number	O
(	O
Southern	O
)	O
and	O
N-myc	O
/	O
GAPDH	O
ratio	O
(	O
PCR	O
)	O
.	O
Serial	O
dilution	O
of	O
N-myc	O
amplified	O
DNA	O
with	O
non	O
-	O
amplified	O
control	O
DNA	O
indicated	O
that	O
the	O
PCR	O
assay	O
was	O
sufficiently	O
sensitive	O
to	O
detect	O
two	O
-	O
fold	O
amplification	O
.	O
Moreover	O
,	O
such	O
serial	O
dilution	O
allowed	O
determination	O
of	O
N-myc	O
copy	O
number	O
.	O
The	O
assay	O
,	O
which	O
requires	O
only	O
small	O
amounts	O
of	O
tissue	O
and	O
does	O
not	O
utilize	O
32P-radioactivity	O
,	O
therefore	O
provides	O
a	O
rapid	O
and	O
sensitive	O
alternative	O
to	O
Southern	O
analysis	O
.	O
PMID	O
:	O
8366868	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
1997	O
Aug;29(	O
2	O
)	O
:	O
135	O
-	O
8.	O
Application	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
to	O
detect	O
N-myc	O
(	O
MYCN	O
)	O
gene	O
amplification	O
on	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
of	O
neuroblastomas	B-malignancy-type
.	O
Hachitanda	O
Y	O
,	O
Saito	O
M,	O
Mori	O
T	O
,	O
Hamazaki	O
M.	O
Department	O
of	O
Pathology	O
,	O
National	O
Children	O
's	O
Hospital	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
was	O
applied	O
to	O
neuroblastoma	B-malignancy-type
for	O
detection	O
of	O
N-myc	O
(	O
MYCN	O
)	O
oncogene	O
amplification	O
,	O
and	O
the	O
results	O
were	O
compared	O
with	O
Southern	O
blot	O
analysis	O
(	O
Southern	O
)	O
.	O
In	O
nine	O
neuroblastomas	B-malignancy-type
(	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
were	O
available	O
in	O
seven	O
cases	O
including	O
two	O
cases	O
with	O
touch	O
preparations	O
,	O
and	O
two	O
cell	O
lines	O
)	O
,	O
all	O
five	O
cases	O
with	O
N-myc	O
amplification	O
detected	O
by	O
Southern	O
had	O
cells	O
with	O
multiple	O
N-myc	O
signals	O
by	O
FISH	O
,	O
and	O
three	O
cases	O
showed	O
no	O
N-myc	O
amplification	O
either	O
by	O
Southern	O
or	O
FISH	O
procedure	O
.	O
One	O
case	O
,	O
not	O
examined	O
by	O
Southern	O
,	O
showed	O
amplified	O
signals	O
of	O
N-myc	O
by	O
FISH	O
.	O
These	O
data	O
indicate	O
that	O
FISH	O
results	O
for	O
N-myc	O
amplification	O
have	O
close	O
correlation	O
with	O
Southern	O
blot	O
analysis	O
.	O
The	O
chromosome	O
2	O
-	O
specific	O
repetitive	O
DNA	O
probe	O
was	O
also	O
applied	O
for	O
the	O
analysis	O
of	O
ploidy	O
by	O
FISH	O
.	O
Six	O
cases	O
with	O
N-myc	O
amplification	O
by	O
Southern	O
and/or	O
FISH	O
had	O
diploid	O
tumors	O
and	O
two	O
cases	O
without	O
amplified	O
N-myc	O
showed	O
aneuploidy	O
.	O
The	O
remaining	O
one	O
case	O
consisted	O
of	O
heterogeneous	O
elements	O
showing	O
diploidy	O
in	O
undifferentiated	O
tissue	O
and	O
both	O
aneuploidy	O
(	O
ganglionic	O
cells	O
)	O
and	O
diploidy	O
(	O
Schwann	O
cells	O
)	O
in	O
differentiated	O
area	O
.	O
We	O
conclude	O
that	O
FISH	O
is	O
a	O
practical	O
,	O
useful	O
and	O
reliable	O
method	O
over	O
Southern	O
especially	O
for	O
analysis	O
of	O
N-myc	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
,	O
and	O
simultaneous	O
cohybridization	O
with	O
a	O
specific	O
chromosome	O
probe	O
is	O
of	O
great	O
value	O
in	O
predicting	O
the	O
prognosis	O
of	O
patients	O
.	O
PMID	O
:	O
9180916	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
.	O
1998	O
May	O
;29(	O
5	O
)	O
:	O
518	O
-21	O
.	O
Utilization	O
of	O
molecular	O
genetics	O
in	O
the	O
differentiation	O
between	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
Fogt	O
F	O
,	O
Vargas	O
MP	O
,	O
Zhuang	O
Z	O
,	O
Merino	O
MJ.	O
Laboratory	O
of	O
Pathology	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
,	O
USA	O
.	O
Distinction	O
between	O
benign	O
adrenal	O
cortical	O
proliferative	O
lesions	O
and	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
carcinoma	I-malignancy-type
has	O
been	O
approached	O
by	O
a	O
combination	O
of	O
histological	O
,	O
immunohistochemical	O
,	O
and	O
macroscopical	O
parameters	O
.	O
Modern	O
imaging	O
studies	O
allow	O
detection	O
of	O
small	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
lesions	I-malignancy-type
that	O
may	O
be	O
incorrectly	O
diagnosed	O
.	O
Differentiation	O
between	O
benign	O
and	O
malignant	O
tumors	O
of	O
the	O
adrenal	O
cortex	O
was	O
attempted	O
by	O
microdissection	O
of	O
nine	O
cases	O
of	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
hyperplasia	I-malignancy-type
,	O
10	O
cortical	B-malignancy-type
adenomas	I-malignancy-type
,	O
and	O
18	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
carcinomas	I-malignancy-type
with	O
subsequent	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
for	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
five	O
microsatellites	O
of	O
putative	O
tumor	O
suppressor	O
gene	O
loci	O
:	O
p53	O
gene	O
(	O
17p	O
)	O
,	O
the	O
neuroblastoma	B-malignancy-type
candidate	O
gene	O
(	O
1p	O
)	O
,	O
the	O
p16	O
gene	O
(	O
9p	O
)	O
,	O
the	O
von	O
Hippel	O
Lindau	O
gene	O
(	O
3p	O
)	O
,	O
and	O
the	O
retinoblastoma	B-malignancy-type
gene	O
(	O
13q	O
)	O
.	O
None	O
of	O
the	O
hyperplastic	O
lesions	O
or	O
cortical	B-malignancy-type
adenomas	I-malignancy-type
showed	O
LOH	O
of	O
any	O
of	O
the	O
gene	O
markers	O
used	O
.	O
Conversely	O
,	O
genetic	O
changes	O
were	O
observed	O
in	O
61	O
%	O
(	O
11	O
of	O
18	O
)	O
of	O
the	O
cases	O
of	O
carcinoma	B-malignancy-type
.	O
Forty	O
-	O
four	O
percent	O
of	O
the	O
lesions	O
showed	O
LOH	O
for	O
p53	O
(	O
7	O
of	O
16	O
)	O
.	O
LOH	O
of	O
1p	O
,	O
3p	O
,	O
and	O
9p	O
were	O
seen	O
in	O
22	O
%	O
,	O
22	O
%	O
,	O
and	O
26	O
%	O
,	O
respectively	O
.	O
LOH	O
of	O
the	O
retinoblastoma	B-malignancy-type
gene	O
was	O
seen	O
in	O
80	O
%	O
or	O
four	O
of	O
five	O
of	O
the	O
informative	O
cases	O
studied	O
.	O
We	O
conclude	O
that	O
LOH	O
studies	O
may	O
be	O
used	O
to	O
distinguish	O
malignant	O
from	O
nonmalignant	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
proliferations	I-malignancy-type
.	O
Relative	O
infrequency	O
of	O
LOH	O
in	O
3p	O
may	O
furthermore	O
help	O
to	O
differentiate	O
adrenal	B-malignancy-type
lesions	I-malignancy-type
from	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
kidney	O
.	O
PMID	O
:	O
9596277	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2001	O
Jun	O
1;284	O
(	O
1	O
)	O
:	O
211-	O
8.	O
VIP	O
gene	O
transcription	O
is	O
regulated	O
by	O
far	O
upstream	O
enhancer	O
and	O
repressor	O
elements	O
.	O
Liu	O
D	O
,	O
Krajniak	O
K,	O
Chun	O
D	O
,	O
Sena	O
M,	O
Casillas	O
R	O
,	O
Lelievre	O
V	O
,	O
Nguyen	O
T	O
,	O
Bravo	O
D	O
,	O
Colburn	O
S	O
,	O
Waschek	O
JA	O
.	O
Department	O
of	O
Psychiatry	O
and	O
Mental	O
Retardation	O
Research	O
Center	O
,	O
University	O
of	O
California	O
at	O
Los	O
Angeles	O
,	O
760	O
Westwood	O
Plaza	O
,	O
Room	O
68-225	O
NPI	O
,	O
Los	O
Angeles	O
,	O
California	O
,	O
90024-1759	O
SK-N-SH	O
human	O
neuroblastoma	B-malignancy-type
subclones	O
differ	O
widely	O
in	O
basal	O
and	O
second	O
messenger	O
induction	O
of	O
the	O
gene	O
encoding	O
the	O
neuropeptide	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
.	O
These	O
differences	O
were	O
recapitulated	O
by	O
a	O
chimeric	O
gene	O
which	O
consisted	O
of	O
5.2	O
kb	O
of	O
the	O
human	O
VIP	O
gene	O
5	O
'	O
flanking	O
sequence	O
fused	O
to	O
a	O
reporter	O
.	O
Subsequent	O
gene	O
deletion	O
experiments	O
revealed	O
several	O
regulatory	O
regions	O
on	O
the	O
gene	O
,	O
including	O
a	O
645-bp	O
sequence	O
located	O
approximately	O
4.0	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
.	O
Here	O
we	O
examined	O
this	O
upstream	O
region	O
in	O
detail	O
.	O
Inhibitory	O
sequences	O
were	O
found	O
to	O
be	O
present	O
on	O
each	O
end	O
of	O
the	O
645-bp	O
fragment	O
.	O
When	O
removed	O
,	O
basal	O
transcription	O
increased	O
more	O
than	O
50	O
-	O
fold	O
.	O
Subsequent	O
deletion	O
/	O
mutation	O
analysis	O
showed	O
that	O
the	O
213	O
-bp	O
fragment	O
contained	O
at	O
least	O
two	O
enhancer	O
elements	O
.	O
One	O
of	O
these	O
was	O
localized	O
to	O
an	O
AT	O
-rich	O
42	O
-bp	O
sequence	O
shown	O
by	O
others	O
to	O
bind	O
Oct	O
proteins	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
while	O
the	O
other	O
corresponded	O
to	O
a	O
composite	O
AP-1	O
/ets	O
element	O
.	O
In	O
addition	O
to	O
these	O
enhancers	O
,	O
a	O
28	O
-bp	O
sequence	O
on	O
the	O
213	O
-bp	O
fragment	O
with	O
no	O
apparent	O
homology	O
to	O
known	O
silencers	O
inhibited	O
transcription	O
.	O
The	O
studies	O
provide	O
molecular	O
details	O
of	O
a	O
complex	O
regulatory	O
region	O
on	O
the	O
VIP	O
gene	O
that	O
is	O
likely	O
to	O
be	O
used	O
to	O
finely	O
tune	O
the	O
level	O
of	O
gene	O
transcription	O
in	O
vivo	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11374892	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2001	O
Sep	O
28;276	O
(	O
39	O
)	O
:	O
3678	O
8	O
-	O
96	O
.	O
Epub	O
2001	O
Jul	O
20	O
.	O
The	O
transmembrane	O
domain	O
of	O
the	O
Alzheimer	O
's	O
beta-secretase	O
(	O
BACE1	O
)	O
determines	O
its	O
late	O
Golgi	O
localization	O
and	O
access	O
to	O
beta	O
-amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
substrate	O
.	O
Yan	O
R	O
,	O
Han	O
P,	O
Miao	O
H,	O
Greengard	O
P,	O
Xu	O
H.	O
Department	O
of	O
Cell	O
&	O
Molecular	O
Biology	O
,	O
Pharmacia	O
Corporation	O
,	O
Kalamazoo	O
,	O
Michigan	O
49007	O
,	O
USA	O
.	O
ryan@pharmacia	O
.com	O
Release	O
of	O
Abeta	O
peptides	O
from	O
beta-amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
requires	O
sequential	O
cleavage	O
by	O
two	O
endopeptidases	O
,	O
beta	O
-	O
and	O
gamma	O
-	O
secretases	O
.	O
beta-Secretase	O
was	O
recently	O
identified	O
as	O
a	O
novel	O
membrane	O
-bound	O
aspartyl	O
protease	O
,	O
named	O
BACE1	O
,	O
Asp2	O
,	O
or	O
memapsin	O
2	O
.	O
Employing	O
confocal	O
microscopy	O
and	O
subcellular	O
fractionation	O
,	O
we	O
have	O
found	O
that	O
BACE1	O
is	O
largely	O
situated	O
in	O
the	O
distal	O
Golgi	O
membrane	O
with	O
a	O
minor	O
presence	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
endosomes	O
,	O
and	O
plasma	O
membrane	O
in	O
human	O
neuroblastoma	B-malignancy-type
SHEP	O
cells	O
and	O
in	O
mouse	O
Neuro-2a	O
cell	O
lines	O
expressing	O
either	O
endogenous	O
mouse	O
BACE1	O
or	O
additional	O
exogenous	O
human	O
BACE1	O
.	O
The	O
major	O
cellular	O
beta-secretase	O
activity	O
is	O
located	O
in	O
the	O
late	O
Golgi	O
apparatus	O
,	O
consistent	O
with	O
its	O
cellular	O
localization	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
single	O
transmembrane	O
domain	O
of	O
BACE1	O
alone	O
determines	O
the	O
retention	O
of	O
BACE1	O
to	O
the	O
Golgi	O
compartments	O
,	O
through	O
examination	O
of	O
recombinant	O
proteins	O
of	O
various	O
BACE1	O
fragments	O
fused	O
to	O
a	O
reporter	O
green	O
fluorescence	O
protein	O
.	O
In	O
addition	O
,	O
we	O
show	O
that	O
the	O
transmembrane	O
domain	O
of	O
BACE1	O
is	O
required	O
for	O
the	O
access	O
of	O
BACE1	O
enzymatic	O
activity	O
to	O
the	O
cellular	O
APP	O
substrate	O
and	O
hence	O
for	O
the	O
optimal	O
generation	O
of	O
the	O
C-terminal	O
fragment	O
of	O
APP	O
(	O
CTF99	O
)	O
.	O
The	O
results	O
suggest	O
a	O
molecular	O
and	O
cell	O
biological	O
mechanism	O
for	O
the	O
regulation	O
of	O
beta-secretase	O
activity	O
in	O
vivo	O
.	O
PMID	O
:	O
11466313	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Klin	O
Padiatr	O
.	O
1991	O
Jul-	O
Aug;203(	O
4	O
)	O
:319	O
-22	O
.	O
[Increased	O
expression	O
of	O
the	O
MYCN	O
oncogene	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
and	O
possible	O
,	O
new	O
therapeutic	O
approaches	O
]	O
[	O
Article	O
in	O
German	O
]	O
Schweigerer	O
L,	O
Fotsis	O
T.	O
Sektion	O
Onkologie	O
/	O
Immunologie	O
,	O
Universitats	O
-Kinderklinik	O
,	O
Ruprecht	O
-	O
Karls	O
-Universitat	O
Heidelberg	O
.	O
Human	O
neuroblastomas	B-malignancy-type
of	O
advanced	O
stages	O
often	O
display	O
amplification	O
with	O
a	O
consecutive	O
enhanced	O
expression	O
of	O
the	O
MYCN	O
oncogene	O
.	O
Enhanced	O
MYCN	O
expression	O
is	O
thought	O
to	O
contribute	O
in	O
a	O
causative	O
manner	O
to	O
the	O
progression	O
of	O
neuroblastomas	B-malignancy-type
,	O
but	O
the	O
mechanisms	O
by	O
which	O
this	O
may	O
occur	O
have	O
remained	O
unclear	O
.	O
By	O
transfecting	O
human	O
neuroblastoma	B-malignancy-type
cells	O
that	O
display	O
a	O
normal	O
MYCN	O
expression	O
with	O
the	O
human	O
MYCN	O
oncogene	O
,	O
we	O
have	O
generated	O
a	O
cell	O
line	O
with	O
enhanced	O
MYCN	O
expression	O
and	O
thereby	O
were	O
able	O
to	O
compare	O
the	O
biological	O
and	O
biochemical	O
properties	O
of	O
the	O
transfected	O
and	O
non	O
-	O
transfected	O
cells	O
.	O
We	O
have	O
demonstrated	O
autocrine	O
growth	O
factors	O
in	O
the	O
MYCN	O
-transfected	O
,	O
but	O
not	O
the	O
non	O
-	O
transfected	O
,	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Identification	O
of	O
the	O
primary	O
structures	O
of	O
these	O
factors	O
may	O
help	O
to	O
develop	O
specific	O
antagonists	O
in	O
order	O
to	O
improve	O
the	O
therapy	O
of	O
advanced	O
neuroblastomas	B-malignancy-type
.	O
Currently	O
,	O
this	O
could	O
be	O
done	O
by	O
application	O
of	O
genistein	O
or	O
tumor	O
necrosis	O
factor	O
.	O
As	O
we	O
could	O
demonstrate	O
for	O
the	O
first	O
time	O
,	O
the	O
dietary	O
constituent	O
genistein	O
is	O
able	O
to	O
inhibit	O
the	O
proliferation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
with	O
enhanced	O
and	O
normal	O
MYCN	O
expression	O
,	O
but	O
also	O
that	O
of	O
cells	O
derived	O
from	O
other	O
solid	B-malignancy-type
pediatric	I-malignancy-type
tumors	I-malignancy-type
.	O
In	O
contrast	O
,	O
tumor	O
necrosis	O
factor	O
is	O
able	O
to	O
inhibit	O
selectively	O
the	O
proliferation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
with	O
enhanced	O
MYCN	O
expression	O
.	O
We	O
suggest	O
that	O
tumor	O
necrosis	O
factor	O
might	O
improve	O
the	O
therapy	O
of	O
advanced	O
human	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
1942938	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
.	O
1990	O
Jul-	O
Aug;10(	O
4	O
)	O
:	O
89	O
7	O
-	O
902	O
.	O
Expression	O
of	O
multiple	O
drug	O
resistance	O
gene	O
,	O
MDR1	O
,	O
and	O
N-myc	O
oncogene	O
in	O
an	O
Italian	O
population	O
of	O
human	O
neuroblastoma	B-malignancy-type
patients	O
.	O
Corrias	O
MV	O
,	O
Cornaglia-Ferraris	O
P,	O
Di	O
Martino	O
D	O
,	O
Stenger	O
AM	O
,	O
Lanino	O
E	O
,	O
Boni	O
L,	O
Tonini	O
GP	O
.	O
Pediatric	O
Oncology	O
Research	O
Laboratory	O
,	O
G.	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genova	O
,	O
Italy	O
.	O
Thirty	O
-	O
four	O
patients	O
of	O
an	O
Italian	O
population	O
affected	O
by	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
were	O
evaluated	O
at	O
diagnosis	O
for	O
multidrug	O
resistance	O
gene	O
(	O
MDR1	O
)	O
and	O
N-myc	O
oncogene	O
amplification	O
.	O
No	O
patients	O
showed	O
MDR1	O
amplification	O
,	O
while	O
extra	O
copies	O
of	O
the	O
N-myc	O
gene	O
were	O
found	O
in	O
9	O
out	O
of	O
34	O
patients	O
(	O
26	O
%	O
)	O
.	O
N-myc	O
amplification	O
was	O
correlated	O
(	O
p	O
=	O
0.008	O
)	O
with	O
a	O
shorter	O
progression	O
-	O
free	O
survival	O
.	O
RNA	O
was	O
purified	O
from	O
fresh	O
tumor	O
biopsies	O
and	O
analysed	O
in	O
29	O
NB	B-malignancy-type
samples	O
.	O
MDR1	O
gene	O
expression	O
was	O
found	O
to	O
be	O
increased	O
in	O
5	O
out	O
of	O
29	O
tumor	O
samples	O
at	O
onset	O
(	O
17	O
%	O
)	O
and	O
in	O
1	O
out	O
of	O
3	O
at	O
relapse	O
,	O
but	O
none	O
of	O
them	O
expressed	O
both	O
MDR1	O
and	O
N-myc	O
genes	O
simultaneously	O
.	O
No	O
correlation	O
was	O
found	O
between	O
MDR1	O
or	O
N-myc	O
genes	O
expression	O
and	O
tumor	O
progression	O
.	O
MDR1	O
mRNA	O
transcription	O
may	O
occur	O
spontaneously	O
after	O
onset	O
,	O
suggesting	O
that	O
certain	O
NB	B-malignancy-type
tumors	O
could	O
be	O
resistant	O
to	O
antineoplastic	O
drugs	O
at	O
onset	O
.	O
All	O
5	O
patients	O
showing	O
MDR1	O
mRNA	O
transcription	O
achieved	O
complete	O
or	O
partial	O
clinical	O
remission	O
after	O
polychemotherapy	O
.	O
This	O
was	O
presumably	O
due	O
to	O
inclusion	O
in	O
the	O
therapeutic	O
protocol	O
of	O
a	O
high	O
dose	O
of	O
Cisplatin	O
,	O
a	O
drug	O
not	O
susceptible	O
to	O
the	O
effects	O
of	O
the	O
MDR1	O
gene	O
product	O
.	O
Our	O
findings	O
show	O
that	O
cells	O
which	O
actively	O
transcribe	O
for	O
the	O
MDR1	O
gene	O
are	O
present	O
in	O
several	O
untreated	O
NB	B-malignancy-type
patients	O
.	O
No	O
gene	O
amplification	O
was	O
detected	O
and	O
probably	O
the	O
MDR1	O
gene	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O
PMID	O
:	O
1974410	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocrinology	O
.	O
1996	O
May	O
;137	O
(	O
5	O
)	O
:	O
1833	O
-40	O
.	O
Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
a	O
rat	O
pituitary	O
G	O
protein	O
-	O
coupled	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
receptor	O
.	O
Chen	O
ZP	O
,	O
Krull	O
N	O
,	O
Xu	O
S	O
,	O
Levy	O
A	O
,	O
Lightman	O
SL	O
.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Bristol	O
,	O
Bristol	O
Royal	O
Infirmary	O
,	O
England	O
.	O
There	O
is	O
increasing	O
evidence	O
that	O
pituitary	O
ATP	O
receptors	O
may	O
play	O
a	O
novel	O
role	O
in	O
modulating	O
pituitary	O
function	O
.	O
This	O
work	O
reports	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
pituitary	O
ATP	O
receptor	O
gene	O
clone	O
from	O
a	O
rat	O
pituitary	O
complementary	O
DNA	O
library	O
.	O
The	O
isolated	O
clone	O
(	O
rpP2U	O
)	O
has	O
a	O
1125-bp	O
coding	O
sequence	O
flanked	O
by	O
483	O
bp	O
of	O
5	O
'	O
-	O
and	O
422	O
bp	O
of	O
3'-untranslated	O
sequences	O
.	O
The	O
deduced	O
374	O
-amino	O
acid	O
product	O
shows	O
structural	O
features	O
common	O
to	O
other	O
G	O
protein	O
-	O
coupled	O
receptors	O
,	O
and	O
when	O
stably	O
transfected	O
into	O
a	O
glioma	B-malignancy-type
cell	O
line	O
lacking	O
endogenous	O
ATP	O
receptors	O
,	O
is	O
functionally	O
characterized	O
as	O
a	O
P2U	O
purinoceptor	O
.	O
Specifically	O
,	O
the	O
ATP	O
-	O
induced	O
intracellular	O
Ca2	O
+	O
mobilization	O
in	O
the	O
transfected	O
cells	O
was	O
inhibited	O
by	O
suramin	O
,	O
2-methylthio-	O
ATP	O
had	O
a	O
modest	O
stimulatory	O
effect	O
on	O
intracellular	O
Ca2	O
+	O
mobilization	O
,	O
and	O
beta	O
,	O
gamma-methylene	O
ATP	O
and	O
alpha	O
,	O
beta-methylene	O
ATP	O
had	O
no	O
effect	O
.	O
The	O
cloned	O
receptor	O
exhibited	O
the	O
agonist	O
potency	O
and	O
efficacy	O
profile	O
of	O
ATP	O
approximately	O
equal	O
to	O
uridine	O
triphosphate	O
>	O
ADP	O
approximately	O
equal	O
to	O
uridine	O
diphosphate	O
>	O
GTP	O
.	O
Such	O
characteristics	O
very	O
closely	O
mimic	O
the	O
pharmacologically	O
defined	O
P2U	O
purinoceptor	O
of	O
primary	O
rat	O
gonadotropes	O
and	O
mixed	O
sheep	O
pituitary	O
cells	O
,	O
and	O
Southern	O
blot	O
analysis	O
further	O
indicates	O
that	O
there	O
is	O
only	O
one	O
allele	O
in	O
rat	O
genome	O
for	O
the	O
P2U	O
purinoceptor	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
P2U	O
purinoceptor	O
is	O
the	O
predominant	O
G	O
protein	O
-	O
linked	O
ATP	O
receptor	O
found	O
in	O
the	O
pituitary	O
.	O
PMID	O
:	O
8612522	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Physiol	O
.	O
1995	O
Apr	O
15	O
;484	O
(	O
Pt	O
2	O
)	O
:	O
307	O
-12	O
.	O
Functional	O
availability	O
of	O
sodium	O
channels	O
modulated	O
by	O
cytosolic	O
free	O
Ca2	O
+	O
in	O
cultured	O
mammalian	O
neurons	O
(	O
N1E-115	O
)	O
.	O
Bulatko	O
AK	O
,	O
Greeff	O
NG.	O
Physiologisches	O
Institut	O
,	O
Universitat	O
Zurich-	O
Irchel	O
,	O
Switzerland	O
.	O
1	O
.	O
Whole	O
-	O
cell	O
sodium	O
currents	O
(	O
INa	O
)	O
were	O
measured	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
(	O
N1E-115	O
)	O
at	O
different	O
[	O
Ca2	O
+	O
]i	O
values	O
using	O
appropriate	O
Ca-EGTA	O
buffers	O
in	O
the	O
pipettes	O
.	O
2.	O
INa	O
was	O
found	O
to	O
be	O
larger	O
at	O
pCa	O
7	O
than	O
at	O
pCa	O
8	O
or	O
9	O
with	O
a	O
ratio	O
of	O
1	O
:0.65	O
or	O
0.55	O
,	O
respectively	O
.	O
The	O
steady	O
-state	O
inactivation	O
(	O
h	O
infinity	O
curve	O
)	O
was	O
independent	O
of	O
[	O
Ca2	O
+	O
]i	O
,	O
thus	O
excluding	O
surface	O
charge	O
effects	O
as	O
a	O
cause	O
of	O
the	O
Ca2	O
+	O
effect	O
.	O
3	O
.	O
Recovery	O
of	O
INa	O
from	O
slow	O
inactivation	O
after	O
changing	O
from	O
resting	O
(	O
-30	O
to	O
-	O
40	O
mV	O
)	O
to	O
holding	O
potential	O
(	O
-70	O
mV	O
)	O
occurred	O
in	O
a	O
similar	O
way	O
at	O
all	O
pCa	O
values	O
.	O
The	O
Ca2	O
+	O
effect	O
appears	O
to	O
be	O
independent	O
of	O
slow	O
inactivation	O
and	O
to	O
occur	O
within	O
the	O
first	O
2	O
min	O
of	O
pipette	O
buffer	O
-	O
cytoplasm	O
equilibration	O
.	O
4	O
.	O
The	O
cell	O
membrane	O
capacitance	O
(	O
Cm	O
)	O
was	O
independent	O
of	O
[	O
Ca2	O
+	O
]i	O
,	O
thus	O
excluding	O
exo	O
-	O
or	O
endocytosis	O
of	O
sodium	O
channel-containing	O
membrane	O
as	O
a	O
cause	O
of	O
the	O
Ca2	O
+	O
effect	O
.	O
5	O
.	O
Non	O
-	O
stationary	O
fluctuation	O
analysis	O
was	O
used	O
to	O
determine	O
simultaneously	O
the	O
single	O
channel	O
current	O
(	O
iNa	O
)	O
and	O
the	O
size	O
of	O
INa	O
.	O
At	O
pCa	O
values	O
of	O
7	O
and	O
9	O
,	O
iNa	O
was	O
identical	O
,	O
i.e	O
.	O
0.59	O
and	O
0.58	O
pA	O
,	O
while	O
INa	O
/	O
Cm	O
differed	O
,	O
i.e	O
.	O
41.1	O
and	O
22.2	O
pA	O
pF-1	O
,	O
respectively	O
.	O
The	O
peak	O
open	O
probability	O
at	O
0	O
mV	O
was	O
about	O
0.5	O
for	O
both	O
pCa	O
values	O
indicating	O
that	O
[	O
Ca2	O
+	O
]i	O
controls	O
the	O
fraction	O
of	O
channels	O
available	O
for	O
activation	O
.	O
6	O
.	O
Since	O
[	O
Ca2	O
+	O
]i	O
in	O
other	O
neurons	O
varies	O
between	O
30	O
and	O
100	O
nM	O
in	O
the	O
resting	O
and	O
active	O
state	O
,	O
respectively	O
,	O
the	O
present	O
data	O
suggest	O
a	O
modulatory	O
role	O
for	O
[	O
Ca2	O
+	O
]i	O
in	O
neuronal	O
excitability	O
.	O
PMID	O
:	O
7602527	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Pharmacol	O
.	O
1993	O
Oct	O
15	O
;247(	O
2	O
)	O
:	O
145-54	O
.	O
Pharmacological	O
and	O
functional	O
characterization	O
of	O
human	O
mineralocorticoid	O
and	O
glucocorticoid	O
receptor	O
ligands	O
.	O
Rupprecht	O
R	O
,	O
Reul	O
JM	O
,	O
van	O
Steensel	O
B	O
,	O
Spengler	O
D	O
,	O
Soder	O
M,	O
Berning	O
B	O
,	O
Holsboer	O
F	O
,	O
Damm	O
K.	O
Max	O
Planck	O
Institute	O
of	O
Psychiatry	O
,	O
Department	O
of	O
Neuroendocrinology	O
,	O
Munich	O
,	O
Germany	O
.	O
We	O
characterized	O
the	O
pharmacological	O
profiles	O
of	O
the	O
human	O
mineralocorticoid	O
and	O
glucocorticoid	O
receptor	O
for	O
11	O
natural	O
and	O
synthetic	O
steroids	O
regarding	O
binding	O
pharmacology	O
,	O
intracellular	O
localization	O
of	O
hormone	O
-	O
receptor	O
complexes	O
,	O
and	O
agonistic	O
or	O
antagonistic	O
properties	O
at	O
the	O
gene	O
expression	O
level	O
.	O
The	O
sex	O
steroid	O
progesterone	O
bound	O
with	O
an	O
affinity	O
(	O
ki	O
<	O
0.01	O
nM	O
)	O
even	O
higher	O
than	O
that	O
of	O
aldosterone	O
to	O
the	O
human	O
mineralocorticoid	O
receptor	O
and	O
effectively	O
antagonized	O
the	O
effect	O
of	O
aldosterone	O
via	O
the	O
human	O
mineralocorticoid	O
receptor	O
in	O
functional	O
co	O
-	O
transfection	O
assays	O
.	O
This	O
indicates	O
that	O
progesterone	O
has	O
potent	O
antimineralocorticoid	O
properties	O
,	O
while	O
its	O
antiglucocorticoid	O
effects	O
were	O
less	O
pronounced	O
.	O
The	O
partial	O
agonistic	O
activities	O
of	O
antihormones	O
in	O
this	O
assay	O
suggest	O
a	O
direct	O
interaction	O
of	O
antihormone	O
-	O
receptor	O
complexes	O
with	O
the	O
response	O
elements	O
on	O
the	O
DNA	O
.	O
These	O
results	O
are	O
supported	O
by	O
immunofluorescence	O
studies	O
,	O
in	O
which	O
both	O
unliganded	O
human	O
mineralocorticoid	O
and	O
glucocorticoid	O
receptors	O
were	O
distributed	O
throughout	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
agonist	O
-	O
as	O
well	O
as	O
antagonist	O
-	O
receptor	O
complexes	O
showed	O
an	O
exclusively	O
nuclear	O
localization	O
.	O
These	O
results	O
contribute	O
to	O
the	O
understanding	O
of	O
antihormone	O
pharmacology	O
and	O
increase	O
our	O
understanding	O
of	O
the	O
role	O
of	O
human	O
mineralocorticoid	O
and	O
glucocorticoid	O
receptors	O
in	O
physiological	O
processes	O
during	O
different	O
endocrine	O
states	O
.	O
PMID	O
:	O
8282004	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1996	O
Dec	O
24;9	O
3	O
(	O
26	O
)	O
:15190	O
-4.	O
Cytoplasmically	O
sequestered	O
wild-type	O
p53	O
protein	O
in	O
neuroblastoma	B-malignancy-type
is	O
relocated	O
to	O
the	O
nucleus	O
by	O
a	O
C-terminal	O
peptide	O
.	O
Ostermeyer	O
AG	O
,	O
Runko	O
E	O
,	O
Winkfield	O
B	O
,	O
Ahn	O
B	O
,	O
Moll	O
UM	O
.	O
Department	O
of	O
Pathology	O
,	O
State	O
University	O
of	O
New	O
York	O
at	O
Stony	O
Brook	O
11794	O
-8691	O
,	O
USA	O
.	O
Cytoplasmic	O
sequestration	O
of	O
wild-type	O
p53	O
protein	O
occurs	O
in	O
a	O
subset	O
of	O
primary	O
human	O
tumors	O
including	O
breast	B-malignancy-type
cancer	I-malignancy-type
,	O
colon	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
.	O
The	O
sequestered	O
p53	O
localizes	O
to	O
punctate	O
cytoplasmic	O
structures	O
that	O
represent	O
large	O
protein	O
aggregates	O
.	O
One	O
functional	O
consequence	O
of	O
this	O
blocked	O
nuclear	O
access	O
is	O
impairment	O
of	O
the	O
p53	O
-	O
mediated	O
G1	O
checkpoint	O
after	O
DNA	O
damage	O
.	O
Here	O
we	O
show	O
that	O
cytoplasmic	O
p53	O
from	O
NB	B-malignancy-type
cells	O
is	O
incompetent	O
for	O
specific	O
DNA	O
binding	O
,	O
probably	O
due	O
to	O
its	O
sequestration	O
.	O
Importantly	O
,	O
the	O
C-terminal	O
domain	O
of	O
sequestered	O
p53	O
is	O
masked	O
,	O
as	O
indicated	O
by	O
the	O
failure	O
of	O
a	O
C-terminally	O
directed	O
antibody	O
to	O
detect	O
p53	O
in	O
these	O
structures	O
.	O
To	O
determine	O
(	O
i)	O
which	O
domain	O
of	O
p53	O
is	O
involved	O
in	O
the	O
aggregation	O
and	O
(ii)	O
whether	O
this	O
phenotype	O
is	O
potentially	O
reversible	O
,	O
we	O
generated	O
stable	O
NB	B-malignancy-type
sublines	O
that	O
coexpress	O
the	O
soluble	O
C-terminal	O
mouse	O
p53	O
peptide	O
DD1	O
(	O
amino	O
acids	O
302-390	O
)	O
.	O
A	O
dramatic	O
phenotypic	O
reversion	O
occurred	O
in	O
five	O
of	O
five	O
lines	O
.	O
The	O
presence	O
of	O
DD1	O
blocked	O
the	O
sequestration	O
of	O
wild-type	O
p53	O
and	O
relocated	O
it	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
accumulated	O
.	O
The	O
nuclear	O
translocation	O
is	O
due	O
to	O
shuttling	O
of	O
wild-type	O
p53	O
by	O
heteroligomerization	O
to	O
DD1	O
,	O
as	O
shown	O
by	O
coimmunoprecipitation	O
.	O
As	O
expected	O
,	O
the	O
nuclear	O
heterocomplexes	O
were	O
functionally	O
inactive	O
,	O
since	O
DD1	O
is	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
wild-type	O
p53	O
.	O
In	O
summary	O
,	O
we	O
show	O
that	O
nuclear	O
access	O
of	O
p53	O
can	O
be	O
restored	O
in	O
NB	B-malignancy-type
cells	O
.	O
PMID	O
:	O
8986786	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
.	O
2002	O
Apr;26(	O
4	O
)	O
:	O
48	O
6-	O
92	O
.	O
C-kit	O
expression	O
in	O
pediatric	O
solid	B-malignancy-type
tumors	I-malignancy-type
:	O
a	O
comparative	O
immunohistochemical	O
study	O
.	O
Smithey	O
BE	O
,	O
Pappo	O
AS	O
,	O
Hill	O
DA	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Tennessee	O
Medical	O
Center	O
,	O
Memphis	O
,	O
Tennessee	O
,	O
USA	O
.	O
The	O
stem	O
cell	O
factor	O
/	O
c-kit	O
tyrosine	O
kinase	O
receptor	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
tumor	O
growth	O
and	O
progression	O
in	O
several	O
cancers	O
,	O
including	O
mast	O
cell	O
diseases	O
,	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
,	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
Ewing	B-malignancy-type
sarcoma	I-malignancy-type
.	O
Studies	O
using	O
the	O
oral	O
agent	O
STI-571	O
(	O
Gleevec	O
,	O
Novartis	O
)	O
,	O
an	O
inhibitor	O
of	O
the	O
tyrosine	O
kinases	O
bcr	O
-	O
abl	O
,	O
c-kit	O
,	O
and	O
PDGFR	O
,	O
have	O
shown	O
significant	O
responses	O
in	O
patients	O
with	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
and	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
.	O
With	O
the	O
aim	O
of	O
identifying	O
additional	O
groups	O
of	O
tumors	O
that	O
may	O
use	O
the	O
stem	O
cell	O
factor	O
/	O
c-kit	O
pathway	O
and	O
secondarily	O
may	O
be	O
responsive	O
to	O
STI-571	O
treatment	O
,	O
this	O
study	O
surveyed	O
151	O
primary	O
tumors	O
from	O
patients	O
treated	O
at	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
for	O
immunohistochemical	O
expression	O
of	O
c-kit	O
.	O
Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
sections	O
were	O
stained	O
with	O
rabbit	O
polyclonal	O
anti	O
-	O
human	O
c-kit	O
(	O
CD117	O
,	O
Dako	O
)	O
using	O
standard	O
avidin	O
-	O
biotin	O
-	O
peroxidase	O
complex	O
technique	O
,	O
antigen	O
retrieval	O
,	O
and	O
an	O
automated	O
stainer	O
.	O
Strong	O
,	O
diffuse	O
staining	O
for	O
c-kit	O
was	O
seen	O
in	O
a	O
proportion	O
of	O
synovial	B-malignancy-type
sarcomas	I-malignancy-type
,	O
osteosarcomas	B-malignancy-type
,	O
and	O
Ewing	B-malignancy-type
sarcomas	I-malignancy-type
.	O
Strong	O
,	O
diffuse	O
staining	O
was	O
less	O
common	O
in	O
neuroblastomas	B-malignancy-type
,	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumors	I-malignancy-type
,	O
and	O
rhabdomyosarcomas	B-malignancy-type
and	O
was	O
negative	O
in	O
alveolar	B-malignancy-type
soft	I-malignancy-type
part	I-malignancy-type
sarcomas	I-malignancy-type
and	O
desmoplastic	B-malignancy-type
small	I-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Tumors	O
with	O
strong	O
,	O
diffuse	O
staining	O
for	O
c-kit	O
in	O
a	O
pattern	O
similar	O
to	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
may	O
represent	O
suitable	O
targets	O
for	O
new	O
therapeutic	O
agents	O
.	O
PMID	O
:	O
11914627	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
2002	O
May	O
28;99	O
(	O
11	O
)	O
:7367	O
-72	O
.	O
15-Deoxy-Delta(	O
12,14)	O
-	O
prostaglandin	O
J(2	O
)	O
:	O
the	O
endogenous	O
electrophile	O
that	O
induces	O
neuronal	O
apoptosis	O
.	O
Kondo	O
M,	O
Shibata	O
T	O
,	O
Kumagai	O
T	O
,	O
Osawa	O
T	O
,	O
Shibata	O
N	O
,	O
Kobayashi	O
M,	O
Sasaki	O
S	O
,	O
Iwata	O
M,	O
Noguchi	O
N	O
,	O
Uchida	O
K.	O
Laboratory	O
of	O
Food	O
and	O
Biodynamics	O
,	O
Graduate	O
School	O
of	O
Bioagricultural	O
Sciences	O
,	O
Nagoya	O
University	O
,	O
Nagoya	O
464	O
-8601	O
,	O
Japan	O
.	O
Prostaglandin	O
D(2	O
)	O
(	O
PGD(2)	O
)	O
,	O
a	O
major	O
cyclooxygenase	O
product	O
in	O
a	O
variety	O
of	O
tissues	O
and	O
cells	O
,	O
readily	O
undergoes	O
dehydration	O
to	O
yield	O
the	O
bioactive	O
cyclopentenone	O
-	O
type	O
PGs	O
of	O
the	O
J(2)	O
-	O
series	O
,	O
such	O
as	O
15	O
-deoxy-Delta(	O
12,14)	O
-PGJ(2	O
)	O
(	O
15d	O
-	O
PGJ(2)	O
)	O
.	O
The	O
observation	O
that	O
the	O
level	O
of	O
15d	O
-	O
PGJ(2	O
)	O
increased	O
in	O
the	O
tissue	O
cells	O
from	O
patients	O
with	O
sporadic	O
amyotrophic	O
lateral	O
sclerosis	O
suggested	O
that	O
the	O
formation	O
of	O
15d	O
-	O
PGJ(2	O
)	O
may	O
be	O
closely	O
associated	O
with	O
neuronal	O
cell	O
death	O
during	O
chronic	O
inflammatory	O
processes	O
.	O
In	O
vitro	O
experiments	O
using	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cells	O
revealed	O
that	O
15d	O
-	O
PGJ(2	O
)	O
induced	O
apoptotic	O
cell	O
death	O
.	O
An	O
oligonucleotide	O
microarray	O
analysis	O
demonstrated	O
that	O
,	O
in	O
addition	O
to	O
the	O
heat	O
shock	O
-	O
responsive	O
and	O
redox-responsive	O
genes	O
,	O
the	O
p53	O
-	O
responsive	O
genes	O
,	O
such	O
as	O
gadd45	O
,	O
cyclin	O
G1	O
,	O
and	O
cathepsin	O
D	O
,	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
cells	O
treated	O
with	O
15d	O
-	O
PGJ(2	O
)	O
.	O
Indeed	O
,	O
the	O
15d	O
-	O
PGJ(2	O
)	O
induced	O
accumulation	O
and	O
phosphorylation	O
of	O
p53	O
,	O
which	O
was	O
accompanied	O
by	O
a	O
preferential	O
redistribution	O
of	O
the	O
p53	O
protein	O
in	O
the	O
nuclei	O
of	O
the	O
cells	O
and	O
by	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
p53	O
DNA	O
binding	O
activity	O
,	O
suggesting	O
that	O
p53	O
accumulated	O
in	O
response	O
to	O
the	O
treatment	O
with	O
15d	O
-	O
PGJ(2	O
)	O
was	O
functional	O
.	O
The	O
15d	O
-	O
PGJ(2)	O
-	O
induced	O
accumulation	O
of	O
p53	O
resulted	O
in	O
the	O
activation	O
of	O
a	O
death	O
-	O
inducing	O
caspase	O
cascade	O
mediated	O
by	O
Fas	O
and	O
the	O
Fas	O
ligand	O
.	O
PMID	O
:	O
12032289	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurochem	O
Res	O
.	O
1988	O
Nov;13(	O
11	O
)	O
:	O
1015-21	O
.	O
Sodium	O
channel	O
activation	O
does	O
not	O
alter	O
lipid	O
metabolism	O
in	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Glanville	O
TN	O
,	O
Spence	O
MW	O
,	O
Cook	O
HW	O
,	O
Palmer	O
FB.	O
Atlantic	O
Research	O
Center	O
for	O
Mental	O
Retardation	O
,	O
Halifax	O
,	O
Nova	O
Scotia	O
,	O
Canada	O
.	O
The	O
interaction	O
of	O
voltage	O
-	O
sensitive	O
Na+-channels	O
and	O
membrane	O
lipid	O
metabolism	O
was	O
examined	O
by	O
incubating	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
with	O
neurotoxins	O
which	O
alter	O
the	O
voltage	O
-	O
dependent	O
relationship	O
between	O
the	O
closed	O
and	O
open	O
conformation	O
of	O
the	O
channel	O
protein	O
.	O
Guanidinium	O
flux	O
rate	O
,	O
a	O
measure	O
of	O
Na+-channel	O
activation	O
,	O
was	O
increased	O
10	O
-	O
fold	O
by	O
the	O
combined	O
action	O
of	O
veratridine	O
(	O
100	O
microM	O
)	O
and	O
scorpion	O
venom	O
(	O
28	O
micrograms	O
/	O
ml	O
)	O
.	O
This	O
response	O
was	O
completely	O
blocked	O
by	O
tetrodotoxin	O
(	O
1	O
microM	O
)	O
.	O
Under	O
the	O
same	O
experimental	O
conditions	O
,	O
the	O
toxins	O
did	O
not	O
increase	O
the	O
efflux	O
of	O
[3H]arachidonic	O
acid	O
from	O
prelabeled	O
cell	O
membrane	O
lipids	O
or	O
stimulate	O
uptake	O
of	O
exogenous	O
[3H]arachidonic	O
acid	O
.	O
In	O
addition	O
,	O
altering	O
membrane	O
fatty	O
acid	O
composition	O
by	O
incubating	O
cells	O
for	O
24	O
hr	O
in	O
a	O
medium	O
containing	O
50	O
microM	O
arachidonic	O
or	O
oleic	O
acid	O
did	O
not	O
alter	O
guanidinium	O
flux	O
rates	O
relative	O
to	O
that	O
of	O
control	O
cultures	O
.	O
When	O
cells	O
were	O
pulsed	O
with	O
32Pi	O
for	O
60	O
min	O
and	O
stimulated	O
by	O
veratridine	O
plus	O
scorpion	O
venom	O
for	O
an	O
additional	O
30	O
min	O
,	O
uptake	O
of	O
32Pi	O
into	O
phosphatidylinositol	O
was	O
reduced	O
;	O
stimulating	O
cells	O
with	O
bradykinin	O
,	O
a	O
receptor	O
agonist	O
which	O
activates	O
the	O
inositol	O
cycle	O
,	O
promoted	O
a	O
3.8	O
fold	O
increase	O
.	O
Polyphosphoinositide	O
turnover	O
was	O
not	O
affected	O
by	O
Na+-channel	O
activation	O
,	O
but	O
was	O
stimulated	O
by	O
bradykinin	O
.	O
These	O
results	O
suggest	O
that	O
voltage	O
-	O
sensitive	O
Na+-channel	O
activation	O
in	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
can	O
function	O
independent	O
of	O
membrane	O
phospholipid	O
and	O
fatty	O
acid	O
metabolism	O
.	O
PMID	O
:	O
2853304	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
.	O
2000	O
May	O
;156	O
(	O
5	O
)	O
:1711-21	O
.	O
Expression	O
of	O
the	O
ALK	O
tyrosine	O
kinase	O
gene	O
in	O
neuroblastoma	B-malignancy-type
.	O
Lamant	O
L,	O
Pulford	O
K,	O
Bischof	O
D	O
,	O
Morris	O
SW	O
,	O
Mason	O
DY	O
,	O
Delsol	O
G	O
,	O
Mariame	O
B.	O
Department	O
of	O
Pathology	O
,	O
Centre	O
Hospitalo-Universitaire	O
Purpan	O
,	O
Toulouse	O
,	O
France	O
.	O
ALK	O
(	O
anaplastic	B-malignancy-type
lymphoma	I-malignancy-type
kinase	O
)	O
is	O
a	O
tyrosine	O
kinase	O
receptor	O
,	O
expressed	O
as	O
part	O
of	O
the	O
chimeric	O
NPM	O
-ALK	O
protein	O
,	O
in	O
anaplastic	B-malignancy-type
large	I-malignancy-type
cell	I-malignancy-type
lymphomas	I-malignancy-type
(	O
ALCLs	B-malignancy-type
)	O
exhibiting	O
the	O
t	O
(	O
2	O
;	O
5	O
)	O
(	O
p23	O
q35	O
)	O
translocation	O
.	O
As	O
a	O
result	O
of	O
this	O
translocation	O
,	O
the	O
NPM	O
(	O
nucleophosmin	O
)	O
gene	O
is	O
fused	O
to	O
the	O
portion	O
of	O
the	O
ALK	O
gene	O
encoding	O
its	O
intracytoplasmic	O
segment	O
.	O
In	O
normal	O
mouse	O
tissues	O
,	O
mRNA	O
encoding	O
the	O
Alk	O
receptor	O
has	O
been	O
found	O
only	O
in	O
neural	O
cells	O
,	O
suggesting	O
involvement	O
of	O
this	O
receptor	O
in	O
the	O
development	O
of	O
the	O
nervous	O
system	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
presence	O
of	O
ALK	O
transcripts	O
and	O
protein	O
in	O
normal	O
human	O
tissues	O
and	O
a	O
variety	O
of	O
cell	O
lines	O
and	O
human	O
tumors	O
.	O
Emphasis	O
was	O
placed	O
on	O
neuroblastomas	B-malignancy-type
because	O
other	O
tyrosine	O
kinase	O
receptors	O
are	O
expressed	O
in	O
human	O
neuroblastomas	B-malignancy-type
.	O
Fifty	O
-six	O
cell	O
lines	O
,	O
including	O
29	O
lines	O
of	O
neural	O
origin	O
,	O
and	O
lymphoid	O
and	O
nonlymphoid	O
tissue	O
specimens	O
,	O
including	O
24	O
neuroblastomas	B-malignancy-type
,	O
were	O
investigated	O
for	O
ALK	O
expression	O
,	O
using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
Western	O
blotting	O
,	O
and	O
immunohistochemistry	O
.	O
The	O
results	O
confirmed	O
that	O
mRNA	O
encoding	O
ALK	O
protein	O
was	O
not	O
detectable	O
in	O
any	O
normal	O
or	O
neoplastic	O
hematopoietic	O
tissue	O
tested	O
,	O
except	O
for	O
t	O
(	O
2	O
;	O
5	O
)	O
-	O
positive	O
ALCL	B-malignancy-type
.	O
The	O
salient	O
finding	O
was	O
that	O
13	O
of	O
the	O
29	O
cell	O
lines	O
of	O
neural	O
origin	O
and	O
22	O
of	O
24	O
neuroblastomas	B-malignancy-type
were	O
found	O
to	O
express	O
ALK	O
transcripts	O
and	O
ALK	O
protein	O
.	O
However	O
,	O
no	O
correlation	O
was	O
evident	O
between	O
any	O
known	O
prognostic	O
factors	O
and	O
the	O
level	O
of	O
ALK	O
expression	O
.	O
PMID	O
:	O
10793082	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Cell	O
Biol	O
.	O
1999	O
Dec;1(	O
8	O
)	O
:479	O
-	O
85	O
.	O
Presenilin-1	O
mutations	O
downregulate	O
the	O
signalling	O
pathway	O
of	O
the	O
unfolded	O
-	O
protein	O
response	O
.	O
Katayama	O
T	O
,	O
Imaizumi	O
K,	O
Sato	O
N	O
,	O
Miyoshi	O
K,	O
Kudo	O
T	O
,	O
Hitomi	O
J,	O
Morihara	O
T	O
,	O
Yoneda	O
T	O
,	O
Gomi	O
F	O
,	O
Mori	O
Y	O
,	O
Nakano	O
Y	O
,	O
Takeda	O
J,	O
Tsuda	O
T	O
,	O
Itoyama	O
Y	O
,	O
Murayama	O
O	O
,	O
Takashima	O
A	O
,	O
St	O
George-Hyslop	O
P,	O
Takeda	O
M,	O
Tohyama	O
M.	O
Department	O
of	O
Anatomy	O
and	O
Neuroscience	O
,	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Osaka	O
University	O
,	O
2-2	O
Yamadaoka	O
,	O
Suita	O
,	O
Osaka	O
56	O
5	O
-0871	O
,	O
Japan	O
.	O
Missense	O
mutations	O
in	O
the	O
human	O
presenilin-1	O
(	O
PS1	O
)	O
gene	O
,	O
which	O
is	O
found	O
on	O
chromosome	O
14	O
,	O
cause	O
early-onset	O
familial	O
Alzheimer	O
's	O
disease	O
(	O
FAD	O
)	O
.	O
FAD	O
-	O
linked	O
PS1	O
variants	O
alter	O
proteolytic	O
processing	O
of	O
the	O
amyloid	O
precursor	O
protein	O
and	O
cause	O
an	O
increase	O
in	O
vulnerability	O
to	O
apoptosis	O
induced	O
by	O
various	O
cell	O
stresses	O
.	O
However	O
,	O
the	O
mechanisms	O
responsible	O
for	O
these	O
phenomena	O
are	O
not	O
clear	O
.	O
Here	O
we	O
report	O
that	O
mutations	O
in	O
PS1	O
affect	O
the	O
unfolded	O
-	O
protein	O
response	O
(	O
UPR	O
)	O
,	O
which	O
responds	O
to	O
the	O
increased	O
amount	O
of	O
unfolded	O
proteins	O
that	O
accumulate	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
under	O
conditions	O
that	O
cause	O
ER	O
stress	O
.	O
PS1	O
mutations	O
also	O
lead	O
to	O
decreased	O
expression	O
of	O
GRP78	O
/	O
Bip	O
,	O
a	O
molecular	O
chaperone	O
,	O
present	O
in	O
the	O
ER	O
,	O
that	O
can	O
enable	O
protein	O
folding	O
.	O
Interestingly	O
,	O
GRP78	O
levels	O
are	O
reduced	O
in	O
the	O
brains	O
of	O
Alzheimer	O
's	O
disease	O
patients	O
.	O
The	O
downregulation	O
of	O
UPR	O
signalling	O
by	O
PS1	O
mutations	O
is	O
caused	O
by	O
disturbed	O
function	O
of	O
IRE1	O
,	O
which	O
is	O
the	O
proximal	O
sensor	O
of	O
conditions	O
in	O
the	O
ER	O
lumen	O
.	O
Overexpression	O
of	O
GRP78	O
in	O
neuroblastoma	B-malignancy-type
cells	O
bearing	O
PS1	O
mutants	O
almost	O
completely	O
restores	O
resistance	O
to	O
ER	O
stress	O
to	O
the	O
level	O
of	O
cells	O
expressing	O
wild-type	O
PS1	O
.	O
These	O
results	O
show	O
that	O
mutations	O
in	O
PS1	O
may	O
increase	O
vulnerability	O
to	O
ER	O
stress	O
by	O
altering	O
the	O
UPR	O
signalling	O
pathway	O
.	O
PMID	O
:	O
10587643	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Clin	O
Oncol	O
.	O
1991	O
Feb;21	O
(	O
1	O
)	O
:	O
1-	O
7.	O
Proposal	O
and	O
assessment	O
of	O
Japanese	O
tumor	O
node	O
metastasis	O
postsurgical	O
histopathological	O
staging	O
system	O
for	O
neuroblastoma	B-malignancy-type
based	O
on	O
an	O
analysis	O
of	O
495	O
cases	O
.	O
Nakagawara	O
A	O
,	O
Morita	O
K,	O
Okabe	O
I	O
,	O
Uchino	O
J,	O
Ohi	O
R	O
,	O
Iwafuchi	O
M,	O
Matsuyama	O
S	O
,	O
Nagashima	O
K,	O
Takahashi	O
H,	O
Nakajo	O
T	O
,	O
et	O
al	O
.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
.	O
In	O
1971	O
,	O
the	O
Japanese	O
Society	O
of	O
Pediatric	O
Surgeons	O
'	O
Committee	O
on	O
Malignancies	O
proposed	O
new	O
criteria	O
for	O
neuroblastoma	B-malignancy-type
staging	O
.	O
It	O
was	O
fundamentally	O
,	O
based	O
on	O
the	O
system	O
of	O
Evans	O
et	O
al	O
.	O
described	O
in	O
1971	O
.	O
The	O
main	O
difference	O
was	O
the	O
separation	O
of	O
stage	O
IV	O
disease	O
into	O
stages	O
IV-A	O
,	O
with	O
metastases	O
to	O
bone	O
,	O
orbita	O
,	O
distant	O
lymph	O
nodes	O
and	O
viscera	O
other	O
than	O
liver	O
,	O
IV-B	O
,	O
the	O
primary	O
tumor	O
extending	O
over	O
the	O
midline	O
and	O
with	O
metastases	O
to	O
bone	O
marrow	O
,	O
liver	O
and	O
skin	O
,	O
and	O
IV-S	O
,	O
which	O
was	O
the	O
same	O
as	O
that	O
of	O
Evans	O
et	O
al	O
.	O
The	O
new	O
criteria	O
did	O
not	O
include	O
the	O
resectability	O
of	O
the	O
primary	O
tumor	O
,	O
assessment	O
of	O
regional	O
lymph	O
node	O
involvement	O
or	O
any	O
other	O
disease	O
assessment	O
resulting	O
from	O
therapeutic	O
intervention	O
.	O
For	O
the	O
purpose	O
of	O
international	O
usage	O
,	O
the	O
Japanese	O
system	O
has	O
been	O
newly	O
formulated	O
and	O
proposed	O
as	O
the	O
Japanese	O
Tumor	O
Node	O
Metastasis	O
(	O
TNM	O
)	O
Postsurgical	O
Histopathological	O
Classification	O
for	O
Neuroblastoma	B-malignancy-type
.	O
In	O
the	O
present	O
report	O
,	O
495	O
neuroblastomas	B-malignancy-type
,	O
registered	O
between	O
1970	O
and	O
1985	O
,	O
were	O
analyzed	O
retrospectively	O
according	O
to	O
the	O
International	O
Union	O
Against	O
Cancer	O
(	O
UICC	O
)	O
TNM	O
classification	O
and	O
the	O
proposed	O
Japanese	O
TNM	O
system	O
.	O
The	O
analyses	O
suggested	O
that	O
the	O
Japanese	O
system	O
reflected	O
both	O
the	O
extent	O
of	O
tumor	O
invasion	O
and	O
its	O
biological	O
neuroblastoma	B-malignancy-type
characteristics	O
better	O
than	O
the	O
UICC	O
TNM	O
classification	O
based	O
on	O
statistical	O
analysis	O
.	O
PMID	O
:	O
2067117	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Med	O
Virol	O
.	O
2003	O
May;70	O
(	O
1	O
)	O
:	O
109	O
-	O
18	O
.	O
Comparative	O
study	O
of	O
enterovirus	O
71	O
infection	O
of	O
human	O
cell	O
lines	O
.	O
Wen	O
YY	O
,	O
Chang	O
TY	O
,	O
Chen	O
ST	O
,	O
Li	O
C	O
,	O
Liu	O
HS	O
.	O
Department	O
of	O
Microbiology	O
and	O
Immunology	O
,	O
College	O
of	O
Medicine	O
,	O
National	O
Cheng	O
Kung	O
University	O
,	O
Tainan	O
,	O
Taiwan	O
.	O
The	O
cell	O
tropism	O
of	O
enterovirus	O
71	O
(	O
Enteroviridae	O
)	O
in	O
neuronal	O
,	O
glial	O
and	O
laryngeal	O
cells	O
.	O
The	O
4643	O
strain	O
,	O
an	O
enterovirus	O
71	O
isolate	O
from	O
a	O
patient	O
in	O
Taiwan	O
,	O
was	O
used	O
to	O
infect	O
three	O
human	O
cell	O
lines	O
representing	O
neuronal	O
cells	O
(	O
SK-N-SH	O
,	O
neuroblastoma	B-malignancy-type
)	O
,	O
glial	O
cells	O
(	O
U373MG	O
,	O
glioblastoma	B-malignancy-type
)	O
,	O
and	O
laryngeal	O
cells	O
(	O
HEp-2	O
,	O
larynx	B-malignancy-type
epidermoid	I-malignancy-type
carcinoma	I-malignancy-type
)	O
.	O
Immunofluorescent	O
staining	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
were	O
used	O
to	O
detect	O
mature	O
enterovirus	O
71	O
4643	O
virions	O
in	O
these	O
cell	O
lines	O
.	O
The	O
three	O
cell	O
lines	O
were	O
also	O
compared	O
for	O
presence	O
of	O
virus	O
-	O
mediated	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
,	O
synthesis	O
of	O
infected	O
cell	O
-	O
specific	O
proteins	O
,	O
viral	O
(	O
-)	O
RNA	O
,	O
and	O
virus	O
replication	O
rate	O
.	O
Virus	O
particles	O
were	O
detected	O
by	O
TEM	O
,	O
and	O
viral	O
replication	O
increased	O
over	O
time	O
,	O
indicating	O
the	O
existence	O
and	O
release	O
of	O
mature	O
viruses	O
from	O
all	O
three	O
infected	O
cell	O
lines	O
.	O
The	O
most	O
severe	O
CPE	O
and	O
the	O
highest	O
viral	O
replication	O
rate	O
were	O
observed	O
in	O
the	O
SK-N-SH	O
cells	O
.	O
Further	O
screening	O
of	O
the	O
infected	O
cell	O
lines	O
by	O
microarray	O
analysis	O
revealed	O
that	O
the	O
neuron	O
growth	O
factor	O
receptor	O
(	O
NGFR	O
)	O
gene	O
was	O
uniquely	O
upregulated	O
in	O
infected	O
SK-N-SH	O
cells	O
,	O
implying	O
that	O
the	O
receptor	O
encoded	O
by	O
this	O
gene	O
may	O
be	O
involved	O
in	O
cell	O
tropism	O
.	O
The	O
data	O
show	O
that	O
neurons	O
are	O
vulnerable	O
to	O
enterovirus	O
71	O
4643	O
infection	O
and	O
are	O
consistent	O
with	O
the	O
clinical	O
observation	O
that	O
enterovirus	O
71	O
4643	O
targets	O
mainly	O
neuronal	O
cells	O
but	O
is	O
also	O
found	O
in	O
many	O
organs	O
in	O
conjunction	O
with	O
an	O
inflammatory	O
reaction	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12629651	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1999	O
Feb	O
19;274(	O
8	O
)	O
:	O
5026-31	O
.	O
The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27	O
(	O
Kip1	O
)	O
is	O
involved	O
in	O
thyroid	O
hormone	O
-	O
mediated	O
neuronal	O
differentiation	O
.	O
Perez-Juste	O
G	O
,	O
Aranda	O
A	O
.	O
Instituto	O
de	O
Investigaciones	O
Biomedicas	O
,	O
Consejo	O
Superior	O
de	O
Investigaciones	O
Cientificas	O
,	O
Arturo	O
Duperier	O
4	O
,	O
28029	O
Madrid	O
,	O
Spain	O
.	O
The	O
thyroid	O
hormone	O
(	O
triiodothyronine	O
,	O
T3	O
)	O
is	O
essential	O
for	O
normal	O
brain	O
maturation	O
.	O
To	O
determine	O
the	O
mechanisms	O
by	O
which	O
T3	O
controls	O
neuronal	O
proliferation	O
and	O
differentiation	O
,	O
we	O
have	O
analyzed	O
the	O
effect	O
of	O
this	O
hormone	O
on	O
the	O
expression	O
and	O
activity	O
of	O
cell	O
cycle	O
-	O
regulating	O
molecules	O
in	O
neuroblastoma	B-malignancy-type
N2a	O
-beta	O
cells	O
that	O
overexpress	O
the	O
beta1	O
isoform	O
of	O
the	O
T3	O
receptor	O
.	O
Our	O
results	O
show	O
that	O
incubation	O
of	O
N2a	O
-beta	O
cells	O
with	O
T3	O
leads	O
to	O
a	O
rapid	O
down	O
-	O
regulation	O
of	O
the	O
c-myc	O
gene	O
and	O
to	O
a	O
decrease	O
of	O
cyclin	O
D1	O
levels	O
.	O
T3	O
also	O
causes	O
a	O
strong	O
and	O
sustained	O
increase	O
of	O
the	O
levels	O
of	O
the	O
cyclin	O
kinase	O
inhibitor	O
p27	O
(	O
Kip1	O
)	O
.	O
This	O
increase	O
is	O
secondary	O
,	O
to	O
the	O
augmented	O
levels	O
of	O
p27	O
(	O
Kip1	O
)	O
transcripts	O
as	O
well	O
as	O
to	O
stabilization	O
of	O
the	O
p27	O
(	O
Kip1	O
)	O
protein	O
.	O
The	O
increased	O
levels	O
of	O
p27	O
(	O
Kip1	O
)	O
lead	O
to	O
a	O
significant	O
increase	O
in	O
the	O
amount	O
of	O
p27	O
(	O
Kip1	O
)	O
associated	O
with	O
cyclin	O
-	O
dependent	O
kinase	O
2	O
(	O
CDK2	O
)	O
,	O
and	O
to	O
a	O
marked	O
inhibition	O
of	O
the	O
kinase	O
activity	O
of	O
the	O
cyclin	O
.	O
CDK2	O
complexes	O
.	O
As	O
a	O
consequence	O
,	O
the	O
retinoblastoma	O
protein	O
(	O
pRb	O
)	O
and	O
the	O
retinoblastoma	O
protein	O
-	O
related	O
protein	O
p130	O
are	O
hypophosphorylated	O
in	O
T3	O
-	O
treated	O
N2a	O
-beta	O
cells	O
.	O
This	O
study	O
shows	O
for	O
the	O
first	O
time	O
that	O
T3	O
-	O
mediated	O
growth	O
arrest	O
and	O
neuronal	O
differentiation	O
are	O
associated	O
with	O
an	O
increase	O
in	O
the	O
levels	O
of	O
a	O
cyclin	O
kinase	O
inhibitor	O
,	O
which	O
does	O
not	O
allow	O
the	O
inactivation	O
of	O
retinoblastoma	O
proteins	O
required	O
for	O
progression	O
through	O
the	O
restriction	O
point	O
in	O
the	O
cell	O
cycle	O
.	O
PMID	O
:	O
9988748	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

In	O
Vitr	O
Mol	O
Toxicol	O
.	O
2000	O
Winter;13(	O
4	O
)	O
:249-	O
62	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cell	O
viability	O
and	O
growth	O
are	O
affected	O
by	O
altered	O
culture	O
conditions	O
.	O
Carlson	O
K,	O
Ehrich	O
M.	O
Virginia-Maryland	O
Regional	O
College	O
of	O
Veterinary	O
Medicine	O
,	O
Blacksburg	O
,	O
Virginia	O
24061	O
,	O
USA	O
.	O
The	O
effects	O
of	O
differing	O
culture	O
parameters	O
are	O
seldomly	O
investigated	O
,	O
even	O
though	O
they	O
influence	O
the	O
way	O
immortalized	O
cells	O
grow	O
and	O
die	O
.	O
In	O
this	O
study	O
,	O
the	O
changes	O
in	O
total	O
cell	O
number	O
,	O
confluency	O
,	O
membrane	O
permeability	O
,	O
and	O
DNA	O
content	O
were	O
evaluated	O
in	O
SH-SY5Y	O
and	O
IMR-32	O
human	O
neuroblastoma	B-malignancy-type
cells	O
following	O
culture	O
at	O
different	O
seeding	O
densities	O
and	O
media	O
consistencies	O
.	O
These	O
four	O
endpoints	O
were	O
determined	O
using	O
a	O
hemacytometer	O
,	O
phase	O
-	O
contrast	O
microscope	O
,	O
trypan	O
blue	O
(	O
0.4	O
%	O
v	O
/	O
v	O
)	O
,	O
and	O
propidium	O
iodide	O
(	O
50	O
microg	O
/	O
mL	O
)	O
,	O
respectively	O
.	O
Both	O
cell	O
lines	O
(	O
SH-SY5Y	O
and	O
IMR-32	O
)	O
responded	O
in	O
a	O
similar	O
manner	O
to	O
changing	O
culture	O
conditions	O
,	O
even	O
though	O
baseline	O
values	O
for	O
all	O
four	O
endpoints	O
were	O
different	O
.	O
Higher	O
seeding	O
densities	O
(	O
19,200	O
and	O
38	O
,400	O
cells	O
/	O
cm2	O
)	O
significantly	O
increased	O
the	O
percent	O
confluency	O
and	O
total	O
cell	O
number	O
over	O
time	O
,	O
but	O
decreased	O
the	O
initial	O
percentage	O
of	O
cells	O
with	O
fragmented	O
(	O
subG1	O
)	O
DNA	O
in	O
both	O
cell	O
lines	O
when	O
compared	O
with	O
lower	O
seeding	O
densities	O
(	O
4800	O
and	O
9600	O
cells	O
/	O
cm2	O
,	O
p	O
<	O
0.05	O
)	O
.	O
Daily	O
media	O
changes	O
significantly	O
increased	O
the	O
percentage	O
of	O
cells	O
in	O
S	O
and	O
G2/M	O
,	O
but	O
decreased	O
the	O
percentage	O
of	O
cells	O
in	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
over	O
time	O
in	O
both	O
cell	O
lines	O
when	O
compared	O
with	O
cultures	O
without	O
media	O
changes	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Results	O
suggest	O
that	O
environmental	O
culture	O
conditions	O
greatly	O
affect	O
cellular	O
mitosis	O
and	O
death	O
.	O
This	O
information	O
may	O
be	O
of	O
particular	O
relevance	O
in	O
the	O
investigation	O
of	O
compounds	O
that	O
act	O
on	O
specific	O
cell	O
-cycle	O
stages	O
,	O
such	O
as	O
antineoplastic	O
agents	O
.	O
PMID	O
:	O
11319276	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2001	O
Mar;76	O
(	O
6	O
)	O
:1670	O
-	O
8.	O
Preferential	O
expression	O
of	O
antioxidant	O
response	O
element	O
mediated	O
gene	O
expression	O
in	O
astrocytes	O
.	O
Murphy	O
TH	O
,	O
Yu	O
J,	O
Ng	O
R	O
,	O
Johnson	O
DA	O
,	O
Shen	O
H,	O
Honey	O
CR	O
,	O
Johnson	O
JA	O
.	O
Kinsmen	O
Laboratory	O
of	O
Neurological	O
Research	O
,	O
Department	O
of	O
Psychiatry	O
,	O
University	O
of	O
British	O
Columbia	O
,	O
Vancouver	O
,	O
British	O
Columbia	O
,	O
Canada	O
.	O
thmurphy@interchange	O
.ubc.ca	O
Transcriptional	O
control	O
of	O
target	O
genes	O
by	O
antioxidant	O
/electrophile	O
response	O
elements	O
has	O
been	O
well	O
described	O
in	O
peripheral	O
tissues	O
.	O
Genes	O
that	O
are	O
regulated	O
by	O
this	O
mechanism	O
include	O
the	O
antioxidant	O
enzymes	O
NAD(P)H	O
:	O
quinone	O
oxidoreductase	O
,	O
gamma-glutamyl	O
cystine	O
synthetase	O
and	O
glutathione-	O
S-transferase	O
.	O
Antioxidant	O
/electrophile	O
response	O
elements	O
within	O
a	O
gene	O
's	O
promoter	O
confer	O
induction	O
by	O
low-molecular	O
-	O
weight	O
electrophilic	O
compounds	O
such	O
as	O
tert	O
-butylhydroquinone	O
and	O
dimethyl	O
fumarate	O
.	O
We	O
have	O
now	O
examined	O
the	O
ability	O
of	O
antioxidant	O
/electrophile	O
response	O
elements	O
to	O
elicit	O
gene	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
in	O
both	O
brain	O
slices	O
and	O
primary	O
cultures	O
using	O
transient	O
transfection	O
of	O
promoter	O
reporter	O
constructs	O
.	O
Our	O
results	O
using	O
a	O
heat	O
-	O
stable	O
human	O
placental	O
alkaline	O
phosphatase	O
reporter	O
indicate	O
that	O
antioxidant	O
/electrophile	O
response	O
element	O
mediated	O
gene	O
expression	O
is	O
largely	O
restricted	O
to	O
astrocyte	O
cell	O
populations	O
.	O
Placental	O
alkaline	O
phosphatase	O
expression	O
was	O
significantly	O
elevated	O
in	O
astrocytes	O
treated	O
with	O
the	O
antioxidant	O
/electrophile	O
response	O
element	O
inducer	O
dimethyl	O
fumarate	O
.	O
Mutant	O
constructs	O
lacking	O
a	O
functional	O
antioxidant	O
/electrophile	O
response	O
element	O
abolished	O
all	O
placental	O
alkaline	O
phosphatase	O
expression	O
in	O
astrocytes	O
.	O
We	O
suggest	O
that	O
astrocytic	O
metabolic	O
processes	O
that	O
normally	O
aid	O
and/or	O
protect	O
neurons	O
may	O
be	O
controlled	O
via	O
this	O
inducible	O
system	O
.	O
PMID	O
:	O
11259485	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2001	O
Aug;78	O
(	O
3	O
)	O
:468	O
-	O
81	O
.	O
The	O
inhibition	O
of	O
phosphatidylinositol-3-kinase	O
induces	O
neurite	O
retraction	O
and	O
activates	O
GSK3	O
.	O
Sanchez	O
S	O
,	O
Sayas	O
CL	O
,	O
Lim	O
F	O
,	O
Diaz-Nido	O
J,	O
Avila	O
J,	O
Wandosell	O
F.	O
Centro	O
de	O
Biologia	O
Molecular	O
'Severo	O
Ochoa'	O
,	O
CSIC-Universidad	O
Autonoma	O
de	O
Madrid	O
,	O
Madrid	O
,	O
Spain	O
.	O
It	O
has	O
been	O
extensively	O
described	O
that	O
neuronal	O
differentiation	O
involves	O
the	O
signalling	O
through	O
neurotrophin	O
receptors	O
to	O
a	O
Ras	O
-	O
dependent	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
cascade	O
.	O
However	O
,	O
signalling	O
pathways	O
from	O
other	O
neuritogenic	O
factors	O
have	O
not	O
been	O
well	O
established	O
.	O
It	O
has	O
been	O
reported	O
that	O
cAMP	O
may	O
activate	O
protein	O
kinase	O
(	O
PKA	O
)	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
PKA	O
-	O
mediated	O
stimulation	O
of	O
MAPK	O
pathway	O
regulates	O
not	O
only	O
neuritogenesis	O
but	O
also	O
survival	O
.	O
However	O
,	O
extracellular	O
regulated	O
kinases	O
(	O
ERKs	O
)	O
mediated	O
pathways	O
are	O
not	O
sufficient	O
to	O
explain	O
all	O
the	O
processes	O
which	O
occur	O
in	O
neuronal	O
differentiation	O
.	O
Our	O
present	O
data	O
show	O
that	O
:	O
in	O
cAMP	O
-	O
mediated	O
neuritogenesis	O
,	O
using	O
the	O
SH-SY5Y	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
there	O
exists	O
a	O
link	O
between	O
the	O
activation	O
of	O
PKA	O
and	O
stimulation	O
of	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3K	O
)	O
.	O
Both	O
kinase	O
activities	O
are	O
essential	O
to	O
the	O
initial	O
elongation	O
steps	O
.	O
Surprisingly	O
,	O
this	O
neuritogenic	O
process	O
appears	O
to	O
be	O
independent	O
of	O
ERKs	O
.	O
While	O
the	O
activity	O
of	O
PI3K	O
is	O
essential	O
for	O
elongation	O
and	O
maintenance	O
of	O
neurites	O
,	O
its	O
inhibition	O
causes	O
retraction	O
.	O
In	O
this	O
neurite	O
retraction	O
process	O
,	O
GSK3	O
is	O
activated	O
.	O
Using	O
both	O
a	O
pharmacological	O
approach	O
and	O
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
GSK3	O
,	O
we	O
conclude	O
that	O
this	O
induced	O
retraction	O
is	O
a	O
GSK3	O
-	O
dependent	O
process	O
which	O
in	O
turn	O
appears	O
to	O
be	O
a	O
common	O
target	O
for	O
transduction	O
pathways	O
involved	O
in	O
lysophosphatidic	O
acid	O
-	O
mediated	O
and	O
PI3K	O
-mediated	O
neurite	O
retraction	O
.	O
PMID	O
:	O
11483649	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Physiol	O
.	O
1998	O
Sep;275	O
(	O
3	O
Pt	O
1	O
)	O
:C772	O
-	O
9.	O
Stimulation	O
of	O
Na+-K+-2Cl	O
-	O
cotransporter	O
in	O
neuronal	O
cells	O
by	O
excitatory	O
neurotransmitter	O
glutamate	O
.	O
Sun	O
D	O
,	O
Murali	O
SG.	O
Department	O
of	O
Neurological	O
Surgery	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Wisconsin	O
,	O
Madison	O
,	O
Wisconsin	O
53792	O
,	O
USA	O
.	O
Na+-K+-2Cl	O
-	O
cotransporters	O
are	O
important	O
in	O
renal	O
salt	O
reabsorption	O
and	O
in	O
salt	O
secretion	O
by	O
epithelia	O
.	O
They	O
are	O
also	O
essential	O
in	O
maintenance	O
and	O
regulation	O
of	O
ion	O
gradients	O
and	O
cell	O
volume	O
in	O
both	O
epithelial	O
and	O
nonepithelial	O
cells	O
.	O
Expression	O
of	O
Na+-K+-2Cl	O
-	O
cotransporters	O
in	O
brain	O
tissues	O
is	O
high	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
their	O
function	O
and	O
regulation	O
in	O
neurons	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
regulation	O
of	O
the	O
Na+-K+-2Cl	O
-	O
cotransporter	O
by	O
the	O
excitatory	O
neurotransmitter	O
glutamate	O
.	O
The	O
cotransporter	O
activity	O
in	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
cells	O
was	O
assessed	O
by	O
bumetanide	O
-	O
sensitive	O
K	O
+	O
influx	O
,	O
and	O
protein	O
expression	O
was	O
evaluated	O
by	O
Western	O
blot	O
analysis	O
.	O
Glutamate	O
was	O
found	O
to	O
induce	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
stimulation	O
of	O
Na+-K+-2Cl	O
-	O
cotransporter	O
activity	O
in	O
SH-SY5Y	O
cells	O
.	O
Moreover	O
,	O
both	O
the	O
glutamate	O
ionotropic	O
receptor	O
agonist	O
N-methyl-	O
D-	O
aspartic	O
acid	O
(	O
NMDA	O
)	O
and	O
the	O
metabotropic	O
receptor	O
agonist	O
(	O
+/-)-1-aminocyclopentane	O
-	O
trans	O
-1,3-dicarboxylic	O
acid	O
(	O
trans	O
-	O
ACPD	O
)	O
significantly	O
stimulated	O
the	O
cotransport	O
activity	O
in	O
these	O
cells	O
.	O
NMDA	O
-	O
mediated	O
stimulation	O
of	O
the	O
Na+-K+-2Cl	O
-	O
cotransporter	O
was	O
abolished	O
by	O
the	O
selective	O
NMDA	O
-	O
receptor	O
antagonist	O
(	O
+)-MK-801	O
hydrogen	O
maleate	O
.	O
trans	O
-	O
ACPD	O
-	O
mediated	O
effect	O
on	O
the	O
cotransporter	O
was	O
blocked	O
by	O
the	O
metabotropic	O
receptor	O
antagonist	O
(	O
+)-alpha-methyl-(4-carboxyphenyl)glycine	O
.	O
The	O
results	O
demonstrate	O
that	O
Na+-K+-2Cl	O
-	O
cotransporters	O
in	O
neurons	O
are	O
regulated	O
by	O
activation	O
of	O
both	O
ionotropic	O
and	O
metabotropic	O
glutamate	O
receptors	O
.	O
PMID	O
:	O
9730961	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Behav	O
Brain	O
Res	O
.	O
1996	O
;73	O
(	O
1-2	O
)	O
:	O
59	O
-	O
62	O
.	O
Determination	O
of	O
transcription	O
initiation	O
sites	O
and	O
promoter	O
activity	O
of	O
the	O
human	O
5-HT2A	O
receptor	O
gene	O
.	O
Shih	O
JC	O
,	O
Zhu	O
Q	O
,	O
Chen	O
K.	O
Department	O
of	O
Molecular	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Southern	O
California	O
,	O
Los	O
Angeles	O
90033	O
,	O
USA	O
.	O
The	O
regulation	O
of	O
5-HT2A	O
receptor	O
(	O
5-HT2AR	O
)	O
expression	O
has	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
pathological	O
processes	O
.	O
Previous	O
data	O
addressing	O
the	O
regulation	O
of	O
this	O
receptor	O
are	O
extremely	O
complicated	O
and	O
controversial	O
.	O
In	O
order	O
to	O
understand	O
the	O
mechanisms	O
of	O
regulation	O
of	O
this	O
receptor	O
,	O
we	O
have	O
identified	O
the	O
promoter	O
region	O
of	O
the	O
human	O
5-HT2AR	O
gene	O
.	O
Anchored	O
PCR	O
has	O
mapped	O
a	O
cluster	O
of	O
transcription	O
initiation	O
sites	O
at	O
nucleotides	O
-	O
1157	O
,	O
-	O
1137	O
,	O
-	O
1127	O
(	O
numbered	O
sequentially	O
as	O
sites	O
1	O
,	O
2	O
and	O
3	O
)	O
.	O
An	O
additional	O
initiation	O
site	O
(	O
site	O
4)	O
was	O
detected	O
at	O
-	O
496	O
,	O
631	O
bp	O
downstream	O
of	O
site	O
3	O
.	O
Promoter	O
activity	O
was	O
defined	O
by	O
transfection	O
studies	O
.	O
Several	O
5	O
'	O
flanking	O
fragments	O
linked	O
to	O
the	O
human	O
growth	O
hormone	O
reporter	O
gene	O
were	O
transfected	O
into	O
two	O
human	O
cell	O
lines	O
,	O
SHSY-	O
5Y	O
(	O
neuroblastoma	B-malignancy-type
)	O
and	O
HeLa	O
(	O
cervix	B-malignancy-type
carcinoma	I-malignancy-type
)	O
which	O
express	O
5-HT2AR	O
.	O
A	O
0.74	O
kb	O
HaeIII	O
/	O
PvuII	O
fragment	O
,	O
which	O
encompasses	O
the	O
initiation	O
sites	O
1	O
to	O
3	O
and	O
5	O
'	O
of	O
the	O
downstream	O
initiation	O
site	O
4	O
,	O
exhibited	O
significant	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O
Inclusion	O
of	O
additional	O
sequences	O
upstream	O
(	O
the	O
1.6	O
kb	O
PvuII	O
/	O
PvuII	O
fragment	O
)	O
had	O
little	O
effect	O
on	O
the	O
promoter	O
activity	O
,	O
but	O
the	O
extension	O
of	O
the	O
0.74	O
kb	O
fragment	O
downstream	O
to	O
include	O
a	O
0.45	O
kb	O
PvuII	O
/	O
SmaI	O
fragment	O
drastically	O
decreased	O
the	O
promoter	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
the	O
promoter	O
activity	O
for	O
human	O
5-HT2AR	O
gene	O
resides	O
in	O
the	O
0.74	O
kb	O
HaeIII	O
/	O
PvuII	O
fragment	O
and	O
the	O
0.45	O
kb	O
PvuII	O
/	O
SmaI	O
fragment	O
may	O
contain	O
a	O
silencer	O
for	O
the	O
gene	O
expression	O
.	O
PMID	O
:	O
8788478	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Pharmacol	O
.	O
1992	O
Jul	O
1;226	O
(	O
3	O
)	O
:	O
265	O
-72	O
.	O
3-	O
position	O
modification	O
of	O
myo	O
-	O
inositol	O
1,4,5-trisphosphate	O
:	O
consequences	O
for	O
intracellular	O
Ca2	O
+	O
mobilisation	O
and	O
enzyme	O
recognition	O
.	O
Safrany	O
ST	O
,	O
Wilcox	O
RA	O
,	O
Liu	O
C	O
,	O
Potter	O
BV	O
,	O
Nahorski	O
SR.	O
Department	O
of	O
Pharmacology	O
and	O
Therapeutics	O
,	O
University	O
of	O
Leicester	O
,	O
UK.	O
The	O
ability	O
of	O
the	O
novel	O
D	O
-myo	O
-	O
inositol	O
1,4,5-trisphosphate	O
(	O
Ins(1,4,5)P3	O
)	O
analogues	O
,	O
L-chiro	O
-	O
inositol	O
2,3,5-trisphosphate	O
(	O
L-ch-	O
Ins(2,3,5)P3	O
)	O
and	O
D-	O
3-	O
deoxy-3-fluoro-myo	O
-	O
inositol	O
1,4,5-trisphosphate	O
(	O
3F-Ins(1,4,5)P3	O
)	O
,	O
to	O
bind	O
to	O
the	O
Ins(1,4,5)P3	O
receptor	O
,	O
mobilise	O
intracellular	O
Ca2	O
+	O
stores	O
and	O
interact	O
with	O
metabolic	O
enzymes	O
has	O
been	O
investigated	O
.	O
L-ch-	O
Ins(2,3,5)P3	O
and	O
3F-Ins(1,4,5)P3	O
were	O
bound	O
by	O
the	O
Ins(1,4,5)P3	O
receptor	O
from	O
bovine	O
adrenal	O
cortex	O
with	O
relatively	O
high	O
affinity	O
(	O
Ki	O
values	O
60.4	O
and	O
8.0	O
nM	O
respectively	O
)	O
but	O
with	O
lower	O
affinity	O
than	O
Ins(1,4,5)P3	O
(	O
KD	O
=	O
5.9	O
nM	O
)	O
.	O
Both	O
analogues	O
were	O
apparent	O
full	O
agonists	O
at	O
the	O
Ca2	O
+	O
mobilising	O
receptor	O
in	O
SH-SY5Y	O
cells	O
,	O
but	O
were	O
less	O
potent	O
than	O
Ins(1,4,5)P3	O
(	O
EC50	O
L-ch-	O
Ins(2,3,5)P3	O
=	O
1.4	O
microM	O
,	O
3F-Ins(1,4,5)P3	O
=	O
0.37	O
microM	O
and	O
Ins(1,4,5)P3	O
=	O
0.12	O
microM	O
)	O
.	O
L-ch-	O
Ins(2,3,5)P3	O
and	O
3F-Ins(1,4,5)P3	O
were	O
resistant	O
to	O
Ins(1,4,5)P3	O
3-kinase	O
,	O
and	O
were	O
potent	O
inhibitors	O
of	O
the	O
enzyme	O
(	O
Ki	O
values	O
7.1	O
and	O
8.6	O
microM	O
respectively	O
)	O
.	O
3F-Ins(1,4,5)P3	O
was	O
hydrolysed	O
by	O
Ins(1,4,5)P3	O
5-phosphatase	O
at	O
a	O
similar	O
rate	O
to	O
Ins(1,4,5)P3	O
,	O
but	O
inhibited	O
dephosphorylation	O
of	O
[3H]Ins(1,4,5)P3	O
with	O
high	O
potency	O
(	O
apparent	O
Ki	O
=	O
3.9	O
microM	O
)	O
L-ch-	O
Ins(2,3,5)P3	O
was	O
also	O
recognised	O
by	O
the	O
enzyme	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
7.7	O
microM	O
)	O
but	O
was	O
resistant	O
to	O
hydrolysis	O
.	O
These	O
results	O
suggest	O
that	O
the	O
environment	O
around	O
C-3	O
is	O
of	O
major	O
importance	O
for	O
recognition	O
not	O
only	O
by	O
Ins(1,4,5)P3	O
3-kinase	O
but	O
also	O
by	O
Ins(1,4,5)P3	O
5-phosphatase	O
.	O
PMID	O
:	O
1330634	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Bull	O
Cancer	O
.	O
1998	O
Mar;8	O
5	O
(	O
3	O
)	O
:	O
262-6.	O
[Biological	O
markers	O
for	O
the	O
prognosis	O
of	O
neuroblastoma	B-malignancy-type
:	O
proposal	O
of	O
a	O
method	O
of	O
analysis	O
]	O
[	O
Article	O
in	O
French	O
]	O
Combaret	O
V	O
,	O
Delattre	O
O	O
,	O
Benard	O
J,	O
Favrot	O
MC	O
.	O
Departement	O
de	O
biologie	O
des	O
tumeurs	O
,	O
Centre	O
Leon	O
-	O
Berard	O
,	O
Lyon	O
.	O
The	O
prognosis	O
of	O
pediatric	O
neuroblastoma	B-malignancy-type
depends	O
both	O
on	O
clinical	O
presentation	O
and	O
on	O
certain	O
cellular	O
and	O
molecular	O
characteristics	O
.	O
At	O
the	O
present	O
time	O
,	O
two	O
hypotheses	O
can	O
be	O
drawn	O
to	O
explain	O
both	O
clinical	O
and	O
biological	O
heterogeneity	O
.	O
In	O
the	O
first	O
hypothesis	O
,	O
neuroblastoma	B-malignancy-type
progresses	O
from	O
early	O
to	O
late	O
clinical	O
stages	O
through	O
a	O
classical	O
multistep	O
process	O
linked	O
to	O
an	O
accumulation	O
of	O
molecular	O
abnormalities	O
.	O
In	O
the	O
second	O
hypothesis	O
,	O
neuroblastoma	B-malignancy-type
represents	O
an	O
heterogeneous	O
group	O
of	O
unrelated	O
diseases	O
,	O
where	O
most	O
of	O
stages	O
I	O
and	O
II	O
or	O
stage	O
IVS	O
neuroblastomas	B-malignancy-type
can	O
rather	O
be	O
considered	O
as	O
benign	O
tumors	O
,	O
and	O
stage	O
IV	O
neuroblastoma	B-malignancy-type
as	O
a	O
true	O
malignant	O
proliferation	O
.	O
To	O
ascertain	O
relevant	O
biological	O
factors	O
for	O
the	O
prognosis	O
of	O
the	O
disease	O
,	O
it	O
is	O
uppermost	O
important	O
that	O
all	O
investigators	O
agree	O
on	O
biological	O
criteria	O
for	O
analysis	O
when	O
neuroblastoma	B-malignancy-type
tissue	O
is	O
available	O
in	O
screened	O
and	O
unscreened	O
populations	O
.	O
This	O
paper	O
reviews	O
the	O
biological	O
tools	O
available	O
for	O
prognosis	O
in	O
neuroblastoma	B-malignancy-type
,	O
the	O
priority	O
for	O
analysis	O
of	O
biological	O
markers	O
according	O
to	O
reliability	O
,	O
feasibility	O
,	O
and	O
reproducibility	O
of	O
analysis	O
procedure	O
,	O
and	O
the	O
conditions	O
of	O
tissue	O
storage	O
for	O
further	O
analysis	O
of	O
these	O
biological	O
markers	O
.	O
The	O
standardized	O
biological	O
evaluation	O
of	O
neuroblastoma	B-malignancy-type
will	O
allow	O
,	O
first	O
,	O
to	O
collect	O
sufficient	O
data	O
for	O
multivariate	O
analysis	O
of	O
prognostic	O
factors	O
and	O
,	O
second	O
,	O
to	O
better	O
define	O
the	O
putative	O
links	O
between	O
various	O
forms	O
of	O
the	O
disease	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9752317	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1999	O
Feb	O
26;445(	O
2-3	O
)	O
:	O
415	O
-	O
9.	O
Differential	O
effects	O
of	O
retinoic	O
acid	O
isomers	O
on	O
the	O
expression	O
of	O
nuclear	O
receptor	O
co	O
-	O
regulators	O
in	O
neuroblastoma	B-malignancy-type
.	O
Lovat	O
PE	O
,	O
Annicchiarico-Petruzzelli	O
M,	O
Corazzari	O
M,	O
Dobson	O
MG	O
,	O
Malcolm	O
AJ	O
,	O
Pearson	O
AD	O
,	O
Melino	O
G	O
,	O
Redfern	O
CP	O
.	O
Department	O
of	O
Child	O
Health	O
,	O
Medical	O
School	O
,	O
University	O
of	O
Newcastle	O
,	O
Newcastle	O
Upon	O
Tyne	O
,	O
UK.	O
Retinoic	O
acid	O
modulates	O
growth	O
and	O
induces	O
differentiation	O
and	O
apoptosis	O
of	O
neuroblastoma	B-malignancy-type
cells	O
in	O
vitro	O
,	O
with	O
the	O
all-trans	O
and	O
9-cis	O
isomers	O
having	O
different	O
biological	O
properties	O
.	O
Transcriptional	O
activation	O
in	O
response	O
to	O
retinoic	O
acid	O
isomers	O
is	O
mediated	O
by	O
retinoic	O
acid	O
receptors	O
and	O
retinoid	O
X	O
receptors	O
.	O
The	O
differential	O
expression	O
of	O
co	O
-	O
activators	O
and	O
co	O
-	O
repressors	O
which	O
preferentially	O
interact	O
with	O
retinoic	O
acid	O
receptors	O
or	O
retinoid	O
X	O
receptors	O
may	O
be	O
a	O
mechanism	O
leading	O
to	O
different	O
cellular	O
responses	O
to	O
9-cis	O
and	O
all-trans	O
retinoic	O
acid	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
the	O
expression	O
of	O
the	O
nuclear	O
receptor	O
co	O
-	O
regulators	O
TIF1alpha	O
,	O
TIF1beta	O
,	O
SUG1	O
and	O
SMRT	O
in	O
the	O
N-type	O
and	O
S-type	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
SH	O
SY	O
5Y	O
and	O
SH	O
S	O
EP	O
.	O
Transcripts	O
for	O
all	O
four	O
co	O
-	O
regulators	O
were	O
expressed	O
in	O
these	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
expression	O
of	O
TIF1alpha	O
,	O
TIF1beta	O
and	O
SUG1	O
did	O
not	O
change	O
in	O
response	O
to	O
retinoic	O
acid	O
;	O
however	O
,	O
SMRT	O
was	O
induced	O
in	O
both	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
but	O
particularly	O
by	O
all-trans	O
retinoic	O
acid	O
in	O
SH	O
S	O
EP	O
cells	O
.	O
An	O
additional	O
co	O
-	O
activator	O
,	O
Trip3	O
,	O
was	O
isolated	O
by	O
differential	O
mRNA	O
display	O
and	O
shown	O
to	O
be	O
preferentially	O
induced	O
by	O
9-cis	O
retinoic	O
acid	O
in	O
SH	O
SY	O
5Y	O
and	O
SH	O
S	O
EP	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
retinoic	O
acid	O
isomer	O
-	O
specific	O
induction	O
of	O
nuclear	O
receptor	O
co	O
-	O
regulators	O
may	O
determine	O
,	O
in	O
part	O
,	O
the	O
differential	O
biological	O
effects	O
of	O
retinoic	O
acid	O
isomers	O
.	O
PMID	O
:	O
10094499	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroscience	O
.	O
1998	O
Nov;87	O
(	O
2	O
)	O
:319	O
-	O
24	O
.	O
Cyclooxygenase-2	O
expression	O
is	O
increased	O
in	O
frontal	O
cortex	O
of	O
Alzheimer	O
's	O
disease	O
brain	O
.	O
Pasinetti	O
GM	O
,	O
Aisen	O
PS	O
.	O
Department	O
of	O
Psychiatry	O
,	O
Brookdale	O
Center	O
for	O
Molecular	O
Biology	O
,	O
The	O
Mount	O
Sinai	O
School	O
of	O
Medicine	O
,	O
New	O
York	O
,	O
NY	O
10029	O
-	O
6574	O
,	O
USA	O
.	O
Many	O
epidemiological	O
studies	O
suggest	O
that	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
delays	O
or	O
slows	O
the	O
clinical	O
expression	O
of	O
Alzheimer	O
's	O
disease	O
,	O
but	O
the	O
mechanism	O
by	O
which	O
these	O
drugs	O
might	O
affect	O
pathophysiological	O
processes	O
relevant	O
to	O
Alzheimer	O
's	O
disease	O
has	O
been	O
unclear	O
.	O
Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
are	O
presumed	O
to	O
act	O
by	O
inhibiting	O
cyclooxygenase	O
,	O
a	O
key	O
enzyme	O
in	O
the	O
metabolism	O
of	O
membrane	O
-	O
derived	O
arachidonic	O
acid	O
into	O
prostaglandins	O
.	O
In	O
recent	O
years	O
,	O
two	O
distinct	O
isoforms	O
of	O
cyclooxygenase	O
have	O
been	O
characterized	O
,	O
a	O
constitutive	O
form	O
,	O
cyclooxygenase	O
-1	O
,	O
and	O
a	O
mitogen	O
-	O
inducible	O
form	O
,	O
cyclooxygenase	O
-2	O
.	O
Cyclooxygenase-2	O
has	O
been	O
identified	O
in	O
rodent	O
brain	O
.	O
Excitotoxic	O
lesions	O
cause	O
up	O
-	O
regulation	O
of	O
cyclooxygenase-2	O
expression	O
coincident	O
with	O
the	O
onset	O
of	O
expression	O
of	O
markers	O
of	O
apoptosis	O
;	O
cyclooxygenase-2	O
thus	O
represents	O
a	O
possible	O
target	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
action	O
in	O
neurodegenerative	O
mechanisms	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
cyclooxygenase-2	O
gene	O
expression	O
in	O
Alzheimer	O
's	O
disease	O
and	O
control	O
cases	O
.	O
We	O
found	O
up	O
-	O
regulation	O
of	O
cyclooxygenase-2	O
expression	O
in	O
Alzheimer	O
's	O
disease	O
frontal	O
cortex	O
.	O
Further	O
,	O
we	O
found	O
that	O
synthetic	O
beta-amyloid	O
peptides	O
induced	O
cyclooxygenase-2	O
expression	O
in	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
in	O
vitro	O
,	O
suggesting	O
a	O
mechanism	O
for	O
cyclooxygenase-2	O
up	O
-	O
regulation	O
in	O
Alzheimer	O
's	O
disease	O
.	O
These	O
findings	O
support	O
the	O
investigation	O
of	O
selective	O
cyclooxygenase-2	O
inhibitors	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O
PMID	O
:	O
9740394	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
.	O
1998	O
Sep	O
1;18	O
(	O
17	O
)	O
:	O
6672	O
-80	O
.	O
Transcriptional	O
effects	O
of	O
estrogen	O
on	O
neuronal	O
neurotensin	O
gene	O
expression	O
involve	O
cAMP	O
/	O
protein	O
kinase	O
A	O
-	O
dependent	O
signaling	O
mechanisms	O
.	O
Watters	O
JJ	O
,	O
Dorsa	O
DM	O
.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Washington	O
,	O
Seattle	O
,	O
Washington	O
98195	O
,	O
USA	O
.	O
Steroid	O
hormones	O
exert	O
dramatic	O
effects	O
on	O
neuronal	O
expression	O
of	O
genes	O
that	O
encode	O
neuropeptides	O
.	O
Expression	O
of	O
the	O
neurotensin	O
/	O
neuromedin	O
(	O
NT	O
/	O
N	O
)	O
gene	O
in	O
preoptic	O
area	O
neurons	O
is	O
dramatically	O
enhanced	O
by	O
estrogen	O
in	O
vivo	O
,	O
even	O
though	O
its	O
promoter	O
lacks	O
palindromic	O
estrogen	O
response	O
elements	O
.	O
We	O
report	O
here	O
that	O
estrogen	O
promotes	O
transcription	O
of	O
this	O
gene	O
by	O
interactions	O
with	O
the	O
cAMP	O
cascade	O
in	O
a	O
neuronal	O
cell	O
line	O
,	O
SK-N-SH	O
,	O
and	O
in	O
a	O
mouse	O
model	O
.	O
In	O
neuroblastoma	B-malignancy-type
cells	O
,	O
estrogen	O
increases	O
cAMP	O
and	O
the	O
phosphorylation	O
of	O
the	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
in	O
a	O
time	O
frame	O
that	O
precedes	O
induction	O
of	O
NT	O
/	O
N	O
gene	O
transcription	O
.	O
Interference	O
with	O
the	O
cAMP	O
/	O
protein	O
kinase	O
A	O
signal	O
transduction	O
cascade	O
blocks	O
the	O
ability	O
of	O
estrogen	O
to	O
elicit	O
increases	O
in	O
transcription	O
of	O
this	O
gene	O
.	O
Furthermore	O
,	O
in	O
studies	O
performed	O
in	O
vivo	O
using	O
mice	O
deficient	O
in	O
protein	O
kinase	O
A	O
,	O
estrogen	O
fails	O
to	O
induce	O
increases	O
in	O
NT	O
/	O
N	O
mRNA	O
but	O
retains	O
its	O
ability	O
to	O
promote	O
estrogen	O
response	O
element	O
-	O
dependent	O
progesterone	O
receptor	O
gene	O
transcription	O
.	O
These	O
data	O
represent	O
the	O
first	O
report	O
of	O
a	O
nonclassical	O
effect	O
of	O
estrogen	O
on	O
the	O
expression	O
of	O
an	O
endogenous	O
estrogen	O
-	O
regulated	O
neuropeptide	O
gene	O
through	O
cAMP	O
-	O
mediated	O
mechanisms	O
both	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
and	O
in	O
hypothalamic	O
neurons	O
.	O
More	O
importantly	O
,	O
this	O
"	O
cross	O
-	O
talk	O
"	O
may	O
represent	O
a	O
more	O
generalized	O
mechanism	O
by	O
which	O
steroid	O
hormones	O
act	O
through	O
other	O
signal	O
transduction	O
cascades	O
to	O
regulate	O
the	O
expression	O
of	O
other	O
genes	O
in	O
the	O
brain	O
.	O
PMID	O
:	O
9712639	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Life	O
Sci	O
.	O
2003	O
Aug	O
15	O
;73	O
(	O
13	O
)	O
:1691	O
-	O
704	O
.	O
Pharmacological	O
characterization	O
of	O
AR	O
-M1000390	O
at	O
human	O
delta	O
opioid	O
receptors	O
.	O
Marie	O
N	O
,	O
Landemore	O
G	O
,	O
Debout	O
C	O
,	O
Jauzac	O
P,	O
Allouche	O
S.	O
Laboratoire	O
de	O
Pharmacologie	O
moleculaire	O
de	O
la	O
tolerance	O
aux	O
opiaces	O
,	O
Universite	O
de	O
Caen	O
,	O
Caen	O
,	O
France	O
.	O
We	O
investigated	O
the	O
pharmacological	O
properties	O
of	O
a	O
newly	O
synthesised	O
delta	O
agonist	O
AR	O
-M1000390	O
,	O
derived	O
from	O
SNC-80	O
(	O
(+)-4-[	O
(alpha	O
R)	O
-alpha-((2S,5R	O
)-4-allyl-2,5-dimethyl-1-	O
piperazinyl)-3-methoxybenzyl]-N,N-dieth	O
yl-benzamide	O
)	O
,	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-BE	O
expressing	O
only	O
human	O
delta-opioid	O
receptors	O
.	O
Binding	O
and	O
functional	O
experiments	O
showed	O
a	O
weak	O
affinity	O
(	O
K(i)	O
=	O
106	O
+/-	O
34	O
nM	O
)	O
correlated	O
with	O
a	O
weak	O
potency	O
(	O
EC(50	O
)	O
=	O
111	O
+/-	O
31	O
nM	O
)	O
to	O
inhibit	O
the	O
forskolin	O
-	O
stimulated	O
cAMP	O
accumulation	O
.	O
Sustained	O
activation	O
of	O
opioid	O
receptors	O
in	O
the	O
presence	O
of	O
the	O
maximal	O
inhibitory	O
concentration	O
of	O
AR	O
-M1000390	O
produced	O
a	O
rapid	O
and	O
strong	O
desensitization	O
.	O
In	O
order	O
to	O
examine	O
the	O
contribution	O
of	O
internalization	O
and	O
down	O
-	O
regulation	O
in	O
the	O
desensitization	O
processes	O
,	O
binding	O
and	O
functional	O
experiments	O
were	O
conducted	O
in	O
the	O
presence	O
or	O
in	O
the	O
absence	O
of	O
hypertonic	O
sucrose	O
solution	O
to	O
block	O
clathrin	O
-	O
dependent	O
opioid	O
receptor	O
endocytosis	O
.	O
We	O
observed	O
both	O
the	O
inability	O
of	O
AR	O
-M1000390	O
to	O
down	O
-	O
regulate	O
opioid	O
receptors	O
and	O
the	O
absence	O
of	O
any	O
effect	O
of	O
sucrose	O
on	O
desensitization	O
.	O
The	O
lack	O
of	O
delta-opioid	O
receptor	O
internalization	O
by	O
AR	O
-M1000390	O
was	O
further	O
corroborated	O
by	O
confocal	O
microscopy	O
using	O
antibodies	O
directed	O
either	O
against	O
the	O
endogenous	O
delta-opioid	O
receptors	O
or	O
the	O
FLAG	O
-tagged	O
delta-opioid	O
receptors	O
stably	O
expressed	O
in	O
the	O
SK-N-BE	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
uncoupling	O
rather	O
than	O
internalization	O
is	O
responsible	O
for	O
delta-opioid	O
receptors	O
desensitization	O
by	O
AR	O
-M1000390	O
.	O
PMID	O
:	O
12875901	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1994	O
Apr	O
15	O
;269	O
(	O
15	O
)	O
:	O
11656-62	O
.	O
Negative	O
modulator	O
of	O
the	O
rat	O
D2	O
dopamine	O
receptor	O
gene	O
.	O
Minowa	O
T	O
,	O
Minowa	O
MT	O
,	O
Mouradian	O
MM	O
.	O
Genetic	O
Pharmacology	O
Unit	O
,	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
The	O
rat	O
D2	O
dopamine	O
receptor	O
gene	O
is	O
transcribed	O
from	O
a	O
TATA	O
-	O
less	O
promoter	O
that	O
has	O
an	O
initiator	O
-	O
like	O
sequence	O
and	O
several	O
putative	O
Sp1	O
binding	O
sites	O
.	O
The	O
main	O
activator	O
of	O
this	O
gene	O
is	O
between	O
nucleotides	O
-	O
75	O
and	O
-	O
29	O
,	O
and	O
a	O
strong	O
negative	O
modulator	O
is	O
located	O
between	O
bases	O
-	O
217	O
and	O
-	O
76	O
(	O
Minowa	O
,	O
T.	O
,	O
Minowa	O
,	O
M.	O
T.	O
,	O
and	O
Mouradian	O
,	O
M.	O
M.	O
(	O
1992	O
)	O
Biochemistry	O
31	O
,	O
8389	O
-8396	O
)	O
.	O
In	O
the	O
present	O
investigation	O
,	O
a	O
small	O
deletion	O
series	O
within	O
this	O
negative	O
modulator	O
fused	O
with	O
the	O
reporter	O
gene	O
for	O
chloramphenicol	O
acetyltransferase	O
was	O
used	O
to	O
transfect	O
the	O
D2	O
-	O
expressing	O
cells	O
,	O
NB41A3	O
.	O
Two	O
cis	O
-	O
acting	O
functional	O
DNA	O
sequences	O
were	O
identified	O
:	O
a	O
41	O
-	O
base	O
pair	O
segment	O
between	O
nucleotides	O
-	O
116	O
and	O
-	O
76	O
(	O
D2Neg	O
-	O
B	O
)	O
,	O
which	O
decreased	O
transcription	O
from	O
the	O
D2	O
promoter	O
by	O
about	O
45	O
%	O
,	O
and	O
a	O
26	O
-base	O
pair	O
segment	O
between	O
nucleotides	O
-	O
160	O
and	O
-	O
135	O
(	O
D2Neg	O
-	O
A	O
)	O
,	O
which	O
,	O
in	O
the	O
presence	O
of	O
the	O
downstream	O
negative	O
modulator	O
,	O
reduced	O
transcription	O
down	O
to	O
the	O
level	O
of	O
a	O
promoterless	O
vector	O
.	O
DNase	O
I	O
footprinting	O
,	O
gel	O
mobility	O
shift	O
,	O
and	O
competitive	O
cotransfection	O
experiments	O
suggested	O
that	O
D2Neg	O
-	O
A	O
functions	O
without	O
trans	O
-	O
acting	O
factors	O
,	O
whereas	O
D2Neg	O
-	O
B	O
interacts	O
with	O
nuclear	O
factors	O
at	O
its	O
Sp1	O
binding	O
sequences	O
.	O
Gel	O
supershift	O
with	O
anti	O
-	O
Sp1	O
antibody	O
and	O
UV	O
cross	O
-	O
linking	O
experiments	O
revealed	O
that	O
a	O
novel	O
130	O
-	O
kDa	O
factor	O
as	O
well	O
as	O
Sp1	O
interact	O
with	O
D2Neg	O
-	O
B	O
in	O
NB41A3	O
cells	O
.	O
This	O
novel	O
protein	O
recognizing	O
Sp1	O
binding	O
sequences	O
in	O
the	O
D2	O
gene	O
negative	O
modulator	O
is	O
also	O
found	O
in	O
nuclear	O
extract	O
from	O
the	O
rat	O
striatum	O
.	O
PMID	O
:	O
8157698	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1996	O
Feb	O
1;77	O
(	O
3	O
)	O
:	O
570	O
-5	O
.	O
Molecular	O
analysis	O
of	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
family	O
:	O
p16	O
(	O
CDKN2	O
/	O
MTS1	O
/	O
INK4A	O
)	O
,	O
p18	O
(	O
INK4C	O
)	O
and	O
p27	O
(	O
Kip1	O
)	O
genes	O
in	O
neuroblastomas	B-malignancy-type
.	O
Kawamata	O
N	O
,	O
Seriu	O
T	O
,	O
Koeffler	O
HP	O
,	O
Bartram	O
CR	O
.	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Cedars-Sinai	O
Research	O
Institute	O
,	O
UCLA	O
School	O
of	O
Medicine	O
90048	O
,	O
USA	O
.	O
BACKGROUND.	O
Chromosomal	O
abnormalities	O
involving	O
band	O
1p32	O
,	O
especially	O
deletions	O
,	O
are	O
frequent	O
in	O
neuroblastomas	B-malignancy-type
,	O
indicating	O
that	O
a	O
tumor	O
suppressor	O
gene(s)	O
is	O
localized	O
at	O
this	O
region	O
.	O
The	O
p18	O
gene	O
,	O
one	O
of	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
(	O
CDKI	O
)	O
genes	O
,	O
maps	O
to	O
this	O
chromosomal	O
region	O
.	O
Complexes	O
of	O
cyclin	O
and	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
play	O
important	O
roles	O
in	O
the	O
cell	O
cycle	O
.	O
CDKIs	O
inhibit	O
the	O
kinase	O
activities	O
of	O
these	O
complexes	O
and	O
block	O
transitions	O
of	O
the	O
cell	O
cycle	O
.	O
Some	O
of	O
the	O
CDKI	O
genes	O
may	O
be	O
tumor	O
suppressor	O
genes	O
.	O
For	O
example	O
,	O
the	O
CDKI	O
genes	O
p16	O
and	O
p15	O
are	O
frequently	O
deleted	O
in	O
various	O
malignancies	O
and	O
are	O
thought	O
to	O
contribute	O
to	O
cellular	O
transformations	O
.	O
METHODS	O
.	O
To	O
elucidate	O
the	O
importance	O
of	O
CDKI	O
genes	O
,	O
including	O
the	O
p18	O
as	O
well	O
as	O
the	O
p16	O
and	O
p27	O
genes	O
in	O
tumorigenesis	O
of	O
neuroblastoma	B-malignancy-type
,	O
25	O
neuroblastomas	B-malignancy-type
were	O
analyzed	O
for	O
deletions	O
by	O
Southern	O
blot	O
analysis	O
and	O
for	O
point	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
.	O
RESULTS	O
.	O
No	O
deletions	O
,	O
rearrangements	O
,	O
nor	O
mutations	O
were	O
detected	O
in	O
these	O
genes	O
,	O
however	O
,	O
polymorphisms	O
reported	O
previously	O
were	O
detected	O
.	O
CONCLUSIONS	O
.	O
Abnormalities	O
,	O
including	O
deletions	O
and	O
point	O
mutations	O
of	O
the	O
p16	O
,	O
p18	O
,	O
and	O
p27	O
genes	O
,	O
were	O
not	O
observed	O
in	O
this	O
series	O
of	O
neuroblastomas	B-malignancy-type
.	O
Other	O
mechanisms	O
to	O
inactivate	O
these	O
genes	O
,	O
such	O
as	O
transcriptional	O
or	O
translational	O
defects	O
,	O
must	O
be	O
analyzed	O
.	O
CDKI	O
genes	O
rarely	O
contributed	O
to	O
tumorigenesis	O
in	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
8630967	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1998	O
Feb	O
1;58	O
(	O
3	O
)	O
:	O
448	O
-52	O
.	O
A	O
lack	O
of	O
neuroblastoma	B-malignancy-type
in	O
Down	O
syndrome	O
:	O
a	O
study	O
from	O
11	O
European	O
countries	O
.	O
Satge	O
D	O
,	O
Sasco	O
AJ	O
,	O
Carlsen	O
NL	O
,	O
Stiller	O
CA	O
,	O
Rubie	O
H,	O
Hero	O
B	O
,	O
de	O
Bernardi	O
B	O
,	O
de	O
Kraker	O
J,	O
Coze	O
C	O
,	O
Kogner	O
P,	O
Langmark	O
F	O
,	O
Hakvoort	O
-	O
Cammel	O
FG	O
,	O
Beck	O
D	O
,	O
von	O
der	O
Weid	O
N	O
,	O
Parkes	O
S	O
,	O
Hartmann	O
O	O
,	O
Lippens	O
RJ	O
,	O
Kamps	O
WA	O
,	O
Sommelet	O
D.	O
Laboratory	O
of	O
Pathology	O
,	O
Centre	O
Hospitalier	O
,	O
Tulle	O
,	O
France	O
.	O
An	O
epidemiological	O
investigation	O
in	O
11	O
European	O
countries	O
comprising	O
a	O
total	O
childhood	O
population	O
of	O
54.1	O
million	O
children	O
and	O
using	O
8	O
separate	O
data	O
sources	O
was	O
conducted	O
to	O
evaluate	O
the	O
occurrence	O
of	O
neuroblastoma	B-malignancy-type
in	O
Down	O
syndrome	O
(	O
DS	O
)	O
.	O
No	O
cases	O
of	O
DS	O
were	O
detected	O
among	O
6724	O
infants	O
and	O
children	O
with	O
neuroblastoma	B-malignancy-type
,	O
although	O
more	O
than	O
five	O
were	O
expected	O
.	O
This	O
highly	O
significant	O
result	O
(	O
P	O
=	O
0.0045	O
according	O
to	O
the	O
Poisson	O
test	O
)	O
is	O
consistent	O
with	O
data	O
in	O
the	O
literature	O
,	O
which	O
contains	O
only	O
two	O
poorly	O
detailed	O
cases	O
in	O
epidemiological	O
studies	O
and	O
one	O
ganglioneuroma	B-malignancy-type
in	O
a	O
DS	O
mosaic	O
patient	O
.	O
Like	O
other	O
tumors	O
,	O
such	O
as	O
leukemias	B-malignancy-type
,	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
and	O
lymphomas	B-malignancy-type
are	O
in	O
excess	O
in	O
DS	O
patients	O
;	O
the	O
lack	O
of	O
neuroblastomas	B-malignancy-type
does	O
not	O
reflect	O
a	O
general	O
decreased	O
incidence	O
of	O
cancer	O
but	O
rather	O
a	O
specific	O
underrepresentation	O
of	O
this	O
precise	O
tumor	O
.	O
S-	O
100	O
b	O
protein	O
,	O
the	O
gene	O
for	O
which	O
maps	O
to	O
the	O
long	O
arm	O
of	O
chromosome	O
21	O
,	O
(	O
a	O
)	O
is	O
overproduced	O
in	O
DS	O
patients	O
,	O
(	O
b)	O
produces	O
growth	O
inhibition	O
and	O
differentiation	O
of	O
neural	O
cells	O
in	O
vitro	O
,	O
(	O
c)	O
is	O
abundant	O
in	O
good	O
-	O
prognosis	O
neuroblastomas	B-malignancy-type
,	O
and	O
(	O
d	O
)	O
has	O
been	O
shown	O
to	O
induce	O
growth	O
inhibition	O
and	O
differentiation	O
and	O
cell	O
death	O
in	O
several	O
human	O
and	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
could	O
be	O
responsible	O
for	O
this	O
variation	O
.	O
Additional	O
epidemiological	O
and	O
experimental	O
studies	O
are	O
warranted	O
to	O
confirm	O
our	O
interpretation	O
of	O
these	O
data	O
.	O
PMID	O
:	O
9458088	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2000	O
Nov	O
24;275	O
(	O
47	O
)	O
:	O
3692	O
0	O
-	O
6.	O
The	O
human	O
synaptotagmin	O
IV	O
gene	O
defines	O
an	O
evolutionary	O
break	O
point	O
between	O
syntenic	O
mouse	O
and	O
human	O
chromosome	O
regions	O
but	O
retains	O
ligand	O
inducibility	O
and	O
tissue	O
specificity	O
.	O
Ferguson	O
GD	O
,	O
Chen	O
XN	O
,	O
Korenberg	O
JR	O
,	O
Herschman	O
HR.	O
Departments	O
of	O
Biological	O
Chemistry	O
and	O
Pharmacology	O
and	O
the	O
Molecular	O
Biology	O
Institute	O
,	O
Medical	O
Genetics	O
Birth	O
Defects	O
Center	O
,	O
Cedars-Sinai	O
Medical	O
Center	O
,	O
UCLA	O
,	O
Los	O
Angeles	O
,	O
California	O
90095	O
,	O
USA	O
.	O
Rat	O
synaptotagmin	O
IV	O
(	O
SYT	O
IV	O
)	O
is	O
a	O
depolarization	O
-	O
inducible	O
synaptic	O
vesicle	O
protein	O
.	O
SYT	O
IV	O
homozygous	O
mutant	O
mice	O
are	O
viable	O
and	O
have	O
deficits	O
in	O
fine	O
motor	O
coordination	O
and	O
some	O
forms	O
of	O
memory	O
.	O
In	O
this	O
study	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
human	O
SYT	O
IV	O
orthologue	O
.	O
The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
human	O
SYT	O
IV	O
clone	O
is	O
nearly	O
90	O
%	O
identical	O
to	O
the	O
rat	O
and	O
mouse	O
SYT	O
IV	O
proteins	O
.	O
In	O
addition	O
,	O
human	O
SYT	O
IV	O
has	O
a	O
characteristic	O
serine	O
for	O
aspartate	O
substitution	O
within	O
the	O
first	O
C2	O
domain	O
that	O
is	O
conserved	O
among	O
Drosophila	O
,	O
Caenorhabditis	O
elegans	O
,	O
mouse	O
,	O
and	O
rat	O
SYT	O
IV	O
sequences	O
.	O
The	O
human	O
SYT	O
IV	O
gene	O
maps	O
to	O
chromosome	O
band	O
18q12.3	O
,	O
a	O
region	O
that	O
defines	O
a	O
break	O
point	O
in	O
the	O
synteny	O
with	O
mouse	O
chromosome	O
18	O
and	O
has	O
been	O
implicated	O
by	O
associated	O
markers	O
in	O
two	O
human	O
psychiatric	O
disorders	O
.	O
In	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK	O
-	O
N	O
-	O
SH	O
,	O
SYT	O
IV	O
is	O
an	O
immediate	O
-	O
early	O
gene	O
inducible	O
by	O
elevated	O
intracellular	O
calcium	O
and	O
by	O
forskolin	O
,	O
an	O
activator	O
of	O
adenylyl	O
cyclase	O
.	O
Expression	O
of	O
human	O
SYT	O
IV	O
mRNA	O
is	O
restricted	O
to	O
brain	O
and	O
is	O
not	O
detectable	O
in	O
non	O
-	O
neuronal	O
tissues	O
.	O
Within	O
brain	O
,	O
human	O
SYT	O
IV	O
mRNA	O
is	O
most	O
highly	O
expressed	O
in	O
hippocampus	O
,	O
with	O
lower	O
levels	O
present	O
in	O
amygdala	O
and	O
thalamus	O
.	O
These	O
results	O
suggest	O
a	O
role	O
for	O
SYT	O
IV	O
in	O
human	O
brain	O
function	O
and	O
in	O
human	O
neurological	O
disease	O
.	O
PMID	O
:	O
10938284	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Control	O
Release	O
.	O
2003	O
Aug	O
28;91(	O
1-2	O
)	O
:173	O
-	O
81	O
.	O
Tumor	O
-	O
targeted	O
gene	O
therapy	O
:	O
strategies	O
for	O
the	O
preparation	O
of	O
ligand	O
-	O
polyethylene	O
glycol	O
-	O
polyethylenimine	O
/	O
DNA	O
complexes	O
.	O
Ogris	O
M,	O
Walker	O
G	O
,	O
Blessing	O
T	O
,	O
Kircheis	O
R	O
,	O
Wolschek	O
M,	O
Wagner	O
E.	O
Pharmaceutical	O
Biology-Biotechnology	O
,	O
Department	O
of	O
Pharmacy	O
,	O
Ludwig-	O
Maximilians	O
-Universitaet	O
,	O
Butenandtstr	O
.	O
5-13	O
,	O
D-	O
81377	O
,	O
Muenchen	O
,	O
Germany	O
.	O
Surface	O
-	O
shielded	O
DNA	O
delivery	O
systems	O
have	O
been	O
synthesized	O
with	O
virus	O
-	O
like	O
characteristics	O
that	O
target	O
gene	O
expression	O
into	O
distant	O
tumor	O
tissues	O
.	O
Polyethylenimine	O
(	O
PEI	O
)	O
/	O
DNA	O
complexes	O
(	O
'	O
polyplexes	O
'	O
)	O
conjugated	O
with	O
the	O
cell	O
-	O
binding	O
ligand	O
transferrin	O
(	O
Tf	O
)	O
or	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
were	O
used	O
to	O
achieve	O
receptor	O
-	O
mediated	O
endocytosis	O
.	O
The	O
surface	O
charge	O
of	O
the	O
complexes	O
was	O
masked	O
by	O
covalently	O
linking	O
PEI	O
to	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
.	O
Three	O
alternatives	O
for	O
generating	O
these	O
surface	O
-	O
shielded	O
formulations	O
were	O
utilized	O
,	O
attaching	O
ligand	O
and	O
PEG	O
molecules	O
to	O
PEI	O
either	O
before	O
or	O
after	O
DNA	O
complex	O
formation	O
.	O
The	O
stabilized	O
formulations	O
could	O
be	O
ultra	O
-	O
concentrated	O
,	O
stored	O
frozen	O
,	O
and	O
applied	O
systemically	O
after	O
thawing	O
.	O
Intravenous	O
injection	O
of	O
Tf	O
-	O
PEG	O
-	O
coated	O
polyplexes	O
resulted	O
in	O
gene	O
transfer	O
to	O
subcutaneous	O
Neuro2a	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
of	O
syngeneic	O
A	O
/	O
J	O
mice	O
;	O
EGF	O
-	O
PEG	O
-	O
coated	O
polyplexes	O
were	O
intravenously	O
applied	O
for	O
targeting	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
xenografts	O
in	O
SCID	O
mice	O
.	O
In	O
these	O
models	O
,	O
luciferase	O
marker	O
gene	O
expression	O
levels	O
in	O
tumor	O
tissues	O
were	O
10	O
-	O
to	O
100	O
-	O
fold	O
higher	O
than	O
in	O
other	O
organ	O
tissues	O
.	O
Repeated	O
systemic	O
application	O
of	O
Tf	O
-	O
PEG	O
-	O
PEI	O
/	O
DNA	O
complexes	O
encoding	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
into	O
tumor	O
-	O
bearing	O
mice	O
induced	O
tumor	O
necrosis	O
and	O
inhibition	O
of	O
tumor	O
growth	O
in	O
three	O
murine	O
tumor	O
models	O
of	O
different	O
tissue	O
origin	O
(	O
Neuro2a	O
,	O
M	O
-	O
3	O
or	O
B16	O
melanoma	B-malignancy-type
)	O
.	O
PMID	O
:	O
12932649	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
Res	O
.	O
1987	O
;	O
2	O
(	O
1	O
)	O
:	O
1-18	O
.	O
Analysis	O
of	O
the	O
c	O
-	O
src	O
gene	O
product	O
structure	O
,	O
abundance	O
,	O
and	O
protein	O
kinase	O
activity	O
in	O
human	O
neuroblastoma	B-malignancy-type
and	O
glioblastoma	B-malignancy-type
cells	O
.	O
O'Shaughnessy	O
J,	O
Deseau	O
V	O
,	O
Amini	O
S	O
,	O
Rosen	O
N	O
,	O
Bolen	O
JB.	O
Laboratory	O
of	O
Tumor	O
Virus	O
Biology	O
and	O
Medicine	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
We	O
have	O
compared	O
in	O
different	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
human	O
glioblastoma	B-malignancy-type
cells	O
the	O
expression	O
level	O
,	O
structure	O
,	O
and	O
tyrosine	O
-	O
specific	O
protein	O
kinase	O
activity	O
of	O
pp60	O
c	O
-	O
src	O
.	O
Our	O
results	O
show	O
that	O
not	O
all	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
express	O
pp60	O
c	O
-	O
src	O
molecules	O
with	O
amino	O
-	O
terminal	O
structural	O
alterations	O
.	O
In	O
neuroblastoma	B-malignancy-type
cells	O
which	O
possess	O
pp60	O
c	O
-	O
src	O
with	O
altered	O
gel	O
migration	O
,	O
the	O
diminished	O
polyacrylamide	O
gel	O
mobility	O
of	O
pp60	O
c	O
-	O
src	O
was	O
found	O
not	O
to	O
be	O
dependent	O
upon	O
amino	O
-	O
terminal	O
phosphorylations	O
since	O
extensive	O
treatment	O
of	O
these	O
molecules	O
with	O
phosphatase	O
did	O
not	O
significantly	O
change	O
their	O
gel	O
migration	O
properties	O
.	O
Similar	O
differences	O
in	O
gel	O
migration	O
were	O
observed	O
when	O
RNA	O
from	O
the	O
various	O
neuroblastoma	B-malignancy-type
and	O
glioblastoma	B-malignancy-type
cells	O
was	O
translated	O
in	O
vitro	O
using	O
either	O
rabbit	O
reticulocyte	O
or	O
wheat	O
germ	O
lysates	O
.	O
White	O
the	O
level	O
of	O
c	O
-	O
src	O
mRNA	O
in	O
the	O
different	O
cells	O
analyzed	O
was	O
found	O
to	O
be	O
similar	O
,	O
the	O
abundance	O
of	O
pp60	O
c	O
-	O
src	O
in	O
these	O
same	O
cells	O
was	O
found	O
to	O
vary	O
by	O
as	O
much	O
as	O
12	O
-	O
fold	O
.	O
This	O
suggests	O
that	O
the	O
abundance	O
of	O
pp60	O
c	O
-	O
src	O
in	O
human	O
neuroendocrine	B-malignancy-type
tumors	I-malignancy-type
is	O
regulated	O
through	O
post	O
-	O
transcriptional	O
and	O
/	O
or	O
post	O
-	O
translational	O
events	O
which	O
may	O
be	O
related	O
to	O
the	O
stage	O
of	O
neuronal	O
differentiation	O
of	O
the	O
cells	O
.	O
Based	O
upon	O
determination	O
of	O
pp60	O
c	O
-	O
src	O
abundance	O
by	O
immunoblot	O
analysis	O
,	O
we	O
demonstrate	O
that	O
pp60	O
c	O
-	O
src	O
molecules	O
derived	O
from	O
human	O
neuroblastoma	B-malignancy-type
and	O
glioblastoma	B-malignancy-type
cells	O
have	O
very	O
similar	O
in	O
vitro	O
protein	O
kinase	O
activities	O
.	O
PMID	O
:	O
3146045	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Cell	O
Res	O
.	O
2001	O
Jan	O
15	O
;262(	O
2	O
)	O
:	O
84	O
-	O
94	O
.	O
Nuclear	O
localization	O
of	O
cystatin	O
B	O
,	O
the	O
cathepsin	O
inhibitor	O
implicated	O
in	O
myoclonus	O
epilepsy	O
(	O
EPM1	O
)	O
.	O
Riccio	O
M,	O
Di	O
Giaimo	O
R	O
,	O
Pianetti	O
S	O
,	O
Palmieri	O
PP	O
,	O
Melli	O
M,	O
Santi	O
S.	O
Institute	O
of	O
Cytomorphology	O
N.P.	O
,	O
C.N.R.	O
c/o	O
Institute	O
"	O
Codivilla-	O
Putti	O
"	O
-I.O.R.	O
,	O
Via	O
di	O
Barbiano	O
1	O
/	O
10	O
,	O
Bologna	O
,	O
40136	O
,	O
Italy	O
.	O
Cystatin	O
B	O
is	O
an	O
anti	O
-	O
protease	O
implicated	O
in	O
myoclonus	O
epilepsy	O
,	O
a	O
degenerative	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
.	O
In	O
vitro	O
,	O
cystatin	O
B	O
interacts	O
with	O
and	O
inhibits	O
proteases	O
of	O
the	O
cathepsin	O
family	O
.	O
Confocal	O
microscopy	O
analysis	O
of	O
the	O
subcellular	O
localization	O
of	O
cystatin	O
B	O
and	O
cathepsin	O
B	O
shows	O
that	O
,	O
in	O
vivo	O
,	O
the	O
two	O
proteins	O
are	O
concentrated	O
in	O
different	O
cell	O
compartments	O
.	O
In	O
fact	O
,	O
cystatin	O
B	O
is	O
found	O
mainly	O
in	O
the	O
nucleus	O
of	O
proliferating	O
cells	O
and	O
both	O
in	O
the	O
nucleus	O
and	O
in	O
the	O
cytoplasm	O
of	O
differentiated	O
cells	O
,	O
while	O
cathepsin	O
B	O
,	O
in	O
either	O
case	O
,	O
is	O
essentially	O
cytoplasmic	O
.	O
However	O
,	O
colocalization	O
of	O
cystatin	O
and	O
cathepsin	O
B	O
is	O
observed	O
in	O
the	O
isolated	O
cell	O
matrix	O
and	O
in	O
the	O
nuclear	O
scaffold	O
of	O
differentiated	O
neuroblastoma	B-malignancy-type
cells	O
but	O
not	O
of	O
proliferating	O
cells	O
.	O
This	O
suggests	O
that	O
at	O
least	O
a	O
fraction	O
of	O
cystatin	O
B	O
is	O
bound	O
to	O
the	O
protease	O
in	O
differentiated	O
cells	O
.	O
The	O
electron	O
microscopy	O
analysis	O
of	O
the	O
cell	O
matrix	O
confirms	O
the	O
observation	O
made	O
with	O
confocal	O
microscopy	O
.	O
The	O
cellular	O
activity	O
of	O
cathepsin	O
B	O
was	O
analyzed	O
with	O
a	O
fluorogenic	O
cytochemical	O
assay	O
.	O
A	O
fluorescent	O
signal	O
is	O
observed	O
in	O
the	O
cytoplasm	O
of	O
proliferating	O
cells	O
but	O
is	O
undetectable	O
in	O
the	O
cytoplasm	O
of	O
differentiated	O
cells	O
,	O
suggesting	O
that	O
cathepsin	O
B	O
is	O
active	O
mainly	O
during	O
the	O
cell	O
cycle	O
.	O
This	O
result	O
is	O
consistent	O
with	O
the	O
separate	O
compartimentalization	O
of	O
cystatin	O
B	O
and	O
cathepsin	O
B	O
that	O
we	O
have	O
observed	O
in	O
growing	O
cells	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11139332	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Radiat	O
Oncol	O
Biol	O
Phys	O
.	O
2000	O
Mar	O
1;46	O
(	O
4	O
)	O
:969	O
-	O
74	O
.	O
Local	O
control	O
with	O
multimodality	O
therapy	O
for	O
stage	O
4	O
neuroblastoma	B-malignancy-type
.	O
Wolden	O
SL	O
,	O
Gollamudi	O
SV	O
,	O
Kushner	O
BH	O
,	O
LaQuaglia	O
M,	O
Kramer	O
K,	O
Rosen	O
N	O
,	O
Abramson	O
S	O
,	O
Cheung	O
NV	O
.	O
Department	O
of	O
Radiation	O
Oncology	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
NY	O
10021	O
,	O
USA	O
.	O
woldens@mskcc.org	O
PURPOSE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
of	O
21	O
Gy	O
hyperfractionated	O
radiotherapy	O
for	O
local	O
control	O
in	O
conjunction	O
with	O
surgery	O
and	O
intensive	O
systemic	O
therapy	O
for	O
patients	O
with	O
Stage	O
4	O
neuroblastoma	B-malignancy-type
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
After	O
achieving	O
a	O
partial	O
or	O
complete	O
remission	O
,	O
47	O
children	O
,	O
ages	O
1	O
-	O
10	O
years	O
,	O
with	O
Stage	O
4	O
neuroblastoma	B-malignancy-type
were	O
treated	O
on	O
four	O
consecutive	O
institutional	O
protocols	O
(	O
N4	O
-	O
N7	O
)	O
with	O
dose	O
-	O
intensive	O
multi	O
-	O
agent	O
chemotherapy	O
,	O
maximal	O
surgical	O
debulking	O
,	O
and	O
hyperfractionated	O
radiotherapy	O
(	O
1.5	O
Gy	O
twice	O
a	O
day	O
to	O
21	O
Gy	O
)	O
.	O
Radiotherapy	O
fields	O
encompassed	O
the	O
initial	O
tumor	O
volume	O
and	O
regional	O
lymph	O
nodes	O
plus	O
a	O
3	O
-	O
cm	O
margin	O
.	O
This	O
was	O
followed	O
by	O
consolidation	O
with	O
either	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
N4	O
and	O
N5	O
)	O
or	O
immunotherapy	O
(	O
N6	O
and	O
N7	O
)	O
.	O
RESULTS	O
:	O
Forty	O
-	O
five	O
of	O
47	O
patients	O
had	O
a	O
complete	O
response	O
to	O
surgery	O
and	O
chemotherapy	O
prior	O
to	O
radiotherapy	O
.	O
Five	O
-	O
year	O
actuarial	O
rates	O
of	O
local	O
control	O
,	O
progression	O
-	O
free	O
survival	O
,	O
and	O
overall	O
survival	O
were	O
84	O
%	O
,	O
40	O
%	O
,	O
and	O
45	O
%	O
,	O
respectively	O
.	O
Among	O
26	O
patients	O
who	O
relapsed	O
,	O
1	O
failed	O
only	O
at	O
the	O
primary	O
site	O
,	O
22	O
developed	O
distant	O
metastases	O
exclusively	O
,	O
and	O
3	O
had	O
both	O
local	O
and	O
distant	O
failures	O
.	O
There	O
were	O
no	O
acute	O
complications	O
of	O
radiotherapy	O
.	O
CONCLUSION	O
:	O
Hyperfractionated	O
radiotherapy	O
to	O
21	O
Gy	O
,	O
in	O
conjunction	O
with	O
dose	O
-	O
intensive	O
systemic	O
therapy	O
and	O
aggressive	O
surgical	O
resection	O
,	O
is	O
well	O
tolerated	O
and	O
is	O
associated	O
with	O
durable	O
local	O
control	O
for	O
most	O
patients	O
with	O
Stage	O
4	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
10705019	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Planta	O
Med	O
.	O
2001	O
Jul;67	O
(	O
5	O
)	O
:	O
400	O
-5	O
.	O
Expression	O
of	O
protein	O
kinase	O
C	O
isoforms	O
in	O
euxanthone	O
-	O
induced	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Mak	O
NK	O
,	O
Lung	O
HL	O
,	O
Wong	O
RN	O
,	O
Leung	O
HW	O
,	O
Tsang	O
HY	O
,	O
Leung	O
KN	O
.	O
Department	O
of	O
Biology	O
,	O
The	O
Hong	O
Kong	O
Baptist	O
University	O
,	O
Kowloon	O
Tong	O
.	O
Euxanthone	O
,	O
a	O
potent	O
neuritogenic	O
compound	O
isolated	O
from	O
the	O
roots	O
of	O
the	O
medicinal	O
herb	O
Polygala	O
caudata	O
,	O
has	O
recently	O
been	O
shown	O
to	O
induce	O
the	O
differentiation	O
of	O
murine	O
neuroblastoma	B-malignancy-type
Neuro	O
2A	O
(	O
BU	O
-	O
1	O
)	O
cells	O
.	O
In	O
this	O
study	O
,	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
the	O
expression	O
of	O
various	O
PKC	O
isoforms	O
in	O
euxanthone	O
-	O
treated	O
BU	O
-	O
1	O
cells	O
were	O
examined	O
.	O
mRNA	O
phenotyping	O
using	O
the	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
showed	O
that	O
BU	O
-	O
1	O
cells	O
express	O
six	O
different	O
PKC	O
isoforms	O
,	O
namely	O
PKC	O
-	O
alpha	O
,	O
-	O
beta	O
,	O
-	O
delta	O
,	O
-	O
epsilon	O
,	O
-	O
lambda	O
,	O
and	O
-	O
zeta	O
.	O
Differential	O
regulation	O
and	O
expression	O
of	O
PKC	O
isoforms	O
was	O
observed	O
in	O
BU	O
-	O
1	O
cells	O
treated	O
with	O
100	O
microM	O
euxanthone	O
.	O
PKC	O
-	O
apha	O
,	O
-	O
beta	O
,	O
-	O
delta	O
,	O
-	O
lambda	O
and	O
-	O
zeta	O
were	O
all	O
up	O
-	O
regulated	O
,	O
with	O
1.7	O
-	O
to	O
9.5	O
-	O
fold	O
increase	O
,	O
at	O
around	O
30	O
to	O
60	O
minutes	O
after	O
euxanthone	O
treatment	O
.	O
The	O
expression	O
level	O
of	O
PKC	O
-	O
epsilon	O
remained	O
relatively	O
constant	O
during	O
the	O
treatment	O
.	O
PKC	O
-	O
gamma	O
,	O
-	O
eta	O
,	O
and	O
-	O
theta	O
were	O
not	O
detected	O
in	O
both	O
untreated	O
and	O
euxanthone	O
-	O
treated	O
BU	O
-	O
1	O
cells	O
.	O
Staurosporine	O
,	O
a	O
broad	O
spectrum	O
PKC	O
inhibitor	O
,	O
was	O
found	O
to	O
inhibit	O
both	O
spontaneous	O
and	O
euxanthone	O
-	O
induced	O
neuritogenesis	O
in	O
BU	O
-	O
1	O
cells	O
.	O
A	O
significant	O
reduction	O
of	O
the	O
euxanthone	O
-	O
induced	O
neuritogenic	O
effect	O
was	O
also	O
observed	O
when	O
the	O
PKC	O
isoform	O
-	O
specific	O
inhibitor	O
Go6976	O
was	O
included	O
in	O
the	O
culture	O
.	O
These	O
results	O
suggest	O
that	O
the	O
euxanthone	O
-	O
induced	O
differentiation	O
of	O
the	O
neuroblastoma	B-malignancy-type
BU	O
-	O
1	O
cells	O
may	O
be	O
mediated	O
through	O
the	O
differential	O
expression	O
of	O
PKC	O
-	O
alpha	O
,	O
-	O
beta	O
,	O
-	O
delta	O
,	O
-	O
lambda	O
and	O
-	O
zeta	O
isoforms	O
.	O
PMID	O
:	O
11488451	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1999	O
Jun;72	O
(	O
6	O
)	O
:2464	O
-	O
70	O
.	O
Activity	O
of	O
alpha	O
-	O
secretase	O
as	O
the	O
common	O
final	O
effector	O
of	O
protein	O
kinase	O
C	O
-	O
dependent	O
and	O
-	O
independent	O
modulation	O
of	O
amyloid	O
precursor	O
protein	O
metabolism	O
.	O
Racchi	O
M,	O
Solano	O
DC	O
,	O
Sironi	O
M,	O
Govoni	O
S.	O
IRCCS	O
Centro	O
San	O
Giovanni	O
di	O
Dio-FBF	O
,	O
Brescia	O
,	O
Italy	O
.	O
The	O
metabolic	O
fate	O
of	O
the	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
is	O
one	O
of	O
the	O
key	O
factors	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O
A	O
complex	O
cellular	O
mechanism	O
regulates	O
the	O
rate	O
at	O
which	O
the	O
precursor	O
is	O
cleaved	O
by	O
alpha	O
-	O
secretase	O
and	O
released	O
as	O
soluble	O
protein	O
in	O
the	O
extracellular	O
space	O
.	O
We	O
show	O
here	O
that	O
alpha	O
-	O
secretase	O
constitutes	O
the	O
common	O
final	O
effector	O
of	O
several	O
independent	O
means	O
of	O
stimulation	O
of	O
soluble	O
APP	O
(	O
sAPP	O
)	O
release	O
.	O
The	O
release	O
of	O
sAPP	O
by	O
alpha	O
-	O
secretase	O
resembles	O
that	O
of	O
several	O
other	O
membrane	O
-	O
bound	O
proteins	O
with	O
soluble	O
counterparts	O
,	O
a	O
process	O
that	O
is	O
sensitive	O
to	O
matrix	O
metalloprotease	O
inhibitors	O
.	O
The	O
hydroxamic	O
acid	O
-	O
based	O
compound	O
KD	O
-	O
IX	O
-	O
73	O
-	O
4	O
inhibits	O
phorbol	O
ester	O
-	O
mediated	O
sAPP	O
release	O
from	O
COS	O
cells	O
with	O
an	O
IC50	O
of	O
8	O
microM	O
,	O
consistent	O
with	O
previous	O
data	O
for	O
the	O
same	O
compound	O
against	O
leukocyte	O
L	O
-	O
selectin	O
shedding	O
.	O
Beyond	O
direct	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
we	O
show	O
that	O
KD	O
-	O
IX	O
-	O
73	O
-	O
4	O
inhibits	O
also	O
receptor	O
-	O
mediated	O
sAPP	O
release	O
induced	O
by	O
carbachol	O
in	O
SH	O
-	O
SY5Y	O
cells	O
and	O
by	O
bradykinin	O
in	O
human	O
skin	O
fibroblasts	O
,	O
with	O
the	O
latter	O
being	O
a	O
PKC	O
-	O
independent	O
mechanism	O
.	O
Altogether	O
these	O
data	O
suggest	O
that	O
all	O
pharmacological	O
means	O
of	O
stimulating	O
sAPP	O
release	O
converge	O
to	O
a	O
hydroxamic	O
acid	O
-	O
based	O
inhibitor	O
-	O
sensitive	O
proteolytic	O
enzyme	O
.	O
Moreover	O
,	O
because	O
KD	O
-	O
IX	O
-	O
73	O
-	O
4	O
was	O
effective	O
in	O
the	O
inhibition	O
of	O
stimulated	O
but	O
not	O
constitutive	O
sAPP	O
release	O
,	O
these	O
data	O
suggest	O
the	O
existence	O
of	O
different	O
enzymes	O
regulating	O
the	O
two	O
metabolic	O
pathways	O
leading	O
to	O
sAPP	O
secretion	O
.	O
PMID	O
:	O
10349856	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2003	O
May	O
2;278	O
(	O
18	O
)	O
:15633	O
-40	O
.	O
Epub	O
2003	O
Feb	O
14	O
.	O
Nicotine	O
modulates	O
the	O
expression	O
of	O
a	O
diverse	O
set	O
of	O
genes	O
in	O
the	O
neuronal	O
SH	O
-	O
SY5Y	O
cell	O
line	O
.	O
Dunckley	O
T	O
,	O
Lukas	O
RJ.	O
Division	O
of	O
Neurobiology	O
,	O
Barrow	O
Neurological	O
Institute	O
,	O
350	O
West	O
Thomas	O
Road	O
,	O
Phoenix	O
,	O
AZ	O
85013	O
,	O
USA	O
.	O
Nicotine	O
exposure	O
can	O
have	O
long	O
lasting	O
effects	O
on	O
nervous	O
system	O
function	O
,	O
some	O
of	O
which	O
must	O
contribute	O
to	O
nicotine	O
dependence	O
.	O
Up	O
-	O
regulation	O
,	O
an	O
increase	O
in	O
numbers	O
of	O
radioligand	O
-	O
binding	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChR	O
)	O
,	O
occurs	O
on	O
exposure	O
to	O
nicotine	O
at	O
high	O
concentrations	O
.	O
To	O
determine	O
whether	O
altered	O
gene	O
expression	O
might	O
account	O
for	O
long	O
term	O
changes	O
and	O
up	O
-	O
regulation	O
following	O
nicotine	O
exposure	O
,	O
we	O
assessed	O
effects	O
of	O
1	O
h	O
of	O
1	O
mm	O
nicotine	O
exposure	O
on	O
alteration	O
of	O
gene	O
expression	O
in	O
the	O
neuron	O
-	O
like	O
SH	O
-	O
SY5Y	O
neuroblastoma	B-malignancy-type
clonal	O
line	O
.	O
Repeat	O
and	O
cross	O
-	O
controlled	O
microarray	O
analyses	O
yielded	O
a	O
list	O
of	O
17	O
genes	O
from	O
the	O
initially	O
screened	O
approximately	O
5,000	O
whose	O
expression	O
was	O
consistently	O
altered	O
following	O
nicotine	O
treatment	O
.	O
Subsequent	O
quantitative	O
,	O
real	O
time	O
reverse	O
transcriptase	O
PCR	O
analyses	O
confirmed	O
altered	O
expression	O
in	O
14	O
of	O
16	O
genes	O
tested	O
.	O
Further	O
,	O
the	O
general	O
nAChR	O
antagonist	O
,	O
d	O
-	O
tubocurarine	O
,	O
blocked	O
all	O
but	O
two	O
of	O
the	O
observed	O
changes	O
in	O
gene	O
expression	O
,	O
indicating	O
that	O
these	O
changes	O
are	O
dependent	O
on	O
nAChR	O
activation	O
.	O
Use	O
of	O
other	O
antagonists	O
revealed	O
that	O
nAChR	O
subtypes	O
can	O
differentially	O
affect	O
gene	O
expression	O
.	O
The	O
genes	O
affected	O
code	O
for	O
proteins	O
that	O
may	O
be	O
broadly	O
categorized	O
into	O
four	O
groups	O
:	O
transcription	O
factors	O
,	O
protein	O
processing	O
factors	O
,	O
RNA	O
-	O
binding	O
proteins	O
,	O
and	O
plasma	O
membrane	O
-	O
associated	O
proteins	O
.	O
Our	O
results	O
suggest	O
that	O
nicotinic	O
activation	O
of	O
nAChR	O
may	O
have	O
a	O
broad	O
role	O
in	O
affecting	O
cellular	O
physiology	O
through	O
modulating	O
gene	O
expression	O
.	O
PMID	O
:	O
12588870	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1994	O
Aug	O
1;54	O
(	O
15	O
)	O
:	O
4238-42	O
.	O
CD44H	O
expression	O
by	O
human	O
neuroblastoma	B-malignancy-type
cells	O
:	O
relation	O
to	O
MYCN	O
amplification	O
and	O
lineage	O
differentiation	O
.	O
Gross	O
N	O
,	O
Beretta	O
C	O
,	O
Peruisseau	O
G	O
,	O
Jackson	O
D	O
,	O
Simmons	O
D	O
,	O
Beck	O
D.	O
Pediatrics	O
Department	O
,	O
University	O
Hospital	O
,	O
Lausanne	O
,	O
Switzerland	O
.	O
The	O
human	O
CD44	O
cell	O
surface	O
glycoprotein	O
has	O
been	O
involved	O
in	O
a	O
variety	O
of	O
functions	O
including	O
lymphocyte	O
homing	O
,	O
extracellular	O
cell	O
matrix	O
attachment	O
,	O
and	O
tumor	O
metastasis	O
.	O
Due	O
to	O
the	O
alternative	O
splicing	O
of	O
the	O
single	O
gene	O
,	O
a	O
large	O
family	O
of	O
different	O
variants	O
or	O
isoforms	O
is	O
generated	O
.	O
Several	O
reports	O
have	O
indicated	O
an	O
up	O
-	O
regulation	O
of	O
CD44	O
variant	O
(	O
v	O
)	O
isoforms	O
in	O
malignant	O
process	O
,	O
conferring	O
metastatic	O
potential	O
to	O
non	O
-	O
metastatic	O
cells	O
.	O
Neuroblastoma	B-malignancy-type
is	O
a	O
tumor	O
characterized	O
by	O
an	O
aggressive	O
and	O
metastatic	O
behavior	O
in	O
advanced	O
stages	O
with	O
amplification	O
of	O
the	O
MYCN	O
protooncogene	O
.	O
In	O
this	O
report	O
we	O
show	O
that	O
the	O
CD44	O
standard	O
molecule	O
is	O
highly	O
expressed	O
in	O
100	O
%	O
of	O
stage	O
I	O
-	O
III	O
,	O
IVs	O
neuroblastomas	B-malignancy-type
and	O
ganglioneuromas	B-malignancy-type
but	O
only	O
in	O
a	O
subset	O
of	O
stage	O
IV	O
tumors	O
.	O
In	O
contrast	O
,	O
no	O
expression	O
of	O
CD44	O
was	O
detected	O
on	O
MYCN	O
amplified	O
stage	O
IV	O
tumors	O
,	O
thus	O
demonstrating	O
a	O
highly	O
significant	O
negative	O
relationship	O
between	O
MYCN	O
amplification	O
and	O
CD44	O
expression	O
in	O
neuroblastoma	B-malignancy-type
.	O
The	O
expression	O
of	O
CD44	O
on	O
neuroblastoma	B-malignancy-type
cultured	O
cell	O
lines	O
was	O
not	O
shown	O
to	O
be	O
related	O
to	O
MYCN	O
amplification	O
but	O
rather	O
linked	O
to	O
the	O
S	O
-	O
type	O
,	O
schwann	O
/	O
glial	O
differentiation	O
lineage	O
.	O
Immunochemical	O
analysis	O
of	O
tumor	O
samples	O
with	O
anti	O
-	O
CD44	O
v3	O
and	O
-	O
v6	O
antibodies	O
and	O
Northern	O
blot	O
analysis	O
of	O
mRNA	O
from	O
cell	O
lines	O
with	O
probes	O
spanning	O
exons	O
4	O
-	O
10	O
did	O
not	O
reveal	O
any	O
expression	O
of	O
splice	O
variants	O
on	O
neuroblastomas	B-malignancy-type
of	O
all	O
stages	O
and	O
cell	O
lines	O
,	O
thus	O
ruling	O
out	O
a	O
major	O
role	O
of	O
these	O
isoforms	O
in	O
neuroblastoma	B-malignancy-type
progression	O
and	O
metastasis	O
.	O
PMID	O
:	O
7518353	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2003	O
Feb;8	O
4	O
(	O
3	O
)	O
:	O
503	O
-13	O
.	O
Rac	O
and	O
Cdc42	O
-	O
dependent	O
regulation	O
of	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinases	O
by	O
the	O
delta	O
-	O
opioid	O
receptor	O
.	O
Kam	O
AY	O
,	O
Chan	O
AS	O
,	O
Wong	O
YH	O
.	O
Department	O
of	O
Biochemistry	O
,	O
the	O
Molecular	O
Neuroscience	O
Center	O
,	O
Hong	O
Kong	O
University	O
of	O
Science	O
and	O
Technology	O
,	O
Clear	O
Water	O
Bay	O
,	O
Kowloon	O
,	O
Hong	O
Kong	O
.	O
Heptahelical	O
opioid	O
receptors	O
utilize	O
Gi	O
proteins	O
to	O
regulate	O
a	O
multitude	O
of	O
effectors	O
including	O
the	O
classical	O
adenylyl	O
cyclases	O
and	O
the	O
more	O
recently	O
discovered	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
.	O
The	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinases	O
(	O
JNKs	O
)	O
belong	O
to	O
one	O
of	O
three	O
subgroups	O
of	O
MAPKs	O
.	O
In	O
NG108	O
-	O
15	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
cells	O
that	O
endogenously	O
express	O
delta	O
-	O
opioid	O
receptors	O
,	O
delta	O
-	O
agonist	O
dose	O
-	O
dependently	O
stimulated	O
JNK	O
activity	O
in	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
manner	O
.	O
By	O
using	O
COS	O
-	O
7	O
cells	O
transiently	O
transfected	O
with	O
the	O
cDNAs	O
of	O
delta	O
-	O
opioid	O
receptor	O
and	O
hemagglutinin	O
(	O
HA	O
)	O
-	O
tagged	O
JNK	O
,	O
we	O
delineated	O
the	O
signaling	O
components	O
involved	O
in	O
this	O
pathway	O
.	O
Sequestration	O
of	O
Gbetagamma	O
subunits	O
by	O
transducin	O
suppressed	O
the	O
opioid	O
-	O
induced	O
JNK	O
activity	O
.	O
The	O
possible	O
involvement	O
of	O
the	O
small	O
GTPases	O
was	O
also	O
examined	O
.	O
Expression	O
of	O
dominant	O
negative	O
mutants	O
of	O
Rac	O
and	O
Cdc42	O
blocked	O
the	O
opioid	O
-	O
induced	O
JNK	O
activation	O
,	O
and	O
a	O
partial	O
inhibition	O
was	O
observed	O
in	O
the	O
presence	O
of	O
the	O
dominant	O
negative	O
mutant	O
of	O
Ras	O
.	O
In	O
contrast	O
,	O
the	O
dominant	O
negative	O
mutant	O
of	O
Rho	O
did	O
not	O
affect	O
the	O
opioid	O
-	O
induced	O
JNK	O
activation	O
.	O
In	O
addition	O
,	O
the	O
receptor	O
-	O
mediated	O
JNK	O
activation	O
was	O
dependent	O
on	O
Src	O
family	O
tyrosine	O
kinases	O
,	O
but	O
independent	O
of	O
phosphatidylinositol	O
-	O
3	O
kinase	O
and	O
EGF	O
receptor	O
tyrosine	O
kinases	O
.	O
Collectively	O
,	O
these	O
results	O
demonstrate	O
functional	O
regulation	O
of	O
JNK	O
by	O
the	O
delta	O
-	O
opioid	O
receptor	O
,	O
and	O
this	O
pathway	O
requires	O
Gbetagamma	O
,	O
Src	O
kinases	O
and	O
the	O
small	O
GTPases	O
Rac	O
and	O
Cdc42	O
.	O
PMID	O
:	O
12558970	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Mol	O
Med	O
.	O
2000	O
Apr;	O
5	O
(	O
4	O
)	O
:	O
379	O
-84	O
.	O
The	O
p73	O
gene	O
is	O
less	O
involved	O
in	O
the	O
development	O
but	O
involved	O
in	O
the	O
progression	O
of	O
neuroblastoma	B-malignancy-type
.	O
Yang	O
HW	O
,	O
Piao	O
HY	O
,	O
Chen	O
YZ	O
,	O
Takita	O
J,	O
Kobayashi	O
M,	O
Taniwaki	O
M,	O
Hashizume	O
K,	O
Hanada	O
R	O
,	O
Yamamoto	O
K,	O
Taki	O
T	O
,	O
Bessho	O
F	O
,	O
Yanagisawa	O
M,	O
Hayashi	O
Y	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Tokyo	O
,	O
Japan	O
.	O
We	O
performed	O
expression	O
,	O
mutation	O
,	O
loss	O
of	O
heterozygosity	O
(	O
LOH)	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analyses	O
of	O
the	O
p73	O
gene	O
in	O
neuroblastomas	B-malignancy-type
(	O
NBs	B-malignancy-type
)	O
.	O
Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
using	O
primers	O
which	O
can	O
detect	O
both	O
the	O
p73alpha	O
and	O
p73beta	O
transcripts	O
was	O
performed	O
on	O
30	O
fresh	O
NBs	B-malignancy-type
and	O
22	O
NB	B-malignancy-type
cell	O
lines	O
.	O
Aberrant	O
expression	O
of	O
the	O
p73	O
gene	O
was	O
found	O
in	O
4	O
(	O
25	O
%	O
)	O
of	O
16	O
primary	O
tumors	O
found	O
by	O
mass	O
screening	O
and	O
in	O
10	O
(	O
71.4	O
%	O
)	O
of	O
14	O
primary	O
tumors	O
found	O
clinically	O
.	O
The	O
rates	O
of	O
expression	O
in	O
these	O
two	O
types	O
of	O
tumors	O
were	O
significantly	O
different	O
(	O
p	O
=	O
0.026	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
The	O
incidence	O
of	O
aberrant	O
expression	O
of	O
the	O
p73	O
gene	O
was	O
significantly	O
higher	O
in	O
stage	O
IV	O
patients	O
than	O
in	O
stages	O
I	O
,	O
II	O
,	O
III	O
plus	O
IVS	O
patients	O
(	O
p	O
=	O
0.0236	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
No	O
homozygous	O
deletions	O
or	O
rearrangements	O
of	O
the	O
p73	O
gene	O
were	O
found	O
in	O
any	O
samples	O
examined	O
.	O
In	O
addition	O
to	O
the	O
polymorphism	O
in	O
exon	O
2	O
,	O
a	O
silent	O
mutation	O
(	O
codon	O
336	O
GCC	O
/	O
GCT	O
)	O
was	O
found	O
in	O
one	O
primary	O
tumor	O
.	O
LOH	O
of	O
the	O
p73	O
gene	O
was	O
detected	O
in	O
5	O
(	O
15	O
%	O
)	O
of	O
33	O
primary	O
NBs	B-malignancy-type
using	O
PCR	O
-LOH	O
analysis	O
.	O
FISH	O
analysis	O
showed	O
that	O
all	O
17	O
NB	B-malignancy-type
cell	O
lines	O
used	O
in	O
this	O
study	O
revealed	O
allelic	O
loss	O
of	O
the	O
p73	O
gene	O
,	O
while	O
most	O
of	O
them	O
expressed	O
the	O
p73	O
gene	O
.	O
These	O
results	O
suggest	O
that	O
the	O
p73	O
gene	O
is	O
not	O
monoallelically	O
expressed	O
in	O
NB	B-malignancy-type
.	O
We	O
conclude	O
that	O
the	O
p73	O
gene	O
is	O
less	O
involved	O
in	O
the	O
development	O
but	O
involved	O
in	O
the	O
progression	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
10719054	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocrinology	O
.	O
2001	O
Feb;142(	O
2	O
)	O
:830	O
-	O
7.	O
Two	O
isoforms	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
are	O
coexpressed	O
in	O
neuronal	O
cell	O
lines	O
.	O
Chen	O
A	O
,	O
Yahalom	O
D	O
,	O
Laskar	O
-	O
Levy	O
O	O
,	O
Rahimipour	O
S	O
,	O
Ben	O
-	O
Aroya	O
N	O
,	O
Koch	O
Y	O
.	O
Department	O
of	O
Neurobiology	O
,	O
Weizmann	O
Institute	O
of	O
Science	O
,	O
Rehovot	O
76100	O
,	O
Israel	O
.	O
GnRH-	O
I	O
serves	O
as	O
the	O
neuropeptide	O
that	O
regulates	O
mammalian	O
reproduction	O
.	O
Recently	O
,	O
several	O
groups	O
have	O
identified	O
in	O
the	O
brain	O
of	O
rodents	O
,	O
monkeys	O
,	O
and	O
humans	O
a	O
second	O
isoform	O
of	O
GnRH	O
(	O
GnRH-II	O
)	O
whose	O
structure	O
is	O
70	O
%	O
identical	O
to	O
that	O
of	O
GnRH-I	O
.	O
In	O
this	O
study	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
human	O
and	O
mouse	O
neuronal	O
cell	O
lines	O
that	O
express	O
both	O
GnRH-	O
I	O
and	O
GnRH-II	O
.	O
Following	O
the	O
screening	O
of	O
several	O
human	O
neuronal	O
cell	O
lines	O
by	O
RT-PCR	O
and	O
Southern	O
hybridization	O
,	O
we	O
demonstrated	O
that	O
two	O
cell	O
lines	O
,	O
TE-671	O
medulloblastoma	B-malignancy-type
and	O
LAN-1	O
neuroblastoma	B-malignancy-type
cells	O
,	O
coexpress	O
messenger	O
RNA	O
encoding	O
the	O
two	O
isoforms	O
of	O
GnRH	O
.	O
Nucleotide	O
sequencing	O
indicated	O
that	O
the	O
complementary	O
DNA	O
fragments	O
are	O
identical	O
to	O
those	O
of	O
the	O
known	O
human	O
GnRH-	O
I	O
and	O
GnRH-II	O
sequences	O
.	O
Extracts	O
obtained	O
from	O
the	O
TE-671	O
and	O
LAN-1	O
cell	O
lines	O
as	O
well	O
as	O
from	O
the	O
immortalized	O
mouse	O
hypothalamic	O
GT1-7	O
neuronal	O
cell	O
line	O
were	O
found	O
to	O
contain	O
the	O
two	O
isoforms	O
of	O
GnRH	O
,	O
which	O
exhibited	O
identical	O
chromatographic	O
properties	O
as	O
synthetic	O
GnRH-	O
I	O
and	O
GnRH-II	O
,	O
in	O
HPLC	O
followed	O
by	O
specific	O
RIAs	O
.	O
Furthermore	O
,	O
double	O
immunofluorescence	O
studies	O
demonstrated	O
the	O
two	O
GnRH	O
isoforms	O
in	O
LAN-1	O
,	O
TE-671	O
,	O
and	O
GT1-7	O
cells	O
.	O
The	O
identification	O
of	O
neuronal	O
cell	O
lines	O
expressing	O
both	O
GnRH-	O
I	O
and	O
GnRH-II	O
provides	O
tools	O
for	O
studying	O
the	O
differential	O
regulation	O
of	O
gene	O
expression	O
and	O
secretion	O
and	O
for	O
studying	O
the	O
interaction	O
between	O
the	O
two	O
isoforms	O
.	O
Such	O
studies	O
may	O
contribute	O
to	O
elucidation	O
of	O
the	O
physiological	O
functions	O
of	O
GnRH-II	O
,	O
which	O
are	O
still	O
unknown	O
.	O
PMID	O
:	O
11159856	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Restor	O
Neurol	O
Neurosci	O
.	O
2001	O
;18	O
(	O
2-3	O
)	O
:	O
67	O
-	O
80	O
.	O
Gene	O
expression	O
profile	O
in	O
early	O
stage	O
of	O
retinoic	O
acid	O
-	O
induced	O
differentiation	O
of	O
human	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Truckenmiller	O
ME	O
,	O
Vawter	O
MP	O
,	O
Cheadle	O
C	O
,	O
Coggiano	O
M,	O
Donovan	O
DM	O
,	O
Freed	O
WJ	O
,	O
Becker	O
KG.	O
Cellular	O
Neurobiology	O
Research	O
Branch	O
,	O
Intramural	O
Research	O
Program	O
,	O
National	O
Institute	O
on	O
Drug	O
Abuse	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
5500	O
Nathan	O
Shock	O
Drive	O
,	O
Baltimore	O
,	O
MD	O
21224	O
,	O
USA	O
.	O
etrucken@intra	O
.nida	O
.nih.go	O
v	O
PURPOSE	O
:	O
The	O
human	O
SH-SY5Y	O
cell	O
line	O
is	O
an	O
established	O
model	O
for	O
retinoic	O
acid	O
(	O
RA	O
)	O
-	O
induced	O
neural	O
differentiation	O
.	O
We	O
employed	O
a	O
broad	O
human	O
15K	O
microarray	O
(	O
15	O
,000	O
genes	O
)	O
and	O
focused	O
Neuroarray	O
(	O
1152	O
genes	O
)	O
to	O
examine	O
changes	O
in	O
gene	O
expression	O
early	O
in	O
the	O
process	O
of	O
differentiation	O
(	O
6	O
hr	O
)	O
,	O
before	O
morphology	O
or	O
growth	O
changes	O
are	O
observed	O
.	O
METHODS	O
:	O
33	O
P-	O
labeled	O
CDNA	O
probes	O
prepared	O
from	O
RNA	O
extracts	O
of	O
RA	O
-	O
treated	O
and	O
control	O
cultures	O
were	O
hybridized	O
to	O
array	O
membranes	O
,	O
and	O
levels	O
of	O
expression	O
were	O
quantified	O
and	O
compared	O
.	O
RESULTS	O
:	O
In	O
the	O
15K	O
array	O
,	O
19	O
%	O
of	O
the	O
genes	O
were	O
decreased	O
(	O
0.4	O
%	O
were	O
named	O
genes	O
and	O
the	O
remainder	O
were	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
or	O
unknowns	O
)	O
,	O
and	O
9	O
%	O
were	O
increased	O
(	O
4.2	O
%	O
named	O
genes	O
)	O
.	O
In	O
the	O
Neuroarray	O
,	O
3	O
%	O
were	O
decreased	O
and	O
8	O
%	O
were	O
increased	O
.	O
CONCLUSIONS	O
:	O
Summary	O
gene	O
profiles	O
are	O
presented	O
,	O
which	O
include	O
transcription	O
factors	O
,	O
genes	O
associated	O
with	O
cell	O
cycle	O
,	O
cell	O
shape	O
,	O
neurotransmission	O
,	O
intermediary	O
filaments	O
,	O
and	O
others	O
.	O
The	O
prevalence	O
of	O
down	O
-	O
regulated	O
genes	O
in	O
the	O
broad	O
15K	O
array	O
and	O
up	O
-	O
regulated	O
genes	O
in	O
the	O
neuro	O
-	O
focused	O
array	O
suggests	O
a	O
pattern	O
shift	O
in	O
gene	O
expression	O
associated	O
with	O
differentiation	O
.	O
The	O
predominance	O
of	O
ESTs	O
among	O
the	O
down	O
-	O
regulated	O
genes	O
indicates	O
a	O
great	O
number	O
of	O
as	O
-	O
yet-unidentified	O
genes	O
are	O
repressed	O
in	O
early	O
stage	O
neural	O
differentiation	O
.	O
PMID	O
:	O
11847429	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Peptides	O
.	O
2001	O
Nov;22	O
(	O
11	O
)	O
:1795-801	O
.	O
Differential	O
expression	O
of	O
adrenomedullin	O
and	O
its	O
receptor	O
component	O
,	O
receptor	O
activity	O
modifying	O
protein	O
(	O
RAMP	O
)	O
2	O
during	O
hypoxia	O
in	O
cultured	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Kitamuro	O
T	O
,	O
Takahashi	O
K,	O
Totsune	O
K,	O
Nakayama	O
M,	O
Murakami	O
O	O
,	O
Hida	O
W	O
,	O
Shirato	O
K,	O
Shibahara	O
S.	O
Department	O
of	O
Molecular	O
Biology	O
and	O
Applied	O
Physiology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
980	O
-	O
8575	O
,	O
Sendai	O
,	O
Miyagi	O
,	O
Japan	O
.	O
Adrenomedullin	O
is	O
a	O
potent	O
vasodilator	O
peptide	O
originally	O
isolated	O
from	O
a	O
pheochromocytoma	B-malignancy-type
.	O
Recently	O
,	O
a	O
novel	O
adrenomedullin	O
receptor	O
has	O
been	O
identified	O
as	O
a	O
complex	O
consisting	O
of	O
calcitonin	O
receptor	O
-	O
like	O
receptor	O
(	O
CRLR	O
)	O
and	O
receptor	O
activity	O
modifying	O
protein	O
(	O
RAMP	O
)	O
2	O
.	O
To	O
explore	O
possible	O
pathophysiological	O
roles	O
of	O
adrenomedullin	O
and	O
its	O
receptor	O
component	O
RAMP2	O
in	O
hypoxic	O
tissues	O
,	O
we	O
studied	O
effects	O
of	O
hypoxia	O
on	O
expression	O
of	O
adrenomedullin	O
and	O
RAMP2	O
in	O
two	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
IMR-32	O
and	O
NB69	O
,	O
by	O
radioimmunoassay	O
and	O
Northern	O
blot	O
analysis	O
.	O
Expression	O
levels	O
of	O
adrenomedullin	O
were	O
increased	O
by	O
hypoxia	O
in	O
both	O
cell	O
lines	O
.	O
Treatment	O
with	O
cobalt	O
chloride	O
or	O
desferrioxamine	O
mesylate	O
also	O
increased	O
expression	O
levels	O
of	O
adrenomedullin	O
mRNA	O
.	O
On	O
the	O
other	O
hand	O
,	O
expression	O
levels	O
of	O
RAMP2	O
mRNA	O
were	O
decreased	O
in	O
IMR-32	O
cells	O
and	O
were	O
not	O
changed	O
in	O
NB69	O
cells	O
by	O
hypoxia	O
.	O
Treatment	O
with	O
cobalt	O
chloride	O
or	O
desferrioxamine	O
mesylate	O
decreased	O
expression	O
levels	O
of	O
RAMP2	O
mRNA	O
in	O
both	O
IMR-32	O
and	O
NB69	O
cells	O
.	O
These	O
findings	O
indicate	O
that	O
adrenomedullin	O
expression	O
is	O
induced	O
during	O
hypoxia	O
in	O
IMR-32	O
and	O
NB69	O
neuroblastoma	B-malignancy-type
cells	O
,	O
but	O
RAMP2	O
expression	O
is	O
rather	O
suppressed	O
under	O
the	O
same	O
conditions	O
.	O
The	O
decreased	O
expression	O
of	O
RAMP2	O
and	O
the	O
ADM	O
expression	O
induction	O
under	O
hypoxia	O
may	O
constitute	O
one	O
mechanism	O
of	O
cellular	O
adaptation	O
to	O
hypoxic	O
stress	O
.	O
PMID	O
:	O
11754965	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Mol	O
Neurobiol	O
.	O
1995	O
Jun;15	O
(	O
3	O
)	O
:	O
307	O
-	O
26	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
neuronal	O
L-type	O
calcium	O
channel	O
alpha	O
1D	O
subunit	O
gene	O
.	O
Kamp	O
TJ	O
,	O
Mitas	O
M,	O
Fields	O
KL	O
,	O
Asoh	O
S	O
,	O
Chin	O
H,	O
Marban	O
E	O
,	O
Nirenberg	O
M.	O
Department	O
of	O
Medicine	O
,	O
Johns	O
Hopkins	O
University	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
,	O
USA	O
.	O
1	O
.	O
The	O
transcriptional	O
regulation	O
of	O
the	O
rat	O
brain	O
L-type	O
calcium	O
channel	O
alpha	O
1D	O
subunit	O
(	O
RB	O
alpha	O
1D	O
)	O
gene	O
was	O
investigated	O
using	O
NG108-15	O
neuroblastoma	B-malignancy-type
-	O
glioma	B-malignancy-type
cells	O
.	O
2.	O
Differentiation	O
of	O
NG108-15	O
cells	O
in	O
the	O
presence	O
of	O
prostaglandin	O
E1	O
or	O
retinoic	O
acid	O
resulted	O
in	O
the	O
appearance	O
of	O
mRNA	O
encoding	O
the	O
RB	O
alpha	O
1D	O
subunit	O
detected	O
using	O
Northern	O
blot	O
analysis	O
.	O
3	O
.	O
A	O
rat	O
genomic	O
DNA	O
library	O
was	O
screened	O
,	O
and	O
a	O
15.2-kb	O
clone	O
was	O
isolated	O
and	O
partially	O
sequenced	O
which	O
included	O
part	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
through	O
the	O
initial	O
part	O
of	O
intron	O
2	O
of	O
the	O
RB	O
alpha	O
1D	O
gene	O
.	O
4	O
.	O
Deletion	O
analysis	O
,	O
using	O
a	O
CAT	O
reporter	O
gene	O
and	O
transfected	O
NG108-15	O
cells	O
,	O
revealed	O
that	O
the	O
1.2-kb	O
5'-upstream	O
sequence	O
from	O
the	O
RB	O
alpha	O
1D	O
gene	O
contains	O
cis	O
-	O
acting	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O
A	O
deletion	O
of	O
the	O
3	O
'	O
end	O
of	O
exon	O
1	O
also	O
suggested	O
the	O
presence	O
of	O
regulatory	O
elements	O
in	O
the	O
first	O
exon	O
.	O
5	O
.	O
DNase	O
footprinting	O
of	O
exon	O
1	O
of	O
the	O
RB	O
alpha	O
1D	O
gene	O
revealed	O
two	O
regions	O
protected	O
from	O
digestion	O
by	O
specific	O
protein	O
binding	O
,	O
and	O
the	O
second	O
region	O
included	O
an	O
(	O
ATG	O
)7	O
trinucleotide	O
repeat	O
sequence	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
nuclear	O
protein(s)	O
binding	O
to	O
the	O
(	O
ATG	O
)7	O
sequence	O
.	O
6	O
.	O
The	O
(	O
ATG	O
)7	O
sequence	O
functions	O
as	O
a	O
enhancer	O
when	O
linked	O
to	O
a	O
thymidine	O
kinase	O
promoter	O
and	O
a	O
CAT	O
reporter	O
gene	O
.	O
7	O
.	O
These	O
results	O
provide	O
the	O
initial	O
description	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
RB	O
alpha	O
1D	O
gene	O
and	O
identify	O
a	O
novel	O
enhancer	O
that	O
consists	O
of	O
an	O
(	O
ATG	O
)7	O
trinucleotide	O
repeat	O
sequence	O
.	O
PMID	O
:	O
7553731	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2000	O
Mar	O
23	O
;19(	O
13	O
)	O
:1719	O
-	O
23	O
.	O
Evidence	O
for	O
a	O
recessive	O
inheritance	O
of	O
Turcot	B-malignancy-type
's	I-malignancy-type
syndrome	I-malignancy-type
caused	O
by	O
compound	O
heterozygous	O
mutations	O
within	O
the	O
PMS2	O
gene	O
.	O
De	O
Rosa	O
M,	O
Fasano	O
C	O
,	O
Panariello	O
L,	O
Scarano	O
MI	O
,	O
Belli	O
G	O
,	O
Iannelli	O
A	O
,	O
Ciciliano	O
F	O
,	O
Izzo	O
P.	O
Dipartimento	O
di	O
Biochimica	O
e	O
Biotecnologie	O
Mediche	O
,	O
CEINGE-Biotecnologie	O
Avanzate	O
,	O
Universita	O
di	O
Napoli	O
Federico	O
II	O
,	O
Italy	O
.	O
Turcot	B-malignancy-type
's	I-malignancy-type
syndrome	I-malignancy-type
is	O
a	O
genetic	O
disease	O
characterized	O
by	O
the	O
concurrence	O
of	O
primary	O
brain	B-malignancy-type
tumors	I-malignancy-type
and	O
colon	B-malignancy-type
cancers	I-malignancy-type
and/or	O
multiple	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
.	O
We	O
report	O
a	O
Turcot	B-malignancy-type
family	O
with	O
no	O
parental	O
consanguinity	O
,	O
in	O
which	O
two	O
affected	O
sisters	O
,	O
with	O
no	O
history	O
of	O
tumors	O
in	O
their	O
parents	O
,	O
died	O
of	O
a	O
brain	B-malignancy-type
tumor	I-malignancy-type
and	O
of	O
a	O
colorectal	B-malignancy-type
tumor	I-malignancy-type
,	O
respectively	O
,	O
at	O
a	O
very	O
early	O
age	O
.	O
The	O
proband	O
had	O
a	O
severe	O
microsatellite	O
instability	O
(	O
MIN	O
)	O
phenotype	O
in	O
both	O
tumor	O
and	O
normal	O
colon	O
mucosa	O
,	O
and	O
mutations	O
in	O
the	O
TGFbeta-RII	O
and	O
APC	O
genes	O
in	O
the	O
colorectal	B-malignancy-type
tumor	I-malignancy-type
.	O
We	O
identified	O
two	O
germline	O
mutations	O
within	O
the	O
PMS2	O
gene	O
:	O
a	O
G	O
deletion	O
(	O
1221	O
del	O
G	O
)	O
in	O
exon	O
11	O
and	O
a	O
four	O
-	O
base	O
-	O
pair	O
deletion	O
(	O
2361	O
del	O
CTTC	O
)	O
in	O
exon	O
14	O
,	O
both	O
of	O
which	O
were	O
inherited	O
from	O
the	O
patient	O
's	O
unaffected	O
parents	O
.	O
These	O
results	O
represent	O
the	O
first	O
evidence	O
that	O
two	O
germline	O
frameshift	O
mutations	O
in	O
PMS2	O
,	O
an	O
MMR	O
gene	O
which	O
is	O
only	O
rarely	O
involved	O
in	O
HNPCC	B-malignancy-type
,	O
are	O
not	O
pathogenic	O
per	O
se	O
,	O
but	O
become	O
so	O
when	O
occurring	O
together	O
in	O
a	O
compound	O
heterozygote	O
.	O
The	O
compound	O
heterozygosity	O
for	O
two	O
mutations	O
in	O
the	O
PMS2	O
gene	O
has	O
implications	O
for	O
the	O
role	O
of	O
protein	O
PMS2	O
in	O
the	O
mismatch	O
repair	O
mechanism	O
,	O
as	O
well	O
as	O
for	O
the	O
presymptomatic	O
molecular	O
diagnosis	O
of	O
at	O
-risk	O
family	O
members	O
.	O
Furthermore	O
,	O
our	O
data	O
support	O
and	O
enlarge	O
the	O
notion	O
that	O
high	O
DNA	O
instability	O
in	O
normal	O
tissues	O
might	O
trigger	O
the	O
development	O
of	O
cancer	O
in	O
this	O
syndrome	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
10763829	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
1990	O
Apr	O
20;112(	O
1	O
)	O
:92	O
-8.	O
Photoaffinity	O
labeling	O
and	O
binding	O
studies	O
reveal	O
the	O
existence	O
of	O
two	O
types	O
of	O
phencyclidine	O
receptors	O
in	O
the	O
NCB	O
-	O
20	O
cell	O
line	O
.	O
Haring	O
R	O
,	O
Zukin	O
RS	O
,	O
Zukin	O
SR.	O
Department	O
of	O
Psychiatry	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Bronx	O
,	O
NY	O
10461	O
.	O
The	O
mouse	O
neuroblastoma	B-malignancy-type
-	O
Chinese	O
hamster	O
brain	O
hybrid	O
cell	O
line	O
NCB	O
-	O
20	O
is	O
the	O
only	O
clonal	O
cell	O
line	O
in	O
which	O
binding	O
studies	O
indicate	O
the	O
presence	O
of	O
phencyclidine	O
(	O
PCP	O
)	O
receptor	O
-	O
like	O
sites	O
.	O
We	O
report	O
here	O
that	O
polypeptide	O
components	O
of	O
NCB	O
-	O
20	O
cell	O
PCP	O
sites	O
were	O
identified	O
with	O
the	O
photolabile	O
PCP	O
derivative	O
[3H]N-[1-(3-	O
azidophenyl)cyclohexyl]piperidine	O
(	O
[3H]AZ-PCP	O
)	O
.	O
The	O
pharmacological	O
selectivity	O
of	O
[3H]AZ-PCP	O
binding	O
(	O
under	O
reversible	O
conditions	O
)	O
was	O
similar	O
to	O
that	O
observed	O
for	O
[3H]N-[1-(2-thienyl)cyclohexyl]piperidine	O
(	O
[3H]TCP	O
)	O
binding	O
to	O
NCB	O
-	O
20	O
cell	O
membranes	O
.	O
Inhibition	O
of	O
[3H]TCP	O
binding	O
by	O
AZ-PCP	O
,	O
dexoxadrol	O
or	O
MK-801	O
was	O
biphasic	O
,	O
suggesting	O
the	O
presence	O
of	O
two	O
types	O
of	O
PCP	O
sites	O
on	O
NCB	O
-	O
20	O
cells	O
.	O
Photolysis	O
of	O
NCB	O
-	O
20	O
cell	O
membranes	O
pre	O
-	O
equilibrated	O
with	O
[3H]AZ-PCP	O
,	O
followed	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-PAGE	O
)	O
,	O
revealed	O
the	O
presence	O
of	O
5	O
major	O
labeled	O
bands	O
(	O
Mr	O
90	O
,000	O
,	O
68	O
,000	O
,	O
49,000	O
,	O
40	O
,000	O
and	O
33	O
,000	O
)	O
,	O
a	O
pattern	O
similar	O
to	O
that	O
observed	O
for	O
rat	O
brain	O
membranes	O
.	O
MK-801	O
and	O
D-	O
2-amino-	O
5-phosphonovaleric	O
acid	O
(	O
D-(-)-	O
AP5	O
)	O
selectively	O
inhibited	O
the	O
labeling	O
of	O
Mr	O
68	O
,000	O
and	O
90	O
,000	O
polypeptides	O
.	O
These	O
results	O
indicate	O
that	O
the	O
labeled	O
bands	O
represent	O
constituents	O
of	O
at	O
least	O
two	O
different	O
PCP	O
binding	O
proteins	O
.	O
The	O
Mr	O
68	O
,000	O
and	O
90	O
,000	O
components	O
appear	O
to	O
correspond	O
to	O
a	O
high	O
-	O
affinity	O
site	O
,	O
which	O
comprises	O
approximately	O
20	O
%	O
of	O
total	O
[3H]TCP	O
sites	O
in	O
these	O
cells	O
,	O
and	O
exhibits	O
the	O
pharmacology	O
expected	O
for	O
the	O
PCP	O
receptor	O
of	O
the	O
N-methyl-	O
D-	O
aspartate	O
(	O
NMDA	O
)	O
-gated	O
channel	O
.	O
PMID	O
:	O
2166931	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
.	O
2003	O
Apr;129(	O
4	O
)	O
:227	O
-	O
33	O
.	O
Epub	O
2003	O
Apr	O
17	O
.	O
Farnesyltransferase	O
inhibitor	O
FTI-277	O
prevents	O
autocrine	O
growth	O
stimulation	O
of	O
neuroblastoma	B-malignancy-type
by	O
BDNF	O
.	O
Girgert	O
R	O
,	O
Wittrock	O
J,	O
Pfister	O
S	O
,	O
Schweizer	O
P.	O
Department	O
of	O
Gynecology	O
and	O
Obstetrics	O
,	O
University	O
of	O
Ulm	O
,	O
Prittwitzstrasse	O
43	O
,	O
89075	O
,	O
Ulm	O
,	O
Germany	O
.	O
rainer	O
.girgert@medizin	O
.uni-ulm	O
.de	O
PURPOSE	O
:	O
Autocrine	O
growth	O
stimulation	O
by	O
IGF-II	O
and	O
BDNF	O
is	O
frequently	O
observed	O
in	O
neuroblastoma	B-malignancy-type
.	O
The	O
signals	O
of	O
the	O
receptors	O
of	O
these	O
growth	O
factors	O
are	O
transduced	O
to	O
the	O
nucleus	O
via	O
the	O
Ras	O
-	O
MAP	O
-	O
kinase	O
pathway	O
where	O
they	O
induce	O
proliferation	O
.	O
Inactivation	O
of	O
Ras	O
-	O
proteins	O
by	O
farnesyltransferase	O
inhibitors	O
such	O
as	O
FTI-277	O
disrupts	O
growth	O
stimulation	O
of	O
ras	O
-	O
transformed	O
cells	O
.	O
We	O
investigated	O
whether	O
FTI-277	O
is	O
also	O
active	O
against	O
tumor	O
cells	O
with	O
constitutively	O
activated	O
growth	O
factor	O
receptors	O
but	O
lacking	O
ras	O
-	O
mutations	O
.	O
METHOD	O
:	O
We	O
analyzed	O
eight	O
different	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
for	O
the	O
expression	O
of	O
BDNF	O
and	O
its	O
receptor	O
trkB	O
.	O
Two	O
of	O
these	O
cell	O
lines	O
with	O
a	O
complete	O
autocrine	O
BDNF	O
loop	O
were	O
treated	O
with	O
FTI-277	O
,	O
and	O
the	O
effects	O
of	O
Ras	O
-	O
inactivation	O
on	O
the	O
signal	O
transduction	O
of	O
BDNF	O
were	O
analyzed	O
.	O
RESULTS	O
:	O
Treatment	O
of	O
neuroblastoma	B-malignancy-type
cells	O
with	O
10	O
microM	O
FTI-277	O
for	O
4	O
days	O
reduced	O
the	O
amount	O
of	O
membrane	O
-bound	O
Ras	O
-	O
protein	O
to	O
almost	O
50	O
%	O
.	O
Activation	O
of	O
MAP-kinase	O
,	O
induction	O
of	O
N-myc	O
expression	O
,	O
and	O
proliferation	O
were	O
clearly	O
reduced	O
in	O
the	O
treated	O
cells	O
.	O
In	O
addition	O
,	O
we	O
observed	O
some	O
cytotoxic	O
effects	O
of	O
FTI-277	O
accompanied	O
by	O
morphological	O
changes	O
of	O
the	O
neuroblastoma	B-malignancy-type
cells	O
and	O
a	O
delayed	O
induction	O
of	O
apoptosis	O
.	O
CONCLUSION	O
:	O
Farnesyltransferase	O
inhibitors	O
are	O
active	O
against	O
neuroblastoma	B-malignancy-type
cells	O
but	O
the	O
mechanism	O
of	O
action	O
is	O
not	O
limited	O
to	O
inactivation	O
of	O
Ras	O
.	O
Further	O
investigations	O
on	O
the	O
targets	O
of	O
FTI-277	O
are	O
recommended	O
.	O
PMID	O
:	O
12700894	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Pathol	O
.	O
1994	O
Sep-Oct;14(	O
5	O
)	O
:	O
823-32	O
.	O
Assessment	O
of	O
MYCN	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
biopsies	O
by	O
differential	O
polymerase	O
chain	O
reaction	O
.	O
Boerner	O
S	O
,	O
Squire	O
J,	O
Thorner	O
P,	O
McKenna	O
G	O
,	O
Zielenska	O
M.	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Amplification	O
of	O
the	O
oncogene	O
MYCN	O
is	O
a	O
genetic	O
change	O
frequently	O
observed	O
in	O
neuroblastoma	B-malignancy-type
and	O
is	O
an	O
indicator	O
of	O
poor	O
prognosis	O
.	O
MYCN	O
copy	O
number	O
is	O
currently	O
determined	O
by	O
Southern	O
blot	O
hybridization	O
.	O
This	O
technique	O
takes	O
2	O
to	O
3	O
weeks	O
,	O
is	O
labor	O
-	O
intensive	O
,	O
is	O
sensitive	O
to	O
DNA	O
degradation	O
,	O
and	O
requires	O
large	O
quantities	O
of	O
DNA	O
.	O
We	O
have	O
evaluated	O
a	O
new	O
,	O
semiquantitative	O
method	O
of	O
estimating	O
gene	O
copy	O
number	O
that	O
uses	O
differential	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
The	O
procedure	O
can	O
be	O
performed	O
in	O
1	O
day	O
,	O
is	O
highly	O
reproducible	O
,	O
and	O
requires	O
only	O
nanogram	O
quantities	O
of	O
DNA	O
.	O
It	O
employs	O
a	O
semiquantitative	O
,	O
nonisotopic	O
PCR	O
technique	O
based	O
on	O
differential	O
competition	O
for	O
PCR	O
substrates	O
.	O
MYCN	O
gene	O
primers	O
are	O
amplified	O
together	O
with	O
primers	O
from	O
a	O
single-copy	O
internal	O
control	O
gene	O
.	O
Following	O
electrophoretic	O
separation	O
,	O
the	O
ratio	O
of	O
the	O
two	O
PCR	O
products	O
is	O
determined	O
visually	O
and	O
by	O
densitometric	O
analysis	O
of	O
ethidium	O
bromide	O
-	O
stained	O
agarose	O
gels	O
.	O
This	O
differential	O
ratio	O
is	O
then	O
compared	O
to	O
a	O
series	O
of	O
ratios	O
generated	O
from	O
standards	O
of	O
known	O
MYCN	O
gene	O
copy	O
number	O
.	O
We	O
compared	O
the	O
results	O
obtained	O
by	O
this	O
differential	O
PCR	O
method	O
with	O
those	O
obtained	O
by	O
conventional	O
Southern	O
blotting	O
in	O
16	O
cases	O
of	O
primary	O
neuroblastoma	B-malignancy-type
.	O
All	O
amplified	O
tumors	O
were	O
detected	O
by	O
differential	O
PCR	O
,	O
and	O
no	O
false	O
positives	O
were	O
observed	O
.	O
We	O
confirmed	O
that	O
differential	O
PCR	O
is	O
a	O
rapid	O
and	O
reliable	O
alternative	O
to	O
Southern	O
blotting	O
for	O
MYCN	O
copy	O
number	O
assessment	O
and	O
is	O
highly	O
suited	O
to	O
the	O
analysis	O
of	O
DNA	O
derived	O
from	O
needle	O
biopsies	O
.	O
PMID	O
:	O
7808981	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
.	O
1999	O
Mar;	O
5	O
(	O
3	O
)	O
:601	O
-	O
9.	O
Rapid	O
detection	O
of	O
MYCN	O
gene	O
amplification	O
and	O
telomerase	O
expression	O
in	O
neuroblastoma	B-malignancy-type
.	O
Hiyama	O
E	O
,	O
Hiyama	O
K,	O
Yokoyama	O
T	O
,	O
Fukuba	O
I	O
,	O
Yamaoka	O
H,	O
Shay	O
JW	O
,	O
Matsuura	O
Y	O
.	O
Department	O
of	O
General	O
Medicine	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
eiso@mcai.med	O
.hiroshima-u.ac.jp	O
Amplification	O
of	O
the	O
MYCN	O
gene	O
and	O
high	O
telomerase	O
activity	O
predict	O
a	O
poor	O
prognosis	O
for	O
the	O
patients	O
with	O
neuroblastoma	B-malignancy-type
.	O
We	O
used	O
PCR	O
techniques	O
for	O
rapid	O
detection	O
of	O
MYCN	O
gene	O
amplification	O
and	O
human	O
telomerase	O
reverse	O
transcriptase	O
(	O
hTERT	O
)	O
expression	O
in	O
neuroblastoma	B-malignancy-type
specimens	O
.	O
The	O
detection	O
of	O
MYCN	O
gene	O
amplification	O
is	O
based	O
on	O
differential	O
PCR	O
in	O
which	O
three	O
primer	O
pairs	O
were	O
used	O
to	O
coamplify	O
a	O
178	O
-bp	O
fragment	O
of	O
target	O
MYCN	O
gene	O
with	O
two	O
reference	O
gene	O
fragments	O
,	O
a	O
237	O
-	O
bp	O
of	O
p53	O
exon	O
7	O
and	O
a	O
120	O
-	O
bp	O
of	O
beta-globin	O
exon	O
3	O
,	O
in	O
a	O
single	O
tube	O
of	O
40	O
surgically	O
resected	O
tumor	O
samples	O
.	O
MYCN	O
amplification	O
was	O
identified	O
by	O
this	O
differential	O
PCR	O
in	O
all	O
10	O
samples	O
carrying	O
more	O
than	O
10	O
copies	O
(	O
already	O
known	O
to	O
have	O
MYCN	O
gene	O
amplification	O
by	O
Southern	O
blot	O
analysis	O
)	O
.	O
There	O
were	O
no	O
false	O
-	O
negative	O
or	O
false	O
-	O
positive	O
cases	O
,	O
and	O
the	O
relative	O
intensity	O
of	O
MYCN	O
bands	O
in	O
the	O
differential	O
PCR	O
correlated	O
significantly	O
with	O
the	O
copy	O
number	O
determined	O
by	O
Southern	O
blot	O
analysis	O
(	O
y	O
=	O
0.99	O
,	O
P<0.0001	O
)	O
.	O
This	O
protocol	O
was	O
also	O
applicable	O
in	O
the	O
biopsy	O
or	O
aspirated	O
samples	O
,	O
as	O
well	O
as	O
the	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
and	O
in	O
detecting	O
intratumoral	O
heterogeneity	O
.	O
Using	O
RT-PCR	O
procedures	O
,	O
hTERT	O
mRNA	O
expression	O
was	O
detectable	O
in	O
all	O
13	O
tumors	O
with	O
high	O
telomerase	O
activity	O
.	O
These	O
nonradioisotopic	O
PCR	O
-	O
based	O
protocols	O
for	O
detecting	O
MYCN	O
gene	O
amplification	O
and	O
hTERT	O
mRNA	O
expression	O
are	O
rapid	O
and	O
reliable	O
and	O
are	O
likely	O
to	O
be	O
useful	O
to	O
determine	O
the	O
biological	O
behavior	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
10100712	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
2002	O
Mar;61	O
(	O
3	O
)	O
:	O
48	O
6-94	O
.	O
Distinct	O
effects	O
of	O
different	O
calcium	O
-mobilizing	O
agents	O
on	O
cell	O
death	O
in	O
NG108-15	O
neuroblastoma	B-malignancy-type
X	O
glioma	B-malignancy-type
cells	O
.	O
Chin	O
TY	O
,	O
Hwang	O
HM	O
,	O
Chueh	O
SH	O
.	O
Department	O
of	O
Biochemistry	O
,	O
National	O
Defense	O
Medical	O
Center	O
,	O
Taipei	O
,	O
Taiwan	O
,	O
Republic	O
of	O
China	O
.	O
The	O
effects	O
of	O
different	O
calcium	O
-mobilizing	O
agents	O
on	O
cell	O
death	O
were	O
characterized	O
in	O
NG108-15	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
cells	O
.	O
Carbonyl	O
cyanide	O
p-	O
trifluoromethoxyphenylhydrazone	O
(	O
FCCP	O
)	O
increased	O
the	O
cytosolic	O
Ca(2+)	O
concentration	O
(	O
[Ca(2+)	O
]	O
(i)	O
)	O
and	O
caused	O
cell	O
death	O
.	O
Thapsigargin	O
(	O
TG	O
)	O
not	O
only	O
increased	O
the	O
[	O
Ca(2+)	O
]	O
(i)	O
and	O
caused	O
cell	O
death	O
but	O
also	O
induced	O
neurite	O
outgrowth	O
via	O
activation	O
of	O
phospholipase_A	O
(2	O
)	O
and	O
cytochrome	O
P450	O
epoxygenase	O
.	O
In	O
contrast	O
,	O
bradykinin	O
increased	O
the	O
[	O
Ca(2+)	O
]	O
(i	O
)	O
,	O
but	O
had	O
no	O
effect	O
on	O
cell	O
morphology	O
or	O
cell	O
death	O
.	O
Cell	O
death	O
occurred	O
by	O
two	O
different	O
mechanisms	O
,	O
one	O
of	O
which	O
was	O
caspase	O
-3	O
-	O
dependent	O
and	O
the	O
other	O
caspase	O
-3	O
-	O
independent	O
.	O
Caspase-3	O
activation	O
was	O
Ca(2+)-dependent	O
,	O
whereas	O
neurite	O
outgrowth	O
was	O
Ca(2+)	O
-	O
independent	O
.	O
TG	O
-	O
or	O
FCCP	O
-	O
induced	O
caspase-3	O
activation	O
occurred	O
at	O
the	O
same	O
time	O
,	O
but	O
the	O
cell	O
death	O
induced	O
by	O
TG	O
was	O
delayed	O
.	O
TG	O
treatment	O
did	O
not	O
enhance	O
the	O
generation	O
of	O
nitric	O
oxide	O
or	O
cAMP	O
or	O
secretion	O
of	O
glial	O
-	O
derived	O
neurotrophic	O
factor	O
or	O
neurotrophin	O
-3	O
,	O
but	O
activated	O
sphingosine	O
kinase	O
.	O
Furthermore	O
,	O
inhibition	O
of	O
sphingosine	O
kinase	O
accelerated	O
TG	O
-	O
induced	O
cell	O
death	O
,	O
and	O
exogenous	O
sphingosine	O
1-phosphate	O
(	O
S1P	O
)	O
protected	O
cells	O
from	O
FCCP	O
-	O
induced	O
cell	O
death	O
by	O
about	O
60	O
%	O
.	O
These	O
results	O
indicate	O
that	O
,	O
in	O
these	O
cells	O
,	O
depletion	O
of	O
intracellular	O
nonmitochondrial	O
or	O
mitochondrial	O
Ca(2+)	O
stores	O
causes	O
cell	O
death	O
,	O
that	O
TG	O
activates	O
phospholipase_A	O
(2	O
)	O
and	O
sphingosine	O
kinase	O
,	O
and	O
that	O
arachidonic	O
acid	O
induces	O
neurite	O
outgrowth	O
,	O
whereas	O
S1P	O
delays	O
cell	O
death	O
.	O
PMID	O
:	O
11854428	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Nucl	O
Med	O
.	O
1998	O
Feb;25(	O
2	O
)	O
:	O
144	O
-	O
9.	O
Activity	O
of	O
iodine	O
-	O
123	O
metaiodobenzylguanidine	O
in	O
childhood	O
neuroblastoma	B-malignancy-type
:	O
lack	O
of	O
relation	O
to	O
tumour	O
differentiation	O
in	O
vivo	O
.	O
Brans	O
B	O
,	O
Laureys	O
G	O
,	O
Schelfhout	O
V	O
,	O
Wiele	O
CV	O
,	O
Potter	O
CR	O
,	O
Dhooge	O
C	O
,	O
Simons	O
M,	O
Dierckx	O
RA.	O
Division	O
of	O
Nuclear	O
Medicine	O
,	O
University	O
Hospital	O
Gent	O
,	O
Gent	O
,	O
Belgium	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
tumour	O
cells	O
have	O
a	O
remarkable	O
tendency	O
to	O
differentiate	O
spontaneously	O
or	O
under	O
the	O
influence	O
of	O
certain	O
drugs	O
.	O
It	O
is	O
not	O
clear	O
whether	O
metaiodobenzylguanidine	O
(	O
MIBG	O
)	O
uptake	O
correlates	O
with	O
differentiation	O
of	O
NB	B-malignancy-type
cells	O
.	O
In	O
28	O
tumours	O
of	O
26	O
patients	O
,	O
iodine	O
-	O
123	O
MIBG	O
uptake	O
in	O
primary	O
NBs	B-malignancy-type
was	O
studied	O
in	O
relation	O
to	O
tumour	O
differentiation	O
,	O
tumour	O
size	O
,	O
cell	O
density	O
and	O
degree	O
of	O
necrosis	O
in	O
subsequently	O
resected	O
specimens	O
.	O
Genetic	O
features	O
such	O
as	O
the	O
presence	O
of	O
chromosomal	O
aberrations	O
(	O
1p	O
-	O
deletion	O
and	O
MYCN	O
amplification	O
)	O
and/or	O
P-glycoprotein	O
(	O
mdr-1	O
gene	O
product	O
)	O
were	O
also	O
evaluated	O
in	O
relation	O
to	O
MIBG	O
uptake	O
.	O
A	O
highly	O
variable	O
and	O
unpredictable	O
intensity	O
of	O
MIBG	O
uptake	O
was	O
observed	O
in	O
primary	O
as	O
well	O
as	O
secondary	O
resected	O
tumours	O
.	O
This	O
intensity	O
did	O
not	O
relate	O
to	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
factors	O
except	O
that	O
there	O
was	O
a	O
trend	O
towards	O
more	O
intense	O
uptake	O
with	O
increasing	O
size	O
of	O
the	O
tumour	O
.	O
We	O
conclude	O
from	O
our	O
observations	O
that	O
,	O
in	O
contrast	O
to	O
commonly	O
held	O
opinion	O
,	O
well	O
-differentiated	O
tumours	O
do	O
not	O
a	O
priori	O
show	O
a	O
lower	O
MIBG	O
uptake	O
in	O
vivo	O
,	O
even	O
when	O
there	O
are	O
a	O
low	O
number	O
of	O
viable	O
cells	O
and	O
a	O
high	O
degree	O
of	O
necrosis	O
.	O
The	O
degree	O
of	O
differentiation	O
or	O
tumour	O
viability	O
and	O
necrosis	O
following	O
longstanding	O
chemotherapeutic	O
treatment	O
cannot	O
be	O
predicted	O
by	O
the	O
MIBG	O
scan	O
findings	O
.	O
The	O
observed	O
MIBG	O
uptake	O
may	O
be	O
importantly	O
influenced	O
by	O
factors	O
other	O
than	O
those	O
associated	O
with	O
cellular	O
differentiation	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
9473262	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2000	O
Jan	O
14;275	O
(	O
2	O
)	O
:	O
1307	O
-	O
14	O
.	O
An	O
element	O
in	O
the	O
region	O
responsible	O
for	O
premature	O
termination	O
of	O
transcription	O
mediates	O
repression	O
of	O
c-myc	O
gene	O
expression	O
by	O
thyroid	O
hormone	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Perez-Juste	O
G	O
,	O
Garcia-Silva	O
S	O
,	O
Aranda	O
A	O
.	O
Instituto	O
de	O
Investigaciones	O
Biomedicas	O
"	O
Alberto	O
Sols	O
"	O
,	O
Consejo	O
Superior	O
de	O
Investigaciones	O
Cientificas	O
and	O
Universidad	O
Aut-noma	O
de	O
Madrid	O
,	O
28029	O
Madrid	O
,	O
Spain	O
.	O
The	O
thyroid	O
hormone	O
(	O
T3	O
)	O
blocks	O
proliferation	O
and	O
induces	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
N2a	O
-beta	O
cells	O
that	O
express	O
the	O
thyroid	O
hormone	O
receptor	O
(	O
TR	O
)	O
beta1	O
isoform	O
.	O
c-Myc	O
is	O
required	O
for	O
cell	O
cycle	O
progression	O
,	O
and	O
this	O
study	O
shows	O
that	O
T3	O
-	O
induced	O
neuronal	O
differentiation	O
is	O
preceded	O
by	O
a	O
rapid	O
decrease	O
of	O
c-myc	O
gene	O
expression	O
.	O
A	O
negative	O
T3	O
responsive	O
element	O
(	O
TRE	O
)	O
,	O
arranged	O
as	O
an	O
inverted	O
palindrome	O
spaced	O
by	O
three	O
nucleotides	O
,	O
has	O
been	O
identified	O
within	O
the	O
first	O
exon	O
between	O
nucleotides	O
+237	O
and	O
+268	O
.	O
The	O
TRE	O
is	O
adjacent	O
to	O
the	O
binding	O
site	O
for	O
the	O
transcriptional	O
repressor	O
CCCTC	O
binding	O
factor	O
and	O
maps	O
precisely	O
within	O
the	O
region	O
of	O
RNA	O
polymerase	O
II	O
pausing	O
and	O
release	O
,	O
suggesting	O
a	O
direct	O
implication	O
of	O
TR	O
on	O
premature	O
termination	O
of	O
transcription	O
.	O
Furthermore	O
,	O
the	O
TRE	O
confers	O
repression	O
by	O
T3	O
to	O
an	O
heterologous	O
promoter	O
only	O
when	O
inserted	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O
Binding	O
of	O
CCCTC	O
binding	O
factor	O
and	O
TR	O
to	O
their	O
cognate	O
sites	O
in	O
the	O
region	O
of	O
transcriptional	O
attenuation	O
,	O
as	O
well	O
as	O
direct	O
interactions	O
between	O
both	O
factors	O
,	O
could	O
facilitate	O
the	O
formation	O
of	O
a	O
repressor	O
complex	O
and	O
the	O
inhibition	O
of	O
c-myc	O
gene	O
expression	O
.	O
These	O
studies	O
provide	O
insight	O
into	O
mechanisms	O
by	O
which	O
TR	O
mediate	O
transcriptional	O
repression	O
and	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
important	O
effects	O
of	O
thyroid	O
hormones	O
on	O
growth	O
and	O
differentiation	O
of	O
neuronal	O
cells	O
.	O
PMID	O
:	O
10625678	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurochem	O
Res	O
.	O
1979	O
Jun;	O
4(	O
3	O
)	O
:	O
339	O
-	O
54	O
.	O
High	O
-	O
affinity	O
uptake	O
of	O
gamma	O
-aminobutyric	O
acid	O
in	O
cultured	O
glial	O
and	O
neuronal	O
cells	O
.	O
Balcar	O
VJ	O
,	O
Mark	O
J,	O
Borg	O
J,	O
Mandel	O
P.	O
Both	O
glial	O
and	O
neuronal	O
cells	O
maintained	O
in	O
primary	O
culture	O
were	O
found	O
to	O
accumulate	O
[3H]GABA	O
by	O
an	O
efficient	O
"	O
high	O
-	O
affinity	O
"	O
uptake	O
system	O
(	O
apparent	O
Km	O
=	O
9	O
muM	O
,	O
Vmax	O
=	O
0.018	O
and	O
0.584	O
nmol	O
/	O
mg	O
/	O
min	O
,	O
respectively	O
)	O
which	O
required	O
sodium	O
ions	O
and	O
was	O
inhibited	O
by	O
1	O
mM	O
ouabain	O
.	O
Strychnine	O
and	O
parachloromercuriphenylsulfonate	O
(	O
pCS	O
)	O
(	O
both	O
at	O
1mM	O
)	O
also	O
strongly	O
inhibited	O
uptake	O
of	O
[3H]GABA	O
,	O
but	O
metabolic	O
inhibitors	O
(	O
2,4-dinitrophenol	O
,	O
potassium	O
cyanide	O
,	O
and	O
malonate	O
)	O
were	O
without	O
effect	O
.	O
Only	O
three	O
structural	O
analogs	O
of	O
GABA	O
(	O
nipecotate	O
,	O
beta-alanine	O
,	O
and	O
2,4-diaminobutyrate	O
)	O
inhibited	O
uptake	O
of	O
[3H]GABA	O
,	O
while	O
several	O
other	O
compounds	O
with	O
structural	O
similarities	O
to	O
GABA	O
(	O
e.g	O
.	O
glycine	O
,	O
L-proline	O
,	O
and	O
taurine	O
)	O
did	O
not	O
interact	O
with	O
the	O
system	O
.	O
The	O
kinetic	O
studies	O
indicated	O
presence	O
of	O
a	O
second	O
uptake	O
(	O
Km	O
=	O
92	O
muM	O
,	O
Vmax	O
=	O
0.124	O
nmol	O
/	O
mg	O
/	O
min	O
)	O
in	O
the	O
primary	O
cultures	O
containing	O
predominantly	O
glioblasts	O
.	O
On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
neuronal	O
cell	O
lines	O
transformed	O
by	O
simian	O
virus	O
SV40	O
appeared	O
to	O
accumulate	O
[3H]GABA	O
against	O
a	O
concentration	O
gradient	O
.	O
Apparent	O
Km	O
of	O
this	O
uptake	O
was	O
relatively	O
high	O
(	O
819	O
muM	O
)	O
,	O
and	O
it	O
was	O
only	O
weakly	O
inhibited	O
by	O
1	O
mM	O
ouabain	O
and	O
1	O
mM	O
pCS	O
.	O
The	O
structural	O
specificity	O
also	O
differed	O
from	O
that	O
of	O
the	O
uptake	O
observed	O
in	O
the	O
primary	O
cultures	O
.	O
Significantly	O
,	O
non	O
of	O
the	O
nontransformed	O
continuous	O
cell	O
lines	O
of	O
either	O
tumoral	O
(	O
glioma	B-malignancy-type
,	O
C6	O
;	O
neuroblastoma	B-malignancy-type
,	O
M1	O
;	O
M1NN	O
)	O
or	O
normal	O
(	O
NN;I6	O
)	O
origin	O
actively	O
accumulated	O
[3H]GABA.	O
It	O
is	O
suggested	O
that	O
for	O
the	O
neurochemical	O
studies	O
related	O
to	O
GABA	O
and	O
requiring	O
homogeneous	O
cell	O
populations	O
,	O
the	O
primary	O
cultures	O
offer	O
a	O
better	O
experimental	O
model	O
than	O
the	O
continuous	O
cell	O
lines	O
.	O
PMID	O
:	O
223077	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prog	O
Clin	O
Biol	O
Res	O
.	O
1994;385	O
:169	O
-	O
75	O
.	O
Expression	O
and	O
function	O
of	O
the	O
nerve	O
growth	O
factor	O
receptor	O
(	O
TRK-A	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Azar	O
CG	O
,	O
Scavarda	O
NJ	O
,	O
Nakagawara	O
A	O
,	O
Brodeur	O
GM	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
MO	O
63110	O
.	O
Nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
is	O
known	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
and	O
survival	O
of	O
normal	O
sympathetic	O
neurons	O
through	O
its	O
interaction	O
with	O
a	O
specific	O
cell	O
surface	O
receptor	O
.	O
We	O
analyzed	O
ten	O
well	O
-characterized	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
for	O
the	O
expression	O
and	O
function	O
of	O
endogenous	O
and	O
exogenous	O
p140TRK-A	O
,	O
and	O
p75LNGFR	O
.	O
Exogenous	O
LNGFR	O
or	O
TRK-A	O
(	O
or	O
both	O
)	O
were	O
introduced	O
by	O
transfection	O
into	O
three	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Transfected	O
and	O
untransfected	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
were	O
analyzed	O
by	O
Northern	O
analysis	O
as	O
well	O
as	O
tyrosine	O
phosphorylation	O
studies	O
.	O
Results	O
indicate	O
that	O
endogenous	O
TRK-A	O
is	O
expressed	O
and/or	O
p140TRK-A	O
is	O
phosphorylated	O
in	O
10	O
of	O
10	O
cell	O
lines	O
.	O
However	O
,	O
no	O
other	O
downstream	O
responses	O
to	O
NGF	O
stimulation	O
(	O
such	O
as	O
tyrosine	O
phosphorylation	O
of	O
PLC	O
gamma	O
1	O
,	O
PI-3	O
kinase	O
,	O
ERK1	O
and	O
ERK2	O
,	O
induction	O
of	O
FOS	O
and	O
NGFI-	O
A	O
mRNAs	O
,	O
and	O
neurite	O
extension	O
)	O
were	O
observed	O
in	O
the	O
unresponsive	O
cell	O
lines	O
.	O
Transfection	O
with	O
p75LNGFR	O
alone	O
had	O
no	O
effect	O
on	O
responses	O
to	O
NGF	O
stimulation	O
.	O
Three	O
cell	O
lines	O
stably	O
transfected	O
with	O
TRK-A	O
exhibited	O
early	O
responses	O
to	O
NGF	O
stimulation	O
,	O
but	O
neurite	O
extension	O
was	O
not	O
observed	O
.	O
Our	O
results	O
indicate	O
that	O
endogenous	O
TRK-A	O
in	O
non	O
-	O
responsive	O
cell	O
lines	O
is	O
either	O
defective	O
,	O
or	O
present	O
in	O
amounts	O
below	O
a	O
threshold	O
level	O
required	O
to	O
elicit	O
measurable	O
responses	O
to	O
NGF	O
.	O
Furthermore	O
,	O
even	O
after	O
transfection	O
with	O
exogenous	O
TRK-A	O
,	O
early	O
responses	O
were	O
restored	O
but	O
later	O
events	O
such	O
as	O
neurite	O
outgrowth	O
did	O
not	O
occur	O
,	O
suggesting	O
that	O
downstream	O
responsiveness	O
is	O
blocked	O
as	O
well	O
.	O
PMID	O
:	O
7972209	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
2000	O
Apr;82	O
(	O
8	O
)	O
:	O
1474	O
-	O
9.	O
Characterization	O
of	O
antigen	O
-	O
presenting	O
properties	O
of	O
tumour	O
cells	O
using	O
virus	O
-	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
.	O
Spierings	O
DC	O
,	O
Agsteribbe	O
E	O
,	O
Wilschut	O
J,	O
Huckriede	O
A	O
.	O
Department	O
of	O
Medical	O
Microbiology	O
,	O
University	O
of	O
Groningen	O
,	O
The	O
Netherlands	O
.	O
Immunotherapy	O
of	O
tumours	O
by	O
induction	O
of	O
tumour	O
-	O
specific	O
cytotoxic	O
T-lymphocytes	O
(	O
CTLs	O
)	O
will	O
only	O
be	O
effective	O
for	O
tumours	O
with	O
a	O
functional	O
antigen	O
processing	O
and	O
presentation	O
machinery	O
.	O
However	O
,	O
many	O
tumours	O
are	O
known	O
to	O
down	O
-	O
regulate	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
and/or	O
to	O
impair	O
antigen	O
processing	O
.	O
It	O
is	O
therefore	O
desirable	O
to	O
evaluate	O
the	O
ability	O
of	O
a	O
given	O
tumour	O
to	O
present	O
antigenic	O
epitopes	O
before	O
developing	O
an	O
immunotherapy	O
protocol	O
.	O
In	O
this	O
study	O
we	O
have	O
used	O
influenza	O
virus	O
as	O
a	O
tool	O
to	O
determine	O
the	O
antigen	O
-	O
presenting	O
capacities	O
of	O
the	O
murine	O
neuroblastoma	B-malignancy-type
C1300	O
cell	O
line	O
NB41A3	O
,	O
a	O
frequently	O
used	O
model	O
for	O
human	O
neuroblastoma	B-malignancy-type
.	O
Immunofluorescence	O
analyses	O
revealed	O
low	O
and	O
moderate	O
expression	O
of	O
MHC	O
class	O
I	O
molecules	O
Dd	O
and	O
Kk	O
respectively	O
.	O
Nevertheless	O
,	O
infected	O
NB41	O
A3	O
cells	O
were	O
lysed	O
efficiently	O
by	O
influenza	O
-	O
specific	O
CTLs	O
.	O
These	O
results	O
demonstrate	O
that	O
all	O
steps	O
of	O
the	O
antigen	O
-	O
processing	O
pathway	O
function	O
properly	O
in	O
the	O
NB	B-malignancy-type
tumour	O
cells	O
,	O
and	O
that	O
the	O
limited	O
MHC	O
class	O
I	O
expression	O
suffices	O
for	O
efficient	O
recognition	O
by	O
CTLs	O
.	O
In	O
addition	O
,	O
lysis	O
of	O
the	O
NB	B-malignancy-type
tumour	O
cells	O
shows	O
that	O
the	O
cells	O
are	O
susceptible	O
to	O
CTL	O
-	O
induced	O
apoptosis	O
,	O
a	O
pathway	O
that	O
is	O
often	O
impaired	O
in	O
tumour	O
cells	O
.	O
These	O
characteristics	O
make	O
neuroblastoma	B-malignancy-type
a	O
suitable	O
target	O
for	O
immunotherapy	O
.	O
The	O
presented	O
assay	O
allows	O
evaluation	O
of	O
various	O
immunological	O
properties	O
of	O
tumour	O
cells	O
and	O
,	O
thus	O
,	O
represents	O
a	O
valuable	O
tool	O
to	O
assess	O
whether	O
a	O
given	O
tumour	O
will	O
be	O
susceptible	O
to	O
immunotherapy	O
or	O
not	O
.	O
PMID	O
:	O
10780529	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Toxins	O
.	O
1999	O
;	O
7	O
(	O
6	O
)	O
:	O
415-21	O
.	O
Reporter	O
gene	O
assays	O
for	O
algal	O
-	O
derived	O
toxins	O
.	O
Fairey	O
ER	O
,	O
Ramsdell	O
JS.	O
Marine	O
Biotoxins	O
Program	O
,	O
NOAA	O
-	O
National	O
Ocean	O
Service	O
,	O
Center	O
for	O
Coastal	O
Environmental	O
Health	O
and	O
Biomolecular	O
Research	O
,	O
Charleston	O
,	O
SC	O
29412	O
,	O
USA	O
.	O
We	O
have	O
modified	O
the	O
cell	O
-	O
based	O
directed	O
cytotoxicity	O
assay	O
for	O
sodium	O
channel	O
and	O
calcium	O
channel	O
active	O
phycotoxins	O
using	O
a	O
c-	O
fos	O
-	O
luciferase	O
reporter	O
gene	O
construct	O
.	O
In	O
this	O
report	O
we	O
describe	O
the	O
conceptual	O
basis	O
to	O
the	O
development	O
of	O
reporter	O
gene	O
assays	O
for	O
algal	O
-	O
derived	O
toxins	O
and	O
summarize	O
both	O
published	O
and	O
unpublished	O
data	O
using	O
this	O
method	O
.	O
N2A	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
,	O
which	O
express	O
voltage	O
-	O
dependent	O
sodium	O
channels	O
,	O
were	O
stably	O
transfected	O
with	O
the	O
reporter	O
gene	O
c-	O
fos	O
-	O
luc	O
,	O
which	O
contains	O
the	O
firefly	O
luciferase	O
gene	O
under	O
the	O
transcriptional	O
regulation	O
of	O
the	O
human	O
c-	O
fos	O
response	O
element	O
.	O
The	O
characteristics	O
of	O
the	O
N2A	O
reporter	O
gene	O
assay	O
were	O
determined	O
by	O
dose	O
response	O
with	O
brevetoxin	O
and	O
ciguatoxin	O
.	O
Brevetoxin-1	O
and	O
ciguatoxin-1	O
induced	O
c-	O
fos	O
-	O
luc	O
with	O
an	O
EC50	O
of	O
4.6	O
and	O
3.0	O
ng	O
ml(-1	O
)	O
,	O
respectively	O
.	O
Saxitoxin	O
caused	O
a	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
brevetoxin-1	O
induction	O
of	O
c-	O
fos	O
-	O
luc	O
with	O
an	O
EC50	O
of	O
3.5	O
ng	O
ml(-1	O
)	O
.	O
GH4C1	O
rat	O
pituitary	O
cells	O
,	O
which	O
lack	O
voltage	O
-	O
dependent	O
sodium	O
channels	O
but	O
express	O
voltage	O
-	O
dependent	O
calcium	O
channels	O
,	O
were	O
also	O
stably	O
transfected	O
with	O
the	O
c-	O
fos	O
-	O
luc	O
.	O
GH4C1	O
cells	O
expressing	O
c-	O
fos	O
-	O
luciferase	O
were	O
responsive	O
to	O
maitotoxin	O
(	O
1	O
ng	O
ml(-1)	O
)	O
and	O
a	O
putative	O
toxin	O
produced	O
by	O
Pfiesteria	O
piscicida	O
.	O
Although	O
reporter	O
gene	O
assays	O
are	O
not	O
designed	O
to	O
replace	O
existing	O
detection	O
methods	O
used	O
to	O
measure	O
toxin	O
activity	O
in	O
seafood	O
,	O
they	O
do	O
provide	O
a	O
valuable	O
means	O
to	O
screen	O
algal	O
cultures	O
for	O
toxin	O
activity	O
,	O
to	O
conduct	O
assay	O
-guided	O
fractionation	O
and	O
to	O
characterize	O
pharmacologic	O
properties	O
of	O
algal	O
toxins	O
.	O
PMID	O
:	O
11122538	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
2001	O
Apr	O
18;89	O
(	O
1-2	O
)	O
:	O
58	O
-	O
70	O
.	O
NF	O
-Y	O
binding	O
is	O
required	O
for	O
transactivation	O
of	O
neuronal	O
aromatic	O
L-amino	O
acid	O
decarboxylase	O
gene	O
promoter	O
by	O
the	O
POU-domain	O
protein	O
Brn	O
-2	O
.	O
Dugast	O
C	O
,	O
Weber	O
MJ.	O
Laboratoire	O
de	O
Biologie	O
Moleculaire	O
Eucaryote	O
,	O
CNRS	O
UMR	O
5099	O
,	O
118	O
route	O
de	O
Narbonne	O
,	O
31062	O
Toulouse	O
,	O
France	O
.	O
We	O
have	O
previously	O
characterized	O
binding	O
sites	O
for	O
the	O
NF	O
-Y	O
transcription	O
factor	O
(	O
-71/-52	O
)	O
and	O
Brn	O
-2	O
POU-domain	O
protein	O
(	O
-92/-	O
71	O
)	O
in	O
the	O
neuronal	O
promoter	O
of	O
the	O
human	O
aromatic	O
L-amino	O
acid	O
decarboxylase	O
gene	O
[Mol	O
.	O
Brain	O
Res	O
.	O
56	O
(	O
1998	O
)	O
227	O
]	O
.	O
e	O
have	O
now	O
explored	O
the	O
functional	O
role	O
of	O
these	O
binding	O
sites	O
in	O
transfected	O
SK-N-BE	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Mutations	O
of	O
the	O
NF	O
-Y	O
site	O
that	O
abolish	O
binding	O
depressed	O
expression	O
of	O
a	O
luciferase	O
reporter	O
gene	O
up	O
to	O
25	O
-	O
fold	O
.	O
The	O
overexpression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
NF	O
-YA	O
subunit	O
depressed	O
expression	O
by	O
60	O
%	O
.	O
Promoter	O
activity	O
was	O
increased	O
by	O
the	O
overexpression	O
of	O
Brn	O
-2	O
.	O
Mutations	O
or	O
deletion	O
of	O
the	O
binding	O
site	O
of	O
Brn	O
-2	O
did	O
not	O
suppress	O
transcriptional	O
activation	O
by	O
overexpressed	O
Brn	O
-2	O
,	O
while	O
promoters	O
defective	O
in	O
NF	O
-Y	O
binding	O
were	O
not	O
transactivated	O
by	O
Brn	O
-2	O
.	O
A	O
GST	O
-	O
pulldown	O
experiment	O
showed	O
that	O
recombinant	O
human	O
Brn	O
-2	O
protein	O
weakly	O
interacts	O
with	O
recombinant	O
NF	O
-Y	O
outside	O
of	O
DNA	O
.	O
Cooperative	O
binding	O
of	O
recombinant	O
NF	O
-Y	O
and	O
GST	O
--	O
Brn	O
-2	O
proteins	O
on	O
the	O
neuronal	O
promoter	O
was	O
evidenced	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
The	O
POU-domain	O
of	O
Brn	O
-2	O
was	O
sufficient	O
for	O
such	O
interaction	O
.	O
The	O
results	O
thus	O
suggest	O
that	O
the	O
activation	O
of	O
the	O
neuronal	O
promoter	O
of	O
the	O
aromatic	O
L-amino	O
acid	O
decarboxylase	O
gene	O
requires	O
a	O
direct	O
interaction	O
between	O
the	O
ubiquitous	O
NF	O
-Y	O
factor	O
and	O
a	O
cell	O
-	O
specific	O
POU-domain	O
protein	O
.	O
The	O
NF	O
-Y	O
,	O
but	O
not	O
the	O
Brn	O
-2	O
binding	O
site	O
,	O
is	O
essential	O
for	O
the	O
recruitment	O
of	O
the	O
NF	O
-Y	O
/	O
Brn	O
-2	O
complex	O
on	O
the	O
promoter	O
.	O
PMID	O
:	O
11311976	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1999	O
May	O
28;274(	O
22	O
)	O
:15466-72	O
.	O
The	O
p75	O
(	O
NTR	O
)	O
-	O
induced	O
apoptotic	O
program	O
develops	O
through	O
a	O
ceramide	O
-	O
caspase	O
pathway	O
negatively	O
regulated	O
by	O
nitric	O
oxide	O
.	O
Lievremont	O
JP	O
,	O
Sciorati	O
C	O
,	O
Morandi	O
E	O
,	O
Paolucci	O
C	O
,	O
Bunone	O
G	O
,	O
Della	O
Valle	O
G	O
,	O
Meldolesi	O
J,	O
Clementi	O
E.	O
Department	O
of	O
Pharmacology	O
and	O
the	O
Bruno	O
Ceccarelli	O
Center	O
,	O
University	O
of	O
Milan	O
,	O
Italy	O
.	O
SK-N-BE	O
neuroblastoma	B-malignancy-type
cell	O
clones	O
transfected	O
with	O
p75	O
(	O
NTR	O
)	O
and	O
lacking	O
Trk	O
neurotrophin	O
receptors	O
,	O
previously	O
reported	O
to	O
undergo	O
extensive	O
spontaneous	O
apoptosis	O
and	O
to	O
be	O
protected	O
by	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
(	O
Bunone	O
,	O
G.	O
,	O
Mariotti	O
,	O
A.	O
,	O
Compagni	O
,	O
A.	O
,	O
Morandi	O
,	O
E.	O
,	O
and	O
Della	O
Valle	O
,	O
G.	O
(	O
1997	O
)	O
Oncogene	O
14	O
,	O
1463-1470	O
)	O
,	O
are	O
shown	O
to	O
exhibit	O
(	O
i)	O
increased	O
levels	O
of	O
the	O
pro	O
-apoptotic	O
lipid	O
metabolite	O
ceramide	O
and	O
(ii)	O
high	O
activity	O
of	O
caspases	O
,	O
the	O
proteases	O
of	O
the	O
cell	O
death	O
cascade	O
.	O
In	O
the	O
p75	O
(	O
NTR	O
)	O
-	O
expressing	O
cells	O
,	O
these	O
parameters	O
were	O
partially	O
normalized	O
by	O
prolonged	O
NGF	O
treatment	O
,	O
which	O
,	O
in	O
addition	O
,	O
decreased	O
apoptosis	O
,	O
similar	O
to	O
caspase	O
blockers	O
.	O
Conversely	O
,	O
exogenous	O
ceramide	O
increased	O
caspase	O
activity	O
and	O
apoptosis	O
in	O
both	O
wild-type	O
and	O
p75	O
(	O
NTR	O
)	O
-	O
expressing	O
cells	O
.	O
A	O
new	O
p75	O
(	O
NTR	O
)	O
-	O
expressing	O
clone	O
characterized	O
by	O
low	O
spontaneous	O
apoptosis	O
exhibited	O
high	O
endogenous	O
ceramide	O
and	O
low	O
caspase	O
levels	O
.	O
A	O
marked	O
difference	O
between	O
the	O
apoptotic	O
and	O
resistant	O
clones	O
concerned	O
the	O
very	O
low	O
and	O
high	O
activities	O
of	O
nitric	O
-oxide	O
(	O
NO	O
)	O
synthase	O
,	O
respectively	O
.	O
Protection	O
from	O
apoptosis	O
by	O
NO	O
was	O
confirmed	O
by	O
results	O
with	O
the	O
NO	O
donor	O
S-nitrosoacetylpenicillamine	O
and	O
the	O
NO-trapping	O
agent	O
hemoglobin	O
.	O
We	O
conclude	O
that	O
the	O
p75	O
(	O
NTR	O
)	O
receptor	O
,	O
while	O
free	O
of	O
NGF	O
,	O
triggers	O
a	O
cascade	O
leading	O
to	O
apoptosis	O
;	O
the	O
cascade	O
includes	O
generation	O
of	O
ceramide	O
and	O
increased	O
caspase	O
activity	O
;	O
and	O
the	O
protective	O
role	O
of	O
NO	O
occurs	O
at	O
step(s)	O
in	O
between	O
the	O
latter	O
events	O
.	O
PMID	O
:	O
10336437	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1993	O
Aug	O
25;268(	O
24	O
)	O
:17987	O
-	O
94	O
.	O
Neuron	O
-	O
specific	O
expression	O
of	O
the	O
human	O
dopamine	O
beta-hydroxylase	O
gene	O
requires	O
both	O
the	O
cAMP	O
-response	O
element	O
and	O
a	O
silencer	O
region	O
.	O
Ishiguro	O
H,	O
Kim	O
KT	O
,	O
Joh	O
TH	O
,	O
Kim	O
KS.	O
Laboratory	O
of	O
Molecular	O
Neurobiology	O
,	O
Cornell	O
University	O
Medical	O
College	O
,	O
Burke	O
Medical	O
Research	O
Institute	O
,	O
White	O
Plains	O
,	O
New	O
York	O
10605	O
.	O
Dopamine	O
beta-hydroxylase	O
(	O
DBH	O
)	O
,	O
the	O
enzyme	O
catalyzing	O
the	O
conversion	O
of	O
dopamine	O
to	O
norepinephrine	O
,	O
is	O
specifically	O
expressed	O
in	O
adrenergic	O
and	O
noradrenergic	O
neurons	O
in	O
the	O
central	O
nervous	O
system	O
.	O
DNase	O
I	O
hypersensitive	O
sites	O
were	O
found	O
in	O
the	O
5'	O
-flanking	O
region	O
of	O
the	O
DBH	O
gene	O
in	O
noradrenergic	O
human	O
euroblastoma	B-malignancy-type
SK-N-BE(2)	O
C	O
cells	O
,	O
but	O
not	O
in	O
DBH	O
-nonexpressing	O
HeLa	O
cells	O
.	O
We	O
report	O
here	O
that	O
the	O
4.3-kilobase	O
upstream	O
sequence	O
of	O
the	O
human	O
DBH	O
gene	O
confers	O
cell	O
type	O
-	O
specific	O
expression	O
as	O
assessed	O
by	O
transient	O
expression	O
assay	O
.	O
Furthermore	O
,	O
deletional	O
and	O
mutational	O
analyses	O
revealed	O
two	O
genetic	O
regulatory	O
elements	O
required	O
for	O
the	O
regulation	O
of	O
cell	O
type	O
specificity	O
.	O
First	O
,	O
deletion	O
of	O
the	O
cAMP	O
-response	O
element	O
(	O
CRE	O
)	O
abolished	O
>	O
95	O
%	O
of	O
the	O
transcriptional	O
activity	O
by	O
the	O
DBH	O
upstream	O
promoter	O
,	O
thus	O
implicating	O
the	O
CRE	O
as	O
an	O
essential	O
positive	O
genetic	O
element	O
.	O
Second	O
,	O
deletion	O
of	O
a	O
region	O
between	O
-	O
490	O
and	O
-	O
263	O
base	O
pairs	O
resulted	O
in	O
10	O
-	O
fold	O
increase	O
of	O
reporter	O
gene	O
activity	O
only	O
in	O
HeLa	O
cells	O
,	O
indicating	O
that	O
this	O
region	O
contains	O
a	O
cell	O
-	O
specific	O
silencer	O
.	O
A	O
13-	O
base	O
pair	O
fragment	O
residing	O
within	O
that	O
region	O
shows	O
77	O
%	O
sequence	O
identity	O
with	O
the	O
neuron	O
-	O
specific	O
silencer	O
motif	O
recently	O
identified	O
in	O
two	O
neuronal	O
genes	O
,	O
i.e	O
.	O
SCG10	O
and	O
type	O
II	O
sodium	O
channel	O
genes	O
.	O
We	O
propose	O
that	O
the	O
interplay	O
between	O
the	O
CRE	O
and	O
this	O
neuron	O
-	O
specific	O
silencer	O
region	O
plays	O
an	O
important	O
role	O
in	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
DBH	O
gene	O
in	O
noradrenergic	O
cells	O
.	O
PMID	O
:	O
7688735	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Neurosci	O
.	O
2003	O
Mar;22	O
(	O
3	O
)	O
:	O
308-18	O
.	O
Regulation	O
of	O
sympathetic	O
neuron	O
and	O
neuroblastoma	B-malignancy-type
cell	O
death	O
by	O
XIAP	O
and	O
its	O
association	O
with	O
proteasomes	O
in	O
neural	O
cells	O
.	O
Yu	O
LY	O
,	O
Korhonen	O
L,	O
Martinez	O
R	O
,	O
Jokitalo	O
E	O
,	O
Chen	O
Y	O
,	O
Arumae	O
U	O
,	O
Lindholm	O
D.	O
Program	O
of	O
Molecular	O
Neurobiology	O
,	O
Institute	O
of	O
Biotechnology	O
,	O
University	O
of	O
Helsinki	O
,	O
Finland	O
.	O
XIAP	O
(	O
X	O
chromosome	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	O
protein	O
)	O
has	O
been	O
shown	O
to	O
inhibit	O
cell	O
death	O
in	O
a	O
variety	O
of	O
cells	O
.	O
XIAP	O
binds	O
to	O
active	O
caspases	O
,	O
but	O
XIAP	O
also	O
has	O
a	O
carboxy-terminal	O
RING	O
domain	O
that	O
can	O
regulate	O
cell	O
death	O
via	O
protein	O
degradation	O
.	O
Here	O
we	O
have	O
studied	O
the	O
function	O
of	O
full	O
-	O
length	O
and	O
RING	O
-deleted	O
XIAP	O
in	O
mouse	O
sympathetic	O
neurons	O
microinjected	O
with	O
expression	O
plasmids	O
and	O
in	O
neuroblastoma	B-malignancy-type
cells	O
stably	O
overexpressing	O
these	O
proteins	O
.	O
Both	O
full	O
-	O
length	O
and	O
RING	O
-deleted	O
XIAP	O
-protected	O
sympathetic	O
neurons	O
against	O
death	O
induced	O
by	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
withdrawal	O
to	O
about	O
the	O
same	O
extent	O
.	O
However	O
,	O
the	O
two	O
proteins	O
were	O
differentially	O
localized	O
in	O
transfected	O
neurons	O
,	O
with	O
RING	O
-deleted	O
XIAP	O
present	O
in	O
the	O
cytoplasm	O
and	O
full	O
-	O
length	O
XIAP	O
found	O
mostly	O
in	O
cytoplasmic	O
protein	O
aggregates	O
,	O
as	O
revealed	O
by	O
transmission	O
electron	O
microscopy	O
.	O
The	O
occurrence	O
of	O
these	O
aggregates	O
was	O
blocked	O
by	O
lactacystin	O
,	O
a	O
proteasome	O
inhibitor	O
.	O
In	O
neuroblastoma	B-malignancy-type
cells	O
,	O
RING	O
-deleted	O
XIAP	O
protected	O
against	O
death	O
induced	O
by	O
staurosporine	O
,	O
thapsigargin	O
,	O
or	O
serum	O
withdrawal	O
,	O
whereas	O
full	O
-	O
length	O
XIAP	O
was	O
without	O
effect	O
.	O
Full	O
-	O
length	O
,	O
but	O
not	O
RING	O
-deleted	O
,	O
XIAP	O
was	O
degraded	O
and	O
ubiquitinated	O
in	O
the	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
results	O
show	O
that	O
the	O
presence	O
of	O
the	O
RING	O
domain	O
differentially	O
affected	O
the	O
neuroprotective	O
ability	O
of	O
XIAP	O
in	O
sensory	O
neurons	O
and	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
RING	O
domain	O
was	O
essentially	O
required	O
for	O
the	O
proteasomal	O
association	O
of	O
XIAP	O
and	O
for	O
its	O
ubiquitination	O
.	O
PMID	O
:	O
12691733	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1996	O
Jun	O
14;271(	O
24	O
)	O
:	O
14221	O
-5	O
.	O
Neural	O
specific	O
expression	O
of	O
the	O
m4	O
muscarinic	O
acetylcholine	O
receptor	O
gene	O
is	O
mediated	O
by	O
a	O
RE1	O
/	O
NRSE-type	O
silencing	O
element	O
.	O
Wood	O
IC	O
,	O
Roopra	O
A	O
,	O
Buckley	O
NJ.	O
Wellcome	O
Laboratory	O
for	O
Molecular	O
Pharmacology	O
,	O
University	O
College	O
London	O
,	O
London	O
,	O
WC1E	O
6BT	O
,	O
United	O
Kingdom	O
.	O
Muscarinic	O
receptor	O
genes	O
are	O
members	O
of	O
the	O
G-protein	O
receptor	O
superfamily	O
that	O
,	O
with	O
the	O
inclusion	O
of	O
the	O
odorant	O
receptors	O
,	O
is	O
believed	O
to	O
contain	O
over	O
a	O
thousand	O
members	O
.	O
Each	O
member	O
of	O
this	O
superfamily	O
,	O
which	O
has	O
been	O
studied	O
to	O
date	O
,	O
appears	O
to	O
have	O
a	O
distinct	O
pattern	O
of	O
expression	O
,	O
but	O
little	O
work	O
has	O
been	O
done	O
on	O
the	O
regulation	O
of	O
these	O
complex	O
expression	O
patterns	O
.	O
We	O
have	O
recently	O
isolated	O
the	O
rat	O
m4	O
muscarinic	O
receptor	O
gene	O
and	O
identified	O
a	O
genomic	O
1520-	O
nucleotide	O
sequence	O
that	O
appeared	O
capable	O
of	O
directing	O
cell	O
-	O
specific	O
expression	O
(	O
Wood	O
,	O
I.	O
C.	O
,	O
Roopra	O
.	O
A.	O
,	O
Harrington	O
,	O
C.	O
,	O
and	O
Buckley	O
,	O
N	O
.	O
J.	O
(	O
1995	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
3093	O
3	O
-30940	O
)	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
constructed	O
a	O
set	O
of	O
deletion	O
promoter	O
constructs	O
to	O
more	O
closely	O
define	O
the	O
DNA	O
elements	O
that	O
are	O
responsible	O
for	O
m4	O
gene	O
expression	O
.	O
We	O
have	O
found	O
that	O
deletion	O
of	O
a	O
RE1	O
/	O
NRSE	O
silencer	O
element	O
between	O
nucleotides	O
-	O
574	O
and	O
-	O
550	O
,	O
similar	O
to	O
that	O
found	O
in	O
other	O
neural	O
specific	O
genes	O
,	O
results	O
in	O
activation	O
of	O
reporter	O
expression	O
in	O
non	O
-	O
m4	O
-	O
expressing	O
cells	O
.	O
Gel	O
mobility	O
shift	O
analysis	O
has	O
shown	O
that	O
a	O
protein	O
present	O
in	O
nonexpressing	O
cells	O
is	O
capable	O
of	O
binding	O
to	O
this	O
element	O
and	O
is	O
probably	O
the	O
recently	O
identified	O
neural	O
silencer	O
,	O
REST	O
/NRSF	O
.	O
Of	O
the	O
constitutively	O
active	O
proximal	O
promoter	O
only	O
a	O
tandem	O
Sp-1	O
site	O
appears	O
to	O
recruit	O
DNA	O
binding	O
proteins	O
that	O
are	O
present	O
in	O
all	O
cells	O
tested	O
.	O
This	O
represents	O
the	O
first	O
report	O
documenting	O
the	O
role	O
of	O
this	O
silencer	O
in	O
regulating	O
expression	O
of	O
a	O
member	O
of	O
the	O
G-protein	O
receptor	O
family	O
.	O
PMID	O
:	O
8662964	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2000	O
Jun	O
23;275	O
(	O
25	O
)	O
:19268	O
-74	O
.	O
Mimosine	O
is	O
a	O
cell	O
-	O
specific	O
antagonist	O
of	O
folate	O
metabolism	O
.	O
Oppenheim	O
EW	O
,	O
Nasrallah	O
IM	O
,	O
Mastri	O
MG	O
,	O
Stover	O
PJ.	O
Division	O
of	O
Nutritional	O
Sciences	O
,	O
Cornell	O
University	O
,	O
Ithaca	O
,	O
New	O
York	O
14853	O
,	O
USA	O
.	O
Iron	O
deficiency	O
and	O
iron	O
chelators	O
are	O
known	O
to	O
alter	O
folate	O
metabolism	O
in	O
mammals	O
,	O
but	O
the	O
underlying	O
biochemical	O
mechanisms	O
have	O
not	O
been	O
established	O
.	O
Although	O
many	O
studies	O
have	O
demonstrated	O
that	O
the	O
iron	O
chelators	O
mimosine	O
and	O
deferoxamine	O
inhibit	O
DNA	O
replication	O
in	O
mammalian	O
cells	O
,	O
their	O
mechanism	O
of	O
action	O
remains	O
controversial	O
.	O
The	O
effects	O
of	O
mimosine	O
on	O
folate	O
metabolism	O
were	O
investigated	O
in	O
human	O
MCF-7	O
cells	O
and	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
.	O
Our	O
findings	O
indicate	O
that	O
mimosine	O
is	O
a	O
folate	O
antagonist	O
and	O
that	O
its	O
effects	O
are	O
cell	O
-	O
specific	O
.	O
MCF-7	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
350	O
microm	O
mimosine	O
were	O
growth-arrested	O
,	O
whereas	O
mimosine	O
had	O
no	O
effect	O
on	O
SH-SY5Y	O
cell	O
proliferation	O
.	O
Mimosine	O
altered	O
the	O
distribution	O
of	O
folate	O
cofactor	O
forms	O
in	O
MCF-7	O
cells	O
,	O
indicating	O
that	O
mimosine	O
targets	O
folate	O
metabolism	O
.	O
However	O
,	O
mimosine	O
does	O
not	O
influence	O
folate	O
metabolism	O
in	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
.	O
The	O
effect	O
of	O
mimosine	O
on	O
folate	O
metabolism	O
is	O
associated	O
with	O
decreased	O
cytoplasmic	O
serine	O
hydroxymethyltransferase	O
(	O
cSHMT	O
)	O
expression	O
in	O
MCF-7	O
cells	O
but	O
not	O
in	O
SH-SY5Y	O
cells	O
.	O
MCF-7	O
cells	O
exposed	O
to	O
mimosine	O
for	O
24	O
h	O
have	O
a	O
95	O
%	O
reduction	O
in	O
cSHMT	O
protein	O
,	O
and	O
cSHMT	O
promoter	O
activity	O
is	O
reduced	O
over	O
95	O
%	O
.	O
Transcription	O
of	O
the	O
cSHMT	O
gene	O
is	O
also	O
inhibited	O
by	O
deferoxamine	O
in	O
MCF-7	O
cells	O
,	O
indicating	O
that	O
mimosine	O
inhibits	O
cSHMT	O
transcription	O
by	O
chelating	O
iron	O
.	O
Analyses	O
of	O
mimosine	O
-	O
resistant	O
MCF-7	O
cell	O
lines	O
demonstrate	O
that	O
although	O
the	O
effect	O
of	O
mimosine	O
on	O
cell	O
cycle	O
is	O
independent	O
of	O
its	O
effects	O
on	O
cSHMT	O
expression	O
,	O
it	O
inhibits	O
both	O
processes	O
through	O
a	O
common	O
regulatory	O
mechanism	O
.	O
PMID	O
:	O
10766749	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Genet	O
Metab	O
.	O
1999	O
Apr;66(	O
4	O
)	O
:	O
265	O
-	O
71	O
.	O
Analysis	O
of	O
intracellular	O
distribution	O
and	O
trafficking	O
of	O
the	O
CLN3	O
protein	O
in	O
fusion	O
with	O
the	O
green	O
fluorescent	O
protein	O
in	O
vitro	O
.	O
Kida	O
E	O
,	O
Kaczmarski	O
W	O
,	O
Golabek	O
AA	O
,	O
Kaczmarski	O
A	O
,	O
Michalewski	O
M,	O
Wisniewski	O
KE.	O
Department	O
of	O
Pathological	O
Neurobiology	O
,	O
NYS	O
Institute	O
for	O
Basic	O
Research	O
in	O
Developmental	O
Disabilities	O
,	O
Staten	O
Island	O
,	O
New	O
York	O
10314	O
,	O
USA	O
.	O
CLN3	O
gene	O
,	O
associated	O
with	O
juvenile	O
neuronal	O
ceroid	O
lipofuscinosis	O
,	O
encodes	O
a	O
novel	O
protein	O
of	O
a	O
predicted	O
438	O
amino	O
acid	O
residues	O
.	O
We	O
have	O
expressed	O
a	O
full	O
-	O
length	O
CLN3	O
protein	O
and	O
fragments	O
thereof	O
in	O
fusion	O
with	O
green	O
fluorescent	O
protein	O
in	O
Chinese	O
hamster	O
ovary	O
and	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
to	O
study	O
its	O
subcellular	O
localization	O
and	O
intracellular	O
trafficking	O
pattern	O
.	O
By	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
,	O
we	O
demonstrate	O
that	O
the	O
full	O
-	O
length	O
CLN3	O
fusion	O
protein	O
is	O
targeted	O
to	O
lysosomal	O
compartments	O
.	O
Tunicamycin	O
treatment	O
did	O
not	O
alter	O
the	O
lysosomal	O
targeting	O
of	O
the	O
CLN3	O
protein	O
,	O
which	O
indicates	O
that	O
extensive	O
N-glycosylation	O
of	O
the	O
full	O
-	O
length	O
CLN3	O
fusion	O
protein	O
is	O
not	O
engaged	O
in	O
its	O
lysosomal	O
sorting	O
.	O
Monensin	O
produced	O
retention	O
of	O
CLN3	O
fusion	O
protein	O
in	O
vesicular	O
structure	O
of	O
the	O
Golgi	O
apparatus	O
in	O
the	O
perinuclear	O
space	O
,	O
suggesting	O
that	O
CLN3	O
fusion	O
protein	O
is	O
transported	O
to	O
the	O
lysosomal	O
compartments	O
through	O
the	O
trans	O
-	O
Golgi	O
cisternae	O
.	O
Neither	O
of	O
the	O
truncated	O
CLN3	O
fusion	O
proteins	O
encompassing	O
its	O
1-138	O
,	O
1-322	O
,	O
and	O
138-438	O
amino	O
acid	O
residues	O
was	O
disclosed	O
in	O
lysosomal	O
compartments	O
.	O
However	O
,	O
CLN3	O
fusion	O
protein	O
showing	O
double	O
-	O
point	O
mutations	O
at	O
amino	O
acid	O
residues	O
425	O
and	O
426	O
,	O
thus	O
at	O
its	O
putative	O
dileucine	O
lysosomal	O
signaling	O
motif	O
,	O
was	O
still	O
targeted	O
to	O
lysosomes	O
,	O
suggesting	O
that	O
a	O
dileucine	O
motif	O
alone	O
is	O
not	O
sufficient	O
for	O
lysosomal	O
sorting	O
of	O
the	O
CLN3	O
fusion	O
protein	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
PMID	O
:	O
10191113	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Surg	O
Oncol	O
.	O
1999	O
Apr;25(	O
2	O
)	O
:194	O
-	O
8.	O
Infrequent	O
somatic	O
mutations	O
of	O
the	O
p73	O
gene	O
in	O
various	O
human	O
cancers	O
.	O
Han	O
S	O
,	O
Semba	O
S	O
,	O
Abe	O
T	O
,	O
Makino	O
N	O
,	O
Furukawa	O
T	O
,	O
Fukushige	O
S	O
,	O
Takahashi	O
H,	O
Sakurada	O
A	O
,	O
Sato	O
M,	O
Shiiba	O
K,	O
Matsuno	O
S	O
,	O
Nimura	O
Y	O
,	O
Nakagawara	O
A	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Sendai	O
,	O
Japan	O
.	O
AIMS	O
:	O
It	O
has	O
already	O
been	O
reported	O
that	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
chromosome	O
1p	O
is	O
frequent	O
in	O
a	O
variety	O
of	O
human	O
cancers	O
.	O
This	O
finding	O
implies	O
the	O
presence	O
of	O
some	O
important	O
tumour	O
suppressor	O
genes	O
in	O
this	O
region	O
.	O
p73	O
,	O
a	O
candidate	O
tumour	O
suppressor	O
gene	O
identified	O
recently	O
in	O
chromosome	O
band	O
1p36.33	O
,	O
encodes	O
a	O
protein	O
highly	O
homologous	O
to	O
p53	O
.	O
To	O
investigate	O
the	O
role	O
of	O
the	O
p73	O
gene	O
in	O
human	O
carcinogenesis	O
,	O
we	O
studied	O
genetic	O
alterations	O
of	O
this	O
gene	O
in	O
various	O
human	O
cancers	O
.	O
METHODS	O
:	O
We	O
analysed	O
the	O
entire	O
coding	O
exons	O
as	O
well	O
as	O
their	O
surrounding	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
p73	O
gene	O
in	O
185	O
cases	O
of	O
various	O
types	O
of	O
tumours	O
(	O
47	O
breast	B-malignancy-type
cancers	I-malignancy-type
,	O
43	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
,	O
31	O
gastric	B-malignancy-type
cancers	I-malignancy-type
,	O
23	O
neuroblastomas	B-malignancy-type
,	O
21	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
and	O
20	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
)	O
;	O
they	O
are	O
known	O
as	O
a	O
group	O
of	O
tumours	O
with	O
frequent	O
LOHs	O
in	O
the	O
1p	O
region	O
.	O
PCR-SSCP	O
analysis	O
was	O
performed	O
and	O
tumours	O
in	O
which	O
aberrant	O
migrating	O
sized	O
bands	O
were	O
observed	O
were	O
subjected	O
to	O
direct	O
sequencing	O
analyses	O
.	O
RESULTS	O
:	O
Of	O
the	O
185	O
cases	O
,	O
only	O
one	O
somatic	O
mis	O
-	O
sense	O
mutation	O
of	O
glutamine	O
from	O
arginine	O
at	O
codon	O
269	O
in	O
exon	O
7	O
was	O
found	O
in	O
one	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
addition	O
,	O
several	O
polymorphisms	O
were	O
found	O
at	O
codons	O
137	O
,	O
336	O
,	O
349	O
,	O
and	O
610	O
,	O
as	O
well	O
as	O
in	O
introns	O
6	O
,	O
8	O
,	O
and	O
9	O
.	O
Monoallelic	O
expression	O
was	O
also	O
observed	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
inactivation	O
of	O
the	O
p73	O
gene	O
does	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
tumour	O
types	O
analysed	O
in	O
the	O
present	O
study	O
.	O
PMID	O
:	O
10218465	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virology	O
.	O
1997	O
Feb	O
17;228(	O
2	O
)	O
:	O
269	O
-	O
77	O
.	O
Propagation	O
of	O
the	O
human	O
polyomavirus	O
,	O
JCV	O
,	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Shinohara	O
T	O
,	O
Nagashima	O
K,	O
Major	O
EO	O
.	O
Laboratory	O
of	O
Molecular	O
Medicine	O
and	O
Neuroscience	O
,	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
,	O
NIH	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
Susceptibility	O
to	O
infection	O
by	O
the	O
human	O
polyomavirus	O
,	O
JCV	O
,	O
is	O
determined	O
by	O
intracellular	O
mechanisms	O
which	O
control	O
transcription	O
and	O
replication	O
.	O
Originally	O
thought	O
to	O
propagate	O
well	O
only	O
in	O
human	O
cells	O
of	O
oligodendroglial	O
lineage	O
,	O
JCV	O
has	O
recently	O
been	O
shown	O
to	O
infect	O
astrocytes	O
,	O
astrogliomas	B-malignancy-type
,	O
and	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
The	O
data	O
reported	O
here	O
describe	O
two	O
cell	O
types	O
that	O
have	O
been	O
subcultured	O
from	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SK-N-SH	O
.	O
The	O
SH-SY5Y	O
subclone	O
displays	O
neuronal	O
phenotypes	O
and	O
is	O
not	O
susceptible	O
to	O
JCV	O
infection	O
,	O
while	O
the	O
SH-EP	O
subclone	O
displays	O
glial	O
cell	O
phenotypes	O
and	O
is	O
susceptible	O
to	O
infection	O
.	O
Binding	O
of	O
nuclear	O
proteins	O
from	O
the	O
permissive	O
SH-EP	O
cells	O
to	O
the	O
nuclear	O
factor-1	O
(	O
NF-1	O
)	O
site	O
in	O
the	O
JCV	O
regulatory	O
DNA	O
sequences	O
results	O
in	O
a	O
gel	O
shift	O
pattern	O
that	O
is	O
different	O
from	O
the	O
nonpermissive	O
SH-SY5Y	O
cell	O
proteins	O
.	O
Northern	O
analysis	O
of	O
mRNA	O
for	O
the	O
four	O
classes	O
of	O
NF-1	O
proteins	O
showed	O
a	O
predominance	O
of	O
the	O
NF-1	O
/	O
X	O
class	O
in	O
SH-EP	O
cells	O
similar	O
to	O
the	O
highly	O
permissive	O
human	O
fetal	O
glial	O
cells	O
.	O
Very	O
low	O
levels	O
of	O
mRNA	O
for	O
NF-1	O
/	O
X	O
were	O
seen	O
in	O
the	O
nonpermissive	O
SH-SY5Y	O
cells	O
,	O
similar	O
to	O
that	O
seen	O
for	O
the	O
nonpermissive	O
HeLa	O
cells	O
.	O
Several	O
other	O
cell	O
lines	O
tested	O
that	O
were	O
permissive	O
for	O
JCV	O
infection	O
also	O
showed	O
synthesis	O
of	O
the	O
NF-1	O
/	O
X	O
class	O
of	O
proteins	O
.	O
SH-EP	O
cells	O
represent	O
a	O
cell	O
line	O
in	O
a	O
glial	O
cell	O
lineage	O
which	O
is	O
susceptible	O
to	O
JCV	O
multiplication	O
.	O
These	O
cells	O
may	O
be	O
a	O
useful	O
cell	O
culture	O
system	O
for	O
the	O
investigation	O
of	O
DNA	O
binding	O
factors	O
which	O
correlates	O
with	O
viral	O
susceptibility	O
.	O
PMID	O
:	O
9123834	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Invest	O
.	O
1992	O
Nov;90	O
(	O
5	O
)	O
:	O
1857	O
-	O
63	O
.	O
Induction	O
of	O
thrombospondin	O
1	O
by	O
retinoic	O
acid	O
is	O
important	O
during	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Castle	O
VP	O
,	O
Ou	O
X	O
,	O
O'Shea	O
S	O
,	O
Dixit	O
VM	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Michigan	O
Medical	O
School	O
,	O
Ann	O
Arbor	O
48109	O
.	O
Neuroblastoma	B-malignancy-type
,	O
a	O
malignant	O
neoplasm	B-malignancy-type
that	O
arises	O
in	O
the	O
adrenal	O
medulla	O
or	O
sympathetic	O
ganglion	O
,	O
is	O
one	O
of	O
the	O
most	O
common	O
solid	B-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
.	O
Reports	O
that	O
neuroblastomas	B-malignancy-type
spontaneously	O
mature	O
to	O
form	O
benign	O
ganglioneuromas	B-malignancy-type
have	O
prompted	O
investigations	O
into	O
the	O
efficacy	O
of	O
using	O
agents	O
that	O
induce	O
neuronal	O
differentiation	O
in	O
the	O
treatment	O
of	O
this	O
malignancy	O
.	O
Retinoic	O
acid	O
is	O
one	O
agent	O
in	O
particular	O
that	O
has	O
been	O
shown	O
to	O
induce	O
growth	O
inhibition	O
and	O
terminal	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
in	O
vitro	O
.	O
Using	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SMH-KCNR	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
the	O
extracellular	O
matrix	O
protein	O
thrombospondin	O
in	O
retinoic	O
acid	O
induced	O
neuroblastoma	B-malignancy-type
differentiation	O
.	O
Treatment	O
with	O
retinoic	O
acid	O
results	O
in	O
a	O
rapid	O
induction	O
(	O
within	O
4	O
h	O
)	O
of	O
thrombospondin	O
(	O
TSP	O
)	O
message	O
which	O
is	O
independent	O
of	O
intervening	O
protein	O
synthesis	O
and	O
superinducible	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O
This	O
suggests	O
that	O
TSP	O
functions	O
as	O
a	O
retinoic	O
acid	O
inducible	O
immediate	O
early	O
response	O
gene	O
.	O
A	O
concomitant	O
increase	O
in	O
both	O
cell	O
associated	O
and	O
soluble	O
forms	O
of	O
TSP	O
protein	O
can	O
be	O
detected	O
within	O
24	O
h	O
of	O
retinoic	O
acid	O
treatment	O
.	O
A	O
functional	O
role	O
for	O
TSP	O
in	O
SMH-KCNR	O
differentiation	O
was	O
established	O
in	O
experiments	O
which	O
showed	O
that	O
exposure	O
to	O
anti	O
-	O
TSP	O
monoclonal	O
antibodies	O
delay	O
retinoic	O
acid	O
differentiation	O
for	O
48	O
h	O
.	O
At	O
the	O
time	O
the	O
cells	O
overcome	O
the	O
effects	O
of	O
TSP	O
inhibition	O
,	O
laminin	O
production	O
becomes	O
maximal	O
.	O
Treatment	O
of	O
the	O
cells	O
with	O
a	O
combination	O
of	O
anti	O
-	O
TSP	O
and	O
antilaminin	O
antibodies	O
results	O
in	O
complete	O
inhibition	O
of	O
differentiation	O
.	O
PMID	O
:	O
1430209	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
2001	O
Jun	O
20;90	O
(	O
2	O
)	O
:174	O
-86	O
.	O
Cell	O
-type	O
non	O
-	O
selective	O
transcription	O
of	O
mouse	O
and	O
human	O
genes	O
encoding	O
neural	O
-	O
restrictive	O
silencer	O
factor	O
.	O
Kojima	O
T	O
,	O
Murai	O
K,	O
Naruse	O
Y	O
,	O
Takahashi	O
N	O
,	O
Mori	O
N	O
.	O
Department	O
of	O
Molecular	O
Genetics	O
,	O
National	O
Institute	O
for	O
Longevity	O
Sciences	O
,	O
Gengo	O
36-3	O
,	O
Morioka	O
,	O
Oobu	O
,	O
474	O
-8522	O
,	O
Aichi	O
,	O
Japan	O
.	O
Neural	O
-	O
restrictive	O
silencer	O
(	O
NRS	O
)	O
has	O
been	O
identified	O
in	O
at	O
least	O
twenty	O
neuron	O
-	O
specific	O
genes	O
,	O
and	O
its	O
nuclear	O
DNA	O
-	O
binding	O
factor	O
,	O
NRSF	O
(	O
also	O
known	O
as	O
RE1	O
-	O
silencing	O
transcription	O
factor	O
(	O
REST	O
)	O
)	O
,	O
has	O
been	O
cloned	O
from	O
human	O
and	O
rat	O
,	O
and	O
was	O
shown	O
to	O
repress	O
transcription	O
by	O
recruiting	O
corepressors	O
mSin3	O
and/or	O
CoREST	O
via	O
its	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
,	O
leading	O
to	O
chromatin	O
reorganization	O
by	O
mSin3	O
-	O
associated	O
histone	O
deacetylase	O
,	O
HDAC	O
.	O
However	O
,	O
it	O
is	O
largely	O
unknown	O
how	O
NRSF	O
gene	O
expression	O
is	O
regulated	O
.	O
To	O
elucidate	O
the	O
mechanisms	O
for	O
gene	O
expression	O
of	O
NRSF	O
,	O
we	O
isolated	O
the	O
transcriptional	O
unit	O
of	O
the	O
NRSF	O
gene	O
from	O
mouse	O
and	O
human	O
,	O
identified	O
three	O
5'-non	O
-	O
coding	O
exons	O
in	O
addition	O
to	O
three	O
coding	O
exons	O
,	O
determined	O
transcription	O
start	O
sites	O
,	O
and	O
identified	O
two	O
basal	O
promoter	O
activities	O
in	O
the	O
upstream	O
of	O
the	O
first	O
two	O
non	O
-	O
coding	O
exons	O
.	O
Both	O
promoters	O
functioned	O
equally	O
in	O
neuronal	O
and	O
non	O
-	O
neuronal	O
cells	O
,	O
suggesting	O
that	O
levels	O
of	O
initial	O
transcripts	O
of	O
NRSF	O
gene	O
are	O
similar	O
in	O
neuronal	O
and	O
non	O
-	O
neuronal	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
level	O
of	O
NRSF	O
gene	O
expression	O
is	O
not	O
determined	O
by	O
transcription	O
per	O
se	O
,	O
and	O
rather	O
is	O
modulated	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
,	O
e	O
.g	O
.	O
splicing	O
,	O
mRNA	O
stability	O
,	O
and/or	O
post	O
-	O
translational	O
modifications	O
,	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O
Consistent	O
with	O
this	O
idea	O
,	O
NRSF	O
protein	O
was	O
apparently	O
present	O
even	O
in	O
neuronal	O
cells	O
and	O
tissues	O
,	O
but	O
was	O
unable	O
to	O
bind	O
to	O
the	O
NRS	O
element	O
,	O
suggesting	O
that	O
NRSF	O
is	O
regulated	O
at	O
least	O
in	O
part	O
post	O
-	O
translationally	O
.	O
PMID	O
:	O
11406295	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pharmacol	O
Exp	O
Ther	O
.	O
1993	O
Jul;266(	O
1	O
)	O
:253	O
-	O
61	O
.	O
The	O
mechanism	O
for	O
the	O
rapid	O
desensitization	O
in	O
bradykinin	O
-	O
stimulated	O
inositol	O
monophosphate	O
production	O
in	O
NG108-15	O
cells	O
involves	O
interaction	O
of	O
a	O
single	O
receptor	O
with	O
multiple	O
signaling	O
pathways	O
.	O
Wolsing	O
DH	O
,	O
Rosenbaum	O
JS.	O
Procter	O
&	O
Gamble	O
Company	O
,	O
Miami	O
Valley	O
Laboratories	O
,	O
Cincinnati	O
,	O
Ohio	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
mechanism	O
for	O
the	O
rapid	O
desensitization	O
in	O
bradykinin	O
(	O
BDK	O
)	O
-	O
stimulated	O
inositol	O
monophosphate	O
(	O
IP	O
)	O
production	O
in	O
NG108-15	O
cells	O
involves	O
both	O
a	O
rapid	O
loss	O
of	O
receptors	O
from	O
the	O
cell	O
surface	O
and	O
an	O
uncoupling	O
of	O
the	O
receptor	O
:	O
G	O
-protein	O
:	O
phospholipase	O
C	O
(	O
PLC	O
)	O
signaling	O
process	O
,	O
with	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
playing	O
a	O
role	O
only	O
at	O
a	O
postreceptor	O
level	O
(	O
Wolsing	O
and	O
Rosenbaum	O
,	O
1991	O
)	O
.	O
In	O
contrast	O
to	O
BDK	O
,	O
a	O
5-	O
min	O
pretreatment	O
with	O
the	O
BDK	O
receptor	O
"	O
antagonist	O
"	O
NPC	O
-567	O
is	O
sufficient	O
to	O
cause	O
a	O
substantial	O
decrease	O
in	O
the	O
subsequent	O
BDK	O
maximal	O
response	O
(	O
Emax	O
)	O
without	O
altering	O
either	O
the	O
BDK	O
potency	O
(	O
EC50	O
)	O
or	O
the	O
BDK	O
receptor	O
number	O
.	O
An	O
18	O
-	O
hr	O
pretreatment	O
of	O
the	O
cells	O
with	O
200	O
ng	O
/	O
ml	O
pertussis	O
toxin	O
(	O
PT	O
)	O
does	O
not	O
alter	O
the	O
BDK	O
response	O
(	O
Fold	O
stim	O
=	O
2.36	O
+/-	O
0.18	O
vs.	O
2.00	O
+/-	O
0.25	O
in	O
controls	O
,	O
N	O
=	O
4	O
)	O
,	O
reiterating	O
previous	O
observations	O
that	O
BDK	O
-	O
stimulated	O
IP	O
production	O
in	O
this	O
cell	O
line	O
is	O
mediated	O
by	O
a	O
pertussis	O
toxin	O
(	O
PT	O
)	O
-	O
insensitive	O
G-protein	O
.	O
However	O
,	O
PT	O
pretreatment	O
significantly	O
(	O
P	O
<	O
.05	O
)	O
attenuates	O
the	O
receptor	O
loss	O
that	O
accompanies	O
the	O
desensitization	O
process	O
.	O
Taken	O
together	O
,	O
these	O
data	O
imply	O
that	O
the	O
BDK	O
receptor	O
in	O
NG108-15	O
cells	O
interacts	O
with	O
both	O
PT	O
-	O
sensitive	O
and	O
PT	O
-	O
insensitive	O
G-proteins	O
.	O
Because	O
NPC	O
-567	O
pretreatment	O
results	O
in	O
a	O
desensitization	O
that	O
is	O
not	O
accompanied	O
by	O
receptor	O
loss	O
,	O
it	O
appears	O
that	O
NPC	O
-567	O
is	O
able	O
to	O
facilitate	O
an	O
agonistic	O
interaction	O
with	O
only	O
the	O
PT	O
-	O
insensitive	O
G-proteins	O
that	O
are	O
available	O
to	O
the	O
receptor	O
.	O
PMID	O
:	O
8392552	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuro-oncol	O
.	O
2001	O
Oct;3(	O
4	O
)	O
:229-40	O
.	O
Ex	O
vivo	O
pediatric	O
brain	B-malignancy-type
tumors	I-malignancy-type
express	O
Fas	O
(	O
CD95	O
)	O
and	O
FasL	O
(	O
CD95L	O
)	O
and	O
are	O
resistant	O
to	O
apoptosis	O
induction	O
.	O
Riffkin	O
CD	O
,	O
Gray	O
AZ	O
,	O
Hawkins	O
CJ	O
,	O
Chow	O
CW	O
,	O
Ashley	O
DM	O
.	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
Royal	O
Children	O
's	O
Hospital	O
,	O
Melbourne	O
,	O
Victoria	O
,	O
Australia	O
.	O
Fas	O
(	O
APO-1	O
/	O
CD95	O
/	O
TNFRSF6	O
)	O
is	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
/	O
nerve	O
growth	O
factor	O
receptor	O
family	O
that	O
signals	O
apoptotic	O
cell	O
death	O
in	O
sensitive	O
cells	O
.	O
Expression	O
of	O
Fas	O
and	O
its	O
agonistic	O
ligand	O
(	O
FasL	O
/	O
TNFSF6	O
)	O
was	O
investigated	O
in	O
ex	O
vivo	O
pediatric	O
brain	B-malignancy-type
tumor	I-malignancy-type
specimens	O
of	O
various	O
histologic	O
types	O
.	O
Fas	O
expression	O
was	O
identified	O
in	O
all	O
of	O
the	O
18	O
tumors	O
analyzed	O
by	O
flow	O
cytometry	O
and	O
immunohistochemistry	O
.	O
FasL	O
expression	O
was	O
identified	O
in	O
most	O
of	O
the	O
13	O
tumors	O
analyzed	O
by	O
both	O
Western	O
analysis	O
and	O
immunohistochemistry	O
.	O
Nine	O
of	O
these	O
tumor	O
specimens	O
were	O
treated	O
with	O
either	O
the	O
agonistic	O
anti	O
-	O
Fas	O
antibody	O
(	O
APO-1	O
)	O
in	O
combination	O
with	O
protein	O
A	O
or	O
FasL	O
in	O
short	O
-term	O
cytotoxicity	O
assays	O
.	O
Sensitivity	O
to	O
apoptosis	O
induced	O
by	O
the	O
topoisomerase	O
II	O
inhibitor	O
,	O
etoposide	O
,	O
was	O
also	O
assessed	O
.	O
Despite	O
the	O
presence	O
of	O
Fas	O
,	O
all	O
the	O
specimens	O
analyzed	O
demonstrated	O
a	O
high	O
degree	O
of	O
resistance	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
These	O
9	O
specimens	O
also	O
showed	O
a	O
high	O
degree	O
of	O
resistance	O
to	O
etoposide	O
.	O
Only	O
2	O
of	O
the	O
9	O
specimens	O
were	O
susceptible	O
to	O
etoposide	O
-	O
induced	O
cell	O
death	O
,	O
whereas	O
only	O
3	O
were	O
sensitive	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
One	O
brain	B-malignancy-type
tumor	I-malignancy-type
was	O
sensitive	O
to	O
both	O
Fas	O
ligation	O
and	O
etoposide	O
treatment	O
.	O
This	O
contrasted	O
with	O
the	O
high	O
degree	O
of	O
susceptibility	O
to	O
both	O
etoposide	O
-	O
and	O
Fas	O
-	O
induced	O
apoptosis	O
observed	O
in	O
the	O
reference	O
Jurkat	O
cell	O
line	O
.	O
The	O
results	O
suggest	O
that	O
Fas	O
expression	O
may	O
be	O
a	O
general	O
feature	O
of	O
tumors	O
of	O
the	O
CNS	O
and	O
that	O
a	O
significant	O
degree	O
of	O
resistance	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
may	O
exist	O
in	O
ex	O
vivo	O
pediatric	O
brain	B-malignancy-type
tumor	I-malignancy-type
specimens	O
.	O
PMID	O
:	O
11584892	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1990	O
Dec;	O
5	O
(	O
12	O
)	O
:	O
1821	O
-	O
7.	O
Prolonged	O
N-myc	O
protein	O
half-	O
life	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
lacking	O
N-myc	O
amplification	O
.	O
Cohn	O
SL	O
,	O
Salwen	O
H,	O
Quasney	O
MW	O
,	O
Ikegaki	O
N	O
,	O
Cowan	O
JM	O
,	O
Herst	O
CV	O
,	O
Kennett	O
RH	O
,	O
Rosen	O
ST	O
,	O
DiGiuseppe	O
JA	O
,	O
Brodeur	O
GM	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Northwestern	O
University	O
Medical	O
Center	O
,	O
Chicago	O
,	O
IL	O
60614	O
.	O
Genomic	O
amplification	O
of	O
the	O
oncogene	O
N-myc	O
is	O
associated	O
with	O
rapid	O
tumor	O
progression	O
and	O
poor	O
prognosis	O
in	O
patients	O
with	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
.	O
However	O
,	O
40	O
%	O
of	O
NBs	B-malignancy-type
which	O
lack	O
N-myc	O
amplification	O
are	O
also	O
clinically	O
aggressive	O
.	O
Factors	O
other	O
than	O
N-myc	O
copy	O
number	O
must	O
therefore	O
play	O
a	O
role	O
in	O
determining	O
tumor	O
progression	O
in	O
these	O
NBs	B-malignancy-type
.	O
We	O
have	O
established	O
an	O
unusual	O
human	O
NB	B-malignancy-type
cell	O
line	O
(	O
NBL-S	O
)	O
from	O
the	O
primary	O
tumor	O
of	O
a	O
patient	O
with	O
rapidly	O
progressive	O
disease	O
which	O
lacks	O
N-myc	O
amplification	O
.	O
The	O
doubling	O
time	O
in	O
vitro	O
(	O
48	O
h	O
)	O
and	O
the	O
time	O
from	O
injection	O
of	O
2	O
x	O
10	O
(	O
7	O
)	O
cells	O
to	O
detectable	O
tumors	O
in	O
nude	O
mice	O
(	O
46	O
days	O
)	O
in	O
similar	O
to	O
NB	B-malignancy-type
cell	O
lines	O
with	O
amplified	O
N-myc	O
.	O
However	O
,	O
karyotype	O
analysis	O
reveals	O
no	O
evidence	O
of	O
double	O
minutes	O
(	O
DMs	O
)	O
,	O
homogeneously	O
staining	O
regions	O
(	O
HSRs	O
)	O
,	O
or	O
chromosome	O
1p	O
deletions	O
,	O
features	O
commonly	O
seen	O
in	O
NB	B-malignancy-type
cell	O
lines	O
.	O
The	O
cells	O
have	O
the	O
cell	O
surface	O
phenotype	O
typical	O
of	O
N-myc	O
amplified	O
NB	B-malignancy-type
(	O
HLA	O
-	O
A	O
,	O
B	O
,	O
C	O
negative	O
and	O
HSAN	O
1.2	O
positive	O
)	O
,	O
and	O
similar	O
to	O
other	O
NB	B-malignancy-type
cell	O
lines	O
,	O
N-myc	O
RNA	O
and	O
protein	O
are	O
expressed	O
.	O
Interestingly	O
,	O
the	O
half-	O
life	O
of	O
the	O
N-myc	O
protein	O
in	O
NBL-S	O
is	O
prolonged	O
(	O
approximately	O
100	O
min	O
)	O
compared	O
to	O
the	O
short	O
N-myc	O
protein	O
half-	O
life	O
previously	O
described	O
in	O
N-myc	O
amplified	O
NB	B-malignancy-type
cell	O
lines	O
(	O
approximately	O
30	O
min	O
)	O
.	O
Because	O
N-myc	O
protein	O
is	O
thought	O
to	O
have	O
a	O
regulatory	O
role	O
,	O
prolongation	O
of	O
the	O
half-	O
life	O
of	O
this	O
protein	O
may	O
be	O
an	O
important	O
factor	O
in	O
the	O
regulation	O
of	O
growth	O
in	O
NBs	B-malignancy-type
which	O
lack	O
N-myc	O
amplification	O
and	O
rapidly	O
progress	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
2284101	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
.	O
2002	O
Mar;20(	O
3	O
)	O
:	O
527	O
-31	O
.	O
Infrequent	O
mutations	O
of	O
the	O
activating	O
transcription	O
factor-2	O
gene	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
Woo	O
IS	O
,	O
Kohno	O
T	O
,	O
Inoue	O
K,	O
Ishii	O
S	O
,	O
Yokota	O
J.	O
Biology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
104	O
-0045	O
,	O
Japan	O
.	O
The	O
activating	O
transcription	O
factor	O
2	O
(	O
ATF-2	O
)	O
gene	O
,	O
which	O
encodes	O
a	O
transcription	O
factor	O
involved	O
in	O
multiple	O
intracellular	O
signal	O
transduction	O
pathways	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
2q32	O
,	O
which	O
is	O
a	O
common	O
region	O
of	O
LOH	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
neuroblastoma	B-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
,	O
a	O
high	O
incidence	O
of	O
LOH	O
was	O
detected	O
on	O
chromosome	O
2q	O
.	O
Recently	O
we	O
found	O
that	O
breast	B-malignancy-type
cancer	I-malignancy-type
is	O
frequently	O
developed	O
in	O
heterozygous	O
mutant	O
mice	O
for	O
the	O
ATF-2	O
gene	O
.	O
Therefore	O
,	O
the	O
ATF-2	O
gene	O
was	O
considered	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
on	O
2q	O
.	O
To	O
assess	O
the	O
role	O
of	O
the	O
ATF-2	O
gene	O
as	O
a	O
tumor	O
suppressor	O
in	O
human	O
carcinogenesis	O
,	O
we	O
examined	O
genetic	O
alterations	O
of	O
the	O
ATF-2	O
gene	O
in	O
9	O
breast	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
10	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
46	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
For	O
this	O
purpose	O
,	O
we	O
first	O
determined	O
the	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
ATF-2	O
gene	O
in	O
the	O
human	O
genome	O
.	O
The	O
ATF-2	O
gene	O
was	O
composed	O
of	O
14	O
exons	O
and	O
13	O
introns	O
,	O
and	O
the	O
ATG	O
start	O
codon	O
and	O
the	O
TGA	O
stop	O
codon	O
were	O
present	O
in	O
exons	O
3	O
and	O
14	O
,	O
respectively	O
.	O
Genetic	O
variants	O
of	O
the	O
ATF-2	O
gene	O
were	O
detected	O
in	O
5	O
of	O
the	O
46	O
(	O
10.6	O
%	O
)	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
but	O
not	O
in	O
neuroblastomas	B-malignancy-type
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
.	O
Three	O
of	O
the	O
five	O
variants	O
detected	O
in	O
lung	B-malignancy-type
cancers	I-malignancy-type
were	O
genetic	O
polymorphisms	O
,	O
while	O
the	O
remaining	O
two	O
,	O
consisting	O
of	O
non	O
-	O
synonymous	O
and	O
synonymous	O
substitutions	O
,	O
were	O
possibly	O
somatic	O
mutations	O
.	O
The	O
present	O
result	O
indicates	O
that	O
the	O
ATF-2	O
gene	O
is	O
not	O
a	O
major	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
2q	O
,	O
however	O
,	O
it	O
is	O
possible	O
that	O
ATF-2	O
alterations	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
small	O
subset	O
of	O
lung	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
11836564	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
.	O
2002	O
Oct	O
1;100(	O
7	O
)	O
:	O
2623	O
-	O
8.	O
Hypoxia	O
-	O
inducible	O
erythropoietin	O
gene	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Stolze	O
I	O
,	O
Berchner	O
-	O
Pfannschmidt	O
U	O
,	O
Freitag	O
P,	O
Wotzlaw	O
C	O
,	O
Rossler	O
J,	O
Frede	O
S	O
,	O
Acker	O
H,	O
Fandrey	O
J.	O
Institut	O
fur	O
Physiologie	O
der	O
Universitat	O
Essen	O
,	O
Dortmund	O
,	O
Germany	O
.	O
Two	O
human	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cell	O
lines	O
,	O
SH-SY5Y	O
and	O
Kelly	O
,	O
were	O
found	O
to	O
express	O
the	O
gene	O
for	O
erythropoietin	O
(	O
EPO	O
)	O
in	O
an	O
oxygen	O
(	O
O(2)	O
)	O
-	O
dependent	O
manner	O
.	O
However	O
,	O
NB	B-malignancy-type
cells	O
had	O
maximal	O
production	O
of	O
EPO	O
with	O
lower	O
partial	O
pressure	O
of	O
O	O
(	O
2	O
)	O
values	O
than	O
the	O
well	O
-characterized	O
hepatoma	B-malignancy-type
cell	O
line	O
HepG2	O
.	O
This	O
maximal	O
EPO	O
expression	O
was	O
preceded	O
by	O
accumulation	O
of	O
the	O
O(2)	O
-	O
sensitive	O
alpha	O
subunit	O
of	O
the	O
heterodimeric	O
transcription	O
-	O
factor	O
complex	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF-1	O
)	O
.	O
Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
amount	O
of	O
the	O
beta	O
subunit	O
of	O
HIF-1	O
,	O
identical	O
to	O
aryl	O
hydrocarbon	O
receptor	O
nuclear	O
translocator	O
1	O
(	O
ARNT1	O
)	O
,	O
and	O
the	O
homolog	O
ARNT2	O
increased	O
in	O
nuclear	O
extracts	O
from	O
SH-SY5Y	O
cells	O
exposed	O
to	O
anoxia	O
.	O
In	O
neuronal	O
cells	O
,	O
ARNT1	O
and	O
ARNT2	O
can	O
form	O
a	O
heterodimer	O
with	O
HIF-1	O
alpha	O
,	O
generating	O
a	O
functional	O
HIF-1	O
complex	O
.	O
Using	O
the	O
hypoxia	O
response	O
element	O
of	O
the	O
human	O
EPO	O
enhancer	O
,	O
we	O
conducted	O
electrophoretic	O
mobility	O
shift	O
assays	O
that	O
showed	O
accumulation	O
and	O
binding	O
of	O
HIF-1	O
complexes	O
containing	O
both	O
ARNT1	O
and	O
ARNT2	O
in	O
NB	B-malignancy-type
cells	O
.	O
In	O
addition	O
to	O
the	O
HIF-1	O
complex	O
,	O
hepatocyte	O
nuclear	O
factor	O
4alpha	O
(	O
HNF4alpha	O
)	O
was	O
found	O
to	O
be	O
indispensable	O
for	O
hypoxia	O
-	O
induced	O
EPO	O
gene	O
expression	O
in	O
hepatoma	B-malignancy-type
cells	O
.	O
Western	O
blot	O
analysis	O
and	O
polymerase	O
chain	O
reaction	O
assessment	O
showed	O
that	O
NB	B-malignancy-type
cells	O
express	O
neither	O
HNF4	O
alpha	O
nor	O
the	O
splicing	O
variant	O
HNF4	O
alpha7	O
and	O
thus	O
express	O
EPO	O
in	O
an	O
HNF4	O
alpha	O
-	O
independent	O
manner	O
.	O
Together	O
,	O
SH-SY5Y	O
and	O
Kelly	O
cells	O
may	O
provide	O
a	O
new	O
in	O
vitro	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
tissue	O
-	O
specific	O
,	O
hypoxia	O
-	O
inducible	O
EPO	O
gene	O
expression	O
.	O
PMID	O
:	O
12239177	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
.	O
1993	O
Dec;	O
7(	O
12	O
)	O
:	O
2034-44	O
.	O
Isolation	O
and	O
characterization	O
of	O
an	O
early	O
T-helper	O
/	O
inducer	O
cell	O
line	O
with	O
a	O
unique	O
pattern	O
of	O
surface	O
phenotype	O
,	O
constitutive	O
cytokine	O
secretion	O
and	O
myc	O
oncogene	O
expression	O
.	O
Gazitt	O
Y	O
,	O
He	O
YJ	O
,	O
Shults	O
K,	O
Stelzer	O
GT	O
,	O
Cohen	O
RJ.	O
Department	O
of	O
Pediatric	O
Hematology	O
/Oncology	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
.	O
The	O
cell	O
line	O
AG	O
-F	O
was	O
isolated	O
from	O
the	O
marrow	O
of	O
a	O
neuroblastoma	B-malignancy-type
patient	O
undergoing	O
myeloablative	O
treatment	O
and	O
autologous	O
bone	O
marrow	O
rescue	O
.	O
A	O
year	O
later	O
,	O
the	O
patient	O
developed	O
a	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
type	I-malignancy-type
lymphoma	I-malignancy-type
.	O
AG	O
-F	O
cell	O
line	O
demonstrated	O
an	O
unusual	O
phenotype	O
,	O
lacking	O
surface	O
CD2	O
and	O
CD3	O
,	O
but	O
expressing	O
high	O
levels	O
of	O
CD4	O
,	O
CD5	O
,	O
CD7	O
,	O
CD29	O
,	O
and	O
CD45RO	O
.	O
Markers	O
associated	O
with	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
cells	O
,	O
CD15	O
and	O
CD30	O
,	O
were	O
also	O
positive	O
.	O
AG	O
-F	O
cells	O
grow	O
in	O
suspension	O
in	O
clusters	O
of	O
50	O
-	O
200	O
cells	O
,	O
with	O
a	O
doubling	O
time	O
of	O
9	O
h	O
.	O
They	O
can	O
also	O
grow	O
in	O
serum	O
-	O
free	O
medium	O
and	O
form	O
tumors	O
in	O
nude	O
mice	O
.	O
AG	O
-F	O
cells	O
have	O
amplified	O
N-myc	O
and	O
c-myc	O
and	O
high	O
levels	O
of	O
the	O
corresponding	O
mRNA	O
transcripts	O
.	O
Cytogenetic	O
analysis	O
revealed	O
a	O
DNA	O
index	O
by	O
flow	O
cytometry	O
of	O
near	O
tetraploid	O
cells	O
and	O
a	O
karyotype	O
of	O
85-87	O
chromosomes	O
,	O
with	O
consistent	O
abnormalities	O
in	O
chromosomes	O
1	O
,	O
5	O
,	O
and	O
9	O
.	O
Gene	O
rearrangement	O
studies	O
revealed	O
rearrangement	O
of	O
the	O
beta	O
gene	O
of	O
the	O
T-cell	O
receptor	O
.	O
AG	O
-F	O
cells	O
secrete	O
high	O
levels	O
of	O
IL-6	O
,	O
IL-8	O
,	O
IL-10	O
,	O
and	O
GM-CSF	O
.	O
Cell	O
adherence	O
and	O
formation	O
of	O
long	O
processes	O
could	O
be	O
induced	O
by	O
fibronectin	O
and	O
were	O
enhanced	O
by	O
exposure	O
to	O
PMA	O
.	O
Cells	O
exposed	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
had	O
increased	O
expression	O
of	O
CD11a	O
,	O
CD11b	O
,	O
CD18	O
,	O
CD45RO	O
,	O
and	O
HLA-	O
DR	O
,	O
whereas	O
expression	O
of	O
CD15	O
and	O
CD30	O
was	O
markedly	O
decreased	O
.	O
Similarly	O
,	O
the	O
level	O
of	O
c-myc	O
and	O
N-myc	O
oncoproteins	O
and	O
the	O
levels	O
of	O
the	O
cytoskeletal	O
proteins	O
,	O
actin	O
,	O
tubulin	O
,	O
and	O
vimentin	O
markedly	O
decreased	O
early	O
after	O
PMA	O
-	O
induced	O
differentiation	O
.	O
PMID	O
:	O
8255104	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virology	O
.	O
2001	O
Oct	O
10	O
;289	O
(	O
1	O
)	O
:	O
129-	O
36	O
.	O
Mutations	O
in	O
the	O
NS3	O
gene	O
and	O
3'-NCR	O
of	O
Japanese	O
encephalitis	O
virus	O
isolated	O
from	O
an	O
unconventional	O
ecosystem	O
and	O
implications	O
for	O
natural	O
attenuation	O
of	O
the	O
virus	O
.	O
Chiou	O
SS	O
,	O
Chen	O
WJ.	O
Institute	O
of	O
Epidemiology	O
,	O
College	O
of	O
Public	O
Health	O
,	O
National	O
Taiwan	O
University	O
,	O
Taipei	O
10018	O
,	O
Taiwan	O
.	O
The	O
T1P1	O
strain	O
of	O
Japanese	O
encephalitis	O
(	O
JE	O
)	O
virus	O
was	O
recently	O
isolated	O
from	O
paddy	O
-free	O
Liu-Chiu	O
Islet	O
in	O
which	O
natural	O
JE	O
antibody	O
has	O
been	O
prevalent	O
.	O
In	O
mouse	O
neuroblastoma	B-malignancy-type
-	O
derived	O
Neuro-2a	O
cells	O
,	O
T1P1	O
appeared	O
significantly	O
lower	O
in	O
virus	O
productivity	O
than	O
another	O
local	O
isolate	O
,	O
CH1392	O
.	O
It	O
implied	O
that	O
this	O
new	O
isolate	O
possesses	O
a	O
characteristic	O
viral	O
replication	O
pattern	O
other	O
than	O
that	O
of	O
CH1392	O
.	O
T1P1	O
has	O
also	O
shown	O
lower	O
neurovirulence	O
,	O
which	O
was	O
reflected	O
by	O
a	O
significantly	O
higher	O
LD(50)	O
(	O
2.44	O
x	O
10(6)	O
PFU	O
)	O
than	O
CH1392	O
(	O
2.87	O
x	O
10(2)	O
PFU	O
)	O
.	O
In	O
comparison	O
of	O
the	O
full	O
-	O
length	O
RNA	O
sequences	O
between	O
T1P1	O
and	O
CH1392	O
,	O
a	O
total	O
of	O
7	O
nucleotides	O
,	O
including	O
1	O
in	O
preM	O
/	O
M	O
and	O
2	O
each	O
in	O
NS3	O
,	O
NS5	O
,	O
and	O
the	O
3'-end	O
noncoding	O
region	O
(	O
NCR	O
)	O
,	O
appeared	O
different	O
.	O
Of	O
them	O
,	O
only	O
the	O
changes	O
in	O
NS3	O
(	O
position	O
325	O
,	O
T	O
for	O
CH1392	O
,	O
A	O
for	O
T1P1	O
;	O
and	O
position	O
364	O
,	O
G	O
for	O
CH1392	O
and	O
A	O
for	O
T1P1	O
)	O
resulted	O
in	O
substitutions	O
of	O
deduced	O
amino	O
acids	O
.	O
There	O
were	O
two	O
additional	O
nucleotide	O
changes	O
appearing	O
in	O
the	O
3'-NCR	O
.	O
The	O
amino	O
acids	O
109	O
Phe	O
and	O
122	O
Glu	O
in	O
NS3	O
of	O
CH1392	O
were	O
substituted	O
by	O
Ile	O
and	O
Lys	O
,	O
respectively	O
,	O
in	O
T1P1	O
.	O
The	O
unique	O
growth	O
properties	O
and	O
low	O
virulence	O
of	O
T1P1	O
presented	O
in	O
this	O
report	O
were	O
likely	O
related	O
to	O
abnormal	O
enzymatic	O
activity	O
due	O
to	O
mutations	O
of	O
the	O
NS3	O
gene	O
(	O
especially	O
position	O
364	O
)	O
and	O
possibly	O
to	O
the	O
mutations	O
in	O
the	O
3'-NCR	O
.	O
The	O
natural	O
attenuation	O
of	O
T1P1	O
that	O
has	O
been	O
circulating	O
in	O
paddy	O
-free	O
Liu-Chiu	O
Islet	O
may	O
account	O
for	O
the	O
absence	O
of	O
clinical	O
JE	O
cases	O
in	O
past	O
years	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11601924	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1990	O
Apr	O
15	O
;265	O
(	O
11	O
)	O
:6403	O
-	O
9.	O
Muscle	O
creatine	O
kinase	O
isoenzyme	O
expression	O
in	O
adult	O
human	O
brain	O
.	O
Hamburg	O
RJ	O
,	O
Friedman	O
DL	O
,	O
Olson	O
EN	O
,	O
Ma	O
TS	O
,	O
Cortez	O
MD	O
,	O
Goodman	O
C	O
,	O
Puleo	O
PR	O
,	O
Perryman	O
MB.	O
Department	O
of	O
Medicine	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
77030	O
.	O
Previous	O
studies	O
have	O
suggested	O
that	O
MM	O
creatine	O
kinase	O
is	O
a	O
muscle	O
-	O
specific	O
protein	O
and	O
is	O
not	O
present	O
in	O
adult	O
brain	O
tissue	O
.	O
We	O
have	O
isolated	O
a	O
protein	O
from	O
human	O
brain	O
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
43	O
,000	O
as	O
determined	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
which	O
is	O
identical	O
to	O
the	O
muscle	O
M	O
creatine	O
kinase	O
isoenzyme	O
subunit	O
at	O
all	O
30	O
sequenced	O
amino	O
acid	O
residues	O
and	O
possesses	O
creatine	O
kinase	O
enzymatic	O
activity	O
following	O
nondenaturing	O
agarose	O
-	O
gel	O
electrophoresis	O
.	O
Immunohistochemistry	O
localizes	O
M	O
creatine	O
kinase	O
to	O
discrete	O
areas	O
of	O
adult	O
human	O
brain	O
.	O
Northern	O
blot	O
analysis	O
of	O
both	O
total	O
and	O
poly(A	O
)	O
-	O
selected	O
RNA	O
isolated	O
from	O
brain	O
did	O
not	O
detect	O
M	O
creatine	O
kinase	O
mRNA	O
.	O
However	O
,	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
cDNA	O
synthesized	O
from	O
human	O
placenta	O
,	O
heart	O
,	O
and	O
brain	O
mRNA	O
detected	O
M	O
creatine	O
kinase	O
message	O
in	O
both	O
heart	O
and	O
brain	O
but	O
not	O
placenta	O
which	O
contains	O
no	O
detectable	O
M	O
creatine	O
kinase	O
protein	O
.	O
N1E115	O
and	O
NS20Y	O
,	O
mouse	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
which	O
have	O
been	O
used	O
as	O
models	O
of	O
neural	O
cell	O
differentiation	O
,	O
were	O
found	O
also	O
to	O
express	O
MM	O
creatine	O
kinase	O
.	O
Moreover	O
,	O
a	O
transiently	O
transfected	O
reporter	O
gene	O
with	O
4,800	O
base	O
pairs	O
of	O
M	O
creatine	O
kinase	O
upstream	O
region	O
fused	O
to	O
chloramphenicol	O
acetyltransferase	O
was	O
expressed	O
during	O
differentiation	O
of	O
these	O
neural	O
cell	O
lines	O
.	O
In	O
summary	O
,	O
MM	O
creatine	O
kinase	O
is	O
present	O
in	O
human	O
brain	O
and	O
we	O
suggest	O
the	O
M	O
creatine	O
kinase	O
upstream	O
region	O
is	O
sufficient	O
to	O
modulate	O
M	O
creatine	O
kinase	O
expression	O
in	O
certain	O
neuronal	O
cells	O
and	O
may	O
be	O
regulated	O
independently	O
from	O
other	O
muscle	O
genes	O
.	O
PMID	O
:	O
1690725	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

DNA	O
Cell	O
Biol	O
.	O
1996	O
Jan;15	O
(	O
1	O
)	O
:	O
53	O
-	O
63	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
human	O
cholecystokinin	O
gene	O
:	O
composite	O
action	O
of	O
upstream	O
stimulatory	O
factor	O
,	O
Sp1	O
,	O
and	O
members	O
of	O
the	O
CREB	O
/	O
ATF-AP-1	O
family	O
of	O
transcription	O
factors	O
.	O
Nielsen	O
FC	O
,	O
Pedersen	O
K,	O
Hansen	O
TV	O
,	O
Rourke	O
IJ	O
,	O
Rehfeld	O
JF.	O
Department	O
of	O
Clinical	O
Biochemistry	O
,	O
Rigshospitalet	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
We	O
have	O
examined	O
cis	O
-	O
elements	O
and	O
trans	O
-	O
acting	O
factors	O
that	O
regulate	O
transcription	O
of	O
the	O
human	O
cholecystokinin	O
(	O
CCK	O
)	O
gene	O
.	O
Transient	O
expression	O
of	O
CCK	O
promoter	O
deletion	O
constructs	O
in	O
human	O
SK-N-MC	O
neuroblastoma	B-malignancy-type
cells	O
depicted	O
positive	O
cis	O
-	O
elements	O
between	O
the	O
positions	O
-	O
100	O
to	O
-	O
92	O
,	O
-	O
84	O
to	O
-	O
74	O
,	O
and	O
-	O
58	O
to	O
-	O
37	O
,	O
5	O
'	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O
Correspondingly	O
,	O
DNase	O
I	O
protection	O
analysis	O
showed	O
that	O
transacting	O
factors	O
bound	O
to	O
elements	O
within	O
these	O
regions	O
.	O
The	O
sequences	O
encompass	O
a	O
putative	O
basic	O
helix-loop-helix	O
leucine	O
zipper	O
(	O
bHLH-ZIP	O
)	O
element	O
,	O
an	O
Sp1	O
element	O
,	O
and	O
a	O
combined	O
cAMP	O
-	O
and	O
TPA	O
-	O
responsive	O
element	O
(	O
CRE	O
/	O
TRE	O
)	O
at	O
positions	O
-	O
97	O
to	O
-	O
92	O
,	O
-	O
39	O
to	O
-	O
34	O
,	O
and	O
-	O
80	O
to	O
-	O
73	O
,	O
respectively	O
.	O
Mobility	O
and	O
supershift	O
assays	O
demonstrated	O
that	O
upstream	O
stimulatory	O
factor	O
(	O
USF	O
)	O
and	O
Sp1	O
bind	O
to	O
the	O
former	O
elements	O
and	O
competition	O
experiments	O
confirmed	O
that	O
CREB	O
/	O
ATF	O
and	O
AP-1	O
bind	O
to	O
the	O
CRE	O
/	O
TRE	O
element	O
.	O
Mutation	O
of	O
the	O
bHLH-ZIP	O
and	O
CRE	O
/	O
TRE	O
elements	O
decreased	O
the	O
activity	O
of	O
the	O
promoter	O
by	O
65	O
%	O
and	O
42	O
%	O
,	O
respectively	O
.	O
The	O
activity	O
of	O
the	O
promoter	O
was	O
increased	O
six	O
-	O
and	O
two	O
-	O
fold	O
after	O
stimulation	O
with	O
forskolin	O
and	O
TPA	O
,	O
respectively	O
.	O
Stimulation	O
was	O
eliminated	O
after	O
mutation	O
of	O
the	O
CRE	O
/	O
TRE	O
element	O
.	O
Co	O
-transfection	O
experiments	O
with	O
pRSV-	O
c-jun	O
,	O
pSV	O
-	O
fos	O
,	O
and	O
pRC-RSV-	O
CREB	O
constructs	O
showed	O
that	O
jun	O
,	O
CREB	O
,	O
and	O
AP-1	O
stimulate	O
transcription	O
.	O
We	O
conclude	O
that	O
USF	O
,	O
Sp1	O
,	O
and	O
members	O
of	O
the	O
CREB	O
/	O
ATF	O
and	O
AP-1	O
family	O
of	O
transcription	O
factors	O
are	O
the	O
major	O
determinants	O
of	O
CCK	O
gene	O
transcription	O
.	O
PMID	O
:	O
8561897	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Physiol	O
.	O
1995	O
Oct;269	O
(	O
4	O
Pt	O
1	O
)	O
:C979	O
-	O
85	O
.	O
Calcium	O
requirement	O
for	O
cGMP	O
production	O
during	O
muscarinic	O
activation	O
of	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Thompson	O
SH	O
,	O
Mathes	O
C	O
,	O
Alousi	O
AA	O
.	O
Department	O
of	O
Biological	O
Sciences	O
,	O
Stanford	O
University	O
,	O
Pacific	O
Grove	O
,	O
California	O
93950	O
,	O
USA	O
.	O
Muscarinic	O
agonists	O
elicit	O
large	O
increases	O
in	O
intracellular	O
Ca2	O
+	O
and	O
guanosine	O
3',5'-cyclic	O
monophosphate	O
(	O
cGMP	O
)	O
in	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Both	O
signals	O
are	O
blocked	O
in	O
cells	O
loaded	O
with	O
the	O
Ca2	O
+	O
buffer	O
1,2-	O
bis(	O
2-aminophenoxy)ethane	O
-	O
N,N,N',N'-tetraacetic	O
acid	O
showing	O
that	O
the	O
increase	O
in	O
intracellular	O
Ca2	O
+	O
concentration	O
(	O
[Ca2	O
+	O
]i	O
)	O
is	O
necessary	O
to	O
stimulate	O
cGMP	O
accumulation	O
.	O
Inhibition	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
blocks	O
the	O
cGMP	O
response	O
without	O
affecting	O
the	O
peak	O
amplitude	O
of	O
the	O
intracellular	O
Ca2	O
+	O
signal	O
,	O
and	O
it	O
is	O
concluded	O
that	O
Ca(2+)	O
-	O
dependent	O
activation	O
of	O
NOS	O
is	O
required	O
for	O
cGMP	O
production	O
.	O
cGMP	O
accumulation	O
is	O
reduced	O
by	O
60	O
%	O
when	O
cells	O
are	O
bathed	O
in	O
Ca(2+)	O
-	O
free	O
saline	O
,	O
but	O
the	O
peak	O
change	O
in	O
[	O
Ca2	O
+	O
]i	O
is	O
not	O
affected	O
.	O
This	O
suggests	O
that	O
Ca2	O
+	O
influx	O
is	O
strongly	O
coupled	O
to	O
the	O
activation	O
of	O
cGMP	O
production	O
,	O
even	O
though	O
it	O
makes	O
a	O
smaller	O
contribution	O
to	O
the	O
intracellular	O
Ca2	O
+	O
signal	O
than	O
does	O
Ca2	O
+	O
release	O
.	O
Thapsigargin	O
,	O
which	O
releases	O
Ca2	O
+	O
from	O
intracellular	O
stores	O
,	O
activates	O
Ca2	O
+	O
influx	O
and	O
increases	O
cGMP	O
.	O
The	O
cGMP	O
increase	O
is	O
transient	O
and	O
follows	O
approximately	O
the	O
same	O
time	O
course	O
as	O
Ca2	O
+	O
store	O
depletion	O
.	O
Ca2	O
+	O
influx	O
remains	O
activated	O
after	O
store	O
depletion	O
,	O
however	O
,	O
which	O
indicates	O
that	O
influx	O
alone	O
cannot	O
sustain	O
cGMP	O
production	O
.	O
It	O
is	O
concluded	O
that	O
summation	O
of	O
Ca2	O
+	O
influx	O
and	O
Ca2	O
+	O
release	O
is	O
necessary	O
to	O
reach	O
a	O
threshold	O
Ca2	O
+	O
level	O
needed	O
to	O
stimulate	O
cGMP	O
accumulation	O
.	O
Because	O
of	O
the	O
large	O
contribution	O
from	O
Ca2	O
+	O
influx	O
,	O
we	O
suggest	O
that	O
NOS	O
or	O
a	O
cofactor	O
necessary	O
for	O
its	O
activation	O
may	O
be	O
located	O
close	O
to	O
Ca2	O
+	O
channels	O
in	O
the	O
membrane	O
.	O
PMID	O
:	O
7485468	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1999	O
Jun	O
9;1445(	O
3	O
)	O
:314	O
-20	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
human	O
ADP-ribosylation	O
factor	O
5	O
(	O
ARF5	O
)	O
gene	O
.	O
Lebeda	O
RA	O
,	O
Johnson	O
SK	O
,	O
Haun	O
RS	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
University	O
of	O
Arkansas	O
for	O
Medical	O
Sciences	O
,	O
4301	O
W	O
.	O
Markham	O
Street	O
,	O
Slot	O
516	O
,	O
Little	O
Rock	O
,	O
AR	O
72205	O
-	O
7199	O
,	O
USA	O
.	O
Hybridization	O
of	O
a	O
blot	O
containing	O
50	O
human	O
RNAs	O
with	O
an	O
ADP-ribosylation	O
factor	O
5	O
-	O
specific	O
(	O
ARF5	O
)	O
oligonucleotide	O
probe	O
revealed	O
that	O
the	O
ARF5	O
gene	O
is	O
expressed	O
in	O
all	O
tissues	O
;	O
however	O
,	O
the	O
level	O
of	O
expression	O
varies	O
significantly	O
with	O
highest	O
levels	O
in	O
pancreas	O
,	O
pituitary	O
gland	O
,	O
and	O
placenta	O
.	O
The	O
5'	O
-flanking	O
region	O
of	O
the	O
human	O
ARF5	O
gene	O
lacks	O
a	O
TATA	O
or	O
CAAT	O
box	O
and	O
is	O
highly	O
GC	O
-rich	O
.	O
Primer	O
extension	O
analysis	O
indicates	O
that	O
transcription	O
initiates	O
at	O
a	O
discrete	O
site	O
62	O
bp	O
5	O
'	O
to	O
the	O
start	O
of	O
translation	O
;	O
however	O
,	O
the	O
sequence	O
surrounding	O
the	O
transcription	O
initiation	O
site	O
does	O
not	O
resemble	O
the	O
initiator	O
elements	O
described	O
for	O
other	O
TATA	O
-	O
less	O
genes	O
.	O
Transient	O
transfection	O
of	O
ARF5	O
/	O
luciferase	O
deletion	O
constructs	O
into	O
human	O
IMR-32	O
neuroblastoma	B-malignancy-type
cells	O
revealed	O
that	O
sequences	O
within	O
169	O
bp	O
of	O
the	O
transcription	O
initiation	O
site	O
were	O
necessary	O
for	O
full	O
expression	O
.	O
Two	O
GC	O
boxes	O
within	O
this	O
region	O
were	O
modified	O
by	O
site	O
-directed	O
mutagenesis	O
and	O
found	O
to	O
be	O
critical	O
for	O
expression	O
of	O
the	O
reporter	O
constructs	O
.	O
Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
demonstrated	O
specific	O
DNA	O
/protein	O
complexes	O
could	O
be	O
formed	O
with	O
oligonucleotides	O
containing	O
each	O
of	O
the	O
GC	O
boxes	O
and	O
these	O
complexes	O
could	O
be	O
effectively	O
competed	O
by	O
oligonucleotides	O
containing	O
either	O
ARF5	O
Sp1	O
site	O
or	O
by	O
an	O
oligonucleotide	O
containing	O
a	O
previously	O
characterized	O
Sp1	O
-	O
binding	O
sequence	O
.	O
The	O
level	O
of	O
ARF5	O
gene	O
expression	O
,	O
therefore	O
,	O
is	O
dependent	O
upon	O
Sp1	O
or	O
an	O
Sp1	O
-	O
like	O
factor	O
but	O
does	O
not	O
rely	O
upon	O
a	O
canonical	O
initiator	O
element	O
for	O
accurate	O
transcription	O
initiation	O
.	O
PMID	O
:	O
10366714	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
.	O
1999	O
Jul;155	O
(	O
1	O
)	O
:17-	O
21	O
.	O
Comment	O
in	O
:	O
Am	O
J	O
Pathol	O
.	O
1999	O
Jul;155	O
(	O
1	O
)	O
:	O
11-5	O
.	O
Use	O
of	O
tumor	O
-	O
specific	O
gene	O
expression	O
for	O
the	O
differential	O
diagnosis	O
of	O
neuroblastoma	B-malignancy-type
from	O
other	O
pediatric	O
small	B-malignancy-type
round	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
malignancies	I-malignancy-type
.	O
Gilbert	O
J,	O
Haber	O
M,	O
Bordow	O
SB	O
,	O
Marshall	O
GM	O
,	O
Norris	O
MD.	O
Children	O
's	O
Cancer	O
Institute	O
Australia	O
for	O
Medical	O
Research	O
,	O
Sydney	O
,	O
Australia	O
.	O
The	O
differential	O
diagnosis	O
of	O
neuroblastoma	B-malignancy-type
from	O
other	O
small	B-malignancy-type
round	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
,	O
although	O
clinically	O
of	O
great	O
importance	O
,	O
is	O
sometimes	O
difficult	O
due	O
to	O
the	O
almost	O
indistinguishable	O
appearance	O
of	O
such	O
tumors	O
by	O
conventional	O
microscopy	O
.	O
Because	O
neuroblastomas	B-malignancy-type
are	O
characterized	O
by	O
the	O
synthesis	O
of	O
catecholamines	O
,	O
we	O
investigated	O
the	O
possibility	O
that	O
expression	O
of	O
genes	O
involved	O
in	O
this	O
pathway	O
could	O
serve	O
as	O
a	O
molecular	O
marker	O
for	O
this	O
disease	O
.	O
A	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
assay	O
was	O
used	O
to	O
analyze	O
expression	O
of	O
tyrosine	O
hydroxylase	O
and	O
dopa	O
decarboxylase	O
in	O
84	O
pediatric	O
malignancies	O
including	O
55	O
neuroblastomas	B-malignancy-type
,	O
6	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcomas	I-malignancy-type
/	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
,	O
7	O
lymphomas	B-malignancy-type
,	O
6	O
leukemias	B-malignancy-type
,	O
2	O
rhabdomyosarcomas	B-malignancy-type
,	O
6	O
osteosarcomas	B-malignancy-type
,	O
and	O
2	O
phaeochromocytomas	B-malignancy-type
.	O
Of	O
the	O
55	O
neuroblastoma	B-malignancy-type
samples	O
analyzed	O
,	O
54	O
expressed	O
clearly	O
detectable	O
levels	O
of	O
both	O
genes	O
.	O
The	O
one	O
sample	O
that	O
did	O
not	O
express	O
either	O
of	O
the	O
genes	O
was	O
rediagnosed	O
both	O
clinically	O
and	O
by	O
molecular	O
genetic	O
analysis	O
as	O
a	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
.	O
Of	O
the	O
29	O
non	O
-	O
neuroblastoma	B-malignancy-type
tumor	O
samples	O
examined	O
,	O
the	O
only	O
tumor	O
samples	O
that	O
expressed	O
clearly	O
detectable	O
levels	O
of	O
both	O
tyrosine	O
hydroxylase	O
and	O
dopa	O
decarboxylase	O
were	O
phaeochromocytomas	B-malignancy-type
.	O
Like	O
neuroblastomas	B-malignancy-type
,	O
these	O
tumors	O
are	O
characterized	O
by	O
high	O
levels	O
of	O
catecholamines	O
.	O
These	O
findings	O
suggest	O
that	O
expression	O
of	O
genes	O
involved	O
in	O
catecholamine	O
biosynthesis	O
may	O
be	O
useful	O
for	O
differentiating	O
neuroblastoma	B-malignancy-type
from	O
other	O
small	B-malignancy-type
round	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
.	O
PMID	O
:	O
10393831	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Sheng	O
Wu	O
Hua	O
Xue	O
Yu	O
Sheng	O
Wu	O
Wu	O
Li	O
Xue	O
Bao	O
(	O
Shanghai	O
)	O
.	O
2003	O
Jun;35	O
(	O
6	O
)	O
:	O
522	O
-8.	O
Differential	O
protein	O
expression	O
induced	O
by	O
transient	O
transfection	O
of	O
metallothionein-3	O
gene	O
in	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Zhou	O
B	O
,	O
Yang	O
W	O
,	O
Ji	O
JG	O
,	O
Ru	O
BG.	O
Proteome	O
Group	O
,	O
National	O
Laboratory	O
of	O
Protein	O
Engineering	O
,	O
College	O
of	O
Life	O
Sciences	O
,	O
Peking	O
University	O
,	O
Beijing	O
100871	O
,	O
China	O
.	O
Metallothionein	O
-	O
3	O
(	O
MT-3	O
)	O
,	O
also	O
known	O
as	O
growth	O
inhibitory	O
factor	O
(	O
GIF	O
)	O
,	O
is	O
predominantly	O
expressed	O
in	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
It	O
belongs	O
to	O
the	O
family	O
of	O
metallothionein	O
(	O
MT	O
)	O
but	O
has	O
several	O
unique	O
properties	O
that	O
are	O
not	O
shared	O
by	O
other	O
family	O
members	O
such	O
as	O
MT-1	O
/	O
MT-2.	O
In	O
the	O
past	O
few	O
years	O
,	O
MT-3	O
had	O
been	O
postulated	O
to	O
be	O
a	O
multipurpose	O
protein	O
which	O
could	O
play	O
important	O
neuromodulatory	O
and	O
neuroprotective	O
roles	O
in	O
CNS	O
besides	O
the	O
common	O
roles	O
of	O
MTs	O
.	O
However	O
,	O
the	O
primary	O
function	O
of	O
MT-3	O
and	O
the	O
mechanism	O
underlying	O
its	O
multiple	O
functions	O
were	O
not	O
elucidated	O
so	O
far	O
.	O
In	O
present	O
study	O
,	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SH-SY5Y	O
was	O
employed	O
to	O
study	O
the	O
overall	O
cellular	O
protein	O
changes	O
induced	O
by	O
transient	O
transfection	O
of	O
MT-3	O
gene	O
,	O
based	O
on	O
comparative	O
proteome	O
analysis	O
.	O
Averagely	O
about	O
750	O
spots	O
were	O
visualized	O
by	O
Coomassie	O
staining	O
in	O
one	O
2D	O
gel	O
,	O
in	O
which	O
17	O
proteins	O
were	O
shown	O
to	O
display	O
significant	O
and	O
reproducible	O
changes	O
by	O
semiquantitative	O
analysis	O
with	O
ImageMaster	O
2D	O
Elite	O
software	O
.	O
Among	O
them	O
,	O
12	O
proteins	O
were	O
up	O
-	O
regulated	O
while	O
other	O
5	O
proteins	O
were	O
down	O
-	O
regulated	O
.	O
Using	O
matrix-assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-flight	O
mass	O
spectrometry	O
,	O
10	O
proteins	O
were	O
further	O
identified	O
to	O
be	O
zinc	O
finger	O
protein	O
,	O
glutamate	O
transporter	O
,	O
and	O
enhancer	O
protein	O
,	O
etc.	O
,	O
which	O
were	O
involved	O
in	O
several	O
important	O
pathways	O
regulating	O
the	O
functions	O
of	O
central	O
nervous	O
system	O
.	O
The	O
results	O
showed	O
that	O
MT-3	O
might	O
exert	O
its	O
unique	O
functions	O
by	O
regulating	O
the	O
expression	O
of	O
these	O
proteins	O
.	O
PMID	O
:	O
12796812	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Cell	O
Growth	O
Differ	O
.	O
2001	O
Jan;12(	O
1	O
)	O
:19	O
-	O
27	O
.	O
Morphologic	O
conversion	O
of	O
a	O
neuroblastoma	B-malignancy-type
-	O
derived	O
cell	O
line	O
by	O
E6	O
-	O
mediated	O
p53	O
degradation	O
.	O
Gaitonde	O
SV	O
,	O
Qi	O
W	O
,	O
Falsey	O
RR	O
,	O
Sidell	O
N	O
,	O
Martinez	O
JD.	O
Cancer	O
Biology	O
Interdisciplinary	O
Program	O
,	O
and	O
Arizona	O
Cancer	O
Center	O
,	O
Department	O
of	O
Radiation	O
Oncology	O
,	O
University	O
of	O
Arizona	O
,	O
Tucson	O
85724	O
,	O
USA	O
.	O
Neuroblastoma	B-malignancy-type
-	O
derived	O
tumor	O
cells	O
,	O
unlike	O
cells	O
from	O
other	O
tumor	O
types	O
,	O
characteristically	O
express	O
a	O
wildtype	O
but	O
cytoplasmically	O
sequestered	O
p53	O
protein	O
.	O
To	O
ascertain	O
whether	O
the	O
p53	O
in	O
these	O
cells	O
retained	O
any	O
physiological	O
activity	O
,	O
we	O
inactivated	O
it	O
in	O
SK-N-SH	O
cells	O
,	O
a	O
neuroblastoma	B-malignancy-type
-	O
derived	O
cell	O
line	O
,	O
by	O
introducing	O
the	O
human	O
papilloma	B-malignancy-type
virus	O
type	O
16	O
E6	O
expression	O
plasmid	O
.	O
Parent	O
SK-N-SH	O
cell	O
cultures	O
are	O
composed	O
of	O
two	O
cell	O
types	O
exhibiting	O
characteristic	O
morphologies	O
designated	O
neuroblastic	O
(	O
N-type	O
)	O
or	O
substrate	O
-	O
adherent	O
fibroblastic	O
(	O
S-type	O
)	O
cells	O
,	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
spontaneously	O
transdifferentiate	O
or	O
interconvert	O
.	O
We	O
report	O
here	O
that	O
down	O
-	O
regulation	O
of	O
p53	O
resulted	O
in	O
conversion	O
of	O
SK-N-SH	O
cells	O
to	O
the	O
substrate	O
-	O
adherent	O
fibroblast	O
-	O
like	O
S-type	O
cells	O
.	O
The	O
morphologic	O
conversion	O
was	O
accompanied	O
by	O
a	O
loss	O
of	O
neurofilament	O
expression	O
,	O
a	O
marker	O
for	O
the	O
neuronal	O
N-type	O
cells	O
,	O
an	O
increase	O
in	O
the	O
expression	O
of	O
vimentin	O
,	O
and	O
a	O
lack	O
of	O
responsiveness	O
to	O
retinoic	O
acid	O
-	O
induced	O
neuronal	O
differentiation	O
.	O
Importantly	O
,	O
we	O
did	O
not	O
observe	O
N-type	O
cells	O
in	O
the	O
E6-transfected	O
cell	O
population	O
,	O
suggesting	O
that	O
they	O
were	O
incapable	O
of	O
transdifferentiating	O
to	O
the	O
N-type	O
morphology	O
.	O
We	O
also	O
tested	O
the	O
ability	O
of	O
these	O
E6-transfected	O
S-type	O
cells	O
to	O
form	O
colonies	O
in	O
soft	O
agar	O
and	O
observed	O
a	O
markedly	O
reduced	O
capacity	O
of	O
these	O
cells	O
to	O
do	O
so	O
when	O
compared	O
with	O
the	O
parent	O
and	O
mutant	O
E6-transfected	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
p53	O
is	O
required	O
for	O
the	O
maintenance	O
of	O
the	O
neuroblastic	O
tumorigenic	O
phenotype	O
.	O
PMID	O
:	O
11205742	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
.	O
1998	O
Dec;89	O
(	O
12	O
)	O
:	O
1276-83	O
.	O
Expression	O
of	O
MRP	O
and	O
cMOAT	O
in	O
childhood	O
neuroblastomas	B-malignancy-type
and	O
malignant	O
liver	B-malignancy-type
tumors	I-malignancy-type
and	O
its	O
relevance	O
to	O
clinical	O
behavior	O
.	O
Matsunaga	O
T	O
,	O
Shirasawa	O
H,	O
Hishiki	O
T	O
,	O
Enomoto	O
H,	O
Kouchi	O
K,	O
Ohtsuka	O
Y	O
,	O
Iwai	O
J,	O
Yoshida	O
H,	O
Tanabe	O
M,	O
Kobayashi	O
S	O
,	O
Asano	O
T	O
,	O
Etoh	O
T	O
,	O
Nishi	O
Y	O
,	O
Ohnuma	O
N	O
.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Chiba	O
University	O
,	O
School	O
of	O
Medicine	O
.	O
Advanced	O
neuroblastoma	B-malignancy-type
and	O
malignant	O
liver	B-malignancy-type
tumor	I-malignancy-type
are	O
representative	O
childhood	O
cancers	O
for	O
which	O
combined	O
chemotherapy	O
including	O
cisplatin	O
and	O
doxorubicin	O
is	O
routinely	O
performed	O
.	O
The	O
prognosis	O
of	O
patients	O
with	O
tumors	O
which	O
develop	O
multiple	O
drug	O
resistance	O
(	O
MDR	O
)	O
is	O
unfavorable	O
.	O
To	O
elucidate	O
the	O
role	O
of	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
(	O
MRP	O
)	O
and	O
canalicular	O
multispecific	O
organic	O
anion	O
transporter	O
(	O
cMOAT	O
)	O
in	O
the	O
clinical	O
behavior	O
of	O
the	O
tumors	O
,	O
we	O
examined	O
42	O
neuroblastomas	B-malignancy-type
and	O
10	O
malignant	O
liver	B-malignancy-type
tumors	I-malignancy-type
for	O
the	O
expressions	O
of	O
MRP	O
and	O
cMOAT	O
by	O
quantitative	O
RNA	O
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
The	O
amplification	O
and	O
expression	O
of	O
N-myc	O
oncogene	O
in	O
the	O
neuroblastomas	B-malignancy-type
were	O
also	O
investigated	O
.	O
We	O
found	O
a	O
close	O
association	O
between	O
MRP	O
and	O
N-myc	O
expression	O
in	O
each	O
neuroblastoma	B-malignancy-type
sample	O
but	O
no	O
significant	O
relationship	O
between	O
MRP	O
expression	O
and	O
the	O
patients	O
'	O
outcome	O
.	O
The	O
forced	O
expression	O
of	O
N-myc	O
failed	O
to	O
enhance	O
the	O
expression	O
of	O
MRP	O
in	O
N-myc	O
transfected	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
cMOAT	O
was	O
rarely	O
expressed	O
in	O
the	O
neuroblastomas	B-malignancy-type
,	O
but	O
was	O
frequently	O
expressed	O
in	O
the	O
malignant	O
liver	B-malignancy-type
tumors	I-malignancy-type
.	O
The	O
expression	O
of	O
MRP	O
and	O
cMOAT	O
in	O
the	O
childhood	O
liver	B-malignancy-type
tumors	I-malignancy-type
was	O
more	O
common	O
and	O
higher	O
,	O
especially	O
in	O
advanced	O
cases	O
with	O
a	O
poor	O
outcome	O
,	O
than	O
that	O
observed	O
in	O
normal	O
liver	O
or	O
in	O
9	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
from	O
adult	O
patients	O
.	O
The	O
enhanced	O
expression	O
of	O
these	O
genes	O
might	O
be	O
characteristic	O
of	O
childhood	O
malignant	O
liver	B-malignancy-type
tumors	I-malignancy-type
and	O
related	O
to	O
their	O
clinical	O
chemoresistance	O
.	O
PMID	O
:	O
10081488	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
2000	O
Oct	O
15	O
;88	O
(	O
2	O
)	O
:172	O
-5	O
.	O
Gene	O
expression	O
of	O
neuronal	O
nitric	O
oxide	O
synthase	O
and	O
adrenomedullin	O
in	O
human	O
neuroblastoma	B-malignancy-type
using	O
real	O
-time	O
PCR	O
.	O
Dotsch	O
J,	O
Harmjanz	O
A	O
,	O
Christiansen	O
H,	O
Hanze	O
J,	O
Lampert	O
F	O
,	O
Rascher	O
W	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Erlangen-	O
Nurnberg	O
,	O
Erlangen	O
,	O
Germany	O
.	O
JoergWDoetsch@yahoo.com	O
The	O
objective	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
gene	O
expression	O
of	O
the	O
antiproliferative	O
systems	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
)	O
and	O
adrenomedullin	O
(	O
AM	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
A	O
novel	O
real	O
-time	O
PCR	O
method	O
was	O
evaluated	O
using	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
for	O
validation	O
.	O
Glyceraldehyd-	O
3-phospate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
and	O
NPY	O
gene	O
expression	O
in	O
neuroblastomas	B-malignancy-type
of	O
50	O
patients	O
were	O
measured	O
in	O
parallel	O
by	O
competitive	O
quantitative	O
and	O
TaqMan	O
real	O
-time	O
RT-PCR	O
.	O
AM	O
and	O
nNOS	O
mRNA	O
were	O
determined	O
by	O
real	O
-time	O
PCR	O
.	O
Our	O
results	O
showed	O
a	O
linear	O
relationship	O
between	O
competitive	O
quantitative	O
and	O
real	O
-time	O
RT-PCR	O
measurements	O
of	O
NPY	O
and	O
GAPDH	O
(	O
r	O
=	O
0.87	O
and	O
r	O
=	O
0.92	O
,	O
respectively	O
)	O
.	O
AM	O
and	O
nNOS	O
mRNA	O
was	O
found	O
in	O
all	O
tumor	O
samples	O
.	O
AM	O
/	O
GAPDH	O
mRNA	O
increased	O
with	O
higher	O
differentiation	O
according	O
to	O
Shimada	O
(	O
p	O
=	O
0.013	O
)	O
.	O
There	O
was	O
no	O
relation	O
between	O
MYCN	O
amplification	O
nor	O
with	O
the	O
tumor	O
stage	O
(	O
p	O
=	O
0.78	O
and	O
p	O
=	O
0.30	O
,	O
respectively	O
)	O
.	O
AM	O
/	O
GAPDH	O
did	O
not	O
relate	O
to	O
recurrence	O
or	O
death	O
in	O
a	O
5-	O
year	O
follow-up	O
period	O
.	O
Neuronal	O
NOS	O
/	O
GAPDH	O
expression	O
did	O
not	O
relate	O
to	O
any	O
biological	O
or	O
clinical	O
parameter	O
of	O
prognosis	O
or	O
differentiation	O
.	O
Similar	O
results	O
were	O
obtained	O
when	O
the	O
neuronal	O
marker	O
protein	O
gene	O
product	O
9.5	O
(	O
PGP9.5	O
)	O
was	O
used	O
to	O
normalize	O
mRNA	O
concentration	O
.	O
In	O
conclusion	O
,	O
TaqMan	O
real	O
-time	O
PCR	O
appears	O
to	O
be	O
a	O
reliable	O
method	O
to	O
quantify	O
gene	O
expression	O
in	O
neuroblastomas	B-malignancy-type
.	O
Adrenomedullin	O
mRNA	O
in	O
neuroblastoma	B-malignancy-type
is	O
linked	O
to	O
tumor	O
differentiation	O
but	O
not	O
to	O
prognostic	O
markers	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
11004664	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Magy	O
Onkol	O
.	O
2002	O
;46	O
(	O
1	O
)	O
:43	O
-	O
8.	O
Epub	O
2003	O
Feb	O
03	O
.	O
[Detection	O
of	O
n	O
-	O
myc	O
gene	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
based	O
methods	O
]	O
[	O
Article	O
in	O
Hungarian	O
]	O
Melegh	O
Z	O
,	O
Balint	O
I	O
,	O
Nagy	O
K,	O
Magyarosy	O
E	O
,	O
Galantai	O
I	O
,	O
Szentirmay	O
Z	O
.	O
Molekularis	O
Pathologiai	O
Osztaly	O
,	O
Orszagos	O
Onkologiai	O
Intezet	O
,	O
Budapest	O
,	O
H1122	O
,	O
Hungary	O
.	O
melegh@oncol	O
.hu	O
We	O
have	O
used	O
semiquantitative	O
and	O
real	O
-time	O
quantitative	O
PCRs	O
to	O
detect	O
n	O
-	O
myc	O
gene	O
-amplification	O
in	O
21	O
frozen	O
neuroblastoma	B-malignancy-type
biopsies	O
and	O
IMR	O
32	O
cell	O
line	O
in	O
order	O
to	O
predict	O
biological	O
behaviour	O
of	O
the	O
tumors	O
.	O
Two	O
primer	O
pairs	O
were	O
used	O
in	O
the	O
semiquantitative	O
method	O
to	O
co	O
-amplify	O
a	O
520	O
-	O
bp	O
fragment	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
-used	O
as	O
a	O
single	O
copy	O
reference	O
standard	O
-	O
and	O
a	O
258	O
-bp	O
fragment	O
of	O
the	O
n	O
-	O
myc	O
gene	O
.	O
After	O
30	O
cycles	O
the	O
PCR	O
products	O
were	O
electrophoresed	O
through	O
an	O
agarose	O
gel	O
and	O
were	O
compared	O
to	O
each	O
other	O
with	O
use	O
of	O
a	O
gel	O
-densitometer	O
.	O
Real	O
-time	O
quantitative	O
analysis	O
was	O
performed	O
in	O
a	O
LightCycler	O
instrument	O
.	O
A	O
single	O
primer	O
pair	O
was	O
used	O
to	O
amplify	O
a	O
120	O
-	O
bp	O
fragment	O
of	O
the	O
n	O
-	O
myc	O
oncogene	O
and	O
a	O
LC640	O
-	O
labelled	O
fluorescent	O
probe	O
pair	O
to	O
detect	O
the	O
product	O
.	O
Calibration	O
curve	O
,	O
which	O
was	O
set	O
up	O
from	O
a	O
serial	O
dilution	O
including	O
samples	O
with	O
1	O
,	O
2	O
,	O
10	O
,	O
13	O
,	O
25	O
-	O
fold	O
n	O
-	O
myc	O
oncogene	O
amplification	O
,	O
was	O
employed	O
for	O
quantitative	O
analysis	O
.	O
Semiquantitative	O
method	O
did	O
not	O
show	O
distinct	O
difference	O
between	O
tumor	O
groups	O
with	O
no	O
amplification	O
and	O
less	O
than	O
10	O
-	O
fold	O
amplification	O
,	O
while	O
quantitative	O
LightCycler	O
analysis	O
was	O
able	O
to	O
detect	O
even	O
2	O
-	O
fold	O
amplification	O
.	O
In	O
situ	O
PCRs	O
were	O
performed	O
in	O
two	O
cases	O
of	O
differentiated	O
tumor	O
samples	O
which	O
contained	O
n	O
-	O
myc	O
amplification	O
.	O
We	O
used	O
biotinylated	O
ATP	O
labelling	O
and	O
the	O
same	O
primer	O
pair	O
as	O
for	O
the	O
LightCycler	O
analysis	O
.	O
In	O
both	O
cases	O
differentiated	O
cell	O
forms	O
did	O
not	O
show	O
n	O
-	O
myc	O
gene	O
amplification	O
,	O
while	O
considerable	O
amplification	O
was	O
detected	O
in	O
the	O
neuroblasts	O
.	O
PMID	O
:	O
12050681	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Mol	O
Med	O
.	O
2003	O
Oct;12(	O
4	O
)	O
:643	O
-	O
9.	O
Identification	O
and	O
characterization	O
of	O
human	O
BCL9L	O
gene	O
and	O
mouse	O
Bcl9l	O
gene	O
in	O
silico	O
.	O
Katoh	O
M,	O
Katoh	O
M.	O
M&M	O
Medical	O
BioInformatics	O
,	O
Narashino	O
275	O
-0022	O
,	O
Japan	O
.	O
mkatoh@ncc.go	O
.jp	O
Human	O
BCL9	O
gene	O
is	O
over	O
-	O
expressed	O
in	O
some	O
cases	O
of	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
with	O
t	O
(	O
1	O
;	O
14	O
)	O
(	O
q21	O
;	O
q32	O
)	O
.	O
Drosophila	O
segment	O
polarity	O
gene	O
legless	O
(	O
lgs	O
)	O
,	O
encoding	O
wingless	O
-	O
armadillo	O
(	O
WNT	O
-	O
beta-catenin	O
)	O
signaling	O
molecule	O
,	O
is	O
the	O
homolog	O
of	O
human	O
BCL9	O
.	O
Here	O
,	O
we	O
identified	O
and	O
characterized	O
human	O
BCL9	O
-	O
like	O
(	O
BCL9L	O
)	O
gene	O
as	O
well	O
as	O
mouse	O
Bcl9	O
-	O
like	O
(	O
Bcl9l	O
)	O
gene	O
by	O
using	O
bioinformatics	O
.	O
Uncharacterized	O
DLNB11	O
cDNA	O
(	O
AB094091.1	O
)	O
was	O
derived	O
from	O
human	O
BCL9L	O
gene	O
.	O
Nucleotide	O
sequence	O
of	O
mouse	O
Bcl9l	O
cDNA	O
was	O
determined	O
in	O
silico	O
by	O
assembling	O
mouse	O
ESTs	O
BF464707	O
,	O
BQ258167	O
,	O
5'-truncated	O
BC003321	O
cDNA	O
,	O
and	O
mouse	O
genome	O
clone	O
RP24-308H8	O
(	O
AC125129.5	O
)	O
.	O
Human	O
BCL9L	O
and	O
mouse	O
Bcl9l	O
genes	O
were	O
found	O
to	O
consist	O
of	O
eight	O
exons	O
.	O
Exon	O
-	O
intron	O
structure	O
was	O
well	O
conserved	O
between	O
human	O
BCL9L	O
and	O
mouse	O
Bcl9l	O
genes	O
.	O
Human	O
BCL9L	O
(	O
1499	O
aa	O
)	O
showed	O
94.0	O
%	O
and	O
34.8	O
%	O
total	O
-amino-acid	O
identity	O
with	O
mouse	O
Bcl9l	O
(	O
1494	O
aa	O
)	O
and	O
human	O
BCL9	O
,	O
respectively	O
.	O
Six	O
domains	O
(	O
B9H1-B9H6	O
)	O
were	O
conserved	O
among	O
mammalian	O
BCL9	O
family	O
proteins	O
.	O
B9H1	O
and	O
B9H2	O
domains	O
,	O
and	O
N-terminal	O
part	O
of	O
B9H3	O
domain	O
were	O
identical	O
to	O
HD1	O
,	O
HD2	O
,	O
and	O
HD3	O
domains	O
conserved	O
between	O
human	O
BCL9	O
and	O
Drosophila	O
lgs	O
.	O
B9H4	O
,	O
B9H5	O
and	O
B9H6	O
were	O
novel	O
domains	O
.	O
B9H4	O
domain	O
was	O
characterized	O
by	O
multiple	O
Ser	O
-	O
Pro	O
repeats	O
.	O
Human	O
BCL9L	O
mRNA	O
was	O
expressed	O
in	O
fetal	O
brain	O
,	O
adult	O
lung	O
,	O
amygdala	O
,	O
eye	O
,	O
prostate	O
,	O
and	O
also	O
in	O
several	O
types	O
of	O
tumors	O
including	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
head	B-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
tumor	I-malignancy-type
and	O
embryonal	O
tumor	O
.	O
BCL9L	O
gene	O
was	O
located	O
between	O
BLR1	O
and	O
UPK2	O
genes	O
within	O
the	O
commonly	O
deleted	O
region	O
of	O
neuroblastoma	B-malignancy-type
at	O
human	O
chromosome	O
11q23.3	O
.	O
This	O
is	O
the	O
first	O
report	O
on	O
human	O
BCL9L	O
and	O
mouse	O
Bcl9l	O
.	O
PMID	O
:	O
12964048	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Blood	O
.	O
1995	O
Oct	O
15	O
;8	O
6(	O
8	O
)	O
:3132	O
-8.	O
Expression	O
of	O
stem	O
cell	O
factor	O
and	O
its	O
receptor	O
by	O
human	O
neuroblastoma	B-malignancy-type
cells	O
and	O
tumors	O
.	O
Beck	O
D	O
,	O
Gross	O
N	O
,	O
Brognara	O
CB	O
,	O
Perruisseau	O
G.	O
Research	O
Laboratory	O
,	O
University	O
Hospital	O
,	O
Lausanne	O
,	O
Switzerland	O
.	O
Bone	O
marrow	O
(	O
BM	O
)	O
is	O
a	O
frequent	O
site	O
of	O
metastasis	O
in	O
children	O
with	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
.	O
Nonhematopoietic	O
cell	O
lines	O
of	O
the	O
same	O
neuroectodermal	O
origin	O
produce	O
both	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
and	O
its	O
receptor	O
,	O
the	O
product	O
of	O
the	O
c-kit	O
protooncogene	O
(	O
c-kit	O
)	O
.	O
Because	O
recombinant	O
SCF	O
is	O
likely	O
to	O
be	O
soon	O
clinically	O
tested	O
to	O
accelerate	O
BM	O
recovery	O
after	O
high	O
-dose	O
chemotherapy	O
,	O
a	O
treatment	O
administered	O
to	O
children	O
with	O
disseminated	O
NB	B-malignancy-type
,	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
SCF	O
/	O
c-kit	O
complex	O
could	O
play	O
a	O
role	O
in	O
the	O
proliferation	O
and	O
metastasis	O
of	O
NB	B-malignancy-type
cells	O
.	O
Northern	O
blot	O
analysis	O
showed	O
SCF	O
mRNA	O
transcripts	O
in	O
7	O
of	O
8	O
(	O
88	O
%	O
)	O
NB	B-malignancy-type
cell	O
lines	O
and	O
c-kit	O
in	O
1	O
(	O
13	O
%	O
)	O
.	O
Neither	O
c-kit	O
nor	O
SCF	O
could	O
be	O
detected	O
by	O
Western	O
blotting	O
in	O
cell	O
extracts	O
or	O
by	O
surface	O
immunofluorescence	O
and	O
flow	O
cytometry	O
.	O
Soluble	O
SCF	O
protein	O
was	O
detected	O
by	O
enzyme	O
immunoassay	O
at	O
low	O
concentrations	O
in	O
the	O
cell	O
supernatants	O
in	O
the	O
same	O
7	O
NB	B-malignancy-type
cell	O
lines	O
.	O
Treatment	O
of	O
4	O
NB	B-malignancy-type
cell	O
lines	O
by	O
SCF	O
+/-	O
cytokines	O
relevant	O
to	O
BM	O
physiology	O
did	O
not	O
induce	O
c-kit	O
antigenic	O
expression	O
or	O
modulate	O
3H-thymidine	O
uptake	O
.	O
Likewise	O
,	O
the	O
latter	O
was	O
not	O
changed	O
by	O
incubating	O
the	O
cells	O
with	O
anti	O
-	O
c-kit	O
neutralizing	O
antibodies	O
.	O
Immunohistochemical	O
analysis	O
showed	O
weak	O
diffuse	O
or	O
focal	O
staining	O
for	O
SCF	O
and	O
c-kit	O
in	O
few	O
primary	O
or	O
metastatic	O
tumor	O
samples	O
,	O
only	O
once	O
simultaneously	O
.	O
We	O
conclude	O
that	O
NB	B-malignancy-type
cell	O
lines	O
usually	O
produce	O
low	O
levels	O
of	O
soluble	O
SCF	O
but	O
do	O
not	O
express	O
c-kit	O
and	O
that	O
both	O
proteins	O
are	O
rarely	O
detected	O
in	O
NB	B-malignancy-type
tumors	I-malignancy-type
.	O
The	O
SCF	O
/	O
c-kit	O
complex	O
appears	O
to	O
be	O
unlikely	O
to	O
stimulate	O
NB	B-malignancy-type
growth	O
or	O
metastasis	O
;	O
thus	O
,	O
recombinant	O
SCF	O
could	O
be	O
safely	O
administered	O
to	O
children	O
with	O
NB	B-malignancy-type
.	O
PMID	O
:	O
7579408	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
J.	O
1994	O
Jan	O
15	O
;297	O
(	O
Pt	O
2	O
)	O
:	O
407	O
-	O
13	O
.	O
A	O
role	O
for	O
protein	O
kinase	O
C	O
subtypes	O
alpha	O
and	O
epsilon	O
in	O
phorbol-ester	O
-	O
enhanced	O
K(+)	O
-	O
and	O
carbachol-evoked	O
noradrenaline	O
release	O
from	O
the	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
.	O
Turner	O
NA	O
,	O
Rumsby	O
MG	O
,	O
Walker	O
JH	O
,	O
McMorris	O
FA	O
,	O
Ball	O
SG	O
,	O
Vaughan	O
PF.	O
Unit	O
of	O
Cardiovascular	O
Studies	O
,	O
University	O
of	O
Leeds	O
,	O
U.K.	O
Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
consists	O
of	O
a	O
family	O
of	O
closely	O
related	O
subtypes	O
which	O
differ	O
in	O
their	O
localization	O
and	O
activation	O
properties	O
.	O
Our	O
previous	O
studies	O
have	O
suggested	O
a	O
role	O
for	O
PKC	O
in	O
the	O
regulation	O
of	O
noradrenaline	O
(	O
NA	O
)	O
release	O
from	O
the	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
.	O
Here	O
we	O
have	O
used	O
two	O
approaches	O
to	O
characterize	O
the	O
PKC	O
subtypes	O
present	O
in	O
SH-SY5Y	O
cells	O
.	O
Firstly	O
,	O
the	O
PCR	O
was	O
used	O
to	O
show	O
that	O
SH-SY5Y	O
cells	O
contain	O
mRNA	O
encoding	O
PKC	O
subtypes	O
alpha	O
,	O
beta	O
,	O
gamma	O
,	O
delta	O
,	O
epsilon	O
and	O
zeta	O
.	O
Secondly	O
,	O
immunoblotting	O
showed	O
that	O
SH-SY5Y	O
cells	O
express	O
PKC	O
subtypes	O
alpha	O
,	O
epsilon	O
and	O
zeta	O
at	O
the	O
protein	O
level	O
.	O
Prolonged	O
(	O
48	O
h	O
)	O
exposure	O
of	O
cells	O
to	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
;	O
100	O
nM	O
)	O
resulted	O
in	O
a	O
marked	O
decrease	O
in	O
the	O
amounts	O
of	O
PKC-alpha	O
and	O
PKC-epsilon	O
,	O
with	O
no	O
change	O
in	O
levels	O
of	O
PKC-zeta	O
.	O
Prolonged	O
PMA	O
treatment	O
had	O
no	O
significant	O
effect	O
on	O
K(+)-evoked	O
NA	O
release	O
from	O
SH-SY5Y	O
cells	O
,	O
whereas	O
carbachol-evoked	O
release	O
was	O
increased	O
2.2	O
-	O
fold	O
.	O
However	O
,	O
prolonged	O
exposure	O
to	O
PMA	O
completely	O
inhibited	O
the	O
ability	O
of	O
acute	O
(	O
12	O
min	O
)	O
PMA	O
treatment	O
to	O
enhance	O
both	O
K(+)	O
-	O
and	O
carbachol-evoked	O
NA	O
release	O
.	O
The	O
specific	O
PKC	O
inhibitor	O
RO	O
31	O
-	O
7459	O
(	O
10	O
microM	O
)	O
was	O
found	O
to	O
inhibit	O
K(+)	O
-	O
and	O
carbachol-evoked	O
release	O
by	O
27	O
%	O
and	O
68	O
%	O
respectively	O
.	O
RO	O
31	O
-	O
7549	O
also	O
completely	O
inhibited	O
the	O
ability	O
of	O
acute	O
PMA	O
treatment	O
to	O
enhance	O
release	O
.	O
These	O
data	O
suggest	O
that	O
PKC-alpha	O
and/or	O
PKC-epsilon	O
play	O
an	O
essential	O
role	O
in	O
the	O
regulation	O
of	O
PMA	O
-	O
enhanced	O
K(+)	O
-	O
and	O
carbachol-evoked	O
NA	O
release	O
in	O
SH-SY5Y	O
cells	O
.	O
PMID	O
:	O
8297348	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
.	O
2001	O
Sep	O
15	O
;21	O
(	O
18	O
)	O
:	O
7037-45	O
.	O
Sp	O
proteins	O
and	O
Phox2b	O
regulate	O
the	O
expression	O
of	O
the	O
human	O
Phox2a	O
gene	O
.	O
Flora	O
A	O
,	O
Lucchetti	O
H,	O
Benfante	O
R	O
,	O
Goridis	O
C	O
,	O
Clementi	O
F	O
,	O
Fornasari	O
D.	O
Department	O
of	O
Medical	O
Pharmacology	O
,	O
University	O
of	O
Milan	O
and	O
Consiglio	O
Nazionale	O
delle	O
Ricerche	O
Cellular	O
and	O
Molecular	O
Pharmacology	O
Center	O
,	O
20129	O
Milan	O
,	O
Italy	O
.	O
Phox2a	O
is	O
a	O
vertebrate	O
homeodomain	O
transcription	O
factor	O
that	O
is	O
involved	O
in	O
the	O
specification	O
of	O
the	O
autonomic	O
nervous	O
system	O
.	O
We	O
have	O
isolated	O
the	O
5	O
'	O
regulatory	O
region	O
of	O
the	O
human	O
Phox2a	O
gene	O
and	O
studied	O
the	O
transcriptional	O
mechanisms	O
underlying	O
its	O
expression	O
.	O
We	O
first	O
identified	O
the	O
minimal	O
gene	O
promoter	O
by	O
means	O
of	O
molecular	O
and	O
functional	O
criteria	O
and	O
demonstrated	O
that	O
its	O
activity	O
relies	O
on	O
a	O
degenerate	O
TATA	O
box	O
and	O
a	O
canonical	O
Sp1	O
site	O
.	O
We	O
then	O
concentrated	O
on	O
the	O
region	O
immediately	O
upstream	O
of	O
the	O
promoter	O
and	O
found	O
that	O
it	O
stimulates	O
transcription	O
in	O
a	O
neurospecific	O
manner	O
because	O
its	O
deletion	O
caused	O
a	O
substantial	O
decline	O
in	O
reporter	O
gene	O
expression	O
only	O
in	O
neuronal	O
cells	O
.	O
This	O
DNA	O
region	O
contains	O
a	O
putative	O
binding	O
site	O
for	O
homeodomain	O
transcription	O
factors	O
,	O
and	O
its	O
mutation	O
severely	O
affects	O
the	O
transcriptional	O
activity	O
of	O
the	O
entire	O
5	O
'	O
regulatory	O
region	O
,	O
thus	O
indicating	O
that	O
this	O
site	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
Phox2a	O
in	O
this	O
cellular	O
context	O
.	O
The	O
use	O
of	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
Phox2b	O
/	O
PMX2b	O
is	O
capable	O
of	O
specifically	O
interacting	O
with	O
this	O
site	O
,	O
and	O
cotransfection	O
experiments	O
demonstrated	O
that	O
it	O
is	O
capable	O
of	O
transactivating	O
the	O
human	O
Phox2a	O
promoter	O
.	O
Many	O
data	O
obtained	O
from	O
knock	O
-	O
out	O
mice	O
support	O
the	O
hypothesis	O
that	O
Phox2a	O
acts	O
downstream	O
of	O
Phox2b	O
during	O
the	O
development	O
of	O
most	O
of	O
the	O
autonomic	O
nervous	O
system	O
.	O
We	O
have	O
provided	O
the	O
first	O
molecular	O
evidence	O
that	O
Phox2b	O
can	O
regulate	O
the	O
expression	O
of	O
Phox2a	O
by	O
directly	O
binding	O
to	O
its	O
5	O
'	O
regulatory	O
region	O
.	O
PMID	O
:	O
11549713	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Lipid	O
Res	O
.	O
1999	O
Dec;40	O
(	O
12	O
)	O
:2204-11	O
.	O
Family	O
of	O
human	O
oxysterol	O
binding	O
protein	O
(	O
OSBP	O
)	O
homologues	O
.	O
A	O
novel	O
member	O
implicated	O
in	O
brain	O
sterol	O
metabolism	O
.	O
Laitinen	O
S	O
,	O
Olkkonen	O
VM	O
,	O
Ehnholm	O
C	O
,	O
Ikonen	O
E.	O
Department	O
of	O
Biochemistry	O
,	O
National	O
Public	O
Health	O
Institute	O
,	O
Mannerheimintie	O
166	O
,	O
00300	O
,	O
Helsinki	O
,	O
Finland	O
.	O
Oxysterol	O
binding	O
protein	O
(	O
OSBP	O
)	O
is	O
a	O
cytosolic	O
protein	O
that	O
undergoes	O
ligand	O
-	O
induced	O
binding	O
to	O
the	O
Golgi	O
apparatus	O
and	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
cellular	O
cholesterol	O
metabolism	O
.	O
In	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
an	O
OSBP	O
homologue	O
is	O
involved	O
in	O
membrane	O
trafficking	O
through	O
the	O
Golgi	O
complex	O
.	O
Prompted	O
by	O
the	O
multitude	O
of	O
OSBP	O
-	O
related	O
genes	O
in	O
the	O
yeast	O
genome	O
,	O
we	O
carried	O
out	O
a	O
search	O
for	O
human	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
displaying	O
homology	O
to	O
the	O
sterol	O
-	O
binding	O
domain	O
of	O
OSBP	O
.	O
This	O
revealed	O
a	O
minimum	O
of	O
six	O
novel	O
OSBP	O
-	O
related	O
proteins	O
,	O
designated	O
ORP-1	O
to	O
ORP-6	O
.	O
ORP	O
cDNA	O
probes	O
were	O
generated	O
by	O
reverse	O
transcription	O
-	O
PCR	O
from	O
human	O
liver	O
mRNA	O
,	O
and	O
used	O
for	O
Northern	O
blot	O
analysis	O
of	O
human	O
tissue	O
transcript	O
panels	O
.	O
This	O
verified	O
that	O
each	O
of	O
them	O
represents	O
a	O
different	O
gene	O
product	O
and	O
showed	O
that	O
they	O
display	O
distinct	O
tissue	O
-	O
specific	O
expression	O
patterns	O
.	O
The	O
ORP	O
-1	O
and	O
-2	O
mRNA	O
expression	O
levels	O
were	O
similar	O
to	O
or	O
higher	O
than	O
that	O
of	O
OSBP	O
while	O
the	O
ORP	O
-3	O
to	O
-	O
6	O
mRNAs	O
were	O
detected	O
at	O
lower	O
levels	O
in	O
specific	O
tissues	O
.	O
The	O
most	O
abundantly	O
expressed	O
new	O
gene	O
,	O
ORP-1	O
,	O
was	O
transcribed	O
at	O
strikingly	O
high	O
levels	O
in	O
the	O
cortical	O
areas	O
of	O
human	O
brain	O
and	O
displayed	O
sterol	O
-	O
regulated	O
expression	O
in	O
a	O
cultured	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
This	O
indicates	O
that	O
ORP-1	O
may	O
play	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
sterol	O
balance	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
.	O
Together	O
with	O
OSBP	O
,	O
the	O
identified	O
gene	O
products	O
constitute	O
a	O
novel	O
human	O
protein	O
family	O
that	O
may	O
provide	O
a	O
link	O
between	O
organellar	O
sterol	O
status	O
and	O
membrane	O
dynamics	O
.	O
PMID	O
:	O
10588946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Free	O
Radic	O
Biol	O
Med	O
.	O
1992	O
;12(	O
4	O
)	O
:	O
281	O
-6.	O
High	O
levels	O
of	O
Mn	O
-	O
superoxide	O
dismutase	O
in	O
serum	O
of	O
patients	O
with	O
neuroblastoma	B-malignancy-type
and	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Kawamura	O
N	O
,	O
Suzuki	O
K,	O
Ishikawa	O
M,	O
Iizuka	O
S	O
,	O
Miyake	O
M,	O
Mino	O
M,	O
Taniguchi	O
N	O
.	O
Department	O
of	O
Biochemistry	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Japan	O
.	O
Levels	O
of	O
serum	O
manganese	O
superoxide	O
dismutase	O
(	O
Mn-SOD	O
)	O
in	O
normal	O
children	O
aged	O
from	O
1	O
to	O
14	O
years	O
and	O
children	O
with	O
various	O
hematological	O
and	O
malignant	O
diseases	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
In	O
the	O
normal	O
children	O
,	O
the	O
serum	O
Mn-SOD	O
levels	O
gradually	O
increased	O
in	O
proportion	O
to	O
age	O
.	O
By	O
8	O
years	O
of	O
age	O
,	O
the	O
Mn-SOD	O
level	O
was	O
nearly	O
at	O
the	O
adult	O
level	O
.	O
The	O
normal	O
values	O
of	O
serum	O
Mn-SOD	O
(	O
mean	O
+/-	O
SD	O
)	O
of	O
children	O
below	O
4	O
and	O
above	O
8	O
years	O
old	O
were	O
48	O
+/-	O
10.2	O
ng	O
/	O
ml	O
and	O
84	O
+/-	O
22.5	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O
Assuming	O
the	O
upper	O
limit	O
of	O
normal	O
Mn-SOD	O
level	O
in	O
serum	O
to	O
be	O
the	O
mean	O
value	O
+/-	O
2	O
SD	O
of	O
children	O
at	O
each	O
age	O
,	O
high	O
serum	O
levels	O
of	O
Mn-SOD	O
were	O
found	O
for	O
8	O
of	O
12	O
patients	O
with	O
neuroblastoma	B-malignancy-type
,	O
three	O
of	O
four	O
patients	O
with	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
,	O
and	O
four	O
of	O
five	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
patients	O
with	O
neuroblastoma	B-malignancy-type
exhibited	O
a	O
transient	O
increase	O
in	O
Mn-SOD	O
following	O
chemotherapy	O
,	O
but	O
after	O
1	O
week	O
the	O
levels	O
decreased	O
markedly	O
to	O
the	O
control	O
levels	O
.	O
The	O
changes	O
in	O
serum	O
Mn-SOD	O
levels	O
in	O
the	O
patients	O
with	O
neuroblastoma	B-malignancy-type
correlated	O
well	O
with	O
the	O
levels	O
of	O
neuron	O
-	O
specific	O
enolase	O
.	O
Mn-SOD	O
was	O
intensely	O
stained	O
in	O
bone	O
marrow	O
cells	O
of	O
patients	O
whose	O
cancer	O
cells	O
had	O
moved	O
into	O
the	O
bone	O
marrow	O
.	O
High	O
levels	O
of	O
Mn-SOD	O
were	O
also	O
found	O
in	O
cultured	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
These	O
data	O
indicate	O
that	O
Mn-SOD	O
is	O
expressed	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
may	O
serve	O
as	O
one	O
of	O
the	O
diagnostic	O
and	O
prognostic	O
markers	O
for	O
the	O
neuroblastoma	B-malignancy-type
,	O
and	O
may	O
be	O
useful	O
to	O
predict	O
the	O
effectiveness	O
of	O
chemotherapy	O
for	O
neuroblastoma	B-malignancy-type
and	O
the	O
recurrence	O
of	O
this	O
disease	O
.	O
PMID	O
:	O
1315710	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
1997	O
Sep	O
17;72	O
(	O
6	O
)	O
:	O
1070	O
-	O
7.	O
Extensive	O
genetic	O
heterogeneity	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
NB(	O
TU)1	O
.	O
Inoue	O
A	O
,	O
Yokomori	O
K,	O
Tanabe	O
H,	O
Mizusawa	O
H,	O
Sofuni	O
T	O
,	O
Hayashi	O
Y	O
,	O
Tsuchida	O
Y	O
,	O
Shimatake	O
H.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
Toho	O
University	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
A	O
neuroblastoma	B-malignancy-type
cell	O
line	O
displaying	O
genetically	O
unique	O
features	O
was	O
established	O
from	O
a	O
stage	O
III	O
case	O
of	O
a	O
20-month	O
-	O
old	O
girl	O
.	O
Southern	O
blotting	O
by	O
the	O
probe	O
pTNB6	O
,	O
which	O
contains	O
exon	O
1	O
of	O
the	O
N-myc	O
gene	O
,	O
showed	O
that	O
the	O
primary	O
tumor	O
had	O
in	O
total	O
4	O
aberrant	O
bands	O
beside	O
the	O
normal	O
amplified	O
band	O
.	O
The	O
established	O
cell	O
line	O
NB(	O
TU)1	O
had	O
an	O
aberrant	O
N-myc	O
band	O
(	O
9.0	O
kb	O
)	O
in	O
addition	O
to	O
the	O
normal	O
band	O
(	O
2.9	O
kb	O
)	O
.	O
Cytogenetic	O
analysis	O
revealed	O
that	O
NB(	O
TU)1	O
has	O
a	O
composite	O
karyotype	O
composed	O
of	O
at	O
least	O
7	O
related	O
karyotypes	O
,	O
which	O
are	O
pseudo-diploid	O
and	O
contain	O
complex	O
chromosomal	O
abnormalities	O
,	O
including	O
translocations	O
,	O
deletions	O
and	O
homogeneously	O
staining	O
regions	O
(	O
HSRs	O
)	O
.	O
Such	O
extensive	O
abnormalities	O
were	O
considered	O
to	O
be	O
prominent	O
among	O
known	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
and	O
it	O
was	O
suggested	O
that	O
NB(	O
TU)1	O
had	O
acquired	O
a	O
certain	O
type	O
of	O
genetic	O
instability	O
.	O
Analysis	O
of	O
N-myc	O
bands	O
in	O
11	O
clones	O
of	O
NB(	O
TU)1	O
showed	O
that	O
the	O
intensity	O
ratio	O
of	O
the	O
normal	O
-	O
sized	O
band	O
(	O
2.9	O
kb	O
)	O
and	O
the	O
aberrant	O
one	O
(	O
9.0	O
kb	O
)	O
markedly	O
varied	O
among	O
clones	O
.	O
Moreover	O
,	O
3	O
clones	O
showed	O
an	O
additional	O
band	O
with	O
the	O
size	O
of	O
3.7	O
kb	O
,	O
which	O
was	O
detectable	O
neither	O
in	O
the	O
parent	O
NB(	O
TU)1	O
nor	O
in	O
the	O
primary	O
tumor	O
.	O
Thus	O
,	O
NB(	O
TU)1	O
was	O
shown	O
to	O
be	O
composed	O
of	O
heterogeneous	O
cell	O
components	O
.	O
To	O
further	O
detect	O
such	O
ongoing	O
chromosomal	O
instability	O
,	O
we	O
examined	O
micronuclei	O
formation	O
.	O
NB(	O
TU)1	O
yielded	O
a	O
larger	O
number	O
of	O
micronuclei	O
than	O
5	O
other	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
We	O
conclude	O
that	O
NB(	O
TU)1	O
has	O
acquired	O
genetic	O
instability	O
detectable	O
by	O
both	O
Southern	O
blotting	O
and	O
cytogenetic	O
analysis	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
9378542	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
.	O
1994	O
Dec;14(	O
12	O
)	O
:	O
8143	O
-	O
54	O
.	O
Multiple	O
positive	O
and	O
negative	O
regulatory	O
elements	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
homeobox	O
gene	O
Hoxb-4	O
.	O
Gutman	O
A	O
,	O
Gilthorpe	O
J,	O
Rigby	O
PW	O
.	O
Laboratory	O
of	O
Eukaryotic	O
Molecular	O
Genetics	O
,	O
MRC	O
National	O
Institute	O
for	O
Medical	O
Research	O
,	O
London	O
,	O
England	O
.	O
Mouse	O
Hoxb-4	O
(	O
Hox-2.6	O
)	O
is	O
a	O
homeobox	O
gene	O
that	O
belongs	O
to	O
a	O
family	O
which	O
also	O
includes	O
Hoxa-4	O
,	O
Hoxc-4	O
,	O
and	O
Hoxd-4	O
and	O
that	O
is	O
related	O
to	O
the	O
Deformed	O
gene	O
in	O
Drosophila	O
melanogaster	O
.	O
We	O
have	O
determined	O
the	O
sequence	O
of	O
1.2	O
kb	O
of	O
5	O
'	O
flanking	O
DNA	O
of	O
mouse	O
Hoxb-4	O
and	O
by	O
nuclease	O
S1	O
and	O
primer	O
extension	O
experiments	O
identified	O
two	O
transcription	O
start	O
sites	O
,	O
P1	O
and	O
P2	O
,	O
285	O
and	O
207	O
nucleotides	O
upstream	O
of	O
the	O
ATG	O
initiator	O
codon	O
,	O
respectively	O
.	O
We	O
have	O
shown	O
that	O
this	O
region	O
harbors	O
two	O
independent	O
promoters	O
which	O
drive	O
CAT	O
expression	O
in	O
several	O
different	O
cell	O
lines	O
with	O
various	O
efficiencies	O
,	O
suggesting	O
that	O
they	O
are	O
subject	O
to	O
cell	O
-type	O
-	O
specific	O
regulation	O
.	O
Through	O
detailed	O
mutational	O
analysis	O
,	O
we	O
have	O
identified	O
several	O
cis	O
-	O
regulatory	O
elements	O
,	O
located	O
upstream	O
and	O
downstream	O
of	O
the	O
transcription	O
start	O
sites	O
.	O
They	O
include	O
two	O
cell	O
-type	O
-	O
specific	O
negative	O
regulatory	O
elements	O
,	O
which	O
are	O
more	O
active	O
in	O
F9	O
embryonal	B-malignancy-type
carcinoma	I-malignancy-type
cells	O
than	O
in	O
neuroblastoma	B-malignancy-type
cells	O
(	O
regions	O
a	O
and	O
d	O
at	O
-	O
226	O
to	O
-	O
186	O
and	O
+169	O
to	O
+205	O
,	O
respectively	O
)	O
.	O
An	O
additional	O
negative	O
regulatory	O
element	O
has	O
been	O
delimited	O
(	O
region	O
b	O
between	O
+22	O
and	O
+	O
113	O
)	O
.	O
Positive	O
regulation	O
is	O
achieved	O
by	O
binding	O
of	O
HoxTF	O
,	O
a	O
previously	O
unknown	O
factor	O
,	O
to	O
the	O
sequence	O
GCCATTGG	O
(	O
+148	O
to	O
+155	O
)	O
that	O
is	O
essential	O
for	O
efficient	O
Hoxb-4	O
expression	O
.	O
We	O
have	O
also	O
defined	O
the	O
minimal	O
promoter	O
sequences	O
and	O
found	O
that	O
they	O
include	O
two	O
12-bp	O
initiator	O
elements	O
centered	O
around	O
each	O
transcription	O
start	O
site	O
.	O
The	O
complex	O
architecture	O
of	O
the	O
Hoxb-4	O
promoter	O
provides	O
the	O
framework	O
for	O
fine	O
-	O
tuned	O
transcriptional	O
regulation	O
during	O
embryonic	O
development	O
.	O
PMID	O
:	O
7969151	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cereb	O
Blood	O
Flow	O
Metab	O
.	O
2001	O
May	O
;21	O
(	O
5	O
)	O
:	O
550	O
-	O
6.	O
Early	O
c-Fos	O
induction	O
after	O
cerebral	O
ischemia	O
:	O
a	O
possible	O
neuroprotective	O
role	O
.	O
Cho	O
S	O
,	O
Park	O
EM	O
,	O
Kim	O
Y	O
,	O
Liu	O
N	O
,	O
Gal	O
J,	O
Volpe	O
BT	O
,	O
Joh	O
TH	O
.	O
Department	O
of	O
Neurology	O
and	O
Neuroscience	O
,	O
Weill	O
Medical	O
College	O
of	O
Cornell	O
University	O
at	O
W	O
.	O
M.	O
Burke	O
Medical	O
Research	O
Institute	O
,	O
White	O
Plains	O
,	O
New	O
York	O
10605	O
,	O
USA	O
.	O
The	O
role	O
of	O
c-Fos	O
in	O
neurodegeneration	O
or	O
neuroprotection	O
after	O
cerebral	O
ischemia	O
is	O
controversial	O
.	O
To	O
investigate	O
whether	O
early	O
c-Fos	O
induction	O
after	O
ischemia	O
is	O
associated	O
with	O
neuroprotection	O
,	O
rats	O
were	O
subjected	O
to	O
10	O
minutes	O
of	O
transient	O
forebrain	O
ischemia	O
and	O
c-Fos	O
expression	O
was	O
examined	O
.	O
Resistant	O
dentate	O
granule	O
cells	O
and	O
neurons	O
in	O
CA2	O
-4	O
displayed	O
more	O
robust	O
immunoreactivity	O
than	O
vulnerable	O
neurons	O
in	O
the	O
CA1	O
region	O
of	O
hippocampus	O
during	O
early	O
hours	O
of	O
reperfusion	O
.	O
By	O
6	O
hours	O
after	O
reperfusion	O
,	O
c-Fos	O
immunoreactivity	O
was	O
greatly	O
diminished	O
in	O
all	O
areas	O
of	O
the	O
hippocampus	O
.	O
Administration	O
of	O
N-acetyl-O-methyldopamine	O
(	O
NAMDA	O
)	O
,	O
a	O
compound	O
previously	O
shown	O
to	O
protect	O
CA1	O
neurons	O
against	O
ischemia	O
,	O
increased	O
c-Fos	O
immunoreactivity	O
in	O
the	O
CA1	O
vulnerable	O
region	O
at	O
6	O
hours	O
after	O
ischemia	O
and	O
protected	O
SK-N-BE(2)	O
C	O
neurons	O
from	O
oxygen	O
glucose	O
deprivation	O
.	O
Further	O
in	O
vitro	O
study	O
showed	O
that	O
NAMDA	O
potentiated	O
phorbol-12	O
myristate-	O
13	O
acetate	O
(	O
PMA	O
)	O
-	O
induced	O
c-Fos	O
expression	O
,	O
AP1	O
binding	O
activity	O
,	O
and	O
late	O
gene	O
expression	O
determined	O
by	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
activity	O
from	O
AP1	O
containing	O
tyrosine	O
hydroxylase	O
promoter	O
-	O
CAT	O
fusion	O
gene	O
in	O
SK-N-BE(2)	O
C	O
neurons	O
.	O
In	O
vivo	O
and	O
in	O
vitro	O
results	O
showed	O
that	O
a	O
neuroprotectant	O
,	O
NAMDA	O
,	O
in	O
concert	O
with	O
another	O
stimulus	O
(	O
for	O
example	O
,	O
ischemia	O
or	O
PMA	O
)	O
up	O
-	O
regulates	O
c-Fos	O
expression	O
and	O
suggested	O
that	O
the	O
early	O
rise	O
of	O
NAMDA	O
-	O
induced	O
c-Fos	O
expression	O
in	O
vulnerable	O
CA1	O
neurons	O
may	O
account	O
for	O
neuroprotection	O
by	O
means	O
of	O
up	O
-	O
regulating	O
late	O
gene	O
expression	O
for	O
survival	O
.	O
PMID	O
:	O
11333365	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2003	O
Feb;8	O
4	O
(	O
4	O
)	O
:73	O
5-42	O
.	O
Functional	O
analysis	O
of	O
connexin	O
-	O
26	O
mutants	O
associated	O
with	O
hereditary	O
recessive	O
deafness	O
.	O
Wang	O
HL	O
,	O
Chang	O
WT	O
,	O
Li	O
AH	O
,	O
Yeh	O
TH	O
,	O
Wu	O
CY	O
,	O
Chen	O
MS	O
,	O
Huang	O
PC	O
.	O
Department	O
of	O
Physiology	O
,	O
Chang	O
Gung	O
University	O
School	O
of	O
Medicine	O
,	O
Kwei-San	O
,	O
Tao	O
-Yuan	O
,	O
Taiwan	O
,	O
Republic	O
of	O
China	O
.	O
hlwns@mail	O
.cgu.edu.tw	O
The	O
physiological	O
importance	O
of	O
connexin	O
-	O
26	O
(	O
Cx26	O
)	O
gap	O
junctions	O
in	O
regulating	O
auditory	O
function	O
is	O
indicated	O
by	O
the	O
finding	O
that	O
autosomal	O
recessive	O
DFNB1	O
deafness	O
is	O
associated	O
with	O
mutations	O
of	O
the	O
Cx26	O
gene	O
.	O
To	O
investigate	O
the	O
pathogenic	O
role	O
of	O
Cx26	O
mutation	O
in	O
recessive	O
hearing	O
loss	O
,	O
four	O
putative	O
DFNB1	O
Cx26	O
mutants	O
(	O
V	O
84	O
L	O
,	O
V	O
95	O
M	O
,	O
R	O
127	O
H	O
,	O
and	O
R	O
143	O
W	O
)	O
were	O
stably	O
expressed	O
in	O
N2A	O
cells	O
,	O
a	O
communication	O
-	O
deficient	O
cell	O
line	O
.	O
In	O
N2A	O
cells	O
expressing	O
(	O
R	O
127	O
H	O
)	O
Cx26	O
gap	O
junctions	O
,	O
macroscopic	O
junctional	O
conductance	O
and	O
ability	O
of	O
transferring	O
neurobiotin	O
between	O
transfected	O
cells	O
were	O
greatly	O
reduced	O
.	O
Despite	O
the	O
formation	O
of	O
defective	O
junctional	O
channels	O
,	O
immunoreactivity	O
of	O
(	O
R	O
127	O
H	O
)	O
Cx26	O
was	O
mainly	O
localized	O
in	O
the	O
cell	O
membrane	O
and	O
prominent	O
in	O
the	O
region	O
of	O
cell	O
-	O
cell	O
contact	O
.	O
Mutant	O
(	O
V	O
84	O
L	O
)	O
,	O
(	O
V	O
95	O
M	O
)	O
,	O
or	O
(	O
R	O
143	O
W	O
)	O
Cx26	O
protein	O
formed	O
gap	O
junctions	O
with	O
a	O
junctional	O
conductance	O
similar	O
to	O
that	O
of	O
wild-type	O
Cx26	O
junctional	O
channels	O
.	O
(	O
V	O
84	O
L	O
)	O
,	O
(	O
V	O
95	O
M	O
)	O
,	O
or	O
(	O
R	O
143	O
W	O
)	O
Cx26	O
gap	O
junctions	O
also	O
permitted	O
neurobiotin	O
transfer	O
between	O
pairs	O
of	O
transfected	O
N2A	O
cells	O
.	O
The	O
present	O
study	O
suggests	O
that	O
(	O
R	O
127	O
H	O
)	O
mutation	O
associated	O
with	O
hereditary	O
sensorineural	O
deafness	O
results	O
in	O
the	O
formation	O
of	O
defective	O
Cx26	O
gap	O
junctions	O
,	O
which	O
may	O
lead	O
to	O
the	O
malfunction	O
of	O
cochlear	O
gap	O
junctions	O
and	O
hearing	O
loss	O
.	O
Further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
exact	O
mechanism	O
by	O
which	O
mutant	O
(	O
V	O
84	O
L	O
)	O
,	O
(	O
V	O
95	O
M	O
)	O
,	O
and	O
(	O
R	O
143	O
W	O
)	O
Cx26	O
proteins	O
,	O
which	O
are	O
capable	O
of	O
forming	O
functional	O
homotypic	O
junctional	O
channels	O
in	O
N2A	O
cells	O
,	O
cause	O
the	O
cochlear	O
dysfunction	O
and	O
sensorineural	O
deafness	O
.	O
PMID	O
:	O
12562518	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
2002	O
Jul	O
12;94	O
3(	O
2	O
)	O
:245-	O
56	O
.	O
Disparity	O
between	O
ionic	O
mediators	O
of	O
volume	O
regulation	O
and	O
apoptosis	O
in	O
N1E	O
115	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
.	O
O'Reilly	O
N	O
,	O
Xia	O
Z	O
,	O
Fiander	O
H,	O
Tauskela	O
J,	O
Small	O
DL.	O
Institute	O
for	O
Biological	O
Sciences	O
,	O
National	O
Research	O
Council	O
,	O
Ottawa	O
,	O
Ontario	O
,	O
Canada	O
.	O
Cellular	O
volume	O
loss	O
or	O
shrinkage	O
is	O
a	O
ubiquitous	O
feature	O
of	O
apoptosis	O
and	O
thus	O
may	O
contribute	O
to	O
this	O
form	O
of	O
degeneration	O
.	O
Chloride	O
(	O
Cl(-)	O
)	O
and	O
potassium	O
(	O
K(+)	O
)	O
efflux	O
has	O
been	O
shown	O
to	O
participate	O
in	O
volume	O
regulation	O
and	O
several	O
recent	O
reports	O
have	O
implicated	O
K(+)	O
efflux	O
in	O
apoptotic	O
neuronal	O
death	O
.	O
Here	O
pharmacological	O
inhibitors	O
of	O
various	O
K(+)	O
and	O
Cl(-)	O
channels	O
and	O
transporters	O
were	O
used	O
to	O
decipher	O
the	O
relationship	O
between	O
cellular	O
volume	O
regulation	O
and	O
apoptosis	O
.	O
Following	O
exposure	O
to	O
a	O
hypotonic	O
media	O
,	O
cells	O
swell	O
but	O
over	O
time	O
gradually	O
recover	O
,	O
returning	O
to	O
their	O
original	O
cell	O
volume	O
in	O
a	O
process	O
known	O
as	O
regulatory	O
volume	O
decrease	O
(	O
RVD	O
)	O
.	O
RVD	O
in	O
N1E	O
115	O
neuroblastoma	B-malignancy-type
cells	O
was	O
monitored	O
using	O
time	O
-	O
lapse	O
videomicroscopy	O
,	O
cell	O
size	O
and	O
DNA	O
degradation	O
were	O
followed	O
using	O
flow	O
cytometry	O
and	O
fragmented	O
apoptotic	O
nuclei	O
were	O
visualized	O
using	O
Hoechst	O
staining	O
.	O
RVD	O
was	O
blocked	O
by	O
high	O
K(+)	O
,	O
TEA	O
and	O
4-	O
AP	O
(	O
K(+)	O
channel	O
blockers	O
)	O
,	O
DIDS	O
and	O
niflumic	O
acid	O
but	O
not	O
SITS	O
(	O
Cl(-)	O
channel	O
blockers	O
)	O
,	O
ethacrynic	O
acid	O
(	O
Cl(-)	O
pump	O
blocker	O
)	O
,	O
bumetanide	O
(	O
Na(+)	O
/	O
K(+)	O
/	O
Cl(-)	O
cotransporter	O
blocker	O
)	O
and	O
furosemide	O
(	O
K(+)	O
/	O
Cl(-)	O
cotransport	O
blocker	O
)	O
.	O
In	O
contrast	O
,	O
only	O
DIDS	O
and	O
SITS	O
(	O
blockers	O
of	O
the	O
Cl(-)	O
/	O
HCO(3)	O
exchanger	O
)	O
inhibited	O
apoptosis	O
,	O
suggesting	O
that	O
a	O
common	O
mechanistic	O
link	O
between	O
RVD	O
and	O
apoptosis	O
is	O
the	O
Cl(-)	O
/	O
HCO(3)	O
exchanger	O
.	O
Thus	O
,	O
this	O
study	O
does	O
not	O
support	O
the	O
notion	O
that	O
K(+)	O
channels	O
are	O
universal	O
anti	O
-	O
apoptotic	O
targets	O
.	O
Instead	O
,	O
the	O
Cl(-)	O
/	O
HCO(3)	O
exchanger	O
may	O
prove	O
to	O
be	O
a	O
viable	O
target	O
of	O
therapeutic	O
intervention	O
for	O
treating	O
pathological	O
apoptosis	O
and	O
neurodegeneration	O
.	O
PMID	O
:	O
12101047	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
Res	O
.	O
2003	O
Jul	O
15	O
;73	O
(	O
2	O
)	O
:	O
215-26	O
.	O
Characterisation	O
of	O
a	O
sphingosine	O
1-phosphate	O
-	O
activated	O
Ca2	O
+	O
signalling	O
pathway	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Villullas	O
IR	O
,	O
Smith	O
AJ	O
,	O
Heavens	O
RP	O
,	O
Simpson	O
PB	O
.	O
Merck	O
Sharp	O
&	O
Dohme	O
Research	O
Laboratories	O
,	O
Neuroscience	O
Research	O
Centre	O
,	O
Terlings	O
Park	O
,	O
Harlow	O
,	O
Essex	O
,	O
United	O
Kingdom	O
.	O
Sphingosine	O
1-phosphate	O
(	O
S1P	O
)	O
has	O
assumed	O
great	O
importance	O
within	O
neuroscience	O
research	O
because	O
of	O
putative	O
links	O
between	O
S1P	O
-	O
sensitive	O
Edg	O
receptors	O
and	O
neuroregeneration	O
,	O
cell	O
survival	O
,	O
and	O
alterations	O
in	O
neurite	O
outgrowth	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
mechanisms	O
by	O
which	O
the	O
endogenous	O
complement	O
of	O
S1P	O
-	O
sensitive	O
human	O
Edg	O
receptors	O
can	O
elevate	O
Ca(2+)	O
in	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SH-SY5Y	O
.	O
Reverse	O
transcriptase	O
-	O
polymersase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
confirmed	O
the	O
expression	O
of	O
mRNA	O
for	O
Edg	O
3	O
,	O
5	O
,	O
and	O
8	O
subtypes	O
of	O
S1P-responsive	O
Edg	O
receptors	O
in	O
SH-SY5Y	O
cells	O
.	O
Neither	O
S1P	O
nor	O
the	O
muscarinic	O
agonist	O
methacholine	O
were	O
able	O
to	O
cause	O
a	O
change	O
in	O
SH-SY5Y	O
cell	O
morphology	O
,	O
whereas	O
retinoic	O
acid	O
caused	O
a	O
range	O
of	O
changes	O
,	O
including	O
an	O
increase	O
in	O
neurite	O
outgrowth	O
,	O
under	O
similar	O
test	O
conditions	O
.	O
Stimulation	O
with	O
S1P	O
resulted	O
in	O
a	O
slowly	O
rising	O
increase	O
in	O
cytosolic	O
Ca(2+)	O
levels	O
.	O
These	O
responses	O
were	O
dependent	O
upon	O
inositol-1,4,5-trisphosphate	O
receptors	O
,	O
thapsigargin	O
-	O
sensitive	O
endoplasmic	O
reticulum	O
,	O
and	O
also	O
intact	O
functional	O
mitochondria	O
.	O
S1P-evoked	O
Ca(2+)	O
responses	O
were	O
similar	O
in	O
mechanism	O
to	O
those	O
of	O
methacholine	O
,	O
which	O
activated	O
a	O
much	O
faster	O
responding	O
,	O
larger	O
amplitude	O
Ca(2+)	O
response	O
.	O
These	O
studies	O
indicate	O
that	O
in	O
an	O
endogenous	O
human	O
expression	O
system	O
,	O
S1P	O
appears	O
to	O
be	O
an	O
efficacious	O
agonist	O
of	O
Edg	O
receptors	O
.	O
Despite	O
its	O
slow	O
time	O
course	O
of	O
response	O
,	O
S1P	O
appears	O
to	O
activate	O
the	O
same	O
single	O
Ca(2+)	O
store	O
in	O
SH-SY5Y	O
cells	O
as	O
is	O
activated	O
by	O
methacholine	O
and	O
other	O
G	O
protein	O
coupled	O
receptors	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12836164	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Adv	O
Exp	O
Med	O
Biol	O
.	O
1995	O
;373	O
:91-6.	O
Expression	O
of	O
cannabinoid	O
receptor	O
mRNA	O
in	O
murine	O
and	O
human	O
leukocytes	O
.	O
Daaka	O
Y	O
,	O
Klein	O
TW	O
,	O
Friedman	O
H.	O
Department	O
of	O
Medical	O
Microbiology	O
and	O
Immunology	O
,	O
University	O
of	O
South	O
Florida	O
College	O
of	O
Medicine	O
,	O
Tampa	O
33612	O
,	O
USA	O
.	O
delta	O
9	O
-tetrahydrocannabinol	O
,	O
the	O
major	O
psychoactive	O
cannabinoid	O
of	O
marijuana	O
modulates	O
immune	O
cells	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
It	O
is	O
possible	O
that	O
the	O
drug	O
exerts	O
it	O
's	O
effect	O
either	O
by	O
inserting	O
into	O
and	O
disrupting	O
the	O
cell	O
membrane	O
(	O
nonreceptor	O
mechanism	O
)	O
or	O
by	O
binding	O
to	O
a	O
cannabinoid	O
receptor	O
moiety	O
and	O
thus	O
altering	O
cell	O
function	O
through	O
some	O
form	O
of	O
signal	O
transduction	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
confirm	O
and	O
extend	O
the	O
findings	O
that	O
mouse	O
and	O
human	O
immune	O
cells	O
express	O
specific	O
cannabinoid	O
binding	O
sites	O
and	O
cannabinoid	O
receptor	O
mRNA	O
.	O
Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
the	O
presence	O
of	O
receptor	O
mRNA	O
not	O
only	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
(	O
N18TG-2	O
)	O
,	O
but	O
also	O
in	O
mouse	O
splenocytes	O
and	O
in	O
cell	O
lines	O
such	O
as	O
NKB61A2	O
(	O
a	O
mouse	O
natural	O
killer	O
-	O
like	O
)	O
,	O
CTLL2	O
(	O
a	O
mouse	O
IL2	O
-	O
dependent	O
T	O
cell	O
)	O
,	O
THP-1	O
(	O
a	O
human	O
monocytic	O
cell	O
)	O
and	O
Raji	O
(	O
a	O
human	O
B	O
cell	O
)	O
but	O
not	O
in	O
Jurkat	O
(	O
a	O
human	O
T	O
cell	O
)	O
.	O
Furthermore	O
,	O
the	O
receptor	O
mRNA	O
was	O
expressed	O
in	O
purified	O
populations	O
of	O
resting	O
splenic	O
T	O
and	O
B	O
lymphocytes	O
but	O
not	O
in	O
resting	O
populations	O
of	O
enriched	O
splenic	O
macrophages	O
.	O
Finally	O
,	O
LPS	O
-	O
stimulated	O
Raji	O
and	O
PMA	O
-	O
stimulated	O
THP-1	O
human	O
cell	O
lines	O
showed	O
increased	O
levels	O
of	O
the	O
cannabinoid	O
receptor	O
mRNA	O
.	O
These	O
results	O
suggest	O
cannabinoid	O
receptors	O
have	O
biological	O
relevance	O
in	O
lymphoid	O
cells	O
because	O
:	O
receptor	O
mRNA	O
is	O
detected	O
in	O
some	O
resting	O
immune	O
cells	O
but	O
not	O
others	O
and	O
the	O
mRNA	O
increases	O
during	O
cell	O
activation	O
.	O
The	O
major	O
psychoactive	O
component	O
of	O
marijuana	O
,	O
delta9	O
-tetrahydrocannabinol	O
(	O
THC	O
)	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
human	O
and	O
mouse	O
immune	O
responses	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
1,2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
7545349	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
.	O
2003	O
May	O
1;101	O
(	O
9	O
)	O
:	O
3514	O
-	O
9.	O
Epub	O
2002	O
Dec	O
27	O
.	O
The	O
PML	O
gene	O
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
MHC	O
class	O
I	O
expression	O
in	O
human	O
cell	O
lines	O
.	O
Bruno	O
S	O
,	O
Ghiotto	O
F	O
,	O
Fais	O
F	O
,	O
Fagioli	O
M,	O
Luzi	O
L,	O
Pelicci	O
PG	O
,	O
Grossi	O
CE	O
,	O
Ciccone	O
E.	O
Department	O
of	O
Experimental	O
Medicine	O
,	O
Section	O
of	O
Human	O
Anatomy	O
,	O
Genoa	O
University	O
,	O
Genoa	O
,	O
Italy	O
.	O
silvia	O
.bruno@unige	O
.it	O
The	O
promyelocytic	O
leukemia	O
gene	O
,	O
PML	O
,	O
is	O
a	O
growth	O
and	O
transformation	O
suppressor	O
.	O
An	O
additional	O
role	O
for	O
PML	O
as	O
a	O
regulator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
antigen	O
presentation	O
has	O
been	O
proposed	O
in	O
a	O
murine	O
model	O
,	O
which	O
would	O
account	O
for	O
evasion	O
from	O
host	O
immunity	O
of	O
tumors	O
bearing	O
malfunctioning	O
PML	O
,	O
such	O
as	O
acute	B-malignancy-type
promyelocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Here	O
we	O
investigated	O
a	O
possible	O
role	O
of	O
PML	O
for	O
the	O
control	O
MHC	O
class	O
I	O
expression	O
in	O
human	O
cells	O
.	O
PML	O
function	O
was	O
perturbed	O
in	O
human	O
cell	O
lines	O
either	O
by	O
PML	O
/	O
RAR	O
alpha	O
transfection	O
or	O
by	O
PML	O
-	O
specific	O
RNA	O
interference	O
.	O
Impairment	O
of	O
wild-type	O
PML	O
function	O
was	O
proved	O
by	O
a	O
microspeckled	O
disassembly	O
of	O
nuclear	O
bodies	O
(	O
NBs	O
)	O
,	O
where	O
the	O
protein	O
is	O
normally	O
localized	O
,	O
or	O
by	O
their	O
complete	O
disappearance	O
.	O
However	O
,	O
no	O
MHC	O
class	O
I	O
down	O
-	O
regulation	O
was	O
observed	O
in	O
both	O
instances	O
.	O
We	O
next	O
constructed	O
a	O
PML	O
mutant	O
,	O
PML	O
mut	O
ex3	O
,	O
that	O
is	O
a	O
human	O
homolog	O
of	O
the	O
murine	O
PML	O
mutant	O
,	O
truncated	O
in	O
exon	O
3	O
,	O
that	O
was	O
shown	O
to	O
down	O
-	O
regulate	O
murine	O
MHC	O
class	O
I	O
.	O
PML	O
mut	O
ex3	O
transfected	O
in	O
human	O
cell	O
lines	O
exerted	O
a	O
dominant-	O
negative	O
effect	O
since	O
no	O
PML	O
molecules	O
were	O
detected	O
in	O
NBs	O
but	O
,	O
instead	O
,	O
in	O
perinuclear	O
and	O
cytoplasmic	O
larger	O
dot	O
-	O
like	O
structures	O
.	O
Nevertheless	O
,	O
no	O
down	O
-	O
regulation	O
of	O
MHC	O
class	O
I	O
expression	O
was	O
evident	O
.	O
Moreover	O
,	O
neither	O
transfection	O
with	O
PML	O
mut	O
ex3	O
nor	O
PML	O
-	O
specific	O
RNA	O
interference	O
affected	O
the	O
ability	O
of	O
gamma	O
-	O
interferon	O
to	O
up	O
-	O
regulate	O
MHC	O
class	O
I	O
expression	O
.	O
We	O
conclude	O
that	O
,	O
in	O
human	O
cell	O
lines	O
,	O
PML	O
is	O
not	O
involved	O
directly	O
in	O
the	O
regulation	O
of	O
MHC	O
class	O
I	O
expression	O
.	O
PMID	O
:	O
12506025	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gene	O
.	O
2003	O
Dec	O
24;323	O
:	O
11-	O
8.	O
Isolation	O
of	O
the	O
mouse	O
Tsll1	O
and	O
Tsll2	O
genes	O
,	O
orthologues	O
of	O
the	O
human	O
TSLC1	O
-	O
like	O
genes	O
1	O
and	O
2	O
(	O
TSLL1	O
and	O
TSLL2	O
)	O
.	O
Fukami	O
T	O
,	O
Satoh	O
H,	O
Williams	O
YN	O
,	O
Masuda	O
M,	O
Fukuhara	O
H,	O
Maruyama	O
T	O
,	O
Yageta	O
M,	O
Kuramochi	O
M,	O
Takamoto	O
S	O
,	O
Murakami	O
Y	O
.	O
Tumor	O
Suppression	O
and	O
Functional	O
Genomics	O
Project	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tsukiji	O
5-1-1	O
,	O
Tokyo	O
104	O
-0045	O
,	O
Chuo	O
,	O
Japan	O
.	O
We	O
have	O
recently	O
identified	O
the	O
human	O
TSLL1	O
and	O
TSLL2	O
genes	O
,	O
which	O
are	O
highly	O
homologous	O
to	O
the	O
human	O
lung	O
tumor	O
suppressor	O
gene	O
,	O
TSLC1	O
.	O
Loss	O
of	O
expression	O
of	O
the	O
TSLL1	O
or	O
TSLL2	O
in	O
several	O
cancers	O
suggests	O
that	O
these	O
genes	O
could	O
also	O
act	O
as	O
tumor	O
suppressors	O
.	O
Here	O
,	O
we	O
report	O
the	O
isolation	O
of	O
the	O
mouse	O
orthologous	O
genes	O
,	O
Tsll1	O
and	O
Tsll2	O
.	O
The	O
Tsll1	O
and	O
Tsll2	O
cDNAs	O
contain	O
a	O
single	O
open	O
reading	O
frame	O
of	O
1188	O
and	O
1164	O
bp	O
encoding	O
a	O
putative	O
immunoglobulin	O
-	O
like	O
cell	O
adhesion	O
molecules	O
of	O
396	O
and	O
388	O
amino	O
acids	O
,	O
which	O
display	O
95	O
%	O
and	O
98	O
%	O
identity	O
with	O
those	O
of	O
human	O
TSLL1	O
and	O
TSLL2	O
,	O
respectively	O
.	O
The	O
Tsll1	O
and	O
Tsll2	O
genes	O
are	O
both	O
composed	O
of	O
nine	O
exons	O
and	O
mapped	O
on	O
mouse	O
chromosome	O
1q	O
H2-H4	O
and	O
on	O
7q	O
A3-B2	O
,	O
respectively	O
,	O
both	O
of	O
which	O
conserve	O
syntenies	O
with	O
human	O
chromosomes	O
1q	O
and	O
19q	O
.	O
Like	O
the	O
human	O
TSLL1	O
,	O
the	O
mouse	O
Tsll1	O
was	O
expressed	O
exclusively	O
in	O
the	O
brain	O
and	O
neurogenic	O
cells	O
,	O
while	O
Tsll1	O
expression	O
was	O
lost	O
in	O
one	O
of	O
four	O
rodent	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Tsll2	O
was	O
expressed	O
in	O
the	O
brain	O
and	O
several	O
organs	O
including	O
the	O
kidney	O
and	O
liver	O
,	O
whereas	O
loss	O
of	O
Tsll2	O
expression	O
was	O
detected	O
in	O
some	O
rodent	O
cancer	O
cells	O
derived	O
from	O
these	O
tissues	O
.	O
Furthermore	O
,	O
both	O
murine	O
TSLL1	O
and	O
TSLL2	O
proteins	O
were	O
expressed	O
on	O
the	O
plasma	O
membrane	O
,	O
especially	O
at	O
the	O
cell	O
-	O
cell	O
attached	O
site	O
.	O
These	O
data	O
,	O
together	O
with	O
their	O
strong	O
conservation	O
during	O
the	O
vertebrate	O
evolution	O
,	O
suggest	O
that	O
TSLL1	O
and	O
TSLL2	O
could	O
play	O
an	O
important	O
role	O
in	O
cell	O
-	O
cell	O
interaction	O
as	O
well	O
as	O
in	O
tumor	O
suppression	O
.	O
PMID	O
:	O
14659875	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
1994	O
Aug	O
22	O
;654	O
(	O
2	O
)	O
:312-8.	O
alpha	O
4	O
beta	O
2	O
subunit	O
combination	O
specific	O
pharmacology	O
of	O
neuronal	O
nicotinic	O
acetylcholine	O
receptors	O
in	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Zwart	O
R	O
,	O
Abraham	O
D	O
,	O
Oortgiesen	O
M,	O
Vijverberg	O
HP	O
.	O
Research	O
Institute	O
of	O
Toxicology	O
,	O
Utrecht	O
University	O
,	O
The	O
Netherlands	O
.	O
Pharmacological	O
characteristics	O
of	O
native	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
-	O
mediated	O
ion	O
currents	O
in	O
mouse	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
have	O
been	O
investigated	O
by	O
superfusion	O
of	O
voltage	O
clamped	O
cells	O
with	O
known	O
concentrations	O
of	O
the	O
agonists	O
acetylcholine	O
,	O
nicotine	O
and	O
cytisine	O
,	O
and	O
the	O
antagonists	O
alpha-bungarotoxin	O
and	O
neuronal	O
bungarotoxin	O
.	O
The	O
sensitivity	O
of	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
for	O
agonists	O
followed	O
the	O
agonist	O
potency	O
rank-order	O
:	O
nicotine	O
approximately	O
acetylcholine	O
>	O
>	O
cytisine	O
.	O
The	O
EC50	O
values	O
of	O
acetylcholine	O
and	O
nicotine	O
are	O
78	O
microM	O
and	O
76	O
microM	O
,	O
respectively	O
.	O
Equal	O
concentrations	O
of	O
acetylcholine	O
and	O
nicotine	O
induce	O
inward	O
currents	O
with	O
approximately	O
the	O
same	O
peak	O
amplitude	O
whereas	O
cytisine	O
induces	O
much	O
smaller	O
inward	O
currents	O
.	O
Acetylcholine	O
-	O
induced	O
currents	O
are	O
unaffected	O
by	O
high	O
concentrations	O
of	O
alpha-bungarotoxin	O
.	O
Conversely	O
,	O
at	O
10	O
and	O
90	O
nM	O
neuronal	O
bungarotoxin	O
reduces	O
the	O
amplitude	O
of	O
the	O
1	O
mM	O
acetylcholine	O
-	O
induced	O
inward	O
current	O
to	O
47	O
%	O
and	O
11	O
%	O
of	O
control	O
values	O
,	O
respectively	O
.	O
Both	O
the	O
agonist	O
potency	O
rank-order	O
and	O
the	O
differential	O
sensitivity	O
to	O
snake	O
toxins	O
of	O
nicotinic	O
receptors	O
in	O
N1E-115	O
cells	O
are	O
consistent	O
with	O
the	O
known	O
pharmacological	O
profile	O
of	O
alpha	O
4	O
beta	O
2	O
nicotinic	O
receptors	O
expressed	O
in	O
Xenopus	O
oocytes	O
and	O
distinct	O
from	O
those	O
of	O
all	O
other	O
nicotinic	O
acetylcholine	O
receptors	O
of	O
known	O
functional	O
subunit	O
compositions	O
.	O
All	O
data	O
indicate	O
that	O
the	O
native	O
nicotinic	O
acetylcholine	O
receptor	O
in	O
N1E-115	O
cells	O
is	O
an	O
assembly	O
of	O
alpha	O
4	O
and	O
beta	O
2	O
subunits	O
,	O
the	O
putative	O
major	O
subtype	O
of	O
nicotinic	O
acetylcholine	O
receptor	O
in	O
the	O
brain	O
.	O
PMID	O
:	O
7527290	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
2003	O
Sep	O
30	O
;100(	O
20	O
)	O
:	O
11523	O
-	O
8.	O
Epub	O
2003	O
Sep	O
22	O
.	O
CCAAT	O
-binding	O
factor	O
regulates	O
expression	O
of	O
the	O
beta1	O
subunit	O
of	O
soluble	O
guanylyl	O
cyclase	O
gene	O
in	O
the	O
BE2	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Sharina	O
IG	O
,	O
Martin	O
E	O
,	O
Thomas	O
A	O
,	O
Uray	O
KL	O
,	O
Murad	O
F.	O
Department	O
of	O
Integrative	O
Biology	O
and	O
Pharmacology	O
and	O
Institute	O
of	O
Molecular	O
Medicine	O
,	O
University	O
of	O
Texas	O
Medical	O
School	O
,	O
6431	O
Fannin	O
,	O
Houston	O
,	O
TX	O
77030	O
,	O
USA	O
.	O
Soluble	O
guanylyl	O
cyclase	O
(	O
sGC	O
)	O
is	O
a	O
cytosolic	O
enzyme	O
producing	O
the	O
intracellular	O
messenger	O
cyclic	O
guanosine	O
monophosphate	O
(	O
cGMP	O
)	O
on	O
activation	O
with	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O
sGC	O
is	O
an	O
obligatory	O
heterodimer	O
composed	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O
We	O
investigated	O
human	O
beta1	O
sGC	O
transcriptional	O
regulation	O
in	O
BE2	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
5	O
'	O
upstream	O
region	O
of	O
the	O
beta1	O
sGC	O
gene	O
was	O
isolated	O
and	O
analyzed	O
for	O
promoter	O
activity	O
by	O
using	O
luciferase	O
reporter	O
constructs	O
.	O
The	O
transcriptional	O
start	O
site	O
of	O
the	O
beta1	O
sGC	O
gene	O
in	O
BE2	O
cells	O
was	O
identified	O
.	O
The	O
functional	O
significance	O
of	O
consensus	O
transcriptional	O
factor	O
binding	O
sites	O
proximal	O
to	O
the	O
transcriptional	O
start	O
site	O
was	O
investigated	O
by	O
site	O
deletions	O
in	O
the	O
800	O
-	O
bp	O
promoter	O
fragment	O
.	O
The	O
elimination	O
of	O
CCAAT	O
-binding	O
factor	O
(	O
CBF	O
)	O
and	O
growth	O
factor	O
independence	O
1	O
(	O
GFI1	O
)	O
binding	O
cores	O
significantly	O
diminished	O
whereas	O
deletion	O
of	O
the	O
NF1	O
core	O
elevated	O
the	O
transcription	O
.	O
Electrophoretic	O
mobility	O
-	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
Western	O
analysis	O
of	O
proteins	O
bound	O
to	O
biotinated	O
EMSA	O
probes	O
confirmed	O
the	O
interaction	O
of	O
GFI1	O
,	O
CBF	O
,	O
and	O
NF1	O
factors	O
with	O
the	O
beta1	O
sGC	O
promoter	O
.	O
Treatment	O
of	O
BE2	O
cells	O
with	O
genistein	O
,	O
known	O
to	O
inhibit	O
the	O
CBF	O
binding	O
to	O
DNA	O
,	O
significantly	O
reduced	O
protein	O
levels	O
of	O
beta1	O
sGC	O
by	O
inhibiting	O
transcription	O
.	O
In	O
summary	O
,	O
our	O
study	O
represents	O
an	O
analysis	O
of	O
the	O
human	O
beta1	O
sGC	O
promoter	O
regulation	O
in	O
human	O
neuroblastoma	B-malignancy-type
BE2	O
cells	O
and	O
identifies	O
CBF	O
as	O
a	O
critically	O
important	O
factor	O
in	O
beta1	O
sGC	O
expression	O
.	O
PMID	O
:	O
14504408	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prog	O
Clin	O
Biol	O
Res	O
.	O
1994;385	O
:	O
51	O
-	O
7.	O
High	O
-	O
resolution	O
mapping	O
of	O
the	O
N-myc	O
amplicon	O
core	O
domain	O
in	O
neuroblastomas	B-malignancy-type
.	O
Hiemstra	O
JL	O
,	O
Schneider	O
SS	O
,	O
Brodeur	O
GM	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
Missouri	O
63110	O
.	O
The	O
N-myc	O
proto	O
-	O
oncogene	O
is	O
amplified	O
in	O
25	O
%	O
of	O
neuroblastomas	B-malignancy-type
.	O
Amplification	O
is	O
strongly	O
correlated	O
with	O
advanced	O
disease	O
stage	O
and	O
rapid	O
tumor	O
progression	O
.	O
We	O
have	O
constructed	O
a	O
detailed	O
restriction	O
map	O
of	O
the	O
amplified	O
core	O
region	O
in	O
neuroblastomas	B-malignancy-type
which	O
will	O
allow	O
the	O
identification	O
of	O
structural	O
features	O
such	O
as	O
joint	O
fragments	O
,	O
rearrangements	O
and	O
CpG	O
islands	O
.	O
Using	O
probes	O
that	O
had	O
been	O
obtained	O
previously	O
,	O
twenty	O
YACs	O
were	O
isolated	O
from	O
a	O
library	O
constructed	O
from	O
a	O
double	O
-	O
minute	O
-	O
containing	O
neuroblastoma	B-malignancy-type
cell	O
line	O
with	O
150	O
-	O
fold	O
amplification	O
of	O
N-myc	O
.	O
Twenty-one	O
YACs	O
also	O
were	O
isolated	O
from	O
two	O
normal	O
human	O
libraries	O
.	O
Normal	O
and	O
neuroblastoma	B-malignancy-type
YAC	O
contiguous	O
arrays	O
(	O
contigs	O
)	O
,	O
each	O
spanning	O
over	O
1	O
Mb	O
of	O
DNA	O
,	O
have	O
been	O
assembled	O
(	O
Molec	O
Cell	O
Biol	O
12	O
:	O
5563	O
,	O
1992	O
)	O
.	O
A	O
high	O
-	O
resolution	O
restriction	O
map	O
of	O
over	O
200	O
kb	O
of	O
contiguous	O
DNA	O
containing	O
N-myc	O
has	O
been	O
generated	O
by	O
subcloning	O
YACs	O
into	O
cosmids	O
.	O
Using	O
cosmids	O
from	O
this	O
region	O
plus	O
additional	O
amplified	O
probes	O
,	O
we	O
have	O
determined	O
that	O
the	O
amplicons	O
from	O
33	O
neuroblastomas	B-malignancy-type
range	O
in	O
size	O
from	O
350	O
kb	O
to	O
over	O
1	O
Mb	O
.	O
Rearrangements	O
and	O
deletions	O
were	O
identified	O
in	O
both	O
tumors	O
and	O
cell	O
lines	O
.	O
However	O
joint	O
fragments	O
were	O
not	O
always	O
amplified	O
to	O
the	O
same	O
level	O
as	O
the	O
major	O
amplicon	O
,	O
and	O
may	O
therefore	O
represent	O
a	O
subset	O
of	O
amplicons	O
.	O
We	O
have	O
defined	O
a	O
130	O
kb	O
region	O
which	O
was	O
amplified	O
in	O
32	O
of	O
the	O
33	O
tumors	O
,	O
and	O
one	O
additional	O
tumor	O
had	O
deleted	O
65	O
kb	O
of	O
this	O
region	O
from	O
its	O
amplicon	O
.	O
The	O
only	O
CpG	O
island	O
found	O
in	O
this	O
region	O
was	O
within	O
the	O
N-myc	O
gene	O
.	O
Cosmids	O
were	O
screened	O
with	O
radiolabeled	O
total	O
cDNA	O
probes	O
and	O
no	O
highly	O
expressed	O
genes	O
other	O
than	O
N-myc	O
were	O
found	O
in	O
the	O
amplicon	O
.	O
PMID	O
:	O
7972237	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Neurosci	O
.	O
1999	O
Mar;11(	O
3	O
)	O
:959	O
-	O
66	O
.	O
Expression	O
of	O
Ras	O
-	O
GRF	O
in	O
the	O
SK-N-BE	O
neuroblastoma	B-malignancy-type
accelerates	O
retinoic	O
-acid	O
-	O
induced	O
neuronal	O
differentiation	O
and	O
increases	O
the	O
functional	O
expression	O
of	O
the	O
IRK1	O
potassium	O
channel	O
.	O
Tonini	O
R	O
,	O
Mancinelli	O
E	O
,	O
Balestrini	O
M,	O
Mazzanti	O
M,	O
Martegani	O
E	O
,	O
Ferroni	O
A	O
,	O
Sturani	O
E	O
,	O
Zippel	O
R.	O
Dipartimento	O
di	O
Fishologia	O
e	O
Biochimica	O
Generali	O
,	O
Univerita	O
degli	O
Studi	O
di	O
Milano	O
,	O
Via	O
Celoria	O
26	O
,	O
20133	O
Milano	O
,	O
Italy	O
.	O
Ras	O
-	O
GRF	O
,	O
a	O
neuron	O
-	O
specific	O
Ras	O
exchange	O
factor	O
of	O
the	O
central	O
nervous	O
system	O
,	O
was	O
transfected	O
in	O
the	O
SK-N-BE	O
neuroblastoma	B-malignancy-type
cell	O
line	O
and	O
stable	O
clones	O
were	O
obtained	O
.	O
When	O
exposed	O
to	O
retinoic	O
acid	O
,	O
these	O
clones	O
showed	O
a	O
remarkable	O
enhancement	O
of	O
Ras	O
-	O
GRF	O
expression	O
with	O
a	O
concomitant	O
high	O
increase	O
in	O
the	O
level	O
of	O
active	O
(	O
GTP	O
-bound	O
)	O
Ras	O
already	O
after	O
24	O
h	O
of	O
treatment	O
.	O
In	O
the	O
presence	O
of	O
retinoic	O
acid	O
,	O
the	O
transfected	O
cells	O
stopped	O
growing	O
and	O
acquired	O
a	O
differentiated	O
neuronal	O
-	O
like	O
phenotype	O
more	O
rapidly	O
than	O
the	O
parental	O
ones	O
.	O
Cells	O
expressing	O
Ras	O
-	O
GRF	O
also	O
exhibited	O
a	O
more	O
hyperpolarized	O
membrane	O
potential	O
.	O
Moreover	O
,	O
treatment	O
with	O
retinoic	O
acid	O
led	O
to	O
the	O
appearance	O
of	O
an	O
inward	O
rectifying	O
potassium	O
channel	O
with	O
electrophysiological	O
properties	O
similar	O
to	O
IRK1	O
.	O
This	O
current	O
was	O
present	O
in	O
a	O
large	O
number	O
of	O
cells	O
expressing	O
Ras	O
-	O
GRF	O
,	O
while	O
only	O
a	O
small	O
percentage	O
of	O
parental	O
cells	O
exhibited	O
this	O
current	O
.	O
However	O
,	O
Northern	O
analysis	O
with	O
a	O
murine	O
cDNA	O
probe	O
indicated	O
that	O
IRK1	O
mRNA	O
was	O
induced	O
by	O
retinoic	O
acid	O
at	O
a	O
similar	O
level	O
in	O
both	O
kinds	O
of	O
cells	O
.	O
Brief	O
treatment	O
with	O
a	O
specific	O
inhibitor	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
reduced	O
the	O
number	O
of	O
transfected	O
cells	O
showing	O
IRK1	O
activity	O
.	O
These	O
findings	O
suggest	O
that	O
activation	O
of	O
the	O
Ras	O
pathway	O
accelerates	O
neuronal	O
differentiation	O
of	O
this	O
cell	O
line	O
.	O
In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
Ras	O
-	O
GRF	O
and/or	O
Ras	O
-	O
pathway	O
may	O
have	O
a	O
modulatory	O
effect	O
on	O
IRK1	O
channel	O
activity	O
.	O
PMID	O
:	O
10103089	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2000	O
Jun;34	O
(	O
6	O
)	O
:	O
394	O
-401	O
.	O
Neuronal	O
differentiation	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
by	O
nerve	O
growth	O
factor	O
following	O
TrkA	O
up	O
-	O
regulation	O
by	O
interferon	O
-	O
gamma	O
.	O
Shikata	O
A	O
,	O
Shikata	O
T	O
,	O
Sotozono	O
Y	O
,	O
Hosoi	O
H,	O
Matsumura	O
T	O
,	O
Sugimoto	O
T	O
,	O
Sawada	O
T.	O
Department	O
of	O
Pediatrics	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Kyoto	O
,	O
Japan	O
.	O
ashikata@mailcity.com	O
BACKGROUND	O
:	O
TrkA	O
mRNA	O
expression	O
has	O
been	O
reported	O
to	O
be	O
related	O
to	O
favorable	O
outcome	O
of	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
.	O
Previously	O
,	O
we	O
found	O
that	O
interferon	O
-	O
gamma	O
(	O
IFN-gamma	O
)	O
can	O
enhance	O
TrkA	O
mRNA	O
expression	O
in	O
NB	B-malignancy-type
cell	O
lines	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
on	O
IFN-gamma	O
-	O
induced	O
TrkA	O
protein	O
to	O
clarify	O
the	O
relationship	O
between	O
TrkA	O
and	O
cell	O
differentiation	O
of	O
NB	B-malignancy-type
.	O
PROCEDURE	O
:	O
The	O
effect	O
of	O
IFN-gamma	O
on	O
the	O
TrkA	O
mRNA	O
expression	O
was	O
screened	O
in	O
six	O
human	O
NB	B-malignancy-type
cell	O
lines	O
and	O
a	O
freshly	O
prepared	O
sample	O
,	O
SK-rib	O
,	O
from	O
a	O
stage	O
IV	O
patient	O
.	O
Using	O
two	O
of	O
them	O
,	O
we	O
examined	O
their	O
morphological	O
change	O
during	O
simultaneous	O
loading	O
of	O
NGF	O
and	O
IFN-gamma	O
.	O
Tyrosine	O
phosphorylation	O
pattern	O
after	O
5	O
min	O
of	O
NGF	O
stimulation	O
was	O
also	O
examined	O
in	O
immunoblot	O
analysis	O
with	O
anti	O
-	O
gp140	O
(	O
trkA	O
)	O
antibody	O
and	O
antiphospho	O
tyrosine	O
antibody	O
.	O
RESULTS	O
:	O
After	O
a	O
4-	O
day	O
treatment	O
with	O
500	O
IU	O
/	O
ml	O
IFN-gamma	O
,	O
TrkA	O
mRNA	O
increased	O
in	O
five	O
cell	O
lines	O
and	O
SK-rib	O
cells	O
in	O
association	O
with	O
growth	O
inhibition	O
.	O
Although	O
the	O
degree	O
of	O
morphological	O
differentiation	O
did	O
not	O
increase	O
in	O
proportion	O
to	O
the	O
TrkA	O
expression	O
induced	O
by	O
IFN-gamma	O
,	O
continuous	O
loading	O
of	O
both	O
IFN-gamma	O
and	O
NGF	O
caused	O
marked	O
morphological	O
differentiation	O
in	O
a	O
cultured	O
KP-N-RT	O
cell	O
line	O
and	O
SK-rib	O
cells	O
during	O
10	O
days	O
.	O
Moreover	O
,	O
5	O
min	O
of	O
NGF	O
stimulation	O
after	O
IFN-gamma	O
treatment	O
caused	O
the	O
phosphorylation	O
of	O
TrkA	O
protein	O
and	O
downstream	O
proteins	O
.	O
CONCLUSIONS	O
:	O
IFN-gamma	O
could	O
induce	O
the	O
functional	O
NGF	O
receptor	O
even	O
in	O
the	O
aggressive	O
phenotype	O
of	O
NB	B-malignancy-type
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
10842245	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Environ	O
Health	O
Perspect	O
.	O
1991	O
Jun;93	O
:121-3.	O
Chromosomal	O
localization	O
of	O
putative	O
tumor	O
-	O
suppressor	O
genes	O
in	O
several	O
human	O
cancers	O
.	O
Yokota	O
J,	O
Sugimura	O
T	O
,	O
Terada	O
M.	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Restriction	O
-	O
fragment	O
-	O
length	O
polymorphism	O
analysis	O
was	O
performed	O
on	O
several	O
different	O
types	O
of	O
human	O
cancers	O
,	O
including	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
cervix	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
pheochromocytoma	B-malignancy-type
,	O
stomach	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
(	O
SCLC	B-malignancy-type
)	O
,	O
to	O
determine	O
the	O
chromosomal	O
loci	O
of	O
putative	O
tumor	O
-	O
suppressor	O
genes	O
in	O
each	O
type	O
of	O
tumor	O
because	O
less	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
is	O
supposed	O
to	O
unmask	O
the	O
recessive	O
mutation	O
of	O
tumor	O
-	O
suppressor	O
gene	O
in	O
the	O
remaining	O
allele	O
.	O
Chromosomal	O
loci	O
showing	O
frequent	O
LOH	O
differed	O
among	O
these	O
tumors	O
,	O
suggesting	O
that	O
there	O
are	O
several	O
tumor	O
-	O
suppressor	O
genes	O
in	O
the	O
human	O
genome	O
and	O
that	O
critical	O
genes	O
for	O
the	O
development	O
of	O
each	O
type	O
of	O
tumor	O
are	O
different	O
.	O
In	O
some	O
cases	O
LOH	O
was	O
observed	O
in	O
the	O
early	O
stage	O
of	O
tumor	O
such	O
as	O
chromosome	O
3p	O
loss	O
in	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
cervix	I-malignancy-type
,	O
and	O
in	O
other	O
cases	O
it	O
was	O
observed	O
only	O
in	O
the	O
advanced	O
stage	O
of	O
tumor	O
such	O
as	O
chromosomes	O
4	O
and	O
16q	O
loss	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
there	O
are	O
two	O
different	O
types	O
of	O
tumor	O
-	O
suppressor	O
genes	O
:	O
one	O
is	O
the	O
gene	O
whose	O
inactivation	O
is	O
responsible	O
for	O
malignant	O
transformation	O
of	O
a	O
normal	O
cell	O
and	O
the	O
other	O
is	O
the	O
gene	O
whose	O
inactivation	O
is	O
responsible	O
for	O
the	O
progression	O
of	O
a	O
tumor	O
cell	O
.	O
In	O
SCLC	B-malignancy-type
,	O
LOH	O
at	O
three	O
different	O
chromosomal	O
loci	O
,	O
3p	O
,	O
13q	O
,	O
and	O
17p	O
,	O
was	O
simultaneously	O
observed	O
in	O
nearly	O
100	O
%	O
of	O
tumors	O
.	O
It	O
was	O
observed	O
even	O
in	O
stage	O
I	O
tumors	O
and	O
an	O
untreated	O
tumor	O
,	O
and	O
it	O
occurred	O
prior	O
to	O
N-myc	O
amplification	O
.	O
These	O
results	O
may	O
imply	O
that	O
at	O
least	O
six	O
genetic	O
alterations	O
are	O
necessary	O
to	O
convert	O
a	O
normal	O
cell	O
into	O
a	O
fully	O
malignant	O
cancer	O
cell	O
in	O
SCLC	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
1685440	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1993	O
Dec	O
1;72	O
(	O
11	O
)	O
:	O
3346-54	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
that	O
express	O
N-myc	O
without	O
gene	O
amplification	O
.	O
Wada	O
RK	O
,	O
Seeger	O
RC	O
,	O
Brodeur	O
GM	O
,	O
Einhorn	O
PA	O
,	O
Rayner	O
SA	O
,	O
Tomayko	O
MM	O
,	O
Reynolds	O
CP	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Children	O
's	O
Hospital	O
of	O
Los	O
Angeles	O
,	O
CA	O
90027	O
.	O
BACKGROUND.	O
About	O
one	O
half	O
of	O
aggressive	O
neuroblastomas	B-malignancy-type
lack	O
N-myc	O
amplification	O
.	O
Cell	O
lines	O
from	O
such	O
tumors	O
are	O
needed	O
to	O
determine	O
the	O
biological	O
basis	O
of	O
aggressive	O
tumor	O
behavior	O
.	O
METHODS	O
.	O
Neuroblastoma	B-malignancy-type
cell	O
lines	O
were	O
established	O
from	O
a	O
primary	O
tumor	O
(	O
SMS	O
-LHN	O
)	O
and	O
a	O
bone	O
marrow	O
metastasis	O
(	O
LA-N-6	O
)	O
of	O
two	O
children	O
with	O
Stage	O
IV	O
neuroblastoma	B-malignancy-type
.	O
Although	O
both	O
cell	O
lines	O
and	O
their	O
original	O
tumors	O
lacked	O
N-myc	O
genomic	O
amplification	O
,	O
these	O
patients	O
died	O
of	O
progressive	O
disease	O
.	O
RESULTS	O
.	O
SMS	O
-LHN	O
and	O
LA-N-6	O
can	O
be	O
distinguished	O
from	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
(	O
PNET	B-malignancy-type
)	O
lines	O
by	O
cell	O
surface	O
antigen	O
expression	O
and	O
catecholamine	O
production	O
.	O
Cytogenetic	O
analysis	O
of	O
each	O
cell	O
line	O
revealed	O
unique	O
genetic	O
rearrangements	O
,	O
whereas	O
both	O
lines	O
showed	O
abnormalities	O
involving	O
chromosome	O
2	O
.	O
Neither	O
cell	O
line	O
contained	O
double	O
-	O
minute	O
chromosomes	O
,	O
homogeneously	O
staining	O
regions	O
,	O
a	O
1p	O
chromosomal	O
deletion	O
,	O
or	O
t	O
(	O
11	O
;	O
22	O
)	O
.	O
The	O
growth	O
rates	O
of	O
these	O
two	O
new	O
lines	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
as	O
xenografts	O
in	O
nude	O
mice	O
)	O
are	O
slower	O
than	O
N-myc	O
amplified	O
neuroblastoma	B-malignancy-type
lines	O
.	O
Both	O
lines	O
express	O
greater	O
amounts	O
of	O
N-myc	O
RNA	O
and	O
protein	O
relative	O
to	O
nonneuroblastoma	O
cell	O
lines	O
(	O
including	O
PNET	O
)	O
,	O
although	O
not	O
to	O
the	O
extent	O
of	O
cell	O
lines	O
with	O
N-myc	O
genomic	O
amplification	O
.	O
CONCLUSIONS	O
.	O
The	O
relatively	O
large	O
amount	O
of	O
N-myc	O
expression	O
in	O
these	O
two	O
new	O
cell	O
lines	O
suggests	O
that	O
N-myc	O
expression	O
without	O
amplification	O
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
neuroblastomas	B-malignancy-type
.	O
These	O
cell	O
lines	O
should	O
be	O
useful	O
for	O
investigating	O
mechanisms	O
and	O
consequences	O
of	O
N-myc	O
gene	O
activation	O
other	O
than	O
genomic	O
amplification	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
8242562	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
2002	O
Oct	O
28;18	O
4	O
(	O
2	O
)	O
:	O
127	O
-47	O
.	O
Genetic	O
parameters	O
of	O
neuroblastomas	B-malignancy-type
.	O
Westermann	O
F	O
,	O
Schwab	O
M.	O
Department	O
of	O
Cytogenetics	O
(	O
H0400	O
)	O
,	O
German	O
Cancer	O
Research	O
Center	O
,	O
Im	O
Neuenheimer	O
Feld	O
280	O
,	O
69120	O
Heidelberg	O
,	O
Germany	O
.	O
f.westermann@dkfz.de	O
Neuroblastoma	B-malignancy-type
is	O
a	O
malignant	O
childhood	O
tumor	O
of	O
migrating	O
neuroectodermal	O
cells	O
derived	O
from	O
the	O
neural	O
crest	O
and	O
destined	O
for	O
the	O
adrenal	O
medulla	O
and	O
the	O
sympathetic	O
nervous	O
system	O
.	O
The	O
biological	O
behavior	O
of	O
neuroblastomas	B-malignancy-type
is	O
extremely	O
variable	O
and	O
in	O
some	O
respects	O
unique	O
.	O
Neuroblastomas	B-malignancy-type
tend	O
to	O
regress	O
spontaneously	O
in	O
a	O
portion	O
of	O
infants	O
or	O
to	O
differentiate	O
into	O
a	O
benign	O
ganglioneuroma	B-malignancy-type
in	O
some	O
older	O
patients	O
.	O
Unfortunately	O
,	O
in	O
the	O
majority	O
of	O
patients	O
neuroblastoma	B-malignancy-type
is	O
metastatic	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
and	O
it	O
usually	O
undergoes	O
rapid	O
progression	O
with	O
a	O
fatal	O
outcome	O
.	O
The	O
mechanisms	O
leading	O
to	O
this	O
diverse	O
clinical	O
behavior	O
of	O
neuroblastomas	B-malignancy-type
are	O
largely	O
unclear	O
.	O
From	O
the	O
analysis	O
of	O
tumors	O
at	O
the	O
cytogenetic	O
and	O
molecular	O
level	O
non	O
-	O
random	O
genetic	O
changes	O
have	O
been	O
identified	O
,	O
including	O
ploidy	O
changes	O
,	O
amplification	O
of	O
the	O
oncogene	O
MYCN	O
,	O
deletions	O
of	O
chromosome	O
1p	O
,	O
gains	O
of	O
chromosome	O
arm	O
17q	O
,	O
and	O
deletions	O
of	O
11q	O
as	O
well	O
as	O
of	O
other	O
genomic	O
regions	O
that	O
allow	O
tumors	O
to	O
be	O
classified	O
into	O
subsets	O
with	O
distinct	O
biological	O
features	O
and	O
clinical	O
behavior	O
.	O
MYCN	O
status	O
is	O
widely	O
accepted	O
for	O
therapy	O
stratification	O
.	O
Additional	O
genetic	O
parameters	O
are	O
currently	O
under	O
investigation	O
to	O
refine	O
risk	O
assessment	O
,	O
but	O
so	O
far	O
the	O
molecular	O
monitoring	O
tools	O
for	O
prediction	O
of	O
therapy	O
response	O
and	O
disease	O
outcome	O
are	O
still	O
incomplete	O
.	O
This	O
should	O
lead	O
to	O
more	O
risk	O
-adapted	O
therapies	O
according	O
to	O
the	O
clinical	O
-	O
genetic	O
parameters	O
by	O
which	O
individual	O
tumors	O
are	O
characterized	O
.	O
This	O
review	O
aims	O
at	O
discussing	O
the	O
role	O
of	O
genomic	O
changes	O
in	O
neuroblastomas	B-malignancy-type
of	O
diverse	O
biological	O
and	O
clinical	O
types	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Academic	O
PMID	O
:	O
12127685	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1998	O
Aug;34	O
(	O
9	O
)	O
:	O
139	O
8-402	O
.	O
Treatment	O
of	O
neuroblastoma	B-malignancy-type
stage	O
4	O
with	O
131I-meta	O
-	O
iodo-benzylguanidine	O
,	O
high	O
-dose	O
chemotherapy	O
and	O
immunotherapy	O
.	O
A	O
pilot	O
study	O
.	O
Klingebiel	O
T	O
,	O
Bader	O
P,	O
Bares	O
R	O
,	O
Beck	O
J,	O
Hero	O
B	O
,	O
Jurgens	O
H,	O
Lang	O
P,	O
Niethammer	O
D	O
,	O
Rath	O
B	O
,	O
Handgretinger	O
R.	O
Childrens	O
Hospital	O
,	O
University	O
of	O
Tubingen	O
,	O
Germany	O
.	O
Disseminated	O
neuroblastoma	B-malignancy-type
after	O
infancy	O
has	O
a	O
prognosis	O
of	O
approximately	O
10-	O
20	O
%	O
with	O
conventional	O
therapy	O
.	O
We	O
investigated	O
the	O
role	O
of	O
high	O
-dose	O
chemotherapy	O
(	O
HDCT	O
)	O
with	O
peripheral	O
blood	O
stem	O
cell	O
(	O
PBSC	O
)	O
rescue	O
in	O
combination	O
with	O
131I-metaiodobenzylguanidine	O
(	O
[131I-m]IBG	O
)	O
.	O
11	O
children	O
with	O
neuroblastoma	B-malignancy-type
stage	O
4	O
were	O
pretreated	O
within	O
the	O
German	O
Neuroblastoma	B-malignancy-type
Trial	O
NB90	O
and	O
included	O
in	O
a	O
high	O
-dose	O
concept	O
for	O
consolidation	O
.	O
Remission	O
was	O
documented	O
by	O
ultrasound	O
,	O
CT	O
,	O
NMR	O
,	O
or	O
[123I-m]IBG	O
scanning	O
.	O
HDCT	O
was	O
a	O
combination	O
of	O
melphalan	O
(	O
180	O
mg	O
/	O
m2	O
)	O
,	O
carboplatin	O
(	O
1,500	O
mg	O
/	O
m2	O
)	O
and	O
etoposide	O
(	O
40	O
mg	O
/	O
kg	O
)	O
.	O
All	O
children	O
were	O
treated	O
by	O
[131I-m]IBG	O
(	O
0.58	O
GBq	O
/	O
kg	O
)	O
prior	O
to	O
high	O
-dose	O
treatment	O
.	O
All	O
11	O
children	O
were	O
additionally	O
treated	O
with	O
antiGD2	O
murine	O
-	O
or	O
chimeric	O
-	O
antibody	O
(	O
ch14.18	O
)	O
.	O
4	O
children	O
had	O
no	O
change	O
to	O
their	O
remission	O
status	O
but	O
three	O
achieved	O
a	O
complete	O
response	O
(	O
from	O
a	O
partial	O
response	O
to	O
first	O
line	O
)	O
and	O
one	O
a	O
partial	O
response	O
(	O
from	O
no	O
response	O
to	O
first	O
line	O
)	O
.	O
The	O
other	O
3	O
children	O
progressed	O
,	O
2	O
dying	O
of	O
their	O
disease	O
.	O
Using	O
Kaplan-Meier	O
analysis	O
,	O
the	O
probability	O
of	O
progression	O
-	O
free	O
survival	O
was	O
0.70	O
+/-	O
0.15	O
with	O
a	O
median	O
observation	O
time	O
of	O
19	O
months	O
.	O
9	O
/	O
11	O
children	O
are	O
alive	O
,	O
8	O
without	O
progression	O
or	O
relapse	O
,	O
whilst	O
2	O
have	O
died	O
of	O
their	O
disease	O
.	O
The	O
combination	O
of	O
mIBG	O
plus	O
high	O
-dose	O
chemotherapy	O
with	O
PBSC	O
support	O
supplemented	O
by	O
immunotherapy	O
with	O
antiGD2	O
antibody	O
appears	O
to	O
be	O
a	O
feasible	O
and	O
effective	O
treatment	O
regimen	O
for	O
disseminated	O
neuroblastoma	B-malignancy-type
in	O
this	O
limited	O
series	O
.	O
Larger	O
numbers	O
of	O
patients	O
should	O
be	O
treated	O
to	O
confirm	O
these	O
results	O
.	O
PMID	O
:	O
9849423	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
Surg	O
.	O
2003	O
Dec;38	O
(	O
12	O
)	O
:1730	O
-4.	O
Differential	O
gene	O
expression	O
profiles	O
between	O
neuroblastomas	B-malignancy-type
with	O
high	O
telomerase	O
activity	O
and	O
low	O
telomerase	O
activity	O
.	O
Hiyama	O
E	O
,	O
Hiyama	O
K,	O
Nishiyama	O
M,	O
Reynolds	O
CP	O
,	O
Shay	O
JW	O
,	O
Yokoyama	O
T.	O
Department	O
of	O
General	O
Medicine	O
,	O
Graduate	O
School	O
of	O
Biomedical	O
Sciences	O
,	O
Hiroshima	O
University	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
PURPOSE	O
:	O
Neuroblastoma	B-malignancy-type
shows	O
remarkable	O
heterogeneity	O
,	O
resulting	O
in	O
favorable	O
or	O
unfavorable	O
outcomes	O
.	O
The	O
authors	O
previously	O
reported	O
that	O
high	O
levels	O
of	O
telomerase	O
activity	O
correlated	O
with	O
unfavorable	O
tumors	O
,	O
and	O
telomere	O
shortening	O
without	O
telomerase	O
activity	O
correlated	O
with	O
tumor	O
regression	O
.	O
To	O
identify	O
the	O
genes	O
responsible	O
for	O
the	O
biological	O
characteristics	O
of	O
neuroblastoma	B-malignancy-type
,	O
the	O
authors	O
applied	O
microarray	O
techniques	O
.	O
METHODS	O
:	O
Mixtures	O
of	O
total	O
RNAs	O
extracted	O
from	O
10	O
neuroblastoma	B-malignancy-type
tissues	O
with	O
high	O
and	O
10	O
with	O
low	O
telomerase	O
activity	O
were	O
labeled	O
with	O
Cy3	O
or	O
Cy5	O
by	O
reverse	O
transcriptase	O
reaction	O
,	O
respectively	O
,	O
and	O
hybridized	O
with	O
our	O
original	O
microarrays	O
prepared	O
with	O
a	O
cDNA	O
library	O
of	O
human	O
fetal	O
brain	O
.	O
RESULTS	O
:	O
Expression	O
of	O
63	O
genes	O
including	O
MYCN	O
,	O
hTERT	O
,	O
HSPCA	O
,	O
and	O
cell	O
cycle	O
-	O
related	O
proteins	O
was	O
found	O
to	O
be	O
increased	O
in	O
neuroblastomas	B-malignancy-type
with	O
high	O
telomerase	O
activity	O
,	O
whereas	O
another	O
46	O
genes	O
,	O
including	O
neural	O
differentiating	O
genes	O
,	O
were	O
detected	O
as	O
highly	O
expressed	O
in	O
tumors	O
with	O
low	O
telomerase	O
activity	O
.	O
CONCLUSIONS	O
:	O
The	O
expression	O
profiling	O
data	O
indicated	O
clusters	O
of	O
upregulated	O
and	O
downregulated	O
genes	O
tumors	O
with	O
high	O
or	O
low	O
telomerase	O
activity	O
.	O
The	O
genes	O
involved	O
in	O
differentiation	O
/	O
growth	O
arrest	O
of	O
tumor	O
cells	O
were	O
closely	O
related	O
to	O
low	O
telomerase	O
activity	O
in	O
neuroblastoma	B-malignancy-type
.	O
The	O
genes	O
overexpressed	O
in	O
tumors	O
with	O
high	O
telomerase	O
activity	O
,	O
including	O
cell	O
-cycle	O
-	O
related	O
genes	O
and	O
transcriptional	O
factors	O
,	O
would	O
be	O
candidates	O
for	O
novel	O
prognosis	O
-	O
predicting	O
factors	O
as	O
well	O
as	O
new	O
therapeutic	O
targets	O
in	O
aggressive	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
14666454	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2002	O
Nov	O
1;	O
62(	O
21	O
)	O
:	O
6108-15	O
.	O
MS-27	O
-275	O
,	O
an	O
inhibitor	O
of	O
histone	O
deacetylase	O
,	O
has	O
marked	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
activity	O
against	O
pediatric	B-malignancy-type
solid	I-malignancy-type
tumors	I-malignancy-type
.	O
Jaboin	O
J,	O
Wild	O
J,	O
Hamidi	O
H,	O
Khanna	O
C	O
,	O
Kim	O
CJ	O
,	O
Robey	O
R	O
,	O
Bates	O
SE	O
,	O
Thiele	O
CJ.	O
Cell	O
and	O
Molecular	O
Biology	O
Section	O
,	O
Pediatric	O
Oncology	O
Branch	O
,	O
Center	O
for	O
Cancer	O
Research	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
The	O
antitumor	O
efficacy	O
of	O
the	O
synthetic	O
benzamide	O
derivative	O
MS-27	O
-275	O
(	O
MS-275	O
)	O
,	O
an	O
inhibitor	O
of	O
histone	O
deacetylation	O
[T.	O
Suzuki	O
et	O
al.	O
,	O
J.	O
Med	O
.	O
Chem.	O
,	O
42	O
:	O
3001-3003	O
,	O
1999	O
]	O
,	O
was	O
evaluated	O
in	O
a	O
series	O
of	O
pediatric	B-malignancy-type
solid	I-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
,	O
including	O
neuroblastoma	B-malignancy-type
,	O
rhabdomyosarcoma	B-malignancy-type
,	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
(	O
EWS	B-malignancy-type
)	O
,	O
retinoblastoma	B-malignancy-type
,	O
medulloblastoma	B-malignancy-type
,	O
undifferentiated	B-malignancy-type
sarcoma	I-malignancy-type
(	O
US	B-malignancy-type
)	O
,	O
osteosarcoma	B-malignancy-type
,	O
and	O
malignant	O
rhabdoid	B-malignancy-type
tumors	I-malignancy-type
.	O
Treatment	O
with	O
MS-275	O
results	O
in	O
an	O
increase	O
in	O
acetylation	O
of	O
histones	O
within	O
4	O
h	O
of	O
drug	O
exposure	O
.	O
The	O
cell	O
lines	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
MS-275	O
for	O
3	O
days	O
and	O
incubated	O
with	O
[	O
(3)H]thymidine	O
for	O
20	O
h	O
before	O
cell	O
harvest	O
.	O
MS-275	O
inhibited	O
[	O
(3)H]thymidine	O
uptake	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
all	O
tumor	O
cell	O
lines	O
examined	O
.	O
The	O
IC(50)	O
ranged	O
from	O
50	O
nm	O
in	O
the	O
D283	O
medulloblastoma	B-malignancy-type
cell	O
line	O
to	O
1.3	O
micro	O
M	O
in	O
the	O
US	B-malignancy-type
.	O
A	O
common	O
feature	O
of	O
MS-275	O
treatment	O
of	O
pediatric	O
tumor	O
cell	O
lines	O
was	O
induction	O
of	O
p21	O
mRNA	O
.	O
However	O
,	O
the	O
effects	O
on	O
cell	O
cycle	O
were	O
diverse	O
because	O
in	O
some	O
cases	O
MS-275	O
induced	O
an	O
increase	O
in	O
G(1)	O
or	O
G(2)	O
,	O
whereas	O
in	O
others	O
,	O
there	O
was	O
an	O
induction	O
of	O
apoptosis	O
.	O
In	O
EWS	B-malignancy-type
,	O
the	O
EWS	O
/	O
fli	O
chimeric	O
transcription	O
factor	O
created	O
by	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
suppresses	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
betaRII	O
transcription	O
,	O
however	O
,	O
MS-275	O
was	O
able	O
to	O
induce	O
an	O
increase	O
in	O
TGF-betaRII	O
mRNA	O
and	O
restore	O
TGF-beta	O
signaling	O
.	O
Using	O
xenograft	O
orthotopic	O
models	O
of	O
US	B-malignancy-type
,	O
EWS	B-malignancy-type
,	O
and	O
neuroblastoma	B-malignancy-type
,	O
we	O
find	O
that	O
the	O
growth	O
of	O
established	O
tumors	O
is	O
inhibited	O
in	O
mice	O
treated	O
with	O
MS-275	O
.	O
PMID	O
:	O
12414635	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Am	O
Coll	O
Nutr	O
.	O
1994	O
Jun;13(	O
3	O
)	O
:	O
298-303	O
.	O
Modification	O
of	O
the	O
expression	O
of	O
adenosine	O
3',5'-cyclic	O
monophosphate	O
-	O
induced	O
differentiated	O
functions	O
in	O
neuroblastoma	B-malignancy-type
cells	O
by	O
beta-carotene	O
and	O
D	O
-	O
alpha-tocopheryl	O
succinate	O
.	O
Prasad	O
KN	O
,	O
Kentroti	O
S	O
,	O
Edwards	O
-	O
Prasad	O
J,	O
Vernadakis	O
A	O
,	O
Imam	O
M,	O
Carvalho	O
E	O
,	O
Kumar	O
S.	O
Department	O
of	O
Radiology	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
,	O
Denver	O
80262	O
-0276	O
.	O
OBJECTIVE	O
:	O
The	O
role	O
of	O
beta-carotene	O
and	O
vitamin	O
E	O
in	O
modifying	O
the	O
effect	O
of	O
cell	O
differentiating	O
agent	O
has	O
not	O
been	O
studied	O
.	O
This	O
study	O
has	O
investigated	O
the	O
effects	O
of	O
beta-carotene	O
and	O
d	O
-alpha-tocopheryl	O
succinate	O
(	O
alpha-TS	O
)	O
on	O
adenosine	O
3',5'-cyclic	O
monophosphate	O
(	O
cAMP	O
)	O
induced	O
differentiated	O
functions	O
in	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
(	O
NBP2	O
)	O
in	O
culture	O
.	O
METHODS	O
:	O
Prostaglandin	O
E1	O
(	O
PGE1	O
)	O
,	O
a	O
stimulator	O
of	O
adenylate	O
cyclase	O
,	O
and	O
4-(3-butoxy-4-methoxy-benzyl)-2-	O
imidazolidinone	O
(	O
R020-	O
1724	O
)	O
,	O
an	O
inhibitor	O
of	O
cyclic	O
nucleotide	O
phosphodiesterase	O
,	O
were	O
used	O
to	O
induce	O
differentiation	O
in	O
NB	B-malignancy-type
cells	O
.	O
RESULTS	O
:	O
Both	O
beta-carotene	O
and	O
alpha-TS	O
markedly	O
enhanced	O
the	O
level	O
of	O
morphologic	O
differentiation	O
(	O
neurite	O
formation	O
)	O
induced	O
by	O
both	O
PGE1	O
and	O
R020-	O
1724	O
.	O
However	O
,	O
beta-carotene	O
and	O
alpha-TS	O
by	O
themselves	O
were	O
ineffective	O
.	O
These	O
vitamins	O
increased	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
activity	O
.	O
However	O
,	O
beta-carotene	O
did	O
not	O
significantly	O
affect	O
PGE1	O
-	O
and	O
R020-	O
1724	O
-	O
stimulated	O
rise	O
in	O
TH	O
activity	O
.	O
alpha-TS	O
at	O
a	O
higher	O
concentration	O
inhibited	O
PGE1	O
-	O
and	O
R020-	O
1724	O
-	O
stimulated	O
increase	O
in	O
TH	O
activity	O
.	O
None	O
of	O
the	O
above	O
treatments	O
affected	O
basal	O
choline	O
acetyltransferase	O
(	O
ChAT	O
)	O
activity	O
.	O
beta-carotene	O
and	O
alpha-TS	O
caused	O
a	O
transient	O
increase	O
in	O
cAMP	O
level	O
,	O
and	O
they	O
also	O
enhanced	O
the	O
effect	O
of	O
PGE1	O
and	O
R020-	O
1724	O
on	O
cAMP	O
level	O
in	O
a	O
transient	O
manner	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
beta-carotene	O
and	O
alpha-TS	O
modify	O
the	O
effects	O
of	O
cAMP	O
stimulating	O
agents	O
on	O
differentiation	O
of	O
NB	B-malignancy-type
cells	O
in	O
culture	O
.	O
PMID	O
:	O
7915734	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biochem	O
.	O
1980	O
Aug	O
16;31(	O
3	O
)	O
:165	O
-	O
75	O
.	O
The	O
effect	O
of	O
tumor	O
-	O
promoting	O
phorbol	O
diesters	O
on	O
terminal	O
differentiation	O
of	O
cells	O
in	O
culture	O
.	O
Abrahm	O
J,	O
Rovera	O
G.	O
Phorbol	O
diesters	O
with	O
tumor	O
-	O
promoting	O
activity	O
,	O
in	O
particular	O
,	O
12	O
-	O
0-tetradecanoyl-phorbol-13	O
-acetate	O
(	O
TPA	O
)	O
,	O
can	O
induce	O
or	O
inhibit	O
terminal	O
differentiation	O
in	O
a	O
variety	O
of	O
cell	O
systems	O
,	O
with	O
specificity	O
for	O
particular	O
cell	O
lineages	O
.	O
The	O
phorbols	O
are	O
excellent	O
tools	O
to	O
investigate	O
the	O
expression	O
and	O
control	O
of	O
differentiation	O
in	O
some	O
cells	O
and	O
the	O
mechanism	O
by	O
which	O
oncogenic	O
agents	O
interfere	O
with	O
the	O
process	O
of	O
terminal	O
differentiation	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
the	O
phorbols	O
on	O
different	O
target	O
cells	O
is	O
not	O
understood	O
at	O
the	O
present	O
time	O
.	O
It	O
is	O
felt	O
that	O
the	O
status	O
of	O
the	O
cell	O
is	O
of	O
major	O
importance	O
as	O
,	O
in	O
some	O
cases	O
,	O
opposite	O
effects	O
can	O
be	O
achieved	O
by	O
the	O
same	O
concentration	O
of	O
the	O
phorbol	O
diester	O
used	O
.	O
Changes	O
in	O
membranes	O
,	O
receptors	O
,	O
in	O
secretion	O
of	O
prostaglandins	O
and	O
in	O
the	O
level	O
of	O
cyclic	O
AMP	O
have	O
all	O
been	O
reported	O
.	O
However	O
,	O
the	O
relationship	O
of	O
these	O
changes	O
with	O
the	O
alterations	O
in	O
the	O
genetic	O
program	O
involved	O
in	O
the	O
differentiation	O
process	O
is	O
not	O
clear	O
,	O
and	O
the	O
recent	O
report	O
of	O
a	O
possible	O
cell	O
receptor	O
for	O
phorbol	O
diesters	O
should	O
elucidate	O
their	O
mechanism	O
of	O
action	O
.	O
The	O
findings	O
on	O
the	O
effect	O
of	O
phorbol	O
diesters	O
on	O
differentiation	O
have	O
suggested	O
the	O
testable	O
hypothesis	O
that	O
promotion	O
could	O
be	O
mediated	O
through	O
inhibition	O
of	O
cellular	O
differentiation	O
.	O
It	O
has	O
also	O
been	O
suggested	O
that	O
changes	O
in	O
differentiating	O
systems	O
could	O
be	O
of	O
future	O
use	O
in	O
screening	O
for	O
unknown	O
tumor	O
promoters	O
,	O
however	O
,	O
this	O
possibility	O
seems	O
quite	O
remote	O
.	O
Finally	O
,	O
phorbol	O
diesters	O
with	O
tumor	O
-	O
promoting	O
activity	O
appear	O
to	O
exert	O
a	O
specific	O
effect	O
on	O
differentiation	O
of	O
leukemic	B-malignancy-type
cells	O
of	O
both	O
mouse	O
and	O
human	O
origin	O
,	O
and	O
therefore	O
,	O
the	O
application	O
of	O
this	O
particular	O
phenomenon	O
in	O
experimental	O
therapy	O
should	O
be	O
the	O
subject	O
of	O
future	O
investigations	O
.	O
PMID	O
:	O
6934372	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Gene	O
Ther	O
.	O
1992	O
Apr;	O
3(	O
2	O
)	O
:	O
129-	O
36	O
.	O
Retrovirus	O
-	O
mediated	O
gene	O
transfer	O
as	O
an	O
approach	O
to	O
analyze	O
neuroblastoma	B-malignancy-type
relapse	O
after	O
autologous	O
bone	O
marrow	O
transplantation	O
.	O
Rill	O
DR	O
,	O
Buschle	O
M,	O
Foreman	O
NK	O
,	O
Bartholomew	O
C	O
,	O
Moen	O
RC	O
,	O
Santana	O
VM	O
,	O
Ihle	O
JN	O
,	O
Brenner	O
MK.	O
Department	O
of	O
Hematology	O
/Oncology	O
,	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
Memphis	O
,	O
TN	O
38101	O
.	O
Disseminated	O
neuroblastoma	B-malignancy-type
is	O
a	O
malignancy	O
of	O
children	O
often	O
treated	O
by	O
intensive	O
chemotherapy	O
/	O
radiotherapy	O
followed	O
by	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
ABMT	O
)	O
.	O
A	O
high	O
proportion	O
of	O
those	O
treated	O
subsequently	O
relapse	O
.	O
It	O
is	O
unknown	O
if	O
relapse	O
is	O
a	O
consequence	O
of	O
residual	O
disease	O
in	O
the	O
patient	O
or	O
of	O
contaminating	O
malignant	O
cells	O
remaining	O
in	O
the	O
infused	O
marrow	O
,	O
which	O
,	O
of	O
necessity	O
,	O
is	O
harvested	O
and	O
stored	O
prior	O
to	O
ablative	O
chemotherapy	O
/	O
radiotherapy	O
.	O
The	O
assumption	O
that	O
residual	O
cells	O
in	O
the	O
infused	O
marrow	O
contribute	O
to	O
relapse	O
has	O
lead	O
to	O
the	O
adoption	O
of	O
marrow	O
purging	O
prior	O
to	O
reinfusion	O
.	O
However	O
,	O
neither	O
the	O
necessity	O
nor	O
the	O
efficacy	O
of	O
the	O
procedure	O
have	O
been	O
established	O
.	O
We	O
now	O
show	O
how	O
retroviral	O
-	O
mediated	O
gene	O
transfer	O
using	O
the	O
LNL6	O
vector	O
may	O
resolve	O
this	O
issue	O
.	O
Clonogenic	O
neuroblastoma	B-malignancy-type
cells	O
in	O
patient	O
marrow	O
can	O
be	O
transduced	O
and	O
the	O
NEOR	O
gene	O
detected	O
by	O
observing	O
individual	O
neuroblastoma	B-malignancy-type
cell	O
colony	O
growth	O
in	O
G418	O
,	O
and	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
of	O
individual	O
colonies	O
.	O
Efficiency	O
of	O
transduction	O
is	O
between	O
0	O
and	O
13.5	O
%	O
.	O
If	O
marrow	O
is	O
exposed	O
to	O
LNL6	O
prior	O
to	O
infusion	O
and	O
marked	O
cells	O
are	O
detected	O
at	O
the	O
time	O
of	O
relapse	O
,	O
this	O
would	O
demonstrate	O
that	O
infused	O
marrow	O
contributed	O
to	O
disease	O
recurrence	O
.	O
The	O
technique	O
could	O
then	O
be	O
used	O
to	O
analyze	O
the	O
efficacy	O
of	O
marrow	O
purging	O
techniques	O
.	O
Since	O
normal	O
progenitor	O
cells	O
from	O
these	O
patients	O
are	O
also	O
marked	O
,	O
the	O
technique	O
can	O
be	O
used	O
to	O
study	O
factors	O
that	O
modify	O
reconstitution	O
and	O
transducibility	O
of	O
infused	O
marrow	O
.	O
Clinical	O
studies	O
using	O
this	O
approach	O
have	O
now	O
begun	O
.	O
PMID	O
:	O
1391032	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
Surg	O
.	O
1992	O
Nov;27	O
(	O
11	O
)	O
:	O
1442-6.	O
Differences	O
of	O
L-myc	O
polymorphic	O
patterns	O
of	O
neuroblastoma	B-malignancy-type
in	O
patients	O
under	O
1	O
year	O
versus	O
older	O
ages	O
:	O
a	O
preliminary	O
report	O
.	O
Murakami	O
T	O
,	O
Ohmori	O
H,	O
Katoh	O
T	O
,	O
Nakamura	O
H,	O
Tsuda	O
T	O
,	O
Shan	O
RC	O
,	O
Akiya	O
S	O
,	O
Nakagawara	O
A	O
,	O
Higashi	O
K.	O
Department	O
of	O
Biochemistry	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Occupational	O
and	O
Environmental	O
Health	O
,	O
Kitakyushu	O
,	O
Japan	O
.	O
The	O
age	O
of	O
the	O
patient	O
at	O
the	O
onset	O
of	O
symptoms	O
or	O
at	O
diagnosis	O
is	O
generally	O
accepted	O
as	O
one	O
of	O
the	O
most	O
important	O
prognostic	O
factors	O
of	O
neuroblastomas	B-malignancy-type
(	O
NBs	B-malignancy-type
)	O
.	O
Children	O
less	O
than	O
1	O
year	O
of	O
age	O
have	O
a	O
better	O
survival	O
rate	O
than	O
older	O
patients	O
,	O
but	O
the	O
reason	O
for	O
this	O
is	O
unknown	O
.	O
Forty-eight	O
unselected	O
NB	B-malignancy-type
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
less	O
than	O
1	O
year	O
(	O
younger	O
NB	B-malignancy-type
patient	O
)	O
and	O
over	O
1	O
year	O
(	O
older	O
NB	B-malignancy-type
patient	O
)	O
of	O
age	O
at	O
diagnosis	O
.	O
Two	O
of	O
12	O
younger	O
NB	B-malignancy-type
patients	O
and	O
18	O
of	O
36	O
older	O
NB	B-malignancy-type
patients	O
had	O
N-myc	O
amplification	O
in	O
their	O
tumors	O
.	O
To	O
elucidate	O
further	O
the	O
possible	O
genetic	O
difference	O
between	O
younger	O
and	O
older	O
NB	B-malignancy-type
patients	O
,	O
studies	O
of	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
of	O
the	O
L-myc	O
gene	O
was	O
carried	O
out	O
in	O
these	O
two	O
groups	O
.	O
The	O
L-myc	O
locus	O
showed	O
2-allele	O
polymorphism	O
,	O
allele	O
L	O
(	O
10	O
kb	O
)	O
and	O
S	O
(	O
6.6	O
kb	O
)	O
,	O
after	O
digestion	O
with	O
EcoRI	O
.	O
Patients	O
homozygous	O
for	O
L-band	O
have	O
been	O
reported	O
as	O
individuals	O
having	O
less	O
metastatic	O
potential	O
in	O
some	O
cancers	O
.	O
The	O
allele	O
frequencies	O
of	O
L	O
and	O
S	O
in	O
neuroblastomas	B-malignancy-type
of	O
younger	O
NB	B-malignancy-type
patients	O
were	O
0.50	O
and	O
0.50	O
,	O
while	O
those	O
of	O
older	O
NB	B-malignancy-type
patients	O
were	O
0.35	O
and	O
0.65	O
,	O
respectively	O
.	O
Although	O
we	O
did	O
not	O
determine	O
L-myc	O
RFLP	O
in	O
normal	O
tissue	O
of	O
individual	O
patients	O
,	O
we	O
expect	O
that	O
the	O
distribution	O
of	O
allele	O
L	O
and	O
S	O
is	O
partly	O
affected	O
by	O
possible	O
allelic	O
loss	O
involving	O
the	O
L-myc	O
region	O
.	O
However	O
,	O
the	O
L-myc	O
RFLP	O
patterns	O
in	O
younger	O
NB	B-malignancy-type
patients	O
were	O
the	O
same	O
as	O
those	O
of	O
normal	O
individuals	O
and	O
significantly	O
differed	O
from	O
those	O
of	O
older	O
NB	B-malignancy-type
patients	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
1362216	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Alzheimers	O
Dis	O
.	O
2002	O
Feb;4(	O
1	O
)	O
:19	O
-30	O
.	O
Cerebrospinal	O
fluid	O
lipoprotein	O
delivery	O
to	O
human	O
neuronal	O
cells	O
is	O
increased	O
in	O
Alzheimer	O
'	O
s	O
disease	O
and	O
is	O
dependent	O
on	O
apoE	O
monomer	O
concentration	O
.	O
Bassett	O
CN	O
,	O
Swift	O
LL	O
,	O
Montine	O
KS	O
,	O
Markesbery	O
WR	O
,	O
Montine	O
TJ.	O
Department	O
of	O
Pathology	O
,	O
Vanderbilt	O
University	O
Medical	O
Center	O
,	O
Nashville	O
,	O
TN	O
37232	O
,	O
USA	O
.	O
Recent	O
studies	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
have	O
shown	O
increased	O
oxidation	O
of	O
CSF	O
lipoproteins	O
in	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
patients	O
,	O
and	O
neurotoxicity	O
from	O
oxidized	O
CSF	O
lipoproteins	O
in	O
culture	O
.	O
Since	O
inheritance	O
of	O
different	O
alleles	O
of	O
the	O
apolipoprotein	O
(	O
apo	O
)	O
E	O
gene	O
is	O
a	O
risk	O
factor	O
for	O
AD	O
and	O
apoE	O
is	O
the	O
major	O
lipoprotein	O
trafficking	O
molecule	O
in	O
brain	O
,	O
we	O
hypothesized	O
that	O
apoE	O
may	O
modify	O
the	O
pathogenesis	O
of	O
AD	O
by	O
directing	O
the	O
delivery	O
of	O
oxidized	O
CSF	O
lipoproteins	O
to	O
neurons	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
we	O
adapted	O
a	O
method	O
previously	O
used	O
with	O
isolated	O
plasma	O
lipoproteins	O
to	O
specifically	O
label	O
lipid	O
particles	O
in	O
situ	O
in	O
native	O
CSF	O
and	O
quantified	O
their	O
delivery	O
to	O
human	O
SK	O
-	O
N	O
-	O
BE(2)	O
C	O
neuroblastoma	B-malignancy-type
cells	O
.	O
CSF	O
lipoproteins	O
were	O
delivered	O
to	O
neuronal	O
cells	O
largely	O
through	O
apoE	O
-	O
dependent	O
processes	O
.	O
Importantly	O
,	O
CSF	O
lipoproteins	O
from	O
AD	O
patients	O
were	O
delivered	O
more	O
efficiently	O
than	O
CSF	O
lipoproteins	O
from	O
age	O
-	O
matched	O
controls	O
;	O
this	O
effect	O
was	O
not	O
associated	O
with	O
apoE	O
genotype	O
or	O
degree	O
of	O
CSF	O
lipoprotein	O
oxidation	O
but	O
was	O
associated	O
with	O
apoE	O
monomer	O
concentration	O
that	O
tended	O
to	O
be	O
lower	O
in	O
AD	O
patients	O
.	O
The	O
inverse	O
relationship	O
between	O
apoE	O
monomer	O
concentration	O
and	O
CSF	O
lipoprotein	O
delivery	O
was	O
duplicated	O
in	O
SK	O
-	O
N	O
-	O
BE(2)	O
C	O
cells	O
,	O
but	O
not	O
human	O
astrocytoma	B-malignancy-type
cells	O
,	O
using	O
artificial	O
lipid	O
particles	O
and	O
purified	O
human	O
apoE	O
.	O
These	O
results	O
suggest	O
that	O
lipoproteins	O
in	O
CSF	O
from	O
AD	O
patients	O
are	O
delivered	O
more	O
efficiently	O
to	O
neurons	O
than	O
are	O
CSF	O
lipoproteins	O
from	O
controls	O
,	O
and	O
that	O
this	O
abnormality	O
may	O
be	O
explained	O
largely	O
by	O
variations	O
in	O
CSF	O
apoE	O
concentration	O
.	O
PMID	O
:	O
12214015	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Med	O
Chir	O
.	O
1985	O
Sep-Oct;	O
7(	O
5	O
)	O
:	O
717-	O
21	O
.	O
[	O
Advantages	O
of	O
a	O
permanent	O
venous	O
access	O
in	O
children	O
treated	O
for	O
cancer	O
.	O
Preliminary	O
results	O
]	O
[	O
Article	O
in	O
Italian	O
]	O
Garaventa	O
A	O
,	O
Rizzo	O
A	O
,	O
Ivani	O
G	O
,	O
Vallarino	O
R	O
,	O
Taccone	O
A	O
,	O
Viscoli	O
C	O
,	O
Perlino	O
G	O
,	O
De	O
Bernardi	O
B.	O
Current	O
therapy	O
for	O
children	O
with	O
cancer	O
includes	O
a	O
variety	O
of	O
invasive	O
procedures	O
many	O
of	O
which	O
require	O
repeated	O
venous	O
access	O
over	O
a	O
considerable	O
period	O
of	O
time	O
.	O
Such	O
procedures	O
are	O
poorly	O
tolerated	O
by	O
children	O
and	O
by	O
their	O
veins	O
.	O
Recently	O
it	O
has	O
become	O
possible	O
to	O
undertake	O
the	O
majority	O
of	O
such	O
procedures	O
by	O
means	O
of	O
permanent	O
indwelling	O
silastic	O
catheters	O
improving	O
the	O
quality	O
of	O
life	O
of	O
the	O
children	O
and	O
their	O
parents	O
and	O
increasing	O
the	O
scope	O
of	O
therapeutic	O
intervention	O
.	O
In	O
the	O
period	O
July	O
'	O
83	O
-	O
August	O
'	O
84	O
we	O
have	O
used	O
46	O
of	O
these	O
catheters	O
in	O
45	O
children	O
with	O
malignant	O
disease	O
,	O
12	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
,	O
12	O
with	O
neuroblastoma	B-malignancy-type
,	O
7	O
with	O
B	B-malignancy-type
cell	I-malignancy-type
leukaemia	I-malignancy-type
-	I-malignancy-type
lymphoma	I-malignancy-type
,	O
6	O
with	O
rhabdomyosarcomas	B-malignancy-type
,	O
2	O
with	O
Ewing	B-malignancy-type
'	I-malignancy-type
s	I-malignancy-type
Sarcoma	I-malignancy-type
,	O
2	O
with	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
and	O
1	O
case	O
each	O
of	O
Hodgkin	B-malignancy-type
'	I-malignancy-type
s	I-malignancy-type
disease	I-malignancy-type
,	O
teratocarcinoma	B-malignancy-type
,	O
osteosarcoma	B-malignancy-type
and	O
juvenile	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
.	O
The	O
children	O
'	O
s	O
ages	O
ranged	O
from	O
2	O
months	O
to	O
14	O
years	O
;	O
22	O
were	O
male	O
and	O
23	O
female	O
.	O
The	O
catheters	O
were	O
inserted	O
under	O
general	O
anaesthesia	O
(	O
duration	O
20	O
-	O
40	O
minutes	O
)	O
usually	O
without	O
difficulty	O
,	O
except	O
for	O
a	O
single	O
patient	O
in	O
whom	O
no	O
suitable	O
vein	O
could	O
be	O
found	O
.	O
No	O
complications	O
connected	O
with	O
the	O
placement	O
of	O
the	O
catheter	O
were	O
observed	O
.	O
Subsequent	O
management	O
of	O
the	O
catheter	O
was	O
initially	O
complicated	O
and	O
time	O
-	O
consuming	O
,	O
but	O
was	O
subsequently	O
simplified	O
so	O
that	O
acceptance	O
by	O
parents	O
,	O
children	O
and	O
nursing	O
staff	O
was	O
eventually	O
excellent	O
.	O
The	O
duration	O
of	O
use	O
of	O
46	O
catheters	O
ranges	O
from	O
7	O
to	O
350	O
+	O
days	O
;	O
24	O
catheters	O
are	O
presently	O
in	O
use	O
at	O
30	O
-	O
350	O
+	O
days	O
from	O
insertion	O
.	O
Eight	O
children	O
died	O
as	O
a	O
result	O
of	O
disease	O
progression	O
and	O
two	O
of	O
sepsis	O
with	O
the	O
catheter	O
in	O
place	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
3837238	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

EXS	O
.	O
1994;	O
71	O
:49-	O
59	O
.	O
Effects	O
of	O
alcohol	O
on	O
gene	O
expression	O
in	O
neural	O
cells	O
.	O
Wilke	O
N	O
,	O
Sganga	O
M,	O
Barhite	O
S	O
,	O
Miles	O
MF.	O
Ernest	O
Gallo	O
Clinic	O
and	O
Research	O
Center	O
,	O
San	O
Francisco	O
,	O
CA.	O
Our	O
studies	O
in	O
the	O
NG108	O
-	O
15	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
cell	O
line	O
previously	O
showed	O
that	O
the	O
molecular	O
chaperonin	O
,	O
Hsc70	O
,	O
is	O
an	O
ethanol	O
-	O
responsive	O
gene	O
(	O
EtRG	O
)	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
ethanol	O
.	O
We	O
recently	O
identified	O
two	O
related	O
molecular	O
chaperonins	O
,	O
GRP94	O
and	O
GRP78	O
,	O
as	O
EtRGs	O
with	O
GRP94	O
mRNA	O
abundance	O
being	O
induced	O
by	O
ethanol	O
more	O
than	O
three	O
-	O
fold	O
vs.	O
control	O
.	O
Stable	O
transfection	O
studies	O
show	O
that	O
GRP78	O
transcription	O
is	O
also	O
regulated	O
by	O
ethanol	O
and	O
that	O
ethanol	O
also	O
potentiates	O
GRP78	O
induction	O
by	O
classical	O
inducing	O
agents	O
such	O
as	O
tunicamycin	O
.	O
Recently	O
,	O
we	O
have	O
found	O
that	O
ethanol	O
induction	O
of	O
Hsc70	O
may	O
require	O
cis	O
-	O
acting	O
promoter	O
sequences	O
recognized	O
by	O
the	O
DNA	O
-	O
binding	O
protein	O
Sp1	O
.	O
Chronic	O
ethanol	O
exposure	O
does	O
not	O
alter	O
Sp1	O
DNA	O
-	O
binding	O
activity	O
,	O
thus	O
suggesting	O
a	O
possible	O
ethanol	O
-	O
induced	O
post	O
-	O
translational	O
modification	O
that	O
activates	O
Sp1	O
function	O
.	O
We	O
predict	O
that	O
the	O
molecular	O
mechanisms	O
underlying	O
ethanol	O
regulation	O
of	O
Hsc70	O
,	O
GRP94	O
and	O
GRP78	O
may	O
be	O
similar	O
since	O
they	O
have	O
related	O
functions	O
.	O
GRP94	O
and	O
GRP78	O
(	O
GRP	O
94	O
/	O
78	O
)	O
are	O
known	O
to	O
be	O
induced	O
by	O
agents	O
which	O
inhibit	O
glycoprotein	O
processing	O
or	O
deplete	O
endoplasmic	O
reticulum	O
stores	O
of	O
calcium	O
.	O
In	O
turn	O
,	O
induction	O
of	O
GRP78	O
expression	O
is	O
known	O
to	O
selectively	O
alter	O
the	O
transport	O
of	O
glycoproteins	O
and	O
produce	O
"	O
tolerance	O
"	O
to	O
depletion	O
of	O
sequestered	O
intracellular	O
calcium	O
.	O
The	O
regulation	O
of	O
these	O
genes	O
by	O
ethanol	O
could	O
thus	O
relate	O
to	O
the	O
known	O
effects	O
of	O
ethanol	O
on	O
calcium	O
homeostasis	O
and	O
protein	O
trafficking	O
.	O
The	O
actions	O
of	O
ethanol	O
on	O
chaperonin	O
gene	O
expression	O
may	O
have	O
important	O
mechanistic	O
implications	O
for	O
CNS	O
adaptation	O
to	O
ethanol	O
,	O
particularly	O
if	O
other	O
EtRGs	O
share	O
the	O
same	O
regulatory	O
mechanisms	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
8032172	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
2003	O
Mar	O
20;104(	O
2	O
)	O
:	O
233	O
-	O
7.	O
Rapamycin	O
inhibits	O
proliferation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
without	O
suppression	O
of	O
MycN	O
.	O
Misawa	O
A	O
,	O
Hosoi	O
H,	O
Tsuchiya	O
K,	O
Sugimoto	O
T.	O
Department	O
of	O
Pediatrics	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Kawaramachi-Hirokoji	O
,	O
Kamigyo-ku	O
,	O
Kyoto	O
,	O
Japan	O
.	O
amisawa@koto.kpu-m	O
.ac.jp	O
MYCN	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
system	O
are	O
important	O
for	O
the	O
pathogenesis	O
and	O
development	O
of	O
neuroblastoma	B-malignancy-type
.	O
We	O
previously	O
reported	O
evidence	O
of	O
a	O
direct	O
linkage	O
between	O
MycN	O
and	O
the	O
IGF	O
system	O
in	O
KP	O
-	O
N	O
-	O
RT	O
human	O
neuroblastoma	B-malignancy-type
cells	O
,	O
where	O
IGF	O
-	O
I	O
induced	O
both	O
MycN	O
expression	O
at	O
the	O
RNA	O
level	O
and	O
G1	O
-	O
S	O
cell	O
cycle	O
progression	O
through	O
the	O
IGF	O
-	O
I	O
receptor	O
(	O
IGF	O
-	O
IR	O
)	O
/	O
MEK	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
(	O
A	O
.	O
Misawa	O
et	O
al	O
.	O
,	O
Cancer	O
Res	O
,	O
2000	O
;	O
60	O
:	O
64	O
-	O
9	O
)	O
.	O
Our	O
data	O
also	O
showed	O
the	O
possibility	O
of	O
a	O
potent	O
IGF	O
-	O
IR	O
downstream	O
signal	O
cascade	O
that	O
accelerates	O
progression	O
into	O
the	O
S	O
-	O
phase	O
,	O
other	O
than	O
the	O
MAPK	O
pathway	O
.	O
In	O
this	O
study	O
,	O
we	O
further	O
investigated	O
the	O
role	O
of	O
this	O
alternative	O
pathway	O
in	O
the	O
growth	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
A	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
inhibitor	O
wortmannin	O
blocked	O
IGF	O
-	O
I	O
-	O
mediated	O
induction	O
of	O
MycN	O
.	O
Our	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
MycN	O
by	O
wortmannin	O
was	O
transmitted	O
through	O
the	O
MAPK	O
pathway	O
.	O
Progression	O
of	O
the	O
cell	O
cycle	O
from	O
G1	O
to	O
S	O
phase	O
was	O
inhibited	O
up	O
to	O
90	O
%	O
by	O
wortmannin	O
or	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
mTOR	O
,	O
which	O
acts	O
downstream	O
of	O
PI3K	O
.	O
Despite	O
its	O
effects	O
on	O
induction	O
of	O
MycN	O
and	O
on	O
progression	O
through	O
S	O
phase	O
,	O
wortmannin	O
did	O
not	O
block	O
proliferation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
rapamycin	O
inhibited	O
both	O
IGF	O
-	O
I	O
-	O
induced	O
cell	O
cycle	O
progression	O
and	O
cell	O
proliferation	O
in	O
complete	O
medium	O
,	O
although	O
it	O
had	O
no	O
effect	O
on	O
IGF	O
-	O
I	O
-	O
mediated	O
MycN	O
induction	O
.	O
Our	O
study	O
indicates	O
maintenance	O
of	O
cell	O
proliferation	O
requires	O
mTOR	O
function	O
,	O
which	O
is	O
independent	O
of	O
MycN	O
induction	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12569580	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1985	O
Jun;82	O
(	O
11	O
)	O
:	O
3736-40	O
.	O
N	O
-	O
myc	O
amplification	O
in	O
multiple	O
homogeneously	O
staining	O
regions	O
in	O
two	O
human	O
neuroblastomas	B-malignancy-type
.	O
Emanuel	O
BS	O
,	O
Balaban	O
G	O
,	O
Boyd	O
JP	O
,	O
Grossman	O
A	O
,	O
Negishi	O
M,	O
Parmiter	O
A	O
,	O
Glick	O
MC	O
.	O
Molecular	O
characterization	O
of	O
two	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
has	O
revealed	O
that	O
both	O
contain	O
multiple	O
homogeneously	O
staining	O
regions	O
(	O
HSRs	O
)	O
,	O
each	O
representing	O
a	O
chromosome	O
site	O
of	O
N	O
-	O
myc	O
amplification	O
.	O
The	O
newly	O
established	O
cell	O
line	O
CHP	O
-	O
382	O
/	O
JK	O
had	O
two	O
cytogenetically	O
distinct	O
populations	O
with	O
several	O
identical	O
chromosomal	O
abnormalities	O
,	O
indicating	O
a	O
common	O
progenitor	O
cell	O
.	O
Each	O
population	O
had	O
one	O
HSR	O
,	O
one	O
on	O
chromosome	O
5	O
at	O
q31	O
-	O
34	O
and	O
the	O
other	O
on	O
chromosome	O
2	O
at	O
q31	O
-	O
32	O
.	O
Chromosomal	O
in	O
situ	O
hybridization	O
with	O
the	O
N	O
-	O
myc	O
probe	O
pNb	O
-	O
1	O
demonstrated	O
that	O
both	O
HSRs	O
contained	O
amplified	O
copies	O
of	O
N	O
-	O
myc	O
.	O
Southern	O
blot	O
analysis	O
confirmed	O
amplification	O
of	O
N	O
-	O
myc	O
sequences	O
in	O
genomic	O
DNA	O
of	O
CHP	O
-	O
382	O
/	O
JK	O
.	O
Chromosomal	O
features	O
of	O
CHP	O
-	O
382	O
/	O
JK	O
shared	O
with	O
other	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
were	O
the	O
deletion	O
of	O
1p	O
and	O
the	O
presence	O
of	O
extra	O
17q	O
material	O
.	O
In	O
addition	O
,	O
the	O
cells	O
were	O
highly	O
reactive	O
to	O
monoclonal	O
antibody	O
PI	O
153	O
/	O
3	O
used	O
to	O
identify	O
human	O
neuroblastoma	B-malignancy-type
.	O
CHP	O
-	O
382	O
/	O
JK	O
cells	O
were	O
further	O
characterized	O
as	O
neuronal	O
cells	O
by	O
the	O
expression	O
of	O
neurotoxin	O
-	O
responsive	O
Na	O
+	O
channels	O
.	O
Another	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
CHP	O
-	O
134	O
,	O
contained	O
a	O
single	O
cell	O
population	O
with	O
three	O
HSRs	O
,	O
one	O
in	O
the	O
short	O
arm	O
of	O
each	O
chromosome	O
7	O
and	O
one	O
in	O
the	O
long	O
arm	O
of	O
a	O
chromosome	O
6	O
.	O
All	O
three	O
HSRs	O
contained	O
amplified	O
copies	O
of	O
N	O
-	O
myc	O
as	O
shown	O
by	O
in	O
situ	O
hybridization	O
with	O
the	O
N	O
-	O
myc	O
probe	O
pNb	O
-	O
1	O
.	O
One	O
of	O
the	O
7p	O
HSRs	O
was	O
acquired	O
during	O
culture	O
of	O
CHP	O
-	O
134	O
cells	O
,	O
whereas	O
the	O
2q	O
HSR	O
of	O
CHP	O
-	O
382	O
/	O
JK	O
was	O
lost	O
.	O
Such	O
findings	O
highlight	O
the	O
continued	O
process	O
of	O
N	O
-	O
myc	O
amplification	O
and	O
transposition	O
in	O
vitro	O
.	O
To	O
our	O
knowledge	O
,	O
amplification	O
of	O
N	O
-	O
myc	O
in	O
multiple	O
HSRs	O
has	O
not	O
been	O
documented	O
previously	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
PMID	O
:	O
2582423	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
.	O
1991	O
Nov;11(	O
11	O
)	O
:	O
5446-53	O
.	O
Expression	O
of	O
CD44	O
is	O
repressed	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Shtivelman	O
E	O
,	O
Bishop	O
JM	O
.	O
Department	O
of	O
Microbiology	O
and	O
Immunology	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
.	O
We	O
have	O
used	O
cDNA	O
subtractive	O
cloning	O
to	O
identify	O
a	O
group	O
of	O
human	O
genes	O
that	O
are	O
expressed	O
in	O
diverse	O
differentiated	O
derivatives	O
of	O
neural	O
crest	O
origin	O
but	O
not	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
One	O
of	O
these	O
genes	O
was	O
identified	O
as	O
CD44	O
,	O
which	O
encodes	O
an	O
integral	O
membrane	O
glycoprotein	O
that	O
serves	O
as	O
the	O
principal	O
receptor	O
for	O
hyaluronate	O
and	O
participates	O
in	O
specific	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
extracellular	O
matrix	O
interactions	O
.	O
The	O
repression	O
of	O
CD44	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
might	O
be	O
relevant	O
to	O
their	O
high	O
metastatic	O
potential	O
.	O
We	O
have	O
cloned	O
full	O
-	O
length	O
cDNAs	O
corresponding	O
to	O
CD44	O
trancscripts	O
and	O
identified	O
a	O
novel	O
splice	O
variant	O
of	O
CD44	O
lacking	O
31	O
amino	O
acids	O
of	O
the	O
extracellular	O
domain	O
.	O
As	O
a	O
first	O
step	O
toward	O
analysis	O
of	O
CD44	O
downregulation	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
we	O
have	O
mapped	O
the	O
CD44	O
RNA	O
initiation	O
site	O
and	O
analyzed	O
the	O
structure	O
of	O
the	O
upstream	O
regulatory	O
region	O
.	O
We	O
constructed	O
a	O
series	O
of	O
plasmids	O
containing	O
different	O
amounts	O
of	O
CD44	O
upstream	O
regulatory	O
region	O
linked	O
to	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
and	O
then	O
analyzed	O
their	O
ability	O
to	O
promote	O
transcription	O
in	O
neuroblastoma	B-malignancy-type
and	O
melanoma	B-malignancy-type
cells	O
.	O
We	O
found	O
that	O
a	O
DNA	O
segment	O
including	O
about	O
150	O
bp	O
of	O
the	O
CD44	O
upstream	O
region	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
itself	O
was	O
sufficient	O
to	O
induce	O
substantial	O
transcription	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
in	O
both	O
neuroblastoma	B-malignancy-type
and	O
melanoma	B-malignancy-type
cells	O
.	O
Several	O
upstream	O
cis	O
-	O
acting	O
elements	O
contribute	O
to	O
the	O
downregulation	O
of	O
CD44	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
the	O
most	O
prominent	O
being	O
a	O
120	O
-	O
bp	O
DNA	O
fragment	O
located	O
450	O
bp	O
upstream	O
to	O
the	O
RNA	O
initiation	O
site	O
.	O
Our	O
data	O
suggest	O
that	O
multiple	O
factors	O
might	O
be	O
involved	O
in	O
downregulation	O
of	O
CD44	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
1922057	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurooncol	O
.	O
1997	O
Jan;31(	O
1-2	O
)	O
:	O
209	O
-15	O
.	O
Evidence	O
of	O
apoptosis	O
in	O
neuroblastoma	B-malignancy-type
at	O
onset	O
and	O
relapse	O
.	O
An	O
analysis	O
of	O
a	O
large	O
series	O
of	O
tumors	O
.	O
Tonini	O
GP	O
,	O
Mazzocco	O
K,	O
di	O
Vinci	O
A	O
,	O
Geido	O
E	O
,	O
de	O
Bernardi	O
B	O
,	O
Giaretti	O
W	O
.	O
Laboratory	O
of	O
Oncology	O
,	O
G.	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genoa	O
,	O
Italy	O
.	O
Neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
is	O
a	O
tumor	O
of	O
pediatric	O
age	O
that	O
is	O
associated	O
with	O
high	O
mortality	O
in	O
metastatic	O
stages	O
,	O
although	O
stage	O
IVS	O
patients	O
undergo	O
frequent	O
spontaneous	O
regression	O
.	O
Since	O
apoptosis	O
has	O
been	O
proposed	O
as	O
a	O
possible	O
cause	O
of	O
remission	O
among	O
cancer	O
patients	O
,	O
we	O
tested	O
this	O
hypothesis	O
among	O
both	O
localized	O
and	O
metastatic	O
NB	B-malignancy-type
and	O
,	O
in	O
particular	O
,	O
NB	B-malignancy-type
metastatic	O
stage	O
IVS	O
.	O
We	O
have	O
assayed	O
36	O
localized	O
and	O
117	O
metastatic	O
neuroblastomas	B-malignancy-type
for	O
evidence	O
of	O
internucleosomal	O
DNA	O
degradation	O
and	O
confirmed	O
DNA	O
fragmentation	O
by	O
the	O
flow	O
cytometric	O
Terminal	O
deoxynucleotidyl	O
Transferase	O
method	O
,	O
which	O
also	O
allowed	O
us	O
to	O
measure	O
DNA	O
content	O
and	O
cell	O
cycle	O
phases	O
.	O
These	O
techniques	O
provided	O
evidence	O
of	O
apoptosis	O
in	O
18	O
out	O
of	O
153	O
samples	O
(	O
11.8	O
%	O
)	O
,	O
that	O
were	O
equally	O
distributed	O
among	O
all	O
stages	O
except	O
IVS	O
,	O
i.e	O
.	O
11.1	O
%	O
in	O
stage	O
I	O
(	O
2	O
/	O
18	O
)	O
,	O
11.1	O
%	O
in	O
stage	O
II	O
(	O
2	O
/	O
18	O
)	O
,	O
13.2	O
%	O
in	O
stage	O
III	O
(	O
5	O
/	O
38	O
)	O
,	O
13.4	O
%	O
in	O
stage	O
IV	O
(	O
9	O
/	O
67	O
)	O
,	O
and	O
0	O
%	O
in	O
stage	O
IVS	O
(	O
0	O
/	O
12	O
)	O
.	O
Tumor	O
tissue	O
samples	O
collected	O
at	O
onset	O
and	O
also	O
at	O
relapse	O
for	O
the	O
same	O
patients	O
showed	O
that	O
apoptosis	O
may	O
occur	O
at	O
relapse	O
.	O
In	O
addition	O
,	O
cells	O
appear	O
to	O
undergo	O
apoptosis	O
independently	O
from	O
N	O
-	O
myc	O
amplification	O
,	O
cell	O
cycle	O
phase	O
and	O
DNA	O
ploidy	O
.	O
In	O
conclusion	O
,	O
apoptosis	O
seems	O
to	O
take	O
place	O
with	O
about	O
an	O
equal	O
frequency	O
for	O
both	O
favourable	O
and	O
unfavourable	O
stages	O
with	O
an	O
exception	O
for	O
IVS	O
.	O
Since	O
DNA	O
fragmentation	O
remained	O
undetected	O
in	O
stage	O
IVS	O
,	O
we	O
suggest	O
that	O
apoptosis	O
is	O
not	O
a	O
mechanism	O
of	O
spontaneous	O
regression	O
for	O
these	O
patients	O
.	O
A	O
better	O
basic	O
understanding	O
of	O
the	O
complex	O
molecular	O
mechanisms	O
and	O
biochemical	O
pathways	O
that	O
control	O
apoptosis	O
in	O
neuroblastoma	B-malignancy-type
appears	O
to	O
be	O
necessary	O
.	O
PMID	O
:	O
9049850	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Microbiol	O
Immunol	O
.	O
2003	O
;47	O
(	O
10	O
)	O
:745-	O
57	O
.	O
Further	O
characterization	O
of	O
a	O
CD99	O
-	O
related	O
21	O
-	O
kDa	O
transmembrane	O
protein	O
(	O
VAP21	O
)	O
expressed	O
in	O
Syrian	O
hamster	O
cells	O
and	O
its	O
possible	O
involvement	O
in	O
vesicular	O
stomatitis	O
virus	O
production	O
.	O
Tochikura	O
TS	O
,	O
Xiao	O
S	O
,	O
Ego	O
T	O
,	O
Sagara	O
J,	O
Kawai	O
A	O
.	O
Department	O
of	O
Molecular	O
Microbiology	O
,	O
Graduate	O
School	O
of	O
Pharmaceutical	O
Sciences	O
,	O
Kyoto	O
University	O
,	O
Kyoto	O
,	O
Kyoto	O
606	O
-8051	O
,	O
Japan	O
.	O
The	O
VAP21	O
,	O
a	O
CD99	O
-	O
related	O
21	O
-	O
kDa	O
transmembrane	O
protein	O
,	O
was	O
first	O
detected	O
in	O
the	O
enveloped	O
virions	O
that	O
were	O
grown	O
in	O
a	O
Syrian	O
hamster	O
-	O
derived	O
cell	O
line	O
,	O
BHK	O
-	O
21	O
(	O
Sagara	O
et	O
al.	O
,	O
1997	O
;	O
Yamamoto	O
et	O
al.	O
,	O
1999	O
)	O
.	O
We	O
further	O
tried	O
to	O
elucidate	O
the	O
nature	O
and	O
properties	O
of	O
VAP21	O
.	O
The	O
VAP21	O
was	O
detected	O
in	O
various	O
organs	O
of	O
the	O
Syrian	O
hamster	O
as	O
well	O
as	O
in	O
the	O
Syrian	O
hamster	O
-	O
derived	O
cell	O
lines	O
(	O
BHK	O
-	O
21	O
and	O
HmLu	O
-	O
1	O
)	O
.	O
We	O
could	O
not	O
detect	O
the	O
VAP21	O
antigen	O
in	O
other	O
cell	O
lines	O
derived	O
from	O
other	O
animal	O
species	O
we	O
examined	O
,	O
including	O
a	O
Chinese	O
hamster	O
(	O
CHO	O
-	O
K1	O
)	O
,	O
mouse	O
(	O
neuroblastoma	B-malignancy-type
C1300	O
,	O
clone	O
NA	O
)	O
,	O
dog	O
(	O
MDCK	O
)	O
,	O
monkey	O
(	O
COS	O
-	O
7	O
)	O
,	O
and	O
human	O
(	O
HeLa	O
,	O
HepG2	O
)	O
.	O
We	O
tried	O
to	O
introduce	O
the	O
VAP21	O
gene	O
into	O
VAP21	O
-	O
negative	O
cell	O
lines	O
using	O
a	O
tetracycline	O
-	O
regulated	O
gene	O
expression	O
system	O
.	O
All	O
of	O
our	O
trials	O
,	O
however	O
,	O
resulted	O
in	O
failure	O
to	O
establish	O
stably	O
positive	O
inducible	O
cell	O
lines	O
.	O
To	O
the	O
contrary	O
,	O
we	O
could	O
easily	O
establish	O
the	O
VAP21	O
-	O
overexpressing	O
cell	O
lines	O
from	O
the	O
Syrian	O
hamster	O
cell	O
lines	O
,	O
which	O
were	O
successfully	O
grown	O
and	O
maintained	O
without	O
any	O
loss	O
of	O
VAP21	O
expression	O
even	O
under	O
the	O
induced	O
culture	O
conditions	O
.	O
In	O
such	O
VAP21	O
-	O
overexpressing	O
cells	O
,	O
production	O
of	O
the	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
was	O
increased	O
several	O
-	O
fold	O
,	O
while	O
suppression	O
of	O
the	O
VAP21	O
expression	O
resulted	O
in	O
reducing	O
the	O
VSV	O
yields	O
.	O
From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
VAP21	O
is	O
a	O
physiologically	O
active	O
cell	O
membrane	O
component	O
of	O
some	O
animal	O
species	O
including	O
the	O
Syrian	O
hamster	O
,	O
and	O
might	O
positively	O
be	O
involved	O
in	O
the	O
VSV	O
replication	O
.	O
PMID	O
:	O
14605441	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1992	O
Oct	O
15	O
;52(	O
20	O
)	O
:	O
572	O
5-31	O
.	O
Glycosylation	O
pathways	O
in	O
the	O
biosynthesis	O
of	O
gangliosides	O
in	O
melanoma	B-malignancy-type
and	O
neuroblastoma	B-malignancy-type
cells	O
:	O
relative	O
glycosyltransferase	O
levels	O
determine	O
ganglioside	O
patterns	O
.	O
Ruan	O
S	O
,	O
Lloyd	O
KO	O
.	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
10021	O
.	O
In	O
order	O
to	O
elucidate	O
some	O
of	O
the	O
factors	O
that	O
determine	O
the	O
characteristic	O
expression	O
of	O
gangliosides	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
neuroblastoma	B-malignancy-type
the	O
levels	O
of	O
ganglioside	O
synthases	O
(	O
glycosyltransferases	O
)	O
were	O
determined	O
in	O
a	O
panel	O
of	O
cell	O
lines	O
from	O
those	O
tumors	O
that	O
exhibited	O
a	O
wide	O
range	O
of	O
ganglioside	O
composition	O
.	O
Sialyltransferases	O
(	O
GM3	O
,	O
GD3	O
,	O
GD1a	O
,	O
and	O
GT1b	O
synthases	O
)	O
,	O
N	O
-	O
acetylgalactosaminyltransferases	O
(	O
GM2	O
and	O
GD2	O
synthases	O
)	O
,	O
and	O
galactosyltransferase	O
(	O
GM1	O
and	O
GD1b	O
synthases	O
)	O
were	O
analyzed	O
in	O
crude	O
membrane	O
preparations	O
from	O
these	O
cells	O
.	O
The	O
results	O
confirmed	O
the	O
importance	O
of	O
GM3	O
and	O
GD3	O
synthases	O
in	O
determining	O
the	O
prominence	O
of	O
the	O
a	O
(	O
GM3	O
to	O
GT1a	O
)	O
or	O
b	O
(	O
GD3	O
to	O
GQ1b	O
)	O
biosynthetic	O
pathways	O
.	O
The	O
overall	O
ganglioside	O
composition	O
in	O
cells	O
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
relative	O
levels	O
of	O
specific	O
enzymes	O
acting	O
sequentially	O
or	O
in	O
competing	O
pathways	O
.	O
In	O
general	O
,	O
the	O
pattern	O
and	O
levels	O
of	O
transferases	O
correlated	O
with	O
the	O
actual	O
ganglioside	O
content	O
of	O
the	O
cell	O
line	O
,	O
although	O
several	O
important	O
discrepancies	O
were	O
noted	O
.	O
For	O
example	O
,	O
in	O
cell	O
lines	O
containing	O
high	O
amounts	O
of	O
GD2	O
ganglioside	O
,	O
the	O
level	O
of	O
the	O
preceding	O
enzyme	O
in	O
the	O
pathway	O
(	O
GD3	O
synthase	O
)	O
was	O
unexpectedly	O
low	O
.	O
Thus	O
,	O
the	O
high	O
GD2	O
:	O
GD3	O
ratios	O
characteristic	O
of	O
most	O
neuroblastomas	B-malignancy-type
result	O
from	O
low	O
levels	O
of	O
GD3	O
synthase	O
as	O
well	O
as	O
high	O
levels	O
of	O
GD2	O
synthase	O
.	O
In	O
other	O
cell	O
lines	O
,	O
GD3	O
synthase	O
was	O
completely	O
absent	O
,	O
resulting	O
in	O
the	O
synthesis	O
of	O
GM2	O
,	O
but	O
not	O
GD2	O
,	O
by	O
N	O
-	O
acetylgalactosaminyltransferase	O
I	O
,	O
as	O
would	O
be	O
expected	O
.	O
It	O
was	O
concluded	O
that	O
different	O
glycosyltransferases	O
play	O
key	O
roles	O
in	O
determining	O
glycolipid	O
expression	O
in	O
different	O
cell	O
types	O
.	O
PMID	O
:	O
1394196	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Neurol	O
.	O
2003	O
May	O
;181	O
(	O
1	O
)	O
:25-38	O
.	O
Dependence	O
on	O
electron	O
transport	O
chain	O
function	O
and	O
intracellular	O
signaling	O
of	O
genomic	O
responses	O
in	O
SH	O
-	O
SY5Y	O
cells	O
to	O
the	O
mitochondrial	O
neurotoxin	O
MPP	O
(+)	O
.	O
Brill	O
LB	O
2nd	O
,	O
Bennett	O
JP	O
Jr	O
.	O
Center	O
for	O
the	O
Study	O
of	O
Neurodegenerative	O
Diseases	O
and	O
Medical	O
Scientist	O
Training	O
Program	O
,	O
University	O
of	O
Virginia	O
,	O
Charlottesville	O
,	O
VA	O
22908	O
,	O
USA	O
.	O
SH	O
-	O
SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
exposed	O
to	O
the	O
complex	O
I	O
inhibitor	O
/	O
parkinsonian	O
neurotoxin	O
methylpyridinium	O
ion	O
(	O
MPP	O
(+)	O
)	O
activate	O
both	O
survival	O
and	O
death	O
-	O
promoting	O
signaling	O
pathways	O
and	O
undergo	O
MEK	O
/	O
ERK	O
-	O
dependent	O
,	O
phosphatidylinositol	O
-	O
3	O
kinase	O
-	O
dependent	O
,	O
and	O
c	O
-	O
Jun	O
kinase	O
-	O
dependent	O
cell	O
death	O
.	O
Because	O
genomic	O
responses	O
to	O
MPP	O
(+)	O
are	O
not	O
extensively	O
characterized	O
,	O
we	O
used	O
nylon	O
cDNA	O
arrays	O
to	O
measure	O
gene	O
expression	O
following	O
exposure	O
to	O
an	O
apoptosis	O
-	O
producing	O
[	O
MPP	O
(+)	O
]	O
.	O
Many	O
changes	O
occurred	O
within	O
5	O
min	O
,	O
and	O
all	O
gene	O
expression	O
changes	O
appeared	O
before	O
biochemical	O
and	O
morphological	O
markers	O
of	O
apoptosis	O
.	O
The	O
majority	O
of	O
gene	O
expression	O
changes	O
in	O
SY5Y	O
were	O
not	O
found	O
in	O
rho(0)	O
cells	O
,	O
indicating	O
dependence	O
of	O
these	O
changes	O
on	O
intact	O
electron	O
transport	O
activity	O
.	O
rho(0)	O
cells	O
exposed	O
to	O
MPP	O
(+)	O
produced	O
different	O
expression	O
profiles	O
,	O
indicating	O
the	O
potential	O
for	O
responses	O
independent	O
of	O
complex	O
I	O
inhibition	O
.	O
MPP	O
(+)	O
-	O
induced	O
gene	O
expression	O
patterns	O
in	O
normal	O
SY5Y	O
cells	O
were	O
sensitive	O
to	O
inhibitors	O
of	O
MEK	O
/	O
ERK	O
(	O
UO	O
126	O
)	O
or	O
phosphatidylinositol	O
-	O
3	O
kinase	O
(	O
LY	O
294002	O
)	O
,	O
demonstrating	O
regulation	O
of	O
gene	O
expression	O
by	O
these	O
survival	O
-	O
promoting	O
signaling	O
pathways	O
.	O
The	O
primary	O
signaling	O
molecules	O
mediating	O
these	O
MPP	O
(+)	O
-	O
induced	O
gene	O
expression	O
changes	O
are	O
unknown	O
but	O
ultimately	O
utilize	O
MEK	O
/	O
ERK	O
and	O
phosphatidylinositol	O
-	O
3	O
kinase	O
signaling	O
.	O
Genes	O
suppressed	O
by	O
UO	O
126	O
or	O
LY	O
294002	O
during	O
MPP	O
(+)	O
exposure	O
may	O
mediate	O
cell	O
survival	O
;	O
those	O
expressed	O
in	O
the	O
presence	O
of	O
UO	O
126	O
or	O
LY	O
294002	O
may	O
mediate	O
cell	O
death	O
in	O
this	O
in	O
vitro	O
model	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O
PMID	O
:	O
12710931	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Cell	O
Res	O
.	O
1985	O
Mar;157	O
(	O
1	O
)	O
:253	O
-64	O
.	O
The	O
cell	O
specificity	O
and	O
biosynthesis	O
of	O
mouse	O
glycophorins	O
studied	O
with	O
monoclonal	O
antibodies	O
.	O
Kasturi	O
K,	O
Harrison	O
P.	O
Murine	O
erythropoiesis	O
represents	O
a	O
favourable	O
system	O
in	O
which	O
to	O
investigate	O
the	O
coordinate	O
regulation	O
of	O
gene	O
expression	O
due	O
to	O
the	O
availability	O
of	O
erythroid	O
precursor	O
cells	O
at	O
various	O
stages	O
of	O
differentiation	O
.	O
In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
biosynthesis	O
and	O
cell	O
specificity	O
of	O
two	O
characteristic	O
murine	O
RBC	O
membrane	O
glycoproteins	O
that	O
resemble	O
the	O
human	O
RBC	O
glycophorins	O
:	O
a	O
major	O
component	O
of	O
apparent	O
molecular	O
mass	O
31	O
kD	O
(	O
glycophorin	O
MA	O
)	O
and	O
a	O
minor	O
46	O
kD	O
component	O
(	O
glycophorin	O
MB	O
)	O
.	O
Both	O
glycophorins	O
bind	O
to	O
wheat	O
germ	O
lectin	O
and	O
share	O
a	O
common	O
protein	O
antigenic	O
determinant	O
recognised	O
by	O
a	O
monoclonal	O
antibody	O
(	O
GP	O
29.4	O
)	O
,	O
but	O
they	O
differ	O
significantly	O
in	O
their	O
carbohydrate	O
components	O
:	O
whilst	O
both	O
glycophorins	O
contain	O
mainly	O
O-	O
linked	O
sugars	O
,	O
glycophorin	O
MA	O
contains	O
in	O
addition	O
at	O
least	O
one	O
N-	O
linked	O
carbohydrate	O
residue	O
and	O
terminal	O
sialic	O
acid	O
residues	O
.	O
Pulse	O
-	O
chase	O
in	O
vivo	O
labelling	O
experiments	O
combined	O
with	O
in	O
vitro	O
translations	O
of	O
glycophorin	O
mRNAs	O
show	O
that	O
the	O
initial	O
precursor	O
to	O
glycophorin	O
MA	O
is	O
a	O
24.5	O
kD	O
polypeptide	O
which	O
is	O
subsequently	O
processed	O
and	O
glycosylated	O
to	O
give	O
the	O
mature	O
31	O
kD	O
molecule	O
via	O
a	O
21.5	O
kD	O
polypeptide	O
intermediate	O
.	O
Both	O
glycophorins	O
MA	O
and	O
MB	O
are	O
synthesized	O
most	O
actively	O
in	O
early	O
to	O
mid	O
erythroblasts	O
(	O
e.g.	O
,	O
Friend	O
cells	O
induced	O
for	O
3	O
days	O
with	O
DMSO	O
)	O
but	O
their	O
synthesis	O
is	O
considerably	O
reduced	O
by	O
the	O
reticulocyte	O
stage	O
.	O
However	O
,	O
of	O
the	O
other	O
cell	O
types	O
tested	O
(	O
neuroblastoma	B-malignancy-type
,	O
myeloma	B-malignancy-type
,	O
fibroblasts	O
,	O
epithelial	O
cells	O
and	O
T-lymphoma	B-malignancy-type
cells	O
)	O
,	O
none	O
synthesizes	O
glycophorin	O
with	O
the	O
possible	O
exception	O
of	O
a	O
low	O
level	O
in	O
thymus	O
tissue	O
.	O
Thus	O
murine	O
glycophorins	O
,	O
in	O
contrast	O
to	O
the	O
RBC	O
cytoskeletal	O
proteins	O
(	O
spectrin	O
,	O
ankyrin	O
,	O
band	O
4.1	O
)	O
seem	O
to	O
be	O
restricted	O
to	O
the	O
erythroid	O
cell	O
lineage	O
like	O
human	O
glycophorin	O
.	O
PMID	O
:	O
3855753	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1995	O
Mar	O
16;10(	O
6	O
)	O
:	O
1087	O
-	O
93	O
.	O
Constitutional	O
translocation	O
t(	O
1	O
;	O
17	O
)	O
(	O
p36.31	O
-	O
p36.13	O
q11.2	O
q12.1	O
)	O
in	O
a	O
neuroblastoma	B-malignancy-type
patient	O
.	O
Establishment	O
of	O
somatic	O
cell	O
hybrids	O
and	O
identification	O
of	O
PND	O
/	O
A12M2	O
on	O
chromosome	O
1	O
and	O
NF1	O
/	O
SCYA7	O
on	O
chromosome	O
17	O
as	O
breakpoint	O
flanking	O
single	O
copy	O
markers	O
.	O
Laureys	O
G	O
,	O
Speleman	O
F	O
,	O
Versteeg	O
R	O
,	O
van	O
der	O
Drift	O
P,	O
Chan	O
A	O
,	O
Leroy	O
J,	O
Francke	O
U	O
,	O
Opdenakker	O
G	O
,	O
Van	O
Roy	O
N	O
.	O
Department	O
of	O
Pediatric	O
Oncology	O
,	O
University	O
Hospital	O
,	O
Ghent	O
,	O
Belgium	O
.	O
Cytogenetic	O
and	O
molecular	O
studies	O
in	O
neuroblastoma	B-malignancy-type
suggest	O
the	O
presence	O
of	O
a	O
tumor	O
suppressor	O
gene	O
at	O
the	O
distal	O
band	O
p36	O
of	O
human	O
chromosome	O
1	O
.	O
We	O
described	O
a	O
constitutional	O
translocation	O
t(	O
1	O
;	O
17	O
)	O
(	O
p36	O
;	O
q12-q21	O
)	O
,	O
involving	O
the	O
critical	O
region	O
1p36	O
,	O
in	O
a	O
patient	O
with	O
neuroblastoma	B-malignancy-type
,	O
and	O
hypothesized	O
that	O
the	O
translocation	O
predisposed	O
the	O
patient	O
to	O
tumor	O
development	O
.	O
Here	O
we	O
report	O
the	O
molecular	O
delineation	O
of	O
the	O
translocation	O
breakpoints	O
.	O
Somatic	O
cell	O
hybrids	O
were	O
generated	O
by	O
fusion	O
of	O
the	O
patient	O
's	O
fibroblasts	O
with	O
the	O
thymidine	O
kinase	O
deficient	O
hamster	O
cell	O
line	O
,	O
a3	O
.	O
In	O
hybrid	O
cell	O
lines	O
which	O
retained	O
the	O
human	O
derivative	O
chromosomes	O
,	O
the	O
position	O
of	O
chromosome	O
1p	O
and	O
17q	O
DNA	O
probes	O
respective	O
to	O
the	O
translocation	O
breakpoints	O
was	O
determined	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
Southern	O
blot	O
analysis	O
.	O
The	O
chromosome	O
1p	O
breakpoint	O
was	O
localized	O
within	O
a	O
repetitive	O
region	O
encoding	O
t-	O
RNA	O
genes	O
,	O
with	O
12A-2	O
(	O
PND	O
)	O
as	O
most	O
distal	O
and	O
pHE2.6	O
(	O
A12M2	O
)	O
as	O
most	O
proximal	O
single-copy	O
breakpoint	O
flanking	O
markers	O
.	O
For	O
the	O
chromosome	O
17	O
breakpoint	O
,	O
the	O
proximal	O
and	O
distal	O
flanking	O
markers	O
were	O
identified	O
as	O
7G4	O
(	O
NF1	O
)	O
and	O
cMCP-3	O
(	O
SCYA7	O
)	O
,	O
respectively	O
.	O
In	O
this	O
study	O
,	O
cMCP-3	O
(	O
SCYA7	O
)	O
,	O
encoding	O
the	O
human	O
monocyte	O
chemotactic	O
protein	O
-3	O
,	O
was	O
mapped	O
between	O
NF1	O
and	O
ERBB2	O
.	O
As	O
a	O
pivotal	O
step	O
towards	O
breakpoint	O
cloning	O
,	O
at	O
present	O
these	O
flanking	O
markers	O
optimally	O
delineate	O
the	O
breakpoint	O
regions	O
of	O
both	O
chromosomes	O
1	O
and	O
17	O
at	O
the	O
molecular	O
level	O
.	O
PMID	O
:	O
7700633	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1992	O
Feb	O
15	O
;89	O
(	O
4	O
)	O
:1512-6.	O
A	O
human	O
Id	O
-	O
like	O
helix-loop-helix	O
protein	O
expressed	O
during	O
early	O
development	O
.	O
Biggs	O
J,	O
Murphy	O
EV	O
,	O
Israel	O
MA.	O
Preuss	O
Laboratory	O
for	O
Molecular	O
Neuro-oncology	O
,	O
Department	O
of	O
Neurological	O
Surgery	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
California	O
,	O
Box	O
0520	O
,	O
San	O
Francisco	O
94143	O
.	O
The	O
interaction	O
of	O
helix-loop-helix	O
(	O
HLH	O
)	O
proteins	O
is	O
known	O
to	O
regulate	O
the	O
differentiation	O
of	O
several	O
different	O
tissues	O
,	O
including	O
mammalian	O
muscle	O
and	O
the	O
insect	O
peripheral	O
nervous	O
system	O
.	O
In	O
myoblasts	O
,	O
the	O
products	O
of	O
myogenic	O
HLH	O
genes	O
such	O
as	O
MyoD	O
and	O
ubiquitous	O
HLH	O
proteins	O
such	O
as	O
E12	O
are	O
present	O
at	O
constant	O
levels	O
throughout	O
development	O
.	O
An	O
E12	O
monomer	O
and	O
a	O
MyoD	O
monomer	O
form	O
a	O
DNA	O
binding	O
heterodimer	O
that	O
activates	O
muscle	O
-	O
specific	O
genes	O
.	O
These	O
two	O
proteins	O
are	O
unable	O
to	O
dimerize	O
in	O
proliferating	O
myoblasts	O
because	O
a	O
negative	O
regulator	O
HLH	O
protein	O
,	O
Id	O
,	O
is	O
present	O
.	O
We	O
now	O
report	O
the	O
sequence	O
and	O
structure	O
of	O
a	O
human	O
HLH	O
gene	O
related	O
to	O
Id	O
,	O
which	O
has	O
been	O
designated	O
Id-2	O
.	O
Two	O
prominent	O
Id-2	O
RNA	O
molecules	O
of	O
2.5	O
and	O
1.3	O
kilobases	O
were	O
found	O
in	O
a	O
number	O
of	O
different	O
human	O
normal	O
and	O
neoplastic	O
tissues	O
.	O
We	O
believe	O
the	O
larger	O
RNA	O
is	O
a	O
precursor	O
of	O
the	O
1.3-kilobase	O
mRNA	O
that	O
encodes	O
an	O
Id-2	O
protein	O
of	O
134	O
amino	O
acids	O
.	O
The	O
HLH	O
region	O
of	O
the	O
Id-2	O
protein	O
is	O
90	O
%	O
homologous	O
to	O
that	O
of	O
myogenic	O
Id	O
,	O
but	O
the	O
homology	O
is	O
much	O
less	O
extensive	O
outside	O
the	O
HLH	O
region	O
.	O
The	O
Id-2	O
gene	O
is	O
highly	O
expressed	O
during	O
early	O
fetal	O
development	O
in	O
several	O
tissues	O
,	O
including	O
those	O
of	O
the	O
central	O
nervous	O
system	O
,	O
but	O
is	O
not	O
expressed	O
in	O
the	O
corresponding	O
mature	O
tissues	O
.	O
Id-2	O
expression	O
is	O
modulated	O
in	O
association	O
with	O
retinoic	O
acid	O
-	O
induced	O
ganglionic	O
differentiation	O
of	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SMS-KCNR.	O
These	O
findings	O
suggest	O
that	O
Id-2	O
is	O
an	O
inhibitor	O
of	O
tissue	O
-	O
specific	O
gene	O
expression	O
,	O
although	O
its	O
distinctive	O
pattern	O
of	O
expression	O
during	O
development	O
suggests	O
a	O
role	O
different	O
from	O
that	O
of	O
Id	O
.	O
PMID	O
:	O
1741406	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virchows	O
Arch	O
.	O
2002	O
May	O
;440	O
(	O
5	O
)	O
:476-84	O
.	O
Epub	O
2001	O
Dec	O
04	O
.	O
Characterization	O
of	O
the	O
malignant	O
melanoma	B-malignancy-type
of	I-malignancy-type
soft	I-malignancy-type
-	I-malignancy-type
parts	I-malignancy-type
cell	O
line	O
GG-62	O
by	O
expression	O
analysis	O
using	O
DNA	O
microarrays	O
.	O
Schaefer	O
KL	O
,	O
Wai	O
DH	O
,	O
Poremba	O
C	O
,	O
Korsching	O
E	O
,	O
van	O
Valen	O
F	O
,	O
Ozaki	O
T	O
,	O
Boecker	O
W	O
,	O
Dockhorn	O
-	O
Dworniczak	O
B.	O
Gerhard	O
-	O
Domagk-	O
Institute	O
of	O
Pathology	O
,	O
University	O
of	O
Munster	O
,	O
Domagkstrasse	O
17	O
,	O
48149	O
Munster	O
,	O
Germany	O
.	O
GG-62	O
is	O
a	O
cell	O
line	O
previously	O
thought	O
to	O
be	O
derived	O
from	O
an	O
atypical	O
Ewing	B-malignancy-type
tumor	I-malignancy-type
(	O
ET	B-malignancy-type
)	O
.	O
Reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
revealed	O
an	O
in	O
-	O
frame	O
fusion	O
between	O
the	O
Ewing	O
sarcoma	O
gene	O
(	O
EWS	O
)	O
codon	O
325	O
and	O
the	O
activating	O
transcription	O
factor	O
1	O
gene	O
(	O
ATF1	O
)	O
codon	O
65	O
which	O
permits	O
the	O
production	O
of	O
chimeric	O
EWS	O
-	O
ATF1	O
oncoproteins	O
.	O
We	O
also	O
identified	O
the	O
genomic	O
breakpoint	O
resulting	O
from	O
a	O
reciprocal	O
t	O
(	O
12	O
22	O
)	O
(q13	O
q12	O
)	O
,	O
which	O
is	O
the	O
hallmark	O
of	O
malignant	O
melanoma	B-malignancy-type
of	I-malignancy-type
soft	I-malignancy-type
parts	I-malignancy-type
(	O
MMSP	B-malignancy-type
)	O
.	O
We	O
applied	O
Affymetrix	O
human	O
cancer	O
G110	O
arrays	O
to	O
compare	O
the	O
gene	O
expression	O
patterns	O
of	O
GG-62	O
and	O
other	O
cell	O
lines	O
derived	O
from	O
small	B-malignancy-type
blue	I-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
.	O
Hierarchical	O
clustering	O
of	O
463	O
differentially	O
expressed	O
genes	O
distinguished	O
GG-62	O
from	O
the	O
ETs	B-malignancy-type
,	O
as	O
well	O
as	O
the	O
neuroblastomas	B-malignancy-type
,	O
and	O
revealed	O
a	O
cluster	O
of	O
36	O
upregulated	O
genes	O
.	O
Several	O
of	O
these	O
genes	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
that	O
may	O
be	O
critical	O
for	O
maintaining	O
cell	O
transformation	O
;	O
some	O
examples	O
are	O
avian	O
erythroblastic	O
leukemia	O
viral	O
oncogene	O
homolog	O
3	O
(	O
ERBB3	O
)	O
,	O
neuregulin	O
1	O
(	O
NRG1	O
)	O
,	O
fibroblast	O
growth	O
factor	O
9	O
(	O
FGF9	O
)	O
,	O
and	O
fibroblast	O
growth	O
factor	O
receptor-1	O
(	O
FGFR1	O
)	O
.	O
Furthermore	O
,	O
genes	O
near	O
the	O
chromosome	O
-	O
12q13	O
breakpoint	O
exhibited	O
increased	O
expression	O
of	O
GG-62	O
including	O
ERBB3	O
,	O
NR4A1	O
(	O
nuclear	O
receptor	O
subfamily	O
4	O
,	O
group	O
A	O
,	O
member	O
1	O
)	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
2	O
(	O
CDK2	O
)	O
,	O
and	O
alpha	O
5	O
integrin	O
(	O
ITGA5	O
)	O
.	O
Altogether	O
our	O
findings	O
demonstrate	O
the	O
MMSP	B-malignancy-type
derivation	O
of	O
GG-62	O
and	O
may	O
shed	O
light	O
on	O
the	O
mechanisms	O
of	O
tumorigenesis	O
in	O
this	O
rare	O
disease	O
.	O
PMID	O
:	O
12021921	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan;36	O
(	O
1	O
)	O
:	O
97	O
-	O
9.	O
Increased	O
expression	O
of	O
p27Kip1	O
arrests	O
neuroblastoma	B-malignancy-type
cell	O
growth	O
.	O
Matsuo	O
T	O
,	O
Seth	O
P,	O
Thiele	O
CJ.	O
Division	O
of	O
Clinical	O
Sciences	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
-1928	O
,	O
USA	O
.	O
BACKGROUND	O
AND	O
PROCEDURE	O
:	O
To	O
investigate	O
the	O
molecular	O
mechanisms	O
by	O
which	O
retinoic	O
acid	O
(	O
RA	O
)	O
alters	O
cell	O
growth	O
,	O
the	O
expression	O
and	O
activity	O
of	O
components	O
of	O
the	O
cell	O
cycle	O
machinery	O
were	O
analyzed	O
.	O
RESULTS	O
AND	O
CONCLUSIONS	O
:	O
Within	O
2	O
days	O
of	O
RA	O
treatment	O
,	O
and	O
prior	O
to	O
the	O
arrest	O
of	O
NB	B-malignancy-type
cells	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
there	O
was	O
a	O
complete	O
downregulation	O
of	O
GI	O
cyclin	O
/	O
cdk	O
activities	O
.	O
Protein	O
levels	O
for	O
the	O
G1	O
cyclin	O
/	O
cdk	O
were	O
essentially	O
unchanged	O
during	O
this	O
time	O
,	O
although	O
there	O
was	O
a	O
decrease	O
in	O
the	O
steady	O
state	O
levels	O
of	O
hyperphosphorylated	O
Rb	O
and	O
p60N-MYC	O
proteins	O
.	O
The	O
cdk	O
inhibitors	O
,	O
p21Cip1	O
and	O
p27Kip1	O
were	O
constitutively	O
expressed	O
in	O
KCNR	O
,	O
while	O
p15	O
INK4B	O
and	O
p16	O
INK4A	O
mRNA	O
were	O
undetected	O
.	O
Within	O
24	O
hr	O
of	O
RA	O
treatment	O
,	O
there	O
was	O
a	O
4	O
-	O
fold	O
increase	O
in	O
the	O
expression	O
of	O
p27Kip1	O
,	O
although	O
p27	O
mRNA	O
levels	O
were	O
unchanged	O
.	O
Levels	O
of	O
p21Cip1	O
were	O
unaltered	O
.	O
Coincident	O
with	O
the	O
decrease	O
in	O
kinase	O
activity	O
there	O
was	O
an	O
increase	O
in	O
p27	O
bound	O
to	O
G1	O
cyclin	O
/	O
cdk	O
.	O
The	O
increase	O
in	O
p27	O
was	O
not	O
due	O
to	O
an	O
increase	O
in	O
transcription	O
.	O
In	O
other	O
cell	O
systems	O
,	O
increased	O
expression	O
of	O
c-MYC	O
has	O
been	O
shown	O
to	O
lead	O
to	O
a	O
decrease	O
in	O
p27	O
levels	O
that	O
is	O
regulated	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
(	O
sequestration	O
)	O
.	O
To	O
determine	O
whether	O
increased	O
levels	O
of	O
N-MYC	O
could	O
affect	O
the	O
level	O
of	O
p27	O
,	O
we	O
evaluated	O
the	O
expression	O
of	O
p27	O
in	O
a	O
series	O
of	O
N-MYC	O
transfected	O
cells	O
and	O
found	O
that	O
constitutive	O
overexpression	O
of	O
N-MYC	O
led	O
to	O
a	O
decrease	O
in	O
the	O
steady	O
-state	O
levels	O
of	O
p27	O
and	O
in	O
p27	O
bound	O
to	O
G1	O
cyclin	O
/	O
cdk	O
complexes	O
.	O
Using	O
adenoviral	O
vectors	O
expressing	O
p27	O
,	O
we	O
found	O
that	O
infection	O
leads	O
to	O
increased	O
p27	O
expression	O
,	O
which	O
causes	O
a	O
decrease	O
in	O
cdk	O
activity	O
and	O
an	O
accumulation	O
of	O
cells	O
in	O
G1	O
.	O
PMID	O
:	O
11464914	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Mol	O
Neurosci	O
.	O
2003	O
;20(	O
3	O
)	O
:	O
267	O
-	O
75	O
.	O
Drug	O
discovery	O
targeted	O
to	O
the	O
Alzheimer	O
's	O
APP	O
mRNA	O
5'-untranslated	O
region	O
:	O
the	O
action	O
of	O
paroxetine	O
and	O
dimercaptopropanol	O
.	O
Payton	O
S	O
,	O
Cahill	O
CM	O
,	O
Randall	O
JD	O
,	O
Gullans	O
SR	O
,	O
Rogers	O
JT.	O
Genetics	O
and	O
Aging	O
Research	O
Unit	O
,	O
Department	O
of	O
Psychiatry	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Charlestown	O
,	O
MA	O
02129	O
,	O
USA	O
.	O
We	O
screened	O
for	O
drugs	O
that	O
specifically	O
interact	O
with	O
the	O
5'-untranslated	O
region	O
of	O
the	O
mRNA	O
encoding	O
the	O
Alzheimer	O
's	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
.	O
Our	O
goal	O
was	O
to	O
use	O
newly	O
discovered	O
APP	O
5	O
'	O
UTR	O
directed	O
compounds	O
to	O
limit	O
amyloid	O
-	O
beta	O
(	O
Abeta	O
peptide	O
output	O
in	O
cell	O
culture	O
systems	O
.	O
The	O
APP	O
5	O
'	O
UTR	O
folds	O
into	O
a	O
stable	O
RNA	O
secondary	O
structure	O
(	O
Gibbs	O
free	O
energy	O
:	O
DeltaG	O
=	O
-	O
54	O
.9	O
kcal	O
/	O
mol	O
)	O
and	O
is	O
an	O
important	O
regulator	O
of	O
the	O
amount	O
of	O
APP	O
translated	O
in	O
response	O
to	O
IL-1	O
(	O
Nilsson	O
et	O
al.	O
,	O
1998	O
;	O
Rogers	O
et	O
al.	O
,	O
1999	O
)	O
and	O
iron	O
(	O
Rogers	O
et	O
al.	O
,	O
2002	O
)	O
.	O
Seventeen	O
drug	O
"	O
hits	O
"	O
were	O
identified	O
from	O
a	O
library	O
of	O
1,200	O
FDA	O
preapproved	O
drugs	O
(	O
Rogers	O
et	O
al.	O
,	O
2002	O
)	O
.	O
Six	O
of	O
the	O
original	O
17	O
compounds	O
were	O
validated	O
for	O
their	O
capacity	O
to	O
suppress	O
reporter	O
gene	O
expression	O
in	O
stable	O
neuroblastoma	B-malignancy-type
transfectants	O
expressing	O
the	O
dicistronic	O
reporter	O
construct	O
shown	O
in	O
Fig	O
.	O
2.	O
These	O
six	O
leads	O
suppressed	O
APP	O
5	O
'	O
UTR	O
driven	O
luciferase	O
translation	O
while	O
causing	O
no	O
effect	O
on	O
the	O
translation	O
of	O
dicistronic	O
GFP	O
gene	O
translated	O
from	O
a	O
viral	O
IRES	O
(	O
negative	O
control	O
to	O
ensure	O
specificity	O
during	O
drug	O
screens	O
)	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
paroxetine	O
(	O
serotonin	O
reuptake	O
blocker	O
)	O
and	O
dimercaptopropanol	O
(	O
Hg	O
chelator	O
)	O
exerted	O
significant	O
effects	O
on	O
APP	O
expression	O
(	O
steady	O
-state	O
levels	O
of	O
APP	O
)	O
,	O
whereas	O
Azithromycin	O
altered	O
APP	O
processing	O
.	O
None	O
of	O
these	O
three	O
compounds	O
altered	O
APLP-1	O
expression	O
.	O
In	O
the	O
future	O
,	O
we	O
will	O
identify	O
further	O
novel	O
compounds	O
that	O
influence	O
Abeta	O
levels	O
,	O
either	O
via	O
translation	O
inhibition	O
or	O
by	O
changing	O
the	O
activity	O
of	O
proteins	O
coupled	O
between	O
APP	O
translation	O
and	O
APP	O
processing	O
.	O
PMID	O
:	O
14501007	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
2002	O
Jan	O
11;92	O
4(	O
2	O
)	O
:159	O
-	O
66	O
.	O
Depletion	O
of	O
intracellular	O
calcium	O
stores	O
is	O
toxic	O
to	O
SH-SY5Y	O
neuronal	O
cells	O
.	O
Nguyen	O
HN	O
,	O
Wang	O
C	O
,	O
Perry	O
DC.	O
Department	O
of	O
Pharmacology	O
,	O
George	O
Washington	O
University	O
Medical	O
Center	O
,	O
2300	O
I	O
St.	O
NW	O
,	O
20037	O
,	O
Washington	O
,	O
DC	O
,	O
USA	O
Inhibiting	O
Ca(2+)	O
uptake	O
by	O
the	O
sarcoendoplasmic	O
reticular	O
Ca(2+)-	O
ATPase	O
pump	O
(	O
SERCA	O
)	O
causes	O
release	O
of	O
Ca(2+)	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
,	O
increased	O
cytosolic	O
Ca(2+)	O
(	O
[Ca(2+)	O
](cyt	O
)	O
)	O
and	O
depletion	O
of	O
ER	O
Ca(2+)	O
stores	O
.	O
These	O
studies	O
were	O
designed	O
to	O
test	O
the	O
effects	O
of	O
SERCA	O
inhibition	O
on	O
neuronal	O
viability	O
,	O
using	O
as	O
a	O
model	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SH-SY5Y	O
.	O
Continuous	O
exposure	O
to	O
the	O
SERCA	O
inhibitor	O
thapsigargin	O
(	O
TG	O
)	O
decreased	O
SH-SY5Y	O
viability	O
to	O
<30	O
%	O
after	O
48	O
h	O
exposure	O
,	O
and	O
produced	O
DNA	O
laddering	O
.	O
Two	O
other	O
SERCA	O
inhibitors	O
,	O
BHQ	O
and	O
cyclopiazonic	O
acid	O
CPA	O
,	O
were	O
similarly	O
toxic	O
,	O
although	O
at	O
1000	O
-	O
fold	O
higher	O
concentrations	O
.	O
BHQ	O
and	O
CPA	O
toxicity	O
was	O
prevented	O
by	O
removing	O
drug	O
within	O
several	O
hours	O
,	O
whereas	O
TG	O
toxicity	O
was	O
essentially	O
irreversible	O
.	O
All	O
three	O
SERCA	O
inhibitors	O
caused	O
an	O
increase	O
in	O
[	O
Ca(2+)	O
](cyt	O
)	O
that	O
was	O
partially	O
blocked	O
by	O
the	O
ryanodine	O
receptor	O
inhibitors	O
,	O
dantrolene	O
and	O
DHBP	O
.	O
Pretreatment	O
with	O
40	O
microM	O
dantrolene	O
gave	O
substantial	O
protection	O
against	O
TG	O
-	O
or	O
BHQ	O
-	O
induced	O
cell	O
death	O
but	O
it	O
did	O
not	O
inhibit	O
death	O
from	O
staurosporine	O
,	O
which	O
does	O
not	O
cause	O
release	O
of	O
ER	O
Ca(2+	O
)	O
.	O
DHBP	O
(	O
20	O
-	O
100	O
microM	O
)	O
also	O
gave	O
partial	O
protection	O
against	O
TG	O
toxicity	O
,	O
as	O
did	O
ruthenium	O
red	O
(	O
2	O
microM	O
)	O
,	O
but	O
not	O
ryanodine	O
(	O
10	O
microM	O
)	O
.	O
Inhibition	O
of	O
capacitative	O
Ca(2+)	O
entry	O
with	O
EGTA	O
or	O
LaCl(3	O
)	O
or	O
low	O
extracellular	O
Ca(2+	O
)	O
,	O
or	O
chelation	O
of	O
[	O
Ca(2+)	O
](cyt	O
)	O
with	O
BAPTA	O
-	O
AM	O
,	O
failed	O
to	O
inhibit	O
TG	O
toxicity	O
,	O
although	O
they	O
prevented	O
increases	O
in	O
[	O
Ca(2+)	O
](cyt	O
)	O
caused	O
by	O
TG.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
toxicity	O
caused	O
by	O
SERCA	O
inhibition	O
in	O
SH-SY5Y	O
cells	O
is	O
caused	O
by	O
ER	O
Ca(2+)	O
depletion	O
,	O
which	O
triggers	O
an	O
apparent	O
apoptotic	O
pathway	O
.	O
PMID	O
:	O
11750901	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Differentiation	O
.	O
1990	O
Jul;44(	O
1	O
)	O
:	O
56-61	O
.	O
Complexities	O
and	O
sequence	O
similarities	O
of	O
mRNA	O
populations	O
of	O
cholinergic	O
(	O
NS20	O
-	O
Y	O
)	O
and	O
adrenergic	O
(	O
N1E-115	O
)	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Strauss	O
WL.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Miami	O
School	O
of	O
Medicine	O
,	O
FL	O
33101	O
.	O
The	O
clonal	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
NS20	O
-	O
Y	O
and	O
N1E-115	O
have	O
been	O
proposed	O
as	O
models	O
for	O
examining	O
the	O
commitment	O
of	O
neural	O
crest	O
cells	O
to	O
either	O
the	O
cholinergic	O
or	O
adrenergic	O
phenotype	O
,	O
respectively	O
.	O
The	O
validity	O
of	O
this	O
model	O
depends	O
in	O
part	O
on	O
the	O
extent	O
to	O
which	O
these	O
two	O
cell	O
lines	O
have	O
diverged	O
as	O
a	O
result	O
of	O
their	O
transformed	O
,	O
rather	O
than	O
neuronal	O
properties	O
.	O
In	O
order	O
to	O
quantitate	O
differences	O
in	O
gene	O
expression	O
between	O
NS20	O
-	O
Y	O
and	O
N1E-115	O
cells	O
,	O
the	O
mRNA	O
complexity	O
of	O
each	O
cell	O
type	O
was	O
determined	O
.	O
An	O
analysis	O
of	O
the	O
kinetics	O
of	O
hybridization	O
of	O
NS20	O
-	O
Y	O
cell	O
mRNA	O
with	O
cDNA	O
prepared	O
from	O
NS20	O
-	O
Y	O
cell	O
mRNA	O
demonstrated	O
the	O
presence	O
of	O
approximately	O
11,700	O
mRNA	O
species	O
assuming	O
an	O
average	O
length	O
of	O
1900	O
nucleotides	O
.	O
A	O
similar	O
analysis	O
using	O
mRNA	O
isolated	O
from	O
N1E-115	O
cells	O
and	O
cDNA	O
prepared	O
from	O
N1E-115	O
cell	O
mRNA	O
demonstrated	O
that	O
the	O
adrenergic	O
cell	O
line	O
expressed	O
approximately	O
11,600	O
mRNA	O
species	O
.	O
The	O
species	O
of	O
mRNA	O
expressed	O
by	O
each	O
cell	O
line	O
were	O
resolved	O
into	O
high	O
,	O
intermediate	O
,	O
and	O
low	O
abundance	O
populations	O
.	O
In	O
order	O
to	O
determine	O
whether	O
mRNAs	O
were	O
expressed	O
by	O
the	O
cholinergic	O
,	O
but	O
not	O
by	O
the	O
adrenergic	O
cell	O
line	O
,	O
NS20	O
-	O
Y	O
cDNA	O
was	O
hybridized	O
to	O
an	O
excess	O
of	O
N1E-115	O
cell	O
mRNA	O
.	O
An	O
analysis	O
of	O
the	O
solution	O
hybridization	O
kinetics	O
from	O
this	O
procedure	O
demonstrated	O
that	O
the	O
two	O
cell	O
lines	O
do	O
not	O
differ	O
significantly	O
in	O
the	O
nucleotide	O
complexity	O
of	O
their	O
mRNA	O
populations	O
.	O
The	O
extensive	O
similarity	O
between	O
the	O
two	O
mRNA	O
populations	O
suggests	O
that	O
only	O
a	O
small	O
number	O
of	O
genes	O
are	O
expressed	O
differentially	O
between	O
the	O
two	O
cell	O
lines	O
and	O
supports	O
their	O
use	O
as	O
models	O
for	O
the	O
differentiation	O
of	O
cholinergic	O
and	O
adrenergic	O
neurons	O
.	O
PMID	O
:	O
2253838	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
.	O
1998	O
Oct;20(	O
2	O
)	O
:	O
189	O
-	O
93	O
.	O
Comment	O
in	O
:	O
Nat	O
Genet	O
.	O
1998	O
Oct;20(	O
2	O
)	O
:	O
104	O
-6.	O
Tumour	O
amplified	O
kinase	O
STK15	O
/	O
BTAK	O
induces	O
centrosome	O
amplification	O
,	O
aneuploidy	O
and	O
transformation	O
.	O
Zhou	O
H,	O
Kuang	O
J,	O
Zhong	O
L,	O
Kuo	O
WL	O
,	O
Gray	O
JW	O
,	O
Sahin	O
A	O
,	O
Brinkley	O
BR	O
,	O
Sen	O
S.	O
Division	O
of	O
Pathology	O
&	O
Laboratory	O
Medicine	O
,	O
University	O
of	O
Texas	O
M.D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
77030	O
,	O
USA	O
.	O
The	O
centrosomes	O
are	O
thought	O
to	O
maintain	O
genomic	O
stability	O
through	O
the	O
establishment	O
of	O
bipolar	O
spindles	O
during	O
cell	O
division	O
,	O
ensuring	O
equal	O
segregation	O
of	O
replicated	O
chromosomes	O
to	O
two	O
daughter	O
cells	O
.	O
Deregulated	O
duplication	O
and	O
distribution	O
of	O
centrosomes	O
have	O
been	O
implicated	O
in	O
chromosome	O
segregation	O
abnormalities	O
,	O
leading	O
to	O
aneuploidy	O
seen	O
in	O
many	O
cancer	O
cell	O
types	O
.	O
Here	O
,	O
we	O
report	O
that	O
STK15	O
(	O
also	O
known	O
as	O
BTAK	O
and	O
aurora2	O
)	O
,	O
encoding	O
a	O
centrosome	O
-	O
associated	O
kinase	O
,	O
is	O
amplified	O
and	O
overexpressed	O
in	O
multiple	O
human	O
tumour	O
cell	O
types	O
,	O
and	O
is	O
involved	O
in	O
the	O
induction	O
of	O
centrosome	O
duplication	O
-distribution	O
abnormalities	O
and	O
aneuploidy	O
in	O
mammalian	O
cells	O
.	O
STK15	O
amplification	O
has	O
been	O
previously	O
detected	O
in	O
breast	B-malignancy-type
tumour	I-malignancy-type
cell	O
lines	O
and	O
in	O
colon	B-malignancy-type
tumours	I-malignancy-type
;	O
here	O
,	O
we	O
report	O
its	O
amplification	O
in	O
approximately	O
12	O
%	O
of	O
primary	O
breast	B-malignancy-type
tumours	I-malignancy-type
,	O
as	O
well	O
as	O
in	O
breast	B-malignancy-type
,	O
ovarian	B-malignancy-type
,	O
colon	B-malignancy-type
,	O
prostate	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
and	O
cervical	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Additionally	O
,	O
high	O
expression	O
of	O
STK15	O
mRNA	O
was	O
detected	O
in	O
tumour	O
cell	O
lines	O
without	O
evidence	O
of	O
gene	O
amplification	O
.	O
Ectopic	O
expression	O
of	O
STK15	O
in	O
mouse	O
NIH	O
3T3	O
cells	O
led	O
to	O
the	O
appearance	O
of	O
abnormal	O
centrosome	O
number	O
(	O
amplification	O
)	O
and	O
transformation	O
in	O
vitro	O
.	O
Finally	O
,	O
overexpression	O
of	O
STK15	O
in	O
near	O
diploid	O
human	O
breast	O
epithelial	O
cells	O
revealed	O
similar	O
centrosome	O
abnormality	O
,	O
as	O
well	O
as	O
induction	O
of	O
aneuploidy	O
.	O
These	O
findings	O
suggest	O
that	O
STK15	O
is	O
a	O
critical	O
kinase	O
-	O
encoding	O
gene	O
,	O
whose	O
overexpression	O
leads	O
to	O
centrosome	O
amplification	O
,	O
chromosomal	O
instability	O
and	O
transformation	O
in	O
mammalian	O
cells	O
.	O
PMID	O
:	O
9771714	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Leukoc	O
Biol	O
.	O
1999	O
Mar;6	O
5	O
(	O
3	O
)	O
:	O
39	O
7-406	O
.	O
Co-	O
expression	O
of	O
several	O
human	O
syntaxin	O
genes	O
in	O
neutrophils	O
and	O
differentiating	O
HL-60	O
cells	O
:	O
variant	O
isoforms	O
and	O
detection	O
of	O
syntaxin	O
1	O
.	O
Martin	O
-Martin	O
B	O
,	O
Nabokina	O
SM	O
,	O
Lazo	O
PA	O
,	O
Mollinedo	O
F.	O
Laboratory	O
of	O
Signal	O
Transduction	O
and	O
Leukocyte	O
Biology	O
,	O
Instituto	O
de	O
Biologia	O
y	O
Genetica	O
Molecular	O
,	O
Facultad	O
de	O
Medicina	O
,	O
Consejo	O
Superior	O
de	O
Investigaciones	O
Cientificas	O
-Universidad	O
de	O
Valladolid	O
,	O
Madrid	O
,	O
Spain	O
.	O
Syntaxins	O
are	O
major	O
components	O
of	O
vesicle	O
trafficking	O
and	O
their	O
pattern	O
of	O
expression	O
depends	O
on	O
the	O
cell	O
type	O
.	O
Using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
,	O
cloning	O
,	O
and	O
sequencing	O
techniques	O
,	O
we	O
have	O
found	O
that	O
human	O
neutrophils	O
and	O
neutrophil-differentiated	O
HL-60	O
cells	O
co	O
-	O
express	O
syntaxins	O
1A	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
9	O
,	O
11	O
,	O
and	O
16	O
.	O
These	O
genes	O
are	O
also	O
expressed	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
,	O
which	O
,	O
unlike	O
neutrophils	O
,	O
also	O
expressed	O
syntaxin	O
10	O
.	O
We	O
have	O
identified	O
two	O
isoforms	O
of	O
syntaxin	O
3	O
.	O
Syntaxin	O
3A	O
,	O
similar	O
to	O
the	O
previously	O
reported	O
syntaxin	O
3	O
,	O
and	O
the	O
novel	O
isoform	O
syntaxin	O
3B	O
,	O
which	O
is	O
identical	O
to	O
syntaxin	O
3A	O
but	O
lacks	O
37	O
amino	O
acid	O
residues	O
at	O
the	O
carboxy-terminal	O
region	O
.	O
Syntaxin	O
1	O
was	O
mainly	O
located	O
to	O
neutrophil	O
granule	O
membranes	O
by	O
confocal	O
microscopy	O
and	O
by	O
immunoblotting	O
of	O
subcellular	O
fractions	O
.	O
These	O
data	O
indicate	O
that	O
syntaxin	O
1	O
cannot	O
be	O
considered	O
specific	O
to	O
neural	O
tissues	O
.	O
The	O
level	O
of	O
expression	O
of	O
syntaxins	O
3	O
,	O
4	O
,	O
6	O
,	O
and	O
11	O
was	O
increased	O
during	O
neutrophil	O
differentiation	O
of	O
HL-60	O
cells	O
,	O
whereas	O
that	O
of	O
syntaxins	O
1A	O
,	O
5	O
,	O
9	O
,	O
and	O
16	O
was	O
unchanged	O
.	O
Syntaxin	O
7	O
was	O
not	O
expressed	O
in	O
undifferentiated	O
HL-60	O
cells	O
,	O
but	O
its	O
expression	O
was	O
induced	O
on	O
neutrophil	O
differentiation	O
.	O
The	O
expression	O
of	O
several	O
syntaxin	O
genes	O
in	O
human	O
neutrophils	O
could	O
be	O
related	O
to	O
the	O
high	O
secretory	O
capacity	O
of	O
these	O
cells	O
as	O
well	O
as	O
to	O
the	O
presence	O
of	O
different	O
cytoplasmic	O
granules	O
with	O
distinct	O
exocytic	O
capabilities	O
.	O
PMID	O
:	O
10080545	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2003	O
Jun	O
20	O
;	O
278	O
(	O
25	O
)	O
:	O
23187-95	O
.	O
Epub	O
2003	O
Apr	O
08	O
.	O
Identification	O
of	O
a	O
mutant	O
amyloid	O
peptide	O
that	O
predominantly	O
forms	O
neurotoxic	O
protofibrillar	O
aggregates	O
.	O
Qahwash	O
I	O
,	O
Weiland	O
KL	O
,	O
Lu	O
Y	O
,	O
Sarver	O
RW	O
,	O
Kletzien	O
RF	O
,	O
Yan	O
R	O
.	O
Department	O
of	O
Cell	O
&	O
Molecular	O
Biology	O
,	O
Pharmacia	O
Corporation	O
,	O
Kalamazoo	O
,	O
Michigan	O
49007	O
,	O
USA	O
.	O
The	O
amyloid	O
peptide	O
(	O
Abeta	O
)	O
,	O
derived	O
from	O
the	O
proteolytic	O
cleavage	O
of	O
the	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
by	O
beta-	O
and	O
gamma	O
-	O
secretases	O
,	O
undergoes	O
multistage	O
assemblies	O
to	O
fibrillar	O
depositions	O
in	O
the	O
Alzheimer's	O
brains	O
.	O
Abeta	O
protofibrils	O
were	O
previously	O
identified	O
as	O
an	O
intermediate	O
preceding	O
insoluble	O
fibrils	O
.	O
While	O
characterizing	O
a	O
synthetic	O
Abeta	O
variant	O
named	O
EV40	O
that	O
has	O
mutations	O
in	O
the	O
first	O
two	O
amino	O
acids	O
(	O
D	O
1	O
E	O
/	O
A	O
2	O
V	O
)	O
,	O
we	O
discerned	O
unusual	O
aggregation	O
profiles	O
of	O
this	O
variant	O
.	O
In	O
comparison	O
of	O
the	O
fibrillogenesis	O
and	O
cellular	O
toxicity	O
of	O
EV40	O
to	O
the	O
wild-type	O
Abeta	O
peptide	O
(	O
Abeta40	O
)	O
,	O
we	O
found	O
that	O
Abeta40	O
formed	O
long	O
fibrillar	O
aggregates	O
while	O
EV40	O
formed	O
only	O
protofibrillar	O
aggregates	O
under	O
the	O
same	O
in	O
vitro	O
incubation	O
conditions	O
.	O
Cellular	O
toxicity	O
assays	O
indicated	O
that	O
EV40	O
was	O
slightly	O
more	O
toxic	O
than	O
Abeta40	O
to	O
human	O
neuroblastoma	B-malignancy-type
SHEP	O
cells	O
,	O
rat	O
primary	O
cortical	O
,	O
and	O
hippocampal	O
neurons	O
.	O
Like	O
Abeta40	O
,	O
the	O
neurotoxicity	O
of	O
the	O
protofibrillar	O
EV40	O
could	O
be	O
partially	O
attributed	O
to	O
apoptosis	O
since	O
multiple	O
caspases	O
such	O
as	O
caspase	O
-	O
9	O
were	O
activated	O
after	O
SHEP	O
cells	O
were	O
challenged	O
with	O
toxic	O
concentrations	O
of	O
EV40	O
.	O
This	O
suggested	O
that	O
apoptosis	O
-	O
induced	O
neuronal	O
loss	O
might	O
occur	O
before	O
extensive	O
depositions	O
of	O
long	O
amyloid	O
fibrils	O
in	O
AD	O
brains	O
.	O
This	O
study	O
has	O
been	O
the	O
first	O
to	O
show	O
that	O
a	O
mutated	O
Abeta	O
peptide	O
formed	O
only	O
protofibrillar	O
species	O
and	O
mutations	O
of	O
the	O
amyloid	O
peptide	O
at	O
the	O
N-terminal	O
side	O
affect	O
the	O
dynamic	O
amyloid	O
fibrillogenesis	O
.	O
Thus	O
,	O
the	O
identification	O
of	O
EV40	O
may	O
lead	O
to	O
further	O
understanding	O
of	O
the	O
structural	O
perturbation	O
of	O
Abeta	O
to	O
its	O
fibrillation	O
.	O
PMID	O
:	O
12684519	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O

J	O
Clin	O
Oncol	O
.	O
1996	O
Jan	O
;	O
14	O
(	O
1	O
)	O
:	O
25-34	O
.	O
Clinical	O
relevance	O
of	O
CD44	O
cell	O
-	O
surface	O
expression	O
and	O
N-myc	O
gene	O
amplification	O
in	O
a	O
multicentric	O
analysis	O
of	O
121	O
pediatric	O
neuroblastomas	B-malignancy-type
.	O
Combaret	O
V	O
,	O
Gross	O
N	O
,	O
Lasset	O
C	O
,	O
Frappaz	O
D	O
,	O
Peruisseau	O
G	O
,	O
Philip	O
T	O
,	O
Beck	O
D	O
,	O
Favrot	O
MC	O
.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
Centre	O
Leon	O
Berard	O
,	O
Lyon	O
,	O
France	O
.	O
PURPOSE	O
:	O
In	O
contrast	O
to	O
other	O
human	O
tumors	O
,	O
a	O
repression	O
of	O
the	O
cell	O
-	O
surface	O
glycoprotein	O
CD44	O
on	O
neuroblastoma	B-malignancy-type
is	O
a	O
marker	O
of	O
aggressiveness	O
that	O
usually	O
correlates	O
to	O
N-myc	O
amplification	O
.	O
We	O
thus	O
compared	O
the	O
prognostic	O
value	O
of	O
both	O
markers	O
in	O
the	O
initial	O
staging	O
of	O
121	O
children	O
treated	O
for	O
neuroblastoma	B-malignancy-type
in	O
collaborative	O
institutions	O
.	O
METHODS	O
:	O
Frozen	O
samples	O
were	O
analyzed	O
by	O
a	O
rapid	O
and	O
well	O
-	O
standardized	O
technique	O
of	O
immunostaining	O
with	O
monoclonal	O
antibodies	O
(	O
MoAbs	O
)	O
against	O
epitopes	O
in	O
the	O
CD44	O
constant	O
region	O
.	O
RESULTS	O
:	O
In	O
this	O
retrospective	O
series	O
,	O
CD44	O
was	O
expressed	O
on	O
102	O
specimens	O
and	O
strongly	O
correlated	O
with	O
favorable	O
tumor	O
stages	O
and	O
histology	O
,	O
younger	O
age	O
,	O
and	O
normal	O
N-myc	O
copy	O
numbers	O
.	O
In	O
univariate	O
analysis	O
,	O
CD44	O
expression	O
and	O
normal	O
N-myc	O
were	O
the	O
most	O
powerful	O
markers	O
of	O
favorable	O
clinical	O
outcome	O
(	O
P	O
<	O
10(-6)	O
and	O
chi	O
2	O
=	O
65.40	O
and	O
P	O
<	O
10(-6)	O
and	O
chi	O
2	O
=	O
42.56	O
,	O
respectively	O
)	O
,	O
but	O
analysis	O
of	O
CD44	O
affords	O
significant	O
prognostic	O
discrimination	O
in	O
subgroups	O
of	O
patients	O
with	O
or	O
without	O
N-myc	O
-	O
amplified	O
tumors	O
.	O
In	O
the	O
subgroup	O
of	O
stage	O
IV	O
neuroblastomas	B-malignancy-type
,	O
CD44	O
was	O
the	O
only	O
significant	O
prognostic	O
marker	O
(	O
P	O
<	O
.02	O
,	O
chi	O
2	O
=	O
5.76	O
)	O
,	O
whereas	O
N-myc	O
status	O
was	O
not	O
discriminant	O
.	O
n	O
multivariate	O
analysis	O
of	O
five	O
factors	O
,	O
ie	O
,	O
N-myc	O
amplification	O
,	O
CD44	O
expression	O
,	O
age	O
,	O
tumor	O
stage	O
,	O
and	O
histology	O
,	O
the	O
only	O
independent	O
prognostic	O
factors	O
of	O
event	O
-	O
free	O
survival	O
were	O
CD44	O
expression	O
and	O
tumor	O
stage	O
.	O
CONCLUSION	O
:	O
The	O
analysis	O
of	O
CD44	O
cell-surface	O
expression	O
must	O
be	O
recommended	O
as	O
an	O
additional	O
biologic	O
marker	O
in	O
the	O
initial	O
staging	O
of	O
the	O
disease	O
.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
8558206	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genomics	O
.	O
1995	O
Sep	O
20	O
;	O
29	O
(	O
2	O
)	O
:	O
426-37	O
.	O
cDNA	O
cloning	O
,	O
molecular	O
characterization	O
,	O
and	O
chromosomal	O
localization	O
of	O
NET	O
(	O
EPHT2	O
)	O
,	O
a	O
human	O
EPH	O
-	O
related	O
receptor	O
protein-tyrosine	O
kinase	O
gene	O
preferentially	O
expressed	O
in	O
brain	O
.	O
Tang	O
XX	O
,	O
Biegel	O
JA	O
,	O
Nycum	O
LM	O
,	O
Yoshioka	O
A	O
,	O
Brodeur	O
GM	O
,	O
Pleasure	O
DE	O
,	O
Ikegaki	O
N	O
.	O
Division	O
of	O
Neurology	O
Research	O
,	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
Pennsylvania	O
19104	O
,	O
USA	O
.	O
By	O
screening	O
a	O
human	O
fetal	O
brain	O
cDNA	O
expression	O
library	O
using	O
a	O
monoclonal	O
anti-phosphotyrosine	O
antibody	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
clone	O
encoding	O
a	O
receptor	O
type	O
protein-tyrosine	O
kinase	O
belonging	O
to	O
the	O
EPH	O
family	O
,	O
NET	O
(	O
neuronally	O
expressed	O
EPH	O
-	O
related	O
tyrosine	O
kinase	O
)	O
.	O
NET	O
shows	O
87%	O
homology	O
in	O
nucleotide	O
sequence	O
and	O
99%	O
homology	O
in	O
the	O
deduced	O
amino	O
acid	O
sequence	O
to	O
rat	O
elk	O
,	O
suggesting	O
that	O
NET	O
is	O
the	O
human	O
homologue	O
of	O
elk	O
.	O
The	O
NET	O
gene	O
is	O
mapped	O
to	O
human	O
chromosome	O
3q21-q23	O
by	O
PCR	O
screening	O
of	O
a	O
human-rodent	O
somatic	O
cell	O
hybrid	O
panel	O
and	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
Examination	O
of	O
NET	O
mRNA	O
expression	O
in	O
several	O
human	O
tissues	O
has	O
shown	O
that	O
the	O
NET	O
gene	O
is	O
expressed	O
preferentially	O
in	O
brain	O
as	O
a	O
5-kb	O
transcript	O
.	O
Steady-state	O
levels	O
of	O
NET	O
mRNA	O
in	O
human	O
brain	O
are	O
greater	O
in	O
the	O
midterm	O
fetus	O
than	O
in	O
the	O
adult	O
.	O
Lower	O
levels	O
of	O
NET	O
mRNA	O
are	O
found	O
in	O
fetal	O
kidney	O
and	O
adult	O
skeletal	O
muscle	O
.	O
The	O
expression	O
pattern	O
of	O
NET	O
mRNA	O
thus	O
differs	O
from	O
that	O
of	O
elk	O
,	O
suggesting	O
that	O
these	O
two	O
gene	O
products	O
may	O
perform	O
distinct	O
roles	O
in	O
human	O
and	O
rat	O
.	O
NET	O
transcripts	O
are	O
detected	O
in	O
human	O
NTera-2	O
teratocarcinoma	B-malignancy-type
cells	O
after	O
retinoic	O
acid	O
-	O
induced	O
neuronal	O
differentiation	O
.	O
Several	O
human	O
tumor	O
cell	O
lines	O
derived	O
from	O
neuroectoderm	O
including	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumor	I-malignancy-type
,	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
neuroblastoma	B-malignancy-type
also	O
express	O
NET	O
transcripts	O
.	O
Since	O
the	O
NET	O
mRNA	O
expression	O
in	O
human	O
brain	O
is	O
developmentally	O
regulated	O
and	O
is	O
induced	O
during	O
neuronal	O
differentiation	O
,	O
NET	O
potentially	O
plays	O
important	O
roles	O
in	O
human	O
neurogenesis	O
.	O
PMID	O
:	O
8666391	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Thyroid	O
.	O
1996	O
Jun	O
;	O
6	O
(	O
3	O
)	O
:	O
233-6	O
.	O
Reversal	O
of	O
TR	O
-	O
T3	O
inhibition	O
of	O
the	O
hTRH	O
gene	O
by	O
excess	O
TR	O
ligand-binding	O
domain	O
:	O
evidence	O
for	O
novel	O
accessory	O
protein	O
.	O
Li	O
QL	O
,	O
Feng	O
P	O
,	O
Koch	O
C	O
,	O
Shi	O
ZX	O
,	O
Wilber	O
JF	O
.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Maryland	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
21201	O
,	O
USA	O
.	O
The	O
thyrotropin	O
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
gene	O
is	O
regulated	O
negatively	O
at	O
the	O
transcriptional	O
level	O
by	O
thyroid	O
hormone	O
(	O
T3	O
)	O
.	O
T3	O
positive	O
regulatory	O
effects	O
on	O
other	O
target	O
genes	O
,	O
such	O
as	O
the	O
growth	O
hormone	O
gene	O
,	O
are	O
mediated	O
through	O
heterodimerization	O
of	O
thyroid	O
hormone	O
receptors	O
(	O
TRs	O
)	O
with	O
RXR	O
or	O
other	O
auxiliary	O
nuclear	O
protein(s)	O
.	O
To	O
explore	O
whether	O
an	O
accessory	O
co	O
-	O
suppressor	O
protein(s)	O
may	O
be	O
involved	O
in	O
T3	O
inhibitory	O
regulation	O
of	O
human	O
TRH	O
gene	O
transcription	O
,	O
transient	O
gene	O
expression	O
studies	O
have	O
been	O
carried	O
out	O
using	O
a	O
hTRH	O
-	O
luciferase	O
(	O
TRH	O
-	O
Luc	O
)	O
chimetric	O
reporter	O
construct	O
,	O
an	O
hTR	O
beta	O
1	O
expression	O
construct	O
,	O
and	O
pABgal	O
-	O
hTR	O
beta	O
1	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
fusion	O
constructs	O
,	O
cotransfected	O
into	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
(	O
HTB-	O
11,ATCC	O
)	O
.	O
Results	O
herein	O
indicate	O
that	O
T3	O
-	O
dependent	O
inhibitory	O
regulation	O
(	O
48-60%	O
of	O
control	O
)	O
of	O
the	O
hTRH	O
gene	O
promoter	O
by	O
hTR	O
beta	O
1	O
-	O
T3	O
complexes	O
could	O
be	O
abrogated	O
completely	O
by	O
cotransfection	O
of	O
a	O
10	O
x	O
excess	O
of	O
hTR	O
beta	O
1	O
-LBD	O
(	O
TR	O
168-456	O
aa	O
)	O
in	O
a	O
pABgal94	O
vector	O
.	O
In	O
striking	O
contrast	O
,	O
cotransfection	O
of	O
a	O
10	O
x	O
excess	O
of	O
highly	O
truncated	O
hTR	O
beta	O
1	O
-LBD	O
(	O
TR	O
452-456	O
aa	O
)	O
failed	O
to	O
reverse	O
T3	O
-	O
mediated	O
TRH	O
promoter	O
inhibition	O
.	O
his	O
squelching	O
effect	O
by	O
excessive	O
intact	O
TR	O
-LBD	O
,	O
moreover	O
,	O
could	O
not	O
be	O
reversed	O
by	O
raising	O
T3	O
concentration	O
100	O
-	O
fold	O
(	O
from	O
10(-8)	O
to	O
10(-6)	O
M	O
)	O
,	O
thus	O
excluding	O
a	O
squelching	O
effect	O
of	O
T3	O
itself	O
by	O
excess	O
LBD.	O
These	O
results	O
suggest	O
that	O
negative	O
regulation	O
of	O
the	O
hTRH	O
gene	O
promoter	O
activity	O
by	O
TR	O
beta	O
1	O
-	O
T3	O
complexes	O
involves	O
interactions	O
with	O
an	O
accessory	O
co	O
-	O
suppressor	O
protein	O
,	O
which	O
may	O
bridge	O
DNA-bound	O
TR	O
beta	O
1	O
-	O
T3	O
complexes	O
to	O
the	O
transcriptional	O
initiation	O
complex	O
.	O
PMID	O
:	O
8837332	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Gene	O
Ther	O
.	O
1995	O
Sep	O
;	O
2	O
(	O
3	O
)	O
:	O
171-81	O
.	O
Sustained	O
cytokine	O
production	O
and	O
immunophenotypic	O
changes	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
transduced	O
with	O
a	O
human	O
gamma	O
interferon	O
vector	O
.	O
Ucar	O
K	O
,	O
Seeger	O
RC	O
,	O
Challita	O
PM	O
,	O
Watanabe	O
CT	O
,	O
Yen	O
TL	O
,	O
Morgan	O
JP	O
,	O
Amado	O
R	O
,	O
Chou	O
E	O
,	O
McCallister	O
T	O
,	O
Barber	O
JR	O
,	O
et	O
al	O
.	O
UCLA	O
Department	O
of	O
Medicine	O
90024-1678	O
,	O
USA	O
.	O
The	O
majority	O
of	O
human	O
neuroblastomas	B-malignancy-type
express	O
low	O
to	O
undetectable	O
levels	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
and	O
II	O
antigens	O
(	O
MHC-	O
I	O
and	O
-	O
II	O
)	O
.	O
We	O
studied	O
the	O
effects	O
of	O
gamma	O
interferon	O
(	O
gamma-	O
IFN	O
)	O
transduction	O
on	O
expression	O
of	O
these	O
antigens	O
in	O
six	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
and	O
without	O
genomic	O
amplification	O
of	O
the	O
N-myc	O
oncogene	O
.	O
All	O
six	O
were	O
stably	O
transduced	O
with	O
an	O
MoMLV-based	O
gamma-IFN	O
retroviral	O
vector	O
(	O
DAh	O
gamma-IFN	O
)	O
.	O
G418-resistant	O
cells	O
were	O
assayed	O
for	O
MHC-I	O
,	O
MHC-II	O
,	O
B7-1	O
,	O
and	O
neuroblastoma	B-malignancy-type
-associated	O
antigen	O
expression	O
,	O
as	O
well	O
as	O
for	O
gamma-IFN	O
levels	O
in	O
cell	O
culture	O
supernatants	O
.	O
Sustained	O
gamma-IFN	O
production	O
,	O
2	O
to	O
>	O
1000	O
units/10(6)	O
cells	O
/	O
d	O
,	O
was	O
attained	O
for	O
five	O
of	O
six	O
transduced	O
cell	O
lines	O
and	O
persisted	O
for	O
up	O
to	O
9	O
months	O
.	O
This	O
resulted	O
in	O
marked	O
upregulation	O
of	O
MHC-I	O
and	O
MHC-II	O
expression	O
in	O
LA-N-1	O
,	O
LA-N-6	O
,	O
and	O
CHLA-127	O
cells	O
and	O
moderate	O
upregulation	O
in	O
SK-N-Fi	O
and	O
SK-N-AS	O
cells	O
.	O
One	O
cell	O
line	O
(	O
LA-N-1	O
)	O
had	O
marked	O
induction	O
of	O
MHC-	O
I	O
and	O
MHC-II	O
despite	O
marginal	O
levels	O
of	O
gamma-	O
IFN	O
production	O
.	O
Expression	O
of	O
CD28	O
ligand	O
B7-1	O
(	O
as	O
determined	O
by	O
BB1	O
antibody	O
)	O
remained	O
unchanged	O
in	O
all	O
gamma-IFN	O
-transduced	O
cell	O
lines	O
tested	O
.	O
Expression	O
of	O
several	O
neuroblastoma	B-malignancy-type
-associated	O
antigens	O
(	O
NKH1A	O
,	O
126-4	O
,	O
HSAN	O
1.2	O
,	O
HNK	O
,	O
459	O
,	O
and	O
390	O
)	O
was	O
upregulated	O
in	O
some	O
of	O
the	O
gamma-IFN	O
-transduced	O
cell	O
lines	O
.	O
These	O
results	O
demonstrate	O
that	O
preparation	O
of	O
gamma-IFN	O
expressing	O
neuroblastoma	B-malignancy-type
cells	O
for	O
immunotherapeutic	O
purposes	O
is	O
feasible	O
and	O
that	O
gamma-IFN	O
transduction	O
results	O
in	O
phenotypic	O
changes	O
that	O
may	O
improve	O
immunogenicity	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
8528960	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Invest	O
.	O
2000	O
Jan;105	O
(	O
2	O
)	O
:161	O
-	O
71	O
.	O
Wnt	O
-	O
1	O
regulation	O
of	O
connexin	O
43	O
in	O
cardiac	O
myocytes	O
.	O
Ai	O
Z	O
,	O
Fischer	O
A	O
,	O
Spray	O
DC	O
,	O
Brown	O
AM	O
,	O
Fishman	O
GI.	O
Section	O
of	O
Myocardial	O
Biology	O
,	O
Zena	O
and	O
Michael	O
A	O
.	O
Wiener	O
Cardiovascular	O
Institute	O
,	O
Department	O
of	O
Medicine	O
,	O
Mount	O
Sinai	O
School	O
of	O
Medicine	O
,	O
New	O
York	O
,	O
New	O
York	O
10029	O
,	O
USA	O
.	O
Gap	O
junction	O
channels	O
composed	O
of	O
connexin	O
43	O
(	O
Cx43	O
)	O
are	O
essential	O
for	O
normal	O
heart	O
formation	O
and	O
function	O
.	O
We	O
studied	O
the	O
potential	O
role	O
of	O
the	O
Wnt	O
family	O
of	O
secreted	O
polypeptides	O
as	O
regulators	O
of	O
Cx43	O
expression	O
and	O
gap	O
junction	O
channel	O
function	O
in	O
dissociated	O
myocytes	O
and	O
intact	O
hearts	O
.	O
Neonatal	O
rat	O
cardiomyocytes	O
responded	O
to	O
Li(+)	O
,	O
which	O
mimics	O
Wnt	O
signaling	O
,	O
by	O
accumulating	O
the	O
effector	O
protein	O
beta	O
-	O
catenin	O
and	O
by	O
inducing	O
Cx43	O
mRNA	O
and	O
protein	O
markedly	O
.	O
Induction	O
of	O
Cx43	O
expression	O
was	O
also	O
observed	O
in	O
cardiomyocytes	O
cocultured	O
with	O
Rat	O
-	O
2	O
fibroblasts	O
or	O
N2A	O
neuroblastoma	B-malignancy-type
cells	O
programmed	O
to	O
secrete	O
bioactive	O
Wnt	O
-	O
1	O
.	O
By	O
transfecting	O
a	O
Cx43	O
promoter	O
-	O
reporter	O
gene	O
construct	O
into	O
cardiomyocytes	O
,	O
we	O
demonstrated	O
that	O
the	O
inductive	O
effect	O
of	O
Wnt	O
signaling	O
was	O
transcriptionally	O
mediated	O
.	O
Enhanced	O
expression	O
of	O
Cx43	O
increased	O
cardiomyocyte	O
cell	O
coupling	O
,	O
as	O
determined	O
by	O
Lucifer	O
Yellow	O
dye	O
transfer	O
and	O
by	O
calcium	O
wave	O
propagation	O
.	O
Conversely	O
,	O
in	O
a	O
transgenic	O
cardiomyopathic	O
mouse	O
model	O
that	O
exhibits	O
ventricular	O
arrhythmias	O
and	O
gap	O
junctional	O
remodeling	O
,	O
beta	O
-	O
catenin	O
and	O
Cx43	O
expression	O
were	O
downregulated	O
concordantly	O
.	O
In	O
response	O
to	O
Wnt	O
signaling	O
,	O
the	O
accumulating	O
Cx43	O
colocalized	O
with	O
beta	O
-	O
catenin	O
in	O
the	O
junctional	O
membrane	O
;	O
moreover	O
,	O
forced	O
expression	O
of	O
Cx43	O
in	O
cardiomyocytes	O
reduced	O
the	O
transactivation	O
potential	O
of	O
beta	O
-	O
catenin	O
.	O
These	O
findings	O
demonstrate	O
that	O
Wnt	O
signaling	O
is	O
an	O
important	O
modulator	O
of	O
Cx43	O
-	O
dependent	O
intercellular	O
coupling	O
in	O
the	O
heart	O
,	O
and	O
they	O
support	O
the	O
hypothesis	O
that	O
dysregulated	O
signaling	O
contributes	O
to	O
altered	O
impulse	O
propagation	O
and	O
arrhythmia	O
in	O
the	O
myopathic	O
heart	O
.	O
PMID	O
:	O
10642594	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Immunol	O
.	O
1992	O
Aug	O
15	O
;149(	O
4	O
)	O
:	O
1223	O
-	O
9.	O
Molecular	O
cloning	O
and	O
characterization	O
of	O
the	O
gene	O
encoding	O
mouse	O
melanoma	O
antigen	O
by	O
cDNA	O
library	O
transfection	O
.	O
Hayashi	O
H,	O
Matsubara	O
H,	O
Yokota	O
T	O
,	O
Kuwabara	O
I	O
,	O
Kanno	O
M,	O
Koseki	O
H,	O
Isono	O
K,	O
Asano	O
T	O
,	O
Taniguchi	O
M.	O
Division	O
of	O
Molecular	O
Immunology	O
,	O
Chiba	O
University	O
,	O
Japan	O
.	O
We	O
have	O
isolated	O
a	O
cDNA	O
(	O
H52	O
)	O
of	O
2.8	O
-	O
kb	O
-	O
long	O
encoding	O
an	O
80	O
-	O
kDa	O
mouse	O
melanoma	O
Ag	O
that	O
is	O
defined	O
by	O
a	O
syngeneic	O
anti	O
-	O
B16	O
melanoma	O
mAb	O
with	O
an	O
ability	O
to	O
block	O
anti	O
-	O
melanoma	B-malignancy-type
cytotoxic	O
T	O
cell	O
responses	O
.	O
H52	O
transfectants	O
were	O
brightly	O
stained	O
with	O
the	O
antibody	O
,	O
and	O
the	O
80	O
-	O
kDa	O
molecule	O
was	O
immunoprecipitated	O
from	O
the	O
transfectants	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
this	O
transcript	O
was	O
detected	O
in	O
mouse	O
melanoma	B-malignancy-type
cells	O
of	O
C57BL	O
/	O
6	O
and	O
DBA	O
/	O
2	O
origin	O
,	O
C1300	O
A	O
/	O
J	O
neuroblastoma	B-malignancy-type
,	O
L	O
cell	O
(	O
C3H	O
)	O
and	O
EL	O
-	O
4	O
T	B-malignancy-type
lymphoma	I-malignancy-type
(	O
C57BL	O
/	O
6	O
)	O
,	O
faintly	O
in	O
BW5147	O
(	O
AKR	O
)	O
T	B-malignancy-type
lymphoma	I-malignancy-type
,	O
but	O
not	O
in	O
other	O
tumors	O
,	O
such	O
as	O
S913	O
fibrosarcoma	B-malignancy-type
(	O
C57BL	O
/	O
10	O
)	O
,	O
NIH3T3	O
,	O
70	O
Z	O
/	O
3	O
pre	B-malignancy-type
-	I-malignancy-type
B	I-malignancy-type
lymphoma	I-malignancy-type
,	O
and	O
P3U1	O
plasmacytoma	B-malignancy-type
(	O
BALB	O
/	O
c	O
)	O
.	O
Since	O
the	O
transcripts	O
were	O
not	O
found	O
in	O
normal	O
C57BL	O
/	O
6	O
tissues	O
of	O
fetus	O
,	O
newborn	O
,	O
and	O
adult	O
origin	O
,	O
the	O
H52	O
expression	O
is	O
associated	O
with	O
transforming	O
phenotypes	O
.	O
However	O
,	O
no	O
tissue	O
-	O
or	O
cell	O
type	O
-	O
specific	O
expression	O
was	O
observed	O
.	O
Nucleotide	O
sequence	O
analysis	O
has	O
clearly	O
demonstrated	O
that	O
H52	O
cDNA	O
encodes	O
the	O
full	O
length	O
of	O
the	O
env	O
gene	O
and	O
long	O
terminal	O
repeat	O
region	O
of	O
endogenous	O
ecotropic	O
murine	O
leukemia	B-malignancy-type
provirus	O
of	O
AKV	O
-	O
type	O
,	O
which	O
is	O
defective	O
in	O
C57BL	O
/	O
6	O
.	O
The	O
H52	O
envelope	O
protein	O
has	O
several	O
amino	O
acid	O
changes	O
compared	O
to	O
those	O
of	O
AKV	O
,	O
one	O
of	O
which	O
is	O
in	O
the	O
env	O
14	O
peptide	O
region	O
preferentially	O
associated	O
with	O
MHC	O
molecule	O
,	O
suggesting	O
the	O
possible	O
reason	O
for	O
the	O
difference	O
of	O
antibody	O
reactivity	O
even	O
in	O
H52	O
-	O
positive	O
tumors	O
.	O
We	O
also	O
demonstrate	O
that	O
CTL	O
against	O
H52	O
transfectant	O
kills	O
B16	B-malignancy-type
melanoma	I-malignancy-type
.	O
Thus	O
,	O
the	O
above	O
results	O
are	O
direct	O
evidence	O
that	O
even	O
the	O
endogenous	O
self	O
molecule	O
,	O
when	O
constitutively	O
expressed	O
,	O
does	O
act	O
as	O
a	O
tumor	O
Ag	O
.	O
PMID	O
:	O
1380036	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Res	O
.	O
1997;	O
9	O
(	O
9	O
)	O
:467	O
-	O
76	O
.	O
Cell	O
lineage	O
and	O
differentiation	O
state	O
are	O
primary	O
determinants	O
of	O
MYCN	O
gene	O
expression	O
and	O
malignant	O
potential	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Spengler	O
BA	O
,	O
Lazarova	O
DL	O
,	O
Ross	O
RA	O
,	O
Biedler	O
JL.	O
Department	O
of	O
Biological	O
Sciences	O
,	O
Fordham	O
University	O
,	O
Bronx	O
,	O
NY	O
10458	O
,	O
USA	O
.	O
Neuroblastoma	B-malignancy-type
cell	O
lines	O
typically	O
exhibit	O
multiple	O
cell	O
phenotypes	O
,	O
counterparts	O
of	O
those	O
comprising	O
the	O
embryonic	O
neural	O
crest	O
.	O
Expression	O
of	O
the	O
MYCN	O
gene	O
,	O
usually	O
amplified	O
in	O
cell	O
lines	O
,	O
differs	O
markedly	O
among	O
the	O
various	O
differentiation	O
phenotypes	O
.	O
Whereas	O
neuroblastic	O
(	O
N	O
-	O
type	O
)	O
and	O
stem	O
cell	O
(	O
I	O
-	O
type	O
)	O
sublines	O
have	O
abundant	O
MYCN	O
RNA	O
and	O
protein	O
,	O
S	O
-	O
type	O
cells	O
(	O
nonneuronal	O
neural	O
crest	O
precursors	O
)	O
have	O
a	O
4	O
-	O
to	O
9	O
-	O
fold	O
lower	O
level	O
of	O
cytoplasmic	O
mRNA	O
and	O
a	O
2	O
-	O
to	O
36	O
-	O
fold	O
lower	O
protein	O
content	O
.	O
N	O
and	O
S	O
sublines	O
with	O
chromosomally	O
integrated	O
MYCN	O
genes	O
have	O
similar	O
gene	O
copy	O
numbers	O
.	O
Thus	O
,	O
in	O
these	O
S	O
cells	O
,	O
MYCN	O
expression	O
is	O
downregulated	O
.	O
Nuclear	O
run	O
-	O
on	O
and	O
mRNA	O
stability	O
assays	O
have	O
revealed	O
similar	O
transcription	O
rates	O
and	O
mRNA	O
half	O
-	O
lives	O
in	O
N	O
and	O
S	O
cells	O
from	O
two	O
cell	O
lines	O
,	O
indicating	O
that	O
downregulation	O
occurs	O
posttranscriptionally	O
prior	O
to	O
mRNA	O
degradation	O
in	O
the	O
cytoplasm	O
.	O
S	O
-	O
type	O
cells	O
derived	O
from	O
double	O
minute	O
chromosome	O
-	O
containing	O
lines	O
show	O
4	O
-	O
to	O
10	O
-	O
fold	O
lower	O
gene	O
copy	O
numbers	O
than	O
N	O
counterparts	O
.	O
Experimental	O
induction	O
of	O
differentiation	O
to	O
neuronal	O
/	O
neuroendocrine	O
or	O
to	O
S	O
-	O
type	O
cells	O
results	O
in	O
a	O
marked	O
reduction	O
of	O
MYCN	O
expression	O
and	O
,	O
in	O
double	O
minute	O
chromosome	O
-	O
containing	O
N	O
-	O
type	O
sublines	O
,	O
in	O
gene	O
loss	O
as	O
well	O
.	O
Malignant	O
potential	O
as	O
indicated	O
by	O
soft	O
agar	O
growth	O
capacity	O
and	O
tumor	O
formation	O
in	O
nude	O
mice	O
is	O
markedly	O
diminished	O
in	O
S	O
cells	O
and	O
,	O
generally	O
,	O
is	O
directly	O
proportional	O
to	O
MYCN	O
mRNA	O
levels	O
.	O
The	O
most	O
plausible	O
relationship	O
suggested	O
by	O
our	O
data	O
is	O
that	O
MYCN	O
expression	O
,	O
regulated	O
by	O
cell	O
lineage	O
and	O
/	O
or	O
differentiation	O
state	O
,	O
directly	O
modulates	O
the	O
malignant	O
potential	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
9495452	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
2001	O
May	O
22;98(	O
11	O
)	O
:	O
6396-401	O
.	O
Epub	O
2001	O
May	O
15	O
.	O
Oncolytic	O
herpes	O
simplex	O
virus	O
vector	O
with	O
enhanced	O
MHC	O
class	O
I	O
presentation	O
and	O
tumor	O
cell	O
killing	O
.	O
Todo	O
T	O
,	O
Martuza	O
RL	O
,	O
Rabkin	O
SD	O
,	O
Johnson	O
PA	O
.	O
Molecular	O
Neurosurgery	O
Laboratory	O
,	O
Department	O
of	O
Neurosurgery	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Charlestown	O
,	O
MA	O
02129	O
,	O
USA	O
.	O
todo@helix.mgh	O
.harvard	O
.edu	O
Oncolytic	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
vectors	O
are	O
promising	O
therapeutic	O
agents	O
for	O
cancer	O
.	O
Their	O
efficacy	O
depends	O
on	O
the	O
extent	O
of	O
both	O
intratumoral	O
viral	O
replication	O
and	O
induction	O
of	O
a	O
host	O
antitumor	O
immune	O
response	O
.	O
To	O
enhance	O
these	O
properties	O
while	O
employing	O
ample	O
safeguards	O
,	O
two	O
conditionally	O
replicating	O
HSV	O
-	O
1	O
vectors	O
,	O
termed	O
G47Delta	O
and	O
R47Delta	O
,	O
have	O
been	O
constructed	O
by	O
deleting	O
the	O
alpha47	O
gene	O
and	O
the	O
promoter	O
region	O
of	O
US11	O
from	O
gamma34.5	O
-	O
deficient	O
HSV	O
-	O
1	O
vectors	O
,	O
G207	O
and	O
R3616	O
,	O
respectively	O
.	O
Because	O
the	O
alpha47	O
gene	O
product	O
is	O
responsible	O
for	O
inhibiting	O
the	O
transporter	O
associated	O
with	O
antigen	O
presentation	O
(	O
TAP	O
)	O
,	O
its	O
absence	O
led	O
to	O
increased	O
MHC	O
class	O
I	O
expression	O
in	O
infected	O
human	O
cells	O
.	O
Moreover	O
,	O
some	O
G47Delta	O
-	O
infected	O
human	O
melanoma	B-malignancy-type
cells	O
exhibited	O
enhanced	O
stimulation	O
of	O
matched	O
antitumor	O
T	O
cell	O
activity	O
.	O
The	O
deletion	O
also	O
places	O
the	O
late	O
US11	O
gene	O
under	O
control	O
of	O
the	O
immediate	O
-	O
early	O
alpha47	O
promoter	O
,	O
which	O
suppresses	O
the	O
reduced	O
growth	O
properties	O
of	O
gamma34.5	O
-	O
deficient	O
mutants	O
.	O
G47Delta	O
and	O
R47Delta	O
showed	O
enhanced	O
viral	O
growth	O
in	O
a	O
variety	O
of	O
cell	O
lines	O
,	O
leading	O
to	O
higher	O
virus	O
yields	O
and	O
enhanced	O
cytopathic	O
effect	O
in	O
tumor	O
cells	O
.	O
G47Delta	O
was	O
significantly	O
more	O
efficacious	O
in	O
vivo	O
than	O
its	O
parent	O
G207	O
at	O
inhibiting	O
tumor	O
growth	O
in	O
both	O
immune	O
-	O
competent	O
and	O
immune	O
-	O
deficient	O
animal	O
models	O
.	O
Yet	O
,	O
when	O
inoculated	O
into	O
the	O
brains	O
of	O
HSV	O
-	O
1	O
-	O
sensitive	O
A	O
/	O
J	O
mice	O
at	O
2	O
x	O
10(6)	O
plaque	O
forming	O
units	O
,	O
G47Delta	O
was	O
as	O
safe	O
as	O
G207	O
.	O
These	O
results	O
suggest	O
that	O
G47Delta	O
may	O
have	O
enhanced	O
antitumor	O
activity	O
in	O
humans	O
.	O
PMID	O
:	O
11353831	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Jan	O
4;277	O
(	O
1	O
)	O
:	O
388	O
-	O
94	O
.	O
Epub	O
2001	O
Oct	O
30	O
.	O
Microarray	O
analysis	O
reveals	O
an	O
antioxidant	O
responsive	O
element	O
-	O
driven	O
gene	O
set	O
involved	O
in	O
conferring	O
protection	O
from	O
an	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
in	O
IMR	O
-	O
32	O
cells	O
.	O
Li	O
J,	O
Lee	O
JM	O
,	O
Johnson	O
JA	O
.	O
School	O
of	O
Pharmacy	O
,	O
Environmental	O
Toxicology	O
Center	O
,	O
Waisman	O
Center	O
,	O
Center	O
for	O
Neuroscience	O
,	O
University	O
of	O
Wisconsin	O
,	O
Madison	O
,	O
Wisconsin	O
53705	O
,	O
USA	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
how	O
tert	O
-	O
butylhydroquinone	O
(	O
tBHQ	O
)	O
prevents	O
hydrogen	O
peroxide	O
-	O
induced	O
apoptosis	O
in	O
IMR	O
-	O
32	O
cells	O
.	O
tBHQ	O
pretreatment	O
(	O
10	O
microm	O
)	O
attenuated	O
hydrogen	O
peroxide	O
-	O
induced	O
cell	O
death	O
and	O
reduced	O
the	O
number	O
of	O
TUNEL	O
(	O
terminal	O
deoxynucleotidyltransferase	O
-	O
mediated	O
,	O
dUTP	O
-	O
incorporated	O
nick	O
end	O
labeling	O
)	O
-	O
positive	O
cells	O
.	O
We	O
hypothesize	O
that	O
tBHQ	O
-	O
mediated	O
activation	O
of	O
the	O
antioxidant	O
responsive	O
element	O
is	O
critical	O
for	O
generating	O
this	O
protective	O
response	O
.	O
Addition	O
of	O
LY294002	O
,	O
a	O
selective	O
inhibitor	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
,	O
30	O
min	O
prior	O
to	O
tBHQ	O
treatment	O
completely	O
reversed	O
the	O
protective	O
effect	O
of	O
tBHQ	O
.	O
Oligonucleotide	O
microarrays	O
were	O
used	O
to	O
analyze	O
the	O
gene	O
expression	O
profile	O
associated	O
with	O
tBHQ	O
treatment	O
in	O
the	O
absence	O
and	O
presence	O
of	O
LY294002	O
.	O
Ranking	O
analysis	O
using	O
Affymetrix	O
'	O
s	O
difference	O
call	O
indicated	O
that	O
the	O
expression	O
of	O
137	O
genes	O
changed	O
with	O
tBHQ	O
treatment	O
.	O
Further	O
analysis	O
using	O
the	O
coefficient	O
of	O
variation	O
for	O
-	O
fold	O
change	O
or	O
average	O
difference	O
change	O
reduced	O
the	O
list	O
to	O
63	O
increased	O
and	O
0	O
decreased	O
genes	O
.	O
Reverse	O
transcription	O
-	O
PCR	O
for	O
selected	O
genes	O
also	O
confirmed	O
the	O
gene	O
expression	O
pattern	O
.	O
Many	O
of	O
these	O
genes	O
function	O
to	O
combat	O
oxidative	O
stress	O
and	O
increase	O
the	O
detoxification	O
potential	O
of	O
the	O
cells	O
.	O
Inhibition	O
of	O
PI3K	O
significantly	O
blocked	O
the	O
enhanced	O
expression	O
of	O
49	O
of	O
the	O
63	O
genes	O
induced	O
by	O
tBHQ	O
.	O
These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
set	O
of	O
programmed	O
cell	O
life	O
genes	O
involved	O
in	O
conferring	O
protection	O
from	O
an	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
.	O
PMID	O
:	O
11687587	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
.	O
1997	O
Dec;20(	O
4	O
)	O
:	O
372	O
-6.	O
Increased	O
copy	O
number	O
at	O
17q22	O
-	O
q24	O
by	O
CGH	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
is	O
due	O
to	O
high	O
-	O
level	O
amplification	O
of	O
two	O
separate	O
regions	O
.	O
Barlund	O
M,	O
Tirkkonen	O
M,	O
Forozan	O
F	O
,	O
Tanner	O
MM	O
,	O
Kallioniemi	O
O	O
,	O
Kallioniemi	O
A	O
.	O
Laboratory	O
of	O
Cancer	O
Genetics	O
,	O
Institute	O
of	O
Medical	O
Technology	O
,	O
University	O
of	O
Tempere	O
,	O
Finland	O
.	O
Studies	O
by	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
have	O
defined	O
a	O
chromosomal	O
site	O
at	O
17q22	O
-	O
q24	O
that	O
is	O
often	O
overrepresented	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
and	O
several	O
other	O
tumor	O
types	O
.	O
Due	O
to	O
the	O
limited	O
resolution	O
and	O
dynamic	O
range	O
of	O
CGH	O
,	O
it	O
remain	O
unclear	O
whether	O
this	O
gain	O
reflects	O
high	O
-	O
level	O
amplification	O
of	O
small	O
subregion(s)	O
or	O
low	O
-	O
level	O
gain	O
of	O
most	O
of	O
the	O
distal	O
17q	O
.	O
We	O
used	O
32	O
physically	O
mapped	O
17q	O
probes	O
to	O
construct	O
more	O
accurate	O
copy	O
number	O
profiles	O
for	O
14	O
breast	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
by	O
interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
Six	O
cell	O
lines	O
(	O
43	O
%	O
)	O
showed	O
an	O
increased	O
copy	O
number	O
of	O
the	O
17q	O
-	O
22q24	O
region	O
by	O
CGH	O
,	O
and	O
seven	O
(	O
50	O
%	O
)	O
by	O
FISH	O
.	O
FISH	O
copy	O
number	O
profiles	O
had	O
a	O
substantially	O
higher	O
dynamic	O
range	O
than	O
did	O
CGH	O
profiles	O
.	O
FISH	O
revealed	O
two	O
independent	O
,	O
highly	O
amplified	O
regions	O
(	O
A	O
and	O
B	O
)	O
at	O
17q23	O
,	O
separated	O
by	O
about	O
5	O
Mb	O
of	O
non	O
-	O
amplified	O
DNA	O
.	O
These	O
regions	O
were	O
distinctly	O
telomeric	O
from	O
the	O
ERBB2	O
gene	O
locus	O
.	O
However	O
,	O
region	O
A	O
was	O
often	O
co	O
-	O
amplified	O
with	O
ERBB2	O
,	O
whereas	O
B	O
was	O
amplified	O
in	O
cell	O
lines	O
that	O
showed	O
no	O
ERBB2	O
amplification	O
.	O
We	O
conclude	O
that	O
distal	O
17q	O
gains	O
recently	O
discovered	O
in	O
breast	B-malignancy-type
cancer	I-malignancy-type
by	O
CGH	O
are	O
due	O
to	O
high	O
-	O
level	O
amplifications	O
of	O
two	O
different	O
regions	O
at	O
17q23	O
.	O
This	O
chromosomal	O
region	O
has	O
previously	O
been	O
reported	O
to	O
undergo	O
allelic	O
loss	O
and	O
therefore	O
was	O
thought	O
to	O
harbor	O
a	O
tumor	O
suppressor	O
gene	O
.	O
The	O
present	O
FISH	O
data	O
provide	O
support	O
for	O
the	O
presence	O
,	O
and	O
a	O
starting	O
point	O
for	O
the	O
positional	O
isolation	O
,	O
of	O
17q23	O
genes	O
whose	O
upregulation	O
by	O
amplification	O
may	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
breast	B-malignancy-type
cancer	I-malignancy-type
and	O
many	O
other	O
tumor	O
types	O
.	O
PMID	O
:	O
9408753	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
2003	O
May	O
19;88	O
(	O
10	O
)	O
:1522	O
-6.	O
Correlation	O
of	O
elevated	O
level	O
of	O
blood	O
midkine	O
with	O
poor	O
prognostic	O
factors	O
of	O
human	O
neuroblastomas	B-malignancy-type
.	O
Ikematsu	O
S	O
,	O
Nakagawara	O
A	O
,	O
Nakamura	O
Y	O
,	O
Sakuma	O
S	O
,	O
Wakai	O
K,	O
Muramatsu	O
T	O
,	O
Kadomatsu	O
K.	O
Department	O
of	O
Biochemistry	O
,	O
Nagoya	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
65	O
Tsurumai	O
-	O
cho	O
,	O
Showaku	O
,	O
Nagoya	O
466-8550	O
,	O
Japan	O
.	O
The	O
heparin	O
-	O
binding	O
growth	O
factor	O
midkine	O
(	O
MK	O
)	O
is	O
the	O
product	O
of	O
a	O
retinoic	O
acid	O
-	O
responsive	O
gene	O
,	O
and	O
is	O
implicated	O
in	O
neuronal	O
survival	O
and	O
differentiation	O
,	O
and	O
carcinogenesis	O
.	O
We	O
previously	O
reported	O
that	O
MK	O
mRNA	O
expression	O
is	O
elevated	O
in	O
neuroblastoma	B-malignancy-type
specimens	O
at	O
all	O
stages	O
,	O
whereas	O
pleiotrophin	O
,	O
the	O
other	O
member	O
of	O
the	O
MK	O
family	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
favourable	O
neuroblastomas	B-malignancy-type
.	O
As	O
MK	O
is	O
a	O
secretory	O
protein	O
,	O
it	O
can	O
be	O
detected	O
in	O
the	O
blood	O
.	O
Here	O
,	O
we	O
show	O
a	O
significant	O
correlation	O
of	O
the	O
plasma	O
MK	O
level	O
with	O
prognostic	O
factors	O
of	O
neuroblastomas	B-malignancy-type
.	O
The	O
plasma	O
MK	O
level	O
was	O
determined	O
in	O
220	O
patients	O
with	O
neuroblastomas	B-malignancy-type
,	O
and	O
compared	O
with	O
that	O
in	O
children	O
without	O
malignant	O
tumors	O
(	O
n	O
=	O
17	O
,	O
<	O
500	O
pg	O
ml(-1)	O
)	O
.	O
The	O
plasma	O
MK	O
level	O
became	O
significantly	O
elevated	O
with	O
advancing	O
stages	O
(	O
stage	O
1	O
:	O
445	O
pg	O
ml(-1)	O
(	O
median	O
)	O
,	O
n	O
=	O
73	O
;	O
stage	O
2	O
:	O
589	O
,	O
n	O
=	O
39	O
;	O
stage	O
3	O
:	O
864	O
,	O
n	O
=	O
40	O
;	O
stage	O
4	O
:	O
1445	O
,	O
n	O
=	O
56	O
;	O
and	O
stage	O
4S	O
:	O
2439	O
,	O
n	O
=	O
12	O
)	O
.	O
More	O
importantly	O
,	O
a	O
higher	O
MK	O
level	O
was	O
strongly	O
correlated	O
with	O
poor	O
prognostic	O
factors	O
:	O
over	O
1	O
year	O
of	O
age	O
(	O
P	O
=	O
0.0299	O
)	O
,	O
MYCN	O
amplification	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
low	O
TrkA	O
expression	O
(	O
P	O
=	O
0.0005	O
)	O
,	O
nonmass	O
screening	O
,	O
sporadic	B-malignancy-type
neuroblastomas	I-malignancy-type
(	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
diploidy	O
/tetraploidy	O
(	O
P	O
=	O
0.0007	O
)	O
.	O
Thus	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
plasma	O
MK	O
level	O
is	O
a	O
good	O
marker	O
for	O
evaluating	O
the	O
progression	O
of	O
neuroblastomas	B-malignancy-type
.	O
Moreover	O
,	O
considering	O
the	O
ability	O
of	O
antisense	O
MK	O
oligodeoxyribonucleotide	O
to	O
suppress	O
tumour	O
growth	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
cells	O
in	O
nude	O
mice	O
,	O
as	O
recently	O
reported	O
,	O
the	O
present	O
study	O
suggests	O
that	O
MK	O
is	O
a	O
possible	O
candidate	O
molecular	O
target	O
for	O
therapy	O
for	O
neuroblastomas	B-malignancy-type
.	O
PMID	O
:	O
12771916	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
J.	O
2000	O
Nov	O
1;351	O
Pt	O
3	O
:	O
661	O
-	O
8.	O
Characterization	O
of	O
the	O
mouse	O
dynamin	O
I	O
gene	O
promoter	O
and	O
identification	O
of	O
sequences	O
that	O
direct	O
expression	O
in	O
neuronal	O
cells	O
.	O
Yoo	O
J,	O
Lee	O
SS	O
,	O
Jeong	O
MJ	O
,	O
Lee	O
KI	O
,	O
Kwon	O
BM	O
,	O
Kim	O
SH	O
,	O
Park	O
YM	O
,	O
Han	O
MY	O
.	O
Cell	O
Biology	O
Laboratory	O
,	O
Korea	O
Research	O
Institute	O
of	O
Bioscience	O
and	O
Biotechnology	O
,	O
P.O	O
.	O
Box	O
115	O
,	O
Yusung	O
,	O
Taejon	O
305	O
-600	O
,	O
Korea	O
.	O
Dynamin	O
I	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
brain	O
and	O
its	O
expression	O
is	O
regulated	O
during	O
the	O
developmental	O
stages	O
of	O
brain	O
.	O
To	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
the	O
expression	O
is	O
tissue	O
-	O
specifically	O
regulated	O
,	O
we	O
cloned	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
mouse	O
dynamin	O
I	O
gene	O
and	O
determined	O
the	O
nucleotide	O
sequence	O
of	O
1036	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
.	O
Transient	O
transfection	O
studies	O
with	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
in	O
neuroblastoma	B-malignancy-type
NS20Y	O
and	O
Lewis	B-malignancy-type
lung	I-malignancy-type
cells	O
demonstrated	O
that	O
the	O
5'	O
-	O
flanking	O
region	O
has	O
a	O
cell	O
-	O
type	O
-	O
specific	O
promoter	O
activity	O
.	O
Deletion	O
analyses	O
demonstrated	O
that	O
the	O
minimal	O
promoter	O
activity	O
was	O
detected	O
in	O
the	O
proximal	O
region	O
195	O
bp	O
upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
(	O
-	O
90	O
to	O
+	O
105	O
)	O
.	O
The	O
minimal	O
promoter	O
was	O
embedded	O
in	O
a	O
GC	O
-	O
rich	O
region	O
(	O
75	O
%	O
GC	O
content	O
)	O
,	O
in	O
which	O
an	O
Sp1	O
-	O
binding	O
motif	O
and	O
a	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
-	O
like	O
element	O
(	O
NE	O
-	O
1	O
)	O
were	O
found	O
,	O
but	O
it	O
lacked	O
TATA	O
and	O
CAAT	O
boxes	O
.	O
Mutational	O
analysis	O
and	O
electrophoretic	O
mobility	O
-	O
shift	O
assay	O
analysis	O
revealed	O
that	O
Sp1	O
binds	O
to	O
the	O
Sp1	O
site	O
and	O
that	O
this	O
element	O
is	O
critical	O
for	O
the	O
promoter	O
activity	O
of	O
the	O
dynamin	O
I	O
gene	O
.	O
We	O
found	O
that	O
the	O
NE	O
-	O
1	O
sequence	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
dynamin	O
I	O
gene	O
but	O
NEBP	O
(	O
NE	O
-	O
1	O
-	O
binding	O
protein	O
)	O
,	O
which	O
binds	O
to	O
the	O
NE	O
-	O
1	O
sequence	O
,	O
is	O
not	O
NF	O
-	O
kappa	O
B	O
.	O
We	O
also	O
found	O
that	O
one	O
base	O
in	O
the	O
NE	O
-	O
1	O
sequence	O
(	O
the	O
underlined	O
G	O
residue	O
in	O
GGGATTCGCGGA	O
)	O
is	O
critical	O
for	O
binding	O
specificity	O
to	O
discriminate	O
between	O
NEBP	O
and	O
NF	O
-	O
kappa	O
B	O
.	O
By	O
UV	O
cross	O
-	O
linking	O
analysis	O
,	O
we	O
found	O
that	O
NEBP	O
is	O
an	O
approx	O
.	O
104	O
kDa	O
nuclear	O
protein	O
.	O
PMID	O
:	O
11042120	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2002	O
No	O
v-Dec;	O
9	O
(	O
6	O
)	O
:	O
119	O
7-203	O
Beta-catenin	O
and	O
cyclin	O
D1	O
expression	O
in	O
human	O
hepatocellular	O
carcinoma	O
.	O
Ueta	O
T	O
,	O
Ikeguchi	O
M,	O
Hirooka	O
Y	O
,	O
Kaibara	O
N	O
,	O
Terada	O
T.	O
The	O
Second	O
Department	O
of	O
Pathology	O
and	O
the	O
First	O
Department	O
of	O
Surgery	O
,	O
Tottori	O
University	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Yonago	O
68	O
3-8504	O
,	O
Tottori	O
,	O
Japan	O
.	O
bug1@grape	O
.med	O
tottor	O
i-u	O
.ac.jp	O
To	O
understand	O
the	O
nature	O
and	O
roles	O
of	O
mutated	O
beta-catenin	O
in	O
human	O
hepatocellular	O
carcinomas	O
(	O
HCCs	O
)	O
,	O
57	O
cases	O
of	O
surgically	O
resected	O
HCCs	O
were	O
studied	O
.	O
DNAs	O
extracted	O
from	O
each	O
tumor	O
were	O
examined	O
for	O
somatic	O
mutations	O
of	O
exon	O
3	O
,	O
and	O
the	O
protein	O
expressions	O
of	O
beta-catenin	O
,	O
cyclin	O
D1	O
,	O
and	O
Ki-67	O
were	O
observed	O
by	O
immunohistochemical	O
staining	O
.	O
beta-catenin	O
mutations	O
in	O
exon	O
3	O
were	O
detected	O
in	O
10	O
(	O
17.5	O
%	O
)	O
out	O
of	O
57	O
HCCs	O
,	O
including	O
nine	O
missense	O
mutations	O
and	O
one	O
deletion	O
mutation	O
.	O
All	O
of	O
the	O
cases	O
with	O
gene	O
alterations	O
had	O
the	O
anti	O
-	O
HCV	O
antibody	O
,	O
and	O
tested	O
negative	O
for	O
the	O
HBs	O
antigen	O
in	O
the	O
sera	O
.	O
All	O
of	O
the	O
mutations	O
occurred	O
at	O
the	O
serine	O
/	O
threonine	O
phosphorylation	O
sites	O
of	O
glycogen	O
synthase	O
kinase-3beta	O
(	O
GSK-3beta	O
)	O
or	O
their	O
neighboring	O
residues	O
.	O
Significant	O
correlation	O
with	O
intracellular	O
expression	O
(	O
p	O
=	O
0.00055	O
)	O
was	O
shown	O
in	O
the	O
HCCs	O
harboring	O
beta-catenin	O
mutations	O
.	O
The	O
intracellular	O
accumulation	O
of	O
beta-catenin	O
showed	O
significant	O
correlation	O
with	O
the	O
cyclin	O
D1	O
expression	O
(	O
p	O
=	O
0.00858	O
)	O
,	O
and	O
with	O
a	O
higher	O
proliferation	O
index	O
(	O
p	O
=	O
0.00072	O
)	O
.	O
In	O
addition	O
,	O
the	O
beta-catenin	O
mutations	O
showed	O
significant	O
association	O
with	O
the	O
cyclin	O
D1	O
expression	O
(	O
p	O
=	O
0.0424	O
)	O
.	O
These	O
results	O
suggest	O
that	O
accumulated	O
beta-catenin	O
proteins	O
may	O
bind	O
to	O
the	O
lymphocyte	O
enhancer	O
binding	O
factor-1	O
(	O
LEF-1	O
)	O
,	O
form	O
the	O
beta-catenin	O
/	O
LEF-1	O
complex	O
,	O
and	O
stimulate	O
such	O
promoters	O
regulating	O
the	O
cell	O
cycle	O
as	O
the	O
cyclin	O
D1	O
gene	O
.	O
This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
a	O
significant	O
correlation	O
between	O
beta-catenin	O
and	O
the	O
cyclin	O
D1	O
expression	O
in	O
human	O
HCCs	O
.	O
PMID	O
:	O
12375019	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Cancer	O
1992	O
May	O
1;6	O
9	O
(	O
9	O
)	O
:	O
238	O
5-92	O
Primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
after	O
prophylactic	O
central	O
nervous	O
system	O
irradiation	O
in	O
children	O
.	O
Association	O
with	O
an	O
activated	O
K-ras	O
gene	O
.	O
Brustle	O
O,	O
Ohgaki	O
H,	O
Schmitt	O
HP	O
,	O
Walter	O
GF	O
,	O
Ostertag	O
H,	O
Kleihues	O
P.	O
Laboratory	O
of	O
Neuropathology	O
,	O
Institute	O
of	O
Pathology	O
,	O
University	O
of	O
Zurich	O
,	O
Switzerland	O
.	O
Three	O
patients	O
had	O
supratentorial	B-malignancy-type
malignant	I-malignancy-type
brain	I-malignancy-type
tumors	I-malignancy-type
7	O
to	O
9	O
years	O
after	O
prophylactic	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
treatment	O
for	O
acute	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
or	O
malignant	B-malignancy-type
T-cell	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Therapy	O
was	O
administered	O
at	O
the	O
age	O
of	O
3	O
to	O
8	O
years	O
and	O
included	O
cranial	O
irradiation	O
(	O
total	O
dose	O
,	O
1800	O
to	O
2400	O
cGy	O
)	O
and	O
intrathecal	O
methotrexate	O
.	O
The	O
brain	B-malignancy-type
tumors	I-malignancy-type
had	O
histologic	O
and	O
immunohistochemical	O
features	O
of	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
(	O
PNET	B-malignancy-type
)	O
,	O
including	O
neuroblastic	O
rosettes	O
,	O
rhythmic	O
arrangement	O
of	O
tumor	O
cells	O
,	O
and	O
immunohistochemical	O
expression	O
of	O
glial	O
,	O
and	O
in	O
one	O
patient	O
neuronal	O
,	O
marker	O
proteins	O
.	O
Using	O
polymerase	O
chain	O
reaction	O
-	O
mediated	O
DNA	O
amplification	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
and	O
subsequent	O
DNA	O
sequence	O
analysis	O
,	O
an	O
activating	O
point	O
mutation	O
was	O
detected	O
in	O
the	O
K-ras	O
protooncogene	O
in	O
one	O
tumor	O
.	O
This	O
mutation	O
was	O
a	O
G	O
to	O
A	O
transition	O
in	O
position	O
2	O
of	O
codon	O
12	O
,	O
substituting	O
aspartate	O
(	O
GAT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
.	O
This	O
type	O
of	O
mutation	O
has	O
not	O
been	O
observed	O
before	O
in	O
human	O
brain	B-malignancy-type
tumors	I-malignancy-type
,	O
but	O
it	O
is	O
frequent	O
in	O
radiation	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
murine	I-malignancy-type
lymphomas	I-malignancy-type
.	O
These	O
observations	O
suggest	O
that	O
PNET	B-malignancy-type
can	O
be	O
induced	O
after	O
completion	O
of	O
the	O
embryonal	O
and	O
fetal	O
development	O
of	O
the	O
human	O
CNS	O
.	O
Oncogene	O
-	O
activating	O
point	O
mutations	O
may	O
represent	O
a	O
pathogenetic	O
mechanism	O
involved	O
in	O
the	O
genesis	O
of	O
radiation	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
brain	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
1314130	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatol	O
1992	O
Mar;1	O
4	O
(	O
2-3	O
)	O
:	O
34	O
2-6	O
Infrequent	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
61	O
of	O
ras	O
oncogenes	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Challen	O
C,	O
Guo	O
K,	O
Collier	O
JD	O
,	O
Cavanagh	O
D	O
,	O
Bassendine	O
MF.	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
Department	O
of	O
Medicine	O
,	O
Medical	O
School	O
,	O
United	O
Kingdom	O
.	O
DNA	O
from	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
codons	O
12	O
and	O
61	O
of	O
the	O
K-ras	O
,	O
H-ras	O
and	O
N-ras	O
genes	O
.	O
The	O
relevant	O
ras	O
sequences	O
were	O
amplified	O
in	O
vitro	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
point	O
mutations	O
detected	O
by	O
selective	O
hybridisation	O
using	O
mutation	O
-	O
specific	O
synthetic	O
oligonucleotides	O
.	O
In	O
one	O
of	O
the	O
19	O
HCCs	B-malignancy-type
a	O
mutation	O
in	O
codon	O
61	O
of	O
the	O
K-ras	O
gene	O
was	O
detected	O
,	O
whilst	O
in	O
3	O
/	O
19	O
HCCs	B-malignancy-type
a	O
mutation	O
was	O
found	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
gene	O
.	O
The	O
mutations	O
were	O
all	O
heterozygous	O
A	O
-	O
T	O
transversions	O
and	O
were	O
found	O
in	O
HCCs	B-malignancy-type
arising	O
in	O
patients	O
with	O
underlying	O
cirrhosis	O
.	O
In	O
two	O
of	O
these	O
patients	O
where	O
the	O
corresponding	O
normal	O
tissue	O
was	O
available	O
only	O
the	O
wild	O
-	O
type	O
ras	O
gene	O
was	O
detected	O
,	O
indicating	O
that	O
oncogenic	O
activation	O
of	O
the	O
ras	O
gene	O
was	O
a	O
consequence	O
of	O
somatic	O
mutation	O
.	O
In	O
another	O
patient	O
the	O
same	O
mutation	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
gene	O
was	O
found	O
in	O
cirrhotic	O
liver	O
tissue	O
and	O
in	O
all	O
four	O
patients	O
the	O
same	O
mutation	O
was	O
also	O
detected	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
liver	O
biopsy	O
HCC	B-malignancy-type
tissue	O
obtained	O
at	O
diagnosis	O
.	O
These	O
results	O
indicate	O
that	O
mutational	O
activation	O
of	O
the	O
ras	O
genes	O
at	O
codon	O
61	O
is	O
an	O
infrequent	O
but	O
possibly	O
early	O
event	O
in	O
the	O
development	O
of	O
HCC	B-malignancy-type
in	O
Britain	O
.	O
PMID	O
:	O
1323601	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surg	O
Oncol	O
1992	O
Dec;	O
1	O
(	O
6	O
)	O
:	O
40	O
5-11	O
Analysis	O
of	O
ras	O
oncogene	O
mutations	O
in	O
human	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
head	I-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
.	O
Nunez	O
F	O
,	O
Dominguez	O
O,	O
Coto	O
E	O
,	O
Suare	O
z-Nieto	O
C,	O
Perez	O
P,	O
Lope	O
z-Larrea	O
C.	O
Department	O
of	O
Otolaryngology	O
,	O
Hospital	O
Central	O
de	O
Asturias	O
,	O
Oviedo	O
,	O
Spain	O
.	O
The	O
presence	O
of	O
proto	O
-	O
oncogene	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
Ha	O
-	O
,	O
Ki	O
-	O
,	O
and	O
N-ras	O
in	O
primary	B-malignancy-type
head	I-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
are	O
analysed	O
in	O
this	O
study	O
.	O
Oncogene	O
ras	O
-	O
specific	O
sequences	O
were	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
probed	O
with	O
mutation	O
specific	O
oligonucleotide	O
probes	O
.	O
Mutations	O
were	O
detected	O
in	O
8	O
of	O
22	O
samples	O
(	O
36.3	O
%	O
)	O
.	O
No	O
mutations	O
were	O
detected	O
on	O
patients	O
'	O
peripheral	O
blood	O
DNA	O
.	O
We	O
found	O
that	O
histologically	O
and	O
clinically	O
,	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
with	O
or	O
without	O
a	O
ras	O
mutation	O
do	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
.	O
PMID	O
:	O
1341278	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
Nov	O
1;5	O
2	O
(	O
21	O
)	O
:	O
599	O
1-6	O
Presence	O
of	O
ras	O
oncogene	O
mutations	O
and	O
human	O
papillomavirus	O
DNA	O
in	O
human	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Anwar	O
K,	O
Nakakuki	O
K,	O
Shiraishi	O
T	O
,	O
Naiki	O
H,	O
Yatani	O
R	O
,	O
Inuzuka	O
M.	O
Department	O
of	O
Pathology	O
,	O
Fukui	O
Medical	O
School	O
,	O
Matsuoka	O
,	O
Japan	O
.	O
The	O
frequency	O
of	O
H-ras	O
,	O
K-ras	O
,	O
and	O
N-ras	O
mutations	O
and	O
the	O
presence	O
of	O
high	O
-	O
risk	O
human	O
papillomavirus	O
(	O
HPV	O
16	O
,	O
18	O
,	O
and	O
33	O
)	O
DNA	O
were	O
studied	O
in	O
75	O
paraffin	O
-	O
embedded	O
specimens	O
obtained	O
from	O
68	O
Japanese	O
patients	O
with	O
a	O
variety	O
of	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
by	O
using	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
hybridization	O
with	O
sequence	O
-	O
specific	O
oligonucleotides	O
.	O
Ten	O
specimens	O
each	O
of	O
normal	O
and	O
benign	B-malignancy-type
hyperplastic	I-malignancy-type
prostatic	I-malignancy-type
tissues	I-malignancy-type
from	O
the	O
same	O
number	O
of	O
patients	O
were	O
also	O
examined	O
for	O
this	O
analysis	O
.	O
Of	O
68	O
carcinoma	B-malignancy-type
cases	O
,	O
ras	O
gene	O
mutations	O
were	O
present	O
in	O
16	O
cases	O
(	O
24	O
%	O
)	O
and	O
HPV	O
DNAs	O
in	O
28	O
cases	O
(	O
41	O
%	O
)	O
.	O
Eleven	O
mutations	O
were	O
detected	O
in	O
codon	O
61	O
of	O
H-ras	O
,	O
4	O
in	O
codon	O
12	O
of	O
N-ras	O
,	O
and	O
2	O
in	O
codon	O
61	O
of	O
K-ras	O
.	O
HPV	O
16	O
,	O
18	O
,	O
and	O
33	O
DNAs	O
were	O
found	O
in	O
11	O
,	O
17	O
,	O
and	O
5	O
cases	O
,	O
respectively	O
.	O
Eight	O
of	O
the	O
16	O
cases	O
with	O
ras	O
mutation	O
also	O
harbored	O
HPV	O
DNAs	O
.	O
The	O
frequency	O
of	O
ras	O
mutations	O
and	O
the	O
HPV	O
infection	O
increased	O
in	O
patients	O
with	O
advanced	O
stages	O
of	O
the	O
tumor	O
and	O
with	O
the	O
higher	O
Gleason	O
score	O
.	O
There	O
was	O
the	O
predominant	O
presence	O
of	O
H-ras	O
codon	O
61.2	O
(	O
CAG	O
-->	O
CTG	O
)	O
mutation	O
and	O
HPV	O
18	O
DNA	O
in	O
prostatic	B-malignancy-type
carcinomas	I-malignancy-type
metastasizing	O
to	O
the	O
bone	O
.	O
None	O
of	O
the	O
normal	O
or	O
benign	B-malignancy-type
hyperplastic	I-malignancy-type
prostatic	I-malignancy-type
specimens	I-malignancy-type
contained	O
either	O
ras	O
mutation	O
or	O
HPV	O
DNA	O
.	O
Our	O
results	O
suggest	O
that	O
ras	O
gene	O
mutations	O
and	O
HPV	O
infections	O
are	O
relatively	O
frequent	O
,	O
at	O
least	O
in	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
of	O
Japanese	O
patients	O
.	O
These	O
two	O
factors	O
appear	O
to	O
be	O
related	O
to	O
the	O
progression	O
of	O
the	O
tumor	O
.	O
Moreover	O
,	O
H-ras	O
codon	O
61.2	O
mutation	O
and	O
HPV	O
18	O
infection	O
may	O
have	O
some	O
predictive	O
roles	O
for	O
bone	O
metastasis	O
in	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
1382850	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1992	O
Oct;8	O
3	O
(	O
10	O
)	O
:	O
105	O
7-62	O
ras	O
mutations	O
in	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
:	O
mutation	O
detection	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
.	O
Yoshimoto	O
K,	O
Iwahana	O
H,	O
Fukuda	O
A	O
,	O
Sano	O
T	O
,	O
Katsuragi	O
K,	O
Kinoshita	O
M,	O
Saito	O
S	O
,	O
Itakura	O
M.	O
Otsuka	O
Department	O
of	O
Clinical	O
and	O
Molecular	O
Nutrition	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Tokushima	O
.	O
To	O
elucidate	O
the	O
molecular	O
basis	O
for	O
endocrine	O
tumorigenesis	O
,	O
ras	O
mutations	O
in	O
human	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
were	O
analyzed	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
analysis	O
.	O
Mutations	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
,	O
N-ras	O
genes	O
were	O
examined	O
in	O
genomic	O
DNAs	O
from	O
169	O
successfully	O
amplified	O
primary	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
out	O
of	O
189	O
samples	O
.	O
Four	O
out	O
of	O
24	O
thyroid	B-malignancy-type
follicular	I-malignancy-type
adenomas	I-malignancy-type
analyzed	O
contained	O
mutated	O
N-ras	O
codon	O
61	O
,	O
and	O
one	O
contained	O
the	O
mutated	O
H-ras	O
codon	O
61	O
.	O
One	O
of	O
the	O
19	O
pheochromocytomas	B-malignancy-type
revealed	O
mutation	O
of	O
the	O
H-ras	O
codon	O
13	O
.	O
No	O
mutations	O
of	O
the	O
ras	O
gene	O
were	O
detected	O
in	O
pituitary	B-malignancy-type
adenomas	I-malignancy-type
,	O
parathyroid	B-malignancy-type
tumors	I-malignancy-type
,	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
,	O
endocrine	B-malignancy-type
pancreatic	I-malignancy-type
tumors	I-malignancy-type
,	O
and	O
adrenocortical	B-malignancy-type
tumors	I-malignancy-type
.	O
Based	O
on	O
these	O
findings	O
we	O
conclude	O
that	O
activation	O
of	O
the	O
ras	O
gene	O
may	O
play	O
a	O
role	O
in	O
the	O
tumorigenesis	O
of	O
a	O
limited	O
number	O
of	O
thyroid	B-malignancy-type
follicular	I-malignancy-type
adenomas	I-malignancy-type
and	O
pheochromocytomas	B-malignancy-type
,	O
and	O
that	O
mutation	O
of	O
the	O
ras	O
gene	O
is	O
not	O
frequent	O
in	O
other	O
human	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
1452458	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
May	O
15	O
;5	O
2	O
(	O
10	O
)	O
:	O
290	O
3-6	O
ras	O
gene	O
mutations	O
as	O
a	O
prognostic	O
marker	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
lung	I-malignancy-type
without	O
lymph	O
node	O
metastasis	O
.	O
Sugio	O
K,	O
Ishida	O
T	O
,	O
Yokoyama	O
H,	O
Inoue	O
T	O
,	O
Sugimachi	O
K,	O
Sasazuki	O
T.	O
Department	O
of	O
Surgery	O
II	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
obtained	O
at	O
surgical	O
resection	O
was	O
examined	O
for	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
oncogenes	O
K-ras	O
,	O
H-ras	O
,	O
and	O
N-ras	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
techniques	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
18	O
of	O
the	O
115	O
cases	O
(	O
15.7	O
%	O
)	O
,	O
and	O
15	O
of	O
18	O
were	O
at	O
codon	O
12	O
,	O
2	O
were	O
at	O
codon	O
13	O
of	O
K-ras	O
,	O
and	O
1	O
was	O
at	O
codon	O
61	O
of	O
N-ras	O
.	O
G	O
to	O
T	O
transversions	O
were	O
most	O
common	O
.	O
The	O
ras	O
gene	O
mutations	O
were	O
more	O
frequent	O
in	O
the	O
male	O
patients	O
(	O
P	O
=	O
0.0048	O
)	O
.	O
No	O
significant	O
differences	O
were	O
found	O
to	O
be	O
related	O
to	O
stage	O
of	O
the	O
disease	O
or	O
tumor	O
-	O
nodes	O
-	O
metastases	O
classification	O
between	O
positive	O
and	O
negative	O
groups	O
of	O
the	O
ras	O
gene	O
mutations	O
.	O
A	O
history	O
of	O
tobacco	O
use	O
was	O
not	O
always	O
a	O
factor	O
contributing	O
to	O
mutation	O
.	O
Of	O
the	O
completely	O
resected	O
group	O
without	O
lymph	O
node	O
metastasis	O
,	O
the	O
5	O
-	O
year	O
survival	O
rate	O
in	O
the	O
ras	O
-	O
positive	O
group	O
was	O
53.3	O
%	O
,	O
which	O
was	O
significantly	O
poorer	O
than	O
the	O
83.6	O
%	O
survival	O
rate	O
in	O
the	O
ras	O
-	O
negative	O
group	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
prognostic	O
,	O
especially	O
in	O
the	O
early	O
stage	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
PMID	O
:	O
1581907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1992	O
;2	O
8	O
(	O
2-3	O
)	O
:	O
33	O
3-6	O
Mutations	O
in	O
the	O
ras	O
protooncogenes	O
are	O
rare	O
events	O
in	O
renal	B-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
.	O
Rochlitz	O
CF	O
,	O
Peter	O
S	O
,	O
Willroth	O
G,	O
de	O
Kant	O
E	O
,	O
Lobeck	O
H,	O
Huhn	O
D	O
,	O
Herrmann	O
R.	O
Abt	O
.	O
Hamatologi	O
e/Onkologie	O
,	O
Klinikums	O
Charlottenburg	O
,	O
Freien	O
Universitat	O
Berlin	O
,	O
F.R.G.	O
Mutations	O
in	O
codon	O
12	O
,	O
13	O
or	O
61	O
of	O
one	O
of	O
the	O
three	O
ras	O
genes	O
,	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
,	O
convert	O
these	O
genes	O
into	O
active	O
oncogenes	O
.	O
To	O
determine	O
the	O
role	O
mutated	O
ras	O
genes	O
play	O
in	O
the	O
carcinogenesis	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
analysed	O
tumour	O
DNA	O
and	O
unaffected	O
renal	O
tissue	O
derived	O
from	O
55	O
patients	O
.	O
The	O
polymerase	O
chain	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
Ki	O
-	O
,	O
Ha	O
-	O
,	O
and	O
N-ras	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
The	O
amplified	O
fragments	O
were	O
then	O
probed	O
on	O
slot	O
-	O
blots	O
with	O
labeled	O
mutation	O
-	O
specific	O
oligomers	O
.	O
A	O
single	O
Ki-ras	O
mutation	O
(	O
codon	O
12	O
,	O
gly	O
-_greater_than	O
val	O
)	O
was	O
detected	O
in	O
a	O
patient	O
with	O
a	O
pT2N2M1	B-malignancy-type
tumour	I-malignancy-type
.	O
We	O
concluded	O
that	O
ras	O
oncogene	O
mutations	O
do	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
initiation	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
1591047	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Singapore	O
Med	O
J	O
1992	O
Feb	O
;	O
33	O
(	O
1	O
)	O
:	O
48	O
-	O
50	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
probes	O
.	O
Chin	O
Y	O
M	O
,	O
Bosco	O
J	O
J	O
,	O
Koh	O
C	O
L	O
.	O
Haematology	O
Division	O
,	O
Institute	O
for	O
Medical	O
Research	O
,	O
Jalan	O
Pahang	O
,	O
Kuala	O
Lumpur	O
,	O
Malaysia	O
.	O
In	O
vitro	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
amplification	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
hybridization	O
with	O
oligonucleotide	O
probes	O
were	O
used	O
to	O
study	O
ras	O
gene	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
The	O
DNA	O
of	O
30	O
AML	B-malignancy-type
patients	O
at	O
presentation	O
of	O
the	O
disease	O
at	O
the	O
University	O
of	O
Malaya	O
Hospital	O
,	O
Kuala	O
Lumpur	O
were	O
screened	O
for	O
ras	O
gene	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
,	O
K-ras	O
and	O
H-ras	O
genes	O
.	O
Four	O
patients	O
(	O
13.3	O
%	O
)	O
had	O
ras	O
gene	O
mutations	O
.	O
They	O
were	O
all	O
below	O
their	O
early	O
thirties	O
in	O
age	O
.	O
Of	O
the	O
four	O
patients	O
with	O
ras	O
gene	O
mutations	O
,	O
three	O
were	O
M3	B-malignancy-type
and	O
one	O
was	O
M4	B-malignancy-type
according	O
to	O
the	O
French	O
American	O
British	O
(	O
FAB	O
)	O
classification	O
of	O
AML	B-malignancy-type
.	O
PMID	O
:	O
1598607	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
1991	O
Aug	O
;	O
6	O
(	O
8	O
)	O
:	O
1353	O
-	O
62	O
Mutations	O
of	O
ras	O
genes	O
distinguish	O
a	O
subset	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
from	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Mitsudomi	O
T	O
,	O
Viallet	O
J	O
,	O
Mulshine	O
JL	O
,	O
Linnoila	O
RI	O
,	O
Minna	O
JD	O
,	O
Gazdar	O
AF.	O
NCI	O
-	O
Navy	O
Medical	O
Oncology	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20889	O
-	O
5105	O
.	O
We	O
screened	O
a	O
panel	O
of	O
103	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
human	O
K	O
-	O
,	O
H	O
-	O
and	O
N-ras	O
genes	O
,	O
using	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLP	O
)	O
,	O
created	O
through	O
mismatched	O
primers	O
during	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
of	O
genomic	O
DNA	O
.	O
We	O
found	O
ras	O
mutations	O
in	O
22	O
/	O
61	O
(	O
36	O
%	O
)	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
cell	O
lines	O
,	O
predominantly	O
in	O
K-ras	O
codon	O
12	O
.	O
Identical	O
mutations	O
were	O
present	O
in	O
uncultured	O
tumor	O
materials	O
corresponding	O
to	O
11	O
cell	O
lines	O
containing	O
mutated	O
ras	O
genes	O
.	O
ras	O
mutations	O
were	O
found	O
not	O
only	O
in	O
adenocarcinoma	B-malignancy-type
cell	O
lines	O
(	O
9	O
/	O
32	O
,	O
28	O
%	O
)	O
,	O
but	O
also	O
in	O
cell	O
lines	O
derived	O
from	O
other	O
types	O
of	O
NSCLC	B-malignancy-type
(	O
13	O
/	O
29	O
,	O
45	O
%	O
)	O
.	O
In	O
contrast	O
,	O
none	O
of	O
37	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
SCLC	B-malignancy-type
)	O
cell	O
lines	O
and	O
five	O
extra	B-malignancy-type
-	I-malignancy-type
pulmonary	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
had	O
ras	O
mutations	O
.	O
ras	O
mutations	O
were	O
not	O
correlated	O
with	O
sex	O
of	O
the	O
patients	O
,	O
tumor	O
extent	O
,	O
prior	O
therapy	O
status	O
or	O
in	O
vitro	O
culture	O
time	O
.	O
G	O
to	O
T	O
or	O
A	O
to	O
T	O
transversions	O
were	O
the	O
most	O
common	O
base	O
substitutions	O
,	O
occurring	O
in	O
codons	O
12	O
and	O
61	O
respectively	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
a	O
subset	O
of	O
NSCLC	B-malignancy-type
but	O
are	O
not	O
involved	O
in	O
SCLC	B-malignancy-type
.	O
PMID	O
:	O
1679529	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
1992	O
Mar	O
1	O
;	O
69	O
(	O
5	O
)	O
:	O
1115	O
-	O
8	O
High	O
incidence	O
of	O
ras	O
gene	O
mutation	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
.	O
Tada	O
M,	O
Omata	O
M,	O
Ohto	O
M.	O
First	O
Department	O
of	O
Medicine	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
DNA	O
sequences	O
around	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
ras	O
gene	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
in	O
18	O
intrahepatic	B-malignancy-type
cholangiocarcinomas	I-malignancy-type
.	O
The	O
ras	O
gene	O
mutations	O
were	O
found	O
in	O
9	O
of	O
18	O
(	O
50	O
%	O
)	O
:	O
6	O
in	O
K-ras	O
codon	O
12	O
,	O
1	O
in	O
K-ras	O
codon	O
13	O
,	O
1	O
in	O
K-ras	O
codon	O
61	O
,	O
and	O
1	O
in	O
N-ras	O
codon	O
12	O
.	O
The	O
incidence	O
of	O
mutations	O
was	O
higher	O
in	O
the	O
hilar	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
intrahepatic	I-malignancy-type
cholangiocarcinomas	I-malignancy-type
,	O
especially	O
when	O
these	O
tumors	O
were	O
large	O
.	O
The	O
incidence	O
and	O
spectrum	O
of	O
the	O
mutations	O
were	O
almost	O
the	O
same	O
as	O
those	O
reported	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
,	O
possibly	O
indicating	O
similar	O
etiologic	O
agent	O
(	O
s	O
)	O
in	O
the	O
carcinogenesis	O
of	O
both	O
cancers	O
.	O
PMID	O
:	O
1739910	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

therapy-related_leukemia	B-malignancy-type
myelodysplastic_syndrome	B-malignancy-type
therapy-related_leukemia	B-malignancy-type
therapy-related_myelodysplastic_syndrome	B-malignancy-type
N-ras	O
K-ras	O
N-ras	O
K-ras	O
mutations	O
codons_12	O
13	O
61	O
N-ras	O
K-ras	O
N-ras	O
mutation	O
aspartic_acid	O
GAT	O
glycine	O
GGT	O
N-ras	O
codon_13	O
mutation	O
valine	O
GTT	O
glycine	O
K-ras	O
codon_12	O
mutations	O
aspartic_acid	O
GAT	O
cysteine	O
TGT	O
glycine	O
GGT	O
K-ras	O
codon_61	O
mutation	O
lysine	O
AAA	O
glutamic_acid	O
CAA	O
loss	O
chromosome_7	O
N-ras	O
K-ras	O
loss_of_heterozygosity	O
chromosome_7	O
herapy-related_leukemia	B-malignancy-type
myelodysplastic_syndrome	B-malignancy-type

Blood	O
1991	O
Feb	O
1	O
;	O
77	O
(	O
3	O
)	O
:	O
594	O
-	O
8	O
Mutations	O
of	O
the	O
ras	O
proto	O
-	O
oncogenes	O
in	O
childhood	O
monosomy	O
7	O
.	O
Neubauer	O
A	O
,	O
Shannon	O
K	O
,	O
Liu	O
E	O
.	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
27599-7295	O
.	O
ras	O
gene	O
mutations	O
are	O
the	O
most	O
frequent	O
molecular	O
changes	O
found	O
in	O
the	O
preleukemic	B-malignancy-type
syndromes	I-malignancy-type
of	O
adults	O
and	O
may	O
play	O
a	O
role	O
in	O
initiating	O
these	O
diseases	O
and	O
in	O
their	O
progression	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
incidence	O
or	O
importance	O
of	O
these	O
genetic	O
mutations	O
in	O
childhood	B-malignancy-type
myeloproliferative	I-malignancy-type
states	I-malignancy-type
(	B-malignancy-type
MPS	I-malignancy-type
)	O
.	O
The	O
bone	O
marrow	O
(	O
BM	O
)	O
monosomy	O
7	O
syndrome	O
accounts	O
for	O
a	O
large	O
percentage	O
of	O
childhood	O
MPS	B-malignancy-type
.	O
Although	O
the	O
duration	O
of	O
the	O
MPS	B-malignancy-type
is	O
quite	O
variable	O
,	O
children	O
with	O
monosomy	O
7	O
eventually	O
develop	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
We	O
investigated	O
20	O
children	O
(	O
13	O
with	O
MPS	B-malignancy-type
,	O
7	O
with	O
AML	B-malignancy-type
)	O
with	O
BM	O
monosomy	O
7	O
or	O
7q-	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
hybridization	O
with	O
mutation	O
-	O
specific	O
oligonucleotides	O
.	O
Mutations	O
of	O
N-ras	O
and	O
K-ras	O
were	O
detected	O
in	O
three	O
children	O
.	O
Two	O
patients	O
carrying	O
a	O
ras	O
mutation	O
were	O
in	O
the	O
myeloproliferative	O
phase	O
,	O
and	O
one	O
had	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
All	O
three	O
patients	O
with	O
ras	O
mutations	O
either	O
died	O
of	O
their	O
disease	O
or	O
relapsed	O
after	O
BM	O
transplantation	O
as	O
compared	O
with	O
8	O
of	O
17	O
without	O
ras	O
mutations	O
.	O
However	O
,	O
this	O
difference	O
is	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
.14	O
,	O
not	O
significant	O
)	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
are	O
observed	O
in	O
childhood	O
monosomy	O
7	O
,	O
though	O
less	O
frequently	O
than	O
in	O
adult	O
MDS	B-malignancy-type
,	O
and	O
may	O
play	O
a	O
limited	O
role	O
in	O
the	O
progression	O
of	O
this	O
disease	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
More	O
patients	O
are	O
needed	O
to	O
address	O
the	O
prognostic	O
role	O
of	O
ras	O
mutations	O
in	O
this	O
rare	O
disease	O
.	O
PMID	O
:	O
1991170	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
1991	O
Apr	O
15	O
;	O
67	O
(	O
8	O
)	O
:	O
2103	O
-	O
10	O
A	O
T-cell	B-malignancy-type
neoplasia	I-malignancy-type
showing	O
clinicopathologic	O
features	O
of	O
malignant	B-malignancy-type
histiocytosis	I-malignancy-type
with	O
novel	O
chromosomal	O
abnormalities	O
and	O
N-ras	O
mutation	O
.	O
Itoyama	O
T	O
,	O
Sadamori	O
N	O
,	O
Sasagawa	O
I	O
,	O
Nakamura	O
H	O
,	O
Tokunaga	O
S	O
,	O
Yamada	O
Y	O
,	O
Ichimaru	O
M	O
,	O
Yoshida	O
T	O
,	O
Kikuchi	O
M	O
,	O
Takeshima	O
F	O
,	O
et	O
al	O
.	O
Department	O
of	O
Hematology	O
,	O
Atomic	O
Disease	O
Institute	O
,	O
Nagasaki	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Malignant	B-malignancy-type
histiocytosis	I-malignancy-type
(	O
MH	B-malignancy-type
)	O
is	O
a	O
distinct	O
disease	O
entity	O
defined	O
clinically	O
and	O
morphologically	O
.	O
However	O
,	O
the	O
neoplastic	O
origin	O
of	O
MH	B-malignancy-type
is	O
not	O
well	O
established	O
.	O
The	O
authors	O
report	O
a	O
26-year-old	O
woman	O
who	O
showed	O
the	O
typical	O
clinicopathologic	O
features	O
of	O
so-called	O
MH	B-malignancy-type
.	O
Cytogenetic	O
and	O
molecular	O
genetic	O
examinations	O
were	O
performed	O
in	O
addition	O
to	O
the	O
morphologic	O
and	O
immunologic	O
approach	O
.	O
The	O
expression	O
of	O
CD2	O
and	O
T-cell	O
receptor	O
gene	O
rearrangements	O
indicated	O
the	O
T-cell	O
origin	O
of	O
this	O
case	O
.	O
CD30	O
,	O
which	O
is	O
positive	O
for	O
anaplastic	B-malignancy-type
large	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
Ki-1	B-malignancy-type
lymphoma	I-malignancy-type
)	O
,	O
was	O
not	O
expressed	O
.	O
The	O
cytogenetic	O
study	O
revealed	O
a	O
clonal	O
chromosome	O
abnormality	O
involving	O
3q25	O
,	O
6p21	O
,	O
11p15	O
,	O
and	O
11q21	O
.	O
An	O
N-ras	O
point	O
mutation	O
within	O
codon	O
12	O
(	O
GGT	O
----	O
GCT	O
)	O
was	O
also	O
detected	O
.	O
These	O
finding	O
indicate	O
that	O
MH	B-malignancy-type
defined	O
clinically	O
and	O
morphologically	O
is	O
not	O
a	O
tumor	O
of	O
true	O
histiocytic	O
origin	O
and	O
that	O
it	O
should	O
be	O
reclassified	O
on	O
the	O
basis	O
of	O
immunologic	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
genetic	O
data	O
.	O
PMID	O
:	O
2004329	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
1991	O
May	O
30	O
;	O
48	O
(	O
3	O
)	O
:	O
409	O
-	O
12	O
Ras	O
mutations	O
in	O
United	O
Kingdom	O
examples	O
of	O
oral	B-malignancy-type
malignancies	I-malignancy-type
are	O
infrequent	O
.	O
Chang	O
SE	O
,	O
Bhatia	O
P	O
,	O
Johnson	O
NW	O
Morgan	O
PR	O
,	O
McCormick	O
F	O
,	O
Young	O
B	O
,	O
Hiorns	O
L	O
.	O
Department	O
of	O
Dental	O
Sciences	O
,	O
Royal	O
College	O
of	O
Surgeons	O
of	O
England	O
,	O
London	O
,	O
UK	O
.	O
Point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
oncogenes	O
Ha-ras	O
,	O
Ki-ras	O
or	O
N-ras	O
have	O
been	O
identified	O
in	O
human	O
malignancies	O
of	O
many	O
types	O
.	O
Using	O
the	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
technique	O
for	O
DNA	O
amplification	O
in	O
vitro	O
and	O
stringent	O
probing	O
of	O
the	O
amplified	O
DNA	O
on	O
dot	O
blots	O
with	O
a	O
library	O
of	O
specific	O
oligonucleotides	O
,	O
we	O
have	O
screened	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
in	O
oral	B-malignancy-type
and	O
para	B-malignancy-type
-	I-malignancy-type
oral	I-malignancy-type
malignancies	I-malignancy-type
and	O
some	O
associated	O
lesions	B-malignancy-type
.	O
The	O
material	O
,	O
from	O
UK	O
patients	O
,	O
consisted	O
of	O
22	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
including	O
5	O
neck	B-malignancy-type
metastases	I-malignancy-type
,	O
1	O
oral	B-malignancy-type
mucosal	I-malignancy-type
dysplasia	I-malignancy-type
,	O
1	O
proliferative	B-malignancy-type
verrucous	I-malignancy-type
leukoplakia	I-malignancy-type
,	O
1	O
antral	B-malignancy-type
and	O
1	O
tonsillar	B-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
basal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
salivary	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
1	O
salivary	B-malignancy-type
adenoid	I-malignancy-type
cystic	I-malignancy-type
carcinoma	I-malignancy-type
and	O
1	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
metastatic	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
gingiva	I-malignancy-type
.	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
tissues	O
which	O
were	O
fresh	O
or	O
preserved	O
in	O
liquid	O
nitrogen	O
.	O
Two	O
DNA	O
samples	O
contained	O
point	O
mutations	O
in	O
codon	O
61	O
of	O
Ki-ras	O
.	O
One	O
of	O
these	O
mutations	O
was	O
in	O
the	O
lymphocytes	O
infiltrating	O
a	O
retromolar	B-malignancy-type
SCC	I-malignancy-type
.	O
The	O
other	O
mutation	O
(	O
CAA	O
to	O
CAU	O
;	O
substitution	O
of	O
glutamine	O
by	O
histidine	O
)	O
was	O
in	O
the	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
metastasis	O
.	O
The	O
absence	O
of	O
ras	O
mutations	O
in	O
the	O
epithelium	O
of	O
primary	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
is	O
of	O
considerable	O
interest	O
as	O
other	O
work	O
in	O
our	O
Department	O
on	O
Indian	O
cases	O
of	O
oral	B-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
chewing	O
tobacco	O
(	O
quid	O
)	O
revealed	O
that	O
35	O
%	O
of	O
these	O
had	O
a	O
codon	O
12	O
,	O
13	O
or	O
61	O
mutation	O
in	O
Ha-ras	O
.	O
While	O
ras	O
activations	O
arising	O
from	O
point	O
mutations	O
may	O
occur	O
in	O
a	O
high	O
proportion	O
of	O
oral	B-malignancy-type
malignancies	I-malignancy-type
associated	O
with	O
chewing	O
tobacco	O
(	O
quid	O
)	O
,	O
this	O
was	O
not	O
the	O
case	O
in	O
UK	O
oral	B-malignancy-type
malignancies	I-malignancy-type
,	O
even	O
where	O
tobacco	O
was	O
smoked	O
.	O
PMID	O
:	O
2040536	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1990	O
Nov	O
1	O
;	O
50	O
(	O
21	O
)	O
:	O
6830	O
-	O
2	O
ras	O
gene	O
mutations	O
in	O
human	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Carter	O
BS	O
,	O
Epstein	O
JI	O
,	O
Isaacs	O
WB.	O
Brady	O
Urological	O
Research	O
Institute	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
and	O
Hospital	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
.	O
Point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
of	O
the	O
Ha	O
-	O
,	O
Ki	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
are	O
able	O
to	O
convert	O
these	O
normal	O
cellular	O
genes	O
into	O
activated	O
oncogenes	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
ras	O
gene	O
mutations	O
occur	O
in	O
a	O
variety	O
of	O
human	O
solid	B-malignancy-type
tumors	I-malignancy-type
and	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
some	O
of	O
these	O
tumors	O
.	O
In	O
order	O
to	O
test	O
the	O
hypothesis	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
associated	O
with	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
have	O
used	O
an	O
oligodeoxynucleotide	O
hybridization	O
assay	O
to	O
detect	O
wild-type	O
and	O
mutant	O
alleles	O
in	O
genomic	O
DNA	O
from	O
prostate	B-malignancy-type
tumors	I-malignancy-type
and	O
prostate	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Twenty-four	O
primary	O
prostate	B-malignancy-type
tumors	I-malignancy-type
(	O
23	O
acinar	B-malignancy-type
tumors	I-malignancy-type
and	O
one	O
ductal	B-malignancy-type
tumor	I-malignancy-type
)	O
and	O
five	O
prostate	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
were	O
examined	O
for	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
Ki-ras	O
,	O
Ha-ras	O
,	O
and	O
N-ras	O
genes	O
.	O
Two	O
mutations	O
were	O
detected	O
:	O
an	O
A	O
----	O
G	O
transition	O
causing	O
a	O
glutamine	O
to	O
arginine	O
amino	O
acid	O
substitution	O
at	O
codon	O
61	O
of	O
the	O
Ha-ras	O
gene	O
in	O
a	O
primary	O
prostatic	B-malignancy-type
duct	I-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
a	O
G	O
----	O
T	O
transversion	O
causing	O
a	O
glycine	O
to	O
valine	O
amino	O
acid	O
substitution	O
at	O
codon	O
12	O
of	O
the	O
Ha-ras	O
gene	O
in	O
a	O
prostate	B-malignancy-type
tumor	I-malignancy-type
cell	O
line	O
(	O
TSU-PR1	O
)	O
derived	O
from	O
a	O
lymph	O
node	O
metastasis	O
.	O
While	O
the	O
overall	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
prostate	B-malignancy-type
tumors	I-malignancy-type
is	O
low	O
,	O
when	O
these	O
mutations	O
do	O
occur	O
they	O
may	O
have	O
a	O
role	O
in	O
the	O
progression	O
of	O
disease	O
or	O
the	O
development	O
of	O
the	O
unusual	O
ductal	O
variant	O
of	O
prostatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
2208148	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Surgery	O
1990	O
Dec	O
;	O
108	O
(	O
6	O
)	O
:	O
994	O
-	O
9	O
;	O
discussion	O
999	O
-	O
1000	O
N-ras	O
61	O
oncogene	O
mutations	O
in	O
Hurthle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Schark	O
C	O
,	O
Fulton	O
N	O
,	O
Jacoby	O
RF	O
,	O
Westbrook	O
CA	O
,	O
Straus	O
FH	O
2nd	O
,	O
Kaplan	O
EL	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Chicago	O
,	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
IL	O
60637	O
.	O
Mutations	O
of	O
ras	O
oncogenes	O
are	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
initiation	O
or	O
progression	O
of	O
human	O
tumors	O
.	O
In	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
the	O
incidence	O
of	O
ras	O
activation	O
by	O
specific	O
point	O
mutations	O
has	O
been	O
reported	O
to	O
range	O
from	O
33	O
%	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
up	O
to	O
60	O
%	O
in	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Because	O
of	O
our	O
long	O
-	O
standing	O
interest	O
in	O
Hurthle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
,	O
we	O
began	O
a	O
study	O
of	O
70	O
such	O
cases	O
to	O
determine	O
the	O
incidence	O
of	O
ras	O
mutations	O
and	O
their	O
clinical	O
correlates	O
.	O
Analysis	O
of	O
N-ras	O
sequences	O
at	O
codon	O
position	O
61	O
,	O
with	O
the	O
polymerase	O
chain	O
reaction	O
method	O
and	O
oligonucleotide	O
probe	O
hybridization	O
,	O
showed	O
point	O
mutations	O
of	O
the	O
normal	O
codon	O
CAA	O
*	O
in	O
eight	O
tumor	O
samples	O
.	O
One	O
was	O
a	O
mutation	O
from	O
CAA	O
to	O
AAA	O
,	O
one	O
from	O
CAA	O
to	O
CTA	O
,	O
*	O
and	O
six	O
from	O
CAA	O
to	O
CGA	O
.	O
These	O
mutations	O
would	O
result	O
in	O
amino	O
acid	O
substitutions	O
of	O
lysine	O
,	O
leucine	O
,	O
or	O
arginine	O
for	O
the	O
normal	O
glutamine	O
at	O
position	O
61	O
in	O
the	O
N-ras	O
protein	O
.	O
Identical	O
ras	O
mutations	O
in	O
two	O
tumors	O
and	O
some	O
of	O
their	O
surrounding	O
thyroid	O
tissue	O
may	O
indicate	O
that	O
activating	O
ras	O
point	O
mutations	O
are	O
an	O
early	O
event	O
in	O
carcinogenesis	O
.	O
The	O
incidence	O
of	O
mutations	O
was	O
1	O
of	O
24	O
(	O
4	O
%	O
)	O
of	O
the	O
histologically	O
benign	O
tumors	O
,	O
5	O
of	O
34	O
(	O
15	O
%	O
)	O
of	O
the	O
intermediate	O
tumors	O
(	O
with	O
vascular	O
or	O
capsular	O
permeation	O
)	O
,	O
and	O
2	O
of	O
12	O
(	O
17	O
%	O
)	O
in	O
the	O
malignant	O
group	O
.	O
Four	O
of	O
these	O
eight	O
patients	O
died	O
of	O
metastatic	O
thyroid	B-malignancy-type
disease	I-malignancy-type
and	O
four	O
are	O
alive	O
without	O
evidence	O
of	O
recurrence	O
.	O
PMID	O
:	O
2247846	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Endocrinol	O
1990	O
Oct;	O
4	O
(	O
10	O
)	O
:	O
147	O
4-9	O
Point	O
mutations	O
of	O
ras	O
oncogenes	O
are	O
an	O
early	O
event	O
in	O
thyroid	O
tumorigenesis	O
.	O
Namba	O
H,	O
Rubin	O
SA	O
,	O
Fagin	O
JA.	O
Department	O
of	O
Medicine	O
,	O
Cedar	O
s-Sinai	O
Medical	O
Center	O
,	O
UCLA	O
School	O
of	O
Medicine	O
90048	O
.	O
Identifying	O
the	O
nature	O
of	O
the	O
genetic	O
mutations	O
in	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
and	O
their	O
prevalence	O
in	O
the	O
various	O
tumor	O
phenotypes	O
is	O
critical	O
to	O
understanding	O
their	O
pathogenesis	O
.	O
Mutational	O
activation	O
of	O
ras	O
oncogenes	O
in	O
human	O
tumors	O
occurs	O
predominantly	O
through	O
point	O
mutations	O
in	O
two	O
functional	O
regions	O
of	O
the	O
molecules	O
,	O
codons	O
12	O
,	O
13	O
(	O
GTP	O
-	O
binding	O
domain	O
)	O
or	O
codon	O
61	O
(	O
GTPase	O
domain	O
)	O
.	O
We	O
examined	O
the	O
prevalence	O
of	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
oncogenes	O
K-ras	O
,	O
N-ras	O
,	O
and	O
H-ras	O
in	O
benign	O
and	O
malignant	O
human	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
by	O
hybridization	O
of	O
PCR	O
-	O
amplified	O
tumor	O
DNA	O
with	O
synthetic	O
oligodeoxynucleotide	O
probes	O
.	O
None	O
of	O
the	O
eight	O
normal	O
thyroid	O
tissues	O
harbored	O
point	O
mutations	O
.	O
Four	O
of	O
nineteen	O
nodules	O
from	O
multinodular	O
goiters	O
(	O
21	O
%	O
)	O
,	O
6	O
/	O
24	O
microfollicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
25	O
%	O
)	O
,	O
3	O
/	O
14	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
(	O
21	O
%	O
)	O
,	O
and	O
0	O
/	O
3	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
contained	O
ras	O
point	O
mutations	O
.	O
The	O
predominant	O
mutation	O
was	O
a	O
valine	O
for	O
glycine	O
substitution	O
in	O
codon	O
12	O
of	O
H-ras	O
.	O
None	O
of	O
the	O
multinodular	B-malignancy-type
goiter	I-malignancy-type
tumors	I-malignancy-type
known	O
to	O
be	O
polyclonal	O
(	O
and	O
thus	O
due	O
to	O
hyperplasia	B-malignancy-type
)	O
had	O
point	O
mutations	O
,	O
whereas	O
one	O
of	O
the	O
two	O
monoclonal	B-malignancy-type
adenomas	I-malignancy-type
arising	I-malignancy-type
in	I-malignancy-type
nodular	I-malignancy-type
glands	I-malignancy-type
contained	O
in	O
H-ras	O
codon	O
12	O
valine	O
substitution	O
,	O
which	O
was	O
confirmed	O
by	O
sequencing	O
the	O
tumor	O
DNA	O
.	O
These	O
data	O
show	O
that	O
ras	O
activation	O
is	O
about	O
equally	O
prevalent	O
in	O
benign	O
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
,	O
and	O
thus	O
may	O
be	O
an	O
early	O
event	O
in	O
the	O
tumorigenic	O
process	O
.	O
PMID	O
:	O
2283998	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Urol	O
1990	O
Jan;14	O
3	O
(	O
1	O
)	O
:	O
17	O
5-8	O
Infrequent	O
ras	O
oncogene	O
point	O
mutations	O
in	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Nanus	O
DM	O
,	O
Mentle	O
IR	O
,	O
Motzer	O
RJ	O
,	O
Bander	O
NH	O
,	O
Albino	O
AP	O
.	O
Department	O
of	O
Medicine	O
,	O
Memorial	O
Sloan	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
NY	O
10021	O
.	O
The	O
role	O
of	O
ras	O
oncogenes	O
in	O
the	O
pathogenesis	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
is	O
unclear	O
.	O
We	O
have	O
previously	O
shown	O
that	O
insertion	O
of	O
a	O
mutated	O
ras	O
oncogene	O
into	O
cultured	O
human	O
proximal	O
tubular	O
cells	O
,	O
the	O
normal	O
counterpart	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
initiates	O
a	O
series	O
of	O
transformation	O
events	O
which	O
results	O
in	O
cells	O
possessing	O
a	O
renal	B-malignancy-type
cancer	I-malignancy-type
phenotype	O
.	O
These	O
data	O
suggested	O
a	O
role	O
for	O
mutated	O
ras	O
genes	O
in	O
the	O
initiation	O
and	O
maintenance	O
of	O
this	O
disease	O
.	O
Therefore	O
,	O
to	O
assess	O
the	O
involvement	O
of	O
ras	O
genes	O
in	O
renal	O
carcinogenesis	O
,	O
51	O
primary	O
and	O
metastatic	O
renal	B-malignancy-type
carcinomas	I-malignancy-type
,	O
including	O
three	O
oncocytomas	B-malignancy-type
,	O
were	O
analyzed	O
for	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
Ha-ras	O
,	O
Ki-ras	O
and	O
N-ras	O
proto	O
-	O
oncogenes	O
using	O
polymerase	O
-	O
catalyzed	O
chain	O
reaction	O
methodology	O
.	O
A	O
mutated	O
Ha-ras	O
gene	O
was	O
found	O
in	O
one	O
renal	B-malignancy-type
cancer	I-malignancy-type
metastatic	O
to	O
lung	O
for	O
an	O
overall	O
incidence	O
of	O
2	O
%	O
.	O
These	O
data	O
indicate	O
that	O
ras	O
oncogenes	O
,	O
activated	O
by	O
point	O
mutations	O
,	O
do	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
initiation	O
,	O
maintenance	O
or	O
metastases	O
of	O
renal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
2403598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Jan;7	O
3	O
(	O
1	O
)	O
:	O
28	O
1-3	O
Analysis	O
of	O
N-RAS	O
exon-1	O
mutations	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Ba	O
r-Eli	O
M,	O
Ahuja	O
H,	O
Gonzale	O
z-Cadavid	O
N	O
,	O
Foti	O
A	O
,	O
Cline	O
MJ.	O
Division	O
of	O
Hematolog	O
y/Oncology	O
,	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
9002	O
4-1678	O
.	O
Mutations	O
in	O
codons	O
12	O
or	O
13	O
of	O
the	O
first	O
exon	O
of	O
the	O
N-RAS	O
gene	O
have	O
been	O
reported	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
in	O
frequencies	O
that	O
vary	O
between	O
9	O
%	O
and	O
40	O
%	O
depending	O
on	O
the	O
techniques	O
used	O
in	O
analysis	O
.	O
Gene	O
amplification	O
and	O
direct	O
sequencing	O
provides	O
the	O
only	O
unambiguous	O
method	O
of	O
detecting	O
those	O
mutations	O
that	O
induce	O
amino	O
acid	O
alterations	O
.	O
Using	O
this	O
technique	O
,	O
we	O
analyzed	O
21	O
MDS	B-malignancy-type
patients	O
for	O
mutations	O
in	O
exon-1	O
of	O
N-RAS	O
.	O
Codon	O
12	O
mutations	O
substituting	O
aspartic	O
acid	O
(	O
GAT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
were	O
found	O
in	O
four	O
cases	O
,	O
and	O
a	O
codon	O
13	O
mutation	O
substituting	O
alanine	O
(	O
GCT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
was	O
detected	O
in	O
one	O
patient	O
.	O
We	O
conclude	O
that	O
N-RAS	O
exon-1	O
mutations	O
in	O
one	O
patient	O
.	O
We	O
conclude	O
that	O
N-RAS	O
exon-1	O
mutations	O
producing	O
amino	O
acid	O
changes	O
occur	O
in	O
about	O
20	O
%	O
to	O
25	O
%	O
of	O
MDS	B-malignancy-type
cases	O
.	O
PMID	O
:	O
2642713	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1989	O
May;7	O
2	O
(	O
1	O
)	O
:	O
3	O
6-9	O
N-RAS	O
mutations	O
in	O
T-cell	B-malignancy-type
acute	I-malignancy-type
lymphocytic	I-malignancy-type
leukaemia	I-malignancy-type
:	O
analysis	O
by	O
direct	O
sequencing	O
detects	O
a	O
novel	O
mutation	O
.	O
Ba	O
r-Eli	O
M,	O
Ahuja	O
H,	O
Foti	O
A	O
,	O
Cline	O
MJ.	O
Division	O
of	O
Hematolog	O
y/Oncology	O
,	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
9002	O
4-1678	O
.	O
A	O
novel	O
mutation	O
of	O
the	O
N-RAS	O
gene	O
of	O
T-ALL	B-malignancy-type
blast	O
cells	O
was	O
detected	O
by	O
a	O
direct	O
sequencing	O
of	O
in	O
vitro	O
amplified	O
exon-1	O
of	O
the	O
N-RAS	O
gene	O
.	O
Threonine	O
(	O
ACA	O
)	O
was	O
substituted	O
for	O
alanine	O
(	O
GCA	O
)	O
at	O
codon	O
11	O
.	O
This	O
mutation	O
would	O
have	O
been	O
overlooked	O
by	O
conventional	O
probe	O
hybridization	O
techniques	O
.	O
A	O
search	O
for	O
other	O
mutations	O
in	O
N-RAS	O
exon-1	O
in	O
T-ALL	B-malignancy-type
revealed	O
a	O
codon	O
13	O
mutation	O
substituting	O
aspartic	O
acid	O
(	O
GAT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
in	O
one	O
of	O
18	O
patients	O
.	O
No	O
mutations	O
at	O
codon	O
12	O
were	O
detected	O
.	O
PMID	O
:	O
2660900	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Tumori	O
1989	O
Aug	O
31;75	O
(	O
4	O
)	O
:	O
33	O
7-40	O
N-ras	O
mutations	O
in	O
myeloid	B-malignancy-type
leukemias	I-malignancy-type
.	O
Saglio	O
G,	O
Serra	O
A	O
,	O
Novarino	O
A	O
,	O
Falda	O
M,	O
Gavosto	O
F.	O
Dipartimento	O
di	O
Scienze	O
Biomediche	O
e	O
Universita	O
di	O
Torino	O
,	O
Italy	O
.	O
The	O
presence	O
of	O
mutations	O
activating	O
the	O
N-ras	O
gene	O
was	O
investigated	O
by	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
in	O
twenty	O
patients	O
with	O
acute	B-malignancy-type
myeloblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
at	O
onset	O
and	O
in	O
four	O
patients	O
with	O
Ph1	B-malignancy-type
positive	I-malignancy-type
chronic	I-malignancy-type
myelogeneous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
either	O
in	O
chronic	O
phase	O
or	O
in	O
blast	O
crisis	O
.	O
Four	O
remission	O
samples	O
and	O
four	O
relapses	O
from	O
the	O
AML	B-malignancy-type
cases	O
were	O
also	O
studied	O
.	O
Mutations	O
were	O
found	O
in	O
five	O
out	O
of	O
twenty	O
(	O
25	O
%	O
)	O
untreated	O
AML	B-malignancy-type
cases	O
at	O
onset	O
.	O
No	O
mutations	O
were	O
detected	O
in	O
the	O
complete	O
remission	O
samples	O
,	O
two	O
of	O
them	O
with	O
N-ras	O
mutations	O
during	O
the	O
leukemic	O
phase	O
.	O
Two	O
out	O
of	O
the	O
four	O
leukemia	B-malignancy-type
relapses	O
were	O
positive	O
for	O
the	O
same	O
N-ras	O
mutation	O
shown	O
at	O
presentation	O
,	O
whereas	O
no	O
new	O
mutations	O
were	O
found	O
in	O
the	O
other	O
two	O
initially	O
negative	O
cases	O
.	O
An	O
N-ras	O
mutation	O
appeared	O
during	O
the	O
blast	O
crisis	O
of	O
one	O
of	O
the	O
four	O
CML	B-malignancy-type
,	O
which	O
were	O
all	O
negative	O
during	O
the	O
chronic	O
phase	O
.	O
In	O
conclusion	O
,	O
whereas	O
some	O
data	O
appear	O
to	O
be	O
consistent	O
with	O
a	O
role	O
of	O
the	O
N-ras	O
mutations	O
as	O
initiating	O
events	O
in	O
myeloid	B-malignancy-type
leukemias	I-malignancy-type
,	O
in	O
other	O
cases	O
N-ras	O
activation	O
seems	O
to	O
represent	O
a	O
factor	O
involved	O
in	O
progression	O
.	O
These	O
data	O
suggest	O
that	O
a	O
partial	O
overlapping	O
between	O
initiation	O
and	O
progression	O
factors	O
could	O
exist	O
in	O
naturally	O
occurring	O
tumors	O
.	O
PMID	O
:	O
2683276	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
Res	O
1989	O
;	O
5	O
(	O
2	O
)	O
:	O
121	O
-	O
7	O
ras	O
mutations	O
in	O
human	O
melanotic	B-malignancy-type
lesions	I-malignancy-type
:	O
K-ras	O
activation	O
is	O
a	O
frequent	O
and	O
early	O
event	O
in	O
melanoma	B-malignancy-type
development	O
.	O
Shukla	O
VK	O
,	O
Hughes	O
DC	O
,	O
Hughes	O
LE	O
,	O
McCormick	O
F	O
,	O
Padua	O
RA	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Heath	O
Park	O
,	O
Cardiff	O
,	O
United	O
Kingdom	O
.	O
We	O
have	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
an	O
amplification	O
procedure	O
,	O
and	O
oligonucleotide	O
hybridization	O
to	O
detect	O
ras	O
gene	O
point	O
mutations	O
in	O
DNA	O
from	O
melanoma	B-malignancy-type
tumor	O
samples	O
.	O
Genomic	O
DNA	O
was	O
examined	O
from	O
40	O
specimens	O
of	O
melanotic	B-malignancy-type
lesions	I-malignancy-type
,	O
including	O
benign	B-malignancy-type
nevi	I-malignancy-type
,	O
primary	O
melanomas	B-malignancy-type
,	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
,	O
and	O
systemic	B-malignancy-type
metastases	I-malignancy-type
.	O
Adjacent	O
normal	O
skin	O
or	O
peripheral	O
blood	O
was	O
analyzed	O
as	O
control	O
material	O
in	O
28	O
cases	O
.	O
ras	O
mutations	O
were	O
detected	O
overall	O
in	O
25	O
%	O
of	O
malignant	O
tumors	O
.	O
In	O
addition	O
,	O
mutations	O
of	O
all	O
three	O
ras	O
genes	O
were	O
detected	O
.	O
We	O
observed	O
ras	O
mutations	O
in	O
2	O
of	O
4	O
benign	B-malignancy-type
atypical	I-malignancy-type
nevi	I-malignancy-type
(	O
2	O
X	O
K	O
12	O
)	O
,	O
4	O
of	O
22	O
primary	O
melanomas	B-malignancy-type
(	O
3	O
X	O
K	O
12	O
,	O
1	O
X	O
H	O
12	O
,	O
1	O
X	O
N	O
61	O
)	O
,	O
and	O
4	O
of	O
14	O
secondary	O
(	O
5	O
X	O
K	O
12	O
,	O
1	O
X	O
N	O
61	O
)	O
tumors	O
.	O
One	O
with	O
a	O
primary	O
melanoma	B-malignancy-type
had	O
concurrent	O
K	O
12	O
and	O
H	O
12	O
,	O
and	O
two	O
patients	O
with	O
secondary	O
tumors	O
had	O
concurrent	O
K	O
12	O
/	O
N	O
61	O
and	O
K	O
12	O
Asp	O
/	O
K	O
12	O
Val	O
mutations	O
,	O
respectively	O
,	O
making	O
a	O
total	O
of	O
10	O
of	O
40	O
(	O
25	O
%	O
)	O
patients	O
with	O
ras	O
mutations	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
K-ras	O
mutations	O
in	O
human	O
melanoma	B-malignancy-type
.	O
The	O
presence	O
of	O
K-ras	O
mutations	O
in	O
nevi	O
,	O
putative	O
melanoma	B-malignancy-type
precursors	O
,	O
suggests	O
that	O
ras	O
activation	O
may	O
be	O
an	O
early	O
event	O
in	O
melanoma	B-malignancy-type
development	O
.	O
No	O
correlation	O
between	O
tumor	O
thickness	O
and	O
the	O
presence	O
of	O
a	O
ras	O
mutation	O
was	O
observed	O
.	O
PMID	O
:	O
2691957	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Res	O
1995	O
Oct;19	O
(	O
10	O
)	O
:	O
74	O
1-8	O
Possible	O
co-existence	O
of	O
RAS	O
activation	O
and	O
monosomy	O
7	O
in	O
the	O
leukaemic	O
transformation	O
of	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
.	O
Stephenson	O
J,	O
Lizhen	O
H,	O
Mufti	O
GJ.	O
Department	O
of	O
Haematological	O
Medicine	O
,	O
Kings	O
College	O
School	O
of	O
Medicine	O
and	O
Dentistry	O
,	O
London	O
,	O
UK.	O
The	O
frequency	O
of	O
RAS	O
activation	O
was	O
studied	O
in	O
48	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
or	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
,	O
in	O
order	O
to	O
address	O
the	O
question	O
of	O
whether	O
patients	O
possessing	O
monosomy	O
7	O
or	O
other	O
alterations	O
of	O
chromosome	O
7	O
have	O
a	O
higher	O
incidence	O
of	O
RAS	O
activation	O
than	O
those	O
lacking	O
chromosome	O
7	O
abnormalities	O
.	O
Samples	O
were	O
screened	O
for	O
oncogenic	O
point	O
mutation	O
by	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
hybridization	O
analysis	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N-RAS	O
and	O
codons	O
12	O
and	O
13	O
of	O
K-RAS	O
.	O
Two	O
additional	O
samples	O
were	O
considered	O
to	O
have	O
activated	O
RAS	O
due	O
to	O
additional	O
karyotypic	O
abnormalities	O
t	O
(	O
5	O
;	O
12	O
)	O
or	O
loss	O
of	O
both	O
copies	O
of	O
chromosome	O
17	O
and	O
hence	O
,	O
the	O
neurofibromatosis	O
(	O
NF1	O
)	O
loci	O
.	O
The	O
group	O
of	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukaemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
patients	O
had	O
activated	O
RAS	O
in	O
4	O
/	O
11	O
cases	O
and	O
inclusion	O
of	O
two	O
CMMLt	B-malignancy-type
patients	O
(	O
with	O
monosomy	O
7	O
)	O
brings	O
this	O
incidence	O
to	O
5	O
/	O
13	O
.	O
No	O
change	O
in	O
frequency	O
of	O
RAS	O
activation	O
was	O
seen	O
between	O
groups	O
containing	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
samples	I-malignancy-type
with	O
or	O
without	O
chromosome	O
7	O
abnormalities	O
(	O
1	O
/	O
5	O
and	O
2	O
/	O
12	O
,	O
respectively	O
)	O
.	O
However	O
,	O
assessment	O
of	O
MDS	O
samples	O
in	O
the	O
process	O
of	O
,	O
or	O
subsequent	O
to	O
,	O
leukaemic	O
progression	O
showed	O
a	O
difference	O
between	O
the	O
two	O
groups	O
.	O
The	O
frequency	O
of	O
RAS	O
activation	O
in	O
samples	O
with	O
monosomy	O
7	O
was	O
4	O
/	O
9	O
samples	O
while	O
none	O
of	O
the	O
seven	O
samples	O
without	O
chromosome	O
7	O
changes	O
showed	O
RAS	O
activation	O
.	O
The	O
co-existence	O
of	O
RAS	O
activation	O
and	O
monosomy	O
7	O
in	O
MDS	B-malignancy-type
indicates	O
that	O
these	O
lesions	O
can	O
co-operate	O
in	O
the	O
multistep	O
process	O
of	O
leukemogenesis	O
.	O
PMID	O
:	O
7500652	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1995	O
Sep;19	O
(	O
9	O
)	O
:	O
59	O
5-603	O
Acute	O
leukemic	O
transformation	O
of	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
--	O
immunophenotypic	O
,	O
genotypic	O
,	O
and	O
cytogenetic	O
studies	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH,	O
Chuang	O
SM	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
KH,	O
Lin	O
DT	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Republic	O
of	O
China	O
.	O
The	O
clinical	O
and	O
biological	O
characteristics	O
of	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
in	O
acute	O
leukemic	O
transformation	O
were	O
studied	O
in	O
23	O
patients	O
.	O
All	O
had	O
myeloid	O
transformation	O
according	O
to	O
FAB	O
criteria	O
,	O
but	O
coexpression	O
of	O
lymphoid	O
-	O
associated	O
antigens	O
was	O
detected	O
in	O
five	O
of	O
the	O
20	O
patients	O
who	O
underwent	O
an	O
immunophenotypic	O
study	O
.	O
Rearrangement	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
was	O
also	O
observed	O
in	O
one	O
of	O
the	O
five	O
patients	O
who	O
coexpressed	O
lymphoid	O
markers	O
and	O
that	O
of	O
the	O
T-cell	O
receptor	O
beta	O
chain	O
gene	O
in	O
another	O
one	O
.	O
None	O
had	O
pure	O
lymphoid	O
transformation	O
.	O
Clonal	O
chromosomal	O
abnormalities	O
were	O
noted	O
in	O
12	O
(	O
63	O
%	O
)	O
of	O
the	O
19	O
patients	O
who	O
underwent	O
cytogenetic	O
study	O
,	O
most	O
commonly	O
-	O
7	O
(	O
six	O
patients	O
or	O
32	O
%	O
)	O
.	O
In	O
the	O
18	O
patients	O
who	O
underwent	O
serial	O
analyses	O
both	O
at	O
MDS	B-malignancy-type
diagnosis	O
and	O
at	O
acute	O
transformation	O
,	O
seven	O
(	O
39	O
%	O
)	O
underwent	O
karyotypic	O
evolution	O
.	O
The	O
most	O
common	O
new	O
or	O
additional	O
aberrations	O
were	O
+	O
8	O
and	O
+	O
21	O
.	O
N-ras	O
gene	O
mutation	O
was	O
detected	O
in	O
two	O
of	O
the	O
nine	O
patients	O
at	O
acute	O
leukemic	O
transformation	O
.	O
The	O
median	O
interval	O
from	O
diagnosis	O
of	O
MDS	B-malignancy-type
to	O
onset	O
of	O
acute	O
transformation	O
was	O
10	O
months	O
(	O
1	O
-	O
36	O
months	O
)	O
.	O
Patients	O
with	O
a	O
normal	O
karyotype	O
at	O
diagnosis	O
had	O
a	O
significantly	O
longer	O
chronic	O
phase	O
duration	O
than	O
those	O
with	O
chromosomal	O
abnormalities	O
(	O
median	O
of	O
20	O
months	O
vs.	O
5	O
months	O
)	O
.	O
However	O
,	O
all	O
had	O
a	O
short	O
survival	O
time	O
after	O
diagnosis	O
of	O
acute	B-malignancy-type
leukemia	I-malignancy-type
,	O
whether	O
chromosomal	O
anomalies	O
were	O
present	O
or	O
not	O
.	O
PMID	O
:	O
7564469	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Recent	O
Results	O
Cancer	O
Res	O
1995	O
;	O
139	O
:	O
57	O
-	O
67	O
Analysis	O
of	O
N-ras	O
mutations	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
:	O
tumor	O
heterogeneity	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
analysis	O
.	O
van	O
Elsas	O
A	O
,	O
Zerp	O
S	O
,	O
van	O
der	O
Flier	O
S	O
,	O
Kruse-Wolters	O
M	O
,	O
Vacca	O
A	O
,	O
Ruiter	O
DJ	O
,	O
Schrier	O
P	O
.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
University	O
Hospital	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Determination	O
of	O
the	O
activation	O
state	O
of	O
oncogenes	O
as	O
well	O
as	O
tumor	O
suppressor	O
genes	O
is	O
a	O
main	O
subject	O
of	O
interest	O
in	O
the	O
analysis	O
of	O
the	O
mechanism	O
of	O
tumor	O
initiation	O
.	O
In	O
human	O
melanoma	B-malignancy-type
,	O
the	O
c-myc	O
and	O
N-ras	O
oncogenes	O
have	O
been	O
found	O
to	O
be	O
activated	O
in	O
approximately	O
50	O
%	O
and	O
15	O
%	O
of	O
the	O
analyzed	O
material	O
,	O
respectively	O
.	O
These	O
studies	O
have	O
mostly	O
been	O
done	O
on	O
fresh	O
tumor	O
material	O
or	O
cell	O
lines	O
.	O
Only	O
in	O
a	O
few	O
cases	O
has	O
an	O
attempt	O
been	O
made	O
to	O
look	O
at	O
tumor	O
heterogeneity	O
or	O
clonality	O
with	O
respect	O
to	O
the	O
activation	O
of	O
oncogenes	O
.	O
We	O
have	O
adjusted	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
technique	O
to	O
screen	O
paraffin	O
-	O
embedded	O
melanoma	B-malignancy-type
material	O
for	O
the	O
presence	O
of	O
N-ras	O
mutations	O
and	O
found	O
genetic	O
defects	O
at	O
particular	O
progression	O
stages	O
.	O
In	O
one	O
melanoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
skin	I-malignancy-type
,	O
we	O
were	O
able	O
to	O
sublocalize	O
an	O
N-ras	O
mutation	O
in	O
the	O
intraepidermal	B-malignancy-type
tumor	I-malignancy-type
part	O
,	O
that	O
was	O
absent	O
in	O
the	O
part	O
deeply	O
invading	O
the	O
dermal	O
layer	O
.	O
We	O
conclude	O
that	O
a	O
thorough	O
investigation	O
of	O
N-ras	O
activation	O
in	O
human	O
melanoma	B-malignancy-type
should	O
include	O
analysis	O
of	O
histologically	O
different	O
parts	O
of	O
the	O
tumor	O
.	O
PMID	O
:	O
7597312	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1995	O
Apr;80	O
(	O
4	O
)	O
:	O
134	O
7-51	O
Genetic	O
alterations	O
in	O
thyroid	B-malignancy-type
hyperfunctioning	I-malignancy-type
adenomas	I-malignancy-type
.	O
Russo	O
D	O
,	O
Arturi	O
F	O
,	O
Wicker	O
R	O
,	O
Chazenbalk	O
GD	O
,	O
Schlumberger	O
M,	O
DuVillard	O
JA	O
,	O
Caillou	O
B	O
,	O
Monier	O
R	O
,	O
Rapoport	O
B	O
,	O
Filetti	O
S	O
,	O
et	O
al	O
.	O
Dipartimento	O
di	O
Medicina	O
Sperimentale	O
e	O
Clinica	O
,	O
Facolta	O
di	O
Farmacia	O
,	O
Universita	O
di	O
Reggio	O
Calabria	O
,	O
Catanzaro	O
,	O
Italy	O
.	O
Thirty-seven	O
thyroid	B-malignancy-type
autonomously	I-malignancy-type
hyperfunctioning	I-malignancy-type
adenomas	I-malignancy-type
were	O
screened	O
for	O
mutations	O
in	O
the	O
TSH	O
receptor	O
(	O
TSHR	O
)	O
,	O
G	O
alpha	O
s	O
(	O
gsp	O
)	O
,	O
and	O
ras	O
genes	O
.	O
Polymerase	O
chain	O
reaction	O
-	O
amplified	O
fragments	O
of	O
the	O
TSHR	O
C	O
-	O
terminal	O
part	O
(	O
exon	O
10	O
)	O
,	O
the	O
G	O
alpha	O
s	O
(	O
exons	O
8	O
and	O
9	O
)	O
,	O
and	O
the	O
three	O
ras	O
genes	O
were	O
obtained	O
from	O
the	O
genomic	O
DNA	O
extracted	O
from	O
37	O
tumors	O
and	O
their	O
adjacent	O
normal	O
tissues	O
and	O
were	O
studied	O
by	O
direct	O
nucleotide	O
sequencing	O
and	O
hybridization	O
with	O
synthetic	O
probes	O
.	O
A	O
point	O
mutation	O
in	O
the	O
third	O
intracellular	O
loop	O
(	O
codon	O
623	O
)	O
of	O
the	O
TSHR	O
was	O
found	O
in	O
3	O
of	O
37	O
adenomas	B-malignancy-type
studied	O
.	O
This	O
mutation	O
codes	O
for	O
a	O
change	O
(	O
Ala	O
to	O
Ser	O
)	O
in	O
the	O
TSHR	O
structure	O
and	O
is	O
somatic	O
and	O
heterozygotic	O
.	O
Constitutive	O
activation	O
of	O
the	O
TSHR	O
was	O
demonstrated	O
by	O
an	O
increase	O
in	O
basal	O
cAMP	O
levels	O
after	O
transfection	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
with	O
a	O
mutated	O
Ser	O
623	O
-	O
TSHR	O
complementary	O
DNA	O
.	O
Nine	O
gsp	O
[00ae]	O
MDRV	O
[00af]	O
-	O
and	O
one	O
ras	O
-	O
activating	O
mutations	O
were	O
also	O
detected	O
.	O
No	O
simultaneous	O
alteration	O
of	O
the	O
studied	O
genes	O
was	O
present	O
.	O
Thus	O
,	O
in	O
hyperfunctioning	B-malignancy-type
thyroid	I-malignancy-type
adenomas	I-malignancy-type
,	O
our	O
data	O
suggest	O
that	O
a	O
mutational	O
activation	O
of	O
the	O
TSHR	O
and	O
gsp	O
genes	O
may	O
play	O
a	O
tumorigenic	O
role	O
through	O
constitutive	O
activation	O
of	O
the	O
cAMP	O
pathway	O
.	O
PMID	O
:	O
7714109	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

World	O
J	O
Surg	O
1994	O
Jul	O
-	O
Aug	O
;	O
18	O
(	O
4	O
)	O
:	O
455	O
-	O
60	O
;	O
discussion	O
460	O
-	O
1	O
Point	O
mutations	O
of	O
ras	O
genes	O
in	O
human	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
tumors	I-malignancy-type
:	O
absence	O
in	O
adrenocortical	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
Yashiro	O
T	O
,	O
Hara	O
H	O
,	O
Fulton	O
NC	O
,	O
Obara	O
T	O
,	O
Kaplan	O
EL	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Chicago	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
Illinois	O
60637	O
,	O
USA	O
.	O
Point	O
mutations	O
of	O
ras	O
genes	O
(	O
K-	O
,	O
H-	O
,	O
and	O
N-ras	O
)	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
and	O
of	O
the	O
Gi2	O
alpha	O
gene	O
at	O
codons	O
179	O
and	O
205	O
,	O
were	O
studied	O
in	O
56	O
primary	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
tumors	I-malignancy-type
and	O
6	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
hyperplasias	I-malignancy-type
.	O
Of	O
56	O
tumors	O
,	O
24	O
were	O
carcinomas	B-malignancy-type
and	O
32	O
were	O
benign	O
.	O
The	O
24	O
carcinomas	B-malignancy-type
and	O
20	O
of	O
the	O
benign	O
tumors	O
were	O
from	O
American	O
patients	O
;	O
the	O
12	O
remaining	O
adenomas	B-malignancy-type
were	O
from	O
Japanese	O
patients	O
.	O
Of	O
the	O
benign	O
tumors	O
12	O
were	O
cortisol	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
adenomas	I-malignancy-type
,	O
15	O
were	O
aldosterone	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
adenomas	I-malignancy-type
,	O
3	O
were	O
nonfunctioning	B-malignancy-type
adenomas	I-malignancy-type
,	O
and	O
2	O
were	O
adenomas	B-malignancy-type
that	I-malignancy-type
produced	I-malignancy-type
a	I-malignancy-type
virilizing	I-malignancy-type
syndrome	I-malignancy-type
.	O
Tumor	O
DNA	O
obtained	O
from	O
archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
or	O
fresh	O
frozen	O
tissue	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
;	O
and	O
point	O
mutations	O
were	O
detected	O
by	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Activating	O
ras	O
mutations	O
were	O
found	O
in	O
7	O
of	O
56	O
(	O
12.5	O
%	O
)	O
of	O
all	O
tumors	O
:	O
3	O
of	O
24	O
(	O
12.5	O
%	O
)	O
carcinomas	O
and	O
4	O
of	O
32	O
(	O
12.5	O
%	O
)	O
adenomas	B-malignancy-type
.	O
Of	O
adenomas	B-malignancy-type
from	O
an	O
American	O
population	O
,	O
4	O
of	O
20	O
(	O
20	O
%	O
)	O
exhibited	O
positive	O
ras	O
mutations	O
,	O
whereas	O
none	O
was	O
present	O
in	O
the	O
Japanese	O
tumors	O
.	O
All	O
mutations	O
detected	O
were	O
adenine	O
to	O
guanine	O
transitions	O
at	O
the	O
second	O
position	O
of	O
N-ras	O
codon	O
61	O
,	O
resulting	O
in	O
a	O
conversion	O
from	O
glutamine	O
to	O
arginine	O
.	O
No	O
mutations	O
were	O
found	O
in	O
K-ras	O
or	O
H-ras	O
genes	O
.	O
Furthermore	O
,	O
no	O
mutations	O
of	O
the	O
Gi2	O
alpha	O
gene	O
were	O
identified	O
.	O
These	O
findings	O
demonstrate	O
that	O
N-ras	O
mutations	O
at	O
codon	O
61	O
may	O
contribute	O
to	O
the	O
genesis	O
of	O
both	O
benign	O
and	O
malignant	O
human	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
tumors	I-malignancy-type
.	O
Finally	O
,	O
no	O
mutations	O
of	O
the	O
ras	O
or	O
Gi2	O
alpha	O
genes	O
were	O
identified	O
in	O
hyperplastic	B-malignancy-type
adrenocortical	I-malignancy-type
tissues	I-malignancy-type
.	O
PMID	O
:	O
7725728	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Haematol	O
1994	O
Nov	O
;	O
88	O
(	O
3	O
)	O
:	O
575	O
-	O
81	O
Karyotypic	O
and	O
ras	O
gene	O
mutational	O
analysis	O
in	O
idiopathic	B-malignancy-type
myelofibrosis	I-malignancy-type
.	O
Reilly	O
JT	O
,	O
Wilson	O
G	O
,	O
Barnett	O
D	O
,	O
Watmore	O
A	O
,	O
Potter	O
A	O
.	O
Department	O
of	O
Haematology	O
,	O
Northern	O
General	O
Hospital	O
,	O
Sheffield	O
.	O
Karyotypic	O
analysis	O
was	O
performed	O
in	O
a	O
total	O
of	O
69	O
patients	O
with	O
well	O
-	O
characterized	O
idiopathic	B-malignancy-type
myelofibrosis	I-malignancy-type
.	O
Karyotypic	O
abnormalities	O
were	O
detected	O
in	O
46	O
%	O
of	O
cases	O
examined	O
during	O
the	O
chronic	O
phase	O
(	O
29	O
/	O
63	O
)	O
;	O
with	O
three	O
abnormalities	O
,	O
del	O
(	O
13q	O
)	O
,	O
del	O
(	O
20q	O
)	O
and	O
partial	O
trisomy	O
1q	O
,	O
accounting	O
for	O
75	O
%	O
of	O
all	O
abnormalities	O
at	O
diagnosis	O
.	O
The	O
absence	O
of	O
del	O
(	O
5q	O
)	O
,	O
trisomy	O
8	O
and	O
21	O
,	O
as	O
well	O
as	O
the	O
rarity	O
of	O
monosomy	O
7	O
,	O
contrasts	O
with	O
pooled	O
published	O
data	O
and	O
may	O
reflect	O
our	O
exclusion	O
of	O
closely	O
related	O
disorders	O
,	O
in	O
particular	O
MDS	B-malignancy-type
with	I-malignancy-type
fibrosis	I-malignancy-type
.	O
Chromosomal	O
aberrations	O
increased	O
to	O
approximately	O
90	O
%	O
(	O
8	O
/	O
9	O
)	O
in	O
patients	O
analysed	O
during	O
acute	O
transformation	O
.	O
Mutational	O
activation	O
of	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N	O
-	O
,	O
Ha	O
-	O
and	O
Ki-ras	O
genes	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
hybridization	O
with	O
synthetic	O
non	O
-	O
radioactive	O
digoxigenin	O
-	O
labelled	O
probes	O
.	O
Three	O
mutations	O
were	O
detected	O
in	O
samples	O
of	O
peripheral	O
blood	O
DNA	O
taken	O
from	O
50	O
patients	O
during	O
the	O
chronic	O
phase	O
of	O
their	O
disease	O
:	O
one	O
N	O
12	O
Asp	O
(	O
GGT	O
-->	O
GAT	O
)	O
and	O
two	O
N	O
12	O
Ser	O
(	O
GGT	O
-->	O
AGT	O
)	O
mutations	O
.	O
The	O
results	O
from	O
this	O
study	O
indicate	O
that	O
karyotypic	O
abnormalities	O
are	O
present	O
in	O
at	O
least	O
29	O
%	O
of	O
cases	O
at	O
diagnosis	O
and	O
that	O
del	O
(	O
13q	O
)	O
,	O
del	O
(	O
20q	O
)	O
and	O
partial	O
trisomy	O
1q	O
are	O
the	O
most	O
frequent	O
findings	O
.	O
Ras	O
mutations	O
were	O
relatively	O
infrequent	O
(	O
6	O
%	O
)	O
and	O
appeared	O
restricted	O
to	O
the	O
N-ras	O
gene	O
.	O
Karyotypic	O
analysis	O
at	O
diagnosis	O
was	O
found	O
to	O
be	O
of	O
prognostic	O
significance	O
.	O
PMID	O
:	O
7819070	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Acta	O
Haematol	O
1994	O
;	O
92	O
(	O
3	O
)	O
:	O
123	O
-	O
5	O
High	O
incidence	O
of	O
conservative	O
RAS	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Aurer	O
I	O
,	O
Labar	O
B	O
,	O
Nemet	O
D	O
,	O
Ajdukovic	O
R	O
,	O
Bogdanic	O
V	O
,	O
Gale	O
RP	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Medical	O
School	O
and	O
University	O
Hospital	O
Rebro	O
,	O
Zagreb	O
,	O
Croatia	O
.	O
RAS	O
mutations	O
are	O
found	O
in	O
about	O
25	O
%	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
cases	O
.	O
The	O
importance	O
of	O
these	O
changes	O
is	O
unknown	O
.	O
If	O
RAS	O
mutations	O
confer	O
growth	O
advantage	O
to	O
leukemia	B-malignancy-type
subclones	O
in	O
which	O
they	O
emerge	O
,	O
substantially	O
more	O
nonconservative	O
than	O
conservative	O
mutations	O
should	O
be	O
found	O
.	O
The	O
incidence	O
of	O
conservative	O
mutations	O
was	O
not	O
reported	O
previously	O
.	O
We	O
sequenced	O
N-RAS	O
and	O
K-RAS	O
codons	O
12	O
and	O
13	O
and	O
N-RAS	O
codon	O
61	O
in	O
20	O
subjects	O
with	O
newly	O
diagnosed	O
AML	B-malignancy-type
.	O
Four	O
nonconservative	O
N-RAS	O
mutations	O
and	O
4	O
conservative	O
K-RAS	O
mutations	O
were	O
found	O
.	O
There	O
were	O
no	O
differences	O
between	O
subjects	O
with	O
AML	B-malignancy-type
and	O
nonconservative	O
RAS	O
mutations	O
and	O
those	O
with	O
conservative	O
or	O
without	O
RAS	O
mutations	O
.	O
Additional	O
studies	O
are	O
needed	O
to	O
examine	O
the	O
incidence	O
of	O
conservative	O
RAS	O
mutations	O
in	O
subjects	O
with	O
AML	B-malignancy-type
.	O
PMID	O
:	O
7871950	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1995	O
Mar	O
;	O
9	O
(	O
3	O
)	O
:	O
466	O
-	O
70	O
Comment	O
in	O
:	O
Leukemia	O
.	O
1995	O
Oct	O
;	O
9	O
(	O
10	O
)	O
:	O
1790	O
-	O
1	O
.	O
RAS	O
and	O
FMS	O
mutations	O
following	O
cytotoxic	O
therapy	O
for	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukaemia	I-malignancy-type
.	O
Taylor	O
C	O
,	O
McGlynn	O
H	O
,	O
Carter	O
G	O
,	O
Baker	O
AH	O
,	O
Warren	O
N	O
,	O
Ridge	O
SA	O
,	O
Owen	O
G	O
,	O
Thompson	O
E	O
,	O
Thompson	O
PW	O
,	O
Jacobs	O
A	O
,	O
et	O
al	O
.	O
Haematology	O
Department	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Health	O
Park	O
,	O
Cardiff	O
,	O
UK	O
.	O
Patients	O
who	O
have	O
received	O
cytotoxic	O
therapy	O
for	O
primary	O
neoplastic	B-malignancy-type
disease	I-malignancy-type
are	O
at	O
an	O
increased	O
risk	O
of	O
developing	O
secondary	O
(	O
therapy	O
-	O
related	O
)	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
or	O
myelodysplasia	B-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
RAS	O
and	O
FMS	O
mutations	O
have	O
been	O
observed	O
in	O
patients	O
with	O
AML	B-malignancy-type
and	O
MDS	B-malignancy-type
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
mutational	O
status	O
within	O
these	O
genes	O
may	O
be	O
predictive	O
of	O
early	O
secondary	O
leukaemic	B-malignancy-type
disease	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
have	O
screened	O
50	O
haematologically	O
normal	O
patients	O
in	O
complete	O
remission	O
from	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukaemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
for	O
activating	O
point	O
mutations	O
in	O
the	O
RAS	O
and	O
FMS	O
proto	O
-	O
oncogenes	O
.	O
Such	O
patients	O
may	O
be	O
considered	O
at	O
risk	O
of	O
therapy	O
-	O
related	O
disease	O
.	O
Codons	O
12	O
,	O
13	O
and	O
61	O
were	O
screened	O
in	O
RAS	O
and	O
codon	O
969	O
in	O
FMS	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
oligonucleotide	O
hybridization	O
(	O
ONH	O
)	O
.	O
Three	O
of	O
the	O
50	O
patients	O
(	O
6	O
%	O
)	O
were	O
found	O
to	O
harbour	O
N12	O
RAS	O
mutations	O
.	O
One	O
of	O
these	O
three	O
patients	O
(	O
2	O
%	O
)	O
had	O
both	O
a	O
N12	O
RAS	O
and	O
FMS	O
969	O
mutation	O
.	O
Upon	O
sequencing	O
the	O
RAS	O
mutations	O
,	O
substitutions	O
of	O
serine	O
,	O
cysteine	O
and	O
aspartic	O
acid	O
for	O
glycine	O
were	O
identified	O
.	O
The	O
FMS	O
969	O
mutation	O
was	O
also	O
confirmed	O
,	O
by	O
sequencing	O
,	O
as	O
a	O
histidine	O
substitution	O
.	O
RAS	O
mutations	O
were	O
not	O
detected	O
in	O
presentation	O
samples	O
indicating	O
that	O
these	O
lesions	O
have	O
been	O
somatically	O
acquired	O
presumably	O
subsequent	O
to	O
cytotoxic	O
therapy	O
for	O
the	O
primary	O
disease	O
.	O
Continued	O
follow-up	O
of	O
these	O
patients	O
may	O
indicate	O
a	O
role	O
for	O
these	O
mutations	O
in	O
the	O
development	O
of	O
secondary	O
malignancies	O
.	O
PMID	O
:	O
7885045	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Hokkaido	O
Igaku	O
Zasshi	O
1994	O
May;6	O
9	O
(	O
3	O
)	O
:	O
54	O
3-54	O
[	O
Molecular	O
study	O
on	O
minute	O
alterations	O
of	O
the	O
p53	O
and	O
the	O
N-ras	O
genes	O
in	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
]	O
[Article	O
in	O
Japanese	O
]	O
Kurosawa	O
M.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Hokkaido	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
Minute	O
alterations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
N-ras	O
oncogene	O
were	O
investigated	O
in	O
106	O
samples	O
for	O
the	O
p53	O
gene	O
and	O
23	O
samples	O
for	O
the	O
N-ras	O
gene	O
obtained	O
from	O
patients	O
with	O
various	O
types	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
and	O
direct	O
nucleotide	O
sequencing	O
.	O
Mobility	O
shifts	O
suggesting	O
sequence	O
alteration	O
were	O
observed	O
in	O
9	O
cases	O
(	O
8.5	O
%	O
)	O
in	O
exons	O
5	O
through	O
8	O
containing	O
evolutionarily	O
highly	O
conserved	O
regions	O
of	O
the	O
p53	O
gene	O
by	O
PCR-SSCP	O
;	O
missense	O
point	O
mutations	O
in	O
3	O
cases	O
(	O
1	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
1	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
in	O
the	O
accelerated	O
phase	O
,	O
and	O
1	O
CML	B-malignancy-type
in	O
the	O
blast	O
crisis	O
)	O
,	O
silent	O
point	O
mutation	O
in	O
1	O
case	O
(	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
)	O
,	O
and	O
frame	O
shift	O
mutations	O
due	O
to	O
insertions	O
and	O
deletions	O
causing	O
stop	O
codons	O
in	O
3	O
cases	O
(	O
1	O
AML	B-malignancy-type
,	O
1	O
CML	B-malignancy-type
in	O
the	O
chronic	O
phase	O
and	O
1	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
)	O
.	O
p53	O
gene	O
alterations	O
did	O
not	O
always	O
cluster	O
within	O
evolutionarily	O
highly	O
conserved	O
regions	O
,	O
and	O
there	O
were	O
various	O
base	O
change	O
forms	O
in	O
cases	O
with	O
p53	O
point	O
mutations	O
.	O
p53	O
mutations	O
were	O
detected	O
in	O
2	O
cases	O
out	O
of	O
4	O
cases	O
with	O
17	O
monosomy	O
.	O
There	O
was	O
no	O
case	O
with	O
p53	O
gene	O
alteration	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
cases	O
.	O
Mobility	O
shifts	O
suggesting	O
sequence	O
alteration	O
were	O
observed	O
in	O
5	O
cases	O
(	O
22	O
%	O
)	O
in	O
exon	O
1	O
and	O
2	O
of	O
the	O
N-ras	O
gene	O
by	O
PCR-SSCP	O
.	O
3	O
cases	O
(	O
1	O
MDS	B-malignancy-type
,	O
1	O
MDS	B-malignancy-type
overt	B-malignancy-type
AML	I-malignancy-type
and	O
1	O
ALL	B-malignancy-type
)	O
were	O
detected	O
to	O
contain	O
missense	O
point	O
mutations	O
.	O
However	O
,	O
simultaneous	O
mutations	O
in	O
both	O
the	O
genes	O
were	O
detected	O
in	O
only	O
2	O
cases	O
out	O
of	O
23	O
,	O
thereby	O
indicating	O
infrequent	O
occurrence	O
of	O
concomitant	O
mutation	O
of	O
both	O
the	O
genes	O
in	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
Alterations	O
of	O
the	O
p53	O
and	O
the	O
N-ras	O
genes	O
are	O
involved	O
in	O
the	O
tumorigenesis	O
,	O
progression	O
and	O
prognosis	O
of	O
at	O
least	O
some	O
cases	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
,	O
in	O
spite	O
that	O
they	O
are	O
relatively	O
infrequent	O
.	O
PMID	O
:	O
7927179	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surg	O
Oncol	O
1994	O
Jun;	O
3	O
(	O
3	O
)	O
:	O
15	O
3-9	O
Analysis	O
of	O
multiple	O
molecular	O
changes	O
in	O
human	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
.	O
Arany	O
I	O
,	O
Rady	O
P,	O
Evers	O
BM	O
,	O
Tyring	O
SK	O
,	O
Townsend	O
CM	O
Jr.	O
Department	O
of	O
Microbiology	O
,	O
University	O
of	O
Texas	O
Medical	O
Branch	O
,	O
Galveston	O
77555	O
.	O
To	O
define	O
the	O
molecular	O
changes	O
occurring	O
in	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
,	O
we	O
have	O
analysed	O
three	O
human	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
established	O
in	O
our	O
laboratory	O
:	O
BON	B-malignancy-type
,	O
a	O
functioning	O
carcinoid	B-malignancy-type
tumour	I-malignancy-type
from	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
;	O
SIM	B-malignancy-type
,	O
a	O
nonfunctioning	B-malignancy-type
carcinoid	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ileum	I-malignancy-type
;	O
and	O
STAN	B-malignancy-type
,	O
a	O
pheochromocytoma	B-malignancy-type
.	O
A	O
homozygous	O
point	O
mutation	O
of	O
the	O
N-ras	O
gene	O
was	O
identified	O
at	O
codon	O
61	O
in	O
BON	B-malignancy-type
cells	O
in	O
conjunction	O
with	O
overexpression	O
of	O
N-ras	O
mRNA	O
and	O
protein	O
.	O
BON	B-malignancy-type
cells	O
also	O
exhibited	O
increased	O
expression	O
of	O
c-myc	O
and	O
cdc2	O
kinase	O
mRNA	O
and	O
protein	O
;	O
TGF-beta	O
1	O
,	O
p53	O
and	O
retinoblastoma	O
(	O
RB	O
)	O
mRNA	O
and	O
protein	O
levels	O
were	O
decreased	O
.	O
In	O
addition	O
,	O
increased	O
expression	O
of	O
the	O
mdm2	O
oncogene	O
and	O
both	O
the	O
truncated	O
and	O
the	O
wild-type	O
RB	O
protein	O
were	O
noted	O
in	O
BON	B-malignancy-type
.	O
SIM	B-malignancy-type
cells	O
exhibited	O
moderately	O
increased	O
N-ras	O
and	O
c-myc	O
mRNA	O
levels	O
along	O
with	O
decreased	O
levels	O
of	O
RB	O
mRNA	O
and	O
protein	O
.	O
Similar	O
to	O
BON	B-malignancy-type
and	O
SIM	B-malignancy-type
,	O
analysis	O
of	O
STAN	B-malignancy-type
showed	O
increased	O
N-ras	O
and	O
c-myc	O
levels	O
.	O
Our	O
data	O
show	O
multiple	O
molecular	O
changes	O
in	O
the	O
three	O
human	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
with	O
the	O
BON	B-malignancy-type
cell	O
line	O
exhibiting	O
the	O
most	O
dramatic	O
changes	O
.	O
Furthermore	O
,	O
our	O
data	O
suggest	O
the	O
existence	O
of	O
different	O
molecular	O
pathways	O
in	O
the	O
pathogenesis	O
of	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
.	O
These	O
cell	O
lines	O
will	O
provide	O
unique	O
in	O
vitro	O
models	O
to	O
further	O
analyse	O
the	O
significance	O
of	O
these	O
molecular	O
alterations	O
.	O
PMID	O
:	O
7952399	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Melanoma	O
Res	O
1994	O
Feb;	O
4	O
(	O
1	O
)	O
:	O
1	O
1-9	O
N-RAS	O
mutations	O
and	O
susceptibility	O
to	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
cells	O
in	O
human	O
melanoma	B-malignancy-type
.	O
Lupetti	O
R	O
,	O
Sensi	O
M,	O
Mortarini	O
R	O
,	O
Anichini	O
A	O
,	O
Clemente	O
C,	O
Parmiani	O
G.	O
Division	O
of	O
Experimental	O
Oncology	O
D	O
,	O
Istituto	O
Nazionale	O
Tumori	O
,	O
Milan	O
,	O
Italy	O
.	O
RAS	O
oncogene	O
expression	O
has	O
been	O
reported	O
to	O
affect	O
several	O
biological	O
features	O
of	O
rodent	O
tumours	O
cells	O
,	O
including	O
lysability	O
by	O
activated	O
natural	O
killer	O
cells	O
.	O
In	O
order	O
to	O
examine	O
whether	O
expression	O
of	O
mutated	O
RAS	O
genes	O
in	O
human	O
melanoma	B-malignancy-type
cells	O
alters	O
their	O
susceptibility	O
to	O
lysis	O
by	O
LAK	O
cells	O
,	O
seven	O
melanoma	B-malignancy-type
lines	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
Ki	O
-	O
and	O
N-RAS	O
genes	O
bearing	O
all	O
possible	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
A	O
panel	O
of	O
21	O
clones	O
deriving	O
from	O
the	O
metastatic	B-malignancy-type
lesion	I-malignancy-type
Me665	I-malignancy-type
/	I-malignancy-type
2	I-malignancy-type
,	O
which	O
had	O
a	O
Gln	O
-->	O
Arg	O
substitution	O
at	O
codon	O
61	O
of	O
N-RAS	O
(	O
N-RAS	O
/	O
61	O
+	O
)	O
,	O
were	O
also	O
examined	O
.	O
Melanoma	B-malignancy-type
cells	O
and	O
clones	O
were	O
used	O
as	O
targets	O
of	O
allogeneic	O
LAK	O
in	O
a	O
4	O
-	O
h	O
51Cr	O
-	O
release	O
assay	O
.	O
LAK	O
showed	O
a	O
higher	O
lysis	O
on	O
melanoma	B-malignancy-type
lines	O
and	O
clones	O
harbouring	O
a	O
mutated	O
RAS	O
compared	O
with	O
counterparts	O
bearing	O
no	O
RAS	O
mutations	O
.	O
In	O
addition	O
,	O
LAK	O
-	O
mediated	O
lysis	O
drastically	O
decreased	O
on	O
Me665	O
/	O
2	O
sublines	O
progressively	O
selected	O
by	O
exposure	O
to	O
LAK	O
.	O
This	O
loss	O
was	O
paralleled	O
by	O
a	O
reduction	O
or	O
even	O
disappearance	O
of	O
N-RAS	O
/	O
61	O
+	O
mRNA	O
signal	O
in	O
Me665	O
/	O
2	O
sublines	O
.	O
To	O
evaluate	O
whether	O
N-RAS	O
could	O
directly	O
modulate	O
LAK	O
susceptibility	O
to	O
lysis	O
,	O
N-RAS	O
/	O
61	O
+	O
gene	O
was	O
transfected	O
in	O
two	O
N-RAS	O
wild	O
type	O
(	O
N-RAS	O
/	O
61	O
-	O
)	O
665	O
/	O
2	O
melanoma	B-malignancy-type
clones	O
by	O
a	O
cosmid	O
vector	O
.	O
In	O
contrast	O
to	O
the	O
high	O
lysability	O
of	O
melanoma	B-malignancy-type
cells	O
constitutively	O
expressing	O
the	O
mutationally	O
active	O
N-RAS	O
oncogene	O
,	O
N-RAS	O
/	O
61	O
+	O
transfectants	O
did	O
not	O
show	O
a	O
consistent	O
high	O
lysability	O
by	O
LAK	O
,	O
compared	O
with	O
some	O
control	O
pSV2neo	O
transfectants	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
8032213	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1993	O
Jan	O
1	O
;	O
53	O
(	O
1	O
)	O
:	O
133	O
-	O
9	O
Mutation	O
of	O
H-ras	O
is	O
infrequent	O
in	O
bladder	B-malignancy-type
cancer	I-malignancy-type
:	O
confirmation	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
designed	O
restriction	O
fragment	O
length	O
polymorphisms	O
,	O
and	O
direct	O
sequencing	O
.	O
Knowles	O
MA	O
,	O
Williamson	O
M	O
.	O
Epithelial	O
Carcinogenesis	O
Laboratory	O
,	O
Marie	O
Curie	O
Research	O
Institute	O
,	O
Oxted	O
,	O
Surrey	O
,	O
England	O
.	O
A	O
series	O
of	O
152	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
,	O
14	O
bladder	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
,	O
and	O
1	O
immortal	O
urothelial	O
cell	O
line	O
were	O
examined	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
designed	O
restriction	O
fragment	O
.	O
length	O
polymorphism	O
analyses	O
for	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
H-ras	O
gene	O
.	O
Nine	O
tumors	O
(	O
6	O
%	O
)	O
contained	O
mutations	O
.	O
There	O
was	O
complete	O
concordance	O
between	O
SSCP	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
analyses	O
.	O
Six	O
mutations	O
in	O
exon	O
1	O
and	O
three	O
in	O
exon	O
2	O
were	O
identified	O
by	O
SSCP	O
analysis	O
.	O
Subsequent	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
showed	O
that	O
of	O
the	O
exon	O
1	O
mutations	O
,	O
four	O
were	O
in	O
codon	O
12	O
and	O
two	O
in	O
codon	O
13	O
,	O
and	O
all	O
three	O
exon	O
2	O
mutations	O
were	O
in	O
codon	O
61	O
.	O
Eight	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
One	O
codon	O
13	O
mutation	O
could	O
not	O
be	O
identified	O
by	O
direct	O
sequencing	O
.	O
Distinct	O
strand	O
mobility	O
shifts	O
detected	O
by	O
SSCP	O
analysis	O
identified	O
specific	O
point	O
mutations	O
,	O
and	O
in	O
all	O
cases	O
,	O
strands	O
containing	O
different	O
mutations	O
migrated	O
differently	O
.	O
The	O
base	O
substitutions	O
identified	O
in	O
these	O
bladder	B-malignancy-type
tumors	I-malignancy-type
were	O
diverse	O
and	O
included	O
four	O
transversions	O
(	O
three	O
G	O
-->	O
T	O
and	O
one	O
A	O
-->	O
T	O
)	O
and	O
four	O
transitions	O
(	O
two	O
G	O
-->	O
A	O
and	O
two	O
A	O
-->	O
G	O
)	O
.	O
This	O
pattern	O
of	O
base	O
substitutions	O
is	O
compatible	O
with	O
interactions	O
of	O
the	O
urothelium	O
with	O
more	O
than	O
one	O
class	O
of	O
environmental	O
agent	O
during	O
bladder	B-malignancy-type
tumor	I-malignancy-type
development	O
.	O
No	O
correlation	O
was	O
found	O
between	O
tumor	O
grade	O
and/or	O
stage	O
and	O
the	O
presence	O
of	O
H-ras	O
mutation	O
.	O
We	O
conclude	O
that	O
H-ras	O
mutation	O
does	O
not	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
transitional	O
cell	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
.	O
PMID	O
:	O
8093230	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1993	O
Nov	O
;	O
11	O
(	O
5	O
-	O
6	O
)	O
:	O
405	O
-	O
10	O
Frequency	O
of	O
RAS	O
and	O
p53	O
mutations	O
in	O
acute	B-malignancy-type
promyelocytic	I-malignancy-type
leukemias	I-malignancy-type
.	O
Longo	O
L	O
,	O
Trecca	O
D	O
,	O
Biondi	O
A	O
,	O
Lo	O
Coco	O
F	O
,	O
Grignani	O
F	O
,	O
Maiolo	O
AT	O
,	O
Pelicci	O
PG	O
,	O
Neri	O
A	O
.	O
Istituto	O
Clinica	O
Medica	O
I	O
,	O
University	O
of	O
Perugia	O
,	O
Italy	O
.	O
The	O
frequency	O
of	O
RAS	O
and	O
p53	O
mutations	O
was	O
investigated	O
in	O
30	O
acute	B-malignancy-type
promyelocytic	I-malignancy-type
leukemias	I-malignancy-type
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O
Only	O
two	O
cases	O
bore	O
N-RAS	O
codon	O
12	O
mutations	O
and	O
none	O
had	O
p53	O
mutations	O
responsible	O
for	O
aminoacid	O
substitutions	O
.	O
It	O
would	O
,	O
therefore	O
,	O
seem	O
that	O
neither	O
RAS	O
nor	O
p53	O
are	O
involved	O
in	O
acute	O
promyelocytic	O
leukemogenesis	O
.	O
PMID	O
:	O
8124213	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Eur	O
J	O
Cancer	O
B	O
Oral	O
Oncol	O
1993	O
Jan	O
;	O
29B	O
(	O
1	O
)	O
:	O
63	O
-	O
7	O
Ras	O
gene	O
point	O
mutation	O
is	O
a	O
rare	O
event	O
in	O
premalignant	O
tissues	O
and	O
malignant	O
cells	O
and	O
tissues	O
from	O
oral	B-malignancy-type
mucosal	I-malignancy-type
lesions	I-malignancy-type
.	O
Yeudall	O
WA	O
,	O
Torrance	O
LK	O
,	O
Elsegood	O
KA	O
,	O
Speight	O
P	O
,	O
Scully	O
C	O
,	O
Prime	O
SS	O
.	O
Department	O
of	O
Oral	O
Medicine	O
,	O
Pathology	O
and	O
Microbiology	O
,	O
University	O
of	O
Bristol	O
Dental	O
School	O
,	O
U.K.	O
Three	O
series	O
of	O
biopsy	O
specimens	O
of	O
premalignant	O
and	O
malignant	O
oral	B-malignancy-type
lesions	I-malignancy-type
,	O
together	O
with	O
seven	O
human	O
keratinocyte	O
cultures	O
,	O
previously	O
established	O
from	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
analysed	O
for	O
point	O
mutation	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
c-Ha-ras	O
,	O
c-Ki-ras	O
and	O
N-ras	O
genes	O
by	O
direct	O
nucleotide	O
sequencing	O
of	O
DNAs	O
amplified	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
Only	O
one	O
out	O
of	O
12	O
biopsy	O
samples	O
(	O
8.3	O
%	O
)	O
,	O
a	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
carcinoma	I-malignancy-type
which	O
was	O
the	O
latest	O
in	O
a	O
series	O
of	O
floor	O
of	O
mouth	B-malignancy-type
lesions	I-malignancy-type
from	O
1	O
of	O
the	O
3	O
patients	O
studied	O
,	O
harboured	O
a	O
mutant	O
c-Ha-ras	O
gene	O
,	O
being	O
heterozygous	O
at	O
codon	O
12	O
for	O
a	O
GGA	O
-	O
GTA	O
change	O
.	O
One	O
cell	O
line	O
(	O
H357	O
)	O
showed	O
heterozygosity	O
in	O
both	O
exons	O
1	O
and	O
2	O
of	O
c-Ha-ras	O
,	O
harbouring	O
a	O
GGT	O
to	O
AGT	O
mutation	O
over	O
codon	O
13	O
and	O
a	O
CAG	O
to	O
CAA	O
mutation	O
over	O
codon	O
61	O
.	O
The	O
remaining	O
six	O
oral	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
(	O
85.7	O
%	O
)	O
were	O
homozygous	O
normal	O
at	O
both	O
exons	O
1	O
and	O
2	O
of	O
c-Ha-ras	O
.	O
All	O
cell	O
lines	O
showed	O
normal	O
c-Ki-ras	O
and	O
N-ras	O
loci	O
.	O
We	O
conclude	O
that	O
ras	O
gene	O
mutation	O
is	O
an	O
infrequent	O
occurrence	O
in	O
the	O
malignant	O
progression	O
of	O
oral	O
epithelial	O
cells	O
,	O
despite	O
the	O
probable	O
importance	O
of	O
chemical	O
carcinogens	O
in	O
the	O
aetiology	O
of	O
the	O
disease	O
.	O
We	O
emphasise	O
the	O
need	O
to	O
search	O
for	O
other	O
cellular	O
sequences	O
which	O
may	O
be	O
targets	O
for	O
chemical	O
or	O
viral	O
carcinogens	O
.	O
PMID	O
:	O
8180579	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Haematol	O
1994	O
Feb	O
;	O
86	O
(	O
2	O
)	O
:	O
298	O
-	O
302	O
Persistence	O
of	O
an	O
activating	O
N-RAS	O
oncogene	O
mutation	O
in	O
clonogenic	O
progenitor	O
cells	O
from	O
an	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
patient	O
in	O
remission	O
.	O
Zaheer	O
HA	O
,	O
Bagnara	O
M	O
,	O
Gibson	O
FM	O
,	O
Robinson	O
G	O
,	O
Rutherford	O
TR	O
,	O
Gordon-Smith	O
EC	O
.	O
Department	O
of	O
Cellular	O
and	O
Molecular	O
Sciences	O
,	O
St	O
George	O
's	O
Hospital	O
Medical	O
School	O
,	O
London	O
.	O
A	O
patient	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
with	O
an	O
activating	O
N-RAS	O
oncogene	O
mutation	O
was	O
studied	O
in	O
a	O
haemopoietic	O
clonogenic	O
progenitor	O
cell	O
assay	O
.	O
Individual	O
colonies	O
and	O
clusters	O
were	O
analysed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
for	O
the	O
original	O
mutation	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
a	O
majority	O
of	O
leukaemic	O
clusters	O
,	O
but	O
also	O
in	O
almost	O
half	O
of	O
the	O
differentiated	O
colonies	O
.	O
After	O
chemotherapy	O
the	O
patient	O
entered	O
clinical	O
remission	O
.	O
However	O
,	O
the	O
mutation	O
could	O
still	O
be	O
detected	O
in	O
the	O
bone	O
marrow	O
.	O
Only	O
differentiated	O
colonies	O
and	O
no	O
leukaemic	O
clusters	O
were	O
grown	O
from	O
the	O
remission	O
bone	O
marrow	O
,	O
but	O
the	O
original	O
mutation	O
was	O
still	O
detectable	O
in	O
almost	O
half	O
of	O
the	O
colonies	O
.	O
PMID	O
:	O
8199018	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
1993	O
Dec	O
2	O
;	O
55	O
(	O
6	O
)	O
:	O
915	O
-	O
20	O
Low	O
incidence	O
of	O
c-Ha-ras	O
gene	O
mutations	O
in	O
benign	O
and	O
malignant	O
cutaneous	B-malignancy-type
lesions	I-malignancy-type
from	O
transplant	O
recipients	O
.	O
Pelisson	O
I	O
,	O
Chardonnet	O
Y	O
,	O
Euvrard	O
S	O
,	O
Schmitt	O
D	O
.	O
INSERM	O
U	O
346	O
affiliee	O
CNRS	O
,	O
Hopital	O
Edouard	O
Herriot	O
,	O
Lyon	O
,	O
France	O
.	O
Transplant	O
recipients	O
successively	O
develop	O
benign	O
,	O
premalignant	O
and	O
malignant	O
skin	B-malignancy-type
lesions	I-malignancy-type
on	I-malignancy-type
sun	I-malignancy-type
-	I-malignancy-type
exposed	I-malignancy-type
areas	I-malignancy-type
.	O
It	O
has	O
been	O
suggested	O
that	O
UV	O
radiations	O
might	O
induce	O
mutations	O
in	O
ras	O
oncogenes	O
and	O
p53	O
tumour	O
-	O
suppressor	O
gene	O
,	O
responsible	O
for	O
skin	B-malignancy-type
cancers	I-malignancy-type
.	O
With	O
PCR	O
and	O
oligoprobe	O
hybridization	O
,	O
we	O
investigated	O
c-Ha-ras	O
gene	O
mutations	O
at	O
codons	O
12	O
and	O
61	O
in	O
120	O
cutaneous	B-malignancy-type
lesions	I-malignancy-type
from	O
grafted	O
patients	O
,	O
since	O
they	O
could	O
represent	O
a	O
marker	O
of	O
the	O
evolution	O
of	O
benign	O
skin	B-malignancy-type
lesions	I-malignancy-type
towards	O
malignancy	O
in	O
this	O
population	O
;	O
29	O
similar	O
skin	O
biopsies	O
from	O
non	O
-	O
immunosuppressed	O
patients	O
were	O
also	O
analyzed	O
.	O
In	O
transplant	O
recipients	O
,	O
we	O
detected	O
mutations	O
at	O
codon	O
12	O
only	O
in	O
1	O
/	O
42	O
non	B-malignancy-type
-	I-malignancy-type
melanoma	I-malignancy-type
skin	I-malignancy-type
cancers	I-malignancy-type
and	O
2	O
/	O
29	O
pre	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
keratoses	I-malignancy-type
.	O
No	O
mutation	O
was	O
detected	O
in	O
11	O
cases	O
of	O
cutaneous	O
Bowen	O
's	O
disease	O
from	O
grafted	O
patients	O
and	O
in	O
pre	O
-	O
malignant	O
and	O
malignant	O
skin	O
samples	O
from	O
control	O
patients	O
.	O
Benign	O
warts	O
exhibited	O
an	O
overall	O
incidence	O
of	O
18	O
%	O
and	O
15	O
%	O
of	O
mutations	O
at	O
codon	O
12	O
of	O
c-Ha-ras	O
gene	O
in	O
grafted	O
and	O
control	O
patients	O
respectively	O
.	O
We	O
detected	O
only	O
one	O
mutation	O
at	O
codon	O
61	O
in	O
a	O
plantar	O
wart	O
.	O
Human	O
papillomaviruses	O
(	O
HPV	O
)	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
malignant	O
evolution	O
of	O
cutaneous	O
disorders	O
in	O
transplant	O
recipients	O
and	O
cooperate	O
with	O
a	O
ras	O
oncogene	O
to	O
induce	O
malignancy	O
in	O
vitro	O
.	O
The	O
presence	O
of	O
HPV	O
DNA	O
in	O
our	O
series	O
of	O
skin	O
samples	O
from	O
grafted	O
patients	O
showed	O
no	O
correlation	O
with	O
the	O
occurrence	O
of	O
c-Ha-ras	O
mutations	O
.	O
Our	O
findings	O
indicate	O
that	O
c-Ha-ras	O
-	O
gene	O
activation	O
by	O
mutations	O
is	O
rare	O
in	O
cutaneous	B-malignancy-type
lesions	I-malignancy-type
from	O
transplant	O
recipients	O
,	O
and	O
is	O
unlikely	O
to	O
play	O
a	O
crucial	O
role	O
in	O
transformation	O
towards	O
malignancy	O
in	O
skin	O
carcinogenesis	O
among	O
grafted	O
patients	O
.	O
PMID	O
:	O
8253528	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
1994	O
;	O
120	O
(	O
3	O
)	O
:	O
143	O
-	O
8	O
Gene	O
analysis	O
of	O
K	O
-	O
,	O
H-ras	O
,	O
p53	O
,	O
and	O
retinoblastoma	O
susceptibility	O
genes	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
by	O
the	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
.	O
Kashii	O
T	O
,	O
Mizushima	O
Y	O
,	O
Monno	O
S	O
,	O
Nakagawa	O
K	O
,	O
Kobayashi	O
M	O
.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Toyama	O
Medical	O
and	O
Pharmaceutical	O
University	O
,	O
Japan	O
.	O
In	O
order	O
to	O
know	O
the	O
involvement	O
of	O
multiple	O
gene	O
alterations	O
in	O
the	O
pathogenesis	O
of	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
examined	O
the	O
genes	O
of	O
K	O
-	O
,	O
H-ras	O
(	O
codons	O
12	O
,	O
13	O
,	O
61	O
)	O
,	O
p53	O
(	O
exons	O
5	O
-	O
9	O
)	O
and	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
(	O
RB	O
)	O
(	O
exons	O
20	O
-	O
22	O
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
in	O
32	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
(	O
5	O
squamous	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
10	O
adenocarcinomas	B-malignancy-type
,	O
3	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
14	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
)	O
.	O
In	O
18	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
lines	O
,	O
gene	O
alterations	O
were	O
found	O
in	O
4	O
for	O
K-ras	O
(	O
22	O
%	O
)	O
,	O
none	O
for	O
H-ras	O
(	O
0	O
%	O
)	O
,	O
4	O
for	O
p53	O
(	O
22	O
%	O
)	O
and	O
none	O
for	O
the	O
RB	O
(	O
0	O
%	O
)	O
gene	O
.	O
In	O
14	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
SCLC	B-malignancy-type
)	O
lines	O
,	O
no	O
gene	O
alterations	O
were	O
found	O
in	O
K-ras	O
(	O
0	O
%	O
)	O
,	O
or	O
H-ras	O
(	O
0	O
%	O
)	O
,	O
but	O
6	O
were	O
found	O
for	O
p53	O
(	O
43	O
%	O
)	O
and	O
3	O
for	O
the	O
RB	O
(	O
21	O
%	O
)	O
gene	O
.	O
Coincident	O
abnormalities	O
of	O
K-ras	O
and	O
p53	O
,	O
or	O
K-ras	O
and	O
RB	O
genes	O
were	O
not	O
found	O
in	O
any	O
cell	O
lines	O
,	O
and	O
those	O
of	O
the	O
p53	O
and	O
RB	O
genes	O
were	O
found	O
in	O
only	O
2	O
SCLC	B-malignancy-type
lines	O
.	O
No	O
association	O
was	O
observed	O
between	O
these	O
three	O
gene	O
alterations	O
and	O
N-myc	O
amplification	O
.	O
Although	O
the	O
above	O
three	O
genes	O
may	O
be	O
involved	O
to	O
some	O
extent	O
in	O
the	O
pathogenesis	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
more	O
factors	O
are	O
required	O
for	O
its	O
development	O
.	O
PMID	O
:	O
8263009	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Carcinog	O
1993	O
;	O
8	O
(	O
4	O
)	O
:	O
312	O
-	O
8	O
Mutations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
the	O
ras	O
gene	O
family	O
in	O
intrahepatic	B-malignancy-type
cholangiocellular	I-malignancy-type
carcinomas	I-malignancy-type
in	O
Japan	O
and	O
Thailand	O
.	O
Kiba	O
T	O
,	O
Tsuda	O
H	O
,	O
Pairojkul	O
C	O
,	O
Inoue	O
S	O
,	O
Sugimura	O
T	O
,	O
Hirohashi	O
S	O
.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
incidence	O
and	O
pattern	O
of	O
mutations	O
of	O
the	O
ras	O
oncogenes	O
and	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
have	O
been	O
shown	O
to	O
differ	O
among	O
different	O
cancer	O
types	O
and	O
even	O
among	O
the	O
same	O
cancer	O
types	O
with	O
different	O
etiological	O
backgrounds	O
.	O
For	O
example	O
,	O
in	O
a	O
previous	O
study	O
we	O
showed	O
that	O
not	O
only	O
the	O
etiology	O
but	O
also	O
the	O
incidence	O
of	O
point	O
mutation	O
of	O
the	O
c-Ki-ras	O
oncogene	O
in	O
cholangiocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
CCCs	B-malignancy-type
)	O
differ	O
between	O
Japanese	O
and	O
Thai	O
patients	O
.	O
In	O
the	O
study	O
presented	O
here	O
,	O
we	O
examined	O
the	O
incidence	O
of	O
mutations	O
in	O
the	O
ras	O
gene	O
family	O
and	O
the	O
p53	O
gene	O
in	O
CCCs	B-malignancy-type
of	O
both	O
Japanese	O
and	O
Thai	O
patients	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
analyses	O
and	O
compared	O
the	O
pattern	O
of	O
p53	O
mutation	O
between	O
these	O
two	O
CCC	B-malignancy-type
groups	O
.	O
Although	O
the	O
incidence	O
of	O
ras	O
mutation	O
differed	O
markedly	O
between	O
Japanese	O
(	O
seven	O
of	O
12	O
,	O
58	O
%	O
)	O
and	O
Thai	O
(	O
two	O
of	O
26	O
,	O
8	O
%	O
)	O
cases	O
,	O
the	O
incidence	O
of	O
p53	O
mutation	O
was	O
similar	O
:	O
four	O
of	O
12	O
(	O
33	O
%	O
)	O
and	O
nine	O
of	O
26	O
(	O
35	O
%	O
)	O
,	O
respectively	O
.	O
Except	O
for	O
one	O
case	O
in	O
which	O
deletion	O
-	O
insertion	O
was	O
detected	O
in	O
the	O
second	O
exon	O
of	O
the	O
N-ras	O
gene	O
,	O
all	O
ras	O
mutations	O
occurred	O
at	O
codon	O
12	O
or	O
13	O
of	O
the	O
c-Ki-ras	O
gene	O
.	O
All	O
p53	O
mutations	O
but	O
one	O
were	O
detected	O
in	O
a	O
highly	O
conserved	O
region	O
,	O
and	O
the	O
predominant	O
form	O
of	O
the	O
mutations	O
was	O
G	O
:	O
C	O
-->	O
A	O
:	O
T	O
transition	O
at	O
CpG	O
sites	O
in	O
both	O
Japanese	O
and	O
Thai	O
cases	O
,	O
similar	O
to	O
that	O
reported	O
for	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
Therefore	O
,	O
in	O
contrast	O
to	O
the	O
ras	O
oncogenes	O
,	O
mutation	O
of	O
the	O
p53	O
gene	O
was	O
frequently	O
involved	O
in	O
the	O
development	O
of	O
CCCs	B-malignancy-type
in	O
both	O
Japanese	O
and	O
Thai	O
patients	O
,	O
irrespective	O
of	O
any	O
difference	O
in	O
etiology	O
.	O
PMID	O
:	O
8280380	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1993	O
Jul	O
;	O
7	O
(	O
7	O
)	O
:	O
946	O
-	O
53	O
Mutations	O
in	O
the	O
P53	O
and	O
RAS	O
family	O
genes	O
are	O
associated	O
with	O
tumor	O
progression	O
of	O
BCR	O
/	O
ABL	O
negative	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
.	O
Gaidano	O
G	O
,	O
Guerrasio	O
A	O
,	O
Serra	O
A	O
,	O
Carozzi	O
F	O
,	O
Cambrin	O
GR	O
,	O
Petroni	O
D	O
,	O
Saglio	O
G	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
&	O
Surgeons	O
of	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
10032	O
.	O
We	O
have	O
investigated	O
the	O
involvement	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
RAS	O
family	O
proto	O
-	O
oncogenes	O
in	O
BCR	O
/	O
ABL	O
-	O
negative	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
(	O
CMPD	O
)	O
,	O
including	O
nine	O
cases	O
of	O
myelosclerosis	O
with	O
myeloid	B-malignancy-type
metaplasia	I-malignancy-type
,	O
four	O
polycythemia	O
vera	O
,	O
10	O
essential	O
thrombocythemia	O
,	O
one	O
juvenile	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
and	O
eight	O
BCR	O
/	O
ABL	O
-	O
negative	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Twenty-five	O
samples	O
were	O
studied	O
in	O
the	O
chronic	O
phase	O
,	O
while	O
seven	O
samples	O
were	O
analyzed	O
in	O
the	O
acute	O
accelerated	O
or	O
blastic	O
phase	O
.	O
The	O
presence	O
of	O
mutations	O
in	O
p53	O
exons	O
5	O
-	O
9	O
,	O
as	O
well	O
as	O
in	O
N	O
-	O
,	O
K	O
-	O
,	O
H	O
-	O
Ras	O
exons	O
1	O
and	O
2	O
(	O
containing	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
was	O
tested	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
single	O
strand	O
conformation	O
polymorphism	O
technique	O
and	O
by	O
PCR	O
direct	O
sequencing	O
.	O
In	O
addition	O
,	O
restriction	O
analysis	O
was	O
performed	O
to	O
screen	O
for	O
gross	O
rearrangements	O
within	O
the	O
p53	O
locus	O
.	O
Alterations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
Ras	O
family	O
proto	O
-	O
oncogenes	O
were	O
detected	O
in	O
2	O
/	O
7	O
and	O
3	O
/	O
7	O
cases	O
of	O
acute	O
phase	O
BCR	O
/	O
ABL	O
-	O
negative	O
CMPD	B-malignancy-type
,	O
respectively	O
,	O
while	O
consistently	O
negative	O
in	O
all	O
the	O
chronic	O
phase	O
samples	O
analyzed	O
.	O
These	O
results	O
suggest	O
that	O
p53	O
inactivation	O
and/or	O
Ras	O
activation	O
might	O
play	O
a	O
role	O
in	O
acute	O
transformation	O
of	O
BCR	O
/	O
ABL	O
-	O
negative	O
CMPD	B-malignancy-type
.	O
PMID	O
:	O
8321046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
1993	O
Jan	O
2;5	O
3	O
(	O
1	O
)	O
:	O
2	O
2-8	O
ras	O
gene	O
mutations	O
and	O
HPV	O
infection	O
are	O
common	O
in	O
human	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Anwar	O
K,	O
Nakakuki	O
K,	O
Naiki	O
H,	O
Inuzuka	O
M.	O
Department	O
of	O
Pathology	O
,	O
Fukui	O
Medical	O
School	O
,	O
Japan	O
.	O
To	O
evaluate	O
the	O
role	O
of	O
ras	O
activation	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	O
in	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
analyzed	O
tumor	O
DNA	O
from	O
43	O
cases	O
,	O
including	O
25	O
primary	O
laryngeal	B-malignancy-type
tumors	I-malignancy-type
,	O
12	O
lymph	B-malignancy-type
-	I-malignancy-type
node	I-malignancy-type
and	O
one	O
skin	B-malignancy-type
metastases	I-malignancy-type
,	O
and	O
5	O
recurrent	B-malignancy-type
laryngeal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Thirteen	O
normal	O
laryngeal	O
tissues	O
and	O
7	O
benign	O
laryngeal	O
nodule	O
biopsy	O
specimens	O
along	O
with	O
normal	O
tissue	O
surrounding	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
in	O
2	O
cases	O
were	O
also	O
included	O
.	O
The	O
polymerase	O
-	O
chain	O
-	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
codon	O
12	O
and	O
61	O
of	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
,	O
also	O
HPV	O
16	O
,	O
18	O
and	O
33	O
DNA	O
,	O
subsequently	O
hybridized	O
with	O
sequence	O
-	O
specific	O
oligonucleotides	O
.	O
DNA	O
samples	O
from	O
22	O
patients	O
with	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
revealed	O
ras	O
mutations	O
(	O
18	O
in	O
N-ras	O
codon	O
12	O
,	O
6	O
in	O
H-ras	O
codon	O
61	O
,	O
and	O
3	O
in	O
K-ras	O
codon	O
61	O
)	O
.	O
Likewise	O
,	O
HPV	O
DNA	O
was	O
found	O
in	O
16	O
cases	O
(	O
HPV	O
16	O
,	O
18	O
and	O
33	O
in	O
3	O
cases	O
,	O
14	O
cases	O
and	O
1	O
case	O
respectively	O
)	O
.	O
ras	O
mutations	O
were	O
significantly	O
higher	O
in	O
metastatic	B-malignancy-type
tumors	I-malignancy-type
(	O
10	O
of	O
13	O
cases	O
)	O
than	O
in	O
primary	O
(	O
11	O
of	O
25	O
cases	O
)	O
and	O
recurrent	B-malignancy-type
laryngeal	I-malignancy-type
carcinomas	I-malignancy-type
(	O
1	O
of	O
5	O
cases	O
)	O
.	O
HPV	O
DNA	O
was	O
detected	O
in	O
60	O
%	O
of	O
recurrent	O
,	O
44	O
%	O
of	O
primary	O
and	O
15	O
%	O
of	O
metastatic	O
tumors	O
.	O
Only	O
2	O
of	O
the	O
13	O
normal	O
laryngeal	O
tissues	O
and	O
1	O
out	O
of	O
7	O
laryngeal	O
nodule	O
specimens	O
were	O
found	O
to	O
contain	O
HPV	O
DNA	O
.	O
These	O
results	O
suggest	O
that	O
ras	O
activation	O
,	O
especially	O
in	O
N-ras	O
codon	O
12.1	O
(	O
GGT	O
-->	O
AGT	O
)	O
and	O
HPV	O
infection	O
are	O
2	O
important	O
factors	O
in	O
(	O
multistage	O
)	O
laryngeal	O
carcinogenesis	O
.	O
The	O
ras	O
mutation	O
may	O
be	O
associated	O
with	O
metastatic	O
ability	O
of	O
the	O
tumor	O
.	O
PMID	O
:	O
8380055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1993	O
Jan	O
1;8	O
1	O
(	O
1	O
)	O
:	O
16	O
6-76	O
Multiple	O
genetic	O
lesions	O
in	O
acquired	B-malignancy-type
immunodeficiency	I-malignancy-type
syndrome	I-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Ballerini	O
P,	O
Gaidano	O
G,	O
Gong	O
JZ	O
,	O
Tassi	O
V	O
,	O
Saglio	O
G,	O
Knowles	O
DM	O
,	O
Dall	O
a	O
-Favera	O
R.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
&	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
10032	O
.	O
Non	B-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
(	O
NHL	B-malignancy-type
)	O
develops	O
in	O
about	O
5	O
%	O
to	O
10	O
%	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
patients	O
.	O
The	O
vast	O
majority	O
of	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
are	O
clinically	O
aggressive	B-malignancy-type
B-cell	I-malignancy-type
NHL	I-malignancy-type
that	O
are	O
histologically	O
classified	O
as	O
small	B-malignancy-type
noncleaved	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
SNCCL	B-malignancy-type
)	O
,	O
large	B-malignancy-type
cell	I-malignancy-type
immunoblastic	I-malignancy-type
plasmacytoid	I-malignancy-type
lymphoma	I-malignancy-type
(	O
LC-IBPL	B-malignancy-type
)	O
,	O
and	O
large	B-malignancy-type
noncleaved	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
LNCCL	B-malignancy-type
)	O
.	O
In	O
an	O
attempt	O
to	O
understand	O
the	O
molecular	O
pathogenesis	O
of	O
these	O
tumors	O
,	O
we	O
have	O
investigated	O
the	O
involvement	O
of	O
dominantly	O
acting	O
oncogenes	O
(	O
c-myc	O
,	O
N	O
-	O
,	O
K	O
-	O
,	O
H	O
-	O
Ras	O
)	O
,	O
tumor	O
suppressor	O
genes	O
(	O
p53	O
,	O
RB1	O
)	O
,	O
and	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
in	O
27	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
samples	O
(	O
16	O
SNCCL	B-malignancy-type
,	O
5	O
LC-IBP	B-malignancy-type
,	O
and	O
6	O
LNCCL	B-malignancy-type
)	O
.	O
The	O
following	O
lesions	O
were	O
detected	O
in	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
:	O
EBV	O
infection	O
(	O
10	O
/	O
24	O
;	O
41.6	O
%	O
)	O
,	O
c-myc	O
rearrangement	O
(	O
19	O
/	O
24	O
;	O
79.1	O
%	O
)	O
,	O
Ras	O
mutation	O
(	O
4	O
/	O
27	O
;	O
14.8	O
%	O
)	O
,	O
and	O
p53	O
loss	O
/	O
mutation	O
(	O
10	O
/	O
27	O
;	O
37.0	O
%	O
)	O
.	O
These	O
lesions	O
are	O
not	O
uniformly	O
distributed	O
,	O
but	O
,	O
rather	O
,	O
cluster	O
with	O
specific	O
types	O
of	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
:	O
EBV	O
infection	O
is	O
preferentially	O
associated	O
with	O
LC-IBPL	B-malignancy-type
(	O
4	O
/	O
4	O
;	O
100	O
%	O
)	O
,	O
while	O
it	O
is	O
present	O
in	O
only	O
a	O
fraction	O
of	O
SNCCL	B-malignancy-type
(	O
5	O
/	O
16	O
;	O
31.2	O
%	O
)	O
and	O
LNCCL	B-malignancy-type
(	O
1	O
/	O
4	O
;	O
25	O
%	O
)	O
;	O
c-myc	O
oncogene	O
activation	O
clusters	O
with	O
SNCCL	B-malignancy-type
(	O
16	O
/	O
16	O
;	O
100	O
%	O
)	O
,	O
whereas	O
it	O
is	O
less	O
frequent	O
in	O
LC-IBPL	B-malignancy-type
(	O
1	O
/	O
4	O
;	O
25	O
%	O
)	O
and	O
LNCCL	B-malignancy-type
(	O
2	O
/	O
4	O
;	O
50	O
%	O
)	O
;	O
p53	O
inactivation	O
is	O
restricted	O
to	O
SNCCL	B-malignancy-type
(	O
10	O
/	O
16	O
;	O
62.5	O
%	O
)	O
and	O
consistently	O
associated	O
with	O
c-myc	O
activation	O
.	O
These	O
data	O
show	O
that	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
are	O
associated	O
with	O
multiple	O
genetic	O
lesions	O
that	O
involve	O
both	O
proto	O
-	O
oncogenes	O
and	O
tumor	O
suppressor	O
genes	O
and	O
may	O
accumulate	O
in	O
the	O
relatively	O
short	O
period	O
of	O
time	O
(	O
4	O
to	O
6	O
years	O
)	O
between	O
human	O
immunodeficiency	O
virus	O
infection	O
and	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
development	O
.	O
These	O
genetic	O
lesions	O
differ	O
in	O
the	O
various	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
subtypes	O
,	O
suggesting	O
the	O
involvement	O
of	O
distinct	O
molecular	O
pathway	O
.	O
PMID	O
:	O
8380252	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1993	O
Jan;6	O
5	O
(	O
1	O
)	O
:	O
1	O
2-20	O
Analysis	O
of	O
karyotype	O
,	O
SCE	O
,	O
and	O
point	O
mutation	O
of	O
RAS	O
oncogene	O
in	O
Indian	O
MDS	B-malignancy-type
patients	O
.	O
Mansoor	O
AM	O
,	O
Bharadwaj	O
TP	O
,	O
Sethuraman	O
S	O
,	O
Chandy	O
M,	O
Pushpa	O
V	O
,	O
Kamada	O
N	O
,	O
Murthy	O
PB.	O
Department	O
of	O
Hematology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Thirty	O
Indian	O
patients	O
diagnosed	O
as	O
having	O
primary	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
as	O
per	O
the	O
French	O
-	O
American	O
-	O
British	O
classification	O
were	O
investigated	O
,	O
on	O
admission	O
,	O
for	O
the	O
frequencies	O
of	O
nonrandom	O
karyotype	O
abnormalities	O
,	O
sister	O
chromatid	O
exchange	O
,	O
and	O
point	O
mutations	O
of	O
the	O
RAS	O
oncogene	O
.	O
Successful	O
karyotype	O
analysis	O
was	O
possible	O
in	O
24	O
patients	O
,	O
of	O
whom	O
9	O
(	O
37.5	O
%	O
)	O
showed	O
nonrandom	O
karyotypic	O
changes	O
.	O
Anomalies	O
of	O
chromosomes	O
5	O
,	O
7	O
,	O
and	O
8	O
were	O
detected	O
in	O
their	O
bone	O
marrow	O
(	O
BM	O
)	O
.	O
In	O
addition	O
,	O
two	O
new	O
anomalies	O
,	O
del	O
(	O
8	O
)	O
(	O
q22	O
)	O
and	O
+	O
19	O
,	O
were	O
observed	O
for	O
the	O
first	O
time	O
in	O
our	O
series	O
.	O
Six	O
MDS	B-malignancy-type
patients	O
were	O
studied	O
for	O
SCE	O
in	O
either	O
BM	O
or	O
peripheral	O
blood	O
.	O
These	O
data	O
revealed	O
a	O
normal	O
SCE	O
incidence	O
.	O
Of	O
the	O
10	O
MDS	B-malignancy-type
patients	O
studied	O
for	O
point	O
mutations	O
of	O
NRAS	O
12	O
and	O
61	O
and	O
KRAS	O
12	O
and	O
61	O
,	O
one	O
patient	O
exhibited	O
a	O
base	O
substitution	O
at	O
position	O
1	O
of	O
the	O
12th	O
codon	O
of	O
the	O
KRAS	O
gene	O
.	O
These	O
data	O
,	O
gathered	O
for	O
the	O
first	O
time	O
on	O
the	O
Indian	O
patients	O
,	O
throw	O
some	O
light	O
on	O
the	O
nature	O
of	O
genetic	O
changes	O
in	O
MDS	B-malignancy-type
of	O
our	O
country	O
.	O
PMID	O
:	O
8431911	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1993	O
Feb;8	O
4	O
(	O
2	O
)	O
:	O
16	O
3-7	O
Infrequent	O
ras	O
mutation	O
in	O
human	O
stomach	B-malignancy-type
cancers	I-malignancy-type
.	O
Koshiba	O
M,	O
Ogawa	O
O,	O
Habuchi	O
T	O
,	O
Hamazaki	O
S	O
,	O
Shimada	O
T	O
,	O
Takahashi	O
R	O
,	O
Sugiyama	O
T.	O
Department	O
of	O
Geriatric	O
Medicine	O
,	O
Kyoto	O
University	O
.	O
Mutations	O
of	O
ras	O
oncogenes	O
in	O
37	O
human	O
stomach	B-malignancy-type
cancers	I-malignancy-type
and	O
13	O
adenomas	B-malignancy-type
were	O
investigated	O
with	O
regard	O
to	O
the	O
histological	O
phenotypes	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
and/or	O
direct	O
sequencing	O
of	O
the	O
PCR	O
products	O
.	O
The	O
ras	O
mutation	O
was	O
found	O
only	O
in	O
one	O
case	O
(	O
2.7	O
%	O
)	O
,	O
the	O
histology	O
of	O
which	O
was	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
found	O
no	O
mutation	O
in	O
stomach	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
mutation	O
consisted	O
of	O
a	O
guanine	O
-	O
to	O
-	O
adenine	O
transition	O
in	O
the	O
first	O
base	O
of	O
codon	O
13	O
of	O
c-Ki-ras	O
which	O
replaced	O
wild-type	O
glycine	O
with	O
serine	O
,	O
indicating	O
that	O
a	O
putative	O
glycine	O
-	O
to	O
-	O
aspartic	O
acid	O
change	O
is	O
not	O
necessarily	O
the	O
critical	O
event	O
for	O
c-Ki-ras	O
gene	O
activation	O
in	O
codon	O
13	O
.	O
These	O
results	O
further	O
confirm	O
the	O
infrequency	O
of	O
ras	O
mutation	O
in	O
stomach	B-malignancy-type
tumors	I-malignancy-type
and	O
also	O
suggest	O
that	O
ras	O
mutations	O
are	O
not	O
specific	O
to	O
the	O
differentiated	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
stomach	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
8463133	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Stem	O
Cells	O
1995	O
Sep;1	O
3	O
(	O
5	O
)	O
:	O
55	O
6-63	O
Analysis	O
of	O
mutations	O
of	O
neurofibromatosis	O
type	O
1	O
gene	O
and	O
N-ras	O
gene	O
in	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Lee	O
YY	O
,	O
Kim	O
WS	O
,	O
Bang	O
YJ	O
,	O
Jung	O
CW,	O
Park	O
S	O
,	O
Yoon	O
WJ	O
,	O
Cho	O
KS	O
,	O
Kim	O
IS	O
,	O
Jung	O
TJ	O
,	O
Choi	O
IY	O
,	O
et	O
al	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Han	O
Yang	O
University	O
Hospital	O
,	O
Seoul	O
,	O
Korea	O
.	O
Neurofibromatosis	O
type	O
1	O
(	O
NF1	O
)	O
gene	O
is	O
a	O
tumor	O
suppressor	O
gene	O
,	O
and	O
the	O
NF1	O
gene	O
product	O
,	O
neurofibromin	O
,	O
can	O
downregulate	O
the	O
N-ras	O
gene	O
.	O
Because	O
the	O
N-ras	O
gene	O
is	O
often	O
mutated	O
in	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
we	O
wondered	O
if	O
the	O
NF1	O
gene	O
might	O
be	O
mutated	O
in	O
those	O
AML	B-malignancy-type
samples	O
not	O
having	O
N-ras	O
mutations	O
.	O
We	O
investigated	O
the	O
mutational	O
status	O
of	O
the	O
N-ras	O
gene	O
and	O
the	O
FLR	O
exon	O
of	O
codons	O
1371	O
-	O
1423	O
of	O
the	O
open	O
reading	O
frame	O
of	O
the	O
full-length	O
NF1	O
cDNA	O
,	O
which	O
has	O
a	O
strong	O
homology	O
with	O
the	O
mammalian	O
ras	O
GTPase	O
-	O
activating	O
protein	O
(	O
GAP	O
)	O
,	O
especially	O
for	O
a	O
stretch	O
of	O
three	O
consecutive	O
amino	O
acids	O
(	O
F	O
,	O
L	O
,	O
R	O
)	O
,	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
in	O
samples	O
from	O
patients	O
with	O
AML	B-malignancy-type
.	O
Of	O
48	O
AML	B-malignancy-type
patients	O
,	O
10	O
(	O
21	O
%	O
)	O
had	O
point	O
(	O
missense	O
)	O
mutations	O
of	O
the	O
N-ras	O
gene	O
involving	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
However	O
,	O
mutations	O
in	O
the	O
FLR	O
exon	O
of	O
the	O
NF1	O
gene	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
AML	B-malignancy-type
samples	O
.	O
We	O
also	O
examined	O
the	O
difference	O
of	O
clinical	O
response	O
to	O
induction	O
therapy	O
between	O
AML	B-malignancy-type
patients	O
with	O
and	O
without	O
N-ras	O
mutation	O
.	O
A	O
significantly	O
lower	O
rate	O
of	O
complete	O
remission	O
was	O
noted	O
in	O
individuals	O
with	O
N-ras	O
gene	O
mutations	O
.	O
These	O
results	O
suggest	O
that	O
mutation	O
of	O
the	O
NF1	O
gene	O
,	O
at	O
least	O
in	O
the	O
FLR	O
exon	O
,	O
is	O
very	O
rare	O
in	O
AML	B-malignancy-type
and	O
the	O
NF1	O
gene	O
probably	O
is	O
not	O
a	O
functional	O
complement	O
of	O
the	O
N-ras	O
gene	O
mutation	O
.	O
The	O
presence	O
of	O
N-ras	O
gene	O
mutation	O
may	O
be	O
associated	O
with	O
a	O
lower	O
clinical	O
response	O
to	O
antileukemic	O
therapy	O
.	O
PMID	O
:	O
8528106	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1996	O
May	O
;87(	O
5	O
)	O
:466	O
-	O
74	O
Detection	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
pancreatic	O
juice	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
by	O
hybridization	O
protection	O
assay	O
:	O
a	O
simple	O
method	O
for	O
the	O
determination	O
of	O
the	O
types	O
of	O
point	O
mutation	O
.	O
Watanabe	O
H	O
,	O
Miyagi	O
C	O
,	O
Yamaguchi	O
Y	O
,	O
Satomura	O
Y	O
,	O
Ohta	O
H	O
,	O
Motoo	O
Y	O
,	O
Okai	O
T	O
,	O
Yoshimura	O
T	O
,	O
Tsuji	O
Y	O
,	O
Sawabu	O
N.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
detect	O
K-ras	O
oncogene	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
by	O
the	O
hybridization	O
protection	O
assay	O
(	O
HPA	O
)	O
method	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
(	O
PC	B-malignancy-type
)	O
.	O
This	O
assay	O
can	O
be	O
carried	O
out	O
within	O
30	O
min	O
and	O
can	O
determine	O
not	O
only	O
the	O
presence	O
of	O
a	O
mutation	O
,	O
but	O
also	O
the	O
mutational	O
type	O
of	O
K-ras	O
at	O
codon	O
12	O
.	O
The	O
minimal	O
ratio	O
of	O
mutant	O
DNA	O
detectable	O
by	O
the	O
HPA	O
was	O
5	O
-	O
10	O
%	O
of	O
the	O
total	O
DNA	O
.	O
PPJ	O
was	O
collected	O
through	O
a	O
cannula	O
under	O
duodenal	O
fiberscope	O
control	O
from	O
20	O
patients	O
with	O
PC	B-malignancy-type
and	O
20	O
patients	O
with	O
chronic	O
pancreatitis	O
(	O
CP	O
)	O
.	O
Analysis	O
of	O
PPJ	O
by	O
the	O
HPA	O
revealed	O
that	O
the	O
incidence	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
was	O
55	O
%	O
(	O
11	O
/	O
20	O
)	O
in	O
patients	O
with	O
PC	B-malignancy-type
and	O
0	O
%	O
(	O
0	O
/	O
20	O
)	O
in	O
those	O
with	O
CP	O
.	O
Mutational	O
types	O
of	O
K-ras	O
at	O
codon	O
12	O
in	O
PC	B-malignancy-type
were	O
aspartic	O
acid	O
(	O
Asp	O
)	O
in	O
nine	O
cases	O
,	O
both	O
Asp	O
and	O
cysteine	O
in	O
one	O
case	O
,	O
and	O
arginine	O
in	O
one	O
case	O
.	O
Analysis	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
PPJ	O
using	O
the	O
HPA	O
method	O
seems	O
promising	O
as	O
a	O
new	O
genetic	O
test	O
for	O
the	O
diagnosis	O
of	O
PC	B-malignancy-type
,	O
because	O
the	O
HPA	O
method	O
is	O
simple	O
,	O
and	O
can	O
easily	O
determine	O
the	O
mutational	O
type	O
.	O
PMID	O
:	O
8641983	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Tongji	O
Med	O
Univ	O
1996;16(	O
1	O
)	O
:58	O
-	O
60	O
C-Ha-ras	O
oncogene	O
in	O
oral	B-malignancy-type
leukoplakia	I-malignancy-type
tissues	O
.	O
Cheng	O
P	O
,	O
Li	O
H	O
,	O
Yang	O
P	O
,	O
Tan	O
Y.	O
Department	O
of	O
Stomatology	O
,	O
Tongji	O
Hospital	O
,	O
Tongji	O
Medical	O
University	O
,	O
Wuhan	O
.	O
The	O
amplification	O
and	O
the	O
G	O
-	O
T	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
C-Ha-ras	O
oncogene	O
in	O
oral	B-malignancy-type
leukoplakia	I-malignancy-type
tissues	O
were	O
analyzed	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
molecular	O
biologic	O
technique	O
.	O
The	O
results	O
showed	O
that	O
these	O
tissues	O
had	O
no	O
amplification	O
of	O
Ha-ras	O
oncogene	O
.	O
Only	O
one	O
case	O
harbored	O
G	O
-	O
T	O
mutation	O
in	O
11	O
oral	B-malignancy-type
leukoplakias	I-malignancy-type
,	O
but	O
this	O
mutation	O
was	O
absent	O
in	O
10	O
normal	O
oral	O
mucosal	O
tissues	O
.	O
The	O
possible	O
role	O
and	O
significance	O
of	O
C-Ha-ras	O
oncogene	O
in	O
oral	B-malignancy-type
precancerous	I-malignancy-type
lesions	I-malignancy-type
were	O
also	O
discussed	O
.	O
PMID	O
:	O
8758750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1996	O
Mar;148(	O
3	O
)	O
:731	O
-	O
8	O
Single	O
somatic	O
ras	O
gene	O
point	O
mutation	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
.	O
Bohle	O
RM	O
,	O
Brettreich	O
S,	O
Repp	O
R,	O
Borkhardt	O
A	O
,	O
Kosmehl	O
H	O
,	O
Altmannsberger	O
HM	O
.	O
Institut	O
fur	O
Pathologie	O
,	O
Justus	O
-	O
Liebig	O
-	O
Universitat	O
Giessen	O
,	O
Germany	O
.	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
within	O
and	O
around	O
the	O
hot	O
spot	O
codons	O
(	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
of	O
all	O
ras	O
genes	O
,	O
(	O
H-ras-1	O
,	O
K-ras-2	O
,	O
and	O
N-ras	O
)	O
was	O
studied	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
DNA	O
sequencing	O
from	O
archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Light	O
microscopy	O
and	O
immunohistochemistry	O
served	O
to	O
define	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytoma	I-malignancy-type
.	O
All	O
of	O
the	O
four	O
differentiation	O
subtypes	O
(	O
storiform	B-malignancy-type
-	I-malignancy-type
pleomorphic	I-malignancy-type
,	O
inflammatory	B-malignancy-type
,	O
myxoid	B-malignancy-type
,	O
and	O
giant	B-malignancy-type
cell	I-malignancy-type
)	O
were	O
investigated	O
.	O
Nine	O
of	O
thirty-two	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
28	O
%	O
)	O
contained	O
ras	O
gene	O
point	O
mutations	O
.	O
The	O
highest	O
incidence	O
was	O
found	O
in	O
the	O
myxoid	B-malignancy-type
subtype	O
(	O
four	O
of	O
nine	O
)	O
.	O
H-ras-1	O
gene	O
codon	O
12.2	O
was	O
the	O
only	O
codon	O
affected	O
and	O
contained	O
in	O
all	O
mutated	O
cases	O
a	O
GGC	O
-->	O
GTC	O
exchange	O
.	O
Seven	O
of	O
the	O
nine	O
mutations	O
were	O
homozygous	O
and	O
probably	O
affected	O
more	O
than	O
80	O
%	O
of	O
the	O
tumor	O
DNA	O
.	O
The	O
flanking	O
regions	O
of	O
all	O
hotspot	O
codons	O
did	O
not	O
contain	O
any	O
point	O
mutation	O
.	O
The	O
presence	O
of	O
a	O
single	O
and	O
often	O
homozygous	O
point	O
mutation	O
of	O
the	O
H-ras-1	O
gene	O
,	O
especially	O
in	O
myxoid	B-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytoma	I-malignancy-type
could	O
serve	O
as	O
a	O
basis	O
for	O
further	O
genomic	O
discrimination	O
of	O
myxoid	B-malignancy-type
sarcomas	I-malignancy-type
.	O
PMID	O
:	O
8774129	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
1996	O
Nov-	O
Dec;16(	O
6B)	O
:3761	O
-	O
6	O
Concomitant	O
point	O
mutation	O
of	O
tumor	O
suppressor	O
gene	O
p53	O
and	O
oncogene	O
c-N-ras	O
in	O
malignant	B-malignancy-type
neuroendocrine	I-malignancy-type
pancreatic	I-malignancy-type
tumor	I-malignancy-type
.	O
Hrascan	O
R,	O
Pavelic	O
K	O
,	O
Pavicic	O
D	O
,	O
Krizanac	O
S,	O
Stajcer	O
-	O
Sittic	O
V	O
,	O
Pecur	O
L,	O
Spaventi	O
S,	O
Klimpfinger	O
M,	O
Pavelic	O
J.	O
Division	O
of	O
Molecular	O
Medicine	O
,	O
Ruder	O
Boskovic	O
Institute	O
,	O
Zagreb	O
,	O
Croatia	O
.	O
Activation	O
by	O
point	O
mutation	O
of	O
ras	O
family	O
genes	O
as	O
well	O
as	O
point	O
mutations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
are	O
found	O
in	O
many	O
tumors	O
.	O
Here	O
we	O
describe	O
a	O
rare	O
case	O
of	O
malignant	B-malignancy-type
neuroendocrine	I-malignancy-type
pancreatic	I-malignancy-type
tumor	I-malignancy-type
with	O
multiple	O
metastases	O
in	O
different	O
organs	O
showing	O
strong	O
positivity	O
for	O
synaptophysin	O
,	O
glucagon	O
-	O
like	O
peptide	O
1	O
,	O
pan-cytokeratin	O
,	O
moderate	O
positivity	O
for	O
chromogranin	O
,	O
Phe-5	O
and	O
calcitonin	O
and	O
weak	O
positivity	O
for	O
vasointestinal	O
peptide	O
.	O
We	O
found	O
a	O
point	O
mutation	O
at	O
codon	O
61	O
of	O
the	O
c-N-ras	O
oncogene	O
,	O
and	O
point	O
mutations	O
in	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
the	O
primary	O
tumor	O
as	O
well	O
as	O
in	O
its	O
metastases	B-malignancy-type
in	I-malignancy-type
liver	I-malignancy-type
.	O
The	O
mutation	O
in	O
the	O
c-N-ras	O
gene	O
was	O
a	O
cytosine	O
to	O
adenine	O
transversion	O
,	O
resulting	O
in	O
the	O
amino	O
-	O
acid	O
lysine	O
.	O
Allele	O
specific	O
hybridization	O
showed	O
that	O
the	O
mutation	O
involved	O
one	O
of	O
two	O
c-N-ras	O
alleles	O
as	O
the	O
oligonucleotide	O
for	O
the	O
normal	O
codon	O
also	O
hybridized	O
to	O
amplified	O
tumor	O
DNA	O
.	O
Concomitant	O
mutation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
at	O
codons	O
248	O
and	O
249	O
was	O
found	O
.	O
The	O
mutation	O
in	O
codon	O
248	O
was	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
resulting	O
in	O
the	O
amino	O
-	O
acid	O
glycine	O
.	O
The	O
mutation	O
in	O
codon	O
249	O
was	O
a	O
third	O
base	O
,	O
G	O
-	O
>	O
T	O
,	O
transversion	O
leading	O
to	O
a	O
change	O
from	O
arginine	O
to	O
serine	O
.	O
This	O
is	O
the	O
first	O
time	O
that	O
concomitant	O
point	O
mutations	O
in	O
c-N-ras	O
and	O
p53	O
have	O
been	O
found	O
in	O
a	O
neuroendocrine	B-malignancy-type
pancreatic	I-malignancy-type
tumor	I-malignancy-type
.	O
Based	O
upon	O
these	O
and	O
our	O
previous	O
results	O
,	O
we	O
concluded	O
that	O
these	O
genetic	O
changes	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
this	O
particular	O
pancreatic	B-malignancy-type
tumor	I-malignancy-type
.	O
PMID	O
:	O
9042254	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1997	O
Mar	O
21	O
;275(5307	O
)	O
:1787	O
-	O
90	O
Comment	O
in	O
:	O
Science	O
.	O
1997	O
Mar	O
21	O
;275(5307	O
)	O
:1752	O
-	O
3	O
.	O
Activation	O
of	O
beta-catenin	O
-	O
Tcf	O
signaling	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
by	O
mutations	O
in	O
beta-catenin	O
or	O
APC	O
.	O
Morin	O
PJ	O
,	O
Sparks	O
AB	O
,	O
Korinek	O
V	O
,	O
Barker	O
N	O
,	O
Clevers	O
H	O
,	O
Vogelstein	O
B	O
,	O
Kinzler	O
KW.	O
Howard	O
Hughes	O
Medical	O
Institute	O
and	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
424	O
North	O
Bond	O
Street	O
,	O
Baltimore	O
,	O
MD	O
21231	O
,	O
USA	O
.	O
Inactivation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
initiates	O
colorectal	B-malignancy-type
neoplasia	I-malignancy-type
.	O
One	O
of	O
the	O
biochemical	O
activities	O
associated	O
with	O
the	O
APC	O
protein	O
is	O
down	O
-	O
regulation	O
of	O
transcriptional	O
activation	O
mediated	O
by	O
beta-catenin	O
and	O
T	O
cell	O
transcription	O
factor	O
4	O
(	O
Tcf-4	O
)	O
.	O
The	O
protein	O
products	O
of	O
mutant	O
APC	O
genes	O
present	O
in	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
were	O
found	O
to	O
be	O
defective	O
in	O
this	O
activity	O
.	O
Furthermore	O
,	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
with	O
intact	O
APC	O
genes	O
were	O
found	O
to	O
contain	O
activating	O
mutations	O
of	O
beta-catenin	O
that	O
altered	O
functionally	O
significant	O
phosphorylation	O
sites	O
.	O
These	O
results	O
indicate	O
that	O
regulation	O
of	O
beta-catenin	O
is	O
critical	O
to	O
APC	O
's	O
tumor	O
suppressive	O
effect	O
and	O
that	O
this	O
regulation	O
can	O
be	O
circumvented	O
by	O
mutations	O
in	O
either	O
APC	O
or	O
beta-catenin	O
.	O
PMID	O
:	O
9065402	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1997	O
Apr;11	O
2	O
(	O
4	O
)	O
:	O
111	O
4-20	O
K-ras	O
mutations	O
are	O
found	O
in	O
DNA	O
extracted	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Anker	O
P,	O
Lefort	O
F	O
,	O
Vasioukhin	O
V	O
,	O
Lyautey	O
J,	O
Lederrey	O
C,	O
Chen	O
XQ	O
,	O
Stroun	O
M,	O
Mulcahy	O
HE	O
,	O
Farthing	O
MJ.	O
Departement	O
de	O
Biochimie	O
et	O
de	O
Physiologie	O
Vegetale	O
,	O
Universite	O
de	O
Geneve	O
,	O
Switzerland	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Circulating	O
DNA	O
can	O
be	O
isolated	O
from	O
the	O
plasma	O
of	O
healthy	O
subjects	O
and	O
from	O
patients	O
with	O
cancer	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
detect	O
K-ras	O
mutations	O
in	O
DNA	O
extracted	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
Tumor	O
and	O
plasma	O
DNA	O
were	O
extracted	O
from	O
14	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
(	O
stages	O
A	O
-	O
D	O
)	O
,	O
and	O
K-ras	O
alterations	O
were	O
detected	O
using	O
a	O
polymerase	O
chain	O
reaction	O
assay	O
that	O
uses	O
sequence	O
-	O
specific	O
primers	O
to	O
amplify	O
mutant	O
DNA	O
.	O
These	O
results	O
were	O
confirmed	O
with	O
another	O
polymerase	O
chain	O
reaction	O
assay	O
that	O
creates	O
an	O
enzyme	O
restriction	O
site	O
in	O
the	O
absence	O
of	O
a	O
K-ras	O
mutation	O
followed	O
by	O
direct	O
sequencing	O
and	O
additional	O
cloning	O
techniques	O
.	O
RESULTS	O
:	O
Seven	O
patients	O
(	O
50	O
%	O
)	O
had	O
a	O
codon	O
12	O
K-ras	O
mutation	O
within	O
their	O
primary	O
tumor	O
,	O
and	O
identical	O
mutations	O
were	O
found	O
in	O
the	O
plasma	O
DNA	O
of	O
6	O
patients	O
(	O
86	O
%	O
)	O
.	O
Mutant	O
DNA	O
was	O
not	O
detected	O
in	O
the	O
plasma	O
specimens	O
of	O
7	O
patients	O
whose	O
tumors	O
tested	O
negative	O
for	O
K-ras	O
alterations	O
or	O
in	O
healthy	O
control	O
subjects	O
.	O
Similar	O
results	O
were	O
obtained	O
using	O
all	O
three	O
molecular	O
biological	O
techniques	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
abnormalities	O
can	O
be	O
detected	O
in	O
circulating	O
DNA	O
extracted	O
from	O
the	O
plasma	O
specimens	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
If	O
these	O
results	O
are	O
confirmed	O
in	O
larger	O
studies	O
,	O
genetic	O
analysis	O
of	O
plasma	O
DNA	O
may	O
have	O
clinical	O
applications	O
in	O
the	O
future	O
.	O
PMID	O
:	O
9097993	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hua	O
Xi	O
Yi	O
Ke	O
Da	O
Xue	O
Xue	O
Bao	O
1996	O
Mar;2	O
7	O
(	O
1	O
)	O
:	O
5-9	O
[	O
Carcinogenic	O
mechanisms	O
of	O
multiple	O
genes	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
]	O
[Article	O
in	O
Chinese	O
]	O
Huang	O
G,	O
Xiao	O
X	O
,	O
Huang	O
Y	O
,	O
Huang	O
R.	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Chengdu	O
.	O
The	O
alterations	O
of	O
multiple	O
genes	O
and	O
their	O
carcinogenic	O
mechanism	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
were	O
studies	O
by	O
molecular	O
hybridisation	O
,	O
PCR	O
and	O
PCR	O
-	O
ASO	O
techniques	O
.	O
The	O
G	O
-	O
T	O
point	O
mutation	O
in	O
the	O
12th	O
coden	O
of	O
Ha-ras	O
was	O
detected	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
with	O
mutation	O
frequency	O
of	O
18.2	O
%	O
(	O
8	O
/	O
44	O
)	O
,	O
and	O
the	O
amplification	O
rate	O
of	O
Ha-ras	O
gene	O
was	O
45	O
%	O
(	O
9	O
/	O
20	O
)	O
.	O
The	O
c-erb	O
B2	O
was	O
amplified	O
3	O
-	O
30	O
fold	O
with	O
an	O
amplification	O
rate	O
of	O
73.3	O
%	O
(	O
11	O
/	O
15	O
)	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
and	O
5	O
cancerous	O
samples	O
showed	O
gene	O
rearrangement	O
.	O
The	O
elevated	O
copies	O
of	O
c-myc	O
gene	O
with	O
amplification	O
rate	O
of	O
91.7	O
%	O
(	O
11	O
/	O
12	O
)	O
were	O
observed	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
study	O
of	O
HPV16	O
viral	O
gene	O
showed	O
that	O
the	O
existence	O
of	O
HPV16	O
DNA	O
sequence	O
was	O
positively	O
associated	O
with	O
c-myc	O
gene	O
amplification	O
in	O
cervical	B-malignancy-type
cancerous	I-malignancy-type
samples	O
.	O
The	O
p53	O
and	O
Rb	O
tumor	O
suppressor	O
genes	O
absence	O
of	O
deletion	O
were	O
observed	O
in	O
the	O
12	O
specimens	O
of	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
investigated	O
.	O
As	O
mentioned	O
above	O
,	O
the	O
study	O
on	O
alteration	O
and	O
carcinogenic	O
mechanism	O
of	O
multiple	O
genes	O
indicated	O
that	O
3	O
oncogenes	O
and	O
HPV16	O
viral	O
gene	O
were	O
activated	O
or	O
integrated	O
throygh	O
different	O
mechanisms	O
and	O
they	O
played	O
roles	O
in	O
co	O
-	O
carcinogenesis	O
.	O
The	O
integration	O
of	O
HPV16	O
gene	O
might	O
promote	O
the	O
c-myc	O
gene	O
at	O
the	O
early	O
stage	O
in	O
carcinogenesis	O
of	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
,	O
while	O
the	O
alteration	O
of	O
Ha-ras	O
and	O
c-erb	O
B2	O
gene	O
might	O
be	O
middle	O
-	O
late	O
event	O
.	O
As	O
for	O
the	O
roles	O
of	O
the	O
p53	O
and	O
Rb	O
tumor	O
suppresor	O
gene	O
in	O
cervical	O
carcinogenesis	O
need	O
further	O
researches	O
.	O
PMID	O
:	O
9208611	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1997	O
Sep	O
16;94	O
(	O
19	O
)	O
:	O
1033	O
0-4	O
Beta-catenin	O
mutations	O
in	O
cell	O
lines	O
established	O
from	O
human	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
Ilyas	O
M,	O
Tomlinson	O
IP	O
,	O
Rowan	O
A	O
,	O
Pignatelli	O
M,	O
Bodmer	O
WF.	O
Cancer	O
Genetics	O
and	O
Immunology	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
Institute	O
of	O
Molecular	O
Medicine	O
,	O
John	O
Radcliffe	O
Hospital	O
,	O
Oxford	O
,	O
OX3	O
9DU	O
,	O
United	O
Kingdom	O
.	O
ilyas@europa.lif.icnet	O
.uk	O
beta-catenin	O
has	O
functions	O
as	O
both	O
an	O
adhesion	O
and	O
a	O
signaling	O
molecule	O
.	O
Disruption	O
of	O
these	O
functions	O
through	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
may	O
be	O
important	O
in	O
the	O
development	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
.	O
We	O
examined	O
the	O
entire	O
coding	O
sequence	O
of	O
beta-catenin	O
by	O
reverse	O
transcriptase	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
direct	O
sequencing	O
of	O
23	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
from	O
21	O
patients	O
.	O
In	O
two	O
cell	O
lines	O
,	O
there	O
was	O
apparent	O
instability	O
of	O
the	O
beta-catenin	O
mRNA	O
.	O
Five	O
different	O
mutations	O
(	O
26	O
%	O
)	O
were	O
found	O
in	O
the	O
remaining	O
21	O
cell	O
lines	O
(	O
from	O
19	O
patients	O
)	O
.	O
A	O
three	O
-	O
base	O
deletion	O
(	O
codon	O
45	O
)	O
was	O
identified	O
in	O
the	O
cell	O
line	O
HCT	O
116	O
,	O
whereas	O
cell	O
lines	O
SW	O
48	O
,	O
HCA	O
46	O
,	O
CACO	O
2	O
,	O
and	O
Colo	O
201	O
each	O
contained	O
single	O
-	O
base	O
missense	O
mutations	O
(	O
codons	O
33	O
,	O
183	O
,	O
245	O
,	O
and	O
287	O
,	O
respectively	O
)	O
.	O
All	O
23	O
cell	O
lines	O
had	O
full-length	O
beta-catenin	O
protein	O
that	O
was	O
detectable	O
by	O
Western	O
blotting	O
and	O
that	O
coprecipitated	O
with	O
E-cadherin	O
.	O
In	O
three	O
of	O
the	O
cell	O
lines	O
with	O
CTNNB1	O
mutations	O
,	O
complexes	O
of	O
beta-catenin	O
with	O
alpha-catenin	O
and	O
APC	O
were	O
detectable	O
.	O
In	O
SW48	O
and	O
HCA	O
46	O
,	O
however	O
,	O
we	O
did	O
not	O
detect	O
complexes	O
of	O
beta-catenin	O
protein	O
with	O
alpha-catenin	O
and	O
APC	O
,	O
respectively	O
.	O
These	O
results	O
show	O
that	O
selection	O
of	O
CTNNB1	O
mutations	O
occurs	O
in	O
up	O
to	O
26	O
%	O
of	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
from	O
which	O
cell	O
lines	O
are	O
derived	O
.	O
In	O
these	O
cases	O
,	O
mutation	O
selection	O
is	O
probably	O
for	O
altered	O
beta-catenin	O
function	O
,	O
which	O
may	O
significantly	O
alter	O
intracellular	O
signaling	O
and	O
intercellular	O
adhesion	O
and	O
may	O
serve	O
as	O
a	O
complement	O
to	O
APC	O
mutations	O
in	O
the	O
early	O
stages	O
of	O
tumorigenesis	O
.	O
PMID	O
:	O
9294210	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
1997	O
Oct;	O
6	O
(	O
10	O
)	O
:	O
84	O
1-7	O
Prognostic	O
value	O
of	O
specific	O
KRAS	O
mutations	O
in	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Siegfried	O
JM	O
,	O
Gillespie	O
AT	O
,	O
Mera	O
R	O
,	O
Casey	O
TJ	O
,	O
Keohavong	O
P,	O
Testa	O
JR	O
,	O
Hunt	O
JD.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Pittsburgh	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Pittsburgh	O
Cancer	O
Institute	O
,	O
Pennsylvania	O
15261	O
,	O
USA	O
.	O
Adenocarcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
remain	O
a	O
significant	O
public	O
health	O
problem	O
.	O
Locally	O
defined	O
(	O
stage	O
I	O
)	O
tumors	O
are	O
considered	O
amenable	O
to	O
resection	O
with	O
curative	O
intent	O
.	O
However	O
,	O
only	O
about	O
45	O
%	O
of	O
these	O
patients	O
survive	O
for	O
5	O
years	O
.	O
The	O
median	O
survival	O
for	O
more	O
advanced	O
tumors	O
is	O
drastically	O
lower	O
.	O
Much	O
research	O
has	O
been	O
focused	O
on	O
identifying	O
a	O
valid	O
genetic	O
biomarker	O
of	O
prognosis	O
.	O
Mutations	O
of	O
the	O
proto	O
-	O
oncogene	O
KRAS	O
have	O
been	O
identified	O
by	O
some	O
groups	O
as	O
being	O
a	O
valid	O
prognostic	O
indicator	O
for	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
To	O
evaluate	O
the	O
effect	O
of	O
KRAS	O
gene	O
mutation	O
on	O
the	O
survival	O
of	O
patients	O
with	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
181	O
archival	B-malignancy-type
tumors	I-malignancy-type
were	O
examined	O
by	O
PCR	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Mutations	O
in	O
either	O
codon	O
12	O
or	O
13	O
were	O
found	O
in	O
31.5	O
%	O
of	O
the	O
samples	O
.	O
The	O
most	O
common	O
mutation	O
was	O
a	O
G	O
-->	O
T	O
transversion	O
in	O
codon	O
12	O
,	O
representing	O
66.7	O
%	O
of	O
the	O
mutations	O
.	O
No	O
difference	O
was	O
observed	O
in	O
the	O
survival	O
of	O
patients	O
with	O
a	O
KRAS	O
mutation	O
versus	O
those	O
whose	O
tumors	O
contained	O
wild-type	O
KRAS	O
.	O
This	O
lack	O
of	O
difference	O
was	O
also	O
observed	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
those	O
with	O
stage	O
I	O
tumors	O
or	O
when	O
patients	O
with	O
stage	O
I	O
or	O
II	O
disease	O
were	O
grouped	O
together	O
.	O
However	O
,	O
certain	O
amino	O
acid	O
substitutions	O
,	O
including	O
cysteine	O
,	O
arginine	O
,	O
and	O
aspartate	O
,	O
indicated	O
a	O
significantly	O
poorer	O
prognosis	O
,	O
whereas	O
hydrophobic	O
amino	O
acid	O
substitutions	O
showed	O
a	O
significantly	O
better	O
prognosis	O
than	O
wild-type	O
(	O
P	O
=	O
0.04	O
)	O
.	O
Sample	O
sizes	O
were	O
small	O
for	O
this	O
analysis	O
due	O
to	O
the	O
number	O
of	O
possible	O
mutations	O
.	O
As	O
expected	O
,	O
the	O
stage	O
of	O
tumor	O
at	O
resection	O
was	O
the	O
most	O
significant	O
predictor	O
of	O
outcome	O
.	O
Based	O
on	O
this	O
study	O
of	O
181	O
patients	O
from	O
two	O
major	O
medical	O
centers	O
located	O
in	O
different	O
cities	O
,	O
we	O
conclude	O
that	O
KRAS	O
mutation	O
status	O
is	O
not	O
a	O
satisfactory	O
predictor	O
of	O
prognosis	O
in	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
but	O
the	O
substitution	O
of	O
a	O
polar	O
or	O
charged	O
amino	O
acid	O
for	O
the	O
wild-type	O
glycine	O
residue	O
may	O
be	O
a	O
negative	O
prognostic	O
indicator	O
.	O
PMID	O
:	O
9332768	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1997	O
Oct	O
15	O
;5	O
7	O
(20	O
)	O
:	O
447	O
8-81	O
Mutations	O
in	O
beta-catenin	O
are	O
uncommon	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
occurring	O
in	O
occasional	O
replication	O
error	O
-	O
positive	O
tumors	O
.	O
Kitaeva	O
MN	O
,	O
Grogan	O
L,	O
Williams	O
JP	O
,	O
Dimond	O
E	O
,	O
Nakahara	O
K,	O
Hausner	O
P,	O
DeNobile	O
JW,	O
Soballe	O
PW,	O
Kirsch	O
IR.	O
Genetics	O
Department	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
2088	O
9-5101	O
,	O
USA	O
.	O
Beta-catenin	O
has	O
been	O
identified	O
as	O
an	O
oncogene	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
and	O
melanoma	B-malignancy-type
.	O
Phosphorylation	O
of	O
sites	O
in	O
exon	O
3	O
of	O
beta-catenin	O
leads	O
to	O
degradation	O
of	O
this	O
protein	O
.	O
These	O
sites	O
are	O
primary	O
targets	O
for	O
activating	O
mutations	O
.	O
The	O
frequency	O
with	O
which	O
oncogenic	O
mutations	O
at	O
these	O
sites	O
are	O
found	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
is	O
unknown	O
,	O
as	O
is	O
the	O
frequency	O
of	O
their	O
occurrence	O
in	O
other	O
malignancies	O
.	O
We	O
analyzed	O
92	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
(	O
CRCs	B-malignancy-type
)	O
and	O
57	O
cancer	O
cell	O
lines	O
(	O
representing	O
a	O
diversity	O
of	O
tumor	O
types	O
)	O
to	O
determine	O
the	O
frequency	O
of	O
activating	O
mutations	O
in	O
this	O
gene	O
.	O
Mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
were	O
found	O
in	O
2	O
of	O
92	O
CRCs	O
and	O
in	O
the	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
HCT	O
116	O
.	O
Both	O
tumors	O
with	O
beta-catenin	O
mutations	O
exhibited	O
widespread	O
microsatellite	O
instability	O
,	O
which	O
is	O
indicative	O
of	O
a	O
replication	O
error	O
phenotype	O
,	O
a	O
phenotype	O
known	O
to	O
be	O
present	O
in	O
HCT	O
116	O
.	O
This	O
suggests	O
that	O
mutations	O
in	O
beta-catenin	O
are	O
infrequent	O
in	O
CRC	B-malignancy-type
and	O
miscellaneous	O
cancer	O
cell	O
lines	O
and	O
may	O
occur	O
in	O
association	O
with	O
a	O
replication	O
error	O
phenotype	O
.	O
PMID	O
:	O
9377556	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
1997	O
Sep;4	O
1	O
(	O
3	O
)	O
:	O
32	O
0-2	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
polyps	I-malignancy-type
,	O
dysplasia	B-malignancy-type
,	O
and	O
K-ras	O
codon	O
12	O
mutations	O
.	O
Entius	O
MM	O
,	O
Westerman	O
AM	O
,	O
Giardiello	O
FM	O
,	O
van	O
Velthuysen	O
ML	O
,	O
Polak	O
MM	O
,	O
Slebos	O
RJ	O
,	O
Wilson	O
JH,	O
Hamilton	O
SR	O
,	O
Offerhaus	O
GJ.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
BACKGROUND	O
:	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
syndrome	I-malignancy-type
(	O
PJS	B-malignancy-type
)	O
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
,	O
polyposis	B-malignancy-type
syndrome	I-malignancy-type
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
gastrointestinal	B-malignancy-type
and	O
extragastrointestinal	B-malignancy-type
malignancy	I-malignancy-type
.	O
Occasionally	O
dysplasia	B-malignancy-type
occurs	O
in	O
PJS	B-malignancy-type
polyps	I-malignancy-type
.	O
AIMS	O
:	O
In	O
colorectal	O
carcinomas	O
,	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
are	O
common	O
and	O
are	O
found	O
at	O
similar	O
frequency	O
in	O
precursor	B-malignancy-type
adenomas	I-malignancy-type
.	O
Therefore	O
,	O
K-ras	O
codon	O
12	O
point	O
mutations	O
in	O
PJS	B-malignancy-type
polyps	I-malignancy-type
,	O
were	O
evaluated	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Fifty	O
two	O
PJS	B-malignancy-type
polyps	I-malignancy-type
,	O
including	O
four	O
with	O
dysplasia	B-malignancy-type
,	O
collected	O
from	O
19	O
patients	O
with	O
PJS	B-malignancy-type
,	O
were	O
analysed	O
for	O
mutations	O
in	O
the	O
K-ras	O
codon	O
12	O
by	O
a	O
mutant	O
enriched	O
polymerase	O
chain	O
reaction	O
procedure	O
,	O
followed	O
by	O
allele	O
specific	O
oligodeoxynucleotide	O
hybridisation	O
.	O
RESULTS	O
:	O
A	O
K-ras	O
codon	O
12	O
mutation	O
was	O
identified	O
,	O
in	O
one	O
colonic	B-malignancy-type
polyp	I-malignancy-type
with	I-malignancy-type
dysplasia	I-malignancy-type
.	O
The	O
mutation	O
was	O
found	O
in	O
the	O
non	O
-	O
neoplasmic	O
epithelial	O
cells	O
and	O
not	O
in	O
the	O
dysplastic	O
component	O
of	O
the	O
polyp	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
K-ras	O
codon	O
12	O
point	O
mutations	O
are	O
very	O
rare	O
in	O
PJS	B-malignancy-type
polyps	I-malignancy-type
,	O
by	O
contrast	O
with	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
findings	O
support	O
previous	O
evidence	O
that	O
there	O
seems	O
to	O
be	O
no	O
intrinsic	O
relation	O
between	O
K-ras	O
codon	O
12	O
mutation	O
and	O
dysplasia	B-malignancy-type
.	O
PMID	O
:	O
9378385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1997	O
Dec;9	O
2	O
(	O
12	O
)	O
:	O
216	O
6-70	O
Comment	O
in	O
:	O
Am	O
J	O
Gastroenterol	O
.	O
1997	O
Dec;9	O
2	O
(	O
12	O
)	O
:	O
214	O
4-6	O
.	O
Detection	O
of	O
Ki-ras	O
mutations	O
by	O
PCR	O
and	O
differential	O
hybridization	O
and	O
of	O
p53	O
mutations	O
by	O
SSCP	O
analysis	O
in	O
endoscopically	O
obtained	O
lavage	O
solution	O
from	O
patients	O
with	O
long	B-malignancy-type
-	I-malignancy-type
standing	I-malignancy-type
ulcerative	I-malignancy-type
colitis	I-malignancy-type
.	O
Lang	O
SM	O
,	O
Heinzlmann	O
M,	O
Stratakis	O
DF	O
,	O
Teschauer	O
W	O
,	O
Loeschke	O
K.	O
Department	O
of	O
Gastroenterology	O
,	O
Medizinische	O
Klinik	O
,	O
Ludwi	O
g-Maximilians	O
Universitat	O
Munchen	O
,	O
Germany	O
.	O
OBJECTIVES	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
the	O
early	O
detection	O
of	O
malignant	O
transformation	O
in	O
patients	O
with	O
long	B-malignancy-type
-	I-malignancy-type
standing	I-malignancy-type
ulcerative	I-malignancy-type
colitis	I-malignancy-type
;	O
therefore	O
,	O
mutations	O
of	O
the	O
Ki-ras	O
and	O
p53	O
gene	O
were	O
analyzed	O
in	O
lavage	O
solution	O
and	O
biopsies	O
obtained	O
at	O
surveillance	O
colonoscopy	O
.	O
METHODS	O
:	O
DNA	O
was	O
isolated	O
from	O
14	O
patients	O
(	O
nine	O
female	O
,	O
five	O
male	O
)	O
with	O
a	O
history	O
of	O
pancolitis	O
for	O
more	O
than	O
10	O
yr	O
.	O
Exon	O
1	O
of	O
the	O
Ki-ras	O
gene	O
and	O
exons	O
5	O
-	O
8	O
of	O
the	O
p53	O
gene	O
were	O
amplified	O
via	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
of	O
the	O
p53	O
gene	O
were	O
detected	O
via	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
;	O
point	O
mutations	O
of	O
the	O
Ki-ras	O
gene	O
were	O
hybridized	O
on	O
dot	O
blots	O
with	O
oligonucleotides	O
marked	O
with	O
digoxigenin	O
.	O
RESULTS	O
:	O
Wild-type	O
Ki-ras	O
and	O
wild-type	O
p53	O
were	O
detected	O
in	O
all	O
cases	O
of	O
ulcerative	B-malignancy-type
colitis	I-malignancy-type
and	O
in	O
four	O
of	O
seven	O
control	O
patients	O
.	O
In	O
two	O
ulcerative	B-malignancy-type
colitis	I-malignancy-type
patients	O
,	O
a	O
mutation	O
was	O
found	O
in	O
the	O
Ki-ras	O
gene	O
(	O
Gly	O
-->	O
Asp	O
12	O
and	O
Gly	O
-->	O
Val	O
12	O
)	O
,	O
and	O
in	O
one	O
patient	O
,	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
the	O
p53	O
gene	O
.	O
Mutations	O
were	O
found	O
only	O
in	O
the	O
lavage	O
fluid	O
,	O
whereas	O
random	O
biopsies	O
were	O
negative	O
.	O
CONCLUSIONS	O
:	O
From	O
colonic	O
lavage	O
fluid	O
,	O
it	O
is	O
possible	O
to	O
extract	O
DNA	O
of	O
sufficient	O
quantity	O
and	O
quality	O
for	O
polymerase	O
chain	O
reaction	O
-	O
based	O
amplification	O
and	O
subsequent	O
analysis	O
via	O
single-strand	O
conformation	O
polymorphism	O
or	O
hybridization	O
.	O
Mutations	O
were	O
found	O
in	O
three	O
of	O
14	O
patients	O
with	O
long	B-malignancy-type
-	I-malignancy-type
standing	I-malignancy-type
ulcerative	I-malignancy-type
colitis	I-malignancy-type
but	O
were	O
not	O
found	O
in	O
controls	O
.	O
The	O
method	O
may	O
be	O
useful	O
for	O
the	O
screening	O
of	O
such	O
patients	O
.	O
PMID	O
:	O
9399746	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1998	O
Jan	O
23;27	O
9	O
(5350	O
)	O
:	O
57	O
7-80	O
Gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
c-kit	O
in	O
human	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	I-malignancy-type
Hirota	O
S	O
,	O
Isozaki	O
K,	O
Moriyama	O
Y	O
,	O
Hashimoto	O
K,	O
Nishida	O
T	O
,	O
Ishiguro	O
S	O
,	O
Kawano	O
K,	O
Hanada	O
M,	O
Kurata	O
A	O
,	O
Takeda	O
M,	O
Muhammad	O
Tunio	O
G,	O
Matsuzawa	O
Y	O
,	O
Kanakura	O
Y	O
,	O
Shinomura	O
Y	O
,	O
Kitamura	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Yamad	O
a	O
-oka	O
2-2	O
,	O
Suita	O
565	O
,	O
Japan	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
in	O
the	O
human	O
digestive	O
tract	O
,	O
but	O
their	O
molecular	O
etiology	O
and	O
cellular	O
origin	O
are	O
unknown	O
.	O
Sequencing	O
of	O
c-kit	O
complementary	O
DNA	O
,	O
which	O
encodes	O
a	O
proto	O
-	O
oncogenic	O
receptor	O
tyrosine	O
kinase	O
(	O
KIT	O
)	O
,	O
from	O
five	O
GISTs	B-malignancy-type
revealed	O
mutations	O
in	O
the	O
region	O
between	O
the	O
transmembrane	O
and	O
tyrosine	O
kinase	O
domains	O
.	O
All	O
of	O
the	O
corresponding	O
mutant	O
KIT	O
proteins	O
were	O
constitutively	O
activated	O
without	O
the	O
KIT	O
ligand	O
,	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O
Stable	O
transfection	O
of	O
the	O
mutant	O
c-kit	O
complementary	O
DNAs	O
induced	O
malignant	O
transformation	O
of	O
Ba	O
/	O
F3	O
murine	O
lymphoid	O
cells	O
,	O
suggesting	O
that	O
the	O
mutations	O
contribute	O
to	O
tumor	O
development	O
.	O
GISTs	B-malignancy-type
may	O
originate	O
from	O
the	O
interstitial	O
cells	O
of	O
Cajal	O
(	O
ICCs	O
)	O
because	O
the	O
development	O
of	O
ICCs	O
is	O
dependent	O
on	O
the	O
SCF	O
-	O
KIT	O
interaction	O
and	O
because	O
,	O
like	O
GISTs	B-malignancy-type
,	O
these	O
cells	O
express	O
both	O
KIT	O
and	O
CD34	O
.	O
PMID	O
:	O
9438854	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
1	O
;	O
58	O
(	O
5	O
)	O
:	O
896	O
-	O
9	O
Sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
contain	O
oncogenic	O
beta-catenin	O
mutations	O
.	O
Zurawel	O
RH	O
,	O
Chiappa	O
SA	O
,	O
Allen	O
C	O
,	O
Raffel	O
C.	O
Department	O
of	O
Neurosurgery	O
,	O
Mayo	O
Clinic	O
and	O
Foundation	O
,	O
Rochester	O
,	O
Minnesota	O
55905	O
,	O
USA	O
.	O
The	O
beta-catenin	O
,	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK-3beta	O
)	O
,	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
products	O
interact	O
to	O
form	O
a	O
network	O
that	O
influences	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
Medulloblastoma	B-malignancy-type
occurs	O
as	O
part	O
of	O
Turcot	O
's	O
syndrome	O
,	O
and	O
patients	O
with	O
Turcot	O
's	O
who	O
develop	O
medulloblastomas	B-malignancy-type
have	O
been	O
shown	O
to	O
harbor	O
germ	O
-	O
line	O
APC	O
mutations	O
.	O
Although	O
APC	O
mutations	O
have	O
been	O
investigated	O
and	O
not	O
identified	O
in	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
,	O
the	O
status	O
of	O
the	O
beta-catenin	O
and	O
GSK-3beta	O
genes	O
has	O
not	O
been	O
evaluated	O
in	O
this	O
tumor	O
.	O
Here	O
we	O
show	O
that	O
3	O
of	O
67	O
medulloblastomas	B-malignancy-type
harbor	O
beta-catenin	O
mutations	O
,	O
each	O
of	O
which	O
converts	O
a	O
GSK-3beta	O
phosphorylation	O
site	O
from	O
serine	O
to	O
cysteine	O
.	O
The	O
beta-catenin	O
mutation	O
seen	O
in	O
the	O
tumors	O
was	O
not	O
present	O
in	O
matched	O
constitutional	O
DNA	O
in	O
the	O
two	O
cases	O
where	O
matched	O
DNA	O
was	O
available	O
.	O
A	O
loss	O
of	O
heterozygosity	O
analysis	O
of	O
32	O
medulloblastomas	B-malignancy-type
with	O
paired	O
normal	O
DNA	O
samples	O
was	O
performed	O
with	O
four	O
microsatellite	O
markers	O
flanking	O
the	O
GSK-3beta	O
locus	O
;	O
loss	O
of	O
heterozygosity	O
with	O
at	O
least	O
one	O
marker	O
was	O
identified	O
in	O
7	O
tumors	O
.	O
Sequencing	O
of	O
the	O
remaining	O
GSK-3beta	O
allele	O
in	O
these	O
cases	O
failed	O
to	O
identify	O
any	O
mutations	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
medulloblastomas	B-malignancy-type
.	O
The	O
GSK-3beta	O
gene	O
does	O
not	O
appear	O
to	O
be	O
a	O
target	O
for	O
inactivation	O
in	O
this	O
tumor	O
.	O
PMID	O
:	O
9500446	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Histopathology	O
1998	O
Mar;	O
32	O
(	O
3	O
)	O
:	O
199	O
-	O
208	O
Immunoperoxidase	O
staining	O
for	O
cytokeratins	O
8	O
and	O
18	O
is	O
very	O
sensitive	O
for	O
detection	O
of	O
occult	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
of	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
:	O
a	O
comparison	O
with	O
genetic	O
analysis	O
of	O
K-ras	O
.	O
Sasaki	O
M	O
,	O
Watanabe	O
H	O
,	O
Jass	O
JR	O
,	O
Ajioka	O
Y	O
,	O
Kobayashi	O
M	O
,	O
Hatakeyama	O
K.	O
First	O
Department	O
of	O
Pathology	O
,	O
Niigata	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
AIMS	O
:	O
Recent	O
reports	O
suggest	O
that	O
genetic	O
examination	O
of	O
K-ras	O
or	O
p53	O
mutation	O
is	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
than	O
conventional	O
examination	O
by	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
staining	O
or	O
immunohistochemistry	O
for	O
gene	O
products	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
,	O
first	O
,	O
to	O
define	O
the	O
microscopic	O
characteristics	O
of	O
metastatic	O
cancer	O
cells	O
in	O
lymph	O
nodes	O
stained	O
by	O
the	O
anti	O
-	O
cytokeratin	O
antibody	O
CAM5.2	O
for	O
cytokeratins	O
8	O
and	O
18	O
,	O
and	O
,	O
second	O
,	O
to	O
compare	O
the	O
detection	O
rate	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
for	O
immunohistochemical	O
vs	O
genetic	O
methods	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
first	O
examined	O
in	O
primary	O
tumours	O
of	O
seven	O
cases	O
which	O
showed	O
distant	B-malignancy-type
metastasis	I-malignancy-type
or	O
local	O
recurrence	O
within	O
5	O
years	O
of	O
the	O
initial	O
surgery	O
in	O
spite	O
of	O
the	O
original	O
reporting	O
of	O
no	O
lymph	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
by	O
routine	O
H	O
&	O
E	O
staining	O
.	O
K-ras	O
mutations	O
were	O
positive	O
in	O
three	O
cases	O
in	O
primary	O
tumours	O
and	O
lymph	O
nodes	O
,	O
and	O
the	O
remaining	O
four	O
primary	O
tumours	O
were	O
negative	O
for	O
p53	O
mutation	O
as	O
well	O
as	O
K-ras	O
mutation	O
.	O
Therefore	O
,	O
genetic	O
analysis	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
was	O
uninformative	O
,	O
but	O
occult	B-malignancy-type
metastasis	I-malignancy-type
was	O
detected	O
by	O
cytokeratin	O
staining	O
in	O
two	O
of	O
these	O
four	O
cases	O
.	O
Comparative	O
study	O
of	O
cytokeratin	O
-	O
positive	O
cells	O
was	O
performed	O
on	O
each	O
of	O
the	O
43	O
lymph	O
nodes	O
from	O
three	O
cases	O
with	O
K-ras	O
mutations	O
.	O
Cancer	O
cells	O
were	O
detected	O
in	O
28	O
of	O
the	O
43	O
lymph	O
nodes	O
(	O
65.1	O
%	O
)	O
by	O
cytokeratin	O
staining	O
and	O
in	O
10	O
of	O
the	O
43	O
corresponding	O
lymph	O
nodes	O
(	O
23.3	O
%	O
)	O
by	O
genetic	O
analysis	O
.	O
Artefactual	O
contamination	O
by	O
cancer	O
cells	O
was	O
present	O
in	O
eight	O
of	O
the	O
28	O
cytokeratin	O
positive	O
lymph	O
nodes	O
,	O
and	O
three	O
of	O
the	O
eight	O
nodes	O
were	O
genetically	O
positive	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
cytokeratin	O
immunohistochemistry	O
is	O
more	O
sensitive	O
and	O
specific	O
for	O
the	O
detection	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
than	O
genetic	O
diagnosis	O
by	O
K-ras	O
mutation	O
in	O
cases	O
with	O
genetic	O
alterations	O
as	O
well	O
as	O
in	O
cases	O
without	O
them	O
.	O
PMID	O
:	O
9568504	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
1998	O
May	O
;	O
22	O
(	O
1	O
)	O
:	O
37	O
-	O
41	O
A	O
beta-catenin	O
mutation	O
in	O
a	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumor	I-malignancy-type
of	O
the	O
RER	O
phenotype	O
and	O
absence	O
of	O
beta-catenin	O
germline	O
mutations	O
in	O
FAP	B-malignancy-type
patients	O
.	O
Muller	O
O	O
,	O
Nimmrich	O
I	O
,	O
Finke	O
U	O
,	O
Friedl	O
W	O
,	O
Hoffmann	O
I	O
.	O
Arbeitsgruppe	O
Tumorgenetik	O
,	O
Abteilung	O
fur	O
Strukturelle	O
Biologie	O
,	O
Max	O
-	O
Planck	O
-	O
Institut	O
fur	O
molekulare	O
Physiologie	O
,	O
Dortmund	O
,	O
Germany	O
.	O
As	O
a	O
signaling	O
protein	O
in	O
the	O
Wnt	O
pathway	O
beta-catenin	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
proliferation	O
.	O
Recently	O
,	O
oncogenic	O
beta-catenin	O
mutations	O
were	O
described	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Since	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
have	O
similar	O
effects	O
on	O
the	O
biochemical	O
level	O
as	O
inactivating	O
mutations	O
in	O
the	O
tumor	O
suppressor	O
gene	O
APC	O
,	O
it	O
is	O
speculated	O
that	O
beta-catenin	O
mutations	O
may	O
substitute	O
APC	O
gene	O
inactivation	O
in	O
carcinogenesis	O
.	O
To	O
address	O
this	O
question	O
we	O
analyzed	O
twenty-three	O
sporadic	O
colorectal	O
tumors	O
of	O
different	O
progression	O
states	O
for	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Eighteen	O
of	O
these	O
tumors	O
showed	O
the	O
wildtype	O
APC	O
gene	O
sequence	O
.	O
In	O
only	O
one	O
of	O
the	O
tumors	O
with	O
wildtype	O
APC	O
a	O
beta-catenin	O
gene	O
mutation	O
was	O
found	O
.	O
This	O
tumor	O
was	O
of	O
the	O
RER	O
(	O
replication	O
error	O
)	O
phenotype	O
which	O
may	O
explain	O
the	O
finding	O
that	O
the	O
mutation	O
occurred	O
in	O
a	O
sequential	O
repeat	O
motif	O
of	O
the	O
beta-catenin	O
gene	O
.	O
The	O
second	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
differences	O
in	O
the	O
phenotypic	O
variability	O
in	O
FAP	B-malignancy-type
(	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
)	O
might	O
be	O
due	O
to	O
inherited	O
alterations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
For	O
this	O
we	O
analyzed	O
DNA	O
from	O
fourteen	O
FAP	B-malignancy-type
patients	O
from	O
eight	O
different	O
families	O
for	O
germline	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
We	O
did	O
not	O
find	O
any	O
beta-catenin	O
gene	O
alteration	O
in	O
these	O
samples	O
.	O
Our	O
results	O
indicate	O
that	O
somatic	O
beta-catenin	O
activating	O
mutations	O
contribute	O
only	O
to	O
a	O
minor	O
part	O
of	O
human	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
and	O
that	O
germline	O
beta-catenin	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
the	O
variability	O
of	O
symptoms	O
in	O
FAP	B-malignancy-type
.	O
PMID	O
:	O
9591632	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
1998	O
May;	O
77	O
(	O
10	O
)	O
:	O
1573	O
-	O
9	O
Analysis	O
of	O
p53	O
,	O
p16MTS	O
,	O
p21WAF1	O
and	O
H-ras	O
in	O
archived	B-malignancy-type
bladder	I-malignancy-type
tumours	I-malignancy-type
from	O
workers	O
exposed	O
to	O
aromatic	O
amines	O
.	O
Sorlie	O
T	O
,	O
Marte	O
l-Planche	O
G,	O
Hainaut	O
P,	O
Lewalter	O
J,	O
Holm	O
R	O
,	O
Borrese	O
n-Dale	O
AL	O
,	O
Montesano	O
R.	O
Department	O
of	O
Genetics	O
,	O
Institute	O
for	O
Cancer	O
Research	O
,	O
The	O
Norwegian	O
Radium	O
Hospital	O
,	O
Oslo	O
.	O
Exposure	O
to	O
aromatic	O
amines	O
is	O
considered	O
a	O
major	O
risk	O
factor	O
for	O
the	O
development	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
pattern	O
of	O
point	O
mutations	O
in	O
several	O
tumour	O
genes	O
in	O
21	O
cases	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
arising	O
among	O
western	O
European	O
workers	O
exposed	O
to	O
aromatic	O
amines	O
in	O
an	O
attempt	O
to	O
determine	O
whether	O
this	O
exposure	O
may	O
be	O
associated	O
with	O
a	O
unique	O
spectrum	O
of	O
mutations	O
.	O
Of	O
the	O
four	O
genes	O
analysed	O
(	O
p53	O
,	O
p16MTS1	O
,	O
p21WAF1	O
and	O
H-ras	O
)	O
,	O
only	O
p53	O
showed	O
a	O
high	O
frequency	O
of	O
mutations	O
(	O
in	O
8	O
out	O
of	O
21	O
cases	O
,	O
38	O
%	O
)	O
.	O
Two	O
mutations	O
were	O
found	O
in	O
p16	O
,	O
one	O
in	O
H-ras	O
and	O
none	O
in	O
p21	O
exon	O
3	O
.	O
All	O
mutations	O
were	O
at	O
G	O
:	O
C	O
base	O
pairs	O
,	O
mostly	O
at	O
non	O
-	O
CpG	O
residues	O
.	O
This	O
spectrum	O
of	O
mutations	O
,	O
which	O
is	O
highly	O
suggestive	O
of	O
an	O
involvement	O
of	O
exogenous	O
carcinogens	O
,	O
is	O
however	O
identical	O
to	O
the	O
spectrum	O
of	O
p53	O
mutations	O
detected	O
in	O
bladder	B-malignancy-type
cancers	I-malignancy-type
of	O
the	O
general	O
population	O
.	O
In	O
exposed	O
workers	O
,	O
p53	O
mutations	O
were	O
associated	O
with	O
tumour	O
grade	O
and	O
with	O
high	O
occupational	O
and	O
tobacco	O
exposure	O
.	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
the	O
same	O
carcinogens	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
bladder	B-malignancy-type
cancers	I-malignancy-type
in	O
workers	O
exposed	O
to	O
aromatic	O
amines	O
and	O
in	O
the	O
general	O
population	O
.	O
PMID	O
:	O
9635831	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Histopathology	O
1998	O
May;	O
32	O
(	O
5	O
)	O
:	O
444	O
-	O
8	O
Clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
:	O
an	O
adenocarcinoma	B-malignancy-type
with	I-malignancy-type
ductal	I-malignancy-type
phenotype	I-malignancy-type
.	O
Luttges	O
J,	O
Vogel	O
I	O
,	O
Menke	O
M,	O
Henn	O
e-Bruns	O
D	O
,	O
Kremer	O
B	O
,	O
Kloppel	O
G.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Kiel	O
,	O
Germany	O
.	O
AIMS	O
:	O
Primary	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
resembling	O
metastatic	B-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
has	O
only	O
rarely	O
been	O
described	O
.	O
To	O
date	O
it	O
has	O
been	O
poorly	O
characterized	O
as	O
a	O
distinct	O
tumour	O
entity	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
report	O
a	O
case	O
of	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
in	O
a	O
53	O
-	O
year	O
-	O
old	O
man	O
involving	O
the	O
head	O
of	O
the	O
pancreas	O
and	O
which	O
had	O
a	O
small	O
intraductal	O
papillary	O
component	O
.	O
The	O
clear	O
cell	O
portion	O
comprised	O
about	O
90	O
%	O
of	O
the	O
tumour	O
mass	O
.	O
It	O
showed	O
predominantly	O
a	O
solid	O
growth	O
pattern	O
with	O
a	O
few	O
scattered	O
tubular	O
structures	O
.	O
Immunocytochemically	O
the	O
tumour	O
cells	O
stained	O
positively	O
for	O
cytokeratins	O
7	O
,	O
8	O
,	O
18	O
and	O
19	O
,	O
whereas	O
the	O
reaction	O
for	O
vimentin	O
and	O
neuroendocrine	O
markers	O
was	O
negative	O
.	O
K-ras	O
analysis	O
revealed	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
with	O
mutation	O
of	O
GGT	O
to	O
GAT	O
.	O
CONCLUSION	O
:	O
The	O
intraductal	O
tumour	O
component	O
of	O
this	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
as	O
well	O
as	O
the	O
cytokeratin	O
pattern	O
and	O
the	O
K-ras	O
mutation	O
suggest	O
that	O
this	O
rare	O
type	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
has	O
a	O
ductal	O
phenotype	O
.	O
PMID	O
:	O
9639120	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Gastroenterol	O
1998	O
Jun;3	O
3	O
(	O
3	O
)	O
:	O
39	O
7-401	O
Primary	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
small	I-malignancy-type
intestine	I-malignancy-type
and	O
mutational	O
analysis	O
of	O
the	O
K-ras	O
and	O
p53	O
genes	O
.	O
Amano	O
M,	O
Imai	O
Y	O
,	O
Hashimoto	O
T	O
,	O
Saito	O
Y	O
,	O
Miyaoka	O
M,	O
Kawaguchi	O
M,	O
Saito	O
T.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Hokuso	O
Shiroi	O
Hospital	O
,	O
Chiba	O
,	O
Japan	O
.	O
A	O
69	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
Hokuso	O
Shiroi	O
Hospital	O
because	O
of	O
recurrent	O
pain	O
in	O
the	O
lower	O
right	O
side	O
of	O
the	O
abdomen	O
.	O
Small	B-malignancy-type
-	I-malignancy-type
intestinal	I-malignancy-type
cancer	I-malignancy-type
was	O
strongly	O
suspected	O
after	O
fluoroscopy	O
of	O
the	O
small	O
intestine	O
.	O
Laparotomy	O
showed	O
advanced	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ileum	I-malignancy-type
,	I-malignancy-type
of	I-malignancy-type
complete	I-malignancy-type
annular	I-malignancy-type
constrictive	I-malignancy-type
type	I-malignancy-type
,	O
9.5	O
x	O
5	O
cm	O
in	O
size	O
.	O
Histologically	O
it	O
was	O
moderately	B-malignancy-type
differentiated	I-malignancy-type
tubular	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Neither	O
visceral	O
nor	O
nodal	O
metastases	O
were	O
found	O
,	O
and	O
the	O
patient	O
has	O
been	O
well	O
for	O
the	O
20	O
months	O
since	O
surgery	O
.	O
The	O
strong	O
resemblance	O
between	O
the	O
epidemiological	O
characteristics	O
of	O
small	B-malignancy-type
-	I-malignancy-type
intestinal	I-malignancy-type
cancers	I-malignancy-type
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
prompted	O
us	O
to	O
investigate	O
the	O
carcinogenetic	O
mechanisms	O
at	O
the	O
molecular	O
level	O
.	O
A	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
was	O
found	O
,	O
while	O
no	O
alterations	O
were	O
noted	O
in	O
the	O
p53	O
gene	O
,	O
whose	O
mutations	O
are	O
frequent	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
carcinogenetic	O
mechanisms	O
of	O
the	O
small	B-malignancy-type
-	I-malignancy-type
intestinal	I-malignancy-type
cancer	I-malignancy-type
we	O
experienced	O
may	O
thus	O
differ	O
from	O
those	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
9658320	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1998	O
Jul	O
21;95	O
(	O
15	O
)	O
:	O
884	O
7-51	O
Somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
frequent	O
in	O
mouse	O
and	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
de	O
La	O
Coste	O
A	O
,	O
Romagnolo	O
B	O
,	O
Billuart	O
P,	O
Renard	O
CA	O
,	O
Buendia	O
MA	O
,	O
Soubrane	O
O,	O
Fabre	O
M,	O
Chelly	O
J,	O
Beldjord	O
C,	O
Kahn	O
A	O
,	O
Perret	O
C.	O
Institut	O
National	O
de	O
la	O
Sante	O
et	O
de	O
la	O
Recherche	O
Medicale	O
U129	O
,	O
Institut	O
Cochin	O
de	O
Genetique	O
Moleculaire	O
,	O
Universite	O
Paris	O
V	O
Rene	O
Descartes	O
,	O
24	O
rue	O
du	O
Faubourg	O
Sain	O
t-Jacques	O
,	O
75014	O
Paris	O
,	O
France	O
.	O
Hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
is	O
the	O
major	O
primary	O
malignant	O
tumor	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
liver	I-malignancy-type
,	O
but	O
the	O
molecular	O
changes	O
leading	O
to	O
liver	O
cell	O
transformation	O
remain	O
largely	O
unknown	O
.	O
The	O
Wnt	O
-	O
beta-catenin	O
pathway	O
is	O
activated	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
and	O
some	O
melanoma	B-malignancy-type
cell	O
lines	O
,	O
but	O
has	O
not	O
yet	O
been	O
investigated	O
in	O
HCC	B-malignancy-type
.	O
We	O
have	O
examined	O
the	O
status	O
of	O
the	O
beta-catenin	O
gene	O
in	O
different	O
transgenic	O
mouse	O
lines	O
of	O
HCC	B-malignancy-type
obtained	O
with	O
the	O
oncogenes	O
c-myc	O
or	O
H-ras	O
.	O
Fifty	O
percent	O
of	O
the	O
hepatic	B-malignancy-type
tumors	I-malignancy-type
in	O
these	O
transgenic	O
mice	O
had	O
activating	O
somatic	O
mutations	O
within	O
the	O
beta-catenin	O
gene	O
similar	O
to	O
those	O
found	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
and	O
melanomas	B-malignancy-type
.	O
These	O
alterations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
point	O
mutations	O
or	O
deletions	O
)	O
lead	O
to	O
a	O
disregulation	O
of	O
the	O
signaling	O
function	O
of	O
beta-catenin	O
and	O
thus	O
to	O
carcinogenesis	O
.	O
We	O
then	O
analyzed	O
human	O
HCCs	B-malignancy-type
and	O
found	O
similar	O
mutations	O
in	O
eight	O
of	O
31	O
(	O
26	O
%	O
)	O
human	O
liver	B-malignancy-type
tumors	I-malignancy-type
tested	O
and	O
in	O
HepG2	O
and	O
HuH6	O
hepatoma	B-malignancy-type
cells	O
.	O
The	O
mutations	O
led	O
to	O
the	O
accumulation	O
of	O
beta-catenin	O
in	O
the	O
nucleus	O
.	O
Thus	O
alterations	O
in	O
the	O
beta-catenin	O
gene	O
frequently	O
are	O
selected	O
for	O
during	O
liver	O
tumorigenesis	O
and	O
suggest	O
that	O
disregulation	O
of	O
the	O
Wnt	O
-	O
beta-catenin	O
pathway	O
is	O
a	O
major	O
event	O
in	O
the	O
development	O
of	O
HCC	B-malignancy-type
in	O
humans	O
and	O
mice	O
.	O
PMID	O
:	O
9671767	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1998	O
Jul;2	O
2	O
(	O
7	O
)	O
:	O
63	O
1-7	O
Significance	O
of	O
chromosomal	O
alterations	O
and	O
mutations	O
of	O
the	O
N-RAS	O
and	O
TP53	O
genes	O
in	O
relation	O
to	O
leukemogenesis	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Misawa	O
S	O
,	O
Horiike	O
S	O
,	O
Kaneko	O
H,	O
Sasai	O
Y	O
,	O
Ueda	O
Y	O
,	O
Nakao	O
M,	O
Yokota	O
S	O
,	O
Taniwaki	O
M,	O
Fujii	O
H,	O
Nakagawa	O
H,	O
Tsuda	O
S	O
,	O
Kashima	O
K.	O
Division	O
of	O
Hematology	O
,	O
Kyoto	O
Prefectural	O
Yosanoumi	O
Hospital	O
,	O
Japan	O
.	O
We	O
examined	O
chromosomes	O
and	O
mutations	O
of	O
the	O
N-RAS	O
and	O
TP53	O
genes	O
in	O
73	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Twenty-six	O
patients	O
showed	O
a	O
reciprocal	O
chromosomal	O
translocation	O
or	O
an	O
inversion	O
,	O
and	O
34	O
patients	O
showed	O
only	O
unbalanced	O
aberrations	O
.	O
Balanced	O
aberrations	O
were	O
predominantly	O
detected	O
in	O
the	O
AML	B-malignancy-type
patients	O
who	O
did	O
not	O
have	O
myelodysplasia	B-malignancy-type
,	O
preceding	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
,	O
and	O
a	O
history	O
of	O
chemotherapy	O
or	O
radiation	O
therapy	O
.	O
In	O
contrast	O
,	O
unbalanced	O
aberrations	O
were	O
more	O
frequently	O
seen	O
in	O
the	O
patients	O
with	O
AML	B-malignancy-type
with	O
trilineage	B-malignancy-type
myelodysplasia	I-malignancy-type
,	O
AML	B-malignancy-type
transformed	O
from	O
MDS	B-malignancy-type
,	O
and	O
therapy	O
-	O
related	O
AML	B-malignancy-type
.	O
Twenty-two	O
mutations	O
of	O
the	O
N-RAS	O
and	O
TP53	O
genes	O
were	O
detected	O
,	O
and	O
these	O
mutations	O
were	O
frequently	O
associated	O
with	O
unbalanced	O
chromosomal	O
aberrations	O
.	O
Furthermore	O
,	O
the	O
spectrum	O
of	O
mutations	O
was	O
suggestive	O
of	O
an	O
exposure	O
to	O
alkylating	O
chemicals	O
.	O
PMID	O
:	O
9680114	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
1998	O
Ju	O
l-Aug;1	O
8	O
(4A)	O
:	O
267	O
5-8	O
Low-frequency	O
mutation	O
of	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
.	O
Olderoy	O
G,	O
Daehlin	O
L,	O
Ogreid	O
D.	O
Center	O
for	O
Molecular	O
Medicine	O
,	O
Haukeland	O
Hospital	O
,	O
Bergen	O
,	O
Norway	O
.	O
BACKGROUND	O
,	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
objective	O
was	O
to	O
study	O
the	O
frequency	O
of	O
mutations	O
of	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
in	O
bladder	B-malignancy-type
tumours	I-malignancy-type
.	O
Transitional	B-malignancy-type
cell	I-malignancy-type
tumours	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
from	O
55	O
patients	O
were	O
subjected	O
to	O
analyses	O
of	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
using	O
a	O
variety	O
of	O
techniques	O
including	O
sequencing	O
to	O
detect	O
mutations	O
.	O
RESULTS	O
:	O
Two	O
tumours	O
(	O
4	O
%	O
)	O
exhibited	O
mutation	O
of	O
the	O
Ki-ras	O
oncogene	O
,	O
both	O
tumours	O
were	O
fast	O
growing	O
and	O
invasive	O
.	O
We	O
did	O
not	O
detect	O
Ha-ras	O
mutation	O
in	O
any	O
of	O
the	O
samples	O
.	O
Nineteen	O
tumours	O
(	O
35	O
%	O
)	O
with	O
established	O
invasion	O
of	O
the	O
detrusor	O
muscle	O
,	O
did	O
not	O
reveal	O
any	O
mutation	O
.	O
CONCLUSION	O
:	O
Analyses	O
of	O
ras	O
oncogenes	O
seem	O
to	O
be	O
of	O
limited	O
value	O
for	O
the	O
biological	O
assessment	O
of	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9703927	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Feb;9	O
0	O
(	O
2	O
)	O
:	O
20	O
5-9	O
Frequent	O
beta-catenin	O
abnormalities	O
in	O
bone	B-malignancy-type
and	O
soft-tissue	B-malignancy-type
tumors	I-malignancy-type
.	O
Iwao	O
K,	O
Miyoshi	O
Y	O
,	O
Nawa	O
G,	O
Yoshikawa	O
H,	O
Ochi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
.	O
We	O
have	O
screened	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
method	O
in	O
62	O
malignant	O
bone	B-malignancy-type
and	O
soft-tissue	B-malignancy-type
tumors	I-malignancy-type
,	O
including	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFHs	B-malignancy-type
)	O
,	O
osteosarcomas	O
,	O
synovial	O
sarcomas	O
,	O
liposarcomas	B-malignancy-type
,	O
malignant	B-malignancy-type
schwannomas	I-malignancy-type
,	O
and	O
other	O
types	O
of	O
tumors	O
,	O
as	O
well	O
as	O
11	O
benign	O
tumors	O
.	O
beta-Catenin	O
-	O
activating	O
missense	O
mutations	O
were	O
found	O
in	O
two	O
malignant	O
tumors	O
.	O
One	O
found	O
in	O
MFH	B-malignancy-type
occurred	O
at	O
codon	O
45	O
and	O
caused	O
an	O
amino	O
acid	O
substitution	O
from	O
serine	O
(	O
one	O
of	O
the	O
GSK3	O
beta	O
-	O
targeted	O
phosphorylation	O
sites	O
)	O
to	O
phenylalanine	O
.	O
The	O
other	O
,	O
detected	O
in	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
at	O
codon	O
32	O
,	O
resulted	O
in	O
an	O
amino	O
acid	O
change	O
from	O
aspartic	O
acid	O
(	O
located	O
adjacent	O
to	O
the	O
phosphorylation	O
target	O
,	O
serine	O
,	O
encoded	O
by	O
codon	O
33	O
)	O
to	O
tyrosine	O
.	O
Furthermore	O
,	O
we	O
found	O
accumulation	O
of	O
beta-catenin	O
by	O
western	O
-	O
blotting	O
analysis	O
in	O
12	O
of	O
19	O
malignant	O
tumors	O
in	O
which	O
we	O
found	O
no	O
mutation	O
involving	O
exon	O
3	O
.	O
Our	O
results	O
suggested	O
the	O
possible	O
involvement	O
of	O
beta-catenin	O
activation	O
,	O
by	O
beta-catenin	O
gene	O
mutation	O
or	O
alteration	O
of	O
other	O
factor(s)	O
,	O
in	O
the	O
formation	O
and/or	O
progression	O
of	O
various	O
types	O
of	O
bone	B-malignancy-type
and	O
soft-tissue	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
10189891	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Feb;9	O
0	O
(	O
2	O
)	O
:	O
24	O
0-8	O
K-ras	O
point	O
mutations	O
in	O
the	O
supernatants	O
of	O
pancreatic	O
juice	O
and	O
bile	O
are	O
reliable	O
for	O
diagnosis	O
of	O
pancreas	B-malignancy-type
and	O
biliary	B-malignancy-type
tract	I-malignancy-type
carcinomas	I-malignancy-type
complementary	O
to	O
cytologic	O
examination	O
.	O
Yamashita	O
K,	O
Kida	O
Y	O
,	O
Shinoda	O
H,	O
Kida	O
M,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
East	O
Hospital	O
,	O
Kanagawa	O
.	O
In	O
order	O
to	O
clarify	O
whether	O
DNA	O
analysis	O
for	O
K-ras	O
mutation	O
can	O
be	O
used	O
to	O
diagnose	O
cancers	O
in	O
supernatants	O
of	O
pancreatic	O
juice	O
and	O
bile	O
,	O
samples	O
from	O
29	O
cases	O
of	O
pancreatic	B-malignancy-type
,	O
biliary	B-malignancy-type
tract	I-malignancy-type
,	O
gastric	B-malignancy-type
,	O
and	O
neuroendocrine	B-malignancy-type
carcinomas	I-malignancy-type
,	O
1	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
case	O
,	O
2	O
cases	O
of	O
pancreatic	B-malignancy-type
adenoma	I-malignancy-type
,	O
9	O
cases	O
of	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
21	O
other	O
non	O
-	O
cancer	O
cases	O
were	O
examined	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
for	O
K-ras	O
gene	O
codons	O
2	O
to	O
97	O
of	O
exons	O
1	O
and	O
2	O
were	O
generated	O
with	O
33	O
/	O
33	O
(	O
100	O
%	O
)	O
pancreatic	O
juice	O
and	O
41	O
/	O
41	O
(	O
100	O
%	O
)	O
bile	O
samples	O
.	O
By	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
method	O
,	O
point	O
mutations	O
were	O
detected	O
in	O
the	O
pancreatic	O
juice	O
or	O
bile	O
supernatants	O
of	O
13	O
/	O
13	O
(	O
100	O
%	O
)	O
pancreas	B-malignancy-type
cancer	I-malignancy-type
cases	O
,	O
5	O
/	O
14	O
(	O
35.7	O
%	O
)	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
cases	O
,	O
1	O
/	O
2	O
(	O
50.0	O
%	O
)	O
pancreatic	B-malignancy-type
adenoma	I-malignancy-type
cases	O
and	O
3	O
/	O
9	O
(	O
33.3	O
%	O
)	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
cases	O
.	O
Direct	O
sequencing	O
confirmed	O
identical	O
point	O
mutations	O
in	O
the	O
supernatants	O
,	O
malignant	O
cells	O
of	O
cytologic	O
smears	O
of	O
pancreatic	O
juice	O
or	O
bile	O
and	O
cancer	O
tissues	O
.	O
The	O
DNA	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
K-ras	O
point	O
mutations	O
in	O
3	O
cases	O
of	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
with	O
false-negative	O
cytologic	O
diagnoses	O
.	O
This	O
novel	O
method	O
allows	O
simultaneous	O
testing	O
for	O
genetic	O
abnormalities	O
in	O
supernatants	O
of	O
pancreatic	O
juice	O
and	O
bile	O
,	O
after	O
removing	O
cells	O
for	O
cytologic	O
diagnosis	O
and	O
screening	O
for	O
pancreatic	B-malignancy-type
and	O
biliary	B-malignancy-type
tract	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
10189896	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
1999	O
Apr;	O
8	O
(	O
4	O
Pt	O
1	O
)	O
:	O
29	O
7-302	O
Erratum	O
in	O
:	O
Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2001	O
Dec;1	O
0	O
(	O
12	O
)	O
:	O
1309	O
Comparison	O
of	O
mutations	O
in	O
the	O
p53	O
and	O
K-ras	O
genes	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
smoking	O
and	O
nonsmoking	O
women	O
.	O
Gealy	O
R	O
,	O
Zhang	O
L,	O
Siegfried	O
JM	O
,	O
Luketich	O
JD	O
,	O
Keohavong	O
P.	O
Department	O
of	O
Environmental	O
and	O
Occupational	O
Health	O
,	O
University	O
of	O
Pittsburgh	O
,	O
Pennsylvania	O
,	O
USA	O
.	O
Lung	B-malignancy-type
cancer	I-malignancy-type
incidence	O
is	O
increasing	O
in	O
women	O
with	O
little	O
or	O
no	O
tobacco	O
exposure	O
,	O
and	O
the	O
cause	O
of	O
this	O
trend	O
is	O
not	O
known	O
.	O
One	O
possibility	O
is	O
increased	O
sensitivity	O
to	O
environmental	O
tobacco	O
smoke	O
in	O
women	O
nonsmokers	O
diagnosed	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
To	O
determine	O
whether	O
mutations	O
associated	O
with	O
tobacco	O
exposure	O
are	O
found	O
in	O
the	O
lung	B-malignancy-type
tumors	I-malignancy-type
of	O
women	O
who	O
are	O
lifetime	O
nonsmokers	O
or	O
occasional	O
smokers	O
,	O
we	O
compared	O
the	O
p53	O
and	O
K-ras	O
mutational	O
spectra	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
23	O
female	O
nonsmokers	O
,	O
2	O
female	O
occasional	O
smokers	O
(	O
<	O
10	O
pack	O
-	O
years	O
)	O
,	O
and	O
30	O
female	O
long-term	O
smokers	O
(	O
20	O
-	O
100	O
pack	O
-	O
years	O
)	O
.	O
We	O
also	O
looked	O
for	O
p53	O
and	O
K-ras	O
mutations	O
in	O
three	O
carcinoid	B-malignancy-type
lung	I-malignancy-type
tumors	I-malignancy-type
,	O
two	O
from	O
female	O
nonsmokers	O
and	O
one	O
from	O
a	O
female	O
occasional	O
smoker	O
.	O
For	O
the	O
p53	O
gene	O
,	O
exons	O
4	O
-	O
8	O
were	O
examined	O
for	O
mutations	O
;	O
for	O
the	O
K-ras	O
gene	O
,	O
exon	O
1	O
was	O
examined	O
.	O
No	O
mutations	O
were	O
found	O
in	O
the	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
.	O
In	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
,	O
p53	O
mutations	O
were	O
identified	O
in	O
six	O
(	O
26.1	O
%	O
)	O
of	O
the	O
cases	O
from	O
lifetime	O
nonsmokers	O
and	O
consisted	O
of	O
five	O
transitions	O
(	O
including	O
three	O
C	O
to	O
T	O
,	O
one	O
G	O
to	O
A	O
,	O
and	O
one	O
T	O
to	O
C	O
)	O
and	O
one	O
T	O
to	O
A	O
transversion	O
.	O
In	O
comparison	O
,	O
p53	O
mutations	O
were	O
identified	O
in	O
10	O
(	O
31.3	O
%	O
)	O
of	O
the	O
32	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
short-term	O
and	O
long-term	O
smokers	O
and	O
consisted	O
of	O
six	O
transversions	O
(	O
four	O
G	O
to	O
T	O
,	O
one	O
A	O
to	O
T	O
,	O
and	O
one	O
G	O
to	O
C	O
)	O
,	O
one	O
A	O
to	O
G	O
transition	O
,	O
one	O
C	O
to	O
T	O
transition	O
,	O
and	O
two	O
deletions	O
of	O
one	O
to	O
four	O
bp	O
.	O
Mutations	O
in	O
the	O
p53	O
gene	O
found	O
in	O
nonsmokers	O
also	O
occurred	O
in	O
either	O
different	O
codons	O
or	O
different	O
positions	O
within	O
a	O
codon	O
compared	O
with	O
those	O
seen	O
in	O
long-term	O
smokers	O
.	O
K-ras	O
mutations	O
in	O
codon	O
12	O
were	O
identified	O
in	O
two	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
(	O
8.7	O
%	O
)	O
from	O
lifetime	O
nonsmokers	O
.	O
The	O
K-ras	O
mutations	O
found	O
were	O
a	O
G	O
to	O
T	O
transversion	O
and	O
a	O
G	O
to	O
A	O
transition	O
.	O
Eight	O
(	O
25	O
%	O
)	O
of	O
the	O
32	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
smokers	O
contained	O
K-ras	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
(	O
four	O
G	O
to	O
T	O
transversions	O
and	O
four	O
G	O
to	O
A	O
transitions	O
)	O
.	O
In	O
addition	O
,	O
six	O
silent	O
mutations	O
that	O
are	O
most	O
likely	O
polymorphisms	O
were	O
found	O
in	O
both	O
smokers	O
and	O
nonsmokers	O
.	O
These	O
results	O
confirm	O
that	O
K-ras	O
mutations	O
are	O
more	O
frequent	O
in	O
smokers	O
than	O
in	O
nonsmokers	O
,	O
but	O
that	O
the	O
same	O
type	O
of	O
mutation	O
in	O
the	O
K-ras	O
gene	O
is	O
found	O
in	O
both	O
groups	O
.	O
In	O
contrast	O
,	O
although	O
the	O
frequency	O
of	O
mutation	O
in	O
the	O
p53	O
gene	O
was	O
similar	O
in	O
lifetime	O
nonsmokers	O
compared	O
with	O
long-term	O
smokers	O
,	O
the	O
types	O
and	O
spectra	O
of	O
mutation	O
are	O
significantly	O
different	O
.	O
Two	O
of	O
the	O
C	O
to	O
T	O
transitions	O
found	O
in	O
nonsmokers	O
,	O
but	O
none	O
of	O
those	O
found	O
in	O
smokers	O
,	O
occur	O
at	O
the	O
C	O
of	O
a	O
CpG	O
site	O
.	O
These	O
results	O
suggest	O
the	O
mutagen(s)	O
and/or	O
mechanisms	O
of	O
p53	O
mutations	O
in	O
women	O
nonsmokers	O
are	O
different	O
from	O
those	O
responsible	O
for	O
p53	O
mutations	O
in	O
women	O
smokers	O
,	O
which	O
are	O
probably	O
largely	O
induced	O
by	O
tobacco	O
mutagens	O
.	O
PMID	O
:	O
10207632	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
1999	O
Jun;44	O
(	O
6	O
)	O
:	O
82	O
2-5	O
Molecular	O
screening	O
of	O
patients	O
with	O
long	O
standing	O
extensive	O
ulcerative	O
colitis	O
:	O
detection	O
of	O
p53	O
and	O
Ki-ras	O
mutations	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
differential	O
hybridisation	O
in	O
colonic	O
lavage	O
fluid	O
.	O
Lang	O
SM	O
,	O
Stratakis	O
DF	O
,	O
Heinzlmann	O
M,	O
Heldwein	O
W	O
,	O
Wiebecke	O
B	O
,	O
Loeschke	O
K.	O
Medizinische	O
Klinik	O
,	O
Klinikum	O
Innenstadt	O
der	O
Universitat	O
Munchen	O
,	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Ziemssenstrasse	O
1	O
,	O
D-80336	O
Munchen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
In	O
patients	O
with	O
long	O
standing	O
ulcerative	O
colitis	O
at	O
risk	O
of	O
developing	O
malignancy	O
,	O
mutations	O
of	O
the	O
p53	O
and	O
Ki-ras	O
gene	O
were	O
investigated	O
in	O
lavage	O
solution	O
obtained	O
at	O
surveillance	O
colonoscopy	O
.	O
METHODS	O
:	O
DNA	O
was	O
isolated	O
from	O
31	O
consecutive	O
patients	O
with	O
total	O
or	O
subtotal	O
ulcerative	O
colitis	O
and	O
a	O
disease	O
duration	O
of	O
between	O
seven	O
and	O
26	O
years	O
.	O
Twenty	O
seven	O
control	O
patients	O
showed	O
no	O
macroscopic	O
or	O
microscopic	O
inflammation	O
on	O
colonoscopy	O
.	O
Exons	O
5	O
-	O
8	O
of	O
the	O
p53	O
gene	O
and	O
exon	O
1	O
of	O
the	O
Ki-ras	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
of	O
the	O
p53	O
gene	O
were	O
detected	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
Point	O
mutations	O
of	O
the	O
Ki-ras	O
gene	O
were	O
hybridised	O
on	O
dot	O
blots	O
with	O
oligonucleotides	O
marked	O
with	O
digoxigenin	O
.	O
RESULTS	O
:	O
In	O
all	O
cases	O
of	O
ulcerative	O
colitis	O
and	O
in	O
all	O
of	O
the	O
27	O
control	O
patients	O
,	O
wild	O
type	O
p53	O
and	O
wild	O
type	O
Ki-ras	O
could	O
be	O
detected	O
.	O
In	O
four	O
patients	O
with	O
ulcerative	O
colitis	O
,	O
a	O
mutation	O
in	O
exon	O
5	O
to	O
7	O
of	O
the	O
p53	O
gene	O
was	O
found	O
,	O
and	O
two	O
patients	O
had	O
a	O
mutation	O
of	O
the	O
Ki-ras	O
gene	O
(	O
Gly	O
to	O
Asp	O
-	O
12	O
,	O
Gly	O
to	O
Val	O
-	O
12	O
)	O
.	O
None	O
of	O
these	O
patients	O
had	O
dysplasia	B-malignancy-type
in	O
serial	O
biopsy	O
specimens	O
,	O
and	O
all	O
but	O
one	O
had	O
had	O
the	O
disease	O
for	O
more	O
than	O
10	O
years	O
.	O
One	O
control	O
patient	O
had	O
a	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Mutations	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
long	O
standing	O
ulcerative	O
colitis	O
(	O
19	O
%	O
)	O
than	O
in	O
control	O
patients	O
(	O
3	O
%	O
,	O
p	O
=	O
0.07	O
)	O
.	O
The	O
technique	O
may	O
be	O
useful	O
for	O
screening	O
for	O
early	O
malignancy	O
in	O
ulcerative	B-malignancy-type
colitis	I-malignancy-type
.	O
PMID	O
:	O
10323884	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
1999	O
Jun;44	O
(	O
6	O
)	O
:	O
82	O
6-33	O
Genetic	O
epidemiology	O
of	O
mutated	O
K-ras	O
proto	O
-	O
oncogene	O
,	O
altered	O
suppressor	O
genes	O
,	O
and	O
microsatellite	O
instability	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
Rashid	O
A	O
,	O
Zahurak	O
M,	O
Goodman	O
SN	O
,	O
Hamilton	O
SR.	O
Division	O
of	O
Gastrointestina	O
l/	O
Liver	O
Pathology	O
,	O
Department	O
of	O
Pathology	O
,	O
Ross	O
Building	O
Room	O
632	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
720	O
Rutland	O
Avenue	O
,	O
Baltimore	O
,	O
MD	O
2120	O
5-2196	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
The	O
genetic	O
epidemiology	O
of	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
has	O
not	O
been	O
studied	O
prospectively	O
in	O
colonoscopy	O
patients	O
without	O
cancer	O
.	O
AIMS	O
:	O
To	O
study	O
genetic	O
alterations	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
correlate	O
these	O
with	O
patient	O
demographics	O
and	O
adenoma	O
characteristics	O
.	O
METHODS	O
:	O
Mutations	O
and	O
allelic	O
deletions	O
in	O
201	O
adenomas	B-malignancy-type
from	O
60	O
patients	O
were	O
compared	O
with	O
demographic	O
features	O
,	O
adenoma	O
characteristics	O
,	O
and	O
family	O
history	O
.	O
RESULTS	O
:	O
The	O
most	O
common	O
alteration	O
was	O
K-ras	O
proto	O
-	O
oncogene	O
mutation	O
,	O
present	O
in	O
35	O
%	O
of	O
adenomas	B-malignancy-type
and	O
65	O
%	O
of	O
patients	O
.	O
Patients	O
65	O
years	O
of	O
age	O
and	O
older	O
had	O
a	O
decreased	O
probability	O
of	O
K-ras	O
mutations	O
(	O
26	O
%	O
versus	O
45	O
%	O
)	O
.	O
Overexpression	O
of	O
p53	O
gene	O
product	O
was	O
present	O
in	O
only	O
6	O
%	O
of	O
adenomas	B-malignancy-type
but	O
was	O
more	O
frequent	O
in	O
villous	B-malignancy-type
or	O
tubulovillous	B-malignancy-type
adenomas	I-malignancy-type
(	O
19	O
%	O
versus	O
3	O
%	O
)	O
.	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
was	O
present	O
in	O
only	O
2	O
%	O
of	O
adenomas	O
and	O
was	O
significantly	O
less	O
frequent	O
than	O
p53	O
overexpression	O
.	O
DNA	O
replication	O
errors	O
(	O
RER	O
)	O
were	O
present	O
in	O
7	O
%	O
of	O
adenomas	B-malignancy-type
and	O
15	O
%	O
of	O
patients	O
,	O
including	O
multiple	O
adenomas	B-malignancy-type
in	O
four	O
patients	O
(	O
two	O
with	O
hereditary	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
polyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
syndrome	O
)	O
.	O
Only	O
36	O
%	O
of	O
RER	B-malignancy-type
positive	I-malignancy-type
adenomas	I-malignancy-type
had	O
alteration	O
of	O
BAT-26	O
alleles	O
,	O
none	O
had	O
alteration	O
of	O
BAT-25	O
,	O
and	O
only	O
one	O
(	O
8	O
%	O
)	O
had	O
mutation	O
in	O
the	O
transforming	O
growth	O
factor	O
beta	O
type	O
II	O
receptor	O
gene	O
.	O
RER	B-malignancy-type
positive	I-malignancy-type
adenomas	I-malignancy-type
were	O
more	O
likely	O
to	O
have	O
a	O
K-ras	O
mutation	O
.	O
In	O
patients	O
with	O
multiple	O
adenomas	B-malignancy-type
,	O
there	O
was	O
concordance	O
of	O
p53	O
overexpression	O
and	O
RER	O
but	O
not	O
of	O
K-ras	O
mutations	O
.	O
CONCLUSIONS	O
:	O
Genetic	O
progression	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
is	O
heterogeneous	O
,	O
involving	O
factors	O
related	O
to	O
patient	O
age	O
and	O
the	O
presence	O
of	O
RER	O
for	O
the	O
occurrence	O
of	O
ras	O
mutations	O
,	O
but	O
different	O
intraindividual	O
characteristics	O
for	O
the	O
occurrence	O
of	O
p53	O
alterations	O
and	O
RER	O
.	O
PMID	O
:	O
10323885	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Res	O
1998;1	O
0	O
(	O
1	O
1-12	O
)	O
:	O
59	O
1-4	O
Frequent	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
in	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
from	O
patients	O
without	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
.	O
Miyoshi	O
Y	O
,	O
Iwao	O
K,	O
Nawa	O
G,	O
Yoshikawa	O
H,	O
Ochi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suit	O
a	O
-shi	O
,	O
Japan	O
.	O
Mutations	O
in	O
the	O
APC	O
gene	O
contribute	O
to	O
development	O
of	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
as	O
well	O
as	O
to	O
the	O
hereditary	O
tumors	O
that	O
usually	O
accompany	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
.	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
cause	O
an	O
intracellular	O
accumulation	O
of	O
beta-catenin	O
that	O
results	O
in	O
abnormal	O
signaling	O
in	O
the	O
wnt	O
/	O
wingless	O
pathway	O
.	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
itself	O
have	O
also	O
been	O
noted	O
in	O
several	O
types	O
of	O
tumors	O
.	O
In	O
this	O
study	O
we	O
screened	O
the	O
beta-catenin	O
gene	O
in	O
13	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
for	O
alterations	O
in	O
exon	O
3	O
,	O
which	O
encodes	O
several	O
serine	O
/	O
threonine	O
residues	O
that	O
are	O
targets	O
for	O
phosphorylation	O
by	O
GSK-3beta	O
.	O
Somatic	O
substitutions	O
at	O
codons	O
41	O
(	O
threonine	O
)	O
and	O
45	O
(	O
serine	O
)	O
were	O
identified	O
in	O
seven	O
independent	O
tumors	O
,	O
respectively	O
.	O
Although	O
no	O
APC	O
mutations	O
were	O
detected	O
among	O
the	O
remaining	O
six	O
tumors	O
,	O
we	O
found	O
accumulation	O
of	O
beta-catenin	O
by	O
Western	O
blotting	O
analysis	O
in	O
one	O
such	O
tumor	O
for	O
which	O
frozen	O
tissues	O
were	O
available	O
.	O
Our	O
results	O
have	O
suggested	O
that	O
possible	O
involvement	O
of	O
beta-catenin	O
activation	O
by	O
beta-catenin	O
gene	O
mutation	O
or	O
alteration	O
of	O
other	O
factor(s)	O
can	O
contribute	O
to	O
desmoid	O
tumorigenesis	O
.	O
PMID	O
:	O
10367940	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1999	O
Jul	O
1;8	O
6	O
(	O
1	O
)	O
:	O
5	O
8-63	O
H-ras	O
and	O
K-ras	O
mutations	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcoma	I-malignancy-type
:	O
comparative	O
studies	O
of	O
sarcomas	B-malignancy-type
from	O
Korean	O
and	O
American	O
patients	O
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
The	O
authors	O
'	O
recent	O
investigation	O
of	O
Korean	O
patients	O
with	O
sarcoma	B-malignancy-type
has	O
suggested	O
that	O
ras	O
gene	O
activation	O
may	O
play	O
a	O
role	O
in	O
oncogenesis	O
.	O
The	O
authors	O
attempted	O
to	O
extend	O
the	O
mutation	O
analysis	O
to	O
sarcomas	B-malignancy-type
in	O
American	O
patients	O
to	O
determine	O
whether	O
there	O
were	O
racial	O
or	O
geographic	O
factors	O
relevant	O
to	O
the	O
initiation	O
or	O
progression	O
of	O
sarcoma	B-malignancy-type
.	O
METHODS	O
:	O
H-ras	O
and	O
K-ras	O
genes	O
were	O
examined	O
in	O
sarcomas	B-malignancy-type
obtained	O
from	O
patients	O
in	O
the	O
midwestern	O
U.	O
S.	O
using	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
and	O
direct	O
automated	O
sequencing	O
analysis	O
.	O
Tumors	O
studied	O
included	O
29	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
,	O
7	O
liposarcomas	B-malignancy-type
,	O
5	O
rhabdomyosarcomas	B-malignancy-type
,	O
and	O
9	O
leiomyosarcomas	B-malignancy-type
.	O
RESULTS	O
:	O
Of	O
the	O
50	O
sarcomas	B-malignancy-type
evaluated	O
,	O
only	O
1	O
(	O
2	O
%	O
)	O
definable	O
mutation	O
was	O
found	O
;	O
a	O
GGC	O
to	O
AGC	O
transition	O
at	O
codon	O
12	O
of	O
H-ras	O
was	O
found	O
in	O
a	O
rhabdomyosarcoma	B-malignancy-type
.	O
None	O
of	O
the	O
patients	O
had	O
a	O
K-ras	O
mutation	O
.	O
The	O
rates	O
of	O
incidence	O
of	O
ras	O
point	O
mutations	O
in	O
these	O
samples	O
were	O
much	O
lower	O
(	O
H-ras	O
:	O
2	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
-	O
11.5	O
%	O
and	O
K-ras	O
:	O
0	O
%	O
)	O
than	O
described	O
for	O
both	O
genes	O
in	O
Korean	O
studies	O
(	O
H-ras	O
:	O
16	O
%	O
;	O
95	O
%	O
CI	O
,	O
5.2	O
-	O
26.8	O
%	O
and	O
K-ras	O
:	O
44	O
%	O
;	O
95	O
%	O
CI	O
,	O
29.5	O
-	O
58.5	O
%	O
)	O
.	O
CONCLUSIONS	O
:	O
Although	O
the	O
reason	O
for	O
this	O
discrepancy	O
is	O
not	O
clear	O
,	O
there	O
were	O
no	O
major	O
differences	O
found	O
in	O
histology	O
or	O
clinical	O
stages	O
.	O
Based	O
on	O
this	O
study	O
of	O
50	O
sarcoma	B-malignancy-type
samples	O
from	O
American	O
patients	O
and	O
the	O
authors	O
'	O
previous	O
study	O
of	O
45	O
Korean	O
tumor	O
samples	O
,	O
the	O
authors	O
conclude	O
that	O
differing	O
genetic	O
and/or	O
environmental	O
mechanisms	O
can	O
affect	O
sarcoma	B-malignancy-type
development	O
or	O
progression	O
.	O
Mutation	O
of	O
the	O
H-ras	O
and	O
K-ras	O
genes	O
appears	O
to	O
be	O
uncommon	O
in	O
sarcomas	B-malignancy-type
occurring	O
in	O
American	O
patients	O
,	O
suggesting	O
that	O
the	O
activation	O
by	O
point	O
mutations	O
of	O
the	O
H-ras	O
and	O
K-ras	O
genes	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
or	O
progression	O
of	O
sarcoma	B-malignancy-type
in	O
these	O
patients	O
.	O
PMID	O
:	O
10391564	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1999	O
Aug;2	O
5	O
(	O
4	O
)	O
:	O
39	O
9-402	O
Beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B-malignancy-type
.	O
Blaker	O
H,	O
Hofmann	O
WJ	O
,	O
Rieker	O
RJ	O
,	O
Penzel	O
R	O
,	O
Graf	O
M,	O
Otto	O
HF.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Heidelberg	O
,	O
Heidelberg	O
,	O
Germany	O
.	O
hendrik_blaeker@ukl	O
.un	O
i-heidelberg.de	O
Hepatoblastoma	B-malignancy-type
is	O
a	O
rare	O
malignant	O
tumor	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O
Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	O
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
.	O
In	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	O
tumor	O
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	O
tumorigenesis	O
.	O
A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta-catenin	O
,	O
a	O
transcription	O
-	O
activating	O
protein	O
with	O
oncogenic	O
potential	O
.	O
In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta-catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	O
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
,	O
we	O
observed	O
increased	O
beta-catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-malignancy-type
.	O
Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	O
samples	O
.	O
Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta-catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-malignancy-type
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	O
type	O
.	O
Genes	O
Chromosomes	O
Cancer	O
25	O
:	O
399	O
-	O
402	O
,	O
1999	O
.	O
Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc.	O
PMID	O
:	O
10398436	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Jul	O
15	O
;5	O
9	O
(	O
14	O
)	O
:	O
334	O
6-51	O
Beta-catenin	O
mutations	O
are	O
specific	O
for	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
with	O
microsatellite	O
instability	O
but	O
occur	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
irrespective	O
of	O
mutator	O
pathway	O
.	O
Mirabell	O
i-Primdahl	O
L,	O
Gryfe	O
R	O
,	O
Kim	O
H,	O
Millar	O
A	O
,	O
Luceri	O
C,	O
Dale	O
D	O
,	O
Holowaty	O
E	O
,	O
Bapat	O
B	O
,	O
Gallinger	O
S	O
,	O
Redston	O
M.	O
Centre	O
for	O
Cancer	O
Genetics	O
,	O
Samuel	O
Lunenfeld	O
Research	O
Institute	O
,	O
Mount	O
Sinai	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Some	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
with	O
wild-type	O
adenomatous	O
polyposis	O
coli	O
gene	O
have	O
activating	O
mutations	O
in	O
beta-catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
that	O
result	O
in	O
decreased	O
phosphorylation	O
by	O
GSK-3beta	O
and	O
increased	O
signaling	O
through	O
the	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
.	O
To	O
investigate	O
the	O
relationship	O
between	O
CTNNB1	O
mutations	O
and	O
underlying	O
pathways	O
of	O
genomic	O
instability	O
,	O
we	O
examined	O
80	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
stratified	O
by	O
the	O
presence	O
or	O
absence	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
CTNNB1	O
mutations	O
were	O
identified	O
in	O
13	O
(	O
25	O
%	O
)	O
of	O
53	O
cancers	O
with	O
high	O
frequency	O
MSI	O
(	O
MSI-H	O
)	O
,	O
including	O
12	O
point	O
mutations	O
at	O
exon	O
3	O
phosphorylation	O
sites	O
(	O
codons	O
41	O
and	O
45	O
)	O
and	O
one	O
deletion	O
of	O
the	O
entire	O
exon	O
3	O
degradation	O
box	O
.	O
No	O
CTNNB1	O
mutations	O
were	O
identified	O
in	O
27	O
microsatellite	O
stable	O
or	O
low	O
frequency	O
MSI	O
(	O
MSI-L	O
)	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
(	O
P	O
<	O
0.01	O
)	O
.	O
In	O
contrast	O
,	O
CTNNB1	O
mutations	O
were	O
identified	O
in	O
3	O
of	O
9	O
(	O
33	O
%	O
)	O
MSI-H	O
and	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
MSS	O
/	O
MSI-L	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
a	O
more	O
generalized	O
involvement	O
in	O
these	O
tumors	O
.	O
Only	O
six	O
(	O
46	O
%	O
)	O
of	O
the	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
CTNNB1	O
mutations	O
occurred	O
at	O
residues	O
directly	O
phosphorylated	O
by	O
GSK-3beta	O
,	O
and	O
only	O
one	O
of	O
these	O
was	O
at	O
either	O
codon	O
41	O
or	O
45	O
.	O
All	O
point	O
mutations	O
in	O
MSI-H	O
cancers	O
were	O
transitions	O
,	O
whereas	O
64	O
%	O
of	O
those	O
in	O
MSS	O
/	O
MSI-L	O
cancers	O
were	O
transversions	O
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
differences	O
in	O
the	O
mutation	O
profiles	O
suggest	O
that	O
there	O
may	O
be	O
molecular	O
fingerprints	O
of	O
CTNNB1	O
mutations	O
,	O
determined	O
by	O
biological	O
factors	O
related	O
to	O
both	O
tumor	O
type	O
and	O
underlying	O
pathways	O
of	O
genomic	O
instability	O
.	O
PMID	O
:	O
10416591	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1999	O
Aug	O
27;8	O
2	O
(	O
5	O
)	O
:	O
62	O
5-9	O
beta-catenin	O
mutation	O
and	O
expression	O
analysis	O
in	O
ovarian	B-malignancy-type
cancer	I-malignancy-type
:	O
exon	O
3	O
mutations	O
and	O
nuclear	O
translocation	O
in	O
16	O
%	O
of	O
endometrioid	B-malignancy-type
tumours	I-malignancy-type
.	O
Wright	O
K,	O
Wilson	O
P,	O
Morland	O
S	O
,	O
Campbell	O
I	O
,	O
Walsh	O
M,	O
Hurst	O
T	O
,	O
Ward	O
B	O
,	O
Cummings	O
M,	O
Chenevi	O
x-Trench	O
G.	O
Joint	O
Experimental	O
Oncology	O
Program	O
,	O
Queensland	O
Institute	O
of	O
Medical	O
Research	O
and	O
University	O
of	O
Queensland	O
,	O
Brisbane	O
,	O
Australia	O
.	O
The	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
generation	O
of	O
epithelial	B-malignancy-type
ovarian	I-malignancy-type
cancers	I-malignancy-type
are	O
poorly	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
the	O
different	O
histological	O
subtypes	O
may	O
arise	O
from	O
independent	O
tumorigenic	O
events	O
.	O
beta-Catenin	O
is	O
emerging	O
as	O
an	O
important	O
oncogene	O
in	O
the	O
transformation	O
of	O
a	O
number	O
of	O
epithelial	B-malignancy-type
cancers	I-malignancy-type
,	O
and	O
mutations	O
have	O
been	O
reported	O
in	O
a	O
small	O
study	O
of	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Mutations	O
in	O
the	O
NH(2)	O
-	O
regulatory	O
domain	O
of	O
beta-catenin	O
stabilise	O
the	O
cytoplasmic	O
levels	O
of	O
this	O
protein	O
,	O
which	O
promotes	O
up	O
-	O
regulation	O
of	O
the	O
beta-catenin	O
-	O
T-cell	O
factor	O
-	O
lymphoid	O
enhancer	O
factor	O
transcriptional	O
complex	O
.	O
We	O
report	O
here	O
beta-catenin	O
(	O
CTNNB1	O
)	O
exon	O
3	O
mutation	O
analysis	O
in	O
149	O
epithelial	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
This	O
revealed	O
10	O
/	O
63	O
(	O
16	O
%	O
)	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
tumours	I-malignancy-type
with	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
.	O
All	O
mutations	O
were	O
missense	O
changes	O
within	O
the	O
GSK3beta	O
consensus	O
site	O
,	O
affecting	O
serine	O
residues	O
at	O
codons	O
33	O
and	O
37	O
and	O
glycine	O
at	O
codon	O
34	O
.	O
Immuno	O
-	O
histochemical	O
analysis	O
identified	O
cytoplasmic	O
stabilisation	O
and	O
nuclear	O
translocation	O
in	O
those	O
endometrioid	B-malignancy-type
tumours	I-malignancy-type
with	O
mutations	O
.	O
This	O
phenotypic	O
change	O
was	O
also	O
identified	O
in	O
3	O
other	O
endometrioid	B-malignancy-type
tumours	I-malignancy-type
that	O
did	O
not	O
have	O
somatic	O
mutations	O
within	O
exon	O
3	O
of	O
CTNNB1	O
.	O
Stabilisation	O
of	O
the	O
free	O
,	O
monomeric	O
pool	O
of	O
beta-catenin	O
and	O
the	O
probable	O
resulting	O
constitutive	O
activation	O
of	O
its	O
Tcf	O
-	O
associated	O
transcriptional	O
complex	O
appears	O
to	O
be	O
a	O
specific	O
oncogenic	O
event	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc.	O
PMID	O
:	O
10417756	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hepatogastroenterology	O
1999	O
Ma	O
y-Jun;46	O
(27	O
)	O
:	O
206	O
3-8	O
K-ras	O
mutations	O
in	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
and	O
in	O
carcinomas	B-malignancy-type
from	O
the	O
non	O
-	O
operated	O
stomach	O
.	O
van	O
Rees	O
BP	O
,	O
Musler	O
A	O
,	O
Caspers	O
E	O
,	O
Drillenburg	O
P,	O
Craanen	O
ME	O
,	O
Polkowski	O
W	O
,	O
Chibowski	O
D	O
,	O
Offerhaus	O
GJ.	O
Department	O
of	O
Pathology	O
,	O
Academic	O
Medical	O
Center	O
,	O
University	O
of	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
b.p.vanrees@amc.uva.nl	O
BACKGROUND	O
/	O
AIMS	O
:	O
Partial	O
gastrectomy	O
is	O
a	O
well	O
-	O
established	O
pre	O
-	O
malignant	O
condition	O
.	O
It	O
is	O
postulated	O
that	O
in	O
the	O
gastric	O
stump	O
an	O
accelerated	O
neoplastic	O
process	O
takes	O
place	O
,	O
similar	O
to	O
that	O
of	O
(	B-malignancy-type
intestinal	I-malignancy-type
type	I-malignancy-type
)	I-malignancy-type
adenocarcinoma	I-malignancy-type
from	O
the	O
non	O
-	O
operated	O
stomach	O
.	O
K-ras	O
codon	O
12	O
mutation	O
is	O
one	O
of	O
the	O
most	O
frequent	O
oncogenic	O
alterations	O
in	O
human	O
solid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
It	O
is	O
rare	O
in	O
conventional	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
and	O
has	O
not	O
been	O
studied	O
in	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
prevalence	O
of	O
K-ras	O
codon	O
12	O
point	O
mutations	O
in	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
with	O
those	O
in	O
conventional	O
carcinomas	B-malignancy-type
from	O
the	O
non	O
-	O
operated	O
stomach	O
.	O
METHODOLOGY	O
:	O
Twenty-four	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
were	O
compared	O
with	O
26	O
conventional	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Stage	O
,	O
histology	O
,	O
and	O
demographics	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
Mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
were	O
examined	O
with	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
based	O
method	O
and	O
subsequent	O
dot	O
blot	O
hybridization	O
with	O
mutation	O
-	O
specific	O
probes	O
.	O
The	O
results	O
of	O
Helicobacter	O
pylori	O
infection	O
,	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
and	O
p53	O
immunohistochemistry	O
were	O
partially	O
known	O
from	O
a	O
previous	O
study	O
.	O
RESULTS	O
:	O
In	O
one	O
of	O
the	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
as	O
well	O
as	O
in	O
one	O
of	O
the	O
conventional	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
a	O
K-ras	O
codon	O
12	O
point	O
mutation	O
was	O
found	O
.	O
p53	O
immunohistochemistry	O
results	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
Interestingly	O
,	O
Helicobacter	O
pylori	O
infection	O
rate	O
and	O
Epstein	O
-	O
Barr	O
virus	O
in	O
situ	O
hybridization	O
for	O
EBER1	O
,	O
as	O
previously	O
studied	O
,	O
appeared	O
were	O
significantly	O
different	O
in	O
the	O
two	O
groups	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
codon	O
12	O
point	O
mutations	O
are	O
rare	O
in	O
both	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
and	O
conventional	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
This	O
supports	O
the	O
postulated	O
hypothesis	O
that	O
the	O
pathways	O
of	O
carcinogenesis	O
in	O
both	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinoma	I-malignancy-type
and	O
conventional	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
share	O
common	O
features	O
.	O
However	O
,	O
these	O
groups	O
differ	O
in	O
infection	O
rate	O
of	O
Helicobacter	O
pylori	O
and	O
of	O
Epstein	O
-	O
Barr	O
virus	O
,	O
which	O
suggests	O
that	O
some	O
neoplastic	O
stimuli	O
differ	O
as	O
well	O
.	O
PMID	O
:	O
10430398	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Aug	O
15	O
;5	O
9	O
(	O
16	O
)	O
:	O
388	O
0-2	O
Mutational	O
activation	O
of	O
the	O
beta-catenin	O
proto	O
-	O
oncogene	O
is	O
a	O
common	O
event	O
in	O
the	O
development	O
of	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumors	I-malignancy-type
.	O
Koesters	O
R	O
,	O
Ridder	O
R	O
,	O
Kop	O
p-Schneider	O
A	O
,	O
Betts	O
D	O
,	O
Adams	O
V	O
,	O
Niggli	O
F	O
,	O
Briner	O
J,	O
von	O
Knebel	O
Doeberitz	O
M.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Heidelberg	O
,	O
Germany	O
.	O
R.Koesters@DKF	O
Z-Heidelberg.de	O
Activation	O
of	O
beta-catenin	O
-	O
mediated	O
transcription	O
is	O
the	O
nuclear	O
end	O
point	O
of	O
organ	O
-	O
specific	O
Wnt	O
signaling	O
.	O
In	O
the	O
developing	O
kidney	O
,	O
Wnt-4	O
,	O
a	O
secreted	O
glycoprotein	O
,	O
acts	O
as	O
an	O
autoinducer	O
of	O
the	O
mesenchymal	O
to	O
epithelial	O
transition	O
that	O
underlies	O
normal	O
nephron	O
development	O
.	O
Dysregulation	O
of	O
this	O
epithelial	O
transformation	O
process	O
may	O
lead	O
to	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumors	I-malignancy-type
(	O
WTs	B-malignancy-type
)	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
the	O
beta-catenin	O
proto	O
-	O
oncogene	O
,	O
a	O
candidate	O
downstream	O
target	O
molecule	O
of	O
Wnt-4	O
signaling	O
,	O
in	O
the	O
development	O
of	O
WTs	B-malignancy-type
.	O
In	O
6	O
of	O
40	O
tumors	O
(	O
15	O
%	O
)	O
,	O
mutation	O
analysis	O
revealed	O
heterozygous	O
missense	O
mutations	O
or	O
small	O
deletions	O
that	O
result	O
in	O
the	O
loss	O
of	O
important	O
regulatory	O
phosphorylation	O
sites	O
within	O
the	O
beta-catenin	O
protein	O
.	O
These	O
findings	O
indicate	O
that	O
activating	O
beta-catenin	O
mutations	O
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
WTs	B-malignancy-type
and	O
establish	O
a	O
direct	O
link	O
between	O
Wilms	O
'	O
tumorigenesis	O
and	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
governing	O
normal	O
kidney	O
development	O
.	O
PMID	O
:	O
10463574	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Endocrinol	O
(	O
Oxf	O
)	O
1999	O
Apr;50	O
(	O
4	O
)	O
:	O
52	O
9-35	O
Prevalence	O
of	O
Ras	O
mutations	O
in	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
.	O
Esapa	O
CT	O
,	O
Johnson	O
SJ	O
,	O
Kendal	O
l-Taylor	O
P,	O
Lennard	O
TW	O
,	O
Harris	O
PE.	O
Department	O
of	O
Diabetes	O
,	O
Endocrinology	O
and	O
Internal	O
Medicine	O
,	O
Guys'	O
,	O
King	O
's	O
and	O
St	O
Thomas	O
'	O
School	O
of	O
Medicine	O
,	O
London	O
,	O
UK.	O
OBJECTIVE	O
:	O
Mutations	O
at	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
ras	O
which	O
result	O
in	O
constitutive	O
activation	O
occur	O
frequently	O
in	O
human	O
malignancies	O
.	O
There	O
have	O
been	O
varied	O
reports	O
on	O
their	O
prevalence	O
and	O
hence	O
their	O
likely	O
significance	O
in	O
the	O
pathogenesis	O
of	O
primary	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
.	O
To	O
address	O
this	O
,	O
we	O
have	O
examined	O
a	O
large	O
series	O
of	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
tumours	I-malignancy-type
for	O
ras	O
mutations	O
.	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Direct	O
DNA	O
sequencing	O
was	O
used	O
to	O
confirm	O
the	O
mutations	O
.	O
PATIENTS	O
:	O
A	O
total	O
of	O
90	O
samples	O
with	O
benign	B-malignancy-type
(	O
66	O
)	O
and	O
malignant	B-malignancy-type
(	I-malignancy-type
24	I-malignancy-type
)	I-malignancy-type
thyroid	I-malignancy-type
disease	I-malignancy-type
were	O
investigated	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
14	O
/	O
90	O
(	O
15.5	O
%	O
)	O
samples	O
had	O
a	O
ras	O
mutation	O
.	O
All	O
mutations	O
were	O
at	O
codon	O
61	O
of	O
either	O
N-ras	O
or	O
K-ras	O
.	O
The	O
positive	O
cases	O
were	O
1	O
/	O
25	O
(	O
4	O
%	O
)	O
nodular	B-malignancy-type
goitre	I-malignancy-type
,	O
7	O
/	O
38	O
(	O
18	O
%	O
)	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
4	O
/	O
9	O
(	O
44	O
%	O
)	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
/	O
1	O
anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
/	O
1	O
follicular	B-malignancy-type
variant	I-malignancy-type
of	I-malignancy-type
papillary	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
1	O
metastatic	B-malignancy-type
follicular	I-malignancy-type
carcinoma	I-malignancy-type
in	O
which	O
the	O
primary	O
tumour	O
had	O
the	O
same	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Our	O
data	O
demonstrate	O
a	O
relatively	O
low	O
overall	O
prevalence	O
of	O
ras	O
mutations	O
in	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
,	O
with	O
a	O
predominance	O
in	O
follicular	B-malignancy-type
neoplasms	I-malignancy-type
.	O
Their	O
presence	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
suggests	O
that	O
they	O
may	O
have	O
an	O
early	O
aetiological	O
role	O
in	O
the	O
development	O
of	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
.	O
PMID	O
:	O
10468914	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Diagn	O
Mol	O
Pathol	O
1999	O
Jun;	O
8	O
(	O
2	O
)	O
:	O
7	O
1-9	O
Analysis	O
of	O
K-ras	O
,	O
N-ras	O
,	O
H-ras	O
,	O
and	O
p53	O
in	O
lung	B-malignancy-type
neuroendocrine	I-malignancy-type
neoplasms	I-malignancy-type
.	O
Couce	O
ME	O
,	O
Bautista	O
D	O
,	O
Costa	O
J,	O
Carter	O
D.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
,	O
USA	O
.	O
This	O
study	O
screened	O
11	O
samples	O
of	O
typical	B-malignancy-type
carcinoid	I-malignancy-type
(	O
TC	B-malignancy-type
)	O
,	O
4	O
samples	O
of	O
atypical	B-malignancy-type
carcinoid	I-malignancy-type
(	O
AC	B-malignancy-type
)	O
,	O
1	O
sample	O
of	O
large	B-malignancy-type
cell	I-malignancy-type
neuroendocrine	I-malignancy-type
carcinoma	I-malignancy-type
(	O
LCNEC	B-malignancy-type
)	O
,	O
and	O
four	O
metastases	O
for	O
point	O
mutations	O
in	O
exons	O
5	O
to	O
8	O
of	O
the	O
p53	O
gene	O
,	O
and	O
exons	O
1	O
and	O
2	O
of	O
the	O
K-ras	O
.	O
H-ras	O
,	O
and	O
N-ras	O
genes	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
and	O
by	O
immunohistochemistry	O
for	O
p53	O
.	O
Exon	O
1	O
of	O
K-ras	O
was	O
mutated	O
in	O
two	O
samples	O
of	O
low-grade	B-malignancy-type
AC	I-malignancy-type
and	O
a	O
metastasis	O
from	O
one	O
of	O
these	O
tumors	O
(	O
GAT12	O
and	O
AGT12	O
,	O
respectively	O
)	O
.	O
No	O
mutations	O
in	O
N-ras	O
or	O
H-ras	O
were	O
found	O
.	O
Mutations	O
in	O
exons	O
5	O
and	O
8	O
of	O
the	O
p53	O
gene	O
were	O
identified	O
in	O
a	O
high-grade	B-malignancy-type
AC	I-malignancy-type
and	O
a	O
LCNEC	B-malignancy-type
.	O
Positive	O
immunostaining	O
for	O
p53	O
was	O
present	O
in	O
three	O
samples	O
,	O
with	O
only	O
one	O
genotypic	O
mutation	O
shown	O
(	O
LCNEC	B-malignancy-type
)	O
.	O
In	O
conclusion	O
,	O
point	O
mutations	O
of	O
the	O
p53	O
gene	O
were	O
infrequent	O
in	O
these	O
pulmonary	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
,	O
did	O
not	O
correlate	O
in	O
all	O
samples	O
with	O
immunostaining	O
,	O
and	O
were	O
associated	O
with	O
the	O
higher-grade	O
tumors	O
.	O
Second	O
,	O
the	O
presence	O
of	O
K-ras	O
mutations	O
seems	O
to	O
be	O
associated	O
with	O
the	O
higher-grade	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Third	O
,	O
N-ras	O
and	O
H-ras	O
mutations	O
were	O
not	O
found	O
with	O
these	O
pulmonary	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
10475381	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Sep;155(	O
3	O
)	O
:703	O
-	O
10	O
Nuclear	O
accumulation	O
of	O
mutated	O
beta-catenin	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
is	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O
Nhieu	O
JT	O
,	O
Renard	O
CA	O
,	O
Wei	O
Y	O
,	O
Cherqui	O
D	O
,	O
Zafrani	O
ES	O
,	O
Buendia	O
MA.	O
Departement	O
de	O
Pathologie	O
,	O
Service	O
de	O
Chirurgie	O
,	O
Hopital	O
Henri	O
Mondor	O
-	O
AP	O
-	O
HP	O
,	O
Creteil	O
,	O
Paris	O
,	O
France	O
.	O
Inappropriate	O
activation	O
of	O
the	O
Wnt	O
pathway	O
resulting	O
from	O
beta-catenin	O
gene	O
alterations	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
development	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	O
)	O
.	O
To	O
explore	O
the	O
in	O
vivo	O
effects	O
of	O
mutated	O
beta-catenin	O
,	O
HCC	B-malignancy-type
specimens	O
from	O
32	O
patients	O
carrying	O
one	O
or	O
several	O
tumors	O
were	O
screened	O
for	O
somatic	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
and	O
the	O
expression	O
and	O
subcellular	O
localization	O
of	O
beta-catenin	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O
Missense	O
mutations	O
or	O
interstitial	O
deletions	O
in	O
beta-catenin	O
exon	O
3	O
were	O
detected	O
in	O
12	O
of	O
35	O
(	O
34	O
%	O
)	O
HCC	B-malignancy-type
samples	O
.	O
After	O
immunostaining	O
,	O
most	O
tumors	O
exhibited	O
increased	O
membranous	O
and/or	O
cytoplasmic	O
expression	O
of	O
beta-catenin	O
compared	O
with	O
adjacent	O
nontumoral	O
liver	O
.	O
Strong	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
observed	O
either	O
focally	O
or	O
uniformly	O
in	O
15	O
of	O
35	O
(	O
43	O
%	O
)	O
tumor	O
specimens	O
,	O
but	O
not	O
in	O
cirrhotic	O
nodules	O
or	O
dysplastic	B-malignancy-type
liver	I-malignancy-type
cells	O
in	O
adjacent	O
liver	O
.	O
Aberrant	O
nuclear	O
expression	O
of	O
beta-catenin	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
P	O
<	O
0.005	O
)	O
.	O
Moreover	O
,	O
nuclear	O
beta-catenin	O
staining	O
correlated	O
significantly	O
with	O
increased	O
Ki-67	O
proliferative	O
index	O
in	O
tumor	O
(	O
P	O
<	O
0.001	O
)	O
and	O
seemed	O
to	O
be	O
associated	O
with	O
poor	O
outcome	O
in	O
patients	O
with	O
HCC	B-malignancy-type
.	O
In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
activation	O
of	O
the	O
Wnt	O
/	O
beta-catenin	O
pathway	O
in	O
HCC	B-malignancy-type
results	O
mainly	O
from	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
and	O
may	O
promote	O
tumor	O
progression	O
by	O
stimulating	O
tumor	O
cell	O
proliferation	O
.	O
PMID	O
:	O
10487827	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
1999	O
Sep;5(	O
9	O
)	O
:2450	O
-	O
4	O
Molecular	O
detection	O
of	O
neoplastic	B-malignancy-type
cells	I-malignancy-type
in	I-malignancy-type
lymph	I-malignancy-type
nodes	I-malignancy-type
of	O
metastatic	B-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
patients	O
predicts	O
recurrence	O
.	O
Sanchez	O
-	O
Cespedes	O
M,	O
Esteller	O
M,	O
Hibi	O
K	O
,	O
Cope	O
FO	O
,	O
Westra	O
WH	O
,	O
Piantadosi	O
S,	O
Herman	O
JG	O
,	O
Jen	O
J,	O
Sidransky	O
D.	O
Department	O
of	O
Otolaryngology	O
-	O
Head	O
and	O
Neck	O
Surgery	O
,	O
The	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
,	O
USA	O
.	O
Disseminated	O
disease	O
,	O
especially	O
to	O
the	O
liver	O
,	O
constitutes	O
the	O
major	O
risk	O
of	O
recurrence	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
However	O
,	O
successful	O
resection	O
can	O
still	O
be	O
achieved	O
in	O
25	O
-	O
35	O
%	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
isolated	O
metastases	O
.	O
To	O
evaluate	O
the	O
clinical	O
value	O
of	O
occult	O
micrometastatic	O
disease	O
detection	O
in	O
lymph	O
nodes	O
,	O
we	O
tested	O
genetic	O
(	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
)	O
and	O
epigenetic	O
(	O
p16	O
promoter	O
hypermethylation	O
)	O
molecular	O
markers	O
in	O
the	O
perihepatic	O
lymph	O
nodes	O
from	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
isolated	O
liver	B-malignancy-type
metastases	I-malignancy-type
.	O
DNA	O
was	O
extracted	O
from	O
21	O
paraffin	O
-	O
embedded	O
liver	B-malignancy-type
metastases	I-malignancy-type
and	O
80	O
lymph	O
nodes	O
from	O
21	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
were	O
identified	O
in	O
DNA	O
from	O
liver	B-malignancy-type
metastases	I-malignancy-type
by	O
PCR	O
amplification	O
followed	O
by	O
cycle	O
sequencing	O
.	O
A	O
sensitive	O
oligonucleotide	O
-	O
mediated	O
mismatch	O
ligation	O
assay	O
was	O
used	O
to	O
search	O
for	O
the	O
presence	O
of	O
K-ras	O
and	O
p53	O
mutations	O
to	O
detect	O
occult	O
disease	O
in	O
68	O
lymph	O
nodes	O
from	O
tumors	O
positive	O
for	O
these	O
gene	O
mutations	O
.	O
Promoter	O
hypermethylation	O
at	O
the	O
p16	O
tumor	O
suppressor	O
gene	O
was	O
examined	O
in	O
both	O
liver	B-malignancy-type
lesions	I-malignancy-type
and	O
lymph	O
nodes	O
by	O
methylation	O
-	O
specific	O
PCR	O
.	O
Sixteen	O
of	O
the	O
21	O
(	O
76	O
%	O
)	O
liver	B-malignancy-type
metastases	I-malignancy-type
harbored	O
either	O
gene	O
point	O
mutations	O
or	O
p16	O
promoter	O
hypermethylation	O
.	O
Twelve	O
of	O
the	O
68	O
lymph	O
nodes	O
were	O
positive	O
for	O
tumor	O
cells	O
by	O
molecular	O
evaluation	O
and	O
negative	O
for	O
tumor	O
cells	O
by	O
histopathology	O
and	O
cytokeratin	O
immunohistochemistry	O
,	O
whereas	O
none	O
were	O
positive	O
for	O
tumor	O
cells	O
by	O
histopathology	O
or	O
negative	O
for	O
tumor	O
cells	O
by	O
molecular	O
analysis	O
(	O
P	O
=	O
0.0005	O
,	O
McNemar	O
's	O
test	O
)	O
.	O
Moreover	O
,	O
in	O
three	O
patients	O
with	O
lymph	O
nodes	O
that	O
were	O
histologically	O
negative	O
at	O
all	O
sites	O
,	O
molecular	O
screening	O
detected	O
tumor	O
DNA	O
at	O
one	O
or	O
more	O
lymph	O
nodes	O
.	O
Survival	O
analysis	O
showed	O
a	O
median	O
survival	O
of	O
1056	O
days	O
for	O
patients	O
without	O
evidence	O
of	O
lymph	O
node	O
involvement	O
by	O
molecular	O
analysis	O
and	O
165	O
days	O
for	O
patients	O
with	O
positive	O
lymph	O
nodes	O
by	O
this	O
approach	O
(	O
P	O
=	O
0.0005	O
)	O
.	O
These	O
results	O
indicate	O
that	O
lymph	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
screening	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
by	O
molecular	O
-	O
based	O
techniques	O
increases	O
the	O
sensitivity	O
of	O
tumor	O
cell	O
detection	O
and	O
can	O
be	O
a	O
good	O
predictor	O
of	O
recurrence	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
resectable	O
liver	B-malignancy-type
metastases	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Multicenter	O
Study	O
PMID	O
:	O
10499618	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1999	O
Jun;105(	O
4)	O
:894	O
-	O
900	O
c-kit	O
proto	O
-	O
oncogene	O
exon	O
8	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
.	O
Gari	O
M,	O
Goodeve	O
A	O
,	O
Wilson	O
G	O
,	O
Winship	O
P	O
,	O
Langabeer	O
S,	O
Linch	O
D	O
,	O
Vandenberghe	O
E	O
,	O
Peake	O
I	O
,	O
Reilly	O
J.	O
Molecular	O
Haematology	O
Unit	O
,	O
Division	O
of	O
Molecular	O
and	O
Genetic	O
Medicine	O
,	O
Royal	O
Hallamshire	O
Hospital	O
,	O
Sheffield	O
,	O
London	O
.	O
Genomic	O
DNA	O
from	O
60	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
was	O
screened	O
for	O
mutations	O
in	O
the	O
c-kit	O
gene	O
.	O
DNA	O
from	O
all	O
21	O
exons	O
was	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
analysis	O
by	O
conformation	O
sensitive	O
gel	O
electrophoresis	O
(	O
CSGE	O
)	O
;	O
exons	O
showing	O
altered	O
CSGE	O
patterns	O
were	O
then	O
sequenced	O
.	O
Mutations	O
were	O
identified	O
only	O
in	O
those	O
patients	O
with	O
inv	O
(	O
16	O
)	O
(	O
3	O
/	O
7	O
cases	O
)	O
or	O
t	O
(	O
8	O
;	O
21	O
)	O
(	O
1	O
/	O
2	O
cases	O
)	O
and	O
comprised	O
three	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
(	O
exon	O
8	O
)	O
and	O
one	O
point	O
mutation	O
(	O
exon	O
10	O
,	O
GTA	O
-->	O
ATA	O
,	O
Val	O
530	O
Ile	O
)	O
.	O
Exons	O
8	O
and	O
10	O
were	O
then	O
analysed	O
in	O
31	O
further	O
cases	O
of	O
inv	O
(	O
16	O
)	O
(	O
n	O
=	O
14	O
)	O
and	O
t	O
(	O
8	O
;	O
21	O
)	O
(	O
n	O
=	O
17	O
)	O
,	O
revealing	O
four	O
additional	O
exon	O
8	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
,	O
all	O
of	O
which	O
were	O
in	O
cases	O
of	O
inv	O
(	O
16	O
)	O
.	O
All	O
exon	O
8	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
(	O
n	O
=	O
7	O
)	O
involved	O
the	O
loss	O
or	O
replacement	O
of	O
the	O
codon	O
for	O
Asp	O
419	O
which	O
is	O
highly	O
conserved	O
cross	O
species	O
and	O
is	O
located	O
in	O
the	O
receptor	O
's	O
extracellular	O
domain	O
.	O
The	O
high	O
frequency	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
exon	O
8	O
deletion	O
plus	O
insertion	O
mutations	O
in	O
AML	B-malignancy-type
suggests	O
an	O
essential	O
role	O
for	O
this	O
region	O
of	O
the	O
receptor	O
's	O
extracellular	O
domain	O
.	O
The	O
association	O
with	O
inv	O
(	O
16	O
)	O
invites	O
speculation	O
as	O
to	O
the	O
link	O
between	O
these	O
two	O
changes	O
in	O
the	O
pathogenesis	O
of	O
AML	B-malignancy-type
.	O
PMID	O
:	O
10554798	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
Nov;12(	O
11	O
)	O
:1001	O
-	O
9	O
Comparative	O
immunohistochemical	O
and	O
molecular	O
analysis	O
of	O
uterine	B-malignancy-type
and	O
extrauterine	B-malignancy-type
leiomyosarcomas	I-malignancy-type
.	O
Rao	O
UN	O
,	O
Finkelstein	O
SD	O
,	O
Jones	O
MW.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Pittsburgh	O
Medical	O
Center	O
,	O
Presbyterian	O
University	O
Hospital	O
,	O
Pennsylvania	O
15213	O
-	O
2582	O
,	O
USA	O
.	O
Histologic	O
criteria	O
defining	O
malignancy	O
in	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
are	O
currently	O
site	O
specific	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
,	O
in	O
leiomyosarcomas	B-malignancy-type
(	O
LMS	B-malignancy-type
)	O
occurring	O
in	O
different	O
anatomic	O
locations	O
,	O
there	O
were	O
differences	O
in	O
patterns	O
of	O
expression	O
of	O
molecules	O
that	O
have	O
been	O
demonstrated	O
to	O
be	O
associated	O
with	O
biologically	O
aggressive	O
behavior	O
in	O
malignant	B-malignancy-type
neoplasms	I-malignancy-type
,	O
and	O
also	O
to	O
determine	O
their	O
diagnostic	O
utility	O
.	O
Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
blocks	O
were	O
selected	O
from	O
16	O
extrauterine	B-malignancy-type
leiomyosarcomas	I-malignancy-type
(	O
EULMS	B-malignancy-type
)	O
,	O
14	O
cases	O
of	O
uterine	B-malignancy-type
leiomyosarcomas	I-malignancy-type
(	O
ULMS	B-malignancy-type
)	O
and	O
from	O
five	O
cases	O
each	O
of	O
uterine	B-malignancy-type
and	O
extrauterine	B-malignancy-type
leiomyomas	I-malignancy-type
(	O
LM	B-malignancy-type
)	O
.	O
Utilizing	O
immunohistochemical	O
(	O
ABC	O
)	O
techniques	O
with	O
antigen	O
retrieval	O
,	O
we	O
assessed	O
serial	O
sections	O
of	O
each	O
tumor	O
for	O
immunoreactivity	O
with	O
Glut1	O
,	O
CD44s	O
,	O
bcl2	O
,	O
cyclin	O
D1	O
,	O
and	O
estrogen	O
receptor	O
.	O
Molecular	O
genotyping	O
for	O
detecting	O
k-ras-2	O
point	O
mutation	O
,	O
p53	O
gene	O
loss	O
,	O
and	O
mdm2	O
gene	O
amplification	O
was	O
performed	O
on	O
microdissected	O
tumor	O
samples	O
from	O
the	O
same	O
histologic	O
sections	O
.	O
All	O
of	O
the	O
uterine	B-malignancy-type
and	O
extrauterine	B-malignancy-type
LM	I-malignancy-type
were	O
diffusely	O
positive	O
for	O
CD44s	O
,	O
bcl2	O
,	O
and	O
cyclin	O
D1	O
,	O
and	O
uniformly	O
negative	O
for	O
Glut1	O
.	O
In	O
contrast	O
,	O
50	O
%	O
of	O
the	O
ULMS	B-malignancy-type
and	O
25	O
%	O
of	O
EULMS	B-malignancy-type
were	O
Glutl	O
positive	O
.	O
Moreover	O
,	O
Glut1	O
positivity	O
closely	O
correlated	O
with	O
aggressive	O
biologic	O
behavior	O
reflected	O
by	O
distant	O
metastatic	O
spread	O
.	O
Eighty	O
-	O
percent	O
of	O
LM	B-malignancy-type
and	O
70	O
%	O
of	O
the	O
ULMS	B-malignancy-type
were	O
estrogen	O
receptor	O
positive	O
,	O
whereas	O
only	O
one	O
retroperitoneal	B-malignancy-type
tumor	I-malignancy-type
had	O
focal	O
weak	O
positivity	O
.	O
Over	O
80	O
%	O
of	O
the	O
extrauterine	B-malignancy-type
and	O
50	O
%	O
of	O
the	O
uterine	B-malignancy-type
sarcomas	I-malignancy-type
showed	O
absence	O
of	O
CD44s	O
immunoreactivity	O
.	O
Percentage	O
of	O
cyclin	O
D1	O
immunoreactivity	O
was	O
independent	O
of	O
tumor	O
grade	O
and	O
inversely	O
proportional	O
to	O
the	O
percent	O
of	O
bcl2	O
positivity	O
.	O
An	O
LMS	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
male	I-malignancy-type
breast	I-malignancy-type
contained	O
k-ras-2	O
exon	O
1	O
point	O
mutation	O
(	O
codon	O
12	O
aspartate	O
substitution	O
of	O
glycine	O
)	O
.	O
P53	O
allelic	O
imbalance	O
was	O
present	O
in	O
29	O
%	O
of	O
ULMS	B-malignancy-type
and	O
57	O
%	O
EULMS	B-malignancy-type
.	O
Mdm2	O
amplification	O
was	O
present	O
in	O
three	O
of	O
six	O
EULMS	B-malignancy-type
but	O
not	O
in	O
ULMS	B-malignancy-type
.	O
In	O
addition	O
to	O
clinical	O
staging	O
,	O
Glut1	O
positivity	O
together	O
with	O
patterns	O
of	O
immunoreactivity	O
of	O
CD44	O
and	O
bcl2	O
may	O
be	O
helpful	O
in	O
identifying	O
aggressive	B-malignancy-type
smooth	I-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
and	O
some	O
EULMS	B-malignancy-type
.	O
The	O
presence	O
of	O
estrogen	O
receptor	O
staining	O
may	O
be	O
helpful	O
in	O
identifying	O
uterine	B-malignancy-type
versus	O
nonuterine	B-malignancy-type
LMS	I-malignancy-type
.	O
Although	O
sample	O
numbers	O
are	O
too	O
small	O
for	O
definite	O
conclusions	O
,	O
this	O
study	O
suggests	O
that	O
there	O
are	O
differences	O
in	O
glucose	O
transport	O
,	O
expression	O
of	O
adhesion	O
molecules	O
,	O
and	O
estrogen	O
receptors	O
in	O
ULMS	B-malignancy-type
and	O
EULMS	B-malignancy-type
,	O
which	O
in	O
part	O
may	O
be	O
due	O
to	O
the	O
estrogen	O
dependency	O
of	O
the	O
ULMS	B-malignancy-type
.	O
P53	O
mutations	O
and	O
mdm2	O
amplifications	O
appear	O
to	O
be	O
more	O
frequent	O
in	O
EULMS	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Randomized	O
Controlled	O
Trial	O
PMID	O
:	O
10574596	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Rinsho	O
Byori	O
1999	O
Nov;47(	O
11	O
)	O
:1059	O
-	O
63	O
[	O
Detection	O
of	O
K-ras	O
mutations	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
by	O
PHA	O
-	O
PHFA	O
(	O
preferential	O
homoduplex	O
formation	O
assay	O
)	O
]	O
[	O
Article	O
in	O
Japanese	O
]	O
Funato	O
T	O
,	O
Zeng	O
Z	O
,	O
Satoh	O
J,	O
Fujiwara	O
J,	O
Kaku	O
M,	O
Sasaki	O
T.	O
Department	O
of	O
Molecular	O
Diagnostics	O
,	O
Tohoku	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Sendai	O
.	O
The	O
mutations	O
of	O
K-ras	O
gene	O
have	O
been	O
demonstrated	O
at	O
frequencies	O
of	O
about	O
40	O
%	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
We	O
applied	O
a	O
developed	O
PCR	O
-	O
preferential	O
homoduplex	O
formation	O
assay	O
(	O
PCR	O
-	O
PHFA	O
)	O
to	O
detect	O
a	O
point	O
mutation	O
of	O
K-ras	O
gene	O
in	O
the	O
surgical	O
specimens	O
from	O
thirty	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
This	O
method	O
is	O
based	O
on	O
the	O
strand	O
competition	O
during	O
hybridization	O
between	O
a	O
double	O
labeled	O
amplicon	O
,	O
prepared	O
from	O
biotin	O
and	O
DNP	O
labeled	O
primers	O
,	O
and	O
an	O
unlabeled	O
amplicon	O
.	O
The	O
procedure	O
of	O
this	O
method	O
is	O
simple	O
and	O
speedy	O
,	O
and	O
suitable	O
to	O
detect	O
mutations	O
in	O
a	O
small	O
number	O
of	O
samples	O
.	O
By	O
using	O
this	O
method	O
,	O
the	O
mutations	O
were	O
found	O
in	O
37	O
%	O
(	O
11	O
/	O
30	O
)	O
and	O
confirmed	O
by	O
sequencing	O
analysis	O
.	O
The	O
results	O
suggest	O
that	O
the	O
PCR	O
-	O
PHFA	O
system	O
may	O
be	O
useful	O
for	O
detecting	O
low	O
frequent	O
mutation	O
of	O
K-ras	O
gene	O
even	O
in	O
the	O
case	O
of	O
an	O
early	O
cancer	O
.	O
PMID	O
:	O
10590684	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Dec;155(	O
6)	O
:1795	O
-	O
801	O
Beta-catenin	O
mutations	O
are	O
frequent	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
associated	I-malignancy-type
with	I-malignancy-type
hepatitis	I-malignancy-type
C	I-malignancy-type
virus	I-malignancy-type
infection	I-malignancy-type
.	O
Huang	O
H	O
,	O
Fujii	O
H	O
,	O
Sankila	O
A	O
,	O
Mahler	O
-	O
Araujo	O
BM	O
,	O
Matsuda	O
M,	O
Cathomas	O
G	O
,	O
Ohgaki	O
H.	O
Unit	O
of	O
Molecular	O
Pathology	O
,	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
(	O
IARC	O
)	O
,	O
Lyon	O
,	O
France	O
.	O
Hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
is	O
one	O
of	O
the	O
most	O
common	O
fatal	O
cancers	O
worldwide	O
.	O
Hepatitis	O
B	O
virus	O
and	O
hepatitis	O
C	O
virus	O
infections	O
,	O
exposure	O
to	O
aflatoxin	O
,	O
and	O
excessive	O
intake	O
of	O
alcohol	O
have	O
been	O
identified	O
as	O
major	O
risk	O
factors	O
.	O
However	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
their	O
development	O
are	O
still	O
poorly	O
understood	O
.	O
Recently	O
,	O
beta-catenin	O
,	O
one	O
of	O
the	O
key	O
components	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
has	O
been	O
found	O
to	O
be	O
mutated	O
in	O
about	O
20	O
%	O
of	O
HCCs	B-malignancy-type
,	O
suggesting	O
a	O
role	O
of	O
the	O
Wnt	O
pathway	O
in	O
their	O
development	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
beta-catenin	O
and	O
APC	O
mutations	O
in	O
22	O
HCCs	B-malignancy-type
associated	I-malignancy-type
with	I-malignancy-type
HCV	I-malignancy-type
infection	I-malignancy-type
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
.	O
beta-Catenin	O
mutations	O
were	O
found	O
in	O
nine	O
(	O
41	O
%	O
)	O
cases	O
,	O
but	O
no	O
APC	O
mutations	O
were	O
found	O
.	O
beta-Catenin	O
immunohistochemistry	O
revealed	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
all	O
nine	O
tumors	O
with	O
a	O
beta-catenin	O
mutation	O
and	O
two	O
additional	O
tumors	O
without	O
a	O
mutation	O
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
by	O
beta-catenin	O
mutation	O
contributes	O
significantly	O
to	O
the	O
hepatocellular	O
carcinogenesis	O
associated	O
with	O
HCV	O
infection	O
.	O
PMID	O
:	O
10595907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Nov	O
11;1	O
8	O
(	O
47	O
)	O
:	O
658	O
3-8	O
Close	O
correlation	O
between	O
beta-catenin	O
gene	O
alterations	O
and	O
nuclear	O
accumulation	O
of	O
the	O
protein	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Terris	O
B	O
,	O
Pineau	O
P,	O
Bregeaud	O
L,	O
Valla	O
D	O
,	O
Belghiti	O
J,	O
Tiollais	O
P,	O
Degott	O
C,	O
Dejean	O
A.	O
Service	O
d'Anatomie	O
Pathologique	O
,	O
Hopital	O
Beaujon	O
,	O
Clichy	O
,	O
France	O
.	O
Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
beta-catenin	O
acquires	O
oncogenic	O
activity	O
when	O
its	O
intracellular	O
concentration	O
increases	O
as	O
a	O
result	O
of	O
either	O
mutation	O
in	O
the	O
beta-catenin	O
gene	O
itself	O
or	O
inactivation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
.	O
In	O
an	O
attempt	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
underlying	O
hepatocellular	O
carcinogenesis	O
,	O
we	O
have	O
studied	O
the	O
frequency	O
of	O
beta-catenin	O
gene	O
alterations	O
in	O
exon	O
3	O
,	O
a	O
region	O
known	O
to	O
represent	O
a	O
mutation	O
hot	O
spot	O
,	O
and	O
its	O
inappropriate	O
protein	O
expression	O
by	O
immunohistochemistry	O
in	O
73	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
.	O
The	O
results	O
were	O
correlated	O
with	O
different	O
clinical	O
and	O
pathological	O
data	O
,	O
particularly	O
with	O
the	O
presence	O
or	O
not	O
of	O
an	O
associated	O
cirrhosis	O
.	O
Fourteen	O
(	O
19	O
%	O
)	O
HCCs	B-malignancy-type
showed	O
beta-catenin	O
gene	O
alterations	O
with	O
missense	O
mutations	O
in	O
nine	O
cases	O
and	O
interstitial	O
deletions	O
in	O
five	O
cases	O
.	O
These	O
genetic	O
alterations	O
were	O
present	O
in	O
both	O
cirrhotic	O
and	O
non	O
-	O
cirrhotic	O
groups	O
.	O
By	O
contrast	O
,	O
we	O
did	O
not	O
find	O
any	O
beta-catenin	O
gene	O
alterations	O
in	O
the	O
nine	O
fibromellar	B-malignancy-type
carcinomas	I-malignancy-type
we	O
examined	O
.	O
Nuclear	O
accumulation	O
of	O
the	O
protein	O
was	O
observed	O
in	O
18	O
of	O
them	O
(	O
25	O
%	O
)	O
.	O
Remarkably	O
,	O
these	O
included	O
ten	O
of	O
the	O
14	O
tumors	O
harboring	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
accumulation	O
of	O
beta-catenin	O
resulting	O
from	O
genetic	O
mutations	O
is	O
a	O
frequent	O
event	O
in	O
non	B-malignancy-type
-	I-malignancy-type
fibrolamellar	I-malignancy-type
type	I-malignancy-type
hepatocellular	I-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
close	O
association	O
between	O
increased	O
beta-catenin	O
protein	O
stability	O
and	O
mutation	O
indicates	O
that	O
immunohistochemistry	O
may	O
be	O
a	O
powerful	O
method	O
for	O
the	O
detection	O
of	O
the	O
mutated	O
protein	O
in	O
future	O
clinical	O
practice	O
.	O
PMID	O
:	O
10597262	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Pathol	O
1999	O
Sep;5	O
2	O
(	O
9	O
)	O
:	O
69	O
5-6	O
A	O
novel	O
case	O
of	O
a	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumour	I-malignancy-type
with	O
mutation	O
of	O
the	O
beta	O
catenin	O
gene	O
.	O
Shitoh	O
K,	O
Konishi	O
F	O
,	O
Iijima	O
T	O
,	O
Ohdaira	O
T	O
,	O
Sakai	O
K,	O
Kanazawa	O
K,	O
Miyaki	O
M.	O
Hereditary	O
Tumour	O
Research	O
Project	O
,	O
Tokyo	O
Metropolitan	O
Komagome	O
Hospital	O
,	O
Japan	O
.	O
A	O
42	O
year	O
old	O
man	O
without	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
had	O
recurrent	O
desmoid	B-malignancy-type
tumours	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
left	I-malignancy-type
subclavicular	I-malignancy-type
site	I-malignancy-type
.	O
Histological	O
examination	O
showed	O
a	O
typical	O
desmoid	B-malignancy-type
tumour	I-malignancy-type
.	O
Molecular	O
analysis	O
was	O
performed	O
in	O
genomic	O
DNA	O
from	O
this	O
tumour	O
,	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
methods	O
.	O
No	O
mutation	O
could	O
be	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
APC	O
gene	O
,	O
nor	O
in	O
H-ras	O
,	O
K-ras	O
,	O
N-ras	O
,	O
or	O
p53	O
genes	O
.	O
On	O
seeking	O
a	O
mutation	O
of	O
the	O
beta	O
catenin	O
gene	O
(	O
CTNNB1	O
)	O
,	O
an	O
activating	O
mutation	O
from	O
ACC	O
(	O
Thr	O
)	O
to	O
GCC	O
(	O
Ala	O
)	O
at	O
codon	O
41	O
was	O
found	O
.	O
Immunohistochemical	O
staining	O
showed	O
that	O
accumulated	O
beta	O
catenin	O
protein	O
was	O
predominantly	O
localised	O
in	O
the	O
nuclei	O
of	O
desmoid	O
cells	O
.	O
This	O
is	O
the	O
first	O
example	O
of	O
a	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumour	I-malignancy-type
in	O
which	O
a	O
mutation	O
of	O
the	O
beta	O
catenin	O
gene	O
was	O
revealed	O
.	O
PMID	O
:	O
10655994	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2000	O
Feb;24(	O
2	O
)	O
:211	O
-	O
22	O
Esophageal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
genetic	O
study	O
of	O
17	O
cases	O
and	O
comparison	O
with	O
esophageal	B-malignancy-type
leiomyomas	I-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
.	O
Miettinen	O
M,	O
Sarlomo	O
-	O
Rikala	O
M,	O
Sobin	O
LH	O
,	O
Lasota	O
J.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
Although	O
rare	O
elsewhere	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
leiomyomas	B-malignancy-type
(	O
LMs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
esophageal	B-malignancy-type
mesenchymal	I-malignancy-type
neoplasms	I-malignancy-type
.	O
In	O
contrast	O
,	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	O
)	O
predominate	O
in	O
the	O
stomach	O
and	O
intestines	O
but	O
have	O
not	O
been	O
documented	O
in	O
the	O
esophagus	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
clinicopathologic	O
features	O
and	O
frequency	O
of	O
esophageal	B-malignancy-type
GISTs	I-malignancy-type
compared	O
with	O
LMs	B-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
(	O
LMSs	B-malignancy-type
)	O
of	B-malignancy-type
the	I-malignancy-type
esophagus	I-malignancy-type
.	O
A	O
total	O
of	O
68	O
stromal	B-malignancy-type
/	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
from	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
and	O
the	O
Haartman	O
Institute	O
of	O
University	O
of	O
Helsinki	O
were	O
reclassified	O
by	O
current	O
histologic	O
and	O
immunohistochemical	O
criteria	O
.	O
There	O
were	O
17	O
GISTs	B-malignancy-type
,	O
48	O
LMs	B-malignancy-type
,	O
and	O
three	O
LMSs	B-malignancy-type
.	O
The	O
esophageal	B-malignancy-type
GISTs	I-malignancy-type
occurred	O
in	O
12	O
men	O
and	O
five	O
women	O
with	O
a	O
median	O
age	O
of	O
63	O
years	O
(	O
range	O
,	O
49	O
-	O
75	O
years	O
)	O
.	O
All	O
tumors	B-malignancy-type
were	O
from	O
the	O
lowest	O
third	O
of	B-malignancy-type
the	I-malignancy-type
esophagus	I-malignancy-type
,	O
and	O
the	O
most	O
common	O
complaint	O
was	O
dysphagia	O
,	O
whereas	O
two	O
tumors	O
were	O
detected	O
incidentally	O
.	O
Histologically	O
the	O
tumors	O
had	O
an	O
overall	O
basophilic	O
appearance	O
and	O
showed	O
combinations	O
of	O
solid	O
,	O
myxoid	O
,	O
and	O
perivascular	O
collarlike	O
patterns	O
with	O
a	O
spindle	O
cell	O
histology	O
in	O
13	O
patients	O
and	O
epithelioid	O
histology	O
in	O
four	O
patients	O
.	O
All	O
tumors	O
were	O
positive	O
for	O
CD117	O
and	O
for	O
CD34	O
,	O
whereas	O
two	O
patients	O
were	O
also	O
positive	O
for	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
SMA	O
)	O
and	O
three	O
patients	O
were	O
positive	O
for	O
desmin	O
.	O
One	O
patient	O
showed	O
a	O
unique	O
immunophenotype	O
with	O
coexpression	O
of	O
CD117	O
,	O
CD34	O
,	O
SMA	O
,	O
and	O
desmin	O
.	O
Nine	O
patients	O
died	O
of	O
disease	O
,	O
including	O
all	O
who	O
had	O
a	O
tumor	O
larger	O
than	O
10	O
cm	O
,	O
and	O
also	O
one	O
patient	O
whose	O
tumor	O
showed	O
five	O
mitoses	O
per	O
50	O
high	O
-	O
power	O
fields	O
.	O
In	O
comparison	O
,	O
esophageal	B-malignancy-type
LMs	I-malignancy-type
(	O
n	O
=	O
48	O
)	O
occurred	O
in	O
a	O
younger	O
population	O
(	O
median	O
age	O
,	O
35	O
years	O
)	O
but	O
,	O
similar	O
to	O
the	O
GIST	O
group	O
,	O
men	O
predominated	O
(	O
67	O
%	O
)	O
.	O
All	O
LMs	B-malignancy-type
were	O
clinically	B-malignancy-type
indolent	I-malignancy-type
tumors	O
with	O
no	O
tumor	O
-	O
related	O
mortality	O
.	O
The	O
LMs	B-malignancy-type
showed	O
eosinophilic	O
cytoplasm	O
,	O
and	O
were	O
positive	O
for	O
desmin	O
and	O
SMA	O
,	O
and	O
negative	O
for	O
CD117	O
and	O
CD34	O
.	O
All	O
three	O
LMSs	B-malignancy-type
were	O
large	B-malignancy-type
high	I-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
tumors	O
that	O
showed	O
muscle	O
cell	O
markers	O
but	O
no	O
CD117	O
.	O
All	O
patients	O
died	O
of	O
disease	O
.	O
Esophageal	B-malignancy-type
GISTs	I-malignancy-type
showed	O
mutations	O
in	O
exon	O
11	O
of	O
c-kit	O
as	O
described	O
previously	O
in	O
gastric	B-malignancy-type
and	O
intestinal	B-malignancy-type
GISTs	B-malignancy-type
.	O
The	O
separation	O
of	O
GISTs	B-malignancy-type
from	O
esophageal	B-malignancy-type
LMs	I-malignancy-type
is	O
important	O
diagnostically	O
because	O
the	O
former	O
group	O
has	O
a	O
high	O
risk	O
of	O
malignant	O
behavior	O
.	O
PMID	O
:	O
10680889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
2000	O
Feb	O
29;97(	O
5	O
)	O
:2225	O
-	O
8	O
APC	O
mutations	O
are	O
sufficient	O
for	O
the	O
growth	O
of	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
Lamlum	O
H	O
,	O
Papadopoulou	O
A	O
,	O
Ilyas	O
M,	O
Rowan	O
A	O
,	O
Gillet	O
C	O
,	O
Hanby	O
A	O
,	O
Talbot	O
I	O
,	O
Bodmer	O
W	O
,	O
Tomlinson	O
I.	O
Molecular	O
and	O
Population	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
44	O
,	O
Lincoln	O
's	O
Inn	O
Fields	O
,	O
London	O
WC2A	O
3PX	O
,	O
United	O
Kingdom	O
.	O
It	O
is	O
not	O
clear	O
whether	O
APC	O
mutations	O
are	O
sufficient	O
for	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
to	O
grow	O
or	O
whether	O
additional	O
mutations	O
at	O
other	O
loci	O
are	O
required	O
.	O
We	O
previously	O
have	O
screened	O
210	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
from	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
for	O
mutations	O
and	O
allelic	O
loss	O
at	O
APC	O
.	O
Here	O
,	O
we	O
determined	O
whether	O
allelic	O
loss	O
at	O
APC	O
had	O
any	O
effect	O
on	O
the	O
nearby	O
alpha	O
-	O
catenin	O
gene	O
.	O
However	O
,	O
loss	O
on	O
5q	O
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
adenomas	I-malignancy-type
rarely	O
extended	O
as	O
far	O
as	O
alpha	O
-	O
catenin	O
,	O
and	O
no	O
differences	O
in	O
alpha-catenin	O
protein	O
expression	O
were	O
found	O
in	O
tumors	O
that	O
showed	O
loss	O
encompassing	O
both	O
APC	O
and	O
alpha-catenin	O
.	O
We	O
then	O
screened	O
all	O
210	O
tumors	O
for	O
mutations	O
at	O
candidate	O
loci	O
other	O
than	O
APC	O
(	O
K-ras	O
,	O
beta-catenin	O
,	O
and	O
allelic	O
loss	O
at	O
1p33	O
-	O
p35	O
and	O
1p36	O
)	O
and	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
Each	O
of	O
these	O
loci	O
has	O
been	O
implicated	O
previously	O
in	O
early	O
colorectal	O
tumorigenesis	O
.	O
One	O
tumor	O
harbored	O
a	O
beta-catenin	O
mutation	O
and	O
another	O
MSI	O
,	O
but	O
none	O
showed	O
K-ras	O
mutation	O
or	O
allelic	O
loss	O
at	O
1p33	O
-	O
p35	O
or	O
1p36	O
.	O
These	O
data	O
support	O
the	O
following	O
hypotheses	O
derived	O
from	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
:	O
beta-catenin	O
mutations	O
are	O
generally	O
an	O
alternative	O
to	O
mutations	O
at	O
APC	O
,	O
MSI	O
is	O
not	O
usually	O
an	O
early	O
phenomenon	O
in	O
colorectal	O
tumorigenesis	O
,	O
and	O
K-ras	O
mutations	O
are	O
more	O
typical	O
of	O
large	B-malignancy-type
-	I-malignancy-type
and	O
moderate	B-malignancy-type
-	I-malignancy-type
sized	I-malignancy-type
adenomas	I-malignancy-type
.	O
Contrary	O
to	O
some	O
previous	O
reports	O
,	O
chromosome	O
1p	O
allelic	O
loss	O
is	O
infrequent	O
in	O
very	O
early	O
adenomas	B-malignancy-type
.	O
APC	O
mutations	O
are	O
generally	O
sufficient	O
for	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
to	O
grow	O
to	O
about	O
1	O
-	O
cm	O
diameter	O
,	O
although	O
chance	O
mutations	O
at	O
other	O
loci	O
can	O
provide	O
these	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
with	O
a	O
selective	O
advantage	O
,	O
and	O
some	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
may	O
develop	O
along	O
a	O
pathway	O
not	O
involving	O
APC	O
.	O
PMID	O
:	O
10681434	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Surg	O
Oncol	O
2000	O
Mar;73(	O
3	O
)	O
:158	O
-	O
63	O
Aberrations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
and	O
APC	O
genes	O
in	O
extrahepatic	B-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
cancer	I-malignancy-type
.	O
Suto	O
T	O
,	O
Habano	O
W	O
,	O
Sugai	O
T	O
,	O
Uesugi	O
N	O
,	O
Funato	O
O	O
,	O
Kanno	O
S,	O
Saito	O
K	O
,	O
Nakamura	O
S.	O
Department	O
of	O
Surgery	O
I	O
,	O
School	O
of	O
Medicine	O
,	O
Iwate	O
Medical	O
University	O
,	O
Morioka	O
,	O
Iwate	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
genetic	O
alterations	O
involved	O
in	O
extrahepatic	B-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
(	I-malignancy-type
EHBD	I-malignancy-type
)	I-malignancy-type
cancer	I-malignancy-type
are	O
poorly	O
understood	O
.	O
Our	O
aim	O
was	O
to	O
identify	O
aberrations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
and	O
APC	O
genes	O
in	O
EHBD	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
We	O
investigated	O
aberrations	O
of	O
these	O
genes	O
in	O
52	O
EHBD	B-malignancy-type
cancers	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
followed	O
by	O
direct	O
sequence	O
determination	O
and	O
a	O
PCR	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O
RESULTS	O
:	O
The	O
K-ras	O
,	O
p53	O
,	O
and	O
APC	O
genes	O
were	O
mutated	O
in	O
9.6	O
%	O
,	O
32.7	O
%	O
,	O
and	O
0	O
%	O
of	O
EHBD	B-malignancy-type
cancers	I-malignancy-type
,	O
respectively	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
p53	O
and	O
APC	O
gene	O
loci	O
was	O
identified	O
in	O
15.6	O
%	O
and	O
38.5	O
%	O
of	O
EHBD	B-malignancy-type
cancers	I-malignancy-type
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
an	O
unknown	O
suppressor	O
gene	O
on	O
5q	O
other	O
than	O
the	O
APC	O
gene	O
may	O
be	O
responsible	O
for	O
EHBD	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10738270	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neuropathol	O
Exp	O
Neurol	O
2000	O
Apr;5	O
9	O
(	O
4	O
)	O
:	O
33	O
3-7	O
Nuclear	O
localization	O
and	O
mutation	O
of	O
beta-catenin	O
in	O
medulloblastomas	B-malignancy-type
.	O
Eberhart	O
CG	O
,	O
Tihan	O
T	O
,	O
Burger	O
PC	O
.	O
Department	O
of	O
Pathology	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
,	O
USA	O
.	O
The	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
a	O
member	O
of	O
the	O
Wingless	O
/	O
Wnt	O
signal	O
transduction	O
pathway	O
,	O
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
medulloblastomas	B-malignancy-type
in	O
Turcot	B-malignancy-type
's	I-malignancy-type
syndrome	I-malignancy-type
.	O
beta-catenin	O
also	O
functions	O
in	O
this	O
highly	O
conserved	O
signaling	O
pathway	O
and	O
is	O
instrumental	O
in	O
growth	O
and	O
development	O
.	O
Mutations	O
in	O
either	O
APC	O
or	O
beta-catenin	O
can	O
stabilize	O
beta-catenin	O
protein	O
.	O
Stabilized	O
beta-catenin	O
complexes	O
with	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
and	O
moves	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
where	O
it	O
regulates	O
the	O
transcription	O
of	O
c-Myc	O
and	O
other	O
genes	O
.	O
Nuclear	O
localization	O
of	O
beta-catenin	O
therefore	O
implies	O
activation	O
of	O
the	O
signaling	O
pathway	O
.	O
We	O
have	O
analyzed	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
in	O
51	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
and	O
in	O
1	O
medulloblastoma	B-malignancy-type
arising	O
in	O
a	O
patient	O
with	O
Turcot	B-malignancy-type
's	I-malignancy-type
syndrome	I-malignancy-type
.	O
Nuclear	O
beta-catenin	O
staining	O
was	O
present	O
in	O
9	O
of	O
the	O
sporadic	O
tumors	O
(	O
18	O
%	O
)	O
and	O
in	O
the	O
1	O
medulloblastoma	B-malignancy-type
from	O
a	O
Turcot	B-malignancy-type
's	I-malignancy-type
patient	O
.	O
The	O
remaining	O
41	O
cases	O
did	O
not	O
show	O
nuclear	O
staining	O
.	O
This	O
confirms	O
earlier	O
observations	O
that	O
Wingless	O
/	O
Wnt	O
signaling	O
is	O
involved	O
in	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
.	O
We	O
also	O
examined	O
48	O
glial	B-malignancy-type
and	O
meningeal	B-malignancy-type
CNS	I-malignancy-type
tumors	I-malignancy-type
,	O
all	O
of	O
which	O
were	O
negative	O
for	O
nuclear	O
beta-catenin	O
.	O
Exon	O
3	O
of	O
beta-catenin	O
was	O
sequenced	O
in	O
6	O
of	O
the	O
9	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
with	O
nuclear	O
beta-catenin	O
staining	O
.	O
Five	O
of	O
the	O
6	O
tumors	O
sequenced	O
had	O
mutations	O
affecting	O
highly	O
conserved	O
beta-catenin	O
phosphorylation	O
sites	O
involved	O
in	O
protein	O
stability	O
.	O
These	O
data	O
suggest	O
a	O
simple	O
immunohistochemical	O
method	O
to	O
screen	O
for	O
beta-catenin	O
mutations	O
in	O
medulloblastomas	B-malignancy-type
.	O
PMID	O
:	O
10759189	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2000	O
Ma	O
y-Jun;	O
7	O
(	O
3	O
)	O
:	O
49	O
7-500	O
Screening	O
of	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
for	O
the	O
presence	O
of	O
Ha-ras	O
codon	O
12	O
mutation	O
.	O
Cattan	O
N	O
,	O
Saiso	O
n-Behmoaras	O
T	O
,	O
Mari	O
B	O
,	O
Mazeau	O
C,	O
Amiel	O
JL	O
,	O
Rossi	O
B	O
,	O
Gioanni	O
J.	O
Laboratoire	O
de	O
Cancerologie	O
du	O
Centre	O
Antoine	O
Lacassagne	O
,	O
06107	O
Nice	O
Cedex	O
02	O
,	O
France	O
.	O
Contradictory	O
results	O
were	O
obtained	O
from	O
previous	O
studies	O
aiming	O
at	O
defining	O
the	O
frequency	O
of	O
Ha-ras	O
codon	O
12	O
mutations	O
in	O
bladder	B-malignancy-type
tumors	I-malignancy-type
.	O
Differences	O
in	O
the	O
sensitivities	O
of	O
the	O
methods	O
used	O
could	O
account	O
for	O
this	O
discrepancy	O
.	O
In	O
this	O
study	O
,	O
we	O
reevaluated	O
the	O
frequency	O
of	O
Ha-ras	O
codon	O
12	O
mutations	O
in	O
a	O
series	O
of	O
87	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
using	O
a	O
combination	O
of	O
two	O
different	O
methods	O
.	O
The	O
first	O
was	O
derived	O
from	O
the	O
protocol	O
of	O
Ooi	O
et	O
al	O
and	O
consisted	O
in	O
a	O
one	O
-	O
step	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
using	O
mismatched	O
primers	O
in	O
two	O
separate	O
PCR	O
.	O
This	O
method	O
is	O
very	O
rapid	O
and	O
highly	O
sensitive	O
,	O
detecting	O
the	O
presence	O
of	O
minor	O
populations	O
(	O
less	O
than	O
10	O
%	O
)	O
of	O
mutant	O
alleles	O
.	O
The	O
second	O
strategy	O
consisted	O
in	O
screening	O
all	O
tumors	O
using	O
natural	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
The	O
two	O
methods	O
were	O
in	O
complete	O
concordance	O
and	O
enabled	O
us	O
to	O
show	O
that	O
only	O
one	O
out	O
of	O
87	O
primary	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
(	O
1	O
%	O
)	O
exhibited	O
the	O
mutation	O
,	O
in	O
accordance	O
with	O
previous	O
studies	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
,	O
even	O
if	O
minor	O
cell	O
populations	O
overexpress	O
codon	O
12	O
Ha-ras	O
mutation	O
,	O
the	O
analysis	O
of	O
this	O
mutation	O
cannot	O
be	O
used	O
to	O
screen	O
potentially	B-malignancy-type
invasive	I-malignancy-type
transitional	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
.	O
PMID	O
:	O
10767358	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2000	O
May;156	O
(	O
5	O
)	O
:	O
164	O
1-51	O
Genetic	O
,	O
immunohistochemical	O
,	O
and	O
clinical	O
features	O
of	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
:	O
A	O
newly	O
described	O
and	O
characterized	O
entity	O
.	O
Wilentz	O
RE	O
,	O
Goggins	O
M,	O
Redston	O
M,	O
Marcus	O
VA	O
,	O
Adsay	O
NV	O
,	O
Sohn	O
TA	O
,	O
Kadkol	O
SS	O
,	O
Yeo	O
CJ	O
,	O
Choti	O
M,	O
Zahurak	O
M,	O
Johnson	O
K,	O
Tascilar	O
M,	O
Offerhaus	O
GJ	O
,	O
Hruban	O
RH	O
,	O
Kern	O
SE.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21231	O
,	O
USA	O
.	O
Medullary	B-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
are	O
a	O
recently	O
described	O
,	O
histologically	O
distinct	O
subset	O
of	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenocarcinomas	I-malignancy-type
that	O
may	O
have	O
a	O
unique	O
pathogenesis	O
and	O
clinical	O
course	O
.	O
To	O
further	O
evaluate	O
these	O
neoplasms	B-malignancy-type
,	O
we	O
studied	O
genetic	O
,	O
pathological	O
,	O
and	O
clinical	O
features	O
of	O
13	O
newly	O
identified	O
medullary	B-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Nine	O
(	O
69	O
%	O
)	O
of	O
these	O
had	O
wild-type	O
K-ras	O
genes	O
,	O
and	O
one	O
had	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
This	O
MSI	B-malignancy-type
medullary	I-malignancy-type
carcinoma	I-malignancy-type
,	O
along	O
with	O
three	O
previously	O
reported	O
MSI	B-malignancy-type
medullary	I-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
examined	O
immunohistochemically	O
for	O
Mlh1	O
and	O
Msh2	O
expression	O
,	O
and	O
all	O
four	O
expressed	O
Msh2	O
but	O
did	O
not	O
express	O
Mlh1	O
.	O
In	O
contrast	O
,	O
all	O
of	O
the	O
medullary	B-malignancy-type
carcinomas	I-malignancy-type
without	I-malignancy-type
MSI	I-malignancy-type
expressed	O
both	O
Msh2	O
and	O
Mlh1	O
.	O
Remarkably	O
,	O
the	O
MSI	B-malignancy-type
medullary	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
in	O
the	O
present	O
series	O
arose	O
in	O
a	O
patient	O
with	O
a	O
synchronous	O
but	O
histologically	O
distinct	O
cecal	B-malignancy-type
carcinoma	I-malignancy-type
that	I-malignancy-type
also	I-malignancy-type
had	I-malignancy-type
MSI	I-malignancy-type
and	O
did	O
not	O
express	O
Mlh1	O
.	O
The	O
synchronous	O
occurrence	O
of	O
two	O
MSI	B-malignancy-type
carcinomas	I-malignancy-type
suggests	O
an	O
inherited	O
basis	O
for	O
the	O
development	O
of	O
these	O
carcinomas	B-malignancy-type
.	O
Indeed	O
,	O
the	O
medullary	O
phenotype	O
,	O
irrespective	O
of	O
MSI	O
,	O
was	O
highly	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	O
in	O
first-degree	O
relatives	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Finally	O
,	O
one	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
with	I-malignancy-type
lymphoepithelioma	I-malignancy-type
-	I-malignancy-type
like	I-malignancy-type
features	I-malignancy-type
contained	O
Epstein	O
-	O
Barr	O
virus	O
-	O
encoded	O
RNA-1	O
by	O
in	O
situ	O
hybridization	O
.	O
Therefore	O
,	O
because	O
of	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
's	O
special	O
genetic	O
,	O
immunohistochemical	O
,	O
and	O
clinical	O
features	O
,	O
recognition	O
of	O
the	O
medullary	B-malignancy-type
variant	I-malignancy-type
of	I-malignancy-type
pancreatic	I-malignancy-type
adenocarcinoma	I-malignancy-type
is	O
important	O
.	O
Only	O
by	O
classifying	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
as	O
special	O
subset	O
of	O
adenocarcinoma	B-malignancy-type
can	O
we	O
hope	O
to	O
further	O
elucidate	O
its	O
unique	O
pathogenesis	O
.	O
PMID	O
:	O
10793075	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Pathol	O
Lab	O
Med	O
2000	O
Jun;12	O
4	O
(	O
6	O
)	O
:	O
89	O
4-7	O
Spindle	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
urinary	I-malignancy-type
bladder	I-malignancy-type
serosa	I-malignancy-type
with	O
phenotypic	O
and	O
genotypic	O
features	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
.	O
Lasota	O
J,	O
Carlson	O
JA	O
,	O
Miettinen	O
M.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
2030	O
6-6000	O
,	O
USA	O
.	O
Most	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
are	O
now	O
referred	O
to	O
as	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
.	O
The	O
tumors	O
differ	O
from	O
ordinary	O
leiomyomas	B-malignancy-type
and	O
schwannomas	B-malignancy-type
in	O
several	O
respects	O
:	O
the	O
GISTs	B-malignancy-type
typically	O
express	O
c-kit	O
protein	O
(	O
CD117	O
)	O
and	O
CD34	O
,	O
30	O
%	O
to	O
50	O
%	O
of	O
them	O
are	O
(	O
often	O
focally	O
)	O
positive	O
for	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
,	O
and	O
all	O
are	O
negative	O
for	O
desmin	O
and	O
S100	O
protein	O
.	O
Recently	O
,	O
mutations	O
in	O
the	O
exon	O
11	O
of	O
the	O
c-kit	O
gene	O
have	O
been	O
identified	O
and	O
confirmed	O
as	O
a	O
molecular	O
genetic	O
marker	O
for	O
the	O
subset	O
of	O
GISTs	B-malignancy-type
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
mesenchymal	B-malignancy-type
tumor	I-malignancy-type
removed	O
from	O
the	O
pelvic	O
cavity	O
of	O
a	O
52	O
-	O
year	O
-	O
old	O
woman	O
,	O
who	O
is	O
alive	O
without	O
disease	O
36	O
months	O
after	O
the	O
surgery	O
.	O
The	O
5	O
-	O
cm	O
tumor	O
was	O
densely	O
attached	O
to	O
the	O
external	O
aspect	O
of	O
the	O
urinary	O
bladder	O
but	O
was	O
attached	O
to	O
small	O
intestine	O
by	O
only	O
filmy	O
adhesions	O
.	O
The	O
tumor	O
grossly	O
resembled	O
a	O
leiomyoma	B-malignancy-type
and	O
was	O
histologically	O
composed	O
of	O
sheets	O
of	O
spindle	O
cells	O
with	O
a	O
dense	O
collagenous	O
background	O
.	O
The	O
mitotic	O
activity	O
was	O
low	O
,	O
less	O
then	O
1	O
per	O
50	O
high	O
-	O
power	O
fields	O
.	O
Immunohistochemically	O
,	O
the	O
tumor	O
cells	O
were	O
negative	O
for	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
and	O
desmin	O
and	O
positive	O
for	O
CD117	O
and	O
CD34	O
.	O
Molecular	O
genetic	O
analysis	O
of	O
the	O
exon	O
11	O
of	O
the	O
c-kit	O
gene	O
revealed	O
a	O
point	O
mutation	O
in	O
the	O
region	O
commonly	O
mutated	O
in	O
GISTs	B-malignancy-type
.	O
This	O
mutation	O
substituted	O
T	O
for	O
A	O
in	O
the	O
codon	O
557	O
,	O
leading	O
to	O
the	O
change	O
of	O
amino	O
acid	O
sequence	O
(	O
tryptophan	O
for	O
arginine	O
)	O
of	O
the	O
KIT	O
protein	O
.	O
This	O
case	O
illustrates	O
that	O
tumors	O
phenotypically	O
and	O
genotypically	O
similar	O
to	O
GISTs	B-malignancy-type
may	O
present	O
in	O
sites	O
other	O
than	O
the	O
tubular	O
gastrointestinal	O
tract	O
.	O
PMID	O
:	O
10835530	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pathol	O
2000	O
Feb;5	O
3	O
(	O
1	O
)	O
:	O
2	O
4-30	O
p53	O
and	O
K-ras	O
gene	O
mutations	O
in	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
among	O
Finnish	O
women	O
.	O
Servomaa	O
K,	O
Kiuru	O
A	O
,	O
Kosma	O
VM	O
,	O
Hirvikoski	O
P,	O
Rytomaa	O
T.	O
North	O
Savo	O
Regional	O
Environment	O
Centre	O
,	O
Kuopio	O
,	O
Finland	O
.	O
kristina	O
.servomaa@vyh	O
.fi	O
AIMS	O
/	O
BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
p53	O
and	O
K-ras	O
gene	O
mutations	O
in	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
among	O
Finnish	O
women	O
.	O
Mutation	O
patterns	O
might	O
give	O
clues	O
to	O
aetiological	O
factors	O
when	O
comparisons	O
are	O
made	O
with	O
other	O
human	O
tumours	O
.	O
METHODS	O
:	O
Of	O
134	O
women	O
with	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
,	O
paraffin	O
wax	O
embedded	O
specimens	O
of	O
the	O
tumour	O
tissue	O
were	O
obtained	O
from	O
118	O
patients	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
,	O
and	O
exons	O
4	O
-	O
8	O
of	O
the	O
p53	O
gene	O
and	O
codons	O
12	O
/	O
13	O
and	O
61	O
of	O
the	O
K-ras	O
gene	O
were	O
amplified	O
,	O
and	O
analysed	O
for	O
mutations	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
.	O
The	O
production	O
of	O
p53	O
and	O
K-ras	O
proteins	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
The	O
overall	O
crude	O
frequency	O
for	O
mutations	O
in	O
the	O
p53	O
gene	O
was	O
35	O
%	O
but	O
the	O
true	O
frequency	O
appears	O
to	O
be	O
higher	O
(	O
up	O
to	O
56	O
%	O
)	O
.	O
In	O
the	O
K-ras	O
gene	O
,	O
the	O
mutation	O
frequency	O
(	O
15	O
%	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
reported	O
for	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
the	O
p53	O
gene	O
,	O
the	O
mutation	O
frequency	O
increased	O
significantly	O
with	O
patient	O
age	O
.	O
In	O
a	O
high	O
proportion	O
of	O
patients	O
(	O
14	O
%	O
)	O
the	O
rectal	B-malignancy-type
tumours	I-malignancy-type
contained	O
small	O
subclones	O
of	O
tumour	O
cells	O
that	O
displayed	O
extremely	O
rare	O
mutations	O
at	O
codons	O
110	O
and	O
232	O
of	O
the	O
p53	O
gene	O
.	O
Hot	O
spot	O
codon	O
175	O
mutations	O
were	O
significantly	O
less	O
common	O
in	O
rectal	B-malignancy-type
cancer	I-malignancy-type
than	O
in	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Rectal	B-malignancy-type
cancer	I-malignancy-type
among	O
Finnish	O
women	O
has	O
characteristics	O
in	O
the	O
mutations	O
of	O
the	O
p53	O
and	O
K-ras	O
genes	O
that	O
are	O
uncommon	O
in	O
other	O
human	O
tumours	O
,	O
including	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
A	O
biological	O
explanation	O
of	O
these	O
findings	O
is	O
not	O
clear	O
at	O
present	O
,	O
but	O
might	O
be	O
associated	O
with	O
an	O
unidentified	O
genetic	O
factor	O
in	O
Finland	O
.	O
PMID	O
:	O
10884918	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2000	O
Aug;83(	O
4)	O
:473	O
-	O
9	O
Multiple	O
molecular	O
marker	O
testing	O
(	O
p53	O
,	O
C-Ki-ras	O
,	O
c-erbB-2	O
)	O
improves	O
estimation	O
of	O
prognosis	O
in	O
potentially	O
curative	O
resected	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
Schneider	O
PM	O
,	O
Praeuer	O
HW	O
,	O
Stoeltzing	O
O	O
,	O
Boehm	O
J,	O
Manning	O
J,	O
Metzger	O
R,	O
Fink	O
U	O
,	O
Wegerer	O
S,	O
Hoelscher	O
AH	O
,	O
Roth	O
JA.	O
Department	O
of	O
Visceral	O
and	O
Vascular	O
Surgery	O
,	O
University	O
of	O
Cologne	O
,	O
Germany	O
.	O
Paul.Schneider@Medizin.Uni-Koeln.de	O
A	O
prospective	O
study	O
was	O
performed	O
in	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
to	O
evaluate	O
the	O
prognostic	O
importance	O
of	O
multiple	O
molecular	O
marker	O
(	O
p53	O
,	O
c-Ki-ras	O
,	O
c-erbB-2	O
)	O
testing	O
.	O
103	O
patients	O
with	O
potentially	O
curative	O
resections	O
(	O
RO	O
resection	O
)	O
for	O
NSCLC	B-malignancy-type
in	O
histopathological	O
stages	O
I	O
-	O
IIIA	O
were	O
included	O
.	O
SSCP	O
analysis	O
and	O
DNA	O
sequencing	O
for	O
p53	O
and	O
c-Ki-ras	O
genes	O
were	O
performed	O
on	O
paired	O
tumour	O
and	O
normal	O
lung	O
tissue	O
samples	O
and	O
immunohistochemistry	O
(	O
c-erbB-2	O
)	O
was	O
done	O
on	O
frozen	O
tissue	O
sections	O
with	O
a	O
specific	O
anti	O
-	O
c-erbB-2	O
monoclonal	O
antibody	O
.	O
46	O
/	O
103	O
(	O
44.6	O
%	O
)	O
NSCLC	B-malignancy-type
showed	O
p53	O
mutations	O
and	O
17	O
/	O
103	O
(	O
16.5	O
%	O
)	O
c-Ki-ras	O
mutations	O
including	O
12	O
/	O
37	O
(	O
32.4	O
%	O
)	O
adenocarcinomas	B-malignancy-type
.	O
Overexpression	O
of	O
c-erbB-2	O
(	O
p185	O
)	O
was	O
detected	O
in	O
56	O
/	O
103	O
(	O
54.4	O
%	O
)	O
tumours	O
.	O
24	O
/	O
103	O
(	O
23.3	O
%	O
)	O
NSCLC	B-malignancy-type
were	O
negative	O
for	O
alterations	O
in	O
all	O
3	O
parameters	O
(	O
c-Ki-ras	O
,	O
p53	O
and	O
p185	O
)	O
whereas	O
79	O
/	O
103	O
(	O
76.7	O
%	O
)	O
were	O
positive	O
for	O
at	O
least	O
one	O
of	O
the	O
3	O
parameters	O
.	O
In	O
a	O
regression	O
model	O
including	O
a	O
multiple	O
molecular	O
marker	O
parameter	O
(	O
negative	O
for	O
all	O
3	O
markers	O
versus	O
positive	O
for	O
at	O
least	O
one	O
marker	O
)	O
,	O
histopathological	O
stage	O
(	O
P	O
<	O
0.00001	O
)	O
,	O
respectively	O
the	O
pT	O
(	O
P	O
<	O
0.01	O
)	O
and	O
pN	O
(	O
P	O
<	O
0.00001	O
)	O
categories	O
and	O
the	O
multiple	O
molecular	O
marker	O
parameter	O
(	O
P	O
<	O
0.01	O
)	O
were	O
of	O
significant	O
prognostic	O
importance	O
.	O
This	O
study	O
demonstrates	O
that	O
testing	O
3	O
molecular	O
markers	O
(	O
c-Ki-ras	O
,	O
p53	O
and	O
c-erbB-2	O
)	O
improves	O
estimation	O
of	O
prognosis	O
compared	O
to	O
single	O
marker	O
testing	O
and	O
appears	O
to	O
define	O
low	O
(	O
82.6	O
%	O
+/-	O
7.9	O
%	O
5	O
-	O
year	O
survival	O
)	O
and	O
high	O
risk	O
(	O
40.2	O
%	O
+/-	O
5.5	O
%	O
5	O
-	O
year	O
survival	O
)	O
groups	O
for	O
treatment	O
failure	O
in	O
potentially	O
curative	O
(	O
RO	O
)	O
resected	O
NSCLC	B-malignancy-type
.	O
PMID	O
:	O
10945494	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2000	O
Sep;13(	O
9	O
)	O
:973	O
-	O
7	O
Missense	O
mutation	O
of	O
the	O
MET	O
gene	O
detected	O
in	O
human	O
glioma	B-malignancy-type
.	O
Moon	O
YW	O
,	O
Weil	O
RJ	O
,	O
Pack	O
SD	O
,	O
Park	O
WS	O
,	O
Pak	O
E	O
,	O
Pham	O
T	O
,	O
Karkera	O
JD	O
,	O
Kim	O
HK	O
,	O
Vortmeyer	O
AO	O
,	O
Fuller	O
BG	O
,	O
Zhuang	O
Z	O
.	O
Radiation	O
Oncology	O
Branch	O
,	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
Multiple	O
mechanisms	O
,	O
such	O
as	O
gene	O
mutations	O
,	O
amplifications	O
,	O
and	O
rearrangements	O
,	O
as	O
well	O
as	O
perturbed	O
mitogen	O
and	O
receptor	O
function	O
,	O
are	O
likely	O
to	O
contribute	O
to	O
glioma	B-malignancy-type
formation	O
.	O
The	O
MET	O
(	O
also	O
known	O
as	O
c-met	O
proto	O
-	O
oncogene	O
located	O
at	O
7q31	O
-	O
34	O
has	O
been	O
shown	O
to	O
be	O
amplified	O
in	O
human	O
gliomas	B-malignancy-type
,	O
and	O
activating	O
mutations	O
within	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
MET	O
have	O
been	O
causally	O
related	O
to	O
tumorigenesis	O
in	O
hereditary	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
To	O
elucidate	O
the	O
role	O
of	O
MET	O
gene	O
in	O
glioma	B-malignancy-type
formation	O
,	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
from	O
11	O
patients	O
were	O
examined	O
for	O
MET	O
gene	O
mutations	O
and	O
allelic	O
duplications	O
or	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
Three	O
of	O
11	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
showed	O
a	O
deletion	O
of	O
one	O
copy	O
of	O
the	O
MET	O
gene	O
,	O
and	O
a	O
specific	O
MET	O
gene	O
missense	O
mutation	O
in	O
the	O
remaining	O
gene	O
copy	O
was	O
detected	O
in	O
one	O
of	O
those	O
tumors	O
.	O
The	O
corresponding	O
sequence	O
in	O
non	O
-	O
tumor	O
DNA	O
was	O
normal	O
in	O
all	O
cases	O
.	O
Three	O
of	O
11	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
showed	O
duplication	O
of	O
one	O
copy	O
of	O
the	O
MET	O
gene	O
,	O
but	O
none	O
of	O
them	O
contained	O
mutations	O
.	O
One	O
tumor	O
showed	O
MET	O
amplification	O
without	O
mutation	O
.	O
Three	O
showed	O
neither	O
allelic	O
change	O
nor	O
mutation	O
.	O
These	O
data	O
suggest	O
that	O
somatic	O
MET	O
gene	O
mutation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
a	O
subgroup	O
of	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
.	O
However	O
,	O
MET	O
mutations	O
appear	O
to	O
be	O
absent	O
in	O
the	O
majority	O
of	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
.	O
PMID	O
:	O
11007037	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
2000	O
Sep;50(	O
9	O
)	O
:725	O
-	O
30	O
beta-catenin	O
expression	O
and	O
mutational	O
analysis	O
in	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Kim	O
YS	O
,	O
Kang	O
YK	O
,	O
Kim	O
JB	O
,	O
Han	O
SA	O
,	O
Kim	O
KI	O
,	O
Paik	O
SR	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Medicine	O
,	O
Korea	O
University	O
,	O
Gojan	O
-	O
Dong	O
,	O
Ansan	O
,	O
Korea	O
.	O
apysk@yahoo.com	O
beta-Catenin	O
acts	O
as	O
a	O
downstream	O
transcriptional	O
activator	O
of	O
the	O
Wingless	O
-	O
Wnt	O
signaling	O
pathway	O
.	O
The	O
beta-catenin	O
-	O
Tcf	O
complex	O
transactivates	O
the	O
downstream	O
genes	O
that	O
regulate	O
cell	O
proliferation	O
or	O
inhibit	O
apoptosis	O
.	O
The	O
activation	O
of	O
this	O
pathway	O
through	O
stabilization	O
of	O
beta-catenin	O
is	O
caused	O
either	O
by	O
inactivating	O
mutations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
or	O
by	O
activating	O
mutations	O
in	O
beta-catenin	O
exon	O
3	O
.	O
To	O
determine	O
whether	O
the	O
abnormal	O
expression	O
and	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
are	O
implicated	O
in	O
renal	O
cell	O
carcinogenesis	O
,	O
52	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
RCC	B-malignancy-type
)	O
were	O
analyzed	O
by	O
immunohistochemistry	O
,	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
PCR	O
-	O
SSCP	O
)	O
,	O
and	O
direct	O
DNA	O
sequencing	O
.	O
Immunohistochemically	O
,	O
all	O
cases	O
,	O
as	O
well	O
as	O
normal	O
kidneys	O
,	O
showed	O
membranous	O
and	O
/	O
or	O
cytoplasmic	O
staining	O
patterns	O
without	O
nuclear	O
localization	O
.	O
However	O
,	O
the	O
cytoplasmic	O
accumulations	O
of	O
beta-catenin	O
were	O
observed	O
in	O
five	O
(	O
22.7	O
%	O
)	O
of	O
22	O
cases	O
of	O
conventional	B-malignancy-type
(	I-malignancy-type
clear	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
,	O
but	O
not	O
in	O
papillary	B-malignancy-type
or	O
chromophobe	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
beta	O
-	O
catenin	O
mutation	O
was	O
identified	O
in	O
only	O
one	O
case	O
of	O
conventional	B-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
and	O
was	O
a	O
single	O
-	O
base	O
missense	O
mutation	O
on	O
codon	O
61	O
,	O
leading	O
to	O
substitution	O
of	O
glutamine	O
by	O
arginine	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
demonstrates	O
that	O
beta-catenin	O
mutations	O
are	O
a	O
relatively	O
rare	O
event	O
in	O
RCC	B-malignancy-type
and	O
that	O
cytoplasmic	O
accumulations	O
of	O
beta-catenin	O
protein	O
are	O
found	O
only	O
in	O
conventional	B-malignancy-type
(	I-malignancy-type
clear	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
These	O
data	O
suggest	O
that	O
the	O
activation	O
of	O
the	O
beta-catenin	O
signaling	O
pathway	O
may	O
partly	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
conventional	B-malignancy-type
RCC	I-malignancy-type
.	O
PMID	O
:	O
11012986	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Carcinogenesis	O
2000	O
Oct;21(	O
10	O
)	O
:1813	O
-	O
9	O
NAD(P)H:quinone	O
oxidoreductase	O
-	O
dependent	O
risk	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
its	O
association	O
with	O
the	O
presence	O
of	O
K-ras	O
mutations	O
in	O
tumors	O
.	O
Lafuente	O
MJ	O
,	O
Casterad	O
X	O
,	O
Trias	O
M,	O
Ascaso	O
C	O
,	O
Molina	O
R,	O
Ballesta	O
A	O
,	O
Zheng	O
S,	O
Wiencke	O
JK	O
,	O
Lafuente	O
A.	O
Department	O
of	O
Surgery	O
,	O
Hospital	O
Clinic	O
,	O
Department	O
of	O
Pharmacology	O
,	O
School	O
of	O
Medicine	O
,	O
Casanova	O
143	O
,	O
E-08036	O
,	O
Barcelona	O
,	O
Spain	O
.	O
alafuente@med	O
.ub.es	O
NAD(P)H:quinone	O
oxidoreductase	O
(	O
NQO1	O
)	O
is	O
a	O
polymorphic	O
enzyme	O
involved	O
in	O
the	O
detoxification	O
of	O
potentially	O
mutagenic	O
and	O
carcinogenic	O
quinones	O
.	O
The	O
homozygous	O
C609T	O
NQO1	O
genotype	O
resulting	O
in	O
loss	O
of	O
reductase	O
activity	O
is	O
found	O
in	O
2	O
-	O
20	O
%	O
of	O
individuals	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
NQO1	O
-	O
dependent	O
risk	O
for	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
CRC	B-malignancy-type
)	O
was	O
studied	O
in	O
247	O
incident	O
CRC	B-malignancy-type
cases	O
and	O
296	O
hospital	O
-	O
based	O
controls	O
recruited	O
during	O
1996	O
-	O
1997	O
.	O
Four	O
subgroups	O
of	O
cases	O
were	O
studied	O
:	O
(i)	O
all	O
CRCs	B-malignancy-type
;	O
(ii)	O
a	O
molecular	O
CRC	B-malignancy-type
subgroup	O
(	O
n	O
=	O
117	O
,	O
cases	O
with	O
molecular	O
tumor	O
analyses	O
)	O
;	O
(iii)	O
within	O
the	O
molecular	O
subgroup	O
those	O
tumors	O
with	O
K-ras	O
mutations	O
in	O
codon	O
12	O
(	O
CRC	B-malignancy-type
K	O
12	O
)	O
;	O
(iv)	O
within	O
the	O
molecular	O
subgroup	O
those	O
tumors	O
with	O
K-ras	O
mutations	O
in	O
codon	O
13	O
(	O
CRC	B-malignancy-type
K	O
13	O
)	O
.	O
The	O
C609T	O
NQO1	O
genotype	O
was	O
found	O
to	O
be	O
twice	O
as	O
prevalent	O
in	O
all	O
CRC	B-malignancy-type
patients	O
(	O
6.8	O
%	O
)	O
compared	O
with	O
controls	O
(	O
3	O
%	O
)	O
and	O
six	O
times	O
more	O
common	O
in	O
the	O
subset	O
CRC	B-malignancy-type
K	O
12	O
(	O
20	O
%	O
)	O
.	O
Multivariant	O
analyses	O
in	O
the	O
overall	O
population	O
of	O
247	O
cases	O
and	O
296	O
controls	O
showed	O
a	O
significant	O
age	O
and	O
gender	O
adjusted	O
risk	O
for	O
CRC	B-malignancy-type
associated	O
with	O
the	O
C609T	O
NQO1	O
genotype	O
(	O
OR	O
2.9	O
,	O
95	O
%	O
CI	O
1.19	O
-	O
6.97	O
;	O
P	O
=	O
0.01	O
)	O
or	O
with	O
any	O
variant	O
genotype	O
(	O
the	O
low	O
activity	O
allele	O
frequency	O
,	O
i.e.	O
heterozygotes	O
plus	O
homozygotes	O
)	O
(	O
OR	O
1.41	O
,	O
95	O
%	O
CI	O
1.02	O
-	O
1.92	O
;	O
P	O
=	O
0.03	O
)	O
.	O
Within	O
cases	O
of	O
the	O
molecular	O
subgroup	O
(	O
n	O
=	O
117	O
)	O
the	O
C609T	O
NQO1	O
genotype	O
was	O
associated	O
with	O
the	O
presence	O
of	O
K-ras	O
codon	O
12	O
mutation	O
(	O
OR	O
6.5	O
95	O
%	O
,	O
CI	O
1.39	O
-	O
34.9	O
;	O
P	O
=	O
0.003	O
)	O
.	O
Logistic	O
regression	O
showed	O
an	O
age	O
and	O
gender	O
adjusted	O
risk	O
for	O
K-ras	O
codon	O
12	O
mutant	O
CRC	B-malignancy-type
associated	O
with	O
the	O
C609T	O
NQO1	O
genotype	O
(	O
OR	O
10.5	O
,	O
95	O
%	O
CI	O
2.99	O
-	O
36.7	O
;	O
P	O
:	O
=	O
0.0002	O
)	O
or	O
with	O
any	O
variant	O
NQO1	O
genotype	O
(	O
OR	O
2.23	O
,	O
95	O
%	O
CI	O
1.23	O
-	O
4.00	O
;	O
P	O
=	O
0.007	O
)	O
compared	O
with	O
the	O
control	O
group	O
.	O
Genetically	O
determined	O
variations	O
in	O
NQO1	O
may	O
modify	O
the	O
risk	O
for	O
CRC	B-malignancy-type
and	O
these	O
risks	O
may	O
be	O
greatest	O
for	O
tumors	O
containing	O
K-ras	O
codon	O
12	O
mutations	O
.	O
CRC	B-malignancy-type
with	O
K-ras	O
codon	O
12	O
mutations	O
may	O
represent	O
a	O
distinct	O
and	O
etiologically	O
more	O
homogeneous	O
subtype	O
of	O
the	O
disease	O
,	O
which	O
may	O
be	O
associated	O
with	O
toxicants	O
that	O
are	O
metabolized	O
via	O
a	O
NQO1	O
-	O
dependent	O
pathway	O
.	O
PMID	O
:	O
11023538	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Surg	O
Oncol	O
2000	O
Nov;75	O
(	O
3	O
)	O
:	O
17	O
6-85	O
Comparison	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
and	O
p21	O
expression	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
between	O
Japanese	O
and	O
Chinese	O
patients	O
.	O
Song	O
MM	O
,	O
Nio	O
Y	O
,	O
Dong	O
M,	O
Tamura	O
K,	O
Furuse	O
K,	O
Tian	O
YL	O
,	O
He	O
SG	O
,	O
Shen	O
K.	O
First	O
Department	O
of	O
Surgery	O
,	O
Shimane	O
Medical	O
University	O
,	O
Izumo	O
,	O
Shimane	O
,	O
Japan	O
.	O
BACKGROUND	O
ANF	O
OBJECTIVES	O
:	O
K-ras	O
(	O
Kirsten-ras	O
)	O
point	O
mutation	O
(	O
PM	O
)	O
in	O
codon	O
12	O
are	O
suggested	O
to	O
be	O
significantly	O
associated	O
with	O
the	O
tumorigenesis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
incidences	O
of	O
K-ras	O
PMs	O
in	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
are	O
reported	O
to	O
be	O
different	O
between	O
Europeans	O
and	O
Japanese	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
compare	O
the	O
incidences	O
and	O
profile	O
of	O
K-ras	O
PMs	O
and	O
ras	O
-	O
p21	O
expression	O
in	O
primary	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinoma	I-malignancy-type
(	I-malignancy-type
IDC	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
between	O
Japanese	O
and	O
Chinese	O
.	O
METHODS	O
:	O
The	O
specimens	O
included	O
51	O
Japanese	O
and	O
34	O
Chinese	O
patients	O
with	O
the	O
primary	O
IDC	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
K-ras	O
PMs	O
were	O
tested	O
by	O
allele	O
specific	O
oligonucleotide	O
dot	O
blot	O
hybridization	O
methods	O
and	O
ras	O
-	O
p21	O
expression	O
was	O
stained	O
by	O
the	O
immunohistochemical	O
method	O
.	O
RESULTS	O
:	O
K-ras	O
PMs	O
were	O
detected	O
in	O
48	O
Japanese	O
IDCs	B-malignancy-type
(	O
94	O
%	O
)	O
and	O
in	O
24	O
Chinese	O
ones	O
(	O
71	O
%	O
)	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O
The	O
GAT	O
mutation	O
was	O
more	O
frequent	O
both	O
in	O
Japanese	O
(	O
61	O
%	O
,	O
33	O
/	O
54	O
)	O
and	O
in	O
Chinese	O
(	O
60	O
%	O
,	O
18	O
/	O
30	O
)	O
IDCs	B-malignancy-type
.	O
The	O
transitions	O
/	O
transversions	O
ratio	O
in	O
the	O
Japanese	O
group	O
was	O
2.4	O
in	O
this	O
study	O
.	O
By	O
contrast	O
,	O
that	O
in	O
the	O
Chinese	O
group	O
was	O
1.5	O
.	O
The	O
expression	O
of	O
p21	O
was	O
detected	O
in	O
24	O
Japanese	O
IDCs	B-malignancy-type
(	O
47	O
%	O
)	O
and	O
in	O
24	O
Chinese	O
IDCs	B-malignancy-type
(	O
71	O
%	O
)	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O
The	O
expression	O
of	O
p21	O
and	O
the	O
patterns	O
of	O
K-ras	O
PMs	O
did	O
not	O
show	O
any	O
significant	O
influence	O
on	O
the	O
survival	O
of	O
the	O
patients	O
both	O
in	O
Japanese	O
and	O
Chinese	O
.	O
In	O
the	O
present	O
study	O
,	O
Chinese	O
IDC	B-malignancy-type
had	O
a	O
lower	O
frequency	O
of	O
K-ras	O
PMs	O
in	O
codon	O
12	O
than	O
Japanese	O
IDC	B-malignancy-type
.	O
The	O
pattern	O
of	O
K-ras	O
PMs	O
in	O
Chinese	O
IDC	B-malignancy-type
was	O
different	O
from	O
that	O
in	O
Japanese	O
and	O
European	O
IDC	B-malignancy-type
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Ki-ras	O
PM	O
and	O
p21	O
expression	O
were	O
frequently	O
seen	O
both	O
in	O
Japanese	O
and	O
Chinese	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Factors	O
such	O
as	O
lifestyle	O
and	O
environment	O
may	O
have	O
influences	O
on	O
pancreatic	O
carcinogenesis	O
in	O
various	O
populations	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11088049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
2000	O
Dec;50	O
(	O
12	O
)	O
:	O
94	O
5-52	O
Aberrant	O
expression	O
of	O
beta-catenin	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
renal	B-malignancy-type
and	O
urothelial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Zhu	O
X	O
,	O
Kanai	O
Y	O
,	O
Saito	O
A	O
,	O
Kondo	O
Y	O
,	O
Hirohashi	O
S.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
present	O
study	O
attempted	O
to	O
clarify	O
the	O
significance	O
of	O
aberrant	O
expression	O
of	O
beta-catenin	O
protein	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
renal	O
and	O
urothelial	O
carcinogenesis	O
.	O
beta-Catenin	O
expression	O
was	O
examined	O
immunohistochemically	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
.	O
beta-Catenin	O
immunoreactivity	O
was	O
observed	O
at	O
the	O
cell	O
membrane	O
in	O
all	O
30	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
RCC	B-malignancy-type
)	O
examined	O
,	O
and	O
no	O
RCC	B-malignancy-type
showed	O
a	O
mobility	O
-	O
shifted	O
SSCP	O
band	O
.	O
Of	O
46	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
TCC	B-malignancy-type
)	O
examined	O
,	O
there	O
was	O
reduced	O
expression	O
of	O
beta-catenin	O
,	O
as	O
compared	O
with	O
its	O
expression	O
in	O
non	O
-	O
cancerous	O
transitional	O
epithelium	O
,	O
in	O
22	O
cases	O
(	O
48	O
%	O
)	O
and	O
beta-catenin	O
accumulation	O
in	O
the	O
nucleus	O
in	O
five	O
cases	O
(	O
11	O
%	O
)	O
.	O
Of	O
four	O
renal	B-malignancy-type
pelvis	I-malignancy-type
TCC	I-malignancy-type
examined	O
,	O
point	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
at	O
codon	O
45	O
resulting	O
in	O
amino	O
acid	O
substitution	O
(	O
Ser	O
to	O
Phe	O
)	O
was	O
detected	O
in	O
one	O
(	O
25	O
%	O
)	O
.	O
The	O
incidence	O
of	O
reduced	O
expression	O
of	O
beta-catenin	O
correlated	O
significantly	O
with	O
the	O
growth	O
pattern	O
(	O
superficial	B-malignancy-type
type	I-malignancy-type
vs	O
invasive	B-malignancy-type
type	I-malignancy-type
)	O
of	O
TCC	B-malignancy-type
(	O
P	O
<	O
0.05	O
)	O
.	O
These	O
data	O
indicate	O
that	O
:	O
(1)	O
aberrant	O
beta-catenin	O
expression	O
may	O
be	O
at	O
least	O
partly	O
involved	O
in	O
urothelial	O
carcinogenesis	O
,	O
but	O
less	O
significantly	O
so	O
in	O
renal	O
carcinogenesis	O
,	O
and	O
(2)	O
it	O
may	O
be	O
associated	O
with	O
the	O
progression	O
of	O
TCC	B-malignancy-type
showing	O
invasive	O
growth	O
.	O
PMID	O
:	O
11123760	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Tumour	O
Biol	O
2001	O
Ma	O
r-Apr;2	O
2	O
(	O
2	O
)	O
:	O
12	O
3-30	O
Mutational	O
analysis	O
of	O
the	O
beta-catenin	O
gene	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Sasaki	O
Y	O
,	O
Morimoto	O
I	O
,	O
Kusano	O
M,	O
Hosokawa	O
M,	O
Itoh	O
F	O
,	O
Yanagihara	O
K,	O
Imai	O
K,	O
Tokino	O
T.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
Previous	O
studies	O
reported	O
that	O
mutation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
was	O
not	O
observed	O
in	O
the	O
majority	O
of	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
To	O
evaluate	O
the	O
role	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
,	O
we	O
analyzed	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
and	O
the	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
An	O
interstitial	O
deletion	O
spanning	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
observed	O
in	O
1	O
of	O
13	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
No	O
missense	O
mutation	O
was	O
found	O
in	O
these	O
13	O
cell	O
lines	O
.	O
Nuclear	O
and/or	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
was	O
observed	O
in	O
16	O
of	O
70	O
primary	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
by	O
immunohistochemistry	O
,	O
while	O
we	O
found	O
no	O
mutations	O
in	O
exon	O
3	O
in	O
35	O
carcinoma	B-malignancy-type
tissues	O
available	O
for	O
PCR	O
amplification	O
.	O
Our	O
findings	O
suggest	O
that	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
rare	O
in	O
human	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
and	O
that	O
accumulation	O
of	O
normal	O
beta-catenin	O
protein	O
in	O
a	O
subset	B-malignancy-type
of	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
may	O
be	O
due	O
to	O
other	O
mechanisms	O
of	O
its	O
activation	O
.	O
Copyright	O
2001	O
S.	O
Karger	O
AG	O
,	O
Basel	O
PMID	O
:	O
11125285	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2001	O
Jan;8	O
4	O
(	O
2	O
)	O
:	O
20	O
9-17	O
beta	O
-	O
Catenin	O
mutations	O
and	O
aberrant	O
nuclear	O
expression	O
during	O
endometrial	O
tumorigenesis	O
.	O
Saegusa	O
M,	O
Hashimura	O
M,	O
Yoshida	O
T	O
,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
1-1	O
5-1	O
Kitasato	O
,	O
Sagamihara	O
,	O
Kanagawa	O
,	O
22	O
8-8555	O
,	O
Japan	O
.	O
msaegusa@med.kitasat	O
o-u.ac.jp	O
To	O
clarify	O
the	O
possible	O
role	O
of	O
aberrant	O
beta-catenin	O
expression	O
during	O
endometrial	O
tumorigenesis	O
,	O
a	O
total	O
of	O
199	O
cases	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
(	I-malignancy-type
endometrioid	I-malignancy-type
type	I-malignancy-type
)	I-malignancy-type
,	O
as	O
well	O
as	O
37	O
cases	O
of	O
simple	O
/	O
complex	O
and	O
32	O
of	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
,	O
was	O
consecutively	O
investigated	O
for	O
immunohistochemistry	O
,	O
along	O
with	O
141	O
normal	O
endometrial	O
samples	O
distant	O
from	O
carcinomas	B-malignancy-type
.	O
Of	O
199	O
carcinoma	B-malignancy-type
cases	O
,	O
73	O
tumours	O
as	O
well	O
as	O
44	O
normal	O
samples	O
were	O
also	O
analysed	O
using	O
a	O
combination	O
of	O
RT-PCR	O
and	O
Southern	O
blot	O
hybridization	O
,	O
Western	O
blot	O
,	O
and	O
mutation	O
gene	O
assays	O
.	O
Cell	O
membrane	O
beta-catenin	O
immunoreactivity	O
showed	O
a	O
stepwise	O
decrease	O
from	O
normal	O
,	O
through	O
atypical	B-malignancy-type
hyperplasia	I-malignancy-type
,	O
to	O
grade	O
3	O
carcinomas	B-malignancy-type
.	O
In	O
contrast	O
,	O
the	O
nuclear	O
accumulation	O
in	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
and	O
grade	O
1	O
or	O
2	O
tumours	O
was	O
higher	O
than	O
in	O
simple	B-malignancy-type
/	O
complex	B-malignancy-type
hyperplasias	I-malignancy-type
.	O
Mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
involving	O
codons	O
33	O
,	O
34	O
,	O
37	O
,	O
41	O
,	O
and	O
45	O
were	O
observed	O
in	O
16	O
(	O
22.9	O
%	O
)	O
of	O
70	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
as	O
well	O
as	O
3	O
(	O
12.5	O
%	O
)	O
of	O
24	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
,	O
the	O
results	O
being	O
significantly	O
related	O
to	O
low	O
membrane	O
and	O
high	O
nuclear	O
immunoreactivity	O
but	O
not	O
relative	O
mRNA	O
expression	O
levels	O
,	O
suggesting	O
that	O
the	O
gene	O
mutations	O
may	O
be	O
closely	O
associated	O
with	O
changes	O
in	O
subcellular	O
distribution	O
.	O
In	O
addition	O
to	O
significant	O
association	O
between	O
beta-catenin	O
mutation	O
and	O
low	O
grade	O
histological	O
malignancy	O
(	O
P	O
=	O
0.048	O
)	O
,	O
the	O
mutations	O
were	O
detected	O
in	O
none	O
of	O
15	O
and	O
13	O
(	O
26	O
%	O
)	O
of	O
50	O
tumours	O
with	O
or	O
without	O
lymph	O
node	O
metastasis	O
,	O
the	O
difference	O
being	O
significant	O
(	O
P	O
=	O
0.027	O
)	O
.	O
These	O
findings	O
suggest	O
that	O
beta-catenin	O
abnormalities	O
may	O
play	O
an	O
important	O
role	O
in	O
a	O
relatively	O
early	O
event	O
during	O
the	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
sequence	O
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11161379	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
2001	O
Mar	O
26;16	O
4	O
(	O
2	O
)	O
:	O
20	O
7-12	O
K-ras	O
exon	O
2	O
point	O
mutations	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
Semczuk	O
A	O
,	O
Schneide	O
r-Stock	O
R	O
,	O
Berbec	O
H,	O
Marzec	O
B	O
,	O
Jakowicki	O
JA	O
,	O
Roessner	O
A.	O
Second	O
Department	O
of	O
Gynecological	O
Surgery	O
,	O
Lublin	O
School	O
of	O
Medicine	O
,	O
Jaczewski	O
street	O
8	O
,	O
2	O
0-954	O
,	O
Lublin	O
,	O
Poland	O
.	O
tomek@asklepios	O
.am.lublin.pl	O
In	O
the	O
present	O
study	O
,	O
we	O
screened	O
for	O
the	O
K-ras	O
exon	O
2	O
point	O
mutations	O
in	O
a	O
group	O
of	O
87	O
gynecological	B-malignancy-type
neoplasms	I-malignancy-type
(	O
82	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
four	O
carcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
cervix	I-malignancy-type
and	O
one	O
uterine	O
carcinosarcoma	O
)	O
using	O
the	O
non	O
-	O
isotopic	O
PCR-SSCP	O
-	O
direct	O
sequencing	O
techniques	O
.	O
Direct	O
sequencing	O
analysis	O
revealed	O
CAA	O
-->	O
CAC	O
(	O
Gln	O
-->	O
His	O
)	O
K-ras	O
codon	O
61	O
point	O
mutations	O
in	O
two	O
(	O
2.4	O
%	O
)	O
of	O
the	O
82	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
mentioned	O
above	O
.	O
These	O
two	O
cases	O
were	O
endometrial	B-malignancy-type
endometrioid	I-malignancy-type
carcinomas	I-malignancy-type
at	O
an	O
early	O
clinical	O
stage	O
of	O
disease	O
(	O
stage	O
IB	O
and	O
IC	O
due	O
to	O
FIGO	O
)	O
.	O
Those	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
that	O
showed	O
K-ras	O
exon	O
2	O
point	O
mutations	O
revealed	O
a	O
strong	O
positivity	O
for	O
heterogeneous	O
nuclear	O
retinoblastoma	O
protein	O
staining	O
;	O
none	O
of	O
these	O
,	O
however	O
,	O
have	O
had	O
the	O
K-ras	O
codon	O
12	O
point	O
mutation	O
.	O
In	O
addition	O
,	O
there	O
were	O
no	O
K-ras	O
gene	O
point	O
mutations	O
in	O
three	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
lacking	O
the	O
Rb	O
protein	O
immunohistochemically	O
.	O
None	O
of	O
the	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
tested	O
had	O
K-ras	O
gene	O
point	O
mutations	O
,	O
whereas	O
one	O
carcinosarcoma	B-malignancy-type
harbored	O
K-ras	O
codon	O
61	O
point	O
mutation	O
(	O
CAA	O
-->	O
CAC	O
)	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
support	O
the	O
view	O
that	O
K-ras	O
exon	O
2	O
point	O
mutations	O
are	O
rare	O
events	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
Rb	O
and	O
K-ras	O
gene	O
abnormalities	O
may	O
occur	O
independently	O
of	O
each	O
other	O
during	O
endometrial	O
carcinogenesis	O
in	O
humans	O
.	O
PMID	O
:	O
11179836	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Clin	O
Pathol	O
2001	O
Feb;11	O
5	O
(	O
2	O
)	O
:	O
23	O
5-42	O
H-ras	O
oncogene	O
mutation	O
in	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
.	O
Polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O
Sakamoto	O
A	O
,	O
Oda	O
Y	O
,	O
Adachi	O
T	O
,	O
Tamiya	O
S	O
,	O
Matsuda	O
S	O
,	O
Tanaka	O
K,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Departments	O
of	O
Anatomic	O
Pathology	O
,	O
Pathological	O
Sciences	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Point	O
mutations	O
of	O
the	O
ras	O
gene	O
family	O
(	O
K-ras	O
,	O
H-ras	O
,	O
and	O
N-ras	O
)	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
Dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
is	O
characterized	O
by	O
the	O
coexistence	O
of	O
well	O
-	O
differentiated	O
(	O
WD	O
)	O
and	O
high-grade	O
anaplastic	O
(	O
HG	O
)	O
components	O
.	O
The	O
presence	O
of	O
point	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
H-ras	O
gene	O
was	O
studied	O
in	O
34	O
liposarcomas	B-malignancy-type
,	O
comprising	O
15	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
liposarcomas	I-malignancy-type
and	O
19	O
dedifferentiated	B-malignancy-type
liposarcomas	I-malignancy-type
,	O
and	O
in	O
8	O
storiform	B-malignancy-type
-	I-malignancy-type
pleomorphic	I-malignancy-type
type	I-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFHs	B-malignancy-type
)	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
direct	O
sequencing	O
analysis	O
.	O
The	O
2	O
components	O
of	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
were	O
analyzed	O
independently	O
.	O
H-ras	O
mutations	O
were	O
seen	O
only	O
in	O
dedifferentiated	B-malignancy-type
liposarcomas	I-malignancy-type
(	O
4	O
/	O
19	O
[	O
21	O
%	O
]	O
)	O
,	O
1	O
in	O
WD	O
components	O
and	O
3	O
in	O
HG	O
components	O
.	O
The	O
mutation	O
was	O
not	O
seen	O
in	O
any	O
of	O
15	O
cases	O
of	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
liposarcoma	I-malignancy-type
.	O
MFHs	B-malignancy-type
showed	O
an	O
H-ras	O
mutation	O
in	O
1	O
(	O
12	O
%	O
)	O
of	O
8	O
cases	O
.	O
Our	O
results	O
seem	O
to	O
suggest	O
that	O
the	O
H-ras	O
mutation	O
is	O
a	O
relatively	O
uncommon	O
event	O
in	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
,	O
which	O
may	O
demonstrate	O
an	O
epiphenomenon	O
of	O
dedifferentiation	O
in	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
.	O
PMID	O
:	O
11211612	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Surg	O
Oncol	O
2001	O
Feb;2	O
7	O
(	O
1	O
)	O
:	O
8	O
0-7	O
Relevance	O
of	O
Ki-67	O
antigen	O
expression	O
and	O
K-ras	O
mutation	O
in	O
colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
.	O
Petrowsky	O
H,	O
Sturm	O
I	O
,	O
Graubitz	O
O,	O
Kooby	O
DA	O
,	O
Stai	O
b-Sebler	O
E	O
,	O
Gog	O
C,	O
Kohne	O
CH,	O
Hillebrand	O
T	O
,	O
Daniel	O
PT	O
,	O
Fong	O
Y	O
,	O
Lorenz	O
M.	O
Department	O
of	O
General	O
and	O
Vascular	O
Surgery	O
,	O
Johann	O
Wolfgang	O
Goeth	O
e-University	O
,	O
60590	O
Frankfurt	O
am	O
Main	O
,	O
Germany	O
.	O
AIMS	O
:	O
The	O
liver	O
is	O
a	O
frequent	O
site	O
of	O
metastases	B-malignancy-type
from	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
.	O
While	O
these	O
lesions	O
are	O
potentially	O
amenable	O
to	O
surgical	O
resection	O
,	O
they	O
are	O
usually	O
very	O
aggressive	O
,	O
and	O
recurrence	O
is	O
frequent	O
.	O
Mutations	O
of	O
the	O
proto	O
-	O
oncogene	O
K	O
-	O
ras	O
are	O
thought	O
to	O
impart	O
a	O
strong	O
growth	O
signal	O
to	O
tumour	O
cells	O
and	O
are	O
closely	O
associated	O
with	O
the	O
development	O
of	O
malignancies	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
and	I-malignancy-type
rectum	I-malignancy-type
.	O
Hepatic	B-malignancy-type
metastases	I-malignancy-type
from	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
have	O
notably	O
elevated	O
proliferative	O
rates	O
.	O
The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
relationship	O
between	O
proliferation	O
K	O
-	O
ras	O
mutation	O
and	O
prognosis	O
following	O
curative	O
resection	O
of	O
colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
.	O
METHODS	O
:	O
Colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
from	O
41	O
patients	O
undergoing	O
curative	O
hepatic	O
resection	O
were	O
examined	O
for	O
proliferation	O
status	O
and	O
presence	O
of	O
K	O
-	O
ras	O
mutations	O
.	O
The	O
proliferative	O
activity	O
was	O
assessed	O
by	O
Ki-67	O
immunohistochemistry	O
.	O
DNA	O
from	O
the	O
same	O
tissue	O
samples	O
was	O
screened	O
for	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K	O
-	O
ras	O
gene	O
using	O
a	O
novel	O
microplate	O
-	O
based	O
allelic	O
-	O
specific	O
hybridization	O
assay	O
.	O
Ki-67	O
scores	O
and	O
K	O
-	O
ras	O
status	O
were	O
then	O
related	O
with	O
patient	O
survival	O
as	O
determined	O
through	O
retrospective	O
analysis	O
.	O
RESULTS	O
:	O
Median	O
survival	O
was	O
40	O
months	O
.	O
Patients	O
with	O
high	O
Ki-67	O
scores	O
(	O
>	O
or	O
=	O
50	O
%	O
)	O
had	O
significantly	O
shorter	O
median	O
survival	O
compared	O
with	O
those	O
with	O
low	O
scores	O
(	O
30	O
vs	O
44	O
months	O
,	O
log	O
-	O
rank	O
P	O
=	O
0.02	O
)	O
.	O
A	O
high	O
Ki-67	O
score	O
was	O
an	O
independent	O
negative	O
prognostic	O
factor	O
by	O
multivariate	O
regression	O
analysis	O
(	O
relative	O
risk	O
=	O
3.04	O
,	O
P	O
=	O
0.036	O
)	O
.	O
K	O
-	O
ras	O
point	O
mutations	O
were	O
detected	O
in	O
6	O
/	O
41	O
patients	O
(	O
15	O
%	O
)	O
,	O
but	O
mutational	O
status	O
did	O
not	O
correlate	O
with	O
Ki-67	O
score	O
or	O
survival	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
tumour	O
proliferative	O
index	O
is	O
a	O
useful	O
predictor	O
of	O
aggressive	O
tumour	O
behaviour	O
and	O
an	O
indicator	O
of	O
patient	O
survival	O
.	O
The	O
presence	O
of	O
K	O
-	O
ras	O
mutations	O
does	O
not	O
appear	O
to	O
correlate	O
with	O
tumour	O
proliferation	O
status	O
or	O
patient	O
survival	O
.	O
Copyright	O
Harcourt	O
Publishers	O
Limited	O
.	O
PMID	O
:	O
11237496	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2001	O
Mar;15	O
8	O
(	O
3	O
)	O
:	O
100	O
5-10	O
Sporadic	B-malignancy-type
fundic	I-malignancy-type
gland	I-malignancy-type
polyps	I-malignancy-type
:	O
common	B-malignancy-type
gastric	I-malignancy-type
polyps	I-malignancy-type
arising	O
through	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Abraham	O
SC	O
,	O
Nobukawa	O
B	O
,	O
Giardiello	O
FM	O
,	O
Hamilton	O
SR	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Gastroenterology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Ross	O
Building	O
,	O
Room	O
632	O
,	O
720	O
Rutland	O
Ave	O
.	O
,	O
Baltimore	O
,	O
MD	O
2120	O
5-2196	O
,	O
USA	O
.	O
sabraham@jhmi	O
.edu	O
Fundic	B-malignancy-type
gland	I-malignancy-type
polyps	I-malignancy-type
(	O
FGPs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
gastric	B-malignancy-type
polyps	I-malignancy-type
.	O
FGPs	B-malignancy-type
traditionally	O
have	O
been	O
regarded	O
as	O
nondysplastic	B-malignancy-type
hamartomatous	I-malignancy-type
or	O
hyperplastic	B-malignancy-type
lesions	I-malignancy-type
,	O
but	O
their	O
pathogenesis	O
remains	O
unclear	O
.	O
We	O
have	O
recently	O
shown	O
that	O
somatic	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
alterations	O
are	O
frequently	O
present	O
in	O
FGPs	O
associated	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
,	O
raising	O
the	O
possibility	O
that	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
affecting	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
might	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
We	O
analyzed	O
somatic	O
beta-catenin	O
gene	O
mutations	O
in	O
57	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
from	O
40	O
patients	O
without	O
FAP	B-malignancy-type
and	O
in	O
19	O
FGPs	B-malignancy-type
from	O
13	O
FAP	B-malignancy-type
patients	O
.	O
Direct	O
DNA	O
sequencing	O
of	O
exon	O
3	O
encompassing	O
the	O
glycogen	O
synthase	O
kinase-3beta	O
phosphorylation	O
region	O
for	O
beta-catenin	O
was	O
used	O
with	O
confirmation	O
by	O
HIN:fI	O
restriction	O
endonuclease	O
digestion	O
.	O
The	O
foveolar	B-malignancy-type
epithelium	I-malignancy-type
and	O
dilated	B-malignancy-type
fundic	I-malignancy-type
glands	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
polyps	I-malignancy-type
were	O
separately	O
microdissected	O
and	O
analyzed	O
in	O
22	O
of	O
57	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
Activating	O
beta-catenin	O
gene	O
mutations	O
were	O
present	O
in	O
91	O
%	O
(	O
52	O
of	O
57	O
)	O
of	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
Both	O
the	O
foveolar	O
epithelium	O
and	O
the	O
dilated	O
fundic	O
gland	O
epithelium	O
comprising	O
the	O
polyps	B-malignancy-type
were	O
shown	O
to	O
have	O
the	O
same	O
somatic	O
beta-catenin	O
mutation	O
in	O
21	O
of	O
22	O
(	O
95	O
%	O
)	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
In	O
contrast	O
,	O
beta-catenin	O
gene	O
mutations	O
were	O
not	O
present	O
in	O
any	O
of	O
the	O
19	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
FGPs	I-malignancy-type
(	O
P	O
:	O
<	O
0.000001	O
)	O
.	O
The	O
high	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
indicates	O
that	O
these	O
lesions	O
arise	O
through	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Beta-catenin	O
mutations	O
in	O
gastrointestinal	B-malignancy-type
tract	I-malignancy-type
polyps	I-malignancy-type
have	O
previously	O
only	O
been	O
demonstrated	O
in	O
a	O
subset	O
of	O
adenomatous	B-malignancy-type
(	I-malignancy-type
dysplastic	I-malignancy-type
)	O
or	O
neoplastic	B-malignancy-type
polyps	I-malignancy-type
.	O
Sporadic	B-malignancy-type
FGPs	I-malignancy-type
are	O
therefore	O
the	O
only	O
lesions	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
to	O
demonstrate	O
beta-catenin	O
mutations	O
while	O
lacking	O
dysplastic	O
morphology	O
.	O
PMID	O
:	O
11238048	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2001	O
Apr	O
6;8	O
4	O
(	O
7	O
)	O
:	O
98	O
2-9	O
Frequent	O
k	O
-	O
ras	O
-	O
2	O
mutations	O
and	O
p16	O
(	O
INK4A	O
)	O
methylation	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
in	O
workers	O
exposed	O
to	O
vinyl	O
chloride	O
.	O
Weihrauch	O
M,	O
Benicke	O
M,	O
Lehnert	O
G,	O
Wittekind	O
C,	O
Wrbitzky	O
R	O
,	O
Tannapfel	O
A.	O
Institute	O
of	O
Occupational	O
and	O
Environmental	O
Medicine	O
,	O
University	O
of	O
Hannover	O
,	O
Germany	O
.	O
Vinyl	O
chloride	O
(	O
VC	O
)	O
is	O
a	O
know	O
animal	O
and	O
human	O
carcinogen	O
associated	O
with	O
liver	B-malignancy-type
angiosarcomas	I-malignancy-type
(	O
LAS	B-malignancy-type
)	O
and	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
.	O
In	O
VC	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
LAS	I-malignancy-type
mutations	O
of	O
the	O
K	O
-	O
ras	O
-	O
2	O
gene	O
have	O
been	O
reported	O
;	O
however	O
,	O
no	O
data	O
about	O
the	O
prevalence	O
of	O
such	O
mutations	O
in	O
VC	B-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
are	O
available	O
.	O
Recent	O
data	O
indicate	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
induce	O
P16	O
methylation	O
accompanied	O
by	O
inactivation	O
of	O
the	O
p16	O
gene	O
.	O
The	O
presence	O
of	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
was	O
analysed	O
in	O
tissue	O
from	O
18	O
patients	O
with	O
VC	B-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
.	O
As	O
a	O
control	O
group	O
,	O
20	O
patients	O
with	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
due	I-malignancy-type
to	I-malignancy-type
hepatitis	I-malignancy-type
B	I-malignancy-type
(	O
n	O
=	O
7	O
)	O
,	O
hepatitis	O
C	O
(	O
n	O
=	O
5	O
)	O
and	O
alcoholic	O
liver	O
cirrhosis	O
(	O
n	O
=	O
8	O
)	O
was	O
used	O
.	O
The	O
specific	O
mutations	O
were	O
determined	O
by	O
direct	O
sequencing	O
of	O
codon	O
12	O
and	O
13	O
of	O
the	O
K	O
-	O
ras	O
-	O
2	O
gene	O
in	O
carcinomatous	O
and	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
after	O
microdissection	O
.	O
The	O
status	O
of	O
p16	O
was	O
evaluated	O
by	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
,	O
microsatellite	O
analysis	O
,	O
DNA	O
sequencing	O
and	O
immunohistochemical	O
staining	O
.	O
All	O
patients	O
had	O
a	O
documented	O
chronic	O
quantitated	O
exposure	O
to	O
VC	O
(	O
average	O
8883	O
ppmy	O
,	O
average	O
duration	O
:	O
245	O
months	O
)	O
.	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
were	O
found	O
in	O
6	O
of	O
18	O
(	O
33	O
%	O
)	O
examined	O
VC	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
and	O
in	O
3	O
cases	O
of	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
.	O
There	O
were	O
3	O
G	O
-->	O
A	O
point	O
mutations	O
in	O
the	O
tumour	O
tissue	O
.	O
All	O
3	O
mutations	O
found	O
in	O
non	O
-	O
neoplastic	O
liver	O
from	O
VC	O
-	O
exposed	O
patients	O
were	O
also	O
G	O
-->	O
A	O
point	O
mutations	O
(	O
codon	O
12	O
-	O
and	O
codon	O
13	O
-	O
aspartate	O
mutations	O
)	O
.	O
Hypermethylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p16	O
gene	O
was	O
found	O
in	O
13	O
of	O
18	O
examined	O
carcinomas	B-malignancy-type
(	O
72	O
%	O
)	O
.	O
Of	O
6	O
cancers	O
with	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
,	O
5	O
specimens	O
also	O
showed	O
methylated	O
p16	O
.	O
Within	O
the	O
control	O
group	O
,	O
K	O
-	O
ras	O
-	O
2	O
mutation	O
were	O
found	O
in	O
3	O
of	O
20	O
(	O
15	O
%	O
)	O
examined	O
HCC	B-malignancy-type
.	O
p16	O
methylation	O
occurred	O
in	O
11	O
out	O
of	O
20	O
(	O
55	O
%	O
)	O
patients	O
.	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
and	O
p16	O
methylation	O
are	O
frequent	O
events	O
in	O
VC	B-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
.	O
We	O
observed	O
a	O
K	O
-	O
ras	O
-	O
2	O
mutation	O
pattern	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
a	O
carcinogenic	O
metabolite	O
of	O
VC	O
.	O
Our	O
results	O
strongly	O
suggest	O
that	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
VC	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
HCC	I-malignancy-type
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11286481	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Apr	O
15;6	O
1	O
(	O
8	O
)	O
:	O
340	O
6-9	O
Beta-catenin	O
mutations	O
in	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
:	O
a	O
population	O
-	O
based	O
study	O
in	O
China	O
.	O
Rashid	O
A	O
,	O
Gao	O
YT	O
,	O
Bhakta	O
S	O
,	O
Shen	O
MC	O
,	O
Wang	O
BS	O
,	O
Deng	O
J,	O
Fraumeni	O
JF	O
Jr	O
,	O
Hsing	O
AW.	O
Department	O
of	O
Pathology	O
,	O
M.D.	O
Anderson	O
Cancer	O
Center	O
,	O
1515	O
Holcombe	O
Boulevard	O
,	O
Houston	O
,	O
TX	O
7703	O
0-4095	O
,	O
USA	O
.	O
beta-Catenin	O
is	O
an	O
ubiquitously	O
expressed	O
cytoplasmic	O
protein	O
that	O
has	O
a	O
crucial	O
role	O
in	O
both	O
cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
and	O
as	O
a	O
downstream	O
signaling	O
molecule	O
in	O
the	O
wingless	O
/	O
Wnt	O
pathway	O
.	O
Activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
at	O
the	O
phosphorylation	O
sites	O
for	O
ubiquitination	O
and	O
degradation	O
of	O
beta-catenin	O
,	O
are	O
present	O
in	O
a	O
variety	O
of	O
cancers	O
.	O
Because	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
are	O
present	O
in	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
and	O
the	O
APC	O
protein	O
modulates	O
levels	O
of	O
beta-catenin	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
beta-catenin	O
in	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
by	O
sequencing	O
the	O
third	O
exon	O
of	O
the	O
beta-catenin	O
gene	O
among	O
107	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
and	O
7	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
from	O
a	O
population	O
-	O
based	O
study	O
in	O
CHINA	O
:	O
Point	O
mutations	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
in	O
exon	O
3	O
of	O
beta-catenin	O
were	O
present	O
in	O
8	O
of	O
107	O
(	O
7.5	O
%	O
)	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
and	O
4	O
of	O
7	O
(	O
57.1	O
%	O
)	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
.	O
Mutations	O
of	O
beta-catenin	O
were	O
more	O
frequent	O
in	O
ampullary	B-malignancy-type
and	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
than	O
in	O
bile	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
(	O
P	O
=	O
0.04	O
)	O
and	O
in	O
papillary	B-malignancy-type
adenocarcinomas	I-malignancy-type
than	O
other	O
histological	O
types	O
of	O
carcinomas	B-malignancy-type
(	O
P	O
=	O
0.02	O
)	O
.	O
These	O
results	O
suggest	O
that	O
the	O
molecular	O
pathways	O
of	O
biliary	B-malignancy-type
tract	I-malignancy-type
neoplasms	I-malignancy-type
vary	O
by	O
anatomical	O
subsite	O
and	O
histological	O
subtype	O
.	O
PMID	O
:	O
11309300	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anal	O
Cell	O
Pathol	O
2000	O
;2	O
1	O
(	O
2	O
)	O
:	O
4	O
9-57	O
Erratum	O
in	O
:	O
Anal	O
Cell	O
Pathol	O
2001;2	O
2	O
(	O
3	O
)	O
:	O
181	O
Intratumor	O
heterogeneity	O
of	O
k-ras	O
and	O
p53	O
mutations	O
among	O
human	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
containing	O
early	O
cancer	O
.	O
Giaretti	O
W	O
,	O
Rapallo	O
A	O
,	O
Sciutto	O
A	O
,	O
Macciocu	O
B	O
,	O
Geido	O
E	O
,	O
Hermsen	O
MA	O
,	O
Postma	O
C,	O
Baak	O
JP	O
,	O
Williams	O
RA	O
,	O
Meijer	O
GA.	O
Laboratory	O
of	O
Biophysics	O
and	O
Cytometry	O
,	O
National	O
Cancer	O
Institute	O
(	O
IST	O
)	O
,	O
Genova	O
,	O
Italy	O
.	O
giaretti@hp380.ist	O
.unige	O
.it	O
The	O
molecular	O
pathways	O
and	O
the	O
timing	O
of	O
genetic	O
events	O
during	O
human	O
colorectal	O
carcinogenesis	O
are	O
still	O
not	O
fully	O
understood	O
.	O
We	O
have	O
addressed	O
the	O
intratumor	O
heterogeneity	O
of	O
the	O
mutational	O
status	O
of	O
the	O
k-ras	O
oncogene	O
and	O
of	O
the	O
p53	O
oncosuppressor	O
gene	O
during	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
by	O
investigating	O
26	O
human	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
containing	O
early	O
cancer	O
.	O
An	O
intratumor	O
comparative	O
analysis	O
was	O
obtained	O
among	O
the	O
adenomatous	O
and	O
carcinomatous	O
component	O
pairs	O
.	O
Additionally	O
,	O
we	O
have	O
analyzed	O
17	O
adenomas	B-malignancy-type
having	O
cancer	O
in	O
the	O
near	O
vicinity	O
.	O
The	O
adenomatous	O
components	O
of	O
the	O
adenomas	B-malignancy-type
containing	O
early	O
cancer	O
and	O
the	O
adenomas	B-malignancy-type
having	O
cancer	O
in	O
the	O
near	O
vicinity	O
had	O
comparable	O
frequencies	O
for	O
k-ras	O
mutations	O
(	O
28	O
and	O
47	O
%	O
)	O
but	O
different	O
for	O
p53	O
mutations	O
(	O
52	O
and	O
7	O
%	O
,	O
p	O
-	O
value	O
=	O
0.01	O
)	O
.	O
Interestingly	O
,	O
the	O
adenomatous	O
and	O
carcinomatous	O
components	O
of	O
the	O
adenomas	B-malignancy-type
containing	O
early	O
cancer	O
were	O
rarely	O
heterogeneous	O
for	O
the	O
k-ras	O
mutational	O
status	O
(	O
only	O
in	O
13	O
%	O
of	O
the	O
cases	O
)	O
but	O
were	O
characterized	O
by	O
heterogeneity	O
of	O
the	O
p53	O
status	O
in	O
59	O
%	O
of	O
the	O
cases	O
(	O
p	O
-	O
value	O
<	O
0.01	O
)	O
.	O
In	O
addition	O
,	O
the	O
mutations	O
of	O
p53	O
for	O
the	O
adenomatous	O
components	O
of	O
the	O
adenomas	B-malignancy-type
containing	O
early	O
cancer	O
were	O
statistically	O
significantly	O
associated	O
with	O
severe	B-malignancy-type
dysplasia	I-malignancy-type
(	O
p	O
-	O
value	O
=	O
0.01	O
)	O
.	O
Intratumor	O
homogeneity	O
of	O
k-ras	O
status	O
during	O
the	O
human	O
colorectal	B-malignancy-type
adenoma	I-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
suggests	O
that	O
the	O
role	O
of	O
k-ras	O
is	O
more	O
related	O
to	O
tumor	O
initiation	O
than	O
to	O
tumor	O
progression	O
.	O
On	O
the	O
contrary	O
,	O
intratumor	O
heterogeneity	O
of	O
p53	O
mutations	O
indicates	O
that	O
the	O
type	O
of	O
the	O
p53	O
mutations	O
may	O
also	O
be	O
relevant	O
for	O
selection	O
and	O
expansion	O
of	O
new	O
subclones	O
leading	O
to	O
tumor	O
progression	O
.	O
PMID	O
:	O
11310641	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2001	O
Feb	O
8;2	O
0	O
(	O
6	O
)	O
:	O
68	O
6-91	O
Loss	O
of	O
heterozygosity	O
at	O
4p16.3	O
and	O
mutation	O
of	O
FGFR3	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Sibley	O
K,	O
Cuthber	O
t-Heavens	O
D	O
,	O
Knowles	O
MA.	O
ICRF	O
Clinical	O
Centre	O
,	O
St	O
James	O
's	O
University	O
Hospital	O
,	O
Beckett	O
Street	O
,	O
Leeds	O
LS9	O
7TF	O
,	O
UK.	O
4p16.3	O
has	O
previously	O
been	O
identified	O
as	O
a	O
region	O
of	O
non	O
-	O
random	O
LOH	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
suggesting	O
the	O
presence	O
of	O
a	O
tumour	O
suppressor	O
gene	O
.	O
One	O
candidate	O
within	O
this	O
region	O
is	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
.	O
Germline	O
mutations	O
in	O
FGFR3	O
are	O
known	O
to	O
cause	O
several	O
autosomal	O
dominant	O
skeletal	B-malignancy-type
dysplasias	I-malignancy-type
,	O
the	O
severity	O
of	O
which	O
depends	O
on	O
the	O
position	O
and	O
nature	O
of	O
the	O
mutation	O
in	O
the	O
protein	O
.	O
We	O
investigated	O
the	O
frequency	O
and	O
nature	O
of	O
FGFR3	O
mutations	O
in	O
a	O
panel	O
of	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
cell	O
lines	O
and	O
studied	O
the	O
possible	O
link	O
between	O
mutation	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
4p16.3	O
.	O
FGFR3	O
coding	O
sequence	O
from	O
63	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
TCC	B-malignancy-type
)	O
of	O
various	O
stages	O
and	O
grades	O
,	O
and	O
18	O
cell	O
lines	O
was	O
analysed	O
by	O
fluorescent	O
SSCP	O
.	O
Samples	O
with	O
abnormal	O
migration	O
patterns	O
were	O
sequenced	O
to	O
identify	O
the	O
mutation	O
or	O
polymorphism	O
.	O
Thirty-one	O
of	O
the	O
63	O
tumours	O
had	O
previously	O
been	O
assessed	O
to	O
have	O
LOH	O
at	O
4p16.3	O
.	O
Twenty-six	O
of	O
the	O
63	O
tumours	O
(	O
41	O
%	O
)	O
and	O
4	O
/	O
18	O
(	O
22	O
%	O
)	O
of	O
the	O
cell	O
lines	O
had	O
missense	O
mutations	O
in	O
FGFR3	O
.	O
All	O
mutations	O
detected	O
in	O
our	O
panel	O
have	O
been	O
reported	O
in	O
the	O
germline	O
where	O
all	O
apart	O
from	O
one	O
cause	O
lethal	O
conditions	O
.	O
One	O
tumour	O
contained	O
K	O
652	O
Q	O
which	O
has	O
recently	O
been	O
identified	O
in	O
less	O
severe	O
cases	O
of	O
skeletal	B-malignancy-type
dysplasia	I-malignancy-type
.	O
Tumours	O
with	O
and	O
without	O
LOH	O
at	O
4p16.3	O
had	O
mutations	O
in	O
FGFR3	O
suggesting	O
that	O
these	O
two	O
events	O
are	O
not	O
causally	O
linked	O
.	O
The	O
frequency	O
of	O
FGFR3	O
mutation	O
indicates	O
that	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
TCC	B-malignancy-type
.	O
PMID	O
:	O
11314002	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
May	O
1;6	O
1	O
(	O
9	O
)	O
:	O
354	O
1-3	O
Mutations	O
in	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
and	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
genes	O
associated	O
with	O
human	O
gastric	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
Jang	O
JH,	O
Shin	O
KH,	O
Park	O
JG.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
11	O
0-744	O
,	O
Korea	O
.	O
Autosomal	O
dominant	O
disorders	O
of	O
skeletal	O
and	O
cranial	O
development	O
have	O
been	O
linked	O
to	O
fibroblast	O
growth	O
factor	O
receptor	O
(	O
FGFR	O
)	O
2	O
and	O
FGFR3	O
.	O
Here	O
we	O
report	O
two	O
identical	O
mutations	O
in	O
FGFR2	O
that	O
cause	O
craniosynostosis	O
syndromes	O
,	O
Crouzon	O
,	O
Apert	O
,	O
and	O
Pfeiffer	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
missense	O
mutation	O
(	O
Ser	O
267	O
Pro	O
)	O
in	O
exon	O
IIIa	O
and	O
a	O
splice	O
site	O
mutation	O
(	O
940	O
-	O
2	O
A	O
-->	O
G	O
)	O
in	O
exon	O
IIIc	O
were	O
detected	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Interestingly	O
,	O
these	O
heterozygous	O
somatic	O
mutations	O
are	O
identical	O
to	O
the	O
germinal	O
activating	O
mutations	O
in	O
FGFR2	O
reported	O
previously	O
in	O
craniosynostosis	O
syndromes	O
.	O
In	O
addition	O
,	O
the	O
two	O
novel	O
mutations	O
of	O
FGFR3	O
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
were	O
identified	O
.	O
All	O
identified	O
mutations	O
occurred	O
at	O
highly	O
conserved	O
sequences	O
,	O
not	O
only	O
in	O
the	O
FGFR	O
family	O
of	O
molecules	O
,	O
but	O
also	O
throughout	O
evolution	O
and	O
clustered	O
in	O
the	O
immunoglobulin	O
-	O
like	O
loop	O
-	O
III	O
domain	O
,	O
highlighting	O
the	O
functional	O
importance	O
of	O
this	O
domain	O
.	O
Our	O
results	O
indicate	O
that	O
FGFR2	O
and	O
FGFR3	O
,	O
in	O
addition	O
to	O
their	O
potential	O
role	O
in	O
skeletal	B-malignancy-type
dysplasias	I-malignancy-type
,	O
play	O
an	O
important	O
role	O
in	O
tumorigenesis	O
.	O
PMID	O
:	O
11325814	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
2001	O
May;194	O
(	O
1	O
)	O
:	O
5	O
9-67	O
Frequent	O
nuclear	O
beta-catenin	O
accumulation	O
and	O
associated	O
mutations	O
in	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
endometrial	I-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
with	I-malignancy-type
squamous	I-malignancy-type
differentiation	I-malignancy-type
.	O
Saegusa	O
M,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
1-1	O
5-1	O
Kitasato	O
,	O
Sagamihara	O
,	O
Kanagawa	O
22	O
8-8555	O
,	O
Japan	O
.	O
msaegusa@med.kitasat	O
o-u.ac.jp	O
Focal	O
squamous	O
differentiation	O
is	O
a	O
common	O
feature	O
of	O
endometrioid	B-malignancy-type
endometrial	I-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
(	O
E-Em	B-malignancy-type
and	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
)	O
.	O
A	O
close	O
association	O
between	O
mutated	O
beta-catenin	O
accumulation	O
and	O
alteration	O
in	O
cellular	O
morphology	O
has	O
recently	O
been	O
demonstrated	O
in	O
murine	O
L	O
cell	O
lines	O
.	O
To	O
clarify	O
the	O
possible	O
role	O
of	O
beta-catenin	O
abnormalities	O
and	O
changes	O
in	O
tumour	O
morphology	O
,	O
60	O
grade	O
(	O
G	O
)	O
1	O
or	O
G2	B-malignancy-type
E-Em	I-malignancy-type
Cas	I-malignancy-type
with	I-malignancy-type
areas	I-malignancy-type
of	I-malignancy-type
squamous	I-malignancy-type
differentiation	I-malignancy-type
(	O
SqD	O
)	O
,	O
including	O
morules	O
and	O
squamous	O
metaplastic	O
(	O
SqM	O
)	O
foci	O
,	O
as	O
well	O
as	O
32	O
G1	O
or	O
G2	O
tumours	O
without	O
such	O
lesions	B-malignancy-type
,	O
were	O
investigated	O
and	O
the	O
results	O
compared	O
with	O
findings	O
for	O
c-jun	O
and	O
wnt-1	O
expression	O
.	O
Twenty-three	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
,	O
with	O
and	O
without	O
SqD	O
lesions	O
,	O
were	O
also	O
examined	O
.	O
In	O
E-Em	B-malignancy-type
Cas	I-malignancy-type
,	O
frequent	O
nuclear	O
beta-catenin	O
accumulation	O
was	O
observed	O
in	O
22	O
(	O
84.6	O
%	O
)	O
of	O
26	O
tumours	O
with	O
morules	O
and	O
15	O
(	O
45.5	O
%	O
)	O
of	O
33	O
with	O
SqM	O
foci	O
,	O
in	O
contrast	O
to	O
4	O
(	O
12.5	O
%	O
)	O
of	O
32	O
without	O
such	O
lesions	B-malignancy-type
.	O
Similar	O
findings	O
were	O
also	O
noted	O
for	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
involving	O
codons	O
32	O
,	O
33	O
,	O
34	O
,	O
37	O
,	O
41	O
,	O
and	O
45	O
,	O
the	O
single	O
nucleotide	O
substitutions	O
being	O
identical	O
between	O
SqD	O
and	O
the	O
surrounding	O
carcinoma	B-malignancy-type
tissue	O
in	O
most	O
informative	O
cases	O
.	O
The	O
mutations	O
were	O
positively	O
related	O
to	O
nuclear	O
immunopositivity	O
,	O
but	O
inversely	O
to	O
membrane	O
expression	O
,	O
while	O
there	O
was	O
no	O
association	O
with	O
the	O
status	O
of	O
c-jun	O
or	O
wnt-1	O
.	O
These	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
,	O
nuclear	O
beta-catenin	O
accumulation	O
and	O
mutations	O
were	O
limited	O
to	O
tumours	B-malignancy-type
with	I-malignancy-type
SqD	I-malignancy-type
features	O
,	O
independent	O
of	O
c-jun	O
and	O
wnt-1	O
status	O
.	O
These	O
data	O
indicate	O
that	O
beta-catenin	O
abnormalities	O
are	O
relatively	O
common	O
in	O
E-Em	B-malignancy-type
and	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
with	I-malignancy-type
SqD	I-malignancy-type
features	O
,	O
implying	O
a	O
role	O
in	O
the	O
squamous	O
differentiation	O
of	O
tumour	O
cells	O
,	O
not	O
necessarily	O
related	O
to	O
c-jun	O
and/or	O
wnt-1	O
status	O
.	O
Copyright	O
2001	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
PMID	O
:	O
11329142	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2001	O
May;1	O
4	O
(	O
5	O
)	O
:	O
44	O
3-51	O
Adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
:	O
a	O
clinicopathologic	O
series	O
of	O
25	O
cases	O
.	O
Kardon	O
DE	O
,	O
Thompson	O
LD	O
,	O
Przygodzki	O
RM	O
,	O
Heffess	O
CS.	O
Department	O
of	O
Endocrine	O
and	O
Otorhinolaryngi	O
c-Head	O
&	O
Neck	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC.	O
2030	O
6-6000	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
is	O
a	O
rare	O
aggressive	O
subtype	O
of	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
describe	O
the	O
clinical	O
,	O
pathologic	O
,	O
and	O
molecular	O
characteristics	O
of	O
25	O
of	O
these	O
lesions	B-malignancy-type
,	O
the	O
largest	O
series	O
to	O
date	O
.	O
METHODS	O
:	O
Twenty-five	O
cases	O
of	O
adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
diagnosed	O
between	O
1961	O
and	O
1994	O
were	O
retrieved	O
from	O
the	O
files	O
of	O
the	O
Endocrine	O
Registry	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Histologic	O
features	O
were	O
reviewed	O
,	O
histochemical	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
(	O
k-ras	O
)	O
studies	O
were	O
performed	O
,	O
and	O
patient	O
follow-up	O
was	O
obtained	O
.	O
RESULTS	O
:	O
The	O
patients	O
included	O
17	O
men	O
and	O
eight	O
women	O
,	O
aged	O
28	O
to	O
82	O
years	O
(	O
mean	O
,	O
65.4	O
y	O
)	O
.	O
The	O
patients	O
usually	O
experienced	O
weight	O
loss	O
(	O
n	O
=	O
17	O
)	O
or	O
painless	O
jaundice	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
also	O
presenting	O
with	O
other	O
abdominal	O
symptoms	O
.	O
The	O
tumors	O
affected	O
the	O
head	O
most	O
frequently	O
(	O
n	O
=	O
17	O
)	O
,	O
followed	O
by	O
the	O
tail	O
(	O
n	O
=	O
9	O
)	O
or	O
body	O
(	O
n	O
=	O
4	O
)	O
.	O
Five	O
cases	O
involved	O
more	O
than	O
one	O
anatomic	O
region	O
of	O
the	O
pancreas	O
.	O
Microscopically	O
,	O
all	O
tumors	O
demonstrated	O
dual	O
differentiation	O
toward	O
adenocarcinoma	B-malignancy-type
and	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
All	O
cases	O
tested	O
were	O
immunoreactive	O
with	O
keratin	O
(	O
AE1	O
:	O
AE3	O
and	O
CK1	O
)	O
,	O
whereas	O
other	O
keratin	O
markers	O
were	O
variably	O
expressed	O
:	O
CK5	O
/	O
6	O
(	O
88	O
%	O
)	O
,	O
CK7	O
(	O
68	O
%	O
)	O
,	O
Cam5.2	O
(	O
41	O
%	O
)	O
,	O
and	O
CK20	O
(	O
26	O
%	O
)	O
.	O
CA-19-9	O
(	O
84	O
%	O
)	O
and	O
CEA	O
(	O
74	O
%	O
)	O
were	O
positive	O
in	O
the	O
majority	O
of	O
the	O
cases	O
.	O
K-ras	O
oncogene	O
mutations	O
were	O
identified	O
in	O
seven	O
of	O
13	O
cases	O
.	O
All	O
patients	O
died	O
from	O
their	O
disease	O
an	O
average	O
of	O
5.8	O
months	O
after	O
diagnosis	O
(	O
range	O
,	O
1	O
to	O
33	O
months	O
)	O
.	O
CONCLUSIONS	O
:	O
Adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
represents	O
a	O
distinct	O
clinical	O
and	O
pathologic	O
entity	O
,	O
demonstrating	O
the	O
expected	O
immunoprofile	O
and	O
k-ras	O
oncogene	O
mutation	O
of	O
a	O
ductal	O
origin	O
,	O
with	O
a	O
worse	O
prognosis	O
than	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
11353055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
2001	O
Jun;120	O
(	O
7	O
)	O
:	O
176	O
3-73	O
Genetic	O
alterations	O
associated	O
with	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
define	O
distinct	O
pathways	O
of	O
hepatocarcinogenesis	O
.	O
Lauren	O
t-Puig	O
P,	O
Legoix	O
P,	O
Bluteau	O
O,	O
Belghiti	O
J,	O
Franco	O
D	O
,	O
Binot	O
F	O
,	O
Monges	O
G,	O
Thomas	O
G,	O
Bioula	O
c-Sage	O
P,	O
Zucma	O
n-Rossi	O
J.	O
INSERM	O
U434	O
,	O
CEPH,	O
Paris	O
;	O
Assistance	O
Publique	O
Hopitaux	O
de	O
Paris	O
,	O
France	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
To	O
evaluate	O
how	O
characterization	O
of	O
genetic	O
alterations	O
can	O
help	O
in	O
the	O
elucidation	O
of	O
liver	O
carcinogenesis	O
pathways	O
,	O
137	O
tumors	O
were	O
analyzed	O
.	O
METHODS	O
:	O
High-density	O
allelotype	O
,	O
p53	O
,	O
Axin1	O
,	O
and	O
beta-catenin	O
gene	O
mutations	O
were	O
determined	O
.	O
Alterations	O
were	O
analyzed	O
according	O
to	O
clinical	O
parameters	O
.	O
RESULTS	O
:	O
Tumors	O
could	O
be	O
divided	O
into	O
2	O
groups	O
according	O
to	O
chromosome	O
stability	O
status	O
.	O
In	O
the	O
first	O
group	O
,	O
demonstrating	O
a	O
chromosome	O
stability	O
,	O
beta-catenin	O
mutation	O
associated	O
with	O
chromosome	O
8p	O
losses	O
were	O
frequently	O
found	O
as	O
the	O
single	O
genetic	O
alterations	O
.	O
beta-catenin	O
mutations	O
were	O
associated	O
with	O
large	O
tumor	O
size	O
and	O
with	O
negative	O
hepatitis	O
B	O
virus	O
status	O
.	O
In	O
the	O
second	O
group	O
,	O
demonstrating	O
a	O
chromosome	O
instability	O
,	O
the	O
most	O
frequent	O
allelic	O
losses	O
were	O
on	O
chromosome	O
1p	O
,	O
4q	O
,	O
6q	O
,	O
9p	O
,	O
13q	O
,	O
16p	O
,	O
16q	O
,	O
and	O
17p	O
;	O
Axin1	O
and	O
p53	O
were	O
frequently	O
mutated	O
.	O
All	O
of	O
these	O
alterations	O
,	O
except	O
losses	O
on	O
6q	O
and	O
9p	O
,	O
were	O
associated	O
with	O
hepatitis	O
B	O
virus	O
infection	O
.	O
P53	O
mutations	O
,	O
17p	O
,	O
13q	O
losses	O
,	O
and	O
a	O
high	O
value	O
of	O
the	O
fractional	O
allelic	O
loss	O
index	O
were	O
associated	O
with	O
poor	B-malignancy-type
differentiated	I-malignancy-type
tumors	I-malignancy-type
,	O
independently	O
of	O
risk	O
factors	O
.	O
Finally	O
,	O
in	O
the	O
whole	O
series	O
,	O
chromosome	O
9p	O
and	O
6q	O
losses	O
were	O
associated	O
with	O
poor	O
prognosis	O
.	O
CONCLUSIONS	O
:	O
Two	O
main	O
pathways	O
defined	O
by	O
genetic	O
alterations	O
show	O
different	O
risk	O
factors	O
and	O
clinical	O
characteristics	O
.	O
Furthermore	O
,	O
loss	O
of	O
chromosome	O
9p	O
or	O
6q	O
is	O
an	O
independent	O
prognostic	O
indicator	O
.	O
PMID	O
:	O
11375957	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
2001	O
Jun	O
1;19	O
(	O
11	O
)	O
:	O
283	O
7-43	O
Discordance	O
between	O
K-ras	O
mutations	O
in	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
and	O
the	O
primary	O
tumor	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Tortola	O
S	O
,	O
Steinert	O
R	O
,	O
Hantschick	O
M,	O
Peinado	O
MA	O
,	O
Gastinger	O
I	O
,	O
Stosiek	O
P,	O
Lippert	O
H,	O
Schlegel	O
W	O
,	O
Reymond	O
MA.	O
Fondation	O
Pour	O
Recherches	O
Medicales	O
,	O
Geneva	O
,	O
Switzerland	O
.	O
PURPOSE	O
:	O
To	O
study	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
from	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
for	O
the	O
presence	O
of	O
K-ras	O
mutations	O
and	O
to	O
compare	O
their	O
genotype	O
with	O
that	O
of	O
the	O
corresponding	O
primary	O
tumor	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Bilateral	O
iliac	O
crest	O
aspiration	O
was	O
performed	O
in	O
51	O
patients	O
undergoing	O
surgery	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
were	O
detected	O
by	O
immunohistochemistry	O
.	O
The	O
presence	O
of	O
K-ras	O
mutations	O
was	O
determined	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
on	O
both	O
primary	O
tumors	O
and	O
paired	O
bone	O
marrow	O
samples	O
and	O
was	O
confirmed	O
by	O
sequencing	O
.	O
RESULTS	O
:	O
In	O
six	O
patients	O
with	O
primary	O
tumor	O
mutations	O
,	O
it	O
was	O
possible	O
to	O
amplify	O
a	O
mutated	O
K-ras	O
gene	O
also	O
from	O
the	O
bone	O
marrow	O
sample	O
.	O
In	O
three	O
of	O
those	O
patients	O
the	O
pattern	O
of	O
K-ras	O
mutations	O
differed	O
between	O
both	O
samples	O
,	O
in	O
two	O
patients	O
the	O
mutation	O
was	O
identical	O
between	O
the	O
bone	O
marrow	O
and	O
its	O
primary	O
tumor	O
,	O
and	O
in	O
one	O
patient	O
the	O
same	O
mutation	O
plus	O
a	O
different	O
one	O
were	O
found	O
.	O
Fifteen	O
of	O
17	O
K-ras	O
mutations	O
found	O
in	O
primary	O
tumors	O
were	O
located	O
in	O
codon	O
12	O
,	O
whereas	O
in	O
bone	O
marrow	O
,	O
five	O
of	O
seven	O
mutations	O
were	O
found	O
in	O
codon	O
13	O
(	O
P	O
=	O
.003	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
demonstrate	O
that	O
,	O
at	O
least	O
for	O
K-ras	O
mutations	O
,	O
disseminated	O
epithelial	O
cells	O
are	O
not	O
always	O
clonal	O
with	O
the	O
primary	O
tumor	O
and	O
they	O
question	O
the	O
malignant	O
genotype	O
of	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
.	O
They	O
also	O
indicate	O
that	O
different	O
tumoral	O
clones	O
may	O
be	O
circulating	O
simultaneously	O
or	O
sequentially	O
in	O
the	O
same	O
patient	O
.	O
Analysis	O
of	O
the	O
type	O
of	O
mutations	O
suggests	O
that	O
cell	O
dissemination	O
might	O
be	O
an	O
early	O
event	O
in	O
colorectal	O
carcinogenesis	O
.	O
PMID	O
:	O
11387355	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
2001	O
Jun	O
6;9	O
3	O
(	O
11	O
)	O
:	O
85	O
8-65	O
Comment	O
in	O
:	O
J	O
Natl	O
Cancer	O
Inst	O
.	O
2001	O
Jun	O
6;9	O
3	O
(	O
11	O
)	O
:	O
79	O
8-9	O
.	O
Detecting	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
in	O
stool	O
with	O
the	O
use	O
of	O
multiple	O
genetic	O
targets	O
.	O
Dong	O
SM	O
,	O
Traverso	O
G,	O
Johnson	O
C,	O
Geng	O
L,	O
Favis	O
R	O
,	O
Boynton	O
K,	O
Hibi	O
K,	O
Goodman	O
SN	O
,	O
D'Allessio	O
M,	O
Paty	O
P,	O
Hamilton	O
SR	O
,	O
Sidransky	O
D	O
,	O
Barany	O
F	O
,	O
Levin	O
B	O
,	O
Shuber	O
A	O
,	O
Kinzler	O
KW,	O
Vogelstein	O
B	O
,	O
Jen	O
J.	O
Division	O
of	O
Head	O
and	O
Neck	O
Cancer	O
Research	O
,	O
Department	O
of	O
Otolaryngolog	O
y-Head	O
and	O
Neck	O
Surgery	O
,	O
The	O
Johns	O
Hopkins	O
Medical	O
School	O
,	O
The	O
Johns	O
Hopkins	O
University	O
,	O
Baltimore	O
,	O
MD	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Colorectal	B-malignancy-type
cancer	I-malignancy-type
cells	O
are	O
shed	O
into	O
the	O
stool	O
,	O
providing	O
a	O
potential	O
means	O
for	O
the	O
early	O
detection	O
of	O
the	O
disease	O
using	O
noninvasive	O
approaches	O
.	O
Our	O
goal	O
was	O
to	O
develop	O
reliable	O
,	O
specific	O
molecular	O
genetic	O
tests	O
for	O
the	O
detection	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
in	O
stool	O
samples	O
.	O
METHODS	O
:	O
Stool	O
DNA	O
was	O
isolated	O
from	O
paired	O
stools	O
and	O
primary	O
tumor	O
samples	O
from	O
51	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Three	O
genetic	O
targets	O
-	O
TP53	O
,	O
BAT26	O
,	O
and	O
K-RAS	O
-	O
were	O
used	O
to	O
detect	O
tumor	O
-	O
associated	O
mutations	O
in	O
the	O
stool	O
prior	O
to	O
or	O
without	O
regard	O
to	O
the	O
molecular	O
analyses	O
of	O
the	O
paired	O
tumors	O
.	O
TP53	O
gene	O
mutations	O
were	O
detected	O
with	O
a	O
mismatch	O
-	O
ligation	O
assay	O
that	O
detects	O
nine	O
common	O
p53	O
gene	O
mutations	O
.	O
Deletions	O
within	O
the	O
BAT26	O
locus	O
were	O
detected	O
by	O
a	O
modified	O
solid-phase	O
minisequencing	O
method	O
.	O
Mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
K-RAS	O
were	O
detected	O
with	O
a	O
digital	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
.	O
RESULTS	O
:	O
TP53	O
gene	O
mutations	O
were	O
detected	O
in	O
the	O
tumor	O
DNA	O
of	O
30	O
patients	O
,	O
all	O
of	O
whom	O
had	O
the	O
identical	O
TP53	O
mutation	O
in	O
their	O
stools	O
.	O
Tumors	O
from	O
three	O
patients	O
contained	O
a	O
noninherited	O
deletion	O
at	O
the	O
BAT26	O
locus	O
,	O
and	O
the	O
same	O
alterations	O
were	O
identified	O
in	O
these	O
patients	O
'	O
stool	O
specimens	O
.	O
Nineteen	O
of	O
50	O
tumors	O
tested	O
had	O
a	O
K-RAS	O
mutation	O
;	O
identical	O
mutations	O
were	O
detected	O
in	O
the	O
paired	O
stool	O
DNA	O
samples	O
from	O
eight	O
patients	O
.	O
In	O
no	O
case	O
was	O
a	O
mutation	O
found	O
in	O
stool	O
that	O
was	O
not	O
also	O
present	O
in	O
the	O
primary	O
tumor	O
.	O
Thus	O
,	O
the	O
three	O
genetic	O
markers	O
together	O
detected	O
36	O
(	O
71	O
%	O
)	O
of	O
51	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
56	O
%	O
to	O
83	O
%	O
)	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
36	O
(	O
92	O
%	O
)	O
of	O
39	O
patients	O
(	O
95	O
%	O
CI	O
=	O
79	O
%	O
to	O
98	O
%	O
)	O
whose	O
tumors	O
had	O
an	O
alteration	O
.	O
CONCLUSION	O
:	O
We	O
were	O
able	O
to	O
detect	O
the	O
majority	O
of	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
by	O
analyzing	O
stool	O
DNA	O
for	O
just	O
three	O
genetic	O
markers	O
.	O
Additional	O
work	O
is	O
needed	O
to	O
determine	O
the	O
specificity	O
of	O
these	O
genetic	O
tests	O
for	O
detecting	O
colorectal	B-malignancy-type
neoplasia	I-malignancy-type
in	O
asymptomatic	O
patients	O
and	O
to	O
more	O
precisely	O
estimate	O
the	O
prevalence	O
of	O
the	O
mutations	O
and	O
sensitivity	O
of	O
the	O
assay	O
.	O
PMID	O
:	O
11390535	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
2001	O
Jun	O
;	O
31	O
(	O
2	O
)	O
:	O
68	O
-	O
73	O
CTNNB1	O
mutations	O
and	O
beta-catenin	O
protein	O
accumulation	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
high	O
exposure	O
to	O
aflatoxin	O
B1	O
.	O
Devereux	O
TR	O
,	O
Stern	O
MC	O
,	O
Flake	O
GP	O
,	O
Yu	O
MC	O
,	O
Zhang	O
ZQ	O
,	O
London	O
SJ	O
,	O
Taylor	O
JA	O
Laboratory	O
of	O
Molecular	O
Carcinogenesis	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
NIH	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
,	O
USA	O
.	O
beta-Catenin	O
plays	O
a	O
key	O
role	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
mutations	O
of	O
CTNNB1	O
,	O
the	O
gene	O
that	O
encodes	O
beta-catenin	O
,	O
have	O
been	O
identified	O
in	O
about	O
one-fourth	O
of	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
from	O
regions	O
of	O
low	O
aflatoxin	O
B1	O
exposure	O
.	O
In	O
this	O
study	O
62	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
from	O
people	O
highly	O
exposed	O
to	O
aflatoxin	O
B1	O
in	O
Guangxi	O
,	O
People	O
's	O
Republic	O
of	O
China	O
,	O
were	O
laser	O
-	O
capture	O
microdissected	O
and	O
examined	O
for	O
CTNNB1	O
mutations	O
.	O
In	O
addition	O
,	O
41	O
of	O
the	O
HCCs	O
were	O
evaluated	O
for	O
the	O
presence	O
of	O
the	O
beta-catenin	O
protein	O
by	O
immunohistochemical	O
methods	O
.	O
Twenty	O
of	O
the	O
HCCs	B-malignancy-type
showed	O
positive	O
results	O
for	O
beta-catenin	O
,	O
with	O
strong	O
membrane	O
staining	O
,	O
while	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
lacked	O
or	O
showed	O
only	O
weak	O
membrane	O
staining	O
.	O
One	O
HCC	B-malignancy-type
,	O
in	O
which	O
a	O
CTNNB1	O
mutation	O
was	O
not	O
detected	O
,	O
showed	O
nuclear	O
staining	O
for	O
the	O
beta-catenin	O
protein	O
.	O
Mutations	O
of	O
CTNNB1	O
were	O
identified	O
in	O
five	O
HCCs	B-malignancy-type
.	O
These	O
consisted	O
of	O
four	O
point	O
mutations	O
in	O
the	O
glycogen	O
serine	O
kinase-3beta	O
phosphorylation	O
region	O
of	O
codons	O
32	O
-	O
45	O
and	O
one	O
deletion	O
of	O
codons	O
32	O
-	O
38	O
.	O
These	O
mutations	O
were	O
similar	O
to	O
those	O
previously	O
reported	O
for	O
human	O
HCC	B-malignancy-type
,	O
although	O
at	O
a	O
lower	O
frequency	O
.	O
A	O
signature	O
mutation	O
profile	O
associated	O
with	O
aflatoxin	O
B1	O
exposure	O
could	O
not	O
be	O
identified	O
.	O
The	O
immunohistochemical	O
findings	O
indicate	O
a	O
role	O
for	O
accumulation	O
of	O
beta-catenin	O
and	O
possibly	O
increased	O
Wnt	O
signaling	O
in	O
aflatoxin	O
B1	O
-	O
associated	O
HCC	B-malignancy-type
.	O
The	O
low	O
frequency	O
of	O
CTNNB1	O
mutations	O
,	O
however	O
,	O
suggests	O
that	O
mutation	O
of	O
another	O
Wnt	O
signaling	O
component	O
,	O
such	O
as	O
the	O
Wnt	O
scaffolding	O
protein	O
axin	O
or	O
the	O
adenomatous	O
polyposis	O
coli	O
protein	O
,	O
both	O
of	O
which	O
modulate	O
beta-catenin	O
stability	O
,	O
also	O
may	O
be	O
involved	O
in	O
aflatoxin	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
HCC	I-malignancy-type
.	O
Published	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
PMID	O
:	O
11429783	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
2001	O
Aug	O
1	O
;	O
93	O
(	O
3	O
)	O
:	O
445	O
-	O
9	O
Somatic	O
mutations	O
of	O
WNT	O
/	O
wingless	O
signaling	O
pathway	O
components	O
in	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
.	O
Koch	O
A	O
,	O
Waha	O
A	O
,	O
Tonn	O
JC	O
,	O
Sorensen	O
N	O
,	O
Berthold	O
F	O
,	O
Wolter	O
M,	O
Reifenberger	O
J,	O
Hartmann	O
W	O
,	O
Friedl	O
W	O
,	O
Reifenberger	O
G,	O
Wiestler	O
OD	O
,	O
Pietsch	O
T.	O
Department	O
of	O
Neuropathology	O
,	O
University	O
of	O
Bonn	O
Medical	O
Center	O
;	O
Bonn	O
,	O
Germany	O
.	O
Primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
(	O
PNETs	B-malignancy-type
)	O
represent	O
the	O
most	O
frequent	O
malignant	O
brain	B-malignancy-type
tumors	I-malignancy-type
in	O
childhood	O
.	O
The	O
majority	O
of	O
these	O
neoplasms	B-malignancy-type
occur	O
in	O
the	O
cerebellum	O
and	O
are	O
classified	O
as	O
medulloblastomas	B-malignancy-type
(	O
MB	B-malignancy-type
)	O
.	O
Most	O
PNETs	B-malignancy-type
develop	O
sporadically	O
;	O
however	O
,	O
their	O
incidence	O
is	O
highly	O
elevated	O
in	O
patients	O
carrying	O
germline	O
APC	O
gene	O
mutations	O
.	O
The	O
APC	O
gene	O
encodes	O
a	O
central	O
component	O
of	O
the	O
WNT	O
/	O
wingless	O
developmental	O
signaling	O
pathway	O
.	O
It	O
regulates	O
the	O
levels	O
of	O
cytoplasmic	O
beta-catenin	O
protein	O
that	O
plays	O
a	O
central	O
role	O
in	O
neural	O
development	O
and	O
cell	O
proliferation	O
.	O
We	O
analyzed	O
87	O
sporadic	B-malignancy-type
PNETs	I-malignancy-type
and	O
10	O
PNET	B-malignancy-type
cell	O
lines	O
for	O
mutations	O
of	O
the	O
APC	O
gene	O
and	O
beta-catenin	O
(	O
CTNNB1	O
)	O
gene	O
using	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
sequencing	O
analysis	O
.	O
We	O
examined	O
the	O
mutation	O
cluster	O
region	O
of	O
APC	O
(	O
codons	O
1255	O
--	O
1641	O
)	O
for	O
germline	O
variants	O
and	O
somatic	O
mutations	O
.	O
The	O
medulloblastoma	B-malignancy-type
cell	O
line	O
MHH-MED-2	O
carried	O
a	O
Glu	O
1317	O
Gln	O
missense	O
germline	O
variant	O
and	O
a	O
sporadic	B-malignancy-type
MB	I-malignancy-type
sample	O
showed	O
a	O
somatic	O
Pro	O
1319	O
Leu	O
substitution	O
.	O
Mutational	O
analysis	O
of	O
exon	O
3	O
of	O
CTNNB1	O
uncovered	O
4	O
PNETs	B-malignancy-type
(	O
4.8	O
%	O
)	O
with	O
somatic	O
missense	O
mutations	O
.	O
These	O
mutations	O
caused	O
amino	O
acid	O
substitutions	O
in	O
3	O
of	O
80	O
medulloblastomas	B-malignancy-type
(	O
Ser	O
33	O
Phe	O
,	O
Ser	O
33	O
Cys	O
and	O
Ser	O
37	O
Cys	O
)	O
and	O
1	O
of	O
4	O
supratentorial	B-malignancy-type
PNETs	I-malignancy-type
(	O
Gly	O
34	O
Val	O
)	O
.	O
All	O
mutations	O
affected	O
GSK-3	O
beta	O
phosphorylation	O
sites	O
of	O
the	O
degradation	O
targeting	O
box	O
of	O
beta-catenin	O
and	O
resulted	O
in	O
nuclear	O
beta-catenin	O
protein	O
accumulation	O
.	O
Deletions	O
of	O
CTNNB1	O
were	O
not	O
detected	O
by	O
PCR	O
amplification	O
with	O
primers	O
spanning	O
exons	O
1	O
--	O
5	O
.	O
Our	O
data	O
indicate	O
that	O
inappropriate	O
activation	O
of	O
the	O
WNT	O
/	O
wingless	O
signaling	O
pathway	O
by	O
mutations	O
of	O
its	O
components	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
subset	O
of	O
PNETs	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11433413	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Ann	O
Diagn	O
Pathol	O
2001	O
Jun;	O
5	O
(	O
3	O
)	O
:	O
129	O
-	O
40	O
A	O
clinicopathologic	O
and	O
immunohistochemical	O
study	O
of	O
35	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
pancreas	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O
Paal	O
E	O
,	O
Thompson	O
LD	O
,	O
Frommelt	O
RA	O
,	O
Przygodzki	O
RM	O
,	O
Heffess	O
CS.	O
Department	O
of	O
Endocrine	O
and	O
Otorhinolaryngic	O
-	O
Head	O
&	O
Neck	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
2030	O
6-6000	O
,	O
USA	O
.	O
Anaplastic	B-malignancy-type
pancreatic	I-malignancy-type
carcinomas	I-malignancy-type
are	O
rare	O
tumors	O
,	O
frequently	O
displaying	O
a	O
variety	O
of	O
growth	O
patterns	O
.	O
The	O
literature	O
lacks	O
a	O
comprehensive	O
study	O
of	O
this	O
tumor	O
.	O
Thirty-five	O
cases	O
of	O
anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
diagnosed	O
between	O
1955	O
and	O
1997	O
were	O
retrieved	O
from	O
the	O
Endocrine	O
Registry	O
at	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Histology	O
,	O
immunophenotype	O
,	O
molecular	O
analysis	O
,	O
and	O
patient	O
follow-up	O
were	O
analyzed	O
.	O
The	O
tumors	O
of	O
10	O
women	O
and	O
25	O
men	O
,	O
aged	O
34	O
to	O
85	O
years	O
(	O
mean	O
age	O
at	O
presentation	O
,	O
62.5	O
years	O
)	O
,	O
were	O
studied	O
.	O
Patients	O
had	O
vague	O
symptoms	O
(	O
weight	O
loss	O
,	O
pain	O
,	O
and	O
fatigue	O
,	O
nausea	O
,	O
or	O
vomiting	O
)	O
,	O
lasting	O
an	O
average	O
of	O
13.2	O
weeks	O
.	O
The	O
tumors	O
,	O
of	O
an	O
average	O
size	O
of	O
9.2	O
cm	O
,	O
were	O
usually	O
in	O
the	O
head	O
or	O
tail	O
of	O
the	O
pancreas	O
.	O
The	O
tumors	O
were	O
widely	O
infiltrative	O
,	O
histomorphologically	O
separated	O
into	O
predominantly	O
large	O
,	O
pleomorphic	O
cell	O
,	O
or	O
spindle	O
cell	O
groups	O
.	O
Tumor	O
phagocytosis	O
and	O
necrosis	O
were	O
noted	O
.	O
Immunohistochemical	O
studies	O
confirmed	O
an	O
epithelial	O
origin	O
with	O
at	O
least	O
one	O
epithelial	O
marker	O
in	O
78	O
%	O
of	O
the	O
tumors	O
.	O
K-ras	O
mutations	O
by	O
sequence	O
analysis	O
were	O
found	O
in	O
eight	O
of	O
12	O
cases	O
tested	O
.	O
Surgical	O
biopsy	O
/	O
excision	O
was	O
used	O
in	O
all	O
patients	O
.	O
Twenty-nine	O
of	O
35	O
patients	O
died	O
of	O
disease	O
(	O
average	O
,	O
5.2	O
months	O
)	O
,	O
three	O
died	O
with	O
no	O
evidence	O
of	O
disease	O
(	O
average	O
,	O
56.9	O
months	O
)	O
,	O
and	O
three	O
patients	O
were	O
alive	O
at	O
last	O
follow-up	O
(	O
average	O
,	O
94.0	O
months	O
)	O
,	O
one	O
with	O
residual	O
disease	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
survival	O
between	O
patients	O
with	O
and	O
without	O
a	O
K-ras	O
mutation	O
.	O
Anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
usually	O
occurs	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
in	O
older	O
men	O
.	O
The	O
epithelial	O
nature	O
of	O
the	O
pleomorphic	O
cells	O
(	O
giant	O
or	O
spindled	O
)	O
can	O
usually	O
be	O
documented	O
.	O
Patients	O
with	O
K-ras	O
mutations	O
have	O
a	O
shorter	O
survival	O
time	O
,	O
even	O
though	O
the	O
overall	O
prognosis	O
for	O
all	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
is	O
fatal	O
(	O
93	O
%	O
fatality	O
;	O
average	O
survival	O
,	O
448	O
days	O
)	O
.	O
Ann	O
Diagn	O
Pathol	O
5	O
:	O
129	O
-	O
140	O
,	O
2001	O
.	O
This	O
is	O
a	O
US	O
government	O
work	O
.	O
There	O
are	O
no	O
restriction	O
on	O
its	O
use	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
11436166	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2001	O
Jul	O
12;2	O
0	O
(	O
31	O
)	O
:	O
424	O
9-57	O
Genetic	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
malignant	O
mesothelioma	B-malignancy-type
and	O
identification	O
of	O
a	O
new	O
3p21.3	O
homozygous	O
deletion	O
.	O
Shigemitsu	O
K,	O
Sekido	O
Y	O
,	O
Usami	O
N	O
,	O
Mori	O
S	O
,	O
Sato	O
M,	O
Horio	O
Y	O
,	O
Hasegawa	O
Y	O
,	O
Bader	O
SA	O
,	O
Gazdar	O
AF	O
,	O
Minna	O
JD	O
,	O
Hida	O
T	O
,	O
Yoshioka	O
H,	O
Imaizumi	O
M,	O
Ueda	O
Y	O
,	O
Takahashi	O
M,	O
Shimokata	O
K.	O
Department	O
of	O
Thoracic	O
Surgery	O
,	O
Nagoya	O
University	O
School	O
of	O
Medicine	O
,	O
Nagoya	O
46	O
6-8550	O
,	O
Japan	O
.	O
The	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
has	O
been	O
shown	O
to	O
be	O
genetically	O
mutated	O
in	O
various	O
human	O
malignancies	O
.	O
To	O
determine	O
whether	O
the	O
beta-catenin	O
gene	O
is	O
responsible	O
for	O
oncogenesis	O
in	O
thoracic	B-malignancy-type
malignancies	I-malignancy-type
,	O
we	O
searched	O
for	O
the	O
mutation	O
in	O
166	O
lung	B-malignancy-type
cancers	I-malignancy-type
(	O
90	O
primary	O
tumors	O
and	O
76	O
cell	O
lines	O
)	O
,	O
one	O
blastoma	B-malignancy-type
and	O
10	O
malignant	O
mesotheliomas	B-malignancy-type
(	O
two	O
primary	O
tumors	O
and	O
eight	O
cell	O
lines	O
)	O
.	O
Among	O
the	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
including	O
43	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
(	O
SCLCs	B-malignancy-type
)	O
and	O
123	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
(	O
NSCLCs	B-malignancy-type
)	O
,	O
we	O
identified	O
four	O
alterations	O
in	O
exon	O
3	O
,	O
which	O
is	O
the	O
target	O
region	O
of	O
mutation	O
for	O
stabilizing	O
beta-catenin	O
.	O
One	O
primary	O
adenocarcinoma	B-malignancy-type
had	O
a	O
somatic	O
mutation	O
from	O
C	O
to	O
G	O
,	O
leading	O
to	O
an	O
amino	O
acid	O
substitution	O
from	O
Ser	O
to	O
Cys	O
at	O
codon	O
37	O
.	O
Among	O
the	O
cell	O
lines	O
,	O
SCLC	B-malignancy-type
NCI-H1092	O
had	O
a	O
mutation	O
from	O
A	O
to	O
G	O
,	O
leading	O
to	O
an	O
Asp	O
to	O
Gly	O
substitution	O
at	O
codon	O
6	O
,	O
NSCLC	B-malignancy-type
HCC15	O
had	O
a	O
mutation	O
from	O
C	O
to	O
T	O
,	O
leading	O
to	O
a	O
Ser	O
to	O
Phe	O
substitution	O
at	O
codon	O
45	O
,	O
and	O
NSCLC	B-malignancy-type
NCI-H358	O
had	O
a	O
mutation	O
from	O
A	O
to	O
G	O
,	O
leading	O
to	O
a	O
Thr	O
to	O
Ala	O
substitution	O
at	O
codon	O
75	O
.	O
One	O
blastoma	B-malignancy-type
also	O
had	O
a	O
somatic	O
mutation	O
from	O
C	O
to	O
G	O
,	O
leading	O
to	O
a	O
Ser	O
to	O
Cys	O
substitution	O
at	O
codon	O
37	O
.	O
Among	O
the	O
10	O
malignant	O
mesotheliomas	B-malignancy-type
,	O
we	O
identified	O
a	O
homozygous	O
deletion	O
in	O
the	O
NCI-H28	O
cell	O
line	O
.	O
Cloning	O
of	O
the	O
rearranged	O
fragment	O
from	O
NCI-H28	O
indicated	O
that	O
all	O
the	O
exons	O
except	O
exon	O
1	O
of	O
the	O
beta-catenin	O
gene	O
are	O
deleted	O
and	O
that	O
the	O
deletion	O
junction	O
is	O
13	O
kb	O
downstream	O
from	O
exon	O
1	O
.	O
Furthermore	O
,	O
Northern	O
blot	O
analysis	O
of	O
26	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
eight	O
mesothelioma	B-malignancy-type
cell	O
line	O
RNAs	O
detected	O
ubiquitous	O
expression	O
of	O
the	O
beta-catenin	O
messages	O
except	O
NCI-H28	O
,	O
although	O
Western	O
blot	O
analysis	O
showed	O
that	O
relatively	O
less	O
amounts	O
of	O
protein	O
products	O
were	O
expressed	O
in	O
some	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
beta-catenin	O
gene	O
is	O
infrequently	O
mutated	O
in	O
lung	O
cancer	O
and	O
that	O
the	O
NCI-H28	O
homozygous	O
deletion	O
of	O
the	O
beta-catenin	O
gene	O
might	O
indicate	O
the	O
possibility	O
of	O
a	O
new	O
tumor	O
suppressor	O
gene	O
residing	O
in	O
this	O
region	O
at	O
3p21.3	O
,	O
where	O
various	O
types	O
of	O
human	O
cancers	O
show	O
frequent	O
allelic	O
loss	O
.	O
PMID	O
:	O
11464291	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
2001	O
Jul;5	O
1	O
(	O
7	O
)	O
:	O
54	O
9-54	O
Adenocarcinoma	B-malignancy-type
arising	O
in	O
gastric	O
heterotopic	O
pancreas	O
:	O
clinicopathological	O
and	O
immunohistochemical	O
study	O
with	O
genetic	O
analysis	O
of	O
a	O
case	O
.	O
Osanai	O
M	O
,	O
Miyokawa	O
N	O
,	O
Tamaki	O
T	O
,	O
Yonekawa	O
M	O
,	O
Kawamura	O
A	O
,	O
Sawada	O
N	O
.	O
Department	O
of	O
Pathology	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
osanaim@post.queensu.ca	O
Heterotopic	O
pancreas	O
in	O
the	O
stomach	O
is	O
a	O
relatively	O
common	O
congenital	O
condition	O
,	O
but	O
the	O
risk	O
of	O
malignant	O
transformation	O
is	O
extremely	O
low	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
a	O
case	O
of	O
adenocarcinoma	B-malignancy-type
arising	O
from	O
a	O
gastric	O
heterotopic	O
pancreas	O
and	O
we	O
consider	O
its	O
morphological	O
and	O
immunohistochemical	O
features	O
and	O
genetic	O
analysis	O
,	O
in	O
order	O
to	O
examine	O
its	O
histogenesis	O
.	O
This	O
unusual	O
sequela	O
was	O
seen	O
in	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
.	O
Image	O
studies	O
showed	O
a	O
protruding	O
lesion	B-malignancy-type
with	O
a	O
central	O
ulcer	O
located	O
in	O
the	O
lesser	O
curvature	O
from	O
the	O
angle	O
to	O
the	O
body	O
of	O
the	O
stomach	O
.	O
A	O
biopsy	O
specimen	O
confirmed	O
this	O
lesion	B-malignancy-type
as	O
adenocarcinoma	B-malignancy-type
before	O
total	O
gastrectomy	O
.	O
The	O
tumor	O
showed	O
mixed	O
patterns	O
of	O
solid	O
neoplastic	O
-	O
cell	O
proliferation	O
and	O
moderately	O
differentiated	O
glandular	O
structures	O
,	O
and	O
also	O
showed	O
transitional	B-malignancy-type
lesions	I-malignancy-type
to	O
obvious	O
malignancy	O
,	O
that	O
is	O
,	O
dysplasia	B-malignancy-type
,	O
or	O
adenocarcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
.	O
Neoplastic	O
cells	O
had	O
positive	O
immunoreactivity	O
for	O
carbohydrate	O
antigen	O
(	O
CA	O
)	O
19	O
-	O
9	O
,	O
mucin	O
(	O
MUC	O
)	O
1	O
,	O
and	O
insulin	O
,	O
and	O
the	O
mutant	O
allele	O
-	O
specific	O
amplification	O
method	O
revealed	O
a	O
point	O
mutation	O
at	O
K-ras	O
codon	O
12	O
(	O
GGT	O
[	O
Gly	O
]	O
-->	O
GAT	O
[	O
Asp	O
]	O
)	O
,	O
which	O
is	O
the	O
most	O
common	O
mutational	O
change	O
observed	O
in	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
features	O
of	O
the	O
present	O
case	O
provide	O
clear	O
evidence	O
that	O
this	O
tumor	O
originated	O
from	O
heterotopic	O
pancreatic	O
tissue	O
rather	O
than	O
from	O
gastric	O
epithelium	O
.	O
PMID	O
:	O
11472568	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Aug;2	O
5	O
(	O
8	O
)	O
:	O
97	O
9-87	O
Comment	O
in	O
:	O
Am	O
J	O
Surg	O
Pathol	O
.	O
2002	O
Mar;2	O
6	O
(	O
3	O
)	O
:	O
396	O
,	O
discussion	O
396	O
.	O
Am	O
J	O
Surg	O
Pathol	O
.	O
2002	O
Mar;2	O
6	O
(	O
3	O
)	O
:	O
39	O
6-7	O
;	O
discussion	O
39	O
7-8	O
.	O
Gastrointestinal	B-malignancy-type
autonomic	I-malignancy-type
nerve	I-malignancy-type
tumor	I-malignancy-type
:	O
immunohistochemical	O
and	O
molecular	O
identity	O
with	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
.	O
Lee	O
JR	O
,	O
Joshi	O
V	O
,	O
Griffin	O
JW	O
Jr	O
,	O
Lasota	O
J	O
,	O
Miettinen	O
M	O
.	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Molecular	O
Medicine	O
and	O
Genetics	O
,	O
Medical	O
College	O
of	O
Georgia	O
,	O
Augusta	O
,	O
Georgia	O
30904	O
,	O
USA	O
.	O
JLEE@mail.mcg.edu	O
Gastrointestinal	B-malignancy-type
autonomic	I-malignancy-type
nerve	I-malignancy-type
tumor	I-malignancy-type
(	O
GANT	B-malignancy-type
)	O
is	O
a	O
gastrointestinal	B-malignancy-type
neoplasm	I-malignancy-type
that	O
ultrastructurally	O
recapitulates	O
the	O
enteric	O
neural	O
plexus	O
.	O
This	O
study	O
identifies	O
and	O
defines	O
the	O
features	O
of	O
10	O
cases	O
of	O
this	O
rare	O
mesenchymal	B-malignancy-type
tumor	I-malignancy-type
and	O
compares	O
its	O
clinicopathologic	O
and	O
molecular	O
genetic	O
features	O
with	O
the	O
data	O
on	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
.	O
The	O
majority	O
of	O
patients	O
in	O
this	O
series	O
presented	O
at	O
an	O
older	O
age	O
(	O
mean	O
64	O
years	O
)	O
.	O
Tumors	O
arose	O
from	O
the	O
stomach	O
(	O
6	O
)	O
,	O
small	O
intestine	O
(	O
2	O
)	O
,	O
and	O
retroperitoneum	O
(	O
2	O
)	O
.	O
Mean	O
tumor	O
size	O
was	O
14	O
cm	O
;	O
however	O
,	O
four	O
neoplasms	O
were	O
<	O
6	O
cm	O
.	O
Histologically	O
,	O
tumors	O
were	O
spindled	O
or	O
epithelioid	O
;	O
one	O
epithelioid	B-malignancy-type
tumor	I-malignancy-type
demonstrated	O
a	O
previously	O
undescribed	O
rhabdoid	O
histologic	O
phenotype	O
.	O
All	O
tumors	O
were	O
positive	O
for	O
CD117	O
(	O
KIT	O
)	O
,	O
while	O
eight	O
of	O
10	O
were	O
positive	O
for	O
CD34	O
.	O
In	O
contrast	O
,	O
only	O
two	O
were	O
positive	O
for	O
S-100	O
,	O
and	O
all	O
were	O
negative	O
for	O
actin	O
and	O
desmin	O
.	O
Five	O
GANTs	B-malignancy-type
demonstrated	O
GIST	B-malignancy-type
-	O
specific	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
juxtamembrane	O
domain	O
of	O
the	O
c-kit	O
gene	O
(	O
50	O
%	O
)	O
.	O
Three	O
of	O
10	O
patients	O
died	O
of	O
disease	O
in	O
22	O
-	O
30	O
months	O
,	O
one	O
patient	O
died	O
in	O
the	O
postoperative	O
period	O
,	O
and	O
one	O
patient	O
died	O
of	O
complications	O
of	O
CML	B-malignancy-type
.	O
The	O
clinicopathologic	O
,	O
histologic	O
,	O
immunohistologic	O
,	O
and	O
molecular	O
features	O
of	O
GANT	B-malignancy-type
are	O
similar	O
to	O
GIST	B-malignancy-type
,	O
indicating	O
that	O
GANT	B-malignancy-type
merely	O
represents	O
a	O
phenotypic	O
variant	O
of	O
GIST	B-malignancy-type
.	O
PMID	O
:	O
11474281	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Aug;2	O
5	O
(	O
8	O
)	O
:	O
109	O
5-9	O
Molecular	O
genetic	O
analysis	O
of	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
adenomas	I-malignancy-type
in	O
identical	O
twins	O
,	O
including	O
one	O
with	O
pseudomyxoma	B-malignancy-type
peritonei	I-malignancy-type
.	O
Shih	O
IM	O
,	O
Yan	O
H	O
,	O
Speyrer	O
D	O
,	O
Shmookler	O
BM	O
,	O
Sugarbaker	O
PH	O
,	O
Ronnett	O
BM	O
.	O
Department	O
of	O
Pathology	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
,	O
USA	O
.	O
Pseudomyxoma	B-malignancy-type
peritonei	I-malignancy-type
(	O
PMP	B-malignancy-type
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
mucinous	O
ascites	O
and	O
peritoneal	B-malignancy-type
lesions	I-malignancy-type
composed	O
of	O
histologically	O
bland	O
to	O
low-grade	O
adenomatous	O
mucinous	O
epithelium	O
within	O
pools	O
of	O
extracellular	O
mucin	O
,	O
often	O
with	O
an	O
associated	O
mucinous	B-malignancy-type
adenoma	I-malignancy-type
of	O
the	O
appendix	O
.	O
There	O
is	O
evidence	O
that	O
the	O
peritoneal	B-malignancy-type
lesions	I-malignancy-type
in	O
PMP	B-malignancy-type
are	O
clonally	O
derived	O
from	O
the	O
associated	O
appendiceal	B-malignancy-type
adenoma	I-malignancy-type
.	O
Little	O
is	O
known	O
about	O
the	O
molecular	O
genetic	O
alterations	O
or	O
hereditary	O
factors	O
involved	O
in	O
the	O
development	O
of	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
and	O
PMP	B-malignancy-type
.	O
We	O
report	O
the	O
only	O
known	O
example	O
of	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
adenomas	I-malignancy-type
in	O
identical	O
twin	O
brothers	O
,	O
one	O
of	O
whom	O
developed	O
PMP	B-malignancy-type
.	O
We	O
analyzed	O
the	O
status	O
of	O
the	O
K-RAS	O
and	O
APC	O
genes	O
in	O
these	O
tumors	O
using	O
digital	O
polymerase	O
chain	O
reaction	O
and	O
digital	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
assay	O
.	O
Identical	O
K-RAS	O
mutations	O
were	O
detected	O
in	O
the	O
appendiceal	B-malignancy-type
adenoma	I-malignancy-type
and	O
peritoneal	O
tumor	O
from	O
the	O
twin	O
with	O
PMP	O
,	O
whereas	O
the	O
adenoma	B-malignancy-type
from	O
the	O
other	O
twin	O
harbored	O
a	O
different	O
mutation	O
.	O
Digital	O
SNP	O
analysis	O
demonstrated	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
only	O
in	O
the	O
adenoma	B-malignancy-type
from	O
the	O
twin	O
without	O
PMP	B-malignancy-type
but	O
not	O
from	O
the	O
appendiceal	B-malignancy-type
or	O
peritoneal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
twin	O
with	O
PMP	B-malignancy-type
.	O
The	O
adjacent	O
normal	O
tissue	O
in	O
each	O
case	O
retained	O
both	O
APC	O
alleles	O
.	O
The	O
K-RAS	O
mutational	O
analysis	O
supports	O
the	O
view	O
that	O
PMP	O
is	O
clonally	O
derived	O
from	O
the	O
associated	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
adenoma	I-malignancy-type
.	O
The	O
lack	O
of	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
in	O
the	O
adenoma	B-malignancy-type
and	O
peritoneal	B-malignancy-type
tumor	I-malignancy-type
from	O
the	O
twin	O
with	O
PMP	B-malignancy-type
suggests	O
that	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
is	O
not	O
necessarily	O
involved	O
in	O
the	O
development	O
of	O
all	O
appendiceal	B-malignancy-type
adenomas	I-malignancy-type
or	O
PMP	B-malignancy-type
.	O
The	O
different	O
types	O
of	O
mutations	O
in	O
K-RAS	O
and	O
the	O
different	O
allelic	O
status	O
of	O
the	O
APC	O
locus	O
in	O
the	O
tumors	O
from	O
both	O
twins	O
suggest	O
that	O
mutation	O
in	O
K-RAS	O
and	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
occurs	O
somatically	O
in	O
adenomas	B-malignancy-type
and	O
is	O
independent	O
of	O
the	O
identical	O
genetic	O
background	O
of	O
the	O
twins	O
.	O
PMID	O
:	O
11474297	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2001	O
Aug	O
15;9	O
3	O
(	O
4	O
)	O
:	O
46	O
8-74	O
Tumor	O
heterogeneity	O
in	O
small	B-malignancy-type
hepatocellular	I-malignancy-type
carcinoma	I-malignancy-type
:	O
analysis	O
of	O
tumor	O
cell	O
proliferation	O
,	O
expression	O
and	O
mutation	O
of	O
p53	O
AND	O
beta-catenin	O
.	O
An	O
FQ	O
,	O
Matsuda	O
M	O
,	O
Fujii	O
H	O
,	O
Tang	O
RF	O
,	O
Amemiya	O
H	O
,	O
Dai	O
YM	O
,	O
Matsumoto	O
Y	O
.	O
First	O
Department	O
of	O
Surgery	O
,	O
Yamanashi	O
Medical	O
University	O
,	O
Tamaho	O
,	O
Yamanashi	O
,	O
Japan	O
.	O
Most	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
first	O
occur	O
as	O
well-differentiated	B-malignancy-type
HCCs	I-malignancy-type
,	O
from	O
which	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
HCC	I-malignancy-type
cells	O
develop	O
because	O
of	O
dedifferentiation	O
.	O
In	O
this	O
study	O
,	O
we	O
try	O
to	O
clarify	O
the	O
changes	O
of	O
dedifferentiation	O
and	O
cell	O
proliferative	O
activity	O
and	O
their	O
relationship	O
in	O
small	B-malignancy-type
HCCs	I-malignancy-type
(	O
less	O
than	O
3.0	O
cm	O
in	O
diameter	O
)	O
and	O
try	O
to	O
learn	O
the	O
mechanism	O
of	O
these	O
changes	O
by	O
analysing	O
the	O
expressions	O
and	O
genetic	O
changes	O
of	O
proliferation	O
-	O
related	O
genes	O
p53	O
and	O
beta-catenin	O
.	O
Of	O
41	O
surgically	O
resected	O
small	B-malignancy-type
HCCs	I-malignancy-type
,	O
11	O
were	O
identified	O
to	O
have	O
tumor	O
heterogeneity	O
.	O
DNA	O
from	O
the	O
11	O
small	B-malignancy-type
HCCs	I-malignancy-type
,	O
consisting	O
of	O
29	O
intratumoral	B-malignancy-type
lesions	I-malignancy-type
and	O
11	O
noncancerous	O
liver	O
tissues	O
adjacent	O
to	O
HCCs	B-malignancy-type
,	O
was	O
extracted	O
from	O
paraffin	O
embedded	O
tissue	O
sections	O
.	O
Exons	O
5	O
-	O
8	O
of	O
p53	O
gene	O
and	O
exon	O
3	O
of	O
beta-catenin	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
by	O
direct	O
sequence	O
.	O
The	O
serial	O
sections	O
were	O
also	O
immunostained	O
by	O
anti	O
-	O
Ki-67	O
,	O
p53	O
and	O
beta-catenin	O
antibody	O
.	O
Immunohistochemistry	O
showed	O
that	O
the	O
p53	O
overexpression	O
was	O
significantly	O
related	O
to	O
the	O
proliferative	O
activities	O
as	O
evaluated	O
by	O
Ki-67	O
immunostaining	O
and	O
to	O
the	O
histological	O
differentiation	O
.	O
The	O
expression	O
of	O
beta-catenin	O
was	O
found	O
to	O
be	O
heterogeneously	O
distributed	O
not	O
only	O
in	O
various	O
histological	O
grades	O
of	O
the	O
same	O
tumor	O
but	O
also	O
in	O
areas	O
of	O
the	O
same	O
histological	O
grade	O
.	O
p53	O
and	O
beta-catenin	O
gene	O
mutations	O
were	O
detected	O
in	O
1	O
tumor	O
respectively	O
,	O
both	O
of	O
which	O
were	O
second	O
primary	O
HCCs	B-malignancy-type
and	O
also	O
recurred	O
later	O
.	O
The	O
p53	O
mutation	O
showed	O
the	O
same	O
mutation	O
pattern	O
in	O
heterogeneous	O
subpopulations	O
.	O
beta-catenin	O
mutation	O
was	O
detected	O
only	O
in	O
the	O
less	B-malignancy-type
differentiated	I-malignancy-type
lesion	I-malignancy-type
but	O
not	O
in	O
the	O
well-differentiated	B-malignancy-type
lesion	I-malignancy-type
of	O
tumor	O
.	O
In	O
conclusion	O
,	O
our	O
findings	O
suggest	O
that	O
there	O
was	O
histological	O
heterogeneity	O
in	O
small	B-malignancy-type
but	O
established	O
HCC	B-malignancy-type
,	O
which	O
was	O
accompanied	O
by	O
increased	O
proliferative	O
activity	O
and	O
p53	O
overexpression	O
.	O
The	O
overexpression	O
of	O
beta-catenin	O
may	O
be	O
related	O
to	O
the	O
proliferative	O
activity	O
and	O
dedifferentiation	O
of	O
HCC	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O
PMID	O
:	O
11477549	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Aug	O
1;92(	O
3	O
)	O
:488	O
-	O
99	O
The	O
association	O
of	O
K-ras	O
gene	O
mutation	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
gene	O
expression	O
in	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Ikeda	O
N	O
,	O
Nakajima	O
Y	O
,	O
Sho	O
M,	O
Adachi	O
M,	O
Huang	O
CL	O
,	O
Iki	O
K	O
,	O
Kanehiro	O
H	O
,	O
Hisanaga	O
M,	O
Nakano	O
H	O
,	O
Miyake	O
M.	O
Department	O
of	O
Thoracic	O
Surgery	O
and	O
Department	O
V	O
of	O
Oncology	O
,	O
Kitano	O
Hospital	O
,	O
Tazuke	O
Kofukai	O
Medical	O
Research	O
Institute	O
,	O
13	O
-	O
3	O
,	O
Kamiyama	O
-	O
cho	O
,	O
Kita	O
-	O
ku	O
,	O
Osaka	O
530	O
-	O
8480	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Previously	O
,	O
the	O
authors	O
reported	O
the	O
role	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
as	O
an	O
angiogenic	O
factor	O
in	O
40	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
they	O
investigated	O
the	O
mechanism	O
underlying	O
the	O
regulation	O
of	O
VEGF	O
gene	O
expression	O
and	O
evaluated	O
VEGF	O
expression	O
and	O
K-ras	O
gene	O
status	O
in	O
48	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
METHODS	O
:	O
The	O
authors	O
used	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
direct	O
sequencing	O
techniques	O
for	O
a	O
retrospective	O
study	O
of	O
VEGF	O
gene	O
expression	O
and	O
K-ras	O
gene	O
status	O
in	O
tumor	O
tissue	O
samples	O
from	O
48	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Immunohistochemistry	O
also	O
was	O
used	O
to	O
investigate	O
VEGF	O
protein	O
expression	O
.	O
RESULTS	O
:	O
Thirty-one	O
tumors	O
(	O
64.6	O
%	O
)	O
were	O
evaluated	O
with	O
high	O
VEGF	O
expression	O
,	O
and	O
17	O
tumors	O
(	O
35.4	O
%	O
)	O
were	O
evaluated	O
with	O
low	O
VEGF	O
expression	O
.	O
Of	O
the	O
48	O
primary	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
studied	O
,	O
33	O
tumors	O
(	O
68.8	O
%	O
)	O
contained	O
mutations	O
of	O
the	O
K-ras	O
gene	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
VEGF	O
expression	O
and	O
K-ras	O
status	O
.	O
Twenty-five	O
of	O
33	O
tumors	O
(	O
75.8	O
%	O
)	O
with	O
mutant	O
K-ras	O
genes	O
showed	O
high	O
VEGF	O
expression	O
,	O
whereas	O
only	O
6	O
of	O
15	O
tumors	O
with	O
the	O
wild	O
type	O
K-ras	O
(	O
40.0	O
%	O
)	O
showed	O
high	O
VEGF	O
expression	O
(	O
P	O
=	O
0.038	O
)	O
.	O
The	O
mean	O
(	O
+/-	O
standard	O
error	O
)	O
VEGF	O
conservation	O
rate	O
for	O
the	O
33	O
tumors	O
with	O
mutant	O
K-ras	O
was	O
1.839	O
+/-	O
1.241	O
,	O
and	O
that	O
for	O
the	O
15	O
tumors	O
with	O
wild	O
type	O
K-ras	O
was	O
1.057	O
+/-	O
0.983	O
(	O
P	O
=	O
0.037	O
)	O
.	O
Furthermore	O
,	O
the	O
median	O
survival	O
for	O
patients	O
with	O
mutant	O
K-ras	O
was	O
shorter	O
than	O
for	O
those	O
with	O
wild	O
type	O
K-ras	O
(	O
10.6	O
months	O
vs.	O
27.6	O
months	O
,	O
respectively	O
;	O
P	O
=	O
0.026	O
)	O
,	O
whereas	O
the	O
median	O
survival	O
for	O
patients	O
with	O
high	O
VEGF	O
expression	O
was	O
shorter	O
compared	O
with	O
that	O
for	O
patients	O
with	O
low	O
VEGF	O
expression	O
(	O
9.5	O
months	O
vs.	O
26.4	O
months	O
,	O
respectively	O
;	O
P	O
=	O
0.002	O
)	O
.	O
Cox	O
regression	O
model	O
analysis	O
indicated	O
that	O
only	O
the	O
VEGF	O
status	O
was	O
a	O
significant	O
factor	O
for	O
prognosis	O
(	O
P	O
=	O
0.024	O
)	O
.	O
Other	O
variables	O
,	O
i.e.	O
,	O
K-ras	O
status	O
,	O
histopathologic	O
tumor	O
grade	O
,	O
tumor	O
status	O
,	O
lymph	O
node	O
status	O
,	O
metastatic	O
status	O
,	O
gender	O
,	O
and	O
age	O
at	O
surgery	O
,	O
were	O
not	O
significant	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
K-ras	O
oncogene	O
mutation	O
may	O
be	O
associated	O
with	O
VEGF	O
expression	O
and	O
that	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
who	O
have	O
high	O
VEGF	O
expression	O
are	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11505392	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Sep	O
15;6	O
1	O
(	O
18	O
)	O
:	O
665	O
6-9	O
Accumulation	O
of	O
beta-catenin	O
protein	O
and	O
mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
gene	O
in	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumor	I-malignancy-type
.	O
Fujimori	O
M,	O
Ikeda	O
S	O
,	O
Shimizu	O
Y	O
,	O
Okajima	O
M,	O
Asahara	O
T.	O
Second	O
Department	O
of	O
Surgery	O
,	O
Hiroshima	O
University	O
Faculty	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
73	O
4-8551	O
.	O
The	O
molecular	O
basis	O
of	O
carcinogenesis	O
in	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumors	I-malignancy-type
is	O
not	O
well	O
understood	O
.	O
To	O
clarify	O
the	O
contribution	O
of	O
the	O
Wnt	O
/	O
beta-catenin	O
signaling	O
to	O
this	O
type	O
of	O
carcinogenesis	O
,	O
we	O
investigated	O
72	O
cases	O
of	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumor	I-malignancy-type
both	O
immunohistochemically	O
and	O
by	O
direct	O
sequencing	O
of	O
beta-catenin	O
.	O
Accumulation	O
of	O
beta-catenin	O
in	O
the	O
cytoplasm	O
and/or	O
nucleus	O
was	O
observed	O
in	O
57	O
cases	O
(	O
79.2	O
%	O
)	O
.	O
We	O
also	O
detected	O
mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
in	O
27	O
cases	O
(	O
37.5	O
%	O
)	O
and	O
one	O
mutation	O
in	O
APC	O
(	O
1.4	O
%	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
alterations	O
in	O
the	O
Wnt	O
/	O
beta-catenin	O
signaling	O
pathway	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
11559529	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
Arch	O
Occup	O
Environ	O
Health	O
2001	O
Aug	O
;	O
74	O
(	O
6	O
)	O
:	O
405	O
-	O
10	O
High	O
prevalence	O
of	O
K-ras-2	O
mutations	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
in	O
workers	O
exposed	O
to	O
vinyl	O
chloride	O
.	O
Weihrauch	O
M	O
,	O
Benick	O
M	O
,	O
Lehner	O
G	O
,	O
Wittekind	O
M	O
,	O
Bader	O
M	O
,	O
Wrbitzk	O
R	O
,	O
Tannapfel	O
A	O
.	O
Abteilung	O
Arbeitsmedizin	O
,	O
Medizinische	O
Hochschule	O
Hannover	O
,	O
Germany	O
.	O
Weihrauch	O
,	O
Markus@mh-hannover.de	O
OBJECTIVES	O
:	O
Vinyl	O
chloride	O
(	O
VC	O
)	O
and	O
its	O
metabolites	O
are	O
human	O
carcinogens	O
associated	O
with	O
liver	B-malignancy-type
angiosarcomas	I-malignancy-type
(	O
LAS	B-malignancy-type
)	O
and	O
also	O
with	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
.	O
In	O
VC	O
associated	O
LAS	B-malignancy-type
mutations	O
of	O
the	O
K-ras-2	O
gene	O
have	O
been	O
reported	O
,	O
however	O
,	O
no	O
data	O
about	O
the	O
prevalence	O
of	O
such	O
mutations	O
in	O
VC	O
-	O
associated	O
HCCs	B-malignancy-type
are	O
available	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
possible	O
specific	O
K-ras-2	O
oncogene	O
mutations	O
in	O
the	O
case	O
of	O
HCCs	B-malignancy-type
due	O
to	O
VC	O
.	O
METHODS	O
:	O
The	O
presence	O
of	O
K-ras-2	O
mutations	O
was	O
analysed	O
in	O
tissue	O
from	O
12	O
patients	O
with	O
VC	O
-	O
associated	O
HCCs	B-malignancy-type
.	O
All	O
patients	O
had	O
known	O
long-term	O
exposure	O
to	O
VC	O
(	O
average	O
exposure	O
amount	O
:	O
9,942	O
ppm	O
-	O
years	O
)	O
.	O
Twenty	O
patients	O
with	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
due	O
to	O
hepatitis	O
B	O
(	O
n	O
=	O
7	O
)	O
,	O
hepatitis	O
C	O
(	O
n	O
=	O
5	O
)	O
and	O
alcoholic	O
liver	O
cirrhosis	O
(	O
n	O
=	O
8	O
)	O
served	O
as	O
a	O
control	O
group	O
.	O
The	O
specific	O
mutations	O
were	O
determined	O
by	O
direct	O
sequencing	O
of	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras-2	O
gene	O
in	O
carcinomatous	O
and	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
after	O
microdissection	O
.	O
Immunohistochemical	O
analysis	O
was	O
performed	O
to	O
detect	O
p21ras	O
protein	O
.	O
RESULTS	O
:	O
K-ras-2	O
mutations	O
were	O
found	O
in	O
five	O
of	O
12	O
(	O
42	O
%	O
)	O
examined	O
HCCs	B-malignancy-type
and	O
in	O
three	O
cases	O
of	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
(	O
25	O
%	O
)	O
.	O
There	O
were	O
three	O
guanine	O
to	O
adenine	O
(	O
G	O
-->	O
A	O
)	O
point	O
mutations	O
in	O
the	O
tumour	O
tissue	O
.	O
All	O
three	O
mutations	O
found	O
in	O
non	O
-	O
neoplastic	O
liver	O
from	O
VC	O
-	O
exposed	O
patients	O
were	O
also	O
G	O
-->	O
A	O
point	O
mutations	O
(	O
codon	O
12	O
-	O
and	O
codon	O
13	O
-	O
aspartate	O
mutations	O
)	O
.	O
Within	O
the	O
control	O
group	O
,	O
K-ras-2	O
mutations	O
were	O
found	O
in	O
three	O
of	O
20	O
(	O
15	O
%	O
)	O
examined	O
HCCs	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
Mutations	O
of	O
the	O
K-ras-2	O
gene	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
VC	O
exposure	O
are	O
frequent	O
events	O
.	O
We	O
observed	O
a	O
K-ras-2	O
mutation	O
pattern	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
one	O
of	O
the	O
carcinogenic	O
metabolites	O
of	O
VC	O
analysed	O
in	O
animal	O
models	O
.	O
Our	O
results	O
suggest	O
that	O
VC	O
had	O
direct	O
toxic	O
effects	O
not	O
only	O
on	O
endothelial	O
cells	O
but	O
also	O
on	O
hepatocytes	O
,	O
as	O
it	O
was	O
previously	O
only	O
described	O
in	O
animal	O
models	O
.	O
PMID	O
:	O
11563603	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
2001	O
Nov	O
15;9	O
2	O
(	O
10	O
)	O
:	O
255	O
5-61	O
Erratum	O
in	O
:	O
Cancer	O
2002	O
Apr	O
1;94	O
(	O
7	O
)	O
:	O
2117	O
The	O
incidence	O
of	O
thanatophoric	O
dysplasia	O
mutations	O
in	O
FGFR3	O
gene	O
is	O
higher	O
in	O
low-grade	O
or	O
superficial	B-malignancy-type
bladder	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Kimura	O
T	O
,	O
Suzuki	O
H,	O
Ohashi	O
T	O
,	O
Asano	O
K,	O
Kiyota	O
H,	O
Eto	O
Y	O
.	O
Department	O
of	O
Urology	O
,	O
Institute	O
of	O
DNA	O
Medicine	O
,	O
Jikei	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
tkimura@jikei	O
.ac.jp	O
BACKGROUND	O
:	O
The	O
point	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
are	O
associated	O
with	O
autosomal	O
dominant	O
human	O
skeletal	O
disorders	O
such	O
as	O
thanatophoric	O
dysplasia	O
(	O
TD	O
)	O
.	O
However	O
,	O
point	O
mutations	O
were	O
reported	O
in	O
a	O
small	O
series	O
of	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
their	O
oncogenic	O
role	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
authors	O
investigated	O
the	O
incidence	O
of	O
TD	O
mutations	O
in	O
the	O
FGFR3	O
gene	O
in	O
a	O
large	O
series	O
of	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
to	O
clarify	O
their	O
role	O
in	O
the	O
progression	O
of	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
METHODS	O
:	O
Specimens	O
of	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
urinary	O
bladder	O
from	O
81	O
patients	O
were	O
screened	O
for	O
the	O
FGFR3	O
mutations	O
(	O
codons	O
248	O
,	O
249	O
,	O
372	O
,	O
373	O
,	O
375	O
,	O
652	O
,	O
809	O
)	O
that	O
have	O
been	O
reported	O
in	O
TD	O
,	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
,	O
single-strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O
RESULTS	O
:	O
Point	O
mutations	O
were	O
detected	O
in	O
25	O
of	O
81	O
carcinomas	B-malignancy-type
(	O
2	O
at	O
codon	O
248	O
,	O
11	O
at	O
codon	O
249	O
,	O
1	O
at	O
codon	O
372	O
,	O
9	O
at	O
codon	O
375	O
,	O
2	O
at	O
codon	O
652	O
)	O
.	O
Although	O
no	O
significant	O
relation	O
was	O
found	O
between	O
the	O
occurrence	O
of	O
TD	O
mutations	O
and	O
patient	O
age	O
and	O
clinical	O
status	O
,	O
the	O
incidence	O
of	O
TD	O
mutations	O
was	O
significantly	O
higher	O
in	O
low-grade	O
or	O
superficial	B-malignancy-type
tumors	I-malignancy-type
than	O
high-grade	O
or	O
muscle	B-malignancy-type
invasive	I-malignancy-type
tumors	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
TD	O
mutations	O
in	O
the	O
FGFR3	O
gene	O
do	O
not	O
cause	O
disease	O
progression	O
of	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11745189	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Dec	O
15	O
;	O
61	O
(	O
24	O
)	O
:	O
8624	O
-	O
8	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
with	O
KIT	O
mutations	O
exhibit	O
a	O
remarkably	O
homogeneous	O
gene	O
expression	O
profile	O
.	O
Allander	O
SV	O
,	O
Nupponen	O
NN	O
,	O
Ringner	O
M	O
,	O
,	O
Hostetter	O
G	O
,	O
Maher	O
GW	O
,	O
Goldberger	O
N	O
,	O
Chen	O
Y	O
,	O
Carpten	O
J	O
,	O
Elkahloun	O
AG	O
,	O
Meltzer	O
PS	O
.	O
Cancer	O
Genetics	O
Branch	O
,	O
National	O
Human	O
Genome	O
Research	O
Institute	O
,	O
NIH	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
,	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
digestive	O
tract	O
,	O
are	O
believed	O
to	O
arise	O
from	O
the	O
interstitial	O
cells	O
of	O
Cajal	O
.	O
GISTs	B-malignancy-type
are	O
characterized	O
by	O
mutations	O
in	O
the	O
proto	O
-	O
oncogene	O
KIT	O
that	O
lead	O
to	O
constitutive	O
activation	O
of	O
its	O
tyrosine	O
kinase	O
activity	O
.	O
The	O
tyrosine	O
kinase	O
inhibitor	O
STI571	O
,	O
active	O
against	O
the	O
BCR	O
-	O
ABL	O
fusion	O
protein	O
in	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
was	O
recently	O
shown	O
to	O
be	O
highly	O
effective	O
in	O
GISTs	B-malignancy-type
.	O
We	O
used	O
13,826	O
-	O
element	O
cDNA	O
microarrays	O
to	O
define	O
the	O
expression	O
patterns	O
of	O
13	O
KIT	O
mutation	O
-	O
positive	O
GISTs	B-malignancy-type
and	O
compared	O
them	O
with	O
the	O
expression	O
profiles	O
of	O
a	O
group	O
of	O
spindle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
from	O
locations	O
outside	O
the	O
gastrointestinal	O
tract	O
.	O
Our	O
results	O
showed	O
a	O
remarkably	O
distinct	O
and	O
uniform	O
expression	O
profile	O
for	O
all	O
of	O
the	O
GISTs	B-malignancy-type
.	O
In	O
particular	O
,	O
hierarchical	O
clustering	O
of	O
a	O
subset	O
of	O
113	O
cDNAs	O
placed	O
all	O
of	O
the	O
GIST	B-malignancy-type
samples	O
into	O
one	O
branch	O
,	O
with	O
a	O
Pearson	O
correlation	O
>	O
0.91	O
.	O
This	O
homogeneity	O
suggests	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
GIST	B-malignancy-type
results	O
from	O
expansion	O
of	O
a	O
clone	O
that	O
has	O
acquired	O
an	O
activating	O
mutation	O
in	O
KIT	O
without	O
the	O
extreme	O
genetic	O
instability	O
found	O
in	O
the	O
common	O
epithelial	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
results	O
provide	O
insight	O
into	O
the	O
histogenesis	O
of	O
GIST	B-malignancy-type
and	O
the	O
clinical	O
behavior	O
of	O
this	O
therapeutically	O
responsive	O
tumor	O
.	O
PMID	O
:	O
11751374	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
2002	O
Jan;16	O
0	O
(	O
1	O
)	O
:	O
1	O
5-22	O
The	O
complexity	O
of	O
KIT	O
gene	O
mutations	O
and	O
chromosome	O
rearrangements	O
and	O
their	O
clinical	O
correlation	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
(	I-malignancy-type
pacemaker	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
.	O
Andersson	O
J,	O
Sjogren	O
H,	O
Mei	O
s-Kindblom	O
JM	O
,	O
Stenman	O
G,	O
Aman	O
P,	O
Kindblom	O
LG.	O
Department	O
of	O
Pathology	O
,	O
Lundberg	O
Laboratory	O
for	O
Cancer	O
Research	O
,	O
Sahlgrenska	O
University	O
Hospital	O
,	O
Goteborg	O
University	O
,	O
Goteborg	O
,	O
Sweden	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
(	I-malignancy-type
pacemaker	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
(	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
)	O
are	O
frequently	O
associated	O
with	O
activating	O
KIT	O
mutations	O
,	O
primarily	O
of	O
exon	O
11	O
and	O
rarely	O
of	O
exons	O
9	O
and	O
13	O
,	O
as	O
well	O
as	O
certain	O
chromosome	O
rearrangements	O
.	O
Reports	O
regarding	O
the	O
frequency	O
and	O
prognostic	O
significance	O
of	O
KIT	O
mutations	O
are	O
conflicting	O
and	O
few	O
cases	O
have	O
been	O
completely	O
sequenced	O
.	O
Furthermore	O
,	O
there	O
are	O
few	O
detailed	O
analyses	O
of	O
chromosome	O
alterations	O
in	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
.	O
In	O
a	O
detailed	O
analysis	O
of	O
14	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
from	O
12	O
patients	O
,	O
we	O
found	O
a	O
wider	O
spectrum	O
of	O
KIT	O
mutations	O
than	O
previously	O
reported	O
,	O
including	O
11	O
different	O
in-frame	O
mutations	O
involving	O
exons	O
11	O
,	O
14	O
,	O
and	O
15	O
.	O
No	O
mutations	O
were	O
detected	O
in	O
four	O
malignant	O
tumors	O
.	O
The	O
shorter	O
(	O
GNNK	O
-	O
)	O
KIT	O
isoform	O
was	O
preferentially	O
expressed	O
.	O
Cytogenetic	O
and	O
spectral	O
karyotype	O
analyses	O
of	O
10	O
tumors	O
revealed	O
clonal	O
abnormalities	O
in	O
eight	O
tumors	O
;	O
the	O
most	O
common	O
were	O
terminal	O
1p	O
deletions	O
and	O
losses	O
of	O
chromosomes	O
14	O
and/o	O
22	O
.	O
Neither	O
KIT	O
mutation	O
status	O
nor	O
chromosome	O
aberrations	O
correlated	O
with	O
tumor	O
phenotype	O
or	O
clinical	O
behavior	O
in	O
our	O
series	O
.	O
Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
role	O
of	O
KIT	O
mutations	O
and	O
chromosomal	O
rearrangements	O
in	O
the	O
pathogenesis	O
of	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
are	O
more	O
complex	O
than	O
previously	O
recognized	O
.	O
PMID	O
:	O
11786393	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
2002	O
Jan;8	O
2	O
(	O
1	O
)	O
:	O
9	O
7-103	O
Possible	O
association	O
between	O
higher	O
beta-catenin	O
mRNA	O
expression	O
and	O
mutated	O
beta-catenin	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
:	O
real-time	O
semiquantitative	O
assay	O
by	O
TaqMan	O
polymerase	O
chain	O
reaction	O
.	O
Saito	O
T	O
,	O
Oda	O
Y	O
,	O
Kawaguchi	O
K,	O
Tanaka	O
K,	O
Matsuda	O
S	O
,	O
Tamiya	O
S	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Maidashi	O
3-	O
1-1	O
,	O
Higash	O
i-ku	O
,	O
Fukuoka	O
81	O
2-8582	O
,	O
Japan	O
.	O
We	O
screened	O
for	O
genetic	O
alterations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta-catenin	O
genes	O
in	O
17	O
frozen	O
specimens	O
from	O
12	O
cases	O
of	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
and	O
then	O
subdivided	O
these	O
cases	O
into	O
two	O
groups	O
according	O
to	O
the	O
results	O
of	O
mutational	O
analysis	O
.	O
We	O
further	O
examined	O
mRNA	O
expression	O
of	O
beta-catenin	O
and	O
cyclin	O
D1	O
by	O
TaqMan	O
PCR	O
and	O
compared	O
the	O
mRNA	O
expression	O
within	O
both	O
groups	O
.	O
Single-strand	O
conformation	O
polymorphism	O
analysis	O
followed	O
by	O
DNA	O
direct	O
sequencing	O
revealed	O
beta-catenin	O
mutation	O
in	O
3	O
of	O
12	O
cases	O
(	O
6	O
of	O
17	O
specimens	O
)	O
,	O
whereas	O
no	O
APC	O
missense	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
were	O
found	O
.	O
TaqMan	O
PCR	O
revealed	O
extremely	O
higher	O
mRNA	O
expression	O
of	O
beta-catenin	O
and	O
cyclin	O
D1	O
in	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
,	O
compared	O
with	O
those	O
of	O
normal	O
skeletal	O
muscles	O
.	O
In	O
the	O
beta-catenin	O
mutated	O
group	O
,	O
cyclin	O
D1	O
mRNA	O
expression	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
beta-catenin	O
wild-type	O
group	O
(	O
p	O
=	O
0.0120	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O
In	O
addition	O
,	O
in	O
the	O
beta-catenin	O
mutated	O
group	O
,	O
beta-catenin	O
mRNA	O
expression	O
was	O
also	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
beta-catenin	O
wild-type	O
group	O
(	O
p	O
=	O
0.0036	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O
All	O
cases	O
of	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
showed	O
detectable	O
beta-catenin	O
nuclear	O
expression	O
immunohistochemically	O
.	O
These	O
results	O
suggest	O
that	O
a	O
continuously	O
elevated	O
beta-catenin	O
protein	O
level	O
caused	O
by	O
the	O
beta-catenin	O
mutation	O
itself	O
may	O
have	O
a	O
stronger	O
power	O
that	O
can	O
transactivate	O
transcription	O
in	O
vivo	O
.	O
Furthermore	O
,	O
the	O
results	O
provide	O
a	O
possible	O
association	O
between	O
higher	O
beta-catenin	O
mRNA	O
expression	O
and	O
mutated	O
beta-catenin	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
.	O
This	O
may	O
suggest	O
that	O
the	O
beta-catenin	O
gene	O
may	O
be	O
up	O
-	O
regulated	O
by	O
mutated	O
or	O
continuously	O
elevated	O
beta-catenin	O
protein	O
,	O
that	O
is	O
,	O
the	O
beta-catenin	O
gene	O
may	O
also	O
be	O
one	O
of	O
the	O
targeted	O
genes	O
in	O
the	O
APC	O
-	O
beta-catenin	O
-	O
Tcf	O
pathway	O
.	O
PMID	O
:	O
11796830	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2002	O
Feb	O
10;9	O
7	O
(	O
5	O
)	O
:	O
56	O
2-6	O
K-ras	O
mutation	O
in	O
helicobacter	O
pylori	O
-	O
associated	O
chronic	O
gastritis	O
in	O
patients	O
with	O
and	O
without	O
gastric	B-malignancy-type
cancer	I-malignancy-type
.	O
Hiyama	O
T	O
,	O
Haruma	O
K,	O
Kitadai	O
Y	O
,	O
Masuda	O
H,	O
Miyamoto	O
M,	O
Tanaka	O
S	O
,	O
Yoshihara	O
M,	O
Shimamoto	O
F	O
,	O
Chayama	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
Mutations	O
of	O
an	O
oncogene	O
,	O
K-ras	O
,	O
are	O
associated	O
with	O
the	O
development	O
and	O
progression	O
of	O
many	O
types	O
of	O
human	O
cancer	O
.	O
To	O
elucidate	O
the	O
significance	O
of	O
K-ras	O
mutations	O
in	O
gastric	O
carcinogenesis	O
,	O
we	O
examined	O
K-ras	O
mutations	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
and	O
in	O
Helicobacter	O
pylori	O
-	O
associated	O
chronic	O
gastritis	O
(	O
H.	O
pylori	O
-	O
CG	O
)	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
the	O
gastric	B-malignancy-type
cancer	I-malignancy-type
development	O
.	O
Specimens	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
and	O
H.	O
pylori	O
-	O
CG	O
were	O
obtained	O
from	O
64	O
gastric	O
cancer	O
patients	O
with	O
H.	O
pylori	O
-	O
CG	O
,	O
99	O
cancer	O
-	O
free	O
H.	O
pylori	O
-	O
CG	O
patients	O
and	O
30	O
H.	O
pylori	O
-	O
negative	O
healthy	O
subjects	O
.	O
K-ras	O
mutations	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
,	O
followed	O
by	O
DNA	O
sequencing	O
analysis	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
4	O
of	O
48	O
(	O
8.3	O
%	O
)	O
gastric	B-malignancy-type
cancers	I-malignancy-type
,	O
in	O
10	O
of	O
163	O
(	O
6.1	O
%	O
)	O
H.	O
pylori	O
-	O
CG	O
and	O
none	O
of	O
the	O
30	O
H.	O
pylori	O
-	O
negative	O
healthy	O
subjects	O
.	O
In	O
the	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
mutated	O
K-ras	O
was	O
detected	O
in	O
differentiated	B-malignancy-type
type	I-malignancy-type
cancers	I-malignancy-type
but	O
not	O
in	O
any	O
of	O
the	O
undifferentiated	B-malignancy-type
type	I-malignancy-type
cancers	I-malignancy-type
.	O
K-ras	O
mutations	O
in	O
H.	O
pylori	O
-	O
CG	O
were	O
significantly	O
more	O
frequent	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patients	O
than	O
in	O
cancer	O
-	O
free	O
patients	O
(	O
10.9	O
%	O
vs.	O
3.0	O
%	O
,	O
p	O
=	O
0.044	O
)	O
.	O
In	O
addition	O
,	O
K-ras	O
mutations	O
in	O
H.	O
pylori	O
-	O
CG	O
were	O
significantly	O
more	O
frequent	O
in	O
patients	O
with	O
K-ras	O
mutated	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
than	O
in	O
patients	O
with	O
K-ras	O
unmutated	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
(	O
50.0	O
%	O
vs.	O
3.7	O
%	O
,	O
p	O
=	O
0.037	O
)	O
.	O
These	O
data	O
suggest	O
that	O
the	O
genetic	O
mechanism(s)	O
of	O
carcinogenesis	O
differs	O
between	O
the	O
differentiated	B-malignancy-type
type	I-malignancy-type
and	O
the	O
undifferentiated	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
and	O
that	O
K-ras	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
early	O
stages	O
of	O
gastric	O
carcinogenesis	O
of	O
the	O
differentiated	O
type	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11807778	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2002	O
Feb;1	O
5	O
(	O
2	O
)	O
:	O
12	O
5-36	O
c-kit	O
mutations	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
occur	O
preferentially	O
in	O
the	O
spindle	O
rather	O
than	O
in	O
the	O
epithelioid	O
cell	O
variant	O
.	O
Wardelmann	O
E	O
,	O
Neidt	O
I	O
,	O
Bierhoff	O
E	O
,	O
Speidel	O
N	O
,	O
Manegold	O
C,	O
Fischer	O
HP	O
,	O
Pfeifer	O
U	O
,	O
Pietsch	O
T.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Bonn	O
Medical	O
Center	O
,	O
Bonn	O
,	O
Germany	O
.	O
eva.wardelmann@ukb.un	O
i-bonn.de	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
coexpress	O
CD34	O
and	O
the	O
Kit	O
tyrosine	O
-	O
kinase	O
receptor	O
(	O
CD117	O
)	O
.	O
A	O
subset	O
of	O
GISTs	B-malignancy-type
carry	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
in	O
its	O
juxtamembrane	O
domain	O
.	O
The	O
relationship	O
between	O
the	O
mutational	O
status	O
and	O
histological	O
as	O
well	O
as	O
immunohistochemical	O
features	O
has	O
not	O
been	O
assessed	O
in	O
detail	O
.	O
36	O
GISTs	B-malignancy-type
and	O
14	O
other	O
gastrointestinal	B-malignancy-type
mesenchymal	I-malignancy-type
tumors	I-malignancy-type
were	O
investigated	O
for	O
their	O
morphology	O
and	O
immunophenotype	O
as	O
well	O
as	O
for	O
the	O
presence	O
of	O
c-kit	O
mutations	O
.	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Exons	O
9	O
,	O
11	O
,	O
13	O
,	O
and	O
17	O
of	O
c-kit	O
were	O
analyzed	O
by	O
SSCP	O
.	O
Bands	O
with	O
altered	O
mobility	O
were	O
excised	O
,	O
reamplified	O
,	O
and	O
sequenced	O
.	O
C-kit	O
mutations	O
in	O
Exon	O
11	O
encoding	O
the	O
juxtamembrane	O
domain	O
were	O
identified	O
in	O
19	O
cases	O
(	O
52.8	O
%	O
)	O
,	O
with	O
deletions	O
in	O
12	O
cases	O
,	O
insertions	O
in	O
3	O
cases	O
(	O
2	O
of	O
these	O
as	O
duplications	O
)	O
,	O
and	O
point	O
mutations	O
in	O
4	O
cases	O
.	O
The	O
mutations	O
clustered	O
between	O
Codons	O
553	O
and	O
561	O
,	O
pinpointing	O
the	O
critical	O
region	O
for	O
deregulated	O
Kit	O
receptor	O
activation	O
.	O
In	O
both	O
Exons	O
9	O
and	O
13	O
,	O
single	O
mutations	O
could	O
be	O
identified	O
,	O
whereas	O
no	O
mutations	O
were	O
found	O
in	O
Exon	O
17	O
.	O
There	O
were	O
c-kit	O
mutations	O
in	O
66.6	O
%	O
of	O
benign	B-malignancy-type
GISTs	I-malignancy-type
(	O
14	O
/	O
21	O
)	O
,	O
83.3	O
%	O
of	O
the	O
malignant	O
(	O
5	O
/	O
6	O
)	O
,	O
and	O
40	O
%	O
of	O
the	O
cases	O
of	O
intermediate	O
malignancy	O
(	O
2	O
/	O
5	O
)	O
.	O
A	O
low	O
frequency	O
of	O
mutations	O
in	O
benign	B-malignancy-type
GISTs	I-malignancy-type
,	O
as	O
reported	O
previously	O
by	O
other	O
researchers	O
,	O
could	O
not	O
be	O
observed	O
in	O
our	O
panel	O
.	O
Interestingly	O
,	O
all	O
GISTs	B-malignancy-type
with	O
c-kit	O
mutations	O
displayed	O
a	O
spindle	O
cell	O
phenotype	O
,	O
whereas	O
mutations	O
were	O
absent	O
in	O
all	O
7	O
tumors	O
with	O
an	O
epithelioid	O
component	O
(	O
P	O
=	O
.03	O
)	O
.	O
This	O
finding	O
suggests	O
a	O
relationship	O
between	O
c-kit	O
mutation	O
and	O
histological	O
subtype	O
in	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
11850541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
2002	O
Mar	O
;	O
48	O
(	O
3	O
)	O
:	O
428	O
-	O
35	O
Diagnostic	O
biochip	O
array	O
for	O
fast	O
and	O
sensitive	O
detection	O
of	O
K-ras	O
mutations	O
in	O
stool	O
.	O
Prix	O
L	O
,	O
Uciechowski	O
P	O
,	O
Bockmann	O
B	O
,	O
Giesing	O
M	O
,	O
Schuetz	O
AJ	O
.	O
Institut	O
fur	O
Molekulare	O
NanoTechnologie	O
,	O
Berghauser	O
Strasse	O
295	O
,	O
45659	O
Recklinghausen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
Tumor	O
cells	O
that	O
shed	O
into	O
stool	O
are	O
attractive	O
targets	O
for	O
molecular	O
screening	O
and	O
early	O
detection	O
of	O
colon	B-malignancy-type
or	O
pancreatic	B-malignancy-type
malignancies	I-malignancy-type
.	O
We	O
developed	O
a	O
diagnostic	O
test	O
to	O
screen	O
for	O
10	O
of	O
the	O
most	O
common	O
mutations	O
of	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
gene	O
by	O
hybridization	O
to	O
a	O
new	O
biochip	O
array	O
.	O
METHODS	O
:	O
DNA	O
was	O
isolated	O
from	O
26	O
stool	O
samples	O
by	O
column	O
-	O
based	O
extraction	O
from	O
9	O
cell	O
lines	O
.	O
Peptide	O
nucleic	O
acid	O
(	O
PNA	O
)	O
-	O
mediated	O
PCR	O
clamping	O
was	O
used	O
for	O
mutant	O
-	O
specific	O
amplification	O
.	O
We	O
used	O
a	O
biochip	O
,	O
consisting	O
of	O
a	O
small	O
plastic	O
support	O
with	O
covalently	O
immobilized	O
13mer	O
oligonucleotides	O
.	O
The	O
read	O
out	O
of	O
the	O
biochip	O
was	O
done	O
by	O
confocal	O
time	O
-	O
resolved	O
laser	O
scanning	O
.	O
Hybridization	O
,	O
scanning	O
,	O
and	O
data	O
evaluation	O
could	O
be	O
performed	O
in	O
<	O
2	O
h	O
.	O
RESULTS	O
:	O
Approximately	O
80	O
ng	O
of	O
DNA	O
was	O
obtained	O
from	O
200	O
-	O
mg	O
stool	O
samples	O
.	O
No	O
inhibition	O
of	O
the	O
PCR	O
by	O
remaining	O
impurities	O
from	O
stool	O
was	O
observed	O
.	O
Mutation	O
detection	O
was	O
possible	O
in	O
1000	O
-	O
fold	O
excess	O
of	O
wild-type	O
sequence	O
.	O
Discrimination	O
ratios	O
between	O
the	O
mutations	O
were	O
>	O
19	O
as	O
demonstrated	O
by	O
hybridization	O
with	O
tumor	O
cell	O
line	O
DNA	O
.	O
Stool	O
samples	O
(	O
n	O
=	O
26	O
)	O
were	O
analyzed	O
in	O
parallel	O
with	O
PNA-PCR	O
,	O
restriction	O
assay	O
for	O
K-ras	O
codon	O
12	O
mutations	O
,	O
sequencing	O
,	O
and	O
hybridization	O
to	O
the	O
biochip	O
.	O
Nine	O
mutations	O
were	O
found	O
by	O
hybridization	O
,	O
all	O
confirmed	O
by	O
sequencing	O
.	O
PNA-PCR	O
alone	O
leads	O
to	O
an	O
overestimation	O
of	O
mutations	O
because	O
suppression	O
of	O
the	O
wild	O
type	O
is	O
not	O
effective	O
enough	O
with	O
high	O
concentrations	O
of	O
wild-type	O
DNA	O
.	O
The	O
restriction	O
assay	O
found	O
only	O
four	O
mutations	O
.	O
CONCLUSIONS	O
:	O
The	O
K-ras	O
biochip	O
is	O
well	O
suited	O
for	O
fast	O
mutation	O
detection	O
from	O
stool	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
screening	O
.	O
PMID	O
:	O
11861435	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Invest	O
Dermatol	O
2001	O
Dec	O
;	O
117	O
(	O
6	O
)	O
:	O
1483	O
-	O
9	O
Analysis	O
of	O
N	O
-	O
and	O
K-ras	O
mutations	O
in	O
the	O
distinctive	O
tumor	O
progression	O
phases	O
of	O
melanoma	B-malignancy-type
.	O
Demunter	O
A	O
,	O
Stas	O
M	O
,	O
Degreef	O
H	O
,	O
De	O
Wolf-Peeters	O
C	O
,	O
van	O
den	O
Oord	O
JJ	O
.	O
Department	O
of	O
Pathology	O
,	O
Laboratory	O
of	O
Morphology	O
and	O
Molecular	O
Pathology	O
,	O
University	O
Hospitals	O
,	O
Katholieke	O
Universiteit	O
Leuven	O
,	O
Leuven	O
,	O
Belgium	O
.	O
anouk.demunter@uz.kuleuven.ac.be	O
Mutations	O
in	O
the	O
ras	O
genes	O
are	O
key	O
events	O
in	O
the	O
process	O
of	O
carcinogenesis	O
;	O
in	O
particular	O
,	O
point	O
mutations	O
in	O
codon	O
61	O
of	O
exon	O
2	O
of	O
the	O
N-ras	O
gene	O
occur	O
frequently	O
in	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
To	O
investigate	O
whether	O
these	O
mutations	O
occur	O
in	O
early	O
or	O
late	O
tumor	O
progression	O
phases	O
,	O
we	O
searched	O
for	O
point	O
mutations	O
in	O
the	O
N	O
-	O
and	O
K-ras	O
genes	O
in	O
69	O
primary	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
,	O
35	O
metastases	B-malignancy-type
,	O
and	O
seven	O
nevocellular	B-malignancy-type
nevi	I-malignancy-type
in	O
association	O
with	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
Lesions	B-malignancy-type
were	O
microdissected	O
in	O
order	O
to	O
procure	O
pure	O
tumor	O
samples	O
from	O
the	O
distinctive	O
growth	O
phases	O
of	O
the	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
;	O
the	O
very	O
sensitive	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
technique	O
was	O
used	O
to	O
visualize	O
the	O
mutations	O
,	O
and	O
was	O
followed	O
by	O
sequencing	O
.	O
Point	O
mutations	O
in	O
the	O
N-ras	O
gene	O
but	O
not	O
in	O
the	O
K-ras	O
gene	O
were	O
detected	O
on	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Twenty-three	O
primary	O
(	O
33	O
%	O
)	O
and	O
nine	O
metastatic	O
(	O
26	O
%	O
)	O
melanomas	B-malignancy-type
showed	O
bandshifts	O
for	O
N-ras	O
.	O
In	O
the	O
majority	O
of	O
cases	O
,	O
mutations	O
occurring	O
in	O
early	O
growth	O
phases	O
(	O
i.e.	O
,	O
the	O
"	O
intraepidermal	O
"	O
radial	O
growth	O
phase	O
)	O
,	O
were	O
preserved	O
in	O
later	O
growth	O
phases	O
(	O
i.e.	O
,	O
the	O
invasive	O
radial	O
growth	O
phase	O
,	O
vertical	O
growth	O
phase	O
,	O
and	O
metastatic	O
phase	O
)	O
,	O
which	O
proves	O
the	O
clonal	O
relationship	O
between	O
the	O
successive	O
growth	O
phases	O
.	O
In	O
three	O
cases	O
,	O
however	O
,	O
the	O
mutations	O
differed	O
between	O
the	O
distinctive	O
growth	O
phases	O
within	O
the	O
same	O
cutaneous	O
melanoma	O
,	O
due	O
to	O
the	O
occurrence	O
of	O
an	O
additional	O
mutation	O
(	O
especially	O
in	O
codon	O
61	O
)	O
in	O
a	O
later	O
tumor	O
progression	O
phase	O
.	O
Our	O
approach	O
also	O
permitted	O
us	O
to	O
analyze	O
the	O
mutational	O
status	O
of	O
nevi	O
,	O
associated	O
with	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
Six	O
out	O
of	O
seven	O
associated	O
nevi	O
carried	O
the	O
same	O
sequence	O
(	O
mutated	O
or	O
wild-type	O
)	O
as	O
the	O
primary	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
,	O
whereas	O
in	O
one	O
case	O
the	O
sequence	O
for	O
N-ras	O
differed	O
between	O
the	O
primary	O
melanoma	B-malignancy-type
and	O
the	O
associated	O
nevus	B-malignancy-type
.	O
In	O
conclusion	O
,	O
this	O
approach	O
allowed	O
us	O
to	O
demonstrate	O
the	O
clonal	O
relationship	O
between	O
subsequent	O
growth	O
phases	O
of	O
melanoma	B-malignancy-type
and	O
associated	O
nevi	B-malignancy-type
;	O
our	O
results	O
suggest	O
that	O
N-ras	O
exon	O
1	O
mutations	O
preferentially	O
occur	O
during	O
early	O
stages	O
of	O
tumor	O
progression	O
and	O
hence	O
may	O
be	O
involved	O
in	O
melanoma	B-malignancy-type
initiation	O
,	O
whereas	O
those	O
in	O
N-ras	O
exon	O
2	O
are	O
found	O
preferentially	O
during	O
later	O
stages	O
and	O
hence	O
are	O
more	O
probably	O
involved	O
in	O
metastatic	O
spread	O
of	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
PMID	O
:	O
11886512	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Pathol	O
2002	O
May	O
;	O
55	O
(	O
5	O
)	O
:	O
340	O
-	O
5	O
Pancreatic	B-malignancy-type
cancer	I-malignancy-type
after	O
remote	O
peptic	O
ulcer	O
surgery	O
.	O
Tascilar	O
M	O
,	O
van	O
Rees	O
BP	O
,	O
Sturm	O
PD	O
,	O
Tytgat	O
GN	O
,	O
Hruban	O
RH	O
,	O
Goodman	O
SN	O
,	O
Giardiello	O
FM	O
,	O
Offerhaus	O
GJ	O
,	O
Tersmette	O
AC	O
.	O
Department	O
of	O
Pathology	O
,	O
Academic	O
Medical	O
Center	O
,	O
University	O
of	O
Amsterdam	O
,	O
1105	O
AZ	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
BACKGROUND	O
:	O
Peptic	O
ulcer	O
surgery	O
may	O
carry	O
an	O
increased	O
risk	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
development	O
.	O
Molecular	O
analysis	O
of	O
K-ras	O
codon	O
12	O
,	O
frequently	O
mutated	O
in	O
conventional	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
might	O
provide	O
insight	O
into	O
the	O
aetiological	O
mechanisms	O
.	O
METHODS	O
:	O
The	O
relative	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
was	O
computed	O
by	O
multivariate	O
and	O
person	O
-	O
year	O
analysis	O
in	O
a	O
cohort	O
of	O
2633	O
patients	O
who	O
had	O
undergone	O
gastrectomy	O
.	O
Lung	B-malignancy-type
cancer	I-malignancy-type
risk	O
was	O
analysed	O
as	O
an	O
indirect	O
means	O
of	O
assessing	O
smoking	O
behaviour	O
.	O
K-ras	O
codon	O
12	O
mutational	O
analysis	O
was	O
performed	O
on	O
15	O
postgastrectomy	B-malignancy-type
pancreatic	I-malignancy-type
cancers	I-malignancy-type
.	O
RESULTS	O
:	O
There	O
was	O
an	O
overall	O
increased	O
risk	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
of	O
1.8	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.3	O
to	O
2.6	O
)	O
five	O
to	O
59	O
years	O
postoperatively	O
,	O
which	O
gradually	O
increased	O
to	O
3.6	O
at	O
35	O
years	O
or	O
more	O
after	O
surgery	O
(	O
chi(2)	O
test	O
for	O
trend	O
,	O
p	O
<	O
0.05	O
)	O
.	O
Multivariate	O
analysis	O
indicated	O
that	O
parameters	O
other	O
than	O
postoperative	O
interval	O
did	O
not	O
influence	O
the	O
risk	O
.	O
Lung	B-malignancy-type
cancer	I-malignancy-type
risk	O
was	O
significantly	O
increased	O
after	O
surgery	O
,	O
but	O
no	O
time	O
trend	O
was	O
observed	O
.	O
The	O
spectrum	O
and	O
prevalence	O
of	O
K-ras	O
codon	O
12	O
mutations	O
were	O
comparable	O
to	O
conventional	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Remote	O
partial	O
gastrectomy	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Postgastrectomy	B-malignancy-type
and	O
non	B-malignancy-type
-	I-malignancy-type
postgastrectomy	I-malignancy-type
pancreatic	I-malignancy-type
cancers	I-malignancy-type
may	O
share	O
similar	O
aetiological	O
factors	O
,	O
such	O
as	O
smoking	O
.	O
However	O
,	O
the	O
neoplastic	O
process	O
in	O
patients	O
who	O
have	O
undergone	O
gastrectomy	O
appears	O
to	O
be	O
accelerated	O
by	O
factors	O
related	O
to	O
the	O
surgery	O
itself	O
.	O
PMID	O
:	O
11986336	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Surg	O
Pathol	O
2002	O
Jun	O
;	O
26	O
(	O
6	O
)	O
:	O
758	O
-	O
66	O
Mutation	O
and	O
altered	O
expression	O
of	O
beta-catenin	O
during	O
gallbladder	O
carcinogenesis	O
.	O
Chang	O
HJ	O
,	O
Jee	O
CD	O
,	O
Kim	O
WH	O
.	O
Department	O
of	O
Pathology	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Korea	O
.	O
Gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
has	O
two	O
main	O
morphologic	O
developmental	O
pathways	O
:	O
a	O
dysplasia	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
and	O
an	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
.	O
beta-Catenin	O
is	O
a	O
key	O
regulator	O
of	O
the	O
cadherin	O
-	O
mediated	O
cell	O
adhesion	O
system	O
,	O
and	O
altered	O
expression	O
and	O
mutation	O
of	O
beta-catenin	O
have	O
been	O
identified	O
in	O
many	O
human	O
malignancies	O
.	O
To	O
clarify	O
its	O
role	O
in	O
gallbladder	O
carcinogenesis	O
,	O
we	O
investigated	O
mutation	O
and	O
immunohistochemical	O
expression	O
of	O
beta-catenin	O
in	O
adenomas	B-malignancy-type
,	O
dysplasias	B-malignancy-type
,	O
and	O
carcinomas	B-malignancy-type
.	O
We	O
classified	O
adenomas	B-malignancy-type
according	O
to	O
the	O
expression	O
of	O
apomucins	O
and	O
cytokeratin	O
and	O
compared	O
the	O
mutational	O
and	O
expression	O
pattern	O
among	O
each	O
type	O
.	O
beta-Catenin	O
mutations	O
were	O
identified	O
in	O
58	O
%	O
(	O
14	O
of	O
24	O
)	O
of	O
the	O
adenomas	B-malignancy-type
,	O
and	O
they	O
were	O
absent	O
from	O
all	O
carcinomas	B-malignancy-type
(	O
37	O
cases	O
)	O
and	O
dysplasias	B-malignancy-type
(	O
13	O
cases	O
)	O
.	O
Altered	O
expression	O
of	O
beta-catenin	O
,	O
such	O
as	O
nuclear	O
or	O
cytoplasmic	O
expression	O
and	O
loss	O
of	O
membranous	O
expression	O
,	O
was	O
also	O
significantly	O
higher	O
in	O
adenomas	B-malignancy-type
than	O
in	O
dysplasias	B-malignancy-type
or	O
carcinomas	B-malignancy-type
(	O
p	O
<	O
0.001	O
)	O
.	O
Of	O
the	O
adenomas	B-malignancy-type
,	O
papillary	B-malignancy-type
adenomas	I-malignancy-type
and	O
tubular	B-malignancy-type
adenomas	I-malignancy-type
of	O
intestinal	O
type	O
showed	O
infrequent	O
beta-catenin	O
abnormality	O
,	O
which	O
was	O
similar	O
to	O
the	O
carcinomas	B-malignancy-type
.	O
The	O
cytoplasmic	O
and	O
nuclear	O
expression	O
of	O
beta-catenin	O
in	O
carcinomas	B-malignancy-type
was	O
correlated	O
with	O
less	O
aggressive	O
tumor	O
behavior	O
;	O
in	O
particular	O
,	O
cytoplasmic	O
expression	O
was	O
associated	O
with	O
improved	O
patient	O
outcome	O
(	O
p	O
=	O
0.028	O
)	O
.	O
Gallbladder	B-malignancy-type
adenoma	I-malignancy-type
may	O
be	O
a	O
heterogeneous	O
entity	O
,	O
and	O
the	O
majority	O
of	O
adenomas	B-malignancy-type
are	O
not	O
responsible	O
for	O
carcinoma	B-malignancy-type
progression	O
.	O
PMID	O
:	O
12023580	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mod	O
Pathol	O
2002	O
Jun;1	O
5	O
(	O
6	O
)	O
:	O
59	O
9-605	O
Mucinous	B-malignancy-type
and	O
nonmucinous	B-malignancy-type
appendiceal	I-malignancy-type
adenocarcinomas	I-malignancy-type
:	O
different	O
clinicopathological	O
features	O
but	O
similar	O
genetic	O
alterations	O
.	O
Kabbani	O
W	O
,	O
Houlihan	O
PS	O
,	O
Luthra	O
R	O
,	O
Hamilton	O
SR	O
,	O
Rashid	O
A.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
,	O
USA	O
.	O
The	O
genetic	O
alterations	O
of	O
appendiceal	B-malignancy-type
carcinomas	I-malignancy-type
have	O
not	O
been	O
reported	O
in	O
detail	O
.	O
We	O
studied	O
the	O
clinicopathological	O
factors	O
and	O
genetic	O
alterations	O
including	O
microsatellite	O
instability	O
,	O
p53	O
overexpression	O
,	O
and	O
mutations	O
of	O
the	O
K-ras	O
proto	O
-	O
oncogene	O
of	O
30	O
appendiceal	B-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
consisting	O
of	O
23	O
mucinous	B-malignancy-type
and	O
7	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Sixteen	O
(	O
70	O
%	O
)	O
mucinous	B-malignancy-type
carcinomas	I-malignancy-type
presented	O
with	O
pseudomyxoma	B-malignancy-type
peritonei	I-malignancy-type
,	O
but	O
6	O
of	O
7	O
(	O
86	O
%	O
)	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
presented	O
with	O
appendicitis	O
(	O
P	O
=	O
.002	O
)	O
.	O
All	O
carcinomas	B-malignancy-type
were	O
microsatellite	O
stable	O
,	O
and	O
p53	O
overexpression	O
was	O
present	O
in	O
only	O
1	O
of	O
30	O
(	O
3	O
%	O
)	O
carcinomas	B-malignancy-type
.	O
K-ras	O
mutation	O
was	O
present	O
in	O
11	O
of	O
20	O
(	O
55	O
%	O
)	O
carcinomas	B-malignancy-type
,	O
including	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
mucinous	B-malignancy-type
and	O
3	O
of	O
4	O
(	O
75	O
%	O
)	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
mean	O
survival	O
of	O
patients	O
with	O
mucinous	B-malignancy-type
carcinomas	I-malignancy-type
was	O
26	O
+/-	O
19	O
months	O
compared	O
with	O
13	O
+/-	O
9	O
months	O
for	O
patients	O
with	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
P	O
=	O
.0002	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
mucinous	B-malignancy-type
and	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
of	O
appendix	O
have	O
similar	O
genetic	O
alterations	O
,	O
but	O
different	O
clinical	O
presentation	O
and	O
prognosis	O
.	O
PMID	O
:	O
12065772	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2002	O
Aug;3	O
3	O
(	O
8	O
)	O
:	O
85	O
2-5	O
Two	O
case	O
reports	O
of	O
childhood	O
liver	B-malignancy-type
cell	I-malignancy-type
adenomas	I-malignancy-type
harboring	O
beta-catenin	O
abnormalities	O
.	O
Takayasu	O
H,	O
Motoi	O
T	O
,	O
Kanamori	O
Y	O
,	O
Kitano	O
Y	O
,	O
Nakanishi	O
H,	O
Tange	O
T	O
,	O
Nakagawara	O
A	O
,	O
Hashizume	O
K.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Tokyo	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
benign	B-malignancy-type
epithelial	I-malignancy-type
neoplasm	I-malignancy-type
liver	I-malignancy-type
cell	I-malignancy-type
adenoma	I-malignancy-type
is	O
rare	O
,	O
especially	O
in	O
childhood	O
.	O
We	O
report	O
2	O
such	O
cases	O
,	O
1	O
of	O
which	O
was	O
associated	O
with	O
Prader	O
-	O
Willi	O
syndrome	O
.	O
Differential	O
diagnosis	O
of	O
the	O
liver	B-malignancy-type
cell	I-malignancy-type
adenomas	I-malignancy-type
on	O
the	O
basis	O
of	O
histopathologic	O
findings	O
proved	O
difficult	O
and	O
was	O
based	O
on	O
the	O
absence	O
of	O
cellular	O
and	O
nuclear	O
atypia	O
,	O
mitotic	O
activity	O
,	O
and	O
invasive	O
growth	O
.	O
In	O
both	O
cases	O
,	O
immunohistochemical	O
staining	O
demonstrated	O
the	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
,	O
and	O
in	O
1	O
case	O
,	O
the	O
tumor	O
cells	O
carried	O
a	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Recently	O
,	O
disregulation	O
of	O
the	O
Wnt	O
/	O
beta-catenin	O
pathway	O
,	O
attributable	O
to	O
abnormalities	O
of	O
the	O
beta-catenin	O
gene	O
,	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
event	O
in	O
the	O
development	O
of	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
and	O
hepatoblastomas	B-malignancy-type
.	O
Our	O
report	O
may	O
be	O
the	O
first	O
to	O
describe	O
the	O
beta-catenin	O
abnormalities	O
in	O
childhood	O
liver	B-malignancy-type
cell	I-malignancy-type
adenoma	I-malignancy-type
.	O
These	O
findings	O
imply	O
that	O
abnormalities	O
of	O
beta-catenin	O
can	O
be	O
an	O
early	O
initiating	O
event	O
in	O
human	O
liver	O
tumorigenesis	O
.	O
Copyright	O
2002	O
,	O
Elsevier	O
Science	O
(	O
USA	O
)	O
.	O
All	O
rights	O
reserved	O
.	O
PMID	O
:	O
12203220	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Urol	O
1997	O
Mar;4(	O
2	O
)	O
:178	O
-	O
85	O
Screening	O
of	O
H-ras	O
gene	O
point	O
mutations	O
in	O
50	O
cases	O
of	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Saito	O
S,	O
Hata	O
M,	O
Fukuyama	O
R,	O
Sakai	O
K	O
,	O
Kudoh	O
J,	O
Tazaki	O
H	O
,	O
Shimizu	O
N.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Keio	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Mutation	O
converts	O
the	O
H-ras	O
gene	O
into	O
an	O
activated	O
oncogene	O
in	O
about	O
10	O
%	O
of	O
human	O
bladder	B-malignancy-type
cancers	I-malignancy-type
.	O
Codons	O
12	O
and	O
61	O
are	O
the	O
major	O
"	O
hot	O
spots	O
"	O
for	O
activation	O
.	O
A	O
simple	O
and	O
accurate	O
method	O
to	O
detect	O
point	O
mutations	O
in	O
these	O
codons	O
may	O
be	O
clinically	O
useful	O
for	O
early	O
diagnosis	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
Bladder	B-malignancy-type
cancer	I-malignancy-type
samples	O
from	O
50	O
patients	O
,	O
plus	O
10	O
samples	O
of	O
normal	O
bladder	O
mucosa	O
,	O
were	O
analyzed	O
for	O
possible	O
point	O
mutation	O
of	O
the	O
H-ras	O
gene	O
at	O
either	O
codon	O
12	O
or	O
codon	O
61	O
.	O
The	O
H-ras	O
gene	O
DNA	O
segments	O
that	O
include	O
these	O
2	O
codons	O
were	O
amplified	O
by	O
PCR	O
methods	O
,	O
then	O
the	O
possible	O
presence	O
of	O
a	O
point	O
mutation	O
was	O
evaluated	O
at	O
each	O
codon	O
by	O
susceptibility	O
of	O
the	O
respective	O
DNA	O
segments	O
to	O
digestion	O
with	O
the	O
restriction	O
enzyme	O
and	O
by	O
dot	O
blot	O
hybridization	O
assay	O
.	O
A	O
bladder	B-malignancy-type
cancer	I-malignancy-type
patient	O
who	O
had	O
an	O
H-ras	O
gene	O
mutation	O
was	O
examined	O
to	O
see	O
whether	O
the	O
mutation	O
was	O
also	O
detectable	O
in	O
the	O
cells	O
released	O
in	O
the	O
urine	O
.	O
RESULTS	O
:	O
Definite	O
or	O
possible	O
point	O
mutations	O
were	O
found	O
in	O
6	O
(	O
12	O
%	O
)	O
out	O
of	O
50	O
bladder	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
while	O
no	O
mutation	O
was	O
detected	O
in	O
normal	O
mucosa	O
.	O
A	O
point	O
mutation	O
could	O
also	O
be	O
detected	O
in	O
cells	O
isolated	O
from	O
the	O
patient	O
's	O
urine	O
sample	O
.	O
CONCLUSION	O
:	O
The	O
prevalence	O
of	O
point	O
mutations	O
at	O
codon	O
12	O
or	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
found	O
in	O
this	O
study	O
was	O
similar	O
to	O
that	O
previously	O
estimated	O
for	O
human	O
bladder	B-malignancy-type
cancer	I-malignancy-type
by	O
DNA	O
transfection	O
assay	O
.	O
The	O
method	O
we	O
have	O
used	O
for	O
detecting	O
point	O
mutations	O
of	O
the	O
H-ras	O
gene	O
provides	O
a	O
simple	O
and	O
highly	O
accurate	O
way	O
to	O
detect	O
mutated	O
cancer	O
cells	O
even	O
in	O
the	O
urine	O
.	O
It	O
may	O
be	O
clinically	O
usable	O
for	O
early	O
diagnosis	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9179693	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Sep;25(	O
9	O
)	O
:1121	O
-	O
33	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
,	O
intramural	B-malignancy-type
leiomyomas	I-malignancy-type
,	O
and	O
leiomyosarcomas	B-malignancy-type
in	O
the	O
rectum	O
and	O
anus	O
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
genetic	O
study	O
of	O
144	O
cases	O
.	O
Miettinen	O
M,	O
Furlong	O
M,	O
Sarlomo	O
-	O
Rikala	O
M,	O
Burke	O
A	O
,	O
Sobin	O
LH	O
,	O
Lasota	O
J.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
miettinen@afip.osd	O
.mil	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
,	O
the	O
specific	O
KIT	O
-	O
positive	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
gastrointestinal	O
tract	O
,	O
have	O
been	O
sporadically	O
reported	O
in	O
the	O
rectum	O
,	O
but	O
there	O
are	O
few	O
clinicopathologic	O
series	O
.	O
In	O
this	O
study	O
we	O
analyzed	O
the	O
clinicopathologic	O
features	O
of	O
133	O
anorectal	B-malignancy-type
GISTs	I-malignancy-type
,	O
3	O
intramural	B-malignancy-type
leiomyomas	I-malignancy-type
(	O
LMs	B-malignancy-type
)	O
,	O
and	O
8	O
leiomyosarcomas	B-malignancy-type
(	O
LMSs	B-malignancy-type
)	O
from	O
the	O
files	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
and	O
the	O
Haartman	O
Institute	O
of	O
the	O
University	O
of	O
Helsinki	O
.	O
Ninety-six	O
GISTs	B-malignancy-type
were	O
documented	O
as	O
KIT	O
-	O
positive	O
and	O
three	O
additional	O
ones	O
as	O
CD34	O
-	O
positive	O
.	O
Thirty-four	O
tumors	O
were	O
included	O
by	O
their	O
histologic	O
similarity	O
to	O
KIT	O
-	O
or	O
CD34	O
-	O
positive	O
cases	O
.	O
GIST	B-malignancy-type
-	O
specific	O
c-kit	O
gene	O
mutations	O
,	O
mostly	O
in	O
exon	O
11	O
,	O
were	O
documented	O
in	O
18	O
of	O
29	O
cases	O
(	O
62	O
%	O
)	O
.	O
The	O
GISTs	B-malignancy-type
occurred	O
in	O
adults	O
with	O
the	O
age	O
range	O
of	O
17	O
-	O
90	O
years	O
(	O
median	O
60	O
years	O
)	O
with	O
a	O
significant	O
male	O
predominance	O
(	O
71	O
%	O
)	O
.	O
The	O
tumors	O
ranged	O
from	O
small	B-malignancy-type
asymptomatic	I-malignancy-type
intramural	I-malignancy-type
nodules	I-malignancy-type
to	O
large	O
masses	O
that	O
bulged	O
into	O
pelvis	O
causing	O
pain	O
,	O
rectal	O
bleeding	O
,	O
or	O
obstruction	O
.	O
They	O
were	O
mostly	O
highly	O
cellular	O
spindle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
;	O
four	O
tumors	O
had	O
an	O
epithelioid	O
morphology	O
.	O
The	O
tumors	O
coexpressed	O
CD34	O
and	O
KIT	O
and	O
were	O
rarely	O
positive	O
for	O
smooth	O
muscle	O
actin	O
or	O
desmin	O
and	O
never	O
for	O
S-100	O
protein	O
.	O
Seventy	O
percent	O
of	O
patients	O
with	O
tumors	O
>	O
5	O
cm	O
with	O
more	O
than	O
5	O
mitoses	O
/	O
50	O
high	O
power	O
fields	O
(	O
HPF	O
)	O
(	O
n	O
=	O
31	O
)	O
died	O
of	O
disease	O
,	O
whereas	O
only	O
one	O
tumor	O
<	O
2	O
cm	O
with	O
<	O
5	O
mitoses	O
/	O
50	O
HPF	O
(	O
n	O
=	O
21	O
)	O
recurred	O
and	O
none	O
caused	O
death	O
.	O
Long	O
latency	O
was	O
common	O
between	O
primary	O
operation	O
and	O
recurrences	O
and	O
metastases	B-malignancy-type
;	O
either	O
one	O
occurred	O
in	O
60	O
of	O
111	O
patients	O
with	O
follow	O
-	O
up	O
(	O
54	O
%	O
)	O
.	O
Distant	O
metastases	B-malignancy-type
were	O
in	O
the	O
liver	B-malignancy-type
,	O
bones	O
,	O
and	O
lungs	O
.	O
Three	O
benign	O
actin	O
-	O
and	O
desmin	O
-	O
positive	O
and	O
KIT	O
-	O
negative	O
intramural	B-malignancy-type
LMs	I-malignancy-type
,	O
similar	O
to	O
those	O
seen	O
in	O
the	O
esophagus	O
,	O
were	O
identified	O
.	O
There	O
were	O
eight	O
LMSs	B-malignancy-type
,	O
six	O
of	O
which	O
formed	O
a	O
polypoid	B-malignancy-type
intraluminal	I-malignancy-type
mass	I-malignancy-type
and	O
were	O
actin	O
-	O
positive	O
and	O
KIT	O
-	O
negative	O
.	O
Despite	O
high	O
mitotic	O
counts	O
,	O
only	O
one	O
LMS	O
patient	O
died	O
of	O
disease	O
.	O
A	O
great	O
majority	O
of	O
rectal	B-malignancy-type
smooth	I-malignancy-type
muscle	I-malignancy-type
and	O
stromal	B-malignancy-type
tumors	I-malignancy-type
are	O
GISTs	B-malignancy-type
,	O
which	O
have	O
a	O
spectrum	O
from	O
minimal	O
indolent	B-malignancy-type
tumors	I-malignancy-type
to	O
overt	O
sarcomas	B-malignancy-type
.	O
Intramural	B-malignancy-type
LMs	I-malignancy-type
are	O
exceptional	O
,	O
and	O
true	O
LMSs	B-malignancy-type
are	O
rare	O
,	O
and	O
similar	O
to	O
colonic	O
ones	O
,	O
often	O
present	O
as	O
intraluminal	B-malignancy-type
polypoid	I-malignancy-type
masses	I-malignancy-type
that	O
appear	O
to	O
have	O
a	O
better	O
prognosis	O
than	O
GISTs	B-malignancy-type
with	O
similar	O
mitotic	O
rates	O
.	O
PMID	O
:	O
11688571	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2001	O
Aug	O
16;20(	O
36	O
)	O
:5025	O
-	O
32	O
Extensive	O
characterization	O
of	O
genetic	O
alterations	O
in	O
a	O
series	O
of	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Gayet	O
J,	O
Zhou	O
XP	O
,	O
Duval	O
A	O
,	O
Rolland	O
S,	O
Hoang	O
JM	O
,	O
Cottu	O
P	O
,	O
Hamelin	O
R.	O
INSERM	O
U434	O
-	O
CEPH	O
,	O
Paris	O
,	O
France	O
.	O
A	O
number	O
of	O
genetic	O
alterations	O
have	O
been	O
described	O
in	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
They	O
include	O
allelic	O
losses	O
on	O
specific	O
chromosomal	O
arms	O
,	O
mutations	O
of	O
oncogenes	O
,	O
tumor	O
suppressor	O
genes	O
and	O
mismatch	O
repair	O
genes	O
,	O
microsatellite	O
instability	O
in	O
coding	O
repeat	O
sequences	O
of	O
target	O
genes	O
and	O
methylation	O
defects	O
in	O
gene	O
promoters	O
.	O
Since	O
these	O
alterations	O
have	O
been	O
reported	O
by	O
different	O
groups	O
on	O
different	O
tumors	O
and	O
cell	O
lines	O
,	O
the	O
complete	O
repertoire	O
of	O
genetic	O
alterations	O
for	O
any	O
given	O
tumor	O
sample	O
remains	O
unknown	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
analysed	O
a	O
series	O
of	O
22	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
for	O
31	O
different	O
genetic	O
alterations	O
.	O
We	O
found	O
significant	O
correlations	O
between	O
mutational	O
profiles	O
in	O
these	O
colorectal	O
cell	O
lines	O
associated	O
with	O
differences	O
in	O
mismatch	O
repair	O
status	O
.	O
This	O
panel	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
is	O
representative	O
of	O
the	O
genetic	O
heterogeneity	O
occurring	O
in	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Our	O
results	O
may	O
prove	O
to	O
be	O
very	O
useful	O
for	O
understanding	O
the	O
different	O
biological	O
pathways	O
involved	O
in	O
the	O
development	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
for	O
groups	O
studying	O
cellular	O
biology	O
and	O
pharmacology	O
on	O
the	O
same	O
cell	O
lines	O
.	O
PMID	O
:	O
11526487	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
2001	O
Jul	O
20	O
;85(	O
2	O
)	O
:235	O
-	O
41	O
Topographic	O
analysis	O
of	O
K	O
-	O
ras	O
mutations	O
in	O
histologically	O
normal	O
lung	O
tissues	O
and	O
tumours	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Keohavong	O
P	O
,	O
Mady	O
HH	O
,	O
Gao	O
WM	O
,	O
Siegfried	O
JM	O
,	O
Luketich	O
JD	O
,	O
Melhem	O
MF.	O
Departments	O
of	O
Environmental	O
and	O
Occupational	O
Health	O
,	O
University	O
of	O
Pittsburgh	O
,	O
Pittsburgh	O
,	O
PA	O
15213	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
K	O
-	O
ras	O
gene	O
are	O
very	O
common	O
in	O
lung	B-malignancy-type
tumours	I-malignancy-type
and	O
are	O
implicated	O
in	O
the	O
development	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
the	O
timing	O
of	O
their	O
occurrence	O
remains	O
poorly	O
understood	O
.	O
We	O
investigated	O
K	O
-	O
ras	O
mutations	O
in	O
cell	O
samples	O
microdissected	O
by	O
laser	O
capture	O
microscopy	O
at	O
multiple	O
sites	O
from	O
lung	O
tissue	O
sections	O
representing	O
tumour	O
tissue	O
and	O
matched	O
histologically	O
normal	O
tissue	O
obtained	O
from	O
48	O
lung	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
K	O
-	O
ras	O
mutations	O
were	O
detected	O
in	O
cell	O
samples	O
from	O
10	O
of	O
38	O
(	O
26.3	O
%	O
)	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
in	O
none	O
of	O
the	O
histologically	O
normal	O
or	O
tumour	O
cell	O
samples	O
taken	O
from	O
10	O
lung	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Of	O
the	O
K	O
-	O
ras	O
mutation	O
-	O
positive	O
adenocarcinomas	B-malignancy-type
,	O
in	O
4	O
cases	O
a	O
mutation	O
was	O
found	O
in	O
only	O
the	O
tumour	O
tissue	O
,	O
in	O
1	O
case	O
a	O
mutation	O
was	O
found	O
only	O
in	O
the	O
histologically	O
normal	O
tissue	O
,	O
and	O
in	O
5	O
cases	O
mutations	O
were	O
found	O
in	O
both	O
the	O
tumour	O
tissue	O
and	O
histologically	O
normal	O
tissue	O
.	O
Among	O
these	O
5	O
cases	O
,	O
2	O
had	O
identical	O
mutations	O
in	O
both	O
the	O
tumour	O
tissue	O
and	O
histologically	O
normal	O
tissue	O
,	O
2	O
had	O
1	O
mutation	O
in	O
the	O
tumour	O
tissue	O
and	O
2	O
mutations	O
in	O
the	O
histologically	O
normal	O
tissue	O
,	O
1	O
of	O
which	O
was	O
identical	O
to	O
the	O
mutation	O
found	O
in	O
the	O
tumour	O
,	O
and	O
1	O
case	O
had	O
2	O
codon	O
12	O
mutations	O
in	O
tumour	O
tissue	O
and	O
2	O
mutations	O
,	O
in	O
codons	O
9	O
and	O
11	O
,	O
in	O
histologically	O
normal	O
tissue	O
.	O
These	O
results	O
showed	O
that	O
K	O
-	O
ras	O
mutations	O
are	O
frequent	O
in	O
histologically	O
normal	O
cells	O
taken	O
from	O
outside	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
suggest	O
that	O
some	O
of	O
these	O
mutations	O
may	O
represent	O
early	O
events	O
which	O
could	O
pave	O
the	O
way	O
of	O
lung	O
carcinogenesis	O
.	O
PMID	O
:	O
11461083	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
2001	O
Mar	O
20;95(	O
2	O
)	O
:108	O
-	O
13	O
Altered	O
expression	O
and	O
mutation	O
of	O
beta-catenin	O
gene	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
and	O
cell	O
lines	O
.	O
Woo	O
DK	O
,	O
Kim	O
HS	O
,	O
Lee	O
HS	O
,	O
Kang	O
YH	O
,	O
Yang	O
HK	O
,	O
Kim	O
WH.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
beta-catenin	O
serves	O
not	O
only	O
as	O
a	O
structural	O
component	O
of	O
the	O
E-cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
system	O
,	O
but	O
also	O
as	O
a	O
signaling	O
molecule	O
of	O
the	O
Wnt	O
/	O
wingless	O
pathway	O
.	O
Deregulated	O
expression	O
of	O
beta-catenin	O
and	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
human	O
malignancies	O
.	O
To	O
determine	O
the	O
role	O
of	O
beta-catenin	O
defects	O
in	O
stomach	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
investigated	O
beta-catenin	O
exon	O
3	O
mutations	O
and	O
altered	O
protein	O
expression	O
in	O
77	O
primary	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
and	O
11	O
cell	O
lines	O
.	O
In	O
addition	O
,	O
the	O
immunohistochemical	O
expression	O
pattern	O
of	O
beta-catenin	O
in	O
303	O
consecutive	O
gastric	B-malignancy-type
cancers	I-malignancy-type
was	O
determined	O
and	O
their	O
relationships	O
with	O
clinicopathologic	O
features	O
and	O
patient	O
outcome	O
were	O
investigated	O
.	O
This	O
study	O
revealed	O
5	O
%	O
(	O
4	O
of	O
77	O
)	O
tumors	O
and	O
27	O
%	O
(	O
3	O
of	O
11	O
)	O
cell	O
lines	O
with	O
beta-catenin	O
gene	O
alteration	O
,	O
6	O
missense	O
mutations	O
,	O
and	O
1	O
interstitial	O
deletion	O
.	O
These	O
genetic	O
changes	O
were	O
shown	O
to	O
correlate	O
closely	O
with	O
nuclear	O
localization	O
of	O
the	O
protein	O
(	O
p	O
=	O
0.001	O
)	O
.	O
In	O
an	O
immunohistochemical	O
analysis	O
,	O
abnormal	O
expressions	O
of	O
beta-catenin	O
,	O
such	O
as	O
nuclear	O
accumulation	O
and	O
loss	O
of	O
membranous	O
distribution	O
,	O
were	O
detected	O
in	O
27	O
%	O
(	O
81	O
of	O
303	O
)	O
of	O
tumors	O
overall	O
.	O
These	O
altered	O
beta-catenin	O
expressions	O
were	O
more	O
commonly	O
observed	O
in	O
37	O
%	O
(	O
58	O
of	O
158	O
)	O
diffuse	O
type	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
(	O
p	O
<	O
0.001	O
)	O
.	O
Loss	O
of	O
membranous	O
beta-catenin	O
staining	O
was	O
associated	O
with	O
poor	O
survival	O
(	O
p	O
=	O
0.045	O
)	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
demonstrate	O
that	O
beta-catenin	O
mutations	O
are	O
common	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
but	O
occur	O
infrequently	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
tissues	O
.	O
These	O
mutations	O
are	O
one	O
of	O
the	O
causes	O
of	O
the	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
.	O
Frequent	O
abnormalities	O
of	O
beta-catenin	O
expression	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
support	O
the	O
idea	O
that	O
both	O
structural	O
and	O
signaling	O
functions	O
of	O
the	O
protein	O
play	O
a	O
critical	O
role	O
in	O
gastric	O
carcinogenesis	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11241321	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Pathol	O
2001	O
Feb;193(	O
2	O
)	O
:193	O
-	O
9	O
K-ras	O
mutations	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
with	O
microsatellite	O
instability	O
.	O
Lagarda	O
H	O
,	O
Catasus	O
L,	O
Arguelles	O
R,	O
Matias	O
-	O
Guiu	O
X	O
,	O
Prat	O
J.	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
Santa	O
Creu	O
i	O
Sant	O
Pau	O
,	O
Autonomous	O
University	O
of	O
Barcelona	O
,	O
Spain	O
.	O
K-ras	O
mutations	O
are	O
known	O
to	O
occur	O
in	O
hyperplasias	B-malignancy-type
and	O
carcinomas	B-malignancy-type
of	O
the	O
endometrium	O
.	O
No	O
clear	O
correlation	O
has	O
been	O
found	O
yet	O
between	O
K-ras	O
mutations	O
and	O
microsatellite	O
instability	O
(	O
MI	O
)	O
in	O
these	O
lesions	B-malignancy-type
.	O
Fifty-eight	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
(	O
ECs	B-malignancy-type
)	O
and	O
22	O
endometrial	B-malignancy-type
hyperplasias	I-malignancy-type
(	O
EHs	B-malignancy-type
)	O
were	O
analysed	O
for	O
K-ras	O
mutation	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
,	O
restriction	O
analysis	O
,	O
and	O
DNA	O
sequencing	O
.	O
MI	O
status	O
had	O
been	O
established	O
previously	O
at	O
five	O
dinucleotide	O
loci	O
and	O
was	O
reconfirmed	O
with	O
markers	O
BAT-25	O
and	O
BAT-26	O
by	O
SSCP	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
11	O
ECs	B-malignancy-type
(	O
18.9	O
%	O
)	O
.	O
All	O
11	O
tumours	O
were	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
K-ras	O
mutations	O
were	O
more	O
frequent	O
in	O
MI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
(	O
6	O
/	O
14	O
,	O
42.8	O
%	O
)	O
than	O
in	O
MI	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
tumours	I-malignancy-type
(	O
5	O
/	O
44	O
,	O
11.3	O
%	O
)	O
(	O
p	O
=	O
0.017	O
)	O
.	O
Methylation	O
-	O
related	O
transitions	O
were	O
detected	O
in	O
five	O
of	O
the	O
six	O
MI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
tumours	I-malignancy-type
but	O
in	O
only	O
one	O
of	O
the	O
five	O
MI	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
carcinomas	I-malignancy-type
.	O
K-ras	O
mutation	O
was	O
identified	O
in	O
only	O
one	O
atypical	B-malignancy-type
EH	I-malignancy-type
(	O
1	O
/	O
22	O
,	O
4.5	O
%	O
)	O
;	O
in	O
this	O
case	O
,	O
the	O
EH	B-malignancy-type
co	O
-	O
existed	O
with	O
EC	B-malignancy-type
and	O
both	O
lesions	B-malignancy-type
exhibited	O
MI	O
.	O
The	O
results	O
support	O
a	O
close	O
relationship	O
between	O
K-ras	O
mutations	O
and	O
the	O
phenomenon	O
of	O
MI	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
frequent	O
occurrence	O
of	O
methylation	O
-	O
related	O
transitions	O
in	O
these	O
tumours	O
may	O
indicate	O
a	O
cause	O
-	O
effect	O
relationship	O
with	O
the	O
altered	O
methylation	O
status	O
which	O
has	O
been	O
described	O
in	O
association	O
with	O
MI	O
.	O
PMID	O
:	O
11180166	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncology	O
2001;60(	O
1	O
)	O
:81	O
-	O
7	O
Genetic	O
changes	O
in	O
contralateral	B-malignancy-type
bronchioloalveolar	I-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
lung	O
.	O
Shin	O
SW	O
,	O
Breathnach	O
OS	O
,	O
Linnoila	O
RI	O
,	O
Williams	O
J,	O
Gillespie	O
JW	O
,	O
Kelley	O
MJ	O
,	O
Johnson	O
BE.	O
Medicine	O
Branch	O
,	O
Division	O
of	O
Clinical	O
Sciences	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Md.	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
The	O
pattern	O
of	O
metastases	B-malignancy-type
and	O
recurrence	O
of	O
bronchioloalveolar	B-malignancy-type
carcinoma	I-malignancy-type
(	O
BAC	B-malignancy-type
)	O
differs	O
from	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
,	O
occurring	O
more	O
frequently	O
within	O
the	O
lung	O
without	O
extrapulmonary	O
involvement	O
.	O
Analyses	O
of	O
genetic	O
differences	O
of	O
contralateral	B-malignancy-type
BACs	I-malignancy-type
may	O
help	O
to	O
explain	O
these	O
clinical	O
differences	O
.	O
METHODS	O
:	O
We	O
compared	O
paired	O
tumors	O
from	O
5	O
patients	O
with	O
contralateral	B-malignancy-type
metachronous	I-malignancy-type
BACs	I-malignancy-type
for	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
6	O
chromosomal	O
arms	O
(	O
2q	O
,	O
3p	O
,	O
5q	O
,	O
9p	O
,	O
13q	O
and	O
17p	O
)	O
and	O
mutational	O
analysis	O
of	O
p53	O
and	O
K-ras	O
.	O
RESULTS	O
:	O
Two	O
patients	O
,	O
patients	O
1	O
and	O
2	O
,	O
had	O
discordant	O
patterns	O
of	O
LOH	O
on	O
2	O
and	O
3	O
of	O
the	O
chromosome	O
arms	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
patient	O
2	O
had	O
a	O
detectable	O
K-ras	O
mutation	O
in	O
his	O
initial	O
tumor	O
but	O
not	O
in	O
his	O
second	O
.	O
These	O
results	O
suggest	O
that	O
in	O
patients	O
1	O
and	O
2	O
,	O
the	O
contralateral	B-malignancy-type
tumors	I-malignancy-type
were	O
clonally	O
unrelated	O
.	O
Patient	O
3	O
had	O
no	O
mutations	O
in	O
the	O
K-ras	O
or	O
p53	O
gene	O
and	O
no	O
LOH	O
on	O
any	O
of	O
the	O
5	O
informative	O
chromosome	O
arms	O
.	O
Patient	O
4	O
had	O
LOH	O
of	O
9p	O
and	O
mutated	O
K-ras	O
in	O
both	O
the	O
first	O
and	O
the	O
second	O
tumor	O
,	O
with	O
a	O
mutation	O
in	O
the	O
p53	O
gene	O
in	O
the	O
first	O
but	O
not	O
in	O
the	O
second	O
tumor	O
.	O
Patient	O
5	O
had	O
LOH	O
of	O
17p	O
and	O
the	O
same	O
p53	O
mutations	O
in	O
both	O
the	O
first	O
and	O
the	O
second	O
tumor	O
,	O
with	O
a	O
mutation	O
of	O
K-ras	O
in	O
the	O
first	O
tumor	O
but	O
not	O
in	O
the	O
second	O
.	O
CONCLUSIONS	O
:	O
The	O
preponderance	O
of	O
evidence	O
suggests	O
that	O
in	O
patients	O
3	O
,	O
4	O
and	O
5	O
,	O
the	O
paired	O
tumors	O
were	O
clonally	O
related	O
.	O
The	O
different	O
patterns	O
of	O
LOH	O
and	O
mutations	O
in	O
clinically	O
similar	O
contralateral	B-malignancy-type
metachronous	I-malignancy-type
BACs	I-malignancy-type
provide	O
evidence	O
of	O
genetic	O
heterogeneity	O
in	O
the	O
tumors	O
of	O
this	O
patient	O
group	O
.	O
PMID	O
:	O
11150913	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2000	O
Nov;24(	O
11	O
)	O
:1501	O
-	O
10	O
Carcinoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
extrahepatic	O
bile	O
ducts	O
:	O
a	O
study	O
of	O
seven	O
cases	O
.	O
Maitra	O
A	O
,	O
Krueger	O
JE	O
,	O
Tascilar	O
M,	O
Offerhaus	O
GJ	O
,	O
Angeles	O
-	O
Angeles	O
A	O
,	O
Klimstra	O
DS	O
,	O
Hruban	O
RH	O
,	O
Albores	O
-	O
Saavedra	O
J.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
,	O
USA	O
.	O
The	O
authors	O
report	O
seven	O
patients	O
with	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
extrahepatic	O
bile	O
ducts	O
(	O
EHBDs	B-malignancy-type
)	O
.	O
All	O
patients	O
were	O
women	O
,	O
with	O
an	O
average	O
age	O
at	O
diagnosis	O
of	O
49.8	O
years	O
(	O
range	O
,	O
37	O
-	O
67	O
yrs	O
)	O
.	O
The	O
most	O
common	O
presenting	O
symptom	O
was	O
painless	O
jaundice	O
with	O
or	O
without	O
pruritus	O
.	O
Although	O
one	O
patient	O
had	O
peptic	O
ulcer	O
disease	O
before	O
the	O
onset	O
of	O
obstructive	O
jaundice	O
,	O
none	O
had	O
systemic	O
endocrine	O
manifestations	O
.	O
These	O
neoplasms	B-malignancy-type
were	O
most	O
often	O
located	O
in	O
the	O
common	O
bile	O
duct	O
.	O
Grossly	O
,	O
the	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
were	O
usually	O
nodular	O
and	O
poorly	O
demarcated	O
,	O
and	O
ranged	O
from	O
1.1	O
to	O
2.7	O
cm	O
in	O
size	O
.	O
Only	O
one	O
of	O
the	O
neoplasms	B-malignancy-type
was	O
polypoid	O
.	O
Microscopically	O
,	O
the	O
tumors	O
had	O
a	O
trabecular	O
or	O
nesting	O
pattern	O
with	O
occasional	O
tubule	O
formation	O
,	O
and	O
were	O
composed	O
of	O
relatively	O
small	O
cells	O
with	O
granular	O
chromatin	O
.	O
All	O
of	O
the	O
neoplasms	B-malignancy-type
expressed	O
chromogranin	O
and	O
two	O
expressed	O
synaptophysin	O
.	O
Three	O
expressed	O
serotonin	O
and	O
two	O
of	O
the	O
three	O
were	O
also	O
immunoreactive	O
for	O
pancreatic	O
polypeptide	O
or	O
somatostatin	O
.	O
Two	O
tumors	O
were	O
focally	O
positive	O
for	O
gastrin	O
and	O
one	O
of	O
these	O
two	O
tumors	O
was	O
also	O
positive	O
for	O
serotonin	O
and	O
pancreatic	O
polypeptide	O
.	O
All	O
seven	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
showed	O
no	O
immunoreactivity	O
for	O
p53	O
,	O
and	O
assays	O
for	O
p53	O
loss	O
of	O
heterozygosity	O
analysis	O
were	O
negative	O
in	O
two	O
,	O
suggesting	O
that	O
p53	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
EHBD	B-malignancy-type
carcinoids	I-malignancy-type
.	O
A	O
mutation	O
in	O
codon	O
12	O
of	O
K-ras	O
was	O
found	O
in	O
one	O
carcinoid	B-malignancy-type
tumor	I-malignancy-type
whereas	O
two	O
of	O
two	O
showed	O
immunoreactivity	O
for	O
Dpc4	O
protein	O
.	O
In	O
view	O
of	O
the	O
small	O
number	O
of	O
carcinoids	B-malignancy-type
studied	O
,	O
the	O
importance	O
of	O
these	O
findings	O
in	O
the	O
pathogenesis	O
of	O
these	O
tumors	O
is	O
unclear	O
.	O
Ultrastructural	O
examination	O
of	O
three	O
of	O
the	O
tumors	O
revealed	O
numerous	O
membrane	O
-	O
bound	O
,	O
round	O
neurosecretory	O
granules	O
.	O
Clinically	O
,	O
these	O
lesions	B-malignancy-type
had	O
an	O
indolent	O
course	O
.	O
Even	O
in	O
the	O
presence	O
of	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
(	O
noted	O
in	O
two	O
patients	O
)	O
,	O
all	O
of	O
the	O
patients	O
remained	O
disease	O
free	O
2	O
to	O
11	O
years	O
(	O
average	O
follow	O
up	O
,	O
6.6	O
yrs	O
)	O
after	O
segmental	O
resection	O
or	O
pancreaticoduodenectomy	O
(	O
Whipple	O
's	O
procedure	O
)	O
.	O
Because	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
EHBD	O
are	O
of	O
low	O
malignant	O
potential	O
,	O
they	O
should	O
be	O
separated	O
from	O
the	O
more	O
common	O
adenocarcinomas	B-malignancy-type
in	O
this	O
location	O
.	O
PMID	O
:	O
11075851	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2000	O
Mar;91(	O
3	O
)	O
:280	O
-	O
6	O
Microsatellite	O
instability	O
and	O
k-ras	O
,	O
p53	O
mutations	O
in	O
thyroid	B-malignancy-type
lymphoma	I-malignancy-type
.	O
Takakuwa	O
T	O
,	O
Hongyo	O
T	O
,	O
Syaifudin	O
M,	O
Kanno	O
H	O
,	O
Matsuzuka	O
F	O
,	O
Narabayashi	O
I	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Departments	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Osaka	O
565	O
-0871	O
,	O
Japan	O
.	O
Patho	O
-	O
epidemiological	O
studies	O
showed	O
that	O
thyroid	B-malignancy-type
lymphoma	I-malignancy-type
(	O
TL	B-malignancy-type
)	O
arises	O
in	O
inflammatory	O
lesions	O
of	O
chronic	O
lymphocytic	O
thyroiditis	O
(	O
CLTH	O
)	O
.	O
Replication	O
error	O
(	O
RER	O
)	O
is	O
found	O
in	O
inflammatory	O
lesions	O
and	O
associated	O
cancer	O
,	O
suggesting	O
that	O
chronic	O
inflammation	O
could	O
be	O
a	O
risk	O
factor	O
for	O
neoplastic	O
development	O
through	O
causing	O
RER	O
.	O
To	O
clarify	O
whether	O
RER	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
TL	O
,	O
we	O
examined	O
the	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
in	O
9	O
cases	O
with	O
CLTH	O
and	O
19	O
with	O
TL	O
,	O
including	O
10	O
diffuse	B-malignancy-type
large	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
DLBL	B-malignancy-type
)	O
,	O
4	O
follicle	B-malignancy-type
center	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
,	O
3	O
marginal	B-malignancy-type
zone	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
extranodal	I-malignancy-type
(	O
MALT	B-malignancy-type
)	O
type	B-malignancy-type
,	O
and	O
2	O
lymphoplasmacytic	B-malignancy-type
type	I-malignancy-type
.	O
Sixteen	O
distinct	O
microsatellite	O
repeats	O
were	O
analyzed	O
.	O
Mutations	O
of	O
p53	O
and	O
k-ras	O
genes	O
were	O
also	O
examined	O
.	O
When	O
alterations	O
at	O
2	O
or	O
more	O
microsatellite	O
loci	O
were	O
judged	O
as	O
positive	O
,	O
only	O
5	O
DLBL	B-malignancy-type
cases	O
exhibited	O
MSI	O
.	O
The	O
frequency	O
of	O
MSI	O
in	O
DLBL	B-malignancy-type
was	O
significantly	O
higher	O
than	O
that	O
in	O
other	O
types	O
of	O
TL	O
and	O
CLTH	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Four	O
of	O
19	O
cases	O
(	O
21.1	O
%	O
)	O
showed	O
point	O
mutation	O
of	O
the	O
k-ras	O
gene	O
.	O
The	O
k-ras	O
mutations	O
occurred	O
in	O
the	O
cases	O
with	O
DLBL	B-malignancy-type
with	O
RER	O
,	O
and	O
four	O
of	O
five	O
cases	O
with	O
RER	O
had	O
a	O
k-ras	O
mutation	O
,	O
indicating	O
a	O
close	O
association	O
between	O
RER	O
and	O
k-ras	O
mutation	O
.	O
p53	O
mutations	O
were	O
not	O
found	O
in	O
the	O
CLTH	O
.	O
Two	O
of	O
19	O
TL	O
cases	O
showed	O
mutations	O
of	O
p53	O
gene	O
.	O
There	O
was	O
no	O
significant	O
association	O
between	O
RER	O
and	O
p53	O
mutation	O
.	O
These	O
findings	O
indicate	O
that	O
genomic	O
instability	O
contributes	O
to	O
the	O
progression	O
of	O
TL	B-malignancy-type
from	O
low	O
grade	O
to	O
high	O
grade	O
,	O
but	O
not	O
to	O
the	O
development	O
of	O
low	O
grade	O
lymphoma	B-malignancy-type
in	O
CLTH	O
lesions	O
.	O
PMID	O
:	O
10760686	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
2000	O
Jan	O
15;95(	O
2	O
)	O
:646	O
-	O
50	O
N-RAS	O
gene	O
mutation	O
in	O
patients	O
with	O
aplastic	O
anemia	O
and	O
aplastic	O
anemia	O
/	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
during	O
evolution	O
to	O
clonal	O
disease	O
.	O
Mortazavi	O
Y	O
,	O
Tooze	O
JA	O
,	O
Gordon	O
-	O
Smith	O
EC	O
,	O
Rutherford	O
TR.	O
Department	O
of	O
Haematology	O
,	O
St.	O
George	O
's	O
Hospital	O
Medical	O
School	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Long	O
-	O
term	O
survivors	O
of	O
aplastic	O
anemia	O
(	O
AA	O
)	O
have	O
a	O
high	O
incidence	O
of	O
clonal	O
disorders	O
,	O
in	O
particular	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
(	O
PNH	O
)	O
,	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
,	O
and	O
acute	B-malignancy-type
nonlymphocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
To	O
investigate	O
the	O
potential	O
involvement	O
of	O
N-RAS	O
gene	O
mutations	O
in	O
the	O
predisposition	O
to	O
leukemic	O
evolution	O
,	O
a	O
subset	O
of	O
patients	O
at	O
potentially	O
increased	O
risk	O
for	O
clonal	O
disease	O
was	O
selected	O
based	O
on	O
evidence	O
of	O
existing	O
clonal	O
evolution	O
.	O
Nine	O
patients	O
showed	O
a	O
monoclonal	O
pattern	O
of	O
X-chromosome	O
inactivation	O
,	O
18	O
demonstrated	O
a	O
PNH	O
clone	O
,	O
and	O
in	O
3	O
MDS	B-malignancy-type
developed	O
during	O
the	O
course	O
of	O
this	O
study	O
.	O
No	O
mutations	O
were	O
detected	O
during	O
the	O
aplastic	O
phase	O
of	O
disease	O
;	O
2	O
of	O
3	O
patients	O
with	O
MDS	B-malignancy-type
after	O
AA	O
also	O
showed	O
no	O
mutations	O
.	O
However	O
,	O
in	O
1	O
patient	O
in	O
whom	O
the	O
disease	O
transformed	O
from	O
AA	O
/	O
PNH	O
to	O
MDS	B-malignancy-type
,	O
a	O
mutation	O
of	O
GGT	O
-->	O
GAT	O
at	O
N-RAS	O
codon	O
13	O
became	O
detectable	O
,	O
whereas	O
the	O
PNH	O
mutation	O
disappeared	O
.	O
The	O
authors	O
conclude	O
that	O
N-RAS	O
mutations	O
are	O
not	O
an	O
early	O
event	O
preceding	O
transformation	O
of	O
AA	O
or	O
AA	O
/	O
PNH	O
to	O
leukemia	B-malignancy-type
.	O
In	O
a	O
subset	O
of	O
patients	O
,	O
RAS	O
mutations	O
may	O
occur	O
at	O
the	O
time	O
of	O
evolution	O
to	O
MDS	B-malignancy-type
,	O
but	O
preexisting	O
RAS	O
mutations	O
do	O
not	O
explain	O
the	O
propensity	O
of	O
AA	O
to	O
leukemogenesis	O
.	O
Although	O
PNH	O
is	O
also	O
associated	O
with	O
leukemia	B-malignancy-type
,	O
this	O
may	O
arise	O
in	O
the	O
non	O
-	O
PNH	O
cells	O
,	O
indicating	O
that	O
PIG-A	O
gene	O
mutation	O
is	O
not	O
per	O
se	O
oncogenic	O
.	O
(	O
Blood.	O
2000	O
;	O
95	O
:	O
646	O
-	O
650	O
)	O
PMID	O
:	O
10627475	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
2000	O
Feb;27(	O
2	O
)	O
:202	O
-	O
8	O
Somatic	O
mutations	O
of	O
the	O
APC	O
,	O
KRAS	O
,	O
and	O
TP53	O
genes	O
in	O
nonpolypoid	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
.	O
van	O
Wyk	O
R,	O
Slezak	O
P	O
,	O
Hayes	O
VM	O
,	O
Buys	O
CH	O
,	O
Kotze	O
MJ	O
,	O
de	O
Jong	O
G	O
,	O
Rubio	O
C	O
,	O
Dolk	O
A	O
,	O
Jaramillo	O
E	O
,	O
Koizumi	O
K	O
,	O
Grobbelaar	O
JJ.	O
Division	O
of	O
Human	O
Genetics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Stellenbosch	O
,	O
South	O
Africa	O
.	O
Colorectal	B-malignancy-type
adenomas	I-malignancy-type
are	O
macroscopically	O
visible	O
morphological	O
changes	O
of	O
the	O
mucosa	O
that	O
can	O
develop	O
focal	B-malignancy-type
carcinoma	I-malignancy-type
in	O
the	O
absence	O
of	O
surgical	O
intervention	O
.	O
The	O
successive	O
molecular	O
changes	O
proposed	O
to	O
occur	O
at	O
different	O
stages	O
in	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
were	O
primarily	O
based	O
on	O
DNA	O
studies	O
of	O
exophytic	B-malignancy-type
,	I-malignancy-type
polypoid	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
adenomas	I-malignancy-type
.	O
Not	O
all	O
colorectal	B-malignancy-type
lesions	I-malignancy-type
,	O
however	O
,	O
display	O
an	O
exophytic	O
phenotype	O
and	O
a	O
presumed	O
distinct	O
colorectal	B-malignancy-type
neoplasm	I-malignancy-type
,	O
the	O
nonpolypoid	B-malignancy-type
adenoma	I-malignancy-type
,	O
was	O
subsequently	O
described	O
as	O
a	O
precursor	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
low	O
incidence	O
of	O
KRAS	O
mutations	O
in	O
nonpolypoid	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
reported	O
previously	O
suggested	O
a	O
different	O
genetic	O
basis	O
for	O
the	O
transformation	O
process	O
in	O
these	O
lesions	O
.	O
We	O
have	O
pursued	O
the	O
identification	O
of	O
genetic	O
changes	O
in	O
benign	B-malignancy-type
sporadic	I-malignancy-type
nonpolypoid	I-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
in	O
a	O
selected	O
Swedish	O
patient	O
group	O
with	O
no	O
family	O
history	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Mutation	O
screening	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
KRAS	O
,	O
and	O
TP53	O
genes	O
was	O
conducted	O
using	O
the	O
protein	O
truncation	O
test	O
,	O
heteroduplex	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
on	O
PCR	O
-	O
amplified	O
fragments	O
.	O
Fourteen	O
mutations	O
in	O
the	O
APC	O
gene	O
were	O
characterized	O
in	O
10	O
/	O
20	O
samples	O
.	O
Mutations	O
in	O
the	O
KRAS	O
and	O
TP53	O
genes	O
were	O
identified	O
in	O
3	O
/	O
57	O
and	O
4	O
/	O
51	O
adenomas	B-malignancy-type
,	O
respectively	O
.	O
The	O
mutation	O
frequencies	O
and	O
distribution	O
of	O
mutations	O
in	O
APC	O
correlate	O
with	O
published	O
data	O
on	O
exophytic	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
low	O
mutation	O
frequency	O
of	O
the	O
TP53	O
gene	O
is	O
consistent	O
with	O
the	O
benign	O
nature	O
of	O
the	O
research	O
material	O
.	O
KRAS	O
activation	O
(	O
an	O
early	O
event	O
in	O
polypoid	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
)	O
apparently	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
nonpolypoid	B-malignancy-type
adenoma	I-malignancy-type
development	O
but	O
may	O
result	O
in	O
the	O
development	O
of	O
a	O
polypoid	O
configuration	O
.	O
Genes	O
Chromosomes	O
Cancer	O
27	O
:	O
202	O
-	O
208	O
,	O
2000	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
10612810	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Growth	O
Differ	O
1999	O
Jun;10(	O
6)	O
:369	O
-	O
76	O
Beta	O
-	O
and	O
gamma	O
-	O
catenin	O
mutations	O
,	O
but	O
not	O
E-cadherin	O
inactivation	O
,	O
underlie	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancer	O
factor	O
transcriptional	O
deregulation	O
in	O
gastric	O
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Caca	O
K	O
,	O
Kolligs	O
FT	O
,	O
Ji	O
X	O
,	O
Hayes	O
M,	O
Qian	O
J,	O
Yahanda	O
A	O
,	O
Rimm	O
DL	O
,	O
Costa	O
J,	O
Fearon	O
ER	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
The	O
Cancer	O
Center	O
,	O
University	O
of	O
Michigan	O
Medical	O
School	O
,	O
Ann	O
Arbor	O
48109	O
,	O
USA	O
.	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
are	O
present	O
in	O
>	O
70	O
%	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
APC	O
protein	O
binds	O
to	O
beta-catenin	O
(	O
beta-cat	O
)	O
,	O
a	O
protein	O
first	O
identified	O
because	O
of	O
its	O
role	O
in	O
E-cadherin	O
(	O
E-cad	O
)	O
cell	O
adhesion	O
.	O
In	O
some	O
colon	B-malignancy-type
cancers	I-malignancy-type
lacking	O
APC	O
defects	O
,	O
mutations	O
in	O
presumptive	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
near	O
the	O
beta-cat	O
NH2	O
terminus	O
appear	O
to	O
render	O
beta-cat	O
resistant	O
to	O
regulation	O
by	O
APC	O
and	O
glycogen	O
synthase	O
kinase	O
3beta	O
.	O
In	O
cells	O
with	O
APC	O
or	O
beta-cat	O
defects	O
,	O
beta-cat	O
is	O
stabilized	O
and	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
activates	O
T-cell	O
factor	O
(	O
Tcf	O
)	O
/	O
lymphoid	O
enhancer	O
factor	O
(	O
Lef	O
)	O
transcription	O
factors	O
.	O
To	O
further	O
explore	O
the	O
role	O
of	O
APC	O
,	O
beta-cat	O
,	O
Tcf	O
,	O
and	O
E-cad	O
defects	O
in	O
gastrointestinal	B-malignancy-type
cancers	I-malignancy-type
,	O
we	O
assessed	O
gastric	B-malignancy-type
and	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
for	O
constitutive	O
Tcf	O
transcriptional	O
activity	O
(	O
CTTA	O
)	O
.	O
Two	O
of	O
four	O
gastric	B-malignancy-type
and	O
two	O
of	O
eight	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
lines	O
showed	O
CTTA	O
.	O
One	O
gastric	B-malignancy-type
and	O
one	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
had	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
phosphorylation	O
sites	O
of	O
beta-cat	O
.	O
The	O
other	O
gastric	B-malignancy-type
cancer	I-malignancy-type
with	O
CTTA	O
had	O
a	O
missense	O
mutation	O
at	O
serine	O
28	O
of	O
gamma-cat	O
,	O
a	O
potential	O
phosphorylation	O
site	O
in	O
this	O
beta-cat	O
-	O
related	O
protein	O
.	O
Although	O
E-cad	O
is	O
an	O
important	O
binding	O
partner	O
for	O
beta-cat	O
and	O
gamma-cat	O
,	O
E-cad	O
inactivation	O
did	O
not	O
result	O
in	O
CTTA	O
.	O
The	O
beta-cat	O
and	O
gamma-cat	O
mutant	O
proteins	O
identified	O
in	O
our	O
studies	O
strongly	O
activated	O
Tcf	O
transcription	O
in	O
vitro	O
,	O
whereas	O
beta-cat	O
mutant	O
proteins	O
with	O
large	O
NH2	O
-	O
terminal	O
deletions	O
had	O
only	O
modest	O
effects	O
on	O
Tcf	O
.	O
Our	O
results	O
suggest	O
a	O
role	O
for	O
Tcf	O
deregulation	O
in	O
gastric	B-malignancy-type
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
resulting	O
from	O
beta-cat	O
and	O
gamma-cat	O
mutations	O
in	O
some	O
cases	O
and	O
,	O
in	O
others	O
,	O
from	O
yet	O
to	O
be	O
defined	O
defects	O
.	O
Furthermore	O
,	O
these	O
data	O
imply	O
that	O
the	O
consequences	O
of	O
APC	O
and	O
beta-cat	O
mutations	O
are	O
distinct	O
from	O
the	O
effects	O
of	O
E-cad	O
inactivation	O
.	O
PMID	O
:	O
10392898	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Mar	O
11	O
;18(	O
10	O
)	O
:1897	O
-	O
902	O
Mutations	O
of	O
c-kit	O
JM	O
domain	O
are	O
found	O
in	O
a	O
minority	O
of	O
human	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Moskaluk	O
CA	O
,	O
Tian	O
Q	O
,	O
Marshall	O
CR	O
,	O
Rumpel	O
CA	O
,	O
Franquemont	O
DW	O
,	O
Frierson	O
HF	O
Jr.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Virginia	O
,	O
Charlottesville	O
22908	O
,	O
USA	O
.	O
The	O
c-kit	O
gene	O
encodes	O
a	O
transmembrane	O
receptor	O
kinase	O
(	O
KIT	O
)	O
which	O
is	O
expressed	O
in	O
the	O
majority	O
of	O
human	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	I-malignancy-type
GISTs	B-malignancy-type
)	O
,	O
a	O
subtype	O
of	O
gastrointestinal	B-malignancy-type
mesenchymal	I-malignancy-type
neoplasms	I-malignancy-type
.	O
A	O
previous	O
study	O
identified	O
mutations	O
in	O
the	O
juxtamembrane	O
(	O
JM	O
)	O
domain	O
of	O
c-kit	O
in	O
five	O
of	O
six	O
GISTs	B-malignancy-type
(	O
Science	O
279	O
:	O
577	O
,	O
1998	O
)	O
.	O
To	O
better	O
define	O
the	O
frequency	O
and	O
spectrum	O
of	O
c-kit	O
gene	O
mutations	O
in	O
mesenchymal	B-malignancy-type
neoplasms	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
GI	I-malignancy-type
tract	I-malignancy-type
that	O
had	O
been	O
characterized	O
for	O
KIT	O
protein	O
expression	O
,	O
we	O
examined	O
archived	O
tissue	O
samples	O
for	O
mutations	O
in	O
the	O
JM	O
domain	O
by	O
PCR	O
amplification	O
and	O
DNA	O
sequencing	O
.	O
c-kit	O
JM	O
domain	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
56	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
(	O
46	O
GISTs	B-malignancy-type
,	O
eight	O
leiomyomas	B-malignancy-type
,	O
two	O
leiomyosarcomas	B-malignancy-type
)	O
and	O
occurred	O
exclusively	O
in	O
GISTs	B-malignancy-type
(	O
21	O
%	O
)	O
.	O
Seven	O
of	O
the	O
nine	O
mutations	O
consisted	O
of	O
intragenic	O
deletions	O
of	O
one	O
to	O
19	O
codons	O
.	O
There	O
was	O
one	O
insertion	O
mutation	O
that	O
added	O
12	O
codons	O
and	O
one	O
missense	O
mutation	O
(	O
Val	O
560	O
Asp	O
)	O
.	O
None	O
of	O
the	O
mutations	O
disrupted	O
the	O
downstream	O
reading	O
frame	O
of	O
the	O
gene	O
.	O
The	O
single	O
missense	O
mutation	O
(	O
Val	O
560	O
Asp	O
)	O
is	O
very	O
similar	O
to	O
the	O
only	O
other	O
missense	O
mutation	O
reported	O
in	O
GISTs	B-malignancy-type
(	O
Val	O
599	O
Asp	O
)	O
.	O
Of	O
the	O
46	O
GISTs	B-malignancy-type
,	O
43	O
were	O
strongly	O
positive	O
for	O
KIT	O
protein	O
expression	O
and	O
negative	O
for	O
diffuse	O
expression	O
of	O
desmin	O
.	O
Neither	O
KIT	O
expression	O
nor	O
gene	O
mutations	O
were	O
found	O
in	O
gastrointestinal	B-malignancy-type
leiomyomas	I-malignancy-type
or	O
leiomyosarcomas	B-malignancy-type
.	O
We	O
conclude	O
that	O
mutation	O
of	O
the	O
c-kit	O
JM	O
domain	O
does	O
not	O
occur	O
in	O
gastrointestinal	B-malignancy-type
mesenchymal	I-malignancy-type
neoplasms	I-malignancy-type
with	O
well	O
developed	O
-	O
smooth	O
muscle	O
differentiation	O
,	O
and	O
is	O
restricted	O
to	O
GISTs	B-malignancy-type
.	O
However	O
,	O
since	O
these	O
mutations	O
are	O
only	O
found	O
in	O
a	O
minority	O
of	O
GISTs	B-malignancy-type
,	O
further	O
investigation	O
into	O
the	O
mechanisms	O
of	O
c-kit	O
gene	O
activation	O
in	O
this	O
group	O
of	O
neoplasms	B-malignancy-type
is	O
warranted	O
.	O
PMID	O
:	O
10086344	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1998	O
Mar;89(	O
3	O
)	O
:299	O
-	O
306	O
Genetic	O
alterations	O
of	O
mixed	B-malignancy-type
hyperplastic	I-malignancy-type
adenomatous	I-malignancy-type
polyps	I-malignancy-type
in	O
the	O
colon	O
and	O
rectum	O
.	O
Uchida	O
H	O
,	O
Ando	O
H	O
,	O
Maruyama	O
K	O
,	O
Kobayashi	O
H	O
,	O
Toda	O
H	O
,	O
Ogawa	O
H	O
,	O
Ozawa	O
T	O
,	O
Matsuda	O
Y	O
,	O
Sugimura	O
H	O
,	O
Kanno	O
T	O
,	O
Baba	O
S.	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Hamamatsu	O
University	O
School	O
of	O
Medicine	O
.	O
Some	O
mixed	B-malignancy-type
hyperplastic	I-malignancy-type
adenomatous	I-malignancy-type
polyps	I-malignancy-type
(	O
MHAPs	B-malignancy-type
)	O
contain	O
dysplastic	B-malignancy-type
lesions	I-malignancy-type
or	O
even	O
carcinomas	B-malignancy-type
.	O
These	O
polyps	B-malignancy-type
are	O
considered	O
to	O
be	O
different	O
from	O
ordinary	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
and	O
may	O
have	O
a	O
preneoplastic	O
potential	O
.	O
We	O
investigated	O
APC	O
and	O
K-ras	O
mutations	O
in	O
MHAPs	B-malignancy-type
of	O
the	O
colon	O
and	O
rectum	O
,	O
and	O
also	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
to	O
identify	O
molecular	O
differences	O
between	O
MHAPs	B-malignancy-type
,	O
adenomas	B-malignancy-type
and	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
,	O
using	O
direct	O
sequencing	O
of	O
mutation	O
cluster	O
regions	O
(	O
MCR	O
)	O
in	O
APC	O
and	O
K-ras	O
.	O
No	O
APC	O
mutations	O
were	O
identified	O
in	O
12	O
MHAPs	B-malignancy-type
and	O
8	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
,	O
whereas	O
10	O
of	O
27	O
(	O
37.0	O
%	O
)	O
adenomas	B-malignancy-type
showed	O
somatic	O
mutations	O
.	O
K-ras	O
mutations	O
were	O
identified	O
in	O
one	O
of	O
12	O
(	O
8.3	O
%	O
)	O
MHAPs	B-malignancy-type
,	O
one	O
of	O
8	O
(	O
12.5	O
%	O
)	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
,	O
and	O
10	O
of	O
27	O
(	O
37.0	O
%	O
)	O
adenomas	B-malignancy-type
.	O
p53	O
mutation	O
was	O
found	O
in	O
a	O
carcinoma	B-malignancy-type
arising	O
in	O
an	O
MHAP	B-malignancy-type
.	O
Mutations	O
other	O
than	O
APC	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
MHAPs	B-malignancy-type
.	O
PMID	O
:	O
9600124	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
Aug;161(	O
2	O
)	O
:611	O
-	O
8	O
Inverse	O
relationship	O
between	O
APC	O
gene	O
mutation	O
in	O
gastric	B-malignancy-type
adenomas	I-malignancy-type
and	O
development	O
of	O
adenocarcinoma	B-malignancy-type
.	O
Lee	O
JH	O
,	O
Abraham	O
SC	O
,	O
Kim	O
HS	O
,	O
Nam	O
JH	O
,	O
Choi	O
C	O
,	O
Lee	O
MC	O
,	O
Park	O
CS	O
,	O
Juhng	O
SW	O
,	O
Rashid	O
A	O
,	O
Hamilton	O
SR	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
MD	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
Gastric	B-malignancy-type
cancer	I-malignancy-type
is	O
common	O
among	O
the	O
world	O
,	O
but	O
genetic	O
mechanisms	O
of	O
gastric	O
carcinogenesis	O
are	O
not	O
well	O
understood	O
.	O
Gastric	B-malignancy-type
polypoid	I-malignancy-type
adenomas	I-malignancy-type
and	O
flat	B-malignancy-type
dysplasias	I-malignancy-type
are	O
regarded	O
as	O
precursor	O
lesions	O
.	O
However	O
,	O
a	O
detailed	O
molecular	O
study	O
of	O
these	O
lesions	B-malignancy-type
has	O
not	O
been	O
done	O
to	O
determine	O
their	O
role	O
as	O
precancerous	O
lesions	O
.	O
We	O
investigated	O
mutations	O
of	O
the	O
APC	O
,	O
beta-catenin	O
,	O
and	O
K-ras	O
genes	O
,	O
and	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
status	O
in	O
35	O
adenomas	B-malignancy-type
and	O
47	O
flat	B-malignancy-type
dysplasias	I-malignancy-type
without	I-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
35	O
adenomas	B-malignancy-type
/	O
dysplasias	B-malignancy-type
associated	O
with	O
adenocarcinomas	B-malignancy-type
,	O
and	O
39	O
adenocarcinomas	B-malignancy-type
(	O
20	O
diffuse	B-malignancy-type
type	I-malignancy-type
and	O
19	O
intestinal	B-malignancy-type
type	I-malignancy-type
)	O
.	O
Somatic	O
APC	O
gene	O
mutations	O
were	O
identified	O
in	O
76	O
%	O
(	O
59	O
of	O
78	O
)	O
of	O
adenomas	O
or	O
flat	B-malignancy-type
dysplasias	I-malignancy-type
without	O
associated	O
adenocarcinoma	B-malignancy-type
,	O
but	O
in	O
only	O
3	O
%	O
(	O
1	O
of	O
30	O
)	O
of	O
adenomas	B-malignancy-type
/	O
dysplasias	B-malignancy-type
associated	B-malignancy-type
with	I-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
and	O
in	O
only	O
4	O
%	O
(	O
3	O
of	O
69	O
)	O
of	O
adenocarcinomas	B-malignancy-type
(	O
P	O
<	O
0.000001	O
)	O
.	O
No	O
mutations	O
of	O
beta-catenin	O
were	O
found	O
in	O
adenocarcinomas	B-malignancy-type
,	O
or	O
adenomas	B-malignancy-type
/	O
dysplasia	B-malignancy-type
without	O
APC	O
mutation	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
5	O
%	O
(	O
4	O
of	O
82	O
)	O
of	O
gastric	B-malignancy-type
adenomas	I-malignancy-type
/	O
dysplasia	B-malignancy-type
without	O
carcinoma	B-malignancy-type
,	O
3	O
%	O
(	O
1	O
of	O
39	O
)	O
of	O
adenocarcinomas	B-malignancy-type
without	O
associated	O
adenoma	B-malignancy-type
/	O
dysplasia	B-malignancy-type
,	O
and	O
not	O
in	O
32	O
adenocarcinomas	B-malignancy-type
with	O
associated	O
adenoma	B-malignancy-type
/	O
dysplasia	B-malignancy-type
.	O
High	O
level	O
of	O
MSI	O
(	O
MSI-H	O
)	O
was	O
more	O
frequent	O
in	O
gastric	B-malignancy-type
adenoma	I-malignancy-type
/	O
dysplasia	B-malignancy-type
associated	O
with	O
carcinoma	B-malignancy-type
(	O
17	O
%	O
,	O
6	O
of	O
35	O
)	O
than	O
in	O
adenomas	B-malignancy-type
/	O
dysplasia	B-malignancy-type
without	O
carcinoma	B-malignancy-type
(	O
3	O
%	O
,	O
2	O
of	O
75	O
;	O
P	O
=	O
0.01	O
)	O
.	O
MSI-H	O
was	O
also	O
more	O
frequent	O
in	O
intestinal	B-malignancy-type
type	I-malignancy-type
adenocarcinoma	I-malignancy-type
(	O
20	O
%	O
,	O
11	O
of	O
54	O
)	O
than	O
in	O
diffuse	B-malignancy-type
type	I-malignancy-type
(	O
0	O
%	O
,	O
0	O
of	O
20	O
;	O
P	O
=	O
0.03	O
)	O
.	O
APC	O
gene	O
mutations	O
were	O
present	O
in	O
six	O
of	O
nine	O
(	O
67	O
%	O
)	O
of	O
gastric	B-malignancy-type
adenomas	I-malignancy-type
/	O
dysplasias	B-malignancy-type
with	O
low	O
level	O
of	O
MSI	O
,	O
but	O
in	O
none	O
of	O
the	O
eight	O
adenomas	B-malignancy-type
/	O
dysplasia	B-malignancy-type
with	O
MSI-H	O
phenotype	O
(	O
P	O
=	O
0.009	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
somatic	O
mutation	O
of	O
the	O
APC	O
gene	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gastric	B-malignancy-type
adenoma	I-malignancy-type
and	O
dysplasia	B-malignancy-type
but	O
has	O
a	O
limited	O
role	O
in	O
neoplastic	O
progression	O
to	O
adenocarcinoma	B-malignancy-type
.	O
Gastric	B-malignancy-type
adenomas	I-malignancy-type
or	O
dysplasias	B-malignancy-type
without	O
APC	O
mutations	O
but	O
with	O
or	O
without	O
MSI	O
may	O
have	O
a	O
different	O
biological	O
behavior	O
,	O
and	O
are	O
precursors	O
of	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
of	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
PMID	O
:	O
12163385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prostate	O
1997	O
Jan	O
1;30(	O
1	O
)	O
:53	O
-	O
7	O
Comparison	O
of	O
ras	O
activation	O
in	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
in	O
Japanese	O
and	O
American	O
men	O
.	O
Konishi	O
N	O
,	O
Hiasa	O
Y	O
,	O
Tsuzuki	O
T	O
,	O
Tao	O
M,	O
Enomoto	O
T	O
,	O
Miller	O
GJ.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Comparative	O
studies	O
of	O
point	O
mutations	O
in	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
-	O
ras	O
oncogenes	O
were	O
performed	O
on	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
from	O
Japanese	O
and	O
American	O
patients	O
to	O
clarify	O
the	O
racial	O
difference	O
.	O
METHODS	O
:	O
We	O
probed	O
for	O
mutations	O
in	O
70	O
Japanese	O
and	O
31	O
American	O
specimens	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
immunohistochemistry	O
for	O
ras	O
p21	O
.	O
RESULTS	O
:	O
Within	O
the	O
70	O
Japanese	O
specimens	O
,	O
eight	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
(	O
five	O
GGT	O
-->	O
GTT	O
transversions	O
and	O
three	O
CGT	O
-->	O
GAT	O
transitions	O
)	O
and	O
one	O
mutation	O
in	O
codon	O
12	O
of	O
the	O
N-ras	O
gene	O
(	O
a	O
GGT	O
-->	O
GTT	O
transversion	O
)	O
were	O
confirmed	O
,	O
whereas	O
the	O
American	O
samples	O
yielded	O
only	O
one	O
definable	O
mutation	O
,	O
a	O
GGT	O
-->	O
GAT	O
transition	O
,	O
in	O
codon	O
12	O
of	O
K-ras	O
.	O
CONCLUSIONS	O
:	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
clinical	O
carcinoma	B-malignancy-type
in	O
Japanese	O
men	O
was	O
higher	O
than	O
that	O
in	O
American	O
men	O
.	O
It	O
is	O
suggested	O
that	O
there	O
may	O
be	O
fundamental	O
differences	O
in	O
the	O
etiology	O
of	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
in	O
Japan	O
and	O
the	O
United	O
States	O
,	O
perhaps	O
based	O
on	O
genetics	O
and/or	O
environmental	O
factors	O
.	O
PMID	O
:	O
9018336	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1997	O
Jan;15(	O
1	O
)	O
:285	O
-	O
91	O
Mutational	O
activation	O
of	O
the	O
K-ras	O
oncogene	O
and	O
the	O
effect	O
of	O
chemotherapy	O
in	O
advanced	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
:	O
a	O
prospective	O
study	O
.	O
Rodenhuis	O
S,	O
Boerrigter	O
L,	O
Top	O
B	O
,	O
Slebos	O
RJ	O
,	O
Mooi	O
WJ	O
,	O
van't	O
Veer	O
L,	O
van	O
Zandwijk	O
N.	O
Division	O
of	O
Medical	O
Oncology	O
,	O
The	O
Netherlands	O
Cancer	O
Institute	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
sroden@nki	O
.nl	O
PURPOSE	O
:	O
To	O
determine	O
whether	O
the	O
clinical	O
course	O
and	O
the	O
response	O
to	O
chemotherapy	O
of	O
patients	O
with	O
advanced	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
depends	O
on	O
the	O
presence	O
or	O
absence	O
of	O
a	O
ras	O
mutation	O
in	O
the	O
tumor	O
.	O
Mutational	O
activation	O
of	O
K-ras	O
is	O
a	O
strong	O
adverse	O
prognostic	O
factor	O
in	O
stage	O
I	O
or	O
II	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
laboratory	O
studies	O
have	O
suggested	O
that	O
ras	O
mutations	O
lead	O
to	O
resistance	O
against	O
ionizing	O
radiation	O
and	O
chemotherapy	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
advanced	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
with	O
measurable	O
or	O
assessable	O
disease	O
received	O
chemotherapy	O
with	O
mesna	O
,	O
ifosfamide	O
,	O
carboplatin	O
,	O
and	O
etoposide	O
(	O
MICE	O
)	O
.	O
Archival	O
biopsies	O
,	O
fresh	O
biopsies	O
,	O
or	O
fine	O
-	O
needle	O
aspirations	O
were	O
tested	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
.	O
Associations	O
of	O
ras	O
mutations	O
with	O
clinical	O
characteristics	O
,	O
response	O
to	O
chemotherapy	O
,	O
and	O
survival	O
were	O
studied	O
.	O
RESULTS	O
:	O
The	O
presence	O
or	O
absence	O
of	O
ras	O
gene	O
mutations	O
could	O
be	O
established	O
in	O
69	O
of	O
83	O
patients	O
(	O
83	O
%	O
)	O
.	O
A	O
total	O
of	O
261	O
courses	O
of	O
MICE	O
were	O
administered	O
to	O
62	O
informative	O
patients	O
,	O
16	O
of	O
whom	O
were	O
shown	O
to	O
have	O
a	O
K-ras	O
mutation	O
-	O
positive	O
tumor	O
.	O
The	O
frequency	O
of	O
mutations	O
(	O
26	O
%	O
)	O
and	O
the	O
type	O
of	O
mutations	O
closely	O
matched	O
the	O
pattern	O
we	O
have	O
previously	O
reported	O
in	O
operable	O
disease	O
.	O
Patients	O
with	O
a	O
ras	O
mutation	O
in	O
their	O
tumor	O
were	O
more	O
likely	O
to	O
have	O
a	O
close	O
relative	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
other	O
clinical	O
characteristics	O
,	O
such	O
as	O
pattern	O
of	O
metastases	B-malignancy-type
,	O
response	O
,	O
and	O
survival	O
,	O
were	O
similar	O
between	O
the	O
ras	O
mutation	O
-	O
positive	O
and	O
ras	O
mutation	O
-	O
negative	O
groups	O
.	O
CONCLUSION	O
:	O
Patients	O
with	O
advanced	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
who	O
harbor	O
a	O
ras	O
mutation	O
may	O
have	O
major	O
responses	O
to	O
chemotherapy	O
and	O
have	O
similar	O
progression	O
-	O
free	O
and	O
overall	O
survival	O
as	O
patients	O
with	O
ras	O
mutation	O
-	O
negative	O
tumors	O
.	O
K-ras	O
mutations	O
may	O
represent	O
one	O
of	O
several	O
ways	O
in	O
which	O
early	O
tumors	O
are	O
enabled	O
to	O
metastasize	O
to	O
distant	O
sites	O
.	O
PMID	O
:	O
8996154	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
1996	O
Dec	O
20	O
;271(	O
51	O
)	O
:32491	O
-	O
4	O
Biochemical	O
characterization	O
of	O
a	O
novel	O
KRAS	O
insertion	O
mutation	O
from	O
a	O
human	O
leukemia	B-malignancy-type
.	O
Bollag	O
G	O
,	O
Adler	O
F	O
,	O
elMasry	O
N	O
,	O
McCabe	O
PC	O
,	O
Conner	O
E	O
Jr	O
,	O
Thompson	O
P	O
,	O
McCormick	O
F	O
,	O
Shannon	O
K.	O
ONYX	O
Pharmaceuticals	O
,	O
Richmond	O
,	O
California	O
94806	O
,	O
USA	O
.	O
bollag@macgate	O
.onyx	O
-	O
pharm	O
.com	O
A	O
novel	O
alteration	O
in	O
exon	O
1	O
of	O
KRAS	O
was	O
detected	O
by	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
DNA	O
amplified	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
myeloid	B-malignancy-type
leukemia	I-malignancy-type
.	O
Sequencing	O
of	O
this	O
mutant	O
allele	O
revealed	O
an	O
insertion	O
of	O
three	O
nucleotides	O
between	O
codons	O
10	O
and	O
11	O
resulting	O
in	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
glycine	O
.	O
Expression	O
of	O
the	O
mutant	O
protein	O
in	O
NIH	O
3T3	O
cells	O
caused	O
cellular	O
transformation	O
,	O
and	O
expression	O
in	O
COS	O
cells	O
activated	O
the	O
Ras	O
-	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O
Surprisingly	O
,	O
Ras	O
.	O
GTP	O
levels	O
measured	O
in	O
COS	O
cells	O
established	O
that	O
this	O
novel	O
mutant	O
accumulates	O
to	O
90	O
%	O
in	O
the	O
GTP	O
state	O
,	O
considerably	O
higher	O
than	O
a	O
residue	O
12	O
mutant	O
.	O
Biochemical	O
analysis	O
confirmed	O
that	O
the	O
higher	O
Ras	O
.	O
GTP	O
levels	O
correspond	O
to	O
a	O
dramatic	O
decrease	O
in	O
intrinsic	O
GTP	O
hydrolysis	O
as	O
well	O
as	O
resistance	O
to	O
GTPase	O
-	O
activating	O
proteins	O
.	O
This	O
mutation	O
is	O
the	O
first	O
dominant	O
Ras	O
mutation	O
found	O
in	O
human	O
cancer	O
that	O
does	O
not	O
involve	O
residues	O
12	O
,	O
13	O
,	O
or	O
61	O
,	O
and	O
its	O
biochemical	O
properties	O
should	O
help	O
elucidate	O
the	O
mechanism	O
of	O
oncogenic	O
activation	O
.	O
PMID	O
:	O
8955068	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Oral	O
Pathol	O
Med	O
1996	O
May	O
;25(	O
5	O
)	O
:232	O
-	O
8	O
Alterations	O
of	O
p16	O
/	O
CDKN2	O
,	O
p53	O
and	O
ras	O
genes	O
in	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
premalignant	B-malignancy-type
lesions	I-malignancy-type
.	O
Matsuda	O
H	O
,	O
Konishi	O
N	O
,	O
Hiasa	O
Y	O
,	O
Hayashi	O
I	O
,	O
Tsuzuki	O
T	O
,	O
Tao	O
M,	O
Kitahori	O
Y	O
,	O
Yoshioka	O
N	O
,	O
Kirita	O
T	O
,	O
Sugimura	O
M.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Japan	O
.	O
Exons	O
1	O
-	O
3	O
of	O
the	O
p16	O
/	O
CDKN2	O
gene	O
,	O
exons	O
4	O
-	O
9	O
of	O
the	O
p53	O
gene	O
and	O
exons	O
1	O
and	O
2	O
of	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
were	O
screened	O
for	O
mutations	O
by	O
a	O
combination	O
of	O
immunohistochemistry	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analyses	O
of	O
polymerase	O
chain	O
reaction	O
products	O
from	O
human	O
surgical	O
samples	O
of	O
both	O
frank	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
premalignant	B-malignancy-type
lesions	I-malignancy-type
.	O
The	O
samples	O
included	O
20	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
10	O
epithelial	B-malignancy-type
dysplasias	I-malignancy-type
and	O
10	O
epithelial	B-malignancy-type
hyperplasias	I-malignancy-type
.	O
No	O
identifiable	O
gene	O
mutations	O
were	O
detected	O
in	O
any	O
of	O
the	O
dysplasias	B-malignancy-type
or	O
hyperplasias	B-malignancy-type
,	O
while	O
2	O
(	O
10	O
%	O
)	O
deletions	O
and	O
2	O
(	O
10	O
%	O
)	O
mutations	O
of	O
p16	O
/	O
CDKN2	O
,	O
along	O
with	O
5	O
(	O
25	O
%	O
)	O
p53	O
mutations	O
were	O
found	O
in	O
the	O
advanced	O
carcinomas	B-malignancy-type
,	O
yielding	O
characteristic	O
p16	O
/	O
CDKN2	O
and	O
p53	O
changes	O
.	O
A	O
mutation	O
in	O
the	O
K-ras	O
gene	O
was	O
found	O
in	O
single	O
carcinoma	B-malignancy-type
and	O
dysplastic	B-malignancy-type
samples	O
.	O
From	O
the	O
data	O
,	O
it	O
can	O
be	O
argued	O
that	O
p16	O
/	O
CDKN2	O
and	O
p53	O
mutations	O
are	O
relatively	O
late	O
occurrences	O
in	O
human	O
oral	O
tumorigenesis	O
and	O
that	O
genetic	O
alterations	O
of	O
the	O
ras	O
genes	O
may	O
not	O
play	O
a	O
significant	O
role	O
in	O
squamous	B-malignancy-type
neoplasia	I-malignancy-type
.	O
PMID	O
:	O
8835820	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
1996	O
Jul;62(	O
1	O
)	O
:49	O
-	O
54	O
Expression	O
and	O
mutation	O
of	O
H-ras	O
in	O
uterine	B-malignancy-type
cervical	I-malignancy-type
cancer	I-malignancy-type
.	O
Lee	O
JH	O
,	O
Lee	O
SK	O
,	O
Yang	O
MH	O
,	O
Ahmed	O
MM	O
,	O
Mohiuddin	O
M,	O
Lee	O
EY	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Medicine	O
,	O
Kyang	O
Hee	O
University	O
,	O
Seoul	O
,	O
Korea	O
.	O
In	O
cervical	B-malignancy-type
cancer	I-malignancy-type
,	O
abnormalities	O
of	O
ras	O
genes	O
have	O
not	O
been	O
fully	O
investigated	O
.	O
We	O
studied	O
the	O
expression	O
and	O
mutation	O
of	O
H-ras	O
oncogene	O
in	O
cervical	B-malignancy-type
cancer	I-malignancy-type
to	O
investigate	O
their	O
relationship	O
and	O
usefulness	O
as	O
an	O
independent	O
prognostic	O
indicator	O
.	O
Twenty-seven	O
paraffin	O
-	O
embedded	O
resection	O
specimens	O
of	O
cervical	B-malignancy-type
cancer	I-malignancy-type
(	O
21	O
squamous	B-malignancy-type
,	O
3	O
adeno	B-malignancy-type
,	O
2	O
adenosquamous	B-malignancy-type
,	O
and	O
1	O
small	B-malignancy-type
cell	I-malignancy-type
)	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
a	O
mAb	O
H-ras	O
p21	O
and	O
by	O
PCR	O
and	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
using	O
H-ras	O
codon	O
12	O
and	O
61	O
amplimers	O
and	O
oligonucleotide	O
probes	O
.	O
A	O
strong	O
immunoreaction	O
was	O
noted	O
in	O
10	O
cases	O
(	O
37	O
%	O
)	O
and	O
weak	O
immunoreaction	O
in	O
an	O
additional	O
6	O
cases	O
(	O
22	O
%	O
)	O
.	O
H-ras	O
codon	O
12	O
mutations	O
were	O
detected	O
in	O
6	O
of	O
27	O
cases	O
(	O
22	O
%	O
)	O
and	O
all	O
of	O
the	O
mutations	O
were	O
guanine	O
to	O
adenine	O
transitions	O
.	O
There	O
was	O
no	O
mutation	O
in	O
codon	O
61	O
.	O
Cases	O
with	O
codon	O
12	O
mutations	O
included	O
all	O
3	O
squamous	B-malignancy-type
,	O
2	O
adeno	B-malignancy-type
,	O
and	O
I	O
adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Only	O
3	O
of	O
16	O
(	O
19	O
%	O
)	O
cases	O
with	O
positive	O
staining	O
and	O
3	O
of	O
11	O
(	O
27	O
%	O
)	O
cases	O
with	O
negative	O
staining	O
showed	O
mutations	O
.	O
No	O
correlation	O
was	O
found	O
between	O
ras	O
gene	O
alterations	O
and	O
patient	O
survival	O
time	O
.	O
Our	O
findings	O
indicate	O
that	O
expression	O
and	O
mutation	O
of	O
H-ras	O
oncogene	O
occur	O
in	O
cervical	B-malignancy-type
cancer	I-malignancy-type
but	O
their	O
determination	O
adds	O
no	O
useful	O
prognostic	O
information	O
.	O
PMID	O
:	O
8690291	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Endocrinol	O
1996	O
Feb;134(	O
2	O
)	O
:177	O
-	O
83	O
Low	O
frequency	O
of	O
p53	O
mutations	O
in	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
;	O
p53	O
and	O
Ras	O
mutation	O
in	O
two	O
out	O
of	O
fifty-six	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
.	O
Salvatore	O
D	O
,	O
Celetti	O
A	O
,	O
Fabien	O
N	O
,	O
Paulin	O
C	O
,	O
Martelli	O
ML	O
,	O
Battaglia	O
C	O
,	O
Califano	O
D	O
,	O
Monaco	O
C	O
,	O
Viglietto	O
G	O
,	O
Santoro	O
M,	O
Fusco	O
A.	O
Cetro	O
di	O
Endocrinologia	O
ed	O
Oncologia	O
Sperimentale	O
del	O
CNR	O
,	O
Facolta	O
di	O
Medicina	O
e	O
Chirurgia	O
,	O
Universita	O
di	O
Napoli	O
,	O
Naples	O
,	O
Italy	O
.	O
OBJECTIVE	O
:	O
p53	O
is	O
a	O
well	O
-	O
known	O
nuclear	O
phosphoprotein	O
encoded	O
by	O
a	O
suppressor	O
gene	O
know	O
to	O
be	O
mutated	O
in	O
various	O
kinds	O
of	O
human	O
tumours	O
.	O
A	O
relationship	O
between	O
p53	O
gene	O
mutation	O
and	O
tumour	O
progression	O
seems	O
to	O
be	O
a	O
common	O
feature	O
of	O
several	O
neoplasias	B-malignancy-type
.	O
DESIGN	O
:	O
In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
p53	O
mutations	O
in	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
DNA	O
samples	O
derived	O
from	O
fifty-six	O
neoplastic	O
tissues	O
,	O
ranging	O
from	O
benign	B-malignancy-type
adenomas	I-malignancy-type
to	O
undifferentiated	B-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
examined	O
for	O
the	O
presence	O
of	O
p53	O
gene	O
mutations	O
.	O
METHODS	O
:	O
The	O
analysis	O
has	O
been	O
conducted	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
the	O
exons	O
5	O
-	O
9	O
of	O
the	O
p53	O
gene	O
followed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
sequence	O
analyses	O
.	O
RESULTS	O
:	O
One	O
anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
and	O
one	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
showed	O
p53	O
gene	O
mutations	O
in	O
exons	O
5	O
and	O
8	O
,	O
respectively	O
.	O
A	O
cell	O
line	O
established	O
from	O
the	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
showed	O
the	O
same	O
mutation	O
present	O
in	O
the	O
original	O
tumour	O
.	O
Both	O
p53	O
mutations	O
were	O
heterozygous	O
.	O
The	O
p53	O
positive	O
samples	O
were	O
analysed	O
for	O
other	O
genetic	O
alterations	O
frequently	O
detected	O
in	O
human	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
(	O
mutations	O
of	O
the	O
RET	O
,	O
TRK	O
,	O
and	O
ras	O
oncogenes	O
)	O
:	O
both	O
p53	O
-	O
mutated	O
samples	O
proved	O
to	O
be	O
mutated	O
at	O
level	O
of	O
codon	O
13	O
of	O
the	O
c-Ki-ras	O
gene	O
.	O
CONCLUSIONS	O
:	O
Our	O
data	O
confirm	O
that	O
p53	O
gene	O
alterations	O
are	O
rare	O
in	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
thyroid	I-malignancy-type
tumours	I-malignancy-type
,	O
that	O
they	O
are	O
an	O
important	O
requirement	O
for	O
the	O
establishment	O
in	O
culture	O
of	O
human	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
and	O
that	O
they	O
can	O
be	O
associated	O
with	O
other	O
genetic	O
alterations	O
,	O
namely	O
ras	O
mutations	O
,	O
in	O
the	O
malignant	O
progression	O
of	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
.	O
PMID	O
:	O
8630516	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Apr;8	O
Suppl	O
1:S27	O
-	O
9	O
Molecular	O
mechanisms	O
of	O
tumor	O
progression	O
in	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
.	O
Gaidano	O
G	O
,	O
Guerrasio	O
A	O
,	O
Serra	O
A	O
,	O
Rege	O
-	O
Cambrin	O
G	O
,	O
Saglio	O
G.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
&	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
10032	O
.	O
We	O
have	O
investigated	O
the	O
involvement	O
of	O
tumor	O
suppressor	O
genes	O
(	O
p53	O
and	O
RB1	O
)	O
and	O
dominantly	O
acting	O
oncogenes	O
(	O
Ras	O
family	O
genes	O
)	O
in	O
BCR	O
/	O
ABL	O
positive	O
and	O
negative	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
(	O
CMPD	B-malignancy-type
)	O
at	O
different	O
stages	O
of	O
the	O
disease	O
,	O
including	O
26	O
cases	O
of	O
BCR	O
/	O
ABL	O
+	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
blast	O
crisis	O
,	O
9	O
myelosclerosis	O
with	O
myeloid	B-malignancy-type
metaplasia	I-malignancy-type
,	O
4	O
polycythemia	B-malignancy-type
vera	I-malignancy-type
,	O
10	O
essential	B-malignancy-type
thrombocythemia	I-malignancy-type
,	O
1	O
juvenile	O
CML	B-malignancy-type
,	O
and	O
8	O
BCR	O
/	O
ABL	O
-	O
CML	B-malignancy-type
.	O
The	O
presence	O
of	O
mutations	O
in	O
p53	O
exons	O
5	O
through	O
9	O
,	O
as	O
well	O
as	O
in	O
RB1	O
exons	O
10	O
-	O
27	O
and	O
in	O
N	O
-	O
,	O
K	O
-	O
,	O
H	O
-	O
Ras	O
exons	O
1	O
and	O
2	O
was	O
tested	O
by	O
the	O
PCR	O
-	O
Single	O
Strand	O
Conformation	O
Polymorphism	O
technique	O
and	O
by	O
PCR	O
-	O
Direct	O
Sequencing	O
.	O
In	O
addition	O
,	O
Southern	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
the	O
occurrence	O
of	O
gross	O
rearrangements	O
in	O
the	O
p53	O
gene	O
as	O
well	O
as	O
loss	O
of	O
heterozygosity	O
at	O
17p13	O
,	O
the	O
site	O
of	O
p53	O
.	O
Acute	O
phase	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
cases	O
displayed	O
a	O
high	O
frequency	O
of	O
p53	O
(	O
2	O
/	O
7	O
)	O
and	O
Ras	O
(	O
3	O
/	O
7	O
)	O
lesions	O
,	O
whereas	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
in	O
chronic	O
phase	O
displayed	O
only	O
germline	O
p53	O
and	O
Ras	O
sequences	O
.	O
Conversely	O
,	O
p53	O
inactivation	O
was	O
restricted	O
to	O
only	O
1	O
/	O
26	O
cases	O
of	O
BCR	O
/	O
ABL	O
+	O
CML	B-malignancy-type
blast	O
crisis	O
.	O
No	O
alterations	O
in	O
the	O
RB1	O
gene	O
were	O
detected	O
in	O
any	O
of	O
the	O
cases	O
analyzed	O
.	O
These	O
data	O
indicate	O
that	O
p53	O
inactivation	O
and/or	O
Ras	O
activation	O
might	O
play	O
a	O
role	O
in	O
acute	O
transformation	O
of	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
and	O
that	O
the	O
molecular	O
mechanisms	O
of	O
tumor	O
progression	O
may	O
be	O
different	O
in	O
BCR	O
/	O
ABL	O
+	O
versus	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
.	O
PMID	O
:	O
8152300	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1993	O
Nov	O
11;55(	O
5	O
)	O
:785	O
-	O
90	O
Screening	O
of	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
and	O
urine	O
sediments	O
for	O
the	O
presence	O
of	O
H-ras	O
mutations	O
.	O
Levesque	O
P	O
,	O
Ramchurren	O
N	O
,	O
Saini	O
K	O
,	O
Joyce	O
A	O
,	O
Libertino	O
J,	O
Summerhayes	O
IC	O
.	O
Department	O
of	O
Surgery	O
,	O
New	O
England	O
Deaconess	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
,	O
MA	O
02215	O
.	O
A	O
series	O
of	O
111	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
were	O
screened	O
using	O
oligonucleotide	O
mutant	O
specific	O
probes	O
,	O
restriction	O
enzyme	O
analysis	O
and	O
single	O
-	O
stranded	O
confirmation	O
polymorphism	O
(	O
SSCP	O
)	O
for	O
the	O
presence	O
of	O
H-ras	O
activation	O
events	O
.	O
Thirty-three	O
tumors	O
were	O
found	O
to	O
harbor	O
H-ras	O
mutations	O
where	O
a	O
glycine	O
to	O
valine	O
(	O
G	O
-->	O
T	O
)	O
change	O
in	O
codon	O
12	O
was	O
the	O
most	O
common	O
point	O
mutation	O
recorded	O
(	O
26	O
tumors	O
)	O
.	O
Additional	O
mutations	O
involved	O
glycine	O
to	O
cysteine	O
at	O
codon	O
13	O
(	O
2	O
tumors	O
)	O
and	O
glutamine	O
to	O
arginine	O
/	O
lysine	O
/	O
leucine	O
at	O
codon	O
61	O
(	O
3	O
/	O
1	O
/	O
1	O
tumors	O
,	O
respectively	O
)	O
.	O
Ambiguous	O
signals	O
recorded	O
with	O
oligonucleotide	O
probes	O
were	O
further	O
analyzed	O
using	O
SSCP	O
analysis	O
revealing	O
the	O
presence	O
of	O
H-ras	O
mutations	O
in	O
restricted	O
regions	O
of	O
some	O
tumors	O
.	O
The	O
apparent	O
sensitivity	O
of	O
SSCP	O
enabled	O
us	O
to	O
extend	O
this	O
study	O
to	O
DNA	O
isolated	O
from	O
urine	O
sediments	O
where	O
4	O
of	O
the	O
9	O
patients	O
studied	O
showed	O
representation	O
of	O
mutant	O
H-ras	O
.	O
Our	O
study	O
demonstrates	O
a	O
sensitive	O
,	O
non	O
-	O
invasive	O
assay	O
for	O
the	O
screening	O
of	O
urine	O
-	O
borne	O
cells	O
,	O
with	O
no	O
requirement	O
for	O
prior	O
knowledge	O
of	O
the	O
mutational	O
change	O
at	O
the	O
H-ras	O
locus	O
.	O
PMID	O
:	O
7902340	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Nov	O
7;92(	O
23	O
)	O
:10560	O
-	O
4	O
Identification	O
of	O
a	O
point	O
mutation	O
in	O
the	O
catalytic	O
domain	O
of	O
the	O
protooncogene	O
c-kit	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
who	O
have	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
.	O
Nagata	O
H	O
,	O
Worobec	O
AS	O
,	O
Oh	O
CK	O
,	O
Chowdhury	O
BA	O
,	O
Tannenbaum	O
S,	O
Suzuki	O
Y	O
,	O
Metcalfe	O
DD.	O
Allergic	O
Diseases	O
Section	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
Both	O
stem	O
cells	O
and	O
mast	O
cells	O
express	O
c-kit	O
and	O
proliferate	O
after	O
exposure	O
to	O
c-kit	O
ligand	O
.	O
Mutations	O
in	O
c-kit	O
may	O
enhance	O
or	O
interfere	O
with	O
the	O
ability	O
of	O
c-kit	O
receptor	O
to	O
initiate	O
the	O
intracellular	O
pathways	O
resulting	O
in	O
cell	O
proliferation	O
.	O
These	O
observations	O
suggested	O
to	O
us	O
that	O
mastocytosis	B-malignancy-type
might	O
in	O
some	O
patients	O
result	O
from	O
mutations	O
in	O
c-kit	O
.	O
cDNA	O
synthesized	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
,	O
aggressive	O
mastocytosis	B-malignancy-type
,	O
solitary	B-malignancy-type
mastocytoma	I-malignancy-type
,	O
and	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
unassociated	O
with	O
mastocytosis	B-malignancy-type
was	O
thus	O
screened	O
for	O
a	O
mutation	O
of	O
c-kit	O
.	O
This	O
analysis	O
revealed	O
that	O
four	O
of	O
four	O
mastocytosis	B-malignancy-type
patients	O
with	O
an	O
associated	O
hematologic	O
disorder	O
with	O
predominantly	O
myelodysplastic	O
features	O
had	O
an	O
A	O
-->	O
T	O
substitution	O
at	O
nt	O
2468	O
of	O
c-kit	O
mRNA	O
that	O
causes	O
an	O
Asp	O
-	O
816	O
-->	O
Val	O
substitution	O
.	O
One	O
of	O
one	O
patient	O
examined	O
who	O
had	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
had	O
the	O
corresponding	O
mutation	O
in	O
genomic	O
DNA	O
.	O
Identical	O
or	O
similar	O
amino	O
acid	O
substitutions	O
in	O
mast	O
cell	O
lines	O
result	O
in	O
ligand	O
-	O
independent	O
autophosphorylation	O
of	O
the	O
c-kit	O
receptor	O
.	O
This	O
mutation	O
was	O
not	O
identified	O
in	O
the	O
patients	O
within	O
the	O
other	O
disease	O
categories	O
or	O
in	O
67	O
of	O
67	O
controls	O
.	O
The	O
identification	O
of	O
the	O
point	O
mutation	O
Asp	O
816	O
Val	O
in	O
c-kit	O
in	O
patients	O
with	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
provides	O
insight	O
not	O
only	O
into	O
the	O
pathogenesis	O
of	O
this	O
form	O
of	O
mastocytosis	B-malignancy-type
but	O
also	O
into	O
how	O
hematopoiesis	O
may	O
become	O
dysregulated	O
and	O
may	O
serve	O
to	O
provide	O
a	O
means	O
of	O
confirming	O
the	O
diagnosis	O
,	O
assessing	O
prognosis	O
,	O
and	O
developing	O
intervention	O
strategies	O
.	O
PMID	O
:	O
7479840	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Nov	O
15	O
;49(	O
22	O
)	O
:6324	O
-	O
7	O
Detection	O
of	O
point	O
mutations	O
in	O
N-ras	O
and	O
K-ras	O
genes	O
of	O
human	O
embryonal	O
rhabdomyosarcomas	B-malignancy-type
using	O
oligonucleotide	O
probes	O
and	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Stratton	O
MR	O
,	O
Fisher	O
C	O
,	O
Gusterson	O
BA	O
,	O
Cooper	O
CS	O
.	O
Section	O
of	O
Chemical	O
Carcinogenesis	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
genes	O
of	O
the	O
ras	O
family	O
(	O
H	O
,	O
K	O
,	O
and	O
N	O
)	O
can	O
be	O
activated	O
by	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
used	O
oligonucleotide	O
probes	O
corresponding	O
to	O
these	O
regions	O
to	O
assess	O
the	O
role	O
of	O
ras	O
gene	O
mutations	O
in	O
the	O
genesis	O
of	O
human	O
rhabdomyosarcoma	B-malignancy-type
.	O
To	O
increase	O
the	O
sensitivity	O
of	O
this	O
method	O
the	O
appropriate	O
regions	O
of	O
the	O
three	O
ras	O
genes	O
were	O
first	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
The	O
results	O
show	O
that	O
35	O
%	O
(	O
5	O
/	O
14	O
)	O
embryonal	O
rhabdomyosarcomas	B-malignancy-type
investigated	O
contain	O
mutations	O
in	O
the	O
N-ras	O
or	O
K-ras	O
genes	O
.	O
Thus	O
ras	O
gene	O
mutation	O
is	O
implicated	O
in	O
the	O
development	O
of	O
mesenchymal	B-malignancy-type
and	O
embryonal	O
tumors	B-malignancy-type
in	O
addition	O
to	O
its	O
previously	O
documented	O
role	O
in	O
epithelial	B-malignancy-type
and	O
hematological	B-malignancy-type
neoplasia	I-malignancy-type
.	O
PMID	O
:	O
2680062	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1991	O
Oct;73(	O
4)	O
:832	O
-	O
6	O
Ras	O
oncogene	O
mutations	O
in	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
.	O
Karga	O
H	O
,	O
Lee	O
JK	O
,	O
Vickery	O
AL	O
Jr	O
,	O
Thor	O
A	O
,	O
Gaz	O
RD	O
,	O
Jameson	O
JL.	O
Department	O
of	O
Pathology	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
02114	O
.	O
Current	O
models	O
for	O
tumorigenesis	O
propose	O
that	O
a	O
series	O
of	O
genetic	O
alterations	O
occur	O
during	O
the	O
progression	O
from	O
the	O
normal	O
cell	O
to	O
the	O
malignant	O
phenotype	O
.	O
Mutations	O
in	O
each	O
of	O
the	O
three	O
ras	O
genes	O
(	O
K-ras	O
,	O
H-ras	O
,	O
and	O
N-ras	O
)	O
have	O
been	O
identified	O
in	O
many	O
human	O
neoplasms	O
,	O
including	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
examined	O
genomic	O
DNA	O
from	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
for	O
mutations	O
that	O
are	O
known	O
to	O
activate	O
the	O
ras	O
oncogenes	O
(	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
.	O
DNA	O
from	O
frozen	O
surgically	O
excised	O
tissue	O
(	O
n	O
=	O
8	O
)	O
and	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
(	O
n	O
=	O
30	O
)	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
screened	O
for	O
mutations	O
using	O
oligonucleotide	O
-	O
specific	O
hybridization	O
.	O
No	O
mutations	O
were	O
identified	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
n	O
=	O
9	O
)	O
.	O
In	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
2	O
of	O
14	O
tumors	O
contained	O
mutations	O
(	O
N-ras	O
61	O
,	O
Gln	O
to	O
Arg	O
)	O
,	O
and	O
both	O
of	O
these	O
patients	O
had	O
bone	B-malignancy-type
metastases	I-malignancy-type
.	O
One	O
of	O
15	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
had	O
a	O
ras	O
mutation	O
(	O
H-ras	O
12	O
,	O
Gly	O
to	O
Ser	O
)	O
.	O
In	O
contrast	O
to	O
other	O
studies	O
,	O
we	O
found	O
that	O
ras	O
mutations	O
are	O
relatively	O
uncommon	O
in	O
both	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
.	O
Studies	O
of	O
larger	O
numbers	O
of	O
tumors	O
and	O
comparisons	O
of	O
different	O
patient	O
populations	O
will	O
be	O
required	O
to	O
assess	O
a	O
possible	O
association	O
of	O
mutations	O
in	O
N-ras	O
61	O
with	O
clinically	O
aggressive	O
follicular	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
1890154	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Oral	O
Pathol	O
Med	O
1992	O
May	O
;21(	O
5	O
)	O
:225	O
-	O
9	O
Point	O
mutations	O
in	O
the	O
Ha-ras	O
oncogene	O
are	O
detectable	O
in	O
formalin	O
-	O
fixed	O
tissues	O
of	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
but	O
are	O
infrequent	O
in	O
British	O
cases	O
.	O
Warnakulasuriya	O
KA	O
,	O
Chang	O
SE	O
,	O
Johnson	O
NW.	O
Department	O
of	O
Dental	O
Sciences	O
,	O
Hunterian	O
Institute	O
,	O
Royal	O
College	O
of	O
Surgeons	O
,	O
London	O
,	O
England	O
.	O
Oncogene	O
expression	O
in	O
human	O
neoplasia	O
has	O
been	O
examined	O
extensively	O
in	O
the	O
past	O
decade	O
.	O
More	O
recently	O
the	O
advent	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
has	O
facilitated	O
studies	O
of	O
oncogenes	O
and	O
other	O
DNA	O
structures	O
.	O
Those	O
few	O
studies	O
which	O
have	O
so	O
far	O
searched	O
for	O
oncogene	O
changes	O
in	O
oral	B-malignancy-type
cancer	I-malignancy-type
have	O
utilized	O
frozen	O
specimens	O
.	O
We	O
report	O
here	O
an	O
adaptation	O
of	O
the	O
PCR	O
technique	O
applicable	O
to	O
DNA	O
extracted	O
from	O
archival	O
specimens	O
.	O
Our	O
data	O
complement	O
recent	O
findings	O
that	O
Ha-ras	O
mutations	O
are	O
infrequent	O
in	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
among	O
white	O
caucasoid	O
populations	O
.	O
PMID	O
:	O
1403838	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Environ	O
Mol	O
Mutagen	O
2002	O
;40(	O
1	O
)	O
:36	O
-	O
40	O
Mutation	O
analysis	O
of	O
K-ras-2	O
in	O
liver	B-malignancy-type
angiosarcoma	I-malignancy-type
and	O
adjacent	O
nonneoplastic	O
liver	O
tissue	O
from	O
patients	O
occupationally	O
exposed	O
to	O
vinyl	O
chloride	O
.	O
Weihrauch	O
M,	O
Bader	O
M,	O
Lehnert	O
G	O
,	O
Koch	O
B	O
,	O
Wittekind	O
C	O
,	O
Wrbitzky	O
R,	O
Tannapfel	O
A.	O
Institute	O
of	O
Occupational	O
Medicine	O
,	O
University	O
of	O
Hannover	O
,	O
Germany	O
.	O
Vinyl	O
chloride	O
(	O
VC	O
)	O
is	O
a	O
potent	O
liver	O
carcinogen	O
that	O
induces	O
angiosarcomas	B-malignancy-type
in	O
humans	O
and	O
animals	O
.	O
Recent	O
evidence	O
shows	O
that	O
liver	B-malignancy-type
tumors	I-malignancy-type
from	O
patients	O
with	O
VC	O
exposure	O
may	O
have	O
a	O
specific	O
K-ras	O
mutation	O
pattern	O
.	O
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
status	O
of	O
K-ras-2	O
in	O
liver	B-malignancy-type
angiosarcomas	I-malignancy-type
(	O
LAS	B-malignancy-type
)	O
from	O
workers	O
occupationally	O
exposed	O
to	O
VC	O
.	O
We	O
examined	O
the	O
presence	O
of	O
K-ras-2	O
mutations	O
in	O
15	O
LAS	B-malignancy-type
from	O
patients	O
with	O
known	O
exposure	O
to	O
VC	O
(	O
median	O
exposure	O
:	O
8,260	O
ppm	O
[	O
range	O
3,900	O
-	O
21,000	O
ppm	O
]	O
]	O
.	O
In	O
all	O
cases	O
,	O
other	O
risk	O
factors	O
for	O
the	O
development	O
of	O
LAS	B-malignancy-type
were	O
excluded	O
.	O
Direct	O
DNA	O
sequencing	O
after	O
microdissection	O
of	O
the	O
tumor	O
cells	O
was	O
used	O
for	O
the	O
analysis	O
.	O
Heterozygous	O
mutations	O
of	O
K-ras-2	O
were	O
detected	O
in	O
8	O
/	O
15	O
LAS	B-malignancy-type
(	O
53	O
%	O
)	O
.	O
Five	O
patients	O
(	O
33	O
%	O
)	O
had	O
a	O
mutation	O
of	O
codon	O
12	O
and	O
three	O
of	O
codon	O
13	O
(	O
20	O
%	O
)	O
.	O
The	O
most	O
common	O
changes	O
were	O
G	O
-->	O
A	O
transitions	O
in	O
five	O
LAS	B-malignancy-type
which	O
lead	O
to	O
the	O
substitution	O
of	O
aspartic	O
acid	O
for	O
glycine	O
in	O
the	O
resulting	O
p21	O
protein	O
.	O
In	O
two	O
patients	O
(	O
13	O
%	O
)	O
,	O
mutations	O
of	O
the	O
K-ras-2	O
gene	O
were	O
identified	O
in	O
the	O
adjacent	O
nonneoplastic	O
liver	O
tissue	O
.	O
These	O
data	O
indicate	O
that	O
VC	O
induces	O
a	O
high	O
frequency	O
of	O
G	O
-->	O
A	O
transitions	O
in	O
human	O
LAS	B-malignancy-type
.	I-malignancy-type
This	O
mutation	O
pattern	O
is	O
likely	O
a	O
consequence	O
of	O
VC	O
-	O
DNA	O
-	O
adduct	O
formation	O
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12211074	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Pathol	O
Lab	O
Med	O
2002	O
Sep;126(9	O
)	O
:1096	O
-	O
100	O
ras	O
Gene	O
mutations	O
and	O
expression	O
of	O
Ras	O
signal	O
transduction	O
mediators	O
in	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Yoo	O
J,	O
Park	O
SY	O
,	O
Robinson	O
RA	O
,	O
Kang	O
SJ	O
,	O
Ahn	O
WS	O
,	O
Kang	O
CS	O
.	O
Department	O
of	O
Pathology	O
,	O
St	O
Vincent	O
's	O
Hospital	O
,	O
Catholic	O
University	O
,	O
Suwon	O
,	O
Kyungkido	O
,	O
South	O
Korea	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
ras	O
gene	O
alteration	O
in	O
human	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
its	O
potential	O
relationship	O
to	O
ras	O
signal	O
transduction	O
mediators	O
.	O
DESIGN	O
:	O
Genomic	O
DNA	O
from	O
104	O
gastric	O
tumors	O
were	O
analyzed	O
by	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
products	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
.	O
All	O
the	O
samples	O
were	O
further	O
investigated	O
with	O
the	O
use	O
of	O
immunohistochemical	O
analysis	O
for	O
ERK1	O
and	O
ERK2	O
.	O
SETTING	O
:	O
Tertiary	O
care	O
teaching	O
hospital	O
.	O
PATIENTS	O
:	O
Seventy	O
patients	O
from	O
a	O
Korean	O
population	O
and	O
34	O
from	O
a	O
Midwestern	O
US	O
population	O
composed	O
of	O
white	O
Americans	O
and	O
African	O
Americans	O
.	O
RESULTS	O
:	O
Fifteen	O
tumors	O
(	O
14	O
%	O
)	O
were	O
positive	O
for	O
either	O
H-ras	O
or	O
K-ras	O
mutation	O
:	O
9	O
(	O
13	O
%	O
)	O
of	O
70	O
Korean	O
patients	O
and	O
6	O
(	O
18	O
%	O
)	O
of	O
34	O
US	O
patients	O
.	O
Seven	O
(	O
78	O
%	O
)	O
of	O
the	O
9	O
mutated	O
tumors	O
from	O
Korean	O
patients	O
and	O
all	O
6	O
(	O
100	O
%	O
)	O
from	O
the	O
US	O
patients	O
were	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
lesions	I-malignancy-type
.	O
Either	O
ERK1	O
and/or	O
ERK2	O
was	O
overexpressed	O
in	O
68	O
samples	O
(	O
65	O
%	O
)	O
.	O
No	O
association	O
was	O
established	O
between	O
ras	O
mutations	O
and	O
overexpression	O
of	O
ERK	O
1	O
/	O
2	O
.	O
However	O
,	O
the	O
correlation	O
between	O
ERK	O
1	O
/	O
2	O
and	O
progression	O
(	O
early	O
vs	O
late	O
)	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.007	O
)	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
that	O
differing	O
racial	O
and/or	O
geographic	O
mechanisms	O
may	O
not	O
underlie	O
ras	O
gene	O
alteration	O
.	O
Most	O
ras	O
mutations	O
were	O
,	O
however	O
,	O
observed	O
in	O
the	O
group	O
of	O
intestinal	O
-	O
type	O
samples	O
,	O
supporting	O
the	O
different	O
genetic	O
mechanisms	O
of	O
carcinogenesis	O
between	O
the	O
intestinal	B-malignancy-type
-	I-malignancy-type
and	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
.	O
It	O
is	O
noteworthy	O
that	O
enhanced	O
ERK	O
1	O
/	O
2	O
activity	O
could	O
be	O
one	O
of	O
the	O
characteristics	O
of	O
tumor	O
invasiveness	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
12204060	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2002	O
Aug	O
10;100(	O
5	O
)	O
:549	O
-	O
56	O
Molecular	O
genetic	O
analysis	O
of	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
for	O
aberrations	O
of	O
the	O
WNT	O
signaling	O
pathway	O
genes	O
CTNNB1	O
,	O
APC	O
,	O
ICAT	O
and	O
BTRC	O
.	O
Reifenberger	O
J,	O
Knobbe	O
CB	O
,	O
Wolter	O
M,	O
Blaschke	O
B	O
,	O
Schulte	O
KW	O
,	O
Pietsch	O
T	O
,	O
Ruzicka	O
T	O
,	O
Reifenberger	O
G.	O
Department	O
of	O
Dermatology	O
,	O
Heinrich	O
-	O
Heine	O
-	O
University	O
,	O
Dusseldorf	O
,	O
Germany	O
.	O
reifenbergerj@med	O
.uni	O
-	O
duesseldorf	O
.de	O
Aberrant	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
has	O
been	O
reported	O
in	O
different	O
human	O
tumor	O
types	O
,	O
including	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
.	O
We	O
investigated	O
37	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
(	O
15	O
primary	O
tumors	O
and	O
22	O
metastases	B-malignancy-type
)	O
for	O
alterations	O
of	O
4	O
genes	O
encoding	O
members	O
of	O
this	O
pathway	O
,	O
i.e.	O
,	O
CTNNB1	O
(	O
beta-catenin	O
gene	O
,	O
3p22.1	O
)	O
,	O
APC	O
(	O
adenomatous	O
polyposis	O
coli	O
gene	O
,	O
5q22.2	O
)	O
,	O
BTRC	O
(	O
beta-transducin	O
repeat	O
-	O
containing	O
protein	O
gene	O
,	O
10q24.3	O
)	O
and	O
ICAT	O
(	O
inhibitor	O
of	O
beta-catenin	O
and	O
Tcf-4	O
,	O
1p36.2	O
)	O
.	O
Mutational	O
analysis	O
of	O
CTNNB1	O
identified	O
somatic	O
mutations	O
in	O
1	O
primary	O
melanoma	B-malignancy-type
and	O
1	O
melanoma	B-malignancy-type
metastasis	I-malignancy-type
from	O
2	O
different	O
patients	O
(	O
5	O
%	O
)	O
.	O
Both	O
mutations	O
affected	O
the	O
N	O
-	O
terminal	O
degradation	O
box	O
of	O
beta-catenin	O
,	O
which	O
is	O
important	O
for	O
the	O
regulation	O
of	O
beta-catenin	O
homeostasis	O
.	O
Another	O
primary	O
melanoma	B-malignancy-type
carried	O
a	O
somatic	O
APC	O
missense	O
mutation	O
within	O
the	O
known	O
mutation	O
cluster	O
region	O
in	O
exon	O
15	O
.	O
Fourteen	O
tumors	O
(	O
40	O
%	O
)	O
showed	O
LOH	O
at	O
microsatellite	O
markers	O
on	O
1p36	O
.	O
None	O
of	O
the	O
tumors	O
had	O
lost	O
both	O
copies	O
of	O
the	O
ICAT	O
gene	O
,	O
but	O
1	O
melanoma	B-malignancy-type
metastasis	O
carried	O
a	O
somatic	O
point	O
mutation	O
altering	O
the	O
translation	O
start	O
codon	O
of	O
ICAT	O
.	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
showed	O
markedly	O
reduced	O
ICAT	O
transcript	O
levels	O
(	O
<	O
or	O
=	O
20	O
%	O
relative	O
to	O
normal	O
skin	O
and	O
benign	B-malignancy-type
melanocytic	I-malignancy-type
nevi	I-malignancy-type
)	O
in	O
28	O
/	O
36	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
(	O
78	O
%	O
)	O
,	O
including	O
13	O
/	O
14	O
tumors	O
with	O
LOH	O
on	O
1p36	O
.	O
Allelic	O
loss	O
on	O
10q	O
was	O
detected	O
in	O
15	O
tumors	O
(	O
44	O
%	O
)	O
.	O
We	O
found	O
neither	O
mutations	O
nor	O
complete	O
loss	O
of	O
expression	O
of	O
the	O
BTRC	O
gene	O
in	O
our	O
melanoma	B-malignancy-type
series	O
.	O
Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
Wnt	O
pathway	O
may	O
be	O
altered	O
in	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
by	O
different	O
mechanisms	O
,	O
including	O
rare	O
somatic	O
mutations	O
in	O
CTNNB1	O
,	O
APC	O
or	O
ICAT	O
,	O
as	O
well	O
as	O
low	O
or	O
absent	O
expression	O
of	O
ICAT	O
transcripts	O
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12124804	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
2002	O
Aug;51(	O
2	O
)	O
:200	O
-	O
6	O
Molecular	O
characteristics	O
of	O
serrated	B-malignancy-type
adenomas	I-malignancy-type
of	O
the	O
colorectum	O
.	O
Sawyer	O
EJ	O
,	O
Cerar	O
A	O
,	O
Hanby	O
AM	O
,	O
Gorman	O
P	O
,	O
Arends	O
M,	O
Talbot	O
IC	O
,	O
Tomlinson	O
IP	O
.	O
Molecular	O
and	O
Population	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
London	O
WC2A	O
3PX	O
,	O
UK.	O
e	O
.sawyer@icrf	O
.icnet	O
.uk	O
BACKGROUND	O
:	O
Serrated	B-malignancy-type
adenomas	I-malignancy-type
(	O
SAs	B-malignancy-type
)	O
of	O
the	O
colorectum	O
combine	O
architectural	O
features	O
of	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
and	O
cytological	O
features	O
of	O
classical	B-malignancy-type
adenomas	I-malignancy-type
.	O
Molecular	O
studies	O
comparing	O
SAs	B-malignancy-type
and	O
classical	B-malignancy-type
adenomas	I-malignancy-type
suggest	O
that	O
each	O
may	O
be	O
a	O
distinct	O
entity	O
;	O
in	O
particular	O
,	O
it	O
has	O
been	O
proposed	O
that	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
distinguishes	O
SAs	B-malignancy-type
from	O
classical	B-malignancy-type
adenomas	I-malignancy-type
and	O
that	O
SAs	B-malignancy-type
and	O
the	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
arising	O
from	O
them	O
develop	O
along	O
a	O
pathway	O
driven	O
by	O
low	O
level	O
microsatellite	O
instability	O
(	O
MSI-L	O
)	O
.	O
AIMS	O
:	O
To	O
define	O
the	O
molecular	O
characteristics	O
of	O
SAs	B-malignancy-type
of	O
the	O
colorectum	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
analysed	O
39	O
SAs	O
from	O
27	O
patients	O
,	O
including	O
eight	O
SAs	B-malignancy-type
from	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
.	O
We	O
screened	O
these	O
polyps	B-malignancy-type
for	O
selected	O
molecular	O
changes	O
,	O
including	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
close	O
to	O
APC	O
(	O
5q21	O
)	O
and	O
CRAC1	O
(	O
15q13	O
-	O
q22	O
)	O
,	O
MSI	O
,	O
and	O
mutations	O
of	O
K-ras	O
,	O
APC	O
,	O
p53	O
,	O
and	O
beta-catenin	O
.	O
Expression	O
patterns	O
of	O
beta-catenin	O
,	O
p53	O
,	O
MLH1	O
,	O
MSH2	O
,	O
E-cadherin	O
,	O
and	O
O(6)-methylguanine	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
were	O
assessed	O
by	O
immunohistochemistry	O
.	O
Comparative	O
genomic	O
hybridisation	O
was	O
performed	O
on	O
several	O
polyps	B-malignancy-type
.	O
RESULTS	O
:	O
MSI	O
was	O
rare	O
(	O
<	O
5	O
%	O
cases	O
)	O
and	O
there	O
was	O
no	O
loss	O
of	O
expression	O
of	O
mismatch	O
repair	O
proteins	O
.	O
Wnt	O
pathway	O
abnormalities	O
(	O
APC	O
mutation	O
/	O
LOH	O
,	O
beta-catenin	O
mutation	O
/	O
nuclear	O
expression	O
)	O
occurred	O
in	O
11	O
SAs	B-malignancy-type
,	O
including	O
6	O
/	O
31	O
(	O
19	O
%	O
)	O
non	B-malignancy-type
-	I-malignancy-type
FAP	I-malignancy-type
tumours	I-malignancy-type
.	O
CRAC1	O
LOH	O
occurred	O
in	O
23	O
%	O
of	O
tumours	O
.	O
K-ras	O
mutations	O
and	O
p53	O
mutations	O
/	O
overexpression	O
were	O
found	O
in	O
15	O
%	O
and	O
8	O
%	O
of	O
SAs	B-malignancy-type
,	O
respectively	O
.	O
Loss	O
of	O
MGMT	O
expression	O
occurred	O
in	O
18	O
%	O
of	O
polyps	B-malignancy-type
and	O
showed	O
a	O
borderline	O
association	O
with	O
K-ras	O
mutations	O
.	O
Aberrant	O
E-cadherin	O
expression	O
was	O
found	O
in	O
seven	O
polyps	B-malignancy-type
.	O
Comparative	O
genomic	O
hybridisation	O
detected	O
no	O
gains	O
or	O
deletions	O
of	O
chromosomal	O
material	O
.	O
CONCLUSIONS	O
:	O
The	O
serrated	O
pathway	O
of	O
colorectal	O
tumorigenesis	O
appears	O
to	O
be	O
heterogeneous	O
.	O
In	O
common	O
with	O
classical	B-malignancy-type
adenomas	I-malignancy-type
,	O
some	O
SAs	B-malignancy-type
develop	O
along	O
pathways	O
involving	O
changes	O
in	O
APC	O
/	O
beta-catenin	O
.	O
SAs	B-malignancy-type
rarely	O
show	O
MSI	O
or	O
any	O
evidence	O
of	O
chromosomal	O
-	O
scale	O
genetic	O
instability	O
.	O
K-ras	O
mutations	O
may	O
however	O
be	O
less	O
common	O
in	O
SAs	B-malignancy-type
than	O
in	O
classical	B-malignancy-type
adenomas	I-malignancy-type
.	O
Some	O
SAs	B-malignancy-type
may	O
harbour	O
changes	O
in	O
the	O
CRAC1	O
gene	O
.	O
Changes	O
in	O
known	O
genes	O
do	O
not	O
account	O
for	O
the	O
growth	O
of	O
the	O
majority	O
of	O
SAs	B-malignancy-type
.	O
PMID	O
:	O
12117880	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Clin	O
Oncol	O
2002	O
Apr;32(	O
4)	O
:146	O
-	O
51	O
Invasive	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
of	O
the	O
remnant	O
pancreatic	O
body	O
9	O
years	O
after	O
resection	O
of	O
an	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreatic	O
head	O
:	O
a	O
case	O
report	O
and	O
comparison	O
of	O
DNA	O
sequence	O
in	O
K-ras	O
gene	O
mutation	O
.	O
Komori	O
T	O
,	O
Ishikawa	O
O	O
,	O
Ohigashi	O
H	O
,	O
Yamada	O
T	O
,	O
Sasaki	O
Y	O
,	O
Imaoka	O
S,	O
Nakaizumi	O
A	O
,	O
Uehara	O
H	O
,	O
Tanaka	O
S,	O
Mano	O
Y	O
,	O
Kasugai	O
T.	O
Department	O
of	O
Surgery	O
,	O
Osaka	O
Medical	O
Center	O
for	O
Cancer	O
and	O
Cardiovascular	O
Diseases	O
,	O
Osaka	O
,	O
Japan	O
.	O
Recently	O
,	O
there	O
have	O
been	O
a	O
few	O
case	O
reports	O
of	O
invasive	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
(	O
IDC	B-malignancy-type
)	O
developed	O
in	O
the	O
remnant	O
pancreas	O
after	O
partial	O
pancreatectomy	O
for	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
neoplasm	I-malignancy-type
(	O
IPMN	B-malignancy-type
)	O
.	O
It	O
is	O
necessary	O
to	O
clarify	O
their	O
histogenetic	O
relationships	O
among	O
two	O
sporadic	B-malignancy-type
tumors	I-malignancy-type
and	O
their	O
surrounding	O
duct	O
epithelium	O
and	O
it	O
would	O
be	O
more	O
reliable	O
if	O
genetic	O
analysis	O
is	O
added	O
to	O
the	O
conventional	O
histology	O
.	O
We	O
report	O
a	O
76	O
-	O
year	O
-	O
old	O
woman	O
who	O
received	O
pancreaticoduodenectomy	O
for	O
IPMN	B-malignancy-type
with	O
a	O
focal	O
in	O
situ	O
carcinoma	B-malignancy-type
(	O
IPMC	B-malignancy-type
)	O
,	O
which	O
was	O
transitional	O
to	O
the	O
surrounding	O
duct	O
epithelium	O
with	O
papillary	O
proliferation	O
and	O
a	O
wide	O
variety	O
of	O
dysplasia	B-malignancy-type
.	O
Nine	O
years	O
after	O
the	O
operation	O
,	O
she	O
died	O
of	O
IDC	B-malignancy-type
in	O
the	O
remnant	O
pancreatic	O
body	O
and	O
its	O
surrounding	O
duct	O
epithelium	O
consisted	O
of	O
hyperplastic	O
mucous	O
cells	O
with	O
slight	B-malignancy-type
-	I-malignancy-type
mild	I-malignancy-type
dysplasia	I-malignancy-type
.	O
Analysis	O
of	O
K-ras	O
mutation	O
at	O
codon	O
12	O
(	O
wild	O
-	O
GGT	O
)	O
by	O
direct	O
sequencing	O
after	O
polymerase	O
chain	O
reaction	O
indicated	O
that	O
their	O
transitioning	O
patterns	O
differed	O
from	O
each	O
other	O
:	O
CGT	O
in	O
IPMC	B-malignancy-type
;	O
no	O
mutation	O
in	O
the	O
mildly	B-malignancy-type
dysplastic	I-malignancy-type
duct	I-malignancy-type
epithelium	I-malignancy-type
around	O
IPMC	B-malignancy-type
;	O
GAT	O
in	O
IDC	B-malignancy-type
of	O
the	O
remnant	O
pancreas	O
;	O
and	O
AGT	O
in	O
mucous	B-malignancy-type
cell	I-malignancy-type
hyperplasia	I-malignancy-type
with	O
mild	B-malignancy-type
dysplasia	I-malignancy-type
close	O
to	O
the	O
IDC	B-malignancy-type
.	O
This	O
is	O
the	O
first	O
report	O
in	O
which	O
the	O
DNA	O
sequence	O
of	O
K-ras	O
mutation	O
was	O
determined	O
for	O
the	O
two	O
sporadic	B-malignancy-type
pancreatic	I-malignancy-type
cancers	I-malignancy-type
and	O
surrounding	O
duct	O
changes	O
.	O
The	O
following	O
two	O
suggestions	O
are	O
made	O
:	O
(1)	O
the	O
cell	O
-	O
origin	O
might	O
have	O
differed	O
between	O
the	O
two	O
types	O
of	O
cancer	O
(	O
IDC	B-malignancy-type
and	O
IPMC	B-malignancy-type
)	O
;	O
and	O
(2)	O
no	O
precursor	O
lesion	O
toward	O
IDC	B-malignancy-type
or	O
IPMC	B-malignancy-type
was	O
identified	O
in	O
their	O
surrounding	O
duct	O
epithelium	O
.	O
PMID	O
:	O
12072425	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatobiliary	O
Pancreat	O
Surg	O
2002;9(	O
1	O
)	O
:76	O
-	O
85	O
p16	O
and	O
p53	O
gene	O
alterations	O
and	O
accumulations	O
in	O
the	O
malignant	O
evolution	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
of	O
the	O
pancreas	O
.	O
Wada	O
K.	O
Department	O
of	O
Surgery	O
,	O
Teikyo	O
University	O
School	O
of	O
Medicine	O
,	O
2	O
-	O
11	O
-	O
1	O
Kaga	O
,	O
Itabashi	O
-	O
ku	O
,	O
Tokyo	O
173	O
-	O
8605	O
,	O
Japan	O
.	O
BACKGROUND	O
/	O
PURPOSE	O
:	O
In	O
general	O
,	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
of	O
the	O
pancreas	O
have	O
a	O
favorable	O
prognosis	O
.	O
However	O
,	O
some	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
show	O
a	O
rapid	O
progression	O
and	O
a	O
poor	O
prognosis	O
,	O
such	O
as	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
pancreas	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
genetic	O
backgrounds	O
underlying	O
the	O
evolution	O
necessary	O
for	O
these	O
tumors	O
to	O
become	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
METHODS	O
:	O
Twenty-three	O
patients	O
with	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
,	O
including	O
9	O
adenomas	B-malignancy-type
,	O
5	O
borderline	B-malignancy-type
tumors	I-malignancy-type
,	O
3	O
noninvasive	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
6	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
,	O
along	O
with	O
24	O
patients	O
with	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
were	O
studied	O
.	O
After	O
microdissection	O
,	O
K	O
-	O
ras	O
mutation	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
the	O
p16	O
and	O
p53	O
genes	O
were	O
investigated	O
.	O
RESULTS	O
:	O
In	O
the	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
,	O
K	O
-	O
ras	O
mutations	O
were	O
frequently	O
seen	O
,	O
without	O
a	O
relationship	O
to	O
histological	O
grade	O
.	O
LOH	O
of	O
the	O
p16	O
gene	O
was	O
observed	O
increasingly	O
with	O
increasing	O
degrees	O
of	O
histological	O
atypia	O
.	O
LOH	O
of	O
the	O
p53	O
gene	O
was	O
seen	O
only	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
frequency	O
of	O
each	O
genetic	O
alteration	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
was	O
the	O
same	O
as	O
that	O
in	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
accumulation	O
of	O
genetic	O
alterations	O
was	O
as	O
common	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
,	O
as	O
they	O
were	O
in	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
The	O
p16	O
and	O
p53	O
gene	O
alterations	O
and	O
accumulations	O
observed	O
are	O
crucial	O
events	O
during	O
the	O
carcinogenesis	O
and	O
malignant	O
progression	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
of	O
the	O
pancreas	O
.	O
PMID	O
:	O
12021900	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
2002	O
Jun;26(	O
6)	O
:601	O
-	O
6	O
A	O
case	O
of	O
smouldering	B-malignancy-type
mastocytosis	I-malignancy-type
with	O
peripheral	O
blood	O
eosinophilia	O
and	O
lymphadenopathy	O
.	O
Hauswirth	O
AW	O
,	O
Sperr	O
WR	O
,	O
Ghannadan	O
M,	O
Schernthaner	O
GH	O
,	O
Jordan	O
JH	O
,	O
Fritsche	O
-	O
Polanz	O
R,	O
Simonitsch	O
-	O
Klupp	O
I	O
,	O
Fodinger	O
M,	O
Lechner	O
K	O
,	O
Valent	O
P.	O
Department	O
of	O
Internal	O
Medicine	O
I	O
,	O
Division	O
of	O
Hematology	O
and	O
Hemostaseology	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
Systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
SM	B-malignancy-type
)	O
is	O
a	O
clonal	O
hematologic	O
disease	O
showing	O
abnormal	O
growth	O
and	O
accumulation	O
of	O
mast	O
cells	O
(	O
MC	O
)	O
in	O
visceral	O
organs	O
with	O
or	O
without	O
skin	O
involvement	O
.	O
The	O
clinical	O
course	O
in	O
SM	B-malignancy-type
is	O
variable	O
.	O
In	O
fact	O
,	O
indolent	O
and	O
aggressive	O
variants	O
have	O
been	O
described	O
.	O
In	O
addition	O
,	O
SM	B-malignancy-type
patients	O
may	O
acquire	O
an	O
associated	O
hematologic	O
clonal	O
non	B-malignancy-type
-	I-malignancy-type
MC	I-malignancy-type
lineage	I-malignancy-type
disease	I-malignancy-type
(	O
AHNMD	B-malignancy-type
)	O
.	O
In	O
some	O
cases	O
,	O
hematologic	O
parameters	O
are	O
indicative	O
of	O
slowly	O
progressing	O
SM	B-malignancy-type
although	O
the	O
clinical	O
course	O
remains	O
indolent	O
over	O
years	O
.	O
These	O
cases	O
have	O
been	O
referred	O
to	O
as	O
smouldering	B-malignancy-type
SM	I-malignancy-type
.	O
We	O
report	O
on	O
a	O
smouldering	B-malignancy-type
patient	O
presenting	O
with	O
typical	O
skin	B-malignancy-type
lesions	I-malignancy-type
,	O
hypercellular	O
marrow	O
with	O
focal	O
MC	O
aggregates	O
,	O
persistent	O
leukocytosis	O
(	O
20,000	O
-	O
30,000	O
/	O
microl	O
)	O
with	O
eosinophilia	O
(	O
5	O
-	O
10	O
%	O
)	O
,	O
marked	O
lymphadenopathy	O
,	O
and	O
splenomegaly	O
.	O
The	O
C-KIT	O
mutation	O
Asp	O
-	O
816	O
-	O
Val	O
confirmed	O
the	O
diagnosis	O
of	O
SM	B-malignancy-type
.	O
The	O
clinical	O
picture	O
remained	O
stable	O
during	O
an	O
observation	O
period	O
of	O
10	O
years	O
without	O
signs	O
of	O
progression	O
to	O
an	O
AHNMD	B-malignancy-type
or	O
a	O
high	O
grade	O
MC	B-malignancy-type
disease	I-malignancy-type
.	O
These	O
data	O
show	O
that	O
some	O
patients	O
with	O
SM	B-malignancy-type
can	O
remain	O
in	O
a	O
clinically	O
indolent	O
smouldering	O
state	O
over	O
years	O
even	O
when	O
presenting	O
with	O
marked	O
eosinophilia	O
and	O
lymphadenopathy	O
.	O
PMID	O
:	O
12007509	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2002	O
Jan;33(	O
1	O
)	O
:39	O
-	O
46	O
Erratum	O
in	O
:	O
Hum	O
Pathol	O
2002	O
Mar;33(	O
3	O
)	O
:379	O
Fibromatosis	B-malignancy-type
of	O
the	O
breast	O
and	O
mutations	O
involving	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
.	O
Abraham	O
SC	O
,	O
Reynolds	O
C	O
,	O
Lee	O
JH	O
,	O
Montgomery	O
EA	O
,	O
Baisden	O
BL	O
,	O
Krasinskas	O
AM	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
MD	O
21205	O
-	O
2196	O
,	O
USA	O
.	O
Fibromatoses	B-malignancy-type
of	O
the	O
breast	O
are	O
nonmetastasizing	B-malignancy-type
tumors	I-malignancy-type
,	O
but	O
can	O
be	O
infiltrative	O
and	O
locally	O
recurrent	O
.	O
Breast	B-malignancy-type
fibromatoses	I-malignancy-type
are	O
rare	O
,	O
and	O
their	O
specific	O
genetic	O
alterations	O
have	O
not	O
been	O
elucidated	O
.	O
However	O
,	O
their	O
occasional	O
occurrence	O
in	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
and	O
their	O
morphologic	O
identification	O
with	O
other	O
deep	O
fibromatoses	B-malignancy-type
(	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
)	O
suggest	O
that	O
alterations	O
of	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
might	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
and	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
breast	I-malignancy-type
fibromatoses	I-malignancy-type
.	O
We	O
analyzed	O
somatic	O
beta-catenin	O
and	O
APC	O
gene	O
mutations	O
in	O
33	O
breast	B-malignancy-type
fibromatoses	I-malignancy-type
(	O
32	O
sporadic	B-malignancy-type
and	O
1	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
)	O
using	O
immunohistochemistry	O
for	O
beta-catenin	O
,	O
5q	O
allelic	O
loss	O
assays	O
,	O
and	O
direct	O
DNA	O
sequencing	O
for	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
and	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
.	O
Nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
present	O
in	O
the	O
stromal	B-malignancy-type
tumor	I-malignancy-type
cells	O
in	O
most	O
(	O
82	O
%	O
)	O
cases	O
but	O
not	O
in	O
normal	O
stroma	O
or	O
mammary	O
epithelial	O
cells	O
.	O
Somatic	O
alterations	O
of	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
were	O
detected	O
in	O
79	O
%	O
of	O
breast	B-malignancy-type
fibromatoses	I-malignancy-type
,	O
including	O
activating	O
beta-catenin	O
gene	O
mutations	O
in	O
15	O
cases	O
and	O
somatic	O
APC	O
alterations	O
(	O
mutation	O
or	O
5q	O
allelic	O
loss	O
or	O
both	O
)	O
in	O
11	O
.	O
These	O
findings	O
indicate	O
that	O
alterations	O
of	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
with	O
resultant	O
nuclear	O
translocation	O
of	O
beta-catenin	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
both	O
sporadic	B-malignancy-type
and	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
breast	I-malignancy-type
fibromatosis	I-malignancy-type
.	O
The	O
spectrum	O
of	O
beta-catenin	O
and	O
APC	O
alterations	O
is	O
similar	O
to	O
that	O
described	O
for	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
abdomen	O
,	O
paraspinal	O
region	O
,	O
and	O
extremities	O
.	O
Copyright	O
2002	O
by	O
W.B.	O
Saunders	O
Company	O
PMID	O
:	O
11823972	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

World	O
J	O
Gastroenterol	O
2001	O
Jun;7(	O
3	O
)	O
:352	O
-	O
6	O
APC	O
and	O
K-ras	O
gene	O
mutation	O
in	O
aberrant	B-malignancy-type
crypt	I-malignancy-type
foci	I-malignancy-type
of	O
human	O
colon	O
.	O
Yuan	O
P	O
,	O
Sun	O
MH	O
,	O
Zhang	O
JS	O
,	O
Zhu	O
XZ	O
,	O
Shi	O
DR.	O
Department	O
of	O
Pathology	O
,	O
Medical	O
College	O
of	O
Fudan	O
University	O
,	O
Shanghai	O
2000	O
32	O
,	O
China	O
.	O
AIM	O
:	O
To	O
study	O
the	O
genetic	O
alteration	O
in	O
ACF	B-malignancy-type
and	O
to	O
define	O
the	O
possibility	O
that	O
ACF	O
may	O
be	O
a	O
very	O
early	O
morphological	O
lesion	O
with	O
molecular	O
changes	O
,	O
and	O
to	O
explore	O
the	O
relationship	O
between	O
ACF	B-malignancy-type
and	O
colorectal	B-malignancy-type
adenoma	I-malignancy-type
even	O
carcinoma	B-malignancy-type
.	O
METHODS	O
:	O
DNA	O
from	O
35	O
CRC	B-malignancy-type
,	O
15	O
adenomas	B-malignancy-type
,	O
34	O
ACF	B-malignancy-type
and	O
10	O
normal	O
mucus	O
was	O
isolated	O
by	O
means	O
of	O
microdissection	O
.	O
Direct	O
gene	O
sequencing	O
of	O
K-ras	O
gene	O
including	O
codon	O
12	O
,	O
13	O
and	O
61	O
as	O
well	O
as	O
the	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
of	O
APC	O
gene	O
was	O
performed	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutation	O
frequency	O
in	O
ACF	B-malignancy-type
,	O
adenoma	B-malignancy-type
and	O
carcinoma	B-malignancy-type
was	O
17.6	O
%	O
(	O
6	O
/	O
34	O
)	O
,	O
13.3	O
%	O
(	O
2	O
/	O
15	O
)	O
,	O
and	O
14.3	O
%	O
(	O
5	O
/	O
35	O
)	O
respectively	O
,	O
showing	O
no	O
difference	O
(	O
P	O
>	O
0.05	O
)	O
in	O
K-ras	O
gene	O
mutation	O
among	O
three	O
pathologic	O
procedures	O
.	O
The	O
K-ras	O
gene	O
mutation	O
in	O
adenoma	B-malignancy-type
,	O
carcinoma	B-malignancy-type
and	O
4	O
ACF	B-malignancy-type
restricted	O
in	O
codon	O
12	O
(	O
GGT	O
GAT	O
)	O
,	O
but	O
the	O
other	O
2	O
mutations	O
from	O
ACF	B-malignancy-type
located	O
in	O
codon	O
13	O
(	O
GGC	O
GAC	O
)	O
.	O
K-ras	O
gene	O
mutation	O
was	O
found	O
more	O
frequently	O
in	O
older	O
patients	O
and	O
patients	O
with	O
polypoid	B-malignancy-type
cancer	I-malignancy-type
.	O
No	O
mutation	O
in	O
codon	O
61	O
was	O
found	O
in	O
the	O
three	O
tissue	O
types	O
.	O
Mutation	O
rate	O
of	O
APC	O
gene	O
in	O
adenoma	B-malignancy-type
and	O
carcinoma	B-malignancy-type
was	O
22.9	O
%	O
(	O
8	O
/	O
35	O
)	O
and	O
26.7	O
%	O
(	O
4	O
/	O
15	O
)	O
,	O
which	O
was	O
higher	O
than	O
ACF	B-malignancy-type
(	O
2.9	O
%	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
APC	O
gene	O
mutation	O
in	O
carcinoma	B-malignancy-type
was	O
not	O
correlated	O
with	O
age	O
of	O
patients	O
,	O
location	O
,	O
size	O
and	O
differentiation	O
of	O
tumor	O
.	O
CONCLUSION	O
:	O
ACF	B-malignancy-type
might	O
be	O
a	O
very	O
early	O
morphological	O
lesion	O
in	O
the	O
tumorogenesis	O
of	O
colorectal	B-malignancy-type
tumor	I-malignancy-type
.	O
The	O
morphological	O
feature	O
and	O
gene	O
mutation	O
status	O
was	O
different	O
in	O
ACF	B-malignancy-type
and	O
adenoma	B-malignancy-type
.	O
ACF	B-malignancy-type
is	O
possibly	O
putative	O
microadenoma	B-malignancy-type
that	O
might	O
be	O
the	O
precursor	O
of	O
adenoma	B-malignancy-type
.	O
In	O
addition	O
,	O
the	O
development	O
of	O
a	O
subgroup	O
of	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
might	O
undergo	O
a	O
way	O
of	O
normal	B-malignancy-type
epithelium	I-malignancy-type
ACF	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
11819789	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
2002	O
Feb;38(	O
2	O
)	O
:104	O
-	O
8	O
Prognostic	O
impact	O
of	O
molecular	O
genetic	O
alterations	O
in	O
hepatoblastoma	B-malignancy-type
.	O
von	O
Schweinitz	O
D	O
,	O
Kraus	O
JA	O
,	O
Albrecht	O
S,	O
Koch	O
A	O
,	O
Fuchs	O
J,	O
Pietsch	O
T.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Basle	O
Childrens	O
'	O
Hospital	O
,	O
Basle	O
,	O
Switzerland	O
.	O
Dietrich	O
.vonSchweinitz@unibas	O
.ch	O
BACKGROUND	O
:	O
During	O
recent	O
years	O
,	O
we	O
identified	O
characteristic	O
genetic	O
alterations	O
in	O
sporadic	B-malignancy-type
hepatoblastoma	I-malignancy-type
(	O
HB	B-malignancy-type
)	O
.	O
These	O
include	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
chromosomal	O
region	O
11p15.5	O
,	O
LOH	O
on	O
chromosome	O
arms	O
1p	O
and	O
1q	O
,	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
as	O
well	O
as	O
overexpression	O
of	O
the	O
c-met	O
oncogene	O
,	O
which	O
encodes	O
the	O
hepatocyte	O
growth	O
factor	O
receptor	O
.	O
We	O
now	O
wanted	O
to	O
evaluate	O
the	O
prognostic	O
relevance	O
of	O
these	O
abnormalities	O
concerning	O
the	O
outcome	O
in	O
a	O
large	O
group	O
of	O
patients	O
.	O
PROCEDURE	O
:	O
All	O
but	O
7	O
of	O
56	O
patients	O
with	O
HB	B-malignancy-type
were	O
treated	O
either	O
with	O
primary	O
resection	O
for	O
small	O
tumors	O
,	O
or	O
neo	O
-	O
adjuvant	O
chemotherapy	O
with	O
ifosfamide	O
,	O
cisplatin	O
and	O
doxorubicin	O
(	O
IPA	O
)	O
before	O
delayed	O
surgery	O
in	O
case	O
of	O
extended	O
disease	O
and	O
additional	O
adjuvant	O
IPA	O
therapy	O
in	O
all	O
cases	O
.	O
Seven	O
tumors	O
were	O
primarily	O
resected	O
and	O
adjuvantly	O
treated	O
with	O
different	O
cytotoxic	O
drugs	O
.	O
LOH	O
11p15.5	O
,	O
LOH	O
1p	O
,	O
and	O
LOH	O
1q	O
were	O
detected	O
in	O
tumor	O
tissue	O
in	O
comparison	O
to	O
normal	O
liver	O
and/or	O
peripheral	O
blood	O
leukocytes	O
by	O
PCR	O
based	O
microsatellite	O
analysis	O
.	O
Beta-catenin	O
mutations	O
were	O
analysed	O
with	O
SSCP	O
,	O
deletion	O
screening	O
and	O
direct	O
sequencing	O
.	O
RT	O
-	O
PCR	O
was	O
used	O
for	O
identification	O
of	O
c-met	O
mRNA	O
overexpression	O
.	O
The	O
results	O
were	O
correlated	O
with	O
the	O
tumors	O
'	O
stage	O
,	O
histological	O
type	O
and	O
epithelial	O
differentiation	O
,	O
as	O
well	O
as	O
with	O
the	O
patients	O
'	O
outcome	O
.	O
RESULTS	O
:	O
Overall	O
disease	O
-	O
free	O
survival	O
after	O
median	O
follow	O
-	O
up	O
of	O
5	O
years	O
was	O
43	O
/	O
56	O
patients	O
(	O
77	O
%	O
)	O
.	O
LOH	O
11p15.5	O
was	O
found	O
in	O
15	O
/	O
56	O
,	O
LOH	O
1p	O
in	O
11	O
/	O
53	O
,	O
LOH	O
1q	O
in	O
7	O
/	O
53	O
and	O
beta-catenin	O
mutations	O
in	O
25	O
/	O
55	O
HB	B-malignancy-type
.	O
13	O
/	O
23	O
HB	B-malignancy-type
had	O
a	O
c-met	O
overexpression	O
.	O
LOH	O
11p15.5	O
and	O
LOH	O
1p	O
were	O
significantly	O
more	O
often	O
found	O
in	O
embryonal	O
HB	B-malignancy-type
,	O
while	O
there	O
was	O
no	O
correlation	O
of	O
other	O
genetic	O
alterations	O
with	O
histological	O
type	O
or	O
differentiation	O
.	O
Furthermore	O
,	O
statistical	O
analysis	O
revealed	O
no	O
correlation	O
of	O
any	O
of	O
these	O
disorders	O
with	O
initial	O
tumor	O
stage	O
,	O
nor	O
with	O
the	O
patients	O
'	O
outcome	O
.	O
CONCLUSION	O
:	O
None	O
of	O
the	O
investigated	O
molecular	O
genetic	O
alterations	O
are	O
suited	O
to	O
serve	O
as	O
a	O
prognostic	O
indicator	O
in	O
HB	B-malignancy-type
.	O
Further	O
investigations	O
,	O
especially	O
genetic	O
screening	O
of	O
tumor	O
tissue	O
may	O
reveal	O
prognostic	O
markers	O
for	O
this	O
neoplasm	B-malignancy-type
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11813174	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Nov	O
15;61(	O
22	O
)	O
:8118	O
-	O
21	O
KIT	O
activation	O
is	O
a	O
ubiquitous	O
feature	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Rubin	O
BP	O
,	O
Singer	O
S,	O
Tsao	O
C	O
,	O
Duensing	O
A	O
,	O
Lux	O
ML	O
,	O
Ruiz	O
R,	O
Hibbard	O
MK	O
,	O
Chen	O
CJ	O
,	O
Xiao	O
S,	O
Tuveson	O
DA	O
,	O
Demetri	O
GD	O
,	O
Fletcher	O
CD	O
,	O
Fletcher	O
JA.	O
Department	O
of	O
Pathology	O
,	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
,	O
75	O
Francis	O
Street	O
,	O
Boston	O
,	O
MA	O
02115	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
they	O
are	O
generally	O
resistant	O
to	O
chemotherapy	O
and	O
radiation	O
therapy	O
.	O
Most	O
GISTs	B-malignancy-type
express	O
the	O
KIT	O
receptor	O
tyrosine	O
kinase	O
protein	O
,	O
and	O
a	O
subset	O
of	O
GISTs	B-malignancy-type
contain	O
activating	O
mutations	O
within	O
the	O
KIT	O
juxtamembrane	O
region	O
.	O
We	O
evaluated	O
48	O
GISTs	B-malignancy-type
,	O
including	O
10	O
benign	O
,	O
10	O
borderline	O
,	O
and	O
28	O
malignant	O
cases	O
,	O
to	O
determine	O
whether	O
KIT	O
expression	O
and	O
activation	O
are	O
general	O
properties	O
of	O
these	O
tumors	O
.	O
Immunohistochemical	O
KIT	O
expression	O
was	O
demonstrated	O
in	O
each	O
case	O
.	O
Somatic	O
KIT	O
mutations	O
were	O
found	O
in	O
44	O
tumors	O
(	O
92	O
%	O
)	O
,	O
of	O
which	O
34	O
(	O
71	O
%	O
)	O
had	O
juxtamembrane	O
region	O
mutations	O
.	O
Other	O
GISTs	B-malignancy-type
had	O
KIT	O
mutations	O
in	O
the	O
extracellular	O
region	O
(	O
n	O
=	O
6	O
)	O
and	O
in	O
two	O
different	O
regions	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
(	O
n	O
=	O
4	O
)	O
.	O
Contrary	O
to	O
previous	O
reports	O
,	O
KIT	O
mutations	O
were	O
not	O
identified	O
preferentially	O
in	O
higher	O
-	O
grade	O
tumors	O
:	O
indeed	O
,	O
they	O
were	O
found	O
in	O
each	O
of	O
10	O
histologically	O
benign	O
GISTs	B-malignancy-type
.	O
Notably	O
,	O
mutations	O
in	O
all	O
KIT	O
domains	O
were	O
associated	O
with	O
high	O
-	O
level	O
KIT	O
activation	O
/	O
phosphorylation	O
,	O
and	O
KIT	O
activation	O
was	O
also	O
demonstrated	O
in	O
the	O
four	O
GISTs	B-malignancy-type
that	O
lacked	O
detectable	O
KIT	O
genomic	O
and	O
cDNA	O
mutations	O
.	O
These	O
studies	O
underscore	O
the	O
role	O
of	O
KIT	O
activation	O
in	O
GIST	B-malignancy-type
pathogenesis	O
,	O
and	O
they	O
suggest	O
that	O
activated	O
KIT	O
might	O
represent	O
a	O
universal	O
therapeutic	O
target	O
in	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
11719439	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
2001	O
Sep;195(	O
2	O
)	O
:222	O
-	O
8	O
beta-catenin	O
nuclear	O
expression	O
correlates	O
with	O
cyclin	O
D1	O
overexpression	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumours	I-malignancy-type
.	O
Saito	O
T	O
,	O
Oda	O
Y	O
,	O
Tanaka	O
K	O
,	O
Matsuda	O
S,	O
Tamiya	O
S,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
The	O
immunohistochemical	O
expression	O
of	O
beta-catenin	O
,	O
cyclin	O
D1	O
,	O
Ki-67	O
and	O
PCNA	O
was	O
Examined	O
in	O
38	O
cases	O
of	O
sporadic	B-malignancy-type
extra	I-malignancy-type
-	I-malignancy-type
abdominal	I-malignancy-type
or	O
abdominal	B-malignancy-type
-	I-malignancy-type
wall	I-malignancy-type
desmoid	I-malignancy-type
tumours	I-malignancy-type
without	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
,	O
to	O
evaluate	O
the	O
hypothesis	O
that	O
the	O
accumulated	O
beta-catenin	O
within	O
the	O
nuclei	O
could	O
affect	O
the	O
regulation	O
of	O
the	O
cyclin	O
D1	O
gene	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
beta-catenin	O
accumulation	O
and	O
cyclin	O
D1	O
overexpression	O
(	O
p	O
=	O
0.029	O
)	O
.	O
Each	O
group	O
with	O
beta-catenin	O
accumulation	O
or	O
cyclin	O
D1	O
overexpression	O
showed	O
a	O
higher	O
PCNA	O
-	O
LI	O
than	O
those	O
without	O
,	O
the	O
difference	O
being	O
statistically	O
significant	O
(	O
p	O
=	O
0.007	O
,	O
p	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O
Differential	O
PCR	O
was	O
also	O
performed	O
to	O
detect	O
amplification	O
of	O
the	O
cyclin	O
D1	O
gene	O
and	O
mutational	O
analysis	O
was	O
undertaken	O
for	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Amplification	O
of	O
the	O
cyclin	O
D1	O
gene	O
was	O
observed	O
in	O
13	O
out	O
of	O
22	O
cases	O
(	O
59.1	O
%	O
)	O
.	O
There	O
were	O
nine	O
-	O
point	O
mutations	O
in	O
7	O
out	O
of	O
18	O
cases	O
(	O
38.9	O
%	O
)	O
.	O
The	O
distribution	O
of	O
beta-catenin	O
mutation	O
fell	O
within	O
a	O
wide	O
range	O
,	O
from	O
codon	O
21	O
to	O
codon	O
67	O
.	O
In	O
conclusion	O
,	O
beta-catenin	O
nuclear	O
expression	O
correlated	O
with	O
cyclin	O
D1	O
overexpression	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumours	I-malignancy-type
,	O
which	O
could	O
be	O
an	O
in	O
vivo	O
model	O
system	O
for	O
the	O
APC	O
-	O
beta-catenin	O
-	O
Tcf	O
pathway	O
.	O
In	O
addition	O
,	O
beta-catenin	O
mutations	O
in	O
desmoid	B-malignancy-type
tumours	I-malignancy-type
occurred	O
at	O
an	O
unusually	O
wide	O
range	O
of	O
sites	O
within	O
the	O
gene	O
.	O
Copyright	O
2001	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
PMID	O
:	O
11592102	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Endocrinol	O
(	O
Oxf	O
)	O
2001	O
Aug;55(	O
2	O
)	O
:241	O
-	O
8	O
Ras	O
mutations	O
are	O
rare	O
in	O
solitary	O
cold	O
and	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
Krohn	O
K	O
,	O
Reske	O
A	O
,	O
Ackermann	O
F	O
,	O
Muller	O
A	O
,	O
Paschke	O
R.	O
III	O
Medical	O
Department	O
,	O
University	O
of	O
Leipzig	O
,	O
Leipzig	O
,	O
Germany	O
.	O
OBJECTIVE	O
:	O
Activation	O
of	O
ras	O
proto	O
-	O
oncogenes	O
as	O
a	O
result	O
of	O
point	O
mutations	O
is	O
detectable	O
in	O
a	O
significant	O
percentage	O
of	O
most	O
types	O
of	O
tumour	O
.	O
Similar	O
to	O
neoplasms	O
of	O
other	O
organs	O
,	O
mutations	O
of	O
all	O
three	O
ras	O
genes	O
can	O
be	O
found	O
in	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
.	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
mutations	O
have	O
been	O
detected	O
in	O
up	O
to	O
20	O
%	O
of	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
and	O
adenomatous	B-malignancy-type
nodules	I-malignancy-type
which	O
were	O
not	O
functionally	O
characterized	O
.	O
This	O
raises	O
the	O
question	O
as	O
to	O
whether	O
ras	O
mutations	O
are	O
specific	O
for	O
hypofunctional	O
nodules	O
and	O
TSH	O
receptor	O
mutations	O
for	O
hyperfunctioning	O
nodules	O
.	O
DESIGN	O
:	O
To	O
investigate	O
ras	O
and	O
TSH	O
receptor	O
mutations	O
with	O
respect	O
to	O
functional	O
differentiation	O
we	O
studied	O
41	O
scintigraphically	O
cold	O
nodules	B-malignancy-type
and	O
47	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
To	O
address	O
the	O
likelihood	O
of	O
a	O
somatic	O
mutation	O
we	O
also	O
studied	O
the	O
clonal	O
origin	O
of	O
these	O
tumours	O
.	O
MEASUREMENTS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
nodular	O
and	O
surrounding	O
tissue	O
.	O
Mutational	O
hot	O
spots	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
H	O
-	O
and	O
K	O
-	O
ras	O
gene	O
were	O
PCR	O
amplified	O
and	O
sequenced	O
using	O
big	O
dye	O
terminator	O
chemistry	O
.	O
Denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
was	O
used	O
to	O
verify	O
sequencing	O
results	O
for	O
the	O
H-ras	O
gene	O
and	O
to	O
analyse	O
the	O
N-ras	O
gene	O
because	O
its	O
greater	O
sensitivity	O
in	O
detecting	O
somatic	O
mutations	O
.	O
Clonality	O
of	O
nodular	O
thyroid	O
tissue	O
was	O
evaluated	O
using	O
X	O
-	O
Chromosome	O
inactivation	O
based	O
on	O
PCR	O
amplification	O
of	O
the	O
human	O
androgen	O
receptor	O
locus	O
.	O
RESULTS	O
:	O
Monoclonal	O
origin	O
was	O
detectable	O
in	O
14	O
of	O
23	O
informative	O
samples	O
from	O
cold	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
In	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
the	O
frequency	O
of	O
clonal	O
tissue	O
was	O
20	O
in	O
30	O
informative	O
cases	O
.	O
Only	O
one	O
point	O
mutation	O
could	O
be	O
found	O
in	O
the	O
N-ras	O
gene	O
codon	O
61	O
(	O
Gly	O
to	O
Arg	O
)	O
in	O
a	O
cold	O
adenomatous	B-malignancy-type
nodule	I-malignancy-type
which	O
was	O
monoclonal	O
.	O
In	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
no	O
ras	O
mutation	O
was	O
detectable	O
.	O
CONCLUSION	O
:	O
Our	O
study	O
suggests	O
that	O
ras	O
mutations	O
are	O
rare	O
in	O
solitary	O
cold	O
and	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
and	O
that	O
the	O
frequent	O
monoclonal	O
origin	O
of	O
these	O
tumours	O
implies	O
somatic	O
mutations	O
in	O
genes	O
other	O
than	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
.	O
PMID	O
:	O
11531932	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
2001	O
Sep;82(	O
3	O
)	O
:450	O
-	O
5	O
Cytoplasmic	O
/	O
nuclear	O
expression	O
without	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
is	O
frequent	O
in	O
the	O
development	O
of	O
the	O
neoplasm	B-malignancy-type
of	O
the	O
uterine	O
cervix	O
.	O
Shinohara	O
A	O
,	O
Yokoyama	O
Y	O
,	O
Wan	O
X	O
,	O
Takahashi	O
Y	O
,	O
Mori	O
Y	O
,	O
Takami	O
T	O
,	O
Shimokawa	O
K	O
,	O
Tamaya	O
T.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Gifu	O
University	O
School	O
of	O
Medicine	O
,	O
40	O
Tsukasa	O
-	O
machi	O
,	O
Gifu	O
,	O
500	O
-	O
8705	O
,	O
Japan	O
.	O
OBJECTIVE	O
:	O
The	O
dual	O
function	O
of	O
beta-catenin	O
(	O
e.g.	O
,	O
as	O
an	O
intermediate	O
protein	O
between	O
adherence	O
junctions	O
and	O
the	O
microfilaments	O
,	O
and	O
as	O
a	O
mediator	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
)	O
is	O
currently	O
known	O
.	O
Stabilization	O
of	O
beta-catenin	O
and	O
subsequent	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
are	O
involved	O
in	O
the	O
development	O
of	O
some	O
malignancies	O
.	O
We	O
analyzed	O
the	O
immunohistochemical	O
localization	O
of	O
beta-catenin	O
and	O
the	O
somatic	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
the	O
malignant	O
phenotype	O
of	O
the	O
uterine	O
cervix	O
.	O
METHODS	O
:	O
Immunohistochemical	O
localization	O
of	O
beta-catenin	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
were	O
analyzed	O
in	O
38	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
and	O
43	O
cancerous	B-malignancy-type
lesions	I-malignancy-type
.	O
RESULTS	O
:	O
In	O
normal	O
cervix	O
,	O
beta-catenin	O
was	O
observed	O
around	O
the	O
plasma	O
membrane	O
of	O
the	O
cells	O
in	O
the	O
basal	O
and	O
parabasal	O
layers	O
of	O
the	O
epithelium	O
.	O
The	O
frequency	O
of	O
cytoplasmic	O
/	O
nuclear	O
beta-catenin	O
expression	O
correlated	O
with	O
a	O
high	O
histological	O
grade	O
of	O
cervical	B-malignancy-type
intraepithelial	I-malignancy-type
neoplasia	I-malignancy-type
.	O
Among	O
invasive	O
carcinomas	B-malignancy-type
,	O
11	O
(	O
73	O
%	O
)	O
of	O
15	O
samples	O
showed	O
cytoplasmic	O
/	O
nuclear	O
localization	O
to	O
variable	O
extents	O
.	O
A	O
mutational	O
analysis	O
showed	O
that	O
mutation	O
occurred	O
in	O
7	O
of	O
68	O
specimens	O
.	O
Six	O
cases	O
with	O
mutations	O
revealed	O
cytoplasmic	O
/	O
nuclear	O
beta-catenin	O
expression	O
,	O
though	O
32	O
(	O
84	O
%	O
)	O
of	O
the	O
38	O
samples	O
showing	O
cytoplasmic	O
/	O
nuclear	O
beta-catenin	O
expression	O
were	O
not	O
associated	O
with	O
the	O
mutation	O
.	O
CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
cytoplasmic	O
/	O
nuclear	O
expression	O
of	O
beta-catenin	O
is	O
associated	O
with	O
the	O
malignant	O
phenotype	O
of	O
the	O
cervix	O
,	O
but	O
the	O
contribution	O
of	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
is	O
limited	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11520139	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Digestion	O
2001;63(	O
4)	O
:229	O
-	O
33	O
K-ras	O
and	O
p53	O
mutations	O
in	O
colonic	O
lavage	O
fluid	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
neoplasias	I-malignancy-type
.	O
Heinzlmann	O
M,	O
Neynaber	O
S,	O
Heldwein	O
W	O
,	O
Folwaczny	O
C.	O
Department	O
of	O
Gastroenterology	O
,	O
Medizinische	O
Klinik	O
Innenstadt	O
,	O
Ludwig	O
-	O
Maximilians	O
-	O
Universitat	O
,	O
Munchen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
The	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
has	O
its	O
molecular	O
basis	O
in	O
several	O
gene	O
mutations	O
of	O
which	O
K-ras	O
and	O
p53	O
are	O
of	O
paramount	O
importance	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
whether	O
these	O
genetic	O
alterations	O
can	O
be	O
detected	O
in	O
colonic	O
lavage	O
fluid	O
from	O
patients	O
with	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
METHODS	O
:	O
In	O
45	O
patients	O
with	O
adenomas	B-malignancy-type
,	O
20	O
patients	O
with	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
and	O
38	O
patients	O
with	O
non	O
-	O
neoplastic	O
and	O
noninflammatory	O
diseases	O
of	O
the	O
colon	O
p53	O
and	O
K-ras	O
mutations	O
were	O
evaluated	O
in	O
colonic	O
lavage	O
fluid	O
employing	O
single	O
-	O
strand	O
confirmation	O
polymorphism	O
analysis	O
and	O
dot	O
-	O
blot	O
hybridization	O
,	O
respectively	O
.	O
RESULTS	O
:	O
Mutations	O
of	O
the	O
K-ras	O
and	O
the	O
p53	O
gene	O
were	O
found	O
in	O
15.6	O
%	O
(	O
p	O
=	O
0.065	O
)	O
of	O
patients	O
with	O
adenomas	B-malignancy-type
,	O
in	O
25.0	O
%	O
(	O
p	O
=	O
0.016	O
)	O
of	O
patients	O
with	O
carcinomas	B-malignancy-type
and	O
in	O
2.6	O
%	O
in	O
the	O
control	O
group	O
.	O
CONCLUSION	O
:	O
Genetic	O
alterations	O
in	O
the	O
colonic	O
lavage	O
fluid	O
could	O
be	O
an	O
additional	O
diagnostic	O
tool	O
for	O
the	O
surveillance	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
neoplasias	I-malignancy-type
.	O
PMID	O
:	O
11435722	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Formos	O
Med	O
Assoc	O
2001	O
May	O
;100(	O
5	O
)	O
:352	O
-	O
4	O
K-ras	O
mutation	O
at	O
codon	O
12	O
in	O
stage	O
I	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
:	O
analysis	O
by	O
laser	O
capture	O
microdissection	O
and	O
direct	O
sequencing	O
.	O
Chang	O
MC	O
,	O
Chang	O
YT	O
,	O
Wu	O
MS	O
,	O
Shun	O
CT	O
,	O
Tien	O
YW	O
,	O
Lin	O
JT.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
7	O
Chung	O
-	O
Shan	O
South	O
Road	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
Pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
has	O
been	O
reported	O
to	O
carry	O
a	O
rate	O
mutation	O
high	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
.	O
To	O
avoid	O
the	O
pitfalls	O
of	O
conventional	O
methods	O
of	O
tissue	O
dissection	O
that	O
might	O
affect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
detecting	O
K-ras	O
mutation	O
,	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
technique	O
was	O
used	O
.	O
Pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
tissues	O
were	O
obtained	O
from	O
15	O
patients	O
who	O
underwent	O
Whipple	O
's	O
procedure	O
.	O
Selected	O
tissues	O
procured	O
by	O
LCM	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
after	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
K-ras	O
sequences	O
at	O
codon	O
12	O
.	O
K-ras	O
mutation	O
was	O
noted	O
in	O
nine	O
patients	O
.	O
All	O
mutations	O
showed	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
12	O
.	O
The	O
mutational	O
pattern	O
(	O
GGT	O
to	O
GAT	O
)	O
is	O
similar	O
in	O
both	O
western	O
and	O
eastern	O
reports	O
.	O
LCM	O
is	O
a	O
feasible	O
method	O
to	O
effectively	O
obtain	O
pure	O
tumor	O
cells	O
from	O
a	O
surgical	O
specimen	O
.	O
It	O
remains	O
to	O
be	O
determined	O
whether	O
this	O
low	O
mutation	O
rate	O
is	O
a	O
result	O
of	O
relatively	O
early	O
stage	O
of	O
disease	O
or	O
different	O
carcinogenesis	O
in	O
different	O
geographic	O
regions	O
.	O
PMID	O
:	O
11432318	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2001	O
Jul	O
-	O
Aug;8(	O
4)	O
:889	O
-	O
92	O
K-ras	O
gene	O
mutations	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
in	O
Japanese	O
.	O
Noda	O
N	O
,	O
Matsuzoe	O
D	O
,	O
Konno	O
T	O
,	O
Kawahara	O
K	O
,	O
Yamashita	O
Y	O
,	O
Shirakusa	O
T.	O
Second	O
Department	O
of	O
Surgery	O
,	O
Fukuoka	O
University	O
School	O
of	O
Medicine	O
,	O
7	O
-	O
45	O
-	O
1	O
Nanakuma	O
,	O
Johnan	O
-	O
ku	O
,	O
Fukuoka	O
City	O
,	O
Fukuoka	O
814	O
-0180	O
,	O
Japan	O
.	O
n	O
-	O
nao@pop17.odn	O
.ne	O
.jp	O
To	O
evaluate	O
the	O
association	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
with	O
the	O
incidence	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
in	O
Japanese	O
patients	O
,	O
410	O
patients	O
treated	O
surgically	O
were	O
studied	O
.	O
DNA	O
was	O
extracted	O
from	O
frozen	O
specimens	O
,	O
and	O
polymerase	O
chain	O
reaction	O
-	O
sequence	O
specific	O
oligonucleotide	O
probe	O
(	O
PCR	O
-	O
SSOP	O
)	O
hybridization	O
assay	O
was	O
used	O
to	O
examine	O
K-ras	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
33	O
patients	O
(	O
8.0	O
%	O
)	O
,	O
and	O
all	O
were	O
smokers	O
or	O
ex	O
-	O
smokers	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
clinical	O
or	O
pathological	O
stage	O
between	O
wild	O
-	O
type	O
cases	O
and	O
mutant	O
cases	O
.	O
The	O
most	O
frequently	O
identified	O
mutation	O
was	O
a	O
G	O
-->	O
T	O
transversion	O
(	O
25	O
/	O
33	O
,	O
75.8	O
%	O
)	O
that	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
glycine	O
for	O
a	O
cysteine	O
or	O
a	O
valine	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
the	O
majority	O
of	O
K-ras	O
mutations	O
among	O
smokers	O
are	O
G	O
-->	O
T	O
transversion	O
.	O
In	O
our	O
study	O
,	O
K-ras	O
mutations	O
were	O
found	O
only	O
in	O
smokers	O
,	O
and	O
there	O
was	O
a	O
high	O
frequency	O
of	O
G	O
-->	O
T	O
transversions	O
.	O
A	O
clear	O
correlation	O
exists	O
between	O
smoking	O
and	O
K-ras	O
gene	O
mutations	O
.	O
PMID	O
:	O
11410804	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Jun	O
1;61(	O
11	O
)	O
:4350	O
-	O
6	O
p53	O
and	O
K-ras	O
mutations	O
in	O
lung	B-malignancy-type
cancers	I-malignancy-type
from	O
former	O
and	O
never	O
-	O
smoking	O
women	O
.	O
Vahakangas	O
KH	O
,	O
Bennett	O
WP	O
,	O
Castren	O
K	O
,	O
Welsh	O
JA	O
,	O
Khan	O
MA	O
,	O
Blomeke	O
B	O
,	O
Alavanja	O
MC	O
,	O
Harris	O
CC.	O
Department	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Oulu	O
,	O
P.	O
O.	O
Box	O
5000	O
,	O
FIN	O
-	O
90014	O
Oulu	O
,	O
Finland	O
.	O
Somatic	O
p53	O
mutations	O
are	O
common	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Active	O
cigarette	O
smoking	O
is	O
positively	O
correlated	O
with	O
the	O
total	O
frequency	O
of	O
p53	O
mutations	O
and	O
G	O
:	O
C	O
to	O
T	O
:	O
A	O
transversions	O
on	O
the	O
nontranscribed	O
(	O
DNA	O
coding	O
)	O
strand	O
.	O
Mutational	O
hotspots	O
within	O
the	O
p53	O
gene	O
,	O
e.g.	O
,	O
codon	O
157	O
,	O
have	O
been	O
identified	O
for	O
tobacco	O
-	O
related	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
whereas	O
these	O
same	O
mutations	O
are	O
found	O
rarely	O
in	O
other	O
cancers	O
.	O
Such	O
data	O
implicate	O
specific	O
p53	O
mutations	O
as	O
molecular	O
markers	O
of	O
smoking	O
.	O
Because	O
limited	O
data	O
exist	O
concerning	O
the	O
p53	O
mutation	O
frequency	O
and	O
spectra	O
in	O
ex	O
-	O
smokers	O
and	O
nonsmokers	O
,	O
we	O
have	O
analyzed	O
p53	O
and	O
K-ras	O
mutations	O
in	O
126	O
lung	B-malignancy-type
cancers	I-malignancy-type
from	O
a	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
of	O
nonsmoking	O
(	O
n	O
=	O
117	O
)	O
or	O
ex	O
-	O
smoking	O
(	O
n	O
=	O
9	O
)	O
women	O
from	O
Missouri	O
with	O
quantitative	O
assessments	O
of	O
exposure	O
to	O
environmental	O
tobacco	O
smoke	O
.	O
Mutations	O
in	O
the	O
p53	O
gene	O
were	O
found	O
in	O
lung	B-malignancy-type
cancers	I-malignancy-type
from	O
lifetime	O
nonsmokers	O
(	O
19	O
%	O
)	O
and	O
ex	O
-	O
smokers	O
(	O
67	O
%	O
;	O
odds	O
ratio	O
,	O
9.08	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
2.06	O
-	O
39.98	O
)	O
.	O
All	O
deletions	O
were	O
found	O
in	O
tumors	O
from	O
patients	O
who	O
were	O
either	O
ex	O
-	O
smokers	O
or	O
nonsmokers	O
exposed	O
to	O
passive	O
smoking	O
.	O
The	O
G	O
:	O
C	O
to	O
A	O
:	O
T	O
transitions	O
(	O
11	O
of	O
28	O
;	O
39	O
%	O
)	O
were	O
the	O
most	O
frequent	O
p53	O
mutations	O
found	O
and	O
clustered	O
in	O
tumors	O
from	O
lifetime	O
nonsmokers	O
without	O
passive	O
smoke	O
exposure	O
.	O
The	O
incidence	O
of	O
K-ras	O
codon	O
12	O
or	O
13	O
mutations	O
was	O
11	O
%	O
(	O
14	O
of	O
115	O
analyzed	O
)	O
with	O
no	O
difference	O
between	O
long	O
-	O
term	O
ex	O
-	O
smokers	O
and	O
nonsmokers	O
.	O
These	O
and	O
other	O
results	O
indicate	O
that	O
p53	O
mutations	O
occur	O
more	O
commonly	O
in	O
smokers	O
and	O
ex	O
-	O
smokers	O
than	O
in	O
never	O
-	O
smokers	O
.	O
Such	O
comparisons	O
provide	O
additional	O
evidence	O
of	O
genetic	O
damage	O
caused	O
by	O
tobacco	O
smoke	O
during	O
lung	O
carcinogenesis	O
.	O
PMID	O
:	O
11389059	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
2001	O
Jul;25(	O
7)	O
:627	O
-	O
34	O
A	O
case	O
of	O
'	B-malignancy-type
smouldering	I-malignancy-type
'	I-malignancy-type
mastocytosis	I-malignancy-type
with	O
high	O
mast	O
cell	O
burden	O
,	O
monoclonal	O
myeloid	O
cells	O
,	O
and	O
C-KIT	O
mutation	O
Asp	O
-	O
816	O
-	O
Val	O
.	O
Jordan	O
JH	O
,	O
Fritsche	O
-	O
Polanz	O
R,	O
Sperr	O
WR	O
,	O
Mitterbauer	O
G	O
,	O
Fodinger	O
M,	O
Schernthaner	O
GH	O
,	O
Christian	O
Bankl	O
H	O
,	O
Gebhart	O
W	O
,	O
Chott	O
A	O
,	O
Lechner	O
K	O
,	O
Valent	O
P.	O
Department	O
of	O
Internal	O
Medicine	O
I	O
,	O
Division	O
of	O
Hematology	O
and	O
Hemostaseology	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
Mastocytosis	B-malignancy-type
is	O
a	O
term	O
used	O
for	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
abnormal	O
growth	O
and	O
accumulation	O
of	O
tissue	O
mast	O
cells	O
(	O
MC	O
)	O
in	O
one	O
or	O
more	O
organ	O
systems	O
.	O
In	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
SM	B-malignancy-type
)	O
the	O
clinical	O
course	O
may	O
be	O
indolent	O
or	O
aggressive	O
or	O
even	O
complicated	O
by	O
leukemic	O
progression	O
or	O
an	O
associated	B-malignancy-type
clonal	I-malignancy-type
hematologic	I-malignancy-type
non	I-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
lineage	I-malignancy-type
disease	I-malignancy-type
(	O
AHNMD	B-malignancy-type
)	O
.	O
However	O
,	O
at	O
first	O
presentation	O
(	O
diagnosis	O
)	O
it	O
may	O
be	O
difficult	O
to	O
define	O
the	O
category	O
of	O
disease	O
and	O
the	O
prognosis	O
.	O
We	O
report	O
on	O
a	O
48	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
SM	B-malignancy-type
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
-	I-malignancy-type
like	I-malignancy-type
skin	I-malignancy-type
lesions	I-malignancy-type
and	O
mediator	O
-	O
related	O
symptoms	O
.	O
She	O
was	O
found	O
to	O
have	O
splenomegaly	O
,	O
a	O
high	O
infiltration	O
grade	O
(	O
MC	O
)	O
in	O
bone	O
marrow	O
biopsies	O
(	O
>	O
30	O
%	O
)	O
,	O
mild	O
anemia	O
,	O
and	O
a	O
high	O
serum	O
tryptase	O
level	O
(	O
>	O
500	O
ng	O
/	O
ml	O
)	O
.	O
In	O
addition	O
,	O
she	O
exhibited	O
discrete	O
histologic	O
signs	O
of	O
myeloproliferation	O
in	O
the	O
'	O
non	O
-	O
affected	O
'	O
marrow	O
and	O
monoclonal	O
blood	O
cells	O
established	O
by	O
C-KIT	O
2468	O
A	O
-->	O
T	O
mutation	O
(	O
Asp	O
-	O
816	O
-	O
Val	O
)	O
-	O
analysis	O
and	O
HUMARA	O
assay	O
.	O
Despite	O
these	O
findings	O
,	O
however	O
,	O
the	O
clinical	O
course	O
was	O
stable	O
over	O
years	O
and	O
no	O
AHNMD	B-malignancy-type
or	O
organ	O
impairment	O
developed	O
.	O
Because	O
of	O
the	O
'	O
intermediate	O
'	O
clinical	O
signs	O
and	O
absence	O
of	O
progression	O
to	O
aggressive	O
disease	O
,	O
we	O
proposed	O
the	O
term	O
'	B-malignancy-type
smouldering	I-malignancy-type
mastocytosis	I-malignancy-type
'	I-malignancy-type
.	O
PMID	O
:	O
11377687	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2001	O
May;92(	O
5	O
)	O
:494	O
-	O
8	O
Mutations	O
in	O
c-kit	O
gene	O
exons	O
9	O
and	O
13	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
among	O
Japanese	O
.	O
Sakurai	O
S,	O
Oguni	O
S,	O
Hironaka	O
M,	O
Fukayama	O
M,	O
Morinaga	O
S,	O
Saito	O
K.	O
Department	O
of	O
Pathology	O
,	O
Jichi	O
Medical	O
School	O
,	O
Minamikawachi	O
-	O
machi	O
,	O
Kawachi	O
-	O
gun	O
,	O
Tochigi	O
329	O
-	O
0498	O
,	O
Japan	O
.	O
ssakurai@jichi	O
.ac.	O
jp	O
Gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
c-kit	O
proto	O
-	O
oncogene	O
exon	O
11	O
has	O
been	O
described	O
in	O
about	O
20	O
--	O
50	O
%	O
of	O
gastrointestinal	B-malignancy-type
stroma	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
.	O
Recently	O
,	O
additional	O
mutational	O
hot	O
-	O
spots	O
in	O
exon	O
9	O
and	O
exon	O
13	O
of	O
the	O
c-kit	O
gene	O
have	O
been	O
reported	O
in	O
GISTs	B-malignancy-type
without	O
mutations	O
of	O
exon	O
11	O
,	O
but	O
a	O
subsequent	O
report	O
in	O
a	O
Western	O
population	O
indicated	O
that	O
only	O
a	O
small	O
portion	O
of	O
GISTs	B-malignancy-type
(	O
eight	O
of	O
200	O
GISTs	B-malignancy-type
,	O
4	O
%	O
)	O
showed	O
mutations	O
in	O
these	O
regions	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
mutations	O
in	O
exon	O
9	O
and	O
exon	O
13	O
of	O
the	O
c-kit	O
gene	O
by	O
both	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
in	O
48	O
GISTs	B-malignancy-type
in	O
a	O
Japanese	O
population	O
,	O
for	O
which	O
the	O
clinicopathological	O
and	O
immunohistochemical	O
features	O
and	O
mutations	O
in	O
exon	O
11	O
had	O
previously	O
been	O
reported	O
.	O
C-kit	O
gene	O
mutation	O
in	O
exon	O
9	O
,	O
representing	O
insertion	O
of	O
GCC	O
TAT	O
,	O
was	O
identified	O
in	O
only	O
4	O
of	O
48	O
GISTs	B-malignancy-type
(	O
8	O
%	O
)	O
,	O
and	O
none	O
of	O
the	O
GISTs	B-malignancy-type
had	O
mutations	O
in	O
exon	O
13	O
.	O
All	O
four	O
GISTs	B-malignancy-type
with	O
mutation	O
in	O
exon	O
9	O
were	O
high	O
-	O
risk	O
,	O
and	O
the	O
patients	O
died	O
of	O
multiple	O
tumor	O
metastasis	O
.	O
Mutations	O
in	O
exon	O
9	O
and	O
exon	O
13	O
of	O
the	O
c-kit	O
gene	O
were	O
also	O
rare	O
events	O
in	O
Japanese	O
GISTs	B-malignancy-type
and	O
were	O
related	O
to	O
a	O
poor	O
prognosis	O
.	O
These	O
results	O
in	O
Japanese	O
are	O
consistent	O
with	O
those	O
in	O
Western	O
populations	O
,	O
although	O
a	O
preferential	O
occurrence	O
of	O
GISTs	B-malignancy-type
with	O
exon	O
9	O
mutation	O
in	O
the	O
small	O
intestine	O
,	O
which	O
was	O
suggested	O
in	O
a	O
previous	O
report	O
,	O
was	O
not	O
observed	O
.	O
PMID	O
:	O
11376557	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Nippon	O
Med	O
Sch	O
2001	O
Apr;68(	O
2	O
)	O
:143	O
-	O
8	O
[	O
Abnormalities	O
of	O
the	O
p53	O
,	O
N-ras	O
,	O
DCC	O
and	O
FLT-3	O
genes	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
]	O
[Article	O
in	O
Japanese	O
]	O
Nakamura	O
K	O
,	O
Inokuchi	O
K	O
,	O
Dan	O
K.	O
Department	O
of	O
3rd	O
Internal	O
Medicine	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
molecular	O
mechanism	O
of	O
carcinogenesis	O
is	O
a	O
multistep	O
process	O
that	O
is	O
characterized	O
by	O
both	O
activation	O
of	O
oncogenes	O
and	O
inactivation	O
of	O
tumor	O
suppressor	O
genes	O
.	O
In	O
the	O
present	O
study	O
,	O
mutations	O
of	O
N-ras	O
,	O
p53	O
and	O
FMS	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	O
FLT-3	O
)	O
genes	O
and	O
loss	O
of	O
expression	O
of	O
the	O
deleted	O
in	O
colorectal	O
carcinoma	O
(	O
DCC	O
)	O
gene	O
were	O
analyzed	O
in	O
59	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Mutations	O
of	O
N-ras	O
,	O
p53	O
,	O
and	O
FLT-3	O
genes	O
were	O
detected	O
in	O
7	O
,	O
7	O
,	O
1	O
of	O
the	O
59	O
patients	O
with	O
MDS	B-malignancy-type
,	O
respectively	O
.	O
Loss	O
of	O
DCC	O
expression	O
was	O
detected	O
in	O
16	O
patients	O
.	O
Type	O
of	O
MDS	B-malignancy-type
patients	O
with	O
N-ras	O
mutation	O
were	O
all	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
in	O
transformation	O
(	O
RAEB-T	O
)	O
.	O
Abnormalities	O
of	O
p53	O
and	O
DCC	O
genes	O
were	O
significantly	O
associated	O
with	O
survival	O
time	O
(	O
p	O
<	O
0.02	O
,	O
p	O
<	O
0.004	O
,	O
respectively	O
)	O
.	O
PMID	O
:	O
11301359	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2001	O
Apr;14(	O
4)	O
:343	O
-	O
9	O
H-ras	O
oncogene	O
mutation	O
in	O
dedifferentiated	B-malignancy-type
chondrosarcoma	I-malignancy-type
:	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O
Sakamoto	O
A	O
,	O
Oda	O
Y	O
,	O
Adachi	O
T	O
,	O
Oshiro	O
Y	O
,	O
Tamiya	O
S,	O
Tanaka	O
K	O
,	O
Matsuda	O
S,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Pathological	O
Sciences	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Dedifferentiated	B-malignancy-type
chondrosarcomas	I-malignancy-type
,	O
which	O
are	O
known	O
for	O
their	O
poor	O
prognosis	O
,	O
are	O
characterized	O
by	O
conventional	B-malignancy-type
chondrosarcoma	I-malignancy-type
with	O
high	O
-	O
grade	O
anaplastic	O
components	O
.	O
Activating	O
mutations	O
in	O
ras	O
genes	O
are	O
a	O
common	O
genetic	O
abnormality	O
in	O
human	O
malignancies	O
.	O
The	O
presence	O
of	O
point	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
H-ras	O
gene	O
was	O
studied	O
in	O
20	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
chondrosarcomas	B-malignancy-type
,	O
comprising	O
11	O
cases	O
of	O
conventional	B-malignancy-type
chondrosarcoma	I-malignancy-type
(	O
six	O
Grade	O
1	O
cases	O
and	O
five	O
Grade	O
2	O
cases	O
)	O
and	O
nine	O
cases	O
of	O
dedifferentiated	B-malignancy-type
chondrosarcoma	I-malignancy-type
,	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
direct	O
sequencing	O
analysis	O
.	O
H-ras	O
mutations	O
were	O
only	O
seen	O
in	O
two	O
out	O
of	O
the	O
nine	O
cases	O
of	O
dedifferentiated	B-malignancy-type
chondrosarcoma	I-malignancy-type
(	O
2	O
/	O
9	O
,	O
22	O
%	O
)	O
and	O
they	O
were	O
not	O
seen	O
in	O
any	O
of	O
the	O
cases	O
of	O
conventional	B-malignancy-type
chondrosarcoma	I-malignancy-type
(	O
0	O
/	O
11	O
,	O
0	O
%	O
)	O
.	O
Dedifferentiated	B-malignancy-type
chondrosarcomas	I-malignancy-type
had	O
a	O
worse	O
prognosis	O
than	O
conventional	B-malignancy-type
chondrosarcomas	I-malignancy-type
(	O
P	O
<	O
.01	O
)	O
;	O
among	O
the	O
patients	O
with	O
dedifferentiated	B-malignancy-type
chondrosarcomas	I-malignancy-type
,	O
those	O
with	O
H-ras	O
mutation	O
(	O
n	O
=	O
2	O
)	O
tended	O
to	O
have	O
a	O
worse	O
prognosis	O
than	O
those	O
without	O
(	O
n	O
=	O
7	O
)	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.068	O
)	O
.	O
Our	O
results	O
would	O
seem	O
to	O
suggest	O
that	O
H-ras	O
mutation	O
may	O
occur	O
during	O
the	O
course	O
of	O
dedifferentiation	O
and	O
may	O
also	O
have	O
some	O
effect	O
on	O
malignant	O
potential	O
.	O
PMID	O
:	O
11301351	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
2001	O
Mar;44(	O
3	O
)	O
:358	O
-	O
63	O
Prognostic	O
significance	O
of	O
K-ras	O
and	O
TP53	O
mutations	O
in	O
the	O
role	O
of	O
adjuvant	O
chemotherapy	O
on	O
survival	O
in	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
.	O
Bleeker	O
WA	O
,	O
Hayes	O
VM	O
,	O
Karrenbeld	O
A	O
,	O
Hofstra	O
RM	O
,	O
Verlind	O
E	O
,	O
Hermans	O
J,	O
Poppema	O
S,	O
Buys	O
CH	O
,	O
Plukker	O
JT.	O
Department	O
of	O
Surgery	O
/	O
Surgical	O
Oncology	O
,	O
University	O
Hospital	O
Groningen	O
,	O
The	O
Netherlands	O
.	O
PURPOSE	O
:	O
Mutations	O
in	O
K-ras	O
and	O
TP53	O
genes	O
are	O
common	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
They	O
affect	O
biologic	O
behavior	O
and	O
might	O
influence	O
chemotherapy	O
susceptibility	O
in	O
these	O
tumors	O
.	O
We	O
investigated	O
whether	O
the	O
survival	O
of	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
treated	O
with	O
adjuvant	O
chemotherapy	O
is	O
influenced	O
by	O
K-ras	O
and	O
TP53	O
mutations	O
.	O
METHODS	O
:	O
Mutation	O
screening	O
of	O
the	O
hot	O
spots	O
of	O
the	O
K-ras	O
gene	O
and	O
of	O
the	O
evolutionarily	O
conserved	O
regions	O
of	O
the	O
TP53	O
gene	O
was	O
performed	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
technique	O
in	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
specimens	O
of	O
55	O
consecutive	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
treated	O
with	O
adjuvant	O
5-fluorouracil	O
-	O
based	O
chemotherapy	O
.	O
The	O
median	O
follow	O
-	O
up	O
was	O
47	O
(	O
range	O
,	O
32	O
-	O
66	O
)	O
months	O
.	O
RESULTS	O
:	O
Alterations	O
in	O
the	O
mutation	O
hot	O
spots	O
of	O
K-ras	O
were	O
found	O
at	O
codon	O
12	O
(	O
n	O
=	O
11	O
)	O
and	O
13	O
(	O
n	O
=	O
4	O
)	O
in	O
15	O
of	O
the	O
55	O
carcinomas	B-malignancy-type
(	O
27	O
percent	O
)	O
.	O
No	O
mutation	O
was	O
found	O
at	O
codon	O
61	O
.	O
Mutations	O
of	O
a	O
probably	O
causative	O
nature	O
in	O
the	O
evolutionarily	O
conserved	O
regions	O
(	O
exons	O
5	O
-	O
8	O
)	O
of	O
the	O
TP53	O
gene	O
were	O
found	O
in	O
24	O
tumors	O
(	O
44	O
percent	O
)	O
.	O
K-ras	O
and	O
TP53	O
mutations	O
were	O
found	O
equally	O
in	O
the	O
group	O
with	O
recurrent	O
disease	O
(	O
7	O
/	O
26	O
(	O
26	O
percent	O
)	O
and	O
12	O
/	O
27	O
(	O
44	O
percent	O
)	O
,	O
respectively	O
)	O
and	O
in	O
the	O
group	O
without	O
recurrences	O
(	O
8	O
/	O
28	O
(	O
24	O
percent	O
)	O
and	O
12	O
/	O
28	O
(	O
43	O
percent	O
)	O
,	O
respectively	O
)	O
.	O
Cancer	O
-	O
specific	O
survival	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
with	O
K-ras	O
or	O
TP53	O
or	O
both	O
mutated	O
and	O
nonmutated	O
tumors	O
,	O
respectively	O
(	O
log	O
-	O
rank	O
test	O
:	O
K-ras	O
,	O
P	O
=	O
0.72	O
and	O
TP53	O
,	O
P	O
=	O
0.77	O
;	O
K-ras	O
and	O
TP53	O
,	O
P	O
=	O
0.8	O
)	O
.	O
Also	O
,	O
potentially	O
aggressive	O
K-ras	O
codon	O
12	O
and	O
13	O
mutations	O
had	O
the	O
same	O
survival	O
as	O
tumors	O
without	O
these	O
mutations	O
(	O
log	O
-	O
rank	O
test	O
;	O
P	O
=	O
0.73	O
)	O
.	O
CONCLUSIONS	O
:	O
Patients	O
with	O
K-ras	O
or	O
TP53	O
or	O
both	O
mutated	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
have	O
the	O
same	O
survival	O
as	O
nonmutated	O
tumors	O
when	O
treated	O
with	O
adjuvant	O
chemotherapy	O
.	O
These	O
data	O
suggest	O
that	O
mutations	O
in	O
K-ras	O
or	O
TP53	O
alone	O
are	O
not	O
prognostic	O
indicators	O
in	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
receiving	O
adjuvant	O
5-Fluorouracil	O
-	O
based	O
therapy	O
.	O
PMID	O
:	O
11289281	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2001	O
Mar	O
;	O
158	O
(	O
3	O
)	O
:	O
1073	O
-	O
8	O
Frequent	O
beta-catenin	O
mutations	O
in	O
juvenile	O
nasopharyngeal	B-malignancy-type
angiofibromas	I-malignancy-type
.	O
Abraham	O
SC	O
,	O
Montgomery	O
EA	O
,	O
Giardiello	O
FM	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Gastroenterology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
720	O
Rutland	O
Ave	O
.	O
,	O
Baltimore	O
,	O
MD	O
21205	O
-	O
2196	O
,	O
USA	O
.	O
Juvenile	O
nasopharyngeal	B-malignancy-type
angiofibromas	I-malignancy-type
(	O
JNAs	B-malignancy-type
)	O
are	O
locally	O
aggressive	O
vascular	B-malignancy-type
tumors	I-malignancy-type
occurring	O
predominantly	O
in	O
adolescent	O
males	O
.	O
The	O
pathogenesis	O
of	O
JNAs	B-malignancy-type
is	O
unknown	O
.	O
Recently	O
,	O
JNAs	B-malignancy-type
have	O
been	O
reported	O
to	O
occur	O
at	O
increased	O
frequency	O
among	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
,	O
suggesting	O
that	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
/	O
beta-catenin	O
pathway	O
might	O
also	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
JNAs	I-malignancy-type
.	O
We	O
analyzed	O
somatic	O
beta-catenin	O
and	O
APC	O
gene	O
mutations	O
in	O
16	O
sporadic	B-malignancy-type
JNAs	I-malignancy-type
from	O
nonfamilial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
using	O
immunohistochemistry	O
for	O
beta-catenin	O
,	O
and	O
direct	O
DNA	O
sequencing	O
for	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
and	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
.	O
Nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
diffusely	O
present	O
in	O
the	O
stromal	O
cells	O
but	O
not	O
in	O
the	O
endothelial	O
cells	O
of	O
all	O
16	O
JNAs	B-malignancy-type
.	O
Activating	O
beta-catenin	O
gene	O
mutations	O
were	O
present	O
in	O
75	O
%	O
(	O
12	O
of	O
16	O
)	O
of	O
JNAs	B-malignancy-type
.	O
Six	O
JNA	B-malignancy-type
patients	O
also	O
had	O
recurrent	O
tumors	O
after	O
surgery	O
,	O
and	O
in	O
all	O
cases	O
the	O
beta-catenin	O
gene	O
status	O
of	O
the	O
recurrent	O
JNA	B-malignancy-type
was	O
identical	O
to	O
the	O
initial	O
tumor	O
.	O
No	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
were	O
detected	O
in	O
the	O
four	O
JNAs	B-malignancy-type
without	O
beta-catenin	O
mutations	O
.	O
The	O
high	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
sporadic	B-malignancy-type
JNAs	I-malignancy-type
and	O
the	O
presence	O
of	O
identical	O
beta-catenin	O
gene	O
mutations	O
in	O
recurrent	O
tumors	O
indicates	O
that	O
activating	O
beta-catenin	O
gene	O
mutations	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
JNAs	B-malignancy-type
.	O
The	O
immunohistochemical	O
localization	O
of	O
beta-catenin	O
only	O
to	O
the	O
nuclei	O
of	O
stromal	O
cells	O
further	O
suggests	O
that	O
the	O
stromal	O
cells	O
,	O
rather	O
than	O
endothelial	O
cells	O
,	O
are	O
the	O
neoplastic	O
cells	O
of	O
JNAs	B-malignancy-type
.	O
PMID	O
:	O
11238055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Oncol	O
2001	O
Jan	O
15	O
;	O
2	O
)	O
:	O
299	O
-	O
304	O
Comment	O
in	O
:	O
J	O
Clin	O
Oncol	O
.	O
2001	O
Jan	O
15	O
;	O
19	O
(	O
2	O
)	O
:	O
286	O
-	O
8	O
.	O
K-ras	O
and	O
p16	O
aberrations	O
confer	O
poor	O
prognosis	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Esteller	O
M,	O
Gonzalez	O
S,	O
Risques	O
RA	O
,	O
Marcuello	O
E	O
,	O
Mangues	O
R,	O
Germa	O
JR	O
,	O
Herman	O
JG	O
,	O
Capella	O
G	O
,	O
Peinado	O
MA.	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
MD	O
,	O
USA	O
.	O
PURPOSE	O
:	O
Mutations	O
in	O
the	O
K-ras	O
gene	O
are	O
frequent	O
in	O
human	O
cancer	O
.	O
ras	O
activation	O
in	O
primary	O
cells	O
results	O
in	O
a	O
cellular	O
senescence	O
phenotype	O
that	O
is	O
precluded	O
by	O
inactivation	O
of	O
p16	O
.	O
At	O
the	O
clinical	O
level	O
,	O
this	O
may	O
imply	O
a	O
differential	O
behavior	O
for	O
tumors	O
with	O
alternative	O
or	O
cooperative	O
activation	O
of	O
K-ras	O
function	O
and	O
impairment	O
of	O
p16	O
pathways	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
have	O
determined	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
and	O
the	O
methylation	O
status	O
of	O
p16	O
promoter	O
in	O
a	O
series	O
of	O
119	O
prospectively	O
collected	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
p53	O
mutations	O
and	O
p14	O
alternative	O
reading	O
frame	O
methylation	O
status	O
were	O
also	O
assessed	O
.	O
Associations	O
with	O
survival	O
were	O
investigated	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
present	O
in	O
44	O
(	O
38	O
%	O
)	O
of	O
115	O
cases	O
,	O
and	O
p16	O
methylation	O
was	O
present	O
in	O
42	O
(	O
37	O
%	O
)	O
of	O
113	O
cases	O
.	O
p53	O
mutations	O
were	O
detected	O
in	O
50	O
%	O
(	O
56	O
of	O
115	O
)	O
and	O
p14	O
methylation	O
in	O
29	O
%	O
(	O
32	O
of	O
112	O
)	O
of	O
cases	O
.	O
K-ras	O
and	O
p16	O
alterations	O
were	O
independent	O
genetic	O
events	O
.	O
Presence	O
of	O
K-ras	O
or	O
p16	O
genetic	O
alterations	O
(	O
analyzed	O
independently	O
)	O
was	O
associated	O
with	O
shorter	O
survival	O
,	O
although	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
Cox	O
analysis	O
of	O
the	O
two	O
variables	O
combined	O
showed	O
a	O
diminished	O
survival	O
as	O
the	O
results	O
of	O
an	O
interaction	O
between	O
p16	O
and	O
K-ras	O
.	O
Alternative	O
alteration	O
of	O
K-ras	O
and	O
p16	O
genes	O
was	O
an	O
independent	O
prognostic	O
factor	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
in	O
univariate	O
and	O
multivariate	O
analysis	O
.	O
Differences	O
were	O
maintained	O
when	O
cases	O
undergoing	O
radical	O
surgery	O
and	O
without	O
distant	O
metastases	O
were	O
considered	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
combined	O
K-ras	O
and	O
p16	O
analyses	O
may	O
be	O
of	O
prognostic	O
use	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Evaluation	O
Studies	O
PMID	O
:	O
11208819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2001	O
Mar	O
-	O
Apr	O
;	O
(	O
2	O
)	O
:	O
249	O
-	O
55	O
Expression	O
of	O
E-cadherin	O
and	O
beta-catenin	O
in	O
primary	O
and	O
peritoneal	B-malignancy-type
metastatic	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Fujioka	O
T	O
,	O
Takebayashi	O
Y	O
,	O
Kihana	O
T	O
,	O
Kusanagi	O
Y	O
,	O
Hamada	O
K	O
,	O
Ochi	O
H	O
,	O
Uchida	O
T	O
,	O
Fukumoto	O
M,	O
Ito	O
M.	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Development	O
,	O
Aging	O
and	O
Cancer	O
,	O
Tohoku	O
University	O
,	O
Aoba	O
-	O
ku	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
fujioka@idac.tohoku.ac.	O
jp	O
Protein	O
expression	O
levels	O
of	O
E-cadherin	O
and	O
beta-catenin	O
were	O
examined	O
in	O
39	O
primary	O
and	O
10	O
metastatic	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
to	O
elucidate	O
the	O
role	O
of	O
these	O
molecules	O
in	O
the	O
extension	O
of	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
by	O
immunohistochemistry	O
.	O
Twenty-two	O
of	O
39	O
(	O
56	O
%	O
)	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
were	O
preserved	O
type	O
and	O
17	O
of	O
39	O
(	O
44	O
%	O
)	O
were	O
reduced	O
type	O
of	O
E-cadherin	O
.	O
In	O
contrast	O
,	O
36	O
of	O
39	O
(	O
92	O
%	O
)	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
were	O
preserved	O
type	O
and	O
3	O
of	O
39	O
(	O
8	O
%	O
)	O
were	O
reduced	O
type	O
of	O
beta-catenin	O
.	O
E-cadherin	O
expression	O
in	O
well	O
-	B-malignancy-type
differentiated	I-malignancy-type
carcinoma	I-malignancy-type
was	O
higher	O
than	O
that	O
in	O
moderately	O
/	O
poorly	O
-	O
differentiated	O
carcinoma	B-malignancy-type
(	O
p	O
<	O
0.05	O
)	O
.	O
Interestingly	O
,	O
6	O
of	O
10	O
(	O
60	O
%	O
)	O
peritoneal	B-malignancy-type
metastatic	I-malignancy-type
lesions	I-malignancy-type
resulted	O
in	O
the	O
reduced	O
expression	O
of	O
E-cadherin	O
compared	O
with	O
primary	O
lesions	O
.	O
In	O
contrast	O
,	O
only	O
2	O
of	O
10	O
(	O
20	O
%	O
)	O
metastatic	O
lesions	O
showed	O
reduced	O
expression	O
of	O
beta-catenin	O
compared	O
with	O
primary	O
lesions	O
.	O
Mutation	O
of	O
exon	O
3	O
of	O
beta-catenin	O
gene	O
was	O
rare	O
(	O
3	O
%	O
,	O
1	O
/	O
39	O
)	O
in	O
carcinoma	B-malignancy-type
.	O
These	O
results	O
suggested	O
that	O
the	O
cell	O
adhesion	O
molecule	O
E-cadherin	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
peritoneal	B-malignancy-type
metastasis	I-malignancy-type
.	O
In	O
contrast	O
,	O
beta-catenin	O
is	O
not	O
a	O
good	O
indicator	O
of	O
metastasis	O
in	O
human	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
11182035	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gut	O
2001	O
Mar	O
;	O
48	O
(	O
3	O
)	O
:	O
403	O
-	O
8	O
K-ras	O
mutations	O
in	O
the	O
bile	O
of	O
patients	O
with	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
.	O
Kubicka	O
S,	O
Kuhnel	O
F	O
,	O
Flemming	O
P	O
,	O
Hain	O
B	O
,	O
Kezmic	O
N	O
,	O
Rudolph	O
KL	O
,	O
Manns	O
M,	O
Meier	O
PN.	O
Department	O
of	O
Gastroenterology	O
and	O
Hepatology	O
,	O
Medizinische	O
Hochschule	O
Hannover	O
,	O
Carl	O
Neubergstrasse	O
1	O
,	O
30625	O
Hannover	O
,	O
Germany	O
.	O
BACKGROUND	O
AND	O
AIMS	O
:	O
The	O
development	O
of	O
cholangiocarcinoma	B-malignancy-type
(	O
CCC	B-malignancy-type
)	O
is	O
a	O
complication	O
of	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
(	O
PSC	B-malignancy-type
)	O
.	O
To	O
date	O
,	O
no	O
reliable	O
factors	O
have	O
been	O
described	O
which	O
can	O
define	O
those	O
PSC	B-malignancy-type
patients	O
at	O
high	O
risk	O
for	O
the	O
development	O
of	O
CCC	B-malignancy-type
and	O
the	O
clinical	O
diagnosis	O
of	O
CCC	B-malignancy-type
in	O
PSC	B-malignancy-type
patients	O
is	O
difficult	O
.	O
Therefore	O
,	O
molecular	O
markers	O
of	O
cholangiocarcinogenesis	O
,	O
such	O
as	O
K-ras	O
mutations	O
,	O
may	O
improve	O
the	O
early	O
diagnosis	O
of	O
CCC	B-malignancy-type
or	O
the	O
timing	O
of	O
liver	O
transplantation	O
.	O
METHODS	O
:	O
K-ras	O
mutations	O
were	O
analysed	O
by	O
enriched	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	O
in	O
the	O
bile	O
fluid	O
of	O
56	O
PSC	B-malignancy-type
patients	O
and	O
20	O
patients	O
with	O
other	O
cholestatic	O
diseases	O
.	O
To	O
assess	O
the	O
value	O
of	O
K-ras	O
mutations	O
as	O
a	O
risk	O
factor	O
for	O
cholangiocarcinogenesis	O
,	O
patients	O
were	O
prospectively	O
investigated	O
over	O
a	O
mean	O
period	O
of	O
31.5	O
months	O
.	O
RESULTS	O
:	O
In	O
contrast	O
with	O
the	O
control	O
group	O
,	O
17	O
(	O
30	O
%	O
)	O
patients	O
with	O
PSC	B-malignancy-type
revealed	O
K-ras	O
mutations	O
in	O
bile	O
fluid	O
.	O
The	O
mean	O
Mayo	O
score	O
was	O
not	O
significantly	O
different	O
between	O
PSC	B-malignancy-type
patients	O
with	O
(	O
mean	O
score	O
0.70	O
)	O
and	O
without	O
(	O
mean	O
score	O
0.13	O
;	O
p	O
=	O
0.2	O
)	O
K-ras	O
mutations	O
.	O
In	O
contrast	O
with	O
the	O
group	O
of	O
PSC	B-malignancy-type
patients	O
without	O
K-ras	O
mutations	O
,	O
four	O
CCCs	B-malignancy-type
and	O
two	O
dysplasia	O
were	O
diagnosed	O
in	O
the	O
group	O
of	O
patients	O
with	O
K-ras	O
mutations	O
during	O
the	O
follow	O
up	O
investigation	O
(	O
p	O
<	O
0.001	O
)	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
K-ras	O
mutations	O
in	O
bile	O
fluid	O
of	O
PSC	B-malignancy-type
patients	O
represent	O
frequent	O
early	O
events	O
during	O
cholangiocarcinogenesis	O
.	O
However	O
,	O
most	O
of	O
the	O
PSC	B-malignancy-type
patients	O
with	O
K-ras	O
mutations	O
remained	O
tumour	O
free	O
after	O
a	O
long	O
follow	O
up	O
investigation	O
which	O
is	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
these	O
mutations	O
are	O
not	O
specific	O
for	O
malignancy	O
but	O
may	O
also	O
occur	O
in	O
normal	O
bile	O
duct	O
mucosa	O
or	O
in	O
dysplasias	B-malignancy-type
.	O
Therefore	O
,	O
analysis	O
of	O
K-ras	O
mutations	O
in	O
bile	O
should	O
not	O
be	O
used	O
for	O
diagnosis	O
of	O
CCC	B-malignancy-type
in	O
PSC	B-malignancy-type
patients	O
.	O
However	O
,	O
the	O
results	O
of	O
our	O
prospective	O
follow	O
up	O
investigation	O
indicate	O
that	O
K-ras	O
mutations	O
in	O
bile	O
fluid	O
of	O
PSC	B-malignancy-type
patients	O
have	O
to	O
be	O
considered	O
as	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CCC	B-malignancy-type
which	O
may	O
have	O
implications	O
for	O
the	O
timing	O
of	O
liver	O
transplantation	O
.	O
PMID	O
:	O
11171833	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2001	O
Feb	O
163	O
(	O
1	O
)	O
:	O
125	O
-	O
30	O
Somatic	O
beta-catenin	O
mutation	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
--	O
an	O
infrequent	O
event	O
that	O
is	O
not	O
specific	O
for	O
microsatellite	O
instability	O
.	O
Tong	O
JH	O
,	O
To	O
KF	O
,	O
Ng	O
EK	O
,	O
Lau	O
JY	O
,	O
Lee	O
TL	O
,	O
Lo	O
KW	O
,	O
Leung	O
WK	O
,	O
Tang	O
NL	O
,	O
Chan	O
FK	O
,	O
Sung	O
JJ	O
,	O
Chung	O
SC	O
.	O
Department	O
of	O
Anatomical	O
and	O
Cellular	O
Pathology	O
,	O
Prince	O
of	O
Wales	O
Hospital	O
,	O
The	O
Chinese	O
University	O
of	O
Hong	O
Kong	O
,	O
Shatin	O
,	O
Hong	O
Kong	O
SAR	O
,	O
PR	O
China	O
.	O
We	O
screened	O
90	O
cases	O
of	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
(	O
GCA	B-malignancy-type
)	O
samples	O
for	O
beta-catenin	O
exon	O
3	O
mutation	O
and	O
assessed	O
its	O
possible	O
relationship	O
with	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
Three	O
mutations	O
were	O
detected	O
in	O
two	O
samples	O
,	O
including	O
a	O
single	O
mutation	O
in	O
an	O
intestinal	B-malignancy-type
type	I-malignancy-type
and	O
double	O
mutations	O
in	O
a	O
diffuse	B-malignancy-type
type	I-malignancy-type
GCA	I-malignancy-type
.	O
One	O
of	O
the	O
mutations	O
found	O
in	O
the	O
diffuse	B-malignancy-type
type	I-malignancy-type
GCA	I-malignancy-type
sample	O
was	O
a	O
non	O
-	O
sense	O
mutation	O
at	O
codon	O
68	O
(	O
CAG	O
-->	O
TAG	O
)	O
.	O
This	O
novel	O
mutation	O
was	O
predicted	O
to	O
disrupt	O
the	O
binding	O
of	O
beta-catenin	O
to	O
alpha-catenin	O
and	O
may	O
be	O
related	O
to	O
the	O
diffuse	O
type	O
morphology	O
.	O
The	O
other	O
two	O
mutations	O
were	O
missense	O
mutations	O
involved	O
or	O
related	O
to	O
the	O
GSK-3beta	O
phosphorylation	O
site	O
,	O
which	O
have	O
been	O
reported	O
previously	O
.	O
No	O
MSI	O
can	O
be	O
demonstrated	O
in	O
the	O
two	O
cases	O
with	O
beta-catenin	O
mutation	O
.	O
Our	O
results	O
suggested	O
that	O
beta-catenin	O
mutation	O
was	O
infrequent	O
in	O
GCA	B-malignancy-type
and	O
appeared	O
not	O
specific	O
for	O
MSI	O
.	O
PMID	O
:	O
11163116	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
2001	O
Jan;84(	O
2	O
)	O
:253	O
-	O
62	O
Pancreatic	B-malignancy-type
tumours	I-malignancy-type
:	O
molecular	O
pathways	O
implicated	O
in	O
ductal	B-malignancy-type
cancer	I-malignancy-type
are	O
involved	O
in	O
ampullary	O
but	O
not	O
in	O
exocrine	O
nonductal	O
or	O
endocrine	O
tumorigenesis	O
.	O
Moore	O
PS	O
,	O
Orlandini	O
S,	O
Zamboni	O
G	O
,	O
Capelli	O
P	O
,	O
Rigaud	O
G	O
,	O
Falconi	O
M,	O
Bassi	O
C	O
,	O
Lemoine	O
NR	O
,	O
Scarpa	O
A.	O
Department	O
of	O
Pathology	O
,	O
Universita	O
di	O
Verona	O
,	O
Italy	O
.	O
Alterations	O
of	O
K	O
-	O
ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
/	O
Smad4	O
characterize	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
cancer	I-malignancy-type
(	O
PDC	B-malignancy-type
)	O
.	O
Reports	O
of	O
inactivation	O
of	O
these	O
latter	O
two	O
genes	O
in	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumours	I-malignancy-type
(	O
PET	B-malignancy-type
)	O
suggest	O
that	O
common	O
molecular	O
pathways	O
are	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
pancreatic	O
exocrine	O
and	O
endocrine	O
epithelia	O
.	O
We	O
characterized	O
112	O
primary	O
pancreatic	B-malignancy-type
tumours	I-malignancy-type
for	O
alterations	O
in	O
p16	O
and	O
DPC4	O
and	O
immunohistochemical	O
expression	O
of	O
DPC4	O
.	O
The	O
cases	O
included	O
34	O
PDC	O
,	O
10	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumours	I-malignancy-type
(	O
IPMT	B-malignancy-type
)	O
,	O
6	O
acinar	B-malignancy-type
carcinomas	I-malignancy-type
(	O
PAC	B-malignancy-type
)	O
,	O
5	O
solid	B-malignancy-type
-	I-malignancy-type
pseudopapillary	I-malignancy-type
tumours	I-malignancy-type
(	O
SPT	B-malignancy-type
)	O
,	O
16	O
ampulla	B-malignancy-type
of	I-malignancy-type
Vater	I-malignancy-type
cancers	I-malignancy-type
(	O
AVC	B-malignancy-type
)	O
and	O
41	O
PET	B-malignancy-type
.	O
All	O
tumours	O
were	O
also	O
presently	O
or	O
previously	O
analysed	O
for	O
K	O
-	O
ras	O
and	O
p53	O
mutations	O
and	O
allelic	O
loss	O
at	O
9p	O
,	O
17p	O
and	O
18q	O
.	O
Alterations	O
in	O
K	O
-	O
ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
were	O
found	O
in	O
82	O
%	O
,	O
53	O
%	O
,	O
38	O
%	O
and	O
9	O
%	O
of	O
PDC	B-malignancy-type
,	O
respectively	O
and	O
in	O
47	O
%	O
,	O
60	O
%	O
,	O
25	O
%	O
and	O
6	O
%	O
of	O
AVC	B-malignancy-type
.	O
Alterations	O
in	O
these	O
genes	O
were	O
virtually	O
absent	O
in	O
PET	B-malignancy-type
,	O
PAC	B-malignancy-type
or	O
SPT	B-malignancy-type
,	O
while	O
in	O
IPMT	B-malignancy-type
only	O
K	O
-	O
ras	O
mutations	O
were	O
present	O
(	O
30	O
%	O
)	O
.	O
Positive	O
immunostaining	O
confirmed	O
the	O
absence	O
of	O
DPC4	O
alterations	O
in	O
all	O
IPMT	B-malignancy-type
,	O
SPT	B-malignancy-type
,	O
PAC	B-malignancy-type
and	O
PET	B-malignancy-type
,	O
while	O
47	O
%	O
of	O
PDC	B-malignancy-type
and	O
38	O
%	O
of	O
AVC	B-malignancy-type
were	O
immunonegative	O
.	O
These	O
data	O
suggest	O
that	O
pancreatic	O
exocrine	O
and	O
endocrine	O
tumourigenesis	O
involves	O
different	O
genetic	O
targets	O
and	O
that	O
among	O
exocrine	B-malignancy-type
pancreatic	I-malignancy-type
neoplasms	I-malignancy-type
,	O
only	O
ductal	B-malignancy-type
and	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
share	O
common	O
molecular	O
events	O
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11161385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Blood	O
2001	O
Feb	O
1	O
97	O
(	O
3	O
)	O
:	O
729	O
-	O
36	O
Comment	O
in	O
:	O
Blood	O
.	O
2001	O
Aug	O
15	O
;	O
98	O
(	O
4	O
)	O
:	O
1271	O
-	O
2	O
.	O
Activated	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
is	O
an	O
oncogene	O
that	O
contributes	O
to	O
tumor	O
progression	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
Chesi	O
M,	O
Brents	O
LA	O
,	O
Ely	O
SA	O
,	O
Bais	O
C	O
,	O
Robbiani	O
DF	O
,	O
Mesri	O
EA	O
,	O
Kuehl	O
WM	O
,	O
Bergsagel	O
PL.	O
Department	O
of	O
Medicine	O
,	O
Division	O
of	O
Hematology	O
-	O
Oncology	O
,	O
New	O
York	O
Presbyterian	O
Hospital	O
-	O
Weill	O
Medical	O
College	O
of	O
Cornell	O
University	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
.	O
The	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
occurs	O
frequently	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
and	O
results	O
in	O
the	O
simultaneous	O
dysregulated	O
expression	O
of	O
2	O
potential	O
oncogenes	O
,	O
FGFR3	O
(	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
)	O
from	O
der	O
(	O
14	O
)	O
and	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
SET	O
domain	O
protein	O
/	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
candidate	O
gene	O
1	O
from	O
der	O
(	O
4	O
)	O
.	O
It	O
is	O
now	O
shown	O
that	O
myeloma	B-malignancy-type
cells	O
carrying	O
a	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
express	O
a	O
functional	O
FGFR3	O
that	O
in	O
some	O
cases	O
is	O
constitutively	O
activated	O
by	O
the	O
same	O
mutations	O
that	O
cause	O
thanatophoric	B-malignancy-type
dysplasia	I-malignancy-type
.	O
As	O
with	O
activating	O
mutations	O
of	O
K-ras	O
and	O
N-ras	O
,	O
which	O
are	O
reported	O
in	O
approximately	O
40	O
%	O
of	O
patients	O
with	O
MM	B-malignancy-type
,	O
activating	O
mutations	O
of	O
FGFR3	O
occur	O
during	O
tumor	O
progression	O
.	O
However	O
,	O
the	O
constitutive	O
activation	O
of	O
ras	O
and	O
FGFR3	O
does	O
not	O
occur	O
in	O
the	O
same	O
myeloma	B-malignancy-type
cells	O
.	O
Thus	O
the	O
activated	O
forms	O
of	O
these	O
proteins	O
appear	O
to	O
share	O
an	O
overlapping	O
role	O
in	O
tumor	O
progression	O
,	O
suggesting	O
that	O
they	O
also	O
share	O
the	O
signaling	O
cascade	O
.	O
Consistent	O
with	O
this	O
prediction	O
,	O
it	O
is	O
shown	O
that	O
activated	O
FGFR3	O
-	O
when	O
expressed	O
at	O
levels	O
similar	O
to	O
those	O
seen	O
in	O
t	O
(	O
4	O
;	O
14	O
)	O
myeloma	B-malignancy-type
-	O
is	O
an	O
oncogene	O
that	O
acts	O
through	O
the	O
MAP	O
kinase	O
pathway	O
to	O
transform	O
NIH	O
3T3	O
cells	O
,	O
which	O
can	O
then	O
generate	O
tumors	O
in	O
nude	O
mice	O
.	O
Thus	O
,	O
FGFR3	O
,	O
when	O
overexpressed	O
in	O
MM	B-malignancy-type
,	O
may	O
be	O
not	O
only	O
oncogenic	O
when	O
stimulated	O
by	O
FGF	O
ligands	O
in	O
the	O
bone	O
marrow	O
microenvironment	O
,	O
but	O
is	O
also	O
a	O
target	O
for	O
activating	O
mutations	O
that	O
enable	O
FGFR3	O
to	O
play	O
a	O
ras	O
-	O
like	O
role	O
in	O
tumor	O
progression	O
.	O
PMID	O
:	O
11157491	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Surg	O
Oncol	O
2000	O
Dec	O
;	O
75	O
(	O
4	O
)	O
:	O
246	O
-	O
51	O
K-ras	O
oncogene	O
mutation	O
in	O
cancer	B-malignancy-type
and	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
of	O
the	O
gallbladder	O
.	O
Kim	O
SW	O
,	O
Her	O
KH	O
,	O
Jang	O
JY	O
,	O
Kim	O
WH	O
,	O
Kim	O
YT	O
,	O
Park	O
YH.	O
Department	O
of	O
Surgery	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
determine	O
whether	O
K-ras	O
mutation	O
plays	O
any	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
,	O
or	O
has	O
any	O
clinical	O
or	O
pathological	O
significance	O
in	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
we	O
investigated	O
the	O
presence	O
and	O
incidence	O
of	O
this	O
mutation	O
in	O
the	O
normal	O
mucosa	O
,	O
and	O
precancerous	B-malignancy-type
and	O
cancerous	B-malignancy-type
lesions	I-malignancy-type
of	O
the	O
gallbladder	O
.	O
METHODS	O
:	O
DNA	O
was	O
obtained	O
from	O
normal	O
mucosa	O
,	O
dysplastic	O
mucosa	O
,	O
primary	O
cancer	O
tissues	O
,	O
and	O
metastatic	B-malignancy-type
lymph	I-malignancy-type
nodes	I-malignancy-type
that	O
were	O
identified	O
and	O
microdissected	O
from	O
the	O
paraffin	O
blocks	O
of	O
20	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
cases	O
.	O
K-ras	O
codon	O
12	O
mutations	O
were	O
investigated	O
using	O
a	O
modified	O
two	O
-	O
step	O
polymerase	O
chain	O
reaction	O
and	O
the	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
,	O
and	O
by	O
direct	O
sequencing	O
with	O
an	O
automated	O
sequencer	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
the	O
tissues	O
of	O
10	O
out	O
of	O
the	O
20	O
patients	O
.	O
A	O
mutation	O
was	O
present	O
in	O
the	O
dysplastic	O
epithelium	O
associated	O
with	O
the	O
primary	O
carcinoma	B-malignancy-type
in	O
3	O
out	O
of	O
12	O
specimens	O
,	O
in	O
metastatic	B-malignancy-type
carcinoma	I-malignancy-type
in	O
1	O
out	O
of	O
5	O
patients	O
,	O
and	O
in	O
primary	O
carcinoma	B-malignancy-type
in	O
8	O
out	O
of	O
20	O
patients	O
.	O
Mutation	O
was	O
found	O
only	O
once	O
in	O
the	O
dysplastic	O
,	O
noncancerous	O
epithelium	O
,	O
and	O
only	O
once	O
in	O
a	O
metastatic	B-malignancy-type
tumor	I-malignancy-type
although	O
not	O
detectable	O
in	O
the	O
primary	O
cancer	O
.	O
Direct	O
sequencing	O
showed	O
that	O
the	O
mutations	O
were	O
G	O
to	O
C	O
substitutions	O
(	O
GGT	O
-->	O
CGT	O
)	O
at	O
the	O
first	O
site	O
of	O
codon	O
12	O
,	O
except	O
in	O
two	O
cases	O
(	O
GGT	O
-->	O
TGT	O
)	O
.	O
There	O
were	O
no	O
correlations	O
between	O
K-ras	O
mutations	O
and	O
clinicopathological	O
factors	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
half	O
of	O
the	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
cases	O
.	O
We	O
suggest	O
that	O
K-ras	O
mutation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
premalignant	B-malignancy-type
lesions	I-malignancy-type
or	O
early	O
carcinogenesis	O
in	O
some	O
gallbladder	B-malignancy-type
cancers	I-malignancy-type
.	O
We	O
were	O
unable	O
to	O
find	O
any	O
evidence	O
that	O
K-ras	O
mutation	O
plays	O
any	O
role	O
in	O
tumor	O
progression	O
or	O
metastasis	O
,	O
or	O
that	O
it	O
has	O
any	O
clinicopathological	O
significance	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11135265	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Prostate	O
2000	O
Dec	O
1;45(	O
4)	O
:323	O
-	O
34	O
Detection	O
and	O
analysis	O
of	O
beta-catenin	O
mutations	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Chesire	O
DR	O
,	O
Ewing	O
CM	O
,	O
Sauvageot	O
J,	O
Bova	O
GS	O
,	O
Isaacs	O
WB.	O
Brady	O
Urological	O
Institute	O
,	O
Research	O
Laboratories	O
,	O
The	O
Johns	O
Hopkins	O
Medical	O
Institutions	O
,	O
Baltimore	O
,	O
Maryland	O
21287	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
E-cadherin	O
and	O
alpha-catenin	O
are	O
components	O
of	O
adherens	O
junctions	O
which	O
mediate	O
calcium	O
-	O
dependent	O
,	O
cell	O
-	O
cell	O
adhesion	O
in	O
a	O
homotypic	O
manner	O
.	O
Both	O
these	O
molecules	O
have	O
been	O
defined	O
as	O
useful	O
tumor	O
markers	O
as	O
their	O
altered	O
expression	O
correlates	O
with	O
increased	O
tumor	O
aggressiveness	O
and	O
dedifferentiation	O
.	O
More	O
recently	O
,	O
alterations	O
of	O
a	O
third	O
component	O
of	O
adherens	O
junctions	O
,	O
beta-catenin	O
,	O
have	O
been	O
observed	O
to	O
play	O
a	O
role	O
in	O
several	O
human	O
cancers	O
.	O
Dysregulation	O
of	O
beta-catenin	O
,	O
either	O
by	O
direct	O
mutation	O
or	O
by	O
defects	O
in	O
interacting	O
pathways	O
/	O
regulators	O
,	O
can	O
result	O
in	O
its	O
cytoplasmic	O
accumulation	O
and	O
nuclear	O
translocation	O
.	O
In	O
the	O
nucleus	O
,	O
beta-catenin	O
forms	O
a	O
transcriptional	O
complex	O
capable	O
of	O
upregulating	O
target	O
genes	O
,	O
many	O
of	O
which	O
encode	O
proliferative	O
factors	O
.	O
Given	O
its	O
oncogenic	O
activity	O
and	O
connection	O
to	O
human	O
cancer	O
,	O
we	O
examined	O
the	O
beta-catenin	O
gene	O
and	O
its	O
expression	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
By	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
DNA	O
sequencing	O
analyses	O
,	O
we	O
screened	O
exon	O
3	O
of	O
beta-catenin	O
from	O
a	O
panel	O
of	O
81	O
primary	O
tumors	O
obtained	O
at	O
radical	O
prostatectomy	O
,	O
22	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
from	O
untreated	O
patients	O
,	O
and	O
a	O
unique	O
set	O
of	O
61	O
metastatic	O
tissues	O
from	O
19	O
patients	O
who	O
died	O
of	O
hormone	O
-	O
refractory	O
disease	O
.	O
RESULTS	O
:	O
We	O
found	O
putative	O
activating	O
mutations	O
(	O
missense	O
and	O
deletion	O
)	O
at	O
a	O
rate	O
of	O
5	O
%	O
(	O
7	O
/	O
138	O
)	O
.	O
One	O
patient	O
had	O
the	O
same	O
72	O
base	O
pair	O
deletion	O
in	O
each	O
of	O
nine	O
separate	O
metastases	B-malignancy-type
examined	O
,	O
indicating	O
that	O
this	O
change	O
was	O
associated	O
with	O
a	O
clonal	O
population	O
of	O
metastatic	O
cells	O
.	O
CONCLUSIONS	O
:	O
Immunohistological	O
staining	O
of	O
mutation	O
-	O
positive	O
tumors	O
demonstrated	O
beta-catenin	O
accumulation	O
and	O
nuclear	O
localization	O
in	O
a	O
heterogeneous	O
fashion	O
.	O
Consistent	O
with	O
this	O
in	O
vivo	O
finding	O
,	O
our	O
in	O
vitro	O
analyses	O
demonstrate	O
that	O
certain	O
mutations	O
can	O
result	O
in	O
increased	O
beta-catenin	O
nuclear	O
activity	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
These	O
data	O
implicate	O
the	O
beta-catenin	O
signaling	O
pathway	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
prostate	B-malignancy-type
cancers	I-malignancy-type
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11102958	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Nov;9(	O
11	O
)	O
:1223	O
-	O
32	O
K-ras	O
and	O
p53	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
association	O
with	O
medical	O
history	O
,	O
histopathology	O
,	O
and	O
environmental	O
exposures	O
in	O
a	O
population	O
-	O
based	O
study	O
.	O
Slebos	O
RJ	O
,	O
Hoppin	O
JA	O
,	O
Tolbert	O
PE	O
,	O
Holly	O
EA	O
,	O
Brock	O
JW	O
,	O
Zhang	O
RH	O
,	O
Bracci	O
PM	O
,	O
Foley	O
J,	O
Stockton	O
P	O
,	O
McGregor	O
LM	O
,	O
Flake	O
GP	O
,	O
Taylor	O
JA.	O
Laboratory	O
of	O
Molecular	O
Carcinogenesis	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
,	O
USA	O
.	O
Pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
a	O
highly	O
fatal	O
cancer	O
with	O
few	O
identified	O
risk	O
factors	O
.	O
Increased	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
in	O
tobacco	O
smokers	O
and	O
among	O
diabetic	O
patients	O
is	O
well	O
established	O
,	O
and	O
some	O
reports	O
have	O
suggested	O
associations	O
with	O
coffee	O
consumption	O
and	O
occupational	O
exposure	O
to	O
organochlorines	O
.	O
At	O
present	O
,	O
there	O
is	O
little	O
information	O
regarding	O
the	O
possible	O
association	O
of	O
these	O
risk	O
factors	O
with	O
the	O
known	O
genetic	O
alterations	O
found	O
in	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
such	O
as	O
activation	O
of	O
the	O
K-ras	O
oncogene	O
and	O
inactivation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
.	O
Knowledge	O
of	O
such	O
relationships	O
may	O
help	O
to	O
understand	O
the	O
molecular	O
pathways	O
of	O
pancreatic	O
tumorigenesis	O
.	O
We	O
investigated	O
the	O
association	O
between	O
these	O
molecular	O
defects	O
and	O
risk	O
factors	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
in	O
61	O
newly	O
diagnosed	O
patients	O
identified	O
through	O
an	O
ongoing	O
study	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
in	O
the	O
San	O
Francisco	O
Bay	O
Area	O
.	O
Interview	O
information	O
was	O
obtained	O
regarding	O
environmental	O
exposures	O
,	O
medical	O
history	O
,	O
and	O
demographic	O
factors	O
.	O
Serum	O
levels	O
of	O
dichlorodiphenyltrichloroethylene	O
(	O
DDE	O
)	O
and	O
polychlorinated	O
biphenyls	O
were	O
available	O
on	O
a	O
subset	O
of	O
24	O
patients	O
.	O
Tumor	O
blocks	O
were	O
located	O
from	O
local	O
hospitals	O
and	O
used	O
for	O
K-ras	O
mutational	O
analysis	O
at	O
codon	O
12	O
and	O
for	O
p53	O
protein	O
immunohistochemistry	O
.	O
The	O
molecular	O
analyses	O
were	O
facilitated	O
through	O
the	O
use	O
of	O
laser	O
capture	O
microdissection	O
,	O
which	O
provides	O
a	O
reliable	O
method	O
to	O
obtain	O
almost	O
pure	O
populations	O
of	O
tumor	O
cells	O
.	O
Mutations	O
in	O
K-ras	O
codon	O
12	O
were	O
found	O
in	O
46	O
(	O
75	O
%	O
)	O
of	O
61	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
.	O
A	O
prior	O
diagnosis	O
of	O
diabetes	O
was	O
significantly	O
associated	O
with	O
K-ras	O
negative	O
tumors	O
(	O
P	O
=	O
0.002	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
The	O
absence	O
of	O
this	O
mutation	O
was	O
also	O
associated	O
with	O
increased	O
serum	O
levels	O
of	O
DDE	O
,	O
although	O
this	O
association	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.16	O
,	O
Wilcoxon	O
's	O
test	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
polychlorinated	O
biphenyl	O
levels	O
between	O
the	O
K-ras	O
wild	O
-	O
type	O
and	O
mutant	O
groups	O
.	O
Immunohistochemical	O
staining	O
for	O
p53	O
protein	O
did	O
not	O
differ	O
by	O
patient	O
characteristics	O
or	O
clinical	O
history	O
,	O
but	O
significant	O
associations	O
were	O
found	O
with	O
poor	O
glandular	O
differentiation	O
(	O
P	O
=	O
0.002	O
,	O
chi2	O
trend	O
test	O
)	O
,	O
severe	B-malignancy-type
nuclear	I-malignancy-type
atypia	I-malignancy-type
(	O
P	O
=	O
0.0007	O
,	O
chi2	O
trend	O
test	O
)	O
,	O
and	O
high	O
tumor	O
grade	O
(	O
P	O
=	O
0.004	O
,	O
chi2	O
trend	O
test	O
)	O
.	O
Our	O
results	O
are	O
suggestive	O
of	O
the	O
presence	O
of	O
K-ras	O
codon	O
12	O
mutation	O
-	O
independent	O
tumorigenesis	O
pathways	O
in	O
patients	O
with	O
prior	O
diabetes	O
and	O
possibly	O
in	O
patients	O
with	O
higher	O
serum	O
levels	O
of	O
DDE	O
.	O
Our	O
results	O
also	O
support	O
a	O
role	O
for	O
the	O
p53	O
tumor	O
suppressor	O
protein	O
in	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
.	O
PMID	O
:	O
11097231	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
2000	O
Nov;192(	O
3	O
)	O
:342	O
-	O
50	O
Prognostic	O
value	O
of	O
the	O
preserved	O
expression	O
of	O
the	O
E-cadherin	O
and	O
catenin	O
families	O
of	O
adhesion	O
molecules	O
and	O
of	O
beta-catenin	O
mutations	O
in	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
.	O
Saito	O
T	O
,	O
Oda	O
Y	O
,	O
Sakamoto	O
A	O
,	O
Tamiya	O
S,	O
Kinukawa	O
N	O
,	O
Hayashi	O
K	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
This	O
study	O
addresses	O
the	O
immunohistochemical	O
expression	O
of	O
the	O
E-cadherin	O
and	O
catenin	O
families	O
and	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
detected	O
by	O
PCR	O
-	O
SSCP	O
in	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
.	O
Immunohistochemical	O
analysis	O
was	O
performed	O
for	O
72	O
cases	O
,	O
with	O
follow	O
-	O
up	O
data	O
available	O
on	O
62	O
.	O
The	O
prognostic	O
value	O
of	O
the	O
expression	O
of	O
these	O
proteins	O
was	O
evaluated	O
.	O
Reduced	O
immunoreactivity	O
for	O
E-cadherin	O
and	O
alpha-catenin	O
was	O
significantly	O
correlated	O
with	O
a	O
poor	O
survival	O
rate	O
(	O
p	O
=	O
0.0040	O
and	O
0.0053	O
,	O
respectively	O
)	O
.	O
According	O
to	O
multivariate	O
analysis	O
,	O
low	O
AJC	O
stage	O
(	O
stages	O
I	O
and	O
II	O
:	O
p	O
<	O
0.0001	O
)	O
,	O
the	O
preservation	O
of	O
alpha-catenin	O
expression	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
and	O
a	O
low	O
necrotic	O
rate	O
(	O
<	O
50	O
%	O
:	O
p	O
=	O
0.0139	O
)	O
were	O
independent	O
favourable	O
prognostic	O
factors	O
.	O
Widespread	O
aberrant	O
staining	O
of	O
beta-catenin	O
protein	O
within	O
cytoplasm	O
and/or	O
nuclei	O
was	O
observed	O
in	O
28	O
cases	O
(	O
38.9	O
%	O
)	O
and	O
was	O
significantly	O
correlated	O
with	O
poor	O
survival	O
(	O
p	O
=	O
0.0122	O
)	O
.	O
In	O
addition	O
,	O
there	O
was	O
a	O
trend	O
towards	O
a	O
correlation	O
between	O
widespread	O
aberrant	O
staining	O
of	O
beta-catenin	O
and	O
the	O
MIB-1	O
labelling	O
index	O
(	O
p	O
=	O
0.0535	O
)	O
.	O
Mutational	O
analysis	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
performed	O
for	O
49	O
cases	O
.	O
Nucleotide	O
sequencing	O
analysis	O
revealed	O
that	O
four	O
(	O
8.2	O
%	O
)	O
contained	O
point	O
mutations	O
(	O
three	O
in	O
codon	O
32	O
,	O
GAC	O
to	O
TAC	O
;	O
one	O
in	O
codon	O
37	O
,	O
TCT	O
to	O
TTT	O
)	O
.	O
Survival	O
data	O
were	O
available	O
for	O
three	O
out	O
of	O
four	O
cases	O
with	O
beta-catenin	O
mutations	O
;	O
two	O
of	O
these	O
patients	O
died	O
within	O
1	O
year	O
(	O
died	O
of	O
disease	O
at	O
6	O
and	O
11	O
months	O
,	O
respectively	O
)	O
.	O
These	O
results	O
suggest	O
that	O
E-cadherin	O
and	O
alpha-catenin	O
undertake	O
important	O
roles	O
as	O
intercellular	O
adhesion	O
molecules	O
;	O
their	O
preserved	O
expression	O
is	O
associated	O
with	O
a	O
better	O
overall	O
survival	O
rate	O
in	O
synovial	O
sarcoma	O
and	O
may	O
have	O
prognostic	O
value	O
.	O
Abnormal	O
levels	O
of	O
beta-catenin	O
,	O
with	O
or	O
without	O
mutation	O
,	O
could	O
contribute	O
to	O
the	O
development	O
and	O
progression	O
of	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
,	O
through	O
increasing	O
the	O
proliferative	O
activity	O
of	O
the	O
tumour	O
cells	O
.	O
Copyright	O
2000	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
PMID	O
:	O
11054718	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2000	O
Sep;13(	O
9	O
)	O
:1005	O
-	O
13	O
Beta-catenin	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
:	O
expression	O
is	O
related	O
to	O
proliferative	O
activity	O
in	O
high	O
-	O
grade	O
sarcomas	B-malignancy-type
.	O
Kuhnen	O
C	O
,	O
Herter	O
P	O
,	O
Muller	O
O	O
,	O
Muehlberger	O
T	O
,	O
Krause	O
L,	O
Homann	O
H	O
,	O
Steinau	O
HU	O
,	O
Muller	O
KM	O
.	O
Institute	O
for	O
Pathology	O
,	O
Limb	O
Tumor	O
Registry	O
,	O
University	O
Hospital	O
Bergmannsheil	O
,	O
Bochum	O
,	O
Germany	O
.	O
patho	O
-	O
bhl@ruhr	O
-	O
uni	O
-	O
bochum	O
.de	O
Besides	O
its	O
role	O
in	O
cell	O
adhesion	O
,	O
beta-catenin	O
exerts	O
a	O
function	O
as	O
an	O
oncoprotein	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
characterization	O
of	O
its	O
expression	O
,	O
possible	O
mutation	O
,	O
and	O
the	O
assessment	O
of	O
beta-catenin	O
as	O
a	O
prognostic	O
indicator	O
for	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
A	O
total	O
of	O
115	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
were	O
analyzed	O
using	O
immunohistochemistry	O
,	O
immunogold	O
-	O
electron	O
microscopy	O
,	O
and	O
DNA	O
analysis	O
.	O
Information	O
from	O
56	O
patients	O
was	O
available	O
for	O
follow	O
-	O
up	O
.	O
A	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
intracellular	O
distribution	O
of	O
beta-catenin	O
and	O
the	O
proliferative	O
activity	O
(	O
MIB-1	O
expression	O
)	O
in	O
high	O
-	O
grade	O
sarcomas	B-malignancy-type
(	O
P	O
=	O
.0008	O
)	O
.	O
Beta-catenin	O
was	O
identified	O
with	O
intracytoplasmic	O
and	O
nuclear	O
accumulation	O
,	O
showing	O
additional	O
membranous	O
staining	O
in	O
sarcomas	B-malignancy-type
with	O
epithelioid	O
pattern	O
.	O
Ultrastructurally	O
,	O
a	O
colocalization	O
between	O
beta-catenin	O
and	O
nuclear	O
heterochromatin	O
was	O
demonstrated	O
.	O
In	O
22	O
analyzed	O
tumors	O
,	O
only	O
one	O
(	O
yet	O
undescribed	O
)	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
(	O
C	O
-	O
A	O
transversion	O
)	O
could	O
be	O
detected	O
.	O
Prognostic	O
validity	O
of	O
the	O
cellular	O
expression	O
of	O
beta-catenin	O
,	O
however	O
,	O
was	O
not	O
proven	O
.	O
Apart	O
from	O
its	O
membranous	O
function	O
as	O
an	O
effective	O
molecule	O
for	O
cell	O
-	O
adhesion	O
in	O
sarcomas	B-malignancy-type
with	O
epithelioid	O
pattern	O
,	O
beta-catenin	O
may	O
act	O
as	O
an	O
oncoprotein	O
in	O
sarcomas	B-malignancy-type
with	O
intracytoplasmic	O
and	O
nuclear	O
localization	O
with	O
binding	O
to	O
nuclear	O
DNA	O
.	O
A	O
previously	O
discussed	O
stimulation	O
of	O
cell	O
proliferation	O
caused	O
by	O
an	O
increased	O
beta-catenin	O
level	O
can	O
also	O
be	O
postulated	O
for	O
high	O
-	O
grade	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
in	O
correlation	O
with	O
the	O
rate	O
of	O
proliferation	O
.	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
probably	O
of	O
lesser	O
importance	O
for	O
the	O
accumulation	O
of	O
beta-catenin	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
PMID	O
:	O
11007041	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
2000	O
Sep;43(	O
9	O
)	O
:1316	O
-	O
8	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
of	O
the	O
rectum	O
with	O
activating	O
mutation	O
of	O
c-kit	O
:	O
report	O
of	O
a	O
case	O
.	O
Kurokawa	O
Y	O
,	O
Nishisho	O
I	O
,	O
Kawahara	O
K	O
,	O
Mishima	O
H	O
,	O
Hirota	O
S,	O
Kikkawa	O
N.	O
Department	O
of	O
Surgery	O
,	O
Osaka	O
National	O
Hospital	O
,	O
Japan	O
.	O
Nonepithelial	B-malignancy-type
malignancies	I-malignancy-type
of	O
the	O
large	O
bowel	O
are	O
rare	O
.	O
A	O
new	O
disease	O
entity	O
,	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
,	O
has	O
attracted	O
attention	O
among	O
primary	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
gastrointestinal	O
tract	O
.	O
Here	O
we	O
present	O
a	O
case	O
of	O
spindle	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
sarcoma	I-malignancy-type
of	O
the	O
rectum	O
,	O
lacking	O
either	O
smooth	O
muscle	O
cells	O
or	O
neural	O
elements	O
.	O
Immunohistochemical	O
findings	O
and	O
sequencing	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
diagnosed	O
this	O
tumor	O
as	O
a	O
malignant	B-malignancy-type
gastrointestinal	I-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
of	O
the	O
rectum	O
.	O
PMID	O
:	O
11005505	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatobiliary	O
Pancreat	O
Surg	O
2000	O
;	O
7	O
(	O
1	O
)	O
:	O
63	O
-	O
71	O
Significance	O
of	O
K-ras	O
mutation	O
and	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
in	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Futakawa	O
N	O
,	O
Kimura	O
W	O
,	O
Yamagata	O
S,	O
Zhao	O
B	O
,	O
Ilsoo	O
H	O
,	O
Inoue	O
T	O
,	O
Sata	O
N	O
,	O
Kawaguchi	O
Y	O
,	O
Kubota	O
Y	O
,	O
Muto	O
T.	O
Department	O
of	O
Surgical	O
Oncology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
early	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
is	O
essential	O
for	O
increasing	O
patient	O
survival	O
rates	O
.	O
In	O
this	O
study	O
,	O
52	O
patients	O
with	O
suspected	O
pancreatic	O
diseases	O
were	O
examined	O
to	O
investigate	O
the	O
value	O
of	O
K-ras	O
codon	O
12	O
point	O
mutation	O
,	O
levels	O
of	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
and	O
carbohydrate	O
antigen	O
(	O
CA19-9	O
)	O
,	O
and	O
cytology	O
of	O
pancreatic	O
juice	O
in	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Pancreatic	O
juice	O
was	O
taken	O
without	O
secretin	O
stimulation	O
.	O
K-ras	O
mutation	O
was	O
detected	O
by	O
enriched	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
.	O
K-ras	O
mutation	O
in	O
pancreatic	O
juice	O
was	O
more	O
frequent	O
in	O
carcinoma	B-malignancy-type
than	O
in	O
benign	O
diseases	O
(	O
P	O
=	O
0.0448	O
)	O
.	O
The	O
positive	O
predictive	O
value	O
of	O
K-ras	O
mutation	O
for	O
the	O
diagnosis	O
of	O
neoplastic	O
disease	O
was	O
83	O
%	O
.	O
The	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
in	O
carcinoma	B-malignancy-type
was	O
significantly	O
greater	O
than	O
that	O
in	O
benign	O
disease	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
When	O
the	O
cutoff	O
level	O
of	O
CEA	O
was	O
set	O
at	O
50	O
ng	O
/	O
ml	O
,	O
its	O
accuracy	O
for	O
the	O
diagnosis	O
of	O
carcinoma	B-malignancy-type
was	O
85	O
%	O
.	O
A	O
multivariate	O
analysis	O
showed	O
that	O
K-ras	O
mutation	O
and	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
,	O
as	O
well	O
as	O
serum	O
CA19-9	O
level	O
and	O
age	O
of	O
the	O
patient	O
were	O
independent	O
variables	O
for	O
the	O
diagnosis	O
of	O
carcinoma	B-malignancy-type
,	O
and	O
the	O
accuracy	O
of	O
diagnosis	O
by	O
this	O
analysis	O
was	O
increased	O
to	O
90	O
%	O
.	O
In	O
conclusion	O
,	O
both	O
K-ras	O
mutation	O
and	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
may	O
be	O
valuable	O
for	O
the	O
diagnosis	O
of	O
carcinoma	B-malignancy-type
.	O
Better	O
discrimination	O
was	O
possible	O
with	O
a	O
multivariate	O
analysis	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10982594	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
2000	O
Sep;157(	O
3	O
)	O
:967	O
-	O
72	O
Mutations	O
and	O
copy	O
number	O
increase	O
of	O
HRAS	O
in	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
with	O
distinctive	O
histopathological	O
features	O
.	O
Bastian	O
BC	O
,	O
LeBoit	O
PE	O
,	O
Pinkel	O
D.	O
Departments	O
of	O
Dermatology	O
and	O
Pathology	O
and	O
UCSF	O
Comprehensive	O
Cancer	O
Center	O
,	O
University	O
of	O
California	O
San	O
Francisco	O
,	O
San	O
Francisco	O
,	O
California	O
94143	O
-	O
0808	O
,	O
USA	O
.	O
bastian@cc.ucsf.edu	O
Spitz	B-malignancy-type
nevus	I-malignancy-type
is	O
a	O
benign	O
melanocytic	B-malignancy-type
neoplasm	I-malignancy-type
that	O
can	O
be	O
difficult	O
or	O
impossible	O
to	O
histologically	O
distinguish	O
from	O
melanoma	B-malignancy-type
.	O
We	O
have	O
recently	O
described	O
copy	O
number	O
increases	O
of	O
chromosome	O
11p	O
in	O
a	O
subset	O
of	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
.	O
To	O
study	O
the	O
molecular	O
and	O
histological	O
features	O
of	O
this	O
group	O
,	O
we	O
studied	O
102	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
for	O
11p	O
copy	O
number	O
increases	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
on	O
tissue	O
arrays	O
.	O
Copy	O
number	O
increases	O
of	O
at	O
least	O
threefold	O
were	O
found	O
in	O
12	O
cases	O
(	O
11.8	O
%	O
)	O
and	O
involved	O
the	O
HRAS	O
gene	O
on	O
chromosome	O
11p	O
.	O
Sequence	O
analysis	O
of	O
HRAS	O
showed	O
frequent	O
oncogenic	O
mutations	O
in	O
cases	O
with	O
copy	O
number	O
increase	O
(	O
8	O
/	O
12	O
or	O
67	O
%	O
)	O
,	O
contrasting	O
with	O
rare	O
HRAS	O
mutations	O
in	O
cases	O
with	O
normal	O
HRAS	O
copy	O
numbers	O
(	O
1	O
/	O
21	O
or	O
5	O
%	O
,	O
P	O
:	O
<	O
0.0001	O
)	O
.	O
Tumors	B-malignancy-type
with	O
11p	O
copy	O
number	O
increases	O
were	O
larger	O
,	O
predominantly	B-malignancy-type
intradermal	I-malignancy-type
,	O
had	O
marked	O
desmoplasia	B-malignancy-type
,	O
characteristic	O
cytological	O
features	O
,	O
and	O
had	O
an	O
infiltrating	O
growth	O
pattern	O
.	O
Proliferation	O
rates	O
in	O
the	O
majority	O
of	O
these	O
cases	O
were	O
low	O
to	O
absent	O
.	O
HRAS	O
activation	O
by	O
either	O
mutation	O
or	O
copy	O
number	O
increase	O
alone	O
could	O
explain	O
several	O
of	O
the	O
histological	O
features	O
that	O
overlap	O
with	O
those	O
of	O
melanoma	B-malignancy-type
.	O
We	O
speculate	O
that	O
HRAS	O
activation	O
in	O
the	O
absence	O
of	O
co	O
-	O
operating	O
additional	O
genetic	O
alterations	O
drives	O
the	O
partially	O
transformed	O
melanocytes	O
of	O
these	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
into	O
senescence	O
or	O
a	O
stable	O
growth	O
arrest	O
.	O
Although	O
there	O
is	O
no	O
data	O
suggesting	O
that	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
with	O
HRAS	O
activation	O
are	O
at	O
risk	O
for	O
progression	O
to	O
melanoma	B-malignancy-type
,	O
future	O
studies	O
are	O
warranted	O
to	O
assess	O
their	O
biological	O
behavior	O
more	O
accurately	O
.	O
PMID	O
:	O
10980135	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pancreas	O
2000	O
Aug;21(	O
2	O
)	O
:152	O
-	O
7	O
Reassessment	O
of	O
K-ras	O
mutations	O
at	O
codon	O
12	O
by	O
direct	O
PCR	O
and	O
sequencing	O
from	O
tissue	O
microdissection	O
in	O
human	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Aoki	O
Y	O
,	O
Hosaka	O
S,	O
Tachibana	O
N	O
,	O
Karasawa	O
Y	O
,	O
Kawa	O
S,	O
Kiyosawa	O
K.	O
The	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Nagono	O
,	O
Japan	O
.	O
yaoki55@hsp.md	O
.shinshu	O
-	O
u.ac.	O
jp	O
K-ras	O
mutations	O
at	O
codon	O
12	O
have	O
been	O
detected	O
in	O
almost	O
all	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
by	O
highly	O
sensitive	O
assays	O
.	O
We	O
reassessed	O
the	O
K-ras	O
mutation	O
status	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
sequencing	O
from	O
tissue	O
microdissection	O
without	O
DNA	O
extraction	O
in	O
10	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
and	O
also	O
assessed	O
the	O
K-ras	O
and	O
DPC4	O
genes	O
in	O
nine	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Eight	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
were	O
found	O
to	O
harbor	O
K-ras	O
mutations	O
at	O
codon	O
12	O
of	O
either	O
GTT	O
or	O
GAT	O
,	O
five	O
of	O
which	O
were	O
inferred	O
to	O
harbor	O
amplified	O
mutant	O
alleles	O
.	O
Mutations	O
at	O
the	O
sites	O
other	O
than	O
codon	O
12	O
were	O
found	O
in	O
seven	O
of	O
70	O
clones	O
(	O
seven	O
of	O
9,380	O
bases	O
)	O
by	O
the	O
TA	O
cloning	O
analysis	O
,	O
suggesting	O
that	O
artifactual	O
mutations	O
at	O
the	O
first	O
or	O
second	O
base	O
of	O
codon	O
12	O
before	O
and	O
during	O
PCR	O
could	O
occur	O
at	O
a	O
frequency	O
of	O
approximately	O
10(-3)	O
,	O
enough	O
for	O
highly	O
sensitive	O
assays	O
to	O
detect	O
.	O
Two	O
cell	O
lines	O
without	O
K-ras	O
mutations	O
at	O
codon	O
12	O
were	O
found	O
to	O
have	O
homozygous	O
deletions	O
at	O
the	O
DPC4	O
gene	O
.	O
Thus	O
the	O
K-ras	O
mutation	O
status	O
was	O
demonstrated	O
to	O
be	O
correctly	O
determined	O
by	O
just	O
direct	O
sequencing	O
from	O
tissue	O
microdissection	O
.	O
All	O
possible	O
mutations	O
or	O
multiple	O
mutations	O
at	O
K-ras	O
codon	O
12	O
that	O
have	O
been	O
reported	O
in	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
might	O
include	O
artifacts	O
or	O
mutations	O
without	O
a	O
selective	O
advantage	O
.	O
In	O
addition	O
,	O
we	O
must	O
be	O
very	O
cautious	O
about	O
contamination	O
.	O
PMID	O
:	O
10975709	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Med	O
Res	O
2000	O
Aug	O
18;5(	O
8	O
)	O
:341	O
-	O
6	O
Detection	O
of	O
K-ras	O
and	O
p53	O
mutations	O
in	O
bronchoscopically	O
obtained	O
malignant	O
and	O
non	O
-	O
malignant	O
tissue	O
from	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
Lang	O
SM	O
,	O
Stratakis	O
DF	O
,	O
Freudling	O
A	O
,	O
Ebelt	O
K	O
,	O
Oduncu	O
F	O
,	O
Hautmann	O
H	O
,	O
Huber	O
RM	O
.	O
Medizinische	O
Klinik	O
Innenstadt	O
,	O
Universitat	O
Munchen	O
,	O
Ziemssenstr.1	O
,	O
D-	O
80336	O
Munchen	O
,	O
Germany	O
.	O
slang@medinn	O
.med	O
.uni	O
-	O
muenchen	O
.de	O
Molecular	O
screening	O
may	O
increase	O
the	O
likelihood	O
to	O
identify	O
early	O
malignant	O
lesions	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
However	O
the	O
presence	O
of	O
gene	O
mutations	O
in	O
non	O
-	O
malignant	O
bronchial	O
tissue	O
has	O
remained	O
controversial	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
systematically	O
the	O
presence	O
of	O
mutations	O
of	O
the	O
K-ras	O
and	O
p53	O
gene	O
in	O
bronchial	O
biopsies	O
taken	O
during	O
routine	O
bronchoscopy	O
of	O
normal	O
as	O
well	O
as	O
tumour	O
tissues	O
from	O
a	O
series	O
of	O
40	O
patients	O
with	O
histologically	O
verified	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
.	O
K-ras	O
mutations	O
were	O
analysed	O
with	O
specific	O
detection	O
oligonucleotides	O
,	O
p53	O
mutations	O
were	O
examined	O
by	O
SSCP	O
analysis	O
.	O
In	O
all	O
biopsies	O
the	O
wildtype	O
of	O
both	O
K-ras	O
and	O
p53	O
could	O
be	O
detected	O
.	O
The	O
overall	O
frequency	O
of	O
mutations	O
was	O
14	O
(	O
35	O
%	O
)	O
with	O
2	O
K-ras	O
mutations	O
(	O
5	O
%	O
)	O
and	O
12	O
mutations	O
of	O
the	O
p53	O
gene	O
(	O
30	O
%	O
)	O
.	O
In	O
3	O
cases	O
(	O
1	O
ras	O
mutation	O
,	O
2	O
p53	O
mutations	O
)	O
the	O
same	O
mutation	O
could	O
be	O
shown	O
in	O
the	O
tumour	O
biopsy	O
and	O
in	O
the	O
distant	O
normal	O
control	O
.	O
In	O
another	O
case	O
only	O
the	O
normal	O
appearing	O
tissue	O
had	O
a	O
mutation	O
of	O
the	O
p53	O
gene	O
.	O
All	O
other	O
mutations	O
could	O
be	O
detected	O
in	O
the	O
tumour	O
tissue	O
only	O
.	O
Our	O
data	O
confirm	O
that	O
K-ras	O
mutations	O
and	O
p53	O
can	O
be	O
detected	O
not	O
only	O
in	O
malignant	O
but	O
also	O
in	O
non	O
-	O
malignant	O
bioptic	O
samples	O
from	O
patients	O
with	O
NSCLC	B-malignancy-type
.	O
The	O
use	O
of	O
molecular	O
screening	O
for	O
the	O
early	O
detection	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
a	O
promising	O
new	O
approach	O
.	O
PMID	O
:	O
10958767	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
2000	O
Jun;95(	O
6)	O
:1576	O
-	O
80	O
Molecular	O
and	O
biological	O
analysis	O
of	O
carcinoma	B-malignancy-type
of	O
the	O
small	O
intestine	O
:	O
beta-catenin	O
gene	O
mutation	O
by	O
interstitial	O
deletion	O
involving	O
exon	O
3	O
and	O
replication	O
error	O
phenotype	O
.	O
Murata	O
M,	O
Iwao	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nagasawa	O
Y	O
,	O
Ohta	O
T	O
,	O
Shibata	O
K	O
,	O
Oda	O
K	O
,	O
Wada	O
H	O
,	O
Tominaga	O
S,	O
Matsuda	O
Y	O
,	O
Ohsawa	O
M,	O
Nakamura	O
Y	O
,	O
Shimano	O
T.	O
Department	O
of	O
Surgery	O
,	O
Ikeda	O
Municipal	O
Hospital	O
,	O
Osaka	O
,	O
Japan	O
.	O
The	O
genetic	O
mechanisms	O
of	O
carcinomas	B-malignancy-type
of	O
the	O
small	O
intestine	O
are	O
not	O
well	O
understood	O
.	O
We	O
report	O
the	O
results	O
of	O
analysis	O
of	O
genetic	O
alterations	O
in	O
a	O
case	O
of	O
small	B-malignancy-type
intestinal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
tumor	O
in	O
the	O
terminal	O
ileum	O
was	O
resected	O
in	O
a	O
59	O
-	O
yr	O
-	O
old	O
woman	O
.	O
Histologically	O
,	O
the	O
tumor	O
was	O
classified	O
as	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
screened	O
for	O
genetic	O
alterations	O
in	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
beta-catenin	O
,	O
K-ras	O
,	O
and	O
p53	O
genes	O
,	O
as	O
well	O
as	O
microsatellite	O
instability	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
colorectal	O
tumorigenesis	O
.	O
The	O
tumor	O
exhibited	O
somatic	O
interstitial	O
deletion	O
of	O
425-bp	O
,	O
which	O
included	O
the	O
entire	O
exon	O
3	O
in	O
beta-catenin	O
gene	O
.	O
Immunohistochemical	O
staining	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
the	O
cytoplasm	O
and	O
nuclei	O
of	O
the	O
malignant	O
tissue	O
.	O
Furthermore	O
,	O
a	O
frameshift	O
mutation	O
in	O
the	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
type	O
II	O
gene	O
with	O
replication	O
error	O
phenotype	O
was	O
detected	O
in	O
the	O
tumor	O
DNA	O
.	O
In	O
contrast	O
,	O
no	O
genetic	O
alterations	O
were	O
found	O
in	O
the	O
APC	O
,	O
K-ras	O
,	O
and	O
p53	O
genes	O
.	O
Our	O
results	O
suggested	O
that	O
both	O
beta-catenin	O
gene	O
mutation	O
and	O
replication	O
error	O
phenotype	O
might	O
contribute	O
to	O
carcinogenesis	O
of	O
the	O
small	B-malignancy-type
intestinal	I-malignancy-type
tumor	I-malignancy-type
in	O
our	O
case	O
.	O
This	O
is	O
the	O
first	O
report	O
that	O
activation	O
of	O
beta-catenin	O
gene	O
by	O
somatic	O
gene	O
mutation	O
is	O
involved	O
in	O
the	O
development	O
of	O
carcinoma	B-malignancy-type
of	O
the	O
small	O
intestine	O
.	O
PMID	O
:	O
10894600	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2000	O
Apr;91(	O
4)	O
:395	O
-	O
8	O
Mutation	O
of	O
the	O
SRC	O
gene	O
in	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Sugimura	O
M,	O
Kobayashi	O
K	O
,	O
Sagae	O
S,	O
Nishioka	O
Y	O
,	O
Ishioka	O
S,	O
Terasawa	O
K	O
,	O
Tokino	O
T	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Chuo	O
-	O
ku	O
,	O
Sapporo	O
060	O
-0061	O
,	O
Japan	O
.	O
Recently	O
,	O
an	O
activating	O
mutation	O
of	O
the	O
SRC	O
gene	O
has	O
been	O
implicated	O
in	O
about	O
one-tenth	O
of	O
advanced	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
SRC	O
531	O
mutation	O
results	O
in	O
truncation	O
of	O
SRC	O
directly	O
C	O
-	O
terminal	O
to	O
the	O
regulatory	O
Tyr	O
530	O
and	O
appears	O
to	O
activate	O
the	O
Tyr	O
530	O
.	O
To	O
investigate	O
whether	O
mutation	O
of	O
SRC	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
gynecological	B-malignancy-type
tumors	I-malignancy-type
,	O
we	O
performed	O
mutational	O
analysis	O
of	O
the	O
entire	O
coding	O
region	O
of	O
SRC	O
in	O
70	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
68	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
and	O
3	O
endometrial	B-malignancy-type
stromal	I-malignancy-type
sarcomas	I-malignancy-type
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
followed	O
by	O
nucleotide	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
We	O
found	O
one	O
truncated	O
mutation	O
at	O
codon	O
531	O
(	O
Gln	O
to	O
Stop	O
)	O
in	O
an	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
However	O
,	O
we	O
found	O
no	O
mutation	O
of	O
this	O
gene	O
in	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
or	O
endometrial	B-malignancy-type
stromal	I-malignancy-type
sarcoma	I-malignancy-type
.	O
Our	O
results	O
suggest	O
that	O
mutation	O
of	O
SRC	O
may	O
be	O
implicated	O
in	O
a	O
small	O
proportion	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
10804287	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
2000	O
Mar;108(	O
4)	O
:729	O
-	O
36	O
Mastocytosis	B-malignancy-type
cells	O
bearing	O
a	O
c-kit	O
activating	O
point	O
mutation	O
are	O
characterized	O
by	O
hypersensitivity	O
to	O
stem	O
cell	O
factor	O
and	O
increased	O
apoptosis	O
.	O
Dror	O
Y	O
,	O
Leaker	O
M,	O
Caruana	O
G	O
,	O
Bernstein	O
A	O
,	O
Freedman	O
MH.	O
Division	O
of	O
Hematology	O
/	O
Oncology	O
,	O
Department	O
of	O
Pediatrics	O
,	O
Research	O
Institute	O
,	O
The	O
Hospital	O
for	O
Sick	O
Children	O
and	O
the	O
University	O
of	O
Toronto	O
,	O
Toronto	O
,	O
Canada	O
.	O
yigal	O
.dror@hotmail	O
.com	O
Mastocytosis	B-malignancy-type
is	O
characterized	O
by	O
abnormal	O
infiltration	O
of	O
mast	O
cells	O
into	O
various	O
organs	O
.	O
An	O
activating	O
mutation	O
in	O
c-kit	O
,	O
involving	O
an	O
A	O
-->	O
T	O
substitution	O
at	O
nucleotide	O
2648	O
has	O
recently	O
been	O
described	O
in	O
some	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
We	O
describe	O
a	O
12	O
-	O
year	O
-	O
old	O
girl	O
with	O
this	O
mutation	O
in	O
her	O
bone	O
marrow	O
cells	O
at	O
diagnosis	O
with	O
a	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
without	O
evidence	O
of	O
mastocytosis	B-malignancy-type
,	O
and	O
then	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
1	O
year	O
later	O
after	O
the	O
emergence	O
of	O
mastocytosis	B-malignancy-type
.	O
The	O
role	O
of	O
the	O
c-Kit	O
receptor	O
and	O
its	O
ligand	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
was	O
analysed	O
in	O
marrow	O
cell	O
clonogenic	O
assays	O
.	O
We	O
show	O
that	O
the	O
genetic	O
abnormalities	O
in	O
the	O
patient	O
resulted	O
in	O
factor	O
-	O
independent	O
growth	O
and	O
hypersensitivity	O
of	O
primitive	O
progenitors	O
to	O
SCF	O
,	O
with	O
increased	O
production	O
of	O
mast	O
cells	O
.	O
Increased	O
apoptosis	O
and	O
cluster	O
formation	O
,	O
consistent	O
with	O
the	O
myelodysplastic	O
nature	O
of	O
the	O
disorder	O
,	O
accompanied	O
accumulation	O
of	O
abnormal	O
cells	O
with	O
increasing	O
concentrations	O
of	O
SCF	O
.	O
PMID	O
:	O
10792276	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Gastroenterol	O
2000	O
Apr;30(	O
3	O
)	O
:307	O
-	O
10	O
Nonfunctioning	B-malignancy-type
islet	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
with	O
high	O
serum	O
CEA	O
&	O
CA19-9	O
,	O
K-ras	O
codon	O
12	O
mutation	O
,	O
and	O
microsatellite	O
instability	O
.	O
Okai	O
T	O
,	O
Kawashima	O
A	O
,	O
Watanabe	O
H	O
,	O
Takahashi	O
Y	O
,	O
Sakai	O
J,	O
Ohtsubo	O
K	O
,	O
Motoo	O
Y	O
,	O
Matsui	O
O	O
,	O
Murakami	O
S,	O
Nakabayashi	O
H	O
,	O
Sawabu	O
N.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
A	O
55	O
-	O
year	O
-	O
old	O
man	O
with	O
nonfunctioning	B-malignancy-type
islet	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
showing	O
elevation	O
of	O
serum	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
and	O
carbohydrate	O
antigen	O
19-9	O
(	O
CA19-9	O
)	O
levels	O
is	O
described	O
with	O
genetic	O
analyses	O
.	O
Pathological	O
examination	O
of	O
the	O
resected	O
specimen	O
revealed	O
two	O
independent	O
islet	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
in	O
the	O
body	O
and	O
the	O
other	O
in	O
the	O
tail	O
of	O
the	O
pancreas	O
.	O
It	O
was	O
proved	O
immunohistochemically	O
that	O
the	O
tumor	O
cells	O
,	O
particularly	O
those	O
in	O
the	O
tail	O
,	O
were	O
immunoreactive	O
to	O
CEA	O
and	O
CA	O
19-9	O
and	O
had	O
the	O
property	O
of	O
duct	O
cells	O
,	O
as	O
well	O
as	O
endocrine	O
cells	O
.	O
Gastrin	O
was	O
demonstrated	O
immunohistochemically	O
in	O
these	O
tumor	O
cells	O
,	O
although	O
its	O
level	O
in	O
serum	O
was	O
not	O
elevated	O
.	O
Genetic	O
analyses	O
of	O
the	O
fresh	O
specimens	O
from	O
the	O
tumor	O
in	O
the	O
body	O
revealed	O
K-ras	O
codon	O
12	O
mutation	O
and	O
microsatellite	O
instability	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
its	O
progressive	O
clinical	O
course	O
and	O
strongly	O
suggest	O
that	O
these	O
tumors	O
originate	O
,	O
not	O
from	O
the	O
islet	O
cells	O
of	O
Langerhans	O
,	O
but	O
from	O
protodifferentiated	O
cells	O
,	O
capable	O
of	O
giving	O
rise	O
to	O
all	O
the	O
pancreatic	O
cell	O
types	O
.	O
PMID	O
:	O
10777194	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Invest	O
2000	O
;18(	O
3	O
)	O
:185	O
-	O
90	O
Prognostic	O
role	O
of	O
K-ras	O
in	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
who	O
received	O
treatment	O
with	O
Marimastat	O
(	O
BB2516	O
)	O
.	O
Nemunaitis	O
J,	O
Cox	O
J,	O
Hays	O
S,	O
Meyer	O
W	O
,	O
Kebart	O
R,	O
Ognoskie	O
N	O
,	O
Courtney	O
A	O
,	O
Yu	O
Y	O
,	O
Rasmussen	O
H	O
,	O
Tong	O
A.	O
PRN	O
Research	O
,	O
Inc.	O
,	O
Dallas	O
,	O
Texas	O
,	O
USA	O
.	O
We	O
determined	O
the	O
prognostic	O
role	O
of	O
K-ras	O
mutation	O
in	O
tumor	O
tissue	O
of	O
patients	O
with	O
refractory	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
who	O
received	O
Marimastat	O
(	O
BB2516	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
stored	O
tumor	O
tissue	O
of	O
27	O
patients	O
who	O
previously	O
failed	O
5-fluorouracil	O
and	O
were	O
treated	O
with	O
BB2516	O
.	O
The	O
presence	O
of	O
K-ras	O
mutation	O
was	O
characterized	O
by	O
Polymerase	O
Chain	O
Reaction	O
using	O
ras	O
-	O
and	O
p53	O
-	O
specific	O
primers	O
.	O
ras	O
and	O
p53	O
oncoprotein	O
expression	O
was	O
analyzed	O
by	O
an	O
automated	O
biotin	O
-	O
avidin	O
immunoproxidase	O
technique	O
.	O
Seventeen	O
patients	O
had	O
a	O
normal	O
K-ras	O
sequence	O
and	O
10	O
patients	O
had	O
a	O
K-ras	O
mutation	O
.	O
Median	O
survival	O
of	O
patients	O
with	O
a	O
normal	O
ras	O
sequence	O
was	O
330	O
days	O
from	O
the	O
time	O
of	O
BB2516	O
treatment	O
compared	O
with	O
160	O
days	O
for	O
patients	O
with	O
a	O
K-ras	O
mutation	O
(	O
p	O
=	O
0.0442	O
,	O
Wilcoxon	O
;	O
0.0130	O
Log	O
-	O
Rank	O
)	O
.	O
No	O
differences	O
in	O
age	O
,	O
sex	O
,	O
cancer	O
stage	O
,	O
surgical	O
treatment	O
,	O
or	O
chemotherapy	O
treatment	O
were	O
observed	O
.	O
Abnormalities	O
involving	O
ras	O
expression	O
did	O
not	O
affect	O
survival	O
.	O
By	O
comparison	O
,	O
median	O
survival	O
for	O
patients	O
with	O
p53	O
mutation	O
or	O
p53	O
overexpression	O
was	O
both	O
158	O
days	O
after	O
BB2516	O
treatment	O
.	O
Patients	O
having	O
both	O
K-ras	O
and	O
p53	O
mutations	O
had	O
the	O
poorest	O
median	O
survival	O
of	O
113	O
days	O
(	O
p	O
=	O
0.035	O
)	O
.	O
There	O
is	O
a	O
suggestion	O
by	O
univariate	O
analysis	O
that	O
the	O
presence	O
of	O
a	O
K-ras	O
mutation	O
may	O
predict	O
survival	O
in	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
.	O
Further	O
assessment	O
with	O
larger	O
patient	O
numbers	O
and	O
multivariate	O
analysis	O
is	O
indicated	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10754986	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2000	O
Mar	O
16;19(	O
12	O
)	O
:1547	O
-	O
55	O
Somatic	O
mutations	O
of	O
the	O
MET	O
oncogene	O
are	O
selected	O
during	O
metastatic	O
spread	O
of	O
human	O
HNSC	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Di	O
Renzo	O
MF	O
,	O
Olivero	O
M,	O
Martone	O
T	O
,	O
Maffe	O
A	O
,	O
Maggiora	O
P	O
,	O
Stefani	O
AD	O
,	O
Valente	O
G	O
,	O
Giordano	O
S,	O
Cortesina	O
G	O
,	O
Comoglio	O
PM	O
.	O
Laboratory	O
of	O
Cancer	O
Genetics	O
,	O
Institute	O
for	O
Cancer	O
Research	O
and	O
Treatment	O
(	O
IRCC)	O
,	O
SP	O
142	O
,	O
Km	O
.	O
3.95	O
,	O
10060	O
Candiolo	O
,	O
Torino	O
,	O
Italy	O
.	O
A	O
metastatic	B-malignancy-type
cancer	I-malignancy-type
develops	O
by	O
accumulation	O
of	O
mutations	O
in	O
genes	O
that	O
control	O
growth	O
,	O
survival	O
and	O
spreading	O
.	O
The	O
latter	O
genes	O
have	O
not	O
yet	O
been	O
identified	O
.	O
In	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
of	O
head	B-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
HNSCC	B-malignancy-type
)	O
,	O
we	O
found	O
mutations	O
in	O
the	O
MET	O
oncogene	O
,	O
which	O
encodes	O
the	O
tyrosine	O
kinase	O
receptor	O
for	O
Scatter	O
Factor	O
,	O
a	O
cytokine	O
that	O
stimulates	O
epithelial	O
cell	O
motility	O
and	O
invasiveness	O
during	O
embryogenesis	O
and	O
tissue	O
remodeling	O
.	O
We	O
identified	O
two	O
somatic	O
mutations	O
:	O
the	O
Y	O
1230	O
C	O
,	O
known	O
as	O
a	O
MET	O
germline	O
mutation	O
which	O
predisposes	O
to	O
hereditary	B-malignancy-type
renal	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
the	O
Y	O
1235	O
D	O
that	O
is	O
novel	O
and	O
changes	O
a	O
critical	O
tyrosine	O
,	O
known	O
to	O
regulate	O
MET	O
kinase	O
activity	O
.	O
The	O
mutated	O
MET	O
receptors	O
are	O
constitutively	O
active	O
and	O
confer	O
an	O
invasive	O
phenotype	O
to	O
transfected	O
cells	O
.	O
Interestingly	O
,	O
cells	O
carrying	O
the	O
MET	O
mutations	O
are	O
selected	O
during	O
metastatic	O
spread	O
:	O
transcripts	O
of	O
the	O
mutant	O
alleles	O
are	O
highly	O
represented	O
in	O
metastases	B-malignancy-type
,	O
but	O
barely	O
detectable	O
in	O
primary	O
tumors	O
.	O
These	O
data	O
indicate	O
that	O
cells	O
expressing	O
mutant	O
MET	O
undergo	O
clonal	O
expansion	O
during	O
HNSCC	B-malignancy-type
progression	O
and	O
suggest	O
that	O
MET	O
might	O
be	O
one	O
of	O
the	O
long	O
sought	O
oncogenes	O
controlling	O
progression	O
of	O
primary	O
cancers	O
to	O
metastasis	O
.	O
PMID	O
:	O
10734314	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

5	O
KIT	O
extracellular	O
and	O
kinase	O
domain	O
mutations	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
JA.	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
neoplasms	I-malignancy-type
arising	O
in	O
the	O
gastrointestinal	O
GISTs	B-malignancy-type
express	O
the	O
KIT	O
receptor	O
tyrosine	O
kinase	O
,	O
and	O
many	O
cases	O
have	O
activating	O
mutations	O
in	O
the	O
KIT	O
juxtamembrane	O
KIT	O
cDNA	O
and	O
genomic	O
sequences	O
in	O
eight	O
GISTs	B-malignancy-type
that	O
lack	O
juxtamembrane	O
region	O
mutations	O
contained	O
heterozygous	O
exon	O
9	O
mutations	O
in	O
which	O
six	O
nucleotides	O
,	O
encoding	O
Ala	O
-	O
Tyr	O
homozygous	O
exon	O
13	O
missense	O
mutations	O
,	O
resulting	O
in	O
substitution	O
of	O
Glu	O
for	O
Lys	O
(	O
642	O
)	O
,	O
that	O
were	O
associated	O
with	O
constitutive	O
KIT	O
tyrosine	O
Sequence	O
analysis	O
of	O
DNAs	O
from	O
nonneoplastic	O
companion	O
tissues	O
revealed	O
that	O
both	O
the	O
exon	O
9	O
and	O
exon	O
13	O
mutations	O
were	O
somatic	O
descriptions	O
,	O
in	O
any	O
tumor	O
,	O
of	O
mutations	O
in	O
KIT	O
exons	O
encoding	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
extracellular	O
domain	O
and	O
the	O
first	O
part	O
of	O
the	O
split	O
kinase	O
domain	O
KIT	O
may	O
be	O
activated	O
by	O
mutations	O
in	O
at	O
least	O
three	O
domains-	O
extracellular	O
,	O
juxtamembrane	O
,	O
and	O
kinase	O
-	O
in	O
GISTs	B-malignancy-type
MEDLINE]	O

Oncol	O
Rep	O
2000	O
Mar	O
-	O
Apr;7(	O
2	O
)	O
:323	O
-	O
6	O
Mutational	O
analysis	O
of	O
the	O
CTNNB1	O
(	O
beta-catenin	O
)	O
gene	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
:	O
frequent	O
mutations	O
at	O
codon	O
34	O
that	O
cause	O
nuclear	O
accumulation	O
.	O
Ikeda	O
T	O
,	O
Yoshinaga	O
K	O
,	O
Semba	O
S,	O
Kondo	O
E	O
,	O
Ohmori	O
H	O
,	O
Horii	O
A.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
Recently	O
,	O
CTNNB1	O
(	O
beta-catenin	O
)	O
has	O
been	O
found	O
to	O
function	O
as	O
an	O
oncoprotein	O
that	O
works	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
mutation	O
of	O
this	O
gene	O
has	O
been	O
reported	O
in	O
various	O
human	O
cancers	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
44	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
and	O
found	O
somatic	O
missense	O
mutations	O
in	O
five	O
(	O
11	O
%	O
)	O
tumors	O
.	O
Interestingly	O
,	O
four	O
(	O
80	O
%	O
)	O
of	O
the	O
five	O
tumors	O
with	O
mutations	O
would	O
cause	O
amino	O
acid	O
alterations	O
at	O
residues	O
next	O
to	O
Ser	O
33	O
,	O
one	O
of	O
the	O
targets	O
for	O
phosphorylation	O
of	O
glycogen	O
synthase	O
kinase	O
(	O
GSK	O
)	O
-	O
3beta	O
.	O
The	O
tumors	O
with	O
mutations	O
showed	O
accumulation	O
of	O
the	O
CTNNB1	O
protein	O
in	O
cytoplasm	O
and	O
nucleus	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
frequent	O
somatic	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
at	O
codons	O
adjacent	O
to	O
those	O
encoding	O
to	O
Ser	O
/	O
Thr	O
residues	O
in	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10671680	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2000	O
Feb	O
1;88(	O
3	O
)	O
:518	O
-	O
23	O
H-ras	O
gene	O
mutations	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
mucoepidermoid	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St.	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
South	O
Korea	O
.	O
BACKGROUND	O
:	O
The	O
authors	O
'	O
recent	O
investigation	O
of	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
in	O
ras	O
gene	O
alteration	O
has	O
suggested	O
that	O
K-ras	O
activation	O
may	O
not	O
play	O
a	O
role	O
in	O
their	O
oncogenesis	O
but	O
H-ras	O
may	O
,	O
especially	O
in	O
mucoepidermoid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
A	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
overall	O
incidence	O
of	O
mutated	O
H-ras	O
genes	O
in	O
mucoepidermoid	B-malignancy-type
carcinomas	I-malignancy-type
and	O
to	O
discover	O
its	O
potential	O
correlation	O
with	O
clinicopathologic	O
parameters	O
.	O
METHODS	O
:	O
Fifty	O
samples	O
from	O
patients	O
with	O
salivary	B-malignancy-type
gland	I-malignancy-type
mucoepidermoid	I-malignancy-type
carcinoma	I-malignancy-type
were	O
analyzed	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
H-ras	O
gene	O
using	O
the	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
automated	O
direct	O
sequencing	O
methodology	O
.	O
RESULTS	O
:	O
Mutated	O
H-ras	O
genes	O
were	O
detected	O
in	O
9	O
patients	O
,	O
for	O
an	O
overall	O
incidence	O
of	O
18	O
%	O
(	O
9	O
of	O
50	O
patients	O
)	O
.	O
All	O
but	O
1	O
of	O
the	O
mutations	O
occurred	O
at	O
codon	O
12	O
:	O
a	O
GGC	O
-	O
to	O
-	O
GTC	O
transversion	O
in	O
8	O
patients	O
and	O
a	O
GGC	O
-	O
to	O
-	O
GAC	O
transition	O
in	O
1	O
patient	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
of	O
valine	O
and	O
aspartic	O
acid	O
,	O
respectively	O
,	O
for	O
glycine	O
.	O
One	O
of	O
the	O
samples	O
showed	O
concurrent	O
mutations	O
at	O
codons	O
12	O
(	O
GGC	O
-	O
to	O
-	O
GTC	O
)	O
and	O
13	O
(	O
GGT	O
-	O
to	O
-	O
GGA	O
)	O
.	O
None	O
of	O
the	O
samples	O
demonstrated	O
mutations	O
involving	O
codon	O
61	O
.	O
The	O
H-ras	O
mutations	O
were	O
observed	O
in	O
5	O
%	O
(	O
1	O
of	O
21	O
)	O
,	O
17	O
%	O
(	O
2	O
of	O
12	O
)	O
,	O
and	O
35	O
%	O
(	O
6	O
of	O
17	O
)	O
of	O
low	O
,	O
intermediate	O
,	O
and	O
high	O
grade	O
lesions	O
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
involvement	O
of	O
H-ras	O
activation	O
in	O
conjunction	O
with	O
other	O
yet	O
-	O
unknown	O
events	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
mucoepidermoid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
It	O
is	O
noteworthy	O
that	O
a	O
stepwise	O
increase	O
in	O
the	O
frequency	O
of	O
H-ras	O
mutations	O
strongly	O
correlates	O
with	O
tumor	O
grade	O
(	O
P	O
=	O
0.017	O
)	O
.	O
Molecular	O
analysis	O
of	O
this	O
gene	O
alteration	O
may	O
provide	O
assistance	O
in	O
the	O
determination	O
of	O
tumor	O
grade	O
and	O
differentiation	O
.	O
Copyright	O
2000	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
10649241	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Nov	O
11	O
;18(	O
47	O
)	O
:6615	O
-	O
20	O
Predominance	O
of	O
beta-catenin	O
mutations	O
and	O
beta-catenin	O
dysregulation	O
in	O
sporadic	B-malignancy-type
aggressive	I-malignancy-type
fibromatosis	I-malignancy-type
(	O
desmoid	B-malignancy-type
tumor	I-malignancy-type
)	O
.	O
Tejpar	O
S,	O
Nollet	O
F	O
,	O
Li	O
C	O
,	O
Wunder	O
JS	O
,	O
Michils	O
G	O
,	O
dal	O
Cin	O
P	O
,	O
Van	O
Cutsem	O
E	O
,	O
Bapat	O
B	O
,	O
van	O
Roy	O
F	O
,	O
Cassiman	O
JJ	O
,	O
Alman	O
BA.	O
Programme	O
in	O
Development	O
Biology	O
,	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Toronto	O
Ontario	O
,	O
Canada	O
.	O
Aggressive	B-malignancy-type
fibromatosis	I-malignancy-type
(	O
also	O
called	O
desmoid	B-malignancy-type
tumor	I-malignancy-type
)	O
occurs	O
as	O
a	O
sporadic	B-malignancy-type
lesion	I-malignancy-type
or	O
as	O
part	O
of	O
Familial	B-malignancy-type
Adenomatous	I-malignancy-type
Polyposis	I-malignancy-type
,	O
which	O
is	O
caused	O
by	O
germ	O
line	O
mutations	O
in	O
the	O
Adenomatous	O
polyposis	O
Coli	O
(	O
APC	O
)	O
gene	O
.	O
APC	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
cellular	O
level	O
of	O
beta-catenin	O
,	O
which	O
is	O
a	O
mediator	O
in	O
Wnt	O
signaling	O
.	O
Mutational	O
analysis	O
of	O
the	O
beta-catenin	O
and	O
APC	O
genes	O
was	O
performed	O
in	O
42	O
sporadic	B-malignancy-type
aggressive	I-malignancy-type
fibromatoses	I-malignancy-type
.	O
Nine	O
tumors	O
had	O
mutations	O
in	O
APC	O
,	O
and	O
22	O
had	O
a	O
point	O
mutation	O
in	O
beta-catenin	O
at	O
either	O
codon	O
45	O
or	O
codon	O
41	O
(	O
producing	O
a	O
stabilized	O
beta-catenin	O
protein	O
product	O
)	O
.	O
Immunohistochemistry	O
showed	O
an	O
elevated	O
beta-catenin	O
protein	O
level	O
in	O
all	O
tumors	O
,	O
regardless	O
of	O
mutational	O
status	O
.	O
Beta-catenin	O
localized	O
to	O
the	O
nucleus	O
,	O
and	O
was	O
not	O
tyrosine	O
phosphorylated	O
in	O
the	O
six	O
tumors	O
in	O
which	O
this	O
was	O
tested	O
.	O
The	O
demonstration	O
of	O
mutations	O
in	O
two	O
mediators	O
in	O
the	O
Wnt	O
-	O
APC	O
-	O
beta-catenin	O
pathway	O
implicates	O
beta-catenin	O
stabilization	O
as	O
the	O
key	O
factor	O
in	O
the	O
pathogenesis	O
of	O
aggressive	B-malignancy-type
fibromatosis	I-malignancy-type
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
somatic	O
beta-catenin	O
mutations	O
in	O
a	O
locally	O
invasive	O
,	O
but	O
non	B-malignancy-type
metastatic	I-malignancy-type
lesion	I-malignancy-type
composed	O
of	O
spindle	O
cells	O
,	O
illustrating	O
the	O
importance	O
of	O
beta-catenin	O
stabilization	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
neoplastic	O
processes	O
.	O
Moreover	O
,	O
this	O
tumor	O
has	O
one	O
of	O
the	O
highest	O
reported	O
frequencies	O
of	O
beta-catenin	O
mutations	O
of	O
any	O
tumor	O
type	O
.	O
PMID	O
:	O
10597266	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Sep	O
15;59(	O
18	O
)	O
:4506	O
-	O
9	O
Frequent	O
mutation	O
of	O
beta-catenin	O
and	O
APC	O
genes	O
in	O
primary	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
from	O
patients	O
with	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
.	I-malignancy-type
Miyaki	O
M,	O
Iijima	O
T	O
,	O
Kimura	O
J,	O
Yasuno	O
M,	O
Mori	O
T	O
,	O
Hayashi	O
Y	O
,	O
Koike	O
M,	O
Shitara	O
N	O
,	O
Iwama	O
T	O
,	O
Kuroki	O
T.	O
Hereditary	O
Tumor	O
Research	O
Project	O
,	O
Tokyo	O
Metropolitan	O
Komagome	O
Hospital	O
,	O
Japan	O
.	O
mmiyaki@opal	O
.	O
famille	O
.ne	O
.jp	O
Hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
HNPCC	B-malignancy-type
)	O
is	O
characterized	O
by	O
defective	O
DNA	O
mismatch	O
repair	O
,	O
which	O
results	O
in	O
genetic	O
instability	O
of	O
tumors	O
;	O
however	O
,	O
only	O
a	O
few	O
target	O
genes	O
have	O
been	O
recognized	O
.	O
Our	O
previous	O
study	O
detected	O
a	O
low	O
frequency	O
of	O
APC	O
gene	O
mutation	O
(	O
21	O
%	O
)	O
in	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
from	O
HNPCC	B-malignancy-type
patients	O
,	O
in	O
contrast	O
to	O
a	O
high	O
frequency	O
of	O
APC	O
gene	O
alteration	O
(	O
>	O
70	O
%	O
)	O
in	O
non	B-malignancy-type
-	I-malignancy-type
HNPCC	I-malignancy-type
tumors	I-malignancy-type
.	O
Because	O
both	O
beta-catenin	O
and	O
ACP	O
gene	O
mutations	O
have	O
recently	O
been	O
shown	O
to	O
activate	O
the	O
same	O
signaling	O
pathway	O
,	O
we	O
analyzed	O
beta-catenin	O
mutation	O
in	O
HNPCC	B-malignancy-type
tumors	I-malignancy-type
.	O
A	O
notable	O
frequency	O
of	O
beta-catenin	O
gene	O
mutation	O
(	O
43	O
%	O
,	O
12	O
of	O
28	O
)	O
was	O
found	O
to	O
occur	O
in	O
HNPCC	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Beta-catenin	O
mutations	O
were	O
not	O
detected	O
in	O
tumors	O
with	O
APC	O
mutations	O
.	O
All	O
beta-catenin	O
mutations	O
detected	O
in	O
HNPCC	B-malignancy-type
tumors	I-malignancy-type
existed	O
within	O
the	O
regulatory	O
domain	O
of	O
beta-catenin	O
.	O
Immunohistochemical	O
staining	O
of	O
tumors	O
with	O
this	O
mutation	O
showed	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
nuclei	O
.	O
These	O
and	O
previous	O
data	O
from	O
our	O
laboratory	O
suggest	O
that	O
activation	O
of	O
the	O
beta-catenin	O
-	O
Tcf	O
signaling	O
pathway	O
,	O
through	O
either	O
beta-catenin	O
or	O
APC	O
mutation	O
,	O
contributes	O
to	O
HNPCC	B-malignancy-type
colorectal	O
carcinogenesis	O
in	O
approximately	O
65	O
%	O
of	O
cases	O
.	O
PMID	O
:	O
10493496	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1999	O
Sep;94(9	O
)	O
:2513	O
-	O
8	O
Diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
by	O
detecting	O
telomerase	O
activity	O
in	O
pancreatic	O
juice	O
:	O
comparison	O
with	O
K-ras	O
mutations	O
.	O
Uehara	O
H	O
,	O
Nakaizumi	O
A	O
,	O
Tatsuta	O
M,	O
Baba	O
M,	O
Takenaka	O
A	O
,	O
Uedo	O
N	O
,	O
Sakai	O
N	O
,	O
Yano	O
H	O
,	O
Iishi	O
H	O
,	O
Ohigashi	O
H	O
,	O
Ishikawa	O
O	O
,	O
Okada	O
S,	O
Kakizoe	O
T.	O
Department	O
of	O
Gastroenterology	O
,	O
Osaka	O
Medical	O
Center	O
for	O
Cancer	O
and	O
Cardiovascular	O
Disease	O
,	O
Higashinari	O
,	O
Japan	O
.	O
OBJECTIVE	O
:	O
Telomerase	O
activity	O
is	O
reported	O
to	O
be	O
specific	O
and	O
very	O
frequent	O
in	O
human	O
malignancy	O
.	O
K-ras	O
mutations	O
are	O
also	O
very	O
frequently	O
detected	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
their	O
specificity	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
controversial	O
.	O
We	O
examined	O
the	O
telomerase	O
activity	O
and	O
K-ras	O
mutations	O
in	O
pancreatic	O
juice	O
from	O
patients	O
with	O
pancreatic	B-malignancy-type
disease	I-malignancy-type
.	O
METHODS	O
:	O
Pancreatic	O
juice	O
was	O
obtained	O
endoscopically	O
at	O
endoscopic	O
retrograde	O
pancreatography	O
from	O
10	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
three	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
,	O
and	O
three	O
with	O
a	O
normal	O
pancreas	O
.	O
The	O
telomerase	O
activity	O
in	O
pancreatic	O
juice	O
was	O
assayed	O
by	O
telomeric	O
repeat	O
amplification	O
protocol	O
.	O
K-ras	O
mutations	O
in	O
exon	O
1	O
codon	O
12	O
were	O
examined	O
by	O
the	O
two-step	O
polymerase	O
chain	O
reaction	O
combined	O
with	O
restriction	O
enzyme	O
digestion	O
,	O
followed	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
Telomerase	O
activity	O
of	O
>	O
5.0	O
was	O
detected	O
in	O
eight	O
of	O
10	O
(	O
80	O
%	O
)	O
subjects	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
in	O
none	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
or	O
normal	O
pancreas	O
.	O
K-ras	O
mutations	O
were	O
detected	O
not	O
only	O
in	O
eight	O
of	O
10	O
(	O
80	O
%	O
)	O
subjects	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
but	O
also	O
in	O
two	O
of	O
three	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
in	O
one	O
of	O
three	O
with	O
a	O
normal	O
pancreas	O
.	O
CONCLUSIONS	O
:	O
It	O
was	O
shown	O
that	O
the	O
detection	O
of	O
telomerase	O
activity	O
in	O
pancreatic	O
juice	O
is	O
a	O
more	O
useful	O
diagnostic	O
tool	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
than	O
that	O
of	O
K-ras	O
mutations	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10484017	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Histopathology	O
1999	O
Sep;35(	O
3	O
)	O
:230	O
-	O
40	O
Protein	O
expression	O
and	O
genetic	O
alterations	O
of	O
p53	O
and	O
ras	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
.	O
Furubo	O
S,	O
Harada	O
K	O
,	O
Shimonishi	O
T	O
,	O
Katayanagi	O
K	O
,	O
Tsui	O
W	O
,	O
Nakanuma	O
Y.	O
Department	O
of	O
Pathology	O
(	O
II	O
)	O
,	O
Kanazawa	O
University	O
School	O
of	O
Medicine	O
,	O
Kanazawa	O
,	O
Japan	O
.	O
AIMS	O
:	O
The	O
significance	O
of	O
molecular	O
and	O
genetic	O
alterations	O
of	O
p53	O
and	O
ras	O
in	O
the	O
development	O
and	O
progression	O
as	O
well	O
as	O
the	O
histological	O
differentiation	O
of	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
(	O
ICC	B-malignancy-type
)	O
was	O
evaluated	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
examined	O
immunohistochemically	O
ras	O
p21	O
protein	O
and	O
p53	O
-	O
related	O
products	O
(	O
p53	O
protein	O
,	O
WAF-1	O
and	O
mdm-2	O
)	O
in	O
43	O
cases	O
of	O
ICC	B-malignancy-type
.	O
In	O
addition	O
,	O
point	O
mutations	O
of	O
ras	O
and	O
p53	O
were	O
examined	O
genetically	O
in	O
selected	O
ICC	B-malignancy-type
cases	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
and	O
direct	O
sequence	O
analysis	O
.	O
Point	O
mutation	O
of	O
K-ras	O
gene	O
codon	O
12	O
was	O
detected	O
in	O
three	O
of	O
14	O
cases	O
and	O
one	O
of	O
15	O
cases	O
by	O
PCR	O
-	O
RFLP	O
and	O
direct	O
sequence	O
analysis	O
,	O
respectively	O
.	O
Immunoreactivity	O
of	O
ras	O
p21	O
protein	O
was	O
not	O
detected	O
.	O
Point	O
mutation	O
of	O
p53	O
was	O
detected	O
in	O
three	O
of	O
15	O
cases	O
.	O
p53	O
protein	O
was	O
immunohistochemically	O
detectable	O
in	O
33	O
of	O
43	O
cases	O
.	O
Immunoreactivity	O
of	O
p53	O
was	O
more	O
frequent	O
in	O
well	O
-	O
differentiated	O
and	O
less	O
frequent	O
in	O
poorly	O
differentiated	O
cases	O
.	O
Immunoreactivity	O
of	O
WAF-1	O
and	O
mdm-2	O
was	O
seen	O
in	O
16	O
and	O
eight	O
of	O
43	O
cases	O
,	O
respectively	O
.	O
Both	O
proteins	O
were	O
frequently	O
detected	O
in	O
the	O
cases	O
positive	O
for	O
p53	O
protein	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
dysregulation	O
of	O
ras	O
is	O
involved	O
in	O
at	O
least	O
20	O
%	O
of	O
ICC	B-malignancy-type
and	O
expression	O
of	O
p53	O
protein	O
is	O
more	O
significantly	O
involved	O
in	O
ICC	B-malignancy-type
,	O
particularly	O
in	O
the	O
well	O
and	O
moderately	O
differentiated	O
cases	O
.	O
While	O
some	O
cases	O
of	O
p53	O
expression	O
may	O
be	O
explainable	O
by	O
point	O
mutation	O
of	O
p53	O
,	O
there	O
may	O
be	O
some	O
epigenetic	O
phenomena	O
that	O
stabilize	O
p53	O
protein	O
in	O
ICC	B-malignancy-type
.	O
That	O
is	O
,	O
wild	O
type	O
p53	O
may	O
be	O
stabilized	O
and	O
then	O
detectable	O
by	O
forming	O
complexes	O
with	O
other	O
molecules	O
of	O
p53	O
downstream	O
effector	O
genes	O
,	O
such	O
as	O
WAF-1	O
and	O
mdm-2	O
.	O
PMID	O
:	O
10469215	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Aug;155(	O
2	O
)	O
:527	O
-	O
36	O
beta-catenin	O
expression	O
pattern	O
in	O
stage	O
I	O
and	O
II	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
:	O
relationship	O
with	O
beta-catenin	O
gene	O
mutations	O
,	O
clinicopathological	O
features	O
,	O
and	O
clinical	O
outcome	O
.	O
Gamallo	O
C	O
,	O
Palacios	O
J,	O
Moreno	O
G	O
,	O
Calvo	O
de	O
Mora	O
J,	O
Suarez	O
A	O
,	O
Armas	O
A.	O
Departamento	O
de	O
Anatomia	O
Patologica	O
,	O
Hospital	O
La	O
Paz	O
,	O
Madrid	O
,	O
Spain	O
.	O
cgamallo@hulp.es	O
The	O
immunohistochemical	O
expression	O
pattern	O
of	O
beta-catenin	O
has	O
been	O
correlated	O
with	O
beta-catenin	O
gene	O
mutations	O
,	O
clinicopathological	O
features	O
,	O
and	O
disease	O
outcome	O
in	O
69	O
stage	O
I	O
and	O
II	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
beta-Catenin	O
expression	O
was	O
localized	O
in	O
the	O
nuclei	O
,	O
in	O
addition	O
to	O
the	O
cytoplasm	O
and	O
membrane	O
,	O
in	O
11	O
tumors	O
(	O
16	O
%	O
)	O
:	O
nine	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
widespread	O
nuclear	O
expression	O
and	O
two	O
serous	B-malignancy-type
carcinomas	I-malignancy-type
with	O
focal	O
nuclear	O
expression	O
.	O
The	O
remaining	O
58	O
carcinomas	B-malignancy-type
(	O
84	O
%	O
)	O
only	O
had	O
membranous	O
beta-catenin	O
expression	O
.	O
All	O
but	O
one	O
of	O
the	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
nuclear	O
beta-catenin	O
expression	O
had	O
considerable	O
squamous	O
metaplasia	O
,	O
and	O
five	O
of	O
these	O
cases	O
had	O
large	O
areas	O
of	O
endometrioid	B-malignancy-type
tumor	I-malignancy-type
of	O
low	O
malignant	O
potential	O
.	O
In	O
addition	O
,	O
beta-catenin	O
nuclear	O
expression	O
was	O
observed	O
in	O
atypical	O
epithelial	O
cells	O
in	O
endometriotic	O
glands	O
adjacent	O
to	O
an	O
endometrioid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Sequencing	O
was	O
performed	O
on	O
25	O
tumors	O
and	O
corresponding	O
normal	O
tissue	O
:	O
all	O
13	O
endometrioid	B-malignancy-type
tumors	I-malignancy-type
as	O
well	O
as	O
12	O
carcinomas	B-malignancy-type
of	O
other	O
histological	O
types	O
(	O
four	O
serous	B-malignancy-type
,	O
two	O
clear	B-malignancy-type
cell	I-malignancy-type
,	O
two	O
mucinous	B-malignancy-type
,	O
and	O
two	O
mixed	B-malignancy-type
)	O
.	O
There	O
were	O
oncogenic	O
mutations	O
in	O
the	O
phosphorylation	O
sequence	O
for	O
GSK-3beta	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
seven	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
beta-catenin	O
nuclear	O
expression	O
.	O
Three	O
mutations	O
affected	O
codon	O
32	O
(	O
D	O
32	O
G	O
,	O
D	O
32	O
Y	O
,	O
and	O
D	O
32	O
Y	O
)	O
,	O
one	O
affected	O
codon	O
33	O
(	O
S	O
33	O
C	O
)	O
,	O
two	O
affected	O
codon	O
37	O
(	O
S	O
37	O
C	O
and	O
S	O
37	O
F	O
)	O
,	O
and	O
one	O
affected	O
codon	O
41	O
(	O
T	O
41	O
A	O
)	O
.	O
No	O
mutations	O
were	O
observed	O
in	O
the	O
other	O
18	O
carcinomas	B-malignancy-type
analyzed	O
,	O
comprising	O
two	O
endometrioid	B-malignancy-type
and	O
two	O
serous	B-malignancy-type
carcinomas	I-malignancy-type
with	O
beta-catenin	O
nuclear	O
expression	O
,	O
and	O
14	O
carcinomas	B-malignancy-type
of	O
different	O
histological	O
types	O
with	O
only	O
membranous	O
expression	O
.	O
In	O
the	O
univariate	O
and	O
multivariate	O
survival	O
analyses	O
,	O
beta-catenin	O
nuclear	O
expression	O
was	O
selected	O
as	O
an	O
indicator	O
of	O
good	O
prognosis	O
,	O
because	O
no	O
patient	O
whose	O
tumor	O
expressed	O
beta-catenin	O
in	O
the	O
nuclei	O
showed	O
relapses	O
or	O
died	O
,	O
in	O
contrast	O
to	O
the	O
19	O
relapses	O
and	O
deaths	O
among	O
patients	O
with	O
tumors	O
that	O
only	O
had	O
beta-catenin	O
membranous	O
expression	O
,	O
including	O
three	O
of	O
the	O
four	O
patients	O
with	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Oncogenic	O
beta-catenin	O
mutation	O
is	O
characteristic	O
of	O
a	O
group	O
of	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
a	O
good	O
prognosis	O
,	O
most	O
of	O
which	O
originate	O
from	O
previous	O
benign	O
or	O
borderline	O
lesions	O
.	O
Endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
exclusively	O
membranous	O
expression	O
of	O
beta-catenin	O
seem	O
to	O
represent	O
a	O
different	O
subgroup	O
of	O
carcinomas	B-malignancy-type
that	O
probably	O
have	O
a	O
worse	O
prognosis	O
.	O
In	O
early-stage	O
ovarian	B-malignancy-type
cancer	I-malignancy-type
,	O
determination	O
of	O
the	O
beta-catenin	O
expression	O
pattern	O
could	O
prove	O
to	O
be	O
a	O
useful	O
marker	O
for	O
selecting	O
low-risk	O
patients	O
.	O
PMID	O
:	O
10433945	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1999	O
Jul	O
15	O
;86(	O
2	O
)	O
:255	O
-	O
64	O
ras	O
gene	O
mutations	O
in	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinoma	I-malignancy-type
:	O
prognostic	O
implications	O
.	O
Perez	O
P	O
,	O
Dominguez	O
O	O
,	O
Gonzalez	O
S,	O
Gonzalez	O
S,	O
Trivino	O
A	O
,	O
Suarez	O
C.	O
Department	O
of	O
ENT	O
,	O
University	O
Hospital	O
Central	O
of	O
Asturias	O
,	O
Oviedo	O
,	O
Spain	O
.	O
BACKGROUND	O
:	O
The	O
presence	O
of	O
mutations	O
of	O
the	O
3	O
ras	O
proto	O
-	O
oncogenes	O
in	O
31	O
cases	O
of	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
an	O
uncommon	O
tumor	O
type	O
epidemiologically	O
related	O
to	O
professional	O
exposure	O
to	O
wood	O
dust	O
,	O
was	O
studied	O
.	O
METHODS	O
:	O
The	O
authors	O
studied	O
31	O
patients	O
with	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
The	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
ras	O
specific	O
sequences	O
of	O
DNA	O
isolated	O
from	O
paraffin	O
embedded	O
tumor	O
samples	O
.	O
ras	O
point	O
mutations	O
were	O
subsequently	O
detected	O
with	O
mutation	O
specific	O
oligonucleotide	O
probes	O
.	O
RESULTS	O
:	O
H-ras	O
was	O
found	O
to	O
be	O
mutated	O
in	O
5	O
cases	O
(	O
16	O
%	O
)	O
.	O
It	O
is	O
noteworthy	O
that	O
all	O
of	O
these	O
mutations	O
were	O
identical	O
and	O
consisted	O
of	O
a	O
G	O
-	O
for	O
-	O
T	O
transversion	O
at	O
the	O
second	O
base	O
of	O
codon	O
12	O
.	O
H-ras	O
mutations	O
were	O
related	O
to	O
a	O
worse	O
prognosis	O
,	O
with	O
shorter	O
tumor	O
free	O
survival	O
(	O
P	O
=	O
0.04	O
)	O
and	O
overall	O
survival	O
(	O
P	O
=	O
0.008	O
)	O
.	O
T	O
classification	O
was	O
a	O
significant	O
clinical	O
factor	O
related	O
to	O
survival	O
(	O
P	O
=	O
0.01	O
for	O
disease	O
free	O
survival	O
and	O
P	O
=	O
0.006	O
for	O
overall	O
survival	O
)	O
.	O
The	O
prognostic	O
value	O
of	O
H-ras	O
mutation	O
was	O
consistent	O
after	O
adjustment	O
for	O
T	O
classification	O
.	O
H-ras	O
mutations	O
showed	O
no	O
association	O
with	O
patients	O
'	O
previous	O
exposure	O
to	O
wood	O
dust	O
.	O
K-ras	O
was	O
found	O
to	O
be	O
transformed	O
in	O
a	O
single	O
case	O
;	O
this	O
was	O
the	O
only	O
patient	O
in	O
the	O
series	O
to	O
develop	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
.	O
In	O
this	O
case	O
,	O
both	O
the	O
nasal	B-malignancy-type
tumor	I-malignancy-type
and	O
the	O
lymph	O
nodes	O
showed	O
the	O
GAT	O
-	O
for	O
-	O
GGT	O
mutation	O
at	O
codon	O
12	O
of	O
K-ras	O
.	O
No	O
activation	O
of	O
the	O
N-ras	O
gene	O
was	O
detected	O
.	O
CONCLUSIONS	O
:	O
The	O
presence	O
of	O
H-ras	O
point	O
mutations	O
defines	O
a	O
subgroup	O
of	O
patients	O
with	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinomas	I-malignancy-type
for	O
whom	O
the	O
prognosis	O
is	O
very	O
poor	O
.	O
The	O
finding	O
that	O
all	O
of	O
these	O
mutations	O
are	O
identical	O
emphasizes	O
the	O
peculiarity	O
of	O
this	O
type	O
of	O
tumor	O
.	O
PMID	O
:	O
10421261	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
Respir	O
J	O
1999	O
May	O
;13(	O
5	O
)	O
:1120	O
-	O
4	O
Additional	O
value	O
of	O
K-ras	O
point	O
mutations	O
in	O
bronchial	O
wash	O
fluids	O
for	O
diagnosis	O
of	O
peripheral	B-malignancy-type
lung	I-malignancy-type
tumours	I-malignancy-type
.	O
Somers	O
VA	O
,	O
van	O
Henten	O
AM	O
,	O
ten	O
Velde	O
GP	O
,	O
Arends	O
JW	O
,	O
Thunnissen	O
FB.	O
Dept	O
of	O
Pathology	O
,	O
Maastricht	O
University	O
,	O
The	O
Netherlands	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
additional	O
diagnostic	O
value	O
of	O
K-ras	O
point	O
mutations	O
in	O
the	O
clinical	O
diagnosis	O
of	O
peripheral	B-malignancy-type
lung	I-malignancy-type
tumours	I-malignancy-type
.	O
To	O
this	O
end	O
,	O
bronchial	O
wash	O
fluids	O
obtained	O
during	O
bronchoscopy	O
from	O
patients	O
suspected	O
of	O
having	O
lung	B-malignancy-type
cancer	I-malignancy-type
were	O
studied	O
.	O
Only	O
those	O
patients	O
were	O
investigated	O
for	O
whom	O
the	O
cytological	O
diagnosis	O
was	O
not	O
conclusive	O
for	O
malignancy	O
.	O
As	O
a	O
control	O
group	O
,	O
patients	O
without	O
lung	B-malignancy-type
cancer	I-malignancy-type
were	O
investigated	O
.	O
The	O
method	O
of	O
"	O
point	O
mutation	O
detection	O
using	O
the	O
exonuclease	O
amplification	O
coupled	O
capture	O
technique	O
"	O
(	O
Point	O
-	O
EXACCT	O
)	O
for	O
analysis	O
of	O
K-ras	O
codon	O
12	O
was	O
performed	O
in	O
bronchial	O
wash	O
fluids	O
and	O
the	O
corresponding	O
tumour	O
tissue	O
,	O
if	O
available	O
.	O
K-ras	O
point	O
mutations	O
were	O
identified	O
in	O
4	O
out	O
of	O
19	O
(	O
21	O
%	O
)	O
bronchial	O
wash	O
fluids	O
from	O
patients	O
without	O
a	O
decisive	O
diagnosis	O
of	O
malignancy	O
.	O
The	O
diagnosis	O
of	O
malignancy	O
was	O
further	O
based	O
on	O
cytological	O
examination	O
of	O
bronchial	O
brush	O
specimens	O
,	O
perthoracic	O
needle	O
aspiration	O
,	O
histological	O
investigation	O
of	O
biopsy	O
and	O
resection	O
specimens	O
,	O
needle	O
aspiration	O
of	O
a	O
lymph	O
node	O
in	O
the	O
neck	O
and	O
pleural	O
fluid	O
examination	O
.	O
Four	O
of	O
the	O
patients	O
who	O
were	O
K-ras	O
-	O
positive	O
yielded	O
positive	O
malignant	O
tissue	O
via	O
bronchoscopy	O
even	O
though	O
the	O
bronchial	O
wash	O
was	O
negative	O
for	O
malignancy	O
.	O
The	O
bronchial	O
wash	O
was	O
positive	O
for	O
K-ras	O
in	O
two	O
of	O
the	O
four	O
patients	O
whose	O
tumour	O
tissue	O
demonstrated	O
the	O
K-ras	O
mutations	O
.	O
Analysis	O
of	O
bronchial	O
wash	O
fluids	O
from	O
11	O
patients	O
without	O
lung	B-malignancy-type
cancer	I-malignancy-type
revealed	O
no	O
K-ras	O
codon	O
12	O
mutations	O
.	O
In	O
conclusion	O
,	O
K-ras	O
point	O
mutations	O
can	O
be	O
identified	O
in	O
bronchial	O
wash	O
fluids	O
obtained	O
during	O
bronchoscopic	O
procedures	O
.	O
K-ras	O
can	O
be	O
used	O
as	O
a	O
biomarker	O
in	O
the	O
clinical	O
diagnosis	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
may	O
serve	O
as	O
an	O
adjunct	O
to	O
cytology	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
diagnosis	O
.	O
PMID	O
:	O
10414414	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1999	O
Jun	O
11	O
;81(	O
6)	O
:902	O
-	O
10	O
Establishment	O
and	O
characterization	O
of	O
12	O
human	O
colorectal	B-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
.	O
Oh	O
JH	O
,	O
Ku	O
JL	O
,	O
Yoon	O
KA	O
,	O
Kwon	O
HJ	O
,	O
Kim	O
WH	O
,	O
Park	O
HS	O
,	O
Yeo	O
KS	O
,	O
Song	O
SY	O
,	O
Chung	O
JK	O
,	O
Park	O
JG.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
Cancer	O
Research	O
Center	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Korean	O
Cell	O
Line	O
Bank	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Republic	O
of	O
Korea	O
.	O
In	O
this	O
article	O
,	O
we	O
describe	O
the	O
characteristics	O
of	O
12	O
human	O
colorectal	B-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
established	O
from	O
6	O
primary	O
tumors	O
and	O
6	O
metastatic	O
sites	O
of	O
11	O
Korean	O
colorectal	B-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
patients	O
,	O
including	O
the	O
morphology	O
in	O
vivo	O
and	O
in	O
vitro	O
and	O
mutations	O
of	O
K-ras2	O
,	O
p15	O
,	O
p16	O
,	O
p53	O
,	O
APC	O
,	O
beta-catenin	O
,	O
hMLH1	O
and	O
hMSH2	O
genes	O
in	O
vitro	O
.	O
No	O
lines	O
were	O
contaminated	O
with	O
Mycoplasma	O
or	O
bacteria	O
.	O
All	O
lines	O
were	O
proven	O
to	O
be	O
unique	O
by	O
DNA	O
-	O
fingerprinting	O
analysis	O
.	O
All	O
lines	O
expressed	O
the	O
surface	O
carcino	O
-	O
embryonic	O
antigen	O
and	O
secreted	O
it	O
into	O
the	O
supernatant	O
fluid	O
.	O
The	O
morphological	O
correlation	O
between	O
the	O
original	O
tumors	O
and	O
cultured	O
cells	O
suggested	O
that	O
the	O
original	O
tumors	O
showing	O
mucinous	B-malignancy-type
adenocarcinoma	I-malignancy-type
correlated	O
with	O
floating	O
aggregates	O
in	O
culture	O
,	O
and	O
degree	O
of	O
desmoplasia	B-malignancy-type
in	O
the	O
original	O
tumor	O
correlated	O
with	O
attached	O
growth	O
in	O
culture	O
.	O
Five	O
of	O
the	O
cell	O
lines	O
showed	O
mutations	O
in	O
the	O
K-ras2	O
gene	O
,	O
and	O
6	O
of	O
the	O
cell	O
lines	O
showed	O
mutations	O
in	O
the	O
p53	O
gene	O
.	O
The	O
p15	O
gene	O
was	O
deleted	O
in	O
2	O
cell	O
lines	O
,	O
and	O
the	O
p16	O
gene	O
was	O
hypermethylated	O
in	O
3	O
cell	O
lines	O
.	O
The	O
mutation	O
of	O
mismatch	O
-	O
repair	O
genes	O
(	O
hMLH1	O
and	O
hMSH2	O
)	O
was	O
found	O
in	O
4	O
lines	O
,	O
the	O
APC	O
gene	O
and	O
beta-catenin	O
gene	O
were	O
mutated	O
in	O
9	O
and	O
2	O
lines	O
respectively	O
.	O
These	O
well	O
-	O
characterized	O
colorectal	B-malignancy-type
-	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
should	O
serve	O
as	O
useful	O
tools	O
for	O
investigating	O
the	O
biological	O
characteristics	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10362137	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Apr	O
8;18(	O
14	O
)	O
:2343	O
-	O
50	O
Novel	O
mutations	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Schmidt	O
L,	O
Junker	O
K	O
,	O
Nakaigawa	O
N	O
,	O
Kinjerski	O
T	O
,	O
Weirich	O
G	O
,	O
Miller	O
M,	O
Lubensky	O
I	O
,	O
Neumann	O
HP	O
,	O
Brauch	O
H	O
,	O
Decker	O
J,	O
Vocke	O
C	O
,	O
Brown	O
JA	O
,	O
Jenkins	O
R,	O
Richard	O
S,	O
Bergerheim	O
U	O
,	O
Gerrard	O
B	O
,	O
Dean	O
M,	O
Linehan	O
WM	O
,	O
Zbar	O
B.	O
Intramural	O
Research	O
Support	O
Program	O
,	O
SAIC	O
Frederick	O
,	O
National	O
Cancer	O
Institute	O
-	O
Frederick	O
Cancer	O
Research	O
and	O
Development	O
Center	O
,	O
Maryland	O
21702	O
,	O
USA	O
.	O
Hereditary	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
(	O
HPRC	B-malignancy-type
)	O
is	O
characterized	O
by	O
multiple	B-malignancy-type
,	I-malignancy-type
bilateral	I-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Previously	O
,	O
we	O
demonstrated	O
missense	O
mutations	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
HPRC	O
and	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
screened	O
a	O
large	O
panel	O
of	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
and	O
various	O
solid	O
tumors	O
for	O
mutations	O
in	O
the	O
MET	O
proto	O
-	O
oncogene	O
.	O
Summarizing	O
these	O
and	O
previous	O
results	O
,	O
mutations	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
were	O
detected	O
in	O
17	O
/	O
129	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
but	O
not	O
in	O
other	O
solid	O
tumors	O
.	O
We	O
detected	O
five	O
novel	O
missense	O
mutations	O
;	O
three	O
of	O
five	O
mutations	O
were	O
located	O
in	O
the	O
ATP	O
-	O
binding	O
region	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
MET	O
.	O
One	O
novel	O
mutation	O
in	O
MET	O
,	O
V	O
1110	O
I	O
,	O
was	O
located	O
at	O
a	O
codon	O
homologous	O
to	O
an	O
activating	O
mutation	O
in	O
the	O
c-erbB	O
proto	O
-	O
oncogene	O
.	O
These	O
mutations	O
caused	O
constitutive	O
phosphorylation	O
of	O
MET	O
when	O
transfected	O
into	O
NIH3T3	O
cells	O
.	O
Molecular	O
modeling	O
studies	O
suggest	O
that	O
these	O
activating	O
mutations	O
interfere	O
with	O
the	O
intrasteric	O
mechanism	O
of	O
tyrosine	O
kinase	O
autoinhibition	O
and	O
facilitate	O
transition	O
to	O
the	O
active	O
form	O
of	O
the	O
MET	O
kinase	O
.	O
The	O
low	O
frequency	O
of	O
MET	O
mutations	O
in	O
noninherited	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
(	O
PRC	B-malignancy-type
)	O
suggests	O
that	O
noninherited	B-malignancy-type
PRC	I-malignancy-type
may	O
develop	O
by	O
a	O
different	O
mechanism	O
than	O
hereditary	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
10327054	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1999	O
Apr;13(	O
4)	O
:585	O
-	O
9	O
Lack	O
of	O
constitutive	O
activation	O
of	O
MAP	O
kinase	O
pathway	O
in	O
human	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
cells	O
with	O
N-Ras	O
mutation	O
.	O
Iida	O
M,	O
Towatari	O
M,	O
Nakao	O
A	O
,	O
Iida	O
H	O
,	O
Kiyoi	O
H	O
,	O
Nakano	O
Y	O
,	O
Tanimoto	O
M,	O
Saito	O
H	O
,	O
Naoe	O
T.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nagoya	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
act	O
as	O
transducers	O
of	O
extracellular	O
signaling	O
via	O
tyrosine	O
kinase	O
-	O
growth	O
factor	O
receptors	O
and	O
G-protein	O
-	O
linked	O
receptors	O
to	O
transcription	O
factors	O
.	O
Constitutive	O
activation	O
of	O
MAP	O
kinase	O
has	O
been	O
observed	O
in	O
a	O
variety	O
of	O
solid	O
tumors	O
including	O
renal	B-malignancy-type
cancer	I-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
Recently	O
,	O
we	O
have	O
reported	O
that	O
constitutively	O
activated	O
MAP	O
kinase	O
was	O
observed	O
in	O
50	O
%	O
of	O
human	O
primary	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
cells	O
.	O
Ras	O
is	O
one	O
of	O
the	O
components	O
of	O
G-proteins	O
and	O
transduces	O
the	O
signal	O
from	O
cytokine	O
receptors	O
to	O
raf-1	O
theoretically	O
resulting	O
in	O
the	O
activation	O
of	O
MAP	O
kinase	O
pathway	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
examined	O
the	O
correlation	O
of	O
Ras	O
mutations	O
and	O
the	O
activation	O
of	O
MAP	O
kinase	O
pathway	O
in	O
patients	O
with	O
AML	B-malignancy-type
.	O
Twenty	O
out	O
of	O
22	O
AML	B-malignancy-type
cases	O
with	O
activating	O
N-Ras	O
mutations	O
showed	O
no	O
phosphorylated	O
forms	O
of	O
ERK2	O
.	O
ERK2	O
phosphorylation	O
was	O
tightly	O
correlated	O
with	O
ERK1	O
phosphorylation	O
and	O
MAP	O
kinase	O
activity	O
detected	O
by	O
in	O
vitro	O
kinase	O
assay	O
.	O
Three	O
samples	O
with	O
N-Ras	O
mutations	O
were	O
stimulated	O
with	O
IL-3	O
,	O
GM-CSF	O
and	O
G-CSF	O
separately	O
but	O
ERK2	O
activation	O
was	O
induced	O
in	O
none	O
of	O
these	O
samples	O
stimulated	O
with	O
these	O
cytokines	O
.	O
In	O
contrast	O
,	O
ERK2	O
was	O
constitutively	O
activated	O
in	O
all	O
of	O
four	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
cases	O
with	O
K-Ras	O
mutation	O
at	O
codon	O
12	O
.	O
These	O
results	O
suggest	O
that	O
function	O
of	O
the	O
Ras	O
mutations	O
may	O
be	O
different	O
between	O
solid	O
tumors	O
,	O
such	O
as	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
and	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
AML	B-malignancy-type
.	O
Mutated	O
Ras	O
does	O
not	O
always	O
stimulate	O
MAP	O
kinase	O
pathway	O
constitutively	O
and	O
may	O
rather	O
inhibit	O
classical	O
MAP	O
kinase	O
cascade	O
in	O
AML	B-malignancy-type
blasts	O
from	O
leukemia	B-malignancy-type
patients	O
.	O
PMID	O
:	O
10214865	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
1999	O
Apr;18(	O
3	O
)	O
:294	O
-	O
9	O
Comment	O
in	O
:	O
Pancreas	O
.	O
2001	O
Jan;22(	O
1	O
)	O
:108	O
-	O
9.	O
Detection	O
of	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
pancreatic	O
juice	O
for	O
the	O
diagnosis	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
.	O
Kaino	O
M,	O
Kondoh	O
S,	O
Okita	O
S,	O
Hatano	O
S,	O
Shiraishi	O
K	O
,	O
Kaino	O
S,	O
Okita	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yamaguchi	O
University	O
School	O
of	O
Medicine	O
,	O
Ube	O
,	O
Japan	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
mutations	O
of	O
the	O
K-ras	O
oncogene	O
and	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
pancreatic	O
juice	O
and	O
to	O
evaluate	O
our	O
method	O
for	O
the	O
diagnosis	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
(	O
IPMT	B-malignancy-type
)	O
.	O
Pancreatic	O
juice	O
was	O
collected	O
endoscopically	O
from	O
12	O
patients	O
with	O
IPMT	B-malignancy-type
who	O
underwent	O
surgical	O
resection	O
(	O
eight	O
carcinomas	B-malignancy-type
and	O
four	O
adenomas	B-malignancy-type
)	O
and	O
eight	O
cases	O
without	O
evident	O
pancreatic	O
diseases	O
.	O
DNA	O
was	O
extracted	O
and	O
both	O
genes	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
In	O
addition	O
,	O
surgically	O
resected	O
specimens	O
were	O
analyzed	O
for	O
both	O
genes	O
by	O
the	O
same	O
methods	O
,	O
and	O
p53	O
overexpression	O
was	O
investigated	O
immunohistochemically	O
.	O
K-ras	O
point	O
mutations	O
were	O
detected	O
in	O
pancreatic	O
juice	O
from	O
all	O
12	O
patients	O
(	O
100	O
%	O
)	O
and	O
p53	O
mutations	O
were	O
detected	O
in	O
five	O
of	O
12	O
(	O
42	O
%	O
)	O
.	O
They	O
were	O
detected	O
not	O
only	O
in	O
carcinoma	B-malignancy-type
but	O
also	O
in	O
adenoma	B-malignancy-type
and	O
there	O
was	O
no	O
difference	O
between	O
the	O
mutations	O
detected	O
in	O
pancreatic	O
juice	O
and	O
surgical	O
specimens	O
.	O
No	O
mutations	O
were	O
found	O
in	O
any	O
cases	O
without	O
pancreatic	O
diseases	O
.	O
These	O
findings	O
suggest	O
that	O
alterations	O
of	O
K-ras	O
and	O
p53	O
gene	O
are	O
common	O
events	O
in	O
the	O
development	O
of	O
IPMT	B-malignancy-type
and	O
that	O
genetic	O
analysis	O
of	O
them	O
in	O
pancreatic	O
juice	O
can	O
be	O
a	O
useful	O
tool	O
for	O
the	O
clinical	O
diagnosis	O
of	O
IPMT	B-malignancy-type
before	O
surgery	O
.	O
PMID	O
:	O
10206488	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
1999	O
Mar;18(	O
2	O
)	O
:133	O
-	O
40	O
Analysis	O
of	O
K-ras	O
codon	O
12	O
point	O
mutations	O
using	O
duodenal	O
lavage	O
fluid	O
for	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Nakamura	O
Y	O
,	O
Onda	O
M,	O
Uchida	O
E.	O
First	O
Department	O
of	O
Surgery	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
We	O
evaluated	O
the	O
diagnostic	O
significance	O
of	O
the	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
duodenal	O
lavage	O
fluid	O
(	O
DLF	O
)	O
compared	O
with	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
.	O
The	O
DLF	O
was	O
easily	O
and	O
safely	O
collected	O
by	O
injecting	O
distilled	O
water	O
into	O
the	O
duodenum	O
and	O
then	O
aspirating	O
through	O
the	O
working	O
channel	O
of	O
the	O
endoscope	O
during	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
.	O
Two	O
types	O
of	O
DLF	O
are	O
collected	O
this	O
way	O
:	O
DLF	O
1	O
is	O
collected	O
just	O
after	O
insertion	O
of	O
the	O
endoscope	O
into	O
the	O
duodenum	O
and	O
DLF	O
2	O
is	O
collected	O
after	O
cholangiopancreatography	O
and/or	O
collection	O
of	O
the	O
PPJ	O
using	O
secretin	O
.	O
Analysis	O
of	O
K-ras	O
mutations	O
was	O
performed	O
using	O
enriched	O
polymerase	O
chain	O
reaction	O
.	O
In	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
(	O
PC	B-malignancy-type
)	O
,	O
K-ras	O
mutations	O
were	O
detected	O
in	O
14	O
of	O
23	O
(	O
60.9	O
%	O
)	O
in	O
DLF	O
1	O
,	O
16	O
of	O
21	O
(	O
76.2	O
%	O
)	O
in	O
DLF	O
2	O
,	O
14	O
of	O
20	O
(	O
70.0	O
%	O
)	O
in	O
PPJ	O
,	O
and	O
19	O
of	O
21	O
(	O
90.5	O
%	O
)	O
in	O
either	O
DLF	O
1	O
or	O
DLF	O
2	O
.	O
In	O
patients	O
with	O
noncancerous	O
pancreatic	O
diseases	O
consisting	O
of	O
pancreatic	B-malignancy-type
cystic	I-malignancy-type
diseases	I-malignancy-type
and	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
,	O
the	O
incidence	O
of	O
K-ras	O
mutations	O
was	O
2	O
of	O
21	O
(	O
9.5	O
%	O
)	O
in	O
DLF	O
1	O
and	O
7	O
of	O
19	O
(	O
36.8	O
%	O
)	O
in	O
DLF	O
2	O
.	O
These	O
values	O
were	O
lower	O
than	O
that	O
in	O
PPJ	O
,	O
and	O
there	O
was	O
significant	O
difference	O
between	O
the	O
incidence	O
in	O
DLF	O
1	O
and	O
PPJ	O
.	O
These	O
results	O
suggested	O
that	O
DLF	O
may	O
provide	O
a	O
new	O
and	O
useful	O
material	O
for	O
analysis	O
of	O
K-ras	O
codon	O
12	O
point	O
mutations	O
in	O
the	O
diagnosis	O
of	O
PC	B-malignancy-type
.	O
PMID	O
:	O
10090410	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Jan;90(	O
1	O
)	O
:55	O
-	O
9	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Kobayashi	O
K	O
,	O
Sagae	O
S,	O
Nishioka	O
Y	O
,	O
Tokino	O
T	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Sapporo	O
Medical	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Hokkaido	O
.	O
To	O
investigate	O
the	O
contribution	O
of	O
beta-catenin	O
to	O
the	O
development	O
of	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
searched	O
for	O
genetic	O
alterations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
primary	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Mutational	O
analysis	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
encoding	O
the	O
serine	O
/	O
threonine	O
residues	O
for	O
GSK-3	O
beta	O
phosphorylation	O
,	O
was	O
performed	O
for	O
35	O
tumors	O
.	O
Nucleotide	O
sequencing	O
analysis	O
revealed	O
that	O
5	O
tumors	O
(	O
5	O
/	O
35	O
,	O
14	O
%	O
)	O
contained	O
mutations	O
(	O
S	O
33	O
C	O
,	O
S	O
37	O
C	O
,	O
S	O
37	O
F	O
,	O
T	O
41	O
A	O
)	O
that	O
altered	O
potential	O
GSK-3	O
beta	O
phosphorylation	O
sites	O
.	O
Each	O
of	O
the	O
mutations	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
/	O
threonine	O
residues	O
that	O
have	O
been	O
implicated	O
in	O
the	O
down-regulation	O
of	O
beta-catenin	O
through	O
phosphorylation	O
by	O
GSK-3	O
beta	O
kinase	O
.	O
Furthermore	O
,	O
the	O
incidence	O
of	O
beta-catenin	O
mutations	O
was	O
significantly	O
higher	O
in	O
early-onset	O
(	O
3	O
of	O
5	O
)	O
than	O
that	O
in	O
late-onset	O
tumors	O
(	O
2	O
of	O
30	O
)	O
(	O
P	O
=	O
0.014	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
Replication	O
error	O
(	O
RER	O
)	O
-	O
positive	O
phenotype	O
was	O
not	O
detected	O
in	O
tumors	O
with	O
the	O
beta-catenin	O
gene	O
mutation	O
,	O
although	O
10	O
of	O
35	O
tumors	O
revealed	O
RER	O
.	O
We	O
performed	O
immunohistochemistry	O
of	O
beta-catenin	O
in	O
17	O
cases	O
for	O
which	O
tissue	O
samples	O
were	O
available	O
.	O
We	O
confirmed	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
both	O
the	O
nucleus	O
and	O
cytoplasm	O
in	O
3	O
tumors	O
,	O
including	O
two	O
in	O
which	O
amino	O
acid	O
alterations	O
had	O
occurred	O
at	O
codon	O
33	O
and	O
37	O
.	O
The	O
other	O
case	O
had	O
no	O
mutation	O
in	O
exon	O
3	O
.	O
Our	O
results	O
suggested	O
that	O
mutations	O
at	O
serine	O
/	O
threonine	O
residues	O
involved	O
in	O
phosphorylation	O
by	O
GSK-3	O
beta	O
affected	O
the	O
stability	O
of	O
beta-catenin	O
.	O
Accumulation	O
of	O
mutant	O
beta-catenin	O
could	O
contribute	O
to	O
the	O
development	O
of	O
a	O
subset	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
particularly	O
those	O
of	O
the	O
early-onset	O
type	O
.	O
PMID	O
:	O
10076565	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virchows	O
Arch	O
1999	O
Feb;434(	O
2	O
)	O
:117	O
-	O
20	O
In	O
serous	B-malignancy-type
ovarian	I-malignancy-type
neoplasms	I-malignancy-type
the	O
frequency	O
of	O
Ki-ras	O
mutations	O
correlates	O
with	O
their	O
malignant	O
potential	O
.	O
Haas	O
CJ	O
,	O
Diebold	O
J,	O
Hirschmann	O
A	O
,	O
Rohrbach	O
H	O
,	O
Lohrs	O
U.	O
Institute	O
of	O
Pathology	O
,	O
Ludwig	O
-	O
Maximilians	O
-	O
Universitat	O
,	O
Munich	O
,	O
Germany	O
.	O
We	O
analysed	O
44	O
tissue	O
samples	O
from	O
serous	B-malignancy-type
ovarian	I-malignancy-type
neoplasms	I-malignancy-type
of	O
different	O
malignant	O
potential	O
for	O
Ki-ras	O
mutations	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
and	O
direct	O
sequencing	O
after	O
microdissection	O
.	O
Point	O
mutations	O
at	O
codon	O
12	O
were	O
found	O
in	O
7	O
of	O
20	O
tumours	O
of	O
low	O
malignant	O
potential	O
(	O
LMP	O
)	O
(	O
35	O
%	O
)	O
and	O
in	O
2	O
of	O
6	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
carcinomas	I-malignancy-type
(	O
33	O
%	O
)	O
.	O
In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
11	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
samples	O
or	O
in	O
the	O
7	O
serous	B-malignancy-type
cystadenomas	I-malignancy-type
.	O
The	O
frequency	O
of	O
Ki-ras	O
mutations	O
in	O
serous	B-malignancy-type
ovarian	I-malignancy-type
tumours	I-malignancy-type
seems	O
to	O
correlate	O
with	O
the	O
malignant	O
potential	O
of	O
the	O
neoplasms	B-malignancy-type
.	O
The	O
data	O
favour	O
the	O
hypothesis	O
of	O
a	O
de	O
novo	O
development	O
of	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
and	O
do	O
not	O
support	O
an	O
evolution	O
from	O
LMP	O
tumours	O
or	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
10071245	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1998	O
Dec;34(	O
13	O
)	O
:2053	O
-	O
7	O
K-ras	O
mutations	O
in	O
colorectal	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
neighbouring	O
transitional	O
mucosa	O
.	O
Zhang	O
H	O
,	O
Nordenskjold	O
B	O
,	O
Dufmats	O
M,	O
Soderkvist	O
P	O
,	O
Sun	O
XF	O
.	O
Division	O
of	O
Cell	O
Biology	O
,	O
Linkoping	O
University	O
,	O
Sweden	O
.	O
The	O
K-ras	O
gene	O
in	O
codons	O
12	O
and	O
13	O
was	O
investigated	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
in	O
matched	O
normal	O
mucosa	O
(	O
n	O
=	O
106	O
)	O
,	O
transitional	O
mucosa	O
(	O
n	O
=	O
69	O
)	O
and	O
tumours	O
(	O
n	O
=	O
149	O
)	O
from	O
149	O
patients	O
with	O
colorectal	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
K-ras	O
mutations	O
in	O
codon	O
12	O
were	O
detected	O
in	O
41	O
/	O
149	O
(	O
28	O
%	O
)	O
of	O
tumours	O
and	O
4	O
/	O
69	O
(	O
6	O
%	O
)	O
of	O
transitional	O
mucosa	O
samples	O
,	O
but	O
not	O
in	O
the	O
normal	O
mucosa	O
.	O
Further	O
,	O
mutation	O
rates	O
were	O
increased	O
in	O
younger	O
patients	O
(	O
P	O
=	O
0.001	O
)	O
and	O
in	O
mucinous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
50	O
%	O
)	O
compared	O
with	O
well	O
differentiated	O
(	O
17	O
%	O
)	O
,	O
moderately	O
differentiated	O
(	O
26	O
%	O
)	O
or	O
poorly	O
differentiated	O
(	O
24	O
%	O
)	O
tumours	O
.	O
Our	O
findings	O
indicate	O
that	O
mucinous	B-malignancy-type
carcinoma	I-malignancy-type
may	O
represent	O
a	O
distinct	O
genetic	O
entity	O
.	O
PMID	O
:	O
10070310	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
1998	O
Jul	O
-	O
Aug;18(	O
4B)	O
:2789	O
-	O
92	O
Mutations	O
of	O
ras	O
genes	O
are	O
relatively	O
frequent	O
in	O
Japanese	O
prostate	B-malignancy-type
cancers	I-malignancy-type
:	O
pointing	O
to	O
genetic	O
differences	O
between	O
populations	O
.	O
Shiraishi	O
T	O
,	O
Muneyuki	O
T	O
,	O
Fukutome	O
K	O
,	O
Ito	O
H	O
,	O
Kotake	O
T	O
,	O
Watanabe	O
M,	O
Yatani	O
R.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Point	O
mutations	O
of	O
the	O
ras	O
gene	O
family	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
However	O
,	O
it	O
remains	O
unknown	O
whether	O
the	O
ras	O
gene	O
might	O
play	O
a	O
key	O
role	O
in	O
prostate	O
carcinogenesis	O
.	O
We	O
therefore	O
analysed	O
Ki	O
-	O
,	O
N	O
-	O
and	O
H	O
-	O
ras	O
gene	O
mutations	O
in	O
a	O
series	O
of	O
81	O
Japanese	O
prostate	B-malignancy-type
cancers	I-malignancy-type
using	O
PCR	O
-	O
SSCP	O
analysis	O
and	O
Mutant	O
-	O
Allele	O
-	O
Specific	O
Amplification	O
(	O
MASA	O
)	O
method	O
.	O
Mutated	O
as	O
genes	O
were	O
detected	O
in	O
20	O
of	O
the	O
81	O
samples	O
(	O
24	O
%	O
)	O
;	O
three	O
of	O
22	O
latent	O
,	O
one	O
of	O
five	O
stage	O
B	O
,	O
four	O
of	O
14	O
stage	O
C	O
and	O
12	O
of	O
40	O
stage	O
D	O
cancers	O
.	O
Of	O
the	O
twenty	O
as	O
gene	O
mutations	O
,	O
13	O
were	O
in	O
Ki-ras	O
(	O
codon	O
12	O
)	O
,	O
five	O
in	O
H-ras	O
codon	O
61	O
and	O
two	O
H-ras	O
codon	O
13	O
.	O
The	O
observed	O
frequency	O
of	O
ras	O
gene	O
mutations	O
was	O
higher	O
than	O
that	O
reported	O
in	O
the	O
literature	O
for	O
some	O
non	O
-	O
Japanese	O
prostate	B-malignancy-type
cancers	I-malignancy-type
,	O
suggesting	O
the	O
possibility	O
of	O
genetic	O
differences	O
between	O
populations	O
.	O
PMID	O
:	O
9713462	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Jun	O
15;58(	O
12	O
)	O
:2524	O
-	O
7	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
in	O
primary	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
by	O
somatic	O
alterations	O
involving	O
exon	O
3	O
.	O
Miyoshi	O
Y	O
,	O
Iwao	O
K	O
,	O
Nagasawa	O
Y	O
,	O
Aihara	O
T	O
,	O
Sasaki	O
Y	O
,	O
Imaoka	O
S,	O
Murata	O
M,	O
Shimano	O
T	O
,	O
Nakamura	O
Y.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Japan	O
.	O
We	O
screened	O
75	O
primary	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
for	O
somatic	O
mutations	O
in	O
the	O
entire	O
coding	O
region	O
of	O
the	O
beta-catenin	O
gene	O
.	O
We	O
detected	O
somatic	O
mutations	O
in	O
14	O
tumors	O
;	O
12	O
were	O
considered	O
to	O
cause	O
amino	O
acid	O
substitutions	O
and	O
2	O
were	O
interstitial	O
deletions	O
of	O
51	O
or	O
195	O
nucleotides	O
of	O
genomic	O
DNA	O
,	O
corresponding	O
to	O
exon	O
3	O
.	O
Among	O
the	O
12	O
point	O
mutations	O
,	O
6	O
occurred	O
at	O
potential	O
serine	O
/	O
threonine	O
phosphorylation	O
residues	O
of	O
codons	O
33	O
,	O
41	O
,	O
or	O
45	O
.	O
The	O
remaining	O
six	O
tumors	O
contained	O
a	O
mutation	O
at	O
codon	O
32	O
(	O
aspartic	O
acid	O
)	O
or	O
34	O
(	O
glycine	O
)	O
,	O
flanking	O
to	O
the	O
serine	O
residue	O
at	O
codon	O
33	O
.	O
By	O
Western	O
blot	O
analysis	O
,	O
we	O
confirmed	O
accumulation	O
of	O
beta-catenin	O
in	O
five	O
tumors	O
for	O
which	O
frozen	O
tissues	O
were	O
available	O
;	O
the	O
five	O
included	O
tumors	O
in	O
which	O
amino	O
acid	O
alterations	O
had	O
occurred	O
at	O
codons	O
32	O
,	O
34	O
,	O
or	O
45	O
,	O
and	O
one	O
with	O
a	O
17	O
-	O
amino	O
acid	O
deletion	O
.	O
Our	O
results	O
suggested	O
that	O
accumulation	O
of	O
beta-catenin	O
due	O
to	O
amino	O
acid	O
substitutions	O
at	O
potential	O
serine	O
/	O
threonine	O
phosphorylation	O
residues	O
or	O
at	O
their	O
neighboring	O
codons	O
or	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
could	O
contribute	O
to	O
hepatocellular	O
carcinogenesis	O
.	O
PMID	O
:	O
9635572	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Apr	O
1;58(	O
7)	O
:1344	O
-	O
7	O
Mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Palacios	O
J,	O
Gamallo	O
C.	O
Departamento	O
de	O
Anatomia	O
Patologica	O
,	O
Hospital	O
Universitario	O
La	O
Paz	O
(	O
Universidad	O
Autonoma	O
de	O
Madrid	O
)	O
,	O
Spain	O
.	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
have	O
recently	O
been	O
implicated	O
in	O
the	O
initiation	O
of	O
some	O
colon	B-malignancy-type
carcinomas	I-malignancy-type
and	O
melanomas	B-malignancy-type
.	O
In	O
these	O
tumors	O
,	O
beta-catenin	O
abnormally	O
accumulates	O
in	O
the	O
cell	O
nuclei	O
.	O
In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
the	O
cadherin	O
-	O
catenin	O
complex	O
protein	O
expression	O
in	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
we	O
observed	O
beta-catenin	O
in	O
tumor	O
cell	O
nuclei	O
in	O
some	O
cases	O
;	O
this	O
prompted	O
us	O
to	O
study	O
whether	O
or	O
not	O
this	O
abnormal	O
immunostaining	O
pattern	O
was	O
due	O
to	O
mutation	O
in	O
the	O
beta-catenin	O
gene	O
itself	O
.	O
This	O
study	O
examines	O
beta-catenin	O
immunohistochemical	O
expression	O
in	O
40	O
stage	O
I	O
and	O
II	O
ovarian	B-malignancy-type
borderline	I-malignancy-type
tumors	I-malignancy-type
and	O
carcinomas	B-malignancy-type
of	O
the	O
most	O
common	O
histological	O
types	O
.	O
Membrane	O
expression	O
was	O
heterogeneous	O
in	O
all	O
40	O
cases	O
.	O
However	O
,	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
five	O
(	O
one	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
four	O
carcinomas	B-malignancy-type
)	O
of	O
the	O
six	O
endometrioid	B-malignancy-type
lesions	I-malignancy-type
contained	O
beta-catenin	O
expression	O
.	O
PCR	O
and	O
sequencing	O
analyses	O
of	O
a	O
200	O
-	O
bp	O
fragment	O
of	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
,	O
encompassing	O
the	O
sequence	O
for	O
glycogen	O
synthetase	O
kinase	O
-	O
3beta	O
phosphorylation	O
,	O
were	O
performed	O
in	O
11	O
tumors	O
.	O
Heterozygous	O
substitution	O
mutations	O
at	O
codon	O
37	O
in	O
two	O
cases	O
(	O
S	O
37	O
F	O
and	O
S	O
37	O
C	O
)	O
and	O
at	O
codon	O
41	O
in	O
one	O
case	O
(	O
T	O
41	O
A	O
)	O
were	O
found	O
in	O
three	O
endometrioid	B-malignancy-type
lesions	I-malignancy-type
(	O
one	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
two	O
carcinomas	B-malignancy-type
)	O
with	O
abnormal	O
beta-catenin	O
expression	O
.	O
Three	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
and	O
five	O
tumors	O
of	O
other	O
histological	O
types	O
analyzed	O
showed	O
normal	O
DNA	O
sequences	O
.	O
These	O
results	O
implicate	O
beta-catenin	O
gene	O
mutations	O
in	O
ovarian	O
malignant	O
transformation	O
with	O
a	O
characteristic	O
phenotype	O
:	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9537226	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1998	O
Mar	O
;	O
21	O
(	O
3	O
)	O
:	O
270	O
-	O
5	O
RAS	O
mutations	O
in	O
pediatric	O
leukemias	B-malignancy-type
with	O
MLL	O
gene	O
rearrangements	O
.	O
Mahgoub	O
N	O
,	O
Parker	O
RI	O
,	O
Hosler	O
MR	O
,	O
Close	O
P	O
,	O
Winick	O
NJ	O
,	O
Masterson	O
M	O
,	O
Shannon	O
KM	O
,	O
Felix	O
CA	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
,	O
USA	O
.	O
Translocations	O
of	O
the	O
MLL	O
gene	O
at	O
chromosome	O
band	O
11q23	O
are	O
the	O
most	O
common	O
cytogenetic	O
alterations	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
leukemia	I-malignancy-type
in	O
infants	O
and	O
in	O
leukemia	B-malignancy-type
related	I-malignancy-type
to	I-malignancy-type
chemotherapy	I-malignancy-type
with	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
.	O
Experiments	O
on	O
knock-in	O
mice	O
suggest	O
that	O
additional	O
mutational	O
events	O
may	O
by	O
required	O
for	O
full	O
leukemogenesis	O
.	O
Therefore	O
,	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
an	O
allele	O
-	O
specific	O
restriction	O
enzyme	O
assay	O
to	O
investigate	O
the	O
frequency	O
of	O
KRAS	O
and	O
NRAS	O
mutations	O
in	O
32	O
pediatric	O
leukemias	B-malignancy-type
with	O
translocation	O
of	O
the	O
MLL	O
gene	O
.	O
Of	O
25	O
de	O
novo	O
cases	O
,	O
13	O
were	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
,	O
10	O
were	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
and	O
2	O
were	O
biphenotypic	O
.	O
Three	O
secondary	O
leukemias	B-malignancy-type
were	O
AML	B-malignancy-type
,	O
1	O
was	O
biphenotypic	O
,	O
1	O
was	O
ALL	B-malignancy-type
,	O
and	O
2	O
were	O
diagnosed	O
as	O
myelodysplasia	B-malignancy-type
.	O
The	O
frequency	O
of	O
RAS	O
mutations	O
was	O
2	O
of	O
10	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
.	O
Both	O
mutations	O
occurred	O
in	O
infant	O
monoblastic	O
variants	O
.	O
RAS	O
mutations	O
were	O
otherwise	O
absent	O
in	O
this	O
series	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
congenital	B-malignancy-type
leukemias	I-malignancy-type
where	O
translocation	O
of	O
the	O
MLL	O
gene	O
and	O
RAS	O
mutation	O
coexist	O
.	O
The	O
frequency	O
of	O
RAS	O
mutations	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
AMLs	I-malignancy-type
with	O
MLL	O
gene	O
translocations	O
is	O
similar	O
to	O
that	O
in	O
other	O
forms	O
of	O
AML	B-malignancy-type
,	O
but	O
RAS	O
mutations	O
play	O
a	O
limited	O
role	O
in	O
lymphoid	B-malignancy-type
and	O
treatment	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
leukemias	I-malignancy-type
with	O
similar	O
translocations	O
.	O
PMID	O
:	O
9523205	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Blood	O
1997	O
Nov	O
15;90(	O
10	O
)	O
:4062	O
-	O
70	O
Comment	O
in	O
:	O
Blood	O
.	O
1998	O
Oct	O
15;92(	O
8	O
)	O
:2987	O
-	O
9.	O
A	O
novel	O
chromosomal	O
translocation	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
involves	O
the	O
fibroblast	O
growth	O
-	O
factor	O
receptor	O
3	O
gene	O
.	O
Richelda	O
R,	O
Ronchetti	O
D	O
,	O
Baldini	O
L,	O
Cro	O
L,	O
Viggiano	O
L,	O
Marzella	O
R,	O
Rocchi	O
M,	O
Otsuki	O
T	O
,	O
Lombardi	O
L,	O
Maiolo	O
AT	O
,	O
Neri	O
A.	O
Laboratorio	O
di	O
Ematologia	O
Sperimentale	O
e	O
Genetica	O
Molecolare	O
,	O
Servizio	O
di	O
Ematologia	O
,	O
Universita	O
degli	O
Studi	O
di	O
Milano	O
,	O
Ospedale	O
Maggiore	O
IRCCS	O
,	O
Milano	O
,	O
Italy	O
.	O
Chromosomal	O
translocations	O
involving	O
the	O
immunoglobulin	O
heavy	O
chain	O
(	O
IGH	O
)	O
locus	O
at	O
chromosome	O
14q32	O
represent	O
a	O
common	O
mechanism	O
of	O
oncogene	O
activation	O
in	O
lymphoid	B-malignancy-type
malignancies	I-malignancy-type
.	O
In	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
,	O
the	O
most	O
consistent	O
chromosomal	O
abnormality	O
is	O
the	O
14q	O
+	O
marker	O
,	O
which	O
originates	O
in	O
one	O
third	O
of	O
cases	O
through	O
a	O
t	O
(	O
11	O
;	O
14	O
)	O
(	O
q13	O
;	O
q32	O
)	O
chromosomal	O
translocation	O
;	O
in	O
the	O
remaining	O
cases	O
,	O
the	O
identity	O
of	O
the	O
partner	O
chromosomes	O
has	O
not	O
been	O
well	O
established	O
.	O
We	O
used	O
a	O
Southern	O
blot	O
approach	O
based	O
on	O
the	O
linkage	O
analysis	O
of	O
the	O
joining	O
(	O
J	O
)	O
and	O
the	O
constant	O
(	O
C	O
)	O
mu	O
,	O
alpha	O
,	O
and	O
gamma	O
regions	O
to	O
detect	O
cases	O
bearing	O
IGH	O
switch	O
-	O
mediated	O
chromosomal	O
translocations	O
.	O
We	O
evaluated	O
DNA	O
of	O
88	O
nonkaryotyped	O
patients	O
with	O
MM	B-malignancy-type
(	O
78	O
cases	O
)	O
or	O
plasma	B-malignancy-type
cell	I-malignancy-type
leukemia	I-malignancy-type
(	O
PCL	B-malignancy-type
)	O
(	O
10	O
cases	O
)	O
and	O
found	O
the	O
presence	O
of	O
"	O
illegitimate	O
"	O
rearranged	O
IGH	O
fragments	O
(	O
no	O
comigration	O
between	O
the	O
J	O
and	O
C	O
regions	O
)	O
in	O
21	O
cases	O
.	O
To	O
confirm	O
this	O
analysis	O
,	O
we	O
cloned	O
the	O
illegitimate	O
rearranged	O
fragments	O
from	O
three	O
samples	O
,	O
and	O
the	O
molecular	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analyses	O
indicated	O
the	O
presence	O
of	O
chromosomal	O
translocations	O
juxtaposing	O
a	O
switch	O
IGH	O
region	O
to	O
sequences	O
from	O
chromosomes	O
11q13	O
(	O
one	O
PCL	B-malignancy-type
case	O
)	O
or	O
4p16.3	O
(	O
two	O
MM	B-malignancy-type
cases	O
)	O
.	O
Interestingly	O
,	O
the	O
breakpoints	O
on	O
4p16.3	O
occurred	O
about	O
14	O
kb	O
apart	O
in	O
a	O
genomic	O
region	O
located	O
approximately	O
50	O
kb	O
centromeric	O
to	O
the	O
fibroblast	O
growth	O
-	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
gene	O
.	O
Moreover	O
,	O
Southern	O
blot	O
analysis	O
using	O
4p16.3	O
genomic	O
probes	O
detected	O
a	O
rearrangement	O
in	O
an	O
additional	O
MM	B-malignancy-type
tumor	O
.	O
FISH	O
analysis	O
of	O
the	O
MM	B-malignancy-type
-	O
derived	O
KMS-11	O
cell	O
line	O
,	O
reported	O
to	O
be	O
associated	O
with	O
a	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
,	O
showed	O
that	O
the	O
FGFR3	O
gene	O
was	O
translocated	O
on	O
14q32	O
.	O
High	O
levels	O
of	O
FGFR3	O
mRNA	O
expression	O
were	O
observed	O
in	O
the	O
cloned	O
MM	B-malignancy-type
tumors	I-malignancy-type
and	O
KMS-11	O
cell	O
line	O
,	O
but	O
not	O
in	O
the	O
cases	O
that	O
were	O
apparently	O
negative	O
for	O
this	O
lesion	B-malignancy-type
.	O
Furthermore	O
,	O
a	O
point	O
mutation	O
at	O
codon	O
373	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
FGFR3	O
gene	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
(	O
Tyr	O
-->	O
Cys	O
)	O
was	O
detected	O
in	O
the	O
KMS-11	O
cell	O
line	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
represents	O
a	O
novel	O
,	O
recurrent	O
chromosomal	O
translocation	O
in	O
MM	B-malignancy-type
,	O
and	O
suggest	O
that	O
the	O
FGFR3	O
gene	O
may	O
be	O
the	O
target	O
of	O
this	O
abnormality	O
and	O
thus	O
contribute	O
to	O
tumorigenesis	O
in	O
MM	B-malignancy-type
.	O
PMID	O
:	O
9354676	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1997	O
May	O
;	O
33	O
(	O
6	O
)	O
:	O
942	O
-	O
9	O
Response	O
to	O
radiotherapy	O
of	O
human	O
uterine	B-malignancy-type
cervix	I-malignancy-type
carcinoma	I-malignancy-type
is	O
not	O
correlated	O
with	O
rearrangements	O
of	O
the	O
Ha-ras-1	O
and/or	O
c-myc	O
genes	O
.	O
Polischouk	O
AG	O
,	O
Scotnikova	O
OI	O
,	O
Sergeeva	O
NS	O
,	O
Zharinov	O
GM	O
,	O
Lewensohn	O
R	O
,	O
Zhivotovsky	O
B	O
.	O
Department	O
of	O
Oncology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
An	O
association	O
between	O
the	O
presence	O
of	O
the	O
activated	O
form	O
of	O
Ha-ras-1	O
and	O
c-myc	O
genes	O
and	O
increased	O
cellular	O
radioresistance	O
has	O
been	O
shown	O
in	O
several	O
cell	O
lines	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
such	O
an	O
association	O
could	O
be	O
observed	O
in	O
clinical	O
tumour	O
biopsies	O
.	O
We	O
examined	O
70	O
tumour	O
specimens	O
and	O
51	O
samples	O
of	O
peripheral	O
blood	O
obtained	O
from	O
untreated	O
patients	O
with	O
carcinoma	B-malignancy-type
of	O
the	O
uterine	O
cervix	O
mainly	O
stage	O
II	O
and	O
III	O
.	O
In	O
addition	O
to	O
initial	O
clinical	O
tumour	O
response	O
to	O
radiotherapy	O
,	O
radiosensitivity	O
was	O
also	O
analysed	O
by	O
the	O
subrenal	O
capsule	O
assay	O
(	O
SRCA	O
)	O
.	O
Mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
Ha-ras-1	O
gene	O
were	O
examined	O
using	O
PCR	O
single-strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
;	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
of	O
the	O
Ha-ras-1	O
gene	O
was	O
analysed	O
using	O
Southern	O
hybridisation	O
.	O
Eight	O
(	O
11	O
%	O
)	O
out	O
of	O
70	O
tumours	O
contained	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
Ha-ras-1	O
gene	O
.	O
Eleven	O
(	O
22	O
%	O
)	O
out	O
of	O
the	O
51	O
tumours	O
displayed	O
rearrangements	O
of	O
the	O
Ha-ras-1	O
gene	O
(	O
six	O
tumours	O
(	O
12	O
%	O
)	O
showed	O
alterations	O
of	O
allele	O
length	O
,	O
one	O
amplification	O
and	O
four	O
(	O
8	O
%	O
)	O
loss	O
of	O
one	O
Ha-ras-1	O
allele	O
)	O
.	O
In	O
addition	O
,	O
12	O
(	O
17	O
%	O
)	O
out	O
of	O
70	O
patients	O
demonstrated	O
the	O
presence	O
of	O
rare	O
alleles	O
.	O
Only	O
one	O
of	O
the	O
70	O
tumours	O
contained	O
an	O
amplified	O
c-myc	O
gene	O
.	O
There	O
was	O
no	O
significant	O
correlation	O
between	O
either	O
rearrangements	O
of	O
the	O
structure	O
of	O
the	O
Ha-ras-1	O
and/or	O
c-myc	O
genes	O
or	O
presence	O
of	O
rare	O
alleles	O
in	O
tumours	O
and	O
tumour	O
response	O
to	O
radiotherapy	O
.	O
PMID	O
:	O
9291819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gastroenterology	O
1997	O
Aug	O
;	O
113	O
(	O
2	O
)	O
:	O
593	O
-	O
8	O
Long-term	O
follow-up	O
of	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
K-ras	O
gene	O
mutation	O
detected	O
in	O
pancreatic	O
juice	O
.	O
Furuya	O
N	O
,	O
Kawa	O
S	O
,	O
Akamatsu	O
T	O
,	O
Furihata	O
K	O
.	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Japan	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Conflicting	O
reports	O
have	O
raised	O
the	O
question	O
whether	O
K-ras	O
gene	O
mutations	O
in	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
are	O
related	O
to	O
the	O
development	O
of	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
this	O
issue	O
by	O
surveying	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
K-ras	O
gene	O
mutation	O
over	O
4	O
years	O
.	O
METHODS	O
:	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
duodenal	O
juices	O
obtained	O
during	O
exocrine	O
function	O
tests	O
were	O
examined	O
by	O
enriched	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
direct	O
DNA	O
sequence	O
analysis	O
,	O
and	O
long-term	O
follow-up	O
of	O
these	O
patients	O
was	O
performed	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutation	O
was	O
found	O
in	O
20	O
of	O
54	O
patients	O
(	O
37	O
%	O
)	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
The	O
types	O
of	O
mutation	O
were	O
GAT	O
in	O
7	O
,	O
GTT	O
in	O
11	O
,	O
and	O
TGT	O
in	O
2	O
patients	O
.	O
Pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
occurred	O
in	O
none	O
of	O
the	O
mutation	O
-	O
positive	O
patients	O
over	O
a	O
mean	O
follow-up	O
period	O
of	O
78	O
months	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
gene	O
mutation	O
in	O
patients	O
with	O
chronic	B-malignancy-type
pencreatitis	I-malignancy-type
did	O
not	O
seem	O
to	O
be	O
related	O
to	O
the	O
development	O
of	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
during	O
the	O
follow-up	O
period	O
,	O
and	O
analysis	O
of	O
K-ras	O
gene	O
mutation	O
seems	O
of	O
little	O
use	O
for	O
diagnosing	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
in	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
PMID	O
:	O
9247481	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Clin	O
Chem	O
1997	O
Jun	O
;	O
43	O
(	O
6	O
Pt	O
1	O
)	O
:	O
936	O
-	O
42	O
Rapid	O
and	O
large-scale	O
method	O
to	O
detect	O
K-ras	O
gene	O
mutations	O
in	O
tumor	O
samples	O
.	O
Lopez	O
-	O
Crapez	O
E	O
,	O
Chypre	O
C	O
,	O
Saavedra	O
J	O
,	O
Marchand	O
J	O
,	O
Grenier	O
J	O
.	O
C.R.L.C.	O
Val	O
d'Aurelle	O
,	O
Laboratoire	O
de	O
Radioanalyse	O
,	O
Montpellier	O
,	O
France	O
.	O
We	O
have	O
developed	O
a	O
rapid	O
and	O
large-scale	O
method	O
for	O
the	O
detection	O
of	O
K-ras	O
gene	O
mutations	O
in	O
tumors	O
.	O
First	O
,	O
DNA	O
is	O
amplified	O
by	O
an	O
asymmetric	O
PCR	O
;	O
second	O
,	O
the	O
single-strand	O
dinitrophenyl	O
(	O
DNP	O
)	O
-	O
labeled	O
amplified	O
DNA	O
is	O
hybridized	O
specifically	O
to	O
oligonucleotide	O
probes	O
affixed	O
on	O
a	O
tube	O
.	O
Finally	O
,	O
perfectly	O
matched	O
duplexes	O
are	O
easily	O
detected	O
by	O
a	O
monoclonal	O
anti	O
-	O
DNP	O
antibody	O
bearing	O
125I	O
.	O
The	O
usefulness	O
of	O
this	O
technique	O
is	O
illustrated	O
by	O
analyzing	O
K-ras	O
codon	O
12	O
mutations	O
in	O
human	O
colorectal	O
samples	O
.	O
This	O
reliable	O
assay	O
procedure	O
can	O
be	O
applied	O
to	O
the	O
rapid	O
screening	O
of	O
virtually	O
any	O
genetic	O
disease	O
caused	O
by	O
previously	O
described	O
point	O
mutations	O
.	O
PMID	O
:	O
9191543	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gynecol	O
Oncol	O
1997	O
May;65(	O
2	O
)	O
:343	O
-	O
7	O
Identification	O
of	O
H	O
,	O
K	O
,	O
and	O
N	O
-	O
ras	O
point	O
mutations	O
in	O
stage	O
IB	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Grendys	O
EC	O
Jr	O
,	O
Barnes	O
WA	O
,	O
Weitzel	O
J,	O
Sparkowski	O
J,	O
Schlegel	O
R.	O
Division	O
of	O
Gynecologic	O
Oncology	O
,	O
Moffitt	O
Cancer	O
Center	O
,	O
University	O
of	O
South	O
Florida	O
,	O
Tampa	O
33612	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
The	O
ras	O
oncogenes	O
,	O
Harvey	O
(	O
H	O
)	O
,	O
Kirsten	O
(	O
K	O
)	O
,	O
and	O
neuroblastoma	O
(	O
N	O
)	O
,	O
are	O
a	O
family	O
of	O
genes	O
coding	O
for	O
a	O
membrane	O
-	O
associated	O
protein	O
(	O
p21	O
)	O
which	O
possesses	O
inherent	O
guanine	O
triphosphatase	O
(	O
GTPase	O
)	O
activity	O
.	O
Point	O
mutagenesis	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
has	O
been	O
implicated	O
in	O
ras	O
activation	O
and	O
subsequent	O
cellular	O
transformation	O
.	O
Given	O
the	O
epidemiologic	O
relationship	O
of	O
HPV	O
infection	O
with	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
and	O
the	O
tumorigenic	O
interaction	O
of	O
HPV	O
and	O
mutated	O
ras	O
oncogenes	O
,	O
this	O
study	O
was	O
undertaken	O
to	O
identify	O
if	O
mutated	O
ras	O
oncogenes	O
were	O
present	O
in	O
early	O
invasive	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
.	O
METHODS	O
:	O
A	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
dot	O
-	O
blot	O
hybridization	O
was	O
used	O
to	O
determine	O
the	O
frequency	O
and	O
types	O
of	O
ras	O
point	O
mutants	O
occurring	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Thirty-three	O
patients	O
with	O
early	O
-	O
stage	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
were	O
identified	O
.	O
DNA	O
was	O
extracted	O
from	O
archival	O
tumor	O
samples	O
.	O
ras	O
genes	O
were	O
PCR	O
amplified	O
using	O
flanking	O
primers	O
and	O
hybridized	O
with	O
a	O
series	O
of	O
labeled	O
allele	O
-	O
specific	O
oligonucleotides	O
corresponding	O
to	O
wild	O
-	O
type	O
forms	O
of	O
K	O
12	O
,	O
61	O
,	O
N	O
12	O
,	O
13	O
,	O
61	O
,	O
and	O
H	O
12	O
,	O
61	O
,	O
as	O
well	O
as	O
to	O
all	O
combinations	O
of	O
substitution	O
mutations	O
(	O
7	O
wild	O
-	O
type	O
,	O
45	O
mutants	O
)	O
.	O
RESULTS	O
:	O
ras	O
mutations	O
were	O
identified	O
in	O
24.2	O
%	O
of	O
specimens	O
.	O
The	O
detected	O
mutations	O
in	O
H	O
,	O
K	O
,	O
and	O
N	O
-	O
ras	O
all	O
occurred	O
at	O
codon	O
61	O
.	O
This	O
was	O
not	O
the	O
result	O
of	O
PCR	O
or	O
hybridization	O
artifact	O
in	O
that	O
mutations	O
were	O
detected	O
in	O
position	O
12	O
and	O
13	O
in	O
appropriate	O
control	O
samples	O
.	O
CONCLUSIONS	O
:	O
Mutant	O
ras	O
has	O
been	O
shown	O
to	O
convert	O
HPV	O
immortalized	O
keratinocytes	O
to	O
the	O
tumorigenic	O
state	O
.	O
Our	O
results	O
indicate	O
that	O
a	O
significant	O
percentage	O
(	O
24.2	O
%	O
)	O
of	O
these	O
early	O
-	O
stage	O
cervical	B-malignancy-type
cancers	I-malignancy-type
contain	O
activated	O
ras	O
.	O
Additional	O
studies	O
will	O
be	O
needed	O
to	O
evaluate	O
whether	O
codon	O
61	O
represents	O
a	O
characteristic	O
"	O
hot	O
-	O
spot	O
"	O
of	O
ras	O
mutation	O
in	O
a	O
subset	O
of	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9159349	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1997	O
May	O
2	O
;	O
71	O
(	O
3	O
)	O
:	O
364	O
-	O
9	O
A	O
one	O
-	O
step	O
DGGE	O
scanning	O
method	O
for	O
detection	O
of	O
mutations	O
in	O
the	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
-	O
ras	O
oncogenes	O
:	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
are	O
rare	O
in	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Nedergaard	O
T	O
,	O
Guldberg	O
P	O
,	O
Ralfkiaer	O
E	O
,	O
Zeuthen	O
J	O
.	O
Department	O
of	O
Tumor	O
Cell	O
Biology	O
,	O
Danish	O
Cancer	O
Society	O
,	O
Copenhagen	O
.	O
Mutations	O
in	O
the	O
N	O
-	O
,	O
K	O
-	O
,	O
and	O
H	O
-	O
ras	O
genes	O
are	O
key	O
events	O
in	O
the	O
process	O
of	O
carcinogenesis	O
of	O
many	O
human	O
cancers	O
and	O
may	O
serve	O
as	O
important	O
targets	O
for	O
therapeutic	O
intervention	O
.	O
We	O
developed	O
a	O
simple	O
diagnostic	O
method	O
that	O
in	O
one	O
step	O
and	O
within	O
5	O
hr	O
determines	O
the	O
mutational	O
status	O
of	O
any	O
of	O
the	O
3	O
ras	O
genes	O
in	O
a	O
given	O
tumor	O
sample	O
.	O
The	O
method	O
combines	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
and	O
allows	O
simultaneous	O
mutation	O
scanning	O
of	O
6	O
regions	O
covering	O
"	O
hot	O
-	O
spot	O
"	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
3	O
ras	O
genes	O
.	O
The	O
sensitivity	O
of	O
the	O
assay	O
was	O
demonstrated	O
by	O
the	O
analysis	O
of	O
control	O
mutations	O
,	O
either	O
naturally	O
occurring	O
or	O
created	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O
We	O
further	O
demonstrate	O
that	O
unambiguous	O
identification	O
of	O
ras	O
mutations	O
can	O
be	O
achieved	O
by	O
heteroduplex	O
analysis	O
in	O
denaturing	O
gradient	O
gels	O
,	O
circumventing	O
sequence	O
analysis	O
.	O
We	O
applied	O
the	O
method	O
to	O
establish	O
the	O
mutational	O
status	O
of	O
all	O
3	O
ras	O
genes	O
in	O
123	O
samples	O
of	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Altogether	O
,	O
one	O
diffuse	B-malignancy-type
large	I-malignancy-type
B	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
and	O
one	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
chronic	I-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
B-CLL	B-malignancy-type
)	O
harbored	O
a	O
mutation	O
(	O
G	O
12	O
S	O
and	O
G	O
12	O
A	O
,	O
respectively	O
)	O
in	O
the	O
K-ras	O
gene	O
,	O
and	O
one	O
B-CLL	B-malignancy-type
harbored	O
a	O
mutation	O
(	O
Q	O
61	O
R	O
)	O
in	O
the	O
N-ras	O
gene	O
.	O
We	O
therefore	O
conclude	O
that	O
ras	O
mutations	O
only	O
contribute	O
rarely	O
,	O
if	O
at	O
all	O
,	O
to	O
carcinogenesis	O
in	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
PMID	O
:	O
9139869	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Anticancer	O
Res	O
1997	O
Mar	O
-	O
Apr	O
;	O
17	O
(	O
2B	O
)	O
:	O
1335	O
-	O
9	O
Mutation	O
of	O
ras	O
oncogene	O
in	O
gastric	B-malignancy-type
adenocarcinoma	I-malignancy-type
:	O
association	O
with	O
histological	O
phenotype	O
.	O
Kim	O
TY	O
,	O
Bang	O
YJ	O
,	O
Kim	O
WS	O
,	O
Kang	O
SH	O
,	O
Lee	O
KU	O
,	O
Choe	O
KJ	O
,	O
Kim	O
NK.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Korea	O
.	O
In	O
order	O
to	O
explore	O
the	O
role	O
of	O
ras	O
oncogene	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
from	O
Korean	O
patients	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
point	O
mutations	O
all	O
three	O
ras	O
oncogenes	O
(	O
Ki	O
-	O
,	O
Ha	O
-	O
,	O
and	O
N	O
-	O
ras	O
)	O
.	O
A	O
total	O
of	O
57	O
DNA	O
samples	O
were	O
prepared	O
from	O
3	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
10	O
malignant	B-malignancy-type
ascites	I-malignancy-type
,	O
and	O
44	O
frozen	O
gastric	B-malignancy-type
tumor	I-malignancy-type
tissues	I-malignancy-type
.	O
Exons	O
1	O
and	O
2	O
of	O
each	O
ras	O
oncogene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
analyzed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
.	O
Mutated	O
ras	O
genes	O
were	O
detected	O
in	O
6	O
out	O
of	O
57	O
samples	O
(	O
10	O
%	O
)	O
.	O
One	O
cell	O
line	O
and	O
2	O
tumors	O
showed	O
a	O
mutation	O
at	O
exon	O
1	O
of	O
Ki-ras	O
.	O
N-ras	O
mutations	O
were	O
also	O
detected	O
at	O
exon	O
1	O
of	O
3	O
tumors	O
.	O
Histologically	O
,	O
all	O
the	O
ras	O
mutation	O
cases	O
exhibited	O
a	O
diffuse	O
phenotype	O
.	O
In	O
summary	O
,	O
we	O
performed	O
a	O
comprehensive	O
analysis	O
to	O
investigate	O
the	O
mutation	O
of	O
all	O
three	O
ras	O
oncogenes	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
results	O
demonstrate	O
infrequent	O
mutations	O
of	O
Ki	O
-	O
and	O
N	O
-	O
ras	O
which	O
may	O
favor	O
the	O
development	O
of	O
diffuse	B-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
carcinomas	I-malignancy-type
,	O
implicating	O
a	O
different	O
genetic	O
pathway	O
in	O
diffuse	B-malignancy-type
and	O
intestinal	B-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9137494	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Pancreatol	O
1997	O
Feb	O
;	O
21	O
(	O
1	O
)	O
:	O
85	O
-	O
90	O
Sclerosing	B-malignancy-type
pancreatitis	I-malignancy-type
showing	O
rapidly	O
progressive	O
changes	O
with	O
recurrent	O
mass	O
formation	O
.	O
Motoo	O
Y	O
,	O
Minamoto	O
T	O
,	O
Watanabe	O
H	O
,	O
Sakai	O
J	O
,	O
Okai	O
T	O
,	O
Sawabu	O
N	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
CONCLUSION	O
:	O
Sclerosing	B-malignancy-type
pancreatitis	I-malignancy-type
might	O
develop	O
repeatedly	O
or	O
might	O
rapidly	O
extend	O
to	O
the	O
whole	O
pancreas	O
with	O
recurrent	O
mass	O
formation	O
.	O
BACKGROUND	O
:	O
Nothing	O
is	O
known	O
concerning	O
course	O
or	O
development	O
of	O
sclerosing	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
METHODS	O
:	O
A	O
63	O
-	O
yr	O
-	O
old	O
male	O
was	O
followed	O
up	O
for	O
2.5	O
yr	O
.	O
RESULTS	O
:	O
The	O
patient	O
was	O
admitted	O
because	O
of	O
a	O
tumor	O
in	O
the	O
body	O
and	O
tail	O
of	O
the	O
pancreas	O
.	O
Serum	O
pancreatic	O
enzymes	O
were	O
transiently	O
elevated	O
,	O
but	O
tumor	O
markers	O
were	O
all	O
negative	O
.	O
Imaging	O
studies	O
showed	O
a	O
tumor	O
7	O
cm	O
in	O
size	O
.	O
The	O
main	O
pancreatic	O
duct	O
was	O
normal	O
in	O
the	O
head	O
and	O
obstructed	O
at	O
the	O
body	O
on	O
endoscopic	O
retrograde	O
pancreatography	O
(	O
ERCP	O
)	O
.	O
The	O
K-ras	O
oncogene	O
mutation	O
was	O
positive	O
in	O
pure	O
pancreatic	O
juice	O
.	O
Distal	O
pancreatectomy	O
was	O
performed	O
because	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
was	O
highly	O
suspected	O
.	O
Pathological	O
findings	O
showed	O
that	O
the	O
tumor	O
was	O
a	O
densely	O
fibrotic	O
mass	O
without	O
malignant	O
cells	O
.	O
Inflammatory	O
cell	O
infiltration	O
was	O
observed	O
in	O
the	O
stroma	O
.	O
One	O
year	O
later	O
,	O
another	O
mass	O
3	O
cm	O
in	O
size	O
was	O
noted	O
in	O
the	O
remnant	O
pancreatic	O
head	O
.	O
ERCP	O
revealed	O
diffuse	O
irregular	O
narrowing	O
of	O
the	O
main	O
pancreatic	O
duct	O
,	O
its	O
branches	O
,	O
and	O
the	O
common	O
bile	O
duct	O
.	O
Liver	O
dysfunction	O
improved	O
and	O
an	O
elevation	O
of	O
serum	O
pancreatic	O
enzymes	O
subsided	O
without	O
any	O
specific	O
treatment	O
,	O
and	O
the	O
mass	O
diminished	O
in	O
size	O
.	O
The	O
patterns	O
of	O
various	O
imaging	O
studies	O
on	O
the	O
second	O
tumor	O
were	O
the	O
same	O
as	O
those	O
of	O
the	O
previous	O
resected	O
mass	O
.	O
Corticosteroid	O
was	O
not	O
administered	O
.	O
PMID	O
:	O
9127178	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Haematol	O
1997	O
Feb	O
;	O
96	O
(	O
2	O
)	O
:	O
374	O
-	O
6	O
A	O
new	O
c-kit	O
mutation	O
in	O
a	O
case	O
of	O
aggressive	B-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
.	O
Pignon	O
JM	O
,	O
Giraudier	O
S	O
,	O
Duquesnoy	O
P	O
,	O
Jouault	O
H	O
,	O
Imbert	O
M	O
,	O
Vainchenker	O
W	O
,	O
Vernant	O
JP	O
,	O
Tulliez	O
M	O
.	O
Service	O
d'Hematologie	O
Biologique	O
,	O
Hopital	O
Henri	O
Mondor	O
,	O
Creteil	O
,	O
France	O
.	O
Systemic	B-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
(	O
SMCD	B-malignancy-type
)	O
is	O
a	O
disorder	O
characterized	O
by	O
a	O
mast	O
cell	O
proliferation	O
in	O
various	O
tissues	O
.	O
Mast	O
cells	O
express	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
.	O
A	O
few	O
cases	O
of	O
c-kit	O
mutations	O
have	O
been	O
described	O
in	O
SMCD	B-malignancy-type
.	O
We	O
report	O
an	O
aggressive	B-malignancy-type
SMCD	I-malignancy-type
in	O
a	O
patient	O
who	O
presented	O
with	O
a	O
bone	O
marrow	O
infiltration	O
by	O
abnormal	O
mast	O
cells	O
.	O
Molecular	O
studies	O
of	O
mast	O
cell	O
DNA	O
and	O
RNA	O
revealed	O
a	O
new	O
c-kit	O
heterozygous	O
mutation	O
(	O
Asp	O
820	O
Gly	O
)	O
.	O
This	O
mutation	O
leads	O
to	O
a	O
drastic	O
amino	O
-	O
acid	O
change	O
and	O
is	O
located	O
close	O
to	O
the	O
highly	O
oncogenic	O
Asp	O
816	O
Val	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
Asp	O
820	O
Gly	O
has	O
a	O
potential	O
role	O
in	O
c-kit	O
activation	O
.	O
PMID	O
:	O
9029028	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Scand	O
J	O
Gastroenterol	O
1997	O
Jan;32(	O
1	O
)	O
:62	O
-	O
9	O
K-ras	O
mutations	O
and	O
prognosis	O
in	O
large	B-malignancy-type
-	I-malignancy-type
bowel	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Andersen	O
SN	O
,	O
Lovig	O
T	O
,	O
Breivik	O
J,	O
Lund	O
E	O
,	O
Gaudernack	O
G	O
,	O
Meling	O
GI	O
,	O
Rognum	O
TO	O
.	O
Institute	O
of	O
Forensic	O
Medicine	O
,	O
National	O
Hospital	O
,	O
University	O
of	O
Oslo	O
,	O
Norway	O
.	O
BACKGROUND	O
:	O
Colorectal	O
carcinogenesis	O
is	O
regarded	O
as	O
a	O
multistep	O
process	O
involving	O
several	O
genetic	O
alterations	O
,	O
with	O
mutation	O
in	O
the	O
K-ras	O
gene	O
in	O
about	O
half	O
of	O
the	O
tumours	O
.	O
We	O
aimed	O
at	O
clarifying	O
the	O
role	O
of	O
this	O
genetic	O
alteration	O
related	O
to	O
survival	O
and	O
clinicopathologic	O
variables	O
.	O
METHODS	O
:	O
One	O
hundred	O
large	B-malignancy-type
-	I-malignancy-type
bowel	I-malignancy-type
carcinomas	I-malignancy-type
operated	O
on	O
between	O
1978	O
and	O
1982	O
were	O
studied	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
gene	O
,	O
using	O
enriched	O
polymerase	O
chain	O
reaction	O
amplification	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
Forty	O
mutations	O
were	O
found	O
(	O
40	O
%	O
)	O
:	O
31	O
in	O
codon	O
12	O
and	O
9	O
in	O
codon	O
13	O
,	O
7	O
different	O
types	O
.	O
There	O
was	O
no	O
relationship	O
between	O
tumours	O
with	O
and	O
without	O
K-ras	O
mutations	O
with	O
regard	O
to	O
Dukes	O
'	O
stages	O
,	O
age	O
or	O
sex	O
of	O
the	O
patient	O
,	O
tumour	O
localization	O
,	O
histologic	O
grade	O
,	O
DNA	O
ploidy	O
pattern	O
,	O
HLA-DR	O
staining	O
pattern	O
,	O
or	O
survival	O
.	O
Samples	O
from	O
5	O
different	O
localizations	O
in	O
7	O
carcinomas	B-malignancy-type
showed	O
identical	O
K-ras	O
mutation	O
pattern	O
,	O
as	O
did	O
19	O
recurrences	O
/	O
metastases	O
originating	O
from	O
11	O
carcinomas	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
When	O
present	O
,	O
the	O
primary	O
tumour	O
shows	O
homogeneous	O
distribution	O
of	O
K-ras	O
mutation	O
,	O
and	O
the	O
mutation	O
follows	O
the	O
carcinoma	B-malignancy-type
in	O
the	O
secondary	O
deposit	O
,	O
regardless	O
of	O
lymphogenous	O
or	O
hematogenous	O
spread	O
.	O
The	O
presence	O
of	O
K-ras	O
mutation	O
does	O
not	O
seem	O
to	O
have	O
prognostic	O
significance	O
for	O
the	O
patient	O
,	O
and	O
the	O
precise	O
nucleotide	O
change	O
is	O
furthermore	O
not	O
predictive	O
of	O
tumour	O
behaviour	O
.	O
PMID	O
:	O
9018769	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surgery	O
1997	O
Jan;121(	O
1	O
)	O
:42	O
-	O
9	O
Analysis	O
of	O
K-ras	O
oncogene	O
mutations	O
in	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
with	I-malignancy-type
ductal	I-malignancy-type
hyperplasia	I-malignancy-type
.	O
Rivera	O
JA	O
,	O
Rall	O
CJ	O
,	O
Graeme	O
-	O
Cook	O
F	O
,	O
Fernandez	O
-	O
del	O
Castillo	O
C	O
,	O
Shu	O
P	O
,	O
Lakey	O
N	O
,	O
Tepper	O
R,	O
Rattner	O
DW	O
,	O
Warshaw	O
AL	O
,	O
Rustgi	O
AK.	O
Department	O
of	O
Surgery	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Boston	O
02114	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
K-ras	O
oncogene	O
mutations	O
have	O
been	O
identified	O
in	O
up	O
to	O
95	O
%	O
of	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
implying	O
their	O
critical	O
role	O
in	O
their	O
molecular	O
pathogenesis	O
.	O
However	O
,	O
the	O
earliest	O
stage	O
in	O
which	O
K-ras	O
mutations	O
can	O
be	O
detected	O
in	O
potential	O
precursor	B-malignancy-type
lesions	I-malignancy-type
of	I-malignancy-type
pancreatic	I-malignancy-type
cancer	I-malignancy-type
remains	O
unclear	O
.	O
This	O
study	O
evaluates	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
hyperplasia	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
setting	I-malignancy-type
of	I-malignancy-type
chronic	I-malignancy-type
pancreatitis	I-malignancy-type
,	O
which	O
predisposes	O
to	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
development	O
,	O
for	O
K-ras	O
codon	O
12	O
and	O
13	O
mutations	O
.	O
METHODS	O
:	O
Paraffin	O
-	O
embedded	O
surgical	O
specimens	O
from	O
42	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
were	O
examined	O
microscopically	O
for	O
the	O
presence	O
of	O
ductal	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
Both	O
hyperplastic	B-malignancy-type
and	O
nonhyperplastic	O
ducts	O
were	O
microdissected	O
from	O
the	O
specimens	O
that	O
contained	O
hyperplasia	B-malignancy-type
(	O
11	O
of	O
42	O
)	O
.	O
Four	O
of	O
the	O
remaining	O
specimens	O
without	O
hyperplasia	B-malignancy-type
served	O
as	O
controls	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
,	O
and	O
polymerase	O
chain	O
reaction	O
and	O
amplification	O
of	O
the	O
K-ras	O
oncogene	O
was	O
performed	O
.	O
Polymerase	O
chain	O
reaction	O
products	O
were	O
evaluated	O
by	O
means	O
of	O
hybridization	O
to	O
mutant	O
specific	O
oligonucleotide	O
probes	O
and	O
by	O
means	O
of	O
automated	O
DNA	O
sequencing	O
.	O
RESULTS	O
:	O
K-ras	O
codon	O
12	O
mutations	O
representing	O
glycine	O
to	O
valine	O
substitutions	O
were	O
present	O
in	O
2	O
of	O
(	O
18	O
%	O
)	O
11	O
patients	O
with	O
ductal	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
No	O
mutations	O
were	O
found	O
in	O
the	O
controls	O
without	O
ductal	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Our	O
study	O
supports	O
the	O
premise	O
that	O
K-ras	O
mutations	O
develop	O
in	O
a	O
subset	O
of	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
associated	I-malignancy-type
hyperplasia	I-malignancy-type
and	O
provides	O
a	O
genetic	O
basis	O
for	O
the	O
potential	O
progression	O
of	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
to	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9001550	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Formos	O
Med	O
Assoc	O
1996	O
Oct;95(	O
10	O
)	O
:741	O
-	O
5	O
Detection	O
of	O
k-ras	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Hsu	O
NY	O
,	O
Chen	O
CY	O
,	O
Wu	O
CH	O
,	O
Liu	O
TJ	O
,	O
Kwan	O
PC	O
,	O
Hsu	O
CP	O
,	O
Hsia	O
JY	O
,	O
Chang	O
WT.	O
Department	O
of	O
Medical	O
Research	O
,	O
Taichung	O
veterans	O
General	O
Hospital	O
,	O
Taiwan	O
,	O
ROC.	O
Point	O
mutations	O
of	O
the	O
K-ras	O
gene	O
have	O
been	O
reported	O
in	O
a	O
wide	O
variety	O
of	O
human	O
tumors	O
.	O
By	O
using	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
,	O
we	O
screened	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
gene	O
in	O
specimens	O
obtained	O
from	O
fresh	O
frozen	O
tumors	O
in	O
38	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Point	O
mutations	O
were	O
detected	O
in	O
two	O
of	O
38	O
(	O
5.3	O
%	O
)	O
resected	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Both	O
of	O
them	O
were	O
G	O
to	O
T	O
transversions	O
.	O
One	O
patient	O
was	O
found	O
to	O
have	O
a	O
K-ras	O
codon	O
13	O
point	O
mutation	O
(	O
GGC	O
to	O
TGC	O
,	O
gly	O
to	O
cys	O
)	O
,	O
while	O
the	O
other	O
had	O
a	O
codon	O
12	O
point	O
mutation	O
(	O
GGT	O
to	O
GTT	O
,	O
gly	O
to	O
val	O
)	O
.	O
Based	O
on	O
the	O
limited	O
numbers	O
in	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
frequency	O
of	O
K-ras	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
among	O
Asian	O
patients	O
with	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
was	O
lower	O
than	O
that	O
detected	O
among	O
Caucasian	O
patients	O
.	O
PMID	O
:	O
8961670	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1996	O
Aug	O
15	O
;13(	O
4)	O
:687	O
-	O
93	O
Prevalence	O
of	O
mutations	O
of	O
ras	O
and	O
p53	O
in	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
from	O
children	O
exposed	O
to	O
radiation	O
after	O
the	O
Chernobyl	O
nuclear	O
accident	O
.	O
Nikiforov	O
YE	O
,	O
Nikiforova	O
MN	O
,	O
Gnepp	O
DR	O
,	O
Fagin	O
JA.	O
Division	O
of	O
Endocrinology	O
,	O
Cedars	O
-	O
Sinai	O
Medical	O
Center	O
,	O
Los	O
Angeles	O
,	O
California	O
,	O
USA	O
.	O
Starting	O
4	O
years	O
after	O
the	O
Chernobyl	O
accident	O
,	O
a	O
dramatic	O
increase	O
in	O
incidence	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
was	O
noticed	O
in	O
children	O
from	O
contaminated	O
areas	O
.	O
The	O
incidence	O
of	O
benign	B-malignancy-type
thyroid	I-malignancy-type
lesions	I-malignancy-type
in	O
the	O
exposed	O
population	O
was	O
also	O
increased	O
.	O
To	O
study	O
the	O
possible	O
role	O
of	O
ras	O
and	O
p53	O
genes	O
in	O
radiation	O
-	O
induced	O
thyroid	O
tumorigenesis	O
,	O
33	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
and	O
22	O
benign	B-malignancy-type
lesions	I-malignancy-type
removed	O
from	O
children	O
aged	O
5	O
-	O
19	O
were	O
screened	O
for	O
point	O
mutations	O
of	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
,	O
as	O
well	O
as	O
of	O
p53	O
(	O
exons	O
5	O
-	O
8	O
)	O
using	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
.	O
Ras	O
point	O
mutations	O
were	O
detected	O
in	O
1	O
/	O
1	O
case	O
of	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
N-ras	O
codon	O
61	O
CAA	O
gln	O
-->	O
AAA	O
lys	O
)	O
,	O
and	O
in	O
3	O
/	O
7	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
N-ras	O
codon	O
61	O
CAA	O
gln	O
-->	O
CGA	O
arg	O
x	O
2	O
,	O
CAA	O
gln	O
-->	O
AAA	O
lys	O
)	O
.	O
None	O
of	O
the	O
cases	O
of	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
was	O
positive	O
for	O
ras	O
oncogene	O
abnormalities	O
.	O
The	O
lack	O
of	O
K-ras	O
mutations	O
was	O
confirmed	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
(	O
ASOH	O
)	O
,	O
and	O
by	O
sequencing	O
in	O
five	O
cases	O
.	O
Somatic	O
point	O
mutations	O
in	O
p53	O
were	O
found	O
by	O
SSCP	O
in	O
2	O
/	O
33	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
,	O
with	O
one	O
missense	O
mutation	O
(	O
exon	O
5	O
,	O
codon	O
160	O
ATG	O
met	O
-->	O
GTG	O
val	O
)	O
and	O
another	O
silent	O
mutation	O
(	O
codon	O
182	O
,	O
TGC	O
cys	O
-->	O
TGT	O
cys	O
)	O
.	O
Immunohisto-chemically	O
,	O
focally	O
positive	O
p53	O
staining	O
was	O
found	O
in	O
four	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
being	O
primarily	O
confined	O
to	O
solid	O
and	O
poorly	O
-	O
differentiated	O
areas	O
in	O
tumors	O
.	O
These	O
data	O
demonstrate	O
that	O
as	O
opposed	O
to	O
the	O
few	O
reports	O
on	O
tumors	O
arising	O
after	O
therapeutic	O
external	O
irradiation	O
,	O
ras	O
mutations	O
are	O
not	O
primary	O
events	O
in	O
the	O
development	O
of	O
post	O
-	O
Chernobyl	O
thyroid	B-malignancy-type
papillary	I-malignancy-type
carcinomas	I-malignancy-type
.	O
p53	O
mutations	O
do	O
not	O
appear	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
these	O
tumors	O
,	O
but	O
may	O
in	O
some	O
cases	O
have	O
a	O
role	O
in	O
progression	O
to	O
a	O
more	O
aggressive	O
phenotype	O
that	O
has	O
not	O
yet	O
fully	O
manifested	O
in	O
these	O
pediatric	O
neoplasms	B-malignancy-type
.	O
PMID	O
:	O
8761289	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1996	O
May	O
;10(	O
5	O
)	O
:844	O
-	O
7	O
Mutation	O
of	O
the	O
ras	O
genes	O
is	O
a	O
rare	O
genetic	O
event	O
in	O
the	O
histologic	O
transformation	O
of	O
follicular	B-malignancy-type
lymphoma	I-malignancy-type
.	O
Clark	O
HM	O
,	O
Yano	O
T	O
,	O
Sander	O
C	O
,	O
Jaffe	O
ES	O
,	O
Raffeld	O
M.	O
Hematopathology	O
Section	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
The	O
role	O
of	O
ras	O
gene	O
mutations	O
in	O
the	O
progression	O
of	O
follicular	B-malignancy-type
lymphoma	I-malignancy-type
has	O
been	O
ascertained	O
by	O
SSCP	O
-	O
PCR	O
and	O
sequencing	O
.	O
A	O
total	O
of	O
40	O
transformed	B-malignancy-type
lymphomas	I-malignancy-type
were	O
studied	O
,	O
16	O
of	O
which	O
had	O
a	O
matched	O
preceding	O
low	O
-	O
grade	O
biopsy	O
.	O
Only	O
one	O
transformed	B-malignancy-type
lymphoma	I-malignancy-type
was	O
found	O
to	O
have	O
a	O
missense	O
mutation	O
at	O
codon	O
12	O
of	O
N-ras	O
,	O
resulting	O
in	O
an	O
amino	O
acid	O
change	O
of	O
glycine	O
to	O
serine	O
.	O
We	O
conclude	O
that	O
mutation	O
within	O
the	O
ras	O
gene	O
family	O
is	O
a	O
rare	O
event	O
in	O
the	O
transformation	O
of	O
follicular	B-malignancy-type
lymphoma	I-malignancy-type
.	O
PMID	O
:	O
8656681	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
1995	O
Jun;61(	O
4)	O
:205	O
-	O
13	O
Double	O
mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
a	O
patient	O
with	O
acute	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Horiike	O
S,	O
Misawa	O
S,	O
Kaneko	O
H	O
,	O
Nakai	O
H	O
,	O
Ueda	O
Y	O
,	O
Nakao	O
M,	O
Hirakawa	O
K	O
,	O
Taniwaki	O
M,	O
Kashima	O
K.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
report	O
a	O
patient	O
with	O
acute	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AMMoL	B-malignancy-type
)	O
who	O
showed	O
two	O
independent	O
point	O
mutations	O
of	O
the	O
N-ras	O
gene	O
at	O
codons	O
12	O
and	O
13	O
.	O
Longitudinal	O
analysis	O
revealed	O
that	O
one	O
mutation	O
at	O
codon	O
13	O
was	O
detectable	O
throughout	O
his	O
disease	O
course	O
and	O
the	O
other	O
at	O
codon	O
12	O
emerged	O
as	O
a	O
second	O
mutation	O
14	O
months	O
after	O
the	O
diagnosis	O
was	O
made	O
,	O
at	O
the	O
refractory	O
stage	O
.	O
Cloning	O
to	O
vector	O
and	O
subsequent	O
sequencing	O
confirmed	O
that	O
these	O
mutations	O
occurred	O
in	O
different	O
alleles	O
.	O
Chromosome	O
findings	O
showed	O
a	O
simple	O
abnormal	O
karyotype	O
at	O
presentation	O
and	O
further	O
karyotypic	O
aberrations	O
during	O
his	O
disease	O
course	O
,	O
concomitantly	O
with	O
the	O
second	O
mutation	O
of	O
the	O
N-ras	O
gene	O
.	O
These	O
findings	O
revealed	O
a	O
close	O
relationship	O
among	O
the	O
disease	O
progression	O
,	O
karyotypic	O
evolution	O
and	O
a	O
newly	O
-	O
appearing	O
N-ras	O
mutation	O
.	O
PMID	O
:	O
8547609	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1995	O
Dec	O
15	O
;86(	O
12	O
)	O
:4579	O
-	O
86	O
Monosomy	O
7	O
and	O
activating	O
RAS	O
mutations	O
accompany	O
malignant	O
transformation	O
in	O
patients	O
with	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
.	O
Kalra	O
R,	O
Dale	O
D	O
,	O
Freedman	O
M,	O
Bonilla	O
MA	O
,	O
Weinblatt	O
M,	O
Ganser	O
A	O
,	O
Bowman	O
P	O
,	O
Abish	O
S,	O
Priest	O
J,	O
Oseas	O
RS	O
,	O
et	O
al	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
-0519	O
,	O
USA	O
.	O
Individuals	O
with	O
severe	O
forms	O
of	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
suffer	O
from	O
recurrent	O
infections	O
.	O
The	O
therapeutic	O
use	O
of	O
recombinant	O
human	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
rhG-CSF	O
)	O
to	O
increase	O
the	O
neutrophil	O
count	O
is	O
associated	O
with	O
fewer	O
infections	O
and	O
an	O
improved	O
quality	O
of	O
life	O
.	O
However	O
,	O
the	O
long-term	O
effects	O
of	O
this	O
new	O
therapy	O
are	O
largely	O
unknown	O
.	O
In	O
particular	O
,	O
it	O
is	O
unclear	O
if	O
myeloid	B-malignancy-type
leukemia	I-malignancy-type
,	O
a	O
known	O
complication	O
of	O
some	O
forms	O
of	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
,	O
will	O
occur	O
with	O
increased	O
frequency	O
among	O
patients	O
who	O
receive	O
long-term	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
We	O
report	O
13	O
patients	O
with	O
congenital	B-malignancy-type
disorders	I-malignancy-type
of	I-malignancy-type
myelopoiesis	I-malignancy-type
who	O
developed	O
leukemic	O
transformation	O
with	O
either	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	I-malignancy-type
or	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
and	O
1	O
who	O
acquired	O
a	O
clonal	O
cytogenetic	O
abnormality	O
without	O
evidence	O
of	O
MDS	B-malignancy-type
or	O
AML	B-malignancy-type
while	O
receiving	O
rhG-CSF	O
.	O
The	O
bone	O
marrows	O
of	O
10	O
patients	O
showed	O
monosomy	O
7	O
and	O
5	O
had	O
activating	O
RAS	O
mutations	O
.	O
These	O
abnormalities	O
were	O
not	O
detected	O
in	O
pretreatment	O
bone	O
marrows	O
and	O
cessation	O
of	O
rhG-CSF	O
was	O
not	O
associated	O
with	O
either	O
clinical	O
improvement	O
or	O
cytogenetic	O
remission	O
.	O
We	O
conclude	O
that	O
patients	O
with	O
severe	O
forms	O
of	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
are	O
at	O
relatively	O
high	O
risk	O
of	O
developing	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
The	O
occurrence	O
of	O
monosomy	O
7	O
and	O
RAS	O
mutations	O
in	O
these	O
cases	O
suggests	O
that	O
the	O
myeloid	O
progenitors	O
of	O
some	O
patients	O
are	O
genetically	O
predisposed	O
to	O
malignant	O
transformation	O
.	O
The	O
relationship	O
between	O
therapeutic	O
rhG-CSF	O
and	O
leukemogenesis	O
in	O
patients	O
with	O
severe	B-malignancy-type
chronic	I-malignancy-type
neutropenia	I-malignancy-type
is	O
unclear	O
.	O
PMID	O
:	O
8541548	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Urol	O
Int	O
1995	O
;55(	O
2	O
)	O
:63	O
-	O
7	O
Infrequent	O
involvement	O
of	O
mutations	O
on	O
neurofibromatosis	O
type	O
1	O
,	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
in	O
urothelial	B-malignancy-type
tumors	I-malignancy-type
.	O
Uchida	O
T	O
,	O
Wada	O
C	O
,	O
Ishida	O
H	O
,	O
Egawa	O
S,	O
Ao	O
T	O
,	O
Yokoyama	O
E	O
,	O
Koshiba	O
K.	O
Department	O
of	O
Urology	O
and	O
Clinical	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
The	O
neurofibromatosis	O
type	O
1	O
(	O
NF1	O
)	O
gene	O
is	O
considered	O
a	O
tumor	O
-	O
suppressor	O
gene	O
whose	O
product	O
acts	O
upstream	O
of	O
ras	O
.	O
The	O
ras	O
gene	O
is	O
an	O
oncogene	O
very	O
commonly	O
detected	O
in	O
human	O
cancers	O
and	O
consists	O
of	O
three	O
families	O
,	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
.	O
These	O
genes	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
in	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
Examination	O
was	O
made	O
of	O
the	O
mutations	O
of	O
these	O
genes	O
in	O
39	O
urothelial	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
(	O
31	O
bladder	B-malignancy-type
cancer	I-malignancy-type
,	O
6	O
renal	B-malignancy-type
pelvic	I-malignancy-type
tumor	I-malignancy-type
,	O
and	O
2	O
ureter	O
tumors	O
)	O
using	O
polymerase	O
chain	O
reaction	O
single-stranded	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
methods	O
.	O
Three	O
of	O
39	O
(	O
7.7	O
%	O
)	O
cases	O
showed	O
mobility	O
shifts	O
in	O
the	O
ras	O
family	O
gene	O
but	O
no	O
point	O
mutations	O
in	O
NF1	O
and	O
N-ras	O
genes	O
could	O
be	O
detected	O
.	O
Mutations	O
were	O
found	O
in	O
1	O
case	O
in	O
H-ras	O
at	O
codon	O
13	O
(	O
GGT	O
-	O
GTT	O
/	O
GGT	O
)	O
and	O
K-ras	O
at	O
codon	O
12	O
in	O
2	O
cases	O
(	O
GGT	O
-	O
GCT	O
/	O
GGT	O
,	O
GGT	O
-	O
GTT	O
/	O
GGT	O
)	O
.	O
All	O
3	O
cases	O
had	O
progressed	O
far	O
beyond	O
grade	O
2	O
and	O
stage	O
pT2	O
.	O
It	O
follows	O
from	O
the	O
above	O
that	O
NF1	O
and	O
ras	O
gene	O
mutations	O
are	O
infrequent	O
in	O
the	O
pathogenesis	O
of	O
urothelial	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8533197	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1993	O
May	O
15	O
;81(	O
10	O
)	O
:2708	O
-	O
13	O
Mutational	O
activation	O
of	O
N	O
-	O
and	O
K	O
-	O
ras	O
oncogenes	O
in	O
plasma	B-malignancy-type
cell	I-malignancy-type
dyscrasias	I-malignancy-type
.	O
Corradini	O
P	O
,	O
Ladetto	O
M,	O
Voena	O
C	O
,	O
Palumbo	O
A	O
,	O
Inghirami	O
G	O
,	O
Knowles	O
DM	O
,	O
Boccadoro	O
M,	O
Pileri	O
A.	O
Department	O
of	O
Medicine	O
and	O
Experimental	O
Oncology	O
,	O
University	O
of	O
Torino	O
,	O
Italy	O
.	O
The	O
frequency	O
of	O
N	O
-	O
and	O
K	O
-	O
ras	O
oncogene	O
mutations	O
was	O
investigated	O
in	O
plasma	B-malignancy-type
cell	I-malignancy-type
dyscrasias	I-malignancy-type
.	O
Genomic	O
DNAs	O
from	O
128	O
patients	O
were	O
selected	O
for	O
this	O
study	O
:	O
30	O
monoclonal	B-malignancy-type
gammopathies	I-malignancy-type
of	O
undetermined	O
significance	O
,	O
8	O
solitary	O
plasmacytomas	O
,	O
77	O
multiple	B-malignancy-type
myelomas	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
,	O
and	O
13	O
plasma	B-malignancy-type
cell	I-malignancy-type
leukemias	I-malignancy-type
(	O
PCL	B-malignancy-type
)	O
.	O
A	O
two	O
-	O
step	O
experimental	O
approach	O
was	O
devised	O
.	O
All	O
samples	O
were	O
screened	O
for	O
mutations	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
.	O
DNA	O
fragments	O
displaying	O
an	O
altered	O
electrophoretic	O
mobility	O
were	O
further	O
studied	O
by	O
direct	O
sequencing	O
to	O
confirm	O
and	O
characterize	O
the	O
nature	O
of	O
the	O
mutations	O
.	O
Ras	O
mutations	O
are	O
not	O
randomly	O
distributed	O
because	O
they	O
are	O
detectable	O
only	O
in	O
MM	B-malignancy-type
(	O
9	O
%	O
)	O
and	O
PCL	B-malignancy-type
(	O
30.7	O
%	O
)	O
.	O
N-ras	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
and	O
K-ras	O
codon	O
12	O
were	O
found	O
to	O
be	O
mutated	O
,	O
but	O
N-ras	O
codon	O
61	O
mutation	O
was	O
the	O
most	O
frequent	O
finding	O
(	O
63.6	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
ras	O
mutations	O
were	O
found	O
in	O
PCL	B-malignancy-type
,	O
and	O
in	O
a	O
subset	O
of	O
MM	B-malignancy-type
characterized	O
by	O
advanced-stage	O
disease	O
and	O
adverse	O
prognostic	O
parameters	O
.	O
Furthermore	O
,	O
based	O
on	O
our	O
findings	O
,	O
it	O
is	O
possible	O
to	O
speculate	O
that	O
ras	O
mutations	O
represent	O
a	O
late	O
molecular	O
lesion	O
in	O
the	O
process	O
of	O
multistep	O
carcinogenesis	O
.	O
PMID	O
:	O
8490179	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1993	O
Jan;6(	O
1	O
)	O
:15	O
-	O
9	O
H-ras-1	O
gene	O
mutations	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
:	O
automated	O
direct	O
sequencing	O
of	O
clinical	O
specimens	O
.	O
Wilke	O
WW	O
,	O
Robinson	O
RA	O
,	O
Kennard	O
CD	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Medicine	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
.	O
Ras	O
oncogenes	O
are	O
activated	O
by	O
point	O
mutations	O
occurring	O
in	O
codons	O
12	O
,	O
13	O
or	O
61	O
and	O
almost	O
any	O
base	O
pair	O
mutation	O
occurring	O
within	O
the	O
first	O
two	O
positions	O
of	O
any	O
of	O
these	O
codons	O
results	O
in	O
activation	O
of	O
the	O
gene	O
.	O
Although	O
ras	O
point	O
mutations	O
have	O
been	O
reported	O
to	O
occur	O
in	O
several	O
skin	B-malignancy-type
neoplasms	I-malignancy-type
including	O
squamous	B-malignancy-type
carcinoma	I-malignancy-type
,	O
keratoacanthoma	B-malignancy-type
and	O
melanoma	B-malignancy-type
,	O
their	O
frequency	O
of	O
occurrence	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
is	O
not	O
known	O
.	O
We	O
examined	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
from	O
13	O
patients	O
for	O
activating	O
mutations	O
in	O
the	O
H-ras-1	O
gene	O
by	O
automated	O
direct	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
assay	O
amplified	O
targets	O
.	O
We	O
amplified	O
sequences	O
in	O
exon	O
1	O
that	O
flanked	O
codons	O
12	O
and	O
13	O
and	O
amplified	O
sequences	O
in	O
exon	O
2	O
that	O
flanked	O
codon	O
61	O
.	O
The	O
PCR	O
products	O
were	O
centrifuged	O
and	O
directly	O
sequenced	O
using	O
antisense	O
primers	O
in	O
an	O
automated	O
sequencer	O
using	O
fluorescent	O
dideoxyterminators	O
.	O
One	O
tumor	O
was	O
found	O
to	O
show	O
an	O
activating	O
G	O
to	O
A	O
transversion	O
in	O
codon	O
13	O
which	O
code	O
for	O
aspartic	O
acid	O
instead	O
of	O
glycine	O
.	O
Although	O
H-ras	O
mutations	O
may	O
be	O
found	O
in	O
some	O
skin	B-malignancy-type
tumors	I-malignancy-type
,	O
they	O
are	O
not	O
frequent	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
From	O
this	O
study	O
we	O
believe	O
that	O
direct	O
sequencing	O
of	O
clinical	O
material	O
is	O
of	O
value	O
and	O
has	O
advantages	O
over	O
other	O
techniques	O
.	O
Additional	O
studies	O
need	O
to	O
be	O
undertaken	O
to	O
understand	O
the	O
true	O
clinical	O
significance	O
of	O
ras	O
mutations	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
when	O
they	O
occur	O
.	O
PMID	O
:	O
8426854	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1993	O
Jul	O
30	O
;54(	O
6)	O
:978	O
-	O
82	O
Possible	O
role	O
of	O
activated	O
ras	O
genes	O
in	O
human	O
esophageal	O
carcinogenesis	O
.	O
Galiana	O
C	O
,	O
Fusco	O
A	O
,	O
Martel	O
N	O
,	O
Nishihira	O
T	O
,	O
Hirohashi	O
S,	O
Yamasaki	O
H.	O
Unit	O
of	O
Multistage	O
Carcinogenesis	O
,	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
,	O
Lyon	O
,	O
France	O
.	O
Activation	O
by	O
point	O
mutation	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
is	O
found	O
in	O
many	O
tumors	O
.	O
However	O
,	O
no	O
such	O
mutation	O
has	O
yet	O
been	O
found	O
in	O
human	O
esophageal	B-malignancy-type
carcinomas	I-malignancy-type
from	O
various	O
parts	O
of	O
the	O
world	O
.	O
We	O
have	O
confirmed	O
the	O
absence	O
of	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
K	O
-	O
and	O
N	O
-	O
ras	O
and	O
at	O
codons	O
12	O
and	O
61	O
of	O
H-ras	O
in	O
25	O
primary	O
tumors	O
obtained	O
in	O
France	O
.	O
In	O
contrast	O
,	O
among	O
7	O
human	O
esophageal	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
(	O
TE1	O
,	O
TE2	O
,	O
TE3	O
,	O
TE8	O
,	O
TE9	O
,	O
TE10	O
,	O
TE13	O
)	O
with	O
different	O
degrees	O
of	O
tumorigenicity	O
in	O
nude	O
mice	O
,	O
3	O
highly	O
tumorigenic	O
lines	O
(	O
TE1	O
,	O
TE2	O
and	O
TE8	O
)	O
exhibited	O
activation	O
of	O
ras	O
oncogenes	O
;	O
2	O
showed	O
a	O
G	O
35	O
to	O
A	O
35	O
transition	O
of	O
K-ras	O
gene	O
and	O
one	O
a	O
H-ras	O
G	O
35	O
to	O
T	O
35	O
transversion	O
.	O
Since	O
these	O
cell	O
lines	O
had	O
been	O
established	O
from	O
tumors	O
of	O
Japanese	O
patients	O
from	O
Sendai	O
,	O
we	O
examined	O
3	O
primary	O
esophageal	B-malignancy-type
tumors	I-malignancy-type
from	O
Tokyo	O
and	O
19	O
from	O
Sendai	O
,	O
including	O
the	O
primary	O
tumors	O
from	O
which	O
the	O
TE	O
cell	O
lines	O
had	O
been	O
derived	O
.	O
No	O
ras	O
mutation	O
was	O
detected	O
,	O
which	O
suggests	O
that	O
the	O
ras	O
gene	O
mutations	O
in	O
the	O
TE	O
cell	O
lines	O
are	O
either	O
due	O
to	O
their	O
long-term	O
culture	O
or	O
that	O
only	O
a	O
small	O
portion	O
of	O
the	O
original	O
tumors	O
contained	O
such	O
mutations	O
.	O
In	O
order	O
to	O
directly	O
examine	O
the	O
effect	O
of	O
ras	O
gene	O
mutation	O
,	O
one	O
of	O
the	O
non	O
-	O
tumorigenic	O
cell	O
lines	O
,	O
TE13	O
,	O
was	O
transfected	O
with	O
a	O
plasmid	O
coding	O
for	O
a	O
mutated	O
H-ras	O
gene	O
(	O
G	O
35	O
to	O
T	O
35	O
)	O
.	O
Transfected	O
clones	O
expressing	O
high	O
levels	O
of	O
mutated	O
ras	O
gene	O
were	O
able	O
to	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O
Thus	O
,	O
although	O
no	O
primary	O
human	O
esophageal	B-malignancy-type
tumor	I-malignancy-type
contained	O
mutated	O
ras	O
genes	O
,	O
our	O
studies	O
do	O
not	O
exclude	O
a	O
significant	O
role	O
of	O
mutated	O
ras	O
genes	O
in	O
cell	O
proliferation	O
and	O
malignant	O
transformation	O
of	O
human	O
esophageal	O
cells	O
.	O
PMID	O
:	O
8335405	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1994	O
Apr;78(	O
4)	O
:842	O
-	O
6	O
H-ras	O
mutations	O
in	O
human	O
pituitary	B-malignancy-type
carcinoma	I-malignancy-type
metastases	I-malignancy-type
.	O
Pei	O
L,	O
Melmed	O
S,	O
Scheithauer	O
B	O
,	O
Kovacs	O
K	O
,	O
Prager	O
D.	O
Department	O
of	O
Medicine	O
,	O
Cedars	O
-	O
Sinai	O
Medical	O
Center	O
-	O
UCLA	O
School	O
of	O
Medicine	O
90048	O
.	O
Molecular	O
mechanisms	O
of	O
pituitary	O
tumorigenesis	O
were	O
studied	O
using	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
with	O
DNA	O
sequencing	O
to	O
identify	O
potential	O
mutations	O
in	O
the	O
ras	O
protooncogenes	O
and	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
in	O
invasive	B-malignancy-type
pituitary	I-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
Sequencing	O
of	O
exons	O
5	O
through	O
8	O
of	O
the	O
p53	O
gene	O
revealed	O
no	O
mutations	O
,	O
nor	O
were	O
mutations	O
detected	O
in	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
protooncogenes	O
in	O
four	O
of	O
the	O
carcinomas	B-malignancy-type
and	O
their	O
respective	O
metastatic	O
deposits	O
.	O
Point	O
mutations	O
of	O
H-ras	O
however	O
,	O
were	O
identified	O
in	O
three	O
distant	O
metastatic	O
pituitary	O
tumor	O
secondaries	O
,	O
but	O
not	O
in	O
their	O
respective	O
primary	O
pituitary	B-malignancy-type
carcinomas	I-malignancy-type
,	O
or	O
in	O
six	O
invasive	B-malignancy-type
adenomas	I-malignancy-type
.	O
Two	O
of	O
the	O
mutations	O
included	O
a	O
G	O
to	O
C	O
substitution	O
at	O
codon	O
12	O
,	O
and	O
a	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
18	O
,	O
resulting	O
in	O
a	O
glycine	O
to	O
arginine	O
,	O
and	O
an	O
alanine	O
to	O
threonine	O
change	O
at	O
these	O
amino	O
acids	O
,	O
respectively	O
.	O
A	O
third	O
mutation	O
involved	O
a	O
single	O
base	O
pair	O
(	O
adenine	O
)	O
deletion	O
in	O
codon	O
3	O
of	O
H-ras	O
which	O
causes	O
a	O
frame	O
shift	O
,	O
resulting	O
in	O
a	O
termination	O
signal	O
at	O
codon	O
19	O
.	O
These	O
results	O
suggest	O
that	O
point	O
mutations	O
in	O
p53	O
and	O
ras	O
are	O
not	O
associated	O
with	O
pituitary	O
tumorigenesis	O
,	O
however	O
,	O
point	O
mutations	O
of	O
the	O
H-ras	O
gene	O
may	O
be	O
important	O
in	O
the	O
formation	O
and	O
or	O
growth	O
of	O
pituitary	B-malignancy-type
metastases	I-malignancy-type
.	O
This	O
observed	O
genomic	O
instability	O
will	O
be	O
of	O
value	O
in	O
predicting	O
the	O
potential	O
metastatic	O
behavior	O
of	O
these	O
aggressive	B-malignancy-type
pituitary	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8157709	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
Apr	O
1	O
;	O
57	O
(	O
1	O
)	O
:51	O
-	O
5	O
Non	O
-	O
involvement	O
of	O
ras	O
mutations	O
in	O
flat	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
Fujimori	O
T	O
,	O
Satonaka	O
K	O
,	O
Yamamura	O
-	O
Idei	O
Y	O
,	O
Nagasako	O
K	O
,	O
Maeda	O
S.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Kobe	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Ras	O
gene	O
mutations	O
occur	O
relatively	O
early	O
during	O
colorectal	O
tumor	O
development	O
and	O
have	O
been	O
observed	O
in	O
40	O
-	O
50	O
%	O
of	O
malignant	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Advances	O
in	O
endoscopic	O
techniques	O
have	O
made	O
it	O
possible	O
to	O
detect	O
small	B-malignancy-type
,	I-malignancy-type
flat	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
that	O
could	O
not	O
be	O
detected	O
by	O
standard	O
examinations	O
.	O
To	O
determine	O
whether	O
ras	O
gene	O
mutations	O
are	O
also	O
involved	O
in	O
the	O
genesis	O
of	O
small	B-malignancy-type
,	I-malignancy-type
flat	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
,	O
we	O
examined	O
ras	O
point	O
mutations	O
in	O
34	O
cases	O
of	O
small	B-malignancy-type
polypoid	I-malignancy-type
or	O
flat	B-malignancy-type
elevated	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
(	O
32	O
adenomas	B-malignancy-type
,	O
2	O
carcinomas	B-malignancy-type
)	O
and	O
in	O
26	O
cases	O
of	O
small	B-malignancy-type
,	I-malignancy-type
flat	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
(	O
13	O
adenomas	B-malignancy-type
,	O
13	O
carcinomas	B-malignancy-type
)	O
by	O
means	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
dot	O
-	O
blot	O
hybridization	O
.	O
Ras	O
gene	O
point	O
mutations	O
were	O
observed	O
in	O
16	O
of	O
the	O
34	O
tumors	O
of	O
the	O
former	O
type	O
(	O
47	O
%	O
)	O
,	O
but	O
in	O
none	O
of	O
the	O
26	O
tumors	O
of	O
the	O
latter	O
type	O
,	O
even	O
though	O
the	O
grade	O
of	O
dysplasia	B-malignancy-type
was	O
severe	O
in	O
the	O
flat	B-malignancy-type
tumors	I-malignancy-type
.	O
Our	O
results	O
suggest	O
that	O
different	O
genetic	O
pathways	O
for	O
tumor	O
progression	O
may	O
exist	O
for	O
polypoid	B-malignancy-type
and	O
for	O
flat	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
8150541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Blood	O
1994	O
Mar	O
15	O
;	O
83	O
(	O
6	O
)	O
:	O
1603	O
-	O
11	O
Prognostic	O
importance	O
of	O
mutations	O
in	O
the	O
ras	O
proto	O
-	O
oncogenes	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
acute	I-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Neubauer	O
A	O
,	O
Dodge	O
RK	O
,	O
George	O
SL	O
,	O
Davey	O
FR	O
,	O
Silver	O
RT	O
,	O
Schiffer	O
CA	O
,	O
Mayer	O
RJ	O
,	O
Ball	O
ED	O
,	O
Wurster	O
-	O
Hill	O
D	O
,	O
Bloomfield	O
CD	O
,	O
et	O
al	O
.	O
Department	O
of	O
Medicine	O
,	O
Lineberger	O
Cancer	O
Research	O
Center	O
,	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
27599	O
-	O
7295	O
.	O
Mutations	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
genes	O
are	O
the	O
most	O
frequent	O
genetic	O
aberrations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
and	O
their	O
detection	O
in	O
preleukemic	O
conditions	O
such	O
as	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
suggests	O
a	O
role	O
in	O
the	O
earliest	O
phases	O
of	O
leukemogenesis	O
.	O
Despite	O
these	O
observations	O
,	O
little	O
is	O
known	O
about	O
the	O
clinical	O
importance	O
of	O
ras	O
mutations	O
in	O
AML	B-malignancy-type
.	O
We	O
studied	O
the	O
clinical	O
impact	O
of	O
ras	O
mutations	O
in	O
99	O
patients	O
with	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
.	O
All	O
patients	O
were	O
treated	O
in	O
two	O
prospective	O
multicenter	O
trials	O
.	O
The	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
areas	O
surrounding	O
the	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
three	O
ras	O
genes	O
N	O
-	O
,	O
K	O
-	O
,	O
and	O
H	O
-	O
ras	O
from	O
DNA	O
from	O
bone	O
marrow	O
cells	O
,	O
ras	O
mutations	O
were	O
detected	O
by	O
an	O
algorithm	O
based	O
on	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Eighteen	O
of	O
99	O
(	O
18	O
%	O
)	O
patients	O
harbored	O
mutations	O
in	O
either	O
N	O
-	O
or	O
K	O
-	O
ras	O
.	O
All	O
of	O
the	O
observed	O
mutations	O
occurred	O
in	O
N-ras	O
(	O
N	O
=	O
10	O
)	O
and	O
K-ras	O
(	O
N	O
=	O
5	O
)	O
or	O
concurrently	O
in	O
both	O
N	O
-	O
and	O
K	O
-	O
ras	O
(	O
N	O
=	O
3	O
)	O
.	O
There	O
were	O
no	O
significant	O
differences	O
between	O
ras	O
-	O
negative	O
and	O
ras	O
-	O
positive	O
patients	O
according	O
to	O
age	O
,	O
sex	O
,	O
blood	O
counts	O
,	O
cytogenetic	O
abnormalities	O
,	O
or	O
French	O
-	O
American	O
-	O
British	O
classification	O
.	O
However	O
,	O
univariate	O
analysis	O
suggested	O
a	O
longer	O
survival	O
in	O
ras	O
-	O
positive	O
patients	O
(	O
P	O
=	O
.11	O
)	O
.	O
When	O
adjusted	O
for	O
age	O
,	O
which	O
was	O
the	O
most	O
important	O
factor	O
affecting	O
outcome	O
,	O
the	O
presence	O
of	O
a	O
ras	O
mutation	O
emerged	O
as	O
a	O
significant	O
predictor	O
for	O
improved	O
survival	O
(	O
P	O
=	O
.03	O
)	O
and	O
along	O
with	O
lower	O
bone	O
marrow	O
blast	O
counts	O
(	O
P	O
=	O
.02	O
)	O
and	O
better	O
cytogenetic	O
category	O
(	O
P	O
=	O
.01	O
)	O
.	O
However	O
,	O
the	O
presence	O
of	O
an	O
aberrant	O
ras	O
allele	O
was	O
strongly	O
correlated	O
with	O
lower	O
bone	O
marrow	O
blast	O
counts	O
(	O
P	O
=	O
.007	O
)	O
.	O
Thus	O
,	O
whether	O
a	O
mutation	O
in	O
the	O
N-ras	O
or	O
K-ras	O
proto	O
-	O
oncogenes	O
directly	O
affects	O
treatment	O
outcome	O
or	O
indirectly	O
through	O
an	O
association	O
with	O
lower	O
leukemic	O
burden	O
remains	O
to	O
be	O
determined	O
.	O
Nevertheless	O
,	O
these	O
findings	O
counter	O
the	O
prevailing	O
bias	O
that	O
oncogene	O
mutations	O
lead	O
to	O
more	O
aggressive	O
behavior	O
in	O
human	O
malignancies	O
.	O
PMID	O
:	O
8123851	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Invest	O
Dermatol	O
1994	O
Mar	O
;	O
102	O
(	O
3	O
)	O
:	O
285	O
-	O
90	O
Ras	O
mutations	O
in	O
human	O
melanoma	B-malignancy-type
:	O
a	O
marker	O
of	O
malignant	O
progression	O
.	O
Ball	O
NJ	O
,	O
Yohn	O
JJ	O
,	O
Morelli	O
JG	O
,	O
Norris	O
DA	O
,	O
Golitz	O
LE	O
,	O
Hoeffler	O
JP	O
.	O
Department	O
of	O
Dermatology	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
,	O
Denver	O
80262	O
.	O
In	O
this	O
study	O
we	O
address	O
whether	O
there	O
is	O
an	O
association	O
between	O
ras	O
mutations	O
and	O
disease	O
progression	O
in	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
.	O
DNA	O
was	O
extracted	O
from	O
100	O
paraffin	O
-	O
embedded	O
melanomas	B-malignancy-type
and	O
sequences	O
around	O
the	O
12th	O
,	O
13th	O
and	O
61st	O
codons	O
of	O
N	O
-	O
,	O
H	O
-	O
,	O
and	O
K	O
-	O
ras	O
were	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
probed	O
for	O
single	O
base	O
pair	O
mutations	O
using	O
synthetic	O
oligonucleotide	O
probes	O
.	O
Thirty-six	O
melanomas	B-malignancy-type
contained	O
mutations	O
,	O
which	O
in	O
25	O
cases	O
(	O
69	O
%	O
)	O
occurred	O
at	O
the	O
61st	O
codon	O
of	O
N-ras	O
.	O
The	O
results	O
from	O
dot	O
blot	O
hybridizations	O
were	O
confirmed	O
by	O
subcloning	O
and	O
sequencing	O
the	O
polymerase	O
chain	O
reaction	O
products	O
from	O
two	O
tumors	O
.	O
No	O
ras	O
mutations	O
were	O
found	O
in	O
Clark	O
's	O
level	O
I	O
melanomas	B-malignancy-type
,	O
whereas	O
19	O
%	O
of	O
level	O
II	O
and	O
45	O
%	O
of	O
the	O
more	O
advanced	O
primary	O
tumors	O
contained	O
ras	O
mutations	O
(	O
Chi	O
squared	O
test	O
:	O
p	O
<	O
0.05	O
)	O
.	O
The	O
median	O
Breslow	O
thickness	O
of	O
primary	O
melanomas	B-malignancy-type
with	O
ras	O
mutations	O
was	O
0.72	O
mm	O
,	O
significantly	O
thicker	O
than	O
the	O
0.42	O
mm	O
of	O
melanomas	B-malignancy-type
without	O
mutations	O
(	O
Mann	O
-	O
Whitney	O
U	O
test	O
,	O
p	O
=	O
0.042	O
)	O
.	O
Ras	O
mutations	O
were	O
found	O
more	O
frequently	O
in	O
primary	O
tumors	O
from	O
continuously	O
exposed	O
skin	O
(	O
56	O
%	O
)	O
than	O
tumors	O
from	O
intermittently	O
or	O
non	O
-	O
sun	O
exposed	O
sites	O
(	O
21	O
%	O
)	O
.	O
Fifty	O
percent	O
of	O
locally	O
recurrent	O
and	O
47	O
%	O
of	O
metastatic	B-malignancy-type
melanomas	I-malignancy-type
had	O
ras	O
mutations	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
occur	O
in	O
a	O
subset	O
of	O
melanomas	B-malignancy-type
from	O
sun	O
-	O
exposed	O
skin	O
as	O
a	O
feature	O
of	O
tumor	O
progression	O
.	O
PMID	O
:	O
8120410	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Oral	O
Maxillofac	O
Surg	O
1993	O
Dec	O
;	O
22	O
(	O
6	O
)	O
:	O
359	O
-	O
61	O
H-ras	O
gene	O
mutations	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
pleomorphic	I-malignancy-type
adenomas	I-malignancy-type
.	O
Milasin	O
J	O
,	O
Pujic	O
N	O
,	O
Dedovic	O
N	O
,	O
Gavric	O
M	O
,	O
Vranic	O
V	O
,	O
Petrovic	O
V	O
,	O
Minic	O
A	O
.	O
Institute	O
of	O
Biology	O
and	O
Human	O
Genetics	O
,	O
School	O
of	O
Stomatology	O
,	O
Belgrade	O
,	O
Yugoslavia	O
.	O
The	O
DNA	O
from	O
17	O
specimens	O
of	O
pleomorphic	B-malignancy-type
adenoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
salivary	I-malignancy-type
glands	I-malignancy-type
was	O
screened	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
various	O
human	O
neoplasias	B-malignancy-type
.	O
By	O
a	O
sensitive	O
method	O
of	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
on	O
in	O
vitro	O
amplified	O
tumor	O
DNA	O
,	O
point	O
mutations	O
,	O
mainly	O
in	O
codon	O
12	O
of	O
the	O
H-ras	O
gene	O
,	O
were	O
detected	O
in	O
six	O
tumor	O
specimens	O
(	O
35	O
%	O
)	O
.	O
This	O
high	O
incidence	O
of	O
mutated	O
ras	O
genes	O
suggests	O
that	O
their	O
alteration	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
pleomorphic	B-malignancy-type
adenomas	I-malignancy-type
.	O
PMID	O
:	O
8106812	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Diagn	O
Mol	O
Pathol	O
1994	O
Jun	O
;	O
3	O
(	O
2	O
)	O
:	O
114	O
-	O
21	O
PCR	O
amplification	O
and	O
analysis	O
of	O
ras	O
oncogenes	O
from	O
thyroid	O
cytologic	O
smears	O
.	O
Sciacchitano	O
S	O
,	O
Paliotta	O
DS	O
,	O
Nardi	O
F	O
,	O
Sacchi	O
A	O
,	O
Andreoli	O
M	O
,	O
Pontecorvi	O
A	O
.	O
Department	O
of	O
Experimental	O
Medicine	O
,	O
University	O
La	O
Sapienza	O
,	O
Rome	O
,	O
Italy	O
.	O
Fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
cytology	O
represents	O
a	O
reliable	O
diagnostic	O
procedure	O
for	O
preoperative	O
identification	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
For	O
improving	O
its	O
diagnostic	O
accuracy	O
,	O
a	O
technique	O
that	O
allows	O
the	O
analysis	O
of	O
cancer	O
-	O
related	O
gene	O
abnormalities	O
on	O
thyroid	O
FNA	O
smears	O
has	O
been	O
developed	O
.	O
Cells	O
were	O
collected	O
by	O
scraping	O
from	O
thyroid	O
smears	O
,	O
DNA	O
-	O
extracted	O
and	O
ras	O
proto	O
-	O
oncogene	O
sequences	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
Preliminary	O
destaining	O
of	O
cytologic	O
smears	O
was	O
essential	O
for	O
efficient	O
PCR	O
amplification	O
.	O
Twelve	O
thyroid	O
FNA	O
cytologic	O
smears	O
,	O
characterized	O
by	O
the	O
indeterminate	O
pattern	O
of	O
follicular	B-malignancy-type
neoplasia	I-malignancy-type
,	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
known	O
to	O
confer	O
an	O
oncogenic	O
potential	O
.	O
The	O
same	O
nucleotide	O
substitution	O
at	O
codon	O
12	O
of	O
the	O
H-ras	O
proto	O
-	O
oncogene	O
was	O
detected	O
in	O
two	O
different	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
among	O
six	O
cases	O
that	O
,	O
at	O
final	O
histology	O
,	O
were	O
identified	O
as	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
No	O
ras	O
mutations	O
were	O
observed	O
in	O
the	O
remaining	O
six	O
cases	O
that	O
were	O
diagnosed	O
as	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
at	O
histologic	O
examination	O
.	O
Molecular	O
analysis	O
of	O
FNA	O
smears	O
may	O
provide	O
additional	O
information	O
on	O
the	O
nature	O
of	O
the	O
lesion	B-malignancy-type
underlying	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
,	O
thus	O
improving	O
diagnostic	O
accuracy	O
of	O
conventional	O
FNA	O
cytology	O
.	O
PMID	O
:	O
8061889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1994	O
Dec	O
1;54(	O
23	O
)	O
:6282	O
-	O
7	O
A	O
truncated	O
beta-catenin	O
disrupts	O
the	O
interaction	O
between	O
E-cadherin	O
and	O
alpha-catenin	O
:	O
a	O
cause	O
of	O
loss	O
of	O
intercellular	O
adhesiveness	O
in	O
human	O
cancer	O
cell	O
lines	O
.	O
Oyama	O
T	O
,	O
Kanai	O
Y	O
,	O
Ochiai	O
A	O
,	O
Akimoto	O
S,	O
Oda	O
T	O
,	O
Yanagihara	O
K	O
,	O
Nagafuchi	O
A	O
,	O
Tsukita	O
S,	O
Shibamoto	O
S,	O
Ito	O
F	O
,	O
et	O
al	O
.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Cadherin	O
cell	O
adhesion	O
molecules	O
play	O
an	O
essential	O
role	O
in	O
creating	O
tight	O
intercellular	O
association	O
and	O
are	O
considered	O
to	O
work	O
as	O
an	O
invasion	O
suppressor	O
system	O
of	O
cancer	O
cells	O
.	O
They	O
form	O
a	O
molecular	O
complex	O
with	O
catenins	O
,	O
a	O
group	O
of	O
cytoplasmic	O
proteins	O
including	O
alpha	O
-	O
and	O
beta	O
-	O
catenins	O
.	O
While	O
alpha-catenin	O
has	O
been	O
demonstrated	O
to	O
be	O
crucial	O
for	O
cadherin	O
function	O
,	O
the	O
role	O
of	O
beta-catenin	O
is	O
not	O
yet	O
fully	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
cadherin	O
-	O
catenin	O
system	O
in	O
two	O
human	O
cell	O
lines	O
,	O
HSC-39	O
and	O
its	O
putative	O
subline	O
HSC-40A	O
,	O
derived	O
from	O
a	O
signet	B-malignancy-type
ring	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
stomach	O
.	O
These	O
cells	O
grow	O
as	O
loose	O
aggregates	O
or	O
single	O
cells	O
,	O
suggesting	O
that	O
their	O
cadherin	O
system	O
is	O
not	O
functional	O
.	O
In	O
these	O
cell	O
lines	O
,	O
an	O
identical	O
321	O
-	O
base	O
pair	O
in-frame	O
mRNA	O
deletion	O
of	O
beta-catenin	O
was	O
identified	O
;	O
this	O
led	O
to	O
a	O
107	O
-	O
amino	O
-	O
acid	O
deletion	O
in	O
the	O
NH2	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
.	O
Southern	O
blot	O
analysis	O
disclosed	O
a	O
homozygous	O
deletion	O
in	O
part	O
of	O
the	O
beta-catenin	O
gene	O
.	O
On	O
the	O
other	O
hand	O
,	O
these	O
cells	O
expressed	O
E-cadherin	O
,	O
alpha-catenin	O
,	O
and	O
plakoglobin	O
of	O
normal	O
size	O
.	O
Immunoprecipitation	O
analyses	O
showed	O
that	O
E-cadherin	O
was	O
coprecipitated	O
with	O
the	O
mutated	O
beta-catenin	O
but	O
not	O
with	O
alpha-catenin	O
,	O
and	O
antibodies	O
against	O
beta-catenin	O
did	O
not	O
copurify	O
alpha-catenin	O
.	O
However	O
,	O
the	O
recombinant	O
fusion	O
protein	O
containing	O
wild-type	O
beta-catenin	O
precipitated	O
alpha-catenin	O
from	O
these	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
dysfunction	O
of	O
E-cadherin	O
in	O
these	O
cell	O
lines	O
is	O
due	O
primarily	O
to	O
its	O
failure	O
to	O
interact	O
with	O
alpha-catenin	O
,	O
and	O
that	O
this	O
defect	O
results	O
from	O
the	O
mutation	O
in	O
beta-catenin	O
.	O
Thus	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
association	O
between	O
E-cadherin	O
and	O
alpha-catenin	O
is	O
mediated	O
by	O
beta-catenin	O
,	O
and	O
that	O
this	O
process	O
is	O
blocked	O
by	O
NH2	O
-	O
terminal	O
deletion	O
in	O
beta-catenin	O
.	O
These	O
findings	O
indicate	O
that	O
genetic	O
abnormality	O
of	O
beta-catenin	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
loosening	O
of	O
cell	O
-	O
cell	O
contact	O
,	O
and	O
may	O
be	O
involved	O
in	O
enhancement	O
of	O
tumor	O
invasion	O
in	O
human	O
cancers	O
.	O
PMID	O
:	O
7954478	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocr	O
J	O
1994	O
Jun;41(	O
3	O
)	O
:301	O
-	O
8	O
Specific	O
PCR	O
amplification	O
for	O
N-ras	O
mutations	O
in	O
neoplastic	B-malignancy-type
thyroid	I-malignancy-type
diseases	I-malignancy-type
.	O
Kaihara	O
M,	O
Taniyama	O
M,	O
Tadatomo	O
J,	O
Tobe	O
T	O
,	O
Tomita	O
M,	O
Ito	O
K	O
,	O
Ban	O
Y	O
,	O
Katagiri	O
T.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
School	O
of	O
Medicine	O
,	O
Showa	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
We	O
analyzed	O
point	O
mutations	O
of	O
N-ras	O
protooncogene	O
codon	O
61	O
in	O
thyroid	O
neoplasms	O
by	O
means	O
of	O
a	O
mutation	O
-	O
specific	O
PCR	O
method	O
.	O
In	O
this	O
method	O
,	O
one	O
of	O
the	O
paired	O
primers	O
has	O
a	O
base	O
at	O
the	O
3'	O
terminal	O
that	O
is	O
complementary	O
to	O
a	O
mutated	O
base	O
of	O
the	O
DNA	O
sequence	O
to	O
be	O
analyzed	O
.	O
With	O
this	O
primer	O
,	O
only	O
alleles	O
which	O
have	O
the	O
same	O
mutation	O
can	O
be	O
amplified	O
.	O
Among	O
24	O
thyroid	O
tissues	O
,	O
we	O
detected	O
2	O
point	O
mutations	O
out	O
of	O
7	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
29	O
%	O
)	O
.	O
One	O
tumor	O
had	O
a	O
cytosine	O
to	O
adenine	O
substitution	O
mutation	O
at	O
the	O
first	O
base	O
of	O
codon	O
61	O
,	O
and	O
the	O
other	O
had	O
an	O
adenine	O
to	O
guanine	O
substitution	O
mutation	O
in	O
the	O
second	O
base	O
of	O
the	O
same	O
codon	O
.	O
The	O
same	O
mutations	O
were	O
not	O
detected	O
in	O
7	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
or	O
1	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
.	O
These	O
results	O
were	O
confirmed	O
by	O
both	O
dot	O
blot	O
hybridization	O
and	O
direct	O
sequencing	O
method	O
.	O
Mutation	O
of	O
N-ras	O
codon	O
61	O
may	O
be	O
significant	O
in	O
malignant	O
transformation	O
of	O
follicular	B-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
.	O
Because	O
of	O
its	O
easy	O
availability	O
,	O
the	O
mutation	O
-	O
specific	O
PCR	O
method	O
is	O
a	O
useful	O
screening	O
test	O
for	O
N-ras	O
mutations	O
.	O
PMID	O
:	O
7951583	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
Oct	O
1;59(	O
1	O
)	O
:39	O
-	O
42	O
ras	O
-	O
family	O
gene	O
mutations	O
in	O
neoplasia	B-malignancy-type
of	O
the	O
ampulla	O
of	O
Vater	O
.	O
Scarpa	O
A	O
,	O
Zamboni	O
G	O
,	O
Achille	O
A	O
,	O
Capelli	O
P	O
,	O
Bogina	O
G	O
,	O
Iacono	O
C	O
,	O
Serio	O
G	O
,	O
Accolla	O
RS	O
.	O
Istituti	O
di	O
Anatomia	O
Patologica	O
,	O
Universita	O
di	O
Verona	O
,	O
Italy	O
.	O
Mutations	O
in	O
the	O
first	O
and	O
second	O
exons	O
of	O
Ha	O
-	O
,	O
Ki	O
-	O
and	O
N	O
-	O
ras	O
oncogenes	O
were	O
investigated	O
in	O
17	O
epithelial	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
ampulla	O
of	O
Vater	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
DNA	O
fragments	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
The	O
panel	O
included	O
12	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
3	O
villous	B-malignancy-type
adenomas	I-malignancy-type
,	O
1	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
and	O
1	O
neuroendocrine	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Six	O
cases	O
(	O
35	O
%	O
)	O
contained	O
ras	O
mutations	O
,	O
affecting	O
codon	O
12	O
of	O
Ki-ras	O
in	O
2	O
adenomas	B-malignancy-type
and	O
3	O
carcinomas	B-malignancy-type
,	O
and	O
of	O
N-ras	O
in	O
1	O
adenoma	O
.	O
All	O
mutations	O
were	O
found	O
in	O
adenomas	O
and	O
among	O
cancers	B-malignancy-type
with	I-malignancy-type
adenomatous	I-malignancy-type
areas	I-malignancy-type
,	O
whereas	O
none	O
of	O
the	O
cases	O
lacking	O
adenomatous	O
areas	O
contained	O
mutations	O
.	O
This	O
suggested	O
that	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
represent	O
heterogeneous	O
diseases	O
with	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
adenomatous	O
areas	O
and	O
,	O
among	O
those	O
with	O
adenomatous	O
areas	O
,	O
with	O
respect	O
to	O
the	O
presence	O
of	O
activated	O
ras	O
genes	O
.	O
Ki-ras	O
mutated	O
cases	O
included	O
3	O
of	O
4	O
tumors	B-malignancy-type
which	I-malignancy-type
mainly	I-malignancy-type
involved	I-malignancy-type
the	I-malignancy-type
intraduodenal	I-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
,	O
thus	O
suggesting	O
that	O
a	O
proportion	O
of	O
Ki-ras	O
-	O
mutated	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
might	O
correspond	O
to	O
those	O
originating	O
from	O
the	O
epithelium	O
of	O
the	O
bile	O
duct	O
component	O
of	O
the	O
ampulla	O
.	O
PMID	O
:	O
7927901	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Apr;86(	O
4)	O
:774	O
-	O
9	O
Point	O
mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
the	O
blood	O
plasma	O
DNA	O
of	O
patients	O
with	O
myelodysplastic	O
syndrome	O
or	O
acute	O
myelogenous	O
leukaemia	O
.	O
Vasioukhin	O
V	O
,	O
Anker	O
P	O
,	O
Maurice	O
P	O
,	O
Lyautey	O
J,	O
Lederrey	O
C	O
,	O
Stroun	O
M.	O
Department	O
of	O
Plant	O
Physiology	O
,	O
Pavillon	O
des	O
Isotopes	O
,	O
Faculty	O
of	O
Science	O
,	O
University	O
of	O
Geneva	O
,	O
Switzerland	O
.	O
Oncogene	O
mutations	O
are	O
frequently	O
found	O
in	O
several	O
tumour	O
types	O
and	O
,	O
among	O
these	O
,	O
point	O
mutations	O
of	O
the	O
ras	O
gene	O
are	O
particularly	O
significant	O
.	O
A	O
predominance	O
of	O
N-ras	O
mutations	O
has	O
been	O
found	O
in	O
the	O
bone	O
marrow	O
DNA	O
of	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
or	O
acute	O
myelogenous	O
leukaemia	O
(	O
AML	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
increased	O
levels	O
of	O
plasma	O
DNA	O
have	O
previously	O
been	O
observed	O
in	O
patients	O
suffering	O
from	O
various	O
malignant	O
diseases	O
.	O
In	O
the	O
present	O
work	O
we	O
have	O
investigated	O
,	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
point	O
mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
the	O
DNA	O
of	O
plasma	O
,	O
blood	O
cells	O
and	O
bone	O
marrow	O
of	O
10	O
patients	O
suffering	O
from	O
AML	O
or	O
MDS	O
.	O
The	O
different	O
ras	O
mutations	O
detected	O
in	O
five	O
cases	O
were	O
always	O
present	O
in	O
the	O
plasma	O
DNA	O
while	O
sometimes	O
absent	O
in	O
the	O
DNA	O
of	O
peripheral	O
blood	O
cells	O
or	O
bone	O
marrow	O
.	O
This	O
indicates	O
that	O
a	O
bone	O
marrow	O
biopsy	O
or	O
aspiration	O
does	O
not	O
necessarily	O
contain	O
all	O
the	O
malignant	O
clones	O
involved	O
in	O
the	O
disease	O
.	O
Plasma	O
could	O
thus	O
prove	O
to	O
be	O
an	O
easily	O
accessible	O
and	O
useful	O
material	O
for	O
detection	O
and	O
monitoring	O
of	O
myeloid	O
disorders	O
.	O
PMID	O
:	O
7918071	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
1995	O
Mar;15(	O
3	O
)	O
:1175	O
-	O
81	O
Loss	O
of	O
E-cadherin	O
-	O
dependent	O
cell	O
-	O
cell	O
adhesion	O
due	O
to	O
mutation	O
of	O
the	O
beta-catenin	O
-	O
gene	O
in	O
a	O
human	O
cancer	O
cell	O
line	O
,	O
HSC-39	O
.	O
Kawanishi	O
J,	O
Kato	O
J,	O
Sasaki	O
K	O
,	O
Fujii	O
S,	O
Watanabe	O
N	O
,	O
Niitsu	O
Y.	O
Fourth	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Detachment	O
of	O
cell	O
-	O
cell	O
adhesion	O
is	O
indispensable	O
for	O
the	O
first	O
step	O
of	O
invasion	O
and	O
metastasis	O
of	O
cancer	O
.	O
This	O
mechanism	O
is	O
frequently	O
associated	O
with	O
the	O
impairment	O
of	O
either	O
E-cadherin	O
expression	O
or	O
function	O
.	O
However	O
,	O
mechanisms	O
of	O
such	O
abnormalities	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
function	O
of	O
E-cadherin	O
was	O
completely	O
abolished	O
in	O
the	O
human	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
HSC-39	O
,	O
despite	O
the	O
high	O
expression	O
of	O
E-cadherin	O
,	O
because	O
of	O
mutations	O
in	O
one	O
of	O
the	O
E-cadherin	O
-	O
associated	O
cytoplasmic	O
proteins	O
,	O
beta-catenin	O
.	O
Although	O
immunofluorescence	O
staining	O
of	O
HSC-39	O
cells	O
by	O
using	O
an	O
anti	O
-	O
E-cadherin	O
antibody	O
(	O
HECD-1	O
)	O
revealed	O
the	O
strong	O
and	O
uniform	O
expression	O
of	O
E-cadherin	O
on	O
the	O
cell	O
surface	O
,	O
cell	O
compaction	O
and	O
cell	O
aggregation	O
were	O
not	O
observed	O
in	O
this	O
cell	O
.	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
using	O
HECD-1	O
exhibited	O
a	O
120	O
-	O
kDa	O
band	O
which	O
is	O
equivalent	O
to	O
normal	O
E-cadherin	O
.	O
Northern	O
(	O
RNA	O
)	O
blotting	O
demonstrated	O
a	O
4.7	O
-	O
kb	O
band	O
,	O
the	O
same	O
as	O
mature	O
E-cadherin	O
mRNA	O
.	O
Immunoprecipitation	O
of	O
metabolically	O
labeled	O
proteins	O
with	O
HECD-1	O
revealed	O
three	O
bands	O
corresponding	O
to	O
E-cadherin	O
,	O
alpha-catenin	O
,	O
and	O
gamma-catenin	O
and	O
a	O
79	O
-	O
kDa	O
band	O
which	O
was	O
apparently	O
smaller	O
than	O
that	O
of	O
normal	O
beta-catenin	O
,	O
indicating	O
truncated	O
beta-catenin	O
.	O
The	O
79	O
-	O
kDa	O
band	O
was	O
immunologically	O
identified	O
as	O
beta-catenin	O
by	O
using	O
immunoblotting	O
with	O
anti	O
-	O
beta-catenin	O
antibodies	O
.	O
Examination	O
of	O
beta-catenin	O
mRNA	O
by	O
the	O
reverse	O
transcriptase	O
-	O
PCR	O
method	O
revealed	O
a	O
transcript	O
which	O
was	O
shorter	O
than	O
that	O
of	O
normal	O
beta-catenin	O
.	O
The	O
sequencing	O
of	O
PCR	O
product	O
for	O
beta-catenin	O
confirmed	O
deletion	O
in	O
321	O
bases	O
from	O
nucleotides	O
+82	O
to	O
+402	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
7862112	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Oct	O
;	O
88	O
(	O
2	O
)	O
:	O
338	O
-	O
42	O
Sequential	O
acquisition	O
of	O
trisomy	O
8	O
and	O
N-ras	O
mutation	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
demonstrated	O
by	O
analysis	O
of	O
isolated	O
leukaemic	O
colonies	O
.	O
Price	O
CM	O
,	O
Marshall	O
CJ	O
,	O
Bashey	O
A	O
.	O
Centre	O
of	O
Cell	O
and	O
Molecular	O
Biology	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
London	O
.	O
Specific	O
chromosomal	O
aberrations	O
and	O
point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
are	O
characteristic	O
genetic	O
alterations	O
in	O
acute	B-malignancy-type
leukaemias	I-malignancy-type
.	O
However	O
,	O
the	O
relationships	O
between	O
these	O
two	O
different	O
genetic	O
changes	O
are	O
unclear	O
.	O
Here	O
we	O
have	O
determined	O
the	O
order	O
of	O
genetic	O
events	O
in	O
a	O
patient	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
characterized	O
by	O
trisomy	O
8	O
and	O
a	O
point	O
mutation	O
of	O
N-ras	O
at	O
codon	O
12	O
(	O
N12	O
-	O
cys	O
)	O
and	O
codon	O
61	O
(	O
N61	O
-	O
his	O
)	O
.	O
30	O
colonies	O
obtained	O
by	O
in	O
vitro	O
clonogenic	O
assay	O
of	O
leukaemic	O
cells	O
from	O
a	O
patient	O
with	O
AML	B-malignancy-type
were	O
individually	O
analysed	O
for	O
the	O
presence	O
of	O
trisomy	O
8	O
and	O
each	O
of	O
two	O
different	O
N-ras	O
mutations	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
Trisomy	O
8	O
was	O
detected	O
in	O
25	O
/	O
26	O
evaluable	O
colonies	O
.	O
19	O
/	O
26	O
colonies	O
contained	O
the	O
N12	O
-	O
cys	O
mutation	O
.	O
The	O
N61	O
-	O
his	O
mutation	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
colonies	O
obtained	O
.	O
All	O
the	O
colonies	O
with	O
the	O
N12	O
cys	O
mutation	O
were	O
also	O
trisomic	O
from	O
chromosome	O
8	O
,	O
whereas	O
6	O
/	O
25	O
colonies	O
with	O
trisomy	O
8	O
had	O
no	O
N-ras	O
mutation	O
.	O
These	O
data	O
suggest	O
that	O
trisomy	O
8	O
was	O
acquired	O
before	O
N12	O
cys	O
mutation	O
in	O
the	O
pathogenesis	O
of	O
this	O
leukaemia	B-malignancy-type
and	O
that	O
two	O
genetic	O
events	O
can	O
co-operate	O
within	O
a	O
single	O
subclone	O
.	O
PMID	O
:	O
7803279	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pathol	O
Int	O
1995	O
Jan;45(	O
1	O
)	O
:45	O
-	O
50	O
N-ras	O
mutation	O
of	O
thyroid	B-malignancy-type
tumor	I-malignancy-type
with	I-malignancy-type
special	I-malignancy-type
reference	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
follicular	I-malignancy-type
type	I-malignancy-type
.	O
Oyama	O
T	O
,	O
Suzuki	O
T	O
,	O
Hara	O
F	O
,	O
Iino	O
Y	O
,	O
Ishida	O
T	O
,	O
Sakamoto	O
A	O
,	O
Nakajima	O
T.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Gunma	O
University	O
School	O
of	O
Medicine	O
,	O
Maebashi	O
,	O
Japan	O
.	O
Using	O
the	O
method	O
of	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
,	O
the	O
point	O
mutations	O
of	O
the	O
ras	O
oncogenes	O
in	O
a	O
total	O
of	O
33	O
thyroid	O
tissues	O
,	O
including	O
12	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
,	O
6	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
11	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
4	O
undifferentiated	B-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
examined	O
.	O
The	O
frequency	O
of	O
the	O
mutation	O
was	O
3	O
%	O
(	O
1	O
/	O
33	O
)	O
in	O
codon	O
12	O
,	O
13	O
of	O
Ki-ras	O
and	O
18	O
%	O
(	O
6	O
/	O
33	O
)	O
in	O
codon	O
61	O
of	O
N-ras	O
,	O
including	O
17	O
%	O
(	O
2	O
/	O
12	O
)	O
in	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
50	O
%	O
(	O
3	O
/	O
6	O
)	O
in	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
0	O
%	O
(	O
0	O
/	O
11	O
)	O
in	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
and	O
25	O
%	O
(	O
1	O
/	O
4	O
)	O
in	O
undifferentiated	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
positivity	O
was	O
observed	O
in	O
microfollicular	O
or	O
trabecular	O
subtypes	O
.	O
Furthermore	O
,	O
the	O
mutation	O
of	O
ras	O
,	O
was	O
examined	O
in	O
histologically	O
different	O
parts	O
,	O
coexisting	O
in	O
the	O
same	O
tumor	O
in	O
a	O
total	O
of	O
four	O
cases	O
.	O
Both	O
the	O
undifferentiated	B-malignancy-type
carcinoma	I-malignancy-type
and	O
coexisting	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
and	O
both	O
the	O
microfollicular	B-malignancy-type
adenoma	I-malignancy-type
and	O
trabecular	B-malignancy-type
nodule	I-malignancy-type
growing	O
in	O
the	O
tumor	O
,	O
had	O
the	O
same	O
N-ras	O
(	O
61	O
)	O
mutation	O
.	O
Direct	O
sequencing	O
analysis	O
showed	O
that	O
all	O
mutations	O
were	O
CAA	O
(	O
Gln	O
)	O
to	O
CGA	O
(	O
Arg	O
)	O
transition	O
of	O
codon	O
61	O
,	O
except	O
for	O
CAA	O
to	O
AAA	O
transversion	O
in	O
one	O
case	O
of	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
similar	O
genetic	O
abnormality	O
of	O
N-ras	O
genes	O
at	O
codon	O
61	O
between	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
and	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
suggests	O
that	O
the	O
mutation	O
of	O
N-ras	O
at	O
codon	O
61	O
might	O
play	O
a	O
part	O
in	O
oncogenesis	O
in	O
follicular	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
7704243	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1993	O
Nov	O
1;82(	O
9	O
)	O
:2829	O
-	O
36	O
p53	O
and	O
N-ras	O
mutations	O
in	O
two	O
new	O
leukemia	B-malignancy-type
cell	O
lines	O
established	O
from	O
a	O
patient	O
with	O
multilineage	O
CD7	O
-	O
positive	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
Abo	O
J,	O
Inokuchi	O
K	O
,	O
Dan	O
K	O
,	O
Nomura	O
T.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Two	O
new	O
myeloid	O
cell	O
lines	O
(	O
K051	O
and	O
K052	O
)	O
were	O
established	O
from	O
a	O
patient	O
with	O
multilineage	O
CD7	O
-	O
positive	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
K051	O
and	O
K052	O
were	O
established	O
from	O
the	O
patient	O
's	O
bone	O
marrow	O
cells	O
at	O
diagnosis	O
and	O
at	O
relapse	O
,	O
respectively	O
.	O
The	O
K051	O
cell	O
expressed	O
myeloid	O
-	O
associated	O
antigens	O
(	O
CD13	O
and	O
CD33	O
)	O
,	O
a	O
platelet	O
-	O
associated	O
antigen	O
(	O
CD41	O
)	O
,	O
and	O
an	O
erythroid	O
antigen	O
(	O
glycophorin	O
A	O
)	O
.	O
The	O
K052	O
cell	O
expressed	O
myeloid	O
-	O
associated	O
antigens	O
(	O
CD13	O
,	O
CD14	O
,	O
and	O
CD33	O
)	O
,	O
lymphoid	O
markers	O
(	O
CD2	O
,	O
CD5	O
,	O
and	O
CD7	O
)	O
,	O
and	O
HLA-DR	O
.	O
Chromosome	O
analysis	O
of	O
both	O
cell	O
lines	O
showed	O
a	O
17p	O
-	O
chromosome	O
.	O
Both	O
cell	O
lines	O
were	O
investigated	O
for	O
aberrations	O
of	O
the	O
p53	O
gene	O
and	O
the	O
N-ras	O
gene	O
.	O
A	O
p53	O
mutation	O
detected	O
in	O
both	O
cell	O
lines	O
consisted	O
of	O
a	O
C	O
-->	O
T	O
substitution	O
in	O
codon	O
248	O
.	O
An	O
N-ras	O
mutation	O
detected	O
only	O
in	O
the	O
K052	O
cell	O
consisted	O
of	O
a	O
G	O
-->	O
C	O
substitution	O
in	O
codon	O
13	O
.	O
Expression	O
of	O
the	O
multidrug	O
resistance	O
gene	O
(	O
MDR1	O
)	O
was	O
also	O
investigated	O
by	O
the	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
MDR1	O
-	O
mRNA	O
was	O
more	O
highly	O
expressed	O
by	O
the	O
K052	O
cell	O
than	O
the	O
K051	O
cell	O
,	O
being	O
equivalent	O
to	O
that	O
in	O
HEL	O
cells	O
.	O
The	O
functional	O
MDR1	O
-	O
protein	O
against	O
vincristine	O
was	O
also	O
observed	O
,	O
and	O
its	O
function	O
was	O
inhibited	O
by	O
verapamile	O
and	O
Cyclosporin	O
A	O
.	O
The	O
K052	O
cells	O
were	O
capable	O
of	O
phenotypic	O
or	O
morphologic	O
differentiation	O
after	O
being	O
incubated	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
,	O
interleukin-2	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
or	O
1,25-dihydroxy-vitamin	O
D3	O
.	O
In	O
contrast	O
,	O
the	O
K051	O
cells	O
responded	O
phenotypically	O
to	O
retinoic	O
acid	O
.	O
Thus	O
,	O
the	O
K051	O
and	O
K052	O
cell	O
lines	O
will	O
be	O
useful	O
for	O
investigating	O
the	O
cellular	O
and	O
molecular	O
events	O
in	O
leukemogenesis	O
and	O
differentiation	O
,	O
and	O
the	O
mechanism	O
of	O
expression	O
of	O
the	O
MDR1	O
gene	O
.	O
PMID	O
:	O
7693050	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Apr;8(	O
4)	O
:638	O
-	O
41	O
Mutations	O
in	O
the	O
ras	O
proto	O
-	O
oncogenes	O
in	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
.	O
Neubauer	O
A	O
,	O
Greenberg	O
P	O
,	O
Negrin	O
R,	O
Ginzton	O
N	O
,	O
Liu	O
E.	O
Department	O
of	O
Medicine	O
and	O
Genetics	O
,	O
Lineberger	O
Cancer	O
Research	O
Center	O
,	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
.	O
Activation	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
proto	O
-	O
oncogenes	O
is	O
the	O
most	O
common	O
molecular	O
abnormality	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
In	O
retrospective	O
studies	O
,	O
approximately	O
3	O
-	O
36	O
%	O
of	O
MDS	B-malignancy-type
patients	O
were	O
reported	O
to	O
harbor	O
a	O
mutated	O
ras	O
proto	O
-	O
oncogene	O
,	O
with	O
some	O
series	O
suggesting	O
the	O
presence	O
of	O
ras	O
-	O
mutations	O
are	O
associated	O
with	O
progressive	O
disease	O
and	O
a	O
poor	O
prognosis	O
.	O
Since	O
hematopoietic	O
growth	O
factors	O
such	O
as	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
are	O
currently	O
used	O
for	O
therapy	O
in	O
MDS	B-malignancy-type
but	O
may	O
stimulate	O
the	O
proliferation	O
of	O
leukemic	O
cells	O
,	O
we	O
assessed	O
the	O
frequency	O
and	O
significance	O
of	O
ras	O
mutations	O
in	O
27	O
MDS	B-malignancy-type
patients	O
,	O
15	O
of	O
whom	O
underwent	O
G-CSF	O
therapy	O
.	O
Patients	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
proto	O
-	O
oncogenes	O
.	O
Only	O
three	O
patients	O
(	O
11	O
%	O
,	O
two	O
refractory	B-malignancy-type
anemia	I-malignancy-type
with	O
excess	O
of	O
blasts	O
(	O
RAEB	B-malignancy-type
)	O
,	O
one	O
RAEB	B-malignancy-type
in	O
transformation	O
(	O
RAEB-T	B-malignancy-type
)	O
)	O
harbored	O
activated	O
ras	O
oncogenes	O
with	O
the	O
mutations	O
localized	O
in	O
N-ras	O
codons	O
12	O
and	O
61	O
.	O
Patients	O
were	O
followed	O
for	O
periods	O
of	O
up	O
to	O
4	O
years	O
or	O
until	O
death	O
supervened	O
.	O
Patients	O
exhibiting	O
ras	O
mutations	O
were	O
no	O
more	O
likely	O
to	O
develop	O
AML	B-malignancy-type
compared	O
to	O
ras	O
-	O
negative	O
patients	O
(	O
1	O
/	O
3	O
vs.	O
10	O
/	O
24	O
)	O
or	O
to	O
have	O
decreased	O
survival	O
(	O
p	O
=	O
0.64	O
)	O
.	O
These	O
data	O
indicate	O
that	O
,	O
in	O
this	O
group	O
of	O
MDS	B-malignancy-type
patients	O
,	O
ras	O
mutations	O
do	O
not	O
appear	O
to	O
correlate	O
with	O
a	O
poor	O
prognosis	O
,	O
and	O
do	O
not	O
adversely	O
interact	O
with	O
exogenously	O
administered	O
G-CSF	O
.	O
PMID	O
:	O
7512175	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nature	O
1987	O
Jun	O
4	O
-	O
10;327(6121	O
)	O
:430	O
-	O
2	O
A	O
point	O
mutation	O
at	O
codon	O
13	O
of	O
the	O
N-ras	O
oncogene	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Hirai	O
H	O
,	O
Kobayashi	O
Y	O
,	O
Mano	O
H	O
,	O
Hagiwara	O
K	O
,	O
Maru	O
Y	O
,	O
Omine	O
M,	O
Mizoguchi	O
H	O
,	O
Nishida	O
J,	O
Takaku	O
F.	O
Patients	O
with	O
a	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
which	O
has	O
a	O
risk	O
of	O
leukaemic	O
change	O
exhibit	O
a	O
variable	O
clinical	O
course	O
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
development	O
of	O
leukaemia	B-malignancy-type
in	O
patients	O
with	O
MDS	B-malignancy-type
may	O
be	O
related	O
to	O
chromosomal	O
abnormalities	O
or	O
genetic	O
alterations	O
:	O
somatic	O
mutation	O
of	O
the	O
N-ras	O
gene	O
is	O
now	O
considered	O
to	O
be	O
a	O
critical	O
step	O
in	O
the	O
genetic	O
basis	O
of	O
human	O
leukaemogenesis	O
.	O
Here	O
we	O
report	O
that	O
DNAs	O
of	O
bone	O
-	O
marrow	O
cells	O
from	O
three	O
out	O
of	O
eight	O
patients	O
with	O
MDS	B-malignancy-type
contained	O
an	O
activated	O
N-ras	O
oncogene	O
,	O
as	O
detected	O
by	O
an	O
in	O
vivo	O
selection	O
assay	O
in	O
nude	O
mice	O
with	O
transfected	O
NIH	O
3T3	O
cells	O
.	O
Molecular	O
analysis	O
revealed	O
the	O
same	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
13	O
in	O
all	O
three	O
transforming	O
N-ras	O
genes	O
.	O
Each	O
of	O
the	O
three	O
patients	O
showed	O
a	O
progression	O
of	O
the	O
disease	O
and	O
a	O
resulting	O
leukaemic	O
change	O
within	O
the	O
following	O
year	O
.	O
Our	O
observation	O
of	O
the	O
mutation	O
at	O
codon	O
13	O
in	O
leukaemic	O
cell	O
DNAs	O
from	O
all	O
three	O
cases	O
suggests	O
that	O
activation	O
of	O
the	O
N-ras	O
gene	O
is	O
important	O
in	O
the	O
development	O
of	O
leukaemia	B-malignancy-type
in	O
some	O
MDS	B-malignancy-type
cases	O
.	O
PMID	O
:	O
3295562	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
Res	O
1988	O
;3(	O
1	O
)	O
:77	O
-	O
86	O
Preferential	O
and	O
novel	O
activation	O
of	O
H-ras	O
in	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Visvanathan	O
KV	O
,	O
Pocock	O
RD	O
,	O
Summerhayes	O
IC	O
.	O
Department	O
of	O
Cell	O
and	O
Molecular	O
Biology	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
London	O
,	O
UK.	O
In	O
a	O
survey	O
of	O
primary	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
from	O
24	O
patients	O
,	O
using	O
the	O
NIH	O
/	O
3T3	O
transfection	O
nude	O
mouse	O
tumor	O
assay	O
,	O
we	O
have	O
detected	O
an	O
activated	O
c-H-ras-1	O
gene	O
in	O
four	O
cases	O
.	O
Two	O
of	O
these	O
scored	O
negative	O
in	O
primary	O
transfections	O
using	O
a	O
NIH	O
/	O
3T3	O
focus	O
assay	O
.	O
Oligonucleotide	O
analysis	O
of	O
genomic	O
and	O
enzymatically	O
amplified	O
DNA	O
revealed	O
substitution	O
of	O
valine	O
at	O
codon	O
12	O
in	O
DNA	O
from	O
three	O
transfectants	O
and	O
their	O
parental	B-malignancy-type
carcinomas	I-malignancy-type
,	O
which	O
was	O
absent	O
from	O
the	O
DNA	O
of	O
normal	O
tissue	O
of	O
each	O
of	O
these	O
patients	O
.	O
The	O
fourth	O
activation	O
was	O
identified	O
as	O
a	O
cysteine	O
substitution	O
at	O
codon	O
13	O
,	O
a	O
novel	O
activation	O
of	O
c-H-ras-1	O
in	O
a	O
solid	B-malignancy-type
tumor	I-malignancy-type
sample	O
.	O
Thus	O
,	O
all	O
seven	O
activated	O
ras	O
genes	O
reported	O
in	O
human	O
urothelial	B-malignancy-type
tumors	I-malignancy-type
(	O
Fujita	O
et	O
al.	O
,	O
Proc.	O
Natl.	O
Acad.	O
Sci.	O
USA	O
82	O
,	O
3849	O
-	O
3853	O
,	O
1985	O
)	O
have	O
been	O
c-H-ras-1	O
genes	O
,	O
strongly	O
suggesting	O
that	O
this	O
member	O
of	O
the	O
ras	O
gene	O
family	O
is	O
preferentially	O
activated	O
in	O
cells	O
of	O
transitional	O
origin	O
.	O
PMID	O
:	O
3144694	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Exp	O
Med	O
1989	O
Nov	O
1;170	O
(	O
5	O
)	O
:	O
171	O
5-25	O
Ras	O
oncogene	O
mutation	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
Neri	O
A	O
,	O
Murphy	O
JP	O
,	O
Cro	O
L,	O
Ferrero	O
D	O
,	O
Tarella	O
C,	O
Baldini	O
L,	O
Dall	O
a	O
-Favera	O
R.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
New	O
York	O
10032	O
.	O
The	O
frequency	O
of	O
ras	O
(	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
)	O
and	O
c-myc	O
oncogenes	O
was	O
investigated	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
.	O
By	O
means	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
oligonucleotide	O
hybridization	O
method	O
,	O
DNA	O
from	O
56	O
tumor	O
biopsies	O
was	O
analyzed	O
for	O
the	O
presence	O
of	O
activating	O
mutations	O
involving	O
codons	O
12	O
and	O
61	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
and	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
.	O
Mutations	O
,	O
involving	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
genes	O
,	O
were	O
detected	O
in	O
18	O
of	O
56	O
(	O
32	O
%	O
)	O
cases	O
of	O
which	O
12	O
/	O
43	O
(	O
27	O
%	O
)	O
were	O
at	O
diagnosis	O
and	O
6	O
/	O
13	O
(	O
46	O
%	O
)	O
were	O
after	O
treatment	O
.	O
In	O
some	O
cases	O
,	O
multiple	O
mutations	O
affecting	O
different	O
ras	O
alleles	O
were	O
detected	O
.	O
Direct	O
nucleotide	O
sequence	O
analysis	O
of	O
PCR	O
products	O
indicated	O
that	O
a	O
more	O
heterogeneous	O
nature	O
of	O
the	O
base	O
pair	O
changes	O
than	O
previously	O
shown	O
for	O
other	O
tumors	O
along	O
with	O
a	O
preferential	O
involvement	O
of	O
N-ras	O
codon	O
61	O
.	O
The	O
heterogeneity	O
of	O
MM	B-malignancy-type
cases	O
with	O
respect	O
to	O
the	O
presence	O
of	O
ras	O
oncogenes	O
prompted	O
an	O
analysis	O
of	O
possible	O
correlations	O
with	O
different	O
clinico	O
-	O
pathologic	O
characteristics	O
of	O
MM	B-malignancy-type
from	O
which	O
a	O
correlation	O
between	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
a	O
partial	O
or	O
complete	O
lack	O
of	O
response	O
to	O
therapy	O
emerged	O
.	O
The	O
frequency	O
of	O
activating	O
rearrangements	O
or	O
mutations	O
of	O
the	O
c-myc	O
gene	O
were	O
studied	O
by	O
Southern	O
blot	O
analysis	O
and	O
PCR	O
sequencing	O
,	O
respectively	O
.	O
However	O
,	O
contrary	O
to	O
previous	O
reports	O
involving	O
mostly	O
MM	B-malignancy-type
cell	O
lines	O
,	O
no	O
structural	O
alterations	O
of	O
the	O
c-myc	O
gene	O
were	O
found	O
.	O
These	O
results	O
indicate	O
that	O
ras	O
,	O
but	O
not	O
c-myc	O
,	O
oncogenes	O
are	O
activated	O
in	O
vivo	O
in	O
MM	B-malignancy-type
cells	O
,	O
representing	O
the	O
first	O
oncogene	O
alteration	O
that	O
has	O
been	O
associated	O
at	O
appreciable	O
frequency	O
with	O
this	O
type	O
of	O
malignancy	O
.	O
While	O
the	O
mechanism	O
of	O
occurrence	O
and	O
biological	O
role	O
of	O
ras	O
activation	O
in	O
MM	B-malignancy-type
remains	O
to	O
be	O
elucidated	O
,	O
the	O
preliminary	O
correlations	O
observed	O
in	O
this	O
study	O
between	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
poor	O
therapeutic	O
response	O
suggest	O
that	O
further	O
investigations	O
of	O
the	O
possible	O
prognostic	O
significance	O
of	O
these	O
alterations	O
are	O
necessary	O
.	O
PMID	O
:	O
2681517	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Oct	O
15	O
;49(	O
20	O
)	O
:5530	O
-	O
3	O
Activated	O
N-ras	O
oncogenes	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Ireland	O
CM	O
.	O
Children	O
's	O
Leukemia	O
and	O
Cancer	O
Research	O
Unit	O
,	O
Prince	O
of	O
Wales	O
Children	O
's	O
Hospital	O
,	O
New	O
South	O
Wales	O
,	O
Australia	O
.	O
Fifteen	O
primary	O
neuroblastomas	B-malignancy-type
and	O
four	O
bone	O
marrow	O
samples	O
from	O
neuroblastoma	B-malignancy-type
patients	O
,	O
representing	O
clinical	O
Stages	O
I	O
to	O
IV	O
,	O
have	O
been	O
screened	O
for	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
N-ras	O
.	O
Neuroblastoma	B-malignancy-type
DNAs	O
were	O
subjected	O
to	O
the	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
the	O
relevant	O
sequences	O
and	O
were	O
then	O
hybridized	O
with	O
specific	O
oligonucleotides	O
to	O
locate	O
and	O
identify	O
point	O
mutations	O
.	O
The	O
results	O
show	O
that	O
one	O
Stage	O
I	O
tumor	O
contained	O
an	O
N-ras	O
gene	O
that	O
was	O
activated	O
by	O
a	O
GC	O
-	O
CG	O
transversion	O
of	O
the	O
first	O
base	O
of	O
codon	O
61	O
,	O
while	O
in	O
one	O
Stage	O
II	O
tumor	O
,	O
activation	O
of	O
N-ras	O
involved	O
a	O
GC	O
-	O
CG	O
transversion	O
of	O
the	O
first	O
position	O
of	O
codon	O
13	O
.	O
N-ras	O
activations	O
were	O
not	O
detected	O
in	O
the	O
six	O
Stage	O
III	O
tumors	O
and	O
eight	O
Stage	O
IV	O
tumors	O
that	O
were	O
examined	O
.	O
PMID	O
:	O
2676145	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
1989	O
Jul;9(	O
7)	O
:3114	O
-	O
6	O
N-ras	O
mutations	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
from	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
van	O
't	O
Veer	O
LJ	O
,	O
Burgering	O
BM	O
,	O
Versteeg	O
R,	O
Boot	O
AJ	O
,	O
Ruiter	O
DJ	O
,	O
Osanto	O
S,	O
Schrier	O
PI	O
,	O
Bos	O
JL.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
Leiden	O
University	O
Hospital	O
,	O
The	O
Netherlands	O
.	O
In	O
7	O
of	O
37	O
patients	O
with	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
,	O
mutations	O
in	O
the	O
N-ras	O
gene	O
were	O
found	O
.	O
The	O
primary	O
tumors	O
of	O
these	O
seven	O
patients	O
were	O
exclusively	O
localized	O
on	O
body	O
sites	O
continuously	O
exposed	O
to	O
sunlight	O
.	O
Moreover	O
,	O
the	O
ras	O
mutations	O
were	O
all	O
at	O
or	O
near	O
dipyrimidine	O
sites	O
known	O
to	O
be	O
targets	O
of	O
UV	O
damage	O
.	O
Two	O
primary	O
tumors	O
were	O
biclonal	O
with	O
respect	O
to	O
ras	O
mutation	O
.	O
An	O
active	O
role	O
for	O
UV	O
irradiation	O
in	O
induction	O
of	O
the	O
mutations	O
is	O
suggested	O
.	O
PMID	O
:	O
2674680	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1989	O
Apr;3(	O
4)	O
:247	O
-	O
56	O
Acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
:	O
analysis	O
of	O
ras	O
gene	O
mutations	O
and	O
clonality	O
defined	O
by	O
polymorphic	O
X	O
-	O
linked	O
loci	O
.	O
Bartram	O
CR	O
,	O
Ludwig	O
WD	O
,	O
Hiddemann	O
W	O
,	O
Lyons	O
J,	O
Buschle	O
M,	O
Ritter	O
J,	O
Harbott	O
J,	O
Frohlich	O
A	O
,	O
Janssen	O
JW.	O
Department	O
of	O
Pediatrics	O
II	O
,	O
University	O
of	O
Ulm	O
,	O
F.R.G.	O
In	O
vitro	O
DNA	O
amplification	O
and	O
synthetic	O
oligonucleotide	O
hybridization	O
was	O
used	O
to	O
analyze	O
57	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemias	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
.	O
We	O
demonstrated	O
mutated	O
alleles	O
in	O
19	O
%	O
of	O
primary	B-malignancy-type
AMLs	I-malignancy-type
(	O
10	O
/	O
51	O
)	O
as	O
well	O
as	O
in	O
five	O
of	O
six	O
secondary	B-malignancy-type
leukemias	I-malignancy-type
.	O
Mutations	O
occurred	O
predominantly	O
at	O
N-ras	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
(	O
13	O
cases	O
)	O
and	O
twice	O
at	O
Ki-ras	O
codons	O
12	O
and	O
13	O
.	O
Ras	O
gene	O
mutations	O
were	O
preferentially	O
associated	O
with	O
an	O
M4	O
morphology	O
according	O
to	O
the	O
FAB	O
(	O
French	O
-	O
American	O
-	O
British	O
)	O
classification	O
,	O
but	O
no	O
particular	O
correlation	O
was	O
observed	O
with	O
respect	O
to	O
clinical	O
parameter	O
(	O
sex	O
,	O
age	O
,	O
course	O
of	O
disease	O
)	O
or	O
immunophenotype	O
and	O
karyotype	O
.	O
Mutated	O
ras	O
alleles	O
were	O
absent	O
in	O
nine	O
mutation	O
-	O
positive	O
cases	O
analyzed	O
during	O
remission	O
.	O
However	O
,	O
a	O
more	O
complex	O
pattern	O
emerged	O
from	O
the	O
five	O
patients	O
analyzed	O
in	O
relapse	O
exhibiting	O
identical	O
ras	O
mutations	O
in	O
three	O
cases	O
,	O
absence	O
of	O
a	O
mutated	O
allele	O
in	O
one	O
patient	O
,	O
and	O
acquisition	O
of	O
a	O
N-ras	O
mutation	O
in	O
yet	O
another	O
case	O
,	O
in	O
which	O
no	O
mutation	O
had	O
been	O
detected	O
initially	O
.	O
Moreover	O
,	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLP	O
)	O
of	O
the	O
X	O
-	O
chromosome	O
genes	O
hypoxanthine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
)	O
and	O
phosphoglycerate	O
kinase	O
(	O
PGK	O
)	O
were	O
studied	O
in	O
19	O
of	O
the	O
AML	B-malignancy-type
patients	O
.	O
Nine	O
cases	O
(	O
47	O
%	O
)	O
were	O
heterozygous	O
for	O
BglI	O
or	O
BamHI	O
RFLPs	O
at	O
the	O
PGK	O
or	O
HPRT	O
loci	O
,	O
respectively	O
,	O
and	O
therefore	O
suitable	O
for	O
clonal	O
analysis	O
investigating	O
X	O
-	O
chromosome	O
inactivation	O
.	O
All	O
of	O
the	O
patients	O
exhibited	O
a	O
monoclonal	O
leukemic	O
cell	O
population	O
at	O
presentation	O
.	O
In	O
addition	O
,	O
five	O
of	O
seven	O
cases	O
studied	O
in	O
remission	O
showed	O
reemergence	O
of	O
a	O
polyclonal	O
pattern	O
.	O
However	O
,	O
two	O
children	O
exhibited	O
persistence	O
of	O
monoclonal	O
hematopoiesis	O
despite	O
complete	O
clinical	O
/	O
hematological	O
remission	O
and	O
a	O
corresponding	O
loss	O
of	O
a	O
mutated	O
ras	O
allele	O
in	O
one	O
of	O
the	O
patients	O
.	O
These	O
data	O
indicate	O
the	O
value	O
of	O
molecular	O
genetic	O
approaches	O
for	O
evaluation	O
of	O
the	O
heterogeneous	O
nature	O
of	O
remission	O
and	O
relapse	O
in	O
AML	B-malignancy-type
.	O
PMID	O
:	O
2564452	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Feb;4(	O
2	O
)	O
:189	O
-	O
93	O
Activated	O
N-ras	O
gene	O
was	O
found	O
in	O
human	O
hepatoma	B-malignancy-type
tissue	O
but	O
only	O
in	O
a	O
small	O
fraction	O
of	O
the	O
tumor	O
cells	O
.	O
Takada	O
S,	O
Koike	O
K.	O
Department	O
of	O
Gene	O
Research	O
,	O
Cancer	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Activated	O
N-ras	O
gene	O
was	O
isolated	O
from	O
human	O
hepatoma	B-malignancy-type
tissue	O
by	O
DNA	O
transfection	O
assay	O
coupled	O
with	O
the	O
neomycin	O
selection	O
method	O
and	O
molecular	O
cloning	O
and	O
a	O
point	O
mutation	O
in	O
the	O
codon	O
61	O
(	O
CAA	O
----	O
AAA	O
)	O
was	O
noted	O
.	O
However	O
,	O
examination	O
of	O
the	O
proportion	O
of	O
the	O
mutated	O
N-ras	O
gene	O
in	O
the	O
tumor	O
part	O
by	O
molecular	O
cloning	O
and	O
by	O
hybridization	O
using	O
synthetic	O
oligonucleotide	O
probes	O
indicated	O
that	O
the	O
mutated	O
gene	O
occurred	O
with	O
very	O
low	O
frequency	O
.	O
The	O
activated	O
N-ras	O
gene	O
appears	O
located	O
only	O
in	O
a	O
small	O
fraction	O
of	O
the	O
tumor	O
cells	O
.	O
The	O
experimental	O
data	O
indicate	O
activation	O
of	O
this	O
gene	O
as	O
possibly	O
not	O
the	O
major	O
cause	O
of	O
carcinoma	B-malignancy-type
,	O
but	O
rather	O
a	O
manifestation	O
of	O
tumor	O
heterogeneity	O
.	O
PMID	O
:	O
2538792	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1990	O
Jul;	O
5	O
(	O
7	O
)	O
:	O
103	O
7-43	O
Detection	O
of	O
ras	O
gene	O
mutations	O
in	O
human	O
lung	B-malignancy-type
cancers	I-malignancy-type
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
products	O
.	O
Suzuki	O
Y	O
,	O
Orita	O
M,	O
Shiraishi	O
M,	O
Hayashi	O
K,	O
Sekiya	O
T.	O
Oncogene	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
A	O
simple	O
,	O
sensitive	O
method	O
of	O
DNA	O
analysis	O
of	O
nucleotide	O
substitutions	O
,	O
namely	O
,	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
products	O
(	O
PCR	O
-	O
SSCP	O
analysis	O
)	O
,	O
was	O
used	O
for	O
detection	O
of	O
mutated	O
ras	O
genes	O
in	O
surgical	O
specimens	O
of	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Of	O
a	O
total	O
of	O
129	O
tumors	O
analysed	O
,	O
22	O
contained	O
a	O
mutated	O
ras	O
gene	O
.	O
Of	O
the	O
66	O
adenocarcinomas	B-malignancy-type
analysed	O
,	O
14	O
contained	O
an	O
activated	O
c-Ki-ras2	O
gene	O
(	O
the	O
mutations	O
in	O
codon	O
12	O
in	O
6	O
,	O
in	O
codon	O
13	O
in	O
4	O
,	O
in	O
codon	O
18	O
in	O
one	O
,	O
and	O
in	O
codon	O
61	O
in	O
3	O
)	O
,	O
one	O
contained	O
a	O
c-Ha-ras1	O
gene	O
with	O
a	O
mutation	O
in	O
codon	O
61	O
and	O
3	O
contained	O
N-ras	O
genes	O
with	O
mutations	O
(	O
in	O
codon	O
12	O
in	O
one	O
and	O
in	O
codon	O
61	O
in	O
2	O
)	O
.	O
Mutated	O
rats	O
genes	O
were	O
also	O
found	O
in	O
2	O
of	O
36	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
c-Ha-ras1	O
genes	O
with	O
mutations	O
in	O
codon	O
61	O
)	O
and	O
2	O
of	O
14	O
large	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
c-Ki-ras2	O
genes	O
with	O
mutations	O
in	O
codon	O
12	O
)	O
.	O
No	O
mutation	O
of	O
the	O
ras	O
gene	O
was	O
detected	O
in	O
8	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
5	O
adenosquamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
ras	O
gene	O
was	O
not	O
frequent	O
(	O
17	O
%	O
)	O
in	O
human	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
that	O
among	O
these	O
lung	B-malignancy-type
cancers	I-malignancy-type
mutation	O
of	O
the	O
ras	O
gene	O
was	O
most	O
frequent	O
in	O
adenocarcinomas	B-malignancy-type
(	O
27	O
%	O
)	O
and	O
73	O
%	O
of	O
the	O
point	O
mutations	O
were	O
in	O
the	O
c-Ki-ras2	O
gene	O
in	O
codon	O
12	O
,	O
13	O
,	O
18	O
or	O
61	O
.	O
PMID	O
:	O
2197591	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1990	O
Feb	O
15	O
;50	O
(	O
4	O
)	O
:	O
112	O
1-4	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
human	O
hepatic	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Tada	O
M,	O
Omata	O
M,	O
Ohto	O
M.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
ras	O
gene	O
is	O
one	O
of	O
the	O
oncogenes	O
most	O
commonly	O
detected	O
in	O
human	O
cancers	O
,	O
and	O
it	O
consists	O
of	O
three	O
families	O
(	O
H-ras	O
,	O
K-ras	O
,	O
N-ras	O
)	O
.	O
These	O
genes	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
occurring	O
in	O
either	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
We	O
analyzed	O
mutations	O
of	O
these	O
codons	O
in	O
23	O
primary	O
hepatic	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
(	O
12	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
nine	O
cholangiocarcinomas	B-malignancy-type
,	O
and	O
two	O
hepatoblastomas	O
)	O
by	O
a	O
method	O
to	O
directly	O
sequence	O
nucleotides	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
a	O
direct	O
sequencing	O
method	O
.	O
Of	O
23	O
hepatic	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
,	O
point	O
mutations	O
at	O
K-ras	O
codon	O
12	O
or	O
K-ras	O
codon	O
61	O
were	O
found	O
in	O
six	O
of	O
nine	O
cholangiocarcinomas	B-malignancy-type
.	O
In	O
contrast	O
,	O
there	O
were	O
no	O
point	O
mutations	O
in	O
any	O
of	O
12	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
or	O
two	O
hepatoblastomas	B-malignancy-type
around	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
of	O
the	O
ras	O
genes	O
.	O
These	O
observations	O
suggest	O
that	O
ras	O
gene	O
mutations	O
are	O
not	O
related	O
to	O
pathogenesis	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
but	O
play	O
an	O
important	O
role	O
in	O
pathogenesis	O
of	O
cholangiocarcinoma	B-malignancy-type
.	O
PMID	O
:	O
2153451	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1990	O
Jan;8	O
1	O
(	O
1	O
)	O
:	O
2	O
2-7	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
in	O
human	O
bladder	B-malignancy-type
cancer	I-malignancy-type
and	O
kidney	B-malignancy-type
cancer	I-malignancy-type
.	O
Nagata	O
Y	O
,	O
Abe	O
M,	O
Kobayashi	O
K,	O
Saiki	O
S	O
,	O
Kotake	O
T	O
,	O
Yoshikawa	O
K,	O
Ueda	O
R	O
,	O
Nakayama	O
E	O
,	O
Shiku	O
H.	O
Department	O
of	O
Oncology	O
,	O
Nagasaki	O
University	O
School	O
of	O
Medicine	O
.	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
were	O
analyzed	O
in	O
26	O
cases	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
and	O
16	O
cases	O
of	O
kidney	B-malignancy-type
cancer	I-malignancy-type
.	O
DNA	O
prepared	O
from	O
either	O
frozen	O
tissues	O
or	O
10	O
%	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
were	O
amplified	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
methods	O
,	O
and	O
mutations	O
were	O
analyzed	O
by	O
dot	O
blot	O
hybridization	O
assays	O
with	O
oligonucleotide	O
probes	O
.	O
In	O
three	O
cases	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
c-ras	O
mutations	O
were	O
found	O
,	O
at	O
codons	O
13	O
and	O
61	O
of	O
c-Ha-ras	O
and	O
at	O
codon	O
61	O
of	O
c-Ki-ras	O
,	O
while	O
no	O
mutation	O
was	O
found	O
in	O
kidney	B-malignancy-type
cancer	I-malignancy-type
.	O
No	O
mutation	O
was	O
found	O
in	O
normal	O
bladder	O
epithelial	O
tissues	O
from	O
the	O
same	O
patients	O
.	O
Our	O
findings	O
,	O
taken	O
together	O
,	O
may	O
indicate	O
relative	O
scarcity	O
of	O
c-ras	O
mutations	O
in	O
these	O
types	O
of	O
human	O
cancer	O
.	O
The	O
results	O
of	O
dot	O
blot	O
hybridization	O
assays	O
and	O
DNA	O
sequencing	O
showed	O
a	O
G	O
-	O
to	O
-	O
C	O
transition	O
of	O
the	O
first	O
nucleotide	O
at	O
codon	O
13	O
c-Ha-ras	O
.	O
This	O
is	O
the	O
first	O
time	O
that	O
such	O
a	O
point	O
mutation	O
has	O
been	O
detected	O
in	O
human	O
cancer	O
tissues	O
.	O
PMID	O
:	O
2108944	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
1991	O
;4(	O
3	O
)	O
:196	O
-	O
202	O
Ras	O
gene	O
mutation	O
and	O
amplification	O
in	O
human	O
nonmelanoma	B-malignancy-type
skin	I-malignancy-type
cancers	I-malignancy-type
.	O
Pierceall	O
WE	O
,	O
Goldberg	O
LH	O
,	O
Tainsky	O
MA	O
,	O
Mukhopadhyay	O
T	O
,	O
Ananthaswamy	O
HN.	O
Department	O
of	O
Immunology	O
,	O
University	O
of	O
Texas	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
77030	O
.	O
Our	O
previous	O
studies	O
have	O
shown	O
that	O
human	O
skin	B-malignancy-type
cancers	I-malignancy-type
occurring	O
on	O
sun	O
-	O
exposed	O
body	O
sites	O
frequently	O
contain	O
activated	O
Ha-ras	O
oncogenes	O
capable	O
of	O
inducing	O
morphologic	O
and	O
tumorigenic	O
transformation	O
of	O
NIH	O
3T3	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
human	O
primary	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCCs	B-malignancy-type
)	O
and	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
BCCs	B-malignancy-type
)	O
occurring	O
on	O
sun	O
-	O
exposed	O
body	O
sites	O
for	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
oncogenes	O
by	O
amplification	O
of	O
genomic	O
tumor	O
DNAs	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
followed	O
by	O
dot	O
-	O
blot	O
hybridization	O
to	O
synthetic	O
oligonucleotide	O
probes	O
designed	O
to	O
detect	O
single	O
base	O
-	O
pair	O
mutations	O
.	O
In	O
addition	O
to	O
the	O
primary	O
human	O
skin	B-malignancy-type
cancers	I-malignancy-type
,	O
we	O
also	O
analyzed	O
Ha-ras	O
-	O
positive	O
NIH	O
3T3	O
transformants	O
for	O
mutations	O
in	O
the	O
Ha-ras	O
oncogene	O
.	O
The	O
results	O
indicated	O
that	O
all	O
three	O
NIH	O
3T3	O
transformants	O
,	O
11	O
of	O
24	O
(	O
46	O
%	O
)	O
SCCs	B-malignancy-type
,	O
and	O
5	O
of	O
16	O
(	O
31	O
%	O
)	O
BCCs	O
contained	O
mutations	O
at	O
the	O
second	O
position	O
of	O
Ha-ras	O
codon	O
12	O
(	O
GGC	O
----	O
GTC	O
)	O
,	O
predicting	O
a	O
glycine	O
-	O
to	O
-	O
valine	O
amino	O
acid	O
substitution	O
,	O
whereas	O
only	O
1	O
of	O
40	O
skin	B-malignancy-type
cancers	I-malignancy-type
(	O
an	O
SCC	B-malignancy-type
)	O
displayed	O
a	O
mutation	O
in	O
the	O
first	O
position	O
of	O
Ki-ras	O
codon	O
12	O
(	O
GGT	O
----	O
AGT	O
)	O
,	O
predicting	O
a	O
glycine	O
-	O
to	O
-	O
serine	O
amino	O
acid	O
change	O
.	O
In	O
addition	O
,	O
three	O
of	O
the	O
SCCs	B-malignancy-type
contained	O
highly	O
amplified	O
copies	O
of	O
the	O
N-ras	O
oncogene	O
in	O
their	O
genomic	O
DNA	O
.	O
Interestingly	O
,	O
two	O
of	O
the	O
SCCs	B-malignancy-type
containing	O
amplified	O
N-ras	O
sequences	O
also	O
had	O
G	O
----	O
T	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
Ha-ras	O
oncogene	O
.	O
These	O
studies	O
demonstrate	O
that	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
Ha-ras	O
oncogene	O
occurred	O
at	O
a	O
high	O
frequency	O
in	O
human	O
skin	B-malignancy-type
cancers	I-malignancy-type
originating	O
on	O
sun	O
-	O
exposed	O
body	O
sites	O
,	O
whereas	O
mutation	O
in	O
codon	O
12	O
of	O
Ki-ras	O
or	O
amplification	O
of	O
N-ras	O
occurred	O
at	O
a	O
low	O
frequency	O
.	O
Since	O
the	O
mutations	O
in	O
the	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
were	O
located	O
opposite	O
potential	O
pyrimidine	O
dimer	O
sites	O
(	O
C	O
-	O
C	O
)	O
,	O
it	O
is	O
likely	O
that	O
these	O
mutations	O
were	O
induced	O
by	O
ultraviolet	O
radiation	O
present	O
in	O
sunlight	O
.	O
PMID	O
:	O
2064725	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
1991	O
;4(	O
3	O
)	O
:189	O
-	O
95	O
Analysis	O
of	O
oncogene	O
alterations	O
in	O
human	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
:	O
prevalence	O
of	O
ras	O
mutations	O
.	O
Boyd	O
J,	O
Risinger	O
JI.	O
Gene	O
Expression	O
Section	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
.	O
The	O
molecular	O
genetics	O
of	O
human	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
have	O
yet	O
to	O
be	O
defined	O
to	O
any	O
significant	O
extent	O
.	O
Cell	O
lines	O
from	O
11	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
were	O
examined	O
for	O
alterations	O
in	O
proto	O
-	O
oncogenes	O
that	O
might	O
predictably	O
be	O
present	O
,	O
based	O
on	O
existing	O
data	O
from	O
the	O
better	O
-	O
characterized	O
human	O
carcinomas	B-malignancy-type
of	O
the	O
uterine	O
cervix	O
,	O
ovary	O
,	O
and	O
breast	O
.	O
Codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
genes	O
were	O
examined	O
for	O
possible	O
point	O
mutations	O
,	O
and	O
the	O
c-erbB2	O
/	O
neu	O
,	O
c-myc	O
,	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
genes	O
were	O
examined	O
for	O
amplification	O
or	O
overexpression	O
.	O
Ras	O
mutations	O
were	O
found	O
in	O
seven	O
of	O
11	O
(	O
64	O
%	O
)	O
tumors	O
,	O
including	O
three	O
in	O
codon	O
61	O
of	O
Ha-ras	O
(	O
CAG	O
----	O
CAT	O
)	O
and	O
four	O
in	O
codon	O
12	O
of	O
Ki-ras	O
(	O
GGT	O
----	O
GAT	O
in	O
two	O
and	O
GGT	O
----	O
GTT	O
in	O
two	O
)	O
.	O
No	O
evidence	O
was	O
found	O
for	O
amplification	O
or	O
overexpression	O
of	O
the	O
c-erbB2	O
or	O
EGFR	O
genes	O
in	O
any	O
tumor	O
.	O
One	O
tumor	O
contained	O
amplified	O
c-myc	O
sequences	O
and	O
exhibited	O
relative	O
overexpression	O
of	O
c-myc	O
.	O
These	O
data	O
suggest	O
that	O
the	O
amplification	O
or	O
overexpression	O
of	O
several	O
proto	O
-	O
oncogenes	O
frequently	O
observed	O
in	O
other	O
human	O
gynecologic	B-malignancy-type
and	O
breast	B-malignancy-type
tumors	I-malignancy-type
are	O
not	O
prevalent	O
in	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
and	O
that	O
ras	O
gene	O
mutations	O
are	O
relatively	O
common	O
in	O
this	O
tumor	O
type	O
.	O
PMID	O
:	O
2064724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
1991	O
;19(	O
4)	O
:240	O
-	O
5	O
Analysis	O
of	O
N-ras	O
gene	O
mutations	O
in	O
medulloblastomas	B-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
probes	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
.	O
Iolascon	O
A	O
,	O
Lania	O
A	O
,	O
Badiali	O
M,	O
Pession	O
A	O
,	O
Saglio	O
G	O
,	O
Giangaspero	O
F	O
,	O
Miraglia	O
del	O
Giudice	O
E	O
,	O
Perrotta	O
S,	O
Cutillo	O
S.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Naples	O
,	O
Italy	O
.	O
Precise	O
data	O
on	O
the	O
incidence	O
of	O
transforming	O
ras	O
oncogenes	O
in	O
pediatric	O
tumors	O
and	O
the	O
correlations	O
with	O
the	O
histopathological	O
properties	O
of	O
the	O
tumors	O
are	O
very	O
limited	O
.	O
Additionally	O
the	O
presence	O
of	O
ras	O
activation	O
in	O
medulloblastomas	B-malignancy-type
has	O
not	O
been	O
investigated	O
so	O
far	O
.	O
Using	O
a	O
combination	O
of	O
techniques	O
including	O
in	O
vitro	O
gene	O
amplification	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
detection	O
of	O
single	O
base	O
mutations	O
by	O
sequence	O
-	O
specific	O
oligonucleotides	O
we	O
studied	O
N-ras	O
activation	O
(	O
mutations	O
at	O
codon	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
in	O
32	O
medulloblastomas	B-malignancy-type
.	O
DNA	O
was	O
isolated	O
from	O
20	O
microns	O
sections	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Mutations	O
were	O
found	O
in	O
3	O
out	O
of	O
32	O
examined	O
medulloblastomas	B-malignancy-type
.	O
In	O
all	O
cases	O
only	O
mutations	O
of	O
codon	O
61	O
were	O
found	O
:	O
two	O
of	O
three	O
mutations	O
were	O
C	O
to	O
A	O
mutations	O
at	O
position	O
1	O
of	O
the	O
codon	O
61	O
(	O
leading	O
to	O
a	O
substitution	O
of	O
a	O
glutamine	O
residue	O
for	O
a	O
lysine	O
)	O
and	O
one	O
was	O
A	O
to	O
T	O
mutation	O
at	O
position	O
3	O
in	O
the	O
same	O
codon	O
(	O
glutamine	O
-	O
histidine	O
)	O
.	O
Our	O
results	O
indicate	O
10	O
%	O
incidence	O
N-ras	O
mutation	O
in	O
medulloblastoma	B-malignancy-type
,	O
higher	O
than	O
in	O
other	O
CNS	B-malignancy-type
tumors	I-malignancy-type
studied	O
so	O
far	O
.	O
The	O
main	O
advantages	O
of	O
the	O
procedure	O
described	O
are	O
its	O
greatly	O
improved	O
sensitivity	O
,	O
the	O
increased	O
speed	O
with	O
which	O
tumor	O
samples	O
can	O
be	O
analyzed	O
,	O
and	O
the	O
possibility	O
of	O
using	O
paraffin	O
-	O
embedded	O
sections	O
to	O
analyze	O
various	O
rare	O
tumors	O
in	O
retrospect	O
.	O
PMID	O
:	O
2056968	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Kobe	O
J	O
Med	O
Sci	O
1991	O
Feb;37(	O
1	O
)	O
:35	O
-	O
45	O
RAS	O
gene	O
mutations	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
and	O
related	O
monoclonal	B-malignancy-type
gammopathies	I-malignancy-type
.	O
Matozaki	O
S,	O
Nakagawa	O
T	O
,	O
Nakao	O
Y	O
,	O
Fujita	O
T.	O
Department	O
of	O
Hematology	O
/	O
Oncology	O
,	O
Hyogo	O
Medical	O
Center	O
for	O
Adult	O
,	O
Akashi	O
.	O
The	O
presence	O
of	O
RAS	O
gene	O
mutations	O
in	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
suggests	O
that	O
they	O
participate	O
in	O
the	O
early	O
stages	O
of	O
neoplastic	O
development	O
.	O
Furthermore	O
,	O
neoplastic	O
progression	O
from	O
monoclonal	B-malignancy-type
gammopathy	I-malignancy-type
of	O
undetermined	O
significance	O
(	O
MGUS	O
)	O
to	O
overt	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
have	O
been	O
frequently	O
observed	O
.	O
These	O
observations	O
prompted	O
us	O
to	O
study	O
the	O
pathogenetic	O
role	O
of	O
RAS	O
genes	O
in	O
MM	O
and	O
related	O
monoclonal	B-malignancy-type
gammopathies	I-malignancy-type
.	O
DNA	O
from	O
18	O
patients	O
with	O
monoclonal	B-malignancy-type
gamma-globulinemia	I-malignancy-type
including	O
12	O
MM	B-malignancy-type
were	O
investigated	O
for	O
the	O
presence	O
of	O
N	O
-	O
and	O
K	O
-	O
RAS	O
gene	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
oligonucleotide	O
hybridization	O
.	O
Mutations	O
involving	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
N-RAS	O
gene	O
were	O
identified	O
in	O
3	O
of	O
the	O
12	O
MM	B-malignancy-type
patients	O
,	O
1	O
of	O
the	O
solitary	B-malignancy-type
plasmacytoma	I-malignancy-type
patients	O
and	O
none	O
of	O
the	O
3	O
of	O
the	O
MGUS	O
patients	O
.	O
In	O
the	O
case	O
of	O
plasmacytoma	B-malignancy-type
,	O
RAS	O
mutations	O
were	O
detected	O
in	O
his	O
bone	O
marrow	O
specimens	O
.	O
PMID	O
:	O
1921261	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
Oct	O
1;51(	O
19	O
)	O
:5308	O
-	O
14	O
K-ras	O
activation	O
in	O
premalignant	O
and	O
malignant	O
epithelial	B-malignancy-type
lesions	I-malignancy-type
of	O
the	O
human	O
uterus	O
.	O
Enomoto	O
T	O
,	O
Inoue	O
M,	O
Perantoni	O
AO	O
,	O
Buzard	O
GS	O
,	O
Miki	O
H	O
,	O
Tanizawa	O
O	O
,	O
Rice	O
JM	O
.	O
Laboratory	O
of	O
Comparative	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
Frederick	O
Cancer	O
Research	O
and	O
Development	O
Center	O
,	O
Maryland	O
21702	O
-	O
1201	O
.	O
We	O
previously	O
reported	O
(	O
Cancer	O
Res.	O
,	O
50	O
:	O
6139	O
-	O
6145	O
,	O
1990	O
)	O
a	O
significant	O
frequency	O
of	O
activating	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
in	O
endometrial	B-malignancy-type
adenocarcinomas	I-malignancy-type
of	O
the	O
uterine	O
corpus	O
(	O
series	O
1	O
)	O
.	O
To	O
further	O
define	O
the	O
role	O
of	O
ras	O
activation	O
in	O
the	O
development	O
of	O
endometrial	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
we	O
surveyed	O
cystic	B-malignancy-type
,	O
adenomatous	B-malignancy-type
,	O
and	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
of	O
uterine	O
endometrium	O
and	O
additional	O
cases	O
of	O
endometrial	B-malignancy-type
and	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
(	O
series	O
2	O
)	O
for	O
the	O
presence	O
of	O
activating	O
mutations	O
in	O
cellular	O
protooncogenes	O
of	O
the	O
ras	O
family	O
.	O
Polymerase	O
chain	O
reaction	O
was	O
performed	O
from	O
deparaffinized	O
sections	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
We	O
screened	O
for	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
K	O
-	O
,	O
H	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
by	O
dot	O
blot	O
hybridization	O
analysis	O
with	O
mutation	O
-	O
specific	O
oligomers	O
.	O
Mutations	O
in	O
K-ras	O
were	O
also	O
confirmed	O
by	O
direct	O
genomic	O
DNA	O
sequencing	O
.	O
Of	O
19	O
endometrial	B-malignancy-type
adenocarcinomas	I-malignancy-type
in	O
series	O
2	O
,	O
point	O
mutations	O
in	O
ras	O
genes	O
were	O
found	O
in	O
7	O
tumors	O
.	O
Six	O
contained	O
single-base	O
substitutions	O
,	O
five	O
in	O
codon	O
12	O
of	O
K-ras	O
and	O
one	O
in	O
codon	O
12	O
of	O
N-ras	O
.	O
The	O
seventh	O
tumor	O
contained	O
two	O
different	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
.	O
In	O
one	O
endometrial	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
tumor	O
cells	O
with	O
point	O
mutations	O
in	O
K-ras	O
were	O
predominantly	O
localized	O
to	O
a	O
portion	O
that	O
had	O
a	O
more	O
aggressive	O
histological	O
pattern	O
.	O
In	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
,	O
K-ras	O
mutations	O
,	O
one	O
in	O
codon	O
12	O
and	O
one	O
in	O
codon	O
13	O
,	O
were	O
found	O
in	O
2	O
of	O
16	O
hyperplasias	B-malignancy-type
histologically	O
classified	O
as	O
atypical	O
and	O
clinically	O
considered	O
premalignant	O
.	O
None	O
of	O
6	O
adenomatous	B-malignancy-type
hyperplasias	I-malignancy-type
and	O
none	O
of	O
12	O
cystic	B-malignancy-type
hyperplasias	I-malignancy-type
,	O
the	O
latter	O
of	O
which	O
is	O
considered	O
clinically	O
benign	O
,	O
contained	O
any	O
detectable	O
ras	O
mutations	O
.	O
No	O
mutations	O
in	O
H-ras	O
were	O
detected	O
in	O
either	O
carcinomas	B-malignancy-type
or	O
hyperplastic	O
tissue	O
.	O
PMID	O
:	O
1913654	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Formos	O
Med	O
Assoc	O
1991	O
Sep;90(	O
9	O
)	O
:825	O
-	O
30	O
Mutation	O
analysis	O
of	O
the	O
ras	O
gene	O
in	O
myelocytic	B-malignancy-type
leukemia	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
probes	O
.	O
Liu	O
TC	O
,	O
Lin	O
SF	O
,	O
Chen	O
TP	O
,	O
Liu	O
HW	O
,	O
Chang	O
JG.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kaohsiung	O
Medical	O
College	O
,	O
R.O.C.	O
Twenty-nine	O
patients	O
with	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
and	O
14	O
patients	O
with	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
were	O
analyzed	O
to	O
detect	O
the	O
presence	O
of	O
mutations	O
in	O
their	O
ras	O
genes	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
methods	O
.	O
Deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
isolated	O
from	O
blood	O
or	O
bone	O
marrow	O
samples	O
was	O
screened	O
for	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N-ras	O
and	O
in	O
codons	O
12	O
and	O
61	O
of	O
K-ras	O
and	O
H-ras	O
.	O
We	O
detected	O
mutations	O
of	O
the	O
ras	O
gene	O
in	O
7	O
patients	O
with	O
AML	B-malignancy-type
(	O
7	O
/	O
29	O
)	O
,	O
all	O
in	O
N-ras	O
.	O
The	O
mutations	O
were	O
3	O
GGT	O
-_greater_than	O
GAT	O
transitions	O
in	O
codon	O
12	O
,	O
1	O
GGT	O
-_greater_than	O
TGT	O
transition	O
in	O
codon	O
13	O
,	O
and	O
3	O
CAA	O
-_greater_than	O
AAA	O
transitions	O
in	O
codon	O
61	O
.	O
No	O
correlation	O
has	O
been	O
observed	O
between	O
French	O
-	O
American	O
-	O
British	O
subtypes	O
and	O
the	O
incidence	O
of	O
N-ras	O
mutation	O
,	O
nor	O
between	O
cytogenetic	O
changes	O
and	O
the	O
incidence	O
of	O
N-ras	O
mutation	O
.	O
All	O
ras	O
gene	O
mutations	O
detected	O
by	O
the	O
oligonucleotide	O
hybridization	O
method	O
were	O
further	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
No	O
mutations	O
were	O
detected	O
in	O
ras	O
genes	O
in	O
samples	O
from	O
the	O
14	O
Philadelphia	O
chromosome	O
-	O
positive	O
CML	B-malignancy-type
patients	O
(	O
12	O
in	O
chronic	O
phase	O
,	O
2	O
in	O
blastic	O
phase	O
)	O
.	O
These	O
findings	O
are	O
in	O
line	O
with	O
previous	O
results	O
indicating	O
that	O
ras	O
gene	O
mutations	O
in	O
the	O
codons	O
tested	O
play	O
only	O
a	O
small	O
role	O
in	O
the	O
tumorigenesis	O
of	O
CML	B-malignancy-type
.	O
PMID	O
:	O
1683380	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Mar	O
12;50(	O
5	O
)	O
:713	O
-	O
8	O
N-ras	O
gene	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
:	O
accurate	O
detection	O
by	O
solid-phase	O
minisequencing	O
.	O
Syvanen	O
AC	O
,	O
Soderlund	O
H	O
,	O
Laaksonen	O
E	O
,	O
Bengtstrom	O
M,	O
Turunen	O
M,	O
Palotie	O
A.	O
National	O
Public	O
Health	O
Institute	O
,	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O
Helsinki	O
,	O
Finland	O
.	O
Mutations	O
in	O
the	O
N-ras	O
gene	O
are	O
found	O
in	O
one-third	O
of	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
N-ras	O
mutations	O
could	O
serve	O
as	O
markers	O
for	O
residual	O
cells	O
,	O
if	O
a	O
highly	O
sensitive	O
method	O
for	O
detecting	O
the	O
mutations	O
was	O
available	O
.	O
We	O
applied	O
a	O
new	O
method	O
,	O
solid-phase	O
minisequencing	O
,	O
to	O
analyze	O
bone	O
-	O
marrow	O
cells	O
from	O
16	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
for	O
mutations	O
in	O
codon	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
gene	O
.	O
In	O
the	O
solid-phase	O
minisequencing	O
technique	O
the	O
mutations	O
are	O
identified	O
by	O
a	O
primer	O
extension	O
reaction	O
,	O
in	O
which	O
a	O
single	O
labelled	O
nucleoside	O
triphosphate	O
is	O
incorporated	O
into	O
an	O
immobilized	O
DNA	O
fragment	O
previously	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
We	O
identified	O
N-ras	O
mutations	O
in	O
5	O
of	O
the	O
patients	O
(	O
30	O
%	O
)	O
.	O
In	O
one	O
patient	O
,	O
we	O
observed	O
2	O
mutations	O
that	O
were	O
shown	O
to	O
be	O
located	O
in	O
different	O
alleles	O
.	O
With	O
the	O
solid-phase	O
minisequencing	O
method	O
,	O
we	O
were	O
able	O
to	O
determine	O
the	O
proportion	O
of	O
mutated	O
cells	O
in	O
the	O
samples	O
.	O
We	O
found	O
that	O
in	O
4	O
of	O
the	O
samples	O
only	O
a	O
fraction	O
(	O
7	O
-	O
64	O
%	O
)	O
of	O
the	O
blasts	O
carried	O
an	O
N-ras	O
mutation	O
,	O
and	O
in	O
one	O
sample	O
practically	O
all	O
blast	O
cells	O
were	O
mutated	O
.	O
The	O
method	O
was	O
highly	O
sensitive	O
,	O
allowing	O
us	O
to	O
identify	O
N-ras	O
mutations	O
even	O
when	O
the	O
sample	O
consisted	O
of	O
99.7	O
%	O
normal	O
cells	O
and	O
only	O
0.3	O
%	O
mutated	O
blasts	O
.	O
PMID	O
:	O
1544704	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1992	O
Mar	O
1;7	O
9	O
(	O
5	O
)	O
:	O
126	O
6-70	O
Longitudinal	O
analysis	O
of	O
point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
in	O
patients	O
with	O
myelodysplasia	B-malignancy-type
using	O
archived	O
blood	O
smears	O
.	O
van	O
Kamp	O
H,	O
de	O
Pijper	O
C,	O
Verlaa	O
n-de	O
Vries	O
M,	O
Bos	O
JL	O
,	O
Leeksma	O
CH,	O
Kerkhofs	O
H,	O
Willemze	O
R	O
,	O
Fibbe	O
WE	O
,	O
Landegent	O
JE.	O
Department	O
of	O
Hematology	O
,	O
University	O
Medical	O
Center	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
We	O
performed	O
a	O
longitudinal	O
analysis	O
of	O
point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
in	O
patients	O
with	O
myelodysplasia	B-malignancy-type
and	O
a	O
follow-up	O
of	O
at	O
least	O
2.5	O
years	O
after	O
diagnosis	O
.	O
Point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
N-ras	O
oncogene	O
were	O
analyzed	O
after	O
in	O
vitro	O
amplification	O
of	O
N-ras	O
specific	O
sequences	O
followed	O
by	O
dot	O
-	O
blot	O
hybridization	O
.	O
Lysed	O
cells	O
scraped	O
from	O
archived	O
blood	O
and	O
bone	O
marrow	O
smears	O
were	O
used	O
as	O
template	O
for	O
a	O
polymerase	O
chain	O
reaction	O
.	O
In	O
3	O
of	O
90	O
patients	O
tested	O
(	O
3.3	O
%	O
)	O
,	O
a	O
mutation	O
in	O
codon	O
12	O
could	O
be	O
detected	O
in	O
the	O
most	O
recent	O
blood	O
smears	O
.	O
All	O
available	O
blood	O
and	O
bone	O
marrow	O
samples	O
of	O
these	O
patients	O
were	O
subsequently	O
analyzed	O
for	O
the	O
occurrence	O
of	O
that	O
particular	O
mutation	O
.	O
In	O
all	O
three	O
cases	O
the	O
mutation	O
was	O
not	O
detectable	O
at	O
diagnosis	O
,	O
but	O
was	O
acquired	O
later	O
during	O
the	O
course	O
of	O
the	O
disease	O
.	O
In	O
two	O
of	O
these	O
patients	O
this	O
event	O
was	O
associated	O
with	O
rapid	O
deterioration	O
and	O
transformation	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
However	O
,	O
the	O
third	O
patient	O
showed	O
a	O
protracted	O
course	O
during	O
a	O
period	O
of	O
5	O
years	O
after	O
acquisition	O
of	O
the	O
mutation	O
.	O
These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
N-ras	O
protooncogene	O
in	O
these	O
three	O
patients	O
represents	O
a	O
secondary	O
phenomenon	O
associated	O
with	O
disease	O
progression	O
in	O
some	O
cases	O
,	O
but	O
compatible	O
with	O
stable	O
disease	O
in	O
others	O
.	O
PMID	O
:	O
1536950	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

